<SEC-DOCUMENT>0001628280-22-005753.txt : 20220310
<SEC-HEADER>0001628280-22-005753.hdr.sgml : 20220310
<ACCEPTANCE-DATETIME>20220310170930
ACCESSION NUMBER:		0001628280-22-005753
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		124
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220310
DATE AS OF CHANGE:		20220310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Foghorn Therapeutics Inc.
		CENTRAL INDEX KEY:			0001822462
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39634
		FILM NUMBER:		22730029

	BUSINESS ADDRESS:	
		STREET 1:		500 TECHNOLOGY SQUARE
		STREET 2:		SUITE 700
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-586-3100

	MAIL ADDRESS:	
		STREET 1:		500 TECHNOLOGY SQUARE
		STREET 2:		SUITE 700
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>fhtx-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:45bd6193-dace-4c5a-b62d-c265e68fd1cf,g:2c36ac82-298b-41b7-8200-caa9bbc65128,d:523559815e87485cb6a9895707f43a02--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:fhtx="http://www.foghorntx.com/20211231" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>fhtx-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl80L2ZyYWc6NGZiZjhmZDg2YjFmNGZjODllYWQ0ZjJkMzI3ZmZjMjgvdGFibGU6Y2Y2ZGM5YzVlZTRkNDM0MDhiYzM1YTI2NjE5MGQ3NjMvdGFibGVyYW5nZTpjZjZkYzljNWVlNGQ0MzQwOGJjMzVhMjY2MTkwZDc2M18yLTEtMS0xLTA_1271a062-2685-473d-8d45-3ba56833bba0">false</ix:nonNumeric><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl80L2ZyYWc6NGZiZjhmZDg2YjFmNGZjODllYWQ0ZjJkMzI3ZmZjMjgvdGFibGU6Y2Y2ZGM5YzVlZTRkNDM0MDhiYzM1YTI2NjE5MGQ3NjMvdGFibGVyYW5nZTpjZjZkYzljNWVlNGQ0MzQwOGJjMzVhMjY2MTkwZDc2M180LTEtMS0xLTA_70ee12db-b408-45b0-af23-2a8183aad252">2021</ix:nonNumeric><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl80L2ZyYWc6NGZiZjhmZDg2YjFmNGZjODllYWQ0ZjJkMzI3ZmZjMjgvdGFibGU6Y2Y2ZGM5YzVlZTRkNDM0MDhiYzM1YTI2NjE5MGQ3NjMvdGFibGVyYW5nZTpjZjZkYzljNWVlNGQ0MzQwOGJjMzVhMjY2MTkwZDc2M181LTEtMS0xLTA_193da678-87d6-426e-8359-bbf9624e8f12">FY</ix:nonNumeric><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl80L2ZyYWc6NGZiZjhmZDg2YjFmNGZjODllYWQ0ZjJkMzI3ZmZjMjgvdGFibGU6Y2Y2ZGM5YzVlZTRkNDM0MDhiYzM1YTI2NjE5MGQ3NjMvdGFibGVyYW5nZTpjZjZkYzljNWVlNGQ0MzQwOGJjMzVhMjY2MTkwZDc2M183LTEtMS0xLTA_84639c82-b19c-46a1-97b1-7f8c5921c4a6">0001822462</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="fhtx-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f6e00ec5e724389b05915a0622249e4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i2f120daef0e24742bb1b5aace13d4d8f_I20220225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7943cc4a71f4b42b53e4c968843494e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c744d00941d4c199a48d89ffa755b17_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81de0ee0ccd449989132fa7f14079ba5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac30a123b0694acb8d72a14f63dac021_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i406407ac43db40d493cf8d79d3921779_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0edcb140d2049a79c39501d27f139b9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f685775719843b4a9fff30dabdaf80a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie54f7d4fc8034f45ba6d2e439e5ab48d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfaabe46efdf4e258762c5f4b7e852b8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i810a9ddbdca940e9b925b274aa1a2543_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if047b911bba14fcf9c9ca20f03db2aa3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i392fd42774c3426791748c8100a4fdd2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib04b5ec0aee746bcaee20b310c94a839_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i755b66d1c0514ffabb5b047a0580e000_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6202585c1f594c04828ca33622ba9f73_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic897dfc3ee8d4be5958083cf9a26f3cf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b60e82482b4491fbaf024954d547c32_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1da796dda74428196d7005b876d4506_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6dc13b3584f4e4aa450e4760484cf39_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f78ce619e064ea1b1cdd9e493e462f3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70fb1b2bd2ea46e881f0145ac62c2a0f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92d1d123424f44d994d5af3872acb232_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fhtx:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43038a8d4df843809b6e00244fcfc5f2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fhtx:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08a673dfc57842d19a4fc0a035015adb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fhtx:SharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if661fd7abbb84486820d9146f777241d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fb4ee0936c34d9094e17460190a277a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if28ce271ce7648a08119c449c9d2ef48_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d7cb7123c0e44e095d8223cbcd8af1b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fadfcdbc6314b66a0e9d9a4c9ad038c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e7fbab3102f466f9aa8f20c9c5e38d5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c1033134ae74e0a98b856d174a6a6f8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f0e298f4e244829a4cc21bc741d457b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">fhtx:ConversionOfRedeemableConvertibleStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fbf615bd0c04b61a3e8c3c5584de518_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">fhtx:ConversionOfRedeemableConvertibleStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff300de84591401db5d227d7c7cf9dac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">fhtx:ConversionOfWarrantLiabilityToEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59f4c12202e9485c860f841d498aebdb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">fhtx:ConversionOfWarrantLiabilityToEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bd62dcf817f4d0eb46e515f34977c6b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">fhtx:ConversionOfNotesPayableInToWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3f9b42353f44a458f9f2c68c488eaac_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">fhtx:ConversionOfNotesPayableInToWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic61be130c3e94434a1523a709ee82e84_D20201027-20201027"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-27</xbrli:startDate><xbrli:endDate>2020-10-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd065cf6469a49619232b52c4f78a47a_I20201027"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c5b1d5196b546fcadb8c83231e484ed_D20201119-20201119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-19</xbrli:startDate><xbrli:endDate>2020-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i598749ee432f4d19b443963f60801a17_I20201119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabf346f1d20b4fbab0cb034770c8cc7b_D20211210-20211210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fhtx:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-10</xbrli:startDate><xbrli:endDate>2021-12-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7545d56c585441a18935d61361a1f6e3_I20211210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fhtx:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i146aef1b1a8a405cb503481b39bfb902_D20211210-20211210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fhtx:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-10</xbrli:startDate><xbrli:endDate>2021-12-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25bd4e2b11bf41efbe5fc4e9eae184b7_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c4d412c57184ef2b09b93a7922fec1d_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic066e702d698456487c1fe09f0556f0f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6459962b97414cb4941639768c219ba0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bc48e6cb48142b59aba9858f119acab_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>fhtx:agreement</xbrli:measure></xbrli:unit><xbrli:context id="i5f7bc146064d4609a9384b2c32e30608_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34e7f6a206ae4fca9926a2b3693a2e1c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12a1c8269d8549d6bdfd75792c409c5d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id03aeb4309314c119fa838863de75a16_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cd2aa71baa24133bcddefb5ee9ce9b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b216a3565b64982af2832ed92b1f204_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id955de6cd1884e8185138e0750ec2ab3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if906371b919e4edb9cbaff3349db1e5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff3838f509af4f0eb1680ed5f138763c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaac48c4990fc4b23a98caf4dc0c46472_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79d6f505bd7d40d1ab1326d0b0e8b296_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0e25902efa14d8496dbe8fa31ab5e18_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i111a519d6a244546ae0ab2247e929789_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i444925a451b6462ba584afd5c61d43e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ef2f7d5ec4b41adb5e4a6ef1777b997_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i968a33b0579d40f3b45433f682345851_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i537352e60a9a414692e0f7409da18813_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2e7eba7312d4e0fba240bde0d9c1bc9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6823127af8d34669a2caa57eb496dd2d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76a6b50908b44d00a55838e4e1cf7176_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad91834ab15d489cb8484081982f739d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ef90d0c133b4dc09242b27430fb6c83_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8bcbd3ea5e74155b41c0255c7c0e7a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib653dca791b64896a08cfb7a0e8446f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62bc1b90709641e48c8ee1248e2a2be0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7a8cdf58951489cbce902c6026e0d71_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7581f3ffb0042c59c5d8ca5c9d3c495_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeb58fd86d1241b285fe06e0d3d62da7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0ceb8decc8347719a807b233cf323cf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eededd25783411791223767f68f1740_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c2443787a9a4bf6899e62de8792aabb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id674ecc28e6a4bec8492a5fad8e88241_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9007fd1a6c114c2f9092e78360752927_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d5b943b47404b9796a02f5deed9fa6d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7c250fe5eb94135b9cb46d4e2a2fe65_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6936f6623d364d4e855208a92198fbff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic48fe4ed0446401abf189c47fbf5e947_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic45ad783abc94d60b6f3fc8c8900675f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8bb1cd7498940d3ba6558a5b1f34d14_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b088f5892d84a34a7cfbb1478042496_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6365a0687d1a4e38b300cbff88436f8c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e14f625a75f45c0be3dc94d6442301d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic737047ef5ac46948883230a983a17e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85f5b7fcbcc1494d82b2b6edf8a4eec6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic38f6e8e2292491e90c063c6222b2448_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26b8aecd6a1c435bb0da7145cba274e6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb18b30cf22f4a32bb4ff93620162dda_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife30eeb6debd49f9a9e6eaccb2f6d4f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0f5fafdc67546f5aec4e0ce4e1aaa67_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57e5da0015844088ba86122ad60975f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if936930eb6674b98aa88bbc4b5ff6632_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fhtx:AssetsNotYetPlacedInServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ae945c2f65f4ae1b715fa4120b4b25e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fhtx:AssetsNotYetPlacedInServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69208d809b134811a688e3aaa1b56f5f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic63ca5a8620e4354a23fe4fb65d45904_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib49c41bde7e24d5eb853d157bd015ed2_I20201119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ec8f3ca08b54640bf525807c9358e0b_I20201119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i8b0e0ca6351c413a82a3c23dea9a45aa_D20201119-20201119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-19</xbrli:startDate><xbrli:endDate>2020-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3a33598e6e946e8956a704040d5cd66_D20201119-20201119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="fhtx:PrepaymentPeriodAxis">fhtx:PrepaymentPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-19</xbrli:startDate><xbrli:endDate>2020-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i308a28a242364292959d00dffcc81a50_D20201119-20201119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="fhtx:PrepaymentPeriodAxis">fhtx:PrepaymentPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-19</xbrli:startDate><xbrli:endDate>2020-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if15ca8afdf684493a8630928aba61256_D20201119-20201119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="fhtx:PrepaymentPeriodAxis">fhtx:PrepaymentPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-19</xbrli:startDate><xbrli:endDate>2020-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a4208db8c414f878b2487dcb43e458b_D20201119-20201119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="fhtx:PrepaymentPeriodAxis">fhtx:PrepaymentPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-19</xbrli:startDate><xbrli:endDate>2020-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c238b9ea3134f76bd3f9653c8e95195_D20201119-20201119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="fhtx:PrepaymentPeriodAxis">fhtx:PrepaymentPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-19</xbrli:startDate><xbrli:endDate>2020-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibda01586c8f04185951a0c2fc97552f9_D20201119-20201119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="fhtx:PrepaymentPeriodAxis">fhtx:PrepaymentPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-19</xbrli:startDate><xbrli:endDate>2020-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d753a4861b4455884ca55cfae0bfb8a_D20201119-20201119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="fhtx:PrepaymentPeriodAxis">fhtx:PrepaymentPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-19</xbrli:startDate><xbrli:endDate>2020-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a5c869b237944468340c8ac74252d01_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i200e1e33978e497897a00efb7d79afa3_D20201027-20201027"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-27</xbrli:startDate><xbrli:endDate>2020-10-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i994acb4549c24113977b0c0609947658_I20201027"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14dfffaa2d514c159c93b8d68536b5ba_D20201119-20201119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-19</xbrli:startDate><xbrli:endDate>2020-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i642c088ef7d642369dbab1bad144e018_I20201119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id726ec1ea7b74a18882e37d4c46d322d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fhtx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66c95f1c25a3420bb352629cf4f1de89_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fhtx:A2016StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1f18e1cd74a4d7aaab2d0502973207a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fhtx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b428a6c1acd40cf865512a4a620af6a_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fhtx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98cc31b8aad74865a5d00291d5e0a72c_I20201021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fhtx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41b3935d055e4939a3944280d0f2de1e_D20201001-20201021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fhtx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia19ec2fabe1a4533bf2258db4754d4d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fhtx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i607096de8c294fdbb48bcd8c3b29b30e_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fhtx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d95bd0fdd7e4e81bd6d70d4f7c1ca41_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4582998cb4fb486daa23cdd87422567d_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59b51c6004e744ce976e8146e0351d7b_D20160401-20160430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-04-01</xbrli:startDate><xbrli:endDate>2016-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0ad5b09bca848e28ffcaee3d672d862_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12b80e675b334f9bb84e42822020fb90_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if52bb65557044014ad2e63a31d0a1950_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d7a3942a9c94293aa8e8f466ced6118_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4ffb19f3c77426aa1c640fbfce74994_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="target"><xbrli:measure>fhtx:target</xbrli:measure></xbrli:unit><xbrli:context id="ibfef7b67aa6c4537931d0aa3b01c282e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>fhtx:program</xbrli:measure></xbrli:unit><xbrli:context id="i2b7a001271974fbf9927a5ce4c667237_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fhtx:ResearchDevelopmentAndRegulatoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf371cc8a9e24160bf8af37cf9d965e0_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:EliLillyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fhtx:SalesBasedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0598fb4888944458a105637a5c365acb_I20211201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dbcc6d4cd8b45da85ef3abc002c76e7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:EliLillyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37050e2af73c4dfbbeb53cfcede910de_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fhtx:ResearchDevelopmentAndRegulatoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0fb78f785ab496ca56695669faf74b4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic857b04717ad4bdaa38f79139b0b4f77_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:MerckMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92aabf8f84a443bb8049e24e529e50a6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:MerckMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26f27415158a4a8dad12c8e3b7e94178_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6b2557e266749eca4da6aa9146a5588_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:MerckMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5dda4379bcf4779a73a8e6da786d5d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1c22c57ec184fa7a48b0db8d9e9cbca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i462afb2928a44e61adc374bf4a44a35a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8566261f099345058fc2de53fdeddc94_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ie777875661fd4e1cafd3e415514e3463_D20200101-20271231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2027-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88337b0a640c41778757a13053c6737c_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42cc5f4d622f43728d16d5f588e05289_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5df226eaed834b4d95b67a71f15df511_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5871025070284091b9843930b1b0739f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9658936ddbd4496bb318be3e882b158_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1de98e2458194d09aea8ba3c1fbd59d9_I20200629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51cd2ef8029b4e6eacda02334700de82_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fhtx:OfficeSpaceInCambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0ecce1083f6481ead8d518a258a5e21_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fhtx:AdditionalOfficeSpaceInCambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e3da7bbe9d045048732fcefce03b848_D20170731-20170731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fhtx:StanfordLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-31</xbrli:startDate><xbrli:endDate>2017-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia71ec7897cbb4006827fd4c8d3854267_D20151001-20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:FlagshipPioneeringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5382aa2bf08f43e88b67b99daf3dd99c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75de76e7d13240f3891598dddc3f678b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cc1a0a9e2cf453689f94cd708f119eb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c734257926a48949b263d60cee94f38_D20151001-20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69d3730be48141eba19fe94753d20597_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2edac33103b46efba125b51d6b34c3f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d894474bd8940b28bf453d051db226a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i273c56330b4b4f6abe4c85c7cd7fcd01_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001822462</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fhtx:ScientificFounderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i523559815e87485cb6a9895707f43a02_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xNjQ5MjY3NDQ1Mzgy_7c6daacf-6b6a-4262-a94e-03b41e59686d">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:2.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.906%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6N2QxM2Y2NzEzODNkNGQ4MGEyYWRkMTljNzljMDQ3MzUvdGFibGVyYW5nZTo3ZDEzZjY3MTM4M2Q0ZDgwYTJhZGQxOWM3OWMwNDczNV8wLTAtMS0xLTIxMTA1_de0ca152-0558-4f0c-9aa6-a5462aa15c00">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xNjQ5MjY3NDQ1NDMy_959749ad-4b5d-4793-9a78-4dfc056d1098"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xNjQ5MjY3NDQ1NDMy_9794dc3f-6251-418e-8aec-c2c40f96f5e4">December 31</ix:nonNumeric>, 2021</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:2.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.906%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6Njk3YTljODg2YzBjNDEzN2E5ZGFiODk1ZTUxYTVkMzQvdGFibGVyYW5nZTo2OTdhOWM4ODZjMGM0MTM3YTlkYWI4OTVlNTFhNWQzNF8wLTAtMS0xLTIxMTE5_72fd969a-aa38-4f03-a60f-c33616f4dca1">&#168;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xNjQ5MjY3NDQ1NDQ0_c6740106-94ea-47ef-a068-fe363c78728c">001-39634</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xNjQ5MjY3NDQ1NDQ2_9b2d4ac3-5c31-4346-b5e4-6ae28fe8a701">Foghorn Therapeutics Inc.</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6NTI3YmIyODAwOWViNDAyNWE1OTQzNzEwYTYyNzZjN2YvdGFibGVyYW5nZTo1MjdiYjI4MDA5ZWI0MDI1YTU5NDM3MTBhNjI3NmM3Zl8wLTAtMS0xLTIxMTM4_ab1f20fc-51d4-49b4-9473-e2ac1416982e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6NTI3YmIyODAwOWViNDAyNWE1OTQzNzEwYTYyNzZjN2YvdGFibGVyYW5nZTo1MjdiYjI4MDA5ZWI0MDI1YTU5NDM3MTBhNjI3NmM3Zl8wLTItMS0xLTIxMTQx_d7e4c5df-a51c-4b10-9a91-b3ee2e48fd74">47-5271393</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(I.R.S. Employer<br/>Identification Number)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6NTI3YmIyODAwOWViNDAyNWE1OTQzNzEwYTYyNzZjN2YvdGFibGVyYW5nZTo1MjdiYjI4MDA5ZWI0MDI1YTU5NDM3MTBhNjI3NmM3Zl8zLTAtMS0xLTIxMTY5L3RleHRyZWdpb246YjU1MjAxNTFjZjk4NDc2ZjljZGZhMjJiODcxOGY1MGZfMTA5OTUxMTYyNzc4NDk_1195d4c0-1e1b-409c-a051-e01e30f069c2">500 Technology Square, Ste 700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6NTI3YmIyODAwOWViNDAyNWE1OTQzNzEwYTYyNzZjN2YvdGFibGVyYW5nZTo1MjdiYjI4MDA5ZWI0MDI1YTU5NDM3MTBhNjI3NmM3Zl8zLTAtMS0xLTIxMTY5L3RleHRyZWdpb246YjU1MjAxNTFjZjk4NDc2ZjljZGZhMjJiODcxOGY1MGZfMTA5OTUxMTYyNzc4NjE_b66ad989-9079-4f16-9ed4-9ce496af57a8">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6NTI3YmIyODAwOWViNDAyNWE1OTQzNzEwYTYyNzZjN2YvdGFibGVyYW5nZTo1MjdiYjI4MDA5ZWI0MDI1YTU5NDM3MTBhNjI3NmM3Zl8zLTAtMS0xLTIxMTY5L3RleHRyZWdpb246YjU1MjAxNTFjZjk4NDc2ZjljZGZhMjJiODcxOGY1MGZfMTA5OTUxMTYyNzc4Nzc_6d9f2416-1eff-4aae-81e6-e10c9eb4a997">Massachusetts</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6NTI3YmIyODAwOWViNDAyNWE1OTQzNzEwYTYyNzZjN2YvdGFibGVyYW5nZTo1MjdiYjI4MDA5ZWI0MDI1YTU5NDM3MTBhNjI3NmM3Zl8zLTItMS0xLTIxMTg4_4f65da7a-9c24-4d90-b11d-11f62559476e">02139</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xMTU0NDg3MjA5NTQzMg_25a9cbc8-4f9d-4774-90f9-d4e052923ef7">617</ix:nonNumeric>-<ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xMTU0NDg3MjA5NTQzNg_1838088d-6f12-4c20-bfea-272142666611">586-3100</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Title&#160;of&#160;each&#160;class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Name&#160;of&#160;each&#160;exchange on&#160;which&#160;registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6OWI0MjQzYjk5NzVmNGFkODgzYWQ4MzkyNTk0NmU4NjQvdGFibGVyYW5nZTo5YjQyNDNiOTk3NWY0YWQ4ODNhZDgzOTI1OTQ2ZTg2NF8xLTAtMS0xLTIxMjA4_0bbd7b06-dbc5-4865-b4a9-18a55c8037f8">Common&#160;Stock,&#160;$0.0001&#160;Par&#160;Value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6OWI0MjQzYjk5NzVmNGFkODgzYWQ4MzkyNTk0NmU4NjQvdGFibGVyYW5nZTo5YjQyNDNiOTk3NWY0YWQ4ODNhZDgzOTI1OTQ2ZTg2NF8xLTItMS0xLTIxMjA4_46b7cdf1-c738-4c39-833c-5c05d77a827d">FHTX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6OWI0MjQzYjk5NzVmNGFkODgzYWQ4MzkyNTk0NmU4NjQvdGFibGVyYW5nZTo5YjQyNDNiOTk3NWY0YWQ4ODNhZDgzOTI1OTQ2ZTg2NF8xLTQtMS0xLTIxMjA4_e05cf969-0630-47e2-9947-27371176a4d9">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;<ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xMTU0NDg3MjA5NTQ5Mg_a3692ac9-f5f4-49e5-9773-4dc41a82a7a3">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xMTU0NDg3MjA5NTQ0Ng_36f08fa1-67a2-4162-8ba7-cd6810549c32">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xMTU0NDg3MjA5NTQ0Nw_97ea975f-2b42-48bc-b8a2-ce899cdf1ae6">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xMTU0NDg3MjA5NTQ0OA_1264a950-0b2c-49eb-8fea-9586844616c6">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#168;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#168;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6NTFlYzM2YTFhMGE2NDEyNTgwMTlhZDkwNDE1MzlmNTkvdGFibGVyYW5nZTo1MWVjMzZhMWEwYTY0MTI1ODAxOWFkOTA0MTUzOWY1OV8yLTAtMS0xLTIxMzE1_1c2f81d9-b8e1-4f01-bb18-87a40fabeb32">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6NTFlYzM2YTFhMGE2NDEyNTgwMTlhZDkwNDE1MzlmNTkvdGFibGVyYW5nZTo1MWVjMzZhMWEwYTY0MTI1ODAxOWFkOTA0MTUzOWY1OV8yLTQtMS0xLTIxMzE3_b29206c4-b0eb-465a-9d99-db8b6487a56c">x</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6NTFlYzM2YTFhMGE2NDEyNTgwMTlhZDkwNDE1MzlmNTkvdGFibGVyYW5nZTo1MWVjMzZhMWEwYTY0MTI1ODAxOWFkOTA0MTUzOWY1OV80LTQtMS0xLTIxMzIx_1146f895-0b80-47de-9413-bbfdd8102a7f">x</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xMTU0NDg3MjA5NTQ0OQ_071ec36d-35cd-4aa9-a13a-76c836a1b2ce">&#168;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xMTU0NDg3MjA5NTQ1MA_0e8240fc-f11a-42d6-96de-a1dee6fe282f">&#168;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xMTU0NDg3MjA5NTQ1MQ_d1fa1652-11a3-44bd-8a4c-7966a68314b0">x</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The aggregate market value of common stock held by non-affiliates of the registrant computed by reference to the price of the registrant&#8217;s common stock as of June 30, 2021, the last business day of the registrant's most recently completed second fiscal quarter, was approximately (based on the last reported sale price on the NASDAQ Global Market as of such date) $<ix:nonFraction unitRef="usd" contextRef="i2f6e00ec5e724389b05915a0622249e4_I20210630" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xMTU0NDg3MjA5NTQ1Mw_9fed4f7c-a0e3-485e-a33b-cac8182c39d5">208.8</ix:nonFraction>&#160;million.</span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of February&#160;25, 2022 there were <ix:nonFraction unitRef="shares" contextRef="i2f120daef0e24742bb1b5aace13d4d8f_I20220225" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xMTU0NDg3MjA5NTQ2OQ_44d01385-35f9-474e-9a2a-4c4baca6514a">41,421,964</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.0001 per share, outstanding.</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i523559815e87485cb6a9895707f43a02_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foghorn Therapeutics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_10">PART I</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_13">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_13">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_19">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_19">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_22">Item&#160;1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_22">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_25">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_25">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_25">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_28">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_28">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_31">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_31">74</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_34">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_37">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_37">75</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_40">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_40">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_40">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_43">Item&#160;7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_43">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_64">Item&#160;7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_64">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_64">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_67">Item&#160;8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_67">Consolidated Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_67">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_172">Item&#160;9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_172">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_172">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_175">Item&#160;9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_175">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_175">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_178">Item&#160;9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_178">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_178">110</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_1887">Item&#160;9</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_1887">C</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_1887">.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_1887">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_1887">111</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_181">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_184">Item&#160;10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_184">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_184">112</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_187">Item&#160;11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_187">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_187">119</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_190">Item&#160;12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_190">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_190">125</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_193">Item&#160;13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_193">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_193">127</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_196">Item&#160;14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_196">Principal Account</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_196">ant</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_196"> Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_196">128</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_199">PART&#160;IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_202">Item&#160;15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_202">Exhibit</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_202"> and</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_202"> Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_202">130</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_208">Item&#160;16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_208">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_208">130</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_211">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_211">134</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements that are based on management&#8217;s beliefs and assumptions and on information currently available to management. All statements other than statements of historical facts contained in this Annual Report on Form 10-K are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning:</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the initiation, timing, progress and results of our research and development programs, preclinical and clinical studies;</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to advance any product candidates that we may develop and to successfully complete preclinical and clinical studies;</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to leverage our initial programs to develop additional product candidates using our Gene Traffic Control platform;</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">the impact of the COVID-19 pandemic on our and our collaborators&#8217; business operations, including our research and development programs and preclinical and clinical studies, as well as recent geopolitical instability and other developments that may negatively impact the ability to utilize contract development and manufacturing organizations, or CDMOs, and contract research organizations, or CROs, that are located outside of the United States;</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">developments related to our competitors and our industry;</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to expand the target populations of our programs and the availability of patients for clinical testing;</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to obtain regulatory approval for FHD-286, FHD-609 and any future product candidates from the U.S. Food and Drug Administration, or FDA, and other regulatory authorities;</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to identify and enter into future license agreements and collaborations;</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to continue to rely on our CDMOs and CROs for our manufacturing and research needs;</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulatory developments in the United States and foreign countries;</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to attract and retain key scientific and management personnel; and</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the scope of protection we are able to establish, maintain and enforce for intellectual property rights covering FHD-286, FHD-609, our future products and our Gene Traffic Control</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Annual Report on Form 10-K are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of known and unknown risks, uncertainties and assumptions, including those described under the section entitled &#8220;Item 1A. Risk&#160;Factors&#8221; in this Annual Report on Form 10-K. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. Moreover, we operate in an evolving environment. New risks and uncertainties may emerge from time to time, and it is not possible for management to predict all risks and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF RISK FACTORS</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary and other risks that we face can be found below under the heading &#8220;Item 1A. Risk Factors&#8221; and should be carefully considered, together with other information in this Annual Report on Form 10-K and our other filings with the SEC, before making an investment decision regarding our common stock.</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We have a limited operating history and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability.</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We have incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our research and product development programs or future commercialization efforts.</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We are heavily dependent on the success of our product candidates, which are in preclinical and Phase&#160;1 clinical development. We may not be successful in our efforts to identify and develop potential product candidates. If these efforts are unsuccessful, or if we experience significant delays, we may never become a commercial stage company or generate any revenues, and our business could be materially harmed.</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We may not be able to file Investigational New Drug Applications, or INDs, or IND amendments to commence clinical trials of our product candidates on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed..</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">There is substantial competition in our field, which may result in others developing or commercializing products before we do.</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Our product candidates utilize novel mechanisms of action, which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or discovery of unknown or unanticipated adverse effects.</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We are highly dependent on our key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">If we are unable to adequately protect our proprietary technology and platform or obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and products may be impaired.</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The continuing outbreak of COVID-19 in the United States and other countries may adversely affect our business and the market price of our common stock.</span></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, which would delay or prevent regulatory approval of the product candidates, limit their commercial potential or result in significant negative consequences following any potential marketing approval.</span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i523559815e87485cb6a9895707f43a02_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless the context otherwise requires, the terms &#8220;Foghorn,&#8221; &#8220;Foghorn Therapeutics,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; relate to Foghorn Therapeutics Inc., together with its consolidated subsidiary.</span></div><div id="i523559815e87485cb6a9895707f43a02_13"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The chromatin regulatory system orchestrates gene expression</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the turning on and off of genes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which is fundamental to how all our cells function. Breakdowns in this system lead to a wide range of diseases impacting millions of patients. Understanding the mechanism of how this system works could lead to an entirely new class of therapeutics. To our knowledge, we are the only company with the ability to study the chromatin regulatory system at scale, in context, and in an integrated way.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system an untapped opportunity for therapeutic intervention in oncology and a wide spectrum of other diseases. Our proprietary Gene Traffic Control</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within the system. Breakdowns in the chromatin regulatory system are associated with over 50&#160;percent of all cancers. Addressing these breakdowns could potentially provide therapies for over 2.5&#160;million patients with cancer. Consequently, we are initially focused in oncology. We are developing FHD-286, a selective, allosteric ATPase inhibitor and are currently enrolling two separate Phase 1 studies in (i) metastatic uveal melanoma and (ii) relapsed and/or refractory acute myeloid leukemia, or AML, and myelodysplastic syndrome, or MDS. We are developing FHD-609, a targeted protein degrader, and are currently enrolling a Phase 1 study in synovial sarcoma. Our vision is to use our Gene Traffic Control platform to discover and develop drugs in oncology and other therapeutic areas, including virology, autoimmune disease and neurology.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">How the Chromatin Regulatory System Orchestrates Gene Expression</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order for DNA to fit in the nucleus of each human cell, DNA is densely packed into what is called chromatin, which needs to be unpacked as a necessary first step to allow for gene expression. Cells have evolved a system known as the chromatin regulatory system that can locate and unpack particular regions of chromatin, thereby enabling and orchestrating gene expression. Two of the major components of the chromatin regulatory system are chromatin remodeling complexes and transcription factors, and these components work in concert to orchestrate gene expression.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Gene Traffic Control Platform</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have built our proprietary Gene Traffic Control platform to give us an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within the system. We are initially using our Gene Traffic Control platform in oncology. In cancer, the mutations that are in or impinge on the chromatin regulatory system create genetically determined dependencies, on which the cancer cells rely for survival. These genetic dependencies result in diseased cell vulnerabilities, creating potential opportunities to selectively drug and kill diseased cells while minimizing impact to healthy cells. With our platform, we are able to produce components of the chromatin regulatory system at scale, thereby allowing us to identify these genetic dependencies, understand their mechanism and target their vulnerabilities. We combine our genomic and epi-genomic tools, our proprietary high throughput screening technology and our expertise in medicinal chemistry to develop enzymatic inhibitors, protein degraders and transcription factor disruptors that target the chromatin regulatory system. While initially focused in oncology, we believe our platform is broadly applicable across other disease areas.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Gene Traffic Control platform encompasses the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Target Identification and Validation&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use genomic screens, and a suite of epi-genome sequencing and computational tools, including aspects of artificial intelligence, or AI, and machine learning, to characterize, identify, and validate targets within the chromatin regulatory system. Our epi-genome sequencing tools allow us to understand the mechanisms of how our drugs are modifying the chromatin structure. Our platform allows for the identification of genetically determined dependencies associated with the chromatin regulatory system.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Production of Chromatin Regulatory System Components at Scale and Proprietary Assays&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have built unique capabilities to purify and synthesize chromatin remodeling complexes and transcription factors. These capabilities allow us to study the chromatin regulatory system at scale and in a context that, to our knowledge, is unavailable to others, and yields unique insights that are critical to systematically drugging this system.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Discovery and Optimization of Chemical Matter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We perform proprietary high throughput screens that leverage our ability to produce the chromatin regulatory system components at scale. For example, we are able to screen for inhibitors of chromatin remodeling complex activity, for binders that we can turn into protein degraders, and for disruptors of transcription factor-chromatin remodeling complex interactions. Once we identify hits from our screens, we use our unique suite of assays involving the relevant component of the chromatin regulatory system to characterize, validate, and optimize our chemical matter.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Targeted Protein Degradation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In cases where our drugging efforts are directed at targets that have no enzymatic activity, we seek to degrade the protein of interest. We have built extensive protein degrader capabilities encompassing linkers and E3 ligase binders, assays to measure protein degradation and guide optimization, and ternary complex modeling. After completing screens and finding small molecule binders to the target of interest, we use our protein degradation know-how to convert binders into selective protein degraders.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Translation to Clinic and Identification of Biomarkers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Early in the drug discovery process, we use various genome and epi-genome analyses to understand the mechanism of the genetic dependency of the disease on the chromatin regulatory system. Our understanding of the mechanism of the dependency enables us to identify biomarkers for patient identification and treatment. We seek to enrich our clinical studies with the genetically relevant patient populations that are most likely to benefit from treatment.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using our proprietary Gene Traffic Control platform, we are developing a broad pipeline of product candidates that target genetically determined dependencies within the chromatin regulatory system. Our current pipeline of product candidates and discovery programs is focused on oncology and is shown below, along with anticipated milestones.</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><img src="fhtx-20211231_g1.jpg" alt="fhtx-20211231_g1.jpg" style="height:326px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the chromatin regulatory system, we have initially focused our development efforts on the BAF chromatin remodeling complex, or the BAF complex, the most mutated among a family of chromatin remodeling complexes, and its interactions with transcription factors. Our precision approach consists of designing novel small molecules to inhibit the ATPase activity of BAF complexes, to selectively degrade mutated or dependent subunits, or to disrupt the interaction between the BAF complex and associated transcription factors. We believe our platform is broadly applicable to other chromatin remodeling complexes and transcription factors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first product candidate, FHD-286, is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM, that we are initially developing in two phase one studies for the potential treatment of (i) metastatic uveal melanoma and (ii) relapsed and/or refractory AML and MDS and. BRG1 and BRM are two highly similar proteins that are the ATPases, or the catalytic engines, across all forms of BAF. In our preclinical studies, we have observed in both AML and uveal melanoma animal xenograft models anti-tumor effects at tolerated doses. As FHD-286 progresses through clinical testing, our intention is to expand into other indications beyond uveal melanoma, AML and MDS.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second product candidate, FHD-609, is a highly potent, selective and intravenous, small molecule protein degrader of BRD9, a component of a form of the BAF complex that we are developing in a Phase 1 clinical study in synovial sarcoma. Nearly all synovial sarcoma cancers contain a translocation, a type of mutation, between a BAF subunit gene, SS18, and another set of genes, SSX1, SSX2 and SSX4. These mutations render the cancer genetically dependent upon BRD9. FHD-609 has two domains: one that binds with high potency and selectivity to BRD9 and the other that binds to a receptor on the E3 ligase complex that directs proteins for destruction. In our preclinical studies in synovial sarcoma animal xenograft models, we have observed anti-tumor effects at tolerated doses. As FHD-609 progresses through clinical testing, our intention is to expand into other indications beyond synovial sarcoma.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have used our Gene Traffic Control platform to generate additional programs targeting both large and small patient populations. Examples of programs targeting large populations include selective BRM and selective ARID1B modulators, which have potential implications in over 100,000 cancer patients and 175,000 cancer patients that harbor BRG1 and ARID1A mutations respectively. We are pursuing other programs with genetically determined dependencies on other chromatin remodeling complexes beyond the BAF complex.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December of 2021, we entered into a strategic collaboration with Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company, to create novel oncology medicines by applying Foghorn&#8217;s proprietary Gene Traffic Control platform. The collaboration includes a co-development and co-commercialization agreement for the aforementioned selective BRM oncology program and an additional undisclosed oncology target. In addition, the collaboration includes three additional discovery programs using Foghorn&#8217;s proprietary Gene Traffic Control platform. Under the terms of the agreement, Foghorn received upfront consideration of $300 million in cash for the collaboration agreement and an equity investment by Lilly of $80 million in shares of Foghorn common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the BRM-selective program and the additional undisclosed target program, Foghorn will lead discovery and early research activities, while Lilly will lead development and commercialization activities with participation from Foghorn in operational activities and cost sharing. Foghorn and Lilly will share 50/50 in the U.S. economics, and Foghorn is eligible to receive royalties on Ex-U.S. sales starting in the low double-digit range and escalating into the twenties based on revenue levels.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the additional discovery programs, Foghorn will lead discovery and early research activities. Foghorn may receive up to a total of $1.3 billion in potential development and commercialization milestones. Additionally, Foghorn will have an option to participate in a percentage of the U.S. economics and is eligible to receive tiered royalties from the mid-single digit to low-double digit range on sales outside the U.S.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are developing compounds that disrupt the interactions between the transcription factors and BAF complexes. We believe that there are more than 100 transcription factors that could be amenable to our approach, one that disrupts the interaction of the transcription factor with the BAF complex. Preclinical activities of these early programs are underway.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approach to disrupting the interactions between transcription factors and the BAF complex is the basis of a collaboration signed with Merck Sharp&#160;&amp; Dohme Corp., or Merck, in July 2020. In this collaboration, we are applying our Gene Traffic Control platform to identify disruptors of a single predetermined transcription factor. As part of the collaboration, we received an upfront payment of $15.0&#160;million, and are also eligible to receive up to $245.0&#160;million upon achievement of specified research, development and regulatory milestones by any product candidate generated by the collaboration, and up to $165.0&#160;million upon achievement of specified sales-based milestones.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Team</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have assembled a team with deep scientific, clinical, manufacturing, business, and leadership expertise in biotechnology, platform research, drug discovery, and development. Our management team has extensive experience discovering, developing, and commercializing drugs to treat patients with serious diseases. Adrian Gottschalk, our President and Chief Executive Officer, has more than 15 years of experience as a biopharmaceutical executive. Prior to joining Foghorn, Mr.&#160;Gottschalk served in various roles at Biogen, Inc., where he was most recently Senior Vice President and Neurodegeneration Therapeutic Area Head. In this role, he was responsible for late-stage development and commercialization of drugs to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease, and amyotrophic lateral sclerosis. Our Chief Medical Officer, Samuel Agresta, M.D., M.P.H.&#160;&amp; T.M., previously served as Chief Medical Officer at Infinity Pharmaceuticals and led the development of the marketed oncology drugs TIBSOVO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and IDHIFA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at Agios. Steven Bellon, PhD. was appointed to serve as the Company&#8217;s Chief Scientific Officer, effective as of January 10, 2022.  Dr. Bellon joined Foghorn Therapeutics in 2016 as head of drug discovery, bringing more than 20 years of drug discovery experience from multiple drug classes. Our research efforts are also guided by world-class scientists and physicians on our Scientific Advisory Board, including David Schenkein, M.D., formerly the chief executive officer of Agios and presently a general partner and co-leader of Google Ventures life science team, Tony </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kouzarides, Ph.D., F.Med.Sci., FRS, professor of cancer biology at the University of Cambridge and deputy director of the Gurdon Institute, United Kingdom, Gerald Crabtree, M.D., founder of Ariad Pharmaceuticals, a Howard Hughes Medical Institute investigator and professor at Stanford University, and Charles Sawyers, M.D., chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer center, a Howard Hughes Medical Institute investigator, and past president of the American Association for Cancer Research, or AACR. We have assembled an exceptional team of 119 employees as of December&#160;31, 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Beginnings: Foghorn Therapeutics and Flagship Pioneering</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foghorn Therapeutics was founded in 2015 by Flagship Pioneering, working together with academic co-founders Dr.&#160;Cigall Kadoch (Dana Farber Cancer Institute, Harvard, Broad Institute and Howard Hughes Medical Institute) and Dr.&#160;Gerald Crabtree (Stanford, Howard Hughes Medical Institute) to develop and commercialize a new category of first-in-class therapeutics to treat patients with cancer and other serious diseases.&#160;Our platform was inspired by work in the academic co-founders&#8217; laboratories at the Dana Farber Cancer Institute and Stanford.&#160;This seminal work made it possible to understand how mutations cause disease by disrupting the machinery&#8212;the chromatin regulatory system&#8212;that orchestrates how cells turn genes on and off. Such mutations are associated with up to 50&#160;percent of cancer and play roles in many other diseases. A Flagship Labs innovation team at Flagship Pioneering, led by Flagship Managing Partner, Dr.&#160;Douglas Cole, and, subsequently, Foghorn&#8217;s research and development team, established a fully integrated drug discovery platform based on this seminal work, which we call our Gene Traffic Control platform.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mission is to leverage our unique insights into the chromatin regulatory system to pioneer the discovery, development and commercialization of a new class of therapies that transform the lives of patients suffering from a wide spectrum of diseases with high unmet need.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approach is to identify and drug genetically determined dependencies within the chromatin regulatory system. Our initial focus is in cancer with a precision oncology approach. Every program we pursue is based on a genetic dependency on the chromatin regulatory system.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve our mission, we are executing a strategy with the following key elements:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Advance our lead precision oncology product candidates, FHD-286 and FHD-609, through clinical development in patients with select solid tumors and hematological cancers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> FHD-286 and FHD-609 are a highly selective and potent enzymatic inhibitor and protein degrader, respectively, that target two different components of a chromatin remodeling complex. We believe our lead product candidates have the potential to address significant unmet medical needs across multiple oncology indications. We are conducting separate Phase 1 studies for (i) metastatic uveal melanoma and (ii) relapsed and/or refractory AML and MDS and expect initial clinical data for FHD-286 in the first half of 2022. We began dosing patients with FHD-609 in 2021 for the treatment of synovial sarcoma.  We anticipate initial clinical data for FHD-609 as early as the first half of 2022.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Expand our precision oncology pipeline by developing proprietary enzymatic inhibitors, degraders and disruptors that target genetically defined dependencies within the chromatin regulatory system.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on our unique insights and understanding of the chromatin regulatory system, we continue to develop proprietary selective inhibitors, protein degraders and disruptors that modulate both chromatin remodeling complexes and transcription factors, two key components of the chromatin regulatory system. For example, using our proprietary platform, we are pursuing two distinct targets, BRM and ARID1B, that have genetically determined dependencies within the chromatin regulatory system with combined potential impact in over 275,000 cancer patients. We intend to utilize our platform to consistently develop novel product candidates to further deepen our precision oncology pipeline. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Harness our platform to develop novel product candidates to address therapeutic areas beyond oncology.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As the orchestrator of gene expression, the chromatin regulatory system has implications in a large array of diseases. Based on academic literature and our research efforts, we believe our platform has significant potential across multiple therapeutic areas. We are committed to applying our Gene Traffic Control platform to additional therapeutic areas including virology, autoimmune diseases and neurology. We believe our platform will allow us to continue to build a long-term pipeline of novel product candidates to address areas of high unmet medical need.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Continue to enhance our platform to extend our leading position in developing novel therapeutics targeting the chromatin regulatory system.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our platform and unique understanding of the chromatin regulatory system is built upon the groundbreaking work of our academic co-founders and has been further developed by our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experienced team. We are committed to continuously integrating new insights, tools, technologies and capabilities to enhance our platform.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Selectively enter into additional strategic partnerships to maximize the potential of our pipeline and our platform.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Given the breadth of opportunities that are implicated by the chromatin regulatory system and the versatility of our platform, we may opportunistically enter into strategic collaborations intended to advance and accelerate our development programs, expand into new therapeutic areas and enhance the capabilities of our platform. In July 2020, we entered into a collaboration with Merck to discover and develop novel oncology therapeutics against a transcription factor target.  In December 2021, we entered into a strategic collaboration with Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company, to create novel oncology medicines. The Loxo Oncology collaboration includes a co-development and co-commercialization agreement for the selective BRM oncology program and an additional undisclosed oncology target. In addition, the collaboration includes three additional discovery programs using Foghorn&#8217;s proprietary Gene Traffic Control platform.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chromatin Regulatory System: An Untapped Opportunity for Therapeutic Intervention</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The chromatin regulatory system orchestrates gene expression. In order for DNA to fit in the nucleus of each human cell, it is densely packed into what is called chromatin. This packing of DNA occurs by winding it around a core of proteins called histones to form what is known as a nucleosome, having the appearance of thread (the DNA) wrapped around a spool (the histones). Multiple nucleosomes cluster further to form more densely packed chromatin. Before DNA can be transcribed to RNA and then translated into protein, chromatin needs to be &#8220;unpacked&#8221; to allow access for the cellular machinery responsible for DNA transcription. Cells have therefore evolved a system known as the chromatin regulatory system that can locate and unpack particular regions of the chromatin to orchestrate and allow for gene expression.</span></div><div style="margin-top:12pt;text-align:center"><img src="fhtx-20211231_g2.jpg" alt="fhtx-20211231_g2.jpg" style="height:178px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"/></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 1: Chromatin Regulatory System Biology: Chromatin remodeling complexes and transcription factors work in concert to unpack chromatin to enable gene expression. The left portion of the figure shows &#8220;packed&#8221; or closed chromatin and the right portion of the figure shows &#8220;unpacked&#8221; or open chromatin with DNA highlighted in green.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Two of the major components of the chromatin regulatory system are chromatin remodeling complexes and transcription factors. Transcription factors specify the locations of genes to be transcribed by binding to specific locations on DNA. Chromatin remodeling complexes, guided by transcription factors, unpack the chromatin to expose DNA for transcription. These two components work in concert in both healthy and diseased cells. While chromatin remodeling complexes have been known in the scientific community for decades, disease relevance was not initially recognized, and consequently chromatin remodeling complexes were underappreciated as a set of relevant drug targets. Transcription factors, on the other hand, while linked decades ago to cancer and understood as relevant targets, have led to few approved oncology drugs, as companies seeking to drug these targets have lacked a systematic approach to doing so. Recently, ground-breaking work by our academic co-founders has revealed that alterations in chromatin remodeling complexes as well as their interactions with transcription factors are strongly associated with various cancers. Broad cancer sequencing initiatives have shown that mutations in the chromatin regulatory system are found in over 50&#160;percent of all cancers, potentially impacting over 2.5&#160;million cancer patients across the United States, Europe and Japan. Further work in the field by our founders and others has highlighted the association of this system in other therapeutic areas, including virology, autoimmune disease and neurology, implying even greater potential for therapeutic intervention.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vulnerabilities in Cancer Created by Genetic Dependencies on the Chromatin Regulatory System</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancer cells often contain many different mutations that lead to their abnormal growth and proliferation. Within cancer cells, these mutations give rise to genetically determined dependencies, upon which the cancer cells rely for their survival. The creation of these dependencies can be directly related to the mutation or to other cellular biology, thereby creating vulnerabilities for cancer cells and the opportunity for therapeutic intervention. In contrast, healthy cells, which lack these mutations and therefore these dependencies, are less susceptible to a therapeutic that targets these genetically determined dependencies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are three primary mechanisms by which genetically determined dependencies on the chromatin regulatory system arise. They are:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Mutations in chromatin remodeling complexes</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Mutations or overexpression of transcription factors</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Mutations elsewhere in the cell that impinge on chromatin remodeling complexes and/or transcription factors</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our platform enables us to identify these genetic dependencies and thereby discover the cancer cells&#8217; vulnerability within the chromatin regulatory system. We believe these vulnerabilities create opportunities to selectively drug and kill cancer cells while minimizing impact to healthy cells.&#160;These genetically determined dependencies enable us to select specific patient populations and enrich our clinical trials using a precision approach. Every program we pursue is based on a genetically determined dependency on the chromatin regulatory system.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Initial Focus&#8212;BAF Complexes and Associated Transcription Factors</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are 28 types of chromatin remodeling complexes. All types of chromatin remodeling complexes use ATP as an energy source for opening and closing chromatin. These remodeling complexes contain a catalytic subunit that is capable of breaking down ATP, known as the ATPase. The ATPase serves as the catalytic engine that drives the function of each chromatin remodeling complex. The breakdown or hydrolysis of each ATP molecule by the ATPase creates energy that, in turn, drives chromatin remodeling. These chromatin remodeling complexes are mutated in approximately 25&#160;percent of cancers.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BAF, which stands for BRG1/BRM-associated factors, one type of chromatin remodeling complex, is mutated in approximately 20&#160;percent of cancers, thus being the most mutated in the family of ATPase chromatin remodelers and among the most mutated targets in cancer. Given the breadth of mutations in cancer, the BAF complex is our initial focus among the ATPase dependent chromatin remodeling complexes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BAF complex is a multicomponent protein structure containing twelve to fifteen protein subunits taken from a larger set of a possible 29 subunits. Three common forms of BAF are known as canonical BAF, or cBAF; non-canonical BAF, or ncBAF; and polybromo BAF, or PBAF. While the exact compositions of these forms of BAF are different, each form contains a number of common subunits, one such being the ATPase catalytic subunit. Each BAF complex contains one of two possible ATPases, either ATPase known as BRM, also known as SMARCA2, or ATPase known as BRG1, also known as SMARCA4.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Different cell types and tissues contain different forms of BAF. This cell and tissue specificity gives rise to the possibility of additional pharmacological selectivity when drugging potential targets.</span></div><div style="margin-top:12pt;text-align:center"><img src="fhtx-20211231_g3.jpg" alt="fhtx-20211231_g3.jpg" style="height:192px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 2. Schematic depicting biochemical subunit compositions of mammalian BAF, ncBAF and PBAF complexes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><img src="fhtx-20211231_g4.jpg" alt="fhtx-20211231_g4.jpg" style="height:284px;margin-bottom:5pt;vertical-align:text-bottom;width:513px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 3. Genetic alterations are commonly found in subunits of the BAF complex in tumors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BAF complex, when aggregating mutations across all of its subunits, is the second most mutated target to the well-known cancer target TP53. Genetic alterations of various subunits of the BAF complex have been observed in a wide range of cancers. These include but are not limited to the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">More than 90&#160;percent of ovarian cancer patients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">34&#160;percent of uterine endometrial patients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">34&#160;percent of stomach cancer patients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">29&#160;percent of bladder cancer patients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">28&#160;percent of non-small cell lung cancer, or NSCLC, patients; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">27&#160;percent of skin cancer patients.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following mechanistic insights provide strategies to target the BAF complex in cancer:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Dependency exists between BAF complex subunits;</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One example is:</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">In some cancer cells, the gene encoding BRG1, a catalytic subunit of the BAF complex, is mutated causing a loss of function in BRG1</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Often this loss of function leads to a dependency on BRM, a similar protein to BRG1 that is the other catalytic subunit of the BAF complex</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">This loss of BRG1 and subsequent dependency on BRM creates a vulnerability by rendering these cancer cells highly sensitive to targeting BRM</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Mutations elsewhere in the cell confer a dependency on the BAF complex;</span></div><div style="margin-top:6pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One example is:</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Mutations in G-protein coupled receptors (GNAQ/GNA11) are found in 85&#160;percent to 95&#160;percent of uveal melanoma, a cancer of the eye</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">In uveal melanoma cell lines with these mutations, we have established a dependency on two transcription factors, MITF and SOX10.</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">These two transcriptions interact with the BAF complex</span></div><div style="margin-top:6pt;padding-left:81pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Targeting the BAF complex then inhibits MITF and SOX10 mediated transcription</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transcription factors, the proteins that guide the chromatin remodeling complexes, help determine which genes are expressed and have long been desirable but elusive targets for drug discovery efforts. Work by our academic co-founder Cigall Kadoch, as well as others in the field, revealed that transcription factors work in concert with chromatin remodeling complexes, BAF as one example, to orchestrate gene expression. A transcription factor recognizes specific guidepost-like sequences, or locations, on DNA. The transcription factor binds to the chromatin remodeling complex and in doing so directs the remodeling complex to the appropriate location on chromatin. Once recruited to the appropriate location, the chromatin remodeling complex unpacks the chromatin, exposing the DNA and allowing transcription machinery to transcribe the corresponding gene.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some transcription factors, such as the estrogen receptor, or ER, have long been the targets of approved and efficacious drugs for the treatment of cancers such as breast cancer. However, the majority of transcription factors have not been amenable to traditional small molecule drug inhibition. While directly blocking the DNA binding site on transcription factors would be an effective way of inhibiting their activity, it is usually not possible to find small molecules that can bind to these sites with the potency and selectivity needed to advance as therapeutics.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Different healthy cell types, such as heart, brain, or muscle cells, use different types of transcription factors. In cancer cells, mutated and/or abnormal levels of specific transcription factors are found. Because many transcription factors are cell and tissue specific, there is the possibility of additional pharmacological selectivity when drugging potential transcription factor-chromatin remodeling complex interactions. We believe that there are more than 100 transcription factors that could be amenable to our approach of disrupting the interactions of transcription factors with the BAF complex.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Approach to Drugging the Chromatin Regulatory System</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on developing small molecule product candidates that target the chromatin regulatory system through the use of enzyme inhibitors, protein degraders and transcription factor disruptors.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Enzyme inhibitors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These candidates have the potential to act on targets such as the ATPases BRG1 and BRM of the BAF complex. Our screening capabilities enable us to find allosteric inhibitors which afford additional selectivity over orthosteric, or direct, inhibitors.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Protein degraders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These candidates are bifunctional degraders in which one portion of the molecule specifically recognizes the target while the other portion is able to direct the destruction of the target by the cell&#8217;s protein degradation system.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Transcription factor disruptors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These candidates will be direct small-molecule disruptors of the protein-protein interactions between transcription factors and chromatin remodeling complexes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We leverage the appropriate mechanism based on the target in the chromatin regulatory system. In some cases, we may take multiple approaches and remain modality agnostic in order to ensure we achieve the best approach and most appropriate molecule.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The two main approaches that we are taking to drugging chromatin remodeling complexes are inhibiting its ATPase activity and degrading mutated or dependent subunits within the chromatin remodeling complex. We are taking a different approach to modulating the activity of transcription factors than previously attempted by the field. We believe this approach can be applied across the broad set of chromatin remodeling complexes and transcription factors with which they interact, as illustrated by the BAF complex. Because transcription factors require collaboration with the BAF complex, disrupting the interaction between the two shuts down the ability of the transcription factor to drive transcription. Our approach is to find small molecule disruptors that bind to either the transcription factor or the BAF complex in order to break the interaction between the two. In order to understand whether it is possible to selectively drug these interactions, there are two important aspects that need to be understood. One is where specifically the transcription factor binds to the BAF complex and the second is how tightly it binds.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our work, we have observed that individual transcription factors bind to the BAF complex at specific sites rather than all binding to a single site, implying that it should be possible to specifically interfere with the binding of one transcription factor to the BAF complex without affecting the binding of every other transcription factor. This is a critical success factor for the specificity of drug candidates binding to the BAF complex. We have also observed that the potencies of these interactions are roughly equivalent to those observed in other protein-protein interactions that have been successfully disrupted by small molecule drugs. Because many transcription factors are cell and tissue specific, there is the possibility of additional pharmacological selectivity when drugging potential transcription factor-chromatin remodeling complex interactions. We believe these findings provide the opportunity to systematically discover and develop a novel class of product candidates that are specific, selective and that will be designed to disrupt the interaction between transcription factors and the BAF complex.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><img src="fhtx-20211231_g5.jpg" alt="fhtx-20211231_g5.jpg" style="height:316px;margin-bottom:5pt;vertical-align:text-bottom;width:533px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 4. We are disrupting transcription factor activity by blocking interactions with the BAF complex.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Gene Traffic Control Platform</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The chromatin regulatory system has remained an untapped opportunity for therapeutic intervention due to the inability to systematically characterize and study the chromatin remodeling complexes and associated transcription factors. Building upon the groundbreaking discoveries of our academic co-founders, we have developed our proprietary Gene Traffic Control platform which allows us to identify and validate targets within the chromatin regulatory system. We have unique capabilities to isolate, synthesize, characterize, and interrogate the BAF complex at a level of scale, precision, and efficiency, that to our knowledge, no others have achieved. We have unique capabilities to understand how transcription factors interact with the BAF complex and have generated unique insights into where and how transcription factors bind. We believe our platform is broadly applicable to other chromatin remodeling complexes and transcription factors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capabilities and insights have allowed for the development of a suite of unique biochemical, biophysical, structural, and functional assays. We use these assays to discover and optimize novel small molecule chemical matter which include enzymatic inhibitors, protein degraders, and transcription factor disruptors to various targets within the chromatin regulatory system. To our knowledge, we are the only company that has the ability to study the chromatin regulatory system at scale, in context, and in an integrated way.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Gene Traffic Control platform encompasses the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Target Identification and Validation</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Production of Chromatin Regulatory System Components at Scale&#160;and Proprietary Assays</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Discovery and Optimization of Chemical Matter</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Targeted Protein Degradation</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Translation to Clinic and Identification of Biomarkers</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key features and capabilities of our platform are described below:</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Target Identification and Validation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use genomic screens and a suite of epi-genome sequencing and computational tools to characterize, identify and validate targets within the chromatin regulatory system. Our epi-genome sequencing tools allow us to understand the mechanisms of how our drugs are modifying the chromatin structure. Our platform allows for the identification of genetically determined dependencies associated with the chromatin regulatory system. Specifically, we:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Conduct and leverage genomic screens to identify dependencies and relationships.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We utilize both broad and specific genomic screens to identify dependencies and relationships associated with the chromatin regulatory system. We use a mix of internal and external data sets that apply CRISPR and shRNA technology to understand relationships across and within a range of cancer cell lines.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Perform broad epi-genome sequencing to validate dependencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We apply cutting edge epi-genome sequencing tools in combination with proprietary tool compounds to further validate targets and enhance our understanding of the impact of drugging the chromatin regulatory system. These tools allow us to rapidly understand the gene expression profiles of specific cancer cell lines, the open / closed state of chromatin, and give us mechanistic understanding of how components of the system work together.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Apply machine learning&#160;and artificial intelligence to enhance discovery efforts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have built tools that allow us to mine and interpret external and internal datasets that aid in our discovery efforts yielding unbiased and unsupervised computer analyses to identify targets and genetic dependencies on the chromatin regulatory system and to further understand mechanism of action. Examples of external data sets include data from The Cancer Genome Atlas (TCGA) and the Broad Institute. Internal data sets include data from cell lines, data from xenograft models and epi-genomic information (RNA-seq, ATAC-seq, CHiP-seq, SNAP-seq). We also use these tools in the preclinical stage to evaluate cancer cell lines&#160;&amp; patient samples to identify biomarkers for patient stratification and patient population identification.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Validate dependencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Where possible, we endeavor to validate targets in various animal models with implanted cancer cells relevant to the disease we are aiming to treat. Specifically, we use mouse xenograft models with inducible CRISPR / shRNA to validate that knockdown of our target of interest results in tumor growth inhibition. We also apply epi-genome sequencing tools in the animal model setting to identify potential biomarkers.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Production of Chromatin Regulatory System Components at Scale&#160;and Proprietary Assays</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have built unique capabilities to purify and synthesize the BAF complex and transcription factors. These capabilities allow us to study the chromatin regulatory system at scale and in context that, to our knowledge, is unavailable to others, and yields insights that are critical to systematically drugging this system. Specifically, we:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Purify and synthesize chromatin remodeling complexes and transcription factors at scale.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our platform has the unique ability to purify and synthesize the BAF complex with potential applications to other chromatin remodeling complexes. Importantly, we are able to purify disease relevant and mutated forms of BAF directly from the cancer cell lines of interest. To our knowledge, we are the only company that has developed the ability to purify and manipulate BAF, sub-complexes of BAF, as well as its host of subunits, in quantities that enable us both to generate structural data to identify potential binding sites for drug candidates and to conduct high throughput screens of small molecule drug candidates against these sites.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Study chromatin remodeling complexes in context leading to relevant insights into the impact of drug intervention.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have found that the properties of subunits of BAF, such as BRG1 or BRM, are different when they are incorporated into the BAF complex than when we test them in isolation. For example, the catalytic activity of these subunits using nucleosomes was increased by over 15-fold when they were incorporated into the BAF complex compared to their activities in isolation (see Figure 5 below). This is the biologically relevant activity of the complex. Additionally, the ability to screen the full complex greatly improves the potential of finding allosteric modulators which may afford additional pharmacological selectivity. These examples underscore the importance of assaying and screening the full complex.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt">Utilize advanced analytical methods to develop and understand critical insights into how transcription factors interact with chromatin remodeling complexes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We integrate multiple technologies and methodologies, including high-throughput-screening, biophysics, affinity screening, and surface mapping to gain unparalleled insights into the chromatin regulatory system and how its primary two components, transcription factors and chromatin remodeling complexes, interact. Based on our protein-protein interaction mapping technology, we have determined precisely the binding sites of multiple transcription factors to the BAF complex, providing us with critical insights into how these factors bind to the BAF complex, and details on how these binding interactions can be disrupted using small, drug-like molecules.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our unique capabilities as applied to the BAF complex and associated transcription factors can be applied to other chromatin remodeling complexes and transcription factors. It is our intention to further leverage our capabilities on other chromatin remodeling complex targets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ATPase activity using nucleosome substrate</span></div><div style="margin-top:12pt;text-align:center"><img src="fhtx-20211231_g6.jpg" alt="fhtx-20211231_g6.jpg" style="height:157px;margin-bottom:5pt;vertical-align:text-bottom;width:284px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 5. ATPase activity of full BAF complex underscores the importance of assaying in the appropriate biological context.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discovery and Optimization of Chemical Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform proprietary high throughput screens that leverage our ability to produce the chromatin regulatory system components at scale. An example screen is the use of the fully assembled BAF complex which is specific to its mutated or disease relevant form (e.g., screening the BRM form of BAF which corresponds to BRG1 mutated cancer). Furthermore, we are able to screen the BAF complex when bound to a relevant transcription factor. We utilize both proprietary and publicly available chemical libraries in our screens.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once we find hits from our screens, we use our unique suite of assays involving the relevant component of the chromatin regulatory system to characterize, validate, and optimize our chemical matter. These assays provide us with biologically relevant insights that guide our medicinal chemistry efforts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Targeted Protein Degradation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In cases where our drugging efforts are directed at targets that have no enzymatic activity, we seek to degrade the protein of interest through targeted protein degraders. Protein degraders are bifunctional small molecules in which one portion of the molecule specifically recognizes the target while the other portion directs the destruction of the target by harnessing the cell&#8217;s proteasome-based degradation system. The two chemical functionalities of the molecule are connected by a variable linker. This approach affords a general method of degrading protein targets of interest.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After completing screens, as described above, and finding small molecule binders to the target of interest, we use our protein degradation know-how to convert binders into selective protein degraders. This know-how and capabilities include:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Proprietary library of linkers and E3 ligase binders</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Biochemical, biophysical, and cellular assays that measure protein degradation and guide optimization, including protein synthesis and degradation kinetics</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Ternary complex modeling and characterization</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Genome wide proteomic analysis of degradation to measure selectivity</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Translation to Clinic and Identification of Biomarkers</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to enrich our clinical studies with the genetically relevant patient populations that are most likely to benefit from treatment. Early in the drug discovery process, we use various genome and epi-genome analyses to understand the genetic dependency of the cancer on the chromatin regulatory system. Our intent is to have clear genetic markers for patients whom we seek to potentially treat.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we progress a drug candidate, we analyze tumor models and where available direct patient samples to understand biomarkers of response (e.g., change in expression level of a particular gene or set of genes, change in protein level of a component of the chromatin regulatory system). We intend to use these biomarkers in our clinical studies to understand tumor response to our drug candidates. Additionally, we will retrospectively analyze our clinical studies for any other biomarkers that will further enhance patient stratification and response.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing a broad pipeline of product candidates that target genetically determined dependencies within the chromatin regulatory system. Our programs consist of enzyme inhibitors, protein degraders and transcription factor disruptors. For FHD-286, we initiated two separate Phase 1 studies for (i) metastatic uveal melanoma and relapsed and/or refractory AML and MDS in May 2021. For our second product candidate, FHD-609, we initiated a Phase 1 study for the treatment of synovial sarcoma in August 2021. Our pipeline is as follows</span></div><div style="margin-top:6pt"><img src="fhtx-20211231_g1.jpg" alt="fhtx-20211231_g1.jpg" style="height:326px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FHD-286</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently advancing our lead product candidate, FHD-286, in two separate Phase 1 clinical studies in (i) metastatic uveal melanoma and (ii) relapsed and/or refractory AML and MDS. FHD-286 is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM, for the potential treatment of uveal melanoma, AML and MDS. BRG1 and BRM are two highly similar proteins that serve as the ATPases, or the catalytic engines, across all forms of BAF. Our preclinical data in both AML and uveal melanoma animal xenograft models demonstrated encouraging anti-tumor activity. The multi-center, Phase 1 studies will primarily assess the safety and tolerability of FHD-286 in adults with uveal melanoma, relapsed and/or refractory AML and MDS. Secondary endpoints are expected to include the pharmacokinetic and pharmacodynamic properties of FHD-286 as well as clinical activity. Proof of mechanism will be based on indicators of target engagement in association with FHD-286 treatment. As we further understand the therapeutic potential of FHD-286 in the course of these initial clinical studies, we may pursue additional clinical studies in these and other indications as a single agent and/or in combination with novel or standard of care agents. Initial data from these studies are expected in the first half of 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AML Disease Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acute myeloid leukemia, or AML, is a heterogeneous group of hematologic cancers characterized by a proliferation of myeloid precursors, commonly known as blasts, with limited ability to differentiate into more mature myeloid cells. These blasts replace normal hematopoietic tissue in the bone marrow, resulting in decreased hematologic cell numbers, or pancytopenia, and the morbidities associated with the cancer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AML is the second most common subtype of leukemia in adults. In major markets (United States, EU4, UK and Japan), AML has an incidence of approximately 35,000 cases annually and is generally a disease of elderly people, with more than 60&#160;percent of diagnosed patients being older than 60 years. The average five-year survival rate for patients with AML is 20&#160;percent, and there are significant differences in prognosis depending on several factors, including the age of the patient and co-morbidities at diagnosis. For patients under the age of 60, the five-year survival rate is approximately 33&#160;percent, while for those over the age of 60 it is less than 15&#160;percent. There are likely multiple reasons for this discrepancy, including the ability of younger patients to tolerate more aggressive therapies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current first-line treatments for patients with AML typically involve aggressive combination chemotherapy regimens with or without hematopoietic stem cell transplantation (HSCT). Older patients or patients who cannot tolerate HSCT, typically those with comorbidities, are often treated with cytarabine and daunorubicin induction followed by high-dose cytarabine consolidation. Patients who cannot tolerate combination chemotherapy receive low dose cytarabine, azacitidine, Venclexta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> , and/or enroll in clinical trials. There is a single biologic, gemtuzumab ozogamicin or Mylotarg, approved by the FDA for newly diagnosed and relapsed-refractory AML. Other, more recently approved therapeutics for AML target subsets of patients with tumors containing specific mutations such as midostaurin marketed as Rydapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by Novartis for those with FLT3 mutations, enasidenib marketed as Idhifa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by Bristol Myers for those with mutations in IDH2, and ivosidenib, marketed as Tibsovo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by Agios for those with mutations in IDH1.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite these advances, patients who do achieve remission, five-year disease-free survival is only 30-40&#160;percent because the majority of patients relapse. Patients in the elderly population have a relapse rate of 80-90&#160;percent. Younger patients have a relapse rate of between 60-80&#160;percent. There remains a significant need for safe, durable and broadly effective AML treatments.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uveal Melanoma Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uveal melanoma is the most frequent type of ocular cancer with approximately 5,000 cases each year in the major markets (United States, EU4, UK and Japan), typically presenting upon a routine eye exam in patients without specific symptoms. Local treatment, primarily with radiation therapy, is effective in preventing local recurrence in over 95&#160;percent of cases. Due to the asymptomatic nature of uveal melanoma, at the time of the diagnosis, a considerable portion of these patients already have metastatic disease, typically in the liver. Roughly half of all patients will eventually develop metastases. For those diagnosed with metastatic disease, the one-year survival is only 15&#160;percent. The poor prognosis associated with metastatic disease and the lack of effective therapy highlights the need for novel therapeutic approaches that specifically target metastatic uveal melanoma. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between 85&#160;percent and 95&#160;percent of uveal melanoma tumors contain mutations in one of two G-protein-coupled receptor subunits: GNAQ or GNA11. We have established through uveal melanoma cell lines with the GNAQ/GNA11 mutations that there is a dependency of these cell lines on two over expressed transcription factors, MITF and SOX10. In uveal melanoma, these two transcription factors abnormally interact with the BAF complex.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Solution: FHD-286</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FHD-286 is a highly potent, selective, allosteric and orally available, small molecule inhibitor of the enzymatic activity of both BRG1 and BRM. In established AML cell line-derived xenograft, or CDX, models MV4-11 and OCI-AML2, we observed robust tumor growth inhibition. In established uveal melanoma CDX models, specifically MP-46 and 92-1, we observed significant tumor growth inhibition and tumor regression, respectively. We are currently conducting separate Phase 1 studies for (i) metastatic uveal melanoma and (ii) relapsed and/or refractory AML and MDS. Initial data from both Phase 1 studies is anticipated in the first half of 2022. Either BRG1 or BRM can serve as the primary ATPase, or catalytic engine, of the BAF complex. BAF complexes will contain only BRG1 or BRM, as they are mutually exclusive subunits, as shown in the figure below. BRG1 or BRM are two proteins which are 76&#160;percent identical at the amino acid level over their entire length and over 90&#160;percent identical in the catalytic region.</span></div><div style="margin-top:6pt;text-align:center"><img src="fhtx-20211231_g7.jpg" alt="fhtx-20211231_g7.jpg" style="height:188px;margin-bottom:5pt;vertical-align:text-bottom;width:410px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 6. The enzymatic activity of the BAF complex is provided by the BRM or BRG1 subunits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we conducted compound screening against a panel of tumor cell lines, a number of these tumor cell lines were shown to be highly sensitive to BRG1 or BRM inhibition over a three-day period. These cell lines include nineteen of twenty-one of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hematopoietic malignancy cell lines tested, all four of the uveal melanoma cell lines, three out of four prostate tumor cell lines, and three out of seven breast tumor cell lines. We observed additional sensitivity in other tumor cell lines tested over a seven-day period. </span></div><div style="margin-top:6pt;text-align:center"><img src="fhtx-20211231_g8.jpg" alt="fhtx-20211231_g8.jpg" style="height:345px;margin-bottom:5pt;vertical-align:text-bottom;width:345px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 7. Certain cell lines, including those derived from uveal melanoma, hematological cancers, prostate cancer, and breast cancer were highly sensitive to BRG1/BRM inhibition.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Preclinical Data for AML</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genetic studies have identified a critical role of BRG1 in the maintenance of the undifferentiated state of AML cells. Knockdown of the expression of BRG1 was found both to inhibit the expression of genes associated with high proliferation and to induce the expression of genes associated with mature myeloid cells. In a mouse model of AML, partial genetic inactivation of BRG1 led to a greater than two-fold increase in overall survival. These data suggest that pharmacological inhibition of BRG1 may provide a therapeutic benefit.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have generated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proof of concept data that demonstrated antitumor activity of FHD-286 in AML patient samples as well as multiple AML CDX models. Using tumor cells isolated from AML patients, we demonstrated that treatment with FHD-286 allowed for appropriate differentiation of AML cells. We treated these tumor cells with a single dose of FHD-286 at increasing exposures and assessed the effects on both myeloid cellular differentiation and cell death. We observed myeloid cellular differentiation at a lower nanomolar exposure relative to where we observed cell death. The data support that pharmacologic inhibition of BRG1 can release the differentiation block associated with BRG1 overexpression in AML. Ongoing research has revealed that transcription factors interacting with over-expressed BRG1 containing BAF complexes are implicated in AML. Targeted treatment that releases a differentiation block has been observed to be clinically meaningful with ATRA treatment in acute promyelocytic leukemia as well as IDH1 and IDH2 inhibition in IDH-mutated AML. The cell killing observed was comparable to the effect of standard of care combinations: cytarabine plus daunorubicin and azacytidine plus venetoclax.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient #1 Sample<br/>BM-de novo AML</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient #2 Sample<br/>BM-secondary AML</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient #3 Sample<br/>BM-secondary AML</span></td></tr><tr style="height:174pt"><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img src="fhtx-20211231_g9.jpg" alt="fhtx-20211231_g9.jpg" style="height:187px;margin-bottom:5pt;vertical-align:text-bottom;width:224px"/></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img src="fhtx-20211231_g10.jpg" alt="fhtx-20211231_g10.jpg" style="height:222px;margin-bottom:5pt;vertical-align:text-bottom;width:221px"/></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img src="fhtx-20211231_g11.jpg" alt="fhtx-20211231_g11.jpg" style="height:183px;margin-bottom:5pt;vertical-align:text-bottom;width:221px"/></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 8. Treatment of patient-derived AML tumor samples with FHD-286 stimulated differentiation and cell death. Dose-dependent reduction of blast counts in samples from three patients. The blast count was normalized and plotted as relative to the level in vehicle DMSO-treated samples. The level of blast count reduction achieved by standards of care (Aza + venetoclax and &#8220;7+3&#8221;) are indicated by the dashed lines. BM = Bone Marrow.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Blasts</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Differentiation-like Blasts</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immature Blasts</span></td></tr><tr style="height:180pt"><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img src="fhtx-20211231_g12.jpg" alt="fhtx-20211231_g12.jpg" style="height:150px;margin-bottom:5pt;vertical-align:text-bottom;width:221px"/></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img src="fhtx-20211231_g13.jpg" alt="fhtx-20211231_g13.jpg" style="height:155px;margin-bottom:5pt;vertical-align:text-bottom;width:222px"/></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img src="fhtx-20211231_g14.jpg" alt="fhtx-20211231_g14.jpg" style="height:155px;margin-bottom:5pt;vertical-align:text-bottom;width:224px"/></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 9: Evidence of a dose-dependent differentiation effect in patient #1 sample.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have confirmed the sensitivity observed in our three-day cell line panel in CDX models created using OCI-AML2 and MV4-11, two AML cell lines with different underlying genetic mutations. In addition, we have observed robust dose response in further evaluation of FHD-286 in MV4-11 CDX models. We have also observed synergy of FHD-286 in combination with cytarabine.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MV4-11 AML CDX Model</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FLT3 ITD, MLL-AF4</span></div><div style="margin-top:12pt;text-align:center"><img src="fhtx-20211231_g15.jpg" alt="fhtx-20211231_g15.jpg" style="height:166px;margin-bottom:5pt;vertical-align:text-bottom;width:682px"/></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OCI-AML-2 AML CDX Model</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MII-AF6, DNMTa3 mut.</span></div><div style="margin-top:12pt;text-align:center"><img src="fhtx-20211231_g16.jpg" alt="fhtx-20211231_g16.jpg" style="height:165px;margin-bottom:5pt;vertical-align:text-bottom;width:682px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 10. FHD-286, dosed as monotherapy, led to tumor growth inhibition in two AML xenograft models MV4-11 and OCI-AML-2.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Preclinical Data for Uveal Melanoma</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In uveal melanoma cell lines that contain GNAQ/GNA11 mutations, genetic studies have revealed that these cells overexpressed two transcription factors, MITF and SOX10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our data showed that the MITF and SOX10 transcription factors abnormally over-interacted with the BAF complex in uveal melanoma cell lines. By inhibiting the ATPase activity, both BRG1 and BRM, of the BAF complex, we observed anti-tumor effects in several CDX and patient-derived xenograft, or PDX, uveal melanoma models.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We established the genetic dependency of uveal melanoma cell lines on MITF and SOX10 by analyzing data from the Project Achilles, a functional genomics screen conducted by the Broad Institute. We found that established uveal melanoma cell lines such as 92-1 and OMM1 were highly dependent on MITF or SOX10.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><img src="fhtx-20211231_g17.jpg" alt="fhtx-20211231_g17.jpg" style="height:234px;margin-bottom:5pt;vertical-align:text-bottom;width:682px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 11. Uveal melanoma cell lines, such as 92-1 and OMM1, were highly dependent on MITF or SOX10.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We found that inhibition of BRG1 and BRM led to suppression of gene expression from several MITF and SOX10-dependent genes. A broader measure of the effect of dual inhibition of BRG1 and BRM on transcription of MITF and SOX10-dependent genes was obtained using a technique known as chromatin immunoprecipitation sequencing, or ChIP-seq. ChIP-seq allows us to find where particular proteins, in this case transcription factors, are binding to chromatin. Treatment of uveal melanoma cells with a research compound with similar properties to that of FHD-286 resulted in decreased binding of both MITF and SOX10 transcription factors to their respective chromatin binding sites. These results validate the mechanism of action of FHD-286 in uveal melanoma cells.</span></div><div style="margin-top:6pt;text-align:center"><img src="fhtx-20211231_g18.jpg" alt="fhtx-20211231_g18.jpg" style="height:383px;margin-bottom:5pt;vertical-align:text-bottom;width:682px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 12. BRG1/BRM inhibitor blocked the ability of MITF and SOX10 to bind to their target sequences as determined by ChIP-seq.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have generated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proof of concept data that demonstrated antitumor activity of FHD-286 in multiple uveal melanoma CDX and PDX models. In two uveal melanoma models, 92-1 and MP-46, oral dosing of FHD-286 at 1.5 mg/kg as monotherapy </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resulted in tumor growth regression and inhibition, respectively. Importantly, doses of FHD-286 of up to 1.5 mg/kg were well-tolerated in that FHD-286 at these doses did not lead to changes in body weight considered to be clinically meaningful compared to controls (e.g., changes greater than 10&#160;percent of body weight), a commonly used measure of safety.</span></div><div id="i523559815e87485cb6a9895707f43a02_16"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">92-1 Uveal Melanoma Model</span></div><div style="margin-top:6pt;text-align:center"><img src="fhtx-20211231_g19.jpg" alt="fhtx-20211231_g19.jpg" style="height:149px;margin-bottom:5pt;vertical-align:text-bottom;width:605px"/></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MP-46 Uveal Melanoma Model</span></div><div style="margin-top:6pt;text-align:center"><img src="fhtx-20211231_g20.jpg" alt="fhtx-20211231_g20.jpg" style="height:156px;margin-bottom:5pt;vertical-align:text-bottom;width:605px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 13. FHD-286 led to dose-dependent tumor growth inhibition in two uveal melanoma xenograft models 92-1 and MP-46.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Plans for FHD-286 in AML and Uveal Melanoma</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently conducting separate Phase 1 studies with FHD-286 in (i) metastatic uveal melanoma and (ii) relapsed and/or refractory AML and MDS. Initial data from both Phase 1 studies are anticipated in the first half of 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first-in-human phase I study in AML and MDS is an accelerated titration design with two parts. Part one is the dose escalation phase that will enroll a single patient per dose (n=1) until certain criteria are met. The trial will convert to a 3+3 design once relevant pharmacokinetics/pharmacodynamics, or PK/PD, safety and or clinical activity are observed. The dose escalation portion will evaluate once daily oral, multiple ascending doses of FHD-286, with a starting dose determined by our GLP toxicology studies. Dose escalation will include patients with relapsed and/or refractory AML or MDS. The second part of the study is an expansion phase. This phase may include multiple distinct cohorts of patients with AML, informed by findings from the dose escalation phase. Initially, biomarkers, such as the association of clinical activity and BRG1 expression levels, will be evaluated retrospectively. The primary objective of this first-in-human study will be the evaluation of safety and tolerability, and the identification of the maximum tolerated dose and the recommended Phase 2 dose. The secondary objectives are expected to include an evaluation of preliminary clinical activity and pharmacokinetics. Biomarkers will be evaluated in an exploratory fashion, evaluating markers associated with response. Prospective enrollment based on biomarker findings may be included in the expansion phase of the study.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first-in-human Phase 1 study in uveal melanoma is an accelerated titration design with two parts. Part one is the dose escalation phase that will enroll a single patient per dose (n=1) until certain criteria are met. The trial will convert to a 3+3 design once relevant PK/PD, safety and or clinical activity are observed. The dose escalation portion will evaluate once daily oral, multiple ascending doses of FHD-286, with a starting dose determined by our GLP toxicology studies. Dose escalation will include patients with metastatic uveal melanoma. The second part of the study is an expansion phase, which will be informed by findings from the dose escalation phase.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective will be the evaluation of safety and tolerability and identification of the maximum tolerated dose and/or recommended Phase 2 dose. The secondary objectives are expected to include an evaluation of pharmacokinetics and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preliminary clinical activity. Biomarkers will be evaluated in an exploratory fashion, evaluating target engagement as well as markers associated with response. Prospective enrollment based on biomarker findings may be included in the expansion phase of the study.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As shown in the graphic below, these two Phase 1 studies are being conducted in parallel. We intend to explore the potential value of multiple biomarkers to further understand and accelerate drug development. Biomarkers will include assessment of various tumor mutations, as well as expression levels of BRG1 and BRM. These biomarkers may be used for future patient selection, measurements of target engagement and biochemical and cellular measures associated with efficacy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A recent data publication highlighted neuroendocrine prostate cancer as being dependent on BAF. We are evaluating multiple tumor types in the preclinical setting to determine our indication expansion strategy for FHD-286.</span></div><div style="margin-top:6pt;text-align:center"><img src="fhtx-20211231_g21.jpg" alt="fhtx-20211231_g21.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:552px"/></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FHD-609</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently advancing FHD-609, a highly potent, selective and intravenous, small molecule protein degrader of BRD9, a subunit of a form of the BAF complex. Nearly all synovial sarcoma cancers harbor SS18-SSX mutations. These mutations render the cancer genetically dependent upon BRD9. FHD-609 has two domains: one that binds with high potency and selectivity to BRD9 and the other that binds to a receptor on the E3 ligase complex that directs proteins for destruction. Our preclinical data in synovial sarcoma animal xenograft models demonstrate anti-tumor effects and supported progressing FHD-609 into clinical studies. We are currently conducting a Phase 1 study with FHD-609 for the treatment of synovial sarcoma and anticipate preliminary data as early as the first half of 2022. This multi-center Phase 1 study is primarily assessing the safety and tolerability of FHD-609 in patients with synovial sarcoma. Secondary endpoints include the PK/PD properties of FHD-609 as well as clinical activity. Proof of mechanism will be based on indicators of target engagement in association with FHD-609 treatment. As we further understand the therapeutic potential of FHD-609 in the course of the initial clinical studies, we may pursue additional clinical studies in synovial sarcoma, as a single agent and/or in combination with novel or standard of care agents. In parallel, and as early as Phase 1 expansion studies, we plan to evaluate FHD-609 in other indications, including SMARCB1-deleted cancers.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Synovial Sarcoma Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Synovial sarcoma is a cancer of the connective tissue and most commonly originates in the arms or legs. Synovial sarcoma occurs most frequently in adolescents and young adults. There is an incidence over 1,800 new cases of synovial sarcoma in the United States, EU4, UK and Japan. Approximately 30&#160;percent of synovial sarcomas occur in patients under 20 years of age with 84&#160;percent of cases occurring in patients under 50 years of age.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delay in diagnosis and treatment of synovial sarcoma is common because it is recognized simply by a lump that gradually grows over time. The primary treatment for synovial sarcoma is surgical excision of the tumor and surrounding normal tissue with the goal of sparing the limb if possible. Failure to adequately excise a sufficient area of tissue surrounding the tumor leads to recurrence rates of over 70&#160;percent. Surgical resection is then followed by adjuvant chemotherapy or radiation therapy or both. However, there appears to be minimal benefit of these post-surgical treatments other than for palliative reasons. Radiation and chemotherapy are used in the neoadjuvant setting, or before surgery, to improve the chances of a successful limb sparing surgery.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately ten percent of cases originally present as metastatic disease, and half of all cases eventually develop into metastatic disease. Eighty percent of metastases are localized in the lungs. Five-year survival rates for younger patients with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">early-stage disease are approximately 76&#160;percent; however, this decreases to approximately 20&#160;percent in patients over age 30 with advanced disease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no therapies specifically approved by the FDA for synovial sarcoma patients with metastatic disease. Pazopanib, marketed as Votrient</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by Novartis has been approved by the FDA for treatment of soft tissue sarcoma in patients who had received prior chemotherapy. In a Phase 3 soft tissue sarcoma trial that included a total of 369 patients, the progression-free survival time for the subset of patients with synovial sarcoma was 4.1 months (N=25) compared to 0.9 months for those who received placebo (N=13). Other chemotherapeutic agents that may be used for palliative purposes include ifosfamide.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Synovial sarcomas are characterized by a chromosomal translocation that results in the fusion of the SS18 gene to one of three genes: SSX1, SSX2 and SSX4, creating SS18-SSX gene fusions. These gene fusions are unique in synovial sarcoma and create a protein not found in healthy patients that fuels the growth and proliferation of the cancer cells. In the scientific literature, the process has been described as the gene fusion &#8220;hijacking&#8221; the BAF complex, altering its function and causing it to unpack chromatin at wrong locations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SS18 is a component of the BAF complex. The SS18-SSX fusion protein can also be incorporated into the BAF complex, leading to synovial sarcoma. Genomic screening in synovial sarcoma cells has identified a genetic dependency between synovial sarcoma cells containing SS18-SSX fusions and BRD9, a subunit of the ncBAF complex.</span></div><div style="margin-top:6pt;text-align:center"><img src="fhtx-20211231_g22.jpg" alt="fhtx-20211231_g22.jpg" style="height:276px;margin-bottom:5pt;vertical-align:text-bottom;width:349px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 14. Synovial sarcoma cell lines were highly dependent on BRD9.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Solution: FHD-609</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FHD-609 is a highly potent, selective and intravenous, small molecule protein degrader of BRD9. Unlike many traditional intracellular drug targets, BRD9 is not an enzyme and does not exhibit enzymatic activity. We therefore designed FHD-609 as a protein degrader, a molecule with two binding domains connected by a linker that drives the removal of targeted proteins by the cell&#8217;s protein degradation system. In cells, these protein degrader molecules bring their target into proximity of the E3 ligase which marks these target proteins for destruction by the cell&#8217;s proteasome system.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One domain of FHD-609 is a potent and selective binder of BRD9. This is chemically linked to a domain that binds to a receptor on the E3 ligase complex. FHD-609 led to the specific degradation of BRD9 in multiple synovial sarcoma tumor cell lines, with a DC50 of less than 1 (one) nM. This resulted in the elimination of detectable BRD9 protein and the concomitant inhibition of proliferation of these synovial sarcoma cell lines.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Preclinical Data for Synovial Sarcoma</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have generated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proof of concept data that demonstrated antitumor activity of FHD-609 in synovial sarcoma CDX models. In the synovial sarcoma SYO1 CDX model containing the SS18-SSX2 mutation, dosing with FHD-609 led to potent inhibition of tumor growth. Intraperitoneal doses of FHD-609 yielded similar antitumor activity whether dosing was delivered as a once-weekly (every 7 days for three weeks) or an equivalent drug amount delivered daily over seven days for three weeks </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.5 mg/kg delivered every week versus 0.5 mg/kg delivered daily over 7 days). This suggests that sustained tumor regression can occur with a less frequent dosing regimen, which will be explored in clinical development. In the model, tumor growth inhibition levels were associated with levels of BRD9 degradation as indicated below.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SYO-1 Synovial Sarcoma CDX Model</span></div><div style="margin-top:6pt;text-align:center"><img src="fhtx-20211231_g23.jpg" alt="fhtx-20211231_g23.jpg" style="height:170px;margin-bottom:5pt;vertical-align:text-bottom;width:484px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 15. FHD-609 led to dose-dependent tumor growth inhibition of synovial sarcoma tumors equivalently at a once weekly or daily treatment schedule. On the right, the western blot shows dose-dependent BRD9 degradation correlating with the anti-tumor activity.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the synovial sarcoma ASKA CDX model containing the SS18-SSX1 mutation, the antitumor activity of FHD-609 was comparable and superior to that observed for other systemic therapeutic agents. In this model FHD-609 was dosed intravenously twice per week, ifosfamide as a monotherapy intravenously on days one through three every three weeks, and pazopanib orally once daily. FHD-609 led to robust tumor suppression, with meaningful suppression observed through 40 days at the highest studied dose of 2 mg/kg.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASKA Synovial Sarcoma CDX Model</span></div><div style="margin-top:6pt;text-align:center"><img src="fhtx-20211231_g24.jpg" alt="fhtx-20211231_g24.jpg" style="height:222px;margin-bottom:5pt;vertical-align:text-bottom;width:484px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 16. FHD-609 resulted in tumor regression in the ASKA synovial sarcoma xenograft model. FHD-609 demonstrated significant tumor growth inhibition compared to either ifosfamide or pazopanib.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Importantly, after discontinuation of FHD-609, treatment with FHD-609 was associated with sustained tumor growth inhibition. Following discontinuance of FHD-609 treatment at 2 mg/kg, at approximately day&#160;21 tumor regrowth was not detectable for at least another 15 days. We believe these results support the targeted degradation of BRD9 and its importance in synovial sarcoma.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASKA Synovial Sarcoma CDX Model</span></div><div style="margin-top:6pt;text-align:center"><img src="fhtx-20211231_g25.jpg" alt="fhtx-20211231_g25.jpg" style="height:233px;margin-bottom:5pt;vertical-align:text-bottom;width:489px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 17. FHD-609 treatment was associated with sustained tumor suppression after treatment withdrawal.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Plans for FHD-609 in Synovial Sarcoma</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first-in-human study in synovial sarcoma will include a standard dose escalation and expansion phase. The dose escalation portion is a Phase 1 design with a starting dose determined by the GLP toxicology studies. Dose escalation may include treatment-na&#239;ve or treatment-experienced patients with metastatic synovial sarcoma. The expansion phase may include multiple distinct cohorts of synovial sarcoma patients, informed by findings from the dose escalation phase. Initially, biomarkers such as the association of clinical activity and SS18-SSX mutational status will be evaluated retrospectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoints of this first-in-human study will be safety, the identification of any dose-limiting toxicities, the maximum tolerated dose, the recommended Phase 2 dose, and the evaluation of pharmacokinetics and pharmacodynamics. The secondary endpoints are expected to include an evaluation of clinical activity: overall response rate, duration of response and additional time to event analyses. Biomarkers will be evaluated in an exploratory fashion, evaluating target engagement as well as markers associated with response and/or resistance. Prospective enrollment based on biomarker findings may be included in the expansion phase of the study. As we further understand the therapeutic potential of FHD-609 in the course of the initial clinical studies, we may pursue additional clinical studies in synovial sarcoma, as a single agent and/or in combination with novel or standard of care agents. In parallel, and as early as Phase 1 expansion studies, we plan to evaluate FHD-609 in other indications, including SMARCB1-deleted cancers.</span></div><div style="margin-top:12pt;text-align:center"><img src="fhtx-20211231_g26.jpg" alt="fhtx-20211231_g26.jpg" style="height:188px;margin-bottom:5pt;vertical-align:text-bottom;width:565px"/></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BRM-Selective Modulators</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Broad cancer sequencing initiatives have shown that BRG1 is one of the most highly mutated subunits of the BAF complex. BRG1 was found to be mutated in approximately five percent of tumors sequenced as part of the Memorial Sloan Kettering Cancer Center MSK-IMPACT study, and in up to ten percent of NSCLC tumors. Beyond NSCLC, the MSK-IMPACT study highlighted BRG1 mutations in over thirty different types of tumors. In many cases, these mutations lead to a loss of enzymatic </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activity in the BRG1 subunit, creating a genetically determined dependency on BRM. This loss of BRG1 and subsequent dependency on BRM leads to a drugging opportunity. We are currently developing selective modulators of BRM to target this genetic dependency in BRG1 mutated cancers. In December 2021, we entered into a strategic collaboration with Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company, to create novel oncology medicines. The Loxo Oncology collaboration includes a co-development and co-commercialization agreement for the selective BRM oncology program.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chromatin Regulatory System: An Untapped Opportunity for Therapeutic Intervention</span></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12 Tumor Types with Highest Prevalence of BRG-1 Mutations</span></div><div style="margin-top:6pt;text-align:center"><img src="fhtx-20211231_g27.jpg" alt="fhtx-20211231_g27.jpg" style="height:198px;margin-bottom:5pt;vertical-align:text-bottom;width:552px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 18. The above chart highlights the cancers with the highest prevalence of BRG1 mutations from the MSK-IMPACT study.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Small Cell Lung Cancer (NSCLC) Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lung cancer is the leading cause of cancer-related death, accounting for approximately 18&#160;percent of all cancer deaths globally or an estimated 1.8&#160;million deaths per year. There are an estimated 228,000 new cases of lung cancer diagnosed and 135,000 deaths in the United States annually. NSCLC accounts for 80 to 85&#160;percent of lung cancer cases. Genetic profiling of tumors has identified a number of genes that are altered in NSCLC. The standard of care for NSCLC has included conventional chemotherapy with or without a checkpoint inhibitor. Targeted therapies developed for the proteins encoded by some of these genes such as the epidermal growth factor receptor, or EGFR, and anaplastic lymphoma kinase gene, or ALK, have been approved and are now part of the standard of care of patents with NSCLC. However, less than 30&#160;percent of NSCLC patients have alterations in these two genes. Up to two thirds of NSCLC patients who are ineligible for or resistant to treatment with EGFR or ALK targeted therapies have tumors that express PD-L1 and are candidates for checkpoint inhibitor therapies, which lead to significant improvements in progression free survival and overall survival compared to standard chemotherapy. Despite the availability of both targeted and conventional therapies, the prognosis in NSCLC remains poor, with an overall five-year survival for all patients diagnosed with NSCLC of 19&#160;percent.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of genomic data in NSCLC cancer patients, collected as part of MSK-IMPACT, revealed that gene alterations in BRG1 were found in ten percent of NSCLC samples. In a retrospective analysis conducted by MSKCC it was observed that among patients with BRG1-deficient NSCLC who received first-line platinum doublet chemotherapy or chemotherapy plus immunotherapy, median progression-free survival was 38 days and 35 days, respectively. Prognosis is poor in patients with BRG1-deficient NSCLC, highlighting the importance of developing novel therapeutics that address this unmet need.</span></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MSK-IMPACT: BRG-1 Mutated in 10% of NSCLC</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><img src="fhtx-20211231_g28.jpg" alt="fhtx-20211231_g28.jpg" style="height:170px;margin-bottom:5pt;vertical-align:text-bottom;width:524px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 19. BRG1 gene alterations are found in 10&#160;percent of NSCLC tumors and have minimal overlap with other actionable mutations present in NSCLC, such as EGFR and ALK.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genomic screening of over 400 cancer cell lines that remove BRM via CRISPR revealed a genetic dependency of certain BRG1-mutated cancers on BRM. This finding suggests that selective inhibition of BRM has the potential to be therapeutically meaningful in certain cancers with BRG1 mutations.</span></div><div style="margin-top:6pt;text-align:center"><img src="fhtx-20211231_g29.jpg" alt="fhtx-20211231_g29.jpg" style="height:226px;margin-bottom:5pt;vertical-align:text-bottom;width:301px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 20. In a screen of over 400 cancer cell lines, inactivation of the BRM gene resulted in selective inhibition of cell lines containing mutations in BRG1.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Solution: Selective BRM Modulators</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With our collaboration partner, Loxo Oncology at Lilly, we are advancing two classes of molecules, an enzymatic inhibitor and a protein degrader, as selective modulators of BRM.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One class consists of selective, allosteric inhibitors of the ATPase activity of BRM. We are designing these inhibitors to be more selective for BRM than the very similar ATPase BRG1. Through our proprietary methods of isolating and screening BAF complexes that contain either BRG1 or BRM, we have identified small molecule inhibitors that are over 10 times more selective for BRM than BRG1. We have shown that this selectivity was also observed in cellular assays. Pharmacokinetic profiles of these molecules have been consistent with the ability to potently inhibit BRM while having minimal inhibitory activity against BRG1.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Enzyme assay using BRG1 and BRM subunits</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Enzyme assay using BRG1 and BRM containing full BAF complexes</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cellular assays for BRG1 and BRM</span></td></tr><tr style="height:180pt"><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img src="fhtx-20211231_g30.jpg" alt="fhtx-20211231_g30.jpg" style="height:171px;margin-bottom:5pt;vertical-align:text-bottom;width:224px"/></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img src="fhtx-20211231_g31.jpg" alt="fhtx-20211231_g31.jpg" style="height:203px;margin-bottom:5pt;vertical-align:text-bottom;width:224px"/></div></td><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img src="fhtx-20211231_g32.jpg" alt="fhtx-20211231_g32.jpg" style="height:174px;margin-bottom:5pt;vertical-align:text-bottom;width:224px"/></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 21. This panel showed biochemical (percent of ATPase activity) and cellular selectivity of a 20X selective inhibitor of BRG1 versus BRM.</span></div><div style="margin-top:12pt"><img src="fhtx-20211231_g33.jpg" alt="fhtx-20211231_g33.jpg" style="height:241px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 22. This panel showed BRM enzymatic inhibitor </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> efficacy in a A549-BRG1 Mutant NSCLC Model with corresponding body weight and plasma exposure versus the vehicle control and Cisplatin.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other approach to selective BRM modulation consists of protein degrader molecules that activate the cell&#8217;s protein degradation system to selectively destroy BRM. One domain of the BRM degrader molecule is a potent and selective binder of BRM. This is chemically linked to a domain that binds to a receptor on the E3 ligase complex. In cells, these protein degrader molecules bring their target into proximity of the E3 ligase which marks these target proteins for destruction by the cell&#8217;s protein degradation system. We have shown that it is possible to identify protein degraders that lead to the destruction of BRM while leaving BRG1 untouched. </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selective Degradation of BRM</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="text-align:center"><img src="fhtx-20211231_g34.jpg" alt="fhtx-20211231_g34.jpg" style="height:212px;margin-bottom:5pt;vertical-align:text-bottom;width:354px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 23. Selective BRM degrading molecules led to the degradation of over 75&#160;percent of BRM while leaving the levels of BRG1 virtually unchanged.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARID1B Selective Modulators and Other Opportunities in the Chromatin Regulatory System</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ARID1A subunit is the most mutated subunit within the BAF complex.&#160;Mutations in ARID1A confer a dependency on the ARID1B subunit of the BAF complex. ARID1A mutations are implicated in ovarian, endometrial, colorectal, bladder, and gastric cancers.&#160;Data suggest that there are over 175,000 patients with ARID1A mutations that would potentially benefit from a therapy selectively targeting ARID1B.</span></div><div style="margin-top:6pt;text-align:center"><img src="fhtx-20211231_g35.jpg" alt="fhtx-20211231_g35.jpg" style="height:204px;margin-bottom:5pt;vertical-align:text-bottom;width:313px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 24. In a screen of over 400 cancer cell lines, inactivation of the ARID1B gene resulted in selective growth inhibition of cell lines containing mutations in ARID1A, establishing the dependency on ARID1B in these cell lines.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since ARID1B is not an enzyme, our strategy is to selectively degrade ARID1B.&#160;Our platform allows us to generate full BAF complexes containing only ARID1A or ARID1B.&#160;Using our platform, we have conducted high throughput screens and have discovered selective binders to the ARID1B protein that we are seeking to optimize as protein degrader product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the significance of mutations within the chromatin regulatory system, we are using our platform to discover and validate additional dependencies. We have several additional early programs underway. We continue to evaluate new target opportunities and intend to further expand our pipeline in oncology as well as other therapeutic areas.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Targeting Transcription Factors: Disrupting Transcription Factor Binding to Chromatin Remodeling Complexes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transcription factors work in concert with chromatin remodeling complexes, BAF as one example, to orchestrate gene expression. In tumor cells, genes encoding transcription factors are often amplified, deleted, rearranged via chromosomal translocation or subjected to point mutations that result in a gain or loss of function. We have developed a set of tools to visualize and study the interactions between transcription factors and chromatin remodeling complexes. To our knowledge, we are the only company with these capabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are using these capabilities to drive our drug discovery efforts across multiple transcription factor programs for a variety of cancer indications. Our strategy is to disrupt the interaction between transcription factors and chromatin remodeling complexes. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our initial focus is on disrupting transcription factor interactions with the BAF complex. We believe that there are over 100 transcription factors in oncology that would be amenable to this new approach. Based on these insights, we are developing small molecule disruptors that block the interaction between transcription factors and the BAF complex. In addition to applications in cancer, we believe that such disruptors could be applied in other therapeutic areas.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approach to disrupting the interactions between transcription factors and the BAF complex is the basis of a collaboration signed with Merck in July 2020. In this collaboration, we intend to apply our Gene Traffic Control platform to identify disruptors of a single predetermined transcription factor. As part of the collaboration, we received an upfront payment of $15.0&#160;million, and are also eligible to receive up to $245.0&#160;million upon achievement of specified research, development and regulatory milestones by any product candidate generated by the collaboration, and up to $165.0&#160;million upon achievement of specified sales-based milestones.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A prototypical example of a chromatin remodeling complex&#8211;transcription factor interaction is exemplified by the ERG transcription factor and BAF. In approximately half of all prostate cancers, the gene encoding ERG is fused to the TMPRRS2 promotor, resulting in the overexpression of ERG and the upregulation of a broad set of additional genes. Furthermore, genetic suppression of ERG expression in cells containing the TMPRRS2-ERG gene fusion has been shown to inhibit cell proliferation. These results support our approach that disrupting the interaction of over expressed transcription factors, such as ERG, with a chromatin remodeling complex has the potential to be therapeutically beneficial to patients.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to ERG, the ability of individual transcription factors to interact with the BAF complex has previously been reported in the literature, but to our knowledge, there have not previously been systematic studies quantifying and describing these binding interactions. We used our Gene Traffic Control platform to produce and purify BAF complexes and multiple transcription factors to study the structural details as well as the biochemical and biophysical properties of their interactions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We observed that different transcription factors bind to different sites on the surface of the BAF complex. This suggests that there is specificity in these interactions. Therefore, it may be possible to block the interaction of a specific transcription factor with the BAF complex without blocking the interactions of other transcription factors.</span></div><div style="margin-top:10pt;text-align:center"><img src="fhtx-20211231_g36.jpg" alt="fhtx-20211231_g36.jpg" style="height:173px;margin-bottom:5pt;vertical-align:text-bottom;width:565px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 25. Illustrative locations of the binding sites of multiple transcription factors to the BAF complex.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also observed that the binding affinities that describe how tightly transcription factors bind to the BAF complex were roughly comparable to those observed for other protein-protein interactions for which small molecule disruptors have been developed. We found that the interactions between multiple transcription factors and the BAF complex had a K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">d</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a measure of binding affinity, in the range of 20 to 350 nM.</span></div><div style="margin-top:6pt;text-align:center"><img src="fhtx-20211231_g37.jpg" alt="fhtx-20211231_g37.jpg" style="height:112px;margin-bottom:5pt;vertical-align:text-bottom;width:565px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 26. Interactions between transcription factors and the BAF complex had K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">d</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">s in the range of 20 to 350 nM. Smaller numbers reflected higher affinity binding.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using the insights of where and how tightly transcription factors bind, we have developed as part of our Gene Traffic Control platform the ability to conduct high throughput screens on chromatin remodeling complex&#8211;transcription factor interactions. We have already validated eight BAF-transcription factor interactions for targets of interest in various cancers. We are applying our know-how to screen several of these BAF-transcription factor interactions to discover and develop transcription factor disruptors. We intend to use our platform to validate and drug additional transcription factors that interact with BAF and other chromatin remodeling complexes both in oncology and other therapeutic areas.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by the rapid evolution of technologies and understanding of disease etiology, intense competition and a strong emphasis on intellectual property. We believe that our approach, strategy, scientific capabilities, know-how and experience provide us with competitive advantages, including, to our knowledge, our being the only company with the ability to study the chromatin regulatory system at scale, in context, and in an integrated way. However, we expect substantial competition from multiple sources, including major pharmaceutical, specialty pharmaceutical, and existing or emerging biotechnology companies, academic research institutions and governmental agencies and public and private research institutions worldwide. Many of our competitors, either alone or through collaborations, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These companies may be or may become interested in the chromatin regulatory system and rapidly develop programs that may compete with ours by studying the chromatin regulatory system at scale, in context and in an integrated way. Even if they do not advance programs with the same mechanism of action as ours, these companies could develop products or product candidates that are competitive with ours or that have a superior product profile and may do so at a rapid pace. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient enrollment in clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result, our competitors may discover, develop, license or commercialize products before or more successfully than we do.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face competition from segments of the pharmaceutical, biotechnology and other related markets that pursue the development of therapies that target broad genetic expression mechanisms, including the chromatin regulatory system. In addition, we may face competition from companies developing product candidates that utilize protein degradation approaches, including Arvinas, Inc., Kymera Therapeutics, Inc., Nurix Therapeutics, Inc., C4 Therapeutics, Inc., and Vividion Therapeutics, Inc. Further, several large pharmaceutical companies have disclosed preclinical investments in this field. Our competitors will also include companies that are or will be developing other targeted therapies, including small molecule, antibody, or protein degraders for the same indications that we are targeting.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could see a reduction or elimination in our commercial opportunity if our competitors develop and commercialize drugs that are safer, more effective, have fewer or less severe side effects, are more convenient to administer, are less expensive or with more favorable labeling than our product candidates, regardless of whether they target the chromatin regulatory system as a mechanism of action. Our competitors also may obtain FDA or other regulatory approval for their drugs more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of all of our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the level of generic competition and the availability of reimbursement from government and other third-party payors.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to protect the intellectual property and proprietary technology that we consider important to our business, including by pursuing patent applications that cover our product candidates and methods of using the same, as well as other relevant inventions and improvements that we believe to be commercially important to the development of our business. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position. Our commercial success depends, in part, on our ability to obtain, maintain, enforce and protect our intellectual property and other proprietary rights for the technology, inventions and improvements we consider important to our business, and to defend any patents we may own or in-license in the future, prevent others from infringing any patents we may own or in-license in the future, preserve the confidentiality of our trade secrets, and operate without infringing, misappropriating or otherwise violating the valid and enforceable patents and proprietary rights of third parties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with other biotechnology and pharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual property position for our product candidates and technologies will depend on our success in obtaining effective patent claims </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and enforcing those claims if granted. However, our pending provisional and PCT patent applications, and any patent applications that we may in the future file or license from third parties, may not result in the issuance of patents and any issued patents we may obtain do not guarantee us the right to practice our technology or commercialize our product candidates. We also cannot predict the breadth of claims that may be allowed or enforced in any patents we may own or in-license in the future. Any issued patents that we may own or in-license in the future may be challenged, invalidated, circumvented or have the scope of their claims narrowed. In addition, because of the extensive time required for clinical development and regulatory review of a product candidate we may develop, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby limiting the protection such patent would afford the respective product and any competitive advantage such patent may provide.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of individual patents depends upon the date of filing of the patent application, the date of patent issuance and the legal term of patents in the countries in which they are obtained. In most countries, including the United States, the patent term is 20&#160;years from the earliest filing date of a non-provisional patent application. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office, or USPTO, in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed patent. The term of a patent claiming a new drug product may also be eligible for a limited patent term extension when FDA approval is granted, provided statutory and regulatory requirements are met. The restoration period granted on a patent covering a product is typically one-half the time between the effective date of a clinical investigation involving human beings is begun and the submission date of an application, plus the time between the submission date of an application and the ultimate approval date. The restoration period cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. Only one patent applicable to an approved product is eligible for the extension, and only those claims covering the approved product, a method for using it, or a method for manufacturing it may be extended. Additionally, the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension or restoration in consultation with the FDA. In the future, if our product candidates receive approval by the FDA, we expect to apply for patent term extensions on any issued patents covering those products, depending upon the length of the clinical studies for each product and other factors. There can be no assurance that patents will issue from our current or future pending patent applications, or that we will benefit from any patent term extension or favorable adjustments to the terms of any patents we may own or in-license in the future. In addition, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. Patent term may be inadequate to protect our competitive position on our products for an adequate amount of time.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 1, 2022, we owned six pending U.S. provisional patent applications, 20 pending U.S. non-provisional patent applications, 14 pending Patent Cooperation Treaty, or PCT, applications, and 28 pending ex-U.S. patent applications. We currently do not own or in-license any issued patents with respect to any of our product candidates, including FHD-286 and FHD-609, or our platform technology, and our intellectual property portfolio is in its very early stages.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FHD-286</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 1, 2022, we owned two pending U.S. provisional patent applications, five pending U.S. non-provisional patent applications, two pending PCT, patent applications, and 14 pending ex-U.S. patent applications that relate to FHD-286, including its composition and various methods of use. Any U.S. or ex-U.S. patent that may issue from these patent applications would be scheduled to expire between 2039-2042, excluding any additional term for patent term adjustment or patent term extension, if applicable.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FHD-609</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 1, 2022, we owned three pending U.S. provisional patent applications, three pending U.S. non-provisional patent applications, one pending PCT patent application, and 11 pending ex-U.S. patent applications that relate to FHD-609, including its composition and various methods of use. Any U.S. or ex-U.S. patent that may issue from a non-provisional patent application claiming priority to these applications would be scheduled to expire between 2039-2042, excluding any additional term for patent term adjustment or patent term extension, if applicable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prosecution of most of our PCT patent applications and our provisional patent applications has not commenced and will not commence unless and until they are timely converted into U.S. non-provisional or national stage applications. Prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the USPTO or other foreign jurisdiction are often significantly narrowed by the time they issue, if they issue at all. Any of our pending PCT patent </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applications are not eligible to become issued patents until, among other things, we file national stage patent applications within 30 months in the countries in which we seek patent protection. If we do not timely file any national stage patent applications, we may lose our priority date with respect to our PCT patent applications and any patent protection on the inventions disclosed in such PCT patent applications. Our provisional patent applications may never result in issued patents and are not eligible to become issued patents until, among other things, we file a non-provisional patent application within 12 months of filing the related provisional patent application. If we do not timely file non-provisional patent applications, we may lose our priority date with respect to our provisional patent applications and any patent protection on the inventions disclosed in our provisional patent applications. While we intend to timely file non-provisional and national stage patent applications relating to our provisional and PCT patent applications, we cannot predict whether any of our current or future patent applications related to FHD-286, FHD-609, or any of our other product candidates, will issue as patents. If we do not successfully obtain patent protection, or, even if we do obtain patent protection, if the scope of the patent protection we obtain with respect to FHD-286, FHD-609, or our other product candidates or technology is not sufficiently broad, we will be unable to prevent others from using our technology or from developing or commercializing technology and products similar or identical to ours or other competing products and technologies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent applications, we rely on unpatented trade secrets, know-how and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and confidential know-how are difficult to protect. In particular, we consider various aspects of our Gene Traffic Control platform to constitute our trade secrets and know-how. We seek to protect our proprietary information, in part, by executing confidentiality agreements with our collaborators and scientific advisors and non-competition, non-solicitation, confidentiality and invention assignment agreements with our employees and consultants. We cannot guarantee that we will have executed such agreements with all applicable employees and contractors, or that these agreements will afford us adequate protection of our intellectual property and proprietary information rights. In addition, our trade secrets and/or confidential know-how may become known or be independently developed by a third party or misused by any person to whom we disclose such information. These agreements may also be breached, and we may not have an adequate remedy for any such breach. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or to obtain or use information that we regard as proprietary. Although we take steps to protect our proprietary information, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information. For more information regarding the risks related to our intellectual property, please see &#8220;Risk Factors&#8212;Risks Related to our Intellectual Property.&#8221;</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreement with Merck</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we entered into a Research Collaboration and Exclusive License Agreement, or the Merck Collaboration Agreement, with Merck Sharp &amp; Dohme Corp., or Merck, to apply our Gene Traffic Control platform to discover and develop novel therapeutics based on disruptors of a specified transcription factor target.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Merck Collaboration Agreement, we are responsible for certain preclinical research activities under a mutually agreed research plan, such as the use of our high throughput screening and compound optimization technology to identify and validate disruptors directed to this transcription factor target, up until our delivery to Merck of a hit package that identifies validated disruptors directed to the transcription factor target. Merck will be responsible for further preclinical research under the Merck Collaboration Agreement and for the clinical development and commercialization of therapeutics arising from the agreement. Merck will have a limited right to substitute the transcription factor target that is the subject of the collaboration for other transcription factors.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Merck Collaboration Agreement, we have granted Merck an exclusive, worldwide, sublicensable license under certain patent rights and know-how to make, have made, use, import, offer to sell and sell therapeutics arising from the collaboration that disrupt the specified transcription factor target.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received an upfront payment of $15.0&#160;million from Merck, and are eligible to receive up to $245.0&#160;million upon achievement of specified research, development and regulatory milestones by any product candidate generated by the collaboration, and up to $165.0&#160;million upon achievement of specified sales-based milestones per approved product from the collaboration, if any. We will be eligible to receive tiered royalties, calculated on a product-by-product basis, on net sales of approved products from the collaboration, if any, at royalty rates ranging from the mid-single digits to low tens, depending on whether the products are covered by patent rights we license to Merck.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merck Collaboration Agreement will expire upon expiration of all of Merck&#8217;s royalty obligations under the agreement. Merck may terminate the Merck Collaboration Agreement for convenience, and either party may terminate the Merck Collaboration Agreement in the event of the other party&#8217;s uncured material breach or such party&#8217;s bankruptcy or insolvency. If </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck terminates the Merck Collaboration Agreement as a result of our breach, the licenses and other rights granted to Merck under the agreement will remain in effect and become perpetual. If the term of the agreement expires, then such licenses and other rights will become fully paid-up.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategic Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 10, 2021, we entered into a strategic collaboration with Loxo Oncology at Lilly.  Under the terms of the collaboration agreement, the parties will seek to leverage our platform technology to research, discover and develop therapeutic molecules directed to the selective BRM target and an additional undisclosed oncology target, and to three additional discovery programs.  Lilly will pursue the clinical development, manufacture and commercialization of products derived from or containing certain compounds developed and Foghorn will have the right to participate in the development and commercialization of these products for the U.S. market.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, Lilly made an upfront payment of $300 million, and a concurrent $80 million equity investment in Foghorn. We are eligible to receive a share of U.S. profits for co-commercialized products. Lilly and Foghorn will share 50/50 in the U.S. economics for products directed to the BRM-selective program and one other undisclosed target. For the three Discovery Programs, Foghorn will have an option to participate in a percentage of the U.S. economics following the successful completion of dose-finding toxicity studies. For these programs, Foghorn is eligible to receive development and commercialization milestones of up to an aggregate of approximately $1.3 billion if Foghorn does not exercise its option to participate in the U.S. economics for any discovery program. In addition, Lilly will pay the Company tiered royalties on product sales on a country-by-country and product-by-product basis (1) at royalty rates ranging from low-double digits to the twenties on ex-U.S. sales for products directed to the BRM-selective program and one other undisclosed target and (2) at royalty rates ranging from mid-single digits to low-double digits on sales outside the U.S. for products directed to the Discovery Programs, during the applicable royalty term and subject to certain royalty step-down provisions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any manufacturing facilities or personnel. We currently rely, and expect to continue to rely, on third parties for the manufacture of our product candidates undergoing preclinical testing, as well as for clinical testing and commercial manufacture if our product candidates receive marketing approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our drug candidates are small molecules and are manufactured in synthetic processes from available starting materials. The chemistry appears amenable to scale up and does not currently require unusual equipment in the manufacturing process. We expect to continue to develop product candidates that can be produced cost-effectively at contract manufacturing facilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally expect to rely on third parties for the manufacture of companion diagnostics for our products, which are assays or tests to identify an appropriate patient population. Depending on the technology solutions we choose, we may rely on multiple third parties to manufacture and sell a single test.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to receiving marketing approvals, we expect to commence commercialization activities by building a focused sales and marketing organization in the United States to sell our products. We believe that such an organization will be able to address the community of oncologists who are the key specialists in treating the patient populations for which our product candidates are being developed. Outside the United States, we expect to enter into distribution and other marketing arrangements with third parties for any of our product candidates that obtain marketing approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also plan to build a marketing and sales management organization to create and implement marketing strategies for any products that we market through our own sales organization and to oversee and support our sales force. The responsibilities of the marketing organization would include developing educational initiatives with respect to approved products and establishing relationships with researchers and practitioners in relevant fields of medicine.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other regulatory authorities at federal, state and local levels, as well as in ex-United States countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, recordkeeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of drugs. We, along with our vendors, contract research organizations and contract manufacturers, will be required to navigate the various preclinical, clinical, manufacturing and commercial approval </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval of our product candidates. The process of obtaining regulatory approvals of drugs and ensuring subsequent compliance with appropriate federal, state, local and ex-United States statutes and regulations requires the expenditure of substantial time and financial resources.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, where we are initially focusing our drug development, the FDA regulates drug products under the Federal Food, Drug, and Cosmetic Act, or FD&amp;C Act, as amended, its implementing regulations and other laws. If we fail to comply with applicable FDA or other requirements at any time with respect to product development, clinical testing, approval or any other legal requirements relating to product manufacture, processing, handling, storage, quality control, safety, marketing, advertising, promotion, packaging, labeling, export, import, distribution, or sale, we may become subject to administrative or judicial sanctions or other legal consequences. These sanctions or consequences could include, among other things, the FDA&#8217;s refusal to approve pending applications, issuance of clinical holds for ongoing studies, suspension or revocation of approved applications, warning or untitled letters, product withdrawals or recalls, product seizures, relabeling or repackaging, total or partial suspensions of manufacturing or distribution, injunctions, fines, civil penalties or criminal prosecution.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process required by the FDA before our product candidates are approved as drugs for therapeutic indications and may be marketed in the United States generally involves the following:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with good laboratory practice, or GLP, requirements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">completion of the manufacture, under cGMP conditions, of the drug substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and stability testing;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">submission to the FDA of an IND, which must become effective before clinical trials may begin;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">approval by an institutional review board, or IRB, or independent ethics committee at each clinical trial site before each trial may be initiated;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">performance of adequate and well-controlled clinical trials in accordance with applicable IND regulations, good clinical practice, or GCP, requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">submission to the FDA of a New Drug Application, or NDA;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a determination by the FDA within 60 days of its receipt of an NDA, to accept the filing for review;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">potentially, satisfactory completion of FDA audit of the clinical trial sites that generated the data in support of the NDA;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">payment of user fees for FDA review of the NDA; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the United States.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Studies and Clinical Trials for Drugs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before testing any drug in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluations of drug chemistry, formulation and stability, as well as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and animal studies to assess safety and in some cases to establish the rationale for therapeutic use. The conduct of preclinical studies is subject to United States federal and state regulation, including GLP requirements for safety/toxicology studies. The results of the preclinical studies, together with manufacturing information and analytical data, must be submitted to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before clinical trials may begin. Some long-term preclinical testing may continue after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks, and imposes a full or partial clinical hold. FDA must notify the sponsor of the grounds for the hold and any identified deficiencies must be resolved before the clinical trial can begin. Submission of an IND may result in the FDA not allowing clinical trials to commence or not allowing clinical trials to commence on the terms originally specified in the IND. A clinical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hold can also be imposed once a trial has already begun, thereby halting the trial until the deficiencies articulated by FDA are corrected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical stage of development involves the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators, who generally are physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP requirements, which include the requirements that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters and criteria to be used in monitoring safety and evaluating effectiveness. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable compared to the anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subject or other grounds, such as a lack of observed efficacy. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trials to public registries. Information about clinical trials, including results for clinical trials other than Phase 1 investigations, must be submitted within specific timeframes for publication on www.ClinicalTrials.gov, a clinical trials database maintained by the National Institutes of Health.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, FDA will nevertheless accept the results of the study in support of an NDA if the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials to evaluate therapeutic indications to support NDAs for marketing approval are typically conducted in three sequential phases, which may overlap.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Phase 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Phase 1 clinical trials involve initial introduction of the investigational product into healthy human volunteers or patients with the target disease or condition. These studies are typically designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, excretion the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness.</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Phase 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Phase 2 clinical trials typically involve administration of the investigational product to a limited patient population with a specified disease or condition to evaluate the drug&#8217;s potential efficacy, to determine the optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks.</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Phase 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Phase 3 clinical trials typically involve administration of the investigational product to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval and physician labeling.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-approval trials, sometimes referred to as Phase 4 clinical trials or post-marketing studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly intended to generate additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of NDA approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA. Written IND safety reports must be submitted to the FDA and the investigators fifteen days after the trial sponsor determines the information qualifies for reporting for serious and unexpected suspected adverse events, findings from other studies or animal or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing that suggest a significant risk for human volunteers and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must also notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible but in no case later than seven calendar days after the sponsor&#8217;s initial receipt of the information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate and finalize a process for manufacturing the drug product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and manufacturers must develop, among other things, methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Marketing Approval for Drugs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA package requesting approval to market the product for one or more indications. An NDA is a request for approval to market a new drug for one or more specified indications and must contain proof of the drug&#8217;s safety and efficacy for the requested indications. The marketing application is required to include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. FDA must approve an NDA before a drug may be marketed in the United States.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA reviews all submitted NDAs before it accepts them for filing and may request additional information rather than accepting the NDA for filing. The FDA must make a decision on accepting an NDA for filing within 60 days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the NDA. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective for the indications sought and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity. Under the goals and polices agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, the FDA targets ten months, from the filing date, in which to complete its initial review of a new molecular entity NDA and respond to the applicant, and six months from the filing date of a new molecular entity NDA for priority review. The FDA does not always meet its PDUFA goal dates for standard or priority NDAs, and the review process is often extended by FDA requests for additional information or clarification.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, under PDUFA, as amended, each NDA must be accompanied by a substantial user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also may require submission of a Risk Evaluation and Mitigation Strategy, or REMS, if it believes that a risk evaluation and mitigation strategy is necessary to ensure that the benefits of the drug outweigh its risks. A REMS can include use of risk evaluation and mitigation strategies like medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk-minimization tools.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP and other requirements and the integrity of the clinical data submitted to the FDA.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA approves a product, depending on the specific risk(s) to be addressed it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drug Designation and Exclusivity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or that affects more than 200,000 individuals in the United States where there is no reasonable expectation that the cost of developing and making the product available in the United States for the disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting an NDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process, though companies developing orphan products are eligible for certain incentives, including tax credits for qualified clinical testing and waiver of application fees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to a seven-year period of marketing exclusivity during which the FDA may not approve any other applications to market the same therapeutic agent for the same indication, except in limited circumstances, such as a subsequent product&#8217;s showing of clinical superiority over the product with orphan drug exclusivity or where the original applicant cannot produce sufficient quantities of product. Competitors, however, may receive approval of different therapeutic agents for the indication for which the orphan product has exclusivity or obtain approval for the same therapeutic agent for a different indication than that for which the orphan product has exclusivity. Orphan drug exclusivity could block the approval of one of our products for seven years if a competitor obtains approval for the same therapeutic agent for the same indication before we do, unless we are able to demonstrate that our product is clinically superior. If an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan drug exclusivity. Further, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expedited Development and Review Programs for Drugs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA maintains several programs intended to facilitate and expedite development and review of new drugs to address unmet medical needs in the treatment of serious or life-threatening diseases or conditions. These programs include Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval, and the purpose of these programs is to either expedite the development or review of important new drugs to get them to patients more quickly than standard FDA review timelines typically permit.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A new drug is eligible for Fast Track designation if it is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address unmet medical needs for such disease or condition. Fast Track designation provides increased opportunities for sponsor interactions with the FDA during preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed. Rolling review means that the agency may review portions of the marketing application before the sponsor submits the complete application. In addition, a new drug may be eligible for Breakthrough Therapy designation if it is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therapy designation provides all the features of Fast Track designation in addition to intensive guidance on an efficient drug development program beginning as early as Phase 1, and FDA organizational commitment to expedited development, including involvement of senior managers and experienced review staff in a cross-disciplinary review, where appropriate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product submitted to the FDA for approval, including a product with Fast Track or Breakthrough Therapy designation, may also be eligible for additional FDA programs intended to expedite the review and approval process, including Priority Review designation and Accelerated Approval. A product is eligible for Priority Review, once an NDA or BLA is submitted, if the drug that is the subject of the marketing application has the potential to provide a significant improvement in safety or effectiveness in the treatment, diagnosis or prevention of a serious disease or condition. Under priority review, the FDA&#8217;s goal date to take action on the marketing application is six months compared to ten months for a standard review. Products are eligible for Accelerated Approval if they can be shown to have an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or an effect on a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, which is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated Approval is usually contingent on a sponsor&#8217;s agreement to conduct additional post-approval studies to verify and describe the product&#8217;s clinical benefit. The FDA may withdraw approval of a drug or an indication approved under Accelerated Approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, the FDA generally requires, as a condition for Accelerated Approval, that all advertising and promotional materials intended for dissemination or publication within 120 days of marketing approval be submitted to the agency for review during the pre-approval review period. After the 120-day period has passed, all advertising and promotional materials must be submitted at least 30 days prior to the intended time of initial dissemination or publication.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval do not change the scientific or medical standards for approval or the quality of evidence necessary to support approval, though they may expedite the development or review process.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric Information and Pediatric Exclusivity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, as amended, certain NDAs and NDA supplements must contain data that can be used to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. The FD&amp;C Act requires that a sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan, or PSP, within 60 days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A drug can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Post-Approval Requirements for Drugs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drugs manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, reporting of adverse experiences with the product, complying with promotion and advertising requirements, which include restrictions on promoting products for unapproved uses or patient populations (known as &#8220;off-label use&#8221;) and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available products for off-label uses, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including investigation by federal and state authorities. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use or first publication. Further, if there are any modifications to the drug, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA or NDA supplement, which may require the generation of additional data or the conduct of additional preclinical studies and clinical trials.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-market testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization. In addition, drug manufacturers and their subcontractors involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMPs, which impose certain procedural and documentation requirements. Failure to comply with statutory and regulatory requirements may subject a manufacturer to legal or regulatory action, such as warning letters, suspension of manufacturing, product seizures, injunctions, civil penalties or criminal prosecution. There is also a continuing, annual prescription drug product program user fee.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, requirements for post-market studies or clinical trials to assess new safety risks, or imposition of distribution or other restrictions under a REMS. Other potential consequences include, among other things:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;</span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">fines, warning letters or holds on post-approval clinical trials;</span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">refusal of the FDA to approve applications or supplements to approved applications, or suspension or revocation of product approvals;</span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">product seizure or detention, or refusal to permit the import or export of products;</span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">injunctions or the imposition of civil or criminal penalties; and</span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; or mandated modification of promotional materials and labeling and issuance of corrective information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companion diagnostics are designed to identify patients who are most likely to benefit from a particular therapeutic product; identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product; or monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. Companion diagnostics are regulated as medical devices by the FDA. In the United States, the FD&amp;C Act, and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption or FDA exercise of enforcement discretion applies, diagnostic tests generally require marketing clearance or approval from the FDA prior to commercialization. The two primary types of FDA marketing authorization applicable to a medical device are clearance of a premarket notification, or 510(k), and approval of a premarket approval application, or PMA.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain 510(k) clearance for a medical device, or for certain modifications to devices that have received 510(k) clearance, a manufacturer must submit a premarket notification demonstrating that the proposed device is substantially equivalent to a previously cleared 510(k) device or to a pre-amendment device that was in commercial distribution before May&#160;28, 1976, or a predicate device, for which the FDA has not yet called for the submission of a PMA. In making a determination that the device is substantially equivalent to a predicate device, the FDA compares the proposed device to the predicate device and assesses whether the subject device is comparable to the predicate device with respect to intended use, technology, design and other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">features which could affect safety and effectiveness. If the FDA determines that the subject device is substantially equivalent to the predicate device, the subject device may be cleared for marketing. The 510(k) premarket notification pathway generally takes from three to twelve months from the date the application is completed, but can take significantly longer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A PMA must be supported by valid scientific evidence, which typically requires extensive data, including technical, preclinical, clinical and manufacturing data, to demonstrate to the FDA&#8217;s satisfaction the safety and effectiveness of the device. The process for developing a PMA, including the gathering of clinical and preclinical data and submission to FDA can take several years or longer. For diagnostic tests, a PMA typically includes data regarding analytical and clinical validation studies. As part of its review of the PMA, the FDA will conduct a pre-approval inspection of the manufacturing facility or facilities to ensure compliance with the quality system regulation, or QSR, which requires manufacturers to follow design, testing, control, documentation and other quality assurance procedures. The FDA&#8217;s review of an initial PMA is required by statute to take between six to ten months, although the process typically takes longer, and may require several years to complete, and PMA approval is not guaranteed. If the FDA evaluations of both the PMA and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA. If the FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny the approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. Once granted, PMA approval may be withdrawn by the FDA if compliance with post-approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;31, 2014, the FDA issued a final guidance document addressing the development and approval process for &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In Vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Companion Diagnostic Devices.&#8221; According to the guidance document, for novel therapeutic products that depend on the use of a diagnostic test and where the diagnostic device could be essential for the safe and effective use of the corresponding therapeutic product, the companion diagnostic device should be developed and approved or cleared contemporaneously with the therapeutic, although the FDA recognizes that there may be cases when contemporaneous development may not be possible. However, in cases where a drug cannot be used safely or effectively without the companion diagnostic, the FDA&#8217;s guidance indicates it will generally not approve the drug without the approval or clearance of the diagnostic device. The FDA also issued a draft guidance in July 2016 setting forth the principles for co-development of an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> companion diagnostic device with a therapeutic product. The draft guidance describes principles to guide the development and contemporaneous marketing authorization for the therapeutic product and its corresponding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> companion diagnostic.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once cleared or approved, the companion diagnostic device must adhere to post-marketing requirements including the requirements of the FDA&#8217;s QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging, and shipping of all medical devices, as well as adverse event reporting, recalls and corrections along with product marketing requirements and limitations. Medical devices, including companion diagnostics, may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. Like drug makers, companion diagnostic makers are subject to unannounced FDA inspections at any time during which the FDA will conduct an audit of the product(s) and the company&#8217;s facilities, facility records, and manufacturing processes for compliance with its authorities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketing Exclusivity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market exclusivity provisions authorized under the FD&amp;C Act can delay the submission or the approval of certain marketing applications. The FD&amp;C Act provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or an NDA submitted under Section&#160;505(b)(2), or 505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FD&amp;C Act alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Regulatory Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing, sales, promotion and other activities of product candidates following product approval, where applicable, or commercialization are also subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, which may include the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&#160;&amp; Health Administration, the Environmental Protection Agency and state and local governments and governmental agencies.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians, and third-party payors will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our business operations and any current or future arrangements with third-party payors, healthcare providers and physicians may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we develop, market, sell and distribute any drugs for which we obtain marketing approval. In the United States, these laws include, without limitation, state and federal anti-kickback, false claims, physician transparency, and patient data privacy and security laws and regulations, including but not limited to those described below.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid; a person or entity need not have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act.</span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The federal civil and criminal false claims laws, including the civil False Claims Act, or FCA, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false, fictitious or fraudulent; knowingly making, using, or causing to be made or used, a false statement or record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. When an entity is determined to have violated the federal civil False Claims Act, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs.</span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The federal civil monetary penalties laws impose civil fines for, among other things, the offering or transfer or remuneration to a Medicare or state healthcare program beneficiary, if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for knowingly and willfully executing a scheme, or attempting to execute a scheme, to defraud any healthcare benefit program, including private payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, or falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services.</span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, impose, among other things, specified requirements on covered entities and their business associates relating to the privacy and security of individually identifiable health information including mandatory contractual terms and required implementation of technical safeguards of such information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates in some cases, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The Physician Payments Sunshine Act, which imposes annual reporting requirements for certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, for certain payments and &#8220;transfers of value&#8221; provided to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Effective January&#160;1, 2022, these reporting obligations will extend to include transfers of value made in the previous year to certain non-physician providers such as physician assistants and nurse practitioners.</span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Federal consumer protection and unfair competition laws broadly regulate marketplace activities and activities that potentially harm consumers.</span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Analogous state and foreign laws and regulations may be broader in scope than the provisions described above and may apply regardless of payor. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and relevant federal government compliance guidance; require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers; restrict marketing practices or require disclosure of marketing expenditures and pricing information. State and foreign laws may govern the privacy and security of health information in some circumstances. These data privacy and security laws may differ from each other in significant ways and often are not pre-empted by HIPAA, which may complicate compliance efforts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other related governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, disgorgement, exclusion from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, additional oversight and reporting obligations if we become subject to a corporate integrity agreement or similar settlement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to similar actions, penalties and sanctions. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from its business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and Reimbursement by Third-Party Payors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, the product. In the United </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">States, the Medicare and Medicaid programs are increasingly used as models for how private and other governmental payors develop their coverage and reimbursement policies for drugs. No uniform policy of coverage and reimbursement for drug products exists, however, among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, which will require additional expenditure above and beyond the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide discounts to purchasers, private health plans or government healthcare programs. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations and financial condition. Additionally, a third-party payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current and Future Healthcare Reform Legislation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare. For example, in March 2010, the United States Congress enacted the Affordable Care Act, which, among other things, includes changes to the coverage and payment for products under government health care programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges and amendments to the Affordable Care Act in the future. For example, various portions of the Affordable Care Act are currently facing legal and constitutional challenges in the Fifth Circuit Court of Appeals and the United States Supreme Court. Additionally, the current administration has issued various Executive Orders which eliminated cost sharing subsidies and various provisions that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices, and Congress has introduced several pieces of legislation aimed at significantly revising or repealing the Affordable Care Act. It is unclear whether the Affordable Care Act will be overturned, repealed, replaced, or further amended. We cannot predict what effect further changes to the Affordable Care Act would have on our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. In August 2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with a temporary suspension from May&#160;1, 2020 through December&#160;31, 2020, unless additional Congressional action is taken. In addition, in January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, including bundled payment models. In addition, recently there has been </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products, which has resulted in several Congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. Although a number of these measures may require additional authorization to become effective, Congress and the current administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;24, 2020, President Trump announced a number of executive orders related to prescription drug pricing that attempt to implement several of the Administration&#8217;s proposals, including a policy that would tie Medicare Part B drug prices to international drug prices; one that directs HHS to finalize the Canadian drug importation proposed rule previously issued by HHS and makes other changes allowing for personal importation of drugs from Canada; and one that directs HHS to finalize the rulemaking process on modifying the anti-kickback law safe harbors for plans, pharmacies, and pharmaceutical benefit managers after HHS confirms that the action is not projected to increase federal spending, Medicare beneficiary premiums, or patients&#8217; total out-of-pocket costs. The probability of success of these newly announced policies and their impact on the U.S. prescription drug marketplace is unknown. There are likely to be political and legal challenges associated with implementing these reforms as they are currently envisioned.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, ensuring coverage and adequate payment for a product also involves challenges. Pricing of prescription pharmaceuticals is subject to government control in many countries. Pricing negotiations with government authorities can extend well beyond the receipt of regulatory approval for a product and may require a clinical trial that compares the cost-effectiveness of a product to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in commercialization. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other U.S. Environmental, Health and Safety Laws and Regulations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Regulation of Drugs Outside of the United States</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of drug products. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical trials or marketing of the product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others. As in the United States, post-approval regulatory requirements, such as those regarding product manufacture, marketing, or distribution would apply to any product that is approved outside the United States.</span></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data Privacy Regulations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conduct of our clinical trials may be subject to privacy restrictions based on U.S. and non-U.S. regulations. For example, we may be subject to the California Consumer Privacy Act, or CCPA. As currently written, the CCPA may impact our business activities and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information. Additionally, the collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the EU and the UK, including personal health data, is subject to the EU General Data Protection Regulation, or GDPR, including as it forms part of the law of England and Wales, Scotland and Northern Ireland by virtue of section 3 of the European Union (Withdrawal) Act 2018 and as amended by the Data Protection, Privacy and Electronic Communications (Amendments etc.) (EU Exit) Regulations 2019 (SI 2019/419), known as UK GDPR. Compliance with the GDPR and the UK GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities. The UK&#8217;s data protection authority, the Information Commissioner&#8217;s Office, has indicated that following Brexit it will continue to enforce the UK GDPR in line with the enforcement of the GDPR in the EU. However, the UK government recently announced its intention to adopt a more flexible approach to the regulation of data, and as a result, there remains a risk of future divergence between the EU and UK data protection regimes.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had 119 full-time employees. 49 of our employees have M.D. or Ph.D. degrees. Within our workforce, 94 employees are engaged in research and development and 25 are engaged in business development, finance, legal, and general management and administration. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Corporate Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were formed as a Delaware corporation in October 2015 under the name Foghorn Therapeutics Inc. Our principal executive office is located at 500&#160;Technology Square, Suite&#160;700, Cambridge, Massachusetts, 02139, and our phone number is 617-586-3100. Our website address is https://foghorntx.com. Our website and the information contained on, or that can be accessed through, the website will not be deemed to be incorporated by reference in, and are not considered part of, this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012. We will remain an emerging growth company until the earlier of: (i)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the completion of the IPO, (b)&#160;in which we have total annual gross revenue of at least $1.07&#160;billion, or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700.0&#160;million as of the prior June&#160;30th, and (ii)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt during the prior three-year period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also a &#8220;smaller reporting company&#8221; as defined in the Securities and Exchange Act of 1934, as amended, or the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year following the determination that our voting and non-voting common stock held by non-affiliates is more than $250&#160;million measured on the last business day of our second fiscal quarter, or our annual revenues are more than $100&#160;million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is more than $700&#160;million measured on the last business day of our second fiscal quarter.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Internet address is https://foghorntx.com. Our Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K, including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to Sections&#160;13(a) and 15(d) of the Exchange Act are available through the &#8220;Investors&#8221; portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information on </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our website is not part of this Annual Report on Form&#160;10-K or any of our other securities filings unless specifically incorporated herein by reference. In addition, our filings with the SEC may be accessed through the SEC&#8217;s Electronic Data Gathering, Analysis and Retrieval system at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</span></div><div id="i523559815e87485cb6a9895707f43a02_19"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report on Form&#160;10-K, including our consolidated financial statements and related notes, before deciding to invest in our common stock. Some of the following risks and uncertainties are, and will be, exacerbated by the COVID-19 pandemic (including any resurgences thereof) and any worsening of the global business and economic environment as a result. If any of the events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer materially, the trading price of our common stock could decline and you could lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company with a limited operating history. We were incorporated in October 2015, and our operations to date have been focused on building our proprietary Gene Traffic Control platform, organizing and staffing our company, business planning, raising capital, conducting discovery and research activities, protecting our trade secrets, filing patent applications, identifying potential product candidates, undertaking preclinical studies and establishing arrangements with third parties for the manufacture of initial quantities of our product candidates and component materials. We are currently in Phase 1 clinical trials for FHD-286 and FHD-609, and all of our other product candidates are in preclinical development. We have not yet demonstrated an ability to successfully complete any clinical trials, obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a young business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our financial condition and results of operations to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant operating losses. As of December&#160;31, 2021, we had an accumulated deficit of $264.3&#160;million. We have financed our operations primarily through private placements of our preferred stock and our initial public offering, as well as through a loan with Oxford Finance LLC, or Oxford Finance, which was repaid in full during fiscal year 2021; our collaboration agreement with Merck; and our strategic collaboration with Loxo Oncology at Lilly and Lilly's concurrent investment in our equity. For further information about our collaborations and Lilly's equity investment, see &#8220;Business&#8212;License Agreement with Merck&#8221; and "Business&#8212;Strategic Collaboration." We have devoted all of our efforts to research and development. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially if and as we:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">advance our FHD-286 and FHD-609 product candidates and continue our preclinical development of product candidates from our current research programs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">identify additional research programs and additional product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">initiate preclinical testing for any new product candidates we identify and develop;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtain, maintain, expand, enforce, defend and protect our trade secrets and intellectual property portfolio and provide reimbursement of third-party expenses related to our patent portfolio;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">hire additional research and development personnel;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">add operational, legal, compliance, financial and management information systems and personnel to support our research, product development and operations as a public company;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expand the capabilities of our platform;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">acquire or in-license product candidates, intellectual property and technologies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">operate as a public company;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">seek marketing approvals for any of our product candidates that successfully complete clinical trials; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ultimately establish a sales, marketing, and distribution infrastructure to commercialize any products for which we may obtain marketing approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two product candidates in Phase 1 clinical development and have not initiated clinical development of any other product candidate and expect that it will be many years, if ever, before we have a product candidate ready for commercialization. To become and remain profitable, we must develop and, either directly or through collaborators, eventually commercialize a medicine or medicines with significant market potential. This will require us to be successful in a range of challenging activities, including identifying product candidates, completing preclinical testing and clinical trials of product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing, and selling those medicines for which we may obtain marketing approval, and satisfying any post-marketing requirements. We may never succeed in these activities and, even if we do, may never generate revenues that are significant or large enough to achieve profitability. We are unable to predict the extent of any future losses or when we will become profitable, if at all. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce, or eliminate our research and product development programs or future commercialization efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our expenses to increase in connection with our ongoing activities, particularly as we identify, continue the research and development of, initiate clinical trials of, and seek marketing approval for, our product candidates. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce, or eliminate our research and product development programs or future commercialization efforts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, our cash, cash equivalents and marketable securities were $154.3 million. The net proceeds of our initial public offering were $107.9&#160;million, after deducting underwriting discounts and commissions and other offering expenses. On November&#160;19, 2020, we received additional net proceeds of $14.2&#160;million in connection with the underwriters&#8217; partial exercise of their option to purchase additional shares of common stock in our initial public offering. On December 10, 2021, we issued and sold to Lilly 4,000,000 shares of our common stock at a price of $20.00 per share for aggregate gross proceeds of $80.0 million, </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional fundraising efforts, when needed, may divert our management&#8217;s attention from their day-to-day activities, which may adversely affect our ability to advance our product candidates or develop new product candidates. We cannot be certain that additional funding will be available on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain funding on a reasonable and timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs, clinical research, or the commercialization of any product candidate. We may be unable to expand our operations or otherwise capitalize on our business opportunities as desired. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never generated revenue from product sales and may never be profitable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently in the Phase 1 clinical development stage for our two most advanced product candidates, FHD-286 and FHD-609, and in the preclinical development stage for our other lead research programs. We expect that it will be many years, if ever, before we have a product candidate ready for commercialization. To become and remain profitable, we must succeed in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developing, obtaining marketing approval for and commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our current or future product candidates, establishing and maintaining arrangements with third parties for the manufacture of clinical supplies of our product candidates, obtaining marketing approval for our product candidates and manufacturing, marketing, selling and obtaining reimbursement for any products for which we may obtain marketing approval. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. federal income tax reform could adversely affect our business and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to&#160;tax&#160;laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. For example, on March&#160;27, 2020, President Trump signed into law the Coronavirus Aid, Relief, and Economic Security Act, which included certain changes in&#160;tax&#160;law intended to stimulate the U.S. economy in light of the COVID-19 coronavirus outbreak, including temporary beneficial changes to the treatment of net operating losses, interest deductibility limitations and payroll tax matters. Additionally, on December&#160;22, 2017, President Trump signed into law the Tax Cuts and&#160;Jobs Act, or the TCJA, which significantly reformed the Internal Revenue Code of 1986, as amended, or the Code. The TCJA included significant changes to corporate and individual taxation, some of which could adversely impact an investment in our common stock. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred substantial losses during our history and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset a portion of future taxable income, if any, subject to expiration in the case of carryforwards generated prior to January&#160;1, 2018. Additionally, we continue to generate business tax credits, including research and development tax credits, which generally may be carried forward to offset a portion of future taxable income, if any, subject to expiration of such credit carryforwards. Under Sections 382 and 383 of the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income or taxes may be limited. Our prior equity offerings and other changes in our stock ownership may have resulted in such ownership changes. We may also experience ownership changes in the future or subsequent shifts in our stock ownership, some of which are outside of our control. As a result, if we earn net taxable income, our ability to use our pre-change NOLs or other pre-change tax attributes to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. Additionally, for taxable years beginning after December&#160;31, 2021, the deductibility of such U.S. federal NOLs is limited to 80% of our taxable income in any future taxable year. There is a risk that under existing tax laws, changes thereto, regulatory changes, or other unforeseen reasons, our existing NOLs or business tax credits could expire or otherwise be unavailable to offset future income tax liabilities. At the state level, there may also be periods during which the use of NOLs or business tax credits is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For these reasons, we may not be able to realize a tax benefit from the use of our NOLs or tax credits, even if we attain profitability.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Discovery and Development</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are heavily dependent on the success of our product candidates, which are in preclinical and Phase 1 clinical development. We may not be successful in our efforts to identify and develop potential product candidates. If these efforts are unsuccessful, or if we experience significant delays, we may never become a commercial stage company or generate any revenues, and our business will be materially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business depends primarily upon our ability to identify, develop, and commercialize product candidates based on our platform. All of our product development programs are still in the research or preclinical or Phase 1 clinical stage of development. Our research programs may fail to identify potential product candidates for clinical development for a number of reasons. Our research methodology may be unsuccessful in identifying potential product candidates, our potential product candidates may be shown to have harmful side effects in preclinical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in&#160;vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> experiments or animal model studies, they may not show promising signals of therapeutic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to administer or market.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occurs, we may be forced to abandon our research or development efforts for a program or programs, which would have a material adverse effect on our business, financial condition, results of operations, and prospects. Research programs to identify new product candidates require substantial technical, financial, and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful, which would be costly and time-consuming.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our product candidates will depend on several factors, including but not limited to the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">successful completion of preclinical studies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">successful submission of INDs and initiation of clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establishing an acceptable safety profile of the products and maintaining such a profile following approval;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">achieving desirable therapeutic properties for our product candidates&#8217; intended indications;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">making arrangements with third-party manufacturers, or establishing manufacturing capabilities, both for clinical and commercial supplies of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">receipt and related terms of marketing approvals from applicable regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establishing sales, marketing and distribution capabilities and launching commercial sales of our products; if and when approved, whether alone or in collaboration with others; acceptance of our products, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtaining and maintaining third-party coverage and adequate reimbursement;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">effectively competing with other therapies; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">sufficiency of our financial and other resources.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not successfully achieve one or more of these factors in a timely manner, or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which could materially harm our business. Moreover, if we do not receive regulatory approvals, we may not be able to continue our operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to file INDs or IND amendments to commence clinical trials of our product candidates on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to commence a clinical trial in the United States, we are required to seek FDA acceptance of an IND for each of our product candidates. We cannot be sure any IND we submit to the FDA, or any similar clinical trial application we submit in other countries, will be accepted. We may also be required to conduct additional preclinical testing prior to filing or acceptance of an IND for any of our product candidates, and the results of any such additional preclinical testing may not be positive.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we may experience manufacturing delays or other delays with IND-enabling studies. Moreover, we cannot be sure that even once clinical trials have begun, issues will not arise that suspend or terminate clinical trials. Additionally, even if the FDA agrees with the design and implementation of the clinical trials set forth in an IND, we cannot guarantee that the FDA will not change its requirements in the future. These considerations also apply to new clinical trials we may submit as amendments to existing INDs or to a new IND. Any failure to file INDs on the timelines we expect or to obtain regulatory authorizations for our trials to proceed may prevent us from completing our clinical trials or commercializing our product candidates on a timely basis, if at all.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There is substantial competition in our field, which may result in others developing or commercializing products before we do.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries utilize rapidly advancing technologies and are characterized by intense competition. While we believe that our scientific knowledge and platform development expertise provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceuticals, specialty pharmaceuticals and biotechnology companies, academic institutions and government agencies, and public and private research institutes that conduct research, development, manufacturing and commercialization. Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, enrolling and conducting clinical trials, and seeking regulatory approvals and product marketing than we do, and have potential to advance products competitive with our product candidates or other programs addressing the chromatin regulatory system at a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rapid pace. In addition, our competitors may compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our competitors may advance competing product candidates that have a more attractive product profile than our product candidates, make progress examining the chromatin regulatory system or bring a product to market before we can. Any of these developments could put us at a significant competitive disadvantage and have a material adverse effect on the prospects of our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product candidates that we and our collaborators successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. While we are not aware of other companies addressing the chromatin regulatory system at scale, in context and in an integrated way, we are aware of efforts to bring products to market that could be competitive with ours if our programs are successful. Specifically, we expect that our product candidates will compete against approved drugs, including Idhifa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by Celgene Corporation, Tibsovo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by Agios Pharmaceuticals, and Rydapt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by Novartis International AG . If our product candidates are approved for the indications for which we are currently planning clinical trials, they will likely compete with the competitor drugs mentioned above and with other drugs that are currently in development. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products. Our competitors may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. Our competitors may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. For additional information regarding our competition, see &#8220;Business&#8212;Competition.&#8221;</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates utilize novel mechanisms of action, which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or discovery of unknown or unanticipated adverse effects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidates utilize novel mechanisms of action, which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or discovery of unknown or unanticipated adverse effects. For example, FHD-609 is a protein degrader. Currently there are no approved medicines using this mechanism of action. Because FHD-609 in particular utilizes a novel mechanism of action that has not been the subject of extensive study compared to more well-known product candidates, there is also an increased risk that we may discover previously unknown or unanticipated adverse effects during our preclinical studies and clinical trials. Any such events could adversely impact our business prospects, financial condition and results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a novel mechanism of action may lengthen the regulatory review process, require us to conduct additional studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. The novel mechanism of action also means that fewer people are trained in or experienced with product candidates of this type, which may make it more difficult to find, hire and retain personnel for research, development and manufacturing positions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, which would delay or prevent regulatory approval of the product candidates, limit the commercial potential, or result in significant negative consequences following any potential marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain the requisite regulatory approvals to market and sell any of our product candidates, we must demonstrate through extensive preclinical studies and clinical trials that such product candidates are safe and effective for use in each targeted indication. Failure can occur at any time during the clinical development process. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. We only began evaluating two product candidates in human clinical trials during 2021. Moreover, we are not aware of any other clinical trials involving products that interact with BAF complexes to affect the chromatin regulatory system in a similar manner to our products. It is impossible to predict when or if any product candidates we may develop will prove safe in humans. Our clinical trials may fail to demonstrate with substantial evidence from adequate and well-controlled trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. There can be no assurance that our clinical trials will not cause undesirable side effects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any product candidates we develop are associated with or cause serious adverse events, undesirable side effects, or unexpected characteristics, we may need to abandon their development or limit development to certain uses or subpopulations in which the serious adverse events, undesirable side effects or other characteristics are less prevalent, less severe, or more acceptable from a risk-benefit perspective, any of which would have a material adverse effect on our business, financial condition, results of operations, and prospects. Many product candidates that initially showed promise in early stage testing for treating cancer or other diseases have later been found to cause side effects that prevented further clinical development of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, if our product candidates are associated with undesirable side effects in preclinical studies or clinical trials or have characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the product candidate if approved.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, adverse developments in clinical trials of pharmaceutical and biopharmaceutical products conducted by others may cause the FDA or other regulatory oversight bodies to suspend or terminate our clinical trials or to change the requirements for approval of any of our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of any product candidates we may identify and develop and could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our clinical trials are successfully completed, clinical data are often subject to varying interpretations and analyses, and we cannot guarantee that the FDA or comparable foreign regulatory authorities will interpret the results as we do. Results acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to support regulatory approval in that other jurisdiction. Even if regulatory approval is secured for a product candidate, the terms of such approval may also limit its commercial potential.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product development is a lengthy and expensive process with an uncertain outcome. We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two product candidates in Phase 1 clinical development; all of our other product candidates are in preclinical development, and their risk of failure is high. We are unable to predict when or if any of our product candidates will prove effective or safe in humans or will receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support our planned INDs in the United States or similar applications in other jurisdictions. We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA or similar regulatory authorities outside the United States will accept our proposed clinical programs or if the outcome of our preclinical testing and studies ultimately will support the further development of our programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to the outcome. A failure of one or more clinical trials can occur at any stage of testing. We cannot guarantee that any of our ongoing and planned clinical trials will be conducted as planned or completed on schedule, if at all. Moreover, we may experience numerous unforeseen events during, or as a result of, clinical trials, that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays in discussions with or obtaining alignment with regulators regarding trial design;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate, including as a result of delays in the testing, validation, manufacturing and delivery of product candidates to the clinical sites by us or by third parties with whom we have contracted to perform certain of those functions;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may experience delays in reaching, or may fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may experience delays in enrolling patients or may compete with other trials to enroll patients, including due to our targeted disease having small patient populations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may experience difficulty in designing clinical trials and in selecting endpoints for diseases that have not been well-studied and for which the natural history and course of the disease is poorly understood;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the selection of certain clinical endpoints may require prolonged periods of clinical observation or analysis of the resulting data;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may fail to perform clinical trials in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s good clinical practices, or GCP, requirements, or regulatory guidelines in other countries;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our product candidates may have undesirable side effects or other unexpected characteristics, or adverse events associated with the product candidate may occur which are viewed to outweigh its potential benefits, causing us or our investigators, regulators or institutional review boards to suspend or terminate the trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulators or institutional review boards may require that we or our investigators suspend or terminate clinical trials for various reasons, including noncompliance with regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">disruptions caused by the&#160;COVID-19&#160;pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting, or completing our planned and ongoing clinical trials; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we could be required to conduct additional clinical trials or testing of our product candidates beyond those that we currently contemplate, which may result in a delay in our market approval, limitation of approval for patient populations, distribution limitations, or not obtaining marketing approval at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs of the institutions in which such trials are being conducted, or the FDA or comparable foreign regulatory authorities, or is recommended for suspension or termination by the data monitoring committee for such trial. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product or treatment, failure to establish or achieve clinically meaningful trial endpoints, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Further, the FDA or comparable foreign regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials, or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs also will increase if we experience delays in preclinical studies or clinical trials or in obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates, or could allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates, which may harm our business, results of operations, financial condition and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment and dosing of patients in our clinical trials, our receipt of necessary regulatory approvals for our product candidates could be delayed or prevented.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in clinical trials of FHD-286, FHD-609 or any other product candidates is critical to our success. The timing of our clinical trials depends on our ability to recruit patients to participate in our studies as well as the dosing of such patients and completion of required follow-up periods. Our competitors may compete for the same limited patient populations. If we or our collaborators are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or other analogous regulatory authorities outside the United States, or as needed to provide appropriate statistical power for a given trial, we may not be able to initiate or continue clinical trials for our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">current and future product candidates. Additionally, we may face similar challenges or delays in our other or potential future clinical trials. If patients are unwilling to participate in our studies because of negative publicity from adverse events related to the biotechnology field, competitive clinical trials for similar patient populations or for other reasons, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of FHD-286, FHD-609 or any other product candidates may be delayed. These delays could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness of our product candidates or termination of the clinical trials altogether. Furthermore, our ability to enroll patients may be significantly delayed by the evolving COVID-19 pandemic and we do not know the extent and scope of such delays at this point.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment is also affected by other factors, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">severity of the disease under investigation;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">size of the patient population and process for identifying patients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">design of the trial protocol;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">availability and efficacy of approved medications for the disease under investigation;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">convenience and ease of administration compared to approved medications for the disease under investigation and the willingness of patients to undergo the surgical procedures necessary to administer our product candidates, such as biopsy;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ability to obtain and maintain patient informed consent;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">risk that enrolled patients will drop out before completion of the trial;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">eligibility and exclusion criteria for the trial in question;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">perceived risks and benefits of the product candidate under trial;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">efforts to facilitate timely enrollment in clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">patient referral practices of physicians;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ability to monitor patients adequately during and after treatment;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">proximity and availability of clinical trial sites for prospective patients; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">factors we may not be able to control, such as current or potential pandemics that may limit patients, principal investigators or staff or clinical site availability (for example, outbreak of COVID-19).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enrollment delays in our clinical trials may result in increased development costs for FHD-286, FHD-609 or any other product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit, or terminate clinical trials for FHD-286, FHD-609 or our other product candidates, or expand to additional jurisdictions, which could impose additional challenges on our company and expose us to risks. If we are not successful in conducting our clinical trials as planned, it would have an adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any favorable preclinical results may not be predictive of results that may be observed in clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data obtained from preclinical activities are subject to varying interpretations and analyses, which may delay, limit or prevent regulatory approval. Many companies that have believed their product candidates performed satisfactorily in preclinical studies have nonetheless failed to demonstrate results in clinical studies. As we generate preclinical results, such results will not ensure that later preclinical studies or clinical trials will demonstrate similar results. There is a high failure rate for drugs and biologics proceeding through clinical trials. Even product candidates that reach the clinical trial stage may fail to show the desired safety and efficacy in a later stage of clinical development. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in later-stage clinical trials even after achieving promising results in the preclinical and early stage clinical trials.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our approach to the discovery of product candidates is unproven, and we may not be successful in our efforts to use and expand our platform to build a pipeline of product candidates with commercial value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key element of our strategy is to use and expand our Gene Traffic Control platform to build a pipeline of product candidates and progress these product candidates through clinical development for the treatment of various cancers and other therapeutic areas. Although our research and development efforts to date have resulted in our discovery and preclinical development of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FHD-286 and FHD-609 for the treatment of cancer, FHD-286 and FHD-609 may not be safe or effective as cancer treatments, and we may not be able to develop any other product candidates. We may not be successful in identifying further targets in the chromatin regulatory system that are relevant in cancer, or other diseases, and which can be &#8220;basketed&#8221; into a group that is large enough to present a sufficient commercial opportunity or that is druggable with one chemical compound. Even if we are successful in building our pipeline of product candidates, the potential product candidates that we identify may not be suitable for clinical development or generate acceptable clinical data, including as a result of being shown to have unacceptable toxicity or other characteristics that indicate that they are unlikely to be products that will receive marketing approval from the FDA or other regulatory authorities or achieve market acceptance. If we do not successfully develop and commercialize product candidates, we will not be able to generate product revenue in the future, which likely would result in significant harm to our financial position and adversely affect our stock price.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to manufacture our preclinical and clinical product supplies, to produce and process clinical quantities of our product candidates and to assist with clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on third parties to manufacture preclinical and clinical product supplies and to manufacture clinical supplies of our product candidates. We need to negotiate and maintain contractual arrangements with these outside vendors for the supply of our product candidates and we may not be able to do so on favorable terms. We have not yet caused any product candidates to be manufactured on a commercial scale and may not be able to do so for any of our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA or other foreign regulatory authorities following inspections that will be conducted after we submit an application to the FDA or other foreign regulatory authorities. We will be completely dependent on our contract manufacturing partners for compliance with cGMP and any other regulatory requirements of the FDA or other regulatory authorities for the manufacture of our product candidates. Beyond periodic audits, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates, if it withdraws any approval in the future, or if it otherwise identifies noncompliance with cGMPs at these facilities, we may need to find alternative manufacturing facilities, which would require the incurrence of significant additional costs and significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Similarly, if any third-party manufacturers on which we will rely fail to manufacture quantities of our product candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost that allows us to achieve profitability, our business, financial condition, results of operations, and prospects could be materially and adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have relied upon and plan to continue to rely upon third-party clinical investigators, contract research organizations, or CROs, and consultants. Relying on third-party clinical investigators, CROs and consultants may force us to encounter delays that are outside of our control. We may be unable to identify and contract with a sufficient number of investigators, CROs and consultants on a timely basis or at all. There can be no assurance that we will be able to negotiate and enter into any additional master services agreement with other CROs, as necessary, on terms that are acceptable to us on a timely basis or at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs or modifications to approved drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December&#160;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in response to the global COVID-19 pandemic, on March&#160;10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and subsequently, on March&#160;18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. In July 2020, the FDA resumed certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA utilized this risk-based assessment </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">system to assist in determining when and where it was safest to conduct prioritized domestic inspections. Additionally, on April 15, 2021, the FDA issued a guidance document in which the FDA described its plans to conduct voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites, among other facilities. According to the guidance, the FDA may request such remote interactive evaluations where the FDA determines that remote evaluation would be appropriate based on mission needs and travel limitations. In May 2021, the FDA outlined a detailed plan to move toward a more consistent state of inspectional operations, and in July 2021, the FDA resumed standard inspectional operations of domestic facilities and was continuing to maintain this level of operation as of September 2021. More recently, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic. In February 2022, the FDA determined that it would conduct both foreign and domestic mission-critical inspections and would proceed with certain foreign surveillance inspections. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee Matters, Managing Growth and Information Technology</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on our key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on Adrian Gottschalk, our Chief Executive Officer. In addition, the loss of the services of any of our executive officers, other key employees and other scientific and medical advisors, and an inability to find suitable replacements could result in delays in product development and harm our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite our efforts to retain Mr.&#160;Gottschalk and other valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had 119 full-time employees. We intend to hire new employees to assume activities and responsibilities within the company, including conducting our research and performing development activities in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We conduct our operations at our facilities in Cambridge, Massachusetts. The Massachusetts region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. Changes to U.S. immigration and work authorization laws and regulations, including those that restrain the flow of scientific and professional talent, can be significantly affected by political forces and levels of economic activity. Our business may be materially adversely affected if legislative or administrative changes to immigration or visa laws and regulations impair our hiring processes and goals or projects involving personnel who are not U.S. citizens.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay or disruption in hiring such new employees could result in delays in our research and development activities and would harm our business. As our development and commercialization plans and strategies develop, and as we transition into operating as a public company, we expect to need additional managerial, operational, sales, marketing, financial and other personnel, as well as additional facilities to expand our operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, or we are not able to effectively build out new facilities to accommodate this expansion, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those used by our third-party CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of the development programs of our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems and those of our current and future CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, and telecommunication and electrical failures. While we have not experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of data from completed or future preclinical studies and clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on multiple CROs to mitigate potential impacts that may affect any one of our CROs. However, CDMOs and other contractors and consultants could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, pandemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The continuing outbreak of&#160;COVID-19&#160;in the United States and other countries may adversely affect our business and the market price of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The evolving global pandemic of&#160;COVID-19&#160;is impacting worldwide economic activity, particularly economic activity in the United States, and poses the risk that we or our employees, contractors, suppliers or other partners may be prevented or delayed from conducting business activities for an indefinite period of time, including due to shutdowns that may be requested or mandated by governmental authorities. The continued prevalence of&#160;COVID-19&#160;and the measures taken by the governments of countries affected could disrupt the supply chain and the manufacture or shipment of both drug substance and finished drug product for our product candidates for preclinical testing or clinical trials, cause diversion of healthcare resources away from the conduct of preclinical and clinical trial matters to focus on pandemic concerns, limit travel in a manner that interrupts key trial activities, such as trial site initiations and monitoring, delay regulatory filings with regulatory agencies in affected areas or adversely affect our ability to obtain regulatory approvals. These disruptions could also affect other facets of our business, including but not limited to:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to recruit employees from outside of the United States;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the ability of our CROs to conduct preclinical studies and clinical trials in countries outside of the United States;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to import materials from outside of the United States; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to export materials to our CROs and other third parties located outside of the United States.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The&#160;COVID-19&#160;outbreak and mitigation measures also may have an adverse impact on global economic conditions, which could adversely impact our business, financial condition or results of operations. Additionally, the&#160;COVID-19&#160;outbreak has resulted in significant financial market volatility and uncertainty. A continuation or worsening of the levels of market disruption and volatility seen in the recent past as a result of the&#160;COVID-19&#160;outbreak could have an adverse effect on our ability to access capital and on the market price of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to adequately protect our proprietary technology and platform or obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and products may be impaired.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend in part on our ability and the ability of our licensors to obtain and maintain proprietary or intellectual property protection in the United States and other countries for our product candidates, and our core technologies, including aspects of our Gene Traffic Control platform. We rely on trade secrets, know-how and continuing technological </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">innovation to develop and maintain our proprietary and intellectual property position. In particular, our Gene Traffic Control platform is not the subject of patent applications.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to protect our proprietary product candidates by filing patent applications in the United States and abroad related to our product candidates that are important to our business. If we or our licensors are unable to obtain or maintain patent protection with respect to our current and future product candidates, competitors and other third parties could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidates and other product candidates that we may pursue may be impaired. As a result, our business, financial condition, results of operations and prospects could be materially harmed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, our patent portfolio, including our portfolio related to our product candidates FHD-286 and FHD-609, is in its earliest stages, primarily consisting of provisional patent applications, which do not themselves issue as patents, and patent applications filed pursuant to the Patent Cooperation Treaty, or PCT. We have no issued patents related to FHD-286 or FHD-609. In order to continue to pursue protection based on provisional patent applications, we will need to file PCT, foreign applications and/or U.S. non-provisional patent applications prior to applicable deadlines. In order to continue to pursue protection based on PCT applications, we will need to file national phase applications in the U.S. and ex-U.S. jurisdictions prior to applicable deadlines. Even then, patents may never issue from our patent applications, or the scope of any patent may not be sufficient to provide a competitive advantage.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of patent protection we require to successfully commercialize our product candidates may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our pending patent applications will issue, or that any of our pending patent applications that mature into issued patents will include claims with a scope sufficient to protect FHD-286 or FHD-609 or our other current or future product candidates. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Furthermore, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally twenty years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing products similar or identical to our product candidates, including generic versions of such products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other parties have developed technologies that may be related or competitive to our own, and such parties may have filed or may file patent applications, or may have received or may receive patents, claiming inventions that may overlap or conflict with those claimed in our own patent applications, in either case that they may rely upon to dominate our patent position in the market. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights cannot be predicted with any certainty.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Further, with respect to most of the pending patent applications covering our product candidates, prosecution has yet to commence. Patent prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the U.S. Patent and Trademark Office, or USPTO, have been significantly narrowed by the time they issue, if at all. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we acquire patent protection that we expect should enable us to maintain such competitive advantage, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. For example, we may be subject to a third-party submission of prior art to the USPTO challenging the priority of an invention claimed within one of our patents, which submissions may also be made prior to a patent&#8217;s issuance, precluding the granting of any of our pending patent applications. We may become involved in opposition, derivation, reexamination, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others from whom we have obtained licenses to such rights. Competitors may claim that they invented the inventions claimed in our issued patents or patent applications prior to us, or may file patent applications before we do. Competitors may also claim that we are infringing on their patents and that we therefore cannot practice our technology as claimed under our patents, if issued. Competitors may also contest our patents, if </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued, by showing the patent examiner that the invention was not original, was not novel or was obvious. In litigation, a competitor could claim that our patents, if issued, are not valid for a number of reasons. If a court agrees, we would lose our rights to those challenged patents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patent applications or technologies, as a result of the work they performed on our behalf. Although we generally require all of our employees, consultants and advisors and any other third parties who have access to our proprietary know-how, information or technology to assign or grant similar rights to their inventions to us, we cannot be certain that we have executed such agreements with all parties who may have contributed to our intellectual property, nor can we be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An adverse determination in any such submission or proceeding may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, without payment to us, or could limit the duration of the patent protection covering our technology and product candidates. Such challenges may also result in our inability to manufacture or commercialize our product candidates without infringing third party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our patent portfolio is unchallenged, it may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. For example, a third party may develop a competitive product that provides benefits similar to one or more of our product candidates but that has a different composition that falls outside the scope of our patent protection. If the patent protection provided by the patents and patent applications we hold or pursue with respect to our product candidates is not sufficiently broad to impede such competition, our ability to successfully commercialize our product candidates could be negatively affected, which would harm our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the protection afforded by patents, we rely upon unpatented trade secret protection, unpatented know-how and continuing technological innovation to develop and maintain our competitive position. With respect to the various aspects of our Gene Traffic Control platform, including our proprietary libraries, we consider trade secrets and know-how to be our primary intellectual property. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our collaborators, scientific advisors, employees and consultants, and invention assignment agreements with our consultants and employees. We may not be able to prevent the unauthorized disclosure or use of our technical know-how or other trade secrets by the parties to these agreements, however, despite the existence generally of confidentiality agreements and other contractual restrictions. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees and consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. We also seek to preserve the integrity and confidentiality of our confidential proprietary information by maintaining physical security on our premises, and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. Enforcing a claim that a third party illegally obtained and is using our trade secrets, like patent litigation, is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trade secrets could otherwise become known or be independently discovered by our competitors. Competitors could purchase our product candidates and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If our trade secrets are not adequately protected so as to protect our market against competitors&#8217; products, our competitive position could be adversely affected, as could our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees on issued patents often must be paid to the USPTO and foreign patent agencies over the lifetime of the patent. While an unintentional lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our products or procedures, we may not be able to stop a competitor from marketing products that are the same as or similar to our product candidates, which would have a material adverse effect on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The intellectual property landscape around our technology, including our Gene Traffic Control platform, is highly dynamic, and third parties may obtain intellectual property rights that could affect our ability to use our platform or otherwise develop and commercialize product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The field of protein modeling, especially in the area of targeting transcription factors, is still in its infancy. Due to the intense research and development that is taking place by several companies, including us and our competitors, in this field, the intellectual property landscape is evolving and in flux, and it may remain uncertain for the coming years. There may be significant intellectual property related litigation and proceedings relating to our owned and in-licensed, and other third party, intellectual property and proprietary rights in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends upon our ability and the ability of our collaborators and licensors to develop, manufacture, market, and sell any product candidates that we may develop and use our proprietary technologies without infringing, misappropriating, or otherwise violating the intellectual property and proprietary rights of third parties. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our Gene Traffic Control platform and related technology and product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of therapies, products or their methods of use or manufacture. There may be third-party patents of which we are currently unaware with claims to technologies, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. We may be unable to obtain a license to such patents held by third-parties on commercially reasonable terms or at all. In the event that we are unable to obtain licenses to such patents, our ability to develop and commercialize one or more product candidates may become severely limited. Even if we were able to obtain such a license, it could be granted on non-exclusive terms, thereby providing our competitors and other third parties access to the same technologies licensed to us.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may initiate or become involved in legal proceedings involving allegations that we are infringing a third party&#8217;s intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part upon our ability and the ability of our collaborators to develop, manufacture and sell our product candidates and use our proprietary technologies without infringing the propriety rights and intellectual property of third parties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by extensive and frequent litigation regarding patents and other intellectual property rights. We may in the future become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates and technology. Our competitors or other third parties may assert infringement claims against us, alleging that our products or technologies are covered by their patents. Given the vast number of patents in our field of technology, we cannot be certain that we do not infringe existing patents or that we will not infringe patents that may be granted in the future. If a patent holder believes our product or product candidate infringes on its patent, the patent holder may sue us even if we have received patent protection for our technology. Moreover, we may face patent infringement claims from non-practicing entities that have no relevant product revenue and against whom our own patent portfolio may thus have no deterrent effect.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are found to infringe a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our product candidates and technology. We may choose to obtain a license, even in the absence of an action or finding of infringement. In either case, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain such a license, it could be granted on non-exclusive terms, thereby providing our competitors and other third parties access to the same technologies licensed to us. Without such a license, we could be forced, including by court order, to cease developing and commercializing the infringing technology or product candidates. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed such third-party patent rights. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. If we lose a foreign patent lawsuit, alleging our infringement of a competitor&#8217;s patents, we could be prevented from marketing our products in one or more foreign countries, which would have a materially adverse effect on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could in the future also be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other proprietary information of former employers or competitors. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may in the future be subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. An inability to incorporate such technologies or features would have a material adverse effect on our business and may prevent us from successfully commercializing our product candidates. In addition, we may lose valuable intellectual property rights or personnel as a result of such claims. Moreover, any such litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our product candidates, which would have an adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time-consuming and unsuccessful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors and other third parties may infringe, misappropriate or otherwise violate our patents, if obtained, and other intellectual property rights. To counter infringement or unauthorized use, we may be required to file infringement claims. A court may disagree with our allegations, however, and may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the third-party technology in question. Further, such third parties could counterclaim that we infringe their intellectual property or that a patent we have asserted against them is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims challenging the validity, enforceability or scope of asserted patents are commonplace. In addition, third parties may initiate legal proceedings against us to assert such challenges to our intellectual property rights. The outcome of any such proceeding is generally unpredictable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. If a defendant were to prevail on a legal assertion of invalidity or unenforceability of our patents covering one of our product candidates, we would lose at least part, and perhaps all, of the patent protection covering such product candidate. Competing products may also be sold in other countries in which our patent coverage might not exist or be as strong.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time-consuming and is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights, or we may be unable to successfully defend ourselves from allegations of infringement or misappropriation. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to effectively enforce our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive. The requirements for patentability may differ in certain countries, particularly in developing countries. Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. Additionally, the patent laws of some foreign countries do not afford intellectual property protection to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property rights. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, if our ability to enforce our patents to stop infringing activities is inadequate. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and resources from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in the major markets for our product candidates, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of any intellectual property, including any patents we may own or&#160;in-license&#160;in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to claims that former employees, collaborators or other third parties have an interest in any patents we may own or&#160;in-license&#160;in the future, trade secrets, or other intellectual property as an inventor or&#160;co-inventor.&#160;We may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates or other technologies. We generally enter into confidentiality and intellectual property assignment agreements with our employees, consultants, and contractors. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, those agreements may not be honored and may not effectively assign intellectual property rights to us. Moreover, there may be some circumstances where we are unable to negotiate for such ownership rights. Disputes regarding ownership or inventorship of intellectual property can also arise in other contexts, such as collaborations and sponsored research. If we are subject to an inventorship dispute, such dispute may lead to litigation which could be expensive and time-consuming. If we are unsuccessful, in addition to paying monetary damages, we could lose valuable rights in intellectual property that we regard as our own, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates and our Gene Traffic Control platform. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents, if obtained, may be eligible for limited patent term extension under the Drug Price Competition </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Patent Term Restoration Action of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our business, financial condition, results of operations and prospects could be materially harmed.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">aspects of our Gene Traffic Control platform are protected by trade secrets, which may be inadequate to safeguard our competitive advantage, and some aspects of our platform may not be protectable by intellectual property rights at all;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">others may be able to make products that are similar to our product candidates or utilize similar technology but that are not covered by the claims of any patents that may issue to us, our licensors or our collaborator;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we or our licensors or collaborators, might not have been the first to make the inventions covered by our pending patent applications, or any patents that may issue in the future;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we or our licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing or misappropriating our intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">it is possible that our present or future pending patent applications will not lead to issued patents;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes to the patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the patents of others may harm our business; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">we may choose not to file a patent application in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes to the patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity and is therefore costly, time-consuming and inherently uncertain. Recent patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act, or Leahy-Smith Act, signed into law on September&#160;16, 2011, could increase those uncertainties and costs. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. In addition, the Leahy-Smith Act has transformed the U.S. patent system into a &#8220;first to file&#8221; system. The first-to-file provisions, however, only became effective on March&#160;16, 2013. Accordingly, it is not yet clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Leahy-Smith Act and its implementation could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could harm our business, results of operations and financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Additionally, there have been recent proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our ability to obtain patent protection for our proprietary technology or our ability to enforce rights in our proprietary technology. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce any patents that we may obtain in the future.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely, and expect to continue to rely, on third parties, including independent clinical investigators, CROs and CDMOs to conduct certain aspects of our discovery and preclinical studies and development, and our clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third-party CROs and CDMOs, as well as potential collaboration partners to conduct certain aspects of our discovery, preclinical studies and development and clinical trials and to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical studies and planned clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors, CROs and CDMOs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties, our CROs or our CDMOs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. Moreover, our business may be adversely affected if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, these investigators, CROs and CDMOs are not our employees and we are not able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If independent investigators, CROs and CDMOs fail to devote sufficient resources to the development of our product candidates, or if CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed or precluded entirely.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Additionally, CROs may lack the capacity to absorb higher workloads or take on additional capacity to support our needs. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently rely and expect to rely in the future on the use of manufacturing suites in third-party facilities or third parties to manufacture our product candidates. Our business could be harmed if we are unable to use third-party manufacturing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">suites or if third-party manufacturers fail to provide us with sufficient quantities of our product candidates or fail to do so at acceptable quality levels or prices.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently own any facility that may be used as our clinical-scale manufacturing and processing facility and instead must currently rely on outside vendors to manufacture our product candidates in clinical quantities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on third parties for clinical quantities exposes us to a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our third-party manufacturers might be unable to timely manufacture our product candidates or produce the quantity and quality required to meet our clinical and commercial needs, if any;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">contract manufacturers may not be able to execute our manufacturing procedures and other logistical support requirements appropriately and incompliance with cGMP; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our third-party manufacturers could breach or terminate their agreements with us.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these risks could delay or prevent the completion of our clinical trials or the approval of any of our product candidates by the FDA or result in higher costs. In addition, we will rely on third parties to perform certain specification tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm and the FDA could place significant restrictions on our company until deficiencies are remedied.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials, by our third-party manufacturers. Our manufacturers are subject to numerous environmental, health and safety laws and regulations, including those governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that our manufacturers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory and Other Legal Compliance Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may fail to demonstrate adequately the safety and efficacy of any of our product candidates, which would delay or prevent further clinical development of those candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain the requisite regulatory approvals to market and sell any of our product candidates, including FHD-286 and FHD-609, and any other future product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our products are safe and effective in humans.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials that we conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. If the results of our ongoing or future clinical trials are inconclusive with respect to the efficacy of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be delayed in obtaining marketing approval, if at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the trials are successfully completed, clinical data are often susceptible to varying interpretations and analyses, and we cannot guarantee that the FDA or other comparable foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. We cannot guarantee that the FDA or other comparable foreign regulatory authorities will view our product candidates as having sufficient efficacy to support the indication studied in the clinical trial even if positive results are observed in early clinical trials. To the extent that the results of the trials are not satisfactory to the FDA or other comparable foreign regulatory authorities for support of a marketing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Additionally, any safety or efficacy concerns observed in any tumor-specific subgroup of our clinical trials could limit the prospects for regulatory approval of our product candidates for a tumor-agnostic indication, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may in the future seek orphan drug status for FHD-286 and FHD-609 and some of our other future product candidates, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug status, including market exclusivity, which may cause our future revenue, if any, to be reduced.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting an NDA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including an NDA, to market the same drug for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even if one of our product candidates receives orphan drug exclusivity, the FDA can still approve other drugs that have a different active ingredient for use in treating the same indication or disease. Furthermore, the FDA can waive orphan drug exclusivity if we are unable to manufacture sufficient supply of our product.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek orphan drug designation for some or all of our other future product candidates, where applicable, in addition to orphan indications in which there is a medically plausible basis for the use of these products. Even when we obtain orphan drug designation, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. In addition, although we intend to seek orphan drug designation for other product candidates, we may never receive such designations. For example, the FDA has expressed concerns regarding the regulatory considerations for orphan drug designation as applied to tissue agnostic therapies, and the FDA may interpret the federal Food, Drug and Cosmetic Act, as amended, or the FD&amp;C Act, and regulations promulgated thereunder in a way that limits or blocks our ability to obtain orphan drug designation or orphan drug exclusivity, if our product candidates are approved, for our targeted indications.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek Breakthrough Therapy designation from the FDA for FHD-286 and FHD-609, and for some or all of our future product candidates. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for other expedited approval programs, including accelerated approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in a faster development process, review or approval compared to candidate products considered for approval under non-expedited FDA review procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product no longer meets the conditions for qualification. Thus, even though we intend to seek Breakthrough Therapy designation for some or all of our future product candidates for the treatment of various cancers, there can be no assurance that we will receive breakthrough therapy designation.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with healthcare providers, physicians, and third-party payors will be subject to applicable anti-kickback, fraud and abuse, anti-bribery, physician payment transparency and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished profits and future earnings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, market, sell, and distribute our medicines for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal Anti-Kickback Statute, which prohibits, among other things, persons from offering, soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual, or the purchasing or ordering of, a good or service for which payment may be made under federal healthcare programs such as Medicare and Medicaid;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person from knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement material to a false claim;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, in addition to privacy protections applicable to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the Physician Payments Sunshine Act, which requires pharmaceutical and medical device companies to report information related to certain payments and transfers of value to certain healthcare providers to the Center for Medicare&#160;&amp; Medicaid Services, as well as ownership and investment interests held by physicians and their immediate family members; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">analogous state and foreign laws and regulations, such as state anti-kickback, anti-bribery and false claims laws, which may apply to healthcare items or services that are reimbursed by non-governmental third-party payors, including private insurers, as well as other state laws that require companies to comply with specific compliance standards, restrict financial interactions between companies and healthcare providers and require companies to report information related to payments to health care providers or marketing expenditures. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Given the breadth of the laws and regulations, limited guidance for certain laws and regulations and evolving government interpretations of the laws and regulations, governmental authorities may possibly conclude that our business practices may not comply with healthcare laws and regulations, including, without limitation, certain of our advisory board agreements with physicians who receive stock or stock options as compensation for services provided to us. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our current or future product candidates or any future product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell a product for which we obtain marketing approval. In particular, in the U.S., there have been and continue to be a number of legislative initiatives at the federal and state level to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, of collectively, the ACA, was enacted, which substantially changed the way healthcare is financed by both government and private payors. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the ACA in the future. It is unclear how any efforts to challenge, repeal, or replace the ACA will impact the ACA or our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i)&#160;changes to our manufacturing arrangements, (ii)&#160;additions or modifications to product labeling, (iii)&#160;the recall or discontinuation of our products or (iv)&#160;additional record-keeping requirements. Further, healthcare reform may result in changes to payment methodologies, the implementation of pharmaceutical and biological product price controls, and reductions in Medicare and other healthcare funding. If any such changes were to be imposed, they could adversely affect the operation of our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The successful commercialization of our product candidates will depend in part on the extent to which third-party payors establish coverage, adequate reimbursement levels and pricing policies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to obtain coverage and adequate reimbursement for our product candidates by governmental healthcare programs, private health insurers, and other third-party payors will have an effect on our ability to successfully commercialize our product candidates. We cannot be sure that coverage and reimbursement will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future. No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our product candidates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to U.S. and international restrictive regulations governing the use, processing and cross-border transfer of data and personal information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The conduct of our clinical trials may be subject to privacy restrictions based on U.S. and non-U.S. regulations. For example, we may be subject to the California Consumer Privacy Act, or CCPA. As currently written, the CCPA may impact our business activities and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information. Additionally, the collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the EU and the UK, including personal health data, is subject to the EU General Data Protection Regulation, or GDPR, including as it forms part of the law of England and Wales, Scotland and Northern Ireland by virtue of section 3 of the European Union (Withdrawal) Act 2018 and as amended by the Data Protection, Privacy and Electronic Communications (Amendments etc.) (EU Exit) Regulations 2019 (SI 2019/419), known as UK GDPR. See &#8220;Business&#8212;Government Regulation.&#8221; Compliance with the GDPR and the UK GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation and reputational harm in connection with our European activities. The UK&#8217;s data protection authority, the Information Commissioner&#8217;s Office, has indicated that following Brexit it will continue to enforce the UK GDPR in line with the enforcement of the GDPR in the EU. However, the UK government recently announced its intention to adopt a more flexible approach to the regulation of data, and as a result there remains a risk of future divergence between the EU and UK data protection regimes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock may be volatile, which could result in substantial losses for our stockholders.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been and may continue to be volatile. Since our initial public offering in October 2020, the closing price of our common stock as reported on the Nasdaq Global Market has ranged from a low of $8.33 on March&#160;10, 2021 to a high of $25.88 on December&#160;18, 2020. Some of the factors that may cause the market price of our common stock to fluctuate include:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the success of existing or new competitive product candidates or technologies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing and results of preclinical studies and clinical trials for any product candidates that we may develop;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the failure or discontinuation of any of our product development and research programs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">results of preclinical studies, clinical trials, or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">commencement or termination of collaborations for our product development and research programs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the recruitment or departure of key personnel;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the level of expenses related to any of our research programs or product candidates that we may develop;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the results of our efforts to develop additional product candidates or products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the announcement or expectation of additional financing efforts;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">sales of our common stock by us, our insiders or other stockholders;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expiration of market stand-off or lock-up agreements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the effects of geopolitical crises and the outbreak or worsening of wars or other armed conflicts;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">effects of public health crises, pandemics and epidemics, such as COVID-19;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in estimates or recommendations by securities analysts, if any, that cover our stock;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">market conditions in the pharmaceutical and biotechnology sectors;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">general economic, industry and market conditions; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. Following periods of such volatility in the market price of a company&#8217;s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities litigation could result in substantial costs and divert management&#8217;s attention and resources from our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities analysts cease to publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business.  If one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A significant portion of our total outstanding shares is eligible to be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Certain holders of shares of our common stock have rights, subject to specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders, until such shares can otherwise be sold without restriction under Securities Act Rule 144 or until the rights terminate pursuant to the terms of the investors&#8217; rights agreement between us and such holders. If additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insiders have substantial influence over us, which could limit your ability to affect the outcome of key transactions, including a change of control.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our directors and executive officers and their affiliates beneficially own shares representing approximately 46% of our outstanding common stock. As a result, these stockholders, if they act together, will be able to influence our management and affairs and all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change in control of our company and might adversely affect the market price of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an &#8220;emerging growth company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may remain an emerging growth company for up to five years. For so long as we remain an emerging growth company, we are permitted and plan to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, or SOX, not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements, reduced disclosure obligations regarding executive compensation, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, the information we provide stockholders will be different than the information that is available with respect to other public companies. In this annual report, we have not included all of the executive compensation related information that would be required if we were not an emerging growth company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to &#8220;opt out&#8221; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i)&#160;irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (ii)&#160;no longer qualify as an emerging growth company. Therefore, the reported results of operations contained in our consolidated financial statements may not be directly comparable to those of other public companies.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur certain costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives and corporate governance practices.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we completed our initial public offering. As a public company, we incur significant legal, accounting, and other expenses that we did not incur as a private company. These expenses will increase once we are no longer an "emerging growth company" pursuant to applicable securities rules and regulations. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Market, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We expect that we will need to hire additional accounting, finance, and other personnel in connection with our becoming, and our efforts to comply with the requirements of being, a public company. Our management and other personnel will need to devote a substantial amount of time towards maintaining compliance with these requirements, which will increase our legal and financial compliance costs and will make </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain activities more time-consuming and costly. For example, we expect that the rules and regulations applicable to us as a public company may make it more difficult and more expensive for us to obtain director and officer liability insurance, which could make it more difficult for us to attract and retain qualified members of our board of directors. We are currently evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to SOX Section&#160;404, we are required to furnish a report by our management on our internal control over financial reporting beginning with our second filing of an Annual Report on Form 10-K with the SEC after we become a public company. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with SOX Section&#160;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants, adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by SOX Section&#160;404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn, or additional global financial crises, could result in a variety of risks to our business, including weakened demand for our product candidates, if approved, or our ability to raise additional capital when needed on acceptable terms, if at all. For example, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets. Similarly, the recent significant volatility associated with the&#160;COVID-19&#160;outbreak has caused significant instability and disruptions in the capital and credit markets. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our amended and restated certificate of incorporation, our amended and restated by-laws and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation, amended and restated by-laws and Delaware law contain provisions that may have the effect of discouraging, delaying or preventing a change in control of us or changes in our management that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. Our amended and restated certificate of incorporation and by-laws include provisions that:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">authorize &#8220;blank check&#8221; preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">create a classified board of directors whose members serve staggered three-year terms;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">specify that special meetings of our stockholders can be called only by our board of directors;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">prohibit stockholder action by written consent;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">provide that our directors may be removed only for cause;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">specify that no stockholder is permitted to cumulate votes at any election of directors;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expressly authorize our board of directors to modify, alter or repeal our amended and restated by-laws; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated certificate of incorporation and amended and restated by-laws.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in the State of Delaware, we are governed by the provisions of Section&#160;203 of the General Corporation Law of the State of Delaware, or the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any provision of our amended and restated certificate of incorporation, amended and restated by-laws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation designates the state or federal courts within the State of Delaware as the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that, subject to limited exceptions, the state or federal courts (as appropriate) within the State of Delaware will be exclusive forums for (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (iii)&#160;any action asserting a claim against us arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated by-laws, (iv)&#160;action against us or any of our directors or officers involving a claim or defense arising pursuant to the Exchange Act or the Securities Act or (v)&#160;any other action asserting a claim against us that is governed by the internal affairs doctrine. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation described above. This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition.</span></div><div id="i523559815e87485cb6a9895707f43a02_22"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i523559815e87485cb6a9895707f43a02_25"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;PROPERTIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters is located at 500 Technology Square, Suite 700, Cambridge, MA 02139, where we lease and occupy approximately 81,441 square feet of office and laboratory space. The current term of our 500&#160;Technology Square lease expires in September 2028, with an option to extend the term five additional years with 12&#160;months&#8217; notice at an agreed upon market rate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our existing facilities are sufficient for our needs for the foreseeable future. To meet the future needs of our business, we may lease additional or alternate space, and we believe suitable additional or alternative space will be available in the future on commercially reasonable terms.</span></div><div id="i523559815e87485cb6a9895707f43a02_28"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i523559815e87485cb6a9895707f43a02_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i523559815e87485cb6a9895707f43a02_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i523559815e87485cb6a9895707f43a02_37"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5.&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Information Regarding the Trading of Our Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades under the symbol &#8220;FHTX&#8221; on the Nasdaq Global Market and has been publicly traded since October&#160;23, 2020. Prior to this time, there was no public market for our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Our Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 25, 2022, there were approximately 35 holders of record of shares of our common stock. This number does not include stockholders for whom shares are held in &#8220;nominee&#8221; or &#8220;street&#8221; name.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 5 of Form 10-K regarding equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth information as to all securities we sold in 2021 which were not registered under the Securities Act:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 10, 2021 the Company entered into a stock purchase agreement, or the Lilly SPA, with Eli Lilly and Company, or Lilly, pursuant to which the Company issued and sold 4,000,000 shares of our common stock at a price of $20.00 per share for aggregate gross proceeds of $80.0 million. The issuance of the shares did not involve any underwriters, underwriting discounts or commissions or a public offering. The Company issued the shares in reliance on the exemption from registration provided for under Section 4(a)(2) of the Securities Act of 1933, as amended. The Company relied on this exemption from registration for private placements based in part on the representations made by Lilly, including the representations with respect to Lilly&#8217;s investment intent. The offer and sale of the shares have not been registered under the Securities Act.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds from Initial Public Offering</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;27, 2020, we closed our initial public offering, or IPO, of our common stock pursuant to which we issued and sold 7,500,000 shares of our common stock at a price to the public of $16.00 per share for aggregate gross proceeds of $120.0&#160;million, before deducting underwriting discounts and commissions and other offering expenses. On November&#160;19, 2020, we sold an additional 951,837 shares of our common stock pursuant to the underwriters&#8217; option to purchase additional shares in the IPO at the public offering price for an additional $15.2&#160;million in gross proceeds.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the shares issued and sold in the IPO were registered under the Securities Act pursuant to the Registration Statement (File No. 333-249264),&#160;which was declared effective by the SEC on October&#160;22, 2020. Goldman Sachs&#160;&amp; Co. LLC, Morgan Stanley&#160;&amp; Co. LLC and Cowen and Company, LLC acted as joint book-running managers and Wedbush Securities Inc. acted as lead manager of our IPO.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received aggregate net proceeds of approximately $122.1&#160;million after deducting underwriting discounts and commissions and other offering expenses. None of the underwriting discounts and commissions or offering expenses were incurred or paid to directors or officers of ours or their associates or to persons owning 10&#160;percent or more of our common stock or to any of our affiliates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have used approximately $65.7 million of the net proceeds from the IPO as of&#160;December&#160;31, 2021 to advance FHD-286 and FHD-609 towards the clinic, to further invest in our pipeline and platform targeting the chromatin regulatory system and for working capital and other general corporate purposes. There has been no material change in our planned use of the net proceeds from the offering as described in our Registration Statement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="i523559815e87485cb6a9895707f43a02_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;6.&#160;&#160;&#160;&#160;[RESERVED]</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i523559815e87485cb6a9895707f43a02_43"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes to those statements included elsewhere in this Annual Report on Form 10-K. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Some of the numbers included herein have been rounded for the convenience of presentation. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed under &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K.</span></div><div id="i523559815e87485cb6a9895707f43a02_46"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Our proprietary Gene Traffic Control platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within the system. Breakdowns in the chromatin regulatory system are associated with over 50&#160;percent of all cancers. Addressing these breakdowns could potentially provide therapies for over 2.5&#160;million patients globally. Consequently, we are initially focused in oncology. We are developing FHD-286, a selective, allosteric ATPase inhibitor that is currently being evaluated in two separate Phase 1 studies in (i) metastatic uveal melanoma and (ii) relapsed and/or refractory AML and MDS. We are developing FHD-609, a targeted protein degrader that is currently being evaluated in a Phase 1 study in synovial sarcoma. Our vision is to use our Gene Traffic Control platform to discover and develop drugs in oncology and other therapeutic areas, including virology, autoimmune disease and neurology.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in October 2015, we have focused substantially all of our resources on building our Gene Traffic Control&#160;platform, organizing and staffing our company, business planning, raising capital, conducting discovery and research activities, protecting our trade secrets, filing patent applications, identifying potential product candidates, undertaking preclinical studies and clinical trial activities, establishing arrangements with third parties for the manufacture of initial quantities of our product candidates and component materials and initiating two strategic collaborations. We do not have any products approved for sale and have not generated any revenue from product sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;27, 2020, we completed our initial public offering, or IPO, pursuant to which we issued and sold 7,500,000 shares of our common stock at a public offering price of $16.00 per share, resulting in net proceeds of $107.9 million, after deducting underwriting discounts and commissions and other offering expenses. On November&#160;19, 2020, we issued and sold an additional 951,837 shares of common stock at the IPO price of $16.00&#160;per share pursuant to the underwriters&#8217; partial exercise of their option to purchase additional shares of common stock, resulting in additional net proceeds of $14.2 million after deducting underwriting discounts and commissions. Prior to our IPO, we funded our operations with proceeds from sales of preferred stock, term loans and an upfront payment of $15.0 million we received in July 2020 under our collaboration agreement with Merck Sharp&#160;&amp; Dohme Corp., or Merck.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 10, 2021, we entered into a collaboration agreement, or the Lilly Collaboration Agreement, with Eli Lilly and Company, or Lilly, for which we received an upfront payment of $300.0 million in January 2022 (see Note 9 to our notes to consolidated financial statements included elsewhere in this Annual Report on Form 10-K). Concurrent with the Lilly Collaboration Agreement, we also entered into the Lilly SPA and issued and sold Lilly 4,000,000 shares of our common stock at a price of $20.00 per share, resulting in net proceeds of $80.0 million, of which </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$42.2 million was allocated to equity upon the issuance of the Company&#8217;s common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant operating losses since our inception. For the years ended December&#160;31, 2021 and 2020, we reported net losses of $101.3 million and $68.8 million, respectively. As of December&#160;31, 2021, we had an accumulated deficit of $264.3 million. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. Our ability to generate any product revenue or product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more product candidates we are developing and may develop.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">advance our FHD-286 and FHD-609 product candidates and continue our preclinical development of product candidates from our current research programs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">identify additional research programs and additional product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">initiate preclinical testing for any new product candidates we identify and develop;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtain, maintain, expand, enforce, defend and protect our trade secrets and intellectual property portfolio and provide reimbursement of third-party expenses related to our patent portfolio;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">hire additional research and development personnel;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">add operational, legal, compliance, financial and management information systems and personnel to support our research, product development and operations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expand the capabilities of our platform;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">acquire or in-license product candidates, intellectual property and technologies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">operate as a public company;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">seek marketing approvals for any product candidates that successfully complete clinical trials; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ultimately establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will not generate revenue from product sales unless and until we successfully commercialize one of our product candidates, after completing clinical development and obtaining regulatory approval. If we obtain regulatory approval for any of our product candidates, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, manufacturing and distribution. Further, we expect to incur additional costs associated with operating as a public company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings and collaborations or licensing arrangements and our collaboration agreements with Merck and Lilly. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back our development or commercialization plans for one or more of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020,&#160;COVID-19&#160;was declared a global pandemic by the World Health Organization, and to date the COVID-19 pandemic continues to present a substantial public health and economic challenge around the world.&#160;The length of time and full extent to which the&#160;COVID-19&#160;pandemic will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain, subject to change and are difficult to predict.&#160;While we continue to conduct our research and development activities, the&#160;COVID-19&#160;pandemic may cause disruptions that affect our ability to initiate and complete preclinical studies, ongoing and future clinical trials or to procure items that are essential for our research and development activities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to continue to closely monitor the ongoing impact of the&#160;COVID-19&#160;pandemic on our employees and our business operations.&#160;In an effort to provide a safe work environment for our employees, we have, among other things, increased the cadence of sanitization of our office and lab facilities, implemented various social distancing measures in our office and labs including replacing in-person&#160;meetings with virtual interactions, and are providing personal protective equipment for our employees present in our office and lab facilities.&#160;We expect to continue to take actions as may be required or recommended by government authorities or as we determine are in the best interests of our employees and other business partners in light of the pandemic.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="i523559815e87485cb6a9895707f43a02_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Our Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the near future. If our development efforts for our product candidates are successful and result in regulatory approval or licenses with third parties, we may generate revenue in the future from product sales, milestone payments under our existing collaboration agreements or payments from other license agreements that we may enter into with third parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December of 2021, we entered into a strategic collaboration with Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company, to create novel oncology medicines by applying Foghorn&#8217;s proprietary Gene Traffic Control platform. The collaboration includes a co-development and co-commercialization agreement for the aforementioned selective BRM oncology program and an additional undisclosed oncology target. In addition, the collaboration includes three additional discovery programs using Foghorn&#8217;s proprietary Gene Traffic Control platform.  Under the terms of the collaboration, Foghorn received upfront consideration of $300.0 million in cash pursuant to the Lilly Collaboration Agreement, together with an equity investment by Lilly of $80.0 million in shares of Foghorn common stock pursuant to the Lilly SPA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the BRM-selective program and the additional undisclosed target program, Foghorn will lead discovery and early research activities, while Lilly will lead development and commercialization activities with participation from Foghorn in operational activities and cost sharing. Foghorn and Lilly will share 50/50 in the U.S. economics, and Foghorn is eligible to receive royalties on ex-U.S. sales starting in the low double-digit range and escalating into the twenties based on revenue levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the additional discovery programs, Foghorn will lead discovery and early research activities. Foghorn may receive up to a total of $1.3 billion in potential development and commercialization milestones. Additionally, Foghorn will have an option to participate in a percentage of the U.S. economics and is eligible to receive tiered royalties from the mid-single digit to low-double digit range on sales outside the U.S. that may be exercised after the successful completion of the dose-finding toxicity studies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot provide assurances as to the timing of future milestones, royalty payments and economics associated with the strategic collaboration with Loxo Oncology at Lilly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized total deferred revenue of $337.8 million related to the Lilly Collaboration Agreement and the Lilly SPA, which included the $300.0 million upfront payment as well as $37.8 million allocated to deferred revenue from the gross proceeds of the Lilly SPA to be recognized over the performance period. During the years ended December&#160;31, 2021 , we recognized $0.6 million of revenue under the Lilly Collaboration Agreement and, as of December&#160;31, 2021, we had $337.2 million of deferred revenue related to the above mentioned upfront payment and revenue allocation from the Lilly SPA remaining on our consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we entered into a strategic research collaboration and license agreement, or the Merck Collaboration Agreement, with Merck, pursuant to which we will apply our proprietary Gene Traffic Control platform to discover and develop novel therapeutics. Under the Merck Collaboration Agreement, we granted Merck exclusive global rights to develop and commercialize drugs that target dysregulation of a single transcription factor. Under the terms of the Merck Collaboration Agreement, we received a nonrefundable upfront payment of $15.0 million from Merck, and are eligible to receive up to $245.0 million upon achievement of specified research, development and regulatory milestones by any product candidate generated by the collaboration, and up to $165.0 million upon achievement of specified sales-based milestones per approved product from the collaboration, if any, as well as royalties on sales of any approved product from the collaboration. We cannot provide assurance as to the timing of future milestone or royalty payments or that we will receive any of these payments at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record revenue over the research term as we satisfy our performance obligation under the Merck Collaboration Agreement. Accordingly, the upfront payment of $15.0 million is being recognized as revenue using the cost-to-cost method, which we believe best depicts the transfer of control to the customer over time. Under the cost-to-cost method, the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified single performance obligation. We expect revenue to fluctuate as the achievement of milestones becomes probable and as our efforts to satisfy our performance obligation vary from period to period. In estimating the total costs to satisfy our performance obligation pursuant to the Merck Collaboration Agreement, we are required to make significant estimates including an estimate of the number of transcription factor substitutions and the expected time and expected costs to fulfill the performance obligation. The cumulative effect of revisions to the total estimated costs to complete our performance obligation will be recorded in the period in which the changes are identified, and amounts can be reasonably estimated. While such revisions will have no impact on our cash flows, a significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods. In June 2021, we re-evaluated our estimates related to the Merck Collaboration Agreement resulting in a reclassification of $1.9 million from short-term deferred revenue to long-term deferred revenue, net of current portion on the Company's consolidated balance sheets. During the years ended December&#160;31, 2021 and 2020, we recognized $0.7 million and $0.4 million, respectively, of revenue under the Merck </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement and, as of December&#160;31, 2021, we had $13.9 million of deferred revenue related to the upfront payment remaining on our consolidated balance sheets.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses are comprised of research and development expenses and general and administrative expenses.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and progressing our programs, which include:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">personnel-related costs, including salaries, benefits and stock-based compensation expense, for employees engaged in research and development functions;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expenses incurred in connection with our research programs and preclinical and clinical development of our product candidates, including under agreements with third parties, such as consultants and contractors and contract research organizations, or CROs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the cost of manufacturing drug substance and drug product for use in our research and preclinical studies and clinical trials under agreements with third parties, such as consultants and contractors and contract development and manufacturing organizations, or CDMOs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">laboratory supplies and research materials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">facilities, depreciation and amortization and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and insurance; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">payments made under third-party licensing agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We track our direct external research and development expenses on a program-by-program basis. These consist of costs that include fees, reimbursed materials, and other costs paid to consultants, contractors, CDMOs, and CROs in connection with our preclinical, clinical and manufacturing activities. We do not allocate employee costs, costs associated with our discovery efforts, laboratory supplies, and facilities expenses, including depreciation or other indirect costs, to specific product development programs because these costs are deployed across multiple programs and our platform and, as such, are not separately classified.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our research and development expenses will increase substantially as we advance our programs into clinical development and expand our discovery, research and preclinical activities in the near term and in the future. At this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any product candidates we may develop.&#160;A change in the outcome of any number of variables with respect to product candidates we may develop could significantly change the costs and timing associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any product candidates we may develop.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of personnel-related costs, including salaries, benefits and stock-based compensation, for employees engaged in executive, legal, finance and accounting and other administrative functions. General and administrative expenses also include professional fees for legal, patent, consulting, investor and public relations and accounting and audit services as well as direct and allocated facility-related costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our programs and platform. We also anticipate that we will continue to incur increased accounting, audit, legal, regulatory, compliance, director and officer insurance costs and investor and public relations expenses associated with operating as a public company.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists of interest expense associated with outstanding borrowings under our loan agreements as well as the amortization of debt discount associated with such agreements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income and Other Income (Expense), Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on our invested cash balances. Other income (expense) consists of sublease income and miscellaneous expense unrelated to our core operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have not recorded any income tax benefits for the net losses we have incurred or for the research and development tax credits earned in each period, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our net operating loss carryforwards and tax credit carryforwards will not be realized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had federal and state net operating loss carryforwards of $228.9 million and $206.0 million, respectively, which may be available to offset future taxable income. The federal net operating loss carryforwards include $12.5 million&#160;which expire at various dates beginning in&#160;2035&#160;and&#160;$216.4 million which carryforward indefinitely but in some circumstances may be limited to offset 80% of annual taxable income. The state net operating loss carryforwards expire at various dates beginning in&#160;2036. As of December&#160;31, 2021, we also had federal and state research and development tax credit carryforwards of $6.1 million and $4.1 million, respectively, which may be available to reduce future tax liabilities and expire at various dates beginning in 2036 and 2031, respectively. Due to our history of cumulative net losses since inception and uncertainties surrounding our ability to generate future taxable income, we have recorded a full valuation allowance against our net deferred tax assets at each balance sheet date.</span></div><div id="i523559815e87485cb6a9895707f43a02_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in Note&#160;2 to our consolidated financial statements appearing elsewhere in this Annual Report on Form&#160;10-K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received significant non-refundable upfront payments under our collaboration agreements with Merck and Lilly, from which we recognize revenue over time using the cost-to-cost method. Under&#160;the&#160;cost-to-cost&#160;method,&#160;the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified single performance obligation. In estimating the total costs to satisfy our performance obligation, we are required to make significant estimates including an estimate of the expected time and expected internal and external costs to fulfill the performance obligation.&#160;In developing these estimates we consider historical experience, relevant entity-specific factors, known market trends and conditions, and a variety of other factors we believe are relevant to estimating the total cost to fulfill the performance obligation. We periodically evaluate estimates against the actual time and costs incurred as well as any anticipated changes to the timing or estimated costs. Any cumulative effect of revisions to the total estimated costs to complete our performance obligation will be recorded in the period in which the changes are identified, and amounts can be reasonably estimated. While such revisions will have no impact on our cash flows, a significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the classification of deferred revenue between short-term and long-term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing our consolidated financial statements, we are required to estimate certain accrued research and development expenses. This process involves estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of the estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include those related to fees paid to:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">vendors in connection with discovery, preclinical and clinical development activities;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">CROs in connection with preclinical studies and testing and clinical trials; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">CDMOs in connection with the process development and scale up activities and the production and manufacturing of materials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base the expense recorded related to contract research and manufacturing on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CROs and CDMOs that conduct services and produce and supply materials. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. While the majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met, some require advance payments. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. We record these as prepaid expenses on our consolidated balance sheets.</span></div><div id="i523559815e87485cb6a9895707f43a02_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31, 2021 and 2020</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the years ended December&#160;31, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,482&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,961&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,734)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,531)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,203)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,906)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(979)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(927)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income and other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of preferred stock warrant liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on debt extinguishment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,011)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(586)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,320)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,800)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,520)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue was $1.3 million for the year ended December&#160;31, 2021, compared to $0.4 million for the year ended December&#160;31, 2020. The increase in collaboration revenue is attributed to the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in Merck collaboration revenue recognition of $0.3&#160;million due primarily to more work completed under the Merck Collaboration Agreement in 2021 compared to the work completed in 2020; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in Lilly collaboration revenue recognition of $0.6&#160;million due to work performed pursuant to the Lilly Collaboration Agreement entered into in December 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses for the years ended December&#160;31, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year&#160;Ended&#160;December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development program expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FHD-286</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,289&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,570&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,719&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FHD-609</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform, research and discovery, and unallocated expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and other early stage research external costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel related (including stock-based compensation)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,405&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,822&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,583&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facility related and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total research and development expenses</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80,325&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,715&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,610&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $80.3 million for the year ended December&#160;31, 2021, compared to $57.7 million for the year ended December&#160;31, 2020. The increase is attributed to the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in personnel-related costs of $7.6 million, including a $2.6 million increase in stock-based compensation expense, due primarily to increased headcount in our research and development function;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in platform and other early stage research costs of $5.2 million, which was due to continued investment and development of our platform and early research pipeline;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in facility-related and other expenses of $4.7 million was due to the increased costs of supporting a growing research and development organization and their research efforts, including increased rent and maintenance expense related to our new facility lease, and purchases of lab supplies, consumables, and equipment; </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in FHD-286 program costs of $4.7 million as the Company initiated Phase 1 clinical trials in Uveal Melanoma and AML and MDS in the first half of 2021; and </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in FHD-609 program cost of $0.5 million as the Company initiated enrollment in a Phase 1 clinical trial in the second half of 2021 in Synovial Sarcoma.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our general and administrative expenses for the years ended December&#160;31, 2021 and 2020:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year&#160;Ended&#160;December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel related (including stock-based compensation)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional and consultant</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,852&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,388&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,464&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facility related and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total general and administrative expenses</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,728&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,246&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,482&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $21.7 million for the year ended December&#160;31, 2021, compared to $11.2 million for the year ended December&#160;31, 2020. The increase is attributed to the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in personnel-related costs of $6.0 million, including a $2.8 million increase in stock-based compensation expense, which was a result of an increase in headcount in our general and administrative function to support our business;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in facility related and other expense of $3.0 million was primarily due to including increased rent, maintenance, and non-capital equipment expense related to our new facility lease; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in professional and consulting costs of $1.5 million, which was due to increased audit, tax, and consulting services associated with being a publicly traded company.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $1.9 million for the year ended December&#160;31, 2021, compared to $1.0 million for the year ended December&#160;31, 2020. The increase was due to the increased outstanding debt balance and higher interest rates on our borrowings throughout 2021 compared to 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income and other income (expense), net was $2.6 million for the year ended December&#160;31, 2021 and consisted primarily of sublease income of $2.5 million related to the sublease that began in July 2020 and $0.1&#160;million of interest income. Interest income and other income (expense), net of $1.0 million for the year ended December&#160;31, 2020 consisted primarily of sublease income of $1.0&#160;million related to the sublease that began in July 2020 and $0.1&#160;million of interest income.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded a loss on debt extinguishment of $1.2 million for the year ended December&#160;31, 2021 compared to $0.2 million for the year ended December&#160;31, 2020. We used cash on hand to repay early the balance of our loan outstanding at the time, including a final payment fee and a prepayment fee during December&#160;31, 2021. During the year ended December&#160;31, 2020, we repaid our then outstanding loan in November 2020, which was contractually lower than the prepayment costs incurred in 2021. </span></div><div id="i523559815e87485cb6a9895707f43a02_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in October 2015, we have incurred significant operating losses. We expect to incur significant expenses and operating losses for the foreseeable future as we support our continued research activities and development of our programs and platform. Through December&#160;31, 2021, we have funded our operations with proceeds from our IPO in October 2020, sales of preferred stock, term loans, an upfront payment of $15.0 million we received in July 2020 under the Merck Collaboration Agreement and proceeds we received in December 2021 under the Lilly SPA of $80.0 million, of which </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$42.2 million was allocated to equity upon the issuance of the Company&#8217;s common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December&#160;31, 2021, we had cash, cash equivalents and marketable securities of $154.3 million.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our sources and uses of cash for each of the periods presented:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(50,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31,286)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(108,914)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">217,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase in cash, cash equivalents and restricted cash</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,341&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,273&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, operating activities used $50.3 million of cash, resulting from our net loss of $101.3 million partially offset by net cash provided by changes in our operating assets and liabilities of $33.4 million and by net non-cash charges of $17.6 million . Net cash provided by changes in our operating assets and liabilities for the year ended December&#160;31, 2021 consisted primarily of $37.8 million of proceeds from the Lilly SPA partially offset by a $4.0 million decrease in operating lease liabilities and a $0.3 million net increase in working capital.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, operating activities used $31.3 million of cash, resulting from our net loss of $68.8 million, partially offset by net non-cash charges of $8.8 million and net cash provided by changes in our operating assets and liabilities of $28.7 million. Net cash provided by changes in our operating assets and liabilities for the year ended December&#160;31, 2020 consisted primarily of a $15.1 million increase in operating lease liabilities resulting from our landlord incentives received, a $14.6 million increase in deferred revenue resulting from the upfront payment received in connection with the Merck Collaboration Agreement and an increase of $3.7 million in accounts payable and accrued expenses and other current liabilities, partially offset by an increase of $4.7 million in prepaid expenses and other assets.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, net cash provided by investing activities was $36.2 million primarily due to the maturity of marketable securities of $139.5 million partially offset by the purchases of marketable securities of $100.0 million and the acquisition of property and equipment of $3.3 million. Property and equipment purchases for the year ended December&#160;31, 2021 were primarily related to leasehold improvements for our new facility in Cambridge, Massachusetts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, net cash used in investing activities was $108.9 million primarily due to the purchases of marketable securities of $93.0 million and the acquisition of property and equipment of $16.2 million. Property and equipment purchases for the year ended December&#160;31, 2020 were primarily related to leasehold improvements for our new facility in Cambridge, Massachusetts.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, net cash provided by financing activities was $22.4 million, consisting primarily of proceeds from the Lilly SPA of $42.2 million and proceeds from the exercise of common stock options of $1.4 million partially offset by the repayment of notes payable of $21.2 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, net cash provided by financing activities was $217.5 million, consisting primarily of proceeds from our IPO, net of underwriting discounts and commissions and other offering expenses of $122.1 million, net proceeds from the sale of our Series B preferred stock of $89.9 million, net borrowings of $4.3 million and proceeds from the exercise of common stock options of $1.2 million.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities, initiate clinical trials for our product candidates in development and continue to fund on-going clinical trials. As of the issuance date of the consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we expect that our cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements for at least twelve months. We have based these estimates as to how long we expect we will be able to fund our operations on assumptions that may prove to be inaccurate. We could use our available capital resources sooner than we currently expect, in which case we would be required to obtain additional financing sooner than planned, which may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to raise sufficient capital as and when needed, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product candidate we may develop, or be unable to expand our operations or otherwise capitalize on our business opportunities. If we raise additional funds through collaborations or licensing arrangements with third parties, we may have to relinquish valuable rights to future revenue streams or product candidates or grant licenses on terms that may not be favorable to us.</span></div><div id="i523559815e87485cb6a9895707f43a02_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-balance&#160;Sheet Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any&#160;off-balance&#160;sheet arrangements, as defined in the rules and regulations of the Securities and Exchange Commission.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note&#160;2 to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.</span></div><div id="i523559815e87485cb6a9895707f43a02_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company, as defined in Rule&#160;12b-2&#160;under the Securities Exchange Act of 1934, as amended, for this reporting period and are not required to provide the information required under this item.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i523559815e87485cb6a9895707f43a02_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;8. CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOGHORN THERAPEUTICS INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Consolidated Financial Statements</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:93.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.132%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_70">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  (PCAOB ID No. <ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl82Ny9mcmFnOjc5ZGRlOGYyYTg4MjQwMzFiZmQzNDJlMTMwNzJhNWViL3RhYmxlOjEzODk1ZmY3OWVkZTRmZjFiMjM5NzNmYjM3ZmI3YmU3L3RhYmxlcmFuZ2U6MTM4OTVmZjc5ZWRlNGZmMWIyMzk3M2ZiMzdmYjdiZTdfMi0wLTEtMS0zMjkzOC90ZXh0cmVnaW9uOmU0ODljOWNjOGI3MTQyYzk5YjEwNmJhY2JhOTEyYWM0XzE2NDkyNjc0NDE3ODQ_e2ea8d0c-f181-4359-b6ed-22ca624d2ac8">34</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_70">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_73">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_73">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_79">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_79">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_82">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_82">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_88">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_88">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_94">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_94">91</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i523559815e87485cb6a9895707f43a02_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Foghorn Therapeutics Inc.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Foghorn Therapeutics Inc. and its subsidiary (the &#8220;Company&#8221;), as of December&#160;31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity, and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83MC9mcmFnOmRmYzI4MjI2YjQyMjQ1Mzk5Yjg3NzA5MjJlZjYyNTQ4L3RleHRyZWdpb246ZGZjMjgyMjZiNDIyNDUzOTliODc3MDkyMmVmNjI1NDhfMTc1OTIxODYwNDczNDY_6814db69-7d8f-46eb-a225-b51f1ce94f2c">Deloitte&#160;&amp; Touche LLP</ix:nonNumeric></span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83MC9mcmFnOmRmYzI4MjI2YjQyMjQ1Mzk5Yjg3NzA5MjJlZjYyNTQ4L3RleHRyZWdpb246ZGZjMjgyMjZiNDIyNDUzOTliODc3MDkyMmVmNjI1NDhfMTc1OTIxODYwNDczNDg_8b7c5234-f260-4d03-a715-ecaa90f00b3f">Boston, Massachusetts</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;10, 2022</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2018.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i523559815e87485cb6a9895707f43a02_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foghorn Therapeutics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfNC0xLTEtMS0w_5655adc3-783a-4105-b7eb-c31acbb49369">101,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfNC0zLTEtMS0w_fb2534a0-55a4-475a-af93-f51e6b6c72bf">92,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfNS0xLTEtMS0w_b897a558-57f6-4717-8bcc-9669f605498e">53,153</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfNS0zLTEtMS0w_52659fd4-2065-4d4e-b577-4c1dbd5c842d">92,975</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfNi0xLTEtMS0yNjAwOA_62216826-fe30-4db1-acca-891b7ab551b7">300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfNi0zLTEtMS0yNjAwOA_309bcbc3-39a1-481b-b7a2-406c0bab37ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfNy0xLTEtMS0w_5b9aa672-18e0-4dcb-ac88-b36135267b7f">5,273</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfNy0zLTEtMS0w_8feb4e4a-5da1-4ef0-91be-98d78c6449a1">4,917</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfOC0xLTEtMS0w_5ae4f33a-2fa4-4742-a937-796cbb2d6f85">459,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfOC0zLTEtMS0w_6f53f0f7-3170-49eb-b3b5-0b7004176085">190,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfOS0xLTEtMS0w_6373f7c8-e7e5-441b-8669-ba69224373a2">17,563</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfOS0zLTEtMS0w_de3b2452-45f9-46db-950b-4555bc9d9bd5">19,528</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTAtMS0xLTEtMA_0f7e815f-6477-4b13-9b5b-eaaae27469a7">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTAtMy0xLTEtMA_2252579c-bb8a-4a9b-aced-dcfdb6d1fc22">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTEtMS0xLTEtMA_3d539ec2-e108-43a8-9891-f8b3a5fc5b20">2,400</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTEtMy0xLTEtMA_fe1d2d70-6f22-4827-893c-5ff50f2e9084">842</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTItMS0xLTEtMA_fcac5920-f27f-4f19-949b-bfbae1381d7f">38,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTItMy0xLTEtMA_4193a442-4b78-44f0-a024-d119c6a12865">42,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTMtMS0xLTEtMA_206fbf18-e07d-44fd-be4d-e50a28938fe6">519,774</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTMtMy0xLTEtMA_5a1e2790-23c6-44f6-b4a3-2eaecf42307b">255,594</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTYtMS0xLTEtMA_083754ad-e7eb-4518-8437-2afcc7dc9f36">3,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTYtMy0xLTEtMA_3a4c3407-9e87-4480-b9f7-6e6f8aff87b7">3,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTctMS0xLTEtMA_07bae81c-a4c4-4999-b2b4-d5c2d934d7b7">9,562</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTctMy0xLTEtMA_dd87f7d5-1beb-40b1-8175-057522b4f284">9,161</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTgtMS0xLTEtMA_effa934e-01ba-4f14-964c-12cdce7a4ef4">6,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTgtMy0xLTEtMA_987b9e50-7ec4-4fd2-8553-b75f18d8fb9b">3,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjAtMS0xLTEtMA_0d5da131-8236-49da-85fe-ce716e703760">28,317</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjAtMy0xLTEtMA_a992b3e2-e48d-4bf7-8ad1-6589f2b7671c">2,024</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjEtMS0xLTEtMA_0ceb6ff8-0d46-4a02-b824-d1af9a757be4">48,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjEtMy0xLTEtMA_41824845-89a0-4e88-a834-16bb21754b4f">18,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes payable, net of discount</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjItMS0xLTEtMA_44147cad-6265-40ff-b0a4-7fc097accaae">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjItMy0xLTEtMA_01350a13-7bf3-458d-9266-4f5925eaf1e2">19,654</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjMtMS0xLTEtMA_f9f18a16-6f4e-4f29-86bc-408a27f836a3">51,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjMtMy0xLTEtMA_e36c846d-23fe-4ae3-8d82-77217b9e90be">58,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue, net of current portion</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjQtMS0xLTEtMA_b68047ee-2f84-447f-9236-730ce7258894">322,730</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjQtMy0xLTEtMA_6252a2b7-7bb5-4a45-a825-e6287bcfb108">12,546</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjUtMS0xLTEtMA_da40edf0-01b2-41d8-b472-ba228ea4bdb4">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjUtMy0xLTEtMA_d2d8d7c5-d261-4bf4-aab9-9847e917d0e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjYtMS0xLTEtMA_471e5dc6-9aa5-48b7-aa80-f23e3c08c827">422,903</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjYtMy0xLTEtMA_ea9c3c17-02d2-4105-8b54-01cfce44ac36">109,407</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies (Note 13)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjctMS0xLTEtMA_fd25fb5f-b709-48da-a935-56d46b5e7c3b"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjctMy0xLTEtMA_b30a80a1-2ed0-40f5-804f-3e23cea0f825"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; equity:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzAtMC0xLTEtMTk3ODcvdGV4dHJlZ2lvbjowYTBkOTRkODViMmI0MmQ4YmNiODZiNGJmNjExNzcwNV8xMTU0NDg3MjA5MTc4Mg_3d7df56c-d097-4312-8e03-2b8940b4bcd9"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzAtMC0xLTEtMTk3ODcvdGV4dHJlZ2lvbjowYTBkOTRkODViMmI0MmQ4YmNiODZiNGJmNjExNzcwNV8xMTU0NDg3MjA5MTc4Mg_90abc8df-90bc-4d98-b9db-876e33fd91d1">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzAtMC0xLTEtMTk3ODcvdGV4dHJlZ2lvbjowYTBkOTRkODViMmI0MmQ4YmNiODZiNGJmNjExNzcwNV8xMTU0NDg3MjA5MTc5Ng_1c172254-558b-4607-889a-f30b3e293920"><ix:nonFraction unitRef="shares" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzAtMC0xLTEtMTk3ODcvdGV4dHJlZ2lvbjowYTBkOTRkODViMmI0MmQ4YmNiODZiNGJmNjExNzcwNV8xMTU0NDg3MjA5MTc5Ng_e1c67916-ff09-4030-acac-327c9d83f0ca">25,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of December&#160;31, 2021 and 2020; <ix:nonFraction unitRef="shares" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzAtMC0xLTEtMTk3ODcvdGV4dHJlZ2lvbjowYTBkOTRkODViMmI0MmQ4YmNiODZiNGJmNjExNzcwNV8xMTU0NDg3MjA5MTgwMQ_2a52c8f9-61ec-48b2-afd0-387c775c1d47"><ix:nonFraction unitRef="shares" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzAtMC0xLTEtMTk3ODcvdGV4dHJlZ2lvbjowYTBkOTRkODViMmI0MmQ4YmNiODZiNGJmNjExNzcwNV8xMTU0NDg3MjA5MTgwMQ_36ea4b76-40c5-4c33-bb9f-b5eb07f5b137"><ix:nonFraction unitRef="shares" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzAtMC0xLTEtMTk3ODcvdGV4dHJlZ2lvbjowYTBkOTRkODViMmI0MmQ4YmNiODZiNGJmNjExNzcwNV8xMTU0NDg3MjA5MTgwMQ_8c61ed02-8183-4d1f-b27e-9d8c20ab364d"><ix:nonFraction unitRef="shares" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzAtMC0xLTEtMTk3ODcvdGV4dHJlZ2lvbjowYTBkOTRkODViMmI0MmQ4YmNiODZiNGJmNjExNzcwNV8xMTU0NDg3MjA5MTgwMQ_e45e7ba3-33d2-4384-8f20-add7e194c220">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzAtMS0xLTEtMA_343a114b-0a90-4719-a485-5389c8c4c314">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzAtMy0xLTEtMA_e4af596b-d8e0-4abd-a266-c2e9a2ad6d76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzEtMC0xLTEtMTk3ODkvdGV4dHJlZ2lvbjowY2ZkNjdkZDBhOWY0ZTI1YmVmYjRiM2JiNWJlZDhhYV8xMTU0NDg3MjA5MTkyNg_62673b55-bbe7-4295-a844-c2e86bffc6ec"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzEtMC0xLTEtMTk3ODkvdGV4dHJlZ2lvbjowY2ZkNjdkZDBhOWY0ZTI1YmVmYjRiM2JiNWJlZDhhYV8xMTU0NDg3MjA5MTkyNg_c7bbe157-3859-44ef-923c-25e9e2abe426">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzEtMC0xLTEtMTk3ODkvdGV4dHJlZ2lvbjowY2ZkNjdkZDBhOWY0ZTI1YmVmYjRiM2JiNWJlZDhhYV8yMTk5MDIzMjU1OTQ4_232abc7b-c629-49a1-80d3-78fa39802cd3"><ix:nonFraction unitRef="shares" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzEtMC0xLTEtMTk3ODkvdGV4dHJlZ2lvbjowY2ZkNjdkZDBhOWY0ZTI1YmVmYjRiM2JiNWJlZDhhYV8yMTk5MDIzMjU1OTQ4_ceaef7fb-0891-4e3c-a73c-3ce2c8f1e154">175,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31, 2021 and 2020; <ix:nonFraction unitRef="shares" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzEtMC0xLTEtMTk3ODkvdGV4dHJlZ2lvbjowY2ZkNjdkZDBhOWY0ZTI1YmVmYjRiM2JiNWJlZDhhYV8xMTU0NDg3MjA5MTk1NA_1f4a4450-f4c7-4d33-8cf3-00027f0245a8"><ix:nonFraction unitRef="shares" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzEtMC0xLTEtMTk3ODkvdGV4dHJlZ2lvbjowY2ZkNjdkZDBhOWY0ZTI1YmVmYjRiM2JiNWJlZDhhYV8xMTU0NDg3MjA5MTk1NA_ef5e722d-8859-4d0f-a3eb-263459f49ecc">41,299,720</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021 and <ix:nonFraction unitRef="shares" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzEtMC0xLTEtMTk3ODkvdGV4dHJlZ2lvbjowY2ZkNjdkZDBhOWY0ZTI1YmVmYjRiM2JiNWJlZDhhYV8xMTU0NDg3MjA5MTk2Ng_8d1a9425-40fc-4642-b617-c9293eef8955"><ix:nonFraction unitRef="shares" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzEtMC0xLTEtMTk3ODkvdGV4dHJlZ2lvbjowY2ZkNjdkZDBhOWY0ZTI1YmVmYjRiM2JiNWJlZDhhYV8xMTU0NDg3MjA5MTk2Ng_9a66bff7-b2f0-4572-8500-39f20e5a8c13">36,790,946</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2020</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzEtMS0xLTEtMA_5b9a5cf8-5d99-43a5-84c7-bc62cf243f26">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzEtMy0xLTEtMA_1e188a31-a9e0-4997-9cd9-faa44c3d0317">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzItMS0xLTEtMA_7c7487a3-6447-4f48-a71d-8dfdee9c3ed2">361,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzItMy0xLTEtMA_b89b604e-b8ce-45c2-94a9-af322a93e941">309,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzMtMS0xLTEtMA_b1f42f56-c29d-4449-bed3-dbc504cf8f75">10</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzMtMy0xLTEtMA_65f10829-923c-4170-97a4-1dfba4256fbf">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzQtMS0xLTEtMA_45d66511-8d95-4513-b0ea-ad008149fea8">264,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzQtMy0xLTEtMA_fa323953-485f-42dd-9692-5462a8a9f694">162,936</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzUtMS0xLTEtMA_7bf1f394-04ed-4fbc-a590-c8a97ac97a71">96,871</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzUtMy0xLTEtMA_2b6be5fd-1969-4bd8-969e-83023898be40">146,187</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzYtMS0xLTEtMA_642a708e-7d90-467b-845d-3cc3af11027e">519,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzYtMy0xLTEtMA_1a3cc34f-9fb3-40c5-a854-4bd5b95608d4">255,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i523559815e87485cb6a9895707f43a02_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foghorn Therapeutics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMi0xLTEtMS0w_5fbdb857-c462-4264-b612-e39eea1d060a">1,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMi0zLTEtMS0w_5b1e108d-ac20-42a6-8595-69036000fd6a">430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfNC0xLTEtMS0w_686dd7d2-8e80-4996-a39f-a251980e383e">80,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfNC0zLTEtMS0w_17e3fccf-a3aa-4b7a-9ad5-7d9db8ddd15f">57,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfNS0xLTEtMS0w_78b9d087-5853-4e8a-9be9-536a62c8ac00">21,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfNS0zLTEtMS0w_66f805cb-d0e1-45dc-a295-09239bb9683b">11,246</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfNi0xLTEtMS0w_1aee3417-2611-4854-b4b6-4d3f1a9716be">102,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfNi0zLTEtMS0w_672da23f-e018-47b6-be2c-6fe3194893ff">68,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfNy0xLTEtMS0w_ddfde6a6-d287-40b6-96ec-ee3c66ea546a">100,734</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfNy0zLTEtMS0w_bd7f7f9e-531f-4971-9ef5-6f60b8bf1e7d">68,531</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfOS0xLTEtMS0w_1d767663-9148-4054-8436-7367e34d3719">1,906</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfOS0zLTEtMS0w_8040b3f2-73ee-4d97-afe4-7e7c50a36d9e">979</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income and other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="fhtx:InterestIncomeAndOtherIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTAtMS0xLTEtMA_2921b5ca-3b39-4a6f-9dfe-0694955c426e">2,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="fhtx:InterestIncomeAndOtherIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTAtMy0xLTEtMA_9a2955f5-7541-428d-af21-7177eaa68da8">1,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of preferred stock warrant liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTEtMS0xLTEtMA_20992289-ce1a-45c9-909a-274b911ac297">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTEtMy0xLTEtMA_7729dee3-7726-4d2d-8fb5-d7ec2e689664">69</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on debt extinguishment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTItMS0xLTEtMA_ceb686d0-e886-47e4-b57b-7b4d01cbc733">1,233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTItMy0xLTEtMA_137a2977-7b0d-4529-b517-7ce75eea5805">222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTMtMS0xLTEtMA_5da7dbde-4373-4114-ad9c-2d2b68df6489">586</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTMtMy0xLTEtMA_a01e3c5f-ef87-4bfd-bd89-425ce1a17954">269</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTQtMS0xLTEtMA_84aac958-4322-4be2-a390-da7688ddd6f2">101,320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTQtMy0xLTEtMA_61d2e38e-bfa5-4e9e-be56-faa65a7af4cf">68,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders&#8212;basic and diluted</span></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTUtMS0xLTEtMA_2e3595e5-117b-49a4-89c0-0d3cfc929b34"><ix:nonFraction unitRef="usdPerShare" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTUtMS0xLTEtMA_ae550761-afcf-4a28-8ebe-c071ed804c79">2.73</ix:nonFraction></ix:nonFraction>)</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTUtMy0xLTEtMA_75a97f3a-6291-4aaa-8284-dffcaa69a2ac"><ix:nonFraction unitRef="usdPerShare" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTUtMy0xLTEtMA_ef81def3-bcd7-4fba-ad52-d136008996da">6.23</ix:nonFraction></ix:nonFraction>)</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding&#8212;basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTYtMS0xLTEtMA_177d06eb-091e-431a-85ad-84b3a3eec6a8"><ix:nonFraction unitRef="shares" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTYtMS0xLTEtMA_4ef62617-a131-4d74-88db-d06c5669d09b">37,171,147</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTYtMy0xLTEtMA_1d3964da-10ac-4c10-a756-3b21aba3610e"><ix:nonFraction unitRef="shares" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTYtMy0xLTEtMA_588ca6d1-2f66-485f-910a-452bfc42ca68">11,046,802</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTgtMS0xLTEtMA_60af6cf4-3697-4734-ad14-d35748e232cc">101,320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTgtMy0xLTEtMA_7ebd8717-3f5a-4597-a1fb-1422591a13b5">68,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMjAtMS0xLTEtMA_9c3734c1-6713-42c1-8652-b13567f748bd">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMjAtMy0xLTEtMA_d26a3016-bdfa-476e-97b7-d3e09fd8647d">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive loss</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMjEtMS0xLTEtMA_44cfe2dc-0167-4c00-8452-4755f3b45e65">3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMjEtMy0xLTEtMA_97ffe409-9874-4eeb-b0db-2af0b6377505">7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMjItMS0xLTEtMA_2b6f1d42-3e35-41f0-ad88-340c0c65e3c8">101,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMjItMy0xLTEtMA_61e9bdb8-569a-49d4-b5a6-f29c80dfe447">68,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="i523559815e87485cb6a9895707f43a02_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foghorn Therapeutics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share amounts)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.806%"></td><td style="width:0.1%"></td></tr><tr style="height:29pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Series A-1, A-2 and B<br/>Convertible<br/>Preferred&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total<br/>Stockholders&#8217;<br/>Equity<br/>(Deficit)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id7943cc4a71f4b42b53e4c968843494e_I20191231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMi0xLTEtMS0yOTEzNg_12905e55-6961-4779-ad4d-df621492730d">28,615,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id7943cc4a71f4b42b53e4c968843494e_I20191231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMi0zLTEtMS0yOTEzNg_00cc3633-805e-4520-aee9-bdb10516156a">86,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5c744d00941d4c199a48d89ffa755b17_I20191231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMi02LTEtMS0yOTEzNg_f6c54392-c6c5-43f7-8648-305b4e5bc837">4,870,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5c744d00941d4c199a48d89ffa755b17_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMi04LTEtMS0yOTkzNg_8e955c14-bc79-468e-aab7-94c331b23b5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i81de0ee0ccd449989132fa7f14079ba5_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMi0xMC0xLTEtMjkxMzY_41df72ce-96bd-4bf1-b635-20d7454f79ed">6,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iac30a123b0694acb8d72a14f63dac021_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMi0xNC0xLTEtMjkxMzY_62d0ea26-26f6-4707-ac15-2fe978430e5c">94,136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i406407ac43db40d493cf8d79d3921779_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMi0xNi0xLTEtMjkxMzY_d544dd52-900f-4d6a-8f02-243c845d947f">88,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of Series B convertible preferred stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ie0edcb140d2049a79c39501d27f139b9_D20200101-20201231" decimals="-3" name="fhtx:StockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMy0wLTEtMS0yOTU1MS90ZXh0cmVnaW9uOmFhNzhkNmZhMmUyNjRjY2Y4YWM2NTFmNDUwMTcxNjIxXzE2NDkyNjc0NDE3NTE_a777712b-ae13-43f7-b9a4-6a3cf03979dd">198</ix:nonFraction></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie0edcb140d2049a79c39501d27f139b9_D20200101-20201231" decimals="INF" name="fhtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMy0xLTEtMS0yOTA2OQ_de466229-1392-4dce-ab13-a6f430b32159">12,007,867</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6f685775719843b4a9fff30dabdaf80a_D20200101-20201231" decimals="-3" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMy0zLTEtMS0yOTA2OQ_8eda4e27-c81d-4e47-97d8-e007e383c519">89,861</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Conversion of preferred stock to common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ie0edcb140d2049a79c39501d27f139b9_D20200101-20201231" decimals="INF" name="fhtx:TemporaryEquityConversionOfStockSharesConverted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNC0xLTEtMS0yOTA2OQ_3fcda242-3999-49b0-a826-8795f621fb47">40,623,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i6f685775719843b4a9fff30dabdaf80a_D20200101-20201231" decimals="-3" name="fhtx:TemporaryEquityConversionOfStockAmountConverted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNC0zLTEtMS0yOTA2OQ_8d2723c4-a2cc-4609-aae6-3ce14b8faf19">176,405</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie54f7d4fc8034f45ba6d2e439e5ab48d_D20200101-20201231" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNC02LTEtMS0yOTA2OQ_a1742dd7-091c-4126-aa68-e358413a918a">21,958,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie54f7d4fc8034f45ba6d2e439e5ab48d_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNC04LTEtMS0yOTA2OQ_50202d57-cdc0-4516-bad7-bb160a31f1ec">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfaabe46efdf4e258762c5f4b7e852b8_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNC0xMC0xLTEtMjkwNjk_4b5faa8f-fad0-4d7b-9ed7-06120768737f">176,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNC0xNi0xLTEtMjkwNjk_14fd3a2a-e1e4-47b3-8da9-a81bb803e151">176,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock upon initial public offering net of underwriting discounts, commissions and offering costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i810a9ddbdca940e9b925b274aa1a2543_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNS02LTEtMS0yOTA2OQ_c2c7d947-2ce6-4a3f-8315-be553d484981">8,451,837</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i810a9ddbdca940e9b925b274aa1a2543_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNS04LTEtMS0yOTA2OQ_ffa6d3ef-8168-48c7-a64e-d179ba49470d">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if047b911bba14fcf9c9ca20f03db2aa3_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNS0xMC0xLTEtMjkwNjk_a35e4673-7dab-4a6e-ab52-be15c3bd5898">122,120</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i392fd42774c3426791748c8100a4fdd2_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNS0xNi0xLTEtMjkwNjk_75997f6f-1c8b-4f91-862e-15c2313d3af1">122,121</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Conversion of warrant liability to equity upon closing of initial public offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfaabe46efdf4e258762c5f4b7e852b8_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNi0xMC0xLTEtMjkwNjk_db4737b4-4110-4705-8968-6efdc075c75b">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNi0xNi0xLTEtMjkwNjk_6ec04123-8ded-4ff9-b178-76c831764e30">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock in connection with the cashless exercise of warrants</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie54f7d4fc8034f45ba6d2e439e5ab48d_D20200101-20201231" decimals="INF" name="fhtx:StockIssuedDuringPeriodConnectionWithExerciseOfWarrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNy02LTEtMS0yOTA2OQ_7ec1e8c0-45a3-4203-8320-df0c1c01b4c4">6,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie54f7d4fc8034f45ba6d2e439e5ab48d_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfOC02LTEtMS0yOTA2OQ_8a7753fc-cbe1-424d-b483-a1e5b44f05e4">611,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfaabe46efdf4e258762c5f4b7e852b8_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfOC0xMC0xLTEtMjkwNjk_5d2a3710-703b-48d0-a917-20b852414509">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfOC0xNi0xLTEtMjkwNjk_f45b3675-b810-4764-b4ce-9013771e2f98">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of warrants in connection with notes payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfaabe46efdf4e258762c5f4b7e852b8_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfOS0xMC0xLTEtMjkwNjk_c78e4e1d-2699-4e58-a236-7b091ec5590d">188</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfOS0xNi0xLTEtMjkwNjk_29c2f460-28e8-4629-9b99-577c383a4747">188</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vesting of restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie54f7d4fc8034f45ba6d2e439e5ab48d_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTAtNi0xLTEtMjkwNjk_c64ed076-2fdd-4079-9b7d-3868fec15fa5">891,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icfaabe46efdf4e258762c5f4b7e852b8_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTEtMTAtMS0xLTI5MDY5_28671f98-2b80-49ac-92d4-bd5e159e20f0">2,961</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTEtMTYtMS0xLTI5MDY5_23d36ec9-2253-41c4-ae3f-c6ceba4af654">2,961</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unrealized losses on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib04b5ec0aee746bcaee20b310c94a839_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTItMTItMS0xLTI5MDY5_cb0b746e-f65d-4507-8444-e5352bdadb84">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTItMTYtMS0xLTI5MDY5_79380e98-c519-46f5-92a2-5312f7eb3e07">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i755b66d1c0514ffabb5b047a0580e000_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTMtMTQtMS0xLTI5MDY5_db3aa17a-b6ad-459c-98ec-b174821f3dee">68,800</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTMtMTYtMS0xLTI5MDY5_5e8d7c69-b09a-4ea4-addd-79aef4527bdb">68,800</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Balances at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6202585c1f594c04828ca33622ba9f73_I20201231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTctMS0xLTEtMA_68350789-8e7a-419a-acca-2bc875d317e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6202585c1f594c04828ca33622ba9f73_I20201231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTctMy0xLTEtMA_914286d2-c764-45bd-930d-9bdcf3a90d0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic897dfc3ee8d4be5958083cf9a26f3cf_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTctNi0xLTEtMA_a983b1d2-612b-4824-b325-1c591e35d411">36,790,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic897dfc3ee8d4be5958083cf9a26f3cf_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTctOC0xLTEtMA_05520674-eb61-4dbb-9331-8db6a29f7e76">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b60e82482b4491fbaf024954d547c32_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTctMTAtMS0xLTA_b308a9a1-14c6-4b1d-8b43-c6a8e7de4d62">309,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if1da796dda74428196d7005b876d4506_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTctMTItMS0xLTA_1393af59-530b-47b8-b706-5d83a8dc361b">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie6dc13b3584f4e4aa450e4760484cf39_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTctMTQtMS0xLTA_d4463a37-7945-4bf0-b020-212abbaed049">162,936</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTctMTYtMS0xLTA_2949f885-f5c9-4053-bdbf-b70883ef4c1e">146,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8f78ce619e064ea1b1cdd9e493e462f3_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTgtNi0xLTEtMA_7c2cf4bd-de9d-4203-9545-eb8969ddf9bd">508,774</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i70fb1b2bd2ea46e881f0145ac62c2a0f_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTgtMTAtMS0xLTA_d2780925-a26f-4cb9-b9a8-1b5630a260c3">1,418</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTgtMTYtMS0xLTA_2e3ae6ff-9685-4ccc-b68e-84e9f9d10294">1,418</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock related to stock purchase agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i92d1d123424f44d994d5af3872acb232_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTktNi0xLTEtMA_df9f0793-d4c8-426c-b579-f1c50b09863a">4,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i43038a8d4df843809b6e00244fcfc5f2_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTktMTAtMS0xLTA_64fd5225-4cbe-4651-8ce7-60fadba1211f">42,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i08a673dfc57842d19a4fc0a035015adb_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTktMTYtMS0xLTA_e3b51eae-d1df-4024-93bf-d17961511232">42,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i70fb1b2bd2ea46e881f0145ac62c2a0f_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjAtMTAtMS0xLTIzMDI4_2df51ced-608b-43ca-a588-bff3b81860a4">8,384</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjAtMTYtMS0xLTIzMDI4_3b37b601-bf34-449d-8558-f0ada1f9da94">8,384</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unrealized losses on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if661fd7abbb84486820d9146f777241d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjEtMTItMS0xLTIzMDI4_6f97079b-0c73-4377-83b8-62eba9c85904">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjEtMTYtMS0xLTIzMDI4_24005803-7729-407c-8357-979ee7cdf6b4">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1fb4ee0936c34d9094e17460190a277a_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjItMTQtMS0xLTIzMDI4_b6addb3a-8cde-40e9-a668-077f034f936f">101,320</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjItMTYtMS0xLTIzMDI4_f13f96a2-c000-4b68-8277-48f8f264264d">101,320</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Balances at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if28ce271ce7648a08119c449c9d2ef48_I20211231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjAtMS0xLTEtMA_b1362299-c575-4f22-8674-404ec5a7a4c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if28ce271ce7648a08119c449c9d2ef48_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjAtMy0xLTEtMA_eb46d3c0-9f13-4939-9217-ebe31659db06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8d7cb7123c0e44e095d8223cbcd8af1b_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjAtNi0xLTEtMA_7e2e7934-8a94-4751-af95-48278c8169e8">41,299,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d7cb7123c0e44e095d8223cbcd8af1b_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjAtOC0xLTEtMA_1ac511eb-4c80-479f-8189-9fe6e5cb3861">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6fadfcdbc6314b66a0e9d9a4c9ad038c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjAtMTAtMS0xLTA_7b780341-112f-46bb-8547-75193126880c">361,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i3e7fbab3102f466f9aa8f20c9c5e38d5_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjAtMTItMS0xLTA_ac0bd1e8-2da2-41b7-b5d9-772be4f7c760">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2c1033134ae74e0a98b856d174a6a6f8_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjAtMTQtMS0xLTA_d561cb77-6bcc-4e2b-9bc5-50162c6a9162">264,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjAtMTYtMS0xLTA_039caaaa-9530-497e-a4a1-3c59430a706e">96,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="i523559815e87485cb6a9895707f43a02_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foghorn Therapeutics Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:79.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.272%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year&#160;ended&#160;December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMy0xLTEtMS0w_4645e3ba-a739-4bb5-ba2a-c7265b7f23c0">101,320</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMy0zLTEtMS0w_906ab585-31aa-4951-a48d-5eca4201bb43">68,800</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to issuance of options and employee stock purchase plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:StockOptionPlanExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNS0xLTEtMS0w_ab6ffaa7-6535-44d4-8e06-4cda1221e846">8,384</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:StockOptionPlanExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNS0zLTEtMS0w_89521ad9-4eb8-4c9e-a231-cec6db8476c6">2,961</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNi0xLTEtMS0w_72ae809b-0bbf-4024-873b-6aa51f1f08ff">3,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNi0zLTEtMS0w_69130eba-6f4c-45e0-b3f8-2a8945ea71d9">1,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on disposal of property and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNy0xLTEtMS0w_a593022e-d8b0-42ba-bab4-c0b1da16f0df">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNy0zLTEtMS0w_b12e41aa-b90b-4d75-bb45-27cb67a68933">206</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on debt extinguishment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfOC0xLTEtMS0w_4d4fa51c-8a9d-44ed-9325-dc61adf1d80a">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfOC0zLTEtMS0w_788b5901-2ffe-427b-84a4-dbc0ab6223fe">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of preferred stock warrant liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfOS0xLTEtMS0w_1d24c4d5-be3f-4caa-ac5a-3761e44fd2ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfOS0zLTEtMS0w_9aee2edf-4a31-404a-9f20-821818ced092">69</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="fhtx:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTAtMS0xLTEtMA_eb48da97-faf0-4b2e-ac24-93467ecb916e">4,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="fhtx:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTAtMy0xLTEtMA_3d4a1b19-8f7f-44b3-a160-c3ccadcf6b56">4,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncash interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTEtMS0xLTEtMA_ad78c6b7-1a72-4cc6-a13a-e45e3048c7b7">318</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTEtMy0xLTEtMA_fbb7c611-7396-42d9-8ec1-9d5986648544">238</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization (accretion) of premium/discount on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTItMS0xLTEtMA_f8342488-48e2-468a-b172-043e14272ca0">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTItMy0xLTEtMA_a812bca0-358b-4cd2-9393-96965f840327">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTQtMS0xLTEtMA_7f682399-b8a0-4ccb-bdad-452ad0fe884f">1,814</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTQtMy0xLTEtMA_d70e35f9-e56a-4a5d-9667-a5f00567467b">4,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTUtMS0xLTEtMjYxOTg_920ba982-7aca-4757-804c-7c7ff21c4bea">300,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTUtMy0xLTEtMjYxOTg_b14863d8-d291-4843-be79-0fc187e91ffc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTUtMS0xLTEtMA_780b491a-80a9-4658-b72b-28a54631fd58">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTUtMy0xLTEtMA_bf71f233-6b89-4357-b92b-3a5cb0501d76">474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTYtMS0xLTEtMA_ff677844-c722-4b02-84af-3fb45b64abb5">2,653</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTYtMy0xLTEtMA_29a71289-43ee-4e51-99b5-e688004ae064">3,194</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" sign="-" name="fhtx:IncreaseDecreaseInOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTctMS0xLTEtMA_871bfd58-96b3-49cb-861a-241dcf8eb879">4,010</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="fhtx:IncreaseDecreaseInOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTctMy0xLTEtMA_db163fa2-8557-43b7-bbf7-a5f537123671">15,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTgtMS0xLTEtMA_fb8da554-8b34-433f-83f7-50fcdf4a5ac6">336,477</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTgtMy0xLTEtMA_477c9a6e-ef95-4a33-955f-654900f66926">14,570</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTktMS0xLTEtMA_d2888b78-f0ca-426f-a428-0f31d7446224">50,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTktMy0xLTEtMA_ea90eeb4-fcc0-4549-bb32-73ba02d8358a">31,286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flows from investing activities:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjEtMS0xLTEtMA_49712969-7a5c-4aa9-a8c2-1dc926fe8985">3,313</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjEtMy0xLTEtMA_fb9ca3b6-dfea-4aa5-917b-168d807bc91f">16,183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from sale of property and equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjItMS0xLTEtMA_be733a13-836a-4108-81e7-176b1a5703ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjItMy0xLTEtMA_0b46e894-607a-4cd5-a27a-370e954e2895">250</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjMtMS0xLTEtMA_34c3be8d-dfd4-4b5a-a131-8a8d3cc8a123">99,984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjMtMy0xLTEtMA_28929cf9-3b91-4eae-a17a-30e5ce69b4a3">92,981</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from maturities of marketable securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjQtMS0xLTEtMjMxNDg_69eed8a9-66c6-4ba0-84f4-8878ed8a0678">139,470</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjQtMy0xLTEtMjMxNDg_c9c72414-dc30-4d12-8269-c47fadcbd25f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjQtMS0xLTEtMA_86376038-2c93-404b-8d63-763b039efa0b">36,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjQtMy0xLTEtMA_a7987344-f53b-46e2-8fc0-405799163db5">108,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flows from financing activities:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from stock purchase agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjctMS0xLTEtMjUzNjk_d0dca883-cfb4-43f6-86c3-4f577cc65fff">42,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjctMy0xLTEtMjUzNjk_b14b8fa3-d37c-42ee-87bb-2d43e89cb902">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from initial public offering, net of underwriting discounts, commissions and offering costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjYtMS0xLTEtMA_6b700d7d-cd68-41ce-a9e3-e362799b096b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjYtMy0xLTEtMA_9ff24f2d-3438-4e8e-af83-adadc438b480">122,121</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from issuance of convertible preferred stock, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjctMS0xLTEtMA_6afea690-7669-4e81-a67a-b3244c38a8ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjctMy0xLTEtMA_7c3aabb2-c9bb-4035-83de-fb77797af71a">89,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjgtMS0xLTEtMA_6f6ba345-6487-4e0b-8660-98a210b486a8">1,418</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjgtMy0xLTEtMA_7518e4ae-2744-48d3-a23e-94022b619f96">1,221</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from issuance of notes payable, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjktMS0xLTEtMA_d39bb1f7-73c5-427b-ac7d-930dd2231039">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjktMy0xLTEtMA_3707228f-516d-4249-9eac-43c109c8f71d">19,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repayments of notes payable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzAtMS0xLTEtMA_143185fb-c7cb-4309-b7c1-4453aaead7a4">21,205</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzAtMy0xLTEtMA_be054087-12b4-4cb2-a1fd-20aa4bf3fc60">15,530</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzEtMS0xLTEtMA_0c05cd55-1580-4c52-a8c3-b73e1803843d">22,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzEtMy0xLTEtMA_4ecefb0c-8ab0-4173-b714-e25ed13493da">217,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzItMS0xLTEtMA_0cc26bb6-550f-4e22-a209-76c1e8f652ba">8,341</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzItMy0xLTEtMA_56d7cc56-7897-414b-b0af-12b3dceb2c98">77,273</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzMtMS0xLTEtMA_95089094-775f-4a01-b8d2-01773f350730">94,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i406407ac43db40d493cf8d79d3921779_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzMtMy0xLTEtMA_a35f3537-aabf-4897-85c5-2edd27222b57">17,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzQtMS0xLTEtMA_b2935841-62ef-4608-919e-834ff9701497">102,869</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzQtMy0xLTEtMA_fea44dd7-6659-437f-ae57-68733ede3bab">94,528</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for interest</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzYtMS0xLTEtMA_d1a30e40-c3f3-4b3c-85ac-4e9e69685b5a">1,716</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzYtMy0xLTEtMA_21b22881-f8fd-44ed-a9c2-2d01a54a941f">660</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental disclosure of noncash investing and financing information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property and equipment included in accounts payable, accrued expenses and other liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzgtMS0xLTEtMA_24eac1b7-0754-481a-a700-bf325ed3e6bd">295</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzgtMy0xLTEtMA_190a6fa6-1005-4455-8971-64c558fe0657">2,400</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conversion of redeemable convertible preferred stock to common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1f0e298f4e244829a4cc21bc741d457b_D20210101-20211231" decimals="-3" name="us-gaap:ConversionOfStockAmountConverted1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzktMS0xLTEtMA_520e8772-5617-4952-b682-90251e7f9b36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5fbf615bd0c04b61a3e8c3c5584de518_D20200101-20201231" decimals="-3" name="us-gaap:ConversionOfStockAmountConverted1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzktMy0xLTEtMA_54c82ea2-bd95-48db-a5f1-dda08e966393">176,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conversion of warrant liability to equity upon closing of initial public offering</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iff300de84591401db5d227d7c7cf9dac_D20210101-20211231" decimals="-3" name="us-gaap:ConversionOfStockAmountConverted1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNDAtMS0xLTEtMA_acc6166b-3d07-4673-8211-7e2dda32bac5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i59f4c12202e9485c860f841d498aebdb_D20200101-20201231" decimals="-3" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNDAtMy0xLTEtMA_fd7075e4-f037-4ef0-bcaf-a20ce335eb9f">114</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of warrants in connection with notes payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7bd62dcf817f4d0eb46e515f34977c6b_D20210101-20211231" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNDEtMS0xLTEtMA_44236339-5057-4d8c-9bdd-ff8ff828c6c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3f9b42353f44a458f9f2c68c488eaac_D20200101-20201231" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNDEtMy0xLTEtMA_91791038-9904-48a7-ab97-e77cccdba3fd">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of cash, cash equivalents and restricted cash:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNDMtMS0xLTEtMA_56a46e95-35bd-4d07-991c-3cb425b2e478">101,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNDMtMy0xLTEtMA_7473ec4e-ef97-4f00-9612-5a73b6dd4eaa">92,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash (current and non-current)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:RestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNDQtMS0xLTEtMA_99914d85-8935-4add-bb83-cb268e696ee5">1,733</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:RestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNDQtMy0xLTEtMA_ad6230c1-be3f-4869-a4ee-dc92f94e2185">1,733</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNDUtMS0xLTEtMA_8ce27f21-b950-421e-b5c8-bbaec9f3238a">102,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNDUtMy0xLTEtMA_f18f351d-fc2b-493d-b302-87a0e48afaeb">94,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="i523559815e87485cb6a9895707f43a02_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foghorn Therapeutics Inc.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div id="i523559815e87485cb6a9895707f43a02_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfNjE3OA_96c3e6a3-0d6f-4db5-8a60-c05f747a6d22" continuedAt="ib67527b02f33428aba46fa6e2d04b213" escape="true">Nature of Business and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="ib67527b02f33428aba46fa6e2d04b213" continuedAt="i6f71092864a04277b09f3f6a4fd4c363"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foghorn Therapeutics&#160;Inc. (the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company discovering and developing a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. The Company uses its proprietary Gene Traffic Control platform to identify, validate and potentially drug targets within the system. The Company was founded in October 2015 as a Delaware corporation. The Company is headquartered in Cambridge, Massachusetts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks similar to those of other early-stage companies in the biopharmaceutical industry, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of whom are larger and better capitalized, the impact of the COVID-19 pandemic and the need to obtain adequate additional financing to fund the development of its products. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be maintained, that any products developed will obtain required regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from the sale of its products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared the global novel coronavirus disease 2019 (&#8220;COVID-19&#8221;)&#160;outbreak a pandemic. The Company&#8217;s operations have not been significantly impacted by the&#160;COVID-19&#160;pandemic. However, the Company cannot at this time predict the specific extent, duration, or full impact that the&#160;COVID-19&#160;pandemic will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the&#160;COVID-19&#160;outbreak on the Company&#8217;s financial performance will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of&#160;COVID-19&#160;on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy are impacted for an extended period, the Company&#8217;s results may be materially adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;27, 2020, the Company completed its initial public offering (&#8220;IPO&#8221;) pursuant to which it issued and sold <ix:nonFraction unitRef="shares" contextRef="ic61be130c3e94434a1523a709ee82e84_D20201027-20201027" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfMjQ5Nw_d61cdb9d-65bb-424c-a362-5c694e1ea93f">7,500,000</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="icd065cf6469a49619232b52c4f78a47a_I20201027" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfMjU1Nw_0f4867fb-cd76-45f0-956c-a88ab387e43d">16.00</ix:nonFraction> per share, resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ic61be130c3e94434a1523a709ee82e84_D20201027-20201027" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfMjYwMA_fae25ad1-15a8-4445-9802-d3006e0c6f30">107.9</ix:nonFraction> million, after deducting underwriting discounts and commissions and other offering expenses. On November&#160;19, 2020, the Company issued and sold an additional <ix:nonFraction unitRef="shares" contextRef="i8c5b1d5196b546fcadb8c83231e484ed_D20201119-20201119" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfMjc1Mg_ced38b19-233c-4a8a-a3a7-76ded05f9d40">951,837</ix:nonFraction> shares of common stock at the IPO price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i598749ee432f4d19b443963f60801a17_I20201119" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfMjc5OA_ab2e037a-476a-429d-993d-f27740eb2b85">16.00</ix:nonFraction> per share pursuant to the underwriters&#8217; partial exercise of their option to purchase additional shares of common stock, resulting in additional net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i8c5b1d5196b546fcadb8c83231e484ed_D20201119-20201119" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfMjk2MQ_b1e205fb-01f2-4558-a35c-e1bb454e2227">14.2</ix:nonFraction> million after deducting underwriting discounts and commissions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 10, 2021, the Company executed a collaboration agreement with Eli Lilly and Company (or "Lilly") (See Note 9). Concurrent with the collaboration agreement the Company completed a stock purchase agreement (the "SPA") with Lilly and issued and sold Lilly <ix:nonFraction unitRef="shares" contextRef="iabf346f1d20b4fbab0cb034770c8cc7b_D20211210-20211210" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfODI0NjMzNzIxNTE4NA_99cb0e08-c85a-475e-856a-0ab66ae76830">4,000,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7545d56c585441a18935d61361a1f6e3_I20211210" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfODI0NjMzNzIxNTE5Mw_d217642c-81d7-4c0d-9918-8f6542750481">20.00</ix:nonFraction> per share, resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="iabf346f1d20b4fbab0cb034770c8cc7b_D20211210-20211210" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfODI0NjMzNzIxNTIzOA_4569002f-0fd6-43b8-8662-70e5ab39dd15">80.0</ix:nonFraction> million of which </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i146aef1b1a8a405cb503481b39bfb902_D20211210-20211210" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfOTg5NTYwNDY2MTkzNg_963d229b-17ea-449e-9e61-68c3710ca114">42.2</ix:nonFraction> million was allocated to equity upon the issuance of the Company&#8217;s common stock (see Note 9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has funded its operations primarily with proceeds from sales of preferred stock, debt financing, an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i25bd4e2b11bf41efbe5fc4e9eae184b7_D20200701-20200731" decimals="-5" name="fhtx:ProceedsFromUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfMzcwOQ_197298bc-8fdd-40f3-8305-8e8701c5183a">15.0</ix:nonFraction> million the Company received in July 2020 under a collaboration agreement with Merck Sharp&#160;&amp; Dohme Corp. (see Note 9), proceeds from the sale of common stock in the IPO completed in October 2020 and most recently, with sale of common stock in the SPA. In January 2022, the Company received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i1c4d412c57184ef2b09b93a7922fec1d_D20220101-20220131" decimals="-5" name="fhtx:ProceedsFromUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfODI0NjMzNzIxNTk3OA_e18e90fa-e318-4674-a00a-3d72b8136338">300.0</ix:nonFraction> million pursuant to the collaboration agreement with Lilly (See Note 9), which was included in current assets on the consolidated balance sheets as of December&#160;31, 2021. The Company has incurred recurring losses, including net losses of $<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfMzk5Mg_db6d6e9b-a2d3-4673-8dbb-18601aebfaf2">101.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfMzk5OQ_6044be6f-5def-4d00-8893-8271d571b7ec">68.8</ix:nonFraction> million for the years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfNDA5OQ_6740e48d-8aa9-4e1b-94a0-66ea6465d456">264.3</ix:nonFraction> million. The Company expects to continue to generate operating losses in the foreseeable future. As of the issuance date of these consolidated financial statements the Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will need to obtain additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements to continue to fund its operations. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborative or strategic alliances or licensing arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. Arrangements with collaborators or others may require the Company to relinquish rights to certain of its </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><ix:continuation id="i6f71092864a04277b09f3f6a4fd4c363"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technologies or programs. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, pipeline expansion or commercialization efforts, which could adversely affect its business prospects. Although management will continue to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations when needed or at all.</span></div><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfNjE3OQ_14140e04-41b7-48c6-beff-7c0d22f9ac16" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div></ix:nonNumeric></ix:continuation><div id="i523559815e87485cb6a9895707f43a02_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODgw_360351ac-b368-46c2-8967-131a5ff4d4a4" continuedAt="ifd2cfeced4974394bc366a08120ce90a" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ifd2cfeced4974394bc366a08120ce90a" continuedAt="ibba79e2dd47f49ef89b2c11a469e8c02"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODgx_c374c118-6fbf-469e-9245-5addd03fa06d" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition and the accrual of research and development expenses. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODcy_d3225a15-96f4-4261-883f-333ac8029c70" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk and of significant suppliers</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. As of December&#160;31, 2021, the Company maintained cash, cash equivalents and marketable securities at financial institutions in excess of federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies, and expects to continue to rely, on a small number of vendors to provide services, supplies and materials for certain activities related to its programs. These programs could be adversely affected by a significant interruption in these services or the availability of materials.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODcz_8a4273eb-a3f3-4211-a116-ccb9ab4580c4" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash equivalents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODc0_ba6a4dc5-d73f-41ae-bb15-d27120e33cae" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketable securities are classified as&#160;available-for-sale&#160;and are carried at fair value with the unrealized gains and losses reported as a component of accumulated other comprehensive loss in stockholders&#8217; equity. Realized gains and losses and declines in value judged to be other than temporary are included as a component of interest income and other income (expense), net based on the specific identification method. The Company classifies its marketable securities with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities are available for current operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODgy_61ea310a-de68-4687-940a-4f7a468a788a" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted cash</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in restricted cash represent amounts pledged as collateral for letters of credit required for security deposits on the Company&#8217;s leased facilities and credit cards. These amounts are classified as restricted cash in the Company&#8217;s consolidated balance sheets.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><ix:continuation id="ibba79e2dd47f49ef89b2c11a469e8c02" continuedAt="i43e22c0767b44a13beb329ba289cfbdb"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODg1_154b78b4-f5fb-49bd-b53a-6b53fbde20cb" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment</span></div><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODY2_68652f15-8495-4a9d-a01f-3a07a2695a8e" continuedAt="iecd31de8a3284684bc168c50a65a4950" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic066e702d698456487c1fe09f0556f0f_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90YWJsZTpiNmEzNDcwZTNkYTI0ZDZmOTBmODk1M2YyZjJmOWM2YS90YWJsZXJhbmdlOmI2YTM0NzBlM2RhMjRkNmY5MGY4OTUzZjJmMmY5YzZhXzEtMS0xLTEtMA_c80feb75-c309-48f7-a43b-8dc2b754b5a5">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6459962b97414cb4941639768c219ba0_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90YWJsZTpiNmEzNDcwZTNkYTI0ZDZmOTBmODk1M2YyZjJmOWM2YS90YWJsZXJhbmdlOmI2YTM0NzBlM2RhMjRkNmY5MGY4OTUzZjJmMmY5YzZhXzItMS0xLTEtMA_160dd3eb-0b75-4d64-8b96-3c7ee9027031">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6bc48e6cb48142b59aba9858f119acab_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90YWJsZTpiNmEzNDcwZTNkYTI0ZDZmOTBmODk1M2YyZjJmOWM2YS90YWJsZXJhbmdlOmI2YTM0NzBlM2RhMjRkNmY5MGY4OTUzZjJmMmY5YzZhXzMtMS0xLTEtMA_ba745b63-c41c-4768-a26f-ee366720cf80">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shorter of useful life or remaining term of lease</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs for capital assets not yet placed into service are depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODgz_2c34ea6a-10c6-4998-af97-12ad19443c07" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of long-lived assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its long-lived assets, which consist primarily of property and equipment and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company did <ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzEwOTk1MTE2NTQ2NjU_42597d8e-b4a7-43cf-9e30-c231dda20193"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzEwOTk1MTE2NTQ2NjU_6bbd40b7-72c8-4cc8-b72e-86a6f119f104">no</ix:nonFraction></ix:nonFraction>t record any impairment losses on long-lived assets during the years ended December&#160;31, 2021 or 2020.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODY3_64610fb4-0164-4a61-8d9e-45487e16ee07" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair value measurements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see Note&#160;3). The carrying values of the Company&#8217;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities. The carrying value of the Company&#8217;s long-term debt approximates its fair value (a level 2 measurement) due to its variable interest rate.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODg0_daf767bb-5599-41bd-81bf-fc9557dcc06e" continuedAt="i01eb6bd95bc9400d8c596c6fbf1663e5" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Collaboration Agreements</span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ASC 808) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.  When the Company has concluded that it has a customer relationship with one of its collaborators the Company follows the guidance in ASC Topic 606,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> Revenue From Contracts With Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (&#8220;ASC 606&#8221;).</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><ix:continuation id="i43e22c0767b44a13beb329ba289cfbdb" continuedAt="i810d75050b864162afdfc19cb048855b"><ix:continuation id="i01eb6bd95bc9400d8c596c6fbf1663e5" continuedAt="i3b3752d7f49f499f9adb0ade359975d9"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its <ix:nonFraction unitRef="agreement" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="INF" name="fhtx:NumberOfCollaborativeAgreements" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzEyMDk0NjI3OTM4ODY0_b55c8bf3-4743-4a38-8421-1f1bb99fb250">two</ix:nonFraction> collaboration arrangements under ASC 606 as the Company concluded that it has a customer relationship with each of its collaborators. For additional information on the Company&#8217;s collaboration agreements, see Note 9,&#160;Collaboration&#160;Agreements, to these consolidated financial statements. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the goods or services promised within each contract and determines those that are performance obligations. The promised goods or services in the Company&#8217;s arrangements would likely consist of licenses, rights to the Company&#8217;s intellectual property, research and development services and related supporting activities. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)&#160;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii)&#160;the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#8220;SSP&#8221;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company&#160;re-evaluates&#160;the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative&#160;catch-up&#160;basis in the period of adjustment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><ix:continuation id="i810d75050b864162afdfc19cb048855b" continuedAt="ia85cc221b7ee4dfd9888294893f3d783"><ix:continuation id="i3b3752d7f49f499f9adb0ade359975d9"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which the royalty has been allocated has been satisfied.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded for deferred revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised goods or services to the customer and the payment by the customer will be one year or less. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based on the use of an output or input method.</span></div></ix:continuation><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODg2_da33cf9f-4a6a-48e8-ba5f-3d0ac7c2c37d" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, and external costs of vendors engaged to conduct research, preclinical and clinical development activities as well as the cost of licensing technology.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments and milestone payments made for the licensing of technology are expensed as research and development over the period to which they relate. Costs for research and development activities are expensed in the period in which they are incurred. Payments for such activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense. Determining the prepaid and accrued balances at the end of any reporting period incorporate certain judgments and estimates by management that are based on information available to the Company including information provided by vendors regarding the progress to completion of specific tasks or costs incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:CapitalizationOfInternalCostsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODc4_2566a2a9-de49-4cdb-8d8e-c660a92a35ff" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODc1_d20e17ce-72f1-4252-b258-f216f2b6c73b" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC&#160;842,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#8217;s economic benefits. The Company determines if an arrangement is a lease or contains an embedded lease at inception. For arrangements that meet the definition of a lease, the Company determines the initial classification and measurement of its right-of-use asset and lease liability at the lease commencement date and thereafter if modified. The lease term includes any renewal options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term. The Company&#8217;s policy is to not record leases with an original term of twelve months or less on its consolidated balance sheets and recognizes those lease payments in the income statement on a straight-line basis over the lease term. The Company&#8217;s existing leases are for office and laboratory space and an equipment lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to rent, the leases may require the Company to pay additional costs, such as utilities, maintenance and other operating costs, which are generally referred to as non-lease components. The Company has&#160;elected to not separate lease and non-lease components. Only the fixed costs for lease components and their associated non-lease components are accounted for as a single lease component and recognized as part of a right-of-use asset and liability. Rent expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the consolidated statements of operations and comprehensive loss.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><ix:continuation id="ia85cc221b7ee4dfd9888294893f3d783" continuedAt="i989e48ab5d644b3ea76b4ee1554c4152"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODc2_c5315dcf-fbe5-4cc8-9459-3c122b6f6d89" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures stock options with service-based vesting or performance-based vesting granted to employees, non-employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. The Company measures restricted common stock awards using the difference between the purchase price per share of the award, if any, and the fair value of the Company&#8217;s common stock at the date of grant. Compensation expense for the awards is recognized over the requisite service period for employees and directors and as services are delivered for non-employees, both of which are generally the vesting period of the respective award. The Company uses the straight-line method to record the expense of awards with only service-based vesting conditions. The Company uses the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing once achievement of the performance condition becomes probable. The Company&#160;accounts for forfeitures of share-based awards as they occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODY5_0ff889ef-43cf-4b2d-a0c5-5b63e8df52a0" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net loss per share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing net income(loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, adjusted for potential dilutive common shares.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s participating securities contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reported a net loss, such losses were not allocated to such participating securities. In periods in which the Company reported a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported a net loss attributable to common stockholders for the years ended December&#160;31, 2021 and 2020.</span></div><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODcw_339c4377-621a-4f88-8c0a-8ad6e5c6def9" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f7bc146064d4609a9384b2c32e30608_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90YWJsZTo4MGQ3ZjM2MGRkMTk0NjAzYThiOWU5OWIwNTljZDVjOC90YWJsZXJhbmdlOjgwZDdmMzYwZGQxOTQ2MDNhOGI5ZTk5YjA1OWNkNWM4XzItMS0xLTEtMA_95ffbdee-1052-48b5-aa09-5b5bfe8fdf03">5,920,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34e7f6a206ae4fca9926a2b3693a2e1c_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90YWJsZTo4MGQ3ZjM2MGRkMTk0NjAzYThiOWU5OWIwNTljZDVjOC90YWJsZXJhbmdlOjgwZDdmMzYwZGQxOTQ2MDNhOGI5ZTk5YjA1OWNkNWM4XzItMy0xLTEtMA_cdaae8cb-c2b8-49fe-8d26-3ef07baca620">5,016,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12a1c8269d8549d6bdfd75792c409c5d_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90YWJsZTo4MGQ3ZjM2MGRkMTk0NjAzYThiOWU5OWIwNTljZDVjOC90YWJsZXJhbmdlOjgwZDdmMzYwZGQxOTQ2MDNhOGI5ZTk5YjA1OWNkNWM4XzMtMS0xLTEtMA_0cb99bb3-ece8-43cb-9c16-e45db772a2d3">18,445</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id03aeb4309314c119fa838863de75a16_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90YWJsZTo4MGQ3ZjM2MGRkMTk0NjAzYThiOWU5OWIwNTljZDVjOC90YWJsZXJhbmdlOjgwZDdmMzYwZGQxOTQ2MDNhOGI5ZTk5YjA1OWNkNWM4XzMtMy0xLTEtMA_e452f97f-0fb4-4596-b49a-267bab562cc2">18,445</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90YWJsZTo4MGQ3ZjM2MGRkMTk0NjAzYThiOWU5OWIwNTljZDVjOC90YWJsZXJhbmdlOjgwZDdmMzYwZGQxOTQ2MDNhOGI5ZTk5YjA1OWNkNWM4XzctMS0xLTEtMA_9eda3456-b6e8-42c1-8b09-5ea6945079f5">5,938,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90YWJsZTo4MGQ3ZjM2MGRkMTk0NjAzYThiOWU5OWIwNTljZDVjOC90YWJsZXJhbmdlOjgwZDdmMzYwZGQxOTQ2MDNhOGI5ZTk5YjA1OWNkNWM4XzctMy0xLTEtMA_0936b5d2-ff02-42bc-be0b-9df922636960">5,034,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODc5_528f5d3e-afc5-481a-b782-a9fc26ca7195" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an entity for which separate discrete financial information is made available and that is regularly evaluated by the chief operating decision maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The Company&#8217;s CODM is its chief executive officer and the Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company is focused on pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system.</span></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODY4_d3464941-39f0-4e0f-b081-9057fe2857b8" continuedAt="i8bc2dd14afb340b78c8b239dce516578" escape="true">Comprehensive loss</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8bc2dd14afb340b78c8b239dce516578">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. For the year ended December&#160;31, 2021 and 2020, the Company&#8217;s only element of other comprehensive loss was unrealized losses on available for sale debt securities.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><ix:continuation id="i989e48ab5d644b3ea76b4ee1554c4152"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODg3_9873f136-50ac-445e-abb1-719557bb564e" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to the provision for income taxes. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. Any resulting unrecognized tax benefits are recorded within the provision for income taxes.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODcx_ca059a5e-da69-4e8e-8a79-411c77d6e283" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i)&#160;irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii)&#160;no longer qualifies as an emerging growth company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No.&#160;2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;The new standard adjusts the accounting for assets held at amortized costs basis, including marketable securities accounted for as available for sale.&#160;The standard eliminates the probable initial recognition threshold and requires an entity to reflect its current estimate of all expected credit losses.&#160;The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For public entities, the guidance was effective for annual reporting periods beginning after December&#160;15, 2019 and for interim periods within those fiscal years. For nonpublic entities and emerging growth companies that choose to take advantage of the extended transition period, the guidance is effective for annual reporting periods beginning after December&#160;15, 2020. Early adoption is permitted for all entities. In November 2019, the FASB issued ASU No.&#160;2019-10, which deferred the effective date for nonpublic entities to annual reporting periods beginning after December&#160;15, 2022, including interim periods within those fiscal years. The Company is evaluating when to adopt this standard and the effect the adoption will have on its consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i523559815e87485cb6a9895707f43a02_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="fhtx:MarketableSecuritiesAndFairValueMeasurementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90ZXh0cmVnaW9uOjE1MmYwYWFiNzAyOTRlOTBhMWQ1Y2RiOWVjNDExNjE5XzE2NjA_d99a2861-2161-4fb7-a3da-868135f1bc4c" continuedAt="i2d60049e71814b0db527666169b0dc1e" escape="true">Marketable Securities and Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i2d60049e71814b0db527666169b0dc1e" continuedAt="i4e51d40b417345beac858c1a58d0d3aa"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90ZXh0cmVnaW9uOjE1MmYwYWFiNzAyOTRlOTBhMWQ1Y2RiOWVjNDExNjE5XzE2NjE_8d0f8de2-f18c-4b1d-9581-6546bc33a658" continuedAt="i581d75ba4e114c3eb4da3dedaa179f14" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, available for sale marketable securities by security type consisted of (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper (due within one year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6cd2aa71baa24133bcddefb5ee9ce9b8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzEtMS0xLTEtMjIyNDQ_d7a934f4-a6ae-4d08-9add-20d225311b91">36,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6cd2aa71baa24133bcddefb5ee9ce9b8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzEtMy0xLTEtMjIyNDQ_6e8aadda-0472-4842-9fbf-dd57aeeb20f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i6cd2aa71baa24133bcddefb5ee9ce9b8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzEtNS0xLTEtMjIyNDQ_22c25c21-7d32-44b1-8909-ba56cb9561d5">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6cd2aa71baa24133bcddefb5ee9ce9b8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzEtNy0xLTEtMjIyNDQ_da153eaa-6243-4166-8ecb-7712f25f0410">36,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds (due within one year)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4b216a3565b64982af2832ed92b1f204_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzItMS0xLTEtMjIyNjI_027911f8-e187-4cf8-8c37-fe3aa79fed59">16,917</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4b216a3565b64982af2832ed92b1f204_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzItMy0xLTEtMjIyNjI_85d14841-c22d-47ac-b552-a347226d0b5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i4b216a3565b64982af2832ed92b1f204_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzItNS0xLTEtMjIyNjI_b5124417-9ea8-4965-9f54-72f82c850e8a">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4b216a3565b64982af2832ed92b1f204_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzItNy0xLTEtMjIyNjI_66a31686-4a76-41fa-9fb7-8cef111a35fa">16,910</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzItMS0xLTEtMjIyNDQ_36da5934-28e4-4a68-8a3c-313accc83893">53,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzItMy0xLTEtMjIyNDQ_79e0762f-2809-4bb9-ae08-d3897bf5a511">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzItNS0xLTEtMjIyNDQ_b13c3728-ae99-4505-b7be-dab5aab8d0d7">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzItNy0xLTEtMjIyNDQ_6cd5f174-895d-4f2c-8866-5ba170751005">53,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, available for sale marketable securities by security type consisted of (in thousands):</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><ix:continuation id="i4e51d40b417345beac858c1a58d0d3aa" continuedAt="i33855b91c0c74707ab71f20d6e2cc391"><div style="margin-top:5pt"><ix:continuation id="i581d75ba4e114c3eb4da3dedaa179f14"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury notes (due within one year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id955de6cd1884e8185138e0750ec2ab3_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpiODgzYWYwZDMyYTY0NDEzOTMxZTFhYTEyMGRlMTZhZS90YWJsZXJhbmdlOmI4ODNhZjBkMzJhNjQ0MTM5MzFlMWFhMTIwZGUxNmFlXzEtMS0xLTEtMA_56ecc156-77f1-4e93-a448-19f4c231c90f">92,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id955de6cd1884e8185138e0750ec2ab3_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpiODgzYWYwZDMyYTY0NDEzOTMxZTFhYTEyMGRlMTZhZS90YWJsZXJhbmdlOmI4ODNhZjBkMzJhNjQ0MTM5MzFlMWFhMTIwZGUxNmFlXzEtMy0xLTEtMA_94db94f9-cb0e-4250-bed3-30e6a1c64345">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id955de6cd1884e8185138e0750ec2ab3_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpiODgzYWYwZDMyYTY0NDEzOTMxZTFhYTEyMGRlMTZhZS90YWJsZXJhbmdlOmI4ODNhZjBkMzJhNjQ0MTM5MzFlMWFhMTIwZGUxNmFlXzEtNS0xLTEtMA_aeb30c8d-a6b3-4d0b-9253-d5b6ee19670b">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id955de6cd1884e8185138e0750ec2ab3_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpiODgzYWYwZDMyYTY0NDEzOTMxZTFhYTEyMGRlMTZhZS90YWJsZXJhbmdlOmI4ODNhZjBkMzJhNjQ0MTM5MzFlMWFhMTIwZGUxNmFlXzEtNy0xLTEtMA_eb189fe7-f2b3-48cd-9c46-a1dd1f4d86b8">92,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpiODgzYWYwZDMyYTY0NDEzOTMxZTFhYTEyMGRlMTZhZS90YWJsZXJhbmdlOmI4ODNhZjBkMzJhNjQ0MTM5MzFlMWFhMTIwZGUxNmFlXzItMS0xLTEtMA_1652453c-8ca1-44ad-8b0e-f063c5a3f0b7">92,982</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpiODgzYWYwZDMyYTY0NDEzOTMxZTFhYTEyMGRlMTZhZS90YWJsZXJhbmdlOmI4ODNhZjBkMzJhNjQ0MTM5MzFlMWFhMTIwZGUxNmFlXzItMy0xLTEtMA_537676ae-d502-4edd-aee7-540f4d64237a">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpiODgzYWYwZDMyYTY0NDEzOTMxZTFhYTEyMGRlMTZhZS90YWJsZXJhbmdlOmI4ODNhZjBkMzJhNjQ0MTM5MzFlMWFhMTIwZGUxNmFlXzItNS0xLTEtMA_efc1902a-fbfd-4dee-87b0-f8b485aab15e">7</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpiODgzYWYwZDMyYTY0NDEzOTMxZTFhYTEyMGRlMTZhZS90YWJsZXJhbmdlOmI4ODNhZjBkMzJhNjQ0MTM5MzFlMWFhMTIwZGUxNmFlXzItNy0xLTEtMA_5d1da2b1-87c0-4ad4-b31e-aeac6c59cb28">92,975</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90ZXh0cmVnaW9uOjE1MmYwYWFiNzAyOTRlOTBhMWQ1Y2RiOWVjNDExNjE5XzE2NTk_1665e0c8-f3f4-46d2-ab5c-fdb0771ea6ba" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Company&#8217;s fair value hierarchy for its assets and liabilities, which were measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at<br/>December 31, 2021 Using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash equivalents:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if906371b919e4edb9cbaff3349db1e5a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzQtMS0xLTEtMA_21725336-01c2-4b6c-9bd5-af6b8fdcd9c6">82,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iff3838f509af4f0eb1680ed5f138763c_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzQtMy0xLTEtMA_bf903ef8-7a09-453e-96e5-e808f727dfb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iaac48c4990fc4b23a98caf4dc0c46472_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzQtNS0xLTEtMA_c4b50511-01ac-4208-bf08-537c82f77c07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i79d6f505bd7d40d1ab1326d0b0e8b296_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzQtNy0xLTEtMA_4aeafd80-6b98-4960-aaf1-134054b0765c">82,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if0e25902efa14d8496dbe8fa31ab5e18_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzYtMS0xLTEtMjM0MzA_f197a4b4-5ada-4817-bf42-a293b0f743ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i111a519d6a244546ae0ab2247e929789_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzYtMy0xLTEtMjM0MzA_2628835a-30de-4b29-a52e-d7aa915b8fee">18,496</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i444925a451b6462ba584afd5c61d43e3_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzYtNS0xLTEtMjM0MzA_a873550a-4ca8-45dc-97c7-5fec6fbd3ec9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0ef2f7d5ec4b41adb5e4a6ef1777b997_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzYtNy0xLTEtMjM0MzA_6f4e5f15-1159-4f57-9c75-15e72a75401c">18,496</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i968a33b0579d40f3b45433f682345851_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzgtMS0xLTEtMjM0NDE_cfeca3f4-9506-4417-9561-2f6ed8ab05b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i537352e60a9a414692e0f7409da18813_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzgtMy0xLTEtMjM0NDE_4aa4eb18-c11f-4616-b4c6-aecf88afeced">36,243</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id2e7eba7312d4e0fba240bde0d9c1bc9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzgtNS0xLTEtMjM0NDE_880d910d-06e1-4724-8fd1-f0d2a30e3188">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6823127af8d34669a2caa57eb496dd2d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzgtNy0xLTEtMjM0NDE_826e45da-c36c-440d-a804-2d1c4a34a949">36,243</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i76a6b50908b44d00a55838e4e1cf7176_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzctMS0xLTEtMA_c9036581-3254-402c-a7c2-56394f78c151">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iad91834ab15d489cb8484081982f739d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzctMy0xLTEtMA_58f1739d-e5e9-4780-866e-13a7e002aebf">16,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ef90d0c133b4dc09242b27430fb6c83_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzctNS0xLTEtMA_8b130bdf-0ab2-4a0b-87bb-bb235fa5dffb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8bcbd3ea5e74155b41c0255c7c0e7a8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzctNy0xLTEtMA_9aa30827-9656-4fd9-b49b-48d01d4c3f4e">16,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib653dca791b64896a08cfb7a0e8446f7_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzgtMS0xLTEtMA_0816e653-f7ae-4054-97ab-ceebfb3bb781">82,252</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i62bc1b90709641e48c8ee1248e2a2be0_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzgtMy0xLTEtMA_cee5dbd7-160d-4bb6-90f4-ba4976b8d1c7">71,649</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7a8cdf58951489cbce902c6026e0d71_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzgtNS0xLTEtMA_93f432a5-aedf-46e0-85d7-49230ab5b9ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie7581f3ffb0042c59c5d8ca5c9d3c495_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzgtNy0xLTEtMA_a7e36124-8ddc-4ae4-b315-d7ab191b7d27">153,901</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at<br/>December 31, 2020 Using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:31.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibeb58fd86d1241b285fe06e0d3d62da7_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzQtMS0xLTEtMA_c47e622c-0e43-42e3-b28a-443b45f27da8">48,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia0ceb8decc8347719a807b233cf323cf_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzQtMy0xLTEtMA_f5b1dfc2-51d8-475b-b948-29222f4618df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7eededd25783411791223767f68f1740_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzQtNS0xLTEtMA_5f647d75-415c-442e-a69e-6ba4c8638d1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8c2443787a9a4bf6899e62de8792aabb_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzQtNy0xLTEtMA_1d14bd52-8cbd-4344-8199-f5ee98ee6582">48,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:31.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id674ecc28e6a4bec8492a5fad8e88241_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzUtMS0xLTEtMjIxNTU_321fe7d0-3616-4ea5-8f9d-53bda56845c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9007fd1a6c114c2f9092e78360752927_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzUtMy0xLTEtMjIxNTU_2daf3ec5-d317-40d8-9ee5-2db949567592">42,997</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9d5b943b47404b9796a02f5deed9fa6d_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzUtNS0xLTEtMjIxNTU_ac70f28e-775d-403c-9d98-ac684b2fb32e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic7c250fe5eb94135b9cb46d4e2a2fe65_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzUtNy0xLTEtMjIxNTU_a49ccd9f-14e0-49c4-b639-b3342d0d789b">42,997</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:31.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6936f6623d364d4e855208a92198fbff_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzYtMS0xLTEtMA_d85693fc-8834-4563-87f1-ace790873849">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic48fe4ed0446401abf189c47fbf5e947_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzYtMy0xLTEtMA_1d9d5f39-096a-4141-8a50-065a6ee9efbe">92,975</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic45ad783abc94d60b6f3fc8c8900675f_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzYtNS0xLTEtMA_e3742785-7a69-4f30-a218-bfb1f6175e65">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia8bb1cd7498940d3ba6558a5b1f34d14_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzYtNy0xLTEtMA_e8af8cb6-39b8-4a58-b739-dcde9d2f53f9">92,975</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5b088f5892d84a34a7cfbb1478042496_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzgtMS0xLTEtMjIxNTU_52e98991-dc9e-403d-a910-1c88e25aa321">48,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6365a0687d1a4e38b300cbff88436f8c_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzgtMy0xLTEtMjIxNTU_07610a0e-0baa-43cb-92b0-67b8afd50556">135,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0e14f625a75f45c0be3dc94d6442301d_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzgtNS0xLTEtMjIxNTU_c4b4e2df-6b80-47c5-97ae-1a30e9999bab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzgtNy0xLTEtMjIxNTU_7a4f9791-e39e-455f-a3a0-d305b66c51a0">184,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i33855b91c0c74707ab71f20d6e2cc391">During the years ended December&#160;31, 2021 and 2020, there were no transfers between Level 1, Level 2 and Level 3.</ix:continuation> </span></div><div id="i523559815e87485cb6a9895707f43a02_112"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90ZXh0cmVnaW9uOjE2MGU3MDFiMDAxYzQxODY5ZGUzZjc5M2JlYzU0NWM1XzIwNQ_15aeaff7-a3da-434e-ba2d-79d840580554" continuedAt="i5667bc4bc4aa482eaba7496d1a2a9f30" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><ix:continuation id="i5667bc4bc4aa482eaba7496d1a2a9f30"><ix:continuation id="iecd31de8a3284684bc168c50a65a4950"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic737047ef5ac46948883230a983a17e5_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzItMS0xLTEtMA_7782afe0-ed71-4dc9-a351-8b1496f07970">4,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i85f5b7fcbcc1494d82b2b6edf8a4eec6_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzItMy0xLTEtMA_6459c00b-3180-4c51-92a1-d1ccb4b7337e">3,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic38f6e8e2292491e90c063c6222b2448_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzMtMS0xLTEtMA_bd6db0c4-66e9-420c-ba07-1c1c2dfcdcbf">815</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26b8aecd6a1c435bb0da7145cba274e6_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzMtMy0xLTEtMA_e1353496-c686-405f-a16a-89c5e72ad7aa">815</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icb18b30cf22f4a32bb4ff93620162dda_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzQtMS0xLTEtMA_de310e6f-c73e-4aef-9569-37118b6c90ed">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife30eeb6debd49f9a9e6eaccb2f6d4f6_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzQtMy0xLTEtMA_7c7ed504-e06d-473b-ab54-6d7fd1a9a4ef">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id0f5fafdc67546f5aec4e0ce4e1aaa67_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzUtMS0xLTEtMA_f04f552b-4478-40d7-8f94-a1904c1de8f9">17,059</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i57e5da0015844088ba86122ad60975f7_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzUtMy0xLTEtMA_9e2eb8f3-47b1-4c8b-a25a-afb304ea3e30">16,961</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets not yet placed in service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if936930eb6674b98aa88bbc4b5ff6632_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzYtMS0xLTEtMA_c926a14e-3f39-4371-bb98-d2898c98d301">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8ae945c2f65f4ae1b715fa4120b4b25e_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzYtMy0xLTEtMA_d2bcff75-aed0-4e29-87f0-d0e48b32a024">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzctMS0xLTEtMA_cf95a397-79e4-4782-b8fa-86b902fb1a2b">22,893</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzctMy0xLTEtMA_1aaeedf8-2a1f-4759-b75c-dd58403e29a9">21,631</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzgtMS0xLTEtMA_8ccf5f50-05ca-4d6e-8b8b-a38b74af8172">5,330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzgtMy0xLTEtMA_d84f0576-1e7b-4e43-a0d1-a893d5d6ad95">2,103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzktMS0xLTEtMA_f49f86f4-7535-4520-a94c-5db4ca49bcad">17,563</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzktMy0xLTEtMA_6444874f-b005-4ecd-a341-392048445ac8">19,528</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was $<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90ZXh0cmVnaW9uOjE2MGU3MDFiMDAxYzQxODY5ZGUzZjc5M2JlYzU0NWM1XzE1MQ_b8d094fb-5701-40c6-8d5b-51b87be1e927">3.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90ZXh0cmVnaW9uOjE2MGU3MDFiMDAxYzQxODY5ZGUzZjc5M2JlYzU0NWM1XzE1OA_75358506-9a40-4324-b774-a414c28740d0">1.3</ix:nonFraction> million for the years ended December&#160;31, 2021 and 2020, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="i523559815e87485cb6a9895707f43a02_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90ZXh0cmVnaW9uOjdlMDQ1ODA2MTI1MjRkMDlhMGU3ZjkzNjAyMWYwMGM0Xzg2_37d4e04b-6019-410b-918c-96cc93664069" continuedAt="ia11781e29680424e85a0f72fc664fc71" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="ia11781e29680424e85a0f72fc664fc71"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90ZXh0cmVnaW9uOjdlMDQ1ODA2MTI1MjRkMDlhMGU3ZjkzNjAyMWYwMGM0Xzg3_f3ca86fc-19a5-4c56-a163-dd319751cdfc" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzItMS0xLTEtMA_7b561a37-d8ea-4bd2-95b1-e402ef80a004">5,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzItMy0xLTEtMA_bbfb5121-a5fa-4d34-ae8d-948b69998955">3,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued tenant improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="fhtx:AccruedTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzMtMS0xLTEtMA_5901c869-f887-44e3-a2fd-aa43eb95d261">13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="fhtx:AccruedTenantImprovements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzMtMy0xLTEtMA_016c7828-c099-4497-96ba-2c3efe9214cb">2,385</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued external research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="fhtx:AccruedResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzQtMS0xLTEtMA_dfb7b592-f42c-47a2-b7c1-54cdf317b815">3,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="fhtx:AccruedResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzQtMy0xLTEtMA_291bc67f-5e74-4acd-b12d-6e93742a1b00">2,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzUtMS0xLTEtMA_fa7e56ae-2701-4b75-9051-73a8945417ed">495</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzUtMy0xLTEtMA_c7ec5c56-1507-457f-8618-d6fab7ced192">979</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzYtMS0xLTEtMA_052f2b5c-251c-44f3-b348-ffdfec2e4e45">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzYtMy0xLTEtMA_e5bfb638-b61e-4209-a355-755ba4cb3b09">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzctMS0xLTEtMA_40639600-17b9-42c6-a062-0752a85e1029">9,562</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzctMy0xLTEtMA_781e7184-a6ae-4de4-b76f-bb1f8bbb7722">9,161</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i523559815e87485cb6a9895707f43a02_118"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzU0ODY_10811b53-c381-4474-ae8e-9c9f2f60c6ab" continuedAt="i4a7e36d3ec3841a69bbb20aff55766c5" escape="true">Notes Payable</ix:nonNumeric></span></div><ix:continuation id="i4a7e36d3ec3841a69bbb20aff55766c5" continuedAt="i253c03d742fd4e71a2fbd58e39345968"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzU0ODE_e70c09e1-3a44-427b-86ca-83d5816190d7" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amount of long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i69208d809b134811a688e3aaa1b56f5f_I20211231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzItMS0xLTEtMA_43e8c5e5-a580-40cb-9a89-afa282254674">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic63ca5a8620e4354a23fe4fb65d45904_I20201231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzItMy0xLTEtMA_2214a87c-5cd3-473f-ad99-e0a6f1ba2688">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion of long-term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i69208d809b134811a688e3aaa1b56f5f_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzMtMS0xLTEtMA_79632491-d1e9-4851-b4e4-2468df3be3aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic63ca5a8620e4354a23fe4fb65d45904_I20201231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzMtMy0xLTEtMA_34aeb2fb-5dd5-4b10-b91b-3844d8d5effb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i69208d809b134811a688e3aaa1b56f5f_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzQtMS0xLTEtMA_e12565de-dc19-455c-b881-998859a56e4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic63ca5a8620e4354a23fe4fb65d45904_I20201231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzQtMy0xLTEtMA_af20fed5-7228-49af-8c62-bb407211f58c">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final payment fee</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i69208d809b134811a688e3aaa1b56f5f_I20211231" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzUtMS0xLTEtMA_b8501068-4d93-4727-958d-95b34ec699f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic63ca5a8620e4354a23fe4fb65d45904_I20201231" decimals="-3" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzUtMy0xLTEtMA_c31f101c-1a0f-4a72-821c-3f9f85a8888e">1,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt discount, net of accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i69208d809b134811a688e3aaa1b56f5f_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzYtMS0xLTEtMA_f3391201-c88b-4d94-9553-8c1099ffa15e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic63ca5a8620e4354a23fe4fb65d45904_I20201231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzYtMy0xLTEtMA_1473671e-c2c4-4ffd-8f4f-23d09ead0a8a">1,346</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, net of discount and current portion</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i69208d809b134811a688e3aaa1b56f5f_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzctMS0xLTEtMA_10401a1d-6083-4744-ba45-d2526ce39f08">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic63ca5a8620e4354a23fe4fb65d45904_I20201231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzctMy0xLTEtMA_27b84733-52c6-4721-ace2-693842081dcc">19,654</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan and Security Agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2020, the Company entered into a loan and security agreement (the "Oxford Loan Agreement"), with Oxford Finance LLC, or Oxford, for an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="ib49c41bde7e24d5eb853d157bd015ed2_I20201119" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzI1OTc_04740b2e-860c-4b88-bf37-b089e316455e">20.0</ix:nonFraction> million (the "Oxford Term Loan A") and up to an additional $<ix:nonFraction unitRef="usd" contextRef="i5ec8f3ca08b54640bf525807c9358e0b_I20201119" decimals="INF" name="fhtx:LineOfCreditAdditionalBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzI2NDU_c31ab15d-ddbd-4ba3-b06e-6f88294b5cbe">5.0</ix:nonFraction> million (the "Oxford Term Loan B"). On November&#160;19, 2020, the Company borrowed $<ix:nonFraction unitRef="usd" contextRef="ib49c41bde7e24d5eb853d157bd015ed2_I20201119" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzI3MTM_e38b76e7-9fe2-43e5-ac8d-9dfc18c8f9de">20.0</ix:nonFraction> million under the Oxford Term Loan A. Oxford Term Loan A and Oxford Term Loan B (the "Term Loans") bear interest at a floating per annum rate equal to the greater of (i) <ix:nonFraction unitRef="number" contextRef="ib49c41bde7e24d5eb853d157bd015ed2_I20201119" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzI4MzI_fac2ef45-5edc-442c-93e7-4e9bd736307d">8.0</ix:nonFraction>% and (ii)&#160;the sum of (a)&#160;thirty-day LIBOR rate plus (b) <ix:nonFraction unitRef="number" contextRef="i8b0e0ca6351c413a82a3c23dea9a45aa_D20201119-20201119" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzI4OTA_6163929f-aed0-4e92-9c41-1208be2573ce">7.84</ix:nonFraction>%. In addition, upon loan maturity or prepayment, the Company is required to make a final payment fee equal to <ix:nonFraction unitRef="number" contextRef="ib49c41bde7e24d5eb853d157bd015ed2_I20201119" decimals="INF" name="fhtx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzMwMDE_2e9b1cf9-754c-4510-bb01-ca18572fb447">5.0</ix:nonFraction>% of the aggregate principal amount borrowed which is being amortized to interest expense over the term of the debt using the effective interest method.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to make monthly interest only payments under the Oxford Loan each month beginning on January&#160;1, 2021. Beginning on December&#160;1, 2023, the Company is required to make consecutive equal monthly payments of principal, together with applicable interest, in arrears, based upon a repayment schedule equal to 24 months, with a final maturity date of November&#160;1, 2025 (the &#8220;Maturity Date&#8221;). At the Company's option, the Company may elect to prepay the loans subject to a prepayment fee equal to the following percentage of the principal amount being prepaid: <ix:nonFraction unitRef="number" contextRef="ib3a33598e6e946e8956a704040d5cd66_D20201119-20201119" decimals="INF" name="fhtx:PercentageOfPrepaymentFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzEwOTk1MTE2Mjg5MDI3_e2ceba0d-4b20-4621-99e0-cd70c98a48b0">2</ix:nonFraction>% if an advance is prepaid during the first <ix:nonNumeric contextRef="i308a28a242364292959d00dffcc81a50_D20201119-20201119" name="fhtx:PrepaymentPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzEwOTk1MTE2MzkxMTI_b63f27df-c948-4418-95b1-f16d362e38d1">12</ix:nonNumeric> months following the applicable advance date, <ix:nonFraction unitRef="number" contextRef="if15ca8afdf684493a8630928aba61256_D20201119-20201119" decimals="INF" name="fhtx:PercentageOfPrepaymentFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzEwOTk1MTE2Mjg5MDIz_4c9bb8db-95ea-4ae8-a336-c564da7d7f5b">1</ix:nonFraction>% if an advance is prepaid after <ix:nonNumeric contextRef="i2a4208db8c414f878b2487dcb43e458b_D20201119-20201119" name="fhtx:PrepaymentPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzEwOTk1MTE2Mjg5MDQ0_38320eff-e2ee-4301-a6f4-a5c4b7c6b63f">12</ix:nonNumeric> months but prior to <ix:nonNumeric contextRef="i3c238b9ea3134f76bd3f9653c8e95195_D20201119-20201119" name="fhtx:PrepaymentPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzEwOTk1MTE2Mjg5MDY0_3bfb988a-9fe8-4420-bb22-8c6153e2134e">24</ix:nonNumeric> months following the applicable advance date, and <ix:nonFraction unitRef="number" contextRef="ibda01586c8f04185951a0c2fc97552f9_D20201119-20201119" decimals="INF" name="fhtx:PercentageOfPrepaymentFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzEwOTk1MTE2Mjg5MDcx_2267648a-52d0-4edc-b662-a6789d28f614">0.5</ix:nonFraction>% if an advance is prepaid any time after <ix:nonNumeric contextRef="i1d753a4861b4455884ca55cfae0bfb8a_D20201119-20201119" name="fhtx:PrepaymentPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzEwOTk1MTE2Mjg5MDkw_2ce55d43-f048-4a87-8b16-1d93173d90dd">24</ix:nonNumeric> months following the applicable advance date but prior to the Maturity Date. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with the Oxford Loan Agreement, the Company granted warrants to purchase <ix:nonFraction unitRef="shares" contextRef="ib49c41bde7e24d5eb853d157bd015ed2_I20201119" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzQ1ODc_65c3a9be-ea1a-4a91-a52c-d46f2758c866">18,445</ix:nonFraction> shares of the Company&#8217;s common stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="ib49c41bde7e24d5eb853d157bd015ed2_I20201119" decimals="2" name="fhtx:WarrantsIssuePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzQ2MzA_1de7f1d4-a980-4543-81eb-db1f85a692c8">16.26</ix:nonFraction> per share. The issued warrants are exercisable for <ix:nonNumeric contextRef="ib49c41bde7e24d5eb853d157bd015ed2_I20201119" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzQ2ODU_745027bf-dcbb-41fe-8c79-0a293f552ae4">10</ix:nonNumeric> years. The Company valued the warrants using the Black-Scholes option pricing model and determined the fair value of the warrants to be $<ix:nonFraction unitRef="usd" contextRef="ib49c41bde7e24d5eb853d157bd015ed2_I20201119" decimals="-5" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzQ4MTg_776c5447-f469-422f-8f07-01ee2e053356">0.2</ix:nonFraction> million. The Company determined the warrants met the criteria for equity classification, and, as such, the fair value of the warrants were recorded as additional paid-in capital upon issuance and as a discount to the debt which is being amortized to interest expense over the term of the Oxford Loan of <ix:nonNumeric contextRef="i8b0e0ca6351c413a82a3c23dea9a45aa_D20201119-20201119" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzUxMDI_93e14d86-a5d1-4c21-bcf4-ddaac1bdd697">five years</ix:nonNumeric>. In addition, the Company incurred debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i8b0e0ca6351c413a82a3c23dea9a45aa_D20201119-20201119" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzgyNDYzMzcyMTUyNzg_0fcf361f-41b0-4c18-9600-914edf3bd40d">0.2</ix:nonFraction> million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company repaid early the outstanding principal balance under the Term Loans as described above plus unpaid accrued interest, the final payment fee and the prepayment fee. The Company recorded a loss on debt extinguishment of $<ix:nonFraction unitRef="usd" contextRef="i5a5c869b237944468340c8ac74252d01_D20211201-20211231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzIxOTkwMjMyNjg2MDg_2fa9c65d-a038-44a3-8748-91d9d77ed84b">1.2</ix:nonFraction>&#160;million related to this repayment for the year ended December&#160;31, 2021. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i253c03d742fd4e71a2fbd58e39345968">During the years ended December&#160;31, 2021 and 2020, the weighted average effective interest rate on outstanding borrowings was approximately <ix:nonFraction unitRef="number" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzUzODU_658a1aaf-acc9-4262-baaf-aa944041b55b">9.5</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzUzOTI_6d280f67-7274-4522-9a6c-2192b2403b57">6.4</ix:nonFraction>%, respectively.</ix:continuation></span></div><div id="i523559815e87485cb6a9895707f43a02_130"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="fhtx:CommonStockTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzAvZnJhZzoxMGVkMmVjYjc1ZWI0NWFkOTZhMTU3MWE1NjkwNTZmMi90ZXh0cmVnaW9uOjEwZWQyZWNiNzVlYjQ1YWQ5NmExNTcxYTU2OTA1NmYyXzgxOA_c1a7cada-cb59-4732-b45c-bc2eb1f6eab7" continuedAt="i7efa1e2596974dd9aa49d0482c98eca7" escape="true">Common Stock</ix:nonNumeric></span></div><ix:continuation id="i7efa1e2596974dd9aa49d0482c98eca7" continuedAt="i0a02bf97dac441bba38e6b602389e7d0"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;27, 2020, the Company completed its initial public offering (&#8220;IPO&#8221;) pursuant to which it issued and sold <ix:nonFraction unitRef="shares" contextRef="i200e1e33978e497897a00efb7d79afa3_D20201027-20201027" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzAvZnJhZzoxMGVkMmVjYjc1ZWI0NWFkOTZhMTU3MWE1NjkwNTZmMi90ZXh0cmVnaW9uOjEwZWQyZWNiNzVlYjQ1YWQ5NmExNTcxYTU2OTA1NmYyXzEzNw_2673740b-18a5-4a16-be96-2e8931c616b8">7,500,000</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i994acb4549c24113977b0c0609947658_I20201027" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzAvZnJhZzoxMGVkMmVjYjc1ZWI0NWFkOTZhMTU3MWE1NjkwNTZmMi90ZXh0cmVnaW9uOjEwZWQyZWNiNzVlYjQ1YWQ5NmExNTcxYTU2OTA1NmYyXzE5Nw_5ab66143-aebc-4797-8e25-570105cdfb58">16.00</ix:nonFraction> per share, resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i200e1e33978e497897a00efb7d79afa3_D20201027-20201027" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzAvZnJhZzoxMGVkMmVjYjc1ZWI0NWFkOTZhMTU3MWE1NjkwNTZmMi90ZXh0cmVnaW9uOjEwZWQyZWNiNzVlYjQ1YWQ5NmExNTcxYTU2OTA1NmYyXzI0MA_386fc6fb-2b07-4edb-b3bf-a6c0024f7e30">107.9</ix:nonFraction> million, after deducting underwriting discounts and commissions and other offering expenses. On November&#160;19, 2020, the Company issued and sold an additional <ix:nonFraction unitRef="shares" contextRef="i14dfffaa2d514c159c93b8d68536b5ba_D20201119-20201119" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzAvZnJhZzoxMGVkMmVjYjc1ZWI0NWFkOTZhMTU3MWE1NjkwNTZmMi90ZXh0cmVnaW9uOjEwZWQyZWNiNzVlYjQ1YWQ5NmExNTcxYTU2OTA1NmYyXzM5Mg_bc55da06-bdc0-4d4a-b405-6cdcdc0268de">951,837</ix:nonFraction> shares of common stock at the IPO price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i642c088ef7d642369dbab1bad144e018_I20201119" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzAvZnJhZzoxMGVkMmVjYjc1ZWI0NWFkOTZhMTU3MWE1NjkwNTZmMi90ZXh0cmVnaW9uOjEwZWQyZWNiNzVlYjQ1YWQ5NmExNTcxYTU2OTA1NmYyXzQzOA_40e1c51d-1bc5-4c11-ab4e-9a947fff69a8">16.00</ix:nonFraction> per share pursuant to the underwriters&#8217; partial exercise of their option to purchase additional shares of common stock, resulting in additional net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i14dfffaa2d514c159c93b8d68536b5ba_D20201119-20201119" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzAvZnJhZzoxMGVkMmVjYjc1ZWI0NWFkOTZhMTU3MWE1NjkwNTZmMi90ZXh0cmVnaW9uOjEwZWQyZWNiNzVlYjQ1YWQ5NmExNTcxYTU2OTA1NmYyXzYwMQ_615fc25d-ec99-4631-93b7-865572f2c614">14.2</ix:nonFraction> million after deducting underwriting discounts and commissions. Upon the closing of the IPO, all of the Company&#8217;s outstanding convertible preferred stock automatically converted into shares of common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 10, 2021, the Company completed a collaboration agreement with Lilly (See Note 9). Concurrent with the collaboration agreement the Company completed a stock purchase agreement with Lilly and issued and sold Lilly <ix:nonFraction unitRef="shares" contextRef="iabf346f1d20b4fbab0cb034770c8cc7b_D20211210-20211210" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzAvZnJhZzoxMGVkMmVjYjc1ZWI0NWFkOTZhMTU3MWE1NjkwNTZmMi90ZXh0cmVnaW9uOjEwZWQyZWNiNzVlYjQ1YWQ5NmExNTcxYTU2OTA1NmYyXzgyNDYzMzcyMDkzMDk_99cb0e08-c85a-475e-856a-0ab66ae76830">4,000,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7545d56c585441a18935d61361a1f6e3_I20211210" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzAvZnJhZzoxMGVkMmVjYjc1ZWI0NWFkOTZhMTU3MWE1NjkwNTZmMi90ZXh0cmVnaW9uOjEwZWQyZWNiNzVlYjQ1YWQ5NmExNTcxYTU2OTA1NmYyXzgyNDYzMzcyMDkzNTQ_d217642c-81d7-4c0d-9918-8f6542750481">20.00</ix:nonFraction> per share, resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="iabf346f1d20b4fbab0cb034770c8cc7b_D20211210-20211210" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzAvZnJhZzoxMGVkMmVjYjc1ZWI0NWFkOTZhMTU3MWE1NjkwNTZmMi90ZXh0cmVnaW9uOjEwZWQyZWNiNzVlYjQ1YWQ5NmExNTcxYTU2OTA1NmYyXzgyNDYzMzcyMDkzOTg_4569002f-0fd6-43b8-8662-70e5ab39dd15">80.0</ix:nonFraction> million of which </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i146aef1b1a8a405cb503481b39bfb902_D20211210-20211210" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzAvZnJhZzoxMGVkMmVjYjc1ZWI0NWFkOTZhMTU3MWE1NjkwNTZmMi90ZXh0cmVnaW9uOjEwZWQyZWNiNzVlYjQ1YWQ5NmExNTcxYTU2OTA1NmYyXzk4OTU2MDQ2NTMzODM_963d229b-17ea-449e-9e61-68c3710ca114">42.2</ix:nonFraction> million was allocated to equity upon the issuance of the Company&#8217;s common stock (see Note 9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0a02bf97dac441bba38e6b602389e7d0">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders. Common stockholders are not entitled to receive dividends, unless declared by the board of directors.</ix:continuation> </span></div><div id="i523559815e87485cb6a9895707f43a02_136"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzY1Mjc_8b57ed7e-91e7-4ef5-b7c9-efcbd43990f7" continuedAt="i8ffe780af9454c4c91f3a4e64029f369" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i8ffe780af9454c4c91f3a4e64029f369" continuedAt="ie89855ae45b44d4d9d1f75415d209fb2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2016 Stock Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2016 Stock Incentive Plan, (the &#8220;2016 Plan&#8221;) provided for the Company to grant incentive stock options or nonqualified stock options and other equity awards to employees, directors and consultants of the Company. Upon the effectiveness of the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;) in October 2020, the Company ceased granting additional awards under the 2016 Plan.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Equity Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Plan provides for the grant of incentive stock options,&#160;non-qualified&#160;options, stock appreciation rights, restricted stock awards, restricted stock units and other&#160;stock-based awards. The number of shares initially reserved for issuance under the 2020 Plan was (i) <ix:nonFraction unitRef="shares" contextRef="id726ec1ea7b74a18882e37d4c46d322d_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzg5Nw_808eb846-10a2-4e46-a27e-0f97f6729e0f">2,200,000</ix:nonFraction> shares (the &#8220;share pool&#8221;), plus (ii)&#160;the number of shares of common stock available for issuance under the 2016 Plan as of the effective date of the 2020 Plan, plus the number of shares of common stock underlying awards under the 2016 Plan that on or after the date of adoption expire or become unexercisable without delivery of shares, are forfeited to, or repurchased for cash, are settled in cash, or otherwise become available again for grant under the 2016 Plan, in each case, in accordance with its terms (up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="i66c95f1c25a3420bb352629cf4f1de89_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzE0MzQ_7450183b-889e-4aca-9819-9975e1af0df6">5,078,295</ix:nonFraction> shares). As of December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="id726ec1ea7b74a18882e37d4c46d322d_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzE0NTY_b956c214-e575-47cd-99a7-689626d43f49">2,271,847</ix:nonFraction> shares remained available for future grant under the 2020 Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The share pool will automatically increase on January&#160;1 of each year from 2021 to 2030 by the lesser of (i)&#160;<ix:nonFraction unitRef="number" contextRef="ib1f18e1cd74a4d7aaab2d0502973207a_D20210101-20211231" decimals="2" name="fhtx:ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzE2NDkyNjc0NTA0MTM_ee406994-1988-4fe6-b686-741ba515dbec">four</ix:nonFraction> percent of the number of shares of our common stock outstanding as of the close of business on the immediately preceding December&#160;31 and (ii)&#160;the number of shares determined by the board of directors on or prior to such date for such year.&#160;The number of shares reserved for issuance under the 2020 Plan was increased by <ix:nonFraction unitRef="shares" contextRef="i6b428a6c1acd40cf865512a4a620af6a_D20220101-20220101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzE5NDg_4e75173d-1287-44f6-9aab-384c7f9e3146">1,651,989</ix:nonFraction> shares effective January&#160;1, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Plan is administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions are determined at the discretion of the board of directors, or its committee if so delegated. Stock options granted with service-based vesting conditions generally vest over <ix:nonNumeric contextRef="ib1f18e1cd74a4d7aaab2d0502973207a_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzIzNzM_9bdfc73a-8d7f-4cfe-80c1-7f6e2846cd0b">four years</ix:nonNumeric> and expire after <ix:nonNumeric contextRef="ib1f18e1cd74a4d7aaab2d0502973207a_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzIzOTM_fa2014dc-85c9-4ffd-8adf-6a0e0c839e4f">ten years</ix:nonNumeric>. The exercise price for stock options granted is not less than the fair value of common stock on the date of grant. The Company bases fair value of common stock on the quoted market price. Prior to the IPO, the board of directors determined the value the Company&#8217;s common stock, taking into consideration its most recently available valuation of common stock performed by third parties as well as additional relevant factors which may have changed since the date of the most recent contemporaneous valuation through the date of grant.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;21, 2020, the Company&#8217;s board of directors adopted and its stockholders approved the 2020 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which became effective on October&#160;21, 2020. The aggregate number of shares of common stock </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><ix:continuation id="ie89855ae45b44d4d9d1f75415d209fb2" continuedAt="ia9fb9896413742818b615ca2c914d910"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available for purchase pursuant to the exercise of options under the ESPP is <ix:nonFraction unitRef="shares" contextRef="i98cc31b8aad74865a5d00291d5e0a72c_I20201021" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzMyNzc_238fbb62-4cf1-4d4d-abda-2fa8f1de0d94">360,000</ix:nonFraction> shares, plus an automatic annual increase, as of January&#160;1 of each year from 2021 to 2030, equal to the lesser of <ix:nonFraction unitRef="number" contextRef="i41b3935d055e4939a3944280d0f2de1e_D20201001-20201021" decimals="2" name="fhtx:ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzE2NDkyNjc0NTA0MzY_aa46ae84-a3e3-4214-a145-ca3a725c4125">one</ix:nonFraction> percent of the number of shares of common stock outstanding as of the close of business on the immediately preceding December&#160;31 and (ii)&#160;the number of shares determined by the board of directors on or prior to such date for such year (up to a maximum of <ix:nonFraction unitRef="shares" contextRef="ia19ec2fabe1a4533bf2258db4754d4d1_I20211231" decimals="INF" name="fhtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzM2NDg_719c45f0-9e5b-45e8-9e91-1b2d5cb67810">3,220,520</ix:nonFraction> shares). The number of shares reserved for issuance under the ESPP was increased by <ix:nonFraction unitRef="shares" contextRef="i607096de8c294fdbb48bcd8c3b29b30e_D20220101-20220101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzM3MzU_f9a4813c-01ba-42d5-ac49-f11a1e97d284">367,894</ix:nonFraction> shares to <ix:nonFraction unitRef="shares" contextRef="i6d95bd0fdd7e4e81bd6d70d4f7c1ca41_I20220101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzQzOTgwNDY1MTk0Mjc_523f5cad-8246-44d1-a28c-ed946a666d5b">780,891</ix:nonFraction> shares effective January&#160;1, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first offering period commenced under the ESPP on September 1, 2021. For the year ended December&#160;31, 2021, the Company recognized a de minimis amount of expense related to the ESPP.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option valuation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock option grants is estimated using the Black-Scholes option-pricing model. The Company currently lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</span></div><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzY1Mjg_a45f6688-4f9b-4b4d-bdc6-887b73f61cc8" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted during the years ended December&#160;31, 2021 and 2020 which was as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTplMjM2ZWVhZmE3ZTQ0YjJjYmE4MTU1ZWEyZGU4NWFkYy90YWJsZXJhbmdlOmUyMzZlZWFmYTdlNDRiMmNiYTgxNTVlYTJkZTg1YWRjXzItMS0xLTEtMA_63aa943f-f838-4053-8812-50618a6d8917">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTplMjM2ZWVhZmE3ZTQ0YjJjYmE4MTU1ZWEyZGU4NWFkYy90YWJsZXJhbmdlOmUyMzZlZWFmYTdlNDRiMmNiYTgxNTVlYTJkZTg1YWRjXzItMy0xLTEtMA_24bf8c76-9fdf-4a95-a8e6-34eaa862abfe">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTplMjM2ZWVhZmE3ZTQ0YjJjYmE4MTU1ZWEyZGU4NWFkYy90YWJsZXJhbmdlOmUyMzZlZWFmYTdlNDRiMmNiYTgxNTVlYTJkZTg1YWRjXzMtMS0xLTEtMA_bbf25ff5-196b-4fa7-95f5-e539e2e7ae23">78.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTplMjM2ZWVhZmE3ZTQ0YjJjYmE4MTU1ZWEyZGU4NWFkYy90YWJsZXJhbmdlOmUyMzZlZWFmYTdlNDRiMmNiYTgxNTVlYTJkZTg1YWRjXzMtMy0xLTEtMA_0505de21-41d3-4656-8db5-6a86f0a3c47c">78.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTplMjM2ZWVhZmE3ZTQ0YjJjYmE4MTU1ZWEyZGU4NWFkYy90YWJsZXJhbmdlOmUyMzZlZWFmYTdlNDRiMmNiYTgxNTVlYTJkZTg1YWRjXzQtMS0xLTEtMA_b56e5ad9-96d7-489d-b11d-8787248b9468">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTplMjM2ZWVhZmE3ZTQ0YjJjYmE4MTU1ZWEyZGU4NWFkYy90YWJsZXJhbmdlOmUyMzZlZWFmYTdlNDRiMmNiYTgxNTVlYTJkZTg1YWRjXzQtMy0xLTEtMA_bca96b34-e1d1-405b-a8c3-5fc036fda03d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTplMjM2ZWVhZmE3ZTQ0YjJjYmE4MTU1ZWEyZGU4NWFkYy90YWJsZXJhbmdlOmUyMzZlZWFmYTdlNDRiMmNiYTgxNTVlYTJkZTg1YWRjXzUtMS0xLTEtMA_aa876855-950e-4bcd-b801-ebd8eb22eec2">6.0</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTplMjM2ZWVhZmE3ZTQ0YjJjYmE4MTU1ZWEyZGU4NWFkYy90YWJsZXJhbmdlOmUyMzZlZWFmYTdlNDRiMmNiYTgxNTVlYTJkZTg1YWRjXzUtMy0xLTEtMA_1e1d90d9-6f41-4fc4-9eed-3a7c89856e8f">6.1</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzY1Mjk_9affee9b-4d62-45d2-9621-65033919e359" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s option activity during the year ended December&#160;31, 2021 which was as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzItMS0xLTEtMA_2a60d652-60a2-407f-b618-502d623c5e51">5,016,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzItMy0xLTEtMA_440d881e-21d1-4084-868e-1a9553cc1845">4.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzItNS0xLTEtMzU4MDA_8abffb48-2a3d-4ec8-9ce0-a479c445875e">8.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzItNy0xLTEtMzU4MDA_9e362c52-240d-4007-abb9-b777bc271595">76,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzMtMS0xLTEtMA_7bc3c66d-cde6-49c2-a269-cad8cb2a3715">1,719,563</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzMtMy0xLTEtMA_6c91da51-f51b-4dde-8e53-42ca5aab7c37">15.41</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzQtMS0xLTEtMA_4be3186e-33eb-450c-9687-fa390e0c5d9f">508,774</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzQtMy0xLTEtMA_557b4b5f-8278-40f1-b98a-a6d7a06ca5ca">2.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzUtMS0xLTEtMA_354f8a93-8ef4-4f46-bda9-b842363137f0">306,740</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzUtMy0xLTEtMA_eb5e5fe2-2eae-4a8e-96b1-b4a5b9726c51">10.22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzYtMS0xLTEtMA_7e8a6a4f-fb91-41c6-8454-b0725529fb4f">5,920,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzYtMy0xLTEtMA_c149957d-5283-407d-8893-85472750778d">7.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzYtNS0xLTEtMA_809fa7de-4878-4794-8336-997873fc4b8b">7.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzYtNy0xLTEtMA_64aca36c-c37b-46a2-8b3c-259984cb2b5c">88,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest as of December 31, 2021</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzctMS0xLTEtMA_3601062b-8f3b-4376-a6e7-7a6c3addd236">5,920,509</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzctMy0xLTEtMA_611746fe-0c67-4195-99f5-51aaa3cb3804">7.88</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzctNS0xLTEtMA_da2fce6b-66f4-44ea-ac4a-fd950be32ffb">7.9</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzctNy0xLTEtMA_91598b08-70ad-454c-8f05-63342746d73d">88,720</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercisable as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzgtMS0xLTEtMA_0cd3f3f8-02fc-49b7-a7a2-01b26dfe83a5">2,435,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzgtMy0xLTEtMA_88915a31-fc68-46ba-8dba-42b77471d053">3.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzgtNS0xLTEtMA_b9a52aa5-fa4a-4d47-955d-a719d4b9070d">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzgtNy0xLTEtMA_98cb8a59-0db0-43f8-a59c-19e6f56e2076">46,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. The aggregate intrinsic value of stock options exercised during the years ended December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzU0MDM_ddebaf99-d221-47ae-823c-21d791c7deee">5.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzU0MTA_dcce7da3-74c3-4040-8031-2fc00aa9e080">3.5</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant-date fair value of stock options granted during the years ended December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzgyNDYzMzcyMTY2MDU_9daeb2a5-3cb8-465b-9c6a-3e1f3b8b6891">10.40</ix:nonFraction> per share and $<ix:nonFraction unitRef="usdPerShare" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzgyNDYzMzcyMTY2MTU_1275264a-8ade-48db-99a7-f077db9129e1">6.01</ix:nonFraction> per share, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><ix:continuation id="ia9fb9896413742818b615ca2c914d910"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted common stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2015, the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="i4582998cb4fb486daa23cdd87422567d_D20150101-20151231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzU2NDM_b088ad9a-8dd5-4d06-8081-e1f35ba830ac">4,459,459</ix:nonFraction> shares of restricted common stock at par value to the scientific founders of the Company. The shares were subject to vesting over a period of <ix:nonNumeric contextRef="i59b51c6004e744ce976e8146e0351d7b_D20160401-20160430" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzEwOTk1MTE2MzQzNDk_2587c89e-dff3-4491-9b46-0c9db2170d6d">five years</ix:nonNumeric> and began vesting in April 2016 and were fully vested as of December&#160;31, 2020. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate fair value of restricted stock that vested during the years ended December&#160;31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzYxMjE_3afb8fda-bc63-48bf-b9ef-73ac9a66d502">4.8</ix:nonFraction> million, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzY1MjY_8f6a6f05-75a2-4faf-bfbc-eaacce60b80f" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to common stock options and restricted common stock in the following expense categories of its consolidated statements of operations and comprehensive loss during the years ended December&#160;31, 2021 and 2020 which was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic0ad5b09bca848e28ffcaee3d672d862_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTo1MzJiOTAzODgxZjU0NjI5OWJlMGUxM2FjYmY3YmU5Mi90YWJsZXJhbmdlOjUzMmI5MDM4ODFmNTQ2Mjk5YmUwZTEzYWNiZjdiZTkyXzItMS0xLTEtMA_26f7ead0-62bb-4f54-83de-e34e2b000fa0">4,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i12b80e675b334f9bb84e42822020fb90_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTo1MzJiOTAzODgxZjU0NjI5OWJlMGUxM2FjYmY3YmU5Mi90YWJsZXJhbmdlOjUzMmI5MDM4ODFmNTQ2Mjk5YmUwZTEzYWNiZjdiZTkyXzItMy0xLTEtMA_c41dcdc7-14d3-4935-a151-8411c2985c7b">1,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if52bb65557044014ad2e63a31d0a1950_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTo1MzJiOTAzODgxZjU0NjI5OWJlMGUxM2FjYmY3YmU5Mi90YWJsZXJhbmdlOjUzMmI5MDM4ODFmNTQ2Mjk5YmUwZTEzYWNiZjdiZTkyXzMtMS0xLTEtMA_f9c9d2a5-464c-477a-bedb-e48cabf428a4">4,060</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d7a3942a9c94293aa8e8f466ced6118_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTo1MzJiOTAzODgxZjU0NjI5OWJlMGUxM2FjYmY3YmU5Mi90YWJsZXJhbmdlOjUzMmI5MDM4ODFmNTQ2Mjk5YmUwZTEzYWNiZjdiZTkyXzMtMy0xLTEtMA_4b44401b-7092-488f-b8b1-f56ba151ae03">1,237</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTo1MzJiOTAzODgxZjU0NjI5OWJlMGUxM2FjYmY3YmU5Mi90YWJsZXJhbmdlOjUzMmI5MDM4ODFmNTQ2Mjk5YmUwZTEzYWNiZjdiZTkyXzQtMS0xLTEtMA_9ef92616-e900-4c40-9ee6-86bedfa0d7bd">8,384</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTo1MzJiOTAzODgxZjU0NjI5OWJlMGUxM2FjYmY3YmU5Mi90YWJsZXJhbmdlOjUzMmI5MDM4ODFmNTQ2Mjk5YmUwZTEzYWNiZjdiZTkyXzQtMy0xLTEtMA_29aa2ae9-da16-4004-b1bb-c646a764ba0a">2,961</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, total unrecognized compensation cost related to unvested options was $<ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzY0NTE_c824bf96-fe8a-4f59-815a-fabfdf53f9ce">20.8</ix:nonFraction> million, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzY1MjQ_7452695c-9ef2-492c-aac0-9ac644fea749">2.7</ix:nonNumeric> years.</span></div></ix:continuation><div id="i523559815e87485cb6a9895707f43a02_142"></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzYzNjk_1dd551c3-76e7-4c59-8e74-57f6a40cf5b5" continuedAt="if9c2e1a797dc42f488a901ff6208078a" escape="true">Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="if9c2e1a797dc42f488a901ff6208078a" continuedAt="i24abd7c9051d4c4a952457eed76e20d4"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lilly Collaboration Agreement and Stock Purchase Agreement</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company entered into a collaboration agreement (the &#8220;Lilly Collaboration Agreement") with Lilly to create novel oncology medicines by applying Foghorn&#8217;s proprietary Gene Traffic Control platform. The collaboration includes a co-development and co-commercialization agreement for the Company&#8217;s selective BRM oncology target, consisting of two programs, and one additional undisclosed oncology target (collectively, the &#8220;Joint Programs&#8221;). The collaboration also includes <ix:nonFraction unitRef="target" contextRef="id4ffb19f3c77426aa1c640fbfce74994_D20211201-20211231" decimals="INF" name="fhtx:NumberOfAdditionalTargets" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzEyMDk0NjI3OTY3OTM4_4e7d6997-93c2-4211-b439-8b402cb0078c">three</ix:nonFraction> additional discovery targets or programs (collectively, the &#8220;Discovery Programs&#8221;) for a total of <ix:nonFraction unitRef="program" contextRef="ibfef7b67aa6c4537931d0aa3b01c282e_I20211231" decimals="INF" name="fhtx:NumberOfPrograms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzEyMDk0NjI3OTY3OTQ3_141748fd-91e2-47bf-ab88-2ad0f2bebcb7">six</ix:nonFraction> programs directed at <ix:nonFraction unitRef="target" contextRef="ibfef7b67aa6c4537931d0aa3b01c282e_I20211231" decimals="INF" name="fhtx:NumberOfTargets" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzEyMDk0NjI3OTY3OTU3_c602d82e-8019-423a-b7ec-f3a5bc09a901">five</ix:nonFraction> targets. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the Joint Programs, the Company will lead discovery and early research activities through the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> successful </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">completion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dose finding toxicity studies </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the identified compound, while Lilly will lead development and commercialization activities of the identified compound with participation from the Company in development activities and 50% cost sharing until registrational clinical trials. The Company and Lilly may jointly develop and commercialize the Joint Program compound though the Company may, in its sole discretion, opt-out on a program-by-program basis of further participation in the development and commercialization efforts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prior to t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he first registrational clinical trial. If the Company does not opt-out, Lilly and the Company will continue to share in the costs to further develop and commercialize the Joint Program compound on a worldwide basis, equally share in the U.S. profits on product sales, subject to certain adjustments and receive royalties on sales outside of the United States (&#8220;Ex-U.S.&#8221;) at royalty rates ranging from low double digits to high twenties. If the Company opts-out of further development and commercialization efforts, it will have no further obligations to share in the development and commercialization costs, will receive royalties rather than profit share on U.S. sales and will receive royalties at a lower rate on Ex-U.S. sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the Discovery Programs, the Company will lead discovery and early research activities through the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">successful completion of dose finding toxicity studies for the identified compounds. The Company may, in its sole discretion, opt in on a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> program-by-program basis after the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">successful c</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ompletion of dose finding toxicity to participate in the further development and commercialization efforts of the Discovery Program compounds. If the Company opts-in to the development and commercialization of the Discovery Program compounds, it will be eligible to receive milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i2b7a001271974fbf9927a5ce4c667237_D20211201-20211231" decimals="-5" name="fhtx:MilestoneReceivableUponAchievement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ2OTYxMzg_c709f5a5-2cff-4169-a6e1-7029a08884ef">10.0</ix:nonFraction> million per program upon specified research and development milestones and up to $<ix:nonFraction unitRef="usd" contextRef="icf371cc8a9e24160bf8af37cf9d965e0_D20211201-20211231" decimals="-5" name="fhtx:MilestoneReceivableUponAchievement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ2OTYxNjA_c20371f3-1340-42d4-8438-3fe9b4f5082d">180.0</ix:nonFraction> million per program upon achievement of specified regulatory and commercial milestones and will also be eligible to share in the U.S. profits at pre-determined percentages on product sales. The Company would also be eligible to receive tiered Ex-U.S. royalty rates, calculated on a product-by-product and country-by-country basis, on net sales outside of the United States, if any, ranging from low single digits to low double digits, but less then teens. If the Company does not opt in to further development and commercialization efforts for the Discovery Programs, it will be eligible to receive milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i2b7a001271974fbf9927a5ce4c667237_D20211201-20211231" decimals="-5" name="fhtx:OptOutMilestoneReceivableUponAchievement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ2OTYxODA_ce154c39-4534-47a7-a104-686a4335fb38">70.0</ix:nonFraction> million per program upon specified research and development milestones and up to $<ix:nonFraction unitRef="usd" contextRef="icf371cc8a9e24160bf8af37cf9d965e0_D20211201-20211231" decimals="-5" name="fhtx:OptOutMilestoneReceivableUponAchievement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ2OTYyMDM_f034e5d5-b635-420a-bd7d-b9bba513504a">360.0</ix:nonFraction> million per program upon achievement of specified regulatory and commercial milestones per approved product, if any. The Company would also be eligible to receive </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><ix:continuation id="i24abd7c9051d4c4a952457eed76e20d4" continuedAt="i6e6889a66e6c4aa793efedad4c266bf9"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tiered royalties on net sales of products worldwide at royalty rates ranging from low single digits to low double digits, but less then teens.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly has the right to make substitutions for each of the five targets during the research term of each program, subject to certain limitations. Pursuant to the Lilly Collaboration Agreement, the Company will also participate in joint decision-making through the joint steering committee and subcommittees. Unless terminated earlier, the Lilly Collaboration Agreement will continue on a product-by-product basis until the expiration of all royalty obligations under the Lilly Collaboration Agreement and when neither the Company nor Lilly is developing, commercializing or manufacturing any product under the Lilly Collaboration Agreement. The Company or Lilly may terminate the Lilly Collaboration Agreement upon an uncured material breach by the other party. Lilly may also terminate the Lilly Collaboration Agreement in its entirety or on a target-by-target, program-by-program or product-by-product basis for any reason upon certain notice to the Company.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Lilly Collaboration Agreement, Lilly agreed to make a nonrefundable upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i1c4d412c57184ef2b09b93a7922fec1d_D20220101-20220131" decimals="-5" name="fhtx:ProceedsFromUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ2OTYyMjQ_e18e90fa-e318-4674-a00a-3d72b8136338">300.0</ix:nonFraction> million to the Company within thirty (30) business days following the effective date of the agreement. Simultaneously with the execution of the Lilly Collaboration Agreement, the Company and Lilly entered into the Lilly SPA, pursuant to which Lilly purchased <ix:nonFraction unitRef="shares" contextRef="iabf346f1d20b4fbab0cb034770c8cc7b_D20211210-20211210" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ2OTYyNDU_99cb0e08-c85a-475e-856a-0ab66ae76830">4,000,000</ix:nonFraction> shares of the Company&#8217;s common stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="i7545d56c585441a18935d61361a1f6e3_I20211210" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ2OTYyNTc_d217642c-81d7-4c0d-9918-8f6542750481">20.00</ix:nonFraction> per share, for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="iabf346f1d20b4fbab0cb034770c8cc7b_D20211210-20211210" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ2OTYyNzA_4569002f-0fd6-43b8-8662-70e5ab39dd15">80.0</ix:nonFraction> million. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Lilly Collaboration Agreement and the stock purchase agreement entered into with Lilly concurrently (the "Lilly SPA") should be evaluated as a combined contract in accordance with ASC 606. The Company determined the fair value of the shares sold under the Lilly SPA to be $<ix:nonFraction unitRef="usd" contextRef="id4ffb19f3c77426aa1c640fbfce74994_D20211201-20211231" decimals="-5" sign="-" name="fhtx:DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ3MTAzNzI_2e364076-a56f-4a54-aa74-adecc1a12581">37.8</ix:nonFraction> million less than the contractual purchase price stipulated in the Lilly SPA. In accordance with the applicable accounting guidance in ASC 815-40, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity&#8217;s Own Equity</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company determined that the sale of stock should be recorded at fair value and therefore allocated the excess consideration received under the Lilly SPA to the Lilly Collaboration Agreement, which along with the non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="i1c4d412c57184ef2b09b93a7922fec1d_D20220101-20220131" decimals="-5" name="fhtx:ProceedsFromUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ3MTAzOTM_e18e90fa-e318-4674-a00a-3d72b8136338">300.0</ix:nonFraction> million will be recognized as revenue over the total estimated period of performance.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for the arrangement under ASC 606 as the Company concluded it has a customer relationship with Lilly. The Company determined that (1) the research activities performed by the Company for both the Joint Programs and the Discovery Programs (2) the development activities and cost sharing for the Joint Program development efforts after dose finding toxicity until registrational clinical trials (3) the research, development, manufacture and commercialization licenses and (4) service on the joint steering committee and subcommittees represent a single performance obligation under the Lilly Collaboration Agreement. The Company determined that Lilly cannot benefit from the licenses separately from the research activities, the development activities until registrational clinical trials and participation on the joint steering committee and subcommittees because these services are specialized and rely on the Company&#8217;s expertise such that these activities are highly interrelated and therefore not distinct. Accordingly, the promised goods and services represent one combined performance obligation, and the entire transaction price was allocated to that single combined performance obligation. The performance obligation will be satisfied over time as the Company performs the research activities, participates and shares in the cost of the development activities for the Joint Programs and participates in a joint steering committee and subcommittees to oversee these activities. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s options to share in further development and commercialization efforts via its opt-in/opt-out rights will be assessed and accounted for as separate units of accounting under the relevant guidance if, and when, such options are exercised by the Company.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of $<ix:nonFraction unitRef="usd" contextRef="i0598fb4888944458a105637a5c365acb_I20211201" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ2OTY0MTA_60ebdf33-917c-4c04-8bff-dfa5d631feb2">337.8</ix:nonFraction> million was initially recorded as deferred revenue and is being recognized as revenue as the performance obligation is satisfied. The Company recognizes revenue using the cost-to-cost method, which it believes best depicts the transfer of control to the customer over time. Under the cost-to-cost method, the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation. Under this method, revenue is recorded as a percentage of the estimated transaction price based on the extent of progress towards completion. As of December 31, 2021, the potential research, development and regulatory milestone payments that the Company is eligible to receive were excluded from the transaction price as they were fully constrained by uncertain events. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and if necessary, the Company will adjust its estimate of the transaction price. Any additions to the transaction price would be reflected in the period as a cumulative revenue catch-up based on the ratio of costs incurred to the total estimated costs expected applied to the revised transaction price. Sales-based royalties and milestone payments, which predominantly relate to the license, will be recognized if and when the related sales occur.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the aggregate amount of the transaction price related to the unsatisfied portion of the performance obligation was $<ix:nonFraction unitRef="usd" contextRef="ibfef7b67aa6c4537931d0aa3b01c282e_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ2OTY0NDE_0ed9052c-6472-40ec-b899-20fcc44ea4dc">337.2</ix:nonFraction> million, which is expected to be recognized as revenue through 2029. The Company does not expect collaboration revenue to be recognized evenly over this period as it will be recognized on a percentage of completion basis (using cost-to-cost method) as the Company performs the research and development activities and participates on the joint </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><ix:continuation id="i6e6889a66e6c4aa793efedad4c266bf9" continuedAt="i2a7cd72eaa2e482996af1baee21ca412"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">steering committee and subcommittees, which will likely vary from period to period. In estimating the total costs to satisfy its single performance obligation pursuant to the Lilly Collaboration Agreement, the Company is required to make significant estimates including an estimate of the number of target substitutions Lilly may elect to make and the expected time and expected costs to fulfill the performance obligation. The cumulative effect of revisions to the total estimated costs to complete the Company&#8217;s single performance obligation will be recorded in the period in which the changes are identified, and amounts can be reasonably estimated. While such revisions will have no impact on the Company&#8217;s cash flows, a significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods and the classification of deferred revenue between short-term and long-term. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception, the Company assessed the Lilly Collaboration Agreement to determine whether a significant financing component exists and concluded that a significant financing component does not exist. For the year ended December 31, 2021, the Company had recorded $<ix:nonFraction unitRef="usd" contextRef="i2dbcc6d4cd8b45da85ef3abc002c76e7_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ2OTY0NTk_dfc4ccbe-0b33-403d-ba97-e0d2882ccbd9">0.6</ix:nonFraction> million of revenue under the Lilly Collaboration Agreement, which was included in deferred revenue at contract inception. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzQzOTgwNDY1MzIwMzE_8c85d1d3-d3cf-4b2c-a024-9a53234cdc19">300.0</ix:nonFraction>&#160;million was recorded as collaboration receivable on the Company's consolidated balance sheets. In January 2022, the $<ix:nonFraction unitRef="usd" contextRef="i1c4d412c57184ef2b09b93a7922fec1d_D20220101-20220131" decimals="-5" name="fhtx:ProceedsFromUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzIxOTkwMjMyNzY1MTI_e18e90fa-e318-4674-a00a-3d72b8136338">300.0</ix:nonFraction> million was collected from Lilly.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merck Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a research collaboration and license agreement (the &#8220;Merck Collaboration Agreement&#8221;) with Merck Sharp&#160;&amp; Dohme Corp. (&#8220;Merck&#8221;). The Company and Merck will apply Foghorn&#8217;s proprietary Gene Traffic Control platform to discover and develop novel therapeutics. Under the Merck Collaboration Agreement, the Company granted Merck exclusive global rights to develop, manufacture and commercialize drugs that target dysregulation of a single transcription factor. Under the terms of the Merck Collaboration Agreement, the Company and Merck are each responsible to perform certain research activities in accordance with a mutually agreed upon research plan. Merck may substitute the selected transcription factor during certain stages of the research program, subject to certain limitations. Following completion of the research program, Merck is responsible for the development and commercialization of the compounds developed pursuant to the research program and any product containing such compounds. Pursuant to the Merck Collaboration Agreement, the Company will also participate on a joint steering committee.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Foghorn received a nonrefundable upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-5" name="fhtx:ProceedsFromUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzEyMjc_3fda42d4-e6c3-42fb-98f2-dafd24f66922">15.0</ix:nonFraction> million from Merck, and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i37050e2af73c4dfbbeb53cfcede910de_D20210101-20211231" decimals="-5" name="fhtx:MilestoneReceivableUponAchievement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzEyNzU_38437919-3464-498a-94cb-78c58316862d">245.0</ix:nonFraction> million upon achievement of specified research, development and regulatory milestones by any product candidate generated by the collaboration, and up to $<ix:nonFraction unitRef="usd" contextRef="ia0fb78f785ab496ca56695669faf74b4_D20210101-20211231" decimals="-5" name="fhtx:MilestoneReceivableUponAchievement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzE0MjM_2aa6de19-77e1-425b-8453-15df186b617b">165.0</ix:nonFraction> million upon achievement of specified sales-based milestones per approved product from the collaboration, if any. The Company will be eligible to receive tiered royalties, calculated on a product-by-product and country-by-country basis, on net sales of approved products from the collaboration, if any, at royalty rates ranging from the mid-single digits to low tens, depending on whether the products are covered by patent rights it licenses to Merck.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated earlier, the Merck Collaboration Agreement will continue in full force and effect until one or more products has received marketing authorization and, thereafter, until expiration of all royalty obligations under the Merck Collaboration Agreement. The Company or Merck may terminate the Merck Collaboration Agreement upon an uncured material breach by the other party or insolvency of the other party. Merck may also terminate the Merck Collaboration Agreement for any reason upon certain notice to the Company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the (1)&#160;research, development, manufacture and commercialization licenses, (2) the research activities performed by the Company and (3)&#160;service on the joint committees represent a single performance obligation under the Merck Collaboration Agreement. The Company determined that Merck cannot benefit from the licenses separately from the research activities and participation on the joint steering committee because these services are specialized and rely on the Company&#8217;s expertise such that these activities are highly interrelated and therefore not distinct. Accordingly, the promised goods and services represent one combined performance obligation and the entire transaction price was allocated to that single combined performance obligation. The performance obligation will be satisfied over the research term as the Company performs the research activities and participates in a joint steering committee to oversee research activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ic857b04717ad4bdaa38f79139b0b4f77_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzMzNjE_33af955b-aac5-4823-9dfe-851f7fce684c">15.0</ix:nonFraction> million was initially recorded as deferred revenue and is being recognized as revenue as the performance obligation is satisfied. The Company recognizes revenue using&#160;the&#160;cost-to-cost&#160;method,&#160;which it believes best depicts the transfer of control to the customer over time. Under&#160;the&#160;cost-to-cost&#160;method,&#160;the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation. Under this method, revenue is recorded as a percentage of the estimated transaction price based on the extent of progress towards completion. As of December&#160;31, 2021, the potential research, development and regulatory milestone payments that the Company is eligible to receive were excluded from the transaction price as they were fully constrained by uncertain events. The Company will reevaluate the transaction price at the end of each reporting period and </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><ix:continuation id="i2a7cd72eaa2e482996af1baee21ca412"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as uncertain events are resolved or other changes in circumstances occur, and if necessary, the Company will adjust its estimate of the transaction price. Any additions to the transaction price would be reflected in the period as a cumulative revenue&#160;catch-up based on the ratio of costs incurred to the total estimated costs expected applied to the revised transaction price.&#160;Sales-based royalties and milestone payments, which predominantly relate to the license, will be recognized if and&#160;when the related sales occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the aggregate amount of the transaction price related to the unsatisfied portion of the performance obligation is $<ix:nonFraction unitRef="usd" contextRef="i92aabf8f84a443bb8049e24e529e50a6_I20201231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzQ5NDM_d52e7e15-74a5-43bd-acbf-06b0d35f52b0">13.9</ix:nonFraction> million, which is expected to be recognized as revenue through 2028. The Company does not expect collaboration revenue to be recognized evenly over this period as it will be recognized on a percentage of completion basis (using cost-to-cost method) as the Company performs the research activities and participates on the joint steering committee, which will likely vary from period to period. In estimating the total costs to satisfy its single performance obligation pursuant to the Merck Collaboration Agreement, the Company is required to make significant estimates including an estimate of the number of transcription factor substitutions and the expected time and expected costs to fulfill the performance obligation.&#160;The cumulative effect of revisions to the total estimated costs to complete the Company&#8217;s single performance obligation will be recorded in the period in which the changes are identified, and amounts can be reasonably estimated. While such revisions will have no impact on the Company&#8217;s cash flows, a significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods and the classification of deferred revenue between short-term and long-term. In June 2021, the Company re-evaluated its estimates related to the Merck Collaboration Agreement resulting in a reclassification of $<ix:nonFraction unitRef="usd" contextRef="i26f27415158a4a8dad12c8e3b7e94178_I20210630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzgyNDYzMzcyMjkwMDU_0d11d678-e21d-4129-bdb6-f4d388d6a5bc">1.9</ix:nonFraction>&#160;million from short-term deferred revenue to long-term deferred revenue, net of current portion on the Company's consolidated balance sheets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception, the Company assessed the Merck Collaboration Agreement to determine whether a significant financing component exists and concluded that a significant financing component does not exist. For the year ended December&#160;31, 2021, the Company had recorded $<ix:nonFraction unitRef="usd" contextRef="if6b2557e266749eca4da6aa9146a5588_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzYzMjI_09134ce7-a824-4258-8f0e-ee2ec0ada3dc">0.7</ix:nonFraction> million of revenue under the Merck Collaboration Agreement, which was included in deferred revenue at the beginning of the period </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the classification of deferred revenue between short-term and long-term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div id="i523559815e87485cb6a9895707f43a02_148"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzM1NzE_3c6afdb0-fb5f-468a-881f-10e74cb4cc0b" continuedAt="icbc6a609ccaa45f7892535d21e15a639" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="icbc6a609ccaa45f7892535d21e15a639" continuedAt="i15985a7efb614412b5c384cd0e19d934"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, the Company recorded no income tax benefits for the net deferred tax assets comprised primarily of net operating losses incurred and research and development tax credits generated in each year, due to its uncertainty of realizing a benefit from these items.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s operating losses since inception have been generated in the United States.</span></div><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzM1NzI_92be6b65-c21b-4c07-b5a1-f0a4f4b76323" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate was as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzItMS0xLTEtMA_2e623f36-7138-4bd2-af21-2c7eae929fd3">21.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzItMy0xLTEtMA_53f90a9f-63fd-4c28-8868-82d816f06425">21.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State taxes, net of federal benefit</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzMtMS0xLTEtMA_d6355b68-2df4-4337-b248-efddcff19084">5.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzMtMy0xLTEtMA_68e991a1-3608-4a3c-87ff-491339a13192">6.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state research and development tax credits</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzQtMS0xLTEtMA_15c0506a-2ae8-4e8f-85a4-d2d23ba42b2e">4.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzQtMy0xLTEtMA_e0e68b82-1afe-4127-b2f8-72c8e14783d2">3.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzUtMS0xLTEtMA_e22f7da3-e072-42c1-a715-ea66a471b10e">0.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzUtMy0xLTEtMA_5b21eb9a-c906-4901-8afa-43c3e018d05f">0.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in deferred tax asset valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzYtMS0xLTEtMA_c14809b4-e65c-4ddb-8b50-b4160eac71b8">30.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzYtMy0xLTEtMA_96ff8756-34d4-4761-92be-4a9aa8b495ed">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective income tax rate</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzctMS0xLTEtMA_951f0e1b-10e4-4344-8223-ff8adc80e2c7">0.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzctMy0xLTEtMA_4da55961-24fb-4043-bdd8-2dcd0d705b90">0.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><ix:continuation id="i15985a7efb614412b5c384cd0e19d934" continuedAt="i815e8182d5824e83b9728a6f9d8357f6"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzM1NzA_4b2e5a85-316a-4dbd-bcf9-85cf1df992f7" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss carryforwards</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzMtMS0xLTEtMA_482adcf0-9254-40cc-8790-71b39f9a84dd">61,083</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzMtMy0xLTEtMA_2866f5f8-c634-443d-b4f3-53ad91e3fb5a">39,289</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development tax credit carryforwards</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzQtMS0xLTEtMA_568bcd81-0fd1-4070-bee4-9586d2508f39">9,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzQtMy0xLTEtMA_6a5f5986-d0e4-4eef-884d-12cb095f86fd">4,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized start-up costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="fhtx:DeferredTaxAssetsCapitalizedStartUpCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzUtMS0xLTEtMA_11f2d0f5-536c-47d1-b3ab-852d2a1498fb">157</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="fhtx:DeferredTaxAssetsCapitalizedStartUpCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzUtMy0xLTEtMA_a8743203-1896-4808-aae6-b273d3427239">174</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzYtMS0xLTEtMA_b423c198-3ab4-45ae-9b27-30040d79f7b0">5,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzYtMy0xLTEtMA_059b8ba3-7ac0-494e-97bd-7d3db06e9e68">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzctMS0xLTEtMA_228b22b8-c755-4d3e-85a6-18e82600e4a7">1,403</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzctMy0xLTEtMA_23db1106-0314-40e5-8ab3-58ec093473ab">436</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="fhtx:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzgtMS0xLTEtMA_b99eea47-fdc4-44c2-8f37-c6735579adab">15,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="fhtx:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzgtMy0xLTEtMA_8d15ef0c-fb20-411a-9944-18c09a18bb16">17,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax assets</span></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzktMS0xLTEtMA_5bfe200d-95d1-4dd9-832a-adf1ca77699e">93,262</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzktMy0xLTEtMA_cf772e27-d81e-4547-ac09-518f35fcdd0a">62,896</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="fhtx:DeferredTaxLiabilitiesDepreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzExLTEtMS0xLTA_2155b374-7aa2-42ac-a7b0-825befd28711">3,551</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="fhtx:DeferredTaxLiabilitiesDepreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzExLTMtMS0xLTA_d38a86bc-f827-4e0e-947a-a1cdedcedb28">2,819</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="fhtx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzEyLTEtMS0xLTA_e376609c-bb5d-4778-a55e-78498e749f5e">10,566</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="fhtx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzEyLTMtMS0xLTA_8cfbf504-0521-4246-90a0-b49ba2c08446">11,694</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax liabilities</span></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzEzLTEtMS0xLTA_4a4901ef-f814-45c7-a51c-943eaca7dc80">14,117</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzEzLTMtMS0xLTA_70209a39-ef2f-44be-9c24-9d113af8592e">14,513</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzE0LTEtMS0xLTA_031c82b8-4131-4c65-a2a6-e78b3ac16f5f">79,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzE0LTMtMS0xLTA_b6562017-c37c-4144-a2ef-22532fc1accc">48,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets</span></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzE1LTEtMS0xLTA_a6853d2d-292c-49a3-ab13-9a77564a1b00">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzE1LTMtMS0xLTA_c19d64df-7584-4a92-beac-11c660312fdf">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had U.S. federal and state net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="ie5dda4379bcf4779a73a8e6da786d5d7_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzY4Nw_15ee66e4-6ab0-4356-862a-804ebaf6ff97">228.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib1c22c57ec184fa7a48b0db8d9e9cbca_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzY5NA_a4fd147b-e60a-4223-a022-d17650cf77c1">206.0</ix:nonFraction> million, respectively, which may be available to offset future taxable income. The federal net operating loss carryforwards include&#160;$<ix:nonFraction unitRef="usd" contextRef="ie5dda4379bcf4779a73a8e6da786d5d7_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzgyMQ_95450c1e-6b39-4eaa-b1fe-18bc73fab67f">12.5</ix:nonFraction> million&#160;which expire at various dates beginning in&#160;2035&#160;and&#160;$<ix:nonFraction unitRef="usd" contextRef="ie5dda4379bcf4779a73a8e6da786d5d7_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2Xzg3NA_16db6637-b8ee-405e-89ed-501549367408">216.4</ix:nonFraction> million&#160;which carryforward indefinitely but in some circumstances may be limited to offset <ix:nonFraction unitRef="number" contextRef="i462afb2928a44e61adc374bf4a44a35a_D20210101-20211231" decimals="2" name="fhtx:OperatingLossCarryforwardLimitPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2Xzk2MA_e09f7d0b-19d2-4356-93dd-378d50124848">80</ix:nonFraction>% of annual taxable income. The state net operating loss carryforwards expire at various dates beginning in&#160;2036.&#160;As of December&#160;31, 2021, the Company also had U.S. federal and state research and development tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="ie5dda4379bcf4779a73a8e6da786d5d7_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzExODA_0e87d09b-992b-4930-bd7b-b9e40501986e">6.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib1c22c57ec184fa7a48b0db8d9e9cbca_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzExODc_bfcb45fd-0413-44eb-884e-533c603e2204">4.1</ix:nonFraction> million, respectively, which may be available to offset future tax liabilities and expire at various dates beginning in 2036 and 2031, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section&#160;382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section&#160;382. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being recorded as an uncertain tax position.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company&#8217;s history of cumulative net losses incurred since inception and its lack of commercialization of any products that would generate revenue from product sales and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December&#160;31, 2021 and 2020. Management reevaluates the positive and negative evidence at each reporting period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzI4MTk_3fb7d5a3-78cd-412f-912e-01f85a29c66b">30.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzI4MjY_1b62ba92-1fef-43c2-bf2b-8a47d539a7df">21.8</ix:nonFraction> million during the years ended December&#160;31, 2021 and 2020, respectively, primarily as a result of the increase in net operating loss carryforwards.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the Company had <ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzEwOTk1MTE2MzEzNTE_6b4d1f15-742e-4865-9d68-5380c7848ae9"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzEwOTk1MTE2MzEzNTE_bcf120fc-b552-4044-b94b-28ac37a15701">no</ix:nonFraction></ix:nonFraction>t recorded any amounts for unrecognized tax benefits. The Company files income tax returns in the U.S. and Massachusetts, as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. Since the Company is in a loss carryforward position, it is generally subject to </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i815e8182d5824e83b9728a6f9d8357f6">examination by the U.S. federal, state, and local income tax authorities for all tax years in which a loss carryforward is available.</ix:continuation></span></div><div id="i523559815e87485cb6a9895707f43a02_154"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzI3ODE_0872c674-360b-45d6-bb79-ee99e3495d6c" continuedAt="i7f4bd8711fa24f23b0200d22d7aa3c94" escape="true"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzI3ODE_f185cf4c-1c7a-4709-85d1-8acf62c3d4af" continuedAt="id9cf3d7599dd4aa4a5f22ec8e3948e0e" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i7f4bd8711fa24f23b0200d22d7aa3c94" continuedAt="id5455b8957394413af284b54082fb185"><ix:continuation id="id9cf3d7599dd4aa4a5f22ec8e3948e0e" continuedAt="i6c817cb9b5dd4b54aa17ed4741c01f1f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into a lease for <ix:nonFraction unitRef="sqft" contextRef="i8566261f099345058fc2de53fdeddc94_I20191031" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzcw_8854c1ce-adc6-490a-82e8-0b7e642022e7">81,441</ix:nonFraction> square feet of office and laboratory space in Cambridge, Massachusetts, commencing in January 2020 (the &#8220;New Lease&#8221;). The initial term of the New Lease was <ix:nonNumeric contextRef="i8566261f099345058fc2de53fdeddc94_I20191031" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzEwOTk1MTE2MzA1NTk_22e0ddf4-2f18-45eb-98eb-c332ff0f9726">eight years</ix:nonNumeric> with a <ix:nonNumeric contextRef="i8566261f099345058fc2de53fdeddc94_I20191031" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzEwOTk1MTE2MzA1ODg_df48f422-660d-4f5b-88a5-4107042a8fec">five-year</ix:nonNumeric> option to extend at fair-market rent at the time of the extension. The base rent payments escalate annually over the <ix:nonNumeric contextRef="i8566261f099345058fc2de53fdeddc94_I20191031" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzEwOTk1MTE2MzA2MDE_d24ea296-eb41-4802-bc58-5d243e11a89a">eight-year</ix:nonNumeric> lease term and totaled approximately $<ix:nonFraction unitRef="usd" contextRef="ie777875661fd4e1cafd3e415514e3463_D20200101-20271231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzQyMw_56a0b143-063d-48fa-acce-206c0a7b7631">60.3</ix:nonFraction> million. In connection with the New Lease, the landlord agreed to fund up to $<ix:nonFraction unitRef="usd" contextRef="i88337b0a640c41778757a13053c6737c_I20191031" decimals="-5" name="fhtx:LeaseholdImprovementsLandlordAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzQ5NQ_fc0a2182-84e0-403c-806b-3c3661705fed">3.0</ix:nonFraction> million in tenant improvements to the leased facility as well as up to an additional $<ix:nonFraction unitRef="usd" contextRef="i88337b0a640c41778757a13053c6737c_I20191031" decimals="-5" name="fhtx:LeaseholdImprovementsLandlordAllowanceToBeRepaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzU3NQ_e305e6d7-7540-4f35-8e06-49f6cb6c7d3a">16.3</ix:nonFraction> million, which resulted in additional rent payments to the landlord over the lease term. During the year ended December&#160;31, 2021 and 2020, $<ix:nonFraction unitRef="usd" contextRef="i42cc5f4d622f43728d16d5f588e05289_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromTenantAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzY4NQ_e4267193-2778-4504-b721-dd97ed4427c7">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5df226eaed834b4d95b67a71f15df511_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromTenantAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzgyNDYzMzcyMTE5NzU_f9537626-6319-4b09-a7d7-79d6248f8395">15.4</ix:nonFraction>&#160;million, respectively, of leasehold improvements were reimbursed by the landlord, which resulted in an increase to operating lease liabilities. The Company is obligated to pay its portion of real estate taxes and costs related to the premises, including costs of operations and management of the leased premises. The Company is required to maintain a cash balance of $<ix:nonFraction unitRef="usd" contextRef="i5871025070284091b9843930b1b0739f_I20211231" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzEwMzI_45615f6f-ea8d-4af0-949f-cb07ccaeb1bf">1.7</ix:nonFraction> million to secure a letter of credit associated with the lease. This amount was classified as restricted cash (non-current) on the consolidated balance sheets as of December&#160;31, 2021 and 2020. On January&#160;1, 2020, the lease commencement date, the Company recorded an operating lease asset of $<ix:nonFraction unitRef="usd" contextRef="ie9658936ddbd4496bb318be3e882b158_I20200101" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzEzMDA_fe16cba3-0ab0-4925-9b17-fdbf38e7ad5f">38.6</ix:nonFraction> million and corresponding lease liability of $<ix:nonFraction unitRef="usd" contextRef="ie9658936ddbd4496bb318be3e882b158_I20200101" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzEzNDA_6a9873da-035e-4c87-8d97-264f9db0f1bf">38.3</ix:nonFraction> million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company amended the New Lease to defer payment of a portion of the base rent and operating expenses and to extend the lease term by nine months to September 2028. The amendment was accounted for as a lease modification and the right-of-use asset and lease liability were remeasured at the modification date of June&#160;29, 2020 resulting in an increase of $<ix:nonFraction unitRef="usd" contextRef="i1de98e2458194d09aea8ba3c1fbd59d9_I20200629" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzE3MTQ_2019811c-dddf-4234-8fec-714c616c98a8"><ix:nonFraction unitRef="usd" contextRef="i1de98e2458194d09aea8ba3c1fbd59d9_I20200629" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzE3MTQ_eaa76276-0a2f-45f8-b65d-6b57f85f12e5">7.4</ix:nonFraction></ix:nonFraction> million to both the right-of-use asset and lease liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had a lease for office and laboratory facilities in Cambridge, Massachusetts under a noncancelable operating lease that began in August 2017 and expired in March 2025. In April 2020, this lease was assigned and assumed by a related party which became effective in October 2020.</span></div><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzI3NzY_776f5542-34d5-48d6-9667-32f063f85276" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense was as follows for the years ended December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo3N2UyNGU4MDMwZTc0NzU5YWFmYTM4N2U1ZWZlYTc2MS90YWJsZXJhbmdlOjc3ZTI0ZTgwMzBlNzQ3NTlhYWZhMzg3ZTVlZmVhNzYxXzItMS0xLTEtMA_92d29bf1-b662-4e86-816c-47da52f7d99c">7,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo3N2UyNGU4MDMwZTc0NzU5YWFmYTM4N2U1ZWZlYTc2MS90YWJsZXJhbmdlOjc3ZTI0ZTgwMzBlNzQ3NTlhYWZhMzg3ZTVlZmVhNzYxXzItMy0xLTEtMA_265f3afe-c9b2-412b-92f3-920298f82770">7,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo3N2UyNGU4MDMwZTc0NzU5YWFmYTM4N2U1ZWZlYTc2MS90YWJsZXJhbmdlOjc3ZTI0ZTgwMzBlNzQ3NTlhYWZhMzg3ZTVlZmVhNzYxXzMtMS0xLTEtMA_36bc4bd1-2989-400b-a5a3-32d22ccb3667">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo3N2UyNGU4MDMwZTc0NzU5YWFmYTM4N2U1ZWZlYTc2MS90YWJsZXJhbmdlOjc3ZTI0ZTgwMzBlNzQ3NTlhYWZhMzg3ZTVlZmVhNzYxXzMtMy0xLTEtMA_688ecdc0-59c9-4398-b6cd-dd3c01904f51">61</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo3N2UyNGU4MDMwZTc0NzU5YWFmYTM4N2U1ZWZlYTc2MS90YWJsZXJhbmdlOjc3ZTI0ZTgwMzBlNzQ3NTlhYWZhMzg3ZTVlZmVhNzYxXzQtMS0xLTEtMA_f86f9c8f-b10d-4aa4-bd96-9f94ff8845a1">2,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo3N2UyNGU4MDMwZTc0NzU5YWFmYTM4N2U1ZWZlYTc2MS90YWJsZXJhbmdlOjc3ZTI0ZTgwMzBlNzQ3NTlhYWZhMzg3ZTVlZmVhNzYxXzQtMy0xLTEtMA_ff2e8278-9735-42ab-b8e5-279a8f03a59e">1,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo3N2UyNGU4MDMwZTc0NzU5YWFmYTM4N2U1ZWZlYTc2MS90YWJsZXJhbmdlOjc3ZTI0ZTgwMzBlNzQ3NTlhYWZhMzg3ZTVlZmVhNzYxXzUtMS0xLTEtMA_66e83356-b0ae-4ba4-94b9-254f8794b219">10,439</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo3N2UyNGU4MDMwZTc0NzU5YWFmYTM4N2U1ZWZlYTc2MS90YWJsZXJhbmdlOjc3ZTI0ZTgwMzBlNzQ3NTlhYWZhMzg3ZTVlZmVhNzYxXzUtMy0xLTEtMA_17f6cf60-4634-4c83-9343-1e99b02932f7">8,310</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental disclosure of cash flow information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo1NTJhNTBiYTMyNDk0ODY2YTUzZGU5NjAyMTQ3MmU3Mi90YWJsZXJhbmdlOjU1MmE1MGJhMzI0OTQ4NjZhNTNkZTk2MDIxNDcyZTcyXzItMS0xLTEtMA_dbef5066-80fc-4ff2-847d-d047c6c190fc">9,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo1NTJhNTBiYTMyNDk0ODY2YTUzZGU5NjAyMTQ3MmU3Mi90YWJsZXJhbmdlOjU1MmE1MGJhMzI0OTQ4NjZhNTNkZTk2MDIxNDcyZTcyXzItMy0xLTEtMA_faf2e8b8-c3c8-4d70-b0b1-b90d93fc6c07">3,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities arising from obtaining right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo1NTJhNTBiYTMyNDk0ODY2YTUzZGU5NjAyMTQ3MmU3Mi90YWJsZXJhbmdlOjU1MmE1MGJhMzI0OTQ4NjZhNTNkZTk2MDIxNDcyZTcyXzMtMS0xLTEtMA_c4e487e4-1b2d-4fd3-ae12-349b44d9d381">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo1NTJhNTBiYTMyNDk0ODY2YTUzZGU5NjAyMTQ3MmU3Mi90YWJsZXJhbmdlOjU1MmE1MGJhMzI0OTQ4NjZhNTNkZTk2MDIxNDcyZTcyXzMtMy0xLTEtMA_c6f005d1-1934-4a23-adc9-319c81f5f045">38,306</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase in operating lease liabilities and right-of-use assets due to lease remeasurement</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-3" name="fhtx:ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo1NTJhNTBiYTMyNDk0ODY2YTUzZGU5NjAyMTQ3MmU3Mi90YWJsZXJhbmdlOjU1MmE1MGJhMzI0OTQ4NjZhNTNkZTk2MDIxNDcyZTcyXzQtMS0xLTEtMA_23e22b9b-207a-460f-ba43-9dd4fa01230a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-3" name="fhtx:ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo1NTJhNTBiYTMyNDk0ODY2YTUzZGU5NjAyMTQ3MmU3Mi90YWJsZXJhbmdlOjU1MmE1MGJhMzI0OTQ4NjZhNTNkZTk2MDIxNDcyZTcyXzQtMy0xLTEtMA_3b34066d-36ca-4679-b946-3e54c05bf4a0">7,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining lease term and discount rate was as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8212;operating leases (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo5ZDRiMWM2MDg3Njk0MWU5YjU3N2UwYWJiNjRmNTAyZS90YWJsZXJhbmdlOjlkNGIxYzYwODc2OTQxZTliNTc3ZTBhYmI2NGY1MDJlXzEtMS0xLTEtMA_69decf80-ae34-46a8-be27-af0d85c34ac9">6.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo5ZDRiMWM2MDg3Njk0MWU5YjU3N2UwYWJiNjRmNTAyZS90YWJsZXJhbmdlOjlkNGIxYzYwODc2OTQxZTliNTc3ZTBhYmI2NGY1MDJlXzEtMy0xLTEtMA_7ad22687-1f5d-4fe9-b063-c28ac40fc951">7.7</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8212;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo5ZDRiMWM2MDg3Njk0MWU5YjU3N2UwYWJiNjRmNTAyZS90YWJsZXJhbmdlOjlkNGIxYzYwODc2OTQxZTliNTc3ZTBhYmI2NGY1MDJlXzItMS0xLTEtMA_87506c10-678e-4a60-b66d-cb8375fd49be">5.35</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo5ZDRiMWM2MDg3Njk0MWU5YjU3N2UwYWJiNjRmNTAyZS90YWJsZXJhbmdlOjlkNGIxYzYwODc2OTQxZTliNTc3ZTBhYmI2NGY1MDJlXzItMy0xLTEtMA_cf0b0581-964a-4bf5-9752-41b6b4d345e3">5.35</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><ix:continuation id="id5455b8957394413af284b54082fb185"><ix:continuation id="i6c817cb9b5dd4b54aa17ed4741c01f1f"><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzI3Nzk_01578c75-585b-44b7-be4a-1ea24c6c15c8" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual minimum lease payments under operating leases as of December&#160;31, 2021 was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZToyN2VjYjc4NGExNTU0ZmI5ODhlZGUzZTZkZjVhMzFjNi90YWJsZXJhbmdlOjI3ZWNiNzg0YTE1NTRmYjk4OGVkZTNlNmRmNWEzMWM2XzAtMS0xLTEtMA_d8482552-6077-4eb0-947d-87e50efd251d">9,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZToyN2VjYjc4NGExNTU0ZmI5ODhlZGUzZTZkZjVhMzFjNi90YWJsZXJhbmdlOjI3ZWNiNzg0YTE1NTRmYjk4OGVkZTNlNmRmNWEzMWM2XzEtMS0xLTEtMA_b3f63fe8-69f5-494d-ba33-b87fae3a9be0">10,051</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZToyN2VjYjc4NGExNTU0ZmI5ODhlZGUzZTZkZjVhMzFjNi90YWJsZXJhbmdlOjI3ZWNiNzg0YTE1NTRmYjk4OGVkZTNlNmRmNWEzMWM2XzItMS0xLTEtMA_d34be657-f576-4074-bcf5-eef0f16aef3f">10,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZToyN2VjYjc4NGExNTU0ZmI5ODhlZGUzZTZkZjVhMzFjNi90YWJsZXJhbmdlOjI3ZWNiNzg0YTE1NTRmYjk4OGVkZTNlNmRmNWEzMWM2XzMtMS0xLTEtMA_ad08835b-9fc1-4a38-a017-000a25b2f4ec">10,626</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZToyN2VjYjc4NGExNTU0ZmI5ODhlZGUzZTZkZjVhMzFjNi90YWJsZXJhbmdlOjI3ZWNiNzg0YTE1NTRmYjk4OGVkZTNlNmRmNWEzMWM2XzQtMS0xLTEtMA_5e3c6dd2-d299-4ac5-902d-6d3fa25a3e26">10,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZToyN2VjYjc4NGExNTU0ZmI5ODhlZGUzZTZkZjVhMzFjNi90YWJsZXJhbmdlOjI3ZWNiNzg0YTE1NTRmYjk4OGVkZTNlNmRmNWEzMWM2XzUtMS0xLTEtMA_4cab97f4-0107-47c5-97b3-47b669b3cd3a">19,705</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZToyN2VjYjc4NGExNTU0ZmI5ODhlZGUzZTZkZjVhMzFjNi90YWJsZXJhbmdlOjI3ZWNiNzg0YTE1NTRmYjk4OGVkZTNlNmRmNWEzMWM2XzYtMS0xLTEtMA_12c68b3b-0790-47f7-aa7c-3a4df17364f7">71,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZToyN2VjYjc4NGExNTU0ZmI5ODhlZGUzZTZkZjVhMzFjNi90YWJsZXJhbmdlOjI3ZWNiNzg0YTE1NTRmYjk4OGVkZTNlNmRmNWEzMWM2XzctMS0xLTEtMA_c0885a5e-e4cc-4ea1-b2fd-b341fb7eee9e">11,802</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: estimated lease incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="fhtx:LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZToyN2VjYjc4NGExNTU0ZmI5ODhlZGUzZTZkZjVhMzFjNi90YWJsZXJhbmdlOjI3ZWNiNzg0YTE1NTRmYjk4OGVkZTNlNmRmNWEzMWM2XzgtMS0xLTEtMA_ea58b4c3-c886-4d00-9407-4550c84064da">1,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZToyN2VjYjc4NGExNTU0ZmI5ODhlZGUzZTZkZjVhMzFjNi90YWJsZXJhbmdlOjI3ZWNiNzg0YTE1NTRmYjk4OGVkZTNlNmRmNWEzMWM2XzktMS0xLTEtMA_26e86eb6-618e-424c-879d-e25f9e0ea87b">58,332</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="fhtx:LeasesBalanceSheetLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzI3ODA_b5585392-2290-49c8-a22f-4acf2990ceed" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Included in the consolidated balance sheets (in thousands):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTpiODU1NWViNTJiMGQ0MjY1YWUzNmRhYTcxYzI0ZGUwZC90YWJsZXJhbmdlOmI4NTU1ZWI1MmIwZDQyNjVhZTM2ZGFhNzFjMjRkZTBkXzEtMS0xLTEtMA_effa934e-01ba-4f14-964c-12cdce7a4ef4">6,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTpiODU1NWViNTJiMGQ0MjY1YWUzNmRhYTcxYzI0ZGUwZC90YWJsZXJhbmdlOmI4NTU1ZWI1MmIwZDQyNjVhZTM2ZGFhNzFjMjRkZTBkXzItMy0xLTEtMzQ3MDU_987b9e50-7ec4-4fd2-8553-b75f18d8fb9b">3,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTpiODU1NWViNTJiMGQ0MjY1YWUzNmRhYTcxYzI0ZGUwZC90YWJsZXJhbmdlOmI4NTU1ZWI1MmIwZDQyNjVhZTM2ZGFhNzFjMjRkZTBkXzItMS0xLTEtMA_f9f18a16-6f4e-4f29-86bc-408a27f836a3">51,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTpiODU1NWViNTJiMGQ0MjY1YWUzNmRhYTcxYzI0ZGUwZC90YWJsZXJhbmdlOmI4NTU1ZWI1MmIwZDQyNjVhZTM2ZGFhNzFjMjRkZTBkXzMtMy0xLTEtMzQ3MDU_e36c846d-23fe-4ae3-8d82-77217b9e90be">58,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTpiODU1NWViNTJiMGQ0MjY1YWUzNmRhYTcxYzI0ZGUwZC90YWJsZXJhbmdlOmI4NTU1ZWI1MmIwZDQyNjVhZTM2ZGFhNzFjMjRkZTBkXzMtMS0xLTEtMA_f2350439-eaec-43ea-8431-b0f12ac3808b">58,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTpiODU1NWViNTJiMGQ0MjY1YWUzNmRhYTcxYzI0ZGUwZC90YWJsZXJhbmdlOmI4NTU1ZWI1MmIwZDQyNjVhZTM2ZGFhNzFjMjRkZTBkXzQtMy0xLTEtMzQ3MDU_e7bc8e09-7392-4b9c-b776-e150ebe1a6f1">62,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sublease agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2020, the Company entered into a <ix:nonNumeric contextRef="i51cd2ef8029b4e6eacda02334700de82_I20200430" name="us-gaap:LessorOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzEwOTk1MTE2MzA2MTI_bd2a7d4e-afea-45a3-8ab5-225024bf767a">two-year</ix:nonNumeric> sublease agreement to sublet approximately <ix:nonFraction unitRef="sqft" contextRef="i51cd2ef8029b4e6eacda02334700de82_I20200430" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzI1MDc_8df7c438-cb48-4c61-915f-e3e73a0c3e41">16,843</ix:nonFraction> square feet of office space under the New Lease, as amended, which began in July 2020. In February 2021, the Company entered into an amendment to the sublease to sublet approximately <ix:nonFraction unitRef="sqft" contextRef="ib0ecce1083f6481ead8d518a258a5e21_I20210228" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzYwNDczMTM5NTYzOTA_bc83f3ac-8a21-4f0d-b2a4-eb1cfd61d843">2,980</ix:nonFraction> square feet of additional office space to the sublessee for the remaining lease term. In July 2021, the Company entered into an amendment to, among other things, extend the sublease through November 30, 2022. As of December&#160;31, 2021, the remaining rent payments due to the Company under the amended sublease were $<ix:nonFraction unitRef="usd" contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzI2ODM_dcaf775c-f7e1-4ed2-a406-3ede4dd1ed55">1.9</ix:nonFraction> million. During the years ended December&#160;31, 2021 and 2020, the Company recorded other income of $<ix:nonFraction unitRef="usd" contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzI3MjQ_6f993554-0ac4-429b-b716-f84e928b4cf3">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzgyNDYzMzcyMTE4NTQ_667adcf2-ecca-4f09-ab1b-c67d5518da59">1.0</ix:nonFraction>&#160;million, respectively,  related to this sublease.</span></div></ix:continuation></ix:continuation><div id="i523559815e87485cb6a9895707f43a02_160"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjAvZnJhZzpkMTZlOTZkMDQ2MmE0ODA3OWY3NDZmYjY3YWMxMTIwZi90ZXh0cmVnaW9uOmQxNmU5NmQwNDYyYTQ4MDc5Zjc0NmZiNjdhYzExMjBmXzMyOTE_4e9e8bca-356a-4ae9-94c4-952d12a9ee60" continuedAt="i7d2de26abc9e4c2f9fb627165f4c3935" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i7d2de26abc9e4c2f9fb627165f4c3935" continuedAt="i67cff94167064107ac60c36b34db5100"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s commitments under its leases are described in Note&#160;11.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various exclusive and non-exclusive license agreements for certain technologies. Under the terms of these license agreements, the Company could be required to reimburse the licensors for patent expenses and remit amounts in the low single-digit as sales-based royalties upon the occurrence of specific events as outlined in the corresponding license agreements. The Company is also required to make annual license maintenance fees of less than $<ix:nonFraction unitRef="usd" contextRef="i3e3da7bbe9d045048732fcefce03b848_D20170731-20170731" decimals="-5" name="fhtx:AnnualLicenseMaintenanceFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjAvZnJhZzpkMTZlOTZkMDQ2MmE0ODA3OWY3NDZmYjY3YWMxMTIwZi90ZXh0cmVnaW9uOmQxNmU5NmQwNDYyYTQ4MDc5Zjc0NmZiNjdhYzExMjBmXzE3NTA_110611c3-d9f7-451b-a5f1-a4eb3b4845db">0.1</ix:nonFraction> million and pay up to $<ix:nonFraction unitRef="usd" contextRef="i3e3da7bbe9d045048732fcefce03b848_D20170731-20170731" decimals="-5" name="fhtx:MilestonesPayableUponEvent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjAvZnJhZzpkMTZlOTZkMDQ2MmE0ODA3OWY3NDZmYjY3YWMxMTIwZi90ZXh0cmVnaW9uOmQxNmU5NmQwNDYyYTQ4MDc5Zjc0NmZiNjdhYzExMjBmXzE4Njk_3c6c72b1-cea2-4460-80a7-5da62a6a7f2c">1.1</ix:nonFraction> million in regulatory milestones on each licensed product upon the occurrence of specific events as outlined in one of the license agreements. None of our product candidates utilize technologies covered by these licenses.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i67cff94167064107ac60c36b34db5100">From time to time, the Company may become involved in litigation or other legal proceedings. The Company is not currently a party to any material litigation or legal proceedings.</ix:continuation></span></div><div id="i523559815e87485cb6a9895707f43a02_163"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjMvZnJhZzowM2YxZTY2MGIxNmY0ZTFhODExMTRmZTA5MWE1YzQ1My90ZXh0cmVnaW9uOjAzZjFlNjYwYjE2ZjRlMWE4MTExNGZlMDkxYTVjNDUzXzI5Mg_7721f8ac-d88d-43b1-96fe-cccb60eb279e" continuedAt="i9dd30a7dbfe243ba963ad3f76e492281" escape="true">Defined Contribution Plan</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9dd30a7dbfe243ba963ad3f76e492281">The Company has a 401(k) defined contribution plan (the &#8220;401(k) Plan&#8221;) for its employees. Eligible employees may make pretax contributions to the 401(k) Plan up to statutory limits. There was no discretionary match made under the 401(k) Plan as of December&#160;31, 2021 and 2020.</ix:continuation></span></div><div id="i523559815e87485cb6a9895707f43a02_166"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjYvZnJhZzowMTJjOWRhYThhN2Q0NTU0OGFkNmYwMjgyNGNhNzg2Yy90ZXh0cmVnaW9uOjAxMmM5ZGFhOGE3ZDQ1NTQ4YWQ2ZjAyODI0Y2E3ODZjXzEwNjU_91afa315-003e-4081-b9d8-95d1e262627e" continuedAt="i3816c5d6bdf54cd4b24f523adb618acd" escape="true">Related Parties</ix:nonNumeric></span></div><ix:continuation id="i3816c5d6bdf54cd4b24f523adb618acd"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, the Company entered into a <ix:nonNumeric contextRef="ia71ec7897cbb4006827fd4c8d3854267_D20151001-20151031" name="fhtx:ServiceAgreementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjYvZnJhZzowMTJjOWRhYThhN2Q0NTU0OGFkNmYwMjgyNGNhNzg2Yy90ZXh0cmVnaW9uOjAxMmM5ZGFhOGE3ZDQ1NTQ4YWQ2ZjAyODI0Y2E3ODZjXzEwOTk1MTE2Mjg4NTM_e3a55fcb-fb18-432d-8789-832d8b4e2bbb">five-year</ix:nonNumeric> service agreement with Flagship Pioneering (&#8220;Flagship&#8221;), an affiliate of one of its stockholders, Flagship Venture Funds,to provide general and administrative services to the Company, including certain consulting services and the provision of employee health and dental benefit plans for the Company&#8217;s employees. The Company made cash payments to Flagship, for services received under this agreement, of $<ix:nonFraction unitRef="usd" contextRef="i5382aa2bf08f43e88b67b99daf3dd99c_D20200101-20201231" decimals="-5" name="fhtx:CashPaymentsRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjYvZnJhZzowMTJjOWRhYThhN2Q0NTU0OGFkNmYwMjgyNGNhNzg2Yy90ZXh0cmVnaW9uOjAxMmM5ZGFhOGE3ZDQ1NTQ4YWQ2ZjAyODI0Y2E3ODZjXzQ1Mw_4d2ade5d-b93c-4a3e-a200-07c2e51ef6ac">1.2</ix:nonFraction> million during the year ended December&#160;31, 2020. As of December&#160;31, 2021 and 2020, the Company had <ix:nonFraction unitRef="usd" contextRef="i75de76e7d13240f3891598dddc3f678b_I20211231" decimals="INF" name="us-gaap:AccountsPayableRelatedPartiesCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjYvZnJhZzowMTJjOWRhYThhN2Q0NTU0OGFkNmYwMjgyNGNhNzg2Yy90ZXh0cmVnaW9uOjAxMmM5ZGFhOGE3ZDQ1NTQ4YWQ2ZjAyODI0Y2E3ODZjXzUzNw_76e56631-15c5-4e5d-83ac-14758d131ddf"><ix:nonFraction unitRef="usd" contextRef="i4cc1a0a9e2cf453689f94cd708f119eb_I20201231" decimals="INF" name="us-gaap:AccountsPayableRelatedPartiesCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjYvZnJhZzowMTJjOWRhYThhN2Q0NTU0OGFkNmYwMjgyNGNhNzg2Yy90ZXh0cmVnaW9uOjAxMmM5ZGFhOGE3ZDQ1NTQ4YWQ2ZjAyODI0Y2E3ODZjXzUzNw_de3e4c66-e764-4bef-97bb-804557f4e0fc">no</ix:nonFraction></ix:nonFraction> accounts payable to Flagship for costs related to the service agreement. This agreement expired in 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, the Company entered into a <ix:nonNumeric contextRef="i0c734257926a48949b263d60cee94f38_D20151001-20151031" name="fhtx:ServiceAgreementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjYvZnJhZzowMTJjOWRhYThhN2Q0NTU0OGFkNmYwMjgyNGNhNzg2Yy90ZXh0cmVnaW9uOjAxMmM5ZGFhOGE3ZDQ1NTQ4YWQ2ZjAyODI0Y2E3ODZjXzEwOTk1MTE2Mjg4NjU_6dafd6b1-b8b2-40d1-909e-b31fa985bdfe">five-year</ix:nonNumeric> consulting agreement with a scientific founder of the Company who is also a board member and a shareholder. In October 2020, this agreement was extended to January&#160;1, 2022, and is subject to automatic <ix:nonNumeric contextRef="i69d3730be48141eba19fe94753d20597_D20220101-20220101" name="fhtx:ServiceAgreementRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjYvZnJhZzowMTJjOWRhYThhN2Q0NTU0OGFkNmYwMjgyNGNhNzg2Yy90ZXh0cmVnaW9uOjAxMmM5ZGFhOGE3ZDQ1NTQ4YWQ2ZjAyODI0Y2E3ODZjXzEwOTk1MTE2MzI5NzQ_d926fc35-fd32-41e9-a7b7-586401e0d918">one-year</ix:nonNumeric> renewal terms until terminated. During the years ended December&#160;31, 2021 and 2020, the Company paid the scientific founder $<ix:nonFraction unitRef="usd" contextRef="if2edac33103b46efba125b51d6b34c3f_D20210101-20211231" decimals="-5" name="fhtx:CashPaymentsRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjYvZnJhZzowMTJjOWRhYThhN2Q0NTU0OGFkNmYwMjgyNGNhNzg2Yy90ZXh0cmVnaW9uOjAxMmM5ZGFhOGE3ZDQ1NTQ4YWQ2ZjAyODI0Y2E3ODZjXzk1Ng_7939fe07-cc9b-45be-85c6-574f5389006f">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6d894474bd8940b28bf453d051db226a_D20200101-20201231" decimals="-5" name="fhtx:CashPaymentsRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjYvZnJhZzowMTJjOWRhYThhN2Q0NTU0OGFkNmYwMjgyNGNhNzg2Yy90ZXh0cmVnaW9uOjAxMmM5ZGFhOGE3ZDQ1NTQ4YWQ2ZjAyODI0Y2E3ODZjXzk2Mw_15229796-332b-4476-aa64-2b77d2095fdc">0.2</ix:nonFraction> million, respectively. As of December&#160;31, 2021 and 2020, the Company had less than $<ix:nonFraction unitRef="usd" contextRef="i273c56330b4b4f6abe4c85c7cd7fcd01_I20211231" decimals="-5" name="us-gaap:AccountsPayableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjYvZnJhZzowMTJjOWRhYThhN2Q0NTU0OGFkNmYwMjgyNGNhNzg2Yy90ZXh0cmVnaW9uOjAxMmM5ZGFhOGE3ZDQ1NTQ4YWQ2ZjAyODI0Y2E3ODZjXzE2NDkyNjc0NDE3ODI0_691a40ad-6227-4cad-8178-21a2362271d9">0.1</ix:nonFraction> million in accounts payable to this scientific founder.</span></div></ix:continuation><div id="i523559815e87485cb6a9895707f43a02_172"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i523559815e87485cb6a9895707f43a02_175"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:106%">ITEM&#160;9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, under the supervision and with the participation of our Principal Executive Officer (our Chief Executive Officer) and Principal Financial and Accounting Officer (our Chief Financial Officer), has evaluated the effectiveness of our disclosure controls and procedures as of period end. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e)&#160;and&#160;15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December&#160;31, 2021, our Principal Executive Officer and Principal Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of consolidated financial statements for external purposes in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Internal control over financial reporting is a process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer, and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pertain to the maintenance of records that accurately and fairly reflect in reasonable detail the transactions and dispositions of the assets of our company;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Provide reasonable assurances regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material adverse effect on our financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assessed our internal control over financial reporting as of December 31, 2021, the end of our fiscal year. Management based its assessment on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Management&#8217;s assessment included evaluation of elements such as the design and operating effectiveness of key financial reporting controls, process documentation, accounting policies, and our overall control environment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on this assessment, management has concluded that our internal controls over financial reporting were effective as of December&#160;31, 2021 and provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with GAAP. We reviewed the results of management&#8217;s assessment with the Audit Committee of our Board of Directors.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal control over financial reporting has inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements will not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Attestation Report of the Registered Public Accounting Firm</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Our report was not subject to attestation by our independent registered public accounting firm pursuant to the rules of the Securities and Exchange Commission for &#8220;emerging growth companies&#8221; that permit us to provide only management&#8217;s report in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No change in our internal control over financial reporting (as defined in Rules&#160;13a-15(f)&#160;and&#160;15d-15(f)&#160;under the Exchange Act) occurred during the three months ended December&#160;31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Internal Controls</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating the disclosure controls and procedures, management does not expect that our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Our management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud.</span></div><div id="i523559815e87485cb6a9895707f43a02_178"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9B.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><div id="i523559815e87485cb6a9895707f43a02_1887"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C. &#160;&#160;&#160;&#160;DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><div id="i523559815e87485cb6a9895707f43a02_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i523559815e87485cb6a9895707f43a02_184"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ITEM&#160;10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">OUR BOARD OF DIRECTORS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Below is a list of the names, ages as of March 10, 2022 and positions of the individuals who serve on our Board of Directors.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:57.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.948%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adrian Gottschalk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Douglas G. Cole, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Biller, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balkrishan (Simba) Gill, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigall Kadoch, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adam M. Koppel, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Mendelsohn, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ian F. Smith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In accordance with our amended and restated certificate of incorporation, our Board of Directors is divided into three classes of directors. At each annual meeting of stockholders, a class of directors will be elected for a three-year term to succeed the class whose terms are then expiring, to serve from the time of election and qualification until the third annual meeting following their election or until their earlier death, resignation or removal. Our directors are divided among the three classes as follows:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Class I directors are Scott Biller, Cigall Kadoch and Michael Mendelsohn, and their terms will expire at our 2024 annual meeting of stockholders. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Class II directors are Adrian Gottschalk, Adam Koppel and Ian F. Smith, and their terms will expire at our 2022 annual meeting of stockholders. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Class III directors are Douglas Cole and Simba Gill, and their terms will expire at our 2023 annual meeting of stockholders.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our amended and restated certificate of incorporation provides that the authorized number of directors may be changed only by resolution of our Board of Directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. The division of our Board of Directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">DIRECTOR BIOGRAPHIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Information concerning our directors is set forth below. The biographical description of each director includes the specific experience, qualifications, attributes and skills that led to the Board of Directors&#8217; conclusion at the time of filing of this Annual Report that each person listed below should serve as a director.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">DIRECTORS WITH TERMS EXPIRING IN 2022 (CLASS II DIRECTORS)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Adrian Gottschalk </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">has served as our President, Chief Executive Officer and as a member of our Board of Directors since May 2017. Prior to joining Foghorn and since 2004, Mr. Gottschalk worked at Biogen Inc. where he was most recently a Senior Vice President and Neurodegeneration Therapeutic Area Head from November 2015 to May 2017. In this role, he was responsible for the late-stage development and commercialization of medicines for Alzheimer&#8217;s disease, Parkinson&#8217;s disease, and amyotrophic lateral sclerosis, or ALS. Mr. Gottschalk holds a B.S. from Texas A&amp;M University, an MBA from the Sloan School of Management at the Massachusetts Institute of Technology and an M.S. from the joint Harvard Medical School / Massachusetts Institute of Technology Division of Health Sciences &amp; Technology (HST) Biomedical Enterprise Program. We believe that Mr. Gottschalk&#8217;s experience as our President and Chief Executive Officer along with over 15 years of experience in the biotechnology field provides him with the qualifications and skills necessary to serve as a member of our Board of Directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Adam M. Koppel, M.D., Ph.D., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">has served as a member of our Board of Directors since July 2017. Dr. Koppel currently serves as Managing Director of Bain Capital Life Sciences, which position he has held since June 2016. He had initially joined Bain Capital Public Equity in 2003 where he was a leader within the healthcare sector until mid-2014. During the period between mid-2014 and mid-2016, Dr. Koppel was at Biogen, where he served as Executive Vice President of Corporate Development and Chief Strategy Officer. Prior to initially joining Bain Capital in 2003, Dr. Koppel was an Associate Principal at McKinsey &amp; Co. in New Jersey where he served a variety of healthcare companies. Dr. Koppel currently sits on the boards </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of directors of Solid BioSciences, Dicerna Pharmaceuticals, Cerevel Therapeutics, Aptinyx and Viacyte. He has also previously served on the boards of Trevena and PTC Therapeutics. Dr. Koppel received an M.D. and Ph.D. in Neuroscience from the University of Pennsylvania School of Medicine. He also received an MBA from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Harvard University with an A.B. and A.M. in History and science. We believe Dr. Koppel is qualified to serve on our Board of Directors due to his background as an executive officer, director and venture capital investor in biopharmaceutical companies, as well as his scientific and medical background.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Ian F. Smith </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">has served as a member of our Board of Directors since April 2021. Mr. Smith currently serves as a Senior Advisor to Bain Capital Life Sciences, which position he has held since January 2021, Chair of the board of directors of Solid Biosciences since April 2020, Executive Chair of the board of directors of Viacyte, member of the board of directors of AavantiBio, and provides advisory and consulting services to these companies and other biotechnology companies. Prior to his current roles, Mr. Smith was Executive Vice President and Chief Operating Officer of Vertex Pharmaceuticals from September 2017 to January 2019 and prior to that served as Chief Financial Officer from October 2001 to September 2017. Prior to 2001, Mr. Smith was a partner in the Life Science and Technology Practice of the accounting firm Ernst &amp; Young LLP. Mr. Smith received a B.A. with honors in accounting and finance from Manchester Metropolitan (UK). We believe Mr. Smith is qualified to serve on our Board of Directors due to his knowledge and experience across multiple roles in the biotechnology industry.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">DIRECTORS WITH TERMS EXPIRING IN 2023 (CLASS III DIRECTORS)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Douglas Cole, M.D., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">has served as a member of our Board of Directors since October 2015. Dr. Cole joined Flagship Pioneering, which conceives, creates, resources and develops first-in-category bioplatform companies, in 2001, and is currently a Managing Partner focused on life science investments. Dr. Cole currently serves on the board of directors of Denali Therapeutics, Sigilon Therapeutics, Sana Biomedicine and a number of private companies. In the past five years, Dr. Cole served on the boards of directors of Quanterix Corporation and Editas Medicine. Dr. Cole received his M.D. from the University of Pennsylvania School of Medicine and his B.A. in English from Dartmouth College. We believe Dr. Cole is qualified to sit on our Board of Directors given his substantial experience as an investor in emerging biopharmaceutical and life sciences companies as well as his experience serving on the boards of directors of multiple public and private biopharmaceutical companies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Balkrishan (Simba) Gill, Ph.D., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">has served as a member of our Board of Directors since July 2017. Dr. Gill is the President, Chief Executive Officer and a member of the board of directors of Evelo Biosciences, which positions he has held since June 2015. In addition, Dr. Gill has served as the Executive Chairman of Blackfynn Inc. since 2015. Dr. Gill has also served as a venture partner at Flagship Pioneering, an innovation enterprise that conceives, creates, resources and develops first-in-category life sciences companies, since 2015. From 2016 to 2019, Dr. Gill served on the board of directors of Realm Therapeutics PLC. Dr. Gill received his Ph.D. from King&#8217;s College, London and his MBA from INSEAD. We believe Dr. Gill is qualified to serve on our Board of Directors due to his knowledge and experience in the venture capital and pharmaceutical industries.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">DIRECTORS WITH TERMS EXPIRING IN 2024 (CLASS I DIRECTORS)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Scott Biller, Ph.D., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">has served as a member of our Board of Directors since January 2020. Dr. Biller currently serves as a Senior Advisor for Agios Pharmaceuticals, where he previously served as the company&#8217;s Chief Scientific Officer from September 2010 to December 2019. Dr. Biller is also currently the sole proprietor of Biller Consulting, a consulting company serving the biopharmaceutical industry, and since December 2021 he has served as an Executive Venture Partner at the venture capital fund GV. From 2003 to 2010, Dr. Biller was Vice President and Head of Global Discovery Chemistry at the Novartis Institutes for Biomedical Research. Prior to that, Dr. Biller held the positions of Vice President, Pharmaceutical Candidate Optimization at the Bristol Myers Squibb, or BMS, Pharmaceutical Research Institute and Executive Director of Drug Discovery chemistry for the BMS research site in Lawrenceville, New Jersey. Since June 2020, Dr. Biller has served on the Board of Directors of Remix Therapeutics and, since February 2021, has served on the Board of Directors of Rome Therapeutics. Dr. Biller earned a S.B. degree from the Massachusetts Institute of Technology, a Ph.D. from Caltech and was an NIH Postdoctoral Fellow at Columbia University in natural product synthesis. We believe Dr. Biller is qualified to serve on our Board of Directors because of his extensive experience in drug discovery and development and his significant leadership experience in the biotechnology industry.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Cigall Kadoch, Ph.D., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our academic co-founder, has served as a member of our Board of Directors since March 2016. She is currently Associate Professor of Pediatric Oncology at the Dana-Farber Cancer Institute, which position she has held since January 2014. Dr. Kadoch also currently serves as Associate Professor of Pediatrics, Harvard Medical School, which she has held since April 2014 and as Institute Member and Epigenomics Program Co-Director at the Broad Institute of Massachusetts Institute of Technology and Harvard University, which she has held since April 2014. In September 2021, Dr. Kadoch was named a Howard Hughes Medical Institute Investigator. Dr. Kadoch received her B.A. from the University of California, Berkeley and her Ph.D. from Stanford University School of Medicine. We believe that Dr. Kadoch is qualified to serve on our Board of Directors due to her expertise and experience as our academic co-founder and her deep understanding of the role of chromatin regulation in human cancer and other serious diseases.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Michael Mendelsohn, M.D., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">has served as a member of our Board of Directors since April 2017. Dr. Mendelsohn is also member of the Board of Directors of Cyclerion Pharmaceuticals, where he has served since April 2019, as well as the Executive Chairman and President of Cardurion Pharmaceuticals, where he has served since May 2016. Since April 2015, Dr. Mendelsohn has also been a senior advisor and consultant to the chief medical and scientific officer of Takeda Pharmaceutical Co. Ltd. From December 2014 to December 2018, he served as senior advisor and consultant and a member of the pharmaceuticals advisory committee for the chief scientific officer and president of research and development at Ironwood Pharmaceuticals. From May 2014 to July 2017, Dr. Mendelsohn was a venture partner for SV Health Investors. Prior to that, from June 2010 to November 2013, Dr. Mendelsohn served as Senior Vice President and Global Head of Cardiovascular Research at Merck Research Laboratories. From 1993 to 2010, Dr. Mendelsohn was a faculty member at Tufts Medical Center and Tufts University School of Medicine, where he founded and was the executive director of the Molecular Cardiology Research Institute from 1997 to 2010 and served as Chief Scientific Officer from 2008 to 2010. Dr. Mendelsohn was previously a member of the cardiovascular faculty at Brigham and Women&#8217;s Hospital and Harvard Medical School. Dr. Mendelsohn received a B.A. from Amherst College and M.D. from Harvard Medical School. We believe Dr. Mendelsohn is qualified to serve on our Board of Directors because of his extensive experience as a clinician and scientist, along with experience and insights as an active advisor and consultant to leadership in research and development for multinational biopharmaceutical companies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Board Membership Criteria</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Nominating and Corporate Governance Committee is responsible for developing and recommending to our Board of Directors criteria for Board membership and, consistent with those criteria, recommending to the Board of Directors director candidates and nominees for the next annual meeting of stockholders. As reflected in our Corporate Governance Guidelines, it is the policy of the Board of Directors that all directors should possess the highest personal and professional ethics, integrity and values, and be committed to representing the long-term interests of the Company&#8217;s stockholders. The Board of Directors believes that each director should possess the requisite ability, judgment and experience to oversee the Company&#8217;s business, and should contribute to the overall diversity of the Board of Directors. The Board of Directors considers the qualifications of directors and director candidates individually and in the broader context of its overall composition and the Company&#8217;s current and anticipated future needs. Stockholders may also nominate persons to be elected as directors in accordance with our bylaws and applicable law. The Nominating and Corporate Governance Committee does not have a written policy regarding stockholder nominations, but it has determined that it is the practice of the committee to consider candidates proposed by stockholders if made in accordance with our bylaws.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Board Meetings and Attendance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Board of Directors held four meetings during the year ended December 31, 2021. Each of the directors attended at least seventy-five percent (75%) of the meetings of the Board of Directors and the committees of the Board of Directors on which he or she served during the year ended December 31, 2021 (in each case, which were held during the period for which he or she was a director and/or a member of the applicable committee and excluding any meetings in which a director was an interested party).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The non-employee directors met in executive session during each of the regularly scheduled Board of Directors meetings during the year ended December 31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Director Attendance at Annual Meeting of Stockholders</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">One director attended our 2021 annual meeting, which was held as a virtual-only meeting due to the ongoing COVID-19 pandemic.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Role of the Board in Risk Oversight</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Board of Directors has an active role, as a whole and also at the committee level, in overseeing the management of our risks. Our Board of Directors is responsible for general oversight of risks and regular review of information regarding our risks, including liquidity risks and operational risks. The compensation committee is responsible for overseeing the management of risks relating to our executive compensation plans and arrangements. The audit committee is responsible for overseeing the management of risks relating to accounting matters and financial reporting. The nominating and governance committee is responsible for overseeing the management of risks associated with the independence of our Board of Directors and potential conflicts of interest. Although each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire Board of Directors is regularly informed through discussions from committee members about such risks. Our Board of Directors believes its administration of its risk oversight function has not negatively affected our Board of Directors&#8217; leadership structure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">BOARD COMMITTEES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Board of Directors has established an audit committee, a compensation committee and a nominating and corporate governance committee, each of which operate pursuant to a charter adopted by our Board of Directors. The Board of Directors may also establish other committees from time to time to assist us and the Board of Directors in their duties. The composition and functioning of all of our committees comply with all applicable requirements of the Sarbanes-Oxley Act, the Nasdaq Stock Market and the Exchange Act. Each committee&#8217;s charter is available on the corporate governance section of our website at </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">https://foghorntx.com. Information contained on our website is not incorporated by reference into this prospectus, and you should not consider information contained on our website to be part of this prospectus or in deciding whether to purchase shares of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table describes which directors serve on each of the Board of Directors&#8217; committees.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.008%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Audit Committee</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compensation Committee</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nominating and Corporate Governance Committee</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adrian Gottschalk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Douglas G. Cole, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">X(1)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Biller, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balkrishan (Simba) Gill, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">X(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigall Kadoch, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adam M. Koppel, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">X(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Mendelsohn, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ian F. Smith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1) Chair of the committee</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Audit Committee</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Audit Committee is composed of Adam Koppel, Simba Gill and Michael Mendelsohn, with Dr. Koppel serving as Chair of the committee. The Board of Directors has determined that each member of the Audit Committee meets the independence requirements of Rule 10A-3 under the Exchange Act and the applicable listing standards of Nasdaq. The Board of Directors has determined that each of Drs. Koppel and Gill is an &#8220;audit committee financial expert&#8221; within the meaning of the SEC regulations and applicable listing standards of Nasdaq. The audit committee&#8217;s responsibilities include:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;        appointing, approving the compensation of, and evaluating the qualifications, performance and independence of our independent registered public accounting firm;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;        pre-approving all audit and permitted non-audit services to be performed by our independent registered public accounting firm;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;        overseeing the work of our independent registered public accounting firm, including through the receipt and consideration of reports from such firm;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;        reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly financial statements and related disclosures, including earnings releases;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;        reviewing and discussing with management and our independent registered public accounting firm any material issues regarding accounting principles and financial statement presentations;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;        coordinating our Board of Directors&#8217; oversight of our internal control over financial reporting, disclosure controls and procedures, code of business conduct and ethics, procedures for complaints and legal and regulatory matters;</span></div><div style="margin-top:6pt;text-indent:35.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;        discussing our risk management policies with management;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;        establishing policies regarding hiring employees from our independent registered public accounting firm and procedures for the receipt and retention of accounting related complaints and concerns;</span></div><div style="margin-top:6pt;text-indent:35.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;        meeting independently with our independent registered public accounting firm and management;</span></div><div style="margin-top:6pt;text-indent:35.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;        reviewing and approving any related person transactions;</span></div><div style="margin-top:6pt;text-indent:35.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;        overseeing our guidelines and policies governing risk assessment and risk management;</span></div><div style="margin-top:6pt;text-indent:35.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;        overseeing the integrity of our information technology systems, process and data;</span></div><div style="margin-top:6pt;text-indent:35.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;        preparing the audit committee report required by SEC rules;</span></div><div style="margin-top:6pt;text-indent:35.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;        reviewing and assessing, at least annually, the adequacy of the Audit Committee&#8217;s charter; and</span></div><div style="margin-top:6pt;text-indent:35.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;        performing, at least annually, an evaluation of the performance of the Audit Committee. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2021, the Audit Committee met four times.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Nominating and Governance Committee</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Nominating and Governance Committee is composed of Douglas Cole and Adam Koppel, with Dr. Cole serving as Chair of the committee. Our nominating and corporate governance committee&#8217;s responsibilities include:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        identifying individuals qualified to become members of our Board of Directors consistent with criteria approved by the board and receiving nominations for such qualified individuals;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        recommending to our Board of Directors the persons to be nominated for election as directors and to each of its committees;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        establishing a policy under which our shareholders may recommend a candidate to the nominating and corporate governance committee for consideration for nomination as a director;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        reviewing and recommending committee slates on an annual basis;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        recommending to our Board of Directors qualified candidates to fill vacancies on our Board of Directors;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        developing and recommending to our Board of Directors a set of corporate governance principals applicable to us and reviewing the principles on at least an annual basis;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        reviewing and making recommendations to our board with respect to our board leadership structure and board committee structure;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        reviewing, in concert with our Board of Directors, our policies with respect to significant issues of corporate public responsibility;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        making recommendations to our Board of Directors processes for annual evaluations of the performance of our Board of Directors, our chief executive officer and committees of our Board of Directors;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        overseeing the process for annual evaluations of our Board of Directors, chief executive officer and committees of our Board of Directors and certifying that performance of our chief executive officer and other members of executive management is being properly evaluated;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        considering and reporting to our Board of Directors any questions of possible conflicts of interest of members of our Board of Directors;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        providing new director orientation and continuing education for existing directors on a periodic basis;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        overseeing the maintenance and presentation to our Board of Directors of management&#8217;s plans for succession to senior management positions in the Company;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        reviewing and assessing, at least annually, the adequacy of the nominating and corporate governance committee&#8217;s charter; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        performing, on an annual basis, an evaluation of the performance of the nominating and corporate governance committee. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2021, the Nominating and Corporate Governance Committee met five times.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Compensation Committee</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Compensation Committee is composed of Simba Gill, Douglas Cole and Michael Mendelsohn, with Dr. Gill serving as Chair of the committee. The Board of Directors has determined that each member of the Compensation Committee is &#8220;independent&#8221; as defined under the applicable listing standards of Nasdaq and meets the independence criteria set forth in Rule 10C-1 under the Exchange Act. Our Compensation Committee&#8217;s responsibilities include:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        assisting our Board of Directors in developing and reviewing potential candidates for executive positions;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        reviewing our overall compensation strategy, including base salary, incentive compensation and equity-based grants;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        reviewing, determining and approving corporate, individual and other goals and objectives relevant to compensation of our chief executive officer and approving the compensation of the CEO;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        reviewing and approving the compensation of our other executive officers;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        reviewing and making recommendations to the Board of Directors with respect to director compensation;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        overseeing and administering our cash and equity incentive plans;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        reviewing, considering and selecting, to the extent determined to be advisable, a peer group of appropriate companies for purposing of benchmarking and analysis of compensation for our executive officers and directors;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        reviewing and approving all employment contract and other compensation, severance and change-in-control arrangements for our executive officers;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        recommending to our Board of Directors any stock ownership guidelines for our executive officers and non-employee directors;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        retaining, appointing or obtaining advice of a compensation consultant, legal counsel or other advisor, and determining the compensation and independence of such consultant or advisor;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        preparing, if required, the compensation committee report on executive compensation for inclusion in our annual proxy statement in accordance with the proxy rules;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        monitoring our compliance with the requirements of Sarbanes-Oxley relating to loans to directors and officers;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        overseeing our compliance with applicable SEC rules regarding shareholder approval of certain executive compensation matters;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        reviewing the risks associated with our compensation policies and practices;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        reviewing and assessing, at least annually, the adequacy of the compensation committee&#8217;s charter; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        performing, on an annual basis, an evaluation of the performance of the compensation committee. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2021, the Compensation Committee met five times.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Compensation Consultants</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a part of determining compensation for our executive officers and directors, the Compensation Committee engaged Pay Governance, LLC, or Pay Governance, as its independent compensation consultant during 2021. Pay Governance provided analysis and recommendations to the Compensation Committee regarding cash and equity compensation for such officers and directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In determining to engage Pay Governance, the Compensation Committee considered its independence, taking into consideration relevant factors, including the absence of other services provided to the Company, the amount of fees the Company paid to Pay Governance as a percentage of its respective total revenue, Pay Governance&#8217;s policies and procedures that are designed to prevent conflicts of interest, any business or personal relationship any individual compensation advisor has with an executive officer of the Company, any business or personal relationship any individual compensation advisor has with any member of the Compensation Committee and any stock of the Company owned by Pay Governance or its individual compensation advisors. The Compensation Committee determined, based on its analysis in light of all relevant factors, including the factors listed above, that the work of Pay Governance and its individual compensation advisors as compensation consultants to the Compensation Committee has not created any conflicts of interest, and that Pay Governance is independent pursuant to the independence standards set forth in the Nasdaq listing standards promulgated pursuant to Section 10C of the Exchange Act.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Delegation of Authority and the Role of Management</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Compensation Committee may delegate to subcommittees, consisting of one or more members of the Compensation Committee, any of the responsibilities of the full committee.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Chief Executive Officer makes compensation-related recommendations to the Compensation Committee with respect to annual base salary, target bonus opportunities and long-term incentive award grants for the named executive officers (other than himself). No member of the management team, including our Chief Executive Officer, has a role in determining his or her own compensation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Code of Ethics and Conduct</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of the code is posted on the investor section of our website. In addition, we intend to post on our website all disclosures that are required by law or listing rules concerning any amendments to, or waivers from, any provision of the code.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">OUR EXECUTIVE OFFICERS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Below is a list of the names, ages as of March 10, 2022, and positions, and a brief account of the business experience of the individuals who serve as our executive officers.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:45.912%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.824%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Age</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Position</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adrian Gottschalk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director (Class II)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allan Reine, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Samuel Agresta, M.D. </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Medical Officer</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steven Bellon, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Scientific Officer</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael LaCascia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Legal Officer</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fanny Cavalie</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Strategy and Business Operations Officer</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">EXECUTIVE OFFICER BIOGRAPHIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Biographical information for Adrian Gottschalk, our Chief Executive Officer and President, is included herein under &#8220;Director Biographies&#8212;Directors with Terms Expiring in 2022 (Class II Directors).&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Allan Reine, M.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">has served as our Chief Financial Officer since September 2019. Prior to joining Foghorn, Dr. Reine served as Chief Financial Officer of Pieris Pharmaceuticals from August 2017 to September 2019. From August 2012 through August 2017, Dr. Reine was a portfolio manager at Lombard Odier Asset Management, where he ran a healthcare portfolio focused on biotechnology and pharmaceutical companies. Before joining Lombard Odier, from 2003 through August 2012, Dr. Reine served as a healthcare portfolio manager at various funds, including Citi Principal Strategies, SAC Capital, Trivium Capital and Alexandra Investment Management. Dr. Reine began his career in 2001 at CIBC World Markets where he worked in both biotechnology investment banking and biotechnology equity research. Dr. Reine is currently a member of the board of directors of ONK Pharmaceuticals where he has served since March 2022. Dr. Reine received his M.D. from the University of Toronto and his B.S. in Statistical Sciences from the University of Western Ontario.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Steven Bellon, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, has served as our Chief Scientific Officer since January 2022. He previously served in the role of Senior Vice President, Drug Discovery, since October 2019, and prior to that served in the role of Vice President, Drug Discovery since June 2016. Prior to joining Foghorn, Dr. Bellon was Senior Director and Executive Director of Constellation Pharmaceuticals, starting in September 2008. At Constellation Pharmaceuticals, Dr. Bellon built the structural biology group and the bromodomain platform. Dr. Bellon has also held positions at Amgen and Vertex Pharmaceuticals and has more than 20 years of experience in drug discovery. Dr. Bellon received his B.S. from Haverford College and his Ph.D. from the Massachusetts Institute of Technology.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Samuel Agresta, M.D., M.P.H. &amp; T.M.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">has served as our Chief Medical Officer since September 2019. Prior to joining Foghorn, Dr. Agresta served as Chief Medical Officer of Infinity Pharmaceuticals from August 2018 to August 2019. Prior to that, Dr. Agresta was Vice President, Clinical Development of Agios Pharmaceuticals from December 2011 to August 2018. During that time, he led the development of the IDH inhibitors from drug candidate stage to FDA approval. Dr. Agresta is currently a member of the board of directors of Infinity Pharmaceuticals where he served since September 2019. Dr. Agresta received his B.S. from Georgetown University and his M.D. and M.P.H. &amp; T.M. from Tulane University.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Michael LaCascia </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">has served as our Chief Legal Officer since November 2020. Prior to joining Foghorn, Mr. LaCascia served as Senior Vice President and General Counsel from May 2019 to April 2020 and Chief Legal Officer from April 2020 through October 2020 of Q-State BioSciences, Inc. From January 2014 through October 2015, Mr. LaCascia was a Vice President, Corporate Legal at Vertex Pharmaceuticals Incorporated and later became Vertex&#8217;s Senior Vice President and General Counsel and Corporate Secretary from October 2015 through February 2019. Prior to his time at Vertex, Mr. LaCascia was an equity partner at WilmerHale and an adjunct lecturer at Boston University School of Law. Mr. LaCascia received his A.B. from Harvard College and his J.D. from Boston University School of Law.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Fanny Cavalie</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> has served as our Chief Strategy and Business Operations Officer since February 2022. She previously served in the role of Senior Vice President, Business and Operations, since August 2020, and prior to that served in the role of Vice President, Business and Operations, since March 2018.  Prior to joining Foghorn, Ms. Cavalie was Senior Director, Global Commercial Development Lead, Alzheimer's Disease at Biogen Inc., where she led the global marketing and new product planning team for a multiple-asset portfolio. Ms. Cavalie also worked for eleven years in the healthcare practice of McKinsey &amp; Company. Ms. Cavalie received her M.B.A. with a concentration in International Management from Hautes Etudes Commerciales Paris.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><div id="i523559815e87485cb6a9895707f43a02_187"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:152%">EXECUTIVE OFFICER AND DIRECTOR COMPENSATION </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:152%">Introduction</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This section provides an overview of the compensation awarded to, earned by, or paid to our principal executive officer and our next three most highly compensated executive officers, listed below, in respect of their service to us for the fiscal year ended December 31, 2021. We refer to these individuals as our named executive officers. Our named executive officers are:</span></div><div style="margin-top:6pt;text-indent:35.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        Adrian Gottschalk, our President and Chief Executive Officer;</span></div><div style="margin-top:6pt;text-indent:35.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        Allan Reine, M.D., our Chief Financial Officer;</span></div><div style="margin-top:6pt;text-indent:35.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        Carl Decicco, Ph.D., our former Chief Scientific Officer*;</span></div><div style="margin-top:6pt;text-indent:35.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;        Samuel Agresta, M.D., our Chief Medical Officer.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">* Dr. Decicco stepped down from his position as Chief Scientific Officer effective January 10, 2022, and served as a Special Advisor to our newly appointed Chief Scientific Officer until January 31, 2022, at which date he retired from the Company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Compensation Committee of our Board of Directors was responsible for determining the compensation of our executive officers during fiscal year 2021, subject, in the case of our Chief Executive Officer, to the approval of our Board of Directors. Our Chief Executive Officer made recommendations to the Compensation Committee about the compensation of his direct reports in respect of fiscal years 2021 and 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Summary Compensation Table</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth the compensation awarded to, earned by, or paid to our named executive officers in respect of their service to us for the fiscal years ended December 31, 2021 and 2020:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-indent:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:112%">Name and principal position </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-indent:11.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:112%">Salary</span></div><div style="text-indent:13.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:112%">($)(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-indent:12.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:112%">Bonus</span></div><div style="text-indent:13.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:112%">($)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center;text-indent:13.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:102%">Option awards</span></div><div style="text-align:center;text-indent:13.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:102%">&#160;($)(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:7.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:102%">Non-equity incentive plan compensation ($)(3)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center;text-indent:3.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:102%">All other compensation ($)(4)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-indent:11.8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:112%">Total ($)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:93%">Adrian Gottschalk </span></div><div style="text-indent:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:93%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:93%">&#160;President and Chief Executive Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;text-indent:2pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:93%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:89%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:89%">540,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:89%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:89%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:89%">3,370,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:89%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:89%">405,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:89%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:89%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:89%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:89%">4,315,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:90%">2020</span></td><td style="padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:90%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:90%">478,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:89%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:90%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:90%">1,834,007&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:90%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:90%">311,318&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:90%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:90%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:90%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:90%">2,624,275&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:90%">Allan Reine, M.D.</span></div><div style="text-indent:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:90%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:90%">&#160;&#160;Chief Financial Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:90%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">416,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:89%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">1,348,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">249,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt;text-indent:3.7pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">2,014,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt;text-indent:3.7pt"></td><td colspan="3" style="padding:0 1pt;text-indent:3.7pt"></td><td colspan="3" style="padding:0 1pt;text-indent:3.7pt"></td><td colspan="3" style="padding:0 1pt;text-indent:3.7pt"></td><td colspan="3" style="padding:0 1pt;text-indent:3.7pt"></td><td colspan="3" style="padding:0 1pt;text-indent:3.7pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">Carl Decicco, Ph.D</span></div><div style="text-indent:11.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:94%">Former Chief Scientific Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:94%">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">428,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:89%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">1,124,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">257,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">1,809,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">2020</span></td><td style="padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">412,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:89%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">542,224&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">214,240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">1,218,464&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">Samuel Agresta, M.D.</span></div><div style="text-indent:11.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:94%">Chief Medical Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">428,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:89%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">1,124,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">257,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">1,809,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">2020</span></td><td style="padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">412,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:89%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">542,224&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">99,573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="padding:2px 0 2px 1pt;text-align:left;text-indent:3.7pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:91%">1,053,797&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1)     The amount reported for Mr. Gottschalk and Drs. Reine, Decicco, and Agresta includes employee contributions made to</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          our 401(k) plan.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2)     The amounts reported represent the aggregate grant date fair value of options to purchase our common stock granted to</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          Mr. Gottschalk and Drs. Reine, Decicco and Agresta in fiscal year 2021 and/or 2020, computed in accordance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          with FASB ASC 718, excluding the effect of estimated forfeitures. The assumptions used to value the stock options for </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          this purpose are set forth in Note 8 to our consolidated financial statements included elsewhere in this Annual Report.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(3)     The amounts reported represent the annual bonus earned by each of the named executive officers for the relevant fiscal </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          year, to the extent applicable, based on the attainment of corporate performance goals as described below under &#8220;Annual</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          Bonuses.&#8221; </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(4)     The amount reported for Dr. Decicco reflects a travel and lodging allowance. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(5)     Dr. Decicco stepped down from his position as our Chief Scientific Officer effective January 10, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Narrative Disclosure to Summary Compensation Table</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Base Salary</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The letter agreement with each named executive officer, described below, establishes a base salary for the officer. For 2021, the base salaries of Mr. Gottschalk was $540,000 and Drs. Decicco and Agresta were $428,500. Mr. Reine's base salary for 2021 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $416,000. For 2022, Dr. Reine's base salary was increased to $435,000, and Dr. Agresta&#8217;s base salary was increased to $445,000.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Annual Bonuses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">With respect to fiscal year 2021, each of Mr. Gottschalk and Drs. Reine, Decicco and Agresta was eligible to receive an annual bonus, with the initial target amount of such bonus for each named executive officer set forth in his letter agreement with us, described below. For fiscal year 2021, the target bonus amount, expressed as a percentage of base salary, for each of Mr. Gottschalk and Drs. Reine, Decicco and Agresta was as follows: up to 50%, up to 40%, up to 40%, and up to 40%, respectively.  Annual bonuses for fiscal year 2021 for our named executive officers were based on the attainment of certain corporate performance goals as determined by the Compensation Committee, including those related to capital raising and financing, senior management recruitment, development of pipeline candidates, and research and development targets. For 2021, the compensation committee determined that, based on the level of attainment of the applicable corporate performance goals and other factors determined relevant by the committee, each eligible executive would be eligible to earn 150% of his bonus target. As a result, Mr. Gottschalk earned a bonus of $405,000, Dr. Reine earned a bonus of $249,600, Dr. Decicco earned a bonus of $257,100, and Dr. Agresta earned a bonus of $257,100.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Agreements With Our Named Executive Officers</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Each named executive officer is (or was, in the case of Dr. Decicco) party to an amended and restated letter agreement with us that sets forth the terms and conditions of his employment. The material terms of the agreements are described below. The terms &#8220;cause,&#8221; &#8220;good reason event&#8221; and &#8220;change of control&#8221; referred to below are defined in the respective named executive officer&#8217;s agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Mr. Gottschalk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. In connection with our initial public offering, we entered into an amended and restated letter agreement with Mr. Gottschalk that provides for an initial base salary of $478,950 per year and an initial target annual bonus of 50% of his annual base salary. The amended and restated letter agreement provides that, as long as he is our Chief Executive Officer, we will nominate Mr. Gottschalk to serve on our Board of Directors and he will serve as a member of our Board of Directors if elected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mr. Gottschalk also entered into an Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment of Inventions Agreement under which he has agreed not to compete with us during his employment and for 12 months following the termination of his employment, except for any termination due to layoff or without cause (as defined in this agreement), in exchange for garden leave pay during the post-employment non-competition period equal to 50% of his highest annual base salary during the two years prior to termination of his employment. We may elect to waive the post-employment non-competition period, in which case no garden leave pay would be due. Pursuant to the terms of this agreement, Mr. Gottschalk also has agreed to a perpetual obligation of confidentiality, the assignment of intellectual property, the protection and return of documents and other materials, and not to solicit our customers or business partners, or solicit or hire our employees or independent contractors, during his employment and for 12 months following termination of his employment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Dr. Reine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. In connection with our initial public offering, we entered into an amended and restated letter agreement with Dr. Reine that provided for an initial base salary of $400,000 per year and a target annual bonus of 40% of his annual base salary.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dr. Reine also entered into an Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment of Inventions Agreement, which has terms substantially similar to Mr. Gottschalk&#8217;s Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment of Inventions Agreement, as described above.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Dr. Decicco</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. In connection with our initial public offering, we entered into an amended and restated letter agreement with Dr. Decicco that provided for an initial base salary of $412,000 per year and a target annual bonus of 40% of his annual base salary.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dr. Decicco also entered into an Employee Non-Competition Agreement and an Employee Non-Solicitation, Confidentiality and Assignment of Inventions Agreement, which together have terms substantially similar to Mr. Gottschalk&#8217;s Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment of Inventions Agreement, as described above.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2022, Dr. Decicco entered into a Transition Agreement with the Company. Pursuant to the Transition Agreement, Dr. Decicco stepped down from his position as Chief Scientific Officer of the Company effective as of January 10, 2022, served as Special Advisor to the Company&#8217;s newly appointed Chief Scientific Officer through January 31, 2022, and retired from the Company on January 31, 2022 (the &#8220;Separation Date&#8221;). Dr. Decicco continued to receive his then-current base salary through the Separation Date and was eligible to receive an annual bonus based on the achievement of the pre-established performance objectives in respect of fiscal year 2021, which was earned and paid as described above. Under the Transition Agreement, any vested stock options held by Dr. Decicco as of the Separation Date will remain exercisable until July 5, 2022.In connection with entering into the Transition Agreement, Dr. Decicco signed a customary release of claims in favor of the Company.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Dr. Agresta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. In connection with our initial public offering, we entered into an amended and restated letter agreement with Dr. Agresta that provides for an initial base salary of $412,000 per year and a target annual bonus of 40% of his annual base salary. The amended and restated letter agreement also provided for repayment by Dr. Agresta if we terminate his employment for cause or if he resigns without good reason, in each case, prior to September 16, 2021, of a one-time transition payment of $65,000 previously paid to him.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dr. Agresta also entered into an Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment of Inventions Agreement, which has terms substantially similar to Mr. Gottschalk&#8217;s Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment of Inventions Agreement, as described above.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Severance Upon Termination of Employment; Change in Control.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Mr. Gottschalk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. If Mr. Gottschalk&#8217;s employment is terminated by us without cause or if he resigns for good reason outside of a change of control, he will be entitled to receive (i) severance in an amount equal to 12 months of his then-current base salary, payable in installments over six months; (ii) payment of the employer portion of COBRA premiums for 12 months, subject to his eligibility for, and timely election of, COBRA coverage; and (iii) any earned but unpaid bonus relating to the calendar year prior to the year of termination, payable at the same time bonuses otherwise are paid to active employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If Mr. Gottschalk&#8217;s employment is terminated by us without cause or if he resigns for good reason within the four months prior to or 12 months following a change of control, he will be entitled to receive (i) severance in an amount equal to 1.5 times the sum of (A) his then-current base salary plus (B) his target annual bonus for the year of termination, payable in installments over 12 months; (ii) payment of the employer portion of COBRA premiums for 18 months, subject to his eligibility for, and timely election of, COBRA coverage; (iii) any earned but unpaid bonus relating to the calendar year prior to the year of termination, payable at the same time bonuses otherwise are paid to active employees; and (iv) full acceleration of time-based stock options and other time-based equity awards.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Dr. Reine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. If Dr. Reine's employment is terminated by us without cause or if he resigns for good reason outside of a change of control, he will be entitled to receive (i) severance in an amount equal to nine months of his then-current base salary, payable in installments over nine months; (ii) payment of the employer portion of COBRA premiums for nine months, subject to his eligibility for, and timely election of, COBRA coverage; and (iii) any earned but unpaid bonus relating to the calendar year prior to the year of termination, payable at the same time bonuses otherwise are paid to active employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If Dr. Reine&#8217;s employment is terminated by us without cause or if he resigns for good reason within the three months prior to or 12 months following a change of control, he will be entitled to receive (i) severance in an amount equal to the sum of (A) his then-current base salary plus (B) his target annual bonus for the year of termination, payable in installments over 12 months; (ii) payment of the employer portion of COBRA premiums for 12 months, subject to his eligibility for, and timely election of, COBRA coverage; (iii) any earned but unpaid bonus relating to the calendar year prior to the year of termination, payable at the same time bonuses otherwise are paid to active employees; and (iv) full acceleration of time-based stock options and other time-based equity awards.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Dr. Agresta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. If Dr. Agresta&#8217;s employment is terminated by us without cause or if he resigns for good reason outside of a change of control, he will be entitled to receive (i) severance in an amount equal to nine months of his then-current base salary, payable in installments over nine months; (ii) payment of the employer portion of COBRA premiums for nine months, subject to his eligibility for, and timely election of, COBRA coverage; and (iii) any earned but unpaid bonus relating to the calendar year prior to the year of termination, payable at the same time bonuses otherwise are paid to active employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If Dr. Agresta&#8217;s employment is terminated by us without cause or if he resigns for good reason within the three months prior to or 12 months following a change of control, he will be entitled to receive (i) severance in an amount equal to the sum of (A) his then-current base salary plus (B) his target annual bonus for the year of termination, payable in installments over 12 months; (ii) payment of the employer portion of COBRA premiums for 12 months, subject to his eligibility for, and timely election of, COBRA coverage; (iii) any earned but unpaid bonus relating to the calendar year prior to the year of termination, payable at the same time bonuses otherwise are paid to active employees; and (iv) full acceleration of time-based stock options and other time-based equity awards.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Dr. Decicco</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Dr. Decicco had been entitled to receive certain severance benefits under his amended and restated employment agreement prior to his termination of employment. Under Dr. Decicco's Transition Agreement, any vested stock options held by Dr. Decicco as of the date he terminated employment with us will remain exercisable until July 5, 2022, and Dr. Decicco will remain eligible to participate in our health, dental and vision plans until December 31, 2022 as if his employment had not terminated.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Severance Subject to Compliance with Restrictive Covenant Obligations and Release of Claims</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Our obligation to provide severance payments and other benefits under each of the named executive officers&#8217; amended and restated letter agreements is conditioned on (i) the executive providing a timely and effective separation agreement containing a release of claims in favor of us; and (ii) the executive&#8217;s continued compliance with applicable restrictive covenant obligations, including any non-competition, non-solicitation and confidentiality restrictions.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Equity Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Each our of named executive officers received a grant of options to purchase our common stock in the fiscal year 2021 pursuant to the terms of the 2020 Equity Incentive Plan. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 28, 2021, Mr. Gottschalk and Drs. Reine, Decicco and Agresta were granted options to purchase 300,000, 120,000, 100,000 and 100,000 shares of our common stock, respectively, each of which option vests as to 25% of the underlying shares on January 28, 2022, and vests as to 6.25% of the underlying shares on the first day of each calendar quarter thereafter, for the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">subsequent 12 calendar quarters, generally subject to the applicable executive&#8217;s continued employment with us through the applicable vesting date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Severance and Change of Control Payments and Benefits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Each of our currently employed named executive officers is entitled to severance and change of control benefits pursuant to the terms of his amended and restated letter agreement as described above under &#8220;Agreements With Our Named Executive Officers.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Employee and Retirement Benefits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We currently provide broad-based health and welfare benefits, and certain commuter benefits, that are available to our full-time employees, including our currently employed named executive officers, including health, life, disability, vision and dental insurance. In addition, we maintain a 401(k) retirement plan for our full-time employees. The 401(k) plan permits us to make discretionary employer contributions. We did not make any employer contributions to the 401 (k) plan in 2019. Other than the 401(k) plan, we do not provide any qualified or non-qualified retirement or deferred compensation benefits to our employees, including our named executive officers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Outstanding Equity Awards at Fiscal Year-end Table</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth information about outstanding equity awards held by each of our named executive officers as of December 31, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-indent:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Name</span></div><div style="text-indent:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center;text-indent:49.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:102%">Number of securities underlying unexercised options exercisable (#)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:14.45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:102%">Number of securities underlying unexercised options unexercisable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(#)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center;text-indent:15.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:102%">Option exercise price ($/share)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center;text-indent:27.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:102%">Option expiration date</span></div></td></tr><tr style="height:14pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:2pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Adrian Gottschalk</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:84.9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">458,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;text-indent:49.8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;text-indent:15.1pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">0.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:22.9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">5/29/2027 (1)</span></td></tr><tr style="height:14pt"><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:84.9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">172,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:49.8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">78,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;text-indent:15.1pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">3.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:22.9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">2/20/2029 (2)</span></td></tr><tr style="height:14pt"><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">97,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:49.8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">213,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;text-indent:15.1pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">8.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:22.9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">8/17/2030 (3)</span></td></tr><tr style="height:14pt"><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:49.8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">300,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;text-indent:15.1pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">16.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:22.9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">1/27/2031 (4)</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allan Reine M.D.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">121,320&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;text-indent:49.8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">136,193&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="padding:2px 0 2px 1pt;text-align:left;text-indent:15.1pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">3.72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:22.9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">9/16/2029 (5)</span></td></tr><tr style="height:14pt"><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">28,717&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;text-indent:49.8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">63,174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="padding:2px 0 2px 1pt;text-align:left;text-indent:15.1pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">8.77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:22.9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">8/17/2030 (6)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;text-indent:49.8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">120,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="padding:2px 0 2px 1pt;text-align:left;text-indent:15.1pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">16.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:22.9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">1/27/2031 (7)</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Carl Decicco, Ph.D</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">69,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:49.8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">117,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;text-indent:15.1pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">3.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:22.9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">2/20/2029 (8)</span></td></tr><tr style="height:14pt"><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:54.3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">34,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;text-indent:15.1pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">3.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:22.9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">2/20/2029 (9)</span></td></tr><tr style="height:14pt"><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">28,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:54.3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">63,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;text-indent:15.1pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">8.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:22.9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">8/17/2030 (10)</span></td></tr><tr style="height:14pt"><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;text-indent:54.3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;text-indent:15.1pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">16.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:22.9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">1/27/2031 (11)</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Samuel Agresta, M.D</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">175,104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;text-indent:49.8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">136,193&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="padding:2px 0 2px 1pt;text-align:left;text-indent:15.1pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">3.72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:22.9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">9/16/2029 (12)</span></td></tr><tr style="height:14pt"><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">28,716&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;text-indent:54.3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">63,175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="padding:2px 0 2px 1pt;text-align:left;text-indent:15.1pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">8.77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:22.9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">8/17/2030 (13)</span></td></tr><tr style="height:14pt"><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;text-indent:54.3pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">100,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="padding:2px 0 2px 1pt;text-align:left;text-indent:15.1pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">16.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:22.9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">1/27/2031 (14)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1)     Represents an option to purchase 905,405 shares of our common stock, granted on May 30, 2017, which vested as to 25% </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          of the underlying shares on May 30, 2018, and vests as to 6.25% of the underlying shares on the first day of each calendar</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          quarter thereafter, for the subsequent 12 calendar quarters, generally subject to Mr. Gottschalk&#8217;s continued employment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          with us through the applicable vesting date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2)     Represents an option to purchase 250,697 shares of our common stock, granted on February 20, 2019, which vested as to</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">         25% of the underlying shares on January 30, 2020, and vests as to 6.25% of the underlying shares on the first day of each </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          calendar quarter thereafter, for the subsequent 12 calendar quarters, generally subject to Mr. Gottschalk&#8217;s continued</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          employment with us through the applicable vesting date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(3)     Represents an option to purchase 310,810 shares of our common stock, granted on August 18, 2020, which vested as to</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          25% of the underlying shares on August 17, 2021, and vests as to 6.25% of the underlying shares on the first day of each</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          calendar quarter thereafter, for the subsequent 12 calendar quarters, generally subject to Mr. Gottschalk&#8217;s continued </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          employment with us through the applicable vesting date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(4)     Represents an option to purchase 300,000 shares of our common stock, granted on January 28, 2021, which vested as to</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          25% of the underlying shares on January 28, 2022, and vests as to 6.25% of the underlying shares on the first day of each </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          calendar quarter thereafter, for the subsequent 12 calendar quarters, generally subject to Mr. Gottschalk's continued </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          employment with us through the applicable vesting date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(5)     Represents an option to purchase 311,297 shares of our common stock, granted on September 17, 2019, which vested as </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          to 25% of the underlying shares on September 16, 2020, and vests as to 6.25% of the underlying shares on the first day of </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          each calendar quarter thereafter, for the subsequent 12 calendar quarters, generally subject to Dr. Reine&#8217;s continued</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          employment with us through the applicable vesting date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(6)     Represents an option to purchase 91,891 shares of our common stock, granted on August 18, 2020, which vested as to</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          25% of the underlying shares on August 17, 2021, and vests as to 6.25% of the underlying shares on the first day of each </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          calendar quarter thereafter, for the subsequent 12 calendar quarters, generally subject to Dr. Reine&#8217;s continued</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          employment with us through the applicable vesting date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(7)     Represents an option to purchase 120,000 shares of our common stock, granted on January 28, 2021, which vested as to</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          25% of the underlying shares on January 28, 2022, and vests as to 6.25% of the underlying shares on the first day of each</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          calendar quarter thereafter, for the subsequent 12 calendar quarters, generally subject to Dr. Reine's continued</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          employment with us through the applicable vesting date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(8)     Represents an option to purchase 468,378 shares of our common stock, granted on February 20, 2019, which vested as to </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          25% of the underlying shares on December 10, 2019, and vested as to 6.25% of the underlying shares on the first day of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          each calendar quarter thereafter, for the subsequent 12 calendar quarters, generally subject to Dr. Decicco&#8217;s continued</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          employment with us through the applicable vesting date. The unvested portion of this option, together with the unvested</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          portion of other options held by Dr. Decicco, terminated in connection with his termination of employment.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(9)     Represents an option to purchase 109,673 shares of our common stock, granted on February 20, 2019, which vested as to</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          25% of the underlying shares on January 30, 2020, and vested as to 6.25% of the underlying shares on the first day of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          each calendar quarter thereafter, for the subsequent 12 calendar quarters, generally subject to Dr. Decicco&#8217;s continued </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          employment with us through the applicable vesting date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(10)   Represents an option to purchase 91,891 shares of our common stock, granted on August 18, 2020, which vest as to 25% </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          of the underlying shares on August 17, 2021, and vested as to 6.25% of the underlying shares on the first day of each</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          calendar quarter thereafter, for the subsequent 12 calendar quarters, generally subject to Dr. Decicco&#8217;s continued </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          employment with us through the applicable vesting date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(11)   Represents an option to purchase 100,000 shares of our common stock, granted on January 28, 2021, which vested as to </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          25% of the underlying shares on January 28, 2022, and vested as to 6.25% of the underlying shares on the first day of </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          each calendar quarter thereafter, for the subsequent 12 calendar quarters, generally subject to Dr. Decicco's continued</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          employment with us through the applicable vesting date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(12)   Represents an option to purchase 311,297 shares of our common stock, granted on September 17, 2019, which vested as </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          to 25% of the underlying shares on September 16, 2020, and vests as to 6.25% of the underlying shares on the first day of </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          each calendar quarter thereafter, for the subsequent 12 calendar quarters, generally subject to Dr. Agresta&#8217;s continued </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          employment with us through the applicable vesting date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(13)   Represents an option to purchase 91,891 shares of our common stock, granted on August 18, 2020, which vest as to 25% </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          of the underlying shares on August 17, 2021, and vests as to 6.25% of the underlying shares on the first day of each </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          calendar quarter thereafter, for the subsequent 12 calendar quarters, generally subject to Dr. Agresta&#8217;s continued</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          employment with us through the applicable vesting date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(14)   Represents an option to purchase 100,000 shares of our common stock, granted on January 28, 2021, which vested as to </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          25% of the underlying shares on January 28, 2022, and vests as to 6.25% of the underlying shares on the first day of each </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          calendar quarter thereafter, for the subsequent 12 calendar quarters, generally subject to Dr. Agresta's continued </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">          employment with us through the applicable vesting date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Director Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth information concerning the compensation awarded to, earned by, or paid to our non-employee directors during the fiscal year ended December 31, 2021. Mr. Gottschalk&#8217;s compensation for 2021 is included with that of our other named executive officers above.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.988%"><tr><td style="width:1.0%"></td><td style="width:28.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.378%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:16.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span><br/></span></div><div style="text-indent:4.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:112%">Name</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Fees Earned or Paid in Cash ($)(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:6.65pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:71%">Option Awards</span></div><div style="text-align:center;text-indent:6.65pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">($)(2)(3)(4)(5)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">All other compensation ($)(6)(7)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span><br/></span></div><div style="text-align:center;text-indent:12.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:112%">Total ($)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:4.35pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">Jose Baselga, M.D., Ph.D</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">11,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">104,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.35pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">Douglas Cole, M.D.</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">99,656&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">75,127&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">174,783&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:4.35pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Simba Gill, Ph.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">52,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">75,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">127,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.35pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">Cigall Kadoch, Ph.</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">48,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">75,127&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">128,640&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">252,517&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:4.35pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Scott Biller, Ph.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">42,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">75,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">117,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.35pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Adam Koppel, M.D., Ph</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">54,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">75,127&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">129,127&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:4.35pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">Michael Mendelsohn, M.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">48,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">75,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">124,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.35pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">Ian Smith</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">23,722&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">195,490&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,446&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">299,659&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:93%">(1)    All cash fees payable in respect of Dr. Cole's board service are remitted to an affiliate of Flagship Pioneering, Inc.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:94%">(2)    In 2021, each of Drs. Cole, Gill, Kadoch, Biller, Koppel and Mendelsohn was granted an option to purchase 12,530 shares</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:94%">         of our common stock on July 13, 2021, following the 2021 annual meeting of stockholders.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:93%">(3)    Mr. Smith was granted an option to purchase 25,060 shares of our common stock on April 27, 2021 upon his appointment </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:93%">         to the Board of Directors.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:93%">(4)    The amounts reported represent the aggregate grant date fair value of options to purchase our common stock granted to</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">         our non-employee directors  in fiscal year 2021, computed in accordance with FASB ASC 718, excluding the effect of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">         estimated forfeitures. The assumptions used to value the stock options for this purpose are set forth in Note 8 to our </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">         consolidated financial statements included elsewhere in this Annual Report.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:93%">(5)    Non-employee directors who served on our Board of Directors during 2021 held the following unexercised stock options </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:93%">         as of December 31, 2021:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.789%"><tr><td style="width:1.0%"></td><td style="width:63.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.384%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number of Shares Underlying Stock Options (#)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:4.35pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">Jose Baselga, M.D., Ph.D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.35pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">Douglas Cole, M.D.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,530&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:4.35pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Simba Gill, Ph.D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.35pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">Cigall Kadoch, Ph.D</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,530&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:4.35pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Scott Biller, Ph.D</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.35pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Adam Koppel, M.D., Ph.D.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,124&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:4.35pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">Michael Mendelsohn, M.D.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.35pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:90%">Ian Smith</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,914&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:93%">(6)    Following the passing of Dr. Baselga in March 2021, the Board of Directors authorized the Company to make a one-time </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:93%">         cash payment in the amount of $92,406 to Dr. Baselga's estate.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:93%">(7)    The amounts reported in this column represent consulting fees earned by Dr. Kadoch and Mr. Smith in fiscal year 2021.</span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Consulting Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Each of Dr. Kadoch and Mr. Smith is party to a consulting agreement with us that sets forth the terms and conditions of certain consulting services provided by the applicable director.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Dr. Kadoch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. We entered into a consulting agreement with Dr. Kadoch, which as amended provides for an annual consulting fee of $225,000. Pursuant to the terms of the consulting agreement, Dr. Kadoch has agreed to a 10-year post-termination obligation of confidentiality, an assignment of intellectual property covenant, and not to compete with us or solicit our customers, business partners, employees or independent contractors during the term of the consulting agreement and for 12 months thereafter. In October 2020, the term of this agreement was extended to January 1, 2022, subject to automatic one-year renewal terms until terminated.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Mr. Smith</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  We entered into a consulting agreement with Mr. Smith, which provides for compensation in the form of an option to purchase up to 12,530 shares of our common stock at an option exercise price of $10.24 per share, the closing price of a share of our common stock on the date the option was granted. Pursuant to the terms of the consulting agreement, the option vests as to one-twelfth of the underlying shares on the first day of each month starting in August 2021, with the balance of then-unvested shares to vest on June 23, 2022. Pursuant to the terms of the consulting agreement, Mr. Smith has agreed to a perpetual obligation of confidentiality and an assignment of intellectual property covenant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Director Compensation Policy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Board of Directors adopted a non-employee director compensation policy in connection with our initial public offering. Under the non-employee director compensation policy, our non-employee directors are compensated as follows:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">each non-employee director receives an annual cash fee of $35,000 ($65,000 for the chair of our Board of Directors);</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">each non-employee director who is a member of the audit committee receives an additional annual cash fee of $7,500 ($15,000 for the audit committee chair);</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">each non-employee director who is a member of the compensation committee receives an additional annual cash fee of $5,000 ($10,000 for our compensation committee chair);</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">each non-employee director who is a member of the nominating and corporate governance committee or the science committee receives an additional annual cash fee of $4,000 ($8,000 for the nominating and corporate governance or science committee chair);</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">each non-employee director who is first elected or appointed to our Board of Directors after the our initial public offering is granted an option under the Foghorn Therapeutics Inc. 2020 Equity Incentive Plan, or the 2020 Plan, to purchase 25,060 shares of our common stock (but in no event will a non-employee director&#8217;s initial grant have a grant date fair value, determined in accordance with FASB ASC 718, that exceeds $600,000); and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">each non-employee director who has served as a member of our Board of Directors for at least a six-month period prior to the first meeting of our Board of Directors following the annual meeting of our stockholders is annually granted an option under the 2020 Plan to purchase 12,530 shares of our common stock (but in no event will a non-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">employee director&#8217;s annual grant have a grant date fair value, determined in accordance with FASB ASC 718, that exceeds $300,000).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The stock options granted to our non-employee directors will have a per share exercise price at least equal to the closing price of a share of our common stock on the date of grant and will expire not later than ten years after the date of grant. The stock option granted to a non-employee director upon his or her initial election to our Board of Directors will vest as to one-third of the underlying shares on each of the first three anniversaries of the date of grant, subject to such director&#8217;s continued service on our Board of Directors. The annual stock options granted to our non-employee directors will vest in full on the first anniversary of the date of grant, subject to the director&#8217;s continued service on our Board of Directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Each non-employee director is entitled to reimbursement for reasonable travel and other expenses incurred in connection with attending meetings of our Board of Directors and any committee on which he or she serves.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the terms of the 2020 Plan, the aggregate value of all compensation granted or paid to any director with respect to any calendar year, including awards granted under the 2020 Plan and cash fees or other compensation paid by us to such director outside of the 2020 Plan for his or her services as a director during such calendar year, is subject to a limit of $750,000 in the aggregate ($1,000,000 in the aggregate with respect to a director&#8217;s first year of service on our Board of Directors).</span></div><div id="i523559815e87485cb6a9895707f43a02_190"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth certain information as of February&#160;25, 2022 (unless otherwise specified), with respect to the beneficial ownership of our common stock by each person who is known to own beneficially more than 5% of the outstanding shares of common stock, each person currently serving as a director, each nominee for director, each named executive officer (as set forth in the Summary Compensation Table above) and all directors and executive officers as a group. The number of shares beneficially owned by each entity or person is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60 days of February 25, 2022, through the exercise of any stock options, warrants or other rights. Except as otherwise indicated, and subject to applicable common property laws, the persons in the table have sole voting and investment power with respect to all shares of common stock held by that person.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Shares of common stock subject to options, warrants or other rights that are now exercisable or are exercisable within 60 days after February&#160;25, 2022, are considered outstanding for purposes of computing the percentage ownership of the persons holding these options, warrants or other rights but are not to be considered outstanding for the purpose of computing the percentage ownership of any other person. As of February&#160;25, 2022, there were 41,421,964 shares of common stock outstanding. Unless otherwise indicated, the address for each beneficial owner is c/o Foghorn Therapeutics Inc., 500 Technology Square, Ste 700, Cambridge, MA 02139.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and address of beneficial owner 5% or greater stockholders:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds affiliated with Flagship Pioneering, Inc. (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,674,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Klarman Family Foundation (2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,139,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.17</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entities affiliated with Fidelity Investments (3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,484,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company (4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.66</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors and named executive officers:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adrian Gottschalk (5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.22</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Douglas G. Cole, M.D. (6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Biller, Ph.D. (7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balkrishan (Simba) Gill, Ph.D. (8)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigall Kadoch, Ph.D. (9)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,624,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.75</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adam M. Koppel, M.D., Ph.D. (10)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Mendelsohn, M.D. (11)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Samuel Agresta, M.D., M.P.H. &amp; T.M. (12)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allan Reine, M.D. (13)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carl Decicco (14)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.27</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ian Smith (15)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All executive officers and directors as a group (14 persons) (16)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,042,754&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.15</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">*              Represents beneficial ownership of less than one percent of our outstanding common stock.</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1)      Consists of (i) 9,330,878 shares of common stock held by Flagship Ventures Fund V, L.P. (&#8220;Flagship Fund V&#8221;); (ii) 1,491,441 shares of common stock held by Flagship Ventures Opportunities Fund I, L.P. (&#8220;Flagship Opportunities Fund I&#8221;); and (iii) 1,851,801 shares of common stock held by Flagship Pioneering Special Opportunities Fund II, L.P, (&#8220;Flagship Opportunities Fund II,&#8221; and together with Flagship Opportunities Fund I and Flagship Fund V, the &#8220;Flagship Funds&#8221;). Flagship Ventures Fund V General Partner LLC (&#8220;Fund V GP&#8221;) is the general partner of Flagship Fund V. Flagship Ventures Opportunities Fund I General Partner LLC (&#8220;Opportunities Fund I GP&#8221;) is the general partner of Flagship Opportunities Fund I. Flagship Ventures Opportunities Fund II General Partner LLC (&#8220;Opportunities Fund II GP&#8221;) is the general partner of Flagship Opportunities Fund II. Flagship Pioneering, Inc. (&#8220;Flagship Pioneering&#8221; and together with Opportunities Fund I GP, Opportunities Fund II GP, and Fund V GP, the &#8220;Flagship General Partners&#8221;) is the manager of Opportunities Fund II GP. Noubar B. Afeyan, Ph.D. is sole director of Flagship Pioneering and may be deemed to have voting and investment control over all shares held by Opportunities Fund II. In addition, Dr. Afeyan serves as the sole manager of Fund V GP and Opportunities Fund I GP and may be deemed to possess sole voting and investment control over all the shares held by Flagship Fund V and Opportunities Fund I. Neither Dr. Afeyan or the Flagship General Partners directly own any of the shares held by the Flagship Funds and each of the Flagship General Partners and Dr. Afeyan disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. The mailing address of the Flagship Funds is 55 Cambridge Parkway, Suite 800E, Cambridge, Massachusetts 02142. This information is based solely on a Schedule 13D filed by the Flagship Funds, the Flagship General Partners and Dr. Afeyan with the SEC on October 29, 2020.</span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2)      Consists of 2,139,639 shares of common stock held directly by the Klarman Family Foundation. Mr. Seth A. Klarman may be deemed to share beneficial ownership of such shares held by the Klarman Family Foundation, however he has no pecuniary interest therein. The mailing address for the Klarman Family Foundation is c/o KFO, LLC, P.O. Box 171627, Boston, Massachusetts 02117. This information is based solely on a Schedule 13G filed by The Klarman Family Foundation and Mr. Klarman with the SEC on February 4, 2021, which reported ownership as of December 31, 2020.</span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(3)      Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#8217; voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act of 1940 (&#8220;Fidelity Funds&#8221;) advised by Fidelity Management &amp; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research Company (&#8220;FMR Co&#8221;), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds&#8217; Boards of Trustees. Fidelity Management &amp; Research Company carries out the voting of the shares under written guidelines established by the Fidelity Funds&#8217; Boards of Trustees. The address for FMR LLC is 245 Summer Street, Boston, MA 02210. This information is based solely on Amendment No. 1 to Schedule 13G filed by FMR LLC and its affiliates with the SEC on February 9, 2022, which reported ownership as of December 31, 2021.</span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(4)&#160;&#160;&#160;&#160;Consists of 4,000,000 shares of common stock held directly by Eli Lilly and Company.  This information is based solely on a Schedule 13G filed by Eli Lilly and Company with the SEC on December 13, 2021.</span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(5)      Consists of (i) 25,225 shares of common stock held by the Adrian Gottschalk Living Trust, of which Mr. Gottschalk is the trustee, (ii) 300,000 shares of common stock held by the Adrian H. Gottschalk 2021 Grantor Retained Annuity Trust, of which Mr. Gottschalk is the trustee, and (iii) 146,479 shares of common stock and options to purchase 892,345 shares of common stock that are exercisable within 60 days of February&#160;25, 2022 held directly by Mr. Gottschalk.</span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(6)      Dr. Cole is a managing partner of Flagship Pioneering but has no voting or investment power with respect to the securities described in footnote 1. </span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(7)      Consists of options to purchase 53,209 shares of common stock that are exercisable within 60 days of February&#160;25, 2022.</span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(8)      Consists of options to purchase 189,188 shares of common stock that are exercisable within 60 days of February&#160;25, 2022. </span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(9)      Consists of (i) 3,329,379 shares of common stock held by the Cigall Kadoch Revocable Trust of 2021, of which Dr. Kadoch is the sole trustee, and (ii) 295,000 shares of common stock held directly by Dr. Kadoch.</span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(10)      Consists of options to purchase 94,594 shares of common stock that are exercisable within 60 days of February&#160;25, 2022. </span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(11)   Consists of options to purchase 94,594 shares of common stock that are exercisable within 60 days of February&#160;25, 2022.</span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(12)    Consists of options to purchase an aggregate of 285,469 shares of common stock exercisable within 60 days of February&#160;25, 2022.</span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(13)    Consists of (i) 53,784 shares of common stock held directly by Dr. Reine and (ii) options to purchase an aggregate of 237,936 shares of common stock that are exercisable within 60 days of February&#160;25, 2022.</span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(14)&#160;&#160;&#160;&#160;Consists of (i) 389,599 shares of common stock held directly by Dr. Decicco and (ii) options to purchase an aggregate of 138,172 shares of common stock that are exercisable within 60 days of February&#160;25, 2022.</span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(15)    Consists of (i) 72,072 shares of common stock held directly by Mr. Smith and (ii) options to purchase an aggregate of 33,720 shares of common stock that are exercisable within 60 days of February&#160;25, 2022.</span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(16)    Includes options to purchase an aggregate of 2,178,517 shares of common stock exercisable within 60 days of February&#160;25, 2022. Includes the securities beneficially owned by Dr. Decicco as set forth in footnote 13.</span></div><div id="i523559815e87485cb6a9895707f43a02_193"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Except as described below, there have been no transactions since January 1, 2021, in which we were a party, the amount involved exceeded or will exceed $120,000 and in which any related person had a direct or indirect material interest.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Consulting Agreement with Cigall Kadoch, Ph.D.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2015, we entered into a consulting agreement with Cigall Kadoch, Ph.D., our academic co-founder and a member of our Board of Directors, pursuant to which Dr. Kadoch provides advisory services related to the manufacturing and sale of products and services related to chromatin remodeling. Under the terms of the consulting agreement, Dr. Kadoch received a grant of 3,953,469 shares of our common stock. Additionally, we agreed to pay Dr. Kadoch a consulting fee of $150,000 per year payable in monthly installments in arrears beginning with the effective date of the consulting agreement, and we agreed to reimburse her for reasonable business expenses incurred in connection with the performance of the services under the agreement. In January 2019, we agreed to increase the consulting fee payable to Dr. Kadoch to $225,000 per year, payable in monthly installments in arrears.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, this agreement was extended to January 1, 2022, subject to automatic one-year renewal terms until terminated. During the years ended December 31, 2021 and 2020, we paid Dr. Kadoch $128,640 and $219,500, respectively, pursuant to this agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Indemnification Agreements and Directors&#8217; and Officers&#8217; Liability Insurance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have entered into indemnification agreements each of our directors and executive officers against certain liabilities, costs and expenses, and have purchased directors&#8217; and officers&#8217; liability insurance. We also maintain a general liability insurance policy which covers certain liabilities of directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Related Person Transactions Policy</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Board of Directors has adopted a written related person transaction policy setting forth the policies and procedures for the review and approval or ratification of related person transactions. This policy covers, with certain exceptions set forth in Item 404 of Regulation S-K under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we were or are to be a participant, where the amount involved exceeds $120,000 in any fiscal year and a related person had, has or will have a direct or indirect material interest, including without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit committee is tasked with considering all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm&#8217;s length transaction and the extent of the related person&#8217;s interest in the transaction.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Director Independence</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the rules of the Nasdaq Stock Market, independent directors must comprise a majority of a listed company&#8217;s board of directors within one year of the completion of its initial public offering. In addition, the Nasdaq Stock Market rules require that, subject to specified exceptions, each member of a listed company&#8217;s audit and compensation committees be independent and that director nominees be selected or recommended for the board&#8217;s selection by independent directors constituting a majority of the independent directors or by a nominating and corporate governance committee comprised solely of independent directors. Under the Nasdaq Stock Market rules, a director will only qualify as &#8220;independent&#8221; if, in the opinion of that company&#8217;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that such person is &#8220;independent&#8221; as defined under Nasdaq Stock Market rules and the Exchange Act rules.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Audit committee members must also satisfy the independence criteria set forth in Rule 10A-3 under the Exchange Act. In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board committee: (1) accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries or (2) be an affiliated person of the listed company or any of its subsidiaries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our Board of Directors has determined that each of our directors, with the exception of Dr. Kadoch and Messrs. Gottschalk and Smith, is an &#8220;independent director&#8221; as defined under applicable rules of the Nasdaq Stock Market, including, in the case of all the members of our audit committee with the exception of Dr. Cole, the independence criteria set forth in Rule 10A-3 under the Exchange Act, and in the case of all the members of our compensation committee, the independence criteria set forth in Rule 10C-1 under the Exchange Act and are &#8220;non-employee directors&#8221; as defined in Section 16b-3 of the Exchange Act. In making such determination, our Board of Directors considered the relationships that each such non-employee director has with our Company and all other facts and circumstances that our Board of Directors deemed relevant in determining his or her independence, including the beneficial ownership of our capital stock by each non-employee director. Mr. Gottschalk is not an independent director under these rules because he is our President and Chief Executive Officer. Each of Dr. Kadoch and Mr. Smith is not an independent director under these rules because of the amount Foghorn has paid to them under their respective consulting agreements.</span></div><div id="i523559815e87485cb6a9895707f43a02_196"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Principal Accountant Fees and Services</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We regularly review the services and fees of Deloitte &amp; Touche LLP, our independent registered public accounting firm. These services and fees are also reviewed by the Audit Committee on an annual basis. The aggregate fees billed for the fiscal years ended December 31, 2021 and 2020 for each of the following categories of services are as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.801%"><tr><td style="width:1.0%"></td><td style="width:46.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.134%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fee Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit Fees (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit-Related Fees (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All Other Fees (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Fees</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673,414&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,354,176&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1)      Audit fees in 2021 and 2020 consist of fees billed for professional services for the audit of our annual consolidated financial statements, the review of our interim consolidated financial statements included in our quarterly reports on Form 10-Q and other professional services normally provided in connection with statutory and regulatory filings, including the issuance of comfort letters and the issuance of consents on registration statements.</span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)      Audit Related Fees consist of fees billed for services provided in connection with our initial public offering.</span></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)      All Other Fees consist of an annual license fee for the use of accounting research software. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Audit Committee pre-approved 100% of services performed since the pre-approval policy was adopted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Audit Committee pre-approves all auditing services, internal control related services and permitted non-audit services (including the fees and terms thereof) to be performed by Deloitte &amp; Touche LLP. The Audit Committee may delegate pre-approval authority to one or more members of the Audit Committee consistent with applicable law and listing standards, provided that the decisions of such Audit Committee member or members must be communicated to the Audit Committee at its next scheduled meeting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><div id="i523559815e87485cb6a9895707f43a02_199"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i523559815e87485cb6a9895707f43a02_202"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;15.&#160;&#160;&#160;&#160;EXHIBIT AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">1. Financial Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a list of the financial statements included herein, see Index to the Consolidated Financial Statements on page&#160;<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i523559815e87485cb6a9895707f43a02_67">85</a> of this Annual Report on Form 10-K, incorporated into this Item by reference.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2. Financial Statement Schedules</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">3. Exhibits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits required by Item&#160;601 of Regulation S-K and Item&#160;15(b) of this Annual Report on Form 10-K are listed in the Exhibit Index immediately preceding the signature page of this Annual Report on Form&#160;10-K.</span></div><div id="i523559815e87485cb6a9895707f43a02_205"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i523559815e87485cb6a9895707f43a02_208"></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description of document</span></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520278568/d71549dex31.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520278568/d71549dex31.htm">Third Amended and Restated Certificate of Incorporation of Foghorn Therapeutics Inc.(Incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520278568/d71549dex31.htm"> 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-39634), filed on October 27, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520278568/d71549dex32.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520278568/d71549dex32.htm">Amended and Restated By-laws of Foghorn Therapeutics Inc. (Incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520278568/d71549dex32.htm"> 3.2 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-39634), filed on October 27, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex41.htm">4.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex41.htm">Specimen stock certificate evidencing shares of common stock (Incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex41.htm"> 4.1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-249264), as amended, filed on October 19, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex42.htm">4.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex42.htm">Amended and Restated Investors&#8217; Rights Agreement, by and among Foghorn Therapeutics Inc. and the investors party thereto, dated as of December</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex42.htm"> 18, 2018 (Incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Registration Statement on Form S-1 (File No.&#160;333-249264), as amended, filed on October 19, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex43.htm">4.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex43.htm">Amendment to the Investors&#8217; Rights Agreement and the Voting Agreement, dated December</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex43.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex43.htm">18, 2018, by and among Foghorn Therapeutics Inc. and the investors party thereto, dated as of April 17, 2020 (Incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex43.htm"> 4.3 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-249264), as amended, filed on October 2, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex44.htm">4.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex44.htm">Form of Warrant to Purchase Series</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex44.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex44.htm">A-2 Preferred Stock of the Registrant issued to Silicon Valley Bank, dated November 29, 2016 (Incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex44.htm"> 4.4 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-249264), as amended, filed on October 2, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520303604/d10278dex41.htm">4.5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520303604/d10278dex41.htm">Form of Warrant to Purchase Common Stock of the Registrant issued to Oxford Finance LLC (Incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520303604/d10278dex41.htm"> 4.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-39634), filed on November 25, 2020.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312521085777/d105868dex46.htm">4.6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312521085777/d105868dex46.htm">Description of Registrant&#8217;s Securities</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312521085777/d105868dex46.htm"> (Incorporated by reference to Exhibit 4.6 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2020 (File no. 001-39634), filed on March 18, 2021).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000162828021024887/ex41amendmenttoira.htm">4.7</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000162828021024887/ex41amendmenttoira.htm">Amendment to Amended and Restated Investors&#8217; Rights Agreement dated December 18, 2018, by and among Foghorn Therapeutics Inc. and the investors party thereto, dated as of December 10, 2021 (Incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000162828021024887/ex41amendmenttoira.htm"> 4.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-39634), filed on December 13, 2021).</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description of document</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex102.htm">10.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex102.htm">Lease Agreement by and between ARE-Tech Square, LLC and Foghorn Therapeutics Inc., dated October 23, 2019 (Incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-249264), as amended, filed on October 2, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex103.htm">10.2++</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex103.htm">Exclusive Collaboration and License Agreement, by and between Merck Sharp</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex103.htm"> &amp; Dohme Corp. and Foghorn Therapeutics Inc., dated as of July 2, 2020 (Incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-249264), as amended, filed on October 2, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex104.htm">10.3&#94;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex104.htm">Foghorn Therapeutics Inc. 2016 Stock Incentive Plan, as amended (Incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex104.htm"> 10.4 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-249264), as amended, filed on October 2, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex105.htm">10.4&#94;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex105.htm">Form of Stock Restriction Agreement under the Foghorn Therapeutics Inc. 2016 Stock Incentive Plan (Incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-249264), as amended, filed on October 2, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex106.htm">10.5&#94;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex106.htm">Form of Incentive Stock Option Grant Notice under the Foghorn Therapeutics Inc. 2016 Stock Incentive Plan (Incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-249264) filed on October 2, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex107.htm">10.6&#94;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex107.htm">Form of Non-Qualified Stock Option Grant Notice under the Foghorn Therapeutics Inc. 2016 Stock Incentive Plan (Incorporated by reference to Exhibit 10.7 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-249264), as amended, filed on October 2, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex108.htm">10.7</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex108.htm">Form of Indemnification Agreement between Foghorn Therapeutics Inc. and its directors and officers (Incorporated by reference to Exhibit 10.8 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-249264), as amended, filed on October 2, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex109.htm">10.8&#94;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex109.htm">Amended and Restated Letter Agreement between Foghorn Therapeutics Inc. and Adrian Gottschalk, dated October</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex109.htm"> 14, 2020 (Incorporated by reference to Exhibit 10.9 to the Registrant&#8217;s Registration Statement on Form S-1 (File No.  333-249264), as amended, filed on October 19, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1010.htm">10.9&#94;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1010.htm">Amended and Restated Letter Agreement between Foghorn Therapeutics Inc. and Samuel Agresta, M.D., M.P.H. &amp; T.M., dated October</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1010.htm"> 14, 2020 (Incorporated by reference to Exhibit 10.10 to the Registrant&#8217;s Registration Statement on Form S-1 (File No.  333-249264), as amended, filed on October&#160;19, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1011.htm">10.10&#94;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1011.htm">Amended and Restated Letter Agreement between Foghorn Therapeutics Inc. and Carl P. Decicco, Ph.D., dated October</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1011.htm"> 14, 2020 (Incorporated by reference to Exhibit 10.11 to the Registrant&#8217;s Registration Statement on Form S-1 (File No.  333-249264), as amended, filed on October 19, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1012.htm">10.11&#94;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1012.htm">Foghorn Therapeutics Inc. 2020 Equity Incentive Plan (Incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1012.htm"> 10.12 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-249264), as amended, filed on October 19, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1013.htm">10.12&#94;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1013.htm">Form of Incentive Stock Option Agreement under the Foghorn Therapeutics Inc. 2020 Equity Incentive Plan (Incorporated by reference to Exhibit 10.13 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-249264), as amended, filed on October 19, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1014.htm">10.13&#94;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1014.htm">Form of Non-Statutory Stock Option Agreement (Employees) under the Foghorn Therapeutics Inc. 2020 Equity Incentive Plan (Incorporated by reference to Exhibit 10.14 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-249264), as amended, filed on October 19, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1015.htm">10.14&#94;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1015.htm">Form of Non-Statutory Stock Option Agreement (Non-Employee Directors) under the Foghorn Therapeutics Inc. 2020 Equity Incentive Plan (Incorporated by reference to Exhibit 10.15 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-249264), as amended, filed on October 19, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1016.htm">10.15&#94;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1016.htm">Foghorn Therapeutics Inc. 2020 Employee Stock Purchase Plan (Incorporated by reference to Exhibit </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1016.htm">10.16 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-249264), as amended, filed on October 19, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description of document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1017.htm">10.16&#94;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1017.htm">Foghorn Therapeutics Inc. 2020 Cash Incentive Plan (Incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1017.htm"> 10.17 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-249264), as amended, filed on October 19, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1018.htm">10.17&#94;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1018.htm">Consulting Agreement between Foghorn Therapeutics Inc. and Cigall Kadoch, dated October</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520271564/d12441dex1018.htm"> 1, 2015 (Incorporated by reference to Exhibit 10.18 to the Registrant&#8217;s Registration Statement on Form S-1 (File No.  333-249264), as amended, filed on October 19, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312521085777/d105868dex1018.htm">10.18&#94;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312521085777/d105868dex1018.htm">Amendment to Consulting Agreement between Foghorn Therapeutics Inc. and Cigall </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312521085777/d105868dex1018.htm">Kadoch,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312521085777/d105868dex1018.htm"> dated October 29, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312521085777/d105868dex1018.htm">2020 (Incorporated by reference to Exhibit 10.18 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2020 (File No. 001-39634), filed on March 18, 2021).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000162828021016418/fhtx-20210630xex101.htm">10.19&#94;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000162828021016418/fhtx-20210630xex101.htm">Consulting Agreement between Foghorn Therapeutics Inc. and Ian F. Smith, dated as of June 23, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000162828021016418/fhtx-20210630xex101.htm"> (Incorporated by reference to Exhibit 10.1 to the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000162828021016418/fhtx-20210630xex101.htm">Registrant's Quarterly</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000162828021016418/fhtx-20210630xex101.htm"> Report on Form </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000162828021016418/fhtx-20210630xex101.htm">10-Q for the quarterly period ended June 30, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000162828021016418/fhtx-20210630xex101.htm"> (File No.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000162828021016418/fhtx-20210630xex101.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000162828021016418/fhtx-20210630xex101.htm">001-39634), filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000162828021016418/fhtx-20210630xex101.htm">August 10, 2021.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000162828021024887/ex101stockpurchaseagreement.htm">10.20</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000162828021024887/ex101stockpurchaseagreement.htm">Stock Purchase Agreement by and between Foghorn Therapeutics Inc. and Eli Lilly and Company, dated as of December 10, 2021 (Incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K (File No. 001-39634), filed on December 13, 2021).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1021-foghornxloxocollabo.htm">10.21++*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1021-foghornxloxocollabo.htm">Collaboration Agreement between Eli Lilly and Company and Foghorn Therapeutics Inc., dated as of December 10, 2021.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1022-aremploymentagreeme.htm">10.22&#94;*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1022-aremploymentagreeme.htm">Amended and Restated Letter Agreement between Foghorn Therapeutics Inc. and Allan Reine, M.D., dated October 14, 2020.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1023-employmentagreement.htm">10.23&#94;*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1023-employmentagreement.htm">Amended and Restated Letter Agreement between Foghorn Therapeutics Inc. and Steve Bellon, Ph.D., dated January 26, 2022.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1024-employmentagreement.htm">10.24&#94;*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1024-employmentagreement.htm">Amended and Restated Letter Agreement between Foghorn Therapeutics Inc. and Fanny Cavalie, dated January 27, 2022.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1025-employmentagreement.htm">10.25&#94;*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1025-employmentagreement.htm">Letter Agreement between Foghorn Therapeutics Inc. and Michael LaCascia, dated October 29, 2020.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1026-transitionagreement.htm">10.26&#94;*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1026-transitionagreement.htm">Letter Agreement between Foghorn Therapeutics Inc. and Carl Decicco, dated January 10, 2022.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1027-emplnoncomp.htm">10.27&#94;*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1027-emplnoncomp.htm">Form of Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement between Foghorn Therapeutics Inc. and each of its executive officers.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex211.htm">21.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex211.htm">List of Subsidiaries of Foghorn Therapeutics Inc. (Incorporated by reference to Exhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001822462/000119312520262469/d12441dex211.htm"> 21.1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-249264), as amended, filed on October 2, 2020).</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex23130503foghornconsent-2.htm">23.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex23130503foghornconsent-2.htm">Consent of Deloitte &amp; Touche LLP</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="fhtx-20211231xex311.htm">31.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="fhtx-20211231xex311.htm">Rule 13a&#8212;14(a) / 15d&#8212;14(a) Certification&#8212;Principal Executive Officer.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="fhtx-20211231xex312.htm">31.2*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="fhtx-20211231xex312.htm">Rule 13a&#8212;14(a) / 15d&#8212;14(a) Certification&#8212;Principal Financial Officer.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="fhtx-20211231xex321.htm">32.1**</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="fhtx-20211231xex321.htm">Section 1350 Certification&#8212;Principal Executive Officer.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="fhtx-20211231xex322.htm">32.2**</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="fhtx-20211231xex322.htm">Section 1350 Certification&#8212;Principal Financial Officer.</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial statements from the Annual Report on Form 10-K of the Company as of and for the period ended December 31, 2021, formatted in Extensible Business Reporting Language (XBRL): (i) Balance Sheets; (ii) Statements of Operations; (iii) Statements of Changes in Redeemable Preferred Stock and Stockholders&#8217; Equity; (iv) Statements of Cash Flows; and (v) Notes to Financial Statements.</span></td></tr></table></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith</span></div><div style="padding-left:36pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#94;&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan, contract or arrangement.</span></div><div style="padding-left:36pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Portions of this exhibit (indicated by asterisks) have been omitted because the Registrant has determined they are not material and would likely cause competitive harm to the Registrant if publicly disclosed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><div id="i523559815e87485cb6a9895707f43a02_211"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.925%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FOGHORN THERAPEUTICS INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March 10, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Allan Reine</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allan Reine</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer<br/>(Principal Accounting and Financial Officer)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i523559815e87485cb6a9895707f43a02_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each person whose individual signature appears below hereby authorizes and appoints Adrian Gottschalk and Allan Reine, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Adrian Gottschalk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director<br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adrian Gottschalk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Allan Reine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer<br/>(Principal Accounting and Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allan Reine, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Biller</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Biller, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Douglas Cole</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Douglas Cole, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Simba Gill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Simba Gill, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Cigall Kadoch</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cigall Kadoch, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Adam Koppel</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adam Koppel, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael Mendelsohn</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Mendelsohn, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Ian Smith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ian Smith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>2
<FILENAME>ex1021-foghornxloxocollabo.htm
<DESCRIPTION>EX-10.21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if2e95c9e2ab04959b9e0e4da068e3443_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Ex 10.21</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CERTAIN INFORMATION IDENTIFIED WITH &#91;***&#93; IN THIS EXHIBIT HAS BEEN OMITTED BECAUSE THE REGISTRANT HAS DETERMINED THAT THEY ARE NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COLLABORATION AGREEMENT</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">between</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ELI LILLY AND COMPANY</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">and</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FOGHORN THERAPEUTICS INC.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="if2e95c9e2ab04959b9e0e4da068e3443_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 1  DEFINITIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 2  GOVERNANCE AND JOINT STEERING COMMITTEE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">28</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.1</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Alliance Managers</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">28</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.2</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Project Leaders</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">29</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.3</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Joint Steering Committee</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">29</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.4</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">JSC Subcommittees</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">29</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.5</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Working Groups</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">30</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.6</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Function and Powers of the JSC and JSC Subcommittees</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">30</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.7</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Meetings</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">35</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.8</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Decisions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">36</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.9</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Authority</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">38</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2.10</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Discontinuation of JSC and JSC Subcommittees</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">38</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 3  RESEARCH PROGRAM</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">38</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.1</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Overview and Purpose</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">38</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.2</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Projects</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">39</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.3</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Research Program Responsibilities</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">40</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.4</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Research Term</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">40</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.5</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Research Plans</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">40</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.6</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Diligence Efforts</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">41</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.7</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Records&#59; Reports</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">41</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.8</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Research Program Funding</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">42</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.9</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Certain Standards Applicable to Work</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">42</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.10</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subcontracting</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">42</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.11</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Project Materials</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">43</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">3.12</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Technical Transfer Assistance</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">43</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.13&#160;&#160;&#160;&#160;&#91;***&#93;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 4  COLLABORATION TARGETS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">44</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.1</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Targets</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">44</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.2</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Targets</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">44</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.3</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Replacement Targets</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">45</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">4.4</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Discontinued Targets</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">46</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 5  LILLY-CONTROLLED PROGRAMS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">47</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.1</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Applicability</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">47</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.2</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lilly Rights and Responsibilities for Lilly-Controlled Products</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">47</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.3</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Development Plan for Lilly-Controlled Products</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">47</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.4</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Development Reports for Lilly-Controlled Products</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">48</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.5</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commercialization Plan for Lilly-Controlled Products</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">48</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.6</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Matters for Lilly-Controlled Products</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">48</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.7</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Adverse Event Reporting</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">49</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">i</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">5.8</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Diligence Efforts</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">49</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 6  JOINT PROGRAMS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">49</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.1</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Overview</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">49</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.2</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Foghorn Opt-Out Right for Selective BRM&#47;&#91;***&#93; Programs</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">49</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.3</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Foghorn Opt-In and Opt-Out Rights for Discovery Programs</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">50</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.4</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lilly Responsibilities</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">52</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.5</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Foghorn Active Participation in Non-Sales Force Joint Program Activities</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">52</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.6</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Foghorn Active Participation in Sales Force Joint Program Activities</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">53</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.7</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Joint Program Competencies</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">53</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.8</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Joint Program Development Plans and Commercialization Plans</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">58</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.9</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Independent Studies</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">58</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">6.10</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Matters for Joint Programs</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">59</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 7  LICENSE RIGHTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">60</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.1</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exclusive License Grant to Lilly</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">60</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.2</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Exclusive License Grants to Foghorn</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">60</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.3</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party Sublicenses</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">61</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.4</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Implied Rights</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">61</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.5</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Safe Harbor Research</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">61</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.6</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#91;***&#93;</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">61</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.7&#160;&#160;&#160;&#160;&#91;***&#93;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">62</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">7.8</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conduct of Activities Requiring Excluded Technology</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">63</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 8  EXCLUSIVITY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">63</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.1</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Foghorn Exclusivity Obligations</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">63</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.2</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lilly Exclusivity Obligations</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">64</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">8.3</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Transactions Involving Competing Programs</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">64</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 9  FEES, ROYALTIES, &#38; PAYMENTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">65</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9.1</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Upfront Payment</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">65</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9.2</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Equity Investment</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">65</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9.3</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Gross Margin and Expense Sharing for Joint Programs</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">65</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9.4</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Milestone Events and Payments</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">67</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9.5</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalties on Products</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">71</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9.6</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Method of Payment&#59; Currency Conversion</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">77</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9.7</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Records and Audits</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">78</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9.8</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Supply Price Confirmation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">79</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9.9</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Late Payments</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">79</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">9.10</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Taxes</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">79</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 10  INTELLECTUAL PROPERTY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">80</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.1</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Inventorship</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">80</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.2</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Ownership of Intellectual Property Rights</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">80</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.3</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Assignments of Intellectual Property Rights</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">81</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.4</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Independent Development</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">82</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ii</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.5</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Contribution of Licensed Foghorn Technology</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">82</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.6</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Patent Prosecution and Maintenance</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">82</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.7</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Infringement or Misappropriation by Third Parties</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">84</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.8</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Defense and Settlement of Third Party Claims</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">86</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.9</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Patent Extension</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">86</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.10</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CREATE Act</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">86</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">10.11</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Trademarks</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">87</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 11  REPRESENTATIONS, WARRANTIES AND COVENANTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">87</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.1</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mutual Representations and Warranties</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">87</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.2</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Foghorn Representations and Warranties</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">87</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.3</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mutual Covenants</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">90</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.4</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compliance</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">90</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">11.5</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disclaimer</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">93</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 12  INDEMNIFICATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">94</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">12.1</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnity</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">94</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 13  CONFIDENTIALITY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">95</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.1</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Proprietary Information</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">95</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.2</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Publicity</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">98</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">13.3</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">99</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 14  TERM &#38; TERMINATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">99</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.1</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">99</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.2</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination for Material Breach</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">100</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.3&#160;&#160;&#160;&#160;&#91;***&#93;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">100</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.4</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Lilly Option to Continue Agreement</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">101</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.5</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination by Lilly</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">101</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.6</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effects of Termination</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">101</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.7</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Survival</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">105</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">14.8</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bankruptcy Code</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">105</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 15  GOVERNING LAW&#59; DISPUTE RESOLUTION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">106</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.1</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">106</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.2</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disputes</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">106</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">15.3</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation&#59; Equitable Relief</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">107</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 16  RESERVED.</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">107</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article 17  MISCELLANEOUS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">107</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17.1</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement&#59; Amendment</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">107</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17.2</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Limitation of Liability</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">108</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17.3</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Independent Contractors</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">108</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17.4</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">108</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17.5</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">109</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17.6</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Use of Names</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">109</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17.7</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">109</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iii</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17.8</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Foghorn Change of Control</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">110</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17.9</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waivers</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">111</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17.10</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Force Majeure</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">111</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17.11</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Interpretation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">112</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17.12</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts&#59; Electronic Signatures</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">112</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17.13</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Expenses</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">112</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17.14</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Further Assurances</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">112</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17.15</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Third Party Beneficiary Rights</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">112</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17.16</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Construction</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">113</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17.17</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cumulative Remedies</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">113</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">17.18</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</a><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Extension to Affiliates</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#if2e95c9e2ab04959b9e0e4da068e3443_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">113</a></font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SCHEDULES</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:117pt;text-indent:-117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 1.30(a)&#160;&#160;&#160;&#160;Patents &#8211; Genus Claims&#47;Selective BRM Projects</font></div><div style="margin-bottom:6pt;padding-left:117pt;text-indent:-117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 1.30(b)&#160;&#160;&#160;&#160;Patents &#8211; Identified Patents&#47;Selective BRM &#38; &#91;***&#93; Projects</font></div><div style="margin-bottom:6pt;padding-left:117pt;text-indent:-117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 1.30(c)&#160;&#160;&#160;&#160;Patents &#8211; FHD-286&#47;609</font></div><div style="margin-bottom:6pt;padding-left:117pt;text-indent:-117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 1.35&#160;&#160;&#160;&#160;Critical Success Factors</font></div><div style="margin-bottom:6pt;padding-left:117pt;text-indent:-117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 1.61 &#160;&#160;&#160;&#160;FHD-286&#47;609</font></div><div style="margin-bottom:6pt;padding-left:117pt;text-indent:-117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 1.73&#160;&#160;&#160;&#160;Foghorn Platform</font></div><div style="margin-bottom:6pt;padding-left:117pt;text-indent:-117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 1.167&#160;&#160;&#160;&#160;Product-Specific Patents</font></div><div style="margin-bottom:6pt;padding-left:117pt;text-indent:-117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 1.217 &#160;&#160;&#160;&#160;Unavailable Targets</font></div><div style="margin-bottom:6pt;padding-left:117pt;text-indent:-117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.3&#160;&#160;&#160;&#160;Research Program Outline</font></div><div style="margin-bottom:6pt;padding-left:117pt;text-indent:-117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.9&#160;&#160;&#160;&#160;(Part A) &#8211; Good Research Practices</font></div><div style="margin-bottom:6pt;padding-left:117pt;text-indent:-117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.9&#160;&#160;&#160;&#160;(Part B) &#8211; Lilly Principles for Animal Care and Use for Third Party Organizations</font></div><div style="margin-bottom:6pt;padding-left:117pt;text-indent:-117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.10&#160;&#160;&#160;&#160;Pre-Approved Foghorn Subcontractors</font></div><div style="margin-bottom:6pt;padding-left:117pt;text-indent:-117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 3.11&#160;&#160;&#160;&#160;Materials Transfer Record</font></div><div style="margin-bottom:6pt;padding-left:117pt;text-indent:-117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 9.3.1(a)&#160;&#160;&#160;&#160;Cost Report</font></div><div style="margin-bottom:6pt;padding-left:117pt;text-indent:-117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 11.2&#160;&#160;&#160;&#160;Disclosures</font></div><div style="margin-bottom:6pt;padding-left:117pt;text-indent:-117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 11.2.4(a)&#160;&#160;&#160;&#160;Existing Patents</font></div><div style="margin-bottom:6pt;padding-left:117pt;text-indent:-117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 11.2.4(d)&#160;&#160;&#160;&#160;Licensed Patents</font></div><div style="margin-bottom:6pt;padding-left:117pt;text-indent:-117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 11.2.10&#160;&#160;&#160;&#160;Regulatory Documentation</font></div><div style="padding-left:117.35pt;text-indent:-117.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 13.2&#160;&#160;&#160;&#160;Press Release</font></div><div style="padding-left:108pt;text-indent:-108pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iv</font></div></div></div><div id="if2e95c9e2ab04959b9e0e4da068e3443_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COLLABORATION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into as of December 10, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Execution Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foghorn Therapeutics Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a corporation organized and existing under the laws of Delaware, with its principal business office located at 500 Technology Square, Suite 700, Cambridge, Massachusetts 02139, U.S.A. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Foghorn</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Eli Lilly and Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a corporation organized and existing under the laws of Indiana, with its principal business office located at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Lilly</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Lilly and Foghorn are each hereafter referred to individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and together as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Foghorn is a biopharmaceutical company that has developed the Foghorn Platform (as further defined below)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Lilly is a pharmaceutical company engaged in the research, development, manufacturing, marketing and distribution of pharmaceutical products, including therapeutic products&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Foghorn has identified or will identify certain compounds which are Directed To (as defined below) the Selective BRM Target, &#91;***&#93; Target and &#91;***&#93; Target&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Foghorn and Lilly desire to collaborate to use Foghorn&#8217;s proprietary technologies, including the Foghorn Platform, to discover, generate, optimize, and select additional compounds which are Directed To Collaboration Targets (as defined below) such that Lilly could select a compound for further development to formulate products (for commercialization) containing or comprising such compounds as active pharmaceutical ingredients Directed To the applicable Collaboration Target&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Foghorn and Lilly desire to engage in joint development and commercialization programs with respect to certain of such compounds and products, and to share in certain expenses and revenues incurred or derived in connection with such programs&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, Lilly desires to obtain from Foghorn, and Foghorn desires to grant to Lilly, certain exclusive license rights to develop Compounds and develop, manufacture, and commercialize Products Directed To Collaboration Targets, subject to the terms and conditions of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Now, Therefore</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Article 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:27.73pt"><br><br>DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Capitalized terms used in this Agreement and the Schedules hereto shall have the following meanings (or the meanings ascribed to them elsewhere in this Agreement)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Acquirer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the definition of &#8220;Change of Control.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Additional Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to a Discovery Product and a particular country or jurisdiction, the receipt of Marketing Approval in such country or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">jurisdiction for such Discovery Product &#91;***&#93;, whether pursuant to the same or separate Marketing Approvals, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that all tumor types contained in a single Marketing Approval shall be considered a single &#8220;tumor type&#8221; for these purposes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Additional Project</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Additional Research Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 3.5.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Additional Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Additional Target Availability Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to any Person, any entity that, at the relevant time (whether as of the Effective Date or thereafter), directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with such Person, for so long as such control exists.  As used in this Section 1.7, &#8220;control&#8221; means&#58;  (a) to possess, directly or indirectly, the power to direct or cause the direction of the management or policies of an entity, whether through ownership of voting securities or by contract relating to voting rights or corporate governance&#59; or (b) direct or indirect ownership of more than fifty percent (50%) (or such lesser percentage that is the maximum allowed to be owned by a foreign entity in a particular jurisdiction) of the voting share capital or other equity interest in such entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 2.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the applicable provisions of any and all federal, national, supranational, regional, state and local laws, treaties, statutes, rules, regulations, guidelines or requirements, administrative codes, guidance, ordinances, judgments, decrees, directives, injunctions, orders, or permits of or from any court, arbitrator, Regulatory Authority, Governmental Authority, taxing authority, national securities exchange or exchange listing organization having jurisdiction over or related to the relevant subject item that may be in effect from time to time during the Term, including data protection and privacy laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means Lilly Background IP or Foghorn Background IP, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means individually or collectively, the Research Budget, Development Budget, and Commercialization Budget, as applicable. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means any day, other than any Saturday, Sunday, or any day that banks are authorized or required to be closed in Indianapolis, Indiana or Cambridge, Massachusetts.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Calendar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means each respective period of three (3) consecutive months ending on March&#160;31, June&#160;30, September&#160;30, and December&#160;31 of any Calendar Year.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Calendar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means each respective period of twelve (12) consecutive months commencing on January 1 and ending on December 31.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Candidate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means a Compound (a) that has achieved the Critical Success Factors for such Compound, and has successfully completed Dose-Finding Tox, in each case, as determined by the JRC or (b) with respect to which a GLP Toxicology Study has been initiated.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to either Party&#58; (a) the acquisition by a Third Party, whether in one transaction or a series of related transactions, of direct or indirect beneficial ownership of more than fifty percent (50%) of the outstanding voting equity securities of such Party&#59; (b) the acquisition by a Third Party, whether in one transaction or a series of related transactions, of majority control of the board of directors or equivalent governing body of such Party or the ability to cause the direction of the management or allocation of corporate resources of such Party&#59; (c) a merger or consolidation involving such Party, as a result of which a Third Party acquires direct or indirect beneficial ownership of more than fifty percent (50%) of the voting power of the surviving entity immediately after such merger, reorganization or consolidation&#59; or (d) a sale of all or substantially all of the assets of such Party in one transaction or a series of related transactions to a Third Party.  The acquiring or combining Third Party in any of (a), (b), (c) or (d), and any of such Third Party&#8217;s Affiliates (whether in existence as of or at any time following the applicable transaction, but other than the acquired Party and its Affiliates as in existence prior to the applicable transaction or Affiliates the acquired Party controls after the applicable transaction) are referred to collectively herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Acquirer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;&#59; &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section&#160;12.1.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means a human clinical trial, including a Phase I Clinical Trial, Phase II Clinical Trial or Phase III Clinical Trial, Phase IV Clinical Trial, or any post-Marketing Approval human clinical trial, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">CMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means a contract manufacturing organization.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Collaboration Targets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, individually or collectively, the Initial Targets, the Additional Targets (once selected and included in the Research Program pursuant to Section 4.2), and the Replacement Targets (once selected and included in the Research Program pursuant to Section&#160;4.3), but in each case excluding any Discontinued Targets.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Combination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the definition of &#8220;Net Sales.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to a Product, or other compound, product or therapy, the following activities&#58; (a) marketing, promoting, distributing, offering for sale, sale, having sold, importing, exporting or otherwise commercializing the Product, or other product, compound, or therapy&#59; and (b)&#160;activities, other than Research, Development and Manufacturing, in preparation for the foregoing activities&#59; &#91;***&#93;. When used as a verb, &#8220;to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Commercializing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means to engage in Commercialization and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Commercialized</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has a corresponding meaning.  For clarity, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; shall not include Research or any Manufacturing or Development activities. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Commercialization Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 6.8.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Commercialization Operational Competency Activity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 6.7.2(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to a Joint Program, a comprehensive written plan for the Commercialization of Products under such Joint Program, as approved by the JCC or the JSC in accordance with the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; of a Party means that level of reasonable, good faith efforts and resources commonly applied by such Party to carry out a particular task or obligation consistent with the general practice followed by such Party relating to other pharmaceutical compounds, products or therapies owned by it, or to which it has exclusive rights, which are of similar market potential at a similar stage in their development or product life, taking into account issues of safety and efficacy, product profile, the competitiveness of Third Party products in development and in the marketplace, supply chain management considerations, the proprietary position of the compound, product or therapy (including with respect to patent or regulatory exclusivity), the regulatory structure involved, the profitability of the applicable compound, product or therapy (including pricing and reimbursement status achieved), and other relevant technical, commercial, legal, scientific, regulatory or medical factors.  For clarity, &#8220;Commercially Reasonable Efforts&#8221; shall be determined on an indication-by-indication, Target-by-Target, product-by-product, and country-by-country basis within the Territory, and it is anticipated that the level of effort for different indications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Targets, products and countries may differ and may change over time, reflecting changes in the status of the Target, compound, product or therapy and the indications and country(ies) involved.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Competing Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section&#160;8.3(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#91;***&#93; has the meaning set forth in Section 8.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Compound</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means &#91;***&#93; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Confidential Proprietary Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 13.1.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Confidentiality Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the following agreements&#58; (a) that certain Confidentiality Agreement entered into between Foghorn and Lilly as of &#91;***&#93;, as it may be amended, (b) that certain Mutual Confidentiality Agreement entered into between Foghorn and Lilly as of &#91;***&#93;, as it may be amended, and (c) that certain Mutual Confidentiality Agreement entered into between Foghorn and Lilly as of &#91;***&#93;, as it may be amended. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to any Know-How, Patents, or other Intellectual Property Rights, that a Party has the legal authority or right (whether by ownership, license, or otherwise) to grant to the other Party a license, covenant not to sue, sublicense, access, or right to use (as applicable) under such Know-How, Patents, or other Intellectual Property Rights, on the terms and conditions set forth herein, in each case without violating any obligations of the granting Party owed to a Third Party, breaching the terms of any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">agreement with a Third Party, or subjecting the granting Party to any additional fee or charge&#59; &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Cover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Critical Success Factors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">CSFs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means the criteria that must be met in order for a Compound to be designated as a Candidate, &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to a Compound or Product, or other compound, product or therapy, (a) all clinical and non-clinical research and development activities (other than Research, Manufacture and Commercialization activities) conducted with respect to such Compound or Product, or other compound, product or therapy, including toxicology, pharmacology test method development and stability testing, process development, formulation development, delivery system development, quality assurance and quality control development, statistical analysis, Clinical Trials, including design and conduct of  Clinical Trials, and the preparation and submission of Regulatory Filings and all regulatory affairs related to the foregoing&#59; and (b) &#91;***&#93;. When used as a verb, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Developing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means to engage in Development and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Developed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has a corresponding meaning.  For clarity, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; shall not include any Research, Manufacture or Commercialization activities.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Development Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 6.8.3. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Development Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means, with respect to a Joint Program and subject to the terms of this Section 1.38, to the extent such costs are incurred by a Party during the Term following the applicable Joint Program Start Date (or with respect to the &#91;***&#93; Programs, following successful completion of Dose-Finding Tox for such programs) in the conduct of activities under a Joint Program and in accordance with this Agreement, the following worldwide (except with respect to Discovery Programs, which shall be limited to U.S. only) costs associated with Research activities pertaining to the applicable Compounds or with obtaining, maintaining and renewing Regulatory Filings and Marketing Approvals pertaining to the applicable Products&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">all &#91;***&#93; costs incurred by the Party &#91;***&#93;, as applicable (including the costs &#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">for any &#91;***&#93;, the &#91;***&#93; associated with &#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">to the extent not included in &#91;***&#93;, costs associated with &#91;***&#93;, including &#91;***&#93; and other &#91;***&#93; costs&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">all &#91;***&#93; costs that are not &#91;***&#93; costs, including, for example, &#91;***&#93; costs, &#91;***&#93; costs, &#91;***&#93; costs, &#91;***&#93; costs&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">all costs for other &#91;***&#93; or related to &#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.03pt">Third Party License Payments and payments pursuant to New Foghorn In-License Agreements and New Lilly In-License Agreements that are applicable to the activities under the Joint Program, in each case payable prior to Product Launch.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All such foregoing costs to the extent incurred during the Term by a Party or such Party&#8217;s Affiliates in the conduct of activities under a Joint Program hereunder (including the carrying out of any Research and Development activities (including the conduct of any Clinical Trials) allocated to such Party hereunder) shall be included in such Party&#8217;s Development Costs to the extent such costs are (i) on a Clinical Trial phase-by-Clinical Trial phase basis, not greater than &#91;***&#93; of the costs (as set forth in the then-current Development Budget) applicable to all activities for which such Party is responsible under the applicable Development Plan relating to that Clinical Trial phase (which for avoidance of doubt, includes costs of all activities in the Development Plan associated with the conduct of the Clinical Trial and all other activities customarily associated with such phase of the applicable Clinical Trial, such as CMC, quality control, regulatory matters, etc.), except to the extent such overages are attributable to activities performed by a Party for which the other Party was responsible under the applicable Development Plan but failed to perform, and (ii) with respect to Discovery Programs, associated with Research activities in the U.S. pertaining to the applicable Compounds (other than activities conducted under a Research Plan) or with obtaining, maintaining and renewing Regulatory Filings and Marketing Approvals pertaining to applicable Products in the U.S. only. For clarity, Development Costs are exclusive of and do not include any costs for which a Party is solely responsible under this Agreement (including under a Development Plan, if applicable). Except to the extent already included in Internal Qualified Expenses, Development Costs shall not include either Party&#8217;s costs to the extent they solely relate to activities associated with overseeing execution of and compliance with this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Development Operational Competency Activity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 6.7.2(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to a Joint Program, a comprehensive written plan for the Development of Products under such Joint Program, as approved by the JDC or the JSC in accordance with the terms of this Agreement. Such written plan shall describe fully the ongoing and proposed preclinical studies, toxicology work, Clinical Trials (including any required materials), product specifications and other key elements for obtaining Marketing Approval (including any elements requested by the JCC). The Parties understand that certain activities may include placeholder assumptions, as necessary in order to effectively estimate the applicable plan&#8217;s total scope. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.41</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Directed To</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section&#160;13.1.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Discontinued Project</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Discontinued Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means any of the following&#58; (a) a Target that was &#91;***&#93;&#59; (b) a Collaboration Target for which &#91;***&#93;&#59; or (c) a Collaboration Target for which &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Discovery Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means a Product arising from a Discovery Program.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.46</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Discovery Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, for each Discovery Project, the Discovery Project, and following the completion of the Discovery Project, the conduct of Exploitation activities under this Agreement with respect to any Product resulting from such Discovery Project.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.47</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Discovery Projects</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, individually or collectively, the Projects relating to the &#91;***&#93; Target, the Additional Targets, and any Replacement Targets (once added to the Research Program in accordance with this Agreement). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 15.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.49</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Dollar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means a U.S. dollar, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; is to be interpreted accordingly.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Dose-Finding Tox</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">DFT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to a Compound or Product, an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> dose-ranging study that is conducted prior to a multi-dose GLP Toxicology Study. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.51</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the Execution Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.52</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Eli Lilly and Company Animal Care and Use Requirement for Animal Researchers and Suppliers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 3.9.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.53</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Eli Lilly and Company Good Research Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 3.9.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.54</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#91;***&#93; has the meaning set forth in Section 7.6.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.55</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Excluded Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.56</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Executive Officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means (a) with respect to Foghorn, the Chief Executive Officer, and (b)&#160;with respect to Lilly, &#91;***&#93;&#59; or any other person that the relevant party designates from time to time. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.57</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Expense and Margin Sharing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 9.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.58</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Exploitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, individually or collectively, the Research, Development, registration, Manufacture, making, having made, use, storage, keeping, importation, exportation, transportation, promotion, marketing, distribution, offering for sale, sale or other exploitation or Commercialization of a Compound or Product or other compound, product or therapy.  When used as a verb, &#8220;to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Exploit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Exploiting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; mean to engage in Exploitation, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Exploited</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has a corresponding meaning.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">FD&#38;C Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the United States Federal Food, Drug and Cosmetic Act, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the United States Food and Drug Administration or any successor agency thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.61</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">FHD-286&#47;609</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, &#91;***&#93;, (a) the compounds with the chemical structures set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 1.61</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#59; &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means any and all purposes, including the diagnostic, prophylactic, and therapeutic treatment of any disease or medical condition in humans or animals.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.63</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Firewalls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means &#91;***&#93; safeguards established between &#91;***&#93;, on the one hand, and on the other hand, &#91;***&#93;, with the goal of ensuring that no &#91;***&#93; are accessible by &#91;***&#93; during the Firewall Period.  For purposes of this definition, &#8220;Firewalls&#8221; shall include, during the Firewall Period, as necessary to satisfy this definition&#58;  (a) &#91;***&#93; administrative safeguards between (i) on the one hand, &#91;***&#93; and (ii) on the other hand, &#91;***&#93;&#59; and (b) processes ensuring that (i) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.64</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Firewall Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 17.8.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.65</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Firewall Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to &#91;***&#93;, the period commencing on &#91;***&#93; and ending on &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the first invoice for commercial quantities of any Product sold to a Third Party by Lilly, its Affiliates or Sublicensees in any country after receipt of all Marketing Approvals (and Pricing and Reimbursement Approvals, outside the U.S.) for such Product in such country.  Supply for nominal consideration solely for test marketing, sampling and promotional uses, clinical trial purposes or compassionate or similar uses shall not be considered to constitute a First Commercial Sale.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.67</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Foghorn</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.68</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Foghorn Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.69</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#91;***&#93; has the meaning set forth in the definition of Foghorn Background IP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.70</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#91;***&#93; has the meaning set forth in the definition of Foghorn Background IP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.71</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#91;***&#93; has the meaning set forth in Section 6.5. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.72</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Foghorn Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means any Patent included in the Foghorn Technology.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.73</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Foghorn Platform</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means an integrated gene traffic control platform Controlled by or proprietary to Foghorn as of the Effective Date and during the term of this Agreement, known as the Gene Traffic Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Product Platform (aka GTC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Product Platform), which is based on production and assembly of chromatin regulatory system components that enable the discovery, identification and delivery of compounds that target disease with genetically determined dependencies in the chromatin regulatory system. &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.74</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Foghorn </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;&#8221; has the meaning set forth in Section 7.6.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.75</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Foghorn Platform-Related </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;&#8221; means &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.76</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Foghorn Program IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 10.2.2(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.77</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Foghorn Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, &#91;***&#93;included in Foghorn Technology unless &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.78</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.79</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">FTE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the equivalent of a full-time employee&#8217;s work performing activities under &#91;***&#93; which is at least &#91;***&#93; work hours per Calendar Year.  If any such individual works partially on work under &#91;***&#93; and partially on other work in a Calendar Quarter, then the &#8220;FTE&#8221; to be attributed to such individual&#8217;s work hereunder shall be calculated &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.80</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">FTE Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the rate of FTE costs incurred by a Party, which for the purpose of this Agreement is deemed to be &#91;***&#93; per FTE per Calendar Year through calendar year 2021 and which shall be increased (or decreased) each subsequent calendar year by the percentage change in the &#91;***&#93; from the prior year. The FTE Rate includes costs of salaries, benefits, supplies, and other employee costs, and supporting overhead and administrative allocations. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.81</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Generic Equivalent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">reference to a Product, any biologic or pharmaceutical product that is sold by a Third Party (other than a licensee of Lilly or any of its Affiliates or any Third Party that purchases such product in a chain of distribution that includes any of Lilly or its Affiliates or licensees) and that is approved for marketing and&#47;or sale by a Regulatory Authority in reliance on or using data from the Regulatory Filings for the Product that were submitted by Lilly, its Affiliates, or their licensees, and that meets the equivalency determination by the applicable Regulatory Authority in such country </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">as is necessary to permit substitution of such product for the Product under Applicable Law in such country</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.82</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">GLP Toxicology Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means, with respect to a Compound or Product, an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> toxicology study that is conducted in compliance with then-current Good Laboratory Practices. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.83</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Good Clinical Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">cGCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means all applicable current Good Clinical Practice standards for the design, conduct, performance, monitoring, auditing, recording, analysis and reporting of Clinical Trials, including, as applicable&#58;  (a) as set forth in the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">ICH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) E6 and any other guidelines for good clinical practice for trials on medicinal products in the Territory&#59; (b) the Declaration of Helsinki (2004) as last amended at the 52</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> World Medical Association in October 2000 and any further amendments or clarifications thereto&#59; (c) U.S. Code of Federal Regulations Title 21, Parts 50, 54, 56, 312 and 314, as may be amended from time to time&#59; and (d) the equivalent Applicable Laws in any relevant country, each as may be amended and applicable from time to time, and in each case (of (a)-(d)), that provide for, among other things, assurance that the clinical data and reported results are credible and accurate and protect the rights, integrity, and confidentiality of trial subjects. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.84</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Good Laboratory Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">GLPs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;  means the then-current standards for laboratory activities for pharmaceuticals, as set forth in the FDA&#8217;s Good Laboratory Practice regulations as defined in 21 C.F.R. Part 58, the Council Directive 87&#47;18&#47;EEC, as amended, the principles for Good Laboratory Practice and&#47;or the Good Laboratory Practice principles of the Organization for Economic Co-Operation and Development, and such standards of good laboratory practice as are required by the European Union and other organizations and governmental agencies in countries in which a Product is intended to be sold, to the extent such standards are not less stringent than United States Good Laboratory Practice. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.85</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Good Research Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">GRP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means research practices consistent with&#58;  (a) the research quality standards defining how Lilly&#8217;s research laboratories conduct good science for non-regulated work as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 3.9 Part A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> of this Agreement&#59; and (b) the Research Quality Association (RQA), 2014 Quality in Research Guidelines for Working in Non-Regulated Research&#59; (c) the WHO Quality Practices in Basic Biomedical Research Guidelines&#59; and (d) the equivalent Applicable Laws if any, in any relevant country, each as may be amended and applicable from time to time. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.86</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Government Official</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 11.4.8.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.87</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means any national, international, federal, state, provincial or local government, or political subdivision thereof, or any multinational organization or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, and any court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.88</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Gross Margin Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 9.3.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.89</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means an investigational new drug application filed with the FDA or any similar application filed with a Regulatory Authority in a country outside the U.S. required to commence Clinical Trials of a pharmaceutical product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.90</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">has the meaning set forth in Section&#160;12.1.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.91</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Indemnitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section&#160;12.1.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.92</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Independent Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 6.9.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.93</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Independent Study Regulatory Achievement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 6.9.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.94</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt"> &#91;***&#93; has the meaning set forth in Section 10.7.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.95</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Initial Discovery Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 9.4.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.96</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Initial Projects</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 3.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.97</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Initial Research Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 3.5.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.98</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Initial Targets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 3.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.99</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Initiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to a Clinical Trial, the first dosing in the first human subject in such Clinical Trial.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.100</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means any and all proprietary rights provided under&#58;  (a) patent law, including any Patents&#59; (b) copyright law&#59; (c) trademark law, or (d) any other applicable statutory provision or common law principle, including trade secret law, that may provide a right in ideas, formulae, algorithms, concepts, inventions (whether or not patentable), or Know-How, or the expression or use thereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.101</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Internal Qualified Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means any expenses incurred or accrued by a Party in the performance of activities directly related to the Development (including activities related to efforts to submit Regulatory Filings) or Commercialization of a Product, with personnel costs charged on a FTE Rate basis unless otherwise mutually agreed by the Parties&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that managerial, secretarial, clerical and administrative activities shall not be included within Internal Qualified Expenses&#59; and no Internal Qualified Expense will be counted multiple times in Development Costs, the Supply Price or U.S. Eligible Costs, as applicable. As used in this definition, the term &#8220;managerial&#8221; shall mean activities performed by individuals who are not (a) directly performing activities under this Agreement&#59; or (b) directly overseeing individuals directly performing activities under this Agreement (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, &#8220;managerial&#8221; activities include activities performed by individuals overseeing those that directly oversee individuals directly performing activities under this Agreement).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.102</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means all Know-How and inventions, whether or not patentable, including all rights, title and interest in and to the Intellectual Property Rights in all of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.103</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Iterated Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 3.13.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.104</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#91;***&#93; has the meaning set forth in Section 3.13.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.105</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">JCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section&#160;2.4. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.106</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">JDC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section&#160;2.4. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.107</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">JECC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section&#160;2.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.108</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Joint IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 10.2.2(c). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.109</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Joint Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 10.6.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.110</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Joint Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 6.1. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.111</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Joint Program Commercialization Operational Competencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> means, with respect to a Joint Program and a specific Commercialization activity allocated to Foghorn in the applicable Commercialization Plan, that Foghorn has sufficient resources, personnel, and infrastructure (including &#91;***&#93;) to conduct such specific Commercialization activity in accordance with the terms of this Agreement and the applicable Commercialization Plan and consistent with the scope of the activity allocated to Foghorn, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that such capabilities are at least consistent with those capabilities commonly applied by independent publicly traded Third Party biotechnology companies with a market capitalization in excess of &#91;***&#93; commercializing similar products for a substantially similar scope of activities without the support of other pharmaceutical companies, if any.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.112</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Joint Program Competencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to a Joint Program, the Joint Program Financial Competencies and the Joint Program Operational Competencies.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.113</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Joint Program Development Operational Competencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to a Joint Program and a specific Development activity allocated to Foghorn in the applicable Development Plan and to be conducted following the Initiation of the first Registrational Clinical Trial under such Joint Program, that Foghorn has sufficient resources, personnel, and infrastructure &#91;***&#93; to conduct such specific Development activity in accordance with the terms of this Agreement and the applicable Development Plan and consistent with the scope of the activity allocated to Foghorn, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that such capabilities are at least consistent with those capabilities commonly applied by independent publicly traded Third Party biotechnology companies with a market capitalization in excess of &#91;***&#93; developing similar products for a substantially similar scope of activities without the support of other pharmaceutical companies, if any.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.114</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Joint Program Financial Competencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to a Joint Program, that Foghorn has or has a reasonable expectation &#91;***&#93; of accessing sufficient financial resources &#91;***&#93; necessary to fund its share of the Expense and Margin Sharing with respect to the Development and Commercialization of Products under such Joint Program in accordance with the terms of this Agreement. For each determination of whether Foghorn has a reasonable expectation of accessing sufficient financial resources as described above &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.115</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Joint Program Operational Competencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to a Joint Program, the Joint Program Development Operational Competencies and the Joint Program Commercialization Operational Competencies. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.116</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Joint Program Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means Candidates and Products arising from a Joint Program.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.117</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Joint Program Start Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means (a) for the Selective BRM Program and the &#91;***&#93; Program, the Effective Date, except as may be modified pursuant to Article 16&#59; and (b) for the Discovery Programs, the date on which Foghorn elects to opt in to Expense and Margin Sharing for such Discovery Program under Section 6.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.118</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">JRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section&#160;2.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.119</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#91;***&#93; has the meaning set forth in Section 1.30.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.120</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section&#160;2.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.121</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">JSC Co-Chairpersons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 2.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.122</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">JSC Subcommittee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the subcommittees of the JSC as the JSC may establish from time to time pursuant to Section&#160;2.4, including the JRC, JDC, JCC, and JECC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.123</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means any proprietary scientific or technical information, inventions, discoveries, results and data of any type whatsoever, in any tangible or intangible form, including inventions, discoveries, databases, safety information, practices, methods, instructions, techniques, processes, drawings, documentation, specifications, formulations, formulae, knowledge, know-how, trade secrets, materials, skill, experience, test data and other information and technology applicable to formulations, compositions or products or to their </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">manufacture, development, registration, use, marketing or sale or to methods of assaying or testing them, including pharmacological, pharmaceutical, medicinal chemistry, biological, chemical, biochemical, toxicological and clinical test data, physical and analytical, safety, quality control data, manufacturing, and stability data, studies and procedures, and manufacturing process and development information, results and data.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.124</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Launch</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to a Product in any country in the Territory, the date of first shipment of the Product to a Third Party in such country for end use or consumption of the Product in such country after Marketing Approval of a Product to market and sell a Product in such country is received or, if earlier, the invoicing of a Third Party for such shipment, excluding, however, any shipment or invoicing or other distribution of a Product for use in (a) a Clinical Trial, compassionate use, named patient programs, sales under a treatment IND, test marketing, or any non-registrational studies&#59; (b) any similar instance where the Product is supplied at or below a Party&#8217;s cost of goods&#59; or (c) any other temporary, limited time, or limited quantity approval. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Launched</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; when used as an adjective shall have its correlative meaning.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.125</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Lilly</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.126</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Lilly Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.127</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Lilly Competitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means a company that&#58;  (a) has &#91;***&#93;&#59; and (b) either (i) has &#91;***&#93;, or (ii) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.128</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Lilly Compound-Related Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.129</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Lilly-Controlled Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 5.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.130</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Lilly Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section&#160;12.1.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.131</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#91;***&#93; has the meaning set forth in Section 6.5. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.132</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Lilly Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means any Patent within the &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.133</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Lilly Product Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.134</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Lilly Program IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 10.2.2(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.135</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#91;***&#93; has the meaning set forth in Section 7.6.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.136</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Litigation Settlement Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means any Third Party to which &#91;***&#93; has granted a license or sublicense to &#91;***&#93;, as a result of a settlement of &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.137</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Loss of Market Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 9.5.6.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.138</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section&#160;12.1.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.139</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Major European Country</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, &#91;***&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.140</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Major Market</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, individually, each of &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.141</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means all activities related to the production, manufacture, formulation, finishing, packaging, labeling, shipping and holding of any Compound or Product, or other compound, product or therapy, or any component, intermediary or precursor thereof (including, for clarity, expression vectors, cell lines, culture media and feeds), and including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial manufacture, quality assurance and quality control (including testing).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.142</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Marketing Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to a Product and a jurisdiction, all approvals, licenses, permits, notifications, registrations, clearances, authorizations, or waivers of any Regulatory Authority, that are necessary to initiate marketing and selling of the Product in the Field in the jurisdiction, including approval of an NDA or BLA and, where required, Pricing and Reimbursement Approval, and including any such approval that is an accelerated approval but not including approval that is in the nature of emergency use authorization.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.143</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Marketing Approval Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means an NDA or BLA or similar application or submission for a Product filed with a Regulatory Authority in a jurisdiction to obtain Marketing Approval for the Product in the jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.144</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Milestone Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 9.4.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.145</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 9.4.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.146</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">NDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means a New Drug Application (as more fully described in the FD&#38;C Act and any applicable regulations promulgated thereunder by the FDA), or any analogous application or submission with any Regulatory Authority outside of the United States.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.147</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Net</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means, with respect to a particular Product, the gross amount invoiced by Lilly or a Lilly Affiliate or any Sublicensee thereof to unrelated Third Parties, excluding any Sublicensee, for the Product in the Territory, less the following items consistent with U.S. Generally Accepted Accounting Principles (U.S. GAAP), consistently applied&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">&#91;***&#93; and &#91;***&#93; allowed&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">&#91;***&#93;, and any other &#91;***&#93; which effectively &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">Product &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Any &#91;***&#93; Product, including &#91;***&#93;, or the portion of the &#91;***&#93;, as applicable, allocates to &#91;***&#93; in accordance &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">&#91;***&#93; fees&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.03pt">&#91;***&#93; expenses&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Any other similar and customary deductions which are in accordance with U.S. GAAP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Such amounts shall be determined from the books and records of Lilly or its Affiliate or Sublicensee, maintained in accordance with U. S. GAAP or, in the case of Sublicensees, such similar accounting principles, consistently applied.  Lilly further agrees in determining such amounts, it will use Lilly&#8217;s then current standard procedures and methodology, including Lilly&#8217;s then current standard exchange rate methodology for the translation of foreign currency sales into U.S. Dollars or, in the case of Sublicensees, such similar methodology, consistently applied.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event that the Product is sold in the form of a combination product containing a Candidate and one or more other active compound(s), ingredient(s) and&#47;or device(s) that is each not a Candidate (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Other Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (whether combined in a single formulation or package, as applicable, or formulated separately but packaged under a single label approved by a Regulatory Authority and sold together for a single price) (such combination product, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Combination Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Net Sales of the Combination Product, for the purposes of determining royalty and commercial milestone payments and the Gross Margin Share, shall be determined by &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event that the weighted average sale price of a Product containing the Candidate that does not contain such Other Product can be determined but the weighted average sale price of the Other Product cannot be determined, Net Sales of the Combination Product for purposes of determining royalty and commercial milestone payments and the Gross Margin Share shall be &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event that the weighted average sale price of the Other Product can be determined but the weighted average sale price of a Product containing the Candidate that does not contain such Other Product cannot be determined, Net Sales of the Combination Product for purposes of determining royalty and commercial milestone payments and the Gross Margin Share shall be &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event that the weighted average sale price of both a Product containing the Candidate that does not contain such Other Product and such Other Product in the Combination Product cannot be determined, the Net Sales of the Combination Product for purposes of determining royalty and commercial milestone payments and the Gross Margin Share shall be &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The weighted average sale price for a Product containing the Candidate that does not contain such Other Product, an Other Product, or a Combination Product shall be calculated once each Calendar Year and such price shall be used during all applicable royalty reporting periods for the entire following Calendar Year. When determining the weighted average sale price of a Product containing the Candidate that does not contain such Other Product, an Other Product, or a Combination Product, the weighted average sale price shall be calculated by dividing the sales dollars (translated into U.S. dollars) by the units of active ingredient sold during the twelve (12) months (or the number of months sold in a partial Calendar Year) of the preceding Calendar Year for the respective Product containing the Candidate that does not contain such Other Product, the Other Product, or the Combination Product, as applicable. In the initial Calendar Year, a forecasted weighted average sale price will be used for the Product containing the Candidate that does not contain such Other Product, the Other Product, or the Combination Product. Any over or under payment due to a difference between forecasted and actual weighted average sale prices will be paid or credited in the first royalty payment or Gross Margin Share of the following Calendar Year.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.148</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#91;***&#93; has the meaning set forth in Section 7.6.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.149</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">New License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 14.6.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.150</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#91;***&#93; has the meaning set forth in Section 7.7.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.151</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">New Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 6.9.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.152</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">New Study Proposal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 6.9.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.153</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Other Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 1.147.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.154</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in the Preamble.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.155</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#91;***&#93; has the meaning set forth in Section 14.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.156</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means&#58; (a)&#160;any and all patents and patent applications, including provisional patent applications and rights to claim priority from any of these patents or patent applications&#59; (b)&#160;any and all divisionals, continuations, continuations-in-part, reissues, renewals, substitutions, registrations, re-examinations, revalidations, extensions (including supplementary protection certificates, patent term extensions, pediatric exclusivity, and the like) and the like of any such patents and patent applications&#59; and (c)&#160;any and all foreign equivalents of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.157</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 9.10.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.158</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means any corporation, limited or general partnership, limited liability company, joint venture, trust, unincorporated association, governmental body, authority, bureau or agency, any other entity or body, or an individual.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.159</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Personal Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, in addition to any definition for any similar term (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, &#8220;personal data&#8221; or &#8220;personally identifiable information&#8221; or &#8220;PII&#8221;) provided by Applicable Laws, or by either Party in any of its own privacy policies, notices or contracts, all information that identifies, could be used to identify or is otherwise associated with an individual person, whether or not such information is directly associated with an identified individual person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.160</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Phase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Clinical</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means a clinical trial of a Product generally consistent with 21 C.F.R. &#167;&#160;312.21(a) (or the non-United States equivalent thereof).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.161</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Phase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Clinical</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means a clinical trial of a Product generally consistent with 21 C.F.R. &#167;&#160;312.21(b) (or the non-United States equivalent thereof).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.162</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Phase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Clinical</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means a clinical trial of a Product generally consistent with 21 C.F.R. &#167;&#160;312.21(c) (or the non-United States equivalent thereof).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.163</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Phase IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Clinical</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means a clinical trial conducted concurrent with Marketing Approval generally consistent with 21 C.F.R. &#167; 312.85 (or the non-United States equivalent thereof). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.164</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#91;***&#93; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.165</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Pricing and Reimbursement Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to a Product, the approval, agreement, determination or decision of any Regulatory Authority establishing the price or level of reimbursement for such Product, as required in a given country or jurisdiction prior to sale of such Product in such country or jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.166</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to a Collaboration Target, any pharmaceutical composition, preparation, formulation or product containing or comprising a Candidate that is Directed To such Collaboration Target, with all formulations, delivery systems or dosage forms containing the same Candidate being considered a single &#8220;Product.&#8221; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.167</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Product-Specific Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means a Patent within &#91;***&#93;, including a Patent &#91;***&#93;, that &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.168</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Program IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 10.2.2.  &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.169</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Project</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 3.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.170</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Project Completion Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 3.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.171</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Project Leader</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 2.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.172</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Proof of Concept</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to a Discovery Product, a successful demonstration, as determined by the JDC, of technical efficacy and feasibility of such Discovery Product for its intended application, including successful completion of an appropriate Clinical Trial.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.173</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Proposed Additional Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.174</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Proposed Additional Target Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.175</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Proposed Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 6.3.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.176</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Proposed Replacement Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.177</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Proposed Replacement Target Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.178</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Prosecute and Maintain</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Prosecution and Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">with respect to a particular Patent, means all activities associated with the preparation, filing, prosecution and maintenance of such Patent, together with the conduct of interferences, derivation proceedings, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">inter partes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> review and post-grant review, the defense of oppositions and other similar proceedings with respect to that Patent, including any activities associated with claims, including as a counterclaim or declaratory judgment action, of unpatentability, invalidity or unenforceability of such Patent that are brought by a Third Party in connection with an &#91;***&#93; under Section&#160;10.7.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.179</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Prosecuting Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 10.6.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.180</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Reactivated Project</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 3.2(c).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.181</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section&#160;13.1.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.182</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Registrational Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means a Clinical Trial that is intended &#91;***&#93; to obtain sufficient data and results &#91;***&#93; to support the filing of an application for a Marketing Approval. A Registrational Clinical Trial includes any Clinical Trial that &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.183</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means any Governmental Authority that has responsibility in its applicable jurisdiction over the testing or Exploitation of pharmaceutical products (including any Product) in any country or jurisdiction.  For countries or jurisdictions where governmental approval is required for pricing or reimbursement for a pharmaceutical product (including any Product) to be reimbursed by national health insurance (or its local equivalent), Regulatory Authority includes any Governmental Authority whose review or approval of pricing or reimbursement of such product is required.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.184</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, collectively, any and all applications, filings, submissions, approvals (including supplements, amendments, pre- and post-approvals, pricing and reimbursement approvals), licenses, registrations, permits, notifications, and authorizations (including marketing and labeling authorizations), non-clinical and clinical study authorization applications or notifications (including all supporting files, writings, data, studies and reports) or waivers with respect to the testing or Exploitation of a Compound or Product made to or received from any Regulatory Authority in a given country or jurisdiction, including INDs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.185</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Replacement Project</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.186</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Replacement Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4.3. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.187</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Replacement Target Availability Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.188</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Research</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means conducting research activities to discover, design, optimize, deliver and advance Compounds and Products, including pre-clinical studies and optimization, but specifically excluding Development, Manufacture and Commercialization activities.  When used as a verb, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Researching</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means to engage in Research and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Researched</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has a corresponding meaning.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.189</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Research Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 3.5.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.190</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Research Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section&#160;3.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.191</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Research Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section&#160;3.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.192</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Residuals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 13.1.5.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.193</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Restricted Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 11.4.7(b). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.194</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Royalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 9.5.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.195</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section&#160;9.5.1.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.196</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Sales Force Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means those costs incurred by a Party that are directly attributable or reasonably allocable to Product detailing activities (but not, for clarity, any costs otherwise allocable to the marketing or other Commercialization activities relating to the Product).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.197</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Sanctioned Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 11.4.7(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.198</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Selective BRM Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the Selective BRM Projects, and following the completion of a Selective BRM Project, the conduct of Exploitation activities under this Agreement with respect to a Product or Products resulting from such Selective BRM Project.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.199</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Selective BRM Projects</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 3.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.200</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Selective BRM Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 4.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.201</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Selective BRM&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%"> Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, individually or collectively, Products arising from the Selective BRM Program or the &#91;***&#93; Program, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.202</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Selective BRM&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%"> Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, individually or collectively, the Selective BRM Program and the &#91;***&#93; Program.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.203</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means a Third Party &#91;***&#93; that is granted a license or sublicense to &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.204</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Supply Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the price for the &#91;***&#93;, including the amounts &#91;***&#93; to &#91;***&#93;, and all activities related to &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.205</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means a biological target, specific protein, gene or gene sequence that can be identified by a UniProt identification number (https&#58;&#47;&#47;www.uniprot.org&#47;) (or similar database) or a specific defined molecular entity and variants thereof, to which a potential therapeutic agent is directed to, binds to, or modulates (including, for example purposes only, nucleic acids, carbohydrates, metabolites, etc.).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.206</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section&#160;14.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.207</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Terminated Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section&#160;14.6.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.208</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Terminated Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section&#160;14.6.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.209</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Terminated Project</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section&#160;14.6.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.210</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means worldwide.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.211</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means any Person, other than&#160;Lilly or Foghorn or an Affiliate of Lilly or Foghorn.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.212</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#91;***&#93; has the meaning set forth in Section 9.5.4. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.213</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Trademark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means all trademarks, service marks, trade names, brand names, sub-brand names, trade dress rights, product configuration rights, certification marks, collective marks, logos, taglines, slogans, designs or business symbols and all words, names, symbols, colors, shapes, designations or any combination thereof that function as an identifier of source or origin or quality, whether or not registered, and all statutory and common law rights therein, and all registrations and applications therefor, together with all goodwill associated with, or symbolized by, any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.214</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">U</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means the United States of America and its territories and possessions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.215</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">U.S. Eligible Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means, with respect to a Product associated with a Joint Program, to the extent incurred following the Joint Program Start Date for the Joint Program and during the Term, and in accordance with this Agreement (and, for clarity, solely to the extent not already counted as a deduction in the definition of Net Sales) each of the following costs to the extent allocable to the United States&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">all &#91;***&#93; costs (other than the &#91;***&#93;) associated with activities related to &#91;***&#93;, including&#58; &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">all &#91;***&#93; costs incurred in accordance with &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">all &#91;***&#93; costs incurred within or materially related to &#91;***&#93; subject to and in accordance with &#91;***&#93; (but, in each case, not including (i) any &#91;***&#93; costs incurred by &#91;***&#93;, or (ii) &#91;***&#93; costs incurred by &#91;***&#93; in fulfilling its &#91;***&#93; hereunder)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">all costs with respect to &#91;***&#93; for &#91;***&#93; to the extent not subject to &#91;***&#93; by &#91;***&#93; under &#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">all costs associated with any &#91;***&#93; of &#91;***&#93; (except to the extent any &#91;***&#93; such &#91;***&#93; hereunder at the time such &#91;***&#93; was &#91;***&#93;, in which case, &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.03pt">all costs incurred in connection with &#91;***&#93; in accordance with &#91;***&#93; after &#91;***&#93;, and in each case not including any &#91;***&#93; costs incurred by &#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">all &#91;***&#93; costs incurred in respect of the &#91;***&#93; of &#91;***&#93; that are not included in the &#91;***&#93; on &#91;***&#93; including, for example, &#91;***&#93; costs, &#91;***&#93; costs, &#91;***&#93; costs, &#91;***&#93; costs&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">all &#91;***&#93; for any &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">any costs incurred by &#91;***&#93; in respect of &#91;***&#93; for &#91;***&#93; to the extent such costs are &#91;***&#93; in the &#91;***&#93; for such &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">any applicable &#91;***&#93; under &#91;***&#93; incurred by &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">&#91;***&#93; and &#91;***&#93; charges with respect to &#91;***&#93; to the extent not included &#91;***&#93;&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">&#91;***&#93; and payments pursuant to &#91;***&#93; (other than solely with respect to &#91;***&#93;) and &#91;***&#93; that are  applicable to the activities under &#91;***&#93;, in each case payable &#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18.69pt">&#91;***&#93; costs of &#91;***&#93;, not to exceed the cost &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">For clarity, &#8220;U.S. Eligible Costs&#8221; are exclusive of and do not include Development Costs, Sales Force Costs, or any costs for which a Party is solely responsible under this Agreement (including under the Development Plan or Commercialization Plan, if applicable). Except to the extent already included in Internal Qualified Expenses, &#8220;U.S. Eligible Costs&#8221; shall not include either Party&#8217;s costs to the extent they solely relate to overseeing execution of and compliance with this Agreement. &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.216</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#91;***&#93; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.217</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Unavailable Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means each of the following&#58; (a) each Target set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 1.217</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and (b) a Target that, at the time Lilly seeks to add such Target (or specific portion or mutation thereof) to the Research Program as a Collaboration Target (either as an Additional Target or Replacement Target), is a Target &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.218</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means a claim that &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.219</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Working Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; has the meaning set forth in Section 2.5.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.220</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.221</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">1.222</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:9pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Article 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:27.73pt"><br><br>GOVERNANCE AND JOINT STEERING COMMITTEE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Alliance Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Within &#91;***&#93; following the Effective Date, each Party shall appoint one (1) employee to act as the Alliance Manager for such Party (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  Without limiting the responsibilities and authorities of the Project Leaders and the JSC (as expressly set forth herein), the Alliance Managers shall each be the primary point of contact for the Parties regarding the collaboration and related activities contemplated by this Agreement and shall help facilitate all such activities hereunder.  For avoidance of doubt, the individual appointed by a Party to act as an Alliance Manager may, but need not, be the same individual appointed by such Party as a Project Leader, but an Alliance Manager may not be appointed to serve simultaneously as a JSC member.  Either Party may change its Alliance Manager at any time upon reasonable prior written notice to the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Project Leaders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Lilly and Foghorn shall each assign one (1) employee to serve as the primary point of contact between the Parties with respect to each Project under the Research Program (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Project Leader</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  The Project Leaders shall regularly communicate with each other to address Project-related issues, needs and updates and facilitate </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">communications and organization of Working Groups (as needed and if established by the JSC) associated with the Research Plan for such Project.  Either Party may change its Project Leaders at any time upon reasonable prior written notice to the other Party.  For clarity, the same employee may, but need not, be the Project Leader for multiple Projects.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Joint Steering Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Within &#91;***&#93; after the Execution Date, the Parties shall establish a cross-functional joint steering committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) comprised of up to &#91;***&#93; senior representatives from each Party (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that each Party has an equal number of representatives on the JSC at all times) that will be responsible for general oversight and coordination of the activities of the Parties hereunder, and shall have the responsibilities designated to it under this Agreement, including the functions and powers further set forth in Section 2.6.  Each Party shall appoint its respective representatives to the JSC from time to time, and may change its representatives, in its sole discretion, effective upon reasonable prior written notice to the other Party designating such change. The representatives from each Party on the JSC shall have appropriate technical credentials, experience and knowledge pertaining to and ongoing familiarity with the collaboration of the Parties under this Agreement and the activities conducted hereunder.  Each Party shall designate one (1) of its representatives on the JSC to serve as a JSC co-chairperson (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">JSC Co-Chairpersons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), who will be jointly responsible for calling meetings of the JSC, circulating agendas and performing administrative tasks required to assure efficient operation of the JSC but shall not have any extra or additional votes or authority.  The JSC Co-Chairpersons or their designees shall alternate responsibility for circulating agendas no later than &#91;***&#93; prior to each JSC meeting and distributing minutes of the JSC meetings pursuant to Section 2.7.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">JSC Subcommittees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The JSC may, from time to time, establish JSC Subcommittees as it deems necessary to further the purposes of this Agreement and the Joint Programs, including as necessary to oversee and coordinate the Parties&#8217; activities related to a Joint Program, and may delegate activities to such JSC Subcommittee. Without limiting the foregoing, the JSC shall establish the following JSC Subcommittees, as follows&#58; (a) no later than &#91;***&#93; following the Execution Date, the JSC shall establish a joint research committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">JRC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), (b) no later than &#91;***&#93; prior to the anticipated date of the first IND filing of a Joint Program Product, the JSC shall establish a joint development committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">JDC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), and (c) (A) no later than &#91;***&#93; prior to the anticipated Initiation of the first Registrational Clinical Trial of a Joint Program Product or (B) if such first Registrational Clinical Trial is determined to be a Registrational Clinical Trial after the deadline set forth in the foregoing clause (A), then no later than &#91;***&#93; after such determination, the JSC shall establish a joint commercialization committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">JCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) and a joint ethics and compliance committee (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">JECC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), each as further detailed below in this Article 2. Each JSC Subcommittee shall undertake the activities specified under this Agreement for such JSC Subcommittee or otherwise delegated to it by the JSC.  During the process of establishing each JSC Subcommittee, to the extent the responsibilities of the JSC Subcommittee are not set forth in this Agreement, such JSC Subcommittee and the JSC shall agree regarding which matters such JSC Subcommittee may resolve on its own (with discretion to refer any matter to the JSC for a final decision) and which matters such JSC Subcommittee will advise the JSC and&#47;or the Project Leaders regarding (and with respect to which such advice-specific matters the JSC must resolve). Each JSC Subcommittee will be comprised of an equal number of members of each Party, such number as agreed by the Parties or otherwise by the JSC.  Each Party may replace any of its designated JSC Subcommittee representatives at any time with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">reasonable prior written notice to the other Party. Each Party shall designate one (1) of its representatives on each JSC Subcommittee to serve as a co-chairperson of such committee, who will be jointly responsible for calling meetings of the JSC Subcommittee, circulating agendas and performing administrative tasks required to assure efficient operation of the JSC Subcommittee, but shall not have any extra or additional votes or authority. The co-chairpersons or their designees shall alternate responsibility for circulating agendas no later than &#91;***&#93; prior to each meeting of the applicable JSC Subcommittee and distributing minutes of the meetings of the applicable JSC Subcommittee pursuant to Section 2.7. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Working Groups</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The JSC may establish working groups consisting of members from both Foghorn and Lilly (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Working Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) to oversee aspects of the activities of the Research Program or each individual Project. From time to time, the Parties may establish additional Working Groups as needed to oversee particular activities and&#47;or projects. Each Working Group shall undertake the activities specified under this Agreement for such Working Group or otherwise delegated to it by the JSC.  During the process of establishing each Working Group, such Working Group and the JSC shall agree regarding which matters such Working Group may resolve on its own (with discretion to refer any matter to the JSC for a final decision) and which matters such Working Group will advise the JSC and&#47;or the Project Leaders regarding (and with respect to which such advice-specific matters the JSC must resolve).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Function and Powers of the JSC and JSC Subcommittees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Notwithstanding anything to the contrary herein, all responsibilities and decision-making authority of the JSC, the JSC Subcommittees and the Working Groups shall be subject to the terms of this Agreement, including Section 2.8.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Joint Steering Committee &#8211; Functions and Powers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The JSC shall be responsible for coordinating and overseeing the activities of the Parties hereunder generally, including the activities of each JSC Subcommittee and Working Groups established hereunder, and in particular shall&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">oversee &#91;***&#93; of &#91;***&#93; under &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">establish &#91;***&#93; and &#91;***&#93; to &#91;***&#93; and &#91;***&#93; the activities of &#91;***&#93;, and &#91;***&#93; or &#91;***&#93;, as necessary&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">align and approve all &#91;***&#93; and &#91;***&#93; with respect to &#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">receive and discuss &#91;***&#93; as may be &#91;***&#93; from &#91;***&#93;, and provide &#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">direct and oversee the &#91;***&#93; on &#91;***&#93; that &#91;***&#93; within the purview of &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.03pt">determine &#91;***&#93; the &#91;***&#93; necessary to &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">review, discuss and approve a &#91;***&#93; that will &#91;***&#93; activities with respect to &#91;***&#93;&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">resolve issues &#91;***&#93;, and &#91;***&#93; within, any &#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">facilitate the &#91;***&#93; or any &#91;***&#93; as required hereunder &#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">designate any &#91;***&#93;, which would not &#91;***&#93; as such by &#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">review and discuss any &#91;***&#93;, and approve the &#91;***&#93;, if and when applicable&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">performing such other duties and tasks as are expressly assigned to the JSC in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Joint Research Committee &#8211; Functions and Powers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The JRC shall be responsible for coordinating and overseeing the activities of the Parties hereunder with respect to the Research Program, and in particular shall&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">review, discuss, and approve &#91;***&#93; and any &#91;***&#93; to the &#91;***&#93; that may be &#91;***&#93;, and prepare, discuss, and approve any &#91;***&#93;, in accordance with &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">oversee (and approve, in the case of &#91;***&#93; the &#91;***&#93; of the &#91;***&#93;, including the &#91;***&#93;, and coordination of &#91;***&#93; and timing &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">approve (in the case of &#91;***&#93;, and refine as necessary &#91;***&#93;, the &#91;***&#93; for &#91;***&#93;, and determine whether &#91;***&#93; has &#91;***&#93; the &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">determine whether &#91;***&#93; with respect to &#91;***&#93; should be &#91;***&#93;, including if &#91;***&#93; with respect to &#91;***&#93;, or the JRC determines &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">discuss the &#91;***&#93; of the &#91;***&#93;, and the &#91;***&#93; and &#91;***&#93; of &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.03pt">review and evaluate &#91;***&#93; as needed in support of &#91;***&#93; (and in support of &#91;***&#93;, upon request by &#91;***&#93;, determine &#91;***&#93; needed to &#91;***&#93;, and whether those &#91;***&#93; have been &#91;***&#93; on the &#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">determine &#91;***&#93; for &#91;***&#93; other than for &#91;***&#93;, as well as &#91;***&#93;, in each case for &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">discuss &#91;***&#93; and &#91;***&#93; that &#91;***&#93; brings to &#91;***&#93; and approve &#91;***&#93; with respect to &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">determine &#91;***&#93; and &#91;***&#93; to &#91;***&#93; as a &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">provide &#91;***&#93; for &#91;***&#93; to &#91;***&#93; relating to &#91;***&#93; and &#91;***&#93;, including &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">address issues arising in &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">oversee &#91;***&#93; with respect to any &#91;***&#93;&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18.69pt">monitor and manage &#91;***&#93;  (including for &#91;***&#93;), and &#91;***&#93; any &#91;***&#93; to &#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt"> perform any and all tasks and responsibilities that are expressly attributed to the JRC under this Agreement or as otherwise agreed by the Parties in writing or delegated to it by the JSC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Joint Development Committee &#8211; Functions and Powers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The JDC shall be responsible for coordinating and overseeing the activities of the Parties hereunder with respect to the Development activities conducted under a Joint Program, and in particular, shall&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">prepare, review, discuss, and approve &#91;***&#93; and &#91;***&#93; for &#91;***&#93; (and all &#91;***&#93; and &#91;***&#93;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">review and evaluate &#91;***&#93; to &#91;***&#93; (e.g., &#91;***&#93;) as needed in support of &#91;***&#93;, determine &#91;***&#93; to &#91;***&#93;, and whether &#91;***&#93; have been &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">review &#91;***&#93; for &#91;***&#93;, and select &#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">provide a forum for &#91;***&#93; and &#91;***&#93; between &#91;***&#93; to &#91;***&#93; of &#91;***&#93; of the &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">review and monitor &#91;***&#93; and &#91;***&#93;, including &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.03pt">review and endorse, &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">discuss and oversee &#91;***&#93; and &#91;***&#93; in &#91;***&#93; to &#91;***&#93; and &#91;***&#93; of &#91;***&#93; to any &#91;***&#93;, as well as during the &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">approve &#91;***&#93; for &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">facilitate &#91;***&#93; in &#91;***&#93; with &#91;***&#93; to ensure that &#91;***&#93; and &#91;***&#93; are &#91;***&#93; and in &#91;***&#93; with &#91;***&#93; in the &#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">make recommendations to &#91;***&#93; whether to &#91;***&#93; for any &#91;***&#93;, such as for &#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">discuss and oversee &#91;***&#93;, such as &#91;***&#93; to support the &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">review, discuss, coordinate and approve the &#91;***&#93;, and the &#91;***&#93; of &#91;***&#93;  (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, &#91;***&#93; with respect thereto), including &#91;***&#93; or the &#91;***&#93; with any &#91;***&#93; (subject to &#91;***&#93;), including coordination with &#91;***&#93; and any &#91;***&#93; for the &#91;***&#93; of &#91;***&#93; thereto (to the extent applicable)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18.69pt">review and confirm &#91;***&#93; of &#91;***&#93; pursuant to, and subject to &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">monitor and manage &#91;***&#93; and &#91;***&#93; any &#91;***&#93; to &#91;***&#93;&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">oversee &#91;***&#93; to &#91;***&#93;, review &#91;***&#93;, and determine &#91;***&#93; has been &#91;***&#93; and &#91;***&#93; has been &#91;***&#93;&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">perform any and all tasks and responsibilities that are expressly attributed to the JDC under this Agreement or as otherwise agreed by the Parties in writing or delegated to it by the JSC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Joint Commercialization Committee &#8211; Functions and Powers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The JCC shall be responsible for coordinating and overseeing the activities of the Parties hereunder with respect to the Commercialization activities conducted under a Joint Program in the United States, and in particular, shall&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">prepare, review, discuss, and approve &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">review and approve &#91;***&#93; for &#91;***&#93; and &#91;***&#93; is &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">prepare and approve &#91;***&#93; for &#91;***&#93;, and review, discuss, and amend &#91;***&#93; as necessary&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">review and evaluate &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.03pt">approve, oversee, manage and coordinate &#91;***&#93; to the &#91;***&#93;, including &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">ensure, &#91;***&#93;, that &#91;***&#93; includes the &#91;***&#93; prior to &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">ensure, &#91;***&#93;, that &#91;***&#93; are &#91;***&#93;, and that any &#91;***&#93; from any &#91;***&#93; are &#91;***&#93; and &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">review and confirm &#91;***&#93; of the &#91;***&#93; to, and subject to &#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">monitor and manage &#91;***&#93; and &#91;***&#93; any &#91;***&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">perform any and all tasks and responsibilities that are expressly attributed to the JCC under this Agreement or as otherwise agreed by the Parties in writing or delegated to it by the JSC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Joint Ethics and Compliance Committee &#8211; Functions and Powers&#59; Compliance Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The JECC shall be responsible for resolving discrepancies between the Parties&#8217; respective compliance policies and procedures, and managing compliance with applicable Party-Specific Regulations.  The Parties will negotiate in good faith and execute written compliance agreements (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Compliance Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) that will set forth and define the compliance policies, standards, and procedures the Parties will adhere to when conducting activities under this Agreement in the applicable portions of the Territory. The Compliance Agreements may also include provisions relating to interactions between the respective compliance organizations of the Parties, sharing of compliance-related information, execution of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">training, implementation and monitoring activities, and resolution of compliance issues that may arise. In the event of a conflict between this Agreement and the Compliance Agreements, the Compliance Agreements shall control.  The JECC may not compel a Party, and no Party may compel the other Party, to be in non-compliance with any Party-Specific Regulations applicable to it.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The JSC, JRC, JDC, JCC, and JECC will each meet at least once per Calendar Quarter for so long as each remains in effect. Other JSC Subcommittees that may be established from time to time shall meet as frequently as agreed upon by the JSC at the time of establishing such committees. The JSC and each JSC Subcommittee may conduct such meetings by telephone, videoconference, or in person.  Each Party may call special meetings with at least &#91;***&#93; prior written notice, or a shorter time period in exigent circumstances, to resolve particular matters requested by such Party that are within the purview of the JSC or applicable JSC Subcommittee.  Meetings are effective only if at least one (1) representative of the JSC or applicable JSC Subcommittee for each Party participates in such meeting.  Each Alliance Manager shall be permitted to attend meetings of the JSC, JRC, JDC, JCC, and JECC, and any Working Group, as a non-voting observer.  Each Party may invite a reasonable number of other participants, in addition to its representatives, to attend JSC, JRC, JDC, JCC, and JECC  meetings in a non-voting capacity&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that if either Party intends to have any Third Party (including any consultant) attend such a meeting, such Party shall provide prior written notice to the other Party.  Such Party shall ensure that such Third Party is bound by confidentiality and non-use obligations consistent with the terms of this Agreement.  Each Party is responsible for its own expenses incurred in connection with participating in and attending all such meetings.  The JSC Co-Chairpersons (and JSC Subcommittee co-chairpersons) or their designees shall keep minutes of each meeting that record in writing all decisions made, action items assigned or completed and other appropriate matters.  The JSC Co-Chairpersons (and JSC Subcommittee co-chairpersons) or their designees shall send meeting minutes to all members of the JSC or applicable JSC Subcommittee promptly after a meeting for review.  Each JSC or applicable JSC Subcommittee member shall have &#91;***&#93; from receipt in which to comment on and to approve the minutes (such approval not to be unreasonably withheld, conditioned or delayed).  If an applicable committee member, within such time period, does not notify the JSC Co-Chairpersons (or JSC Subcommittee co-chairpersons) or their designees that s&#47;he does not approve of the minutes, the minutes shall be deemed to have been approved by such member.  The Parties acknowledge and agree that, notwithstanding the requirements of this Section 2.7 for the JSC, JRC, JDC, JCC, and JECC to meet once per Calendar Quarter, the Parties shall communicate and meet (as appropriate, including via the Project Leaders) on a more informal basis as needed to discuss the progress of the Projects, the Research Program, the Joint Programs, or other matters within their respective authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Decisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12pt">The JSC and each JSC Subcommittee will endeavor to make decisions by consensus, with the representatives of each Party having, collectively, one (1) vote on behalf of that Party. If the JSC or applicable JSC Subcommittee cannot reach consensus or a Dispute arises that cannot be resolved within the JSC or applicable JSC Subcommittee, either Party may pursue resolution of the Dispute in accordance with Section 15.2&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that in the case of Disputes </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">arising at the applicable JSC Subcommittees, the Dispute shall first be referred to the JSC for attempted resolution. If consensus cannot be reached in accordance with Section 15.2.1, then&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">subject to the foregoing clause (a), &#91;***&#93;&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">subject to the foregoing clauses (a) and (b), &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">notwithstanding the foregoing clauses (a)-(c), &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12pt">Notwithstanding the foregoing or anything to the contrary in this Agreement, in exercising its final decision-making authority, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">neither</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Party may resolve any such Dispute in a manner that&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">excuses, reduces, or delays its obligations under this Agreement &#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">&#91;***&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">&#91;***&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">increases the other Party&#8217;s payment or cost-bearing obligations, &#91;***&#93; by (x) more than &#91;***&#93; of the relevant amount set forth in the latest applicable &#91;***&#93;, as applicable, that is &#91;***&#93; (or otherwise determined pursuant to Section 2.8.1(d)), except to the extent &#91;***&#93;, which, if &#91;***&#93;, &#91;***&#93;&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.03pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The Alliance Managers, Project Leaders, JSC, JRC, JDC, JCC, JECC, and other JSC Subcommittees (including the JSC Co-Chairpersons and applicable JSC Subcommittee co-chairpersons), and each Working Group have only the powers assigned expressly to them in this Article 2 and elsewhere in this Agreement (or in the case of Working Groups, as expressly assigned to them by the JSC).  Each Party retains the rights, powers, and discretion granted to it under this Agreement and neither Party may delegate or vest such rights, powers, or discretion in the Alliance Manager, a Project Leader, the JSC, JRC, JDC, JCC, JECC or any other JSC Subcommittee (including the JSC Co-Chairpersons and applicable JSC Subcommittee co-chairpersons), or any Working Group, unless expressly provided for in this Agreement or the Parties expressly so agree in writing.  Except as otherwise expressly authorized under this Agreement, the Alliance Managers, Project Leaders, the JSC, JRC, JDC, JCC, JECC and other JSC Subcommittees (including the JSC Co-Chairpersons and applicable JSC Subcommittee co-chairpersons), and any Working Groups shall not have the power to amend, waive or modify any term of this Agreement, and no decision of the JSC or any JSC Subcommittee or Working Group shall be in contravention of any terms and conditions of this Agreement.  It is understood and agreed that issues to be formally decided by the JSC, JRC, JDC, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">JCC, JECC, and applicable JSC Subcommittees are limited to those specific issues that are expressly provided in this Agreement to be decided by them, respectively.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Discontinuation of JSC and JSC Subcommittees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The JRC will automatically disband with immediate effect at the end of the Research Term.  The JSC shall remain in effect during the Research Term and thereafter for so long as a Joint Program remains in effect and remains a Joint Program. If any program ceases to be a Joint Program, the responsibilities of the JDC, JCC, and JECC shall automatically cease to apply to such program.  If at any time after the Research Term there is no longer a Joint Program in effect under this Agreement, the JSC, JDC, JCC and JECC shall automatically disband with immediate effect until a Joint Program is subsequently established under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br><br>RESEARCH PROGRAM</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Overview and Purpose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  During the Research Term, Lilly and Foghorn will collaborate in a research and development program with the intended purpose of researching, discovering, and developing therapeutic molecules that are Directed To Collaboration Targets, from which therapeutic molecules a Candidate could be selected by Lilly and further developed in accordance with the terms of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Research Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). The Research Program will consist of Projects for each Collaboration Target, and will be conducted pursuant to Research Plans, as further set forth in this Article 3. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Projects</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">The Research Program will consist of up to &#91;***&#93; projects (with the Selective BRM Program consisting of up to &#91;***&#93; projects), on a Collaboration Target-by-Collaboration Target basis (other than with respect to the Selective BRM Program, which will consist of up to &#91;***&#93; projects Directed to a single Collaboration Target) (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Project</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  As of the Effective Date, the Research Program consists of (a) &#91;***&#93; Projects relating to the Selective BRM Target (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Selective BRM Projects</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), (b) the Project relating to the &#91;***&#93; Target (the &#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%"> Project</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), and (c) the Project relating to the &#91;***&#93; Target ((a)-(c) collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Initial Projects</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  The Research Program will consist of the Initial Projects and up to &#91;***&#93; Additional Projects (as may be added pursuant to Section 4.2), plus any Replacement Projects (as may be added pursuant to Section 4.3), but excluding all Discontinued Projects. For clarity, there shall be no more than &#91;***&#93; Projects under this Agreement at any given time (with the Selective BRM Program consisting of up to &#91;***&#93; Projects). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The goal for each Project shall be to identify (if not already identified), assess, optimize, and develop a Candidate for the relevant Collaboration Target.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">Each Project shall end upon the earliest of the following&#58; (i) the expiration of the Research Term, (ii) &#91;***&#93;, (iii) &#91;***&#93; or (iv) &#91;***&#93; (the earliest to occur of the events &#91;***&#93; with respect to a Project, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Project Completion Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; for such Project). Notwithstanding the foregoing, if a Project expires prior to the expiration of the Research Term as a result of a Project Completion Event &#91;***&#93; but Lilly thereafter determines (in accordance with its customary standards) before the expiration of the Research Term that all Compounds resulting from such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Project as of the date of such expiration have failed GLP Toxicology Studies, then Lilly may, by providing written notice to Foghorn thereof prior to the expiration of the Research Term, reactivate the Project with the intention of identifying one (1) or more additional Compounds that achieve the Critical Success Factors (such reactivated Project, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Reactivated Project</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), in which event (A) the Reactivated Project shall once again be deemed to be an active Project under this Agreement and shall remain in effect until the occurrence of a subsequent Project Completion Event, (B) Lilly shall bear any and all costs and expenses incurred by either Party in the conduct of activities conducted under the Reactivated Project, except to the extent such costs and expenses are subject to the Expense and Margin Sharing for a Joint Program, as further detailed in Section 9.3, and (C) the JSC shall agree upon an updated Research Plan for such Reactivated Project and a Research Budget for such Reactivated Project, each in accordance with Section 3.5. Notwithstanding anything to the contrary in this Agreement, multiple Products Directed To the same Collaboration Target may derive from the same Project. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Research Program Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  An outline of certain anticipated activities and responsibilities of the Parties during a typical Project under the Research Program is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Research Program Outline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  As between the Parties, (a) Foghorn will lead and be primarily responsible for all Research activities under each Project, on a Project-by-Project basis, until completion of Dose-Finding Tox for such Project, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that (i) Foghorn shall accommodate any reasonable request from Lilly to participate in any Research activities (including &#91;***&#93;) that would not require (A) disclosure to Lilly of any portion of the Foghorn Platform (including, without limitation, any tools or systems used therein) maintained as trade secrets by Foghorn in order to facilitate such participation, (B) the transfer of any assays or reagents (other than &#91;***&#93;) that relate to the Foghorn Platform by or on behalf of Foghorn in order to facilitate such participation, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that in such case the Parties will discuss an alternative request that would facilitate Lilly&#8217;s participation without necessitating the transfer of such assays or reagents or (C) Foghorn to incur any costs or expenses in connection with such participation, and (ii) Lilly shall lead and be primarily responsible for each such Research activity allocated to Lilly under a Research Plan, and (b) Lilly will lead and be primarily responsible for all Research activities following Dose-Finding Tox.  For clarity, Lilly shall have the right, in its sole discretion, to select Candidates. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Research Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The Research Program shall be conducted for a period commencing on the Effective Date and continuing for &#91;***&#93; thereafter (as may be extended by Lilly pursuant to this Section 3.4) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Research Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  To ensure the Parties have sufficient time to perform Research activities, Lilly shall have the option to extend the Research Term for an additional period of up to &#91;***&#93; by notifying Foghorn via the JRC of such election no later than &#91;***&#93; prior to the end of the then-current Research Term.  Lilly may exercise such option to extend the Research Term up to, but no more than, &#91;***&#93; times. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Research Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Content</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Parties shall conduct activities under the Research Program through the completion of Dose-Finding Tox pursuant to a mutually agreed upon, comprehensive written plan for each Project that is approved in accordance with the terms of this Agreement (each such plan, as may be amended from time to time in accordance with the terms of this Agreement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Research Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). Each Research Plan shall set forth, for the applicable Project&#58; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)&#160;the objective of the applicable Research Plan and the Research activities to be conducted by each of the Parties&#59; (b) the expected resources to be allocated to performing such Research&#59; (c)&#160;the anticipated timeline and milestones of achieving such activities&#59; (d) a budget setting out by Calendar Quarter the anticipated Internal Qualified Expenses to be incurred by Foghorn (or any of its Affiliates) in the conduct of the Research activities for the applicable Project under such Research Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Research Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;)&#59; and (e)&#160;the Critical Success Factors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Preparation of Research Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The Research Plans for the Initial Projects (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Initial Research Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) shall be mutually prepared by the Parties within &#91;***&#93; following the Execution Date, and shall be consistent with the Research Program Outline, except to the extent the Parties agree to any material deviations with respect to any particular Collaboration Target. The Research Plans for each Additional Project and each Replacement Project (each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Additional Research Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), as applicable, shall be mutually prepared by the Parties within &#91;***&#93; following the addition of the relevant Collaboration Target to the Research Program (pursuant to Section 4.2 or Section 4.3, respectively), and shall substantially follow, in form and substance, the form of the Initial Research Plans, except to the extent the Parties agree to any deviations from such form with respect to any particular Collaboration Target. Each Research Plan shall only become effective once it has been approved by the JRC and subject to the decision-making terms set forth in Section 2.8.  The JRC shall use reasonable efforts to approve each Research Plan within &#91;***&#93; following the submission of such Research Plan to the JRC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Approval and Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The JRC shall regularly review the Research Plans (including the coordination of the activities across the Research Program and to account for the number of active Projects and Research Plans at any given time) and the progress of activities being conducted under the Research Plans, in no event less frequently than one (1) time per Calendar Quarter.  Either Party may propose amendments to the Research Plan for a particular Project from time to time as appropriate, to take into account completion, commencement, or cessation of activities contemplated in the then-current Research Plan for such Project or any newly available information related to such Project.  Such amendments shall be effective upon JRC approval and subject to the decision-making terms set forth in Section 2.8.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Diligence Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The Parties shall use Commercially Reasonable Efforts to execute and to perform, or cause to be performed, in a good scientific manner and in compliance with Applicable Law, the Research activities assigned to them, respectively, in each Research Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Records&#59; Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Each Party shall maintain, or cause to be maintained, during the Research Term and for a reasonable period of time thereafter that is consistent with industry standards and applicable regulations, complete and accurate records (paper and&#47;or electronic) of its Research data and results (including raw data) for each Project in sufficient detail and in a good scientific manner appropriate for scientific, patent, and regulatory purposes, which records will reasonably reflect all work performed by or on behalf of such Party under the Research Plan for each Project.  &#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Reports and Data Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Each Party shall regularly report to the other Party through the JRC (or the designated Project Leader or Working Group) its results in conducting Research under the Research Plan for each Project.  For each Project, each Party shall provide the JRC with&#58;  (a) the deliverables set forth in the Research Plan for such Project and allocated to such Party therein, including, if applicable, a written report summarizing the data and information generated under each Project, within &#91;***&#93; after the completion of such Party&#8217;s Research for such Project&#59; and (b) on a Calendar Quarter basis during the Research Term, all data and results (including raw data) that are generated by or on behalf of such Party in the performance of the Research for such Project under this Agreement and reasonably requested by the other Party, including such data and results as are relevant to a determination of whether Critical Success Factors for each Project have been achieved, but in the case of Foghorn&#8217;s data and results excluding disclosure of any portion of the Foghorn Platform (including, without limitation, any tools or systems used therein) maintained as trade secrets by Foghorn, if applicable, unless required in association with a Regulatory Filing in which case, disclosure of such trade secrets shall be subject to Article 13, and the Parties shall cooperate to limit disclosure to solely what is necessary for the applicable Regulatory Filing. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Research Program Funding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Except to the extent such costs and expenses are subject to the Expense and Margin Sharing for a Joint Program, as further detailed in Section 9.3, (a) Lilly shall bear any and all costs and expenses incurred by either Party in the conduct of activities conducted under the Reactivated Project, (b) Lilly shall be responsible for all costs and expenses incurred by Lilly in the conduct of any activity allocated to Lilly pursuant to Section 3.3(a)(i), and (c) otherwise each Party shall bear any and all costs and expenses it incurs associated with its activities conducted under the Research Program.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Certain Standards Applicable to Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">All Research conducted by either Party for non-regulated work under this Agreement will be conducted in accordance with the Research Plans, Eli Lilly and Company Good Research Practices, Eli Lilly and Company Animal Care and Use Requirement for Animal Researchers and Suppliers and all Applicable Laws, including those regarding data privacy and data security laws and regulations.  For purposes of this Agreement, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Eli Lilly and Company Good Research Practices</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the compiled set of shared research quality standards defining how Lilly&#8217;s research laboratories conduct good science for non-regulated work as set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 3.9 Part A</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  For purposes of this Agreement, &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Eli </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Lilly </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">and Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%"> Animal Care and Use </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Requirement for Animal Researchers and Suppliers</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means the guidelines relating to animal care and use for research done on behalf of Lilly as set forth in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 3.9 Part B</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  If Lilly reasonably requests, Foghorn will complete a self-assessment examination form based on such quality standards.  If it has not done so prior to the Effective Date, a duly authorized representative of Lilly may make an on-site visit to Foghorn for the purpose of conducting a quality assessment or quality audit for non-regulated work, which shall be performed at Lilly&#8217;s cost and expense.  Additionally, Lilly may conduct compliance audits of Foghorn and&#47;or Foghorn&#8217;s Affiliates and Third Party subcontractors engaged in work related to this Agreement, during normal business hours, no more than once annually, except in the case of audits for cause to ensure compliance with applicable cGCP, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">G</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">LP and GRP requirements, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that Lilly has requested such audit with written notice of at least </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">and such audit does not unreasonably interfere with the audited entity&#8217;s operations.  All such audits shall be done at Lilly&#8217;s cost and expense.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Subcontracting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Subject to the terms of this Section 3.10, each Party may engage its Affiliates or Third Party subcontractors (including contract research organizations and contract manufacturing organizations) to perform portions of its obligations under this Agreement.  The activities of any such Third Party subcontractors will be considered activities of such subcontracting Party under this Agreement.  The subcontracting Party shall ensure compliance by such Third Party subcontractors with the terms of this Agreement, including any applicable Research Plans, Development Plans or Commercialization Plans, or any Compliance Agreement.  The subcontracting Party shall ensure, prior to engaging any Third Party subcontractor, that such Third Party subcontractor is subject to written agreements containing terms and conditions that&#58;  (a)&#160;impose obligations of confidentiality on such Third Party subcontractor that are no less than the obligations of confidentiality on each Party under this Agreement (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, &#91;***&#93;) and obligations consistent with the intellectual property provisions of Article 10&#59; (b) do not under any circumstance impose any payment obligations or liability on the non-subcontracting Party&#59; and (c)&#160;are otherwise consistent with the terms of this Agreement.  If Foghorn or any of its Affiliates intends to engage a Third Party subcontractor to perform any of its obligations under this Agreement, Foghorn shall provide the JSC written notice no less than thirty (30) days prior to engaging such Third Party subcontractor, which notice shall include the identity of such subcontractor and a high level description of the services such subcontractor will perform, and if Lilly advises Foghorn that Lilly has a reasonable basis to believe that such subcontractor&#8217;s involvement would pose material risks from a legal, compliance or quality perspective, Foghorn and its Affiliates shall not engage such subcontractor or permit such subcontractor to conduct activities under the Research Program unless and until Lilly has approved such subcontractor and the anticipated responsibilities to be allocated to such subcontractor. Notwithstanding the foregoing or anything to the contrary in this Agreement, Foghorn may engage any of the entities set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 3.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and their Affiliates as subcontractors under this Agreement without Lilly&#8217;s consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Project Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  In the event that it is necessary to enable execution of a Research Plan or to facilitate activities under a Clinical Trial, each Party may need to transfer certain materials to the other Party that are not otherwise delivered under a supply or other separate agreement between the Parties or their Affiliates. In each such case, the Parties will mutually agree on the terms of such material transfer (including execution of a quality agreement, with respect to the transfer of materials to facilitate activities under a Clinical Trial), which in any case shall be subject to the terms of Article 10 of this Agreement.  Any such materials provided by one Party to the other Party shall be accompanied by a materials transfer record substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 3.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Materials Transfer Record</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  In the event of such transfer, unless otherwise mutually agreed, the providing Party shall be responsible for obtaining all necessary approvals and&#47;or filings as required under Applicable Laws for the exportation of any such materials to the receiving Party and the receiving Party shall be responsible for obtaining all necessary approvals and&#47;or filings as required under Applicable Laws for their importation and use by the receiving Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Technical Transfer Assistance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Following the conclusion of each Project, Foghorn shall reasonably cooperate with Lilly and provide Lilly all necessary assistance reasonably requested by Lilly in connection with the preparation and submission by Lilly of the applicable IND or BLA&#47;NDA, including assistance with technical transfer with respect to Manufacturing Know-How for the Collaboration Target, Compound or Product. All such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">activities shall be at Lilly&#8217;s cost, except to the extent such activities are subject to the Expense and Margin Sharing terms under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">3.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br><br>COLLABORATION TARGETS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Initial Targets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  As of the Effective Date, the Parties have identified the following Targets to be initially subject to the Research Program as Collaboration Targets pursuant to this Agreement&#58; (i) the protein coding gene referred to as SMARCA2 (UniProt identifier &#8220;P51531&#8221;) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Selective BRM Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), (ii) the protein coding gene referred to as &#91;***&#93; (UniProt identifier &#8220;&#91;***&#93;&#8221;) (the &#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%"> Targe</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">t&#8221;), and (iii) the protein coding gene referred to as &#91;***&#93; (UniProt identifier &#8220;&#91;***&#93;&#8221;) (the &#8220;&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%"> Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; and together with the Selective BRM Target and the &#91;***&#93; Target, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Initial Targets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  During the Research Term, Lilly may select Additional Targets (pursuant to Section 4.2) for inclusion in the Research Program, and may replace Collaboration Targets (pursuant to Section 4.3) as permitted under this Agreement, in each case, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that such Targets are not Unavailable Targets at the time Lilly proposes such addition or replacement. Notwithstanding anything to the contrary in this Agreement, there shall be no more than &#91;***&#93; Collaboration Targets at any given time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Additional Targets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Lilly shall have the right at any time during the Research Term to propose additional Targets as Collaboration Targets under this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Additional Targets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) in accordance with the terms of this Section 4.2&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that at no time may there be more than &#91;***&#93; Collaboration Targets. If Lilly intends to propose one (1) or more Targets (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Proposed Additional Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) as Additional Targets, it shall provide written notice thereof to Foghorn during the Research Term, which notice shall identify the applicable Proposed Additional Targets (each such notice, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Proposed Additional Target Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). Within &#91;***&#93; following Foghorn&#8217;s receipt of a Proposed Additional Target Notice, Foghorn shall provide written notice to Lilly disclosing whether the Proposed Additional Targets that are the subject of such Proposed Additional Target Notice are Unavailable Targets (each such notice from Foghorn to Lilly, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Additional Target Availability Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). If an Additional Target Availability Notice discloses that a Proposed Additional Target is not an Unavailable Target, Lilly shall have &#91;***&#93; following its receipt of such Additional Target Availability Notice to determine whether such Proposed Additional Target shall be deemed an Additional Target and a Collaboration Target, and during such &#91;***&#93; period (a) the Proposed Additional Target shall not become an Unavailable Target, and Foghorn shall not cause or permit such Proposed Additional Target to become an Unavailable Target, and (b) the Parties shall facilitate, in good faith, any necessary scientific discussions regarding the viability of such Proposed Additional Target. If Lilly provides a written notice to Foghorn within &#91;***&#93; following its receipt of the applicable Additional Target Availability Notice designating such Proposed Additional Target as an Additional Target and a Collaboration Target, then such Proposed Additional Target shall thereafter be deemed to be an Additional Target and a Collaboration Target. In such case a Project associated with such Additional Target shall be added to the Research Program as an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Additional Project</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">,&#8221; and the Parties (through the JRC) shall prepare the Research Plan for the Additional Project (in accordance with Section 3.5.2). Lilly shall have an iterative right to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">provide Proposed Additional Target Notices to Foghorn during the Research Term until there are &#91;***&#93; Collaboration Targets. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Replacement Targets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  If during the Research Term (a) &#91;***&#93;, the JRC elects to discontinue all Projects with respect thereto and (b) &#91;***&#93;, then&#58; (i) such Collaboration Target shall thereafter no longer be considered a Collaboration Target and shall be deemed a Discontinued Target (and the corresponding Project or Projects, as applicable, each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Discontinued Project</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;)&#59; (ii) Foghorn shall have no further obligations under the Research Plan with respect to such Discontinued Target&#59; and (iii) Lilly shall have the right to select a Target that is not an Unavailable Target to replace such Discontinued Target in the Research Program (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Replacement Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) in accordance with the terms of this Section 4.3. If Lilly intends to designate a Target (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Proposed Replacement Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) as a Replacement Target, it shall provide written notice thereof to Foghorn during the Research Term, which notice shall identify the Proposed Replacement Target (each such notice, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Proposed Replacement Target Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). Within &#91;***&#93; following Foghorn&#8217;s receipt of a Proposed Replacement Target Notice, Foghorn shall provide a written notice to Lilly disclosing whether the Proposed Replacement Target that is the subject of such Proposed Replacement Target Notice is an Unavailable Target (each such notice from Foghorn to Lilly, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Replacement Target Availability Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). If a Replacement Target Availability Notice discloses that a Proposed Replacement Target is not an Unavailable Target, then such Proposed Replacement Target shall automatically be deemed to be a Replacement Target and a Collaboration Target upon Lilly&#8217;s receipt of such Replacement Target Availability Notice, and in such case a Project associated with such Replacement Target shall replace the Project for the Discontinued Target as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Replacement Project</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">,&#8221; and the Parties (through the JRC) shall prepare the Research Plan for the Replacement Project (in accordance with Section 3.5.2). Lilly shall have an iterative right to provide Proposed Replacement Target Notices to Foghorn during the Research Term until a Discontinued Target has been replaced with a Replacement Target. For avoidance of doubt, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Discontinued Targets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The provisions of this Section 4.4 shall apply to each Discontinued Target&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that each provision of Section 4.4 shall cease to apply with respect to such Discontinued Target to the extent that it becomes the subject of a Reactivated Project pursuant to Section 3.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">4.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12pt">If a Collaboration Target becomes a Discontinued Target, except as set forth in this Section 4.4, all rights and licenses granted under this Agreement will terminate with respect to such Discontinued Target&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">4.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12pt">If either Party believes that one or more Collaboration Targets may become Discontinued Targets because the Research Term, after having been extended the maximum number of times permitted under Section&#160;3.4, will expire prior to the achievement of the applicable Critical Success Factors for at least one (1) Compound Directed To each such Target or the initiation of the first GLP Toxicology Study of a Compound Directed To each such Target, but a further extension of the Research Term may permit such Collaboration Target(s) to achieve such Critical Success Factors or such initiation of GLP Toxicology Study, such Party may, by written notice to the other Party identifying each such Collaboration Target and delivered no later than &#91;***&#93; prior to the expiration of the Research Term (after the Research Term has been extended the maximum number of times permitted under Section&#160;3.4), request a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">one (1) time further &#91;***&#93; extension of the Research Term so that the Parties may continue to advance such Collaboration Targets during such extension period (with the costs of work under the extended Research Term being borne as described in Section 3.8), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that the non-requesting Party may, with notice delivered to the requesting Party no later than &#91;***&#93; following receipt of the requesting Party&#8217;s extension request, decide that such extension should not occur. Notwithstanding anything to the contrary in this Agreement, the Research Term may only be extended one (1) time for an additional &#91;***&#93; period pursuant to Section 4.4. If (a) Lilly requests an extension of the Research Term with respect to a Collaboration Target pursuant to Section 4.4 and Foghorn declines such extension and the Collaboration Target then becomes a Discontinued Target because there has not been at least one (1) Compound Directed To such Target that timely achieved the applicable Critical Success Factors or the initiation of the first GLP Toxicology Study of a Compound Directed To such Target, or (b) following a further extension of the Research Term pursuant to this Section 4.4.2, the extended Research Term expires and a Collaboration Target becomes a Discontinued Target because there has not been at least one (1) Compound Directed To such Target that timely achieved the applicable Critical Success Factors or the initiation of the first GLP Toxicology Study of a Compound Directed To such Target, and in either of case (a) or (b) the relevant Target was a Collaboration Target under this Agreement for at least &#91;***&#93; prior to the date of Lilly&#8217;s request or the Research Term expiration (as applicable), then in each such case (a) and (b), Foghorn shall not Exploit Compounds and Products Directed To the applicable Discontinued Targets, in the Field and in the Territory, for a period of &#91;***&#93; following the expiration of the Research Term. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">4.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12pt">If a Collaboration Target becomes a Discontinued Target because Foghorn exercised its right to terminate under Section 14.2, Lilly exercised its right to terminate under Section 14.5 or if Lilly does not request an extension of the Research Term or declines a Foghorn request to extend the Research Term, in each case under Section 4.4.2, then&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">Lilly will, and hereby does, grant to Foghorn a non-exclusive, perpetual, irrevocable, royalty-free license, with the right to grant sublicenses through multiple tiers, under Lilly&#8217;s interest in any &#91;***&#93; and any &#91;***&#93;  (excluding any Excluded Technology) that, in each case, solely and exclusively relates to the Discontinued Target, to Research, Develop, Manufacture, Commercialize or otherwise Exploit Compounds and Products Directed To such Discontinued Target, in the Field and in the Territory&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Lilly shall in good faith consider reasonable requests from Foghorn to license Lilly&#8217;s interest in &#91;***&#93; or &#91;***&#93; (excluding any Excluded Technology) not otherwise licensed to Foghorn pursuant to Section 4.4.3(a), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that any such license granted to Foghorn shall include appropriate financial consideration payable to Lilly for Foghorn&#8217;s use of such &#91;***&#93; or &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br><br>LILLY-CONTROLLED PROGRAMS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Applicability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The terms and provisions of this Article 5 shall apply solely with respect to any Discovery Program, Selective BRM Program and &#91;***&#93; Program that is not a Joint Program, and Candidates and Products arising from such programs (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Lilly-Controlled Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). Joint Programs and Joint Program Products shall be the subject of Article 6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Lilly Rights and Responsibilities for Lilly-Controlled Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Except with respect to the Research activities to be conducted by Foghorn pursuant to a Research Plan, Lilly shall be solely responsible for and shall have the exclusive right to Exploit Lilly-Controlled Products in the Field in the Territory, including with respect to the conduct of GLP Toxicology studies.  Subject to the terms of this Agreement, all decisions concerning the Exploitation of Lilly-Controlled Products following Research, including the clinical and regulatory strategy of Lilly-Controlled Products, the Development, Manufacturing, marketing and sales (or, as applicable, any Product recalls) of Lilly-Controlled Products, and the design, price, promotion, and other Commercialization of Lilly-Controlled Products, is within the sole discretion of Lilly.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Development Plan for Lilly-Controlled Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Within &#91;***&#93; following the occurrence of the Project Completion Event for each Discovery Project, Lilly shall provide Foghorn with a high level written development plan summarizing the Development activities that it expects to conduct, whether directly or through its Affiliates or Sublicensees, for all Lilly-Controlled Products with respect to such Discovery Project. Within &#91;***&#93; following Foghorn&#8217;s decision to opt out of the Expense and Margin Sharing with respect to either of the Selective BRM Program or the &#91;***&#93; Program, Lilly shall provide Foghorn with a high level written development plan summarizing the Development activities that it expects to conduct, whether directly or through its Affiliates or Sublicensees, for all Lilly-Controlled Products with respect to such program.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Development Reports for Lilly-Controlled Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Within &#91;***&#93; following the occurrence of the Project Completion Event for each Discovery Project, Lilly shall provide Foghorn with a high level written development plan summarizing the Development activities that it expects to conduct, whether directly or through its Affiliates or Sublicensees, for all Lilly-Controlled Products with respect to such Discovery Project. If Foghorn elects to opt out of the Expense and Margin Sharing with respect to either of the Selective BRM Program or the &#91;***&#93; Program, then within &#91;***&#93; following such election, Lilly shall provide Foghorn with a high level written development plan summarizing the Development activities that it expects to conduct, whether directly or through its Affiliates or Sublicensees, for all Lilly-Controlled Products with respect to such program. On an annual basis thereafter, Lilly shall provide Foghorn with high level updates to each such development plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Commercialization Plan for Lilly-Controlled Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Within &#91;***&#93; following the first Marketing Approval Application for a Lilly-Controlled Product, Lilly shall provide Foghorn with a high level written commercialization plan summarizing the Commercialization activities that it expects to conduct, whether directly or through its Affiliates or Sublicensees, with respect to the Lilly-Controlled Products in the subsequent year. On an annual basis thereafter, Lilly shall provide Foghorn with high level updates to such commercialization plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Regulatory Matters for Lilly-Controlled Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">5.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Lilly Regulatory Control for Lilly-Controlled Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Except as provided in this Section 5.6 or under a Research Plan, as between the Parties, Lilly shall have the sole and exclusive right and responsibility for and control of the preparation, submission, and maintenance of all Regulatory Filings and obtaining Marketing Approvals (including the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">preparation and submission of an IND, BLA&#47;NDA (and any other documents needed for clinical submissions in the European Union or otherwise), or marketing authorization application (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">MAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) and including obtaining IND, BLA&#47;NDA, or MAA approval) with respect to Lilly-Controlled Products, and shall have sole control over all interactions with the applicable Regulatory Authority. Foghorn shall reasonably cooperate with Lilly, at Lilly&#8217;s reasonable request and expense, with respect to any regulatory matters related to Lilly-Controlled Products.  Lilly will own all right, title and interest in and to any and all Regulatory Filings and Marketing Approvals for Products and, as between the Parties, all such Regulatory Filings and Marketing Approvals will be held in the name of Lilly.  Foghorn shall execute all documents and take all actions as are necessary or reasonably requested by Lilly to vest such title in Lilly.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">5.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Foghorn Involvement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. For each Lilly-Controlled Product, (a) Lilly will keep Foghorn reasonably informed as to all material interactions with Regulatory Authorities relating to such Lilly-Controlled Product in the U.S. and (b) Lilly will provide Foghorn a written update, on a Calendar Quarter basis, providing a high-level summary of all material interactions with Regulatory Authorities relating to such Lilly-Controlled Product in Major Markets outside the U.S.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Adverse Event Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Lilly shall establish, hold, and maintain the global safety database for Lilly-Controlled Products with respect to information on adverse events concerning the Lilly-Controlled Products, as and to the extent required by Applicable Law.  If necessary for the development of Lilly-Controlled Products, upon request of either Party, the Parties shall negotiate in good faith the terms of a pharmacovigilance agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">5.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Diligence Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  On a program-by-program basis, for each program that is not a Joint Program, Lilly shall use Commercially Reasonable Efforts to (a) &#91;***&#93; and (b) &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br><br>JOINT PROGRAMS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Overview</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  During the Term, on a program-by-program basis, Foghorn shall have the right and obligation to share in the Expense and Margin Sharing for certain programs as provided in this Agreement (each such program, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Joint Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) and may, as further described herein, also actively participate in such Joint Program, subject to demonstrating Joint Program Competencies.  As of the Effective Date, the Selective BRM Program and the &#91;***&#93; Program shall be considered Joint Programs, in each case, until such time as Foghorn elects to opt out of its participation in the Expense and Margin Sharing for such Selective BRM&#47;&#91;***&#93; Program pursuant to Section 6.2.  In addition, Foghorn may elect to include Discovery Programs as Joint Programs pursuant to Section 6.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Foghorn Opt-Out Right for Selective BRM&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12pt">For each of the Selective BRM Program and the &#91;***&#93; Program, no earlier than &#91;***&#93; prior to, and no later than &#91;***&#93; prior to, the anticipated date of enrollment of the first patient in the first Registrational Clinical Trial under the program, Lilly shall provide to Foghorn a written budget and Development Plan for Development work under each such program commencing with the first Registrational Clinical Trial. Foghorn shall have the option to opt out </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">of the Expense and Margin Sharing with respect to the Selective BRM Program and&#47;or the &#91;***&#93; Program as follows&#58; (i) immediately upon providing Lilly written notice of such decision, if such written notice is provided prior to the &#91;***&#93; following the earlier of (A) Foghorn&#8217;s receipt of the Development Plan and budget for such program, as applicable, or (B) Lilly&#8217;s notice to Foghorn of a subsequent determination that a Clinical Trial that has already been Initiated is the first Registrational Clinical Trial under such program (which notice Lilly will provide to Foghorn promptly following any such determination), or (ii) by providing &#91;***&#93; written notice of such decision, if such written notice is provided at any time after the deadline set forth in the foregoing clause (i) for such program. If the effective date of such opt-out is not the last day of a Calendar Quarter, such effective date will be adjusted to the last day of the Calendar Quarter in which the effective date of such opt-out would otherwise have fallen&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that this adjustment shall not affect the notice periods for the opt-out notice set forth in this Section 6.2.1. In the case of such a Foghorn opt-out, the following shall apply&#58; (a) Foghorn shall thereafter have no right to participate in the Development, Commercialization, or other Exploitation of the applicable Candidates or Products, except as set forth in this Agreement, (b) the Expense and Margin Sharing shall no longer apply to such program (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, Foghorn shall have no further obligation to share in the relevant expenses for such program and shall have no further right to receive a share of the Gross Margin Share for such program), (c) the Royalties set forth in Article 9 shall apply with respect to Products for such program, (d) the program shall cease to be a Joint Program, the applicable Candidates and Products shall cease to be Joint Program Products and shall instead be considered Lilly-Controlled Products, and the provisions of Article 5 shall instead apply to such program and such Candidates and Products, and (e) the JSC, and any applicable JSC Subcommittees or Working Groups specific to such program, shall immediately be disbanded with respect to such program (or shall no longer oversee and have any approval authority with respect to such program), and all approval rights of the JSC or final decision-making authority granted to Foghorn pursuant to Section 2.8 or Article 6 with respect to such program shall become approval rights of Lilly for such program. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12pt">Notwithstanding the foregoing, if (a) Foghorn elects to opt out of its participation in the Selective BRM Program or the &#91;***&#93; Program pursuant to Section 6.2.1 after Lilly exercises its final decision-making authority under Section 2.8.1(c) to approve a Development Plan (or amendment thereto) for such program and (b) Lilly subsequently either amends such Development Plan to reduce the budget therefor, or completes the work under such Development Plan at a cost below the budgeted amount included therein, in each case, by the greater of &#91;***&#93; or &#91;***&#93;, then (i) Lilly shall promptly notify Foghorn in writing of such amendment or deviation and provide Foghorn with an updated Development Plan, if applicable, and (ii) within &#91;***&#93; following receipt of such notice, Foghorn may, upon written notice to Lilly, elect to opt back in to participating in such program, in which case (A) such program will again be considered a Joint Program under this Agreement, (B) the terms of Section 6.2.1(a)-(e) will no longer apply to such Joint Program, (C) unless the Parties mutually agree otherwise, the materially amended Development Plan for such program will be deemed to be the Development Plan for the corresponding Joint Program, and (D) Foghorn shall, prior to the &#91;***&#93; anniversary of the later of (y) the date on which Foghorn opts back in to participating in the applicable program or (z) the date on which Lilly provides an invoice for the applicable reimbursement amount, reimburse Lilly (in regular installments, the cadence of which shall be agreed to by the Parties) for amounts actually incurred by Lilly completing activities under the applicable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Development Plan which, but for Foghorn&#8217;s election to opt out of such program, would have been allocated to Foghorn pursuant to Section 9.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Foghorn Opt-In and Opt-Out Rights for Discovery Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12pt">Foghorn shall have the option, on a Discovery Program-by-Discovery Program basis, to participate in the Expense and Margin Sharing for such Discovery Program. Within &#91;***&#93; following the successful completion of Dose-Finding Tox for a Discovery Program, Lilly shall provide to Foghorn a proposed high-level development plan and budget with respect to such Discovery Program that is substantially similar in scope to Development Plans for Joint Programs (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Proposed Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). Foghorn may exercise such option with respect to a Discovery Program at any time within &#91;***&#93; following its receipt of a Proposed Development Plan for such Discovery Program by notifying the JSC of such determination, after which the following shall apply&#58;  (a) subject to the terms of Section 6.7, Foghorn shall have the right to participate in the Development and Commercialization, in the U.S. only, of the Candidates and Products arising from such Discovery Program, as further described herein, (b) Foghorn shall participate in the worldwide Expense and Margin Sharing for such Discovery Program, as further detailed in Article 9, (c) such Discovery Program shall be considered a Joint Program for purposes of this Agreement and the provisions of Article 5 shall thereafter cease to apply to such program, (d) notwithstanding anything to the contrary in this Agreement, the Proposed Development Plan for such Discovery Program shall be deemed to be the Development Plan for the corresponding Joint Program (unless the Parties mutually agree otherwise), and (e) the relevant Milestone Payments and Royalties shall be adjusted, as further described in Article 9.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12pt">Once Foghorn has exercised such option with respect to a Discovery Program, Foghorn may subsequently elect to opt out of its participation in such Discovery Program as a Joint Program (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, to cease participating in Development and Commercialization activities and in the Expense and Margin Sharing for such program) at any time (A) following (but not prior to) the Initiation of the first Registrational Clinical Trial for such program or (B) if such Registrational Clinical Trial is not determined to be a Registrational Clinical Trial until after its Initiation, then following Lilly&#8217;s notice to Foghorn of such determination (which notice Lilly will provide to Foghorn promptly following any such determination), in each case by providing written notice thereof to Lilly, and in which case, the following shall apply, subject to Foghorn&#8217;s right to subsequently opt in to such Discovery Program under Section 6.3.3&#58; (a) Foghorn shall thereafter have no right to participate in the Development, Commercialization or other Exploitation of the applicable Candidates and Products, except as set forth in this Agreement, (b) the Expense and Margin Sharing shall no longer apply to such program (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, Foghorn shall have no further obligation to share in the relevant expenses for such program and shall have no further right to receive a share of the Gross Margin Share for such program), (c) the Royalties applicable to the applicable Products for such program shall be revised, as set forth in Section 9.5.3(b), (d) the program shall cease to be a Joint Program, the applicable Candidates and Products shall cease to be Joint Program Products and shall revert to being Lilly-Controlled Products, and the provisions of Article 5 shall instead apply to such program and such Candidates and Products, and (e) any applicable JSC Subcommittees or Working Groups specific to such program, shall immediately be disbanded with respect to such program (or shall no longer oversee and have any approval authority with respect to such program), and all approval </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">rights of the JSC or final decision-making authority granted to Foghorn pursuant to Section 2.8 or Article 6 with respect to such program shall become approval rights of Lilly for such program.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12pt">Notwithstanding the foregoing, if (a) Foghorn elects to opt out of its participation in a Discovery Program as a Joint Program pursuant to Section 6.3.2 after Lilly exercises its final decision-making authority under Section 2.8.1(c) to approve a Development Plan (or amendment thereto) for such program and (b) Lilly subsequently either amends such Development Plan to reduce the budget therefor, or completes the work under such Development Plan at a cost below the budgeted amount included therein, in each case, by the greater of &#91;***&#93; or &#91;***&#93;, then (i) Lilly shall promptly notify Foghorn in writing of such amendment or deviation and provide Foghorn with an updated Development Plan, if applicable, and (ii) within &#91;***&#93; following receipt of such notice, Foghorn may, upon written notice to Lilly, elect to opt back in to participating in such program, in which case (A) such program will again be considered a Joint Program under the Agreement, (B) the terms of Section 6.3.2(a)-(e) will no longer apply to such Joint Program, (C) unless the Parties mutually agree otherwise, the amended Development Plan for such program will be deemed to be the Development Plan for the corresponding Joint Program, and (D) Foghorn shall, prior to the &#91;***&#93; anniversary of the later of (y) the date on which Foghorn opts back in to participating in the applicable program or (z) the date on which Lilly provides an invoice for the applicable reimbursement amount, reimburse Lilly (in regular installments, the cadence of which shall be agreed to by the Parties) for amounts incurred by Lilly completing activities under the Development Plan which, but for Foghorn&#8217;s election to opt out of such program, would have been allocated to Foghorn pursuant to Section 9.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Lilly Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Except with respect to any Research activities to be conducted by Foghorn pursuant to a Research Plan and as set forth in Section 6.5, Lilly shall lead and be primarily responsible for the conduct of all worldwide Development, Manufacturing, Commercialization, and other Exploitation activities with respect to each Joint Program, including with respect to Regulatory Filings, seeking and obtaining Marketing Approvals, and the conduct of GLP Toxicology studies and all Clinical Trials, unless and until the Parties have entered into a separate Development Plan or Commercialization Plan setting forth the applicable responsibilities of Foghorn with respect to any such activities.  Subject to the terms of this Agreement, including Section 2.8, all decisions concerning the Exploitation of Discovery Products following Research, including the clinical and regulatory strategy of Discovery Products, the Development, marketing and sales of Discovery Products, and the design, price, promotion, and other Commercialization of Discovery Products, shall be subject to discussion by the JSC with Lilly having the final decision-making authority, unless otherwise agreed in a Development Plan or Commercialization Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Foghorn Active Participation in Non-Sales Force Joint Program Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Other than with respect to sales force activities (which are addressed in Section 6.6 below), Foghorn may participate in any U.S. Development, U.S. Commercialization, or other U.S. Exploitation activities (but excluding (A) Manufacturing activities and (B) medical affairs activities (other than sale force and medical field force activities)) with respect to a Joint Program, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that Foghorn shall notify Lilly of the specific activities in which Foghorn would like to participate, and following such notice, in the case of activities following the Initiation of the first Registrational Clinical Trial under such Joint Program, the applicable JSC Subcommittee determines that Foghorn satisfies the Joint Program Operational Competencies </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">necessary to conduct such activities. Without limiting the foregoing, the Parties shall endeavor to &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Foghorn Active Participation in Sales Force Joint Program Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  As part of the JSC&#8217;s assessment of Foghorn&#8217;s Joint Program Commercialization Operational Competencies with respect to U.S. sales force and medical field force activities (as provided in Section 6.7.2), Foghorn shall notify Lilly of the percentage of the U.S. sales force and medical field force efforts it wishes to provide for such Joint Program, which percentage shall be between &#91;***&#93; and &#91;***&#93; for the Selective BRM&#47;&#91;***&#93; Programs and between &#91;***&#93; and &#91;***&#93; for all other applicable Discovery Programs. Subject to the JSC confirming that Foghorn satisfies the Joint Program Commercialization Operational Competencies at the level proposed by Foghorn (as such proposal may be modified pursuant to Section 6.7.2(b))&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12pt">with respect to the Selective BRM&#47;&#91;***&#93; Programs, (A) if Foghorn contributes &#91;***&#93; of the U.S. sales force and medical field force efforts for such Joint Programs, Foghorn&#8217;s share of the U.S. Gross Margin and U.S. Eligible Expenses under Section 9.3.6 will remain unadjusted, (B) if Foghorn contributes &#91;***&#93; of the U.S. sales force and medical field force efforts for such Joint Programs, Foghorn&#8217;s share of the U.S. Gross Margin and U.S. Eligible Expenses under Section 9.3.6 shall be adjusted whereby Lilly shall be entitled to and responsible for &#91;***&#93; of the Gross Margin Share and U.S. Eligible Expenses and Foghorn shall be entitled to and responsible for &#91;***&#93; of the Gross Margin Share and U.S. Eligible Expenses, and (C) if Foghorn contributes a percentage of U.S. sales force and medical field force efforts between &#91;***&#93; and &#91;***&#93; then Foghorn&#8217;s percentage allocation of Gross Margin Share and U.S. Eligible Expenses will be equal to the result of the following formula, in which &#91;***&#93; is the percentage of such efforts contributed by Foghorn&#58; &#91;***&#93;, with Lilly&#8217;s percentage share equaling 100% minus Foghorn&#8217;s share. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12pt">for each other Discovery Programs for which Foghorn has opted to participate in the Expense and Margin Sharing, (A) if Foghorn contributes &#91;***&#93; of the U.S. sales force and medical field force efforts for such Joint Program, Foghorn&#8217;s share of the U.S. Gross Margin and U.S. Eligible Expenses under Section 9.3.6 will remain unadjusted, (B) if Foghorn contributes &#91;***&#93; of the U.S. sales force and medical field force efforts for such Joint Program, Foghorn&#8217;s share of the U.S. Gross Margin and U.S. Eligible Expenses under Section 9.3.6 shall be adjusted whereby Lilly shall be entitled to and responsible for &#91;***&#93; of the Gross Margin Share and U.S. Eligible Expenses and Foghorn shall be entitled to and responsible for &#91;***&#93; of the Gross Margin Share and U.S. Eligible Expenses, and (C) if Foghorn contributes a percentage of U.S. sales force and medical field force efforts between &#91;***&#93; and &#91;***&#93; then Foghorn&#8217;s percentage allocation of Gross Margin Share and U.S. Eligible Expenses will be equal to the result of the following formula, in which &#91;***&#93; is the percentage of such efforts contributed by Foghorn&#58; &#91;***&#93;, with Lilly&#8217;s percentage share equaling 100% minus Foghorn&#8217;s share.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Joint Program Competencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Joint Program Financial Competencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The following terms of this Section 6.7.1 &#91;***&#93;&#58; Foghorn shall be required to demonstrate that it satisfies the Joint Program Financial Competencies for each Joint Program (&#91;***&#93; Foghorn does not satisfy the Joint Program Financial Competencies with respect to a Joint Program &#91;***&#93;, then the program shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">cease to be a Joint Program, the applicable Candidates and Products shall cease to be Joint Program Products and &#91;***&#93;, and the provisions of Article 5 shall instead apply to such program and such Candidates and Products, (b) Foghorn shall thereafter have no right to participate in the Development, Commercialization or other Exploitation of the applicable Candidates and Products, except as set forth in this Agreement, (c) the Expense and Margin Sharing shall no longer apply to such program &#91;***&#93;, (d) the Royalties applicable to the applicable Products for such program shall be based on the applicable Royalty Table in Article 9, and (e) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Joint Program Operational Competencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:22.7pt">  Development Operational Competencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> The following terms of this Section 6.7.2(a) shall apply on a Joint Program-by-Joint Program and activity-by-activity basis with respect to each specific Development activity allocated to Foghorn in a Development Plan and to be conducted following the Initiation of the first Registrational Clinical Trial under the applicable Joint Program (each such activity, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Development Operational Competency Activity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;)&#58; Foghorn shall be required to demonstrate, as a condition to participating in a Development Operational Competency Activity, that it satisfies the Joint Program Development Operational Competencies for such Development Operational Competency Activity (such satisfaction as determined by the JSC) no later than (A) &#91;***&#93; prior to the anticipated Initiation of the first Registrational Clinical Trial under the applicable Joint Program or (B) if such Registrational Clinical Trial is not determined to be a Registrational Clinical Trial until after its Initiation, &#91;***&#93; following Lilly&#8217;s notice to Foghorn of such determination (which notice Lilly will provide to Foghorn promptly following any such determination)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that in such event, the Parties shall cooperate in good faith to (i) accelerate initiation and completion of any necessary assessment of Joint Program Development Operational Competency, and (ii) attain such Joint Program Development Operational Competency as soon as reasonably practicable. The Parties shall begin good faith discussions regarding such Joint Program Development Operational Competencies no later than (x) &#91;***&#93; prior to the anticipated Initiation of the first Registrational Clinical Trial under the applicable Joint Program or (y) if such Registrational Clinical Trial is not determined to be a Registrational Clinical Trial until after its Initiation, as soon as reasonably practicable, but in no event later than &#91;***&#93; following Lilly&#8217;s notice to Foghorn of such determination (which notice Lilly will provide to Foghorn promptly following any such determination), and Foghorn shall cooperate in good faith with Lilly to respond to reasonable requests from Lilly or the JSC for documents and information (subject to appropriate confidentiality restrictions) necessary for the JSC to determine whether Foghorn satisfies such Joint Program Development Operational Competencies.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:22.02pt">Commercialization Operational Competencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The following terms of this Section 6.7.2(b) shall apply on a Joint Program-by-Joint Program and activity-by-activity basis with respect to each specific Commercialization activity allocated to Foghorn in a Commercialization Plan (each such activity, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Commercialization Operational Competency Activity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;)&#58; Foghorn shall be required to demonstrate, as a condition to participating in a Commercialization Operational Competency Activity, that it satisfies the Joint Program Commercialization Operational Competencies for such Commercialization Operational Competency Activity (such satisfaction as determined by the JSC) no later than (i) with respect to any sales force-related Joint Program Commercialization Operational Competencies, &#91;***&#93; prior to the estimated receipt of the first Marketing Approval in the United States of a Product </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">under the applicable Joint Program and (ii) with respect to all other Joint Program Commercialization Operational Competencies, the later of (A) &#91;***&#93; prior to the estimated receipt of the first Marketing Approval in the United States of a Product under the applicable Joint Program and (B) &#91;***&#93; after the date of approval of the applicable Commercialization Plan. The Parties shall begin good faith discussions regarding such Joint Program Commercialization Operational Competencies no later than &#91;***&#93; prior to the estimated receipt of the first Marketing Approval in the United States of a Product under the applicable Joint Program, and Foghorn shall cooperate in good faith with Lilly to respond to reasonable requests from Lilly or the JSC for documents and information (subject to appropriate confidentiality restrictions) necessary for the JSC to determine whether Foghorn satisfies such Joint Program Commercialization Operational Competencies. For sales force and medical field force activities, if the JSC determines that Foghorn does not satisfy the Joint Program Commercialization Operational Competencies at the percentage level specified by Foghorn, the JSC may permit Foghorn to submit a lower level of participation for evaluation by the JSC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Subsequent Monitoring of Joint Program Operational Competencies&#59; Foghorn Failure to Satisfy Joint Program Operational Competencies.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:22.7pt">Subsequent Monitoring of Joint Program Development Operational Competencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. On a Development Operational Competency Activity-by- Development Operational Competency Activity basis, if, following the initial determination of Joint Program Development Operational Competencies with respect to a Development Operational Competency Activity Lilly or the JDC determine in good faith that Foghorn is failing to satisfy the Joint Program Development Operational Competencies with respect to such Development Operational Competency Activity, then Lilly may request that the JSC conduct a subsequent review of Foghorn&#8217;s Joint Program Development Operational Competencies with respect to such Development Operational Competency Activity in a manner substantially similar to the manner set forth in Section 6.7.2&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, subsequent reviews of Foghorn&#8217;s Joint Program Development Operational Competencies shall not occur more than &#91;***&#93; across all Joint Programs absent Cause. For the purposes of this Section 6.7.3, &#8220;Cause&#8221; shall mean any material deficiency in Joint Program Operational Competency, as determined by Lilly or the JDC&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that any disagreement between the Parties as to whether cause is present shall be resolved in accordance with Section 15.2.2. In addition to the foregoing, if Foghorn determines in good faith that it is more likely than not expected to fail to satisfy the Joint Program Development Operational Competencies with respect to any Development Operational Competency Activity, Foghorn will promptly so notify Lilly and the Parties shall meet to discuss the matter in good faith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:22.02pt">Subsequent Monitoring of Joint Program Commercialization Operational Competencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. On a Commercialization Operational Competency Activity-by- Commercialization Operational Competency Activity basis, if, following the initial determination of Joint Program Commercialization Operational Competencies with respect to a Commercialization Operational Competency Activity, (i) Lilly or the JCC determines in good faith that Foghorn is failing to satisfy the Joint Program Commercialization Operational Competencies with respect to such Commercialization Operational Competency Activity or (ii) there is any material increase in the responsibilities allocated to Foghorn with respect to a Commercialization Operational Competency Activity in comparison to the responsibilities set </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">forth in the relevant initial Commercialization Plan, then in each case ((i) and (ii)) Lilly may request that the JSC conduct a subsequent review of Foghorn&#8217;s Joint Program Commercialization Operational Competencies with respect to such Commercialization Operational Competency Activity in a manner substantially similar to the manner set forth in Section 6.7.2&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, subsequent reviews of Foghorn&#8217;s Joint Program Commercialization Operational Competencies shall not occur more than &#91;***&#93; across all Joint Programs absent Cause. In addition to the foregoing, if Foghorn determines in good faith that it is more likely than not expected to fail to satisfy the Joint Program Commercialization Operational Competencies with respect to any Commercialization Operational Competency Activity, Foghorn will promptly so notify Lilly and the Parties shall meet to discuss the matter in good faith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:22.7pt">Foghorn Failure to Satisfy Joint Program Operational Competencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. If, as a result of any such subsequent review under Section 6.7.3(a) or Section 6.7.3(b), the JSC determines that Foghorn does not satisfy the Joint Program Development Operational Competencies with respect to a Development Operational Competency Activity or the Joint Program Commercialization Operational Competencies with respect to a Commercialization Operational Competency Activity, as applicable, then the relevant Joint Program will remain a Joint Program, but in such case, (i) Lilly shall have the sole and exclusive right to conduct the applicable Development Operational Competency Activity or Commercialization Operational Competency Activity, as applicable, under the relevant Joint Program, and (ii) the Expense and Margin Sharing for such Joint Program shall continue to apply.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">On-Going Monitoring of Joint Program Financial Competency&#59; Foghorn Default With Respect to Joint Program Financial Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. &#91;***&#93;, if, following the initial determination of Joint Program Financial Competencies with respect to a Joint Program, &#91;***&#93; in good faith that Foghorn is failing to satisfy the Joint Program Financial Competencies with respect to &#91;***&#93; under such Joint Program, then &#91;***&#93; conduct a subsequent review of Foghorn&#8217;s Joint Program Financial Competencies with respect to &#91;***&#93; under such Joint Program in a manner substantially similar to the manner set forth in Section 6.7.1&#59; &#91;***&#93; Foghorn does not satisfy the Joint Program Financial Competencies with respect to &#91;***&#93; under a Joint Program, or (B) Foghorn defaults on its obligations under Section 9.3.6 to pay Collaboration Amounts it owes Lilly with respect to such Joint Program and fails to cure such default within &#91;***&#93;, then in either case, the applicable program shall cease to be a Joint Program, the applicable Candidates and Products shall cease to be Joint Program Products and shall revert to &#91;***&#93;, and the provisions of Article 5 shall instead apply to such program and such Candidates and Products, (B) Foghorn shall thereafter have no right to participate in the Development, Commercialization or other Exploitation of the applicable Candidates and Products, except as set forth in this Agreement, (C) the Expense and Margin Sharing shall no longer apply to such program &#91;***&#93;, (D) the Royalties applicable to the applicable Products for such program shall be based on the applicable Royalty Table in Article 9, and (E) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Joint Program Development Plans and Commercialization Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Timing of Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. On a Joint Program-by-Joint Program basis, no later than &#91;***&#93; following the later of (a) initiation of the first GLP Toxicology Study with respect to a Joint Program or (b) with respect to a Discovery Program, Foghorn&#8217;s opt-in to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">such Joint Program under Article 6, the Parties shall enter into a Development Plan setting forth the responsibilities and strategies of the Parties with respect to the Development activities to be conducted under such Joint Program.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Timing of Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. On a Joint Program-by-Joint Program basis, no later than &#91;***&#93; prior to the estimated receipt of the first Marketing Approval in the United States of a Product under a Joint Program, the Parties shall enter into a Commercialization Plan setting forth the responsibilities and strategies of the Parties with respect to the Commercialization activities to be conducted under such Joint Program.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Contents of Development and Commercialization Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Each Development Plan and Commercialization Plan shall be consistent with the key Development or Commercialization strategies, as applicable, that are approved by the JSC for the relevant Joint Program and shall set forth for such Joint Program&#58; (a)&#160;the objective of the applicable Development Plan or Commercialization Plan, and the Exploitation activities to be conducted by each of the Parties&#59; (b) the expected resources to be allocated by each Party to performing such activities&#59; (c)&#160;the anticipated timeline and milestones of achieving such activities&#59; (d) a budget setting out on a Clinical Trial phase-by-Clinical Trial phase basis (for the Development Plan) or by Calendar Year (for the Commercialization Plan) the anticipated costs to be incurred by Foghorn (or any of its Affiliates) and Lilly (or any of its Affiliates) in the conduct of its activities under such plan (such budget for the Development Plan, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Development Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; and for the Commercialization Plan, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Commercialization Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;)&#59; and (e) with respect to each Commercialization Plan, an estimate of costs to be incurred by each Party in connection with its participation in the sales force under the applicable Joint Program pursuant to Section 6.6, set forth in terms of the estimated number of FTEs required and the sales force costs per FTE. Each Development Plan and Commercialization Plan shall only become effective once it has been approved by the applicable JSC Subcommittee and subject to the decision making in accordance with Section 2.8, and shall be subject to the JSC review process and update and amendment procedures consistent with those of Research Plans in Section 3.5.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Independent Studies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12pt">Notwithstanding any provision in this Agreement to the contrary, Lilly shall be permitted to conduct Clinical Trials or other Development activities for Joint Program Products in the Territory, the costs of which are not included in the then-current mutually agreed Development Budget, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that Lilly complies with the provisions of this Section 6.9 (each such activity, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">New Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). If Lilly desires to undertake a New Study, then Lilly will submit a proposed work plan, timeline and updated Development Budget for such New Study to Foghorn and the JDC for review (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">New Study Proposal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), and will provide Foghorn and the JDC with additional information related to such New Study that is reasonably requested by Foghorn or the JDC. Notwithstanding the foregoing, if the New Study described in a New Study Proposal is the first Registrational Clinical Trial of a Product under a Joint Program, then Foghorn shall participate in such Registrational Clinical Trial, subject to Foghorn&#8217;s ability to opt-out of the applicable Joint Program under Section 6.2 and Section 6.3.1, and the costs of such Registrational Clinical Trial shall be included in a mutually agreed Development Budget. Except as set forth in the immediately prior sentence, if, at any time within &#91;***&#93; after Foghorn&#8217;s receipt of a New Study Proposal (which &#91;***&#93; period may be extended by an additional thirty (30) days </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">if Foghorn or the JDC reasonably requests any additional information with respect to such New Study within &#91;***&#93; after Foghorn&#8217;s receipt of such New Study Proposal), Foghorn provides a written notice to Lilly opting out of participation in such New Study, then such New Study will be considered an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Independent Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.&#8221; Foghorn will have no obligation under this Agreement to conduct any portion of any Independent Study or to pay the costs of such Independent Study except as provided in this Section 6.9.1. Lilly shall use Commercially Reasonable Efforts to conduct each Independent Study in a manner that is consistent with the corresponding New Study Proposal provided to Foghorn. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12pt">Upon the completion of each Independent Study, Lilly will provide Foghorn with a reasonably detailed data package relating to the Independent Study. If such Independent Study results in, or the data from such Independent Study is used in a substantive manner as the basis for obtaining, a Marketing Approval for any Joint Program Product in the Field in the Territory (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Independent Study Regulatory Achievement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), then Lilly may offset from any subsequent payments to Foghorn under this Agreement with respect to the applicable Joint Program an amount equal to &#91;***&#93; of the amount that Foghorn would be required to pay to Lilly with respect to such Independent Study under Section 9.3 if the lesser of (x) the costs incurred by Lilly in conducting such Independent Study or (y) the costs budgeted by Lilly with respect to such Independent Study in the applicable New Study Proposal were included in Lilly&#8217;s Development Costs for the applicable Joint Program (to the extent such costs would have otherwise qualified as Development Costs). Notwithstanding anything to the contrary in this Agreement, except as set forth in the immediately prior sentence, the costs incurred by Lilly in conducting any Independent Study will not be included in the Development Costs or otherwise subject to the Expense and Margin Sharing terms. If the Parties do not agree as to whether an Independent Study met the requirements for an Independent Study Regulatory Achievement then such determination shall be resolved through the Dispute resolution process set forth in Section 15.2. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Regulatory Matters for Joint Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Responsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Lilly shall have the sole and exclusive right, responsibility for, and control over the preparation, submission and maintenance of all Regulatory Filings and obtaining Marketing Approvals with respect to the Joint Program Products (other than with respect to the Foghorn IND&#47;Trials). &#91;***&#93; Further, Lilly shall provide Foghorn with a copy of any material documents relating to Regulatory Filings or sought Marketing Approvals with respect to the Joint Program Products in Major Markets. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Regulatory Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Prior to the initiation of the first Clinical Trial for a Joint Program, the Parties shall enter into an appropriate safety and regulatory agreement governing the exchange of patient information under such Joint Program. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Transfer of Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. In the event that Foghorn is responsible for submitting any Regulatory Filings with respect to a Joint Program Product under a Joint Program, Foghorn will cooperate with Lilly with respect to the submission of such Regulatory Filings and the delivery and assignment to Lilly of such Regulatory Filings. Without limiting the foregoing, upon Lilly&#8217;s request, Foghorn will execute and deliver, or will cause to be executed and delivered, to Lilly such endorsements, assignments, and other documents as may be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">reasonably necessary to assign, convey, transfer, and deliver to Lilly, all of Foghorn&#8217;s rights, title, and interests in and to the applicable Regulatory Filings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Adverse Event Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Unless otherwise agreed by the Parties, Lilly shall establish, hold, and maintain the global safety database for Joint Program Products with respect to information on adverse events concerning the Joint Program Products, as and to the extent required by Applicable Law.  If necessary for the development of Joint Program Products, upon request of either Party, the Parties shall negotiate in good faith the terms of a pharmacovigilance agreement or product quality agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.10.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Diligence Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Each of Foghorn and Lilly shall use Commercially Reasonable Efforts to execute and to perform, or cause to be performed, in a good scientific manner and in compliance with Applicable Law, the Development, Manufacturing (solely in the case of Lilly), and Commercialization activities for which they are responsible under a Joint Program or assigned to them, respectively, in each Development Plan or Commercialization Plan (if applicable). Without limiting the foregoing, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br><br>LICENSE RIGHTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Exclusive License Grant to Lilly</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Foghorn (on behalf of itself and its Affiliates) hereby grants to Lilly and its Affiliates an exclusive (even as to Foghorn and its Affiliates, subject to the remainder of this Section 7.1), royalty-bearing (as set forth in Article 9), license, with the right to grant sublicenses (through multiple tiers, subject to Section&#160;7.3), under the Foghorn Technology to the extent necessary or reasonably useful to (a) Research and Manufacture Compounds and (b) Research, Develop, Manufacture, Commercialize, or otherwise Exploit Candidates and Products, in each case ((a) and (b)) in the Field in the Territory, subject to a right retained by Foghorn to perform activities to be conducted by Foghorn as contemplated under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Non-Exclusive License Grants to Foghorn</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Lilly hereby grants to Foghorn a worldwide, fully paid, royalty-free, non-sublicensable (except to Third Party subcontractors acting on its behalf, as permitted by Section 3.10, and subject to Section 7.3), non-exclusive license under the Lilly Background IP and &#91;***&#93; (in each case, excluding any Excluded Technology), solely as and to the extent necessary for Foghorn or its Affiliates (or Third Party subcontractors) to perform its obligations with respect to the Collaboration Targets and Compounds or Products under this Agreement, including its Research activities under the Research Plans during the Research Term and any Development or Commercialization activities (whether under an applicable Development Plan or Commercialization Plan or otherwise) with respect to any Joint Programs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Third Party Sublicenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Lilly and Foghorn may grant sublicenses under the rights and licenses granted to it under Section&#160;7.1 (in the case of Lilly) or Section 7.2 (in the case of Foghorn), but solely to Third Party subcontractors acting on its behalf and, with respect to Foghorn&#8217;s subcontractors, to the extent provided in Section 3.10, approved by Lilly or listed in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 3.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">), in full or in part, to Third Parties (with the right to sublicense through multiple tiers)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that&#58; (a) neither Party nor its Affiliates, licensees, Sublicensees or Litigation </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Settlement Sublicensees will have the right to grant sublicenses under any rights or licenses granted under this Agreement to Develop, Manufacture, Commercialize, or otherwise Exploit Compounds or Products in the United States other than to subcontractors engaged in accordance with this Agreement&#59; (b)&#160;any such permitted sublicense is consistent with and subject to the terms and conditions of this Agreement, including the confidentiality provisions of Article 13, the intellectual property provisions of Article 10, and the audit provisions of Section 9.7&#59; and (c)&#160;the Party granting such sublicense shall remain responsible for performance of such Party&#8217;s obligations under this Agreement and shall be responsible for all actions of each Sublicensee as if such Sublicensee or Litigation Settlement Sublicensee were the Party hereunder. &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">No Implied Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Except as expressly set forth in this Agreement, neither Party shall be granted, by implication, estoppel, or otherwise, any license or right to or under any other Intellectual Property Right, including any Trademarks, Know-How, or Patents, of the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Safe Harbor Research</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Except to the extent Foghorn has granted exclusive rights to Lilly under this Agreement, neither Party, by entering into this Agreement, is forfeiting any rights that such Party may have to perform research activities in compliance with 35 U.S.C. &#167;&#160;271(e)(1) or any experimental or research use exemption that may apply under Applicable Law or in any country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21pt">&#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7.6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Conduct of Activities Requiring Excluded Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Notwithstanding anything to the contrary in this Agreement, to the extent that any activity that is allocated to Foghorn under this Agreement would reasonably require Foghorn to access or receive rights under any Excluded Technology that is Controlled by Lilly, Lilly shall conduct such activity in accordance with the terms of this Agreement and the applicable Research Plan, Development Plan, or Commercialization Plan, and Foghorn shall be relieved from any obligation to perform any such activities.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br><br>EXCLUSIVITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Foghorn Exclusivity Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Except with respect to its rights and obligations expressly set forth in this Agreement, Foghorn and its Affiliates shall not (by themselves, or with or through any Third Party), directly or indirectly during the Term&#58;  (a) engage in &#91;***&#93;&#59; (b) use &#91;***&#93;  to &#91;***&#93; or &#91;***&#93; other than pursuant to &#91;***&#93;, or &#91;***&#93; into any &#91;***&#93; with, or &#91;***&#93;, any &#91;***&#93; involving &#91;***&#93; or &#91;***&#93;&#59; (c) itself, or enable an Affiliate or Third </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">49</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Party to, &#91;***&#93; that is the &#91;***&#93;&#59; (d) itself use, or enable an Affiliate or Third Party to use, &#91;***&#93;. For clarity, the foregoing restrictions under this Section 8.1 &#91;***&#93; (i) &#91;***&#93;, or (ii) &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Lilly Exclusivity Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Transactions Involving Competing Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">8.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Acquisition or In-License of Competing Program by Either Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  If, after the Effective Date, (a) any Third Party becomes &#91;***&#93; as a result of a merger, acquisition, consolidation, asset sale, or other similar transaction (whether in a single transaction or series of related transactions), and, as of the closing date of such transaction, such Third Party is engaged in (i) &#91;***&#93; or (ii) &#91;***&#93;, in each case of (i) and (ii) that would, if conducted &#91;***&#93; (such activities in (i) and (ii), that would, if conducted by a Party, cause such Party to be in breach of such exclusivity obligations, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Competing Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) or (b) &#91;***&#93;, then in each case ((a) or (b)) &#91;***&#93;, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that (A) the acquiring Party provides the other Party with written notice of such transaction promptly, but no later than &#91;***&#93;, following the earlier of the first public announcement of such transaction or the execution of a definitive agreement relating to such transaction (if such disclosure is not prohibited under Applicable Law), and (B) &#91;***&#93;, within &#91;***&#93;, either&#58;  (x) &#91;***&#93;or (y) &#91;***&#93;, and (C) prior to &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">8.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Existing Competing Program of a Foghorn Acquirer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  If, after the Effective Date any Third Party becomes an Acquirer of Foghorn as a result of a Change of Control of Foghorn and, as of the closing date of such transaction, such Third Party is engaged in a Competing Program, then the provisions of Section 17.8 shall apply.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">8.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12pt">&#91;***&#93; </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.73pt"><br><br>FEES, ROYALTIES, &#38; PAYMENTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  As partial consideration for the rights granted by Foghorn to Lilly pursuant to the terms of this Agreement, Lilly shall pay to Foghorn a one-time, non-refundable, non-creditable payment equal to Three Hundred Million Dollars ($300,000,000) within &#91;***&#93; following the Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Equity Investment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  As of the Effective Date, the Parties entered into the Stock Purchase Agreement for an equity investment of eighty million Dollars ($80,000,000).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Gross Margin and Expense Sharing for Joint Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  In respect of each Joint Program, from and after the Joint Program Start Date for such Joint Program, the Parties will share in Development Costs and U.S. Gross Margins (minus U.S. Eligible Costs), (such share, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Expense and Margin Sharing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), as further set forth below in this Section 9.3, as follows&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Foghorn Cost Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. No later than &#91;***&#93; after the end of each Calendar Quarter including and following the Joint Program Start Date for a Joint Program, Foghorn will provide to Lilly a high-level non-binding good faith estimate of the Development </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Costs (including Foghorn&#8217;s FTE costs and number of FTEs) and U.S. Eligible Costs incurred by Foghorn or its Affiliates in such Calendar Quarter in accordance with the applicable Research Plan, Development Plan or Commercialization Plan, as applicable, for the Joint Program (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Foghorn Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). No later than &#91;***&#93; after the end of each Calendar Quarter including and following the Joint Program Start Date for a Joint Program, Foghorn will provide to Lilly a detailed, itemized report of the Foghorn Costs, such report to be in the form set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 9.3.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> or in such other form as the Parties may mutually agree from time-to-time. In addition to the JSC approval of the relevant Research Budget, Development Budget and Commercialization Budget, as applicable, for such Joint Program, prior to the commencement of (i) each Clinical Trial phase for a Joint Program and (ii) each Calendar Year, Foghorn will provide Lilly with a non-binding good faith estimate of its anticipated Development Costs (including estimated number of FTEs) and U.S. Eligible Costs for such Joint Program with respect to such Clinical Trial phase or Calendar Year, as applicable&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that the Parties will review and discuss such estimated costs at the JSC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Lilly Cost Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. No later than &#91;***&#93; after the end of each Calendar Quarter including and following the Joint Program Start Date for a Joint Program, Lilly will provide to Foghorn a high-level non-binding good faith estimate of the Development Costs and U.S. Eligible Costs incurred by Lilly or its Affiliates in such Calendar Quarter in accordance with the applicable Research Plan, Development Plan or Commercialization Plan, as applicable, for the Joint Program (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Lilly Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). No later than &#91;***&#93; after the end of each Calendar Quarter including and following the Joint Program Start Date for a Joint Program, Lilly will provide to Foghorn a detailed, itemized report of the Lilly Costs, such report to be in the form set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 9.3.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> or in such other form as the Parties may mutually agree from time-to-time. In addition to the JSC approval of the relevant Research Budget, Development Budget and Commercialization Budget, as applicable, for such Joint Program, prior to the commencement of (i) each Clinical Trial phase for a Joint Program and (ii) each Calendar Year, Lilly will provide Foghorn with a non-binding good faith estimate of its anticipated Development Costs (including estimated number of FTEs) and U.S. Eligible Costs for such Joint Program with respect to such Clinical Trial phase or Calendar Year, as applicable&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that the Parties will review and discuss such estimated costs at the JSC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Gross Margin Share Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. On a Joint Program Product-by-Joint Program Product basis, no later than &#91;***&#93; after the end of each Calendar Quarter beginning in the Calendar Quarter in which such Joint Program Product is first Launched (or from the date such Product becomes a Joint Program Product), Lilly will provide Foghorn with a high-level non-binding good faith estimate of the U.S. Gross Margin minus U.S. Eligible Costs (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Gross Margin Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) calculated by Lilly in respect of such Product for such Calendar Quarter for all sales of such Product in the U.S., and no later than &#91;***&#93; after the end of each Calendar Quarter beginning in the Calendar Quarter in which such Joint Program Product is first Launched (or from the date such Product becomes a Joint Program Product), Lilly will provide Foghorn with a report setting out the Gross Margin Share calculated by Lilly in respect of such Product for such Calendar Quarter for all sales of such Product in the U.S. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Income Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Subject to Section 9.10, income and withholding taxes imposed on either of the Parties hereunder will not be included in cost sharing hereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Budget Overruns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Each Party will promptly notify the other Party upon becoming aware that the anticipated Foghorn Costs or Lilly Costs (as applicable) to be incurred by such Party for a given Clinical Trial phase, where applicable, or otherwise for a given Calendar Year will be in excess of, or once its actual costs incurred have reached &#91;***&#93; of, the relevant costs set forth in the applicable approved Budget in the Research Plan, Development Plan or Commercialization Plan, as applicable, in which case the Parties, through the JRC, JDC, or JCC (as applicable), shall discuss in good faith how to manage such potential overruns, including whether to amend or adjust the applicable Budget, or the Research Plan, Development Plan, or Commercialization Plan (as applicable). Each Party shall use reasonable efforts to manage its Foghorn Costs or Lilly Costs (as applicable) incurred in connection with its activities under a Joint Program to avoid exceeding the applicable Budget, absent any change in the Research Plan, Development Plan or Commercialization Plan (as applicable), or any scientific or regulatory reasons beyond the reasonable control of such Party (taking into account matters of objectively reasonable calculation and efficiency of application of such costs), or as otherwise agreed by the Parties or via the JSC (or applicable JSC Subcommittee). Unless otherwise agreed by the Parties in advance in writing, Foghorn Costs and Lilly Costs reported by a Party pursuant to Sections 9.3.1 or 9.3.2, respectively, incurred with respect to a Joint Program in excess of &#91;***&#93; of the aggregate amounts to be incurred by or on behalf of such Party for its activities under such Joint Program in the applicable Clinical Trial phase or otherwise for the applicable Calendar Year as set forth in the then-current applicable Budget, will not be included in the calculation of the Collaboration Amount.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Allocation, Reconciliation and True-up</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:22.7pt">Allocation of Development Costs and U.S. Eligible Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. On a Calendar Quarter-by-Calendar Quarter basis, in respect of each Joint Program, the Development Costs and U.S. Eligible Costs will be shared as follows&#58; (i) with respect to Selective BRM&#47;&#91;***&#93; Programs, Lilly and Foghorn shall &#91;***&#93; of such Development Costs and U.S. Eligible Costs, and (ii) with respect to Discovery Programs for which Foghorn has opted to participate in the Expense and Margin Sharing pursuant to Section 6.3, Lilly shall be responsible for &#91;***&#93; and Foghorn shall be responsible for &#91;***&#93; of such Development Costs and U.S. Eligible Costs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:22.02pt">Allocation of Gross Margin Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. On a Calendar Quarter-by-Calendar Quarter basis, in respect of each Joint Program Product, the Gross Margin Share (positive or negative) will be shared as follows&#58; (i) with respect to Selective BRM&#47;&#91;***&#93; Products, Lilly and Foghorn shall &#91;***&#93; of the Gross Margin Share, and (ii) with respect to Joint Program Product from a Discovery Program, Lilly shall be entitled to or responsible for &#91;***&#93; and Foghorn shall be entitled to or responsible for &#91;***&#93; of the Gross Margin Share for such Product. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:22.7pt">True-up</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Within &#91;***&#93; after the end of each Calendar Quarter, Lilly will provide to Foghorn a report of the amount each Party is responsible for under Section 9.3.6(a) for such Calendar Quarter, and a report of the amount each Party is entitled to receive under Section 9.3.6(b), as Lilly calculates such amounts based on the reports provided by each Party under Sections 9.3.1 and 9.3.2, and the report provided by Lilly under Section 9.3.3 (the net of such amounts, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Collaboration Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). The Parties will make a balancing payment </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">between the Parties in order to effect the sharing of the Collaboration Amounts within &#91;***&#93; after delivery of such report of the Collaboration Amount.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Applicability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  For avoidance of doubt, the Expense and Margin Sharing set forth in this Section 9.3 shall only apply with respect to a Product to the extent such Product is a Joint Program Product at the applicable time, and therefore (i) if Foghorn exercises its option to cease participation in the Joint Program and Expense and Margin Sharing with respect to a Selective BRM&#47;&#91;***&#93; Program pursuant to Section 6.2 or a Discovery Program pursuant to Section 6.3.1, this Section 9.3 shall cease to apply with respect to the applicable Selective BRM&#47;&#91;***&#93; Program, and thereafter Foghorn shall have no further right to receive a share of U.S. Gross Margin for the applicable Product, and the Royalty rates in Section 9.5 shall instead become applicable, and (ii) the Expense and Margin sharing in this Section 9.3 shall not apply with respect to any Discovery Program unless and until Foghorn exercises its option to participate in the Expense and Margin Sharing for such Discovery Program pursuant to Section 6.3.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Milestone Events and Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Milestone Events and Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. On a Discovery Product-by-Discovery Product basis, Lilly shall pay to Foghorn certain milestone payments, as follows&#58;  (a) within &#91;***&#93; following any Compound Directed To a given Collaboration Target achieving a discovery and development milestone event set forth in Table 9.4(a) or Table 9.4(b)  below (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Development Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), as applicable (pursuant to Section 9.4.2), Lilly shall pay to Foghorn the corresponding Milestone Payment indicated in Table 9.4(a) or Table 9.4(b), as applicable (each such Milestone Payment, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Development Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;)&#59; and (b) within &#91;***&#93; following the end of the Calendar Quarter in which any commercial milestone event set forth in Table 9.4(a) or Table 9.4(b), as applicable (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Commercial Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) is achieved, Lilly shall pay to Foghorn the corresponding Milestone Payment indicated in Table 9.4(a) or Table 9.4(b), as applicable (each such Milestone Payment, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Commercial Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  The Development Milestone Events and Commercial Milestone Events may be referred to individually or collectively as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Milestone Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">,&#8221; and Development Milestone Payments and Commercial Milestone Payments may be referred to individually or collectively as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;  In the event that a given Development Milestone Event or Commercial Milestone Event is achieved in respect of a Discovery Product before payment by Lilly of all earlier Development Milestone Payments or Commercial Milestone Payments (as applicable) in respect of such Discovery Product, all such earlier payments shall also become due.  In the event that First Commercial Sale is achieved in respect of a Discovery Product before payment by Lilly of all Development Milestone Payments in respect of such Discovery Product, all Development Milestone Payments shall also become due in respect of such Discovery Product. For avoidance of doubt, the provisions of this Section 9.4 shall not apply to any Selective BRM&#47;&#91;***&#93; Program (or portions thereof) or any Selective BRM&#47;&#91;***&#93; Product, and in no event shall Lilly have any obligation to pay Milestone Payments for a Selective BRM&#47;&#91;***&#93; Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Applicability of Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The amounts and applicability of certain Milestone Payments set forth in Table 9.4(a) or Table 9.4(b) shall be subject to whether or not Foghorn has exercised its option to participate in the Expense and Margin Sharing for the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">applicable Discovery Program pursuant to Section 6.3.1 or opt out of such participation pursuant to Section 6.3.1, as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">For as long as the applicable Discovery Program is not a Joint Program, the Development Milestone Payments and Commercial Milestone Payments in Table 9.4(a) shall apply&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">For as long as the applicable Discovery Program is a Joint Program, the Development Milestone Payments and Commercial Milestone Payments set forth in Table 9.4(b) shall apply&#59; and, for avoidance of doubt, no Development Milestone Payments shall be payable for achievement of Development Milestone Events in the U.S., and Commercial Milestone Payments shall not apply to Net Sales in the U.S.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Limitations per Discovery Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Each Milestone Payment shall be payable only once per Discovery Product, and no Milestone Payment shall be payable for subsequent or repeated achievements of the same Milestone Event with respect to (a) the same Discovery Product or (b) a subsequent Discovery Product that (i) arises from the same Discovery Program as a Discovery Product that has achieved the relevant Milestone Event (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Initial Discovery Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), (ii) is Directed To the same Collaboration Target as the Initial Discovery Product and (iii) is intended for use by, or is otherwise marketed to, a substantially similar market segment as the Initial Discovery Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Table 9.4(a) &#8211;  Milestone Payments (Prior to Foghorn Opt-In to Joint Program and Following Foghorn Opt-Out of Joint Program)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:3pt;padding-left:58.55pt;padding-right:58.55pt;text-align:center;text-indent:-112.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Milestones</font></div></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center;text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Milestone Event</font></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:3pt;padding-left:58.55pt;padding-right:58.55pt;text-align:center;text-indent:-112.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Milestone Payment</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:1.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Occurrence of the earlier of (a) &#91;***&#93; or (b) &#91;***&#93; for a Discovery Product</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; for a Discovery Product</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Occurrence of the earlier of (a) &#91;***&#93; with respect to a Discovery Product or (b) &#91;***&#93; for such Discovery Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; of a Discovery Product &#91;***&#93;.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; of a Discovery Product &#91;***&#93;.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; of a Discovery Product &#91;***&#93;.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; of a Discovery Product &#91;***&#93;.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; of a Discovery Product &#91;***&#93;.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; of a Discovery Product &#91;***&#93;.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Total Development Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="6" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercial Milestones</font></div></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:6.67pt;padding-right:6.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercial Milestone Event</font></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercial Milestone Payment</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:10.6pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">First Calendar Quarter in which worldwide Net Sales of a Discovery Product for &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:10.6pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">First Calendar Quarter in which worldwide Net Sales of a Discovery Product for &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:10.6pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">First Calendar Quarter in which worldwide Net Sales of a Discovery Product for &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:10.6pt;padding-right:2.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Total Commercial Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">55</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Table 9.4(b) &#8211;  Milestone Payments (Following Foghorn Opt-In to Joint Program and Prior to Foghorn Opt-Out of Joint Program)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">56</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:3pt;padding-left:58.55pt;padding-right:58.55pt;text-align:center;text-indent:-112.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Milestones</font></div></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center;text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Milestone Event</font></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:3pt;padding-left:58.55pt;padding-right:58.55pt;text-align:center;text-indent:-112.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Milestone Payment</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Occurrence of the earlier of (a) &#91;***&#93; for a Discovery Product</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:3pt;padding-left:58.55pt;padding-right:58.55pt;text-align:center;text-indent:-112.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; for a Discovery Product</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:3pt;padding-left:58.55pt;padding-right:58.55pt;text-align:center;text-indent:-112.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Occurrence of the earlier of (a) &#91;***&#93; for such Discovery Product  &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:3pt;padding-left:58.55pt;padding-right:58.55pt;text-align:center;text-indent:-112.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; of a Discovery Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; of a Discovery Product &#91;***&#93;. </font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; of a Discovery Product &#91;***&#93;.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; of a Discovery Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:right;text-indent:-1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Total Development Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="6" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercial Milestones</font></div></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:6.67pt;padding-right:6.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercial Milestone Event</font></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Commercial Milestone Payment</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:10.6pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">First Calendar Quarter in which Net Sales of a Discovery Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:10.6pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">First Calendar Quarter in which Net Sales of a Discovery Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:10.6pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">First Calendar Quarter in which Net Sales of a Discovery Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Total Commercial Milestone Payments&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:58.5pt;padding-right:58.5pt;text-align:center;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Royalties on Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">57</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Lilly shall pay Foghorn royalties as set forth in this Section&#160;9.5 on a country-by-country and Product-by-Product basis in the Territory during the period of time beginning on the date of the First Commercial Sale of such Product in such country and continuing until the latest to occur of&#58;  &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Royalty Rates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  On a Product-by-Product and country-by-country basis, during the Royalty Term, Lilly shall pay to Foghorn a tiered royalty (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Royalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) equal to the percentages of annual Net Sales of such Product in such country as set forth in the tables below in Section 9.5.3 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Royalty Tables</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), calculated by multiplying the applicable Royalty rate percentage by the corresponding portion of aggregate Net Sales for such Product either worldwide or worldwide excluding the U.S., as applicable, in such Calendar Year, subject to the rules of applicability set forth in Section 9.5.3.  For clarity, the Royalty rates set forth below are intended to be tiered and incremental, and the higher incremental rate will only apply to that portion of the annual Net Sales either worldwide or worldwide excluding the U.S., as applicable, of the applicable Product that falls within the indicated range of sales. Notwithstanding the Royalty rates set forth in the Royalty Tables below, all Royalties payable pursuant to this Section 9.5 are subject to reduction as further described in Sections 9.5.4 - 9.5.6 below or as expressly stated elsewhere in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Applicability of Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The amounts and applicability of certain Royalty amounts shall be determined based on whether the Product is a Selective BRM&#47;&#91;***&#93; Product or a Discovery Product, and whether the applicable Product is, at the relevant time, part of a Joint Program, as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">with respect to Selective BRM&#47;&#91;***&#93; Products, (i) unless and until Foghorn has exercised its option pursuant to Section 6.2 to opt out of the Joint Program with respect to such Selective BRM&#47;&#91;***&#93; Product, the Royalty rates set forth in Royalty Table 9.5.3(a) (i) shall apply, and (ii) following Foghorn&#8217;s exercise of such option, the Royalty rates set forth in Royalty Table 9.5.3(a)(ii) shall apply&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">with respect to Discovery Products, (i) unless and until Foghorn has exercised its option to participate in the Expense and Margin Sharing for such Discovery Program pursuant to Section 6.3 (or if Foghorn opts out of such participation after having previously exercised such option), the Royalty rates set forth in Royalty Table 9.5.3(b)(i) shall apply, and (ii) following Foghorn&#8217;s exercise of such option, the Royalty rates set forth in Royalty Table 9.5.3(b)(ii) shall apply (unless Foghorn subsequently opts out of such participation, in which case the Royalty rates shall revert to those set forth in Royalty Table 9.5.3(b)(i)).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">58</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Royalty Table 9.5.3(a)(i) &#8211; Royalty Rates for Selective BRM&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"> Products (prior to Foghorn opt-out of Joint Program) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="padding-left:14.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.551%"><tr><td style="width:1.0%"></td><td style="width:78.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Annual Net</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">of the Applicable Selective BRM&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> Product</font></div></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Royalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Rate</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the portion of annual Net Sales of the Selective BRM&#47;&#91;***&#93; Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.0%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the portion of annual Net Sales of the Selective BRM&#47;&#91;***&#93; Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the portion of annual Net Sales of the Selective BRM&#47;&#91;***&#93; Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the portion of annual Net Sales of the Selective BRM&#47;&#91;***&#93; Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the portion of annual Net Sales of the Selective BRM&#47;&#91;***&#93; Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the portion of annual Net Sales of the Selective BRM&#47;&#91;***&#93; Product &#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">59</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Royalty Table 9.5.3(a)(ii) &#8211; Royalty Rates for Selective BRM&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"> Products (following Foghorn opt-out of Joint Program)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.212%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.245%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Annual Net</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">of the Applicable Selective BRM&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> Product</font></div></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">U.S. Royalty Rate</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Ex-U.S. Royalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Rate</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the portion of annual Net Sales of the Selective BRM&#47;&#91;***&#93; Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the portion of annual Net Sales of the Selective BRM&#47;&#91;***&#93; Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the portion of annual Net Sales of the Selective BRM&#47;&#91;***&#93; Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the portion of annual Net Sales of the Selective BRM&#47;&#91;***&#93; Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the portion of annual Net Sales of the Selective BRM&#47;&#91;***&#93; Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the portion of annual Net Sales of the Selective BRM&#47;&#91;***&#93; Product &#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">60</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Royalty Table 9.5.3(b)(i) &#8211; Royalty Rates for Discovery Products (prior to Foghorn opt-in to Joint Program or following Foghorn opt-out of Joint Program)</font></div><div style="padding-left:35.92pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.775%"><tr><td style="width:1.0%"></td><td style="width:77.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.883%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Annual Net</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">of the Applicable Discovery Product</font></div></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Royalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Rate</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the portion of annual worldwide Net Sales of the Discovery Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the portion of annual worldwide Net Sales of the Discovery Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the portion of annual worldwide Net Sales of the Discovery Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the portion of annual worldwide Net Sales of the Discovery Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the portion of annual worldwide Net Sales of the Discovery Product &#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Royalty Table 9.5.3(b)(ii) &#8211; Royalty Rates for Discovery Products (following Foghorn opt-in to Joint Program and prior to Foghorn opt-out of Joint Program)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Annual Net</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">of the Applicable Discovery Product</font></div></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:3pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Ex-U.S. Royalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Rate</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the portion of annual worldwide Net Sales of the Discovery Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the portion of annual worldwide Net Sales of the Discovery Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the portion of annual worldwide Net Sales of the Discovery Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the portion of annual worldwide Net Sales of the Discovery Product &#91;***&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the portion of annual worldwide Net Sales of the Discovery Product &#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">61</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.5.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Third</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> On a &#91;***&#93; may &#91;***&#93; from any &#91;***&#93; to &#91;***&#93; with respect to &#91;***&#93; of any (a) &#91;***&#93; and (b) &#91;***&#93;, in each case ((a) and (b)) &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that &#91;***&#93;. A portion of &#91;***&#93; for a &#91;***&#93;. Any such &#91;***&#93;. Any &#91;***&#93; in connection with such &#91;***&#93;. For purposes of this Section 9.5.4, &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.5.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Valid Claim and Regulatory Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  In any Calendar Quarter during the Royalty Term for a Product in a country for which (a) there is no longer a Valid Claim that Covers such Product in such country and (b) all data and regulatory exclusivity periods for such Product in such country have expired, the Royalty rates provided in the Royalty Tables for the Product will be reduced in such country by &#91;***&#93; for such Calendar Quarter (in addition to any reductions in Section 9.5.4 and Section&#160;9.5.6) and thereafter for the remainder of the Royalty Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.5.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Generic Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. On a country-by-country and Product-by-Product basis, following the commercial launch of a Generic Equivalent of a Product in a given country (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Loss of Market Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), the Royalty rates provided above in Section 9.5.2 and Section 9.5.3 for the Product will be permanently reduced in such country, as follows&#58; (a) to &#91;***&#93; of the rates provided above in Section 9.5.2 and Section 9.5.3 upon Loss of Market Exclusivity&#59; and (b) thereafter, to &#91;***&#93; of the rates provided above in Section 9.5.2 when, for two (2) consecutive Calendar Quarters, the Net Sales of the applicable Product in the applicable country are &#91;***&#93; or less than those Net Sales recorded for such Product in such country in the Calendar Quarter immediately preceding Loss of Market Exclusivity (measured by total sales of saleable units of the applicable Product in the applicable country, over the respective Calendar Quarter). Reductions pursuant to clause (a) above shall be in addition to any reductions pursuant to Section 9.5.4 and Section 9.5.5.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.5.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Cumulative Royalty Reductions and Limitations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Each of the potential Royalty reductions in the foregoing Sections 9.5.4, 9.5.5, and 9.5.6, may be taken in addition to, and not in lieu of, the potential reductions in the other such Section&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that in no circumstances will the Royalties payable to Foghorn under this Article 9 in any Calendar Quarter for a Product in a given country be reduced (a) as a result of Sections 9.5.4 and 9.5.5 in the aggregate, below &#91;***&#93; of the royalties otherwise payable under this Article 9 and (b) as a result of &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.5.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:12pt">Payment&#59; Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Royalty payments due by Lilly to Foghorn under this Article 9 will be calculated and reported for each Calendar Quarter. Within &#91;***&#93; after the end of each Calendar Quarter for which royalty payments are due under this Article 9, Lilly shall provide Foghorn a non-binding good faith estimate of all royalty payments due under this Article 9 for such Calendar Quarter. All Royalty payments due under this Article 9 shall be paid to Foghorn within &#91;***&#93; after the end of the applicable Calendar Quarter and shall be accompanied by a report setting forth, with respect to the applicable Calendar Quarter, on a Product-by-Product and country-by-country basis&#58; (a) Net Sales of the Product by Lilly and its Affiliates and Sublicensees in such country, and (b) a calculation of the Royalties due on such Net Sales.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Method of Payment&#59; Currency Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Unless otherwise agreed by the Parties, all payments due under this Agreement shall be paid in Dollars by wire transfer or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">62</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">electronic funds transfer of immediately available funds to an account designated by the payee&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that Lilly shall only be required to disburse funds to the payee&#8217;s jurisdiction of incorporation or to a jurisdiction in which the payee has a significant business presence.  When conversion of payments from any currency other than Dollars is required, Lilly&#8217;s then-current standard exchange rate methodology will be employed for the translation of foreign currency sales into Dollars&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that this methodology is used by Lilly in the translation of its foreign currency operating results, is consistent with U.S. GAAP, is audited by Lilly&#8217;s independent certified public accountants in connection with the audit of the consolidated financial statements of Lilly, and is used for external reporting of foreign currency operating results.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Records and Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12pt">Lilly (including its Affiliates and Sublicensees) shall keep complete and accurate books and records which may be necessary to ascertain properly and to verify the Royalty payments due hereunder, as well as the Lilly Costs, Collaboration Amounts and the Gross Margin Share.  Such records shall be kept for such period of time required by Applicable Laws, but no less than &#91;***&#93; following the end of the Calendar Year to which they pertain.  Within the Term, Foghorn shall have the right, exercisable not more than once each Calendar Year, to have a &#91;***&#93; inspect Lilly&#8217;s records for the purpose of determining the accuracy of the Royalty payments due hereunder, as well as the Lilly Costs, Collaboration Amounts and the Gross Margin Share.  No period will be audited more than once.  The &#91;***&#93; shall keep confidential any information obtained during such inspection and shall report to Foghorn and Lilly only the amounts of Net Sales, and Royalties, Collaboration Amount, and Gross Margin Share due and payable.  Such audits may be exercised during normal business hours upon reasonable prior written notice to Lilly.  Foghorn shall bear the full cost of such audit unless such audit discloses an underpayment by Lilly of more than &#91;***&#93; of the amount of Royalties, Collaboration Amount, Gross Margin Share or other payments due under this Agreement for the audited period, and which underpayment is also at least &#91;***&#93;&#59; in which case, Lilly shall bear the cost of such audit.  Lilly shall remit to Foghorn the amount of any underpayment within &#91;***&#93; following the date the auditor&#8217;s written report is received.  Any overpayment by Lilly revealed by an audit under this Section 9.7.1 shall be credited against subsequent payments due to Foghorn under this Agreement (with any remaining balance returned to Lilly no later than &#91;***&#93; after expiration or termination of this Agreement), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that such overpayment amount shall accrue interest beginning on the thirtieth (30th) day after the date on which an audit discloses such overpayment to Foghorn until the date(s) on which such amount is credited against subsequent payments or otherwise paid by Foghorn to Lilly or otherwise paid to Lilly, at the rate of prime plus &#91;***&#93; (as reported in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">The Wall Street Journal </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(Eastern U.S. edition)) or the maximum rate allowable by Applicable Law, whichever is less. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12pt">Foghorn (including its Affiliates and Sublicensees) shall keep complete and accurate books and records which may be necessary to ascertain properly and to verify the Foghorn Costs.  Such records shall be kept for such period of time required by Applicable Laws, but no less than &#91;***&#93; following the end of the Calendar Year to which they pertain.  Within the Term, Lilly shall have the right, exercisable not more than once each Calendar Year, to have a &#91;***&#93; inspect such records for the purpose of determining the accuracy of the Gross Margin Share payable hereunder and any amounts to be paid by Lilly to Foghorn pursuant to the true-up </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">63</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">in Section 9.3.6(c), as well as the Foghorn Costs.  No period will be audited more than once.  The &#91;***&#93; shall keep confidential any information obtained during such inspection and shall report to Lilly only the amounts of Foghorn Costs and Gross Margin Share.  Such audits may be exercised during normal business hours upon reasonable prior written notice to Foghorn.  Lilly shall bear the full cost of such audit unless such audit discloses any overpayment by Lilly that is a result of Foghorn&#8217;s act or omission. Any overpayment by Lilly revealed by an audit under this Section 9.7.2 shall be credited against subsequent payments due to Foghorn under this Agreement (with any remaining balance returned to Lilly no later than &#91;***&#93; after expiration or termination of this Agreement), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that such overpayment amount shall accrue interest beginning on the thirtieth (30th) day after the date on which an audit discloses such overpayment to Foghorn until the date(s) on which such amount is credited against subsequent payments or otherwise paid by Foghorn to Lilly or otherwise paid to Lilly, at the rate of prime plus &#91;***&#93;  (as reported in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">The Wall Street Journal </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(Eastern U.S. edition)) or the maximum rate allowable by Applicable Law, whichever is less. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Supply Price Confirmation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Upon request of Foghorn, at Foghorn&#8217;s expense, Lilly will have Lilly&#8217;s &#91;***&#93; provide confirmation to Foghorn that &#91;***&#93; the Supply Price &#91;***&#93; the Supply Price &#91;***&#93;.  Foghorn shall only be entitled to make one (1) such request in any consecutive twelve (12) month period and such right shall expire &#91;***&#93; following the end of the Calendar Year to which the Supply Price pertains. &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:21pt">Late Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  If any payment properly due under this Agreement and not subject to a good faith Dispute is not paid when due in accordance with the applicable provisions of this Agreement, the payment shall accrue interest from the date due at the rate of prime plus &#91;***&#93; (as reported in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">The Wall Street Journal </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(Eastern U.S. edition)) or the maximum rate allowable by Applicable Law, whichever is less.  The payment of such interest shall not limit the Party entitled to receive payment from exercising any other rights it may have as a consequence of the lateness of any payment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Coordination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Except as otherwise provided in this Section 9.10, each Party shall pay all income and other taxes (including interest) (other than withholding taxes required by Applicable Law to be deducted from Payments and remitted by the payor) imposed on or measured with respect to its own income accruing to it under this Agreement. The Parties acknowledge and agree that it is their mutual objective and intent to minimize, to the extent feasible and in compliance with Applicable Laws, taxes payable with respect to their collaborative efforts under this Agreement and that they shall use reasonable efforts to cooperate and coordinate with each other to achieve such objective, including by completing and filing documents required or permitted under the provisions of any Applicable Laws in connection with a claim of exemption from, or entitlement to a reduced rate of, withholding taxes or in connection with any claim to a refund of or credit for any payment of such taxes.  Notwithstanding the foregoing, for clarity, it is Foghorn&#8217;s sole responsibility to prepare and file required documents necessary to claim an exemption from withholding tax or to claim a reduced rate of withholding tax with respect to Payments to Foghorn, at Foghorn&#8217;s sole expense.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">64</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The upfront, milestones, royalties and other amounts payable by Lilly to Foghorn under this Agreement (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) shall be paid free and clear of any and all taxes, except for any withholding taxes required by Applicable Law.  Except as provided in this Section 9.10, Foghorn shall be solely responsible for paying any and all taxes (other than withholding taxes required by Applicable Law to be deducted from Payments and remitted by Lilly) levied on account of, or measured in whole or in part by reference to, any Payments it receives.  Lilly shall deduct or withhold from the Payments any taxes that it is required by Applicable Law to deduct or withhold.  Notwithstanding the foregoing, if Foghorn is entitled under any applicable tax treaty to a reduction in the rate of, or the elimination of, any applicable withholding tax, it may deliver to Lilly or the appropriate Governmental Authority (with the assistance of Lilly to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve Lilly of its obligation to withhold such tax and Lilly shall apply the reduced rate of withholding or dispense with withholding as the case may be&#59; provided that Lilly has received Foghorn&#8217;s delivery of all applicable forms in a form satisfactory to Lilly (and, if necessary, evidence, in a form satisfactory to Lilly, of Foghorn&#8217;s receipt of appropriate governmental authorization) at least &#91;***&#93; prior to the time Payments are due.  If in accordance with the foregoing, Lilly withholds any amounts of tax, it shall pay to Foghorn the balance when due, make timely payment to the proper tax authority of the withheld amount and send to Foghorn proof of such payment &#91;***&#93; within &#91;***&#93; following such payments.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Value Added Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  It is understood and agreed between the Parties that any payments made by any Party under this Agreement are exclusive of any value added tax or similar tax imposed upon such payments. Where such tax is properly chargeable in respect of any supply of goods or services made under this Agreement, the Party paying the consideration for that supply will pay the amount of such tax subject to receipt of a valid tax invoice issued in accordance with Applicable Law. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.73pt"><br><br>INTELLECTUAL PROPERTY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Inventorship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  Inventorship as between the Parties will be determined in accordance with U.S. patent laws.  All such determinations shall be documented to ensure that the Patent claims in any divisional or continuation patent applications reflect appropriate inventorship.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Ownership of Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Background IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  As between the Parties, and subject to the licenses granted under this Agreement (a) Lilly shall solely own (or retain ownership of) all rights, title and interests in and to the Lilly Background IP, and (b) Foghorn shall solely own (or retain ownership of) all rights, title and interests in and to the Foghorn Background IP.  &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Program IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Ownership of Inventions and Know-How that are conceived, reduced to practice, discovered, developed, or made by or on behalf of either Party (or any of their Affiliates) in the course of performing activities under the Research Program or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">65</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">otherwise in the course of performing activities under this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Program IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) shall be as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">Lilly shall solely own (or retain ownership of) all Program IP, other than Foghorn Platform-Related Program IP, &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Lilly Program IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Foghorn shall solely own (or retain ownership of) (i) all Foghorn Platform-Related Program IP and (ii) all other Program IP &#91;***&#93; (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Foghorn Program IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">Lilly and Foghorn shall jointly own all Program IP, other than Foghorn Platform-Related &#91;***&#93; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Joint IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Assignments of Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Inventor Assignment Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Each Party shall cause all of its Affiliates, employees, agents, independent contractors, consultants, and others who perform activities for such Party under this Agreement to be under an obligation to assign (or, if such Party is unable to cause such person or entity to agree to such assignment obligation despite such Party using reasonable efforts to negotiate such assignment obligation, provide a license, preferably exclusive, under) to such Party their rights in and to any Inventions created, conceived of, reduced to practice, or acquired in the course or scope of the Research Program or otherwise related to this Agreement and all Intellectual Property Rights therein, except where Applicable Law requires otherwise, except with respect to improvements to background intellectual property of Third Party subcontractors, and except in the case of governmental, not-for-profit and public institutions that have standard policies against such an assignment (in which case a Party shall obtain a suitable license, preferably exclusive, or right to obtain such a license).  Each Party shall use reasonable efforts to promptly disclose to the other Party in writing all Inventions arising in the course or scope of the Research Program or otherwise under this Agreement, including any invention disclosures, or other similar documents, submitted to it by its employees, agents or independent contractors describing such Inventions, and all information relating to such Inventions to the extent necessary or useful for the preparation, filing and maintenance of any Patent with respect to such Invention.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Assignment of Foghorn Platform-Related Program IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Lilly (on behalf of itself and its Affiliates) shall and does hereby assign to Foghorn its right, title and interest in and to the Foghorn Platform-Related Program IP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Assignment of Joint IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Foghorn (on behalf of itself and its Affiliates) shall and does hereby assign to Lilly, and Lilly (on behalf of itself and its Affiliates) shall and does hereby assign to Foghorn, an equal, undivided interest in and to the Joint IP.  Subject to the licenses and obligations of exclusivity granted under this Agreement, each Party shall have full rights to Exploit and license Joint IP (and any Patent rights therein), without any obligation or requirement of an accounting to the other Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that, in Exploiting or licensing such Joint IP, neither Party shall have any right or license to the underlying Background IP of the other Party, in each case, not otherwise expressly granted elsewhere in this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">66</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Independent Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Subject to the licenses and obligations of exclusivity granted hereunder, nothing in this Agreement shall be construed as limiting either Lilly&#8217;s or Foghorn&#8217;s right to research, develop, improve and in-license technology related to the Lilly Background IP (in the case of Lilly) or Foghorn Background IP (in the case of Foghorn) outside the scope of this Agreement in its ordinary course of business.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Contribution of Licensed Foghorn Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Foghorn shall inform Lilly in writing, prior to contributing to any Research to be conducted under any Research Plan any portion of the Foghorn Technology that is in-licensed from a Third Party, the contribution of which would prevent or conflict with the ownership and use rights with respect to Patents and Know-How contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Patent Prosecution and Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Rights to Prosecute and Maintain Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Subject to Sections 10.6.2, 10.6.3 and 10.6.4, each Party shall control the Prosecution and Maintenance of Patents claiming Inventions that such Party Controls (other than Control obtained pursuant to a grant of rights under this Agreement). For clarity, Foghorn shall control the Prosecution and Maintenance of Patents within the Foghorn Platform-Related Program IP. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Product-Specific Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  As between the Parties, Lilly shall have the first right, but not the obligation, to Prosecute and Maintain any Product-Specific Patents at &#91;***&#93; sole cost and expense. With respect to any Product-Specific Patents within Foghorn Technology, Lilly shall keep Foghorn reasonably informed of the status of such Product-Specific Patents and shall promptly provide Foghorn with all material correspondence received from any patent authority in connection therewith, and in addition, Lilly shall promptly provide Foghorn with drafts of all proposed material filings and correspondence to any patent authority with respect to such Product-Specific Patents for Foghorn&#8217;s review and comment prior to the submission of such proposed filings and correspondences, and Lilly shall consider Foghorn&#8217;s reasonable comments in good faith.  Lilly shall notify Foghorn of its intention to suspend or cease any Prosecution and Maintenance of any Product-Specific Patent within Foghorn Technology, and Lilly shall provide such notice no later than &#91;***&#93; prior to any filing or payment due date, or any other due date that requires action, in connection with such Product-Specific Patent.  In such event, Lilly shall permit Foghorn, at Foghorn&#8217;s discretion and at &#91;***&#93; expense, to continue Prosecution and Maintenance of such Product-Specific Patent, subject to the foregoing information sharing obligation and review and comment rights applied </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">mutatis mutandis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that Foghorn shall not continue such Prosecution and Maintenance if Lilly objects to such Prosecution and Maintenance consistent with Lilly&#8217; strategic decision-making rights &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Joint Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Lilly shall have the first right, but not the obligation, to Prosecute and Maintain the Patents (other than Product-Specific Patents) in the Joint IP (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Joint Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  The Party handling the Prosecution and Maintenance of a given Joint Patent (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Prosecuting Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) shall keep the other Party reasonably informed of the status of such Joint Patents and shall promptly provide such other Party with all material correspondence received from any patent authority in connection therewith.  In addition, the Prosecuting Party shall promptly provide the other Party with drafts of all proposed material filings and correspondence to any patent authority for such other Party&#8217;s review and comment prior to the submission of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">67</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">such proposed filings and correspondences, and the Prosecuting Party shall consider the other Party&#8217;s reasonable comments in good faith.  The Prosecuting Party shall notify the other Party of its intention to suspend or cease any Prosecution and Maintenance of any Joint Patent no later than &#91;***&#93; prior to any filing or payment due date, or any other due date that requires action, in connection with such Joint Patent.  In such event, the Prosecuting Party shall permit the other Party, at &#91;***&#93; expense, to continue Prosecution and Maintenance of such Joint Patent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that in the case where Lilly is the Prosecuting Party and Foghorn desires to continue Prosecution and Maintenance of such Joint Patent, Foghorn shall not continue such Prosecution and Maintenance if Lilly is ceasing or suspending such Prosecution and Maintenance for strategic reasons, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Restrictions on Foghorn Prosecution Rights&#59; Separation of Patent Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">Both Parties shall consult and cooperate with each other in good faith to determine Prosecution and Maintenance strategies with respect to any Foghorn Patents Covering a Compound or Product and determine a course of action to ensure the separation of Product-Specific Patents from other Foghorn Patents. &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">&#91;***&#93;    </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Each Party shall cooperate fully with the other Party in the Prosecution and Maintenance of Patents under this Section 10.6 at &#91;***&#93; cost (except as expressly set forth otherwise in this Article 10), including by&#58; (a)&#160;executing all papers and instruments, or requiring its employees or contractors, to execute such papers and instruments, to enable the other Party to apply for and to Prosecute and Maintain such Patents in any country as permitted by this Section&#160;10.6&#59; and (b)&#160;promptly informing the other Party of any matters coming to such Party&#8217;s attention that may affect the Prosecution and Maintenance of any such Patents.  Each Party will use reasonable efforts via good faith consultation to avoid creating potential issues in Prosecution and Maintenance of Patents under this Section 10.6.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Infringement or Misappropriation by Third Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Each Party shall notify the other within &#91;***&#93; of becoming aware of any alleged or threatened infringement by a Third Party of any of the Foghorn Patents, Lilly Patents or Program IP, which infringing activity involves the using, making, importing, offering for sale or selling a Compound or Product, in each case in the Field in the Territory, and any related declaratory judgment, opposition or similar action alleging the invalidity, unenforceability or non-infringement of any of the Foghorn Patents, Lilly Patents or Program IP (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Subject to Sections 10.7.3, 10.7.4 and 10.7.5, each Party shall have the sole right to bring and control any legal action in connection with any Infringement of Patents claiming Inventions that such Party Controls (other than Control obtained pursuant to a grant of rights under this Agreement).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Product-Specific Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  As between the Parties, Lilly shall have the first right to bring and control any legal action in connection with any Infringement of any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">68</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Product-Specific Patents at &#91;***&#93; expense.  Lilly shall keep Foghorn reasonably informed of the status of such enforcement efforts for such Product-Specific Patents and shall consider in good faith Foghorn&#8217;s comments thereon.  Foghorn may, at &#91;***&#93; expense, be represented in any such action by counsel of its own choice.  If Lilly does not bring such legal action within &#91;***&#93; after the notice provided pursuant to Section&#160;10.7.1, Foghorn may bring and control any legal action in connection with such Infringement of such Product-Specific Patent at &#91;***&#93; expense as it reasonably determines appropriate &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Foghorn Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  As between the Parties, Foghorn shall have the sole right to bring and control any legal action in connection with any Infringement of the Foghorn Patents that are not Joint Patents or Product-Specific Patents at &#91;***&#93; expense.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Lilly Patents and Joint Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Subject to Section 10.7.3 and Section 10.7.4, as between the Parties, Lilly shall have the first right to bring and control any legal action in connection with any Infringement of any Lilly Patents or Joint Patents at &#91;***&#93; expense as it reasonably determines appropriate. Solely with respect to Joint Patents, if Lilly does not bring such legal action within &#91;***&#93; after the notice provided pursuant to Section&#160;10.7.1, Foghorn may bring and control any legal action in connection with such Infringement of such Joint Patent at &#91;***&#93; expense as it reasonably determines appropriate so long as Lilly does not reasonably object to such action consistent with Lilly&#8217;s strategic decision-making rights.   The enforcing Party shall keep the other Party reasonably informed of the status of such enforcement efforts for the Joint Patents and shall consider in good faith such other Party&#8217;s comments thereon.  The enforcing Party shall provide the other Party with drafts of all material papers to be filed with the court and shall in good faith incorporate all reasonable comments thereto by such other Party before filing such papers.  The other Party may, at &#91;***&#93; expense, be represented in any such action by counsel of its own choice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.7.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Allocation of Recoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. If an enforcement action relating to a claim of Infringement applies to a Joint Program Product and to the United States, the Parties&#8217; costs and expenses in connection therewith &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.7.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  At the request and expense of the Party bringing an action under this Section&#160;10.7, the other Party shall provide reasonable assistance in connection therewith, including by executing reasonably appropriate documents, cooperating in discovery and joining as a party to the action if required by Applicable Law to pursue such action.  In connection with any such enforcement action, the Party bringing the action shall not enter into any settlement that disclaims, limits the scope of, admits the invalidity or unenforceability of, or grants a license, covenant not to sue or similar immunity under a Patent Controlled by the other Party or its Affiliates without the prior written consent of the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Defense and Settlement of Third Party Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Each Party shall promptly notify the other in writing of&#58;  (a) any allegation by a Third Party that the activity of either of the Parties pursuant to this Agreement infringes or may infringe the Intellectual Property Rights of such Third Party&#59; or (b) any declaratory judgment action that is brought naming either Party as a defendant and alleging invalidity of any of the Lilly Patents, Joint Patents or Foghorn Patents.  Foghorn has the sole right to control any defense of any such claim described in clause (a) involving alleged infringement of Third Party rights by Foghorn&#8217;s activities at &#91;***&#93; expense </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">69</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93; and by counsel of its own choice, and Lilly may, &#91;***&#93;, be represented in any such action by counsel of its own choice.  Lilly has the sole right to control any defense of any such claim described in clause (a) involving alleged infringement of Third Party rights by Lilly&#8217;s activities or related to the Joint Patents at &#91;***&#93; expense &#91;***&#93; and by counsel of its own choice, and Foghorn may, at &#91;***&#93;, be represented in any such action by counsel of its own choice.  Neither Party may settle any action under this Section&#160;10.8 without the written consent of such other Party, which consent shall not be unreasonably withheld, conditioned, or delayed, &#91;***&#93;.  Nothing in this Section 10.8 will limit any indemnification rights or obligations of a Party under Article 12.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Patent Extension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Lilly shall be solely responsible for determining which Patent claiming or Covering a Product should be extended and obtaining such extensions, and thereafter Foghorn shall cooperate in obtaining patent term restorations, supplemental protection certificates or their equivalents, and other forms of patent term extensions for a given Product with respect to any applicable Foghorn Patent or Lilly Patent in any country or region where applicable.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:9pt">CREATE Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  It is the Parties&#8217; intention that this Agreement is a &#8220;joint research agreement&#8221; as that phrase is defined in 35 U.S.C. &#167;&#160;102(c) as amended by the Cooperative Research and Technology Enhancement (CREATE) Act, including the provisions of 35 U.S.C. &#167;&#160;102(b)(2)(c).  The Parties agree to cooperate and to take reasonable actions to maximize the protections available for the Compounds and Products under such safe harbor provisions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:9pt">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Lilly shall have the right to select, and will be free, in its sole discretion, to use and to register in any trademark office in the Territory, any Trademark for use with a Product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Product Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  As between the Parties, Lilly shall own all right, title and interest in and to any such Product Trademarks adopted by Lilly for use with Product, and is responsible for the registration, filing, maintenance and enforcement thereof.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.73pt"><br><br>REPRESENTATIONS, WARRANTIES AND COVENANTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Mutual Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Each of Lilly and Foghorn represent and warrant, as of the Effective Date, that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:6pt">it is duly organized and validly existing under the Applicable Laws of the jurisdiction of its incorporation or formation, as applicable, has full corporate, limited liability company or other power and authority, as applicable, to enter into this Agreement and to carry out the provisions hereof, and other than with respect to any Development Operational Competency Activity or Commercialization Operational Competency Activity, has sufficient facilities, experienced personnel or other capabilities (including via Affiliates and&#47;or Third Parties) to enable it to perform its obligations under this Agreement&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:6pt">it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the individual executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate, limited liability company or other action, as applicable&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">70</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:6pt">this Agreement is legally binding upon it and enforceable in accordance with its terms (except as the enforceability thereof may be limited by bankruptcy, bank moratorium or similar laws affecting creditors&#8217; rights generally and laws restricting the availability of equitable remedies and may be subject to general principles of equity whether or not such enforceability is considered in a proceeding at law or in equity) and the execution, delivery and performance of this Agreement by it have been duly authorized by all necessary corporate action and do not and will not&#58;  (a)&#160;conflict with, or constitute a default or result in a breach under, any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, or violate any Applicable Law&#59; or (b)&#160;require any consent or approval of its stockholders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Foghorn Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Foghorn represents, warrants and covenants, as applicable, to Lilly that, as of the Effective Date, except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">No Unavailable Targets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  No Initial Target is an Unavailable Target, and the Initial Targets are not subject to an executed agreement between Foghorn and a Third Party (or Foghorn&#8217;s commitment to negotiate an agreement with a Third Party) that would prevent, or conflict with, the inclusion of the Target as a Collaboration Target under this Agreement on an exclusive basis as set forth in Section 7.1 and Section 8.1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 1.217</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> sets forth a complete list of all Targets that are Unavailable Targets as of the Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">No Grants that Conflict with this Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Foghorn and its Affiliates have not granted, and will not grant during the Term, any rights (or other encumbrances) to any Third Party under Foghorn Technology that conflict with the rights granted to Lilly hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Control over Know-How and Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Foghorn has Control over all Know-How and Patents owned by it or its Affiliates that are necessary or reasonably useful for the Exploitation of Compounds or Products in the Field, as known to be contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Existing Patents and Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">All Patents contained in the Foghorn Technology existing as of the Effective Date that are issued or subject to a pending application for issuance are listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 11.2.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Existing Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). To Foghorn&#8217;s knowledge, no Third party is infringing or threatening to infringe or misappropriating or threatening to misappropriate any Know-How or any issued Patents contained in the Foghorn Technology.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Except as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 11.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, all Existing Patents are&#58;  (i) to the extent issued, subsisting and, to Foghorn&#8217;s knowledge, not invalid or unenforceable, in whole or in part, or confer a valid right to claim priority thereto&#59; (ii) solely and exclusively owned by, or exclusively licensed to Foghorn, free of any encumbrance, lien or claim of ownership by any Third Party&#59; (iii) to the extent subject to a pending application for issuance, being diligently prosecuted in good faith in the respective patent offices in which such applications have been filed in accordance with Applicable Law and, to Foghorn&#8217;s knowledge, all material references, documents and information have been presented to the relevant patent office in respect of such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">71</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Existing Patents to the extent required by such patent office&#59; and (iv) filed and maintained in accordance with applicable Patent office rules, and all applicable fees applicable thereto have been paid on or before any final due date for payment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">Neither Foghorn nor any of its Affiliates have taken any action that would render unpatentable (including by means of the &#8220;on-sale bar&#8221; doctrine or prior publication) any invention claimed in the Existing Patents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">To Foghorn&#8217;s knowledge, other than the rights granted under this Agreement, no rights or licenses are required under any Third Party Patent or Know-How rights not Controlled by Foghorn (except Licensed Patents set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 11.2.4(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">) to practice the Foghorn Technology as contemplated in the Research Plan. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">To Foghorn&#8217;s knowledge, other than the rights granted under this Agreement, no right or licenses are required under any Third Party Patent or Know-How rights not Controlled by Foghorn to Exploit the Compounds or Products as contemplated herein solely by reason of the incorporation of Foghorn Technology in such Compounds or Products. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.03pt">To Foghorn&#8217;s knowledge, the Exploitation of the Compounds that are identified by Foghorn in accordance with this Agreement does not and will not violate, infringe, misappropriate or otherwise conflict or interfere with any Patent, Know-How, or any other intellectual property or proprietary right of any Third Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">No Third Party Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  There is no license or other agreement with Third Parties regarding the exploitation of any Foghorn Technology or other materials contemplated to be provided by Foghorn to Lilly hereunder, to which Foghorn or its Affiliate is a party (i) that is inconsistent with or diminishes or would conflict with or prevent the rights and licenses granted to Lilly under this Agreement, or (ii) under which rights are extended to Lilly hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Litigation and Actions Relating to Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Foghorn&#58;  (a) has not received any written notice of any threatened claims or litigation seeking to invalidate or otherwise challenge the Foghorn Technology, including the Foghorn Patents, or Foghorn&#8217;s or its Affiliates&#8217; rights therein&#59; and (b) is not aware of any pending or threatened action, suit, proceeding or claim by a Third Party asserting that Foghorn or any of its Affiliates is infringing or has misappropriated or otherwise is violating any Patent right, trade secret or other proprietary right of any Third Party as would reasonably be expected to impair the ability of Foghorn to fulfill any of its obligations under this Agreement.  To Foghorn&#8217;s knowledge, the conduct of Foghorn&#8217;s activities under this Agreement, including conception, development, and reduction to practice of the Compounds or Products, does not and will not infringe or misappropriate any Patent, Know-How or other intellectual property or proprietary right of any Third Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Other Material Claims and Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  There are no claims, actions, or proceedings pending or, to Foghorn&#8217;s knowledge, threatened by any Third Party&#59; and to Foghorn&#8217;s knowledge, there are no formal inquiries initiated or written notices received that may lead to the institution of any such legal proceedings&#59; in each case (or in aggregate) against Foghorn or its properties, assets or business, which if adversely decided, would, individually or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">72</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">in the aggregate, have a material adverse effect on, or prevent Foghorn&#8217;s ability to conduct the Research or to grant the licenses or rights granted to Lilly under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Assignment by Employees, Agents and Consultants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Foghorn has obtained from each of its current employees, consultants and contractors, in each case who perform research or development activities pursuant to this Agreement, written agreements containing obligations of confidentiality and non-use and an assignment to Foghorn of all inventions (and all of such Person&#8217;s rights thereto) for which Foghorn or Lilly is intended to have ownership or license rights under this Agreement such that no such employee, contractor or consultant shall retain any rights to such inventions that would prevent or conflict with Lilly&#8217;s rights of ownership or use of such inventions contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.2.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">No Government Funding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The inventions claimed or covered by the Foghorn Patents&#58;  (a) were not conceived, discovered, developed or otherwise made in connection with any research activities funded, in whole or in part, by, or otherwise using the resources of, any Governmental Authority&#59; (b) are not a &#8220;subject invention&#8221; as that term is described in 35 U.S.C. Section 201(e) and (c) are not otherwise subject to the provisions of the Patent and Trademark Law Amendments Act of 1980, as amended, codified at 35 U.S.C. &#167;&#167;&#160;200-212, as amended, as well as any regulations promulgated pursuant thereto, including in 37 C.F.R. Part 401 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Bayh-Dole Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  Foghorn and its Affiliates have complied with the applicable provisions of the Bayh-Dole Act, in a manner that protects and preserves Foghorn&#8217;s right, title and interest in such inventions to the maximum extent permitted by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Regulatory Documentation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Except as summarized on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 11.2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, no Regulatory Documentation exists or has been generated relating to Foghorn&#8217;s contemplated activities and obligations under this Agreement.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Regulatory Documentation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means all&#58;  (a) applications (including all INDs, or equivalent, BLA&#47;NDAs, and applications for Regulatory Filings), registrations, licenses, authorizations and approvals (including approvals received for Regulatory Filings)&#59; (b) correspondence and reports submitted to or received from Regulatory Authorities (including minutes and official contact reports relating to any communications with any Regulatory Authority) and all supporting documents with respect thereto, including all adverse event files and complaint files&#59; (c) supplements or changes to any of the foregoing following approval of a Regulatory Filing&#59; and (d) clinical and other data, including Clinical Trial data, contained or relied upon in any of the foregoing&#59; in each case ((a)&#8211;(d)) relating to a Collaboration Target and Products Directed To a Collaboration Target.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Mutual Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Each Party represents, warrants and covenants to the other Party that neither it nor its officers, employees, agents, consultants or any other person used by such Party in the performance of the respective research and development activities under this Agreement is&#58;  (a) debarred or disqualified under the FD&#38;C Act&#59; (b) listed by any government or regulatory agencies as ineligible to participate in any government healthcare programs or government procurement or non-procurement programs (as that term is defined in 42 U.S.C. &#167;&#160;1320a-7b(f)), or excluded, debarred, suspended or otherwise made ineligible to participate in any such program&#59; or (c) convicted of a criminal offense related to the provision of healthcare items or services, or is subject to any such pending action.  Each Party will not during the Term </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">73</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">knowingly, employ or use, directly or indirectly, including through Affiliates the services of any such person.  In the event that either Party becomes aware of the debarment or disqualification or threatened debarment or disqualification of any person providing services to such Party, directly or indirectly, including through Affiliates or, in the case of Lilly, Sublicensees, which directly or indirectly relate to activities contemplated by this Agreement, such Party shall promptly notify the other Party in writing and such Party shall cease employing, contracting with, or retaining any such person to perform any such services.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Protection of Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Each Party agrees that during the Term of this Agreement, and without limiting its obligations hereunder, each Party shall implement technical and organizational measures to protect all information under the Agreement that are appropriate and that provide no less protection than both (i) good industry practice (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, in accordance with ISO 27001 and&#47;or similar industry standards) and (ii) such Party&#8217;s measures to protect its own information of a similar nature or importance.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Compliance with this Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Each of the Parties shall, and shall cause their respective Affiliates to, comply in all material respects with the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Compliance with Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Each Party covenants to the other that in the performance of its obligations under this Agreement, such Party shall comply, and shall cause its Affiliates and its and its Affiliates&#8217; employees and contractors to comply, with all Applicable Laws.  No Party shall, or shall be required to, undertake any activity under or in connection with this Agreement which violates, or which it believes, in good faith, may violate, any Applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.4.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Compliance with Party-Specific Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. In carrying out their respective obligations under this Agreement, the Parties agree to cooperate with each other as may reasonably be required to help ensure that each is able to fully meet its obligations with respect to all judgments, decrees, orders or similar decisions issued by any Governmental Authority specific to a Party, and all consent decrees, corporate integrity agreements, or other agreements or undertakings of any kind by a Party with any Governmental Authority, in each case as the same may be in effect from time to time and applicable to a Party&#8217;s activities contemplated by this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Party-Specific Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  Each Party shall be responsible for providing the other Party with any Party-Specific Regulations applicable to the other Party, including any updates to such Party-Specific Regulations, and the covenant in the preceding sentence shall only apply to the extent such Party-Specific Regulations and any updates thereto have been provided to the other Party.  Neither Party shall be obligated to pursue any course of conduct that would result in such Party being in material breach of any Party-Specific Regulation applicable to it&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that in the event that a Party refuses to fulfill its obligations under this Agreement in any material respect on such basis, the other Party shall have the right to terminate this Agreement in accordance with Section&#160;14.2&#59; however, under such circumstances, such termination, including the applicable effects of such termination set forth in Sections 14.7 and 14.6, shall be the sole remedy for such terminating Party and such terminating Party shall not be entitled to any other remedy under law or equity.  All Party-Specific </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">74</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Regulations are binding only in accordance with their terms and only upon the Party to which they relate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Compliance with Internal Compliance Codes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  All Internal Compliance Codes shall apply only to the Party to which they relate.  The Parties agree to cooperate with each other to help ensure that each Party is able to comply with the substance of its respective Internal Compliance Codes and, to the extent practicable, each Party shall operate in a manner consistent with its Internal Compliance Codes applicable to its performance under this Agreement, unless agreed to otherwise within the Compliance Agreement.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Internal Compliance Codes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">,&#8221; as used in this Section 11.4.4, means a Party&#8217;s internal policies and procedures intended to ensure that a Party complies with Applicable Laws, Party-Specific Regulations, and such Party&#8217;s internal ethical, medical and similar standards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Compliance with Anti-Corruption Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  In connection with this Agreement, the Parties shall comply with all applicable local, national, and international laws, regulations, and industry codes dealing with government procurement, conflicts of interest, corruption or bribery, including, if applicable, the U.S. Foreign Corrupt Practices Act of 1977, as amended, and any laws enacted to implement the Organisation of Economic Cooperation and Development Convention on Combating Bribery of Foreign Officials in International Business Transactions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.4.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Compliance with Privacy Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  In connection with this Agreement, Foghorn and its Affiliates, and any Person acting for or on its or their behalf, will comply with all Applicable Laws with respect to data protection and privacy laws with respect to the receipt, collection, compilation, use, storage, processing, sharing, safeguarding, security (technical, physical and administrative), disposal, destruction, disclosure, or transfer (including cross-border) of Personal Information, including providing any notice, obtaining any consent or prior authorization, and conducting any assessment required under Applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.4.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Compliance with Trade Sanctions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. In connection with this Agreement&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">The Parties agree to comply with all applicable trade sanctions and export control laws and regulations, including where applicable the U.S. trade sanctions administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Control (31 C.F.R. Part 501 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">et seq.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">), the U.S. Export Administration Regulations (15 C.F.R. Part 734 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">et seq.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">), and European Union trade sanctions and export laws (including without limitation Council Regulation (EC) No. 428&#47;2009 (as amended)). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Each Party represents and warrants that neither it, its directors, executive officers, agents, shareholders nor any person having a controlling interest in each Party (on behalf of themselves), is (i) a person targeted by trade of financial sanctions under the laws and regulations of the United Nations, the United States, the European Union and its Member States, the United Kingdom or any other jurisdiction that is applicable to the licenses granted hereunder or activities contemplated by this Agreement, including but not limited to persons designated on the U.S. Department of the Treasury, Office of Foreign Assets Control&#8217;s List of Specially Designated Nationals and Other Blocked Persons and Consolidated Sanctions List, the U.S. State Department&#8217;s Non-proliferation Sanctions Lists, the UN Financial Sanctions Lists, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">75</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">EU&#8217;s Consolidated List of Persons, Groups and Entities Subject to EU Financial Sanctions, and the UK HM Treasury Consolidated Lists of Financial Sanctions Targets&#59; (ii) incorporated or headquartered in, or organized under the laws of, a territory subject to comprehensive U.S. sanctions (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Sanctioned Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) (currently, Cuba, Iran, Crimea, North Korea, Syria and Venezuela but subject to change at any time) or (iii) directly or indirectly owned or controlled by such persons (together &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Restricted Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;). Each Party further represents and warrants that each Party (on behalf of themselves) shall notify the other Party in writing immediately if a Party or any of its directors, executive officers, agents, shareholders or any person having a controlling interest in a Party becomes a Restricted Person or becomes directly or indirectly owned or controlled by one or more Restricted Persons. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">Each Party agrees, and shall ensure that any Sublicensee agrees, that the licenses granted hereunder and products contemplated by this Agreement will not be manufactured in, used, sold, exported, reexported, transferred or otherwise made available, directly or indirectly, to or for the benefit of a Sanctioned Territory or Restricted Person without prior written approval from the other Party. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.4.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Prohibited Conduct</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Without limiting the other obligations of the Parties set forth in this Section 11.4, each Party covenants to the other that, as of the Effective Date and in the performance of its obligations under this Agreement through the expiration and termination of this Agreement, such Party and, to its knowledge, its Affiliates and its and its Affiliates&#8217; employees and contractors, in connection with the performance of their respective obligations under this Agreement, have not made, offered, given, promised to give, or authorized, and will not make, offer, give, promise to give, or authorize, any bribe, kickback, payment or transfer of anything of value, directly or indirectly through Third Parties, to any Government Official for the purpose of&#58;  (a) improperly influencing any act or decision of the Person or Government Official&#59; (b) inducing the Person or Government Official to do or omit to do an act in violation of a lawful or otherwise required duty&#59; (c) securing any improper advantage&#59; or (d) inducing the Person or Government Official to improperly influence the act or decision of any organization, including any government or government instrumentality, to assist any Party in obtaining or retaining business.  For the purpose of this Section 11.4.8 &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Government Official</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221; means&#58;  (x) any officer, employee (including physicians, hospital administrators, or other healthcare professionals), agent, representative, department, agency, de facto official, representative, corporate entity, instrumentality or subdivision of any government, military or international organization, including any ministry or department of health or any state-owned or affiliated company or hospital&#59; (y) any candidate for political office, any political party or any official of a political party, in each case for the purpose of obtaining or retaining business for or with, or directing business to, any Person, including either Party&#59; or (z) any Person acting in an official capacity on behalf of any of the foregoing. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.4.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Obligation to Train</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Foghorn agrees to provide, on an annual basis, all Foghorn personnel providing services under this Agreement training relating to anti-corruption compliance, either by using the anti-corruption training module provided by Lilly to Foghorn on or prior to the Effective Date or through the provision of comparable anti-corruption training. Foghorn agrees to provide relevant documents to Lilly, or an independent party nominated by Lilly, to show compliance with this requirement within &#91;***&#93; after the Effective Date and annually thereafter. Such documentation evidencing compliance with the training requirement </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">76</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">should, at a minimum, contain the following information&#58; (i) number of employees trained, (ii) positions of those trained employees, (iii) whether Foghorn conducted training using the Lilly-provided anti-corruption training module or their own comparable anti-corruption training, and (iv) the date(s) training was completed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Disclaimer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS Article 11 OR ELSEWHERE IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, QUALITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, OR VALIDITY OF PATENT CLAIMS.  NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN BY EITHER PARTY THAT EITHER PARTY WILL BE SUCCESSFUL IN OBTAINING ANY PATENTS OR THAT ANY PATENTS WILL ISSUE BASED ON A PENDING APPLICATION.  WITHOUT LIMITING THE RESPECTIVE RIGHTS AND OBLIGATIONS OF THE PARTIES EXPRESSLY SET FORTH HEREIN, EACH PARTY SPECIFICALLY DISCLAIMS ANY GUARANTEE THAT ANY PROGRAM OR PRODUCTS WILL BE SUCCESSFUL, IN WHOLE OR IN PART.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.73pt"><br><br>INDEMNIFICATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Indemnity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">12.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">By Foghorn</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Subject to Section&#160;12.1.4, Foghorn shall defend, indemnify and hold harmless Lilly and its Affiliates, and their respective directors, officers, employees, agents, subcontractors, and representatives (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Lilly Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) from and against any and all costs, fees, expenses, losses, liabilities, and damages, including reasonable legal expenses and attorneys&#8217; fees (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) to which any Lilly Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third Party (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) to the extent such Claim and Losses arise out of&#58; (a)&#160;the gross negligence, fraud or willful misconduct of Foghorn or its Affiliates in connection with performance of its activities under this Agreement&#59; (b)&#160;the breach of this Agreement or the representations, warranties and covenants made hereunder by Foghorn&#59; (c) &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">except</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, in each case, to the extent such Losses result from matters described in any of clause (a)-(c) of Section&#160;12.1.2. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">12.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">By Lilly</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Subject to Section&#160;12.1.4, Lilly shall defend, indemnify and hold harmless Foghorn, its Affiliates, and their respective directors, officers, employees, agents, subcontractors, and representatives (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Foghorn Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) from and against any and all Losses to which any Foghorn Indemnitee may become subject as a result of any Claim to the extent such Claim and Losses arise out of&#58; (a)&#160;the gross negligence, fraud or willful misconduct of Lilly, its Affiliates, or their respective Sublicensees in connection with performance of its or their activities under this Agreement&#59; (b)&#160;the breach of this Agreement or the representations, warranties and covenants made hereunder by Lilly&#59; or (c) &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">except</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, in each case, to the extent such Losses result from matters described in any of clause (a)-(d) of Section&#160;12.1.1.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">77</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">12.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Losses&#59; Joint Program Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Any Loss relating to the Exploitation of a Joint Program Product in or for the U.S., including any applicable Third Party product liability Claims, will be deemed to be U.S. Eligible Costs to the extent (a) neither Party is entitled to indemnification hereunder with respect to such Losses and (b) such Losses are allocable to a Joint Program Product and to the United States.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">12.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  A Party that intends to claim indemnification under this Article 12 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) shall promptly notify the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Indemnitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) in writing of any Claim in respect of which the Indemnitee intends to claim such indemnification.  The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any action with respect to a Claim shall only relieve the Indemnitor of its indemnification obligations under this Article 12 if and to the extent the Indemnitor is actually and materially prejudiced thereby.  The Indemnitor has sole control of the defense or settlement thereof.  The Indemnitee shall cooperate fully with the Indemnitor and its legal representatives in the investigation of any action with respect to a Claim covered by this indemnification.  The Indemnitee may participate at its expense in the Indemnitor&#8217;s defense of and settlement negotiations for any Claim with counsel of the Indemnitee&#8217;s own selection.  The Indemnitor shall not settle any Claim without the prior written consent of the Indemnitee, not to be unreasonably withheld, conditioned or delayed&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that such consent will not be required with respect to any settlement involving only the payment of monetary awards for which the Indemnitor will be fully responsible.  So long as the Indemnitor is actively defending the Claim in good faith, the Indemnitee shall not settle or compromise any such Claim without the prior written consent of the Indemnitor.  If the Indemnitor does not assume and conduct the defense of the Claim as provided above&#58;  (a) the Indemnitee may defend against, consent to the entry of any judgment, or enter into any settlement with respect to such Claim in any manner the Indemnitee may deem reasonably appropriate (and the Indemnitee need not consult with, or obtain any consent from, the Indemnitor in connection therewith)&#59; and (b) the Indemnitor shall remain responsible to indemnify the Indemnitee as provided in this Article 12. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">12.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Section 12.1 shall not apply with respect to &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">12.1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  During the Term, each Party shall maintain such types and amounts of liability insurance (including self-insurance) as is normal and customary in the industry generally for similarly situated parties and adequate to cover its obligations under this Agreement, and Foghorn will upon request provide Lilly with a certificate of insurance in that regard.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.73pt"><br><br>CONFIDENTIALITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">13.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Confidential Proprietary Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">13.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Confidential Proprietary Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  In connection with this Agreement, each Party may disclose technical, business or other confidential information in connection with this Agreement, whether prior to, on, or after the Effective Date, including&#58;  (a) any unpublished Patents&#59; and (b) any information regarding the scientific, regulatory or business affairs or other activities of either Party (such confidential information, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Confidential </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">78</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Proprietary Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  Without limiting the foregoing, the existence and terms of this Agreement are the Confidential Proprietary Information of both Parties and shall be treated confidentially by each of the Parties (with both Parties being considered Receiving Parties with respect thereto), subject to the exceptions set forth in Section&#160;13.1.6.  Information exchanged by the Parties pursuant to any of the Confidentiality Agreements shall be treated as Confidential Proprietary Information under this Agreement and governed by the terms of this Agreement.  Without limiting the foregoing, until such time as the applicable information has become available to the public in accordance with this Agreement, Foghorn agrees not to disclose the structure of any Compound except pursuant to Section 13.1.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">13.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  A Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) that receives Confidential Proprietary Information from the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) shall keep all the Disclosing Party&#8217;s Confidential Proprietary Information in confidence with the same degree of care with which the Receiving Party holds its own confidential information (but in no event less than a commercially reasonable degree of care).  A Receiving Party shall not use the Disclosing Party&#8217;s Confidential Proprietary Information except in connection with the performance of its obligations and exercise of its rights under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">13.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The obligations of confidentiality and restriction on use of Confidential Proprietary Information under Section 13.1.2 do not apply to any information that the Receiving Party can prove by competent written evidence&#58;  (a)&#160;is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party, generally known or available to the public&#59; (b)&#160;is known by the Receiving Party at the time of receiving such information, other than by previous disclosure of the Disclosing Party, or its Affiliates, employees, agents, consultants, or contractors&#59; (c)&#160;is hereafter furnished to the Receiving Party without restriction by a Third Party who has no obligation of confidentiality or limitations on use with respect thereto, as a matter of right&#59; or (d)&#160;is independently discovered or developed by the Receiving Party without the use of or reference to Confidential Proprietary Information belonging to the Disclosing Party.  Specific information shall not be deemed to be within any of the foregoing exclusions merely because it is embraced by more general information falling within those exclusions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">13.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Permitted Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The Receiving Party may disclose Confidential Proprietary Information belonging to the Disclosing Party as expressly permitted by this Agreement or if and to the extent such disclosure is reasonably necessary in the following instances&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">made by or on behalf of the Receiving Party to a Patent authority as may be reasonably necessary or useful for purposes of Prosecution and Maintenance of Patents as permitted by this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that neither Party shall file a patent application that discloses &#91;***&#93; that is solely owned by the other Party pursuant to this Agreement without the prior written consent of the owning Party (such consent not to be unreasonably withheld, conditioned or delayed)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">made by or on behalf of the Receiving Party to Regulatory Authorities as required in connection with any Regulatory Filings for a product that such Party has a license or right to develop in a given country or jurisdiction&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">79</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">made by or on behalf of the Receiving Party as may be reasonably necessary for prosecuting or defending litigation as permitted by this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">made by or on behalf of the Receiving Party for the purpose of complying with a valid order of a court of competent jurisdiction or other Governmental Authority of competent jurisdiction or, if in the opinion of the Receiving Party&#8217;s legal counsel, such disclosure is otherwise required by Applicable Law&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">made by or on behalf of the Receiving Party where such disclosure is required by, or advisable to comply with the rules and regulations of, a Regulatory Authority (including in filings with the U.S. Securities and Exchange Commission or other agency) or any securities exchange&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.03pt">made by or on behalf of the Receiving Party as of the Effective Date in response to a valid request by a U.S., state, foreign, provincial, or local tax authority, in which case either Party may disclose a copy of this Agreement (including any Schedules, Appendices, ancillary agreements, and amendments hereto)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">made by the Receiving Party to its and its Affiliates&#8217; employees, consultants, contractors and agents, and to Sublicensees and Litigation Settlement Sublicensees (in the case of Lilly), in each case on a need-to-know basis (as reasonably determined by the Receiving Party) in connection with the Exploitation of Products or Terminated Products (if applicable) in the Field in the Territory, in each case under written obligations of confidentiality and non-use at least as stringent as those herein&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">made by the Receiving Party to potential and actual investors, acquirers, licensees and other financial or commercial partners, or their respective attorneys, accountants or advisors, solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition, or collaboration, in each case under written obligations of confidentiality and non-use at least as stringent as those herein&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that with respect to disclosure to actual or bona fide potential investors, financial partners or acquirers or their respective attorneys, accountants or advisors, such disclosure is under a written obligation of confidentiality that is consistent with market terms, including a shorter period of time during which such information must be held confidential.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if a Party is required to make a disclosure of the other Party&#8217;s Confidential Proprietary Information pursuant to Section&#160;13.1.4(c) or Section 13.1.4(d), it shall, except where impracticable, give reasonable advance notice to the other Party of such disclosure and use efforts to secure confidential treatment of such Confidential Proprietary Information at least as diligent as such Party would use to protect its own Confidential Proprietary Information, but in no event less than reasonable efforts.  Any information disclosed pursuant to this Section 13.1.4 remains Confidential Proprietary Information and subject to the restrictions set forth in this Agreement, including the foregoing provisions of this Article 13.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">13.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Public Domain Information and Residual Knowledge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Nothing in this Agreement shall prevent a Party from using any information that is in the public domain.  A Party shall also not be restricted under, and shall not be in breach of, this Agreement from using, within or outside this Agreement and for any purpose, any general knowledge, skill, and expertise acquired by its employees (or its Affiliates&#8217; employees) in their performance of this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">80</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Residuals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) solely to the extent such Residuals shall have been retained in the unaided memory (without intentional memorization) of such employees in intangible form and without use by the Party or such employees of tangible copies of any Confidential Proprietary Information of the other Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that this provision will not be deemed in any event to provide any right to infringe, or to grant any license to or under, the Patent rights of the other Party or of Third Parties that have licensed or provided materials to the other Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, further, that a Party&#8217;s use of such Residuals is on an &#8220;as is, where is&#8221; basis, with all faults and all representations and warranties disclaimed and at such Party&#8217;s sole risk.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">13.1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Disclosure of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Notwithstanding the foregoing, either Party or its Affiliates may disclose the relevant terms of this Agreement&#58;  (a) to the extent required or advisable to comply with the rules and regulations promulgated by the U.S. Securities and Exchange Commission or any equivalent governmental agency in any country in the Territory or any securities exchange, provided that such Party shall submit a confidential treatment request in connection with such disclosure and shall submit with such confidential treatment request only such redacted form of this Agreement, which redacted form of this Agreement shall be provided to the other Party for review and comment and which comments shall be considered in good faith by the disclosing Party&#59; (b) upon request from a Governmental Authority (such as a tax authority), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that the disclosing Party uses reasonable efforts to ensure the Governmental Authority maintains such terms as confidential&#59; (c) to applicable licensors, to the extent necessary to comply with the terms of any Third Party license agreement, the rights under which are sublicensed to the other Party under this Agreement&#59; and (d)&#160;to the extent necessary to perform obligations or exercise rights under this Agreement, to any sublicensee, collaborator or potential sublicensee or potential collaborator of such Party, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that any sublicensee, collaborator or potential sublicensee or collaborator agree in writing to be bound by obligations of confidentiality and non-use no less protective of the Disclosing Party than those set forth in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">13.1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Each Party&#8217;s obligations under this Section&#160;13.1 (other than Section 13.1.5) shall apply during the Term and continue for &#91;***&#93; thereafter with respect to Confidential Proprietary Information, except for information which is a &#8220;trade secret,&#8221; for which each Party&#8217;s obligations under this Section&#160;13.1 shall remain in place as long as the applicable Confidential Proprietary Information retains its status as a trade secret under Applicable Laws.  Section 13.1.5 shall apply during the Term and shall survive any expiration or termination of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The Parties will issue a joint press release to announce the execution of this Agreement, which will be substantially in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Schedule 13.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and which will be used in responding to inquiries about this Agreement. Thereafter, Foghorn and Lilly may each disclose to Third Parties (including media interviews and disclosures to financial analysts) the information contained in such press release (but only such information) without the need for further approval by the other&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that (a)&#160;such information is still accurate and used in the same context as in its originally approved and presented form, and (b) the publishing Party shall notify the other Party of such intended publication and will provide a copy of such publication to such other Party. Subject to the preceding sentence, each Party will have the right to issue additional press releases and disclosures regarding the terms of this Agreement only with the prior approval of the other Party. Notwithstanding the foregoing, any disclosure which is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">81</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">required by Applicable Law or the rules of the U.S. Securities and Exchange Commission (SEC) or any securities exchange, as reasonably advised by the disclosing Party&#8217;s counsel, may be made without the prior consent of the other Party, although such other Party shall be given prompt notice of any such legally required disclosure and the disclosing Party shall provide such other Party an opportunity to comment on the proposed disclosure. The disclosing Party shall specify with each such proposed press release or public statement, taking into account the urgency of the matter being disclosed, a reasonable period of time within which the other Party may provide any comments on such proposed press release or public statement.  If such other Party provides any comments, the Parties shall consult with one another on such proposed press release or public statement and work in good faith to prepare a mutually acceptable press release or public statement.  The Parties may repeat any information relating to this Agreement that has already been publicly disclosed in accordance with this Section&#160;13.2, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that such information continues as of such time to be accurate.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">13.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Subject to this Section 13.3, Lilly shall be entitled to issue scientific publications and make presentations with respect to the Research Program, the Collaboration Targets, the Compounds, the Products, and their testing in accordance with Lilly&#8217;s internal guidelines. Lilly shall be in control of any publications or scientific presentations regarding the Products or their testing. Notwithstanding the foregoing or anything to the contrary in this Agreement, Foghorn may issue, without Lilly&#8217;s consent, scientific publications or presentations that (I) do not reference a Compound, Product or Collaboration Target and (II) relate to (A) Foghorn programs FHD-286 and FHD-609, (B) targets other than any Collaboration Target or (C) the Foghorn Platform. Lilly may issue scientific publications and make presentations with respect to the activities contemplated under a Research Plan or under a Joint Program solely in accordance with the terms of a publication plan that is approved by the JSC. If Lilly intends to issue any publication or presentation related to any activities conducted under this Agreement, Lilly shall first provide Foghorn with a copy of the applicable proposed abstract, manuscript, or presentation no less than &#91;***&#93; (&#91;***&#93; in the case of abstracts) prior to its intended submission for publication or presentation. Foghorn will respond in writing promptly and in no event later than &#91;***&#93; (&#91;***&#93; in the case of abstracts) after receipt of the proposed material with (a) any concerns regarding the disclosure of any information or subject matter that, in Foghorn&#8217;s reasonable discretion, would present issues as to patentability of the relevant subject matter or (b) any request for the removal of any Foghorn Confidential Proprietary Information. In the event of any concern raised regarding protection of intellectual property rights of Foghorn, Lilly will not submit such publication or make such presentation that contains the relevant information until the Parties are given a reasonable period of time, and in no event less than &#91;***&#93;, to seek patent or other intellectual property protections in accordance with the terms of this Agreement covering any material in such publication or presentation that it believes is protectable. Subject to Sections 13.1.4, 13.1.6 and 13.2, Lilly shall remove any Confidential Information of Foghorn for which Foghorn requests such removal from any such proposed publication or presentation prior to publication or presentation, as applicable.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">82</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.73pt"><br><br>TERM &#38; TERMINATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Agreement commences on the Execution Date and, unless terminated earlier as provided in this Article 14, shall continue on a Product-by-Product basis until (a) in case of Lilly-Controlled Products, the expiration of the last &#91;***&#93; in the Territory for such Lilly-Controlled Product and (b) in case of Joint Program Products, such time as when neither Party nor any of its Affiliates, Sublicensees or Litigation Settlement  Sublicensees is Developing, Commercializing or Manufacturing such Joint Program Product under this Agreement (and such cessation of Development, Manufacturing and Commercialization activities is acknowledged by the Parties in writing to be permanent) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Termination for Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Either Party may terminate this Agreement upon written notice to the other Party if such other Party materially breaches its obligations under this Agreement and, after receiving written notice from the non-breaching Party identifying such material breach in reasonable detail, fails to cure such material breach within &#91;***&#93; from the date of such notice&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that (i) with respect to a material breach of this Agreement relating to a Party&#8217;s performance of obligations with respect to a Joint Program, such termination shall be in-part only with respect to the Joint Program to which such material breach relates, and (ii)  if a non-payment related breach is not reasonably capable of cure within such &#91;***&#93; period, the breaching Party may submit, prior to the end of such &#91;***&#93; period, a reasonable plan to cure the breach within an additional &#91;***&#93;, in which case the other Party may not terminate this Agreement for so long as the breaching Party is using Commercially Reasonable Efforts to implement such cure plan within such additional &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  If the alleged breaching Party Disputes in good faith the existence or materiality of a breach specified in a notice provided by the other Party in accordance with Section 14.2.1, and such alleged breaching Party provides the other Party notice of such Dispute within such &#91;***&#93; period, then the non-breaching Party may not terminate this Agreement under Section 14.2.1 unless and until it has been finally determined pursuant to Article 15 that the alleged breaching Party has materially breached this Agreement and such Party fails to cure such breach within &#91;***&#93; following such court&#8217;s decision.  During the pendency of such Dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Lilly Option to Continue Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Notwithstanding anything to the contrary in this Agreement, if Foghorn &#91;***&#93;, Lilly shall be entitled, in lieu of terminating this Agreement, to (a) &#91;***&#93;&#59; and (b) &#91;***&#93;.  For clarity, in such scenarios, the Agreement shall continue in accordance with its terms, save as expressly set forth in this Section 14.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Termination by Lilly</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">83</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14.5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Partial Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Lilly may, at any time in its sole discretion and without cause, terminate this Agreement on a Collaboration Target-by-Collaboration Target, Project-by-Project, or Product-by-Product basis upon &#91;***&#93; prior written notice to Foghorn.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14.5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Lilly may, in its sole discretion, terminate this Agreement in its entirety at any time and without cause upon &#91;***&#93; prior written notice to Foghorn.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Effects of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Upon any termination of this Agreement, the provisions of this Section 14.6 will apply, provided, that if this Agreement is terminated only with respect to specified Products (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Terminated Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) Foghorn Patents (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Terminated Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) or Projects (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Terminated Projects</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) and not in its entirety, then the following will apply to such Terminated Products, Terminated Patents or Terminated Projects only, and if this Agreement is terminated in its entirety, then all Products will be deemed Terminated Products, all Foghorn Patents will be deemed to be Terminated Patents, and all Projects will be deemed Terminated Projects. If this Agreement is terminated with respect to a Collaboration Target, all Products Directed To such Collaboration Target will be deemed Terminated Products and the Project relating to such Collaboration Target will be deemed a Terminated Project. If this Agreement is terminated solely with respect to specified Projects or a Collaboration Target, the applicable Collaboration Target (the subject of such Project) shall be deemed to no longer be a Collaboration Target and the Terminated Products shall be deemed to no longer be Compounds or Products, in each case, except for the purposes of the provisions of this Agreement relating to the effects of such termination. Further, (i) the provisions of Section 14.6.5 shall only apply (A) upon a termination of this Agreement, either in whole or in part, by Foghorn in accordance with Section 14.2 or Section 14.3 or by Lilly in accordance with Section 14.5.1 or Section 14.5.2, and (B) with respect to any Candidate that is the subject of an active Clinical Trial as of the date of such termination and any Terminated Product that was marketed, promoted, distributed, offered for sale or sold as of the date of such termination, and (ii) other than as set forth in (i) the provisions of Section 14.6.5 shall not be applicable, and the provisions of Section 4.4 alone shall be applicable. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14.6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Termination of Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  All licenses for Terminated Products and all licensed under Terminated Patents granted by Foghorn under Article 7 shall terminate automatically as of the termination effective date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that, if Lilly (or its Affiliates or Sublicensees) has inventory of usable Terminated Product(s) as of the effective date of termination, then Lilly (and its Affiliates and Sublicensees) may continue to sell off such inventory of Terminated Products in the Field in the Territory (and fulfill customer orders therefor, including to manufacture Terminated Products for customer orders placed prior to the effective date of termination) until the earlier to occur of &#91;***&#93; after the effective date of termination and the date on which Lilly (or its Affiliates or Sublicensees) no longer has such inventory of Terminated Product(s) and shall pay Foghorn any applicable payments due based on such sales.   Upon termination of this Agreement for any reason, upon the request of any Sublicensee not then in breach of its sublicense agreement or the terms of this Agreement applicable to such Sublicensee, Foghorn hereby automatically grants to each such Sublicensee a direct license on the same terms as this Agreement, taking into account any difference in license scope, territory, and duration of sublicense grant (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">New License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  &#91;***&#93; of said termination (or such longer time period as is mutually agreed by Foghorn and such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">84</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Sublicensee), Foghorn will enter into a confirmatory New License Agreement between Foghorn to such Sublicensee. Under any such New License Agreement between Foghorn and such former Sublicensee, such Sublicensee will be required to pay to Foghorn the same amounts in consideration for such direct grant as Foghorn would have otherwise received from Lilly pursuant to this Agreement on account of such Sublicensee&#8217;s Exploitation of the Terminated Products had this Agreement not been terminated. Under such New License Agreement, the Parties agree that Foghorn will not be bound by any grant of rights broader than, and will not be required to perform any obligation other than those rights and obligations contained in, this Agreement and all applicable rights of Foghorn set forth in this Agreement will be included in such New License Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14.6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Destruction of Confidential Proprietary Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Subject to the potential transfer of any data and information covered below in Section&#160;14.6.5, each Receiving Party shall destroy (at the Disclosing Party&#8217;s written request) all such Confidential Proprietary Information of the Receiving Party in its possession as of the effective date of expiration or termination (with the exception of one (1) copy of such Confidential Proprietary Information, which may be retained by the legal department of the Receiving Party to confirm compliance with the non-use and non-disclosure provisions of this Agreement), and any Confidential Proprietary Information of the Disclosing Party contained in its laboratory notebooks or databases, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">that each Receiving Party may retain and continue to use such Confidential Proprietary Information of the Disclosing Party to the extent necessary to exercise any surviving rights, licenses or obligations under this Agreement.  Notwithstanding the foregoing, a Receiving Party shall not be required to destroy any computer files created during automatic system back up that are subsequently stored securely by it and not readily accessible to its employees, consultants, or others who received the Disclosing Party&#8217;s Confidential Proprietary Information under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14.6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Transfer of Prosecution Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Upon the expiration or termination of this Agreement in whole or in-part, Lilly will promptly cooperate and assist in transitioning to Foghorn the prosecution and maintenance of (a) all Terminated Patents that Lilly is prosecuting or maintaining pursuant to Section 10.6 as of the effective date of termination, if the Agreement is terminated in its entirety or solely with respect to specific Foghorn Patents, or (b) all Foghorn Patents that solely relate to the applicable Terminated Products that Lilly is prosecuting or maintaining pursuant to Section 10.6 as of the effective date of termination, if the Agreement is not terminated in its entirety but is terminated with respect to specific Products or Projects, including (in each case ((a) and (b)) by executing documents in a timely manner as may be reasonably necessary to allow Foghorn to continue such prosecution and maintenance.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14.6.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:6pt">&#91;***&#93; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14.6.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Terminated Product Reversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">Lilly will grant and hereby does grant to Foghorn, upon termination, a worldwide, perpetual, nonexclusive license, with the right to grant sublicenses through multiple tiers, under the Lilly Product Technology to use, import, offer to sell and sell Terminated Products with respect to the Terminated Projects in the Field in the Territory. The Parties shall negotiate in good faith commercially reasonable royalty and milestone terms with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">85</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">respect to any Terminated Product, which shall account for the reasons for termination. In the event that the Parties are unable to agree upon commercially reasonable royalty and milestone terms within &#91;***&#93; following the date of termination of this Agreement with respect to any Terminated Product, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Unless expressly prohibited by any Regulatory Authority, at Foghorn&#8217;s written request, Lilly will and hereby does, and will cause its Affiliates and any Sublicensees not taking a direct license from Foghorn pursuant to Section 14.6.1 to (i) effective as of the date of termination, assign to Foghorn all of its rights, title, and interests in and to all Clinical Trial data, Regulatory Filings, and Regulatory Approvals applicable to any Terminated Products and then owned or otherwise Controlled by Lilly or any of its Affiliates or such Sublicensees, and (ii) to the extent assignment pursuant to clause (i) is delayed or is not permitted by the applicable Regulatory Authority, permit Foghorn to cross-reference and rely upon any Clinical Trial data, Regulatory Filings and Regulatory Approvals filed by Lilly or its Affiliates or such Sublicensees with respect to any such Terminated Product. Lilly will take all reasonable steps to cause its Affiliates and Sublicensees to make any Clinical Trial data, Regulatory Filings and Regulatory Approvals available to Foghorn.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">Unless expressly prohibited by any Regulatory Authority, at Foghorn&#8217;s written request, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Foghorn will have the right at its discretion (and without limiting Lilly&#8217;s right to sell such inventory in accordance with Section 14.6), to purchase from Lilly any or all of the inventory of the Terminated Products, in each case held by Lilly and its Affiliates as of the date of termination, at a mutually agreed upon transfer price. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">Provided that the Parties agree upon a commercially reasonable license agreement, which shall include quality control terms regarding the use of Lilly&#8217;s Trademarks, Lilly shall grant Foghorn a fully paid-up and royalty-free license to use the Trademarks owned by Lilly or its Affiliates solely identifying each Terminated Product for the purpose of commercializing any inventory purchased from Lilly which existed as of the date of termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.03pt">To the extent that any &#91;***&#93;, the Parties will &#91;***&#93; to which &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Expiration or termination of this Agreement shall not relieve the Parties of any obligation or right accruing prior to such expiration or termination.  Except as set forth below or elsewhere in this Agreement, the obligations and rights of the Parties under the following provisions of this Agreement shall survive expiration or termination of this Agreement&#58; Article 1 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">) (for the purpose of interpreting those surviving sections set forth herein)&#59; Section 3.13(z) (&#91;***&#93;), Section 3.7.1 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">)&#59; Section 3.12 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Technical Transfer Assistance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">) (to the extent Foghorn&#8217;s assistance is required in connection with preparation or submission of an IND or BLA&#47;NDA, if applicable)&#59; Section 4.4.2 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Discontinued Targets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">) (to the extent an extension requested by Lilly is declined)&#59; Section 4.4.3 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Discontinued Targets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">)&#59; Section 6.10.3 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Transfer of Regulatory Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">) (to the extent Lilly requires Foghorn&#8217;s support with respect to any transfer of Foghorn&#8217;s interest in a Regulatory Filing)&#59; Article 9 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Fees, Royalties, &#38; Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">) (solely with respect to (i) the calculation and payment of amounts owed by a Party, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">86</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">which accrued prior to the effective date of termination, and (ii) those obligations set forth in Section 9.7 requiring performance following termination of this Agreement)&#59; Article 10 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">), Article 11 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Representations, Warranties and Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">)&#59; Article 12 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">(Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">) (with respect to Section 12.1.3, Losses which accrue after the effective date of termination which would have been deemed to be U.S. Eligible Costs prior to such termination shall be allocated amongst the Parties in accordance with this Agreement notwithstanding such termination)&#59; Article 13 (Confidentiality)&#59; Section 14.6 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Effects of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">)&#59; this Section 14.7&#59; Article 15 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Governing Law&#59; Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">)&#59; and Article 17 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Bankruptcy Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  If this Agreement is rejected or disclaimed by a Party as a debtor under Section 365 of the United States Bankruptcy Code, or similar provisions in the bankruptcy, insolvency, reorganization or debtor relief laws of another jurisdiction (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), then, notwithstanding anything else in this Agreement to the contrary, all licenses and rights to licenses granted under or pursuant to this Agreement by the Party in bankruptcy to the other Party are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the Code (or similar provision in the bankruptcy laws of the jurisdiction), licenses of rights to &#8220;intellectual property&#8221; as defined under Section 101(35A) of the Code (or similar provision in the bankruptcy laws of another applicable jurisdiction).  The Parties agree that a Party that is a licensee of rights under this Agreement shall retain and may fully exercise all of its rights and elections under the Code, and that upon commencement of a bankruptcy proceeding by or against a Party under the Code, the other Party shall be entitled to a complete duplicate of, or complete access to (as such other Party deems appropriate), any such intellectual property and all embodiments of such intellectual property, if not already in such other Party&#8217;s possession, shall be promptly delivered to such other Party&#58;  (a) upon any such commencement of a bankruptcy proceeding upon written request therefor by such other Party, unless the bankrupt Party elects to continue to perform all of its obligations under this Agreement&#59; or (b) if not delivered under the foregoing subclause (a), upon the rejection of this Agreement by or on behalf of the bankrupt Party upon written request therefor by the other Party.  The foregoing provisions of this Section 14.6 are without prejudice to any rights a Party may have arising under the Code.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.73pt"><br><br>GOVERNING LAW&#59; DISPUTE RESOLUTION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">15.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Agreement is governed by and will be construed in accordance with the laws of the State of New York, without reference to its conflict of laws principles.  The United Nations Convention of International Contracts on the Sale of Goods (the Vienna Convention) does not apply to this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">15.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">15.2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:6pt">The Parties recognize that controversies or claims arising out of, relating to, or in connection with this Agreement may arise from time to time.  It is the objective of the Parties to establish procedures to facilitate the resolution of Disputes in an expedient manner by mutual cooperation and without resort to litigation.  To accomplish this objective, the Parties shall follow the procedures set forth in this Article 15 to resolve any Dispute. If any dispute, claim or controversy of any nature arising out of or relating to this Agreement, including (a) any action or claim based on tort, contract or statute concerning the interpretation, effect, termination, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">87</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">validity, performance or breach of this Agreement and (b) any dispute (i) arising out of a JSC Subcommittee that is escalated to the JSC or (ii) arising out of the JSC, in each case ((i) or (ii)) that is not resolved pursuant to a Party&#8217;s exercise of its final decision-making authority under Section 2.8 (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), arises between the Parties, then either Party may request in writing that the Dispute be submitted to the Executive Officers of each Party for resolution within &#91;***&#93; of such written notice&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that any applicable escalation mechanisms through the JSC or a JSC Subcommittee set forth in this Agreement have been exhausted. To the extent that the Executive Officers have not succeeded in negotiating a resolution of the Dispute within &#91;***&#93; after the notice of Dispute, and a Party wishes to continue pursuing the matter, then the provisions of Sections 15.2.2 through Section 15.2.4 shall apply, as applicable. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">15.2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:6pt">&#91;***&#93; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">15.2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:6pt">Subject to Section 15.2.2, any Dispute at the JSC that is subject to a Party&#8217;s final decision-making authority under Section 2.8 will be resolved in accordance with such Party&#8217;s exercise of such decision-making authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">15.2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:6pt">Subject to Section 15.2.2 and Section 15.2.3, either Party may seek to resolve the Dispute in any federal court having jurisdiction thereof located in New York, New York as further described in Section 15.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">15.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Litigation&#59; Equitable Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The Federal courts located in New York, New York shall have exclusive jurisdiction over, and shall be the exclusive venue for resolution of, any Dispute not resolved through the Dispute resolution procedures described in Section 15.2. If, within &#91;***&#93; following a notice by either Party to the other that it does not believe the Dispute can be resolved through Executive Officers, neither Party has commenced proceedings seeking to resolve such Dispute pursuant to Section 15.2, then such Dispute and all related rights, demands, claims, actions, causes of action, suits, proceedings and Losses of every kind and nature shall be deemed to have been irrevocably waived and released, to the fullest extent permitted under Applicable Laws. Notwithstanding anything to the contrary in this Agreement, either Party may, at any time and without waiving any remedy under this Agreement, seek from any court having jurisdiction any temporary injunctive or provisional relief necessary to protect the rights or property of that Party.  Any final judgment resolving a Dispute may be enforced by either Party in any court having appropriate jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.73pt"><br><br>RESERVED</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Article 17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.73pt"><br><br>MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Entire Agreement&#59; Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Agreement, including the Schedules hereto, sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto with respect to the subject matter hereof and supersedes, as of the Effective Date, all prior </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">88</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">and contemporaneous agreements and understandings between the Parties with respect to the subject matter hereof, including the Confidentiality Agreements.  The foregoing may not be interpreted as a waiver of any remedies available to either Party as a result of any breach, prior to the Effective Date, by the other Party of its obligations under any Confidentiality Agreement.  No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  NEITHER PARTY MAY RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">PROVIDED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">HOWEVER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, THAT THIS SECTION&#160;17.2 SHALL NOT BE CONSTRUED TO LIMIT EITHER PARTY&#8217;S INDEMNIFICATION OBLIGATIONS UNDER ARTICLE 12, EITHER PARTY&#8217;S LIABILITY FOR BREACH OF ITS EXCLUSIVITY OBLIGATIONS UNDER ARTICLE 8, EITHER PARTY&#8217;S LIABILITY FOR BREACH OF ITS CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 13, OR LIABILITY OF A PARTY FOR ITS INFRINGEMENT OR MISAPPROPRIATION OF ANY INTELLECTUAL PROPERTY RIGHTS OR FOR A PARTY&#8217;S GROSS NEGLIGENCE, WILLFUL MISCONDUCT OR FRAUD.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Independent Contractors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The relationship between Lilly and Foghorn created by this Agreement is solely that of independent contractors.  This Agreement does not create any agency, distributorship, employee-employer, partnership, joint venture or similar business relationship between the Parties.  Neither Party is a legal representative of the other Party, nor can either Party assume or create any obligation, representation, warranty, or guarantee, express or implied, on behalf of the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Any notice required or permitted to be given by this Agreement must be in writing, in English.  Any and all notices or other communications or deliveries required or permitted to be provided hereunder must be in writing and will be deemed given and effective if&#58;  (a) delivered by hand or by overnight courier with tracking capabilities&#59; (b) mailed postage prepaid by first class, registered, or certified mail&#59; or (c) delivered by electronic mail, in each case, addressed as set forth below unless changed by notice so given&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">89</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="padding-left:14.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.307%"><tr><td style="width:1.0%"></td><td style="width:31.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.609%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If to Foghorn&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Foghorn Therapeutics Inc.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">500 Technology Square, Suite 700</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cambridge, Massachusetts 02139</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58; Head of Business Development</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">With a copy to (which will not constitute notice)&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Foghorn Therapeutics Inc.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">500 Technology Square, Suite 700</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cambridge, Massachusetts 02139</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58; Head of Legal</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; legal&#64;foghorntx.com</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">And&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ropes &#38; Gray LLP</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Prudential Tower</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">800 Boylston Street, Boston, MA 02199</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58; Marc Rubenstein</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; marc.rubenstein&#64;ropesgray.com</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If to Lilly&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Eli Lilly and Company <br>Lilly Corporate Center<br>Indianapolis, Indiana 46285<br>Attn&#58;  Vice President, Corporate Business Development <br>Fax&#58;  (317) 651-3051</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with a copy (which shall not constitute notice) to&#58;<br><br>Eli Lilly and Company<br>Lilly Corporate Center<br>Indianapolis, IN 46285<br>Attn&#58; General Counsel</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; counsel_general&#64;lilly.com<br>Fax&#58; (317) 433-3000</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Party shall also provide a copy of any notice (via e-mail if available) to the other Party&#8217;s Alliance Manager.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction&#58;  (a) such adjudication shall not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Agreement&#59; (b)&#160;this Agreement shall be construed and enforced as if such invalid, unenforceable or illegal provision had never comprised a part hereof&#59; and (c) all </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">90</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">remaining portions will remain in full force and effect and shall not be affected by the invalid, unenforceable or illegal provision or by its severance herefrom.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Non-Use of Names</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Foghorn shall not use the name, trademark, logo, or physical likeness of Lilly or its officers, directors or employees, or any adaptation of any of them, in any advertising, promotional or sales literature, without Lilly&#8217;s prior written consent.  Foghorn shall require its Affiliates to comply with the foregoing.  Lilly shall not use the name, trademark, logo, or physical likeness of Foghorn or its officers, directors or employees, or any adaptation of any of them, in any advertising, promotional or sales literature, without Foghorn&#8217;s prior written consent.  Lilly shall require its Affiliates and Sublicensees to comply with the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of the other, except that a Party may make such an assignment or transfer without the other Party&#8217;s consent to&#58;  (a) its Affiliate, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that such Party shall remain primarily liable for any acts or omissions of such Affiliate&#59; or (b) to an Acquirer in connection with a Change of Control, subject to Section 17.8.  Any permitted assignee shall, in writing to the non-assigning Party, expressly assume performance of such assigning Party&#8217;s rights and obligations.  Any permitted assignment is binding on the successors of the assigning Party.  Any assignment or attempted assignment by either Party in violation of the terms of this Section&#160;17.7 is null, void and of no legal effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Foghorn Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Notification of Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Foghorn shall provide Lilly with written notice of any Change of Control of Foghorn promptly, but no later than &#91;***&#93;, following the earlier of the first public announcement of such Change of Control or the execution of a definitive agreement relating to such Change of Control (if such disclosure is not prohibited under Applicable Law or by the terms of any written agreement between Foghorn and any third party), which notice shall describe in reasonable detail the nature of the transaction and the identity of the Acquirer (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Change of Control Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;).  If Foghorn undergoes a Change of Control, then the terms of Section 17.8.2 through Section 17.8.5 shall apply.  For avoidance of doubt, a Change of Control of Foghorn shall not in any way limit or alter Lilly&#8217;s termination rights in accordance with Section 14.5, and the provisions of Section 17.8.2 below shall only apply if Lilly has not exercised any such termination right.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Effects of Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  If Foghorn undergoes a Change of Control, and at such time Foghorn &#91;***&#93;, then Lilly shall have the option, &#91;***&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, that &#91;***&#93;.  In addition, in the event of a Change of Control of Foghorn, &#91;***&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.8.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:6pt">&#91;***&#93;. Following any Change of Control of Foghorn to an Acquirer that owns or controls any &#91;***&#93; Foghorn shall cause the Acquirer to refrain from &#91;***&#93;. The obligations of this Section 17.8.3 apply with respect to any Acquirer, &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.8.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Firewalled Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Promptly following the occurrence of any of the following events in relation to an Acquirer of Foghorn&#58;  (a) the effective date of a Change of Control of Foghorn &#91;***&#93;, (b) Lilly&#8217;s delivery to Foghorn of a Proposed Additional Target Notice pursuant to Section 4.2 or a Proposed Replacement Target Notice pursuant to Section 4.3 (if applicable) specifying the identity of a Target that Lilly desires to include as a Collaboration </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">91</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Target under this Agreement, &#91;***&#93;, or (c) the initiation of a &#91;***&#93; (each of (a), (b) and (c), with respect to such Competing Program, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Firewall Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;), Foghorn shall implement and enforce Firewalls between the applicable Research Program and Competing Program for the duration of the applicable Firewall Period. &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.8.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:6pt">Firewall Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Lilly shall have the right, through a designated Third Party auditor reasonably acceptable to Foghorn, to audit Foghorn&#8217;s (and, as applicable, its Affiliates&#8217;) obligations under this Agreement regarding implementation and enforcement of Firewalls under this Section 17.8 for purposes of confirming compliance with the Firewalls, identifying any vulnerabilities or breaches and requiring Foghorn (or its Affiliates) to promptly remediate any non-compliance identified by such audit.  In connection with such audit, duly authorized representatives of Lilly&#8217;s designated auditor may make an on-site visit to Foghorn (or its Affiliate) for the purpose of conducting such audit.  Lilly may conduct such audits from time to time as reasonably necessary to confirm Foghorn&#8217;s compliance with such Firewall requirements no more than once per Calendar Year or more frequently if Lilly reasonably believes at any time that Foghorn is not in compliance with such Firewall requirements&#59; &#91;***&#93;.  Any audits described under this Section 17.8.5 shall be conducted during Foghorn&#8217;s regular business hours, for a duration only as reasonably necessary to confirm Foghorn&#8217;s compliance with the applicable Firewall requirements, and shall not unreasonably interfere with or impede Foghorn&#8217;s business operations.  Lilly shall provide Foghorn with written notice of such audit no later than &#91;***&#93; prior to such requested audit (or such shorter period as may be designated by Lilly if Lilly reasonably believes at any time that Foghorn is not in compliance with such Firewall requirements).  All such audits shall be conducted at Lilly&#8217;s cost and expense.  If the auditor identifies any breach of the Firewall, Lilly and&#47;or the auditor will notify Foghorn, and Foghorn will promptly (and will use reasonable efforts to ensure its Affiliates promptly) take all action necessary to remedy such breach, and will provide Lilly with reasonable assurance that such action has been taken, at Foghorn&#8217;s sole expense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:15pt">Waivers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance.  Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:9pt">Force</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Neither Party shall be responsible to the other for any failure or delay in performing any of its obligations under this Agreement or for other nonperformance hereunder (excluding, in each case, the obligation to make payments when due) if such delay or nonperformance is caused by strike, fire, flood, earthquake, accident, war, act of terrorism, epidemics, pandemics, quarantines</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> act of God or of the government of any country or of any local government, or by any other cause unavoidable or beyond the control of any Party hereto.  In such event, such affected Party shall use Commercially Reasonable Efforts to resume performance of its obligations and will keep the other Party informed of actions related thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:9pt">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The captions and headings to this Agreement are for convenience only, and are to be of no force or effect in construing or interpreting any of the provisions of this Agreement.  Unless specified to the contrary, references to Articles, Sections, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">92</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Appendices or Schedules mean the particular Articles, Sections, Appendices&#160;or Schedules to this Agreement and references to this Agreement include all Schedules hereto.  In the event of any conflict between the main body of this Agreement and any Schedule hereto, the main body of this Agreement shall prevail.  Unless context otherwise clearly requires, whenever used in this Agreement&#58;  (a)&#160;the words &#8220;include&#8221; or &#8220;including&#8221; shall be construed as incorporating, also, &#8220;but not limited to&#8221; or &#8220;without limitation&#8221;&#59; (b)&#160;the word &#8220;day&#8221; or &#8220;year&#8221; means a calendar day or year unless otherwise specified&#59; (c)&#160;the word &#8220;notice&#8221; means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement&#59; (d)&#160;the words &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby&#8221; and derivative or similar words refer to this Agreement as a whole and not merely to the particular provision in which such words appear&#59; (e)&#160;the words &#8220;shall&#8221; and &#8220;will&#8221; have interchangeable meanings for purposes of this Agreement&#59; (f) provisions that require that a Party, the Parties or a committee hereunder &#8220;agree,&#8221; &#8220;consent&#8221; or &#8220;approve&#8221; or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes, email or otherwise&#59; (g) words of any gender include any other gender&#59; (h) words using the singular or plural number also include the plural or singular number, respectively&#59; (i) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement law, rule or regulation thereof&#59; (j) the phrase &#8220;non-refundable&#8221; shall not prohibit, limit or restrict either Party&#8217;s right to obtain damages in connection with a breach of this Agreement&#59; (k) the word &#8220;or&#8221; is used in the inclusive sense (&#8220;and&#47;or&#8221;)&#59; and (l) neither Party shall be deemed to be acting on behalf of the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:9pt">Counterparts&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Electronic</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Agreement may be executed in any number of counterparts, each of which is deemed an original, but all of which together constitute one instrument.  This Agreement may be executed and delivered electronically and upon such delivery such electronic signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:9pt">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Each Party shall pay its own costs, charges and expenses incurred in connection with the negotiation, preparation and execution of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:9pt">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Lilly and Foghorn hereby covenant and agree without the necessity of any further consideration, to execute, acknowledge and deliver any and all documents and take any action as may be reasonably necessary to carry out the intent and purposes of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:9pt">No Third Party Beneficiary Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  This Agreement is not intended to and shall not be construed to give any Third Party any interest or rights (including any Third Party beneficiary rights) with respect to or in connection with any agreement or provision contained herein or contemplated hereby, except for Lilly Indemnitees and Foghorn Indemnitees as expressly provided in Section 12.1 or as otherwise expressly provided for in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:9pt">Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  The Parties hereto acknowledge and agree that&#58;  (a) each Party and its counsel reviewed and negotiated the terms and provisions of this Agreement and have contributed to its revision&#59; (b) the rule of construction to the effect that any ambiguities are resolved against the drafting Party shall not be employed in the interpretation of this Agreement&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">93</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">and (c) the terms and provisions of this Agreement shall be construed fairly as to all Parties hereto and not in a favor of or against any Party, regardless of which Party was generally responsible for the preparation of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:9pt">Cumulative Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  No remedy referred to in this Agreement is intended to be exclusive unless explicitly stated to be so, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;padding-left:9pt">Extension to Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Except as expressly set forth otherwise in this Agreement, each Party shall have the right to extend the rights and immunities granted in this Agreement to one or more of its Affiliates.  All applicable terms and provisions of this Agreement, except this right to extend, shall apply to any such Affiliate to which this Agreement has been extended to the same extent as such terms and provisions apply to the Party extending such rights and immunities.  For clarity, the Party extending the rights and immunities granted hereunder shall remain primarily liable for any acts or omissions of its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Signature page follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">94</font></div></div></div><div id="if2e95c9e2ab04959b9e0e4da068e3443_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div id="if2e95c9e2ab04959b9e0e4da068e3443_13"></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">In Witness Whereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties have caused this Agreement to be executed as of the Effective Date by their duly authorized representatives.</font></div><div style="margin-bottom:30pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Eli Lilly and Company</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; David Ricks&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;David Ricks<br>Title&#58;&#160;&#160;&#160;&#160;Chairman and Chief Executive Officer</font></div><div id="if2e95c9e2ab04959b9e0e4da068e3443_16"></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;SIGNATURE PAGE TO THE COLLABORATION AGREEMENT&#93;</font></div></div></div><div id="if2e95c9e2ab04959b9e0e4da068e3443_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CONFIDENTIAL</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">In Witness Whereof</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties have caused this Agreement to be executed as of the Effective Date by their duly authorized representatives.</font></div><div style="margin-bottom:30pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Foghorn Therapeutics Inc.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Adrian Gottschalk&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Adrian Gottschalk<br>Title&#58;&#160;&#160;&#160;&#160;President and Chief Executive Officer</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">114</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>3
<FILENAME>ex1022-aremploymentagreeme.htm
<DESCRIPTION>EX-10.22
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i83a6942160c34f0c83390bb87bd15fc7_1"></div><div style="min-height:48.96pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.22</font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:26.053%"><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:218px"></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:45.4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:280%">October 14, 2020 Allan Reine</font></div><div style="margin-top:0.15pt;padding-left:41pt;padding-right:46.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:232%">By Email Delivery Dear Allan&#58;</font></div><div style="margin-top:1.95pt;padding-left:5pt"><font><br></font></div></div><div style="display:inline-block;max-width:47.892%;min-width:46.892%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:26.055%"><div style="padding-left:5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Execution Version</font></div></div></div><div style="padding-left:77pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:102%">This letter agreement (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:102%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:102%">&#8221;) amends and restates the offer letter dated</font></div><div style="padding-left:41pt;padding-right:6.25pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">July 23, 2019, as amended August 29, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Offer Letter</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), by and among you and Foghorn Therapeutics Inc. (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). This Agreement sets forth the terms and conditions of your continued employment with the Company. This Agreement will be effective as of the date on which the Company becomes subject to the reporting obligations of Section 12 of the Securities Exchange Act of 1934, as amended. Should this not occur for any reason, this Agreement shall be void and of no force or effect.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">POSITION AND DUTIES</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:6.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Your position shall be Chief Financial Officer. In this role, you will report to the Chief Executive Officer of the Company and perform the duties and responsibilities of your position, and such other duties as reasonably may be assigned to you from time to time consistent with your position. As a member of our team, we expect you to devote all of your professional and working time and energies to the business and affairs of the Company. You shall not engage in non-Company related business activities (including consulting activities, board memberships and academic appointments) without the prior written consent of the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or its designee. You agree that, should you receive the Company&#8217;s consent to conduct any such non-Company related business activities, you shall conduct such activities so as not to interfere with the performance of your duties hereunder or violate the provisions of your Confidentiality Agreement (as defined below). You shall be employed on an at-will basis, which means that neither you nor the Company are guaranteeing this employment relationship for any specific period of time.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">COMPENSATION</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During your employment hereunder, as compensation for all services performed for the Company and its affiliates, the Company will provide you with the following compensation and benefits&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:48.96pt;width:100%"><div><font><br></font></div></div><div style="padding-left:41pt;padding-right:6.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.88pt">Salary</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Your initial base salary shall be at a rate of $400,000 on an annualized basis, and shall be payable in accordance with the Company&#8217;s normal payroll practices. Your base</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i83a6942160c34f0c83390bb87bd15fc7_4"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="margin-top:1.95pt;padding-left:41pt;padding-right:6.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">salary shall be subject to adjustment from time to time by the Board or the Compensation Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation Committee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), in its respective sole discretion.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:2.6pt;padding-left:41pt;padding-right:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.88pt">Annual Performance Bonus</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In accordance with the Company&#8217;s annual bonus plan (as in effect from time to time), with respect to each fiscal year completed during your employment with the Company, you will be able to earn an annual bonus based upon the achievement, as determined by the Board or the Compensation Committee, in its respective sole discretion, of specified performance goals established by the Board or the Compensation Committee for such fiscal year. Your target annual bonus will be forty percent (40%) of your base salary. The annual bonus, to the extent earned, shall be paid to you no later than March 15 of the calendar year immediately following the calendar year to which it relates. Except as expressly provided below, you must be employed by the Company or on an approved leave of absence on the date of payment of the bonus in order to be eligible for and have earned the annual bonus.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:6.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.37pt">Equity Grants</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You shall be eligible for future grants of stock options and other equity awards in the sole discretion of the Board or the Compensation Committee, subject to the terms and conditions of the Company&#8217;s equity incentive plan and any applicable award agreements.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.78pt">Benefits</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You shall be eligible to participate in the Company&#8217;s benefit plans to the same extent as, and subject to the same terms, conditions and limitations applicable to, other Company employees of similar rank and tenure. These benefits may be modified, changed or eliminated from time to time at the sole discretion of the Company, and the provision of such benefits does not change your status as an at-will employee. Where a particular benefit is subject to a formal plan (for example, medical insurance or life insurance), eligibility to participate in and receive any particular benefit is governed solely by the applicable plan document.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">d.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.37pt">Travel and Lodging Allowance</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Pursuant to the terms of the Offer Letter, the Company agreed to provide you with a monthly gross allowance of $6,666.67 per month ($120,000.00 in total for the eighteen- (18) month period), less required deductions for federal and state taxes and other applicable withholdings, for up to eighteen (18) months following your commencement of employment with the Company on September 16, 2019 (your &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Start Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for reasonable travel and lodging expenses related to your commute between your home location and the Company&#8217;s office location in Cambridge, Massachusetts, subject to required repayment upon your voluntary termination of employment not qualifying as a Resignation for Good Reason or upon termination of your employment by the Company for Cause, in each case, prior to the eighteen- (18) month anniversary of your Start Date. You hereby acknowledge and agree that, as of November 1, 2020, you will no longer be entitled to receive such an allowance. The Company, in its sole discretion, may determine that it is appropriate to provide you with a travel allowance in the future, in which case such allowance shall be separately communicated to you in writing. The requirement of you to repay any amounts in respect of the travel allowance previously paid to you under the Offer Letter on a voluntary termination of employment not qualifying as a Resignation for Good Reason or upon termination of your employment by the</font></div><div style="text-align:justify"><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:1.95pt;padding-left:41pt;padding-right:6.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company for Cause, in each case, prior to the eighteen- (18) month anniversary of your Start Date shall remain in effect under the terms of this Agreement.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">f.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.01pt">Expense Reimbursement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company shall reimburse you for all ordinary and reasonable out-of-pocket business expenses incurred in furtherance of the Company&#8217;s business in accordance with the Company&#8217;s policies with respect thereto as in effect from time to time. You must submit any request for reimbursement no later than ninety (90) days following the date that such business expense is incurred. All reimbursements hereunder shall be made or provided in accordance with the requirements of Section 409A (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the Internal Revenue Code and the rules and regulations thereunder (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) including, where applicable, the requirement that&#58; (i) any reimbursement is for expenses incurred during your lifetime (or during a shorter period of time specified in this Agreement)&#59; (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year&#59; (iii) the reimbursement of an eligible expense shall be made no later than the last day of the calendar year following the year in which the expense is incurred&#59; and</font></div><div style="padding-left:41pt;padding-right:6.25pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv) the right to reimbursement or in kind benefits is not subject to liquidation or exchange for another benefit.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">SEVERANCE BENEFIT UPON CERTAIN TERMINATIONS OF EMPLOYMENT</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.88pt">Termination Not in Connection with a Change in Control</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding the at-will nature of the parties&#8217; relationship, should you be subject to an Involuntary Termination other than an Involuntary Termination that occurs in the CIC Period, then, conditioned upon your timely execution and non-revocation of a separation agreement containing a release of claims and other customary terms in the form provided by the Company (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and compliance with your Confidentiality Agreement&#58; (i) the Company shall provide you with a payment in an amount equal to nine (9) months of your then-current base salary, payable in the form of salary continuation over the nine- (9) month period following the date of separation, commencing on the first regular Company payday that is at least five (5) business days following the effective date of the Release&#59; (ii) (A) if you properly elect to receive benefits under Consolidated Omnibus Budget Reconciliation Act (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">COBRA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or similar state law and (B) the premium subsidy described below is not illegal or discriminatory under the Code, the Patient Protection and Affordable Care Act or the Health Care and Education Reconciliation Act, then the Company shall provide you with nine (9) months of your COBRA premiums at the Company&#8217;s normal rate of contribution for employees for your coverage at the level in effect immediately prior to your termination, such premiums to be provided on a monthly basis&#59; and (iii) the Company shall pay the amount of any annual bonus previously awarded to you by the Board or the Compensation Committee, as applicable, with respect to the calendar year concluded prior to the date of termination that remains unpaid as of the date of termination, which annual bonus shall be paid at the same time as bonuses are paid to active employees of the Company.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.37pt">Termination in Connection with a Change in Control</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If you are subject to an Involuntary Termination that occurs in the CIC Period, then, conditioned upon your timely execution and non-revocation of the Release and compliance with your Confidentiality</font></div><div style="text-align:justify"><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:1.95pt;padding-left:41pt;padding-right:6.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement, in lieu of the payments and benefits provided under </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above&#58; (i) the Company shall provide you with a payment in an amount equal to the sum of (A) your then- current base salary plus (B) your target annual bonus for the year in which termination occurs, which amount shall be payable in the form of salary continuation over the twelve- (12) month period following the date of separation, commencing on the first regular Company payday that is at least five (5) business days following the effective date of the Release&#59; (ii) (A) if you properly elect to receive benefits under COBRA or similar state law and (B) the premium subsidy described below is not illegal or discriminatory under the Code, the Patient Protection and Affordable Care Act or the Health Care and Education Reconciliation Act, then the Company shall provide you with twelve (12) months of your COBRA premiums at the Company&#8217;s normal rate of contribution for employees for your coverage at the level in effect immediately prior to your termination, such premiums to be provided on a monthly basis&#59; (iii) the Company shall pay the amount of any annual bonus previously awarded to you by the Board or the Compensation Committee, as applicable, with respect to the calendar year concluded prior to the date of termination that remains unpaid as of the date of termination, which annual bonus shall be paid at the same time as bonuses are paid to active employees of the Company&#59; and (iv) the vesting and, if applicable, the exercisability of each of your outstanding time-based stock options and other equity awards under the Company&#8217;s equity incentive plan(s) shall be fully accelerated as of the effective date of the Release (with the vesting of any performance-based equity awards determined based on the terms of the award agreements governing such awards).</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.78pt">Timing of Payments</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any severance payments paid under this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall commence within sixty (60) days after the date of termination (or at such earlier time as provided in this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), with the initial payment to include any amounts that would have been payable by their terms prior to such payment commencement date&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if the sixty-</font></div><div style="margin-top:0.1pt;padding-left:41pt;padding-right:6.25pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(60) day period begins in one calendar year and ends in a second calendar year, the severance payments shall begin to be paid following the last day of such sixty- (60) day period in the second calendar year.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:6.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">d.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.37pt">Other Termination Events</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Should you voluntarily terminate your employment for any reason (other than a Resignation for Good Reason) or should your employment be terminated for Cause (whether before or after a Change of Control) or as a result of your death or disability, then you shall not be entitled to any severance payments described herein. Nothing in this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall alter your status as an at-will employee.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:2.6pt;padding-left:41pt;padding-right:6.1pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">e.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.76pt">Certain Definitions</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For purposes of this Agreement, the following terms shall have the meanings and be subject to the provisions set forth below&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any one or more of the following actions&#58; (i) your material breach of the terms of this Agreement or any other written agreement between you and the Company or any of its affiliates&#59; (ii) your material dishonesty, willful misconduct, gross negligence or reckless conduct, in each case, in connection with the performance of your services to the Company or any of its affiliates&#59; (iii) your commission of an act of fraud, theft, misappropriation or embezzlement&#59; (iv) your indictment for, or pleading nolo contendere to, any crime involving</font></div><div style="text-align:justify"><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:1.95pt;padding-left:41pt;padding-right:6.2pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">moral turpitude or any felony&#59; or (v) your material violation of a Company policy that had been previously provided to you in writing or your willful refusal to perform, or substantial negligence in the performance of, your assigned duties to the Company or any of its affiliates (other than as a result of your mental or physical impairment). For purpose of clauses (i), (ii) and (v), &#8220;Cause&#8221; shall only exist if&#58; (y) the Company delivered to you a written description of the events or conditions giving rise to your termination for Cause&#59; and (z) if curable, you have been given at least fifteen (15) days to cure such events or conditions and you fail to cure such events or conditions within such time period given.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means&#58; (i) any &#8220;Person&#8221; (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) that becomes the &#8220;Beneficial Owner&#8221; (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company&#8217;s then outstanding voting securities (excluding for this purpose any such voting securities held by the Company or its affiliates or by any employee benefit plan of the Company) pursuant to a transaction or a series of related transactions&#59; or (ii) a merger or consolidation of the Company whether or not approved by the Board, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) more than 50% of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation, as the case may be, outstanding immediately after such merger or consolidation&#59; or (iii) the sale or disposition by the Company of all or substantially all of the Company&#8217;s assets in a transaction requiring stockholder approval&#59; notwithstanding the foregoing, no transaction or series of transactions shall constitute a Change of Control unless such transaction or series of transactions constitutes a &#8220;change in control event&#8221; within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(i).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CIC Period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the period commencing on the date that is three (3) months prior to the date on which a Change of Control occurs and ending on the date that is twelve (12) months following such occurrence.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Involuntary Termination</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means either (i) your Termination Without Cause or (ii) your Resignation for Good Reason.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Resignation for Good Reason</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a termination of your employment after one of the following conditions has come into existence without your consent&#58; (i) a reduction in your base salary other than in connection with an across-the-board reduction affecting all similarly situated executives of the Company&#59; (ii) a material diminution of your title, authority, duties or responsibilities&#59; (iii) a material breach of this Agreement by Company&#59; or (iv) a relocation of your principal workplace by more than fifty (50) miles. A Resignation for Good Reason shall not be deemed to have occurred unless you give the Company written notice of the condition within ninety (90) days after the condition comes into existence, the Company fails to remedy the condition within thirty (30) days after receiving your written notice and you terminate your employment within thirty (30) days after the end of the cure period.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:1.95pt;padding-left:41pt;padding-right:6.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Without Cause</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a termination of your employment by the Company without Cause (and not as a result of your death or disability), provided you are willing and able to continue performing services within the meaning of Treasury Regulation Section 1.409A- 1(n)(1).</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">CONFIDENTIALITY AND OTHER OBLIGATIONS</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As part of your employment with the Company, you shall be exposed to, and provided with, valuable confidential and trade secret information concerning the Company and its present and prospective clients. As a result, in order to protect the Company&#8217;s legitimate business interests, you have previously entered into the Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment of Inventions Agreement (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) attached as </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto. You hereby acknowledge and agree that you continue to be bound by the terms thereof, which are not modified in any way by this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">CERTIFICATION</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:6.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By signing this Agreement, you are certifying to the Company that&#58; (i) your employment with the Company does not and shall not require you to breach any agreement entered into by you prior to employment with the Company (i.e., you have not entered into any agreements with previous employers that are in conflict with your obligations to the Company)&#59; (ii) to the extent you are subject to restrictive agreements with any prior employer that may affect your employment with the Company, you have provided us with a copy of that agreement&#59; (iii) your employment with the Company does not violate any order, judgment or injunction applicable to you, and you have provided the Company with a copy of any such order, judgment, or injunction&#59; and (iv) all facts you have presented to the Company are accurate and true, including all statements made to the Company pertaining to your education, training, qualifications, licensing and prior work experience on any job application, resume or c.v., or in any interview. The Company does not want you to disclose any confidential information belonging to a previous employer or to incorporate the proprietary information of any previous employer into the Company&#8217;s proprietary information and expects that you shall abide by restrictive covenants to prior employers.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">SECTIONS 409A AND 280G OF THE CODE</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.88pt">Notwithstanding any other provision of this Agreement to the contrary, if any amount (including imputed income) to be paid to you pursuant to this Agreement as a result of your termination of employment is &#8220;deferred compensation&#8221; subject to Section 409A of the Code, and if you are a &#8220;Specified Employee&#8221; (as defined under Section 409A of the Code and as determined by the Company) as of the date of your termination of employment hereunder, then, to the extent necessary to avoid the imposition of excise taxes or other penalties under Section 409A of the Code, the payment of benefits, if any, scheduled to be paid by the Company to you hereunder during the first six- (6) month period following the date of a termination of employment hereunder shall not be paid until the date which is the first business day after six (6) months have elapsed since your termination of employment for any reason other than death.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:1.95pt;padding-left:41pt;padding-right:6.15pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any deferred compensation payments delayed in accordance with the terms of this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be paid in a lump sum after six (6) months have elapsed since your termination of employment. Any other payments shall be made according to the schedule provided for herein.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.37pt">If any of the benefits set forth in this Agreement are &#8220;deferred compensation&#8221; under Section 409A of the Code, any termination of employment triggering payment of such benefits must constitute a &#8220;separation from service&#8221; under Section 409A of the Code (after giving effect to the presumptions contained therein) before distribution of such benefits can commence. To the extent that the termination of your employment does not constitute a &#8220;separation from service&#8221; under Section 409A of the Code (as the result of further services that are reasonably anticipated to be provided by you to the Company at the time your employment terminates), any benefits payable under this Agreement that constitute &#8220;deferred compensation&#8221; under Section 409A of the Code shall be delayed until after the date of a subsequent event constituting a &#8220;separation from service&#8221; under Section 409A of the Code. For purposes of clarification, this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.b</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall not cause any forfeiture of benefits on your part but shall only act as a delay until such time as a &#8220;separation from service&#8221; occurs.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6.3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.78pt">It is intended that each installment of the payments and benefits provided under this Agreement shall be treated as a separate &#8220;payment&#8221; for purposes of Section 409A of the Code. Neither the Company nor you shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A of the Code.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">d.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.37pt">This Agreement shall be interpreted and at all times administered in a manner that avoids the inclusion of compensation in income under Section 409A of the Code. Any provision inconsistent with Section 409A of the Code shall be read out of this Agreement. For purposes of clarification, this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.d</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be a rule of construction and interpretation and nothing in this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.d</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall cause a forfeiture of benefits on the part of you. You acknowledge and agree that the Company does not guarantee the tax treatment or tax consequences associated with any payment or benefit arising under this Agreement, including but not limited to consequences related to Section 409A of the Code, and that in no event shall the Company or any of its affiliates have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section 409A of the Code.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">e.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.76pt">If any payment or benefit you would receive from the Company or one of its affiliates in connection with a Change of Control or otherwise, whether or not paid or provided under this Agreement (for purposes of this section, a &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), would (i) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G the Code&#59; and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Excise Tax</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then such Payment shall be either (y) the full amount of such Payment&#59; or (z) such lesser amount as would result in no portion of the Payment being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local employments taxes, income taxes and the Excise Tax, results in your receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the</font></div><div style="text-align:justify"><font><br></font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:1.95pt;padding-left:41pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Excise Tax. With respect to subsection (z), any such reduction shall be made in a manner that complies with Section 409A of the Code.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">INDEMNIFICATION</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:6.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company shall indemnify and hold you harmless for any liability, including reasonable attorneys&#8217; fees and costs, incurred by reason of any act or omission by you in your capacity as an employee and&#47;or officer of the Company to the extent permitted by the Company&#8217;s certificate of incorporation, as amended.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">GENERAL</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:6.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof, and supersedes all prior and contemporaneous oral or written agreements and understandings relating to the subject matter hereof (for the avoidance of doubt, including the Offer Letter). The terms and provisions of this Agreement may be modified or amended only by written agreement executed by the parties hereto, and may be waived (or consent for the departure therefrom granted) only by a written document executed by the party entitled to the benefits of such terms or provisions. This Agreement may be executed in counterparts (and may be transmitted by email or other electronic delivery), each of which shall be deemed an original and all of which together shall constitute one and the same instrument. The captions and headings in this Agreement are for convenience only and in no way define or describe the scope or content of any provision of this Agreement. All payments made by the Company under this Agreement shall be reduced by any tax or other amounts required to be withheld by the Company under applicable law. The Company may assign its rights and obligations hereunder to any person or entity that succeeds to all or substantially all of the Company&#8217;s business. You may not assign your rights and obligations hereunder without the prior written consent of the Company and any such attempted assignment by you without the prior written consent of the Company shall be void. If any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision hereof in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by the internal law of Massachusetts, without giving effect to the conflict of law principles of any jurisdiction. By entering into this Agreement, you agree that any action, demand, claim or counterclaim in connection with any aspect of your employment with the Company, or any separation of employment (whether voluntary or involuntary) from the Company, shall be brought in the courts of Massachusetts or of the United States of America for the District of Massachusetts, and shall be resolved by a judge alone, and you waive and forever renounce your right to a trial before a civil jury.</font></div><div><font><br></font></div><div style="margin-top:9.3pt;padding-left:167.55pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Remainder of Page Intentionally Left Blank</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="height:56.88pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i83a6942160c34f0c83390bb87bd15fc7_7"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="margin-top:9.3pt;padding-left:40.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Please sign below to acknowledge your acceptance of the terms of this Agreement. Keep one copy for your files and return one executed copy to the Company.</font></div><div style="margin-top:9.3pt;padding-left:40.5pt"><font><br></font></div><div style="margin-top:9.3pt;padding-left:40.5pt"><font><br></font></div><div style="margin-top:9.3pt;padding-left:288pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Very truly yours,</font></div><div style="margin-top:9.3pt;padding-left:288pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FOGHORN THERAPEUTICS INC.</font></div><div style="margin-top:9.3pt;padding-left:288pt"><font><br></font></div><div style="margin-top:9.3pt;padding-left:288pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Adrian Gottschalk&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; Adrian Gottschalk<br>Title&#58; President and CEO</font></div><div style="margin-top:9.3pt;padding-left:40.5pt"><font><br></font></div><div style="margin-top:9.3pt;padding-left:40.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted and agreed&#58;</font></div><div style="margin-top:9.3pt;padding-left:40.5pt"><font><br></font></div><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Allan Reine&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Allan Reine</font></div><div style="height:64.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page to Letter Agreement&#93;</font></div></div></div><div id="i83a6942160c34f0c83390bb87bd15fc7_10"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="padding-left:39.15pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:1.95pt;padding-left:231.17pt;padding-right:231.17pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit A</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:2.55pt;padding-left:91.02pt;padding-right:91.02pt;text-align:center;text-indent:0.3pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EMPLOYEE NON-COMPETITION, NON-SOLICITATION, CONFIDENTIALITY AND ASSIGNMENT OF INVENTIONS AGREEMENT</font></div><div><font><br></font></div><div style="margin-top:9.3pt;padding-left:231.22pt;padding-right:231.22pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(attached)</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>4
<FILENAME>ex1023-employmentagreement.htm
<DESCRIPTION>EX-10.23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie09e9bae1d864b708e5f487770b03722_1"></div><div style="min-height:69.84pt;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibit 10.23</font></div></div><div style="margin-top:0.15pt;padding-right:-80.7pt"><font><br></font></div><div style="padding-left:5pt"><img alt="image_0.jpg" src="image_0.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:218px"></div><div><font><br></font></div><div style="padding-left:41pt;padding-right:27.3pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:285%">January 26, 2022</font></div><div style="padding-left:41pt;padding-right:18.3pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:285%"> Steve Bellon, Ph.D.</font></div><div style="padding-left:41pt;padding-right:46.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:232%">By Email Delivery</font></div><div style="padding-left:41pt;padding-right:46.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:232%"> Dear Steve&#58;</font></div><div style="padding-left:77pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:99%">This letter agreement (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:99%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:99%">&#8221;) amends and restates the offer letter dated</font></div><div style="padding-left:41pt;padding-right:5.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">April 27, 2016 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Offer Letter</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by and among you and Foghorn Therapeutics Inc. (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). This Agreement sets forth the terms and conditions of your continued employment with the Company. This Agreement will be effective as of the date on which the Company becomes subject to the reporting obligations of Section 12 of the Securities Exchange Act of 1934, as amended. Should this not occur for any reason, this Agreement shall be void and of no force or effect.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">POSITION AND DUTIES</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:5.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Your position shall be </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Chief Scientific Officer</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In this role, you will report to the Chief Executive Officer of the Company and perform the duties and responsibilities of your position, and such other duties as reasonably may be assigned to you from time to time consistent with your position. As a member of our team, we expect you to devote all of your professional and working time and energies to the business and affairs of the Company. You shall not engage in non-Company related business activities (including consulting activities, board memberships and academic appointments) without the prior written consent of the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or its designee. You agree that, should you receive the Company&#8217;s consent to conduct any such non-Company related business activities, you shall conduct such activities so as not to interfere with the performance of your duties hereunder or violate the provisions of your Non-Competition Agreement and your Confidentiality Agreement (each as defined below). You shall be employed on an at-will basis, which means that neither you nor the Company are guaranteeing this employment relationship for any specific period of time.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">COMPENSATION</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During your employment hereunder, as compensation for all services performed for the Company and its affiliates, the Company will provide you with the following compensation and benefits&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.88pt">Salary</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Your base salary shall be at a rate of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">$435,000</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> on an annualized basis and shall be payable in accordance with the Company&#8217;s normal payroll practices. Your base   salary shall be subject to adjustment from time to time by the Board or the Compensation Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation Committee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), in its respective sole discretion.</font></div><div><font><br></font></div><div style="padding-left:41.05pt;padding-right:5.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:21.32pt">Annual Performance Bonus</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. In accordance with the Company&#8217;s annual bonus plan (as in effect from time to time), with respect to each fiscal year completed during your employment with the Company, you will be able to earn an annual bonus based upon the achievement, as determined by the Board or the Compensation Committee, in its respective sole discretion, of specified performance goals established by the Board or the Compensation Committee for such fiscal year. Your target annual bonus will be forty percent (</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">40%</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) of your base salary. The annual bonus, to the extent earned, shall be paid to </font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="padding-left:41.05pt;padding-right:5.05pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">you no later than March 15 of the calendar year immediately following the calendar year to which it relates. Except as expressly provided below, you must be employed by the Company or on an approved leave of absence on the date of payment of the bonus in order to be eligible for and have earned the annual bonus.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.78pt">Equity Grants</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You shall be eligible for future grants of stock options and other equity awards in the sole discretion of the Board or the Compensation Committee, subject to the terms and conditions of the Company&#8217;s equity incentive plan and any applicable award agreements.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">d.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.37pt">Benefits</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You shall be eligible to participate in the Company&#8217;s benefit plans to the same extent as, and subject to the same terms, conditions and limitations applicable to, other Company employees of similar rank and tenure. These benefits may be modified, changed or eliminated from time to time at the sole discretion of the Company, and the provision of such benefits does not change your status as an at-will employee. Where a particular benefit is subject to a formal plan (for example, medical insurance or life insurance), eligibility to participate in and receive any particular benefit is governed solely by the applicable plan document.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:1.95pt;padding-left:41pt;padding-right:5.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">e.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.76pt">Expense Reimbursement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company shall reimburse you for all ordinary and reasonable out-of-pocket business expenses incurred in furtherance of the Company&#8217;s business in accordance with the Company&#8217;s policies with respect thereto as in effect from time to time. You must submit any request for reimbursement no later than ninety (90) days following the date that such business expense is incurred. All reimbursements hereunder shall be made or provided in accordance with the requirements of Section 409A (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the Internal Revenue Code and the rules and regulations thereunder (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) including, where applicable, the requirement that&#58; (i) any reimbursement is for expenses incurred during your lifetime (or during a shorter period of time specified in this Agreement)&#59; (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year&#59; (iii) the reimbursement of an eligible expense shall be made no later</font></div><div><font><br></font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.917%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:110%">-2-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="margin-top:1.95pt;padding-left:41.05pt;padding-right:5.05pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">than the last day of the calendar year following the year in which the expense is incurred&#59; and</font></div><div style="padding-left:41pt;padding-right:5.3pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv) the right to reimbursement or in kind benefits is not subject to liquidation or exchange for another benefit.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">SEVERANCE BENEFIT UPON CERTAIN TERMINATIONS OF EMPLOYMENT</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:4.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.88pt">Termination Not in Connection with a Change in Control</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding the at-will nature of the parties&#8217; relationship, should you be subject to an Involuntary Termination other than an Involuntary Termination that occurs in the CIC Period, then, conditioned upon your timely execution and non-revocation of a separation agreement containing a release of claims and other customary terms in the form provided by the Company (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and compliance with your Non-Competition Agreement and your Confidentiality Agreement&#58; (i) the Company shall provide you with a payment in an amount equal to nine (9) months of your then-current base salary, payable in the form of salary continuation over the nine- (9) month period following the date of separation, commencing on the first regular Company payday that is at least five (5) business days following the effective date of the Release&#59; (ii) (A) if you properly elect to receive benefits under Consolidated Omnibus Budget Reconciliation Act (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">COBRA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or similar state law and (B) the premium subsidy described below is not illegal or discriminatory under the Code, the Patient Protection and Affordable Care Act or the Health Care and Education Reconciliation Act, then the Company shall provide you with nine (9) months of your COBRA premiums at the Company&#8217;s normal rate of contribution for employees for your coverage at the level in effect immediately prior to your termination, such premiums to be provided on a monthly basis&#59; and</font></div><div style="padding-left:41pt;padding-right:5.15pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii) the Company shall pay the amount of any annual bonus previously awarded to you by the Board or the Compensation Committee, as applicable, with respect to the calendar year concluded prior to the date of termination that remains unpaid as of the date of termination, which annual bonus shall be paid at the same time as bonuses are paid to active employees of the Company.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:41pt;padding-right:4.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.37pt">Termination in Connection with a Change in Control</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If you are subject to an Involuntary Termination that occurs in the CIC Period, then, conditioned upon your timely execution and non-revocation of the Release and compliance with your Non-Competition Agreement and your Confidentiality Agreement, in lieu of the payments and benefits provided under </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above&#58; (i) the Company shall provide you with a payment in an amount equal to the sum of (A) your then-current base salary plus (B) your target annual bonus for the year in which termination occurs, which amount shall be payable in the form of salary continuation over the twelve- (12) month period following the date of separation, commencing on the first regular Company payday that is at least five (5) business days following the effective date of the Release&#59;</font></div><div style="padding-left:41pt;padding-right:5.25pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) (A) if you properly elect to receive benefits under COBRA or similar state law and (B) the premium subsidy described below is not illegal or discriminatory under the Code, the Patient Protection and Affordable Care Act or the Health Care and Education Reconciliation Act, then the Company shall provide you with twelve (12) months of your COBRA premiums at the Company&#8217;s normal rate of contribution for employees for your coverage at the level in effect immediately prior to your termination, such premiums to be provided on a monthly basis&#59; (iii) the Company shall pay the amount of any annual bonus previously awarded to you by the Board or the</font></div><div><font><br></font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.917%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:110%">-3-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="padding-left:41pt;padding-right:5.25pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Compensation Committee, as applicable, with respect to the calendar year concluded prior to the date of termination that remains unpaid as of the date of termination, which annual bonus shall be paid at the same time as bonuses are paid to active employees of the Company&#59; and</font></div><div style="padding-left:41pt;padding-right:5.2pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv) the vesting and, if applicable, the exercisability of each of your outstanding time-based stock options and other equity awards under the Company&#8217;s equity incentive plan(s) shall be fully accelerated as of the effective date of the Release (with the vesting of any performance-based equity awards determined based on the terms of the award agreements governing such awards).</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:41pt;padding-right:4.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.78pt">Timing of Payments</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any severance payments paid under this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall commence within sixty (60) days after the date of termination (or at such earlier time as provided in this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), with the initial payment to include any amounts that would have been payable by their terms prior to such payment commencement date&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if the sixty-</font></div><div style="margin-top:0.1pt;padding-left:41pt;padding-right:5.25pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(60) day period begins in one calendar year and ends in a second calendar year, the severance payments shall begin to be paid following the last day of such sixty- (60) day period in the second calendar year.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">d.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.37pt">Other Termination Events</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Should you voluntarily terminate your employment for any reason (other than a Resignation for Good Reason) or should your employment be terminated for Cause (whether before or after a Change of Control) or as a result of your death or disability, then you shall not be entitled to any severance payments described herein. Nothing in this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall alter your status as an at-will employee.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:2.55pt;padding-left:41pt;padding-right:5.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">e.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.76pt">Certain Definitions</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For purposes of this Agreement, the following terms shall have the meanings and be subject to the provisions set forth below&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any one or more of the following actions&#58; (i) your material breach of the terms of this Agreement or any other written agreement between you and the Company or any of its affiliates&#59; (ii) your material dishonesty, willful misconduct, gross negligence or reckless conduct, in each case, in connection with the performance of your services to the Company or any of its affiliates&#59; (iii) your commission of an act of fraud, theft, misappropriation or embezzlement&#59; (iv) your indictment for, or pleading nolo contendere to, any crime involving moral turpitude or any felony&#59; or (v) your material violation of a Company policy that had been previously provided to you in writing or your willful refusal to perform, or substantial negligence in the performance of, your assigned duties to the Company or any of its affiliates (other than as a result of your mental or physical impairment). For purpose of clauses (i), (ii) and (v), &#8220;Cause&#8221; shall only exist if&#58; (y) the Company delivered to you a written description of the events or conditions giving rise to your termination for Cause&#59; and (z) if curable, you have been given at least fifteen (15) days to cure such events or conditions and you fail to cure such events or conditions within such time period given.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means&#58; (i) any &#8220;Person&#8221; (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) that becomes the &#8220;Beneficial Owner&#8221; (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company&#8217;s then outstanding voting securities (excluding for this purpose any such voting securities held by the Company or its </font></div><div><font><br></font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.917%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:110%">-4-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="padding-left:41.75pt;padding-right:5.05pt;text-align:justify;text-indent:-0.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">affiliates or by any employee benefit plan of the Company) pursuant to a transaction or a series of related transactions&#59; or (ii) a merger or consolidation of the Company whether or not approved by the Board, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) more than 50% of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation, as the case may be, outstanding immediately after such merger or consolidation&#59; or (iii) the sale or disposition by the Company of all or substantially all of the Company&#8217;s assets in a transaction requiring stockholder approval&#59; notwithstanding the foregoing, no transaction or series of transactions shall constitute a Change of Control unless such transaction or series of transactions constitutes a &#8220;change in control event&#8221; within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(i).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:5.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CIC Period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the period commencing on the date that is three (3) months prior to the date on which a Change of Control occurs and ending on the date that is twelve (12) months following such occurrence.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Involuntary Termination</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means either (i) your Termination Without Cause or (ii) your Resignation for Good Reason.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Resignation for Good Reason</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a termination of your employment after one of the following conditions has come into existence without your consent&#58; (i) a reduction in your base salary other than in connection with an across-the-board reduction affecting all similarly situated executives of the Company&#59; (ii) a material diminution of your title, authority, duties or responsibilities&#59; (iii) a material breach of this Agreement by Company&#59; or (iv) a relocation of your principal workplace by more than fifty (50) miles. A Resignation for Good Reason shall not be deemed to have occurred unless you give the Company written notice of the condition within ninety (90) days after the condition comes into existence, the Company fails to remedy the condition within thirty (30) days after receiving your written notice and you terminate your employment within thirty (30) days after the end of the cure period.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Without Cause</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a termination of your employment by the Company without Cause (and not as a result of your death or disability), provided you are willing and able to continue performing services within the meaning of Treasury Regulation Section 1.409A- 1(n)(1).</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">CONFIDENTIALITY AND OTHER OBLIGATIONS</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As part of your employment with the Company, you shall be exposed to, and provided with, valuable confidential and trade secret information concerning the Company and its present and prospective clients. As a result, in order to protect the Company&#8217;s legitimate business interests, you will be asked to execute and deliver an Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employee Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), substantially in the form attached as </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto.  You, upon execution and delivery of those agreements, acknowledge and agree that you are bound by the terms each such agreement, which are not modified in any way by this Agreement.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">CERTIFICATION</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By signing this Agreement, you are certifying to the Company that&#58; (i) your employment with the Company does not and shall not require you to breach any agreement entered into by you prior to employment with the Company (i.e., you have not entered into any agreements with previous employers that are in conflict with your obligations to the Company)&#59; (ii) to the extent you are subject to restrictive agreements with any prior employer that may affect your employment with the Company, you have provided us with a copy of that agreement&#59; (iii) your employment with the Company does not violate any order, judgment or injunction applicable </font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.917%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:110%">-5-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="padding-left:41pt;padding-right:5.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to you, and you have provided the Company with a copy of any such order, judgment, or injunction&#59; and (iv) all facts you have presented to the Company are accurate and true, including all statements made to the Company pertaining to your education, training, qualifications, licensing and prior work experience on any job application, resume or c.v., or in any interview. The Company does not want you to disclose any confidential information belonging to a previous employer or to incorporate the proprietary information of any previous employer into the Company&#8217;s proprietary information and expects that you shall abide by restrictive covenants to prior employers.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">SECTIONS 409A AND 280G OF THE CODE</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:5.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.88pt">Notwithstanding any other provision of this Agreement to the contrary, if any amount (including imputed income) to be paid to you pursuant to this Agreement as a result of your termination of employment is &#8220;deferred compensation&#8221; subject to Section 409A of the Code, and if you are a &#8220;Specified Employee&#8221; (as defined under Section 409A of the Code and as determined by the Company) as of the date of your termination of employment hereunder, then, to the extent necessary to avoid the imposition of excise taxes or other penalties under Section 409A of the Code, the payment of benefits, if any, scheduled to be paid by the Company to you hereunder during the first six- (6) month period following the date of a termination of employment hereunder shall not be paid until the date which is the first business day after six (6) months have elapsed since your termination of employment for any reason other than death. Any deferred compensation payments delayed in accordance with the terms of this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be paid in a lump sum after six (6) months have elapsed since your termination of employment. Any other payments shall be made according to the schedule provided for herein.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:1.95pt;padding-left:41pt;padding-right:5.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.37pt">If any of the benefits set forth in this Agreement are &#8220;deferred compensation&#8221; under Section 409A of the Code, any termination of employment triggering payment of such benefits must constitute a &#8220;separation from service&#8221; under Section 409A of the Code (after giving effect to the presumptions contained therein) before distribution of such benefits can commence. To the extent that the termination of your employment does not constitute a &#8220;separation from service&#8221; under Section 409A of the Code (as the result of further services that are reasonably anticipated to be provided by you to the Company at the time your employment terminates),   any   benefits   payable   under   this   Agreement   that   constitute   &#8220;deferred </font></div><div><font><br></font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.917%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:110%">-6-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="margin-top:1.95pt;padding-left:41.05pt;padding-right:5.05pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">compensation&#8221; under Section 409A of the Code shall be delayed until after the date of a subsequent event constituting a &#8220;separation from service&#8221; under Section 409A of the Code. For purposes of clarification, this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.b</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall not cause any forfeiture of benefits on your part but shall only act as a delay until such time as a &#8220;separation from service&#8221; occurs.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:5.3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.78pt">It is intended that each installment of the payments and benefits provided under this Agreement shall be treated as a separate &#8220;payment&#8221; for purposes of Section 409A of the Code. Neither the Company nor you shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A of the Code.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">d.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.37pt">This Agreement shall be interpreted and at all times administered in a manner that avoids the inclusion of compensation in income under Section 409A of the Code. Any provision inconsistent with Section 409A of the Code shall be read out of this Agreement. For purposes of clarification, this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.d</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be a rule of construction and interpretation and nothing in this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.d</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall cause a forfeiture of benefits on the part of you. You acknowledge and agree that the Company does not guarantee the tax treatment or tax consequences associated with any payment or benefit arising under this Agreement, including but not limited to consequences related to Section 409A of the Code, and that in no event shall the Company or any of its affiliates have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section 409A of the Code.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:5.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">e.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.76pt">If any payment or benefit you would receive from the Company or one of its affiliates in connection with a Change of Control or otherwise, whether or not paid or provided under this Agreement (for purposes of this section, a &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), would (i) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G the Code&#59; and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Excise Tax</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then such Payment shall be either (y) the full amount of such Payment&#59; or (z) such lesser amount as would result in no portion of the Payment being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local employments taxes, income taxes and the Excise Tax, results in your receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. With respect to subsection (z), any such reduction shall be made in a manner that complies with Section 409A of the Code.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">INDEMNIFICATION</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company shall indemnify and hold you harmless for any liability, including reasonable attorneys&#8217; fees and costs, incurred by reason of any act or omission by you in your capacity as an employee and&#47;or officer of the Company to the extent permitted by the Company&#8217;s certificate of incorporation, as amended.</font></div><div><font><br></font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.917%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:110%">-7-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">GENERAL</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof, and supersedes all prior and contemporaneous oral or written agreements and understandings relating to the subject matter hereof (for the avoidance of doubt, including the Offer Letter). The terms and provisions of this Agreement may be modified or amended only by written agreement executed by the parties hereto, and may be waived (or consent for the departure therefrom granted) only by a written document executed by the party entitled to the benefits of such terms or provisions. This Agreement may be executed in counterparts (and may be transmitted by email or other electronic delivery), each of which shall be deemed an original and all of which together shall constitute one and the same instrument. The captions and headings in this Agreement are for convenience only and in no way define or describe the scope or content of any provision of this Agreement. All payments made by the Company under this Agreement shall be reduced by any tax or other amounts required to be withheld by the Company under applicable law. The Company may assign its rights and obligations hereunder to any person or entity that succeeds to all or substantially all of the Company&#8217;s business. You may not assign your rights and obligations hereunder without the prior written consent of the Company and any such attempted assignment by you without the prior written consent of the Company shall be void. If any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision hereof in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by the internal law of Massachusetts, without giving effect to the conflict of law principles of any jurisdiction. By entering into this Agreement, you agree that any action, demand, claim or counterclaim in connection with any aspect of your employment with the Company, or any separation of employment (whether voluntary or involuntary) from the Company, shall be brought in the courts of Massachusetts or of the United States of America for the District of Massachusetts, and shall be resolved by a judge alone, and you waive and forever renounce your right to a trial before a civil jury.</font></div><div><font><br></font></div><div style="margin-top:9.35pt;padding-left:167.55pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Remainder of Page Intentionally Left Blank</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.917%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:110%">-8-</font></div></td></tr></table></div></div></div><div id="ie09e9bae1d864b708e5f487770b03722_4"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.3pt;padding-left:41.2pt;text-indent:36.05pt"><font style="color:#010101;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:140%">Please sign below to acknowledge your acceptance of the terms of this Agreement. Keep one copy for your files and return one executed copy to the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:257.6pt"><font style="color:#010101;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Very truly yours,</font></div><div><font><br></font></div><div style="padding-left:257.4pt"><font style="color:#010101;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">FOGHORN THERAPEUTICS INC.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:7.05pt;padding-left:257.65pt"><font style="color:#010101;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Adrian Gottschalk</font></div><div style="margin-top:2.7pt;padding-left:257.2pt;padding-right:130.15pt;text-indent:0.4pt"><font style="color:#010101;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:140%">Name&#58; Adrian Gottschalk Title&#58;&#160;&#160;&#160;&#160;President and CEO</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.65pt;padding-left:41.05pt"><font style="color:#010101;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Accepted</font></div><div style="margin-top:0.65pt;padding-left:41.05pt"><font style="color:#010101;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.65pt;padding-left:41.05pt"><font style="color:#010101;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Steve Bellon&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.65pt;padding-left:41.05pt"><font style="color:#010101;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Steve Bellon</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:185.25pt"><font style="color:#010101;font-family:'Arial',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page to Letter Agreement&#93;</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie09e9bae1d864b708e5f487770b03722_7"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="margin-top:1.95pt;padding-left:132.37pt;padding-right:132.37pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit A</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:23.5pt;padding-right:23.5pt;text-align:center;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:9.35pt;padding-left:132.42pt;padding-right:132.42pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(attached)</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>5
<FILENAME>ex1024-employmentagreement.htm
<DESCRIPTION>EX-10.24
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9eeced2eca1345cea35583cf04bb5e92_1"></div><div style="min-height:69.84pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibit 10.24</font></div></div><div style="margin-top:0.15pt;padding-right:-80.7pt"><font><br></font></div><div style="padding-left:5pt"><img alt="image_0.jpg" src="image_0.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:218px"></div><div><font><br></font></div><div style="padding-left:41pt;padding-right:27.3pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:285%">January 27, 2022</font></div><div style="padding-left:41pt;padding-right:18.3pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:285%"> Fanny Cavalie</font></div><div style="padding-left:41pt;padding-right:46.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:232%">By Email Delivery </font></div><div style="padding-left:41pt;padding-right:46.1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:232%">Dear Fanny&#58;</font></div><div style="padding-left:77pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:99%">This letter agreement (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:99%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:99%">&#8221;) amends and restates the offer letter dated</font></div><div style="padding-left:41pt;padding-right:5.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 14, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Offer Letter</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by and among you and Foghorn Therapeutics Inc. (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). This Agreement sets forth the terms and conditions of your continued employment with the Company. This Agreement will be effective as of the date on which the Company becomes subject to the reporting obligations of Section 12 of the Securities Exchange Act of 1934, as amended. Should this not occur for any reason, this Agreement shall be void and of no force or effect.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">POSITION AND DUTIES</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:5.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Your position shall be </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Chief Strategy and Business Operations Officer</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In this role, you will report to the Chief Executive Officer of the Company and perform the duties and responsibilities of your position, and such other duties as reasonably may be assigned to you from time to time consistent with your position. As a member of our team, we expect you to devote all of your professional and working time and energies to the business and affairs of the Company. You shall not engage in non-Company related business activities (including consulting activities, board memberships and  academic appointments) without the prior written consent of the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or its designee. You agree that, should you receive the Company&#8217;s consent to conduct any such non-Company related business activities, you shall conduct such activities so as not to interfere with the performance of your duties hereunder or violate the provisions of your Non-Competition Agreement and your Confidentiality Agreement (each as defined below). You shall be employed on an at-will basis, which means that neither you nor the Company are guaranteeing this employment relationship for any specific period of time.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">COMPENSATION</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During your employment hereunder, as compensation for all services performed for the Company and its affiliates, the Company will provide you with the following compensation and benefits&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.88pt">Salary</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Your base salary shall be at a rate of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">$370,000</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> on an annualized basis and shall be payable in accordance with the Company&#8217;s normal payroll practices. Your base salary shall be subject to adjustment from time to time by the Board or the Compensation Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation Committee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), in its respective sole discretion.</font></div><div style="margin-top:1.95pt;padding-left:41pt;padding-right:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.37pt">Annual Performance Bonus</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In accordance with the Company&#8217;s annual bonus plan (as in effect from time to time), with respect to each fiscal year completed during your employment with the Company, you will be able to earn an annual bonus based upon the achievement, as determined by the Board or the Compensation Committee, in its respective sole discretion, of specified performance goals established by the Board or the Compensation Committee for such fiscal year. Your target annual bonus will be forty percent (</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">40%</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) of your </font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="margin-top:1.95pt;padding-left:41pt;padding-right:5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">base salary. The annual bonus, to the extent earned, shall be paid to you no later than March 15 of the calendar year immediately following the calendar year to which it relates. Except as expressly provided below, you must be employed by the Company or on an approved leave of absence on the date of payment of the bonus in order to be eligible for and have earned the annual bonus.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.78pt">Equity Grants</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You shall be eligible for future grants of stock options and other equity awards in the sole discretion of the Board or the Compensation Committee, subject to the terms and conditions of the Company&#8217;s equity incentive plan and any applicable award agreements.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">d.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.37pt">Benefits</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You shall be eligible to participate in the Company&#8217;s benefit plans to the same extent as, and subject to the same terms, conditions and limitations applicable to, other Company employees of similar rank and tenure. These benefits may be modified, changed or eliminated from time to time at the sole discretion of the Company, and the provision of such benefits does not change your status as an at-will employee. Where a particular benefit is subject to a formal plan (for example, medical insurance or life insurance), eligibility to participate in and receive any particular benefit is governed solely by the applicable plan document.</font></div><div style="padding-left:41pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">e.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.76pt">Expense Reimbursement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company shall reimburse you for all ordinary and reasonable out-of-pocket business expenses incurred in furtherance of the Company&#8217;s business in accordance with the Company&#8217;s policies with respect thereto as in effect from time to time. You must submit any request for reimbursement no later than ninety (90) days following the date that such business expense is incurred. All reimbursements hereunder shall be made or provided in accordance with the requirements of Section 409A (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the Internal Revenue Code and the rules and regulations thereunder (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) including, where applicable, the requirement that&#58; (i) any reimbursement is for expenses incurred during your lifetime (or during a shorter period of time specified in this Agreement)&#59; (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year&#59; (iii) the reimbursement of an eligible expense shall be made no later</font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.917%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:110%">-3-</font></div></td></tr></table></div></div></div><div id="i9eeced2eca1345cea35583cf04bb5e92_4"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="margin-top:1.95pt;padding-left:41pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">than the last day of the calendar year following the year in which the expense is incurred&#59; and</font></div><div style="padding-left:41pt;padding-right:5.3pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv) the right to reimbursement or in kind benefits is not subject to liquidation or exchange for another benefit.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:77pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">SEVERANCE BENEFIT UPON CERTAIN TERMINATIONS OF EMPLOYMENT</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:4.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.88pt">Termination Not in Connection with a Change in Control</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding the at-will nature of the parties&#8217; relationship, should you be subject to an Involuntary Termination other than an Involuntary Termination that occurs in the CIC Period, then, conditioned upon your timely execution and non-revocation of a separation agreement containing a release of claims and other customary terms in the form provided by the Company (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and compliance with your Non-Competition Agreement and your Confidentiality Agreement&#58; (i) the Company shall provide you with a payment in an amount equal to nine (9) months of your then-current base salary, payable in the form of salary continuation over the nine- (9) month period following the date of separation, commencing on the first regular Company payday that is at least five (5) business days following the effective date of the Release&#59; (ii) (A) if you properly elect to receive benefits under Consolidated Omnibus Budget Reconciliation Act (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">COBRA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or similar state law and (B) the premium subsidy described below is not illegal or discriminatory under the Code, the Patient Protection and Affordable Care Act or the Health Care and Education Reconciliation Act, then the Company shall provide you with nine (9) months of your COBRA premiums at the Company&#8217;s normal rate of contribution for employees for your coverage at the level in effect immediately prior to your termination, such premiums to be provided on a monthly basis&#59; and</font></div><div style="padding-left:41pt;padding-right:5.15pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii) the Company shall pay the amount of any annual bonus previously awarded to you by the Board or the Compensation Committee, as applicable, with respect to the calendar year concluded prior to the date of termination that remains unpaid as of the date of termination, which annual bonus shall be paid at the same time as bonuses are paid to active employees of the Company.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:41pt;padding-right:4.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.37pt">Termination in Connection with a Change in Control</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If you are subject to an Involuntary Termination that occurs in the CIC Period, then, conditioned upon your timely execution and non-revocation of the Release and compliance with your Non-Competition Agreement and your Confidentiality Agreement, in lieu of the payments and benefits provided under </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3.a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above&#58; (i) the Company shall provide you with a payment in an amount equal to the sum of (A) your then-current base salary plus (B) your target annual bonus for the year in which termination occurs, which amount shall be payable in the form of salary continuation over the twelve- (12) month period following the date of separation, commencing on the first regular Company payday that is at least five (5) business days following the effective date of the Release&#59;</font></div><div style="padding-left:41pt;padding-right:5.25pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) (A) if you properly elect to receive benefits under COBRA or similar state law and (B) the premium subsidy described below is not illegal or discriminatory under the Code, the Patient Protection and Affordable Care Act or the Health Care and Education Reconciliation Act, then the Company shall provide you with twelve (12) months of your COBRA premiums at the Company&#8217;s normal rate of contribution for employees for your coverage at the level in effect immediately prior to your termination, such premiums to be provided on a monthly basis&#59; (iii) the Company shall pay the amount of any annual bonus previously awarded to you by the Board or the</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.917%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:110%">-4-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:1.95pt;padding-left:41pt;padding-right:5.25pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Compensation Committee, as applicable, with respect to the calendar year concluded prior to the date of termination that remains unpaid as of the date of termination, which annual bonus shall be paid at the same time as bonuses are paid to active employees of the Company&#59; and</font></div><div style="padding-left:41pt;padding-right:5.2pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv) the vesting and, if applicable, the exercisability of each of your outstanding time-based stock options and other equity awards under the Company&#8217;s equity incentive plan(s) shall be fully accelerated as of the effective date of the Release (with the vesting of any performance-based equity awards determined based on the terms of the award agreements governing such awards).</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:41pt;padding-right:4.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.78pt">Timing of Payments</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any severance payments paid under this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall commence within sixty (60) days after the date of termination (or at such earlier time as provided in this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), with the initial payment to include any amounts that would have been payable by their terms prior to such payment commencement date&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if the sixty-</font></div><div style="margin-top:0.1pt;padding-left:41pt;padding-right:5.25pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(60) day period begins in one calendar year and ends in a second calendar year, the severance payments shall begin to be paid following the last day of such sixty- (60) day period in the second calendar year.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">d.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.37pt">Other Termination Events</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Should you voluntarily terminate your employment for any reason (other than a Resignation for Good Reason) or should your employment be terminated for Cause (whether before or after a Change of Control) or as a result of your death or disability, then you shall not be entitled to any severance payments described herein. Nothing in this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall alter your status as an at-will employee.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:2.55pt;padding-left:41pt;padding-right:5.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">e.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.76pt">Certain Definitions</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For purposes of this Agreement, the following terms shall have the meanings and be subject to the provisions set forth below&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any one or more of the following actions&#58; (i) your material breach of the terms of this Agreement or any other written agreement between you and the Company or any of its affiliates&#59; (ii) your material dishonesty, willful misconduct, gross negligence or reckless conduct, in each case, in connection with the performance of your services to the Company or any of its affiliates&#59; (iii) your commission of an act of fraud, theft, misappropriation or embezzlement&#59; (iv) your indictment for, or pleading nolo contendere to, any crime involving moral turpitude or any felony&#59; or (v) your material violation of a Company policy that had been previously provided to you in writing or your willful refusal to perform, or substantial negligence in the performance of, your assigned duties to the Company or any of its affiliates (other than as a result of your mental or physical impairment). For purpose of clauses (i), (ii) and (v), &#8220;Cause&#8221; shall only exist if&#58; (y) the Company delivered to you a written description of the events or conditions giving rise to your termination for Cause&#59; and (z) if curable, you have been given at least fifteen (15) days to cure such events or conditions and you fail to cure such events or conditions within such time period given.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means&#58; (i) any &#8220;Person&#8221; (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) that becomes the &#8220;Beneficial Owner&#8221; (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company&#8217;s then outstanding voting securities (excluding for this purpose any such voting securities held by the Company or its</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.917%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:110%">-5-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:1.95pt;padding-left:41pt;padding-right:5.2pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">affiliates or by any employee benefit plan of the Company) pursuant to a transaction or a series of related transactions&#59; or (ii) a merger or consolidation of the Company whether or not approved by the Board, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) more than 50% of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation, as the case may be, outstanding immediately after such merger or consolidation&#59; or (iii) the sale or disposition by the Company of all or substantially all of the Company&#8217;s assets in a transaction requiring stockholder approval&#59; notwithstanding the foregoing, no transaction or series of transactions shall constitute a Change of Control unless such transaction or series of transactions constitutes a &#8220;change in control event&#8221; within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(i).</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:5.15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CIC Period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the period commencing on the date that is three (3) months prior to the date on which a Change of Control occurs and ending on the date that is twelve (12) months following such occurrence.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Involuntary Termination</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means either (i) your Termination Without Cause or (ii) your Resignation for Good Reason.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Resignation for Good Reason</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a termination of your employment after one of the following conditions has come into existence without your consent&#58; (i) a reduction in your base salary other than in connection with an across-the-board reduction affecting all similarly situated executives of the Company&#59; (ii) a material diminution of your title, authority, duties or responsibilities&#59; (iii) a material breach of this Agreement by Company&#59; or (iv) a relocation of your principal workplace by more than fifty (50) miles. A Resignation for Good Reason shall not be deemed to have occurred unless you give the Company written notice of the condition within ninety (90) days after the condition comes into existence, the Company fails to remedy the condition within thirty (30) days after receiving your written notice and you terminate your employment within thirty (30) days after the end of the cure period.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Without Cause</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a termination of your employment by the Company without Cause (and not as a result of your death or disability), provided you are willing and able to continue performing services within the meaning of Treasury Regulation Section 1.409A- 1(n)(1).</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">CONFIDENTIALITY AND OTHER OBLIGATIONS</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As part of your employment with the Company, you shall be exposed to, and provided with, valuable confidential and trade secret information concerning the Company and its present and prospective clients. As a result, in order to protect the Company&#8217;s legitimate business interests, you will be asked to execute and deliver an Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employee Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), substantially in the form attached as </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto.  You, upon execution and delivery of those agreements, acknowledge and agree that you are bound by the terms each such agreement, which are not modified in any way by this Agreement.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">CERTIFICATION</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By signing this Agreement, you are certifying to the Company that&#58; (i) your employment with the Company does not and shall not require you to breach any agreement entered into by you prior to employment with the Company (i.e., you have not entered into any agreements with previous employers that are in conflict with your obligations to the Company)&#59; (ii) to the extent you are subject to restrictive agreements with any prior employer that may affect your employment with the Company, you have provided us with a copy of that agreement&#59; (iii) your </font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.917%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:110%">-6-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="padding-left:41pt;padding-right:5.1pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employment with the Company does not violate any order, judgment or injunction applicable to you, and you have provided the Company with a copy of any such order, judgment, or injunction&#59; and (iv) all facts you have presented to the Company are accurate and true, including all statements made to the Company pertaining to your education, training, qualifications, licensing and prior work experience on any job application, resume or c.v., or in any interview. The Company does not want you to disclose any confidential information belonging to a previous employer or to incorporate the proprietary information of any previous employer into the Company&#8217;s proprietary information and expects that you shall abide by restrictive covenants to prior employers.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">SECTIONS 409A AND 280G OF THE CODE</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:5.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.88pt">Notwithstanding any other provision of this Agreement to the contrary, if any amount (including imputed income) to be paid to you pursuant to this Agreement as a result of your termination of employment is &#8220;deferred compensation&#8221; subject to Section 409A of the Code, and if you are a &#8220;Specified Employee&#8221; (as defined under Section 409A of the Code and as determined by the Company) as of the date of your termination of employment hereunder, then, to the extent necessary to avoid the imposition of excise taxes or other penalties under Section 409A of the Code, the payment of benefits, if any, scheduled to be paid by the Company to you hereunder during the first six- (6) month period following the date of a termination of employment hereunder shall not be paid until the date which is the first business day after six (6) months have elapsed since your termination of employment for any reason other than death. Any deferred compensation payments delayed in accordance with the terms of this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be paid in a lump sum after six (6) months have elapsed since your termination of employment. Any other payments shall be made according to the schedule provided for herein.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:1.95pt;padding-left:41pt;padding-right:5.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.37pt">If any of the benefits set forth in this Agreement are &#8220;deferred compensation&#8221; under Section 409A of the Code, any termination of employment triggering payment of such benefits must constitute a &#8220;separation from service&#8221; under Section 409A of the Code (after giving effect to the presumptions contained therein) before distribution of such benefits can commence. To the extent that the termination of your employment does not constitute a &#8220;separation from service&#8221; under Section 409A of the Code (as the result of further services that are reasonably anticipated to be provided by you to the Company at the time your employment terminates), any benefits payable under this Agreement that constitute &#8220;deferred<br></font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.917%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:110%">-7-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="margin-top:1.95pt;padding-left:41.05pt;padding-right:5.05pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">compensation&#8221; under Section 409A of the Code shall be delayed until after the date of a subsequent event constituting a &#8220;separation from service&#8221; under Section 409A of the Code. For purposes of clarification, this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.b</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> shall not cause any forfeiture of benefits on your part but shall only act as a delay until such time as a &#8220;separation from service&#8221; occurs.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:5.3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.78pt">It is intended that each installment of the payments and benefits provided under this Agreement shall be treated as a separate &#8220;payment&#8221; for purposes of Section 409A of the Code. Neither the Company nor you shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A of the Code.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">d.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.37pt">This Agreement shall be interpreted and at all times administered in a manner that avoids the inclusion of compensation in income under Section 409A of the Code. Any provision inconsistent with Section 409A of the Code shall be read out of this Agreement. For purposes of clarification, this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.d</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be a rule of construction and interpretation and nothing in this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 6.d</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall cause a forfeiture of benefits on the part of you. You acknowledge and agree that the Company does not guarantee the tax treatment or tax consequences associated with any payment or benefit arising under this Agreement, including but not limited to consequences related to Section 409A of the Code, and that in no event shall the Company or any of its affiliates have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section 409A of the Code.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:5.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">e.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.76pt">If any payment or benefit you would receive from the Company or one of its affiliates in connection with a Change of Control or otherwise, whether or not paid or provided under this Agreement (for purposes of this section, a &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), would (i) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G the Code&#59; and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Excise Tax</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then such Payment shall be either (y) the full amount of such Payment&#59; or (z) such lesser amount as would result in no portion of the Payment being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local employments taxes, income taxes and the Excise Tax, results in your receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. With respect to subsection (z), any such reduction shall be made in a manner that complies with Section 409A of the Code.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">INDEMNIFICATION</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company shall indemnify and hold you harmless for any liability, including reasonable attorneys&#8217; fees and costs, incurred by reason of any act or omission by you in your capacity as an employee and&#47;or officer of the Company to the extent permitted by the Company&#8217;s certificate of incorporation, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.917%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:110%">-8-</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:1.95pt;padding-left:77pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.77pt">GENERAL</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:41pt;padding-right:5.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof, and supersedes all prior and contemporaneous oral or written agreements and understandings relating to the subject matter hereof (for the avoidance of doubt, including the Offer Letter). The terms and provisions of this Agreement may be modified or amended only by written agreement executed by the parties hereto, and may be waived (or consent for the departure therefrom granted) only by a written document executed by the party entitled to the benefits of such terms or provisions. This Agreement may be executed in counterparts (and may be transmitted by email or other electronic delivery), each of which shall be deemed an original and all of which together shall constitute one and the same instrument. The captions and headings in this Agreement are for convenience only and in no way define or describe the scope or content of any provision of this Agreement. All payments made by the Company under this Agreement shall be reduced by any tax or other amounts required to be withheld by the Company under applicable law. The Company may assign its rights and obligations hereunder to any person or entity that succeeds to all or substantially all of the Company&#8217;s business. You may not assign your rights and obligations hereunder without the prior written consent of the Company and any such attempted assignment by you without the prior written consent of the Company shall be void. If any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision hereof in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by the internal law of Massachusetts, without giving effect to the conflict of law principles of any jurisdiction. By entering into this Agreement, you agree that any action, demand, claim or counterclaim in connection with any aspect of your employment with the Company, or any separation of employment (whether voluntary or involuntary) from the Company, shall be brought in the courts of Massachusetts or of the United States of America for the District of Massachusetts, and shall be resolved by a judge alone, and you waive and forever renounce your right to a trial before a civil jury.</font></div><div><font><br></font></div><div style="margin-top:9.35pt;padding-left:167.55pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Remainder of Page Intentionally Left Blank</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="height:48.24pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.917%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:110%">-9-</font></div></td></tr></table></div></div></div><div id="i9eeced2eca1345cea35583cf04bb5e92_7"></div><hr style="page-break-after:always"><div style="min-height:69.12pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.3pt;padding-left:41.2pt;text-indent:36.05pt"><font style="color:#010101;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:140%">Please sign below to acknowledge your acceptance of the terms of this Agreement. Keep one copy for your files and return one executed copy to the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:257.6pt"><font style="color:#010101;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Very truly yours,</font></div><div><font><br></font></div><div style="padding-left:257.4pt"><font style="color:#010101;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">FOGHORN THERAPEUTICS INC.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:7.05pt;padding-left:257.65pt"><font style="color:#010101;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Adrian Gottschalk</font></div><div style="margin-top:2.7pt;padding-left:257.2pt;padding-right:130.15pt;text-indent:0.4pt"><font style="color:#010101;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:140%">Name&#58; Adrian Gottschalk Title&#58;&#160;&#160;&#160;&#160;President and CEO</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.65pt;padding-left:41.05pt"><font style="color:#010101;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Accepted</font></div><div style="margin-top:0.65pt;padding-left:41.05pt"><font style="color:#010101;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.65pt;padding-left:41.05pt"><font style="color:#010101;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Fanny Cavalie&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.65pt;padding-left:41.05pt"><font style="color:#010101;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Fanny Cavalie</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:185.25pt"><font style="color:#010101;font-family:'Arial',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature Page to Letter Agreement&#93;</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9eeced2eca1345cea35583cf04bb5e92_10"></div><hr style="page-break-after:always"><div style="min-height:69.84pt;width:100%"><div><font><br></font></div></div><div style="margin-top:1.95pt;padding-left:132.37pt;padding-right:132.37pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit A</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:23.5pt;padding-right:23.5pt;text-align:center;text-indent:-36.05pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-top:9.35pt;padding-left:132.42pt;padding-right:132.42pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(attached)</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>6
<FILENAME>ex1025-employmentagreement.htm
<DESCRIPTION>EX-10.25
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2508a75c0b654d94987adf18d37e6520_1"></div><div style="min-height:77.76pt;width:100%"><div style="text-align:justify"><img alt="image_0b.jpg" src="image_0b.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:218px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.25</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 29, 2020</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Michael LaCascia</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By Email Delivery</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear Mike&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter agreement (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) amends and restates the offer letter dated September&#160;11, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Offer Letter</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by and among you and Foghorn Therapeutics Inc. (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  This Agreement sets forth the terms and conditions of your employment with the Company.  This Agreement will be effective as of the date on which the Company becomes subject to the reporting obligations of Section&#160;12 of the Securities Exchange Act of 1934, as amended.  Should this not occur for any reason, this Agreement shall be void and of no force or effect.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">POSITION AND DUTIES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Your position shall be Chief Legal Officer.  In this role, you will report to the Chief Executive Officer of the Company and perform the duties and responsibilities of your position, and such other duties as reasonably may be assigned to you from time to time consistent with your position.  We anticipate that your employment will start on or before November&#160;9, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Start Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  As a member of our team, we expect you to devote all of your professional and working time and energies to the business and affairs of the Company.  You shall not engage in non-Company related business activities (including consulting activities, board memberships and academic appointments) without the prior written consent of the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or its designee.  You agree that, should you receive the Company&#8217;s consent to conduct any such non-Company related business activities, you shall conduct such activities so as not to interfere with the performance of your duties hereunder or violate the provisions of your Confidentiality Agreement (as defined below).  You shall be employed on an at-will basis, which means that neither you nor the Company are guaranteeing this employment relationship for any specific period of time.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">COMPENSATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During your employment hereunder, as compensation for all services performed for the Company and its affiliates, the Company will provide you with the following compensation and benefits&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.88pt">Salary</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Your initial base salary shall be at a rate of $412,000 on an annualized basis and shall be payable in accordance with the Company&#8217;s normal payroll practices.  Your base salary&#160;shall be subject to adjustment from time to time by the Board or the Compensation Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation Committee</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), in its respective sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.37pt">Signing Bonus</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the first pay cycle following your Start Date, you shall receive a one-time signing bonus (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Signing Bonus</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in the amount of $60,000, less required deductions for federal and state taxes and other required withholdings.  If, prior to the first anniversary of your Start Date, you voluntarily terminate your employment and such voluntary termination does not qualify as a Resignation for Good Reason (as defined below) or your employment is terminated by the Company for Cause (as defined below), you shall repay the Signing Bonus in full within sixty (60) days following the date your employment terminates.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.78pt">Annual Performance Bonus</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In accordance with the Company&#8217;s annual bonus plan (as in effect from time to time), with respect to each fiscal year completed during your employment with the Company, you will be able to earn an annual bonus based upon the achievement, as determined by the Board or the Compensation Committee, in its respective sole discretion, of specified performance goals established by the Board or the Compensation Committee for such fiscal year.  Your target annual bonus will be forty percent (40%) of your base salary.  The annual bonus, to the extent earned, shall be paid to you no later than March&#160;15 of the calendar year immediately following the calendar year to which it relates.  Except as expressly provided below, you must be employed by the Company or on an approved leave of absence on the date of payment of the bonus in order to be eligible for and have earned the annual bonus.  Notwithstanding the foregoing, you shall not be eligible to earn an annual bonus for 2020.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">d.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.37pt">Equity Grants</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You shall be eligible for grants of stock options and other equity awards in the sole discretion of the Board or the Compensation Committee, subject to the terms and conditions of the Company&#8217;s equity incentive plan and any applicable award agreements.    Specifically, but not in limitation of the foregoing, following your Start Date you will be eligible to be granted a stock option (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), subject to the approval of the Board or the Compensation Committee and the terms and conditions of the Company&#8217;s equity incentive plan and the applicable award agreement, for the purchase of an aggregate of 162,162 shares of common stock of the Company, with an exercise price per share equal to the fair market value of a share of the common stock on the date of grant.  The Option shall vest twenty five percent (25%) on the first anniversary of the date of grant, and the remaining seventy five percent (75%) of the Option shall vest on a quarterly basis on the first day of each calendar quarter for the twelve (12) quarters thereafter, subject to your continued employment with the Company and the specific terms of the applicable award agreement.  The Option shall be, to the maximum extent permissible, treated as an &#8220;incentive stock option&#8221; within the meaning of Section&#160;422 of the Internal Revenue Code and the rules and regulations thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">e.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.76pt">Benefits</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You shall be eligible to participate in the Company&#8217;s benefit plans to the same extent as, and subject to the same terms, conditions and limitations applicable to, other Company employees of similar rank and tenure.  These benefits may be modified, changed or eliminated from time to time at the sole discretion of the Company, and the provision of such benefits does not change your status as an at-will employee.  Where a particular benefit is subject to a formal plan (for example, medical insurance or life insurance), eligibility to participate in and receive any particular benefit is governed solely by the applicable plan document.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">f.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:29.01pt">Expense Reimbursement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company shall reimburse you for all ordinary and reasonable out-of-pocket business expenses incurred in furtherance of the Company&#8217;s business in accordance with the Company&#8217;s policies with respect thereto as in effect from time to time.  You must submit any request for reimbursement no later than ninety (90) days following the date that such business expense is incurred.  All reimbursements hereunder shall be made or provided in accordance with the requirements of Section&#160;409A (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;409A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the Internal Revenue Code and the rules and regulations thereunder (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) including, where applicable, the requirement that&#58;  (i)&#160;any reimbursement is for expenses incurred during your lifetime (or during a shorter period of time specified in this Agreement)&#59; (ii)&#160;the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year&#59; (iii)&#160;the reimbursement of an eligible expense shall be made no later than the last day of the calendar year following the year in which the expense is incurred&#59; and (iv)&#160;the right to reimbursement or in kind benefits is not subject to liquidation or exchange for another benefit.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">SEVERANCE BENEFIT UPON CERTAIN TERMINATIONS OF EMPLOYMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.88pt">Termination Not in Connection with a Change in Control</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the at-will nature of the parties&#8217; relationship, should you be subject to an Involuntary Termination other than an Involuntary Termination that occurs in the CIC Period, then, conditioned upon your timely execution and non-revocation of a separation agreement containing a release of claims and other customary terms in the form provided by the Company (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and compliance with your Confidentiality Agreement&#58;  (i)&#160;the Company shall provide you with a payment in an amount equal to  nine (9) months of your then-current base salary, payable in the form of salary continuation over the nine- (9) month period following the date of separation, commencing on the first regular Company payday that is at least five (5) business days following the effective date of the Release&#59; (ii)&#160;(A)&#160;if you properly elect to receive benefits under Consolidated Omnibus Budget Reconciliation Act (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">COBRA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or similar state law and (B)&#160;the premium subsidy described below is not illegal or discriminatory under the Code, the Patient Protection and Affordable Care Act or the Health Care and Education Reconciliation Act, then the Company shall provide you with nine (9) months of your COBRA premiums at the Company&#8217;s normal rate of contribution for employees for your coverage at the level in effect immediately prior to your termination, such premiums to be provided on a monthly basis&#59; and (iii)&#160;the Company shall pay the amount of any annual bonus previously awarded to you by the Board or the Compensation Committee, as applicable, with respect to the calendar year concluded prior to the date of termination that remains unpaid as of the date of termination, which annual bonus shall be paid at the same time as bonuses are paid to active employees of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.37pt">Termination in Connection with a Change in Control</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If you are subject to an Involuntary Termination that occurs in the CIC Period, then, conditioned upon your timely execution and non-revocation of the Release and compliance with your Confidentiality Agreement, in lieu of the payments and benefits provided under </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;3.a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> above&#58;  (i)&#160;the Company shall provide you with a payment in an amount equal to the sum of (A)&#160;your then-current base salary plus (B)&#160;your target annual bonus for the year in which termination occurs, which amount shall be payable in the form of salary continuation over the twelve- (12) month period following the date of separation, commencing on the first regular Company payday that is at least five (5) business days following the effective date of the Release&#59; (ii)&#160;(A)&#160;if you properly elect to receive benefits under COBRA or similar state law and (B)&#160;the premium subsidy described below is not illegal or discriminatory under the Code, the Patient Protection and Affordable Care Act or the Health Care and Education Reconciliation Act, then the Company shall provide you with twelve (12) months of your COBRA premiums at the Company&#8217;s normal rate of contribution for employees for your coverage at the level in effect immediately prior to your termination, such premiums to be provided on a monthly basis&#59; (iii)&#160;the Company shall pay the amount of any annual bonus previously awarded to you by the Board or the Compensation Committee, as applicable, with respect to the calendar year concluded prior to the date of termination that remains unpaid as of the date of termination, which annual bonus shall be paid at the same time as bonuses are paid to active employees of the Company&#59; and (iv)&#160;the vesting and, if applicable, the exercisability of each of your outstanding time-based stock options and other equity awards under the Company&#8217;s equity incentive plan(s) shall be fully accelerated as of the effective date of the Release (with the vesting of any performance-based equity awards determined based on the terms of the award agreements governing such awards).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27.78pt">Timing of Payments</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any severance payments paid under this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall commence within sixty (60) days after the date of termination (or at such earlier time as provided in this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), with the initial payment to include any amounts that would have been payable by their terms prior to such payment commencement date&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that if the sixty- (60) day period begins in one calendar year and ends in a second calendar year, the severance payments shall begin to be paid following the last day of such sixty- (60) day period in the second calendar year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">d.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.37pt">Other Termination Events</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Should you voluntarily terminate your employment for any reason (other than a Resignation for Good Reason) or should your employment be terminated for Cause (whether before or after a Change of Control) or as a result of your death or disability, then you shall not be entitled to any severance payments described herein.  Nothing in this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall alter your status as an at-will employee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">e.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.76pt">Certain Definitions</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For purposes of this Agreement, the following terms shall have the meanings and be subject to the provisions set forth below&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any one or more of the following actions&#58;  (i)&#160;your material breach of the terms of this Agreement or any other written agreement between you and the Company or any of its affiliates&#59; (ii)&#160;your material dishonesty, willful misconduct, gross negligence or reckless conduct, in each case, in connection with the performance of your services to the Company or any of its affiliates&#59; (iii)&#160;your commission of an act of fraud, theft, misappropriation or embezzlement&#59; (iv)&#160;your indictment for, or pleading nolo contendere to, any crime involving moral turpitude or any felony&#59; or (v)&#160;your material violation of a Company policy that had been previously provided to you in writing or your willful refusal to perform, or substantial negligence in the performance of, your assigned duties to the Company or any of its affiliates (other than as a result of your mental or physical impairment).  For purpose of clauses&#160;(i), (ii) and (v), &#8220;Cause&#8221; shall only exist if&#58;  (y)&#160;the Company delivered to you a written description of the events or conditions giving rise to your termination for Cause&#59; and (z)&#160;if curable, you have been given at least fifteen (15) days to cure such events or conditions and you fail to cure such events or conditions within such time period given.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means&#58;  (i)&#160;any &#8220;Person&#8221; (as such term is used in Sections&#160;13(d) and 14(d) of the Exchange Act) that becomes the &#8220;Beneficial Owner&#8221; (as defined in Rule&#160;13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company&#8217;s then outstanding voting securities (excluding for this purpose any such voting securities held by the Company or its affiliates or by any employee benefit plan of the Company) pursuant to a transaction or a series of related transactions&#59; or (ii)&#160;a merger or consolidation of the Company whether or not approved by the Board, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) more than 50% of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation, as the case may be, outstanding immediately after such merger or consolidation&#59; or (iii)&#160;the sale or disposition by the Company of all or substantially all of the Company&#8217;s assets in a transaction requiring stockholder approval&#59; notwithstanding the foregoing, no transaction or series of transactions shall constitute a Change of Control unless such transaction or series of transactions constitutes a &#8220;change in control event&#8221; within the meaning of Treasury Regulation Section&#160;1.409A-3(i)(5)(i).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CIC Period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the period commencing on the date that is three (3) months prior to the date on which a Change of Control occurs and ending on the date that is twelve (12) months following such occurrence.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Involuntary Termination</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means either (i)&#160;your Termination Without Cause or (ii)&#160;your Resignation for Good Reason.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-4-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Resignation for Good Reason</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a termination of your employment after one of the following conditions has come into existence without your consent&#58;  (i)&#160;a reduction in your base salary other than in connection with an across-the-board reduction affecting all similarly situated executives of the Company&#59; (ii)&#160;a material diminution of your title, authority, duties or responsibilities&#59; (iii)&#160;a material breach of this Agreement by Company&#59; or (iv)&#160;a relocation of your principal workplace by more than fifty (50) miles.  A Resignation for Good Reason shall not be deemed to have occurred unless you give the Company written notice of the condition within ninety (90) days after the condition comes into existence, the Company fails to remedy the condition within thirty (30) days after receiving your written notice and you terminate your employment within thirty (30) days after the end of the cure period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Without Cause</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a termination of your employment by the Company without Cause (and not as a result of your death or disability), provided you are willing and able to continue performing services within the meaning of Treasury Regulation Section&#160;1.409A-1(n)(1).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">CONFIDENTIALITY AND OTHER OBLIGATIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As part of your employment with the Company, you shall be exposed to, and provided with, valuable confidential and trade secret information concerning the Company and its present and prospective clients.  As a result, in order to protect the Company&#8217;s legitimate business interests, you agree, as a condition of your employment on the terms of this Agreement, to enter into the Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment of Inventions Agreement (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) attached as </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto.  You must sign and return the Confidentiality Agreement in connection with the execution of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">CERTIFICATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By signing this Agreement, you are certifying to the Company that&#58;  (i)&#160;your employment with the Company does not and shall not require you to breach any agreement entered into by you prior to employment with the Company (i.e., you have not entered into any agreements with previous employers that are in conflict with your obligations to the Company)&#59; (ii)&#160;to the extent you are subject to restrictive agreements with any prior employer that may affect your employment with the Company, you have provided us with a copy of that agreement&#59; (iii)&#160;your employment with the Company does not violate any order, judgment or injunction applicable to you, and you have provided the Company with a copy of any such order, judgment, or injunction&#59; and (iv)&#160;all facts you have presented to the Company are accurate and true, including all statements made to the Company pertaining to your education, training, qualifications, licensing and prior work experience on any job application, resume or c.v., or in any interview.  The Company does not want you to disclose any confidential information belonging to a previous employer or to incorporate the proprietary information of any previous employer into the Company&#8217;s proprietary information and expects that you shall abide by restrictive covenants to prior employers.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">SECTIONS&#160;409A AND 280G OF THE CODE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.88pt">Notwithstanding any other provision of this Agreement to the contrary, if any amount (including imputed income) to be paid to you pursuant to this Agreement as a result of your termination of employment is &#8220;deferred compensation&#8221; subject to Section&#160;409A of the Code, and if you are a &#8220;Specified Employee&#8221; (as defined under Section&#160;409A of the Code and as determined by the Company) as of the date of your termination of employment hereunder, then, to the extent necessary to avoid the imposition of excise taxes or other penalties under </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-5-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section&#160;409A of the Code, the payment of benefits, if any, scheduled to be paid by the Company to you hereunder during the first six- (6) month period following the date of a termination of employment hereunder shall not be paid until the date which is the first business day after six (6) months have elapsed since your termination of employment for any reason other than death.  Any deferred compensation payments delayed in accordance with the terms of this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be paid in a lump sum after six (6) months have elapsed since your termination of employment.  Any other payments shall be made according to the schedule provided for herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.37pt">If any of the benefits set forth in this Agreement are &#8220;deferred compensation&#8221; under Section&#160;409A of the Code, any termination of employment triggering payment of such benefits must constitute a &#8220;separation from service&#8221; under Section&#160;409A of the Code (after giving effect to the presumptions contained therein) before distribution of such benefits can commence.  To the extent that the termination of your employment does not constitute a &#8220;separation from service&#8221; under Section&#160;409A of the Code (as the result of further services that are reasonably anticipated to be provided by you to the Company at the time your employment terminates), any benefits payable under this Agreement that constitute &#8220;deferred compensation&#8221; under Section&#160;409A of the Code shall be delayed until after the date of a subsequent event constituting a &#8220;separation from service&#8221; under Section 409A of the Code.  For purposes of clarification, this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.b</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall not cause any forfeiture of benefits on your part but shall only act as a delay until such time as a &#8220;separation from service&#8221; occurs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.78pt">It is intended that each installment of the payments and benefits provided under this Agreement shall be treated as a separate &#8220;payment&#8221; for purposes of Section&#160;409A of the Code.  Neither the Company nor you shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section&#160;409A of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">d.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.37pt">This Agreement shall be interpreted and at all times administered in a manner that avoids the inclusion of compensation in income under Section&#160;409A of the Code.  Any provision inconsistent with Section&#160;409A of the Code shall be read out of this Agreement.  For purposes of clarification, this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.d</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall be a rule of construction and interpretation and nothing in this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section&#160;6.d</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall cause a forfeiture of benefits on the part of you.  You acknowledge and agree that the Company does not guarantee the tax treatment or tax consequences associated with any payment or benefit arising under this Agreement, including but not limited to consequences related to Section&#160;409A of the Code, and that in no event shall the Company or any of its affiliates have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section&#160;409A of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">e.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.76pt">If any payment or benefit you would receive from the Company or one of its affiliates in connection with a Change of Control or otherwise, whether or not paid or provided under this Agreement (for purposes of this section, a &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), would (i)&#160;constitute a &#8220;parachute payment&#8221; within the meaning of Section&#160;280G the Code&#59; and (ii)&#160;but for this sentence, be subject to the excise tax imposed by Section&#160;4999 of the Code (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Excise Tax</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then such Payment shall be either (y)&#160;the full amount of such Payment&#59; or (z)&#160;such lesser amount as would result in no portion of the Payment being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local employments taxes, income taxes and the Excise Tax, results in your receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  With respect to subsection&#160;(z), any such reduction shall be made in a manner that complies with Section&#160;409A of the Code.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-6-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">INDEMNIFICATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company shall indemnify and hold you harmless for any liability, including reasonable attorneys&#8217; fees and costs, incurred by reason of any act or omission by you in your capacity as an employee and&#47;or officer of the Company to the extent permitted by the Company&#8217;s certificate of incorporation, as amended.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">GENERAL</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof, and supersedes all prior and contemporaneous oral or written agreements and understandings relating to the subject matter hereof (for the avoidance of doubt, including the Offer Letter).  The terms and provisions of this Agreement may be modified or amended only by written agreement executed by the parties hereto, and may be waived (or consent for the departure therefrom granted) only by a written document executed by the party entitled to the benefits of such terms or provisions.  Your employment with the Company is conditioned on your eligibility to work in the United States.  For purposes of completing the USCIS I-9 form, you must provide us with sufficient documentation to demonstrate your identity and eligibility to work in the United States on or before your Start Date.  This Agreement may be executed in counterparts (and may be transmitted by email or other electronic delivery), each of which shall be deemed an original and all of which together shall constitute one and the same instrument.  The captions and headings in this Agreement are for convenience only and in no way define or describe the scope or content of any provision of this Agreement.  All payments made by the Company under this Agreement shall be reduced by any tax or other amounts required to be withheld by the Company under applicable law.  The Company may assign its rights and obligations hereunder to any person or entity that succeeds to all or substantially all of the Company&#8217;s business.  You may not assign your rights and obligations hereunder without the prior written consent of the Company and any such attempted assignment by you without the prior written consent of the Company shall be void.  If any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision hereof in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.  This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by the internal law of Massachusetts, without giving effect to the conflict of law principles of any jurisdiction.  By entering into this Agreement, you agree that any action, demand, claim or counterclaim in connection with any aspect of your employment with the Company, or any separation of employment (whether voluntary or involuntary) from the Company, shall be brought in the courts of Massachusetts or of the United States of America for the District of Massachusetts, and shall be resolved by a judge alone, and you waive and forever renounce your right to a trial before a civil jury.</font></div><div style="margin-bottom:12pt;margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Remainder of Page Intentionally Left Blank</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-7-</font></div></div></div><div id="i2508a75c0b654d94987adf18d37e6520_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Please sign below to acknowledge your acceptance of the terms of this Agreement.  Keep one copy for your files and return one executed copy to the Company.</font></div><div style="margin-top:36pt;padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Very truly yours,</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FOGHORN THERAPEUTICS INC.</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Adrian Gottschalk&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Adrian Gottschalk</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;President and CEO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted and agreed&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Michael LaCascia&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Michael LaCascia</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Signature Page to Letter Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div></div></div><div id="i2508a75c0b654d94987adf18d37e6520_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit&#160;A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EMPLOYEE NON-COMPETITION, NON-SOLICITATION,<br>CONFIDENTIALITY AND ASSIGNMENT OF INVENTIONS AGREEMENT</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(attached)</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>7
<FILENAME>ex1026-transitionagreement.htm
<DESCRIPTION>EX-10.26
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iea752164f12c49abb28b1320e324ebd1_1"></div><div style="min-height:48.96pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.26</font></div></div><div style="padding-left:5pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:218px"></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">January 10, 2022</font></div><div><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Carl Decicco</font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By Email Delivery</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear Carl&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) confirms the terms of the remainder of your employment with Foghorn Therapeutics Inc. (together with its subsidiary, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and certain benefits to be provided to you by the Company. We agree as follows&#58;</font></div><div style="margin-top:6pt;padding-left:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Transition Period.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Transition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to earlier termination as provided herein, from the date of this Agreement through the end of the business day on January 31, 2022 (the actual date of your termination of employment, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Separation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), you will serve as a Special Advisor to the Company&#8217;s Chief Scientific Officer (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Special Advisor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). From the date hereof until the Separation Date, the terms of the Amended and Restated Employment Letter Agreement between you and the Company, dated October 14, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall continue in effect, except as expressly modified by this Agreement, including your new role as Special Advisor. You acknowledge and agree that nothing contained in this Agreement shall give rise to a claim for &#8220;Resignation for Good Reason&#8221; (as defined in the Employment Agreement) under the Employment Agreement. On the Separation Date, you will be deemed to resign from any and all&#58;</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.69pt">officer positions you hold with the Company or any of its affiliates&#59; (ii) memberships you hold on any boards of directors, boards of managers or other governing boards or bodies of the Company or any of its affiliates&#59; and (iii) memberships you hold on any of the committees of any such boards or bodies, including any joint steering, research or similar committees on behalf of the Company.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:6pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Duties and Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. From the date of this Agreement until the Separation Date, you will continue to perform your duties as Special Advisor. You will at all times continue to devote your best professional efforts to the Company and use your best efforts to abide by all of its policies and procedures as are in effect from time to time.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. From the date hereof until the Separation Date, you will continue to receive your current base salary, payable in accordance with the Company&#8217;s regular payroll practices, and to participate in all employee benefit plans and programs of the Company in accordance with the terms of those plans and programs. Notwithstanding the requirement that you remain employed on the date that annual bonuses are paid to employees of the Company, you will be eligible to receive an annual bonus in respect of the Company&#8217;s 2021 fiscal year, based on achievement of the pre-established performance objectives and payable at the same time and in the same manner as bonuses are paid to other executives of the Company (or earlier at the Company&#8217;s discretion).</font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="iea752164f12c49abb28b1320e324ebd1_4"></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.005%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-top:0.7pt;padding-left:1pt"><font><br></font></div></td></tr></table></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Stock Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All outstanding stock options (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Stock Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) previously granted by the Company to you under the Company&#8217;s 2020 Equity Incentive Plan or the Company&#8217;s 2016 Stock Incentive Plan (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), or portions thereof, that are unvested as of the date hereof shall continue to vest in accordance with the terms of the Plans and the applicable award agreements between you and the Company evidencing the Stock Options (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) through the Separation Date, it being understood there shall be no further vesting of any Stock Options following the Separation Date.</font></div><div><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Employment Termination.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Resignation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. On the Separation Date, your employment with the Company will terminate and you will be deemed to&#58; (i) resign any and all positions with the Company and (ii) resign from all other positions you hold with the Company, as provided under Section 1(a) of this Agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Final Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You will receive, on or as soon as reasonably practicable following the Separation Date, (i) your base salary for the final payroll period of your employment, through the Separation Date, and (ii) reimbursement for business expenses incurred by you but not yet paid to you as of the Separation Date, in accordance with the Company&#8217;s reimbursements procedures and practices in effect from time to time&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that you submit all expenses and supporting documentation required within ten (10) days of the Separation Date. You acknowledge and agree that, upon a termination of your employment on January 31, 2022, you shall not be entitled to any severance payments or benefits under Section 3 of the Employment Agreement.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Employee Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For period commencing immediately following the Separation Date and ending on December 31, 2022, you will continue to participate in the Company&#8217;s health, dental and vision plans as if your employment had not terminated on the Separation Date (i.e., the Company will pay the employer&#8217;s portion of such benefit coverage). Thereafter, you may have the right to continue participation in the Company&#8217;s health, dental and vision plans under applicable law, which will be communicated to you under separate cover, at your expense. Nothing in this Agreement will affect any vested rights you may have under the Company&#8217;s employee benefit plans and programs.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">No Further Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You acknowledge and agree that the payments and benefits described in Sections 2(b) and 2(c) and the extended exercise period of vested Stock Options described in Section 3 are in complete satisfaction of any and all compensation or benefits due to you from the Company, whether for services provided or otherwise, through the Separation Date, and that, except as expressly provided under this Agreement, no further compensation or benefits are owed or will be paid or afforded to you. For the avoidance of doubt, from and after the Separation Date, you will not be eligible to receive any severance payments and benefits under any severance plan or policy of the Company or pursuant to the Employment Agreement.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Release of Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In consideration of the payments and benefits set forth in this Agreement, including your eligibility to receive an annual bonus in respect of 2021 as provided under Section 1(c) above and the extended exercise period of vested Stock Options provided in</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:0.42pt;padding-right:0.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div style="text-align:center"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.005%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-top:0.7pt;padding-left:1pt"><font><br></font></div></td></tr></table></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3 below, and other good and valuable consideration, the receipt and sufficiency of which you hereby acknowledge, you agree to execute and return to the Company a release of claims in the form attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to this Agreement (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) within the time period specified therein (but in no event prior to the Separation Date). The execution and non-revocation of the Release is a condition to the receipt of the annual bonus under Section 1(c) and the benefits provided under Section 3 of this Agreement.</font></div><div><font><br></font></div><div style="padding-left:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Extended Option Exercise Period.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Vested Stock Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You and the Company acknowledge that, (i) as of January 31, 2022, the portion of the Stock Options that will have vested under the Equity Documents is as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (such portion, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Vested Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and (ii) pursuant to the terms of the Equity Documents, you are afforded a three-month period following termination of employment to exercise the Vested Options in accordance with their terms (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Standard Vesting Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). You further acknowledge and agree that the portion of the Stock Options that is not vested under the Equity Documents as of the Separation Date will automatically terminate with no consideration due to you.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Extended Option Exercise Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In consideration of the terms of this Agreement and notwithstanding the Standard Vesting Period, the Vested Options shall remain exercisable until July 5, 2022, and following such date, the Vested Options, if not exercised in accordance with the terms of the Equity Documents, shall no longer be exercisable and shall automatically terminate with no consideration due to you. The Vested Options shall in all other respects remain subject to and evidenced by the Equity Documents. You acknowledge and agree that any Vested Option that is intended to qualify as an incentive stock option under Section 422 of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) that is exercised more than three (3) months following the Separation Date will be treated as a non-qualified stock option. Nothing herein, however, constitutes tax advice to you and you are urged to consult your own independent tax advisors regarding the tax treatment of the Stock Options.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Early Termination of Employment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">It is expected that your employment with the Company will continue until January 31, 2022. If your employment terminates prior to such date for any reason, your right to severance payments and benefits, if any, the terms and conditions of such severance payments and benefits will be as set forth in the Employment Agreement and you will forfeit your rights under this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Withholding. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company shall have the right to withhold from all payments made under this Agreement or otherwise paid or provided to you in respect of your employment with the Company any taxes or any other amounts required to be withheld by the Company under applicable law, which amounts may be withheld in the discretion of the Company from any amounts payable under this Agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Continuing Obligations&#59; Cooperation&#59; Non-Disparagement.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:6.05pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Continuing Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You acknowledge and agree that the restrictive covenants referenced in Section 4 of the Employment Agreement and set forth in the Employee Non-Solicitation, Confidentiality and Assignment Agreement between you and the Company,</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:0.42pt;padding-right:0.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div style="text-align:center"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.005%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-top:0.7pt;padding-left:1pt"><font><br></font></div></td></tr></table></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">dated as of January 4, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and in the Employee Non- Competition Agreement between you and the Company, dated as of January 17, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Non-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competition Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), together with any other confidentiality, non-solicitation, invention assignment or other restrictive covenants in favor the Company or any of its affiliates to which you are bound (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), shall continue to apply in accordance with their terms.</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.07pt;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You agree to cooperate with the Company and its affiliates with respect to all matters arising during or related to your employment, including but not limited to all matters in connection with any governmental investigation, litigation or regulatory or other proceeding which may have arisen or which may arise following the signing of this Agreement, which such agreement to cooperate shall survive the termination of your service hereunder. The Company will reimburse your out-of-pocket expenses incurred in complying with Company requests hereunder, provided such expenses are authorized by the Company in advance.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.75pt;text-decoration:underline">Non-Disparagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You agree that you will not, directly or indirectly, at any time disparage or criticize the Company, any of its affiliates, or any of their respective management, businesses, products or services, or any of the other Released Parties (as defined below). The Company agrees (i) to instruct its executive officers and directors as of the Separation Date not to disparage or criticize you and (ii) not to disparage you in any authorized corporate communications to any third parties.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 409A.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)    This Agreement and the payments and benefits provided hereunder are intended to be exempt from, or comply with, the requirements of Section 409A of the Code, and shall be construed consistently with that intent. Notwithstanding the foregoing, in no event shall the Company have any liability relating to the failure or alleged failure of any payment or benefit under this Agreement to be exempt from, or comply with, the requirements of Section 409A of the Code. Each payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments.</font></div><div style="margin-top:6.05pt;padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any reimbursement for expenses payable to you hereunder that would constitute nonqualified deferred compensation subject to Section 409A of the Code shall be subject to the following additional rules&#58; (i) no reimbursement of any such expense shall affect your right to reimbursement of any such expense in any other taxable year&#59; (ii) reimbursement of the expense shall be made, if at all, promptly, but not later than the end of the calendar year following the calendar year in which the expense was incurred&#59; and (iii) the right to reimbursement shall not be subject to liquidation or exchange for any other benefit.</font></div><div style="margin-top:6pt;padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Agreement, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">separation from service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 1.409A-1(h) of the Treasury Regulations (after giving effect to the presumptions contained therein), and the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">specified employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an individual determined by the Company to be a specified employee under Section 1.409A-1(i) of the Treasury Regulations.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:0.42pt;padding-right:0.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div style="text-align:center"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.005%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-top:0.7pt;padding-left:1pt"><font><br></font></div></td></tr></table></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.5pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Miscellaneous. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement constitutes the entire agreement between you and the Company, and replaces all prior and contemporaneous agreements, whether written or oral, with respect to the subject matter of this Agreement and all related matters&#59; it being understood, for the avoidance of doubt, that the Restrictive Covenants shall remain in effect in accordance with their terms. This Agreement may not be amended and no breach will be deemed waived unless agreed to in a signed writing by you and an authorized officer of the Company. The headings and captions in this Agreement are for convenience only and in no way define or describe the scope or content of any provision of this Agreement. The Company may assign its rights and obligations hereunder to any person or entity that succeeds to all or substantially all of the Company&#8217;s business. You may not assign your rights and obligations hereunder without the prior written consent of the Company and any such attempted assignment by you without the prior written consent of the Company shall be void. If any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision hereof in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed by the internal law of the Commonwealth of Massachusetts, without giving effect to the conflict of law principles of any jurisdiction. By entering into this Agreement, you agree that any action, demand, claim or counterclaim in connection with any aspect of the subject matter of this Agreement shall be brought in the courts of Massachusetts or of the United States of America for the District of Massachusetts, and shall be resolved by a judge alone, and you waive and forever renounce your right to a trial before a civil jury. This Agreement may be executed in separate counterparts (including by electronically delivered .pdf files or copies of manually signed signature pages), each of which will be deemed to be an original and all of which taken together will constitute one and the same agreement.</font></div><div><font><br></font></div><div style="margin-top:10.9pt;padding-left:95.97pt;padding-right:95.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Remainder of page intentionally left blank.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:0.42pt;padding-right:0.42pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div style="text-align:center"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.005%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-top:0.7pt;padding-left:1pt"><font><br></font></div></td></tr></table></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:5.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the foregoing is acceptable to you, please sign this Agreement in the space provided and return it to the Company. The enclosed copy of this letter, which you should also sign and date, is for your records.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:185.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sincerely,</font></div><div style="padding-left:185.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FOGHORN THERAPEUTICS INC.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:212.05pt;padding-right:78.15pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Adrian Gottschalk&#160;&#160;&#160;&#160;</font></div><div style="padding-left:212.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and CEO</font></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted and agreed&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.4pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Carl Decicco&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Carl Decicco</font></div><div style="margin-top:0.05pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; 1&#47;9&#47;2022</font></div><div style="padding-left:33.9pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:137.27pt;padding-right:137.27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Signature Page to Transition Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.005%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-top:0.7pt;padding-left:1pt"><font><br></font></div></td></tr></table></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:220.45pt;padding-right:216.3pt;text-align:justify;text-indent:-4.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%;text-decoration:underline">Release</font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:24.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For and in consideration of certain benefits to be provided to me under the letter agreement, dated &#91;DATE&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), between me and Foghorn Therapeutics Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which are conditioned on my signing this General Release and Waiver of Claims (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Release of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and to which I am not otherwise entitled, and other good and valuable consideration, the receipt and sufficiency of which I hereby acknowledge, on my own behalf and on behalf of my heirs, executors, administrators, beneficiaries, representatives, successors and assigns, and all others connected with or claiming through me, I hereby release and forever discharge the Company, and all of its past, present and future officers, directors, shareholders, employees, employee benefits plans, administrators, trustees, agents, representatives, consultants, successors and assigns, and all those connected with any of them, in their official and individual capacities (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Released Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), from any and all causes of action, suits, rights and claims, demands, damages and compensation of any kind and nature whatsoever, whether at law or in equity, whether now known or unknown, suspected or unsuspected, contingent or otherwise, which I now have or ever have had against the Released Parties, or any of them, including those in any way related to, connected with or arising out of my employment and&#47;or other relationship with the Company or any of its affiliates or the termination thereof, including under or pursuant to Title VII of the Civil Rights Act, the Americans With Disabilities Act, the Family and Medical Leave Act, the Age Discrimination in Employment Act (as amended by the Older Workers Benefit Protection Act), the Employee Retirement Income Security Act, the wage and hour, wage payment and fair employment practices laws of the state or states in which I have provided services to the Company (each, as amended from time to time) and&#47;or any other federal, state or local law, regulation, or other requirement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) through the date that I sign this Release of Claims, and I hereby waive all such Claims.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:5.7pt;text-align:justify;text-indent:24.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I understand that nothing contained in this Release of Claims shall be construed to prohibit me from filing a charge with or participating in any investigation or proceeding conducted by the federal Equal Employment Opportunity Commission or a comparable state or local agency, provided, however, that I hereby agree to waive my right to recover monetary damages or other individual relief in any charge, complaint or lawsuit filed by me or by anyone else on my behalf. I further understand that nothing contained in this Release of Claims shall be construed to limit, restrict or in any other way affect my communicating with any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, concerning matters relevant to the governmental agency or entity.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:24.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I acknowledge that I will continue to be bound by my obligations under the Agreement, the Employment Agreement (as defined in the Agreement), and the Confidentiality Agreement (as defined in the Agreement that survive the termination of my employment by the terms thereof or by necessary implication, including without limitation my confidentiality, and non-solicitation obligations set forth in the Agreement, the Employment Agreement, and the Confidentiality Agreement.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.8pt;text-align:justify;text-indent:24.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I understand that nothing contained in this Release of Claims will adversely affect my rights to enforce the terms of the Agreement, and shall not adversely affect my rights to any defense,</font></div><div style="text-align:justify"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.005%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-top:0.7pt;padding-left:1pt"><font><br></font></div></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">indemnification, contribution and&#47;or coverage under the Company&#8217;s director&#8217;s and officer&#8217;s liability insurance policy or the charter or bylaws of the Company, in each case, in accordance with its respective terms by reason of services I rendered for the Company or any of its subsidiaries as an officer, director and&#47;or an employee thereof. Further, this release does not include and will not preclude&#58; (a) rights to vested benefits under any applicable employee benefit plans of the Company&#59; (b) rights under the Equity Documents (as defined in the Agreement)&#59; (c) any rights to indemnification in accordance with the Employment Agreement&#59; and&#47;or (d) claims that cannot be waived under applicable law by singing this Release of Claims.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5pt;padding-right:5.85pt;text-align:justify;text-indent:22.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I acknowledge that this Release of Claims creates legally binding obligations and that the Company has advised me to consult an attorney before signing it. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">I understand that I cannot sign this Release of Claims until the date my employment with the Company terminates. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In signing this Release of Claims, I give the Company assurance that I have signed it voluntarily and with a full understanding of its terms&#59; that I have had sufficient opportunity of not less than twenty- one (21) days before signing this Release of Claims to consider its terms and to consult with an attorney, if I wished to do so&#59; and that I have not relied on any promises or representations, express or implied, that are not set forth expressly in this Release of Claims. I understand that I will have seven (7) days after signing this Release of Claims to revoke my signature, and that, if I intend to revoke my signature, I must do so in writing addressed and delivered to the Chief Legal Officer of the Company prior to the end of the seven (7)-day revocation period. I understand that this Release of Claims will become effective upon the eighth (8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) day following the date that I sign it, provided, that I do not revoke my acceptance in accordance with the immediately preceding sentence.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:7.95pt;padding-left:95.97pt;padding-right:95.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Remainder of page intentionally left blank.&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.005%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-top:0.7pt;padding-left:1pt"><font><br></font></div></td></tr></table></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted and agreed&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:68pt;padding-right:283.9pt;text-indent:-63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%">Signature&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%"> Carl Decicco</font></div><div style="margin-top:10.2pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:297.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">Agreed and acknowledged by&#58; FOGHORN THERAPEUTICS INC.</font></div><div style="padding-left:25.4pt;padding-right:283.9pt;text-indent:-20.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%"> Name&#58; Adrian Gottschalk</font></div><div style="padding-left:25.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; President &#38; CEO</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:95.97pt;padding-right:95.97pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Signature Page to General Release and Waiver of Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:35.28pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.005%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-top:0.7pt;padding-left:1pt"><font><br></font></div></td></tr></table></div></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:95.92pt;padding-right:95.92pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:95.95pt;padding-right:95.95pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Vested Option Schedule</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>8
<FILENAME>ex1027-emplnoncomp.htm
<DESCRIPTION>EX-10.27
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0ffa4048d60c4033a1db0d46eccb1549_1"></div><div style="min-height:67.68pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.27</font></div></div><div style="margin-top:3.9pt;padding-left:47pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:7.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In consideration and as a condition of my employment or continued employment by Foghorn Therapeutics, Inc. (the &#8220;Company&#8221;) and other good and valuable consideration (including, without limitation, the payments described in Section 8 below), I, the undersigned of this Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement (&#8220;Agreement&#8221;), hereby agree as follows&#58;</font></div><div style="height:38.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i0ffa4048d60c4033a1db0d46eccb1549_4"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.976%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:2.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:23.5pt;text-decoration:underline">Proprietary Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. I agree that all information, whether or not in writing, whether or not disclosed before or after I was first employed by the Company, concerning the Company&#8217;s business, technology, business relationships or financial affairs that the Company has not released to the general public (collectively, &#8220;Proprietary Information&#8221;), and all tangible embodiments thereof, are and will be the exclusive property of the Company. By way of illustration, Proprietary Information may include information or material that has not been made generally    available     to     the     public, such as&#58;  (a) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">corporate information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, including plans, strategies, methods, policies, resolutions, notes, email correspondence, negotiations       or       litigation&#59; (b)&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">marketing information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, including strategies, methods, customer identities or other information about customers, prospect identities or other information about prospects, or market analyses or projections&#59; (c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">financial information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, including cost and performance data, debt arrangements, equity structure, investors and holdings, purchasing and sales data and price lists&#59; and (d) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">operational and technological information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, including plans, specifications, manuals, forms, templates, software, designs, methods, procedures, formulas, discoveries, inventions, improvements, biological or chemical materials, concepts and ideas&#59; and (e) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">personnel information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, including personnel lists, reporting or organizational structure, resumes, personnel data, compensation structure, performance evaluations and termination arrangements or documents. Proprietary Information specifically includes, without limitation, (1) information received in confidence by the Company from its customers or suppliers or other third parties, and (2) all biological or chemical materials and other tangible embodiments of the Proprietary Information.</font></div><div style="margin-bottom:6pt;margin-top:5.95pt;padding-left:5pt;padding-right:1.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:23.5pt;text-decoration:underline">Recognition of Company&#8217;s Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. I will not, at any time, without the Company&#8217;s prior written permission, either during or after my employment, disclose or transfer any Proprietary Information to anyone outside of the Company, or use or permit to be used any Proprietary Information for any purpose other than the performance of my duties as an employee of the Company. I will cooperate with the Company and use my best efforts to prevent the unauthorized disclosure of all Proprietary Information. I will deliver to the Company all copies and other tangible embodiments of Proprietary Information in</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:5pt;padding-right:6.05pt;text-align:justify"><font><br></font></div></div><div style="display:inline-block;max-width:6.046%;min-width:5.046%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.978%"><div style="margin-bottom:6pt;padding-left:5pt;padding-right:6.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">my possession or control upon the earlier of a request by the Company or termination of my employment.  Nothing in this Agreement limits, restricts or in any other way affects my communicating with any governmental agency or entity, or communicating with any official or staff person of a governmental agency or entity, concerning matters relevant to the governmental agency or entity.  I understand that I cannot be held criminally or civilly liable under any federal or state trade secret law for disclosing a trade secret (a) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating a suspected violation of law, or (b) in a complaint or other document filed under seal in a lawsuit or other proceeding.&#160;&#160; Notwithstanding this immunity from liability, I understand that I may be held liable if I unlawfully access trade secrets by unauthorized means.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:23.5pt;text-decoration:underline">Rights of Others</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. I understand that the Company is now and may hereafter be subject to non- disclosure or confidentiality agreements with third persons which require the Company to protect or refrain from use of third party proprietary information. I agree to be bound by the terms of such agreements in the event I have access to such third party proprietary information.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:23.5pt;text-decoration:underline">Commitment to Company&#59; Avoidance of Conflict of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. While an employee of the Company, I will devote my full-time efforts to the Company&#8217;s business and I will not engage in any other business activity that conflicts with my duties to the Company. I will advise the president of the Company or his or her nominee at such time as any activity of either the Company or another business presents me with a conflict of interest or the appearance of a conflict of interest as an employee of the Company. I will take whatever action is requested of me by the Company to resolve any conflict or appearance of conflict which it finds to exist.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:23.5pt;text-decoration:underline">Developments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. I hereby assign and transfer and, to the extent any such assignment cannot be made at present, will assign and transfer, to the Company and its successors and assigns, all my right, title and interest in and to all Developments (as defined below) that&#58; (a) are created, developed, made, conceived or reduced to practice by me (alone or jointly with others) or under my direction (collectively, &#8220;conceived&#8221;) during the period of my employment and six (6) months thereafter and that relate to the business of the Company or to products, methods or services being researched, developed, manufactured or sold by the Company&#59; or (b) result from tasks assigned to me by the Company&#59; or (c) result from the use of premises, Proprietary Information or personal property (whether tangible or intangible) owned, licensed or leased by the Company (collectively, &#8220;Company-Related Developments&#8221;), and all patent rights, trademarks, copyrights and other intellectual property rights in all countries and territories worldwide claiming, covering or otherwise arising from or pertaining to Company- Related Developments (collectively, &#8220;Intellectual Property Rights&#8221;). I will make full and prompt disclosure to the </font></div></div></div><div style="height:40.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.976%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company of all Company-Related Developments, as well as all other Developments conceived by me during the period of my employment and six (6) months thereafter. I acknowledge that all work performed by me as an employee of the Company is on a &#8220;work for hire&#8221; basis. I hereby waive all claims to any moral rights or other special rights which I may have or accrue in any Company-Related Developments. &#8220;Developments&#8221; mean inventions, discoveries, designs, developments, methods, modifications, improvements, processes, biological or chemical materials, algorithms, databases, computer programs, formulae, techniques, trade secrets, graphics or images, audio or visual works, and other works of authorship.</font></div><div style="margin-bottom:6pt;margin-top:5.95pt;padding-left:5pt;padding-right:1.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To preclude any possible uncertainty, I have set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> attached hereto a complete list of Developments conceived by me before my employment that are not Company-Related Developments (&#8220;Prior Inventions&#8221;). I have also listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> all patent rights of which I am an inventor, other than those contained within Intellectual Property Rights (&#8220;Other Patent Rights&#8221;). If no such disclosure is attached, I represent that there are no Prior Inventions or Other Patent Rights. If, in the course of my employment with the Company, I incorporate a Prior Invention into a Company product, process or research or development program or other work done for the Company, I hereby grant to the Company a nonexclusive, royalty-free, fully paid-up, irrevocable, perpetual, worldwide license (with the full right to sublicense through multiple tiers) to make, have made, modify, use, offer for sale, import and sell such Prior Invention. Notwithstanding the foregoing, I will not incorporate, or permit to be incorporated, Prior Inventions in any Company-Related Development without the Company&#8217;s prior written consent.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:2.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I understand that to the extent this Agreement is required to be construed in accordance with the laws of any state which precludes a requirement in an employee agreement to assign certain classes of inventions made by an employee, this Section will be interpreted not to apply to any invention which a court rules and&#47;or the Company agrees falls within such classes.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:23.5pt;text-decoration:underline">Documents and Other Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. I will keep and maintain adequate and current records of all Proprietary Information and Company-Related Developments conceived by me, which records will be available to and remain the sole property of the Company at all times. All files, letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification sheets, program listings, blueprints, models, prototypes, materials or other written, photographic or other tangible material containing or embodying Proprietary Information, whether created by me or others, which come into my custody or possession, are the exclusive property of the Company to be used by me only in the performance of my duties for the Company. In the event of the termination of my employment for any reason, I will deliver to the Company all of the foregoing, and all other materials of any nature pertaining to the Proprietary Information of the </font></div></div><div style="display:inline-block;max-width:6.046%;min-width:5.046%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.978%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company and to my work, and will not take or keep in my possession any of the foregoing or any copies. Any property situated on the Company&#8217;s premises and owned by the Company, including laboratory space, computers, disks and other storage media, filing cabinets or other work areas, is subject to inspection by the Company at any time with or without notice.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:23.5pt;text-decoration:underline">Enforcement of Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. I will cooperate fully with the Company, both during and after my employment with the Company, with respect to the procurement, maintenance and enforcement of Intellectual Property Rights, as well as all other patent rights, trademarks, copyrights and other intellectual property rights in all countries and territories worldwide owned by or licensed to the Company. I will sign, both during and after the term of this Agreement, all papers, including copyright applications, patent applications, declarations, oaths, assignments of priority rights, and powers of attorney, which the Company may deem necessary or desirable in order to protect its rights and interests in any Company-Related Development or Intellectual Property Rights. If the Company is unable, after reasonable effort, to secure my signature on any such papers, I hereby irrevocably designate and appoint each officer of the Company as my agent and attorney- in-fact to execute any such papers on my behalf, and to take any and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in the same.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:23.5pt;text-decoration:underline">Non-Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. In order to protect the Company&#8217;s legitimate business interests, including without limitation its trade secrets and other Proprietary Information and good will, during my employment and for a period of twelve (12) months following the termination of my employment for any reason except termination due to layoff or termination by the Company without Cause (as defined below) (the &#8220;Non-Compete Period&#8221;), I will not directly or indirectly, whether as owner, partner, shareholder, director, consultant, agent, employee, co-venturer or otherwise,  provide the Services (as defined below) with respect to any business activity in the Restricted Area (as defined below) that develops, manufactures or markets any products, or performs any services, that compete with the products or services of the Company, or products or services that the Company has under development or that are the subject of active planning at any time during my employment&#59; provided that this will not prohibit any possible investment in publicly traded stock of a company representing less than one percent of the stock of such company. If I violate any fiduciary duty to the Company or unlawfully take any confidential or proprietary information or other property belonging to the Company, the Non-Competition Period will extend by the time during which I engage in such violation(s), for up to a total of two (2) years following the termination of my employment.  Notwithstanding the foregoing, this Section 8 will apply following termination of my employment only if (i) the Company does not waive the restrictions set forth in this Section 8 at the time of termination and (ii) the Company pays me at a rate equal to 50% of my highest annualized base </font></div></div></div><div style="height:40.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.976%"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">salary within the two (2) years immediately preceding termination of my employment for the duration of the Non-Competition Period that follows such termination (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Competition Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), provided that my right to receive and retain any Non-Competition Payments is conditioned on my compliance in full with this Section 8 following termination of my employment.  For the avoidance of doubt, if the Company elects to waive the restrictions set forth in this Section 8 at the time of termination, it will have no obligation to pay me any Non-Competition Payments.  Any Non-Competition Payments that the Company elects to pay me will be payable as salary continuation and subject to tax withholding in accordance with the Company&#8217;s regular payroll practices, consistent with the requirements for the payment of wages under section 148 of chapter 149 of the Massachusetts general laws.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:23.5pt;text-decoration:underline">Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  During my employment and for a period of twelve (12) months following the termination of my employment for any reason (the &#8220;Non-Solicitation Period&#8221;), I will not, directly or indirectly, in any manner, other than for the benefit of the Company, (a) call upon, solicit, divert or take away the business of any customer, client, vendor, supplier or other business partner (collectively, &#8220;Business Partners&#8221;) of the Company or prospective Business Partners of the Company, and&#47;or (b) hire or solicit for hiring any employee or independent contractor of the Company or solicit, entice or attempt to persuade any employee or independent contractor of the Company to leave the services of the Company for any reason. For the purposes of this Agreement, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; or an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">independent contractor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; of the Company is any person who was such at any time within the six (6)-month period immediately preceding the activity restricted by this Section 9.  I acknowledge and agree that if I violate any of the provisions of this Section, the running of the Non-Solicitation Period will be extended by the time during which I engage in such violation(s).    </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:1.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:18.5pt;text-decoration:underline">Government Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. I acknowledge that the Company may have from time to time agreements with other persons or with the United States Government or its agencies which impose obligations or restrictions on the Company regarding inventions made during the course of work under such agreements or regarding the confidential nature of such work. I agree to comply with any such obligations or restrictions upon the direction of the Company. In addition to the rights assigned under Section 5, I also assign to the Company (or any of its nominees) all rights which I have or acquired in any Developments, full title to which is required to be in the United States under any contract between the Company and the United States or any of its agencies.</font></div><div style="margin-bottom:6pt;margin-top:5.95pt;padding-left:5pt;padding-right:2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:18.5pt;text-decoration:underline">Prior Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. I hereby represent that I am not bound by the terms of any agreement with any previous employer or other party to refrain from becoming an employee of the Company. I further represent that my performance of all the terms of this Agreement as an employee of the Company does not and will not breach any agreement to keep in confidence proprietary information, knowledge or data acquired by me in confidence or in trust prior to </font></div></div><div style="display:inline-block;max-width:6.046%;min-width:5.046%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.978%"><div style="margin-bottom:6pt;margin-top:5.95pt;padding-left:5pt;padding-right:2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">my employment with the Company. I will not disclose to the Company, or induce the Company to use, any confidential or proprietary information or material belonging to any previous employer or other party.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5.05pt;padding-right:2.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:18.45pt;text-decoration:underline">Remedies Upon Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. I understand and agree that the restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company and are reasonable in respect to subject matter, length of time and geographic area. My breach of this Agreement will cause the Company substantial and irreparable damage and therefore, in the event of such breach or threatened breach, the Company, in addition to such other remedies which may be available, will be entitled to specific performance and preliminary and permanent injunctive relief, without having to post bond, together with an award of its reasonable attorneys&#8217; fees incurred in enforcing its rights hereunder.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:6.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:18.5pt;text-decoration:underline">Use of Voice, Image and Likeness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. I give the Company permission to use my voice, image or likeness, with or without using my name, for the purposes of advertising and promoting the Company, or for other purposes deemed appropriate by the Company in its reasonable discretion, except to the extent expressly prohibited by law.</font></div><div style="margin-bottom:6pt;margin-top:5.95pt;padding-left:5pt;padding-right:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:18.5pt;text-decoration:underline">Publications and Public Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. I will obtain the Company&#8217;s written approval before publishing or submitting for publication any material that relates to my work at the Company and&#47;or incorporates any Proprietary Information. To ensure that the Company delivers a consistent message about its products, services and operations to the public, and further in recognition that even positive statements may have a detrimental effect on the Company in certain securities transactions and other contexts, any statement about the Company which I create, publish or post during my period  of  employment  and  for six (6) months thereafter, on any media accessible by the public, including but not limited to electronic bulletin boards and Internet-based chat rooms, must first be reviewed and approved by an officer of the Company before it is released in the public domain.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:18.5pt;text-decoration:underline">No Employment Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. I understand that this Agreement does not create an obligation on the Company or any other person to continue my employment. I acknowledge that, unless otherwise agreed in a formal written employment agreement signed on behalf of the Company by an authorized officer, my employment with the Company is at-will and therefore may be terminated by the Company or me at any time and for any reason.</font></div><div style="margin-bottom:6pt;margin-top:5.95pt;padding-left:5pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:18.5pt;text-decoration:underline">Survival and Assignment by the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. I understand that my obligations under this Agreement will continue in accordance with its express terms regardless of any changes in my title, position, duties, salary, compensation or benefits or other terms and conditions of employment. I further understand that my obligations under this Agreement will continue following the termination of my employment regardless of the manner of such termination and will be binding upon my heirs, executors and administrators. The Company will have the right to assign this Agreement to its </font></div></div></div><div style="height:40.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.976%"><div style="margin-bottom:6pt;margin-top:5.95pt;padding-left:5pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">affiliates, successors and assigns. I expressly consent to be bound by the provisions of this Agreement for the benefit of the Company or any parent, subsidiary or affiliate to whose employ I may be transferred without the necessity that this Agreement be resigned at the time of such transfer.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5.05pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:18.45pt;text-decoration:underline">Disclosure to Future Employers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. I will provide a copy of this Agreement to any prospective employer, partner or co-venturer prior to entering into an employment, partnership or other business relationship with such person or entity.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:1.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:18.5pt;text-decoration:underline">Exit Interview</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If and when I depart from the Company, I may be required to attend an exit interview and sign an &#8220;Employee Exit Acknowledgement&#8221; to reaffirm my acceptance and acknowledgement of the obligations set forth in this Agreement. During the Non-Competition Period following termination of my employment, I will notify the Company of any change in my address and of each subsequent employment or business activity, including the name and address of my employer or other post-Company employment plans and the nature of my activities.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:1.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:18.5pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. In case any provisions (or portions thereof) contained in this Agreement will, for any reason, be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other provisions of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained herein. If, moreover, any one or more of the provisions contained in this Agreement will for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it will be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it will then appear.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:5pt;padding-right:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:18.5pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement constitutes the entire and only agreement between the Company and me respecting the subject matter hereof, and supersedes all prior agreements and understandings, oral or written, between us concerning such subject matter. No modification, amendment, waiver or termination of this Agreement or of any provision hereof will be binding unless made in writing and signed by an authorized officer of the Company. Failure of the Company to insist upon strict compliance with any of the terms, covenants or conditions hereof will not be deemed a waiver of such terms, covenants or conditions. In the event of any inconsistency between this Agreement and any other contract between the Company and me, the provisions of this Agreement will prevail.</font></div><div style="margin-bottom:6pt;margin-top:5.95pt;padding-left:5pt;padding-right:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:18.5pt;text-decoration:underline">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. This Agreement will be deemed to be made and entered into in the Commonwealth of Massachusetts, and will in all respects be interpreted, enforced and governed under the laws of the Commonwealth of Massachusetts. I hereby agree to consent to personal jurisdiction of the state and federal courts situated within Suffolk County, Massachusetts for purposes of enforcing this Agreement, and waive any objection that I might have to personal jurisdiction or venue in those courts. </font></div></div><div style="display:inline-block;max-width:6.046%;min-width:5.046%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.978%"><div style="margin-bottom:6pt;margin-top:5.95pt;padding-left:5pt;padding-right:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As used in this Agreement, &#8220;including&#8221; means &#8220;including but not limited to&#8221;.</font></div><div style="margin-bottom:6pt;margin-top:5.95pt;padding-left:5pt;padding-right:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:18.5pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  For purposes of this Agreement, and only this Agreement, the following definitions shall apply&#58;</font></div><div style="margin-bottom:6pt;margin-top:5.95pt;padding-left:5pt;padding-right:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means (notwithstanding any other agreement between the Company and me containing this defined term) the occurrence of any of the following, as determined by the Company in its reasonable discretion&#58;  (i) my failure to perform my duties and responsibilities to the Company, or the performance of my duties and responsibilities to the Company in a manner deemed by the Company to be in any way unsatisfactory&#59; (ii) my breach of this Agreement or any other agreement between me and the Company&#59; (iii) my commission of, or plea of nolo contendere to, a felony or other crime&#59; (iv) any misconduct by me or other conduct by me that is or could reasonably be expected to be harmful to the business interests or reputation of the Company&#59; (v) my violation or disregard for any rule or procedure or policy of the Company&#59; or (vi) any other reasonable basis for Company dissatisfaction with me, including for reasons such as lack of capacity or diligence, failure to conform to usual standards of conduct, or other culpable or inappropriate behavior.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:4.3pt;padding-right:6.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;Restricted Area&#8221; means any geographic area in which the Company or any of its Affiliates does business or is actively planning to do business during my employment or, with respect to the portion of the Non-Competition Period that follows the termination of my employment, any geographic area in which I, at any time within the last two (2) years of my employment with the Company, provided services or had a material presence or influence.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:4.5pt;padding-right:6.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;Services&#8221; means any of the services that I provided to the Company at any time during my employment with the Company or, with respect to the portion of the Non-Competition Period that follows the termination of my employment, during the last two (2) years of my employment with the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><div style="height:40.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div></div></div><div id="i0ffa4048d60c4033a1db0d46eccb1549_7"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I acknowledge that (1) the Company provided me with this Agreement by the earlier of (a) the date of a formal offer of employment from the Company or (b) ten (10) business days before the commencement of employment with the Company, (2) I have been and am hereby advised of my right to consult an attorney before signing this Agreement, and (3) I have carefully read this Agreement and understand and agree to all of the provisions in this Agreement.</font></div><div style="padding-left:5pt;padding-right:7.9pt;text-indent:36pt"><font><br></font></div><div style="margin-top:5.85pt;padding-left:5pt;padding-right:7.9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the undersigned has executed this agreement as a sealed instrument as of the date set forth below.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_____________________________________________________________________________________________</font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div></div></div><div id="i0ffa4048d60c4033a1db0d46eccb1549_10"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:3.9pt;padding-left:212.22pt;padding-right:212.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>9
<FILENAME>ex23130503foghornconsent-2.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9c1af2656dbe4d1b9b19225c9c30b5b2_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Ex 23.1</font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">We consent to the incorporation by reference in Registration Statement Nos. 333-262713 and 333-252119 on Form S-8 of our report dated March 10, 2022, relating to the consolidated financial statements of Foghorn Therapeutics Inc. appearing in this Annual Report on Form 10-K for the year ended December 31, 2021. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#47;s&#47; Deloitte &#38; Touche LLP </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Boston, Massachusetts</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">March 10, 2022</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>10
<FILENAME>fhtx-20211231xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i25cebab86a05481faadf39709808c781_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Adrian Gottschalk, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Annual Report on Form 10-K of Foghorn Therapeutics Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">(Paragraph omitted pursuant to SEC Release Nos. 33-8238&#47;34-47986 and 33-8392&#47;34-49313)&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 10, 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Adrian Gottschalk</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adrian Gottschalk</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>11
<FILENAME>fhtx-20211231xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id65c500030e14c0e812510d15ab3255f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Allan Reine, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Annual Report on Form 10-K of Foghorn Therapeutics Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">(Paragraph omitted pursuant to SEC Release Nos. 33-8238&#47;34-47986 and 33-8392&#47;34-49313)&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 10, 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Allan Reine</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allan Reine, M.D.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting and Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>12
<FILENAME>fhtx-20211231xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ica77814c68df411fb9dec1d2f432d97c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Foghorn Therapeutics Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 10, 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Adrian Gottschalk</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adrian Gottschalk</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>13
<FILENAME>fhtx-20211231xex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1813c671c7ab4b4da39887f52ef52f92_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Foghorn Therapeutics Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 10, 2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Allan Reine</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allan Reine, M.D.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting and Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>fhtx-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:45bd6193-dace-4c5a-b62d-c265e68fd1cf,g:2c36ac82-298b-41b7-8200-caa9bbc65128-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:fhtx="http://www.foghorntx.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.foghorntx.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fhtx-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fhtx-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fhtx-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fhtx-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.foghorntx.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.foghorntx.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.foghorntx.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.foghorntx.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" roleURI="http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity">
        <link:definition>1004006 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityParenthetical" roleURI="http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityParenthetical">
        <link:definition>1005007 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentation" roleURI="http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentationDetails" roleURI="http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails">
        <link:definition>2402401 - Disclosure - Nature of Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.foghorntx.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAmortizationDetails" roleURI="http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAmortizationDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Property and Equipment are Stated at Cost Less Accumulated Depreciation and Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofEarningsPerShareDilutedAntiDilutiveImpactDetails" roleURI="http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofEarningsPerShareDilutedAntiDilutiveImpactDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies - Summary of Earnings Per Share Diluted Anti Dilutive Impact (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurements" roleURI="http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurements">
        <link:definition>2109103 - Disclosure - Marketable Securities and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsTables" roleURI="http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsTables">
        <link:definition>2310302 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails" roleURI="http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails">
        <link:definition>2411405 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Available for Sale Marketable Securities By Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>2412406 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.foghorntx.com/role/PropertyandEquipmentNet">
        <link:definition>2113104 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.foghorntx.com/role/PropertyandEquipmentNetTables">
        <link:definition>2314303 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" roleURI="http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails">
        <link:definition>2415407 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetAdditionalInformationDetails" roleURI="http://www.foghorntx.com/role/PropertyandEquipmentNetAdditionalInformationDetails">
        <link:definition>2416408 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.foghorntx.com/role/AccruedExpenses">
        <link:definition>2117105 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTable" roleURI="http://www.foghorntx.com/role/AccruedExpensesTable">
        <link:definition>2318304 - Disclosure - Accrued Expenses (Table)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.foghorntx.com/role/AccruedExpensesDetails">
        <link:definition>2419409 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayable" roleURI="http://www.foghorntx.com/role/NotesPayable">
        <link:definition>2120106 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayableTables" roleURI="http://www.foghorntx.com/role/NotesPayableTables">
        <link:definition>2321305 - Disclosure - Notes Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayableSummaryofLongTermDebtDetails" roleURI="http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails">
        <link:definition>2422410 - Disclosure - Notes Payable - Summary of Long Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayableAdditionalInformationDetails" roleURI="http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails">
        <link:definition>2423411 - Disclosure - Notes Payable - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://www.foghorntx.com/role/CommonStock">
        <link:definition>2124107 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockDetails" roleURI="http://www.foghorntx.com/role/CommonStockDetails">
        <link:definition>2425412 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.foghorntx.com/role/StockBasedCompensation">
        <link:definition>2126108 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.foghorntx.com/role/StockBasedCompensationTables">
        <link:definition>2327306 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>2428413 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedtoEstimateFairValueofStockOptionsandRestrictedStockAwardsusingBlackScholesOptionPricingModelDetails" roleURI="http://www.foghorntx.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedtoEstimateFairValueofStockOptionsandRestrictedStockAwardsusingBlackScholesOptionPricingModelDetails">
        <link:definition>2429414 - Disclosure - Stock-Based Compensation - Schedule of Weighted Average Assumptions Used to Estimate Fair Value of Stock Options and Restricted Stock Awards using Black-Scholes Option Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofShareOptionActivityDetails" roleURI="http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails">
        <link:definition>2430415 - Disclosure - Stock-Based Compensation - Schedule of Share Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails" roleURI="http://www.foghorntx.com/role/StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails">
        <link:definition>2431416 - Disclosure - Stock-Based Compensation - Summary of Stock-based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://www.foghorntx.com/role/CollaborationAgreements">
        <link:definition>2132109 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementDetails" roleURI="http://www.foghorntx.com/role/CollaborationAgreementDetails">
        <link:definition>2433417 - Disclosure - Collaboration Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.foghorntx.com/role/IncomeTaxes">
        <link:definition>2134110 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.foghorntx.com/role/IncomeTaxesTables">
        <link:definition>2335307 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2436418 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofReconciliationoftheUSfederalstatutoryincometaxratetotheCompanyseffectiveincometaxrateDetails" roleURI="http://www.foghorntx.com/role/IncomeTaxesSummaryofReconciliationoftheUSfederalstatutoryincometaxratetotheCompanyseffectiveincometaxrateDetails">
        <link:definition>2437419 - Disclosure - Income Taxes - Summary of Reconciliation of the U.S. federal statutory income tax rate to the Company's effective income tax rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofNetDeferredTaxAssetsDetails" roleURI="http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails">
        <link:definition>2438420 - Disclosure - Income Taxes - Summary of Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.foghorntx.com/role/Leases">
        <link:definition>2139111 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.foghorntx.com/role/LeasesTables">
        <link:definition>2340308 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://www.foghorntx.com/role/LeasesAdditionalInformationDetails">
        <link:definition>2441421 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofLeaseCostDetails" roleURI="http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails">
        <link:definition>2442422 - Disclosure - Leases - Summary of Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofSupplementalCashFlowInformationRelatedtoLeasesDetails" roleURI="http://www.foghorntx.com/role/LeasesSummaryofSupplementalCashFlowInformationRelatedtoLeasesDetails">
        <link:definition>2443423 - Disclosure - Leases - Summary of Supplemental Cash Flow Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofWeightedAverageRemainingLeaseTermandDiscountRateLeasesDetails" roleURI="http://www.foghorntx.com/role/LeasesSummaryofWeightedAverageRemainingLeaseTermandDiscountRateLeasesDetails">
        <link:definition>2444424 - Disclosure - Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofMinimumLeasePaymentDetails" roleURI="http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails">
        <link:definition>2445425 - Disclosure - Leases - Summary of Minimum Lease Payment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofMinimumLeasePaymentDetails_1" roleURI="http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails_1">
        <link:definition>2445425 - Disclosure - Leases - Summary of Minimum Lease Payment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofOperatingLeaseLiabilitiesDetails" roleURI="http://www.foghorntx.com/role/LeasesSummaryofOperatingLeaseLiabilitiesDetails">
        <link:definition>2446426 - Disclosure - Leases - Summary of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.foghorntx.com/role/CommitmentsandContingencies">
        <link:definition>2147112 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.foghorntx.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2448427 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DefinedContributionPlan" roleURI="http://www.foghorntx.com/role/DefinedContributionPlan">
        <link:definition>2149113 - Disclosure - Defined Contribution Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedParties" roleURI="http://www.foghorntx.com/role/RelatedParties">
        <link:definition>2150114 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesDetails" roleURI="http://www.foghorntx.com/role/RelatedPartiesDetails">
        <link:definition>2451428 - Disclosure - Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="fhtx_MilestoneReceivableUponAchievement" abstract="false" name="MilestoneReceivableUponAchievement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="fhtx_PrepaymentPeriod" abstract="false" name="PrepaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" abstract="true" name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="fhtx_TemporaryEquityConversionOfStockAmountConverted" abstract="false" name="TemporaryEquityConversionOfStockAmountConverted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fhtx_PrepaymentPeriodThreeMember" abstract="true" name="PrepaymentPeriodThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" abstract="true" name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="fhtx_StockIssuanceCosts" abstract="false" name="StockIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fhtx_ConversionOfRedeemableConvertibleStockMember" abstract="true" name="ConversionOfRedeemableConvertibleStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fhtx_FlagshipPioneeringMember" abstract="true" name="FlagshipPioneeringMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fhtx_DeferredTaxLiabilitiesDepreciation" abstract="false" name="DeferredTaxLiabilitiesDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fhtx_StockIssuedDuringPeriodConnectionWithExerciseOfWarrant" abstract="false" name="StockIssuedDuringPeriodConnectionWithExerciseOfWarrant" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="fhtx_ProceedsFromUpfrontPayment" abstract="false" name="ProceedsFromUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fhtx_AssetsNotYetPlacedInServiceMember" abstract="true" name="AssetsNotYetPlacedInServiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fhtx_OfficeSpaceInCambridgeMassachusettsMember" abstract="true" name="OfficeSpaceInCambridgeMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fhtx_NumberOfPrograms" abstract="false" name="NumberOfPrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="fhtx_TermLoanAMember" abstract="true" name="TermLoanAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fhtx_AccruedResearchAndDevelopmentExpenses" abstract="false" name="AccruedResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fhtx_A2016StockIncentivePlanMember" abstract="true" name="A2016StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fhtx_LeaseholdImprovementsLandlordAllowanceToBeRepaid" abstract="false" name="LeaseholdImprovementsLandlordAllowanceToBeRepaid" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fhtx_ServiceAgreementRenewalTerm" abstract="false" name="ServiceAgreementRenewalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="fhtx_ConversionOfNotesPayableInToWarrantsMember" abstract="true" name="ConversionOfNotesPayableInToWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fhtx_OperatingLossCarryforwardLimitPercentage" abstract="false" name="OperatingLossCarryforwardLimitPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="fhtx_WarrantsIssuePricePerShare" abstract="false" name="WarrantsIssuePricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="fhtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="fhtx_DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice" abstract="false" name="DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fhtx_MarketableSecuritiesAndFairValueMeasurementsTextBlock" abstract="false" name="MarketableSecuritiesAndFairValueMeasurementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="fhtx_MilestonesPayableUponEvent" abstract="false" name="MilestonesPayableUponEvent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember" abstract="true" name="OfficeAndLaboratorySpaceInCambridgeMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fhtx_LineOfCreditAdditionalBorrowingCapacity" abstract="false" name="LineOfCreditAdditionalBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fhtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fhtx_PrepaymentPeriodOneMember" abstract="true" name="PrepaymentPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fhtx_WeightedAverageContractualTermAbstract" abstract="true" name="WeightedAverageContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="fhtx_LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives" abstract="false" name="LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fhtx_PrepaymentPeriodDomain" abstract="true" name="PrepaymentPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fhtx_PrepaymentPeriodTwoMember" abstract="true" name="PrepaymentPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fhtx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fhtx_TermLoanBMember" abstract="true" name="TermLoanBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fhtx_OptOutMilestoneReceivableUponAchievement" abstract="false" name="OptOutMilestoneReceivableUponAchievement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fhtx_AccruedTenantImprovements" abstract="false" name="AccruedTenantImprovements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fhtx_DeferredTaxAssetsCapitalizedStartUpCosts" abstract="false" name="DeferredTaxAssetsCapitalizedStartUpCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fhtx_NumberOfCollaborativeAgreements" abstract="false" name="NumberOfCollaborativeAgreements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="fhtx_TemporaryEquityConversionOfStockSharesConverted" abstract="false" name="TemporaryEquityConversionOfStockSharesConverted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="fhtx_StanfordLicenseAgreementMember" abstract="true" name="StanfordLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fhtx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" abstract="false" name="DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="fhtx_ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement" abstract="false" name="ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fhtx_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fhtx_LeasesBalanceSheetLocationTableTextBlock" abstract="false" name="LeasesBalanceSheetLocationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="fhtx_SharePurchaseAgreementMember" abstract="true" name="SharePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fhtx_ServiceAgreementTerm" abstract="false" name="ServiceAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="fhtx_NumberOfAdditionalTargets" abstract="false" name="NumberOfAdditionalTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="fhtx_SalesBasedMilestoneMember" abstract="true" name="SalesBasedMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fhtx_TwoThousandTwentyEquityIncentivePlanMember" abstract="true" name="TwoThousandTwentyEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fhtx_AdditionalOfficeSpaceInCambridgeMassachusettsMember" abstract="true" name="AdditionalOfficeSpaceInCambridgeMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fhtx_CollaborationAgreementAbstract" abstract="true" name="CollaborationAgreementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="fhtx_MerckMember" abstract="true" name="MerckMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fhtx_ConversionOfWarrantLiabilityToEquityMember" abstract="true" name="ConversionOfWarrantLiabilityToEquityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fhtx_CashPaymentsRelatedParty" abstract="false" name="CashPaymentsRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fhtx_CommonStockTextBlock" abstract="false" name="CommonStockTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="fhtx_InterestIncomeAndOtherIncomeExpense" abstract="false" name="InterestIncomeAndOtherIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fhtx_PercentageOfPrepaymentFee" abstract="false" name="PercentageOfPrepaymentFee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="fhtx_PrepaymentPeriodAxis" abstract="true" name="PrepaymentPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="fhtx_ResearchDevelopmentAndRegulatoryMember" abstract="true" name="ResearchDevelopmentAndRegulatoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fhtx_NumberOfTargets" abstract="false" name="NumberOfTargets" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="fhtx_EliLillyMember" abstract="true" name="EliLillyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fhtx_TwoThousandTwentyEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandTwentyEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="fhtx_AnnualLicenseMaintenanceFees" abstract="false" name="AnnualLicenseMaintenanceFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fhtx_DeferredTaxAssetsOperatingLeaseLiabilities" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fhtx_LeaseholdImprovementsLandlordAllowance" abstract="false" name="LeaseholdImprovementsLandlordAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fhtx_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="fhtx_ScientificFounderMember" abstract="true" name="ScientificFounderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>fhtx-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:45bd6193-dace-4c5a-b62d-c265e68fd1cf,g:2c36ac82-298b-41b7-8200-caa9bbc65128-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.foghorntx.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="fhtx-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.foghorntx.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_581c2c6a-a73b-4314-8ca7-e3e9172f38a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ef9f502c-2519-4c1f-bde7-f2ef195e48c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_581c2c6a-a73b-4314-8ca7-e3e9172f38a1" xlink:to="loc_us-gaap_AccountsPayableCurrent_ef9f502c-2519-4c1f-bde7-f2ef195e48c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_65aff98e-fce7-4b1d-b7eb-072737b19f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_581c2c6a-a73b-4314-8ca7-e3e9172f38a1" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_65aff98e-fce7-4b1d-b7eb-072737b19f98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_387dfdd0-b92e-4393-80b2-39923130235e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_581c2c6a-a73b-4314-8ca7-e3e9172f38a1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_387dfdd0-b92e-4393-80b2-39923130235e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9a495d2f-bc21-498a-8cb2-c1a99b76c7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_581c2c6a-a73b-4314-8ca7-e3e9172f38a1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9a495d2f-bc21-498a-8cb2-c1a99b76c7ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3ce80ef7-e13a-486c-98be-684e0c86c1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_99a7514b-0697-474e-bf60-f16966f9ad7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3ce80ef7-e13a-486c-98be-684e0c86c1ca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_99a7514b-0697-474e-bf60-f16966f9ad7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_d0d34210-74ea-404c-9633-f9a8818578ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3ce80ef7-e13a-486c-98be-684e0c86c1ca" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_d0d34210-74ea-404c-9633-f9a8818578ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c1f8a13a-2750-47a2-ba55-e07d6d45df55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3ce80ef7-e13a-486c-98be-684e0c86c1ca" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c1f8a13a-2750-47a2-ba55-e07d6d45df55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_078ff719-662e-4811-9112-9413f2407903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3ce80ef7-e13a-486c-98be-684e0c86c1ca" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_078ff719-662e-4811-9112-9413f2407903" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b464dd36-c7bd-4884-af30-fbce48fb3e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3ce80ef7-e13a-486c-98be-684e0c86c1ca" xlink:to="loc_us-gaap_AssetsCurrent_b464dd36-c7bd-4884-af30-fbce48fb3e89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_45a8848d-c5db-4a51-805a-1980a1d527c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a35772d6-49b3-4c30-befd-2d03efc6ae0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_45a8848d-c5db-4a51-805a-1980a1d527c5" xlink:to="loc_us-gaap_Liabilities_a35772d6-49b3-4c30-befd-2d03efc6ae0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bca27313-2c49-4dfc-bd0e-adc70fc37d15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_45a8848d-c5db-4a51-805a-1980a1d527c5" xlink:to="loc_us-gaap_StockholdersEquity_bca27313-2c49-4dfc-bd0e-adc70fc37d15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_91eb1af3-9891-4fc6-af68-f35cdc1f4a29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_45a8848d-c5db-4a51-805a-1980a1d527c5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_91eb1af3-9891-4fc6-af68-f35cdc1f4a29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e8d92d29-ee38-44df-87a1-9c40da9bb8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c0c8a876-5f1c-4dad-8957-255528eec731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e8d92d29-ee38-44df-87a1-9c40da9bb8cf" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c0c8a876-5f1c-4dad-8957-255528eec731" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dfdce7cc-b84a-4cc2-9996-39369a0f03b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e8d92d29-ee38-44df-87a1-9c40da9bb8cf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dfdce7cc-b84a-4cc2-9996-39369a0f03b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7fb4f2c3-46b2-462e-bae6-263f9f696b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e8d92d29-ee38-44df-87a1-9c40da9bb8cf" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7fb4f2c3-46b2-462e-bae6-263f9f696b6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c2b0edb9-0c28-42f6-af8d-9e667080a20b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e8d92d29-ee38-44df-87a1-9c40da9bb8cf" xlink:to="loc_us-gaap_LiabilitiesCurrent_c2b0edb9-0c28-42f6-af8d-9e667080a20b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_db81b622-e33c-4214-bc0d-4a947ae52036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e8d92d29-ee38-44df-87a1-9c40da9bb8cf" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_db81b622-e33c-4214-bc0d-4a947ae52036" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_593f8851-60f0-4aef-966d-e79f72c535f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4d393b33-c499-424d-8277-b4294607c2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_593f8851-60f0-4aef-966d-e79f72c535f5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4d393b33-c499-424d-8277-b4294607c2b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_181f1151-8086-456b-9ee8-3506a2bdc1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_593f8851-60f0-4aef-966d-e79f72c535f5" xlink:to="loc_us-gaap_MarketableSecurities_181f1151-8086-456b-9ee8-3506a2bdc1ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5d3c0d07-a2d6-41e9-9098-b6d3ac6f28b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_593f8851-60f0-4aef-966d-e79f72c535f5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5d3c0d07-a2d6-41e9-9098-b6d3ac6f28b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_53d24208-85d7-4a4d-a0d3-dab692c3c67d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_593f8851-60f0-4aef-966d-e79f72c535f5" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_53d24208-85d7-4a4d-a0d3-dab692c3c67d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_08b0a250-bc4a-484e-bb2b-c4cccc332767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_32d32a71-0bdc-4c07-9940-baf40f4a529d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_08b0a250-bc4a-484e-bb2b-c4cccc332767" xlink:to="loc_us-gaap_CommonStockValue_32d32a71-0bdc-4c07-9940-baf40f4a529d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6c85a054-83b9-4135-be2f-89803552af20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_08b0a250-bc4a-484e-bb2b-c4cccc332767" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6c85a054-83b9-4135-be2f-89803552af20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_58c8de02-fa32-4b6b-8d7c-db19c501ab9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_08b0a250-bc4a-484e-bb2b-c4cccc332767" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_58c8de02-fa32-4b6b-8d7c-db19c501ab9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4ff80d85-2e2d-4c13-a523-d1128a515160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_08b0a250-bc4a-484e-bb2b-c4cccc332767" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4ff80d85-2e2d-4c13-a523-d1128a515160" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_d1d7e778-202b-49d0-bdbb-227164711801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_08b0a250-bc4a-484e-bb2b-c4cccc332767" xlink:to="loc_us-gaap_PreferredStockValue_d1d7e778-202b-49d0-bdbb-227164711801" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="fhtx-20211231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b23537cc-ce59-4337-826c-10e0d357f889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a0806aa4-6d7c-4530-9e94-154469342956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b23537cc-ce59-4337-826c-10e0d357f889" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a0806aa4-6d7c-4530-9e94-154469342956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_91d96b47-ada0-448c-bb0a-8c610a29bf26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ac46331d-4710-4b42-bb3a-70f5908d53b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_91d96b47-ada0-448c-bb0a-8c610a29bf26" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ac46331d-4710-4b42-bb3a-70f5908d53b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_32b7af6e-cbe9-4c14-b6d9-379f723b8936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_91d96b47-ada0-448c-bb0a-8c610a29bf26" xlink:to="loc_us-gaap_NetIncomeLoss_32b7af6e-cbe9-4c14-b6d9-379f723b8936" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d4ee924c-07c4-47e8-b798-273e8cfcb119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_bc4d9918-c8ff-43ac-b9ef-e79b837e04c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d4ee924c-07c4-47e8-b798-273e8cfcb119" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_bc4d9918-c8ff-43ac-b9ef-e79b837e04c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_58645d35-616b-4b26-8f26-2a406a9b7813" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d4ee924c-07c4-47e8-b798-273e8cfcb119" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_58645d35-616b-4b26-8f26-2a406a9b7813" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_db5d7175-1b32-4bc1-9a91-e6d6ad2abbd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_2ce9bb85-ccda-481b-b96b-be6deaab4d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_db5d7175-1b32-4bc1-9a91-e6d6ad2abbd9" xlink:to="loc_us-gaap_OperatingExpenses_2ce9bb85-ccda-481b-b96b-be6deaab4d8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_36dc6f4f-ffdf-42e0-962c-458ac5365305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_db5d7175-1b32-4bc1-9a91-e6d6ad2abbd9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_36dc6f4f-ffdf-42e0-962c-458ac5365305" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_582158cb-80f3-483c-a619-11ca61c34955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d2ea0e7b-9796-4fe9-b1da-ecca6487e99f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_582158cb-80f3-483c-a619-11ca61c34955" xlink:to="loc_us-gaap_OperatingIncomeLoss_d2ea0e7b-9796-4fe9-b1da-ecca6487e99f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_72a9cca8-87e9-48e4-b9c4-56a4e80cfdc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_582158cb-80f3-483c-a619-11ca61c34955" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_72a9cca8-87e9-48e4-b9c4-56a4e80cfdc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_67241cd0-19e8-4e08-a97c-024dbd169bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_94deddea-207c-4eec-8ee0-b3ad3e7e051d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_67241cd0-19e8-4e08-a97c-024dbd169bf6" xlink:to="loc_us-gaap_InterestExpense_94deddea-207c-4eec-8ee0-b3ad3e7e051d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_InterestIncomeAndOtherIncomeExpense_402b3b3b-f8a4-40ef-807f-629f89acde81" xlink:href="fhtx-20211231.xsd#fhtx_InterestIncomeAndOtherIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_67241cd0-19e8-4e08-a97c-024dbd169bf6" xlink:to="loc_fhtx_InterestIncomeAndOtherIncomeExpense_402b3b3b-f8a4-40ef-807f-629f89acde81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_d51cb3a4-2684-42b4-96b2-a8b689010636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_67241cd0-19e8-4e08-a97c-024dbd169bf6" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_d51cb3a4-2684-42b4-96b2-a8b689010636" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_674fa83d-ffb3-4a0c-93ce-01920140f6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_67241cd0-19e8-4e08-a97c-024dbd169bf6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_674fa83d-ffb3-4a0c-93ce-01920140f6e6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="fhtx-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b44efd45-31ad-4990-b1fd-e146323dcc92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_df770080-ab95-4b21-8864-6a884898a9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b44efd45-31ad-4990-b1fd-e146323dcc92" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_df770080-ab95-4b21-8864-6a884898a9a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6bf43822-02fd-4a9e-81c9-5a215402c8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b44efd45-31ad-4990-b1fd-e146323dcc92" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6bf43822-02fd-4a9e-81c9-5a215402c8c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_73030c47-d91a-44fd-a3c5-95a8b67cfad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b44efd45-31ad-4990-b1fd-e146323dcc92" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_73030c47-d91a-44fd-a3c5-95a8b67cfad7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_2db79107-41d9-4776-8f0d-4c275929f7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b44efd45-31ad-4990-b1fd-e146323dcc92" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_2db79107-41d9-4776-8f0d-4c275929f7e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_9e873fb6-936f-4679-9539-2e9829e23dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b44efd45-31ad-4990-b1fd-e146323dcc92" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_9e873fb6-936f-4679-9539-2e9829e23dc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_ab816c86-a5e4-41eb-9634-b2873ee77794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b44efd45-31ad-4990-b1fd-e146323dcc92" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_ab816c86-a5e4-41eb-9634-b2873ee77794" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_6821ba03-c210-4b3c-b1c8-5d30ceb06745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31bfb600-f153-4af7-ac9b-3991e7932a99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_6821ba03-c210-4b3c-b1c8-5d30ceb06745" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_31bfb600-f153-4af7-ac9b-3991e7932a99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_931b3d0f-2614-4b07-bf4a-a88ed69262f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_6821ba03-c210-4b3c-b1c8-5d30ceb06745" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_931b3d0f-2614-4b07-bf4a-a88ed69262f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_efa18d96-7ade-41aa-a5ad-90368944e587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_6821ba03-c210-4b3c-b1c8-5d30ceb06745" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_efa18d96-7ade-41aa-a5ad-90368944e587" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc6192b2-dc45-4821-810e-6419b382dd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_552b45b3-5af9-4813-a2cd-89114864825d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc6192b2-dc45-4821-810e-6419b382dd5b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_552b45b3-5af9-4813-a2cd-89114864825d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_53bd6c8d-7634-4b39-96f9-2e447d1eafca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc6192b2-dc45-4821-810e-6419b382dd5b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_53bd6c8d-7634-4b39-96f9-2e447d1eafca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3dfcd0a2-880d-42d4-85d9-bad97175b912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc6192b2-dc45-4821-810e-6419b382dd5b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3dfcd0a2-880d-42d4-85d9-bad97175b912" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_IncreaseDecreaseInOperatingLeaseLiabilities_1f07f5b7-6b00-459a-a7cb-a9be06a210d5" xlink:href="fhtx-20211231.xsd#fhtx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc6192b2-dc45-4821-810e-6419b382dd5b" xlink:to="loc_fhtx_IncreaseDecreaseInOperatingLeaseLiabilities_1f07f5b7-6b00-459a-a7cb-a9be06a210d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_cc0b3d7d-cf11-4407-a166-4a89713b7b00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc6192b2-dc45-4821-810e-6419b382dd5b" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_cc0b3d7d-cf11-4407-a166-4a89713b7b00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b2d12e22-00e0-4d3b-8601-6ce1f7d934b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc6192b2-dc45-4821-810e-6419b382dd5b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b2d12e22-00e0-4d3b-8601-6ce1f7d934b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_a85a95cd-785f-4ef6-b54b-92866becee26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc6192b2-dc45-4821-810e-6419b382dd5b" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_a85a95cd-785f-4ef6-b54b-92866becee26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_85110c52-f14e-42b7-a786-e61ba7804f53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc6192b2-dc45-4821-810e-6419b382dd5b" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_85110c52-f14e-42b7-a786-e61ba7804f53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_ac60e59b-8800-4a46-b435-1198e61a3595" xlink:href="fhtx-20211231.xsd#fhtx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc6192b2-dc45-4821-810e-6419b382dd5b" xlink:to="loc_fhtx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_ac60e59b-8800-4a46-b435-1198e61a3595" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_a5d8cdb4-1a4b-489e-9235-e7b990146a85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc6192b2-dc45-4821-810e-6419b382dd5b" xlink:to="loc_us-gaap_PaidInKindInterest_a5d8cdb4-1a4b-489e-9235-e7b990146a85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionPlanExpense_7b3ed2bd-da79-4df0-ac3d-80e4ef5bead5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionPlanExpense"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc6192b2-dc45-4821-810e-6419b382dd5b" xlink:to="loc_us-gaap_StockOptionPlanExpense_7b3ed2bd-da79-4df0-ac3d-80e4ef5bead5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3350b037-6ac9-4b1a-9cff-d91acf4506ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc6192b2-dc45-4821-810e-6419b382dd5b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3350b037-6ac9-4b1a-9cff-d91acf4506ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_7881579a-6582-4e0f-9f22-a1b740ebc0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc6192b2-dc45-4821-810e-6419b382dd5b" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_7881579a-6582-4e0f-9f22-a1b740ebc0dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_092d4fc6-d4a3-4a6c-bb24-be9b34a20526" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc6192b2-dc45-4821-810e-6419b382dd5b" xlink:to="loc_us-gaap_NetIncomeLoss_092d4fc6-d4a3-4a6c-bb24-be9b34a20526" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_7a188a7c-d878-4eed-850d-9217d832d84b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bc6192b2-dc45-4821-810e-6419b382dd5b" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_7a188a7c-d878-4eed-850d-9217d832d84b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f73425f8-e376-4908-8da7-b5cf867fc1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9c38a5c2-bc98-4edf-befd-02d531f2bbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f73425f8-e376-4908-8da7-b5cf867fc1d5" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9c38a5c2-bc98-4edf-befd-02d531f2bbd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_3a68df6d-26a3-4d29-b442-2f6b964a840a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f73425f8-e376-4908-8da7-b5cf867fc1d5" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_3a68df6d-26a3-4d29-b442-2f6b964a840a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_9d82410e-71be-401d-a060-2330027ace8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f73425f8-e376-4908-8da7-b5cf867fc1d5" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_9d82410e-71be-401d-a060-2330027ace8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_3e3206ca-3e83-4d78-98cf-2685fb145382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f73425f8-e376-4908-8da7-b5cf867fc1d5" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_3e3206ca-3e83-4d78-98cf-2685fb145382" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fe4aa9ca-7180-48b4-a55d-365b2c1a11ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalents_e045ef42-bc00-4cdf-957a-b400117fffb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fe4aa9ca-7180-48b4-a55d-365b2c1a11ef" xlink:to="loc_us-gaap_RestrictedCashEquivalents_e045ef42-bc00-4cdf-957a-b400117fffb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43e4cc38-f50e-42f1-a523-a1d1d593cd37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fe4aa9ca-7180-48b4-a55d-365b2c1a11ef" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43e4cc38-f50e-42f1-a523-a1d1d593cd37" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails"/>
  <link:calculationLink xlink:role="http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_665882bb-59d8-47fa-8dbc-f49ba8cbeffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d8044671-4555-46d2-bf12-043dd35e220b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_665882bb-59d8-47fa-8dbc-f49ba8cbeffe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d8044671-4555-46d2-bf12-043dd35e220b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_88b3f2df-9641-4aad-924d-39e8fd2d6715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_665882bb-59d8-47fa-8dbc-f49ba8cbeffe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_88b3f2df-9641-4aad-924d-39e8fd2d6715" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_30f9d63a-2820-443b-9d59-da0a2e500a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_665882bb-59d8-47fa-8dbc-f49ba8cbeffe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_30f9d63a-2820-443b-9d59-da0a2e500a8a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_feb43de9-9fba-4ce6-8c20-26fe56fdcae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0ec637dc-0c70-41cc-9a1b-f6642cc0f968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_feb43de9-9fba-4ce6-8c20-26fe56fdcae5" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0ec637dc-0c70-41cc-9a1b-f6642cc0f968" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_435e57f4-a731-40c2-9259-3be367939da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_feb43de9-9fba-4ce6-8c20-26fe56fdcae5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_435e57f4-a731-40c2-9259-3be367939da9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_78fbc6a0-0879-46c7-9371-5aad3161bf43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_6ebc245e-712a-4ad6-9294-9f700c7c1236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_78fbc6a0-0879-46c7-9371-5aad3161bf43" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_6ebc245e-712a-4ad6-9294-9f700c7c1236" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_3c208e66-5633-431f-8a9e-9b8e2fc8f375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_78fbc6a0-0879-46c7-9371-5aad3161bf43" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_3c208e66-5633-431f-8a9e-9b8e2fc8f375" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.foghorntx.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6f392c71-0a34-4c21-999e-d86bb5a19892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5ac55004-95f5-463f-bf5e-3030051babcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6f392c71-0a34-4c21-999e-d86bb5a19892" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5ac55004-95f5-463f-bf5e-3030051babcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_AccruedTenantImprovements_494c458d-cec3-4dac-99a6-e39398f6dc99" xlink:href="fhtx-20211231.xsd#fhtx_AccruedTenantImprovements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6f392c71-0a34-4c21-999e-d86bb5a19892" xlink:to="loc_fhtx_AccruedTenantImprovements_494c458d-cec3-4dac-99a6-e39398f6dc99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_AccruedResearchAndDevelopmentExpenses_fe53935d-60aa-4c9c-83e1-2508d2194a35" xlink:href="fhtx-20211231.xsd#fhtx_AccruedResearchAndDevelopmentExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6f392c71-0a34-4c21-999e-d86bb5a19892" xlink:to="loc_fhtx_AccruedResearchAndDevelopmentExpenses_fe53935d-60aa-4c9c-83e1-2508d2194a35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_45c97468-b8cb-46e9-a658-19ac1ad6a255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6f392c71-0a34-4c21-999e-d86bb5a19892" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_45c97468-b8cb-46e9-a658-19ac1ad6a255" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_c07ae5d4-3a35-4a78-bfae-3bb9cdeffb17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_6f392c71-0a34-4c21-999e-d86bb5a19892" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_c07ae5d4-3a35-4a78-bfae-3bb9cdeffb17" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#NotesPayableSummaryofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_33045c36-ed01-4fa7-9335-6baead71897f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_e1b77518-8508-4f7e-9a27-1c6fa505d65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_33045c36-ed01-4fa7-9335-6baead71897f" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_e1b77518-8508-4f7e-9a27-1c6fa505d65e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_c2642def-0d39-4d62-9815-0002af7be0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_33045c36-ed01-4fa7-9335-6baead71897f" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_c2642def-0d39-4d62-9815-0002af7be0a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_71b0f7e1-2928-40a1-bce4-1edab6c2fac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_33045c36-ed01-4fa7-9335-6baead71897f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_71b0f7e1-2928-40a1-bce4-1edab6c2fac8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_efe9e21d-4cb9-44ab-a0da-0fb36676311b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_3dd34e18-563e-4b88-8824-d69e77f8ff81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_efe9e21d-4cb9-44ab-a0da-0fb36676311b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_3dd34e18-563e-4b88-8824-d69e77f8ff81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7dc4132f-42ac-4afd-bc08-ad2fa454fd22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_efe9e21d-4cb9-44ab-a0da-0fb36676311b" xlink:to="loc_us-gaap_LongTermDebtCurrent_7dc4132f-42ac-4afd-bc08-ad2fa454fd22" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_368f9069-dedd-47e1-a41a-204df36c94f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_59f855b9-04f1-496f-bb6d-4410cc6632dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_368f9069-dedd-47e1-a41a-204df36c94f1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_59f855b9-04f1-496f-bb6d-4410cc6632dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_9378f67c-48ae-4b5f-94ec-a29397cbec4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_368f9069-dedd-47e1-a41a-204df36c94f1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_9378f67c-48ae-4b5f-94ec-a29397cbec4b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/IncomeTaxesSummaryofReconciliationoftheUSfederalstatutoryincometaxratetotheCompanyseffectiveincometaxrateDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#IncomeTaxesSummaryofReconciliationoftheUSfederalstatutoryincometaxratetotheCompanyseffectiveincometaxrateDetails"/>
  <link:calculationLink xlink:role="http://www.foghorntx.com/role/IncomeTaxesSummaryofReconciliationoftheUSfederalstatutoryincometaxratetotheCompanyseffectiveincometaxrateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a192c2b6-b3e5-4c36-a21e-8d5a975d63fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2bc195cf-a529-4fe6-82a7-828087adb141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a192c2b6-b3e5-4c36-a21e-8d5a975d63fa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2bc195cf-a529-4fe6-82a7-828087adb141" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4210b646-23f4-453f-bc81-2af774ebe666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a192c2b6-b3e5-4c36-a21e-8d5a975d63fa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4210b646-23f4-453f-bc81-2af774ebe666" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8b59dcb2-a19e-4893-9547-568c60260e54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a192c2b6-b3e5-4c36-a21e-8d5a975d63fa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8b59dcb2-a19e-4893-9547-568c60260e54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_a4c98a19-bc06-4760-be88-f9fd3ae3732f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a192c2b6-b3e5-4c36-a21e-8d5a975d63fa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_a4c98a19-bc06-4760-be88-f9fd3ae3732f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_6c04620a-804e-4196-b75d-bf1cdbf57c41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a192c2b6-b3e5-4c36-a21e-8d5a975d63fa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_6c04620a-804e-4196-b75d-bf1cdbf57c41" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#IncomeTaxesSummaryofNetDeferredTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_01dc623c-85d8-41c7-b8b2-5517457b42b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b1a0bc43-a62c-44f6-a686-1ef092ba50c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_01dc623c-85d8-41c7-b8b2-5517457b42b9" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b1a0bc43-a62c-44f6-a686-1ef092ba50c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2c51b287-2e50-45d7-a875-6739e02ef411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_01dc623c-85d8-41c7-b8b2-5517457b42b9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2c51b287-2e50-45d7-a875-6739e02ef411" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_DeferredTaxAssetsCapitalizedStartUpCosts_f9d5cebc-3aa6-4711-a1f8-f9f3e821df2f" xlink:href="fhtx-20211231.xsd#fhtx_DeferredTaxAssetsCapitalizedStartUpCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_01dc623c-85d8-41c7-b8b2-5517457b42b9" xlink:to="loc_fhtx_DeferredTaxAssetsCapitalizedStartUpCosts_f9d5cebc-3aa6-4711-a1f8-f9f3e821df2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_3b16da2a-31ec-4d44-94b5-35f30034d679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_01dc623c-85d8-41c7-b8b2-5517457b42b9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_3b16da2a-31ec-4d44-94b5-35f30034d679" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_d4eae74a-d04c-4be3-94d5-d2d26549dced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_01dc623c-85d8-41c7-b8b2-5517457b42b9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_d4eae74a-d04c-4be3-94d5-d2d26549dced" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_DeferredTaxAssetsOperatingLeaseLiabilities_b26e062b-25e9-4664-bebc-8463cb83e737" xlink:href="fhtx-20211231.xsd#fhtx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_01dc623c-85d8-41c7-b8b2-5517457b42b9" xlink:to="loc_fhtx_DeferredTaxAssetsOperatingLeaseLiabilities_b26e062b-25e9-4664-bebc-8463cb83e737" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_dd9f2bde-c176-47cb-b56a-dc489004744a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_7edaa156-b964-4c8c-ab78-530fc84504b3" xlink:href="fhtx-20211231.xsd#fhtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_dd9f2bde-c176-47cb-b56a-dc489004744a" xlink:to="loc_fhtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_7edaa156-b964-4c8c-ab78-530fc84504b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_DeferredTaxLiabilitiesDepreciation_0b228d3d-657f-4f77-a574-bc07caa7da82" xlink:href="fhtx-20211231.xsd#fhtx_DeferredTaxLiabilitiesDepreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_dd9f2bde-c176-47cb-b56a-dc489004744a" xlink:to="loc_fhtx_DeferredTaxLiabilitiesDepreciation_0b228d3d-657f-4f77-a574-bc07caa7da82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_a413a0c3-fe6f-41c4-9896-0ad87406e25a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_21b4c5b7-b131-416c-8a5e-6d39c02d8444" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_a413a0c3-fe6f-41c4-9896-0ad87406e25a" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_21b4c5b7-b131-416c-8a5e-6d39c02d8444" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_a056a52c-e85a-48b0-9f24-10c65223be7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_a413a0c3-fe6f-41c4-9896-0ad87406e25a" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_a056a52c-e85a-48b0-9f24-10c65223be7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_23e11b5f-86c3-4c23-a6c1-86bdb775735a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_a413a0c3-fe6f-41c4-9896-0ad87406e25a" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_23e11b5f-86c3-4c23-a6c1-86bdb775735a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#LeasesSummaryofLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_0d4cfcaa-59e3-4ea5-a621-5c0fdf4d2d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_8fa0b74c-2e4a-4f0a-95a9-51d7dd40e410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0d4cfcaa-59e3-4ea5-a621-5c0fdf4d2d16" xlink:to="loc_us-gaap_OperatingLeaseCost_8fa0b74c-2e4a-4f0a-95a9-51d7dd40e410" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_b1b885d3-ead6-4f30-bcab-aeb9e8c2e6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0d4cfcaa-59e3-4ea5-a621-5c0fdf4d2d16" xlink:to="loc_us-gaap_VariableLeaseCost_b1b885d3-ead6-4f30-bcab-aeb9e8c2e6e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_fd54be61-febb-448c-93c4-432f2f281a64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0d4cfcaa-59e3-4ea5-a621-5c0fdf4d2d16" xlink:to="loc_us-gaap_ShortTermLeaseCost_fd54be61-febb-448c-93c4-432f2f281a64" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#LeasesSummaryofMinimumLeasePaymentDetails"/>
  <link:calculationLink xlink:role="http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_aec45a47-9e6c-489a-b5d7-530b97a44e07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4b24dd77-f2cd-4283-88a4-85dda791a436" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_aec45a47-9e6c-489a-b5d7-530b97a44e07" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4b24dd77-f2cd-4283-88a4-85dda791a436" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_54e1325e-0826-4fdc-a654-02d248900f41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_aec45a47-9e6c-489a-b5d7-530b97a44e07" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_54e1325e-0826-4fdc-a654-02d248900f41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_23bf3419-3e44-48c3-aadd-3f5f92e94643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_aec45a47-9e6c-489a-b5d7-530b97a44e07" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_23bf3419-3e44-48c3-aadd-3f5f92e94643" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4fd87491-57f6-4b99-afff-57827941ea14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_aec45a47-9e6c-489a-b5d7-530b97a44e07" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4fd87491-57f6-4b99-afff-57827941ea14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e6e787a7-1b16-41da-b71f-c08c9652a10b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_aec45a47-9e6c-489a-b5d7-530b97a44e07" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e6e787a7-1b16-41da-b71f-c08c9652a10b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e526472c-2ab4-43f0-baec-b88de030344e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_aec45a47-9e6c-489a-b5d7-530b97a44e07" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e526472c-2ab4-43f0-baec-b88de030344e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails_1" xlink:type="simple" xlink:href="fhtx-20211231.xsd#LeasesSummaryofMinimumLeasePaymentDetails_1"/>
  <link:calculationLink xlink:role="http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b67d574c-89db-4a7d-a7eb-473e698bc793" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives_78185b19-54b6-457c-b2ef-543ed0dea195" xlink:href="fhtx-20211231.xsd#fhtx_LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b67d574c-89db-4a7d-a7eb-473e698bc793" xlink:to="loc_fhtx_LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives_78185b19-54b6-457c-b2ef-543ed0dea195" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bba41958-1848-4f9f-9600-4973fe5ca295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b67d574c-89db-4a7d-a7eb-473e698bc793" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bba41958-1848-4f9f-9600-4973fe5ca295" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b364cca4-f341-4e16-aaab-4a95b3fcb25d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b67d574c-89db-4a7d-a7eb-473e698bc793" xlink:to="loc_us-gaap_OperatingLeaseLiability_b364cca4-f341-4e16-aaab-4a95b3fcb25d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/LeasesSummaryofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#LeasesSummaryofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.foghorntx.com/role/LeasesSummaryofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6f612d5c-8490-4436-af55-220b43d0cb09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_11a1ad65-aafc-479f-82e0-3df0ccb94c80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_6f612d5c-8490-4436-af55-220b43d0cb09" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_11a1ad65-aafc-479f-82e0-3df0ccb94c80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5a60d17d-06a5-4593-b573-b256e46e0595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_6f612d5c-8490-4436-af55-220b43d0cb09" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5a60d17d-06a5-4593-b573-b256e46e0595" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>fhtx-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:45bd6193-dace-4c5a-b62d-c265e68fd1cf,g:2c36ac82-298b-41b7-8200-caa9bbc65128-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" xlink:type="simple" xlink:href="fhtx-20211231.xsd#ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" xlink:type="extended" id="ie0ad29cb3bed4396bea5e2bdb06df196_ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2a7cb4d3-ff76-48d7-8b84-a5912cb78e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_e23ce7be-45c0-4e1c-83e5-6166aa98b441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2a7cb4d3-ff76-48d7-8b84-a5912cb78e4f" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_e23ce7be-45c0-4e1c-83e5-6166aa98b441" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_8ce0b49d-b83e-41f9-8b42-0faacff7e0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_e23ce7be-45c0-4e1c-83e5-6166aa98b441" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_8ce0b49d-b83e-41f9-8b42-0faacff7e0f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_7c7a1276-c06d-4002-83d6-79d78a3b0219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_e23ce7be-45c0-4e1c-83e5-6166aa98b441" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_7c7a1276-c06d-4002-83d6-79d78a3b0219" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_e5ebf372-012a-483e-a54f-e94523b702fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_e23ce7be-45c0-4e1c-83e5-6166aa98b441" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_e5ebf372-012a-483e-a54f-e94523b702fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_ea72ee40-608b-4ef8-9174-1f33f883cbd3" xlink:href="fhtx-20211231.xsd#fhtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_e23ce7be-45c0-4e1c-83e5-6166aa98b441" xlink:to="loc_fhtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_ea72ee40-608b-4ef8-9174-1f33f883cbd3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_TemporaryEquityConversionOfStockAmountConverted_b79ecf48-0671-4d5d-972c-f5ce7246e101" xlink:href="fhtx-20211231.xsd#fhtx_TemporaryEquityConversionOfStockAmountConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_e23ce7be-45c0-4e1c-83e5-6166aa98b441" xlink:to="loc_fhtx_TemporaryEquityConversionOfStockAmountConverted_b79ecf48-0671-4d5d-972c-f5ce7246e101" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_TemporaryEquityConversionOfStockSharesConverted_1dd13190-3def-4d5a-a856-676b868349a8" xlink:href="fhtx-20211231.xsd#fhtx_TemporaryEquityConversionOfStockSharesConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_e23ce7be-45c0-4e1c-83e5-6166aa98b441" xlink:to="loc_fhtx_TemporaryEquityConversionOfStockSharesConverted_1dd13190-3def-4d5a-a856-676b868349a8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_ab015854-7969-4c96-b305-5654eacaa4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_cb74e748-eb0a-4d3b-8ce6-b47bbee0a313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2a7cb4d3-ff76-48d7-8b84-a5912cb78e4f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_73de022d-4162-4d60-a822-a51660c1d7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_StockholdersEquity_73de022d-4162-4d60-a822-a51660c1d7d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1e85f689-a235-48c9-a051-c0015f5091b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1e85f689-a235-48c9-a051-c0015f5091b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1d2a816b-50a2-4836-bebf-075f74da1235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1d2a816b-50a2-4836-bebf-075f74da1235" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_2002cc84-e605-4c75-8397-1d7fc0bae122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_2002cc84-e605-4c75-8397-1d7fc0bae122" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3b8ba3b5-5702-4b3f-b735-c3707533b695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3b8ba3b5-5702-4b3f-b735-c3707533b695" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52a94a96-3ae0-4132-9f03-cf3a0f63187d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52a94a96-3ae0-4132-9f03-cf3a0f63187d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_42a054eb-5043-412f-94ca-2a8a7a1bc191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_42a054eb-5043-412f-94ca-2a8a7a1bc191" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_StockIssuedDuringPeriodConnectionWithExerciseOfWarrant_87e7de04-c0a1-4a7d-a14c-3e31194e2cd5" xlink:href="fhtx-20211231.xsd#fhtx_StockIssuedDuringPeriodConnectionWithExerciseOfWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_fhtx_StockIssuedDuringPeriodConnectionWithExerciseOfWarrant_87e7de04-c0a1-4a7d-a14c-3e31194e2cd5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_180b674c-d33e-4d85-98b8-19ac37cd6dea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_180b674c-d33e-4d85-98b8-19ac37cd6dea" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_995b5df0-c9a3-4ce4-8907-4022703bb8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_995b5df0-c9a3-4ce4-8907-4022703bb8b9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_4053252f-e5da-483f-ad2c-a48df048f1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_4053252f-e5da-483f-ad2c-a48df048f1a1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_6a2951da-b218-48be-82e5-bad19c99bc82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_6a2951da-b218-48be-82e5-bad19c99bc82" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_20b508ee-aad2-4c8f-a5a4-04ab526ff0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_20b508ee-aad2-4c8f-a5a4-04ab526ff0d8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_13d3ba33-7024-4c29-b985-47a088ac4897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_13d3ba33-7024-4c29-b985-47a088ac4897" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_be54d869-e8e5-40cb-8cff-61174e515cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_NetIncomeLoss_be54d869-e8e5-40cb-8cff-61174e515cb1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_79a60050-44f9-4147-8287-cf07df2eef0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a1ca44c9-c0a1-4b39-88e4-bb280945ca47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8fb673e2-70c5-49a0-8f23-3a70ccaf254b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2a7cb4d3-ff76-48d7-8b84-a5912cb78e4f" xlink:to="loc_us-gaap_StatementTable_8fb673e2-70c5-49a0-8f23-3a70ccaf254b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f1cf6721-310d-4fea-bdc0-af237da417c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8fb673e2-70c5-49a0-8f23-3a70ccaf254b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f1cf6721-310d-4fea-bdc0-af237da417c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f1cf6721-310d-4fea-bdc0-af237da417c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f1cf6721-310d-4fea-bdc0-af237da417c8" xlink:to="loc_us-gaap_ClassOfStockDomain_f1cf6721-310d-4fea-bdc0-af237da417c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f11036a1-929a-424a-9c9a-0148d6ee0d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f1cf6721-310d-4fea-bdc0-af237da417c8" xlink:to="loc_us-gaap_ClassOfStockDomain_f11036a1-929a-424a-9c9a-0148d6ee0d5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_1e20d97f-0960-4405-8c7b-ccf5f8f658e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f11036a1-929a-424a-9c9a-0148d6ee0d5f" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_1e20d97f-0960-4405-8c7b-ccf5f8f658e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b43dc616-d2f0-4086-a825-2ebbf88dd1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8fb673e2-70c5-49a0-8f23-3a70ccaf254b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b43dc616-d2f0-4086-a825-2ebbf88dd1bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b43dc616-d2f0-4086-a825-2ebbf88dd1bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b43dc616-d2f0-4086-a825-2ebbf88dd1bb" xlink:to="loc_us-gaap_EquityComponentDomain_b43dc616-d2f0-4086-a825-2ebbf88dd1bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b5c7bb20-7e91-4f74-aaf3-d9429a66e9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b43dc616-d2f0-4086-a825-2ebbf88dd1bb" xlink:to="loc_us-gaap_EquityComponentDomain_b5c7bb20-7e91-4f74-aaf3-d9429a66e9ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_8d04ef4f-7823-4875-9d70-20899deae9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b5c7bb20-7e91-4f74-aaf3-d9429a66e9ec" xlink:to="loc_us-gaap_PreferredStockMember_8d04ef4f-7823-4875-9d70-20899deae9fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5dd480e6-5e5e-49b9-8122-fa59f8c9c077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b5c7bb20-7e91-4f74-aaf3-d9429a66e9ec" xlink:to="loc_us-gaap_CommonStockMember_5dd480e6-5e5e-49b9-8122-fa59f8c9c077" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ee405ea3-25a9-4c88-aadc-7bcb1045c72d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b5c7bb20-7e91-4f74-aaf3-d9429a66e9ec" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ee405ea3-25a9-4c88-aadc-7bcb1045c72d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_679c581f-fc48-4f59-a9d1-d927eb548181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b5c7bb20-7e91-4f74-aaf3-d9429a66e9ec" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_679c581f-fc48-4f59-a9d1-d927eb548181" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e67e890c-de2c-4547-aa69-91193c3eb56b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b5c7bb20-7e91-4f74-aaf3-d9429a66e9ec" xlink:to="loc_us-gaap_RetainedEarningsMember_e67e890c-de2c-4547-aa69-91193c3eb56b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_309dd6af-108c-4ca2-a5d5-9293eb24f55d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8fb673e2-70c5-49a0-8f23-3a70ccaf254b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_309dd6af-108c-4ca2-a5d5-9293eb24f55d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_309dd6af-108c-4ca2-a5d5-9293eb24f55d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_309dd6af-108c-4ca2-a5d5-9293eb24f55d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_309dd6af-108c-4ca2-a5d5-9293eb24f55d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2bdda8e6-ec3a-4ab0-9e54-81b3cf860f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_309dd6af-108c-4ca2-a5d5-9293eb24f55d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2bdda8e6-ec3a-4ab0-9e54-81b3cf860f0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_6a4eb641-3dc0-4a18-b0bd-985626cbb4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2bdda8e6-ec3a-4ab0-9e54-81b3cf860f0a" xlink:to="loc_us-gaap_IPOMember_6a4eb641-3dc0-4a18-b0bd-985626cbb4c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_SharePurchaseAgreementMember_1d0b5a8a-6435-4225-8bec-80f53ec64c23" xlink:href="fhtx-20211231.xsd#fhtx_SharePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2bdda8e6-ec3a-4ab0-9e54-81b3cf860f0a" xlink:to="loc_fhtx_SharePurchaseAgreementMember_1d0b5a8a-6435-4225-8bec-80f53ec64c23" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityParenthetical" xlink:type="simple" xlink:href="fhtx-20211231.xsd#ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityParenthetical" xlink:type="extended" id="ia9ca5f85b30849018626e97977581bd6_ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e471e604-c906-4a99-968c-e6301f18068e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_StockIssuanceCosts_b5fef407-3138-4e7d-9efe-554f8f764be2" xlink:href="fhtx-20211231.xsd#fhtx_StockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e471e604-c906-4a99-968c-e6301f18068e" xlink:to="loc_fhtx_StockIssuanceCosts_b5fef407-3138-4e7d-9efe-554f8f764be2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5398e915-12aa-4589-9453-195e11b6ed85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e471e604-c906-4a99-968c-e6301f18068e" xlink:to="loc_us-gaap_StatementTable_5398e915-12aa-4589-9453-195e11b6ed85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2ae36f93-dcc0-483c-8d90-23d5948c3188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5398e915-12aa-4589-9453-195e11b6ed85" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2ae36f93-dcc0-483c-8d90-23d5948c3188" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2ae36f93-dcc0-483c-8d90-23d5948c3188_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2ae36f93-dcc0-483c-8d90-23d5948c3188" xlink:to="loc_us-gaap_ClassOfStockDomain_2ae36f93-dcc0-483c-8d90-23d5948c3188_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_69283a68-5ab5-415f-90d6-487781190f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2ae36f93-dcc0-483c-8d90-23d5948c3188" xlink:to="loc_us-gaap_ClassOfStockDomain_69283a68-5ab5-415f-90d6-487781190f38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_5a12e700-5aee-470e-9197-a1bba4c997d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_69283a68-5ab5-415f-90d6-487781190f38" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_5a12e700-5aee-470e-9197-a1bba4c997d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d4b01f59-25bc-4fec-8fa3-1c7a3850c297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5398e915-12aa-4589-9453-195e11b6ed85" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d4b01f59-25bc-4fec-8fa3-1c7a3850c297" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d4b01f59-25bc-4fec-8fa3-1c7a3850c297_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d4b01f59-25bc-4fec-8fa3-1c7a3850c297" xlink:to="loc_us-gaap_EquityComponentDomain_d4b01f59-25bc-4fec-8fa3-1c7a3850c297_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0e949d62-6b47-42a2-ab23-4082ed94281c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d4b01f59-25bc-4fec-8fa3-1c7a3850c297" xlink:to="loc_us-gaap_EquityComponentDomain_0e949d62-6b47-42a2-ab23-4082ed94281c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_9ad10652-ce0f-42a1-98d5-9837fb57363d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0e949d62-6b47-42a2-ab23-4082ed94281c" xlink:to="loc_us-gaap_PreferredStockMember_9ad10652-ce0f-42a1-98d5-9837fb57363d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="fhtx-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i5592451c242f4e9e8a59899d188dd3b5_ConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b89effec-0cf7-4c6c-9dff-13f57a2c174e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_52c253bc-8cf7-414c-b7b4-e251bf2fc7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b89effec-0cf7-4c6c-9dff-13f57a2c174e" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_52c253bc-8cf7-414c-b7b4-e251bf2fc7a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4ce37606-c903-4532-b84d-0888150ab225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_52c253bc-8cf7-414c-b7b4-e251bf2fc7a9" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4ce37606-c903-4532-b84d-0888150ab225" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_13dd4f10-16ab-42c9-a153-36ea5e0327b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_52c253bc-8cf7-414c-b7b4-e251bf2fc7a9" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_13dd4f10-16ab-42c9-a153-36ea5e0327b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_80605b5a-58b2-4146-9eaf-3c53135c7229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_52c253bc-8cf7-414c-b7b4-e251bf2fc7a9" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_80605b5a-58b2-4146-9eaf-3c53135c7229" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_598c3ff8-da59-4f9b-a24e-53828bceb0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b89effec-0cf7-4c6c-9dff-13f57a2c174e" xlink:to="loc_us-gaap_StatementTable_598c3ff8-da59-4f9b-a24e-53828bceb0ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_eb62142b-2635-44c7-9800-f4e36b0547a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_598c3ff8-da59-4f9b-a24e-53828bceb0ba" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_eb62142b-2635-44c7-9800-f4e36b0547a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_eb62142b-2635-44c7-9800-f4e36b0547a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_eb62142b-2635-44c7-9800-f4e36b0547a6" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_eb62142b-2635-44c7-9800-f4e36b0547a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_a12b8807-f08a-4e89-97b7-1377e97e754e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_eb62142b-2635-44c7-9800-f4e36b0547a6" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_a12b8807-f08a-4e89-97b7-1377e97e754e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ConversionOfRedeemableConvertibleStockMember_dc136949-812c-47ea-b77e-d3d2db970ba2" xlink:href="fhtx-20211231.xsd#fhtx_ConversionOfRedeemableConvertibleStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_a12b8807-f08a-4e89-97b7-1377e97e754e" xlink:to="loc_fhtx_ConversionOfRedeemableConvertibleStockMember_dc136949-812c-47ea-b77e-d3d2db970ba2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ConversionOfWarrantLiabilityToEquityMember_2c6b0096-32dd-46f8-a811-914a0cacf109" xlink:href="fhtx-20211231.xsd#fhtx_ConversionOfWarrantLiabilityToEquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_a12b8807-f08a-4e89-97b7-1377e97e754e" xlink:to="loc_fhtx_ConversionOfWarrantLiabilityToEquityMember_2c6b0096-32dd-46f8-a811-914a0cacf109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ConversionOfNotesPayableInToWarrantsMember_9d3b292e-a723-4bf2-a590-58d57c57f7ff" xlink:href="fhtx-20211231.xsd#fhtx_ConversionOfNotesPayableInToWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_a12b8807-f08a-4e89-97b7-1377e97e754e" xlink:to="loc_fhtx_ConversionOfNotesPayableInToWarrantsMember_9d3b292e-a723-4bf2-a590-58d57c57f7ff" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#NatureofBusinessandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="extended" id="i5b20fae49452473f893c964f9ade7209_NatureofBusinessandBasisofPresentationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_8a908cc9-123c-42c2-afe1-fc85cb72c859" xlink:href="fhtx-20211231.xsd#fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3510c762-a1ab-4a39-a79f-d5fe371c0a53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_8a908cc9-123c-42c2-afe1-fc85cb72c859" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3510c762-a1ab-4a39-a79f-d5fe371c0a53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1980a55b-c44c-4f1d-92b8-3d29b29aa095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_8a908cc9-123c-42c2-afe1-fc85cb72c859" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1980a55b-c44c-4f1d-92b8-3d29b29aa095" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3455fce7-2221-4dcb-9db1-f6e974294f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_8a908cc9-123c-42c2-afe1-fc85cb72c859" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3455fce7-2221-4dcb-9db1-f6e974294f3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ProceedsFromUpfrontPayment_d694815d-52c4-474d-948e-b80534cfb10b" xlink:href="fhtx-20211231.xsd#fhtx_ProceedsFromUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_8a908cc9-123c-42c2-afe1-fc85cb72c859" xlink:to="loc_fhtx_ProceedsFromUpfrontPayment_d694815d-52c4-474d-948e-b80534cfb10b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bb917782-7f43-458b-9b76-92aecfd02c60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_8a908cc9-123c-42c2-afe1-fc85cb72c859" xlink:to="loc_us-gaap_NetIncomeLoss_bb917782-7f43-458b-9b76-92aecfd02c60" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9a0894b6-3f9f-40a7-8ac4-8105c2d2a0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_8a908cc9-123c-42c2-afe1-fc85cb72c859" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9a0894b6-3f9f-40a7-8ac4-8105c2d2a0b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8aee1595-e2bd-4da1-8f90-0a34984184fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_8a908cc9-123c-42c2-afe1-fc85cb72c859" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8aee1595-e2bd-4da1-8f90-0a34984184fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_4bca8611-b176-45d7-bcaf-a6a34e85fe9d" xlink:href="fhtx-20211231.xsd#fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_8a908cc9-123c-42c2-afe1-fc85cb72c859" xlink:to="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_4bca8611-b176-45d7-bcaf-a6a34e85fe9d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f057a12a-21a0-43e2-9446-4233b5e63a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_4bca8611-b176-45d7-bcaf-a6a34e85fe9d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f057a12a-21a0-43e2-9446-4233b5e63a6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f057a12a-21a0-43e2-9446-4233b5e63a6b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f057a12a-21a0-43e2-9446-4233b5e63a6b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f057a12a-21a0-43e2-9446-4233b5e63a6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70dd820d-f974-468c-bcf4-07734f7cc91b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f057a12a-21a0-43e2-9446-4233b5e63a6b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70dd820d-f974-468c-bcf4-07734f7cc91b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_10083900-06d9-4c52-b364-ab84e069b3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70dd820d-f974-468c-bcf4-07734f7cc91b" xlink:to="loc_us-gaap_IPOMember_10083900-06d9-4c52-b364-ab84e069b3d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_30895fa8-d379-462c-9211-31ffe14ad1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70dd820d-f974-468c-bcf4-07734f7cc91b" xlink:to="loc_us-gaap_OverAllotmentOptionMember_30895fa8-d379-462c-9211-31ffe14ad1d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_SharePurchaseAgreementMember_c2f7843c-86be-4b09-a86a-330a60cae405" xlink:href="fhtx-20211231.xsd#fhtx_SharePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70dd820d-f974-468c-bcf4-07734f7cc91b" xlink:to="loc_fhtx_SharePurchaseAgreementMember_c2f7843c-86be-4b09-a86a-330a60cae405" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5a69ccd9-e0a9-440a-a6ca-e129e86c6bb4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_4bca8611-b176-45d7-bcaf-a6a34e85fe9d" xlink:to="loc_srt_CounterpartyNameAxis_5a69ccd9-e0a9-440a-a6ca-e129e86c6bb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5a69ccd9-e0a9-440a-a6ca-e129e86c6bb4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5a69ccd9-e0a9-440a-a6ca-e129e86c6bb4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5a69ccd9-e0a9-440a-a6ca-e129e86c6bb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6afc8c02-1aff-40a4-942f-c82ec9bf89b5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5a69ccd9-e0a9-440a-a6ca-e129e86c6bb4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6afc8c02-1aff-40a4-942f-c82ec9bf89b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_EliLillyMember_2b7a619c-0f3d-4db7-acbd-a49518ce2156" xlink:href="fhtx-20211231.xsd#fhtx_EliLillyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6afc8c02-1aff-40a4-942f-c82ec9bf89b5" xlink:to="loc_fhtx_EliLillyMember_2b7a619c-0f3d-4db7-acbd-a49518ce2156" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_90ad5583-b950-40d3-bff4-3b88b8f0256f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_4bca8611-b176-45d7-bcaf-a6a34e85fe9d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_90ad5583-b950-40d3-bff4-3b88b8f0256f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_90ad5583-b950-40d3-bff4-3b88b8f0256f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_90ad5583-b950-40d3-bff4-3b88b8f0256f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_90ad5583-b950-40d3-bff4-3b88b8f0256f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e35d29c8-759e-4079-89b8-cc003dc1ede7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_90ad5583-b950-40d3-bff4-3b88b8f0256f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e35d29c8-759e-4079-89b8-cc003dc1ede7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_cfe1356d-f835-416d-8b64-878e9fa6791e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e35d29c8-759e-4079-89b8-cc003dc1ede7" xlink:to="loc_us-gaap_SubsequentEventMember_cfe1356d-f835-416d-8b64-878e9fa6791e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4e48e4a0-9f83-4f7c-8601-70a1f1b15298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_4bca8611-b176-45d7-bcaf-a6a34e85fe9d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4e48e4a0-9f83-4f7c-8601-70a1f1b15298" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4e48e4a0-9f83-4f7c-8601-70a1f1b15298_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4e48e4a0-9f83-4f7c-8601-70a1f1b15298" xlink:to="loc_us-gaap_ClassOfStockDomain_4e48e4a0-9f83-4f7c-8601-70a1f1b15298_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bd8afcf8-5eaa-47a9-a577-200a5b33be10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4e48e4a0-9f83-4f7c-8601-70a1f1b15298" xlink:to="loc_us-gaap_ClassOfStockDomain_bd8afcf8-5eaa-47a9-a577-200a5b33be10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2260486b-4849-4c3b-bdd1-87546c1394df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bd8afcf8-5eaa-47a9-a577-200a5b33be10" xlink:to="loc_us-gaap_CommonStockMember_2260486b-4849-4c3b-bdd1-87546c1394df" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="i4ae1b56f9aa4458da3c216536e636904_SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_fca7b502-3c37-45cd-be0f-166ff2377d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_NumberOfCollaborativeAgreements_6fdfb53c-01c6-4cf2-984d-7d1c51a6ad22" xlink:href="fhtx-20211231.xsd#fhtx_NumberOfCollaborativeAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fca7b502-3c37-45cd-be0f-166ff2377d98" xlink:to="loc_fhtx_NumberOfCollaborativeAgreements_6fdfb53c-01c6-4cf2-984d-7d1c51a6ad22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_0bb25872-9e5d-4d9a-ba45-22487f68f9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fca7b502-3c37-45cd-be0f-166ff2377d98" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_0bb25872-9e5d-4d9a-ba45-22487f68f9f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cb8c0289-a6ab-4d2f-92a9-e055416a1483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fca7b502-3c37-45cd-be0f-166ff2377d98" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cb8c0289-a6ab-4d2f-92a9-e055416a1483" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8681ace6-c79c-4dba-8eb7-f1a8b43d050f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cb8c0289-a6ab-4d2f-92a9-e055416a1483" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8681ace6-c79c-4dba-8eb7-f1a8b43d050f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8681ace6-c79c-4dba-8eb7-f1a8b43d050f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8681ace6-c79c-4dba-8eb7-f1a8b43d050f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8681ace6-c79c-4dba-8eb7-f1a8b43d050f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11d949f5-15d1-4331-b14d-6bb620427e09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8681ace6-c79c-4dba-8eb7-f1a8b43d050f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11d949f5-15d1-4331-b14d-6bb620427e09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_6bd2874f-592a-42e7-b6fb-f95c78abd51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11d949f5-15d1-4331-b14d-6bb620427e09" xlink:to="loc_us-gaap_IPOMember_6bd2874f-592a-42e7-b6fb-f95c78abd51d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAmortizationDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#SummaryofSignificantAccountingPoliciesSummaryofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAmortizationDetails"/>
  <link:definitionLink xlink:role="http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAmortizationDetails" xlink:type="extended" id="i7d1df9d4fc9a47b99985133563272940_SummaryofSignificantAccountingPoliciesSummaryofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAmortizationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61336ca5-695b-4f6a-83cc-5c16f96eaad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6ad245b9-155b-4b5b-9e1c-b2602953c38a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61336ca5-695b-4f6a-83cc-5c16f96eaad3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6ad245b9-155b-4b5b-9e1c-b2602953c38a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0153276a-fe53-4702-b410-fc76465d448c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61336ca5-695b-4f6a-83cc-5c16f96eaad3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0153276a-fe53-4702-b410-fc76465d448c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce3338c6-d26c-4171-a269-d6a36a81d882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0153276a-fe53-4702-b410-fc76465d448c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce3338c6-d26c-4171-a269-d6a36a81d882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce3338c6-d26c-4171-a269-d6a36a81d882_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce3338c6-d26c-4171-a269-d6a36a81d882" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ce3338c6-d26c-4171-a269-d6a36a81d882_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96d17fb9-0b36-44c1-8abd-d9c64a267a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce3338c6-d26c-4171-a269-d6a36a81d882" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96d17fb9-0b36-44c1-8abd-d9c64a267a63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_87e5be24-b4ff-496e-99af-07d49de56dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96d17fb9-0b36-44c1-8abd-d9c64a267a63" xlink:to="loc_us-gaap_EquipmentMember_87e5be24-b4ff-496e-99af-07d49de56dfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_9a581a97-bdd3-40dc-a21a-96018a20b420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96d17fb9-0b36-44c1-8abd-d9c64a267a63" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_9a581a97-bdd3-40dc-a21a-96018a20b420" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_ddb0f8bb-e16a-49ea-980a-e848db7a7884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96d17fb9-0b36-44c1-8abd-d9c64a267a63" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_ddb0f8bb-e16a-49ea-980a-e848db7a7884" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofEarningsPerShareDilutedAntiDilutiveImpactDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#SummaryofSignificantAccountingPoliciesSummaryofEarningsPerShareDilutedAntiDilutiveImpactDetails"/>
  <link:definitionLink xlink:role="http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofEarningsPerShareDilutedAntiDilutiveImpactDetails" xlink:type="extended" id="ie1e3ffd4b4fd4a65a54fddd6607a0cf8_SummaryofSignificantAccountingPoliciesSummaryofEarningsPerShareDilutedAntiDilutiveImpactDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5148b785-0bb4-4daf-8163-54232ae6f13f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_353e3c80-acbc-456d-a6d6-c093220f8040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5148b785-0bb4-4daf-8163-54232ae6f13f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_353e3c80-acbc-456d-a6d6-c093220f8040" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4674e55b-af91-491d-869f-980da471b288" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5148b785-0bb4-4daf-8163-54232ae6f13f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4674e55b-af91-491d-869f-980da471b288" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_57c9e50a-12a3-445a-9f00-df0180506fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4674e55b-af91-491d-869f-980da471b288" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_57c9e50a-12a3-445a-9f00-df0180506fa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_57c9e50a-12a3-445a-9f00-df0180506fa5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_57c9e50a-12a3-445a-9f00-df0180506fa5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_57c9e50a-12a3-445a-9f00-df0180506fa5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6b7317ba-aef3-40b0-8dc6-e5330e478d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_57c9e50a-12a3-445a-9f00-df0180506fa5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6b7317ba-aef3-40b0-8dc6-e5330e478d96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d309fcbd-d327-471a-b1e0-80df2efeeb02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6b7317ba-aef3-40b0-8dc6-e5330e478d96" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d309fcbd-d327-471a-b1e0-80df2efeeb02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_125cb60b-a89f-4a3c-a090-863755466d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6b7317ba-aef3-40b0-8dc6-e5330e478d96" xlink:to="loc_us-gaap_WarrantMember_125cb60b-a89f-4a3c-a090-863755466d7f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails"/>
  <link:definitionLink xlink:role="http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails" xlink:type="extended" id="i220b0664d30d4797a8d391a454855130_MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f4aea0ff-551d-476c-9817-ac5d99b18662" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cb292cc5-8ec3-40e0-af7d-10b040760e68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f4aea0ff-551d-476c-9817-ac5d99b18662" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cb292cc5-8ec3-40e0-af7d-10b040760e68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fbabbd4a-f6dd-4162-a105-1fbe355231ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f4aea0ff-551d-476c-9817-ac5d99b18662" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fbabbd4a-f6dd-4162-a105-1fbe355231ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4802495b-9504-4889-9bf1-4a9d600c8f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f4aea0ff-551d-476c-9817-ac5d99b18662" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4802495b-9504-4889-9bf1-4a9d600c8f3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7280bb7e-6fc4-4f28-ba2d-97021a6efe87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f4aea0ff-551d-476c-9817-ac5d99b18662" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7280bb7e-6fc4-4f28-ba2d-97021a6efe87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_05ed5563-f8a9-4f40-bb93-aee7adf50197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f4aea0ff-551d-476c-9817-ac5d99b18662" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_05ed5563-f8a9-4f40-bb93-aee7adf50197" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_01dc3691-1414-442a-9545-4772597ad52d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_05ed5563-f8a9-4f40-bb93-aee7adf50197" xlink:to="loc_us-gaap_InvestmentTypeAxis_01dc3691-1414-442a-9545-4772597ad52d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_01dc3691-1414-442a-9545-4772597ad52d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_01dc3691-1414-442a-9545-4772597ad52d" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_01dc3691-1414-442a-9545-4772597ad52d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_117daee2-6ab0-4b8c-9225-084500c0191f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_01dc3691-1414-442a-9545-4772597ad52d" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_117daee2-6ab0-4b8c-9225-084500c0191f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_50fd9933-81f9-4967-8943-96698e078e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_117daee2-6ab0-4b8c-9225-084500c0191f" xlink:to="loc_us-gaap_CommercialPaperMember_50fd9933-81f9-4967-8943-96698e078e1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7ff6b51f-9bf8-4a33-8e59-8c3471e5a891" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_117daee2-6ab0-4b8c-9225-084500c0191f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7ff6b51f-9bf8-4a33-8e59-8c3471e5a891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_f087ff16-d225-4fd9-bfe1-0af5f6fe7588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_117daee2-6ab0-4b8c-9225-084500c0191f" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_f087ff16-d225-4fd9-bfe1-0af5f6fe7588" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="ie248c6eb1e804d64a974d8f61bbda3e6_MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e44fdf6-ce9d-4680-b904-4539236d00b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a434efc0-c255-423d-8049-a06ed631338d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e44fdf6-ce9d-4680-b904-4539236d00b6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a434efc0-c255-423d-8049-a06ed631338d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b51a387e-dae5-47ec-8fe4-770ee5e11450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e44fdf6-ce9d-4680-b904-4539236d00b6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b51a387e-dae5-47ec-8fe4-770ee5e11450" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2a9c9c3c-cc33-442f-b970-ebc10343fe79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e44fdf6-ce9d-4680-b904-4539236d00b6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2a9c9c3c-cc33-442f-b970-ebc10343fe79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1ee4f02a-7e86-4c1e-a653-faec66aaf7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e44fdf6-ce9d-4680-b904-4539236d00b6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1ee4f02a-7e86-4c1e-a653-faec66aaf7fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2c42b832-8db7-4a84-a1e8-3b486801071a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1ee4f02a-7e86-4c1e-a653-faec66aaf7fd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2c42b832-8db7-4a84-a1e8-3b486801071a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2c42b832-8db7-4a84-a1e8-3b486801071a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2c42b832-8db7-4a84-a1e8-3b486801071a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2c42b832-8db7-4a84-a1e8-3b486801071a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d14bbff6-ef99-4e7a-b3e6-58f1dada9c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2c42b832-8db7-4a84-a1e8-3b486801071a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d14bbff6-ef99-4e7a-b3e6-58f1dada9c9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8400db33-cc8b-4537-8831-e9db57a4f8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d14bbff6-ef99-4e7a-b3e6-58f1dada9c9e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8400db33-cc8b-4537-8831-e9db57a4f8dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fc985286-61ce-4cb1-ab23-7739f65a7f77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1ee4f02a-7e86-4c1e-a653-faec66aaf7fd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fc985286-61ce-4cb1-ab23-7739f65a7f77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc985286-61ce-4cb1-ab23-7739f65a7f77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fc985286-61ce-4cb1-ab23-7739f65a7f77" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc985286-61ce-4cb1-ab23-7739f65a7f77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef337687-09f2-4cf3-a4f8-aef92a37d2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fc985286-61ce-4cb1-ab23-7739f65a7f77" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef337687-09f2-4cf3-a4f8-aef92a37d2a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6b7c1a13-9bf4-4730-a124-18879af57bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef337687-09f2-4cf3-a4f8-aef92a37d2a9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6b7c1a13-9bf4-4730-a124-18879af57bc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_cd60469a-47c7-4ac9-a75c-ba279811b935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef337687-09f2-4cf3-a4f8-aef92a37d2a9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_cd60469a-47c7-4ac9-a75c-ba279811b935" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_22bd034d-ccf1-45c4-89ae-5b224ca1c68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef337687-09f2-4cf3-a4f8-aef92a37d2a9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_22bd034d-ccf1-45c4-89ae-5b224ca1c68a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_dc4746b1-4e67-40d7-86ca-80832de583d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1ee4f02a-7e86-4c1e-a653-faec66aaf7fd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_dc4746b1-4e67-40d7-86ca-80832de583d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dc4746b1-4e67-40d7-86ca-80832de583d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_dc4746b1-4e67-40d7-86ca-80832de583d1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dc4746b1-4e67-40d7-86ca-80832de583d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_83ec3226-6742-4646-b827-ff0b28a04f03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_dc4746b1-4e67-40d7-86ca-80832de583d1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_83ec3226-6742-4646-b827-ff0b28a04f03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_a26a640e-82c7-44d8-831a-d2874ee15d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_83ec3226-6742-4646-b827-ff0b28a04f03" xlink:to="loc_us-gaap_MoneyMarketFundsMember_a26a640e-82c7-44d8-831a-d2874ee15d7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_ff200c15-f65d-48b6-8b79-a21e3bcfa3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_83ec3226-6742-4646-b827-ff0b28a04f03" xlink:to="loc_us-gaap_CommercialPaperMember_ff200c15-f65d-48b6-8b79-a21e3bcfa3f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_93b77ae7-9f75-4586-b809-6fb7ab80c557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_83ec3226-6742-4646-b827-ff0b28a04f03" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_93b77ae7-9f75-4586-b809-6fb7ab80c557" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1863b976-6acc-4f94-a4c5-01c6fd700246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1ee4f02a-7e86-4c1e-a653-faec66aaf7fd" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1863b976-6acc-4f94-a4c5-01c6fd700246" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1863b976-6acc-4f94-a4c5-01c6fd700246_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1863b976-6acc-4f94-a4c5-01c6fd700246" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1863b976-6acc-4f94-a4c5-01c6fd700246_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_822780a2-7045-4e3f-ac06-9c4daf0ff968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1863b976-6acc-4f94-a4c5-01c6fd700246" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_822780a2-7045-4e3f-ac06-9c4daf0ff968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_d688212c-3098-424f-a6cd-124462c29c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_822780a2-7045-4e3f-ac06-9c4daf0ff968" xlink:to="loc_us-gaap_CommercialPaperMember_d688212c-3098-424f-a6cd-124462c29c4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_372ff078-54e9-4eb9-851c-e73735073362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_822780a2-7045-4e3f-ac06-9c4daf0ff968" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_372ff078-54e9-4eb9-851c-e73735073362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a19ea075-ecb4-460f-8938-1cdd0cb34ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_822780a2-7045-4e3f-ac06-9c4daf0ff968" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a19ea075-ecb4-460f-8938-1cdd0cb34ad9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" xlink:type="extended" id="i8e38d4f2ce8d4a81957ac754e6334f82_PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0d9b512-23dc-4549-a8b3-b6590a21c006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_380d8306-1e71-495b-b46c-de7eaa40e410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0d9b512-23dc-4549-a8b3-b6590a21c006" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_380d8306-1e71-495b-b46c-de7eaa40e410" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_1e355565-7d6c-45df-b0c4-e8ae5dfe3c39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0d9b512-23dc-4549-a8b3-b6590a21c006" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_1e355565-7d6c-45df-b0c4-e8ae5dfe3c39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_247ce767-7781-47aa-bb95-9f59525e6c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0d9b512-23dc-4549-a8b3-b6590a21c006" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_247ce767-7781-47aa-bb95-9f59525e6c3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a6bc0e32-d551-4f52-88c4-610cdd17c313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0d9b512-23dc-4549-a8b3-b6590a21c006" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a6bc0e32-d551-4f52-88c4-610cdd17c313" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e0f8a998-80c1-4236-a023-52137cb7b0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a6bc0e32-d551-4f52-88c4-610cdd17c313" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e0f8a998-80c1-4236-a023-52137cb7b0f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e0f8a998-80c1-4236-a023-52137cb7b0f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e0f8a998-80c1-4236-a023-52137cb7b0f9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e0f8a998-80c1-4236-a023-52137cb7b0f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9acbd34e-ae51-4b58-9e73-2e50e17830bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e0f8a998-80c1-4236-a023-52137cb7b0f9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9acbd34e-ae51-4b58-9e73-2e50e17830bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_3e902381-fc74-4e3c-9849-ff048c62c23a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9acbd34e-ae51-4b58-9e73-2e50e17830bb" xlink:to="loc_us-gaap_EquipmentMember_3e902381-fc74-4e3c-9849-ff048c62c23a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_8897ae36-aed4-468b-b998-d4f01905db39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9acbd34e-ae51-4b58-9e73-2e50e17830bb" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_8897ae36-aed4-468b-b998-d4f01905db39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_296411dd-ab01-4caf-a438-f0063a4f8149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9acbd34e-ae51-4b58-9e73-2e50e17830bb" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_296411dd-ab01-4caf-a438-f0063a4f8149" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_b748d01f-7569-469a-9215-9193dca941d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9acbd34e-ae51-4b58-9e73-2e50e17830bb" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_b748d01f-7569-469a-9215-9193dca941d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_AssetsNotYetPlacedInServiceMember_43e06345-6b42-425b-8a79-920d00fa93f0" xlink:href="fhtx-20211231.xsd#fhtx_AssetsNotYetPlacedInServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9acbd34e-ae51-4b58-9e73-2e50e17830bb" xlink:to="loc_fhtx_AssetsNotYetPlacedInServiceMember_43e06345-6b42-425b-8a79-920d00fa93f0" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#NotesPayableSummaryofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails" xlink:type="extended" id="i48e1fd806a7547b3b57079a826c91c3f_NotesPayableSummaryofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_2f5c933b-0e4d-45e6-8c78-0dee740a2d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_61ea313d-846d-462f-9812-76ff3b17931d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2f5c933b-0e4d-45e6-8c78-0dee740a2d40" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_61ea313d-846d-462f-9812-76ff3b17931d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_a4e74b47-13bf-449b-adb8-45007c83918d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2f5c933b-0e4d-45e6-8c78-0dee740a2d40" xlink:to="loc_us-gaap_LongTermDebtCurrent_a4e74b47-13bf-449b-adb8-45007c83918d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_01aa0d4a-8983-4476-8d84-418b75a03a44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2f5c933b-0e4d-45e6-8c78-0dee740a2d40" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_01aa0d4a-8983-4476-8d84-418b75a03a44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_944ea2f4-4a64-42ee-b9f9-bdc099040db2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2f5c933b-0e4d-45e6-8c78-0dee740a2d40" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_944ea2f4-4a64-42ee-b9f9-bdc099040db2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7def766d-a51c-49b4-868a-a0ed66c128cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2f5c933b-0e4d-45e6-8c78-0dee740a2d40" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7def766d-a51c-49b4-868a-a0ed66c128cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2bafcbc4-45cb-48ec-acda-111003f8e45d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2f5c933b-0e4d-45e6-8c78-0dee740a2d40" xlink:to="loc_us-gaap_LongTermDebt_2bafcbc4-45cb-48ec-acda-111003f8e45d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_efef7be0-f378-485d-9a66-6877e773459d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2f5c933b-0e4d-45e6-8c78-0dee740a2d40" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_efef7be0-f378-485d-9a66-6877e773459d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_77245c68-d550-4146-835b-f2eea28c3943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_efef7be0-f378-485d-9a66-6877e773459d" xlink:to="loc_us-gaap_DebtInstrumentAxis_77245c68-d550-4146-835b-f2eea28c3943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_77245c68-d550-4146-835b-f2eea28c3943_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_77245c68-d550-4146-835b-f2eea28c3943" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_77245c68-d550-4146-835b-f2eea28c3943_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4302dac6-0d14-4488-8adf-fc7b54b05eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_77245c68-d550-4146-835b-f2eea28c3943" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4302dac6-0d14-4488-8adf-fc7b54b05eda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_TermLoanAMember_8f558bd7-3dd2-49ca-b7e6-36c437c4ab8e" xlink:href="fhtx-20211231.xsd#fhtx_TermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4302dac6-0d14-4488-8adf-fc7b54b05eda" xlink:to="loc_fhtx_TermLoanAMember_8f558bd7-3dd2-49ca-b7e6-36c437c4ab8e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#NotesPayableAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" xlink:type="extended" id="ieaa7df8c74bd43bf8e14a3229de2bbb5_NotesPayableAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_b6c7ac62-b0d4-424a-b3f7-84d80722f81b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_b6c7ac62-b0d4-424a-b3f7-84d80722f81b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_LineOfCreditAdditionalBorrowingCapacity_76bdf8d9-c830-4b5b-a66e-2aceb8b5cb2e" xlink:href="fhtx-20211231.xsd#fhtx_LineOfCreditAdditionalBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_fhtx_LineOfCreditAdditionalBorrowingCapacity_76bdf8d9-c830-4b5b-a66e-2aceb8b5cb2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0643d7e2-c636-4436-aab3-b865d2c4105a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0643d7e2-c636-4436-aab3-b865d2c4105a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8b18b4cc-4033-4b1b-a1a4-6bca4f420e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8b18b4cc-4033-4b1b-a1a4-6bca4f420e77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage_2fec9c4d-8f8a-402d-875f-a3e0d29f1fdc" xlink:href="fhtx-20211231.xsd#fhtx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_fhtx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage_2fec9c4d-8f8a-402d-875f-a3e0d29f1fdc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_PercentageOfPrepaymentFee_f7221523-e7f0-469a-ad88-5bf1496486d7" xlink:href="fhtx-20211231.xsd#fhtx_PercentageOfPrepaymentFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_fhtx_PercentageOfPrepaymentFee_f7221523-e7f0-469a-ad88-5bf1496486d7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_PrepaymentPeriod_5868c742-cfba-48f3-935a-42d5b066a65b" xlink:href="fhtx-20211231.xsd#fhtx_PrepaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_fhtx_PrepaymentPeriod_5868c742-cfba-48f3-935a-42d5b066a65b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a0c1bb1b-45bf-4659-93d1-f6270115aced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a0c1bb1b-45bf-4659-93d1-f6270115aced" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_WarrantsIssuePricePerShare_dc1369cb-2bbd-47a8-ba68-c57dbf15207a" xlink:href="fhtx-20211231.xsd#fhtx_WarrantsIssuePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_fhtx_WarrantsIssuePricePerShare_dc1369cb-2bbd-47a8-ba68-c57dbf15207a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_41e1afe7-ac42-4e93-8646-b38a319fe86f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_41e1afe7-ac42-4e93-8646-b38a319fe86f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_df830a0b-c6ae-41b8-b87e-080e5fde2976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_df830a0b-c6ae-41b8-b87e-080e5fde2976" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_5a9d4ab9-8dd8-4a55-81ad-66a1de3a3e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_us-gaap_DebtInstrumentTerm_5a9d4ab9-8dd8-4a55-81ad-66a1de3a3e78" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_34c1b9f8-8d21-4993-be9f-9c42a2baeef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_34c1b9f8-8d21-4993-be9f-9c42a2baeef1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_008ef988-83fe-4182-bdb8-98f7dda3f731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_008ef988-83fe-4182-bdb8-98f7dda3f731" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_7165c0db-80e5-42a6-ba80-a9347d53c376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_7165c0db-80e5-42a6-ba80-a9347d53c376" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_10df504a-bf30-425c-a012-4cb38f417e62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_10df504a-bf30-425c-a012-4cb38f417e62" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_94b800fe-b264-4f8c-a98b-f2b04bd33ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_10df504a-bf30-425c-a012-4cb38f417e62" xlink:to="loc_us-gaap_DebtInstrumentAxis_94b800fe-b264-4f8c-a98b-f2b04bd33ca9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_94b800fe-b264-4f8c-a98b-f2b04bd33ca9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_94b800fe-b264-4f8c-a98b-f2b04bd33ca9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_94b800fe-b264-4f8c-a98b-f2b04bd33ca9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4bb729f9-8b4b-4b4b-957e-4450e1ec7238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_94b800fe-b264-4f8c-a98b-f2b04bd33ca9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4bb729f9-8b4b-4b4b-957e-4450e1ec7238" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_TermLoanAMember_f4c74ded-9a41-40e3-b3ba-65acec487e98" xlink:href="fhtx-20211231.xsd#fhtx_TermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4bb729f9-8b4b-4b4b-957e-4450e1ec7238" xlink:to="loc_fhtx_TermLoanAMember_f4c74ded-9a41-40e3-b3ba-65acec487e98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_TermLoanBMember_00e43593-d861-4187-8f81-7e0466c8e776" xlink:href="fhtx-20211231.xsd#fhtx_TermLoanBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4bb729f9-8b4b-4b4b-957e-4450e1ec7238" xlink:to="loc_fhtx_TermLoanBMember_00e43593-d861-4187-8f81-7e0466c8e776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b0d58d50-0a28-4034-a345-9896da744fdc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_10df504a-bf30-425c-a012-4cb38f417e62" xlink:to="loc_srt_RangeAxis_b0d58d50-0a28-4034-a345-9896da744fdc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b0d58d50-0a28-4034-a345-9896da744fdc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b0d58d50-0a28-4034-a345-9896da744fdc" xlink:to="loc_srt_RangeMember_b0d58d50-0a28-4034-a345-9896da744fdc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b622d797-912a-4cd7-9a52-a66a83232e99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b0d58d50-0a28-4034-a345-9896da744fdc" xlink:to="loc_srt_RangeMember_b622d797-912a-4cd7-9a52-a66a83232e99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b4dd0843-d0fd-4d58-90ff-299978c8c55d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b622d797-912a-4cd7-9a52-a66a83232e99" xlink:to="loc_srt_MaximumMember_b4dd0843-d0fd-4d58-90ff-299978c8c55d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_258e5588-773a-44ad-bc33-b799af066250" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b622d797-912a-4cd7-9a52-a66a83232e99" xlink:to="loc_srt_MinimumMember_258e5588-773a-44ad-bc33-b799af066250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_PrepaymentPeriodAxis_e4c61b14-419d-467e-98ca-a026fa44ed4f" xlink:href="fhtx-20211231.xsd#fhtx_PrepaymentPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_10df504a-bf30-425c-a012-4cb38f417e62" xlink:to="loc_fhtx_PrepaymentPeriodAxis_e4c61b14-419d-467e-98ca-a026fa44ed4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_PrepaymentPeriodDomain_e4c61b14-419d-467e-98ca-a026fa44ed4f_default" xlink:href="fhtx-20211231.xsd#fhtx_PrepaymentPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_fhtx_PrepaymentPeriodAxis_e4c61b14-419d-467e-98ca-a026fa44ed4f" xlink:to="loc_fhtx_PrepaymentPeriodDomain_e4c61b14-419d-467e-98ca-a026fa44ed4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_PrepaymentPeriodDomain_7a401516-389f-4212-b5d5-8c48b2aeb8bb" xlink:href="fhtx-20211231.xsd#fhtx_PrepaymentPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_fhtx_PrepaymentPeriodAxis_e4c61b14-419d-467e-98ca-a026fa44ed4f" xlink:to="loc_fhtx_PrepaymentPeriodDomain_7a401516-389f-4212-b5d5-8c48b2aeb8bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_PrepaymentPeriodOneMember_2e3f99df-1dbb-47e1-9437-a2b6db488e81" xlink:href="fhtx-20211231.xsd#fhtx_PrepaymentPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fhtx_PrepaymentPeriodDomain_7a401516-389f-4212-b5d5-8c48b2aeb8bb" xlink:to="loc_fhtx_PrepaymentPeriodOneMember_2e3f99df-1dbb-47e1-9437-a2b6db488e81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_PrepaymentPeriodTwoMember_7f463ac5-305e-4163-bcf9-d81422799f90" xlink:href="fhtx-20211231.xsd#fhtx_PrepaymentPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fhtx_PrepaymentPeriodDomain_7a401516-389f-4212-b5d5-8c48b2aeb8bb" xlink:to="loc_fhtx_PrepaymentPeriodTwoMember_7f463ac5-305e-4163-bcf9-d81422799f90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_PrepaymentPeriodThreeMember_59297058-2ff1-43f7-a59f-3173236e7006" xlink:href="fhtx-20211231.xsd#fhtx_PrepaymentPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_fhtx_PrepaymentPeriodDomain_7a401516-389f-4212-b5d5-8c48b2aeb8bb" xlink:to="loc_fhtx_PrepaymentPeriodThreeMember_59297058-2ff1-43f7-a59f-3173236e7006" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/CommonStockDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#CommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.foghorntx.com/role/CommonStockDetails" xlink:type="extended" id="i5f79733b4b2a40059c481cbbf307891f_CommonStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e3b85f1e-1695-4676-b0a1-23eb63e3effc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0ce77d70-3fd2-456f-8c48-49ed919afca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e3b85f1e-1695-4676-b0a1-23eb63e3effc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0ce77d70-3fd2-456f-8c48-49ed919afca7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_0f3848f7-46d3-4a75-963a-6b9c8a13e419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e3b85f1e-1695-4676-b0a1-23eb63e3effc" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_0f3848f7-46d3-4a75-963a-6b9c8a13e419" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3aacad8f-0f6e-4993-9d62-bf9bcbba38fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e3b85f1e-1695-4676-b0a1-23eb63e3effc" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3aacad8f-0f6e-4993-9d62-bf9bcbba38fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_59b1bde4-9acf-4733-837a-69d02591404f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e3b85f1e-1695-4676-b0a1-23eb63e3effc" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_59b1bde4-9acf-4733-837a-69d02591404f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c13b6b14-50cd-4158-b758-b2c259922854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_e3b85f1e-1695-4676-b0a1-23eb63e3effc" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c13b6b14-50cd-4158-b758-b2c259922854" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_22ab1e91-31f7-4d8e-8f7c-1ee838123b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c13b6b14-50cd-4158-b758-b2c259922854" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_22ab1e91-31f7-4d8e-8f7c-1ee838123b8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_22ab1e91-31f7-4d8e-8f7c-1ee838123b8e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_22ab1e91-31f7-4d8e-8f7c-1ee838123b8e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_22ab1e91-31f7-4d8e-8f7c-1ee838123b8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388d1cda-fd0d-49b2-91c7-4912779ee6d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_22ab1e91-31f7-4d8e-8f7c-1ee838123b8e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388d1cda-fd0d-49b2-91c7-4912779ee6d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_2640a1f9-a0bc-46bc-8ef0-68daf14bc74b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388d1cda-fd0d-49b2-91c7-4912779ee6d9" xlink:to="loc_us-gaap_IPOMember_2640a1f9-a0bc-46bc-8ef0-68daf14bc74b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_c6de6de3-5d88-4192-84d6-a3bc4bd18e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388d1cda-fd0d-49b2-91c7-4912779ee6d9" xlink:to="loc_us-gaap_OverAllotmentOptionMember_c6de6de3-5d88-4192-84d6-a3bc4bd18e37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_SharePurchaseAgreementMember_0b0e7382-6692-4e76-b20d-6ad1e193cb8c" xlink:href="fhtx-20211231.xsd#fhtx_SharePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388d1cda-fd0d-49b2-91c7-4912779ee6d9" xlink:to="loc_fhtx_SharePurchaseAgreementMember_0b0e7382-6692-4e76-b20d-6ad1e193cb8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d8a909cf-d52b-42ff-93bf-84d9f9a8055f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c13b6b14-50cd-4158-b758-b2c259922854" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d8a909cf-d52b-42ff-93bf-84d9f9a8055f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d8a909cf-d52b-42ff-93bf-84d9f9a8055f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d8a909cf-d52b-42ff-93bf-84d9f9a8055f" xlink:to="loc_us-gaap_ClassOfStockDomain_d8a909cf-d52b-42ff-93bf-84d9f9a8055f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0f04cda9-8d44-47fc-ad99-187f6bc0d2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d8a909cf-d52b-42ff-93bf-84d9f9a8055f" xlink:to="loc_us-gaap_ClassOfStockDomain_0f04cda9-8d44-47fc-ad99-187f6bc0d2cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_747f65c9-ed3f-4179-aa05-2e53f4bb4fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0f04cda9-8d44-47fc-ad99-187f6bc0d2cf" xlink:to="loc_us-gaap_CommonStockMember_747f65c9-ed3f-4179-aa05-2e53f4bb4fd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d425bdf1-6356-4f44-8e24-15335ef074c6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c13b6b14-50cd-4158-b758-b2c259922854" xlink:to="loc_srt_CounterpartyNameAxis_d425bdf1-6356-4f44-8e24-15335ef074c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d425bdf1-6356-4f44-8e24-15335ef074c6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d425bdf1-6356-4f44-8e24-15335ef074c6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d425bdf1-6356-4f44-8e24-15335ef074c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76dce9a5-1896-4498-868e-09720da584a5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d425bdf1-6356-4f44-8e24-15335ef074c6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76dce9a5-1896-4498-868e-09720da584a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_EliLillyMember_980c3d38-e569-4d2d-aed5-73a7765677cd" xlink:href="fhtx-20211231.xsd#fhtx_EliLillyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76dce9a5-1896-4498-868e-09720da584a5" xlink:to="loc_fhtx_EliLillyMember_980c3d38-e569-4d2d-aed5-73a7765677cd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="i8c4ad00fb7d04f3a8f8561a33793b036_StockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a6ecd84c-2555-48d9-b872-a29799750b90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a6ecd84c-2555-48d9-b872-a29799750b90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c19c8336-2659-43ab-b825-ab03e976773d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c19c8336-2659-43ab-b825-ab03e976773d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage_f69f5d4a-d4e0-491f-847a-5a4d57507d91" xlink:href="fhtx-20211231.xsd#fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage_f69f5d4a-d4e0-491f-847a-5a4d57507d91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_81ee6411-0efc-485a-9f25-4bae7e4ca4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_81ee6411-0efc-485a-9f25-4bae7e4ca4fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fb613273-82b3-4b99-bc9e-4e1392896351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fb613273-82b3-4b99-bc9e-4e1392896351" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_db1a9c20-71bc-4e45-85d5-3ff1eeb2a836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_db1a9c20-71bc-4e45-85d5-3ff1eeb2a836" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares_859a0747-1722-4a75-887f-e71d2fba1732" xlink:href="fhtx-20211231.xsd#fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares_859a0747-1722-4a75-887f-e71d2fba1732" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4fdd6758-1c9b-445e-895d-90d3dc8efa9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4fdd6758-1c9b-445e-895d-90d3dc8efa9e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_da370d99-02ff-4ae7-9fda-4a0073683f59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_da370d99-02ff-4ae7-9fda-4a0073683f59" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_25c8f2d5-6e5e-44bf-b99b-196909b372c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_25c8f2d5-6e5e-44bf-b99b-196909b372c7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_751b2b1d-b768-46ee-b246-be0f4c8f27ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_751b2b1d-b768-46ee-b246-be0f4c8f27ec" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b6849b4b-4491-42ae-b07f-ac39b1f46e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b6849b4b-4491-42ae-b07f-ac39b1f46e70" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_22e20cde-0710-47fc-973a-7808aef471e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_22e20cde-0710-47fc-973a-7808aef471e5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0079720-3f9e-44b6-833b-ec54a10fb31c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0079720-3f9e-44b6-833b-ec54a10fb31c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ee7729df-26d4-4aab-b4ca-bd5b88d837a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0079720-3f9e-44b6-833b-ec54a10fb31c" xlink:to="loc_us-gaap_PlanNameAxis_ee7729df-26d4-4aab-b4ca-bd5b88d837a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ee7729df-26d4-4aab-b4ca-bd5b88d837a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ee7729df-26d4-4aab-b4ca-bd5b88d837a1" xlink:to="loc_us-gaap_PlanNameDomain_ee7729df-26d4-4aab-b4ca-bd5b88d837a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_43d4cb34-970a-4f0e-8c02-c0023cf4f9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ee7729df-26d4-4aab-b4ca-bd5b88d837a1" xlink:to="loc_us-gaap_PlanNameDomain_43d4cb34-970a-4f0e-8c02-c0023cf4f9aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_TwoThousandTwentyEquityIncentivePlanMember_07519b8c-d8c2-4f1f-8a1e-013a655f5c95" xlink:href="fhtx-20211231.xsd#fhtx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_43d4cb34-970a-4f0e-8c02-c0023cf4f9aa" xlink:to="loc_fhtx_TwoThousandTwentyEquityIncentivePlanMember_07519b8c-d8c2-4f1f-8a1e-013a655f5c95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_A2016StockIncentivePlanMember_2875c695-1ead-439e-b33f-c2508feaf6a9" xlink:href="fhtx-20211231.xsd#fhtx_A2016StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_43d4cb34-970a-4f0e-8c02-c0023cf4f9aa" xlink:to="loc_fhtx_A2016StockIncentivePlanMember_2875c695-1ead-439e-b33f-c2508feaf6a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_TwoThousandTwentyEmployeeStockPurchasePlanMember_a781bde9-a01e-4790-8d43-90a5942bfe86" xlink:href="fhtx-20211231.xsd#fhtx_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_43d4cb34-970a-4f0e-8c02-c0023cf4f9aa" xlink:to="loc_fhtx_TwoThousandTwentyEmployeeStockPurchasePlanMember_a781bde9-a01e-4790-8d43-90a5942bfe86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d89437d1-ec2b-4abd-b042-407ff774148f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0079720-3f9e-44b6-833b-ec54a10fb31c" xlink:to="loc_us-gaap_AwardTypeAxis_d89437d1-ec2b-4abd-b042-407ff774148f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d89437d1-ec2b-4abd-b042-407ff774148f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d89437d1-ec2b-4abd-b042-407ff774148f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d89437d1-ec2b-4abd-b042-407ff774148f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e29b5125-7bbf-42ae-af7c-d36a6bdcf9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d89437d1-ec2b-4abd-b042-407ff774148f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e29b5125-7bbf-42ae-af7c-d36a6bdcf9ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f0a677ac-37ce-4b79-8cfa-f9c204ba9796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e29b5125-7bbf-42ae-af7c-d36a6bdcf9ec" xlink:to="loc_us-gaap_RestrictedStockMember_f0a677ac-37ce-4b79-8cfa-f9c204ba9796" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b6b0f521-6932-4002-b670-958607f6659f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0079720-3f9e-44b6-833b-ec54a10fb31c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b6b0f521-6932-4002-b670-958607f6659f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b6b0f521-6932-4002-b670-958607f6659f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b6b0f521-6932-4002-b670-958607f6659f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b6b0f521-6932-4002-b670-958607f6659f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f66b9f0e-b078-47bc-bf30-f3684787206a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b6b0f521-6932-4002-b670-958607f6659f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f66b9f0e-b078-47bc-bf30-f3684787206a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d10023ae-d1de-4990-85af-f72c8537e6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f66b9f0e-b078-47bc-bf30-f3684787206a" xlink:to="loc_us-gaap_SubsequentEventMember_d10023ae-d1de-4990-85af-f72c8537e6ee" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails"/>
  <link:definitionLink xlink:role="http://www.foghorntx.com/role/StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails" xlink:type="extended" id="icda9238a96e4467c8b64211dacdeacec_StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_00202bf9-289f-46f1-99f8-9ffb707f335a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8f0e3b7d-6f19-47dc-8ac1-5f8c075c7111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_00202bf9-289f-46f1-99f8-9ffb707f335a" xlink:to="loc_us-gaap_ShareBasedCompensation_8f0e3b7d-6f19-47dc-8ac1-5f8c075c7111" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7777481a-2e85-4212-890e-3fba69209fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_00202bf9-289f-46f1-99f8-9ffb707f335a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7777481a-2e85-4212-890e-3fba69209fd4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b4318573-f000-4054-b1ff-a31477f252a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7777481a-2e85-4212-890e-3fba69209fd4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b4318573-f000-4054-b1ff-a31477f252a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b4318573-f000-4054-b1ff-a31477f252a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b4318573-f000-4054-b1ff-a31477f252a3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b4318573-f000-4054-b1ff-a31477f252a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_be634f34-b9b4-4d53-8257-69b6aa34da55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b4318573-f000-4054-b1ff-a31477f252a3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_be634f34-b9b4-4d53-8257-69b6aa34da55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4a5e965f-72ab-41ab-be8b-c4b88559fa88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_be634f34-b9b4-4d53-8257-69b6aa34da55" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4a5e965f-72ab-41ab-be8b-c4b88559fa88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c7e9a938-dfff-4275-9106-dc58721e70fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_be634f34-b9b4-4d53-8257-69b6aa34da55" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c7e9a938-dfff-4275-9106-dc58721e70fb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/CollaborationAgreementDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#CollaborationAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.foghorntx.com/role/CollaborationAgreementDetails" xlink:type="extended" id="i0363c96b8de44609bf423cb597091530_CollaborationAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_NumberOfAdditionalTargets_c33556f6-cd0e-40fc-bd92-83f1534121ab" xlink:href="fhtx-20211231.xsd#fhtx_NumberOfAdditionalTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_fhtx_NumberOfAdditionalTargets_c33556f6-cd0e-40fc-bd92-83f1534121ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_NumberOfPrograms_0dd9692e-5cc5-4856-a4c2-ad1e8b4f81a2" xlink:href="fhtx-20211231.xsd#fhtx_NumberOfPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_fhtx_NumberOfPrograms_0dd9692e-5cc5-4856-a4c2-ad1e8b4f81a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_NumberOfTargets_02edbafb-07ce-43c6-b0bd-3e73ff36b18d" xlink:href="fhtx-20211231.xsd#fhtx_NumberOfTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_fhtx_NumberOfTargets_02edbafb-07ce-43c6-b0bd-3e73ff36b18d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_MilestoneReceivableUponAchievement_c41510f1-1f71-477b-b261-cc0671f2fc04" xlink:href="fhtx-20211231.xsd#fhtx_MilestoneReceivableUponAchievement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_fhtx_MilestoneReceivableUponAchievement_c41510f1-1f71-477b-b261-cc0671f2fc04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_OptOutMilestoneReceivableUponAchievement_b6e042ef-bb30-4e25-a40a-c34d02175b40" xlink:href="fhtx-20211231.xsd#fhtx_OptOutMilestoneReceivableUponAchievement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_fhtx_OptOutMilestoneReceivableUponAchievement_b6e042ef-bb30-4e25-a40a-c34d02175b40" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ProceedsFromUpfrontPayment_16336a49-9a15-4c82-a460-1b789ede5526" xlink:href="fhtx-20211231.xsd#fhtx_ProceedsFromUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_fhtx_ProceedsFromUpfrontPayment_16336a49-9a15-4c82-a460-1b789ede5526" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6627dbc7-ff9d-4d7b-9a14-299b4f24fd74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6627dbc7-ff9d-4d7b-9a14-299b4f24fd74" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d58afe6d-744b-41da-ad4b-762027cb443b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d58afe6d-744b-41da-ad4b-762027cb443b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9f14b246-6a36-42aa-82a2-4c4a596b90a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9f14b246-6a36-42aa-82a2-4c4a596b90a2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice_ffb8274c-4ef2-4b2d-aadd-0e39d69e3c72" xlink:href="fhtx-20211231.xsd#fhtx_DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_fhtx_DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice_ffb8274c-4ef2-4b2d-aadd-0e39d69e3c72" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7e5084cb-1f3b-4cdd-b87c-3bc087453726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7e5084cb-1f3b-4cdd-b87c-3bc087453726" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_556f2235-504e-4be1-9227-df6d3ea69b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_556f2235-504e-4be1-9227-df6d3ea69b18" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_007bfdbc-0436-47ef-8d56-dc5bf67e1419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_us-gaap_ContractWithCustomerLiability_007bfdbc-0436-47ef-8d56-dc5bf67e1419" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_fcd6a886-3d4d-4d88-a212-ef6fec8fc517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_fcd6a886-3d4d-4d88-a212-ef6fec8fc517" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d85e401a-ad69-434e-826a-8b0c0231011b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d85e401a-ad69-434e-826a-8b0c0231011b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b23d13d-f6df-468e-9465-96c191119abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b23d13d-f6df-468e-9465-96c191119abd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4a413aa1-a568-4883-8f80-9b1e3f120296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b23d13d-f6df-468e-9465-96c191119abd" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4a413aa1-a568-4883-8f80-9b1e3f120296" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4a413aa1-a568-4883-8f80-9b1e3f120296_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4a413aa1-a568-4883-8f80-9b1e3f120296" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_4a413aa1-a568-4883-8f80-9b1e3f120296_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bc8b43d0-0189-4dc2-8c07-ee5de0a6ea18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4a413aa1-a568-4883-8f80-9b1e3f120296" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bc8b43d0-0189-4dc2-8c07-ee5de0a6ea18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ResearchDevelopmentAndRegulatoryMember_771f2394-9d45-4142-9ba8-71e61176ded8" xlink:href="fhtx-20211231.xsd#fhtx_ResearchDevelopmentAndRegulatoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bc8b43d0-0189-4dc2-8c07-ee5de0a6ea18" xlink:to="loc_fhtx_ResearchDevelopmentAndRegulatoryMember_771f2394-9d45-4142-9ba8-71e61176ded8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_SalesBasedMilestoneMember_b398c63b-dee0-489a-8f80-ee87eb9d5a39" xlink:href="fhtx-20211231.xsd#fhtx_SalesBasedMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bc8b43d0-0189-4dc2-8c07-ee5de0a6ea18" xlink:to="loc_fhtx_SalesBasedMilestoneMember_b398c63b-dee0-489a-8f80-ee87eb9d5a39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2deee84f-a05a-428e-af7f-1ee27843429f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b23d13d-f6df-468e-9465-96c191119abd" xlink:to="loc_srt_RangeAxis_2deee84f-a05a-428e-af7f-1ee27843429f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2deee84f-a05a-428e-af7f-1ee27843429f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2deee84f-a05a-428e-af7f-1ee27843429f" xlink:to="loc_srt_RangeMember_2deee84f-a05a-428e-af7f-1ee27843429f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_95300bd7-b9db-46cf-81cc-872181421005" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2deee84f-a05a-428e-af7f-1ee27843429f" xlink:to="loc_srt_RangeMember_95300bd7-b9db-46cf-81cc-872181421005" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7d661b34-837b-4cad-96dd-c298ce4bf4d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_95300bd7-b9db-46cf-81cc-872181421005" xlink:to="loc_srt_MaximumMember_7d661b34-837b-4cad-96dd-c298ce4bf4d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8ff69626-98c2-4aae-8dbb-e93156464300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b23d13d-f6df-468e-9465-96c191119abd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8ff69626-98c2-4aae-8dbb-e93156464300" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8ff69626-98c2-4aae-8dbb-e93156464300_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8ff69626-98c2-4aae-8dbb-e93156464300" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8ff69626-98c2-4aae-8dbb-e93156464300_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7d55ec27-c5b1-47ba-841f-39d01fde35c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8ff69626-98c2-4aae-8dbb-e93156464300" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7d55ec27-c5b1-47ba-841f-39d01fde35c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_736b6888-8318-47de-87ba-85e4da48bf90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7d55ec27-c5b1-47ba-841f-39d01fde35c9" xlink:to="loc_us-gaap_SalesMember_736b6888-8318-47de-87ba-85e4da48bf90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a1b6b34b-b22d-49df-ae12-adb5e05161d0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b23d13d-f6df-468e-9465-96c191119abd" xlink:to="loc_srt_CounterpartyNameAxis_a1b6b34b-b22d-49df-ae12-adb5e05161d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a1b6b34b-b22d-49df-ae12-adb5e05161d0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a1b6b34b-b22d-49df-ae12-adb5e05161d0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a1b6b34b-b22d-49df-ae12-adb5e05161d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5cc303c9-37e2-467a-86c6-c2bc5f5f9cd8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a1b6b34b-b22d-49df-ae12-adb5e05161d0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5cc303c9-37e2-467a-86c6-c2bc5f5f9cd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_EliLillyMember_a31b04fe-2fd5-4120-b57a-a23cf9d1dab2" xlink:href="fhtx-20211231.xsd#fhtx_EliLillyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5cc303c9-37e2-467a-86c6-c2bc5f5f9cd8" xlink:to="loc_fhtx_EliLillyMember_a31b04fe-2fd5-4120-b57a-a23cf9d1dab2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_MerckMember_e82df9e8-b811-483f-a7a6-7ee9a8d8560d" xlink:href="fhtx-20211231.xsd#fhtx_MerckMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5cc303c9-37e2-467a-86c6-c2bc5f5f9cd8" xlink:to="loc_fhtx_MerckMember_e82df9e8-b811-483f-a7a6-7ee9a8d8560d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_38993cfc-59e7-4c93-a9bc-b515d66ad698" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b23d13d-f6df-468e-9465-96c191119abd" xlink:to="loc_srt_StatementScenarioAxis_38993cfc-59e7-4c93-a9bc-b515d66ad698" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_38993cfc-59e7-4c93-a9bc-b515d66ad698_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_38993cfc-59e7-4c93-a9bc-b515d66ad698" xlink:to="loc_srt_ScenarioUnspecifiedDomain_38993cfc-59e7-4c93-a9bc-b515d66ad698_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_37be1987-f6d4-4a92-8983-77eefca037f6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_38993cfc-59e7-4c93-a9bc-b515d66ad698" xlink:to="loc_srt_ScenarioUnspecifiedDomain_37be1987-f6d4-4a92-8983-77eefca037f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioAdjustmentMember_5685fa55-9526-4005-bce8-4f44ea7ee35a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScenarioAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_37be1987-f6d4-4a92-8983-77eefca037f6" xlink:to="loc_us-gaap_ScenarioAdjustmentMember_5685fa55-9526-4005-bce8-4f44ea7ee35a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_bc67e787-5110-4146-b07e-a48bcbe9ded2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b23d13d-f6df-468e-9465-96c191119abd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_bc67e787-5110-4146-b07e-a48bcbe9ded2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bc67e787-5110-4146-b07e-a48bcbe9ded2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_bc67e787-5110-4146-b07e-a48bcbe9ded2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bc67e787-5110-4146-b07e-a48bcbe9ded2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6a365c55-89c6-4d2c-b5ff-f181f1406c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_bc67e787-5110-4146-b07e-a48bcbe9ded2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6a365c55-89c6-4d2c-b5ff-f181f1406c5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7b07c18e-f805-4bda-8b36-cc95401d3175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6a365c55-89c6-4d2c-b5ff-f181f1406c5d" xlink:to="loc_us-gaap_SubsequentEventMember_7b07c18e-f805-4bda-8b36-cc95401d3175" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d675a11e-0225-42f8-a3d3-5f7dbd73792c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b23d13d-f6df-468e-9465-96c191119abd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d675a11e-0225-42f8-a3d3-5f7dbd73792c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d675a11e-0225-42f8-a3d3-5f7dbd73792c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d675a11e-0225-42f8-a3d3-5f7dbd73792c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d675a11e-0225-42f8-a3d3-5f7dbd73792c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_78183d47-43d8-4f88-b051-0271bd3e8051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d675a11e-0225-42f8-a3d3-5f7dbd73792c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_78183d47-43d8-4f88-b051-0271bd3e8051" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_SharePurchaseAgreementMember_bfd74be3-430d-41a4-acc5-d2f0e142b975" xlink:href="fhtx-20211231.xsd#fhtx_SharePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_78183d47-43d8-4f88-b051-0271bd3e8051" xlink:to="loc_fhtx_SharePurchaseAgreementMember_bfd74be3-430d-41a4-acc5-d2f0e142b975" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="i4d031ee647394893bd44b6c20fe851e6_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_2522d8d1-f62b-4001-8f12-52aa9a7d0cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_91e870c1-7687-4f05-9c58-5709386c58b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2522d8d1-f62b-4001-8f12-52aa9a7d0cb8" xlink:to="loc_us-gaap_OperatingLossCarryforwards_91e870c1-7687-4f05-9c58-5709386c58b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_7d8fd923-c3dc-4bea-9b22-f993001f0fef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2522d8d1-f62b-4001-8f12-52aa9a7d0cb8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_7d8fd923-c3dc-4bea-9b22-f993001f0fef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_dd2b1f49-277d-4d5b-a8c3-71e91977165e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2522d8d1-f62b-4001-8f12-52aa9a7d0cb8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_dd2b1f49-277d-4d5b-a8c3-71e91977165e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_OperatingLossCarryforwardLimitPercentage_9972894e-9079-4eb0-ad16-f16f28293514" xlink:href="fhtx-20211231.xsd#fhtx_OperatingLossCarryforwardLimitPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2522d8d1-f62b-4001-8f12-52aa9a7d0cb8" xlink:to="loc_fhtx_OperatingLossCarryforwardLimitPercentage_9972894e-9079-4eb0-ad16-f16f28293514" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_6c1adb91-913e-46a4-92db-29e4a5adc269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2522d8d1-f62b-4001-8f12-52aa9a7d0cb8" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_6c1adb91-913e-46a4-92db-29e4a5adc269" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_a73f3659-5f91-45b0-8353-2d2a623a5b48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2522d8d1-f62b-4001-8f12-52aa9a7d0cb8" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_a73f3659-5f91-45b0-8353-2d2a623a5b48" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_2b3fe054-64f1-492c-81de-cf8b36224cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2522d8d1-f62b-4001-8f12-52aa9a7d0cb8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_2b3fe054-64f1-492c-81de-cf8b36224cd3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_48e11226-8d36-4eae-8bd2-642b8404eaaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2522d8d1-f62b-4001-8f12-52aa9a7d0cb8" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_48e11226-8d36-4eae-8bd2-642b8404eaaf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6a80a6fd-d32a-4f69-9f97-3efa91eec0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_48e11226-8d36-4eae-8bd2-642b8404eaaf" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6a80a6fd-d32a-4f69-9f97-3efa91eec0f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6a80a6fd-d32a-4f69-9f97-3efa91eec0f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6a80a6fd-d32a-4f69-9f97-3efa91eec0f9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6a80a6fd-d32a-4f69-9f97-3efa91eec0f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d4983533-6a7d-4500-a67e-493fcdc1d464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6a80a6fd-d32a-4f69-9f97-3efa91eec0f9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d4983533-6a7d-4500-a67e-493fcdc1d464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_34363e04-04e1-4498-91d3-37edc74b8eef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d4983533-6a7d-4500-a67e-493fcdc1d464" xlink:to="loc_us-gaap_DomesticCountryMember_34363e04-04e1-4498-91d3-37edc74b8eef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_eb9dac6c-63c0-424a-89f7-313fb49e419e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d4983533-6a7d-4500-a67e-493fcdc1d464" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_eb9dac6c-63c0-424a-89f7-313fb49e419e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#LeasesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" xlink:type="extended" id="if6a605a6e74b4996a8596217533425a4_LeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_1eb8a493-7dc1-4869-b885-5b5642873288" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_1eb8a493-7dc1-4869-b885-5b5642873288" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b1283016-2130-4d50-a688-df5e142ab101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b1283016-2130-4d50-a688-df5e142ab101" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_1c6b94bc-3f9c-447b-a27f-f2d898ea22c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_1c6b94bc-3f9c-447b-a27f-f2d898ea22c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_9c301a70-6233-4c13-bc1f-8927cb2b651e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_us-gaap_OperatingLeaseExpense_9c301a70-6233-4c13-bc1f-8927cb2b651e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_LeaseholdImprovementsLandlordAllowance_b47733e5-0eb8-455d-bb9e-2000a34de32a" xlink:href="fhtx-20211231.xsd#fhtx_LeaseholdImprovementsLandlordAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_fhtx_LeaseholdImprovementsLandlordAllowance_b47733e5-0eb8-455d-bb9e-2000a34de32a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_LeaseholdImprovementsLandlordAllowanceToBeRepaid_150473a8-1672-4e0d-820a-3c3e938e9cb9" xlink:href="fhtx-20211231.xsd#fhtx_LeaseholdImprovementsLandlordAllowanceToBeRepaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_fhtx_LeaseholdImprovementsLandlordAllowanceToBeRepaid_150473a8-1672-4e0d-820a-3c3e938e9cb9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_c8636f21-5ffd-425d-8dd0-7a9ec32793e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_c8636f21-5ffd-425d-8dd0-7a9ec32793e2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_652c0792-45b0-4ad2-8efc-99d3ecef1259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_652c0792-45b0-4ad2-8efc-99d3ecef1259" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5c01d92b-9339-4a05-a334-ff370219a2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5c01d92b-9339-4a05-a334-ff370219a2d5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1092f1f8-d14b-45eb-b960-864bba5c49be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_us-gaap_OperatingLeaseLiability_1092f1f8-d14b-45eb-b960-864bba5c49be" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_1066d78e-48af-4028-b0aa-748d49f72303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_1066d78e-48af-4028-b0aa-748d49f72303" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_c98be11e-02f9-465b-837a-b81cfeefd831" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_c98be11e-02f9-465b-837a-b81cfeefd831" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_9b042f99-bd10-4dcb-a9e7-8157d21335ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_us-gaap_SubleaseIncome_9b042f99-bd10-4dcb-a9e7-8157d21335ef" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_ecd539c4-b3df-441a-89d1-1d2e0889f509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_ecd539c4-b3df-441a-89d1-1d2e0889f509" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6a1aa471-e7d2-44a3-b53e-2ca209b5b485" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ecd539c4-b3df-441a-89d1-1d2e0889f509" xlink:to="loc_srt_RangeAxis_6a1aa471-e7d2-44a3-b53e-2ca209b5b485" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6a1aa471-e7d2-44a3-b53e-2ca209b5b485_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6a1aa471-e7d2-44a3-b53e-2ca209b5b485" xlink:to="loc_srt_RangeMember_6a1aa471-e7d2-44a3-b53e-2ca209b5b485_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a506315d-c568-4f7f-aca7-789b4374d3c0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6a1aa471-e7d2-44a3-b53e-2ca209b5b485" xlink:to="loc_srt_RangeMember_a506315d-c568-4f7f-aca7-789b4374d3c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3a6a0835-5cf6-49a6-b27a-cbf3508cb468" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a506315d-c568-4f7f-aca7-789b4374d3c0" xlink:to="loc_srt_MaximumMember_3a6a0835-5cf6-49a6-b27a-cbf3508cb468" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7a2a3178-1348-45fd-9348-b38002cd7152" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ecd539c4-b3df-441a-89d1-1d2e0889f509" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7a2a3178-1348-45fd-9348-b38002cd7152" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7a2a3178-1348-45fd-9348-b38002cd7152_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7a2a3178-1348-45fd-9348-b38002cd7152" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_7a2a3178-1348-45fd-9348-b38002cd7152_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_814aa4e9-7310-4aea-a7a1-212fec93e6c7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7a2a3178-1348-45fd-9348-b38002cd7152" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_814aa4e9-7310-4aea-a7a1-212fec93e6c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_d2e9ac4f-3f36-4aa3-b740-5d333a6a71a2" xlink:href="fhtx-20211231.xsd#fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_814aa4e9-7310-4aea-a7a1-212fec93e6c7" xlink:to="loc_fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_d2e9ac4f-3f36-4aa3-b740-5d333a6a71a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_OfficeSpaceInCambridgeMassachusettsMember_8fcbec9e-a8fa-4eb1-8ef9-801207ef8e13" xlink:href="fhtx-20211231.xsd#fhtx_OfficeSpaceInCambridgeMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_814aa4e9-7310-4aea-a7a1-212fec93e6c7" xlink:to="loc_fhtx_OfficeSpaceInCambridgeMassachusettsMember_8fcbec9e-a8fa-4eb1-8ef9-801207ef8e13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_AdditionalOfficeSpaceInCambridgeMassachusettsMember_06863a16-a262-44fb-9c99-34312f540c50" xlink:href="fhtx-20211231.xsd#fhtx_AdditionalOfficeSpaceInCambridgeMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_814aa4e9-7310-4aea-a7a1-212fec93e6c7" xlink:to="loc_fhtx_AdditionalOfficeSpaceInCambridgeMassachusettsMember_06863a16-a262-44fb-9c99-34312f540c50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_55b67ab9-ad4a-43fa-aea0-da0ee16851ec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ecd539c4-b3df-441a-89d1-1d2e0889f509" xlink:to="loc_srt_StatementScenarioAxis_55b67ab9-ad4a-43fa-aea0-da0ee16851ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_55b67ab9-ad4a-43fa-aea0-da0ee16851ec_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_55b67ab9-ad4a-43fa-aea0-da0ee16851ec" xlink:to="loc_srt_ScenarioUnspecifiedDomain_55b67ab9-ad4a-43fa-aea0-da0ee16851ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_79a0a162-c77d-40bd-ba07-757481ade0fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_55b67ab9-ad4a-43fa-aea0-da0ee16851ec" xlink:to="loc_srt_ScenarioUnspecifiedDomain_79a0a162-c77d-40bd-ba07-757481ade0fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_743507a4-3cd6-4dc6-8203-5c86d062d95e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_79a0a162-c77d-40bd-ba07-757481ade0fe" xlink:to="loc_srt_ScenarioForecastMember_743507a4-3cd6-4dc6-8203-5c86d062d95e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioAdjustmentMember_c8af2d61-7e7b-4efb-9bb4-b92b3f839617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScenarioAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_79a0a162-c77d-40bd-ba07-757481ade0fe" xlink:to="loc_us-gaap_ScenarioAdjustmentMember_c8af2d61-7e7b-4efb-9bb4-b92b3f839617" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.foghorntx.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="ice4dedfd838141a8aa61da46b66c6ab0_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_50e56e5f-eed8-438c-8798-9fc73792f8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_AnnualLicenseMaintenanceFees_61324370-9782-49ed-96d8-7a4f8d3e74e2" xlink:href="fhtx-20211231.xsd#fhtx_AnnualLicenseMaintenanceFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_50e56e5f-eed8-438c-8798-9fc73792f8e6" xlink:to="loc_fhtx_AnnualLicenseMaintenanceFees_61324370-9782-49ed-96d8-7a4f8d3e74e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_MilestonesPayableUponEvent_c54ab9cb-9374-4b3c-b2a8-c652794de21e" xlink:href="fhtx-20211231.xsd#fhtx_MilestonesPayableUponEvent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_50e56e5f-eed8-438c-8798-9fc73792f8e6" xlink:to="loc_fhtx_MilestonesPayableUponEvent_c54ab9cb-9374-4b3c-b2a8-c652794de21e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_d4a13e49-7ea2-4eb4-b601-312aa5284518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_50e56e5f-eed8-438c-8798-9fc73792f8e6" xlink:to="loc_us-gaap_LossContingenciesTable_d4a13e49-7ea2-4eb4-b601-312aa5284518" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d0355cba-a3a7-4030-b028-8f5d0e3883d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_d4a13e49-7ea2-4eb4-b601-312aa5284518" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d0355cba-a3a7-4030-b028-8f5d0e3883d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d0355cba-a3a7-4030-b028-8f5d0e3883d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d0355cba-a3a7-4030-b028-8f5d0e3883d0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d0355cba-a3a7-4030-b028-8f5d0e3883d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_47bc5ab0-fa6d-4e90-8db0-d644a6eb4eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d0355cba-a3a7-4030-b028-8f5d0e3883d0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_47bc5ab0-fa6d-4e90-8db0-d644a6eb4eb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_StanfordLicenseAgreementMember_34b32fcf-f6fc-4422-b292-a10860b09f7f" xlink:href="fhtx-20211231.xsd#fhtx_StanfordLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_47bc5ab0-fa6d-4e90-8db0-d644a6eb4eb3" xlink:to="loc_fhtx_StanfordLicenseAgreementMember_34b32fcf-f6fc-4422-b292-a10860b09f7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_db54bb75-98e4-406e-80ce-59a23332d1b4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_d4a13e49-7ea2-4eb4-b601-312aa5284518" xlink:to="loc_srt_RangeAxis_db54bb75-98e4-406e-80ce-59a23332d1b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_db54bb75-98e4-406e-80ce-59a23332d1b4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_db54bb75-98e4-406e-80ce-59a23332d1b4" xlink:to="loc_srt_RangeMember_db54bb75-98e4-406e-80ce-59a23332d1b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_11dd9964-a9a6-4c7f-8f05-198ef5474d83" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_db54bb75-98e4-406e-80ce-59a23332d1b4" xlink:to="loc_srt_RangeMember_11dd9964-a9a6-4c7f-8f05-198ef5474d83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f49861d1-8bc1-415f-8451-5b9dbcfa4781" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_11dd9964-a9a6-4c7f-8f05-198ef5474d83" xlink:to="loc_srt_MaximumMember_f49861d1-8bc1-415f-8451-5b9dbcfa4781" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/RelatedPartiesDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#RelatedPartiesDetails"/>
  <link:definitionLink xlink:role="http://www.foghorntx.com/role/RelatedPartiesDetails" xlink:type="extended" id="i5f82fd2aeb2d4bb9ab9c856e64c671ab_RelatedPartiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_7bff5467-c3df-4099-8102-703340ce4bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ServiceAgreementTerm_b6ed3514-4f5c-4a59-9d3b-4838a7e7ad86" xlink:href="fhtx-20211231.xsd#fhtx_ServiceAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7bff5467-c3df-4099-8102-703340ce4bf9" xlink:to="loc_fhtx_ServiceAgreementTerm_b6ed3514-4f5c-4a59-9d3b-4838a7e7ad86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ServiceAgreementRenewalTerm_662b2584-f1f7-49a4-9325-e4e2a1d0c095" xlink:href="fhtx-20211231.xsd#fhtx_ServiceAgreementRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7bff5467-c3df-4099-8102-703340ce4bf9" xlink:to="loc_fhtx_ServiceAgreementRenewalTerm_662b2584-f1f7-49a4-9325-e4e2a1d0c095" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_CashPaymentsRelatedParty_d7a58fe2-b6eb-4188-8207-3182620cec5e" xlink:href="fhtx-20211231.xsd#fhtx_CashPaymentsRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7bff5467-c3df-4099-8102-703340ce4bf9" xlink:to="loc_fhtx_CashPaymentsRelatedParty_d7a58fe2-b6eb-4188-8207-3182620cec5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_4951672c-29fa-488d-b96b-8001cb5c720b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7bff5467-c3df-4099-8102-703340ce4bf9" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_4951672c-29fa-488d-b96b-8001cb5c720b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18aefa2f-da7c-4225-87b2-8653504efda6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7bff5467-c3df-4099-8102-703340ce4bf9" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18aefa2f-da7c-4225-87b2-8653504efda6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_890ca288-f851-41d5-9aa1-7b45b6acd2fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18aefa2f-da7c-4225-87b2-8653504efda6" xlink:to="loc_srt_CounterpartyNameAxis_890ca288-f851-41d5-9aa1-7b45b6acd2fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_890ca288-f851-41d5-9aa1-7b45b6acd2fe_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_890ca288-f851-41d5-9aa1-7b45b6acd2fe" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_890ca288-f851-41d5-9aa1-7b45b6acd2fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7ef7527b-ccd4-4f6d-bfbb-34935346528a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_890ca288-f851-41d5-9aa1-7b45b6acd2fe" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7ef7527b-ccd4-4f6d-bfbb-34935346528a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_FlagshipPioneeringMember_f6fa288e-7133-459a-b1b1-21b9daf246f5" xlink:href="fhtx-20211231.xsd#fhtx_FlagshipPioneeringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7ef7527b-ccd4-4f6d-bfbb-34935346528a" xlink:to="loc_fhtx_FlagshipPioneeringMember_f6fa288e-7133-459a-b1b1-21b9daf246f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_15098f2c-dc50-47b7-8e7e-94ab4b0a5159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18aefa2f-da7c-4225-87b2-8653504efda6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_15098f2c-dc50-47b7-8e7e-94ab4b0a5159" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_15098f2c-dc50-47b7-8e7e-94ab4b0a5159_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_15098f2c-dc50-47b7-8e7e-94ab4b0a5159" xlink:to="loc_us-gaap_RelatedPartyDomain_15098f2c-dc50-47b7-8e7e-94ab4b0a5159_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8e183662-f1f4-47fa-ae4f-caa55304a7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_15098f2c-dc50-47b7-8e7e-94ab4b0a5159" xlink:to="loc_us-gaap_RelatedPartyDomain_8e183662-f1f4-47fa-ae4f-caa55304a7b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_050c9dcb-3730-490e-a77a-d9caefecc526" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8e183662-f1f4-47fa-ae4f-caa55304a7b9" xlink:to="loc_srt_AffiliatedEntityMember_050c9dcb-3730-490e-a77a-d9caefecc526" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_d863f48a-e233-4531-b28e-bf8b715a9f34" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18aefa2f-da7c-4225-87b2-8653504efda6" xlink:to="loc_srt_TitleOfIndividualAxis_d863f48a-e233-4531-b28e-bf8b715a9f34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d863f48a-e233-4531-b28e-bf8b715a9f34_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_d863f48a-e233-4531-b28e-bf8b715a9f34" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d863f48a-e233-4531-b28e-bf8b715a9f34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d3113dd7-dd3e-4b85-b8d9-e84b01c69af2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_d863f48a-e233-4531-b28e-bf8b715a9f34" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d3113dd7-dd3e-4b85-b8d9-e84b01c69af2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_3730fb3f-a8c2-4b1d-a830-197e25ee4cfb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d3113dd7-dd3e-4b85-b8d9-e84b01c69af2" xlink:to="loc_srt_DirectorMember_3730fb3f-a8c2-4b1d-a830-197e25ee4cfb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ScientificFounderMember_7f386b75-eac7-4956-bc08-5d62854639bf" xlink:href="fhtx-20211231.xsd#fhtx_ScientificFounderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d3113dd7-dd3e-4b85-b8d9-e84b01c69af2" xlink:to="loc_fhtx_ScientificFounderMember_7f386b75-eac7-4956-bc08-5d62854639bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ea1b7361-97ec-4dfd-9e60-cc8492bba37a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18aefa2f-da7c-4225-87b2-8653504efda6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ea1b7361-97ec-4dfd-9e60-cc8492bba37a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ea1b7361-97ec-4dfd-9e60-cc8492bba37a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ea1b7361-97ec-4dfd-9e60-cc8492bba37a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ea1b7361-97ec-4dfd-9e60-cc8492bba37a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bd8465d7-4fbc-4693-ae9f-1666426594d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ea1b7361-97ec-4dfd-9e60-cc8492bba37a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bd8465d7-4fbc-4693-ae9f-1666426594d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_40c1dd15-7fb8-46a9-b6a1-51398c62c88f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_bd8465d7-4fbc-4693-ae9f-1666426594d9" xlink:to="loc_us-gaap_SubsequentEventMember_40c1dd15-7fb8-46a9-b6a1-51398c62c88f" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>fhtx-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:45bd6193-dace-4c5a-b62d-c265e68fd1cf,g:2c36ac82-298b-41b7-8200-caa9bbc65128-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_56cb9c9e-90d4-4c7b-a15e-8399499e96e0_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2cdb7328-bfd3-4ce4-85e7-19b5e1c65afa_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal statutory income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_db6ef2d7-e4c9-41ba-b635-6b65824360c3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c146c094-c0ac-4f16-85b8-c76015d5d8e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_8990321b-9a84-4aa1-8b9f-ce7d553ff59f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a2447b87-c645-4671-84d1-6595babd0e91_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_1ffd6221-8fea-47b3-a5c3-70c99982bb6d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_036093a0-9c11-4487-bb51-aadd74b621a4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_b3809416-e4d4-4e1a-b80b-a14087f4c36b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proferred stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_e728afb4-d54a-4cde-b2dd-bd0c6ddbde60_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_e2441c62-b575-4fe6-9f13-a544865797f3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_84356582-c608-4349-b154-9900bc189ef2_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_4ae372ca-1258-417a-80a6-4585c2942589_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_AnnualLicenseMaintenanceFees_5ecdffd8-19aa-4477-bdbb-8a3a7889753d_terseLabel_en-US" xlink:label="lab_fhtx_AnnualLicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license maintenance fees</link:label>
    <link:label id="lab_fhtx_AnnualLicenseMaintenanceFees_label_en-US" xlink:label="lab_fhtx_AnnualLicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual License Maintenance Fees</link:label>
    <link:label id="lab_fhtx_AnnualLicenseMaintenanceFees_documentation_en-US" xlink:label="lab_fhtx_AnnualLicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license maintenance fees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_AnnualLicenseMaintenanceFees" xlink:href="fhtx-20211231.xsd#fhtx_AnnualLicenseMaintenanceFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_AnnualLicenseMaintenanceFees" xlink:to="lab_fhtx_AnnualLicenseMaintenanceFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_6bdfcaa7-89b4-4efa-9357-19e41806fcc9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ad22d1d2-1662-4885-8daa-f041c9d04af5_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name&#160;of&#160;each&#160;exchange on&#160;which&#160;registered</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_674094e9-ea0f-4425-afa8-c31778b9cce1_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_3bc4118a-ec76-4562-9c85-64450cf9de71_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_ResearchDevelopmentAndRegulatoryMember_0376f63d-3a16-4723-917a-d415846c3a6c_terseLabel_en-US" xlink:label="lab_fhtx_ResearchDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Development And Regulatory</link:label>
    <link:label id="lab_fhtx_ResearchDevelopmentAndRegulatoryMember_label_en-US" xlink:label="lab_fhtx_ResearchDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Development And Regulatory [Member]</link:label>
    <link:label id="lab_fhtx_ResearchDevelopmentAndRegulatoryMember_documentation_en-US" xlink:label="lab_fhtx_ResearchDevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research development and regulatory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ResearchDevelopmentAndRegulatoryMember" xlink:href="fhtx-20211231.xsd#fhtx_ResearchDevelopmentAndRegulatoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_ResearchDevelopmentAndRegulatoryMember" xlink:to="lab_fhtx_ResearchDevelopmentAndRegulatoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_75d3a5e7-c88e-4953-bf22-e162d15e9148_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d1f85b94-0358-488a-bd79-7e045f23c819_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term&#8212;operating leases (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_c68ebece-3737-416a-8d8a-f1666d0fad63_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_28189b52-0ca9-4f0f-8aa7-43640da08f18_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_8f78defb-4a0d-4243-b98b-4e7c524f7de6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7f7772d8-c8f7-4539-8d20-8ee0d7f6eefa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3ad0b7f8-5d9d-4391-9e48-ababeb598bb4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_AccruedResearchAndDevelopmentExpenses_c8bb0e6d-137f-4980-9466-d646e1f39192_terseLabel_en-US" xlink:label="lab_fhtx_AccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued external research and development expenses</link:label>
    <link:label id="lab_fhtx_AccruedResearchAndDevelopmentExpenses_label_en-US" xlink:label="lab_fhtx_AccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expenses</link:label>
    <link:label id="lab_fhtx_AccruedResearchAndDevelopmentExpenses_documentation_en-US" xlink:label="lab_fhtx_AccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for expenses related to research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_AccruedResearchAndDevelopmentExpenses" xlink:href="fhtx-20211231.xsd#fhtx_AccruedResearchAndDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_AccruedResearchAndDevelopmentExpenses" xlink:to="lab_fhtx_AccruedResearchAndDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_ca1deb36-7fe2-44c7-b3ff-114a184f6959_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0321d751-5be2-4070-8568-dcf436b694a2_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e3c82144-f510-4dcd-bc0f-3e0ad1ed560a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_487a2c22-95a9-4817-bee9-2db161078957_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_be764694-51dc-4dbf-9eaa-87678ab8d22a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of stock options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_c292357f-1af4-4ac2-be36-60f62ae4fd33_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available for Sale Marketable Securities By Security Type</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_6f882b70-503b-4407-87ad-2af9b7adbc38_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_16002e9a-1338-44f7-b024-a75a1dd9e2dc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_87574efe-00d5-4a72-8eb6-b0459a7bbe82_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_ffbc1209-2f29-442d-847d-3ef5c72683e8_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_059edb43-7c85-46cd-85c1-41aae789449c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate&#8212;operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8612a099-8de9-41d4-935b-ce7d2ae2adaa_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_48b4c873-97d0-4262-b2bd-7553ce9076f3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_edc5afa9-d61b-4c97-bd27-1aa6ef9b8345_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_7273107c-4154-4754-ab76-55639f4a04a4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_63568cc3-96fc-4bf6-aa77-070be40c83a7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_584b4f83-2aeb-4d4f-8a04-f0a39b17d922_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair value of restricted stock that vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_433dcf4a-6280-4426-b120-6c2ed7b9f150_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_1125b046-6473-4718-8173-61524908b54a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_01ad8843-4b1f-41be-b094-9dc44048dfdc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_671802c2-6fd9-43d9-a397-9c1dc6c7bd11_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b2615473-178e-4e32-a3f6-35ae1d38e2b1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_eca848cb-2a30-4d4a-b1cf-56e37a1fff5b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_53b10783-bbc6-430c-ba17-b80b90be79fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_00e456b7-5bfd-46a8-9cda-49c3490a5815_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_b956df4d-4ac7-477d-9479-37916df25917_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 25,000,000 shares authorized as of December&#160;31, 2021 and 2020; no shares issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_de2ca9f7-b07b-42a3-bb79-be6105636fb7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2ba3298c-1326-4ef6-87e1-d35a2ccd25ee_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3ba0c453-103d-47fe-b89b-bc4cea0b3816_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a3c1d1bc-e533-4d96-b54b-92bf1df53d0a_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_1ed095c9-404c-418f-b89b-98a46c44bf13_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_b248ad3f-13d9-4c97-91ca-1e00a598d6f2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5518a018-0513-4c2a-9612-f2f78d1b98e6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_5f3b4e35-6803-4e56-b110-47bc138d9ce9_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of leased property</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_07f8d291-b3d8-4866-8bd4-fc9ba06231bb_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_f90eddfe-c70d-415a-9e67-bd93639f24c8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e059bdfa-2451-427a-9223-60058c43cd98_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_788685ea-ce57-4725-aafa-296ed543aea1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_label_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Weighted Average Interest Rate, over Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:to="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bee2bcb7-b2b8-44ce-bc70-208856b296bc_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e41c9aa7-ff3b-4c5f-aea8-ebd7cf23eb38_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment included in accounts payable, accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_369af1aa-6240-4313-aee1-aa4b48d5e183_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities arising from obtaining right-of-use assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_PrepaymentPeriodAxis_633eb08c-728e-47d4-86e5-b65f45df2a21_terseLabel_en-US" xlink:label="lab_fhtx_PrepaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Period [Axis]</link:label>
    <link:label id="lab_fhtx_PrepaymentPeriodAxis_label_en-US" xlink:label="lab_fhtx_PrepaymentPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_PrepaymentPeriodAxis" xlink:href="fhtx-20211231.xsd#fhtx_PrepaymentPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_PrepaymentPeriodAxis" xlink:to="lab_fhtx_PrepaymentPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_8ae10d4e-c5c3-492a-92a1-f90450256ea7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Net Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_3d805207-e49a-4229-9a60-f20794f4fb49_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_938d860b-76e1-452a-9ca0-c2d8d5d6f406_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7375f3d7-b1db-49b1-a595-015a878d6b43_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_2484193a-d20f-4cb7-8073-69da684bcef1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final payment fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_PrepaymentPeriodThreeMember_4e2b4262-9f97-4300-8232-e008c3cb153e_terseLabel_en-US" xlink:label="lab_fhtx_PrepaymentPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Period Three</link:label>
    <link:label id="lab_fhtx_PrepaymentPeriodThreeMember_label_en-US" xlink:label="lab_fhtx_PrepaymentPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Period Three [Member]</link:label>
    <link:label id="lab_fhtx_PrepaymentPeriodThreeMember_documentation_en-US" xlink:label="lab_fhtx_PrepaymentPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Period Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_PrepaymentPeriodThreeMember" xlink:href="fhtx-20211231.xsd#fhtx_PrepaymentPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_PrepaymentPeriodThreeMember" xlink:to="lab_fhtx_PrepaymentPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_MilestoneReceivableUponAchievement_f16d9a73-6314-4671-9e2f-99b033d38ff0_terseLabel_en-US" xlink:label="lab_fhtx_MilestoneReceivableUponAchievement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount receivable for achievement of milestones</link:label>
    <link:label id="lab_fhtx_MilestoneReceivableUponAchievement_label_en-US" xlink:label="lab_fhtx_MilestoneReceivableUponAchievement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Receivable Upon Achievement</link:label>
    <link:label id="lab_fhtx_MilestoneReceivableUponAchievement_documentation_en-US" xlink:label="lab_fhtx_MilestoneReceivableUponAchievement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of consideration to be received upon achievement of specified milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_MilestoneReceivableUponAchievement" xlink:href="fhtx-20211231.xsd#fhtx_MilestoneReceivableUponAchievement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_MilestoneReceivableUponAchievement" xlink:to="lab_fhtx_MilestoneReceivableUponAchievement" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_FlagshipPioneeringMember_108da10b-78aa-4470-b6aa-b218b175f6ed_terseLabel_en-US" xlink:label="lab_fhtx_FlagshipPioneeringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Flagship Pioneering</link:label>
    <link:label id="lab_fhtx_FlagshipPioneeringMember_label_en-US" xlink:label="lab_fhtx_FlagshipPioneeringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Flagship Pioneering [Member]</link:label>
    <link:label id="lab_fhtx_FlagshipPioneeringMember_documentation_en-US" xlink:label="lab_fhtx_FlagshipPioneeringMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Flagship Pioneering.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_FlagshipPioneeringMember" xlink:href="fhtx-20211231.xsd#fhtx_FlagshipPioneeringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_FlagshipPioneeringMember" xlink:to="lab_fhtx_FlagshipPioneeringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_28f26edb-c397-4a2a-a0da-de3164b28c18_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5c700f0d-3db6-45f2-9446-306051fbf2e5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0ad9ae82-44a3-42a2-a201-1160e1ab3692_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders&#8212;basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_ConversionOfWarrantLiabilityToEquityMember_e8754a63-2083-4959-9ede-00d8e5069b5c_terseLabel_en-US" xlink:label="lab_fhtx_ConversionOfWarrantLiabilityToEquityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Warrant Liability to Equity</link:label>
    <link:label id="lab_fhtx_ConversionOfWarrantLiabilityToEquityMember_label_en-US" xlink:label="lab_fhtx_ConversionOfWarrantLiabilityToEquityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Warrant Liability to Equity [Member]</link:label>
    <link:label id="lab_fhtx_ConversionOfWarrantLiabilityToEquityMember_documentation_en-US" xlink:label="lab_fhtx_ConversionOfWarrantLiabilityToEquityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of warrant liability to equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ConversionOfWarrantLiabilityToEquityMember" xlink:href="fhtx-20211231.xsd#fhtx_ConversionOfWarrantLiabilityToEquityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_ConversionOfWarrantLiabilityToEquityMember" xlink:to="lab_fhtx_ConversionOfWarrantLiabilityToEquityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_ffbacb51-062b-4984-a776-9b0949331824_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease rent payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_235c7f53-dc8e-49cd-a043-ea2cb16e698a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss subject to expiration expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8236bc0d-9ede-4930-bc3e-d1540d6ca188_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_817251f8-85ef-43cc-ac26-8af58fd6977f_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income recorded as other income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_StanfordLicenseAgreementMember_a125875a-474c-4c9e-b1e6-8f5a3f3cff81_terseLabel_en-US" xlink:label="lab_fhtx_StanfordLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stanford License Agreement</link:label>
    <link:label id="lab_fhtx_StanfordLicenseAgreementMember_label_en-US" xlink:label="lab_fhtx_StanfordLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stanford License Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_StanfordLicenseAgreementMember" xlink:href="fhtx-20211231.xsd#fhtx_StanfordLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_StanfordLicenseAgreementMember" xlink:to="lab_fhtx_StanfordLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionPlanExpense_404e048d-f15f-4818-b8b3-b48110968c26_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionPlanExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense related to issuance of options and employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockOptionPlanExpense_label_en-US" xlink:label="lab_us-gaap_StockOptionPlanExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock or Unit Option Plan Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionPlanExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionPlanExpense" xlink:to="lab_us-gaap_StockOptionPlanExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_AuditInformationAbstract_label_en-US" xlink:label="lab_fhtx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_fhtx_AuditInformationAbstract_documentation_en-US" xlink:label="lab_fhtx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_AuditInformationAbstract" xlink:href="fhtx-20211231.xsd#fhtx_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_AuditInformationAbstract" xlink:to="lab_fhtx_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_InterestIncomeAndOtherIncomeExpense_037be65e-ee42-442b-ac2f-ea97b908cbc7_terseLabel_en-US" xlink:label="lab_fhtx_InterestIncomeAndOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income and other income (expense), net</link:label>
    <link:label id="lab_fhtx_InterestIncomeAndOtherIncomeExpense_label_en-US" xlink:label="lab_fhtx_InterestIncomeAndOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income And Other Income Expense</link:label>
    <link:label id="lab_fhtx_InterestIncomeAndOtherIncomeExpense_documentation_en-US" xlink:label="lab_fhtx_InterestIncomeAndOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of interest income and income (expense) related to nonoperating activities, classified as other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_InterestIncomeAndOtherIncomeExpense" xlink:href="fhtx-20211231.xsd#fhtx_InterestIncomeAndOtherIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_InterestIncomeAndOtherIncomeExpense" xlink:to="lab_fhtx_InterestIncomeAndOtherIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_ac116d54-eddb-4acd-966e-b525ce81d4ec_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper (due within one year)</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_b79421c0-4b89-4374-9305-ad28cea2cba0_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_46ca0037-974f-4f7f-8e21-6d6f3b59726e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_07fadaa4-decb-407b-818f-3d885a96139a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage_bdc323bf-84d9-431b-a6c3-c5e03be10d2b_terseLabel_en-US" xlink:label="lab_fhtx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, final payment fee percentage</link:label>
    <link:label id="lab_fhtx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage_label_en-US" xlink:label="lab_fhtx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid Percentage</link:label>
    <link:label id="lab_fhtx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage_documentation_en-US" xlink:label="lab_fhtx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt, as a percentage of the amounts drawn under the Term Loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xlink:href="fhtx-20211231.xsd#fhtx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xlink:to="lab_fhtx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_3cb3eb5e-aa89-4fd1-acc7-6bfd44cebbae_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_NumberOfTargets_b29ffc99-aefd-4ce3-b8cb-cfcb265b3d13_terseLabel_en-US" xlink:label="lab_fhtx_NumberOfTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of targets</link:label>
    <link:label id="lab_fhtx_NumberOfTargets_label_en-US" xlink:label="lab_fhtx_NumberOfTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Targets</link:label>
    <link:label id="lab_fhtx_NumberOfTargets_documentation_en-US" xlink:label="lab_fhtx_NumberOfTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_NumberOfTargets" xlink:href="fhtx-20211231.xsd#fhtx_NumberOfTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_NumberOfTargets" xlink:to="lab_fhtx_NumberOfTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_LineOfCreditAdditionalBorrowingCapacity_5d443c2a-bda9-4d03-af54-a61b19b8b04f_terseLabel_en-US" xlink:label="lab_fhtx_LineOfCreditAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of long-term debt</link:label>
    <link:label id="lab_fhtx_LineOfCreditAdditionalBorrowingCapacity_label_en-US" xlink:label="lab_fhtx_LineOfCreditAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Additional Borrowing Capacity</link:label>
    <link:label id="lab_fhtx_LineOfCreditAdditionalBorrowingCapacity_documentation_en-US" xlink:label="lab_fhtx_LineOfCreditAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Additional Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_LineOfCreditAdditionalBorrowingCapacity" xlink:href="fhtx-20211231.xsd#fhtx_LineOfCreditAdditionalBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_LineOfCreditAdditionalBorrowingCapacity" xlink:to="lab_fhtx_LineOfCreditAdditionalBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_EliLillyMember_b1d235f8-8c79-4f67-b3cd-d0890e868240_terseLabel_en-US" xlink:label="lab_fhtx_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly</link:label>
    <link:label id="lab_fhtx_EliLillyMember_label_en-US" xlink:label="lab_fhtx_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly [Member]</link:label>
    <link:label id="lab_fhtx_EliLillyMember_documentation_en-US" xlink:label="lab_fhtx_EliLillyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_EliLillyMember" xlink:href="fhtx-20211231.xsd#fhtx_EliLillyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_EliLillyMember" xlink:to="lab_fhtx_EliLillyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_4a1b67da-17db-4a6d-89ec-1dc831958a6e_terseLabel_en-US" xlink:label="lab_fhtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series B convertible preferred stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_fhtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_fhtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label id="lab_fhtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_documentation_en-US" xlink:label="lab_fhtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of shares of new stock classified as temporary equity issued during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="fhtx-20211231.xsd#fhtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_fhtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_50a09e20-b0ef-4c43-ba58-24dc1120dd7c_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_8b0c946a-b602-4140-b21f-6353dec0e556_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_dcf5f37d-c85f-42fd-a4b0-20b97f3ae832_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of discount and current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_ea8830c0-b764-4ffb-9e1f-64961dbf6d2e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_41d51fac-f066-4cc7-9f2f-59f0cb5cb956_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_820bfc9e-ec29-41a4-98a6-63f509240ec8_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_8752163e-d7eb-4c84-9768-363c2f10f4ab_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_OfficeSpaceInCambridgeMassachusettsMember_c4ec2961-6023-4941-bbb1-b08ba4c73b02_terseLabel_en-US" xlink:label="lab_fhtx_OfficeSpaceInCambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space In Cambridge, Massachusetts</link:label>
    <link:label id="lab_fhtx_OfficeSpaceInCambridgeMassachusettsMember_label_en-US" xlink:label="lab_fhtx_OfficeSpaceInCambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space In Cambridge, Massachusetts [Member]</link:label>
    <link:label id="lab_fhtx_OfficeSpaceInCambridgeMassachusettsMember_documentation_en-US" xlink:label="lab_fhtx_OfficeSpaceInCambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space In Cambridge, Massachusetts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_OfficeSpaceInCambridgeMassachusettsMember" xlink:href="fhtx-20211231.xsd#fhtx_OfficeSpaceInCambridgeMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_OfficeSpaceInCambridgeMassachusettsMember" xlink:to="lab_fhtx_OfficeSpaceInCambridgeMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_087d215b-e9ba-4e0d-98c2-3a52d41ea6bb_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_59e85f19-f7c9-4746-b859-9b99a35ea90c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_2f65a2a1-6a7a-42af-816c-77fbd78e4c80_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_7e70de0a-7ac5-404a-89d1-18b8981e285d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_86c2eade-41d6-4434-abe6-b5e3905b9fae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_c278eabf-d439-4b73-9b16-538cc35fe2ad_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future sublease income outstanding</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_9b746cf1-6905-4cf6-aca4-fc074b74a802_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_fbe3567d-a209-4771-bc38-9e56b3e06b02_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f2c73b31-419d-43d3-a2e6-e707b80058f7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_e3594881-c3cf-4dda-bf56-4153f739906a_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_DeferredTaxAssetsCapitalizedStartUpCosts_2a159451-6912-485e-aec9-f9a51cd77fc7_terseLabel_en-US" xlink:label="lab_fhtx_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized start-up costs</link:label>
    <link:label id="lab_fhtx_DeferredTaxAssetsCapitalizedStartUpCosts_label_en-US" xlink:label="lab_fhtx_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Capitalized Start Up Costs</link:label>
    <link:label id="lab_fhtx_DeferredTaxAssetsCapitalizedStartUpCosts_documentation_en-US" xlink:label="lab_fhtx_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capitalized start-up costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:href="fhtx-20211231.xsd#fhtx_DeferredTaxAssetsCapitalizedStartUpCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:to="lab_fhtx_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8f825ee7-cdc4-407c-b4f4-939147c58958_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_aaf2e876-ef9d-4584-b82d-cef67f2af830_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_c864b6de-237c-4cf0-a18f-5fe698ed9c63_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_aa967468-e5a8-451e-a545-b71203e2eb49_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_f5a771b5-46b8-43c4-9a73-9e2be3e2fc2d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from initial public offering, net of underwriting discounts, commissions and offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_fe293348-b38f-455e-9f76-3a8b4b5cc99b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_289e4f27-e140-418b-b8e1-14703c9b0544_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_92d50536-a0c8-4ec6-892a-fae7ef7ed2ea_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeaseTermOfContract_b02530e5-90c2-4d3e-8d8f-b4919baf712f_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_41c8b214-af35-4b7f-ac69-5440acc3f7e8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_afa09f85-eee5-4a04-a653-fa6b94e7544d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_90379317-0648-4e24-9553-4f94f67c6be8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_efe5d3ca-cd18-4494-b2e1-402c0aa091c7_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_4c5891a8-b52e-4909-9f8c-817d58424076_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal and state research and development tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2be94bd4-b5ef-4efe-8861-e15b418ece53_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_f08001ab-e654-424e-9fe6-e73052898096_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_dc31ccf4-c2d4-41d5-91ff-7b8e83b20b4c_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_737b43a9-e822-46a0-83f9-fce5ca2c34f0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScenarioAdjustmentMember_53def404-1ecc-4fc3-bc66-d6d80b6002de_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Adjustment</link:label>
    <link:label id="lab_us-gaap_ScenarioAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_ScenarioAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScenarioAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioAdjustmentMember" xlink:to="lab_us-gaap_ScenarioAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_TermLoanAMember_cdefbe86-1109-446c-b24d-e2653a85562f_terseLabel_en-US" xlink:label="lab_fhtx_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A</link:label>
    <link:label id="lab_fhtx_TermLoanAMember_label_en-US" xlink:label="lab_fhtx_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_TermLoanAMember" xlink:href="fhtx-20211231.xsd#fhtx_TermLoanAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_TermLoanAMember" xlink:to="lab_fhtx_TermLoanAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_4ba8b9ac-60dd-464f-9572-e9485e851d47_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of notes payable, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_10cb1bf7-1f92-40d7-b06e-b5bb31ea4065_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_fdf39797-4397-4ce6-be33-226c49c6d318_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_83660c3a-3649-4bb5-a4c9-5909e2a2f928_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_AccruedTenantImprovements_e1a8192f-0fde-4adb-8d4e-c742f6681021_terseLabel_en-US" xlink:label="lab_fhtx_AccruedTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued tenant improvements</link:label>
    <link:label id="lab_fhtx_AccruedTenantImprovements_label_en-US" xlink:label="lab_fhtx_AccruedTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Tenant Improvements</link:label>
    <link:label id="lab_fhtx_AccruedTenantImprovements_documentation_en-US" xlink:label="lab_fhtx_AccruedTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_AccruedTenantImprovements" xlink:href="fhtx-20211231.xsd#fhtx_AccruedTenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_AccruedTenantImprovements" xlink:to="lab_fhtx_AccruedTenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_0d17801a-c4da-43a1-966d-97e2c16b0a9e_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_5894f6d2-d9aa-4f37-abc3-5144f69c0cd5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_f97fe486-77f7-4975-a336-a4ae67b3feed_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_efd99124-05a1-4386-816d-2a0e93a9a435_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a3a43126-627c-472d-9b5c-ba5af2d48ee4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_WarrantsIssuePricePerShare_9ab2575d-cccc-4be2-b908-1f83f3e8bb5e_terseLabel_en-US" xlink:label="lab_fhtx_WarrantsIssuePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issue price per share (in dollars per share)</link:label>
    <link:label id="lab_fhtx_WarrantsIssuePricePerShare_label_en-US" xlink:label="lab_fhtx_WarrantsIssuePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issue Price Per Share</link:label>
    <link:label id="lab_fhtx_WarrantsIssuePricePerShare_documentation_en-US" xlink:label="lab_fhtx_WarrantsIssuePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per unit amount of warrant issued.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_WarrantsIssuePricePerShare" xlink:href="fhtx-20211231.xsd#fhtx_WarrantsIssuePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_WarrantsIssuePricePerShare" xlink:to="lab_fhtx_WarrantsIssuePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_2a48b896-4366-46d1-b60c-ebc28aa8970e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_61dc18a8-4164-4ea4-9cc6-0e64c4c9f667_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury notes (due within one year)</link:label>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Notes Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_PrepaymentPeriodDomain_7acbeb46-8f37-4021-b754-d2fb73e3d1a6_terseLabel_en-US" xlink:label="lab_fhtx_PrepaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Period [Domain]</link:label>
    <link:label id="lab_fhtx_PrepaymentPeriodDomain_label_en-US" xlink:label="lab_fhtx_PrepaymentPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_PrepaymentPeriodDomain" xlink:href="fhtx-20211231.xsd#fhtx_PrepaymentPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_PrepaymentPeriodDomain" xlink:to="lab_fhtx_PrepaymentPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7bee0536-85f5-458b-889b-44a9da72274e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_c6ff09ba-c4e4-49e7-9a55-2eb04cd3bb3f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock during the period new shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_bb272573-bea6-458d-ae1e-707503950c0c_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_f4dde368-fec3-424d-b95d-f7457ef3d2d3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a1ca28cb-afb2-49f9-b088-67eda1494594_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d0cb6945-5bee-4289-b9eb-69ddd1cea99e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7fb08c5c-baa8-4130-b7d9-dfb6712293fc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_a230fa58-c20c-44b5-8591-485e19f7fa5f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_3eb53507-c3e0-4bf0-8bf8-6d348317d84c_negatedLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_e6355bfd-bf1c-47ce-9a77-009bc48ee160_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_AdditionalOfficeSpaceInCambridgeMassachusettsMember_14b654dd-83a7-4152-b24f-518c5826c9c7_terseLabel_en-US" xlink:label="lab_fhtx_AdditionalOfficeSpaceInCambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Office Space In Cambridge, Massachusetts</link:label>
    <link:label id="lab_fhtx_AdditionalOfficeSpaceInCambridgeMassachusettsMember_label_en-US" xlink:label="lab_fhtx_AdditionalOfficeSpaceInCambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Office Space In Cambridge, Massachusetts [Member]</link:label>
    <link:label id="lab_fhtx_AdditionalOfficeSpaceInCambridgeMassachusettsMember_documentation_en-US" xlink:label="lab_fhtx_AdditionalOfficeSpaceInCambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Office Space In Cambridge, Massachusetts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_AdditionalOfficeSpaceInCambridgeMassachusettsMember" xlink:href="fhtx-20211231.xsd#fhtx_AdditionalOfficeSpaceInCambridgeMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_AdditionalOfficeSpaceInCambridgeMassachusettsMember" xlink:to="lab_fhtx_AdditionalOfficeSpaceInCambridgeMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_20b973f4-f1bd-4f74-a770-d0766375ba2f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6bb00ef6-480f-4084-9f57-833a7b894dda_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during the period shares new issues shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_ScientificFounderMember_5772c352-061d-441e-ab78-9371226f38b4_terseLabel_en-US" xlink:label="lab_fhtx_ScientificFounderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scientific Founder</link:label>
    <link:label id="lab_fhtx_ScientificFounderMember_label_en-US" xlink:label="lab_fhtx_ScientificFounderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scientific Founder [Member]</link:label>
    <link:label id="lab_fhtx_ScientificFounderMember_documentation_en-US" xlink:label="lab_fhtx_ScientificFounderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scientific Founder.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ScientificFounderMember" xlink:href="fhtx-20211231.xsd#fhtx_ScientificFounderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_ScientificFounderMember" xlink:to="lab_fhtx_ScientificFounderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_NumberOfAdditionalTargets_a5ee0d44-f1ad-41a3-9974-4d654c291483_terseLabel_en-US" xlink:label="lab_fhtx_NumberOfAdditionalTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional targets</link:label>
    <link:label id="lab_fhtx_NumberOfAdditionalTargets_label_en-US" xlink:label="lab_fhtx_NumberOfAdditionalTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Additional Targets</link:label>
    <link:label id="lab_fhtx_NumberOfAdditionalTargets_documentation_en-US" xlink:label="lab_fhtx_NumberOfAdditionalTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Additional Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_NumberOfAdditionalTargets" xlink:href="fhtx-20211231.xsd#fhtx_NumberOfAdditionalTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_NumberOfAdditionalTargets" xlink:to="lab_fhtx_NumberOfAdditionalTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_3f5ee82c-7118-4732-98af-f46a9e480d58_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f3e5cbce-7c44-4392-a5b8-3da7f21ef447_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_bbda9a7f-63f9-4bfb-9851-c142f1a0cfc9_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_01e933ac-7b44-4ae4-b925-8980889d72b3_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_35a6f748-d1f3-4f2a-8a26-86cfede9ab7b_terseLabel_en-US" xlink:label="lab_fhtx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash lease expense</link:label>
    <link:label id="lab_fhtx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_fhtx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Operating Lease Right Of Use Asset</link:label>
    <link:label id="lab_fhtx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_fhtx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase (decrease) in right-of-use assets under an operating lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="fhtx-20211231.xsd#fhtx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_fhtx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_a2b5a80e-d71e-4629-9128-0cf2a9e466ef_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 175,000,000 shares authorized at December&#160;31, 2021 and 2020; 41,299,720 shares issued and outstanding at December&#160;31, 2021 and 36,790,946 shares issued and outstanding at December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_6fbbc3ef-d7db-4ef6-be0c-a70fbae416c5_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2062bd33-4989-4695-8d65-500e03a666f6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period of unrecognized compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_abf9232e-6c18-48a9-a48a-ceac2416a484_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1a361db0-6474-4860-b8f8-8da1f24a68b9_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_6c91ac44-8ba9-4029-990a-33e6f931171c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 13)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_87f7d4ec-acc1-49e7-ab0c-5f470c0fc1ad_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9e0932a8-6daf-45c3-975b-b8aaa5039a24_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_93cf2d09-9327-472f-9f92-9f0e7fb0bab0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_f8029e6a-bc37-4f54-83ea-d56fde538267_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_6099d9f9-7d4b-4c5a-b561-5856268b9a56_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_24ea1893-9f61-4799-9806-28701653cadc_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_168fd08d-a51d-4b05-b622-4f97f1141459_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options and Restricted Stock Awards using Black-Scholes Option Pricing Model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_5b4e9001-a4b8-46f2-8459-6675b8341b44_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_2bda1e4c-99d5-4633-8351-4f70e31a7537_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_92ec5450-5fa7-4726-97cb-de93e0b34829_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_TermLoanBMember_394d11ef-7805-4378-9793-6a8430d51f1e_terseLabel_en-US" xlink:label="lab_fhtx_TermLoanBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B</link:label>
    <link:label id="lab_fhtx_TermLoanBMember_label_en-US" xlink:label="lab_fhtx_TermLoanBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_TermLoanBMember" xlink:href="fhtx-20211231.xsd#fhtx_TermLoanBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_TermLoanBMember" xlink:to="lab_fhtx_TermLoanBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_c04461aa-e822-491b-a585-d29a5a811430_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_408d161f-e8fd-4bf3-98c4-ae86dc8867f0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_aeb47195-33ef-42a2-a099-10e8aaaa80b3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7af6d950-914b-401e-b5dd-f5e4d8588907_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_946e81fa-7534-4a36-914f-2b8a052ce491_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_62ece686-a0f9-4a46-a6a7-3e88eb788fff_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6a29e9db-e642-408d-968f-4a89a431baf7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_cbb8f7f0-9e31-4ca1-b285-75911e28c7c8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ac681d35-935e-4d95-afdc-6a23adea993c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock consideration received on the transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4441ebfa-bf6e-4ec9-a027-1b087c093d96_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_950758f8-4119-414e-97d4-0755e3e93da0_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_b1a682c7-a2ae-43b9-9ded-92fff3cfbd4d_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_f2b4f997-14b2-43df-a3b3-de2060fe068e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="lab_us-gaap_ShortTermDebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_efddd691-055d-43f6-8850-1fad078a81fe_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6c61014e-fc45-4a01-9412-39affa7304c8_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ec611b36-e4d3-4dc8-b416-3c496643a8d0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2ec60677-7100-4666-82ee-8ff41d4f9500_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_ProceedsFromUpfrontPayment_d260773b-a0c4-4807-bb30-c778e8614bbf_terseLabel_en-US" xlink:label="lab_fhtx_ProceedsFromUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_fhtx_ProceedsFromUpfrontPayment_label_en-US" xlink:label="lab_fhtx_ProceedsFromUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Upfront Payment</link:label>
    <link:label id="lab_fhtx_ProceedsFromUpfrontPayment_documentation_en-US" xlink:label="lab_fhtx_ProceedsFromUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from upfront payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ProceedsFromUpfrontPayment" xlink:href="fhtx-20211231.xsd#fhtx_ProceedsFromUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_ProceedsFromUpfrontPayment" xlink:to="lab_fhtx_ProceedsFromUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_3711623a-b0f5-4bf6-b1db-d9ac003b17ea_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock purchase agreement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_PrepaymentPeriod_baa80895-4ee8-4104-ab03-9b32a9027304_terseLabel_en-US" xlink:label="lab_fhtx_PrepaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment period</link:label>
    <link:label id="lab_fhtx_PrepaymentPeriod_label_en-US" xlink:label="lab_fhtx_PrepaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Period</link:label>
    <link:label id="lab_fhtx_PrepaymentPeriod_documentation_en-US" xlink:label="lab_fhtx_PrepaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_PrepaymentPeriod" xlink:href="fhtx-20211231.xsd#fhtx_PrepaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_PrepaymentPeriod" xlink:to="lab_fhtx_PrepaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_bbb830b9-aa23-4f56-8c70-5003fa456d43_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_PrepaymentPeriodOneMember_ffdeca30-ace9-4808-ae1a-673354bc4b54_terseLabel_en-US" xlink:label="lab_fhtx_PrepaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Period One</link:label>
    <link:label id="lab_fhtx_PrepaymentPeriodOneMember_label_en-US" xlink:label="lab_fhtx_PrepaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Period One [Member]</link:label>
    <link:label id="lab_fhtx_PrepaymentPeriodOneMember_documentation_en-US" xlink:label="lab_fhtx_PrepaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_PrepaymentPeriodOneMember" xlink:href="fhtx-20211231.xsd#fhtx_PrepaymentPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_PrepaymentPeriodOneMember" xlink:to="lab_fhtx_PrepaymentPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_SalesBasedMilestoneMember_c0fd9fc0-f1ac-4c5d-8007-f2a310a93788_terseLabel_en-US" xlink:label="lab_fhtx_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Based Milestone</link:label>
    <link:label id="lab_fhtx_SalesBasedMilestoneMember_label_en-US" xlink:label="lab_fhtx_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Based Milestone [Member]</link:label>
    <link:label id="lab_fhtx_SalesBasedMilestoneMember_documentation_en-US" xlink:label="lab_fhtx_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Based Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_SalesBasedMilestoneMember" xlink:href="fhtx-20211231.xsd#fhtx_SalesBasedMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_SalesBasedMilestoneMember" xlink:to="lab_fhtx_SalesBasedMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_33b0ce0b-8431-4961-b460-4b04b4408ad0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_031dd36a-7ba0-4091-9694-bb49258d5023_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_3c505fd5-7fd2-4883-b9a3-a7aa4886e117_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_9669d732-419f-4447-a0dd-080e44e9d758_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss without expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_02a21b85-d782-4d36-a799-a9cd24accf17_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of preferred stock warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_e3b1da37-f07d-4f37-bba9-b3eb71ee0d5d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of preferred stock warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_PrepaymentPeriodTwoMember_ce8cf0eb-e364-40ea-907e-2c7aa2016922_terseLabel_en-US" xlink:label="lab_fhtx_PrepaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Period Two</link:label>
    <link:label id="lab_fhtx_PrepaymentPeriodTwoMember_label_en-US" xlink:label="lab_fhtx_PrepaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Period Two [Member]</link:label>
    <link:label id="lab_fhtx_PrepaymentPeriodTwoMember_documentation_en-US" xlink:label="lab_fhtx_PrepaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_PrepaymentPeriodTwoMember" xlink:href="fhtx-20211231.xsd#fhtx_PrepaymentPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_PrepaymentPeriodTwoMember" xlink:to="lab_fhtx_PrepaymentPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_8104b971-c8cb-4561-84dd-59e6b16a3d12_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_2c8be1b5-b2e7-457a-8992-c3a34a266434_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5288f798-c893-46f7-b7ec-dfac0bbad50a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_e23d0188-ad6b-4ada-ab01-b8cd04c608d3_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants not settlable in cash, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Not Settleable in Cash, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_4e6838d0-3895-4cc0-a3f6-e273c9a6778b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_80cbf7cd-09fc-4002-9d0a-cc617c37ad95_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8c50fb6f-66e2-4958-afc2-be4d35463d49_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_01506acc-bc85-4c91-a0c2-f2f95c26e585_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_e2a24a0c-7cfc-4aa4-836d-499c701f3657_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series B convertible preferred stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fadb656e-d5a2-4770-b4ea-9fbc2e5c3930_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_b95c5e56-6f7f-4685-a8b4-75cde5cc59ff_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_655090b8-d803-4e97-9d30-30b716e3ee16_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense related to issuance of options and employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_d1c9fec3-7c5a-41c3-a239-bb363c0a8dd9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_da4e13f9-5768-48f7-a770-4f05f45192f8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e33fb4cf-1621-41b0-b5a9-e85a1683de37_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_89b9bcb9-cc4d-4c80-af36-527745f4299e_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_76f579fa-3085-4932-b69e-4c65a44f713b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d94c9a6d-7f38-44b4-aa58-1c14496d8cbe_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, number of securities called by warrants or rights (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0e168e44-88ff-4379-983d-d92ed50b61c3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_IncreaseDecreaseInOperatingLeaseLiabilities_82c31314-32ce-40ee-ae8d-b0371a339a80_terseLabel_en-US" xlink:label="lab_fhtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_fhtx_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_fhtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:label id="lab_fhtx_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_fhtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) in operating lease liabilities during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="fhtx-20211231.xsd#fhtx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_fhtx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_ConversionOfNotesPayableInToWarrantsMember_93f68721-a0c8-48ea-9705-894213092d61_terseLabel_en-US" xlink:label="lab_fhtx_ConversionOfNotesPayableInToWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Notes Payable in to Warrants</link:label>
    <link:label id="lab_fhtx_ConversionOfNotesPayableInToWarrantsMember_label_en-US" xlink:label="lab_fhtx_ConversionOfNotesPayableInToWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Notes Payable in to Warrants [Member]</link:label>
    <link:label id="lab_fhtx_ConversionOfNotesPayableInToWarrantsMember_documentation_en-US" xlink:label="lab_fhtx_ConversionOfNotesPayableInToWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of notes payable in to warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ConversionOfNotesPayableInToWarrantsMember" xlink:href="fhtx-20211231.xsd#fhtx_ConversionOfNotesPayableInToWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_ConversionOfNotesPayableInToWarrantsMember" xlink:to="lab_fhtx_ConversionOfNotesPayableInToWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_6d89af33-13c3-4339-b0f9-de2983681675_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c5fc8511-5c6c-4358-8070-6e1ea812394b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_61490260-3c3e-4dba-853f-90094eccc879_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of convertible preferred stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_89962a3c-2d3d-41f7-8105-6f07136e565e_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_23aef0fe-2634-4a17-bd48-2f587a8ebcfe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_95e12199-9063-4220-b47d-b91acb0434df_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c9816ef9-3dc6-4fc4-9b36-b59765eb8c5f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7d4add6e-3252-45be-92cf-cf6ad7dc13ce_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_73805030-c6a7-4398-8345-45f7c893bee7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_0506afec-d33b-4da1-b363-53623e76e8b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_f008ac5e-e88e-464e-a1c5-825762e8d540_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_6c2a2038-51d2-4d90-87f5-79d6cdf28805_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_73b2e937-fc36-4657-b8c0-25621120035e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_StockIssuedDuringPeriodConnectionWithExerciseOfWarrant_95cb72ec-a778-42f0-82b5-a41b554920b4_terseLabel_en-US" xlink:label="lab_fhtx_StockIssuedDuringPeriodConnectionWithExerciseOfWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with the cashless exercise of warrants</link:label>
    <link:label id="lab_fhtx_StockIssuedDuringPeriodConnectionWithExerciseOfWarrant_label_en-US" xlink:label="lab_fhtx_StockIssuedDuringPeriodConnectionWithExerciseOfWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Connection With Exercise Of Warrant</link:label>
    <link:label id="lab_fhtx_StockIssuedDuringPeriodConnectionWithExerciseOfWarrant_documentation_en-US" xlink:label="lab_fhtx_StockIssuedDuringPeriodConnectionWithExerciseOfWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Connection With Exercise Of Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_StockIssuedDuringPeriodConnectionWithExerciseOfWarrant" xlink:href="fhtx-20211231.xsd#fhtx_StockIssuedDuringPeriodConnectionWithExerciseOfWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_StockIssuedDuringPeriodConnectionWithExerciseOfWarrant" xlink:to="lab_fhtx_StockIssuedDuringPeriodConnectionWithExerciseOfWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_0bdea9ee-c0ca-4278-a5e5-5e1e5085ca58_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_fad2ccbd-38c5-47ed-9d45-aefe72c60a48_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1a55ea19-8180-48da-b2d7-1cdbe5faa9e7_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_6072fcfe-1743-44e4-82c2-ff242fa114ea_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of warrants in connection with notes payable</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_2c7fbd4a-73e4-49a3-a5d4-560ac23fd25a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carry forward</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_af25cbc7-d31e-4e89-b941-fd025b73db17_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_154330fb-8050-4ba9-9020-2baa65c1c5f0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_917da6c3-a766-42f8-9482-ab4b19c9c102_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_879f98ab-88c2-4d55-bb73-f75fe62991a8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_6ba3abf3-bfd0-4154-9792-b01ce47cd60c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_c6e9dbde-6158-4f20-a9e9-c218c20d413e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of warrants in connection with notes payable</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7fe76310-0522-40e5-8495-3395c83cfc14_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_208f9a5d-c891-423b-9416-80a5ab88daf6_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on debt extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_299c48a3-faf9-4f45-b60b-cdb14d4b56a7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on debt extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_ed7cb098-e7bc-4aa5-b400-0dcf0b2aeee2_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_51caa7b5-e209-47a8-96a9-78fd1b79e267_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_c7a4c306-77dd-4079-a515-ee78cf9359ba_verboseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_a414fd0e-66cd-4fbf-bcbd-3a7db1b0d4bb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of credit risk and of significant suppliers</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_433d87fe-1d50-4cec-bdb0-4694198d4f09_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_be8803d9-eecb-49c4-bc46-453a616ad5a4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_de1afe02-bf79-4655-a92d-0f258bc6626f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_6aa5f5ef-2387-452e-be2b-57070fa110b2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_b0e8f0a1-f252-498f-a50f-cdda7feeadb4_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_8a708cae-659a-4b4d-8c9d-75355e0511b5_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_DeferredTaxAssetsOperatingLeaseLiabilities_fd2a46fe-7247-4f27-badb-19f9e660e837_terseLabel_en-US" xlink:label="lab_fhtx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_fhtx_DeferredTaxAssetsOperatingLeaseLiabilities_label_en-US" xlink:label="lab_fhtx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Operating Lease Liabilities</link:label>
    <link:label id="lab_fhtx_DeferredTaxAssetsOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_fhtx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:href="fhtx-20211231.xsd#fhtx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lab_fhtx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4a97d9ab-6597-4a03-9a58-087d6d2ddb1f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8f62c52a-0f8d-4550-96be-004ad90760c2_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_DeferredTaxLiabilitiesDepreciation_c5b347da-71cb-4f48-9109-ace6e7e50ef8_negatedLabel_en-US" xlink:label="lab_fhtx_DeferredTaxLiabilitiesDepreciation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_fhtx_DeferredTaxLiabilitiesDepreciation_label_en-US" xlink:label="lab_fhtx_DeferredTaxLiabilitiesDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities Depreciation</link:label>
    <link:label id="lab_fhtx_DeferredTaxLiabilitiesDepreciation_documentation_en-US" xlink:label="lab_fhtx_DeferredTaxLiabilitiesDepreciation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from depreciation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_DeferredTaxLiabilitiesDepreciation" xlink:href="fhtx-20211231.xsd#fhtx_DeferredTaxLiabilitiesDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_DeferredTaxLiabilitiesDepreciation" xlink:to="lab_fhtx_DeferredTaxLiabilitiesDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_446f6c96-8963-4aa2-af22-adfe6c2d5455_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_95dc67af-3b84-4aaa-85a0-78fc625bf3b1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option expiry period (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_a8bad5ca-8463-43dd-9b95-fee09a7caabf_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of stock, amount converted</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_0a7e13a3-011f-4570-93f1-74ff10a66805_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_2f70050d-38bd-4f4c-ace6-08f98be78b9c_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_99b6f67b-443e-4ff5-9273-6982c6ad7613_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2df82f5f-70fe-4703-ad10-92edd78873d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_28002360-9fa6-45f8-bae0-ce55a02b16f1_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury notes</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_3fa196ca-0896-4d05-bbe2-3f4c5310688f_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_f6e1f923-92aa-4e74-9c6d-95707ec4b999_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_cb44c127-f7fe-48a5-a7c0-497b020cc525_terseLabel_en-US" xlink:label="lab_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements</link:label>
    <link:label id="lab_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_label_en-US" xlink:label="lab_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label id="lab_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_documentation_en-US" xlink:label="lab_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization consolidation and presentation of financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:href="fhtx-20211231.xsd#fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="lab_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_556beb43-93c0-4993-bf34-291cc696736c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_2832a032-cfb6-4872-98cb-6cbfa6751bfd_terseLabel_en-US" xlink:label="lab_fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory Space In Cambridge, Massachusetts</link:label>
    <link:label id="lab_fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_label_en-US" xlink:label="lab_fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory Space In Cambridge, Massachusetts [Member]</link:label>
    <link:label id="lab_fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_documentation_en-US" xlink:label="lab_fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and Laboratory Space In Cambridge, Massachusetts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember" xlink:href="fhtx-20211231.xsd#fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember" xlink:to="lab_fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_01bdafc3-dfef-42c3-84ab-d5943861c191_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement_4bf4d079-3c2e-4a56-b791-0a2ace8d334a_terseLabel_en-US" xlink:label="lab_fhtx_ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in operating lease liabilities and right-of-use assets due to lease remeasurement</link:label>
    <link:label id="lab_fhtx_ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement_label_en-US" xlink:label="lab_fhtx_ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Operating Lease Liability Right Of Use Asset Re-Measurement</link:label>
    <link:label id="lab_fhtx_ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement_documentation_en-US" xlink:label="lab_fhtx_ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) in the operating lease liability and right of use asset as the result of a lease remeasurement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement" xlink:href="fhtx-20211231.xsd#fhtx_ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement" xlink:to="lab_fhtx_ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c3331c5d-6cdf-4972-8577-fec12673ea6e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of restricted common stock to scientific founders (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_fb4d0dd4-037e-4c7a-90f1-e8e6bbfc4a70_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_9ad2c330-ceeb-4c4e-acac-308fe64a9d9d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_4c4134f8-7a47-4ff2-884f-c8db1152ab31_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f4e5f756-1aff-423b-8cfe-ce45020c9be3_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_478ba28d-3b99-4f2e-9e4f-6c46da3629d4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_0d875688-52c5-4a63-9311-bcc512e48f45_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_30315dd7-6869-4b34-84d8-ee758e6c7322_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_352231e8-acfb-453b-b844-eaa0fb32c087_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c1160f30-f80e-46cc-8427-c8b68dd95c7b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1b072ef3-57a1-47b7-8f3d-01b05f0aaf5d_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_46ce664a-52eb-43d5-b2ac-08484f5fb429_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_OptOutMilestoneReceivableUponAchievement_9d7533d6-89a1-4c89-b1eb-367b8b04a40e_terseLabel_en-US" xlink:label="lab_fhtx_OptOutMilestoneReceivableUponAchievement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts receivable for opt out milestones</link:label>
    <link:label id="lab_fhtx_OptOutMilestoneReceivableUponAchievement_label_en-US" xlink:label="lab_fhtx_OptOutMilestoneReceivableUponAchievement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opt Out Milestone Receivable Upon Achievement</link:label>
    <link:label id="lab_fhtx_OptOutMilestoneReceivableUponAchievement_documentation_en-US" xlink:label="lab_fhtx_OptOutMilestoneReceivableUponAchievement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opt Out Milestone Receivable Upon Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_OptOutMilestoneReceivableUponAchievement" xlink:href="fhtx-20211231.xsd#fhtx_OptOutMilestoneReceivableUponAchievement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_OptOutMilestoneReceivableUponAchievement" xlink:to="lab_fhtx_OptOutMilestoneReceivableUponAchievement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9300c14b-013f-4b23-b57a-decd092d4f90_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_eabcf3db-c26b-486b-8df4-e65943471212_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_03de7c3e-7f8c-494d-aa5d-ce0c082726d8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of warrant liability to equity upon closing of initial public offering</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e3eefed8-f6fe-4378-aa9b-5625af0cf844_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_53a241e5-63a5-4b54-96b4-90ca0fb189ea_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b7b13d7e-45fa-4c27-a535-223368344e48_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_9a07a121-39ee-4e22-88e6-23b87693ecd6_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_ca12847b-9a8f-4357-83df-fba3dd54c43b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_e9544976-9fff-4916-a300-668f1fd941db_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_ac2e70d4-3671-4138-9724-26915bd42137_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_dcbd3d67-c5ea-43fd-9a51-37412fc5682d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_5232d32f-d034-4045-a4ba-a9fd51895783_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_cc2e8ae4-09c4-443d-8c79-e98253050d0c_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_22d1bbd4-70b8-41d6-a4c0-4d8c6f599e9b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value of stock options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_3d78f074-ce08-47ac-802e-68cfd34d6a4c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_WeightedAverageContractualTermAbstract_059391aa-3129-4236-8984-3727213e42b8_terseLabel_en-US" xlink:label="lab_fhtx_WeightedAverageContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Contractual Term</link:label>
    <link:label id="lab_fhtx_WeightedAverageContractualTermAbstract_label_en-US" xlink:label="lab_fhtx_WeightedAverageContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Contractual Term [Abstract]</link:label>
    <link:label id="lab_fhtx_WeightedAverageContractualTermAbstract_documentation_en-US" xlink:label="lab_fhtx_WeightedAverageContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_WeightedAverageContractualTermAbstract" xlink:href="fhtx-20211231.xsd#fhtx_WeightedAverageContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_WeightedAverageContractualTermAbstract" xlink:to="lab_fhtx_WeightedAverageContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_73c49ed7-427b-4deb-b266-60150f127a29_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_fe6471f6-137c-4bac-b055-bbaab420a0fe_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e91cecf3-e500-4c63-8659-3a97b07ebc31_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_3f7dbe55-ad84-444e-af11-fc4d810220a5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_54bc634d-b404-4c76-920d-cbeec821bdeb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5710daac-1a92-421f-820f-5599e12c9c13_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_2da20054-0354-474e-afbc-7a5fcc56a4c6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6e45b1bf-9520-452e-ae15-2744b17a715f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_08c35c65-1eba-4664-901e-5ba9c7255ac0_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_0dc2cffa-3408-46be-9692-ae1f4ab2d659_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_CommonStockTextBlock_4797a279-ea74-4b57-bc96-c090c30b3dd6_terseLabel_en-US" xlink:label="lab_fhtx_CommonStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_fhtx_CommonStockTextBlock_label_en-US" xlink:label="lab_fhtx_CommonStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Text Block]</link:label>
    <link:label id="lab_fhtx_CommonStockTextBlock_documentation_en-US" xlink:label="lab_fhtx_CommonStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for common stock, including, but not limited to voting rights, dividends, and stock splits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_CommonStockTextBlock" xlink:href="fhtx-20211231.xsd#fhtx_CommonStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_CommonStockTextBlock" xlink:to="lab_fhtx_CommonStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_16665476-1b8e-4229-a12e-a910b8d5b9a9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsatisfied portion of the performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_80e2cfef-8419-4919-a4e2-e5f9d4b767c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_5ed5ac0f-0a97-419e-9c0e-4ff86b8ef30e_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0b3fefad-9177-4bd0-89e9-32d25daec885_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3005f701-09cd-4ef7-9716-09c99df7ffc9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_bf8f05e5-f2a7-4570-91dd-f769aaea4717_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in deferred tax asset valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_a865fe4f-9914-4911-8958-685ce449b3ee_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockNameDomain" xlink:to="lab_us-gaap_ConversionOfStockNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_5c26c3aa-f762-4892-b139-15a1def8d1d1_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_13c9e3f9-cb08-4c75-a39a-0f31f248acb5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_4d7e980b-47e2-40b7-b59b-48e1372a0200_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_f09ea829-9625-4fcb-b43b-d0e209817772_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2ad832c5-6794-4b0c-983f-d01a58008c36_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a57c09f9-48e2-4074-9514-1a4425999ff7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_821fd9e0-0b01-444c-a7fe-c4f14e7d3e04_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_ebb83fe1-dfb1-43a5-9e1d-a094e00a46c7_verboseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_e5f46d4c-d535-4bac-9cb4-2f724c08eda2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_51c72535-4341-4a9e-be1b-f6cbf4060161_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_0d96b4dd-39ca-4069-9bc4-c50c58e6823e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, related party</link:label>
    <link:label id="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b0583fa3-55f6-4412-a107-3ded060a661b_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_LeaseholdImprovementsLandlordAllowanceToBeRepaid_3f887af8-61ba-4122-a827-5fb6293b0c64_terseLabel_en-US" xlink:label="lab_fhtx_LeaseholdImprovementsLandlordAllowanceToBeRepaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements landlord allowance to be repaid</link:label>
    <link:label id="lab_fhtx_LeaseholdImprovementsLandlordAllowanceToBeRepaid_label_en-US" xlink:label="lab_fhtx_LeaseholdImprovementsLandlordAllowanceToBeRepaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements Landlord Allowance To Be Repaid</link:label>
    <link:label id="lab_fhtx_LeaseholdImprovementsLandlordAllowanceToBeRepaid_documentation_en-US" xlink:label="lab_fhtx_LeaseholdImprovementsLandlordAllowanceToBeRepaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">An additional monetary allowance granted by the landlord to a tenant to entice tenant to move into landlord's building which will enable the tenant to prepare the leased premises for tenant's occupancy. This additional amount will result in additional rent payments to the landlord.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_LeaseholdImprovementsLandlordAllowanceToBeRepaid" xlink:href="fhtx-20211231.xsd#fhtx_LeaseholdImprovementsLandlordAllowanceToBeRepaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_LeaseholdImprovementsLandlordAllowanceToBeRepaid" xlink:to="lab_fhtx_LeaseholdImprovementsLandlordAllowanceToBeRepaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_c5ab1cbb-7c19-4def-99a0-05acd26710d6_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_2e093b21-4a9e-439c-85de-f9f198c4b4f2_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_96739457-7270-4eb4-8bcb-001a39490568_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_73536b17-f420-4551-bd98-6b9c7a0fdea0_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_aa7d12e5-8156-489a-816a-3d12bbb14a13_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0fbeac3b-8d70-4704-95c3-02420894a443_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_2ff6db01-2116-4d77-b8a4-0775cca8764d_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_830a522d-7a47-4637-985e-e03b2201ec54_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6852d4f1-2d91-481b-b45b-d0e65b0de7b1_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title&#160;of&#160;each&#160;class</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_A2016StockIncentivePlanMember_97c229ae-7204-4b89-82cb-69a3979f7cb1_terseLabel_en-US" xlink:label="lab_fhtx_A2016StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan</link:label>
    <link:label id="lab_fhtx_A2016StockIncentivePlanMember_label_en-US" xlink:label="lab_fhtx_A2016StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_fhtx_A2016StockIncentivePlanMember_documentation_en-US" xlink:label="lab_fhtx_A2016StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Stock Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_A2016StockIncentivePlanMember" xlink:href="fhtx-20211231.xsd#fhtx_A2016StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_A2016StockIncentivePlanMember" xlink:to="lab_fhtx_A2016StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e7d6847d-7641-4eef-9981-a9433b73d019_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_cf7e2b8c-b965-438f-afbb-d52da2eefe1a_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_e58e47a7-f3d1-4eaf-b44c-455d4dbac9c7_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_f2f29a04-3abf-4486-aca8-47f5880f92b6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_d3a4835f-f492-4aa7-9e32-c3f20cde7a3c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_LeaseholdImprovementsLandlordAllowance_625601c0-19a7-435a-ae23-df0d826ab9d2_terseLabel_en-US" xlink:label="lab_fhtx_LeaseholdImprovementsLandlordAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements landlord allowance</link:label>
    <link:label id="lab_fhtx_LeaseholdImprovementsLandlordAllowance_label_en-US" xlink:label="lab_fhtx_LeaseholdImprovementsLandlordAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements Landlord Allowance</link:label>
    <link:label id="lab_fhtx_LeaseholdImprovementsLandlordAllowance_documentation_en-US" xlink:label="lab_fhtx_LeaseholdImprovementsLandlordAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The monetary allowance granted by the landlord to a tenant to entice tenant to move into landlord's building which will enable the tenant to prepare the leased premises for tenant's occupancy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_LeaseholdImprovementsLandlordAllowance" xlink:href="fhtx-20211231.xsd#fhtx_LeaseholdImprovementsLandlordAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_LeaseholdImprovementsLandlordAllowance" xlink:to="lab_fhtx_LeaseholdImprovementsLandlordAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_0622c478-70f0-447b-938d-e3469a2b4c0c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_3caf2539-6d30-4d23-85b7-27e704bf3b2e_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_39e0a599-7deb-4bbd-a32d-a1a0e9d7d2a0_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of notes payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_230a2b30-d64c-4284-9d18-6c30630a3e07_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_f030da25-8456-4419-904b-6a40ecf2d17a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_9bc979f0-753a-42b9-bf3c-58a0ea151943_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_ConversionOfRedeemableConvertibleStockMember_817dadf9-9ebd-4cd1-b7be-06660232ddfd_terseLabel_en-US" xlink:label="lab_fhtx_ConversionOfRedeemableConvertibleStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Redeemable Convertible stock</link:label>
    <link:label id="lab_fhtx_ConversionOfRedeemableConvertibleStockMember_label_en-US" xlink:label="lab_fhtx_ConversionOfRedeemableConvertibleStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Redeemable Convertible stock [Member]</link:label>
    <link:label id="lab_fhtx_ConversionOfRedeemableConvertibleStockMember_documentation_en-US" xlink:label="lab_fhtx_ConversionOfRedeemableConvertibleStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of redeemable convertible stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ConversionOfRedeemableConvertibleStockMember" xlink:href="fhtx-20211231.xsd#fhtx_ConversionOfRedeemableConvertibleStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_ConversionOfRedeemableConvertibleStockMember" xlink:to="lab_fhtx_ConversionOfRedeemableConvertibleStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_dde48035-7c06-4759-82cc-54fe5289f878_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease term extension</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_NumberOfPrograms_e207f894-126f-45c5-ae46-bedfd0f9c604_terseLabel_en-US" xlink:label="lab_fhtx_NumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of programs</link:label>
    <link:label id="lab_fhtx_NumberOfPrograms_label_en-US" xlink:label="lab_fhtx_NumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Programs</link:label>
    <link:label id="lab_fhtx_NumberOfPrograms_documentation_en-US" xlink:label="lab_fhtx_NumberOfPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_NumberOfPrograms" xlink:href="fhtx-20211231.xsd#fhtx_NumberOfPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_NumberOfPrograms" xlink:to="lab_fhtx_NumberOfPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_f931e2b4-9c04-411e-ab58-d1cb479f7d65_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_079091ff-d944-430d-b7b0-a8118137ef92_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_fd8b115d-1121-4bca-8853-8055d4bb0f22_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_f9e7e603-c731-451b-ae0c-88e15ebb51a4_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carry forward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_70650231-8af6-4a9c-b148-a15859199990_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasis[Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_e3e4ee33-8094-43e0-af79-c55bfa3df425_verboseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_ac0eb7fe-8ed5-4263-a54a-eaba884a56f6_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_9e768a8a-fb8c-4e90-a485-f4e06827e4ff_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Lease Cost and Lease Details</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_TwoThousandTwentyEquityIncentivePlanMember_3122f518-b2f9-48dd-90aa-c95a63e4fed5_terseLabel_en-US" xlink:label="lab_fhtx_TwoThousandTwentyEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Incentive Plan</link:label>
    <link:label id="lab_fhtx_TwoThousandTwentyEquityIncentivePlanMember_label_en-US" xlink:label="lab_fhtx_TwoThousandTwentyEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_TwoThousandTwentyEquityIncentivePlanMember" xlink:href="fhtx-20211231.xsd#fhtx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="lab_fhtx_TwoThousandTwentyEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_392bef3f-b02c-4032-9a5a-d642dadeba30_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_NumberOfCollaborativeAgreements_e4f6653c-ca10-4b8c-b374-22894e503ff7_terseLabel_en-US" xlink:label="lab_fhtx_NumberOfCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of collaborative agreements</link:label>
    <link:label id="lab_fhtx_NumberOfCollaborativeAgreements_label_en-US" xlink:label="lab_fhtx_NumberOfCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Collaborative Agreements</link:label>
    <link:label id="lab_fhtx_NumberOfCollaborativeAgreements_documentation_en-US" xlink:label="lab_fhtx_NumberOfCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Collaborative Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_NumberOfCollaborativeAgreements" xlink:href="fhtx-20211231.xsd#fhtx_NumberOfCollaborativeAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_NumberOfCollaborativeAgreements" xlink:to="lab_fhtx_NumberOfCollaborativeAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d2c7f2a4-3952-49d1-aee2-f8a76c27826c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding&#8212;basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b8cae91f-37ac-4bba-b62d-df5cab0586f5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders&#8212;diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_1378231d-fe35-48dd-8588-2701e5a07727_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_MarketableSecuritiesAndFairValueMeasurementsTextBlock_9a891bc3-f416-478d-8c53-3c0e156e3b68_terseLabel_en-US" xlink:label="lab_fhtx_MarketableSecuritiesAndFairValueMeasurementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities and&#160;Fair Value Measurements</link:label>
    <link:label id="lab_fhtx_MarketableSecuritiesAndFairValueMeasurementsTextBlock_label_en-US" xlink:label="lab_fhtx_MarketableSecuritiesAndFairValueMeasurementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities And Fair Value Measurements [Text Block]</link:label>
    <link:label id="lab_fhtx_MarketableSecuritiesAndFairValueMeasurementsTextBlock_documentation_en-US" xlink:label="lab_fhtx_MarketableSecuritiesAndFairValueMeasurementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for marketable securities and fair value measurements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_MarketableSecuritiesAndFairValueMeasurementsTextBlock" xlink:href="fhtx-20211231.xsd#fhtx_MarketableSecuritiesAndFairValueMeasurementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_MarketableSecuritiesAndFairValueMeasurementsTextBlock" xlink:to="lab_fhtx_MarketableSecuritiesAndFairValueMeasurementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_9012b462-fac1-424a-a5f8-ad2a3df1c700_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock issue price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_a01c3177-7717-4b2e-afbf-de0217c8e767_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock issue price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_5cdb7ccd-efd1-4991-a912-c0da52a46cc3_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales based</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_TemporaryEquityConversionOfStockAmountConverted_eb2fe6c8-da3e-44ea-87d3-081d909a5569_negatedTerseLabel_en-US" xlink:label="lab_fhtx_TemporaryEquityConversionOfStockAmountConverted" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock</link:label>
    <link:label id="lab_fhtx_TemporaryEquityConversionOfStockAmountConverted_label_en-US" xlink:label="lab_fhtx_TemporaryEquityConversionOfStockAmountConverted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Conversion of Stock, Amount Converted</link:label>
    <link:label id="lab_fhtx_TemporaryEquityConversionOfStockAmountConverted_documentation_en-US" xlink:label="lab_fhtx_TemporaryEquityConversionOfStockAmountConverted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_TemporaryEquityConversionOfStockAmountConverted" xlink:href="fhtx-20211231.xsd#fhtx_TemporaryEquityConversionOfStockAmountConverted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_TemporaryEquityConversionOfStockAmountConverted" xlink:to="lab_fhtx_TemporaryEquityConversionOfStockAmountConverted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_5902087b-38cd-442a-a39c-2d04a03ddbd1_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leaseholds and Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_CashPaymentsRelatedParty_554c5f59-c231-44a0-8dbf-bac285fd51fb_terseLabel_en-US" xlink:label="lab_fhtx_CashPaymentsRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments made to related party under service agreement</link:label>
    <link:label id="lab_fhtx_CashPaymentsRelatedParty_label_en-US" xlink:label="lab_fhtx_CashPaymentsRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Payments Related Party</link:label>
    <link:label id="lab_fhtx_CashPaymentsRelatedParty_documentation_en-US" xlink:label="lab_fhtx_CashPaymentsRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments made during the period to related parties as part of a service or consulting agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_CashPaymentsRelatedParty" xlink:href="fhtx-20211231.xsd#fhtx_CashPaymentsRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_CashPaymentsRelatedParty" xlink:to="lab_fhtx_CashPaymentsRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_MerckMember_e7ea6755-38d2-46b9-867b-a1bea9986190_terseLabel_en-US" xlink:label="lab_fhtx_MerckMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck</link:label>
    <link:label id="lab_fhtx_MerckMember_label_en-US" xlink:label="lab_fhtx_MerckMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck [Member]</link:label>
    <link:label id="lab_fhtx_MerckMember_documentation_en-US" xlink:label="lab_fhtx_MerckMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_MerckMember" xlink:href="fhtx-20211231.xsd#fhtx_MerckMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_MerckMember" xlink:to="lab_fhtx_MerckMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_bc589154-c426-4592-8a47-0f5883869376_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_23832e6e-0e81-4355-8427-a1df906038f0_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_dcefec91-9078-4aef-9cdc-82102469e1ab_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizationOfInternalCostsPolicy_a8f19bee-a956-4aba-ad88-e4d15535a319_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizationOfInternalCostsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent costs</link:label>
    <link:label id="lab_us-gaap_CapitalizationOfInternalCostsPolicy_label_en-US" xlink:label="lab_us-gaap_CapitalizationOfInternalCostsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization of Internal Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizationOfInternalCostsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizationOfInternalCostsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizationOfInternalCostsPolicy" xlink:to="lab_us-gaap_CapitalizationOfInternalCostsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_30ff16ab-4062-4433-b557-1a575a489853_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7a184038-6033-4f93-bba6-8773208950c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period (years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_0c6212e5-3e13-4e75-8c82-36e8e5cbdd96_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes and bonds (due within one year)</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_73c02eab-8cff-4e60-bb8e-3068900f166e_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes and bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ae51016a-053c-4e97-8442-752ddd64c515_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Reconciliation of the U.S. federal statutory income tax rate to the Company's effective income tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_d6d9ac76-e3a7-4f8c-b4e1-08f908314c52_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_a62ee9e8-a309-4276-a4b9-b30f6507eaf5_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment losses on long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_07cb80ac-f0b8-4dee-94b6-72b8df6cc5a4_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7583205a-0a18-4943-94e9-9406ae58e591_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_dba49e8a-26dc-4cb9-b52c-89f362e893fd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8711a325-1a09-446b-8515-fe3dd4b42985_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_c9ca9dae-7d5e-4b28-b0f1-a04b154f38f2_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-1, A-2 and B Convertible Preferred&#160;Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_13ce74a9-d8df-48a8-881f-62340f7b3d17_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration receivable</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b95f6065-2c01-4630-bfaa-96bdd6ddb96a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_53b73a42-27ad-45f1-8b73-d95e40e10a7f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6af2a8a1-8b5e-488f-9da7-8b0d29aaabbb_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_931c57e1-3ff1-4df2-96ab-76866a01a01e_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_bd781fef-165d-4403-bbc5-6a154a7c13f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c0f82d54-60a2-49f7-8f65-67829a81a68e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_da2b1e65-6e31-4ab9-b62a-57fabc7e7d93_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_40d6d98f-0625-460f-92e1-9bdb0230801a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_459ac6f4-ac63-43df-9f1a-d3a42186b9ea_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d3b45e85-e937-4a7e-922b-675bf62202b6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ae2aab23-859b-4025-94e0-8e164a7ca3be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_ebf60db1-657c-4e7e-9d20-53e739d4d7ce_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_397a1aa1-986d-4ceb-8fc8-8f5509f3b2df_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_6c8b035a-44b4-4e6a-b07e-5eb1cf8fdbde_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_98c5b1ad-7269-4046-9843-e0f0a24a4f89_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Property and Equipment are Stated at Cost Less Accumulated Depreciation and Amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_c4287fdf-2b69-4a34-bdcc-cdc10bd83244_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sumary of Property and Equipment Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1bc69f2b-3239-4d8f-900d-b52768d82642_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_19d6921e-6c0c-4540-a76b-9bc3f4badce6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_2502c380-2d25-4989-97b9-4c7ba6f4781d_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of loan</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_9ec2d2f5-28b0-4fa5-8dfa-a52f8eb6f082_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursements from lessor</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Tenant Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_710c91af-82a7-4c7b-a57c-bf3a911863df_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of noncash investing and financing information:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3e254c99-429d-4643-adb1-f41badbfd971_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_a72c4932-1bba-4962-aff0-51766df6a889_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0f77e2a8-6fb2-48b2-9082-0ffaecaf4f72_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_9513cc8c-2b97-4faa-90cd-066eee9af448_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_ServiceAgreementRenewalTerm_44825356-661d-4d66-8be4-9d41a81666be_terseLabel_en-US" xlink:label="lab_fhtx_ServiceAgreementRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service agreement renewal term</link:label>
    <link:label id="lab_fhtx_ServiceAgreementRenewalTerm_label_en-US" xlink:label="lab_fhtx_ServiceAgreementRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Agreement Renewal Term</link:label>
    <link:label id="lab_fhtx_ServiceAgreementRenewalTerm_documentation_en-US" xlink:label="lab_fhtx_ServiceAgreementRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Agreement Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ServiceAgreementRenewalTerm" xlink:href="fhtx-20211231.xsd#fhtx_ServiceAgreementRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_ServiceAgreementRenewalTerm" xlink:to="lab_fhtx_ServiceAgreementRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_61132c94-60e8-4bc9-a769-07bd444ed2dd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_8ebda5dc-f4f8-4fce-bee2-d1bb4e9c302a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Long Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalents_85d0e250-fb71-4445-9f11-2243ad8c9840_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash (current and non-current)</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_LeasesBalanceSheetLocationTableTextBlock_792db665-8426-49ce-a474-42e91118c043_terseLabel_en-US" xlink:label="lab_fhtx_LeasesBalanceSheetLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_fhtx_LeasesBalanceSheetLocationTableTextBlock_label_en-US" xlink:label="lab_fhtx_LeasesBalanceSheetLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, Balance Sheet Location [Table Text Block]</link:label>
    <link:label id="lab_fhtx_LeasesBalanceSheetLocationTableTextBlock_documentation_en-US" xlink:label="lab_fhtx_LeasesBalanceSheetLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of operating lease liabilities included in the consolidated balance sheet.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_LeasesBalanceSheetLocationTableTextBlock" xlink:href="fhtx-20211231.xsd#fhtx_LeasesBalanceSheetLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_LeasesBalanceSheetLocationTableTextBlock" xlink:to="lab_fhtx_LeasesBalanceSheetLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a9648a80-7f3b-4fe7-bc0f-7bcab7500226_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_cd0e7ecf-e28e-4455-a9df-cc1eb3597b0f_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_794b4ed6-5604-4f0d-a09c-8f31c26e1191_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol(s)</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_0d3a4dbc-0f2c-4e7d-bb5d-3c5ba8be12ae_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_SharePurchaseAgreementMember_2526a7e1-b6b4-47c7-8bb0-018f425df76b_terseLabel_en-US" xlink:label="lab_fhtx_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement</link:label>
    <link:label id="lab_fhtx_SharePurchaseAgreementMember_label_en-US" xlink:label="lab_fhtx_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement [Member]</link:label>
    <link:label id="lab_fhtx_SharePurchaseAgreementMember_documentation_en-US" xlink:label="lab_fhtx_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_SharePurchaseAgreementMember" xlink:href="fhtx-20211231.xsd#fhtx_SharePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_SharePurchaseAgreementMember" xlink:to="lab_fhtx_SharePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_eb1fa8aa-f2f0-403a-98a7-4f08c5e709bb_verboseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_3e6a536a-af55-4ba7-b153-9cd95dd05679_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_788e443b-7786-46b1-a94c-47014113bb11_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e89773e0-0b22-42a3-940a-3633542cee1d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_69a81f03-e6ad-4b05-8609-249aa59bcf53_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_16d5ea37-6bca-44ab-9398-e224704771b1_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_98f34f4d-991a-4e81-8ee2-d7a09b6d1c27_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercisable term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_3c1ca883-f089-458e-a439-be95220274ec_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, net of discount</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_94d7a899-5475-4c6f-b0d3-8fdef7353c51_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, net of discount</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_80441366-949c-468a-96c5-27883aa10720_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e0a684e4-76eb-451f-b0ab-71f02b0a1927_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a8935e00-7143-4939-bdf9-d64610747ccc_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9fb20628-bc70-44c7-aecb-8d619753f587_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_8971c21f-718e-4b22-b57f-2e3ede0a3c6c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_fe17c86e-176c-465c-8f43-ccebb707d229_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization (accretion) of premium/discount on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_b4687266-0d56-4c5e-b66b-feaef71fbae2_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_42cd86d1-bc97-4b39-bf78-82af458857b3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_6eb2e21d-6b3b-4288-95ea-86c11b53cb76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_26c808a7-0939-4e75-a286-d949a74abd78_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ba4f4549-53a1-42f0-8094-76ce8d815905_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_98f561f5-6954-419d-8dad-53d7ac11f1f8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7b10b94f-e474-45b2-8042-449047033da7_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_824a38b9-8fc4-4368-89cf-7781fb0c6132_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_07556cb6-54bc-4f71-985d-b82a5ca1f32a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_f153ad7d-3e14-4335-b72c-c0516172b950_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives_e41db7fb-0b99-41dd-b02e-c160908a5988_negatedLabel_en-US" xlink:label="lab_fhtx_LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: estimated lease incentives</link:label>
    <link:label id="lab_fhtx_LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives_label_en-US" xlink:label="lab_fhtx_LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Estimated Lease Incentives</link:label>
    <link:label id="lab_fhtx_LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives_documentation_en-US" xlink:label="lab_fhtx_LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of estimated lease incentives used by lessee to determine present value of operating lease payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives" xlink:href="fhtx-20211231.xsd#fhtx_LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives" xlink:to="lab_fhtx_LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_18f80b5c-2f3f-4719-9228-a3769fff26fe_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_8500645a-1865-458f-9a8e-fca4ee0d1144_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_f6505cc0-dc03-405b-95bf-0fafe718119c_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5935dd73-d075-4505-abd5-9cefbb157583_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_069ff966-855b-4fe7-a387-19f2a9b61464_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_CollaborationAgreementAbstract_9368398b-1cc4-46de-8ef3-e1244d553cbe_terseLabel_en-US" xlink:label="lab_fhtx_CollaborationAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement [Abstract]</link:label>
    <link:label id="lab_fhtx_CollaborationAgreementAbstract_label_en-US" xlink:label="lab_fhtx_CollaborationAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement [Abstract]</link:label>
    <link:label id="lab_fhtx_CollaborationAgreementAbstract_documentation_en-US" xlink:label="lab_fhtx_CollaborationAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_CollaborationAgreementAbstract" xlink:href="fhtx-20211231.xsd#fhtx_CollaborationAgreementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_CollaborationAgreementAbstract" xlink:to="lab_fhtx_CollaborationAgreementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_caa02fb5-721d-4ae1-8627-57458b6416a4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements and Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9835a91c-53db-426c-8d5a-c90742fbe8e5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c1bb554f-fc9b-43f6-85e1-b4ca8bb608d0_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cf0788e8-bf8c-43d6-a15c-3a2dc752fdd9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding&#8212;diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_ServiceAgreementTerm_4d97b0dd-53ba-4f7f-a86d-581fcc7371e1_terseLabel_en-US" xlink:label="lab_fhtx_ServiceAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service agreement term</link:label>
    <link:label id="lab_fhtx_ServiceAgreementTerm_label_en-US" xlink:label="lab_fhtx_ServiceAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Agreement Term</link:label>
    <link:label id="lab_fhtx_ServiceAgreementTerm_documentation_en-US" xlink:label="lab_fhtx_ServiceAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The term of a service agreement in 'PnYnMnDTnHnMnS' format.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ServiceAgreementTerm" xlink:href="fhtx-20211231.xsd#fhtx_ServiceAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_ServiceAgreementTerm" xlink:to="lab_fhtx_ServiceAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_1eebbd77-96fc-4f6b-808d-8446588987da_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_d25f2ce7-254a-4e3f-a6b2-727b14bd3d99_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_c73ce2c1-980e-48f7-8707-66f988c3a260_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_TwoThousandTwentyEmployeeStockPurchasePlanMember_feceb1a8-7b92-4c74-a8c6-535fadf4347b_terseLabel_en-US" xlink:label="lab_fhtx_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_fhtx_TwoThousandTwentyEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_fhtx_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:href="fhtx-20211231.xsd#fhtx_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:to="lab_fhtx_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_bd22b45f-2792-4b33-b947-13cc89d8b165_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30aa4e2a-cd69-4fa0-9aa3-435901bf5dba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c7374ae4-24ed-4d7f-a13e-fbd73939658b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares_5ca7063a-5173-4369-95f9-0c8fc8f596dd_terseLabel_en-US" xlink:label="lab_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate number of shares added to plan (in shares)</link:label>
    <link:label id="lab_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares_label_en-US" xlink:label="lab_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Maximum Future Increase Shares</link:label>
    <link:label id="lab_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares_documentation_en-US" xlink:label="lab_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate number of shares that may be added to the plan in future years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares" xlink:href="fhtx-20211231.xsd#fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares" xlink:to="lab_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage_d0875bcc-5cdb-48c9-8572-1401c05a8b52_terseLabel_en-US" xlink:label="lab_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of automatic annual increase in number of shares</link:label>
    <link:label id="lab_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage_label_en-US" xlink:label="lab_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Automatic Annual Increase, Percentage</link:label>
    <link:label id="lab_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage_documentation_en-US" xlink:label="lab_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of shares authorized to be automatically increased on the first day of the fiscal year, under a share based payment arrangement, as a percentage of common stock outstanding on the last day of the previous fiscal year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage" xlink:href="fhtx-20211231.xsd#fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage" xlink:to="lab_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7b392c63-fc13-4a23-a720-8aabdc52a4e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Earnings Per Share Diluted Anti Dilutive Impact</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_c904c38d-e556-447e-9b22-de92f81f6c5e_terseLabel_en-US" xlink:label="lab_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label id="lab_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_label_en-US" xlink:label="lab_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label id="lab_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_documentation_en-US" xlink:label="lab_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization consolidation and presentation of financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:href="fhtx-20211231.xsd#fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="lab_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_0b6257a0-8992-41fe-a37a-5703fcdf9636_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2ec41fa6-ee24-40ec-83e5-9668bb6582f5_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_cae0bb59-b9a4-424a-a76c-19f01ffe51dc_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ecbd0ff4-a2e6-4bee-a537-fb9a672728e3_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_OperatingLossCarryforwardLimitPercentage_380f4aaa-04b4-476f-9842-864b98112401_terseLabel_en-US" xlink:label="lab_fhtx_OperatingLossCarryforwardLimitPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforward limit percentage</link:label>
    <link:label id="lab_fhtx_OperatingLossCarryforwardLimitPercentage_label_en-US" xlink:label="lab_fhtx_OperatingLossCarryforwardLimitPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforward Limit Percentage</link:label>
    <link:label id="lab_fhtx_OperatingLossCarryforwardLimitPercentage_documentation_en-US" xlink:label="lab_fhtx_OperatingLossCarryforwardLimitPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The limit that may be applied to operating loss carryforwards, as a percentage of annual taxable income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_OperatingLossCarryforwardLimitPercentage" xlink:href="fhtx-20211231.xsd#fhtx_OperatingLossCarryforwardLimitPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_OperatingLossCarryforwardLimitPercentage" xlink:to="lab_fhtx_OperatingLossCarryforwardLimitPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_8d5ea412-be23-4314-8c84-2d34ec52eee5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_25cae371-40a9-4f91-820e-415cf6268224_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Street</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ea3a668-3c2c-4050-b49e-de07122fadd0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cf2c8f71-b97c-4958-81c1-8f1c0a5ee12a_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b820699a-6832-4df3-a0b8-7899b056a934_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_264a77cb-b42c-4851-96db-e408d36ba0fd_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_919a8b1c-34fc-4b98-921b-cd410bc3c9d7_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4d8eb064-c4d3-41f6-9f8a-9cc7d5b3a401_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6c1da45b-8525-42ff-a49b-3c6dcf3413ce_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_280bc701-8f14-45b2-84ba-388526a8d808_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice_15aeda91-3837-4c1c-a3f1-e4ef45738781_negatedTerseLabel_en-US" xlink:label="lab_fhtx_DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Difference between fair value of shares and contract price</link:label>
    <link:label id="lab_fhtx_DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice_label_en-US" xlink:label="lab_fhtx_DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Difference Between Fair Value OF Shares And Contractual Purchase Price</link:label>
    <link:label id="lab_fhtx_DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice_documentation_en-US" xlink:label="lab_fhtx_DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Difference Between Fair Value OF Shares And Contractual Purchase Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice" xlink:href="fhtx-20211231.xsd#fhtx_DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice" xlink:to="lab_fhtx_DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_309e08f1-b2fb-4dec-91bb-8c6b4f5f18a8_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_7daccebc-d96e-4eb0-ba55-70991aa0a883_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_62ac34fc-820f-4ba6-8afb-3644a9f6ce61_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_TemporaryEquityConversionOfStockSharesConverted_cc588c53-9673-427e-a390-09ea900fe28c_negatedTerseLabel_en-US" xlink:label="lab_fhtx_TemporaryEquityConversionOfStockSharesConverted" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock to common stock (in shares)</link:label>
    <link:label id="lab_fhtx_TemporaryEquityConversionOfStockSharesConverted_label_en-US" xlink:label="lab_fhtx_TemporaryEquityConversionOfStockSharesConverted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Conversion of Stock, Shares Converted</link:label>
    <link:label id="lab_fhtx_TemporaryEquityConversionOfStockSharesConverted_documentation_en-US" xlink:label="lab_fhtx_TemporaryEquityConversionOfStockSharesConverted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_TemporaryEquityConversionOfStockSharesConverted" xlink:href="fhtx-20211231.xsd#fhtx_TemporaryEquityConversionOfStockSharesConverted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_TemporaryEquityConversionOfStockSharesConverted" xlink:to="lab_fhtx_TemporaryEquityConversionOfStockSharesConverted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_f91a4474-95a8-4caa-aa7b-8f55b4835ddf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_PercentageOfPrepaymentFee_ec57987d-b03c-48f2-a8b4-82efc35aa8c8_terseLabel_en-US" xlink:label="lab_fhtx_PercentageOfPrepaymentFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of prepayment fee</link:label>
    <link:label id="lab_fhtx_PercentageOfPrepaymentFee_label_en-US" xlink:label="lab_fhtx_PercentageOfPrepaymentFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Prepayment Fee</link:label>
    <link:label id="lab_fhtx_PercentageOfPrepaymentFee_documentation_en-US" xlink:label="lab_fhtx_PercentageOfPrepaymentFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The fee for prepayment of a loan, as a percentage of the principal amount being prepaid.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_PercentageOfPrepaymentFee" xlink:href="fhtx-20211231.xsd#fhtx_PercentageOfPrepaymentFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_PercentageOfPrepaymentFee" xlink:to="lab_fhtx_PercentageOfPrepaymentFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_51e64e7d-6968-4186-b18b-28564ab98af1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_0e872b5b-c33c-4683-97b6-e9c1bbdb393b_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6d0907c3-899a-42cf-98c6-c4aa3ad89935_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_64103ea9-6319-4625-b23f-2fbc1e754a8d_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently issued accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_df81dc9f-ce2d-422f-a8a6-7bfe1aee23cf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation costs related to unvested options and unvested restricted stock</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_789520e3-7d52-49f6-9ac7-f8cb0d9dfc2b_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_AssetsNotYetPlacedInServiceMember_727a8326-0d14-4812-ab4d-88b7da2646a8_terseLabel_en-US" xlink:label="lab_fhtx_AssetsNotYetPlacedInServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets not yet placed in service</link:label>
    <link:label id="lab_fhtx_AssetsNotYetPlacedInServiceMember_label_en-US" xlink:label="lab_fhtx_AssetsNotYetPlacedInServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Not Yet Placed In service [Member]</link:label>
    <link:label id="lab_fhtx_AssetsNotYetPlacedInServiceMember_documentation_en-US" xlink:label="lab_fhtx_AssetsNotYetPlacedInServiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Not Yet Placed In service[Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_AssetsNotYetPlacedInServiceMember" xlink:href="fhtx-20211231.xsd#fhtx_AssetsNotYetPlacedInServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_AssetsNotYetPlacedInServiceMember" xlink:to="lab_fhtx_AssetsNotYetPlacedInServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_StockIssuanceCosts_2b8eae73-694c-4ce0-88b4-fe078ea2d26a_terseLabel_en-US" xlink:label="lab_fhtx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_fhtx_StockIssuanceCosts_label_en-US" xlink:label="lab_fhtx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs</link:label>
    <link:label id="lab_fhtx_StockIssuanceCosts_documentation_en-US" xlink:label="lab_fhtx_StockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs incurred directly with the issuance of an equity or temporary equity security.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_StockIssuanceCosts" xlink:href="fhtx-20211231.xsd#fhtx_StockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_StockIssuanceCosts" xlink:to="lab_fhtx_StockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_e210903b-5593-4764-8cb4-4a5a227e8ef1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_1d899e81-f2b0-4962-b751-c1987bf972f4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_d443d8e4-9a01-471c-89c8-dd31b72d4464_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_0f9f9373-ea8a-41b0-937c-d36c0a92d5b7_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3428e120-623a-4a2e-91fe-7a6de5227013_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_05cfb820-f9fa-4f26-ba3c-8d451ff52b20_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_9b379d39-d48b-401f-b9e1-85bb61fc1709_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_1a621eca-bea7-46c5-b248-35d8a947b8c0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_442019b4-0490-4c47-aa94-2e7bbe17b549_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_ff9a6803-e04b-4ed5-abe7-25342e2306a2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Parties</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_MilestonesPayableUponEvent_dca60825-0b90-413a-96cf-c49572ce5f54_terseLabel_en-US" xlink:label="lab_fhtx_MilestonesPayableUponEvent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones payable upon event</link:label>
    <link:label id="lab_fhtx_MilestonesPayableUponEvent_label_en-US" xlink:label="lab_fhtx_MilestonesPayableUponEvent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones Payable Upon Event</link:label>
    <link:label id="lab_fhtx_MilestonesPayableUponEvent_documentation_en-US" xlink:label="lab_fhtx_MilestonesPayableUponEvent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount the Company will pay for regulatory milestones on each licensed product upon the occurrence of specific events as outlined in the license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_MilestonesPayableUponEvent" xlink:href="fhtx-20211231.xsd#fhtx_MilestonesPayableUponEvent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_MilestonesPayableUponEvent" xlink:to="lab_fhtx_MilestonesPayableUponEvent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_2f864ffd-296f-4506-8415-2bae102aa1d3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discount, net of accretion</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_fhtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_dc65f4ba-8109-482f-8519-9f20ed1f1b1f_negatedLabel_en-US" xlink:label="lab_fhtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_fhtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_fhtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities Operating Lease Right Of Use Assets</link:label>
    <link:label id="lab_fhtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_fhtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from operating lease right-of-use assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:href="fhtx-20211231.xsd#fhtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fhtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="lab_fhtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4668ce17-09fa-4607-a55e-b6f4db9ed50e_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>fhtx-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:45bd6193-dace-4c5a-b62d-c265e68fd1cf,g:2c36ac82-298b-41b7-8200-caa9bbc65128-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.foghorntx.com/role/CoverPage" xlink:type="simple" xlink:href="fhtx-20211231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_cce7264b-0b67-4cbb-bf6e-9592cbfb5fc3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_DocumentType_cce7264b-0b67-4cbb-bf6e-9592cbfb5fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_c2e57223-9473-4de9-bd32-53b1a54fd8e3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_DocumentAnnualReport_c2e57223-9473-4de9-bd32-53b1a54fd8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_77ee4461-642f-4fc0-bfbd-7634112ee984" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_CurrentFiscalYearEndDate_77ee4461-642f-4fc0-bfbd-7634112ee984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ebf6cd36-8f56-4079-a179-eef9aa31de2d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_DocumentPeriodEndDate_ebf6cd36-8f56-4079-a179-eef9aa31de2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_781b3f46-2e29-4cfe-9646-548c4ed3edf3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_DocumentTransitionReport_781b3f46-2e29-4cfe-9646-548c4ed3edf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f0d775ef-2d5b-4ca4-97a2-516b5f9e8293" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_EntityFileNumber_f0d775ef-2d5b-4ca4-97a2-516b5f9e8293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6e0ef313-0ff8-460d-adfc-4d82f3c83817" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_EntityRegistrantName_6e0ef313-0ff8-460d-adfc-4d82f3c83817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_10143d3e-0114-4180-a805-4836c1f5bad9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_10143d3e-0114-4180-a805-4836c1f5bad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_8b48ec63-1846-41e7-a1f5-25da4e3854f4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_EntityTaxIdentificationNumber_8b48ec63-1846-41e7-a1f5-25da4e3854f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0d50d753-a81d-4674-a6d3-0e060d1b7b62" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_EntityAddressAddressLine1_0d50d753-a81d-4674-a6d3-0e060d1b7b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_33771e11-1e48-40f6-bbf4-082911e01152" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_EntityAddressCityOrTown_33771e11-1e48-40f6-bbf4-082911e01152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0ec6bf2b-0187-4f48-baa0-83a8e5813a67" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_EntityAddressStateOrProvince_0ec6bf2b-0187-4f48-baa0-83a8e5813a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d9539ff2-8b00-476e-8a3d-cf59dd134133" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_EntityAddressPostalZipCode_d9539ff2-8b00-476e-8a3d-cf59dd134133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_98c89a26-f7e7-4e24-9490-c2990fe37967" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_CityAreaCode_98c89a26-f7e7-4e24-9490-c2990fe37967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_45acef08-9470-4c0a-99f6-c8b4c1eec9c4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_LocalPhoneNumber_45acef08-9470-4c0a-99f6-c8b4c1eec9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4d28bf97-31cb-4185-bd84-56f4a1c9ce95" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_Security12bTitle_4d28bf97-31cb-4185-bd84-56f4a1c9ce95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_327b8b4e-7f7f-470e-8a48-2435bc5fbcac" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_TradingSymbol_327b8b4e-7f7f-470e-8a48-2435bc5fbcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4762685b-c871-4692-8de7-ff90342684af" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_SecurityExchangeName_4762685b-c871-4692-8de7-ff90342684af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_114429f6-a0eb-4c8e-afd0-f6e3bc501400" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_114429f6-a0eb-4c8e-afd0-f6e3bc501400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_02f42d37-9c38-4f00-81d3-04984a587ef1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_EntityVoluntaryFilers_02f42d37-9c38-4f00-81d3-04984a587ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_a7ca4c54-92f0-48df-abb5-978effecfffd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_EntityCurrentReportingStatus_a7ca4c54-92f0-48df-abb5-978effecfffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_c7a4066e-52f4-4f78-9e8a-ac67576f726c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_EntityInteractiveDataCurrent_c7a4066e-52f4-4f78-9e8a-ac67576f726c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_03a0c26a-9ffa-4750-828b-dee5776ae630" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_EntityFilerCategory_03a0c26a-9ffa-4750-828b-dee5776ae630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_3c30d248-c46b-462d-8c0b-573dddaebc50" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_EntitySmallBusiness_3c30d248-c46b-462d-8c0b-573dddaebc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_78366e12-2f3d-4869-9d5d-2a64e75922fe" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_EntityEmergingGrowthCompany_78366e12-2f3d-4869-9d5d-2a64e75922fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_48b316d5-7baa-46bf-b1bf-f8355b86be94" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_EntityExTransitionPeriod_48b316d5-7baa-46bf-b1bf-f8355b86be94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_2887654b-3dc4-40e4-b8e7-b8d27fc4a8b7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_IcfrAuditorAttestationFlag_2887654b-3dc4-40e4-b8e7-b8d27fc4a8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d057dec5-c2d1-4b0f-895f-340158817685" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_EntityShellCompany_d057dec5-c2d1-4b0f-895f-340158817685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_bdfb44e1-873a-4718-b67b-69068775b7c2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_EntityPublicFloat_bdfb44e1-873a-4718-b67b-69068775b7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3e86630d-4df4-4495-9689-a7065ebdda7c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3e86630d-4df4-4495-9689-a7065ebdda7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_311b2757-24fd-4e8d-9e43-bd5fd1101c8c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_AmendmentFlag_311b2757-24fd-4e8d-9e43-bd5fd1101c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_9b75c30a-4492-4ae5-8b9c-1f475f322d82" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_DocumentFiscalYearFocus_9b75c30a-4492-4ae5-8b9c-1f475f322d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_95ffeaa6-5401-44a6-9a37-88c86447686a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_95ffeaa6-5401-44a6-9a37-88c86447686a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_aa6e5649-7647-4f3a-9e46-488e9110c2e3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e3ef668e-d50f-4ce3-aee0-fb2021f9fad1" xlink:to="loc_dei_EntityCentralIndexKey_aa6e5649-7647-4f3a-9e46-488e9110c2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/AuditInformation" xlink:type="simple" xlink:href="fhtx-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_AuditInformationAbstract_dd5f18bb-06d9-4d76-893f-0602bb21848e" xlink:href="fhtx-20211231.xsd#fhtx_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_5a23e0a1-1bb3-4770-a1ff-a62c047742ed" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fhtx_AuditInformationAbstract_dd5f18bb-06d9-4d76-893f-0602bb21848e" xlink:to="loc_dei_AuditorName_5a23e0a1-1bb3-4770-a1ff-a62c047742ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_6ddc6d70-4517-4c8f-bf25-859e5a7fe73f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fhtx_AuditInformationAbstract_dd5f18bb-06d9-4d76-893f-0602bb21848e" xlink:to="loc_dei_AuditorFirmId_6ddc6d70-4517-4c8f-bf25-859e5a7fe73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_9a87e2ee-4cfc-4fd3-a411-f110db880de4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fhtx_AuditInformationAbstract_dd5f18bb-06d9-4d76-893f-0602bb21848e" xlink:to="loc_dei_AuditorLocation_9a87e2ee-4cfc-4fd3-a411-f110db880de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="fhtx-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c7ab469b-1335-48a4-a6df-588c5315d484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_f0782569-2aed-4665-a070-d10934f95654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c7ab469b-1335-48a4-a6df-588c5315d484" xlink:to="loc_us-gaap_AssetsAbstract_f0782569-2aed-4665-a070-d10934f95654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_733e953c-3219-4c80-ab0f-44de184b8b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f0782569-2aed-4665-a070-d10934f95654" xlink:to="loc_us-gaap_AssetsCurrentAbstract_733e953c-3219-4c80-ab0f-44de184b8b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8e772589-f0ea-49cf-9377-4166504840e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_733e953c-3219-4c80-ab0f-44de184b8b8a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8e772589-f0ea-49cf-9377-4166504840e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_fd8c5a2c-ba6a-45d1-a8cb-4ae7308f07f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_733e953c-3219-4c80-ab0f-44de184b8b8a" xlink:to="loc_us-gaap_MarketableSecurities_fd8c5a2c-ba6a-45d1-a8cb-4ae7308f07f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_0867f8d4-51b5-4de8-a1ad-84a8c7b6d139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_733e953c-3219-4c80-ab0f-44de184b8b8a" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_0867f8d4-51b5-4de8-a1ad-84a8c7b6d139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_576b965e-ac66-4507-bf36-db0a49ddfc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_733e953c-3219-4c80-ab0f-44de184b8b8a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_576b965e-ac66-4507-bf36-db0a49ddfc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f7cfae31-7d8a-4d37-8847-67746ba6e934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_733e953c-3219-4c80-ab0f-44de184b8b8a" xlink:to="loc_us-gaap_AssetsCurrent_f7cfae31-7d8a-4d37-8847-67746ba6e934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_673c0486-951e-46ee-8042-29f2722796cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f0782569-2aed-4665-a070-d10934f95654" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_673c0486-951e-46ee-8042-29f2722796cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_bbe0fa6f-9577-4d4b-82bf-3eccb5f2ed8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f0782569-2aed-4665-a070-d10934f95654" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_bbe0fa6f-9577-4d4b-82bf-3eccb5f2ed8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5796649d-d69d-4f58-b42e-3aa3a273ed5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f0782569-2aed-4665-a070-d10934f95654" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5796649d-d69d-4f58-b42e-3aa3a273ed5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b81583a-c208-40d4-bb37-31355e242e18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f0782569-2aed-4665-a070-d10934f95654" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b81583a-c208-40d4-bb37-31355e242e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_318a0c40-fe34-4b0e-804b-747666811637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f0782569-2aed-4665-a070-d10934f95654" xlink:to="loc_us-gaap_Assets_318a0c40-fe34-4b0e-804b-747666811637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_052ef9bf-66ef-494e-aa5c-33428fd9ed94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c7ab469b-1335-48a4-a6df-588c5315d484" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_052ef9bf-66ef-494e-aa5c-33428fd9ed94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_afd555cc-562c-4fd6-b2fb-a9741ea4edd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_052ef9bf-66ef-494e-aa5c-33428fd9ed94" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_afd555cc-562c-4fd6-b2fb-a9741ea4edd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c657f6dd-9c43-4651-bb66-58950d553887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_afd555cc-562c-4fd6-b2fb-a9741ea4edd7" xlink:to="loc_us-gaap_AccountsPayableCurrent_c657f6dd-9c43-4651-bb66-58950d553887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_10f364b2-2a63-4b57-a05a-d76f0a4a7693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_afd555cc-562c-4fd6-b2fb-a9741ea4edd7" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_10f364b2-2a63-4b57-a05a-d76f0a4a7693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_86484252-b2f5-4fcb-8242-97686e5c3ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_afd555cc-562c-4fd6-b2fb-a9741ea4edd7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_86484252-b2f5-4fcb-8242-97686e5c3ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a78af3ff-1e94-4a93-9810-dcabbf3498fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_afd555cc-562c-4fd6-b2fb-a9741ea4edd7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a78af3ff-1e94-4a93-9810-dcabbf3498fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a68349d1-2506-441d-8f53-a6912e06958f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_afd555cc-562c-4fd6-b2fb-a9741ea4edd7" xlink:to="loc_us-gaap_LiabilitiesCurrent_a68349d1-2506-441d-8f53-a6912e06958f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_b1409b96-e677-4e23-a8aa-41edbae18ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_052ef9bf-66ef-494e-aa5c-33428fd9ed94" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_b1409b96-e677-4e23-a8aa-41edbae18ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d562693d-d313-4ed7-a93c-f1e4373cd732" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_052ef9bf-66ef-494e-aa5c-33428fd9ed94" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d562693d-d313-4ed7-a93c-f1e4373cd732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2490512e-8f9a-4892-9314-e00ad318ec3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_052ef9bf-66ef-494e-aa5c-33428fd9ed94" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2490512e-8f9a-4892-9314-e00ad318ec3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b02e50a9-cd0c-4507-93c1-5d1778d04878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_052ef9bf-66ef-494e-aa5c-33428fd9ed94" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b02e50a9-cd0c-4507-93c1-5d1778d04878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_914fb447-8f91-4f0c-a902-02910a3dd433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_052ef9bf-66ef-494e-aa5c-33428fd9ed94" xlink:to="loc_us-gaap_Liabilities_914fb447-8f91-4f0c-a902-02910a3dd433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_52a0f03e-e102-4f5d-a951-81eecadbe03b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_052ef9bf-66ef-494e-aa5c-33428fd9ed94" xlink:to="loc_us-gaap_CommitmentsAndContingencies_52a0f03e-e102-4f5d-a951-81eecadbe03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_abbcca90-7517-4bc9-b979-696974dc3e16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_052ef9bf-66ef-494e-aa5c-33428fd9ed94" xlink:to="loc_us-gaap_StockholdersEquityAbstract_abbcca90-7517-4bc9-b979-696974dc3e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_85cf389f-a975-4fbb-83bc-5c2b74131f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_abbcca90-7517-4bc9-b979-696974dc3e16" xlink:to="loc_us-gaap_PreferredStockValue_85cf389f-a975-4fbb-83bc-5c2b74131f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_446a5060-e15d-4bf8-b908-8986c3f791f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_abbcca90-7517-4bc9-b979-696974dc3e16" xlink:to="loc_us-gaap_CommonStockValue_446a5060-e15d-4bf8-b908-8986c3f791f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_09c16670-55e2-4858-b1ee-c20af16ed0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_abbcca90-7517-4bc9-b979-696974dc3e16" xlink:to="loc_us-gaap_AdditionalPaidInCapital_09c16670-55e2-4858-b1ee-c20af16ed0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b65812e6-651d-4a24-8740-30590e68d303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_abbcca90-7517-4bc9-b979-696974dc3e16" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b65812e6-651d-4a24-8740-30590e68d303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d547498c-981a-42f6-b8fd-9236cb4d7909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_abbcca90-7517-4bc9-b979-696974dc3e16" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d547498c-981a-42f6-b8fd-9236cb4d7909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1e6dac0a-5e34-4652-8d67-3f764fea9d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_abbcca90-7517-4bc9-b979-696974dc3e16" xlink:to="loc_us-gaap_StockholdersEquity_1e6dac0a-5e34-4652-8d67-3f764fea9d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_55ebcd57-2106-43be-95ae-81f2a73c1c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_052ef9bf-66ef-494e-aa5c-33428fd9ed94" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_55ebcd57-2106-43be-95ae-81f2a73c1c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="fhtx-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2ead5b64-47de-4f5a-8505-afde10023468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8e29d0e6-e196-487c-8146-dc9a7beca369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2ead5b64-47de-4f5a-8505-afde10023468" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8e29d0e6-e196-487c-8146-dc9a7beca369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d68fed26-42e2-4b4c-a0c5-74786c6a6a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2ead5b64-47de-4f5a-8505-afde10023468" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d68fed26-42e2-4b4c-a0c5-74786c6a6a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_8932f383-949d-4f2f-bfc0-6cd997b1b55f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2ead5b64-47de-4f5a-8505-afde10023468" xlink:to="loc_us-gaap_PreferredStockSharesIssued_8932f383-949d-4f2f-bfc0-6cd997b1b55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_21233b9d-c4ff-424b-91a1-ee2afdbde2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2ead5b64-47de-4f5a-8505-afde10023468" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_21233b9d-c4ff-424b-91a1-ee2afdbde2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_90c88445-fe88-4156-8d4d-673e4d926d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2ead5b64-47de-4f5a-8505-afde10023468" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_90c88445-fe88-4156-8d4d-673e4d926d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b216c0d9-4d51-4f44-bc01-ce219d4cf189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2ead5b64-47de-4f5a-8505-afde10023468" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b216c0d9-4d51-4f44-bc01-ce219d4cf189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b077c58e-ec13-40f3-90c8-42e16334440b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2ead5b64-47de-4f5a-8505-afde10023468" xlink:to="loc_us-gaap_CommonStockSharesIssued_b077c58e-ec13-40f3-90c8-42e16334440b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_42e8e19a-3002-4618-8254-cda5d84ec407" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2ead5b64-47de-4f5a-8505-afde10023468" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_42e8e19a-3002-4618-8254-cda5d84ec407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="fhtx-20211231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_8fcb561c-8631-4d61-b8d1-cd4aad4b123f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a51f4421-f5e2-4449-9ca7-e691346b9f74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fcb561c-8631-4d61-b8d1-cd4aad4b123f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a51f4421-f5e2-4449-9ca7-e691346b9f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4389593b-893b-44fa-84e4-24601b90c3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fcb561c-8631-4d61-b8d1-cd4aad4b123f" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4389593b-893b-44fa-84e4-24601b90c3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8e23492d-d2c2-4a52-a93d-89465918787b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4389593b-893b-44fa-84e4-24601b90c3f1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8e23492d-d2c2-4a52-a93d-89465918787b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b868470f-261a-4ba0-9339-d345b1217e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4389593b-893b-44fa-84e4-24601b90c3f1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b868470f-261a-4ba0-9339-d345b1217e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1f5b1bfd-95ab-4309-9cbb-2303c3f9ef57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4389593b-893b-44fa-84e4-24601b90c3f1" xlink:to="loc_us-gaap_OperatingExpenses_1f5b1bfd-95ab-4309-9cbb-2303c3f9ef57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fb024851-b2fc-4b6f-a388-ef65f6f75903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fcb561c-8631-4d61-b8d1-cd4aad4b123f" xlink:to="loc_us-gaap_OperatingIncomeLoss_fb024851-b2fc-4b6f-a388-ef65f6f75903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0109640d-2a75-4da8-9018-748b784eba43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fcb561c-8631-4d61-b8d1-cd4aad4b123f" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0109640d-2a75-4da8-9018-748b784eba43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_43c7a886-28f2-4eda-bf05-c376838a1b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0109640d-2a75-4da8-9018-748b784eba43" xlink:to="loc_us-gaap_InterestExpense_43c7a886-28f2-4eda-bf05-c376838a1b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_InterestIncomeAndOtherIncomeExpense_17a3f3ec-ec6a-41f5-bc19-5b9f152c81e9" xlink:href="fhtx-20211231.xsd#fhtx_InterestIncomeAndOtherIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0109640d-2a75-4da8-9018-748b784eba43" xlink:to="loc_fhtx_InterestIncomeAndOtherIncomeExpense_17a3f3ec-ec6a-41f5-bc19-5b9f152c81e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_c20e7ea1-1892-4140-b976-717c894bbcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0109640d-2a75-4da8-9018-748b784eba43" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_c20e7ea1-1892-4140-b976-717c894bbcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6e91c30e-eee3-4809-bf26-2c8fa679dcc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0109640d-2a75-4da8-9018-748b784eba43" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6e91c30e-eee3-4809-bf26-2c8fa679dcc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_efe23a14-dad9-4e7a-bfb6-8c647c8c17b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0109640d-2a75-4da8-9018-748b784eba43" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_efe23a14-dad9-4e7a-bfb6-8c647c8c17b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d6f4bc83-064d-4443-9917-3ca832f3d90e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fcb561c-8631-4d61-b8d1-cd4aad4b123f" xlink:to="loc_us-gaap_NetIncomeLoss_d6f4bc83-064d-4443-9917-3ca832f3d90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_aa97c1f3-6d25-4ac1-b73e-781355bc667a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fcb561c-8631-4d61-b8d1-cd4aad4b123f" xlink:to="loc_us-gaap_EarningsPerShareBasic_aa97c1f3-6d25-4ac1-b73e-781355bc667a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_54a27b0a-94ed-49b2-acae-4ecdaedc2583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fcb561c-8631-4d61-b8d1-cd4aad4b123f" xlink:to="loc_us-gaap_EarningsPerShareDiluted_54a27b0a-94ed-49b2-acae-4ecdaedc2583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_aa2fa1f4-fc8c-4cc5-9731-e66bf2659ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fcb561c-8631-4d61-b8d1-cd4aad4b123f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_aa2fa1f4-fc8c-4cc5-9731-e66bf2659ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ec3ca8b9-65ef-4e82-af9b-3f57492cb8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fcb561c-8631-4d61-b8d1-cd4aad4b123f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ec3ca8b9-65ef-4e82-af9b-3f57492cb8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_00250dea-d491-4910-aeb8-70363c24ee71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8fcb561c-8631-4d61-b8d1-cd4aad4b123f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_00250dea-d491-4910-aeb8-70363c24ee71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_25e23e49-a56d-4092-8ab2-a7e04eac7cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_00250dea-d491-4910-aeb8-70363c24ee71" xlink:to="loc_us-gaap_NetIncomeLoss_25e23e49-a56d-4092-8ab2-a7e04eac7cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_beab4b8c-3b27-4227-849d-e716b0d639c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_00250dea-d491-4910-aeb8-70363c24ee71" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_beab4b8c-3b27-4227-849d-e716b0d639c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b35f0a66-99ac-4ee0-80cd-311027ee9de1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_beab4b8c-3b27-4227-849d-e716b0d639c0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_b35f0a66-99ac-4ee0-80cd-311027ee9de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_466481b2-3b11-4b70-b2dc-af5ef56d00c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_beab4b8c-3b27-4227-849d-e716b0d639c0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_466481b2-3b11-4b70-b2dc-af5ef56d00c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_fe2cd680-2b89-4250-8a40-60678c080bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_beab4b8c-3b27-4227-849d-e716b0d639c0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_fe2cd680-2b89-4250-8a40-60678c080bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" xlink:type="simple" xlink:href="fhtx-20211231.xsd#ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7656bef7-64e2-4268-a6d4-4f2addb32c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8fb673e2-70c5-49a0-8f23-3a70ccaf254b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7656bef7-64e2-4268-a6d4-4f2addb32c4f" xlink:to="loc_us-gaap_StatementTable_8fb673e2-70c5-49a0-8f23-3a70ccaf254b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f1cf6721-310d-4fea-bdc0-af237da417c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8fb673e2-70c5-49a0-8f23-3a70ccaf254b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f1cf6721-310d-4fea-bdc0-af237da417c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f11036a1-929a-424a-9c9a-0148d6ee0d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f1cf6721-310d-4fea-bdc0-af237da417c8" xlink:to="loc_us-gaap_ClassOfStockDomain_f11036a1-929a-424a-9c9a-0148d6ee0d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_1e20d97f-0960-4405-8c7b-ccf5f8f658e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f11036a1-929a-424a-9c9a-0148d6ee0d5f" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_1e20d97f-0960-4405-8c7b-ccf5f8f658e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b43dc616-d2f0-4086-a825-2ebbf88dd1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8fb673e2-70c5-49a0-8f23-3a70ccaf254b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b43dc616-d2f0-4086-a825-2ebbf88dd1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b5c7bb20-7e91-4f74-aaf3-d9429a66e9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b43dc616-d2f0-4086-a825-2ebbf88dd1bb" xlink:to="loc_us-gaap_EquityComponentDomain_b5c7bb20-7e91-4f74-aaf3-d9429a66e9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_8d04ef4f-7823-4875-9d70-20899deae9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b5c7bb20-7e91-4f74-aaf3-d9429a66e9ec" xlink:to="loc_us-gaap_PreferredStockMember_8d04ef4f-7823-4875-9d70-20899deae9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5dd480e6-5e5e-49b9-8122-fa59f8c9c077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b5c7bb20-7e91-4f74-aaf3-d9429a66e9ec" xlink:to="loc_us-gaap_CommonStockMember_5dd480e6-5e5e-49b9-8122-fa59f8c9c077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ee405ea3-25a9-4c88-aadc-7bcb1045c72d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b5c7bb20-7e91-4f74-aaf3-d9429a66e9ec" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ee405ea3-25a9-4c88-aadc-7bcb1045c72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_679c581f-fc48-4f59-a9d1-d927eb548181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b5c7bb20-7e91-4f74-aaf3-d9429a66e9ec" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_679c581f-fc48-4f59-a9d1-d927eb548181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e67e890c-de2c-4547-aa69-91193c3eb56b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b5c7bb20-7e91-4f74-aaf3-d9429a66e9ec" xlink:to="loc_us-gaap_RetainedEarningsMember_e67e890c-de2c-4547-aa69-91193c3eb56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_309dd6af-108c-4ca2-a5d5-9293eb24f55d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8fb673e2-70c5-49a0-8f23-3a70ccaf254b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_309dd6af-108c-4ca2-a5d5-9293eb24f55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2bdda8e6-ec3a-4ab0-9e54-81b3cf860f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_309dd6af-108c-4ca2-a5d5-9293eb24f55d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2bdda8e6-ec3a-4ab0-9e54-81b3cf860f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_6a4eb641-3dc0-4a18-b0bd-985626cbb4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2bdda8e6-ec3a-4ab0-9e54-81b3cf860f0a" xlink:to="loc_us-gaap_IPOMember_6a4eb641-3dc0-4a18-b0bd-985626cbb4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_SharePurchaseAgreementMember_1d0b5a8a-6435-4225-8bec-80f53ec64c23" xlink:href="fhtx-20211231.xsd#fhtx_SharePurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2bdda8e6-ec3a-4ab0-9e54-81b3cf860f0a" xlink:to="loc_fhtx_SharePurchaseAgreementMember_1d0b5a8a-6435-4225-8bec-80f53ec64c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2a7cb4d3-ff76-48d7-8b84-a5912cb78e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8fb673e2-70c5-49a0-8f23-3a70ccaf254b" xlink:to="loc_us-gaap_StatementLineItems_2a7cb4d3-ff76-48d7-8b84-a5912cb78e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_e23ce7be-45c0-4e1c-83e5-6166aa98b441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2a7cb4d3-ff76-48d7-8b84-a5912cb78e4f" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_e23ce7be-45c0-4e1c-83e5-6166aa98b441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_8ce0b49d-b83e-41f9-8b42-0faacff7e0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_e23ce7be-45c0-4e1c-83e5-6166aa98b441" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_8ce0b49d-b83e-41f9-8b42-0faacff7e0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_7c7a1276-c06d-4002-83d6-79d78a3b0219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_e23ce7be-45c0-4e1c-83e5-6166aa98b441" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_7c7a1276-c06d-4002-83d6-79d78a3b0219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_e5ebf372-012a-483e-a54f-e94523b702fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_e23ce7be-45c0-4e1c-83e5-6166aa98b441" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_e5ebf372-012a-483e-a54f-e94523b702fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_ea72ee40-608b-4ef8-9174-1f33f883cbd3" xlink:href="fhtx-20211231.xsd#fhtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_e23ce7be-45c0-4e1c-83e5-6166aa98b441" xlink:to="loc_fhtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_ea72ee40-608b-4ef8-9174-1f33f883cbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_TemporaryEquityConversionOfStockAmountConverted_b79ecf48-0671-4d5d-972c-f5ce7246e101" xlink:href="fhtx-20211231.xsd#fhtx_TemporaryEquityConversionOfStockAmountConverted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_e23ce7be-45c0-4e1c-83e5-6166aa98b441" xlink:to="loc_fhtx_TemporaryEquityConversionOfStockAmountConverted_b79ecf48-0671-4d5d-972c-f5ce7246e101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_TemporaryEquityConversionOfStockSharesConverted_1dd13190-3def-4d5a-a856-676b868349a8" xlink:href="fhtx-20211231.xsd#fhtx_TemporaryEquityConversionOfStockSharesConverted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_e23ce7be-45c0-4e1c-83e5-6166aa98b441" xlink:to="loc_fhtx_TemporaryEquityConversionOfStockSharesConverted_1dd13190-3def-4d5a-a856-676b868349a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_ab015854-7969-4c96-b305-5654eacaa4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_e23ce7be-45c0-4e1c-83e5-6166aa98b441" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_ab015854-7969-4c96-b305-5654eacaa4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_cb74e748-eb0a-4d3b-8ce6-b47bbee0a313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_e23ce7be-45c0-4e1c-83e5-6166aa98b441" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_cb74e748-eb0a-4d3b-8ce6-b47bbee0a313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2a7cb4d3-ff76-48d7-8b84-a5912cb78e4f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_73de022d-4162-4d60-a822-a51660c1d7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_StockholdersEquity_73de022d-4162-4d60-a822-a51660c1d7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1e85f689-a235-48c9-a051-c0015f5091b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1e85f689-a235-48c9-a051-c0015f5091b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1d2a816b-50a2-4836-bebf-075f74da1235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1d2a816b-50a2-4836-bebf-075f74da1235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_2002cc84-e605-4c75-8397-1d7fc0bae122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_2002cc84-e605-4c75-8397-1d7fc0bae122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3b8ba3b5-5702-4b3f-b735-c3707533b695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3b8ba3b5-5702-4b3f-b735-c3707533b695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52a94a96-3ae0-4132-9f03-cf3a0f63187d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52a94a96-3ae0-4132-9f03-cf3a0f63187d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_42a054eb-5043-412f-94ca-2a8a7a1bc191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_42a054eb-5043-412f-94ca-2a8a7a1bc191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_StockIssuedDuringPeriodConnectionWithExerciseOfWarrant_87e7de04-c0a1-4a7d-a14c-3e31194e2cd5" xlink:href="fhtx-20211231.xsd#fhtx_StockIssuedDuringPeriodConnectionWithExerciseOfWarrant"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_fhtx_StockIssuedDuringPeriodConnectionWithExerciseOfWarrant_87e7de04-c0a1-4a7d-a14c-3e31194e2cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_180b674c-d33e-4d85-98b8-19ac37cd6dea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_180b674c-d33e-4d85-98b8-19ac37cd6dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_995b5df0-c9a3-4ce4-8907-4022703bb8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_995b5df0-c9a3-4ce4-8907-4022703bb8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_4053252f-e5da-483f-ad2c-a48df048f1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments_4053252f-e5da-483f-ad2c-a48df048f1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_6a2951da-b218-48be-82e5-bad19c99bc82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_6a2951da-b218-48be-82e5-bad19c99bc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_20b508ee-aad2-4c8f-a5a4-04ab526ff0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_20b508ee-aad2-4c8f-a5a4-04ab526ff0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_13d3ba33-7024-4c29-b985-47a088ac4897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_13d3ba33-7024-4c29-b985-47a088ac4897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_be54d869-e8e5-40cb-8cff-61174e515cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_NetIncomeLoss_be54d869-e8e5-40cb-8cff-61174e515cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_79a60050-44f9-4147-8287-cf07df2eef0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_StockholdersEquity_79a60050-44f9-4147-8287-cf07df2eef0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a1ca44c9-c0a1-4b39-88e4-bb280945ca47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d76dbb18-8fb3-408e-9933-68353fa6bc35" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a1ca44c9-c0a1-4b39-88e4-bb280945ca47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityParenthetical" xlink:type="simple" xlink:href="fhtx-20211231.xsd#ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4d44fa29-264f-4c6a-a7bc-7dff34b23717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5398e915-12aa-4589-9453-195e11b6ed85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4d44fa29-264f-4c6a-a7bc-7dff34b23717" xlink:to="loc_us-gaap_StatementTable_5398e915-12aa-4589-9453-195e11b6ed85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2ae36f93-dcc0-483c-8d90-23d5948c3188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5398e915-12aa-4589-9453-195e11b6ed85" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2ae36f93-dcc0-483c-8d90-23d5948c3188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_69283a68-5ab5-415f-90d6-487781190f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2ae36f93-dcc0-483c-8d90-23d5948c3188" xlink:to="loc_us-gaap_ClassOfStockDomain_69283a68-5ab5-415f-90d6-487781190f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_5a12e700-5aee-470e-9197-a1bba4c997d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_69283a68-5ab5-415f-90d6-487781190f38" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_5a12e700-5aee-470e-9197-a1bba4c997d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d4b01f59-25bc-4fec-8fa3-1c7a3850c297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5398e915-12aa-4589-9453-195e11b6ed85" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d4b01f59-25bc-4fec-8fa3-1c7a3850c297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0e949d62-6b47-42a2-ab23-4082ed94281c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d4b01f59-25bc-4fec-8fa3-1c7a3850c297" xlink:to="loc_us-gaap_EquityComponentDomain_0e949d62-6b47-42a2-ab23-4082ed94281c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_9ad10652-ce0f-42a1-98d5-9837fb57363d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0e949d62-6b47-42a2-ab23-4082ed94281c" xlink:to="loc_us-gaap_PreferredStockMember_9ad10652-ce0f-42a1-98d5-9837fb57363d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e471e604-c906-4a99-968c-e6301f18068e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5398e915-12aa-4589-9453-195e11b6ed85" xlink:to="loc_us-gaap_StatementLineItems_e471e604-c906-4a99-968c-e6301f18068e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_StockIssuanceCosts_b5fef407-3138-4e7d-9efe-554f8f764be2" xlink:href="fhtx-20211231.xsd#fhtx_StockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e471e604-c906-4a99-968c-e6301f18068e" xlink:to="loc_fhtx_StockIssuanceCosts_b5fef407-3138-4e7d-9efe-554f8f764be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="fhtx-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_ce0baa88-8309-4a47-b43c-91f745ebf104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0d1732d2-1206-4c41-a6a3-a1735fb41b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce0baa88-8309-4a47-b43c-91f745ebf104" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0d1732d2-1206-4c41-a6a3-a1735fb41b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_61633f30-f785-461a-a277-a9493500fb15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0d1732d2-1206-4c41-a6a3-a1735fb41b86" xlink:to="loc_us-gaap_NetIncomeLoss_61633f30-f785-461a-a277-a9493500fb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_21aa22cd-459a-43da-94a7-95020a94085e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0d1732d2-1206-4c41-a6a3-a1735fb41b86" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_21aa22cd-459a-43da-94a7-95020a94085e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionPlanExpense_3deeb0ab-888b-45aa-a362-d67cd79d16e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionPlanExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_21aa22cd-459a-43da-94a7-95020a94085e" xlink:to="loc_us-gaap_StockOptionPlanExpense_3deeb0ab-888b-45aa-a362-d67cd79d16e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4646d4d3-73c2-4e08-8cc0-a4afef8e24d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_21aa22cd-459a-43da-94a7-95020a94085e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4646d4d3-73c2-4e08-8cc0-a4afef8e24d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_d8086ee1-925b-4098-bbca-6e2a3b4a6730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_21aa22cd-459a-43da-94a7-95020a94085e" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_d8086ee1-925b-4098-bbca-6e2a3b4a6730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_737c7eee-4442-4889-aec0-dc78fb851264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_21aa22cd-459a-43da-94a7-95020a94085e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_737c7eee-4442-4889-aec0-dc78fb851264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_4d478cd6-bd59-40fb-ac97-13e0954b45f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_21aa22cd-459a-43da-94a7-95020a94085e" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_4d478cd6-bd59-40fb-ac97-13e0954b45f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_049833eb-1e6c-413d-b00a-5955f324a2d4" xlink:href="fhtx-20211231.xsd#fhtx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_21aa22cd-459a-43da-94a7-95020a94085e" xlink:to="loc_fhtx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_049833eb-1e6c-413d-b00a-5955f324a2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_bc74de55-10fc-4ee4-a848-742769b226ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_21aa22cd-459a-43da-94a7-95020a94085e" xlink:to="loc_us-gaap_PaidInKindInterest_bc74de55-10fc-4ee4-a848-742769b226ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_26c5d3ac-74d7-4184-9210-c06319d69664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_21aa22cd-459a-43da-94a7-95020a94085e" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_26c5d3ac-74d7-4184-9210-c06319d69664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36d7c66b-3ea9-433f-9708-cebe69dc8cad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0d1732d2-1206-4c41-a6a3-a1735fb41b86" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36d7c66b-3ea9-433f-9708-cebe69dc8cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_db3f27f8-e2f9-4344-974f-638c472f1d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36d7c66b-3ea9-433f-9708-cebe69dc8cad" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_db3f27f8-e2f9-4344-974f-638c472f1d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_3ca8abcc-1c74-42ce-8caf-b93345397eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36d7c66b-3ea9-433f-9708-cebe69dc8cad" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_3ca8abcc-1c74-42ce-8caf-b93345397eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c6f2f3c4-f480-414e-b8e5-2b9cc7b55c44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36d7c66b-3ea9-433f-9708-cebe69dc8cad" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c6f2f3c4-f480-414e-b8e5-2b9cc7b55c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1efba56a-506b-42b5-bfcb-48f50c9312bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36d7c66b-3ea9-433f-9708-cebe69dc8cad" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1efba56a-506b-42b5-bfcb-48f50c9312bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_IncreaseDecreaseInOperatingLeaseLiabilities_fb2a13ea-53a5-44f5-9952-7f111400c610" xlink:href="fhtx-20211231.xsd#fhtx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36d7c66b-3ea9-433f-9708-cebe69dc8cad" xlink:to="loc_fhtx_IncreaseDecreaseInOperatingLeaseLiabilities_fb2a13ea-53a5-44f5-9952-7f111400c610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_dbe48369-4b86-40b4-8691-b91cb246681e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_36d7c66b-3ea9-433f-9708-cebe69dc8cad" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_dbe48369-4b86-40b4-8691-b91cb246681e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dbc31f85-98a2-41da-bf0b-5ef8da0d8737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0d1732d2-1206-4c41-a6a3-a1735fb41b86" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dbc31f85-98a2-41da-bf0b-5ef8da0d8737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5725504f-bee0-40e5-b029-5441501deb95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce0baa88-8309-4a47-b43c-91f745ebf104" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5725504f-bee0-40e5-b029-5441501deb95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9993a3bb-a444-4ca4-9427-11a262d00a79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5725504f-bee0-40e5-b029-5441501deb95" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9993a3bb-a444-4ca4-9427-11a262d00a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_58245267-b761-4085-b907-05833caee92b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5725504f-bee0-40e5-b029-5441501deb95" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_58245267-b761-4085-b907-05833caee92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_784ded45-c421-46f8-b3be-cb91ec20dacc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5725504f-bee0-40e5-b029-5441501deb95" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_784ded45-c421-46f8-b3be-cb91ec20dacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_09091636-033e-4e46-b777-a8fed5804f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5725504f-bee0-40e5-b029-5441501deb95" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_09091636-033e-4e46-b777-a8fed5804f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c8ef80d-8c98-4d23-8418-8d691d9d69ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5725504f-bee0-40e5-b029-5441501deb95" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c8ef80d-8c98-4d23-8418-8d691d9d69ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_108f477c-8bdc-4327-9c91-df413c39d95f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce0baa88-8309-4a47-b43c-91f745ebf104" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_108f477c-8bdc-4327-9c91-df413c39d95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_838f885b-fc44-49f2-b937-9fe8a954b26f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_108f477c-8bdc-4327-9c91-df413c39d95f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_838f885b-fc44-49f2-b937-9fe8a954b26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_57be97ce-1339-42e1-bb6c-d649d9ed48ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_108f477c-8bdc-4327-9c91-df413c39d95f" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_57be97ce-1339-42e1-bb6c-d649d9ed48ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_e4257f7b-0c88-4546-b81b-3d8e3318ea5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_108f477c-8bdc-4327-9c91-df413c39d95f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_e4257f7b-0c88-4546-b81b-3d8e3318ea5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_fb8292d0-04a9-4b5b-8bf6-4a25ea18a611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_108f477c-8bdc-4327-9c91-df413c39d95f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_fb8292d0-04a9-4b5b-8bf6-4a25ea18a611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_04507ea3-a6f1-4973-bb23-f335573b2db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_108f477c-8bdc-4327-9c91-df413c39d95f" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_04507ea3-a6f1-4973-bb23-f335573b2db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_fdf55eb7-b13e-499c-abe1-59c1baf3a3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_108f477c-8bdc-4327-9c91-df413c39d95f" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_fdf55eb7-b13e-499c-abe1-59c1baf3a3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_447e8a54-4aa1-44ce-b3d3-88d9ee23218e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_108f477c-8bdc-4327-9c91-df413c39d95f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_447e8a54-4aa1-44ce-b3d3-88d9ee23218e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_51588a80-ffcd-4813-bec4-75d1eb9b59b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce0baa88-8309-4a47-b43c-91f745ebf104" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_51588a80-ffcd-4813-bec4-75d1eb9b59b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0275a3e5-5e1f-4552-a349-3695c3b6f92a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce0baa88-8309-4a47-b43c-91f745ebf104" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0275a3e5-5e1f-4552-a349-3695c3b6f92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fa42f8e9-4405-45fc-a60b-9ca966913835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce0baa88-8309-4a47-b43c-91f745ebf104" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fa42f8e9-4405-45fc-a60b-9ca966913835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_8427be0e-e896-4586-8afe-7a06d32bbb82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce0baa88-8309-4a47-b43c-91f745ebf104" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_8427be0e-e896-4586-8afe-7a06d32bbb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_98e38dc6-9081-44a3-99d1-34acadaa8d01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_8427be0e-e896-4586-8afe-7a06d32bbb82" xlink:to="loc_us-gaap_InterestPaidNet_98e38dc6-9081-44a3-99d1-34acadaa8d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_598c3ff8-da59-4f9b-a24e-53828bceb0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce0baa88-8309-4a47-b43c-91f745ebf104" xlink:to="loc_us-gaap_StatementTable_598c3ff8-da59-4f9b-a24e-53828bceb0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_eb62142b-2635-44c7-9800-f4e36b0547a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_598c3ff8-da59-4f9b-a24e-53828bceb0ba" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_eb62142b-2635-44c7-9800-f4e36b0547a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_a12b8807-f08a-4e89-97b7-1377e97e754e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_eb62142b-2635-44c7-9800-f4e36b0547a6" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_a12b8807-f08a-4e89-97b7-1377e97e754e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ConversionOfRedeemableConvertibleStockMember_dc136949-812c-47ea-b77e-d3d2db970ba2" xlink:href="fhtx-20211231.xsd#fhtx_ConversionOfRedeemableConvertibleStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_a12b8807-f08a-4e89-97b7-1377e97e754e" xlink:to="loc_fhtx_ConversionOfRedeemableConvertibleStockMember_dc136949-812c-47ea-b77e-d3d2db970ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ConversionOfWarrantLiabilityToEquityMember_2c6b0096-32dd-46f8-a811-914a0cacf109" xlink:href="fhtx-20211231.xsd#fhtx_ConversionOfWarrantLiabilityToEquityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_a12b8807-f08a-4e89-97b7-1377e97e754e" xlink:to="loc_fhtx_ConversionOfWarrantLiabilityToEquityMember_2c6b0096-32dd-46f8-a811-914a0cacf109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ConversionOfNotesPayableInToWarrantsMember_9d3b292e-a723-4bf2-a590-58d57c57f7ff" xlink:href="fhtx-20211231.xsd#fhtx_ConversionOfNotesPayableInToWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_a12b8807-f08a-4e89-97b7-1377e97e754e" xlink:to="loc_fhtx_ConversionOfNotesPayableInToWarrantsMember_9d3b292e-a723-4bf2-a590-58d57c57f7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b89effec-0cf7-4c6c-9dff-13f57a2c174e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_598c3ff8-da59-4f9b-a24e-53828bceb0ba" xlink:to="loc_us-gaap_StatementLineItems_b89effec-0cf7-4c6c-9dff-13f57a2c174e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_52c253bc-8cf7-414c-b7b4-e251bf2fc7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b89effec-0cf7-4c6c-9dff-13f57a2c174e" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_52c253bc-8cf7-414c-b7b4-e251bf2fc7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4ce37606-c903-4532-b84d-0888150ab225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_52c253bc-8cf7-414c-b7b4-e251bf2fc7a9" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4ce37606-c903-4532-b84d-0888150ab225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_13dd4f10-16ab-42c9-a153-36ea5e0327b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_52c253bc-8cf7-414c-b7b4-e251bf2fc7a9" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_13dd4f10-16ab-42c9-a153-36ea5e0327b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_80605b5a-58b2-4146-9eaf-3c53135c7229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_52c253bc-8cf7-414c-b7b4-e251bf2fc7a9" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_80605b5a-58b2-4146-9eaf-3c53135c7229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_fc6adda9-9adb-429e-903b-60ef66129cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ce0baa88-8309-4a47-b43c-91f745ebf104" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_fc6adda9-9adb-429e-903b-60ef66129cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6a3f18de-a5bf-4f28-a745-3ea6140da0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_fc6adda9-9adb-429e-903b-60ef66129cc9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6a3f18de-a5bf-4f28-a745-3ea6140da0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalents_43749130-c451-447b-8ca5-2dc2099ec042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_fc6adda9-9adb-429e-903b-60ef66129cc9" xlink:to="loc_us-gaap_RestrictedCashEquivalents_43749130-c451-447b-8ca5-2dc2099ec042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6bd44504-a220-492d-a9e8-33ef3a897ead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_fc6adda9-9adb-429e-903b-60ef66129cc9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6bd44504-a220-492d-a9e8-33ef3a897ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="fhtx-20211231.xsd#NatureofBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_08211132-6f99-41ab-82a0-5cfc9902e9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_e574b21c-b05a-4dec-a8cc-da3e9d8ce1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_08211132-6f99-41ab-82a0-5cfc9902e9fb" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_e574b21c-b05a-4dec-a8cc-da3e9d8ce1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#NatureofBusinessandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14840689-04db-4e19-8cec-201bc548fdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_4bca8611-b176-45d7-bcaf-a6a34e85fe9d" xlink:href="fhtx-20211231.xsd#fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_14840689-04db-4e19-8cec-201bc548fdf8" xlink:to="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_4bca8611-b176-45d7-bcaf-a6a34e85fe9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f057a12a-21a0-43e2-9446-4233b5e63a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_4bca8611-b176-45d7-bcaf-a6a34e85fe9d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f057a12a-21a0-43e2-9446-4233b5e63a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70dd820d-f974-468c-bcf4-07734f7cc91b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f057a12a-21a0-43e2-9446-4233b5e63a6b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70dd820d-f974-468c-bcf4-07734f7cc91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_10083900-06d9-4c52-b364-ab84e069b3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70dd820d-f974-468c-bcf4-07734f7cc91b" xlink:to="loc_us-gaap_IPOMember_10083900-06d9-4c52-b364-ab84e069b3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_30895fa8-d379-462c-9211-31ffe14ad1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70dd820d-f974-468c-bcf4-07734f7cc91b" xlink:to="loc_us-gaap_OverAllotmentOptionMember_30895fa8-d379-462c-9211-31ffe14ad1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_SharePurchaseAgreementMember_c2f7843c-86be-4b09-a86a-330a60cae405" xlink:href="fhtx-20211231.xsd#fhtx_SharePurchaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70dd820d-f974-468c-bcf4-07734f7cc91b" xlink:to="loc_fhtx_SharePurchaseAgreementMember_c2f7843c-86be-4b09-a86a-330a60cae405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5a69ccd9-e0a9-440a-a6ca-e129e86c6bb4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_4bca8611-b176-45d7-bcaf-a6a34e85fe9d" xlink:to="loc_srt_CounterpartyNameAxis_5a69ccd9-e0a9-440a-a6ca-e129e86c6bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6afc8c02-1aff-40a4-942f-c82ec9bf89b5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5a69ccd9-e0a9-440a-a6ca-e129e86c6bb4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6afc8c02-1aff-40a4-942f-c82ec9bf89b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_EliLillyMember_2b7a619c-0f3d-4db7-acbd-a49518ce2156" xlink:href="fhtx-20211231.xsd#fhtx_EliLillyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6afc8c02-1aff-40a4-942f-c82ec9bf89b5" xlink:to="loc_fhtx_EliLillyMember_2b7a619c-0f3d-4db7-acbd-a49518ce2156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_90ad5583-b950-40d3-bff4-3b88b8f0256f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_4bca8611-b176-45d7-bcaf-a6a34e85fe9d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_90ad5583-b950-40d3-bff4-3b88b8f0256f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e35d29c8-759e-4079-89b8-cc003dc1ede7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_90ad5583-b950-40d3-bff4-3b88b8f0256f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e35d29c8-759e-4079-89b8-cc003dc1ede7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_cfe1356d-f835-416d-8b64-878e9fa6791e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e35d29c8-759e-4079-89b8-cc003dc1ede7" xlink:to="loc_us-gaap_SubsequentEventMember_cfe1356d-f835-416d-8b64-878e9fa6791e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4e48e4a0-9f83-4f7c-8601-70a1f1b15298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_4bca8611-b176-45d7-bcaf-a6a34e85fe9d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4e48e4a0-9f83-4f7c-8601-70a1f1b15298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bd8afcf8-5eaa-47a9-a577-200a5b33be10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4e48e4a0-9f83-4f7c-8601-70a1f1b15298" xlink:to="loc_us-gaap_ClassOfStockDomain_bd8afcf8-5eaa-47a9-a577-200a5b33be10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2260486b-4849-4c3b-bdd1-87546c1394df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bd8afcf8-5eaa-47a9-a577-200a5b33be10" xlink:to="loc_us-gaap_CommonStockMember_2260486b-4849-4c3b-bdd1-87546c1394df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_8a908cc9-123c-42c2-afe1-fc85cb72c859" xlink:href="fhtx-20211231.xsd#fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_4bca8611-b176-45d7-bcaf-a6a34e85fe9d" xlink:to="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_8a908cc9-123c-42c2-afe1-fc85cb72c859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3510c762-a1ab-4a39-a79f-d5fe371c0a53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_8a908cc9-123c-42c2-afe1-fc85cb72c859" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3510c762-a1ab-4a39-a79f-d5fe371c0a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1980a55b-c44c-4f1d-92b8-3d29b29aa095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_8a908cc9-123c-42c2-afe1-fc85cb72c859" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1980a55b-c44c-4f1d-92b8-3d29b29aa095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3455fce7-2221-4dcb-9db1-f6e974294f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_8a908cc9-123c-42c2-afe1-fc85cb72c859" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3455fce7-2221-4dcb-9db1-f6e974294f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ProceedsFromUpfrontPayment_d694815d-52c4-474d-948e-b80534cfb10b" xlink:href="fhtx-20211231.xsd#fhtx_ProceedsFromUpfrontPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_8a908cc9-123c-42c2-afe1-fc85cb72c859" xlink:to="loc_fhtx_ProceedsFromUpfrontPayment_d694815d-52c4-474d-948e-b80534cfb10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bb917782-7f43-458b-9b76-92aecfd02c60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_8a908cc9-123c-42c2-afe1-fc85cb72c859" xlink:to="loc_us-gaap_NetIncomeLoss_bb917782-7f43-458b-9b76-92aecfd02c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9a0894b6-3f9f-40a7-8ac4-8105c2d2a0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_8a908cc9-123c-42c2-afe1-fc85cb72c859" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9a0894b6-3f9f-40a7-8ac4-8105c2d2a0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8aee1595-e2bd-4da1-8f90-0a34984184fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_8a908cc9-123c-42c2-afe1-fc85cb72c859" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8aee1595-e2bd-4da1-8f90-0a34984184fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="fhtx-20211231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d7486cad-a0f4-4b25-a0bd-42f8836764fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_43737c29-abaf-46fb-8e2c-9cb62aa66f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d7486cad-a0f4-4b25-a0bd-42f8836764fd" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_43737c29-abaf-46fb-8e2c-9cb62aa66f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="fhtx-20211231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ae3b2d9f-0206-4c4d-9d5d-fd03b2945654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1acc3700-c7a1-4bfc-9db2-db07efbf09b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae3b2d9f-0206-4c4d-9d5d-fd03b2945654" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1acc3700-c7a1-4bfc-9db2-db07efbf09b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_dcf5f329-4e01-44b8-960d-11fdb3566c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae3b2d9f-0206-4c4d-9d5d-fd03b2945654" xlink:to="loc_us-gaap_UseOfEstimates_dcf5f329-4e01-44b8-960d-11fdb3566c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_6ccbda0a-3fc4-4196-a3ea-e8c7c883498e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae3b2d9f-0206-4c4d-9d5d-fd03b2945654" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_6ccbda0a-3fc4-4196-a3ea-e8c7c883498e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_bad615aa-a64c-41f1-9a41-93766e9ce0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae3b2d9f-0206-4c4d-9d5d-fd03b2945654" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_bad615aa-a64c-41f1-9a41-93766e9ce0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_bdcc6c6a-dce5-4a81-839a-27e47b2343f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae3b2d9f-0206-4c4d-9d5d-fd03b2945654" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_bdcc6c6a-dce5-4a81-839a-27e47b2343f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3482511b-294e-4461-8a31-08ee5c1c5541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae3b2d9f-0206-4c4d-9d5d-fd03b2945654" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3482511b-294e-4461-8a31-08ee5c1c5541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ffb796de-7f9a-4f6b-8a2f-c5b967a5f28a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae3b2d9f-0206-4c4d-9d5d-fd03b2945654" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ffb796de-7f9a-4f6b-8a2f-c5b967a5f28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_bd96d4b6-864f-4168-b778-f55dfbed9371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae3b2d9f-0206-4c4d-9d5d-fd03b2945654" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_bd96d4b6-864f-4168-b778-f55dfbed9371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_28b24aae-50c9-405d-8c9f-2d27f34cc5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae3b2d9f-0206-4c4d-9d5d-fd03b2945654" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_28b24aae-50c9-405d-8c9f-2d27f34cc5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5676401c-ea4b-49e0-a090-1408fa5a519e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae3b2d9f-0206-4c4d-9d5d-fd03b2945654" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5676401c-ea4b-49e0-a090-1408fa5a519e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_849f58cb-c793-4ad7-9297-1df20c987c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae3b2d9f-0206-4c4d-9d5d-fd03b2945654" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_849f58cb-c793-4ad7-9297-1df20c987c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizationOfInternalCostsPolicy_44660521-7d97-49d0-8733-d1ea647f52ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizationOfInternalCostsPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae3b2d9f-0206-4c4d-9d5d-fd03b2945654" xlink:to="loc_us-gaap_CapitalizationOfInternalCostsPolicy_44660521-7d97-49d0-8733-d1ea647f52ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_314605f7-bbe1-4305-8cce-d45c09beabf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae3b2d9f-0206-4c4d-9d5d-fd03b2945654" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_314605f7-bbe1-4305-8cce-d45c09beabf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_d572ca0b-4a06-40b9-958b-b917dd88b2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae3b2d9f-0206-4c4d-9d5d-fd03b2945654" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_d572ca0b-4a06-40b9-958b-b917dd88b2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_f0c49a8d-4f9e-4b52-9791-cb0085244589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae3b2d9f-0206-4c4d-9d5d-fd03b2945654" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_f0c49a8d-4f9e-4b52-9791-cb0085244589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_836a56b9-3eb2-4f7b-abd6-16bf79bf615b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae3b2d9f-0206-4c4d-9d5d-fd03b2945654" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_836a56b9-3eb2-4f7b-abd6-16bf79bf615b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_38e0128f-e47a-4ad5-8cb0-3339223617a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae3b2d9f-0206-4c4d-9d5d-fd03b2945654" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_38e0128f-e47a-4ad5-8cb0-3339223617a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_3a41ebc1-5f74-4aa2-9fd8-810c4a3e8e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae3b2d9f-0206-4c4d-9d5d-fd03b2945654" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_3a41ebc1-5f74-4aa2-9fd8-810c4a3e8e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_17a20954-893f-4645-ada5-629bb4bc5963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae3b2d9f-0206-4c4d-9d5d-fd03b2945654" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_17a20954-893f-4645-ada5-629bb4bc5963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="fhtx-20211231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_90bd89e5-93ed-4fbc-a3d3-2b08e96b8917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_49495e9d-ae65-4e87-afa2-3f3e3a7ff325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_90bd89e5-93ed-4fbc-a3d3-2b08e96b8917" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_49495e9d-ae65-4e87-afa2-3f3e3a7ff325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2c9679f5-046a-48c5-aa86-a0870b8094b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_90bd89e5-93ed-4fbc-a3d3-2b08e96b8917" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2c9679f5-046a-48c5-aa86-a0870b8094b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_21f269dd-b301-46ef-86c4-fa13e690ad5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cb8c0289-a6ab-4d2f-92a9-e055416a1483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_21f269dd-b301-46ef-86c4-fa13e690ad5b" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cb8c0289-a6ab-4d2f-92a9-e055416a1483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8681ace6-c79c-4dba-8eb7-f1a8b43d050f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cb8c0289-a6ab-4d2f-92a9-e055416a1483" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8681ace6-c79c-4dba-8eb7-f1a8b43d050f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11d949f5-15d1-4331-b14d-6bb620427e09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8681ace6-c79c-4dba-8eb7-f1a8b43d050f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11d949f5-15d1-4331-b14d-6bb620427e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_6bd2874f-592a-42e7-b6fb-f95c78abd51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11d949f5-15d1-4331-b14d-6bb620427e09" xlink:to="loc_us-gaap_IPOMember_6bd2874f-592a-42e7-b6fb-f95c78abd51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_fca7b502-3c37-45cd-be0f-166ff2377d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cb8c0289-a6ab-4d2f-92a9-e055416a1483" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_fca7b502-3c37-45cd-be0f-166ff2377d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_NumberOfCollaborativeAgreements_6fdfb53c-01c6-4cf2-984d-7d1c51a6ad22" xlink:href="fhtx-20211231.xsd#fhtx_NumberOfCollaborativeAgreements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fca7b502-3c37-45cd-be0f-166ff2377d98" xlink:to="loc_fhtx_NumberOfCollaborativeAgreements_6fdfb53c-01c6-4cf2-984d-7d1c51a6ad22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_0bb25872-9e5d-4d9a-ba45-22487f68f9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_fca7b502-3c37-45cd-be0f-166ff2377d98" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_0bb25872-9e5d-4d9a-ba45-22487f68f9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAmortizationDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#SummaryofSignificantAccountingPoliciesSummaryofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAmortizationDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7f9f2f16-289b-46d5-be66-612803f733fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0153276a-fe53-4702-b410-fc76465d448c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f9f2f16-289b-46d5-be66-612803f733fa" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0153276a-fe53-4702-b410-fc76465d448c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce3338c6-d26c-4171-a269-d6a36a81d882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0153276a-fe53-4702-b410-fc76465d448c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce3338c6-d26c-4171-a269-d6a36a81d882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96d17fb9-0b36-44c1-8abd-d9c64a267a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ce3338c6-d26c-4171-a269-d6a36a81d882" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96d17fb9-0b36-44c1-8abd-d9c64a267a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_87e5be24-b4ff-496e-99af-07d49de56dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96d17fb9-0b36-44c1-8abd-d9c64a267a63" xlink:to="loc_us-gaap_EquipmentMember_87e5be24-b4ff-496e-99af-07d49de56dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_9a581a97-bdd3-40dc-a21a-96018a20b420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96d17fb9-0b36-44c1-8abd-d9c64a267a63" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_9a581a97-bdd3-40dc-a21a-96018a20b420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_ddb0f8bb-e16a-49ea-980a-e848db7a7884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_96d17fb9-0b36-44c1-8abd-d9c64a267a63" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_ddb0f8bb-e16a-49ea-980a-e848db7a7884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61336ca5-695b-4f6a-83cc-5c16f96eaad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0153276a-fe53-4702-b410-fc76465d448c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61336ca5-695b-4f6a-83cc-5c16f96eaad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6ad245b9-155b-4b5b-9e1c-b2602953c38a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61336ca5-695b-4f6a-83cc-5c16f96eaad3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6ad245b9-155b-4b5b-9e1c-b2602953c38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofEarningsPerShareDilutedAntiDilutiveImpactDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#SummaryofSignificantAccountingPoliciesSummaryofEarningsPerShareDilutedAntiDilutiveImpactDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofEarningsPerShareDilutedAntiDilutiveImpactDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_62014615-f8c6-4e0f-aeba-cd4ca22e0b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4674e55b-af91-491d-869f-980da471b288" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62014615-f8c6-4e0f-aeba-cd4ca22e0b14" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4674e55b-af91-491d-869f-980da471b288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_57c9e50a-12a3-445a-9f00-df0180506fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4674e55b-af91-491d-869f-980da471b288" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_57c9e50a-12a3-445a-9f00-df0180506fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6b7317ba-aef3-40b0-8dc6-e5330e478d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_57c9e50a-12a3-445a-9f00-df0180506fa5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6b7317ba-aef3-40b0-8dc6-e5330e478d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d309fcbd-d327-471a-b1e0-80df2efeeb02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6b7317ba-aef3-40b0-8dc6-e5330e478d96" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d309fcbd-d327-471a-b1e0-80df2efeeb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_125cb60b-a89f-4a3c-a090-863755466d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6b7317ba-aef3-40b0-8dc6-e5330e478d96" xlink:to="loc_us-gaap_WarrantMember_125cb60b-a89f-4a3c-a090-863755466d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5148b785-0bb4-4daf-8163-54232ae6f13f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4674e55b-af91-491d-869f-980da471b288" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5148b785-0bb4-4daf-8163-54232ae6f13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_353e3c80-acbc-456d-a6d6-c093220f8040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5148b785-0bb4-4daf-8163-54232ae6f13f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_353e3c80-acbc-456d-a6d6-c093220f8040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurements" xlink:type="simple" xlink:href="fhtx-20211231.xsd#MarketableSecuritiesandFairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_867ec5bc-174a-49a9-bfea-19ae1be4958a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_MarketableSecuritiesAndFairValueMeasurementsTextBlock_dc378c22-d97d-48fd-8819-a5703bd710ec" xlink:href="fhtx-20211231.xsd#fhtx_MarketableSecuritiesAndFairValueMeasurementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_867ec5bc-174a-49a9-bfea-19ae1be4958a" xlink:to="loc_fhtx_MarketableSecuritiesAndFairValueMeasurementsTextBlock_dc378c22-d97d-48fd-8819-a5703bd710ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsTables" xlink:type="simple" xlink:href="fhtx-20211231.xsd#MarketableSecuritiesandFairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c68b30e5-bdf9-4f0a-b402-cb42a446aebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_a54a637d-c1e2-4968-86f0-546d99fe37a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c68b30e5-bdf9-4f0a-b402-cb42a446aebf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_a54a637d-c1e2-4968-86f0-546d99fe37a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_9526e163-da3a-48b9-8bdf-b242c05c10d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c68b30e5-bdf9-4f0a-b402-cb42a446aebf" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_9526e163-da3a-48b9-8bdf-b242c05c10d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5dd5726e-a3a7-4882-ba71-b5cd73d39d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_05ed5563-f8a9-4f40-bb93-aee7adf50197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5dd5726e-a3a7-4882-ba71-b5cd73d39d4d" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_05ed5563-f8a9-4f40-bb93-aee7adf50197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_01dc3691-1414-442a-9545-4772597ad52d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_05ed5563-f8a9-4f40-bb93-aee7adf50197" xlink:to="loc_us-gaap_InvestmentTypeAxis_01dc3691-1414-442a-9545-4772597ad52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_117daee2-6ab0-4b8c-9225-084500c0191f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_01dc3691-1414-442a-9545-4772597ad52d" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_117daee2-6ab0-4b8c-9225-084500c0191f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_50fd9933-81f9-4967-8943-96698e078e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_117daee2-6ab0-4b8c-9225-084500c0191f" xlink:to="loc_us-gaap_CommercialPaperMember_50fd9933-81f9-4967-8943-96698e078e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7ff6b51f-9bf8-4a33-8e59-8c3471e5a891" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_117daee2-6ab0-4b8c-9225-084500c0191f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7ff6b51f-9bf8-4a33-8e59-8c3471e5a891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_f087ff16-d225-4fd9-bfe1-0af5f6fe7588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_117daee2-6ab0-4b8c-9225-084500c0191f" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_f087ff16-d225-4fd9-bfe1-0af5f6fe7588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f4aea0ff-551d-476c-9817-ac5d99b18662" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_05ed5563-f8a9-4f40-bb93-aee7adf50197" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f4aea0ff-551d-476c-9817-ac5d99b18662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cb292cc5-8ec3-40e0-af7d-10b040760e68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f4aea0ff-551d-476c-9817-ac5d99b18662" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cb292cc5-8ec3-40e0-af7d-10b040760e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fbabbd4a-f6dd-4162-a105-1fbe355231ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f4aea0ff-551d-476c-9817-ac5d99b18662" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fbabbd4a-f6dd-4162-a105-1fbe355231ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4802495b-9504-4889-9bf1-4a9d600c8f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f4aea0ff-551d-476c-9817-ac5d99b18662" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4802495b-9504-4889-9bf1-4a9d600c8f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7280bb7e-6fc4-4f28-ba2d-97021a6efe87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f4aea0ff-551d-476c-9817-ac5d99b18662" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7280bb7e-6fc4-4f28-ba2d-97021a6efe87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_adf08381-0f56-4dd1-8a49-781266be9ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1ee4f02a-7e86-4c1e-a653-faec66aaf7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_adf08381-0f56-4dd1-8a49-781266be9ae8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1ee4f02a-7e86-4c1e-a653-faec66aaf7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2c42b832-8db7-4a84-a1e8-3b486801071a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1ee4f02a-7e86-4c1e-a653-faec66aaf7fd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2c42b832-8db7-4a84-a1e8-3b486801071a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d14bbff6-ef99-4e7a-b3e6-58f1dada9c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2c42b832-8db7-4a84-a1e8-3b486801071a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d14bbff6-ef99-4e7a-b3e6-58f1dada9c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8400db33-cc8b-4537-8831-e9db57a4f8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d14bbff6-ef99-4e7a-b3e6-58f1dada9c9e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8400db33-cc8b-4537-8831-e9db57a4f8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fc985286-61ce-4cb1-ab23-7739f65a7f77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1ee4f02a-7e86-4c1e-a653-faec66aaf7fd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fc985286-61ce-4cb1-ab23-7739f65a7f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef337687-09f2-4cf3-a4f8-aef92a37d2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fc985286-61ce-4cb1-ab23-7739f65a7f77" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef337687-09f2-4cf3-a4f8-aef92a37d2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6b7c1a13-9bf4-4730-a124-18879af57bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef337687-09f2-4cf3-a4f8-aef92a37d2a9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6b7c1a13-9bf4-4730-a124-18879af57bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_cd60469a-47c7-4ac9-a75c-ba279811b935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef337687-09f2-4cf3-a4f8-aef92a37d2a9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_cd60469a-47c7-4ac9-a75c-ba279811b935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_22bd034d-ccf1-45c4-89ae-5b224ca1c68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef337687-09f2-4cf3-a4f8-aef92a37d2a9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_22bd034d-ccf1-45c4-89ae-5b224ca1c68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_dc4746b1-4e67-40d7-86ca-80832de583d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1ee4f02a-7e86-4c1e-a653-faec66aaf7fd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_dc4746b1-4e67-40d7-86ca-80832de583d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_83ec3226-6742-4646-b827-ff0b28a04f03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_dc4746b1-4e67-40d7-86ca-80832de583d1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_83ec3226-6742-4646-b827-ff0b28a04f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_a26a640e-82c7-44d8-831a-d2874ee15d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_83ec3226-6742-4646-b827-ff0b28a04f03" xlink:to="loc_us-gaap_MoneyMarketFundsMember_a26a640e-82c7-44d8-831a-d2874ee15d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_ff200c15-f65d-48b6-8b79-a21e3bcfa3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_83ec3226-6742-4646-b827-ff0b28a04f03" xlink:to="loc_us-gaap_CommercialPaperMember_ff200c15-f65d-48b6-8b79-a21e3bcfa3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_93b77ae7-9f75-4586-b809-6fb7ab80c557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_83ec3226-6742-4646-b827-ff0b28a04f03" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_93b77ae7-9f75-4586-b809-6fb7ab80c557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1863b976-6acc-4f94-a4c5-01c6fd700246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1ee4f02a-7e86-4c1e-a653-faec66aaf7fd" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1863b976-6acc-4f94-a4c5-01c6fd700246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_822780a2-7045-4e3f-ac06-9c4daf0ff968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1863b976-6acc-4f94-a4c5-01c6fd700246" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_822780a2-7045-4e3f-ac06-9c4daf0ff968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_d688212c-3098-424f-a6cd-124462c29c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_822780a2-7045-4e3f-ac06-9c4daf0ff968" xlink:to="loc_us-gaap_CommercialPaperMember_d688212c-3098-424f-a6cd-124462c29c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_372ff078-54e9-4eb9-851c-e73735073362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_822780a2-7045-4e3f-ac06-9c4daf0ff968" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_372ff078-54e9-4eb9-851c-e73735073362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a19ea075-ecb4-460f-8938-1cdd0cb34ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_822780a2-7045-4e3f-ac06-9c4daf0ff968" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a19ea075-ecb4-460f-8938-1cdd0cb34ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e44fdf6-ce9d-4680-b904-4539236d00b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1ee4f02a-7e86-4c1e-a653-faec66aaf7fd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e44fdf6-ce9d-4680-b904-4539236d00b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a434efc0-c255-423d-8049-a06ed631338d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e44fdf6-ce9d-4680-b904-4539236d00b6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a434efc0-c255-423d-8049-a06ed631338d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b51a387e-dae5-47ec-8fe4-770ee5e11450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e44fdf6-ce9d-4680-b904-4539236d00b6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b51a387e-dae5-47ec-8fe4-770ee5e11450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2a9c9c3c-cc33-442f-b970-ebc10343fe79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e44fdf6-ce9d-4680-b904-4539236d00b6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2a9c9c3c-cc33-442f-b970-ebc10343fe79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="fhtx-20211231.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e306ab6b-be5c-46ec-bfc7-b5ef7294730b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_c47a43dc-0ed7-4b2a-86d8-3deabe881cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e306ab6b-be5c-46ec-bfc7-b5ef7294730b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_c47a43dc-0ed7-4b2a-86d8-3deabe881cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="fhtx-20211231.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0c2b2c38-7ef7-4a5a-8c6e-1a64b4a4f8d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_994203a0-6f96-468a-b0da-dea1a27e08ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0c2b2c38-7ef7-4a5a-8c6e-1a64b4a4f8d8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_994203a0-6f96-468a-b0da-dea1a27e08ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_905f265b-54a5-46e7-9a23-a26fd172cff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a6bc0e32-d551-4f52-88c4-610cdd17c313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_905f265b-54a5-46e7-9a23-a26fd172cff1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a6bc0e32-d551-4f52-88c4-610cdd17c313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e0f8a998-80c1-4236-a023-52137cb7b0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a6bc0e32-d551-4f52-88c4-610cdd17c313" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e0f8a998-80c1-4236-a023-52137cb7b0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9acbd34e-ae51-4b58-9e73-2e50e17830bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e0f8a998-80c1-4236-a023-52137cb7b0f9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9acbd34e-ae51-4b58-9e73-2e50e17830bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_3e902381-fc74-4e3c-9849-ff048c62c23a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9acbd34e-ae51-4b58-9e73-2e50e17830bb" xlink:to="loc_us-gaap_EquipmentMember_3e902381-fc74-4e3c-9849-ff048c62c23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_8897ae36-aed4-468b-b998-d4f01905db39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9acbd34e-ae51-4b58-9e73-2e50e17830bb" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_8897ae36-aed4-468b-b998-d4f01905db39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_296411dd-ab01-4caf-a438-f0063a4f8149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9acbd34e-ae51-4b58-9e73-2e50e17830bb" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_296411dd-ab01-4caf-a438-f0063a4f8149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_b748d01f-7569-469a-9215-9193dca941d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9acbd34e-ae51-4b58-9e73-2e50e17830bb" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_b748d01f-7569-469a-9215-9193dca941d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_AssetsNotYetPlacedInServiceMember_43e06345-6b42-425b-8a79-920d00fa93f0" xlink:href="fhtx-20211231.xsd#fhtx_AssetsNotYetPlacedInServiceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9acbd34e-ae51-4b58-9e73-2e50e17830bb" xlink:to="loc_fhtx_AssetsNotYetPlacedInServiceMember_43e06345-6b42-425b-8a79-920d00fa93f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0d9b512-23dc-4549-a8b3-b6590a21c006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a6bc0e32-d551-4f52-88c4-610cdd17c313" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0d9b512-23dc-4549-a8b3-b6590a21c006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_380d8306-1e71-495b-b46c-de7eaa40e410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0d9b512-23dc-4549-a8b3-b6590a21c006" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_380d8306-1e71-495b-b46c-de7eaa40e410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_1e355565-7d6c-45df-b0c4-e8ae5dfe3c39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0d9b512-23dc-4549-a8b3-b6590a21c006" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_1e355565-7d6c-45df-b0c4-e8ae5dfe3c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_247ce767-7781-47aa-bb95-9f59525e6c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d0d9b512-23dc-4549-a8b3-b6590a21c006" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_247ce767-7781-47aa-bb95-9f59525e6c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/PropertyandEquipmentNetAdditionalInformationDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#PropertyandEquipmentNetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/PropertyandEquipmentNetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e7ed7427-81a7-4d9f-b5cb-231668645ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ca5bbaa3-213e-4a92-a7af-8e7950fdb1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e7ed7427-81a7-4d9f-b5cb-231668645ecf" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ca5bbaa3-213e-4a92-a7af-8e7950fdb1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/AccruedExpenses" xlink:type="simple" xlink:href="fhtx-20211231.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_efa1a68e-c94c-4215-a0ce-a31b157b3d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_742a92fe-08d5-4a55-9939-62dae0ef9622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_efa1a68e-c94c-4215-a0ce-a31b157b3d3a" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_742a92fe-08d5-4a55-9939-62dae0ef9622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/AccruedExpensesTable" xlink:type="simple" xlink:href="fhtx-20211231.xsd#AccruedExpensesTable"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/AccruedExpensesTable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_aed2242f-7df4-44e8-b644-8123d8a1820b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d66d3714-aa50-4250-aa68-96844f769ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_aed2242f-7df4-44e8-b644-8123d8a1820b" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d66d3714-aa50-4250-aa68-96844f769ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_dccdf11e-f763-47d6-aeaa-f2d2bb7b6d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9c9739e3-5405-4d49-a510-0fa6a7ef5d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dccdf11e-f763-47d6-aeaa-f2d2bb7b6d0c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9c9739e3-5405-4d49-a510-0fa6a7ef5d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_AccruedTenantImprovements_e7ac1263-533d-4ced-a68b-5cc5bc75bbef" xlink:href="fhtx-20211231.xsd#fhtx_AccruedTenantImprovements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dccdf11e-f763-47d6-aeaa-f2d2bb7b6d0c" xlink:to="loc_fhtx_AccruedTenantImprovements_e7ac1263-533d-4ced-a68b-5cc5bc75bbef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_AccruedResearchAndDevelopmentExpenses_5bf04b96-2d6e-44f7-96b6-23572c18dfaf" xlink:href="fhtx-20211231.xsd#fhtx_AccruedResearchAndDevelopmentExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dccdf11e-f763-47d6-aeaa-f2d2bb7b6d0c" xlink:to="loc_fhtx_AccruedResearchAndDevelopmentExpenses_5bf04b96-2d6e-44f7-96b6-23572c18dfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_e023a2ad-c8a3-4ade-867c-8a56604e2e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dccdf11e-f763-47d6-aeaa-f2d2bb7b6d0c" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_e023a2ad-c8a3-4ade-867c-8a56604e2e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_cc2f5e13-4c00-45f0-a466-d7f91ffa84fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dccdf11e-f763-47d6-aeaa-f2d2bb7b6d0c" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_cc2f5e13-4c00-45f0-a466-d7f91ffa84fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_96b10137-6dcb-4c86-8c2d-16904185b6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dccdf11e-f763-47d6-aeaa-f2d2bb7b6d0c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_96b10137-6dcb-4c86-8c2d-16904185b6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/NotesPayable" xlink:type="simple" xlink:href="fhtx-20211231.xsd#NotesPayable"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/NotesPayable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e53403cd-3e6f-4611-98b8-2f5d37fa549e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_a3097ad7-62b3-477e-9ad7-b3f56396b6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e53403cd-3e6f-4611-98b8-2f5d37fa549e" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_a3097ad7-62b3-477e-9ad7-b3f56396b6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/NotesPayableTables" xlink:type="simple" xlink:href="fhtx-20211231.xsd#NotesPayableTables"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/NotesPayableTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_26814659-3100-4705-8fe7-ea72e11e7163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_f1887066-bf1b-4e32-8292-0b316eff3a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_26814659-3100-4705-8fe7-ea72e11e7163" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_f1887066-bf1b-4e32-8292-0b316eff3a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#NotesPayableSummaryofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2c746727-3cd2-49d4-99e8-a633bf8464e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_efef7be0-f378-485d-9a66-6877e773459d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2c746727-3cd2-49d4-99e8-a633bf8464e9" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_efef7be0-f378-485d-9a66-6877e773459d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_77245c68-d550-4146-835b-f2eea28c3943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_efef7be0-f378-485d-9a66-6877e773459d" xlink:to="loc_us-gaap_DebtInstrumentAxis_77245c68-d550-4146-835b-f2eea28c3943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4302dac6-0d14-4488-8adf-fc7b54b05eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_77245c68-d550-4146-835b-f2eea28c3943" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4302dac6-0d14-4488-8adf-fc7b54b05eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_TermLoanAMember_8f558bd7-3dd2-49ca-b7e6-36c437c4ab8e" xlink:href="fhtx-20211231.xsd#fhtx_TermLoanAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4302dac6-0d14-4488-8adf-fc7b54b05eda" xlink:to="loc_fhtx_TermLoanAMember_8f558bd7-3dd2-49ca-b7e6-36c437c4ab8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_2f5c933b-0e4d-45e6-8c78-0dee740a2d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_efef7be0-f378-485d-9a66-6877e773459d" xlink:to="loc_us-gaap_ShortTermDebtLineItems_2f5c933b-0e4d-45e6-8c78-0dee740a2d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_61ea313d-846d-462f-9812-76ff3b17931d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2f5c933b-0e4d-45e6-8c78-0dee740a2d40" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_61ea313d-846d-462f-9812-76ff3b17931d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_a4e74b47-13bf-449b-adb8-45007c83918d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2f5c933b-0e4d-45e6-8c78-0dee740a2d40" xlink:to="loc_us-gaap_LongTermDebtCurrent_a4e74b47-13bf-449b-adb8-45007c83918d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_01aa0d4a-8983-4476-8d84-418b75a03a44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2f5c933b-0e4d-45e6-8c78-0dee740a2d40" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_01aa0d4a-8983-4476-8d84-418b75a03a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_944ea2f4-4a64-42ee-b9f9-bdc099040db2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2f5c933b-0e4d-45e6-8c78-0dee740a2d40" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_944ea2f4-4a64-42ee-b9f9-bdc099040db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7def766d-a51c-49b4-868a-a0ed66c128cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2f5c933b-0e4d-45e6-8c78-0dee740a2d40" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7def766d-a51c-49b4-868a-a0ed66c128cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2bafcbc4-45cb-48ec-acda-111003f8e45d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2f5c933b-0e4d-45e6-8c78-0dee740a2d40" xlink:to="loc_us-gaap_LongTermDebt_2bafcbc4-45cb-48ec-acda-111003f8e45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#NotesPayableAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_457f30bd-a448-4980-bec0-4a344e615f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_10df504a-bf30-425c-a012-4cb38f417e62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_457f30bd-a448-4980-bec0-4a344e615f3f" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_10df504a-bf30-425c-a012-4cb38f417e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_94b800fe-b264-4f8c-a98b-f2b04bd33ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_10df504a-bf30-425c-a012-4cb38f417e62" xlink:to="loc_us-gaap_DebtInstrumentAxis_94b800fe-b264-4f8c-a98b-f2b04bd33ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4bb729f9-8b4b-4b4b-957e-4450e1ec7238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_94b800fe-b264-4f8c-a98b-f2b04bd33ca9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4bb729f9-8b4b-4b4b-957e-4450e1ec7238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_TermLoanAMember_f4c74ded-9a41-40e3-b3ba-65acec487e98" xlink:href="fhtx-20211231.xsd#fhtx_TermLoanAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4bb729f9-8b4b-4b4b-957e-4450e1ec7238" xlink:to="loc_fhtx_TermLoanAMember_f4c74ded-9a41-40e3-b3ba-65acec487e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_TermLoanBMember_00e43593-d861-4187-8f81-7e0466c8e776" xlink:href="fhtx-20211231.xsd#fhtx_TermLoanBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4bb729f9-8b4b-4b4b-957e-4450e1ec7238" xlink:to="loc_fhtx_TermLoanBMember_00e43593-d861-4187-8f81-7e0466c8e776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b0d58d50-0a28-4034-a345-9896da744fdc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_10df504a-bf30-425c-a012-4cb38f417e62" xlink:to="loc_srt_RangeAxis_b0d58d50-0a28-4034-a345-9896da744fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b622d797-912a-4cd7-9a52-a66a83232e99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b0d58d50-0a28-4034-a345-9896da744fdc" xlink:to="loc_srt_RangeMember_b622d797-912a-4cd7-9a52-a66a83232e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b4dd0843-d0fd-4d58-90ff-299978c8c55d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b622d797-912a-4cd7-9a52-a66a83232e99" xlink:to="loc_srt_MaximumMember_b4dd0843-d0fd-4d58-90ff-299978c8c55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_258e5588-773a-44ad-bc33-b799af066250" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b622d797-912a-4cd7-9a52-a66a83232e99" xlink:to="loc_srt_MinimumMember_258e5588-773a-44ad-bc33-b799af066250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_PrepaymentPeriodAxis_e4c61b14-419d-467e-98ca-a026fa44ed4f" xlink:href="fhtx-20211231.xsd#fhtx_PrepaymentPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_10df504a-bf30-425c-a012-4cb38f417e62" xlink:to="loc_fhtx_PrepaymentPeriodAxis_e4c61b14-419d-467e-98ca-a026fa44ed4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_PrepaymentPeriodDomain_7a401516-389f-4212-b5d5-8c48b2aeb8bb" xlink:href="fhtx-20211231.xsd#fhtx_PrepaymentPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fhtx_PrepaymentPeriodAxis_e4c61b14-419d-467e-98ca-a026fa44ed4f" xlink:to="loc_fhtx_PrepaymentPeriodDomain_7a401516-389f-4212-b5d5-8c48b2aeb8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_PrepaymentPeriodOneMember_2e3f99df-1dbb-47e1-9437-a2b6db488e81" xlink:href="fhtx-20211231.xsd#fhtx_PrepaymentPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fhtx_PrepaymentPeriodDomain_7a401516-389f-4212-b5d5-8c48b2aeb8bb" xlink:to="loc_fhtx_PrepaymentPeriodOneMember_2e3f99df-1dbb-47e1-9437-a2b6db488e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_PrepaymentPeriodTwoMember_7f463ac5-305e-4163-bcf9-d81422799f90" xlink:href="fhtx-20211231.xsd#fhtx_PrepaymentPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fhtx_PrepaymentPeriodDomain_7a401516-389f-4212-b5d5-8c48b2aeb8bb" xlink:to="loc_fhtx_PrepaymentPeriodTwoMember_7f463ac5-305e-4163-bcf9-d81422799f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_PrepaymentPeriodThreeMember_59297058-2ff1-43f7-a59f-3173236e7006" xlink:href="fhtx-20211231.xsd#fhtx_PrepaymentPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fhtx_PrepaymentPeriodDomain_7a401516-389f-4212-b5d5-8c48b2aeb8bb" xlink:to="loc_fhtx_PrepaymentPeriodThreeMember_59297058-2ff1-43f7-a59f-3173236e7006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_10df504a-bf30-425c-a012-4cb38f417e62" xlink:to="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_b6c7ac62-b0d4-424a-b3f7-84d80722f81b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_b6c7ac62-b0d4-424a-b3f7-84d80722f81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_LineOfCreditAdditionalBorrowingCapacity_76bdf8d9-c830-4b5b-a66e-2aceb8b5cb2e" xlink:href="fhtx-20211231.xsd#fhtx_LineOfCreditAdditionalBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_fhtx_LineOfCreditAdditionalBorrowingCapacity_76bdf8d9-c830-4b5b-a66e-2aceb8b5cb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0643d7e2-c636-4436-aab3-b865d2c4105a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_0643d7e2-c636-4436-aab3-b865d2c4105a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8b18b4cc-4033-4b1b-a1a4-6bca4f420e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_8b18b4cc-4033-4b1b-a1a4-6bca4f420e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage_2fec9c4d-8f8a-402d-875f-a3e0d29f1fdc" xlink:href="fhtx-20211231.xsd#fhtx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_fhtx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage_2fec9c4d-8f8a-402d-875f-a3e0d29f1fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_PercentageOfPrepaymentFee_f7221523-e7f0-469a-ad88-5bf1496486d7" xlink:href="fhtx-20211231.xsd#fhtx_PercentageOfPrepaymentFee"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_fhtx_PercentageOfPrepaymentFee_f7221523-e7f0-469a-ad88-5bf1496486d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_PrepaymentPeriod_5868c742-cfba-48f3-935a-42d5b066a65b" xlink:href="fhtx-20211231.xsd#fhtx_PrepaymentPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_fhtx_PrepaymentPeriod_5868c742-cfba-48f3-935a-42d5b066a65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a0c1bb1b-45bf-4659-93d1-f6270115aced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a0c1bb1b-45bf-4659-93d1-f6270115aced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_WarrantsIssuePricePerShare_dc1369cb-2bbd-47a8-ba68-c57dbf15207a" xlink:href="fhtx-20211231.xsd#fhtx_WarrantsIssuePricePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_fhtx_WarrantsIssuePricePerShare_dc1369cb-2bbd-47a8-ba68-c57dbf15207a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_41e1afe7-ac42-4e93-8646-b38a319fe86f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_41e1afe7-ac42-4e93-8646-b38a319fe86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_df830a0b-c6ae-41b8-b87e-080e5fde2976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_df830a0b-c6ae-41b8-b87e-080e5fde2976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_5a9d4ab9-8dd8-4a55-81ad-66a1de3a3e78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_us-gaap_DebtInstrumentTerm_5a9d4ab9-8dd8-4a55-81ad-66a1de3a3e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_34c1b9f8-8d21-4993-be9f-9c42a2baeef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_34c1b9f8-8d21-4993-be9f-9c42a2baeef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_008ef988-83fe-4182-bdb8-98f7dda3f731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_008ef988-83fe-4182-bdb8-98f7dda3f731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_7165c0db-80e5-42a6-ba80-a9347d53c376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_40d9b38c-7b19-4a1e-afb9-42735487b1c3" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_7165c0db-80e5-42a6-ba80-a9347d53c376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/CommonStock" xlink:type="simple" xlink:href="fhtx-20211231.xsd#CommonStock"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8f50902a-9402-4875-bc17-eb9393129f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_CommonStockTextBlock_6bc9bf96-ee1e-4e9b-a1be-c1b7d30954fe" xlink:href="fhtx-20211231.xsd#fhtx_CommonStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8f50902a-9402-4875-bc17-eb9393129f0e" xlink:to="loc_fhtx_CommonStockTextBlock_6bc9bf96-ee1e-4e9b-a1be-c1b7d30954fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/CommonStockDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#CommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/CommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6c923635-58be-457a-9f27-3f3868e77ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c13b6b14-50cd-4158-b758-b2c259922854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6c923635-58be-457a-9f27-3f3868e77ebe" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c13b6b14-50cd-4158-b758-b2c259922854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_22ab1e91-31f7-4d8e-8f7c-1ee838123b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c13b6b14-50cd-4158-b758-b2c259922854" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_22ab1e91-31f7-4d8e-8f7c-1ee838123b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388d1cda-fd0d-49b2-91c7-4912779ee6d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_22ab1e91-31f7-4d8e-8f7c-1ee838123b8e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388d1cda-fd0d-49b2-91c7-4912779ee6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_2640a1f9-a0bc-46bc-8ef0-68daf14bc74b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388d1cda-fd0d-49b2-91c7-4912779ee6d9" xlink:to="loc_us-gaap_IPOMember_2640a1f9-a0bc-46bc-8ef0-68daf14bc74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_c6de6de3-5d88-4192-84d6-a3bc4bd18e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388d1cda-fd0d-49b2-91c7-4912779ee6d9" xlink:to="loc_us-gaap_OverAllotmentOptionMember_c6de6de3-5d88-4192-84d6-a3bc4bd18e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_SharePurchaseAgreementMember_0b0e7382-6692-4e76-b20d-6ad1e193cb8c" xlink:href="fhtx-20211231.xsd#fhtx_SharePurchaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_388d1cda-fd0d-49b2-91c7-4912779ee6d9" xlink:to="loc_fhtx_SharePurchaseAgreementMember_0b0e7382-6692-4e76-b20d-6ad1e193cb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d8a909cf-d52b-42ff-93bf-84d9f9a8055f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c13b6b14-50cd-4158-b758-b2c259922854" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d8a909cf-d52b-42ff-93bf-84d9f9a8055f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0f04cda9-8d44-47fc-ad99-187f6bc0d2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d8a909cf-d52b-42ff-93bf-84d9f9a8055f" xlink:to="loc_us-gaap_ClassOfStockDomain_0f04cda9-8d44-47fc-ad99-187f6bc0d2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_747f65c9-ed3f-4179-aa05-2e53f4bb4fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0f04cda9-8d44-47fc-ad99-187f6bc0d2cf" xlink:to="loc_us-gaap_CommonStockMember_747f65c9-ed3f-4179-aa05-2e53f4bb4fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d425bdf1-6356-4f44-8e24-15335ef074c6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c13b6b14-50cd-4158-b758-b2c259922854" xlink:to="loc_srt_CounterpartyNameAxis_d425bdf1-6356-4f44-8e24-15335ef074c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76dce9a5-1896-4498-868e-09720da584a5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d425bdf1-6356-4f44-8e24-15335ef074c6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76dce9a5-1896-4498-868e-09720da584a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_EliLillyMember_980c3d38-e569-4d2d-aed5-73a7765677cd" xlink:href="fhtx-20211231.xsd#fhtx_EliLillyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76dce9a5-1896-4498-868e-09720da584a5" xlink:to="loc_fhtx_EliLillyMember_980c3d38-e569-4d2d-aed5-73a7765677cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e3b85f1e-1695-4676-b0a1-23eb63e3effc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c13b6b14-50cd-4158-b758-b2c259922854" xlink:to="loc_us-gaap_ClassOfStockLineItems_e3b85f1e-1695-4676-b0a1-23eb63e3effc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0ce77d70-3fd2-456f-8c48-49ed919afca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e3b85f1e-1695-4676-b0a1-23eb63e3effc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0ce77d70-3fd2-456f-8c48-49ed919afca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_0f3848f7-46d3-4a75-963a-6b9c8a13e419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e3b85f1e-1695-4676-b0a1-23eb63e3effc" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_0f3848f7-46d3-4a75-963a-6b9c8a13e419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3aacad8f-0f6e-4993-9d62-bf9bcbba38fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e3b85f1e-1695-4676-b0a1-23eb63e3effc" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3aacad8f-0f6e-4993-9d62-bf9bcbba38fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_59b1bde4-9acf-4733-837a-69d02591404f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e3b85f1e-1695-4676-b0a1-23eb63e3effc" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_59b1bde4-9acf-4733-837a-69d02591404f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="fhtx-20211231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cebd3157-920b-4f27-ba4f-d6b706500ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ca62a5d3-5a37-4109-aefc-47feaed5b0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cebd3157-920b-4f27-ba4f-d6b706500ecc" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ca62a5d3-5a37-4109-aefc-47feaed5b0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="fhtx-20211231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_08953916-c4e6-4bc2-8efb-3bb63055758e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c442a8cc-ba7f-47f3-ac93-2ac5dfd4f495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_08953916-c4e6-4bc2-8efb-3bb63055758e" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c442a8cc-ba7f-47f3-ac93-2ac5dfd4f495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d9231362-db0e-4b52-8088-3e1f242c2269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_08953916-c4e6-4bc2-8efb-3bb63055758e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d9231362-db0e-4b52-8088-3e1f242c2269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a9231865-0181-4e4c-9431-c0ba8371d79c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_08953916-c4e6-4bc2-8efb-3bb63055758e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a9231865-0181-4e4c-9431-c0ba8371d79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_630da4d4-97ad-4b42-8dbd-2c0d688ce42e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0079720-3f9e-44b6-833b-ec54a10fb31c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_630da4d4-97ad-4b42-8dbd-2c0d688ce42e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0079720-3f9e-44b6-833b-ec54a10fb31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ee7729df-26d4-4aab-b4ca-bd5b88d837a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0079720-3f9e-44b6-833b-ec54a10fb31c" xlink:to="loc_us-gaap_PlanNameAxis_ee7729df-26d4-4aab-b4ca-bd5b88d837a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_43d4cb34-970a-4f0e-8c02-c0023cf4f9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ee7729df-26d4-4aab-b4ca-bd5b88d837a1" xlink:to="loc_us-gaap_PlanNameDomain_43d4cb34-970a-4f0e-8c02-c0023cf4f9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_TwoThousandTwentyEquityIncentivePlanMember_07519b8c-d8c2-4f1f-8a1e-013a655f5c95" xlink:href="fhtx-20211231.xsd#fhtx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_43d4cb34-970a-4f0e-8c02-c0023cf4f9aa" xlink:to="loc_fhtx_TwoThousandTwentyEquityIncentivePlanMember_07519b8c-d8c2-4f1f-8a1e-013a655f5c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_A2016StockIncentivePlanMember_2875c695-1ead-439e-b33f-c2508feaf6a9" xlink:href="fhtx-20211231.xsd#fhtx_A2016StockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_43d4cb34-970a-4f0e-8c02-c0023cf4f9aa" xlink:to="loc_fhtx_A2016StockIncentivePlanMember_2875c695-1ead-439e-b33f-c2508feaf6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_TwoThousandTwentyEmployeeStockPurchasePlanMember_a781bde9-a01e-4790-8d43-90a5942bfe86" xlink:href="fhtx-20211231.xsd#fhtx_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_43d4cb34-970a-4f0e-8c02-c0023cf4f9aa" xlink:to="loc_fhtx_TwoThousandTwentyEmployeeStockPurchasePlanMember_a781bde9-a01e-4790-8d43-90a5942bfe86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d89437d1-ec2b-4abd-b042-407ff774148f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0079720-3f9e-44b6-833b-ec54a10fb31c" xlink:to="loc_us-gaap_AwardTypeAxis_d89437d1-ec2b-4abd-b042-407ff774148f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e29b5125-7bbf-42ae-af7c-d36a6bdcf9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d89437d1-ec2b-4abd-b042-407ff774148f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e29b5125-7bbf-42ae-af7c-d36a6bdcf9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_f0a677ac-37ce-4b79-8cfa-f9c204ba9796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e29b5125-7bbf-42ae-af7c-d36a6bdcf9ec" xlink:to="loc_us-gaap_RestrictedStockMember_f0a677ac-37ce-4b79-8cfa-f9c204ba9796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b6b0f521-6932-4002-b670-958607f6659f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0079720-3f9e-44b6-833b-ec54a10fb31c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b6b0f521-6932-4002-b670-958607f6659f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f66b9f0e-b078-47bc-bf30-f3684787206a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b6b0f521-6932-4002-b670-958607f6659f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f66b9f0e-b078-47bc-bf30-f3684787206a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d10023ae-d1de-4990-85af-f72c8537e6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f66b9f0e-b078-47bc-bf30-f3684787206a" xlink:to="loc_us-gaap_SubsequentEventMember_d10023ae-d1de-4990-85af-f72c8537e6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f0079720-3f9e-44b6-833b-ec54a10fb31c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a6ecd84c-2555-48d9-b872-a29799750b90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a6ecd84c-2555-48d9-b872-a29799750b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c19c8336-2659-43ab-b825-ab03e976773d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c19c8336-2659-43ab-b825-ab03e976773d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage_f69f5d4a-d4e0-491f-847a-5a4d57507d91" xlink:href="fhtx-20211231.xsd#fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage_f69f5d4a-d4e0-491f-847a-5a4d57507d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_81ee6411-0efc-485a-9f25-4bae7e4ca4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_81ee6411-0efc-485a-9f25-4bae7e4ca4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fb613273-82b3-4b99-bc9e-4e1392896351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fb613273-82b3-4b99-bc9e-4e1392896351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_db1a9c20-71bc-4e45-85d5-3ff1eeb2a836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_db1a9c20-71bc-4e45-85d5-3ff1eeb2a836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares_859a0747-1722-4a75-887f-e71d2fba1732" xlink:href="fhtx-20211231.xsd#fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares_859a0747-1722-4a75-887f-e71d2fba1732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4fdd6758-1c9b-445e-895d-90d3dc8efa9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4fdd6758-1c9b-445e-895d-90d3dc8efa9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_da370d99-02ff-4ae7-9fda-4a0073683f59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_da370d99-02ff-4ae7-9fda-4a0073683f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_25c8f2d5-6e5e-44bf-b99b-196909b372c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_25c8f2d5-6e5e-44bf-b99b-196909b372c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_751b2b1d-b768-46ee-b246-be0f4c8f27ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_751b2b1d-b768-46ee-b246-be0f4c8f27ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b6849b4b-4491-42ae-b07f-ac39b1f46e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b6849b4b-4491-42ae-b07f-ac39b1f46e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_22e20cde-0710-47fc-973a-7808aef471e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_119a2ac2-c5d6-4755-960f-5635c7659432" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_22e20cde-0710-47fc-973a-7808aef471e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedtoEstimateFairValueofStockOptionsandRestrictedStockAwardsusingBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedtoEstimateFairValueofStockOptionsandRestrictedStockAwardsusingBlackScholesOptionPricingModelDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedtoEstimateFairValueofStockOptionsandRestrictedStockAwardsusingBlackScholesOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b74bfd6c-776a-4e90-bed5-c09b9c40fd89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_baa6fd0c-4418-4146-b796-4b978358d445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b74bfd6c-776a-4e90-bed5-c09b9c40fd89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_baa6fd0c-4418-4146-b796-4b978358d445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3a006e23-3a6c-4b39-9c4c-4e3da0cad754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b74bfd6c-776a-4e90-bed5-c09b9c40fd89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3a006e23-3a6c-4b39-9c4c-4e3da0cad754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e040f67b-95f7-4985-88b9-7b075eed7b57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b74bfd6c-776a-4e90-bed5-c09b9c40fd89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e040f67b-95f7-4985-88b9-7b075eed7b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d5e00bb5-9f53-46ba-9689-89958556cdfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b74bfd6c-776a-4e90-bed5-c09b9c40fd89" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d5e00bb5-9f53-46ba-9689-89958556cdfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#StockBasedCompensationScheduleofShareOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_101d5d58-10cc-40bd-802d-d2f5ca87dbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_55b19a1d-3ca1-4859-b51d-83daaed7732d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_101d5d58-10cc-40bd-802d-d2f5ca87dbbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_55b19a1d-3ca1-4859-b51d-83daaed7732d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_37f56e5b-5bfa-4a15-a19b-8860a4cfa8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_55b19a1d-3ca1-4859-b51d-83daaed7732d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_37f56e5b-5bfa-4a15-a19b-8860a4cfa8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_aac63165-e436-4fc7-9fd8-6a252d2b014d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_55b19a1d-3ca1-4859-b51d-83daaed7732d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_aac63165-e436-4fc7-9fd8-6a252d2b014d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e7211a57-6451-4b48-87b4-415d5b5c43dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_55b19a1d-3ca1-4859-b51d-83daaed7732d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e7211a57-6451-4b48-87b4-415d5b5c43dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d584dfa6-a565-4e4d-82d2-9ff0c05f6ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_55b19a1d-3ca1-4859-b51d-83daaed7732d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d584dfa6-a565-4e4d-82d2-9ff0c05f6ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_483b173e-9377-4439-8bdf-7344e683b576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_55b19a1d-3ca1-4859-b51d-83daaed7732d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_483b173e-9377-4439-8bdf-7344e683b576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8f62d9bc-3fc2-40d6-80c1-a7566638a379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_101d5d58-10cc-40bd-802d-d2f5ca87dbbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8f62d9bc-3fc2-40d6-80c1-a7566638a379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_bc2235fd-59d1-4b69-9f96-6b4e26911eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_101d5d58-10cc-40bd-802d-d2f5ca87dbbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_bc2235fd-59d1-4b69-9f96-6b4e26911eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7ef195ed-3590-4279-9b5c-f338ccf924c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_101d5d58-10cc-40bd-802d-d2f5ca87dbbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7ef195ed-3590-4279-9b5c-f338ccf924c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e7d956b2-4cb9-488f-b332-8bc9c2d7430c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7ef195ed-3590-4279-9b5c-f338ccf924c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e7d956b2-4cb9-488f-b332-8bc9c2d7430c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_919c380b-c698-481d-8a48-ec700c573fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7ef195ed-3590-4279-9b5c-f338ccf924c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_919c380b-c698-481d-8a48-ec700c573fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9db277ad-3d85-4a1c-bc92-f2593724d090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7ef195ed-3590-4279-9b5c-f338ccf924c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9db277ad-3d85-4a1c-bc92-f2593724d090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b33a006b-2f2c-4c0c-ba10-5e18ff1051f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7ef195ed-3590-4279-9b5c-f338ccf924c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b33a006b-2f2c-4c0c-ba10-5e18ff1051f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c86d9075-55fd-43a4-86a5-e9562b74f44d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7ef195ed-3590-4279-9b5c-f338ccf924c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c86d9075-55fd-43a4-86a5-e9562b74f44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_663ffe5b-72c1-4e0b-bc14-f2080a0ea84b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_101d5d58-10cc-40bd-802d-d2f5ca87dbbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_663ffe5b-72c1-4e0b-bc14-f2080a0ea84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_561812ff-bf10-49fb-afeb-44b8104a80ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_101d5d58-10cc-40bd-802d-d2f5ca87dbbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_561812ff-bf10-49fb-afeb-44b8104a80ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_WeightedAverageContractualTermAbstract_619f50d5-ad4c-4d16-a8b7-8a8e541d29ee" xlink:href="fhtx-20211231.xsd#fhtx_WeightedAverageContractualTermAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_101d5d58-10cc-40bd-802d-d2f5ca87dbbd" xlink:to="loc_fhtx_WeightedAverageContractualTermAbstract_619f50d5-ad4c-4d16-a8b7-8a8e541d29ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_db477d06-a3ec-4f40-a418-a45f13e67fda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fhtx_WeightedAverageContractualTermAbstract_619f50d5-ad4c-4d16-a8b7-8a8e541d29ee" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_db477d06-a3ec-4f40-a418-a45f13e67fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_a5df52d7-5574-486f-9ce3-7d5f5bebbc73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_101d5d58-10cc-40bd-802d-d2f5ca87dbbd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_a5df52d7-5574-486f-9ce3-7d5f5bebbc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d026492f-0ed0-409b-ab8a-e84ec936478d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_101d5d58-10cc-40bd-802d-d2f5ca87dbbd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d026492f-0ed0-409b-ab8a-e84ec936478d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c4bade3f-2e69-41dd-b829-3005b6c08d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_101d5d58-10cc-40bd-802d-d2f5ca87dbbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c4bade3f-2e69-41dd-b829-3005b6c08d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_63a344bd-d860-4ddc-83b2-a66f11646e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c4bade3f-2e69-41dd-b829-3005b6c08d98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_63a344bd-d860-4ddc-83b2-a66f11646e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_e38653ab-715e-451a-b8fb-8c0ae2ee4690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_101d5d58-10cc-40bd-802d-d2f5ca87dbbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_e38653ab-715e-451a-b8fb-8c0ae2ee4690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_acd7f15f-3458-4a06-a927-63e044b05f15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_101d5d58-10cc-40bd-802d-d2f5ca87dbbd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_acd7f15f-3458-4a06-a927-63e044b05f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fa3aa776-1ba4-4189-9c8b-c165676e1927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7777481a-2e85-4212-890e-3fba69209fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fa3aa776-1ba4-4189-9c8b-c165676e1927" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7777481a-2e85-4212-890e-3fba69209fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_b4318573-f000-4054-b1ff-a31477f252a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7777481a-2e85-4212-890e-3fba69209fd4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_b4318573-f000-4054-b1ff-a31477f252a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_be634f34-b9b4-4d53-8257-69b6aa34da55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_b4318573-f000-4054-b1ff-a31477f252a3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_be634f34-b9b4-4d53-8257-69b6aa34da55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4a5e965f-72ab-41ab-be8b-c4b88559fa88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_be634f34-b9b4-4d53-8257-69b6aa34da55" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4a5e965f-72ab-41ab-be8b-c4b88559fa88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c7e9a938-dfff-4275-9106-dc58721e70fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_be634f34-b9b4-4d53-8257-69b6aa34da55" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c7e9a938-dfff-4275-9106-dc58721e70fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_00202bf9-289f-46f1-99f8-9ffb707f335a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7777481a-2e85-4212-890e-3fba69209fd4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_00202bf9-289f-46f1-99f8-9ffb707f335a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8f0e3b7d-6f19-47dc-8ac1-5f8c075c7111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_00202bf9-289f-46f1-99f8-9ffb707f335a" xlink:to="loc_us-gaap_ShareBasedCompensation_8f0e3b7d-6f19-47dc-8ac1-5f8c075c7111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="fhtx-20211231.xsd#CollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_CollaborationAgreementAbstract_d0f4dd7d-5402-439a-a6b7-303b4f031b56" xlink:href="fhtx-20211231.xsd#fhtx_CollaborationAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_a71ace41-cdf8-4fa5-b09a-0a514eef6768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fhtx_CollaborationAgreementAbstract_d0f4dd7d-5402-439a-a6b7-303b4f031b56" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_a71ace41-cdf8-4fa5-b09a-0a514eef6768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/CollaborationAgreementDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#CollaborationAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/CollaborationAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_CollaborationAgreementAbstract_050a2cf2-0608-42a6-af54-6b6e4fcfef98" xlink:href="fhtx-20211231.xsd#fhtx_CollaborationAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b23d13d-f6df-468e-9465-96c191119abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_fhtx_CollaborationAgreementAbstract_050a2cf2-0608-42a6-af54-6b6e4fcfef98" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b23d13d-f6df-468e-9465-96c191119abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4a413aa1-a568-4883-8f80-9b1e3f120296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b23d13d-f6df-468e-9465-96c191119abd" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4a413aa1-a568-4883-8f80-9b1e3f120296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bc8b43d0-0189-4dc2-8c07-ee5de0a6ea18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4a413aa1-a568-4883-8f80-9b1e3f120296" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bc8b43d0-0189-4dc2-8c07-ee5de0a6ea18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ResearchDevelopmentAndRegulatoryMember_771f2394-9d45-4142-9ba8-71e61176ded8" xlink:href="fhtx-20211231.xsd#fhtx_ResearchDevelopmentAndRegulatoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bc8b43d0-0189-4dc2-8c07-ee5de0a6ea18" xlink:to="loc_fhtx_ResearchDevelopmentAndRegulatoryMember_771f2394-9d45-4142-9ba8-71e61176ded8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_SalesBasedMilestoneMember_b398c63b-dee0-489a-8f80-ee87eb9d5a39" xlink:href="fhtx-20211231.xsd#fhtx_SalesBasedMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bc8b43d0-0189-4dc2-8c07-ee5de0a6ea18" xlink:to="loc_fhtx_SalesBasedMilestoneMember_b398c63b-dee0-489a-8f80-ee87eb9d5a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2deee84f-a05a-428e-af7f-1ee27843429f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b23d13d-f6df-468e-9465-96c191119abd" xlink:to="loc_srt_RangeAxis_2deee84f-a05a-428e-af7f-1ee27843429f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_95300bd7-b9db-46cf-81cc-872181421005" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2deee84f-a05a-428e-af7f-1ee27843429f" xlink:to="loc_srt_RangeMember_95300bd7-b9db-46cf-81cc-872181421005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7d661b34-837b-4cad-96dd-c298ce4bf4d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_95300bd7-b9db-46cf-81cc-872181421005" xlink:to="loc_srt_MaximumMember_7d661b34-837b-4cad-96dd-c298ce4bf4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8ff69626-98c2-4aae-8dbb-e93156464300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b23d13d-f6df-468e-9465-96c191119abd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8ff69626-98c2-4aae-8dbb-e93156464300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7d55ec27-c5b1-47ba-841f-39d01fde35c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8ff69626-98c2-4aae-8dbb-e93156464300" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7d55ec27-c5b1-47ba-841f-39d01fde35c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_736b6888-8318-47de-87ba-85e4da48bf90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7d55ec27-c5b1-47ba-841f-39d01fde35c9" xlink:to="loc_us-gaap_SalesMember_736b6888-8318-47de-87ba-85e4da48bf90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a1b6b34b-b22d-49df-ae12-adb5e05161d0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b23d13d-f6df-468e-9465-96c191119abd" xlink:to="loc_srt_CounterpartyNameAxis_a1b6b34b-b22d-49df-ae12-adb5e05161d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5cc303c9-37e2-467a-86c6-c2bc5f5f9cd8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a1b6b34b-b22d-49df-ae12-adb5e05161d0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5cc303c9-37e2-467a-86c6-c2bc5f5f9cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_EliLillyMember_a31b04fe-2fd5-4120-b57a-a23cf9d1dab2" xlink:href="fhtx-20211231.xsd#fhtx_EliLillyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5cc303c9-37e2-467a-86c6-c2bc5f5f9cd8" xlink:to="loc_fhtx_EliLillyMember_a31b04fe-2fd5-4120-b57a-a23cf9d1dab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_MerckMember_e82df9e8-b811-483f-a7a6-7ee9a8d8560d" xlink:href="fhtx-20211231.xsd#fhtx_MerckMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5cc303c9-37e2-467a-86c6-c2bc5f5f9cd8" xlink:to="loc_fhtx_MerckMember_e82df9e8-b811-483f-a7a6-7ee9a8d8560d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_38993cfc-59e7-4c93-a9bc-b515d66ad698" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b23d13d-f6df-468e-9465-96c191119abd" xlink:to="loc_srt_StatementScenarioAxis_38993cfc-59e7-4c93-a9bc-b515d66ad698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_37be1987-f6d4-4a92-8983-77eefca037f6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_38993cfc-59e7-4c93-a9bc-b515d66ad698" xlink:to="loc_srt_ScenarioUnspecifiedDomain_37be1987-f6d4-4a92-8983-77eefca037f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioAdjustmentMember_5685fa55-9526-4005-bce8-4f44ea7ee35a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScenarioAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_37be1987-f6d4-4a92-8983-77eefca037f6" xlink:to="loc_us-gaap_ScenarioAdjustmentMember_5685fa55-9526-4005-bce8-4f44ea7ee35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_bc67e787-5110-4146-b07e-a48bcbe9ded2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b23d13d-f6df-468e-9465-96c191119abd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_bc67e787-5110-4146-b07e-a48bcbe9ded2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6a365c55-89c6-4d2c-b5ff-f181f1406c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_bc67e787-5110-4146-b07e-a48bcbe9ded2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6a365c55-89c6-4d2c-b5ff-f181f1406c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7b07c18e-f805-4bda-8b36-cc95401d3175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6a365c55-89c6-4d2c-b5ff-f181f1406c5d" xlink:to="loc_us-gaap_SubsequentEventMember_7b07c18e-f805-4bda-8b36-cc95401d3175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d675a11e-0225-42f8-a3d3-5f7dbd73792c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b23d13d-f6df-468e-9465-96c191119abd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d675a11e-0225-42f8-a3d3-5f7dbd73792c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_78183d47-43d8-4f88-b051-0271bd3e8051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d675a11e-0225-42f8-a3d3-5f7dbd73792c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_78183d47-43d8-4f88-b051-0271bd3e8051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_SharePurchaseAgreementMember_bfd74be3-430d-41a4-acc5-d2f0e142b975" xlink:href="fhtx-20211231.xsd#fhtx_SharePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_78183d47-43d8-4f88-b051-0271bd3e8051" xlink:to="loc_fhtx_SharePurchaseAgreementMember_bfd74be3-430d-41a4-acc5-d2f0e142b975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0b23d13d-f6df-468e-9465-96c191119abd" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_NumberOfAdditionalTargets_c33556f6-cd0e-40fc-bd92-83f1534121ab" xlink:href="fhtx-20211231.xsd#fhtx_NumberOfAdditionalTargets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_fhtx_NumberOfAdditionalTargets_c33556f6-cd0e-40fc-bd92-83f1534121ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_NumberOfPrograms_0dd9692e-5cc5-4856-a4c2-ad1e8b4f81a2" xlink:href="fhtx-20211231.xsd#fhtx_NumberOfPrograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_fhtx_NumberOfPrograms_0dd9692e-5cc5-4856-a4c2-ad1e8b4f81a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_NumberOfTargets_02edbafb-07ce-43c6-b0bd-3e73ff36b18d" xlink:href="fhtx-20211231.xsd#fhtx_NumberOfTargets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_fhtx_NumberOfTargets_02edbafb-07ce-43c6-b0bd-3e73ff36b18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_MilestoneReceivableUponAchievement_c41510f1-1f71-477b-b261-cc0671f2fc04" xlink:href="fhtx-20211231.xsd#fhtx_MilestoneReceivableUponAchievement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_fhtx_MilestoneReceivableUponAchievement_c41510f1-1f71-477b-b261-cc0671f2fc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_OptOutMilestoneReceivableUponAchievement_b6e042ef-bb30-4e25-a40a-c34d02175b40" xlink:href="fhtx-20211231.xsd#fhtx_OptOutMilestoneReceivableUponAchievement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_fhtx_OptOutMilestoneReceivableUponAchievement_b6e042ef-bb30-4e25-a40a-c34d02175b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ProceedsFromUpfrontPayment_16336a49-9a15-4c82-a460-1b789ede5526" xlink:href="fhtx-20211231.xsd#fhtx_ProceedsFromUpfrontPayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_fhtx_ProceedsFromUpfrontPayment_16336a49-9a15-4c82-a460-1b789ede5526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6627dbc7-ff9d-4d7b-9a14-299b4f24fd74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6627dbc7-ff9d-4d7b-9a14-299b4f24fd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d58afe6d-744b-41da-ad4b-762027cb443b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d58afe6d-744b-41da-ad4b-762027cb443b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9f14b246-6a36-42aa-82a2-4c4a596b90a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_9f14b246-6a36-42aa-82a2-4c4a596b90a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice_ffb8274c-4ef2-4b2d-aadd-0e39d69e3c72" xlink:href="fhtx-20211231.xsd#fhtx_DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_fhtx_DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice_ffb8274c-4ef2-4b2d-aadd-0e39d69e3c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7e5084cb-1f3b-4cdd-b87c-3bc087453726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7e5084cb-1f3b-4cdd-b87c-3bc087453726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_556f2235-504e-4be1-9227-df6d3ea69b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_556f2235-504e-4be1-9227-df6d3ea69b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_007bfdbc-0436-47ef-8d56-dc5bf67e1419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_us-gaap_ContractWithCustomerLiability_007bfdbc-0436-47ef-8d56-dc5bf67e1419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_fcd6a886-3d4d-4d88-a212-ef6fec8fc517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_fcd6a886-3d4d-4d88-a212-ef6fec8fc517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d85e401a-ad69-434e-826a-8b0c0231011b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c1463d2-a016-4088-9bab-1f4953d216d0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d85e401a-ad69-434e-826a-8b0c0231011b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="fhtx-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2ddbb806-c635-4180-ba33-20e7da244a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_0ba5fab5-4e09-4137-a70c-0379bfa8304d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2ddbb806-c635-4180-ba33-20e7da244a3a" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_0ba5fab5-4e09-4137-a70c-0379bfa8304d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="fhtx-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a9dcc2a8-c4d6-4bb5-ab9c-691f9b6a2c07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_c04bf1b7-5ed8-4422-8a31-5a1824ec6718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a9dcc2a8-c4d6-4bb5-ab9c-691f9b6a2c07" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_c04bf1b7-5ed8-4422-8a31-5a1824ec6718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_239dc502-cef7-4c80-ac14-3b3eaa144a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a9dcc2a8-c4d6-4bb5-ab9c-691f9b6a2c07" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_239dc502-cef7-4c80-ac14-3b3eaa144a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_330b772b-f24c-41ac-b65c-639bbd50d9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_48e11226-8d36-4eae-8bd2-642b8404eaaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_330b772b-f24c-41ac-b65c-639bbd50d9c7" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_48e11226-8d36-4eae-8bd2-642b8404eaaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6a80a6fd-d32a-4f69-9f97-3efa91eec0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_48e11226-8d36-4eae-8bd2-642b8404eaaf" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6a80a6fd-d32a-4f69-9f97-3efa91eec0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d4983533-6a7d-4500-a67e-493fcdc1d464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6a80a6fd-d32a-4f69-9f97-3efa91eec0f9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d4983533-6a7d-4500-a67e-493fcdc1d464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_34363e04-04e1-4498-91d3-37edc74b8eef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d4983533-6a7d-4500-a67e-493fcdc1d464" xlink:to="loc_us-gaap_DomesticCountryMember_34363e04-04e1-4498-91d3-37edc74b8eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_eb9dac6c-63c0-424a-89f7-313fb49e419e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d4983533-6a7d-4500-a67e-493fcdc1d464" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_eb9dac6c-63c0-424a-89f7-313fb49e419e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_2522d8d1-f62b-4001-8f12-52aa9a7d0cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_48e11226-8d36-4eae-8bd2-642b8404eaaf" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_2522d8d1-f62b-4001-8f12-52aa9a7d0cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_91e870c1-7687-4f05-9c58-5709386c58b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2522d8d1-f62b-4001-8f12-52aa9a7d0cb8" xlink:to="loc_us-gaap_OperatingLossCarryforwards_91e870c1-7687-4f05-9c58-5709386c58b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_7d8fd923-c3dc-4bea-9b22-f993001f0fef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2522d8d1-f62b-4001-8f12-52aa9a7d0cb8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_7d8fd923-c3dc-4bea-9b22-f993001f0fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_dd2b1f49-277d-4d5b-a8c3-71e91977165e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2522d8d1-f62b-4001-8f12-52aa9a7d0cb8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_dd2b1f49-277d-4d5b-a8c3-71e91977165e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_OperatingLossCarryforwardLimitPercentage_9972894e-9079-4eb0-ad16-f16f28293514" xlink:href="fhtx-20211231.xsd#fhtx_OperatingLossCarryforwardLimitPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2522d8d1-f62b-4001-8f12-52aa9a7d0cb8" xlink:to="loc_fhtx_OperatingLossCarryforwardLimitPercentage_9972894e-9079-4eb0-ad16-f16f28293514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_6c1adb91-913e-46a4-92db-29e4a5adc269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2522d8d1-f62b-4001-8f12-52aa9a7d0cb8" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_6c1adb91-913e-46a4-92db-29e4a5adc269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_a73f3659-5f91-45b0-8353-2d2a623a5b48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2522d8d1-f62b-4001-8f12-52aa9a7d0cb8" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_a73f3659-5f91-45b0-8353-2d2a623a5b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_2b3fe054-64f1-492c-81de-cf8b36224cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2522d8d1-f62b-4001-8f12-52aa9a7d0cb8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_2b3fe054-64f1-492c-81de-cf8b36224cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/IncomeTaxesSummaryofReconciliationoftheUSfederalstatutoryincometaxratetotheCompanyseffectiveincometaxrateDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#IncomeTaxesSummaryofReconciliationoftheUSfederalstatutoryincometaxratetotheCompanyseffectiveincometaxrateDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/IncomeTaxesSummaryofReconciliationoftheUSfederalstatutoryincometaxratetotheCompanyseffectiveincometaxrateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_be528d2a-3a0d-4d09-8596-98d5ae176ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_47e680bb-8df9-44a8-9adf-fdd8f9aa98b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_be528d2a-3a0d-4d09-8596-98d5ae176ffa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_47e680bb-8df9-44a8-9adf-fdd8f9aa98b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_acf146e6-f35f-41c6-b9ae-d55c5e141409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_be528d2a-3a0d-4d09-8596-98d5ae176ffa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_acf146e6-f35f-41c6-b9ae-d55c5e141409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_f6e0180d-d9ab-45a4-bc65-ff53be5b989a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_be528d2a-3a0d-4d09-8596-98d5ae176ffa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_f6e0180d-d9ab-45a4-bc65-ff53be5b989a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_aaa812f8-88db-4f2a-a251-b2fcb13499a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_be528d2a-3a0d-4d09-8596-98d5ae176ffa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_aaa812f8-88db-4f2a-a251-b2fcb13499a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_231bc404-3356-4e9f-90aa-ce96a5774af2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_be528d2a-3a0d-4d09-8596-98d5ae176ffa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_231bc404-3356-4e9f-90aa-ce96a5774af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ee2471c2-1b5f-4b87-9a9b-8dbd80cd5db5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_be528d2a-3a0d-4d09-8596-98d5ae176ffa" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ee2471c2-1b5f-4b87-9a9b-8dbd80cd5db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#IncomeTaxesSummaryofNetDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_93d1ed98-9a46-485b-8a48-9f97efffc162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_70ff2b8c-d06c-4bec-a4e0-b7d34f7bf8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_93d1ed98-9a46-485b-8a48-9f97efffc162" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_70ff2b8c-d06c-4bec-a4e0-b7d34f7bf8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b4eeea6e-1ea0-48c6-a7de-a53760d677a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_70ff2b8c-d06c-4bec-a4e0-b7d34f7bf8f9" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b4eeea6e-1ea0-48c6-a7de-a53760d677a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1764920a-3b31-4ca3-9d9a-d4bd486e075f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_70ff2b8c-d06c-4bec-a4e0-b7d34f7bf8f9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1764920a-3b31-4ca3-9d9a-d4bd486e075f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_DeferredTaxAssetsCapitalizedStartUpCosts_6c98060c-8803-44f5-a401-68a15419b246" xlink:href="fhtx-20211231.xsd#fhtx_DeferredTaxAssetsCapitalizedStartUpCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_70ff2b8c-d06c-4bec-a4e0-b7d34f7bf8f9" xlink:to="loc_fhtx_DeferredTaxAssetsCapitalizedStartUpCosts_6c98060c-8803-44f5-a401-68a15419b246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_dbb56f9f-46d1-4267-8575-f658a6738ced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_70ff2b8c-d06c-4bec-a4e0-b7d34f7bf8f9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_dbb56f9f-46d1-4267-8575-f658a6738ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4be2fbd9-b10e-4e92-8558-be09ddf4ab13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_70ff2b8c-d06c-4bec-a4e0-b7d34f7bf8f9" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4be2fbd9-b10e-4e92-8558-be09ddf4ab13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_DeferredTaxAssetsOperatingLeaseLiabilities_fe05ac2c-35a5-40d9-925b-12a6f99bdc80" xlink:href="fhtx-20211231.xsd#fhtx_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_70ff2b8c-d06c-4bec-a4e0-b7d34f7bf8f9" xlink:to="loc_fhtx_DeferredTaxAssetsOperatingLeaseLiabilities_fe05ac2c-35a5-40d9-925b-12a6f99bdc80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_08567a9a-8076-4b4d-8518-7ceeb8091633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_70ff2b8c-d06c-4bec-a4e0-b7d34f7bf8f9" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_08567a9a-8076-4b4d-8518-7ceeb8091633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1aafb32b-8915-4c61-905e-7cfddfba017e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_93d1ed98-9a46-485b-8a48-9f97efffc162" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1aafb32b-8915-4c61-905e-7cfddfba017e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_DeferredTaxLiabilitiesDepreciation_a2c931d6-8a49-42f6-a230-6294c0fb82cd" xlink:href="fhtx-20211231.xsd#fhtx_DeferredTaxLiabilitiesDepreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1aafb32b-8915-4c61-905e-7cfddfba017e" xlink:to="loc_fhtx_DeferredTaxLiabilitiesDepreciation_a2c931d6-8a49-42f6-a230-6294c0fb82cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_2460734e-9f9e-48b2-8d82-ee75d7d56c3b" xlink:href="fhtx-20211231.xsd#fhtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1aafb32b-8915-4c61-905e-7cfddfba017e" xlink:to="loc_fhtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_2460734e-9f9e-48b2-8d82-ee75d7d56c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_a9bfd625-96c1-44c6-bd1d-da687db7a2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1aafb32b-8915-4c61-905e-7cfddfba017e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_a9bfd625-96c1-44c6-bd1d-da687db7a2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1a8fab43-abd8-4a9f-802d-fa1649555068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1aafb32b-8915-4c61-905e-7cfddfba017e" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1a8fab43-abd8-4a9f-802d-fa1649555068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_5725e4c3-2273-49fc-964a-0ab6981864e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1aafb32b-8915-4c61-905e-7cfddfba017e" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_5725e4c3-2273-49fc-964a-0ab6981864e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/Leases" xlink:type="simple" xlink:href="fhtx-20211231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f0e10cf9-576b-43bf-abe9-4d3444af1b21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_0f604b0c-7945-48eb-83a0-8e37bf5127de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f0e10cf9-576b-43bf-abe9-4d3444af1b21" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_0f604b0c-7945-48eb-83a0-8e37bf5127de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_b9562924-b3df-42d2-8cef-398646324ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f0e10cf9-576b-43bf-abe9-4d3444af1b21" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_b9562924-b3df-42d2-8cef-398646324ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/LeasesTables" xlink:type="simple" xlink:href="fhtx-20211231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9ed8fd1b-e8d0-49e2-a16f-0a49c1da08f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_31dfe604-63df-48b3-ba57-5f294e7c4973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9ed8fd1b-e8d0-49e2-a16f-0a49c1da08f2" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_31dfe604-63df-48b3-ba57-5f294e7c4973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1d5205af-7833-40da-800d-4b679a124dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9ed8fd1b-e8d0-49e2-a16f-0a49c1da08f2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1d5205af-7833-40da-800d-4b679a124dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_LeasesBalanceSheetLocationTableTextBlock_c1295048-53f9-460e-ae67-26a42910d8c9" xlink:href="fhtx-20211231.xsd#fhtx_LeasesBalanceSheetLocationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9ed8fd1b-e8d0-49e2-a16f-0a49c1da08f2" xlink:to="loc_fhtx_LeasesBalanceSheetLocationTableTextBlock_c1295048-53f9-460e-ae67-26a42910d8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cfdf3809-55ac-4225-8a87-3b5c458f86e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_ecd539c4-b3df-441a-89d1-1d2e0889f509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cfdf3809-55ac-4225-8a87-3b5c458f86e5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_ecd539c4-b3df-441a-89d1-1d2e0889f509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6a1aa471-e7d2-44a3-b53e-2ca209b5b485" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ecd539c4-b3df-441a-89d1-1d2e0889f509" xlink:to="loc_srt_RangeAxis_6a1aa471-e7d2-44a3-b53e-2ca209b5b485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a506315d-c568-4f7f-aca7-789b4374d3c0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6a1aa471-e7d2-44a3-b53e-2ca209b5b485" xlink:to="loc_srt_RangeMember_a506315d-c568-4f7f-aca7-789b4374d3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3a6a0835-5cf6-49a6-b27a-cbf3508cb468" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a506315d-c568-4f7f-aca7-789b4374d3c0" xlink:to="loc_srt_MaximumMember_3a6a0835-5cf6-49a6-b27a-cbf3508cb468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7a2a3178-1348-45fd-9348-b38002cd7152" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ecd539c4-b3df-441a-89d1-1d2e0889f509" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7a2a3178-1348-45fd-9348-b38002cd7152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_814aa4e9-7310-4aea-a7a1-212fec93e6c7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_7a2a3178-1348-45fd-9348-b38002cd7152" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_814aa4e9-7310-4aea-a7a1-212fec93e6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_d2e9ac4f-3f36-4aa3-b740-5d333a6a71a2" xlink:href="fhtx-20211231.xsd#fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_814aa4e9-7310-4aea-a7a1-212fec93e6c7" xlink:to="loc_fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember_d2e9ac4f-3f36-4aa3-b740-5d333a6a71a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_OfficeSpaceInCambridgeMassachusettsMember_8fcbec9e-a8fa-4eb1-8ef9-801207ef8e13" xlink:href="fhtx-20211231.xsd#fhtx_OfficeSpaceInCambridgeMassachusettsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_814aa4e9-7310-4aea-a7a1-212fec93e6c7" xlink:to="loc_fhtx_OfficeSpaceInCambridgeMassachusettsMember_8fcbec9e-a8fa-4eb1-8ef9-801207ef8e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_AdditionalOfficeSpaceInCambridgeMassachusettsMember_06863a16-a262-44fb-9c99-34312f540c50" xlink:href="fhtx-20211231.xsd#fhtx_AdditionalOfficeSpaceInCambridgeMassachusettsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_814aa4e9-7310-4aea-a7a1-212fec93e6c7" xlink:to="loc_fhtx_AdditionalOfficeSpaceInCambridgeMassachusettsMember_06863a16-a262-44fb-9c99-34312f540c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_55b67ab9-ad4a-43fa-aea0-da0ee16851ec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ecd539c4-b3df-441a-89d1-1d2e0889f509" xlink:to="loc_srt_StatementScenarioAxis_55b67ab9-ad4a-43fa-aea0-da0ee16851ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_79a0a162-c77d-40bd-ba07-757481ade0fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_55b67ab9-ad4a-43fa-aea0-da0ee16851ec" xlink:to="loc_srt_ScenarioUnspecifiedDomain_79a0a162-c77d-40bd-ba07-757481ade0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_743507a4-3cd6-4dc6-8203-5c86d062d95e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_79a0a162-c77d-40bd-ba07-757481ade0fe" xlink:to="loc_srt_ScenarioForecastMember_743507a4-3cd6-4dc6-8203-5c86d062d95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioAdjustmentMember_c8af2d61-7e7b-4efb-9bb4-b92b3f839617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScenarioAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_79a0a162-c77d-40bd-ba07-757481ade0fe" xlink:to="loc_us-gaap_ScenarioAdjustmentMember_c8af2d61-7e7b-4efb-9bb4-b92b3f839617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ecd539c4-b3df-441a-89d1-1d2e0889f509" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_1eb8a493-7dc1-4869-b885-5b5642873288" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_1eb8a493-7dc1-4869-b885-5b5642873288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b1283016-2130-4d50-a688-df5e142ab101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b1283016-2130-4d50-a688-df5e142ab101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_1c6b94bc-3f9c-447b-a27f-f2d898ea22c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_1c6b94bc-3f9c-447b-a27f-f2d898ea22c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_9c301a70-6233-4c13-bc1f-8927cb2b651e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_us-gaap_OperatingLeaseExpense_9c301a70-6233-4c13-bc1f-8927cb2b651e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_LeaseholdImprovementsLandlordAllowance_b47733e5-0eb8-455d-bb9e-2000a34de32a" xlink:href="fhtx-20211231.xsd#fhtx_LeaseholdImprovementsLandlordAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_fhtx_LeaseholdImprovementsLandlordAllowance_b47733e5-0eb8-455d-bb9e-2000a34de32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_LeaseholdImprovementsLandlordAllowanceToBeRepaid_150473a8-1672-4e0d-820a-3c3e938e9cb9" xlink:href="fhtx-20211231.xsd#fhtx_LeaseholdImprovementsLandlordAllowanceToBeRepaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_fhtx_LeaseholdImprovementsLandlordAllowanceToBeRepaid_150473a8-1672-4e0d-820a-3c3e938e9cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_c8636f21-5ffd-425d-8dd0-7a9ec32793e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_c8636f21-5ffd-425d-8dd0-7a9ec32793e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_652c0792-45b0-4ad2-8efc-99d3ecef1259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_652c0792-45b0-4ad2-8efc-99d3ecef1259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5c01d92b-9339-4a05-a334-ff370219a2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5c01d92b-9339-4a05-a334-ff370219a2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1092f1f8-d14b-45eb-b960-864bba5c49be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_us-gaap_OperatingLeaseLiability_1092f1f8-d14b-45eb-b960-864bba5c49be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_1066d78e-48af-4028-b0aa-748d49f72303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_1066d78e-48af-4028-b0aa-748d49f72303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_c98be11e-02f9-465b-837a-b81cfeefd831" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_c98be11e-02f9-465b-837a-b81cfeefd831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_9b042f99-bd10-4dcb-a9e7-8157d21335ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_13c824f7-dd52-4071-8fc8-7891d016cf99" xlink:to="loc_us-gaap_SubleaseIncome_9b042f99-bd10-4dcb-a9e7-8157d21335ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#LeasesSummaryofLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_19d49dc8-8883-46c7-a3b3-76f29a407d42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_e49b8315-f894-4674-b089-c36698d32ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19d49dc8-8883-46c7-a3b3-76f29a407d42" xlink:to="loc_us-gaap_OperatingLeaseCost_e49b8315-f894-4674-b089-c36698d32ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_bdfd5977-e6fb-4542-be0a-b930f52c3cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19d49dc8-8883-46c7-a3b3-76f29a407d42" xlink:to="loc_us-gaap_ShortTermLeaseCost_bdfd5977-e6fb-4542-be0a-b930f52c3cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_46199ce4-f1f2-4539-be2b-e90b569150f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19d49dc8-8883-46c7-a3b3-76f29a407d42" xlink:to="loc_us-gaap_VariableLeaseCost_46199ce4-f1f2-4539-be2b-e90b569150f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_cd3f4cfa-aa6f-41a1-bbaf-ec2a64a4abb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19d49dc8-8883-46c7-a3b3-76f29a407d42" xlink:to="loc_us-gaap_LeaseCost_cd3f4cfa-aa6f-41a1-bbaf-ec2a64a4abb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/LeasesSummaryofSupplementalCashFlowInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#LeasesSummaryofSupplementalCashFlowInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/LeasesSummaryofSupplementalCashFlowInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_04ab286d-ef73-46a0-8e13-8542862947d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_2c4ce3c4-7e09-4887-8992-6d91ab9e7e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_04ab286d-ef73-46a0-8e13-8542862947d8" xlink:to="loc_us-gaap_OperatingLeasePayments_2c4ce3c4-7e09-4887-8992-6d91ab9e7e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_47c89fbb-b9fe-4514-b661-c1bbc11fe75c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_04ab286d-ef73-46a0-8e13-8542862947d8" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_47c89fbb-b9fe-4514-b661-c1bbc11fe75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement_7cb803cf-1d30-4068-a216-bc0977f59df2" xlink:href="fhtx-20211231.xsd#fhtx_ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_04ab286d-ef73-46a0-8e13-8542862947d8" xlink:to="loc_fhtx_ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement_7cb803cf-1d30-4068-a216-bc0977f59df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/LeasesSummaryofWeightedAverageRemainingLeaseTermandDiscountRateLeasesDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#LeasesSummaryofWeightedAverageRemainingLeaseTermandDiscountRateLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/LeasesSummaryofWeightedAverageRemainingLeaseTermandDiscountRateLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0daaa0e1-e887-463a-9d68-8a6b607b833e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_319957f1-fe0b-4ef6-97ef-acd0f3883b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0daaa0e1-e887-463a-9d68-8a6b607b833e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_319957f1-fe0b-4ef6-97ef-acd0f3883b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_96f02283-e4e9-42f6-9459-929093cdb283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0daaa0e1-e887-463a-9d68-8a6b607b833e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_96f02283-e4e9-42f6-9459-929093cdb283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#LeasesSummaryofMinimumLeasePaymentDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9c2ef7ec-977e-4d46-8d76-c5fbbe7d2582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_df7b4f64-28f7-4902-9649-4a27cf719454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9c2ef7ec-977e-4d46-8d76-c5fbbe7d2582" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_df7b4f64-28f7-4902-9649-4a27cf719454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9c62d46e-5114-4b1d-adc5-3d0ab69a9e76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_df7b4f64-28f7-4902-9649-4a27cf719454" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9c62d46e-5114-4b1d-adc5-3d0ab69a9e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6d5fc930-d346-4c09-a2f7-23a548a4fa81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_df7b4f64-28f7-4902-9649-4a27cf719454" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6d5fc930-d346-4c09-a2f7-23a548a4fa81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e056d8ff-a3f1-4cbe-b52d-6f7a68326600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_df7b4f64-28f7-4902-9649-4a27cf719454" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e056d8ff-a3f1-4cbe-b52d-6f7a68326600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3cba3ffa-5246-4bfd-98eb-a254a5acff6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_df7b4f64-28f7-4902-9649-4a27cf719454" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3cba3ffa-5246-4bfd-98eb-a254a5acff6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_610161e3-100f-421d-8410-05c8aed72937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_df7b4f64-28f7-4902-9649-4a27cf719454" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_610161e3-100f-421d-8410-05c8aed72937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_78661dbf-1af1-4c5c-b76a-39ff05172aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_df7b4f64-28f7-4902-9649-4a27cf719454" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_78661dbf-1af1-4c5c-b76a-39ff05172aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a449dccf-2b5e-4e0e-bc3e-e8e5b5e4daaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_df7b4f64-28f7-4902-9649-4a27cf719454" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a449dccf-2b5e-4e0e-bc3e-e8e5b5e4daaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6e092632-009c-48d8-92e1-ce9604a59209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_df7b4f64-28f7-4902-9649-4a27cf719454" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6e092632-009c-48d8-92e1-ce9604a59209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives_0e9f022f-59c1-4a79-b056-757c2c29b7a5" xlink:href="fhtx-20211231.xsd#fhtx_LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_df7b4f64-28f7-4902-9649-4a27cf719454" xlink:to="loc_fhtx_LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives_0e9f022f-59c1-4a79-b056-757c2c29b7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8cc9062b-91a7-451e-ae78-b4f5ac1029ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_df7b4f64-28f7-4902-9649-4a27cf719454" xlink:to="loc_us-gaap_OperatingLeaseLiability_8cc9062b-91a7-451e-ae78-b4f5ac1029ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails_1" xlink:type="simple" xlink:href="fhtx-20211231.xsd#LeasesSummaryofMinimumLeasePaymentDetails_1"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.foghorntx.com/role/LeasesSummaryofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#LeasesSummaryofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/LeasesSummaryofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_fdb68f16-2a46-4e52-8874-77ad753f0246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_35662c6d-73b7-4246-a70e-d38d8cf00f90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fdb68f16-2a46-4e52-8874-77ad753f0246" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_35662c6d-73b7-4246-a70e-d38d8cf00f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9b843338-f35d-42a8-8910-181ae9884eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fdb68f16-2a46-4e52-8874-77ad753f0246" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9b843338-f35d-42a8-8910-181ae9884eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bdde1dab-ab5e-4956-b46a-58c4e41d07f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fdb68f16-2a46-4e52-8874-77ad753f0246" xlink:to="loc_us-gaap_OperatingLeaseLiability_bdde1dab-ab5e-4956-b46a-58c4e41d07f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="fhtx-20211231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_05b4d667-897e-4ae3-8e4d-51fbdfa1290d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6b84be52-895f-4582-8968-4592f03a0a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_05b4d667-897e-4ae3-8e4d-51fbdfa1290d" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6b84be52-895f-4582-8968-4592f03a0a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2b138e84-dbec-4573-baa2-297647cec979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_d4a13e49-7ea2-4eb4-b601-312aa5284518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2b138e84-dbec-4573-baa2-297647cec979" xlink:to="loc_us-gaap_LossContingenciesTable_d4a13e49-7ea2-4eb4-b601-312aa5284518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d0355cba-a3a7-4030-b028-8f5d0e3883d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d4a13e49-7ea2-4eb4-b601-312aa5284518" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d0355cba-a3a7-4030-b028-8f5d0e3883d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_47bc5ab0-fa6d-4e90-8db0-d644a6eb4eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d0355cba-a3a7-4030-b028-8f5d0e3883d0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_47bc5ab0-fa6d-4e90-8db0-d644a6eb4eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_StanfordLicenseAgreementMember_34b32fcf-f6fc-4422-b292-a10860b09f7f" xlink:href="fhtx-20211231.xsd#fhtx_StanfordLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_47bc5ab0-fa6d-4e90-8db0-d644a6eb4eb3" xlink:to="loc_fhtx_StanfordLicenseAgreementMember_34b32fcf-f6fc-4422-b292-a10860b09f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_db54bb75-98e4-406e-80ce-59a23332d1b4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d4a13e49-7ea2-4eb4-b601-312aa5284518" xlink:to="loc_srt_RangeAxis_db54bb75-98e4-406e-80ce-59a23332d1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_11dd9964-a9a6-4c7f-8f05-198ef5474d83" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_db54bb75-98e4-406e-80ce-59a23332d1b4" xlink:to="loc_srt_RangeMember_11dd9964-a9a6-4c7f-8f05-198ef5474d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f49861d1-8bc1-415f-8451-5b9dbcfa4781" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_11dd9964-a9a6-4c7f-8f05-198ef5474d83" xlink:to="loc_srt_MaximumMember_f49861d1-8bc1-415f-8451-5b9dbcfa4781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_50e56e5f-eed8-438c-8798-9fc73792f8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d4a13e49-7ea2-4eb4-b601-312aa5284518" xlink:to="loc_us-gaap_LossContingenciesLineItems_50e56e5f-eed8-438c-8798-9fc73792f8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_AnnualLicenseMaintenanceFees_61324370-9782-49ed-96d8-7a4f8d3e74e2" xlink:href="fhtx-20211231.xsd#fhtx_AnnualLicenseMaintenanceFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_50e56e5f-eed8-438c-8798-9fc73792f8e6" xlink:to="loc_fhtx_AnnualLicenseMaintenanceFees_61324370-9782-49ed-96d8-7a4f8d3e74e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_MilestonesPayableUponEvent_c54ab9cb-9374-4b3c-b2a8-c652794de21e" xlink:href="fhtx-20211231.xsd#fhtx_MilestonesPayableUponEvent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_50e56e5f-eed8-438c-8798-9fc73792f8e6" xlink:to="loc_fhtx_MilestonesPayableUponEvent_c54ab9cb-9374-4b3c-b2a8-c652794de21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/DefinedContributionPlan" xlink:type="simple" xlink:href="fhtx-20211231.xsd#DefinedContributionPlan"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/DefinedContributionPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_69c06c05-0a70-446d-82c0-8e21b29f3dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_00eb8747-5fe5-49b6-b465-096dc2bb935e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_69c06c05-0a70-446d-82c0-8e21b29f3dbb" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_00eb8747-5fe5-49b6-b465-096dc2bb935e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/RelatedParties" xlink:type="simple" xlink:href="fhtx-20211231.xsd#RelatedParties"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/RelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_4d039047-1ff2-486d-ba6e-b378d966d962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_539d7e1f-3ab3-496f-a56e-e3675b32021a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_4d039047-1ff2-486d-ba6e-b378d966d962" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_539d7e1f-3ab3-496f-a56e-e3675b32021a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.foghorntx.com/role/RelatedPartiesDetails" xlink:type="simple" xlink:href="fhtx-20211231.xsd#RelatedPartiesDetails"/>
  <link:presentationLink xlink:role="http://www.foghorntx.com/role/RelatedPartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_69d5d5cc-dea8-40b3-835e-16cfccba64ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18aefa2f-da7c-4225-87b2-8653504efda6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_69d5d5cc-dea8-40b3-835e-16cfccba64ca" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18aefa2f-da7c-4225-87b2-8653504efda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_890ca288-f851-41d5-9aa1-7b45b6acd2fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18aefa2f-da7c-4225-87b2-8653504efda6" xlink:to="loc_srt_CounterpartyNameAxis_890ca288-f851-41d5-9aa1-7b45b6acd2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7ef7527b-ccd4-4f6d-bfbb-34935346528a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_890ca288-f851-41d5-9aa1-7b45b6acd2fe" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7ef7527b-ccd4-4f6d-bfbb-34935346528a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_FlagshipPioneeringMember_f6fa288e-7133-459a-b1b1-21b9daf246f5" xlink:href="fhtx-20211231.xsd#fhtx_FlagshipPioneeringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7ef7527b-ccd4-4f6d-bfbb-34935346528a" xlink:to="loc_fhtx_FlagshipPioneeringMember_f6fa288e-7133-459a-b1b1-21b9daf246f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_15098f2c-dc50-47b7-8e7e-94ab4b0a5159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18aefa2f-da7c-4225-87b2-8653504efda6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_15098f2c-dc50-47b7-8e7e-94ab4b0a5159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8e183662-f1f4-47fa-ae4f-caa55304a7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_15098f2c-dc50-47b7-8e7e-94ab4b0a5159" xlink:to="loc_us-gaap_RelatedPartyDomain_8e183662-f1f4-47fa-ae4f-caa55304a7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_050c9dcb-3730-490e-a77a-d9caefecc526" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8e183662-f1f4-47fa-ae4f-caa55304a7b9" xlink:to="loc_srt_AffiliatedEntityMember_050c9dcb-3730-490e-a77a-d9caefecc526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_d863f48a-e233-4531-b28e-bf8b715a9f34" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18aefa2f-da7c-4225-87b2-8653504efda6" xlink:to="loc_srt_TitleOfIndividualAxis_d863f48a-e233-4531-b28e-bf8b715a9f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d3113dd7-dd3e-4b85-b8d9-e84b01c69af2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_d863f48a-e233-4531-b28e-bf8b715a9f34" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d3113dd7-dd3e-4b85-b8d9-e84b01c69af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_3730fb3f-a8c2-4b1d-a830-197e25ee4cfb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d3113dd7-dd3e-4b85-b8d9-e84b01c69af2" xlink:to="loc_srt_DirectorMember_3730fb3f-a8c2-4b1d-a830-197e25ee4cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ScientificFounderMember_7f386b75-eac7-4956-bc08-5d62854639bf" xlink:href="fhtx-20211231.xsd#fhtx_ScientificFounderMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d3113dd7-dd3e-4b85-b8d9-e84b01c69af2" xlink:to="loc_fhtx_ScientificFounderMember_7f386b75-eac7-4956-bc08-5d62854639bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ea1b7361-97ec-4dfd-9e60-cc8492bba37a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18aefa2f-da7c-4225-87b2-8653504efda6" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ea1b7361-97ec-4dfd-9e60-cc8492bba37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bd8465d7-4fbc-4693-ae9f-1666426594d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ea1b7361-97ec-4dfd-9e60-cc8492bba37a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bd8465d7-4fbc-4693-ae9f-1666426594d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_40c1dd15-7fb8-46a9-b6a1-51398c62c88f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_bd8465d7-4fbc-4693-ae9f-1666426594d9" xlink:to="loc_us-gaap_SubsequentEventMember_40c1dd15-7fb8-46a9-b6a1-51398c62c88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_7bff5467-c3df-4099-8102-703340ce4bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_18aefa2f-da7c-4225-87b2-8653504efda6" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_7bff5467-c3df-4099-8102-703340ce4bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ServiceAgreementTerm_b6ed3514-4f5c-4a59-9d3b-4838a7e7ad86" xlink:href="fhtx-20211231.xsd#fhtx_ServiceAgreementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7bff5467-c3df-4099-8102-703340ce4bf9" xlink:to="loc_fhtx_ServiceAgreementTerm_b6ed3514-4f5c-4a59-9d3b-4838a7e7ad86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_ServiceAgreementRenewalTerm_662b2584-f1f7-49a4-9325-e4e2a1d0c095" xlink:href="fhtx-20211231.xsd#fhtx_ServiceAgreementRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7bff5467-c3df-4099-8102-703340ce4bf9" xlink:to="loc_fhtx_ServiceAgreementRenewalTerm_662b2584-f1f7-49a4-9325-e4e2a1d0c095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fhtx_CashPaymentsRelatedParty_d7a58fe2-b6eb-4188-8207-3182620cec5e" xlink:href="fhtx-20211231.xsd#fhtx_CashPaymentsRelatedParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7bff5467-c3df-4099-8102-703340ce4bf9" xlink:to="loc_fhtx_CashPaymentsRelatedParty_d7a58fe2-b6eb-4188-8207-3182620cec5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_4951672c-29fa-488d-b96b-8001cb5c720b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7bff5467-c3df-4099-8102-703340ce4bf9" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_4951672c-29fa-488d-b96b-8001cb5c720b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" $=!'0# 2(  A$! Q$!_\0
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M'?[1_B'3?!WQ(U6RM()8/)LUN2\*9@C)Q&^5&22>G>ON2OSL_;9_Y.;\3_\
M76W_ /2>.OR/Q8Q>*P>04:F'J2A+VJUBVG\,^J.;.YSIX:+B[._3T9UG@O\
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M:*^U_P!7LD_Z!X?<?F'^N/%/_094_P# F?=W_$1+_P %!O\ GGX&_P#";?\
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M =4_]'V]?1<*X;#XO.Z=*M%2BU+1[?"SXWC[&XO+N%ZU?#3<)IPLUHU>:3_
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MVG\:ZS:V^N?M3?'2VT8. TF@>$+87,X!_A:ZF C1AW"QR+Z,:\O,,ZRS*_\
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MO^R@:C_Z.:O#:]R_X*9_\I!/C%_V4#4?_1S5X;7]$9=_R+Z/^&/Y(_C3./\
MD;XC_KY/_P!*85^BO_!M7_R>+XP_[)Y-_P"EMK7YU5^BO_!M7_R>+XP_[)Y-
M_P"EMK7G\3?\B'$?X?U1[/ __)683_'^C/VSHHHK\'/ZR"BBB@ K\^/^"KG_
M  6C\/?LM&^^ /[-=W::O\0MIBU75B!+:^'R1T(Z2W/HGW4ZOD_(7?\ !:7_
M (*MG]ECP]+^S5\ ==3_ (6)K-F#JVJ6[ GP]:2+P1Z7,@.4'5%.\\E*_$"\
MO+O4;N74-0NI)YYY&DGGF<L\CL<EF)Y)))))ZU^@<*\*QQ<5C,8O<^S'^;S?
MEV77TW_(./N/I9?*66Y;+]YM.:^S_=C_ 'N[^SMOMI>.O'GC3XG>+;[QY\0_
M%%]K.LZG.9K_ %+4;AI9IW/4LQ_0= .!@5DT45^IQC&,4DK)'X).<IR<I.[>
M[8445ZC^S=^Q;^T_^UMJYTKX _![5==CCDV7.IK&(;&V/I)<RE8E..=N[<>P
M-15K4J%-SJR48KJW9?>S3#X;$8NJJ5"#G)[))MOY(\NHK]1_@?\ \&SGQ#U:
MV@U/]HG]HO3-&+ -+I/A337O9,'^$W$QB56'?$;CT)ZU]%^#_P#@W0_8%\/V
MZKXAU?QYKTP'SO?:_%"I/LL$"$#ZD_6OFL1QED.'E93<O\*?YNR/M\'X:\68
MN"E*DJ:?\TDG]RNU\T?A;17[YWG_  0 _P"";UU 88O /B.W8])8?%=QN'_?
M1(_2O-_B/_P;4_LH:[;R2?##XT^./#UTP.S^T3:ZC A[?((X7(^LE84^.,CG
M*TG*/K'_ ";.NMX6<54HWBH2\E+_ .227XGXJ45]Z?M%_P#!O5^VE\(K:?7/
MA-J&B_$?3806\K2939ZAM'4FWG.UN/X4E=CT ]?A[QAX+\8?#WQ'=>$/'OA7
M4=%U:RDV7FF:K9/;SPMZ-'( RGZBOHL%F6 S&/-AJBEZ;KU6Z^:/B\SR3-LF
MGRXVC*'JM'Z-:/Y,S****[CRSTS]E?\ :Y^.G[''Q*@^)WP.\8S:?<J56_T^
M0E[348@<F*>+.'7T/#+G*D'FOWN_X)W?\%)/@]_P4 ^'K:CX;=='\7Z7"G_"
M2>$[B8-+;$\>=$>/-@8]' R"<, <9_G%KK?@;\<?B=^SC\4-*^,'P@\43Z3K
MND3B2VN(C\LB_P 44B])(V'RLAX(-?-\0<.8;.J+DO=JK:7?R?=?BNG9_;<(
M<:8[AG$*$FYT&_>CV\X]GY;/KT:_J;HKP/\ X)W_ +>7P^_;Z^!4'Q'\.+'8
M>(-.V6OB[P]YF6T^[VYW+GEH9,%HV[@%3\RL![Y7XKB,/6PE>5&JK2B[-'].
M8+&8;,,+#$X>7-":NFOZ^]='H%%%%8G4>+?\%&_^3#/B]_V3_4__ $G:OYH*
M_I?_ ."C?_)AGQ>_[)_J?_I.U?S05^J^'_\ N-;_ !+\C\!\7_\ D:X;_ __
M $H****^_/R$**_0_P#X)[?\$//"?[;O[+^D?M"ZM^T/J/AZ?4[Z\MVTNW\.
MQW"QB"=X@=YF4G.W/3C->V_\0P_@+_H[[6/_  CXO_DFOG<1Q5D>%KRHU*MI
M1;3]V6Z^1]E@^ .*L=A88BC03A-*2?/!735UHY7/R#HK]?/^(8?P%_T=]K'_
M (1\7_R31_Q##^ O^COM8_\ "/B_^2:R_P!<>'O^?O\ Y++_ ".G_B&W&/\
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M=XR2:?=-705XG_P4D_Y,$^,/_9/-4_\ 2=Z]LKQ/_@I)_P F"?&'_LGFJ?\
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MP3P?5XGQ;G5O&A#XGU;_ )5Y]WT7JCEOV!_^"7W[._[!WAJ&Y\+Z/'KOC.:
M+JOC/4K=3<.Q'S) #D6\7^RO)&-S,:^DZ**_&<5BL1C:SJUY.4GU?]?@?TS@
M<!@\LPT</A8*$([)?UJ^[>K"BBBN<ZPHHHH *Y'XU? ;X/?M%^![CX<?&SX>
MZ;XCT>Y'S6NHVX8QMC >-QAHG'9T(8=C77454)SIS4X.S6S6YG5I4J]-TZD5
M*+T::NFO-'XC?\%(_P#@A-\0OV=K:_\ C'^RPU_XL\&0AIK_ $)U\S4])CZE
MAM'^DQ#^\ '4=0P!:OEC]A3]B7XG?MU?'6R^$7@2%[6QB(N/$FO20EHM*LPV
M&D;IN<_=1,Y9CV 8C^F @$8(ZURGPT^!GP?^#=]KNI?"OX<Z3H$_B74SJ&NR
M:9:+$;RY*A?,;'L.@P,ECC+$G[?"\<8^C@)4JJYJEK1E_P#)+JUT[]3\OQ_A
M7E.(S>&(H2Y*-[SA^D7T3ZKHMNQ6_9\^ 7PS_9C^$6B_!3X1Z"NGZ)HMJ(H5
MX,D[GEYY6_CD=LLS=R>PP*[2BBOB:E2=6;G-W;U;[L_4*-&E0I1ITTE&*226
MR2V2"BBBH- K\<_^#F__ )+3\+?^Q7OO_2E*_8ROQS_X.;_^2T_"W_L5[[_T
MI2OJ>#/^2@I^DO\ TEGP7B7_ ,D?7]8?^EH_,.BBBOVL_F ]6_80_P"3X?@U
M_P!E6\._^G.WK^G*OYC?V$/^3X?@U_V5;P[_ .G.WK^G*ORSQ!_WRA_A?YG[
MWX/_ /(MQ7^./Y!1117Y\?L(4444 %%%% !1110!_-3_ ,%,_P#E()\8O^R@
M:C_Z.:O#:]R_X*9_\I!/C%_V4#4?_1S5X;7]$9=_R+Z/^&/Y(_C3./\ D;XC
M_KY/_P!*85^BO_!M7_R>+XP_[)Y-_P"EMK7YU5^BO_!M7_R>+XP_[)Y-_P"E
MMK7G\3?\B'$?X?U1[/ __)683_'^C/VSHHHK\'/ZR"O"?^"BO[:WAG]A3]FC
M5OBYJ AN=<N<V'A+2I6_X_-0=3LR.OEH 9'_ -E, Y85[MTZU_/U_P %K_VS
MYOVK_P!KV_\ #7AK5S-X1\ /+H^AI&^8Y[A6Q=W(['?(NP'ND2'N:^AX9RC^
MU\R4)_!'67IT7S?X7/CN..(_]7,DE4IO][/W8>O67_;JU];+J?*?CWQWXN^*
M'C75/B)X]UV?4]:UJ^DO-3O[ELO/,[%F8_B>@X X' K(HHK]RC&,4DE9(_E:
M4I3DY2=V]V%2V%A?:I>PZ9IEG+<7-Q*L<%O!&7>1V. JJ.223@ 5%7[0?\$1
M_P#@E)IOPA\+Z;^U[^T+X:67Q?JMN)_">C7T.1HMLXRMPZD<7#J<C/,:D=&)
MQY6<YOALFPCK5=7LEU;_ ,N[Z'O\-<.XSB7,5AJ&B6LI=(KOYOLNK\KLX'_@
MFS_P0&L[W3[#XT_MT6,N956?3?AY%*4VKU5KYU(.?^F*D8_C;JE?JIX1\'>$
M_ 'ART\'^!_#5AH^E6$0BLM-TRT2""!!T5$0!5'T%:5%?BN:9QCLWK>TQ$M.
MBZ+T7Z[G]/9%PYE7#N&5+"0L^LG\4O5_HM%T04445Y9[H4444 %>1_M8?L._
MLV_MH^$6\+_'3X>VU[<1Q%-.UVU40ZAIY/0PS@;@,\[&RA[J:]<HK6C6K8>J
MJE*3C);-:,PQ.%P^,H2HUX*4'NFKI_(_GB_X*-_\$I?C5^P/KK>(PTGB7P!>
M7&S3/%5M!@P,3\L-T@SY4G8-]Q^Q!RH^5*_JT\;>"?"7Q(\):AX$\=^'K35M
M'U6U>VU#3KZ$213Q,,%64_Y'6OP!_P""L7_!-37?V"?BTFL^$8[F]^'7B:X=
MO#>H2Y9K*7[S6,S?WU'*,?OH,]5;'ZSPOQ3_ &FUA<5I5Z/^;_@_F?SWQWP%
M_8:>.P";H-ZK=POY]8]+O5=;GR31117VQ^7'M_\ P3\_;4\:?L*_M&:5\7_#
MSS7&D2NMGXKT:-\+J.GLP\Q,=/,7&]#V=1G@L#_2%X \=^$_BAX(TGXC>!-9
MBU'1M<T^*]TR^@.5FAD0,C#TX(X/(/!YK^4ZOV!_X-ROVS9O$OA'6_V+O&VK
M%[G0D?5_!YF?EK-W'VFW7/\ <D82 >DK]EKX+C?)HXC#?7J:]Z&DO./?Y?EZ
M'ZYX6\2RPF.>55Y>Y4UAY3[>DE^*7=GZCT445^4'] 'BW_!1O_DPSXO?]D_U
M/_TG:OYH*_I?_P""C?\ R89\7O\ LG^I_P#I.U?S05^J^'_^XUO\2_(_ ?%_
M_D:X;_ __2@HHHK[\_(3]_/^"!O_ "C3\*?]AO5__2V6OLROC/\ X(&_\HT_
M"G_8;U?_ -+9:^S*_ <]_P"1UB/\<OS9_7G"G_),X+_KU#_TE!1117DGT 44
M44 %5=;T/1?$NDW.@>(M)MK^QO(6BN[*\@66*:-A@HZ,"&4C@@C%6J*:;3NA
M-)JS/QL_X+)?\$<M!^!VAWO[5G[*NAO!X8BD\SQ7X4A!9=*#'_CYM^I$&3\R
M?\L\@CY<A?S*K^KOQ'X>T7Q;H%]X6\2:;%>:?J5I):WUI.@9)H9%*NC ]05)
M!^M?S&_MA_ N;]FC]J'QS\"G+F+PYXAGM[)Y/O/:D^9;L?<PO&?QK];X,SRM
MF%&6%Q#O.&J?5QVU\T^OF?SQXF<+8;)\3#'82/+3JMIQ6REOIV4E?3HT^YYM
M1117W!^5GZT_\&SW[05U<6WQ"_9>U:^+1VXA\2:)"S?<!*V]U@>F3:GCN3ZU
M^K]?S_?\$&?'4_@[_@I3X1TE9RD/B/2M4TRYYX(^QRW"@_62W3\:_H!K\8XU
MPL</GDI1^W%2_-/\C^F?#''3QG"L82=W2E*'RTDOPE;Y!7B?_!23_DP3XP_]
MD\U3_P!)WKVRO$_^"DG_ "8)\8?^R>:I_P"D[U\]E_\ O]+_ !1_-'V6;_\
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M& JC %+13<I-6;)4(1;:5KA1112*/Y0M?_Y#M[_U]R?^A&JE6]?_ .0[>_\
M7W)_Z$:J5_2BV1_$L_B85^Q'_!L;_P DB^*O_8R:=_Z3RU^.]?L1_P &QO\
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M^'_P3/\ ^C@V_P#";O\ _P",T?\ #\/_ ()G_P#1P;?^$W?_ /QFOYZZ*/\
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M?^%I8_\ QVC_ (:Y_91_Z.<^'G_A:6/_ ,=K^7FBC_B'V&_Y_O\ \!7^8?\
M$8<;_P! D?\ P)_Y']0W_#7/[*/_ $<Y\//_  M+'_X[2?\ #7/[*/\ T<[\
M//\ PM+'_P".U_+U11_Q#[#?\_W_ . K_,/^(PXW_H$C_P"!/_(_J]T'7]!\
M5:-;>(_#&MVFI:?>Q"6SO["Y6:&>,]'1T)5E/J"15NO!_P#@E]_RCT^#_P#V
M(ME_Z!7O%?FN*HK#XF=)._*VON=C]NP.(>+P5*NU9SC&5NUTF%?CG_P<W_\
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MN(C\+=EZ+1??O\S^N.$\G>19!0PDOB2O+_%+5_=>WR"O$_\ @I)_R8)\8?\
MLGFJ?^D[U[97B?\ P4D_Y,$^,/\ V3S5/_2=ZY,O_P!_I?XH_FCT<W_Y%.(_
MP3_])9_-'1117]$'\:!7]%O_  1O_P"4:OPL_P"P1<?^ED]?SI5_1;_P1O\
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MOB1\/]>GTS6M%O8[O3;^V;#PRH<@CU'8@\$$@\&O*SS)Z.<X)T9Z26L7V?\
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M3446]KW_ $1[65\.YUG5.4\%1<U%V=FM'\VC\TJ*_2W_ (AF/VD?^CB_ _\
MX"WG_P ;H_XAF/VD?^CB_ __ ("WG_QNN'_6G(/^?Z^Y_P"1ZG^H7%W_ $"2
M^^/^9^:5%?I;_P 0S'[2/_1Q?@?_ ,!;S_XW1_Q#,?M(_P#1Q?@?_P !;S_X
MW1_K3D'_ #_7W/\ R#_4+B[_ *!)??'_ #/S2HK]+?\ B&8_:1_Z.+\#_P#@
M+>?_ !NC_B&8_:1_Z.+\#_\ @+>?_&Z/]:<@_P"?Z^Y_Y!_J%Q=_T"2^^/\
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M10 4444 %%%% '%_M(:G%HO[/'CW69F 2T\&:I,Y;H EI*QSCZ5_+77])/\
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M5_2BV1_$L_B85^P__!L;_P DC^*W_8QZ=_Z3RU^/%?L1_P &QO\ R2+XJ_\
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MO\4?S1YV;_\ (IQ'^"?_ *2S^:.BBBOZ(/XT"OZ+?^"-_P#RC5^%G_8(N/\
MTLGK^=*OZ+?^"-__ "C5^%G_ &"+C_TLGKX7C[_D54_\:_\ 29'ZKX1?\E!6
M_P"O3_\ 2H'TW1117Y*?T.%1W5K;7UK)97MM'-#-&4EBE0,KJ1@J0>"".,5)
M10&Y^"?_  68_P""9UU^QC\5C\6OA5HSGX:^++QFL5B4E=$O&RS63'M&>6B)
M_A!3DID_$=?U.?''X*?#O]HKX4ZU\&?BKH2:CH>O6;6]Y WWD/59$/\ #(C
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M_K[D_P#0C52OZ46R/XEG\3"OV(_X-C?^21?%7_L9-._])Y:_'>OV(_X-C?\
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M_FA6_P##+XF^,?A%XPM?''@;56M;ZV./5)4/WHW7^)3W'X]0#7S/$_#M+/\
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M+6SC .V//+RN1]V-$#.S=E4FOZ5_V3_V;?!/[)'P \.? /P%&&L]"L0EQ>%
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MX.?$#5_A=\2/#\^EZYH=\]IJ5A<+AHI%//L5(P0PX8$$9!%85?N-_P %N_\
M@F*O[3WP_D_:5^"OA\-\0/#%B3J5C:Q_/KNGH"2F!]Z>,9*=V7*<G9C\.F5D
M8HZD$'!!'2OW3(\XHYU@E5CI):279_Y/H?RGQ5PWB>&<S>'GK!ZPEWC_ )K9
MKY[-"4445[)\R%%%% 'MW_!-;_D__P"#O_90]+_]*%K^EJOYI?\ @FM_R?\
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M  3._:Y_;2OH;CX5_#B:TT!Y )_%FNAK73XUSR5<C=,1_=B5SZXK]C/V8?\
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MWU;[MZA1117,=H4444 >+?\ !1O_ ),,^+W_ &3_ %/_ -)VK^:"OZ=_VVO
M/BWXI_LB?$CX;^ M(;4-:USP=?66EV22*AGGDA940,Q"C)/4D"OPM_X<M?\
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M17U+_P .6O\ @I?_ -&QWO\ X.K#_P"/T?\ #EK_ (*7_P#1LE[_ .#JP_\
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M5VMG:6,"VUE:QPQJ,+'$@51] *DHJ95)S^)METZ5*DK0BEZ*P4445!H%%%%
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M6%_Z Y?^!K_Y$_J7HK^6C_AHC]H#_HN?C'_PI[O_ ..4?\-$?M ?]%S\8_\
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MRA:7_P"E*5^PY3_R2L/^O;_)G\X<0_\ )P*G_7Z/YH_ICHHHK\0/ZD"O(?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** /A_P#X.$?^4=&H?]C?I?\
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MQ^P7_$3C\(/^C5O$O_A0V_\ \;H_XB<?A!_T:MXE_P#"AM__ (W7Y2?\,_\
MQX_Z(GXN_P#";NO_ (W1_P ,_P#QX_Z(GXN_\)NZ_P#C=<'^J?#/\O\ Y._\
MSUO^(@\<_P __E./_P B?JW_ ,1./P@_Z-6\2_\ A0V__P ;KBOVC_\ @X>^
M%GQR_9\\<_!;3OV;/$%A<>+?".HZ/!?3ZY Z6[W-M)")&4("P4OD@=<5^;/_
M  S_ /'C_HB?B[_PF[K_ .-U#J/P0^-&D6$^JZM\(?%%K:VT32W-S<:!<I'%
M&HRSLS( J@ DD\ "KI\+<-TZBG&.J::]][_>95N/>-:U&5.<_=::?[N.SW^R
M<O7[F?\ !N/_ ,F':I_V4"^_])[6OPSK]S/^#<?_ ),.U3_LH%]_Z3VM9<<?
M\B)_XH_J='A9_P E4O\ !+]#[\KX?_X.$?\ E'1J'_8W:7_Z&]?<%?#_ /P<
M(_\ *.C4/^QNTO\ ]#>OS+A__D=X?_''\S]RXO\ ^27QG_7N7Y'X+U^I_P"R
M/_P< _!?]G+]F?P3\"]=^ 7BC4;SPMX?@T^XOK34+98IV08+*&.0#[U^6%>A
M>&OV1_VJ_&>@VGBKP?\ LS^/]5TN_A$UCJ.F^#KV>"XC/1TD2(JZGU!(K]GS
M7+LNS&C&&,^%.ZUMK]Z/YEX?SC.LFQ$ZF6_%)6?N\VE[[6?4_5+_ (B:_@%_
MT;1XP_\ !G:_XT?\1-?P"_Z-H\8?^#.U_P :_+O_ (8@_;/_ .C1_B;_ .$)
MJ'_QFC_AB#]L_P#Z-'^)O_A":A_\9KPO]5^%?+_P-_YGU?\ KWQ_Y_\ @I?_
M ")^HG_$37\ O^C:/&'_ (,[7_&OK?\ X)\?M]^#/^"A/PRUKXF^"? 6I^'[
M?1==.ERVVJW$<CR.(8Y=X,? &) /7@U^ G_#$/[9X_YM(^)O_A":A_\ &:_7
MC_@WC^$OQ4^$'[,7C71/BQ\-=?\ #%[<^/&GMK/Q#H\]E++%]BME\Q5F52R[
ME(R.,@CM7A<1Y'D.!RN5;"_&FOM7W>NESZS@OBKBS-<^AA\??V;4F_<4=4M-
M;(_0"O-OVS/^3/\ XK?]DUUW_P!-\]>DUYM^V9_R9_\ %;_LFNN_^F^>O@L)
M_O=/_$OS/UO'_P"XU?\ #+\F?S 5^UG_  ;3?\FE>-O^Q_;_ -([>OQ3KU[]
MGO\ ;S_:X_94\+WG@O\ 9^^-%[X;TN_OC>7=I;6-M*))RBIO)FB<@[54<''%
M?N/$&65LWRV6&I-)MIZWMH_),_E;@_/,+P]G<<;B(N44I*T;7U5NK2_$_IJH
MK^=/_A\K_P %,?\ HZS5O_!1I_\ \CU'<_\ !8S_ (*6W=NUM+^U=K05Q@F+
M3;%&_!E@!'X&O@/]0,U_Y^P^^7_R)^O?\1=R#_GQ5^Z'_P F?T ?'/X]?"7]
MF_X<W_Q4^,WC6ST31M/B+R3W4H#RL!Q%$GWI)&Z!%!)-?S;?MG?M':C^UM^U
M!XR_:%U"R>U7Q'JOF65I(06M[2-%AMXV(X++#'&"1P2":YOXL_';XS_'?6QX
MC^,_Q3U[Q1>IGRIM;U26X\H'J$#DA![* *N_L^_LW_&G]J3XBVOPM^!O@2\U
MS5KE@76WCQ#:QYP9IY#\L,8[LQ [#)(%?79!P[A^'H3KUJB<FM7LDM_^';['
MYUQ;QCB^,JM/"8:DXTT[J/Q2E+9-V[)M)*^[U?3ZF_X( _!'5_B=^WUIWQ C
MLG.F>!-'N]2O;C9\JRRQ-;0IGLQ,K,!W$;>E?O4.E?/'_!-C]@3PA^P!\!H_
M -G>0ZEXFU>1;SQ;KD<9 N;G;A8X\\B&,$JH/)RS$ L0/H>OS?B;-:>;9K*K
M3^"*Y8^:77YMOY6/VO@;(*O#V0QH5OXDFYR79NRM\DE?SN%%%<)^TY\=O#7[
M,WP!\5_';Q6Z_9/#>CRW2Q,V#<38VQ0CW>0H@_WJ\*G3G6J*$%=MV7JSZRM6
MIX>C*K4=HQ3;?9+5L_(C_@XG_:Q_X6A^T5I7[,GAG4]^D^ +;S]72-_EDU6X
M0,0>Q,4.Q1Z&605\I?\ !/?]F"]_:^_:Y\'_  4%L[:;=:@+OQ#*@XBTZ#]Y
M.2>VY1Y8/]Z1:\O^(GCSQ+\4O'NL_$GQE?M=:MKVJ3W^HW#'[\TKEW/L,L<#
ML*_7S_@W!_91_P"$-^$/B+]K;Q-INV^\77)TKPX\B<KI]N_[Z13Z23@J?^O8
M>M?L^,G3X8X:Y(/WDN5><I;O[[OT1_,V6TJO'7&_M:J]R4N:2[4X[+YJT?5W
M/TMT_3[+2K"#2]-M4@MK:%8K>&)<+&BC"J!V   K\*/^"_/[)_\ PH;]L'_A
M<'AS3?*T#XEVS:B#&F$BU*/:EVGU;,<WN9F]*_=VOE?_ (+&?LGC]J[]B'Q'
MINB:9Y_B3PDI\0^'-B9=Y+=&,T*]SYD!E4+W?R_05^;\+YG_ &;F\)2?NS]V
M7H]G\G9^ES]KX[R-9WPY4IP7OT_?CZQW7S5UZV/Q3_X)O_M3W7['O[8'A+XP
M2W;QZ1]L&G^)8U/$FG3D)*2.^SY90/[T0K^D^RO+74+.*_L;A)89XUDAEC;*
MNI&0P/<$<U_)Y7[_ /\ P0Y_:R_X:6_8JTSPOX@U+SO$?P^D70]4#OEY+=5S
M:3'N08ODSW:%J^MX]RSFI0QT%M[LO1[/[[KYH_//"7//9UJN55'I+WX>JTDO
MFK/Y,^R:***_,#]U/R*_X.?/^1M^#?\ V#M<_P#1EC7Y?^"O^1RTG_L)P?\
MHQ:_4#_@Y\_Y&WX-_P#8.US_ -&6-?EII&HR:1JMKJT48=K6X294;HQ5@<'\
MJ_<>%->&Z'I+_P!*D?RUX@M+C3$M]X?^D0/ZO;7_ (]H_P#KF/Y4^OQEB_X.
M9?VB8HUC'[.'@L[5 R;Z[_\ BJ)?^#F?]HUHV6+]G+P2K$?*QO+L@'Z;^:_.
M?]2\_;_AK_P)?YG[+_Q$WA&W\67_ (!+_(_9HD*,DX'K7X2_\%]OVN?!W[1O
M[5&G?#GX<:Q#J.C?#S3Y;"?4+:0/%/J$L@:XV,.&5 D<>1_$CXXQ7%_M.?\
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MXTO5G]+87_=:?^%?D%%%%9'0?@!_P7M_Y28>,/\ L#Z/_P"D$-<?_P $<O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHHK\0/ZD"O(?^"@G_)B'QG_[)7K_ /Z;YZ]>KR'_ (*"?\F(?&?_ +)7K_\
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MNH=?V6[D@C(/_"4Z3_\ )=+_ ,.3/^"G_P#T:U<_^%3I'_R77]#EK_Q[1_\
M7,?RI]?#_P"OV;_\^Z?W2_\ DC]27A'P[_S^J_?#_P"0/P9^&O\ P;Y?\%"?
M&U[''XLT/PQX2MB1YL^L^(4F91WPEJ)23[$@>]?=G[&?_! ']FC]GS6+3Q[\
M<]:?XD^(+1Q);VM]9B#2K>0<@_9MS&<@_P#/5BIZ[ :^^J*\S'<79WCH.#FH
M)_RJWXZO\3V\J\.^&,JJJJJ;J26SF[V^22C]Z&Q116\2P01*B(H5$1<!0.@
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M?IM@3(]7'8U^S9Q*GE/#$Z3>T%!>;:Y?^"?S/PW&MQ#QS3KI?%5=5^24N?\
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M3=^P1_R9!\(O^R;:+_Z115]QX@_[G0_Q/\C\L\'_ /D9XG_ O_2CUJOYW_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1J*THPBGZJ*3_$****Y3O/Q _P"#E'_D^OPM_P!DHL/_ $Y:G7RW_P $[?\
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M3A*VZ_\ !;_^1*CP5XAJ2NI?^#8__)GZ>Z,[RZ1:RR.69K9"S$Y).T<UY_\
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MQEJU9JSZVNEH]_+7R/MN#H\04,J6&S:GRSIZ1ES1ES1Z7LWJMM=U;K<_/_\
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MXA_^%9=?_%U^D'_$,/X _P"CO=8_\(^+_P"2:/\ B&'\ ?\ 1WNL?^$?%_\
M)-'^LO"/=?\ @M__ "(?ZD^(?:7_ (-C_P#)GQ-^Q_\ MO?MB^)_VKOAMX;\
M1?M/^.[[3[_QSI5O>V5WXGN7BGB>ZC5D=2^&4@D$'J#7]$M?FS\&/^#<_P #
M_!WXN^&/BS:_M3ZK?R>&M?M-4CLI/"L4:SF"99!&6%P=H.W&<'&>E?I,#D9K
MX?BS,<KS#$4G@K62=[1<>OFD?J7A_D^?9/A*\,TOS2DG&\E+2VNS=@K\8?\
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M;6_X(8>'OV8=/_X2?PO^TC>:C93J[P6-_P"%T$L8'9I4N &/N(U^E?'WA?\
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8% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_0a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !7 58# 2(  A$! Q$!_\0
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M^,7_ $,UO_X*[?\ ^-T?\-P?&+_H9K?_ ,%=O_\ &Z^]_P#ACKX.?]"'8?\
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MZK+8:<9?MD<?F8FCQQ7>A@1[5X.-J5ZM3_:#Z7*J.$IT/]C^ GHHHKC/;/S
M_;\^'=KX.^,L.M6,(@M]?M/M$A5.MQ'^[D_3RJ]6_P"":?BN>ZT_QIX9D?\
MT>"2VU"WC_ZZ>8DG_HN.L#_@I5KEO<>*?!.E1R)Y]O:W,\@_W_+"?K$:9_P3
M0L))O&'C>_\ +_T:.SMK;S/^FGF225]K4O4R?WS\RHVI\16@>7?MSG_C)GQ/
M_P!>]G_Z3QU]B?L&'_C'716/:[O,_P#?]J^.OV[>/VE_$X_Z=[/_ -)XZ\Z\
M+?&;QUX-TT:-H'B_4M)TY/WD=E;3[(_62M9X1XS+J4*9PTL;3P&<8BO4_P"G
MA^S;,I&0,_C7G_Q=^*&C?"7P/J&N:K/''''!)Y%O_P M)Y,?NXXZ_+5/VEOB
MJW$?C[7!_P!O58+2^-?C%XBMX9+C5?&.ML/W<<LDD[@?],_,K@IY"Z;YZM16
M/<J<40J4^3#T_P!X8.DZ1=^(M3L]+LXWN;V]N([>"./_ )Z2&OVCETX:;X)G
ML?\ GC8>1^4>*^5/V3?V-IO 6JP>,O')@EUF ?Z%I4/[R.TS_P M'/\ STKZ
M_P!=Q_8&I?\ 7O)_Z :YLWQM/$U5"F=O#^6U,'AZE2K_ ,O#\2M"_P"0UI7_
M %\1_P Z^H/VT_V;)/A]KK^.O#=J#X;OY/\ 3+:*/_CPN7X,G_7.3_T8?>OE
M_1!_Q.=*_P"OB/\ ]&5^UFO:!8>*-"O=*U2VCO=.O(GM[BWD7(DC?J*]C-,6
M\'B:51'RV0X&GF&'Q%.H?G1^Q;^TA_PJ[Q)'X0\0W+'PKJD@^SR2_P#+A</V
M_P"N<E?I2LBRI\K\5^0W[1'P-U+X%^.)K"3?<Z#>R22:7?.<B2/_ )YN>[Q_
MQU]:_L-?M(_\)9I\?P^\2W7FZS:1_P#$LO)?^7RWC_Y9_P#72.O-S/"4\13^
MNX<]O(\=4P]3^S\6?!/C'_D:=?\ ^PA<?^C*_9[X<_\ )/\ PU_V#;?_ -%B
MOQB\:_\ (T^(/^PA<?\ HROV=^'/_)/_  U_V#;?_P!%BNG/OAI'-PM_O&(.
MIHHHKXX_23\)KG[\E?MWX2_Y%?1O^O6/_P! K\1+G[\G^KK]O/"G_(K:3_UZ
MQ_\ H(K[/B+>F?FO!_QU3=HHHKXP_2CB/B7X#A^)?@'6_#5T_EV^I6<EN9.\
M;G[C_P!?PK\=]<TC5O!'B:>QO$?3M<TB[V.1_!)')7[;)(&53T!KY@_:I_9)
MMOC-'_PD&@3V^F^+[>/RR9/]5?ISLCDR?O\ I)7OY3CEA7[.I_#9\CGN53QM
M-5:?\2F=1^S3^TKI7QQ\,6\4]U';>+;2/_B8:=CRW?\ Z:1C_GG7NQ&1RN1]
M:_%/7_#WBKX4>)X[75+"_P##>LP29C.?+D_[92?\M/\ MG7H^D?MH_&'1K3[
M)%XN%Q''_P M+VWM[B0_]M/+KMKY(ZD_:8;8\S"\2^SA[/&4S]5-6UFTT'3;
MB_O[J*RL8$\R2XN'V1QI]:_+G]KC]H&/XY>.8(-(=_\ A%=),D=J?^?B7_EI
M)7G7Q!^-7C;XIR)_PD_B.[U&+.4MA)Y=N?\ MG'^[KV+]GC]C#Q!\4KJ'5O$
MT-SX>\)*=_[P;+B[0]-@_P#:G_HRML+@*>5?[3B:AQ8[,J^>_P"QX2F>J_\
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M]I5J'JXKB7#U*?L\/"YK_L]#'QX\ ?\ 8<L__1E?J#^TY_R0'Q[_ -@>Y_\
M1=?)_P"RW^Q?XB@\6:/XT\8O)H$%A<1WEGI2X-S)(G^K,G_/./\ Z9_?_P"N
M=?5_[3#9_9_\?_\ 8'N?_1=+,L13Q.,INEY%Y-A*F'RRI[0_+7X&2?\ %[?
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M"]O;:9+BSGM))(Y(^1(AC-<688%X*O9? >IE.9?VA0_>?Q#\5M#_ .0SI?\
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M_P"1!\.?]@VW_P#18KU.(O@IGA<)?Q*AU%%%%?&GZ4>=#]G_ .''?P+X>/\
MW#(O\*[R*".VB2.-%CC3[B)4HQ3QP*J4YS^-F5.$*?P"T445)J%-V"G44 8'
MB/PSHOBK3S9:SI5IJUF_6&]@26/\GKRNZ_8Z^#]S/Y[^";..3UBDE3^4E>W9
M/8_I3>:TC6G3_ALY:E"A4_B0//?!GP(^'_@27S]!\(Z587./]?';B23\)'R?
MUKT<+Q3!MJ0<"E.3GN:PIPI_ +1114&HS'&*X7QG\'/!?Q ;/B+POIFK28_U
MUU;(9/\ OY]_]:[OCUIIQ54Y<GP&52G"?QGAL?[&7P;\SS/^$*M#)_MSW'_Q
MRO2/"GPU\+>!+<P>'_#^GZ1&>UC;)%O_ "KJ^3[5&1[UI.O4G\<SFAA,/2_A
MTR>LO6-&L==TNYL-2M8+ZRN(_+GMKB/S(Y$]"E:E%8G<>>Z?\$? .DWUO?VG
M@W0K:\@E\V.XAT^)'C?^^#BO0 O%,&VI!P*N4G/<RA3A3^ :JUA>)/"&B^,M
M--CKFDVFM6>_?]GO84ECW_0UO YI&:I-/C.*\/?"3P7X1U(ZGHWA;1M+U#9L
M^TV=E''+CTW@5VN.,4U2*?TIN?-J9PIPI_ )LXQ7,^(/ NB>)USJFEVMZ,??
MEB!?_&NG_AJ-EHC.</@%4HPKZ31 +&-+3R G[K9LV5R'@OX.^#?AVI_X1KPO
MIVCRD?/<0VX\U_\ MI]^NZP/6C ]:?,Q\D!U%%%0:G$:]\(/!/BG49-2U/PI
MHVJ7\@P]S<V4<DK_ / R*V=!\+:5X4TJ+3-'TVUTFPC'R6UE D40_P" "MHM
MN% ;:*OGGL9<D+\Y)5>:UCF22-T22.3[Z/TJQ14&IYNO[/7PV_Z$7PY_X*XO
M\*Z_2=!T_1M'MM*L+""RTJ"+RHK6*/9'&G]S96KQ3B:J<YRZF5.$*?P'GD/P
M"^'44GF1^!_#R/Z_V9%_A7H6,#%)Q3B:)SG+J%.G"'P#J***DU//=0^"'@#4
M;Z>_OO!FAW=Y._F22S:?&\DC^N2.M=M;6<-I;QV]NB10(FQ(XT^1!5@$'I3L
MX^E4YSEN94Z<*?P#J***DU"BBB@ HHHH **** /AWQC\6/VI/ ^B:MKNI>'M
M M=&L8_/EF"1R&./_<%S5/P7\:?VH/B1X8M]>\->'O#]]I5P)#;W $<?F;)-
MG_+2X]C7T-^U2?-_9W\?!C\QTQP?:N?_ &(6\K]FKPF%.7$EYC_P)DKW%4A]
M5]M[-7O^ESXSV%3Z_P#5/K%3X.?\;'._M.?';QI\'M.^''V"'3S?:U,8=1BN
M(_,P_P"Z!$?[SU<U]/!=K?6OBS_@HZ\]LOPSEM8_,N4O[B2./_II_H^*TS\=
M?VF]R9^$6G C..6_^2*R^K<^'IU(=;G73QWL,9B*=3I[,[#X2?';Q-XU_:6\
M>^!=2-C_ &+H\<CV@BMWCD^1XTYDZ'[]<C\</V@?BGH7[0T/P\\!VVD74D]F
MDMO'?V_WY#%)(?WGF?\ 3.N,_8WU76=8_:R^(%_XBL8]-UVYL+B2[LXSG[/)
MY]O^[K-_:"UCQ)X<_;>T_4?"FCQZUXFCTU/LNG2G$<X^SR=\I_TT[UW4\/3^
MMNG[/_EW^AYE3%U/J'M?:?\ +P]';Q+^U]M^;PSX7V_[\?\ \D5Z3XY\?>.?
M /[--_XLUBUL;+QM8V4<ET@7S+=)3(B=/,Y'/K7G'_"Z_P!J!DQ_PJ'22/7[
M0/\ Y(KTG]KZ1W_9B\;23)Y4IM+<R_['^D1UQ58WG3A.G#?H>A&:]A7J4ZE3
M^'_5O,\8\%_%?]J+Q_X:L-?T/0?#=UI=]'YL$TOEQ[^=GW/M'J,UT'PE_:D\
M5R?$^'X;_%?PY!H'B&[&;*:U.(I9!G@\OD'^!T.#WK@/@7^VQX=^$OP@T'PW
M?^%]>N9-,CDCDO;:./[/_K))/^>E3?#V/Q#^U=^T5H7Q'_L*3P]X1\.>4([F
M60/Y^SS'$8 X=_,?#_\ //'K7;4P_P#$=6E:']6."ABYM8?ZO4]I4/NUHP5P
M?NFOB'XP?MK:]X,^.MSIFBQ6]SX(T.\M[/4Y?L_F2-_S\8D[8S_Y#KZ:^/?Q
M,A^$OPHU[Q)N0W<,02SC(^_<.=D8_.OCOX4^%O &J?LP^)-*U_Q=X>MO&7B?
MS-1,M[?Q1RP2))_H_F?223/_ &\25Q8*C#^/5IW6QZ&:XJI[18?#U+/XS]!+
M&^AU&UM[NV82P3)YD<B'[]?*/[17[0'Q-\%_'/1O G@2#2+A]3T^.:"._M_O
MR.\@_P!9YGI'6Y^PC\5CXU^$":'=SB75/#D@LGSU>WY\@_E^[_[95Y)^T_XU
ML/AY^VCX-\3:KY_]F6&EP/<?9HO,DZW-&&PG)B*E"HMAX['^TP%/$4W[/VAT
M/B#X]_M&_"&R76O&'@;1[W08QF=[4\H/7S(Y)-G_ '[KV#Q=\>5U3]F'5/B=
MX4:.*0V@N(HKU-_DR"4(Z28]#7B7QD_;?\/?$CP+JOA#P9H.K:MK6MVSV6)+
M?,<<<G[O_EF[^9)6W??#74OA1^P!X@TC6/W>JO:?:[FW[0227$?[NNF=*FU3
M]M3]G4]I_6AS0KU+U*>'J>TI^S,[P3\5_P!J/X@>&=/\0Z%H7ABZTJ_C\V"2
M4QQ[^=G_ #T]:]8^"VL_'^]\72)\1])T:S\/""3$EB8_,\S/R='->$? 7XG_
M !XT/X4^'=/\'_#O3-;T".&3[)J$DH_>#S).WF1U]*_ ;QC\3O&*ZV?B/X1M
M?"HM_*%C]G(_TC?YGF?\M).F(_S-1CX^S]HO9TPRZ?UA4_WE0XWX7_'GQ-XQ
M_:F\<> +W[#_ &%I%O)+;^7;D2DQO&.7\S_IIZ5[A\0==N- \">(-4M!&;O3
M["XN81)T+I&7'\J^3O@&/*_;Y^*B'^.RN/\ T9;U]2_%P*/A-XQ]M'O!_P"0
MWKS\93ITZE-4^T#T<#7J5</4J5/[YXC\&_C-\1OBY^SAKOB33[/3KCQJEW);
MV$:1^7;DCR^O[S_;?G/:O)_B3^T/^T=\)-+L[WQ5HN@Z?97$GV=)-D<OF28W
M_P#+.3VKU'_@G6N?@#,I3_F,7'_HN.L'_@I8G_%M?!ZK_P!!D_\ I/+7IX?V
M;Q_U=T[ZGEUIXAY7]<]I_P NS6^'GC#]I;5/%.A_\))X:T.V\-2SHUW<0^69
M1 _H/M!Y'TK6U'XX^*+3]L;3OAG&MC_PC,]MYK_N/](_X]I)/O\ F?\ /0>E
M?0?AC)\.:7_U[1_^@5\?ZXW_ !LMT9AT^Q_^XZ2N;#^SQ%2K>FM(,Z\3[3!T
M\/[.I_$J4SW/]H+X_P"D_L_^$TU*^1]0U"[D=+'3TDV>81]\N_0(F>3_ /K'
MA5GX[_:L\>V,>O:5H>E:)I\R"2.PF2..1T[9$G[S/_?NLO\ :,6+Q%^W+\.-
M'UO_ )!,<5I)'')_JY#YDLG_ *,CCK[F?]R""VR,>V:SFJ>#HT_W>M0<75S"
MO4_><D*9X+^S;\<?&OQ.DUK2O&/@RYT+4](D$4][$ICMW?'W C\_]^RX]Z\]
M\;_M&?$?QQ\5-8\ ?"/1].=]'WIJ&JZFQVB6,[' !Z<GT>OKR.)$5,?*HS@5
M\3_$/X"_%7X4_%SQ%\0/A7<6^I6NMR27%WI\OEB09??(@1_OY<^O>E0G0G.?
M0TQL,71H4X*I_C.O^'OQ9^/&@?$31O"GCKP1;ZKI^I/Y?]M:<VSR$'WY&D3,
M?I\F(S7U@?=<GZU\>_#_ /;:U>S\8V/A/XI>"F\*:C>R)%%>0JZ1B3/R>9')
MG]WQ_K(Y).E?8)8,,YP/I66-IU*<UST['7EM2G4I_NZGM"S1117">T%%%% !
M1110 4444 %%%% !1110 4444 >._M5Q&7]G;QZB]?[-DK _8?@:W_9L\)(R
MA'WWG3_KYDHHKTG_ ,B[_N)^A\_/_D<?]P__ '(>7?\ !0NSDO+SX5!%#_\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_0b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0b.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" $=!'0# 2(  A$! Q$!_\0
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M'?[1_B'3?!WQ(U6RM()8/)LUN2\*9@C)Q&^5&22>G>ON2OSL_;9_Y.;\3_\
M76W_ /2>.OR/Q8Q>*P>04:F'J2A+VJUBVG\,^J.;.YSIX:+B[._3T9UG@O\
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M:*^U_P!7LD_Z!X?<?F'^N/%/_094_P# F?=W_$1+_P %!O\ GGX&_P#";?\
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M =4_]'V]?1<*X;#XO.Z=*M%2BU+1[?"SXWC[&XO+N%ZU?#3<)IPLUHU>:3_
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MVG\:ZS:V^N?M3?'2VT8. TF@>$+87,X!_A:ZF C1AW"QR+Z,:\O,,ZRS*_\
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MO^R@:C_Z.:O#:]R_X*9_\I!/C%_V4#4?_1S5X;7]$9=_R+Z/^&/Y(_C3./\
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M (1\7_R31_Q##^ O^COM8_\ "/B_^2:R_P!<>'O^?O\ Y++_ ".G_B&W&/\
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M=XR2:?=-705XG_P4D_Y,$^,/_9/-4_\ 2=Z]LKQ/_@I)_P F"?&'_LGFJ?\
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MP3P?5XGQ;G5O&A#XGU;_ )5Y]WT7JCEOV!_^"7W[._[!WAJ&Y\+Z/'KOC.:
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MD\U3_P!)WKVRO$_^"DG_ "8)\8?^R>:I_P"D[U\]E_\ O]+_ !1_-'V6;_\
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M& JC %+13<I-6;)4(1;:5KA1112*/Y0M?_Y#M[_U]R?^A&JE6]?_ .0[>_\
M7W)_Z$:J5_2BV1_$L_B85^Q'_!L;_P DB^*O_8R:=_Z3RU^.]?L1_P &QO\
MR2+XJ_\ 8R:=_P"D\M?+\9?\D_5]8_\ I2/NO#3_ )+"AZ3_ /2)'Z@4445^
M)G]0!1110 4444 %%%% !1110 4DCI$C22.%502S,< #UI:\6_X**?&B7]G_
M /8D^)/Q1LKLP7MGX8GM]-E5L%;JXQ;PD>X>53^%:T*,\17A2CO)I+YNQSXO
M$T\'A:F(J?#"+D_1*[/P6_X*5_M)W/[5G[:7C?XJ1WK3:6FJ-IOA\;LJMA;$
MQ1%?0/M:7ZR&O":"23DFBOZ)P]"GA</"C#:*27RT/XTQN+JX[%U,35=Y3DY/
MU;N%=1\$OA%XP^/GQ<\._!CP!9>?K'B75H;"R4@[49V ,CXZ(BY=CV52>U<O
M7Z8?\&VG[-UKXO\ C9XM_:<UZP$D/@_35TO0WD7@7MV&\V13_>2!&0^UQ7'F
M^/669;4Q/6*T]7HOQ/2X<RB6>9U1P2VD]?**UD_N3MYGZO?LT_L_>!/V6O@=
MX=^!'PYM!'IGA_3U@$Q0![J8_-+<28_CDD+.?=L#@"NZHHK\ J5)UJCG-W;=
MV^[9_7E&C2P]&-*FK1BDDELDM$@HHHJ#4**** "BBB@ HHHH *^*/^"AGP+A
M\'^+[?XN>';,1V&NR&/4DC7"QW@!.[V\Q03_ +R,>]?:]<;^T!\-X/BQ\(-<
M\%/"&GGLVDL21RMPGSQD>GS  ^Q-?*<9Y#3XAR"KA[?O(KF@_P"\ME_V]\+]
M3BS##+%864>JU7J?F312R(\;F.12&4X8'L:2OY"/A %?>W[ /Q*?QQ\#X_#M
M]<;[OPY<FS;<<DP$;HC] "5'^Y7P37T5_P $W/&;:-\7M1\'RS8BUG2F9$)X
M,L)W#_QTR5]]X:YI++>*Z4;^[5O!_/X?_)DCT\HK.CC8KI+3_+\3[>HHHK^J
MC[4_+S_@Y1_:4ET#X>>#?V5]"ORLNOW3:YK\:/R;: F.W1AW#2EV^L K\>J^
MJ?\ @M'\9Y?C/_P42\=W$5V9;+PU<1:!8#.0BVJ!90/K.9C^-?*U?N_#6"6!
MR6C"VK7,_66OX*R^1_)W&^9RS7B;$5;WC&7)'TCI^+N_F%%%==\ _A)K7QZ^
M-GA3X+^'LB\\3Z_:Z=$X7/EB60*SGV526/LIKVYSC3@YR=DM6?,4J52O5C3@
MKRDTDO-['ZX?\&\7[$5K\._A)>?MD>.=(']N>,%>S\+"9/FM=+1\/*N>C32I
MU_N1*0<.<_I561X \#^'/AGX&T?X=>$+!;72M"TR"PTZW0<1P0QK&@_[Y45K
MU_/V:YA4S3'SQ,^KT79=%]WXG]?Y!D]'(LHI8*G]E:OO)_$_F_PL@HHHKSCV
M0HHHH **** "BBB@ HHHH **** "BBB@ K\<_P#@YO\ ^2T_"W_L5[[_ -*4
MK]C*_'/_ (.;_P#DM/PM_P"Q7OO_ $I2OJ>#/^2@I^DO_26?!>)?_)'U_6'_
M *6C\PZ***_:S^8#U;]A#_D^'X-?]E6\._\ ISMZ_IRK^8W]A#_D^'X-?]E6
M\._^G.WK^G*ORSQ!_P!\H?X7^9^]^#__ "+<5_CC^04445^?'["%%%% !111
M0 4444 ?S4_\%,_^4@GQB_[*!J/_ *.:O#:]R_X*9_\ *03XQ?\ 90-1_P#1
MS5X;7]$9=_R+Z/\ AC^2/XTSC_D;XC_KY/\ ]*85^BO_  ;5_P#)XOC#_LGD
MW_I;:U^=5?HK_P &U?\ R>+XP_[)Y-_Z6VM>?Q-_R(<1_A_5'L\#_P#)683_
M !_HS]LZ***_!S^LCP+_ (*<_M+M^RA^Q1XU^*>FWH@UB73_ .S/#S9^;[=<
M_NHV7U* M+](S7\VLDCRNTLKEF8DLS'))]37ZR_\',_QMF2+X;_L[:?>$(YN
M?$&J1*W7'^CV^?\ R8K\F:_8^","L-D_MFM:C;^2T7ZOYG\V>*.:2QW$?U9/
MW:,4O^WG[TG^2^04445]B?FQ]I_\$0_V%K;]KG]I\>._'ND"X\%?#[RM0U6*
M9,QWUZ6/V6U.>&4LC2..05BVG[XK]]%4*H51@ 8 KY;_ .".7[,UM^S/^P?X
M1T^\TX0ZWXLM_P#A(M>=DPYENE5HD/<;+<0ICLP8]S7U+7X=Q1FDLSS6;3]R
M'NQ^6[^;_"Q_5/ >0PR/A^FFOWE1*<^]VM%_VZM/6[ZA1117SA]F%%%% !11
M10 4444 %><?M:?LS^ OVO/@%X@^ WQ"MU^RZQ:$6EZ(PTEA=KS#<Q_[2/@X
M_B&5/#&O1Z*TI5:E"K&I3=I)W3\T95Z%'%4)4:L>:,DTT^J>Z/Y6_C#\*/&?
MP+^*6O\ P?\ B%IIM-:\.:I-8ZA#SC?&Q&Y3_$C##*W=6![US=?IO_P<D?LP
M6WA+XM>%/VJO#FG".#Q9:-I/B%XTP#>VR@PRL?[SP'9]+:OS(K]^RC,(YIEU
M/$K>2U\FM'^)_(?$>43R+.JV">T7H^\7K%_<U?S"O3_V,/VA-5_98_:A\%_'
M339Y%CT/6XFU*.,_ZZR<^7<1^^Z)W'UP>U>845W5J4*]*5.:NI)I^C/*PV(J
MX7$0K4G:46FGYIW1_6#I>IV.M:9;ZQI=RD]M=P)-;S1ME9(V4,K ]P00:GKY
MF_X(_P#QIG^.7_!/3X>>(-0NC-?:1IKZ'?LS9;?9N84)]S$L;?\  J^F:_G?
M%X>6$Q4Z$MXMK[G8_LK+L9#,<!2Q4-JD8R^]7/%O^"C?_)AGQ>_[)_J?_I.U
M?S05_2__ ,%&_P#DPSXO?]D_U/\ ])VK^:"OTWP__P!QK?XE^1^&^+__ "-<
M-_@?_I04445]^?D)^_G_  0-_P"4:?A3_L-ZO_Z6RU]F5\9_\$#?^4:?A3_L
M-ZO_ .ELM?9E?@.>_P#(ZQ'^.7YL_KSA3_DF<%_UZA_Z2@HHHKR3Z **** "
MBBB@ K\ /^"]6EV.G?\ !2GQ;-9JH:[TC2IY\=W-G&O/X*M?O_7\WW_!5SXQ
MZ;\=/^"@7Q*\;:'=K/I\&MC2[&5&RKI9Q);%E/<,\3L#Z-7W/ -.<LVJ36R@
M[_-JWY'Y7XMUJ4>'Z5-_%*HFOE&5W^*^\^>****_6S^=SZ6_X(]?:?\ AY3\
M*/LN=W]N3YQ_=^QS[O\ QW-?T95_/W_P0>\$7'B__@I7X-U-(-\/A_3=4U*Y
MXX5?L4L"'\))X_QK^@2OR/CZ<99O3BND%_Z5(_HGPDIRCP[5D^M5V^48!7B?
M_!23_DP3XP_]D\U3_P!)WKVRO$_^"DG_ "8)\8?^R>:I_P"D[U\GE_\ O]+_
M !1_-'Z%F_\ R*<1_@G_ .DL_FCHHHK^B#^- K])O%__  3%'[2__!)GX8_M
M._!30 WCWPUX;N?[7L+6/Y]<T]+NX)  ^]/$,E>[*"G)""OS9K^BW_@CA_RC
M5^%G_8(N/_2R>OD^+<PQ&68:CB*+U4UZ-<KNGY,_0?#O*,'GF.Q.#Q*O&5)Z
M]4^:-FO-?\#8_G3961BCJ00<$$<@TE?I+_P74_X)ACX*^*KC]L+X%^'=GA+7
M;S/B[2[.+Y-(OI&_X^%4?=@E8\]DD..CJ!^;5>[EF8X?-<''$47H]UU3ZI^G
M_!/E<\R7&9!F4\'B5K'9])+I)>3_  =UN@KZ2_X)C_\ !03Q=^P+\>8/$SR7
M%YX,UQX[7QCHD;9\R#/%Q&N<>=%DLO\ >&Y"1NR/FVBM\5A:&,P\J%97C)6:
M_K\#CP&.Q668R&*PTN6<'=/^NCV:ZK0_JS\"^-_"?Q+\&Z7\0/ >OV^J:-K-
MC'>:9J-H^Z.XAD4,K@^X/3J.AYK5K\4O^"%__!3L_ 7QA;_LB?'#7]O@OQ!>
MG_A%]2NI?DT74)&YB)/W8)F/T20[NCN1^UH((R*_"L[RBMDV-=&>L7K%]U_F
MNI_5W"_$>%XERN.)IZ26DX_RR_R>Z?;SN%%%%>0?1A7X^_\ !SK_ ,E/^$O_
M & =4_\ 1]O7[!5^/O\ P<Z_\E/^$O\ V =4_P#1]O7U/!O_ "4%+TE_Z2SX
M/Q*_Y(^OZP_]+B?ES1117[6?R^>W?\$UO^3_ /X._P#90]+_ /2A:_I:K^:7
M_@FM_P G_P#P=_[*'I?_ *4+7]+5?E7B!_OU'_"_S/W_ ,(/^13B?\:_])04
M445\ ?KH4444 %%%% '\H6O_ /(=O?\ K[D_]"-5*MZ__P AV]_Z^Y/_ $(U
M4K^E%LC^)9_$PK])?^"%G[?'[+'['/PZ^(&@_M#?$@Z%=:WK=E<:;&-+N+CS
M8XX9%8YAC8#!8=<5^;5%<&9Y=0S7!RPU5M1=MM]'?JF>KD><XK(,RAC<.DYQ
MO92NUJFGLT^O<_H4_P"'X?\ P3/_ .C@V_\ ";O_ /XS1_P_#_X)G_\ 1P;?
M^$W?_P#QFOYZZ*^7_P!0LG_GG]\?_D3[O_B+?$?_ #ZI?=+_ .3/Z%/^'X?_
M  3/_P"C@V_\)N__ /C-'_#\/_@F?_T<&W_A-W__ ,9K^>NBC_4+)_YY_?'_
M .1#_B+?$?\ SZI?=+_Y,_H4_P"'X?\ P3/_ .C@V_\ ";O_ /XS1_P_#_X)
MG_\ 1P;?^$W?_P#QFOYZZ*/]0LG_ )Y_?'_Y$/\ B+?$?_/JE]TO_DS^A3_A
M^'_P3/\ ^C@V_P#";O\ _P",T?\ #\/_ ()G_P#1P;?^$W?_ /QFOYZZ*/\
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M?^%I8_\ QVC_ (:Y_91_Z.<^'G_A:6/_ ,=K^7FBC_B'V&_Y_O\ \!7^8?\
M$8<;_P! D?\ P)_Y']0W_#7/[*/_ $<Y\//_  M+'_X[2?\ #7/[*/\ T<[\
M//\ PM+'_P".U_+U11_Q#[#?\_W_ . K_,/^(PXW_H$C_P"!/_(_J]T'7]!\
M5:-;>(_#&MVFI:?>Q"6SO["Y6:&>,]'1T)5E/J"15NO!_P#@E]_RCT^#_P#V
M(ME_Z!7O%?FN*HK#XF=)._*VON=C]NP.(>+P5*NU9SC&5NUTF%?CG_P<W_\
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MN(C\+=EZ+1??O\S^N.$\G>19!0PDOB2O+_%+5_=>WR"O$_\ @I)_R8)\8?\
MLGFJ?^D[U[97B?\ P4D_Y,$^,/\ V3S5/_2=ZY,O_P!_I?XH_FCT<W_Y%.(_
MP3_])9_-'1117]$'\:!7]%O_  1O_P"4:OPL_P"P1<?^ED]?SI5_1;_P1O\
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MOB1\/]>GTS6M%O8[O3;^V;#PRH<@CU'8@\$$@\&O*SS)Z.<X)T9Z26L7V?\
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M3446]KW_ $1[65\.YUG5.4\%1<U%V=FM'\VC\TJ*_2W_ (AF/VD?^CB_ _\
MX"WG_P ;H_XAF/VD?^CB_ __ ("WG_QNN'_6G(/^?Z^Y_P"1ZG^H7%W_ $"2
M^^/^9^:5%?I;_P 0S'[2/_1Q?@?_ ,!;S_XW1_Q#,?M(_P#1Q?@?_P !;S_X
MW1_K3D'_ #_7W/\ R#_4+B[_ *!)??'_ #/S2HK]+?\ B&8_:1_Z.+\#_P#@
M+>?_ !NC_B&8_:1_Z.+\#_\ @+>?_&Z/]:<@_P"?Z^Y_Y!_J%Q=_T"2^^/\
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M10 4444 %%%% '%_M(:G%HO[/'CW69F 2T\&:I,Y;H EI*QSCZ5_+77])/\
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M5_2BV1_$L_B85^P__!L;_P DC^*W_8QZ=_Z3RU^/%?L1_P &QO\ R2+XJ_\
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MO\4?S1YV;_\ (IQ'^"?_ *2S^:.BBBOZ(/XT"OZ+?^"-_P#RC5^%G_8(N/\
MTLGK^=*OZ+?^"-__ "C5^%G_ &"+C_TLGKX7C[_D54_\:_\ 29'ZKX1?\E!6
M_P"O3_\ 2H'TW1117Y*?T.%1W5K;7UK)97MM'-#-&4EBE0,KJ1@J0>"".,5)
M10&Y^"?_  68_P""9UU^QC\5C\6OA5HSGX:^++QFL5B4E=$O&RS63'M&>6B)
M_A!3DID_$=?U.?''X*?#O]HKX4ZU\&?BKH2:CH>O6;6]Y WWD/59$/\ #(C
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M_K[D_P#0C52OZ46R/XEG\3"OV(_X-C?^21?%7_L9-._])Y:_'>OV(_X-C?\
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M_FA6_P##+XF^,?A%XPM?''@;56M;ZV./5)4/WHW7^)3W'X]0#7S/$_#M+/\
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M+6SC .V//+RN1]V-$#.S=E4FOZ5_V3_V;?!/[)'P \.? /P%&&L]"L0EQ>%
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MX.?$#5_A=\2/#\^EZYH=\]IJ5A<+AHI%//L5(P0PX8$$9!%85?N-_P %N_\
M@F*O[3WP_D_:5^"OA\-\0/#%B3J5C:Q_/KNGH"2F!]Z>,9*=V7*<G9C\.F5D
M8HZD$'!!'2OW3(\XHYU@E5CI):279_Y/H?RGQ5PWB>&<S>'GK!ZPEWC_ )K9
MKY[-"4445[)\R%%%% 'MW_!-;_D__P"#O_90]+_]*%K^EJOYI?\ @FM_R?\
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M  3._:Y_;2OH;CX5_#B:TT!Y )_%FNAK73XUSR5<C=,1_=B5SZXK]C/V8?\
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MWU;[MZA1117,=H4444 >+?\ !1O_ ),,^+W_ &3_ %/_ -)VK^:"OZ=_VVO
M/BWXI_LB?$CX;^ M(;4-:USP=?66EV22*AGGDA940,Q"C)/4D"OPM_X<M?\
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M17U+_P .6O\ @I?_ -&QWO\ X.K#_P"/T?\ #EK_ (*7_P#1LE[_ .#JP_\
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M5VMG:6,"VUE:QPQJ,+'$@51] *DHJ95)S^)METZ5*DK0BEZ*P4445!H%%%%
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M6%_Z Y?^!K_Y$_J7HK^6C_AHC]H#_HN?C'_PI[O_ ..4?\-$?M ?]%S\8_\
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MRA:7_P"E*5^PY3_R2L/^O;_)G\X<0_\ )P*G_7Z/YH_ICHHHK\0/ZD"O(?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** /A_P#X.$?^4=&H?]C?I?\
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MQ^P7_$3C\(/^C5O$O_A0V_\ \;H_XB<?A!_T:MXE_P#"AM__ (W7Y2?\,_\
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MFK/Y,^R:***_,#]U/R*_X.?/^1M^#?\ V#M<_P#1EC7Y?^"O^1RTG_L)P?\
MHQ:_4#_@Y\_Y&WX-_P#8.US_ -&6-?EII&HR:1JMKJT48=K6X294;HQ5@<'\
MJ_<>%->&Z'I+_P!*D?RUX@M+C3$M]X?^D0/ZO;7_ (]H_P#KF/Y4^OQEB_X.
M9?VB8HUC'[.'@L[5 R;Z[_\ BJ)?^#F?]HUHV6+]G+P2K$?*QO+L@'Z;^:_.
M?]2\_;_AK_P)?YG[+_Q$WA&W\67_ (!+_(_9HD*,DX'K7X2_\%]OVN?!W[1O
M[5&G?#GX<:Q#J.C?#S3Y;"?4+:0/%/J$L@:XV,.&5 D<>1_$CXXQ7%_M.?\
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MXTO5G]+87_=:?^%?D%%%%9'0?@!_P7M_Y28>,/\ L#Z/_P"D$-<?_P $<O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHHK\0/ZD"O(?^"@G_)B'QG_[)7K_ /Z;YZ]>KR'_ (*"?\F(?&?_ +)7K_\
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MNH=?V6[D@C(/_"4Z3_\ )=+_ ,.3/^"G_P#T:U<_^%3I'_R77]#EK_Q[1_\
M7,?RI]?#_P"OV;_\^Z?W2_\ DC]27A'P[_S^J_?#_P"0/P9^&O\ P;Y?\%"?
M&U[''XLT/PQX2MB1YL^L^(4F91WPEJ)23[$@>]?=G[&?_! ']FC]GS6+3Q[\
M<]:?XD^(+1Q);VM]9B#2K>0<@_9MS&<@_P#/5BIZ[ :^^J*\S'<79WCH.#FH
M)_RJWXZO\3V\J\.^&,JJJJJ;J26SF[V^22C]Z&Q116\2P01*B(H5$1<!0.@
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M?IM@3(]7'8U^S9Q*GE/#$Z3>T%!>;:Y?^"?S/PW&MQ#QS3KI?%5=5^24N?\
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M3=^P1_R9!\(O^R;:+_Z115]QX@_[G0_Q/\C\L\'_ /D9XG_ O_2CUJOYW_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1J*THPBGZJ*3_$****Y3O/Q _P"#E'_D^OPM_P!DHL/_ $Y:G7RW_P $[?\
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M3A*VZ_\ !;_^1*CP5XAJ2NI?^#8__)GZ>Z,[RZ1:RR.69K9"S$Y).T<UY_\
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MQEJU9JSZVNEH]_+7R/MN#H\04,J6&S:GRSIZ1ES1ES1Z7LWJMM=U;K<_/_\
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MXA_^%9=?_%U^D'_$,/X _P"CO=8_\(^+_P"2:/\ B&'\ ?\ 1WNL?^$?%_\
M)-'^LO"/=?\ @M__ "(?ZD^(?:7_ (-C_P#)GQ-^Q_\ MO?MB^)_VKOAMX;\
M1?M/^.[[3[_QSI5O>V5WXGN7BGB>ZC5D=2^&4@D$'J#7]$M?FS\&/^#<_P #
M_!WXN^&/BS:_M3ZK?R>&M?M-4CLI/"L4:SF"99!&6%P=H.W&<'&>E?I,#D9K
MX?BS,<KS#$4G@K62=[1<>OFD?J7A_D^?9/A*\,TOS2DG&\E+2VNS=@K\8?\
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M;6_X(8>'OV8=/_X2?PO^TC>:C93J[P6-_P"%T$L8'9I4N &/N(U^E?'WA?\
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8% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>fhtx-20211231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0$!( $@  #_X1"417AI9@  34T *@    @ ! $[  (
M   +   (2H=I  0    !   (5IR=  $    6   0=NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $)E;B!3=')A
M:6X    !ZAP !P  " P   AH     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2=W)S\^_]L
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ME9WXB($AM9UEV9Z9VDXZ&G9AS+N7:***0PHHHH **** "BBB@ HHHH ****
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M0 ;LKV).1W'(JN52@ERVU9'.X59/FOHM;>?W'::;\3YAXR@\,^*_#LVA7UR
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ME\O5;+Y5#>6"#E>"H)QPN<^M9WP/\1Z-X=TW6M.UZ^M]-NTN1(1=.(]P VD
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M>2ROK7'VBUE(.W.>5/\ $.,= 0>HY&=CQ18ZCJGA>_L=%N4M;VYB\J.:0D!
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MHTTXVMUVOY$2K.,[W^SNEYG=0_%.ZL?%=GH7C#PS-H4M\56"47:W"$L<#)4
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M@#FN<OM1L]+_ &H#<ZE=0VEN+< S3R!$4FVXRQX%3>([3PXWCJZU+PO\08=
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M8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M _AW5KO3[G4-/\Z;355;5O/D7RPI!' 8 \@=<U+XA\'Z%XJDM'UZQ^U-9EC
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M&L<:Y)VJHP!D\]!4M%%W:P^57O;4****0PHHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT?\ "Q_B1_=G_P#!</\ XFOH6BCZS3_Y]H/J-;_G]+^OF?/7_"Q_B1_=G_\
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M(_NS_P#@N'_Q-'_"Q_B1_=G_ /!</_B:^A:*/K-/_GV@^HUO^?TOZ^9\]?\
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MHUO^?TOZ^9\]?\+'^)']V?\ \%P_^)H_X6/\2/[L_P#X+A_\37T+11]9I_\
M/M!]1K?\_I?U\SYZ_P"%C_$C^[/_ ."X?_$T?\+'^)']V?\ \%P_^)KZ%HH^
MLT_^?:#ZC6_Y_2_KYGSU_P +'^)']V?_ ,%P_P#B:/\ A8_Q(_NS_P#@N'_Q
M-?0M%'UFG_S[0?4:W_/Z7]?,^>O^%C_$C^[/_P""X?\ Q-'_  L?XD?W9_\
MP7#_ .)KZ%HH^LT_^?:#ZC6_Y_2_KYGSU_PL?XD?W9__  7#_P")H_X6/\2/
M[L__ (+A_P#$U]"T4?6:?_/M!]1K?\_I?U\SYZ_X6/\ $C^[/_X+A_\ $T?\
M+'^)']V?_P %P_\ B:^A:*/K-/\ Y]H/J-;_ )_2_KYGSU_PL?XD?W9__!</
M_B:]D\!ZEJ6K^";"^US<+Z7S/-W1^6>)& ^7 QP!70T5E5K1G&R@D;X?#5*4
MN:51R]3QSQYXU\;:1XVO['0Q*;&+R_*VV0D',:D_-M.>2:YW_A8_Q(_NS_\
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M^A:*/K-/_GV@^HUO^?TOZ^9\]?\ "Q_B1_=G_P#!</\ XFC_ (6/\2/[L_\
MX+A_\37T+11]9I_\^T'U&M_S^E_7S/GK_A8_Q(_NS_\ @N'_ ,31_P +'^)'
M]V?_ ,%P_P#B:^A:*/K-/_GV@^HUO^?TOZ^9\]?\+'^)']V?_P %P_\ B:/^
M%C_$C^[/_P""X?\ Q-?0M%'UFG_S[0?4:W_/Z7]?,^>O^%C_ !(_NS_^"X?_
M !-'_"Q_B1_=G_\ !</_ (FOH6BCZS3_ .?:#ZC6_P"?TOZ^9\]?\+'^)']V
M?_P7#_XFC_A8_P 2/[L__@N'_P 37T+11]9I_P#/M!]1K?\ /Z7]?,^>O^%C
M_$C^[/\ ^"X?_$T?\+'^)']V?_P7#_XFOH6BCZS3_P"?:#ZC6_Y_2_KYGSU_
MPL?XD?W9_P#P7#_XFC_A8_Q(_NS_ /@N'_Q-?0M%'UFG_P ^T'U&M_S^E_7S
M/GK_ (6/\2/[L_\ X+A_\31_PL?XD?W9_P#P7#_XFOH6BCZS3_Y]H/J-;_G]
M+^OF?/7_  L?XD?W9_\ P7#_ .)H_P"%C_$C^[/_ ."X?_$U]"T4?6:?_/M!
M]1K?\_I?U\SYZ_X6/\2/[L__ (+A_P#$T?\ "Q_B1_=G_P#!</\ XFOH6BCZ
MS3_Y]H/J-;_G]+^OF?/7_"Q_B1_=G_\ !</_ (FC_A8_Q(_NS_\ @N'_ ,37
MT+11]9I_\^T'U&M_S^E_7S/GK_A8_P 2/[L__@N'_P 31_PL?XD?W9__  7#
M_P")KZ%HH^LT_P#GV@^HUO\ G]+^OF?/7_"Q_B1_=G_\%P_^)H_X6/\ $C^[
M/_X+A_\ $U]"T4?6:?\ S[0?4:W_ #^E_7S/GK_A8_Q(_NS_ /@N'_Q-'_"Q
M_B1_=G_\%P_^)KZ%HH^LT_\ GV@^HUO^?TOZ^9\]?\+'^)']V?\ \%P_^)H_
MX6/\2/[L_P#X+A_\37T+11]9I_\ /M!]1K?\_I?U\SYZ_P"%C_$C^[/_ ."X
M?_$T?\+'^)']V?\ \%P_^)KZ%HH^LT_^?:#ZC6_Y_2_KYGSU_P +'^)']V?_
M ,%P_P#B:/\ A8_Q(_NS_P#@N'_Q-?0M%'UFG_S[0?4:W_/Z7]?,^>O^%C_$
MC^[/_P""X?\ Q-'_  L?XD?W9_\ P7#_ .)KZ%HH^LT_^?:#ZC6_Y_2_KYGS
MU_PL?XD?W9__  7#_P")H_X6/\2/[L__ (+A_P#$U]"T4?6:?_/M!]1K?\_I
M?U\SYZ_X6/\ $C^[/_X+A_\ $T?\+'^)']V?_P %P_\ B:^A:*/K-/\ Y]H/
MJ-;_ )_2_KYGSU_PL?XD?W9__!</_B:/^%C_ !(_NS_^"X?_ !-?0M%'UFG_
M ,^T'U&M_P _I?U\SYZ_X6/\2/[L_P#X+A_\31_PL?XD?W9__!</_B:^A:*/
MK-/_ )]H/J-;_G]+^OF?/7_"Q_B1_=G_ /!</_B:/^%C_$C^[/\ ^"X?_$U]
M"T4?6:?_ #[0?4:W_/Z7]?,^>O\ A8_Q(_NS_P#@N'_Q-'_"Q_B1_=G_ /!<
M/_B:^A:*/K-/_GV@^HUO^?TOZ^9\]?\ "Q_B1_=G_P#!</\ XFC_ (6/\2/[
ML_\ X+A_\37T+11]9I_\^T'U&M_S^E_7S/GK_A8_Q(_NS_\ @N'_ ,31_P +
M'^)']V?_ ,%P_P#B:^A:*/K-/_GV@^HUO^?TOZ^9\]?\+'^)']V?_P %P_\
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M  7#_P")KZ%HH^LT_P#GV@^HUO\ G]+^OF?/7_"Q_B1_=G_\%P_^)H_X6/\
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M?\_I?U\SYZ_X6/\ $C^[/_X+A_\ $T?\+'^)']V?_P %P_\ B:^A:*/K-/\
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M?6:?_/M!]1K?\_I?U\SYZ_X6/\2/[L__ (+A_P#$T?\ "Q_B1_=G_P#!</\
MXFOH6BCZS3_Y]H/J-;_G]+^OF?/7_"Q_B1_=G_\ !</_ (FC_A8_Q(_NS_\
M@N'_ ,37T+11]9I_\^T'U&M_S^E_7S/GK_A8_P 2/[L__@N'_P 31_PL?XD?
MW9__  7#_P")KZ%HH^LT_P#GV@^HUO\ G]+^OF?/7_"Q_B1_=G_\%P_^)H_X
M6/\ $C^[/_X+A_\ $U]"T4?6:?\ S[0?4:W_ #^E_7S/GK_A8_Q(_NS_ /@N
M'_Q-'_"Q_B1_=G_\%P_^)KZ%HH^LT_\ GV@^HUO^?TOZ^9\]?\+'^)']V?\
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M_B:^A:*/K-/_ )]H/J-;_G]+^OF?/7_"Q_B1_=G_ /!</_B:/^%C_$C^[/\
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M9\]?\+'^)']V?_P7#_XFC_A8_P 2/[L__@N'_P 37T+11]9I_P#/M!]1K?\
M/Z7]?,^>O^%C_$C^[/\ ^"X?_$T?\+'^)']V?_P7#_XFOH6BCZS3_P"?:#ZC
M6_Y_2_KYGSU_PL?XD?W9_P#P7#_XFC_A8_Q(_NS_ /@N'_Q-?0M%'UFG_P ^
MT'U&M_S^E_7S/GK_ (6/\2/[L_\ X+A_\31_PL?XD?W9_P#P7#_XFOH6BCZS
M3_Y]H/J-;_G]+^OF?/7_  L?XD?W9_\ P7#_ .)KM_AAXJ\5Z]K5Y#XE$@@C
MMM\>^U$7S;@.N!GC->G45$Z\)1:4$C2EA*D)J3JM^7],****Y#T HHJ)Y"K$
M#% $M%0^<WH*/.;T% $U%0^<WH*/.;T% $U%0^<WH*/.;T% $U%0^<WH*/.;
MT% $U%0^<WH*/.;T% $U%0^<WH*/.;T% $U%0^<WH*/.;T% $U%0^<WH*/.;
MT% $U%0^<WH*/.;T% $U%0^<WH*/.;T% $U%0^<WH*/.;T% $U%0^<WH*/.;
MT% $U%0^<WH*/.;T% $U%0^<WH*/.;T% $U%0^<WH*/.;T% $U%0^<WH*/.;
MT% $U%0^<WH*/.;T% $U%0^<WH*/.;T% $U%0^<WH*/.;T% $U%0^<WH*/.;
MT% $U%0O,RP[@!G.*B^UOZ+^5 %NBJGVM_1?RH^UOZ+^5 %NBJGVM_1?RH^U
MOZ+^5 %NBJGVM_1?RH^UOZ+^5 %NBJGVM_1?RH^UOZ+^5 %NBJGVM_1?RH^U
MOZ+^5 %NBJGVM_1?RH^UOZ+^5 %NBJGVM_1?RH^UOZ+^5 %NBJGVM_1?RH^U
MOZ+^5 %NBJGVM_1?RH^UOZ+^5 %NBJGVM_1?RH^UOZ+^5 %NBJGVM_1?RH^U
MOZ+^5 %NBJGVM_1?RH^UOZ+^5 %NBJGVM_1?RH^UOZ+^5 %NBJGVM_1?RH^U
MOZ+^5 %NBJGVM_1?RH^UOZ+^5 %NBJGVM_1?RH^UOZ+^5 %NBJGVM_1?RH^U
MOZ+^5 %NBJGVM_1?RH^UOZ+^5 %NBJGVM_1?RH^UOZ+^5 %NBJGVM_1?RH^U
MOZ+^5 %NBJGVM_1?RH^UOZ+^5 %NBJGVM_1?RH^UOZ+^5 %NBJGVM_1?RJQ$
MY>(,>I]* 'T5$\I5B!BD\YO04 345#YS>@H\YO04 345#YS>@H\YO04 345#
MYS>@H\YO04 345#YS>@H\YO04 345#YS>@H\YO04 345#YS>@H\YO04 345#
MYS>@H\YO04 345#YS>@H\YO04 345#YS>@H\YO04 345#YS>@H\YO04 345#
MYS>@H\YO04 345#YS>@H\YO04 345#YS>@H\YO04 345#YS>@H\YO04 345#
MYS>@I))F6(, ,DXH GHJI]K?T7\J/M;^B_E0!;HJI]K?T7\J/M;^B_E0!;HJ
MI]K?T7\J/M;^B_E0!;HJI]K?T7\J/M;^B_E0!;HJI]K?T7\J/M;^B_E0!;HJ
MI]K?T7\J/M;^B_E0!;HJI]K?T7\J/M;^B_E0!;HJI]K?T7\J/M;^B_E0!;HJ
MI]K?T7\J/M;^B_E0!;HJI]K?T7\J/M;^B_E0!;HJI]K?T7\J/M;^B_E0!;HJ
MI]K?T7\J/M;^B_E0!;HJI]K?T7\J/M;^B_E0!;HJI]K?T7\J/M;^B_E0!;HJ
MI]K?T7\J/M;^B_E0!;HJI]K?T7\JF,K!5/'(S0!+14/G-Z"CSF]!0!-14/G-
MZ"CSF]!0!-14/G-Z"CSF]!0!-14/G-Z"CSF]!0!-14/G-Z"CSF]!0!-14/G-
MZ"CSF]!0!-14/G-Z"CSF]!0!-14/G-Z"CSF]!0!-14/G-Z"CSF]!0!-14/G-
MZ"CSF]!0!-14/G-Z"CSF]!0!-14/G-Z"CSF]!0!-14/G-Z"CSF]!0!-14/G-
MZ"CSF]!0!-14/G-Z"CSF]!0!-14(F;/04R6X=)"H P/6@"S153[6_HOY4?:W
M]%_*@"W153[6_HOY4?:W]%_*@"W153[6_HOY4?:W]%_*@"W153[6_HOY4?:W
M]%_*@"W153[6_HOY4?:W]%_*@"W153[6_HOY4?:W]%_*@"W153[6_HOY4?:W
M]%_*@"W153[6_HOY4?:W]%_*@"W153[6_HOY4?:W]%_*@"W153[6_HOY4?:W
M]%_*@"W153[6_HOY4?:W]%_*@"W153[6_HOY4?:W]%_*@"W153[6_HOY4?:W
M]%_*@"W153[6_HOY4?:W]%_*@"W153[6_HOY4?:W]%_*@"W15:*X=Y I"X-/
M,S9Z"@":BH?.;T%'G-Z"@":BH?.;T%'G-Z"@":BH?.;T%'G-Z"@":BH?.;T%
M'G-Z"@":BH?.;T%'G-Z"@":BH?.;T%'G-Z"@":BH?.;T%'G-Z"@":BH?.;T%
M'G-Z"@":BH?.;T%'G-Z"@":BH?.;T%'G-Z"@":BH?.;T%'G-Z"@":BH?.;T%
M'G-Z"@":BH?.;T%'G-Z"@":BH?.;T%'G-Z"@":BH?.;T%'G-Z"@":BH?.;T%
M'G-Z"@":BH?.;T%'G-Z"@":BH?.;T%'G-Z"@":BH?.;T%'G-Z"@":BH?.;T%
M'G-Z"@":BH?.;T%'G-Z"@":BH?.;T%'G-Z"@":BH?.;T%'G-Z"@":BH?.;T%
M'G-Z"@":BH?.;T%'G-Z"@":BH?.;T%'G-Z"@":BH?.;T%.CD+DYQ0!)1110
M5!+_ *PU/4$O^L- #**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC^U-/_Y_K;_O\O\ C7FU%']LU/Y$'UA]CTG^U-/_ .?ZV_[_ "_XT?VII_\
MS_6W_?Y?\:\VHH_MFI_(@^L/L>D_VII__/\ 6W_?Y?\ &K+:OINQ/^)A:_='
M_+9?\:\MHH_MFI_(@^L/L>H?VMIW_00M?^_R_P"-']K:=_T$+7_O\O\ C7E]
M%']LU/Y$'UA]CU#^UM._Z"%K_P!_E_QH_M;3O^@A:_\ ?Y?\:\OHH_MFI_(@
M^L/L>H?VMIW_ $$+7_O\O^-']K:=_P!!"U_[_+_C7E]%']LU/Y$'UA]CU#^U
MM._Z"%K_ -_E_P :/[6T[_H(6O\ W^7_ !KR^BC^V:G\B#ZP^QZA_:VG?]!"
MU_[_ "_XT?VMIW_00M?^_P O^->7T4?VS4_D0?6'V/4/[6T[_H(6O_?Y?\:M
M(ZR(KQL&5AE64Y!'K7DM>H:3_P @6R_Z]X__ $$5Z&!QTL5)IJUC6G4<V7**
M**]4W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH !U%1W'^O:I!U
M%1W'^O:@".BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** )(/]>M2'J:C@_UZU(>IH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ J2'[Q^E1U)#]X_2@":BBB@ J"7_ %AJ>H)?]8: &4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !)_Q[?\"JO5B3_CV_X%5>@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *O6__
M ![K^/\ .J-7K?\ X]U_'^= 'F_B[_D:;O\ X!_Z M8M;7B[_D:;O_@'_H"U
MBU\+BO\ >)^K_,\V?Q,**W] CLK>U>[U.&.6*:=;5-XR$SRS<],#'/6DTG3T
MM_&2V5U$LJ1O("LB@A@$8@X_(U4<-*2@[_$[>E]@4&[>9@T5LWNF)+XDC@M1
MMM[PK+$1@ (W)/L!S^5;4EM8SZVC06D*P2:69501C&<G!QZXQS50PDI-J^SL
M-0;.,HHK3\/007.NVT-U'YB.3\IZ9P<9]1FN:G!SFH+J0E=V,RBM[Q''%#%:
MQ2PV\.H+N,Z6R@*%/W<X[X_G6;I*+)K5DDBAT:XC#*PR"-PX-7.BX5?9W[%.
M-G8IT5N^);&-=6CDT^(+%<Y540  .K;&4#Z@?G6T+&P74M%BCMH'0?:(Y"8P
M?-*+C+<<\@FMXX.4IRC?9K\6E^MRE3;=CB**WK#58+Z]CM+[3++RKAA&6@A"
M.A)P""*LZ?I7D17Z6MM#?:A;W'E".<<",?QA3UR?\^LQPW/9P=U_702A?8YB
MBMC5Y$:UC2YTW[#?K(<^7#Y:.F/3US[?C6/7/4AR2M<EJS"BBBH)"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP7IT]OX?A>:Z"^'VC:U(=<OL4*-_R\\*.F*M>)/#5GXHL(+34))XXX+E+E3
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MU'6;O3HV#)IEQ>EK4$-N'R #(SV)[FI%^&FCVNB6>BQW5^;6QU!;^$M(A8.
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MSS:BO2?[+T__ )\;;_ORO^%']EZ?_P ^-M_WY7_"C^QJG\Z#ZN^YYM17I/\
M9>G_ //C;?\ ?E?\*/[+T_\ Y\;;_ORO^%']C5/YT'U=]SS:BO2?[+T__GQM
MO^_*_P"%']EZ?_SXVW_?E?\ "C^QJG\Z#ZN^YYM17I/]EZ?_ ,^-M_WY7_"C
M^R]/_P"?&V_[\K_A1_8U3^=!]7?<\VHKTG^R]/\ ^?&V_P"_*_X4?V7I_P#S
MXVW_ 'Y7_"C^QJG\Z#ZN^YYM17I/]EZ?_P ^-M_WY7_"C^R]/_Y\;;_ORO\
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M% !1110 4444 %%%% !1110!)!_KUJ0]34<'^O6I#U- !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,$,2[-L:#9]S"CY?I
MZ5%)86<VWS;2"3;G&Z,'&>:L44[L5D1FWA*X,,9&[=@J.OK]:#!"T:HT2%$X
M52HPO&./PJ2BD%D126T$T(BFACDC&,(R@@?A3?L-IY:1_98=D;;D7RQA3Z@=
MC4]%.["R&E%+[RJ[L8W8YQZ5&UK;N(P\$3"(YC!0'9]/2IJ*061&+>$7!G$2
M"9A@R!1N(],U)110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M *PTV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "B;_CW7_>HHF_X]U_WJ *]%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %6F^Y'_NBJM6F^Y'_NB@!M%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444  ZBH[C_7M4@ZBH[C_
M %[4 1T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!)!_KUJ0]34<'^O6I#U- !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/FV>@4445RG>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9<_M;4?^@A=?]_F_QH_M;4?^@A=?]_F_QJG11[6I_,_O#F9<_M;4?^@A=?\
M?YO\:/[6U'_H(77_ '^;_&J=%'M:G\S^\.9ES^UM1_Z"%U_W^;_&C^UM1_Z"
M%U_W^;_&J=%'M:G\S^\.9ES^UM1_Z"%U_P!_F_QH_M;4?^@A=?\ ?YO\:IT4
M>UJ?S/[PYF7/[6U'_H(77_?YO\:/[6U'_H(77_?YO\:IT4>UJ?S/[PYF7/[6
MU'_H(77_ '^;_&@ZMJ)&#J%T1_UV;_&J=%'M:G\S^\.9EO\ M34/^?ZY_P"_
MS?XT?VIJ'_/]<_\ ?YO\:J44>UJ?S/[PYF6_[4U#_G^N?^_S?XT?VIJ'_/\
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M_:FH?\_US_W^;_&JE%'M:G\S^\.9EO\ M34/^?ZY_P"_S?XT?VIJ'_/]<_\
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MPOT4]"6^A(%<L)*=9T5O^:[FTJT81YI:'7T5P']B_$6UVWD7B.SNYR07LY8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M INBEPD,4);HI=L_-P>/;ZXG\*>,_P#A(KV^TZ^TR?2=4L-IGM)F#_*PX(8
M9_+N/6N9TZZUCQ7XQ\20:%JEGX=AL;G[/-]GLHY;BZ*[EWNS>X.#VZ>YI_#U
MHU^+>O16^LRZR@LE#WDK!C(P* X(XP,D#'%2Z<>5]TO/_ABU5GSIWT;:Z?\
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MPHHHH **** )(/\ 7K4AZFHX/]>M2'J: "BBB@ HHHH **** "BBB@ HHHH
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M#'U.*BDFDFV^;([[%"+N8G:HZ >U,HIN4FK-A=A1114B"BBB@ HHHH ****
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M6+'EB3U)[U=HHN[6'97N4]5TNSUO2YM.U*(RVLX D02,FX @XRI!ZCUKE_\
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M !H VZ*Q-^O_ //./\U_QHWZ_P#\\X_S7_&@#;HK$WZ__P \X_S7_&C?K_\
MSSC_ #7_ !H VZ*Q-^O_ //./\U_QHWZ_P#\\X_S7_&@#;HK$WZ__P \X_S7
M_&C?K_\ SSC_ #7_ !H VZ*Q-^O_ //./\U_QHWZ_P#\\X_S7_&@#;D_X]O^
M!57K,=]?\KYHX]N?5>OYU%OUO_GFGYK_ (T ;%%8^_6_^>:?FO\ C1OUO_GF
MGYK_ (T ;%%8^_6_^>:?FO\ C1OUO_GFGYK_ (T ;%%8^_6_^>:?FO\ C1OU
MO_GFGYK_ (T ;%%8^_6_^>:?FO\ C1OUO_GFGYK_ (T ;%%8^_6_^>:?FO\
MC1OUO_GFGYK_ (T ;%%8^_6_^>:?FO\ C1OUO_GFGYK_ (T ;%%8^_6_^>:?
MFO\ C1OUO_GFGYK_ (T ;%%8^_6_^>:?FO\ C1OUO_GFGYK_ (T ;%%8^_6_
M^>:?FO\ C1OUO_GFGYK_ (T ;%%8^_6_^>:?FO\ C1OUO_GFGYK_ (T ;%%8
M^_6_^>:?FO\ C1OUO_GFGYK_ (T ;%%8^_6_^>:?FO\ C1OUO_GFGYK_ (T
M;%%8^_6_^>:?FO\ C1OUO_GFGYK_ (T ;%%8^_6_^>:?FO\ C1OUO_GFGYK_
M (T ;%%8^_6_^>:?FO\ C1OUO_GFGYK_ (T ;%%8^_6_^>:?FO\ C1OUO_GF
MGYK_ (T ;%%8^_6_^>:?FO\ C1OUO_GFGYK_ (T ;%%8^_6_^>:?FO\ C1OU
MO_GFGYK_ (T ;%%8^_6_^>:?FO\ C1OUO_GFGYK_ (T ;%%8^_6_^>:?FO\
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MQ!_PA.G?\]KK_OM?_B:/^$)T[_GM=?\ ?:__ !-3[]?_ .><?YK_ (T;]?\
M^><?YK_C1]1PW\B#V<.Q!_PA.G?\]KK_ +[7_P")I)/!6G+$&$UUDG'WU_\
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M #S3\U_QH^HX;^1![.'8@_X0[3_^>US_ -]+_P#$T?\ "':?_P ]KG_OI?\
MXFI]^M_\\T_-?\:-^M_\\T_-?\:/J.&_D0>SAV(/^$.T_P#Y[7/_ 'TO_P 3
M1_PAVG_\]KG_ +Z7_P")J??K?_/-/S7_ !HWZW_SS3\U_P :/J.&_D0>SAV(
M/^$.T_\ Y[7/_?2__$T?\(=I_P#SVN?^^E_^)J??K?\ SS3\U_QHWZW_ ,\T
M_-?\:/J.&_D0>SAV(/\ A#M/_P">US_WTO\ \31_PAVG_P#/:Y_[Z7_XFI]^
MM_\ /-/S7_&C?K?_ #S3\U_QH^HX;^1![.'8@_X0[3_^>US_ -]+_P#$T?\
M"':?_P ]KG_OI?\ XFI]^M_\\T_-?\:-^M_\\T_-?\:/J.&_D0>SAV(/^$.T
M_P#Y[7/_ 'TO_P 31_PAVG_\]KG_ +Z7_P")J??K?_/-/S7_ !HWZW_SS3\U
M_P :/J.&_D0>SAV(/^$.T_\ Y[7/_?2__$T?\(=I_P#SVN?^^E_^)J??K?\
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M_&CZCAOY$'LX=B#_ (0G3O\ GM=?]]K_ /$T?\(3IW_/:Z_[[7_XFI]^O_\
M/./\U_QHWZ__ ,\X_P U_P :/J.&_D0>SAV(/^$)T[_GM=?]]K_\31_PA.G?
M\]KK_OM?_B:GWZ__ ,\X_P U_P :-^O_ //./\U_QH^HX;^1![.'8@_X0G3O
M^>UU_P!]K_\ $T?\(3IW_/:Z_P"^U_\ B:GWZ_\ \\X_S7_&C?K_ /SSC_-?
M\:/J.&_D0>SAV(/^$)T[_GM=?]]K_P#$T?\ "$Z=_P ]KK_OM?\ XFI]^O\
M_/./\U_QHWZ__P \X_S7_&CZCAOY$'LX=B#_ (0G3O\ GM=?]]K_ /$UO6\"
MVUK%!&25B0(I;J0!BLC?K_\ SSC_ #7_ !HWZ_\ \\X_S7_&M:6'I47>G&Q4
M8QCLC;HK$WZ__P \X_S7_&C?K_\ SSC_ #7_ !K<HVZ*Q-^O_P#/./\ -?\
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M7_&C?K?_ #S3\U_QH V**Q]^M_\ /-/S7_&C?K?_ #S3\U_QH V**Q]^M_\
M/-/S7_&C?K?_ #S3\U_QH V**Q]^M_\ /-/S7_&C?K?_ #S3\U_QH W(/]>M
M2'J:P8WUWS!LC3=VY7_&GE]?S_JX_P U_P : -NBL3?K_P#SSC_-?\:-^O\
M_/./\U_QH VZ*Q-^O_\ /./\U_QHWZ__ ,\X_P U_P : -NBL3?K_P#SSC_-
M?\:-^O\ _/./\U_QH VZ*Q-^O_\ /./\U_QHWZ__ ,\X_P U_P : -NBL3?K
M_P#SSC_-?\:-^O\ _/./\U_QH VZ*Q-^O_\ /./\U_QHWZ__ ,\X_P U_P :
M -NBL3?K_P#SSC_-?\:-^O\ _/./\U_QH VZ*Q-^O_\ /./\U_QHWZ__ ,\X
M_P U_P : -NBL3?K_P#SSC_-?\:-^O\ _/./\U_QH VZ*Q-^O_\ /./\U_QH
MWZ__ ,\X_P U_P : -NBL3?K_P#SSC_-?\:-^O\ _/./\U_QH VZ*Q-^O_\
M/./\U_QHWZ__ ,\X_P U_P : -NBL3?K_P#SSC_-?\:-^O\ _/./\U_QH VZ
M*Q-^O_\ /./\U_QHWZ__ ,\X_P U_P : -NBL3?K_P#SSC_-?\:-^O\ _/./
M\U_QH VZ*Q-^O_\ /./\U_QHWZ__ ,\X_P U_P : -NBL3?K_P#SSC_-?\:-
M^O\ _/./\U_QH VZ*Q-^O_\ /./\U_QHWZ__ ,\X_P U_P : -NBL3?K_P#S
MSC_-?\:-^O\ _/./\U_QH VZ*Q-^O_\ /./\U_QHWZ__ ,\X_P U_P : -NB
ML3?K_P#SSC_-?\:-^O\ _/./\U_QH VZ*Q-^O_\ /./\U_QHWZ__ ,\X_P U
M_P : -NBL3?K_P#SSC_-?\:-^O\ _/./\U_QH VZ*Q-^O_\ /./\U_QHWZ__
M ,\X_P U_P : -NBL3?K_P#SSC_-?\:-^O\ _/./\U_QH VZ*Q-^O_\ /./\
MU_QHWZ__ ,\X_P U_P : -NI(?O'Z5@;]?\ ^><?YK_C5_26U(SO_:"*J;?E
MQCKGVH UJ*** "H)?]8:GJ"7_6&@!E%%<9\3_%]_X*\,V^HZ5#;332WBP,MR
MK,H4H[9^5@<Y4=ZJ,7)V1$YJ$7)[([.BO+(_$7QAEB22/PKHY1U#*?-7D'_M
MO6KX@\;ZQHOC/PQHOV:T"ZJ(Q=[U8M&Q8!@A#8]>N:OV3O9-&7UB-KM-?([Z
MBN4^(_BB]\(>$6U338K>6<3I'MN%9EP<YX!!_6LKQMX\U/PW\.](UZQ@M)+J
M^>%9$F1B@WQ,YP P/51W/%*-.4K6ZE2K0@VGTU/0**\CN_&WQ3TO3CJ>H^%=
M--BB>9(\)+$)C.[Y96(&!G)'%>@^$O%%GXO\.PZK8*T:N2DD3]8G'5<]^O7N
M".G2B5.45<(5HS?+L_/0VZ*Q_%7B.U\)^&[K5[U3(D  6)6 :1R<*HS[GGT
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MOJ9NO%7=G9=3TBBN-O\ Q#?+\4/#^F6ER1IM]92SR1&(?.0I*G)&X=N.*O\
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M9 P!QQ2J-)<OH.C%R:G;JSC/#>K:E=Z'*W@?PO9V>C32RNEUJ=\Q\X[L,[*
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MW4=5U"-#'%<:C<>:T2D8(7  '?MW/K5_2?#EIHVJZKJ%K).\NJ2K+,LC JI
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M'4I-0\;:I;;Q93V=O:Z6K"*'S4*.^7Y)*GH1UQZ5'-=+6RL:<C4G>-W>]_\
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M7_XFC_A#M/\ ^>US_P!]+_\ $T?V5B>R^\/83.*HKM?^$.T__GM<_P#?2_\
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M9/S%:V!Z48'I0!D_\)##_P \9/S%'_"0P_\ /&3\Q6M@>E&!Z4 9/_"0P_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M HHHH **** "BBB@ JTWW(_]T55JTWW(_P#=% #:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH !
MU%1W'^O:I!U%1W'^O:@".BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** )(/]>M2'J:C@_P!>M2'J
M: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"BQQQJ%1$& H'  '84^L3I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH ****  =14=Q_KVJ0=14=Q_KVH CHHHH **** "BBB@ HHHH ****
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M< @#-4=,OO[.U!+KR_,V!AMW8SE2.OXU4HINM-M/MMH@YF%;":\4N=-E%O\
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M0 4444 %%%% !1110 4444 %%%% !1110!)!_KUJ0]34<'^O6I#U- !1110
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M#_$&E74_BK7_ .S+B.;9%']LAAW+M!SAP2><\BNH^&TW]D?%R\T'PUJLVJ:
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MC_SW'_?)_P * +M%4O[7L?\ GN/^^3_A1_:]C_SW'_?)_P * +M%4O[7L?\
MGN/^^3_A1_:]C_SW'_?)_P * +M%4O[7L?\ GN/^^3_A1_:]C_SW'_?)_P *
M +M%4O[7L?\ GN/^^3_A1_:]C_SW'_?)_P * +M%4O[7L?\ GN/^^3_A1_:]
MC_SW'_?)_P * +M%4O[7L?\ GN/^^3_A1_:]C_SW'_?)_P * +M%4O[7L?\
MGN/^^3_A1_:]C_SW'_?)_P * +M%4O[7L?\ GN/^^3_A1_:]C_SW'_?)_P *
M +M%4O[7L?\ GN/^^3_A1_:]C_SW'_?)_P * +M%4O[7L?\ GN/^^3_A1_:]
MC_SW'_?)_P * +M%4O[7L?\ GN/^^3_A1_:]C_SW'_?)_P * +M%4O[7L?\
MGN/^^3_A1_:]C_SW'_?)_P * +M%4O[7L?\ GN/^^3_A1_:]C_SW'_?)_P *
M +M%4O[7L?\ GN/^^3_A1_:]C_SW'_?)_P * +M%4O[7L?\ GN/^^3_A1_:]
MC_SW'_?)_P * +M%4O[7L?\ GN/^^3_A1_:]C_SW'_?)_P * +M%4O[7L?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^_92QW(5&3RQR3Z^M;GQ-_Y)GKG_ %[?^S"NF@@BMH$AMHDAB082.-0JJ/0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5ZW_ ./=?Q_G5&KUO_Q[K^/\Z /-_%W_ "--W_P#_P! 6L6MKQ=_R--W_P
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M:QIFIR2QZ;J-I=O"<2+!.LA0^X!XKSS5]1T_Q!X9\-:#X:A72K/Q)<.)8H8
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MZ&Y#;3#)=QJX.<8VDYSFM2O'M&L?"WAS24T/Q_X66RNBQ1]4N(!-#<L?XEN
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MT3C>W5(Q<9VOLFV]G^2,?2?B)/:^$/%4J7W]K_V*R"SOI$P9EF)6/>.Y5NO
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MF->3ED5AU,:=$!)SCG' KF/$_ASQ-JWPWM+"[D75-9^TQ33E/+B4 ') ^Z,
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MI$:57=Q%&Q98%8Y$88\D+Z__ *ZZ.BI<VX\I<:2C+FN%%%%9FH4444 %%%%
M!1110 5)#]X_2HZDA^\?I0!-1110 5!+_K#4]02_ZPT ,HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "3_CV_P"!57JQ)_Q[?\"JO0 4444
M9^M:-;Z]8"ROGE%L9%>6.-MHF"G.QN/NGN!C/K5]5"*%0!548  P *6BG=VL
M*RO<****0PHHHH **** "BBB@ HHHH **** "BBB@"O?6-MJ=A-97\*SVTZ%
M)(VZ,#7))\+M)\F.TNM3UF[TZ+&S3I[TF  $$#: "0,<<UVM%5&<H[,B5.$]
M9(15"*%0!548  P *6BBI+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *O6_P#Q[K^/\ZHU>M_^/=?Q_G0!YOXN_P"1IN_^
M ?\ H"UBUM>+O^1IN_\ @'_H"UBU\+BO]XGZO\SS9_$PHHHKG("BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKN?!W_(O2_\ 7TW_ * M<-7<^#O^1>E_Z^F_] 6O4RK_ 'E>C-Z'QFW1117U
MQW!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %6F^Y'_ +HJK5ION1_[HH ;1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M.HJ.X_U[5(.HJ.X_U[4 1T444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!)!_KUJ0]34<'^O6I#U-
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^>DWYC_"@#2\Z/\ YZ+_ -]"CSH_^>B_]]"LW_A'[7_GI-^8_P */^$?M?\
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MOG1?\]$_[Z%'G1?\]$_[Z%97_"-6G_/6;\Q_A1_PC5I_SUF_,?X4 :OG1?\
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M\])OS'^% &EYT?\ ST7_ +Z%'G1_\]%_[Z%9O_"/VO\ STF_,?X4?\(_:_\
M/2;\Q_A0!I>='_ST7_OH4>='_P ]%_[Z%9O_  C]K_STF_,?X4?\(_:_\])O
MS'^% &EYT?\ ST7_ +Z%'G1_\]%_[Z%9O_"/VO\ STF_,?X4?\(_:_\ /2;\
MQ_A0!I>='_ST7_OH4>='_P ]%_[Z%9O_  C]K_STF_,?X4?\(_:_\])OS'^%
M &EYT?\ ST7_ +Z%'G1_\]%_[Z%9O_"/VO\ STF_,?X4?\(_:_\ /2;\Q_A0
M!I>='_ST7_OH4>='_P ]%_[Z%9O_  C]K_STF_,?X4?\(_:_\])OS'^% &EY
MT?\ ST7_ +Z%'G1_\]%_[Z%9O_"/VO\ STF_,?X4?\(_:_\ /2;\Q_A0!I>=
M'_ST7_OH4>='_P ]%_[Z%9O_  C]K_STF_,?X4?\(_:_\])OS'^% &EYT?\
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M=%_ST3_OH5E?\(U:?\]9OS'^%'_"-6G_ #UF_,?X4 :OG1?\]$_[Z%'G1?\
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M5I_SUF_,?X4 :OG1?\]$_P"^A1YT7_/1/^^A65_PC5I_SUF_,?X4?\(U:?\
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MYT?_ #T7_OH4>='_ ,]%_P"^A6;_ ,(_:_\ /2;\Q_A1_P (_:_\])OS'^%
M&EYT?_/1?^^A1YT?_/1?^^A6;_PC]K_STF_,?X4?\(_:_P#/2;\Q_A0!I>='
M_P ]%_[Z%'G1_P#/1?\ OH5F_P#"/VO_ #TF_,?X4?\ "/VO_/2;\Q_A0!I>
M='_ST7_OH4>='_ST7_OH5F_\(_:_\])OS'^%'_"/VO\ STF_,?X4 :7G1_\
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M (%5>K$G_'M_P*J] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5>M_^/=?Q_G5&KUO_ ,>Z_C_.@#*O]?TVROI+>YN=DJ8W
M+Y;'&0#V'O5?_A*=&_Y_/_(3_P"%<IXN_P"1IN_^ ?\ H"UBU\W6S6O3JR@D
MM&UU_P SDE7DI-'HO_"4Z-_S^?\ D)_\*/\ A*=&_P"?S_R$_P#A7G5%9?VQ
MB.R_'_,GZQ(]%_X2G1O^?S_R$_\ A1_PE.C?\_G_ )"?_"O.J*/[8Q'9?C_F
M'UB1Z+_PE.C?\_G_ )"?_"C_ (2G1O\ G\_\A/\ X5YU11_;&([+\?\ ,/K$
MCT7_ (2G1O\ G\_\A/\ X4?\)3HW_/Y_Y"?_  KSJBC^V,1V7X_YA]8D>B_\
M)3HW_/Y_Y"?_  H_X2G1O^?S_P A/_A7G5%']L8CLOQ_S#ZQ(]%_X2G1O^?S
M_P A/_A1_P )3HW_ #^?^0G_ ,*\ZHH_MC$=E^/^8?6)'HO_  E.C?\ /Y_Y
M"?\ PH_X2G1O^?S_ ,A/_A7G5%']L8CLOQ_S#ZQ(]%_X2G1O^?S_ ,A/_A1_
MPE.C?\_G_D)_\*\ZHH_MC$=E^/\ F'UB1Z+_ ,)3HW_/Y_Y"?_"C_A*=&_Y_
M/_(3_P"%>=44?VQB.R_'_,/K$CT7_A*=&_Y_/_(3_P"%'_"4Z-_S^?\ D)_\
M*\ZHH_MC$=E^/^8?6)'HO_"4Z-_S^?\ D)_\*/\ A*=&_P"?S_R$_P#A7G5%
M']L8CLOQ_P P^L2/1?\ A*=&_P"?S_R$_P#A1_PE.C?\_G_D)_\ "O.J*/[8
MQ'9?C_F'UB1Z+_PE.C?\_G_D)_\ "C_A*=&_Y_/_ "$_^%>=44?VQB.R_'_,
M/K$CT7_A*=&_Y_/_ "$_^%'_  E.C?\ /Y_Y"?\ PKSJBC^V,1V7X_YA]8D>
MB_\ "4Z-_P _G_D)_P#"KUOJ%MJ-CYME)YB+(5)VD<XSW'N*\LKN?!W_ "+T
MO_7TW_H"UVX+,:N(K<DTK?/_ #-*=64I69MT445[ATA1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %6F
M^Y'_ +HJK5ION1_[HH ;1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%%  .HJ.X_U[5(.HJ.X_U[4
M1T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!)!_KUJ0]34<'^O6I#U- !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJO5B3_CV_P"!57H CGFCMK>2>9ML<2%W;&< #)-<?_PMWP/_ -!O_P E)_\
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MJ)J7]:I_H#FV;\^N6ESJ5]Y\4QL;U8PVW D4HHP1SCJ#1!KEEIDUNNEVKF-
MPFEE $L@;L".F.U8%%/ZU5OS=>_SO^8^=[F]>:S;-830V]QJ=P\N #=W!VH.
M_"GYOQJ'4-3L[[7(KJ2"22V"*KQL=K' P>AK'HJ98F<M'Y?A_P .)S;-^YUJ
MU&E7%I;27UR;C:/],8%8P#G(P3S^58%%%14JRJ-.703DWN%=SX._Y%Z7_KZ;
M_P! 6N&KN?!W_(O2_P#7TW_H"UWY5_O*]&:T/C-NBBBOKCN"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *M-]R/_=%5:M-]R/\ W10 VBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  =14=Q_KVJ0=14=Q
M_KVH CHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"2#_7K4AZFHX/\ 7K4AZF@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.>%+FWD@F&Z.5"CC.,@C!J2
MB@"EI&D6>A:7%I^FQF*VASL0L6QDDGD\]31J]EIVH:9+!K,4,MH>7$^ H]\]
MC[U=IDL4<\;1S(LB-U5QD'\*KF=[D\JY>5+0X[2? '@FWODN;&V@N9%;Y%>X
M,J@CG[I)'O71ZD^CWEDUIJLMG);S @QS.N&P<=SV/Y&N=M/"M[#8Z!#"?[/D
MM&E:YEMO+W#*D#J"#G..E9P\,:S:RV#_ &26Z\FWECD,<D&XEIRX)\Q2.0<\
M 5T/WW=S.*+=.-HT[7[+T_S+MM\.? T6I[8[6&6=3D6[W3.!W^X6_G70SZ)H
M]QJ]KJ$D:"ZTM"L6V3:(5([J#C&/6L!?#&H#Q#_:$D<;VYU1KDQ($$@78 K!
M^N,C!7(R/R,</AS78IKN]D^SR3:K!-'=PIPR%E)CRQ;#;>$X X)-$FY:N812
MCHJ77M]S-_6+70?$&G1C4YX)K6"=9%=;C:JR#..0?<\59NH-+UB$><T-PJJ6
M5TD&0,X)R#TR/TKDI_!=[;:+;O!_I-[OMC+%"D4058U;IN!5FRQY;.:M-INL
MP1B:UTOS'N+!K*2*2>)&B;>Q#DJ I!W'.T9]J225N60W)RNIT]]]+FLNF^&Q
MXE.JL;1]5D545WF#,/EP-JD\$CN!DU*+'1+/7FUQI88KV]B$(E>? D48P%!.
M#T'2J=KX:^S:M83-;P2+;:9]G:;:,F4% #Z]%/-9MGH.H:<EJ9]&M]5W:=;V
MK)+*@^S,@.X?,""I)!RO.1T/%+1_:*U7V.M_^";TND:)<>*HM2)C&KV\>W,<
MY5RG^TH/(Y[BK.D:)8Z%;S0:9$8HYIFG<%RV7;&3S]*Q;/1[^U\9/=06:Q6<
MDLDLTDDD<@8LN 4^4.K$@9!.W&:ZJHFVK*]S6FDVY.-G=F9#X>TRW\0S:W!;
M"._GC\N256(W#CJ.F>!SUK3HHK-MO<U45'9!1112*"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *DA^\?I4=20_>/TH FHHHH *@E_UAJ>H)?\
M6&@!E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 2?\>W_ JK
MU8D_X]O^!57H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#J*CN/\ 7M0!'1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% $D'^O6I#U-1P?Z]:D/4T %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5)#]X_2HZDA^\?I0!-1110 'D'M6)J.GWT]^\D%ZT49QA Q&
M./:MNH)?]8: ,'^R=2_Z"3_]]M1_9.I?]!)_^^VK;HH Q/[)U+_H)/\ ]]M1
M_9.I?]!)_P#OMJVZ* ,3^R=2_P"@D_\ WVU']DZE_P!!)_\ OMJVZ* ,3^R=
M2_Z"3_\ ?;4?V3J7_02?_OMJVZ* ,3^R=2_Z"3_]]M1_9.I?]!)_^^VK;HH
MQ/[)U+_H)/\ ]]M1_9.I?]!)_P#OMJVZ* ,3^R=2_P"@D_\ WVU']DZE_P!!
M)_\ OMJVZ* ,3^R=2_Z"3_\ ?;4?V3J7_02?_OMJVZ* ,3^R=2_Z"3_]]M1_
M9.I?]!)_^^VK;HH Q/[)U+_H)/\ ]]M1_9.I?]!)_P#OMJVZ* ,3^R=2_P"@
MD_\ WVU']DZE_P!!)_\ OMJVZ* ,3^R=2_Z"3_\ ?;4?V3J7_02?_OMJVZ*
M,3^R=2_Z"3_]]M1_9.I?]!)_^^VK;HH Q/[)U+_H)/\ ]]M1_9.I?]!)_P#O
MMJVZ* ,3^R=2_P"@D_\ WVU']DZE_P!!)_\ OMJVZ* ,3^R=2_Z"3_\ ?;4?
MV3J7_02?_OMJVZ* ,3^R=2_Z"3_]]M1_9.I?]!)_^^VK;HH Q/[)U+_H)/\
M]]M1_9.I?]!)_P#OMJVZ* ,3^R=2_P"@D_\ WVU']DZE_P!!)_\ OMJVZ* ,
M3^R=2_Z"3_\ ?;4?V3J7_02?_OMJVZ* ,1M)U,19.I.1GIO:HO[,U#_H(-_W
MTU=!)_Q[?\"JO0!C_P!F:A_T$&_[Z:C^S-0_Z"#?]]-6Q10!C_V9J'_00;_O
MIJ/[,U#_ *"#?]]-6Q10!C_V9J'_ $$&_P"^FH_LS4/^@@W_ 'TU;%% &/\
MV9J'_00;_OIJ/[,U#_H(-_WTU;%% &/_ &9J'_00;_OIJ/[,U#_H(-_WTU;%
M% &/_9FH?]!!O^^FH_LS4/\ H(-_WTU;%% &/_9FH?\ 00;_ +Z:C^S-0_Z"
M#?\ ?35L44 8_P#9FH?]!!O^^FH_LS4/^@@W_?35L44 8_\ 9FH?]!!O^^FH
M_LS4/^@@W_?35L44 8_]F:A_T$&_[Z:C^S-0_P"@@W_?35L44 8_]F:A_P!!
M!O\ OIJ/[,U#_H(-_P!]-6Q10!C_ -F:A_T$&_[Z:C^S-0_Z"#?]]-6Q10!C
M_P!F:A_T$&_[Z:C^S-0_Z"#?]]-6Q10!C_V9J'_00;_OIJ/[,U#_ *"#?]]-
M6Q10!C_V9J'_ $$&_P"^FH_LS4/^@@W_ 'TU;%% &/\ V9J'_00;_OIJ/[,U
M#_H(-_WTU;%% &/_ &9J'_00;_OIJ/[,U#_H(-_WTU;%% &/_9FH?]!!O^^F
MH_LS4/\ H(-_WTU;%% &/_9FH?\ 00;_ +Z:C^S-0_Z"#?\ ?35L44 8_P#9
MFH?]!!O^^FH_LS4/^@@W_?35L44 8_\ 9FH?]!!O^^FH_LS4/^@@W_?35L44
M 8_]F:A_T$&_[Z:C^S-0_P"@@W_?35L44 8_]F:A_P!!!O\ OIJZ#3(I(=.B
MCFD,CC.6)SGDU7J];_\ 'NOX_P Z ,?4=.OI[^22"^:*-L80,1C@56_LG4O^
M@D__ 'VU:MUJ-E!<M'/>6\;KC*O*H(X]":A_M;3O^@A:_P#?Y?\ &LW4@G9M
M"NBA_9.I?]!)_P#OMJ/[)U+_ *"3_P#?;5?_ +6T[_H(6O\ W^7_ !H_M;3O
M^@A:_P#?Y?\ &CVM/^9?>',BA_9.I?\ 02?_ +[:C^R=2_Z"3_\ ?;5?_M;3
MO^@A:_\ ?Y?\:/[6T[_H(6O_ '^7_&CVM/\ F7WAS(H?V3J7_02?_OMJ/[)U
M+_H)/_WVU7_[6T[_ *"%K_W^7_&C^UM._P"@A:_]_E_QH]K3_F7WAS(H?V3J
M7_02?_OMJ/[)U+_H)/\ ]]M5_P#M;3O^@A:_]_E_QH_M;3O^@A:_]_E_QH]K
M3_F7WAS(H?V3J7_02?\ [[:C^R=2_P"@D_\ WVU7_P"UM._Z"%K_ -_E_P :
M/[6T[_H(6O\ W^7_ !H]K3_F7WAS(H?V3J7_ $$G_P"^VH_LG4O^@D__ 'VU
M7_[6T[_H(6O_ '^7_&C^UM._Z"%K_P!_E_QH]K3_ )E]X<R*']DZE_T$G_[[
M:C^R=2_Z"3_]]M5_^UM._P"@A:_]_E_QH_M;3O\ H(6O_?Y?\:/:T_YE]X<R
M*']DZE_T$G_[[:C^R=2_Z"3_ /?;5?\ [6T[_H(6O_?Y?\:/[6T[_H(6O_?Y
M?\:/:T_YE]X<R*']DZE_T$G_ .^VH_LG4O\ H)/_ -]M5_\ M;3O^@A:_P#?
MY?\ &C^UM._Z"%K_ -_E_P :/:T_YE]X<R*']DZE_P!!)_\ OMJ/[)U+_H)/
M_P!]M5_^UM._Z"%K_P!_E_QH_M;3O^@A:_\ ?Y?\:/:T_P"9?>',BA_9.I?]
M!)_^^VH_LG4O^@D__?;5?_M;3O\ H(6O_?Y?\:/[6T[_ *"%K_W^7_&CVM/^
M9?>',BA_9.I?]!)_^^VH_LG4O^@D_P#WVU7_ .UM._Z"%K_W^7_&C^UM._Z"
M%K_W^7_&CVM/^9?>',BA_9.I?]!)_P#OMJ/[)U+_ *"3_P#?;5?_ +6T[_H(
M6O\ W^7_ !H_M;3O^@A:_P#?Y?\ &CVM/^9?>',BA_9.I?\ 02?_ +[:C^R=
M2_Z"3_\ ?;5?_M;3O^@A:_\ ?Y?\:/[6T[_H(6O_ '^7_&CVM/\ F7WAS(H?
MV3J7_02?_OMJ1])U(1@G4G(STWM6A_:VG?\ 00M?^_R_XU.+F"YM ]M-',H?
M!:-@P!QTXIJI"3LF%TS$_LS4/^@@W_?34?V9J'_00;_OIJV**L9C_P!F:A_T
M$&_[Z:C^S-0_Z"#?]]-6Q10!C_V9J'_00;_OIJ/[,U#_ *"#?]]-6Q10!C_V
M9J'_ $$&_P"^FH_LS4/^@@W_ 'TU;%% &/\ V9J'_00;_OIJ/[,U#_H(-_WT
MU;%% &/_ &9J'_00;_OIJ/[,U#_H(-_WTU;%% &/_9FH?]!!O^^FH_LS4/\
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MU+_H)/\ ]]M6W10!B?V3J7_02?\ [[:C^R=2_P"@D_\ WVU;=% &)_9.I?\
M02?_ +[:C^R=2_Z"3_\ ?;5MT4 8G]DZE_T$G_[[:C^R=2_Z"3_]]M6W10!B
M?V3J7_02?_OMJ/[)U+_H)/\ ]]M6W10!B?V3J7_02?\ [[:C^R=2_P"@D_\
MWVU;=% &)_9.I?\ 02?_ +[:C^R=2_Z"3_\ ?;5MT4 8G]DZE_T$G_[[:C^R
M=2_Z"3_]]M6W10!B?V3J7_02?_OMJ/[)U+_H)/\ ]]M6W10!B?V3J7_02?\
M[[:C^R=2_P"@D_\ WVU;=% &)_9.I?\ 02?_ +[:C^R=2_Z"3_\ ?;5MT4 8
M@TC4\_\ (3?_ +[:F2:5J2R$-J+D^N]JWAU%1W'^O:@##_LS4/\ H(-_WTU'
M]F:A_P!!!O\ OIJV** ,?^S-0_Z"#?\ ?34?V9J'_00;_OIJV** ,?\ LS4/
M^@@W_?34?V9J'_00;_OIJV** ,?^S-0_Z"#?]]-1_9FH?]!!O^^FK8HH Q_[
M,U#_ *"#?]]-1_9FH?\ 00;_ +Z:MBB@#'_LS4/^@@W_ 'TU']F:A_T$&_[Z
M:MBB@#'_ +,U#_H(-_WTU']F:A_T$&_[Z:MBB@#'_LS4/^@@W_?34?V9J'_0
M0;_OIJV** ,?^S-0_P"@@W_?34?V9J'_ $$&_P"^FK8HH Q_[,U#_H(-_P!]
M-1_9FH?]!!O^^FK8HH Q_P"S-0_Z"#?]]-1_9FH?]!!O^^FK8HH Q_[,U#_H
M(-_WTU']F:A_T$&_[Z:MBB@#'_LS4/\ H(-_WTU']F:A_P!!!O\ OIJV** ,
M?^S-0_Z"#?\ ?34?V9J'_00;_OIJV** ,?\ LS4/^@@W_?34?V9J'_00;_OI
MJV** ,F/2M1:0!=1<'UWM3SI&IY_Y";_ /?;5KP?Z]:D/4T 8G]DZE_T$G_[
M[:C^R=2_Z"3_ /?;5MT4 8G]DZE_T$G_ .^VH_LG4O\ H)/_ -]M6W10!B?V
M3J7_ $$G_P"^VH_LG4O^@D__ 'VU;=% &)_9.I?]!)_^^VH_LG4O^@D__?;5
MMT4 8G]DZE_T$G_[[:C^R=2_Z"3_ /?;5MT4 8G]DZE_T$G_ .^VH_LG4O\
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MJ7_02?\ [[:C^R=2_P"@D_\ WVU;=%(9B?V3J7_02?\ [[:C^R=2_P"@D_\
MWVU;=% &)_9.I?\ 02?_ +[:C^R=2_Z"3_\ ?;5MT4 8G]DZE_T$G_[[:C^R
M=2_Z"3_]]M6W10!B?V3J7_02?_OMJ/[)U+_H)/\ ]]M6W10!B?V3J7_02?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5>M_\
MCW7\?YU1J];_ /'NOX_SH \W\7?\C3=_\ _] 6L6MKQ=_P C3=_\ _\ 0%K%
MKX7%?[Q/U?YGFS^)A1117.0%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7<^#O\ D7I?^OIO_0%KAJ[GP=_R
M+TO_ %]-_P"@+7J95_O*]&;T/C-NBBBOKCN"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *M-]R/_=%5
M:M-]R/\ W10 VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\;O#^M77V#5["6PBN!Y?F2L)(R#QANF <^A%<OJ7V27]HXKXGV&T\U1&)O\
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ME;WEM=KNM;B*8<\QN&Z'!Z>]<P/!MVMO)'%?V\;RJPDF2W.]\GUW<#;E=O0
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M?'GA31K&]FMTEFEN[L0DC='&F55L$95B2,=/R%=7=R2PV,\EO'YLR1LT<?\
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M*P_[3U;_ *!__CC4?VGJW_0/_P#'&H W**P_[3U;_H'_ /CC4?VGJW_0/_\
M'&H W**P_P"T]6_Z!_\ XXU']IZM_P! _P#\<:@#<HK#_M/5O^@?_P".-1_:
M>K?] _\ \<:@#<HK#_M/5O\ H'_^.-1_:>K?] __ ,<:@#<HK#_M/5O^@?\
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MFC^T-4_Y\?\ QTT ;%%8_P#:&J?\^/\ XZ:/[0U3_GQ_\=- &Q16/_:&J?\
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MBL?^T-4_Y\?_ !TT?VAJG_/C_P".F@#8HK'_ +0U3_GQ_P#'31_:&J?\^/\
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M**P_[3U;_H'_ /CC4?VGJW_0/_\ '&H W**P_P"T]6_Z!_\ XXU']IZM_P!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH )/^/;_@55ZL2?\ 'M_P*J] !1110 4444 %%%%
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M_P"Z* &T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 #J*CN/]>U2#J*CN/]>U $=%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 20?Z]:D/4U'!_KUJ0]30 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4D/WC]*CJ2'[
MQ^E $U%%% !4$O\ K#4]02_ZPT ,HHHH **** "BBB@ HHHH **** "BBB@
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M&(-1L_$":7!-+'Y=\EK]I5PW10O/7U[53IRC+E9$:T)0YD_R.DHKA->\:?\
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M_P" ?^@+6+7PN*_WB?J_S/-G\3"BBBN<@**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NY\'?\B]+_P!?3?\
MH"UPU=SX._Y%Z7_KZ;_T!:]3*O\ >5Z,WH?&;=%%%?7'<%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5:;[D?\ NBJM6F^Y'_NB@!M%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444  ZBH[C_7M4@ZBH[C_7
MM0!'1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% $D'^O6I#U-1P?Z]:D/4T %%%% !1110 4444
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 2?\
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M)GV@2RA3TSA1GOSGG-5&6\GK_F93A\,5ITMY=?Z\QUY:P2?'[3@\*,(-#W1
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M^1E[&:U]?Q=S2\ 64NG>!-,M+B^M;]X491<6<GF1.N]MNUL#.!@?A6-\0_\
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MA;Q2_'S5)9(U:2'28S&S#)0DJ"1Z'&1GT)]:U].\ :=9:S%J=YJ&J:O<0?\
M'O\ VG=><L!]5&!S[G/KUYK2@\.6EOXLN?$*23F[N;=;=T+#RPH(((&,YX]:
MCGBH\J[&GLYRES-=5^%SF=8T768O'EUKO@S4-,GO?LJ0W^G7K$E1C*8*\KN
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*[GP=_R+TO\ U]-_Z M<-7<^#O\ D7I?^OIO_0%KU,J_WE>C-Z'QFW1117UQ
MW!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %6F^Y'_NBJM6F^Y'_NB@!M%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444  ZB
MH[C_ %[5(.HJ.X_U[4 1T444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!)!_KUJ0]34<'^O6I#U-
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MZGKG-1&C&SNN_P"!K/$34E9]NW7\3K)O^3G;?_KR/_HEJ]:KR6;_ ).=M_\
MKR/_ *):O6JQK?9]$=&'^W_B9\]_$_X8:+X*\,V^HZ5=7\TTMXL#+<R(RA2C
MMGY4!SE1WKN-&\"^&/AQ:_\ "7O>Z@?L]KN=971E.\ 8 " Y)( YZFHOC_\
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M@ HHHH **** "BBB@ '45'<?Z]JD'45'<?Z]J (Z*** "BBB@ HHHH ****
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MHE+F-:<%!-(****@T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'?G;GOBN\HJ<_-S2ZA1]GR<L-4BI-I.G7&I1:A/86LM["NV*Y>%3(@YX#$9
MY/3U--O=&TO4IHY=1TVTNY(L>6\\"NR8Y&"1Q5VN:\.^.])\2QZK):I<6T>E
M-MN'N551_%DC#'CY3UQ4+F:NNAHW!.SZFS%H^F0ZBVH0Z=:1WK*$:Y2!1(5
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "I
M(?O'Z5'4D/WC]* )J*** "H)?]8:GJ"7_6&@!E<!\:-2FT_X:W*0':;R:.W9
MAU"DEC^87'T)KOZX/XS:9)J/PUO&A7<UI(EP1_L@X;\@Q/X5K2M[17,,1?V4
MK=CG?B#81:9\ M+M(%"K&+;.#G+$98_B23^-<_X)UR/X>WEX;E1''J>@0ZA
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MBBBL3I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH )/^/;_@55ZL2?\ 'M_P*J] !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5>M_\ CW7\?YU1J];_ /'NOX_SH YG6?%G
M]F:O-:?8O-\O;\_FXSE0>F/>J/\ PG7_ %#O_(__ -C67XN_Y&F[_P" ?^@+
M6+7RF(S#$PK3C&6B;Z+OZ'%*K-2:3.N_X3K_ *AW_D?_ .QH_P"$Z_ZAW_D?
M_P"QKD:*P_M/%_S_ (+_ ")]M/N==_PG7_4._P#(_P#]C1_PG7_4._\ (_\
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MZ_ZAW_D?_P"QKD:*/[3Q?\_X+_(/;3[G7?\ "=?]0[_R/_\ 8T?\)U_U#O\
MR/\ _8UR-%']IXO^?\%_D'MI]SKO^$Z_ZAW_ )'_ /L:/^$Z_P"H=_Y'_P#L
M:Y&BC^T\7_/^"_R#VT^YUW_"=?\ 4._\C_\ V-'_  G7_4._\C__ &-<C11_
M:>+_ )_P7^0>VGW.N_X3K_J'?^1__L:W-*U;^V=+-QY/D[)BFW?NSP#GH/6O
M-:[GP=_R+TO_ %]-_P"@+7H9?C:]:OR5)75NR-*524I6;-NBBBOHCK"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *M-]R/_ '156K3?<C_W10 VBBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  =14=Q_KV
MJ0=14=Q_KVH CHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@"2#_ %ZU(>IJ.#_7K4AZF@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **;O7^\/SI00
M>AS0 M%("#T(-+0 44Q9HFD,:R(77JH89'X4[(SC/- "T4A('4XI2<=: "BF
MHZR+NC96'JIS2EE'4@?C0 M% .>G-("#T.: %HI,CU%+0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5)#]X_2HZDA^\?I0!-1110 5!+
M_K#4]02_ZPT ,J.>"*YMY(+A!)%*A1T;HRD8(_*I** ,CPUX<M?"NBKI>G37
M$EK'([QB=@QC#')4$ <9)/.3SUK7HHIMMN[$DHJR"BBBD,**** "LOQ)X?M?
M%/AZYT?4))H[>YV;V@8!QM<,,$@CJH[5J44TVG=":4E9F?H6C6_A_0[72K)Y
M7@M4V(TI!8C.>2 !W]*T***&[N[!))604444AF'H/A.P\/ZEJE_;27$]WJDY
MFGEN&5B.20JX PHR<"MRBBFVV[L48J*L@HHHI#"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH )/^/;_@55ZL2?\ 'M_P*J]
M!7&V/Q ^V_#6?Q;_ &9L\D.?LGVC.=K;?O[?Z5V5>-:%_P FU7_^[-_Z,K:G
M%26O='/6G*+T[/\ "QZ/?>)7LO"-MK_V!YH'BBGN8XWRT,3 %G''S;0<D<<
MGBMJ">.YMXYX'$D4J!T=>C*1D'\JR] MXKOP/IMO<('AFTZ*.13_ !*8P"/R
MK%^%=S/-X$AM[ES(UC/+:J[-DE$8[?R! 'L!4N*Y6UT949/F2?5$GBCQI?:)
MXET[0])T+^UKN_B>2-?MBP8VY)'S*1T!/451N_'^N:(BW7BGP;/ING;@LEW#
M?1W/E9(&651P.?Z5F>.+J^L_C!X8GTG3_P"TKM+6?R[7SUA\S*N#\[<# )/X
M8JSKT?C?QII,FAS>'+70K6Y*B>ZGOTN"%#!OE5!U^7'/KVZULHQM&Z5NNO\
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M  .HJ.X_U[5(.HJ.X_U[4 1T444 %%%% !1110 4444 %%%% !1110 4444
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M_>/TH FHHHH *@E_UAJ>H)?]8: &4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !)_P >W_ JKU8D_P"/;_@55Z "N TWP)J=G\(KGPK+/:&^
MF$@617;RAN?<,G;GI[5W]%5&3CL1*G&3N_-?>8<MS_PB?@,37A5VTS3U#[<D
M.R(!@=.I&.W6J7PWT>?1O MC%>[OM5QNN9]W4-(=V/RQ^.:WM1TNSU:&.'48
M!/%%*LRHS$*64Y!(!Y&>QR*MT^;W;"4/?3[(Y75?#%[??$G0_$,4L M-.AEC
ME1F/F,71@-HQC^(=2*ZJBBDY-VOT*C%1;:ZG,^(?#EWJWC#PUJMM) L&DR3M
M.LC$,P=5 V@ @_=/4BD\3>&+S4-8L-=T"]BL]6L%:-?/C+Q3QMU1\'('7D<\
MGV(Z>BFIM6\B73B[WZG&6'AC7M3\36VL^,[NR;^SR3966G;_ "@Q&-[E^21_
MGTI\/AW7;'XB:GJ]G+ITNDZNL(NX9]XE7RTV?+@$'OU/?VKL**?M&+V,?QN<
M'I_ACQ;X5@FTWPK?:5-I32.]NFHK*)+4,<[5*Y# $D\]3]:DU/P3JU[\+[OP
M])J[:AJ=TR2/=7LC;-PD5R!P2% 7 &/RSQW%%'M)7N+V$+6Z;'*3>%[V3QSH
M6M++;_9M.LGMY5+-O9F4@%1C&.>Y%2ZCX<N[OXC:1K\<D M;&VEBD1F/F$L"
M!@8QCGU%=-12YW^A7LH_C<K:C;O>:7=6T14/-"\:EN@)4@9_.N \.:#\1?#'
MA^VTBPD\+R6]MNV-,UP7.YBQR0 .K'M7I%%$9N*L$J:E+FOJ<IX6\)7>F:M=
MZ[XAOUU#6KR,1/)''LCBC!^XHXR.%Y(SQ]<U!X7\1>'M9U&Z\'76FM9:C/\
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M 2_W5.1D#/UZ5W5%%*4G(<8*-VNH4445)84444 %%%% !1110 4444 %%%%
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M'Z5'4D/WC]* )J*** "H)?\ 6&IZS;O4[.VNFBFF".,9&#Z4 6**H_VUI_\
MS\C_ +Y/^%']M:?_ ,_(_P"^3_A0!>HJC_;6G_\ /R/^^3_A1_;6G_\ /R/^
M^3_A0!>HJC_;6G_\_(_[Y/\ A1_;6G_\_(_[Y/\ A0!>HJC_ &UI_P#S\C_O
MD_X4?VUI_P#S\C_OD_X4 7J*H_VUI_\ S\C_ +Y/^%']M:?_ ,_(_P"^3_A0
M!>HJC_;6G_\ /R/^^3_A1_;6G_\ /R/^^3_A0!>HJC_;6G_\_(_[Y/\ A1_;
M6G_\_(_[Y/\ A0!>HJC_ &UI_P#S\C_OD_X4?VUI_P#S\C_OD_X4 7J*H_VU
MI_\ S\C_ +Y/^%']M:?_ ,_(_P"^3_A0!>HJC_;6G_\ /R/^^3_A1_;6G_\
M/R/^^3_A0!>HJC_;6G_\_(_[Y/\ A1_;6G_\_(_[Y/\ A0!>HJC_ &UI_P#S
M\C_OD_X4?VUI_P#S\C_OD_X4 7J*H_VUI_\ S\C_ +Y/^%']M:?_ ,_(_P"^
M3_A0!>HJC_;6G_\ /R/^^3_A1_;6G_\ /R/^^3_A0!>HJC_;6G_\_(_[Y/\
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MK6/_ #\#_OD_X4?VM8_\_ _[Y/\ A0!<HJG_ &M8_P#/P/\ OD_X4?VM8_\
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M_P#/P/\ OD_X4?VM8_\ /P/^^3_A0!<HJG_:UC_S\#_OD_X4?VM8_P#/P/\
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MD_X4?VUI_P#S\C_OD_X4?V/A^[_#_(/J\3B/^$6UG_GS_P#(J?XT?\(MK/\
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M^1_WR?\ "B36=/:$ 7(SG^Z?\*Z,/EU+#SYX-W^7^1<:48NZ)J*I_P!K6/\
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M_P#/P/\ OD_X4 7**I_VM8_\_ _[Y/\ A1_:UC_S\#_OD_X4 7**I_VM8_\
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MK6/_ #\#_OD_X4?VM8_\_ _[Y/\ A0!<HJG_ &M8_P#/P/\ OD_X4?VM8_\
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MHH I_P!E67_/NOYFC^RK+_GW7\S5RB@"G_95E_S[K^9H_LJR_P"?=?S-7**
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ML/\ GV7\S5VB@"E_8]A_S[+^9H_L>P_Y]E_,U=HH I?V/8?\^R_F:/['L/\
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M2J.,[)[-+?TZ?J=5;>*?%>L^)=<TC0[+2U73+@)]KNS(%"$'"E5.68D$Y&
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M1+XE\3:)XETRP\5VNER6NJN889M.9P8I.P8.?F!XY&/Z5V]<'\0_^1F\%?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%%  .HJ.X_P!>U2#J*CN/]>U $=%%% !1110 4444 %%%% !1110
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M 5>M_P#CW7\?YU1J];_\>Z_C_.@#S?Q=_P C3=_\ _\ 0%K%K:\7?\C3=_\
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MH **** "BBB@ HHHH **** "BBB@ HHHH ****  =14=Q_KVJ0=14=Q_KVH
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M****@U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR_X1WS(?MG]C_8=^X^7YGD[,YQG;GVSCM7FOB_PU>>$O@)'I.HR02SQWP8M
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MZ_\ WS_]>@#8HK'_ +";_G]?_OG_ .O1_83?\_K_ /?/_P!>@#8HK'_L)O\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %7K?\
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M"%K_ -_E_P :\OHH_MFI_(@^L/L>H?VMIW_00M?^_P O^-']K:=_T$+7_O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444  ZBH[C_7M4@ZBH[C_ %[4 1T444 %%%% !1110 4444 %%%%
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MSS9_$PHHHKG("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KN?!W_ "+TO_7TW_H"UPU=SX._Y%Z7_KZ;_P!
M6O4RK_>5Z,WH?&;=%%%?7'<%%%% !1110 4444 %%%% !1110 4444 %%%%
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MDY=W<X+QK_R4SP)_UVN__0$I/%)D\/?$C2_%5Q;SS:8;)K&ZE@B,AMOF+*[
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MZ#JNK:0EE)&(I[V&.1[F501U!PH)'4U49QEK+N9SIS@K0[6V_P"&MN9.H_\
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M@\'@G/)Q@XKV>BBE.?,.E3]G?^D%%%%9FP4444 %%%% !1110 4444 %%%%
M!1110 5>M_\ CW7\?YU1J];_ /'NOX_SH \W\7?\C3=_\ _] 6L6MKQ=_P C
M3=_\ _\ 0%K%KX7%?[Q/U?YGFS^)A1117.0%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7<^#O\ D7I?^OIO
M_0%KAJ[GP=_R+TO_ %]-_P"@+7J95_O*]&;T/C-NBBBOKCN"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *M-]R/_=%5:M-]R/\ W10 VBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  =14=Q_KVJ0=14=Q
M_KVH CHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"2#_7K4AZFHX/\ 7K4AZF@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ JOJ%NUWIMS;(0K30O&">@)!%
M6**%H)JZL8?@W0IO#7A6TTJYECFE@WY>/.TY8MW^M0>+?",7B:&WEBN7L=1L
MWWVMW&,E#Z$=QP*Z.HKJ*2>V>.&=[=V'$J $K] 016BJ2Y^>^IDZ4/9^SMH<
M'<^$?&6NP#3_ !%XCMQIQ(\T6<.V28#L3@8_SP:V]>\#:?J_AVTTRV9K%K#!
MLIXOO0L/YY[_ )UFV&LZU%9Z%-YTNJ2Z@\IDA(BCX5#@ X &",U0_P"$IU22
M73UN+XVHF@F>0"6WC(99V0#,@P< 8P/3-=/[UM6:5NW]>1Q7H*+YDW?OKVZ_
M,FN?"WCG5;%M+U7Q)9?89%V2R16^99$[@\#K]:T6\$/#X@\-W5G<K]DT6!H2
MLN2\@VX!X&*K1:[JK>*O(%S-Y#:FUNOF1Q"W,:H&*[OO[^<CUHA\77LMWJ4C
M>8EG<6\SZ:[P%5#1*<88C#[P"X] *'[7I;_AQI4.M]^K[:]^YK>-O#=QXGTN
MTM;6>.%H+Q+@F3."%!&.._-6]2T66:_74--N/LUV!M8D95Q[UR4FN>(;;0X;
MNXN+B*"XEME2:Y$$3DLK&0*?NA?NX+<]:T4\2O9HQO-4C\M],>:&262)M\P=
M@0&3Y6(&T8%**J02Y6.3H56^9/6WEML3ZUX.NO$GB.*;6=0WZ-;%9(M/C7&]
MP.2Y],Y]>/2K-GX:N+;XB7WB$S1&WN;1;=8@#N4C;R>V/EJK:S:O+K6GI<:I
M/&LNFB[EM_)C WKL!7[N0"2<U3M-?NKR.U_M+7DT@?V;;W*.4C'VEW!WGYA@
M@8 VK@\_2I]^UKZ6*_=*7,T[WO\ UKYE^S\*76C^-I]5T:XABTZ^&;RS<'[_
M #\Z8XSG^9_"QX.\-S>'-+O;6\EBG^TWDEP-@. K #!S]*JV6M7/_";/8W5^
M)HY9'2"*W:)D4!,X=?\ 6*PP>>0>/:NMJ*DII6?6QK2A3;YHK9O\=SB?#OP^
MC\->.;S5]/F1;"XA9$ML'=&Q8$@=MO'%=M116<YRF[R-J=*%)<L%9!1114&@
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4D/WC]*CJ2'[Q^E $
MU%%% !4$O^L-3U!+_K#0 RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH )/\ CV_X%5>K$G_'M_P*J] !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5>M_P#CW7\?YU1J];_\>Z_C_.@#S?Q=
M_P C3=_\ _\ 0%K%KU:ZTZRGN6DGL[>1VQEGB4D\>I%0_P!DZ=_T#[7_ +\K
M_A7SU;*9U*DIJ2U;9RRH-MNYY?17J']DZ=_T#[7_ +\K_A1_9.G?] ^U_P"_
M*_X5G_8U3^=$_5WW/+Z*]0_LG3O^@?:_]^5_PH_LG3O^@?:_]^5_PH_L:I_.
M@^KON>7T5ZA_9.G?] ^U_P"_*_X4?V3IW_0/M?\ ORO^%']C5/YT'U=]SR^B
MO4/[)T[_ *!]K_WY7_"C^R=._P"@?:_]^5_PH_L:I_.@^KON>7T5ZA_9.G?]
M ^U_[\K_ (4?V3IW_0/M?^_*_P"%']C5/YT'U=]SR^BO4/[)T[_H'VO_ 'Y7
M_"C^R=._Z!]K_P!^5_PH_L:I_.@^KON>7T5ZA_9.G?\ 0/M?^_*_X4?V3IW_
M $#[7_ORO^%']C5/YT'U=]SR^BO4/[)T[_H'VO\ WY7_  H_LG3O^@?:_P#?
ME?\ "C^QJG\Z#ZN^YY?17J']DZ=_T#[7_ORO^%']DZ=_T#[7_ORO^%']C5/Y
MT'U=]SR^BO4/[)T[_H'VO_?E?\*/[)T[_H'VO_?E?\*/[&J?SH/J[[GE]%>H
M?V3IW_0/M?\ ORO^%']DZ=_T#[7_ +\K_A1_8U3^=!]7?<\OHKU#^R=._P"@
M?:_]^5_PH_LG3O\ H'VO_?E?\*/[&J?SH/J[[GE]%>H?V3IW_0/M?^_*_P"%
M']DZ=_T#[7_ORO\ A1_8U3^=!]7?<\OHKU#^R=._Z!]K_P!^5_PH_LG3O^@?
M:_\ ?E?\*/[&J?SH/J[[GE]=SX._Y%Z7_KZ;_P! 6M?^R=._Z!]K_P!^5_PJ
M<6\%M:!+:&.%2^2L:A03CKQ77@\NGAZOM'*YI3I.$KW&4445[1T!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %6F^Y'_NBJM6F^Y'_NB@!M%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444  ZBH[C_7M4@ZB
MH[C_ %[4 1T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!)!_KUJ0]34<'^O6I#U- !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,$,2[-L:#9]
MS"CY?IZ5%)86<VWS;2"3;G&Z,'&>:L44[L5D1FWA*X,,9&[=@J.OK]:#!"T:
MHT2%$X52HPO&./PJ2BD%D126T$T(BFACDC&,(R@@?A3?L-IY:1_98=D;;D7R
MQA3Z@=C4]%.["R&E%+[RJ[L8W8YQZ5&UK;N(P\$3"(YC!0'9]/2IJ*061&+>
M$7!G$2"9A@R!1N(],U)110,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "I(?O'Z5'4D/WC]* )J***  YP<=>U8>I0ZL]^YLYD6'
MC:#CTY[5N5!+_K#0!@?9]>_Y^8_T_P */L^O?\_,?Z?X5N44 8?V?7O^?F/]
M/\*/L^O?\_,?Z?X5N44 8?V?7O\ GYC_ $_PH^SZ]_S\Q_I_A6Y10!A_9]>_
MY^8_T_PH^SZ]_P _,?Z?X5N44 8?V?7O^?F/]/\ "C[/KW_/S'^G^%;E% &'
M]GU[_GYC_3_"C[/KW_/S'^G^%;E% &']GU[_ )^8_P!/\*/L^O?\_,?Z?X5N
M44 8?V?7O^?F/]/\*/L^O?\ /S'^G^%;E% &']GU[_GYC_3_  H^SZ]_S\Q_
MI_A6Y10!A_9]>_Y^8_T_PH^SZ]_S\Q_I_A6Y10!A_9]>_P"?F/\ 3_"C[/KW
M_/S'^G^%;E% &']GU[_GYC_3_"C[/KW_ #\Q_I_A6Y10!A_9]>_Y^8_T_P *
M/L^O?\_,?Z?X5N44 8?V?7O^?F/]/\*/L^O?\_,?Z?X5N44 8?V?7O\ GYC_
M $_PH^SZ]_S\Q_I_A6Y10!A_9]>_Y^8_T_PH^SZ]_P _,?Z?X5N44 8?V?7O
M^?F/]/\ "C[/KW_/S'^G^%;E% &']GU[_GYC_3_"C[/KW_/S'^G^%;E% &']
MGU[_ )^8_P!/\*/L^O?\_,?Z?X5N44 8?V?7O^?F/]/\*/L^O?\ /S'^G^%;
ME% &(UOKWE?-<Q[<^W7\JB\C6O\ GX3]/\*Z"3_CV_X%5>@#'\C6O^?A/T_P
MH\C6O^?A/T_PK8HH Q_(UK_GX3]/\*/(UK_GX3]/\*V** ,?R-:_Y^$_3_"C
MR-:_Y^$_3_"MBB@#'\C6O^?A/T_PH\C6O^?A/T_PK8HH Q_(UK_GX3]/\*/(
MUK_GX3]/\*V** ,?R-:_Y^$_3_"CR-:_Y^$_3_"MBB@#'\C6O^?A/T_PH\C6
MO^?A/T_PK8HH Q_(UK_GX3]/\*/(UK_GX3]/\*V** ,?R-:_Y^$_3_"CR-:_
MY^$_3_"MBB@#'\C6O^?A/T_PH\C6O^?A/T_PK8HH Q_(UK_GX3]/\*/(UK_G
MX3]/\*V** ,?R-:_Y^$_3_"CR-:_Y^$_3_"MBB@#'\C6O^?A/T_PH\C6O^?A
M/T_PK8HH Q_(UK_GX3]/\*/(UK_GX3]/\*V** ,?R-:_Y^$_3_"CR-:_Y^$_
M3_"MBB@#'\C6O^?A/T_PH\C6O^?A/T_PK8HH Q_(UK_GX3]/\*/(UK_GX3]/
M\*V** ,?R-:_Y^$_3_"CR-:_Y^$_3_"MBB@#'\C6O^?A/T_PH\C6O^?A/T_P
MK8HH Q_(UK_GX3]/\*/(UK_GX3]/\*V** ,?R-:_Y^$_3_"CR-:_Y^$_3_"M
MBB@#'\C6O^?A/T_PH\C6O^?A/T_PK8HH Q_(UK_GX3]/\*Z#3%F73HA=,&EY
MW$?4_P!*KU>M_P#CW7\?YT 8^HPZLU_(;29%AXV@XXX&>WK57[/KW_/S'^G^
M%;TO^L--H P_L^O?\_,?Z?X4?9]>_P"?F/\ 3_"MRB@##^SZ]_S\Q_I_A1]G
MU[_GYC_3_"MRB@##^SZ]_P _,?Z?X4?9]>_Y^8_T_P *W** ,/[/KW_/S'^G
M^%'V?7O^?F/]/\*W** ,/[/KW_/S'^G^%'V?7O\ GYC_ $_PK<HH P_L^O?\
M_,?Z?X4?9]>_Y^8_T_PK<HH P_L^O?\ /S'^G^%'V?7O^?F/]/\ "MRB@##^
MSZ]_S\Q_I_A1]GU[_GYC_3_"MRB@##^SZ]_S\Q_I_A1]GU[_ )^8_P!/\*W*
M* ,/[/KW_/S'^G^%'V?7O^?F/]/\*W** ,/[/KW_ #\Q_I_A1]GU[_GYC_3_
M  K<HH P_L^O?\_,?Z?X4?9]>_Y^8_T_PK<HH P_L^O?\_,?Z?X4?9]>_P"?
MF/\ 3_"MRB@##^SZ]_S\Q_I_A1]GU[_GYC_3_"MRB@##^SZ]_P _,?Z?X4/;
MZ]Y8W7,>W/'3_"MRB;_CW7_>H Y_R-:_Y^$_3_"CR-:_Y^$_3_"MBB@#'\C6
MO^?A/T_PH\C6O^?A/T_PK8HH Q_(UK_GX3]/\*/(UK_GX3]/\*V** ,?R-:_
MY^$_3_"CR-:_Y^$_3_"MBB@#'\C6O^?A/T_PH\C6O^?A/T_PK8HH Q_(UK_G
MX3]/\*/(UK_GX3]/\*V** ,?R-:_Y^$_3_"CR-:_Y^$_3_"MBB@#'\C6O^?A
M/T_PH\C6O^?A/T_PK8HH Q_(UK_GX3]/\*/(UK_GX3]/\*V** ,?R-:_Y^$_
M3_"CR-:_Y^$_3_"MBB@#'\C6O^?A/T_PH\C6O^?A/T_PK8HH Q_(UK_GX3]/
M\*/(UK_GX3]/\*V** ,?R-:_Y^$_3_"CR-:_Y^$_3_"MBB@#'\C6O^?A/T_P
MH\C6O^?A/T_PK8HH Q_(UK_GX3]/\*/(UK_GX3]/\*V** ,?R-:_Y^$_3_"I
MC;Z_M7-S'C''3I^5:56F^Y'_ +HH P?L^O?\_,?Z?X4?9]>_Y^8_T_PK<HH
MP_L^O?\ /S'^G^%'V?7O^?F/]/\ "MRB@##^SZ]_S\Q_I_A1]GU[_GYC_3_"
MMRB@##^SZ]_S\Q_I_A1]GU[_ )^8_P!/\*W** ,/[/KW_/S'^G^%'V?7O^?F
M/]/\*W** ,/[/KW_ #\Q_I_A1]GU[_GYC_3_  K<HH P_L^O?\_,?Z?X4?9]
M>_Y^8_T_PK<HH P_L^O?\_,?Z?X4?9]>_P"?F/\ 3_"MRB@##^SZ]_S\Q_I_
MA1]GU[_GYC_3_"MRB@##^SZ]_P _,?Z?X4?9]>_Y^8_T_P *W** ,/[/KW_/
MS'^G^%'V?7O^?F/]/\*W** ,/[/KW_/S'^G^%'V?7O\ GYC_ $_PK<HH P_L
M^O?\_,?Z?X4?9]>_Y^8_T_PK<HH P_L^O?\ /S'^G^%'V?7O^?F/]/\ "MRB
M@##^SZ]_S\Q_I_A1]GU[_GYC_3_"MRB@#$%OKV?^/F/]/\*9)!K@D.^X0MWZ
M?X5O#J*CN/\ 7M0!A^1K7_/PGZ?X4>1K7_/PGZ?X5L44 8_D:U_S\)^G^%'D
M:U_S\)^G^%;%% &/Y&M?\_"?I_A1Y&M?\_"?I_A6Q10!C^1K7_/PGZ?X4>1K
M7_/PGZ?X5L44 8_D:U_S\)^G^%'D:U_S\)^G^%;%% &/Y&M?\_"?I_A1Y&M?
M\_"?I_A6Q10!C^1K7_/PGZ?X4>1K7_/PGZ?X5L44 8_D:U_S\)^G^%'D:U_S
M\)^G^%;%% &/Y&M?\_"?I_A1Y&M?\_"?I_A6Q10!C^1K7_/PGZ?X4>1K7_/P
MGZ?X5L44 8_D:U_S\)^G^%'D:U_S\)^G^%;%% &/Y&M?\_"?I_A1Y&M?\_"?
MI_A6Q10!C^1K7_/PGZ?X4>1K7_/PGZ?X5L44 8_D:U_S\)^G^%'D:U_S\)^G
M^%;%% &/Y&M?\_"?I_A1Y&M?\_"?I_A6Q10!DQP:X9!LN$#=NG^%/-OKV?\
MCYC_ $_PK7@_UZU(>IH P_L^O?\ /S'^G^%'V?7O^?F/]/\ "MRB@##^SZ]_
MS\Q_I_A1]GU[_GYC_3_"MRB@##^SZ]_S\Q_I_A1]GU[_ )^8_P!/\*W** ,/
M[/KW_/S'^G^%'V?7O^?F/]/\*W** ,/[/KW_ #\Q_I_A1]GU[_GYC_3_  K<
MHH P_L^O?\_,?Z?X4?9]>_Y^8_T_PK<HH P_L^O?\_,?Z?X4?9]>_P"?F/\
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M;1#'+Y+ P2Y#=^-O08Z]!QSR*Y/P1X8OM&^*-S>2ZAX9@>6!H[K2M)N&W(,
M@B)AE1D*>HQGCTK'^$/A[2=;\2^*)]7T^WOC:SJL2W$8D5=[29.T\9^44O94
MU=WT5@]O5?+%))N_X'J6M^._#7AWR1K&K16[S*'2,*SOM(R"54$@'U(%:6D:
MSIVO:>M]H]W'=VS$J'C/0CJ".H/L:\+L[+4]<^,WB6.*UT*\O5FE$<6NJ[H8
MU;:NQ5SDA0O7H.E;_A#1-2\,VGC*:RU;0YGDL99%L]'NFD-M.H?8-I&5 R1U
MSQ[<$J,5'?4(8F<I:K37\#MM0^)7A2UO+C3?[=MTOHPZ@%6V*X!X+XV=1W/7
MBLGX/>*-8\5:!?W.O7GVJ:&Z\M&\I$PNT'&% [FN5^&&@^$;_P"%^HW>N063
MRK)(+JXN%!>W7'RX/5>.1C!)K3_9]_Y%75/^OT?^@+52A",))=+$TZM2=2#D
M]&GM^IN_%_Q)JWA;PC:WNA7?V6XDODA9_+1\H8Y"1A@1U4?E7+ZO-\6O#^@-
MKMUK^G7=K$BR211PQ[@I[G,2^O8YK4^/_P#R(-E_V$X__14M9T_@?XE^(M)A
ML=7\4V TR6-=R1*0VW (!"QKNZ#@FG3Y5!-V^9-9S=62C?96LSL]'^(6FS_#
MVR\4:Y(MA#,?+EVJT@60,5( 4$X)7(]B*O:3X\\-:[JRZ;I&JQW5VT?FA$1\
M%<9^\1C//3.:X7XE>'[;PM\$K?2+(EH[>XB#2$8,C$DLQ^I)X[=.U7[71K?0
M_@:U]H%E'%J4^B+))=11*)FWH'?YP,G&3CTP/2L^2#7,NKLC95:JERNVBNSH
MKSXF^#K#4FL+K7(5N$8JP5'95(.""P4J.GK70R:E91::VH/=PBS5#(;C>"FT
M=]W3%>0> _#W@V^^#US=:A#9277ES&\N9=OFV[98)ACRG 4C'7\<5R/]H:HW
M[/CP.9C:_P!M+"K$G'E>7OV_[HD /ID^U5["+=ET=B/K4XKFDEJKJWZGM,/Q
M2\&3VUW/%K<;1V:AIOW,@(!8*"!MRW) ^7.,U>O?''AW3M*L-2O-0\NTU''V
M63R)#YG&>@7(_$"O,/B#X?\ "FG_  @TZYTN"Q6Z(A^SW,0427!Q\^6'+=R<
MYQ63\0O^2.^"?^N?_L@IQHPE:U]784L35@I7MHD_Q/9--\=>&M72^?3]6AEC
MT]2US(595C7UW, "..HSFJMA\3/!^I:BMC::Y UP[[%#H\:LWH&90ISCCGGC
M'45B^.++PCX)^'\D=QH*36EQ+%";>W8P-<NN67S)$P2!ACDYY[5YOX^FUFXT
MWPQ)JNB:=H]EG%A#!)OF$?RGGG[N"OOGKUQ4PI0GM?\  JKB*E/>UUOO_2/;
M]6\9^']"UB+2]7U)+2[FB\Y$D1MNSYN2V-H^ZW4]JKZ?\1/">J0W4MEK=NR6
M:&2<N&CV*"!N^8#(RP&1W(%>=_$?3[;5?CQX;LKZ,2V\UK"LD9Z,/-E.#[55
MOO#>C']HZRTL:9:KI\D7F/:+&%B++ S#Y!QC*@D=#WZFFJ4'&[OM<)8BJI-)
M*U['K'A[QEH'BHS#0=12[:#!D38R, >^& )'O6W7CWARRMM*_:0UBSTV".TM
MELAB&%0B#,<3$ #C&><5[#6-2*BU;J=%&I*<7S;IM!11161N%%%% !1110 4
M444 %%%% !)_Q[?\"JO5B3_CV_X%5>@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *O6_P#Q[K^/\ZHU>M_^/=?Q_G0!Y_XH
MU&]@\274<%Y<1HNS"I*P ^1>P-9/]K:C_P!!"Z_[_-_C5[Q=_P C3=_\ _\
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M_P"@A=?]_F_QH_M;4?\ H(77_?YO\:IT4>UJ?S/[PYF7/[6U'_H(77_?YO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEG'#?:IK=U)#M$$\UZ&>! /N("NT+T[9X&"*]"HK*-2459,WE2IS=Y(YG4?
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MC:E*4KMOJ_P84445F;!5ZW_X]U_'^=4:O6__ ![K^/\ .@#S?Q=_R--W_P
M_P#0%K%K:\7?\C3=_P# /_0%K%KX7%?[Q/U?YGFS^)A1117.0%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M<^#O^1>E_P"OIO\ T!:X:NY\'?\ (O2_]?3?^@+7J95_O*]&;T/C-NBBBOKC
MN"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *M-]R/\ W156K3?<C_W10 VBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  =
M14=Q_KVJ0=14=Q_KVH CHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"2#_7K4AZFHX/]>M2'J:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTD9,D\3@LC@_>R5R<=,@&M&HZQ7339??<Q4IZ3?77=^MK;;'<2_$CPC!K/\
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M_P */^$AE_Z!\G_?1_PH W**P_\ A(9?^@?)_P!]'_"C_A(9?^@?)_WT?\*
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M/[<E_P"?%_\ OH_X4 ;%%8_]N2_\^+_]]'_"C^W)?^?%_P#OH_X4 ;%%8_\
M;DO_ #XO_P!]'_"C^W)?^?%_^^C_ (4 ;%%8_P#;DO\ SXO_ -]'_"C^W)?^
M?%_^^C_A0!L45C_VY+_SXO\ ]]'_  H_MR7_ )\7_P"^C_A0!L45C_VY+_SX
MO_WT?\*/[<E_Y\7_ .^C_A0!L45C_P!N2_\ /B__ 'T?\*/[<E_Y\7_[Z/\
MA0!L45C_ -N2_P#/B_\ WT?\*/[<E_Y\7_[Z/^% &Q16/_;DO_/B_P#WT?\
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MQ#_PA.G?\]KK_OM?_B:/^$)T[_GM=?\ ?:__ !-3?\)#+_T#Y/\ OH_X4?\
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MU'#?R(/9P[$/_"$Z=_SVNO\ OM?_ (FC_A"=._Y[77_?:_\ Q-3?\)#+_P!
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M^^C_ (4 ;%%8_P#;DO\ SXO_ -]'_"C^W)?^?%_^^C_A0!L45C_VY+_SXO\
M]]'_  H_MR7_ )\7_P"^C_A0!L45C_VY+_SXO_WT?\*/[<E_Y\7_ .^C_A0!
ML5:;[D?^Z*YW^W)?^?%_^^C_ (5,?$4I51_9TG Q]X\_I0!M45A_\)#+_P!
M^3_OH_X4?\)#+_T#Y/\ OH_X4 ;E%8?_  D,O_0/D_[Z/^%'_"0R_P#0/D_[
MZ/\ A0!N45A_\)#+_P! ^3_OH_X4?\)#+_T#Y/\ OH_X4 ;E%8?_  D,O_0/
MD_[Z/^%'_"0R_P#0/D_[Z/\ A0!N45A_\)#+_P! ^3_OH_X4?\)#+_T#Y/\
MOH_X4 ;E%8?_  D,O_0/D_[Z/^%'_"0R_P#0/D_[Z/\ A0!N45A_\)#+_P!
M^3_OH_X4?\)#+_T#Y/\ OH_X4 ;E%8?_  D,O_0/D_[Z/^%'_"0R_P#0/D_[
MZ/\ A0!N45A_\)#+_P! ^3_OH_X4?\)#+_T#Y/\ OH_X4 ;E%8?_  D,O_0/
MD_[Z/^%'_"0R_P#0/D_[Z/\ A0!N45A_\)#+_P! ^3_OH_X4?\)#+_T#Y/\
MOH_X4 ;E%8?_  D,O_0/D_[Z/^%'_"0R_P#0/D_[Z/\ A0!N45A_\)#+_P!
M^3_OH_X4?\)#+_T#Y/\ OH_X4 ;E%8?_  D,O_0/D_[Z/^%'_"0R_P#0/D_[
MZ/\ A0!N45A_\)#+_P! ^3_OH_X4?\)#+_T#Y/\ OH_X4 ;@ZBH[C_7M60/$
M,N?^0=)_WT?\*9)K\KR%C8.,]MQ_PH UJ*Q_[<E_Y\7_ .^C_A1_;DO_ #XO
M_P!]'_"@#8HK'_MR7_GQ?_OH_P"%']N2_P#/B_\ WT?\* -BBL?^W)?^?%_^
M^C_A1_;DO_/B_P#WT?\ "@#8HK'_ +<E_P"?%_\ OH_X4?VY+_SXO_WT?\*
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M_?1_PH_X2&7_ *!\G_?1_P * -RBL/\ X2&7_H'R?]]'_"C_ (2&7_H'R?\
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M(S*%G4!LJ<'@$C]:GE=KEJ<6[)FQ1114EA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !)_Q[?\"JO5B3_CV_X%5>@
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ME.L_\_G_ )"3_"C^V,/V?X?YA]8B>BT5YU_PE.L_\_G_ )"3_"C_ (2G6?\
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MH **** "BBB@ HHHH **** "BBB@ HHHH ****  =14=Q_KVJ0=14=Q_KVH
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MV*)%.R[A%EY@6QW(!)_"NG\*^%]8TWXM>(]:O;/RM/O486\WFH=Y+*?N@Y'
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MKD$#/S*ISC\J2BV[(<I**NSHZ*YPZU?RV/ARXBN=)MCJ/E-<QW<C(T@902L
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M_P >Z_C_ #JC5ZW_ ./=?Q_G0!YOXN_Y&F[_ . ?^@+6+6UXN_Y&F[_X!_Z
MM8M?"XK_ 'B?J_S/-G\3"BBBN<@**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "NY\'?\ (O2_]?3?^@+7#5W/
M@[_D7I?^OIO_ $!:]3*O]Y7HS>A\9MT445]<=P4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5ION1_[
MHJK5ION1_P"Z* &T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 #J*CN/]>U2#J*CN/]>U $=%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 1G!ZCL?2LG&5N9HZ%*"?(GKV-6BN;UKX@^%?#UX;35M8AAN%^]$BM*R>S!
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M , _] 6L6MKQ=_R--W_P#_T!:Q:^%Q7^\3]7^9YL_B84445SD!1110 4444
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M$)U'_GM:_P#?;?\ Q-'_  A.H_\ /:U_[[;_ .)H^HXG^1A[.?8YRNY\'?\
M(O2_]?3?^@+63_PA.H_\]K7_ +[;_P")KH]#TN?2-':"Y:-F:<N#&21C:!W
M]*]'+L+6I5^:<;*S-J4)*5VB]1117TIUA1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %6F^Y'_NBJM6F
M^Y'_ +HH ;1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%%  .HJ.X_U[5(.HJ.X_U[4 1T444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!)!_KUJ0]34<'^O6I#U- !1110 4444 8?C6 7/@/78BNXG3Y]
MHSCD1DC]<5Q>@-_PG>H:!;G>VC^'[*VN9RR\37K1@HASU"*23CN<'J*])OK2
M/4-/N+.?=Y5Q$T3[3@[6!!Q^=9WA?PQIWA'0TTO25?R5=G9Y2"\C'JS$  G
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M>F1V]*GVVM[]S3ZO9)6[7\]=3S?Q!X=MI-5NM?O]//B?PY*H^RW6F7K;].1
M%.U%;:P7:<GGE<G'-=#XQ6"/X06-K87-UJ!NY+-+":<AYI2TJ.N2 .=H(Z9J
M])\*]&::X6#4=9MK"Y=GFTVWOBELY;KE ,X/U[58_L>36/%-BAM6M-"\/$?9
M8F5D%Q<!=JL%./DC7@'H23C(HYT[:["5*2YE;?3_ #^7J=?1117*=X4444 %
M20_>/TJ.I(?O'Z4 34444 %0R*QD. :FHH K;&_NFC8W]TU9HH K;&_NFC8W
M]TU9HH K;&_NFC8W]TU9HH K;&_NFC8W]TU9HH K;&_NFC8W]TU9HH K;&_N
MFC8W]TU9HH K;&_NFC8W]TU9HH K;&_NFC8W]TU9HH K;&_NFC8W]TU9HH K
M;&_NFC8W]TU9HH K;&_NFC8W]TU9HH K;&_NFC8W]TU9HH K;&_NFC8W]TU9
MHH K;&_NFC8W]TU9HH K;&_NFC8W]TU9HH K;&_NFC8W]TU9HH K;&_NFC8W
M]TU9HH K;&_NFC8W]TU9HH K;&_NFC8W]TU9HH K;&_NFC8W]TU9HH KR(QM
M\!3G=TJ#RI/[C?E5^B@"AY4G]QORH\J3^XWY5?HH H>5)_<;\J/*D_N-^57Z
M* *'E2?W&_*CRI/[C?E5^B@"AY4G]QORH\J3^XWY5?HH H>5)_<;\J/*D_N-
M^57Z* *'E2?W&_*CRI/[C?E5^B@"AY4G]QORH\J3^XWY5?HH H>5)_<;\J/*
MD_N-^57Z* *'E2?W&_*CRI/[C?E5^B@"AY4G]QORH\J3^XWY5?HH H>5)_<;
M\J/*D_N-^57Z* *'E2?W&_*CRI/[C?E5^B@"AY4G]QORH\J3^XWY5?HH H>5
M)_<;\J/*D_N-^57Z* *'E2?W&_*CRI/[C?E5^B@"AY4G]QORH\J3^XWY5?HH
M H>5)_<;\J/*D_N-^57Z* *'E2?W&_*CRI/[C?E5^B@"AY4G]QORH\J3^XWY
M5?HH H>5)_<;\J/*D_N-^57Z* *'E2?W&_*CRI/[C?E5^B@"AY4G]QORH\J3
M^XWY5?HH H>5)_<;\JMP K"H(P:DHH AD5C(< TS8W]TU9HH K;&_NFC8W]T
MU9HH K;&_NFC8W]TU9HH K;&_NFC8W]TU9HH K;&_NFC8W]TU9HH K;&_NFC
M8W]TU9HH K;&_NFC8W]TU9HH K;&_NFC8W]TU9HH K;&_NFC8W]TU9HH K;&
M_NFC8W]TU9HH K;&_NFC8W]TU9HH K;&_NFC8W]TU9HH K;&_NFC8W]TU9HH
M K;&_NFC8W]TU9HH K;&_NFC8W]TU9HH K;&_NFB5&,*@*2<^E6:* *'E2?W
M&_*CRI/[C?E5^B@"AY4G]QORH\J3^XWY5?HH H>5)_<;\J/*D_N-^57Z* *'
ME2?W&_*CRI/[C?E5^B@"AY4G]QORH\J3^XWY5?HH H>5)_<;\J/*D_N-^57Z
M* *'E2?W&_*CRI/[C?E5^B@"AY4G]QORH\J3^XWY5?HH H>5)_<;\J/*D_N-
M^57Z* *'E2?W&_*CRI/[C?E5^B@"AY4G]QORH\J3^XWY5?HH H>5)_<;\J/*
MD_N-^57Z* *'E2?W&_*CRI/[C?E5^B@"AY4G]QORH\J3^XWY5?HH H>5)_<;
M\J/*D_N-^57Z* *'E2?W&_*K!5MB<'A14]% %;8W]TT;&_NFK-% %;8W]TT;
M&_NFK-% %;8W]TT;&_NFK-% %;8W]TT;&_NFK-% %;8W]TT;&_NFK-% %;8W
M]TT;&_NFK-% %;8W]TT;&_NFK-% %;8W]TT;&_NFK-% %;8W]TT;&_NFK-%
M%;8W]TT;&_NFK-% %;8W]TT;&_NFK-% %;8W]TT;&_NFK-% %;8W]TT;&_NF
MK-% %;8W]TT;&_NFK-% %;8W]TT;&_NFK-% %<(V1\IJ.>-VF8A21]*N44 4
M/*D_N-^5'E2?W&_*K]% %#RI/[C?E1Y4G]QORJ_10!0\J3^XWY4>5)_<;\JO
MT4 4/*D_N-^5'E2?W&_*K]% %#RI/[C?E1Y4G]QORJ_10!0\J3^XWY4>5)_<
M;\JOT4 4/*D_N-^5'E2?W&_*K]% %#RI/[C?E1Y4G]QORJ_10!0\J3^XWY4>
M5)_<;\JOT4 4/*D_N-^5'E2?W&_*K]% %#RI/[C?E1Y4G]QORJ_10!0\J3^X
MWY4>5)_<;\JOT4 4/*D_N-^5'E2?W&_*K]% %#RI/[C?E1Y4G]QORJ_10!0\
MJ3^XWY4>5)_<;\JOT4 4X8W6925('TJ0HV3\IJQ10!6V-_=-&QO[IJS10!6V
M-_=-&QO[IJS10!6V-_=-&QO[IJS10!6V-_=-&QO[IJS10!6V-_=-&QO[IJS1
M0!6V-_=-&QO[IJS10!6V-_=-&QO[IJS10!6V-_=-&QO[IJS10!6V-_=-&QO[
MIJS10!6V-_=-&QO[IJS10!6V-_=-&QO[IJS10!6V-_=-&QO[IJS10!6V-_=-
M&QO[IJS10!6V-_=-&QO[IJS10!6V-_=-&QO[IJS10!6V-_=-&QO[IJS10!6V
M-_=-&QO[IJS10!6V-_=-&QO[IJS10!6V-_=-&QO[IJS10!6V-_=-&QO[IJS1
M0!6V-_=-&QO[IJS10!6V-_=-&QO[IJS10!6V-_=-&QO[IJS10!6V-_=-&QO[
MIJS10!6V-_=-&QO[IJS10!6V-_=-&QO[IJS10!6V-_=-21*0QR,<5+10 444
$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>fhtx-20211231_g10.jpg
<TEXT>
begin 644 fhtx-20211231_g10.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2!:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (#Z^@E0X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%>6$<         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@              J@   *D
M 0                         !              "I    J@
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    J@    !29VAT
M;&]N9P   *D    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M    5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   *H     4F=H=&QO;F<   "I     W5R
M;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53
M;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /
M15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N
M9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO
M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M C_P        .$))3001       ! 0 X0DE-!!0       0    #.$))300,
M     !8+     0   )\   "@   !X  !+    !7O !@  ?_8_^T #$%D;V)E
M7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,
M#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,
M# P,# P,# P,# P,# P,# P,# S_P  1" "@ )\# 2(  A$! Q$!_]T !  *
M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M>J]0;EY%&!C5W-PJVV9+K;?3)WASVU8X#+/?L9_.7^E3_P""+1Q<AF5C59+
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M2P["[J>:PY#K S9MI+FD-ENY\-:-_P!+]Y:"S<'&H9U?J-[& 0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M%B)1%Q@C)#(S@9'P-38W0E-4<723TB8G-$-65V%B=J&QL[71U/_$ !P! 0$
M P$! 0$            !! 4& P('"/_$ $P1  $# @0#! @# P8,!P$   $
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M_7N3R5GT5A^&6#71*F4=H&RO G8$AS$%('X_PP7.'W3R[\(HGZ X4:)IB#Z
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M57%$\_:6J6X[A^"TT A:WU3#+AU3/,Z3-<.#PUMK&]U\-7BF#6^^'[/S;,]
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D-4(AC; +>'3[<QX V[D5@.5$X1.$3A$X1.$3A$X1.$3A%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>fhtx-20211231_g11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1\ 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'N2^>0@X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%>I=P         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@              C    *D
M 0                         !              "I    C
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    C     !29VAT
M;&]N9P   *D    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M1BD%A@_TBAO\5M+!^N9PATJG[3Z?JG+Q1B[P"[U/7J_F9_PGI>I]%)3L8F(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$  @,! 0               04"! 8#!__$ $D1  $# P$%!04% PD%"0
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MV@_T-+MF^/9_#PMT[UV!>H/_ .#'87Y\?^09/^/X^Y'\_P#7^G-G5/ZOJO\
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M]GSZ^W)H8$KN[:,*EK"K6PGK-;%*!KX*JN#8^<MX&KI+.U,B@8YT,5U%,_\
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MC-G'LGND$IW<V #"TEP'^(=.]<[M?NO0]:WH%-4]'=J]G0&UK+"2ZPH^:EK
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MWV.Q:Q7/[![1LL/49VU#ZTWNSEOF*Z>KRP5>2?1K]K"3[;:,L\2.)_OF4?\
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?&D((^)C'3.:OE.% %O+ \%=KA2G")PB<(G")PB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>fhtx-20211231_g12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g12.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1EL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &5"^9( X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%>:A<         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@              @    +P
M 0                         !              "\    @
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    @     !29VAT
M;&]N9P   +P    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M?IN%K/0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_\0 %@$! 0$                   $"_\0 *A$  @$# P,$ P$! 0$
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M9SG.:LEYR.5K&L\NS$3@*9>E(M36S>URRC@HX X X X X X X X X X X X
M[(OY3OP2%HO!U!NK1.K.H+!KO7VUL.HLNH+JOFPE'<5<*P-7%EQB1V65666
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MJ321!0/=I$:T%3,BPI4%GN>YV":(!Z*JN]M&N15!.K4:-]]=^D]2R[@HX X
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>fhtx-20211231_g13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g13.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1C:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &+Z^8S0X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%>:A<         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@              @0   +@
M 0                         !              "X    @0
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    @0    !29VAT
M;&]N9P   +@    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M2#+['722217*22224I))))2DDDDE/__0ZCJMF<WJ.2UUF4W.=8QO2756EF$
M6M]%F8S>VC>Z_P!7[15DU^OD4_T/U/8NM7#]=Q&U=1S6Y5%K,7+?M9EVFIM0
M=D"BK(=3D66^W(]+&;1A>M55]CL]6W]9]3TUVZ2EUB](%XZ[UKURPDOH+-@(
M&STSZ>[>Y_Z3;]-S?8K>1UK"Q^H-Z>]WZ4TOO?!!+6LU_FQ^EL?8WU'-;6S_
M  :S?JU?AY/5>LY&$7NINLH?-@M:[<ZN7^S+#;&,_<9M]+_1I*>A22224I))
M))2DDDR2FGU>QS.GVM9_.W115_6N(H;_ )OJ;D+I==6+=EX-30RNI[;*FC0;
M+&CC_KC+%++/K=0P\<:MKWY-G]@>E0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M%4$)%B)181<C)C)QD20W@25VL;71,S4X0D-%4G6A\/_$ !L! 0$  P$! 0
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MQBI@<YS@0 [CF'D1*B=^_."1[>RDN%4PB81,(F$3")A%ZF.!>.0-Y'CD"B/
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MH_JFDNIM+BUKFF'07 $WD$\QY 6"SWKHTPB81,(F$3")A$PB81,(J27OJ3W
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M[$33(":9 X   "$*!0#@/ >V;+3H(%N4>_L+<M5TS6AH:T6 $-&D-   B!H
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M5_P^WQ!^O\2XK.FX]U#%_!?AZV.^(?B'XKPTT7U8<6"E ;!X(TO=;KTRB "
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M#H>G._\ /-0?9%UB==TZ<N,TJ9-E",'#KTR"'J.W(% &;% GNJZ>NA1:-D@
M1466(0 Y$,^&)KMPU%]=P+A3'^V8XB2 !M,F "+W,;KQYAC*.7X/$8NNX-IT
M:;G&8!<Z(93;S<]T-:+RX@ &0L3=/%'EX^'F+_=RD7OVRG:=BGC&3X-%M5B
M,576XFX,1I#L3)-2DX 3G(90W)S&Y\^ HOITW5JDC$8@_$J7GA&K&"= WE,3
M>>6G\.X&O3HULQQX#LRS-_ZC$R"?A,(BEAFD@13I4X!;H7 NBYFR)2E('!0
MH?D 9[@ +!=*O;*B81>IBE-[@ _ER']LD#[^O/Y(JH[II\W5K.EO?6[!5Q<*
MY'%:7&N,S=A=B41)4R[V(.F  4;'$ 9:2K+K@RGJD7CCG!N_5[?!B\,]CACJ
M#N$M_P"LP?\ K,8-]I&Q(L1!L5R>>8/$X;$LS_*6%^.P5(,QN%!AN:9<'%U;
M"@"WZRE_UL)4-RYCZ+OV/6?*'=J_?ZO"VFL/RR,1+L$'C1<@\"!%2^4%R"/<
MBY0.!T'**A2J(+IG24*4Y# 'KHUV8BFVLS_:]H=MN-P)N-^LVY;_  .,P^.P
MU'%82H'T*U-M1IO+0X \+IT<V[7 P00=PIH'L'],^J]J81,(F$3")A$PBTS=
M1O19NK8^_P"V7V)UQJZ]U":W16-D&=6>X2\#.3%*ANG^LZP6U-+),C$]2H??
MR$=WQ2,$_P  ^<O3G<)&64.)J??3Y 6](^ZQ;-[[]-YVV-Y,S: MME$9O(^H
M5QC(0<36WS.&CFSJ!@A 8:)71:ID5CXP2E(4S%H<!1;&*4H"D0@\!D/3I]+_
M #5%R3WJ?M'K/52W"JH!]IO*TF,Z.MJ)7>K.[6SE8]I%1;9K6S64(^9=R#0C
M.3=(E*;Y>U;#W>M)F "M0-R)@ <CFAP(.AL5\Z@:X$. <"TM<T_\FN!!!M<&
M\_RLC:QZ8M"):LJ1&FJJ<S-+TJKF?*-HENW774-#,53',X2*54J@J"*G>F<I
MQ'\7=R.>)N69>USG#"TFN>07N8T->Z.;@-5HV>%_#[&U!3R? 4_C0:A;08TN
M.H)+>$R'7!%YOU6)-]].6TX'6TXGTN[$OU=LRJ[$&-4-9U5H4R(.T!=)QZDJ
M#I2)(FU!50@,E$P4  3,(E.(#K,SR[',P=8Y/7>W%!K318^I_IB7 .NZ0#PD
M@"-@-(*YGQ)X;SAF48FGX0S+&8''NX/A8>IBW-PT![2_X;JK7FC^SBX> BX
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M>.*Z^/'P"SV/5=3ZH#\6T1E?2<$25.)2/$RD, F1*.<R[%>(,3G='#5\&QN
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MSSZ+)DR8M4P$$F;!FT8-$T6;5!$A) U(L/74#T'U]%- ,41$ $!$/< 'D0\
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;[\Y^J 6\B?E('RLK Y%4PB81,(F$3")A%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>fhtx-20211231_g14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g14.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2584&AO=&]S:&]P(#,N,  X0DE-! 0
M    )3R^E3(X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%>BZ,         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@              @0   +H
M 0                         !              "Z    @0
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    @0    !29VAT
M;&]N9P   +H    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M C_P        .$))3001       ! 0 X0DE-!!0       0    #.$))300,
M     !L)     0   *    !O   !X   T"   !KM !@  ?_8_^(,6$E#0U]0
M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(               $  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M=P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M @(# 0             '" 8) @0! P4*_\0 .A    8" 0,"!0($! 4%
M 0(#! 4&  <1"!(A$Q0)%2(Q0191(V&1\#)"<8$7)5*AT3,T5V;A_\0 ' $!
M 0 # 0$! 0            $"!08'! ,(_\0 .!$  0,# @0$! 4#!0 #
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M/X]DQK11N*H)%"NUP?#7-)VWHJ>J3D>WG["!1Y /' \#^0[@, #_ "SL2/\
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M)(66*%5%&S0_(*)*G+(-@.R=)F#\;6L*!%E=U *K ?Z=[B)N*3/[GN)C\XD
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M([@R"#//E"B[:.L*ILFLKUNPQJCA$YB+,I)HL9"7@Y) 0593$0_ P.&4DS7
MJK==$W/@R:H'1443-^5>WI7;"RM$C\U-V06O&Q!;  ZSCH#E;C0M?U+AO4J.
MI:;4<VHUKJ%Q3>/Q*%U:5<5[:YHG_P"1;UVRVK2((<2'8+012#0O599H7;UO
MZ?\ <RDH#&MR2%=UQM*:J\M6XZ_+I%$#-'CZ19H1*DT!1*"0-'!"27IF4:IG
M,"@!SEAK-9FI76D:G0JVQI/\%A>OI5!0OVD R'AOX8>"2!#@' $@ KV7C3X:
MZ?<<(Z-Q[P?<6ES6U&G5N^).%K'4;&]N^':1.+D6-&HZ_99 _P#*Y['_ (!<
M/&&,RMEZ!Q42(<3%/W%[NXH<%, _80_8/]S<_?GR&=1GF(]_?=>!@ST/<>_O
ME>T? "/[ .%53_JNZM:MTPTM.=D2)3]GD'C1K!TJ/7]6=ED3O6Z4D_0:)(+K
M)-8MDHJX776(1OZH(-P5,LNDF;2ZYK=OH%B+NZIU*KR]K6T:+34J.!(!(8T>
M*/"?$3C8KTOX8?##6OB=K533M/>VPL+>C5JW>LWC -.MBUA=2I5*[ZM%CJ]5
M[13IT:;G53XB_P ):QQ2!ZS=82,$PG9>'VU5HR59-W\=(SVF=FDC5VCI$BZ+
M@DS'560AO;J)G)Z:XOO3^KR(B8@#*.NV5=H=-S2EH>#4TZ_8QK'1#G/=1+6B
M#))( D;S"^;4/AAQ'85+B@V[X:O;FW>^E4L[+B[ABXU-KZ;BU[#IK-4-V'!P
M((_ DQ)&). />O"C.MT4#5M.>4VT15U375<696^1$"X@/EHIFDF\E7I=JC((
M.A06(K&-W"C9:842=MV9?5;*E#YW<1V9U6WTZA5M:IKL.3=-:X.D3X:9IASW
M"6D-#LYV )70TO@QQ/3X3U_B75+#6]/J:,;7\.T;H=W=TKPWG_ VC?VY?:/9
MXORUJK*CVT/$R27.#3>I.49KD361>(K)+&*"0HB5=,P=H&Y36;@LF8#E\@(G
M$H\\<YT8_,/REA( +H=&_GORV'J=UXZ^A68]U.I1KTWM=^9E2FYIID3(<(!I
M[1^8@YCDO:@]1<*F327(H<#?60! #) '( (IF(4X<B <<\\" ^?W'!\)\,YF
M' GEN 3U[?HH*=3P"J656L<8:7TW-88.0TN:/$.X)Y+Z.$3")A$PB81::/B)
MV!:S;#US$U>.V%69ZBJS,BYVJVU-M/=$%3319HM][]+0S/6MHUSL=HY(^*1O
M;Y>RTYU$K-7[*#GU%VD@DU<_*#Z;S'3SWSR6)((D9S@ QG;YD?(="%MOI+_Y
MK4:U)#(C+B_@XIX,H,4,$,B+EB@L+[Y,914T7[OO]?V!E5!:=_H=YO3YPJ/G
MDQS]\PJ7S/\ Q[BNJB:G 8;'D=;%0!%FG&2+%W1#UEQ6ZTT9MVU<<2S1,;:W
MN1IY\\?*-".RQ7J]SX[4S-L2@\LY[>\],_0J.\X@8Z_N1C( ^RAW7L1US15#
MV<PKTA4G<A^HY=T:Q=1T9L,[Z7A'4.LL[:P4#7MU7=E#$BGICLFB\3(Q$&_:
M%171K[17U3&G7W'E_,\XV3$]]P-\=>QGION5/WPY D Z,-(A+>S^:?*+!\R&
M/*L1@+_]86$'8LB.3J."-!7]06Y%U%%BH]@*',<#"*(]<HT@[&8\^<QNKN86
M281,(F$3"+U*(IK%$JA , B(\")OS^? @(#Q^PAQ^,H)&RQ\(/?)SS&3L1D1
MG987>*+6K[6Y&K66%92\+*)^@Y9/" (< 8!(NW6*(+,W;8X%6:NFYDW#98A5
M$E"& #!^52C2KTZE*NQKV/:YN1,2,&<D0>;2",$00OOTS5-1T._MM5TFXJ6M
M]:U/'3JTS!+2"VI3>(+7TZC"6U*;PYE1I+7 @PJI*7FV])C1RRV6]L-[T8S3
M5/ ; 08NYNW41LGY3@+HU9)KO)N);I_1'6A) KE)(A6\LBH( \'1FXK:*PMN
M@:NG,!-.NQKWU*#!,,J@!SG-')\=CU7I5+1K#XF5:;^':-II/&55P%UH=2O0
ML]-UBHZ2Z[TFI4=3IV]W4<?]W3WN#*CB76[Q_P :^;#=8C7?3,L'TLQ\I;IU
M=8S:2MEG@9> IU&0\ I)S2CYJV<3;H""<\; 1AR.)!<A4W#ABV]1RG:&M,U)
MOATAO]4"? ^XK!].G2R 3+F@.(_\@'Q;?E!\0_>^^%=WP36_J_B54&C6E&FV
MM;Z197-K<ZQK-0M\3+:A3IU7"TMW.+6U[VL"VBTO+&57M#%/FJ-%5S782,Y*
MKKW?8EB*DI;-AV-,B\_-*%$ZH,FB1A,W@X!D8QB1D#&@1FT3 #*>X="JZ4V-
MO84J+?'4_P!^XJ9JU*H!/B)V;.&L!,-:  T 0"29XOB+B[4->_ L:-*GI&@:
M<3_I6BV3O#;6@( -6H^!5N[NIX0ZK=7+GU'OGP_ATXIJ<P:H 0Q2I%*4Q0+V
M  ]G:4  @=GDH 7@/I ..?/'(Y]QDX).-L^_ED+DP TRT029G<>(9!['N([Y
MA4EW!T+Z>W/NFI;PO+BSR-AJ2,2U8UGW\2XI<DTA7;IX1M*PLC$O%W*#Y1TH
M#YN1ZBBY3[""!![CYS^H<+Z9JNI6NJ7)N36M"TM:*KFT7!KR_P +Z;0/$PEQ
M\0:1(,?VB%ZYPE\;>,.".#-9X(T.EI-O8ZXZY-:^%"LS6J)N:3:3ZMG?T+BD
M^E6I-;XK=[F5/P7@.;E9H]Z2-7L3D?:]<WC43PHF5 ^K[Q8*K'@J?D1$U9%T
M_I[@"B;N]-Q7ETA @)G*)1$H_<=)MV%YMGU+)SA J6SWCPEH(:6M>YU,#E_Q
MDP3U6BI_$KB.I3IT=:HZ3Q10;$4^(M-MKRX,%I_/J%*G;ZF_^V"77IW)!S*H
M/TX:1ZTM+[?W%9R5;7DK"V&25<0DSL&=2"?L31-PNFW9FF:.1NP@55T.Q\]5
M5HCM%9VY45*W0-W";D-$L.*;2_U-]2A;5+=]<NMJES5=^-68#$G\.&MEH!,4
M#^8F#)E>W?$7C'X.<3\)\'Z=0O=?M=1TZT\&HT-)TVA2L;:M58U[WTVZ@]U:
MO2HU2ZE3:Z^#Q18QH>Z 1<J[]5MWU54)R=VCH"\PCN#8F=G?5E\SN5*>"D4!
M4']20[4TQ%M!#D?>S-39HEY#U.SSQTMSJU:PM:]Q>V9:ZWIOJO\  XOHAK,S
MXVM+MMBY@YS"\HT?X;Z=Q/K&GZ;PWQGI%XW4+AE!E.\I5M+U2GXS (LKHBVN
M7 X\%#4/$_/A!, RSTV[P2Z@=:0NS&T.G QUB!PK'1X336:5*V1,4O>NX;-&
M0(.!,(@HT,CZB(=HG$>\./HT;4F:QIU'4:3?#3KR:;9\7Y08!+@-SS! CZ+G
MOB!P>_@+B>[X8K7PO[BP 9<5_P"EJV7^[N6LHUJE1SV#'AK ^%V0-I-A/[_O
MG-HN,3")A%^?7XIFL8Q_N)I?:-2-42$P;6BS/8%A?U*E;(MDJ[;2J<;'5UY4
M[-/-4T!CF4E#2+<6\2J]EX9:>34?-R1#1)=[]^\P>A6(\B-]QO/Z=AG SR6\
M'3I'1-5:[!]'(0[P*560=1+9-@FWBW 0S,%V")(LI(TB317N03(P(1F0I (V
M*5$" #W^RHY^9_6/GC[XF%)' ?L'],*P.BCC;L(XL&L[O#LK5+T=U(5R4;I6
MF 58MI>',+140=,EY%J\9$6* "0!<-E2 !A^GG@0*&-]L].\GR!YG'<D*M7P
MXVQF?1AI!HH^<2BK6&GVRDF\,F=W('0N%A3,\<G2(FD9=R)175,DFFD90YA(
M0I1  (/(#?W_ )@XRKNX53")A$PB81,(O':7SX#SY'P'D1^XC^_.$49;4I;F
M[T*TU.-DQ@GU@AY&);3*:"3D\8J_;G;B\(U7,5!8Z('[@(8//'@WWSY[FV_J
MK2YM2_\ "_J&/;XFC(+@0#('B)$^1Y[!;70-2HZ+KNDZO7L1J%/3+VA=FT=4
M-)M7\&H*GA\8@@N+8D9&_G ?1MTQN>EW6KG7SJYJ79,9M],,Y%>*;QBC4C]-
M(JS0A$'#DZQ1.05>Y94W GX*4I1XS5</:)_H&G.L!<U+@.J/>34DD!V0/S;B
M<[_1=U\7/B-1^*/%+.)1HC=$JMLZ-HZBRZ=<A_X0(#Y\+0V1 /Y0(&<Y5QP(
M7@/I > X\@'/G[_U_.;R,9Z1^^Z\P7/CD.!X$/\ 3QEVV0B<%<1(4P !BE,
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MVI#$.5NB4Z8"4AP(4#% >>0*;CD \C^?R/[X5\(Z#W^GFO*K1JN("NW16$/
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4   R+( #9<\*IA$PB81,(F$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>fhtx-20211231_g15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g15.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1)\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $F"^1P0X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O
M;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M        4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U
M8D!OX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M                0FQD(%5N=$8C4FQT                4G-L=%5N=$8C
M4'AL0%>!P0         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@              D    DX
M 0                         !              ).    D
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    D     !29VAT
M;&]N9P   DX    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M C_P        .$))3001       ! 0 X0DE-!!0       0    #.$))300,
M      @N     0   *     G   !X   22    @2 !@  ?_8_^T #$%D;V)E
M7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,
M#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,
M# P,# P,# P,# P,# P,# P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0'_P  1" "3 EH# 1$  A$! Q$!_\0 '@ !  $$ P$!
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MHQ&BK@WTQC1=?++^+(\P_B%=F:V?JG!]9&=&O[%U]91 [(>V#U.OBZZTUMW
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MDK&O]&T>L>O7D2?Z6[N[UMN_-9T5W?D^M:FPI^L@>QZFYZZ/T!0Y(Y.@$HI
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M#@#@#@$&J3_I%-I_3_ZK%5_L3_\ $.I_\5_\N 3EX X X X X X X X X X
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M&OT)]Z6Q8YE<;&"Z)8FA0M0%IP\C$'@A24V;IO)JBSU164-)6>8WD +6T],
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M\7*F&<FEL1+*&&9>P:IR12RB2RL8]6IZHQSD<J??T7T^PNJT>G#1_$V"\$'
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MOZKRG_WS?(+_ (B%_P#+[_\ A_9P";/ ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' (D>9'6%]V_UK78L##R[BC32U.DO
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M<6-@*=8SCG&SDZR[C803'(^$6<86)6P5X,8X$GN . . . . . . . . . .
M. . . :/N]Z3JKN'SH$?GM/UK:Z[":CKV&_/U.PZ_6WS\BT0;HJKK6OGL9+R
M6P@>,L]G'(.Y@M[.5 X&9ZL=&_)>7/&,Z<]<9?AZYY-X/!!P!P"$_A5_5>4_
M^^9Y _\ $0O Z^N2]:DV. . . . . . . . . . . 80\D>SLKTUTAV'V;MM
M #E<OD:@<^VT%EH[7)!5<<]K7UX\\V@I*ZVLP/<88/#$@M>0IDTD8,WQ0%2S
MQ\-Q&4J-2,-[><7N[M25*65AK$X>]'ARX_ZO1MFTV+5H4=J652Z=)6\:R59U
MK*CM&EW<HRC+?L[B4*-98E_W23IO%6"<X13P7T5Y<X#L_I?":CJ0R7NJQT--
M,9'/EM-9Z//A_"88,38Z[LC35=5%3!#DP>^Q&F!-O:P::-X%%9UL<!4WQ:*I
M&VHJJI*IN)SWZLJTMYK+WJDTI-^#TC_JFTCF[0U+6MMK:-2QE1G9NZG&VE;V
M5#9U%THXC#NK.WE*E3CNI>]%YJO_ "R2E-I8=\D-M5:WIOM";L'65O:,*XR[
M]O4G78-E8],-BF%?$\3L/8#&5PFQ@'5[&6]?9:RM#F5D<U?D@RG>B\>T+F5I
M975S"._.C1G4C!\).*RHYP^/#7/$R>R&QZ':#M/L/8MU6_36^TMI6UI6KK#=
M&G6GB57#:QN++>&L)/WEQ,!_@5Y_&XSQY[&Q^.PG6V%%J>P8B2H>OP#P9;HB
MRKE*?8WZV=]?%$$P^Y! E9,.*,&QL$ [41572]E]N7&W+:XKW%O^FE2K1A"&
M6]Z#AO;VL8O&=,M'J'MT]F&Q_9?MO8^S-C[8GMFE?[.JW=>XDHKNJT+ATE3Q
M"=1)N/O-;V>>.;W?O8R1CHY&-D8]%:YCVHYKD7^E'-5%147_ $*G.SGAA&B+
MPX\8X?(=?*Z+IG$,\@G9]^9_6:VH@30)4RA3UDK&R^WXVE2U91%5(<D:&/K)
MI 73*,Y8^!RQR;SCEGR^OGJ27:UK&M8QJ-8QJ-:UJ(C6M:GHUK43[(B(B(B)
M]D1/1. 11NO";QUO9)9S,62PJ?LO5]M3&"Z&_&+DV.WDIGZ:;ZB&Q9*RJLF9
MVB'6CC<RJ&%J01A1(81V,0.:>=5ZQ]OBD?)/A/X_S?HE(-GM!5'X40<3(VU-
MM=966U"@N<K<E"17V(EO&3":W/50M=]:DBD_&XB3Y?F)FD>+GRUZI/[E5PWA
M_P!%=<]E.[:RF:L0=Q-!+$9:D:706"6$DH<0#B[ 8^Q(',+:)"R&*<B.1\7[
MSXU:][G*)GZ:$G> . . . . . . . . . 1"\W:VIM.D)VV.SI<&94ZW):.D
MT5Y3VFA$#M*6WAFA<M'3"G6%@V1DKQI6,#G'9$0Y2D;$Y7("UT71\\:<^A6?
M#70WVFZ!R]IHRQK*Q2XV(#+@&FDH*^]KZO67%?5WM?43B $A@7  X]@'&4&.
M4HY$;B(F2JY.!Y>''ZDI. . 09I/^D4VG^ZO5?\ CV'5?W< G-P!P!P!P!P!
MP!P!P!P""_7GF%XP%ZCN @3L[+U[*BPKSC'&I^5R20"5 E=-"!%/%$1:%NL1
M28(@*^(DR<C]V&![I6>[0;)VOLW:-YM"E95XU)TYTY3BH..(QIQIO5I)_P"2
M,ESU3?#!ZWV_]GW;3LEV=[(WO:39EQ96ES;7="A5JUX58SK3NZUW"*4:DVF[
M6M2FFUI&2CR:7@J^W:CNRZ%U%KG>P;[&U!33,=U74XJYAL+"<:3W"[':MT$-
M"#,0O]=3T*&DC5T3HBIF2'JZ1N_/)/7KU\S(W:W8G?-AUIMINH.F;T/0IF;1
MN8,T-[0TUZ)<H*] 91\M)!9CG+%-[?C'DM8&3*B,5S&KZI@;3E=QV?>RL8RE
M>*WJ.VC%1;=;=?=I*7NYWL?[:=>9VGL/3V!6[7]FZ7:JI"EV<J;8LH[;J595
M84X;.=:*N93E0S5C%4\MNFG)+@C W@WB>Y-SBIM9Y6UUN9I,[J[1F$H+UM?'
M0@P/DDDL+^.EK)9*TRW6VFL H;$Z*0H&%I(X:QPE3+)I>R4]L3V?5>V82A65
MS45)2A"#[IX<L*'%*KOK77330]._]0-M[.[;M?8Q]G%>C7V;+8MI+:$J%6ZK
M05ZDXT4W=Q4U+]#&VEB'NM23?O92V4.158YK'>QRM5&O1$=[%5%1'(U?W5]J
M^B^B_9?3T7[<[2^#UQX]/$\)32:;64FFUJLKFLK59X::EF8C)GY$*P"+TAFB
M8=<6]TUYE=6 .&*O+8^ZL6QI700))'*;83.8V7W?$QK&1^UJ*G,:VH3MXSC*
MM*MO5*E3,H0@U*K4G5G_ *))IRF^/!)8-UMS:U#:]>WKT=F4-FNA9V=E*-&X
MNKA5:=A:6]E;2D[FI4<91H6T%+=QOR;E++P7%<NN&U9KJ!@$EPD/K7LM%G2O
M=/[F_8I1G,G2/V>_^K<CO=[?OZ>O,DTAKFJ]%^(8_P FK"L.HLLG234,^C*D
MK069Y?:*Q1_990R_I0Y?G]R-^23T<Y%1_JWT]>ITJO:7_P!Q3IU*:_X/$MR:
MA1XJ*W??_P#E_P!L\>.G4]^O=G^Q9>QRUO+2\;]J+=#]1;?J]HMK->2K?]/+
M_H<*EN_Z^:][4G=M)-0WK34R >D6P3(W#@OR=TZ)'>?EA'TJUSW.4A%:7\:P
M.]_RHY&JCO<B+SMAX":U<]1>;&,S.,CJ-$1<WEUXU[/2;!^TT'8NPA&WGU/5
MBTD-;);7DY57M6--U2#A1R)4MB2P2,5/8U6B\7T7V7Y_(Z/U7D>S1X(N)G:^
MUWKM3OF]RXW=WMM58,? #=:WT^'?3&7@QF?S]V9V+%B8(C,^&03."5?)8*D3
MIV/>ECX<<_'\$QPR^O#B]7Q\D^?%X\667V?V)Y(&W'8KL5J^QZ.MC[)MLQ?B
MWHFK1E0-7D]I$5E[1OR]8,7G\15V=;B\)5SXPB>QWBS4VLTZ-KK>W@8X>/R]
M:>LE]+Y+.4]<_P!):F5?%3M/R'EWQL_D''J@_P [CN:\FB*K[5HF26'2QUW6
MSCX&1NS3K#89F2.UEGR,<3X)(C':ESBOB=&)S:^N'CEP^QD4/==R57D-HX[*
M3;$9Z KLR"YHTJBS<C6Y<,.K;TM99]C6-#DM;\J:R==N!E0V2:/X[18XHX7<
M H75NW\@Z_J;M7Z+\UV>XJM-0PYK6:0372UMFZ_))==""YW4$R6 +<:SXQ#(
MZ][*4J5T,H*/A8_U>O70&%>Q_,#R?Z<R%S<]D 9>A00HI]#=E9@KVZ0X ?L7
MZ/'@TT,R$SEZ!<A0%N-&:YXC=#(QKAH5'F@#XMY>,8X<.'77[<BY=3WOY3=;
M[_L+26&=-;U5H>MJ?94^DOVR%TN*NF7G;+$!6HD>,RD "ZNI<]N-$LDKI3M,
M!6YM&1D7KI'!C#X_WQ>OB]%RTZ&70>\][W%X3=\Z/"V)EAW0!U+Y)R]?VN3J
M["EGN#:+4=Y]>].:C.-D:QT%OI9.MP+L: 9S91C"AB8X1QRPVJ"Y93\5S\O,
MQ+8YWOGKVRJZ_N+LGN2/K&]J-G?9N7J_0[72:S/[-E!@Z_/Y'3:WZDC3W*'7
M FLT><!.D3-RSWQE-:N&$I:YRAG'+/+7@_RO'FL-HSMH]GW+:>.&+?8/T-7O
MZZWQ=9WZ3CAIX-319^<.<G5F9-XC&2R6L#G5/RSU#G$CCRV"C*XF)(W"IXU?
M1_V\]"']+V#VSH;_ %2U^C\EX,+74FJAZ!>=^F@>GT.T&V<4%4'NHR5:Z^J/
MR]%0(C83OC)H7RDSJA+6LX'+.4WSY?)?SX>+W%Y*2_ERN9EU<<$.HDS]-)I(
MA?:@T5^^N&=<1CHU$:D#+%26P^U$;\:-]$1."%P< < < < U;_HCVDMX-FOU
M4=F-[@%[FGUB=RHE&G4Y&:GN'2R-(LDLOS"6C_1YRC"XZ2B=$)8?&Z.='Q)-
MR:^O7K'(=>G+KZ]>+VD<H,%W7DQT7GJZXMK7L:FBKZ#:6?7=P0-!:6/T.SI:
M,?2W%%+%6@%S.)JZ$F&T/ECC>*((KY)IV?%*C *OG>^NH=8_;MSNYJ;-.N1"
MK#8RPQGQC5->"7= &V$94X<0UH"&=G+L(HRHE/''+KIQYI&2K&R3YE*,(RG)
MXC"+E)O@HQ3;;\DFSEH4*MS7HVU"#JU[BK3HT:<<.52K5G&%.$<M+>G.48K+
M6K\'B#GX;OD3T?W.5Y6U?5?9F6W5@-Y4]SZ\@7/FN+DBS6CT,*T5T_\ R3&M
M"M$AE^D?[O=(D;E]J>B\X:5U0KRW:53>EW<:N-V<7W<VU&7O1CHVFNJYI91L
MK_86U=ETN_OK1T:/ZJM8]XJUO6BKNWC&56BW0JU<2A&47EXC)/W7+#QL_<YK
M&JY[FM:B>JN<J-:B?Z55?1$3_;S(-044K2YP'U^MT%()Z?T_56H _IZ?T^OR
MSL]/^W@%OS]I=9"N]A/8N$'=_P"[/KL_$[_NDL&K_P"' +=TG?W2&1H+C4:#
MMKKROHZ"N*MK8Y=?1$(* %"^<F=8!3IB)?CB8YWQP0R2/]/1C'*J)R2DHIRD
M\))MOP6KT6K^!R4J-2M4A1IQ<JE2480CE1S*3Q%9DU%9?.32\2*GC!^*3X2>
M8 &R.Z/[@&OW82U_*[^O,IK<&U;'*^9@-L%7M%(G-J+11R% )A19I$A?\PT"
MJQ'3?BY;N==U2QA\'IDLJ%6--57!]VZG=*64_P#)N[V[A/>X:YQA\FR11'E!
MT>*JM(V)$+T541DN3VD"N<GKZ-:Z?.Q1^J^GHBN>UG]JN1/OPY17&45YM+[L
MD:56>=RE4GCE"$I/AGDNFOD15\NOQ)<%XT>/_8O<V?P&W[/LLG60+G\Y4!!0
M,T%Y8G#UU:$]/S)]U&-\I"E$O&IYYD%'E:C8W.;(WCG<4(8WJM-;TE!>_'64
MGA+CS>GGIQ,^WV-M6[=14-GWE3NJ-2XJ-6]7$:-);U2;;AC$(^\\:X3>-#''
M@%^*-)YJ]#5W9AW1&LZ\W$5O8T.CQ]M8U=37"FAR^HQ5<9?&"VTH-@&^$J-\
MU7_D_D6-LL_M5ZHW%";E&-6#E!I36\LQ;2DD]>.&LXX=<DK;'VG0I6]>I8W2
MHW5.52A4[BKNU(1G*G*2]UX6_%I9>6EG&&FY8]J=^=M8CJWL#L"LZBS3X\ID
M+Z_&(/[6JI(63U]?.0*I@0&=)G?$I#84?##*Y\B.]C7(J^Y+4K4J-.=:I4C"
ME3BYSFWI&,>+>,Z(X[+9E_M&]M=G6=K6KWUY7A;6MM&.[4K5ZCW84X[^ZMZ3
MT66C4M^$Y^)9Y<>6W77:MAY*E=!=5:S&:^"*B;L8+'/G7&=LV6$OQ!5->;2C
M3PU#Q1QQC&.,-/;,KR8T>B*N+9[3L-H=Y^BNZ-SW6[O]VWB*GEQRVDM4N3^1
MO^TW8;M7V/\ TG_N/85_LA7SK1M?UE.$76E;RC&JH*$YOW'.*RTD\Z-D^[SR
M"T5D<^ORO8?<G9EM.]T!.:Z9Z-KAL_!,JJU@\.VV]72EBBRK]OS4.VL5AC3Y
M8WN<GM7)E7A%[JWIR_\ &$6V_)Z1^II*.RKJM!59.A;4>#JW-Q3IJ.>&]!.5
M9?"ET>#7Y^))T#Y ^3OBAL>N+#KOMG+X77WV.KM7!I.U-%V)MA(@-"'?0WE1
MFH3)LVRI'MZFNFL4D%=,&$R1T2*W]U-7M:ZVA2LY5=GV[=:%2DTJSQ%PWUWB
ME&#<]W<SJFGG'+4[_P"SSL_V2VAVEI[.[6;;I4MG7-C?P[W9\>\G"X=O)VDJ
M%Q<JE1C7_4."C"I3G&4=]<=UE[?A,^$&HZD\2L_UE:1QEYC+;#5+G NS@]-)
M,Z&RLVWRZBORT=B/F$F*L+([Z(Z:L6>05$BD5T;&(GQLBOM6[M'7O(T*-2I5
MFXQC&HU"G[N[N;SU6,XWEQ;Z'+[1]D=A.SO:".S.SMQM7:EI:V-M"K<5*]G'
MOKR+J*XC<*E3;A4C-*,E2E%)1BTD\HV7=U>._9&[Z:V_7]#V@.V>]K!_H:*;
M%Y:ESA1H-B!91A6$]#7A6J EJ%]+,^(E)U9+[G/56\S+NTKW%M6HJY;<XZ)P
MA&.5)22;A%3QIC1Y\3KW9SM%LC8^V]G;1GL6,*=K7<IU:5W<U:\83I5*3J0I
MUYSH.I'?WTI0QF..#+1\)>B.T.IB.R])V=G.O,6=M%R(E=D^N2+DVI 'S-0^
MNE-(-NIYIY2K"5WS.9&C(XD_=:B^G,?9%C5LU7=6%*GWG=*-.DZDHQ4(M/6H
MV\MO.%HC;>T3M5L[M'+95+9]S?WRL(WLJU[M"A;4*U:=W756,5"VC"+C2C%1
M4I+>:XX)S7+K=M6<ZA8!)<(/(M='9K.@#R?3_)M*49S)TA5?\]8W([T_H5/Z
M>;D\T-<M7HOQ#'^5%C5'4.6;T0QQ?T94M: S-N1,>DP_LM(9OTK=ZZ/U8U99
M/N5ZPO\ 4)$3G4J57M*^TU2E4IX[/YGN3[N@N%IF'OK_ #?_ &<K7CP>A[_>
MV'L7C[$K2]M+O>]K,E;_ *FU5WM)M-[?E3KYMI+] E_PN)>[G&DU_D)G]Q%;
MD3H;M S,)-'V2-U-LB:!,\DKIX]M%D;&6L2D2573.E;>-A2M21SI5<D/O57^
MJ\[:> &O/54'FSU[DP@L'HB+R[L?'CR'TMZ1I='V-M60;D>BZRCZ]'HR[F\)
ML*_61%_I,^E 6=:EA4IDT(K9)9U<'KARY]/A_17>LM/W_#NHB:Q.TMGN8^Q^
MWXMYBMG>6]3UO%UN+H"(NOG4QMT.90T%K,"E>ZIGH@R9#0W62V:L>R%5%QY>
MOVYF*>U.QO)@F;LL[K_1]E544.F%K"JJW&TTTH),)5_.MG0K2U0K:C-.FCJ,
M\ )0RD);K$RUMTC&+(;QQ^).G+7E_?WTR9@\7NT?(1>UK&'OM-/"!<5U72"5
MDM?<I5TMD:W+BYTDE'QNHOGO3"+=SB:9D),+72K=O1D$?H'3\_WY>M3)E-MN
MVP/)'?A7!6UER[+30UD-5)5&D9*MR,V8PK>O[RC6.+Z.2V,W)VG".E'D4V4"
M,UUI\8U> Y1,^?W7[KY8\>ML=.;SR#%Z4V#T'M]9V /M.JJFOUVE#UCZ\Z?:
MW67J-^L69TY<UG5Q]>P'6EA9BUDK,Y[_ $94>X<6=[Q?H8:[#\N/*3J#.D%=
MC 92B8_KNVV=+J"\W.V.YW=9/NJBBZ=&I(B%G(/UD6.#U!-L+&]]7)>P ,=
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MA@AC8GHV.**-&LC8U/LUK6HB)]D3@AW\ < A-X5?U7E/_9_^<WR"_P"(A?\
MX_\ 9P";/ ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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MRQ/:^.5C9(WM7U:]CVHYCVK_ &M<U45%_M1> ?? ' ' ' ' ' ' ' ' ' '
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M> . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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M3Z_7^&5XTPN6O'CU]:<>.AF7]DC7?ZW?E!_.M9_@W)KU^GG_ !\AGP7'//\
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M8.C9(8H[$@N?W333O(=)+(KA>N%A-I_(D=P0< < < < < < < < < < < <
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M,JCS1RK/'+ JQJL4C)U69CX_:YLJK(U4>ONX!4. . . . . . . . . . .
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7 . . . . . . . . . . . . . ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>fhtx-20211231_g16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g16.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1(>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $@*^1A X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O
M;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M        4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U
M8D!OX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M                0FQD(%5N=$8C4FQT                4G-L=%5N=$8C
M4'AL0%>K.D         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@              C@   DD
M 0                         !              ))    C@
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    C@    !29VAT
M;&]N9P   DD    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M C_P        .$))3001       ! 0 X0DE-!!0       0    #.$))300,
M      ?0     0   *     G   !X   22    >T !@  ?_8_^T #$%D;V)E
M7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,
M#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M 0T+"PT.#1 .#A 4#@X.
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MBC)^-<_*6*!J^XT94G$!@.2#\?80A5;SORUZ)WO?<WJX(, 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P#IV..IU3ZF&MO*:VPIW;:-N*8V
MKW;94O>O=MK:OTMM[WM&]_7T]< IH==@(YC0H$)$A#:0\WH<6/$'9TV1[M/H
M^&TTE'L>TM>G4^GM<TI6E:WK>\$LNB.PJ#A3F_A&Q,:6ULA@O;9(0SZ-E"H:
M;&)VEUM2=OL-LLMLN^GO;0TVE"M)0G6A3WM,,L^_;++36W5^]S;:$H^(OTUK
MWK]NM>Y7IK6O7?KOTUK7X:P#R.Q,6^.6&_' O"'K<<.&<$86P8M[?JZLII3>
MVWUN[^KBG4JVO?U5O>\ \[]=@"14 D0D2^&WIC38CT<(X,C0RO</I#*V=MIT
MPK])K6DZ^'OZH]-X%M;\]CU-Q<:UI*6H\)M*5(4G2!64Z2IO2M(5K24:UK:-
M*5I.]?5.E*UKTUO> =*(.%;-9DFXB-1(CL*&8.0",DQD=:O>MAHG36GFV5*_
M24VE>D;W]=ZP"J8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M8&1< 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M:Q/37*+C P8$Y5H=^#$D0)J U+^I +[S^TOL.;^'[TK]%)^OIK!/4EK@# &
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M (W']=F2GR82/G1&3&'(^*^6%':22QIIIUU7Q]H6UMM'LWI6]A:^_73V)H8
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M;B=[UO7JE6_3>MZWZ;UO6 2F@?Y#AOZICO\ 0V<BV7H"JY0, 8 P!@# & ,
M8 P!@'%:T-I4M:DH0A*EK6M6DI0A.M[4I2M[UI*4ZUO:E;WK6M:WO>_3 /#'
M2T5,-./Q,G'RC+3NV77HXT8UIM[24KVTXX,XZA#ND+0K;:MZ5I*DJ]/16M[
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M+$6ROOS,H8 P"&'CCO\ A^\S]>GX=(H?U_;_ &DI_P"; )GX P!@# & , 8
MP!@# (-V9:>W>85:J?KHGGWBO!,](M>_HL$SK]P9*C^>Q3^OTFGUUJ"8GK8K
MVJT1%3 D(MUO22F][#O?\?+Z]"F^&/2J-<^A>:T;6+''S!J?*:6G],"+5M;D
M*KCO%:NF4:]R4Z>"W8*W/0^B6MJ:V=$G#Z5MP=S6HEOZ_A*^FA.=_)?=OVW)
M[92C & 4J9G86NA;D9^6CH4#3J&=FRA@X(NGG-*VVUM\EQMOXB](5M"/=[E:
M2KTUOTW@$3^/_: >'/>^A]*Y5R?OE%MU\Y',,P5Z@A37PU1TD^4^"RB.-DA@
MX^PCN&C/B).KQ4H%LAI;/S'Q-;3@6>CMOJB170.B5WFD/'V"TN$#09<W'PI<
MLVVVH"#3(I(VW+S9+CK38$,PMA+1)RE*2TZ0.GV*^)KT P*_YK\'# ARCYJ9
M"-ESX\!,(NOR9,N(Y(DF,L[='!9*:*=:&#5*%Q\8^?*"1+X\@0"VP[I6A;>G
MS][>7O;F562\P>&QP4V;NS.'(@=:=.3&".'I8%<B@9H8@XL?:P(1PV-.24%'
M6 J*EBVAREL +2SM6PMV_H9CYYT^C=6AB+!09YBP1(IZHU\ME@L;22="BG-;
MTT:P,\L8L X*0CS$-J$D(\L8X)Y\5]IU8A?N , 8 P!@# & , 8 P!@# & 1
M4\P#I4GF4-SN"F"8.9[5>8?DH<@/!@3J66+#$S\E+N$LR5LIXHHPT'!R9JR%
M2)JWUC-Q:8:2U(J;0'?7T^I8_B)#L<]LG8.0&0=#B)^D2T$O9]!Y-3^8QEKK
M\A%-.0MD(U4;;9]R1Q;'HDUJ>8@Y4$G3C2 7P_A&.@3CP!@$3O.O^9[Y$_XL
M+!_U2, DY _6#AM_^:H[_0V<BT271(%5R@8 P!@# & , 8 P"R[YT?G_ "V!
M5:>EW>J4"M(+$ 78+E/Q=;ADG2#R1@0U24N4('HHPA:&1F-O?%?=4EMM*E;U
MK (D3GD5T#O$N=0_#0.&F8@"0)A;SY0V@8@SC=)(%><%E(OG; SXI';[_&/M
MNC$15:+%H]?.8*"MMZAYL5J .%Z7];=?X7UVM=,S+Q[QHYWR-N<EE:DNB])N
M@ORW1>N=&<%L-]O+2M.>^./,4*Q'0M5:VZ]J.HU8CH:GQB77EBPVBB32BA-=
MKNW3DC*-&YKSGF$<;$<UH%)YY$R,@Y+2$71JK!5*./E76&!G9,T*  CQBI!P
M848=PQ]IPE; [#2G-MLMI2!>N , X.NMLMN//+0TTTA;KKKBM(0VVVG:UK6I
M6])2A"=;4I6]ZTG6M[WOTU@$/;S]H!X<<V[)SS@-S[_0H;J_5-/?D15UR#I7
MWHII?P]-DRX3!$+#O$N_O0+,S(@.GNZVV$A]25:T*DVFTKI;LE>).1<E$_?<
M0:-,1BF'R&"XI]HYDM ^G-.)%=86MIY?O;6UK2%[_?=;1O>MZWZ"$<(OS%X@
M?H11DZ;"(+CZN5\24CW=H"D;"(:9(P$NJ/4?J%E*,V,(W?W97Y2*JCTS"MR4
MDWL]OT6[_O;W&O1\_DN:ZK2ZMNCSP7FAP2>A:I.,V0\0>WPILS'1YL))MV%&
MHZO4VWG";K+0[U@/^3J-XB;45*PT;)U\6M,2$\3+M10Z"W0>F_+OM;\MR_N<
M^1/*>I3CE6JEBT_:6(Z0E"X @4AHL0>+>AT'M/$I0Y&[D QK+5Y0R+:.<D@H
MBTUN3,%8#FXYTAY=-_+EKTU%K?;U].OL9OP!@# & , 8 P!@# -:7VCO5*I0
MZ=6 [OSXZ=KRI48O=MF>Y6OQUHH!\B--ALPR>@TR>BY22M&V(X@S58-9T#N-
M<1*,D+('6AAY?U]7H+7:6FM]/EUT>_7[DC>:72&XKXH<DLG2;!,R@-8Y5S<&
M?LH\18K7*21SD##QNY4H:(5:I=[1QSB7S9(DV0'%2ZX;)R^QT/'8*]&].;V]
M?2/V7HMCH)\RN%-6*SU,":L-@L%5E6*Z;&5FGV.?(-M#Q) CE7B]1D>1HJ>%
M?"/20&YMA'LCI-UAYYJ,/6,%N^]?7^2O\V\I^+];G(Z#HEADI=4R#)F0DN[6
M;#&UZ:=@FQ7+)%1LW(QPH)$S6M&B(GHW;B'XYY]([FMOI<;0]N^A/G\G]=-+
M\O0QMXWK0OOOF>I"M+3^<BB:TI.TJ3O^TE/TTI/KZ^GZ_K], FC@# & , 8
MP!@# & 6#U+HE>Y+SNY=*M1;04!38$Z;/?><^$A6AF_08;3F]*TEPTQ8X3.]
MZWKXQ#>M_3> 84\/>?SM0Y"U:KP,Z/T[M$[*=CZ.DI'L.#F[I\$B'KA:=[7M
MIZGU$>O5<D=#BATR,4>2/I.BU:V!*G & , 8!Q6A#FO:M"5I]?7VK3I6O77X
M;]-ZWKUU@63W5S G+_%CQTXI=^C])Y/QNAT&]]<E$S/2+16X,<"5MDBAYXE+
M\B\CU2A&BB""OE@T#"_-$/D[8^.\XXH&V]&[KH]3*EUI56Z-59ND7:&&L%5L
M8GR$W#&+?0-("?%;?^ \L5Y@A*?BLMK]6GFU>Y&OTO3UUL#%#GBUP-VTJNBN
M=@:LBFXMO9S<M8V6/6&$4!'/:BVIE$2DMD-6QG#4@Z,*:TE);[_L1[0/%OQ+
M\??B3"T<_P#@-6%C8]A %M5V$B)]O48S#LJG84:R-1,P\'&L-B1Q,B$23&(V
MZJ/=&<??6XWMY.Z]1_@R-R[D?.N+UQRI<RK3%5KKA[DEN,'.E9!I!3@XHG[R
M[,'R)(XK0H8S P##S8(C36D"C,Z4OW 9'P!@# & , 8 P!@# & , 8 P# ?D
MUNJL<9MTI<^4/]E@8$5,\73Q)>CUPMK45[R56 :S]!MU%K]9<@6DNG*G_P I
MXT^-:2Z\&YM7OU@?GOD89\*+_P 1O$'=5\0YY"TB)%E(URP',]?XKV&T669(
MC65:+M%@Y%U[M)+CX(_L !=N5M1+K#9;0* P"EI.A6K/^K;>R\_>Y*7I?2JI
MR2GR-ZNK\H-78IT%DU^'K\Y93&UR)K  N_NRO1\E(? V20TE\M0Z1 V][?+?
M892IS0EK_P"4ON84LGF1Q.K3S]<DC+6]([E'*U"[C:;.R ELO#$>-+&<^JA0
MXRFIBY@Q9HIY<0WMM#0SR5Z*7M*TH%MZ?-$=_/WRAX= ?9\]?ZG:KN/4:;<J
MI.TR%.LD?*QQ"K@J6*K3E9+"T$\2)*,S\:?%.?%1H-1(RG&"WA7&2'>.I5A2
M47-R_=)1BHPG.3;Y*,(REYMVLEJVD;>#P.)QTZL<-&DW0IRK595L3AL+3A3A
M:[=7%5:-*[;2C!3<YMI1C)Z$M>+>1'#>Q<LJG1^:]5I%LI4K6-2P<\#.AL#_
M ';$C-MRAI8YZPS8YB/VC:S5R HNAF5-ONZ0PZTXNPJ1J14XMV=]XR@TTW%W
MC-1E&S3_ -R3TV,,7A:^"Q%3#8A4XUJ:@Y*E6H8BFU4IQJPE"MAJE6A4C*G.
M,E*G4E&SM>Z:5[[Z]R9-GEZ0KJ'.]7.OQ#U@GJCNZUK5GA($=Y([\W+P&Y/[
MUC8A@A:&'I(T1D)MY26EO)6K2=YFL7(Y;*JSM27;-7VE(^\]KTY,QR-HU"2(
M4/,[5I1.MI^Z9:2CHN3]?3Y"1/""*^$24PTX']?7;Y\CXJWU-&]:79ZZG>WR
MQM:5-1J=[) F45TX?6MDZWM\*P.(@BVO[H-,K1&/)0:K3&P/BK?4T[<2JT5U
M.V7=L/:5-1NMM/:EE0.V7-;)UM#NIU*H7;:O1>I9*H[>OG-;9P"BA]3YC(R4
MA"Q_1J&?,1+NF96)#M]?*DHQY16@=,R #$BLH)W9JDAZ;)::7LI6A]:^-O2,
M KB;;5%[:TBS5Y6WFVWF=)FHU6W6G2E!-.M:T3OXC;AB5"-K3ZI64E0Z=[=U
MM&@(P]Z\[_%KQJF^95WK?5ZW 2_8)EN!Y^(U*19CD](.2"8K6ATH/2KY=$@O
MY1TM*5CLD)4RZXAW7LS@K5U1<$Z=>IQR45\&C.JHWYS<$U"/64K)<V=IEV4U
M<RAB9T\7EF&6%INK-9AF.&P,JD4F^'#QQ$X/$5':T:5+BJ2;246=_1?.GQ6Y
MM,?DF=UN%NG0%DM L<OY )+=GZ<X>23L(01^A\N M=CB=%&IV&V;.@Q46@C2
MD$',Z0XI'.=99]'ZO1?-Z7VTO?5=3'"N_P#E!UQ&V>0<CYYPB )6$RQT'RBZ
M+7Y:U)U*%$ Q1D/P/C$U:7)1N3+$+&#CKMV;E4ZHD4@5R)24R\.V&B=F[^G\
M_P )^Q%[RK^R\YYY^\VAZ!Y>>9G4>CF!V>LW."&YL3R_EW/H.5)^]H^/>JE
M8A;=*D,V*/\ RAB8U^ZWJ_'ZT@U4,>ET0I*P3X=59<E?7VUYZ\K/I8VF\U"Y
M?SBA\[YE0YJOC52I4^F5"C1S4]'&.NUL"N*'J*1G4$;7);D8" *-#+:2O<J/
M'R$@QMUM@EQ E[ZWOYEWL7&HDH%=&M5<(;.^4^2<8G(QU!GS\21/ ?*K;*4D
MCYV#$*FA/A;7\S$C$2+/O#9<>2 U<:BIK;Z;37%,Z6VWM[4Y&;:TX]%:G6F]
MN:*]FENPF]3+:/7W+BMZD$ZV)O3V.5^77D.=N?3G\CZNWU)O3RG+174)&_OC
M:YN,3IC_ &M;F/W[:B=::_VH>9E?T_;_ +6NMG?WJXEW8'U5NJB5N-JL]>2X
MTVMUU"IJ-TMMIL-,@XZXG9.E(;;CUH.6M6M)0&I)*MZ95I>P*XR\R2RT0.ZT
M0.0TAYA]E:'67V74:6VZTXC:D.-.(4E:%H4I"T*TI.]ZWK>!OYF"[EXN^/'0
MNKT+NEWX[0[-U[EZ7DT#H$M!#$V.L?'5I>U1Y>]:3MQES7Q0W2&WW 'M[>"6
M.[O:]M]7OU"T5EHMS.Z4I0G24)2A.OP2G6DIU]?7Z:UK6M?7Z_37XX!'J1\3
M_'J56,Z;S2+V\)>I[I3;XTG8@'W+G:'Q";%*EO@3 SIS$T_'@.R,,:LB")4$
M+\2-WH=K2 .)OB?P$[<"XJB+"*JX"XNNR,+;;Q7Y>% =J=9HCX\=,P5ECI47
M15.I]?KABVC$NF10;XI2WD24I\Z!7J/XZ<7YM=I;HM(HP=?N,[&N1,O,"R<\
M]H\-UN"97M^.,E28G9BAZQ "?>:04R6@HL8+1>A=+96'?W_E_-F:\ 8 P!@#
M & , 8 P#65YQ7NQUGHG._R1NX35IKL$].P5&Y0YHSRH98GRIF%L,Y6JK+\E
M\C*7::+9!(V.B!6[3R:G!Q%AK<F8OL$6"\>""[[[_(YK[:6=_-VX;=;W>WK+
MRD<SJ,UXXT?E3M9N%2I;O+ZE66ZA:C(]%YKD,%"1K(D%8SH<Z8C/RCBVAF0Y
M=Z-D9$)1[)&Q2R&=H=4!C8_PDY$397[9'R=VKLX-9K!>*B7!2%<'70;S<)'<
MI<[?6G#*L<_(2UK+6_N3&NSUO@Q&2BAX&(AF7UHV[W?VO;Y#OOOFSLJ7@YX_
M5-E,-NN$6NB-Q,[&,\OO>H:W\[2[;?D%7.5*@9B%?>F3K<_& ES(\^?*PK98
MZ7XB(BEJ<VM>_?N+W[]S'?AGSCGG*>L^8M+Y=0Z7S:G1_3*4\!4Z!5H2G5H)
MXJEI<)=%@J\#'18SA#G[X\M@5"G5_I.;4KZX%V]W<V!8 P!@# & , 8 P#Q2
M1;@$<><R ;*O!!%%M1D=\I]X23@S#CR  /GRP ?G3%(T.+\Z<&)\=QOY@L=G
MWO( U6$]XC//'H'+^)0W-NDT>D05H/Z;VJ+Z6+2AB)>M<XDU1T+6U,TF\7D)
MZ,GKWIB/E0I(V.*) &V:$P2*VI[0&V# & , 8 P"P>H1UQEJ!;(VA2 ,9:3:
M_-BQ11PI9/H61$',"(#<"FH%V//V:X,H224=ML):-NK8<^BF^*NJDJ514G&-
M1PDHN2;U<6E:TH-.]K2OH^1V&55<%1S'!U<PIU*N$IXFA.M"G.$?V1K4Y3<U
M.AB%4IJ"GQTE3O43X5*/.#7BSS/M-4Z4N6D*CU3GE6URRLPMM;[+UN8[*/;K
M^)/3),O,TT)7<KVW4].QSX2'"W00&GV]-#ZC=J9VK.JP&'Q-.OQ.G7H4UAX0
MJ+$8B6(56LI2<I4U^JJ\&C6K2TTMII[_ ,79MD>,RM4:>-R?,\9_Y?%U\'+)
M,DH9%/!9=4P]"-&ACJB\/Y<\;PU8U+056I*+;E\6TK$C/(CCME[$5S&-B9O[
MFK\%:#)>W>NTOH.C] ):$%7%O?V+(Z43[O31'][;W\9K]/.Z/F!$.]>,ODV0
M-"Z8O,O=:O&WBW29W-MV4*OBO50T:/8B(X:8&#!D9#;VAWT_=LW+.Q\;I7J-
M[-[WO ]EY[]/7J7U.\D\DV>6%5N,0*3&2=V7*UNBAW2[ZM'-*Z0:(MD$WH;7
M1JH[>8Z*89-+!JCFXH(0Z09#<F)6$C&8Y\.^^_GNX\2'B]YHJE#U-])Z@=65
MGZ<EP'>N$-V.P*"A"X^E.Q\OJ42.@<0]<9+=(*?8@9%XL4]BI,F,/,.82ZVZ
M]Z<K)+V"T?MT5E[6UNMN6VJ-BMZJ_1>A\XYXV(N6IMUK?7..V&>&B;=-PHLA
M7J#V&KF7MA\N.D7"IVNVNCPT\^+7K ^:W,!2@D;/MK?<)4EWW<O/3;6U[-V\
M]+7\TM]58L]FC]?>\I >E(58PZ._"/UR=AIB\,2-#'K$:!:=1IM4J,6P :!T
MR5MQ4$=)'3&Y>OKHJS!E$HL0T6Q&WKK]US[?]F/2ZL_5/W^7N1UD:]YU\_K#
MEIM78+A<!6(NL)M4+5ZWS29LJ'7Q/&G=D708VN<;26J679%>2(8*I 25CQZX
M;6U/,Q[HH<W!F_3Y6^W?T+;;^7M\_+RN]+ZLMF$IGGFY6:;VC=L=A[A+\:=5
MTVJS \6?96[4!SI^,@G8R(%K!M5$-7:H\&XV*!@Z((\5*3)<7$_+C1Q$)8YO
M]>BYO;?E;^"^2M:ZU>]EKK97MK9?N?-OH9XYJ1WKJOC1T.K6H.]1=ZLL?U$2
MFVGH8T'69]N,.N-HB*.#+QU7@ZDX 8)5QX:061N'%+>!,'T8<5)?-$J$>[TT
MTZ6V6VK>_74Q65XE]5I[3 04G/\ 5F92F$!U]+G0)6FPW&^K&S#ANKY7(9)I
M#@\-'@*&82@,Z7ER% +CE"ICI(I:1=+M]>MGTY.R7/;T\S/?7J9TZZU+F#[]
M+,Z")47)AB_<T)NVJ2OHQVZ\U%P-@W+!K^40,!/H=G$A2*F7&-/:(;%<+&':
M4(8)X3PGR,@[35IJ\!R43.BVB$FY:YE=3DK D*@A/2_S?*5PZ'WFK7I4<_'0
M;,Q,#CZTV*W84N-2_J,@%\O+3K^>^9M"P!@# & , CGY95,RY>/O3(B.(M2#
MVZS*R(0%.*6++S90 !3S$2KY8,V3(#>=T@E\:":38'%"-*A%[DD#-.!>WXZW
M\B%_A+U#R WT%WG]Q<MG4.:R,1MR/Z7/4KKM-<K$K#0,.2] NL=,KD0LD99!
MS\:V1\7W&%1[Q#!)3RB @@Y^VGFM-=/D^=[FR^]TN'Z)4IJESZC$0\\.T,<J
M/?0,9IIDI@M/P'W&2$-JVZ.WI6U,K]4;5K6M;WI6@(RVGPDYC:K+JSO6SI,2
M7'6=_H%0#B)*HI H?33(D*".Z16=2=*DS2+(;$1XH+T?:CK-3FT-[=%JHQ*U
MOJ%3:O;GHR'GVF/V?GC=UKP(O--Z'6C+,1R*!L]\I]Y+^XFNAC60^>)MDX1^
M5 D P]'A6*=/)*FHBOC0D42UMD)@,8$88=KBJTOB\/[YTW"7$I0X;]'%J<)Q
M<6M&G'T:-W X[]$ZZ>%PN,IXBDZ-2EBU7<%>2E&I"6'KX>I&I3DE*$OB.*:_
M="2T+KJGV+7V9;?'Z'SJ6\3N:V!BMU0>(:NI,9JO=0F!BDNE.O6/HM$W4;1.
M'>I:V-&G'N$?*M,,*6I+*=YQ+"4N!1E*LVFVYQKU:523DVVY2H2I7M=I:)*-
MDDDCL/\ V+'1Q$J]*AEE.#C2C3PE7*L!F.#H0I4X4HQH4<WH9A\-24%.H^)R
MJ5)3J3DY3DWK)_V.)4HKS--[U1>@7&@T-<[(*BE1';[L9;XFK&T!ZO*CVOFJ
M@BWD2A$P\X(885V-X5RJO.A("03[5:TOTV81DJ5.O3CAXUW5C6G)U\2J;INT
M&JU*<92^)>\Y3E-0?"I;'J5G_@ZI0EC\9E.+Q.;5<IIX/$930I1RO(:F.CC4
MY8R%7+<PP]>C2> 22P='"0P[QJ^-*FXN47/M7V871X-Q6X?O-DMH"=&^T.P^
M0_VDE0G'OO$T:1D-.S])\^AJVWJ0-"$-.^%SO223QF#7DN.,-)1S_#S*-[8C
M"5EOPU<-5A-N_.I3Q*C:W+X)U7ZSP'B%_JY'XER^H[)U,#G^78G#0WXG'"8S
M(/U#>NG%F6RM>[<CUI\-NGP*=)DN?=EGV&'7W]'T+[53S)/E'W")!,J2\W6N
MJON L//RC;<FO3]W-41(I28^]HA&G]WXN80?[L)0J1TUI8N2EY_Z=3#12M:^
ME5WNUR,)9?X,Q#MAO$>;X-O3@S+P[0E2BO/%8'.<14GO9M8"$K:J+>BY[Y#'
MPVW-V6I?:D4M&U_%(D N[1'5HUQSY[<FI\=N"ZCT&REZ^\U*D/<76V"G#O4S
M8^R%:<55C9Q_Y<#C*?\ ]E&C6B]]O@UYS>FNL(ORZQ^%\'6M^A\7>%\6Y;4:
ME;-LLK+RF\RRG"86+?6&+G'K)&EGQ.\*^G\[\\^Q>4%MLGDK-<;\N)/JR>6@
M<FOTHQY$2+E"LH1B&.MAS-:J086FD2#*VR3)2':B3D;^.ZTM;>]:T,T<G2?Z
M6LXUW65)0C>H_@M74J<^!P_W*[FU%/I<[S%> :=&&84__8,JIXC*(95/'2Q<
MG3P,(YE"I*$J&-H+$_J[.D[0P]&<I)_Z;J*[6Z'7BIT:W:1^3G/O*R!9VA+;
M<CW+[1KL]#/$9T]LAM;5:\>;1=&"?AOJ41H%%M@M)>VI:2F7-^_6Q\?&U/\
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M3*5G-;X685Y9I1Q&&P]&6+I.EAJ-)WE5A>U5/CJS<MMN>A/C8P!@# & , 8
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M>P/\APW]51W^B,X6B2Z JN , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MC_UC*K.;2\DTBX,S-88 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MZI_EMSK_ %M__,#W^_?>SV/O[HWNW]##JO\ EKSK_6^"#?D;W;^AAU3?X_\
MCKSK_6WZ\%LNO7D^OYW/G[H[NW]"_JG^6W.O];8"2YNWLRC\+\O+UWB"YO=:
M_P"+O2X?GG2X^'FXNY2UEI/RH%?FF$$C2YT:/)+D?AH86AQP9II1'U]-)WO
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MW>K12&U_,C/I3I2$:6H"0F , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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/# & , 8 P!@# & , __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>fhtx-20211231_g17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g17.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1,:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $OZ^2&(X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%>_*P         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@              S@   E@
M 0                         !              )8    S@
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    S@    !29VAT
M;&]N9P   E@    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
M       !
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MVMOU)\]W@+[X]]>M5"!/J+)DKGDYH&4OE"1_T[\)AWWX7=7NW_O9_</B+X>
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MG:TT>Q:7MZI![D.;#OY_$#WX,\O(?:H)WM_BU7?4X1'H2)H-%I7^IP=V+O\
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MS"7,F#W2!L:" IB5 ,;-N22D@ M<"[<N]B[NRDAH%D@SLBB3<!RBA<"'0.C
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MRQ[<$B.<TK$@'?Q$CF\02U@1<E3$D;L7:VRM)6;!"@]+K:24H +S(8$@GE4
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M)6$3EDM.U^4%E)ON7)(8.VS@]2[;_<YMA5LF8!RYDD*%$6Z0!*22[\VX</\
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M"'(/3S(+@V8N6PH"I74Q!:,SZ'), A *K%O"Y4.IY5.2X&S))Y6NX8.#92+
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M4O9,#F+>G! +?GS?<;=[DMB.04(VCY*D6);DFZ@;MB!*0R6*9I$O8CTQ??\
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M#W8_RF#&YN')V.%(.1X("):<C'@;4Q J88"?2X;_ $*#8.]P%#^PZX4BYYS
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M<Q+37/ B*A\J26YB$V =T[%Q]6SW/?%L;6P?6@G2&2SD7N[^"/E7VX><(D"
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M017J;$23$FDH0OE4D[,DAP"!L2&!Z-OB^1]^!JW01F39B8.UP7GRKM)JT@H
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M-QA4R6M,CJ!UV@<G,157^J[G8BQV]]P 6'O-L*$K.X.;-WY(D6@VH904I0L
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M&Q)[#%%QF:A,2%LVI8F.N,BSC@5"K9M"F94N[.BP!!(OUW'WGN7$C 6]_O\
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MR.FQ(2PX.QN* 3R@[AG!/W ;"XW_ &,,*H,!V9!'FS<[3.]XH42"$V)=V#L
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M'0G"H AL '>\3(!*:Z"< "%(AK)"X,-0+AE .;$-<;D6/3OA0C<&%:0I.,#
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M;^'S!VS<,3+'.I4ZCN7?8E@ 0-AN2X('F1Y$J>"B#SORW: D8A4W!9+D,S$
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M#2D.+,;V,3=J.L/9<@=^5:2EH.6=_,[,O>!%>QR_F"GYCI$I6I!2E2TQ#5$
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M$D$#"BBS*C+_ "AF6#.V4+&CE2-T@[] DAR  X)<W;=B0"X4'*H#)7)EX!3
M#Y&7F#E\J6 Y02.@# CH#S'9B&!.XL" V%4'[%[+QQI+@29$1/H@ZK#WLD.
M P^H6 8 @$6NS,,* B9"DALD%\U>_)R: E(Y;,&<DL227+%KN '20_4 .^%
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M=F4FR #R."0G<*][5]5H18D)4  $D\H#'8#S #= .XQ*EKY0ALGF01OU-U3
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M7OA5& ,^!3O"0NHR$02:O8.Y9P02"3?8ERY VV21TPJ6$%&P"")S <^-]J"
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M^)Z-A4 %LA1UW/=<B#ROFH-7ISM[4D Q/^F2WA#M_P!@6ZC?WDOA[]S[VVJ
M0_H?1$VE H-P:9J].%C59%P2&];EG(-@X]#:["P;S5MBP_?E?ZT46$A7ZF/R
MSOML*9J].N?:DC9_],E[D;\WYDD,S#N$CSQ.2^_2B#<2]EB;23%SDJD*O3K'
MVI(O9_TR7N[W)$ >786OM=[]SG/I3NCPY0;V@6\7XHABL4T$CVG([])J I1)
M-AR)A E]@ 7+L"Y!PH19@21SL\IVW.^&^3VG3^L]!.S,E0:X+V[]68=Q;%4K
M/4?.U90$X_\ 28(Y+H)DLHBH74Y#E61/0>8)402%@A02;\RC;WGPC<!\4 L
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M+1M:\"3BZM4E*0=T]24@)?<,D=N@8NURYZ*!QTW*)G/@SFVE .J"4WLGF+6
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M)J'3\KU"?BT:@YRJ4*%+97J=3A+4(4.!.KK<&I)3-KAKEY*+$A"%/K7RQ5*
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M1>$&0*\+C]H_M'$.MQI T F3!)"DDR3L5L02=;] 4A?$[QZ)58#4[0\O<O\
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M7P;(\ALZMF??F"07Y?,OY [WLZDB8!ZV[R@Y"DK8F;N@P(2UP2;$D))^KS?
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MVBZ+M<FFU@X9QL0.:P?H" Q:^[W]RES,W'BPP+&WA*DMR''0]"72+;[;CO\
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MW2[?[_CA3#Q9%D1./8(5K# 6Y00'8%W)][]W&S&_7"G.[+>W5R@$4X3M-5<
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M+$D-?H"S;A@W0NY\FON^%#8_Q$;\@V1@@B+YM84!B'4!LIWZGM[@&[.;C"D
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M?:P[$=[D!B=C^.%#DF=LJX)P"B8%P["U6"6V+;&SN_;J.O\ YO(X50S!((U
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M]8&;L2#2 8$DW'BW# $ 'E(#"UG;K\0I<LYA'EJV;OAX(PBB4@V)2IWZL0;
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MI7U()6IEO[IH)"QO(HZBX<+VLYZ!STPHAAB-MC$*XL,JV]'JE49_:J!T8R2
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M-(:1<66_Y7"2&W.BM%;JW_.4@OM]Q?KA^)IM^%+$RK_+Z/I5'#[+GMO;#_\
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MN7EY#+(C0YE49,2(J=BPHD/\PB)$MK$^'A[-"4%W6L9^L1!YEVK9=@@D;@%
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MP#^+V#@</A_S:M/:^%K('^+N 26H8Z*:X/G-Q-M_%SIUOTS]/W!W#?-I_O\
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M/Q-O;3730D@.?I%G&;=C^YLGR'1B+N'Q.Y\.SQ>)'^C7:$>DO^M/Q?VC!/\
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M< EF(<<VGA]A&E'4;$$GO:2;,@$&4DV"RQ6>+QOB1U#\@/YD$=)P@"1@EL
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M0J)&V .[K8"PNSLJS%GB'/S/WK(TZ>9_ZCFR1DB284)9JO59<DLA1V<&)$8
MJ8,QYKAR.@=WN^"Z^9V6]7N:5+G^;O&;WDB-G,J8IF5@$L$$ #_M(P-B>O.
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8#AO"Y%W8;#Q=QA4)4 ^!#7GEW07RK__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>fhtx-20211231_g18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g18.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1B 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &&2^8D0X0DE-! 0      " < 5H  QLE1QP!6@ #&R5'' (   (  !P"
M4  $1V5N83A"24T$)0      $.')"A7;Y_SV*:I=Z)!5H1(X0DE-!#H
M .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L
M  !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG
M3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"<F14
M56YT1B-2;'0               !";&0@56YT1B-2;'0               !2
M<VQT56YT1B-0>&Q 5J&J          IV96-T;W)$871A8F]O; $     4&=0
M<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M     %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M        $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O
M;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T
M4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M    $ .__C4  @ " [_^-0 "  (X0DE-!"8       X             /X
M #A"24T#\@      "@  ________   X0DE-! T       0   !X.$))3009
M       $    'CA"24T#\P      "0           0 X0DE-)Q        H
M 0         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ !
M *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M   !.$))30/X      !P  #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  ,U    !@             !/@   C8          0
M       !              (V   !/@                     !
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M;&]N9P   3X     4F=H=&QO;F<   (V     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M       ! 0 X0DE-!!0       0    #.$))300,      X3     0   *
M  !:   !X   J,    WW !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" !: * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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MNFD,]*UU;8)U#=ON25;=:[<T.$B1,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! ?_  !$( 5$"6 ,!$0 "$0$#$0'_Q  >  $  0,% 0
M        " $"!P,$!08)"O_$ &T0  $# P($ @8$!P<)$0T'!0$" P0%!A$
M!P@2(3$300D4(E%A<14R@9$6(S.AL<'P%Q@D.$)RT28T-5)4D[+2\24G*$9'
M5E=B='5V@K.TMM/A&38W0T1C<W>#AI:DPT5F9Y*4H\)3A(>BU/_$ !L! 0$!
M  ,! 0             ! @0%!@,'_\0 3!$  0(#!08$!0,# 00( PD  0 1
M B$Q P1!46$%$G&!D?"AL<'1!A,BX?$4,D(C4G(5%B0T8B4S-4-C@K+"!U.3
M)C9$5&1S=)*B_]H # ,!  (1 Q$ /P#[^-$31$T1-$31$T1-$31$T1-$31$T
M1-$31$T1-$6*][[CJ=G;1[DW;1GT1JM;=D7+6::^XTEUMF? I<B1$=6E05S)
M;>;2HIP0K&"#G1,1D\^"^..H>G1XK&N$^HTY-VMHXDHV\$.<BL(MVA>N+V9>
MMFJ2FY::>8BH35.D7?3!27*AX8EM4AU2PM$UP+US]W9AO9'S+W^B_2Q$1[ME
M^H_6?Z>8H;,C]GR/]3:SBB WOTCQ#^K,>U-W_P#A[_M)'9"__$Y^$_\ 9RVM
M+.]F[7#_ %O_ &J'P5';V-VCL=PW7_18O_B!N7"TM81^J_V8,5Y$0OX$:G'$
MXP^/7>YGCE58._=#VP1PLQZ%=E%4NQJ3715J,[:,"J2[?D*>#9;<=FO.+,[\
M8O"N7DP"1P._'L>:\7(29I#R?6IGX5*P;O)QO>D/V.X5>#/="[.*R-)K'%_N
M; IM0N&D[04:IS=N[8;BS%OQ*/;T8J=N&3*>:;4HY8<"0$)/M9U)UQ\/OX'"
M2CAN!8TQ!/*0U'!>^_HX+OW+W!V,<O+<K>JM;XSZI<%213[FN';-&UE4AQ&%
MI0::Y;:7'5(:8="_#>4XH+"NF ,:O9[P0LY($C0YASH)<APDO0C1$T1-$31$
MT1-$31$T1-$31$T1-$31$T1-$31$T1-$7G#Z5#<SB8VGX2KFNKA/8B2-UC<-
MMTQ>'J>;CC6E-FJ%SR['@51Q,*IW?'@H"Z3#6AUQP^+X;2UA/*[[[ZJ3!# '
M1GGY4>N++PZVQ])]Q [>\-W$$RSOW<&[.YU-O*P[,V^@[^[?)L;>#:^;?4F/
M#FU2]:>VRBC5FDTUYQQ=(>;5R.A',XE*>5 F3>,\\,J!O1)FI$I%@QH#4,'X
M/EQD,K=#CHX6.)SAYX8-WN*^=OC1^.S;R[J/;5Y&VZ+2+GV4W630O7Z)<]OL
MP IF;:E*F28CDF/,(8DQ6WQE"^5:+R)PEKW-)RH!,4!D \P&DSB;S9W *ZQP
M(<;G'-Q4\0%4VDKFXMA3U\)%I772-RJ=;50I(=XD[ZIEQU^WJ-5ECU-*Z)2E
M_1;+LQZG*<;"0W*_\L]G[VMA%8V=VM3'9Q0WJSCM8(8(Q%'!#!;VM@8;:%AN
M1F*R,<,)?>LXH(_Y,.YVCL2\[,V;L#:5M>=GV]E\17&^;0NME=+T+>]W2RN>
MV-H;%M;':E@(88KC>K2\;,MKS86$<444=QM[K>@1#;PPCB)7I+.,S;CA>](3
MN/N@JC4_>':W>2S]K]N:'$;@5*@;??AO454QA^!(;AQO7(U-COM/J745R2J:
MV%./*0L(1\[0V1$'RH;0$0 6OS(X8A%:O%O16>Y!"8(-TP@01;\0B$1,;$ <
M2^1;.C%R_P!/L;Y8Q0W*SAVC^MO-A>8;;:(M;3YUM<OD72Z&[7**RBN\-G=K
M>*]6]G:0VT<5[M(;2""R]'_1?[Y<0MVW;Q3<.W$;?4/=>Z.&^\K5I%*W.:A1
MZ=4+FI-W6_\ 3*6:K$B8BHE4V0A]E) +OA*0'"2 =8[Y>O%<&*&4W&\SZ%@9
MB@P!:3R"]>DXP"!@8 [8/3H,Z*\:]NKM$31$T1-$31$T1-$31$T1-$31$T1-
M$31$T1-$31$T145T!_IQ^WZ^VBD5#R\U4=AGOYZ*IHB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB*A('4D >\G'Q\_AUT1='W$M.
MG;B6+=MD39RXL*[+>JUO2I45:5.QV*I$=B.NM]2DN-H=)1S=.;IHH3W]^SD"
MO#*7Z 3ATD2*K+5?=RIJE6V&=V0$OU>,!&B/7FB[47(%A']F&V@]2V%'!$9]
MQ*5$9U)X-SSUE1NNBKB;[QW@1+@?$])<%+[;7T9NW>VC/%?%I]\5^>KBLMV%
M;MS"5X*31&(5!C41N33T@!2I"VHP><&% .*)&,#%4))I.4LJ 2>CC$8OSTK@
M]&3MW7[2X(+4FWC6Y$#@FO*'=]M(F,QI*;P>:0^A4.L-/)4CP@72$)Y .0:=
M]_= 78LQJSSIN^1GE(:+T\IU/I].;+%-A0X$<%1\"$PS&9"R05GP6$(;"E'J
MI24^T>I/71!S]*G-IY\ER&1G&1GW9&?N[Z*JNB)HB:(FB)HB:(FB)HB:(FB)
MHB:(FB)HB:(FB*A('<@9[9.,Z(HI\8?#'9?%QM*]M'=]R7'9[BJY1[HMV[+,
MJZZ3==N7';[ZI5,J=*=:4E;P2I;C4F.<H=CN+"OJC5 =^^)/?WR30.SRU)<$
M-AAB"H+6=Z'?89FV]ZHN\U]7WOA?6_,.CP+IW'NF1#:KU*;ML(_!TT5$)M C
M2Z2MI+J)2@7%*.5GSU%26%)Z%^\Z9Z+2VZ]$18MH5VMWW>?$+NYNKN,SMA<F
MU&UU\7C4HTFH;/6Y<U/72)T^S, B%7VJ<ZY'CU)*DO,Y0X%<R4J!"0-"S3+5
M]VU-<"R[YL[Z)KAVX?;]V&W.V?JUT6E>6S%LS;7JM9@S&2YNQ3ZD])E3I&X3
MC2 :Q4')DQ^0F2X5*3EM&3X8)(XPH69SIFS^!*[E<OHTM@[NL_BKLFX)5R5*
MD<5MS4^ZKT\9QLO4&NTK\=2Y]ME;>&E0Y*6I )R,MCJG).AF&!(=L1WSPGQ4
MF\VD#+-R&.)8]7S=ED7@EX'K-X,:'?4>DWC=6Y%[;F7#'N2_MP[TD(D5ZXYT
M*+ZA3FWB@<B68$- 9:"5*)RI1P21IDW?!L&5=ZU?4]92E^9J= (/8@_+KHJF
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(J'..GO'EG\P_;Y:+,5*
M^CZ.3+N1HJZ+2:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)
MHB:(FB)HB\=_34[W;I[/\->W5)VNOJ9M4[O!OQM_M7>&Z%/;:,VR[.N%V9]+
MS(LI])8IK\I++;**@XMGU=*5A+R/$)U"^'8]A4]@O5AXX:F@KP*\Q>*6PI'!
M;L9Q)T[A_P#2![G[FUR79-FUV/LU=E[+N^XK2J\^?#6N[(5ZMOJJ=*IU7=<*
M'::Q(:;1'?Y0V0D'1Y_;UHQPY\HQ,W(F9$Y9N\39>ZQ=Q#<?W%W6=@*GL;N#
M%I.UN[&SVX/ Q<,6_=J[IK*5W38F[E49CRJ1=$V6_*?=JLB+X$B4AMU+3Y=E
MAY"@&R+H15\Q@2\APR&JO @,Q-#/?$.N (9B3)C@H\19G&%O5Q-<1+FQUR\7
M%T;PV9Q7(I5L7!2MPU0]@[0L2G3HHG4FO4"6V[&=!A@\S/,E">99*5$ZDIY3
MX^&/CU2$E@"3,!G(9V%7K3$<Y,O4:V_3&[[6UQ<?N#;V;;[?V195!J53M-R=
M/769-6ON=;-F2*],JMJWE394JW7;CJ,RGOQXMMRH450,AM(/B9.J[/KWXZJ-
M,5=Y4&%2^ #ZR<R"Q[M7Z>K=FK4"[]Q;WX?J"]M_,L"ZKTV]BVI*K356HS](
MK7T13*1>%3J$F2U,]>*VI$J93X;:&SXB.9K!"3DGSQ_+BF3(PJ'I24G<B6;'
M37-3,X'_ $C'$OO3Q.VGPZ<06V^T- -[["N;ZT>X-M*_/J<B#3)KH53*)58T
MJ5,;;ELQ5!,EY"FR7_JIQD!GWZ^ZDWTXC@<'\6U7N P1G&%9P4I)43S(3T2L
MYQU4.OG\,=-%1CWWTZU6ZT531$T1-$31$T1-$31$T1-$31$T1-$31$T1<94W
M5LMEQM(*VFGGFTJ *776VU*0R/,*6H !23D9T[]UDM(EVQRYC[.[:+Y([.M>
MV>)]/%+Q;<2''QNAPZ;Q[.\4BK%V\%(O-^D4#:NU[<N*G1*/0&MM$.-_A.W>
MJ79$60\Y"?$A"W7>5Q+3Q 3>A!>LZ<M']66S*CCG@6DU"#UE( K:6UQU<7VP
MO$AQQ[B6W<-K;L[)63Q ;=V=6XVX%0K'TFJEW8_'IS4BQX,=R/ H#CP5ZX_$
M5&2VDK"$M@@@#4O*9TY?99A!(9W8!SBVZ'8OK,L9TE6%N\V_F^-[QZ31W[UW
MXO2E7?Z2=5K3=M[ W%DVE=ESV9/MQ4]FQ*!<:2XFE4I'BAH(#>?'#+I;5R]7
M''@"VC49U8@06!(($GG2%SE.3FA+%FPF#9_$GZ2'T>O#U7*I7;$N 6KN/O5<
M\C;2E;X7-'W6W%VIVQIS4=<1NJLM3:54J_&D>VT_*'.N PTJ0AE(409IWHU.
MP51,\ZDEIXDL)XZ8NLH[L^G-WW=@[/4G9"V-I+HNF;M!/W:W+G*I]PR:-='T
M4Y+9?M.RH]1DT]%*D/*BAJH3Y50D*A2)3?A,*8;<<3N& &R-H;2S$4-I#!\K
MZ_F$10QQ&TA^@V9@@,(@C>TACWHX1#!%#O1#FBYV1V=:W_\ U"YPVT%\L+H-
MEQF]_P"HVUE;6%XMHK_9B&ZFXBXW>.P@N]L;2_0WOY]XN_RKI;6)M;:Q[3O!
MZ9SBO:B;D[D;4[:;-VEMQLE;^Q_X:6/NI59J]Q:K<6[-*@U6HLVZ['FL-3HM
MN*>D042&&%M34AI]&<N<OS#G0>LWPP.3/5S1<$R!Q+AI-*4Y4D7,B:R 9?29
MM+=DB_-MK$O67&1#EW;:%O7))B,K)8C2*S3(T]UAE)RH-MK>4A!42HI R<ZT
MH'\,R?3[K(NBJ:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB*U8R.V<'
M./V_5HLQTPKCS[G+-7#L-%I-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$
M31%0J"1DG [==$6BN5&;)2N0PA0[I6ZVDCY@J!T16^NP_P"ZXW]_:_Q]$3UV
M'_=<;^_M?X^B)Z[#_NN-_?VO\?1$]=A_W7&_O[7^/HB>NP_[KC?W]K_'T18B
MWQVBVIX@MNZUM;NS;=(O6R[@2WZ]2)RHZPAZ,2Y&F17E$F)-C+]J-);Y7&U$
M\JAG10]_C%J^4U#BQO1;\$EAVA>=G4S;E-0A[AMP&KMJEPUQRM5^?!IDA$B#
M3?I>6M<AJ'&<:;+<5M7AI"$C'33OO@CSIQ+,*:2_!T7?+P]'WPC7Y4*U5+FV
M^@SI==1MDU5'#40T)C>SSZ)%@!20<E5&=;0E!.2M (("3IWWQ2F%3C.0^H<@
M: K-6SNP.SVQ50W!J6VMOP[>E[JW3+O.]'VYB'OI.X)R$IDRW$DCP@H) Y$^
MR>XZG)9T]^^2D\BS@!JCB\FUR+'%1ZE>C@X/I6\[6_<^P(U7ON)7W+MC,U.J
M&;;[-S/,.17:U'HDDKC-3E1G'6^=( RO)'D2NG-VY$#[S#R*X:P_1D\&>VLV
M]I%K[=1A"O>CU2@5:C5.J&H4:)1*R\J34*?1*:[S,04.R%^,DLI!:6!R]4Z)
M/I@U<17263UQ"Q)P[>B]V[X7N-2-Q$[0UKZ)V[3LY-VZ=L^KU=ZKU-%1E2Q(
M;D,S)BE+:I[* $M16U!#7*$A.,Z@#9\RZIF7XB089^E?LO7)N=%4/:?C)P!U
M\=H?9CFR,?=VU5!B^9^WAXK5]=A_W7&_O[7^/HJGKL/^ZXW]_:_Q]'%'GDB>
MNP_[KC?W]K_'T1/78?\ =<;^_M?X^B*Y$F,Z2&Y#+A R0VZA9 'GA*B=$6N"
M#V(/R^/;[]$31$T1-$5"0D9) 'O/QT1:!F1$DI5*CA0[@OM CY@JR-$5/78?
M]UQO[^U_CZ(GKL/^ZXW]_:_Q]$3UV'_=<;^_M?X^B)Z[#_NN-_?VO\?1%M9,
MB(LMD2(J\$@Y?:RD$?6 *L9![GN!VT[ZR4+R9JA^N'!0$W!]&WP6[G;O)WJO
M/:>B52[TS(-8GLMRDQ[;KU=IT@O0JM6[=9*854J,5PI=:ER6U+"D@@Y!T8>?
MY[FFC9,:GQZFM'?!=NJO GPKUY6ZCE5V^I2OW8[MH5[7]';EM)CUFXK<?3)H
M\]#:>C!C/)2H) Z8P<#LKY]]4#N&D X,JT:5,/"4EQ5)]'MPB4&O6]<E,V\I
ML>KVONBSO%1)'T@E9C7^Q#1":JX2?-+"$(QT'LYSUT4<FHF,\7R(,M:LZR9Q
M(\*^Q/%51:31-Y;?1<,2A//.TQR'5U4Z;$]:2$2FFI$=P+,>2D<CK2AR+02"
M,$Z("9N]3AAI*N%>&L?[K]%YP.WM;FWEK53:.DTRC;6PG*;:8H51%'J**<\Z
M7Y4"HS(7*[/A2W25OL/**'EE7,#S:$>_'!NY8:*O66+8%G:=:<9S>2Q5QJ^B
M5X;.*>U*FNW:73]O-SI5/LVDT^[Z?*+<)%+LUZ&FFQZC2F"&)C[%/AHAQY$A
M"G&DDI!2%'3OT0%\&[X,U:8-P'IUMI;\6P[$LVRE5&-+5:5J4&W53@XTVF8J
MD4Z/"4^$\P \0L%> .G-@Z(.#'OPR\%WOUV'_=<;^_M?X^BJ>NP_[KC?W]K_
M !]$3UV'_=<;^_M?X^B)Z[#_ +KC?W]K_'T1/78?]UQO[^U_CZ(M1#[#@);>
M:<">Y;<2O&>V>4G&B+5T1-$31$T1-$31$T1-$31$T1-$31%0G'89^'[=M%F*
MA^WJ0JZ+2:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+2>&4I]HI <0
M20GF)"3DIQ@_6 Y3@9 )/8'10X<?0GT7FU8.Q%N[U[G\0E=O:[MRB[2-T:A1
M:3!H]X3J-3*;3F(4-U#,6&RVM"4E;JU%6<$$= 029*3S-6+/QRTDM$LU1(5I
M.4IO,DX--9A7P1;28'-=.[N">A_=&J9R>ONCGMDX_8:H#2"SO.\R6;N?-:8X
M(=H3T%T;O9_]8M4__P";&BJN1P0;1G(3=&[I[9!W%J@Z9_W.._F-%"6Q9Y=L
MM7]Y!M/G/X3[NY_]8U3Z=<YZ,#KG48=SXU>N.:F^/[CXX4Z*G[Q_:;K_ %3[
MN]3D_P">-4N__P"GU0&DF_#GX'V51P0;3 Y%S[N@]?\ 5%J?GCI_6_;H-1AP
MX$C/W]TWP:GP/MHG[R#:;O\ A-NYT.1_GC5/_J/T_P!&KWWBF_#GX'V5J^"/
M:5)!5=&[H)( _P \:I^1\AZOCSZ].H^W4WOET8.&=@3*@G-V"T#O2!):>/KG
MXGDJ?O(]I".871NX<X('[H]2P?\ ]C&3D]OL\M5WGG-'%)/7O 5E+@JIX)-I
M%GI<^[BL =/W1:I@>7DP#D8P>N/?U'08M_Z2QW3D!Z4'<D+AC.>383Q./;51
M? ]M(OK^$V[J?YNXU4Z_86#]PQHW?AY*.U7R!+3Z4\%I_O&MI3_IIW@'_P#D
M>I_KCZ*;\.?@>_RKT\#NTJ3D7/N]]NXU3/V]8YZZC5UY'J&HF_#PY%^')%<#
MNTJSDW/N\#W.-QJF,_/^#G\V-&YY/AWU3>&#G@#RZX(G@=VE0<BY]WB<8Z[C
M5,X^(_@_?1AB)YX]0F^!B1UEHM0<$.TXZ"Y]W .O^J+4^Y\^K!_H^&C/5^I'
MDP3?AS\#[*P\$.TO,D&Z-W>;/,!^Z-4^N 1U'J^".I[]SY^6C92QDWLKO AZ
M@2?)N/L5CBA;/439GB@VPIUG7)?\RDW):%U+K--N.ZI5<ITA41 5'?,>4V@H
M<95@I*!USCIJI%, '$B7&O"GW7H-'5SEPA*D)!",*'UR ,.)5DY0H8Y1GWY
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M$N[>WBVM^D;O;L/;W3'4<*-V618-9M)N,W]%;CI]7CN774ZQ%R%-2ZBL/ML
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M(FB)HB:(FB+@[D>3'H59?40 S2*J[E1  \.!(5Y_+KH02(H0'BB&[##C$20
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M/?$4/S+O=K,!XX[W=P &,1 M 8C"#5@'-6&3SUN(CDB;L\.=3QU1<U4ADGL
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MI=;2"2M( 3S$YZ<N0,Y'3 )&?=G11QWP?R52ZV,Y6D8]Y ^[/?[,Z*H'$$I
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MEWJU 4*C.I5TT@+D0I,6*%<_J<YP(C 97X.5>_15@XB):<(RS&%2W.>84A^
MR1'F<,=@3HA*HTYRX9;2E!:%E#MP5%2>9MSVVU=3S(."GH-.Y],?-27?+[>"
MF+HB:(FB)HB:(M)?UT8[X7Y?[7I^OIKY1?\ 609,?.%_17^$? >N*VX4 A(
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MB)HB:(FB)HB:(H?<>VX%'VRX1]\+SK5E4K<2!1;1=\:T*_SBWJFY-DQH4<7
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MB  $1!^DFL.8H*K*7$7",W9:_4);6H_0LA9"4E7*(ZT.<Q&20!@GM@#L?+7
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M13:-2(R5%*I$VH29"6V&&^=9"%JY0D*(*%RX\Q^7F,A(AC)8QK_%KP]VKN=
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MUM2SB/\ W5C$Q>0BF93&8K3D\RT%(0D9 P,8)&<CN,?#_+KS^\"6>;^/DO4
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M.M**(Y:=8;0VI(U-9^/E5#.1+X.92\^KXKZF6\<ZN7'*!RC \@<#K\P<9ZD
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M*"I.?IVQX+6T531$T1<-<7]@*W_O5/\ ^:NZ+)_=#S\E&#@=_BXV9_NRY/\
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MF4D.GQ(SM=>"W:L\EQ.0I;;KI0,=4D8)Z9UW5J?TVS3#%^^WWK0C]I 9V(&
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M6IVY;LE3;TK\QX8=<EU@JG\BE*ZE+27 V,], 8 U]=NV]E# 1\P"&RLC#4
M@%ZT(HQ,EP?A:PM#!#';69%I;VF]$8@7 CG"'X%VU<T<=BX=P[+BWM=#H4M5
MPW=-)<P<>KP0([923W&3T(Z''0]<:_.?@X6D=XVS;6D$4,,=O!\N,TC$_P!N
M8H^O K] ^*+2&$[.NMC%#'!96/U;M 8A0L200Q%%(*ILHF1)450)2_&=:!3[
MGFUI/YSV[=L^>O87NSACN]H(@X$)Y.&&6*\Y8VALK6"(2:('BS/[9@.RCOP]
M/)B4B\[;?2M+MOW746$I<Z'DD+\5DJ'7 6 ?@0#\=>2^$[W#^KVK9[XW+M:B
M&*(F4(BBW6G.<FRES])\4V$,5ELVW@W8HKQ=G$(#O$ [58@%W%):K&FROB[5
M[[;G[52EJ31;T>5N-9R7#R-M*GE1KL1GF^N&Y7ANX2>@<!Y<'.OU3:-G%>KA
M97V"$Q6-FT-K:@?1"2P#Q83F,#.2_--G6@NVT+:Y6D8AMHR=RRB+1EB3* :2
M)+ -H7G!&6VOG+:TJR4DA)Z XZ_M_P!FN@A8PPQ0SA/[2*%JKT+M''#B/W"3
M@R8''K[D[G56DT1-$31%0D#J3@ ]?SC])&BR?W#0$GG+O@HGV0 .*;>I7?-K
M67GW'^"+R/L['&F/277S]%7H ,R[\..:E<W]1/RT4'[HI9> [TUH]^BTFB)H
MB:(FB)HB:(FB)HB:(FB*U0)'3R.=%F*CY9XNX:7%7?GT5%!A(2R315-$31$T
M1-$31$T1-$31%Y[\?8N^R=G=S=Y(NXM9M^S[/VRGPJK9]+H%%K2)-1E5B*47
M=S5IWU=UREPWE(73W8KJ'6FUD*R-.^^_N!HX():8PXODV<L3.7E[PV6SM#=]
MR[55]'I)]I-PX]R2J--E[5R]D=K(DVX7IR&E*M64ME"WF9*G'#%>46?$4Z.8
M(. =0 "@\&]E230D\'<=O-?1;0*'0[;@M4:W*+2J!1X8*8E*HM,ATBFP0I14
MMN-!@M,160XLJ=466DA2EE1SG.JLAS6K,SRXCCKDRY24E2DI"4%?M'(2/: Q
MW22" H>6>_8$=]$/? U[ZKSNXN>%S?W?.MO(VUW5M"B;?718<NP[OV[W(LX7
M)1Z8_.E.+7?UIO-(>=CW5&@.&%'9<0PEMU*)(EI5@"EW)=SX<N^% D-&9JU>
MF&KO.;@.S8J+R/15[AVY39^U-B[X08VP.X#]GSMU*17Z'4)5ZS9ML):3/%OR
MFG7(3+->"76UJE/-KAMK3REPI)U%2:]^3#C)<G ]%G=SDAG:BX-VJ5(X4;:O
M>_-P[.LNE4::SN#'J]XVW(H=.HM3K3JE0#3+8FO-5F-*BA4J>XTN,\VPV\EQ
MJ-XUF<A[<:H]1A*HZC6IZ@38OPY]%KNQ>]#C47=_?>F5ES;JQHMC[&52U[?G
M1)5 =I$DR*-<EVJJ#H5)J$8-1FI+,(NMR.5Q05A026D^]1WXJDUQF3U4T>%'
MA=W,VFNW<S=/?'<.@;E;E[C42S+/>D6_2)--HD"U;,1.3&C*8F_C94N>]4)$
MN4I326T*4I YDJ(36 )Q\,.&!G/7 K)BH)B=&?$&KEG#OH'GCVSA:ID"D73Q
M&0:7#@4^ WO'62W#I\=,9IM:X<)2U*0A*4<RRKF/*,9/?R!6GGUFIAZ(FB)H
MB:(FB+;R$Y2%]RWS*2DD *.,=<^0[_T:;S PR^L$!^KT--/%8B#D1%_I<L,9
M=.^*AKQ+2_PLN#:O9^FK*I5T7-$K=;2WE:6Z)2%A]_QD)ZAI3B0GF5T!4.F-
M=OL<?H8+>W)W6A(!!F(HG<M3'Q=@Q73;7'ZTV%WA&\Y$9HQA#B8X&<L&)!4O
M*4RF,PW&;0EMMAAII"4CE 2A("3CW+3C'OY#GJ-=3:O'>;:VB+FT9R[EW)(Y
M/FW1=O=X19W>SLP-W<#;K,&8,>QG-<MJ+ZKBZS!BU2FS:7-92_$J,25"DLK
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M;A[V2KAMRG;BV!;UA4,3[B17515W)6Z^S$@)=MBI6B@RY45Y00$+BEL<JB%
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M3NPM&NZAV+4MU+1C71<<>%*H\+Z3C*]:9J00:<#(0I3#:YP<1ZHVXM*G^8!
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MSKD65WCMW$ $6!^H AWXR\:-5<>VMX;(_42!.;.*#3MU@3]_APN E2MT:4"
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M(0PI,M7+C<]4$1D>)(6AM ^L5E* D $Y42<)'OR>GO!UQ;>^6-U&]>+6&SA
MF8L-9#SPS7VAL;2U806<5H29"$.>BQ==6\.WE$!:FUQB3+:4HBFTO^'3W%@'
MV?#8YN3)'UE*0">F3G7 /Q-LJ$1_IKW9WFVA'U65F^]"")$[T+,2PK7 LN:-
M@[2MA9Q6UVM+"PBB&[:1@"$D.X !WG +T$J3=8TF[I7[>S7T=MS9-4I_K "4
M5^Y6#%BQ4$X#[;045NE.0L(6.N.NO,WS:^V=HVQL;O<;:"QBEOG=:$$D.&;
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MYR3TUYF]?"1O)A-WM3=XQ$8HHH=X;P-'$)U?US[NR^)K2P AMX+.\0@M"+8
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M2.AP$C^:E"<<J1V QCMUU[RPL!=[(0 ONAAA.G;28.%Y:*,VD;F=)G'-ZR
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M<UW65(>E6Y+K=?FE<F7#I[LF04P\(:4'U\P*N52:)=UECW1.\2*@T<R<. 7
M<RJLI[U\'.R^_5X4R_;YHM33=%+M&OV(NKT"JOT655K4N'E,^BULQ4CZ6@M+
M1ST]N65B(I;A;QSXU&]>,\E'(PP8LXRG5IY'E(3Z6KT?/#<J[Z3?";3J/X2T
M?9VJ;$PYZZU-Y&=O*S3GJ9.B^K\Y;-5,.0^TU4BDO-^(H)Y>F-2QY4K[5=E
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M^H$W;"@/75=XMGA*G/[@;T7?<-\WK;J+YOZ;7Z1!M^N/1(7T8N+&;;=\!M2
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MC;*IS:-?R*7,+DBU:E3T..2XM7CK;;?CJ:0TXKG"%-J"3RK/3144D,3R.-'
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MJ:25F0L>"0K)UB)F#F<Y$#^WWGC,<%J;U:$@!^)+O3@0P!ZO _APW XD-O\
M8W:JR*5N*]MK/7PA7?<5H2KP0EE%*I\F]ZNU;3KTZ1%7*IZ'*(J*S3U*4$L-
MJ:7RCE!U\@XQF'F#KA^>JTTAB["4R)!R6<G68+Z$A=3JM\5Z\.%7C/V!W&W
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MRJA-8HCU2:J%-:N2I5-AIT-JFSJI/=<0^D)4EH^%T2G4GWWV?#3!FD"2[OD
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MOT=.VFX^YJ-Q[FN*XENHV"K7#\]28Q0VQ)MVM4A-(<JZ) =YVJBPTD/-I#9
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>fhtx-20211231_g19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g19.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1+,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $K"^1X0X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%?=D8         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@              E0   EL
M 0                         !              );    E0
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    E0    !29VAT
M;&]N9P   EL    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$!
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         /_A/UAH='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ
M<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N
M8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY-:6-R;W-O
M9G3"KB!7;W)D(&9O<B!-:6-R;W-O9G0@,S8U/"]P9&8Z4')O9'5C97(^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\B/@H@(" @(" @(" \>&UP.D-R96%T;W)4
M;V]L/DUI8W)O<V]F=,*N(%=O<F0@9F]R($UI8W)O<V]F=" S-C4\+WAM<#I#
M<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C$M,#,M
M,394,#DZ,C$Z,#@K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \
M>&UP.DUO9&EF>41A=&4^,C R,2TP,RTQ-E0Q,3HP,CHU,2LP-3HS,#PO>&UP
M.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C$M
M,#,M,394,3$Z,#(Z-3$K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%
M=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C
M945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B/@H@(" @(" @
M(" \>&UP34TZ1&]C=6UE;G1)1#YU=6ED.C<V.48U-31"+3-#,#8M-$8Y12U!
M-3$S+45$-T)!.3$W1#)$.#PO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @
M/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HY-$(U.$4U0C$X.#9%0C$Q038R
M,T(Y,T4S,T1&1C8U,#PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM
M<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C<V.48U-31"+3-#,#8M-$8Y
M12U!-3$S+45$-T)!.3$W1#)$.#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$
M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI3
M97$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z.3)"-3A%-4(Q.#@V14(Q,4$V,C-".3-%,S-$1D8V
M-3 \+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C$M,#,M,394,3$Z,#(Z-#,K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HY
M,T(U.$4U0C$X.#9%0C$Q038R,T(Y,T4S,T1&1C8U,#PO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TP,RTQ
M-E0Q,3HP,CHU,2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N
M861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E
M<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F
M<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O
M97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z.31"-3A%-4(Q.#@V14(Q,4$V,C-".3-%,S-$1D8V
M-3 \+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C$M,#,M,394,3$Z,#(Z-3$K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @
M(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z.3-"-3A%
M-4(Q.#@V14(Q,4$V,C-".3-%,S-$1D8V-3 \+W-T4F5F.FEN<W1A;F-E240^
M"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/G5U:60Z-S8Y1C4U-$(M
M,T,P-BTT1CE%+4$U,3,M140W0D$Y,3=$,D0X/"]S=%)E9CID;V-U;65N=$E$
M/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z
M-S8Y1C4U-$(M,T,P-BTT1CE%+4$U,3,M140W0D$Y,3=$,D0X/"]S=%)E9CIO
M<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R
M;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T
M<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z
M8W)E871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D^1V5N83PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^
M"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YI
M;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO
M=&]S:&]P+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT
M/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$(
M )8"7@,!$0 "$0$#$0'_Q  >  $  @$% 0$             !P@& 0(#! D%
M"O_$ %00  $$ 0,# @0"!@<$! <1  $" P0%!@ '$0@2(1,Q%!4B00E1%A@C
M,F%Q%U*!D:&Q\"0S1]%"P=?A)28G-U-BDB@T-38X1DA46&9V=X>8LK6W_\0
M' $! 0 " P$!              $"! ,%!@<(_\0 .A$  0($ P8%! $#! ,
M P   0 1 @,A,01!41)A<8&1\ 6AL<'1!A,BX?$'%#(5(T)2,V)R))*B_]H
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M5N!\VSZ*S_1 E]'2/T^(E+0[*;VSQ]N2ZVD(0[(;96AYY"$DA"77$J<2@'A
M4$_;555J-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1;>X<]ON1QR
M!]N?8G^&B=]O1;"\@**2?(!/VXX'[QY)]DCRH_8>3QHH_=+:\%IZR2D*2%KY
M25)"1R5 'CZ?(22?<>>"//.BO?ZU1;[2$@J5[@<)'E1Y^P'W(^X'/'!YT4<>
M;<].^-EJIY"2GGD]Y"4E(*@5$\<>/(X]R2  /).B./;GIW[K0/ME*E?4"@$K
M04GO3P>/*1R3^8XYY'MI[HX]VN?)URI4%#D<\?;D<<_Q_/\ OX/\-%5KHB:(
MFB)HB:(FB)HB:(JO=5NX%GM7L/N7N+10Z6PL<7IJUU:<B98DU42OF7U1!M+6
M4Q+DP6KA^FIKVRM*RH,UAFTLHS%>VHON%.KWD<^]?-8Z#7-["@U+FMWO6JBS
MH"WJO=_]A:W<"YIJ2F>-FJO0BHHHN/L/DT5'+LVG*:&IUF)\KO9]E4L.,$"P
M@5D*:A$82%,I>O3M_:MU(KY,U7)S+4 K8D:5&BS_ #KHWV;SW+[G.;ZDLI&0
M7MA4W,IZ'=S8,:)E-+5XO24V=5\5"_1A9G1UV+4[<#((X1-2Q61H_=R>\19"
MO(L?)\\CY/0T*[V+=(FSF%Y#4Y)2TM@)54Y(G2&9EU/FU][D<BMGU+^9W]=(
M4N+;9=*@6=A"G7<Y#LF4U-?"R0KC3OR4UJ'#BMP" >;-S:XJH-VXQ3'\6_$9
MWK@X[1T]%%=Z1^G]R3'IZ^+6Q9+CFY^_G[9Z+!:8C+D!3+B?7+96$$#D\\"9
M]\O0^2/3?;(6!).@H''+)>C(\ #\M59)HB:(M@<!('"@2>."/;^>BQ$3M0A]
M13=7?DL:R;-,6PRL5=97>UF/5#;I8=L[B9'KX#+H4$]CTJ4ZTRV2>>WN6.>U
M1^VLH8(HG:K5N.^^*SA&T[-2[EO5NRMK>;XH]0MY2U>UKF-.PE6*+],MCY.J
M GG_ &L6)6(I85QPVX'2ESD=A/<GGBF3(99$,0B!.@);CQR5BA,,8@-RUB"*
MZD4XZ9KPAQ_J-_$'W#_%6RG",&VIQBLZ2)>UC+%!NW?4:CZV.,6#SL7)HJES
M8]I/F2;Y<J) BO1A7.EH+>C*:(6KDB!$O[A_Q/,CB/VZLR691 ,4#Y"&(%Z6
MM;S"]>&=B*^^6B3N7F^3[D/)<]1=79R&J/$W'!Y#CF(4GPE0_(;5X;E/-+=2
MD^2>-2P=C6MCG_/4KCH&!,+G(1 M4TI5]W2Q4?\ 4KCN"XYM7#IAA\>3&D95
MB[\:JIL4D7*6S6VT:2V[\/!KYBHS<9MM:U/NH()!^H<\Z@(.NM1V%C,B,N Q
MF&*( LT ,9-K 7-:MI>[6\A28\R'"EQ$J:C/QF78Z?04RXVPZTEQM"FEA*F2
M$*2DME"5-_N\#@@59!RQ9K7NQN#H136RAO&L#S^GW0S[-[*_QF90YA$H8C-+
M!J;*-9POT=8L(T!QVQ>FO-.J4U8.J>[64I*Q]  \:(PI2V\T)[IIDRD#+\%Q
M?<"GDX[E]'$R&DF!+4J#8A?P[S(Y[T.)96VM:5#@*"E^?/L?&G[OO#/Q48U:
MCD'2U]?2]Z+LXQB5+A5-!Q['*R+44E8DMU]?#2I,2,VH !MEDJ44!I("&RM:
MCVI^Q)Y*COO]FYW++4>$(!/)"4\D@ GP/) \#G\AX'VT56[1%\.8^XM#R(I1
M\6&WT,^NEWX93_D,HDI0M+RV>X_6&UH/'L0>.* 2#N9_/EW18FD<(,).T!^4
M(VH1M4_,@?B6 <&P7BMU9W7XOT7JWZ8ZOIKC[0IZ=I=RA&\SSE>^8":U=I7M
M6*<B5;/R+= :I(TDU)I7V5N2E]JRT%I<U1#$1M4:N8>FZ_DV3O1:\S%0R\3*
MPWV,3,BF&&$39<HQR(-H@?[DP'\0 1%$X+"M2P7L=B[&;R*(-YRYCK5Z\7T/
MJQ)-E'JTQU ICF.+.3+G,OA)*UN)?'#@!2/&L>_A;!!=P6IQSS'6QZ9^6VY6
M5=9>(6F6U>,0LGE5.U69S,9CY7*8BV47,,3WBR=&6U^61X%HU/CY SM!C%=$
MV^>C3HQ2Y-N'K!N/\3 1)7'+G<!QNP[RKE549/<Z:YJ+L?W0_$.QRAVXN[_&
M+W(9>9Y7OCD65UCF.Q3)VUK*J9ND:6M(8D![)ZN766=-<8E0W*GS'&.T$ %:
MG0M-2FOG9@QX;^.]91@>]'7(QN^FFF8_?9#MIDV[T)=1D^3X@S5OY-@SD7:_
M%+QIFI8,DXA70JV-D.;U0A2JQ-EDUI?/S8YK6FX*"-WGJ;:YKVG; "$ $J 0
MD!1/<2 !P2K[D^Y/W]]%0MVB)HB:(FB)HB:(FB)HB:(FB)HB\J_Q/H&2+P?
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MPD[Q:87PT,44,+DC_&]##_D 7;:M5A16D;8;<<Y]1M7W"FUI61Y\$D'@$?\
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MN^G9ST0N9"7X:$+*E.=QT)LC$1 F7$ YI"[,W_MY"F:[SP7$^'X2?"<9!'L
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MPH@@^#RD^01K,38(@\(+%B*%FS#[LZY%MVO/PN(P\V*3.@C@FPD@PF$NX%+
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MMAY+QV)PDF*,S),6&B@B_P 8(8S#'"(83M&*$@L7&IU "\,,2WF_$8J_Q/\
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M9099D)0\W("V^UUM+K)94".Q37EM86/"BL%)Y\\#C6<'^Y)CAA_Q9LB_$9T
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M!$B1Z_$<?9>AMJ99??KV9[Z&RHJ3V3)XDR0M(XY6M:UJ(Y6HG79"3)A80PT
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M&&Y@41SRHD\ZXL+A9^&EQP@O%$8B(@0P<O8TH;\=RV_%_&Y?B6+@GB5##+#
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MB1"*$PP@,]*&N^JXJZMAU<>)#B->G&B($)(]9R0&DI(0VV%K4I:R$+0D D^
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MB3*>:82M(1#94I/8.$\*!U,,9@<12XA^1,.TVVQ+ 1"S!A77HL/J6'PH&"/
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M<0  - (B\3-$7<O3^%W7B?U!%C,-.E2I,$N9/,N*=%MQ$S3+@,$+B*4(86A
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MWX:K<7VOZX(]^001_?SHJ[73UVO/U>W^O]?R.BCBF_TUX)\0U_6'^'V]_O\
M;1'&HI[)\0U_6_R_YZ(X-C?OO?1<9FQDK6VIT(*$I4I:P4M\J]0A </""X$M
MJ6IL*[TME"U )6DDCCA:AO7+BN3XAG[+21^8((_OT3:%0XIO"?$-?UO\O^>B
M @V/STNGQ#7];_7]^B.-1I?/1;?BF02"L)X_K?3R .XJ!/@I2#]2AX2?!\Z(
MXU[9_1;OB&_/:2O@<\(25D\D#P$@^>#W<?U?J]@=$<=][PN5*@H<CV_CX/\
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M:IQY+;_/,92 70WW!)<_COFROD&SIRW-G0J>T=$>1I2D#K7ZQ^  !W93LX5
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M^JH=^5V%3U]N:]-ZR.]$KH4:0L./QXK#+KB4]@6XVVE*UA(6L)"U J"4J*4
MA*3P!HJ-Z[VB)HBCO=''[;(L%RRKH:C'K^ZLJ&?!K:/+7Y4;%[28^RI$>)D;
MD-F5)73%TH<FLQ6 ^ZRAQIM04\3IW3]D*=W*\_\ 9OH[W0PG-L,RFZA8! <A
M9'4Y5<6=3?3Y%CBRX$:8Q>8;@M;^C$=B!@^7RY+=E)J&KJ%&KUQVVWH=G(YE
M KY=[OE>G[">QI">U2> ?I6XIU0\D^5J6XH\GR.5JX' Y'' (N71$T1-$31$
MT1-$31$T1-$31$T1-$31$T1-$31$T1=)+3BN"I !2>Y7?]2"XE("%L-A]:4)
MY[CVJ4D\GGD<DZ=E8L3E9LA=RY#'@:G5=W_7^O?19)HBKAOCOC8[0RMO:FBV
MPR/=+*=S<DFXWCV,X[98CCTEM5?4/W=B_*LLRR"BIUHCQ8SCH2F:E;JN6F4+
M>X2LI2O4\^[_  5'6.]<_3Y/K:A>4Y/.VXO["7-J[#%<QJK9F5C^05KSK%A0
MW-U30[C%X]I&3'D26X3-R4OP6'K!L.0FG7VWMWS]5&R<G.^;W^ S4-"64LTO
M4_L/D6>';.AW&J[C-$S)-<Y5U\&ZE1F+"(E];T"5=LU:J"+.+49]]F'(LVI$
MF.V9,9IU@APEDJQO_B$;:5.ZM[M[FV.V>)T--G68X"<[EY-MO95\FRPQ$5R1
M+>PNHRN?N1'J;5Z2B/56#N)IC/S0VREX.O,I<=YT[WV6+&M=U1ZV<7/.A9PI
M+O\ KNZ9J7'["]8W"?NS6UEE:O5./8QEEG;H56AU#U1:0TT2GL9NRXRMINFR
M04]F\M"O2BN >70FM"_7M^%E>&KY5<UZ==ZYMRNIR[PR3L]^C.QV<;A4^\BZ
MINDNJS(<$QIJHFV=<FU;CWL#,<JH;QM;->I4A2FJEZ,A39:]0/%*"3KYTYF]
ML_0KZ]3UN],5JN'&1NG71Y4D2FW!*ILH8@QI5?(?@S6)%T]1-4K?IV,65 C/
MJG)C6<J.XU6.2U< E5AL[\0CI>K\BK*)S.;0,3HEJ_)MEXAF3%=42*Y*7!77
M*)= S90+2R:=:?HX3L9#]S'=:D53<QA:'"IK73L^RQJ<@S'-Q7=G9\J%91"Z
MY>E:QAN3(.Z\%T,R4051UXWG#-J\\'7V)(AUJ\9;M)\>ID19+%],AQ9$/'WH
M[[=Z_7K:<"2K6I:M3GY[]:LL;ONO+IHK9%=75>>O9?,N<LQG$$,X]CV7365S
M<IMZRGC2X-C\E^36M=6N6\!=HNIGRU0T2&W)/H=W*3V^&]O7+@FKU'7DS6]5
M=M'<$("BE2@E/<4 I05<#DI22HI23Y2"I1 X')]]%5NT1=53:U$ IX3RI1*7
M5CR' 4\K2IMPGL4L^F>6QY3W =O+OOOW4(/KF<SQ&73*U>)IE]"G.X@I*@0$
MH0TE*B%%3C(#KI25%1]0+(*R21]^;WPXTKQ4;=DV7"A!) [%;]\<\>??[\'D
M<_SX'/\ /@?RU%DFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)
MHB:(FB)HB:(N%QSL<;0 ?K[R3Y/'8@J ]_'/'L/?@^/).JU]W\*&X&I]!^@.
M:\U\HZO,VPW*MP,ERFLPEW:;"-]T;,R*UAZ?2YRN&G;;#LZ_2@6UA9,8_,8A
MSLM7$E0)Z:JIC5;#EA87$5B-.?9:L&J0.1N^IH::THH-[EP'YN"&%A_-P2M:
M/\2C;"YAO%O;G==G('<@L<=HL5^44,VYRRYH4X187[&*)J\NGP;-%9AF?8UN
M X($M^%,Q1F[GU4NS9AR'1#V68-W?2^:H!M1["KFMWSX:MDU/I9%UI2;?9+!
M-U=LZ&51R,VWLI=J957F.-W&>7V,?%MS$EV=A&VUS>Y!86_PL2,\*F$_'MFU
M3&U2(#JD*+U'NP<<N/J_K#O-JEKO\'EYKXU%UZV]+CTQG=/8;=&!E>/RKRDR
M*-C-/7EQW)8F*9QN3BE%!PVTR:!N"BUSO:O%H&81''<:574-AEM5C5W:1[^J
ML(L:*MRKEF6/77DI1V(ZJI_4Y8;DUN!8>K#FL6Q;$;.AR#*K6BO2_>W.4;@X
MK<U-W0X=D<^77R,:N,%M85G7OV+,F'(6J+8MPYC,F$U7W4?/T\J$,X\HVIJ=
M*6L?D%PZ@K%^OO),-VWQ3,=Y\&LLIL,IH9&9%[:"B@1*O&J)W/XVUE#16%?E
MF;BXM+BVRV36-*?J$V+,!BT^83Q JH<V3'<<Z[\P_7+/-.# B@OH[=\7>BZ&
MX'XHV'8_1*DT6TFX,W*7\6R.WJJK(48U0F%E&-8W<9-+Q2]3,OU6-'+>QZ@O
M9]99NQ'*>\AI3,JK&5&D-+<G?=D9AU%*,YRNVOP+9K,_$EPZI7>3,AV3W?IL
M:QQRW-[E$D[?3JQFIJ[_ '-Q5V?&J*S/)=Y8*GY/M;DE3!@1*9ZW<08DN5$8
M@R(\AYIOKK_'#.ZK7+]:.X'Q<!A:ZXJ3\2##<E2DT>R.]#TJ,[3BZ7.J<1K&
MJG]*\@IL8Q9X*L,G^*LXU]97E,N(*%%HN,TOB8B-\%+;CG?E2S6[YUWHUZG7
M^ 7Y7TR#7;V&W#F[M;.[>;F6-#^C$W.L8K,FD41GQK(UJ[9A,LQS-AO/QGBG
MU//HO.(024)40G14=T92YHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(H W<V3A[M/X2]^G.;;>WNW602,FQ[),&3ABK-B3
M/B3:=YI47,,/RN@<2N.\KE3M&XKCD%2R2=#UXK%FK8 5 M[5;/XK4R[_  V-
MH$27<BI+#)+;*8L6QDU<7.;.HNJ&URR3C]SCTJ\R:U&)+SIJ#?F_DVV38]CF
M356/V%R19BJ$AF.6S4?1LG=W]GKD64,08%J7WT(]VS67[7]!NVFWT[9C*3D&
M42\KVBQV'#1/B''XXR"<$STS)MQ=RL?F;@S8MC.L9<NSICG#%/:2&X<^=!=G
M,!P4!BUZMS=N0&5.2KEGR9]^9^!<9U%%+;_2[M/*HMSJ5JK>B6&Z>36^:Y!E
ML1N"QE\:VN+B#:A==D+D638"/6VM;#DP:ZQ>L:XH82T_'<;)1HS$@Y.K<!K4
MY<-XYBG-0GD'X<6T606D2[O,PW(N,BD/Y).R+(Y\O!1?W]AD:9+EK.7<P=OX
M5E1,.R)/QCV-X?)QC%;.4S%>MJ>6N.I<B=Z?*%V>S5I7U;VXJS]AM+C=Q VN
MK[*RO)AVGEUMACTQ]<82YCD:J-*Q\U4RAIIXF, ITLM,I4[RI*0DA K$<B?_
M .:_PIM \QI2IV;/KY*J=]^&WT[9+-I[UYG)8;]35.U+DQ@X3)N)L>-96UE4
M2D7UC@DW**"763+F>AO]"LEQ/XJ&6F;=ZV"2#.^^_P!-"*.WF1O;B6)9;,6_
M#5V0PZ9"L*O*-QVWUVJ+:8J/(P>MCW,EJ&TP6K2KJ<&@5#3,E4=$B<[6084R
M>\%JL)$UQ]]YPKKN_GW&=:V7U\^_#>V$W#>Q:=<1[<2L/&0-TCCR<.R*+"AY
M/>S[N\BFDSK!<QQN8IUZSGM0);U*W)JV5M)K5PY#:9B5,N^7[3CY$^M'X,ON
M5'09LU70L1B8U/S/'7=MLD8R+$I4"RQU*X%[%L:6Y:E.-?HF&Y$9F935SJ(:
M^&G 'F7.&@UPY^GPA+9:F^0TWU^317N;"@VV%$E00D*)4%$J"0"2H)0%$GDE
M00@$^>U/L""PX+?HJFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(N(D%12>24_M![<<<<=O/Y'R"./(/OHL2X?@2#HP
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MV$JB>GBZ^4B,^S\*BM<N8C=M*JVV&XTBT3\Q<=5+<>6NC+>6L,B*9TKFX_\
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GU%DOO:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>fhtx-20211231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #  H0# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ4N![_2G5XW\'?%WB?5/$$5EXAU.'5%NM%M]51DM! 87=V4IP3D84'\:]DH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+0][+JBG.U]CT>EI*6O(/H HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOKVA26UK'$IGU0JJ0W 1I%#?>&3D@#'/M5KQEKMS9_$ZX?\ M)?,4F&WN+:
MS0Q$]2&)X-<9\3+&YU36-'LH]4DAOYIA.;J4 EPOWL'/R_0"@#>\8WR:?;VL
M=^LVK:VR?NYXV;R+3 Z)U)^N.*^C/V?5@;X86.H+(Q>Z+2SM*6&ULXQS@C&.
MM?-_B#Q!+X=MK6Z647"P@QO)$GF22$CJ .>*]YT#6+NZ_9]LY++3KS[1=6K!
M$6,LP[EF'4 \T!U/!?BUXLC\1^.-7O+Z;?:)+]GL[>!0KE1QDD=3WKS*WUFR
MD\07NFG5#/=P@,(-X,BKZE1UK<69)KZ\0VWV:^8'=(R[MOM[8KCO!_AL:+K6
MIO:VOG71<[]0N)02H/.,8S^M=<\'2Q"C[2-SY[ZW4HRK0@[-GH'@74HM/UG3
MX=3N)#;R7:"64J,KEOE'4=:^K?V@M732?AU%-;QFXO)+B)+1$!+-DC./PKXW
MCU:PT6RBDU"X^S%9LNQC,DKC/#*IQD]>^/>O7OB7\0G\2S>';K3+IM+T[[(O
MESWD) BPN"2,E02!Q@FN/V4*+<*:LCVZ-65:E&<G?0HVLUE:^,-/MFMH[.:=
M";UY&WR3G'RQ!LC:*]+^W:H=4BO3<LEHB>3!;0 B-!]!_.O!_&WA=;C5M!NC
MJ"Q:-',L\UZ"<SOZD@<#Z&O;O#.M73QV\\"?Z!L*HTH(8G^]C%,V/;/!&H)>
M:2J#<'4Y.XFNDK@_!UQMNT=A([.F"V"!^5=Y0 4444 1S?ZLTT21QPE\X11D
M]Z=<9,38&:PKYE_L6[5YOL( .93SG\*!'C?C[Q7<>(O$5^MFD@M+5 J3G &>
MXQG-<%X'U*]UN\U.65HX]/$@@6WL!MDN-H^YP<!<]3_.MN38L[V\TUS>1MOD
MCA9&$3C/!.!G%<#\.+67P_KWB'4P[WFIW$VQ+6-"L,//#G&<8'YXH&>G^#9Y
M8O%UH]WIT^AZ:9]QMR<*KC&.>=P/<YS[5]**05!'3M7R5;KXFO+[3IWTB^UR
M-;E<S LL.%.3D8ZY_2OK"U:22UC>51'(R@LJ] : )Z*** "FY_.G57F25E8Q
ME0V.,Y% CA?CAM_X57XG1L$&PFR",]5-?G[;(OVB+Y1C>.P]:^D_C=\8O%NF
MVNI^&=;\-P6D=Y$\"7D4[,LB'(#*2O7'8X-?-D;%9$(Y(.1SUQ7S^.JIRCY'
MR6:UE*M%)['Z4^%R5T*Q'1?(C  /3Y16W7SI\&_C!XP\?/:V=IX;@BTNV58Y
MM0:=\8&!Q\O)X[<>]?16?:O;IS4XW1]-1J1J03B+1116IT!1110!3U2\^P6$
MUQMW;%R*^3KBXAM[[7;F_OXFD>258[*W;?-)-E>,GA1EO6OIGQ]-&OAVY1KL
MVK,I"[%#.Q] "1FOB;45OO#VK7MC<F.UW;=J-'B7!QDEN_;GWK6E3526IQ8N
MNL/3]I:Y%X5TM-6O-=:YN;4E)B1I<2#._:!F4@#/(Z#%8/BCQ1J_A>WL[U8+
M620WB+Y3(>@##$8[C![>@K=^%.BV5FVL3VMOY-Y<S[)9GE+%E]1[U)XN\"^*
M-$NK6\>/^RM&-W&;.\:'<>0QQM.2<9YP *QY?9OE21VJ<IK?1G8K):_VQHVN
M:QJ$UGJ-Y"+2:TD)5_*/SA2S#[S$ ?0FI_''BS7=!6?4;B0365UA;>UMH<".
M&/ "*P' !/(##.37!_$+PO#K5EI$TCRZO9"X2:YEW('G; "XR!L SVKU&V;Q
M#K5VUA;VD,S74 BBMXFY15PS*I/ )QRV*8'-:)KQ\9>$=1>]M+>PTD"26'3S
M.9T#[&(FN 2K2?=QL&.:OZ+XGBU'X7V.C6E]<:A::+:KBYMN'O+L?=(W,"57
M)X!/05R6B_#F3P3XFU6SOI$N=5DB5IK&W9G$1+%E#-C'&>6&?O#K70^#=%\0
MZ;?:E#'))?:9'B6V@AB PW\1W ?-_P "S0!YI\4GUS0UL-5N4D@>&9)UC8"-
MI(W$@;>2"><8_P!H]A7775X/&'A>PU1X[;3=#TI'NQIL\8$%Q,APJR+N!8<G
MYC^5=!XVT^_:^TV\URWN(=/DGB%U<1VK,L>"2IP1T!)R*U]!^$VH?$.U6TU&
MYNKJ"X'ES7BQ!8DB+9('\)^HS0![_P#!6XFOO %A<W-\FH7,A9I)X2#'DGHA
M'51VKNZY'X7>#)/ /A&VT1S"4MGD\O[.NU-A;*\=CBNNH **** "BBB@!&^Z
M?Z5\I_%[2Q<?&C7);?3%%Z;6#.J. XC38HV@9SGV(Q[U]6?3K7S9^T-X7O+O
MQ-#-I-G?->74L?FS!@L3 !0 ISG=D?2@#R3X8ZUJWA_5=?EO5:/P]:A8[%+H
MYFFD! ^7&2 ?FX]Q537M-M]:O-5-Q'->7VHR^:\D#L$A3^'!(&"!U%>H3?#3
M7O\ A*;J5M*9CI\ 0'.0X* LWOU_,5RC::VH-865U:-%=3SLNUHFB! /W>O)
M- 'C&LVK>*)+_P"R^7)]AE*(CML150?,W/\ .OI72=>O=9^#.@6FEPW.NFUF
MC:[U24_N(P<[XU)P<J& P!C/?O79Z+^S!X?FGN&UBUAN[2>%<1QAHVSG/.#U
M&*T?'GPSOM)\'G0_"873M%>1&EAMR[3%CD-R6P5/!/TH ^;M=FT;PSXL76YT
MNIH(9#&K0/NB20DY<KT(49/X^U)XFT6>WFGOK.))+Z^S(UQ,Q88'&[IT&>E>
M_P"M? B?^QM,@L8;>9UAQ=*_'[S ^;!'/>N+U7X8^--'FCDETJ&\5IEMPT+!
MF9 .F.P)ZGVH ^?;CPU=ZHNL8LYS8V%GQ+;QEB."6(&/TKU_X:>$9?%/PR^T
M6MI<645A*L$>Y6\V1NOFX*CKTKZ.^&_PSB\(+)=3R-)>W4066/\ @7V [UW$
M-I';Q>7$BJN,;5&!^E 'Q[X2^&NM6\EW:QZ8MO9F9Y[K]T4>XPVX$MQQCK]*
MFT#PBD_BXV+W"I#JDQ+LZ!_G+#!P6'.<"OK^2%949' 96R"I'&",8KYP\?>(
M-&\$?%#26T/49(I;=U2_M4C5XA&6!(&>C8STH ]T\(^%XO"&AQ6<0CDEC7YY
M4389#[UXY\2O"_B/Q5XLCBOD=_+B/V.VM7(B1L#+[B/FY&2,"O>K&\34+.&Y
MB),<J!UR,<'VJ7RUW!BH+#H<<B@#XV\;_#W75\,W,+Z7?/<QLH;CS6W9XP>P
M-7_ WA_5_&6GFTDA>YO0=LHDB5?+Z#!(' 'YU]=[:K6>EVNGO*UM;QP&5MSF
M-<;CZF@#ROPY^S3X7T+6M/UI!<#4X C2GS,I(R\C@CC!]*L_%S3]9U>.*WN!
M(FB>:-ZV3DO*.RMQQGV->JTUHPXPP!'<$9S0!\K1_#G6M$:^8:5?/!+^]RV]
MQCL.O8>U<9\/_#>K_;+O2)=+N1OF:86Z_*6#-G)!'J3^=?;NVJZZ;;"]-X($
M%TRA#,%&['IF@#P_1OV9]&U^U34/$5M-%JJR9B:*4@H@_AQTJQ\:;/2=2TU=
M&LM-M[[4F 0S2';Y"K@9+<9P/<U[BWMUK)USPU9^(K,V]Y$KKG<&XR/TIWMJ
M&ZL?!-]I%SH]W=Z8T#(R$[I9,!''/W 37/>%U:&.33WMH_)4L&?^-QU&<5^A
M.H?#W0=4\@76EVLXA(*[XP3Q[UDW'P7\*S:A:7D>F0V\EN^_$:X#GWKN6)6F
MAX,LM<N:SW/FOX>_L\W?Q0TF_74=1OM*TTF,VQ505EQDD$$@D XKLO%W@73O
M".GZ/I>D7MU?Z]#^[-S"P$4:D[3N&>.G2OI:"U2VB"1(B*!@!1@"N=U;X>Z;
MJ<OFQQBSF:0/(\/'FC.2&'>N.<N:39[%&G[*FH7O8XSX?[FMXX)IEN;B$[9)
M<<Y'KBO6(#F%>O3O5.QT&PTU56WM8XMO=!BKZC:,"H-A:*** ,_4-+-Y$0K*
M&]UKR[QI\+]2U#5(+Z#R[A P4IM^91ZU[#10!QGA;X<VNCK-)>".\FF4*R2(
M&11[ BNAN]!MKC3?L,>ZTMP-H6V/EX'IQ6E10!Y)>_!)]0A>V:]C@AADWVTB
M1 M@]=_3)KAO&'[-^LWFL:=J%M?)<1V[ ;47#\GYFYKZ4I* .#\%?"V#PO,M
MY/<M>W7EF,;AA5!Z_6M#QO8ZO)HDUKH@AA5XBC/R'4?[&.*ZRF-&3CGF@1\B
M^(/@7K][';7FD6DYMP/+F@WJ))&SRY)/?TKB[KX!^,-)\0)<S:6\:7$BQJZ-
MD9[9 K[N:+<!T.*&0MC(4XYR:WC6E%6.&>#ISFYOJ>-?"WX$6WAVRNY/$%M:
MW]W=##1RQB1(Q[9'7Z8K+^+.@ZIKS:?I,ND_9/#MO)MCLH]I6? PN2!\OTKW
MK:W;%(T*N!N4-@YYK*4G)W9U4J<:,5".R/EV[^$'BBYT:2VETC;M'[F*'&!C
MH22?Z5U?P\\*^(3-'I^JVCQ3QH-TLC9 '^->]=>M)M&[.!4FI!8V:6-O'$@'
MRC&[O5FBB@ HHHH *J:CIL.J6SPSH&5ABK=% '$W7PGT>\C7S3-YPX:2-RNX
M>F*XVU_9ITK3_$JZA!>S/;2$M/%)C=[!< <?6O:** ,_1]%M=!L4M+./RH%_
MAW$_C5^EHH *C:95Y-/KS+Q!X@U+4/$6JV=M?2Z;::;%'(?LUJ+B:5GSC*E6
M.T8[#/(H(E+E5STOSDVDYXI&88'8]N>M>2V?QEM[*:SM&C:^G*J;F6)&A8;F
M*AEB89SE3P<=*M77QA:PBEN;W29+6T*S&&19@S2F,D<CMG!]:GF1BL13M>YU
M?C/P'I7CG2Y+#5+5)X6&1G 9&]0>QKYXTG]C^2/Q<WV_5(W\/(V^../(FF_V
M6.,#_>!S7NWA;XC1:[8ZA-/;26S6(#2[6+QD%=WRL0.WM7/V?QL%U8W-V-+D
M-O#$MT3&Y;]QD;B3C&\ YVC/'?M6$Z5.H[LYZL<-5:G-:G?:%X?L?#>EV]AI
M\,5M;0KMCC0 8Q6UN'K7ETGQ6NI(_M$>AN]FMO\ ;99&N0"(3T(&/O$<^F.^
M:9<?&<QPB9M*V17%R]M:/)<D"4J"2Q(4[1P>F3[5LN6*LCH5:$58]4WKZTNX
M8![&O+8_C(LEU8Q_V7+#'<*HWSR^6Y8L5P@8 ,01R"0W3@U4D^+@N%D46C63
MQ7EO"RK(K3%6E"X>,J"O4'C(YZT^9#^L0[GKGF+Z@4N:\KE^+LEK81W,FC2!
M+N+[18@7',R%D4;LC]V?G4]^OKQ79^$?$LOB*WO/M%H;&YM+@P2Q"3S%W;5;
M@X!QAAVJO0N-2,G9,T]4T6TU>-DN85DXP&Q\R^X/:N3OO@_X>U1;<WMBMY)"
M6Q),Q+,#V)_ST%=U2+G'.,^U--K5%2C&:Y9*YPOA_P"#/AKPOJKWMA8HFZ/R
M_*<;ES_>Y[UB?$SX4ZEXPU.QU"WU .]G(?(MVB0)&I&,<CGZUZMS1S2ZW+/)
MX?V=]%FT,:?J-W=7BD)NPP0 @@G&![5UG@_X;Z9X.M]MNIGN<%3=2G+[2>GM
MQ76T4 >7WGP T"Z\3V^L,968+MN(9'+B?/\ >W$\<#CVKT+2]$L=%MU@LK:.
MWB48VHM7J* *M]IUOJEJ]O=PI/"PPR.,@T^WM(K6".&"-88HQM144 */8=*G
MHH **** "BBB@ HHHH *AN+.&[V>=#'+Y;!TWJ#A@<@CT-344 1^6>^"?7O[
M?TJO=:3:7DD,D]M#,\+[XVD0,5/J/2KE% "4$9!%+10 FVD5=N>!SZ"G44 (
M!@#O2T44 %<O=?#?0;SQ/%K\EA$=11=I8J"C>Y7IGWKJ** $"[>!TI:** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2N:UKP'IVN7"W,Z
M3QW*C;YMK=20,R^A*L,_C7344":3W.._X5CH8FMI$M)(?("A$AG=%.#D;P&Q
M)SS\P-37'PXT>YM4@DM \:>;A68_\M"2_P">3]*ZNBBR,_9P['/:+X.L=#M)
MX8(9'^T?ZUKB=Y6;C&"S$MT]ZRX_A7HL$;1K;RR0L5_=R7#N %.54!F/RY_A
MZ'TKM:*6@_9Q:M8\Z;X0V+:R9CYGV#R!$+5;B0+G>7(/S<J2>GX5LW/PXTB:
MS^SB"2,><TX>"9HG#M]XAE((ZGC-=9119"5*"Z'%O\+-#D\K-K)MBV@1_:'V
MOM.5+ '#$$GDY)]:5?A7H@?>]O)*VY67S+AWV;9!( N3@#< <#'I79T460>S
MAV.*A^$^A1Y_T>0C@*'N9'" .' 0%OE&Y5/RXZ8KI-+T.VTB2\>W38]U-YTI
MSG+;57/Y**T:*92A&.R&MGM3J**"PHHHH **** "BBB@ HHHH **** "BBB@
' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>fhtx-20211231_g20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1*F4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $HJ^1T8X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%>,>P         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@              F@   E,
M 0                         !              )3    F@
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    F@    !29VAT
M;&]N9P   E,    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M    5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   )H     4F=H=&QO;F<   )3     W5R
M;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53
M;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /
M15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N
M9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO
M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M C_P        .$))3001       ! 0 X0DE-!!0       0    #.$))300,
M      A8     0   *     I   !X   3.    @\ !@  ?_8_^T #$%D;V)E
M7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,
M#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,
M# P,# P,# P,# P,# P,# P,# S_P  1"  I * # 2(  A$! Q$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0D4>?=%31%:\;,<4FW;V,Q\CH95_&%'G:2-;0)-LTVG*DY)KVW%>C]JHJEW
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M\013A.E^.7#DN34C-I'H)%_3Q[N8P+T:IEVD)BVD"I$9.1ZTGFYKH]AM(2L
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M1!;U[Y:YJMHJFB)HB:(FB)HB:(FB*"_7EBK65;*5389%48S*QS/\?R:LL;V
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MMP[6RFR*RU<>K8$-F:W":6/#>JG&W2[5B$H 9JG/*J/DN>OQ]EQ-H)(>X$Z
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MQ"]LZZQQ;+LG_*"([$;K65Q+'[&_DTR^H7J_'R&:\VV505$C,>[QRJ$K2#Z
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M6[M1N%".5!PN/C[V 7,I/AYTFMEQYE11@$6JE*I.Q[JSC2X;#9(\@)YK$V'
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MOO$RZM8]"ENQX[H-)):Y4%,5UP-J?BX3P0XAM#NTK&5)OYD7J%]!\#&P>)[
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MC?#@YVTM!/\ K[@W2'!S@ZI!,88-;0%*/9_[7O%\PW0Z5L2L<9;QO*<FAX]
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MP_#C;>5C3$V_F9)+8"XR1N-][SOB?O"4K/WP01W)@2WVGHC2-Q):&C<B.XT
M-@2H,&LF::",C:>=SYW5CVPVT^+73%[B>+Q:*>,TY<EJKGV#4*<+L6XAI$G5
MYR7(Q5\1B_M9D2H;99K69TIZ0W$1X0,238ZFDQG3I0S>34*E'Z=]EH]?<5\/
M!JR/79 ^Y-LX[,RWCI-=DHKJ-DC%@V]%"$JE,@Q8WHQZJ2^[(KFH;CAEJ]\K
M5TK:J&9I2?6_"0>AF!4*XF-E]KFH>-Q6,,IBA8G"=@8Z "\KD",[D5)E3JMR
M/7)V4X_D6-45Y(D2W)$B59U[<U]UQYQ\G9IP@CH9'JGK-#RBDC6T_86P94=$
MNQ>-[G#NBS3S7I3,%VLJ<:>G/,8K4-RZV-7S9$.I;<!HY\V- 9!]]WN-USAX
M^YYL'1*SP]^N5Q%O6:+JY)T.[&7V<8OF\"ML\=<QH7%&CQBV>J*>PDHEDC4V
M='CF'?+CG:2W1(%00E$$IM ?1QPB$]YG6*C^0I)0\*Q*NM1O$K(3V0N8ZQBJ
MV,U]R3.EX]%(7VX+YO$7KMMO#ZKBH!$;BF9$JDJZ4[ZQWS4'2<H)(@VX6$Q[
M2K&HM@-I,?L/O;&,<8H;!;2KM')5=9VB.=]=:M7#%9$%Z8ZU#HIDYL')]-#%
MBME< +T5SVT[U3@2)IEF;:>5[&B\#->EOIVSF_GY/ENVU!<WMC"NH=A).=<1
MU?:R:M6FN5.)&L&(;!6\#B+.L6H[,XVVXQ+)'T6R!$^_\<<T,@^G"QN*D"9S
MUF@67MN]O,(VYJ)5;@U)'J(%E8OVLUT94ZQF6D]\&FCG6%I:29EE8.BPPQ$B
MNRY;ZLUT6%$8((T=AL"HK^8]N"C3U<?DJ-%C*[L;N/;6;/WUNF'9&S$JJ-&\
MAL[QIJ3 9O,NR6);5.-U+@U$RK2/(H2.Q*P)I+*O[A4:<L_M4]TFI4$BL&IF
MI&@H*CC%J"M@%F/8:GVDQS:S%:79B76V&VU=7NQ,=ET]PE_7NQO7?DO&S9MR
MYD<VS>D.DO#W8BKZ0@+3;8 Y=\,I/)($#> IKTTH+6M;DLXIQPG'MPG'[OI[
M>/[M19+[HB@O=?\ O&L$3C_[H^XJ\\>_^M;;;Z_3C]O//MJ9]Z'N+9ZIWW=3
MH_S_ )]M51MAR'LFBJ:(FB)HBZK\@(K;CSQ@#0*I&9NM-@VW_M&X3JMB(A[K
M\R^.=%.6L4BG/EI7DK,R7/*+%J2;D-Q=5\"JA-JXY*=(7Q>014A;A-1G'3ER
M)"JVVW&8)R0I. @,FX8-$[[[]DGC4TBEQ>8]?2ZT!?:'[&9YU4=3_1;GEMU'
MRNEG"J'+[!EC I666E)DV74Q5CF26U_(J8TFF;J;"RKZD,2C0;*3(?"-D3+$
M]JJ>FR(CSGV.Y7,9X6_%PAM&ZYS' F0V;&"!#@1EE6I@AI*WMG/VUV<Q>&S*
M?Q;!,;@B@^F\Y HH4>6[\SSPOR%B/RDDODXKSPL.S9C[KCKQF\X8E29-8'(=
MU7$.$<,$"H&8(/+ZFDQG23G$YZ^^M'=G=K+,!JG^G_ \AD1SRNI<M,HR2HB5
M559QA?=:J&:BKR.377TM)MZ58,6R@USD&14OB^KAQG1,NC\8?C%@9AB8+ WZ
M00)(-CF7#J1'!?:?Z)8?PWA^-^([3XWC-!&Q$-8]VTM&[NXWS'EV ]H(;A S
M():(<((!4B=L]J-Q,UP/$I&\VY&01YLNIKBM\/PF'%PBJ:<^$95VLLYC,RYM
MK%6E1&G7ZBTIA54(19:1>P>PV)CO[,-Q"0YS9@"*N !F!].=-:#1?-/BEFS#
MXL\0VKPHN_LV;6]^"ULEI8T4<7/G$(=4@DDV)),SX.-]*6WN(;[KN13[<_".
M18"+"R-<F?L'?O!TWVY#Y!8SI,[UG8B"VZCRNIQPJ(1?I%Z_#\,+MJ..UA:X
MT#]]I-S!(R$0!G457K,?^H/B0^"V?#C=H#L ;3C8CL 8>[NM>6N(#RV"?F-W
MYWX$QNW4V(#1"VOJ (IV*VVC9)P(*O/A0X[51%X51X4O=??7>[HPV-8+@5'+
M6X,Y\E\MP6OQL1^-B&Y-3!-9-P9]N"]% +YNT^WN7RB<+_<JDG'LJ^%36,ST
MD>I^\K:]LNEM!%Y[*[H"HIPJJJ^_G]R)Q_+19 $ 3WKF9JNK*)P>T@'GCE%^
M84\%RBHJ+[IX3W14UDT R#<V[XT\B*2M>(7M@M$Y7 K7GW7)15W/Z8J7/,YQ
MC<+&\KO-LLLJ*?)*5^=B,2G-V[K,FGX[*M6K$;2%+;(6RQ^$#: V*=LAWE?"
M+KA;1LSL1SBQQ8;3?>F09J(H*@T/1>I\(^(<78ME.%BX3=H9O->T.<&_+>QI
M.&6QADD[P=#A!;69! 62]F]I\3V@PRDQ'%@[FJ.JKJB3</LLLS+9J!%^$:F3
MO1$&7)<CM;>=1![44^T$$>!2[)LYV;#<TB"YY,P)- )N=!GKQ75>)^*XOB^T
M?W&(?\1N-:"3NM)+@TF&R1-]T7GB,:9ATC[=9MD&\N4W4=B1D.[L+'H#EO*@
M17YV/P:3'8>/+!K9)-=Z19C<19#[2JJ*X\:*J\ZY7.M9$Y4@=!QKQ775%K:
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M2K;>*_\ =5=5C*MJ:\SK)(?QU@#;JN).L,R6':*^R3LVMKHC,H'&4]/3O/\
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M;VTGVSJ6HM28%#CC%%\)(J;(F(LF ^!O/.PIE*+$A]PY4EDI)J\O(&S   @
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MV;F$LHE<NY\*YCO1(U=>#698W,#.8BJ$ZYGQSF0@8KX]=4-0E8A3YK+K0CG
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M\<PNQ\)\!\&QO#\3$:S"\0/]T<+'<7X^ =GV;=+CB.!<T8YP@1+& %\T<#O
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M1<#Z2,X)W'H$@X$J>,S=S;9E&FI#=?9H*@JH2EZ/*(GS>/*<3;<5^$P.PH!
M)@C>DBE9B\V'W ';^$^%G;G%N,2&DF"!! X":P,RT@KU^BC[4W+NN+9E_=/:
M?I9S>5+;RR;BRP)N64%1C$5R%$KY:R9V2389V;8DDPF'!C8Q*4#!41%5/&O8
M<?%QW'YL0+P T"UX!)S-[<I6_P 6\'9L#</Y>+!>/I^8)<8DF@( : --Z;Z+
M+NY^+=>^]^#9?C[66[*;%P;O&KFL2IQJAN=P\R(["*XT$1<XR";68[6\BXC9
M6,?!%D-N<26&HRH+3>W;QM&$S>P7!M)DM:[D/JF3H9%LZ3PO!\?PPXQPO$<!
MV+NOW7$8V)ABCMTF,,4F;;SHN"0M5'V:OV,^[73[FN[5WU#9M*R"'D_W5-HV
M7K6ISVO^.>L7SDR;"ORC'YM3)L27M)Z<D!LR?4G1;;(^$XFP8FVXSW#'>"T5
M #&-GA+01%]#2^:]%XIB?#.#@L=L>R.&(9!#MIVMX%#,M<YL?5NQSRD%;7-X
MND+(,AL=NIE2UB&YU3B+631I6([HU-'!HE6]&I!JPAQ\3H*D7)]<-8ZK!/>H
MH^NYP2*Z?=CMGA[-LQ/]5@Q TNAKZ $S%HF!!$UD&L+E>!?%NT^#X.+A[#M&
M)L0Q0QIQ-F: _P"6QP<UI?B;[P)):ZL.:8,P"LP; ],F.X#M9B6+YI2U.0Y%
M2049D//G*L:J$ZCKCGH4<6R>>"OAQT)&X[3#;2  (B"GA$SV78O[/##,&6-!
MB/\ -H;I#B3'/CP75?$?CNT^+;<=L?BA^*0TG$.%A-<7 220QH:3-S634U4@
M<CVHV]SC%7\2RW$Z>YQV>V 3:B5$;^#D(T2$T3C(( D3:B)-DOS J(HJBZY^
MX'X89B &0)$9_8^JZ79?$]MV3&_N<'&W<<U+RQCS6XA[7"N8SA-N=H=N=I:,
ML<V[Q:MQ:F.4]-.%6-JT!RWT$79!DJD9.J( "&I*HB(B*HB)J86!A8((PV[L
M\23YDE7;/$]NV]_S-JQSB. @?1AL;_[6-:VN=*YJU<^Z:-B-TKV%DVX>U^)9
MA?U\=J)#MKZJCV$UF.PY(=991]\2<)MMR5((!,B05=/C]9=8'9-G.,<<X8.*
MX@EQ+B"0-T?3.[;@N3L7Q#XSX=A8F!L6V' PL0RYH9ADS %"6$M@4 ! $F+E
M9E&NBBPS&%OL88 6F6@50!MH!00; 15$$  1$13P(B@HB(G&N3T&5@!80%U8
MQL4/=B;WUO.\YT R9)FHB3)),"222K,SG:O;[<NL8ILZQ:JR:LC2VY[$.UCC
M)9:F-$!-2 $T7M<;-MLP)/(D JGMKCXFRX&*\XCV$N,2=YP_Q;NB@(%J6R7.
MV#Q;;_#,5V-L6/\ *>X;I)P\-X@$F-U[7-%2; 75QUF-4]+7PZNHAM5T"O:1
MB'&C"@-,-H*"@@*>$\(GGW1?/.JW9\%L0R(B*NI%HKJN+M6U[1MFT.VG:,4X
MN.XEQ<X 7-MT -W<HB(HL P^CSIX@[DCNY'VXJF\_"ZD9$-Z$B<!)=R@="19
M_!C(2#\6\CSJNO+'[S-PG"5255UH/ANQNVC^Z.$3C"*E[RWZ;?07;NF62[MW
MQ=\0.V >&?WC?[3=+-T;-LS7AAB1\T88Q3:GUVD6*DD,..*"B OR)P*J1*J)
M]$YY]D^B?37-(!:6FQXD>1O^<UYQQ<]_S'F7G,4'D($]/O./LHV<VMS:X@7^
M7X)C.2W-8@#7V-W51+&5#1LB-M&')3;BMH!D9#Q^JI%QQRNL68;,-NZUHB2X
MS]1).I=)Z6X+F?W^V#9';#\_$_M7/.(<&?HWR "X9@D  D$6&@7NW6"8ED?P
MGWY15MLD%Q'HB6$1F9\.XA=W<WZXGV\^!)$\$ B"\BB(F<#0>0]-$V?;]LV3
M#?A;/M.+A8>("U[6G_($%IDD$FA,5I,B%<L2(Q"9&/'!&V@X0 'P("(B @*>
MP@ "( *<"(B@HB(FGET 'LN$!!<:DN<7DG-SC)/Z79T531$T1-$31$T1-$31
M$T1-$31$T1-$31$T1-$6(]]\FKL1VCSVYL[.IJ&6\<M(K$Z\C.3JMN;.AO18
M83(++4AZ8P\^Z#3D9J-))P")"8<;0TT3OR6O?[+MZF=K=VTQT6&ZD[+%Y*C+
MCU;5W(M'*^P"TGQW:S%\55W$9,H"'%Q?9LAB1FI,9B:'#C:E*R)@WK%O4WZ6
MXA;9-%4T10UP[E.O???]O2ITNJGG\-SNJM/;5/\ QY?<K%MO+_XM4RM19)HB
M:(FB)HB:(FB)HB:(FB)[Z(J7H-=XGV_,*<)Y7C^*<\+_ !U  +3U4(#CO&9_
M<V[HJ?PC/S)P2(9]Y(ADG))QQSPO*IXY[5^7GGQYT(!B<C-*91EW-5DXEX <
M9 $#*@,W$$UU79U5$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T
M1-$5$([3:"((J (H -\KV  @#8@(^R (@BH*>$)2+W)=%([\OP%]]$%[N451
M)%%0554.%7G]7VT2+<.^_*Q(55$X3A/9/":*K ^3=06!XKN%6[;6TZ;'OK*5
M50DDA7F[30)]YW_<]9967>*1)MJC9% 0F";<'E2)>-%*^?F*=0>[J%^Z]3M)
MNEUR8YB&YD?!,KPRQZ4,_;MJ?)9U184LF4WNKMNZVS(9DNDPX2"V0HRI 9@K
MCH!RVFL<3#:\ &"(FHST,??ADMVS;?M6 XMPY: =T$!M+P1<B]^:F)M;AG3Y
MLEBXXEM+5;;;?8T4HK'[@Q-ZDI:I)[JMD[+6"Q*;%'C)L.\S'U5[.#]E36.'
MAMPY AH.@/G3/N5GM>W;3CQ\QSWEH(!<!(:001) B10W'DLE-Y5@Z'ZIY)C9
M.*2GR5Y5KPXJ]RE_Z:J+Y5>..>/I]-;GN+F[A@M @4RB%PFX 81B$$.=]4U@
M$UO0&.S"KIE^%"VC8Y1CRBB\KW7U87/:2FA%S,Y4NY>>Y?K[^$U@T##_ ,8%
M^-[WZGU6PCYL-)WJ@YFMQ2N>H_*ZOY6XJHB 93CP,DXH"JWE81+Y;_L!*6HN
M*+J(T:?[7?W(JJOG,N!@P"2))!H3)O&>=Q>ME@UC\)V[7=:2!4Q$ 4G2M(D&
M\&J[89AAHHJ)E.."*KY'[]JD5%Y\^TU./KX3QSX_'6*V%Q=&]4QF*=3'O6PT
M78'-\.043\J<<\(B?\>57X>/>9S[?WZ*3W!/K"I_EOBBJ1IE>-H'/:G?=U78
M/CD2(DF(7<XORB//'/TT2O=LIZUIR\^?Y:XHJ*J95C"*B^1*\K4-/V*/Q?A5
M3VY7]O[-$KS[O?\ /7+[^6^(=O\ ZTXYSSQS]^5?;_\ S%7CCZ^VBJ+G&'IQ
M_P *<<X\\_Z<JOPY3C^N?Y_?HBZ[^<XLB#Z.4XTO/**JW=6JB7*^GX26OR.$
MGIJ7GA>>%\*J%*S;GQM$6XWTR51K.<1($)S*L9557G]'=UB(*?020IG*&B>_
MLG//":))RBU)D?;GZ6E5/RXP_P#Z4XYQ^R\JE7]OM,]N/Y_S)7A'6U.%Y[O!
M<WP_Z95CG_7E4OE?9/$S^_1 33\'[Q^M3943SK%.\ ;R?&W",V40$NZQ31OO
M_K+IHDO@0::7U$7GRJ*B\HNGVGO\Z)7VMZR=!<6T7NUUM76S1/5EA!L6FS4#
M>KY+$MCN3RH(ZPXZ"&@D!**DA<$!*B"8JI.N>E(%",[\Y'0KTT7E.4]E\IH@
M,B1FFBJ:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+&&[VU=%O)A4O",AFVU=!
MDS(5@W.I)[];9Q)E>XKL9Z+,CFVZT0FJ\]I)W"JBJ*BKHH3 )T6-NGSIEP[I
MY&W3%LBS#(7+F%6ULA_+<@F7KL>%3.378$2&4UUTH[+#EC,7M;X1?57NYX3@
MH"";@G(P1?G^=:465=V<W/;;;7-L];C,S#Q+'+.]&(^X33<I:Z,Y(^'5P4(A
M)WL[!5!+YE3PNBR6O[9WK]R/<;(JFMN,&@4L9FZJ,;R:L9>?DY.MID;^X*5\
MNCJV7Y /5E;'P)J18G\1/4VLB:$G8DF";128O;W-:=W4K;.)F*<KCI7FL=XK
MUI;:1^MC>;)"PW>HX%ITX=.-(S&#:O(';:'(JMP.IR:^Y+KV45Z-7O#8,#&F
M/(7KRQEQP5!8\4FW*W7]^JEK "H&9I8=;?=2T_IV[3\_^I.^W'_[.Y5SSSQ_
MS7[%_NT67??HOG].[:9?;"=]^/K_ *G,K_A_\'\=$KEWV)3^G;M/SQ^1.^_/
MGPFSF5_M_P#E?N_GHI]64>9X<.?HN)==VTX@1+A.^J<"J\KL[E0BGX*I*S[)
M[JOTT5URXJVL6^T7V-S"M"YQN@WGO*HI5E""QK]ILF>B.R:6RE4UNT#@1^%>
M@VL.7!<:1>?685/KHI7VF3^K^717-_3MVH5>!PG?;^.SF5__ $>/;_O_ &:)
MSCO\_JMUR_IV[3_]"=]_/"I_J=RKV7A$Y_1?CHKKP1>NS:=.57"=]D1$Y55V
M=RI$1$YY55]+PB>_/T3G13,"1.?Y[^U;>R'[1'8_$ZF5>Y)CF]--51'(+$F5
M-VFR9MIJ18SF*V"P!JPB..RYDEAEH47E2-$3A51-$K2-:GE?\+WAZ[]IE3N_
M(G?91)$(>-G,KY[5]N?T.B"3!U />?/I&:Y)UV[4?7"-]^/I_J<ROZ^WNSIT
M]O*_ZXJU_/-??Z=FT_\ T)WW_!/]3N5>_M_S7XZ* SIW!]C]\X'Q.N[:?QSA
M.^WUYXV=ROZ>?^9_#W_EIT]O._[X*JUYWVBNR,'):O$9&/[S,Y'=4UY=5-,>
MTV2I-L*S&;*@KLDLF6O04E:ISR6D)U$^4_O !5.4'12IFVFO\<B+ZA72G79M
M.J)_P)WV\\)_['<J\^_/'Z']BZ(3 K'.#[5X9HG79M/_ -"-]_/MQLYE7M^W
M]%HKWWW1?/Z=NTZ^V$[[^_'_ +',K_BG]E_X:*5G*.=?9/Z=NTR\HF$[[\^?
M"[.97_\ 1_DGG17O\JW:3[0[93(YEU$IL>WGFN4%L./V[<?:;)7'*R\1B),?
MK9PI'7T)3-;:U5FK1>?A)#9JJ(2\E/+\"OX]ZE3OB2$E1(LH4)!DQV) H39M
M$B/-"XB$TY^D;+@O+9_."_*7S(NBJ[&B)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HBBYF737C^:[EQ,]GWUBS7.S<<M<BQ-F/&6!?V>'B^WCLQ^>9)80
MT@@^X+D:,HI(1/)(G&G8I[]E8R:#7,&+7.=#E6:Y*)MM]GMTUS>J.ERTL'Q1
M[%VMG,KH+/$BR*W^]G<FM\PQN[A7*P2O$LY# 0:RP#AGM9;<,34>WG@MHQGM
M$ -LVNZ,M9%(O6M3%0I+KT%=)1JIN[-4INFJDX:W.5JIF7DR5?OY/)%RJ^$Y
M5>>-#4R5F['Q'7W?_8VG*E(7Q>@CI&)./S,4B?M2YRI%3^/W][ZQ#0#O5)))
MJ217AET_$:<4G&;NO)(B*&+<OXX+KKT$=(X\%^9FE444T<[[S*D[0'N3O\WR
M(J)QSY^B\_CJN <(,BLT\HY7XSZ:683<([S-XF<W$Q<$]SRD*-&UG07TY-[M
M=0MA:8WA^3T%YF>*W&WN+P,PO[.7A]#4X'B^.7$237Q<D-^H67FE-=371?;
MR!3=5/4(UUB,-L9Z7M;^/V0N2[&>6P=VQ$[L2*W,3O0 32XM-5)MKH)Z1R;
MBV8HU(A125+C*^%)?*JG^G_95YXTW&\5AS53^@1TC?\ X+TG_7.5_P#]]K(
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M>HDXO(>BL>D@K5'2[8=M9.8<6-.CC%EL(;<U2T2-(M I49"N@J3S\]C;:(@
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M3L:;NIB7-^['&#$72#'?K>/+DJ"+=F9,B-:J8'2IMYD>UVRU'A^4(3=C&O\
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M55%>$\<<\E51.*VZVK;JDZ)(J&A]GSB0D)":" H2$!J!<I^JB<<+RJICOJI
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M*<U^8Y)=:DNBXZ7>7*F@_6G)(XGT\[?K@LPXYCM1B5'5XU01!@4E)"C5M5
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..$T1-$31$T1-$31%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>fhtx-20211231_g21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g21.jpg
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M 0 "$0,1 #\ ZE^=\#\KPX . #@ X . #@ X . #@ X . #@ X . #@ X .
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MP < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P <
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M&!P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P
M< ' !P < ' #_1\]F?T ^B)1?N*+^SYQAX[XNZQ57M;G>/T8Z-, =4:'V%ON
M#V9_0#Z(E%^XHO[/CQWQ=UBJO:W.\.C3 '5&A]A;[@]F?T ^B)1?N*+^SX\=
M\7=8JKVMSO#HTP!U1H?86^X/9G] /HB47[BB_L^/'?%W6*J]K<[PZ-, =4:'
MV%ON#V9_0#Z(E%^XHO[/CQWQ=UBJO:W.\.C3 '5&A]A;[@]F?T ^B)1?N*+^
MSX\=\7=8JKVMSO#HTP!U1H?86^X/9G] /HB47[BB_L^/'?%W6*J]K<[PZ-,
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M\.C3 '5&A]A;[@]F?T ^B)1?N*+^SX\=\7=8JKVMSO#HTP!U1H?86^X/9G]
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MSX\=\7=8JKVMSO#HTP!U1H?86^X/9G] /HB47[BB_L^/'?%W6*J]K<[PZ-,
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M\.C3 '5&A]A;[@]F?T ^B)1?N*+^SX\=\7=8JKVMSO#HTP!U1H?86^X/9G]
M/HB47[BB_L^/'?%W6*J]K<[PZ-, =4:'V%ON#V9_0#Z(E%^XHO[/CQWQ=UBJ
MO:W.\.C3 '5&A]A;[AO)S%AG < ' !P < ' !P < ' !P < ' !P < ' !P
M< ' !P < ' !P < ' !P < ' !P < ' #\[;Z:8QG?;77&=M=<9VVQKC.VV?
M%KKC.<X\>VV<XQKC'Y<YSXL8\? #]< ' !P < ' !P < ' !P < ' !P < '
M !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P
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M.PXX74:M<36HB  )6HNP^Z]65R[>I'<]?ZR+AFT"ZGB[@F,W*"K'N:)&V4K
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M.Y^^T=LG)%(< ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P
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M>9:(9SOMYQRJNLH BMY3WGO/_CR"YN!(< ' !P < ' !P < ' !P < ' !P
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M\T'RX?JO_K7\I'5'P9_UV_VW_/AZ,K8_G"DO_$,_^F,N:#'5 KO@ X . #@
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M$LTH<)Y*57-*T$X24:6BLE),U(;61D9+;0LE(*[.6HO0X . #@ X . #@ X
M. #@ X . #@!T*?A%G^XC#O^9. ?]A6KS;/(U^E<K_!)?[Y3QH?X1'Z"P_\
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MQQM2758\)UH(FNO#F]-)0B@20E;=+6O=@RNY!2J,'P<!(W!@SZ031P%:6K*
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M(MFEF=\K9%MONL>?ERRS&OE66AW]HX=#J[>";DLF2UZSKZ7V ,E-)63.M+H
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MHDEE1#+P,49' I%NHGLFX9% AP:--A"K)9N1#F1S J-=-7[-LX2"!]8A#XM
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MM(_LRR\A^YEZ?U!?"'VB>=--3NU1U<O(_)D&"=KNY>YA1R0A*%Z:2K:AZPT
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M1\2B<?!MBNC+LTZD/9*U*LED[ZO>9EI5\B];1K<,XE+-Z6MD(,-UPX"M7:
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M^D;,<" X ="GX19_N(P[_F3@'_85J\VSR-?I7*_P27^^4\:'^$1^@L/_ #)
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M?[B,._YDX!_V%:O-L\C7Z5RO\$E_OE/&A_A$?H+#_P R0/W"JCQ%<Z?'$X<
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M < ' !P < ' !P < ' !P Z=97W4LGKY-^T.+)E$.D8]1]VMD%(#I&U>Q-!
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MG=$'OZ:43 (K$Q>!T.SB/$I)O%'<L/OCM436:)6K% !"X(O+)!"JX/A&0F0
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MBEJKNOJDGA=31--1;&FN%5$TL[[))[J8QY>VB>RJNR>FV<ZZ94WSKC&=]O&
M%44E]-DEDDUD]LZYV35TU4TVSIMC?7.VF^,ZYSKOKC?7.<?DVQC;'BSC&> '
MXRU;9RKMENAG9?.<K[913SE;.4M4,Y5SG7QJ9RAKJCGR_'XTM=4__P!,8Q@
MTHK9==[WW[-MGBRKMM%:#ZU,XNW<J;KH1MI)S=QNY*U )*[;IAVTA=1R/.3B
M [5ND6< @RS_ %<*"V.R 3N+SG]A=Y_6-WN! < ' !P < ' !P < ' !P <
M' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P
M < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < '
$ #__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>fhtx-20211231_g22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g22.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1NH4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &XR^<%(X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%>9U<         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             !5    :\
M 0                         !              &O   !5
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !5     !29VAT
M;&]N9P   :\    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M    5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   50     4F=H=&QO;F<   &O     W5R
M;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53
M;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /
M15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N
M9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO
M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M2W9?F[*\C+NN]:SU?T7V>XRGZWNQK*W7U,O^W$LNAA_4X):STO3+&_I-K/\
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MKLRZA6XLL<]NT/8_[0SU*:_3KK:_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! ?_  !$( 5H!M@,!$0 "$0$#$0'_Q  >  $  @(" P$
M            !P@&"0$% @0* __$ &(0   & @( ! ,#! H+"0L- 0$" P0%
M!@ '"!$2$R$Q"11!%2)1%F%QD1<C,CA3=X&AT? 8)"4U4E:3E;&VTR8G*#,T
M0F*2M0H9-T1&55=GEL'A*38Y0T5'5'-U@H>EIO'_Q  = 0$!  (# 0$!
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M9O+W?!?4^F[,AZ]>OF, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , >GI_-_\ # & /0?P'^? Z'YK+)MTE5UC@FB@F=550W[DB:9!.<YOP I
M$1_,& 1IJ?=&K=YUY_:]2W6&O5>B[!,560E81555JUL, Y%G,12IE4D3 Z8.
M0%%<H%$H'#[IC!ZXE/)R.JCDS\MP[MU3Q_IYK_N2[PNOJ:25BX4]@GE546 2
MLV[(QBF0G126/Y[UVHF@B'@Z$Y@[$ ]<2N(,=W?QNTWR/2UJ7;U1:6Y/4VS*
MON&@?,JK)!![ IZQW-=L"'DF+XUV"JACID4[(;O[Q1],C4^LN?7@QT?!VUUO
MQ1.H  >@!UZ '\@>@90<X P!@# & /\ 3]/S8 P!@# 'OW^K & , 8 P!@#
M(INN\-3ZZNVO=<W:\PE<N^UW<BPUW6Y%95.1M;N)0*YD4(LA$CD4.T0.514%
M%$^BF#KO)*F)O^_T$Q^S?P/UU5NG5F[XB8GM476&O$1 6*5J<R_A5554(^QP
MC@S65B7 JI)&*Z9."&26*!1*!B_=,8/7*/"/6?CF2C@# & , 8 P!@# & ,
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M%5C?=*(@4 [RY*/5^>9=9S=EY*$6<P!@# & , 8 P!@# & , 8 P!@# & ,
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M5"AT4Q0.0ANA#H!+V'J 9+RL[2WPAS\U&2T\#YQI&<S/+E/FYL7YRE& , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MYY<CSP48 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M<%\:"R2Q!'H#I*%4*(] /H8HB'L(#[^V!GYWOZ\C]<%& , 8 P!@# & , 8
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M"'N(94H2\IXPEZ\3*A?C?"%;+6U^KRF9Z0X+V5XAUOL,P^@?D-;N@^@"6 D
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M]E/Q'T]O=N'??UZ'\V1U):STN.].;BVB>:=N7PG)Z *S9!'TKTY[B =Q+X
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M0#H?"(CUWT/YP]?K]?7KV'Z==,_#W/3U]1FW'.(6:<RDGF\X\;PE'!C=B B
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MV\025<0;(@(_NW8E* ^,>]1MM3P=X[KQ4I6-5M&QU<$L3">-354_[V"J*?\
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M>3]?3XH-3F6VX9_O1^,G\0VJ/]2(7(IB]GK>?70%E<H& , 8 P!@# & , 8
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MY@X=-N5%/[WN\^FGW_M/W_?N^-LI;[FU;RVW&4V;6)M&(^<6:X3X'8./^3.
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MGSOS*LOWUGB[?I:(@V%92+I'(8*, 8 P!@# & , 8 P!@# & , 8 P!@# &
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MD A#!X@ !Z'+#B=/W^C)WUP?.V76Y^:B]/0!67/'1Y5)%,J3AX6'(+ETD("
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M6O7\T&[P1Y/3PGW&=<,_WH_&3^(;5'^I$+D5EKXYE+*Y0, 8 P!@# & , 8
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MU_[$0N 65P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , KWNQ9-I;=!/%"]@GM,S7Q=]>'Y^HV-N'8^W1
ME!3#H?<>LU.\I6T;IJ4Q3M[54<*MEVBF,]6T>@=B\.K&W1V^P:6IJ[*TXL.+
M^PWQNW$<:RDF^G4L)_[LVQY^<#[>_7Y_P_7@% $:M$0OQ#C3<>P%L]LNDW+B
M6=^)3RWKEI*((I& #&$@&32\0"!  ._4P"/6=26S8>'VR^\48?=KQ]T5+%K4
MOONG&I5.<I0I3B/F>^8F]=LVS_!Y6P8^/[79]V=N<'#V7"BE/ P\;9,3$K7X
M4JFJJX:=4YV<&P#.VG@9P(] (_@ C@%=.-12*5G8$B40,:2W3M=4QP#T.5K;
MG\>B(#]0\IH4 '\.N\U.YVW@;2WF]X[P\J=IQ**<M.[33'!9GH?VD-K>>X,!
MIK[MV+[)X</1XFZ,#:*O_%C.=)EI7+&9MCSP8 P!@# *8?$3#O@YRE#OK_>6
MO7K^B#=#AC(SKAG^]'XR?Q#:I_U)A<BF%.>H+*Y0, 8 P!@# & , 8 P!@#
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M[YJ)C)]?&TN?V-B'#,!#B/QE ?<-#ZI#_P#Q,+_4<BR71&197*!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MA*#68NL.C-FC5=@S"(L<(C,UY6*!R@V3=-%8<Z2O@:%-\F0 17(B<O@"^,]
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MJ-C6QW6E<:,L=FT/.Q@# & >)B%.4Q3E Q3 (&*8/$40$.A 0'L.A#T'T]<
MKY7N)O&FI24Q+UG1VLX&3L"JB\V]BZC#LEY5=5]]I*+/E$&I#.53O_[;,=43
M&,O^V"(F]<!6Y]2O/.75VNJ%PQYESE*I-:J\O<]27F2M,C!P[&.=SS\L$]Z=
M2:[9%,[I;LYC"=43")S&./WC"(QY.\<^'/UX$:LU.D2W\62#Q[J(W[@5I2E
M]^SAM7&/7T"#_P KY@&@R>NXIH#@4!.F"OE"KXQ)XR>/KP^(H#V&-=*Q<.NB
M85=%5,Q,*I1,<IX^*S.'O'9/O^P[7L??]E]ZV?&P/:=WO]QXM#H[W=FGO=V9
MA-3EWD:D@^ U(@!>^1"(^$ #O\A.O8 ]0ZL/H/IWWZ]=_FSKE/9U4JFG[U79
M)?DHO&OY<_$\,?V)8S<_XP8,N9_X.Q(NY;C[Y?E=<=87 _ ;DA*8O]D,EZ]C
MW^0A1'OH0[[&Q?G['T'L?P^E?9Z4U][KEJ'^"F(\%-LE?))NYA_D2VE76_\
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MU#KNNSK QBG,REH>J13"0:F.01*8R#I!5(3%$0$2B(>F"DZ8 P!@# & , 8
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M0@6B]W&53=NY2Y13QTG$/)!60,@^AV[)9,J2J*I#QJZ:\9;]RR+Q]UOC?X&
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MUWKV1T_LBWTZ1J+^>WILZ_54@1E;=PK"5KL%4K17&*4%*%=1C<S9Y%M6J2(
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# A<.?CQ& , 8 P!@#
2& , 8 P!@# & , 8 P!@'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>fhtx-20211231_g23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g23.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2,D4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (PB^B6@X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%?)1\         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@              U    ED
M 0                         !              )9    U
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    U     !29VAT
M;&]N9P   ED    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M C_P        .$))3001       ! 0 X0DE-!!0       0    #.$))300,
M     !C6     0   *     X   !X   :0   !BZ !@  ?_8_^(,6$E#0U]0
M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(               $  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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MWD8B1F=&JT;P1S5'>T? 2 5(2TB12-=)'4EC2:E)\$HW2@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
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M(+=?]$?R'IP$Z-R2,;$WU? /<D@YKI]1Y'MCMP0$MZ/A)XNYOD^=$G^B1Y$
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M_B?TX01GY@'</>>8%%QQ_5^%@;S8L6%Z#R^S&S2YK:BI_P"$?I']?_5:UEO
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M% ]BDB@;@X."/3/;A_IGU/\ EX'_ /=A3]=X'_S-_);.M-U;5S)Z7!25_-O
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M4BYN1WFDW((!QCQC?&XP?0_X8/G@L0\^S/P!!&C:;GKW.<8_P!]._;T/!,J
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M6IV_[3;;BS:A\T4R')6:OTQY54#+JH##Q2[(#:D)2'0E"BSY#DS&Y?VIPJ>
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M]R-AT^A'!%M:FDN12A?2DJ03D]>%=]TG)S^G\>'?+NB9]]_:J;>5 7\]XA_
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M8 O35Z@5H4I[X&VY.<^<9/V'^X^."GJ&:F=&OW$NE';.2 ,9]\8W'G!P?O\
MEC@F5[:<#H^SYBJ;'/YD9WSX!WQ]@/\ )*Y7IT=Z/&MZL4$8S@=CX[[X((SV
M)[''WQP2.<MP8Q0-40(NJN^-^X.^/((P<?X=N"D#61%8O(CC6X9(-R2-@3W.
M<GUP/0_Y] 0Y%GOZ;QR.1J5)P,@;$9[>.Y!\#8[>^?S*M-9!-[V(S+B>%*A
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M!,L^AL=0D-1T43\1\MM*0IMD/J<2HDA:0E)!)5D#?/#IO]BHOIC^&+KOK;S
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M$?*:N=0*@\>CU*/<'<8./ & 1_(;[Y.,X[\%/2E:UJ2[.Y,@ ATI&Y(&Y/\
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M4F#$BMM1NII">L]#3:.M24_+Z<I)( QG'$) =[7W2;-J^7SZKKCRBE1TI'S
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M%B*F*W< .]#[RA..H^N/'8> 02.X]O?[$RT$?+B*F,V:M53[@]\CT]1C^/\
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MJ5A.D%MH"2 5=$+\L$01G;'GU&V.!:S\2_L%9D<B^(": CS/-,Q$2MH8YB:
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M,O$&=C_EH;YV"#8^?"O^43[[9P/?&3Z^A#]LA&3U@/Q$.R.K!^D9'I]6?XC
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M+;?=A4P.%QL?.2A'6LA>4C*%$?2, $*& C<@Y'!%T#I-/<A6<U3PM#3B:?\
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M%'Z7W[S1Q;$6&MG H!:+!WK!61P<D X/C;&01YP-CY&?R X+&_J[6B9MRJR
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M0K_H]OU>HU"4IUXITW8NJ;9D&ELI4C\- D4ZIOLX)#A4>E%:K:N16!H:6?\
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MIV>8USR[;5;%[2[6I]R29\)B+)?DLPZ/6ZM\Q!8F1W"E*@HEP-I2I0<"./\
MQ)_PU^*_\.>)^5XN$X2?#&-\.'!BP.\X3XGF\7PP8);S^8LQPX87/!Y2';KA
M!<@AVPN:1((I5.AS':YT[E[TQEZG5.DL5>.S<]BVHW#D7+"LZGHE7M=M&M"E
MR)U<J;:Z- BTR9653YLB9)C--,1U-EY+SC0'POP_QC]0#A\;%Y,0)Q']HQ,)
MAL(8.S7(+.[+L!^Z@8YARPM.[02ST%F:IO/1IC#J5'H^J-2T_P!.W*]IS<FI
M]'K/];%CW)9M9I5HW+1Z+)I]&N5:H4*J5IX5963%=<;4(:U,K5\UE2/4+@L*
MR*Z!A&6AFD+@00Q#F)!&_$0;!]#+Z+IU\0)J_:'!OIC1&ZZ-HS_2[1RRZOJ'
M_2JT92J#6M7K,TRO"W'YEJ!A#R[6IZ]4K9MMZM0''9(>8-04RB"E<E!\A<U-
MN&GK0+3'I;,;N/NSE.YJISAV1I5K/:NATVE1ZO=-S0[8K-4CKO"U:*NDT?4"
M\Y]CTIZ/2JY6($J[7W:O1JI-:CPF&'C1HHI[215ID:"^.NG?=-$&E)]2_P!D
MU4+XA=!GN6S0X>E=U-7+J;&T^KFC=#J%Q6G3*=>%F:@1-2JC0KAJM8=EHB69
M%BPM+[E==BRE/U)Y:+?CQVG:C.GQ8L<5L,]*]7J.:-\5/S76IS"EK86M]%U/
MT-HFN%C4BN7!3;CLM=WTBV:>JGJN"<44PU$T-DORF*,*PN<$TU#K\IJ(5KZB
M\&@7$UHX32KF.0>ZSI-6?02YAJFK W>J8:!SJ6RG1#576>LVE-I:-'ZS-MVX
M:&S<%%JT6=<::A2J5"AT:\HL]5+=B.U.M4^FR?FM!F)/DNQG>@0I :CG["/@
M=C):8">QQK-\^)=P[,YK=/JOHI2M;KWD4FS+:JDV/3&44VY&M2DFJRYBX#%,
MCN6;&J*:A4S+:<85 @MR)+"D.?-;0A"E [Z"V?&!/9TA! @E[3?B\;G:3/E@
M<\_*U4J6NK0=48TJ(ER RPVW0+Q_'U!=1$_\.:-1S;XJU<;2JEU%N8[1H4]J
MFNP93-07%=9<0*=QJ9YEPIY1EBYX>5::?9:?4.?G0^)?ED6\U4#*LZ^K;57J
M?J6F:6+?9=6TS(@454&2VU5EU&I,R&%0XC<$O22\AMII;F4B+3/=JO-(H^G6
M.+WVKS,Z*7I?1TVMB^HE4O7\/4)35%12+CCHE,TA+*JJ:=5)=)CT:IJIOSVF
MYS5/J,IR,ZHLO(2\A:$E@^=RU)IV[^EDR',%SE4;0.]:?8IL=VOUZK&S&81D
M71;]HV\IZ]KG5;<0SJG6&%JA"-(S)?D/)2VN/Y2H9XI+0SY3+5JYPTT9UH F
M9!EPS!SP!XN^MT[6@^O](UNL*X;U9I+MK*M>X:_:U<I_[<HUTP6*C;28[]2E
M4NX;?E3J76H*&I*5(FP'WFBDJ;5\M]MYAE7OGD."A@B1 8Y@0U7:6G5VAU'N
MM<]1M^B-:A5+12[W-)J]6Z[0+$OQFX:%+?KTZD/U&"PY,MAEUR90HMQU*!)@
MV]*>0^74!F3468B',"+5:5&;[.UX=BO32OB :>UJ[KELNE6C=$R53*QI31+;
MJZ95)3$O:=J3.MJG*51T=;2VVK0DW?0'J^[);C1UIJ0,92D1IIC.^V_E1GJ'
M<UR:E2>#!M&*Z&) "0!@ ;8 Z0,;82!V'H,G';/!3!0[GV57!;1P1'!$<$1P
M1'!$<$1P1'!$<$1P1>=XA(.  HD*!7DI44@D X)*>V,D)'H3P63=@[UH6::.
M*Y4OOP/IWQ">9>Z^9SF6TM@U&P*3:6B-Y7/2*+;CO+!K;=RKGI%MV8W<2OVG
MKQ3[\9TNMFHS9#JX[4&3;C3ZPA"5E*BIQ4<N:0&KZQ=\S#0K#.U6/.[4&9;=
M,=5?C4:L5G1.DWE8ED4V#>D/E0N36&Z3J/I7J/:%JR-2*-=]JV]33;2YE?H@
MO.SYL*J5!4]=#K<]*93#!2ZPR\RT+\'>:<I:)/)&'.-V?.KRZG3I9SZ75I1J
M]J]HOSV7YH7;+MBZ<Z6ZJ6UJO:3%8L2TJW0=1)]P6_$M.JT:[JQ7YD2Z&*[1
MPIA4*X*BQ/CO_BF2T'@Q%=N;:]_"$7'2^F1?6CN^<)J?\:/5>HP.8&]F[:TW
MC6]1(.J$'0:SZU96I-*JE?N/3W5>U])8M87?2JI_1&\;=ES;H3<5X4FG,6I7
M8%&DTN/;M9JDLUM-&<7^UN#<^2,_5C$/[G;[X#57XO7-?I';%\IN&S]'HD[0
M6M\P=+U,U$B6#J3*L'5BJZ*R],ZE0; L&ETR[)ZM.KOOJR+]E5*-5[GN6X*+
M2'K-K;2Y<AJ('%)MO0'@7$C,.$;>8J=^&_!?0;4+KN6Y=&7KTTY8MVFWQ=&F
M4BZ+-@WE,?@4"'6ZK;1J=,9N6HT^,Y4&J)2:K*9767H+,>41A/S8CCOS57NM
M6^QZ*7'&S,X<GH=9JH2\G_-EK;JEIAS2R=8:#9CVKG+CJ1>MEL4JR;=O.REW
MBU;>GMO7E3I;=@7G+K%XTN'<52GU")05F9\VZJ3!C7 S$I#55$*.>)F#6PZ4
M#L9H(NC%\A4S=W;-N0KFRT3D4YY-6-8]/-<ZOS/0J):6JVB]K6]J!>&BM'T?
MN;3.\[%MVX;(5?$!FIF\=0;WI%T3JK$8GP8=2@2:/&+\8HE1H+ZPUP#N;,(J
M^NW![O#L+-9B9RWRMSS,'4+:^-)IC6I=!;J'+1S)6O1:XK12>[<]9BZ5OT*W
M;8Y@)'[.TLN2MM4K4^35X[-=JS+](=H,.F/W!3),=V56Z7!B*$E<>^=7KU%?
M15LK6.A@P>+4H(64K7Q;+7NJBW'&TNTCU-H]>KM KK^AM_WY3K4<T_U$F1M3
M:#I!%J<>D434"5=D*$W=URPYB8%P4:D5#]E1)KKD9EHI4L2VTZMOW[(TOSD^
MCLU83:<O?QDK;KUO:_0-7+3JE0O?ENK5UL:CITJHT%NAP8*=0I-B:;VM3(ET
MWA"JM1O2[I"(Z_GPH\NA06G<S:A#=24 ^S5>.VZ;V$/GS9GZ. 8A=$N5#F_H
MO-*YJ=2XVFFI&E=RZ.W-3;4O2V-1E6FNH0ZO5:'"K3*8+UH7-=,&6PS&FM'Y
MLB9]2B3]"LMBO-A%HS]=(L E ?>;QR.?/+F/S??$\U[T:URO?26T%Z56W0:+
MK?IYIK!O*X-,=2=3ZU3J/<]@.W74ITBS-/KDI-;K=2<J"$,18]-1&?8A*4M:
M)(25<1S9AS/J9&AYHV9<SI6\7:'4\.4_F;U:U*Y/;FY@];[#C6[=%K,ZD3&*
M?1J'<]CQ[QMJR_QC])N6G6Q=4%R\;4C70Q%_$BE5B349<4Y+CRD*&213;2_<
M; U4!8OQ N=B!8^@NL-55RW7-:7-I^WZ?IQI[:MN74U?6E-;>H5=K]B5"Z*L
MQ>U;AWS3YB*$J)7F8](M=27G08<ESH=#*VNC='A7O=1R9^.EK744UBJ4+3C3
M]RV[DTZMFUM,IOX.M/R*CS8)%-%\634&(E094F@TY<MWY5/ EU5E;#B)$Y[I
M'3.];_'%1I?YUBN?#2C?41;9JYH5)_;_ ."_;HIE.%933T+1#35?P$8U%,=+
MKS[OR!,+Y8^:L.A@M)6"H%:Z@9HIN_JLWP51P1'!$<$36:NJO%G3ZZ)5BUVW
MK9KT2!*F&N75;]7N:CPXD-OY\UU^AT"L6_6*DLTYJ0U%9IE9@3!-7'<9<<6C
MY#UJ-J;2_&?718$-F27LY>'J,W >26#B.2/P^V;S;URI=>U4I=:=?OG2>N7!
MHU=UX_TKN&K5ZT45BW%W"Y0JW<?,3K2;;B5 SK?JLFW7J);$AMA<2,VM;D*H
MQ8\ 8QD\'0BS4%MG%'N*<)K1FULP(SN,\V7;W&3V]]P2?7<]@-AL/MZ\%RIP
M%HRYE_0$. JCC<X!^P!.?\]^"@W9(-R"1@G/;.<>_O[[?X<%H!R!SHSS1P;<
MVR (Y]<VO_Z2_P /_(/_ ,,6H?8D?][]>/&/\[[=RV8!:SGEB-JF;F!Q*Z!X
M.!VW[#!W]?M[=.,^/'!8O2FK&EKL-79I:4=)VSC??/\ @21N3Z;X\C@IP=JU
M,#8VM0:I1V.,#.=CXQXQV_/]1P6FD#(ABT2TO!+G[%)L0,;G&/M]R<X'V'C8
MCMP4^:1=B(9K!ZB:)1VQVVQG&0?8#L<^O<^F_!3J:N+.UZZ'(WE+C<8R#VW&
MQQ]O7^&.PVX)::>A/V%$N-M\C8YR<X[;]\>3Z'T'!1 \9&Y[[[[>=O'\-_?@
MB3MO@8'G;?M@C&<8WV'?P,G )5>&H35Q(4^1%CJG3(L22]'IS;K;#TZ0PRMU
MJ(TY(4VRVJ0M*&DONJ2PV5];CB6T*(-WT6@""'B?N^POZJ%UL\W:;NMYY^A:
M8W0W>TNYKGT^LZSY]7MR1-N&Z+-N&HVI=\^HOT"IU9J@6O:]5H[/[;K=73$6
MTB:U&IC4ZH2H<60<%\^X:&AS2U!*Z&!.4F;F6+$FC9YEV*>72S2.1;$V;>E\
M28]TZI7"W';K]RM-*C4ZCP8BG7J=:]D05.NKM^TZ0F0['9@(4Y*J+SDF?6)<
MZ=(DRY*W\O\ 'NH<59#$%NHB_L9(+"7\]/<>OGOXV]<X[_;@N2IW&=P0,Y!.
M<#SON=O<?[>"M6C1^X-Q6UFFV7F\I3G<X( !R0>V, ['S@@_QXP?$P#$,!Q-
MB- QGHW5:\F+*NOK/&\BBJ+B H@J(/TYP"K?&P[$^=\C[XXN+'AP,<19R ()
MDP* IY,1!80"<AO#Z62A7?ZO/YD>-L'\\8]^-*6H([D@BMG=S3)!W!.03W !
M]/."=C_+?SP2.&?W .K&7(!H&'BPE>75#=().^RB=@, ;$@>GY9XY8_#PD^<
MUPR\VXMM"ZTCD,@.^Y4%N<3D1TGYS+<H=MWO,N.UC0Z\*\W5;)?A4JISI:HS
MT9$>J2U0)+BXI8?601TXP.I0(./T'X#_ ,8?BWX!XOB8_H<'G_,\,>%Y?%Q8
M,>##A!!;#A\7#BPX7()<87.<E=/[6-*@@@$6DL7BTD0,@LUR@\E>F7)S84NQ
M;&>KMQHDW)4KG-<N]R%*K[4F4U'C+:BRV(2'?EI1&: )R5I(*3Q/QW_BG\5_
M'OJ!X_UV#R-X7Y>+#AQ^'AP8P,\'AX1@+6_:X>286 6PD"CDEP'@M4!S2CI[
M=6M+K?UDMB#:%QF8BD0[QT^NZ4&D1RW/E6/=]$O2#39B9C#S$FESY-#1'K#+
M\;YBFG3]"%*21\'P?#\,$XQ6<\I%1+M%YHTL/B8,)/FQ,)!8$RSC*0X)D !W
M(("UZL\O&GU7U!3J*[ @-OHTWKFFL:FL4NEII$*D7!6(E4D52*E<%]0GN/1H
MY+L>5&:4D*4M.ZNGIMQW[?UBBSYMJT>T"S@DN,A+/!49+!^'E;%DTJ%9;>K]
M]UG21JO:77C5M*9$"RV:)7;ETFLVR;-MZ54*U&MU5T*I$Q&FEK2A3/VL(A=I
MSJ4'K<2  +L8H_\ #ZC7.BI(M+NVK6^[-T6VW1R#Z*5&XVIUIQ?ZM*#4F=/X
MUYV19=,I$2AWG&T^U%?U%LZ.XY^!DU"DM1[B7)=DN4E4-MR!*D!:^F/*4V(#
MW ZY3(WW;= 2SLY]8L]CKQD,M<_T>MF*MV;0I-\W%5!&I-AV-9SUPT*S:_&M
MC373BIWS4+4LM=%JM!E4BOLLOWM5%2)]<9>J#\*';\18;53UHFUC_$T]M:*/
M26I9JOG2A=_5/]IIH$_IGIG6-%K<O.X:+85.MJAVEINNBF/3[KLBD4ZVJ93I
MDN'7T1PY,JDJLPYU8#[L1+#0G-14J*DK;"Q%HG)P8YFHD,2$JQ9ZQL:C(Q(B
MK$PM'MKE/-N4:_*?&UCO1-=U)KB+DNZYH=*LRD5"5<-+CV[3;;J46)3;:ATJ
M [38EN,1Y,<4QS]O"74'J^[4Y+B90,:EP.[1%)HGFL&)L)&XD?&PJLQ1N56V
M*59<>U:K=5R5V4G5AK66MW)+9I4>56KM%3F3)+3T.G4Z)28M.=?G.H,6##C)
M;2REP]*<N*A#WAP>KTU9 6LT4F&<FK!I#-Z!1LU0Y#)T*A:?UG0BO2&=1-.F
M*31+:J-?N.)0H,.A1*A==8=J,=Z+:%V4Q-4=D71(1);F6[)@.,)1^',13:5R
M7WVTU[HK+Z-Q!UG+NCTV3\-6T'=-M/:'J9==:N*^+.4_73=U/?C%R'>"FH3%
M-J=&E*I].94W;;L)ERENKA1Q)"I*I#3C;_X9L@-(8,=@W3KZKQ:?<GFO]H:S
M.7'&U)I]+LFU!=3EF-_CV+LGOS[TDTYVK3)M$GV?313C-BPY1FKGUFON)E26
MTT];#2$E)5^^^/(J46K'*)I]K9J/0=1+UESY4RAO68M='=CT>32JFW8]QJN6
M$BJ1Y%-"^B5*7^%?#>06LH 3@9=]]\E'J^9O,;7T$\4\].L=5&J\*'0Y5+HV
MGC5M3J9(L*#1X,6*]4Y<MH-5F-+BQHSD9MN%\R-(28YCO?,05*VR;M>._;FH
M6(I0W>V9;67!%=U$-WD2AN7=9LA[7#4*=I=8MP5VN4#1FH_T?G6;'>KTB347
MFY#JJ<)\MN!+F2*A11(<6FGI==::44%/$[[[Y(^0!?(A[^TU:LT?9=.N0S2?
M3>?H+4:;4[EER]!)E]RJ/^(EA2:\Y?#:E,)N%L-@RX]N)C4A%N)6!^$=H--^
M7TJ9.+R@OO3[<'0/+@S$/#.;A[USAKJ>J>KI'5WV![;D  G8 ;G)[#V &!Q$
MP_W?_4?95<%I'!$<$1P1'!$<$1P14*<0DI"E!)42$A1P5$=PG.,GT SGQG@E
M$O6/&3[A*B/U QP1 6DG )!]""G/VZ@,_EG@B0.()"0<DY[ D;#.Y P/;)&>
MPR>"*TX224A*E *1U )."G?JQL!VQV._!8(#OS'EK4%Q7^[EFH_6]RU:5VK&
MUABT*W7HC6NU>J%R:CAZ=,F"K5BI4M%&E2V(\M;S$ .0&FF@B 8@24?,"?F$
MDF$YF:5>9-;FRKFP8#,'T IQ$UHF9N;X>/+%>6GMNZ7UVR*LNSK6TGK&BE @
M1KJNF%,IMA5NH4JJ5"GLU6'66IZ)"I=&@+9DA]:XZV5AO^S4D 0^?""A-"+\
MVB<Z:7&4[?HAR6:": ,7._95ES:Q7+U50Q=5R:D7#7]3;IK$2W(ZXU"I\JOW
MK4:M4%4^C1I$EJFT],A,2.\M*TMA("P86+[AC4PHY,M%F=WSLXTS36O?#*Y1
MWJOJA55:8.N#5:BWY1:S1'[HN>1:=N#4BHTFIWS6+#M@5)BB637[PJM!H]:K
ME5MBGTFJOU6 W*;JC#Z%.R08::6&P]Z\@J[T>.4,7@"2\6.RPU1^%IRFU:S;
M9L2=9UWOT*A5JZ;@JBEZB7O^TM0EWS-@S;TI>JTYVO2)6H<*Y5TZELUF#<DF
M?"J<2$Y >^3"=<;D(O.7I.C.J232NL,[L:=LT*;UYZ<V??\ I_<6EMVT"+-L
M>\;7E6A<=OY^1"G4>K4M=#ET=N1'CLR66EP$AEN8PJ+(C!B$8I97TI;M987@
M<^7MQ4!:'-@':[LT-:.55%[3GX?O+QIM19%%MZG7M.;KM6N&L7=5*WJ3?-P5
M:_#7[!7I>]3[TJU8KTZ?<%O0+.>53K>H-3ERJ51/P<*12(D-R,TELS:&_+31
MA.UD>EQ.4LS&6U(TG;8]&^1[0;0ZVM2K8M"@W'/;U8I#-N7O<5U7;7KONNM6
MQ$MM5ET6VG+AN&=.J:+>MRV@W!H5,;EB-2HZ4(A,MAM#:9'?>9/*IA5S>FDO
M6P?[Z46 1\/#E<13H].-A2E,LTC0RB#_ *HKD;=_!<N]6?KFF*5R8U1CK+=(
MJ,E]V<VA"&JYU%FL,S6%K04-3O90DO'$-;3/87,EH4,M$/@_4;3KF$3J[?&H
M<&[K0MJIW!4]/[!MJ@7/:4:COUN[XEXLF6'+WJ]%A-PJO"B37Z=:%"M6AU"2
MT9,VDOOK6I;=5X-XMKD8?AZI_M2?A>\OEQ6AJ!2K$M:F6?>%_4N]8<VZIR*M
M7H#TV_;I:O&LS:_0EU.&S7FX-PH=JM BK=BNT.HR%SJ-.IKR4%+/OEWS27:O
M"!$2_P Y0F]Y//AAU'EKK3%YW+K/<-X76]J54-1JPQ0W+HHUOUI;]KTJU(%%
MK;%R75>=;KT>'%IB9SDBLU^:XY-<4MI+"0A"2A=C6@EC5SD)V9N!4NJSR4:!
MW%JU_776+0FR;^5?M%U*_:R:S5&6E79;UNNVK2IK]+;?1!6B/175,*3]7S%%
M*U)*AU<$!B^1O/"O#D+.?0M&XU*O/5"ZI]<JMP0-3HEOP)-I5=Z3,MJWX-"I
M4JF.1J)2IKDZ'%;K")2EU8-,M"4M/4L*)R"LEZ4B+Z@T&DJ$MN_".Y1[0UEM
M'6VTK<O:@W78M3FU2U(2+_N6I6A0V:DX_P#M:BTFSZO4IE I5(JB)<EN13X%
M.82AAU:8LJ*3TEQ[[W1RP9M:A^=.]UO].^&?R?4*B6%0:=I%38U/TSUKK/,'
M9L-52JCS5,U/KI=54:W\UZ5(DNQGOG.*--6LPV5!*68W2@*+G]IO%-/Y@)NU
M-I';S4,P@KH,TI" 6PL$(/2D$@D)2D)PI04>H@I/4I1ZL_O;]RH:2[@N7VBO
M<;*[UIP5?5@=\I5G8D=L9[@^.V#V()("#([[])HJN"J0J .#GUV2H_R!X(D"
M@3@9SC.""#CMG<#OX]<'&<'!$Q7,-4:=3=++CGU'5(:/QXKL(*OIVG46MQZ8
MIZJ0F1$D4:OTVM4NJ,58K_8;L&137WGT5);,$L5!R))94<T%_NL0[UDZLS.P
ML?4SH>>W(!;C=%U.O*;"T,A1;88M5QBW^8V#;ERV# N"F,U-"H5HT+3B]YLR
MN6[3%P2FK51RAQJ3;\RI18AC4I*4M*:9QTS+\X*ID,*Y/:E/: ];KKNI]A/4
M%.I2I""ZI 4E2TM@=7S"D946P,[XQG8;[<%R:L.Q:K-)]6A^4A ?:ST]8'2D
MK4">D(;22E3BSMTIRE6ZCCZ5$$@'!5CEG5C ;-@U'.5(<&I+S2C@.?402!A0
M)3A)RD*&2 %I)QD G?M@%0""'##/4B*&<JML2N?W-H1_PE^0$?\ )UCU!ZL8
M..O3]SI_^UTD[;C&_%Z5])'>:T3#@OZR0W*U-&704D;#)\9!!/ZCU'G!SGOG
MB+#6(&>7(@, =0S9.DQDD'QXSW\X \)]O'KZ$)BAWM<%VO9S46S-A]\?N[G'
MI@G!3[^V_H>"L_< =0'!=R)J;B0C&,8V! R<[?<GWSMC&_IP4SS!.^=)I+O:
M'HEW'5@%6-LYW^WKMY([G?[%,J"'8TG>*3-HEE2>X!W 'G[9[;8/C!]LYX):
M,^3V.E*OI0I5>!G? (P#W\$$>O!!M\:;4SIDA2@D$G/T@J( )5@=M@"3GN4_
MO';8G@@VK'\2)&6JI4M/U#J1U ?N%8R5$;)/<@*/TXP203@'8<%H82^HUBI9
MY!UBC")B*/-U=K].T1U$L*V[AJ%$U.U0TXO*T-.YU%F(A5NW*S7*).I#M_R*
MJ<IH%NV&[485?JUQRE-Q:<U#0&7'9CT5EP_7*+%B5L8;N"P#/R(SN8-)B%QA
M_P#<^/)=?/*W:O,'7]1M<;3U;N*[M2JU;$.BVS6G+D3:L+3F]+QM.JUM<R?4
M952;?O>M-*K*)2FHZ)]&9A/R1)DJ:>3-0:UR/?=F$UB@<0:ANDSE+P5])X/;
M'H1D[^< D^^.VV<^W%7)O:^>ADUKZH!))/?<9]!W'TG/C^(X(>6]]Q9[6IJ3
M2K9*L9P 22<=\'OD#/@G<[?EP5%0XT'I\L8_<7>%X>E*UI60DH"0%$G*0<;
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MESYM*'1(KE!FRY;$]^W)JD]41],9;KB%#Y:% #CS_7_A^'Z;%C\OB8<>$ D
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M.* V[<4TRZG-*3):9C(K=5Y9X@"1>[N2]NR0ZM(MRAT1U:Z32*;2TRW$ORA
MA1(2I3J5J4R9I:82XX\RGY;BG2Z?F/Y6K*B5<#W[]:*EV/'[ _86Y[4,@$X^
MD!1SZ@ [8]#G.,>I'!<F<L*D@ :G.6'",P**S^(83TI4XD=8VSMU94,8.Q.Q
M]?(V/;CCC\?P<&,>'C\3#AQEB,)=R]+-8WU6CX>,21I+5O?/.M<TID,K1]+J
M,*& 0<X)R -MLG!^@GJSMVX[@&(.8^=NB@P$EZBI(EQ?([\;U:F\-1J=0IK=
M#HL>5=-X/( 9MRFK0'6 L!*'ZF^D*:ID<DI47)2VUE(*F4.*PD]?!\'%B\;#
MC\3S8/"IBQAB)DEKO($$&V8N/"0/V@D@T<LQXLU&,M65RJTAY6]0:!SA5F_K
MKO&ZI3$JOM7C^U85*J,93\Z0C\(JQ%5UUU0?M.F-(#Y;4T4R)#A4A#8)Q^V^
MK^O_  _'^%>3PCX6+Q#X9P'PL6)L6'",/]?D &$XBX(PO!DT7B.'ZC\S^D^4
M$2,.&1D<3DG5@!7==L1@[@;#N-OR.3@[><]_MQ^#7KY/FQ=\F#@&;4T*0E6.
MVQ!P!@9/^&?3SX[\%8>X+Y@L<SG>11I%SYE-'H40C"QOO@DY!\$XV&Y';;;U
M&3A8$X0^(4F_&.:VX)()@CAE7^<H:=9KU"H-QTR91[AIL"KTF='*)\*IM-RZ
M?-:Z2I;$J,ZTME+*0<A15N1@$G(/?P/J?J<!&+",6$X0 ,6$@8@3L7>QJ^0*
MS^F\/&YJ34&>A+'@U9(7HI5&I5#ID&DT2)$IM*I<>/&@P8#8BP8[4-*1$C1V
M$CY;,5MGI2KY.>L@)).".'C>-XN,G%B&+%BQ/4OB)Q'REZ$EQ0LPAF+K.'PA
MA9@,( ?1Q38 N^<,R\5?H%!N:"Q"N>E0:A3HU5HE4CMS@G\.BJT&JM56D2P7
M 6_F19L2#+9658^8T@)*EE*>//@>3B#$[6)R/V9F==/S,6$OA!?,:DAZ2&#Q
MLZL2+3M:;<#MT/T>F2;@_8$ZV5U4M)7)_8OXN++F4=PA:U?L]Z5%CEQ@!2NH
M)2M(*SG>HU'?H8]4<@-84S.+0!XTLV03.6[RH\NENW-3[QH.DEBP[FHW[.,*
MKPJ)%$EA-O4:/;=KI:"4!I9@6_3X4*-(Q^*:;AP5)>"$-+-(]O1SR1S(9JZP
M+M5C\-F-VNG1W2^]+LMF[[LLNVJU<UGNLFWZO*IK+]2I3S-1BU9;*Y"L-.&)
M5VZ?6Z>VXQE+C"I#*"703#7AGM\<)" 10M-<GR:(H /E:HGEEY?V:=<=$&EE
MFQ:3==8-:KT*-2XL>-4:K$GSI[<J864LM)<AU"KS6Z>XE!6PY5:H4#YE0DCB
MLS9>GI-8BEPCDO8S>2VX-7!)K*WJ@Z2V#0HUUTN#;4)FA7BS&IE5H:T_/H*J
M/3+=I=JLT6G4IT?A:?2U4NFM P8S08<>$A\]1=4M3,\*S]X<92A=A1ZD6+<M
M(/-@5K='T T8MNWY%LT6P+8C4:1$K<"92X]/:4Q)C7*TU3Z\R_UJ>6\S5&HB
M8TQ<SYX1$3\H8 Z1%7>9#$]'K9NCIR:A:=J52FTRDU&D4^5 HLVGSJ7%>;;?
MBPYM&;+%)F-H4D(2_": 4P$CZ$I*@ $A7%^W;9=PZF=J@:6V!R .=32.&KG*
M-I3JO:%.M9NEP[%<ISL9-/K%OTR@.RXT6&]5GA2(L6JP)=--.#M4FRXS9BD-
M//.*0VTKK49GS[]I]$>P+[\!7J;EW6;T\Y4M"]/;"H&FU.L&@U.AVW3Y]/87
M6:9"F2Y8JL9J+6I\A]##25/5IEE":@X $.!MF.T$M,H2*;4X/UH_7T4#F9$M
MI#R),4>Q9I=-=0^0K1NCZF7!J0Y)JLZ14XTBFP*,XBC4N#;L28]"D.(I\^DT
MV!671U0(L?\ XPJ,U264_+2Z@G/$('\]]8NM/FSNT<^$;J4=<TYT[K-=I]S7
M3:=O5"X:(NFN4ZMU&GQ'YD1=,E"?3%PYSJ4K"X<X?B(_4HJ1)[*).33I3O4\
M?9T<WXS03-!MUL5FC;5$EW7%O=05)K,*AR[>BOMON*A)IDR6U.EM+80[^%?>
M<D1FRB0X@J93UMMK5NGADW9^=E"(W%[!C\T<9.P3,JY6.7:3?J-4$:56>QJ-
M"E/3V[D8IK:*DT[,=Z:@E3@* IN=T]<U"FPTXE22^ESK)7#/?;(Y:),4MNY>
M=A<Q5.+0M']+:$Y93]!LVVJ<JPGZ^]9+U.I<2.N@R;I;FHN)^E&.VE$$5=F=
M43,7'Z4O_BW% #IQP[Z:=O5'-LYB\5):UV,<$[[9RA).,X&0DY .!D Y.1GL
M?3'!,-#J2=]1HJ^"TC@B."(X(C@B."(X(M7KE[V=;+K;%QW30*"\]GY+58JT
M&G..@=RTB6\TIP>Z 1XXZX?!\7$/-AP$@T(;Y7+%XWA82<.+& 14%W].JU\Z
MQ:3I*@K4BR$%"4*7UW-2$!*7 "A2E*EA(2<C))P#LK!XOZ?Q_P#T\7)3]1X,
M?\P32#\:=N$TFL\[0_6K3.]M+;EU5H,*W;YH\FA5=^WK[@T2N-P):0B1^SZE
M!J#,J,5MI^4M:$J7T.*P5=0XV/H_J<3-X'B%V8@1.M)W"?G>$6(QX9+T?, V
MRU9ZLRY'Z:?#1T(TQK,.5&YI:7=ULTO5.^]0J3;=]W'!N/\ !Q;FT\%C4BD)
MES:PXPF;1T],O]L+B.R)"6V6UH2I)7Q?T7U?_H>)RY_&Z?G^&?[P 6EQ]]-#
M/'J)RKP]+.7;0;3S1=S6>RKD=LBFS(0JRJ_2(JI+<JKU&K)2B,:BZ4-Q43Q$
M04K*5)8#@2@*Z$9_2?4B#X6-\B &J6K';R5#X_@T_,PB9.1$BVFQ K1Y!_US
M:3!.3J/90V6K N.E*_[&?J'TR3]>X(1^^K(Z4G/#])]0/_*Q=/E7\_P6_P#$
MP@0U1M9;]&J=/F169T26S)AR6$RF)+"OFM.QUH#B74+;"@I*D$*&-R#VSMQR
M.#&,1PG"1B!8@B_IQI>BV/$P$.,0(9X<QFFS>USTK8?7%<NQE,A#RHRFQ2ZZ
MM0D)6MLM8;I:LK*VW$@#/5T$HZAOQUP_2?48YP^$3QP^^)<SX^ %ABPD<7BN
M5%9&O>DJDE2;QB' )(_9U:"@$A"E*Z?V;U!"4K25*P4IR"H@!6.O^G?6_P#3
MX^>'_P!RS^I\-R/-ABS$FCZ:2U)R>HZ\Z3A1']+XQ V.*97#DYQE)%,Z5).Q
M2I)*5 A224D'A_IWUO\ T^/GA_\ <GZGPQ7'A!R;%V^XIP6,J.O&E80OY5UL
ME:F7'$*32*RX\ASKBQ$/1V54Y!?<2_-C;Y4@):<00#U$4?AOUL__  ^/GAK7
M_*X!XLGZCPB!^_"Y(<2+USR&88LN2KW*=9E-T4Y<[4MSF#H"-7M"-8+]UEFW
MS<>F=4N6@WW>>IM(O:C7]5;CM= BNR')-)N^LJILARJ)5&E18SA2ZTVW$2'X
M;]:?_P!OC&KX6M_NC?\ @Z_4>"_]8>C38G,=EI8NIG\E-.TRY3>673#E^D:H
M0[M=T\A5R$JX&K=K--:G_M:YZU<"2S3VJ<IN$U'15DQ6XZ%%#2&4MC&,<3_3
MOKO^GQ\\&;?Y=%C%]1X3EO$Y$@>DEWX=)6)UYTIZ<JNU@=U$FE5X)",G*^LT
MOI" <IZBKIZ@49Z@1P_TWZ[_ *?'G7!FW^2?J?#;^O#2_F)=_>O'*52K7S2<
M* %V1U9Z2"*=6L'J.$XS3/)('L3@[\<L7TGU& G#B\+$,09P3A<.Q%\B%K\_
MP3)Q828IT[,%KPLY;NK%A754OV10J^U.G_+<<+"(=3:^AH]+BOFR(++'TJR"
M/FYSV&W&3]/XV$$GPR *F/GNBH\?PR0,.('/23_.EZPMR:JV+:5013*]7&X,
MUQE,A#'X*IR5J96,AP*API".G'?*LIWZ@.+A^F\?$/-A\,D.0X.&HK>S>F85
M/C^$/_,PB'ESTY\5@4:^Z2+25?TQC)2DJZUFFULMM]!2"''?V9T-J^I.RU))
MSL#OQK]']33\G'TWS63]1X=L> \2)SVTJKJ=>=)U8*;PBK2<CK33:V4G'E*A
M3"E0]"DD$^>-X?H/K,0?#X&,BC_MMN5/U7A?YA^)'1N=LD?U\:4 D&[XVR2O
M)IE<2.D'<]2J8$D[]LY_4<7_ $[ZW_I\?/#_ .Y/U/A-_7A' Y=)]LBHH<RM
M,TCU\K6B-1.I-/H2M(=7+:U-=(MFJ5&3<$>B%Y#UOA;E.;<AA]#_ %)?0ITH
M6 HH2 3P_P!.^M_Z?'SPMK_=M97]1X(DXPY$LYRLT/66YKF-5_APZ:U^7J5&
MJ/,ZRBW)C6IDG1.F,Z>503K'J.I>I-)U0K3ER3I"%/W/%9N:DLPA&Q!5-I<Q
M^$ZM3"DGA_IOUO\ T^*+OAO_ /<ZH^H\%O\ Q!;?[=&V4\^2VQK4Y9W-?J_>
M6L%O7C<.ONI4'4BM.VQ8-7LFWZ--B691;273J/;[#$U,9CKH'XEU:7BJ1-F2
MGBVE)"E/]-^N_P"GQS2<&G^ZE9X60_4>$SCQ S&E:/<')F:[J>@UVTG1A/\
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MMNX-/'[YN;6BJ7<Q;-,I=9MBUTQ(5CP:#+J\V?5;B7$IK<=$JX:2V6%R67'
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M=L9QG /8>AX(QHUA5N6Q(AI#@O58RK5ZCT2!,J%7J<&EP8#1D29D^2W%BLM
M+45N/O*0V$ ))40H].-\$CB C$0 7)+ 7)V3REZ$4#@T@<8NVSL%&*3J+?\
MJR](I6B\!NAVO\]4:;JY<E.6B Z4%(<-F6_)2U*KKK ZNBI3DM04K4V0EYO)
M.B"#0CJUIZKHU'+VB./\9J[4>471&[+;J% U3LR!JDY75,5*XZIJ*E-R3ZS5
MDH;^:[(#RD-M0V2EU,>#"#-/CLKZ&V%J3U\1Z"YIF=.\TF37*@UKD3';I\K+
MLFU=-[:HEHV90J;:UKVXTF#1Z%3$&-!I5.6HK;APF4J^2S$2HE1:&0VD$=QO
M:VMZ2:WV;JLES#F\%G)@ 1:?FRW25,B0XLF5)D-18L9EUV1(?6&VH[+'7\Y]
MU:R EIKI45N'"0$YZL;\7#@Q>)BP^'@PG'CQD8<.'#)Q8L1880!4DEFJZP(;
M$8 +DP P9XB,RF'H7,EHA=M!FUNTM0J+<,.)5JC05LT-TU6>Y5Z>Z69#+,".
MVN4ZEMWHZ7BRF$ZE;*T2%-/MN*]OU'X5]?\ 18AA^J^D\7Z=\(QG\P>4>4DL
M^(.Q+&*AQ 0>/X.*GB82] \N#E[BO!5-UW5&\&NFWJ,BR:(H/!5>NAM#]=DM
MN%98D4^@E1_#MCJ^D5-U8.$_+0DY!RWT?A@XL>,^+B9_)@<8<+"F+%1_,"X;
M^DO5>C!Y3B'F(&%PYFCR0P(IG"OP]'K0>:?-S&H7G59C$AJ9-N.6N>LJDM?V
MPAPW#^%A-]#A4T&&R&LI*5@I!'D\/\5\3P?J<)^C\SN,7_+Q,<)!! +L2S!P
M]ZF5CZCPO#Q'$V($!P&;$*/(8F7).0%<Z]+="M*M$H\Z+IK9T"TXM;EB55&(
M"E+2_)#A?1)="E*)*E*4D@$)05X2,;<>KZ_\6^K^K'ACZOQ,6-B,. '^WS,,
M0BLBU&=<?#\+!A=@ 6))@Z@N]6S@NU GK_$M@G*<@#?*@-@#D_X^H^_'B!!Q
M>4$'$[,""5N@?SL.@+OV.<0F\C:S:42ZZW:\74>QI%QNS5TYJA,W117*P9S2
MB'(@IR9:I9D(((4U\KJ24D$9X]A^A^LPX#XA^F\88!A\QQ>3%Y?*SN[4:=EE
M\,'SA]*T9JQI3)FA.7L0,DYSL3Y&_??UX\BK6W)AJ,[10AJM,FP*[#JP,C&,
MG\OR.^".W?TX*:2#).L$UJ]01-[NK #GRL=)ZLD>@[]^_D['MQG$Y! KWV=,
MZ'HX<EQ2CW#]/NJ@@D!(2$E6"O8+0,#(V/DYVQ_ACA@=AYA([[=#B N*MW[Y
M0]75HH5TJQU+4@GH"@ @]R0$C;]?'W/$Q^9OV@G.1[M72;2@,EZ@]#1MXX\%
M9<:6XE* QE06E("L)0E;*1)CR-\D?+> 2WC=*\D=L\:P0 ]K78EFKD>"/ASW
MR-*VR&CM<+T?*4DE:02"2GH4$DG)STES&3'R2HI[> .*C@0X:K7#%^D !GY,
MO*U%^5DA) P3TY'2EO!^2TVE*01\EDF.G"L)22$D)5@%#B#5K&D5FLTSH0,[
MRF5*PX$=*D.N/ I)"2LI&ZT*R5DXP DIP0#P1P P(J&8:[S2TW%E08X!< 9'
M0XD$D8(^:0<J;;(PA)Z<EU74OL<Y!X=T[Y?*03HQ&AY2+"A=PPH4,Q&F7'Y3
M<9M$F5D2%H;0A<A*&^F*)*@ I8C,I#""K( R$C&,6-N^VZYJ.-+ 979[,)!9
MZM94N,$(PAH]2?W4I4 !A25-A*D@!+2R/]9  ZDG&^.(J"'K4\[!G9B&8ZQ6
M!6AM38Q\O)6E(45@K)7C9:U@IZPGMD)!\Y[\$<0:5)%7.I&19JNXBBU&[K%M
MN^Z.JA7E;D"YJ49<>:F#4F0\D2F%N%N1C(#:D)6YT#?I;=+1V4<$?(X=#1N#
M2*LY9\R%L=*HU.I-/B4JET^)3:; 9;8B08S C18S++?0VRPPV.A+00<%  !&
MY!\N\T>F\VLV]ZRQA\M-IFEEB46XZG<].LNW8=>K"2*E5(U,8,J6T'0ZAEYQ
MQ*@"70'G%LI;470E><@'@JXKU,0?5VW%VE;K^&6KK3\KY:3]."5= ^0H*94E
M*RI1ZB2#@YP,Y!WXH:'SXL:S2&OFLDS4$$1<!K$!RT2S#,$*XJ(R7Q+,=*I1
M2N.7_E)+P8>4A1;#N0M#/SD(=6@$ D D$C/$6@009#WRIF12'OQ"J,48;RVW
MUAWYJ2&_F)3(5LIX%1ZD92"@G/;QC'#NO;J$T+V+@"*/6HJ)S;97?D*^I)'4
MEQ25=/4HD=&>A(4=DCT.XVSVX/\ '-2")KJ:3P :*"*,:+W)STCJV. 2,YQM
MN,CO@^?/?@M8*'<UJ=U5P6D<$1P1'!$<$1P1'!$SMWZTZ>V15I-(N&L")48@
M:>?81%>>* ^UUL.=8& L,GJ4 .D X/% !J0+:]ZNRP210$AZU!T=XF&%V7)'
M6;3FS;R/-:O2[F:G:55?F=GV"*C5J;;2W95M4*U*7^RJS2H"DJ:2XNY(Z#'?
M</0J+'>6$JZCG@PKYAR/6-85.+%;"3N0&C<O1HT4NN5&[M/M"]$;/TIJE^T&
MYW;087 AU2V+.3:=/<A+45QL4F,M;8D#)-0FJ6MR2^7'EE2EGCGB\3$"0,&(
M@!G#,6T9Z2"9XD(<6)Z$P_')S6],Z0I*_P#"+TH:2"*VMH@*!"8CZNEPC/7O
MW0"2<^1OQ/S,1_\ +QS\0[[-I&:.30'D/3S/KMS7(F_>7^WM3^935C5S4WF<
MF7%8&I-J3=/8MB-6I^ N"P;)J$-MBH4W3V]6W3,MF;47_F/U*I1H_P")EMK^
M0'4M)4E3RC'^[$,6$D4N&@4S8/U=/,1'E-BU0]]*7YA/9R+Z0<O?)8[JY"LS
M5^]KQH>I]W0;BIU)N^2_54VI I-/C4YFD-NJ:;_&2UM-)0W5%I2XXTPVD@!(
M/%_+PB7.9<\^ ;X:4\^(L#A-":^KP*VXRNC+.OFEX0DFX"L)*B5&*]U$9)!)
MVR0,9.-SOQT&$ !CA%!)E]8N2_%4.9FE"*,_0!N 7-SGJLR'S1U_295 YB:?
M85C:=W";GKU@5NQOZ3VUJ#58;D=^DMW+%7(CF9 IBFW5Q8;OS&'Y3Y+S:@R@
M\0C7D_V6ABQ86I,\G<B<XY)J-(^7'2;2_F[:YFI_, BN.-W)==Z)I4>R85+N
M"KW%?>G-.TZK=$K5T,?ZW4-/J0S0X%:MFV5I"*9-B4QI*BAO(S^;CPOA'ADX
M0#A=A((=Q=W+#;93%CQ$EP3UB,VTSG-EUT8YA-*G&FUBN* 4DG!C2,XZMAOO
ML!WS^7&?/B-?#Q#E7GZ<%@XCD?\ M?KYESWY]=,[$YO*'3K>I^L%*L:DRK)U
M!T_NU-1T\H]WSW[6U*@0Z34JI9]3JS*Y=K7U;Z:6N31*K 6WT?CD+D]?RXH:
MT/'\3"#A'AXI)DC"; U+L"P%+%:\V("!BX19X#^MX<46[VW1-$;6YEM/]?:=
MJ+++5B\M*^7");LBGO2%3J>[>5(N)5PS*L]F2Y)^71X[3C;RG%OJ1\]2_JQP
M/CX\0(_*(!(<L 3(<B;-L1TAQ&D_U,Y#BN^I;/B6F<QS#Z3/,A::XLHWR?P[
M^P!(!..V1@D?W<])SCC(\0FOA^(Y)MU?75F5<Y&_&<B7HHH<Z$70SFQT)NC1
M&M7P[;::O4K6N2CUU%)_:35,N2R;BI%VT!^=39"2U4Z8]4*.U%J<!WZ)4)U;
M6<D<!XV/#(\+$8NT7@&IV.=74\Q!!;$*VG@'??AFN?D;D]M V38^GJN:Z3%M
MN-K O6:_Z!2=/*93J/*NE=YQKPB+T[0D"18,: J.Y2$QZ>YT.4N7)86DJD%0
MZ?\ BCS8FP&#Y2 #0@.*"FMT\^*OE)=Y<TAG9[9\-.U\+F$TD8B1V47"ZM#+
M#2$J<BOEQ24("07#O]>$@J))R<Y)W/%;46SOPYY* F^$YB[<ZW.=&3>ZL:M:
M&:C:?WQIU<5T28]"ORTJ]:=1>B17!)9AUZF2J7*>96H9;>::DK4TA74AQ0![
M*/&,6 $E^8T]<LF5\V(?VD%@1K0\@>PN,]E<F.G=@6+<=$HG,O;;U<J2;:H=
M-34]&K>J-GMVG:5"DT*FHJ-MR&E,/W-)@R0]-N6/\NH2J@PR5N!O/$_+PYDL
MS??N2- 4\^+_ !Q7A]?>X;(KJOROW1H;RZ:%:<:+TF^ZC<T:QZ'^ _;=4BK;
MFU!^5,EU&4\XS' CQFQ(F.HBQ&@$18R68Z<_+SQ"?) P8L0B0U]R\1;/B\Q-
M0:[DTS(;=B$_3W,EI,W]8N!:4%2<'\,YTI(R#GJ25=)VZ\'?88]<_FXO_1\3
MD+OK;X0DB6+<*\SIV0N->I'*+R^7US(7KK7"UXFVG1=0+D8OZYJ)2K2CMW;_
M $S8M65:"?V?>:.FH,6W)@RTR:A15=4=Z3%96D !1XZCZCQ;^$6LXPDPU6V&
M\O#!7S8HC%I_!,4A/;R Z9:0\FD?4%ES6*+=\Z\J;8UO-QK=LY%L6_'@:=TV
M=28%8=I3!4B==E?CS$N7#6ED.5!UAEPX"4\3%XV/$P/AXF=X JV3Z-[(<6(L
MX+ZR!G?X71Y[F*TI4A:5U\!/RG$I0(\CI^EQ6SGT]G&U!*0#DMJ?3MU#C(\7
M$)_*QF<II;G>XE1SD>F<0_-<4ZCRQ69;.M&J>L-B<U<JR[IO(ZU5>S+AB6%$
M<NRA5O6RFPHDU-TUQ2P[<U)L2-%!LFDRO[&+4(5*0.A44K5H?4>(!_X1=X<8
M;16QAX>[*^8@4)L1SM.^4U4T>1>HZ<\I&BZ=);GUDI>H;S-RU"LLW/3;+- J
M=974C&_&5:Z7D//2*_<M5FQI%7K-?FNJE2G:@(^$QX;"$T8\6-SBP^4NP$4S
MC=IF+@A6H#@N#<V%*17D=)722QM3+1U%9FOVK.-48I[B4R7 RICY:I"EK;'2
MO!(<0GJ"QLHA8VQQI@SP]&O_ !W*'RC^X.[5T$V?X9B93(<X=#U@K^E]NP=$
MOE-WJWJSI+4'7):7U4R/;T._:"[<9K2(R5O/45%!%0358Z4.)D0B\PM"FW5#
MB=^O9_E9@$O>9;8 T+Q'&K.L=R_:1:MZ?73-J-ZTW0"!19U%7&;<TJLR9;=?
M>FJELR NIS7J9"3)C/@../1%.+_MTM/;J0""F(_M+@\A+WB*S:=YF(#C8DC(
M\]QOC)/YC'ICVX+GDTL<C+3RK$&=80D *'<D_P "!O\ [??[\%9<'+/,9]:M
M S#(4KI25+P$C'<@Y).!OV )4 !OX_--@_<\@KA(!RAIAM\Z5B287//FR<2>
M9GX?Y)P#K!J'G;&W] 5ISL,'<@#]>,?F8QB&!F\U8MSR->QL_P!)8\0??>.B
MZ$]:.KISE0P% G?"CU).W;/?O_MXVL %B)B0XT(;5Z"F=F0XZVA"OJ! !WR%
M[C?! SC8>1C\^\+-+-=Z=4 +@D5)TC=W>3K"\Z74]!/S&T[9W3]0! *<[=B#
M_G..,^;PP#.$"\CJVBW+T.7]47FKT[A8^HUJE4B)(F5:H0X$..VM<B7-D-1(
MK#:%)2M3K[SC;;8!( ZU [[9R.,GQL H7,M<..Y"GE:2683=@)@F0V8W#+C3
M\57X@.L6@W++<=[<E]GS-4KZHM;I\2N7)#M2H5^U+0M^0_\ AYM0?<#!;G/-
M**0V(X>:)*@7$[8]'A>%C\<?MPEB]1Z"_*E0J^&KBKZ\C+Q9MD\?(Q#U?YI>
M732+7GG#HLB)?]?H;54_JC,=NBV=0?PRYL6!5)M#*TJJU0K$=F/5&'JDGY<9
MB6VA+#C.5B^+X)\-\$''Y7'[2/*7A^;G*Q<JG%A9W#=>6?-ETO\ F0J1';2\
MN!"BL("&P W":0S& *$-@EMIE*$C#:6O[,@#.V,<,&#QR6)&)F!;"29@.U+1
MF&4&(';.T3PX@>BC-S%\WVE?+Y:"+AJ=1CW/79]2_8-J6C;LR+/K-PUIY/0U
M%:0TZKY+2'EI$J0O^SC(/S'" ,<?:_#_ ,$^K_$/%P@>%XF#PL/EQ8_%.#$1
M@!)9A#E@3P8V3$1AP^9P8)PAW,1J=SD=U7IUS+T_6:V8M<TIM"X+F94](I\\
M3A&H])H%>IKR6*O1JE59BE-2I,*6L,OLLA2NKZ$$]0/&_J_PG%]#XF+POJ/%
M\/#B&(^4"<?B8"XPXA@9A0EZP5P/C/(PO=V8!YJ:9,'G@F\YI9%<AZ#:G7%K
M-<$Z!I_3[4J1N"RM*_F*NFM0I[Y81"@W),,2>),Q+YA(C0$J:6ZKH0OZ1GK^
M$>%_^H_1?IQA_.P?4>%XF#Q?'PD^#AQ>#CP^(#CP &F(8?-A/]0<W4QXSBPX
ML.+^G&#A(%6Q/A8'(RS!Y=0(^''<6D&F%U7=0;OI]_6_?-%LZGKI=?U&M(6M
M D:>TFHII5MMTV,PEQR75U1YX56:A\M:YKA;;=<4S#C8_4_\7>-X_P!81B\+
M%X6/PCCPCQ!X1Q8L7G;$?$)H!@&)AA_N!\I(!<+AX'TXP&<.)V,'07]6$$DK
MK?*YA-.4OJ9I+]9N&4Z[\DL4*WJE45JD,-ASY&5L-H1U-X5U=00D$K)[\?S\
M?3XW&'$,.%S<PQ)!.4&2#6B^A1SZDD<G]%&7FNUYU/A\NFIM0T3LV^:1?K=#
MIR+0N.JTV)2FX4RH5NDTYF6EN4XMQQF0AU]*%=!ZNEP8P >/K_@_X=])XWXA
M]/@\?'X!\,XVQ^&'!Q08&)H9P[&0+DE<G%G+,Q-!-&VXPX 90GY);P^)%2-7
M+JM;F+N"E792ZAIW1[JMY%WR?P,&&IZJ2T2/DJI$54DJ9CM(4KJ1DI[9S@_H
M_P ;_#_^'L/T8\7Z$X0</C?E8L7@?OQ8?%'F?"<.+]H!8!P7<"RV,.(']S2(
MM#R[!^!$NNK\I6M-1:4VJ[]/;;<*RPMFDTFJ5IT.*9+O0A538C)4[\G+B.HA
M!P.H@9X_&^%XGT.#QL&''X7B^('G_F#!BQ&+LX#UJ<E<6 $P6$6+6 C(47S7
MZ/\ P[M;K8YFM*N9"JW%1ZA3Y/,K(?J"(\Q4:HS&'ZC5GW)3C"%.,,"2A*5&
M&E9".D)V\_U;Z[\:_"_].\7Z/"X\8?0#%08L!\WA^481B(!Q$.\2\F5X_P I
MB,31YHS+&"P,=Q(7UQD*.Y([?P&_8 @C_=]N/XRO2XVS#%G(:22/:\W00!GR
M?)[#!&WZ;$ >V/3@@DA[VJ2QX5D/N]7)E6-COGL -N_?;SY]/OG@H12W7*)-
MA(S< 0Q2;=)R=_3WR /OVW^^>^Y*Y!JM,.14;9"T$.0(!Y&,D;G[@XV_(_;M
MMZE.)=Z[C6X(BF;M(JSCM@Y)W\8W[_8YW\@=^"%X!!HU)T X-L]'K2<X(QL>
MP^^XP.^1OG_8."1>6K#0(K5J6?*:KC88 R<D#N /(W\YQ^?MG@IG]GTX7O89
M%"3WVSL3WP ".V_V ^WVX*\:G3$3WD0'C5E&<*&^P& -]L=@?MM]]]\\%&9N
M-1ET.SU@Q4/8G'[V.WY;9]/]O!!79ZB;ZUEZ\X"48QGSYVSGR1[Y_3TX)?T<
MLU@[4(ND.!N0,$X.3VR?!] <DCUWVX*US<4BH9I&H8:C,LYO@E.=SDD]]O&,
M>N1CV]#P1I8D6&@!N+4GC8I"2 ?.,;^1G?!SOWQZ@]MCP5 !T<&*N79X@LY9
MF:K-)3 V.V", 9(P?)^P\\$<DQ)%\P"XRJ6Y15DO<@@;D8)QG.=LXQMC'M^8
MX*;LS4H<V$TE[PUV"3<?3W&1GU_Q[^G<@=AP5:'$5;B\/%":T!-30'J.P()S
MCL",_GL,>O! .+&EBQ9J:N^M*I=O \X([>NP],Y/L"#C@C-#VJ^Q)%BS @"6
M(RBL'(^VW?/;_;WX+>"AU+\P*;4X)>"TC@BM+>:;Z>MQ*.M12DJ/2"I.01DX
M P1C<C)P!DD D[[YI2ZT%!)6D*4E2@"1NE*DH4<]L!2TI[[D[9P<%'&80'FB
M>D.)R4A8&0#TJ44 [^"H%(]QC@JE+K:0HJ6 $8ZB3@#(!!)[8PH'.<;\$2%Y
MH'!<3DD #.Y)2%8 \_203C.!WX(N6?-$N/\ UJ5UU;X2V(M)24DHZ5$0 % $
MG^8\D=R.'?*B@]SZE1 GL4V7)#C9"05 G&/K/?8#_E?;/$NVBJW2ALMH;0&\
M@*" C8C)5V&<8R0-O?['A?U[[VE,_BW?J:+/NK"6W$*1]2<(4-B>I9PD;;G/
M8$;</MWP[LG?>ZU)X-+><"TC.23GZ@ /I)/CN"/R/MQ5DD_NJ:,U;O1STKHY
M60HHC"84CIP%@$8P.P./0=R<]NW;@KWMZ:?)6_/!*4.J& VD)/5XPK"4G/NH
M$?<'TXR"207J)!<<1QCEF%IPQ#7<&*9'NJ;^L,,.2'"^H?000GJ _NI[#TV\
M8]#N.-+)AC)S#.T_Q,ME58A,6.]):6G "%M@ C]TJV2"<;%2O/ODC'$[KKR0
M/YFL9<V.3V"<R.I#;+;?3U%)^7D8/UY)Z?.X[8SM@[['AWUF,UKOLU;18VJ
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M&RL#8\:PR0:,'S;E4/ENM 87;(&*\WU,<[A<J^:V^KDGZ^:5W'0]/KIKEO\
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M23^%?D0'77&,G<%I:U((.X*3Z<6QW'NI<;'_ /'NZZ%8'U9VWW]-E'^)QO\
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MIS^R0''F+UN=M#.^567NY?\ F;UXN[F*NGE[U\T;LW3"X*#I?#U1@5*RK_\
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M--IC4 7O*U>YJXFW*%5ZQ^SJO6S2XSDLTFBQA+J=1<#:EMPH;14E#CKBTAM
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M_<@9X*WV UM=XH##P6 H4HR1YSG8[;>N""#CUQ@>@[\$IM6\Y00>#C6X2#!
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MSJRWE K>CC:D=T"8B&/$=/N ^94R0M&2D.)ZDX*T#!("U%(R,]BI"T@[Y*5
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MH0WO\?.J0XSL1D$  X&" ?S/?MX/G@G?"J4;8SWQ[Y[9/KG?MZ9P/3@B/O\
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M31HK5OTNLT>92J',:NBJ_CZM'F27( $52H*%)0C@328$GBX/0 OPS4S.K7H
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M@C/Z$$CSMC@JUF;/3)P6G5P,KA*<#8C.2/\ '<D ;^N_Y\%/CXKID=FT3]T
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M0^9<59NG^FNJ,6?7$:DPXJ(LNPH[]'_K3K5$NZJS57+%T^BWQ=LNF5*W:/\
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M]T&W;</>@48XPL9I4$X)ZCD98[_2<G[;\%/, QEC3.*^S<5ZFH4*G$F!!A1
JXD)7^'CM1P0@Y2DI9;0" 5*.^3D^@'"W?>W'BQ'RG=[/P9Q&LDWHO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>fhtx-20211231_g24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g24.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1I:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &CZ^9Q@X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%>_*P         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             !%    E@
M 0                         !              )8   !%
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !%     !29VAT
M;&]N9P   E@    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MI^+FX1-E>:_TZ7!KCW>USW>T;&L])WO?[%/,NRK,JC#QF
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0T1667:&LL72_\0 ' $! 0$! 0$! 0$           $" P0%!@<(_\0 0!$
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MMP2$RN5BPIR+#EI1:)@HT 6#,S]CEL#8.KQEJQ>=G0RHZ.W3J7==\25".D5
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M[L^7+@#QOMPA >V3VSY<8VP<Y;T.&.4(&V=SD#O]P!Z[DYW&7'"'GE/+0_;
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MRXR?8=^$&+MUKK4N -C=6,,;!B"S@OML6)\;-]6VX1+FH]$S9E0[4H+-)]W
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MR'/\N$,NH=CH YH0P) I<K$BIA\Q8C);]Q]M_IOPB)E=:LK:YFE]D6.%:\*
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M;4FVZU8%UT#02?IETWC/6';-<MNF2*JBNNF5DY>I4<3]7N.H099,U6/TU"H
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MQZCT[C]D Q56.:J1TN,Q<5HH<'8@-]@ ?E[[@/\ OEN$ FFNY(0HMEHF8J2
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M.I&J2%>ILK4*;:\"65-*N60E9N:EI>2CQ8DQ38=0B*A0^N66.(FS^F_5XT2
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M@D$-W &? QYX0%'UU#@$4+%0G?(PR<89_&2?48S]>$1'TL2&T56?YA9+/]G
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M , /ER7_ &X0S0M=%0;KIXSRVV&""<>.YW\=+ -WVX1.I"(%KLXH*T)L@*0
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M A!V^A'UVR XR[ES_7A" NS#& !G^1P7'OGQPA -@[D^N-G9_P#)\\('Q(1
M<98[Y)]CG!+=@XX11?),AFH4;HM<LHA%+H5E( 9SO@$$G!<#R#@>2.$4,1DK
M@VJBJWL:HD8 Y@-6(NG-CJ5;].BW%?=WSZ;7T^MM$I'G5U6Y9U*TRX73H8$2
M/*4M"%U*J)7\-$&5@ 1XL$S$ Q$=4=R2I[5IDU[]8U%<B_+3RY:+\W.I%]4K
MESU&IVI5T2E!@TW62X] -4+=H<W=L])34UJI4Z95JW:\A;UK2]1K,Q$0)V%,
MPY:-*)@B5CK@+CA9'3/Y=>OEXO, 1,9FE<E6 ?(%K6NL;T*_7I"AT:?JU1B"
M#3Z=)QIN=BQ(<3X0@0H:XRU B&>L)0@E7PRH))25]/4EZ1-*B!9E8*!H"3DM
M/D1D2SXLRX0YU>5Q*JT!,Q%6JY!B@%2NJG4ZYK1U$NN0NV<N*Y;PHERJEZ98
MMY5^!;^GJ/SPMR73-42@U*6AQXDL4U*HR4.,:A+5*>Z)N!"5*P$\>N7BL3#P
M,7# ^TX9D,JA)B2'(Y45!4DE$"H8^[A\;/@\)B\-.$FQ<*:0(9)@J( TI#AU
M)H@6-@<I/)J5.DJA3Q&1!FY=,U+?GD3<C,1$1$!2?S4.HRB)V49QU0XTJ(R-
MO@J5\O'A!G)68"4,48DZ,$3WK'P<26:]04*&45?+E  =0"3D4CPDM>%WKOLV
MI,VK2H<I+R$E5XU;B7%,*CII<W-199*X4G_9N (TRF)+S'_,US$&(@H"I@P8
M*A&'I$N 9)C^M,)P%&&,,D&8JBS&82@44N4H"R[D,LN',)YB)C(1*'/,7","
M%IDRG-,O=26#%^O^$LXPWL >X!8DX[-QPC@A][BT2& Q[ !^SY#?M^_")!MO
M]&'JP'CN/&V[/PA"\NS9W.-VWS]NSMGLA";PX/8$E@![%@/?'9N$7?J;NU[U
M+;V89RY?!(<8VV/^##?=^$%2EQ\IWJJLA(3,]7=RQ<@?ON!Z?MPAI[:+WO\
MD!1!EL$$C"<C \;;G;U^F4+E;N6SNR9J/W@Q[';#!MGW+$^2,^V.$'^7>Q<]
MB0#;,+"V<.,#)8$G/J=M@7]N$7+JCL+C\Y."66 MG&,99B/9T_U+>G"(/87I
M=RZ,O=D*F)#MA_7[D,7/J,G]CPB0. 2&QY( #Y!=V?Z;Y[<(0%QME^VX&#A]
M\EL[#<^.$(,-V/;/?V?!)(<[_P N$(;#8^QSD_;T^P\#A"$,,!W&-MV[G.6
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MRJ*3CA T.QR^?EHVP0MU9[J\AW; R,^'<@\(Q-278:I2K%1LG5HY&[G [O\
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M(HE)V52(J).%,BGPRJ$$3L&34\(?6P>"P\0.3S$%W45>I&1"RGN\5!0_D:%
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M&G#N5R1;H0B ZAVT!C@77H*>LF7FRA%1_25G\K,K4F*2D=:>B"LKA'J'Q(Z
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M7(W8 .!V<^/N'X1:(>OK?3;;844)0M:RF&A"5*4M1"4I2D=2E*46"4@!U$D
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M_P"H/'<OU/A?H>-B_3N(F,^'Q XKZ9AX<\DJ S8<F+Q>%CSR@@H3A2@D$ S
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MJ9%FH$C'7*Q(*9B(@Q $OQZ(YR4Z^;C?:T::]%:;9]#U%T=T5UFU+U_T:I%
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M!%$%9AS<"67'E(WP(P@STJB/)Q3#4(<=391@@VERHP*%BU\W8/J*Q:PQ$?\
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MSIZ4ND@ @A<X1D9;N>$*\U=G5$UN:HG=1&U) <GW4-VR2EG'=S]M^$0_VR[
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M,PX\>-BG$GF)H2=:NY>X9VI' 84DC!" C"@NR)F*@Y41/4!4,*00KJ)+AB[
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M@H B*BF--3$.& $_,%)*CATOQUP\'%QI^3#DFGG1>664DH- "?V!CIA@\P1
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MC/\ 57#<!"UIZXHA0(<:(HA"%J+.I+[GJ+I(W< 9;C^(V37I^_F<?<(52E@
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M0P2?3LD,/V)V_P X[<(#5<R];N*G2C.M3'$(T,**3$3U%)7_ ! GH2KH).^
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M>R_-]H_+A_X07R2\X&L/-7I+J)I9<<XNP+YFK.TKM"BJOM%LPJ?J%.)B_ 7
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M4-1\)4FI$%L;$^.%T\\:*.= 6I==*VR[V5(E_K+?P_\ <\WF@C?_ !,M\?\
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M_01HEVT9TJ;_ .'UJ#TV_L_Z8SVX0YI<_?X@_P!!&B7;1G2IQ_\ D]M3N_\
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MVSPBJ#0FA# _BN44SY_^46W=6>4;6[3[1G0_3>>U/N.@4&6M.%2[8LBV)_\
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M9\ASV=R6[#/".,#=_&&;';8=LC#._DX9"$KL_J3W&V<."?3L [MPA"<,Y4$
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M>%/242$E29N J(_B-D*":T2AR9:E/@JL9P^+"!3U188ZP5H'6'6EX8ZDEP5
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M%I</7\K3(V+ I)7@%CO]\ ?4G?L>$!J_?U8L!6^41)?J+D8'[C8>^#[>G"-
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M'#<(I,PW4E .@[A?=+PA$ANE/4DA14WS)(/3OTYSTN.K=GSOPB=+;9DJ$S!
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MBN<^HT4 "@Z&[7@4I(R2$@@%R0"-_."2,;]O3A!"C@W6M+&A1"O<I=#J06R
M[I&0'5D=(\J "L9;/GA#[D7,K3K:BM3*R0@H* ^<9#@@@@@$LI)!SM]1GA"G
M<MDM >BW.1%814D))$1)"=PZ6#$ OG&=W[XWX0<JST)?5=D:F5P4@*QN%#J?
M9Q\K#.YP^_;[9X14M_!-; $H U:AA02&P+Y)]'(;/22[XV;</PB$)U"W3T1
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MC)2'DEPKR=L>.V^QSZ!O/"% XTSH'%6<@]P51(1)=0!<9[=R68?YV<@8X10
M="!V9060)ZJ@)>(@.Y?T[X#'[X'G(?N1PBD)2N:JX1JNYN Y6@B1<*QOW]2
M^0-OMZCA&54$(*L,@=4S1R?2H.H,'9PXPX/?/<>K?R;A$*E:-^0-^^MUA_Q,
M^&+>,$ .-PSO[C;U1:>I>Q"LR$&E"-6A_*/90'UW_P G9L>>$1SJ7R-'?/N<
MAK'OTJSL/ .SN>Y&&[GZ\(>!1;0/4Z,;UA]L8#,SN'R2,9V=S[-MPAXPV0HB
M)V6\!;<'#DGN#D N/K_AOP@.R4-**>JYU5'L13!\;L'\?;=NE_KPB@D/DK+T
MZ K9R1:HB27/<.0Q/AG;9@[=]MQC"'8$ -8M5#=-$N"I"H,-P[ AA_,G]OW\
M.AJKY !GH O?-4?[DDDCQD!GRV?(]3X=\EAPBD*>@4,H LN8 =4-E,'4P(4,
MGMLX/M^_?^B)<%>RE$-.F],V4&^X8A@V6#C<$=WS[_9 ;,'NY=7!T;;-5&(!
M;#[ G([/[Y ]'R>$*Y-5*)5%'5J!/MA@ /V 5OO@#^N=NY;A"J"C4#*I;4VJ
MY 76) N^&8MPC<@;J;;>D/A&X.$(BK;=L^'['#<(S/3K7+7^'B.W@92Q<9&S
M@=LY/ER'X1SZ&A!9'KZ=$0%&2/"ZB:B67IA9ERWQ?=QTBV+7M2FQ:M7ZS5YN
M'+R=,I\N08DQ,%2PL)=28<, %2XL2&@ ]3<(U+S+2H531T4ZDY*.D5ZY6.>/
MEAYQJ;<M6Y?M4:'?,&TIT4ZX84M$5*SM/C*7&1 7,2DS\-7Y6;^#$5*S"$]$
M9"5D''"-3% &J46P>JYA0F6M[<1EIB0P82T1%1"GX9!2M)=V((<,/XG#ET\(
MQ*JADJ!NCDACOT%HK+,\RMF4FNZWV_79"HT:=T)M^6NNLPYI'2*Y;\[3(E1D
M*A1P5 37YI:3)!)<?F5I@GY_E+SSVC9%$1"M*4-J.[AT98Z4MS8Z1PK0AW-5
MKDD:168ECQKV58,[4Y2'=<"232%5Y,K,217T09^+3T]<*16L3 !#PN_"*AWW
MSU1F:RZY\%H<WND&H%H6G=5HW%2JU!N29M65G:4FKR$M5;<1=J8*Y&/684>*
MA*82$QP4E!(B&&M,/J4DCAYYV@0Q%GJS961*7:.W6N;7162K%FT>D7C1;LB7
MC>2+.$Q0:E*QH-%GUR<>83-U128B3#D3^6B#\V'@_*2%D))#P^OG2!5_2S95
M<M=GR6,P6!JCIUJ49]=A7C0[M%(CH@5(T2H09Y4A&B?'1TS AGJ1+Q8DNO\
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M%MV2J=F3<A.25.2F];0L"-,3\?XO3"E:;=-Y42GQED]2.F92W7"4!///*]A
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MJDU*3A3!(F5Q9:=DHTDB=*TIZ9CX*8"STQ2WU,'CI9N'FX?'$TV',92.100
M')*4+ 51Z-'8%*$"O[]24"V**M(^II1HA3K(ID2-6YG]8NFKUJIW36ZE*QJA
M3I"-5:Y&,Y,F4IOQC @IAJET(+H!(!)/40>/'Q7$'&Q:(%( R !1TTOEJ$A_
ME8S_ #,%4:3C0(*A#BQ9<_ 4IXJ8<523#0HD.KI"BE1*7/2"6P4\<(RM50!J
ME56F@UKG=8UA:<?A\T*P>5J_]-Y*CV_"UKOG2S52QIV]?U&O+ILQ4+Y@5R'+
M1IN!&G%2L26AQYN1,W#@4R&2B&>E?^UPBKV4@EF1//V(C%FL'X8DE4K2TQE-
M(:59]I73:FE-Y67==1F9NLQ8=9J]RT6WI6#.0Q&CS28<I"G:5-QIHPDP/DB2
MZNDB'TE!7(R_A-"MB_QF"0Y9-?=7+QT_N/6VN4+3:FZ36+6;3M*!HS<E2BW9
M'K-<E:;(SM=F:_4:.J6A03(4N70J4@0(ZDQ(T48_C"!*"NF:;^>K1AR]_P -
M^ZIR_P"]8]NU>C5JBZDW%9EQU/5:Z:G4YS5JU%6K2S3JK*TV8@P8,O.QZZDK
M2?RZ)670F(H325J(X(?-O6N@[04$H+)YTO\ F/H3G(YK1==O42U[U_T<U"DZ
M3:<7)96F4/\ ,5P&Y)JKUB+/256K\6%"EH]$G)"0B]$&+3XL14&HPD3#+ (*
M"B,R\L&@6J?+C79^>G*;*UZ>UMO4U74*>7<-1KT2T*);UOJE;?0JMU"$G]=J
M,:8B3(F8R_RJ5PXD"' AE4,J*',"Z]SM^VVCQU=1^4W5.[=1[[I$A/VJC2+5
MO4O3;5BY9R<FIR#<]"J6GYD(TW;M/EH$K%EYE%:12)!")^+%!E2F/T*'4";7
MSM4^U(G,!FQ(^2>@ZF^<9]UFTFOW66QK#I=21;-&N.U-<M.=19@R\>9C2L6V
M["U&I5PKED3:H"8D.HSM I\&"4ADF,2"K'$<]_$$/8#/YI1$<?CXW,?RUSFM
MVHFGET1(= FZ596G>MEN19&M2:)L_KFH]M2%O4>>@R\5$1 1+0):H"),,8B4
M101OP\Z0! ;:U;*$+!A9.\:XM6>42X]#(NAVJLA+6S4Y'26R^5^S(]KP;<J5
M8MFO7/IM(ZV4RN7)?4I1I(J3;T6'J,)ZD5^++S,Q(565AKB0U)0$D0&Z&];Y
M?B*"JZ$C\>B1YK1/D=U?UQY<M285ZPJ1I\-4+QGZA8]"IR)^AJMVUZMSB7#K
MI=L]2EF'!F*3,UBUZ?9<2U"96"42TDF%$9)4 2_A#_/CP4* 2E?0*_[YK'C=
M<]!-3N7^TZ_IQ)VS;NI4:O\ +%=_+QIR*O:M7JJ8MK0+IK]6LNO0HTI38\NC
M52H0KDATF^T3$6&N>JU,H]S_ !A3I6*CA3X_?IGIU+5PU?/ Q&VZ32B2U(J.
MF]YV!=]KR5NPJ/;U/LVT)M$U$CFL4^:T[H:9N>GDJ ,M&E:Y/U61^##=H<D
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M+A'5T8@"TJ<=2201\J5#N'8A^K/<,_@<(42E:H<__P"JM8HBJ82HB(8ZB0,
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M,'%QN0"0D@@2@E2,?%#*'("V(0@>7 QAB8LP$AE^V8S$S$I_ZF4 J]#47C]
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M+$F_M.V?7]DZ1M42 WUW#CMCQV/H,\(Y$J?#YXYK'','I@1B '"%EBX=@?\
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M36(X1 2^;A57PFIK2+)<C<.[5V-J!<-4F[T78-TZ@3%:T8MO4&K3=;ON@V%
MH5$@I%>GZBK]2EINYJ@*G7Z;1JBL3]-I<Y"E9XIC)C*-%V9^BL^QV@0AKD6S
MNRJX9K J\7T0.E*0&+)2 $IZ$L  2E#GI#Y <L&#]^)'(U.Y]X^>I:4_F%A/
M5&"E&'"R.L!0\#)+%R/*O(XSAGFFF!24"9"=,_G>NG64 E:(25N6&0955$52
MK &*L:R:HZN6Q;EVS=K:13%6GZ7)S<2E3!N"DKEIR'!1$^!.JE9=YV(8<-*8
MYID5HR1_=+(B!^/']3FGPL*<X4AG$H50"H93,0A5!K9418^%]7^H<1PN'C38
M&!-B_IX<TQFE)21EYD$DQF("E 2 7((!$8'Y5^8+F'U!TZEZS?NDDU.5F)4X
MLM"G9*;D;8AU602LIAS4>F7 TQ#(0#$,.4ZH9)(A (;CP\)C8N)@R33233*)
M09@UE((,I+("P! 8Y1\OZ)]9XSC 9SP\\TG.1^L9A(I8$(<(<W*5>5 ".4E0
ML;&Z1'CS5/@QYN55)3,>7AQ(\HJ(B*J6BJ0%+@F+#_NXAAJ)3UH^4E)( !;C
M[.&2902$39,_/EX_8J9I02'(!0K6U4.4:Z?Q(*U=U'L;0VG6G+W[5(UV\QEF
MT"L6WIE=$C9UZ7+1(MLWG%CT2EUVI5JE2LF)J)+2T:.LU*G,B3"BM!ZB-EJ;
MLJT--53XA*&"Y$)45=:]:Y)%3(6K/,URNTFL4B;E9VA(U N:OUW2'336>J5/
M7K4>V;.M.UH4]5XDY4=.:T)#\E-5A49YJO:@1(M D9B"\]42/AA1]F*7_/X2
M+4(M"Y"CI_'>/=R'/7KC?%.THN&P9'2JJ*N+3%6JNJ%C1J;<2J_I_;%(D)R9
MJ*YFNRUQ3=*_5*Q,21D[5MZKTB%4YR'$B3B@KX0,0Y/GL+(_Q%"#3]]Z_)CS
M]X?B!Z_6=1[1G:G1=$:M4=7[(I%^V',4:H7! I%A24Y==+HRJ9J''G)Z/\>.
M92IICRM5DX-%2BH2T603#2%A?!2HHGJVGOOWB:]:'T3:._??/[K+;<U<NF,&
M#I95-5++N"\92:J=!M?46\Z5=-#MBVX=QP*I1K:H\[+2]'EH""J2N*?NF]85
M/I$529R# J0/Y-+MYKETAZ=E'O'#;OX@&OET4:!J-3[4TVIU@T6:Y=I*ZJ/.
MS-=B7;45:V!2:PJE5B'$C4&5A4.:0M<J)GJBSI EH:4?"'#SSS-,XB!U=70Z
M9#:,":><YVO=K7'K[JG3)ZU:]I]IW9%E5NNZ8W9<5PU"ZZRJ)JYK1;E4EM.!
M#4)B5KU2E*'(S4&#/HB(BSWY&D2Z4RDK!6F=_5/YSZ+%0+1\_P ^(SQN_P!7
MM6:=ISI#>NJ,*CW!=,.VZ),U2%;=L4RH52XYJ>END"F2=.I4C49J)5_SDW D
MIB3$FJ- B0XD&*D_"6KC2Y+D3T#5T.^5HB!2#FHZ747<5?>L:->7_7G4/66\
MHVDU^:M7Y$IEX\ZM3D;]K4K3+JTW5;5%5REHU#M[3"TZG7J?2C1:%)7_ $A5
M-@RT:2A?K<-$NE1F!<PFHL5?,OQ3IM%HI3.U>Q?2_>+R6KS$:L6-R#VUJ13%
MTF]+\D-49?1JU:K?*I^9IMRT6H\SL70FTKDK4S1FC3T=5J*H]>54$N*FM?YU
M9*XZW4&8]<J^N12Y:#*0AS!7:SY(U%JAC"-R<_\ S-:8TF]KMONU=)+@HEHZ
MNZW:*3-)M&#=")RIW%I98]9O>F7>)FM5* N7M6JPI>6MZI2$E1ZM%E(L&/5D
MQX9F?A0FH&:53OHH_>%0%T)'P6^(]%4N:#6V]KKNCEPN"M:;F[ZQ4] YBV;J
MT@J-RHFI>WKUI]S:A7=+STQ4IN>@P54&@6<FE2T\F,$U5%714#+2PF4R\.VH
M%RW%56K!B4!)B(XRO:C (CAS:B/1<2<N//OK%4]*;4LU<A1I:\I6YM/]+Z16
M]7IJL0*K6X]R2-Q52+K#78M-!E8MFU*3H\U2:#)0X"36ZI+S/QZM(Q8)AIR"
MSK3+*R$DKWBHE\_ UU.L;/>4?6V[-9K/N^+J%&L-5U6?JK?NFZIBQIV;B6[<
MDK95;F:;#K-&3/1(TUT3B$HC+AICS:("^I"9J*AHANC7H_E13UO"JJ'" H4#
MU-LT+W=12-9-STSF#U-Y@>9NEZ94'7>I7/:>LUN4*S-2Z9K#0[8TDL"F2T"E
MU&KPZ]8DY6D3%<")$S:%P_[)5M,RJ8'3/R&>&U;15 O2/HRDW<-V:+:\\PVH
M6NU^VIKYI1>]WTVWK;HEVPJ!:MI1K4F96%0;5_L'"B&WKB@7(5?/,5M$Q-S7
MYT&2BH*0 @55$!'BV(]KQM8J6H-UGEPG[VI\E)S^HDII.BXXE&AIAPQ"NB):
MD.LQZ?'EX 5^5B09Y45*9&(REJAL6!3P-/&K:IZ;1'6B"Q9WSLK,BG.-3$W?
M%&T_L'EXU7L#F5O*Z^8;5&+94]=E@UF^YFKRE^4:\IF5D[UEY#3Z9A5442!9
M46;G(<*HVW392:HYIB8M2CQ$*04S6Z(>M?/S%-P:!P5\(_#1+1^LW!8>GO)?
MJK:NL>H5U:GZP:JT2UM1;$K^H0O6CWE:M>NJL4RY8T.W:U'CR] A46CB#584
MS08<G-+_ "@4N!#B%S<D=?/--6@?;/W\2-^4J@(AD!RZU$J=:@HX#I,12E].
M.GYCN"WR]/" =Q?SR^;QV>$6#A"#_/M_CPC$]!O\&(LWIVQC<]F]6\CT /".
M4=*>EI6=EUR\Y!EYF!%8+@S4 1X*TC=X9QU,%,=O3/"-R5?+W(%:QTZ=2J/3
MXD15*I]/E#$2 O\ *R:9=:^G_>6D)!2,,&=]W9^");(LFCGIUSBS. 2P7-2R
MTJE& :E(^E,0T1841,5"8B !$4A0 !,,B(@%@7 4E)&07 +CNA+7O=M?_P#6
MF;FP\E)6Q:]-KM5NR1HM*D;@N&'+P*Y6H,D@56KP:<CX4FF<FTI"HB92&0F"
M%?P[ $<(V32JJ4&:*-J%:CXCX:],K"C4:ZZ%,6E1(U%O>HS=2NRF+ITO$@71
M4HZX,>9J-72M?3'CS1@0 KK#_P!TDJ\<(/Z6JNBL(QQ2^47EEH-YJU+IF@NE
MLA?D.H)K7]K9>S*-^NHJZ$(0F?@3I3\2%,PH:$0D1 H-TA22V.%_W\]NRP<M
M:Z[*B4R"J>L9&U%TETUU?HZ;7U1L*W+[HB(J)Y%'NBD4VJ20F8*@G\Q#$5"C
M!BQ2H?&(_C0Z0V7>7[>=XCU0[-H]=V5](\W,\NVALW6[2NV+I38@N/3^7E9&
MS:X+8I0J-JRU.(_(PJ7%^"L0H,@I*8DHA">J'$0A0+@GAY[-^;'W#F1TV]U?
ML5*J^GG*IRL:#S,+4!,MIC9] J.K,I4J'?%9H5OTR2J=;EJJ\:<@3,U"@HBF
M6GXH,Y-(Z^I4\T6(8H)7Q6]L^V79%%<@=:T*)O3+,+5Z-'W=3.730O5^7M60
MU8TKLO4.7LV)%CVK)WM1)6XX= BS<O(4R(JC_G0N%*?&@R$G!C?*GJA]1#?.
MGAM8>POJE<]:D"0BYIFIT2QJ]*(B)Z:7TBTVI5JVE9<A8=MR-G:<S%+G[+H$
M.DR$2EVS&H$2)%I,[0I92")&:D#'CS$J1#4(<:&DI ZC\0$8!Z)H6L6T\$"2
M222C.:DAT?N3>@CP6H_+3IG?UB5JR8%N42TU5*4O*0DJS0K<MJ+-V]%U$J<E
M<%[QY&3K=)K%&F)2ZYR4AQ+DITY2IJ%5S$C2ZXD%$2',RQFJA'6I[NO1 U@4
M:E4*T+$@9T]2KNN*.7#D;TAY=Z5?:9"G2-Z7)J?-5!5[5J-:-I6Q*3U#K%'H
MEOS-$E[5MN7HUL4ZWHU)MZFR\_3Y*35&FX0B)4DJ6R912BJ@!RS5:UT2RP>8
MU0BHKJ#J5 _9U[6OG)?I?K=(25+DA1M/IZDS=&CSLQ2-/;!N>5KE*H5-C4NB
MR5>D[NMJ>BS,Q29*,J';DS)U&7703#AF$J*F&E"[RT.;6KE732"US#H] GB4
M]3'L^7_E2TRY;Z/1*/9,&;BQ*19,A:,6>J"*6J/5J72YVH5&"J=@2U*EH$O_
M ,YJ4R42T@N#!0CIAETAR\.[_B"E45ZZ +M4Y+U$9)F](]):C;,:UJC85I3U
MJSM?5=DS1IFAP(E(G+JB3Z9]5:BTY:%I34A440YI,UN%N0H.1Q$:C4[K^\0D
M@YH%7-TT3UH(^O+::VO2[[GM2):53+W35;;DK2C3" TI^ATZ;$]*R,& D=4L
MA,5@>@E/2 &;' ?GV^(I!1R CYK=Z-T75S&-J?RC\L]'O:/J52] ]+I>_P"9
MJ4:L1;U_L;09NX#4IU_S<ZBISD,3D*965*_OH:DJ 4KI!);@SJ!Z.=5!!ZY5
M@53((K+1-Y>SVCWTII#IC2YNUZE(Z?6K*S5CJK4>TYJ4HTA+S=JQ:_\ '56%
MTB,E+RPJQCQS,_!/63%)4H;@S-YIE#5T5!Z#-U-%1')U^W:EH6G9L6I2]J6W
M1+>%P5ZH7!7(=#IT*0_/5^:0#.5>?BI(_-34_"E99$9805.GYE*#D5T[>H)'
MEHDQJ%L=V+O1&<7[1[MV#NSE\A\%\8]&._IQ(Y#SHY](9?8GZ[;D#L0</YR_
MIPA$5A*D+"DA22E86CLH=TY !<.'+;[]^$!7REZ0H<.'"2T- A@;I P,/VW9
MWP?Z\(Z+S D,0"MV*DCKFD-9(2HI.1D._2"V IBY2[.P?)9\\-XYBMNM.L8M
MC:3:;S%;BW)-V1:4>N3E>@W1,5:=H\*<J$>O0*!'M*5KD6+$00:JBWY^9H<2
M-U'XE/F%0RKI!2:0-Q0T%>[%,GO';JF5[C\H0I&12/!2W*9RXR5+NJ@2&B6G
M,I1[YBP)N[Y&%:5&3 KBX$X9Z5,T""/S$G4 FH0HOPUI3&0D@%6!&R'G[-M
M*0H*Y997<I6RQV);EHY?H5#%HIT<T^308=.3;JJ1_9>D&0@TF8FA6A3("!
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MT--42E,9-*5/@1# *""0#\H"2+F<M@@8 ^4JL9(=$#FCO0FXIJF@S\A+<O\
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MGZ3:-%EZ/)S54APT2\&:7!E@F"A8@)" E" F&EX:%]&[5,_!LNL'*A5HQLS
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K @FA;*+%2_08?5#'2A:U*2ES@$YP26=0462>D/CA%&OY_$<_"+!PA'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>fhtx-20211231_g25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g25.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1D84&AO=&]S:&]P(#,N,  X0DE-! 0
M    &/R^8Y8X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%>;1T         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             !(    EH
M 0                         !              ):   !(
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !(     !29VAT
M;&]N9P   EH    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M9AY-=5#WO:VJ_%>+6&M[J+:KIRJ_?7=58W^;5?/Z7U8A^0W)W6.(WC%8^IQ
M:6_]S6M?[?\ IJW]7OZ!;_X=S_\ V\RUIH\1\/LBIYS%Z3UFQ[O5R'X[:]FS
M>;+&O@[_ .;9G.^AMV6;_98KU]'UA%V.]O4,9E+7_IV_9G>]KH:ROW9+_P _
M\[?7_P!=6JA9'\V/Z]?_ %;$1(^'^+%5)4DE"QQ96YS1N+1,$Q_!R:IFDDDD
MI22222E))))*4DDDDI22222E))))*?_0[6JVZOZP]5JQVML<S&9?72&MGUG
MMU?8ZKW6[&,_GJZMBF,KZWBZEKL/&=4X,-K@XMB0/5;_ #K]OI_1WM;=_P!>
M3XKF.^MF96&-_1X];S8'V[]SS&QU;G_9MFQN[]'7_P!_6XDIR?JP;3TIQN:U
MEIR\XV,8XO:'?;,K>UECF5.L9N_/]*O^HM99GU>_H%O_ (=S_P#V\RUII*4A
M9'\V/Z]?_5L15G?6!]S.CY/V;;]I<S9CBP.<TVN(90US*_>[]*6_124Z*K9[
M!9CFLS[B(@8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E F0# 1$
M A$! Q$!_\0 'P !  (" @,! 0            @)!PH%!@$#! (+_\0 51
M  8" 0,"! ($!PL(!PD  0(#! 4&  <("1$2$Q05%B$Q"B(7(T%1&#(Y57&5
MTQDD,S5987:!D;/!)39"4Y.7H=<I0T96L='A-%)F=7>2M?#Q_\0 ' $!  (#
M 0$!              $"! 4& P<(_\0 4!$  @$# @0"!P4$!0D&! <   $"
M P01(3$%$D%18? &$R)Q@9&A%#*QP=$'%>'Q%B-"4I0D,U568H*3T]0T4W)S
MDK(E0V/5-394=8/"Q/_:  P# 0 "$0,1 #\ W^, 8 P!@# & , 8 P!@# &
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M*+;2:;CI))IM-ZI-=,K74^K*DC & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M8?9<$XAQVYY8WEBG1T7VBH_L]3']YT\/G>/[/)#+U<]2[W/D!U8P!@# & ,
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M$ET3 'B<O?2MMMMO+>K;W;[LRSF\ 8 P!@# & , 8 P!@# & , 8 P!@# &
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M)ITZ^A7*>$M3:N#IDR".J\;'!#O&,<U%VU0>2,@HF[5.LJ4@E_+1?KGWO/\
M(D+@@8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M3]_^?&B?V]__ %NU?_[V_9_3WP6?W(^^?X_+]=S9&P5& , 8 P!@# & , 8
MP!@# (]Z">:V=O-Z!KJ]WF\+M=[6EIL!*ZR-UD4Z9L).MT\\O2JA\Y-6Q&5.
MC(M2$D(UA5#.JD@[EI$8UT9P=ZDB&,?)/X-O7XO/CWZ$A, 8 P!@# & 1&Y;
MQ4D2(U7?203ZUUG56UH"]76M1S<'CYU76+*39K2K-@)@^(NH%R];R1&(!^N(
MDH;R+Z7UZ7T:J4W5XE9.M"VN.)<-KV=I7J2Y(*XG.G.-*<__ )<:\82I\_\
M9;7<\*Z>(3QS1IS4Y1_V<-92ZN.<I&)[]MFD<G+;HBL:0"4M,G5-O5#9%BN9
M*_,Q$50ZS5S+NIQF[DIA@P!66GFZR<4WBF@.D'A55#+'%-$HYL[/A=YZ/6O&
M+CB_J[:G=<,NK"WM?7TJM6\KW"C&C.%.C.?]51:=2563BXZ<JRSSE4A7E25+
M,N6I&HY<K2BHYRFVEJTVL=2Q$/M]^_\ G_?_ )\X<RQ@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , T_N6EZHE6ZE7,TVU^?'+KATNY=:F1K$?Q0JSUE6;G7VNLZ\1-[>I%
MO4YH)FYQ3L[J..Z.*HDC$F)".O3\6K8626-$MVWE]?#587AWR;+G"N6@9SC#
MJ*5K.W-C[W@WE6:JQVV-MI*([$NJ B8"R]H3581:A9%;L/J =BW'L ?JPQ^>
MNN?SV]Q5[O\ +;X$.^JY'PD9KF V-L7E'MC26LZFVG6K;5^E9J1K%^W?M"69
M+-J'7XB7K[E"Q/UFTJ=JHG"-"*M#F*+AWX)^0'$K/1)Z=<:>.NGS*Y^4LEU*
M:+TI-'6ZV[I=:XGZ[&U*4W2[?-G3O>%D3E+S%-ZC47MM1?-TXM4(%R4UPD2,
MU9.07(5D*B!16*(LN7F[KZ=WIAOW+ZL^3GILO=>P-];YI</OG;6I8/B+TM(S
MESKU/7-TE*BA/[D=2*C9&9NA8]9$+/%QJ,44@Q\@*J @\<%,4"K'\GN(26Z6
M[Y<M=-,+PSGIKIH1;W9RJY.;VK/(3D*??FU-2V7B+P"XA[\UO5:):7U7J,[M
M39<1!72[6:UUMH=*/M3*?(J[JY8R50=1Z,<_]-%$JX$.$+5+W+SU)22?364D
MWC7&R7AGPQW\"WOE1U7MY\;)K3T!3>GAO'DXTV-H#7.X):\:SG!B:_7Y^YJ3
MJ$A15VIZ38S?$X8D*VDUE#/TS"TG&*9FJ8IBJM+TZ9\5C\VG]"%%/.9)8;6J
M\/'&^Q7QT%-P3^_.H[U@=OVG5UCTM8+W+Z#FY35]M<^\L=-<JNMM)&B9=S\/
MBO6=I@D"AC?#FG<IR_J@[=QA=?AH^_G&S[]<DR22CAY7M:XQUVZK3WOQU-KS
M)*# & , 8 P!@# & , 8 P!@&,=;*[*57V)^D:M4RN()[%F$]?*4]\Z>JV#7
MI8J#&(L%M*Z23!G;G<H,VVD&;85&J;!G&'(<3J*  :=/+,G8 P!@# & , Q)
MN=PNXJ2-/8JG2DMD3,=0VQT1$KA%C-'.:S/VQP^I5XBIMIV82,';L=@'U+W\
M@V?"4HW7VJ:3IV%*=[)-9BYT<?9X27]VK<RHTGX3/.H_9Y5C,WR+7&C^\UUT
MCE_ XO1D<PC8F\MX]FU9H(;/NC5%-L@DB4C=L\0201 $RA^K1(4")D^Q"@ !
M]LOQ><YSLI3G*;?#K:3<FVW*7.VWEO5]7U%-)*:6W/+\OP,WYJ3T& , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M3):,X33<)QFEHW&2DD^SPV<MGD6& , 8 P!@# & , 8 P!@# & , 8 P!@#
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MV;(^"HP!@# & , 8 P!@# & , 8!!VY\N(SCLMM1SR1K9JA!U^4LEUKUCU[
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MNHFRU"?(B1P>'L,+((MWK)8Z"B;EFX,C[21:*)O&*R[=0B@B&FM&3&P0, 8
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MMS;418H;8C#3=7F[-:(*DS\)*3($@VJCEQ'@0K[T&KQ4$S)I^\412 _T,<
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M16'TP.)_I@$>=S<X>/&C;GQTHEQN\>><Y0V]U4M6GBUTGT6]%A%*RKV:D)=
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M?WWC1/\ X*[5#_X?3_4&.OR[>?'XEG]V/^]^)LC8*C & , 8 P!@# & , 8
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MTAIG7U9L#=RP?%91<2Z9S-G3C'14UFK.Q'<1;9JLHDF=ZG!>X*4[86RROO\
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M\\[/+C?M#C)O=]S"Y05;9T3M&+WWL#J"-=G:*V#2.&%VW'L9WJ@)V(?:ZM]
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M?04 1!F+ & ?DY1.0Y2G,F)BF*"A/ 3IB(" '("A3D$Q1'R+YD.3N >13!W
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M-)K.&DUE-/#UU32:?@TFNJ/IRI(P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & =3E*)3YJU5J[R]=BY*V4U&51JDZ];@X?5XLXV]E+GB3J"8C)Q(,A.
MR<ND"%<G9JK-/6!NNLF<#MF , XR+A(:#3>)0L3&Q"4A)R,T_3C639B1[,2[
MM5_*RKLK9-(KB1DWRZSQ^]6 [EVY5477444.8P@<G@# & , 8 P!@# -2;J!
MWBM:6YP<BKA \DNJSHZ7LR-*?[ :\7N.==LFDG85^C0[-E,)6MZX;MYMXUAD
M&Z$G-R20O&8-QC%'@LH]N1)\<=/=X[/\]MBZQA+"?^]AK5_'X?'=Z;#O RXH
M[ XD:/N;:^;8V<UL5+CY-K?=X03"M[1M#9P!CHRMMAHM16/9R+@G8QB-%5$3
M$\3$.8![X*O=]-=NQ*B:FX6MQ3^=L4O%P$'%MSNY.9FI!I%14<U)V [E_(OE
MD&;1N01 #K.%DTR]P[F#N&"#TOK+7(N 6M<G/PL=5V\>67<61]*L6D A%'2*
MN236F'"Z<<E'G0.18KT[DK8R1RJ J)# (@=?F-H:SKS>MNI_8E%@VMR%H%/<
MS%M@(QO:Q?I)KL0K:SV003G1>H+(K- BS.O<)*IJ(^9#E$0/LGM@4.K3$#7K
M/=JC7)^U.?9UB#GK)#1$Q9'8&(06L#&2#UN]F'('43)Z$>@X5\CD+X]S  @=
MNP#6XZ5O\LEURO\ 3C1/?_M=J]O_  [?M'M]NP?M=?@OET+/[L??+\?G^78V
M1\%1@# & , 8 P!@# & , 8!#3E]/V"RQM*XR4*3=1-VY'2KRKS4Y&K'1E*1
MIB-;E<[@O#)PC^NCI1M5U5*U494GY&=]LM5]8/24.(0\]._T\^\E8USV?SV7
MZ_ S=IV$N]8AK#5K35];5&KU>T*UW343K5Y,N6I-.PT!7V%1^:&LO%QB,3;6
M[A"78O(J$%_!M8EI#>T?JK'=$2DCS\=?RQ]49=P!@# .+G)AE7H:5G9(XIL(
M:.>2;PY?'R*V8MU'*W@!C%*)Q33,!"B8H&.(%[AW[YZ4J4ZU6G1IK,ZLXTX+
MIS3DHK.^%EZO&BU(;PFWLDW\BM^QGY*[]K:.XH"!UW#T,K&0/ Z^E',Z%MMM
M/*Z!9U\5FD0&.CG<JFS\FK9!H4A"#X+*]_%0_=T%P'@EP^%UZU]6O'.FJ]]3
MC1^S6UURXAZJE_G)QI.>)2<WEY:TT6&_758JHE!1Y<J+YN:4>J;SA9UQHU@G
MAJ?8<9M;7E7OL2T6CFM@C_6/&.1(9Q&/6RRK*0CEC$ I3&9O6ZZ!5 (GZJ9"
M*^DGY^!>.XE8U.'7US95)JI*A4Y?61^[4C)*<*BU?WX2C+&7AMK+QDRJ<U4A
M&:TYEG'9[-?!F1,P2XP!@# & , ZS=+0PI52LEME%DD&%=AI"6<*+&\$@*R;
M*+%*<W</$%%"D3[]P^IPS(M+>=W<V]M33<Z]6%**BLOVY)-I>";?P/.K4C2I
MSJ2:481<FV\+19W\=BNB=:[-::!-1H;C[MVZW/9+N-VM:;3!JZK:P(S]GGFE
MC<PSU2S[/KT_\2K<"VBZR(C7_;F)%,RE<J=U5"=U1?#Y\;^V5>-\+M+3AZJ<
M,M[:LN(RK.A;4)V\:T%;\/KT/5W%:52XTK\V:DWRK1/325PK1THV=>I4KN-Q
M4J0=NH<]22FXOGK4YYIQ4:?W/[*U>N)^:\N\Q>(Y\^F=8[ U>LS>%:I1>P1I
M R$BF9(JHOF/R-=;NQ]H4PBB;WCUFZ]4IO%L9/LH/%WUG2LZD(4N(67$5*/,
MZEC]K]7!YQR3^V6EI/F:U]F$HX_M9T-O1JSJQ;G;UK=IX4:SI-R7=>JJU5CI
MJT_ R#F">PP"*^_DRWR]Z5TF!?7CI^R.]DWA  \T5*CK<C=PPCGI0[BB$I<)
M2#?,%#!V44K;M,O<2F$.BX,_L=GQ;BSTJ4;>-A9O9JZOVXSJ0_O>KM:=:$TM
M4KB,LI(Q+C^LJ4*'24W5J?\ @I:I;/[TW''_ (7KH2E]-/\ ZLG_ .TO_P L
MYTRS]X P!@# & , Z;;;Y7:2FDK/#-@5=)95+X15;18^Y4"B8X*GKT/)IM1[
M%'Q]X=N4WW WC]<R[6RKWC:H>IS%I/UMU;6^KVPKBM2<O]U2*RG&'WL_",I?
M^U,AE06.\>2$%([89[PL&KHYU+2R&O:=4XB%4BF;".<'19N+A\6CUWTVY>F*
M4[MFH=H5J03)%+W[AG57L^$< KT^&SX/0XE4A3I._NKBM652<YQ3G&T]7.-.
MC&">(S7/SO5OJ8\/65DZBJR@FWR148X264N;*?-GY>&V,IZ#Y!?.E=+"WP'X
M[!@K5,T::=P=-M;FO2\E"/ 9EET9.-A7D#%I2)#$66;+R:16*GJ J""0D*&N
MXUP3[)7]=9.G]AK6U*\I1K7=M&O2IUH\WJG3J585ZCIO*4E3?.MG)ILM1K<R
MY9YYXR<'B,FFXZ9SAQUZZZ>"P2LSFS(((]3S95YT[T^^7>T=:662IU^HNBK]
M9*E:8A0J4G!3D9".7#"28J'(H0CEJN0JJ1C$, '*'<H_;!*66EW:7U*8.FAN
MN2V^QJ%Z4Y^=0?:>U8OBK/[9N^JMP:_:5_0;FT/]5-VDT6'M:^L84\TTJMQM
M;>:HYF5J<+R189C(G<2;-%V*PLXM-9BL-I;M_P#]FM4O=XY9#"0ZU^Q"=&!$
MB%YY-I<TP2(D??1M66DM2,X_3>HF=0-K#'#5#)&I@! %.!_ 7':* /=!V"NK
M2Z/1O3IU6WR+JGF>,:/QV[[ZZ:]RPN5)RKY:=43D9QUK?./D)QSH&J>.7';8
M-7C-3NJD=@M:+S0(=W-.9B/LU=F4W35Q*>K(N&[55BJX5<N"^Y(4Y1);S_'8
M\\)13W;;6N<8279X6^O79DI.FGS[E)G2^X:WSEWMJV+O_'#?UHT')[CN\[3=
M3P^S3Q**<E#27MY1]"P19XT4X1))(Q?@5=<AUR-D@,(8$EK[*T:RDD]/GJ5B
M\I.H]MB_\Q>3$75>4W(G16E^+<IK^)IUIXY:?I.XM'HI2I6$A.[.Y'R\D^8N
M9W7D@F[(R;,J[/D5:-Q._1+[?L<8^??SI_$E132T3SG3+3?3"QX_//0Y[E;S
M-Y?7;8W.G9FGN5MBU[1>G;I34VPJI6->UNJHT7>U@L$6PL]DF[PQL45/RCZL
MV:$]4L)")RQ"PQG:"B;IQZ:Q7!O'E?F%';1^TVNNB73MG.>CSX8,;\T.H[R/
M-8=Y[,<\O;-P^?:>XD\>^0?%+2<' U0]7Y-6+9%0:VZ[)SZ=IK<U(WB/8RK@
MM-3B(^22;P1"!-N$?0;2?NSZ^[]?<OK\B(I/"Y<Y;3>99CC'3*7?1K=8?AM-
M<6]MO-^\:./>\I%@WBY+<.D]7;-DXQH"@-(V3O-)A++(L&GJG.J+5F]DEV[8
MRASG,@FF8QC&$1&2I1)U#.0_+&\<QN66F=&\D;MQPIO!;I[R/+ADAK^*J;EW
MM'<*"<[:V$7?'-G@9OXCKWY8AFT*O6VQ&R9I%561575(99DL\^=OQ+))I=6Y
M)+P6F<8ZZ]=-M-'FX[BEO^[[_P""^D>2*%88S&R]E\<:?L\*<@]+!Q<Q?IR@
M,[ -=;22J;PL3&R=A6^'(2"J#@&35<KE1!0$Q2%YU*XQE=FU[\%?730WKS.V
M-S8Y_:YY?V:MC+:[;:8D:QK+7[Z0?:YUBSML&_DA@JZYE&C-_(ODVGM$9R9<
MH)GEI%%9V! *H&"6DL8SJM<OKE].GGL2&YB]1^9XP\B=<<8J'QFNO(;9FT-.
MW3;]?:U>\5BG,6D;2'[MI*M)EU8V:R;1H1!F=TK*-C/5DO4202B71C"<L9UQ
MX9^I*2PVWC7'QZ><$9-)]<".VU8^,RDWQ"VOK+4W);94EHZ#VS9KQ1WS6$W1
M"M';N8K)JM$^M*R=78E:'*%T6<PX.1\O;P)Q3$HR1C?5-K??OCKC.N-%GOL<
M#LOKK)T:L;.W#!\+=M73C-K[=_\ ![8[Y;; I,1&V'8K2S,JK+ I4'#1W/1%
M:;RSPC6.GB'EBRCI1L@9FQ(LLNU>?/\ $GEU2RL]?#3/G\3 /54Y=\C* TZB
M.T],[IN>M*KQ4K?"K4$2U@Y4Z$6CLC;V^:G9=D60K8Q5602K;6*T'6EUE$A=
M(1-H>I)G]-\?Q='X8SGMG7Y?GVSA%)R@I8PW+.K[:)XP^[3TV62<*?6:U2OQ
MGY0\S&>I;D_XR:,O#'6&I[VQG(I>>Y.WU[8(RG$;:^IXLDU8&LGMLS&Q[:PS
MLNH[=QRKB43@ 49N(X@<KREIEI/';OG3=+5XR9'XV=1^];=Y<H<+MT\0KYQG
MV^/'*2Y(N0LFQ:A?()6KM;U 4EBQA9&KL6X2IG3F<4!Z^7)%FC9:&EHD(]Z@
MDVEG3SY\_D0UA*64TWC3=/#>OR?\BP?=%FEJ5IW;%R@54D9RI:TO=FAEET4W
M**,M U:5E8Y59NJ!DETDWC1$ZB*A3)JD 2' 2F$,$%?/&?ECM60ONOF.^[%!
MJT?=G%.M;TH,PA"1T&G#V6I1Z1-PPKQRS0;@[12;G:V]$IA<F8,Y(&R7I-T2
M% "3G#':&R]WZA<;BV(5%@RV'<[7-:TKJ<8VCEJ[J]&34C*FTD3I)E</Y)XB
MR<2;AZ\44552=M_ $R !<#R]]_CDAKSCY37O5?*[4^GFG)=;C9KRS:+N^PY*
M<CM(,]SRDU:8*X0<*P8F9J52U/8Q@G&OG2JAT$&R:ROB45O4 H Z_/\ +SY9
M/1OLTOGG]#IVN.;N^MAZPX92\=;Z;+OMV\I=Q:0EKQ 59@S2O=*I6K=Q6"IV
M@]0DEY5Q0+'(SM.@GDM7G(MWK<&JI%8]@SE CTHUT]_3XOQ]WQ)PM<:X2ZYP
M\K333J8[MO4>WW'::XF7B)=UD)FI1]TV7SN4/76:J1-7<=]WU;CGO9")0/\
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M_P!^BYNX:_N4Y,P+W^ME;VJU]?54JBT?]12S.?-VC/"AG7+DD29
M.P 'T  #[  ?L ,YXSQ@# & 1:U (7O=&[]L''UXV)D6.EJ:OW[D^%4([A:U
MJ)!]2B*M[D; F5PG]'#-!J'D8J91SHN*+[%PKA'#=54JTY\6NX[8J7JBK9/K
MI94Z+<7]V;EW,2CBI7KUMTFJ%-]HT_O^&M5RPT]5C/0E+G.F6, 8 P!@# &
M>! # (& ! ?H(" " @/T$! ?I]L ANZXRWRMOYYEIS=LWKBBVN1>R<U41A8F
M<+'.I-0QY%2I2$@V4<U\SH3F.(HF4\%>RA?J'8.JCZ06=Q"A/BO"*-_>6M.%
M*C=>NJT74C325-74(24:ZCC9I96FF6S']3*+:IU'",FW*/*GAOK%_P!E_HNQ
M(?5^M:]J>G1U-K@.56C-1R\>2$@M[F2EY9^J+B2EY)R(%%=\^<"*JRGB4._B
M4I0*4H!H^(W]?B=U4N[CE4YJ,8TZ<>6G2IPBHTZ5./\ 9A"*Q%'K""IQ45LL
MMM[MO=OQ?4R%F"7(U<QN/Q^5?%S>O').QEJ!]RZWLU )9SL1DRP9K#'JL0D3
M1X+-Q=@V%7U!0!9(5.WCYE[]\$IX:?9I_(^K4F@FVK^+6N..9)5I(.J'Q]J&
MCE;<C&)M#RAZQKJ-HBD^+,#G42*^/'_$A9F<J"05 2,L<Q?,0;]IRVUSCIOD
MKF>])$7G2:1Z9GZ6V1'J38C?]+?RGW WAML^SO+X!\0!8!%,_P (_P 8C]0]
MQ_%'TL%N?V^?&N<X.*VETR^59>7VR.6'%WFI$: F-IZOU=JZU1+[2M8V,X5B
M-:U.-KB#AD\M)GK>/<NEV;B0279M$7" N")F54]$HX(36,.*>NCRT]<=M'MU
M,^Z!Z3_%;6/']/1^XZ/6^4ZTM>YK:UZMN]*M7;D]M6R["81E+,9@_C#1[ Y4
MO%FP2;-B&:L4TV_J' O? YGG*;7;#?;!%[D!T:9NXW_<_P#!QWY&\=]!\I:C
M5Z-R2TNPUI SK:?KU:319%+KB74!L:@O7T2@2/7700?$23*06B3<"B404M5E
M9P\_S][WZ^)QF_>BE)W>[7']!G(]_IO36\M7ZRT]R0UN]ID5;7]\IFK6T;&1
M"E8L;H4%JM.RD-'A&3,@HA(I+HJ&%NV;"93S#F>FVC;6^F?C_$R-R]Z5VV.0
M\@VHNO\ E8[UEQGF]-UK1MXU!,:]K]YE&%,@&J<,[4U/;9A,[G7TK8ZRF2#G
MG2;>03=H%]0J*2ACF,QG\/F$TM<9><KHODNSU_AHYB:4UGNS5/(QSK^$EG+3
MA-K3BQJG7&J:6]B8!(D7L"L2)H(J\5/MS+6>839T2":-)DDR+-BU<.XPT>D\
M56=K-A&F/'+S],?F1-YS]+.^<D]X7+>>A>1I^/=AWAQR><3N1[!W1XZ\Q^P=
M-/I-\Z7& (]5;*5>[#%RC^ )8RJ.TTHL&R23),X.E'(9T2[/*>6L/3M[EM@F
MSIOC?=M$67352U[M8['BQIOC7 :1B=&NZS%.)&0M]5=,6<#LEU>/2)+ LWJ;
M!."<0B?@P<KF/(G)ZXX\^?/\(SOG=O.?#&V/?EG!Z3XA*ZAY<\L>4![HG-)\
MF6^M$$ZF6*,T/5?T?0BL08QY(72H2/Q(5/7 "MV_MP#P_6=_+ [>'ZM_F==V
MWPD6V?SAU/S"+?$HI+6?'?:FB34HT,9RI*GV2Y=."V$LJ#M,K8L7[@"BR%J<
M7'AW!9/O](PLYZKSY_EB<Z8\4_/O(FT_I$'K&M.&VO'&X6TDEQ4Y4V/DB[=_
M*QT279O8$)) ]3*C\2.,49,D@(&D3'= <""'H%\OI(;;;>FJQU7;\U_ H5Y)
M<8^3%A;[KX1Z3K7+F+H=RYJ1.SZ?I"R:DJKO4R+F3V7$6&T7Y]R&;-TEE:$+
M1HK8:]5 6;+Q;\K!%Z9R9-P0XME+VGC9[9SLEAK&%UV3C\38(WATIWF\N(_+
M7CC8MMQZ5GY6<GF/("P;!"J+N$HZ(@+WKF<JU)7B5I4ZSY.)I^N(RL"[]\D@
M=RZ=2"#1!(_M0>=/?XY]Q5/#75)8W>V&M/'+\Z8C7ROZ5<'JWB_U#JEJUK>+
M3QZWL\UING7W%[3D9&Q5QTWO6DV>IN)J_:>?OE31/PN01A&%FL-'/&BK*(5]
M:*@W;-1VBW%KC3Q:]_A\EX$IZIZ9UU>7G1X3^>_33L1BX84SFQM[FUN?EI-S
M_(6USU:Z95ST+7]M;;T+4M-2C3>,WL!O<*;6-:ZL6581,RP@VT,E-23N9<F8
MRUPD90KR22CWC<B)='X-8UZX?OW7;??J0VDL:9YLZ+*T23;?BM-\K7P1L1:\
MHFW;EP\KNL]]V)NZW;;=!%I&U+2W9,2-E+[8:2K!V6;2CHQ-I'E3+*O'#P&;
M%-!J %]% ")^(@&F=-L_3Z_F1WV_T^QV=QIT'HV/V8ZJ5HT@C!P9-BQL5Y.Y
MRDK0XUK8]3%B9QW:L+[7##'NA]<YFITFZQ1.*8@8,ZY]^-=NSSX$M1KM^IUL
MTC4M<$AV.F*[7[!!WI@X8('?IMHFOLVE&+$O 4(=L<'Z2@/RIH&*LG^8Y@$>
MV"-R.W(GB]O&]\B:!R(T9MK7>OYVIZHM&J96(V)K1WL*/E(VQ66*L@2#(K6Q
MP L';5:,*AW.+@JA%!^@  @(=]]6G\NGGQ[G2-==/9Y37.E+%,;3&Q72B<K;
MKROV%*)UMG#Q%MM5TU19=6.:_68*.,W:52#CV,O&O&B8@_<**1[D[Q=RY?*.
M"B<[^Y+IW3[=U[]=V<K0^G31JU<N;\G9;$O:J1S!A24]I2EF*:#?6])FXRTN
M]C0,6N)E$W0WN^7>RW"4<BBD8ZJL:U6*J$>DH(-O"QHUMOOTSKT\,8Z&?^&_
M'9SQ8X[T?3,K<7&Q;3#O+E9[UL-XS]B]O5^V)=[%L"Z6ATU]58S<TE8;,_,W
M;&65]HQ3:LR'%)NF  WEYQCP[+H24D(]C+,'L7)LVTA&R31PPD&#U!-RS>LG
M:)V[IHZ;K%.DNV<H**(KHJD,FJD<Q#E$IA 1!K%\E9W9VSN57*C6VD=I\-.'
M%+X<Q55<(U_;NIZ++6'<<K,4EO=7<^]5FO8&:TH_K_!&0QJ3LI_#W!T_<%$%
MXPGG3Z;[>?@7SHL\S;SC5K'33?7]2ZOIW[L><B.&NB-O2-1A*3(VZFM7#^"K
M#(D?6"O&JBK)Q(5IH0B9$8&55;FD(HI2]O9N$A 3!V$9*O&7AMK+U>[_ !)6
M76DU'8]4G*-?:Y$6ZG69B>-L%:GV2,C#S$>H<BAV<@Q<%.BY;F.FF8R2A1*)
MB%$0^F"#YYK7](L='=ZTGJK!R^OW\"2K/:>_CT'-?=5Q)JFR3A5HU0HMU(XC
M1)-N5J8@I@D0I +V , Q-L#B/QBVJVH#/9&B-879KJMFPC]<H6.I14FG3&$6
M@U:QS&OE<(&]@S9MV31%NV2[(IIMTBE)V(&!MMIG<^[8G%GCCMNV4^][-TCK
M2]7&@"V^2[)9:G$RDM6BLG"3MFG%.W+<YVR+5T@BX;HAW1163(HF0IB@.!EI
M8R\>\SW]OM@&MSTK?Y9'KE?N&\:)^G[OUFU0'_;]_P#-D=7\/CYQCX>XL_NQ
M_P![\?TT^ILC9)48 P!@# & , 8 P!@# -,_\2+P"V/S"W34ME<=E4[E;=(:
M8E'NZZPX=E:1M3J0S"2U:>IR1_-L%@EU32@I0!BE<O&#)P_]1--EX*NWGST^
M1Z4YJ+P]4]?=C*T_/&N4MB<WX=;I;[@X!ZKVCLS>\C%-KUR ;TQ>)I<$_&1:
MUNI0S=_(,W4L\*1)!::EE9=(PMTDS!'-VIB>LH9T?QA+!$Y*3TSA=^[WZOLO
M.VP%KM39*BU__2+"4R&1)L&6)K\]/<OG"DQKX(N$&(F;8#WZ-[:XDQFFT@W9
M_P!YD8M(PZ7YU% "2GZ?7+_+!DC & , Z)LJS*5*F34LT*HK*&0"/A&R( 9P
MYF9(P-(Y)N01+ZBI5U07\/(.Y$3_ %#MF986ZN;NC3FTJ:ESUI2>(QI4_:J.
M3UPN58ST;12I)Q@VM\87O>BZHCM7',Q5)N@^VU9M!PPJ]<G8^7=DA(@3NYF7
M7!TY=-R&L &70</3N%2JG$ABI&( E_8&\KPI7-.^YN)</4[FXHSI1E5JKEI4
ME*,8R:H8BXPY4UC5YU/)9BX>Q/2+3T6[W>^W;/T)<1[L7[)J],T>,#.42+"R
MD$B(O6HG#OZ+I)-59--8GV.4BJA0'Z <0^N<S./).4.:,^5M<\&W"6.L6TFT
M^C:3\#W3RLZKP>Y]F5)& , 8 P"%7,K5E6DM6;$V.8\VRMT7 1J;&3C)R1C@
M;%1E6#8ADT6JR:0'%%PJ0Y^WD8##W'.N]%.)W-+B5C8)49VM6O4<Z=2C3J<W
M-2G+64DWA22>,]#5\3H4W;5JV9*HHQ2DIM8Q)+1)XV;SWZGIXXZOJ4?M_<>Q
M*NV>DA895KJ:KJ/I%W)>810M9>XNVJKM10?;NY8T4BD=$0*)V;I,_<Q1[3Q_
MB-U4X5PFQN94W5K*?$[A4Z<*:7K.>E:0E&"7M0I>MDT\_?BUC)%E;TXW-U6@
MFH1Q;T\MO[N)56F]<.7+\FB;><@;48!\SQP+1HZ=E;N7AFK9=P#1F0JCMT**
M1E ;M4SG2(HY7$OI($.HF4RIBE,<@")@M&/-*,>:,>:2CS3;48Y:7-)I-J*S
MEM)M)/"9#>$WAO";PMWCHO%]"!NU>=C.@1-M8DT-R ;W:-IHS\#&2U,KK=D[
M?34FI5:<1TY2N3CTVLS<U&,* IIK+E47 00. @ ]EP[T.G>U;:;XUP-VE2Z5
M"M4IW=Q*484J:N;KEB[-9E2M5.KC*6%C*-=6XAZN,U]FN?61@I1BX02;E+DA
ME^LVE/3OX$F./]!'6>GJ'3U3NEY".@FJTR\?E LB_FWQ?>RKZ1['4\WSEXNJ
MHY4$YS'5$QC&$1[YS_&KW]X<4O;I<JA4K25*,'FG"C#V*4*>BQ",(I1226-C
M+MJ?JJ%.&K:BG)M8;D]6Y?[3;U\3,>:L]Q@# & , 8 P!@$$-^=1'C_QT4*Z
MO2=W>5="TEIDK>*Y6OBE3BK* =UXA:1.^;*.W;,/S/?8-W*"!>X>N93]6/9\
M$]!.-\>7+9.SA<NW^UT[.XN'2NJMN_NUHTU3DHPGM#GE&4O[J6IJ+SC5G8ZU
ME5=-5/52JP@I4XU/[K?,FVEJ\)KQ)?:_O]0VE3*]L"A3C*R5&TQR,K!S+!3U
M&SQHN ]C!]C$43.!TEDC@!TE2'(8.X9R]]8W7#;NO8WM&=O=6U1TJU*:Q*$E
M^*:PXM:---;FRHUJ5Q2A6HS52G4CS0E'9K]4]&NC.XYB'J8/Y*[WK'&'0FV.
M0=T82<I5-0TB=O<_'PQ4SRKR,@&2KYTW8$5$$S.E$TA*D!Q HF$.X]L$I9:2
MZO'S(.<>.IXXY!/*J]:\/.2]"UU;Z#,;)BMLW*%@FU'-5F-#D;_#OC.VLDLZ
M\+1',VK.$$&WZU[*L2J@F0QQ*&.F5G.,:[_+!SCKJEZ2:=.]/J1*5:ZCI]1
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M?\AU -], ^=EL&A24G'0L==Z@_F9B/"6B8EE989U)RD6("(24<P0>J.GL>(
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MN3_IQHG_ 'FU?O\ ZP'(6[^&7^7P_,L_NP_WO_=^2P;(V25& , 8 P!@# &
M, 8!@/D/N8=/4M!6#COF39-SDVU/U=3D1 75CN,L(I,2'3#N<D5& )I.:=^(
MIM8]LL=02@(#@$=8?I[:TFZ@_0VO/WBR7J_D<RFXIV$N$K L;O898A1?IN63
M4W8T+%)=HBOLC"4C.,1*)2%7<N3J 2:T[H6FZ0;OV=/D[F^:/VL<R!M:[7(V
M1%BUBTSI-$8TC\1!D0J1P3."7^$*1,#?Q P#A= K:T5>;U_1Q8+?/+)[XM26
MP26Q_+/DH389:W3QF(2JEE4TRLJHUC#0JS%E&><8D^<R9T#BJJX[!Y\_(D-@
M# & 8:GC%M^TZ]6B_K8JB-OF^;+_ !DC3;HHMZXT5[=P*LV(=62*0W\=,P#V
M[!WS:T4[7AU>XVJ7DOLM%]52C[5Q)=U+"IM]'MJ>;]JHH](^T_?_ &5GXY,R
MYJCT& , 8 P!@# *I^?^P=F3>D.6Y:59&E/JNC-=MW\CXQ3>2E[C:'#9&<19
M&6=& L3"QQ$$BJ*MRF<O%Q[!V2 1#Z5Z$6/#J/&/1?[9;RNKGC-_*%/-5TZ5
MI;QE*BYM1_SM6HVVE)J,%XLY_C%:O.UXCZJ<:=.THJ3]E2E4J-*267]V,<8T
MU;R= Z,'+^4Y,Z*M-7M<2U8W/5MA.26EF)#$0LZ=K<OIL\NX(81!*0]ZLX3<
MD PE,0403[$3[!F_M9]%:?H]QJWN+:K*=IQ*@G2I3^];NVC"CZI-;T^5)Q>^
M5+.YX>B_$Y<0M*D*D4JMO/$I+:HJC<^9]I9SE+3&$MBY?/E!TXP#H&V+@ZU[
MJS95^8M$'[VCT"Y7!FQ='.FV>.JU79&:;M'"B?ZPB#A5D1%8Z?YRIG,8GY@#
M,WAMK&]XC86<Y.$+N]M;64XI.4(UZ\*4I13T;BIMI/3*U/.M-TZ56HEETZ<Y
MI/9N,7))_(TDMG=<_<FRMFUF_2NEM>-4:V-90>UM";L!XZPMZ=/SEIA6T@NJ
MF"R9$;+(QDS^J*/]\0#$ _*HJ(?K7A_[(.%</X?<65+BM])W"N'"X=*@JE"5
MU1HVU:4(IX;=O"I266O9K3?1(^?U?2.O5JQJ.WI>QR)QYI8FJ<I3CG3.DVI:
M?W4NINWZLMSJ_:XH]U>M$&#NU5F(G7+)L<ZC=JM(LTG*B")U/UADTS*"4AC_
M )A  $?KGY*XC:QLK^\M(2<XVUQ5HQG))2DJ<W%-I:9:6N#Z!1FZE*G4:2<X
M1DTMLM9.^YA'H, 8 P!@# & 8WOVNE;V:/,G?=ATKV * (46Q%@BO?4'N O@
M,R=^N*?V3'\GB'[^V;"ROU9*HG96%WSX_P"VV[K.&,?<:G#ESUW/"M0=9Q:K
M5J7+TI3Y$_\ Q://AV-?#J0Z4W5/\8=>\5:CJ78-TNU1VFL\C;5$0RTO%7N!
M>&7.A:'\XD!2%G5S+?\ +:#H@*HJ$!0YQ 0 /N'H!Q?A-#TBOO26ZXG8VEG=
M<-4:MK5K*E5LJ\5%.VIT7ENC'']3*.C3:6N_&\=M+JIP^CP^E;UJM6G<9C4C
M%RC5IYTJ2DMI//M)ZI]RR+I]\-+SQ^X\ZEK6P=G;,8VN%(:<F:/$6P$Z9&K/
MW/O KZL8+%05D$B"4K],C@A3K*+)AX^(B/ ^G'I99\<X[Q.XL>'</G;57ZFE
M>5;5N[J1A'D]>JG.L-O+@^7*BDS=\&X76LK*UIUKBO&I!<\Z4*G]4FWGD<<:
MK&DEG?)9KGSTWQ79U;8:7L733YL0<#&2$S,RG'G8[*-BHIHN_D7[M> =$1;,
MV;9-5PY<*&$"II(IG.<W8"E$?IA[/^7UZ$QT:?BO#J11X <+KAIKA[K/:$WR
M&Y#WMW:."%7BU=([ ETG-+IDI9=05:4-&0E?!DB_8/:HNS4KD,U6,9=HR57:
M*D,K]A+QS[+V9/77O[WN:_,IT^K^7H"(;<#8_)]2[G13<?P;1?RAJ.0Q^0ZD
M8+<NO@COB14@8]K$!/#Z.^[\?U0]PJ\I)+798]VN?H74_;3:CA/.=.V-^[T]
MV-<X++#\GJEPEZO_ "DV?N*A[GD*C?N+?%VL561UYJRSW=*1GJ_KB$5D8X58
MIMZ""J)UB-S^2IA(X Z1RE.F8,L4W26FF>R_'X[>&3)' 70W4+9\<=V;5X\O
M:'QGN/)3E1<MRP].W_19&=&%UB_:)1T4W&NLE6JD/(RZR RH < [)+=CAYX#
M:TSEX2V:WZZZ]_I\2L[D_K'<6A>3?.A_M.0Y!*\IMT1NM;]Q.L>A(FUM-3WK
M;!&4;&.6\FTC45V L&<DW52=Q4\H=HTC51 2";N?!.F%LTLJ6<;=-'UQEZ9Z
MI=CLW*-CN;4UKZB>J]NZOV58MO=0;C3H.#U-*U6E2T_!2NS%JU$5ZYP"LI'M
ME&D0M V!TZDGJ:QDDVS=,3E#L7N5X_#Y9)32Y-?NMYZ/?/OU7G)[.H/JBP:2
M9[3T51'O(FK[CY)<%]"ZKO5(K&IB;!H'(B^4BE-->PT7!7(B1W%-D(URFI'V
M]0X]Q@#+.&WBJL8Q3_D$VVM8_>>'G&$]\YQE/?.#9,X1[)K^M:[HSI]69.SD
MWYH#A7H2PWM1U!NR5-1C&UV UZ_2B+.H/M9-\RLC!=LLR2**R#4$5E3?F !%
M'U?=O\<_G\7DI6ZE;VP\<^=W.F_V[7>Q+=4.:?2VE^/FCIJF4^6MK%SN11"R
M4Q/7;Y2-;KA$.'+B58V)=1P)42,G2;@>YC]RQW]WZ^?++1PU'5+$FWEXTT?Y
M/XLLAT'.(:=X3Z>Z>VR*!MNR[HB.F4SL=K@*?"O6+1Y&0]#1US9:# 7]8AXF
M-V2>4%TPKL0L N_HV?E+Z09)66LFUUD^OCW?OW*Q.FW&5R)YI\<X3@C6^5%"
MTS":5L[+E]1M].[8]K-7G6\FW2K4(DI.D3A0NC9T#LJ:U>10;.6!5E *)3!V
M>?/U+/5-MK.5C&->^SZ^*Z)>"EWS_P!!M-^]6?C!6K[3K%;M/H<(N0;Z<9(_
M'T:BO;(Z4E'%<:S3B+6;LU'WJJ LS9.EO47,5,2I' H!D:\RTTQOX^?Q\"$\
M1>'KE:>'G+^&.I5YQSXW6;75$Z5VV:M3=AQ.Y'G/^[4FZ6R0-<G,PRU$WCYM
M&"KE@3?+JILJ$R530.U0=-T6'<PCYF$P9),GOAK#2>RU>5VZ[O7Y;$/^5J]9
MI_';DU [1UIN<.=C;GXE*3.\?0M)ZJ.HYS;4$C561KFA(%@E:Z]@U%(>(K1$
M5%6CYVT_*0X!XPW\-5J_K^FN-?@$TVM5RI9Q[EK[WG7.O7KDL^ZB5 V#N+@[
MU<-V055L;NW[0Y?\<-1Z\BB0,F]EOD7C=M34<&E)L&!&QGCF%6N4W?9<ZK=(
MS8Z#91T)S(D]0)[_ *XTT_#P*Q>M/79/7;=/^'AG&N=##5XUQR@UMP5ZL?&>
MV1EWL7-.&V[J[;VT=Y0#B?8N^3O&^VWFF2DG^C>>?'(E%GK4$A:*U*U&&72(
MQ:.",BI*+OC F+)Q33PL)-*+V32>$^ZRT\^_L9@X<[=XQTOJU6W9/&_5.W-3
M\<*9TD;_ +'?T>=JULBG<W(57==1<V&PTRB3;UT]7<*QD,6NE*U(D:5LD1+@
MB45%U%%'7Y_EY\LB2Q%-M/-1;:M9BUJ]M6UEM]L&Q?8MH5SD-PAMVW=<H3+J
MK[>XSVZY4UM)Q:\?/.(NVZWE'\.@\AS^HY:R:J3M%-1@/FLFX,*/8QP[8*M8
M;3Z97R*MK*EL;C5H?A=RDUO2[!+W9QQ^CN,UVK49$/%I0[V\0Q5]3S<W'HHB
MY(QIM]%<\JX<I@+1E(@4PE*4  %AOWY:?33IEO3/37N6<<<("D<7M=:%XX2<
MDJ6_6Z"L$R45D%E7%DM;=#YJOK]X]["472+F24#U%S HJ@DB4/XO8 *].>\O
M'U+G[H^U63=6RN/U:/Q;V3"!?M?5Q>:.^F'&Q*RY1KKM4(R0;H'4;IG?))F
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MJ?TJ4TR)$(DD0B:29"IIIIE A$R$ "D(0A0 I2%* %*4H !0     ,L>9^\
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MGW;HG2NYSPY:\?;NI=<;// $>#(D@SWZG0UK-#ED!;M!?%C!EA9%>"T:BZ!
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M]5XE>5[RLHQG6EE0A]VG!)1A3CUQ"*44WOCX&13@J<%%:XZ]V=_S"+C & ,
M8 P",.TQ#9NUZ)IE'NM7J\5MM79A2]S(+LXQX9"DUIT)1],Y92=25EWC4YDW
M"2,7%NTP,DMW'H>'+]W\,O.+-\M>NY<-X?IJI5(*5Y<1SJO5T&J4)).+E5J0
M>&C N/Z^XI6J^Y#EN*^SRE+^JIM/3VIIR:W7+&2)/9SQGC & >!$"@)C" %
M!$1$0    [B(B/T  #ZB(_0 QC.,?+OX BCQS+^DR;OO)Y^7UFVT'#6L:?\
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MF*8I3%,!BF #%,40$IBB'<#%$.X" @(" @/80^H8(-;KI6_3K(]<K_3C1/\
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M?1]M9;$VEMAG/4MA(M-B;IB$X+9EL;./(R4M:HM']4VD').QA*F)B"3Q$IA
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MU?=[[:?3'T)TX(& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M*^22R)@* =WS\^?T+2VD\IIM8>VB?NWQTWWR;C62>8P!@# & , 8 P!@# &
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M#UBO14Y.G!2;F8V%C6,M,' PG \K(M6R3R0.!A$P&=K+"!A$0'N(C@'8< 8
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M$C'4U&I_F_(PE%VJCYF3\QORMUTR_F-]/J. =CP!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M'C!HF@E&NE4I-J\;ISY\?CY?O$WF3URM,:YZ+S_##+Y\%1@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8!#KE=P7T1S35UZVWZ2_V&IZ]F0F
MR:XAMB6>KZXNSI.0BI1JCLBHPCUI'W1K'OX9FXC228>K'G%S[19('2WFW)3:
MSC&OAJO<]U\/B3!22202300331113(DBBD0J:22290(FFFF0 (FFF0 *0A0
MI2@!2@   8(/9@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
I& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>fhtx-20211231_g26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g26.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2&J4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (8Z^A9 X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%@&%(         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@              R@   E\
M 0                         !              )?    R@
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    R@    !29VAT
M;&]N9P   E\    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M C_P        .$))3001       ! 0 X0DE-!!0       0    #.$))300,
M     !=<     0   *     U   !X   8V   !=  !@  ?_8_^(,6$E#0U]0
M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(               $  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ R@)> P$1  (1 0,1 ?_$ !\
M 0 !! ,! 0$            !!08'" ($"0,*"__$ '40   % P(# @@%!Q(.
M#@8+  $#! 4& @<1 "$(,4%180D2$Q07&G&!%188D:$*(B8G5['!(R0H,C0U
M-C<X1$=56&9TE-'P)3-"0T9(5%9D=X:6QN$9.4524V)G<X23E]/6\6-R@H.F
MMF6%AXB2I*>RM,+2_\0 ' $!  (# 0$!              $# @0&!0<(_\0
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MG^0,%U(_N71:A_\ L/'ZR(=^.UOTHV@X?W8Q#VA_'#Y=O&[L'RQ.*7?EF_\
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M-_F$! =F=F_H_@N[^2Z'S/(#N_'SV+OQVM^E&T'VSB'M$3\NWC<_=B<4F?\
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MQ]0/IZQXH@.?3<=PVSD>G7EMSR'> \I?J/O[^;L>(D=^@[B&VXB&VXX'8.8
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M?6H?8XD/J<3A6^[=Q!=X>>VY]_\ 8#C?KM[-1SN8YX.PGZE9[7&0^ S9T/\
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M7:W5#F,V=\+XV_\ GT/G_@=[P]7%X5LY]-W$#_'+<\^W] //4\[F.>#<*?\
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MS@-]3S04S/\ '<_]#EGT3_1#GXKOH]2?IT[]A$^LG7"V_(M0S?D'I'>Q'/\
MFV'7KC'?R'3F@IC_ "W/\=%+_;^_;#GXK_H]2?IT[]A$>LG7"_<M0SGUN.]A
MM@1S^AL>F,#RW^:.:"F&N-S_ -"1^W^_J:'/Q7_1ZD_3IW[")'ZI/N$']JU#
M>>,^D=[V_P#AO.<8]O,.Z>:"F\-S_P!#E_MQ]T.?BN^CU)^G3OV$1ZR=<+?\
MBU#-@^Z.]XWV#<(V/7LS\^HYH*;PW/\ T.7P_I_%N\D.?BN^CU)^G3OV$2'U
M2=<(1'\BU#<!U]([WV=\:VQUY\^0:<T-+X<GZ/\ B<O]O#GXKOH]2?IT[]C
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M8W%JZ<$F)4BRHM+7@G:BA0F6:D390FU4REEKER:F;*2I"PA(FS%2)29<U14
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M4@&,?R9TC(MIQO<%+GK42[_K:.?/W=H#S]_M^GGI&&GCZQH_5V>;2..>F $
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MB87'SCQ5*%X4PV@9!42>F A(0-*!>H2/ BW!6JFFH0J8H)RI)#A0+LK(2&U
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M!<2K954N;4TM3,31+37T\Z74TZ<1-(4S:9-!+R3DR/EB9=;-+,LR9:% 'R=
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MES;P"E2"J@U&0>GR$V><R4DDC,HG*DJ2+%;*()"20ZDADD;F)$%2Y0RJ&X)
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MBLALA63!\M,HI2,E6)5')FU4RFI)TV4E,A<A<R5+6K+,29JE&6@H4>@%EU'
M[;T$I8,B3B$^;GHA.Q"?)HY=76R)$U:ZA$^7+GS4I"I:N1EI$^8)B0TQ20R1
MKI9_BFM9!8S>]@7(;C0U1<*X3O,69TMQ'K>N2R0Q5:C=4J:U4S"7J_,66*>6
M6IG%0>VMLI*)4$UT$LAAU"9>3[%?@E=4SL-FI51U(I*2733)=7.JT)E3T+0I
M5;3\@G-,GL@I F+DE0+F8$ND^)ANT&'TM/BLA2:ZE-96SJF2N@D42ESJ9:)B
M$X;5]TJ")5,"I,Q1EHJ0%!A)?+,&RA7A(+/LQ#0LCL.N(6Z(FM21'6M3';>M
M[19$P8"$5^!+8.;8\>>O;(]O5(R%V4NS=&32%!E1I;8XKJ*5@^.=D<0F*F)F
MU%*4*6DSEB=5KF8DU3RXF5LM<H2Y<R7+^20$3)Z2S9T).6/=3MOALE,M4BFK
MN51+4),I5/0RY.$'N(4YE8?,1,4N;*G31RTQ<Q%.H*<A"ULLT]K\(?9@Q*M5
M/4,N"G?UB!F/F0ML:MZY);ZKDD"511=&KHN#J\$KF^-TO!Q$C3.K>FD*U4I3
M45*&-.M"A;1DK9+$,P3+J*-4M*IB:?-.JT'#$*JDSTS:-$N64JF\F#),M9E)
M2DEIJDNF*Y>V>&%*U3::L1-4F4:K)3T<Q.++31JIET^(3)DU*D2!.4F>)J$S
MUJ4AU24J:8.%'A+(XK3S..JRKCL$#5D67/@\/:8]#GB/MZNWBPI3*6EYCZV2
M-*"IKDGB@8#K0<YN:FM,GI5D)C*J5:8=C9R54TY)HYM4E6("IJ)DZIES5)JD
ME,B9+FIDS%&9)%LA$M <Y5* RJCOYDJ15R%]VR*1:<+-)2RY%--D)50K"JB7
M-D*J)2.3GL_*/,F+*1F""0M.FW&O?BWG$/=5#/+>,LI:R0C:!L?5DJ+4HU#J
M[IC#JZU:%H<)[=-S:D!11E)!*==<&0;4Y2TMB4"D!70[.875X31+I:M<A9,Y
M:Y0D,H(EE@$KF(I:)$Q:CTB4TDK4YBM3K/-;4XM1XSB":RBE5$H&0A$Y=3G2
M5SDDDJ1*F5N)3)2<IR@3*V<2W1Y-+(C3T*L\L<@'/T".W3';@>6>[H..O9IY
M-/3',@N][MZ;$V W-J0QUTMZD^!GJSX0BR./^%?<[?\ T6;CNW]^N*^$'\E,
M2[)6G](GR]5A'T'X+B^VV$%S\Z<X L/DE /V_='[:[Y?T]C$1Q@I3UWSXX<L
M;^_ AW#K\PHU/I]_>T?LI3N&OK;R7+VMV@WL8P)D!'&>7,>[;KRWYB(8_"%D
M5L0';70==]VMM "_J+ETZ_3W;9'<.8[]>6D-=^[S==V%CH+;M8C(B \]A[!
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M(#]0LP ZO7XN$9)UC$PTA#2$-(0TA#2$-(0TA#2$422"-+$Z54U#34"0P0J
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ME\A1K^+Y*9ID\JI1I$F>#-9&5*95R^:UZUX#M%W9M!2R-J\6FHP?*BCGF?7
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M04E<Q"0IS+6X ).7HDENF&8_-ZE<V53S9LHI2J4@S?E$*4%)0A2BADS);9B
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MS^"&U6H;V%5B<.5,* E:98F"2!F*EYES91FGYLL!( 2JQ!NP)(S*3:,5$HS
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M\/36C,?,IV=^%] VMVX-ZQ&XANBW$=N[7SZ;]=T55,.W41\6D-^0;" !OD,
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M<W HIUJR3LEBP-:I573JY>8B892JJ=R-8@3Q---5B7A\J;+EI1\DF89M8HI
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M">DT4J(@Y6I L:O()235!OBE%UUA(2I7S4E3:L"6NV[KMVQ!(&I [2!H'.O
M7[(K8" AD!R [@(<A#MU$3#2$-(0TA#2$-(0TA#2$?G3\)WX(7B(XUN)NN]-
ML9Y9J.QJJWT4B?P?.GN:H'SX08E#R:K/\@P0*0H?,S*'$D$]7PB)U55)OE""
MO%H&OZQL;M[A6SN###:RDQ"=.[KGS\]-+IERLLT2PD S:F4K,,A?H-HQ.[X=
M\('P98YM7CYQ7#ZS"Y%.:.GI\E9-JD3N4DF:5%I-'/04'E!E/* V+I%G\\ ^
MIS.,O;-V>&@>W[*+H8'D/(;3#C?<?:.NKYV]G_!^,/QY&B<_[<(XCF-VIO\
MA+ ;_P"48AZ\.AZN9QEY#[;/#1@.GQHNA^&TP_R]_74\[> >#\8_U5%[= ?
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MTA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA%#DOYP.O\
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M6H+ &^H[6>[\= 1P$9/OOQ*WLLPCM"B)@\74R.60!WD<Q.4)*%4;^/3'3$"
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MK77GDTD<$,U9S%#RB<I2VP1P2)EZ8XARE'FRIQ/GN>2,JR2L+<@)5E"BI)4
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M[!5@0V ,YR XY@Y3F!5=1!5T@D[VU9[/8=;B^2-3>[!@0Y+G3Q7>PN2#%2(
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M@8-(@.B9:U?FD!B7((!"=6+7(ZH%:1O!+@$ BSZ/PT.K1WJ[M6KH;%[W7<N
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MR,<$3ZA9YA&5MS8C'8I<)F:HI/(W9VTJZU+%+HZ*\%<O<U;&3<Z1QV/W$F2
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M ,U>_7\Z*!1T@TI:8=DB4/\ ]8? [3^U;=MN'XQ3<^W^E:=T3_[_ #O]8O\
M^43W)2_X-3_ZF7_\8D&EJ <@V-X#ON"), [\]P*Z]=.Z)_\ ?YW^L7_\HGN6
MF&E/(OK\C+O_ /UCE\&-NP_!Z'(<A\T3[>S\3VU'+3O[]-X_VQ>O'6)[FIQI
M3R1_Y4O_ .,<@;F\.2%&'L3$!_\ TTY:=_?9MM/E%6\\.YY TD21_P"6C_XQ
MR!"B#.$:4,\\)R0S[<4;ZCE9O]\F?75^N)Y&3_>97^K1OUW1R\S2!R2IP_\
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82$-(0TA#2$-(0TA#2$-(0TA#2$-(1__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>fhtx-20211231_g27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g27.jpg
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MUR$Y455XF+>2E-,D(B4Q-$$C<W:R)C(V-SAA<7>TM;;_Q  < 0$! 0 " P$
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M R?44=:MI@B4:-!SX>1AA&LI5RK$LR4155;5E)515L2U4G+;K(BKORM4G<W
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MS0*YMSW,G^IP3T8,==,7HI.4KA5_2;HD*Z.7N76]47:_Y;D7Z223-V/W)%<
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MN4YSEZBF\H[E97M\RWAS#FV@!,0.(F\XVOJFX9(</R%I'U,?;E-U,ZB65Y2
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MLYHJ6ZD196[;>M"R>(O^[XWV?T;;GO\ "4XH2C^<H_KL_P R'B*;_P#ET/\
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M'B*;_P#ET/\ W*7_ ,EM=OV=2?0G\#I<W\MKZS7\5/M5,B@% * 4 H!0"@%
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M":<RYH:6Z7#]$(AF:O)$^=\FV%34MO59+7]NR19-""@% * 4 H!0"@% * 4
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M?W3EQH[<G;/\+LZ?A, _4"FBZ-]^A7O'O@QI8@/<(O[IRXT=N3MG^%V=/PF
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MY _5*FB^K_>HOB'/@!I6K'W2#89]_,!VW^[3[C[?_E'('ZI4T7U?[U%\0Y\
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MK0*3>J]:K<Q)'.BC?1R*?)<[M6Z*>>LJV32Y.WE.4L%2Q4MEZY3_  +)H04
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MD7_!G([5'?K\?''ASB+R!5S#JG=*8V(\832%7"^%P,,X(=JCOU^/CCPYQ%Y
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M7Z4%]#I!VBO)D.><F@*FI;>JR6O[=DBR:$% * 4 H!0"@% * 4 H!0"@% *
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MTVR!(\Q" NC'/3R,SYES0LOTF,Z'2#M5>3?\[Y- 5-2V]5DM?V[)%DT(* 4
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M2ZY2DGV^K5/'1?B7L\EY/P#CO&V+%7R^5,ZR_#LX8R&6B@TSQ<\B&"\L9A+
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MK/;JU63UF QC/L\91X:)F3#\WR>+9Q*9<SA XSFJ\5&SIR.J"-[60<3Q @\
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MR<S7<-'L$S/"$4BJ1G.>XG;VYE,9R^7F*C.;X%QL!RYJ30"%<10FUW%9+#I
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M+V8F4TDK5LU6K9_J:^U>M3$D=J6UXN3EQHMMPP05+3\$(B\Z(D\1P%^\F4;
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K$[VEB:ZR3K12U@YUUN;VV>III?Z]HK,YI)9>O7L-AJ$% * 4 H!0"@/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>fhtx-20211231_g28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g28.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2(D4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (@B^AQ(X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%>T_@         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@              Q    E<
M 0                         !              )7    Q
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    Q     !29VAT
M;&]N9P   E<    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M    5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   ,0     4F=H=&QO;F<   )7     W5R
M;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53
M;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /
M15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N
M9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO
M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M C_P        .$))3001       ! 0 X0DE-!!0       0    #.$))300,
M     !?5     0   *     T   !X   88   !>Y !@  ?_8_^(,6$E#0U]0
M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(               $  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                                        9&5S
M8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A
M8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'
M0B!C;VQO=7(@<W!A8V4@+2!S4D="                             &1E
M<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V
M,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I
M;VX@:6X@245#-C$Y-C8M,BXQ                                  !V
M:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,
M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
MGP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P /8 ^P$! 0<!#0$3
M 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6<!;@%U 7P!@P&+ 9(!F@&A :D!
ML0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"% (= B8"+P(X D$"2P)4 ET"9P)Q
M GH"A *. I@"H@*L K8"P0++ M4"X +K O4#  ,+ Q8#(0,M S@#0P-/ UH#
M9@-R WX#B@.6 Z(#K@.Z \<#TP/@ ^P#^00&!!,$( 0M!#L$2 15!&,$<01^
M!(P$F@2H!+8$Q 33!.$$\ 3^!0T%' 4K!3H%2058!6<%=P6&!98%I@6U!<4%
MU07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L &T0;C!O4'!P<9!RL'/0=/
M!V$'= >&!YD'K >_!]('Y0?X" L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)
M$ DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS
M"PL+(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-
M)@U #5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z
M#Y8/LP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2
M)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P
M%1(5-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8
M&QA &&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC
M&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY 'FH>E!Z^'ND?
M$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/ A'"%((74AH2'.(?LB)R)5(H(BKR+=
M(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G
M&"=))WHGJR?<* TH/RAQ**(HU"D&*3@I:RF=*= J BHU*F@JFRK/*P(K-BMI
M*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP
M-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43
M-4TUAS7"-?TV-S9R-JXVZ3<D-V WG#?7.!0X4#B,.,@Y!3E".7\YO#D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0'_P  1" #& EX# 1$  A$! Q$!_\0 '@   @ ' 0$
M      $" P0%!@<("0K_Q !K$  ! P," P,%!PP($0D' P4! @,$!081!R$
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M38J(Y=R7*2^/?5O\-ZE\T6E^!QG[0_X8/7;@8LOB*R^\<?\ 53'C)$+W9/\
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M96'&E@GQ&W'P':/L;#[5),?2>TH:BNCQ''4(_P!>C/CU"-\Y$]GX,50]I.G
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M UC@)6>$IF02IH#*XS69:OAV%$-@!^8 M E4(J!*:RD9!0;QY8=I'5>X=/\
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M@3;:)\MU[9=F=N=H:7'@N1M&T9QQ]\!\N.QU=%Y[SY"YF0Y-Z2*&1CF61UW
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M]5K*Y^]?;9__ *9H)_VZ7_6Q_1'-63G]I]E^@_6M3SX^'OCMO_-OP^VNTO\
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M+$29MHA *O%5OONNG-H Z5[HD2*"Y@9*AYRP0>@/CZ3OG;Q&_3U\-7$ )+Q
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M3P'94.\.Y2=ENL&\^>][IH5T,)?W0O5+O)CY#M0W_:_I\/#[4C?1_2[V?[O
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MV3.:EHCV6=11D*F6ZDCJ/+91P<^E,/!^;Y^AXSU$OA&-0;E\,N!F$%6ACA9
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MLQI.GWZ5'XCY.#K!E\16D(S^PD'\;=./'^[GP/"Q"K9=OOWE/FJRXL]YT_\
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M4G3ZCM.I%PU>B4!J-3:W<\YE;_?(AOW2Q<-/IJ!'#3]-@0:FETHGM@52]*F
MI6:2!%1>=][&ZCD)2MEQ"@"%H*<'/B.NQ!VZ[$';8@\4.T*R,CODDEGM0*U$
MR!B6\:KMN^N3=2-96'*A,9CV]JA=5*BH:FRTI,=**6ZA02'L)[L(*4H',,.*
M5G/7DTQXN:/%>=D19(R&L=SJB]%NW4V'-8GPAVN82DI][SQ!:W,5NJO--/-U
M.I*0\@%L^72P"20E7]?P !D@GQ&/^MP0S%>AV@3?21,J$Y*D]J-V0]&UKEI
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M:L)^!5Q@*(&U*E^/I^I#PZ^/IZ<4:/WA($**!+Q>H++8(KZ_,?+%&EIT0OU
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M8-E7'@';%*F?/@=V?9G'&PBG<KF=V"9_)MVM_%0I0?(4Y*-C'Q1ZC_@3<?\
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M+%_!BZ^F?M.F?[2^CT^'#6P_%R>]&NJB>'^8>K,=KBQ=_P!K%V=,[0Z8?_\
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M?VCICVC:%I$4$JZ'" "E8CCJ+9.)4H5H:JWTW8?8\![M/0C'<<CPGHUAZ 7
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MEA(,2&0C!251D*4"-P02-L* 4-NHWXUOPW7T) )$E.$_FV94W\9_-IPID$
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M=<>?*AN18TN)$B&DU>@4FH4^I/3HS'D%895<=-F)I<Q+#[D-Q+OFEQH+$@2
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MJEB4W-C08EO7?<+<J-&E0VUU)B:W9->B1'J?W[#LF') >(C. Y6@0)+),"H
MV\98$%&===?)E8/;;T7NJA6W4[@KT*R*I=$IN-2[;JTQ<ZJ8=1%[MZ<F%"Q3
M&E/S(\8.5%,5GOU%(=/*H H)P%+LTNQJIOK>SKT;(9G;4[,L"+4)DG5:AMQJ
M9/;I<MU4:KIY*@['\I:80TJG!]Y+C(6XB0PT['4AMQ7>!*">,93G2F>&Q64]
M+VO3W:U[.T9V<T_JI;*%4VDM5J:M+LI]AJ \PU)2M,J/%=C/2 T^RM<%AUR<
MV'$=Y&22!Q4&.%W&^[]&-6VKVCM.+WNJW+=M2K-5J'=U$K=6MNX(CF*;49=M
MR U7J&I#S;4B+5*8QF6^S(0E88'-R#(/%D94E>E1A*2[17*9M'=LCM/TCL\I
ML557NDVPBZJV*:QF,7TREMJ;4M)4E"N4%M1QTR/.XYHD<N/V%(10* @"^=Q6
M7"56U/177"'34K4@4ESNXT;/Z]VKK#L_6#2?1&OHJ35>U7TYN6_[?K_=(30
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M7<H25?JQM21?<SK3@-1J3!U0N2-:CKT.77+?]Z*:\[49M+8N*)29$6L..B3
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M)F-K8\H0"MLG">[(<YAWA1S#E)'*.4DG.P!STX!TGBE^*8<<&-JJPM9[<O\
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M]#J2HY0LR4B*4I,(05"@D@+A(L:)N,ELA*%!Q*\K0%%'U)20P6BD!I(4A'<
MAUWO9"#R\CA"B$V00IB)E!<111O*DR-)L:!NGAJ2M]I##:G  I?*"IU23SJ=
MY0@.!YT.OM!UZ2_Y,RVREEO#TA/ !$...),D(,UG4E!D2SKKKS:P770[3K\>
M*W=D.D3&F'7?)4U3N^7ODY3(+'.ZR,J2/22 ,J SD4@$+@OGFE\JBLFVN%YU
M0 \00";-Q-">Z]-,IYHU_:7SI;* A4<!:60!RH0TVM7=N)5RK"VG&"A2% \J
MEMH\[!R,0"0DP -U56H7:) Y%M31=TTVI9"6^90)0$A*EA(PE1;2EHN$@86K
MO"X$N92GS"#P0"Y9C/>4G,(4GL0,9=V0L%2"L<O>MNE#/*%*/(XH#NFG&GE(
M'>.$+ !40%;!/%0X"<J))0%( V$@FB[C1-L);5S-=X7%<OU0!!#B4_8MK6EI
M3:4)2?-V0O/V2CDGBD#$K=-"<E1.%Z+4,9EI*UA>2'$EP\RGU.!#P24EON@X
ME!^IDE22,9).Y"2,44DWK)"J%%1#*23FDD"4!J&/28,3RR1 A1(CLP]_++#+
M4<S'D<X;=DI;*"LMA60MQP.+"MW"D<A &91!L*F> *A#1$X,:YK2DMH!Y A0
M;;2 H-(0$J2.9KE"@E24@EM*2<$) *=SP0!75N1**5!4&DEI>QD['4X>9(;'
M,DI7DY&%#F#BT%!4XMEQ*5-#O&\!;GV) !M$(HE;R)73)(N,DF"$J9KC+4M3
MK;@)Y2IHK4\G+BEAS+@:6A"FTEJ.$)+:E<B'4*)#[I5"\ 3*A.\\1*DIRE<&
M,O(N7NPVI+:4 I)0EL*Y<MJ24EQMX@I[KNP@%*$M.K">4M-'B!X9C$A ?I2@
ME/*9H)-*A2VW&I42'+9<4I18F1VY,?"HAAE*6'4J:0E314VH!)"FG7T8P\L&
M**HIS$LI+<0!>H5:HQ/78T#U.#B"TEN,6U=VI:5-I2%.,DJ;YT=VMI:%'D00
M6PMM+86A:EA'=K01$J*R&*2$K\)8DH6GGZ<6F+@AQ94ONU$!)1SH[SNE\R2M
M*4_4T*;PA"F^\2HH='>'F( XMH&J^BU%< $)OFUZZIN:),(I7MW7=^<E"4H6
MWW3:@ I"4!Q3:N<#SB$M[[A.^ M!09RI0)NH5OIE<AA4-0*E-EI//]DA:5K0
M2!R!9'-@>8 %H0AL.G)<6KB6JHH6Z[>I,R*XWJQH!"40D*[L$8RYYJU!*,@(
M;0XP6VDN(/*OE P  .?&3;0SHF*"4IE)I5.-QF8 4I+BBDO8"5O%+9<Y$I(2
MD'N@A605-E00VH-+6E)!.>):&&^_C0K?*<P<6;6E.4P/-N,R/)Y4=Q"T+8D,
MJ=2XE;BG.[<4\Z^%-'S M#C;H5RG 2E00@H5>(25YDI,B:RQHJ,:K3'6$-ME
MQ*TI*N]*VTE3Z5(6E7.0 $K6I7.HI 2-TI1R;<96G<#?A>$Q"8RSQ+&QRWK+
MH%K(FMT*E0:<*CW3LTM)6I<E]"%-J[U:\J+?(I83C<*<6HIP GC%1<"*7[5K
M<1TC.NI#JYLB5$RZISG"N<I"@\.\ :&%%EM"2TE(2ZE+S;SG?.H<6Z 0@I"5
MH%%7>A)&%WS*S64S,10E 0A2TE*G%)5WKJMUE9!5WBG"H)*R0DGE!2D#" $B
MVA1")$ C?<N=Y.2*QI;L-:P %M@)4"E*4=R-E)P'%(YEJ 0E((;4SSE 2H]V
MM2 M!")H<A+@1=]55AZZ",TQ"WR)04\C;80@GD"D@@!:$CN5 ((0D$A65<Z\
M@<J.%H%%60R,]XW[=C&M\Z@0:B[#=F0X4ER#($N*^^PT[(B2FPL(?C.+9*F7
M%=XH.+BKB/E&4=^I"UI,4*J*N(P$K[S,H!A,,:Z(86 KO%I<45\R2DNM) V.
M,=XX<@YZ*"<'EY<#)MH3K.J(/F3NI=)C2G(?>*"R49Y5H4%)"SRK!2>[6I)4
M@J!PLD**D?4TE RHQ0MZ(AD%OHJ^?R8TING!LD@I;0IM"%--X4VH-(4RR%!U
M"QRI;(5E 0YS@)<<>0!@KM4N3D@J2-Q!3$L:9Y&L.I=2L!0;*#N0!@\R>1(3
MR@E>%EQX2%(Y2A PXM1MH5,Y8#: ,EJ2"<,6-&(B>4H\WDYW7.4\ZR5/]X7,
MJ6I2@.=UQ:0D@)"PVD)0@ K01 "+TVA*DG.[A5C2VJ>TQYC*6V6<N+7'9:;9
M9<>?=+TAY32$<@6\ZY)>>5@J?=E.K=)6E*^%H8%+A3RR5935+@6-&(92V\$E
M"77EJRXVE30#7>@,I"4+QWC$9*&@O'GEM)(",HXBB4MJ2-12<T22WS-[.ND9
M+A]\D)?PM))4M"5+0.8\A"TK&'4N-<G*TIM37FJ5S> %+SIN,T6EWI,7*K&4
M6#Y*V6PM)YE]Z2VDMH[Q:@IY0;RM2B\OF<<6\\\XIQQ:^<9 "T) C$XSV%5W
MK4HC&3D-:TDDI6OG*N11;[M25+"@VLJC.**(YRM@!(/.!SG!)$#P2:[$")O!
M,IHQI4FEMR IEQ+3D-ULM/QE( 0ZDI4E274J2ZR\TL*(6P64(422X7!YG D%
M*I>E?-*K<&-#!HT2F,M0Z=%AP8#)668<5D1V65*&ZF6V TV@+/V;:4);'5(Z
MC@KJTE.28WU] +@QICT!;SB5$1^0)='*L/. J<0E(6M!=2V^D@%)9<3A)Y'D
M+YT!)6A/>D@3=68!I?>DRQJD1<)"<@I#G>!*BM7G E2"%J6I8PKE)"N=!"0G
MD"=N,@^%,I5I.JB_%3M,D8TL0U)W2YA7-SC*6RA)Y<\I"&VUK1WX[\Y<2HKS
MN$^9Q+0SK@,+T1>],BC&EN4UM]M3$I#4R.ZHJ>8DH;6A6%*6CF :"'@@I9:2
MEQO/=)4'5OGE' O*!*F,^L.*S0LZ+5<=MQ">9[NPZM*.\#146TJ&?,25!)6$
M A >4A"W$)3S(1RA(R=*KN67EZF9E@SKKK:U1QC8.(Y^C&.%@XCGZ,8X6#B.
M?HQCA8.(Y^C&.%@XCGZ,8X6#B.?HQCA8.(Y^C&.%@XCGZ,8X6#B.?HQH5C*2
M,9]7IQOPL/8CGZ,:V5!\LQED!0Y4Y&R$I"@KS22X.[ *L!(4G[+9)!W&QUU
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..8X,8X,8X,8X,8X,;_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>fhtx-20211231_g29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g29.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1AZ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &%Z^8C@X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%>3$$         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             !%P   7(
M 0                         !              %R   !%P
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !%P    !29VAT
M;&]N9P   7(    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M+)>!8"0(9^<]LKG*JZA]>[K';@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                            _^$_6&AT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED
M/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN
M<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@
M-2XS+6,P,3$@-C8N,30U-C8Q+" R,#$R+S R+S V+3$T.C4V.C(W(" @(" @
M(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G
M+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT
M=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R
M;V1U8V5R/DUI8W)O<V]F=,*N(%=O<F0@9F]R($UI8W)O<V]F=" S-C4\+W!D
M9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS
M.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @
M(#QX;7 Z0W)E871O<E1O;VP^36EC<F]S;V9TPJX@5V]R9"!F;W(@36EC<F]S
M;V9T(#,V-3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.D-R96%T
M941A=&4^,C R,2TP,RTQ-E0P.3HR,3HP."LP-3HS,#PO>&UP.D-R96%T941A
M=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3 S+3$V5#$Q.C(P
M.C,P*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A
M9&%T841A=&4^,C R,2TP,RTQ-E0Q,3HR,#HS,"LP-3HS,#PO>&UP.DUE=&%D
M871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM
M<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @
M(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E
M9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E
M4F5F(R(^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/G5U:60Z-S8Y1C4U
M-$(M,T,P-BTT1CE%+4$U,3,M140W0D$Y,3=$,D0X/"]X;7!-33I$;V-U;65N
M=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C$Y.3DX
M0S(U,4(X-D5",3%!-C(S0CDS13,S1$9&-C4P/"]X;7!-33I);G-T86YC94E$
M/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-S8Y
M1C4U-$(M,T,P-BTT1CE%+4$U,3,M140W0D$Y,3=$,D0X/"]X;7!-33I/<FEG
M:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @
M(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HQ-SDY.$,R-3%".#9%0C$Q
M038R,T(Y,T4S,T1&1C8U,#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R,2TP,RTQ-E0Q,3HR,#HR-2LP-3HS
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N
M8V5)1#YX;7 N:6ED.C$X.3DX0S(U,4(X-D5",3%!-C(S0CDS13,S1$9&-C4P
M/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M=VAE;CXR,#(Q+3 S+3$V5#$Q.C(P.C,P*S U.C,P/"]S=$5V=#IW:&5N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA
M;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P
M<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO
M<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T
M179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E
M<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O
M<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HQ.3DY.$,R-3%".#9%0C$Q
M038R,T(Y,T4S,T1&1C8U,#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R,2TP,RTQ-E0Q,3HR,#HS,"LP-3HS
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES
M=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^
M>&UP+FEI9#HQ.#DY.$,R-3%".#9%0C$Q038R,T(Y,T4S,T1&1C8U,#PO<W12
M968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^
M=75I9#HW-CE&-34T0BTS0S V+31&.44M034Q,RU%1#="03DQ-T0R1#@\+W-T
M4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O
M8W5M96YT240^=75I9#HW-CE&-34T0BTS0S V+31&.44M034Q,RU%1#="03DQ
M-T0R1#@\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X
M;7!-33I$97)I=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^
M"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*
M(" @(" @(" @(" @(" @/')D9CIL:3Y'96YA/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @
M(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QP:&]T;W-H
M;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD
M/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_\  $0@!' %Y P$1  (1 0,1 ?_$ !X  0 !! ,! 0
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M,A],O)1<T1*(M5_5_P#\L[I8_P#9/U!?^^XZK;U]/+ZK7HZ]?D6GOT7U7?\
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M[/#X$"FY@.]NN.X-YQS,Q&DG\8[_ &%M202$I^)VC25=R?C7P >]*NT:_P!
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M&R"#O[#?TK=T<0'4]YQO)(R YBYGG&9@KJ>TJ)HXG#T:+!NU:#JIEI+MYKH
M:1 #2)!$'0R"O9?>IV^8W8+I>9MAARQ;HJY"@PX&_"3KN*5.DZ&]D;_UUMZF
M/<QY:-TB^?'3(@6["Y#9.R6X[>%;?81>6VL,Q!!SX^<*^&>HN-Z+3DRR2&.^
M%\:?14E]STU+'I@-A6M^E\RAO?N1O6JW#<;3%-U6I[K1P(L2;3)'TOP6TQF
M;A=H4\(][A1>"#5< TM=N^Z23#0-XC>U )BXA6=Q_P!;/%.>9"K%F7KI;+RQ
M9;1>7T3;:\(_H7*Q6J\N .-EPI4TF[QVPG1)4E2?!WK:/VM3%3<:6BXS(-B)
MC]5K$$&\SP,KLFT_ 6V]D8*GM'%T'MP>(+AAZAIUV!VZ\-(WZE%E-Q:2&NW7
MF#G)$&;\9YOXYRQB6[9\DBN_!3+C;Y'KM/10F;:I#D28R%/H0E2FY#:FRD$G
MN&O?P-YA\4*I$N %YM&6LWST&>EUU3&8#$X3=WZ9;[0$TR08,1O"X'Z9$G*]
MB<U=R<VQMQ<A#5_LZU,,QY#B/C&0XPR^M325O(+@*4K=;=2G>CM)'N*U78BB
MUS6[[228LX?">4GTLL:.S\=B*=*I2H5',Q+GT\.YM-Y%2I2$U6M@'>+28,9=
M5]]BXQY.S'>;?2E2T*4TI*TA;9TH$H6=$^P'_4:U6/;4$M(,D@7&G?'R6UJ,
MJTYWFD7+?TF9;9POE!!YS9>D/'N/=VI'@ $Z42?MO7G]-U20,R!I<B_3BKH2
M 20)-K1IS'F/W!U3G:6RGM[M+!\GM^I&O;Z:]O\ JR(C7,3;L+!K@X&9#H,<
M)N!G-LNRO1462X/L=$ _3?W/M4,P8S@QU4D<1ZJ@!SQM2?U&C6(+SH!S@_"5
M5RLJ"%%.NX!13L$C>CV[ \GSK8&OT_6^]!_3.F<>:A,#,#A/?R7SS*?;9*W.
MP+T-?+VI[CX]B=ZW[?6LF->X@'=Y[L_7E\>2QJ/:RB'S#R+@W&\<K 3&N9M/
M5<H?EJ0@$(]56E#:%=O:".[QON]MZ^Q.SXK*!O1-N/0?=/?-%KQ&^8WA!M>\
M 3IG.I'%?2K%9I1$HBUT_B9\IYUQ7TTKO>!<O\<<$W?(N1\/X_D9UR+AN2\@
M($7,9\_'6[5B&#8]$>E9-FL^2[ EVF'<XSMC,.%/=D!^.$2&])[LQS&A^/&_
ME !Z%I9P3\*'IQE\U\O8;QOU<\IR/Q,\$''7+5SY =L<7A;$$6&]3;=<Q/MN
M \?6&W6&]8I>;:NXV^YM(N=TF0KV&6I:(B4*BJQB<CST&4<3PGA;X4G@ )GK
MWI\M9_559HTJ%:+7#FOHE38MNA1YDI"2E$F4S&;;D2$I(!"7WDK= (!^;R :
MUA8!165RKR)$XKP'*<_N,-ZX6_&+>9KL2(H>O(6MUJ*RTI:P$,(,J0REUQ/K
M+;;4IST2$$&J3?OL:<9&2Q==ZO\ (4XI;'&N,[<OD29G^3<?2,;7G$<8C'N>
M'XI'S>\/MYPU9GEN1Y6/2/3M3CF/,MR+VVNV.*:;[9BBOF+Y?'UMPX'RQXYO
MR1/*O57T:WK'+;<G',BZ>^7\U1 5&)<CVG)XG&4R(PX^E2FE2F"^$/*;[F_!
M 3OS6VKFX'3IK]PMQ1!W9Y\8X7R(BQ!%\CR4PNX#EB6)*5XW>DNI2MCTTQ2X
M?E7&;)[Q\JN]"WG$D#Q\J3OM43QN)H5'-D P=3O'(P<@8O;.1K=<KA,;1P^&
MV@#NETX:)+02=YP@2YIR,ZFP(FRA:T\8<C#'>"&SB%Z4_9YL63=6TPU!45;>
M$W>(ON2I94A'QLA*4A0*AW)025>3L*.%JEX&Z0<C9VNN46ZW%QJN\;:VUAZK
MO$30]CA[+9@:0YAG<]B'Q%0W:6P[4&Q4@\B<<YY+PG)8T'%+U(E/VMYAAE$1
M16ZHNLE  WY[4+<*M:V0"  -'=XG!57,)W2;:APZ >[8$7SYKB-B8S 4_$&P
ML;4JTVNPU7$.)+Z32WVF&J4[W!$[P:#OM!)B3K%ETXKY&=MW(R1AM\6_.L>'
M(B=L,D.NQF+4E]I.R3W-*2ZE>SY6CQY!KCZ6"J[XLZ =)\S.Z1<"VMEV>AM3
M9U+8_AC#_F:4X'Q!MG%@>UH[S6XA]1P</>$3O9PR;^^3,3F./\V_+>TXO=P6
MK860T8BN]Q9A%OL!*@.\*(!)&CO0&JYC\K4;1#0#:3$$P#:]A]>JZ0S&89NW
M,36IU&&FY[W;V^PMDO.3@[=F^A,S;6?A8+QOG,/#L<AR\6O,:1&A*9=:<B*"
MD*1*D!"5;(&_2]-1^Y._ T!LZ.&J[XLZ>0=.8UCZ9+:[?VBRK4:T%KHS_28@
M2 ??^F64*.LGXNY$D<Y\>W9&&WU=N@VJ:S)EHAJ]%LR&;E&4A1)_C#<HJ!/R
MDE!/<-A6%3 5'[4I/(/]@T3!@14?:0"+9G(Q?-=\V%XAPV&_#7;.R*CZ9J5L
M=B\0*9=3D[^$PE*=UU5I,^S('N$S8.X7S&X\SA'(]UG.XQ=VX;V#6>())BE+
M29,/(<D?]%1*M;2S*86H[_\ A$CP#YU,5@JK:[  3.Y!&\9]XD#](N0)YCS(
MZQB-J4:7@/%T:3F&I6QE4BFTM+R'81K+,:^2);&1O!NKS&%9=^[7^SEU6E+C
M.EHC]R-N.MJ<2=*T2ML$,C>PK15WC8.\VK2J.PC6B2X, (&](( F1&A$01F+
M\#U_"XMF%/AW% M#A1V::@]T[A:6.>''>;ND20076.>A$$].'%7(MFP2\P[O
MA5_MDAWD#/)K<:3$T_\ !S,EGR(;R]=NP]'<;<2>T!25!02/%;#8V">QCWN!
M;),3,$ZQ+1PDWM)&B[OX]VI0VKC]D$5&.]CA:1)WFN@^V>X3#WS[IG2UQQ57
M._&/(UUMMK1:<-OUP<CQ<B2I,:W2GRER3#BML)68[;J4]Y2LA*BE9\:&M [+
M:.S\3B<4',8\[C2PD"I8S)'Z'"8.4B^D1'/?AKXJP>R,=MJAB:M.FVOB :3G
MOI,#PQFZ-TOK,)!R$!T\<U>_%_'6>0, Q2#/Q*^PYD2V)9>9DVZ2VH!"UJ1H
M/)94?"EA1 4#X]CO?+;.P-6B!OAS8(S:ZP&<RUI$3<<)TA=(\7[2H8_Q;6JT
M74W-<7 /:6%N5X<'N%K\(RS"OU6"YGX(QV[GN]M05DG^7S^=>/;^[VK>XUKB
MZCN@V#Q(#H)WFP+6(TN)FRZA5J%NT*MP6N>T@_J'Z&C]4P/CZKG]@,S5O>-W
MA22DMJ[8:D%+;O[M:AW*5_#W@GQH>#YU6#\-4<R"'$D'.3 RU!S\R<H-XW%6
MO3I8BF]Q!W7 YC*0 9)!@:F8T!LH.F<9<B)ZCVLC<PZ]?EB.#YML-Q$0IB+O
M!RQ$U-O0"LD/N(]0MI[R>U!.CK9X.I@*OM) =<F;.L)%_P!'$#S^'IM7Q#AA
MX1VC2;49O%^!W6AS"2YF(HV/\:?T;SOTR!<D"0I X\X]SBWX#BL.3BM[8D0+
M#"BN-.125LJ9B,L>BZ4D#UN[Y5$=NR0- URM'!5-QMHL!DX$DW&;9X\>O'K?
MB?:E"KB,<YI:7>SPH%V.N*= .; <9(@V&47B#$:O<7\A.<-MVU.&7]4]-ULK
MBXJ(WSH::R.WRGG"?/@,-K4D'V(/=W:T=!V!J[E5H:1:TAUYRS:9'"UXF-5V
MYVW<*SQ1@ZK:M,BG2PX)#F #=P9F3[01!L0;_21>.>.LXAX;;(4K%;W&E!4H
MNM/1=J0DRY#C:CI0_B1VG>_8^-5J[*PCV;Y?(!)'O2)Y>\+_ #Y!=3V[M:AM
M3:6TB7L+=P;OO,+9]X0":CY$BT3KD<ZXW'>=IY N\L8O>/A',<@1TO\ P2E(
M6ZF0'"A/:L:4$DD_IH&M+#X2I3VEBSNDS3$0"1=[?^SG:^G#-;7$[1I/\);.
MP;7-!H[6Q54M+FQ!HEHL'F+G/= OGF%>B./\TWH8S=R=;U\$M)'T/E2SY]OL
M/UKE/8NS(Z'=)OUBWDNLBJV8):;38B1U!/R5?[ 9FV.Y>,W=( 41_BBCHA)4
M![Z\J !'C?W'O6+L.Y['M:#=CL@1%N0-C8%:E+$4:56B^I&ZVJPB2P0X.#@?
M>-HB9SS@J .&^+^0[5?>5U7'#[Y!9G\A9#,@.2(:O\9@O9#?I4:0D;&@MJ4%
MJ)(3VJ&@/-=<V;@:@QCW.#@ 7F^] !=/^CK?62O5OQ \28;:E;P=094IN;0V
M;LP/(<QP9+PR'$5GAI !)) #0)M*GDX'F2B2G';LI)!*5)AK'</<'?>1KZ[&
M][.CYU7//PKS6WX/]F0(F,YSW1<\9&65EYEB,12;M#:M-I!8:F+<T@M(/O.
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M8 DV(N8"M1'4;PQ-43%Y+Q%P(1(<*?SZV;48@<<DI\3.W_%VVG%.I.M!!)4
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M;Y)CO-W)V:U*0RZMDMD$AO%H]Z9O?B9GN3:>80\OW/>=LM25^BQ (2D%2ED
M?,H *5^I"4I )_1('Z5K"P["+Y-YQ^SY%;;E9[[ 8NUJNT9<.X6^<GUXDB,X
MDI+:F%_NTD [2XA*7DJ"5AP*2DBHH=5TQ<%JQI.(*P&'^0H>:DI83=;^U/\
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M)FH "#<-@S[H.4Y'.RJ8B-QUN.(4XI3@2#ZBN[03O02= _SV3NH0"]U3_.<
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MCO9U*EO82B3N@-<-\%MS<V8&-Y3)&^_H&2A'2EPN$H2D+Q^2Z4A*4 *3/DZ
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M?]TY\PN4\)_WC^(&=_'VS[Q_V6>6N4Y@\EORZ"/^2GPK_P VY?\ _(2:]/\
M"7]R;'_V1W^\J+XN_I"?\\'C+_;J?_I<.LW*[6O&4HB41:9_Q=9V <E\063B
MNW<M<"V[E#C?F'C#F&?PGS3GEIQC&^4L=QJ;<IS^"Y@R[-1,CV;)8CC=WBNE
MGM>_+6@HM&2A2=)T9:R3\?3*#Y&\J@:QQO\ "V61CSA8&?@G<497:^;#FV7W
M'IRQ.3A/ ;G$=KX]X.Y)M&=Y%F-M_;>1DR<WS=FSRW(%L@8VQ<8F-V$-=ZGH
M#K(=;2^VM:L69YY7\O,_&?*)2?F3ZPOU$I(*01X! T/'M_0D?V$UK R)XJ*J
MJB418.<F_P#+VZ7M?^A3J-__ '7&5%B1,CB!\S^_[9K..BR2B)1$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B*E:0M"
MD$D!22DD>XV-;'ZT4(D$<01;.ZH]( ) 4H%*0D'QO0WY]M;V=_THJ+ #@J5M
M)"'"-E122-Z\$ D?3^6][\4,D>4?S6+1N\_49>?RNL'^IGB 7BXXIR%CUM<D
M7N+D-@C7\,AM 39(#.17!V:Y\GS*8>N)[E!0!;T .[5<+M' 4GT'UI>'M =:
M-TQ)-HMRCAF(7IG@3Q/B=F-=L5E&@ZCM+&_F*E2H7>T:_$,I8>&$/:/=%( !
MP=[SCG9:.,"U\;(5]?5SQ/Z'5JO0_0^PKS?V[G.KL+6@-;5W3>=<[\25]P[>
MHM;X?\$M!)%'$[%8).8EHDP,SNZ$3.0LK>Y#/;>^.-?3@@#Z[U^6GS^GM_V5
MP]0_X?A#_P#DF.SY!P^BWGA(SM'\0)@?^T# ?)G$P,M;'R*WY]!/_)3X5_YM
MROZ_Y0D?ZO/\Q7I_A+^Y-C_[([_>5.]%\7?TA/\ G@\9?[=3_P#38=9N5VM>
M,I1$HBTA?B[]!F'\X8!9N:<#Z7L%YMYDQ+F'BK+>1+3+BPX>:\G</8<_-:R'
MC^SY%(>83%EW!EBSJCL.NMM.1F7X;J_3?6E6D\:BQF_,99Z9 GK=4=8&>N<B
M]LM3DH4_#)X,FQ^LK/>?./\ H79Z#>%I/!L+CJ;A%]=QPY5FV;QLD_,DY+"B
M8_+E1K;!CQ'7H,PM^D)9;M[CJ5/([A&_J!$@<"<ICA;,QE?4Q*'OY^O'T7Z)
MD?P)T"/ ]_?^M:PMW]E%!_.O.6/\(8;<<CNB5R[D&'6[%:&XL]_\SN(<99:9
M>>AQW41&.Y]"W'9#C"/30X$N]P HI-].'GG\M(\U 4GJFS>/Q!?\M=M_'$3-
M<2SJ7A5X9>N5WDXS=Y$:+:)S2\4B1I O=UD3TWJ):XC"'W/\I(?=43%;(!56
M[><BGY%UO=)+]ZLLFPWJ1T[\Y7&ZVQPAUJVW&X_X,7IMM$@%2'EP'PXP5)4H
M=R2.Y6B24B9\AZ3P.1G);$ =@'_;^^BJYHB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(N%#8(^X(_M%0Y&<H
M,HK;R.")6/7J/WE)7:YC04  ?FB$$_V#6]^Q4-BMKB[X.L)(FDX3K9O[?NN1
MV36.'VEL^J!O>SQ>'<02;[M4'ZSU *_+[AS0C7>XQ]DH:G<BLLK4@_O"Q;[R
MA161X3ON.M:]O'^=7D+?[;$SI[896@$B>MNX 7Z,;2J>V\/>$73/^$[#,3$2
M6F./$<OBK8Y" -ZXY)WO_ 0D^!_ZN5X_ZO\ 77&O_P OPE@(V)CL\OTFYZS=
M;[PFV-H_B!P/C_9^?1N<==%ORZ"2?]ZGPK_S;EC^@N$G7_0*]/\ "/\ <FQ_
M]E=Q_P!-_'Z6U7Q=_2$_YX/&7^W4_P#TN'6;E=L7C*41*(M.'XVBKD.D?&"T
M]RX[C*>H3BQ/)]AX0DW&WY]E?&*9EW>RS'[3=;:%2;,\];5MW)-U4DQQ(MK$
M%8[I[%:-;W6ETGH/,#CE?/C-LU 1SUMQB+]/G\L;/PEX'2#%YVS973]AG6]C
MV8?X.BW>)'4W?,LNF%FU"[6PJC6A%^CMPQD"E!AQ3L99<6VW("@ %&L:3MXY
M$1,WXQW(.8T@2/GY=^=E^B$#0 V3KZGWK<9*KY]QM,"[1I,*XQ8\R',8<C3(
MTEEMYN0PX""TXE8*5(&R0E0(WY&B-T118_T^\.2K5;+')P"P/VFSRV;A;H2F
M'DM19[#GJ-3FBA]*Q,2H[^([BX? WVI2 4CGWKZ\\M%CMR! C0>N[I4BQ4*:
MCQ.$.H&-&:2M9#<>$_QHVPR2HJ6M(0L)VM2E$(!42K:B3RR$\NQ'E99VCQ]=
M^3_>=Z_I[452B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HBI42$J(]PDD?S H;@CBB\DAI$R%*CO'M;?9=8<
M(/LAQOL40?<>%'^M:=6D'TS3)(#VQ(S&\"#\RLJ-<T:S*K8WJ-1KVDY2QV\"
M> ]V3-AJOSG\G\<1.)>9LLPF+*=E,M,9)<F'"H::3>,=GW):B/("NYXM#1'<
MD!1[3XKRO:>"&SL14:UYJ>UWS)  :*E\KSQC*\=?O[PYMX>(_ GA7:;J;:%2
MGM/96%-)KBX30>:9<'$ P[<WKC4B;2L;N0-&]\=>XUP.G7G1/^3B/I]M?]8K
M@*C(VAA!,G^I<</_ -DVZY"9GU7<_"-5KMH^/[@ >/\ 9_\ ]@YS$9Y+?GT$
M@?[U/A?1V4XY)'MK_P",)(/W]O[Z].\*-W=A[&O,X1WE[[\N7R7QG_2# /XP
M>,KF/SS(M?\ R7#GC&G']LVZ[2O&$HB41:L_Q;<SY3P;I>A7CC>\YWB=A=YB
MXVMO.>;<8VZ1=N0L*X$N$BX,YSE.+PH:)+J9<=_\MM+T_P"$DNP84^0\U&6X
MVQ(CZ-?^SSUX3D#^QY^:@S/4V\\_,SP\X!6M#\$CJ'YBYIY(C1+-GG.W)_"V
M+=/:+/R+=^7;-<DVZV<SV?,Y[6/Q;!DMWAQWKI?+UATA,^]J#KZ2Z$%USN16
MEAC)=G<:CID;VF8^&2O?!?IX:7ZC:%Z*>Y*5:4-*&Q[']1]:W:*NB)1%@+S+
M>%6CKQZ5'$6V?=%2>(NH>)Z5N:]9<8.2N,O\:EI.O2B)T4EX;'<=$>*7-O@H
M=9L( FPXZ^?KYK,%[-764W,_LIE;B[=+5%0AFSR7?S )5HR(*VT+0\Q]2M)T
M/(/S BG&V7"+_1)D6SCT//H;'55.YHMO\P/[+Y6L0HT>2WV628KXTOQFGUQX
MNFM./QU.*8>1L%+S3B1OMHJN4YDLNH:.,92.ZU&YEW\FE^BESM"A;5+]+Q<2
M#KT/)[@112<^1_F?*_HJ&LU<=_+2<5RMI,]E;KH<LLU*[>I!4 W-3Z7[I:M
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M/N?Y^?FI)U%_AG\P.4*MS-G&FYR_V4RQTPKBS;T(:LDU2IR7'FVE3X8](>I
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MA+M0XOP)L+#;T/I;>V?[2GK3<]XJ%D%LRW?%ITSF8P,SK-,M5>\6]3CN^L_
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M\0Q&6"PB0\H(0ULD!!^VHRF>D_92915:@?QI>8<BX;Z3<=N=JYBO? &+99U
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M9]>^.5\7JG<VY-;\F7!Q=R]HOZH\"4U;XTR-JX^LZEEI],9 >4E+(T#1%M3
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MT_MSQ*B?<KI$N*LHR0V2!!+JK7=+@CC[+4/M7MM&AZ$>T2)LN.I:@!/CQ?\
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MA8&Z1LC&SK(SY1I.?FOOK^C16;A?P^VD PN=C/$^SF-<"!N&!3)<#,R?>M!
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M[@ OB62H>^])B*&CY]R?(U_6O'_%_P#RAPN@_J?&^5^,?=?>7]',1X!J"/\
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M/3C'>QR,_P Y<5M2,P=6QBL=><X\E[(7FI)AN-6=LSPN>XB4"PI$<+4ET%!
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2$2B)1$HB41*(E$2B)1$HB__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>fhtx-20211231_g3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #Q G(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX4[_ )CGGGT-?49?A)*F^;1L\ZM44F=]\2/B;KFCV]A:VTT,%P(V,JVS!DZ
M=>N>M9/A7QKJWB0I=G58].U" 8AEF3"2C^Z2/>LGP_K_ (=T;0\ZND=Q=NXS
M',"P49_E75W&D^%=6T?[0FLVRF!E*26TH1$'4K@X[>]>Q*,8QY>4Y-F>^_ '
MXH:WIXO;?Q8RK!)<"*&Z\P%=V.WM7T)!XHTZZ9E@O[>1E.-JN.OI7PY8Z]X8
MLGCMK:>748[<+(LDS@8;/8YP<5T6FZQK6K>=J6F+,D1F8"-H#Y4XXPP9>./K
M7A8C PJ2]HM$SICB/9JS/JVV^(FG7&LS:>LH,L3%&^HK8C\16$O"W4>?]ZO
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MIUJ+74+9BLB;4MY&/"]>#VJN9W.6[+'A.Q\VWFM=4U1X9V0/:1+B0,P/0KG
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MUKZ0_:*^&^OV'C;4]?U.&.YTN^=C$]JA(AC PI?CAL8!]:^:M<\6#P[.()+
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MCGVKV#%?+XBHZDWJ)*QP?Q!^#OA;XC0J=<TJ*YG3.R=1MD4XX.X=J_-/XH>
M(?A'X^UO0WO$O)+60GS"20%<!E!SZ!A7ZRNFY0*\1^,/[)WAKXN:I>ZM<75S
MIVJW$*Q^;#@IN7HQ7'/''7H*]#+<=]5FU4;Y2)QYEH?)?P%_:>U7X0^'VT*R
MTF/68[J^\T&25@X+!4VJ .<X7%?HUIMT]U:V\LD)@>2)7,;=5) )'X9KY_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
)110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>fhtx-20211231_g30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g30.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1JN4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &I*^: (X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%>%'L         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@              D@   +\
M 0                         !              "_    D@
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    D@    !29VAT
M;&]N9P   +\    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M$);[/W/Q"FDDIAOL_<_$);[/W/Q"FDDIAOL_<_$);P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^$_6&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
M/#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C
M>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@
M>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q+" R
M,#$R+S R+S V+3$T.C4V.C(W(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN
M<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A
M>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F
M+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/DUI8W)O<V]F=,*N(%=O
M<F0@9F]R($UI8W)O<V]F=" S-C4\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^36EC
M<F]S;V9TPJX@5V]R9"!F;W(@36EC<F]S;V9T(#,V-3PO>&UP.D-R96%T;W)4
M;V]L/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,2TP,RTQ-E0P.3HR
M,3HP."LP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z36]D
M:69Y1&%T93XR,#(Q+3 S+3$V5#$Q.C(S.C X*S U.C,P/"]X;7 Z36]D:69Y
M1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,2TP,RTQ-E0Q
M,3HR,SHP."LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C
M(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @(" @(#QX;7!-
M33I$;V-U;65N=$E$/G5U:60Z-S8Y1C4U-$(M,T,P-BTT1CE%+4$U,3,M140W
M0D$Y,3=$,D0X/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ
M26YS=&%N8V5)1#YX;7 N:6ED.C)%.30W-$4R,4(X-D5",3%!-C(S0CDS13,S
M1$9&-C4P/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ3W)I
M9VEN86Q$;V-U;65N=$E$/G5U:60Z-S8Y1C4U-$(M,T,P-BTT1CE%+4$U,3,M
M140W0D$Y,3=$,D0X/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @
M(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#HQ03DY.$,R-3%".#9%0C$Q038R,T(Y,T4S,T1&1C8U,#PO<W1%
M=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^
M,C R,2TP,RTQ-E0Q,3HR,SHP-2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C%".3DX0S(U
M,4(X-D5",3%!-C(S0CDS13,S1$9&-C4P/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 S+3$V5#$Q.C(S
M.C X*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP
M:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P
M;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S
M=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#HR13DT-S1%,C%".#9%0C$Q038R,T(Y,T4S,T1&1C8U,#PO<W1%
M=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^
M,C R,2TP,RTQ-E0Q,3HR,SHP."LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI3
M97$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-
M.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HQ0CDY.$,R-3%".#9%
M0C$Q038R,T(Y,T4S,T1&1C8U,#PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @/'-T4F5F.F1O8W5M96YT240^=75I9#HW-CE&-34T0BTS0S V+31&
M.44M034Q,RU%1#="03DQ-T0R1#@\+W-T4F5F.F1O8W5M96YT240^"B @(" @
M(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HW-CE&-34T
M0BTS0S V+31&.44M034Q,RU%1#="03DQ-T0R1#@\+W-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R
M;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIC<F5A=&]R
M/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL
M:3Y'96YA/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @
M(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P
M<V8\+V1C.F9O<FUA=#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @
M(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM
M;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O
M,2XP+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O
M<VAO<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \
M+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ E0## P$1
M  (1 0,1 ?_$ !X  0 !! ,! 0             ' 0(&" 0%"0,*_\0 1Q
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MA!; 6=93CE0K;,;-R\%Q)&$G#17?W+.DOAZ9RG>F5V94=X*=#O989F#QL_\
M:]$=B_[I&/T K/U,T!P+YOCPD93^!!2TQ\NS(N%1+YYKXE6&.G,X/,# W5M!
ML.9+736:[:6A&*4V4=EZ*\H ]86E0"EZ=!UVXW$89/F!Z>9(JF=A)FI5,:]S
M+40L%KDD#-F$:=9B[:@^+:\[=-'98EROY0R\SMN:V)R$S<GR*&B+87$&V2^I
MZ./+*OP@DJ:4YT(#I4 2!H!.]E455<*67A]1O(D2%E2$*1NL2^:M6+ZF^N@@
M"<]2 YU(LVNK#V,2Y] C]/2)UH-DD$3#L;7YF@>CL-CI^/R^W[\>>//O@SLX
MO>QN!S]K/X:Q7Z QI(]=:>WI[B8024AT>[\/OOS5;_RH_P!WNBL.N]^O+*+3
MCT<]O76H!;+?::1V+"8Y5_5_GZ4!?5_UI4O7?7"($@7U[SUR[K1>:%A2E*,R
MS&UJ<&IA !7(1)( Z.P2I ;3^C*E-_?? E_70:]6TBL+YEP!<\ WU\[Q:F@8
M2-"?:_P]S-))Z2Z1L^7]RZ=_KT-C^'N@P&G*S^G#/,<3SB@Q^/T@>NM>PT#Z
MU6]="4;WT:WI/5O7YB3]]<5^[R'!NN=\XFZ#?-_N_>XR[K1<JA85\SK0?/Q,
M/WT?^K^W3V_Q.]\2*POG?F?. H(X45>MM#L@])FDIV'?.[#H[;/M/?NW[?[^
M$"'^XL8HG'V$I*1/M3L!.S-)4 &GFNQ\L?9Y2O@^]+:OX.Z! ^_BQ/>[ 'D\
M%8_'4DI]=:C?5M0FD*]Z(Z#WZ/MZ="A^BUNG^/00(!S&7E;E%30,%87ZVT!!
M!T)J@DD/+?\ <.CO[EE'_P#,)1]M\,[==<HOY]8M_9Z/_P =:_ &O6JT--J;
MW^3Y(42?U4 K[<(C#/7CKF[?3D(N- PK>YUI[@1_MA[;0$=OP^Q &Q^BB5?/
M" #996LYS'CPLW(13]GX_3T^NM-;4=^M._<MM9&^CXVV !]DJ4/XMA A^/F1
M[1S8=:U"<<=0_+=+B @ID/EU*1YCCNT)*4]*MN%)/<]"4I^VRZR'/ES]H -Q
M\2_XZX1V/"+#A"'"$.$(B+.-_P YG)77_P"7S??^'[%6/"(?J/>WK&*95E*Y
MW.K'N6MKR9.2XU:T4N=*YAV-/!L:BM=::DNB MR5&?0A)7'0TZE;K:O-D,]#
M;A5L<L[ L*KL.FUU8,.J)\J8)2*2JII$^<I!*7*!-0HE/^S96+D,([=-B.(4
M=J*MJZ5).^?AJF=(25"P)[):74'+*9[-QC+9O(GE%.4ZY^P='7//#W2*)EW'
M9"5$:"T/43U<XVX/D*0H*WK>] #5IVR&S4XE7Z/22%EO\E&E5#,!!W@0NC7(
M4"#<%QPRCVI.V.U$I@<;KJA"<I=<M.(2BX (,NN14)(M<$$&QXQ!TCP^X;CO
M-A69\M<[;K.<*,?\MBGS&Q5E;<BF#:(;:G8LB4B]C1UM,(B?4@]-6TRCI0VX
MD="NFJFKJ *P; -K)],L 5:<"Q2>G$J90!8+*%D8C)EK4X,P3IJ01O!!-CZJ
M,7EUU(BLQ_9:34T';?#*QG"J=6%ST35!S+[26E6'S9DM+*3*,F4I3[O:)=Q+
M^/<T92+6+A7-/'TX=E%@EUJMD%]J=B.6*922_P#L_;]DK=#8\U=79LP;1#1Z
MEP^C:N.6@VCGRZN5A>T%)^DXE-M331,[7#L14E+K-#5AAOAM[X>>F34!)?LF
MO'2KMG)*Z2;BNSU;^KX;)(-5+,LR<3PT++(^/HW4R"3NBHIUSJ8J!2)KL(C<
MKY)9?S:R+EOC,:[P_F1C\1-G-OL2BR\<84LI05DO,M"EM'4]2"Z)L&2AX'V+
M4K:N/I#8E3X?(K9W9U-#.5V:)=0I,\ZVW5'M98(!(*5)(;PC47!40#\P'!VS
M8\-3KK?2,Z<O.:'+12UY1$5S'PQK17D=!#2SEE1'3_6/W./H7T6;#0]RY-(7
MI!0E2E5S0&^.J)='6 =BH451?_#.43(FJ.0ES6/9DFP3,W4O_P"R,AZ9OU[^
MT8YRD\3F.\X.9N;\O\<I;/T6(0&IS63N);%;9]3L5EQI"0XIYAP+E)#:'6T+
M/DR M*%(2%<]?@E1AU%2U<^8C>J5%/87$Q'[B";!)#)+L;.G-[8!3J(&E@='
M9^_WY:QL]QXL9PX0APA#A"'"$.$(<(0X0APA#A"'"$.$(<(0X0C33Q1>(_F!
MR,O,)@<N^62^<D^^KKVRM<"J6LJK,C%53R:M,F_C9LC&;/E7BE=7,S'?5.<U
M\LY?4TU:VTPLD#[*XSF+@D@DL '9@SD@%RW"P"G(!L7>*Q9QFY ?)1 ?=&KG
MBQ U(UV$Y4<P7N9V$UV72L+RWE],E2+&#-Q3-8U8Q>5DVJGR*V4DR*.TNZ"V
MKGWXRWZJ]Q^ZMJ*[KW(UE4V,R%)9>7F0Q;NS!!N'8@W!&H-[1@"X<AN+Y>!R
M/G'ECSZ\7_B3PCQ09/RXITP<=Y0P9$*!994]@EE>VV"X[]#B3Y?,6=!;(:DT
M3]P_](KK>1*<K;!UU4-NNC2H3C[W&DF[ZK(%Q8 J !9FW[;MR3=B"0(Y-T.U
M_P!@5;YG)W0<O_FY.6[D06C:7#.8O.+,,K\,,_*N7,9%5<4V;6LW,4WD6IE2
M+?\ 9RXCPXXPJ6S]0AL652W&N$RE3%,I]2&FV@DHUR$,2QT&=V+7T&N<<;OD
MV9;FQ+,Q.8#NY#:$1NP)MMKO3*'M)[3HA]WEJ4$_UFNZPEO>] JZNZ4D\+<?
M3\\>[['/#Q<9<3[ZP,VUU_8RR>HC7KH@]OX6E;\S[A;AU\CR3_OHW(MS9K=_
MX\O#*[1*>3F(*YO?SX*Q29^WYIFJ V'UQ/HQ#3UP_/%<'O(,I->VPR5[Z%,%
M"4L^J#SJM9_L_ /[G.V'PR_UTT8H/B>VF]GV &X'D;_9=IN-+<)8I MO.J-H
M_O+: ;*_V:*F7^@_&G$/ANQE=M\025%/Q 09AE;[S C>_>3?= 2,VRO'H>;4
MLG'LEQ1-E62T(64.3HK;T:2TV'6),.2V\F1$GQ).O338ZT.,NI#R%]'YO7Q#
M#:+%Z2918A(3.D3 "4J<*0M+E$V5,2RY4V6J\J:@I4E0<$#/QL-Q.OPBLEUV
M'U"J>HE$@+0Q2N6KY5RITM8*)TF:EQ-E+!0M!W5 Y1IGRDYM9C3>)#*N1.1V
M&%9!$QZ@9117/X,?/;5MGRUQZ^ZM$R%1;2RKXKGESV6V(Y06_,2VI2E<?+-F
M=K<8D[>8CL#B.(X;74&%T*9N'U!7,&*326*9=5\YD3*F7*(%0$2Y9<!?S$D1
M]:VHV1PF?_3W"_Z@8;AN*T-;B=>J5B-, A6$R/W)7-I4B6)LBFG3033E<V:D
M@]FZ0 8WO];::)%(O>R->MAC:>L#8VX/X25Z.OCI[D\?8OEX\+6?EKGJ';OM
M?XM?)@W?;VB%LCY>Y!5WSV>\KJ^%CN52>DY!3R94=K%\T827#Y=RQ%"G(5LT
M$@1+Z$TJ4@O!N8S-CI4TGTI58B9*32U^_-D)_P"*:DO/I>)E%1 4@L-Z2KY=
M4J2J\0@NX8'7_M;5K]Q>S9-GF.$<R#G$&<N)0RJZ[I):JS)L;LID)BXQ^V;9
M0]Z2='+A)CRDJ\ZLL6NN'90EM3HCKC+FT]:JI5TRD@J3,E34]I(GH?LYTMVW
MDDBQ!!0M!^:6L%*@"()).F7?Q#Y@9#G<:G.,Z,RT!T*=1'6M.Q-B#VA]+:7-
M%8.ELDR.G\P"2V?>0#U[6OJ7L;7SYOG%OPROGJVEO!XH)MJ0-TJP?;V,Z&=;
M\SJ[AP[*>E'^;S!W]JM+<2W=]'^L+\!YG[>\4];;:!^BK!(V4^NA[!Z0>DGS
M-?F)1L$CMU?!'$Z]OSY0<\!Y_CI_"+C,M!\4ZS\_$V(/@IUO;@[D$GML#I()
M[CBVX]?Q!SP];=_GR_%?66G41](5T[ ZO6Q>X\PI)">O[-_BZ)&Q[/S#7"W$
M^7YX?;G"_!GYY6[CK;U:+1-MM;^BK!Z=Z,Z'O?ENJZ>SA&^M#;>]ZVZ%;Z4+
M(6XGR_,'.3#S<Z<1H\%3+4!133*40"0!.B#J(2P0-J6-$J<=0"=#]W*CH.-[
M6<WRR+9Y>7CPA?@SYWZ?+VYL];:[']#*[G1)G1.P\U2-]EG?X8#VOG2@C\X(
M$X7_ !!S>W<'SZRB@FVQ!W2J! ! ]?#.R4*41OK_ (5 ().@>KJ&P#PA=\K<
M7^GY^T7";:G?]#K&MZW-B=_:"!L.'6U$HV1]M_!WQ;<3Y?F(ZO\ Y\C]VBWU
MMMH'Z*H':AKU\/L M*0=]?\ $DJ7KY 1TGW* X6X^8_F*YO8<KY\=+?>.7%?
MF/+6), Q$I3M*S(8>ZU=:T](#2E%.D)2O:@![PD>Y*N)U?\ DPOK[_QT_CSN
M$6/"O^4JY.<M+#G+A.<JQBFYI9ME$>WH<BP9&,<B(N4+IHE?A;#$>-S/YQ<E
M\_Y>44"H@LN7*,;YF6=7:7CU^\BCR2)3M,5#>&2F /S%)403;,!12X<9@[M\
MW!>*;H#DV?<!!8BQ4 KB[9^8((/MCA[+$?%,;8C1E0X[-'5M,Q%JJEJBMMPV
M4HCJ51-LTJE,I ;*JEEJN)23#;1'*$C,^/B[^+W\[Q@+LU@Q9LG/D[<PW<8R
M/A&41'F__27R5[;_ *7S?_V58_\ /?\ ]=<(AROQ'OT(ESA%APA#A"'"$0=S
M(Y)XME M,KQZ@HJ7FJWZ2QI,YCUD-F\1:U'OKVI5DAM,IV%)2E4"8VMPAR*^
ML*V4(UJ..;)X9B!J,3HZ"CIMHT]E/I,8ETTA%:*FE=4A$VIW!-7)6"9,U)40
M9:SJ VW8%M=B>'?#X96UU;5[-GM9%7@LRIGKH335?RU"Y5*9G9)GH)$^4I*0
M>U0FX!+Y?RSSAO.\7CV3T9RONX+[U/DU0\ F14W]>0U81'4$[""LID1SL]<9
M]H@J/5QZF 8N,9P]%0I!D5<I:Z:OI5AETU9).[.E*' EERR'!0I)<EX\S:#"
M#@V(S*9,P3Z2<A%5AU6FZ*JAGNJ1-2=2 \N8+$34+#91(0.QOYX]J/$B'>8V
M"6DB?%YB\OC&@<R:"/Y" ^M3%9F= E9>EX?DGEI45Q)2OQ:JRZ%RZ*S#,V,5
M,*F1)?>I:E 0JDJ7523BY(#KIIK,FHDW%TY3$/NS994FR]U:<5!\L\N7CRR=
M[6UR.7X+G%3GU&BXK$284AB0_6W='9-^GN,=O(92BQI;:-LEF9"=4!U)*X\N
M.Y'G0W7H<F.\[PU--,I9G9K8@@+E3$'>ESI2OF1,EJU2H:%E)(*%I2I)2*';
MORUY/?Z$\B8S/CKQ8<(0X0APA#A"'"$.$(<(0X0APA#A"'"$>*/\IEC+6)Y7
M+YH6^:9SB6(67)/F0AN3!1ZG"7.:E6,2BXC0SG8;<65B]GE5,S8Q1E,RTA18
MX@1EMV57Z):9N !*EA@7[,I&1)<A8!#-9G<WWP1DQKV22+ J<L"P(&ZH@N27
MMD/VD AR8]>>6[WJ.7V$/^4MCSL5H7?)<FFR6WUUL970JP*W#-*=]Y)6OS?S
ME:M]1Y%-O*;)RW<\<:#\B20ULLVOES/A<Y#2-8<]\>/)# N9^1\GWF<PR;/<
M<CPPNFQ2NHK"1;7LY ?8Q.FC3LEK)[^0>D*IJA+AP:;R&W4HN%24&/QBX-^;
M=YN_DQS;(L\<A!#.#EO6&A8!];N&;V>,Q'-;!,^S3P\VM'D-<E_(!FMW$HI\
M^NC9%'AG$;2*_P"MITS'9#*H<UIZ#)<;\Z*F4RXAJ0ZGI6JD$9\O4.#XB\8$
MV'>'Y,;GTC9?U\'O^^Q.PV?WEGL.DKV??\= *]_'2"KX!/",H>O@ZWZV)K9&
M_4LZV"@$;Z_D%QL']"XC_>3M$Y>S6'VLT5]="_XR+\@?[0U\E:FP/S_)<0M
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MRE@C6O@LH2UKXZ$I'VX^A_8 >$?.F'#K/WO$:X?R)Y98+DN9Y9CV/ICW.?6
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MY W]-LM;+JV>Y])H#S&U#9( 1TN$^6M"U7GIQ:WG$) UOPU\HH+VM/\ '+^
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@SE14$(6-($ Z>.O'/.)GX18<(0X0APA#A"'"$.$(_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>fhtx-20211231_g31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g31.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1VD4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '8B^=6 X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%=N8          *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@              K0   +X
M 0                         !              "^    K0
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    K0    !29VAT
M;&]N9P   +X    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MY&%=D!T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M=S3XA"4Q(;57S;:<S'I8MEQ$]>Z5!>LW LJ?",;Y(#==UT@$9D"-8S@3QXJ
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MEWY^'(*ST/IG]?IIQA5-PV/]1M3[^U>\?;CZ#Y\\#YG@_($ZI$<1Y3^%)_\
MJ[V_*&X;!X]#:_CZ!XC^M\KGG]I^W]0U^4(">^D=1[_C^?:;.>AY</&>S[JJ
M;AM0Y$&U'V"O@UT@'LPX_P!/!3]\ALMA/OYRFVCPI8TCJ.'N)_@]4GH>/+AE
MS[UTS5#<-C_4;7W([5[Y]BV.>P/;\H"#\PAPCLA7".H]_P >?\Y)/0^W'Q/J
MJ_&&^ ?0VO<@?]'O\]U%/<<<\ I)/;LDA7LH$HZCL]?7PZI/0^WY[\C 7#9
M/H;4<\=C7O\ (Y"CWX! ^[P>_8E(/<Z1EJ/#.?I_"3T/M^?Y5#<-C_4;4_9*
MN!7O<]D(7Q[?>4'.E(]RM*T^Z3J=\OKDD]#[?G@N1MD!03Z&TY)(Y$!TI'#X
MC\DCMP5'S ?;R07?N#G5CJ.S'\^&:D]#YQEQY\!^-5Q^,-\ ^AM>X!X^'O\
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M,=HSCEU09[MO6(FP=QJ6Q157"$*%>J7'ARX(;E(C(<GQ@8<MR;!GH2YZN(V
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M8#3:8\:SL$)D*B.1W<9@NF2-TN:!^[>WF-(' RW/0QN@?]I%B8T&;6G>'RD
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M')P,E8 _,0T9:G423Q!TY>F2V0T-]59-4PKRCFLV%98-)?BR65<I4A7NE:2
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MQRIHT0ZR1*EU\9-;#:BAF%)G-,S'XR/+X:<DM-O*3P5H2>PR)DD\R3S6+00
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MYQ+U?,2V\ORWE(<<=CE]CS.%ATD@ZUJO:7%N ZHPFF?VU:9^)2<.&Z]LC,:
MP8X+,1R&O37\CHKY8ATTEM+L:/7/LD=*'6&X[K9"0ILA*VPI)Z05MG@GC[23
M\QKCD%I((((U!!!S\>GMXI \?'/L+["LKASQ ACGW_-VN_L._P!CO[#_ '#4
M2!$1EWWT5#5UI]X$0^_^KM?,A1_N_-0!_$ _(:*K[LQ(L8DQX[+!*0@EII#9
M*02H)/2!R I2E<'YDGW)T4  T 78T531$T14) [D@ #DDG@#\?D!^TG1./\
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MG5V)M6%*F8^\JPL<72XVVS&R9 (+I()R:-V&-W-V'9&3OC>!EQAT#= 61+7
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FQ^!_]4ZG$^ ^KD5=5$T4;H/ ?1-%4T1-$31$T1-$31$T1-$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>fhtx-20211231_g32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g32.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1T44&AO=&]S:&]P(#,N,  X0DE-! 0
M    '/B^=!8X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%>FFH         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@              D@   +L
M 0                         !              "[    D@
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    D@    !29VAT
M;&]N9P   +L    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M])<W]:*<?[?3;N%MEK?1NI-U57LEKVL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M=VL2OD9%-LH=A82DRD8_C]PB')<:"21$00TAT&.\&F#OPN@GA$F>$D@ @H1
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MP+N">/R67S<0-Z2Z&W,O <MZ_P"7NPLJY;<4EI2MDOLEP@SL1Z^7W]P5J;Z
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MKJ E:92^.QIT W3;BV?IMX^]?58^E6;\0TFT\$@L:.&8#AD.GC!QPB:G!!)
M Y&/F9.T#U5@HVJ&FTM7"-G^&.K&P*$9-3%0)]@ 9@)_V'6K-G=MWM;@?^S4
M_P#RI#FG ()Z @J,J_47/9NN%C0-L86]HTC&HTFNRB->P7;61D"D15.Q2AN<
MOD2\Y+8\H,! CL,OI=\Q:DGV5+6T9IK*O%<MU+XQ:^@ZDX4FT>_#Y+1RX/\
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MX-V4<"5$DMB0H26MFU<9J_92C4U!G:/1*=M8=I+>F^FVX--K:.HT'EKJEGJ
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M"RU7LJ%O VDB30X=.3Q @] .Z())#0),F<DQTA2#+2"0"TC.8!(=D@9XC@
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M9),DDR3SD]8 \O+&Q5W/@-'R"O@U3R!!W^'1-]T[E)!\KW25*(]]BH[;$G=
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MSE2K.FI_+RJX]:F'-2TJV/IH,52[9]1+;1O=:&\\'&PX6M: /.)]=T=WG<4
M @R.I+B[./&/DKN=2B=$5#/$)X3+O4O-K3.\-7B*YUI'P+XS19G99!\&RHX5
MF=9D?P>X2S67\:%3RZZ++A^7"K)#:WWPJ5!=0I:Q42 YN.$N:X-S@M;483Y@
MN#F[@$<L$V+AP@!LN#7MGS>UW)PD$-+73G//91=7>#+6!=UH._<7FG:8NE,3
M2JN?NH=ODLR^JH.G.>XAG]DSA[4K%X[33.8-U-Q@MG&D6=<E.+M5,A]V9ZF9
M3P[L(:23WCP4VR<Y8Q[#ON'EP<Z3N,R0"<;^\  WA/&\X)V>]CA_\.$AN/F
M<?43J!X^_?R\@K)T1.B)T1.B)T1.B)T1.B)T15S\4VK>1Z+Z4'*\49Q_X]9Y
MKI]A$&TRT2U8KCJLXS"IQIS(;]J!(A2Y42M:L%JBP&I]=\2M7*ZO<L8#4I<M
MDGOW*JA=^.:_T@R#,<"S7\P==+O3A%1D6=Y3I)81L,8QW#,IR:-BF/QIN)Y3
MD.0+E9\Q:/N/6^-U63S([5&W&M3.CR["-3DJYY_H(GSGTGKOL!T6/?E.4Y)8
MXYCD70?((669W0N9M@E=<9UAU546>"18TB7/N;_(YLIJ#C-HTS$>$>EDHEI?
M<X>98QV0\^S.(YS](S[]4D[XC.(,XY;\_&,QC,+\L=_*B1<TOWL=Q#P[ZFVD
MNSNJC'<+G37X-3CV0W%C<Q*.3'D99)95B;#$65)4^S-HKS)HLR&RIU+K3KK#
M#L>GS('ZJ<\_H)Y^<[>&%U."_E,\HRF3DTV3H4&Z"NRB931'$Y]CE7(I:G%\
M9S*]SBXR:;>/0JP-P9.&SX%(B$X$VBGHSCKD1MUQ<<-_#>=_H,G"3CKRV()/
MA)R!SSD9G!7G\=_*EWN9YU48[!T@D8C30)%K$SM^_<G3;R%(9M-%54;F/4TY
MG$I=A"MJ?5CRI,J2PRF/,A+L:A.05,=IVR''OW]<(/'?^>4^8F)7MGORG4AR
MLK7ZCP]9+:VV0:?T^LN/5C>>X8VP_I)D&G^K.H]5;V]DF0\S3YB:31W)(4_"
MRW+,&WL\=CKN5Q9=C,JGOP0&9Q!@'U\X_7T5E-1_&=A&G=OC=5*Q^XG'*M/-
M,]1:ET2JR&X[6ZG:Q8-H]6P3&D20ZJ=6V.=5]Q8):\QL0H[K#2UR7&D*=?#H
MGH)Z[2?3]E2#PZ_E)=7=9LB\+^#66%8-%RK,\MM*SQ%&NCW;$;#,?RG#,ASO
M0J;BT25<2'6Y.H.,4CMQ,782K5FO;BOQ@SSDLN-/?OV54SL2,QSSG<1T\H,#
M)W*^U'173HB=$3HB=$3HB=$3HB=$3HB=$3HB=$3HB=$747M!1933V./9/2U.
M14%JPJ':4=[70[>HLHJRE2HUA6V#,B',84I*5*9D,N-DI22G< ]%&\^!_8?=
M1HQX>- (L/'ZZ-H=I#'K\2G2;/%H+.FV&MQ,;LICR)$NPH8Z*8-5$V5(;;D2
M94!$=]]]"'77%N)2H$CS]3]_'W 78W&A^BV0PFJV^TATPNJZ.U"98@6N!8M8
M0V6:UYR17LM1I54ZRVU ?>=>AMH0E$5UUQQ@(6M1)('CZG[K>JT2T9HKN3DM
M)I)IG3Y'-<AO3+^LP3%X%U*>KEM.U[LBTBU;4YYV"XPRY#<<?4N,XTTME2%-
MI(*5^T;1O2&'(G3(>E>G$279QGX=E*C81C+$BPB26K!F1%FOM5B'94=]FVM&
MGF7U+;<:LK!M:2B9(#A1 ],[F/39=-4>'G0''W*]VAT/T@I7:F:JRJW:G37#
M:]RML5LL1EV$!<2E95$G+CQ8S"Y<<MR%,QV&U.%#+824KLJ?1'1C'4V**#2/
M3&D1;R[&?;)J,#Q:N39SK>!-JK698"'5,B;*LZJQL*RPD2?,=F5\Z9"D+<C2
M7FEE$ ^_&?U"\YDOALT/S+4?%M5,NTVQ/*,NP?%F<0PU[(:*JNJW%:N->Q<C
MB2,=JK*%)A4MO#M(41V';UK<:=%;CLLL/(0V@)*??K]5[:JTKTPHI4:=2:<X
M)338:ZMV),JL1Q^NE17:.KD4E*Y'D1*]EUERGI9<JHJEMK2JOK),B!$+,5]U
AI11 _OGWLO=CN ?Q Z(TR >L[>:ST4IT1.B)T1.B+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>fhtx-20211231_g33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g33.jpg
M_]C_X  02D9)1@ ! 0$!( $@  #_X1#L17AI9@  34T *@    @ ! $[  (
M   +   (2H=I  0    !   (5IR=  $    6   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $)E;B!3=')A
M:6X    %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,Q,@  DI(
M @    ,Q,@  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*O_  !$( P (>P,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#1M?^/9/Q_G4U0VO_'LGX_SJ:N=[G;'X4%%%%(H**** *-[_KA_N_UJ
MM5F]_P!</]W^M5JWCL<<_B844451 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% &C:_\>R?C_.IJAM?^/9/Q_G4U<[W.V/PH****104444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &==?\?+_ (?R
MJ&IKK_CY?\/Y5#70MCBE\3"BBBF2%%%% !1110 445C^+=9_X1[PCJ6J X>W
M@)C. ?WA^5.O^T132N[";25V>'^/KB7QG\7AI=LYV1S)I\9/\.#\YX]&+?@/
MPJW\;?#R:7KUAJ%I'LM[JW$)P,X:, #)_P!W:.?[IKE?!MSX@L=>_MKP_I$V
MJW-ON#'[-),JEP1D[.<D$]_6ND\7ZYXZ\6Z,+36?"4L,,$GGB:+3KA&0@$'D
MDC&"<UWV<9)+9'E74H2;W9[-X+UO_A(?!NFZB6#2R0A9C_TT7Y6_4$_C7B7Q
M?O\ [=\3WA$?GBSBAMQ&/X_XRO'/5R/6NG^!'B!3%?\ A^=CN!^U09/&.%<?
M^@G'N:Z>Y\=^#T\<IIMSIY.K+<BW%T]JG[M_N@[R<X[9'8U@DZ=1V5SIDU5I
M1N['(2?&7Q3I=Y&VN^&XH+:0[E1H9879.>C,2#]<=J]:T77M/U_18M5TV</;
M2*22W!0CJ&'8C_/%<I\9C:CX;70N=OF&>(6^3CY]W./7Y-]>;Z-?:CIGP'U:
M2VF:%+C4A"I P=A1=^#Z'I^='+&<;I6U'[25*;C)W5KFIK=Y<_%KXB0Z1IDI
M&A:>VYI0" R\;W^I^ZN>WIDU@?"1!%\5;6-<X59U&?9&JCX3^(VI^#;"6UTF
MQT]_.??)+/'(SMZ#(<# ^G<UD>'_ !+>>&_$2:S8QP27";\+,I*?,"#P"#W]
M:Z.1\KBMCD]I%RC-[WU.Y^/,4H\8:?,P/DM8!4.>"PD<M^C+7I>LZSI$OPEN
M;MKB%K.;33&G(Y=H\*@'9LX&.H/IBLWQ-?\ A?Q!X'T@>-[N.QGO[2*ZB>)&
MW1NR L4X/'.,'/&.^#7)#X2:%9:!-XCN/$#WNF+:M<PJ(/)WC:2@+%LY)P,8
M!)XX-8:.*4M+'2^:,Y..M_P*?P&GD7QAJ%N#^[DL"[#U*R(!_P"A&O>Z\*^
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MC:IKTBBE&3B[H)P4X\K.-\4>#+C7OAK;Z!&]N+ZVC@$<DC$1JZ *QR%)^[N
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M*S>7Y;I(?NJRCC!Z @=QVYKURHE!P=F:0J1J*Z"BBBH+"BBB@ HHHH ****
M"BBB@#1M?^/9/Q_G4U0VO_'LGX_SJ:N=[G;'X4%%%%(H**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#.NO\ CY?\
M/Y5#4UU_Q\O^'\JAKH6QQ2^)A1113)"BBB@ HHHH **** "BBB@ HHHH ***
MXSXM_P#)+=7_ .V/_HY*J*NTB92Y8N78[.BOFKX7>,3X5\3K'=2!=.OB(KC<
M<+&<_+)^&3GV)]J]H^*7_),M9_ZYI_Z,6M)4G&2CW,85U.#EV.MHKR7X!?\
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M<[EL%%%%(84444 9UU_Q\O\ A_*H:FNO^/E_P_E4-="V.*7Q,****9(4444
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M'W^OOVI^V]^]M!?5_P!WRWUW//[OXU>'O^$8:ZM'E_M1HOEL3&V4D/'+XVD
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MFM/(FH^6K>+L_,Y/QAXC3Q5X\?5((GBMY'C2!7'S%%P,GZD$^W3M7I/Q]_Y
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M"4EX!Q]?K41E9RLS2<6XQO%[=-Q-(^*GBGPUKL=AXWADE@.!()8!'+&IXW#
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MU=1G%P\8^5I/GW$<#@G/85MZ)X1^*NE6KZ/ITWV"QD<DR&YB*KSU4C+J#UX
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MJ:H;7_CV3\?YU-7.]SMC\*"BBBD4%%%% !1110 4444 %%%% !1110 4444
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M359D9H#<PWR[1RZ9&X#/&<JPKT[Q'\1O#2>"KNZM-4M[F6YMF2&VCD!E+LI
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH SKK_CY?\ #^50U-=?\?+_ (?RJ&NA;'%+
MXF%%%%,D**** "BBB@ HHHH **** "BBB@ K,\1:#:^)M N=(OY)H[>XV[VA
M(#C:P88)!'51VK3HIIV=Q-)JS,#PCX-T_P &6$]II<US+'/+YK&Y96(. .-J
MCCBG^*_".F^,=+2QU;S56.021RP,%=#TX)!&"#R,?R%;E%/F=[]1<D>7EMH<
M[X0\%:=X+M;F#2YKJ5;AP[FY=6((&.-JBD\1^ ?#WBEVFU2Q'VH@#[3"Q23C
MU(X;CCD&NCHHYI7O<7)'EY;:'F\?P,\+)-O:XU.1<G]VTZ;?T0']:[;0O#VE
M^&]/^QZ-:+;0YW-C)9SC&23R36E13E.4MV$:<(N\40WEE;:C9R6E]!'<6\HP
M\4JAE8>X-<#>?!#PI<S%X6U"T7_GG#."O_CZL?UKT2BE&4H[,)4XS^)',>&?
MAYX>\)SFYTRU9[H@@7%P^]U![#L/P&>:V=;TB#7M$NM+O'D2"Z38[1$!@,YX
M)!'Z5>HH<FW=C48I<J6AYG_PHCPQ_P _VK?]_HO_ (W1_P *(\,?\_VK?]_H
MO_C=>F457M9]S/V%/L4=$TB#0=$M=+LWD>"U38C2D%B,YY( 'Z5S6O?"GPMK
M]V]U+:R6=Q(29'LWV;SZE2"N>^0.3US79T5*E).Z9HX1:LT<#IGP8\)Z=<K-
M+'=7Y4Y"7<H*_DJKG\:[U5"*%0!548  P *6BB4G+=A&$8?"@KE/%WP[TGQI
M>6]SJEQ>Q/;QF-!;.B@@G/.Y375T4E)Q=T$HJ2LS$U7PI8:QX0'AVZ><6BQQ
M1B1"OF 1E2#D@C/R\\=S5;P?X&TOP5%=)I4MS*;IE,C7#JQ^7. -JCCD_G72
M44^9VL')&_-;4XVT^&&BV?C)O$L5U?F\:YDN3&TB>7N<DD8V9Q\Q[UT^IZ79
M:SI\ECJELES;2?>C<<'T/L?>K=%#DWJP4(I62/.9?@=X5DN/,2748E_YY).N
MW]5)_6NRT#PWI7AFQ^RZ-:);H0-[@9>0CNS=2>OYUJ44W.4E9L4:<(NZ1D>(
M_"VD^*[%;76K;S5C;=&ZG:\9]B/Y=#^%<SI'P;\+:5?1W3+=WS1-N5+N163/
M;(51GZ'BN]HH4Y)63!TX2=VCDO"/PXTCP9J,UYI=S>RR31>4PN'1@!D'C:HY
MXJ]XG\$Z'XN1/[8M2TT:[8[B)RDB#.<9Z$>Q!')K?HI<TKWOJ'LXJ/+;0\\L
M?@EX5L[I9I6OKP*0?+N)EVG'KM49KM[[2[>^T.XTI@8;6XMVMB(0%V(RE?EX
MP, \<5<HH<Y/=A&G&*LD<MX0^'^E>"I[J72KB\E:Z55<7+JP !)&-JCUKJ:*
M*3;;NRHQ459!1112&%%%% !1110 4444 %%%% !1110 4444 :D/^I3_ '1_
M*GTR'_4I_NC^5/KG>YW+8****0PHHHH SKK_ (^7_#^50U-=?\?+_A_*H:Z%
ML<4OB84444R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -&U_X]D_'^=35#
M:_\ 'LGX_P ZFKG>YVQ^%!1112*"BBB@"C>_ZX?[O]:K59O?]</]W^M5JWCL
M<<_B844451 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &C:_P#'LGX_SJ:H
M;7_CV3\?YU-7.]SMC\*"BBBD4%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVC#V*[F7Y,G_ #S;_ODT>3)_SS;_ +Y-:E%'M&'L5W,OR9/^>;?]\FCR9/\
MGFW_ 'R:U**/:,/8KN9?DR?\\V_[Y-'DR?\ /-O^^36I11[1A[%=S+\F3_GF
MW_?)H\F3_GFW_?)K4HH]HP]BNYE^3)_SS;_ODT>3)_SS;_ODUJ44>T8>Q7<R
M_)D_YYM_WR:/)D_YYM_WR:U**/:,/8KN9?DR?\\V_P"^31Y,G_/-O^^36I11
M[1A[%=S+\F3_ )YM_P!\FCR9/^>;?]\FM2BCVC#V*[F7Y,G_ #S;_ODT>3)_
MSS;_ +Y-:E%'M&'L5W,OR9/^>;?]\FCR9/\ GFW_ 'R:U**/:,/8KN9?DR?\
M\V_[Y-'DR?\ /-O^^36I11[1A[%=S+\F3_GFW_?)H\F3_GFW_?)K4HH]HP]B
MNYE^3)_SS;_ODT>3)_SS;_ODUJ44>T8>Q7<R_)D_YYM_WR:/)D_YYM_WR:U*
M*/:,/8KN9?DR?\\V_P"^31Y,G_/-O^^36I11[1A[%=S+\F3_ )YM_P!\FCR9
M/^>;?]\FM2BCVC#V*[F7Y,G_ #S;_ODT>3)_SS;_ +Y-:E%'M&'L5W,OR9/^
M>;?]\FCR9/\ GFW_ 'R:U**/:,/8KN9?DR?\\V_[Y-'DR?\ /-O^^36I11[1
MA[%=S+\F3_GFW_?)H\F3_GFW_?)K4HH]HP]BNYE^3)_SS;_ODT>3)_SS;_OD
MUJ44>T8>Q7<R_)D_YYM_WR:/)D_YYM_WR:U**/:,/8KN9?DR?\\V_P"^31Y,
MG_/-O^^36I11[1A[%=S+\F3_ )YM_P!\FCR9/^>;?]\FM2BCVC#V*[F7Y,G_
M #S;_ODT>3)_SS;_ +Y-:E%'M&'L5W,OR9/^>;?]\FCR9/\ GFW_ 'R:U**/
M:,/8KN16P*VZA@0>>#]:EHHJ'JS5*RL%%%%(84444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444A(526(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 $
M@#)X%1K<P.VU9HV;T#@FO&OB/::-J?C2\M_$?Q8GT2VC6/9HUL1"8<HN2S@Y
M;=][D<9KDH_ _P )HY0]E\4M0AN2?ED6_7.?P4']: /I:BN3\"^$=7\(QWEO
MJ?BJ[\06DGE_9$O(@'M@-V[+Y)?.5Z]-OO764 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4CNL<;/(P1%&69C@ >M
M+575--M=9TF[TS48_-M+R%X)T#%=R,"K#(Y'!/(H \RURZ@NOVF/![6T\<RC
M2KL$QN&QPWI7J]>&6?@7P]X$_:.\+6OA>Q:SAN=-NI)5,SR;F"L <N3CCTKW
M.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#R#X&_\A_Q]_V&!_)J]?KR#X&_\A_Q]_V&!_)J]?H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH \"^+_P ./"UWXNN_$^H>,[/2=0F$?F6U_$D\8"HJ
M#Y/O<@ \^M<#H5Q:-KZV$'PWTWQ3;J05O]/M)8-_N,_+^E>D?$SX+#5_&NI>
M-I_%5IHMNZQ%FN8@5BV1JF2S''.W]:Y>UL%MS'';_'>R2,,,11R!0>>F <4
M?3=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% 'EGB/_DYKP=_V"KO^35ZG7EGB/_DYKP=_V"KO^35ZG0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !117!_&'Q]-\// 4FJ642R7MQ,MK;;QE4=@QW$=\!3^.* .<^!O_(?\??\
M88'\FKU^OC#X2_%S6/#/CP_;I%NK'6[M?MRL@!WL<"0$#@C/3H17V<K!E##H
M1D4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG!I]C!9VB"."WC6.-!V4# %>=_M"G_BQ^M_[]M_Z41UZ77FG[0O_ "0_6O\
M?MO_ $HCH ]+HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY,<T:R)D8.",C^= $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M26?PD+31+E9/^)BDA*@J<8_,$5ZC?_\ (-N?^N3?R-><_L[?\D.T;_KI<?\
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MLWQ63PF? <\WCVU>[TNWE658(Y'1Y)>0H7:RDGD\9KPG0/\ A5ESKUK;:_\
M#'5M MKJ98[6_N;ZY,;,3\N[+* /H30!]54444 %%%% !1110 5YI^T+_P D
M/UK_ '[;_P!*(Z]+KS3]H7_DA^M?[]M_Z41T >ET444 %%%% !1110 4444
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YOXAPZE/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#D_B3X.D\;^#WTZUNA:7D,\=U:3L,J
MDJ'()'IR:\U;P7\6/&]Q;:/\0;[38=!AN$FF-L$\RX"'(QMY'3VKM/C;)JT7
MPUG?1ENG1;F(WXLR1,;4',FPCD'I^&>U>8>(?BII'C5_#UA\-X-?'B2TGB6T
MR=L:H"-PE <[Q@<YX]30!](T444 %%%% !1110 5YI^T+_R0_6O]^V_]*(Z]
M+KS3]H7_ )(?K7^_;?\ I1'0!Z71110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S?Q#N=-L
MOAYK=SKEE]OL8K1WEM=Y7S@!PN1R,GO7RW#HNO7D*7-C\%+*2VF&^)O*O6W*
M>ASY_/%?4/Q*NX+'X9>(;BZLQ>PK82[X#P'!4CD]A[UXAX>N/VAK?P[81:59
M1262P+]G:=K9G*8^7)9MW3UYH ]O^'$%Q;?#S2(;S25T:9( 'L4#@0G^[AR6
M_,FNBNI)(K262"/S950E$SC<<<"LKP>^NR>$K!O%J+'K!B'VI4VX#_\  21^
M5;5 '@G@R_\ %T_[297QI,D5Q+HSRK86\A,-LA8;5]SW)]2:J^(-/U+Q[XI\
M?:DVNZA8MX81(],M[6?RXU8(79G'\62#Z=:[!-%U(?M0MJ_V*;^SO[%,7VK8
M?+WY'RY]:YKQ'IOB[PGXF\:6FA^'9]6M_%JQFSNH6&V!]NUQ)D\=3^GO0!%>
M:]J'Q,7X<:%<ZE=V%IK%G+=:A)9OY<LS194 -VR5)/UJA_PENM^%_ACXW\.0
MZE/->:-J<5C:WLK;I$BG;CYNY 5OIGZ5NZGX,USP)'X!UO1]+DU?_A'K62UO
M[2W(\PB09ROKABWZ52C^'/B7Q#\,/%U_=V(L]>UW4(]0M[.1AD+$V55CGJ06
MX/>@#0\):?<_#KXQ:+X?AUC4-1T_Q%ICR,M]-YI6>-=Y<>F0"/QKTW6/'WA/
MP_J+6&M^(-/L;M5#-#/.%8 ]#BO//!]KXB\8_%33?$VN>'[C1++0M.>VB6Y(
MW23NNUB!GI@GFO1]5\$>%M=OS>ZUX>TR_NF4*9KFU21R!T&2,T >:S^)M$\3
M?M)>$I_#^J6NHQ1:9=)(]M('"':QP<5[/7C=UX=T;P[^TGX2AT#2K/38I=,N
MVD2T@6,.=K<D*.37LE !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% &!XS\4:1X2\,W.H:]=K;0;&1>[2,1]U1W-?-O@GQ'>>+?AOH'
MPL\+220W=S+.VK7)7 AMS*S8![Y5AG\JU?VK[HOJ^AVR7R,L<+L]H'R58GAR
M.W'%<3^SUI>J7OQ:L+G3!(D%H&>ZE4':(R,%2?>@#[!T#0K'PUH-IH^DQ"*T
MM(Q&B]SZD^I)Y/UK1HHH ***P/&'B^S\&:5%?W\$\\<LPB"P 9!()SR1QQ4R
MDH+FEL;4:-3$5%2I*\GLCF_A?_R%O%?_ &$1_(UZ'7A7@?XF:9HVKZJ+BSNW
M_M6]5XM@7Y >/FY]^U>Z*VY0PZ$9KFPE2,J=HO;_ #/;X@PM>AC'.I&RDE;S
MM%)BT445UGSP4444 %%%% !1110 4444 ><^(?C'I_@_Q=-I/BS2-1L+'<HM
M]66$R029&3G R,=.-Q]J[71?$&D^([!;W0M1MK^W;'SP2!MOL1U!]CS7GGCB
M]^(FNZ]=^'O#MAI.DZ, $?5M4VR>;D9(2-L@^GW2/<5R>G_ L^&/LNJ>"?$U
MQ>^)K.[BDN5AECAA:)F!=2@Y P#P6YZ8] #Z HI!G:,]<<TM !1110 5Y1XO
MU_1M8^+?P\ATC5K&_EM[Z[\Y+6Y25H_W&/F"DXZ'KZ5ZO7DOBSPUH>A_%SX>
MS:+H]AI\MQ?7?G/:VR1-+^XS\Q4#/)/7UH ]:HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@!&QM.[&,<YJD'TFRWW :SM^[R JOYFN#^/,E['\,_P#1
M+F>TMFOX%O[BWSNBMBQ#MQSC.VOG_6O#^C^'_$=SH=[>:WJ.HK?0-IUMRT.H
MVSX(W<Y4GG_"@#[*HHHH **** "BBB@ KS3]H7_DA^M?[]M_Z41UZ77FG[0A
MQ\$-:)&?WEMQ_P!O$= 'I=%9+Z3>L=-VZU<K]D&)\(O^E<#[W''X>M5)9/L4
MFI7K:Y-=1RL8(;6,(WDR]-JXY+9[&F[):L'9*[9A^-/B/%X6\6:1I@V-%(V^
M^8_\LXV^5?R.6^@'K7>(ZR(KHP96&00<@BO%+_X(Z[KEPU_JOB13>SG=(S1Y
M8<8"DCC@8''I7::!X%U?0K6 0>)IT>*/8T(C\R!SV8JQSG'H0*Y:;J\\N9:=
M/Z\SBHRK^TESKW>G]>9W%%<4(?$FG:9=VNK7=[<&:3?'J-@BRM N<[?*P&]N
M WUK5LV35Y+"73?$4CK9#;<Q($S.<?\ +0$94]\<5T*46[7.M2BW:YT%%92:
M5>K<W\C:S<LET"(8RBXMO=>.?QJ)M$U!M*L[4:_=K/!+OEN1&FZ<9/RD8P!R
M.GI5V7<NR[FU16<--N_[<:]_M6<VS1;!9;5V X^]G&<U571-1&CW%H?$%V;B
M67>EWY:;XESG:!C&.U%EW"R[FW168^EWC7UA.NKW"Q6R;9H0B[;DXQN8XR#W
MXIB:1?+_ &CNUNZ;[43Y&43_ $7_ '>.?QHLNX61K45C-HNH-IUC;C7KM9;:
M3=+<!$W7 SG:PQ@>G%6!IMW_ &S->'5;@V\D6Q;3:NR,X^\#C.>]%EW"R-&B
ML3^P]1_L-[+_ (2&\^TM+O6\\M-ZKG[N,8QVJS)IMV^J6=RNJW"0V\>V6V"K
MMG.#\S'&0>>WI19=PLNYI45D)H]\L.HH=<NF:Z),#E$S:_[O'/XTCZ/?M;Z?
M&-<NE>U<--($3-T,]&XX_"BR[A9=S8HK-73+M=6NKLZM<-!-'MCM2J[83C[P
M.,D]^:J_V'J7]AFR_P"$AO/M/F[_ +;Y:;]N?NXQC%%EW"R[FY16<^FW3:Q;
MW:ZI<+;Q1;'M-J[)6Y^8G&<\]O2JZ:-?K8W\#:]=M)<MF&8HFZV'HHQ@_C2L
MNX61LT5D/I%\R:<JZW=*;1@9V")_I0R.&XX_#UJ1-,NUU&]N&U:X:*X3;%;E
M5VVYQ]Y3C)/UHLNX61IT5AMH6I'18[,>(;P7"2;VO/+3>X_ND8QBKCZ?=-KD
M5ZNISK;)%L:SVKL=N?F)QG/^%.R[A9&A16*FB:@NFWMNVOW;37#[HK@HFZW'
MHHQ@_C4KZ3>M)IS+K-RHM/\ 7J$7_2NGWN..G;UHLNX67<U:*S(M+O([N_E?
M5[B1+I<0Q%%Q;'GE>.>O?TJLVAZBVCP6@\0WBW$<F][L1IOD']TC&,467<++
MN;E%4/[/N?[=^W?VE/\ 9O*V?8MJ[-W][.,YJDNAZBNCW%H?$-XT\LFY+LQI
MOB']T#&,467<+(W**RY-+O'N=/D76+E$M5Q-&$7%T>.6XXZ=O6I+'3[JUU&\
MN)]3GNHKA@8K>15"P#GA2!D]>_I2LNX61H4444A!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !15?4+=KK3;FWC(#S
M0NBEN@)!'->#_P#"A_$__/\ :3_W^E_^-USUJM2#7)#F/8RW X3%*3Q&(5*U
MK75[_BCI_CEK.IZ3_8?]E:C=V/F_:/,^S3M'OQY>,[2,XR?SKR7_ (3+Q/\
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M2'\.F]:V\M.9O/9-V[&[[H QG'M5+XH:1X>MOV?M3M8H[4:79Z>K6##:55@
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M\XW[>N,\9J[7B'A3PW'X8_:;FM$OKS4)IO#AGN+J]EWR2R-, 3Z 8   X %
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MK'</E'TKWB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP<+_  JJ2\\ 8&?2M6TT77+_ ..&F>+;K2C9V+^%Q;3!KF*0PW!F+F/Y6RV
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M574KH!0, #S*]1K@?A%X8U3PU\/Y-*\06K6ER][<2%%F4G8[9!#(QP<>AR*
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M[QC<Y*X'"\=L\9(!T_P-U*^U?X,:%?:K>7%]=R_:/,N+F5I)'Q<2 99B2<
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MLD ,=F1CRAZ5TE<U\.M-U'1_AQH6GZT-M[;V4<<J$Y*$+]T^XZ5TM !1110
M4444 %%%% 'EGB/_ ).:\'?]@J[_ )-7J=>6>(_^3FO!W_8*N_Y-7J= !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM>B@ HHHH **** "LGP]X<L_#=K<16;33RW5P]S<W5PP:6>1CRS$ #@84
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M^ DL<'P=M99W6.-)YV9W. H#=23TH ]/KR'Q?\0]7\5Z[)X*^%9$UY]W4-8
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M1^&:N07$5S$);>194/1E.15QJ1D[;/L7"K&;Y=GV>_\ 7FM"2BBBM#4****
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MYN@KL=>G=._?OV/-C@Z[37*^F]N]_P C@=,3_A//'FCPZ/X0L?"KZ'=BXO\
M9(D<Q4,IP8PJ-U7&=IP6'3OT'A;1=-\3_%WQC<>)K>*_N+&9(K6WN5#HL9W#
M.P\'@+],YZFNH\3>#8]8\9:;K.D:BVD:S9#+SK;&1;B/^X_S*/4=>A(],9_B
MWP#8>(]3;Q)H^KW^A:M'B.6[MD8EP%V_=!5LXP,@XP.0:S]M!Z7MI]QHL+66
MO+?6_372R.?\$>)/A[J?Q.AF\-:-J6GZE>0M"B>7'%;+M0LS;$<X)5<=,9 .
M,Y-0^)_",'AWXF>$;]KRXOK_ %35WDN+BX<GY0T>Q%&> H..Y_# '5^%O -O
MH.NVFKZ[KNI>(-7V,EK<71?;"A&" "6(.&;JV.>@/-:OB'PU'XI\3:'?)?-;
M-H%T9FC-N6$V2O ;(Q]SKSUH]K!3]UZ6']6JNE[T=;W_ !1U=>.:1;>)OB-;
MZ]KMAXFO]+N;;4&MM-M(KDQVZ*FUOWJJ#NR& SZ]<CBO8Z\XU+X47$USJT>B
M>)I]*TK69/-O;!;19 S$Y;:Y(* ^@'L<C K.E)*]]#2O&4K65UZV,;QWXCUA
M/&6E>%WNM;D@ALA<7LGAV#9=7,A! *C)VH, D9[GKP10GU+7[KX.^+K/Q!;Z
MJL-HT?V&XU:W:*>6)I!@,3]XC R<G[WTKN];^'AO;C2-0T/7+K2]7TJ'[/'?
MR*+EIHL'B0,1N.23GI\QX/&%F\ W5WX%U/0=1\1WE_=ZD^^6^N5+A#N#82+=
MA%XZ ]SVP!JJD$E_74PE2JN4OG^6QQ<G_([?"O\ [!:_^B15WPAK.IW.F_$9
MKG4;N9K.>X%L9)V8P "3 3)^7&!T]!73M\/MVM^%=0_M/_D7K46_E_9_^/C"
M;=V=WR^N.:SKSX67;ZIKLND^*;G3K#769[VS2U1RS,&SAR<@98Y  )'!/<'/
M!JS?]7#V52+NE_5K?F<-J%[=:C\.?AU=:A<S75Q)JYWS3R%W;$S 98\G@ 5J
M>.=4U#4?$^NPZ)J_B2ZFTVW&(-)86EI9$*6;SI2QWGACC:"<;0?3IV^%F[PO
MX;T?^V/^0%=FY\[[+_K_ )RVW&_Y>N,Y-&H_"ZXN-=UB[TOQ-=:;8ZX/^)A9
MQVZN93SG:Y/R@Y/;N1G!JO:0OOW_ #(]C5M:W;\O\SCM:\3>(K_X8^"+NWUB
MYM=0OKTP27$+E#)AV12P! ;H"0>#7K_A_0QH&G-:#4]2U+=(9#/J5R9I.0!C
M=@8''3W/K7'CX5.?"_AW1WUL,-#O3=+,+/'G#>6VD;^.I&<GZ5Z)6-2<6K1\
MSHH4YI\T^R_+4\*>[N+'7?BM<6;%)E@ 5EZJ"2"1^!/-=3X)\!>$K_X66#7F
MF6<K7EIYEQ>.B^:K$?,1(>5VGTX&/K6_I'@.'3O$WB/5+J[%Y#KPVR6K0[0B
M\Y!;<=V0?05R<_P/F3SK+2?&6IV.BS-EM.*LZD'&X$AU4YQW7TSG%:NI&6G-
M;;\C%4IQ=W&^^FG>YH>(_AZVL^ =#T#P;J%NFF6\Z3FXN)C+YB8/S+@$-DL6
MQPOI@=,F\\3^)='N/%GA;7M2359HM&EO+._CMEA8#9@@JO QDD=>G7G ZC5/
MA=I=SX7TK2M(N9M+N-'D$UE?( [J^<LS#C=N(!.,<@8P!BI_#W@!=.O]4U/Q
M#J<FNZGJD/V:>XDA$*B' !144\9P,\]AC'.952-M7?Y:ENE/F]U6^>FVUCS7
M6((K/X$^#+NTC5;B+4HI$D4<AB9"?U _(5[U7G&G_"1K:YT^VOO$=S?:%I=R
M;FSTQ[=5*-G(W2 Y8#)XP.O:O1ZBK)/9]S3#PE&[DK:)?<%%%%8'4%%%% !1
M110 4444 %%%% %?4+=KK3;FWC(#S0NBEN@)!'->#_\ "AO$_P#S_P"D_P#?
MZ7_XW7T!17/6P].M;GZ'+B,)2Q#3GT/G_P#X4-XG_P"?_2?^_P!+_P#&ZXZX
M\&:Y;^*QX=:Q=M09L(B_==?[X;^[CG/;!SC!KZQIAAB,XG,:&55*"3:-P4D$
MC/ID#CVKEGEU)_"['%/*:+MRMH\"_P"%#>)_^?\ TG_O]+_\;H_X4-XG_P"?
M_2?^_P!+_P#&Z^@**O\ L^@:?V7ANS^\S?#FG3:1X8TW3KED::TM8X7:,DJ2
MJ@'&0#CCTKS#XPZ%IWB7XI?#;2-;M_M-C=2Z@LT6]DW 1Q$<J01R!T->PUEZ
MCX:TG5M<TO5]0M/-OM(:1K*7S'7RC( 'X! ;( Z@X[5W))*R/2BE%)(YK0O@
MSX"\-:Y;:OHF@_9KZU8M#+]LG?:2"#PSD'@GJ*XO5?!/A_QQ^TAK-EXHT_[=
M;P:'!+&GG21[7W@9RC G@FO;:RX?#>E0>*+CQ%%:[=5N;=;:6X\QSNC4Y"[<
M[1R.H&:8SP?XX?"7P3X/^&<^K>'=%^QWJ7,2++]KFDPK'!&'<C]*^A-1_P"0
M7=?]<7_]!-4?$OA?1_&&BMI/B*S^V63NKM%YKQY9>0<H0?UK4DC66)XY!E'4
MJP]0: /./V?/^2$^'O\ MY_]*9:O7'_"VO\ A()?LG_"%_V/]J/E>;]K^T?9
M]_&<?+OV^G&?:NI\/>'M+\*Z#;Z-H-M]ET^VW>5#YC/MW,7/S,23\S$\GO6E
M0!X7%X!\->.OVA/'\?BK3?MZ6D5@T(\^2+86MUS]QAGH.M+J?A_2?A7\4O"=
MM\.6>UEUN\6UU/21<&99+?O*0Y++M!9LY[?6NE\2?"?0_%/B&ZUK6_"-K>7L
MY6.64ZG/&92%"I)A6"J@55!7&[KUP-]KPQ\.M.\%W1NO#OA'3(+E<Q^>;EY)
M"S#'F(\A8I'C&4SNY;&<#?'.NWX'3]7E_,OO1S5_X0T'QC^TGK5KXETY+^"#
M0X)(T=V4*V\#/RD=B:R]3\+Z-\%?BEI>O0:7:-X4U63R)I;B$2OI-QCY720@
MLBGZG@/T^6O4(=%O+;Q1<>(HM$M#JLUNMC-<"[<><H.5<*255 0,C&_KR=HW
MN\0:1>^)]$GTC7]#LK^QFQ'+";EH_-8$%95(Y1 0,C.[KC.!O.==F'U:7\T?
MO1Q^NZ=;ZO\ M,?V;>J6MKSP7);RJ.Z/<.I'Y$URWA;4KGQ%8^$_AE?NS7NA
MZQ,NK@,#_H]D=T0(/.QF:)1C.=AP17IMAX4?2]9L]5M-!MC?:?IZZ1#,;Z4D
MP Y4@,Q&P'KNR_)P3M&Y]CX7;2O%=_XEL?#M@FKWR"WNKI;EP9_NXD"DE43Y
M5+*!N)R>2HWG.NS#ZM+^:/WH\_TS_D7/CE_UWOO_ $G>O1_A5_R2/PO_ -@N
M#_T 56B\*-;VVN01Z!:-%KS2+J:B]D'VMY%*M*,D^6F#@J,,,G'W1NW?#6GS
MZ1ID&E+9P6=C80K;P)'(TF\+P&!8DA<8X8ELYYX!9J5V3*@XJ]U]Z*&L:UH6
MK^)I_A]K5O,TFH:8UR0YV17,)8HR*P8-O&"2  <<YKSFQT&T\*?&F?P;X%N'
MATO5M'FN-3TTNTL5G)M*QR@DDH22N1GH1V*X]5\2^$-!\7V<5MXCTV*^CA;?
M$6+*\3>JNI#+VZ$=!Z5'X8\%>'?!MO+%X:TJ&R\]MTL@+/)*<D_-(Q+-U. 3
MQGBJ,#D/@KK%A9_!6R6^N8[5M$\^#45G8+]E=)&+!_3@@_0T_P" \##X;-J)
MBDB35M2NKZ)91AMC2$*2.V0N>_7/>MC6/A-X'U[5I=3U3P_#+=3.))F262-9
MF!SET1@K\_W@<\^M==##%;6\<%O&D4,2A(XXU"JB@8  '0 =J /,/B,H;XV_
M"T, 1Y^H'!'<11D58UR")_VC_"TKQ(TB:-=E7*@E3D#@]N&8?B?6NVU'PUI.
MK:YI>KZA:>;?:0TC64OF.OE&0 /P" V0!U!QVI\^@:9<>(K779K;=J5I"\$,
M_F,-B.<L-N=ISCJ1F@#R;Q-!>77QW\4V^E[C?3> 9TMMO7S#* N/QQ72_"_5
M]"/P$TJYEEM6TZSTTQWRMM**54^:KCID\D@]=V>]=;-X:L$\17'B6RM(QKSV
M)LDN99'VF/=O"E0<8W '(&?>O$Y])TR[EN+C6_@SJ<OC&5Y"RVD+G399OFVR
M,YD\K:<Y)()R>^<T =W^SY_R0GP]_P!O/_I3+5S6;AM<^-6@Z-'L>VT.SEU:
MZ#'(\UP881CLP#2,,]CGCC.E\,?#$_@WX9Z+H5X?])MH2TXW!MLCNTC*"."
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MJ2",KYC@O@\XP?8 '>4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\S3-"'^K@7LT@[GV_P#U5H^!_AG>W.M_\)I\2I!J/B&7F"V;YH;!>RJO3/\
M+ZDUZG0!SGC+6=*TCPS?6U]>06CS64RP1N=N[Y", ?B*\^_9VUW2XOAK::9+
M?PK>O=3E8"_S$9ST^E<_^T?=7;ZQI5OI20W$BP2"93( T>2,<9[\UYI\,-%U
M6]\7:9HMVIM+2:1A)/#(-Z@@GC![]/QKAG7DIM*V_<^IPN4TJF'A.ISI.+;:
M@VD^FMMK;GU#XA^)&B:%*;6%VU&_SA;6U^8Y]">U89T_QSXV)_M.=?#>EO\
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M/0=: /?**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=="!+&4N&3:V2?F.#FO>* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCQ7"W>O3W6N7@Y\R\E+ >V.X^M=W174J$;WGJ_,[5AH7O/WGY_Y;$-K9VUC
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M17E&A:S\9O$/A[3]8LHO J6]_;I<1++]L#A74, 0,C.#V)J_GXV_W? /YWM
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M1:SH1MV+%])N?):7(QAC@Y [5X_\8OAO<^'_ (6:IJ4OCCQ3JJQ- #::A?\
MF0R9F1?F7'.,Y'N!7T)7.>/O"$7COP7>>'I[Q[)+IHR9D0.5V2*_0D==N* .
M6_X4[>?]%,\;_P#@T_\ L:/^%.WG_13/&_\ X-/_ +&O3** /"]>\ >(--\?
M^%=%LO'OC:>PU;[7]MN3J#$V_E1ADPP&!N)(Y_"NH_X4[>?]%,\;_P#@T_\
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M3/&__@T_^QKL?!OAM/"'@[3M BN6NTL8O+$S)M+\DYQSCK6W0!X5\1/ .O\
MA7PI_:.A^/?&U_=?:H8O);4&<;6;#'"C/ KJ3\';OM\2_''_ (-/_L:],HH
M\S_X4[>?]%,\;_\ @T_^QKEO&7@'7] OO#<.E>/?&UVFIZM%9W;'4&;R86SE
MQM'!&.IXKW6B@#S/_A3MY_T4SQO_ .#3_P"QH_X4[>?]%,\;_P#@T_\ L:],
MHH ^=M1\(^*K7XVZ3X2M_&WC631+RS:>>_-](6C<)*0N\#:.47J/XOI7>_\
M"G;S_HIGC?\ \&G_ -C7IE% 'F?_  IV\_Z*9XW_ /!I_P#8UR^@^ /$&I?$
M#Q5HM[X]\;0:?I/V3[%<C4&!N/-C+/EB,':1CC\:]THH \S_ .%.WG_13/&_
M_@T_^QH_X4[>?]%,\;_^#3_[&O3** /!? G@O5_%5SXGCO?B+XQA&CZW/IT/
ME:F?GCCQAFR#\W/; ]JZ[_A3MY_T4SQO_P"#3_[&NI\)>$(_"<^O2Q7CW/\
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M23RD^7D; ,=3UKOC\';OM\2_''_@T_\ L:],HH \S_X4[>?]%,\;_P#@T_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG0IRIQY9,QP]*5*'))KY!1116YTA1110!S?B[P]JNOQP)I.M/I?ED^9L7/F
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M2<*H &22?J:LT4 %%%<'\6_'<W@GPC(VDIYVLW:LMG$%W;=HR\A']U1SS[4
M:%AX5O;7XKZMXHDF@-G>Z=#:QQJ3YBLC$DD8QCGUKK*\?E\<^);_ ,)^!-/T
MN^AM]8\3+^_U"6 .(E5=S,$X!)KJ?ACXGU37]+U.R\1-#)JNC7\EC<30IL67
M;RK8[9!H [>BBB@ HHHH **** "BBB@#BOBKX1E\;^#&TNQN[>"\@N([J%+G
M!BE9,X1Q_=.?2O';3X8_$#Q#>S:9K]CX?T?2;K4([R>:U5-T93C]P 3MR/IG
MUQ6E\6O@]XHU_P"(-]XETJ6"YL+D1 VINS R!8E4\GCJI/XUYS:V/@73]<&F
M>*6\4:7>QLO^KF2X1CGMMYQ0!]ET444 %%%% !1110 5X?XJAU?QM\1/%ME%
MXAU/28O#>FK)8PV-P8E:<J6#R8^\.,8_(CO[A7E7B[P#XL'BW5]5\$W5BL7B
M&R%G?I=@AH"!CS4(ZG!Z4 =9\--?N/%'PUT/5[YM]U<6J^<^,;W7Y6;'N037
M4UC^$O#\7A7PCIFAP2>:MC;I"9",;R!RV/<Y-;% !1110 4444 %%%% !111
M0 4444 %>2_'+4[R*;PSI=JFM/;W5X\EX-$W?:#&B\!<8ZD]SVKUJN+\=:+X
MMNM0TO5_!.IQQ7%B6$VGW3$072GUQT(]: *WPCO-#O?"\[^'KW6;@+<%;B'6
MIB]S;R#JC9Z5WM<5\-/!M_X4L-3N==N8;C5=8O#=W7V=<1H2.%7Z>M=K0 44
M44 %%%% !1110 4444 %%%% !7B/B;4_&,7QV\'0ZQ=16>E75Y<+:V-G*WSQ
MHJ_/,>C$[N!T&*]NK@_&7@[4]=^)?@S7;(P_9-%DG:ZWMAL.% VCO]TT <AX
ML35/&WQ/\4:.NO:GI-KX:TN.:TCTZY,(EF>/S-[D#D#@8]/2N]^%GB"[\3_#
M31]3U)_,O)(=D[XQN9203^E<UXP\">*AXSU37O ]S8#^WK%;+4(KT$;-HVB1
M2/1>U=MX*\-1^#_!FFZ#'+YWV*$(TN,;VZD_F: -VBBB@ HHHH **** "BBB
M@ HHHH *\8^/>I>,+'28Y-.N8=.T-+NW1I8)6%S<.S<C(QM08^IKV>N'^+?A
M'4O&O@N/2]'\K[0M]#.?-;:-JG)Y]: .:^,NIWL>A>%-.L_[89;V^B:[_LC=
M]H>%4)95((P3D<D^];GP?O="O/#MZ= O-<E:.[9+NWUV8O<6T@ &TYZ#&#^?
M0Y%6?&?A_P 67$>B:AX-U5+:]TMOWMC<,?L]VI4 AL=^.#VR:=\-_!^H^&HM
M8U#Q!<0RZMK=ZUY<I;#$41/ 5?7'K0!VU%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTLCYE*8Y"].37J<,,5O&(X(UC0=%1< 5E>)M&NM=TK[)8ZK<Z7)O#>?;,5;
M[9%3.G5E%WE]VA%2C6E!\T_DDD?.W@'0M=US7GL](N;BRB/%Y.A(V)WS[^@K
MVS3/A1X9L9!+=PS:G..?-O92YS^&*SM"^%EYH6J1W5MXJU )]H6>>%6VK<$'
MD-@\YZ<UZ-6.%PJA']XM3GP6#4(?O8Z^>I!:V5K91B.SMHH$QC$:!?Y5/117
MH;'J));!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JZI ]SH]Y!"
M,R2P.B#.,DJ0*\FL?AGKTO[/D/AB=(;;7+6?[5 CR!HS(LI=02.Q''XU['10
M!YSX$\/>)9O'&K>+_&5E;:;<W%K%8VME!.)MD:<LQ8>K<XKT:BB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KSKXO6?C75])M-)\%VGF6MRQ_M*5+E89/*&
M/W:$]-V3D]L>]>BT4 >0WO@[Q!J_PTLK"P\-V>@7^@WT5UIUB;L2QS!.3N<=
M"<GD]ZW_ (>>'=>@\0Z_XI\6VL%CJ&KO&D=G#-YH@B1< %AP23S7?T4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% ''^-CXUM;_3K_P;!:ZE:QATO=,N
M)!%YN1\KASTP>U<%!\,/%.C>#- O;".SN?$&E:S)JK:=YNR#;+P\*-T&!CGI
MG/M7MM% '#?#/PUK&D+KNL^*(X8-5U[4&NY+:%]ZV\8&U(]W<@9YKN:** "B
MBB@ HHHH **** "BBB@ HHHH **** "O+/B3\,=<\2ZEJ.MZ'X@>"XETMK&.
MQ:!65E/+*'8_)NX!(KU.B@#Q6V^'GC'1_!O@N\M?(U37?#DKNUE/(L2F)UQY
M0<<?+Z]Z[3X8^%]3\/Z5J=YXA6*/5M9OY+ZYBA?>L1;A4#=\ #FNVHH ****
M "BBB@ HHHH **** /GOXJ_#;XC>*/B-?7VCHMYH3I$L-I/J!2(XC4,#&''\
M0;ZU5T+P1\5/#S1+I7@OPC;*C#Y_+21P,\G<TA;]:^CJ* "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN3\>_$32
MOAY8VEUK4%W,EW*8D%K&'((&><D5R&E?M'>$-8U:UT^TL]5\VZG2!"UN-JLS
M!1D[N!DT >MT5C>&/$L/B?1_[0ALKRQ3S&C\J]B\M\@]<9Z5LYH **,Y'% (
M/0]* "BF32QV\#S3.$CC4L[L<!0!DDUP[?%S05\+Z5K_ -GOOL6K7OV.U_=
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MUX._[!5W_)J]3KRSQ'_R<UX._P"P5=_R:O4Z "BBLW7?$6D>&=/-[KVHV]C
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M+N\MU?:=K;3G!]*^6-5AU&U^!6J6%S=0/91>(HTLUM;XW(MD9LM#YG^R2/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***X;XQ>);_PM\,[^]T:3RK^1H[>"4C/EEW"EOKC./?% '<T5XOX075_
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M+?\ [^K_ (T 6:*K?VE8_P#/Y;_]_5_QH_M*Q_Y_+?\ [^K_ (T 6:*1'61
M\;!E89#*<@BEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA?C)X<O_$WPRO[
M/1XO/OHGCN(81_RT*.&*_EFNZHH \4\(2ZMX_P#BYI/B.[\/ZAHUAX>TUX1]
MOB,9DGD780N>HP2:[/Q3\'O!GC+7'U?Q!ILEQ>NBHTBW4B A1@<*P%=Q10!\
MZ:S\'?!5G\;_  WX<M]+D73+[3[B:XB-U*2[H&VG=NR,8[&N[_X9T^&O_0$F
M_P# Z;_XJNGU'P6-0^)FC^+OMYC.F6DMM]D\G/F[P?FWYXQGI@UU- 'E_P#P
MSI\-?^@)-_X'3?\ Q5<[\0/@'X-TSP!J]YX9T"ZEU:&#=:K%<32L6W#HFX[N
M,\8KW*B@#R#0?V>_ %SX<TV?4M"N$O);2)[A6NYE(D* ME=W!SGCM5__ (9T
M^&O_ $!)O_ Z;_XJO4** /+_ /AG3X:_] 2;_P #IO\ XJO-/"'P4TJ^^,WB
M;2]<\-ZA'X<M8W.GR2&:.-B'0#;+D;^"W<U]-T4 >7_\,Z?#7_H"3?\ @=-_
M\51_PSI\-?\ H"3?^!TW_P 57J%% 'S[\4O@5X8T;P4;KP=X>O)M2^U0H%@E
MFG;RRV&^7)XQWQQ79?\ #.OPU_Z DW_@=-_\57J%% 'E_P#PSI\-?^@)-_X'
M3?\ Q5 _9U^&O_0$F/\ V_3?_%5ZA10!\^_#/X%>&-7T+4I?%OA^]BNHM5GB
MMQ-+-"3 -NP@9&1U^;O79?\ #.GPU_Z DW_@=-_\57J%% 'E_P#PSI\-?^@)
M-_X'3?\ Q5<)\1_@YX)\/:OX,M]*TN2*/5-=AL[L&ZE;?$W5>6X^HYKZ+KE_
M&/@L>+-0\.W1OS:?V'JD>H;1%O\ .V?P9R-N?7GZ4 <O_P ,Z?#7_H"3?^!T
MW_Q5'_#.GPU_Z DW_@=-_P#%5ZA10!Y/?_L\?#J+3;F2VT.=IEA<Q@7LQ);:
M<<;N>:YWX:? ;PEJ_P .=*OO%N@7D6L2K(;E)IYH7!$K!<ID8^4+VKWJB@#R
M_P#X9T^&O_0$F_\  Z;_ .*H_P"&=/AK_P! 2;_P.F_^*KU"B@#YEO\ X*:3
M'^T%INC6WAS4#X2DM2]Q*#,8A)Y4A&9L\?,$XS[=Z]*_X9T^&O\ T!)O_ Z;
M_P"*KU"B@#R__AG3X:_] 2;_ ,#IO_BJP_&GP \$:?X'UF[T#0;J34X;.1[5
M8[F:1C(%^7"[CN.>V*]LHH \:\+?L^^!+SP?HUSK.A7*:C-8027:O=3(PE,8
M+@KN&T[B>.U:O_#.GPU_Z DW_@=-_P#%5ZA10!Y?_P ,Z?#7_H"3?^!TW_Q5
M<=X5^!/A>]^('C&SUGP]>)I-G+;#2F>69%961C)M?(W\@=SBOH&B@#R__AG3
MX:_] 2;_ ,#IO_BJ/^&=/AK_ - 2;_P.F_\ BJ]0HH ^=OC'\&O!/A#X6ZEK
M.@Z7+;WT#PB.1KJ5P-TJJ>&8@\$UVZ?L[?#5HU8Z)-R ?^/Z;_XJNL^(?@T>
M/O!%YX>:^-@+IHV\\1>9MV.K_=R,YVXZUTJ+L15ZX&* /,/^&=/AK_T!)O\
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M<^^*['_AG3X:_P#0$F_\#IO_ (JO4** /+_^&=/AK_T!)O\ P.F_^*K%\9?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,G ]35?0+"'QCXM\<R> +%[/P]J.@R6A/DF**:Z=2,JIQSDG)^OK67IFK?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)H8KB(Q3QI+&W
M5'4$'\#3Z* &>5&(?*$:^7MV[-ORX],>E)!!#;1".VB2*,=$C4*!^ J2B@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH KW&GV5VX>ZLX)V P&DB5B/S%
M.MK*ULPPM+:& -RPBC"Y_*IJ* (H+6WM=WV:".'><MY:!<GU.*EHHH ****
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MQ!")M\8/F@(O#>OXUJ0Z=I\'[5UU#'96B(N@[XHS$H42!EP0,8S[T >D:O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MIM 14L6\S[H48&?7I3-?^&_AOQ)XDL]>U*S8ZC:;?+FBD*$A3D!L=<&NJHH
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B1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>fhtx-20211231_g34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g34.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1@04&AO=&]S:&]P(#,N,  X0DE-! 0
M    %_2^83(X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%>6$<         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             !'0   =P
M 0                         !              '<   !'0
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !'0    !29VAT
M;&]N9P   =P    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M64:6G:X-!AK]GJD
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0H'P&"12D:&Q,\'1%R5BX?$F.$-R=I(H-#56@K5E9J+_Q  < 0$!  (# 0$
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M*5ELY0H93C16[/:E&L0Y=_1:^;5'/51U3'D5 VATY8R03@TS= Y)&!DYR<
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M^KV'?VP=%7&O;\.-&SLK JETJ<BAVVO2]9MU4D)K$-88>2HAF/V'S(>2 LN
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M?@Y4EUMMHGDX2C\(_0:ZWX\_4W9OAS 0SX9D)BB <F;(H^8?$2Z#/*QS79_
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M_CV_NA@D8F1 3&&RCB8NU"RXJN43K O^G3XE?NG:S;&+58,F(BD4./6:U76
MZG"F7JF^M$(%(P@OPFCPR5)[A)'$XK9?ZH^)ME;2E;0CV+LECNX$;,@VUA<3
M'*CAB,?\3%&9^],<0_#,K<$/S;PLN3PN._238FT]G8K"3/$NTHY$0F8R#'XC
M8T&&F3((@81(EF5+C^&*F.":(MX-"YJVL6P_0ON=1+LK%2N^])]GTE+<QEN9
MMW7%(J]?5*(/K_%.4]R9&*?22N4R^\ KDWP"_1/#SKP1^E_B7#[0GQ[?VQM6
M*$"+<CE;0QT1W@(W(.(PI(C(8&KBCAW7J/CC]9_",_9>'PGA7P[LF?$! (AM
M'8N$BA^6*&(;YP^*@W]R($O# 0X!>%W&VC/1I8;W:IWSO)<CP2W\4JI[@UIQ
MU145'"VHPBMMI5QQQ[X\=@,K]/@_3>&?B)@/B7Q1!+@^&?AS]LS8)9WH3\LJ
M 8?= !'S"M8G&2\FF?JACH94N*9X2\(PQ1[^Y,POA\2XR7.\9D4>*C,6[O0[
MC'Y6S<-7_8HV"Y)^)MJ[ISWS(Y2[KN%WDI925*4E$L N$H20M?-2%#*"#WUS
M _3/ F49<6U]LQO"T1CVM</6IPP>F5>+KA8_U+VC\3>@V;LR2=YQ\+9,HL2
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M>%,LU^+ ) F[] S;V_N[E79C$+N%?BXF"$2YIAGB$-!69,B@A #@[Q&Z*C=
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M LB283 23 ;PG^D\X;'R4HCL-_@9:1VQ\J$@8_0#\M9N7=R^KEUCNP[NX !
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MB74<$C';P21W/D^3YT1.">W;P<CN?)[?71$X)''M^'/'N>V?/OW_ )Z*,!Y
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M DE4@)4H =L9 T5K7APY\AZTS.:I5>D%M4Q"J9<ZU0U\2I-L5KTY/( YC*$
ME:$Y[$@*QW.3X>?"EU'HY(XU#<'HX%F^M54;RA OG[LN?#$5$H@6Q6SZO- 4
M(\<_=_[Q\9PM"L$+RE)[:=]_GV5\FSY*I-X1%I;*J;<C7J1$S!_[.5KD@*!(
MC.#X!83([$*;)"P>V!Y-#:M4BH/G0'O5T=V]PQ'>5O)=?[A;I6_:UK3+LJ[%
M>@1:339]5!FVY6D-LNPXSCK33Y3""PN0ZE#;2 %E96/D..W#;=VK*V/@,3/G
M3&AGR)F'D@011 SC#%%"(C!+F10.PK'NR_\ <ZY/9&QX]MX_#8>3##%%)G2Y
MTPF9# ?@B(0S##\29+AC8$G=@$R.CB%G(Z(Z7:;)H5IS]P[JIM>:O7=JXDW3
M70BWJXZB)2GV@Y1*:UF"4QX<:"\A1PTVMY]YXR/54TDIZA^ENQ9F P.U9N+
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M%-/I=S2BO'+3\EM;D=0\"\H2W"VFF7*G%/5/*U6S6^/89,,9@#^^GPVT>RE
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M26D(XXY?+G')2E?H"5$D@?PC^'P,:*K5S;%(3U3=4*4@!*;.Z=DI [  0MU
M ![ # _3'TT4-CR*VGT531$T1-$31$T1-$31$T1-$7&2<ID!1< "P A!3DE2
M4Y/?Z]L]_'Y^-8S(IGPS\*,0Q2WBC!A$6]"30![<ZZ+7NP_%'Q 8H8VA@#D
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M2F*V?1[-A32S@@D^HKY@2=%7%_,D-9^&N2.6W55FHK3=593\7\.N-Q1&)B!
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M<Z4N6O5BB2#=M8#C\EN0A:41OW3:.PCH'HDAM1.5 Y)('<:(:T.=@QU!KJW
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MD_Z?3]=$(Y]#IK7/O)0I'+'S*&/\)Q_N#_U[:(0[^SD#/35ZJ<$D$_PG(P2
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MIL./KYC 2$E)\9! SW((."#G'^^M4Z1!-,J**I@,5*9D/0@W R927,B@,VC
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MFK#+FQ$CX^"M<1S"'X_*_H.:NM55A:%DOQ,MY#N'@"VH#)2MO*NX[ @.'O\
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M9E9K*/22&T@<02<C."3W)R !D^YQYSGOK="(@/FB,1<U))+:.<A8#(*@ 4
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MJ.C6T2A(.X>ZPY) <"KOG\BGW;"O4*FT9[\4G!."<ZXH[8BB,1CP6"F&(O\
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M<JJ./\1YGIGWP0='%J)((W&W5R%AWO=TXCU1_P#$QZGXOI_ST.VB;X'!G_\
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M_MB^_'IDR/1F]_NV:D='%II4E:=Q=U0I/X3^U\["<>"!SQS'^/'+ZDZVC;)
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MZ9G)IR@FX@7G"G*1,"FP,\OA2<:@\_-O=*:L;5(=NK\U7]W7B!+ N"A#FH&
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M_=*#,"[6I6K=>=E4Y2[P*):(]PT!@+:0FG*%M37%07 M!=6\57*!,2ZD.)"
M(I05I5ZB@@I77N_'U[[LE*#> ;)QQ'-Z]FJN.4^\%*<*+@H+05%X, 6U+):G
M%2,S%$W$ ZV6_51\+Q0<K2KXC]V4KGE?C;2Z./\ +R('6F?IP4"!>(=CJ_:"
MWRTAE8EM?LS+"I4@A ;D!P7'^Y2V4DEK@Z5%7_%3Q&F7L:_>R/#J.A S\_5C
MHJ6Z9=X$+UK@H+W#UOO0BVI2/O$$<6 T#<*Q!]  <R?B_5([>EV =]]E/E=W
M'F&//7TXTHH9IMZ(2SZERT%:TR%N/K3:\M'KQ?F#<9*1<I#2FP4Y?!<"^.?1
M25'4KP\ORJX>A<V9Q[:CIZ!2*9>"6G6Q<%!)7*#B%*MB9^[C%676 !<OS.+3
MA*'\I#9'(LK\:M>Q^5+#,4N2"QMYF_5G4/4R\'3+].XJ"UZJ&D0O_9J6[\*$
MJ'K*?"KC G*<0"ELD1TLGYBESQHE,J\CR&1 I?@31?31&'VF61)?0_)0TEM]
MUAGX9AY:?_B)CEQ\M?DD/+QD]R#@%1EE>E/I].KK(<25I*0>.<=\9Q@@^.WG
M&/YZH+$'12*'># M:M[<,U97'YE7)9XJQ\H!20$XXCDA:5=BD>",CL<@D'09
M<SXF_#-8 ON[@.6I+]LMA,)@W##1F?>/&O7GRK56DPDH4%I6H*&<D<R<$8[9
M<(! )P2"<]_.LS\8QB+XWR.=Z7\.'YJ4^8,0Q^;/31M4,J5#40'>RBWXBPS#
M$D'\JZ8X5RY*2YR5R(=0%C*1Q00 I(!">RB!E0^F3G-9-Q[^_IJ"J?AE 8#Z
MCV[J6A)6>YPE11Z:2A*3A*>/($)45JQ@WONFOI1&MH&U>G$$9<%4(Y1PX*1A
M(7_Q&@M14M)',*"D$*)_XA(47$_+E/G40!L\F=ON34YZYJA,4@@EW!2E*4J0
MC@L C]X"HK5E)5A38(RUC!+G;!&Z\3SZ=&MDJE14J6E94<A;CA"<@*6XWZ.2
M.1SAKL <IY?/CL!HC>]>/8T_"@12"YR=4Z%A)PZE*R5!(2KGCBDMG@VH--H:
M0%AQ2@OU" 1M:\V[XH(@R IUQ;:4*0&UX5V6"5K+N/6+BU$\OW@:X (#(("]
M5_HW3T/?%S995YE[UO?IDRI^$PA+:7 A*3R ;:2VGD5%:TG@4J]%2N!+:5)6
MHI(===2M23$ ;EHP[LP' *ZJ.%%9]1Q)4  4$ ((45\T)4%H"R5$%122482<
M@9)&XD=]CE1$QD(5E)X#CPX(0A+>.165%'$I*U*)RH!.?8#SHC#U?KKSXW5H
MPDE25<_G1D-K*25I025*2/FX)*B2%.-H;<*/EY>Y(W',^1ROEJI5#2M'%;KJ
MB4J!42%8*B22&UA;*@"H\0\T[Q& #V!T?2G)&R]Z_BE*E_5%PPL*2IYPH);*
M&R$A"/3)/IE+81S86.*5LJ/%24E))"E:>B-K6WIZ>GL%F:*IHB:(FB)HBQ/A
M4>IZGRI'S# 0"5(6>2FUJ7R4&^8#@;;+;97W6A?<:(L!=%CE96VH-A:PIUE+
M+267DI4%I:<X)2Z&4+YNAE#J6''''#):?0M39=]_50A^_P!O0CT"O1*3&IS#
M$6FM1X$>.E26V8T2,P@<E(4I 2PVTA#3JD\WD-I0I:P@I<0$X-?4=-.6GJ."
M-1G.KYGGK]J+3"MT'J5L/?O=._-L=K-JMQ+-W!M[;*GQ)-Z;YW;MG7Z;4; B
MW5#E1S2J7LCN6W4V)QN4J:F+J3"DM0RXZU+,G,9UO?S_  ]%#EPYN>(K5GK?
M/B_U"=P>MT) 5TQ=/Q4 ,D=7%YX)QW(STEH.#Y[H2?JD>-15AF!Y?O[GFN!N
M#=[K9H,!N6CI-V3K#SLV'#^[J1U879(F-IE38T14QY+G2JTTW#9;?7*4X7"X
M6V%)+:">224T9M0UJT\_=<C.W-ZUX45^4.ES8.0667GA$9ZMKP,Y_P!%OU/3
MCLCI/+;BU'"0"\DYP<$8T2F@+\M*>CLRX"1O7ULQK55<W]D':)]]$1N9^S<;
MJHNM=Q.I<(3\/&B*Z6&V79;6>3[*I#24(&4N.'*0KH]1T1H=!Y9=_34*'=[.
MMUJHVU!_L?[/K1<;3SBZBGJNN<0* IFF+J9;K[J^EI#L)2@@PD^DS(S/*8X!
M"@YHI\MF&MO/O1</'Z@NM^0:1_\ @LVSCBJUNOT9:9/5/<33U.^X:;6*A][S
MF_[,*D-46LJI*(="FATKFR*C!2]'BES&FO>GW5:'0>EOV'HM;-]_M*NI3IT=
MV1:W&Z);4B#?K>+:#9&T?@^IFL+^[KRWKE7A!MAJX%3NG" Q'9HTFT'G+R;I
M;U6E6_!JE-F%B8'@TIWWFC#0/R6Z[>XG6RXA"T],.P/%20H9ZM[S0<$ @%"^
MDM*T*'A2%I"DJY)4D$=B,=6&@ ^QXGKDN$N'=WK;M^E2ZDGI,V5K;L4Q0W2Z
M)U7W=,JDKXB0&7%L,.=*<=OTXZ#ZKBU.I)2%)">Q5HHPS8G,L.+>RY9K<KK5
M<8;D#I?V';0M#:_2=ZM+N1(3ZB.:F2RCI2< DM=T.M>KQ#B5)2XI(Y:(_%A8
M4%.#&KN#0"KKYRF[U=;=1MMZOKZ1-G*>^U&GR$T6=U7W8W4Y*H'K8C0T(Z4W
M4.R9I9'P*%EI+R74%:VE'CHFGS$\0 WMZ+&7OGUMI@6W/1T=[3N"X9-/CN0A
MU5W**C0/C\#UJ_'5TNI1#8A**A/<:>D_#I 6 YRX@@:Q8D< _KSO0+'?WYZW
M&!)/]C;:MTQ[UI-H<6^JFY5*F1:G,I,1R[*>/[+V9%LTY%5^)FS'?AG&V*?4
M<-%3" Z2E*#A:G9-[/Q(?6+J<^TEZF^D[9ZH[V[H=#]K+L^D/N,5)N@]2]9E
M5*'(_P"TRW-L*9&>;J'3=3(*9MTU"YH5<L^'\?\ $5RWF9<YQ$!;"F=#3U?@
MW?N^3OE.0-.'+T6ZC.XO6R\VVZCI@V"2EQMIQ*%]7%X)=;]1I#A:>2GI.<;2
M\TI1;<])UYA2D<V7G6E(<4LC/_26' "^O?FL*L;I=;M*I=3J3?2EL94G*=3Y
MD]$"#U;7:J7/7%B2)#<*$'.E!"7)4AQA+"$+*0"\A84L@MZ9/^_?858ZGR'V
M[]YA;I=:TZ%$F)Z6MBX:I;273!J'5G>$>;!RP7O2J+;?2=(;CN%0]-(;>?22
M0I2D)S@L7(S)OD-/H6-6#&Y7'TC>#K6JJ*JM?2ALC3ONZIU"FLIJ'5A=R%U#
MX&4J.B5$".E)0,62/3=;<4< +QR7QR2MJFN;M;,.WN N!_[?.M[]EH%S_P!C
M+:X.SI+#"K</5/<Z+ECMNSEPE/O4]?2ZAM*&@@RE!<E ,527.04>&BK0Z"^@
MOWI]%36-_NMND*N5/]C3:RI)MZ-19+"Z;U4W*^FX_O<2E/1+>#G2\TJ;/I28
MP34(SB8Z$//(;2^I.'%.A[SY*  L0!Y#L=YKHOJ+Z_.J_IDVHO\ WEOWH?M"
M=9FV[E=5<+MM]3%P3YSE,HELMW$*[3F)'3/"CR:14'7F[?AOO2HS[E>1)B)C
M*:83(=*M"<@;:=/PMAMO]]NL3<FQ;,W!H72WLA&HU\6O0;MI42K=6%U1JK&I
MEPTN+5H#%29B=+,^&Q46H\I+<V-&G3&XTE#C0D.<>1*4:H .A8>M5]4YN-UL
M,_BZ7]@U905@-]6MX$K4%MMAI!/2>$^JM3J5 .%MOT6Y#JGDJ:0VZ2F1;D <
MV%@;Y<\V7!VWO%UJW'0J175])^REOJJD"+-71;BZKKO@UZG*E^FI$>=";Z4I
M#3+B6W E8,GFF4E<53:2GU#6S[Y4SX%*9UY@4XV%.-1ZJ:;O!UKSJC7($CI0
MV5IZ*&_%C?>,CJNN\4^K.R:7%J9717O[*/.='8^)7">?])D(F19#2D@IU!6B
M&E0PK5@.=<Z"M*^ZX8;[];RJ-7ZLCHVVJ+M#J=1IC5*7U57,S4*Y]W241U5"
MC)D]+C$9^FRDK]>#)?D1U2F@"VT2< JU*E]'9L^&EU:J6_?6U3)+D=71IMA+
M;;M95SF1"ZI+E=:=(E,QA;C"%],#3KUSJ]8O"GAL15--NK34%!/<H-UZ ..'
M>?D5UWN1UA]9&UUIW7>=?Z'[(?HMG4"%<56DT_J>KBFUP9%,FU68B*[*Z:HJ
M7)%(9A&+44.AE+50?CQFUN)<#VB?*<AI5N@\K<%G]-G6!U3=4>Q^W._6WW2O
MLY3K2W-MUBYJ'3;GZJ;JI]P1(#\J9$2BJ18/2S4H4:3SAK4643W7.#B#Q Y<
M39]]\4^4EF!.=!Z\5W>O</K;0 K^R_L KYVAQ3U<W>%E"G4)>],+Z4$)4ZA@
MNN--J6VAYQ"65/,I<+S95H=!Y#OAS7 V_O#ULUVFRJ@[TE[,47X2KW#2%0ZO
MU67?&F2#;M<JU#54H;*>E1?KTJMN4I%3MR62V:I1JG3)ZFHQD+9:*?*[,#G8
M6I7U]#FJ(^\?6R]<\VVE=)6RS"(5(@595=<ZK;N%"?-0GU6&BG1Y?]E/F[4H
MR*<P_.CI9_NWQ[2.3B4I==*M#H/(+C%;Z=;C:+R<5T<;3K3:,82& SU4W6I5
MV!5&%81&M4N=*[3<Z6I)%-].4Y!815LPW)* "Z&???[H:!Q3,L*^OUM5VNJ)
M._'6ZQ^SZ4=&>ULE==HU2K#B&NJNX5+M]=/@M5!%*N CI@]*+59Z'3!A,P'*
MC'75&W8:Y3:$B2HH"#<O0$@@>?#6Y;R7S-5ZG^MFE4EZKN]#]B.LLT1FO*C#
MJDK$:6F.M[TI%/=$WILCQF:S 0%3)T%4GTVX*%O,RGW &20L+4XMH:Y9Y>CK
MM+H6ZNX?6QL+3-[H=BR-NER[IO"TY]JRKA:N==/GV?6Y-$E.MU=NCT%<IB4]
M&+S)=I$$AM8"?5QR)4/:_%F_#OE2AS9;D:*IHB:(FB)HB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(K*FLE93Q2HCY5@'D,D*4"0H$A1 R$E)
MQY)/?11O?E0FMN'F:E74C"4@G)  )R3G QG)))_4DD^Y)T5LK#D?U"K*CQ4M
M"RGN!\@'$$I(5CDE*B"2GMW!.BG=?IIKQ]J?AOEXA24_*XD\$XY<T\1DDE0Q
MY^50/;SWT1K>PL>A>E3V JEL9:],*^;T^')7)7L ,D*2O (SV6#^>B-W]%9+
M((*2OY4<3Q 3Q"TI *\*2HJ4D\2 M2NX'?.<E&L/.V358@V]V>EL!_F5I;"V
MDH4A#48/("07"DEQLIRT5LEL%*F4J<<7E)9+'I+624XT!8%ZZNX):S>U%Q]2
M@4R>I"JA"CS&X+XGQ!,C-O\ P-1CQ'%&3%]="EHE+BNJ+;R.;10'TJ0A\/(>
MHZU[IKGIS2K<JUI;(UHXL[TO6JYKXU3.6RP2&W4-J//TPE"PI>4\TAM?P[2X
M[CZ4.%"6E/%E3BXRF2/?1J]4!RT /2NCUIE?)9 S):YH('-0.%Y4$A! (3Q4
MVH?,GGA>% DA:$JRE+ON_IP*I#CAWHV>O[75-$C((0HC)4D')5A0R<D]ARR/
M?(\ZBC>P I9GJ.3T]U0F, "%*)^4H'=1 !SG\2CC.?X<$?PE/C15M:Y9VZD]
M3F@C@HXJ((+80I/$%*L?A4>?)9XCL 5E/U!T0C-@_$9Y56+(^5S"2[ZR&%<G
M$H0"6B0%J;46G$>HA?!8:/IA2L$!2.>'??>2E(?+@.I;K6W![\;.IM/J[1A5
M.'#J;*E-K+$YEJ0RXXRVI7J);X_#AY!]-])RAQ?'(#:4(4AWWZ]E*BVC];,[
M!\KEZ>?)-/(C!$=MHEH^MZ*T*:#64J6M#2 V EMM#2'"IQ80E);"277G!RO,
M^_3+EYCI0>'DS7Y^?6^>5VE,Y3V;='%04%CFT<A:2DA"T$Y4.^#V!4.Y3J(0
M_M[C7B?J%!CJ*<%SECE\BAEI0( "7$YY+2G&0"K()/?&,4%NZWRT*$<:-;HU
M[D>KYJ@Q/HI(!&%?*2I8[DMK)40IHK4HE 2,# 21C)B-W74G5L]-#5E+<0MI
M "QR2" OAR4I/<I0LK*B4@D$\2G./8:(S=WHU5C2"(OIJ6>:U*4&N#(5P/'&
M ,!*$D%>5+=;SGB%*5@:)85-[FWFUN=,M%B.PX=5AR8<YAFH09(>9?;F,H=C
M2&%->D6'XRPXU)PH96VIKT@, I#R5ZK]_35NJAZZ.X#-5^98'2F55<@^E"90
MTPVPAL(:CMLI0(,>,8L=2#$B(6@+,1HMJ<:2&U!MI3[J7'$)2@,@-'[[X#17
MI=NZUI>P:IN5R.?B%+2D!!97QY$J)!4%<BD#BD%<=2%-N)6HA+RDD(4D@SZ]
M^_J$-18'G^+4MS0Q<H4CF ,*0@I2>20I04I965%:GB1R]0J ]0)7QSGE7UK^
M+=^R-0@4NQO>IXOUR!X*RS"<:<<7ZX*5E ;1Q5B.VA"&RVP%+*6TN!M*G!Q(
M4XIU0 Y )G??)"'X'7OUU5280"%ME8PI?-/%((2,@\>#I<1Q2K_ACCA [:(U
M1J;Z%N>F35Y@4H?3Z/!QUP8YE*2A@K7S=^4JR$.E',?*XL!*$())"<<@4K0&
MKWM;.YXU86L!18TE$61%?BS&&7HCB/2DLK0S+BO-$*+D=QM0!6 DCFGT^2PX
M"$J *@Y?;FI05^4 Y]@5H*:UN*T4V-&IC3$2'&BQ8<9AJ/'BPVU,18Z7%\@T
MRTVGT6T(;2@H:])M395Q*E>J5:=]UY>NBKVXG-^F1R#FW%G7(+*9C:F#P0L$
M+*%*"\AIP8*T)4E9:6\A39\!Q"%C*2< K4BS5L>'0]UH@AD.*<#[AY+4L<U*
M4H<UK44%95R++7J+,9K(2RI:L I"$H*,[.V5&&5QRK30YM10B%Z>?3<XY! '
MS%*5%QU9?">6/B5^LLN._P :PE2@0,:=]Y=%6+&O+][OQ]-;+S'H(>65*4AU
M:0I*$*4/WAX+]1L<DJ;<!!="6_F<4I9* 2I!",^\QY5L&SK54(=3\JDI("0$
MH*?25E2/W:VFDI6OTU 8+G!"4H3W*E*SDH32U!<-[.&+9M;VAXM\%K4I(4V"
MI8!8/-Q/8'U'A\P9)&'."?F(22I)*01ZY:<:5[8$EQ1A7'I<>#34.1Z=!:@Q
MTNJ>=C1DLL,MR)!+KJELIXM-....*=?4R$AQU64E[*E"MZA^[YAOLJ_!V+<1
MQ-LC5K<<L]RI-H(^0$<RDGU6P0GBM86!D\RI"%/!MHN.?#A3O'DGTS.P-5"6
M-N/(5O2CM2_T62B2E;GIA"A\Q"5*P M*6TK4M'$JP I26^#A;=*@X?3X-\E%
M7MWWR+&^A"R=%4T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$
M31$T1-$31$T1-$6 H9D*">PQ@ GLMU1Y*R?8!".)^N0!HL37@Q:YT!^OUX'\
MY5]PYHVZWNZUDW)= ZC+$Z[:38=J5=NXZBRBD6=3-S;"L*G[4LT5N0B FW;M
MHE5GM/0Y$=UV0]<3L@+YN,.-E?;DO0#K?A)W-WMZ&.GVXY%5>VEWJW;W$E[E
MTBE5>=2&KOB[;[(W]N':%J56;3Y3#[]%J-RT2)5I].4X(L^'1GVG&%ME;2V=
M+>O=_HH*/SK<U)M;CYDV6D-5M[=*L= GVD>V>W6^%Y[>V+TN[W=8EI6G5J$M
MF;=$[:6R]GH^YMO[84VYZNU4*A28-!O*\#92JG37F:JS:]"?H;4QA#+(9&A/
M!Z=N5=/0EL_J>2]N>G!<AS8'9=R8LN2W-L;(7*4H.\OB56[3U/)*GR7UE+A4
MGU'E+><QS=<<<4I:BJ[IT1-$31%Y]?:5W+<-N=+]UM6[7:A;<BZ[IVRL"JUR
MF2GX51HUJWY?] M2[:I3YS*FG*=)BV_59ZTSHKJ9D7'KLJ26R23OV;R74'2Y
M:U,V(ZY.H;ISVYDU.'L[%V!V-W2@V;.K%0K5-LJ^JM<-]6]5GJ;\?(D/T\W-
M!I,";4VE/!J3(I3TC@7Y#BR[]N\RIUO;RZK Z@;=W'I7VE701=U0W>N:7MS=
MMV;\V_0-HHT6/3K.H3-*Z5=Q+@FW!61#CM3KAK\VIPE.P15Y3]/I#,6'\#!:
MFNS9$E6_'M^_JH]PUA:CVTJ.&?)F?UF@LI99*$ A'(!OL@)+:&FVFU(X 92M
MM"5#/X<EM.$(2-%1]>;\1P]K+-T531$T1?'7W3+AJ]M5BFVG7$6U<TZFS(U$
MKSE/CU-JDSW&B&:@J%)0XS(7$/[YIEUM;2W4I#B%)[:*$MU?A8:Z^6=5YU?9
MFT>ZK4LKJEM>\MP+FW0KEM=86X]'FWI=SPF5FKH_8;:VIOR'FHS,>- C>M4I
M*HE-IS#,6"P&H[#*4#B0[;7\%0AS8:"]C?E2Q]5YT[Z?>==M/[3SJPJUPW''
MWWZ4.H"DT'86J1KAJ\)%DV_8-B;37W;MM0Z1%GHC2*;N+5[NKE/N2"W$#]TQ
M9D.E8]>&VX5K7R[%?)5AY]7%NO>J_293AED.J*O4>0VXX.2"UR<YOY;#80VK
MB7RPI\-H4\&$E8)0-%>V[K^RY#1$T1-$7G-]J7:FY-R=(FY4RP-U[@VLA6Q;
M]6N&[5VK%A_?UUTN'';,.WHM8?C2)="C/3BARH2J8J/,?BA<=+Z$J.5^]*E0
MM<\O,@+62[;-H_4%O9TU[+[KRZG4]L*9T,3MVJ?;PKE3I<2K[AQEV';T>Y*H
MF)*BNS*C;4&M2YM-=F%PQI!54$%4II"PNSGL=:MI9,BV3L^N5VOKJ35<9 WN
MW/H_V,>XFZL&[:_,W&LS:S>^A6Y>LB1+F5A42R-P+[L.T*_)DO.)>G51%OT6
MERVYX=<FR51VYY?$A;6!]M,T]:^5OJ'_ &7973WMY;_3?UP[;[2[1U.M&P=W
M.B6Z]Q=P:%-N2K7#&F7WMEN7LO0+7W%DN521*0W6KKI6Y][L5:9%4TY6W82)
M$SU%1&.#M^N7M^4ZLQ:G*GN#F!T7KT%\B,#L>??V'!03C]3G/Y8(T05JS4-Q
M6_>:KT56)-:+S);2H(4I7$%38='SI4A7R$$9XJ44GQR "LI*DDH2P[_'6J\?
M-T+9W/M+[4;IHN6K;M7-=-JW=MSU'JMC;",ENF6=:L6W+*I3L98IM-:937*_
M*DJ4N=5:T[,>]+THL-#2$!.HU0= W1":$U\ONWF:#-:(?>%:L#9#IYZTK9K]
MQ/=16ZO4C=-#OFI.7)6'W;LHE8N2[K=DV'-H<B8MH4NWZ;2H,B%2VFDJB.LF
M0P4XXFJT^OY7:/3K27=OD_9K[^VS<5Q3=T.J?<R\[?WTGS*Q4*TQ?M.N>W[X
MK=19JE,?E/PFF;+J5$@.T65'CH-$:I;C2PAIUXD#8^[B]&/LL2Q<9CT.7 ]N
MMJ-_[%H'4-U^Q-DMV:E4YNUMD]&UY[IV]:<*MU2@TZH[A5'<:T+7>O5UR#+B
M_$U.RZ2ZMBBR'5EJCOU]B8QB2EA8,:W]FJ.IKW='&6IZW.=&/L<LMF_LWKQN
MB_.B[I]N:\ZS-N&XGK,=HDBXJFZZ_4+@A6G7:[:='K$V6]^_GS:M2J!'JS\R
M4MV1(7->DJ=6F2V4OIZ)GDVO%K-JP%3ES6].BR31$T1-$31$T1-$31$T1-$3
M1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T165M<BKN %>?.00D@$$>#D
M]_R_/11C^W.GI=:353[/[I_K.\J]Z9T*ZQ4I-Z4C<RHV''NJ>WM55]RJ&PTQ
M3;\JMA^F:9-NB'\+3Y$:J.*]1J938,K@78[:@1CKZ=WZ\M>;OWHCV?W$LN?:
M->FW\'G-TW-Z+>NJ!>]5@WG8VX:X9@_>=C7,TA4^VHAAN2J8NGPDJC*I50J,
M,MEN4X-%>^^_S]7:729M#973W=G331*;4?\ L\OJW]Q*!>4JH5%VH73=:]U8
M]8:ONX;BN!Y/Q55N>X9%=J$V?69"3(=DN-JPE#:$)*-QS]*4^O9?OFU+;IUG
M6S0+3HZ'&Z3;=(@4.EMO/+?=;IU+C-PX3;CSGSNK1&9:2M:NZE GWT5[_%@O
MH-$31$T1=8[O[36=O?M]=.V.X%*9K=H7?1I=&K-->6MKUH\I(3ZC+[0]6)*8
M4$OQ)K!3(BR6VGF2%(&BC5)?EP^GHZUSLOH(V4L>R[_M"#5=SJO,W.=ME=Z;
M@7'N!5:QN;6HMG%*K9I,F]'6VZB:-1CZR8<!(2TE$F2E047W%*)6M<Z<N7YX
M\!WS=FR5FWON'L_N?<;4V5=>Q]:NNO6+);F.(8CS[ULJN6#7U3H_'A+#UO5Z
M7%94HA382@^<Z*KMYM'!.,Y/;DK 3R(2$@X'8?*E(P.W;1!0 :*O1$T1-$5E
MY"UC"2G&%=E9'S8^4A2>XP?Q8\C/OC18D/7.S]<M#?+JM;3TL;>(L[>&R(,F
MY*-2=[KSKE_WE(H=?FTJL_M/<=)H5&JLNE5B,$RZ8A<*WH#;'H96T0I0)(2-
M%E^/3OV76M_?9]=/NX^["MV[B@W2:A4:U9=Q7;9E.N>;3MM[_N#;V6U,L^O7
M]9S#9@W36:"\C,*?.6EQ33,2,^'&(S824;H&(IZ-HRW:894SZ@*RI*EK4E![
MAL*==6$I4<$("%H2EO'!O@0CLK1&9^/?YYDK(T531$T1?!;G[<6SN[85S[:W
MG%>FVI>-+?HM>B1Y+D-]^G2>/K-LR6@5LN'B.*P#@^=$6O>[_1)LYO32-OJ=
M<,B^+7J.V= -J6M=NW5X5"SKRC6JY3F*3+MF3<$)IR3,H53I\9ANITYY/I27
M$!S*5)2H$[[[^K\Q"Z.=DJ?3J/;\6A346=1-H:WLC%L-=5E.63)L:XI-+E5=
MJHVZH?!3:S,=IG-5<=29R%SJBH*)EN'3OOS4KWS^WGP7&=./15M#TQUVMW38
M\V_+DN6M6M0[$17=R;RJ%\U6@V-;4J3+HEF6Q/J;:'Z);,1^27W*7'Y-R9#$
M)U]:U0V2"M6X^CK;S&/'YG_,Y/\ KHB:(K;@6I(""D'/<JR1C!QV'G"L'![$
M9]\:)==1W#LC8]T;K;>;S5>'(?OC;"EW92+4EMS'6846)>T)B#<'KP$@M/NR
M&(S26G%*!:P2,DZ*-?CKF>/"@MQ6O5O?9\=/]L[K)W9@,7C)FL7)6KQI=D52
M[9L_;&W+MN1"FJY<UM6.ZQ]VTBMSFW7DN36%DY?>4$I4ZHZ)7TOQ[97=L/L_
M-@-H]QCN5:<:[W*E!5=SMHV]6;LJ%3LS;N1?BI9NZ7M_;+J!"MB77$S93,V1
M")6J/)D,H]-#JLD;6OIY\Z/EPJRXV]_L\=C[_M^QZ)6*QN=3JAM]3+HH-!OJ
MVK_JU#W$D6U>LMV7=-KURZV&W)M7MJL*=;;>HT@?#-M4ZF!HH7&2M)5;<;?;
M>6UM?:-HV#9-,BT.SK)MZ#;-O42(DHC4ZE4N.S%@QV$>"H--J^(D+R\\H))_
M&YDHV=+DVR.7M7@ONM%4T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$3
M1$T1-$31$T1-$31$T1-$31$T1-$31$T18CTM+"B'$A"!DEQ;C:$! ;*RLE1&
M$@A2>_CBI1PD9T4) OWYKYVDW[9=>G2Z90[JMVLU*!R$Z!2ZU39\V(I)PI+\
M:+)=>;4#VXK0DY(^NB/2U6MW]*\++Z)<QM(!"'%Y("0A/)1SY) _"E/@D^#V
M.,:(#PRYA\QS52Y3:>. 5!9PE0(X'N  5>$J43A*3@G!QHCC*O+[V=JLZH7-
M;:;4\Z"VTG!YJ('RDA))3^))"C@((Y$@X&B/;CQR9W4?'-87E+@4AI;W (*E
MJ0@CD$I'<N)"D*4W^)(6G/G1'H]L^7/[71<YM![H6I)P0I "N:3C"D '*^((
M4X!W:00I> 1JMWIS1^Z5&H9W]U!G-I4T@@!;H64H+B K]UQ]4 $@J4V5$%*0
M3E)P,=]1"6]>%N?;5YOO"/Q:/-/[TH2C*@ I3A/IA*O"N82L@C_#^8T0ELB>
M0YJ%U!EH\72EI7S\4N.(1R],CD4E1 XX((5G!R .YT1^8O>EL^'5E;;J]/=>
MEL-RF''H"DHFMMOM.+B+6 IM$E"%*4PMQ*@M"74I4M&5I! T1QQ8L';7N]JK
M)5*0C *23Z@;4$X44*RGD2!_"VE06M0[!&3['1'OIK[OHUJJ3*:! R.1XA()
M "BL** E1['(0L_EQ.?(R1Z.W'MG'+52W)2L*4I#C*4K"#ZR?345%9;&$GYB
MA2N/!>.*PL%).#HC]\;LW)C^RXR;7Z93EPFZA,A07JF^F+36)<Z+'?J$E327
MC'A-.N(5)?2CU3Z3(6M7I' ^=&2KWX=]A7IU:IU-,3X^7'A"<ZEB(9DAF*'W
MU@%N.T7UH]22Z3AF.CDZZ4J"$GB=%"6#_CG?A5EGM/I=*@E*@  0I0QR!\%(
M/<C_ ,0R,Y&<C1'O0T]>2O:*IHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)
MHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(
MFB)HB\L/M;;QN^WNG_;FT+5N>J6?$WOZC-H]C[SN.CU!VF5&F65>\RJO7 F!
M/BN1IT&?4HM)%+CRH\R,6D3'\.I=4TAQEQ[X]ZJ9]WI6U#4YU#*BN_9Z=(>S
M]0VFW.VV<3TWW3MC=E(J(O6UJI4:=5=P8B(DAJ79E\IJE74+P>N9'SEVK,U"
MI*D(28K3J\(2[\U'(.9H;L 3?2_HSY@K5>;UT]:,39JJ==$6W]D1TK4N^Y-.
M9V95]\S-X*GM[!N<VF[=\:\H2%6ZS79#_.HM6VS2'.#+;C,FHB02V@KK2V=&
M>]GO7ASLL:]^M[KMG4'K(WLVUC[!1-C^CK<*HP9E!N2E71.OG=BU:5:=N7?4
MXT2IT=Y%+M2L4BGUAQMJ2^W6&JA*=:CRXU,2RZYH4:_'IT>]+<,EVZ.J#KBZ
MB;]WM<Z3*/LC;UE=.[%@QZA;FZB:O)N3=J\KFL:D[AU.V:+6:4Y"I>WM,C4F
MMTB/ K-?34VZE4)RE/0X<&+*ELN^^^:<_2WWSO:CT6I^^WVN6\U(W;WTM&PJ
MYLIM5(Z;8%G4BK[;;AVO?6X5P;O[F5*P*)?UTV=:]Z[>0IEMV+2Z=+N!JR:3
M<,Q%=16K@A2*FW%-M.Q:JL:^7FULBV03U>U,BS_?4\67<U,ZU>M[J5O/="#T
MQ4C9S;JR;"Z7^GKJ&3+WKHMRU"XTU+>G;BNWTC;J=1*0Q#^9;EONP*A7)+D5
M<"-*@+ATBI^D\L'>U0P8\ZD-P0->@J?=O6BZ^MWJ4ZG=WNI3IOZB*#<5CV[8
MMS?9M7)OS4=JI\>N5!ANL*:@5"IQ8\UJIM4ERJR+J9:ATRN+I"7H5O+<B.)]
M1:6W \T.E1IR-:%M!RLS9?94/K2ZY:;TI6/U([J75TD;84/?&IVN;+EWC4KB
MMR%M70*S%JCU0?N)FI.Q9NY%S3W8L!=&MBSHS:QF:A^7&BM)EN%&K1P#0@>?
M30MKK5:;[L==/4_U)=.N[5E4?<O;%VZ=F^IWI^MQO>&R[7O^QK8W&M6]JM2I
MM-<;MB=4(5?HC$2:\EFII55:Q1+EIZ.<>865XT[>H]\M%6KS+L:^6>0^RV]K
M'5]NMM3O)U+[7[:V-M?(ZA;_ .HO8/8RU[HFO7%2K5KEWW7MU-JM6O.\6WY-
M6":=06(;Z:?3*+'IBZBVMF*XM<L(=#OODC/5R'XOZ,17-NF:R=[NO[K+Z4Z/
MOGMGNI1=G=R-\; LO:3=#:V]K1@5JUK%O"U;^W7H&UU<H]QVK4W:I7[:KE$J
M-?B,MRHDRKQZ@Q,0Z1'<;7'!0"Q!-N;_ )UZYU6X'3MO=U947J^N/I6ZI)NT
M%VR:ST[,]05F7)M)1Z];\*B)IU^TNP[EL^N-7 X^[5E&=7J7(IE9:;IZG8R'
MTR*>RZZ$-7/NG*N655-T :LYJS.V;Y9:C6Z[RG;]W'"Z[J/TRKATD6-4NDBZ
M-]GZLI+Z:VBYZ)O':VW/W>F=ZP;%)8I-=GRW ZTEQ4SX0-+"DJR;T#_:ULGN
MRKVR)(I:]*ZLQ;(Y9+P#ZT=T=VNL+;+HRW5H3_W/NAMWO7URWY95/LIZLPZ?
M<+G25?#<FU*$_%B3%F9*NRVMO#3Y\:2'&W7ZLKBTB-*#BYWWKU=7,WZVYCZ\
MO/Z_[13?F?U8WKT0U_;.Y*K#VWVIO'I/WBNQVES'(\2LWGU WK0X]F6_4U17
MN*W*-;-%GU1^GE<AM3=S12\@!2B@C"KV.O*[OF!Z/JOU&0&^#;:D\."H[../
M );4$_,TTE#: &LY7^)0YJ5@ =R0=\-+AZ@N7L5R&BJ:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(NA^HWIXL'J?VIN7:#<J/+=MNXO@I3,ZEO(AUV
MWJW29#4VAW';]0?9FMT^MT:>TF9"F(BE06/27R:6Z%E&J]/KP'F[]%I90?LV
M:]6[PVOJ_4AU9;M]3-D;)5B)<6V6V=W6SMY:%OQZ]3&WH]'J]]3K2H$>L;@3
MJ/'=_N+E4FPXZ9($MZ&Z^.9*K@Y?V4U F0)VUCG49O".E.I;A2-RI?3;\-9K
ME)%8DU9-?<MUK<%V@+OE%AKK:$SS;#=0:6@A;+=32PXIK3OOT4^U_P 5U/Y7
M><SH,L^5M1U>[2IO6O1Z+U>UVZ*Y<LUB%%1*LXW59E&LR7"MUL/^FY'C0Z+'
MD1E/%I8=<6E?)2?540AVR8\Z=YY574EW?9DF57;]E[6=36[6S5L[UVG9-H;[
MVG;-)LRJMWXQ95MQK.8N&W:[6J._6]O[JJUJM.T6L5&#*K423'$!^-3X-0IL
M6:!#]LS6LVCZNE>=?3NW!6:Y]F&FA5C<!73IU-;N].5H;RV79%E;NV=;4"TK
MO;KZ+$V]I.U5-N^V[ANZDS;DM&_*MM]1(%NW+<=.J2U5J5&IUUO1F[HI+50E
M#P/YOY99FR,:^F;'K=C4?1EL5M9T96AM%=V\=U6S=EV3?^V#:;9C:&9!N&?]
M^2*'0MC[/NZS+7J*:[/2]6;BK<^GW6[)K=5K\F34)\Z(W)DRWRO@F]U[_8:W
M2M+4>F1TK[TJN@V/LQZ%08?3RQ9.^%_6TO8CIYN+IEG(51[8JD'<C;"OTAN"
MN!78TZ"Z]2:BQ4&6:HW5*;*<>0ME$=+10IQ:XJN6O7[-JV[@VCZ4[ M7=BZ;
M(O/H\GIJ^TNYC=O6I<[Z:FY2319[UPVG<5-E4BK-U"&4Y#,BGR8;K+:HLI*7
M'DJ44:KOG^UFTS!I2RZQJ/V2E'K=(WU%P]2FZE<O7?ZX-N[]N>_9- L:+4*'
MN/MNN(Y2KCMRB4^C1J%'HLE4)@.6F]%7#BI2?2G.**E$C:9=L[%?:7%]E]:E
MXM;KUFX=Y;]8W.W+O[:G=:#NE;E.M^BW+9FX^TE$>HM&N2D1FXCM'F-5=#RW
MJS2IE/$=QM;D1AYM"@\"%SHV;O;@RP*W]EK0]PZ'NO+WKW\W W7W9W>8VVHU
M<W3GVU:%LKH%F[77M OZWK/M"U+:APH5+ILBX8#<VK2I]3J\^=(*'2^VAE#)
M:\4J_#UXW?Z<PU=R9?3K;RNJ2%U5*K52-R1]D*EL(JV TU]S2*!7+_MV^E5=
MQ\N%]-1BU2A,LM(0T$+8=45.I*0DT._*HZ54(H7SO4C0"PS_ !4+0OJ3Z6-]
MMW_M&]O-T]KMU[]Z?*+:O1A?=D2=W;2H5I773IE9N#>FU:F[M_7*!=<>33Y,
MF7!9E7!3Y,= =A2J'&<'JA:U,+ZNW/ET9O=!05:_+G9Z@T[<]I[!?9L6'L;2
MNFRD4W<:]+J1TS7IU 7=1*M<T*CFJWK)W\KE6J5Q1+M<IR(D62JE.3?2ASV8
M:'9D-N.Q(:0EH:6XWRU#<_MQ5H7NW&MB>F5== OA=O\ [(G9W;;:FX-J;9OV
M\6:=6^I:S>HUBJ5!N/5JA1'-OZE$F6;MQ3#)?;#=H6] @Q*-3DDAUJ''2X&4
MK4I&HG0-WDR]8XT<QT!',K'!I., )!;;2A12D 8#A!6H9[*)QVT3IP\G;O[+
M)T531$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$3
M1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1
M-$31$T1-$31%C/$\\9[!AU8'L%I4T4JQ_B2>Z5>0?!&KD>8]074S'(^A#+'<
M "X*0 $JJ,DJ2!A*CZ%0=RH>"?4 <[_Q@+_$ =#?H/8(+=3[E9+7X\^Y9:)/
MN3@]R?)/ZZB"\7/Z!9&BJ:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
6)HB:(FB)HB:(FB)HB:(FB)HB:(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>fhtx-20211231_g35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g35.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[13F4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %,J^4R(X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%>#R$         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@              ^P   8$
M 0                         !              &!    ^P
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    ^P    !29VAT
M;&]N9P   8$    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M539T9>+RLX3#TW4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $
M 8D# 1$  A$! Q$!_\0 '@   P " @,!              $"" D&!P,$!0K_
MQ !A$  ! 08$! ,%! 8$"08&$P !$0(#! 4A,0 &05$'$F%Q"(&1$Q0BH;$5
M,L'1"1880E+P(R3A\1<E)B@T-CABDC-$:'*"HB=&57:8TC4W0T5'2%169&=T
M=7=XA*6RM,+_Q  = 0$!  $% 0$              0(#! 4&!P@)_\0 9A$
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M]2J_EH*G")!J2*TJ%Z60*$["ZU-L(0B$5%*A+6%Z>5 **=SA%_'WK\'W@!%
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MA$T!44!45"@?BO0BJ[81EST7H!X4#[C4(7LBJA HBI7^(("NW;"(RNQ&KT9
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M2#M7"!"5;WLK>99HI5H*@[V1 MZKIW5<()[WT_%/10E!2NU5-42ZDK6V@P@
MOOVPO"0FC2Z6 _O72@PBLQ!#&AV3VI(6P$)5"FJ%+5"IW'D1YVP@ "S"KV^8
MK79PQ,4+* #L@1/4X1#5"W-^5!HWRA"Y*7J!O92!H4*7J3A!/?H"Z(S;/1(
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M,C<,99D+.D! <(<W<1H6$B74P@XR F4-#,062I1,YP(\2XLYEGKY66_9NO\
M%D'&/&""[YPC( (^X-F4EQ0:QA_XP.,$UXK^".!F68X,.LX9>\7_ (9<BYT@
M)=+WD-!2/,$I\0W":8OH<EY$Q0?0K,#,9>V[C7+]XP]:BV&2RPVR\99>?OWI
MR@$!( J 39/M#VC:7 &WW*T4U$P\W8;9#'NN9)_#.R"3S,LS!X]9:)T*O"#:
MU ,4E23K&,P1%1$ 2E!6H4E5YG4O]*?3J79:D4YS'.(EB%E,BEDPG$RB6VN1
MAQ 2Z%>QD6];+2 !ARY;:\B-1B1B I"!_0C=2#>PHPM&O2%\>C$UX>2;,T+)
MLJR6?QO$S]1)U S><Q,UE.7Y?%0,;-Y).XV(D'MHIK[5DT/#QS+AD?T'O'*]
MY>1H8'8>_#\3M3/N^A#!ZN$*A*IL4>L>-UXZLQQLA=14OX?RB(F47*8V/D\6
M)K&?J]/&G&<H3*<),I<];=NXLR2.:B6HEVV\Y7[)</'1-.8/O\JQ1*%-6 -G
M6S(NI52SWCL3-/BHSYD#+_$IWFKA6ZC\[\,XC*<3-8++<Y+S+KW+&<6)H\@<
MR-QL2RW$0CN$^Q9JZBH)HO7[;UTX9=MLB(9+)].>WXV](AE% :@HJ61!JE-4
M2KE>:1WBGRS ^)N6^'AZXE[(CY0Y<MS\S6&$2[SS,9=-,R2C*+,JY_;M-1.6
M,O3F9/HKEY'+PRR'4-QKL-/?RB(LJJI&NHJR*^[EECA&<_&*\R9G^'R/'9-8
M:;EO%^:9(SK'F.;8=99R(Q <.G\ASX]!81XZF<RXN9$E[UPT0Z=&(FCP-$2]
MYR/F!XP[O/\ 1IN&+OR#766/-EKQ!\:,W9IX/0,LR#DN"RWQ>RS/<ZRR)F,U
MF@F\ORUEV)RO[[[PX=O6'+<?&0.:8:(@F RR[9:=-,/&6N:@+?KM\4>*90!,
M^E=4"436]ZTC-YD$@<P :K\(-">44!-TL#T4UPC!2UM2+.7;K74HR0A^\ %I
M6FJ^>EM]$.$*5YJ]Y0@^;$450QI4"V) "KJ 5)!U&HU*"^$"E%8&8I1C1-5L
MS5I""T0E%  *6JJ]AZ&FF$0\MZD];L;/4JJ)#4$!I4LHTI4^:#TP@'9%\>EP
M$4^.M(D$$U1 !OT 7=+5W.B815T*L;(ER!LRCR *PR: &P N%N*44(;Z['LB
MW*7TYV(!:]'U8@GP\J$V-"EEMZUIZUPB.JC1W%C1] @>M7@L+]1?XK$ ]J'L
M4WPBG>]:*'()"55P6J 6""&M_-D$=;6L@3^_",?B[[5TJ]#9*H8": BI_&@4
M]>EJKIA#IZ*CG3SMRA$H2:BUNM04T- "-?JBTLOM#K<L:<T0 !4D%2+%0>E>
MI%L($A.=:M= - 5L4\%+(K-R+HI)N>B62E[BN$.1++3T*>)()8%B (:@C2QT
MH@J"G2R+=4PBHA14<7<$L7LH4JE ("3;H*BY)(MW"]\(Q1Z71U'BZM=VO"-U
M1:Z*2M"0 ME7M7""^:V0Z!_4!MU)AU"DD"MQH4-AJ:A;T[816YCP9:5*;(ZF
MCB&T/G1.I!"D_AVP@#S47V4*@/7Q*A'$ @T:%5 HJDBE:^J76F$539BY"T2K
M,&*,"P1U6'8\RE=!<U4"_J/0A<('2P4%&T)UIH% 10S0$J0:I14LE0NXJH34
M81CT!=B>E;,S$H'6$*KY@):XH.A)],(JTO=3X5#MSZ-#*ZA-:: J;[DH@W%D
MP@/79F%^3J:@%:J(&BUZHED4@@WZ_+9<(H2NSUU9ATN7(T,):)2B@"J'T(7O
MV-21A!AL^H">3:$45: %636@"[K8G2U]M+G?"(!NWJ O6C[-_@JR:DW! -M*
M _(!5MZX1$M=41E6S\_=(#1"0M2$2]#<=2J=#UP@J>2/3V$!H5"4J@>I)7:X
M )3H25W-,(-;U=V<HB>%=H;5DJ0!I9"J=T0?7"*&?[BHJ!1%!/P=(DH$4 J%
M1=S>J\QKU2N$5SJQ'D K,@!&RJ+@10!" (:J2B$#^5'GH,(BM<"@=5UHFQT9
M2IJ$DLH 3JHW5?(FZ:*!A U6W.U$8@E*+=#O" "(/)=5Y@131 2.IPA38;*=
M#0GDJM$HS_%_W3A#O#3_ $?_  Q5SV11H!9KIM7KTHB:(^GP4:AV7R_29*52
MB#Y$@4[%>A&$6R!R]!L%1]B&50O604)I<V&VX%Z:;@]%"*B@M0ES75RZLJBH
M34H>NY_PDX:YIS)#YNS!DJ0S3,T/"-0+B=1<)S1[,*TPT[#LO6&F5+MVTTRY
M>M@O7 ::]@\=J<(@) J;(GXIH"H) LT>\UPYR,8>=0QRU+"YS#(8#+$[#+MX
MP\F,@E<._A)=*HB(9>"(;A82'B8AVX99>,M,!\VT&BT2UA%7[W"A7+J@?8.
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M(FJG74J?CU._,(0*MD[$JJK<BOKA#;GJ*"AM9SXD62#_ '/4_GA%3_!F]_\
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MT M1%5"$6H&FM,(H.].?PUI #4LUT N@0=U0W^IPA:S*?2OP6KBM4*!:4*J
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M9+U[LD?)47PL:"5OQ2DPTJJ2!05 !4+]5/94]-\( J#55#"MRU=] %)=A%W
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M>AT^9INF$5Z'>P 86(Z@DL*V6 74T(5>IJ1042BKK3"(?$4%"?GRE:NSNF]
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M@!"FB^9U[_5%%<(A6HY,Z(/A8[$J46"X0)8H.BKY% #6Y-=<(O.A+\J-8H]
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M05M=2VE'N4 74,KP@!=:FP-U(I];[UZ81;W0'5 EPAUTJEC6 $A$0A=!5%5
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M_P 8Q9Y)I,/,9G*SX,ZA,223A^3PIS* 20F)ASR%0'E+$%8[QVBXKD,WV4[
M9#+9F3%S?".$\9R_$<&66<397%S/:CC6=P))YC*)9CB93,X&,/JYIY0,1"1,
M#*.!9K\-_&V.^T683(4R?^VRE/H!T6(R3(U%Q;H,PT/\<Q"-O#8E614--,E#
MC+/8.+B_7"3#,W>X?F\*7]$KB3R)+*Y<SG4 ,Z/&'9GB>0R,O#QFLS+@_4]K
M.!<0Q.]+B))D\KBDX^.>[(5&$""90LY!^S*2&^_(?#UQDA))*H:(R/,73]Q
M0KA\[,9*26&V'# :8/+'FS00D%.ZXW65DGP\O@8<X$O=PL.6:6LTLPE .S&U
M!K'!<<S.!F^-<5S.7Q/K,''SV9Q<+$E! GPY\:>:68"82S 32H1*0)ELK1]4
M\ >+PJ<DQY0 (S%R@]S2/4GZW-L:Z%PE5<?%37D(X@$'YH4\42.69=X=>(O*
M;3+6797F.5NV7S,1[M#S:7"">/0 "V^@VI@W"O"0 R>=TTH"-4&"3! "90*A
M2Z$Z *NF](JR&54[QMMT8]'M'=V1<]>*6!A?9YRX:.9YR1\R9:>LQ,IEL:W!
M"/?" Y3#3!["J(,.N4^[!IL\OM?C#1QHY<XYPR<8"6?ZS& ! 4R#$F&$2920
M^&)2SNDR%AR'%L/ALN:DEX;.9\O^1\/FGF'?/[[FR6!-GI3-/*)FS9Q@WV0@
M$GV4)R8REF:<3V$::GF4IUE68.F>9XXC6H*,A7ERD)%P,2_+XAG[S#V&AFU0
M,LM AH[GRLA/W!-XXDRI<472B?CXI'I3KB9E/+T-,8V;OIU!0LJAWD5'1#>5
M<TO7;B&AW1?/7H+F3//:,\@(8#@O6WK9#+MEIH@'2GQ9,.3$Q)R99,*6:><]
MR<I+(%F( E)F04$HF)H 3&\RV1Q\WFLID\O+AXF8SN-A8&7P_KL&038N//+A
MX4LV)/B2X>$3/-*#]?-ARR*9IS)*XXK^T+P@9B?=7N<'4/%&%<QI<1,IGL.\
M9A8@ N7I8B)6[: ;_A/Q,&C0Q)<;"G/=EF6;N2XB&68$23?HS$3 $ [H1>,L
M?AN<RV#-C8N#W<$9G%RGU@GPYY?RG _C,(&2>8$R@_I#[$R_9)9/+_A_X0&V
M=8-#I[C-B#Z0 VTQJ$@5("T4QLS+,I(E\"$<)H/0+S<O]H#A"%Y<Z05J?U*;
M>M)?\RI.XQ8G<F+]TD"M+65>5V=!'%LR^+7P\Y0:@&,Q\29?+&IHU%L0/M)7
M/WOO#<!!OIA%(8>5/0[#F$AGSYHO"QS!CD8+3998.QSG$\CP\X(SF8EP/KSB
M2X7>EGF[YPL*;&Q #)+,!W<*2:<JBB4HI0'LG9[L=VE[4RYV?@/"\3B,O#AE
M9LY]7BY;".#+G<UA9+++]?C81G^MS.-AX4OU??,IF[TPED!F'*?V@>#]5SK!
M$)4^Y3;<V27@($*Z[C&]T>M-XZT9)@:)6X^<?->>)/@BZF<-*&\^0+$RC(6(
MC(>%]PG+1>PL(VY=1#WF,N]E_1-OW++3):#?,V"SS,J1IG'PI<:3 ,X^NQ))
M\221U,F&91/,J(DIFE!4JI8,4W^'PO/XO#LQQ63+F?A^5S.7RF8S'>D$N%F<
MU)B8F!A&4S#$7$DP,4B:64R#N$3$%H]X^(/@^PRVTUG:!99 ):6!F] R*E/L
M\H$!) %A8::A( ))  "GEJE8VDN'/.991*3--,)91K-,0DJDU4FI#FMSXH3Q
M%<&HN'=Q,+GB!>N'H+;MY[C-PRTPI"LAJ7AID$@T:5$.))/+B2RSR'O2S!92
M%<4NAC5S.3S&4Q\7+9G".%CX)[N+AK*3),Q0F4F4_9(*RE*/4Q['[0/"#3.L
M"*6]RFQ'_P#0%$V ZK;&4;?N3:$U*A% U/K4Z*(?[0'""G^6<$A(H(&;63_[
MOK6IZ#OA$[DVAHNVK&AA_M \($7]=()+!(&;52P_T#RHJW&V$.Y,BH4CTWWB
M+X+P[V&</L\P3#Z.;>,0S'N4X5ZTZ8+QXR#]GEEE'8YCS<O,H04!QA-B22S2
M233 38A(DE-9B I3D(W6#DLUCX.9S&%@F? R4DD^9G63]RDQ)^Y(2#,)YN].
MP$H.I25X]K]H#A *_KI!)IRP,TII<R_\JZ)C-117TC;"0I2NJA7#=".H-BD>
M)]XA.#KAV\?/L[03+MVP7C;1@IPC## 5II/<"@ 4E 24MMC-/+)+-/,?LR F
M8U0"N["T:F#@8N-BX>#A2&;$Q)Y<.210L\\Q$LLKD *2CD5*E&CP2_Q(<%9I
M!.(^7Y\@(J"B66FW+\0$X ;99;:=M-!EN7,M!&V&A5AD***""<,+&P\?#EQ<
M*;OX<X)EG0@$ D$N!<&-SG^&YWAF<QLAG\O-E\YEYA+C8!FDF,DT\DL\LI.'
M/-(09)Y"LLQJ02M/2A_$_P "XHM"'X@0+Y(IW!%)?/&0(EX\>.6':M2P(6GK
MMXPH'*"S\389(+6G)F\OB?H8H(^L&$H!?$,TT@EI7O2D/HM'C=YCL_Q?+)]?
MDY\,G*SYP#OX)7+86%AXT^+]G$+#"Q<.<RD]])FE)[PE^DQXBN#+R)B(1C/$
M$U$PKMP^?._<)N2[=Q1?!RTIE_*C9AGX91JA8(: 4$ZPGE,\V&#]J662:8%D
M&(9A*Y1SW)N5XXZ?)YC#R^!FI\-,OF,3,86#BK*1/B9:7!FQI$4S#ZL9C!)6
M4 _6!"4*>?\ P_\ ""_Z[08300,V1DZ@I+V5&NA^@SC0[I#(JJM+'4,+(Y$>
M!GQ$\&S$-PHSS F(=N6'[3OW*<$LNFVFF&&R3+PQ\3;#0^\T:5 !"XB>4SG#
M!^V)1.1_@S$@3:(2"-6HA"[@Y3'&6DS1PB,OB8T^#+BK*AQ9)99YY&68=V6:
M5&[I[U54#Y$%XI^ LR<Q\1!<0Y>_=2F+:@Y@V)=/&1#1+) :<M<\J8+=6@.9
MVRVP5HT4*;?#SN5Q9<6;#QI9I<"<X>*0)OL3RE#*5E<KHL<KG.R_'.'XV0R^
M<R&)@8W%,K+G<A)-/@DYC+3@S2X@[N),)01+,0,2:68(X5(^X/$!P@!YAG6"
MY2:I!3>Z*@ @$3L2/5,;E0BJ$CA)I"E#< M5;DFY_ .ORG7B?X%OF7C3K/\
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MK'$,MU9;J 3FR 6F\VFJ'2]?/''9;]'$#C]_X=4+G-8JMI2M8[7V@3O81O\
MM6SZU3N_FCAMKW3D=6[(@B1FC,!/PDRK+E!44>SX4I1>QM2F.;D*YO,HA_<,
MK6CS9A%9:>58\]SK=F^ J@_A/M#2W[CP,-4-LK@BB1R$K5MG<7I]!:P0*NN-
MT%=7?P$=<W%!T<(M]QX[1\%VTN98XJ*R>""U*#WJ*("$4([)K9,;64)G<3?
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MO,J-C5HXGQ14RR6LE%$>Q="0KQQ7K_;4XX_CJ?58)=?K!_I2?*.S?1J?W_Q
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MZ>1+F%:?B(>.73;;#LAG",@%!8L68IS1:U:BD!*Q\/,/B,X-Y2G68LN9CSK
MR:;Y6DLTS#.(:80\=#,N91)(%J:3:*AXAY#,P\;]GP#+47$NH-Z_>.G++3;3
M)#+2(G=*!!JQ?;E8/J58(F#_ .D0SYE?B3X.<MYOR;,?M7+\S\1WA2,%'!Q$
M0[+\.O$GPR8;:88B7;IX6"T*-<B%*&F$9R?S@4![H9K3 JU"X]7MM,'Q 4JC
M(%]1<CU(3<*N$:=%%/,AZ"@-JTJ'JZ@%*@'>E[H.H"#J;X0U"(?.E-JE:*@
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M$.72E6*(@??;NA6A4*U^$(/3YU (6ETJ<(<JEUIZ( E]"*HP-JB@&Z$!2%]
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MD(;X12M_%;ZJO+9$.AAHE 2HUL-@HJH1!0&HTPB+4E$I<IR=5J7*%XE"239
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MBG9#3?"%%'( 6%3?0L]B;/#OK1$0C5/4J%L3K73",8=52M@NHUII>RVTIA"
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M+7#(J#4A4$%+TO\ *P/6A.$1:<_914)\(= *T4Z*J][DGRVKA#X!U]].::B
MH5(0]1Y4[[=4\T2GR@L$!.G?I4432Q6HJ3A"! 1N%]%V/F"I4&_7"$([&YHJ
M +V[[<P.H"81>37O7[G(+I<P?(A2B5-#>I!76YZ@X114>9T>S!$7DL(!:$VJ
MBU VNH&A">>$12'U2UP_)?)##Y0EJZT%;H"A14(J2J6.R"U3I5@"R&ONBI#
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M WY[&ROX\V,#*76NY-Z;EG3HO73"(5_"E]&=SZ-%IMK14L-M_HE:BF$2%8V
M%-+42I5-@/,)KA")0DH":!3I4U2Z5]!N<(H9R%TZ/\O2Z@*UH22*JAMU%/)
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MZ]J6 PV'9'M&3RD- H.(X[EORKA/$<.7#EGQILEF9<(F4&83384P24H2.]1
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MHTN<(NKE K,+7 .I2GR#+*"A-":VT'7HG7ZHC$)1@@!5U-6-%5*\R88) L@
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M!6J55*K0'H=@GR 73",6;E3:G0FJ\RE%H 7N0M]34&GYZ$81/(;>_>L0@H;
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)^ >H_+"$?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>fhtx-20211231_g36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g36.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1=@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %T2^658X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%>9+          *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@              N    E4
M 0                         !              )5    N
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    N     !29VAT
M;&]N9P   E4    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M    5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   +@     4F=H=&QO;F<   )5     W5R
M;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53
M;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /
M15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N
M9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO
M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M2'U:@O=2QUGTRT%VD0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@ NP)? P$1  (1 0,1 ?_$ !X  0 !! ,! 0             (!@<)"@,$
M!0$"_\0 1Q   00!! $# P(#! @$! 4% 0(#! 4&  <1$B$($S$4(D$)%2-1
M818R<8$7)$*1H;'!\#-2T?$8)8+A&28T8I(H0U-RQ?_$ !X! 0  !P$! 0
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M?^U1K]ZGI32E-*4TI32E-*4TI32E-*4TI7$X4@*45=>$GSQSP?@*/] 2#R?
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M[14V5I2E3"%-=5GTWX?L'/\ 0="<#BD$:=8J4D)04*0;=L@$$22$D J!Y$@
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M,MNH<DM,$E0<*> HA(Y5Y)!!(D_DF>>#.1ZOQG=TX_ _7"O>(]3+2GF5[[<
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M1K%#2V0%K82-@!42F1@ YDJD0,@#O@9BL=<^*5*<2E=T I*@$)*1ZE$P /\
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MM(;[*<ZA7"D@K63_ %%&XT_R05.I*4\G)/N9A1X]C(K*VOC#^:4&+6Y\UY2
M6D)24JDJVS):2E)Y$$G@]*F7L3:;AW>%1I^XU4*F]3*E)8B(]I+WT@<6VER1
M[:E()64]D$$DH*%>00=:G=A ?<#9E 4G;R)]"=V")PJ1)/0P!78=!5>NZ;;*
MOD+3<E*RM*RC=!=<VR4>DRWY9'4")S-7WU:UL%-*4TI32E>:VZRRA20KW5*>
M4DI22%!?SP>.>OCR.>/ Y'.K)"4V22DDK4\ZI21ZA)5)@$E7'?'3%3*F1(C
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M*FCPR#N.FRQG=141JUM*:;N%5YM>K5"G9G)COK7-3):;!*''99,AIE8007
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ME "$_P!QI/4#J>#V'QSYUH^K;@X!$)G.#@]<R>3D5Z>\#H:;TY"9 =CU),S
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M_O\ WZUQ/ ^E=2K]:C2FE*:4II2FE*:4KA<>90A3CJTMMHY*UK(0E 'R5*)
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M" %"(P (J]M7F&.U=3(Q!BG^FF7D)I0JG*WO"E3H,\/P5!E20I*GF9*FC)
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MS'!@2)Z#K%_TW9+A-UD^?8]N;$DLP[2HEIJFFVPEB=8MR4*CQI"B0CB4DDN
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MOR-R9*6)2TBQI&:]R49U<EM02M<?SVXX)= ''*CKEGBCPOYA<O0@^9;H6_\
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MGY]T@YGGM56Y9N,U3)Q?,W[_ /M%9S.E,TE"&82V'4-!M,9A//\ %2CH$I>
M)4D!0/GDQ\G8HH(*%[C"2(5))/U$E1QCOQ6%N+9I:R-XF!,$1CH( F/IG[53
MU9N=.I,D;RE")$:0^W+A6<>TDLJ9>_=DD-N1NGWR5PTDDKX[)X\^1SJ]-O+:
M4+2H#T*[9201R#&1/O$3FI%)?90CR6UJA)"2$DR((_,& >^?I9"3LD;*WM,Z
M&>T#]/(MW&C&#S;]G:1K%WFQC2T%7N1PP5D1U]0>$@?C0K;0K:2 4C/1,#C)
M$$^TX(]IJ:T>>"I<;<0>NX$'W)!/'/3')ZU<.)B]I33K&E5D"(]5.:91033)
M:<J98#00V%%7(A3V6P$J6L]2&^>"3SJ-PANXMA"9!2?E3),&/N#TQ'0\5.V\
MXN[<&U2F]X@PH""!)$F($F<'(S'%6UVYVBR/:/-CF]=G$B;8V.4QVD2:AJ'(
MBQHKTLOOI?;^[HI]:UQPXH)#RVU.()"D\:FYX>M+A94XE(),^K:,23@%L]Q)
MZC\*GU2T#S2H25&# ^:(!R/3SVR/RFLCNPFX.:W5S?54-QVWQJ!E1N8UU-82
MJ.B:].EMS(=E#:'1<EN9 DQF0WU :8;!Y6E6N8^)[.WL+^[MFE(*6O*P#GUL
MH7,@#!G.)!Y'6M!O;%I*D-J(2XD^I"HE!(29(@]"",&!,QS6T=Z0I#EKB,?-
M9,654(N*J&IN ^A#(EF2AI7U[;/5*RRZI16TK\MJ"N> >>.:NI2E$?,!)D9X
MD]R.( YDDYKTA\.V FS#N IU*-H20-^[;E*0,@P3VDF#4VVE)4VDI*2...4_
MW>02#_Q!Y_KSK )P #TG]:Z:H$$R"#SGF#D3]HKDU-4*:4II2N,NMA105I"D
MI[*22.0D^.Q'SQ_74N]&_P O<G>!N*)&X \$CD ]S2J)S'<C#<$56(RF^KZ7
M]W=<9@.3Y#4=MY;825]5.K0%= H%0220//!U4;0MUQ+325..KPEM *E*S&$C
M)S5M<WEK9IWW5PS;IS!><2V#$3E1'$C\:M5:>J/9.'N?@.S_ /;6KGYWN2]D
M<.@H:]UJ4[(CXSC%QE5S93%-+)C5D6!3/Q4R%GVUSIT9E!4I?&EPTMB]7I;Z
M%-ZB+!.IJLE@IN1IZWS:HO"R86+95R"PEZ CSALW;JC;W+%W:*U"V>:?L6WU
M6R[II:7+<7 0APLJ=3*0X$+0K;.[:I)B"*ICU09SMQ2[6/JSB@K,^IYMS&@J
MH),EMMN3-2X^ZV\RLK0L?1/)+:"GR4NM#L0H Y7P_:7]\^18-7#JVB0LVS1=
M* ""K<D3 F,S*8C$S6+U/4;)AL%RX9 6=J=SJ4!:QN(2D]3@B.L1F,8]_2?-
MRY[<MU=?8.6F$1FWGK1E,1E^CBJ90AJ+7B>24LS:V.L+5PH*6WT40 3SO&KW
M+"[)YIUQ";ZW66?)"PA]"D"'$%$E4[TE*AWD1-6FGMO;2M3:PA:MZ2I)VJ;*
M4E)&X009)21 QR:E3E**V]>C7&UL+'*;(HMQ.M[Y^ZC"J_>IZ&UM*7U:3Q("
M&D-H2YR2]U">"2-8'2W%^6__ #27RAT);2E*5$IXDD_,-Q(D\")K/! *,;=T
M<$2HX_+C'8GZQC2_4#8CW?IQA;DYCD6#N*P:^8D3H=+6(8MER%.K08,J."AQ
M;BUDMM]T'W4D*'Y!W_P1?/V6HOLK0\TAY22VIS<$%M,!125*.>2<$1..E:+X
MCM[I1:4RTXN H0A!49*E9Q_2)C Y[@&->NM]3^.WN7L85025T<'(H<M%;"<J
MFC^W*5]TF5$ENM]R_(4WT0E!Y;(* >2>>\+NK%Q#8-TTX^H F7$[C& DP8!@
MQ'4GC%<_N+74=Q+EJ^A 5C<TH<C_ .0DCJ2.W(FKF5V>7==;.NHOW8<-F1%2
MQ*G-!]2FF_89*%L*^T+<6"KJ1Y(!'GG5X^TD(8VYE)DA4X)!D1QU F3GF!5%
M33:6R'5(0N"0A9 )/!B0)@SG/]J]W)=P&\-RZ6F/8&WM<KBJEBPK(X^H^D*6
MF7%M(:'\-N.M\-N*2 $J<0#\#46&PH *1C'I/0@X[]0>9Z$YQ6'79I6X=D%,
MF" 2#NR8]/'$X^\S5-P,U<15Y?AAGMQX&>5S-:S*OU<N4KZ/KUR+E@I\L(6Z
M4,.+</5Q0:2"5(X%RNW*RVM(42C<<'$*3$+P 9Y'7=QP287=NILL!")DJ*H3
MQ!04P1Q/JXY!DC%6&Q3T_6M/)KW[3(,8:BWS\Z9 KV9Q2M<^*IM$6<]*>4%-
M.R@L.+C)/"4EL_[2=4_.6T"-JH3.Z4GGF<D8Z=1(B<&+EJ=@3!F!@SB9D^W8
MS'/;FLYV(9;E&'W>*R[N)5W3J["N5^]K990&$MI EQ4K"5+C.I ^GD<%+A22
MDZL[X6]T&TO*2-I44!0!DJ3& 03.!N!Z<=:F9;(4LE,I( F(GGVXCM_:NAL3
MCV6[&QYU1(R^08%W1S56<I5>F:VB0PXX([<1;G5*0E2%%1')" #XX'.LZOHM
MNFW+B=J@!E< 3/)/I(&('0R#Q6(U*R;>W*"0,F$\P2.AB3V&))Y!K*YZ6MU,
MLMSC=[D=&+"OH4_M#3C\1+Z[:(ZMM+3L%IKL5/CLDN-_<E*"  #QSQW4PPRM
MU"74@R00%)F!(XY'>1/VFL#::2M5XA3;1<2TI*E2@K2D2 2J  (XGW/28VC]
MBJT56&L%9+#LQ:IQKW&1%=KVGD-J]AZ.H)6TI!\*! X_('.N8ZPHE[TY1/S]
MST$\' )/O]Z]1>$+9#.GH0%#S" ?*!$I)@GT@#D$1[5?9M84!PH*!0D^/CR!
M\'\@_/YUA$D;E"1NDD@<Q/)_'_.>-K((,$$<\]Q7+J>H4TI32E?APJ">4#D\
M_P N?'!_&HB"<X]^W[^WUJ54QB9GI^_UQ5NL\W+QG;BI_>LQL6:>L,N/#$J1
MRA!D2EE#* 0H'[U @'D#QY/D:F0@NJ"&P5K) "4#<<]@))_41!&<6EQ=HMD%
M;Q2V@22M>! R29Q&/\1T\&CWRVWR*TC5=3D\"9)E-@QO:<*6W5E/8M)=4KVB
MYUYZM E9/A///F_N=%U=FU-TK3+Y+$H'G*MW UZB!\VV![9R3VS6)M?%&@W5
MX+)G5K!RZVK4+=%RV7O0/6KR]VX@ &3MZY[#PM]]S,3Q';?*;.TC5>3Q6(34
M>9C\I^,MB>F:\S$$20AQ12$/J?0@]AS]P(\D:N-*TVZ>>:/EO-CD+"#(4E*B
M(D1,@X..^#5Z_J%J5%I%PRXX?Z X"J,8@$G$C\?>L4&Q;V0Y-O:F]P]<B'CA
MM%6^0457!^GH\=AMAOZ#'W9#*5?WB$K:7X"RWYX;*M;O?%MG3%MJ6-_^TD;H
MWJ4%)"R!@[BD*40,Q/2K,)<#H(0H R9B4QR 2<D P),' /:IS9ZJ/F2IM9CS
M5?BV3?O=4E_)K:J6(MF]2E2ZMN!95R2J=[:'5QWE*43%:4ZZ> VKC7[0K;"E
M>IU&T[6TGA*]I6HA4#!3($G@I S5ZH[D0  HG)R)5)B",?7,&:Q]>KR*G,_3
MAN(SN+N!0_N. 6<3)&J550!:<UH7"<8@)/2?-8=DR&WFWE(6'#U;=/MJ4#O/
MA-?D:[8.%LM,N+<#CI)0U!9<V[BI6P>I0V@;2>!DBM/\0-7:K*Y*&G5D;( 0
M2K+B02,<8CMD'BM9USU4%.4T\2!"R''ZC);"=3-__+68L&2ZX$PC/]EYDQVY
M*^2GVH:U.MJ*5N) !UZ 7=:9;I\NXN+=#Z$I44K<2A2,!22H%0,'TE(/S R)
M!,\Z79:HA)<?MKIIJ0-ZVEH2K=@1N$$0<GD8$\5=7&8$K<+=?;3;UN7-?IIV
M3M3[!E3RI"U4M"@V4A]:D @<6+, /!0ZMI<2#Y4G7D_^,'QPYX-^!OCV^4\T
MQ=W>C>7H[3R_)7J%R;VQ*VK,*6DONH967-K4J"028!QV/X->&U7_ (X\,NFW
M6MD7ZBXXE!4E"1;7&22@@ $ &3S/&*S3Y52-Y!C%_2O);2BZH[& $E/+;3TF
M([%:"!Q\@]%E(\]@#\D:_.;H^IW6D>-M)\:V[I1_*:A;:B+M*EAI5VA8=N&_
M-2I,N-**@I/F;D&943-?1I6DMWWAG6+-"/-\NTND(2E(5*@E4""DYX@1,'KU
MP7;=Y[-PU\E4B1&D5T2ZP2_CW!4LRGD39-3*E*:D'LE^/'@LRF_ 6AI:E^$G
MD_JA^#^N6WC#X:^$]02ZV^M[2[&_0XA87N<=M@[!4E2U&-WJE65'GFOD-K5A
M=V?BGQ#;N6[S7D./EM"VR@DE_*4@@>J)(XQP8JW<#8^,Y:2,K1G]/(J+2Y0T
MVB&AJ7.GL3GO]97-:0I2HZX84L,H Y5U'/&NL-7 MP4*E!@GU^D=QE6#^7UK
M#FX6C*DE/L02>LXW<#F?TG-;,8A8%N[QF?D**@3Y9-#)?DM3JR=526OI_K6D
M<_9T[GE(/"5)ZGP"-6]XY;W3+J%*04K:6A>0#Z@H'.8]I',CIBHEQU?J*%^6
M"?,7!"4I&25'@ "222 !B>]'[+;96.Q-Y66]7F-M*8O)5U$NYM0VA;"Z9/=Y
MPLE25--&0GNTPM1"/<(')'.M4NM"LO)4IHH40)P08G(CTC[2>),8BK*[93<)
M46P5P!\N0?41C!!R9,<@$=:R3>F#<#.I$:OFK2;+',4MGIE5:O1X[Z;>-,<+
MWTWM@JXE.-H6A,IOA+*@IWCA)UR+7FTV[Y;2 ).TCK)Z< $XQS/3%:F]IH;N
M$.$%*D.((E/!!X@I@\#F3/' K:O]-;,EK"F[68R[6O7WTTS]K>4@N0TK8!_B
M)0D%'<#GD@'@@^>1KEFNY<  /IW20"1V@$\F8D<3^%>E_ 3);TX*5"2["DHD
M!4=]O0$<$C/S9J3;*DD< @\^>!\#_(?X_)_I\\ZP X'T%;V4E*C@@29D9Q^Q
M^)]JYM1J--*5\Y ^2!_GJ$@=1^-*=AQSR.."KG^@XY/^'D:B"#D&1W%*LED.
M_&V^+9-+P^_R:%67T&"Q-?@2@ME:4RNQC*"UD<AX)_A\<]B2 2=7[&FWET)M
MK6XN!W::4L'G *01G[Q!S6%O-9L+#%[=,6H"9A]8;23.#N6H';VR,=.*J+'-
MT<1RN%(F45U"E-Q>OU".Z&'&.XY074K6"WV!!'8 'G^H!F>TK4+<I#]G<LE9
M(0'6%H*R "8F"8!DQF,Q5.TU_2KY+AM+ZT?\L#S/*>;7M!D)D@]3@3G'XX__
M %M;K89[D3"7*FCFVUC2/38V8O>S)L<;69*?:<@>US.6THMJ40WRCA8_F.=G
M\/6CZ'0MP.M)!(VJ2$H5C^K<!!R#(XZ]8H/:C:.+\M%PPI9@@)<259& ,Y!/
M&#SR.:Y_3>[?XSM+*E9Y"M+R#8*CB!#G0F?KY4 +^YUB,^/=E-/-GW$H4%'J
ML!7GQJIX@6PNY0&74A32%%T@D@*($)7M](,\CWXFLS:(+;)6Y_MI,960!!SN
M!.8SS.0,37+FJ\@HK2PS#$,II\<Q>RD4]9)JE45@9-#&00X2_#4T6D-'Q[[Q
M2&V>24D)&J=HOS0TVI!>*4R""%;\ &%)((.3 P>]6C[;I"RE*H)($))$'@R0
M9!]L1C YP*_J=YGB.U6\U9E;=A'SJYS^@@SELXW5_6M&8P@5T1;TB.%HAR'7
MTJ7&96 MTI\#D'7</ EW;MVP;N5BS0VI3<7"PDQ.X$%1X(5R#F(KG'B&ROU.
M%3-N^Z3DEMM1,R,@  "8ZX)YK'!@.^$[<>LN(\Z7>"9@-VIAF'-+,=<B3/;5
MV^K]IIMU2F>ZEMQU>4I 21R!K?4W-@ZXL,W-NN5J3"'0O"20E0@D  &0<^V1
M-:RFQNVP%75N\RD@$EUM2(D@GD&!@3/WQ$7)P?,I$>2FKG95,JV[&/*B6*1[
M4E^<RVU_!2TV[RN.R6U(<?6D#HA7*CSY%X6%+ 4EM2A((4!,=CC'!@#)Z>]8
M^^:MX(2X@J(R 1.%!41SS (C )GWI\;B--BWPB&U)EU6/S9T9]<-^'[;TN"5
M.--I>2KEQ*)16T"H]BI)'][QJJED@"01P"#$ ]1QG\/>>UL+%&Q#@*25I"C
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MAQSKI7A;PTM3C;R]P"05( !&8!)*O*X' 3',=:X[XR\;(82Y;,R224K65(,
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MG*,\ESUDS*NIR)5'<X)QP;L0JR4F#A\+'L1;H\0MKN-6U36-Q516K5U#\O\
MM!%4XT&53)C@"9,M,A<R+(<6EYIMX*2,[>:A*20HDJP95/'"1!Q !@#W)DG-
MFZP7.G'!'OS)S/&3F>1,5@KO?4S.R/<'(]M,PQ"QP2[K[54E*'I@8@R*MA#C
M:$2D2RW*<<FA'U">6PMT+[A/)UOG@_75>4VS/R-AL F1@=9<Y[8$CIBM+O\
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MA2VT>X0V%$;&T^18"YLRHJ2A"F]H5N3E*2 $%*@1GJ#@''-6]TVI;;C:A&X
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M28BY;6R J0K)X M+J,D../,&)$L@8<<%]XO,KBE<LH 6ION"!T!#VU&3Z=H
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MI%E*EK$IU]Q;JBZN5,!4@.NJ*E+5W'9:B1SK8&W_ #&T+Y*TI7'3U $S)/\
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MJR>9B)=2M*W9+M6Y)DNO]@IL.$HU$-.72!ISUVXS; % <\Q\I"22$C<AMX)
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MBTK<<=9(7"BAQU)4"<?U),#"2!)SF,D'TG;>*M.U%II/\[9A]200D7%OY@(
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ML"7)*/!W\<_\3S?PH\'+\"Z1?LCQ;XAMELLH8NEIO].:<!:W/"UUFQO;$DJ
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M%)X ?;65\K))0>.".Q&K=-N2VX%B#M!@&09!F93!@R1'7GH:E:665D\@]C)
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MHD$]RKI!JL8^/Q7OJVK"P'U+C_ON1J](;?=;6HJ)6DGE9//W%*>A/)\#C5H
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MBI1"@$J'^XO:8*1$IB21)&8BIP-)"4< *3RMQ9"B207%J<5Y/X[+/ ^ .
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M<-Z&W'L)2%EI*1*CQ.%,-J"_=]M21R$D]@3SQX(X U>)*5!2D$*&[E)! @R
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MH<VG.PT1K>ZAS+!;C"XN1?3NI#< MKX;2KW'%*'4DDL*\?:H#K6GL(M[!.T
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M,21CMSB<MMHOQ[.IA6;ST:"M*P^^VA"T*02#I7BW1FTMKN0^RA]MA]AMUQT
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M6X[U 5W+8)3P23^=8@:EYYV).4^D"21 $"/5V';N(JRO_AYJ^GE27+=85)4
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MQ*AR.SJ$29JVGTO2)A0I0]MQUIIMM+*'.1RZH\'61T-"KU\A:H#2_+&XQ*0
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M>6?,0EUHI(0202D$DD\#].HO+&X<A*2E6.X5.1)!) ^Y'UC%;=D179 *NH<
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M7&7!PI#2D):<ZI0>2I(  U!,QP3!/8$>PXG]>09$5W33-40^E*09)XZ8Q Z
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MM0W[4.OK&2A ;#BW '75@O/+[+5RIU2E<<)!X XIW5T[>W#MT^LN.O*WN+(
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M)2VJ 2"1$YB.QZ<=JLKG36+Q0+B)P1UQ&9&0.OVFL4_ZM_I]VBJ=A$Y?68A
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MR9+ZOND/.$]W'E<*<65+/)4=<ON;MRY67'"%*,\"!GD]9X'6NB<)">-N /\
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M[)*3^?\ UYU*I(4DI/!Y_'[5$&#(Z5QAI 4.0>1R1\@?CGQSY/Y_/_/1(*8
M. "(CH?>I2D$R1_;]*Y"D%0)/Q\?X^>/^>H%$J"IR#(_?_:H\8[X_O\ VK]:
MGI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI0 #GC\GG_/3FG'ZU^
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MF)*0"?21R36;UODQX_D\E#?/D\_)\\_T_.O;UP8#1X_WFI]Q/]^:X<S\@_\
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M,&.TUZ\^%B66M'M;A025AMH F/\ C$9Q@C),P<C.:D3Z$3__ %9;C^?M_P!
MV(^!SQQ_;[.?Q_\ 4H__ %'QY.O0?\"2$M^'_&2$_*C6T!/L/Y&U/WR29Z8%
M<\^.*MZT+3@./;DQB 0,<]\=?PS6;%H\1H_(_#?/QX/*@/Z?U_IKWA<@PV.O
MG-#\\?3]BN",_(/_ +#7BJ4EN3*;<7[:7GU.]B>#R@= !_0@GG_?_35DIY#
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M=C(6AN/ J*R,N=8S)"U^$1VH\1SNL\)0CW%'P#J9QU+!NKJZ*$6UJTIQ*UB
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MDY(B!'<"3,YX&.OO:^3Z@]M(LB1&E6]BS(C/.,.-IHKPI"VSP>JDP%)4"?\
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M%'L7"6TH64VF N2)MLTPR@"53&R9>Y=C12C@?\0'P\O?&^A!NP\U+J&G$*+
M>WJA*R0"T%*.Y*MO68'0FMY\(ZZUI[FQT2E2DE)5L@04[A!,B=N3R5$@QQ4&
M*ZP@VL.-:0)#$J#/BQ;"!+:4"9,68.IX!/VK3\+3_>2KGM]P(U\:=<T5[2-0
M>T.W#G\RU=.VZB0HNE:%DPKTATE,3M(F)%>P+>Y9NV6A:K"-S39)9(2/4E)_
MH.">AQ [@&NZH%L*'' '8I)!Y\\_D\_X\?CSYY.J!N%:9;'2;MD-W3DJ\Y"
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M396P2H$\R!,P.>!BN?\ QL26RTT9_P!IP(SS("R?OG/TK->U_P#IXW_^C?\
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M_P#ZC_%"RR?EIH\_/+:?_33<K_DK\3_FFQ'_  3_ /J/\5]*4@=0E(!!'X2
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MD) 2>Q)5X X^XDD^/)))\G2E$I2GMU2E/8]E=0!V5P$]E< <GJE*>3YX2!\
M:4HE*4@!*4I ! "0  ">2!P/ ) )X^2.3I2!VH$( ("$@'@D!( )  !( \\!
M*0.?@  > -*5]X'GP//SX^?QY_R\:4K[I2OG5/(5U3V (!X'(!^0#\@'\C2E
M?.B.".J>#\CJ.#R>3R..#R?/^/G2E?/;;X4/;1POGN.B>%\@ ]AQ]W( !YYY
M  ^ -*5^B 000"% A0(!!!'!!!\$$>#S^/&E*<#DJX'8@ G@<D D@$_/ ))
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%*:4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>fhtx-20211231_g37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g37.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1(^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $B*^1D(X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%?GK@         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/T       2 #4    ! "T
M   &       !.$))30/W       <  #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      ,U    !@              >    EP          0
M                       !              )<    >
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG    >     !29VAT;&]N
M9P   EP    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   '@     4F=H=&QO;F<   )<     W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    !.$))300,
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
M   !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^$_6&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
M/#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C
M>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@
M>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q+" R
M,#$R+S R+S V+3$T.C4V.C(W(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN
M<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A
M>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F
M+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/DUI8W)O<V]F=,*N(%=O
M<F0@9F]R($UI8W)O<V]F=" S-C4\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^36EC
M<F]S;V9TPJX@5V]R9"!F;W(@36EC<F]S;V9T(#,V-3PO>&UP.D-R96%T;W)4
M;V]L/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,2TP,RTQ-E0P.3HR
M,3HP."LP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z36]D
M:69Y1&%T93XR,#(Q+3 S+3$V5#$Q.C,P.C0S*S U.C,P/"]X;7 Z36]D:69Y
M1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,2TP,RTQ-E0Q
M,3HS,#HT,RLP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C
M(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @(" @(#QX;7!-
M33I$;V-U;65N=$E$/G5U:60Z-S8Y1C4U-$(M,T,P-BTT1CE%+4$U,3,M140W
M0D$Y,3=$,D0X/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ
M26YS=&%N8V5)1#YX;7 N:6ED.D(V0C-!1C<X,4,X-D5",3%!-C(S0CDS13,S
M1$9&-C4P/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ3W)I
M9VEN86Q$;V-U;65N=$E$/G5U:60Z-S8Y1C4U-$(M,T,P-BTT1CE%+4$U,3,M
M140W0D$Y,3=$,D0X/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @
M(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#I"-$(S048W.#%#.#9%0C$Q038R,T(Y,T4S,T1&1C8U,#PO<W1%
M=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^
M,C R,2TP,RTQ-E0Q,3HS,#HS,BLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D(U0C-!1C<X
M,4,X-D5",3%!-C(S0CDS13,S1$9&-C4P/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 S+3$V5#$Q.C,P
M.C0S*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP
M:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P
M;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S
M=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#I"-D(S048W.#%#.#9%0C$Q038R,T(Y,T4S,T1&1C8U,#PO<W1%
M=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^
M,C R,2TP,RTQ-E0Q,3HS,#HT,RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI3
M97$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-
M.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#I"-4(S048W.#%#.#9%
M0C$Q038R,T(Y,T4S,T1&1C8U,#PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @/'-T4F5F.F1O8W5M96YT240^=75I9#HW-CE&-34T0BTS0S V+31&
M.44M034Q,RU%1#="03DQ-T0R1#@\+W-T4F5F.F1O8W5M96YT240^"B @(" @
M(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HW-CE&-34T
M0BTS0S V+31&.44M034Q,RU%1#="03DQ-T0R1#@\+W-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R
M;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIC<F5A=&]R
M/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL
M:3Y'96YA/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @
M(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P
M<V8\+V1C.F9O<FUA=#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @
M(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM
M;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O
M,2XP+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C$\+W!H;W1O
M<VAO<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \
M+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_\  "P@ >0)> 0$1 /_$ !X  0 " @(# 0             (
M"08' P4! @0*_\0 2A    8" @$# @,!"PD$"P   0(#! 4&  <($1()$Q05
M(18B,2,7,S9!47%S=K*U\ H8)"4R87BQMCAW@;@F)S5"4E-B<I&AT?_:  @!
M 0  /P#]_&,8QC&,93.\Y1>H[!<H-QZ:FZYPG<4G36E(KD)+RL7^[HG:IBAV
M&3V1&1$!' [D31*-L;J:^54D7#AN$0)'Z8-A$R9@+V?IK\[]R<SW;*<MVSN"
MDY /=?-;9)ZTT!8]DR^ZJ#*2SA (V.O+.S2;R":(,TROV,M\=(JWU-%,C<P)
M H7.CBO5G>6WG;-<2*1HC9$S U=6VMYNQNM<7F+GG#NG4*#M$@UC3RJ$;64#
MO9R7-7XQS+/V4<L)63I9Z@A(H+!,[@WR?O'*O7.P[EL+5"FE['2=Z[;U(M07
M4Y'V*6BVNN;8]K[)6>E(=V_A5IQVV;)N)-.%>NXQ!RH9)HX53)YC-/&,8QC&
M,8QC&52\]N2?.3CWLW0$/H:O\4YZ@;^VY1-%PRNV_P!UPMP@KM<%),59N2&G
M/VL*M5F:#1OX(-B'E3*G7$P&)X $=:SZC7)^Q<P]D<5)38'IU:\L6JMBZUUJ
M^J%XLFX6NS]ERMJH-2MT[(ZRA4)4B"S$TA8'D36T9-L=P<S9O\X55#*YO?U$
M_5"0X.7&DT:+U'>]B3-AI][O$P]C:!>9NNL(6O5F6- $:3M;8N&1W;Z]!6X.
M=(J<WT6*F ?N"IF4;";AA^='*6-W3QRK^S] Z]I>M>2-]C=9TJJ*6R?#D<Y*
M76+>]6;=KFCBR=0L#JVNS/SZ]+UFP.F=T@6K-*5FW+=X_8P:]N>,8QC&,8QC
M&,9T=FFR5FNSMB5C9B93@HB0EE(BO,32<])DCVJKHS"&CBJ(F?2CL$A08M"J
MIF<.3I) <HF P5:Q_K%\=W45N&=D-,\O*U":'<#%[-E;+H1_&LJ_9#.Z\R:5
M%10+ X,K9Y%:T0HL(P"%%=-V"@K$ ALF3Q[Y107(6/L<HQU+OG4<?6D&+I5S
MO;6ZFMD95H^17< [@U',M()OVS5%$5'RPF0(U(HD8XB!Q$NEYGU/>($,^MD8
M6]RD[)4XUU3D8ZIUR0ML@^<T>\H:X>M()A7OJ#V8<S5O<)QE9(S0.67()GY3
MHL"&<A(KCSR0UOR;ITG<=<C9F(5VSS-*MU6O%8DZ==:=;J^X%M+5ZS5N633=
M1[]JIXG*8AW#-T@=-PS=.$#E4'?>,8QC&,8QC&,J%MW(SU&(7FDMQSBX+A6M
M0%]67;?<;/OR[Q"X!K.FWBI5-6!?)MY$(7\=.TK<T=$<(-Q@"*-'(&#Q,F0<
M2].SU"=T\S+FQ-8=C<$?P\LAL!Y,Z;U99-ER7)"HM:S9)NLQ!K''3<FXK+81
M=,(]W-'!L4@-'P T!-4Q"AS[%]6]G6.9Z7$^MZ;V)*((;'U/KJ4N,EK#8S>.
M:/;2:WSNPI DHC'DAS1U6H=5-8(5][AVLJ5PX>F4&,C'BI)&\-^=A^7V\>5=
M*@*,6#U/I$FI%M4;!7>JJ2&X86]/-L0L]=$HPQ2)Q56)9=7R,93CB4SB?B4!
MM!%58F:B1+8GC&,8QC&,8QC&<1ED2 )CJI$ !$HB90I2@8 $3%$1$ \B@41$
M!^X  ]@'0Y%2:XP1%BW9NO=06YV5?<_'*M\>7D,@S:JM89C7)78\F2Q-'GN&
M.Y=N1V&ND=FJ4$4PCD3 <16.!<_X[:0K_'72VL]11#A"42UM1X&FC9E8YG'2
M$VA LDVA9!^5L7Q(JX!,5E">X<A3&'HP_KD.-%>EGQVTGR8N?*MDF^G]HVVP
M7&Q,WSIY((MX1>VV*3E3ILVY)%1!RG'P[UG741<)*%.SC6ZQBE6,8<EEQ\T-
M'Z 9;6:-;$XG@VIO3:6ZESO&J#(8M[LZRNK&O H>TH<'*$6HY%L@Y4$JS@A
M.=,IA$ D(!BF$P%,41*/1@ 0$2B(=@!@ >P'K[]#]^A_DSVQC&,8QC&,9Q&7
M1(7R,LD0H"("8QR 7LO8F#L3  "4 [-W^@?K_'D9.1/&Z)Y%3''B==VIW _N
M [[IF]8XD>U:ODK$^IWRRI0#M10X?%://EF]URAY+)B4 *4>Q#/&F^,-;U%M
MCDIM@DD6PRO(G9L!LETA(1+%,U2<0%"KE&2C(QX!3N%T54J\21,NH9,Y%G)T
MR% J91&*O,GTL])<U=QU[;FT9V237@:C7*@G!LU'"+9U Q6QJ[>9PBJR,DWZ
M&PQ\(O5EU01$&T=,/%B^XN" I]9IWT^-IZHY:3_)**Y-QEIJLP:'JD/0[+J.
M#GYFAZ5KK-NTB=-Z]V"^GW4C4:Z"J RDPZAV#=]8II8TG.G?N4VQT+6A52+Y
M]J)A[0=J=G*'ME'[@)^Q_( ]=]FZ >N_XLY $!#L![ ?N A^@A_+C&,8QC&,
M8QC&4H[;X3;OO&B?4XUVQAV@2_*#DA5[]K$&EI^D.']/9.=0C(OSS#)5N\KD
MFW0J<X=J=)9%\@NV;K-5B+'1.6PR@\<8C4^D;KK:I6#9EL=VRKRB*W[N&W-E
M<A#I3+ZID@@C6KK=-LN:K:LF403!:KM736N.#*NU5F'F^=**T3\*?2SY7<.K
M'LO>435=!VO8C?6T%5:Q1TZ+3M?NK>>RV!6Z;'*QV33&Z<Y4Y^.<S4K!P<X;
MS(\6C887)4XUBS!"U+TTN/NT]!4?=Q-C5I>@QFT-[6_:-%UQ-7YQMBYTV%M
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MY96J8I<QNNE;=L_*V,TQKU.8A6+G2BUPNS^RP=\AFSJ?8Q%@3W!7U5H&1>S
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MO$!(W]Y,AD5$U3VU8QC&,J9YP>J7&<,MEO-:J:<3V;(-]6S.R4U(_;E,J+]
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M,R]L5CD$VG(S9*174S.22BK^5D%?$3N7KM11=PH)E%#B8PY.S&,8QC&,\"(
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M?V2'=(CY?+,JBJL)"^*19WIIIHID22(1))(A2)ID*!2$(4  I2E   I2@
M    !GOC&,9T\_88"J1#ZPVB<AZW 1:(N).<GY-E#1$<W P%%=])2*S=DT1
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M6[/*CK"L1--A)"UH3$_9Y%G"*)0*3^PSIHUL>6EG2Z8+/I$Z"0.?,[P"$;B
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M\0*GX*&'P.4P\@W^O@!!$LU^T334+_J"8[\54U52>73/\A@(B?R*;HQ#>)3
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FQC&,8QC&,8QC&,8QG@WZ#_,/_+/.>B?^P'\YO[0Y[XQC&,8S_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>fhtx-20211231_g4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %C H,# 2(  A$! Q$!_\0
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MT %%)FC</6@!:*2C(]: %HHHH ***2@!:**2@!:*** "BDI: "BBB@ HHHH
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M;9W3W$K*X4@"K<**KC" 'VH5ZEI(3M'0EWG/6F^<=Q%.W#=SBDWKN_AQ6NI
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M5-W$[,6*Y/1AQ7NWP#^(&H_$SX8Z5X@U>*WBO+K<66W4A!@XXR35#XB?LV>
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M2N>ABJ<:;3>K+JX:<*OO1T1U/AOXS:WJNNV]K-#9B&9BI"QMD#!(/WJLZ/\
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M=6^M:U%-:2F*-9_-6U4 *5([>N#7TPO:OG<3I))GMY9=TVQ]%%%<A[(4444
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MI=HW?>_2C:!CG]*D8?+N[T_"DBF<;OO4_:,\FFA!M&3S2%1ZT;1N/-! '>K
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M 4444 %%%% !24M<A\7?$=WX.^%OB[7]/V_;]+TFZO;?S%W+YD<3.N1W&5%
M'749KX!\"_M@>.[W_A65W_PF_AOQ??\ B34+6TO_  M9Z>8+FT256,CF3I^[
MQT[UZ-^U/^TMXV^'?CY]*\#PVEW9>&-)CU[Q+'+#YCFW>Y2,1*?X6V%I,^E
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M  4=UGPWH?AF\C\(6$W]K69NG5IWQ&=Y7 ]JR2ES7>Q?NVTW/N^_LX;AD:1
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M3^-U,D&Q^-)Q2\;J1L=J )5I::M.JD(****8!1110 44E&: %HI-P]:-P]:
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M X%6(X(Y0ZB3.X8Z5C",U%)Q-IRO)LJ'[.T,^)6/R<X%9NGQVK72K'-(6;(
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M6,YBN-0M8)EZQR3*I_+-2Q%YEZ4K+T-,CE2YB22%UEC895U;((]C3V!P.*0
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M[?X>EB-G)+!\LZ'=*D,<VT<\?+*.?536]J7A_P !6,,US=6NG(L5JTK?,/\
M4B(H3@'_ )YDC/<8]*BU;3/"/CK1;R&8P017\Q5+@L 9FDAC)9<]<QE1]!0!
MR^I?':;2?$=Y:7-EM6U"VLEO&P<&X=X2KAQQL\N4$^^1UK9\/_&6+6-<T?3V
MTV6T341L$T\@ ,@,@VK_ 'O]63GN'6NL_P"%?>'EMFMAI< B*%",=1NWYSUS
MN ;/7Y>*FM_ VA6=]97<&EV\<]G'Y<+J#E ,X]B>6Y/(S0!T*_=&.E+38UVQ
MJ,DX&/FZTZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@!C+E@<4-G:V!3Z* . \1Z9]BU#S5&$F.?H:WO!_\ QYR@
M]=^3^57M=TX:A9.@'SXRM9OAE6CM9N""KX/'M73S<U*QP1IN%>ZV9T$A+<+R
M<U\^7FL>,/[2\0PQS:L21*RND#G[.!*NU2OEXQMR-R%B1DXXK/A^('B7['K,
M,FOW#3-Y;2SK&%CLLR$')\K= 2 !APX'&3S74V_C'Q/)X;TB^MKV:XADL-0W
M;K96EFEC'[N7<I"D'M@#/6N8]#J,T?4_%]QX?TBZ2;4MT-[<1R0F+<;A/+<H
M0[(IV @ $J,]ZK?"B[\1W>N:3_PD4T]Q*L]UY$LR,H*F.,D+N4'@Y![9Z<5!
M\)_BAJTFM)8^)-94I-;D6TTRC;/+YS+A6PH;"X'05U_A^\U2Z\3:+_:TZW-U
M#?:I"LJQ>6IC5D"X'IB@;T9Z4^=QQ7Y=_MO?!WQSXM_:$US4=%\):QJMA)%
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M2/=GG]:"1RYS1\U W?6EYR: (\-OZ9I_.[D8I<MNH^;=0 C*3TI>AI#FCYJ
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MLK%D%ON6V!:)5R!\Y8-WQVQ6CHUE%)^TGJKWUJIU".0O9S-#*SI"T*ABKC"
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MWJ5^96P,'K7KD2E5YZT -M]WE_,,'ITP.G4>GTJ:BB@ HHHH **** "BBB@
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M'---RM__ ,))96<L=I&P.T65X@$LF6QD,!Q7WM2T%.38U#D=<TZBB@@****
M&-]:^?OC5?>&_"OC.&76]/3?JOEQ^=_:+Q^:,J#F-48#.Q03D$A?3-?09&>A
MQ7AOQXT'^UO$6@+<6T^J0O,I%M9VXDG4!AU##;Y?7)++U/6@ _:8:PA\&>'[
MF\NK>TLXKZ-SYB+(2-A "*\<BL>1]Y"/I61\2/&6M^&OACX4USPYKL>EZ7*L
M5L5:)-\C.VU,*L!4?@%'M72?M%K8GP'IUI=6U],\UQY4$.GPAY=X1CT,4A
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MR++YY^7ER@)&6P%!&<4 +X:M;J']H75YH;*Z%G-<R+*S0J54BW4^;YAM\@'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIU_I0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>fhtx-20211231_g5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %3 ?0# 2(  A$! Q$!_\0
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MF1BHVOE54#G(-1?\(G\3;KPJ_P 4UMM+C<ZR?$ZVVV;^T5ML;/(Z;<"$]/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M80?D24445F=84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ[>WD-RL&B"RM(;D1"&9>(SZ'\J]M<M]#'5HY^3Q9-X/2:*.5C=2QM$()!D
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M:WHM;ADL[2=\6S7$:R+%.P5N1G&/6@#2HJJ=1MT;:\\2MD+M9P#D]N:L@Y%
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M_9--M(+"TWO)Y%M&(T#,Q9B .Y8DGZU?&<#/6@!:*** "BBB@ HHHH ****
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M9QV<"0Q*$C1=JJ.@%3'I7ZK!-1U/E1:***T **** "BBB@ HHHH **2C/M0
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M&<9 /?(KAOA'X2\3W'Q(CUZ_TGQ$/M'A.XL+N]UWRD+7A>)A''%&VU%&'Q@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7G/;I71AZ2JU5%G+B:CI4G)'(^,_&2WGB3[9<(K6EZ_G)YY),6..G;UKB_\
MA+;_ $W4)+R_%O>Z<S?Z.G=:YRYOGNIU6=F=U'#,>![5G0W.V2XMY%#+)P%/
M\/O7V$.6G'EB?#5(RJ3]I)G>6'C6*ZT^_O-3NF$3,PC@7L*ZBQUGPM)X62XU
M!_)$8W(JMG=7S%XTN+[^VM/TFQD:*.8@<=&JO=:IKND^,+707'V^SD9,P[>5
M]2M<.(J)OE/3R^=/#U%&3^(^S/"=Q+X@T5)XM*A,6W:C@;7VD9!_*N3^(7Q"
MG\#B+272>V8,LV[.6/N/:MRYU]+'18;[3I)(6MT"3+C:@ & HKA_'$UE\2K>
MU:\B9M0C;;'=1M@[?[I]JY.7WCZH[#PSXQT?X@>!IK?4I0^H*^U))CC!KDX_
M"*>$C-<&[%U/.V(V0X55KS&Q\.ZIH^IM;7$4T*^8P=FR%/O727&L7-C;?9E/
MFN@R"QSQ5Q7*(CU9R=9E<LJL(_O$]:YCQ9;^1X:G'V9)49<%NOWN]/U_7F01
M27/EJ[?*KL<!?K7E'Q)^*$VE:0MG]JAEBNLKB)ADGL0?2F(\K\0>$;3PCKD[
M6ERTBR+O.X<JQ.=HJI)<Q>241'A,W#2*Q%7/!=HOB*UO9[R],L_FG D?=BMK
M3]/@CF$4D!F+<!CV]Q7MX>BY4ERD2E$YW1])O=+/EI?3""0Y"D=<^M:EQ!/H
MMQ_HS"660D^9MXR:[*"&WM76&6(2+@ /U/L#5IM)L@S3K!EU *H3E0?:NU48
MI<MS&_D<G!H%[I^FOJU[>-+<QC=M;[N*X/5M:DU#6H[[:R1@@",?SKU_QIIL
MFK^&8UM96$RDF:/'#+VQ[UP=EX;;R8WE8J V "O/UK&I3=U&)4%#=HS-)L+J
MZCFN&O?+C#>8B,/F/TKT#X?^/-2MY_LD3.Y7ET //OBJ^DZ+ L[!RL\F!M.,
M#G^0KUS2='_X05X&TE%$<SV\.MWUK&EQ*F]LJMMW.5^]CH:Y:U2.#VU82HJM
ML<Y'K3:]-<"6$M8MADF.=I8 D@'UXKJ/ 7[1WC'P/JE]H_@^VAOEF8()KF'-
MK9.4'S[\??Q@[<\YK0U70?"-BE_)/"UG8W$!86(D+"V@?8J/;8ZW/RG<AY&X
MU])_L9V/A[_A6MMX0GT%%:S+:A#)<QJWVI'GD*N6[R* NX'IN KP<9BGB$I6
MLC-8)J2FGL>A? ?X)Z3X=LX/&.IS3^(O&6K1+/<ZWJ/,HW '9&O_ "S0# "C
ML*]H4;1BF6L8CMT10%51@ # J6O#>KNCTEMJ%%%%(84444 ,<@ FO _V25&A
M6?Q%\+$X&B>+;^)$_NQR,)E_#$E>^MCJ?K7SY\.9_P#A'OVNOBIH@^2+5M/T
M_68EZ ML\J0C\8Q0!]"4M(#FEH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1L;3GI2TAZ4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&3D)CCD#GU->1F6#G4?MEHDC2G.VA]TCBEID?W!CIVQ3Z^5.H**** "BBDH
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M:D/%FFQW-M+;N\:[1$& .._XUQTWV>SNXVO&PB#E <$U3N;V'3=,O;O3;?\
M>[2\:<X<^@KYQTES71Z,79>1I>5?W-T(;-&:Y)VB)^ /SKUSP;XZN?#HTC3K
MJYD69)U2;8,[5)]J\L\&^)KRXDBN+RP6%=@(7/SAL<Y->Z_L\V$&M>*]8N7M
M(YK=8E.Z8;BK9[5WX.C.KBX0,:THPI-]SZ3M9!+"K@Y#*"/IBIJCC^\_&!4E
M?J2V/E@HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD 4444 %%%% !1110 4444 %%%% !1110!0UK1[37M/ELKV(36\HPRM7)_\
M"GO";1PQOH\#B+[K-G=^)[UW)7+ TM92I0J.\E<I2<=B&TMX[2!(8E"1Q@*J
MCH .E3TU5VYIU:(D****8!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
0 !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>fhtx-20211231_g6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #& 60# 2(  A$! Q$!_\0
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M>%=/:]U6\CM( < N>6/95'4D^@KDO/\ $_Q"51!'-X4T%CEII0/MURGHJ?\
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MJ:9%?I#DPZ/#Y5M$A)*(B_[*D#/?&:[B@ HHHH *\8^*'_)QGP;_ .O;6O\
MT"TKV>O&?B?_ ,G&?!S_ *]M:_\ 0;2@#V:BBB@ HHHH **** "BBB@ J*XN
M8K.WDGGE6&&,;GDD("J/4DUSOB3XC:)X:E-K+=+<ZF>(].MOGG=CT 4?UK%M
M/".J>.+B._\ %Y\FR5M]OH,+_NU]&F(^^WMT%;1IZ<T]%_6Q-^B$?Q5J_C]V
MM_"H-AI&2DNNW"<MZB!#U_WSQZ UT?A7P5IG@^W=+.-I+B8[Y[R=M\TS=V9C
MR:W(84MXUCB18XU&%51@ >PI]*533ECHOZW';N%%%%9#"BBB@ HHHH ****
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M223ZUT= !1110 5XQ\3_ /DXSX.?]>VM_P#H%I7L]>,?%#_DXSX.?]>VM?\
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M]YUP0?QH ]:HKS'_ (7K;_\ 0F>+O_!?'_\ ':/^%ZV__0F>+O\ P7Q__':
M/3J*\Q_X7K;_ /0F>+O_  7Q_P#QVHF_:$T>UU#2K74/#_B/2AJ5[%807%Y8
MJL7G2-M121(<9/M0!ZG1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 <GKGPK\*>)/%^F^*-2T6UN]=T\*+:\D7+IM)*_7:6)&
M>A)Q7#^./B_X:T7XO:1I%[X?N+^]TZ2&U.MJJ[-.DO0?+3GGY_*7./\ 9KV2
MO(/&'[/L?BKXF1^)QK<UI833V5W?Z6L2L+F:TW>0P<\J!N&0.NT4 >OT444
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H0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>fhtx-20211231_g7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g7.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1LV4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &QJ^:3@X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%>&5D         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@              Q@   ;
M 0                         !              &P    Q@
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    Q@    !29VAT
M;&]N9P   ;     &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M57W=*QCLSJ+V
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MNZ'8D\CU2.J]'N:%3*25 J(WEH4 _P#2M6>_#&"2U3O3^IHU2E#RI( ( YD
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M.C1I# S>"NY)(+N"0"=]C^Q\@TX6Q( ;EFX>0#W/J1$M4=<URNGIN"6OK\4
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M&F?P=B@'*W&UW!*<ER1+#(^@,:=%^)KR]8=/YCXEVV@)'_\ HY#()&T.3,
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M::?_ +3][\?W%UQE*NN(]/ZH%:.KHV7(R5VLU)/I?X@]FVB3GW2UGZPHLNW
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M[[#>$+&6 V ']A_??Y03DC[&)<!QW=_S& U5GK-DVD@INA965!21NW):>0D
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MC#G]@?MR?]A38Z[U=H.#!6J>H\MCWI9BM8I1U9+,/^E;J0Y3DVS%0.:MO]I
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M@Z1LY+)8.S7PN#HWLI=H0W,G92K5'U4:QH9[,H*0UT?VWEF8.L0C$A4E.C6
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M)9]1>UB(LJ,E&_M/+=:: 1M"S1M,CMQDB1G9=BI78 $1Z-6FQ;V+*=ML+*W
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M_584E [;6# YPS 2P<>X[-418UME5Q1W)3=\00I0 VP20"ISN,"0P$NTVO\
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M;L%&=GAFE>O%,D44%3:2?ZR2%HZ_#WBI$9V;'J]I-RW96L)-U8M@%264I1
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M>GV=5<UB%&\GQ4"S_+";:OE26*P%-D@L8>)K47;96JVE&W:Z1C+3!(+"<O\
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M"TVE[5['1WYAR]QQ6@GL)*\(9 R\491[GMGR0-DE:6]XME2-VTK/BI*R!L(
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M+ULN5<_0^_$>%F0[%5+$^%\R][XAMW%@V+K("]IVD@ @L1"O?'T9R[/_ *&
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M@I0&U#?%N=X_9,C^[&%C/,L@XJ>2]->JWUF_;7;M@VTBV"RB%+)N%*D[0'+
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M $\]\+FLL19[2:RCQU:=B^+Q&8OS1QO@(Y!5]Q6,@_\ PLAIU=Y!]V\"[/\
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MMH8N#_=#R#]PYSU[X M=:LI0B\M:K1*B0HD@G:IB3M#;5-'I,YM>]W_ZH_\
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M'F>0<MX('CIE:M:F[<&ZXI20P9@9)@0V7[R<YA$V$H>'EQ." 03#RT$ 0)?
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M,$JQ[/EF@[HHZD;MYC-'8[)2TK-F*G=IM=D]M:]RLDL]H%R-T5IHQQ;<;C8
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M%R.KL5,VJ\(:L-/-X^PYRB12 .D4EB*7F5V8[^X7\_O^*IU._H46U)LVDIW
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M4LD8$H).QX\N._X_ ;ZK4(TH)B'P3E_8N0V2WE<^M(6^GJ7Q)_NX#@-\Y #
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M^!8U%NZ1LT[&VA:2H/XA7AP3M46.X!V96Q:N^%>_BKGB'PU%((0D$A)\KH)
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M6ZMB&Q0R,J PPBU*\#OLQBD<[MR/J6EU?\,5BX]XDNLHM.7$G:5A#0( Y,-
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MRR<XR6+!QQ'M!B1$BILHVVD$@@AL@C)<3+AS+\M P],+5]92D@Y"(! _IF
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M1%%N\)AFAEC'NAD<QLP 1^KWT>Q>T]JT@"$[QA!^:XI0,J40Q)&6 X;,;?\
MBBQI.H7M H@+LJM0203XEFW<;_L'*52=Q/J\A\= 3SQ9*#'3B.FSLLDBWOHU
M=+4D*I.JND2F158-&B.2$V"[!@>K@-3J+=H,DN!(= +<P$G#8EL<!I$ZP:ZT
MZ#"X@RY((#E*8((,Y? :'AL8J'%2$XUI(Y4JRV+1>5C!(RS<8A&@;VHMT.X:
M)49_E^3;MTW.KN7CO62"0Q,8$!P '<=PX[]V_A>&K:H.T@D3+,0Q.7#LP))+
M16-O-D]-:=N:E'MM<MV8(JOLRJLM<2.I'&4[S)L0&DV8!M_N!Z<(3XC9D=XG
MZ@?K]:PTD\ L'(.,_K !I2:?U=/F8K]/,V()LNZ*\B&R9FFCD@]E)2P?B&>,
MM&$ '!E# <SN-S92$[6<DNQ>"\Y?!)D'WPU*"V%#=,$O^KLQ[,-H:2[4O<)K
MI,=0S6 6"L3DYL=)]#+75H?JZ,K216EC"B,'>1BQ  E*_P [W/ #*]ITA86T
MHP7(^8.9)(+$.<<4DI2DAB8R1R6<N"V?O(,L7KNBPN,S=O(7A]#0R$,#V3[4
MT=2'ZT-[AMRU9(I(9HW]SC[,"* $VX!>(*FG:U:*B"7N$E3'^U./,P(9G8O)
MR  DJ\83([\EH/9W9E '&#!<^Z+$" YN6].KV)366H,(T(MV+;UH3[K1+"GT
ME,C[8XY(C-<G66&*Q5]OW&05U$ A(+;2SJ=4!Q(VA^X<E@>:60ZR[.29P,.0
MQ]0#( <?@AI=(Y#!W:^8%*PLV0G]];&40/)( R0M+!,NS+#$Z,KP$L8I0\4D
MDS+[AWN+%ZTNZ"";7E(<@AV(@A\$202Q?N*51;2E8=O,QB6R._?G#Y-2]U?Z
M6<=4]+"^JO#:N2_J&SK&GI#):7A->#'8G&V7,-O(S.E>>W_$P%YU_?9*7LDL
M2LA#CF'6_B%?\=<Z>;12A-D74WC N*)*=J7MD,!EYW,#!A/J:+9TQ5NQN2SE
MW;)8@YSB#&:LR_3(["^G3U!=E>XG;76^EL-9UY4R=;(5-5U(OHM6UL3;J/\
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M+0S>4#))?TD2<AY%)>&@EU"9=N8D.XX/HT4G]<:SNZ4TY<R5>+ZNRK%:=:%
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MIM&+J@1ARR &AWP'<9!P7=QLU6JC(XW*PTTM0K!,MF2.175MY&5N:L=FX#=
M#\; #XZ4)_#OWDF'^\'$MBH9%V]:)VJ88B##1D, 'Y;\JCEK_M30N9:WG=.U
MXY(K AMW,?&/])$RQ;EZT2@(S%MV<#?<[EB3OUD*,.[#/8"2/7.,R?1STGX1
M^)S91;T=]0"PM6U2LD+5 (X'#C@>@J)>KLUJ?&M9Q-S M+6FMJE6=V>.Q7F9
MOY4+\" HDVV*'X'VGY)ZW[9[03@B'9YD2_K79AU&S_#!>Y(\I5[L.#WX_<^*
M3&Y/'4(98W6C):O0KEZRS\I8GD WC!+$QD*%.P(V+?.Q'1XJ0[SD 'LQ+MQ/
M[F&]C4IU:#=07 60XX(8M'8G_-._@L)?N8R)?<=HHF:9W8E79 0H3_ZM@GD_
M)W&^Q'1XZ !*7PY9F[1@??GN'7  [A^W)]N9$R)]JZL_F\-BZ=ULC46:I7QD
MW-C$DC3,#*/ICRW)8 !]_'B0?.QZ:W?.M"A# X[N>?Q)XI,G^8S G:Q]9+9@
MN3 P^>08;Z+U1%FM7P2P&^E"M.TM&"PKJ:BQ6?=%>JVVRH&17V'^VR[@,0$@
M2L*(Y<OQSB>T]V(+<4[6R4X@\=H8N(8/'TBK :.=.?6SDC%#]3-''_6JQR'9
M@L@C50.3$#?8[C<[_N.F_A(N7[:%G^DEG(< N_8R^2&"06Q36VA)):2%%F_J
M'/(EB]32]$OHIQ_J_P"[U:'4N6&.T%I6I_&\Y1J6)(<AEHX[$<"T)HXAS12V
M[<QQ8 [[_'5$^._BS4] L&SIV)*=H5M0IB06 >4IY+.3B*E=+9?:XE^<,))(
M[YC]7K< [2=L=&]G]#870&@\-%A=.8"M'4J5H]F:4H/NL3S'^98L2D\I)I2S
MMN/.PZ\UZOJ>IZKJKVKU16;BU94S,>$ $LD$8[U-(3L#.[>C<F2T/,F,4Y?3
M>MZ.BBCHHHZ**.BBCHHHZ**-]O\ RZ*' R6KS20I( LB>XH;<!@2!L/!^1OX
M)\?'C]O@G@L8_P!_PK! (8R#4<_4;Z=NWG>_0&IL%J/ 8-LGDL7-5J:@O4:\
ML^.;B7$K3NNZQ(%)))V7P3U(=,UU[3:JTLE12 I)3, QY0^?H^2S5$=4Z;9U
M>EN)"$BX/.%X<I!/F(&&)[<5IS]XNSDO;3.:GB[?Z@BN5=/9FWB[*T)%LXZ9
MZ>YFD)7=02%"HB^ ?']^NT]-_P#5:5)(=.TEWD0X=AR!([BN)W4>-K+NE4 K
M:5@,2Y9G#O\ +S AW:8>+26437/:?%'6U-L9>6+W,5//R1[,:$QJGNMYC19
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MV8+9,44%VC7E%BU7 ALR,TH4[O[DD/ ;J#R*@#STX2K2+L*NJWAK94Y6 "H
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M _;Q\_'0SAT,#W9Q['%!+!_RKF-]AO\ .PW_ ,_SUM6:^]%%'111T44=%%?
M-AMN3_GM_P"@'0<']_E6 &^LGWKIFKQ3C:1 ?QRV7D ?QR() _'C]^LH4M'/
MXEC[A\S&6^U:KMH6&4D'U8/[/FL?<PV-R=66AD:-:Y3EC:&6O9A2>&6%QQ:-
MXYE=)%==P>:ML"=B/'6EN[?0HJ2I0)43_4,G,,?M[9K6Y9M7$[%(24L Q .
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M+F?L/HSTJIV_J$EBPD $XP7*H9\?4.AA?XKC:%-+I$EV&NL%F<LI5W5 N^Q
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MV]R/'7;W\'IXJ.<;^U'+8<.%XB29R.1[?TW_ %5N(TJ=)K+0MOM N6;-P )
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M'/8L@8.88X)/%X'HE_3R[=>E6OC]:-8S.:[LY'3Z5<]F+UN"?&8N>Z$;(X[
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ME#AL@D._(=ZD3ANXNE-2X7)21;SUM.9&ICKXAA%J'ZIJU>623WA$GNQ2>Z)
MRJO$.4.Y4MUU3I74_P"-MH22_P J3R [Q_W%&3,P'@$37.M=I%:>X0P&XD@.
MRBEF+N$@Q+DLHL\%JR,V9Q,V,EL:?@)D=TJ&=8/;6.W9DLB-YE()>.)8XBO
MHP4;$DCEU-E(1Y6 G 8</!P7]BQ'O44222"6 !!EQ!+!(?';AB^"X[= SYNK
MB(L?J6]4RN3$UJP;,"/!$T<]F6>K"Z,[MM6@DCK#DY.T8_;H<%@X<YYD01 G
M@P!F7H+;G3 $MPR4^A[N6<I@,PK.P7;AR,]=+?O"P^TE8R2B/8?"H(GB0<?C
M[@3X&_P>C!8Y9I:.TSB.W:D_Z6R7<$.'Y9@>3VB8%8#5D63RUZ' X^];IM'%
M%-]20S5N>_F&5RP+*GP I##Q]WCH(EAC$,7^V3V[]APHG;M<A_0D)(@2<DLS
M2\4TW=ZKKF]AGTGH'4,V&U-5>G);R$<CPM=1]MX:S)7E,:J1NZN9&EY\4*D$
MD019N&\KY0@I*AM=P00 5>5V;^J'=H(I_IPA=I*5(2LB\HL "P(!#D$'B6GU
M!8U=1^DMV-[I874=[NKKB*WCZL&EVTO;GD-JO_B>S;^GFJ6?IIE1F^BD$DBR
M'8<IY&!(90OG_P#U2Z[H]9<5IK1MFZ5IE/A'Y% DJ*5J9TP 0"28';NO^F_2
M]19MG4*"TV0%%*25A@00(4@ \.'@=QF_.(DJ>1W(9@2.0!(.QV#$D#<'QN=O
MC???KBT#T?\ '\GKK98XQ]#]R '/>'[U]>-9 0>0WV')'>-]@=]@\;*X']@=
MO[=8)[,2[=_?D8K%=0@4D;LY"J5!9B[#<_U<Y.3D[';?EM^PW\]: +4H*)4D
M ,P)3]8DG@N6;AWK##_F6]G?_'I788D(_/A>(._E1_;QN=_D\M^MU#<"'(?/
M[^M&T# D!@>S^]<88$AY<"?OX\M]OE01OX \G?R3OOX_;I*U939W;7\Y!+MD
M/, =Y]JS7=TM11T44=%%'111T44=%%'111T44=%%'111T44=%%'117!P&4@D
M ;J3OMM]K!MCN"-CML?&^Q.Q!V(P02"!D_YK(+3&")]0SY$AW'KEQ%-QW0[=
MX7N1H3/:-S,,,M3*XR:M$+ _E0VUC85++LB^X3#-[4GR1M&#LI'(.]%J5Z6\
MBX"[$!3$D[3##S /&8>1@D%AU#1(UMA=M20Y=0#  *EC*5"!Z$8["M4'U(>G
M#(^FGNY#%-FQ>STN/E2\^+J65Q]JG;D>2E*Z6X)&DBCC_P!>6D.VQX<"!UV/
MHW4]/JM*E*U)"%AU;M@4GRAAYED @Y=W(AJXIUSIU_1:I:;:5%:5G;M"B'>2
MC:@%B,,QGEWIFM5UL_J32]VFVG<K7QQB BU$GUL6.KV& W>?W*<<*5YB28![
M@\'[G?XZ-3J-$%E*+J1+?-9#1#D*,XR&G K1-C6V[*;R[2S#ET7I?)^4,!]/
MKFF)TU_&>V7.GJ(8Q=$UJMG)+D18+WYLCY8O7'NB-H#_ $RQ_3F5Q_1,I\]/
MM)I;-U/C)N.4>9@M!D8=DDGD00_%=;^ /]0;W3;FGT:U*"5K2BX";B0 X9PK
M5H26X)29X.*=6SF,%9>G9G69?KJ-6U7G>'E[L5J RD#91LG@*H\$ [$DC?IP
M'=P[9^C@'UX8  $_A7KWIVIL=2Z<-:G:72LN-A9DN\+7D%W*G?N&%83,&S+)
M'%A95JJ)H9>4BND<T ='E5ONW)9-U4IL/(!!'V]"G8CL"0[I"N2\,6!D$ NY
M8M+31W3J/X@%MMM%Q@1AB0!\Q#,##,[@D<*T9.6SCP4G2(Q(BSE9 -S&-RL
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M_K>W[XFDZB*]/7RTN4HYF6S(AKXJ\EH>[]"(BR"5&X%ER,S,OQVQSW^HDA<
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M'111T44=%%'111T44=%%'111T44=%%'111T44=%%?&8*K,?A06/D#P!N?)(
M\?DD#]ST45I@_P#:4<'VCU-ZV_T_\#W^U5E=&]F,M@;^.[D:HPMT4<IA-,2:
MBSSW\G1LKC\NE>Y"&0Q-)C[T;; &K84F)\=O3_C]_C6!'JW_ #/;V[-57'JP
M[>_I<>F9NT?=S]*_U?\ =CO;ZM,#W3TNNEM!:EQU+N-@<E7;( 7+$%NOVGTS
M2P-Y)#4KI"9K5J]]0R5Q7D16(T3AN?S-9G[OC]&X/T]JLF_52[)0^LS]1_\
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8Z*P"3N<D^8YGM3G=%;4=%%'111T45__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>fhtx-20211231_g8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g8.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1\"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'N:^>1 X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O
M;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M        4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U
M8D!OX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M                0FQD(%5N=$8C4FQT                4G-L=%5N=$8C
M4'AL0%>")L         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@             !:P   6L
M 0                         !              %K   !:P
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !:P    !29VAT
M;&]N9P   6L    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M C_P        .$))3001       ! 0 X0DE-!!0       0    #.$))300,
M     !2T     0   *    "@   !X  !+    !28 !@  ?_8_^T #$%D;V)E
M7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,
M#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,
M# P,# P,# P,# P,# P,# P,# S_P  1" "@ * # 2(  A$! Q$!_]T !  *
M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MKP):WZA*STA*[Y&/-0D_WYU()W+29(;2OS\O?JA;^]JWUE/M)+%G-1/#%IU
MT\ON:JGB>\*EQ>*BU_V?%ID]%D+8MFSZ9=TQ:\.03&EIJM7;'@5>5@(@R4S*
MRL0A@I94AM9/>IM)P.96]T#G=R0IT]1]K_.:BR^OND4QHW?/AYUKMSPI:KZ_
MZ61:_?.G=ZS7W.TJ15I*FKO>BV=5Z]/6+=LI4YBGS4[9MVT>#$WP HS(5Y:H
M4Y>7OZ?2ZJ-P=@B\9#]=X(:G8[1WQ%:Q73]D'2_$W6KQB3>LD?P=UK4R9O#[
ME2(:EWQ T\G:[ K(DH<$4F&J7J,&&H27D& J(G:H%R>I.3OY/,_C!(J2[E8O
M>Y95L*VR(KB-X&?M)?$??EZ>"F8J7C7U,U7N[6VLRTIJ]I+JYH+0M,]):/2I
MJ5B&HBS=7$6Q;TM7Z_30F'^R:?2:M515)LI0E,1:E T>_P":U6%:G]J;X@F\
M2,W4/M(-4[4\0EI:X:BV/H9X7*3X9*9>5!OZ6H=83(V+:_[S26G\63EIBXIN
M+]PGYJ-=LI4)6##$0[%+#*>X]BNH5?\ %1XU_$[KY8_A1DM98G@NF--?!M;W
MB9\56H5NV;1:[>\S<%QP)"FQK-M.EW4B>I]MP*/-F<J=4C0(46<IY2N6A*7$
MA^J=8^\8M^>5J>_?ORK+W@K\6OB2O_0#Q+T71[Q :'?:1ZO:77S;,+1RY)*-
M6]()R/8][5E-,ID;758MN4I%-J= A4:Y*Q+R]LRR5772:'6"F(M,S3]]WY?@
M'[U&ESB]K_7EBZ2K!^@WCE\5EU_9)7KJY?FHJZKXIKO\1UQ>'VQ[HH%(DY:6
MI]T5W7^2TSIZZ!2X2)<2]&M&@1*S.P!4X)J2Y.DF>FTB.B(OI27R_P WY=)?
M*M"]:/M'?$M8VN7CEM*Y_'7KMIO4?#O>M9HND]F63X:Z5JM:MPBBTF3CHE[X
MN63LV/3Z%)Q:PJ8@3,2<K$NO]GJ3,*B%(S.Y])C8V]/I3';K_FLN>)/[2GQ&
M4E7V<434?Q=Q/"W:FO6@%W7UK3J#H]8E,U<EEW#19B(JES4M1).V[SC(A3!1
M#@3L.B[ONJE1840I2A24NI4X7835]^_?K6.[C^TI\?</P->*O5/2_7VY-2+3
MM76G2*S_  T^+"X=&:;IW6;^H]SUJ7E+F1^Y56M6'+5&3AQ%"4\Y-HH,NF($
MKBH4I1(NPW9Z=5SWZ)5(=[8?V_->/UM^V5\8%=L?P&T/2'4U=MW_ $:D4^>\
M:LW!I% J$>;G)/7>UO#_ "-'JB*E*JA4:-<E:J-1K$S&H\.5G_+\LB"@I4U_
MD<^L?YZ)4R??OIR>:^UB47'5+03$9478!%6E/H7%!(BKA;HN[R5Q I4%^(10
MS#H??L>OK68/^XCEXOH\;>D5.IC^;!W*VEN ,?4!0'/SCMTI;49)Y!G>_('8
M[C)JBHOV/(&"7'R>^1\9.'STJ8C97*/BV!-YSS)%FC\EF]@7)!X8,?Y]@&?L
M.E ",AW8OOD2P#:YY.D!)=RQ=GP'^"&#I8<\L[CI5(?YN090;*(V@$PPZ<,D
M$N#P0?R^DAV#8+^H9? ['I4,8Z%(M$F!A($A(SB&L0"">%$N"S%]H/8GD A\
M !AZATI= R003&)A#8*)DJE!8DXW$ X#I89=^Y/9B.Q['I3"E.2N9W8$R?5&
M#JSXQ_"Y9?C$T+NO0V^IZI4NGUY=.JM(KM$BP8%=MFY*%-B?HEP4J(N&I7WF
M0G$0X@  "D)4A_405:!N9(^I&PV/6^*T!TZ^S4UVK5\4NY?%IXR+UUYH%FZ<
MW/IGIU:%$H%(T[H4"C7-2542<J]Y2=&I\*)<]PRE/*42E1J4<H^\),9251"_
M3W[]NK/\'WV@D=:QQX8/L:YKP\U>5E9G6"U;DT^LRQ;ZL;3*DR>D%F4F\I65
MO"4GY25J][7M*R"JW<=3H:)^)"AS4&8EO/@I0F81$6A"DPBW)CFB,<[31B>7
MM=9'5QFLF>%[[)V#X=+X\"=XIU7GK@B>#/3K7FPON46DRL"#>2=;9B<C1IJ+
M$3!$6331OO2$PD[O40%[O0XO?WS_ (_RW'+$;^WDO8UE7QE>!75[7KQ)>'WQ
M0Z&>(>'H-J+H%9FHEB2,S,6)1+]E*I2M0XE%C5C=+5]$63EU0Y>G190SBD*C
M)@S,>'#V")%"K$=)ZL_95!9=@"K "_>"FC%>4G_L]]<]3*KIC>'B%\3\#56^
M].;&\2]AR]S4_3RAVG+U"E>(2T;8MB3)I=',O(*7:(H,:=AK3!!J<2;/W@K\
MB$$SO @ ]^OU^]'*&G=X]O!*>]>)H?V1E#DK(\!.GU;U3F*M0O!?+7_(U%<&
MBP(*]1*??-IQ;4GY:+'$RI=&C0($Q%C&++PU#S%X2DE14^N/?E5:O;>R]?QB
M\KSWA(^R%C^&'5NQ+E&JUIW%IEI+/UZK6#;,#2*R9&^X\6L+FE2,.[]0%4R/
M7*H*) F%0:8J47)32@ J),+22@J,'_!Y+S85;A:Z>".F:X^,'PN>*.K7%+IE
M?#E3+[D38LY19.I25U_O=3!)RL><C3R8RY2/38RM\O#1"AH27B A:$ H8C[D
M=+?:H,WZ&!/F9R2V61FK+X__  (S/C!TSTPLVP;ZINE4[I/JQ1-5:1(QK7DK
MGL"Z9JC2\Y+Q+5O:T%F6DJ[0:@9Z.N8E(JDP5Q84'SQ$@^9!6I8A EW,\DW[
M$UJ%IW]C5.V10[8H\_K9+5:';?VB]D_:$;I.R:50969K5NV-,6G6]/TT^FF6
MIDK;\=2H"Z.*9)4^'39-,65B)F//,9$7ED&Q]\E5)Q8KKY;J]K5?M<OL<[:U
MKJ/B:N*=U.B25W:U^(:P_$=9$[.6U3JM3+%NFQ;;E;9EZ+7*)/"9E+HM^K2D
MI$^_R<<0HL1"8>R.C9M7:/RWOE7=[N_5Q5GD_L?JG5-,;:MB[M:+>F;PE?$I
M9WB$K5=M'2JU+*MU$&S3,_<+.H]N4*G22):D"%'B0H,S/KGIB$H)6B80J&-R
MC4F*ZMZ963JG:]W:I5?4/5U=_P!MW=<T&JZ<VU^Q:/1$::VM"DX4JNWX4[*2
MZ)VN)5,H5-Q*C.1(D59B&&I12 SW[\JA$9A3W>3CG8&,US4\0?V:&O\ ?6IF
MN-PZ'^,"N:::<>)>6E9+5O3:\K+H6I5.DME/B4F8G=.YFX9&<5:$>=I4:8@F
M-3%05PHT4QTK2L!WO_'OTJG#&_2+$_:"JPK?'V%]M2!T>J6@.J-,LVY].O#^
MCPTUVHZI6);VK%'N6T$5R:NJ6NFCTRO2BX5O7O2+EJE9_9%2EE!,&6F$R42#
M,2QCP(I=7]KV^_XH\L(V^X=OO?:MFK&^S IE@:VRFL%-U*BQY20\!$SX*(=%
M7;=%D!%5,7'4+CF[_0B@TZET:#%5-S\Y,1*-"I,&77,1YLDM'4U\Q$\GF)1!
M%"=YF%R^[!]NM7;E^Q,NB9\/FB.@U$UYM2X*%I7I_7; J-)U0TCM*^;2G36Z
MU.56'?EKRE7DXM:MF^I)-1BPI*I2-7,C"B0T%$D"[PXS'E)>3VMZTEF.XSM!
MREE<\5E6!]CK29>7U IB]9JU.TJ\O!M;/A)7&J%)@+JLLBUH<%"+I7,)C)EH
MD:9C2R(L.1E9*6W)"4KBK8@O:^]'>R&6+['8U[O0_P"S3O&R=9O"OJ]JUK7
MU'JWAOT-OK0Q%*E;-I]!E+NH%U4_]E4F,I4O$29:/1*0E$*HPP!#J,0+,9"M
MQ=1\MMO?/HMU7D]#?L;;!T/HGC<I-N:DU6HQ/%C:EVZ>6?&J4C#F86C=BW.B
MY)VH6K;:(@2%TA5P7!/5M4B%"63.P8,5,/> KIW6*CY,38.<+U$.59T79/V:
MMU>'C4GPC:X6%K'-34/PI^&.:\/6HELFRY*NSVKNFM-B2=P?LZW9*+,0Q3;A
MJ<2B?<$19>) BKB14+3%AJAA?16]V_@KI5!;S /8CET._E%:]_9"^#ZL6WXF
M?&;XOJ_IO?\ IE85[WK6K.\+=@:H2\&4N.RM-KEO&X-0]1D25OP)J=_8E,N+
M4.M&9DX,./!!@P/,5A(60A\_6WXH95ONVL;,S@HUT,\2_@JNC7+Q,Z >)&RM
M49.QI[2NW+UL6[+>G;;E:])7OII?D:',UZCI^]1%FEU-81$D_P!IR^V/ \X1
M86U<)/3W[]_S >1Y_E-@195II9GV.=S4:<L'2*Y/$Q7[F\'FE>LT77*R]$HU
MIT.0KR;K@5R/<-,IM1OB5DH=0G:!2ZE,&-)R\)4&86$M,15%2RI1PT7LC?WS
MMTK<O[0KP0W-XR:!HA"L+5I6C=XZ%ZJTO5:T+D_=F1NJ FL4>"40(,]3)^%&
MEX\.%%VQ(:5@@+"207Z4!^EA*(N(].AK7VC_ &4%3OF?U[U \5?B.N[7K6O6
MO0VJ^'26O?\ =ZV[1H>G=@5V-'FIV#9ELV_3960D)Y4S,1(DS.32(D6+OB0U
M$A9<G_AI9[7JNT7R$I/WZ9G-8GM#['C4]=7T[K.K7BYK=WP=*O"-J]X.;+_=
M.SJ19LS:VGFHEIPK'MVMTRJTLP)D79:-*E)*:JE9J<28FI],"$DJW0@D/?Y_
M%%RR]YY#[XOO7F]%/L2:[IO5:+5J_K];=9G)#PG:J>$R!"M[2^B6FFH6SJ!3
MX4.#>M=7(F'4[ANZ6G]D:Z*O4IF/-5J,M"XAE% =*3,><;6O]OJ:Z;Z>>#F#
M8O@(DO!+^^42?1)>'F?T.AWJJGPD3*X4Y:TQ:\2M(D@DP@D"8^\*@E*@I8*L
MG/40YF?:^VU1SBT;KU!!A6KG9I']D'K;;-L: Z1:J^,.8OKP]>'RO6[<%KZ<
MT#2JS[4K53F++C?>Z#+S]XR],1<2X4I,_B391.P_OD!T%6TL2[R^D*KFW?W[
MV!E9)E?L;],ZCX9=;?#U>5Y*K-5U-URO#7ZR=1Z=29:EW+IG>EPST"?H<]09
MJ%$3,K@T&8EH.Z&F(#'.X*Q$/5HY S_&WL7EQ5QU ^S.UEG;AT>U]TT\5,[I
M[XNM/-*(.B%[:K(L>@5NS=:[(@PY;[O#U(LBX).J09Z=E8TN)R6CIFH*1/18
MT4)2J(D!'E[\Y.T5"FI+ZPWZ19[XK-O@(^S\F/!W<'B!U.O?5F?UBUJ\35:L
MJOZD7*NWZ'9UOR\UIW1YVFVS3+3M*@2DI*4NERLO48J(DHE<4+7!0E41127J
M21OOAQ+?^$:$G((0+78A;K.+N+XFT<^RWBZ2V#H%I7%U3-S63I%XJ]4/%)7I
M"8HD64BWE6+O3>L2T:/&C0YA"9,V=6+TB34"-#2!-B3@+V@@DRJ^38M_E>[W
M%8QNG[*[Q(P]7O%1?^CGC)@:6V?XMKYJMWZA6G%T<LR[:G+0:O(IH\W3J-<%
MR4^KS5+C_LZ&A$.;@0T+066 ^[I1XS]5?"8V^E>[TD^Q^L'1W43P@7'2]0*G
M<]M^%O3;4>PYF@792I*H1K_CZC1YF8J-4JRH,I+R$!25S46'"@RLK+PH:"$H
MAI#]/M1GDR8!V%_\VZWK&5R_8P(59VM^C%B:XU"V-!-5-8[)ULMG3.;HL"?D
MM,+EMZX9:X*M(4"/'F 9>CW2N6,M%E(,&&A*D)=)2E)!9]]L"C'3KCD>?TS7
MD(GV"=B2U;\3E:H>J,Y2JAX@M;]']6J=,JH,DI-E4O3O421U&K-GTV%YI$5-
MP7%(0ZA%CD IB"5!!5+H4"]]*/\ &S/)_P")\OH=A/$AH4I*%*(918!E))24
MD)6I(4D@I4 H@*! 9FZ5C]P@&(_VGO@YYQ4AW;E,,#@@AR"<@?4OGL6]NE#<
MDVQLY<)'+S@%Q2DC:#G'R['';N[/[#/TZ57!\D8NT\N4<E DHNFX #'U=V/'
MQQ_XR_2H8%P$X(G,)E@GT1Q*;1G\O_F']N2W]&+%NE,,EEP7 L/1[$2P"":5
M+@L!Z20#\ .27]L$ >WOCI50*16SRQ)D2=P/0FEW,%8 4"YW<%^X(^@_D/CI
M484P>;9%S@2F'DN9-*<%PW*NQ./]5ODY/9^E$SJFQ!=D2X%VK"0C94PI (!8
M[7R><Y9^6!# .!R_2EDTKB8@0%*;P^0S2[4J401^9BK#?0.[L7QV_4]*$D/)
M[=2=T" 0#B;"$,-(65)2D$@ D %1#%../<@XRY^O2J'$E[#?+@A +,"PL*:$
MI3Z4IVA(5] &+N'X.$Y]B>E0%@OES9F++<Y 8V%4E$,@H,,$!:E[?]I:BI9+
M^ZR2?ESQTIV;MN1)/U&I+*40XPH>]*PE+AB"06&T+"2!VV!2@&;"NGOWY59"
MF8G=%(N O%L7UIAA0CL(AH24@$ IR&=@![^HE\_F8X Z4DK,X*!N7',%\PQD
M54.!!AI9$-*0"%IQ_$"2X=W().7Y;CI4G<L/N)(!EGD(AIT[9#(VA(+'>!@N
M7W.[=E 'ZEOHJR[IW-E<[Q<A7"!M!5,.&-IV ;=P203Z4K)4?;)*0>"7;I4#
M5XR@ K&/.1:X5A31"A(" E*70E"1W9*$+A#EQMVDI /()?@='?G?ZT) 4V@
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M5##@0_1"ZL$;EV>#5)X)QN=OEG(;^O9\_&>E9S$$/E<C<@'O<+,"N4AS^8N
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M;\@L2.9A")M2I(3^8'EQV&"Q(SRY;MGI1@J^Q5Y&8F S=$!<Z2H;BV-S%N&
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MPUP25* 2H+VE8%QSC\F\C&WUJ$8E$OH3CN6>JC?8JLU22H],G:I/3<.7E*?
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M;N(6 I3!2MJ2HJ5D?>_Z%_TRT_TU_3OQ/PVK4/\ J/CS\/K^( \>E:OA]/$
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M;8:R<5V(^S<\%-8\(>F%P4R]JQ3:]?%\UZ'7J]%I$1<:DTY4K+JEI25D(NV
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M2=17^SB\-V:)U NRFMJM"]2YG5C3^E73,RT&4G8J8D*>EH"M\LB:@K"%(@N
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M0,U@\+22=1?B?BG62 29,$^?V%$H@PV4>^W8X40D@C("0 !@%OY=9KEU:B-
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MY( _JP_D>W_/I6SWQSM+Y+>_(H4T." 0S@\')8,&^1EW[GI4$N+#:2$4@(Y
MLQUH6,XBR38]48 ]W\I;G^@5\GYZ>_?OZU'(D9,0/]^<>R**RH9[,X(Y=()
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M9A YGUKT)/+EAZF)[!U D>^0#\ CL_2LE@R&'!/>X:,-!@N]Y3;APQ8#W )
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M@?GMU*!' ,+JG(:+P;*#(LISN!(4S@YSCCG/+^_T=NE5D2;!X2V02Z"^Y1U
M#@/,0F/_ &*QM<>_#D=LE_<< YZN#U'W]VJ75_[3?ZQ,PP.Q(,D*< E@0Q+C
MXP.X!SD@9_JTJY 1O [NV%(>0\(%P4-P!?LQ;!)9V^KE^P8^W2H!ON#>R)QL
M6 $[O:HE!YH8'^&<>_(S['L#P /<]*T;V.9%\6Y&W683J8'!<>QR'!X&7Y?&
M1[%L]*R5?L$;=Q 4)Q(_<19CLY[MR P(Y8#W RX#DG'.%+@G!YHDRY9@#!V\
MQSF8B\X@(;AN>2'[_P \=N]P.I^@S]>U!_<5@8A<K -[P)V@E)(/)<DGY( <
M,P9G!#N_;N_4HG$M*R$[B9ML !']JI&("N0Q&7RG(/;\Q9L#Z'D]*"XO.5+"
M&2NL&'N0!82BF+,+<8F!" Q^5R3_ %X_5^J;:>C]3_$[*J &5<'K"2],V.38
MENH$@%^"[DMW)X]^>?\ C*F$&R6;,$FR@L(S&_2LL23W9W+$_0#+=N/UZ5F$
M\L$PW*<D$@EOL"KD>2;RCW>-%(^'4KW_ $/< #L6ZI"*Y#Z!UK2D.3BZYG;E
M8MX=$D@G#[B2 '8N"./8,_(9A^O4H9)4B["/H2BHB42V+5 4A)BE*F AD$$.
M-VT E@_8@,'X X8]*@)$;DH-'S)L&;LMPVG2S& APSH0HN2SJ ;V;LY[\]4W
M/4U=*S_XW VMW$!V$"GI.'W.0X.WEOC#%N?D,1\2@$F% 6DO8,Q-H>6CD4R.
MIH)+<8R'=V#OG;_X]NE22$ F6+*S .Y0VV)YMEF,%'Y0&. -S9)<\-R,#'N&
M?H;G[W[U;)(";+I!=C#=K-I>)U+(%@WTI)! M.NJ!)?,2GQT*'ZIP/;GI6@<
M62"*?*>DH"ZFK]:RPBV;>1M/IHE* =206^XP&Y^.E5'<7.";E[BKZL@.2-Q!
M4 &(_P!HD@]@0Q*<$.Y+D!6,ZD3SF;J,9AR,"13A^5B4^Q2^UW#LY+]^W(_E
MTH1^Z!TN9!$G[OJ"3>A^8 #TYVGD@.W<8 +LY?Z]*K8#8).Z0)*V<#O@ND?<
MX5D@.",,^.< /[D@\MTJ-224S&Q%H."W:"JIW!2&(X&0#N#?[;GN7?LW'2J+
MLA$;N7EJ=@(5H) K5_7?Q4V-X?*K2)*]*->$W2(U.@UNY;EH=MU.J6_95 F:
MO"M^4JUR527@&7A0XU7FH4$2=/,[4H4A!J-7FY.!1Z9-ST.QE\EU]YVP:(SB
M3R<"TE6R[DL&*V2EYD34JB,EV62L'R8T(!*X2UH01'0A:EPTJ2B,%)2I$81(
M2TI6A:1*O]I/,>O[BSUW^U8_TB==FP"K)_:E9('R*C,9X+XQG_R>Q6;D@.0V
MV@92Q@&\#::R/'/HC !AY)/#?Q=CE_T+?'5%QU'UJ@?M+VQ+ $$>WV0#H;^7
M! )4###I!<8#N2"<=VW.>.I0$H .PF.PE;&;"Y=Q*Y)2"=I#$G )P0.2[GCW
M#LW)Z5E(%2XR@)8:M+DBP-C4$RK\%:@IB%(PY#$J*/21R2^6)#@N6ZH#(&]6
M +, C #*U7]QD-N:&Y2DK!!2D ,/?!!8G)&WMPR@6ZE"<#K90/[9;3R2WY4K
M>HG/?(!+-[@.Y^1G(/2IRM+FP!-@Q&7B#AT).[C!!P08D/+ .ZN#W^I('T/(
MNF_8KJN4T(AB @.H8GZ)S$D46 -C,'5A@0<MR&#MVSP.2!GJ53,S=MAC]H/K
M<H8L:4%7I<_Q%)#LWL#M&2SMP'(&2Q*ERB"EM,,6D@,QRO%A)HGR1@-O0"X=
M1)  &"3^8#)[%/( )UI_N'?M%34E<[C DO-[XMFB"IEQ 2$_DRQ+^DGAB/\
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M2N C# $\WDI)1ZA$0 P?.[CDG/L06Y</U0'Y3GW]KU"08L$%?IW08;&TH$'
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M  RP(P6.T\#/5%B._<?Y^UR%< @(VS<L).+7R2\$$M3@<;GP3N( <AP [\\
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MFPOG// Q]ZL,F I:((<S@[)[@9%%$,[I+=F)X&?5EG?AR,/G!ZE"5@ E DR
M\>3)L.9=(^ =C\_E# <N^2/U?GI4880%HO8V ODG%HQ DDQ@DA(+QE/@L?40
MY/!8$,<_+GJG[#MN.4OZY=-,C;DS)D]!;$\Q:C5*?(RR@&SC.7(.T]B'XYSU
M*I*)8F2,0AVQY Q@PJ(!C!DDF&1DJ#D)<C)8.22W\0))+9*LF0#;[ E^(9.
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M9.,]N_0W-KXMVY5!9[0)M^T<NQV9,)U(2-KCABSY<N0P+<>W&2_TE"4%XC"
M 8-@=XNI!2W=0QE?@J4IPQ0Q.",D]_ET#WQWZ518DJ5W42BDASS!M4R3N0D#
M@0PZC_FW)_(>.7'2D%,A@E[=.LCRI X+C"<CX!8?J"Q+9_W]*D%HY!;3[).S
MB\7F@YPO"8.?Q88(&']3#]?D'+GJB_8_0^_2LFQ6P>-K"Z,8%@CBC2&2#V&U
MW<DLGX..W;OV[2MAV,*8-DN20//!NBZ!<D;B6&0!R"/<Y)Y ]G?MTI<$ D.
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ME^!VSVZ4Y8!B^2US:N8C%SKGXG-(*KK-85!MVA3E/D*A1M6="K_F)NI1(L.
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M22  Q]7#@E]O( !^7 ;JFYZ[OUS60(+4E!Q;EAR"7ZW\7J8?_5_?0+.+2K1
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MZ^+7D-/9&QE^)*6IJJE1HLI^^E6LZWJ-*3,A!2I*ZF4Q8R%SZ)6+!/ED)30
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M6B+"B1XR (DT(:@F'&)/J]21_%R_+\??OZ5_-_F'S3Y%PM7S#Q?ZRTD$^&Q
M86G#-B^=?+/US\%\M^!^;<;A_ <,:>%< :B9>J2PV3!/(@[UL3"$01%!2TD%
M&!M^4D$Y]B1CY<GKZ;JU/BG3X2%I_N<%$!+>:]'TZ=8 .K4/"X" 13>7#Z=0
MJJ>4!!\WD)4"7'8J*0,\-[=RYZWI3#MS]_6*I8&1&\W&1C&X0LT3 '63W.Q3
M#G\I&URSA\M@,2XYZE:(B66AB+LYGSF!BHU("AM(!"F?<>SN<\!R P9OZ=*S
MOLR"))Y"Q#9;DS!BL$:GZ"6IJ/4Y:N3\Q/4ZHP_)EXTQ(K2@Q9=]NPN#ZB"
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M$C!&Y@2Y=GR_?@DX^>_'4J"V4(!6ZV?(@PRD2#2N'=W(+I=FX[NWZ>Q=NE2
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M.!"CD]QL(.,'@=W+_4?K$>7F/S4!A@& F!]=]U"0%JHS3)(\J-C!=!2V';)
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MC^&:OBLQNK.=Q*$V1Q=23]X!<F%&;@LE0!)[9!"7!X'/TZ+F/,=L_P"*@)
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MNTM-$K50I4C.5>CHB_>$TZIQY6%$GI),P I$5$M,*BP0N$N)#44>F(6+*R2
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MDK(.\(<()\T.A3?Q,XP.X)+9RX!SI^&XG#U^(:SJT()\366+V.E;B]T*X?\
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M@W#@'S%.Q=F]/N_N007?@JI3OJDF[%QB&2(0Z*HMI3, M_V;N8BF #C:P0S
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M[<CIM0W*'V9@\D3).0@>1R'';9'&"\$E@';U</W'=V^O07'VOVH!!).%.!S
MS.[+Q3X.(4-*=Q_#1[* !_B [D=W(;Z]#)- 8&ZL8! ])8-L*)J8,HGW#E."
MDCD9?);AF8 L07Z5D@@FZF\LIAC?8](;J":2505=F4E9!2SDD@.SA1!*0P8@
MI=^.J"B/=XW'UJB0NEHF2QVL1I9$8=4M10B"'.Y2221N/^&D*[D$8)Y'/(':
M&-.K5C2&?XQ]* #QZ=-_&3ITI(("YY;B8W-!Q9H04;SO(B!2 D,761^98W8
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ME$6)""U*:&I1&U1VK/Y=H&.ON7Z!_4''_4'R;A?&<?B\'B<35HT^(Z=>K4V
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MB9-XRX_M/,+MYS4JCM8, [$!V#EP>&/ZD,Y;OA4O+D S ,.X<#LV[!5&O"2
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MCP.'(!)PV.I4$P.<Y(NG#)<@F 1ET\8VAW()"G!R27QCA\OPX#$.Q4&.Q$!
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M," 3SCX(+MTHTH(0:"O-X%P[3!C-4-N!N=^'<*8'@ !G&0?\AGI223F"U%Q
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M(6"2[E6"V0?H 1\D]4?8_3WUMSK)+!M8=0 <Q<F?KBC" 6]PPPPSM8\L#CL
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M5(G<  0,%B2X=A@Y3P.P(([NS=*R9-VRP.ZW :2!Y@B:I:622%*8 EW?#,P
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MVC0X']XBIY/DH]7+98#LQ?LQYRPZN!U/VJ9> ',N#YHE HP/,HDI892YPS*
M(<E@SD'VP?;J4%PFAVO FQ(V*!+NR:HX=0R2,,6!R-H<#U$.R>'3@ NY4!A
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M6C$ <G8;T+/R\O\ =XA$&&"%(SM42Q5DI^I# C#'H R'F_UH2-(A#:]Y;Z.
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M5(-KVX2I*?\ 0-(&T9V[:?+I9_<,Q^>E9(!+.DGN/S5_5N=3'@*+#D@]\C&
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MK*46I\$'RH?=X8;<X.$\\-G'; RXZ&Y_S4"AAL"P8N5S=W=DF(F0=E,X+@@
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MX(,J+7@6J&+@ I&XB+#9/8Y9P X8/P /KTK6&4# ;#@YW/[;S. '11(R '+
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MX P #,;OLA! )F]ZE.[VR E2E%(+D9(#=P!\AP XP2J6Y1'-GM&Q)M(#,0S
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MI0(()6V",!B"H$'=DL/ECR'W ]*@;]&R5!NH)&Q4V$NG*R!M<@*]3%MV,Y?
M?G('UZ52! '-#!<L(CH&1RYBE_O$8#O!06_,P#@.>>0&9R6S[]7 ZF?+Z?>E
M]29!0]Q&29#!1$11((8#\SH#D':2 <8)"N.[L1V8]2I8S^W8;-3M<6*5PC3N
M<@D# [,QR"V['  X.2P!+A49(1 A;[F"7"Q((M8FA9<_WF8<,2_+/A6' P6<
M\'#_ "6IL._VGT7:KSG^T2F&FC=C)@XLIG]0<NS$D^G<V'*F88)!+X.1]#*7
MYQ<L-XD(&8#4CL[X*B2^"%,_U *0 W.07X?I40(8O9?W"%UQY6H:3!, @%CY
ML3.0_K/)8''U^O5-^P^@^GL"J@B<@I'#Q,*7E9>20?4H@'D/V<NS,!E@^%9R
M,Y!$H6BWD69DP\;2!R$@5 MB8H 8*AJ41D!98N7#^I+,V0X) !+]*CV(3CEG
M,SGHA!1=*_\ 5X8R/PT#!2<GVV[BS,S]LELD4W/4_6D*!@?1G+77)"-J<^YB
M'QD)&6=O4%<<=@7#GW;J50WS8L1%X*%M^2V H:)"0DQBDI,5>=J?4K(R2 DK
M9W?)X&1U!I U>*S(:4I9(CSYFM:=(\0M</! LP"?-W-Z;+("X 0H+"2D@LDE
ME GTD*"F([@\8+@'K6L G4,'[^XKDXBU%Z?"9*\*#!"YB))OB\UX_4-"86GU
M[I3C;:EQ$8Y"J5,,1^5@5%L@.K#OUG3I&D#2+#?SPJX@/"@HZV9:.#=.YE5?
MK7"?W9MUU!Q0J0#N$-W%/EPQW,<,V1_/GH+#$5C5J+,D2K[5Z%1 "G=09B,
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ME.[4&U4=I2HDI ;;C_\ M'!!?N^[V;I3O+D9/9BT2\,$ "H$J'WA8*DE)A)
M&X)&X<I]/+#L "/;L+@=3]!4)1[774N27,W#(\YBLL05 L0['!'<*<AF &?3
MSCGJ58PWSQ^X"+W=YD9+I^Y#%94,Y8D!PE@X2>Y4D .20&8@\*A$@"0 FG!D
M6[X'-@T/!(\^9R,DAE$,3V!X/ .""6+8 8W _CWY_0UH6OCF!&42.@(4MU,"
M&8@%)+>S-DN7V,/A@_('4J&#F<!)387!=O1VI04?4@8<A^6?< ,#Y.&9AR5(
M9)U)Y##BV1$%RW%#2BD^00 DO'B#L!^?DY<X[G]>'-+<OO?O0?VQOAXGMO\
M231*E %]Q"222Q9F 8OZL/\ 0%W. >I2X)L8$H%^CA)Y'>HE,512[$PCNRX6
M" D.6# L'4$X!#%/2J#GFIN(#4&7=F3$DU4LL&722IO2EANR& </D\_ &<
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MT!,&,3$4$>6Q48> HJ  *@.3@9)R1C(Z6(?\>C^]5W$OH6T3 \DUU*-/@SD
MP88$4AD#U&$2''(!8YW!E>V<N.B9*%V0.73'M5EH3@ 0#>9<0BP'S"J83<$#
M,;@'T^60[=L)X(;O[NS!B.VWK[[9J1_Y$H3+!=[X)272\CS,W ,NO\8X4D#\
M,@@[5;4L RB0G'N0.W"03W'I/IC?RJW:<(AL[HLV%VX5KRZ#-P%(A[HP+H"@
M!#X#%(!.T=P<]U#!YZ9C^?L;<JAEW$(L%-NX:FIDS$#TM%4'[>6?9V5Z7(.3
MGG);HC[^G7<8S5<DDM""N:8P$NC-S04],P!!2\5208J Y0H.Z@ .P).0 .K.
MDS]C_COU1J%$(%[1:23)#VM?::.^\0DX5%(_*&,,^DA/!<>Q'RY8MU$?OZKZ
MUHD2/$1LNC<#^*:F;E]P5YBB$A@##.&].&#@9?Z\<MT\)_P0=]CR-9:R=@@6
M;3,2A W%!SLU ,NH"*7)0_X7++*G# $%G5W';WZJ(+(@;H_</KOY4/[F B2N
M6UG>-T;X-%F9EW_QL;$*"2@EW#);'!;.0_(=GZBE9:55A %PB" 829GJ[)<Z
M=][@)R(A*B0#^&0Z?H$C^?L>B/WN''+[7OM4!##*0B"0#BY)C: [<QHT]"9+
MQ2!YD-GAE(YSGE_Y\X'?HO?\]>W,7K3:GQ9@6G:XAK,&]J*B3D%]HB*!VA0_
M#)!!(RY'';VRQ^"/UY6O0EPV(D M@\MT9&::)N7 *O,)9P (1*@D.26 R -R
M2>6<GH01<5D,F#B3-TKSU#[(T'%FH9C23Q5LKS>81&\>6LE0?_9P2.2'/1)C
M)A1OG:W6V'6CJR"U)ZFP$=1:UT4:,,U+@-YRE*!=R@G+@YQDL"0';Z$=$;_<
M;/Z34AIF;H$"R@; A6>"V4BIN"&4(JAZ3A,(G/#.1SG#?##L"/ES!^E'B20(
M\0,N\ 6C,G<30IGH(F8 5%4"82W282@3R?RE(8^XY///11Y==K<RN?G0F;G:
MPVED'#9P*+^]P#@Q59!!/EMCL&"?T!9PPRV>GA.WOEOVJ,(28-T8G%[BXME,
M(T9J Q:,5$ $-#.5)"BQ 2"Y+88%V;WZ(IKW[]P:K!,,PE,/)+/F!8T&9^7,
MTG\8J:&"4B%DH.[!P/D$Y23CL.J 4E)D7?797YS0ERX##(A[@29BR5U)HU,W
M '$;/<*0IV#\,.<=S_EU$=O*>\8YU"08+ZA@>+,'&^6]Z:)F #B*I+AV\I\^
M^4G./9AV+=$?LF'M:]7Q"6(=U]8ZC<@VH5$S ,TK\=:CM#?A$XSD,"1AVP _
M16MYWDSLL>MJK,X#OL< A [,HQ&YHL3,$L#&9P'/ED=PR7"7=G)?OE\8OAU;
M&IXM(2),S>8DI@/KUFJ5-0%9WM__ "B6;@9!#*R2,\8;),1G87D)VW]OG0$&
MY),3/H!,*\-DFA($Y ,6.4QR^6&W>3C<%8!<L=W)].X^W0@P(@?S+ZWL<$T>
M9 Z7L$"-UL",47][E]H'FJ_5!W?Y#)/(/(/''3PDXY>_S:C (+'8$80]+;.'
M-5]ZE\G>0[@@((/P>/YCCL!T1V\I^E&7)R"B#"DIB$/.Y5"2DU"\EQ&+"/$"
M1Y9<%RXX?+X#O[XZ(GG9X ^EO<4! "/61<&02F^=MJ+^\P I0,0C!<&'E60^
M"",L,,.,,_1'S0N,VJD[&S_VG8MFX6X2<NG_ 'F"%+/F^G8^(2O2/<DH. &+
M%A\%SU%^/*H-16>^0L2(@\[3-#P)J"J$ (X+)!4=BF;:EBX2[/D/CL7 ZJ/F
M5NS[-3Q <D_]HN<R6.C-A:GB;@8!BJXR-A+G&<]BQ<<=7PF(O:1GO5>F49E$
M A!<A9_7<5J]XG-*YS52UY:!0IJ$FK4N:^]R\O&"X<&,200F(H )*BS942Q]
MN?6OGWRO_K>%J $HL)]5^THON^L=3\Y^ U?&_##3I1*@%+&2#U1 )Y5XCPMZ
M,5_31-:K%SS$JB=K"(4O#DY;S(D*7EI8J6F(%!)28I6I3,06P">#UWZ=^3:O
M@>+JUZ@'JA0B 7"TAVMSKQ/T[\IU? :]6HA:N(M)T_M$ @L$ "\"_;.SE^S<
M)>G-Z!*<BU;C!B!)2D%=,FE J< !2PH$@MZ@0!D=>ZJ_?(< \V/\)U[/Q_V\
M8@M_M!!+OITY:0PG 1FO46M#4;8MPIV$?L&D9(+XI\N""P[%Q[ALYZGI7'/_
M )=O#]YKT)+%6 XS^NX@,^.,_4^PZ5F6\LRBP 1:XMRN;N*3<Y=+$#LV2.,'
MOZN/DOVZ591)%T"1>R-K*\CEM3G<$G (<!^^ ' R?@Y'2LPLNWI8EH EM(G,
MNL*:SZ36YK+;L*TKH_:TI#E:Q1;GMZO6_/QJ76K>N>WIM,W2:M2ZA#!,M/R4
MV$3$)DE,2&B(E;E@5;TVA[)$"9LR.<;]*Q!$\&^FHTYK.FD>H7E/VW<M.N:)
M=(C5^;B5"O73<]7IM<G+WCS@"8RKRD:O3I.:HE7=*Y'R$(A@(0@!0F[(N$\8
M/W[MQ5PE_"-IL=(M4M*:S-73=$EK7<$S<FI=PUVIJG;LNFX(LG;-*DI^9JC)
M"(-.H5GT"DRL"&$08<E2X,+:3N=3==L.\##8OMYUM2B"CR(*%(7%A!0A@%)*
MEP%PUH3#C)7^:$F$4PUI(+Q$$D9?J^7L\H^U3 E@$%PU/IC!OB*P+9E?N6S*
M1%H$UIK=,VJ4J55B0YNFR\D9*-+S,]'CRZX"3$24 08B0S88]N(SY6IJ G<D
M,--=7N(J_5#4RNP92-&5I5?2A!@18BDPI.3B1E>4DQ E,(1BE>[:P<%3XYST
MH$ 0$D606;74]/58IM*U2K4]3Y.>AZ47W"ASDK"F!#B2<FB/#5%&]28T)44>
M6L$\ #DN._3M[]W]'5(>SZD X+&9A=&<4>-1Z\2W]EE\##@?=9'@X#M&?DN,
M_'?I0SL3:^8<2%#2A1-K=6=5ZW2Z=.U&)I-?4>')2BYH0(<E*1(L2*F)"APA
M#0B*5+5^*LD-^5*C[]/O[D5%%W<L_NMD=)MDSBC9?4NM1H28B-*;X0@IA% ^
MZ284$K@HB)!!C8VJBJ!'N%/CH'D+W<40E+8N+IM7)<8#@14QU&K98G2J]<EW
M7+R8;VXC98AN/ICIV7E]B:HY$$\R^J-QC=<[U9ZQJK5J?+P)B/I+?T:$J=EX
M01*2<K%4%K7M0N*GS21#2HN5# _3I4++'[>=RGU"P([YJYC46ND[SIE>JE#>
M5)$M)[QNVJ02#&"6 #$@ON'5]+>D/S\I%7<DZ2,.4#SY@@>70RC4BN<_V67P
M7 '_ %61#\D9\_W]_P!#E^I4 =S:+LM3*VE#F[(6.X=5:W2Z7%FXFE&H,8F/
M)PDHE9&3C1@J9FH4NX0B*5;$(B*5$4Q2$@G'2?>?9W55"X,($ D[&[.S6TP5
M5Z3J+6T[2C2V\R"50F^[RGG;8*4;5$&+M\MUJ;OC'=GO_%0=;9& @;%H$.>0
MO2C4>NMZM*[Y/;,K)9((R?Q@WT+#^O2B#.#<HFY!2&8>[F-K95]6*W3X4K$7
MI)?LPF-/R<HT"2DHBDJF8NQ,583%.V'#+%:L!(R<=*"478_QD S-WR+JYHU%
MK@"/_5;>A6E"@=TM)^9M*V#?C;6 ]1![!QTJFZ8%P)D920PMB-VC3O[1:Z2E
M)TMO4)40DJB2TF$94'=2(VX$C #,_.'Z5!$P'+),[E!=<D6M:T5'5FLR<Y2)
M8:2Z@1OOLW'EX46#(RBY> ($I'C%<98BDHAK3"4A"BVY:DI?('3L_?453B0"
MXP\+F<B#TJ[+U%K;I5_97>OJ(W/+29 88!:,6+^W!ST]^_?\B#N$B""5SN/:
M!W--&H=96P.E=YA);)@2H90/I)_'X<,X!;I3_P#$&02^^PZD/FZLL?56M2]8
MI]..D]_+BS$*:B^;"DI2)+H8$;5Q3%*4D\IR/D8 ZN#VJ71!C+)=X3#W$\P#
M<U>_[1ZYN<Z5WPE0/_[-)$$MPWG8QS[_ *=2JDY-G:4+\K\M\DFJ&H]="BVE
M=\#+D_=9(L?X2D"/RZDE@W9^7Z>_=Z)1=K+\RFKWO8)JK&-5JQ^W$TC^RF__
M #OV9"F/O!I\F(("(RB4*B^;LWELI?D\.Q#W[Q_BHB#<"( RL/I#DYBU7W^T
M>NES_9;>YYQ]UD .2&_QG[L3]".E2;Q82SJ9 >$HN5O<&HSJ)75.VE-Y\$ _
M=Y5PV/\ Y_8]*K-GI9VU'.S![5:I?56L*JE0D4:47VF+*2T)?FJDI8(65#*4
M+,7:5'V!/N0W)QGI[VSZ52!D@'?(F9B,8YWJ\?VCUXA_[+;XP<_W61#!SE_.
MSCVY<?3I45UYLF1A2D2Y>]Y"G4>O,QTKO@#T@@RLB7R0/^WP,AS]>E3H27#:
MVMS,Q.":L--U9K4_/5F11I+?\-=(FX<(QH]/E)>%'0NGI4%05B(!$05E224D
MLHM@#!F1R'U?X\ZTMBR#+W (%HB-JO@U(KP'_P!%=[G*?_AI$@%@68QL =L>
MY<'I3P@S-KW=Y:GI:S"JAJ-7G<Z67QG@?=9+U'C)$9\=N/Z=*D [R2V(!F&\
M=[G(JRT?5BL525B3*=(=09>%#FX\OLG).3ADJA150U14 17*%$;D*X*5#J]S
M16(.G88#FR)RHY8J^?VD5T$'^RR]RER TK(J!&1N<QG(=B'<X^>I52AJ#-C*
M)0L(!^O.HXFI%;A0XD16E]]+0(,>*M EI,E4.&DD0\1LG: $AB3GOT$Q44(G
M&( O)'.6O*&+90]5JS4Z=)SD/22^H"9C<A:(LE*0UA"1Z-Z510H @!L98N"3
MFDDG,6D1TLO(4 '(O^",EC);QL%=AJ16PP&E5\!(;:!*R7 ?_P"V!'T.1C'4
M;OZT(&X -L\\X> AYP#/ZE5N5EYB:.E5\1DPX,>,J%!DY-<51EX14E.WSO4M
M1_* <GCC&M.D:X) $#]T@O[;QVKDTK6M+ %@Q$FR,!7WFUJBI>I]:GJ=*32=
M)K\@)F96'%,*+)2:(R"M(.V*@Q_2MWW   G/&>IJX>GAOP^%[:0&L,Y]M5=6
MD<%'3K&HM(*(N$&219@=:M-V7E<=<M:OT.4TQO*!'J]$JU.EXDRF3ARZ(T:1
MF F+&2B(HX)88*B0!_$>H)_FLDG43J-]2OR)4=/+M6;Z!!F).AT:4CI*8\M2
MY"7C)6$I4F-!E84.*DA*2/2M*@XY ?OT]Q7&=:)#SM__ -"UK5>"EU%1/&$A
M\#;C+XR3_4]*.2'8ZC%\FUB+Y):M:FI )(<L%$GD#D\'C;^K9]\]*H);@X5B
M(!E.<&,8 *5E<,V20#EV_P \?Y_7I62 T+,=VH<QS\V52,'QR?X68.['N_S[
M=NE#<V5C,*$-AL\%FUJ4'#_R)(8-EA[MG. 6/OTH(,'JV)=R.; 9:9LH5RP)
MP#R>5;B^T-QAP0?@#I5!3+$O8"!=262.X+O%*64'_,V0X+G(<ANWLWR.W2KD
M#([.8"FV#.^73<@'(RV&<I+D9 X'/ +9S[*G^[/<D@@XGRDA&)(FCP=K'/(R
M_N?TR3GD]*)6## OM8&1+BR [TKDL=W+I.,#.0<AL9<\<=^E&#M%L".09(C$
M*2(#4L 5#:S>HAAE.'?V=G8=NW2EF)@@#,FR!PF &]QD,?<0 ?S!()/*@02P
M'T!#CL%G@'I1PT&7D)KO)%P;E0;A?=R&+EA[I#%7P"?T#=*J@,0Q>]XQ82$4
MV;0*5@&!;L/9W_U0#D<AL\/WZ5"!(8EGR<%L7N29G:F[@[%8(8'ECM!+G.2
M<'L"/=G5=EN2XO$%$!GN>:)IS)*6Y)]1 /8.?I_XSTJ$)%RS+WLSB%]I(JD-
M@D 9V@<X+,,\D''=@0Q;I5!#AE]$Q()V:]"PZ0 .0"%, &!R&4 Q/_>"QVX/
MSTK. ]H%S+%KR,0W_<$ %!2<!27"2D\.R20&'+'(]L%G(Z4!()Z/?$FY[=I
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ME;%@[YZYIVX!1=0?ALA@'4"QP3G#8P[G Z5@RPY)V@ 'PCKRP]DZH%20S@@
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M_P#NIJ7IW%IP@W;<7[L32(J;IB2M2E).0IT./-4N!4JG)ST"$K0'7N_H?O\
MBL.^''P+T#4J[K7U N'3"X],=-(-ABN0(],ULNNH71=>JMT0H2;IU)TSOJSK
MX3<5+LN]:(1^]EOW-6($:X)V.F=J%L2<6 9KI5KH-J]K5:'A0MC3;2VQK+AU
MFX;H@SE'TVT_DZO(6?0X5/MVE3=:J]4K^H=<CKI5&EI"0D8\[4JA'C5>X*A%
M^\QJ=1[EGXPA%W'3[U+W#%QM[\QAWKF_?7C;E?%1(U2ET*_[VTYLBKZ07%3I
MBU].=+J9KI3JMK+,UJM4%-AZK4:#:%QW)6M,[QI%%K$QI],424LNE:EP8-P2
M)N"0N.!*VS,0D<P(($N'YWD* F,T Z.UE&P]G.]= _"1X89G3_3_ $AK&I\E
M#J%]Z=6O"I&FD9<>=E[OTGLF[[7LZ8J^A]<N*D3LW*WU;MFUVE3%'H%P3\14
M06I(4*2G43=6E*G6*S;WZCR4&^%D21 I;;H.M_(L_?&SFIFK5AZ54VB3]TU^
M6IIK=<D;5H-*ET3-2GZW6JD B4IEO4NC2,S6*M-RRWB>5"$I*2TG$FYF=G)2
M7AB+"6^N]^7LVY5 FKJ7W,/E;G+S7!.]M:+^^T.E:#;<UI-9]>I=75<YTWMA
M=5F$258$M&D)+46C56G7I9$Y3Y"^;*I9I=,MR_XLK3Y&AU"N7+#HPFY^534Y
MI[]^_O6E[Z=/9Z5U6\*_@ZD=*[>L*X]4:A6]0-6[4I$.FT.JW3?5V7)+692T
M(5+4V@TVFS%=-EU"IV]2/*H:;XD[/HURUR1@%-5G(L-7E$.]O;Q49P+I,K#Z
MXZSL*WIG$[9>(I/GJ5!W;8D%$!4R51,'R%3)3+0P=S;XY$ND B,##W=6_?;W
M_-9W ?,DK*DA%!7E.4'7$3Q3SVHNBGBNEK]U-O&V:-I?J=$E*+ICXCKHI,W=
MBM *7(V] 3=FCNG>F<>B5FQ_[3M8#+19BBZG5S[O-U.3F*G;,63N']CT*TZW
M/.6;==O>!6A# 4"!]\F6+_>LQZ#>&Z#2-8=$_$-H[I7?&A]HUJDZN6=?FCET
MUJ3%J4+2BY962KE N&AV"NK5R:TQN^Z+RM&PZO2K!MB?%I6]2)V]IV?IU.N^
MX*Y%GP"0WWS-[D@/F^U#(-XV;[6Q;%C74&IU2BT=$M GZE2:3^T)_P#9\@(T
MQ)RZ9J>F8LW$EY.2ASI3 FJC%A0)^+,R<#=,JEX,W%0 (2EIL=\>_I4E[L7$
M#"R=R>;RE7,#Q;>.60I::EI1H=7;D%_RMR5"CW)<EMV?/5-5,MVS)OR]38NG
M$_7:#7;"N>\K*A*@B>H55EONZ 9V++1#.R\K!CRKX1[:\FO3;:L1Z#^ *U-1
M(=#O*]D0YF3EJY&NM>IMF5";LZ8\1=/K,*+5;2U4GJI8]2M"Z--=:;=B3":/
M<%:HBX,S,0X$6GRT*8IZUB$ <?0%GEG[9.RA*[064!:9N9&_YZP6_1--]#;#
ME*33$T>RK"M*1G5(_:=0CQ)625%C1*G4)^HUNN34[48TW-S,W-SM3K-9FUU&
MHSTRJ>GXD9412E7TY^_Q_(B3<VB$9M(Z,_2N=OB_\86K=B7+?NFNB$.EJ@?V
M<REM1]8:Y0ZO.V?HGKS>HWZ;R>I=P08<Y(2-%N^EQD2,.KTJFUBF6/<-0MBN
MW/3IZ@5N:EQ&><>7^8[\T:(0TYA-Y4AQR73%84LKP95WQ,WI:VN-2U2UF@6A
M%L>HTVG574.%:=4UIL6Y:;-5.W=2M++MMVZ[,K%EWI^[-SS-TU/2G52A6]!K
M=D3U=NJBT6>N.SJU054XLRE!3!?>T?C-4D 8?5<SUP;CG>NM5HZ*Z=6+6[5K
M5N40PZS8>G<MI709Z:JMP3L>FVE+S")]5/DY&/69VDRT6HS*9./5:S,2**]&
MAR,E#J$[/2R*>B4;3'TO[BI<$BY'+:.><UXNHZJ4?4*\]3= [>KM=L/5>S)6
M0K=.34*?$DT5RFS$&'.TNN6WYAB1+@M:-/IATFYYR75 (B":ET182EHB)?5P
MNONR7.KB;6+EXY?2<5S*@:&Z^^*O4>AP-8A:5W6YI[?-RV/KM8=^T>HT.:IE
MFW13UPEP=*+\L^DT*!J39\]*^76K8BU7]AW;:U<3$EJE<D]$DY=$>)\Q90K^
M^7>EF>_ORKK!I%H;IMH-(5BF:=TZM*%3C24S7JU<UXW+?MQU==,D$R-(DZS=
M5Z5.O7!'ATRGK5!H\@B?ARDC"1M24"<7YFN]_+OTZ5.?D=L(/?>Q.)5>,_M^
MBZBZ7:E7CX?J=*7K?^FMRUNVZMIS>!J=H5!-R6O/0X=9LJK)GDQ)JWJG<%(W
M56U*K'EHE(CFH6_-S"(LHJ(HN>?*R7N\.D"+#TR3BPC82N5<[="=/+AUX\3.
MI6I=MRU]R^D59M6GVS?4]K=IQ6:;<%^6[>,"XXU[^%_4ZV;S1;\>K3NDE9K"
MY[3^_:1'N:F6;;MTW%I;]TN6%*_M"#*N.O\ F'!Y>==.;7\-NC%IU^T[HI%I
M3!KNGUNR]F6C5JS<UX7%^P*1*0%R2XE*IM9N&JTV3J8EH8IZJ^BFRU<_9R3(
MQ*NJGO)DO,QZ^_/F:D9(B1:4"RAS=E(K%&NGB9J%O5NSM.M"8NENH6J-X5ZY
M+;F)>Y]0HMOVQ:M3MFA(K$_0K@F+9E;QK%%N^K2,: F@4>:H<-4S'1%F8JD@
M$].Z[H\DN<845<6,GD;^81SW-<]_!QX?K@U@JEQZQW+38LE<%Q75<E/O34.K
M1:/<$#6W3R<G8]&N[1_4*ATN)0H52CV/,R\9=CW-)6O+TY$(R4S%2*A#GH$R
M]^W3Z)(#Z*W^%S[+659%EZ96[1[7M&D2M!IE,DI*FTZ73$G9^>$M3J>BG22U
M5"J1A7*LJD4^!]W7%CQU1$TO#J'-@8Z2^HN7U;L74DB#]G8B5]B+@UI#XOO%
MU>>E-1A:?Z-4M56OJ2ATBY[]J<_;U+J<&U=.JC+5I0O&E4.^KZTCM^NVS$N>
MCTNVKMNB'J;^S],(5?$S=L.&I=O)B21^?JA-I5WRJ[V][]0H^M:R^'C1F_\
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M4X;& R5V4)B'@U18\<\DNE_@?PGZ< 9YQTJ;$#(L (O ER&9*Y,I2,.Y(8
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M2F5APH<M*R\G*@#;*2Q7N4$[4T]L?3V^=0VU89SNQY"RL0)#J\3!V0E*&U0
M9E. I*F\S:4@LHH/X8 8J9(YZE1M@#!QVM=J+^AC5SQ"^&6U/$#)6Q-3U;NN
MQ;VM"<F9BWM0-.JN;9O.6IE8296X+?%>$/SX5!N6149:J2,)XL%81-2JDS4"
M$L*V/X)Q![#>4$K(BLJZ5Z>V7I1:U%L"QJ1#HMO4&6*9>728DQ'CS40_WVH5
M2?CI1'GJG/S)7%FIV<5$JM3C+5-S9*2#TH;?XGE/\=:R?$W!$4HW/M41M =V
M?TN" HA@3M();!'2L61624#(0.(""/.5N]']6/!E:.K>HZ-0H=T79I\F[J%
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MI29!)'(E[3W5K4]@5-PI*?S<MAB4\LY=QW#OD=*6DF&9#9VF!:Q'07-*DNV
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MK,"+QAIDX.QV!%A3J!<AB<L<,_8?!+YP>PZ5#, M'%^4Y*@7LR1BAEF[$DI
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-B/<A^E<GA'/S/YK_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>fhtx-20211231_g9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fhtx-20211231_g9.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1Y$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'BB^=R X0DE-! 0      !@< 5H  QLE1QP"   "   < E  !$=E;F$X
M0DE-!"4      !"ZEVQ$]2R5(VA#VC^P4=%J.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%=^,H         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE-! T
M      0   !X.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      ,U    !@              BP   *8
M 0                         !              "F    BP
M           !                         !     !        ;G5L;
M  (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    BP    !29VAT
M;&]N9P   *8    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M!F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
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M;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MMW1^A&YVWW>KL]/^6M19WUCO;1T'/L<U[QZ%C=M;'6.ES2P>RL.=M;N][O\
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M2>GZWZ+]+6NF24NL[ZPL>_H74&LL=4?L]IWM#28#7$M_2-L9[_HK10
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$!_\  $0@ C@"J P$1  (1 0,1 ?_$ !X  0 !! ,! 0
M   (!08'"0$#! H"_\0 /1   00" @$# P,!!08$!P  ! $" P4&!P 1$@@3
M(0D4,14B05$6%R-A@3)QD:&QP1DD,_ W0I>WT>'Q_\0 &P$! 0 # 0$!
M          $" P0%!@?_Q !)$0 ! @0#!08% @0!!PT!   ! A$  R$Q!!)!
M!5%A<? &$X&1H;$4(L'1X3+Q!Q4C0E(6)3,T56*5%R1#<H*%DI.BHZ7"TM7_
MV@ , P$  A$#$0 _ /OXXC'D=[\Z4?3R:]!:'$5-A;P\N'L(CUNO&]CVF3Z9
MOL$N\K'K<9V"&=F^.4-K6UM9?XLZ"5#F7D12C%6D<"HS[4"*PC'?,Y'3P2M[
M<U Z>5M]V:H\PSU>(STN#^JLS>FY+[&<ER/#*G,*R>;$KW:3#,XP;"VPST;J
MFIQO6])N0>A,F*C9<K:FRX_CUH/(L?C?&C*T265I4WWGC8.0'Z8LTT=FL]P?
M9Z:?1HSMZ0]C;)V3K/(2]KVV.7V:8CM/8NO3[S%<=(Q6FN!\.O'UH5C!0$W6
M02ULI$"-=/"MN8WS15:]$7Q;8;A2VM:T&O-KB]HE/Q"SZ/JUC9VJ+U=Z^#PX
M@"!>E@*/I9P[];Q#B+STK9AI5Z^^]Q#B+#B,='(;>"UN;/J2W$CA#B+X ,[/
M]+L'(]FM%NY9D];AF-W>5W3#75%!7SV=C^F@DV9R!C-\R)(  XY"25BC\I'1
MPL>_VV/?UTU>;L-AYF+Q$G#2LG>SUIER^\6F6C,HLD*6HA*7- 2P>CAXQ)"4
MJ4:,"0 *TNP>II4"Y%!6ODP;-*;86+U.88\VR2ENQT+KW6U893FR#N549))7
MGQPEP)(B>3/=B8KF*CD3I>9XO"S<%B)N%G=WWLE10ONYB)J H7 6@E)\#%2H
M* (=F!<@IOP-1JX-N-XNWG-%WU_'DW/?#B!-'T;QZN]'X0XC%@D-4O[T;D^X
MN/"[B+1GXFOY-MP+M9C4"'$ "+EZ5!KNWUW^<.(RKT-//U](<0Z$.(QNS[WL
M0*:U%/05-28<1CE3_O> +>%#2'$9W<'QHUW]-*5I<PXA1QOJW77O#B+'F,@D
M)%('B)F#EGADBC*']OWAWO8YK9HDE9)$LD:JCV><;V]M3R:J=IQ$_/5[U%?:
MD0;^GQ4&4&H]CTUA?VF4FUOJ.WD,3D-T@B6MM*S+Y%<6<@ P8:3O\D:[V!88
M^FITS\JJ(0[58M4=7;?S;?$[>(N@J[ZC7?:SU\8<0W$N^[BQ_(W>D.(/X<^;
M<O5X<11QX^]/2'$33U;C>]?QHT.(EKE_;DUSNKJ1?2.'J[V1)J3TU[BS^&DF
MR&6DPTZ%M3 ]\<I*74D%$][7LCE<B"LLE+?^QR*P=4=TG:I[G9K C:6WMEX)
M4X2!.Q2#WJ@X3W05.#AT_J,L(N*JI6-&*F"3AYLTIS9$@E()#DD V!+UW$[F
MO%J>AG;,NZO3)K7-Y\>(QE\M9)5?I1,CY9&)43O"0CSDBA<K2$B]UO[$1&N3
MI53YYT=K=FC96W\?@TSQB F8)AF   F:,Y2P)_2[:/=A$PDXS\/+FY2C,FB5
M.X(/J#IPHT2ZY\W'37E7S$.(O77K#B,=Y+-8Z:D;N(UN];PXA8$@/2QMY:<O
M"\.(NZE+\M*#]H<0WTX:%V//WL8<1;],?N(<1/(5]_&YKYZZN(-S\R/1Z<H@
M?E_K-OZ6VV!=8SH[),NTKJ+)L@Q/96U1[^N =5VF'&OKLV(H\5(&?87]9B)T
M!HEL9 3"GOUMDV%CD%_>Z^T/#5O<O;HEHG%66(MO7 6H,B2A608QPDJ?'N#%
M0LGA?TORGE&]J]+\HJ]+^.(7TU]C?K2/=Q%ZZZ^L=),+"!YH'ODC9-$^-\D4
MBQ2,:]JM<Z.1/F-[47MKT^6JB*GXXB&VXV?<_5.+1!_T!5@U+JK9E4&8;8"A
M>I'><$!MB=)9'$1MRZ1R2E'RJZ0J155465RJJHC4_CB+^+1.;B$.(0XB!A0:
M"'$6'$3<U!7=I1N1X0X@QKXL>)))\J1C?<$4L^K=@C#TI>1$F8E> BTH S##
M+ LX"4,2& :149(]I$T<BJJI[;6.D3Y;SNV80G:."49J9"48F3,5.6HI2A,M
M86HDBWRI(;4EM8PFL):_E*OE/RI#E1(LVI^D4?04) NH,$#,QT_%30:$0(RD
MLPHZ\T0D9GM2^Z-$JL;[CFJ]KD5?-JHY5^>;-L$*VEC%B>C$I7.6M,Z6LS$+
M2HN"%&MC8U$)7^C1\I2P RD,0W#V^\9@YYL;(<1'MQ);UKUOAQ%AQ"'$(<0A
MQ#KKJT.(;_3R'U>'$(^=;?.:4YNS]U#8*S8%;A0FPMV9?N744&TP<?P;,<:T
MU=4V/[,R.RHV5A1U3;[0S4X@6@QR0N"/-(8BK=\D,1ZN<]J5Y_GS](<=:V%6
M9N?Z0QCZ"L4*#.QC'C:X-U?7ETE60$"]O@\,68*&0<5S/PU8(G,C5/X5O72<
M1.FN??K4Q7^(L>2PB$F!,A/\/L91IHR_<>L3/MGQN;-YR-<US&^VKO)Z.:K4
M[5%3KOB)IK]?O]?&-0'TYPWU6=["Q;"<TL$U)7YUOG(*'#P2V6&/.FBV2+21
M21'S2E&D0HP^4IKGD2.4F-BJ]6(K>>XV&_R>[T864,3_ #%.'^)^;O.Z[I<Y
MA7+4H"0;E+QJKWQ^<D9$D(+,^8@J^K;P(W%<\.-QYMQAQ$KO?T+?7TAQ T^M
M_8 O#B +TU%QUOZL8<18<1!QOUZ0XAQ)MO\ '[M]X<1>NO6'$3Z[S[>_&'$'
M#MK#B+UU[\X<1+:C3AN<^S>$.(=<>J^&EZ.($MY@><.(L.(0XB.-X\Q'S*^J
M6UH:/U:[5"PCU 4FX+',=CT;=B::P[!M=XI>Z[-Q\\$D&BRK9=YAU[B.0&4$
ML<1<5=G^58B:SPC5J%DQ0]PO2SWU;76VHHSBM(@UNUM :FO$-1J_IXEH^E>E
M<KJ>J<[R\G5P2KYN'>]%4>->GO$5PKG)_+AG+ J_,*K'XKRP!JSV >E/2QN&
MJ(QML7;M;KC)]98S88]D=H[9N5Q8D%<58<,E-0FD1J\::^,GG@0>(ES5B'C'
M:01(]%_PD:GEQU]XMJ?7<0/$VORK&'#_ %BZC!RK.\5S>$O%,6Q!]]66&;Y,
MZJ9BEH;CTM(/>US(F'$64;84R$!8Y3ZX<4QBD-BD>Z)6N0/#Z?FO-KWC37].
M"QW9:>M3,3]91U*^D<S.-\D4,F.C8Z'C_P#8R2^>\=U8,*V$R$9V<?IJ,9!"
MQWDJJC$'61W/T0CL\?X>D@_YZ^/0 /ZP_K]ZJE/D<X,3"#^D ?XJ'S0,7_,D
MES\+W9<.DC])M_<?G*3OJ]G$?0MM*WR#'M=9ID&+3U8]_0XY:75<^YAFGK'2
M5(LEA+"5% YDRM(''E@C<QW;)96/5'(U6K\-@)<F=C<+)Q"9BI,Z?+E3!)($
MQIB@@%)4"'"E U%0"*7'<LJ""4D!24J/S?I^6^HW,"=#4N#'YU;;9'?Z^Q&]
MRPBJ)O[FD M3Y*6"8>M;(>.PEL0T1$DDJ)"R5(G*]W[G-5R(WX3C'RY$K&8B
M5AQ-$F7-6A G%)F,DE+J*0 Y9Z1DARA)4V8@$T8.:E@26!-16+_YR1G#B'TA
MQ$/CX?77P%>$.(7)Y#>*'?7A6@W%X<1.-02'W&GB17<?I1Q%%-YK[U].'E&/
M2-J8 +G@NLB,E BSHT);$7''/<A\X+417$L9X]+"U%3R?Y=)WTJHJISL3L_&
M*P:MH)D+.#1,[M4_^P+W/OX1CWB,_=YAG(<)U(%VY:QD+G'UUUSC*OY^GWXZ
M0XB.>!K3P!(!=ZV+T^[B%:/QUI74V=S8<?)Q%_'K3]^$.(4]OO\ 2'$'Z%>'
MIK#B%*58F@U.CW?=T3#B( 6%2*6I3A:/G4W;)B5IG7J4V+E57NRJWWA>U-CB
MZFUMBOH@R3-]6YG58=<$A85)D.7P>FW+Q<U=LV "*SMLJ;LH90?UMJ EU*5J
M^,! <T!?>UB"="[/PJ"[1"PH1P)R[Z"HU9A0>4?0;BY!)F-X^68&VO,)I*N<
MH%L#AD#(E"ADF$:.]K7P-@D<Z)(7-:Z+Q\%:BHJ)8MK!JUH;'RX/N\(\F389
MC68K3KD-<A[\>M8;RFD0DH:6OMAV/8.=!()/!(V>%KW+$Y7+X.7S:B.1%1UU
M^8R->OO%AT.E=6Z^R/(-BT>,$LR.SKBFVI:&WU].4R1!9K"82I*,/A6UM5K0
M4L"P@TL[5P8L9$LZL8WA]U.40@&]N);QZ^T:G_179;JSG/<WS+5.(6^#8;<[
M W[4DY?M#7ID8,),VQ!+@>M+Q8C,<0S2A.1E?) ]ME0?^K(.QT4,4GOI]5A%
M;'1L%:,?.5/GG'HGHP.&GJP^)"!*F22M2IF"Q$@CYPK()B3E)4232.=?>]\D
M(3E24$&8I*5@DL6_TB%&B6?*7(T:LN?53JCU6;#]/FU,4'W+K2C<;BY)LUCC
MV$9CC=NT.DF@NSQ1;F#.K601;$*OF F1 IF$0$S#2HV&61[>OL]M+LW@=M;.
MQ*MD[0FA&(2D(GXW"3Y6><E4E"E2E8&6%9%S$K!SI*2 I/S "-6*E8F9AYLM
M$Y"%J0<JN[4EBX4SIF&X"DG6I(CJ]*>H_5;KG0.N,5)W/K6_>-1Q&Q6.185F
MF26ZC6KG6(HI5P3G57(4@0Y,8D7_ )"%D,<+(HT<R-'.O:+:?9S:&V<?BD[*
MQ\CO)Q!1A\9A9$K,@!"U"4,%-8K4DJ+++DDZPPDG$29$N6N>B84IJ52U$EZC
MYN]!I8.Y %WM(9,=]4O\[.TU_P#2W*U_Z[(__O/$[_L]_L_:O_$L-7_X_KUC
MH G&O>2FW"4IN3][7B:?;E<>]4O\;-TU_KJW*^O_ +D]_P#/_7E$_L[KL_:I
M_P"\L-__ #HK3J?U)9W_ -)0?_W37Q Y03'O5+^%V9IE?GOM-6Y8BJG]._[R
ME3_DJ]?E?E%1W_9W_9VU;_[3PUO^'7/A$:?;O);[Q*4S?^9X4(%"Y=A&$R\I
M]9L&^Z74L>3Z DQVUP'(,YDRAV&9JRU'BH+*AI9@&4/]L7#RRSV.25CHG_JS
M6H$TV9Z))#%%-ZB9'996R)VT?A]M=_*QLC"'#_%80RSW\N?-0LXCX5PR,/-<
M=R2590*9BG458GOA+S2<BD*4^5>=TD4RA1']P_N%GK8YL_L]ZI53_P")NFD_
MS_NMRO\ X=+LA/\ C_/\=)\<\OO^SM?\W;5X$[3PQ]!LX>\; F:0QF2]"QDD
MD;W>9KOWU>K1T25OJR#17PY5HJ\\>U^VGQ'-Z!TG\HU"XLHOTC[_  KE$DZ5
M?+KX5%"9V<50X;:\G_>&*PD]N.4X:0_+,/&*!/#5EJ%*95)#6_Q*((N2Q#.&
M#"(6#>L2OJ?7AB&E=NXM!A^P'X63C4%C1W0UUA]@;=D0VE?+#:6$-+8"MF'A
M<S[8FN69)E2-CI/AR_5GLRN9V-Q.U=FX@XK!#%IQ*D3I*I6+EHDI5*6%2Y?>
MH4RBY4)F7*'+6CA.+2G'HP\T*1,*&20H&6HJ90#DI(+4^9*7.BM=LG_?Y_/?
M/SB/3/*W+ZZ;S>'$&?QOQ&@?HCQAQ$KO/)FWD_VN!N-R>,.(!JTH3S!##>+-
M3=N,.(RAQ#E#B)<::W'H6XWW^I<1@0ERZ5'BQKQO&LGUC^J7;FFMD_V=PD\.
MEI:O6@.:4\2Z?R_:C=BY>3>WH!&$W608M9B@:HJAZ^KKY6Y-DS P'_JY-BEB
MX.AL!T:MUUOW4WQG<$L[&A&CCC1KUMI=A&Q^@.)M*.GLC1XQ3#ZL$PH:&5L\
M0Y!(T<TL,<S%<R6..1[F,D:YS7-1'(Y47M5H@8U#5&ZNE'W>==:-%7XC*.DF
M5\(\TT<,I#XHGR,'@6))IG,:KDBB69\<*2/5/%GNR,C\E3R>U.U1$+ $ZZ<2
M>&IB$/H$L2K?5NS;(VGL<?+,]26\YB*6V?7265=([+I$48R2J.LZYTS41'*H
M9Y,72MZE5?)$0]FXAOMS-M+Q+G-\0K,^Q2]PZY(MAJG(0I*ZQDI+>QHK11)E
M:A$(UK5D"GAH3$CAYU&GC64>6:%ZNBE>UW1A,5,P>(DXJ2):ILB8%RQ.E(G2
M\Z;%4J:E2%Y349DD!0!%0#&*AF!2IV*6.4D'F"*N]K:WCC!\.J\ Q:GQ"D)N
M"JFB$8#7R7MQ8WUDT6+XBBGM;4@H\E(F=1Q+.1(K(FL8SIK43C%XF9C,1-Q,
MY,I,R<HK6),F7(EYBSM+E)2A+ER62'+DUN0E*0$C-1_U$J.AJI1).@<G<V^+
MC4P/[C[3[L;[OKR^V^XC0CKKOOV//W%3KY[\>NOG\<T95-FRG+9\I9W:]HR\
M]]CRTOKO]HP-ZI\WQ+76@MF9?F\]R-CE3C9LAA&/S&CV\4DD;HA7A3UQ@!D4
MC2'QK[D!<3VIVOETG/8[/X3$X[;.S\+@Q*5B)N(0$"<$JEEBZ@I*TJ21E>A2
M1&J?,1*DS)BRH(2DE12^8 THQ!=R *AMX:+<]%V?XILSTTZORW#";XVG,I?M
MI"LF*L#+@BU!GD%N9B2K0VQ-G1]C&0Z%\I3T=&K?!(V=-;N[48+$X#;NT<-B
MQ)3-3.SY9 0F4F6L!4I*0A"$AI92%,EW>I-8UX::B=AY4Q&8H4EG625DBY4;
MDN&J0PH7 I$.\].^>3_55PC<D>T'PXFS5>49&[!5*MO\2OIZRGP0NI; VP2O
M5AUQEE9D;F.#]ERTOG)'(3#!-%]-*VY@Q_#O%[).SP<2=HX>3\;DEN%S)LS&
MI7FRYSEE85>'_4X$U@6*TGF.&F'::,1WOR"3,>5\QH,B0;Y;K!#A_EHQ94;8
M>?G4>E84H=UW:GCINT=H?C_VGQ_GQ ,SC6M.A&O7;.J-);$]5=;79)A-"3E5
MKJVW@3*78@Z2U#NV&COIC!\J6HDB%M AFJ\&9MBV:&-KHV/8BJQ?M=F[1VK@
M>S<R9A\7.3AY>TI2OAQB0):I.0B<E6&,X%4M2B L=UD42Y<AQR3)<I>) ,M)
M692G7E&8$LS*"7!:H+N!;=$G]$Y7:W^'D4.3/EDS#7MP9@^3RSN\I3BJAL+J
MVY<JHCI/UJF(KSI)?%&/->;&U?\ "7GSVU\/+DXE,W#Y?A<;*1C,.$V0F:5!
M<IM.ZG)F2P/\ 2=8W2U%22#^M!RK<.Z@S%[%TL27#*H[",U\\N-EF:["GH7/
MC?AJ T.(C&EG\6<$L7<$UO0[]7AQ&0' .*.W6G["P<0/MT_#7P\H<0.[>#UZ
MPXC&QJ:@<7+/OH=:L/!X<1A\NM3J6)?_ -0C4AZLC/0WK;?))FU_3G%L38>7
M8:'DV;Y2/55!@8&.5 N9V57+:P6]H(TTL@#$<OG1@8DBRCU2#DSK+(&.^<O?
MAU;G&T5=Z:.*Z^#:].VUF@)KC:.G,IXTAJ2JP$BMB;%[+8@)AHY!(TA1$2)&
M0.8U(T1$8B>*?"<L* ;K<>'&*MQ%CSE/(C&(D%A:02R&1PX[Y?89-,UBK'$Z
M;PD]IKW(C5D\'^"+Y>+NNE1"'KKH?7K[&(.?3[-O+#4NR#<EIA\?OB?4?O*6
MTIA+%+<:N*7+GH\>*R:*$AC&HC52;[6'OM4\$Z[5#=?WMUY\6B=2(B)TB=(G
M\<1*$::BN_6F_A?SCGB+YZ5?B?;UU>-29FT,O_\ %'&P7^Y8-<=9@D8C=F_H
M-LI+X7B1FNL5MD9^GJ^.9RU"3(Y42*)!U7R:K>?HZ-G8;_D]7C!M57Q!QI7\
M!WTO*&64=V)9.?Y@!-RM<YK$&/,5/7_,DRA( 1W;&=\SJUJ11J90_(\-A6_\
M6J<TT]GN,7>'SYZ#;8^<,N*CCBDS6Q#H7_:Q1PED"#.<TCVWI[D\:)X]]]HG
M/BMCXF9A-IX/$2L4,$N5.0L8E14$R@#\Q44)6;.*)/)H[YJ$S)<Q"T9TJ!&1
MA\P9F^:EZN]-^D4#TMX76Z^T/KK$JS!R-=LJ:.& [%2H!!R K955;6>1@11@
MZJ::LQB2,(>LC94>Y&JJM3?V@Q4S&[8Q^)F8M..,V<HIQ*5*4E<H4EI!6E"O
MD0R&*6<&IN<9"$RY$M"99E@( RL 4D"I(!(=ZT)-N0R7+K? ILV%V1+B5#)G
M@04M<)ESZX=U\,!/"^"8.&R5GW+!I89'QR1->C'M=TY%Z3K@&.Q@PJL",3.&
M#6L3%8;O%=RI:2Z5F6^4J!#@LXTC,RT9@MAG RA7]S&XN+U.YZZ1>R?^_P#M
M_P OSSEC( @W<,0-]2#7>=_GJ8<1?RWC7KSY=2P0K(DJPQ+*B=)+X-]Q$_HD
MG7FB?[EY7+,Y;<Y;RM ];_#CY<XCF4DN">HT UTJ08YN7&9*.:+_ &8O[=XG
M'-:54KEZ1K9#L=;>0.7M'331"1_N5&]>VEL9L-:+S]EX@3DN:_!XHB5- U(3
MB.X(']H*C8QI/RS07($U.5Z_K344HWRYO%HDCSPXVT%R=^M6\VJ;4K2'$#NU
M>COH*U&\/J3Q<4<1>&NK4WU%^O*'$6'$.NOQ#B)]=6K[>\.(GS"V5M+VC1U]
M0FWP+*/4%J=:\/7]QE.*0(PFRVS0OLM=4[*S)KJIL1YFC5#\BFNAYUM1EBJ;
M,89T4K%E]X:69)(38BK$AN%7X.XH[BK.(K7%GKQ-K<_#?<QNTJ%1:JM5OVOB
MH BI]E&^(/I8(U3[6.3]\8_7_HL?^YL?BCOE%Y8!F#;M*CSUCU2E"P200S$P
M0S$N5@T4LT<<A#VIVYD#'N1TKD3Y5L:.5$^53KB%:NS=7WTCR3F-D:8'6EUZ
MW$8TDD0L\J2+%*YJI!(6-#(TEHZR^*/5O@KF]HUWDJ<1;6ZZT\HA']/=,G;J
M'8R9G)2RY2GJ-WE^N28Y$9!1N._M?)[BUD5A,0:P;Q\4:A,\DGDCE5W2HB(G
M"MO/ZO\ ?RG=Q%\&UAQ$]=7ZYTC%$NIJN3:T6VG9#E"7,5(N/LIFVLB8XE=Y
M^\YBUOCX>;B.R%D\N_=<Y?Z=>@-HS$[..S1)PW<JG=^9O=#XCO&9^]=VRLD"
MP C#NQG[S,I\K,#\K4-N+.=YC*_Q^?\ G_ESSXS'#KSK#B'CT*'UAQ%ZZZKP
MAQ$/1%Z=?2'$.M+?8M#B+$./7G828OZ9M@;'KRCZ_(]6B0[ Q:SJY&Q6 5YC
MTS2AE@E>UR-82U'B$HJ*V06>:-R*UZISZ?L?+&)V_@L"M$N9(V@I6"GRY@="
MI4])2IQ2J3E4EB^8 BH$<N,4)>&F3'(,I/>)*;YD5 %[AQ6C&M'CM]!NZ9]_
M^F#7>S3"KTZQMH[0*U,R*<8BR*MJFR( L9O,2&"%HCRX9?L8D9Y1"I%&]SG-
M55G;#9/\E[0X_9X3)0B6J6N6F0DIEIE3):5RPRBHE021G43\RG5K$P,\8G"R
M9P))6DOF8J!"B"[;R*<*:1+I2AVS(.XB!I#_ )9 LL:3.3Q\OB/R\U3I'+VC
M?PBK^.?-,6=BV]BWG;UCJMR&OG[4KK'HY(L.(0XB.#8[_-Z^(^M;B'$*>_H:
M]?>'$6/GF^I)1V6"[_MLDQX?)3Z;,L'QZ3+OU;/<DK\:DFFGV(D='C5-CV-6
M*!3EGU%=4'*^P'*)N,UI$]R.-Z/9'%@P85TU/1:VL2M>=-=U^>NY^$;]L/>C
M\4QER#R"(^AJ7(-+[BR#HH,"I!(LO<OG'WX*LG[U5J^7[NTY8/0>ES]G^HK$
M4/4#IG96=;7P3,<0= 54T]95!HLU[-4OQ.XJ\EFNRLA%$;*R*TEN*I[*%T#F
MR)&Q/<D:C$[XA=^-+"W%]Q<-H]1K%B5F@?4##N+;N>8SF$6M7;"KY9A[ZSD$
MV,/7GOGI' !TV+SDUC*Z . *Q8>R4IPTSR8I1I%=YHDKUS\-/7?%Z^_7M%;^
MGE79!4:=V%6Y7D$65Y&'ZB]WP7&1PU45'%<',RU_NFQU$!!40#9?CH>,B9K.
ME7S7M>K#KKK\SRXAJW[0XB%A7=2G3>=H<1?QZ]>T.(==;X<0Z'6L.(EO4GH:
MD^=8<0\M/7WX'7=#B'A>^FG["'$'W$4OPZ_,6AGV)PYWAN28A/..-#D-295R
M$%5PUO! TN)T2ROKBU:,6C$=Y)%*Y&.5$[5/SSIP>).$Q6'Q20I1D343 E,Q
M4I2LI=A,1\R'_P 0!:[1BM 6A22WS BH!OPL8B%J_56<^C?&@\5P< W;6J%?
M]T935@0M9EN+6TJ^!]E2UD4D@]M5V;(X"C:Z*3[V*S0PP=KHS710?2X_:.$[
M3XA6(QDQ&S-HETHFS%JF83$2Q67+G32 J5,EN4IF*&0R\J%$% 4KGERE85(2
M@9Y5RE(&9)U*0&<*-P*YOF:IC7MG._=@R_4\UWDC0<PQ[3%?B\8MR-?8Y=UT
MP[",1)0Y" )%;$\EMXR%!YEA<](%G=&JM57)]IA-D8(?P^QTCO,+.VJO$O*5
M)GR9B2H8I.7+, <),@$J^9G">+\2IL[^:2[HD=T0H+!222EPX)_4%:-8\#&U
MVT]7F@J( JSN\WBIJT*-LI9]H$6$&-$YS6))*1/&R../S<UJN>Y$1SD15[7G
MYW*[-;9G+3+DX0S5K.5*$+0I2CN"022=S"ND>BK$R4)4I2PE*:DEP -]6IQ\
MHS7@^=XALG&P<NP7(:S*,:LT>H-Q4%1& D>"]2-CGA<YCEC<OB].U5J_"\\K
M%X/%8&>K#8R1,P\]#9I4U)0M+V)2:AVI&Q$Q$P9I:DK2:YDEQP8VZXQ=O.:,
MX<0$.(1H0^H/@&3XYZ@\?NM?X+F]U29'6SW=T7C[MK9=5VNP#(,M-B#R67'<
MUKZ;7%,'95.$BLD.KQ:R83)SK1DT<%$3"Z;C7=HU'?Z/JX$0:C7G7AR=GH!>
M-Z>,O*DQVA>= P4U]/6N+&CF4F,<APD2S0L(5SUF;')Y,;*KWK(B>2N<JJJV
M(+ .#3TL_6M(KG$7K]_.SQYBX/N12!O?F&^XADA0@=[6$0+*U6I+ ][7M;+&
MJ^4:N8Y$<B=M5/CB%NCH_3GSB#7T^*-V.:BV-1275QD3ZOU';R%6[OB("KFS
M5F72JI5B0*,&/*0_RZ<^$:%G36HC$7\H&O(\;WX;J\;6O.[B):N@:ERU:\-[
MU) TK#B+URM3[U_#B+U:O7!H<1&J_A[=6K2L.(/N&E]SO<$@PXB%R:&VZXOH
M=]&>C.:0XBW%SHQ!#GZ-[[K.X@*W;A5Z"Q^OE#B!(#CW=CPMKN'&EX<0O^#]
M:0Z_'^7XXB/Q% '%3Q!?B-3:F^.APPSY4F>/ ^9$\4E=%&Z5&_*=)(K5>B=*
MJ=(O7RO*"0&!+;G,-X N:OY.W&H>F^HC!GJ8TP_?VC=AZB#MAL=*S>E2JANI
MQ%*B >TP8M)9((E9)(Q?M_!6L<B_N[^>NE]?8.U?Y-M? [35+5/3A)O>&4%9
M2L%*DD EP"RJ.&C3/DB=(F20H)*TY2I@6+NY&MK19WHQ].1GI5T-C>G#\E&R
MPNC,M2Y;D,.4 >=;$I2$9&-,^21B1HOBJN=\K\HB<ZNU.W$=HMLS]J(D*PR9
MR):!*4H+4.[2SE085C'!X<83#HDYLV5R5-E#GAI$J^?.QU===-OAQ$L+O>I\
M3O _&X5AQ&.56\_^(C_ZQH8S7T5^HNQ]2>2; /\ 39K;:&#6NS]QY-D5@9ZE
MKS#"MNX[E.9U%UJ$#86+086=!8T^JL?KGU5?B-F<?3I.L#H6/';)$^-PW^H-
MJBM8R9^#6Y VL*;JD5?=&]NNC6$ *)1(0%B$'C4$9S7CAJR)C5%@>QD;'0P*
MGM1N;&QJL:BHQJ+TE@SBP;[>5B/(>7LXAYTY\JC\-K'F,%A.%)#)]S[<J"4>
M9(IYAY/:E8K)/">"2*:%_BJ^,L4C)&+^YCVN1%1 B_$$<*T;S\?:(,_3YQVG
MP[46Q\:HU+934WJ.WB#7)8VUE=FH/'ETCFH3;W1MC:6$RJYRN(..)G<G2.D5
M&IR$@!RR1Y ;K]<X5-*DEV &YW)+4HQ)&ZD3M5S6M\NVHU$3Y541O77:?*])
MUU^/X_[5QOB5JP+UHQ(?>#2_D*EFK''FWKR\V^+>_)45.D_'Y7OX_P!WS^?X
M_/(XWB*UG!<6^7V#>VZC UY1[7=^+FN7^B.1?^G:_P#7@$&Q!' OU3C%((N"
M.88^1]8X21CE5&O8JI\=(Y%^?Y3I%[[_ /RG%+.Y\'ZTM C>.3B"O:CD;Y-1
M57KKR;WVJ=I\*O??\(G7^G7SROUZM&+%B0"SN"S@VJX&^SN=;!H*]K55%>U%
M3Y1%5J*J?ZK_ %[_ *=?"+_59XZ\/+JL4 JL"0 *U<NQ=VUYBU7>G+G-3KMZ
M-_GY5$[3_7^/]W]/SP2!4D-SON;[>7$'+L"2-"]'K>NFFC5T;A7(B=^343\=
MJY/'O^G?Q_G^/^'!(%S[>EH,2& >FH^@\B"S;C#S:K?+R:B)^556JB?Y=H[K
M_GRQ=3O=N/ >M!QXP1[?Y>Q5[_A4Z3_]?'Y_K\?G@%XQ((-F+O4WLY8\S4,?
M..6O:[X1S7+_ ).15Z_K\<CC>(K'4$,PU8AC8L+.?$>,<+(WOKR3O^B*BKWW
MTJ(GY54^>T_/QTB*OQPXWB#:LPI5J4+:AJT9JG0EA'"R,1W2R-143Y:JM1?G
MY3\JG7:(OPO\?T_/#\N%>N/E  FS^() 9W<_G1W(-?TKVHJ(KF^2]=)WTJ]_
MCX[5?G^O#@7(&[2+7<:78>NK#G'ZY80XC&N]S8\]*:<P&(<D:AQ$R#AY'_\
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MTA0&DFPC1FZ:TDJ]-LAP*R&*Q.ICA"FS3K,$@T+%FE,?'&Q?)JM79C%['5*
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M %'K&;#\(P^TM:2\L<9I#+?&WGR4-C/6BO*J7V@S1+!X,JQ>4#BQ6-@G5O\
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1Z;DDWX@W-?HXBMS\S]#'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559134286472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 25, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Foghorn Therapeutics Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-5271393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Street</a></td>
<td class="text">500 Technology Square, Ste 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">586-3100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title&#160;of&#160;each&#160;class</a></td>
<td class="text">Common&#160;Stock,&#160;$0.0001&#160;Par&#160;Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol(s)</a></td>
<td class="text">FHTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name&#160;of&#160;each&#160;exchange on&#160;which&#160;registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,421,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001822462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559137780216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte&#160;& Touche LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559132882904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 101,136<span></span>
</td>
<td class="nump">$ 92,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">53,153<span></span>
</td>
<td class="nump">92,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Collaboration receivable</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,273<span></span>
</td>
<td class="nump">4,917<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">459,562<span></span>
</td>
<td class="nump">190,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">17,563<span></span>
</td>
<td class="nump">19,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,733<span></span>
</td>
<td class="nump">1,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">38,516<span></span>
</td>
<td class="nump">42,804<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">519,774<span></span>
</td>
<td class="nump">255,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,819<span></span>
</td>
<td class="nump">3,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">9,562<span></span>
</td>
<td class="nump">9,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">6,994<span></span>
</td>
<td class="nump">3,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">28,317<span></span>
</td>
<td class="nump">2,024<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">48,692<span></span>
</td>
<td class="nump">18,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Notes payable, net of discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">51,338<span></span>
</td>
<td class="nump">58,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">322,730<span></span>
</td>
<td class="nump">12,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">422,903<span></span>
</td>
<td class="nump">109,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 25,000,000 shares authorized as of December&#160;31, 2021 and 2020; no shares issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 175,000,000 shares authorized at December&#160;31, 2021 and 2020; 41,299,720 shares issued and outstanding at December&#160;31, 2021 and 36,790,946 shares issued and outstanding at December&#160;31, 2020</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">361,133<span></span>
</td>
<td class="nump">309,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(264,256)<span></span>
</td>
<td class="num">(162,936)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">96,871<span></span>
</td>
<td class="nump">146,187<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 519,774<span></span>
</td>
<td class="nump">$ 255,594<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559132842072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Proferred stock, shares, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">175,000,000<span></span>
</td>
<td class="nump">175,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">41,299,720<span></span>
</td>
<td class="nump">36,790,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">41,299,720<span></span>
</td>
<td class="nump">36,790,946<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559132881304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 1,319<span></span>
</td>
<td class="nump">$ 430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">80,325<span></span>
</td>
<td class="nump">57,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">21,728<span></span>
</td>
<td class="nump">11,246<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">102,053<span></span>
</td>
<td class="nump">68,961<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(100,734)<span></span>
</td>
<td class="num">(68,531)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,906)<span></span>
</td>
<td class="num">(979)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_InterestIncomeAndOtherIncomeExpense', window );">Interest income and other income (expense), net</a></td>
<td class="nump">2,553<span></span>
</td>
<td class="nump">1,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of preferred stock warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="num">(1,233)<span></span>
</td>
<td class="num">(222)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(586)<span></span>
</td>
<td class="num">(269)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (101,320)<span></span>
</td>
<td class="num">$ (68,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders&#8212;basic (in dollars per share)</a></td>
<td class="num">$ (2.73)<span></span>
</td>
<td class="num">$ (6.23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders&#8212;diluted (in dollars per share)</a></td>
<td class="num">$ (2.73)<span></span>
</td>
<td class="num">$ (6.23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding&#8212;basic (in shares)</a></td>
<td class="nump">37,171,147<span></span>
</td>
<td class="nump">11,046,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding&#8212;diluted (in shares)</a></td>
<td class="nump">37,171,147<span></span>
</td>
<td class="nump">11,046,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (101,320)<span></span>
</td>
<td class="num">$ (68,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized losses on marketable securities</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive loss</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (101,323)<span></span>
</td>
<td class="num">$ (68,807)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_InterestIncomeAndOtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income and income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_InterestIncomeAndOtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559130685448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>IPO</div></th>
<th class="th"><div>Share Purchase Agreement</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th">
<div>Common&#160;Stock </div>
<div>IPO</div>
</th>
<th class="th">
<div>Common&#160;Stock </div>
<div>Share Purchase Agreement</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>IPO</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Share Purchase Agreement</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Series A-1, A-2 and B Convertible Preferred&#160;Stock</div></th>
<th class="th">
<div>Series A-1, A-2 and B Convertible Preferred&#160;Stock </div>
<div>Preferred Stock</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,544<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,615,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series B convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series B convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,007,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_TemporaryEquityConversionOfStockAmountConverted', window );">Conversion of preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (176,405)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_TemporaryEquityConversionOfStockSharesConverted', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,623,413)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="num">$ (88,016)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (94,136)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,870,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock</a></td>
<td class="nump">176,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,958,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock during the period new shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares new issues shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,451,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Conversion of warrant liability to equity upon closing of initial public offering</a></td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_StockIssuedDuringPeriodConnectionWithExerciseOfWarrant', window );">Issuance of common stock in connection with the cashless exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">1,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">611,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments', window );">Issuance of warrants in connection with notes payable</a></td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">891,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">2,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized losses on marketable securities</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(68,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 146,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(162,936)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">36,790,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,790,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock during the period new shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares new issues shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 1,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">508,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 8,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized losses on marketable securities</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(101,320)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101,320)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 96,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 361,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10)<span></span>
</td>
<td class="num">$ (264,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">41,299,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,299,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_StockIssuedDuringPeriodConnectionWithExerciseOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Connection With Exercise Of Warrant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_StockIssuedDuringPeriodConnectionWithExerciseOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_TemporaryEquityConversionOfStockAmountConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Conversion of Stock, Amount Converted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_TemporaryEquityConversionOfStockAmountConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_TemporaryEquityConversionOfStockSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Conversion of Stock, Shares Converted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_TemporaryEquityConversionOfStockSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559136392232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Series A-1, A-2 and B Convertible Preferred&#160;Stock | Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_StockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred directly with the issuance of an equity or temporary equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559134069960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (101,320)<span></span>
</td>
<td class="num">$ (68,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock-based compensation expense related to issuance of options and employee stock purchase plan</a></td>
<td class="nump">8,384<span></span>
</td>
<td class="nump">2,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">3,227<span></span>
</td>
<td class="nump">1,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Gain on disposal of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">1,233<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of preferred stock warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Noncash lease expense</a></td>
<td class="nump">4,288<span></span>
</td>
<td class="nump">4,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Noncash interest expense</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization (accretion) of premium/discount on marketable securities</a></td>
<td class="nump">179<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,814)<span></span>
</td>
<td class="num">(4,670)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Collaboration receivable</a></td>
<td class="num">(300,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">2,653<span></span>
</td>
<td class="nump">3,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(4,010)<span></span>
</td>
<td class="nump">15,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">336,477<span></span>
</td>
<td class="nump">14,570<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(50,250)<span></span>
</td>
<td class="num">(31,286)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(3,313)<span></span>
</td>
<td class="num">(16,183)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(99,984)<span></span>
</td>
<td class="num">(92,981)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">139,470<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">36,173<span></span>
</td>
<td class="num">(108,914)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from stock purchase agreement</a></td>
<td class="nump">42,205<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of underwriting discounts, commissions and offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">122,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">89,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">1,418<span></span>
</td>
<td class="nump">1,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes payable, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
<td class="num">(21,205)<span></span>
</td>
<td class="num">(15,530)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">22,418<span></span>
</td>
<td class="nump">217,473<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">8,341<span></span>
</td>
<td class="nump">77,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">94,528<span></span>
</td>
<td class="nump">17,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">102,869<span></span>
</td>
<td class="nump">94,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,716<span></span>
</td>
<td class="nump">660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable, accrued expenses and other liabilities</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">101,136<span></span>
</td>
<td class="nump">92,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalents', window );">Restricted cash (current and non-current)</a></td>
<td class="nump">1,733<span></span>
</td>
<td class="nump">1,733<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">102,869<span></span>
</td>
<td class="nump">94,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=fhtx_ConversionOfRedeemableConvertibleStockMember', window );">Conversion of Redeemable Convertible stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of stock, amount converted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">176,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=fhtx_ConversionOfWarrantLiabilityToEquityMember', window );">Conversion of Warrant Liability to Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of stock, amount converted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=fhtx_ConversionOfNotesPayableInToWarrantsMember', window );">Conversion of Notes Payable in to Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Issuance of warrants in connection with notes payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in operating lease liabilities during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right-of-use assets under an operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=fhtx_ConversionOfRedeemableConvertibleStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=fhtx_ConversionOfRedeemableConvertibleStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=fhtx_ConversionOfWarrantLiabilityToEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=fhtx_ConversionOfWarrantLiabilityToEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=fhtx_ConversionOfNotesPayableInToWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=fhtx_ConversionOfNotesPayableInToWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559133779640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
<td class="text">Nature of Business and Basis of Presentation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foghorn Therapeutics&#160;Inc. (the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company discovering and developing a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. The Company uses its proprietary Gene Traffic Control platform to identify, validate and potentially drug targets within the system. The Company was founded in October 2015 as a Delaware corporation. The Company is headquartered in Cambridge, Massachusetts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks similar to those of other early-stage companies in the biopharmaceutical industry, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of whom are larger and better capitalized, the impact of the COVID-19 pandemic and the need to obtain adequate additional financing to fund the development of its products. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be maintained, that any products developed will obtain required regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from the sale of its products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared the global novel coronavirus disease 2019 (&#8220;COVID-19&#8221;)&#160;outbreak a pandemic. The Company&#8217;s operations have not been significantly impacted by the&#160;COVID-19&#160;pandemic. However, the Company cannot at this time predict the specific extent, duration, or full impact that the&#160;COVID-19&#160;pandemic will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the&#160;COVID-19&#160;outbreak on the Company&#8217;s financial performance will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of&#160;COVID-19&#160;on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy are impacted for an extended period, the Company&#8217;s results may be materially adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;27, 2020, the Company completed its initial public offering (&#8220;IPO&#8221;) pursuant to which it issued and sold 7,500,000 shares of its common stock at a public offering price of $16.00 per share, resulting in net proceeds of $107.9 million, after deducting underwriting discounts and commissions and other offering expenses. On November&#160;19, 2020, the Company issued and sold an additional 951,837 shares of common stock at the IPO price of $16.00 per share pursuant to the underwriters&#8217; partial exercise of their option to purchase additional shares of common stock, resulting in additional net proceeds of $14.2 million after deducting underwriting discounts and commissions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 10, 2021, the Company executed a collaboration agreement with Eli Lilly and Company (or "Lilly") (See Note 9). Concurrent with the collaboration agreement the Company completed a stock purchase agreement (the "SPA") with Lilly and issued and sold Lilly 4,000,000 shares of its common stock at a price of $20.00 per share, resulting in net proceeds of $80.0 million of which </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$42.2 million was allocated to equity upon the issuance of the Company&#8217;s common stock (see Note 9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has funded its operations primarily with proceeds from sales of preferred stock, debt financing, an upfront payment of $15.0 million the Company received in July 2020 under a collaboration agreement with Merck Sharp&#160;&amp; Dohme Corp. (see Note 9), proceeds from the sale of common stock in the IPO completed in October 2020 and most recently, with sale of common stock in the SPA. In January 2022, the Company received an upfront payment of $300.0 million pursuant to the collaboration agreement with Lilly (See Note 9), which was included in current assets on the consolidated balance sheets as of December&#160;31, 2021. The Company has incurred recurring losses, including net losses of $101.3 million and $68.8 million for the years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, the Company had an accumulated deficit of $264.3 million. The Company expects to continue to generate operating losses in the foreseeable future. As of the issuance date of these consolidated financial statements the Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will need to obtain additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements to continue to fund its operations. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborative or strategic alliances or licensing arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. Arrangements with collaborators or others may require the Company to relinquish rights to certain of its </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technologies or programs. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, pipeline expansion or commercialization efforts, which could adversely affect its business prospects. Although management will continue to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations when needed or at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559135412264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition and the accrual of research and development expenses. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk and of significant suppliers</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. As of December&#160;31, 2021, the Company maintained cash, cash equivalents and marketable securities at financial institutions in excess of federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies, and expects to continue to rely, on a small number of vendors to provide services, supplies and materials for certain activities related to its programs. These programs could be adversely affected by a significant interruption in these services or the availability of materials.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash equivalents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketable securities are classified as&#160;available-for-sale&#160;and are carried at fair value with the unrealized gains and losses reported as a component of accumulated other comprehensive loss in stockholders&#8217; equity. Realized gains and losses and declines in value judged to be other than temporary are included as a component of interest income and other income (expense), net based on the specific identification method. The Company classifies its marketable securities with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities are available for current operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted cash</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in restricted cash represent amounts pledged as collateral for letters of credit required for security deposits on the Company&#8217;s leased facilities and credit cards. These amounts are classified as restricted cash in the Company&#8217;s consolidated balance sheets.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shorter of useful life or remaining term of lease</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs for capital assets not yet placed into service are depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of long-lived assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its long-lived assets, which consist primarily of property and equipment and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company did not record any impairment losses on long-lived assets during the years ended December&#160;31, 2021 or 2020.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair value measurements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see Note&#160;3). The carrying values of the Company&#8217;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities. The carrying value of the Company&#8217;s long-term debt approximates its fair value (a level 2 measurement) due to its variable interest rate.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Collaboration Agreements</span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ASC 808) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.  When the Company has concluded that it has a customer relationship with one of its collaborators the Company follows the guidance in ASC Topic 606,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> Revenue From Contracts With Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (&#8220;ASC 606&#8221;).</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its two collaboration arrangements under ASC 606 as the Company concluded that it has a customer relationship with each of its collaborators. For additional information on the Company&#8217;s collaboration agreements, see Note 9,&#160;Collaboration&#160;Agreements, to these consolidated financial statements. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the goods or services promised within each contract and determines those that are performance obligations. The promised goods or services in the Company&#8217;s arrangements would likely consist of licenses, rights to the Company&#8217;s intellectual property, research and development services and related supporting activities. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)&#160;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii)&#160;the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#8220;SSP&#8221;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company&#160;re-evaluates&#160;the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative&#160;catch-up&#160;basis in the period of adjustment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which the royalty has been allocated has been satisfied.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded for deferred revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised goods or services to the customer and the payment by the customer will be one year or less. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based on the use of an output or input method.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, and external costs of vendors engaged to conduct research, preclinical and clinical development activities as well as the cost of licensing technology.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments and milestone payments made for the licensing of technology are expensed as research and development over the period to which they relate. Costs for research and development activities are expensed in the period in which they are incurred. Payments for such activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense. Determining the prepaid and accrued balances at the end of any reporting period incorporate certain judgments and estimates by management that are based on information available to the Company including information provided by vendors regarding the progress to completion of specific tasks or costs incurred.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC&#160;842,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#8217;s economic benefits. The Company determines if an arrangement is a lease or contains an embedded lease at inception. For arrangements that meet the definition of a lease, the Company determines the initial classification and measurement of its right-of-use asset and lease liability at the lease commencement date and thereafter if modified. The lease term includes any renewal options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term. The Company&#8217;s policy is to not record leases with an original term of twelve months or less on its consolidated balance sheets and recognizes those lease payments in the income statement on a straight-line basis over the lease term. The Company&#8217;s existing leases are for office and laboratory space and an equipment lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to rent, the leases may require the Company to pay additional costs, such as utilities, maintenance and other operating costs, which are generally referred to as non-lease components. The Company has&#160;elected to not separate lease and non-lease components. Only the fixed costs for lease components and their associated non-lease components are accounted for as a single lease component and recognized as part of a right-of-use asset and liability. Rent expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures stock options with service-based vesting or performance-based vesting granted to employees, non-employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. The Company measures restricted common stock awards using the difference between the purchase price per share of the award, if any, and the fair value of the Company&#8217;s common stock at the date of grant. Compensation expense for the awards is recognized over the requisite service period for employees and directors and as services are delivered for non-employees, both of which are generally the vesting period of the respective award. The Company uses the straight-line method to record the expense of awards with only service-based vesting conditions. The Company uses the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing once achievement of the performance condition becomes probable. The Company&#160;accounts for forfeitures of share-based awards as they occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net loss per share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing net income(loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, adjusted for potential dilutive common shares.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s participating securities contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reported a net loss, such losses were not allocated to such participating securities. In periods in which the Company reported a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported a net loss attributable to common stockholders for the years ended December&#160;31, 2021 and 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,920,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,016,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,445&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,445&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,938,954&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,034,905&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an entity for which separate discrete financial information is made available and that is regularly evaluated by the chief operating decision maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The Company&#8217;s CODM is its chief executive officer and the Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company is focused on pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive loss</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. For the year ended December&#160;31, 2021 and 2020, the Company&#8217;s only element of other comprehensive loss was unrealized losses on available for sale debt securities. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to the provision for income taxes. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. Any resulting unrecognized tax benefits are recorded within the provision for income taxes.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i)&#160;irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii)&#160;no longer qualifies as an emerging growth company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No.&#160;2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;The new standard adjusts the accounting for assets held at amortized costs basis, including marketable securities accounted for as available for sale.&#160;The standard eliminates the probable initial recognition threshold and requires an entity to reflect its current estimate of all expected credit losses.&#160;The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For public entities, the guidance was effective for annual reporting periods beginning after December&#160;15, 2019 and for interim periods within those fiscal years. For nonpublic entities and emerging growth companies that choose to take advantage of the extended transition period, the guidance is effective for annual reporting periods beginning after December&#160;15, 2020. Early adoption is permitted for all entities. In November 2019, the FASB issued ASU No.&#160;2019-10, which deferred the effective date for nonpublic entities to annual reporting periods beginning after December&#160;15, 2022, including interim periods within those fiscal years. The Company is evaluating when to adopt this standard and the effect the adoption will have on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559136423848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_MarketableSecuritiesAndFairValueMeasurementsTextBlock', window );">Marketable Securities and&#160;Fair Value Measurements</a></td>
<td class="text">Marketable Securities and Fair Value Measurements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, available for sale marketable securities by security type consisted of (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper (due within one year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds (due within one year)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,917&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,910&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,163&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,153&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, available for sale marketable securities by security type consisted of (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury notes (due within one year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,982&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,975&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Company&#8217;s fair value hierarchy for its assets and liabilities, which were measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at<br/>December 31, 2021 Using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash equivalents:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,496&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,496&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,243&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,243&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82,252&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,649&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153,901&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at<br/>December 31, 2020 Using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:31.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:31.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,997&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,997&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:31.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,975&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,975&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,770&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135,972&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184,742&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>During the years ended December&#160;31, 2021 and 2020, there were no transfers between Level 1, Level 2 and Level 3.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_MarketableSecuritiesAndFairValueMeasurementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for marketable securities and fair value measurements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_MarketableSecuritiesAndFairValueMeasurementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559135433240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">815&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">815&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,059&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,961&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets not yet placed in service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,893&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,631&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,563&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,528&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was $3.2 million and $1.3 million for the years ended December&#160;31, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559136499256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued tenant improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,385&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued external research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">495&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">979&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,562&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,161&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559135417816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text">Notes Payable<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amount of long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion of long-term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final payment fee</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt discount, net of accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,346)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, net of discount and current portion</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,654&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan and Security Agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2020, the Company entered into a loan and security agreement (the "Oxford Loan Agreement"), with Oxford Finance LLC, or Oxford, for an aggregate principal amount of $20.0 million (the "Oxford Term Loan A") and up to an additional $5.0 million (the "Oxford Term Loan B"). On November&#160;19, 2020, the Company borrowed $20.0 million under the Oxford Term Loan A. Oxford Term Loan A and Oxford Term Loan B (the "Term Loans") bear interest at a floating per annum rate equal to the greater of (i) 8.0% and (ii)&#160;the sum of (a)&#160;thirty-day LIBOR rate plus (b) 7.84%. In addition, upon loan maturity or prepayment, the Company is required to make a final payment fee equal to 5.0% of the aggregate principal amount borrowed which is being amortized to interest expense over the term of the debt using the effective interest method.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to make monthly interest only payments under the Oxford Loan each month beginning on January&#160;1, 2021. Beginning on December&#160;1, 2023, the Company is required to make consecutive equal monthly payments of principal, together with applicable interest, in arrears, based upon a repayment schedule equal to 24 months, with a final maturity date of November&#160;1, 2025 (the &#8220;Maturity Date&#8221;). At the Company's option, the Company may elect to prepay the loans subject to a prepayment fee equal to the following percentage of the principal amount being prepaid: 2% if an advance is prepaid during the first 12 months following the applicable advance date, 1% if an advance is prepaid after 12 months but prior to 24 months following the applicable advance date, and 0.5% if an advance is prepaid any time after 24 months following the applicable advance date but prior to the Maturity Date. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with the Oxford Loan Agreement, the Company granted warrants to purchase 18,445 shares of the Company&#8217;s common stock at $16.26 per share. The issued warrants are exercisable for 10 years. The Company valued the warrants using the Black-Scholes option pricing model and determined the fair value of the warrants to be $0.2 million. The Company determined the warrants met the criteria for equity classification, and, as such, the fair value of the warrants were recorded as additional paid-in capital upon issuance and as a discount to the debt which is being amortized to interest expense over the term of the Oxford Loan of five years. In addition, the Company incurred debt issuance costs of $0.2 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company repaid early the outstanding principal balance under the Term Loans as described above plus unpaid accrued interest, the final payment fee and the prepayment fee. The Company recorded a loss on debt extinguishment of $1.2&#160;million related to this repayment for the year ended December&#160;31, 2021. </span></div>During the years ended December&#160;31, 2021 and 2020, the weighted average effective interest rate on outstanding borrowings was approximately 9.5% and 6.4%, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559136427016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_CommonStockTextBlock', window );">Common Stock</a></td>
<td class="text">Common Stock<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;27, 2020, the Company completed its initial public offering (&#8220;IPO&#8221;) pursuant to which it issued and sold 7,500,000 shares of its common stock at a public offering price of $16.00 per share, resulting in net proceeds of $107.9 million, after deducting underwriting discounts and commissions and other offering expenses. On November&#160;19, 2020, the Company issued and sold an additional 951,837 shares of common stock at the IPO price of $16.00 per share pursuant to the underwriters&#8217; partial exercise of their option to purchase additional shares of common stock, resulting in additional net proceeds of $14.2 million after deducting underwriting discounts and commissions. Upon the closing of the IPO, all of the Company&#8217;s outstanding convertible preferred stock automatically converted into shares of common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 10, 2021, the Company completed a collaboration agreement with Lilly (See Note 9). Concurrent with the collaboration agreement the Company completed a stock purchase agreement with Lilly and issued and sold Lilly 4,000,000 shares of its common stock at a price of $20.00 per share, resulting in net proceeds of $80.0 million of which </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$42.2 million was allocated to equity upon the issuance of the Company&#8217;s common stock (see Note 9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div>Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders. Common stockholders are not entitled to receive dividends, unless declared by the board of directors.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_CommonStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for common stock, including, but not limited to voting rights, dividends, and stock splits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_CommonStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559136353464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2016 Stock Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2016 Stock Incentive Plan, (the &#8220;2016 Plan&#8221;) provided for the Company to grant incentive stock options or nonqualified stock options and other equity awards to employees, directors and consultants of the Company. Upon the effectiveness of the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;) in October 2020, the Company ceased granting additional awards under the 2016 Plan.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Equity Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Plan provides for the grant of incentive stock options,&#160;non-qualified&#160;options, stock appreciation rights, restricted stock awards, restricted stock units and other&#160;stock-based awards. The number of shares initially reserved for issuance under the 2020 Plan was (i) 2,200,000 shares (the &#8220;share pool&#8221;), plus (ii)&#160;the number of shares of common stock available for issuance under the 2016 Plan as of the effective date of the 2020 Plan, plus the number of shares of common stock underlying awards under the 2016 Plan that on or after the date of adoption expire or become unexercisable without delivery of shares, are forfeited to, or repurchased for cash, are settled in cash, or otherwise become available again for grant under the 2016 Plan, in each case, in accordance with its terms (up to an aggregate of 5,078,295 shares). As of December&#160;31, 2021, 2,271,847 shares remained available for future grant under the 2020 Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The share pool will automatically increase on January&#160;1 of each year from 2021 to 2030 by the lesser of (i)&#160;four percent of the number of shares of our common stock outstanding as of the close of business on the immediately preceding December&#160;31 and (ii)&#160;the number of shares determined by the board of directors on or prior to such date for such year.&#160;The number of shares reserved for issuance under the 2020 Plan was increased by 1,651,989 shares effective January&#160;1, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Plan is administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions are determined at the discretion of the board of directors, or its committee if so delegated. Stock options granted with service-based vesting conditions generally vest over four years and expire after ten years. The exercise price for stock options granted is not less than the fair value of common stock on the date of grant. The Company bases fair value of common stock on the quoted market price. Prior to the IPO, the board of directors determined the value the Company&#8217;s common stock, taking into consideration its most recently available valuation of common stock performed by third parties as well as additional relevant factors which may have changed since the date of the most recent contemporaneous valuation through the date of grant.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;21, 2020, the Company&#8217;s board of directors adopted and its stockholders approved the 2020 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which became effective on October&#160;21, 2020. The aggregate number of shares of common stock </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available for purchase pursuant to the exercise of options under the ESPP is 360,000 shares, plus an automatic annual increase, as of January&#160;1 of each year from 2021 to 2030, equal to the lesser of one percent of the number of shares of common stock outstanding as of the close of business on the immediately preceding December&#160;31 and (ii)&#160;the number of shares determined by the board of directors on or prior to such date for such year (up to a maximum of 3,220,520 shares). The number of shares reserved for issuance under the ESPP was increased by 367,894 shares to 780,891 shares effective January&#160;1, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first offering period commenced under the ESPP on September 1, 2021. For the year ended December&#160;31, 2021, the Company recognized a de minimis amount of expense related to the ESPP.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option valuation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock option grants is estimated using the Black-Scholes option-pricing model. The Company currently lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted during the years ended December&#160;31, 2021 and 2020 which was as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s option activity during the year ended December&#160;31, 2021 which was as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,016,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,719,563&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(508,774)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(306,740)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,920,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest as of December 31, 2021</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,920,509&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.9</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88,720&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercisable as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,435,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. The aggregate intrinsic value of stock options exercised during the years ended December&#160;31, 2021 and 2020 was $5.3 million and $3.5 million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant-date fair value of stock options granted during the years ended December&#160;31, 2021 and 2020 was $10.40 per share and $6.01 per share, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted common stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2015, the Company issued and sold 4,459,459 shares of restricted common stock at par value to the scientific founders of the Company. The shares were subject to vesting over a period of five years and began vesting in April 2016 and were fully vested as of December&#160;31, 2020. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate fair value of restricted stock that vested during the years ended December&#160;31, 2020 was $4.8 million, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to common stock options and restricted common stock in the following expense categories of its consolidated statements of operations and comprehensive loss during the years ended December&#160;31, 2021 and 2020 which was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,724&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,060&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,237&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,384&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,961&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, total unrecognized compensation cost related to unvested options was $20.8 million, which is expected to be recognized over a weighted average period of 2.7 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559136419848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_CollaborationAgreementAbstract', window );"><strong>Collaboration Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text">Collaboration Agreements<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lilly Collaboration Agreement and Stock Purchase Agreement</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company entered into a collaboration agreement (the &#8220;Lilly Collaboration Agreement") with Lilly to create novel oncology medicines by applying Foghorn&#8217;s proprietary Gene Traffic Control platform. The collaboration includes a co-development and co-commercialization agreement for the Company&#8217;s selective BRM oncology target, consisting of two programs, and one additional undisclosed oncology target (collectively, the &#8220;Joint Programs&#8221;). The collaboration also includes three additional discovery targets or programs (collectively, the &#8220;Discovery Programs&#8221;) for a total of six programs directed at five targets. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the Joint Programs, the Company will lead discovery and early research activities through the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> successful </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">completion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dose finding toxicity studies </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the identified compound, while Lilly will lead development and commercialization activities of the identified compound with participation from the Company in development activities and 50% cost sharing until registrational clinical trials. The Company and Lilly may jointly develop and commercialize the Joint Program compound though the Company may, in its sole discretion, opt-out on a program-by-program basis of further participation in the development and commercialization efforts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prior to t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he first registrational clinical trial. If the Company does not opt-out, Lilly and the Company will continue to share in the costs to further develop and commercialize the Joint Program compound on a worldwide basis, equally share in the U.S. profits on product sales, subject to certain adjustments and receive royalties on sales outside of the United States (&#8220;Ex-U.S.&#8221;) at royalty rates ranging from low double digits to high twenties. If the Company opts-out of further development and commercialization efforts, it will have no further obligations to share in the development and commercialization costs, will receive royalties rather than profit share on U.S. sales and will receive royalties at a lower rate on Ex-U.S. sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the Discovery Programs, the Company will lead discovery and early research activities through the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">successful completion of dose finding toxicity studies for the identified compounds. The Company may, in its sole discretion, opt in on a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> program-by-program basis after the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">successful c</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ompletion of dose finding toxicity to participate in the further development and commercialization efforts of the Discovery Program compounds. If the Company opts-in to the development and commercialization of the Discovery Program compounds, it will be eligible to receive milestone payments of up to $10.0 million per program upon specified research and development milestones and up to $180.0 million per program upon achievement of specified regulatory and commercial milestones and will also be eligible to share in the U.S. profits at pre-determined percentages on product sales. The Company would also be eligible to receive tiered Ex-U.S. royalty rates, calculated on a product-by-product and country-by-country basis, on net sales outside of the United States, if any, ranging from low single digits to low double digits, but less then teens. If the Company does not opt in to further development and commercialization efforts for the Discovery Programs, it will be eligible to receive milestone payments of up to $70.0 million per program upon specified research and development milestones and up to $360.0 million per program upon achievement of specified regulatory and commercial milestones per approved product, if any. The Company would also be eligible to receive </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tiered royalties on net sales of products worldwide at royalty rates ranging from low single digits to low double digits, but less then teens.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lilly has the right to make substitutions for each of the five targets during the research term of each program, subject to certain limitations. Pursuant to the Lilly Collaboration Agreement, the Company will also participate in joint decision-making through the joint steering committee and subcommittees. Unless terminated earlier, the Lilly Collaboration Agreement will continue on a product-by-product basis until the expiration of all royalty obligations under the Lilly Collaboration Agreement and when neither the Company nor Lilly is developing, commercializing or manufacturing any product under the Lilly Collaboration Agreement. The Company or Lilly may terminate the Lilly Collaboration Agreement upon an uncured material breach by the other party. Lilly may also terminate the Lilly Collaboration Agreement in its entirety or on a target-by-target, program-by-program or product-by-product basis for any reason upon certain notice to the Company.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Lilly Collaboration Agreement, Lilly agreed to make a nonrefundable upfront payment of $300.0 million to the Company within thirty (30) business days following the effective date of the agreement. Simultaneously with the execution of the Lilly Collaboration Agreement, the Company and Lilly entered into the Lilly SPA, pursuant to which Lilly purchased 4,000,000 shares of the Company&#8217;s common stock at $20.00 per share, for an aggregate purchase price of $80.0 million. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Lilly Collaboration Agreement and the stock purchase agreement entered into with Lilly concurrently (the "Lilly SPA") should be evaluated as a combined contract in accordance with ASC 606. The Company determined the fair value of the shares sold under the Lilly SPA to be $37.8 million less than the contractual purchase price stipulated in the Lilly SPA. In accordance with the applicable accounting guidance in ASC 815-40, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity&#8217;s Own Equity</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company determined that the sale of stock should be recorded at fair value and therefore allocated the excess consideration received under the Lilly SPA to the Lilly Collaboration Agreement, which along with the non-refundable payment of $300.0 million will be recognized as revenue over the total estimated period of performance.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for the arrangement under ASC 606 as the Company concluded it has a customer relationship with Lilly. The Company determined that (1) the research activities performed by the Company for both the Joint Programs and the Discovery Programs (2) the development activities and cost sharing for the Joint Program development efforts after dose finding toxicity until registrational clinical trials (3) the research, development, manufacture and commercialization licenses and (4) service on the joint steering committee and subcommittees represent a single performance obligation under the Lilly Collaboration Agreement. The Company determined that Lilly cannot benefit from the licenses separately from the research activities, the development activities until registrational clinical trials and participation on the joint steering committee and subcommittees because these services are specialized and rely on the Company&#8217;s expertise such that these activities are highly interrelated and therefore not distinct. Accordingly, the promised goods and services represent one combined performance obligation, and the entire transaction price was allocated to that single combined performance obligation. The performance obligation will be satisfied over time as the Company performs the research activities, participates and shares in the cost of the development activities for the Joint Programs and participates in a joint steering committee and subcommittees to oversee these activities. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s options to share in further development and commercialization efforts via its opt-in/opt-out rights will be assessed and accounted for as separate units of accounting under the relevant guidance if, and when, such options are exercised by the Company.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price of $337.8 million was initially recorded as deferred revenue and is being recognized as revenue as the performance obligation is satisfied. The Company recognizes revenue using the cost-to-cost method, which it believes best depicts the transfer of control to the customer over time. Under the cost-to-cost method, the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation. Under this method, revenue is recorded as a percentage of the estimated transaction price based on the extent of progress towards completion. As of December 31, 2021, the potential research, development and regulatory milestone payments that the Company is eligible to receive were excluded from the transaction price as they were fully constrained by uncertain events. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and if necessary, the Company will adjust its estimate of the transaction price. Any additions to the transaction price would be reflected in the period as a cumulative revenue catch-up based on the ratio of costs incurred to the total estimated costs expected applied to the revised transaction price. Sales-based royalties and milestone payments, which predominantly relate to the license, will be recognized if and when the related sales occur.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the aggregate amount of the transaction price related to the unsatisfied portion of the performance obligation was $337.2 million, which is expected to be recognized as revenue through 2029. The Company does not expect collaboration revenue to be recognized evenly over this period as it will be recognized on a percentage of completion basis (using cost-to-cost method) as the Company performs the research and development activities and participates on the joint </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">steering committee and subcommittees, which will likely vary from period to period. In estimating the total costs to satisfy its single performance obligation pursuant to the Lilly Collaboration Agreement, the Company is required to make significant estimates including an estimate of the number of target substitutions Lilly may elect to make and the expected time and expected costs to fulfill the performance obligation. The cumulative effect of revisions to the total estimated costs to complete the Company&#8217;s single performance obligation will be recorded in the period in which the changes are identified, and amounts can be reasonably estimated. While such revisions will have no impact on the Company&#8217;s cash flows, a significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods and the classification of deferred revenue between short-term and long-term. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception, the Company assessed the Lilly Collaboration Agreement to determine whether a significant financing component exists and concluded that a significant financing component does not exist. For the year ended December 31, 2021, the Company had recorded $0.6 million of revenue under the Lilly Collaboration Agreement, which was included in deferred revenue at contract inception. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the upfront payment of $300.0&#160;million was recorded as collaboration receivable on the Company's consolidated balance sheets. In January 2022, the $300.0 million was collected from Lilly.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merck Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a research collaboration and license agreement (the &#8220;Merck Collaboration Agreement&#8221;) with Merck Sharp&#160;&amp; Dohme Corp. (&#8220;Merck&#8221;). The Company and Merck will apply Foghorn&#8217;s proprietary Gene Traffic Control platform to discover and develop novel therapeutics. Under the Merck Collaboration Agreement, the Company granted Merck exclusive global rights to develop, manufacture and commercialize drugs that target dysregulation of a single transcription factor. Under the terms of the Merck Collaboration Agreement, the Company and Merck are each responsible to perform certain research activities in accordance with a mutually agreed upon research plan. Merck may substitute the selected transcription factor during certain stages of the research program, subject to certain limitations. Following completion of the research program, Merck is responsible for the development and commercialization of the compounds developed pursuant to the research program and any product containing such compounds. Pursuant to the Merck Collaboration Agreement, the Company will also participate on a joint steering committee.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Foghorn received a nonrefundable upfront payment of $15.0 million from Merck, and is eligible to receive up to $245.0 million upon achievement of specified research, development and regulatory milestones by any product candidate generated by the collaboration, and up to $165.0 million upon achievement of specified sales-based milestones per approved product from the collaboration, if any. The Company will be eligible to receive tiered royalties, calculated on a product-by-product and country-by-country basis, on net sales of approved products from the collaboration, if any, at royalty rates ranging from the mid-single digits to low tens, depending on whether the products are covered by patent rights it licenses to Merck.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated earlier, the Merck Collaboration Agreement will continue in full force and effect until one or more products has received marketing authorization and, thereafter, until expiration of all royalty obligations under the Merck Collaboration Agreement. The Company or Merck may terminate the Merck Collaboration Agreement upon an uncured material breach by the other party or insolvency of the other party. Merck may also terminate the Merck Collaboration Agreement for any reason upon certain notice to the Company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the (1)&#160;research, development, manufacture and commercialization licenses, (2) the research activities performed by the Company and (3)&#160;service on the joint committees represent a single performance obligation under the Merck Collaboration Agreement. The Company determined that Merck cannot benefit from the licenses separately from the research activities and participation on the joint steering committee because these services are specialized and rely on the Company&#8217;s expertise such that these activities are highly interrelated and therefore not distinct. Accordingly, the promised goods and services represent one combined performance obligation and the entire transaction price was allocated to that single combined performance obligation. The performance obligation will be satisfied over the research term as the Company performs the research activities and participates in a joint steering committee to oversee research activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The upfront payment of $15.0 million was initially recorded as deferred revenue and is being recognized as revenue as the performance obligation is satisfied. The Company recognizes revenue using&#160;the&#160;cost-to-cost&#160;method,&#160;which it believes best depicts the transfer of control to the customer over time. Under&#160;the&#160;cost-to-cost&#160;method,&#160;the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation. Under this method, revenue is recorded as a percentage of the estimated transaction price based on the extent of progress towards completion. As of December&#160;31, 2021, the potential research, development and regulatory milestone payments that the Company is eligible to receive were excluded from the transaction price as they were fully constrained by uncertain events. The Company will reevaluate the transaction price at the end of each reporting period and </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as uncertain events are resolved or other changes in circumstances occur, and if necessary, the Company will adjust its estimate of the transaction price. Any additions to the transaction price would be reflected in the period as a cumulative revenue&#160;catch-up based on the ratio of costs incurred to the total estimated costs expected applied to the revised transaction price.&#160;Sales-based royalties and milestone payments, which predominantly relate to the license, will be recognized if and&#160;when the related sales occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the aggregate amount of the transaction price related to the unsatisfied portion of the performance obligation is $13.9 million, which is expected to be recognized as revenue through 2028. The Company does not expect collaboration revenue to be recognized evenly over this period as it will be recognized on a percentage of completion basis (using cost-to-cost method) as the Company performs the research activities and participates on the joint steering committee, which will likely vary from period to period. In estimating the total costs to satisfy its single performance obligation pursuant to the Merck Collaboration Agreement, the Company is required to make significant estimates including an estimate of the number of transcription factor substitutions and the expected time and expected costs to fulfill the performance obligation.&#160;The cumulative effect of revisions to the total estimated costs to complete the Company&#8217;s single performance obligation will be recorded in the period in which the changes are identified, and amounts can be reasonably estimated. While such revisions will have no impact on the Company&#8217;s cash flows, a significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods and the classification of deferred revenue between short-term and long-term. In June 2021, the Company re-evaluated its estimates related to the Merck Collaboration Agreement resulting in a reclassification of $1.9&#160;million from short-term deferred revenue to long-term deferred revenue, net of current portion on the Company's consolidated balance sheets. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception, the Company assessed the Merck Collaboration Agreement to determine whether a significant financing component exists and concluded that a significant financing component does not exist. For the year ended December&#160;31, 2021, the Company had recorded $0.7 million of revenue under the Merck Collaboration Agreement, which was included in deferred revenue at the beginning of the period </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the classification of deferred revenue between short-term and long-term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_CollaborationAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_CollaborationAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559136405400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, the Company recorded no income tax benefits for the net deferred tax assets comprised primarily of net operating losses incurred and research and development tax credits generated in each year, due to its uncertainty of realizing a benefit from these items.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s operating losses since inception have been generated in the United States.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate was as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State taxes, net of federal benefit</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state research and development tax credits</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in deferred tax asset valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective income tax rate</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss carryforwards</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,083&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,289&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development tax credit carryforwards</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized start-up costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,403&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">436&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax assets</span></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93,262&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62,896&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,551)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,819)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,694)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax liabilities</span></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,117)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,513)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79,145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets</span></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had U.S. federal and state net operating loss carryforwards of $228.9 million and $206.0 million, respectively, which may be available to offset future taxable income. The federal net operating loss carryforwards include&#160;$12.5 million&#160;which expire at various dates beginning in&#160;2035&#160;and&#160;$216.4 million&#160;which carryforward indefinitely but in some circumstances may be limited to offset 80% of annual taxable income. The state net operating loss carryforwards expire at various dates beginning in&#160;2036.&#160;As of December&#160;31, 2021, the Company also had U.S. federal and state research and development tax credit carryforwards of $6.1 million and $4.1 million, respectively, which may be available to offset future tax liabilities and expire at various dates beginning in 2036 and 2031, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section&#160;382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section&#160;382. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being recorded as an uncertain tax position.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company&#8217;s history of cumulative net losses incurred since inception and its lack of commercialization of any products that would generate revenue from product sales and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December&#160;31, 2021 and 2020. Management reevaluates the positive and negative evidence at each reporting period.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance increased by $30.8 million and $21.8 million during the years ended December&#160;31, 2021 and 2020, respectively, primarily as a result of the increase in net operating loss carryforwards.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the Company had not recorded any amounts for unrecognized tax benefits. The Company files income tax returns in the U.S. and Massachusetts, as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. Since the Company is in a loss carryforward position, it is generally subject to </span></div>examination by the U.S. federal, state, and local income tax authorities for all tax years in which a loss carryforward is available.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559135441064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into a lease for 81,441 square feet of office and laboratory space in Cambridge, Massachusetts, commencing in January 2020 (the &#8220;New Lease&#8221;). The initial term of the New Lease was eight years with a five-year option to extend at fair-market rent at the time of the extension. The base rent payments escalate annually over the eight-year lease term and totaled approximately $60.3 million. In connection with the New Lease, the landlord agreed to fund up to $3.0 million in tenant improvements to the leased facility as well as up to an additional $16.3 million, which resulted in additional rent payments to the landlord over the lease term. During the year ended December&#160;31, 2021 and 2020, $2.5 million and $15.4&#160;million, respectively, of leasehold improvements were reimbursed by the landlord, which resulted in an increase to operating lease liabilities. The Company is obligated to pay its portion of real estate taxes and costs related to the premises, including costs of operations and management of the leased premises. The Company is required to maintain a cash balance of $1.7 million to secure a letter of credit associated with the lease. This amount was classified as restricted cash (non-current) on the consolidated balance sheets as of December&#160;31, 2021 and 2020. On January&#160;1, 2020, the lease commencement date, the Company recorded an operating lease asset of $38.6 million and corresponding lease liability of $38.3 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company amended the New Lease to defer payment of a portion of the base rent and operating expenses and to extend the lease term by nine months to September 2028. The amendment was accounted for as a lease modification and the right-of-use asset and lease liability were remeasured at the modification date of June&#160;29, 2020 resulting in an increase of $7.4 million to both the right-of-use asset and lease liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had a lease for office and laboratory facilities in Cambridge, Massachusetts under a noncancelable operating lease that began in August 2017 and expired in March 2025. In April 2020, this lease was assigned and assumed by a related party which became effective in October 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense was as follows for the years ended December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,547&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,439&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,310&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental disclosure of cash flow information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities arising from obtaining right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,306&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase in operating lease liabilities and right-of-use assets due to lease remeasurement</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining lease term and discount rate was as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8212;operating leases (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8212;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual minimum lease payments under operating leases as of December&#160;31, 2021 was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,051&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,626&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,705&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,802)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: estimated lease incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,461)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,332&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Included in the consolidated balance sheets (in thousands):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,332&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sublease agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2020, the Company entered into a two-year sublease agreement to sublet approximately 16,843 square feet of office space under the New Lease, as amended, which began in July 2020. In February 2021, the Company entered into an amendment to the sublease to sublet approximately 2,980 square feet of additional office space to the sublessee for the remaining lease term. In July 2021, the Company entered into an amendment to, among other things, extend the sublease through November 30, 2022. As of December&#160;31, 2021, the remaining rent payments due to the Company under the amended sublease were $1.9 million. During the years ended December&#160;31, 2021 and 2020, the Company recorded other income of $2.5 million and $1.0&#160;million, respectively,  related to this sublease.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into a lease for 81,441 square feet of office and laboratory space in Cambridge, Massachusetts, commencing in January 2020 (the &#8220;New Lease&#8221;). The initial term of the New Lease was eight years with a five-year option to extend at fair-market rent at the time of the extension. The base rent payments escalate annually over the eight-year lease term and totaled approximately $60.3 million. In connection with the New Lease, the landlord agreed to fund up to $3.0 million in tenant improvements to the leased facility as well as up to an additional $16.3 million, which resulted in additional rent payments to the landlord over the lease term. During the year ended December&#160;31, 2021 and 2020, $2.5 million and $15.4&#160;million, respectively, of leasehold improvements were reimbursed by the landlord, which resulted in an increase to operating lease liabilities. The Company is obligated to pay its portion of real estate taxes and costs related to the premises, including costs of operations and management of the leased premises. The Company is required to maintain a cash balance of $1.7 million to secure a letter of credit associated with the lease. This amount was classified as restricted cash (non-current) on the consolidated balance sheets as of December&#160;31, 2021 and 2020. On January&#160;1, 2020, the lease commencement date, the Company recorded an operating lease asset of $38.6 million and corresponding lease liability of $38.3 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company amended the New Lease to defer payment of a portion of the base rent and operating expenses and to extend the lease term by nine months to September 2028. The amendment was accounted for as a lease modification and the right-of-use asset and lease liability were remeasured at the modification date of June&#160;29, 2020 resulting in an increase of $7.4 million to both the right-of-use asset and lease liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had a lease for office and laboratory facilities in Cambridge, Massachusetts under a noncancelable operating lease that began in August 2017 and expired in March 2025. In April 2020, this lease was assigned and assumed by a related party which became effective in October 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense was as follows for the years ended December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,547&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,439&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,310&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental disclosure of cash flow information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities arising from obtaining right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,306&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase in operating lease liabilities and right-of-use assets due to lease remeasurement</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining lease term and discount rate was as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8212;operating leases (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8212;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual minimum lease payments under operating leases as of December&#160;31, 2021 was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,051&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,626&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,705&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,802)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: estimated lease incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,461)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,332&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Included in the consolidated balance sheets (in thousands):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,332&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sublease agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2020, the Company entered into a two-year sublease agreement to sublet approximately 16,843 square feet of office space under the New Lease, as amended, which began in July 2020. In February 2021, the Company entered into an amendment to the sublease to sublet approximately 2,980 square feet of additional office space to the sublessee for the remaining lease term. In July 2021, the Company entered into an amendment to, among other things, extend the sublease through November 30, 2022. As of December&#160;31, 2021, the remaining rent payments due to the Company under the amended sublease were $1.9 million. During the years ended December&#160;31, 2021 and 2020, the Company recorded other income of $2.5 million and $1.0&#160;million, respectively,  related to this sublease.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559136419848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s commitments under its leases are described in Note&#160;11.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various exclusive and non-exclusive license agreements for certain technologies. Under the terms of these license agreements, the Company could be required to reimburse the licensors for patent expenses and remit amounts in the low single-digit as sales-based royalties upon the occurrence of specific events as outlined in the corresponding license agreements. The Company is also required to make annual license maintenance fees of less than $0.1 million and pay up to $1.1 million in regulatory milestones on each licensed product upon the occurrence of specific events as outlined in one of the license agreements. None of our product candidates utilize technologies covered by these licenses.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div>From time to time, the Company may become involved in litigation or other legal proceedings. The Company is not currently a party to any material litigation or legal proceedings.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559138686152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text">Defined Contribution PlanThe Company has a 401(k) defined contribution plan (the &#8220;401(k) Plan&#8221;) for its employees. Eligible employees may make pretax contributions to the 401(k) Plan up to statutory limits. There was no discretionary match made under the 401(k) Plan as of December&#160;31, 2021 and 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559136386088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text">Related Parties<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, the Company entered into a five-year service agreement with Flagship Pioneering (&#8220;Flagship&#8221;), an affiliate of one of its stockholders, Flagship Venture Funds,to provide general and administrative services to the Company, including certain consulting services and the provision of employee health and dental benefit plans for the Company&#8217;s employees. The Company made cash payments to Flagship, for services received under this agreement, of $1.2 million during the year ended December&#160;31, 2020. As of December&#160;31, 2021 and 2020, the Company had no accounts payable to Flagship for costs related to the service agreement. This agreement expired in 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, the Company entered into a five-year consulting agreement with a scientific founder of the Company who is also a board member and a shareholder. In October 2020, this agreement was extended to January&#160;1, 2022, and is subject to automatic one-year renewal terms until terminated. During the years ended December&#160;31, 2021 and 2020, the Company paid the scientific founder $0.1 million and $0.2 million, respectively. As of December&#160;31, 2021 and 2020, the Company had less than $0.1 million in accounts payable to this scientific founder.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559130660680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition and the accrual of research and development expenses. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk and of significant suppliers</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk and of significant suppliers</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. As of December&#160;31, 2021, the Company maintained cash, cash equivalents and marketable securities at financial institutions in excess of federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies, and expects to continue to rely, on a small number of vendors to provide services, supplies and materials for certain activities related to its programs. These programs could be adversely affected by a significant interruption in these services or the availability of materials.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash equivalents</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash equivalents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketable securities are classified as&#160;available-for-sale&#160;and are carried at fair value with the unrealized gains and losses reported as a component of accumulated other comprehensive loss in stockholders&#8217; equity. Realized gains and losses and declines in value judged to be other than temporary are included as a component of interest income and other income (expense), net based on the specific identification method. The Company classifies its marketable securities with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities are available for current operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted cash</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in restricted cash represent amounts pledged as collateral for letters of credit required for security deposits on the Company&#8217;s leased facilities and credit cards. These amounts are classified as restricted cash in the Company&#8217;s consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shorter of useful life or remaining term of lease</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs for capital assets not yet placed into service are depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of long-lived assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its long-lived assets, which consist primarily of property and equipment and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company did not record any impairment losses on long-lived assets during the years ended December&#160;31, 2021 or 2020.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair value measurements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2&#8212;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see Note&#160;3). The carrying values of the Company&#8217;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities. The carrying value of the Company&#8217;s long-term debt approximates its fair value (a level 2 measurement) due to its variable interest rate.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Collaboration Agreements and Revenue recognition</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Collaboration Agreements</span></div><div style="margin-top:6pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ASC 808) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.  When the Company has concluded that it has a customer relationship with one of its collaborators the Company follows the guidance in ASC Topic 606,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> Revenue From Contracts With Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (&#8220;ASC 606&#8221;).</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its two collaboration arrangements under ASC 606 as the Company concluded that it has a customer relationship with each of its collaborators. For additional information on the Company&#8217;s collaboration agreements, see Note 9,&#160;Collaboration&#160;Agreements, to these consolidated financial statements. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the goods or services promised within each contract and determines those that are performance obligations. The promised goods or services in the Company&#8217;s arrangements would likely consist of licenses, rights to the Company&#8217;s intellectual property, research and development services and related supporting activities. Arrangements that include rights to additional goods or services that are exercisable at a customer&#8217;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)&#160;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii)&#160;the entity&#8217;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#8220;SSP&#8221;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company&#160;re-evaluates&#160;the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative&#160;catch-up&#160;basis in the period of adjustment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which the royalty has been allocated has been satisfied.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded for deferred revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised goods or services to the customer and the payment by the customer will be one year or less. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based on the use of an output or input method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, and external costs of vendors engaged to conduct research, preclinical and clinical development activities as well as the cost of licensing technology.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments and milestone payments made for the licensing of technology are expensed as research and development over the period to which they relate. Costs for research and development activities are expensed in the period in which they are incurred. Payments for such activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense. Determining the prepaid and accrued balances at the end of any reporting period incorporate certain judgments and estimates by management that are based on information available to the Company including information provided by vendors regarding the progress to completion of specific tasks or costs incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizationOfInternalCostsPolicy', window );">Patent costs</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC&#160;842,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#8217;s economic benefits. The Company determines if an arrangement is a lease or contains an embedded lease at inception. For arrangements that meet the definition of a lease, the Company determines the initial classification and measurement of its right-of-use asset and lease liability at the lease commencement date and thereafter if modified. The lease term includes any renewal options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term. The Company&#8217;s policy is to not record leases with an original term of twelve months or less on its consolidated balance sheets and recognizes those lease payments in the income statement on a straight-line basis over the lease term. The Company&#8217;s existing leases are for office and laboratory space and an equipment lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to rent, the leases may require the Company to pay additional costs, such as utilities, maintenance and other operating costs, which are generally referred to as non-lease components. The Company has&#160;elected to not separate lease and non-lease components. Only the fixed costs for lease components and their associated non-lease components are accounted for as a single lease component and recognized as part of a right-of-use asset and liability. Rent expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based compensation</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures stock options with service-based vesting or performance-based vesting granted to employees, non-employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. The Company measures restricted common stock awards using the difference between the purchase price per share of the award, if any, and the fair value of the Company&#8217;s common stock at the date of grant. Compensation expense for the awards is recognized over the requisite service period for employees and directors and as services are delivered for non-employees, both of which are generally the vesting period of the respective award. The Company uses the straight-line method to record the expense of awards with only service-based vesting conditions. The Company uses the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing once achievement of the performance condition becomes probable. The Company&#160;accounts for forfeitures of share-based awards as they occur.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net loss per share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing net income(loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, adjusted for potential dilutive common shares.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s participating securities contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reported a net loss, such losses were not allocated to such participating securities. In periods in which the Company reported a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an entity for which separate discrete financial information is made available and that is regularly evaluated by the chief operating decision maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The Company&#8217;s CODM is its chief executive officer and the Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company is focused on pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive loss</a></td>
<td class="text">Comprehensive lossComprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. For the year ended December&#160;31, 2021 and 2020, the Company&#8217;s only element of other comprehensive loss was unrealized losses on available for sale debt securities.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to the provision for income taxes. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. Any resulting unrecognized tax benefits are recorded within the provision for income taxes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i)&#160;irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii)&#160;no longer qualifies as an emerging growth company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No.&#160;2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses (Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;The new standard adjusts the accounting for assets held at amortized costs basis, including marketable securities accounted for as available for sale.&#160;The standard eliminates the probable initial recognition threshold and requires an entity to reflect its current estimate of all expected credit losses.&#160;The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For public entities, the guidance was effective for annual reporting periods beginning after December&#160;15, 2019 and for interim periods within those fiscal years. For nonpublic entities and emerging growth companies that choose to take advantage of the extended transition period, the guidance is effective for annual reporting periods beginning after December&#160;15, 2020. Early adoption is permitted for all entities. In November 2019, the FASB issued ASU No.&#160;2019-10, which deferred the effective date for nonpublic entities to annual reporting periods beginning after December&#160;15, 2022, including interim periods within those fiscal years. The Company is evaluating when to adopt this standard and the effect the adoption will have on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizationOfInternalCostsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for capitalizing internal costs associated with exploration and production activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 360<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123726384&amp;loc=d3e516343-122869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123726172&amp;loc=d3e511914-122862<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizationOfInternalCostsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559133742904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment are Stated at Cost Less Accumulated Depreciation and Amortization</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shorter of useful life or remaining term of lease</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">815&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">815&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,059&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,961&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets not yet placed in service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,893&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,631&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,563&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,528&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Earnings Per Share Diluted Anti Dilutive Impact</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,920,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,016,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,445&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,445&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,938,954&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,034,905&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559137548648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Available for Sale Marketable Securities By Security Type</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, available for sale marketable securities by security type consisted of (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper (due within one year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds (due within one year)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,917&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,910&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,163&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,153&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, available for sale marketable securities by security type consisted of (in thousands):</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury notes (due within one year)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,982&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,975&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Company&#8217;s fair value hierarchy for its assets and liabilities, which were measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at<br/>December 31, 2021 Using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash equivalents:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,496&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,496&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,243&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,243&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82,252&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,649&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153,901&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value Measurements at<br/>December 31, 2020 Using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:31.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:31.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,997&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,997&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:31.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. treasury notes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,975&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,975&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,770&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135,972&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184,742&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559133741496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Sumary of Property and Equipment Net</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment and software</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shorter of useful life or remaining term of lease</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">815&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">815&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,059&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,961&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets not yet placed in service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,893&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,631&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,330)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,563&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,528&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559136386088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Table)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued tenant improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,385&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued external research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">495&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">979&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,562&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,161&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559136423000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Summary of Long Term Debt</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amount of long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion of long-term debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final payment fee</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt discount, net of accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,346)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, net of discount and current portion</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,654&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559138548504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options and Restricted Stock Awards using Black-Scholes Option Pricing Model</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted during the years ended December&#160;31, 2021 and 2020 which was as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.1</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share Option Activity</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s option activity during the year ended December&#160;31, 2021 which was as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,016,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,719,563&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(508,774)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(306,740)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,920,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest as of December 31, 2021</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,920,509&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.9</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88,720&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercisable as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,435,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense related to common stock options and restricted common stock in the following expense categories of its consolidated statements of operations and comprehensive loss during the years ended December&#160;31, 2021 and 2020 which was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,724&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,060&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,237&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,384&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,961&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559134267944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Reconciliation of the U.S. federal statutory income tax rate to the Company's effective income tax rate</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate was as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal statutory income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State taxes, net of federal benefit</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state research and development tax credits</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in deferred tax asset valuation allowance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective income tax rate</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Net Deferred Tax Assets</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss carryforwards</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,083&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,289&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development tax credit carryforwards</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized start-up costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,403&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">436&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax assets</span></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93,262&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62,896&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,551)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,819)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,694)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax liabilities</span></div></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,117)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,513)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79,145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets</span></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559138556616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Cost and Lease Details</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense was as follows for the years ended December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,547&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,439&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,310&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental disclosure of cash flow information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities arising from obtaining right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,306&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increase in operating lease liabilities and right-of-use assets due to lease remeasurement</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining lease term and discount rate was as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8212;operating leases (in years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8212;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Minimum Lease Payments</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual minimum lease payments under operating leases as of December&#160;31, 2021 was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,051&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,626&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,705&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,802)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: estimated lease incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,461)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating lease liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,332&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_LeasesBalanceSheetLocationTableTextBlock', window );">Balance Sheet Location</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Included in the consolidated balance sheets (in thousands):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,332&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_LeasesBalanceSheetLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of operating lease liabilities included in the consolidated balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_LeasesBalanceSheetLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559130163016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 10, 2021</div></th>
<th class="th"><div>Nov. 19, 2020</div></th>
<th class="th"><div>Oct. 27, 2020</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_ProceedsFromUpfrontPayment', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101,320)<span></span>
</td>
<td class="num">$ (68,800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264,256<span></span>
</td>
<td class="nump">$ 162,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fhtx_EliLillyMember', window );">Eli Lilly | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_ProceedsFromUpfrontPayment', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares new issues shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock consideration received on the transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares new issues shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock consideration received on the transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares new issues shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">951,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock consideration received on the transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option | Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares new issues shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">951,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock consideration received on the transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=fhtx_SharePurchaseAgreementMember', window );">Share Purchase Agreement | Eli Lilly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share (in dollars per share)</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock consideration received on the transaction</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=fhtx_SharePurchaseAgreementMember', window );">Share Purchase Agreement | Eli Lilly | Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock consideration received on the transaction</a></td>
<td class="nump">$ 42,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_ProceedsFromUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from upfront payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_ProceedsFromUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fhtx_EliLillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fhtx_EliLillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=fhtx_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=fhtx_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559130523912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_NumberOfCollaborativeAgreements', window );">Number of collaborative agreements | agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses on long-lived assets | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_NumberOfCollaborativeAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Collaborative Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_NumberOfCollaborativeAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559136759752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Property and Equipment are Stated at Cost Less Accumulated Depreciation and Amortization (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559135123304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Earnings Per Share Diluted Anti Dilutive Impact (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">5,938,954<span></span>
</td>
<td class="nump">5,034,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">5,920,509<span></span>
</td>
<td class="nump">5,016,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">18,445<span></span>
</td>
<td class="nump">18,445<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559136636232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Summary of Available for Sale Marketable Securities By Security Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 53,163<span></span>
</td>
<td class="nump">$ 92,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">53,153<span></span>
</td>
<td class="nump">92,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper (due within one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">36,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">36,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes and bonds (due within one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">16,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 16,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. treasury notes (due within one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,975<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559131509480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 53,153<span></span>
</td>
<td class="nump">$ 92,975<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">82,252<span></span>
</td>
<td class="nump">48,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">71,649<span></span>
</td>
<td class="nump">135,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">153,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">36,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">16,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">82,252<span></span>
</td>
<td class="nump">48,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">18,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | U.S. treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">82,252<span></span>
</td>
<td class="nump">48,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">36,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">16,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | U.S. treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">18,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | U.S. treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559134001592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Property and Equipment Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 22,893<span></span>
</td>
<td class="nump">$ 21,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(5,330)<span></span>
</td>
<td class="num">(2,103)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, net</a></td>
<td class="nump">17,563<span></span>
</td>
<td class="nump">19,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="nump">4,889<span></span>
</td>
<td class="nump">3,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="nump">815<span></span>
</td>
<td class="nump">815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="nump">17,059<span></span>
</td>
<td class="nump">16,961<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fhtx_AssetsNotYetPlacedInServiceMember', window );">Assets not yet placed in service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=fhtx_AssetsNotYetPlacedInServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=fhtx_AssetsNotYetPlacedInServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559136382104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 3,227<span></span>
</td>
<td class="nump">$ 1,327<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559134323576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee compensation and benefits</a></td>
<td class="nump">$ 5,596<span></span>
</td>
<td class="nump">$ 3,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_AccruedTenantImprovements', window );">Accrued tenant improvements</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">2,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_AccruedResearchAndDevelopmentExpenses', window );">Accrued external research and development expenses</a></td>
<td class="nump">3,079<span></span>
</td>
<td class="nump">2,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">495<span></span>
</td>
<td class="nump">979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">379<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 9,562<span></span>
</td>
<td class="nump">$ 9,161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for expenses related to research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_AccruedTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Tenant Improvements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_AccruedTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559135348888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable - Summary of Long Term Debt (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 19, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Notes payable, net of discount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19,654,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fhtx_TermLoanAMember', window );">Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Notes payable, net of discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Final payment fee</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount, net of accretion</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,346,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of discount and current portion</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19,654,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fhtx_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fhtx_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559131641448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 19, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,200,000)<span></span>
</td>
<td class="num">$ (1,233,000)<span></span>
</td>
<td class="num">$ (222,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Debt, weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fhtx_TermLoanAMember', window );">Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">7.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage', window );">Debt, final payment fee percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, number of securities called by warrants or rights (in shares)</a></td>
<td class="nump">18,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_WarrantsIssuePricePerShare', window );">Warrants Issue price per share (in dollars per share)</a></td>
<td class="nump">$ 16.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants not settlable in cash, fair value disclosure</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of loan</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fhtx_TermLoanAMember', window );">Term Loan A | Prepayment Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_PercentageOfPrepaymentFee', window );">Percentage of prepayment fee</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fhtx_TermLoanAMember', window );">Term Loan A | Prepayment Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_PercentageOfPrepaymentFee', window );">Percentage of prepayment fee</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fhtx_TermLoanAMember', window );">Term Loan A | Prepayment Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_PercentageOfPrepaymentFee', window );">Percentage of prepayment fee</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fhtx_TermLoanAMember', window );">Term Loan A | Maximum | Prepayment Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_PrepaymentPeriod', window );">Prepayment period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fhtx_TermLoanAMember', window );">Term Loan A | Maximum | Prepayment Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_PrepaymentPeriod', window );">Prepayment period</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fhtx_TermLoanAMember', window );">Term Loan A | Minimum | Prepayment Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_PrepaymentPeriod', window );">Prepayment period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fhtx_TermLoanAMember', window );">Term Loan A | Minimum | Prepayment Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_PrepaymentPeriod', window );">Prepayment period</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fhtx_TermLoanBMember', window );">Term Loan B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_LineOfCreditAdditionalBorrowingCapacity', window );">Principal amount of long-term debt</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt, as a percentage of the amounts drawn under the Term Loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_LineOfCreditAdditionalBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Additional Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_LineOfCreditAdditionalBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_PercentageOfPrepaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee for prepayment of a loan, as a percentage of the principal amount being prepaid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_PercentageOfPrepaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_PrepaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_PrepaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_WarrantsIssuePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per unit amount of warrant issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_WarrantsIssuePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated over time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtWeightedAverageInterestRateOverTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fhtx_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fhtx_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_PrepaymentPeriodAxis=fhtx_PrepaymentPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_PrepaymentPeriodAxis=fhtx_PrepaymentPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_PrepaymentPeriodAxis=fhtx_PrepaymentPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_PrepaymentPeriodAxis=fhtx_PrepaymentPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_PrepaymentPeriodAxis=fhtx_PrepaymentPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_PrepaymentPeriodAxis=fhtx_PrepaymentPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fhtx_TermLoanBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fhtx_TermLoanBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559131572344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Dec. 10, 2021</div></th>
<th class="th"><div>Nov. 19, 2020</div></th>
<th class="th"><div>Oct. 27, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares new issues shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock consideration received on the transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares new issues shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock consideration received on the transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares new issues shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">951,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock consideration received on the transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option | Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during the period shares new issues shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">951,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock consideration received on the transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=fhtx_SharePurchaseAgreementMember', window );">Share Purchase Agreement | Eli Lilly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share (in dollars per share)</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock consideration received on the transaction</a></td>
<td class="nump">$ 80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares)</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=fhtx_SharePurchaseAgreementMember', window );">Share Purchase Agreement | Common&#160;Stock | Eli Lilly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock consideration received on the transaction</a></td>
<td class="nump">$ 42.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=fhtx_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=fhtx_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fhtx_EliLillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fhtx_EliLillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559130476776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Oct. 21, 2020</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of stock options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.40<span></span>
</td>
<td class="nump">$ 6.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Aggregate fair value of restricted stock that vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs related to unvested options and unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of unrecognized compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="nump">780,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Sale of restricted common stock to scientific founders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,459,459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fhtx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,271,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage', window );">Percentage of automatic annual increase in number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option expiry period (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fhtx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Incentive Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">1,651,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fhtx_A2016StockIncentivePlanMember', window );">2016 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,078,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fhtx_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage', window );">Percentage of automatic annual increase in number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares', window );">Maximum aggregate number of shares added to plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,220,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=fhtx_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">367,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of shares authorized to be automatically increased on the first day of the fiscal year, under a share based payment arrangement, as a percentage of common stock outstanding on the last day of the previous fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate number of shares that may be added to the plan in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fhtx_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fhtx_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fhtx_A2016StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fhtx_A2016StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fhtx_TwoThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fhtx_TwoThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559134208776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Weighted Average Assumptions Used to Estimate Fair Value of Stock Options and Restricted Stock Awards using Black-Scholes Option Pricing Model (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">78.80%<span></span>
</td>
<td class="nump">78.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559130444776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Share Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">5,016,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,719,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(508,774)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(306,740)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">5,920,509<span></span>
</td>
<td class="nump">5,016,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">5,920,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">2,435,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 4.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">15.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">2.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">10.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">7.88<span></span>
</td>
<td class="nump">$ 4.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">7.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options, exercisable (in dollars per share)</a></td>
<td class="nump">$ 3.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_WeightedAverageContractualTermAbstract', window );"><strong>Weighted Average Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 88,720<span></span>
</td>
<td class="nump">$ 76,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">88,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable</a></td>
<td class="nump">$ 46,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_WeightedAverageContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_WeightedAverageContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559134030152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense related to issuance of options and employee stock purchase plan</a></td>
<td class="nump">$ 8,384<span></span>
</td>
<td class="nump">$ 2,961<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense related to issuance of options and employee stock purchase plan</a></td>
<td class="nump">4,324<span></span>
</td>
<td class="nump">1,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense related to issuance of options and employee stock purchase plan</a></td>
<td class="nump">$ 4,060<span></span>
</td>
<td class="nump">$ 1,237<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559130974424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 10, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>target </div>
<div>program</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>target </div>
<div>program</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_ProceedsFromUpfrontPayment', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,319<span></span>
</td>
<td class="nump">$ 430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Collaboration receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,317<span></span>
</td>
<td class="nump">2,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember', window );">Scenario, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fhtx_EliLillyMember', window );">Eli Lilly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_NumberOfAdditionalTargets', window );">Number of additional targets | target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_NumberOfPrograms', window );">Number of programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_NumberOfTargets', window );">Number of targets | target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice', window );">Difference between fair value of shares and contract price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 337,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fhtx_EliLillyMember', window );">Eli Lilly | Share Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock consideration received on the transaction</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fhtx_EliLillyMember', window );">Eli Lilly | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_ProceedsFromUpfrontPayment', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fhtx_MerckMember', window );">Merck</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Unsatisfied portion of the performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Sales based</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_MilestoneReceivableUponAchievement', window );">Amount receivable for achievement of milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fhtx_ResearchDevelopmentAndRegulatoryMember', window );">Research Development And Regulatory | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_MilestoneReceivableUponAchievement', window );">Amount receivable for achievement of milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fhtx_ResearchDevelopmentAndRegulatoryMember', window );">Research Development And Regulatory | Maximum | Eli Lilly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_MilestoneReceivableUponAchievement', window );">Amount receivable for achievement of milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_OptOutMilestoneReceivableUponAchievement', window );">Amounts receivable for opt out milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fhtx_SalesBasedMilestoneMember', window );">Sales Based Milestone | Eli Lilly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_MilestoneReceivableUponAchievement', window );">Amount receivable for achievement of milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_OptOutMilestoneReceivableUponAchievement', window );">Amounts receivable for opt out milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference Between Fair Value OF Shares And Contractual Purchase Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_MilestoneReceivableUponAchievement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration to be received upon achievement of specified milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_MilestoneReceivableUponAchievement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_NumberOfAdditionalTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Additional Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_NumberOfAdditionalTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_NumberOfPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_NumberOfPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_NumberOfTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_NumberOfTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_OptOutMilestoneReceivableUponAchievement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Opt Out Milestone Receivable Upon Achievement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_OptOutMilestoneReceivableUponAchievement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_ProceedsFromUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from upfront payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_ProceedsFromUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fhtx_EliLillyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fhtx_EliLillyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=fhtx_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=fhtx_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fhtx_MerckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fhtx_MerckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fhtx_ResearchDevelopmentAndRegulatoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fhtx_ResearchDevelopmentAndRegulatoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fhtx_SalesBasedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fhtx_SalesBasedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559132087832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 30,800,000<span></span>
</td>
<td class="nump">$ 21,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forward</a></td>
<td class="nump">228,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss subject to expiration expiration</a></td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss without expiration</a></td>
<td class="nump">$ 216,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_OperatingLossCarryforwardLimitPercentage', window );">Operating loss carryforward limit percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry forward</a></td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forward</a></td>
<td class="nump">206,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry forward</a></td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_OperatingLossCarryforwardLimitPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The limit that may be applied to operating loss carryforwards, as a percentage of annual taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_OperatingLossCarryforwardLimitPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559135691704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Reconciliation of the U.S. federal statutory income tax rate to the Company's effective income tax rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="num">(5.80%)<span></span>
</td>
<td class="num">(6.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Federal and state research and development tax credits</a></td>
<td class="num">(4.40%)<span></span>
</td>
<td class="num">(3.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in deferred tax asset valuation allowance</a></td>
<td class="nump">30.40%<span></span>
</td>
<td class="nump">31.60%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559130547000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Net Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 61,083<span></span>
</td>
<td class="nump">$ 39,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">9,367<span></span>
</td>
<td class="nump">4,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_DeferredTaxAssetsCapitalizedStartUpCosts', window );">Capitalized start-up costs</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">5,300<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,403<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">15,952<span></span>
</td>
<td class="nump">17,032<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">93,262<span></span>
</td>
<td class="nump">62,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_DeferredTaxLiabilitiesDepreciation', window );">Depreciation</a></td>
<td class="num">(3,551)<span></span>
</td>
<td class="num">(2,819)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="num">(10,566)<span></span>
</td>
<td class="num">(11,694)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(14,117)<span></span>
</td>
<td class="num">(14,513)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">79,145<span></span>
</td>
<td class="nump">48,383<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_DeferredTaxAssetsCapitalizedStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capitalized start-up costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_DeferredTaxAssetsCapitalizedStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_DeferredTaxLiabilitiesDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_DeferredTaxLiabilitiesDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559133863608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">96 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2027 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jan. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 1,733<span></span>
</td>
<td class="nump">$ 1,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">38,516<span></span>
</td>
<td class="nump">42,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">58,332<span></span>
</td>
<td class="nump">62,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Future sublease income outstanding</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income recorded as other income</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember', window );">Office and Laboratory Space In Cambridge, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease term extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Reimbursements from lessor</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">$ 15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember', window );">Office and Laboratory Space In Cambridge, Massachusetts | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease rent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember', window );">Office and Laboratory Space In Cambridge, Massachusetts | Scenario, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fhtx_OfficeSpaceInCambridgeMassachusettsMember', window );">Office Space In Cambridge, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Lessor, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fhtx_AdditionalOfficeSpaceInCambridgeMassachusettsMember', window );">Additional Office Space In Cambridge, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of leased property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Office and Laboratory Space In Cambridge, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_LeaseholdImprovementsLandlordAllowance', window );">Leasehold improvements landlord allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_LeaseholdImprovementsLandlordAllowanceToBeRepaid', window );">Leasehold improvements landlord allowance to be repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_LeaseholdImprovementsLandlordAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The monetary allowance granted by the landlord to a tenant to entice tenant to move into landlord's building which will enable the tenant to prepare the leased premises for tenant's occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_LeaseholdImprovementsLandlordAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_LeaseholdImprovementsLandlordAllowanceToBeRepaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An additional monetary allowance granted by the landlord to a tenant to entice tenant to move into landlord's building which will enable the tenant to prepare the leased premises for tenant's occupancy. This additional amount will result in additional rent payments to the landlord.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_LeaseholdImprovementsLandlordAllowanceToBeRepaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fhtx_OfficeSpaceInCambridgeMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fhtx_OfficeSpaceInCambridgeMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fhtx_AdditionalOfficeSpaceInCambridgeMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=fhtx_AdditionalOfficeSpaceInCambridgeMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559136781032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 7,547<span></span>
</td>
<td class="nump">$ 7,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">2,892<span></span>
</td>
<td class="nump">1,217<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">$ 10,439<span></span>
</td>
<td class="nump">$ 8,310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559133734280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Supplemental Cash Flow Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 9,737<span></span>
</td>
<td class="nump">$ 3,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liabilities arising from obtaining right-of-use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">38,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement', window );">Increase in operating lease liabilities and right-of-use assets due to lease remeasurement</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,384<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the operating lease liability and right of use asset as the result of a lease remeasurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559136506712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term&#8212;operating leases (in years)</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate&#8212;operating leases</a></td>
<td class="nump">5.35%<span></span>
</td>
<td class="nump">5.35%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559130671608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Minimum Lease Payment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 9,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">10,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">10,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">10,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">10,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">19,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">71,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(11,802)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives', window );">Less: estimated lease incentives</a></td>
<td class="num">(1,461)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 58,332<span></span>
</td>
<td class="nump">$ 62,342<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated lease incentives used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559133769032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">$ 6,994<span></span>
</td>
<td class="nump">$ 3,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">51,338<span></span>
</td>
<td class="nump">58,361<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 58,332<span></span>
</td>
<td class="nump">$ 62,342<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559137567048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Stanford License Agreement - Maximum<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jul. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_AnnualLicenseMaintenanceFees', window );">Annual license maintenance fees</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_MilestonesPayableUponEvent', window );">Milestones payable upon event</a></td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_AnnualLicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual license maintenance fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_AnnualLicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_MilestonesPayableUponEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount the Company will pay for regulatory milestones on each licensed product upon the occurrence of specific events as outlined in the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_MilestonesPayableUponEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fhtx_StanfordLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fhtx_StanfordLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140559133834984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_ServiceAgreementRenewalTerm', window );">Service agreement renewal term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_CashPaymentsRelatedParty', window );">Payments made to related party under service agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_ServiceAgreementTerm', window );">Service agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_CashPaymentsRelatedParty', window );">Payments made to related party under service agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Scientific Founder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=fhtx_FlagshipPioneeringMember', window );">Flagship Pioneering | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fhtx_ServiceAgreementTerm', window );">Service agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_CashPaymentsRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments made during the period to related parties as part of a service or consulting agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_CashPaymentsRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_ServiceAgreementRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Service Agreement Renewal Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_ServiceAgreementRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fhtx_ServiceAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The term of a service agreement in 'PnYnMnDTnHnMnS' format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fhtx_ServiceAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fhtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=fhtx_ScientificFounderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=fhtx_ScientificFounderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=fhtx_FlagshipPioneeringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=fhtx_FlagshipPioneeringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>fhtx-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:fhtx="http://www.foghorntx.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="fhtx-20211231.xsd" xlink:type="simple"/>
    <context id="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2f6e00ec5e724389b05915a0622249e4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2f120daef0e24742bb1b5aace13d4d8f_I20220225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
        </entity>
        <period>
            <instant>2022-02-25</instant>
        </period>
    </context>
    <context id="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id7943cc4a71f4b42b53e4c968843494e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5c744d00941d4c199a48d89ffa755b17_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i81de0ee0ccd449989132fa7f14079ba5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iac30a123b0694acb8d72a14f63dac021_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i406407ac43db40d493cf8d79d3921779_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie0edcb140d2049a79c39501d27f139b9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6f685775719843b4a9fff30dabdaf80a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie54f7d4fc8034f45ba6d2e439e5ab48d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icfaabe46efdf4e258762c5f4b7e852b8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i810a9ddbdca940e9b925b274aa1a2543_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if047b911bba14fcf9c9ca20f03db2aa3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i392fd42774c3426791748c8100a4fdd2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib04b5ec0aee746bcaee20b310c94a839_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i755b66d1c0514ffabb5b047a0580e000_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6202585c1f594c04828ca33622ba9f73_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic897dfc3ee8d4be5958083cf9a26f3cf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b60e82482b4491fbaf024954d547c32_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if1da796dda74428196d7005b876d4506_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6dc13b3584f4e4aa450e4760484cf39_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8f78ce619e064ea1b1cdd9e493e462f3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i70fb1b2bd2ea46e881f0145ac62c2a0f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i92d1d123424f44d994d5af3872acb232_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fhtx:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i43038a8d4df843809b6e00244fcfc5f2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fhtx:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i08a673dfc57842d19a4fc0a035015adb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fhtx:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if661fd7abbb84486820d9146f777241d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1fb4ee0936c34d9094e17460190a277a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if28ce271ce7648a08119c449c9d2ef48_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d7cb7123c0e44e095d8223cbcd8af1b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6fadfcdbc6314b66a0e9d9a4c9ad038c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e7fbab3102f466f9aa8f20c9c5e38d5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c1033134ae74e0a98b856d174a6a6f8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f0e298f4e244829a4cc21bc741d457b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">fhtx:ConversionOfRedeemableConvertibleStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5fbf615bd0c04b61a3e8c3c5584de518_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">fhtx:ConversionOfRedeemableConvertibleStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iff300de84591401db5d227d7c7cf9dac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">fhtx:ConversionOfWarrantLiabilityToEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i59f4c12202e9485c860f841d498aebdb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">fhtx:ConversionOfWarrantLiabilityToEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7bd62dcf817f4d0eb46e515f34977c6b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">fhtx:ConversionOfNotesPayableInToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia3f9b42353f44a458f9f2c68c488eaac_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">fhtx:ConversionOfNotesPayableInToWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic61be130c3e94434a1523a709ee82e84_D20201027-20201027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-27</startDate>
            <endDate>2020-10-27</endDate>
        </period>
    </context>
    <context id="icd065cf6469a49619232b52c4f78a47a_I20201027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-27</instant>
        </period>
    </context>
    <context id="i8c5b1d5196b546fcadb8c83231e484ed_D20201119-20201119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-19</startDate>
            <endDate>2020-11-19</endDate>
        </period>
    </context>
    <context id="i598749ee432f4d19b443963f60801a17_I20201119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-19</instant>
        </period>
    </context>
    <context id="iabf346f1d20b4fbab0cb034770c8cc7b_D20211210-20211210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fhtx:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-10</startDate>
            <endDate>2021-12-10</endDate>
        </period>
    </context>
    <context id="i7545d56c585441a18935d61361a1f6e3_I20211210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fhtx:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-10</instant>
        </period>
    </context>
    <context id="i146aef1b1a8a405cb503481b39bfb902_D20211210-20211210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fhtx:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-10</startDate>
            <endDate>2021-12-10</endDate>
        </period>
    </context>
    <context id="i25bd4e2b11bf41efbe5fc4e9eae184b7_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i1c4d412c57184ef2b09b93a7922fec1d_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="ic066e702d698456487c1fe09f0556f0f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6459962b97414cb4941639768c219ba0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6bc48e6cb48142b59aba9858f119acab_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5f7bc146064d4609a9384b2c32e30608_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i34e7f6a206ae4fca9926a2b3693a2e1c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i12a1c8269d8549d6bdfd75792c409c5d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id03aeb4309314c119fa838863de75a16_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6cd2aa71baa24133bcddefb5ee9ce9b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4b216a3565b64982af2832ed92b1f204_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id955de6cd1884e8185138e0750ec2ab3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if906371b919e4edb9cbaff3349db1e5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff3838f509af4f0eb1680ed5f138763c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaac48c4990fc4b23a98caf4dc0c46472_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i79d6f505bd7d40d1ab1326d0b0e8b296_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if0e25902efa14d8496dbe8fa31ab5e18_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i111a519d6a244546ae0ab2247e929789_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i444925a451b6462ba584afd5c61d43e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0ef2f7d5ec4b41adb5e4a6ef1777b997_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i968a33b0579d40f3b45433f682345851_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i537352e60a9a414692e0f7409da18813_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id2e7eba7312d4e0fba240bde0d9c1bc9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6823127af8d34669a2caa57eb496dd2d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i76a6b50908b44d00a55838e4e1cf7176_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad91834ab15d489cb8484081982f739d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ef90d0c133b4dc09242b27430fb6c83_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia8bcbd3ea5e74155b41c0255c7c0e7a8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib653dca791b64896a08cfb7a0e8446f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i62bc1b90709641e48c8ee1248e2a2be0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7a8cdf58951489cbce902c6026e0d71_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie7581f3ffb0042c59c5d8ca5c9d3c495_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibeb58fd86d1241b285fe06e0d3d62da7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia0ceb8decc8347719a807b233cf323cf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7eededd25783411791223767f68f1740_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8c2443787a9a4bf6899e62de8792aabb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id674ecc28e6a4bec8492a5fad8e88241_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9007fd1a6c114c2f9092e78360752927_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d5b943b47404b9796a02f5deed9fa6d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic7c250fe5eb94135b9cb46d4e2a2fe65_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6936f6623d364d4e855208a92198fbff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic48fe4ed0446401abf189c47fbf5e947_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic45ad783abc94d60b6f3fc8c8900675f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8bb1cd7498940d3ba6558a5b1f34d14_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b088f5892d84a34a7cfbb1478042496_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6365a0687d1a4e38b300cbff88436f8c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0e14f625a75f45c0be3dc94d6442301d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic737047ef5ac46948883230a983a17e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i85f5b7fcbcc1494d82b2b6edf8a4eec6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic38f6e8e2292491e90c063c6222b2448_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i26b8aecd6a1c435bb0da7145cba274e6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb18b30cf22f4a32bb4ff93620162dda_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife30eeb6debd49f9a9e6eaccb2f6d4f6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id0f5fafdc67546f5aec4e0ce4e1aaa67_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i57e5da0015844088ba86122ad60975f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if936930eb6674b98aa88bbc4b5ff6632_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fhtx:AssetsNotYetPlacedInServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8ae945c2f65f4ae1b715fa4120b4b25e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">fhtx:AssetsNotYetPlacedInServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i69208d809b134811a688e3aaa1b56f5f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic63ca5a8620e4354a23fe4fb65d45904_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib49c41bde7e24d5eb853d157bd015ed2_I20201119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-19</instant>
        </period>
    </context>
    <context id="i5ec8f3ca08b54640bf525807c9358e0b_I20201119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-19</instant>
        </period>
    </context>
    <context id="i8b0e0ca6351c413a82a3c23dea9a45aa_D20201119-20201119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-19</startDate>
            <endDate>2020-11-19</endDate>
        </period>
    </context>
    <context id="ib3a33598e6e946e8956a704040d5cd66_D20201119-20201119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="fhtx:PrepaymentPeriodAxis">fhtx:PrepaymentPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-19</startDate>
            <endDate>2020-11-19</endDate>
        </period>
    </context>
    <context id="i308a28a242364292959d00dffcc81a50_D20201119-20201119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="fhtx:PrepaymentPeriodAxis">fhtx:PrepaymentPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-19</startDate>
            <endDate>2020-11-19</endDate>
        </period>
    </context>
    <context id="if15ca8afdf684493a8630928aba61256_D20201119-20201119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="fhtx:PrepaymentPeriodAxis">fhtx:PrepaymentPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-19</startDate>
            <endDate>2020-11-19</endDate>
        </period>
    </context>
    <context id="i2a4208db8c414f878b2487dcb43e458b_D20201119-20201119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="fhtx:PrepaymentPeriodAxis">fhtx:PrepaymentPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-19</startDate>
            <endDate>2020-11-19</endDate>
        </period>
    </context>
    <context id="i3c238b9ea3134f76bd3f9653c8e95195_D20201119-20201119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="fhtx:PrepaymentPeriodAxis">fhtx:PrepaymentPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-19</startDate>
            <endDate>2020-11-19</endDate>
        </period>
    </context>
    <context id="ibda01586c8f04185951a0c2fc97552f9_D20201119-20201119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="fhtx:PrepaymentPeriodAxis">fhtx:PrepaymentPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-19</startDate>
            <endDate>2020-11-19</endDate>
        </period>
    </context>
    <context id="i1d753a4861b4455884ca55cfae0bfb8a_D20201119-20201119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fhtx:TermLoanAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="fhtx:PrepaymentPeriodAxis">fhtx:PrepaymentPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-19</startDate>
            <endDate>2020-11-19</endDate>
        </period>
    </context>
    <context id="i5a5c869b237944468340c8ac74252d01_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i200e1e33978e497897a00efb7d79afa3_D20201027-20201027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-27</startDate>
            <endDate>2020-10-27</endDate>
        </period>
    </context>
    <context id="i994acb4549c24113977b0c0609947658_I20201027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-27</instant>
        </period>
    </context>
    <context id="i14dfffaa2d514c159c93b8d68536b5ba_D20201119-20201119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-19</startDate>
            <endDate>2020-11-19</endDate>
        </period>
    </context>
    <context id="i642c088ef7d642369dbab1bad144e018_I20201119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-19</instant>
        </period>
    </context>
    <context id="id726ec1ea7b74a18882e37d4c46d322d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fhtx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66c95f1c25a3420bb352629cf4f1de89_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fhtx:A2016StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib1f18e1cd74a4d7aaab2d0502973207a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fhtx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6b428a6c1acd40cf865512a4a620af6a_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fhtx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="i98cc31b8aad74865a5d00291d5e0a72c_I20201021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fhtx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-21</instant>
        </period>
    </context>
    <context id="i41b3935d055e4939a3944280d0f2de1e_D20201001-20201021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fhtx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-21</endDate>
        </period>
    </context>
    <context id="ia19ec2fabe1a4533bf2258db4754d4d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fhtx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i607096de8c294fdbb48bcd8c3b29b30e_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fhtx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="i6d95bd0fdd7e4e81bd6d70d4f7c1ca41_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i4582998cb4fb486daa23cdd87422567d_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i59b51c6004e744ce976e8146e0351d7b_D20160401-20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="ic0ad5b09bca848e28ffcaee3d672d862_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i12b80e675b334f9bb84e42822020fb90_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if52bb65557044014ad2e63a31d0a1950_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8d7a3942a9c94293aa8e8f466ced6118_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4ffb19f3c77426aa1c640fbfce74994_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibfef7b67aa6c4537931d0aa3b01c282e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b7a001271974fbf9927a5ce4c667237_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fhtx:ResearchDevelopmentAndRegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icf371cc8a9e24160bf8af37cf9d965e0_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:EliLillyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fhtx:SalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0598fb4888944458a105637a5c365acb_I20211201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-01</instant>
        </period>
    </context>
    <context id="i2dbcc6d4cd8b45da85ef3abc002c76e7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:EliLillyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i37050e2af73c4dfbbeb53cfcede910de_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fhtx:ResearchDevelopmentAndRegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia0fb78f785ab496ca56695669faf74b4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic857b04717ad4bdaa38f79139b0b4f77_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:MerckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92aabf8f84a443bb8049e24e529e50a6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:MerckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i26f27415158a4a8dad12c8e3b7e94178_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if6b2557e266749eca4da6aa9146a5588_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:MerckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie5dda4379bcf4779a73a8e6da786d5d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib1c22c57ec184fa7a48b0db8d9e9cbca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i462afb2928a44e61adc374bf4a44a35a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8566261f099345058fc2de53fdeddc94_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="ie777875661fd4e1cafd3e415514e3463_D20200101-20271231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2027-12-31</endDate>
        </period>
    </context>
    <context id="i88337b0a640c41778757a13053c6737c_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="i42cc5f4d622f43728d16d5f588e05289_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5df226eaed834b4d95b67a71f15df511_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5871025070284091b9843930b1b0739f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie9658936ddbd4496bb318be3e882b158_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="i1de98e2458194d09aea8ba3c1fbd59d9_I20200629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fhtx:OfficeAndLaboratorySpaceInCambridgeMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-29</instant>
        </period>
    </context>
    <context id="i51cd2ef8029b4e6eacda02334700de82_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fhtx:OfficeSpaceInCambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="ib0ecce1083f6481ead8d518a258a5e21_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">fhtx:AdditionalOfficeSpaceInCambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i3e3da7bbe9d045048732fcefce03b848_D20170731-20170731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fhtx:StanfordLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-31</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="ia71ec7897cbb4006827fd4c8d3854267_D20151001-20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">fhtx:FlagshipPioneeringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="i5382aa2bf08f43e88b67b99daf3dd99c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i75de76e7d13240f3891598dddc3f678b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4cc1a0a9e2cf453689f94cd708f119eb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0c734257926a48949b263d60cee94f38_D20151001-20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="i69d3730be48141eba19fe94753d20597_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="if2edac33103b46efba125b51d6b34c3f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6d894474bd8940b28bf453d051db226a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i273c56330b4b4f6abe4c85c7cd7fcd01_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001822462</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">fhtx:ScientificFounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="agreement">
        <measure>fhtx:agreement</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="target">
        <measure>fhtx:target</measure>
    </unit>
    <unit id="program">
        <measure>fhtx:program</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl80L2ZyYWc6NGZiZjhmZDg2YjFmNGZjODllYWQ0ZjJkMzI3ZmZjMjgvdGFibGU6Y2Y2ZGM5YzVlZTRkNDM0MDhiYzM1YTI2NjE5MGQ3NjMvdGFibGVyYW5nZTpjZjZkYzljNWVlNGQ0MzQwOGJjMzVhMjY2MTkwZDc2M18yLTEtMS0xLTA_1271a062-2685-473d-8d45-3ba56833bba0">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl80L2ZyYWc6NGZiZjhmZDg2YjFmNGZjODllYWQ0ZjJkMzI3ZmZjMjgvdGFibGU6Y2Y2ZGM5YzVlZTRkNDM0MDhiYzM1YTI2NjE5MGQ3NjMvdGFibGVyYW5nZTpjZjZkYzljNWVlNGQ0MzQwOGJjMzVhMjY2MTkwZDc2M180LTEtMS0xLTA_70ee12db-b408-45b0-af23-2a8183aad252">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl80L2ZyYWc6NGZiZjhmZDg2YjFmNGZjODllYWQ0ZjJkMzI3ZmZjMjgvdGFibGU6Y2Y2ZGM5YzVlZTRkNDM0MDhiYzM1YTI2NjE5MGQ3NjMvdGFibGVyYW5nZTpjZjZkYzljNWVlNGQ0MzQwOGJjMzVhMjY2MTkwZDc2M181LTEtMS0xLTA_193da678-87d6-426e-8359-bbf9624e8f12">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl80L2ZyYWc6NGZiZjhmZDg2YjFmNGZjODllYWQ0ZjJkMzI3ZmZjMjgvdGFibGU6Y2Y2ZGM5YzVlZTRkNDM0MDhiYzM1YTI2NjE5MGQ3NjMvdGFibGVyYW5nZTpjZjZkYzljNWVlNGQ0MzQwOGJjMzVhMjY2MTkwZDc2M183LTEtMS0xLTA_84639c82-b19c-46a1-97b1-7f8c5921c4a6">0001822462</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xNjQ5MjY3NDQ1Mzgy_7c6daacf-6b6a-4262-a94e-03b41e59686d">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6N2QxM2Y2NzEzODNkNGQ4MGEyYWRkMTljNzljMDQ3MzUvdGFibGVyYW5nZTo3ZDEzZjY3MTM4M2Q0ZDgwYTJhZGQxOWM3OWMwNDczNV8wLTAtMS0xLTIxMTA1_de0ca152-0558-4f0c-9aa6-a5462aa15c00">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xNjQ5MjY3NDQ1NDMy_959749ad-4b5d-4793-9a78-4dfc056d1098">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xNjQ5MjY3NDQ1NDMy_9794dc3f-6251-418e-8aec-c2c40f96f5e4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6Njk3YTljODg2YzBjNDEzN2E5ZGFiODk1ZTUxYTVkMzQvdGFibGVyYW5nZTo2OTdhOWM4ODZjMGM0MTM3YTlkYWI4OTVlNTFhNWQzNF8wLTAtMS0xLTIxMTE5_72fd969a-aa38-4f03-a60f-c33616f4dca1">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xNjQ5MjY3NDQ1NDQ0_c6740106-94ea-47ef-a068-fe363c78728c">001-39634</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xNjQ5MjY3NDQ1NDQ2_9b2d4ac3-5c31-4346-b5e4-6ae28fe8a701">Foghorn Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6NTI3YmIyODAwOWViNDAyNWE1OTQzNzEwYTYyNzZjN2YvdGFibGVyYW5nZTo1MjdiYjI4MDA5ZWI0MDI1YTU5NDM3MTBhNjI3NmM3Zl8wLTAtMS0xLTIxMTM4_ab1f20fc-51d4-49b4-9473-e2ac1416982e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6NTI3YmIyODAwOWViNDAyNWE1OTQzNzEwYTYyNzZjN2YvdGFibGVyYW5nZTo1MjdiYjI4MDA5ZWI0MDI1YTU5NDM3MTBhNjI3NmM3Zl8wLTItMS0xLTIxMTQx_d7e4c5df-a51c-4b10-9a91-b3ee2e48fd74">47-5271393</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6NTI3YmIyODAwOWViNDAyNWE1OTQzNzEwYTYyNzZjN2YvdGFibGVyYW5nZTo1MjdiYjI4MDA5ZWI0MDI1YTU5NDM3MTBhNjI3NmM3Zl8zLTAtMS0xLTIxMTY5L3RleHRyZWdpb246YjU1MjAxNTFjZjk4NDc2ZjljZGZhMjJiODcxOGY1MGZfMTA5OTUxMTYyNzc4NDk_1195d4c0-1e1b-409c-a051-e01e30f069c2">500 Technology Square, Ste 700</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6NTI3YmIyODAwOWViNDAyNWE1OTQzNzEwYTYyNzZjN2YvdGFibGVyYW5nZTo1MjdiYjI4MDA5ZWI0MDI1YTU5NDM3MTBhNjI3NmM3Zl8zLTAtMS0xLTIxMTY5L3RleHRyZWdpb246YjU1MjAxNTFjZjk4NDc2ZjljZGZhMjJiODcxOGY1MGZfMTA5OTUxMTYyNzc4NjE_b66ad989-9079-4f16-9ed4-9ce496af57a8">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6NTI3YmIyODAwOWViNDAyNWE1OTQzNzEwYTYyNzZjN2YvdGFibGVyYW5nZTo1MjdiYjI4MDA5ZWI0MDI1YTU5NDM3MTBhNjI3NmM3Zl8zLTAtMS0xLTIxMTY5L3RleHRyZWdpb246YjU1MjAxNTFjZjk4NDc2ZjljZGZhMjJiODcxOGY1MGZfMTA5OTUxMTYyNzc4Nzc_6d9f2416-1eff-4aae-81e6-e10c9eb4a997">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6NTI3YmIyODAwOWViNDAyNWE1OTQzNzEwYTYyNzZjN2YvdGFibGVyYW5nZTo1MjdiYjI4MDA5ZWI0MDI1YTU5NDM3MTBhNjI3NmM3Zl8zLTItMS0xLTIxMTg4_4f65da7a-9c24-4d90-b11d-11f62559476e">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xMTU0NDg3MjA5NTQzMg_25a9cbc8-4f9d-4774-90f9-d4e052923ef7">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xMTU0NDg3MjA5NTQzNg_1838088d-6f12-4c20-bfea-272142666611">586-3100</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6OWI0MjQzYjk5NzVmNGFkODgzYWQ4MzkyNTk0NmU4NjQvdGFibGVyYW5nZTo5YjQyNDNiOTk3NWY0YWQ4ODNhZDgzOTI1OTQ2ZTg2NF8xLTAtMS0xLTIxMjA4_0bbd7b06-dbc5-4865-b4a9-18a55c8037f8">Common&#160;Stock,&#160;$0.0001&#160;Par&#160;Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6OWI0MjQzYjk5NzVmNGFkODgzYWQ4MzkyNTk0NmU4NjQvdGFibGVyYW5nZTo5YjQyNDNiOTk3NWY0YWQ4ODNhZDgzOTI1OTQ2ZTg2NF8xLTItMS0xLTIxMjA4_46b7cdf1-c738-4c39-833c-5c05d77a827d">FHTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6OWI0MjQzYjk5NzVmNGFkODgzYWQ4MzkyNTk0NmU4NjQvdGFibGVyYW5nZTo5YjQyNDNiOTk3NWY0YWQ4ODNhZDgzOTI1OTQ2ZTg2NF8xLTQtMS0xLTIxMjA4_e05cf969-0630-47e2-9947-27371176a4d9">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xMTU0NDg3MjA5NTQ5Mg_a3692ac9-f5f4-49e5-9773-4dc41a82a7a3">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xMTU0NDg3MjA5NTQ0Ng_36f08fa1-67a2-4162-8ba7-cd6810549c32">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xMTU0NDg3MjA5NTQ0Nw_97ea975f-2b42-48bc-b8a2-ce899cdf1ae6">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xMTU0NDg3MjA5NTQ0OA_1264a950-0b2c-49eb-8fea-9586844616c6">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6NTFlYzM2YTFhMGE2NDEyNTgwMTlhZDkwNDE1MzlmNTkvdGFibGVyYW5nZTo1MWVjMzZhMWEwYTY0MTI1ODAxOWFkOTA0MTUzOWY1OV8yLTAtMS0xLTIxMzE1_1c2f81d9-b8e1-4f01-bb18-87a40fabeb32">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6NTFlYzM2YTFhMGE2NDEyNTgwMTlhZDkwNDE1MzlmNTkvdGFibGVyYW5nZTo1MWVjMzZhMWEwYTY0MTI1ODAxOWFkOTA0MTUzOWY1OV8yLTQtMS0xLTIxMzE3_b29206c4-b0eb-465a-9d99-db8b6487a56c">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGFibGU6NTFlYzM2YTFhMGE2NDEyNTgwMTlhZDkwNDE1MzlmNTkvdGFibGVyYW5nZTo1MWVjMzZhMWEwYTY0MTI1ODAxOWFkOTA0MTUzOWY1OV80LTQtMS0xLTIxMzIx_1146f895-0b80-47de-9413-bbfdd8102a7f">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xMTU0NDg3MjA5NTQ0OQ_071ec36d-35cd-4aa9-a13a-76c836a1b2ce">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xMTU0NDg3MjA5NTQ1MA_0e8240fc-f11a-42d6-96de-a1dee6fe282f">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xMTU0NDg3MjA5NTQ1MQ_d1fa1652-11a3-44bd-8a4c-7966a68314b0">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i2f6e00ec5e724389b05915a0622249e4_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xMTU0NDg3MjA5NTQ1Mw_9fed4f7c-a0e3-485e-a33b-cac8182c39d5"
      unitRef="usd">208800000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i2f120daef0e24742bb1b5aace13d4d8f_I20220225"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xL2ZyYWc6ODRlNDVkNDk3ZTgxNDBmOWEyNTlhOWYzMDU4ZjYzMjUvdGV4dHJlZ2lvbjo4NGU0NWQ0OTdlODE0MGY5YTI1OWE5ZjMwNThmNjMyNV8xMTU0NDg3MjA5NTQ2OQ_44d01385-35f9-474e-9a2a-4c4baca6514a"
      unitRef="shares">41421964</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl82Ny9mcmFnOjc5ZGRlOGYyYTg4MjQwMzFiZmQzNDJlMTMwNzJhNWViL3RhYmxlOjEzODk1ZmY3OWVkZTRmZjFiMjM5NzNmYjM3ZmI3YmU3L3RhYmxlcmFuZ2U6MTM4OTVmZjc5ZWRlNGZmMWIyMzk3M2ZiMzdmYjdiZTdfMi0wLTEtMS0zMjkzOC90ZXh0cmVnaW9uOmU0ODljOWNjOGI3MTQyYzk5YjEwNmJhY2JhOTEyYWM0XzE2NDkyNjc0NDE3ODQ_e2ea8d0c-f181-4359-b6ed-22ca624d2ac8">34</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83MC9mcmFnOmRmYzI4MjI2YjQyMjQ1Mzk5Yjg3NzA5MjJlZjYyNTQ4L3RleHRyZWdpb246ZGZjMjgyMjZiNDIyNDUzOTliODc3MDkyMmVmNjI1NDhfMTc1OTIxODYwNDczNDY_6814db69-7d8f-46eb-a225-b51f1ce94f2c">Deloitte&#160;&amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83MC9mcmFnOmRmYzI4MjI2YjQyMjQ1Mzk5Yjg3NzA5MjJlZjYyNTQ4L3RleHRyZWdpb246ZGZjMjgyMjZiNDIyNDUzOTliODc3MDkyMmVmNjI1NDhfMTc1OTIxODYwNDczNDg_8b7c5234-f260-4d03-a715-ecaa90f00b3f">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfNC0xLTEtMS0w_5655adc3-783a-4105-b7eb-c31acbb49369"
      unitRef="usd">101136000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfNC0zLTEtMS0w_fb2534a0-55a4-475a-af93-f51e6b6c72bf"
      unitRef="usd">92795000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfNS0xLTEtMS0w_b897a558-57f6-4717-8bcc-9669f605498e"
      unitRef="usd">53153000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfNS0zLTEtMS0w_52659fd4-2065-4d4e-b577-4c1dbd5c842d"
      unitRef="usd">92975000</us-gaap:MarketableSecurities>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfNi0xLTEtMS0yNjAwOA_62216826-fe30-4db1-acca-891b7ab551b7"
      unitRef="usd">300000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfNi0zLTEtMS0yNjAwOA_309bcbc3-39a1-481b-b7a2-406c0bab37ed"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfNy0xLTEtMS0w_5b9aa672-18e0-4dcb-ac88-b36135267b7f"
      unitRef="usd">5273000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfNy0zLTEtMS0w_8feb4e4a-5da1-4ef0-91be-98d78c6449a1"
      unitRef="usd">4917000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfOC0xLTEtMS0w_5ae4f33a-2fa4-4742-a937-796cbb2d6f85"
      unitRef="usd">459562000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfOC0zLTEtMS0w_6f53f0f7-3170-49eb-b3b5-0b7004176085"
      unitRef="usd">190687000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfOS0xLTEtMS0w_6373f7c8-e7e5-441b-8669-ba69224373a2"
      unitRef="usd">17563000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfOS0zLTEtMS0w_de3b2452-45f9-46db-950b-4555bc9d9bd5"
      unitRef="usd">19528000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTAtMS0xLTEtMA_0f7e815f-6477-4b13-9b5b-eaaae27469a7"
      unitRef="usd">1733000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTAtMy0xLTEtMA_2252579c-bb8a-4a9b-aced-dcfdb6d1fc22"
      unitRef="usd">1733000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTEtMS0xLTEtMA_3d539ec2-e108-43a8-9891-f8b3a5fc5b20"
      unitRef="usd">2400000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTEtMy0xLTEtMA_fe1d2d70-6f22-4827-893c-5ff50f2e9084"
      unitRef="usd">842000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTItMS0xLTEtMA_fcac5920-f27f-4f19-949b-bfbae1381d7f"
      unitRef="usd">38516000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTItMy0xLTEtMA_4193a442-4b78-44f0-a024-d119c6a12865"
      unitRef="usd">42804000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTMtMS0xLTEtMA_206fbf18-e07d-44fd-be4d-e50a28938fe6"
      unitRef="usd">519774000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTMtMy0xLTEtMA_5a1e2790-23c6-44f6-b4a3-2eaecf42307b"
      unitRef="usd">255594000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTYtMS0xLTEtMA_083754ad-e7eb-4518-8437-2afcc7dc9f36"
      unitRef="usd">3819000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTYtMy0xLTEtMA_3a4c3407-9e87-4480-b9f7-6e6f8aff87b7"
      unitRef="usd">3680000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTctMS0xLTEtMA_07bae81c-a4c4-4999-b2b4-d5c2d934d7b7"
      unitRef="usd">9562000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTctMy0xLTEtMA_dd87f7d5-1beb-40b1-8175-057522b4f284"
      unitRef="usd">9161000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTgtMS0xLTEtMA_effa934e-01ba-4f14-964c-12cdce7a4ef4"
      unitRef="usd">6994000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMTgtMy0xLTEtMA_987b9e50-7ec4-4fd2-8553-b75f18d8fb9b"
      unitRef="usd">3981000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjAtMS0xLTEtMA_0d5da131-8236-49da-85fe-ce716e703760"
      unitRef="usd">28317000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjAtMy0xLTEtMA_a992b3e2-e48d-4bf7-8ad1-6589f2b7671c"
      unitRef="usd">2024000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjEtMS0xLTEtMA_0ceb6ff8-0d46-4a02-b824-d1af9a757be4"
      unitRef="usd">48692000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjEtMy0xLTEtMA_41824845-89a0-4e88-a834-16bb21754b4f"
      unitRef="usd">18846000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjItMS0xLTEtMA_44147cad-6265-40ff-b0a4-7fc097accaae"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjItMy0xLTEtMA_01350a13-7bf3-458d-9266-4f5925eaf1e2"
      unitRef="usd">19654000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjMtMS0xLTEtMA_f9f18a16-6f4e-4f29-86bc-408a27f836a3"
      unitRef="usd">51338000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjMtMy0xLTEtMA_e36c846d-23fe-4ae3-8d82-77217b9e90be"
      unitRef="usd">58361000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjQtMS0xLTEtMA_b68047ee-2f84-447f-9236-730ce7258894"
      unitRef="usd">322730000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjQtMy0xLTEtMA_6252a2b7-7bb5-4a45-a825-e6287bcfb108"
      unitRef="usd">12546000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjUtMS0xLTEtMA_da40edf0-01b2-41d8-b472-ba228ea4bdb4"
      unitRef="usd">143000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjUtMy0xLTEtMA_d2d8d7c5-d261-4bf4-aab9-9847e917d0e5"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjYtMS0xLTEtMA_471e5dc6-9aa5-48b7-aa80-f23e3c08c827"
      unitRef="usd">422903000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjYtMy0xLTEtMA_ea9c3c17-02d2-4105-8b54-01cfce44ac36"
      unitRef="usd">109407000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjctMS0xLTEtMA_fd25fb5f-b709-48da-a935-56d46b5e7c3b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMjctMy0xLTEtMA_b30a80a1-2ed0-40f5-804f-3e23cea0f825"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzAtMC0xLTEtMTk3ODcvdGV4dHJlZ2lvbjowYTBkOTRkODViMmI0MmQ4YmNiODZiNGJmNjExNzcwNV8xMTU0NDg3MjA5MTc4Mg_3d7df56c-d097-4312-8e03-2b8940b4bcd9"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzAtMC0xLTEtMTk3ODcvdGV4dHJlZ2lvbjowYTBkOTRkODViMmI0MmQ4YmNiODZiNGJmNjExNzcwNV8xMTU0NDg3MjA5MTc4Mg_90abc8df-90bc-4d98-b9db-876e33fd91d1"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzAtMC0xLTEtMTk3ODcvdGV4dHJlZ2lvbjowYTBkOTRkODViMmI0MmQ4YmNiODZiNGJmNjExNzcwNV8xMTU0NDg3MjA5MTc5Ng_1c172254-558b-4607-889a-f30b3e293920"
      unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzAtMC0xLTEtMTk3ODcvdGV4dHJlZ2lvbjowYTBkOTRkODViMmI0MmQ4YmNiODZiNGJmNjExNzcwNV8xMTU0NDg3MjA5MTc5Ng_e1c67916-ff09-4030-acac-327c9d83f0ca"
      unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzAtMC0xLTEtMTk3ODcvdGV4dHJlZ2lvbjowYTBkOTRkODViMmI0MmQ4YmNiODZiNGJmNjExNzcwNV8xMTU0NDg3MjA5MTgwMQ_2a52c8f9-61ec-48b2-afd0-387c775c1d47"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzAtMC0xLTEtMTk3ODcvdGV4dHJlZ2lvbjowYTBkOTRkODViMmI0MmQ4YmNiODZiNGJmNjExNzcwNV8xMTU0NDg3MjA5MTgwMQ_36ea4b76-40c5-4c33-bb9f-b5eb07f5b137"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzAtMC0xLTEtMTk3ODcvdGV4dHJlZ2lvbjowYTBkOTRkODViMmI0MmQ4YmNiODZiNGJmNjExNzcwNV8xMTU0NDg3MjA5MTgwMQ_8c61ed02-8183-4d1f-b27e-9d8c20ab364d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzAtMC0xLTEtMTk3ODcvdGV4dHJlZ2lvbjowYTBkOTRkODViMmI0MmQ4YmNiODZiNGJmNjExNzcwNV8xMTU0NDg3MjA5MTgwMQ_e45e7ba3-33d2-4384-8f20-add7e194c220"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzAtMS0xLTEtMA_343a114b-0a90-4719-a485-5389c8c4c314"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzAtMy0xLTEtMA_e4af596b-d8e0-4abd-a266-c2e9a2ad6d76"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzEtMC0xLTEtMTk3ODkvdGV4dHJlZ2lvbjowY2ZkNjdkZDBhOWY0ZTI1YmVmYjRiM2JiNWJlZDhhYV8xMTU0NDg3MjA5MTkyNg_62673b55-bbe7-4295-a844-c2e86bffc6ec"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzEtMC0xLTEtMTk3ODkvdGV4dHJlZ2lvbjowY2ZkNjdkZDBhOWY0ZTI1YmVmYjRiM2JiNWJlZDhhYV8xMTU0NDg3MjA5MTkyNg_c7bbe157-3859-44ef-923c-25e9e2abe426"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzEtMC0xLTEtMTk3ODkvdGV4dHJlZ2lvbjowY2ZkNjdkZDBhOWY0ZTI1YmVmYjRiM2JiNWJlZDhhYV8yMTk5MDIzMjU1OTQ4_232abc7b-c629-49a1-80d3-78fa39802cd3"
      unitRef="shares">175000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzEtMC0xLTEtMTk3ODkvdGV4dHJlZ2lvbjowY2ZkNjdkZDBhOWY0ZTI1YmVmYjRiM2JiNWJlZDhhYV8yMTk5MDIzMjU1OTQ4_ceaef7fb-0891-4e3c-a73c-3ce2c8f1e154"
      unitRef="shares">175000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzEtMC0xLTEtMTk3ODkvdGV4dHJlZ2lvbjowY2ZkNjdkZDBhOWY0ZTI1YmVmYjRiM2JiNWJlZDhhYV8xMTU0NDg3MjA5MTk1NA_1f4a4450-f4c7-4d33-8cf3-00027f0245a8"
      unitRef="shares">41299720</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzEtMC0xLTEtMTk3ODkvdGV4dHJlZ2lvbjowY2ZkNjdkZDBhOWY0ZTI1YmVmYjRiM2JiNWJlZDhhYV8xMTU0NDg3MjA5MTk1NA_ef5e722d-8859-4d0f-a3eb-263459f49ecc"
      unitRef="shares">41299720</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzEtMC0xLTEtMTk3ODkvdGV4dHJlZ2lvbjowY2ZkNjdkZDBhOWY0ZTI1YmVmYjRiM2JiNWJlZDhhYV8xMTU0NDg3MjA5MTk2Ng_8d1a9425-40fc-4642-b617-c9293eef8955"
      unitRef="shares">36790946</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzEtMC0xLTEtMTk3ODkvdGV4dHJlZ2lvbjowY2ZkNjdkZDBhOWY0ZTI1YmVmYjRiM2JiNWJlZDhhYV8xMTU0NDg3MjA5MTk2Ng_9a66bff7-b2f0-4572-8500-39f20e5a8c13"
      unitRef="shares">36790946</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzEtMS0xLTEtMA_5b9a5cf8-5d99-43a5-84c7-bc62cf243f26"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzEtMy0xLTEtMA_1e188a31-a9e0-4997-9cd9-faa44c3d0317"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzItMS0xLTEtMA_7c7487a3-6447-4f48-a71d-8dfdee9c3ed2"
      unitRef="usd">361133000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzItMy0xLTEtMA_b89b604e-b8ce-45c2-94a9-af322a93e941"
      unitRef="usd">309126000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzMtMS0xLTEtMA_b1f42f56-c29d-4449-bed3-dbc504cf8f75"
      unitRef="usd">-10000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzMtMy0xLTEtMA_65f10829-923c-4170-97a4-1dfba4256fbf"
      unitRef="usd">-7000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzQtMS0xLTEtMA_45d66511-8d95-4513-b0ea-ad008149fea8"
      unitRef="usd">-264256000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzQtMy0xLTEtMA_fa323953-485f-42dd-9692-5462a8a9f694"
      unitRef="usd">-162936000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzUtMS0xLTEtMA_7bf1f394-04ed-4fbc-a590-c8a97ac97a71"
      unitRef="usd">96871000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzUtMy0xLTEtMA_2b6be5fd-1969-4bd8-969e-83023898be40"
      unitRef="usd">146187000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzYtMS0xLTEtMA_642a708e-7d90-467b-845d-3cc3af11027e"
      unitRef="usd">519774000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83My9mcmFnOmIzMmQ5ZTg2YzYzZTQyMjhiOTNmZjA2MDM2YjczZDA0L3RhYmxlOmQwY2ViNmJiM2ViYzQxZmViNjU2YmZhNjA3ZDNjOWJhL3RhYmxlcmFuZ2U6ZDBjZWI2YmIzZWJjNDFmZWI2NTZiZmE2MDdkM2M5YmFfMzYtMy0xLTEtMA_1a3cc34f-9fb3-40c5-a854-4bd5b95608d4"
      unitRef="usd">255594000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMi0xLTEtMS0w_5fbdb857-c462-4264-b612-e39eea1d060a"
      unitRef="usd">1319000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMi0zLTEtMS0w_5b1e108d-ac20-42a6-8595-69036000fd6a"
      unitRef="usd">430000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfNC0xLTEtMS0w_686dd7d2-8e80-4996-a39f-a251980e383e"
      unitRef="usd">80325000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfNC0zLTEtMS0w_17e3fccf-a3aa-4b7a-9ad5-7d9db8ddd15f"
      unitRef="usd">57715000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfNS0xLTEtMS0w_78b9d087-5853-4e8a-9be9-536a62c8ac00"
      unitRef="usd">21728000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfNS0zLTEtMS0w_66f805cb-d0e1-45dc-a295-09239bb9683b"
      unitRef="usd">11246000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfNi0xLTEtMS0w_1aee3417-2611-4854-b4b6-4d3f1a9716be"
      unitRef="usd">102053000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfNi0zLTEtMS0w_672da23f-e018-47b6-be2c-6fe3194893ff"
      unitRef="usd">68961000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfNy0xLTEtMS0w_ddfde6a6-d287-40b6-96ec-ee3c66ea546a"
      unitRef="usd">-100734000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfNy0zLTEtMS0w_bd7f7f9e-531f-4971-9ef5-6f60b8bf1e7d"
      unitRef="usd">-68531000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfOS0xLTEtMS0w_1d767663-9148-4054-8436-7367e34d3719"
      unitRef="usd">1906000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfOS0zLTEtMS0w_8040b3f2-73ee-4d97-afe4-7e7c50a36d9e"
      unitRef="usd">979000</us-gaap:InterestExpense>
    <fhtx:InterestIncomeAndOtherIncomeExpense
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTAtMS0xLTEtMA_2921b5ca-3b39-4a6f-9dfe-0694955c426e"
      unitRef="usd">2553000</fhtx:InterestIncomeAndOtherIncomeExpense>
    <fhtx:InterestIncomeAndOtherIncomeExpense
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTAtMy0xLTEtMA_9a2955f5-7541-428d-af21-7177eaa68da8"
      unitRef="usd">1001000</fhtx:InterestIncomeAndOtherIncomeExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTEtMS0xLTEtMA_20992289-ce1a-45c9-909a-274b911ac297"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTEtMy0xLTEtMA_7729dee3-7726-4d2d-8fb5-d7ec2e689664"
      unitRef="usd">69000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTItMS0xLTEtMA_ceb686d0-e886-47e4-b57b-7b4d01cbc733"
      unitRef="usd">-1233000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTItMy0xLTEtMA_137a2977-7b0d-4529-b517-7ce75eea5805"
      unitRef="usd">-222000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTMtMS0xLTEtMA_5da7dbde-4373-4114-ad9c-2d2b68df6489"
      unitRef="usd">-586000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTMtMy0xLTEtMA_a01e3c5f-ef87-4bfd-bd89-425ce1a17954"
      unitRef="usd">-269000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTQtMS0xLTEtMA_84aac958-4322-4be2-a390-da7688ddd6f2"
      unitRef="usd">-101320000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTQtMy0xLTEtMA_61d2e38e-bfa5-4e9e-be56-faa65a7af4cf"
      unitRef="usd">-68800000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTUtMS0xLTEtMA_2e3595e5-117b-49a4-89c0-0d3cfc929b34"
      unitRef="usdPerShare">-2.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTUtMS0xLTEtMA_ae550761-afcf-4a28-8ebe-c071ed804c79"
      unitRef="usdPerShare">-2.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTUtMy0xLTEtMA_75a97f3a-6291-4aaa-8284-dffcaa69a2ac"
      unitRef="usdPerShare">-6.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTUtMy0xLTEtMA_ef81def3-bcd7-4fba-ad52-d136008996da"
      unitRef="usdPerShare">-6.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTYtMS0xLTEtMA_177d06eb-091e-431a-85ad-84b3a3eec6a8"
      unitRef="shares">37171147</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTYtMS0xLTEtMA_4ef62617-a131-4d74-88db-d06c5669d09b"
      unitRef="shares">37171147</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTYtMy0xLTEtMA_1d3964da-10ac-4c10-a756-3b21aba3610e"
      unitRef="shares">11046802</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTYtMy0xLTEtMA_588ca6d1-2f66-485f-910a-452bfc42ca68"
      unitRef="shares">11046802</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTgtMS0xLTEtMA_60af6cf4-3697-4734-ad14-d35748e232cc"
      unitRef="usd">-101320000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMTgtMy0xLTEtMA_7ebd8717-3f5a-4597-a1fb-1422591a13b5"
      unitRef="usd">-68800000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMjAtMS0xLTEtMA_9c3734c1-6713-42c1-8652-b13567f748bd"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMjAtMy0xLTEtMA_d26a3016-bdfa-476e-97b7-d3e09fd8647d"
      unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMjEtMS0xLTEtMA_44cfe2dc-0167-4c00-8452-4755f3b45e65"
      unitRef="usd">-3000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMjEtMy0xLTEtMA_97ffe409-9874-4eeb-b0db-2af0b6377505"
      unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMjItMS0xLTEtMA_2b6f1d42-3e35-41f0-ad88-340c0c65e3c8"
      unitRef="usd">-101323000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl83OS9mcmFnOjFkODU3Y2Q1MzBiNTQzOTNiMzIxZDZjNDUxYjE4MzUzL3RhYmxlOmI4M2NkMGVhNThhNTQ2OGQ5YjFlNjQ0MWVlMGFmZWExL3RhYmxlcmFuZ2U6YjgzY2QwZWE1OGE1NDY4ZDliMWU2NDQxZWUwYWZlYTFfMjItMy0xLTEtMA_61e9bdb8-569a-49d4-b5a6-f29c80dfe447"
      unitRef="usd">-68807000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="id7943cc4a71f4b42b53e4c968843494e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMi0xLTEtMS0yOTEzNg_12905e55-6961-4779-ad4d-df621492730d"
      unitRef="shares">28615546</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="id7943cc4a71f4b42b53e4c968843494e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMi0zLTEtMS0yOTEzNg_00cc3633-805e-4520-aee9-bdb10516156a"
      unitRef="usd">86544000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5c744d00941d4c199a48d89ffa755b17_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMi02LTEtMS0yOTEzNg_f6c54392-c6c5-43f7-8648-305b4e5bc837"
      unitRef="shares">4870851</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5c744d00941d4c199a48d89ffa755b17_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMi04LTEtMS0yOTkzNg_8e955c14-bc79-468e-aab7-94c331b23b5d"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i81de0ee0ccd449989132fa7f14079ba5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMi0xMC0xLTEtMjkxMzY_41df72ce-96bd-4bf1-b635-20d7454f79ed"
      unitRef="usd">6120000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac30a123b0694acb8d72a14f63dac021_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMi0xNC0xLTEtMjkxMzY_62d0ea26-26f6-4707-ac15-2fe978430e5c"
      unitRef="usd">-94136000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i406407ac43db40d493cf8d79d3921779_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMi0xNi0xLTEtMjkxMzY_d544dd52-900f-4d6a-8f02-243c845d947f"
      unitRef="usd">-88016000</us-gaap:StockholdersEquity>
    <fhtx:StockIssuanceCosts
      contextRef="ie0edcb140d2049a79c39501d27f139b9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMy0wLTEtMS0yOTU1MS90ZXh0cmVnaW9uOmFhNzhkNmZhMmUyNjRjY2Y4YWM2NTFmNDUwMTcxNjIxXzE2NDkyNjc0NDE3NTE_a777712b-ae13-43f7-b9a4-6a3cf03979dd"
      unitRef="usd">198000</fhtx:StockIssuanceCosts>
    <fhtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="ie0edcb140d2049a79c39501d27f139b9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMy0xLTEtMS0yOTA2OQ_de466229-1392-4dce-ab13-a6f430b32159"
      unitRef="shares">12007867</fhtx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="i6f685775719843b4a9fff30dabdaf80a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMy0zLTEtMS0yOTA2OQ_8eda4e27-c81d-4e47-97d8-e007e383c519"
      unitRef="usd">89861000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <fhtx:TemporaryEquityConversionOfStockSharesConverted
      contextRef="ie0edcb140d2049a79c39501d27f139b9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNC0xLTEtMS0yOTA2OQ_3fcda242-3999-49b0-a826-8795f621fb47"
      unitRef="shares">40623413</fhtx:TemporaryEquityConversionOfStockSharesConverted>
    <fhtx:TemporaryEquityConversionOfStockAmountConverted
      contextRef="i6f685775719843b4a9fff30dabdaf80a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNC0zLTEtMS0yOTA2OQ_8d2723c4-a2cc-4609-aae6-3ce14b8faf19"
      unitRef="usd">176405000</fhtx:TemporaryEquityConversionOfStockAmountConverted>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="ie54f7d4fc8034f45ba6d2e439e5ab48d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNC02LTEtMS0yOTA2OQ_a1742dd7-091c-4126-aa68-e358413a918a"
      unitRef="shares">21958588</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ie54f7d4fc8034f45ba6d2e439e5ab48d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNC04LTEtMS0yOTA2OQ_50202d57-cdc0-4516-bad7-bb160a31f1ec"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="icfaabe46efdf4e258762c5f4b7e852b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNC0xMC0xLTEtMjkwNjk_4b5faa8f-fad0-4d7b-9ed7-06120768737f"
      unitRef="usd">176402000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNC0xNi0xLTEtMjkwNjk_14fd3a2a-e1e4-47b3-8da9-a81bb803e151"
      unitRef="usd">176405000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i810a9ddbdca940e9b925b274aa1a2543_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNS02LTEtMS0yOTA2OQ_c2c7d947-2ce6-4a3f-8315-be553d484981"
      unitRef="shares">8451837</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i810a9ddbdca940e9b925b274aa1a2543_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNS04LTEtMS0yOTA2OQ_ffa6d3ef-8168-48c7-a64e-d179ba49470d"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if047b911bba14fcf9c9ca20f03db2aa3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNS0xMC0xLTEtMjkwNjk_a35e4673-7dab-4a6e-ab52-be15c3bd5898"
      unitRef="usd">122120000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i392fd42774c3426791748c8100a4fdd2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNS0xNi0xLTEtMjkwNjk_75997f6f-1c8b-4f91-862e-15c2313d3af1"
      unitRef="usd">122121000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="icfaabe46efdf4e258762c5f4b7e852b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNi0xMC0xLTEtMjkwNjk_db4737b4-4110-4705-8968-6efdc075c75b"
      unitRef="usd">114000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNi0xNi0xLTEtMjkwNjk_6ec04123-8ded-4ff9-b178-76c831764e30"
      unitRef="usd">114000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <fhtx:StockIssuedDuringPeriodConnectionWithExerciseOfWarrant
      contextRef="ie54f7d4fc8034f45ba6d2e439e5ab48d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfNy02LTEtMS0yOTA2OQ_7ec1e8c0-45a3-4203-8320-df0c1c01b4c4"
      unitRef="shares">6728</fhtx:StockIssuedDuringPeriodConnectionWithExerciseOfWarrant>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie54f7d4fc8034f45ba6d2e439e5ab48d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfOC02LTEtMS0yOTA2OQ_8a7753fc-cbe1-424d-b483-a1e5b44f05e4"
      unitRef="shares">611048</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icfaabe46efdf4e258762c5f4b7e852b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfOC0xMC0xLTEtMjkwNjk_5d2a3710-703b-48d0-a917-20b852414509"
      unitRef="usd">1221000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfOC0xNi0xLTEtMjkwNjk_f45b3675-b810-4764-b4ce-9013771e2f98"
      unitRef="usd">1221000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
      contextRef="icfaabe46efdf4e258762c5f4b7e852b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfOS0xMC0xLTEtMjkwNjk_c78e4e1d-2699-4e58-a236-7b091ec5590d"
      unitRef="usd">188000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfOS0xNi0xLTEtMjkwNjk_29c2f460-28e8-4629-9b99-577c383a4747"
      unitRef="usd">188000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ie54f7d4fc8034f45ba6d2e439e5ab48d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTAtNi0xLTEtMjkwNjk_c64ed076-2fdd-4079-9b7d-3868fec15fa5"
      unitRef="shares">891894</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icfaabe46efdf4e258762c5f4b7e852b8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTEtMTAtMS0xLTI5MDY5_28671f98-2b80-49ac-92d4-bd5e159e20f0"
      unitRef="usd">2961000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTEtMTYtMS0xLTI5MDY5_23d36ec9-2253-41c4-ae3f-c6ceba4af654"
      unitRef="usd">2961000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ib04b5ec0aee746bcaee20b310c94a839_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTItMTItMS0xLTI5MDY5_cb0b746e-f65d-4507-8444-e5352bdadb84"
      unitRef="usd">-7000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTItMTYtMS0xLTI5MDY5_79380e98-c519-46f5-92a2-5312f7eb3e07"
      unitRef="usd">-7000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i755b66d1c0514ffabb5b047a0580e000_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTMtMTQtMS0xLTI5MDY5_db3aa17a-b6ad-459c-98ec-b174821f3dee"
      unitRef="usd">-68800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTMtMTYtMS0xLTI5MDY5_5e8d7c69-b09a-4ea4-addd-79aef4527bdb"
      unitRef="usd">-68800000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i6202585c1f594c04828ca33622ba9f73_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTctMS0xLTEtMA_68350789-8e7a-419a-acca-2bc875d317e8"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i6202585c1f594c04828ca33622ba9f73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTctMy0xLTEtMA_914286d2-c764-45bd-930d-9bdcf3a90d0d"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic897dfc3ee8d4be5958083cf9a26f3cf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTctNi0xLTEtMA_a983b1d2-612b-4824-b325-1c591e35d411"
      unitRef="shares">36790946</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic897dfc3ee8d4be5958083cf9a26f3cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTctOC0xLTEtMA_05520674-eb61-4dbb-9331-8db6a29f7e76"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2b60e82482b4491fbaf024954d547c32_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTctMTAtMS0xLTA_b308a9a1-14c6-4b1d-8b43-c6a8e7de4d62"
      unitRef="usd">309126000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if1da796dda74428196d7005b876d4506_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTctMTItMS0xLTA_1393af59-530b-47b8-b706-5d83a8dc361b"
      unitRef="usd">-7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie6dc13b3584f4e4aa450e4760484cf39_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTctMTQtMS0xLTA_d4463a37-7945-4bf0-b020-212abbaed049"
      unitRef="usd">-162936000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTctMTYtMS0xLTA_2949f885-f5c9-4053-bdbf-b70883ef4c1e"
      unitRef="usd">146187000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8f78ce619e064ea1b1cdd9e493e462f3_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTgtNi0xLTEtMA_7c2cf4bd-de9d-4203-9545-eb8969ddf9bd"
      unitRef="shares">508774</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i70fb1b2bd2ea46e881f0145ac62c2a0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTgtMTAtMS0xLTA_d2780925-a26f-4cb9-b9a8-1b5630a260c3"
      unitRef="usd">1418000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTgtMTYtMS0xLTA_2e3ae6ff-9685-4ccc-b68e-84e9f9d10294"
      unitRef="usd">1418000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i92d1d123424f44d994d5af3872acb232_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTktNi0xLTEtMA_df9f0793-d4c8-426c-b579-f1c50b09863a"
      unitRef="shares">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i43038a8d4df843809b6e00244fcfc5f2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTktMTAtMS0xLTA_64fd5225-4cbe-4651-8ce7-60fadba1211f"
      unitRef="usd">42205000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i08a673dfc57842d19a4fc0a035015adb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMTktMTYtMS0xLTA_e3b51eae-d1df-4024-93bf-d17961511232"
      unitRef="usd">42205000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i70fb1b2bd2ea46e881f0145ac62c2a0f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjAtMTAtMS0xLTIzMDI4_2df51ced-608b-43ca-a588-bff3b81860a4"
      unitRef="usd">8384000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjAtMTYtMS0xLTIzMDI4_3b37b601-bf34-449d-8558-f0ada1f9da94"
      unitRef="usd">8384000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="if661fd7abbb84486820d9146f777241d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjEtMTItMS0xLTIzMDI4_6f97079b-0c73-4377-83b8-62eba9c85904"
      unitRef="usd">-3000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjEtMTYtMS0xLTIzMDI4_24005803-7729-407c-8357-979ee7cdf6b4"
      unitRef="usd">-3000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1fb4ee0936c34d9094e17460190a277a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjItMTQtMS0xLTIzMDI4_b6addb3a-8cde-40e9-a668-077f034f936f"
      unitRef="usd">-101320000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjItMTYtMS0xLTIzMDI4_f13f96a2-c000-4b68-8277-48f8f264264d"
      unitRef="usd">-101320000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="if28ce271ce7648a08119c449c9d2ef48_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjAtMS0xLTEtMA_b1362299-c575-4f22-8674-404ec5a7a4c4"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="if28ce271ce7648a08119c449c9d2ef48_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjAtMy0xLTEtMA_eb46d3c0-9f13-4939-9217-ebe31659db06"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8d7cb7123c0e44e095d8223cbcd8af1b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjAtNi0xLTEtMA_7e2e7934-8a94-4751-af95-48278c8169e8"
      unitRef="shares">41299720</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8d7cb7123c0e44e095d8223cbcd8af1b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjAtOC0xLTEtMA_1ac511eb-4c80-479f-8189-9fe6e5cb3861"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6fadfcdbc6314b66a0e9d9a4c9ad038c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjAtMTAtMS0xLTA_7b780341-112f-46bb-8547-75193126880c"
      unitRef="usd">361133000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3e7fbab3102f466f9aa8f20c9c5e38d5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjAtMTItMS0xLTA_ac0bd1e8-2da2-41b7-b5d9-772be4f7c760"
      unitRef="usd">-10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2c1033134ae74e0a98b856d174a6a6f8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjAtMTQtMS0xLTA_d561cb77-6bcc-4e2b-9bc5-50162c6a9162"
      unitRef="usd">-264256000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84Mi9mcmFnOmNlMzI4NDRjOWQ2ZDRjMzdiY2NiNmUxMjliOTI0NDkyL3RhYmxlOjdlMTdmNmY5ZmU2ZTRlNTk5NjQ1ZjUxMjBkYTJjMGEzL3RhYmxlcmFuZ2U6N2UxN2Y2ZjlmZTZlNGU1OTk2NDVmNTEyMGRhMmMwYTNfMjAtMTYtMS0xLTA_039caaaa-9530-497e-a4a1-3c59430a706e"
      unitRef="usd">96871000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMy0xLTEtMS0w_4645e3ba-a739-4bb5-ba2a-c7265b7f23c0"
      unitRef="usd">-101320000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMy0zLTEtMS0w_906ab585-31aa-4951-a48d-5eca4201bb43"
      unitRef="usd">-68800000</us-gaap:NetIncomeLoss>
    <us-gaap:StockOptionPlanExpense
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNS0xLTEtMS0w_ab6ffaa7-6535-44d4-8e06-4cda1221e846"
      unitRef="usd">8384000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNS0zLTEtMS0w_89521ad9-4eb8-4c9e-a231-cec6db8476c6"
      unitRef="usd">2961000</us-gaap:StockOptionPlanExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNi0xLTEtMS0w_72ae809b-0bbf-4024-873b-6aa51f1f08ff"
      unitRef="usd">3227000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNi0zLTEtMS0w_69130eba-6f4c-45e0-b3f8-2a8945ea71d9"
      unitRef="usd">1327000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNy0xLTEtMS0w_a593022e-d8b0-42ba-bab4-c0b1da16f0df"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNy0zLTEtMS0w_b12e41aa-b90b-4d75-bb45-27cb67a68933"
      unitRef="usd">206000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfOC0xLTEtMS0w_4d4fa51c-8a9d-44ed-9325-dc61adf1d80a"
      unitRef="usd">-1233000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfOC0zLTEtMS0w_788b5901-2ffe-427b-84a4-dbc0ab6223fe"
      unitRef="usd">-222000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfOS0xLTEtMS0w_1d24c4d5-be3f-4caa-ac5a-3761e44fd2ba"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfOS0zLTEtMS0w_9aee2edf-4a31-404a-9f20-821818ced092"
      unitRef="usd">69000</us-gaap:FairValueAdjustmentOfWarrants>
    <fhtx:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTAtMS0xLTEtMA_eb48da97-faf0-4b2e-ac24-93467ecb916e"
      unitRef="usd">4288000</fhtx:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <fhtx:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTAtMy0xLTEtMA_3d4a1b19-8f7f-44b3-a160-c3ccadcf6b56"
      unitRef="usd">4201000</fhtx:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:PaidInKindInterest
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTEtMS0xLTEtMA_ad78c6b7-1a72-4cc6-a13a-e45e3048c7b7"
      unitRef="usd">318000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTEtMy0xLTEtMA_fbb7c611-7396-42d9-8ec1-9d5986648544"
      unitRef="usd">238000</us-gaap:PaidInKindInterest>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTItMS0xLTEtMA_f8342488-48e2-468a-b172-043e14272ca0"
      unitRef="usd">-179000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTItMy0xLTEtMA_a812bca0-358b-4cd2-9393-96965f840327"
      unitRef="usd">1000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTQtMS0xLTEtMA_7f682399-b8a0-4ccb-bdad-452ad0fe884f"
      unitRef="usd">1814000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTQtMy0xLTEtMA_d70e35f9-e56a-4a5d-9667-a5f00567467b"
      unitRef="usd">4670000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTUtMS0xLTEtMjYxOTg_920ba982-7aca-4757-804c-7c7ff21c4bea"
      unitRef="usd">300000000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTUtMy0xLTEtMjYxOTg_b14863d8-d291-4843-be79-0fc187e91ffc"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTUtMS0xLTEtMA_780b491a-80a9-4658-b72b-28a54631fd58"
      unitRef="usd">135000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTUtMy0xLTEtMA_bf71f233-6b89-4357-b92b-3a5cb0501d76"
      unitRef="usd">474000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTYtMS0xLTEtMA_ff677844-c722-4b02-84af-3fb45b64abb5"
      unitRef="usd">2653000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTYtMy0xLTEtMA_29a71289-43ee-4e51-99b5-e688004ae064"
      unitRef="usd">3194000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <fhtx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTctMS0xLTEtMA_871bfd58-96b3-49cb-861a-241dcf8eb879"
      unitRef="usd">-4010000</fhtx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <fhtx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTctMy0xLTEtMA_db163fa2-8557-43b7-bbf7-a5f537123671"
      unitRef="usd">15135000</fhtx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTgtMS0xLTEtMA_fb8da554-8b34-433f-83f7-50fcdf4a5ac6"
      unitRef="usd">336477000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTgtMy0xLTEtMA_477c9a6e-ef95-4a33-955f-654900f66926"
      unitRef="usd">14570000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTktMS0xLTEtMA_d2888b78-f0ca-426f-a428-0f31d7446224"
      unitRef="usd">-50250000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMTktMy0xLTEtMA_ea90eeb4-fcc0-4549-bb32-73ba02d8358a"
      unitRef="usd">-31286000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjEtMS0xLTEtMA_49712969-7a5c-4aa9-a8c2-1dc926fe8985"
      unitRef="usd">3313000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjEtMy0xLTEtMA_fb9ca3b6-dfea-4aa5-917b-168d807bc91f"
      unitRef="usd">16183000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjItMS0xLTEtMA_be733a13-836a-4108-81e7-176b1a5703ac"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjItMy0xLTEtMA_0b46e894-607a-4cd5-a27a-370e954e2895"
      unitRef="usd">250000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjMtMS0xLTEtMA_34c3be8d-dfd4-4b5a-a131-8a8d3cc8a123"
      unitRef="usd">99984000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjMtMy0xLTEtMA_28929cf9-3b91-4eae-a17a-30e5ce69b4a3"
      unitRef="usd">92981000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjQtMS0xLTEtMjMxNDg_69eed8a9-66c6-4ba0-84f4-8878ed8a0678"
      unitRef="usd">139470000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjQtMy0xLTEtMjMxNDg_c9c72414-dc30-4d12-8269-c47fadcbd25f"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjQtMS0xLTEtMA_86376038-2c93-404b-8d63-763b039efa0b"
      unitRef="usd">36173000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjQtMy0xLTEtMA_a7987344-f53b-46e2-8fc0-405799163db5"
      unitRef="usd">-108914000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjctMS0xLTEtMjUzNjk_d0dca883-cfb4-43f6-86c3-4f577cc65fff"
      unitRef="usd">42205000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjctMy0xLTEtMjUzNjk_b14b8fa3-d37c-42ee-87bb-2d43e89cb902"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjYtMS0xLTEtMA_6b700d7d-cd68-41ce-a9e3-e362799b096b"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjYtMy0xLTEtMA_9ff24f2d-3438-4e8e-af83-adadc438b480"
      unitRef="usd">122121000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjctMS0xLTEtMA_6afea690-7669-4e81-a67a-b3244c38a8ea"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjctMy0xLTEtMA_7c3aabb2-c9bb-4035-83de-fb77797af71a"
      unitRef="usd">89861000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjgtMS0xLTEtMA_6f6ba345-6487-4e0b-8660-98a210b486a8"
      unitRef="usd">1418000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjgtMy0xLTEtMA_7518e4ae-2744-48d3-a23e-94022b619f96"
      unitRef="usd">1221000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjktMS0xLTEtMA_d39bb1f7-73c5-427b-ac7d-930dd2231039"
      unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMjktMy0xLTEtMA_3707228f-516d-4249-9eac-43c109c8f71d"
      unitRef="usd">19800000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzAtMS0xLTEtMA_143185fb-c7cb-4309-b7c1-4453aaead7a4"
      unitRef="usd">21205000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzAtMy0xLTEtMA_be054087-12b4-4cb2-a1fd-20aa4bf3fc60"
      unitRef="usd">15530000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzEtMS0xLTEtMA_0c05cd55-1580-4c52-a8c3-b73e1803843d"
      unitRef="usd">22418000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzEtMy0xLTEtMA_4ecefb0c-8ab0-4173-b714-e25ed13493da"
      unitRef="usd">217473000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzItMS0xLTEtMA_0cc26bb6-550f-4e22-a209-76c1e8f652ba"
      unitRef="usd">8341000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzItMy0xLTEtMA_56d7cc56-7897-414b-b0af-12b3dceb2c98"
      unitRef="usd">77273000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzMtMS0xLTEtMA_95089094-775f-4a01-b8d2-01773f350730"
      unitRef="usd">94528000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i406407ac43db40d493cf8d79d3921779_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzMtMy0xLTEtMA_a35f3537-aabf-4897-85c5-2edd27222b57"
      unitRef="usd">17255000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzQtMS0xLTEtMA_b2935841-62ef-4608-919e-834ff9701497"
      unitRef="usd">102869000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzQtMy0xLTEtMA_fea44dd7-6659-437f-ae57-68733ede3bab"
      unitRef="usd">94528000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzYtMS0xLTEtMA_d1a30e40-c3f3-4b3c-85ac-4e9e69685b5a"
      unitRef="usd">1716000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzYtMy0xLTEtMA_21b22881-f8fd-44ed-a9c2-2d01a54a941f"
      unitRef="usd">660000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzgtMS0xLTEtMA_24eac1b7-0754-481a-a700-bf325ed3e6bd"
      unitRef="usd">295000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzgtMy0xLTEtMA_190a6fa6-1005-4455-8971-64c558fe0657"
      unitRef="usd">2400000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="i1f0e298f4e244829a4cc21bc741d457b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzktMS0xLTEtMA_520e8772-5617-4952-b682-90251e7f9b36"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="i5fbf615bd0c04b61a3e8c3c5584de518_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfMzktMy0xLTEtMA_54c82ea2-bd95-48db-a5f1-dda08e966393"
      unitRef="usd">176405000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="iff300de84591401db5d227d7c7cf9dac_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNDAtMS0xLTEtMA_acc6166b-3d07-4673-8211-7e2dda32bac5"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="i59f4c12202e9485c860f841d498aebdb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNDAtMy0xLTEtMA_fd7075e4-f037-4ef0-bcaf-a20ce335eb9f"
      unitRef="usd">114000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i7bd62dcf817f4d0eb46e515f34977c6b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNDEtMS0xLTEtMA_44236339-5057-4d8c-9bdd-ff8ff828c6c6"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ia3f9b42353f44a458f9f2c68c488eaac_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNDEtMy0xLTEtMA_91791038-9904-48a7-ab97-e77cccdba3fd"
      unitRef="usd">188000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNDMtMS0xLTEtMA_56a46e95-35bd-4d07-991c-3cb425b2e478"
      unitRef="usd">101136000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNDMtMy0xLTEtMA_7473ec4e-ef97-4f00-9612-5a73b6dd4eaa"
      unitRef="usd">92795000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashEquivalents
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNDQtMS0xLTEtMA_99914d85-8935-4add-bb83-cb268e696ee5"
      unitRef="usd">1733000</us-gaap:RestrictedCashEquivalents>
    <us-gaap:RestrictedCashEquivalents
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNDQtMy0xLTEtMA_ad6230c1-be3f-4869-a4ee-dc92f94e2185"
      unitRef="usd">1733000</us-gaap:RestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNDUtMS0xLTEtMA_8ce27f21-b950-421e-b5c8-bbaec9f3238a"
      unitRef="usd">102869000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl84OC9mcmFnOjU4MjY2NmNkMGQ3NjRjZjlhNjQwZTZiZTVhZDkyZjNmL3RhYmxlOmNkZDEwYzI3MWQyYzQxODU4NWIxOTE1OWYxZGFmMzg4L3RhYmxlcmFuZ2U6Y2RkMTBjMjcxZDJjNDE4NTg1YjE5MTU5ZjFkYWYzODhfNDUtMy0xLTEtMA_f18f351d-fc2b-493d-b302-87a0e48afaeb"
      unitRef="usd">94528000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfNjE3OA_96c3e6a3-0d6f-4db5-8a60-c05f747a6d22">Nature of Business and Basis of Presentation&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foghorn Therapeutics&#160;Inc. (the &#x201c;Company&#x201d;) is a clinical-stage biopharmaceutical company discovering and developing a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. The Company uses its proprietary Gene Traffic Control platform to identify, validate and potentially drug targets within the system. The Company was founded in October 2015 as a Delaware corporation. The Company is headquartered in Cambridge, Massachusetts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks similar to those of other early-stage companies in the biopharmaceutical industry, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of whom are larger and better capitalized, the impact of the COVID-19 pandemic and the need to obtain adequate additional financing to fund the development of its products. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be maintained, that any products developed will obtain required regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from the sale of its products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the World Health Organization declared the global novel coronavirus disease 2019 (&#x201c;COVID-19&#x201d;)&#160;outbreak a pandemic. The Company&#x2019;s operations have not been significantly impacted by the&#160;COVID-19&#160;pandemic. However, the Company cannot at this time predict the specific extent, duration, or full impact that the&#160;COVID-19&#160;pandemic will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the&#160;COVID-19&#160;outbreak on the Company&#x2019;s financial performance will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of&#160;COVID-19&#160;on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy are impacted for an extended period, the Company&#x2019;s results may be materially adversely affected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October&#160;27, 2020, the Company completed its initial public offering (&#x201c;IPO&#x201d;) pursuant to which it issued and sold 7,500,000 shares of its common stock at a public offering price of $16.00 per share, resulting in net proceeds of $107.9 million, after deducting underwriting discounts and commissions and other offering expenses. On November&#160;19, 2020, the Company issued and sold an additional 951,837 shares of common stock at the IPO price of $16.00 per share pursuant to the underwriters&#x2019; partial exercise of their option to purchase additional shares of common stock, resulting in additional net proceeds of $14.2 million after deducting underwriting discounts and commissions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 10, 2021, the Company executed a collaboration agreement with Eli Lilly and Company (or "Lilly") (See Note 9). Concurrent with the collaboration agreement the Company completed a stock purchase agreement (the "SPA") with Lilly and issued and sold Lilly 4,000,000 shares of its common stock at a price of $20.00 per share, resulting in net proceeds of $80.0 million of which &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$42.2 million was allocated to equity upon the issuance of the Company&#x2019;s common stock (see Note 9)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Since inception, the Company has funded its operations primarily with proceeds from sales of preferred stock, debt financing, an upfront payment of $15.0 million the Company received in July 2020 under a collaboration agreement with Merck Sharp&#160;&amp;amp; Dohme Corp. (see Note 9), proceeds from the sale of common stock in the IPO completed in October 2020 and most recently, with sale of common stock in the SPA. In January 2022, the Company received an upfront payment of $300.0 million pursuant to the collaboration agreement with Lilly (See Note 9), which was included in current assets on the consolidated balance sheets as of December&#160;31, 2021. The Company has incurred recurring losses, including net losses of $101.3 million and $68.8 million for the years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, the Company had an accumulated deficit of $264.3 million. The Company expects to continue to generate operating losses in the foreseeable future. As of the issuance date of these consolidated financial statements the Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will need to obtain additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements to continue to fund its operations. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborative or strategic alliances or licensing arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company&#x2019;s stockholders. Arrangements with collaborators or others may require the Company to relinquish rights to certain of its &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;technologies or programs. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, pipeline expansion or commercialization efforts, which could adversely affect its business prospects. Although management will continue to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations when needed or at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic61be130c3e94434a1523a709ee82e84_D20201027-20201027"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfMjQ5Nw_d61cdb9d-65bb-424c-a362-5c694e1ea93f"
      unitRef="shares">7500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="icd065cf6469a49619232b52c4f78a47a_I20201027"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfMjU1Nw_0f4867fb-cd76-45f0-956c-a88ab387e43d"
      unitRef="usdPerShare">16.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ic61be130c3e94434a1523a709ee82e84_D20201027-20201027"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfMjYwMA_fae25ad1-15a8-4445-9802-d3006e0c6f30"
      unitRef="usd">107900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8c5b1d5196b546fcadb8c83231e484ed_D20201119-20201119"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfMjc1Mg_ced38b19-233c-4a8a-a3a7-76ded05f9d40"
      unitRef="shares">951837</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i598749ee432f4d19b443963f60801a17_I20201119"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfMjc5OA_ab2e037a-476a-429d-993d-f27740eb2b85"
      unitRef="usdPerShare">16.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i8c5b1d5196b546fcadb8c83231e484ed_D20201119-20201119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfMjk2MQ_b1e205fb-01f2-4558-a35c-e1bb454e2227"
      unitRef="usd">14200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iabf346f1d20b4fbab0cb034770c8cc7b_D20211210-20211210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfODI0NjMzNzIxNTE4NA_99cb0e08-c85a-475e-856a-0ab66ae76830"
      unitRef="shares">4000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i7545d56c585441a18935d61361a1f6e3_I20211210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfODI0NjMzNzIxNTE5Mw_d217642c-81d7-4c0d-9918-8f6542750481"
      unitRef="usdPerShare">20.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iabf346f1d20b4fbab0cb034770c8cc7b_D20211210-20211210"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfODI0NjMzNzIxNTIzOA_4569002f-0fd6-43b8-8662-70e5ab39dd15"
      unitRef="usd">80000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i146aef1b1a8a405cb503481b39bfb902_D20211210-20211210"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfOTg5NTYwNDY2MTkzNg_963d229b-17ea-449e-9e61-68c3710ca114"
      unitRef="usd">42200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <fhtx:ProceedsFromUpfrontPayment
      contextRef="i25bd4e2b11bf41efbe5fc4e9eae184b7_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfMzcwOQ_197298bc-8fdd-40f3-8305-8e8701c5183a"
      unitRef="usd">15000000</fhtx:ProceedsFromUpfrontPayment>
    <fhtx:ProceedsFromUpfrontPayment
      contextRef="i1c4d412c57184ef2b09b93a7922fec1d_D20220101-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfODI0NjMzNzIxNTk3OA_e18e90fa-e318-4674-a00a-3d72b8136338"
      unitRef="usd">300000000</fhtx:ProceedsFromUpfrontPayment>
    <us-gaap:NetIncomeLoss
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfMzk5Mg_db6d6e9b-a2d3-4673-8dbb-18601aebfaf2"
      unitRef="usd">-101300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfMzk5OQ_6044be6f-5def-4d00-8893-8271d571b7ec"
      unitRef="usd">-68800000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfNDA5OQ_6740e48d-8aa9-4e1b-94a0-66ea6465d456"
      unitRef="usd">-264300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl85Ny9mcmFnOjEyZmE4ZDMyZDRlYjQyYTE5Y2M1ZGE1NTM4ZTljN2VjL3RleHRyZWdpb246MTJmYThkMzJkNGViNDJhMTljYzVkYTU1MzhlOWM3ZWNfNjE3OQ_14140e04-41b7-48c6-beff-7c0d22f9ac16">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODgw_360351ac-b368-46c2-8967-131a5ff4d4a4">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition and the accrual of research and development expenses. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of credit risk and of significant suppliers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. As of December&#160;31, 2021, the Company maintained cash, cash equivalents and marketable securities at financial institutions in excess of federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies, and expects to continue to rely, on a small number of vendors to provide services, supplies and materials for certain activities related to its programs. These programs could be adversely affected by a significant interruption in these services or the availability of materials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s marketable securities are classified as&#160;available-for-sale&#160;and are carried at fair value with the unrealized gains and losses reported as a component of accumulated other comprehensive loss in stockholders&#x2019; equity. Realized gains and losses and declines in value judged to be other than temporary are included as a component of interest income and other income (expense), net based on the specific identification method. The Company classifies its marketable securities with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities are available for current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts included in restricted cash represent amounts pledged as collateral for letters of credit required for security deposits on the Company&#x2019;s leased facilities and credit cards. These amounts are classified as restricted cash in the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shorter of useful life or remaining term of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs for capital assets not yet placed into service are depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its long-lived assets, which consist primarily of property and equipment and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company did not record any impairment losses on long-lived assets during the years ended December&#160;31, 2021 or 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair value measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2&#x2014;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see Note&#160;3). The carrying values of the Company&#x2019;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities. The carrying value of the Company&#x2019;s long-term debt approximates its fair value (a level 2 measurement) due to its variable interest rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (ASC 808) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.  When the Company has concluded that it has a customer relationship with one of its collaborators the Company follows the guidance in ASC Topic 606,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt; Revenue From Contracts With Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (&#x201c;ASC 606&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its two collaboration arrangements under ASC 606 as the Company concluded that it has a customer relationship with each of its collaborators. For additional information on the Company&#x2019;s collaboration agreements, see Note 9,&#160;Collaboration&#160;Agreements, to these consolidated financial statements. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the goods or services promised within each contract and determines those that are performance obligations. The promised goods or services in the Company&#x2019;s arrangements would likely consist of licenses, rights to the Company&#x2019;s intellectual property, research and development services and related supporting activities. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)&#160;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii)&#160;the entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#x201c;SSP&#x201d;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company&#160;re-evaluates&#160;the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative&#160;catch-up&#160;basis in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s control such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which the royalty has been allocated has been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded for deferred revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised goods or services to the customer and the payment by the customer will be one year or less. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based on the use of an output or input method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, and external costs of vendors engaged to conduct research, preclinical and clinical development activities as well as the cost of licensing technology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront payments and milestone payments made for the licensing of technology are expensed as research and development over the period to which they relate. Costs for research and development activities are expensed in the period in which they are incurred. Payments for such activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense. Determining the prepaid and accrued balances at the end of any reporting period incorporate certain judgments and estimates by management that are based on information available to the Company including information provided by vendors regarding the progress to completion of specific tasks or costs incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patent costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC&#160;842,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#x2019;s economic benefits. The Company determines if an arrangement is a lease or contains an embedded lease at inception. For arrangements that meet the definition of a lease, the Company determines the initial classification and measurement of its right-of-use asset and lease liability at the lease commencement date and thereafter if modified. The lease term includes any renewal options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term. The Company&#x2019;s policy is to not record leases with an original term of twelve months or less on its consolidated balance sheets and recognizes those lease payments in the income statement on a straight-line basis over the lease term. The Company&#x2019;s existing leases are for office and laboratory space and an equipment lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to rent, the leases may require the Company to pay additional costs, such as utilities, maintenance and other operating costs, which are generally referred to as non-lease components. The Company has&#160;elected to not separate lease and non-lease components. Only the fixed costs for lease components and their associated non-lease components are accounted for as a single lease component and recognized as part of a right-of-use asset and liability. Rent expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures stock options with service-based vesting or performance-based vesting granted to employees, non-employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. The Company measures restricted common stock awards using the difference between the purchase price per share of the award, if any, and the fair value of the Company&#x2019;s common stock at the date of grant. Compensation expense for the awards is recognized over the requisite service period for employees and directors and as services are delivered for non-employees, both of which are generally the vesting period of the respective award. The Company uses the straight-line method to record the expense of awards with only service-based vesting conditions. The Company uses the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing once achievement of the performance condition becomes probable. The Company&#160;accounts for forfeitures of share-based awards as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net loss per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing net income(loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, adjusted for potential dilutive common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s participating securities contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reported a net loss, such losses were not allocated to such participating securities. In periods in which the Company reported a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reported a net loss attributable to common stockholders for the years ended December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,920,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,016,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,938,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,034,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an entity for which separate discrete financial information is made available and that is regularly evaluated by the chief operating decision maker (&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. The Company&#x2019;s CODM is its chief executive officer and the Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company is focused on pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those with stockholders. For the year ended December&#160;31, 2021 and 2020, the Company&#x2019;s only element of other comprehensive loss was unrealized losses on available for sale debt securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to the provision for income taxes. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. Any resulting unrecognized tax benefits are recorded within the provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#x201c;emerging growth company&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#x201c;opt out&#x201d; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i)&#160;irrevocably elects to &#x201c;opt out&#x201d; of such extended transition period or (ii)&#160;no longer qualifies as an emerging growth company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No.&#160;2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#160;The new standard adjusts the accounting for assets held at amortized costs basis, including marketable securities accounted for as available for sale.&#160;The standard eliminates the probable initial recognition threshold and requires an entity to reflect its current estimate of all expected credit losses.&#160;The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For public entities, the guidance was effective for annual reporting periods beginning after December&#160;15, 2019 and for interim periods within those fiscal years. For nonpublic entities and emerging growth companies that choose to take advantage of the extended transition period, the guidance is effective for annual reporting periods beginning after December&#160;15, 2020. Early adoption is permitted for all entities. In November 2019, the FASB issued ASU No.&#160;2019-10, which deferred the effective date for nonpublic entities to annual reporting periods beginning after December&#160;15, 2022, including interim periods within those fiscal years. The Company is evaluating when to adopt this standard and the effect the adoption will have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODgx_c374c118-6fbf-469e-9245-5addd03fa06d">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition and the accrual of research and development expenses. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODcy_d3225a15-96f4-4261-883f-333ac8029c70">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of credit risk and of significant suppliers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. As of December&#160;31, 2021, the Company maintained cash, cash equivalents and marketable securities at financial institutions in excess of federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies, and expects to continue to rely, on a small number of vendors to provide services, supplies and materials for certain activities related to its programs. These programs could be adversely affected by a significant interruption in these services or the availability of materials.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODcz_8a4273eb-a3f3-4211-a116-ccb9ab4580c4">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODc0_ba6a4dc5-d73f-41ae-bb15-d27120e33cae">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s marketable securities are classified as&#160;available-for-sale&#160;and are carried at fair value with the unrealized gains and losses reported as a component of accumulated other comprehensive loss in stockholders&#x2019; equity. Realized gains and losses and declines in value judged to be other than temporary are included as a component of interest income and other income (expense), net based on the specific identification method. The Company classifies its marketable securities with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities are available for current operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODgy_61ea310a-de68-4687-940a-4f7a468a788a">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts included in restricted cash represent amounts pledged as collateral for letters of credit required for security deposits on the Company&#x2019;s leased facilities and credit cards. These amounts are classified as restricted cash in the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODg1_154b78b4-f5fb-49bd-b53a-6b53fbde20cb">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shorter of useful life or remaining term of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs for capital assets not yet placed into service are depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODY2_68652f15-8495-4a9d-a01f-3a07a2695a8e">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shorter of useful life or remaining term of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets not yet placed in service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic066e702d698456487c1fe09f0556f0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90YWJsZTpiNmEzNDcwZTNkYTI0ZDZmOTBmODk1M2YyZjJmOWM2YS90YWJsZXJhbmdlOmI2YTM0NzBlM2RhMjRkNmY5MGY4OTUzZjJmMmY5YzZhXzEtMS0xLTEtMA_c80feb75-c309-48f7-a43b-8dc2b754b5a5">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6459962b97414cb4941639768c219ba0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90YWJsZTpiNmEzNDcwZTNkYTI0ZDZmOTBmODk1M2YyZjJmOWM2YS90YWJsZXJhbmdlOmI2YTM0NzBlM2RhMjRkNmY5MGY4OTUzZjJmMmY5YzZhXzItMS0xLTEtMA_160dd3eb-0b75-4d64-8b96-3c7ee9027031">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6bc48e6cb48142b59aba9858f119acab_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90YWJsZTpiNmEzNDcwZTNkYTI0ZDZmOTBmODk1M2YyZjJmOWM2YS90YWJsZXJhbmdlOmI2YTM0NzBlM2RhMjRkNmY5MGY4OTUzZjJmMmY5YzZhXzMtMS0xLTEtMA_ba745b63-c41c-4768-a26f-ee366720cf80">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODgz_2c34ea6a-10c6-4998-af97-12ad19443c07">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its long-lived assets, which consist primarily of property and equipment and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company did not record any impairment losses on long-lived assets during the years ended December&#160;31, 2021 or 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzEwOTk1MTE2NTQ2NjU_42597d8e-b4a7-43cf-9e30-c231dda20193"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzEwOTk1MTE2NTQ2NjU_6bbd40b7-72c8-4cc8-b72e-86a6f119f104"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODY3_64610fb4-0164-4a61-8d9e-45487e16ee07">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair value measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2&#x2014;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash equivalents and marketable securities are carried at fair value, determined according to the fair value hierarchy described above (see Note&#160;3). The carrying values of the Company&#x2019;s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities. The carrying value of the Company&#x2019;s long-term debt approximates its fair value (a level 2 measurement) due to its variable interest rate.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODg0_daf767bb-5599-41bd-81bf-fc9557dcc06e">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (ASC 808) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement.  When the Company has concluded that it has a customer relationship with one of its collaborators the Company follows the guidance in ASC Topic 606,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt; Revenue From Contracts With Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; (&#x201c;ASC 606&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its two collaboration arrangements under ASC 606 as the Company concluded that it has a customer relationship with each of its collaborators. For additional information on the Company&#x2019;s collaboration agreements, see Note 9,&#160;Collaboration&#160;Agreements, to these consolidated financial statements. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses the goods or services promised within each contract and determines those that are performance obligations. The promised goods or services in the Company&#x2019;s arrangements would likely consist of licenses, rights to the Company&#x2019;s intellectual property, research and development services and related supporting activities. Arrangements that include rights to additional goods or services that are exercisable at a customer&#x2019;s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses whether each promised good or service is distinct for the purpose of identifying the performance obligations in the contract. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i)&#160;the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer (that is, the good or service is capable of being distinct) and (ii)&#160;the entity&#x2019;s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract (that is, the promise to transfer the good or service is distinct within the context of the contract). In assessing whether a promised good or service is distinct, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. The Company also considers the intended benefit of the contract in assessing whether a promised good or service is separately identifiable from other promises in the contract. If a promised good or service is not distinct, an entity is required to combine that good or service with other promised goods or services until it identifies a bundle of goods or services that is distinct.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price is then determined and allocated to the identified performance obligations in proportion to their standalone selling prices (&#x201c;SSP&#x201d;) on a relative SSP basis. SSP is determined at contract inception and is not updated to reflect changes between contract inception and when the performance obligations are satisfied. Determining the SSP for performance obligations requires significant judgment. In developing the SSP for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company validates the SSP for performance obligations by evaluating whether changes in the key assumptions used to determine the SSP will have a significant effect on the allocation of arrangement consideration between multiple performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the consideration promised in a contract includes a variable amount, the Company estimates the amount of consideration to which it will be entitled in exchange for transferring the promised goods or services to a customer. The Company determines the amount of variable consideration by using the expected value method or the most likely amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company&#160;re-evaluates&#160;the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative&#160;catch-up&#160;basis in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an arrangement includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s control such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements with licenses of intellectual property that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes royalty revenue and sales-based milestones at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which the royalty has been allocated has been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded for deferred revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the transaction price, the Company adjusts consideration for the effects of the time value of money if the timing of payments provides the Company with a significant benefit of financing. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised goods or services to the customer and the payment by the customer will be one year or less. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time, and if over time, recognition is based on the use of an output or input method.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <fhtx:NumberOfCollaborativeAgreements
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzEyMDk0NjI3OTM4ODY0_b55c8bf3-4743-4a38-8421-1f1bb99fb250"
      unitRef="agreement">2</fhtx:NumberOfCollaborativeAgreements>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODg2_da33cf9f-4a6a-48e8-ba5f-3d0ac7c2c37d">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, laboratory supplies, depreciation, and external costs of vendors engaged to conduct research, preclinical and clinical development activities as well as the cost of licensing technology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront payments and milestone payments made for the licensing of technology are expensed as research and development over the period to which they relate. Costs for research and development activities are expensed in the period in which they are incurred. Payments for such activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid expense or accrued research and development expense. Determining the prepaid and accrued balances at the end of any reporting period incorporate certain judgments and estimates by management that are based on information available to the Company including information provided by vendors regarding the progress to completion of specific tasks or costs incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CapitalizationOfInternalCostsPolicy
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODc4_2566a2a9-de49-4cdb-8d8e-c660a92a35ff">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patent costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:CapitalizationOfInternalCostsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODc1_d20e17ce-72f1-4252-b258-f216f2b6c73b">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC&#160;842,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company accounts for a contract as a lease when it has the right to control the asset for a period of time while obtaining substantially all of the asset&#x2019;s economic benefits. The Company determines if an arrangement is a lease or contains an embedded lease at inception. For arrangements that meet the definition of a lease, the Company determines the initial classification and measurement of its right-of-use asset and lease liability at the lease commencement date and thereafter if modified. The lease term includes any renewal options that the Company is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its estimated secured incremental borrowing rate for that lease term. The Company&#x2019;s policy is to not record leases with an original term of twelve months or less on its consolidated balance sheets and recognizes those lease payments in the income statement on a straight-line basis over the lease term. The Company&#x2019;s existing leases are for office and laboratory space and an equipment lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to rent, the leases may require the Company to pay additional costs, such as utilities, maintenance and other operating costs, which are generally referred to as non-lease components. The Company has&#160;elected to not separate lease and non-lease components. Only the fixed costs for lease components and their associated non-lease components are accounted for as a single lease component and recognized as part of a right-of-use asset and liability. Rent expense for operating leases is recognized on a straight-line basis over the reasonably assured lease term based on the total lease payments and is included in operating expense in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODc2_c5315dcf-fbe5-4cc8-9459-3c122b6f6d89">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures stock options with service-based vesting or performance-based vesting granted to employees, non-employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. The Company measures restricted common stock awards using the difference between the purchase price per share of the award, if any, and the fair value of the Company&#x2019;s common stock at the date of grant. Compensation expense for the awards is recognized over the requisite service period for employees and directors and as services are delivered for non-employees, both of which are generally the vesting period of the respective award. The Company uses the straight-line method to record the expense of awards with only service-based vesting conditions. The Company uses the graded-vesting method to record the expense of awards with both service-based and performance-based vesting conditions, commencing once achievement of the performance condition becomes probable. The Company&#160;accounts for forfeitures of share-based awards as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODY5_0ff889ef-43cf-4b2d-a0c5-5b63e8df52a0">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net loss per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing net income(loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, adjusted for potential dilutive common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s participating securities contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reported a net loss, such losses were not allocated to such participating securities. In periods in which the Company reported a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODcw_339c4377-621a-4f88-8c0a-8ad6e5c6def9">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,920,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,016,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,938,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,034,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5f7bc146064d4609a9384b2c32e30608_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90YWJsZTo4MGQ3ZjM2MGRkMTk0NjAzYThiOWU5OWIwNTljZDVjOC90YWJsZXJhbmdlOjgwZDdmMzYwZGQxOTQ2MDNhOGI5ZTk5YjA1OWNkNWM4XzItMS0xLTEtMA_95ffbdee-1052-48b5-aa09-5b5bfe8fdf03"
      unitRef="shares">5920509</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i34e7f6a206ae4fca9926a2b3693a2e1c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90YWJsZTo4MGQ3ZjM2MGRkMTk0NjAzYThiOWU5OWIwNTljZDVjOC90YWJsZXJhbmdlOjgwZDdmMzYwZGQxOTQ2MDNhOGI5ZTk5YjA1OWNkNWM4XzItMy0xLTEtMA_cdaae8cb-c2b8-49fe-8d26-3ef07baca620"
      unitRef="shares">5016460</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i12a1c8269d8549d6bdfd75792c409c5d_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90YWJsZTo4MGQ3ZjM2MGRkMTk0NjAzYThiOWU5OWIwNTljZDVjOC90YWJsZXJhbmdlOjgwZDdmMzYwZGQxOTQ2MDNhOGI5ZTk5YjA1OWNkNWM4XzMtMS0xLTEtMA_0cb99bb3-ece8-43cb-9c16-e45db772a2d3"
      unitRef="shares">18445</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id03aeb4309314c119fa838863de75a16_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90YWJsZTo4MGQ3ZjM2MGRkMTk0NjAzYThiOWU5OWIwNTljZDVjOC90YWJsZXJhbmdlOjgwZDdmMzYwZGQxOTQ2MDNhOGI5ZTk5YjA1OWNkNWM4XzMtMy0xLTEtMA_e452f97f-0fb4-4596-b49a-267bab562cc2"
      unitRef="shares">18445</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90YWJsZTo4MGQ3ZjM2MGRkMTk0NjAzYThiOWU5OWIwNTljZDVjOC90YWJsZXJhbmdlOjgwZDdmMzYwZGQxOTQ2MDNhOGI5ZTk5YjA1OWNkNWM4XzctMS0xLTEtMA_9eda3456-b6e8-42c1-8b09-5ea6945079f5"
      unitRef="shares">5938954</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90YWJsZTo4MGQ3ZjM2MGRkMTk0NjAzYThiOWU5OWIwNTljZDVjOC90YWJsZXJhbmdlOjgwZDdmMzYwZGQxOTQ2MDNhOGI5ZTk5YjA1OWNkNWM4XzctMy0xLTEtMA_0936b5d2-ff02-42bc-be0b-9df922636960"
      unitRef="shares">5034905</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODc5_528f5d3e-afc5-481a-b782-a9fc26ca7195">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an entity for which separate discrete financial information is made available and that is regularly evaluated by the chief operating decision maker (&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. The Company&#x2019;s CODM is its chief executive officer and the Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company is focused on pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODY4_d3464941-39f0-4e0f-b081-9057fe2857b8">Comprehensive lossComprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those with stockholders. For the year ended December&#160;31, 2021 and 2020, the Company&#x2019;s only element of other comprehensive loss was unrealized losses on available for sale debt securities.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODg3_9873f136-50ac-445e-abb1-719557bb564e">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to the provision for income taxes. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. Any resulting unrecognized tax benefits are recorded within the provision for income taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDAvZnJhZzo3MTYwZjIxMzAzZjI0MWE2ODNiNjZkMTJiYjBiOTU3MS90ZXh0cmVnaW9uOjcxNjBmMjEzMDNmMjQxYTY4M2I2NmQxMmJiMGI5NTcxXzI2ODcx_ca059a5e-da69-4e8e-8a79-411c77d6e283">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#x201c;emerging growth company&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#x201c;opt out&#x201d; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i)&#160;irrevocably elects to &#x201c;opt out&#x201d; of such extended transition period or (ii)&#160;no longer qualifies as an emerging growth company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No.&#160;2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#160;The new standard adjusts the accounting for assets held at amortized costs basis, including marketable securities accounted for as available for sale.&#160;The standard eliminates the probable initial recognition threshold and requires an entity to reflect its current estimate of all expected credit losses.&#160;The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For public entities, the guidance was effective for annual reporting periods beginning after December&#160;15, 2019 and for interim periods within those fiscal years. For nonpublic entities and emerging growth companies that choose to take advantage of the extended transition period, the guidance is effective for annual reporting periods beginning after December&#160;15, 2020. Early adoption is permitted for all entities. In November 2019, the FASB issued ASU No.&#160;2019-10, which deferred the effective date for nonpublic entities to annual reporting periods beginning after December&#160;15, 2022, including interim periods within those fiscal years. The Company is evaluating when to adopt this standard and the effect the adoption will have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <fhtx:MarketableSecuritiesAndFairValueMeasurementsTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90ZXh0cmVnaW9uOjE1MmYwYWFiNzAyOTRlOTBhMWQ1Y2RiOWVjNDExNjE5XzE2NjA_d99a2861-2161-4fb7-a3da-868135f1bc4c">Marketable Securities and Fair Value Measurements&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, available for sale marketable securities by security type consisted of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes and bonds (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, available for sale marketable securities by security type consisted of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury notes (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the Company&#x2019;s fair value hierarchy for its assets and liabilities, which were measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements at&lt;br/&gt;December 31, 2021 Using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;82,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;82,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;82,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;153,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements at&lt;br/&gt;December 31, 2020 Using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:31.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:31.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:31.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;135,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;During the years ended December&#160;31, 2021 and 2020, there were no transfers between Level 1, Level 2 and Level 3.</fhtx:MarketableSecuritiesAndFairValueMeasurementsTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90ZXh0cmVnaW9uOjE1MmYwYWFiNzAyOTRlOTBhMWQ1Y2RiOWVjNDExNjE5XzE2NjE_8d0f8de2-f18c-4b1d-9581-6546bc33a658">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, available for sale marketable securities by security type consisted of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes and bonds (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, available for sale marketable securities by security type consisted of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury notes (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6cd2aa71baa24133bcddefb5ee9ce9b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzEtMS0xLTEtMjIyNDQ_d7a934f4-a6ae-4d08-9add-20d225311b91"
      unitRef="usd">36246000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6cd2aa71baa24133bcddefb5ee9ce9b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzEtMy0xLTEtMjIyNDQ_6e8aadda-0472-4842-9fbf-dd57aeeb20f6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6cd2aa71baa24133bcddefb5ee9ce9b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzEtNS0xLTEtMjIyNDQ_22c25c21-7d32-44b1-8909-ba56cb9561d5"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6cd2aa71baa24133bcddefb5ee9ce9b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzEtNy0xLTEtMjIyNDQ_da153eaa-6243-4166-8ecb-7712f25f0410"
      unitRef="usd">36243000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4b216a3565b64982af2832ed92b1f204_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzItMS0xLTEtMjIyNjI_027911f8-e187-4cf8-8c37-fe3aa79fed59"
      unitRef="usd">16917000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4b216a3565b64982af2832ed92b1f204_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzItMy0xLTEtMjIyNjI_85d14841-c22d-47ac-b552-a347226d0b5b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4b216a3565b64982af2832ed92b1f204_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzItNS0xLTEtMjIyNjI_b5124417-9ea8-4965-9f54-72f82c850e8a"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4b216a3565b64982af2832ed92b1f204_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzItNy0xLTEtMjIyNjI_66a31686-4a76-41fa-9fb7-8cef111a35fa"
      unitRef="usd">16910000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzItMS0xLTEtMjIyNDQ_36da5934-28e4-4a68-8a3c-313accc83893"
      unitRef="usd">53163000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzItMy0xLTEtMjIyNDQ_79e0762f-2809-4bb9-ae08-d3897bf5a511"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzItNS0xLTEtMjIyNDQ_b13c3728-ae99-4505-b7be-dab5aab8d0d7"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTowMGY2M2JlZjVkNTg0N2UwODIzN2YyYzA2ZDk5MTM0Ni90YWJsZXJhbmdlOjAwZjYzYmVmNWQ1ODQ3ZTA4MjM3ZjJjMDZkOTkxMzQ2XzItNy0xLTEtMjIyNDQ_6cd5f174-895d-4f2c-8866-5ba170751005"
      unitRef="usd">53153000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id955de6cd1884e8185138e0750ec2ab3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpiODgzYWYwZDMyYTY0NDEzOTMxZTFhYTEyMGRlMTZhZS90YWJsZXJhbmdlOmI4ODNhZjBkMzJhNjQ0MTM5MzFlMWFhMTIwZGUxNmFlXzEtMS0xLTEtMA_56ecc156-77f1-4e93-a448-19f4c231c90f"
      unitRef="usd">92982000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id955de6cd1884e8185138e0750ec2ab3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpiODgzYWYwZDMyYTY0NDEzOTMxZTFhYTEyMGRlMTZhZS90YWJsZXJhbmdlOmI4ODNhZjBkMzJhNjQ0MTM5MzFlMWFhMTIwZGUxNmFlXzEtMy0xLTEtMA_94db94f9-cb0e-4250-bed3-30e6a1c64345"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id955de6cd1884e8185138e0750ec2ab3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpiODgzYWYwZDMyYTY0NDEzOTMxZTFhYTEyMGRlMTZhZS90YWJsZXJhbmdlOmI4ODNhZjBkMzJhNjQ0MTM5MzFlMWFhMTIwZGUxNmFlXzEtNS0xLTEtMA_aeb30c8d-a6b3-4d0b-9253-d5b6ee19670b"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id955de6cd1884e8185138e0750ec2ab3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpiODgzYWYwZDMyYTY0NDEzOTMxZTFhYTEyMGRlMTZhZS90YWJsZXJhbmdlOmI4ODNhZjBkMzJhNjQ0MTM5MzFlMWFhMTIwZGUxNmFlXzEtNy0xLTEtMA_eb189fe7-f2b3-48cd-9c46-a1dd1f4d86b8"
      unitRef="usd">92975000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpiODgzYWYwZDMyYTY0NDEzOTMxZTFhYTEyMGRlMTZhZS90YWJsZXJhbmdlOmI4ODNhZjBkMzJhNjQ0MTM5MzFlMWFhMTIwZGUxNmFlXzItMS0xLTEtMA_1652453c-8ca1-44ad-8b0e-f063c5a3f0b7"
      unitRef="usd">92982000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpiODgzYWYwZDMyYTY0NDEzOTMxZTFhYTEyMGRlMTZhZS90YWJsZXJhbmdlOmI4ODNhZjBkMzJhNjQ0MTM5MzFlMWFhMTIwZGUxNmFlXzItMy0xLTEtMA_537676ae-d502-4edd-aee7-540f4d64237a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpiODgzYWYwZDMyYTY0NDEzOTMxZTFhYTEyMGRlMTZhZS90YWJsZXJhbmdlOmI4ODNhZjBkMzJhNjQ0MTM5MzFlMWFhMTIwZGUxNmFlXzItNS0xLTEtMA_efc1902a-fbfd-4dee-87b0-f8b485aab15e"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpiODgzYWYwZDMyYTY0NDEzOTMxZTFhYTEyMGRlMTZhZS90YWJsZXJhbmdlOmI4ODNhZjBkMzJhNjQ0MTM5MzFlMWFhMTIwZGUxNmFlXzItNy0xLTEtMA_5d1da2b1-87c0-4ad4-b31e-aeac6c59cb28"
      unitRef="usd">92975000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90ZXh0cmVnaW9uOjE1MmYwYWFiNzAyOTRlOTBhMWQ1Y2RiOWVjNDExNjE5XzE2NTk_1665e0c8-f3f4-46d2-ab5c-fdb0771ea6ba">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the Company&#x2019;s fair value hierarchy for its assets and liabilities, which were measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements at&lt;br/&gt;December 31, 2021 Using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;82,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;82,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;82,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;153,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements at&lt;br/&gt;December 31, 2020 Using:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:31.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:31.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:31.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;135,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if906371b919e4edb9cbaff3349db1e5a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzQtMS0xLTEtMA_21725336-01c2-4b6c-9bd5-af6b8fdcd9c6"
      unitRef="usd">82252000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iff3838f509af4f0eb1680ed5f138763c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzQtMy0xLTEtMA_bf903ef8-7a09-453e-96e5-e808f727dfb0"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iaac48c4990fc4b23a98caf4dc0c46472_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzQtNS0xLTEtMA_c4b50511-01ac-4208-bf08-537c82f77c07"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i79d6f505bd7d40d1ab1326d0b0e8b296_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzQtNy0xLTEtMA_4aeafd80-6b98-4960-aaf1-134054b0765c"
      unitRef="usd">82252000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if0e25902efa14d8496dbe8fa31ab5e18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzYtMS0xLTEtMjM0MzA_f197a4b4-5ada-4817-bf42-a293b0f743ee"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i111a519d6a244546ae0ab2247e929789_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzYtMy0xLTEtMjM0MzA_2628835a-30de-4b29-a52e-d7aa915b8fee"
      unitRef="usd">18496000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i444925a451b6462ba584afd5c61d43e3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzYtNS0xLTEtMjM0MzA_a873550a-4ca8-45dc-97c7-5fec6fbd3ec9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0ef2f7d5ec4b41adb5e4a6ef1777b997_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzYtNy0xLTEtMjM0MzA_6f4e5f15-1159-4f57-9c75-15e72a75401c"
      unitRef="usd">18496000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i968a33b0579d40f3b45433f682345851_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzgtMS0xLTEtMjM0NDE_cfeca3f4-9506-4417-9561-2f6ed8ab05b1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i537352e60a9a414692e0f7409da18813_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzgtMy0xLTEtMjM0NDE_4aa4eb18-c11f-4616-b4c6-aecf88afeced"
      unitRef="usd">36243000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id2e7eba7312d4e0fba240bde0d9c1bc9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzgtNS0xLTEtMjM0NDE_880d910d-06e1-4724-8fd1-f0d2a30e3188"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6823127af8d34669a2caa57eb496dd2d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzgtNy0xLTEtMjM0NDE_826e45da-c36c-440d-a804-2d1c4a34a949"
      unitRef="usd">36243000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i76a6b50908b44d00a55838e4e1cf7176_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzctMS0xLTEtMA_c9036581-3254-402c-a7c2-56394f78c151"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iad91834ab15d489cb8484081982f739d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzctMy0xLTEtMA_58f1739d-e5e9-4780-866e-13a7e002aebf"
      unitRef="usd">16910000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9ef90d0c133b4dc09242b27430fb6c83_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzctNS0xLTEtMA_8b130bdf-0ab2-4a0b-87bb-bb235fa5dffb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia8bcbd3ea5e74155b41c0255c7c0e7a8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzctNy0xLTEtMA_9aa30827-9656-4fd9-b49b-48d01d4c3f4e"
      unitRef="usd">16910000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib653dca791b64896a08cfb7a0e8446f7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzgtMS0xLTEtMA_0816e653-f7ae-4054-97ab-ceebfb3bb781"
      unitRef="usd">82252000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i62bc1b90709641e48c8ee1248e2a2be0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzgtMy0xLTEtMA_cee5dbd7-160d-4bb6-90f4-ba4976b8d1c7"
      unitRef="usd">71649000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib7a8cdf58951489cbce902c6026e0d71_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzgtNS0xLTEtMA_93f432a5-aedf-46e0-85d7-49230ab5b9ff"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie7581f3ffb0042c59c5d8ca5c9d3c495_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTo3ZTdlYjc3MmM4ZTA0NmU3OWZjY2RiMzVmZWJiNjBmMi90YWJsZXJhbmdlOjdlN2ViNzcyYzhlMDQ2ZTc5ZmNjZGIzNWZlYmI2MGYyXzgtNy0xLTEtMA_a7e36124-8ddc-4ae4-b315-d7ab191b7d27"
      unitRef="usd">153901000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibeb58fd86d1241b285fe06e0d3d62da7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzQtMS0xLTEtMA_c47e622c-0e43-42e3-b28a-443b45f27da8"
      unitRef="usd">48770000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia0ceb8decc8347719a807b233cf323cf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzQtMy0xLTEtMA_f5b1dfc2-51d8-475b-b948-29222f4618df"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7eededd25783411791223767f68f1740_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzQtNS0xLTEtMA_5f647d75-415c-442e-a69e-6ba4c8638d1a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8c2443787a9a4bf6899e62de8792aabb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzQtNy0xLTEtMA_1d14bd52-8cbd-4344-8199-f5ee98ee6582"
      unitRef="usd">48770000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id674ecc28e6a4bec8492a5fad8e88241_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzUtMS0xLTEtMjIxNTU_321fe7d0-3616-4ea5-8f9d-53bda56845c7"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9007fd1a6c114c2f9092e78360752927_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzUtMy0xLTEtMjIxNTU_2daf3ec5-d317-40d8-9ee5-2db949567592"
      unitRef="usd">42997000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9d5b943b47404b9796a02f5deed9fa6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzUtNS0xLTEtMjIxNTU_ac70f28e-775d-403c-9d98-ac684b2fb32e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic7c250fe5eb94135b9cb46d4e2a2fe65_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzUtNy0xLTEtMjIxNTU_a49ccd9f-14e0-49c4-b639-b3342d0d789b"
      unitRef="usd">42997000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6936f6623d364d4e855208a92198fbff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzYtMS0xLTEtMA_d85693fc-8834-4563-87f1-ace790873849"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic48fe4ed0446401abf189c47fbf5e947_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzYtMy0xLTEtMA_1d9d5f39-096a-4141-8a50-065a6ee9efbe"
      unitRef="usd">92975000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic45ad783abc94d60b6f3fc8c8900675f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzYtNS0xLTEtMA_e3742785-7a69-4f30-a218-bfb1f6175e65"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia8bb1cd7498940d3ba6558a5b1f34d14_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzYtNy0xLTEtMA_e8af8cb6-39b8-4a58-b739-dcde9d2f53f9"
      unitRef="usd">92975000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5b088f5892d84a34a7cfbb1478042496_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzgtMS0xLTEtMjIxNTU_52e98991-dc9e-403d-a910-1c88e25aa321"
      unitRef="usd">48770000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6365a0687d1a4e38b300cbff88436f8c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzgtMy0xLTEtMjIxNTU_07610a0e-0baa-43cb-92b0-67b8afd50556"
      unitRef="usd">135972000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0e14f625a75f45c0be3dc94d6442301d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzgtNS0xLTEtMjIxNTU_c4b4e2df-6b80-47c5-97ae-1a30e9999bab"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMDYvZnJhZzoxNTJmMGFhYjcwMjk0ZTkwYTFkNWNkYjllYzQxMTYxOS90YWJsZTpmYTg0ZTVkYzEzNmE0N2ZiYmM2ODMwODAzZWU4NmM4Zi90YWJsZXJhbmdlOmZhODRlNWRjMTM2YTQ3ZmJiYzY4MzA4MDNlZTg2YzhmXzgtNy0xLTEtMjIxNTU_7a4f9791-e39e-455f-a3a0-d305b66c51a0"
      unitRef="usd">184742000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90ZXh0cmVnaW9uOjE2MGU3MDFiMDAxYzQxODY5ZGUzZjc5M2JlYzU0NWM1XzIwNQ_15aeaff7-a3da-434e-ba2d-79d840580554">Property and Equipment, Net&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets not yet placed in service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,330)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense was $3.2 million and $1.3 million for the years ended December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ic737047ef5ac46948883230a983a17e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzItMS0xLTEtMA_7782afe0-ed71-4dc9-a351-8b1496f07970"
      unitRef="usd">4889000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i85f5b7fcbcc1494d82b2b6edf8a4eec6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzItMy0xLTEtMA_6459c00b-3180-4c51-92a1-d1ccb4b7337e"
      unitRef="usd">3740000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ic38f6e8e2292491e90c063c6222b2448_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzMtMS0xLTEtMA_bd6db0c4-66e9-420c-ba07-1c1c2dfcdcbf"
      unitRef="usd">815000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i26b8aecd6a1c435bb0da7145cba274e6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzMtMy0xLTEtMA_e1353496-c686-405f-a16a-89c5e72ad7aa"
      unitRef="usd">815000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="icb18b30cf22f4a32bb4ff93620162dda_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzQtMS0xLTEtMA_de310e6f-c73e-4aef-9569-37118b6c90ed"
      unitRef="usd">100000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ife30eeb6debd49f9a9e6eaccb2f6d4f6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzQtMy0xLTEtMA_7c7ed504-e06d-473b-ab54-6d7fd1a9a4ef"
      unitRef="usd">100000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="id0f5fafdc67546f5aec4e0ce4e1aaa67_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzUtMS0xLTEtMA_f04f552b-4478-40d7-8f94-a1904c1de8f9"
      unitRef="usd">17059000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i57e5da0015844088ba86122ad60975f7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzUtMy0xLTEtMA_9e2eb8f3-47b1-4c8b-a25a-afb304ea3e30"
      unitRef="usd">16961000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="if936930eb6674b98aa88bbc4b5ff6632_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzYtMS0xLTEtMA_c926a14e-3f39-4371-bb98-d2898c98d301"
      unitRef="usd">30000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i8ae945c2f65f4ae1b715fa4120b4b25e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzYtMy0xLTEtMA_d2bcff75-aed0-4e29-87f0-d0e48b32a024"
      unitRef="usd">15000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzctMS0xLTEtMA_cf95a397-79e4-4782-b8fa-86b902fb1a2b"
      unitRef="usd">22893000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzctMy0xLTEtMA_1aaeedf8-2a1f-4759-b75c-dd58403e29a9"
      unitRef="usd">21631000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzgtMS0xLTEtMA_8ccf5f50-05ca-4d6e-8b8b-a38b74af8172"
      unitRef="usd">5330000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzgtMy0xLTEtMA_d84f0576-1e7b-4e43-a0d1-a893d5d6ad95"
      unitRef="usd">2103000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzktMS0xLTEtMA_f49f86f4-7535-4520-a94c-5db4ca49bcad"
      unitRef="usd">17563000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90YWJsZTo3NTUwMmQ5MmU4MjY0NWJkOTBiM2IwOTc1MGEzZGM0Ni90YWJsZXJhbmdlOjc1NTAyZDkyZTgyNjQ1YmQ5MGIzYjA5NzUwYTNkYzQ2XzktMy0xLTEtMA_6444874f-b005-4ecd-a341-392048445ac8"
      unitRef="usd">19528000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90ZXh0cmVnaW9uOjE2MGU3MDFiMDAxYzQxODY5ZGUzZjc5M2JlYzU0NWM1XzE1MQ_b8d094fb-5701-40c6-8d5b-51b87be1e927"
      unitRef="usd">3200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTIvZnJhZzoxNjBlNzAxYjAwMWM0MTg2OWRlM2Y3OTNiZWM1NDVjNS90ZXh0cmVnaW9uOjE2MGU3MDFiMDAxYzQxODY5ZGUzZjc5M2JlYzU0NWM1XzE1OA_75358506-9a40-4324-b774-a414c28740d0"
      unitRef="usd">1300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90ZXh0cmVnaW9uOjdlMDQ1ODA2MTI1MjRkMDlhMGU3ZjkzNjAyMWYwMGM0Xzg2_37d4e04b-6019-410b-918c-96cc93664069">Accrued Expenses&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued tenant improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued external research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90ZXh0cmVnaW9uOjdlMDQ1ODA2MTI1MjRkMDlhMGU3ZjkzNjAyMWYwMGM0Xzg3_f3ca86fc-19a5-4c56-a163-dd319751cdfc">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued tenant improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued external research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzItMS0xLTEtMA_7b561a37-d8ea-4bd2-95b1-e402ef80a004"
      unitRef="usd">5596000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzItMy0xLTEtMA_bbfb5121-a5fa-4d34-ae8d-948b69998955"
      unitRef="usd">3513000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <fhtx:AccruedTenantImprovements
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzMtMS0xLTEtMA_5901c869-f887-44e3-a2fd-aa43eb95d261"
      unitRef="usd">13000</fhtx:AccruedTenantImprovements>
    <fhtx:AccruedTenantImprovements
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzMtMy0xLTEtMA_016c7828-c099-4497-96ba-2c3efe9214cb"
      unitRef="usd">2385000</fhtx:AccruedTenantImprovements>
    <fhtx:AccruedResearchAndDevelopmentExpenses
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzQtMS0xLTEtMA_dfb7b592-f42c-47a2-b7c1-54cdf317b815"
      unitRef="usd">3079000</fhtx:AccruedResearchAndDevelopmentExpenses>
    <fhtx:AccruedResearchAndDevelopmentExpenses
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzQtMy0xLTEtMA_291bc67f-5e74-4acd-b12d-6e93742a1b00"
      unitRef="usd">2146000</fhtx:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzUtMS0xLTEtMA_fa7e56ae-2701-4b75-9051-73a8945417ed"
      unitRef="usd">495000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzUtMy0xLTEtMA_c7ec5c56-1507-457f-8618-d6fab7ced192"
      unitRef="usd">979000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzYtMS0xLTEtMA_052f2b5c-251c-44f3-b348-ffdfec2e4e45"
      unitRef="usd">379000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzYtMy0xLTEtMA_e5bfb638-b61e-4209-a355-755ba4cb3b09"
      unitRef="usd">138000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzctMS0xLTEtMA_40639600-17b9-42c6-a062-0752a85e1029"
      unitRef="usd">9562000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTUvZnJhZzo3ZTA0NTgwNjEyNTI0ZDA5YTBlN2Y5MzYwMjFmMDBjNC90YWJsZToxMDk1MzUxOWQxZGU0NTlhYjkwNzMyYWI5MjFlNjEyMy90YWJsZXJhbmdlOjEwOTUzNTE5ZDFkZTQ1OWFiOTA3MzJhYjkyMWU2MTIzXzctMy0xLTEtMA_781e7184-a6ae-4de4-b76f-bb1f8bbb7722"
      unitRef="usd">9161000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzU0ODY_10811b53-c381-4474-ae8e-9c9f2f60c6ab">Notes Payable&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal amount of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Final payment fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt discount, net of accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt, net of discount and current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loan and Security Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;19, 2020, the Company entered into a loan and security agreement (the "Oxford Loan Agreement"), with Oxford Finance LLC, or Oxford, for an aggregate principal amount of $20.0 million (the "Oxford Term Loan A") and up to an additional $5.0 million (the "Oxford Term Loan B"). On November&#160;19, 2020, the Company borrowed $20.0 million under the Oxford Term Loan A. Oxford Term Loan A and Oxford Term Loan B (the "Term Loans") bear interest at a floating per annum rate equal to the greater of (i) 8.0% and (ii)&#160;the sum of (a)&#160;thirty-day LIBOR rate plus (b) 7.84%. In addition, upon loan maturity or prepayment, the Company is required to make a final payment fee equal to 5.0% of the aggregate principal amount borrowed which is being amortized to interest expense over the term of the debt using the effective interest method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to make monthly interest only payments under the Oxford Loan each month beginning on January&#160;1, 2021. Beginning on December&#160;1, 2023, the Company is required to make consecutive equal monthly payments of principal, together with applicable interest, in arrears, based upon a repayment schedule equal to 24 months, with a final maturity date of November&#160;1, 2025 (the &#x201c;Maturity Date&#x201d;). At the Company's option, the Company may elect to prepay the loans subject to a prepayment fee equal to the following percentage of the principal amount being prepaid: 2% if an advance is prepaid during the first 12 months following the applicable advance date, 1% if an advance is prepaid after 12 months but prior to 24 months following the applicable advance date, and 0.5% if an advance is prepaid any time after 24 months following the applicable advance date but prior to the Maturity Date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, in connection with the Oxford Loan Agreement, the Company granted warrants to purchase 18,445 shares of the Company&#x2019;s common stock at $16.26 per share. The issued warrants are exercisable for 10 years. The Company valued the warrants using the Black-Scholes option pricing model and determined the fair value of the warrants to be $0.2 million. The Company determined the warrants met the criteria for equity classification, and, as such, the fair value of the warrants were recorded as additional paid-in capital upon issuance and as a discount to the debt which is being amortized to interest expense over the term of the Oxford Loan of five years. In addition, the Company incurred debt issuance costs of $0.2 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the Company repaid early the outstanding principal balance under the Term Loans as described above plus unpaid accrued interest, the final payment fee and the prepayment fee. The Company recorded a loss on debt extinguishment of $1.2&#160;million related to this repayment for the year ended December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;During the years ended December&#160;31, 2021 and 2020, the weighted average effective interest rate on outstanding borrowings was approximately 9.5% and 6.4%, respectively.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzU0ODE_e70c09e1-3a44-427b-86ca-83d5816190d7">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal amount of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Final payment fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt discount, net of accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt, net of discount and current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i69208d809b134811a688e3aaa1b56f5f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzItMS0xLTEtMA_43e8c5e5-a580-40cb-9a89-afa282254674"
      unitRef="usd">0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic63ca5a8620e4354a23fe4fb65d45904_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzItMy0xLTEtMA_2214a87c-5cd3-473f-ad99-e0a6f1ba2688"
      unitRef="usd">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtCurrent
      contextRef="i69208d809b134811a688e3aaa1b56f5f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzMtMS0xLTEtMA_79632491-d1e9-4851-b4e4-2468df3be3aa"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ic63ca5a8620e4354a23fe4fb65d45904_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzMtMy0xLTEtMA_34aeb2fb-5dd5-4b10-b91b-3844d8d5effb"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i69208d809b134811a688e3aaa1b56f5f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzQtMS0xLTEtMA_e12565de-dc19-455c-b881-998859a56e4a"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic63ca5a8620e4354a23fe4fb65d45904_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzQtMy0xLTEtMA_af20fed5-7228-49af-8c62-bb407211f58c"
      unitRef="usd">20000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="i69208d809b134811a688e3aaa1b56f5f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzUtMS0xLTEtMA_b8501068-4d93-4727-958d-95b34ec699f7"
      unitRef="usd">0</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="ic63ca5a8620e4354a23fe4fb65d45904_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzUtMy0xLTEtMA_c31f101c-1a0f-4a72-821c-3f9f85a8888e"
      unitRef="usd">1000000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i69208d809b134811a688e3aaa1b56f5f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzYtMS0xLTEtMA_f3391201-c88b-4d94-9553-8c1099ffa15e"
      unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ic63ca5a8620e4354a23fe4fb65d45904_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzYtMy0xLTEtMA_1473671e-c2c4-4ffd-8f4f-23d09ead0a8a"
      unitRef="usd">1346000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="i69208d809b134811a688e3aaa1b56f5f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzctMS0xLTEtMA_10401a1d-6083-4744-ba45-d2526ce39f08"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic63ca5a8620e4354a23fe4fb65d45904_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90YWJsZTowYzJiZTJmZDZjMWY0ODcwOWRmZmNkYzRmZjY4Mzc4Ni90YWJsZXJhbmdlOjBjMmJlMmZkNmMxZjQ4NzA5ZGZmY2RjNGZmNjgzNzg2XzctMy0xLTEtMA_27b84733-52c6-4721-ace2-693842081dcc"
      unitRef="usd">19654000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib49c41bde7e24d5eb853d157bd015ed2_I20201119"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzI1OTc_04740b2e-860c-4b88-bf37-b089e316455e"
      unitRef="usd">20000000</us-gaap:DebtInstrumentFaceAmount>
    <fhtx:LineOfCreditAdditionalBorrowingCapacity
      contextRef="i5ec8f3ca08b54640bf525807c9358e0b_I20201119"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzI2NDU_c31ab15d-ddbd-4ba3-b06e-6f88294b5cbe"
      unitRef="usd">5000000</fhtx:LineOfCreditAdditionalBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib49c41bde7e24d5eb853d157bd015ed2_I20201119"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzI3MTM_e38b76e7-9fe2-43e5-ac8d-9dfc18c8f9de"
      unitRef="usd">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib49c41bde7e24d5eb853d157bd015ed2_I20201119"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzI4MzI_fac2ef45-5edc-442c-93e7-4e9bd736307d"
      unitRef="number">0.080</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i8b0e0ca6351c413a82a3c23dea9a45aa_D20201119-20201119"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzI4OTA_6163929f-aed0-4e92-9c41-1208be2573ce"
      unitRef="number">0.0784</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <fhtx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage
      contextRef="ib49c41bde7e24d5eb853d157bd015ed2_I20201119"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzMwMDE_2e9b1cf9-754c-4510-bb01-ca18572fb447"
      unitRef="number">0.050</fhtx:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage>
    <fhtx:PercentageOfPrepaymentFee
      contextRef="ib3a33598e6e946e8956a704040d5cd66_D20201119-20201119"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzEwOTk1MTE2Mjg5MDI3_e2ceba0d-4b20-4621-99e0-cd70c98a48b0"
      unitRef="number">0.02</fhtx:PercentageOfPrepaymentFee>
    <fhtx:PrepaymentPeriod
      contextRef="i308a28a242364292959d00dffcc81a50_D20201119-20201119"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzEwOTk1MTE2MzkxMTI_b63f27df-c948-4418-95b1-f16d362e38d1">P12M</fhtx:PrepaymentPeriod>
    <fhtx:PercentageOfPrepaymentFee
      contextRef="if15ca8afdf684493a8630928aba61256_D20201119-20201119"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzEwOTk1MTE2Mjg5MDIz_4c9bb8db-95ea-4ae8-a336-c564da7d7f5b"
      unitRef="number">0.01</fhtx:PercentageOfPrepaymentFee>
    <fhtx:PrepaymentPeriod
      contextRef="i2a4208db8c414f878b2487dcb43e458b_D20201119-20201119"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzEwOTk1MTE2Mjg5MDQ0_38320eff-e2ee-4301-a6f4-a5c4b7c6b63f">P12M</fhtx:PrepaymentPeriod>
    <fhtx:PrepaymentPeriod
      contextRef="i3c238b9ea3134f76bd3f9653c8e95195_D20201119-20201119"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzEwOTk1MTE2Mjg5MDY0_3bfb988a-9fe8-4420-bb22-8c6153e2134e">P24M</fhtx:PrepaymentPeriod>
    <fhtx:PercentageOfPrepaymentFee
      contextRef="ibda01586c8f04185951a0c2fc97552f9_D20201119-20201119"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzEwOTk1MTE2Mjg5MDcx_2267648a-52d0-4edc-b662-a6789d28f614"
      unitRef="number">0.005</fhtx:PercentageOfPrepaymentFee>
    <fhtx:PrepaymentPeriod
      contextRef="i1d753a4861b4455884ca55cfae0bfb8a_D20201119-20201119"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzEwOTk1MTE2Mjg5MDkw_2ce55d43-f048-4a87-8b16-1d93173d90dd">P24M</fhtx:PrepaymentPeriod>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ib49c41bde7e24d5eb853d157bd015ed2_I20201119"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzQ1ODc_65c3a9be-ea1a-4a91-a52c-d46f2758c866"
      unitRef="shares">18445</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <fhtx:WarrantsIssuePricePerShare
      contextRef="ib49c41bde7e24d5eb853d157bd015ed2_I20201119"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzQ2MzA_1de7f1d4-a980-4543-81eb-db1f85a692c8"
      unitRef="usdPerShare">16.26</fhtx:WarrantsIssuePricePerShare>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ib49c41bde7e24d5eb853d157bd015ed2_I20201119"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzQ2ODU_745027bf-dcbb-41fe-8c79-0a293f552ae4">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="ib49c41bde7e24d5eb853d157bd015ed2_I20201119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzQ4MTg_776c5447-f469-422f-8f07-01ee2e053356"
      unitRef="usd">200000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:DebtInstrumentTerm
      contextRef="i8b0e0ca6351c413a82a3c23dea9a45aa_D20201119-20201119"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzUxMDI_93e14d86-a5d1-4c21-bcf4-ddaac1bdd697">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i8b0e0ca6351c413a82a3c23dea9a45aa_D20201119-20201119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzgyNDYzMzcyMTUyNzg_0fcf361f-41b0-4c18-9600-914edf3bd40d"
      unitRef="usd">200000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5a5c869b237944468340c8ac74252d01_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzIxOTkwMjMyNjg2MDg_2fa9c65d-a038-44a3-8748-91d9d77ed84b"
      unitRef="usd">-1200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzUzODU_658a1aaf-acc9-4262-baaf-aa944041b55b"
      unitRef="number">0.095</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMTgvZnJhZzplNGNlODNhODc3NWU0YmM5YmFmMDMzNmM3ZjljMzYwZC90ZXh0cmVnaW9uOmU0Y2U4M2E4Nzc1ZTRiYzliYWYwMzM2YzdmOWMzNjBkXzUzOTI_6d280f67-7274-4522-9a6c-2192b2403b57"
      unitRef="number">0.064</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <fhtx:CommonStockTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzAvZnJhZzoxMGVkMmVjYjc1ZWI0NWFkOTZhMTU3MWE1NjkwNTZmMi90ZXh0cmVnaW9uOjEwZWQyZWNiNzVlYjQ1YWQ5NmExNTcxYTU2OTA1NmYyXzgxOA_c1a7cada-cb59-4732-b45c-bc2eb1f6eab7">Common Stock&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October&#160;27, 2020, the Company completed its initial public offering (&#x201c;IPO&#x201d;) pursuant to which it issued and sold 7,500,000 shares of its common stock at a public offering price of $16.00 per share, resulting in net proceeds of $107.9 million, after deducting underwriting discounts and commissions and other offering expenses. On November&#160;19, 2020, the Company issued and sold an additional 951,837 shares of common stock at the IPO price of $16.00 per share pursuant to the underwriters&#x2019; partial exercise of their option to purchase additional shares of common stock, resulting in additional net proceeds of $14.2 million after deducting underwriting discounts and commissions. Upon the closing of the IPO, all of the Company&#x2019;s outstanding convertible preferred stock automatically converted into shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 10, 2021, the Company completed a collaboration agreement with Lilly (See Note 9). Concurrent with the collaboration agreement the Company completed a stock purchase agreement with Lilly and issued and sold Lilly 4,000,000 shares of its common stock at a price of $20.00 per share, resulting in net proceeds of $80.0 million of which &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$42.2 million was allocated to equity upon the issuance of the Company&#x2019;s common stock (see Note 9)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders. Common stockholders are not entitled to receive dividends, unless declared by the board of directors.</fhtx:CommonStockTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i200e1e33978e497897a00efb7d79afa3_D20201027-20201027"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzAvZnJhZzoxMGVkMmVjYjc1ZWI0NWFkOTZhMTU3MWE1NjkwNTZmMi90ZXh0cmVnaW9uOjEwZWQyZWNiNzVlYjQ1YWQ5NmExNTcxYTU2OTA1NmYyXzEzNw_2673740b-18a5-4a16-be96-2e8931c616b8"
      unitRef="shares">7500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i994acb4549c24113977b0c0609947658_I20201027"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzAvZnJhZzoxMGVkMmVjYjc1ZWI0NWFkOTZhMTU3MWE1NjkwNTZmMi90ZXh0cmVnaW9uOjEwZWQyZWNiNzVlYjQ1YWQ5NmExNTcxYTU2OTA1NmYyXzE5Nw_5ab66143-aebc-4797-8e25-570105cdfb58"
      unitRef="usdPerShare">16.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i200e1e33978e497897a00efb7d79afa3_D20201027-20201027"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzAvZnJhZzoxMGVkMmVjYjc1ZWI0NWFkOTZhMTU3MWE1NjkwNTZmMi90ZXh0cmVnaW9uOjEwZWQyZWNiNzVlYjQ1YWQ5NmExNTcxYTU2OTA1NmYyXzI0MA_386fc6fb-2b07-4edb-b3bf-a6c0024f7e30"
      unitRef="usd">107900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i14dfffaa2d514c159c93b8d68536b5ba_D20201119-20201119"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzAvZnJhZzoxMGVkMmVjYjc1ZWI0NWFkOTZhMTU3MWE1NjkwNTZmMi90ZXh0cmVnaW9uOjEwZWQyZWNiNzVlYjQ1YWQ5NmExNTcxYTU2OTA1NmYyXzM5Mg_bc55da06-bdc0-4d4a-b405-6cdcdc0268de"
      unitRef="shares">951837</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i642c088ef7d642369dbab1bad144e018_I20201119"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzAvZnJhZzoxMGVkMmVjYjc1ZWI0NWFkOTZhMTU3MWE1NjkwNTZmMi90ZXh0cmVnaW9uOjEwZWQyZWNiNzVlYjQ1YWQ5NmExNTcxYTU2OTA1NmYyXzQzOA_40e1c51d-1bc5-4c11-ab4e-9a947fff69a8"
      unitRef="usdPerShare">16.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i14dfffaa2d514c159c93b8d68536b5ba_D20201119-20201119"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzAvZnJhZzoxMGVkMmVjYjc1ZWI0NWFkOTZhMTU3MWE1NjkwNTZmMi90ZXh0cmVnaW9uOjEwZWQyZWNiNzVlYjQ1YWQ5NmExNTcxYTU2OTA1NmYyXzYwMQ_615fc25d-ec99-4631-93b7-865572f2c614"
      unitRef="usd">14200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iabf346f1d20b4fbab0cb034770c8cc7b_D20211210-20211210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzAvZnJhZzoxMGVkMmVjYjc1ZWI0NWFkOTZhMTU3MWE1NjkwNTZmMi90ZXh0cmVnaW9uOjEwZWQyZWNiNzVlYjQ1YWQ5NmExNTcxYTU2OTA1NmYyXzgyNDYzMzcyMDkzMDk_99cb0e08-c85a-475e-856a-0ab66ae76830"
      unitRef="shares">4000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i7545d56c585441a18935d61361a1f6e3_I20211210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzAvZnJhZzoxMGVkMmVjYjc1ZWI0NWFkOTZhMTU3MWE1NjkwNTZmMi90ZXh0cmVnaW9uOjEwZWQyZWNiNzVlYjQ1YWQ5NmExNTcxYTU2OTA1NmYyXzgyNDYzMzcyMDkzNTQ_d217642c-81d7-4c0d-9918-8f6542750481"
      unitRef="usdPerShare">20.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iabf346f1d20b4fbab0cb034770c8cc7b_D20211210-20211210"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzAvZnJhZzoxMGVkMmVjYjc1ZWI0NWFkOTZhMTU3MWE1NjkwNTZmMi90ZXh0cmVnaW9uOjEwZWQyZWNiNzVlYjQ1YWQ5NmExNTcxYTU2OTA1NmYyXzgyNDYzMzcyMDkzOTg_4569002f-0fd6-43b8-8662-70e5ab39dd15"
      unitRef="usd">80000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i146aef1b1a8a405cb503481b39bfb902_D20211210-20211210"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzAvZnJhZzoxMGVkMmVjYjc1ZWI0NWFkOTZhMTU3MWE1NjkwNTZmMi90ZXh0cmVnaW9uOjEwZWQyZWNiNzVlYjQ1YWQ5NmExNTcxYTU2OTA1NmYyXzk4OTU2MDQ2NTMzODM_963d229b-17ea-449e-9e61-68c3710ca114"
      unitRef="usd">42200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzY1Mjc_8b57ed7e-91e7-4ef5-b7c9-efcbd43990f7">Stock-Based Compensation&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2016 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s 2016 Stock Incentive Plan, (the &#x201c;2016 Plan&#x201d;) provided for the Company to grant incentive stock options or nonqualified stock options and other equity awards to employees, directors and consultants of the Company. Upon the effectiveness of the 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;) in October 2020, the Company ceased granting additional awards under the 2016 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2020 Plan provides for the grant of incentive stock options,&#160;non-qualified&#160;options, stock appreciation rights, restricted stock awards, restricted stock units and other&#160;stock-based awards. The number of shares initially reserved for issuance under the 2020 Plan was (i) 2,200,000 shares (the &#x201c;share pool&#x201d;), plus (ii)&#160;the number of shares of common stock available for issuance under the 2016 Plan as of the effective date of the 2020 Plan, plus the number of shares of common stock underlying awards under the 2016 Plan that on or after the date of adoption expire or become unexercisable without delivery of shares, are forfeited to, or repurchased for cash, are settled in cash, or otherwise become available again for grant under the 2016 Plan, in each case, in accordance with its terms (up to an aggregate of 5,078,295 shares). As of December&#160;31, 2021, 2,271,847 shares remained available for future grant under the 2020 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The share pool will automatically increase on January&#160;1 of each year from 2021 to 2030 by the lesser of (i)&#160;four percent of the number of shares of our common stock outstanding as of the close of business on the immediately preceding December&#160;31 and (ii)&#160;the number of shares determined by the board of directors on or prior to such date for such year.&#160;The number of shares reserved for issuance under the 2020 Plan was increased by 1,651,989 shares effective January&#160;1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2020 Plan is administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions are determined at the discretion of the board of directors, or its committee if so delegated. Stock options granted with service-based vesting conditions generally vest over four years and expire after ten years. The exercise price for stock options granted is not less than the fair value of common stock on the date of grant. The Company bases fair value of common stock on the quoted market price. Prior to the IPO, the board of directors determined the value the Company&#x2019;s common stock, taking into consideration its most recently available valuation of common stock performed by third parties as well as additional relevant factors which may have changed since the date of the most recent contemporaneous valuation through the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October&#160;21, 2020, the Company&#x2019;s board of directors adopted and its stockholders approved the 2020 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), which became effective on October&#160;21, 2020. The aggregate number of shares of common stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;available for purchase pursuant to the exercise of options under the ESPP is 360,000 shares, plus an automatic annual increase, as of January&#160;1 of each year from 2021 to 2030, equal to the lesser of one percent of the number of shares of common stock outstanding as of the close of business on the immediately preceding December&#160;31 and (ii)&#160;the number of shares determined by the board of directors on or prior to such date for such year (up to a maximum of 3,220,520 shares). The number of shares reserved for issuance under the ESPP was increased by 367,894 shares to 780,891 shares effective January&#160;1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The first offering period commenced under the ESPP on September 1, 2021. For the year ended December&#160;31, 2021, the Company recognized a de minimis amount of expense related to the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock option valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock option grants is estimated using the Black-Scholes option-pricing model. The Company currently lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies. The expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted during the years ended December&#160;31, 2021 and 2020 which was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s option activity during the year ended December&#160;31, 2021 which was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,016,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,719,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(508,774)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(306,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,920,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested and expected to vest as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,920,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercisable as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,435,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#x2019;s common stock. The aggregate intrinsic value of stock options exercised during the years ended December&#160;31, 2021 and 2020 was $5.3 million and $3.5 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant-date fair value of stock options granted during the years ended December&#160;31, 2021 and 2020 was $10.40 per share and $6.01 per share, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted common stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2015, the Company issued and sold 4,459,459 shares of restricted common stock at par value to the scientific founders of the Company. The shares were subject to vesting over a period of five years and began vesting in April 2016 and were fully vested as of December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate fair value of restricted stock that vested during the years ended December&#160;31, 2020 was $4.8 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense related to common stock options and restricted common stock in the following expense categories of its consolidated statements of operations and comprehensive loss during the years ended December&#160;31, 2021 and 2020 which was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, total unrecognized compensation cost related to unvested options was $20.8 million, which is expected to be recognized over a weighted average period of 2.7 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="id726ec1ea7b74a18882e37d4c46d322d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzg5Nw_808eb846-10a2-4e46-a27e-0f97f6729e0f"
      unitRef="shares">2200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i66c95f1c25a3420bb352629cf4f1de89_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzE0MzQ_7450183b-889e-4aca-9819-9975e1af0df6"
      unitRef="shares">5078295</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="id726ec1ea7b74a18882e37d4c46d322d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzE0NTY_b956c214-e575-47cd-99a7-689626d43f49"
      unitRef="shares">2271847</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <fhtx:ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage
      contextRef="ib1f18e1cd74a4d7aaab2d0502973207a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzE2NDkyNjc0NTA0MTM_ee406994-1988-4fe6-b686-741ba515dbec"
      unitRef="number">0.04</fhtx:ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i6b428a6c1acd40cf865512a4a620af6a_D20220101-20220101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzE5NDg_4e75173d-1287-44f6-9aab-384c7f9e3146"
      unitRef="shares">1651989</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ib1f18e1cd74a4d7aaab2d0502973207a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzIzNzM_9bdfc73a-8d7f-4cfe-80c1-7f6e2846cd0b">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ib1f18e1cd74a4d7aaab2d0502973207a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzIzOTM_fa2014dc-85c9-4ffd-8adf-6a0e0c839e4f">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i98cc31b8aad74865a5d00291d5e0a72c_I20201021"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzMyNzc_238fbb62-4cf1-4d4d-abda-2fa8f1de0d94"
      unitRef="shares">360000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <fhtx:ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage
      contextRef="i41b3935d055e4939a3944280d0f2de1e_D20201001-20201021"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzE2NDkyNjc0NTA0MzY_aa46ae84-a3e3-4214-a145-ca3a725c4125"
      unitRef="number">0.01</fhtx:ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage>
    <fhtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares
      contextRef="ia19ec2fabe1a4533bf2258db4754d4d1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzM2NDg_719c45f0-9e5b-45e8-9e91-1b2d5cb67810"
      unitRef="shares">3220520</fhtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i607096de8c294fdbb48bcd8c3b29b30e_D20220101-20220101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzM3MzU_f9a4813c-01ba-42d5-ac49-f11a1e97d284"
      unitRef="shares">367894</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i6d95bd0fdd7e4e81bd6d70d4f7c1ca41_I20220101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzQzOTgwNDY1MTk0Mjc_523f5cad-8246-44d1-a28c-ed946a666d5b"
      unitRef="shares">780891</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzY1Mjg_a45f6688-4f9b-4b4d-bdc6-887b73f61cc8">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted during the years ended December&#160;31, 2021 and 2020 which was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTplMjM2ZWVhZmE3ZTQ0YjJjYmE4MTU1ZWEyZGU4NWFkYy90YWJsZXJhbmdlOmUyMzZlZWFmYTdlNDRiMmNiYTgxNTVlYTJkZTg1YWRjXzItMS0xLTEtMA_63aa943f-f838-4053-8812-50618a6d8917"
      unitRef="number">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTplMjM2ZWVhZmE3ZTQ0YjJjYmE4MTU1ZWEyZGU4NWFkYy90YWJsZXJhbmdlOmUyMzZlZWFmYTdlNDRiMmNiYTgxNTVlYTJkZTg1YWRjXzItMy0xLTEtMA_24bf8c76-9fdf-4a95-a8e6-34eaa862abfe"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTplMjM2ZWVhZmE3ZTQ0YjJjYmE4MTU1ZWEyZGU4NWFkYy90YWJsZXJhbmdlOmUyMzZlZWFmYTdlNDRiMmNiYTgxNTVlYTJkZTg1YWRjXzMtMS0xLTEtMA_bbf25ff5-196b-4fa7-95f5-e539e2e7ae23"
      unitRef="number">0.788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTplMjM2ZWVhZmE3ZTQ0YjJjYmE4MTU1ZWEyZGU4NWFkYy90YWJsZXJhbmdlOmUyMzZlZWFmYTdlNDRiMmNiYTgxNTVlYTJkZTg1YWRjXzMtMy0xLTEtMA_0505de21-41d3-4656-8db5-6a86f0a3c47c"
      unitRef="number">0.785</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTplMjM2ZWVhZmE3ZTQ0YjJjYmE4MTU1ZWEyZGU4NWFkYy90YWJsZXJhbmdlOmUyMzZlZWFmYTdlNDRiMmNiYTgxNTVlYTJkZTg1YWRjXzQtMS0xLTEtMA_b56e5ad9-96d7-489d-b11d-8787248b9468"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTplMjM2ZWVhZmE3ZTQ0YjJjYmE4MTU1ZWEyZGU4NWFkYy90YWJsZXJhbmdlOmUyMzZlZWFmYTdlNDRiMmNiYTgxNTVlYTJkZTg1YWRjXzQtMy0xLTEtMA_bca96b34-e1d1-405b-a8c3-5fc036fda03d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTplMjM2ZWVhZmE3ZTQ0YjJjYmE4MTU1ZWEyZGU4NWFkYy90YWJsZXJhbmdlOmUyMzZlZWFmYTdlNDRiMmNiYTgxNTVlYTJkZTg1YWRjXzUtMS0xLTEtMA_aa876855-950e-4bcd-b801-ebd8eb22eec2">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTplMjM2ZWVhZmE3ZTQ0YjJjYmE4MTU1ZWEyZGU4NWFkYy90YWJsZXJhbmdlOmUyMzZlZWFmYTdlNDRiMmNiYTgxNTVlYTJkZTg1YWRjXzUtMy0xLTEtMA_1e1d90d9-6f41-4fc4-9eed-3a7c89856e8f">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzY1Mjk_9affee9b-4d62-45d2-9621-65033919e359">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s option activity during the year ended December&#160;31, 2021 which was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,016,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;76,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,719,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(508,774)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(306,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,920,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested and expected to vest as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,920,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercisable as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,435,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzItMS0xLTEtMA_2a60d652-60a2-407f-b618-502d623c5e51"
      unitRef="shares">5016460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzItMy0xLTEtMA_440d881e-21d1-4084-868e-1a9553cc1845"
      unitRef="usdPerShare">4.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzItNS0xLTEtMzU4MDA_8abffb48-2a3d-4ec8-9ce0-a479c445875e">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzItNy0xLTEtMzU4MDA_9e362c52-240d-4007-abb9-b777bc271595"
      unitRef="usd">76941000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzMtMS0xLTEtMA_7bc3c66d-cde6-49c2-a269-cad8cb2a3715"
      unitRef="shares">1719563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzMtMy0xLTEtMA_6c91da51-f51b-4dde-8e53-42ca5aab7c37"
      unitRef="usdPerShare">15.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzQtMS0xLTEtMA_4be3186e-33eb-450c-9687-fa390e0c5d9f"
      unitRef="shares">508774</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzQtMy0xLTEtMA_557b4b5f-8278-40f1-b98a-a6d7a06ca5ca"
      unitRef="usdPerShare">2.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzUtMS0xLTEtMA_354f8a93-8ef4-4f46-bda9-b842363137f0"
      unitRef="shares">306740</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzUtMy0xLTEtMA_eb5e5fe2-2eae-4a8e-96b1-b4a5b9726c51"
      unitRef="usdPerShare">10.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzYtMS0xLTEtMA_7e8a6a4f-fb91-41c6-8454-b0725529fb4f"
      unitRef="shares">5920509</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzYtMy0xLTEtMA_c149957d-5283-407d-8893-85472750778d"
      unitRef="usdPerShare">7.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzYtNS0xLTEtMA_809fa7de-4878-4794-8336-997873fc4b8b">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzYtNy0xLTEtMA_64aca36c-c37b-46a2-8b3c-259984cb2b5c"
      unitRef="usd">88720000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzctMS0xLTEtMA_3601062b-8f3b-4376-a6e7-7a6c3addd236"
      unitRef="shares">5920509</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzctMy0xLTEtMA_611746fe-0c67-4195-99f5-51aaa3cb3804"
      unitRef="usdPerShare">7.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzctNS0xLTEtMA_da2fce6b-66f4-44ea-ac4a-fd950be32ffb">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzctNy0xLTEtMA_91598b08-70ad-454c-8f05-63342746d73d"
      unitRef="usd">88720000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzgtMS0xLTEtMA_0cd3f3f8-02fc-49b7-a7a2-01b26dfe83a5"
      unitRef="shares">2435439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzgtMy0xLTEtMA_88915a31-fc68-46ba-8dba-42b77471d053"
      unitRef="usdPerShare">3.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzgtNS0xLTEtMA_b9a52aa5-fa4a-4d47-955d-a719d4b9070d">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTpkYmExNDM0MWQwNTk0NWE1YTcyYmI2NzM5ZTNkNDdlMi90YWJsZXJhbmdlOmRiYTE0MzQxZDA1OTQ1YTVhNzJiYjY3MzllM2Q0N2UyXzgtNy0xLTEtMA_98cb8a59-0db0-43f8-a59c-19e6f56e2076"
      unitRef="usd">46882000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzU0MDM_ddebaf99-d221-47ae-823c-21d791c7deee"
      unitRef="usd">5300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzU0MTA_dcce7da3-74c3-4040-8031-2fc00aa9e080"
      unitRef="usd">3500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzgyNDYzMzcyMTY2MDU_9daeb2a5-3cb8-465b-9c6a-3e1f3b8b6891"
      unitRef="usdPerShare">10.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzgyNDYzMzcyMTY2MTU_1275264a-8ade-48db-99a7-f077db9129e1"
      unitRef="usdPerShare">6.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i4582998cb4fb486daa23cdd87422567d_D20150101-20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzU2NDM_b088ad9a-8dd5-4d06-8081-e1f35ba830ac"
      unitRef="shares">4459459</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i59b51c6004e744ce976e8146e0351d7b_D20160401-20160430"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzEwOTk1MTE2MzQzNDk_2587c89e-dff3-4491-9b46-0c9db2170d6d">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzYxMjE_3afb8fda-bc63-48bf-b9ef-73ac9a66d502"
      unitRef="usd">4800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzY1MjY_8f6a6f05-75a2-4faf-bfbc-eaacce60b80f">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense related to common stock options and restricted common stock in the following expense categories of its consolidated statements of operations and comprehensive loss during the years ended December&#160;31, 2021 and 2020 which was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="ic0ad5b09bca848e28ffcaee3d672d862_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTo1MzJiOTAzODgxZjU0NjI5OWJlMGUxM2FjYmY3YmU5Mi90YWJsZXJhbmdlOjUzMmI5MDM4ODFmNTQ2Mjk5YmUwZTEzYWNiZjdiZTkyXzItMS0xLTEtMA_26f7ead0-62bb-4f54-83de-e34e2b000fa0"
      unitRef="usd">4324000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i12b80e675b334f9bb84e42822020fb90_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTo1MzJiOTAzODgxZjU0NjI5OWJlMGUxM2FjYmY3YmU5Mi90YWJsZXJhbmdlOjUzMmI5MDM4ODFmNTQ2Mjk5YmUwZTEzYWNiZjdiZTkyXzItMy0xLTEtMA_c41dcdc7-14d3-4935-a151-8411c2985c7b"
      unitRef="usd">1724000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if52bb65557044014ad2e63a31d0a1950_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTo1MzJiOTAzODgxZjU0NjI5OWJlMGUxM2FjYmY3YmU5Mi90YWJsZXJhbmdlOjUzMmI5MDM4ODFmNTQ2Mjk5YmUwZTEzYWNiZjdiZTkyXzMtMS0xLTEtMA_f9c9d2a5-464c-477a-bedb-e48cabf428a4"
      unitRef="usd">4060000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i8d7a3942a9c94293aa8e8f466ced6118_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTo1MzJiOTAzODgxZjU0NjI5OWJlMGUxM2FjYmY3YmU5Mi90YWJsZXJhbmdlOjUzMmI5MDM4ODFmNTQ2Mjk5YmUwZTEzYWNiZjdiZTkyXzMtMy0xLTEtMA_4b44401b-7092-488f-b8b1-f56ba151ae03"
      unitRef="usd">1237000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTo1MzJiOTAzODgxZjU0NjI5OWJlMGUxM2FjYmY3YmU5Mi90YWJsZXJhbmdlOjUzMmI5MDM4ODFmNTQ2Mjk5YmUwZTEzYWNiZjdiZTkyXzQtMS0xLTEtMA_9ef92616-e900-4c40-9ee6-86bedfa0d7bd"
      unitRef="usd">8384000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90YWJsZTo1MzJiOTAzODgxZjU0NjI5OWJlMGUxM2FjYmY3YmU5Mi90YWJsZXJhbmdlOjUzMmI5MDM4ODFmNTQ2Mjk5YmUwZTEzYWNiZjdiZTkyXzQtMy0xLTEtMA_29aa2ae9-da16-4004-b1bb-c646a764ba0a"
      unitRef="usd">2961000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzY0NTE_c824bf96-fe8a-4f59-815a-fabfdf53f9ce"
      unitRef="usd">20800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xMzYvZnJhZzoyYTU3ZjZhM2FlZjc0N2FmYjUxZDg5ZmJmYmYxYzIwMi90ZXh0cmVnaW9uOjJhNTdmNmEzYWVmNzQ3YWZiNTFkODlmYmZiZjFjMjAyXzY1MjQ_7452695c-9ef2-492c-aac0-9ac644fea749">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzYzNjk_1dd551c3-76e7-4c59-8e74-57f6a40cf5b5">Collaboration Agreements&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lilly Collaboration Agreement and Stock Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the Company entered into a collaboration agreement (the &#x201c;Lilly Collaboration Agreement") with Lilly to create novel oncology medicines by applying Foghorn&#x2019;s proprietary Gene Traffic Control platform. The collaboration includes a co-development and co-commercialization agreement for the Company&#x2019;s selective BRM oncology target, consisting of two programs, and one additional undisclosed oncology target (collectively, the &#x201c;Joint Programs&#x201d;). The collaboration also includes three additional discovery targets or programs (collectively, the &#x201c;Discovery Programs&#x201d;) for a total of six programs directed at five targets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to the Joint Programs, the Company will lead discovery and early research activities through the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; successful &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;completion of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;dose finding toxicity studies &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the identified compound, while Lilly will lead development and commercialization activities of the identified compound with participation from the Company in development activities and 50% cost sharing until registrational clinical trials. The Company and Lilly may jointly develop and commercialize the Joint Program compound though the Company may, in its sole discretion, opt-out on a program-by-program basis of further participation in the development and commercialization efforts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;prior to t&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he first registrational clinical trial. If the Company does not opt-out, Lilly and the Company will continue to share in the costs to further develop and commercialize the Joint Program compound on a worldwide basis, equally share in the U.S. profits on product sales, subject to certain adjustments and receive royalties on sales outside of the United States (&#x201c;Ex-U.S.&#x201d;) at royalty rates ranging from low double digits to high twenties. If the Company opts-out of further development and commercialization efforts, it will have no further obligations to share in the development and commercialization costs, will receive royalties rather than profit share on U.S. sales and will receive royalties at a lower rate on Ex-U.S. sales.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to the Discovery Programs, the Company will lead discovery and early research activities through the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;successful completion of dose finding toxicity studies for the identified compounds. The Company may, in its sole discretion, opt in on a&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; program-by-program basis after the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;successful c&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ompletion of dose finding toxicity to participate in the further development and commercialization efforts of the Discovery Program compounds. If the Company opts-in to the development and commercialization of the Discovery Program compounds, it will be eligible to receive milestone payments of up to $10.0 million per program upon specified research and development milestones and up to $180.0 million per program upon achievement of specified regulatory and commercial milestones and will also be eligible to share in the U.S. profits at pre-determined percentages on product sales. The Company would also be eligible to receive tiered Ex-U.S. royalty rates, calculated on a product-by-product and country-by-country basis, on net sales outside of the United States, if any, ranging from low single digits to low double digits, but less then teens. If the Company does not opt in to further development and commercialization efforts for the Discovery Programs, it will be eligible to receive milestone payments of up to $70.0 million per program upon specified research and development milestones and up to $360.0 million per program upon achievement of specified regulatory and commercial milestones per approved product, if any. The Company would also be eligible to receive &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tiered royalties on net sales of products worldwide at royalty rates ranging from low single digits to low double digits, but less then teens.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lilly has the right to make substitutions for each of the five targets during the research term of each program, subject to certain limitations. Pursuant to the Lilly Collaboration Agreement, the Company will also participate in joint decision-making through the joint steering committee and subcommittees. Unless terminated earlier, the Lilly Collaboration Agreement will continue on a product-by-product basis until the expiration of all royalty obligations under the Lilly Collaboration Agreement and when neither the Company nor Lilly is developing, commercializing or manufacturing any product under the Lilly Collaboration Agreement. The Company or Lilly may terminate the Lilly Collaboration Agreement upon an uncured material breach by the other party. Lilly may also terminate the Lilly Collaboration Agreement in its entirety or on a target-by-target, program-by-program or product-by-product basis for any reason upon certain notice to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Lilly Collaboration Agreement, Lilly agreed to make a nonrefundable upfront payment of $300.0 million to the Company within thirty (30) business days following the effective date of the agreement. Simultaneously with the execution of the Lilly Collaboration Agreement, the Company and Lilly entered into the Lilly SPA, pursuant to which Lilly purchased 4,000,000 shares of the Company&#x2019;s common stock at $20.00 per share, for an aggregate purchase price of $80.0 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the Lilly Collaboration Agreement and the stock purchase agreement entered into with Lilly concurrently (the "Lilly SPA") should be evaluated as a combined contract in accordance with ASC 606. The Company determined the fair value of the shares sold under the Lilly SPA to be $37.8 million less than the contractual purchase price stipulated in the Lilly SPA. In accordance with the applicable accounting guidance in ASC 815-40, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts in Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company determined that the sale of stock should be recorded at fair value and therefore allocated the excess consideration received under the Lilly SPA to the Lilly Collaboration Agreement, which along with the non-refundable payment of $300.0 million will be recognized as revenue over the total estimated period of performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounted for the arrangement under ASC 606 as the Company concluded it has a customer relationship with Lilly. The Company determined that (1) the research activities performed by the Company for both the Joint Programs and the Discovery Programs (2) the development activities and cost sharing for the Joint Program development efforts after dose finding toxicity until registrational clinical trials (3) the research, development, manufacture and commercialization licenses and (4) service on the joint steering committee and subcommittees represent a single performance obligation under the Lilly Collaboration Agreement. The Company determined that Lilly cannot benefit from the licenses separately from the research activities, the development activities until registrational clinical trials and participation on the joint steering committee and subcommittees because these services are specialized and rely on the Company&#x2019;s expertise such that these activities are highly interrelated and therefore not distinct. Accordingly, the promised goods and services represent one combined performance obligation, and the entire transaction price was allocated to that single combined performance obligation. The performance obligation will be satisfied over time as the Company performs the research activities, participates and shares in the cost of the development activities for the Joint Programs and participates in a joint steering committee and subcommittees to oversee these activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s options to share in further development and commercialization efforts via its opt-in/opt-out rights will be assessed and accounted for as separate units of accounting under the relevant guidance if, and when, such options are exercised by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price of $337.8 million was initially recorded as deferred revenue and is being recognized as revenue as the performance obligation is satisfied. The Company recognizes revenue using the cost-to-cost method, which it believes best depicts the transfer of control to the customer over time. Under the cost-to-cost method, the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation. Under this method, revenue is recorded as a percentage of the estimated transaction price based on the extent of progress towards completion. As of December 31, 2021, the potential research, development and regulatory milestone payments that the Company is eligible to receive were excluded from the transaction price as they were fully constrained by uncertain events. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and if necessary, the Company will adjust its estimate of the transaction price. Any additions to the transaction price would be reflected in the period as a cumulative revenue catch-up based on the ratio of costs incurred to the total estimated costs expected applied to the revised transaction price. Sales-based royalties and milestone payments, which predominantly relate to the license, will be recognized if and when the related sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the aggregate amount of the transaction price related to the unsatisfied portion of the performance obligation was $337.2 million, which is expected to be recognized as revenue through 2029. The Company does not expect collaboration revenue to be recognized evenly over this period as it will be recognized on a percentage of completion basis (using cost-to-cost method) as the Company performs the research and development activities and participates on the joint &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;steering committee and subcommittees, which will likely vary from period to period. In estimating the total costs to satisfy its single performance obligation pursuant to the Lilly Collaboration Agreement, the Company is required to make significant estimates including an estimate of the number of target substitutions Lilly may elect to make and the expected time and expected costs to fulfill the performance obligation. The cumulative effect of revisions to the total estimated costs to complete the Company&#x2019;s single performance obligation will be recorded in the period in which the changes are identified, and amounts can be reasonably estimated. While such revisions will have no impact on the Company&#x2019;s cash flows, a significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods and the classification of deferred revenue between short-term and long-term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At inception, the Company assessed the Lilly Collaboration Agreement to determine whether a significant financing component exists and concluded that a significant financing component does not exist. For the year ended December 31, 2021, the Company had recorded $0.6 million of revenue under the Lilly Collaboration Agreement, which was included in deferred revenue at contract inception. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the upfront payment of $300.0&#160;million was recorded as collaboration receivable on the Company's consolidated balance sheets. In January 2022, the $300.0 million was collected from Lilly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Merck Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, the Company entered into a research collaboration and license agreement (the &#x201c;Merck Collaboration Agreement&#x201d;) with Merck Sharp&#160;&amp;amp; Dohme Corp. (&#x201c;Merck&#x201d;). The Company and Merck will apply Foghorn&#x2019;s proprietary Gene Traffic Control platform to discover and develop novel therapeutics. Under the Merck Collaboration Agreement, the Company granted Merck exclusive global rights to develop, manufacture and commercialize drugs that target dysregulation of a single transcription factor. Under the terms of the Merck Collaboration Agreement, the Company and Merck are each responsible to perform certain research activities in accordance with a mutually agreed upon research plan. Merck may substitute the selected transcription factor during certain stages of the research program, subject to certain limitations. Following completion of the research program, Merck is responsible for the development and commercialization of the compounds developed pursuant to the research program and any product containing such compounds. Pursuant to the Merck Collaboration Agreement, the Company will also participate on a joint steering committee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Foghorn received a nonrefundable upfront payment of $15.0 million from Merck, and is eligible to receive up to $245.0 million upon achievement of specified research, development and regulatory milestones by any product candidate generated by the collaboration, and up to $165.0 million upon achievement of specified sales-based milestones per approved product from the collaboration, if any. The Company will be eligible to receive tiered royalties, calculated on a product-by-product and country-by-country basis, on net sales of approved products from the collaboration, if any, at royalty rates ranging from the mid-single digits to low tens, depending on whether the products are covered by patent rights it licenses to Merck.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless terminated earlier, the Merck Collaboration Agreement will continue in full force and effect until one or more products has received marketing authorization and, thereafter, until expiration of all royalty obligations under the Merck Collaboration Agreement. The Company or Merck may terminate the Merck Collaboration Agreement upon an uncured material breach by the other party or insolvency of the other party. Merck may also terminate the Merck Collaboration Agreement for any reason upon certain notice to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the (1)&#160;research, development, manufacture and commercialization licenses, (2) the research activities performed by the Company and (3)&#160;service on the joint committees represent a single performance obligation under the Merck Collaboration Agreement. The Company determined that Merck cannot benefit from the licenses separately from the research activities and participation on the joint steering committee because these services are specialized and rely on the Company&#x2019;s expertise such that these activities are highly interrelated and therefore not distinct. Accordingly, the promised goods and services represent one combined performance obligation and the entire transaction price was allocated to that single combined performance obligation. The performance obligation will be satisfied over the research term as the Company performs the research activities and participates in a joint steering committee to oversee research activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The upfront payment of $15.0 million was initially recorded as deferred revenue and is being recognized as revenue as the performance obligation is satisfied. The Company recognizes revenue using&#160;the&#160;cost-to-cost&#160;method,&#160;which it believes best depicts the transfer of control to the customer over time. Under&#160;the&#160;cost-to-cost&#160;method,&#160;the extent of progress towards completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified performance obligation. Under this method, revenue is recorded as a percentage of the estimated transaction price based on the extent of progress towards completion. As of December&#160;31, 2021, the potential research, development and regulatory milestone payments that the Company is eligible to receive were excluded from the transaction price as they were fully constrained by uncertain events. The Company will reevaluate the transaction price at the end of each reporting period and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as uncertain events are resolved or other changes in circumstances occur, and if necessary, the Company will adjust its estimate of the transaction price. Any additions to the transaction price would be reflected in the period as a cumulative revenue&#160;catch-up based on the ratio of costs incurred to the total estimated costs expected applied to the revised transaction price.&#160;Sales-based royalties and milestone payments, which predominantly relate to the license, will be recognized if and&#160;when the related sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the aggregate amount of the transaction price related to the unsatisfied portion of the performance obligation is $13.9 million, which is expected to be recognized as revenue through 2028. The Company does not expect collaboration revenue to be recognized evenly over this period as it will be recognized on a percentage of completion basis (using cost-to-cost method) as the Company performs the research activities and participates on the joint steering committee, which will likely vary from period to period. In estimating the total costs to satisfy its single performance obligation pursuant to the Merck Collaboration Agreement, the Company is required to make significant estimates including an estimate of the number of transcription factor substitutions and the expected time and expected costs to fulfill the performance obligation.&#160;The cumulative effect of revisions to the total estimated costs to complete the Company&#x2019;s single performance obligation will be recorded in the period in which the changes are identified, and amounts can be reasonably estimated. While such revisions will have no impact on the Company&#x2019;s cash flows, a significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods and the classification of deferred revenue between short-term and long-term. In June 2021, the Company re-evaluated its estimates related to the Merck Collaboration Agreement resulting in a reclassification of $1.9&#160;million from short-term deferred revenue to long-term deferred revenue, net of current portion on the Company's consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At inception, the Company assessed the Merck Collaboration Agreement to determine whether a significant financing component exists and concluded that a significant financing component does not exist. For the year ended December&#160;31, 2021, the Company had recorded $0.7 million of revenue under the Merck Collaboration Agreement, which was included in deferred revenue at the beginning of the period &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and the classification of deferred revenue between short-term and long-term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <fhtx:NumberOfAdditionalTargets
      contextRef="id4ffb19f3c77426aa1c640fbfce74994_D20211201-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzEyMDk0NjI3OTY3OTM4_4e7d6997-93c2-4211-b439-8b402cb0078c"
      unitRef="target">3</fhtx:NumberOfAdditionalTargets>
    <fhtx:NumberOfPrograms
      contextRef="ibfef7b67aa6c4537931d0aa3b01c282e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzEyMDk0NjI3OTY3OTQ3_141748fd-91e2-47bf-ab88-2ad0f2bebcb7"
      unitRef="program">6</fhtx:NumberOfPrograms>
    <fhtx:NumberOfTargets
      contextRef="ibfef7b67aa6c4537931d0aa3b01c282e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzEyMDk0NjI3OTY3OTU3_c602d82e-8019-423a-b7ec-f3a5bc09a901"
      unitRef="target">5</fhtx:NumberOfTargets>
    <fhtx:MilestoneReceivableUponAchievement
      contextRef="i2b7a001271974fbf9927a5ce4c667237_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ2OTYxMzg_c709f5a5-2cff-4169-a6e1-7029a08884ef"
      unitRef="usd">10000000</fhtx:MilestoneReceivableUponAchievement>
    <fhtx:MilestoneReceivableUponAchievement
      contextRef="icf371cc8a9e24160bf8af37cf9d965e0_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ2OTYxNjA_c20371f3-1340-42d4-8438-3fe9b4f5082d"
      unitRef="usd">180000000</fhtx:MilestoneReceivableUponAchievement>
    <fhtx:OptOutMilestoneReceivableUponAchievement
      contextRef="i2b7a001271974fbf9927a5ce4c667237_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ2OTYxODA_ce154c39-4534-47a7-a104-686a4335fb38"
      unitRef="usd">70000000</fhtx:OptOutMilestoneReceivableUponAchievement>
    <fhtx:OptOutMilestoneReceivableUponAchievement
      contextRef="icf371cc8a9e24160bf8af37cf9d965e0_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ2OTYyMDM_f034e5d5-b635-420a-bd7d-b9bba513504a"
      unitRef="usd">360000000</fhtx:OptOutMilestoneReceivableUponAchievement>
    <fhtx:ProceedsFromUpfrontPayment
      contextRef="i1c4d412c57184ef2b09b93a7922fec1d_D20220101-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ2OTYyMjQ_e18e90fa-e318-4674-a00a-3d72b8136338"
      unitRef="usd">300000000</fhtx:ProceedsFromUpfrontPayment>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iabf346f1d20b4fbab0cb034770c8cc7b_D20211210-20211210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ2OTYyNDU_99cb0e08-c85a-475e-856a-0ab66ae76830"
      unitRef="shares">4000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i7545d56c585441a18935d61361a1f6e3_I20211210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ2OTYyNTc_d217642c-81d7-4c0d-9918-8f6542750481"
      unitRef="usdPerShare">20.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iabf346f1d20b4fbab0cb034770c8cc7b_D20211210-20211210"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ2OTYyNzA_4569002f-0fd6-43b8-8662-70e5ab39dd15"
      unitRef="usd">80000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <fhtx:DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice
      contextRef="id4ffb19f3c77426aa1c640fbfce74994_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ3MTAzNzI_2e364076-a56f-4a54-aa74-adecc1a12581"
      unitRef="usd">-37800000</fhtx:DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice>
    <fhtx:ProceedsFromUpfrontPayment
      contextRef="i1c4d412c57184ef2b09b93a7922fec1d_D20220101-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ3MTAzOTM_e18e90fa-e318-4674-a00a-3d72b8136338"
      unitRef="usd">300000000</fhtx:ProceedsFromUpfrontPayment>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i0598fb4888944458a105637a5c365acb_I20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ2OTY0MTA_60ebdf33-917c-4c04-8bff-dfa5d631feb2"
      unitRef="usd">337800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ibfef7b67aa6c4537931d0aa3b01c282e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ2OTY0NDE_0ed9052c-6472-40ec-b899-20fcc44ea4dc"
      unitRef="usd">337200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2dbcc6d4cd8b45da85ef3abc002c76e7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5Xzk4OTU2MDQ2OTY0NTk_dfc4ccbe-0b33-403d-ba97-e0d2882ccbd9"
      unitRef="usd">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzQzOTgwNDY1MzIwMzE_8c85d1d3-d3cf-4b2c-a024-9a53234cdc19"
      unitRef="usd">300000000</us-gaap:ContractWithCustomerAssetNet>
    <fhtx:ProceedsFromUpfrontPayment
      contextRef="i1c4d412c57184ef2b09b93a7922fec1d_D20220101-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzIxOTkwMjMyNzY1MTI_e18e90fa-e318-4674-a00a-3d72b8136338"
      unitRef="usd">300000000</fhtx:ProceedsFromUpfrontPayment>
    <fhtx:ProceedsFromUpfrontPayment
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzEyMjc_3fda42d4-e6c3-42fb-98f2-dafd24f66922"
      unitRef="usd">15000000</fhtx:ProceedsFromUpfrontPayment>
    <fhtx:MilestoneReceivableUponAchievement
      contextRef="i37050e2af73c4dfbbeb53cfcede910de_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzEyNzU_38437919-3464-498a-94cb-78c58316862d"
      unitRef="usd">245000000</fhtx:MilestoneReceivableUponAchievement>
    <fhtx:MilestoneReceivableUponAchievement
      contextRef="ia0fb78f785ab496ca56695669faf74b4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzE0MjM_2aa6de19-77e1-425b-8453-15df186b617b"
      unitRef="usd">165000000</fhtx:MilestoneReceivableUponAchievement>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ic857b04717ad4bdaa38f79139b0b4f77_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzMzNjE_33af955b-aac5-4823-9dfe-851f7fce684c"
      unitRef="usd">15000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i92aabf8f84a443bb8049e24e529e50a6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzQ5NDM_d52e7e15-74a5-43bd-acbf-06b0d35f52b0"
      unitRef="usd">13900000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i26f27415158a4a8dad12c8e3b7e94178_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzgyNDYzMzcyMjkwMDU_0d11d678-e21d-4129-bdb6-f4d388d6a5bc"
      unitRef="usd">1900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6b2557e266749eca4da6aa9146a5588_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDIvZnJhZzo4NWUzMTNhZjZmZDg0NTRhYmM3MzI1M2JiNmE3YjdkOS90ZXh0cmVnaW9uOjg1ZTMxM2FmNmZkODQ1NGFiYzczMjUzYmI2YTdiN2Q5XzYzMjI_09134ce7-a824-4258-8f0e-ee2ec0ada3dc"
      unitRef="usd">700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzM1NzE_3c6afdb0-fb5f-468a-881f-10e74cb4cc0b">Income Taxes&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021 and 2020, the Company recorded no income tax benefits for the net deferred tax assets comprised primarily of net operating losses incurred and research and development tax credits generated in each year, due to its uncertainty of realizing a benefit from these items.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s operating losses since inception have been generated in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal and state research and development tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in deferred tax asset valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development tax credit carryforwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized start-up costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,819)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had U.S. federal and state net operating loss carryforwards of $228.9 million and $206.0 million, respectively, which may be available to offset future taxable income. The federal net operating loss carryforwards include&#160;$12.5 million&#160;which expire at various dates beginning in&#160;2035&#160;and&#160;$216.4 million&#160;which carryforward indefinitely but in some circumstances may be limited to offset 80% of annual taxable income. The state net operating loss carryforwards expire at various dates beginning in&#160;2036.&#160;As of December&#160;31, 2021, the Company also had U.S. federal and state research and development tax credit carryforwards of $6.1 million and $4.1 million, respectively, which may be available to offset future tax liabilities and expire at various dates beginning in 2036 and 2031, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section&#160;382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section&#160;382. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being recorded as an uncertain tax position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company&#x2019;s history of cumulative net losses incurred since inception and its lack of commercialization of any products that would generate revenue from product sales and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December&#160;31, 2021 and 2020. Management reevaluates the positive and negative evidence at each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation allowance increased by $30.8 million and $21.8 million during the years ended December&#160;31, 2021 and 2020, respectively, primarily as a result of the increase in net operating loss carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, the Company had not recorded any amounts for unrecognized tax benefits. The Company files income tax returns in the U.S. and Massachusetts, as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. Since the Company is in a loss carryforward position, it is generally subject to &lt;/span&gt;&lt;/div&gt;examination by the U.S. federal, state, and local income tax authorities for all tax years in which a loss carryforward is available.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzM1NzI_92be6b65-c21b-4c07-b5a1-f0a4f4b76323">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal and state research and development tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in deferred tax asset valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzItMS0xLTEtMA_2e623f36-7138-4bd2-af21-2c7eae929fd3"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzItMy0xLTEtMA_53f90a9f-63fd-4c28-8868-82d816f06425"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzMtMS0xLTEtMA_d6355b68-2df4-4337-b248-efddcff19084"
      unitRef="number">0.058</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzMtMy0xLTEtMA_68e991a1-3608-4a3c-87ff-491339a13192"
      unitRef="number">0.064</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzQtMS0xLTEtMA_15c0506a-2ae8-4e8f-85a4-d2d23ba42b2e"
      unitRef="number">0.044</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzQtMy0xLTEtMA_e0e68b82-1afe-4127-b2f8-72c8e14783d2"
      unitRef="number">0.037</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzUtMS0xLTEtMA_e22f7da3-e072-42c1-a715-ea66a471b10e"
      unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzUtMy0xLTEtMA_5b21eb9a-c906-4901-8afa-43c3e018d05f"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzYtMS0xLTEtMA_c14809b4-e65c-4ddb-8b50-b4160eac71b8"
      unitRef="number">0.304</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzYtMy0xLTEtMA_96ff8756-34d4-4761-92be-4a9aa8b495ed"
      unitRef="number">0.316</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzctMS0xLTEtMA_951f0e1b-10e4-4344-8223-ff8adc80e2c7"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZTo4ODY4MTY0NjMwZTQ0ODI0OTg3MDc2NTQyNjY2OThkNi90YWJsZXJhbmdlOjg4NjgxNjQ2MzBlNDQ4MjQ5ODcwNzY1NDI2NjY5OGQ2XzctMy0xLTEtMA_4da55961-24fb-4043-bdd8-2dcd0d705b90"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzM1NzA_4b2e5a85-316a-4dbd-bcf9-85cf1df992f7">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development tax credit carryforwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized start-up costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;93,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,819)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzMtMS0xLTEtMA_482adcf0-9254-40cc-8790-71b39f9a84dd"
      unitRef="usd">61083000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzMtMy0xLTEtMA_2866f5f8-c634-443d-b4f3-53ad91e3fb5a"
      unitRef="usd">39289000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzQtMS0xLTEtMA_568bcd81-0fd1-4070-bee4-9586d2508f39"
      unitRef="usd">9367000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzQtMy0xLTEtMA_6a5f5986-d0e4-4eef-884d-12cb095f86fd"
      unitRef="usd">4955000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <fhtx:DeferredTaxAssetsCapitalizedStartUpCosts
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzUtMS0xLTEtMA_11f2d0f5-536c-47d1-b3ab-852d2a1498fb"
      unitRef="usd">157000</fhtx:DeferredTaxAssetsCapitalizedStartUpCosts>
    <fhtx:DeferredTaxAssetsCapitalizedStartUpCosts
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzUtMy0xLTEtMA_a8743203-1896-4808-aae6-b273d3427239"
      unitRef="usd">174000</fhtx:DeferredTaxAssetsCapitalizedStartUpCosts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzYtMS0xLTEtMA_b423c198-3ab4-45ae-9b27-30040d79f7b0"
      unitRef="usd">5300000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzYtMy0xLTEtMA_059b8ba3-7ac0-494e-97bd-7d3db06e9e68"
      unitRef="usd">1010000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzctMS0xLTEtMA_228b22b8-c755-4d3e-85a6-18e82600e4a7"
      unitRef="usd">1403000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzctMy0xLTEtMA_23db1106-0314-40e5-8ab3-58ec093473ab"
      unitRef="usd">436000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <fhtx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzgtMS0xLTEtMA_b99eea47-fdc4-44c2-8f37-c6735579adab"
      unitRef="usd">15952000</fhtx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <fhtx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzgtMy0xLTEtMA_8d15ef0c-fb20-411a-9944-18c09a18bb16"
      unitRef="usd">17032000</fhtx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzktMS0xLTEtMA_5bfe200d-95d1-4dd9-832a-adf1ca77699e"
      unitRef="usd">93262000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzktMy0xLTEtMA_cf772e27-d81e-4547-ac09-518f35fcdd0a"
      unitRef="usd">62896000</us-gaap:DeferredTaxAssetsGross>
    <fhtx:DeferredTaxLiabilitiesDepreciation
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzExLTEtMS0xLTA_2155b374-7aa2-42ac-a7b0-825befd28711"
      unitRef="usd">3551000</fhtx:DeferredTaxLiabilitiesDepreciation>
    <fhtx:DeferredTaxLiabilitiesDepreciation
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzExLTMtMS0xLTA_d38a86bc-f827-4e0e-947a-a1cdedcedb28"
      unitRef="usd">2819000</fhtx:DeferredTaxLiabilitiesDepreciation>
    <fhtx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzEyLTEtMS0xLTA_e376609c-bb5d-4778-a55e-78498e749f5e"
      unitRef="usd">10566000</fhtx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <fhtx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzEyLTMtMS0xLTA_8cfbf504-0521-4246-90a0-b49ba2c08446"
      unitRef="usd">11694000</fhtx:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzEzLTEtMS0xLTA_4a4901ef-f814-45c7-a51c-943eaca7dc80"
      unitRef="usd">14117000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzEzLTMtMS0xLTA_70209a39-ef2f-44be-9c24-9d113af8592e"
      unitRef="usd">14513000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzE0LTEtMS0xLTA_031c82b8-4131-4c65-a2a6-e78b3ac16f5f"
      unitRef="usd">79145000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzE0LTMtMS0xLTA_b6562017-c37c-4144-a2ef-22532fc1accc"
      unitRef="usd">48383000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzE1LTEtMS0xLTA_a6853d2d-292c-49a3-ab13-9a77564a1b00"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90YWJsZToxZTc5MzdmOTEwMWI0YzU0OTU5NWJlODc4ZTcwZTJmZC90YWJsZXJhbmdlOjFlNzkzN2Y5MTAxYjRjNTQ5NTk1YmU4NzhlNzBlMmZkXzE1LTMtMS0xLTA_c19d64df-7584-4a92-beac-11c660312fdf"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ie5dda4379bcf4779a73a8e6da786d5d7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzY4Nw_15ee66e4-6ab0-4356-862a-804ebaf6ff97"
      unitRef="usd">228900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ib1c22c57ec184fa7a48b0db8d9e9cbca_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzY5NA_a4fd147b-e60a-4223-a022-d17650cf77c1"
      unitRef="usd">206000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="ie5dda4379bcf4779a73a8e6da786d5d7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzgyMQ_95450c1e-6b39-4eaa-b1fe-18bc73fab67f"
      unitRef="usd">12500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="ie5dda4379bcf4779a73a8e6da786d5d7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2Xzg3NA_16db6637-b8ee-405e-89ed-501549367408"
      unitRef="usd">216400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <fhtx:OperatingLossCarryforwardLimitPercentage
      contextRef="i462afb2928a44e61adc374bf4a44a35a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2Xzk2MA_e09f7d0b-19d2-4356-93dd-378d50124848"
      unitRef="number">0.80</fhtx:OperatingLossCarryforwardLimitPercentage>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ie5dda4379bcf4779a73a8e6da786d5d7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzExODA_0e87d09b-992b-4930-bd7b-b9e40501986e"
      unitRef="usd">6100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ib1c22c57ec184fa7a48b0db8d9e9cbca_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzExODc_bfcb45fd-0413-44eb-884e-533c603e2204"
      unitRef="usd">4100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzI4MTk_3fb7d5a3-78cd-412f-912e-01f85a29c66b"
      unitRef="usd">30800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzI4MjY_1b62ba92-1fef-43c2-bf2b-8a47d539a7df"
      unitRef="usd">21800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzEwOTk1MTE2MzEzNTE_6b4d1f15-742e-4865-9d68-5380c7848ae9"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNDgvZnJhZzpiNTU5NDdlOWExZmI0OTFhODMwMTcwNmM1OGVkZDRkNi90ZXh0cmVnaW9uOmI1NTk0N2U5YTFmYjQ5MWE4MzAxNzA2YzU4ZWRkNGQ2XzEwOTk1MTE2MzEzNTE_bcf120fc-b552-4044-b94b-28ac37a15701"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzI3ODE_0872c674-360b-45d6-bb79-ee99e3495d6c">Leases&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, the Company entered into a lease for 81,441 square feet of office and laboratory space in Cambridge, Massachusetts, commencing in January 2020 (the &#x201c;New Lease&#x201d;). The initial term of the New Lease was eight years with a five-year option to extend at fair-market rent at the time of the extension. The base rent payments escalate annually over the eight-year lease term and totaled approximately $60.3 million. In connection with the New Lease, the landlord agreed to fund up to $3.0 million in tenant improvements to the leased facility as well as up to an additional $16.3 million, which resulted in additional rent payments to the landlord over the lease term. During the year ended December&#160;31, 2021 and 2020, $2.5 million and $15.4&#160;million, respectively, of leasehold improvements were reimbursed by the landlord, which resulted in an increase to operating lease liabilities. The Company is obligated to pay its portion of real estate taxes and costs related to the premises, including costs of operations and management of the leased premises. The Company is required to maintain a cash balance of $1.7 million to secure a letter of credit associated with the lease. This amount was classified as restricted cash (non-current) on the consolidated balance sheets as of December&#160;31, 2021 and 2020. On January&#160;1, 2020, the lease commencement date, the Company recorded an operating lease asset of $38.6 million and corresponding lease liability of $38.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company amended the New Lease to defer payment of a portion of the base rent and operating expenses and to extend the lease term by nine months to September 2028. The amendment was accounted for as a lease modification and the right-of-use asset and lease liability were remeasured at the modification date of June&#160;29, 2020 resulting in an increase of $7.4 million to both the right-of-use asset and lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had a lease for office and laboratory facilities in Cambridge, Massachusetts under a noncancelable operating lease that began in August 2017 and expired in March 2025. In April 2020, this lease was assigned and assumed by a related party which became effective in October 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense was as follows for the years ended December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental disclosure of cash flow information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities arising from obtaining right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increase in operating lease liabilities and right-of-use assets due to lease remeasurement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average remaining lease term and discount rate was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2014;operating leases (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future annual minimum lease payments under operating leases as of December&#160;31, 2021 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: estimated lease incentives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Included in the consolidated balance sheets (in thousands):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sublease agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In April 2020, the Company entered into a two-year sublease agreement to sublet approximately 16,843 square feet of office space under the New Lease, as amended, which began in July 2020. In February 2021, the Company entered into an amendment to the sublease to sublet approximately 2,980 square feet of additional office space to the sublessee for the remaining lease term. In July 2021, the Company entered into an amendment to, among other things, extend the sublease through November 30, 2022. As of December&#160;31, 2021, the remaining rent payments due to the Company under the amended sublease were $1.9 million. During the years ended December&#160;31, 2021 and 2020, the Company recorded other income of $2.5 million and $1.0&#160;million, respectively,  related to this sublease.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzI3ODE_f185cf4c-1c7a-4709-85d1-8acf62c3d4af">Leases&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, the Company entered into a lease for 81,441 square feet of office and laboratory space in Cambridge, Massachusetts, commencing in January 2020 (the &#x201c;New Lease&#x201d;). The initial term of the New Lease was eight years with a five-year option to extend at fair-market rent at the time of the extension. The base rent payments escalate annually over the eight-year lease term and totaled approximately $60.3 million. In connection with the New Lease, the landlord agreed to fund up to $3.0 million in tenant improvements to the leased facility as well as up to an additional $16.3 million, which resulted in additional rent payments to the landlord over the lease term. During the year ended December&#160;31, 2021 and 2020, $2.5 million and $15.4&#160;million, respectively, of leasehold improvements were reimbursed by the landlord, which resulted in an increase to operating lease liabilities. The Company is obligated to pay its portion of real estate taxes and costs related to the premises, including costs of operations and management of the leased premises. The Company is required to maintain a cash balance of $1.7 million to secure a letter of credit associated with the lease. This amount was classified as restricted cash (non-current) on the consolidated balance sheets as of December&#160;31, 2021 and 2020. On January&#160;1, 2020, the lease commencement date, the Company recorded an operating lease asset of $38.6 million and corresponding lease liability of $38.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company amended the New Lease to defer payment of a portion of the base rent and operating expenses and to extend the lease term by nine months to September 2028. The amendment was accounted for as a lease modification and the right-of-use asset and lease liability were remeasured at the modification date of June&#160;29, 2020 resulting in an increase of $7.4 million to both the right-of-use asset and lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had a lease for office and laboratory facilities in Cambridge, Massachusetts under a noncancelable operating lease that began in August 2017 and expired in March 2025. In April 2020, this lease was assigned and assumed by a related party which became effective in October 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense was as follows for the years ended December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental disclosure of cash flow information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities arising from obtaining right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increase in operating lease liabilities and right-of-use assets due to lease remeasurement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average remaining lease term and discount rate was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2014;operating leases (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future annual minimum lease payments under operating leases as of December&#160;31, 2021 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: estimated lease incentives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Included in the consolidated balance sheets (in thousands):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sublease agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In April 2020, the Company entered into a two-year sublease agreement to sublet approximately 16,843 square feet of office space under the New Lease, as amended, which began in July 2020. In February 2021, the Company entered into an amendment to the sublease to sublet approximately 2,980 square feet of additional office space to the sublessee for the remaining lease term. In July 2021, the Company entered into an amendment to, among other things, extend the sublease through November 30, 2022. As of December&#160;31, 2021, the remaining rent payments due to the Company under the amended sublease were $1.9 million. During the years ended December&#160;31, 2021 and 2020, the Company recorded other income of $2.5 million and $1.0&#160;million, respectively,  related to this sublease.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i8566261f099345058fc2de53fdeddc94_I20191031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzcw_8854c1ce-adc6-490a-82e8-0b7e642022e7"
      unitRef="sqft">81441</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i8566261f099345058fc2de53fdeddc94_I20191031"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzEwOTk1MTE2MzA1NTk_22e0ddf4-2f18-45eb-98eb-c332ff0f9726">P8Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i8566261f099345058fc2de53fdeddc94_I20191031"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzEwOTk1MTE2MzA1ODg_df48f422-660d-4f5b-88a5-4107042a8fec">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i8566261f099345058fc2de53fdeddc94_I20191031"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzEwOTk1MTE2MzA2MDE_d24ea296-eb41-4802-bc58-5d243e11a89a">P8Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseExpense
      contextRef="ie777875661fd4e1cafd3e415514e3463_D20200101-20271231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzQyMw_56a0b143-063d-48fa-acce-206c0a7b7631"
      unitRef="usd">60300000</us-gaap:OperatingLeaseExpense>
    <fhtx:LeaseholdImprovementsLandlordAllowance
      contextRef="i88337b0a640c41778757a13053c6737c_I20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzQ5NQ_fc0a2182-84e0-403c-806b-3c3661705fed"
      unitRef="usd">3000000</fhtx:LeaseholdImprovementsLandlordAllowance>
    <fhtx:LeaseholdImprovementsLandlordAllowanceToBeRepaid
      contextRef="i88337b0a640c41778757a13053c6737c_I20191031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzU3NQ_e305e6d7-7540-4f35-8e06-49f6cb6c7d3a"
      unitRef="usd">16300000</fhtx:LeaseholdImprovementsLandlordAllowanceToBeRepaid>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="i42cc5f4d622f43728d16d5f588e05289_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzY4NQ_e4267193-2778-4504-b721-dd97ed4427c7"
      unitRef="usd">-2500000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="i5df226eaed834b4d95b67a71f15df511_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzgyNDYzMzcyMTE5NzU_f9537626-6319-4b09-a7d7-79d6248f8395"
      unitRef="usd">-15400000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i5871025070284091b9843930b1b0739f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzEwMzI_45615f6f-ea8d-4af0-949f-cb07ccaeb1bf"
      unitRef="usd">1700000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie9658936ddbd4496bb318be3e882b158_I20200101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzEzMDA_fe16cba3-0ab0-4925-9b17-fdbf38e7ad5f"
      unitRef="usd">38600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="ie9658936ddbd4496bb318be3e882b158_I20200101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzEzNDA_6a9873da-035e-4c87-8d97-264f9db0f1bf"
      unitRef="usd">38300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i1de98e2458194d09aea8ba3c1fbd59d9_I20200629"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzE3MTQ_2019811c-dddf-4234-8fec-714c616c98a8"
      unitRef="usd">7400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1de98e2458194d09aea8ba3c1fbd59d9_I20200629"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzE3MTQ_eaa76276-0a2f-45f8-b65d-6b57f85f12e5"
      unitRef="usd">7400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzI3NzY_776f5542-34d5-48d6-9667-32f063f85276">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense was as follows for the years ended December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental disclosure of cash flow information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities arising from obtaining right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Increase in operating lease liabilities and right-of-use assets due to lease remeasurement&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average remaining lease term and discount rate was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2014;operating leases (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo3N2UyNGU4MDMwZTc0NzU5YWFmYTM4N2U1ZWZlYTc2MS90YWJsZXJhbmdlOjc3ZTI0ZTgwMzBlNzQ3NTlhYWZhMzg3ZTVlZmVhNzYxXzItMS0xLTEtMA_92d29bf1-b662-4e86-816c-47da52f7d99c"
      unitRef="usd">7547000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo3N2UyNGU4MDMwZTc0NzU5YWFmYTM4N2U1ZWZlYTc2MS90YWJsZXJhbmdlOjc3ZTI0ZTgwMzBlNzQ3NTlhYWZhMzg3ZTVlZmVhNzYxXzItMy0xLTEtMA_265f3afe-c9b2-412b-92f3-920298f82770"
      unitRef="usd">7032000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo3N2UyNGU4MDMwZTc0NzU5YWFmYTM4N2U1ZWZlYTc2MS90YWJsZXJhbmdlOjc3ZTI0ZTgwMzBlNzQ3NTlhYWZhMzg3ZTVlZmVhNzYxXzMtMS0xLTEtMA_36bc4bd1-2989-400b-a5a3-32d22ccb3667"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo3N2UyNGU4MDMwZTc0NzU5YWFmYTM4N2U1ZWZlYTc2MS90YWJsZXJhbmdlOjc3ZTI0ZTgwMzBlNzQ3NTlhYWZhMzg3ZTVlZmVhNzYxXzMtMy0xLTEtMA_688ecdc0-59c9-4398-b6cd-dd3c01904f51"
      unitRef="usd">61000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo3N2UyNGU4MDMwZTc0NzU5YWFmYTM4N2U1ZWZlYTc2MS90YWJsZXJhbmdlOjc3ZTI0ZTgwMzBlNzQ3NTlhYWZhMzg3ZTVlZmVhNzYxXzQtMS0xLTEtMA_f86f9c8f-b10d-4aa4-bd96-9f94ff8845a1"
      unitRef="usd">2892000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo3N2UyNGU4MDMwZTc0NzU5YWFmYTM4N2U1ZWZlYTc2MS90YWJsZXJhbmdlOjc3ZTI0ZTgwMzBlNzQ3NTlhYWZhMzg3ZTVlZmVhNzYxXzQtMy0xLTEtMA_ff2e8278-9735-42ab-b8e5-279a8f03a59e"
      unitRef="usd">1217000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo3N2UyNGU4MDMwZTc0NzU5YWFmYTM4N2U1ZWZlYTc2MS90YWJsZXJhbmdlOjc3ZTI0ZTgwMzBlNzQ3NTlhYWZhMzg3ZTVlZmVhNzYxXzUtMS0xLTEtMA_66e83356-b0ae-4ba4-94b9-254f8794b219"
      unitRef="usd">10439000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo3N2UyNGU4MDMwZTc0NzU5YWFmYTM4N2U1ZWZlYTc2MS90YWJsZXJhbmdlOjc3ZTI0ZTgwMzBlNzQ3NTlhYWZhMzg3ZTVlZmVhNzYxXzUtMy0xLTEtMA_17f6cf60-4634-4c83-9343-1e99b02932f7"
      unitRef="usd">8310000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo1NTJhNTBiYTMyNDk0ODY2YTUzZGU5NjAyMTQ3MmU3Mi90YWJsZXJhbmdlOjU1MmE1MGJhMzI0OTQ4NjZhNTNkZTk2MDIxNDcyZTcyXzItMS0xLTEtMA_dbef5066-80fc-4ff2-847d-d047c6c190fc"
      unitRef="usd">9737000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo1NTJhNTBiYTMyNDk0ODY2YTUzZGU5NjAyMTQ3MmU3Mi90YWJsZXJhbmdlOjU1MmE1MGJhMzI0OTQ4NjZhNTNkZTk2MDIxNDcyZTcyXzItMy0xLTEtMA_faf2e8b8-c3c8-4d70-b0b1-b90d93fc6c07"
      unitRef="usd">3086000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo1NTJhNTBiYTMyNDk0ODY2YTUzZGU5NjAyMTQ3MmU3Mi90YWJsZXJhbmdlOjU1MmE1MGJhMzI0OTQ4NjZhNTNkZTk2MDIxNDcyZTcyXzMtMS0xLTEtMA_c4e487e4-1b2d-4fd3-ae12-349b44d9d381"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo1NTJhNTBiYTMyNDk0ODY2YTUzZGU5NjAyMTQ3MmU3Mi90YWJsZXJhbmdlOjU1MmE1MGJhMzI0OTQ4NjZhNTNkZTk2MDIxNDcyZTcyXzMtMy0xLTEtMA_c6f005d1-1934-4a23-adc9-319c81f5f045"
      unitRef="usd">38306000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <fhtx:ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo1NTJhNTBiYTMyNDk0ODY2YTUzZGU5NjAyMTQ3MmU3Mi90YWJsZXJhbmdlOjU1MmE1MGJhMzI0OTQ4NjZhNTNkZTk2MDIxNDcyZTcyXzQtMS0xLTEtMA_23e22b9b-207a-460f-ba43-9dd4fa01230a"
      unitRef="usd">0</fhtx:ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement>
    <fhtx:ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo1NTJhNTBiYTMyNDk0ODY2YTUzZGU5NjAyMTQ3MmU3Mi90YWJsZXJhbmdlOjU1MmE1MGJhMzI0OTQ4NjZhNTNkZTk2MDIxNDcyZTcyXzQtMy0xLTEtMA_3b34066d-36ca-4679-b946-3e54c05bf4a0"
      unitRef="usd">7384000</fhtx:ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo5ZDRiMWM2MDg3Njk0MWU5YjU3N2UwYWJiNjRmNTAyZS90YWJsZXJhbmdlOjlkNGIxYzYwODc2OTQxZTliNTc3ZTBhYmI2NGY1MDJlXzEtMS0xLTEtMA_69decf80-ae34-46a8-be27-af0d85c34ac9">P6Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo5ZDRiMWM2MDg3Njk0MWU5YjU3N2UwYWJiNjRmNTAyZS90YWJsZXJhbmdlOjlkNGIxYzYwODc2OTQxZTliNTc3ZTBhYmI2NGY1MDJlXzEtMy0xLTEtMA_7ad22687-1f5d-4fe9-b063-c28ac40fc951">P7Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo5ZDRiMWM2MDg3Njk0MWU5YjU3N2UwYWJiNjRmNTAyZS90YWJsZXJhbmdlOjlkNGIxYzYwODc2OTQxZTliNTc3ZTBhYmI2NGY1MDJlXzItMS0xLTEtMA_87506c10-678e-4a60-b66d-cb8375fd49be"
      unitRef="number">0.0535</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTo5ZDRiMWM2MDg3Njk0MWU5YjU3N2UwYWJiNjRmNTAyZS90YWJsZXJhbmdlOjlkNGIxYzYwODc2OTQxZTliNTc3ZTBhYmI2NGY1MDJlXzItMy0xLTEtMA_cf0b0581-964a-4bf5-9752-41b6b4d345e3"
      unitRef="number">0.0535</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzI3Nzk_01578c75-585b-44b7-be4a-1ea24c6c15c8">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future annual minimum lease payments under operating leases as of December&#160;31, 2021 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;71,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: estimated lease incentives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZToyN2VjYjc4NGExNTU0ZmI5ODhlZGUzZTZkZjVhMzFjNi90YWJsZXJhbmdlOjI3ZWNiNzg0YTE1NTRmYjk4OGVkZTNlNmRmNWEzMWM2XzAtMS0xLTEtMA_d8482552-6077-4eb0-947d-87e50efd251d"
      unitRef="usd">9954000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZToyN2VjYjc4NGExNTU0ZmI5ODhlZGUzZTZkZjVhMzFjNi90YWJsZXJhbmdlOjI3ZWNiNzg0YTE1NTRmYjk4OGVkZTNlNmRmNWEzMWM2XzEtMS0xLTEtMA_b3f63fe8-69f5-494d-ba33-b87fae3a9be0"
      unitRef="usd">10051000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZToyN2VjYjc4NGExNTU0ZmI5ODhlZGUzZTZkZjVhMzFjNi90YWJsZXJhbmdlOjI3ZWNiNzg0YTE1NTRmYjk4OGVkZTNlNmRmNWEzMWM2XzItMS0xLTEtMA_d34be657-f576-4074-bcf5-eef0f16aef3f"
      unitRef="usd">10378000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZToyN2VjYjc4NGExNTU0ZmI5ODhlZGUzZTZkZjVhMzFjNi90YWJsZXJhbmdlOjI3ZWNiNzg0YTE1NTRmYjk4OGVkZTNlNmRmNWEzMWM2XzMtMS0xLTEtMA_ad08835b-9fc1-4a38-a017-000a25b2f4ec"
      unitRef="usd">10626000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZToyN2VjYjc4NGExNTU0ZmI5ODhlZGUzZTZkZjVhMzFjNi90YWJsZXJhbmdlOjI3ZWNiNzg0YTE1NTRmYjk4OGVkZTNlNmRmNWEzMWM2XzQtMS0xLTEtMA_5e3c6dd2-d299-4ac5-902d-6d3fa25a3e26"
      unitRef="usd">10881000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZToyN2VjYjc4NGExNTU0ZmI5ODhlZGUzZTZkZjVhMzFjNi90YWJsZXJhbmdlOjI3ZWNiNzg0YTE1NTRmYjk4OGVkZTNlNmRmNWEzMWM2XzUtMS0xLTEtMA_4cab97f4-0107-47c5-97b3-47b669b3cd3a"
      unitRef="usd">19705000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZToyN2VjYjc4NGExNTU0ZmI5ODhlZGUzZTZkZjVhMzFjNi90YWJsZXJhbmdlOjI3ZWNiNzg0YTE1NTRmYjk4OGVkZTNlNmRmNWEzMWM2XzYtMS0xLTEtMA_12c68b3b-0790-47f7-aa7c-3a4df17364f7"
      unitRef="usd">71595000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZToyN2VjYjc4NGExNTU0ZmI5ODhlZGUzZTZkZjVhMzFjNi90YWJsZXJhbmdlOjI3ZWNiNzg0YTE1NTRmYjk4OGVkZTNlNmRmNWEzMWM2XzctMS0xLTEtMA_c0885a5e-e4cc-4ea1-b2fd-b341fb7eee9e"
      unitRef="usd">11802000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <fhtx:LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZToyN2VjYjc4NGExNTU0ZmI5ODhlZGUzZTZkZjVhMzFjNi90YWJsZXJhbmdlOjI3ZWNiNzg0YTE1NTRmYjk4OGVkZTNlNmRmNWEzMWM2XzgtMS0xLTEtMA_ea58b4c3-c886-4d00-9407-4550c84064da"
      unitRef="usd">1461000</fhtx:LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZToyN2VjYjc4NGExNTU0ZmI5ODhlZGUzZTZkZjVhMzFjNi90YWJsZXJhbmdlOjI3ZWNiNzg0YTE1NTRmYjk4OGVkZTNlNmRmNWEzMWM2XzktMS0xLTEtMA_26e86eb6-618e-424c-879d-e25f9e0ea87b"
      unitRef="usd">58332000</us-gaap:OperatingLeaseLiability>
    <fhtx:LeasesBalanceSheetLocationTableTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzI3ODA_b5585392-2290-49c8-a22f-4acf2990ceed">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Included in the consolidated balance sheets (in thousands):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</fhtx:LeasesBalanceSheetLocationTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTpiODU1NWViNTJiMGQ0MjY1YWUzNmRhYTcxYzI0ZGUwZC90YWJsZXJhbmdlOmI4NTU1ZWI1MmIwZDQyNjVhZTM2ZGFhNzFjMjRkZTBkXzEtMS0xLTEtMA_effa934e-01ba-4f14-964c-12cdce7a4ef4"
      unitRef="usd">6994000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTpiODU1NWViNTJiMGQ0MjY1YWUzNmRhYTcxYzI0ZGUwZC90YWJsZXJhbmdlOmI4NTU1ZWI1MmIwZDQyNjVhZTM2ZGFhNzFjMjRkZTBkXzItMy0xLTEtMzQ3MDU_987b9e50-7ec4-4fd2-8553-b75f18d8fb9b"
      unitRef="usd">3981000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTpiODU1NWViNTJiMGQ0MjY1YWUzNmRhYTcxYzI0ZGUwZC90YWJsZXJhbmdlOmI4NTU1ZWI1MmIwZDQyNjVhZTM2ZGFhNzFjMjRkZTBkXzItMS0xLTEtMA_f9f18a16-6f4e-4f29-86bc-408a27f836a3"
      unitRef="usd">51338000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTpiODU1NWViNTJiMGQ0MjY1YWUzNmRhYTcxYzI0ZGUwZC90YWJsZXJhbmdlOmI4NTU1ZWI1MmIwZDQyNjVhZTM2ZGFhNzFjMjRkZTBkXzMtMy0xLTEtMzQ3MDU_e36c846d-23fe-4ae3-8d82-77217b9e90be"
      unitRef="usd">58361000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTpiODU1NWViNTJiMGQ0MjY1YWUzNmRhYTcxYzI0ZGUwZC90YWJsZXJhbmdlOmI4NTU1ZWI1MmIwZDQyNjVhZTM2ZGFhNzFjMjRkZTBkXzMtMS0xLTEtMA_f2350439-eaec-43ea-8431-b0f12ac3808b"
      unitRef="usd">58332000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90YWJsZTpiODU1NWViNTJiMGQ0MjY1YWUzNmRhYTcxYzI0ZGUwZC90YWJsZXJhbmdlOmI4NTU1ZWI1MmIwZDQyNjVhZTM2ZGFhNzFjMjRkZTBkXzQtMy0xLTEtMzQ3MDU_e7bc8e09-7392-4b9c-b776-e150ebe1a6f1"
      unitRef="usd">62342000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LessorOperatingLeaseTermOfContract
      contextRef="i51cd2ef8029b4e6eacda02334700de82_I20200430"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzEwOTk1MTE2MzA2MTI_bd2a7d4e-afea-45a3-8ab5-225024bf767a">P2Y</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i51cd2ef8029b4e6eacda02334700de82_I20200430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzI1MDc_8df7c438-cb48-4c61-915f-e3e73a0c3e41"
      unitRef="sqft">16843</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="ib0ecce1083f6481ead8d518a258a5e21_I20210228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzYwNDczMTM5NTYzOTA_bc83f3ac-8a21-4f0d-b2a4-eb1cfd61d843"
      unitRef="sqft">2980</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzI2ODM_dcaf775c-f7e1-4ed2-a406-3ede4dd1ed55"
      unitRef="usd">1900000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:SubleaseIncome
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzI3MjQ_6f993554-0ac4-429b-b716-f84e928b4cf3"
      unitRef="usd">2500000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i9a152fe698f8422299c9477542ad5c5b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNTQvZnJhZzo3ZmFiNWQ0Yjg5YTc0MjMyYjllOTA0OTExMDBlNTIwYS90ZXh0cmVnaW9uOjdmYWI1ZDRiODlhNzQyMzJiOWU5MDQ5MTEwMGU1MjBhXzgyNDYzMzcyMTE4NTQ_667adcf2-ecca-4f09-ab1b-c67d5518da59"
      unitRef="usd">1000000</us-gaap:SubleaseIncome>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjAvZnJhZzpkMTZlOTZkMDQ2MmE0ODA3OWY3NDZmYjY3YWMxMTIwZi90ZXh0cmVnaW9uOmQxNmU5NmQwNDYyYTQ4MDc5Zjc0NmZiNjdhYzExMjBmXzMyOTE_4e9e8bca-356a-4ae9-94c4-952d12a9ee60">Commitments and Contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s commitments under its leases are described in Note&#160;11.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various exclusive and non-exclusive license agreements for certain technologies. Under the terms of these license agreements, the Company could be required to reimburse the licensors for patent expenses and remit amounts in the low single-digit as sales-based royalties upon the occurrence of specific events as outlined in the corresponding license agreements. The Company is also required to make annual license maintenance fees of less than $0.1 million and pay up to $1.1 million in regulatory milestones on each licensed product upon the occurrence of specific events as outlined in one of the license agreements. None of our product candidates utilize technologies covered by these licenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;From time to time, the Company may become involved in litigation or other legal proceedings. The Company is not currently a party to any material litigation or legal proceedings.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <fhtx:AnnualLicenseMaintenanceFees
      contextRef="i3e3da7bbe9d045048732fcefce03b848_D20170731-20170731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjAvZnJhZzpkMTZlOTZkMDQ2MmE0ODA3OWY3NDZmYjY3YWMxMTIwZi90ZXh0cmVnaW9uOmQxNmU5NmQwNDYyYTQ4MDc5Zjc0NmZiNjdhYzExMjBmXzE3NTA_110611c3-d9f7-451b-a5f1-a4eb3b4845db"
      unitRef="usd">100000</fhtx:AnnualLicenseMaintenanceFees>
    <fhtx:MilestonesPayableUponEvent
      contextRef="i3e3da7bbe9d045048732fcefce03b848_D20170731-20170731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjAvZnJhZzpkMTZlOTZkMDQ2MmE0ODA3OWY3NDZmYjY3YWMxMTIwZi90ZXh0cmVnaW9uOmQxNmU5NmQwNDYyYTQ4MDc5Zjc0NmZiNjdhYzExMjBmXzE4Njk_3c6c72b1-cea2-4460-80a7-5da62a6a7f2c"
      unitRef="usd">1100000</fhtx:MilestonesPayableUponEvent>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjMvZnJhZzowM2YxZTY2MGIxNmY0ZTFhODExMTRmZTA5MWE1YzQ1My90ZXh0cmVnaW9uOjAzZjFlNjYwYjE2ZjRlMWE4MTExNGZlMDkxYTVjNDUzXzI5Mg_7721f8ac-d88d-43b1-96fe-cccb60eb279e">Defined Contribution PlanThe Company has a 401(k) defined contribution plan (the &#x201c;401(k) Plan&#x201d;) for its employees. Eligible employees may make pretax contributions to the 401(k) Plan up to statutory limits. There was no discretionary match made under the 401(k) Plan as of December&#160;31, 2021 and 2020.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i8d44aeede1f74892bf721c7699eee869_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjYvZnJhZzowMTJjOWRhYThhN2Q0NTU0OGFkNmYwMjgyNGNhNzg2Yy90ZXh0cmVnaW9uOjAxMmM5ZGFhOGE3ZDQ1NTQ4YWQ2ZjAyODI0Y2E3ODZjXzEwNjU_91afa315-003e-4081-b9d8-95d1e262627e">Related Parties&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2015, the Company entered into a five-year service agreement with Flagship Pioneering (&#x201c;Flagship&#x201d;), an affiliate of one of its stockholders, Flagship Venture Funds,to provide general and administrative services to the Company, including certain consulting services and the provision of employee health and dental benefit plans for the Company&#x2019;s employees. The Company made cash payments to Flagship, for services received under this agreement, of $1.2 million during the year ended December&#160;31, 2020. As of December&#160;31, 2021 and 2020, the Company had no accounts payable to Flagship for costs related to the service agreement. This agreement expired in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2015, the Company entered into a five-year consulting agreement with a scientific founder of the Company who is also a board member and a shareholder. In October 2020, this agreement was extended to January&#160;1, 2022, and is subject to automatic one-year renewal terms until terminated. During the years ended December&#160;31, 2021 and 2020, the Company paid the scientific founder $0.1 million and $0.2 million, respectively. As of December&#160;31, 2021 and 2020, the Company had less than $0.1 million in accounts payable to this scientific founder.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <fhtx:ServiceAgreementTerm
      contextRef="ia71ec7897cbb4006827fd4c8d3854267_D20151001-20151031"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjYvZnJhZzowMTJjOWRhYThhN2Q0NTU0OGFkNmYwMjgyNGNhNzg2Yy90ZXh0cmVnaW9uOjAxMmM5ZGFhOGE3ZDQ1NTQ4YWQ2ZjAyODI0Y2E3ODZjXzEwOTk1MTE2Mjg4NTM_e3a55fcb-fb18-432d-8789-832d8b4e2bbb">P5Y</fhtx:ServiceAgreementTerm>
    <fhtx:CashPaymentsRelatedParty
      contextRef="i5382aa2bf08f43e88b67b99daf3dd99c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjYvZnJhZzowMTJjOWRhYThhN2Q0NTU0OGFkNmYwMjgyNGNhNzg2Yy90ZXh0cmVnaW9uOjAxMmM5ZGFhOGE3ZDQ1NTQ4YWQ2ZjAyODI0Y2E3ODZjXzQ1Mw_4d2ade5d-b93c-4a3e-a200-07c2e51ef6ac"
      unitRef="usd">1200000</fhtx:CashPaymentsRelatedParty>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="i75de76e7d13240f3891598dddc3f678b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjYvZnJhZzowMTJjOWRhYThhN2Q0NTU0OGFkNmYwMjgyNGNhNzg2Yy90ZXh0cmVnaW9uOjAxMmM5ZGFhOGE3ZDQ1NTQ4YWQ2ZjAyODI0Y2E3ODZjXzUzNw_76e56631-15c5-4e5d-83ac-14758d131ddf"
      unitRef="usd">0</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="i4cc1a0a9e2cf453689f94cd708f119eb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjYvZnJhZzowMTJjOWRhYThhN2Q0NTU0OGFkNmYwMjgyNGNhNzg2Yy90ZXh0cmVnaW9uOjAxMmM5ZGFhOGE3ZDQ1NTQ4YWQ2ZjAyODI0Y2E3ODZjXzUzNw_de3e4c66-e764-4bef-97bb-804557f4e0fc"
      unitRef="usd">0</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <fhtx:ServiceAgreementTerm
      contextRef="i0c734257926a48949b263d60cee94f38_D20151001-20151031"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjYvZnJhZzowMTJjOWRhYThhN2Q0NTU0OGFkNmYwMjgyNGNhNzg2Yy90ZXh0cmVnaW9uOjAxMmM5ZGFhOGE3ZDQ1NTQ4YWQ2ZjAyODI0Y2E3ODZjXzEwOTk1MTE2Mjg4NjU_6dafd6b1-b8b2-40d1-909e-b31fa985bdfe">P5Y</fhtx:ServiceAgreementTerm>
    <fhtx:ServiceAgreementRenewalTerm
      contextRef="i69d3730be48141eba19fe94753d20597_D20220101-20220101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjYvZnJhZzowMTJjOWRhYThhN2Q0NTU0OGFkNmYwMjgyNGNhNzg2Yy90ZXh0cmVnaW9uOjAxMmM5ZGFhOGE3ZDQ1NTQ4YWQ2ZjAyODI0Y2E3ODZjXzEwOTk1MTE2MzI5NzQ_d926fc35-fd32-41e9-a7b7-586401e0d918">P1Y</fhtx:ServiceAgreementRenewalTerm>
    <fhtx:CashPaymentsRelatedParty
      contextRef="if2edac33103b46efba125b51d6b34c3f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjYvZnJhZzowMTJjOWRhYThhN2Q0NTU0OGFkNmYwMjgyNGNhNzg2Yy90ZXh0cmVnaW9uOjAxMmM5ZGFhOGE3ZDQ1NTQ4YWQ2ZjAyODI0Y2E3ODZjXzk1Ng_7939fe07-cc9b-45be-85c6-574f5389006f"
      unitRef="usd">100000</fhtx:CashPaymentsRelatedParty>
    <fhtx:CashPaymentsRelatedParty
      contextRef="i6d894474bd8940b28bf453d051db226a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjYvZnJhZzowMTJjOWRhYThhN2Q0NTU0OGFkNmYwMjgyNGNhNzg2Yy90ZXh0cmVnaW9uOjAxMmM5ZGFhOGE3ZDQ1NTQ4YWQ2ZjAyODI0Y2E3ODZjXzk2Mw_15229796-332b-4476-aa64-2b77d2095fdc"
      unitRef="usd">200000</fhtx:CashPaymentsRelatedParty>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="i273c56330b4b4f6abe4c85c7cd7fcd01_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUyMzU1OTgxNWU4NzQ4NWNiNmE5ODk1NzA3ZjQzYTAyL3NlYzo1MjM1NTk4MTVlODc0ODVjYjZhOTg5NTcwN2Y0M2EwMl8xNjYvZnJhZzowMTJjOWRhYThhN2Q0NTU0OGFkNmYwMjgyNGNhNzg2Yy90ZXh0cmVnaW9uOjAxMmM5ZGFhOGE3ZDQ1NTQ4YWQ2ZjAyODI0Y2E3ODZjXzE2NDkyNjc0NDE3ODI0_691a40ad-6227-4cad-8178-21a2362271d9"
      unitRef="usd">100000</us-gaap:AccountsPayableRelatedPartiesCurrent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>119
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M'0=C+7W?Q9W[)>L$6I6DN,R$)2L5!1OL<W7+,N#B_OW_!)X:<;C.S1C#*<N
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M!KB^EM+L&_8!AW]K7/X'4$L#!!0    ( ">):E3=-G'.* (  'D%   8
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MK]K'#24:O!'0WZ^Y)MO#B[G.[OY\L?P74$L#!!0    ( ">):E2=#<N9VP(
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M ;GBDF1*"*8-*4%7Y;W>5]XJ1=^G<&_GRYBV**58RY?-,IXTVU+0:11T+E%
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MP2%=&T@A;A3!"HTC@UYOI^).<A0I-JFQ@9Y')5U;)/UW-#NDQ$9ZL;8M98[
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M*PAM[(88T6R1U#&2KPA*MG<]X4-KCL8/&_N !JJ[8:%1, Z2[5^_^65F76B
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M^<C$RM!89Q5HO2.79Z VB+<&!@5+40-]4,)M*)CDC2?O?,2$8IL8WX].PR2
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M(8JN@@'5A@(A4;@%WQ9)D[#_% )6S/PFR10A4Z/ L71ZYR=>=#A@(#P\/+4
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M30RI9S?[,)?STFK2R;-.FGB]+,HGCR3CD!"7*"=SV!254DB?.,60PH%9!)!
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MUQFT%V$\',GQ!QA=57UR;GV=W2P$,HEPJ/'O)>SQ)I?M@\;/.@2N%F"8GU3
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M#&B] Z_7QM!EX@.,_YK-/U!+ P04    "  GB6I4>GO^*I<"  ":!0  &0
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M*G2)OE+UF@Y5C1G=6E'G]NB<D$A9I=(,R>2/F.Z,JC/5B))$I=O:L:)R:N2
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M;"]W;W)K<VAE971S+W-H965T,38N>&ULW5IKC]NX%?TKQ#0M$D#CD>7G;![
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M\<!U#>NTTP2*#I#HIX:=]+P)P-=+U.)()V7";(IS4:\FPU@(5*S'%R\'A?P
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MU&QMN&O[O%/[O%/[Y^S4>+>!D+^_<ZK-9??'"?W4Z<:Q]G@;C\C19NS!W J
MM3VZGUQW85>"08_@/:9XL.09V/MVQJ,NBGSRYQ==\#]KG?3 5>-QSO\0J\8O
MCJ\:3P32AZ\:"=C2K&U1A!^UZ552G\[BU7SJ=YBN>C]RA99JS3_EY62D*K]W
M%3]5X=?"WLF/9'6/RT^-_:!K,.%49E8X"OF]N) I9GC3E!7_9-:R;-"_\<N-
MT9 G/8#O5R5Z!_^&$,3?4'O[?U!+ P04    "  GB6I4%1WM%30)  #F&
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MU@*14N5<N2Y:0IJ<+H81T[ZS927- SHGLXX8C!6ZD1L0C;DR:J&#%VALIC=
M )2S<@ZT1"&]5W@/CLIICX?X@\;5Q8.P"R8'-#@9R#C$U<-4R*^9GTPA;Z3+
M5GR3JSL 0(5V#BP\ Q5I7\(,R "+-D))4)./D<AKF F#05*;3+D ? FL&-!3
MZ!^D5&Z<$ MG2W+"*W"HTL?BIBB(N!>(O_YEEB9G/_O'5GN8K<AV53%2K.2=
M@FAE=JTC6=^,IKO;@(>DA:-K,EUHR:RMRF_Q;2P6*@=S(3R(ZV#=0S_\))4<
M/&2@6BP4@]4CAK7T2 M25@!,_87X)V+5M-Z!<J!2$!]>-.(X3>+AB?AI>\'>
M$8'R49/G1>?,)N+'DWAV(HZG\?BDTT%Y]LS[JM0?CXGY>!2?G8A?$0<GAO%,
M' _CR8EXMY)F2?X?*$EQ)XNZ";>D.$C*WF@8C^%Z/!6_/!F]83R$=\WOOS]9
M[9@WGG+<IK*)-57+,=> K3V<\B<73T7\_6.I%ZQNM^Y$)IU[0/.MI<N].!+3
M)!K.1K@8G4?I[%Q\>3F&>S+.H]'T3(RC\\E$O).5#M0HBG/BPINZ@G,>+B:3
M,Y&<C<5-EKD:K]4])CSUP20:#8<"9B1#U(#-OK^A>9<S H"B"7D2C8<C,1Y-
MQ:];?Q3H!'I@CD8(6I$.6)%"330<I>*KA2D'PWT^BM)I*J9I-#N?[H:N)XYB
M#7#,VB8['D6328+2 5=R?O+($$>3^(U=O*EQTRHZ3H;19#H%4Y)$TW,4W@&C
M^AX<)^,H2<Y.^&*2C$[$;P?*[NP\2L83,9Y%(^3NJ:(Z$MS;Z<^]JQM/%?:H
MAG:Q>R7S72S9MMAC_-VK!D@_2M-9?(ZUH2C8;# ?I<,I&J!]%%&G5DV[% ^1
M6*\T"JZ4#^AS(>^D+N2\8)RRBP6UWJ(.-#_A&[]H.BP67ZE16A-?- Q,19TK
M<92D\:0SKE&-6M20+ZG)G4:OB9R0%N8LM3$D$$V8#D>3UID$ +0GHJ\,U,B'
M)M#&U)K7@=@]@4*F75:7""6RZ#<>%[ID>-_Z.QO^1(&4QM1P[9#;K\S&:QV;
MQJ^K#%EX^UQYO *!#]3+-$YVJV6\?? _U,I.8Y'<5T>CW6DH!GWML?@6(._'
MTT/W#S3**W>5/:[6<5_/?X=5Y+:D&ZJHH-D +ADNJ<;,&K7HQ&US'/%B-$M9
M&P%'Z\%'$Y0SX/H""TQ-V4:?X&5R/IM&3(U=C@)A34[>5,[>:<_B0-7X6\AU
MMS[9-?87O]* ?AZH'FH0=%YP;-;N:D#6.\H![76N(<AL7>0-Q6;S:;+)-0]4
M?2R8XL'.,K4L;6UX<=B-6B-=&@I=S2GD99%"!?4OX R;MUM-,6+6;FD%!>B1
M81'M2XP!4#1_V(2?HL\EA<.;;]=')S'CVN1 (?9,O]F[MU+)HV8;1;@Q(E>V
M0%8]F5;5\T)G8NEL7?E-V)B((8125UG7U (L*2TY""/%A$#F#K4A<>^4>D,K
ML$#):ILW(+.=!QYK/.7'Y'5&4(6B"W7.H:-A@^)>KQ0O4[*- )N,0YK#V9+X
MN[S#Y TM_5*]O;=$6'2%P&^RVY.QORVWI<;.ZJ71"XW\!EX:"G6OL;0W=>L#
M66AIB$/Y6H<5^H4ZKO$ F5SLS3Y&341!05=^R)]GDXM"(S%!EVK?YJBMO1WX
M>'F@NC\!$VONI#V@,"^A WF 06 >^A3484W%\EF)(+1S0 J4UO_?F[E:4-7V
MHA>+#[6C\D%, 7Q%5Y#:MR40FMSL#"^3<VYZSH'\NT&;171,;= #R.RH'LF!
M[A!+!R"S/1*RJ97UNK%EOU=4<U2@D8XW#1UJG/0;M91\ _#+J<*@2?)!NZ[(
M'E+/*,.]U1PZ%8LYL.'%XI,T<JDX>J28CQ%(:*MY_X2WPA&#SF)4RC6:K;&$
M<K9_D-[O-C*=;"MD RN(<:D<FJI?SN0^1@-!1 NY31ENCK-PIYDO#'PMI?"R
M:,=SZP&O:7DC *6 %#%F%?H[;5,,701&_+Z?WC46!G[3CUKWO:$MT(-1Q)$$
M:482:,&0F (0=.BT1P8R4"G,/*"N7U%I+%$0/CS[,4,>WJVZ3R<[B004M_7C
M7U,_B )_P'"*>Y'&<P_"#[G13IFF08Y&=/S=W=63WI/\CW\&VEW8MI]OJ(DV
M4-*F8V,*0<M+V/'DBOK$%RA:4YMRV#0Q84#;X_3YJ3;T"K/C1YNM3;'L=O1"
M%TUK=*=ZA2W!=+.6%T RX1.RC4S@^!>"YR%!G]8RI^=;+.)%0JZ[>OP=X?6Y
M[N9_N]_J32C:78.+BSX'%[0D.<_C:%ZC33%[=]U&O_1 7]W+4IMN^C_>4W<,
MH/6:1K*L*NP4M -Q*.@)?A@;3$ F 98XFO,N2 [UE,#<6\:./9/@F7R<TPY#
MH[;3VYT**GH^'/I8>MK[]@PD6O(7=H(/9+?Y#-T][3[BWS3?KK?DS7\ /DF'
M]1_8IA9@'<9GDT%SEM_<!%OQE^RY#<&6?+E2$H$D KQ?6!LV-Z2@^]?&]7\!
M4$L#!!0    ( ">):E3D5A7OHP@  $ H   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;.U::V_;.!;]*X0WNV@ Q9;D=YL$2-LIML7.M)AT9[!8[ =:
MHBVBDJ@AJ3K^]WLN*<FOV&WGVP &FEJFR<MS'^?>2T*W:Z6_F$P(RYZ*O#1W
MO<S:ZN5@8)),%-ST525*_+)4NN 67_5J8"HM>.H6%?D@#L/)H."R[-W?NK%/
M^OY6U3:7I?BDF:F+@NO-:Y&K]5TOZK4#O\I59FE@<'];\95X%/;?U2>-;X-.
M2BH+41JI2J;%\J[W$+U\/:;Y;L)O4JS-SC,C319*?:$O[].[7DB 1"X22Q(X
M/KZ*-R+/21!@_-'(['5;TL+=YU;Z.Z<[=%EP(]ZH_'>9VNRN-^NQ5"QYG=M?
MU?J?HM'' 4Q4;MS_;.WG1IB<U,:JHED,!(4L_2=_:NRPLV 6GE@0-PMBA]MO
MY%"^Y9;?WVJU9IIF0QH].%7=:H"3)3GET6K\*K'.WO]+0"5S.["012.#I%GW
MVJ^+3ZR+8O:S*FUFV$]E*M)] 0. Z)#$+9+7\5F);T729\,H8'$81V?D#3O-
MAD[>\*QF[+\/"V,UG/^_,S)'G<R1DSGZ86M]SSKVOF0?$ZL60D/):!XPFPGV
M1A45+S=,E%9HD3)96L4XRVD) ^O8+ I&HPCQ6G.-$6*J6N+?4B:"\3)E.5\H
MS:W2&V8JCD%9LC>\6&B9KD3 ?N;&\"2KC;#6!"Q1!4B5R')%\S[P$F(W9/20
MO2 \__C;+([#5[^ 4 ZV^QZ]NNZSSQF)EE;RG %K03!H13>5K;EAC@=L([@V
MB&6;09<EB'=#(TQ5CHO04#Q9 >S<LB67^@89X0L4T[ "C9%8"_*W6[C9E @\
M"N*AGUOQ#;2QV-8D/.>6+ *-\GS#U%?8V2TF1'Y_;U4'GBQGE>4Y;,ZK2JLG
M"9(+++R:A/TAR);G;D-X+5%EV:01I]*>UMZ-.>3E2D/62@M!HMFRQA9U18]7
MPW[82B2S0QL.]++ OE^%UP#3G""2F<(JB<REW3"8=(VD19]>%D<N2U-):."(
MJVBR!1NP=2:3#*8QR$HNF';G[ENLW:\%WMEK:Z0^>UMKBA0:=@84Q'8&KHJ"
MPKCEJ[,FQ5# KN+^N%.5AJ^B<7^T10ALE7"Y.-\$Y%^W7:;R=-\<:[ !DV6Q
MJ#499+'9@_NLJF3;1'OX"L$F0 N"[S7*)5^03:4P/HQ:ZDG#U"*7*VZ]XV B
M)@&A4MKY'" A-$>,68HPRY] 9E(M40;3M,C;E800Q;&0H'M 8/(Z)0!^(M'6
M8U*E%U#P$J6/%&XCO7%_*^0(J!9_U%+[W:CH6DZ*LX2;#+2 =1)'FJNH/^V\
M@*E&)#7L27G%PK,T!89"9""NC$JD4Z"+;0>"ML:&O% UX!&UDQR3Y5(28P@)
M$JM,:*';_46IRAOL0E%VS6A;2 )SC,IEZN2W^%RY,B0#,$['4I]]W"8H_V,8
M[$1HD\F\^6B'_82J18(X(:SE42A #Y]&KX:S_F0O7+&(0E25Z7'D;-HE^^GA
M0UV*'70M %YXMNSG2#@#70/T;8A((OENJ-F]!$>0MNC%$[HQTT3?-HONLY:H
M4J("L<)7:,Q[%)7U5@;,F0\J!\\A(-_R)"$_4^9!S:&!1F*A4K@\X;8U$&VF
M74I5RYNZ,Z:K1 ?6:CA<8+BFF&TR^YY(<ARI[8TX]VYN:-T4J5U>DP.FVWQ"
MRBU4$[;?A>J(_1E/]^KM\Y6UR<=8?:Z\,J1\&)DS<"&A6(>$7!R%G\U@B858
M.<780[U"HT<MP=3M"B=+WPE N$:.@T7&+M >*BWS+M) SKPKN\3,5>FBG=B)
M)MOG3-ZEIXIK<HG+F@N1P/U,+)<^%=->V]:$J/?9D;< #UPV;O-T&X'-GC!8
MCK[>.,.U1<)\LTJP%U0#,U4;C)CKE^P_5%M^.K'*K?AX8$+*J.R*38/Q:.H^
MPV','C/0Z,9Q8&<6=3!1_(I-(O8;U])Y9.?G.)C-8^27.")!41B,AG,\S()A
M%++'NJIREV&0_U-IDEQ1*+O\24EO">UA/'\Z\@>5KACDONL[L-2/J_Z&-JJX
M;*CI\K%IBHL/$T<J3[(VI9PI?E!N'DR'I.TP"&>3(]ONSH7!#/VRU H-WX+*
M#7T]IAJ);2T-P3!?.$',-K25QSEX;Q<$QG,BTUITEMPF$J?C[F[38#@;N9!=
MNV:/:(!N!J65%C60#WH_<J:K;)H2T+Z37NY8__=&XLTYB0V4 Q6]LQTEKMD$
M!7F*OR-Y>T!."1KWAV/V]_;C76U=-7>M+AT+95&W(=_U=SX5'4DZ576_$::8
M$[O F8]']&5(3 G'SD@C>AY.9RY1T?,DGM#SA)YGLX@\@S!84N.!8\\T'+//
MU'FC0W9ZG%!@&@7C^1AET\ AZ UKW^;1,0FT?1%%P2R,KYO?,>3Z]S;=@QX0
M@M0&57" FD37S9[GB3%&W"*1G"+E^P/2G6MOGK%@2VC?)'T#RB28ST>.HW.8
M\ Q' U;Z9J9IOKIF8AQ!F9G3";GO!]3'YG$P'"&AUHNF8:)3C>/=41DZ>82U
M:^5/7>98"K6D-&H/SE[1))B-AB<.N_YTZ^/ZX A&P>O;K: K<4UY_5#GFZ:H
M ?L[L=#MB3<Z![_<:9":SK[3XQ3Z&*X*#\'O',#V]-@5BFPGNAKZ7()I^LS\
M1W$'5"\@"2V2,QJD(EYVVL:M3IE6]2ICO] )S,5[Z#)#W&</SZ>,X #M_O&R
M2=V[0+>>:UOC;G?7*>+0,M\VU@='SV]W%2?:?Z\Z\H'R]PG/'%"WA_/#\^G>
MV0X-5PNX?^8V:=S=)HW_Y&W2]ZR[W"9=;I,NMTF7VZ3+;=+E-NERFW2Y3;K<
M)EUNDRZW29?;I,MMTN4VZ7*;=+E-NMPF_<5ODP8[;W450J_<NVLX-E%V]R]X
M=:/=ZW$/_JVP[73_;AT:OY4LJ<%;8FG8GXY[OD"V7ZRJW#MB:'ZM*MQC)CCL
M2Q/P^U(IVWZA#;J7!N__#U!+ P04    "  GB6I48T-*<@8%  #."P  &0
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MD3L)J ^PX>+O>F$Z@7//OH\W\A@D6QQ*I!8E&!*'E+9COD1<K#2.>4?:TOK
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M-7E35'F==?2*(;GJNVR;WYAL94P#8/N\I>>J!N]!VJO^0+S8;TEP/&7V;45
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M,L>J)^_?%0*;4H0V(K?+L'@].]H=KR.;H+^$#69VZ%'B>-:4G>PSN++Q,Z.
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MNWTO"S?60=8$W4%9Q;T6I=B(JTL#WU:]W'GS<4P'\?FT3%O@OSM;$ILOLLC
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M4>+RO7AOM'7&1G)55G*-WC?ZU';-'9?^-FY_4)R@E5VO768U=DSWN4^W1M<
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MBE1<WFL4X-E[ O%"XZU* N>D[@]CJ2Y.#Y3ZQ<AU]J!4)K7^0X%DF(M;\/P
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M4WMG?'9TYBV24&$T9YA5E,YMY$F?/,\@,C&GCCY,#KO\Q)PO<8?Z_&ZZM/"
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MY.CT. +3]I9VX70=ZGFI'76',*VH':/Q!G1>:JKI;N$#] U^]A=02P,$%
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MY=%JVI6D9R>/5L7/S6N**X$;E5&MC7#INO@F9BF:RU';DAD6;L<5Y'4)&9Z
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MCYOX]^7*6 U9\,\(9C)@)@XS.8+YT.4P415Q\.1:&4NH+/OM#;.4"W/(G>/
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M>6T_,-TVGW9"JO8%?Z7(M@\_W-B&C=H=L/NE4K2?N O"7X#Q/U!+ P04
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MK%*;V,8 <,+<%5T!;5A<8LJ+CK(2"^8]G?+=8IAR3YZ@.@;<83OOZBR,G_/
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M@?S[;9SCJ+XI#EPW!^P7OP!02P,$%     @ )XEJ5"9QA<YD P  40T  !D
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M((5$&PB&?P=809H:).3QJP9UFGN:Q.[X&?VS+1Z+>6 *5B+]FV_T?N'$#MG
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M#HQSH/.5UKC=N ##Z,Q_ U!+ P04    "  GB6I4<9% .KH"  "E!P  &0
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M% ;#I!\_:?"3L_"QMSEH>QRBA1SZ*9,.P' 2GT!V8R8M(Z\81PWCZ%W&'Z8
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M9>Z6N#NJZ70BQ19),QK0S(5EWUH#7[PPA?*H);SE8*>G?PG-%)K1%SK/&+I
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MB3>'[Z^1/"BUL>LUL?R6L=BH4I%E5"KWM#G TL]E/<!AGPR/!.CZ$O8WIBI
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MAU5T 58?0+9)7W21S$3QS);30!>QXN[$%3\M<E:O^$[0<"^%'&-1,V,;NO4
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M8YW?6["6)1,7*0%T"]9[S CX[Z ?+53J$_$&KNZ)P$G*K^7LQ_4]N/IR#;X
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MFWN"8\+4!/E\2ZEX[R@'];>6^6]02P,$%     @ )XEJ5.V@N\/? @  ]P@
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M%22]>HY%RQ"2N\QPK\QP+U.+3V?XGJ)K(4BRR7,<4K<V_EUMJ4!J2Q)4$[*
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M2?_] #M>VCFDVTL"^)YS[^'"Y4ZV7#S* D"A74F9G'J%4M5Y$,BT@!)+GU?
M])><BQ(K/17K0%8"<&9!)0WB,!P&)2;,FTWLVIV83?A&4<+@3B"Y*4LLGN=
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M,"W6MR<8Z*G0 O#^P+EZ6>B1L?N+L/X?4$L#!!0    ( ">):E1%(7VD=@4
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M8*:*B_"B8>0BOR6=2&-DDC_..8NXRCK ]ZF4YJ61#5#].V+X'U!+ P04
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M\#3B"*8 -&!(%#7GX,YY%*[/J7#S&]'D-U!+ P04    "  GB6I4EXJ[',
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M4$L! A0#%     @ )XEJ5/\?;K[M    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ )XEJ5)E<G",0!@  G"<
M !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  GB6I4@?5^Y=T%  #B&   &               @($,"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ )XEJ5-TV<<XH @  >04
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M965T-BYX;6Q02P$"% ,4    "  GB6I4;,+^1T4"  #+!   &
M    @(';)@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
M)XEJ5(^J OCJ"   P"<  !@              ("!5BD  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ">):E3[(E^" PP  *\?   8
M          " @78R  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    "  GB6I4 \."_G(A  !Y;   &0              @(&O/@  >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ">):E0U$/M5U@,  &<*
M   9              " @5A@  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ )XEJ5.M).Q#] @  =P8  !D              ("!960
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  GB6I4>GO^
M*I<"  ":!0  &0              @(&99P  >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( ">):E17,^$!L 8   01   9
M  " @6=J  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
M)XEJ5 K1<''( P  30D  !D              ("!3G$  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    "  GB6I4N=]=\*P+  #Q(0  &0
M            @(%-=0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( ">):E1?XUDB)Q(  $]-   9              " @3"!  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ )XEJ5!4=[14T"0
MYA@  !D              ("!CI,  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    "  GB6I4Y%85[Z,(  ! *   &0              @('Y
MG   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ">):E1C
M0TIR!@4  ,X+   9              " @=.E  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ )XEJ5(T!RWJ! @  CP4  !D
M     ("!$*L  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ">):E1-ABJ9= ,  *8'   9              "
M@?'=  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ )XEJ
M5!,.FF^> @  D04  !D              ("!G.$  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    "  GB6I4H3I)IJ4"  #L!0  &0
M        @(%QY   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   ( ">):E2=B^5SVP0  .H+   9              " @4WG  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ )XEJ5-N-+\H7!   CPD
M !D              ("!7^P  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    "  GB6I4P1[J8( $  "9"P  &0              @(&M\
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ">):E1.DR!1
M\ 0  (@9   9              " @63U  !X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @ )XEJ5.?&<,5X @  U@4  !D
M ("!B_H  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  G
MB6I44^.W*:0"   ."   &0              @($Z_0  >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ">):E2^\KT.XP(  %X)   9
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M970S.2YX;6Q02P$"% ,4    "  GB6I4<9% .KH"  "E!P  &0
M    @(&P$P$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (
M ">):E2#V9W5Y (  , )   9              " @:$6 0!X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L! A0#%     @ )XEJ5**/@Q(S!0  &A@  !D
M             ("!O!D! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"
M% ,4    "  GB6I4@.<.N=\#  !]$@  &0              @($F'P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( ">):E0-C-+G=@4
M *$7   9              " @3PC 0!X;"]W;W)K<VAE971S+W-H965T-#0N
M>&UL4$L! A0#%     @ )XEJ5+<'GL'P @  , @  !D              ("!
MZ2@! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  GB6I4
M+C0)N6X$  !W$0  &0              @($0+ $ >&PO=V]R:W-H965T<R]S
M:&5E=#0V+GAM;%!+ 0(4 Q0    ( ">):E3MH+O#WP(  /<(   9
M      " @;4P 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%
M  @ )XEJ5)T_JOP1!@  "QX  !D              ("!RS,! 'AL+W=O<FMS
M:&5E=',O<VAE970T."YX;6Q02P$"% ,4    "  GB6I4PA9\8E4#   >"P
M&0              @($3.@$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+
M 0(4 Q0    ( ">):E3N$,B+%P,  , )   9              " @9\] 0!X
M;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ )XEJ5(UX^/R?
M P  +@P  !D              ("![4 ! 'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6Q02P$"% ,4    "  GB6I412%]I'8%  ":&   &0
M@('#1 $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( ">)
M:E0NYLT<C@(  -@&   9              " @7!* 0!X;"]W;W)K<VAE971S
M+W-H965T-3,N>&UL4$L! A0#%     @ )XEJ5#BBO]74 @  (P<  !D
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M=#4X+GAM;%!+ 0(4 Q0    ( ">):E1B/NQ5+@,  $$,   9
M  " @;Y: 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @
M)XEJ5+<6RN,= P  ,!(   T              ( !(UX! 'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    "  GB6I4EXJ[',     3 @  "P              @ %K
M80$ 7W)E;',O+G)E;'-02P$"% ,4    "  GB6I4:SY3R+D$   3)P  #P
M            @ %48@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ )XEJ
M5%EV ?CU 0  .",  !H              ( !.F<! 'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ )XEJ5!?(S!O; 0  T2(  !,
M         ( !9VD! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $, 0P!,
)$@  <VL!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>174</ContextCount>
  <ElementCount>418</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>64</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders??? Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders??? Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentation</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2109103 - Disclosure - Marketable Securities and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurements</Role>
      <ShortName>Marketable Securities and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2113104 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.foghorntx.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2132109 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2134110 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2139111 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2147112 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2149113 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/DefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2150114 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.foghorntx.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.foghorntx.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsTables</Role>
      <ShortName>Marketable Securities and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.foghorntx.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2318304 - Disclosure - Accrued Expenses (Table)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/AccruedExpensesTable</Role>
      <ShortName>Accrued Expenses (Table)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.foghorntx.com/role/AccruedExpenses</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2321305 - Disclosure - Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.foghorntx.com/role/NotesPayableTables</Role>
      <ShortName>Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.foghorntx.com/role/NotesPayable</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2327306 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.foghorntx.com/role/StockBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2335307 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.foghorntx.com/role/IncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2340308 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.foghorntx.com/role/Leases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Nature of Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails</Role>
      <ShortName>Nature of Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Property and Equipment are Stated at Cost Less Accumulated Depreciation and Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAmortizationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Property and Equipment are Stated at Cost Less Accumulated Depreciation and Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies - Summary of Earnings Per Share Diluted Anti Dilutive Impact (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofEarningsPerShareDilutedAntiDilutiveImpactDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Earnings Per Share Diluted Anti Dilutive Impact (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Available for Sale Marketable Securities By Security Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Summary of Available for Sale Marketable Securities By Security Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Summary of Property and Equipment Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/PropertyandEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.foghorntx.com/role/AccruedExpensesTable</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Notes Payable - Summary of Long Term Debt (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails</Role>
      <ShortName>Notes Payable - Summary of Long Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Notes Payable - Additional Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails</Role>
      <ShortName>Notes Payable - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/CommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.foghorntx.com/role/CommonStock</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2428413 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Stock-Based Compensation - Schedule of Weighted Average Assumptions Used to Estimate Fair Value of Stock Options and Restricted Stock Awards using Black-Scholes Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedtoEstimateFairValueofStockOptionsandRestrictedStockAwardsusingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Weighted Average Assumptions Used to Estimate Fair Value of Stock Options and Restricted Stock Awards using Black-Scholes Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Stock-Based Compensation - Schedule of Share Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Share Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Stock-Based Compensation - Summary of Stock-based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2433417 - Disclosure - Collaboration Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/CollaborationAgreementDetails</Role>
      <ShortName>Collaboration Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.foghorntx.com/role/CollaborationAgreements</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2436418 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2437419 - Disclosure - Income Taxes - Summary of Reconciliation of the U.S. federal statutory income tax rate to the Company's effective income tax rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/IncomeTaxesSummaryofReconciliationoftheUSfederalstatutoryincometaxratetotheCompanyseffectiveincometaxrateDetails</Role>
      <ShortName>Income Taxes - Summary of Reconciliation of the U.S. federal statutory income tax rate to the Company's effective income tax rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2438420 - Disclosure - Income Taxes - Summary of Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Summary of Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2441421 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2442422 - Disclosure - Leases - Summary of Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails</Role>
      <ShortName>Leases - Summary of Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2443423 - Disclosure - Leases - Summary of Supplemental Cash Flow Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/LeasesSummaryofSupplementalCashFlowInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Summary of Supplemental Cash Flow Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2444424 - Disclosure - Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/LeasesSummaryofWeightedAverageRemainingLeaseTermandDiscountRateLeasesDetails</Role>
      <ShortName>Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2445425 - Disclosure - Leases - Summary of Minimum Lease Payment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails</Role>
      <ShortName>Leases - Summary of Minimum Lease Payment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2446426 - Disclosure - Leases - Summary of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/LeasesSummaryofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Summary of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.foghorntx.com/role/CommitmentsandContingencies</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="fhtx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2451428 - Disclosure - Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.foghorntx.com/role/RelatedPartiesDetails</Role>
      <ShortName>Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.foghorntx.com/role/RelatedParties</ParentRole>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="fhtx-20211231.htm">fhtx-20211231.htm</File>
    <File>ex1021-foghornxloxocollabo.htm</File>
    <File>ex1022-aremploymentagreeme.htm</File>
    <File>ex1023-employmentagreement.htm</File>
    <File>ex1024-employmentagreement.htm</File>
    <File>ex1025-employmentagreement.htm</File>
    <File>ex1026-transitionagreement.htm</File>
    <File>ex1027-emplnoncomp.htm</File>
    <File>ex23130503foghornconsent-2.htm</File>
    <File>fhtx-20211231.xsd</File>
    <File>fhtx-20211231_cal.xml</File>
    <File>fhtx-20211231_def.xml</File>
    <File>fhtx-20211231_lab.xml</File>
    <File>fhtx-20211231_pre.xml</File>
    <File>fhtx-20211231xex311.htm</File>
    <File>fhtx-20211231xex312.htm</File>
    <File>fhtx-20211231xex321.htm</File>
    <File>fhtx-20211231xex322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>fhtx-20211231_g1.jpg</File>
    <File>fhtx-20211231_g10.jpg</File>
    <File>fhtx-20211231_g11.jpg</File>
    <File>fhtx-20211231_g12.jpg</File>
    <File>fhtx-20211231_g13.jpg</File>
    <File>fhtx-20211231_g14.jpg</File>
    <File>fhtx-20211231_g15.jpg</File>
    <File>fhtx-20211231_g16.jpg</File>
    <File>fhtx-20211231_g17.jpg</File>
    <File>fhtx-20211231_g18.jpg</File>
    <File>fhtx-20211231_g19.jpg</File>
    <File>fhtx-20211231_g2.jpg</File>
    <File>fhtx-20211231_g20.jpg</File>
    <File>fhtx-20211231_g21.jpg</File>
    <File>fhtx-20211231_g22.jpg</File>
    <File>fhtx-20211231_g23.jpg</File>
    <File>fhtx-20211231_g24.jpg</File>
    <File>fhtx-20211231_g25.jpg</File>
    <File>fhtx-20211231_g26.jpg</File>
    <File>fhtx-20211231_g27.jpg</File>
    <File>fhtx-20211231_g28.jpg</File>
    <File>fhtx-20211231_g29.jpg</File>
    <File>fhtx-20211231_g3.jpg</File>
    <File>fhtx-20211231_g30.jpg</File>
    <File>fhtx-20211231_g31.jpg</File>
    <File>fhtx-20211231_g32.jpg</File>
    <File>fhtx-20211231_g33.jpg</File>
    <File>fhtx-20211231_g34.jpg</File>
    <File>fhtx-20211231_g35.jpg</File>
    <File>fhtx-20211231_g36.jpg</File>
    <File>fhtx-20211231_g37.jpg</File>
    <File>fhtx-20211231_g4.jpg</File>
    <File>fhtx-20211231_g5.jpg</File>
    <File>fhtx-20211231_g6.jpg</File>
    <File>fhtx-20211231_g7.jpg</File>
    <File>fhtx-20211231_g8.jpg</File>
    <File>fhtx-20211231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="580">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>124
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "fhtx-20211231.htm": {
   "axisCustom": 1,
   "axisStandard": 24,
   "contextCount": 174,
   "dts": {
    "calculationLink": {
     "local": [
      "fhtx-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "fhtx-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "fhtx-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "fhtx-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fhtx-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "fhtx-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 518,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 4
   },
   "keyCustom": 42,
   "keyStandard": 376,
   "memberCustom": 23,
   "memberStandard": 36,
   "nsprefix": "fhtx",
   "nsuri": "http://www.foghorntx.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.foghorntx.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.foghorntx.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fhtx:MarketableSecuritiesAndFairValueMeasurementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109103 - Disclosure - Marketable Securities and Fair Value Measurements",
     "role": "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurements",
     "shortName": "Marketable Securities and Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fhtx:MarketableSecuritiesAndFairValueMeasurementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113104 - Disclosure - Property and Equipment, Net",
     "role": "http://www.foghorntx.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Accrued Expenses",
     "role": "http://www.foghorntx.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Notes Payable",
     "role": "http://www.foghorntx.com/role/NotesPayable",
     "shortName": "Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fhtx:CommonStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Common Stock",
     "role": "http://www.foghorntx.com/role/CommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fhtx:CommonStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Stock-Based Compensation",
     "role": "http://www.foghorntx.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132109 - Disclosure - Collaboration Agreements",
     "role": "http://www.foghorntx.com/role/CollaborationAgreements",
     "shortName": "Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134110 - Disclosure - Income Taxes",
     "role": "http://www.foghorntx.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139111 - Disclosure - Leases",
     "role": "http://www.foghorntx.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.foghorntx.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147112 - Disclosure - Commitments and Contingencies",
     "role": "http://www.foghorntx.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149113 - Disclosure - Defined Contribution Plan",
     "role": "http://www.foghorntx.com/role/DefinedContributionPlan",
     "shortName": "Defined Contribution Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150114 - Disclosure - Related Parties",
     "role": "http://www.foghorntx.com/role/RelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)",
     "role": "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsTables",
     "shortName": "Marketable Securities and Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://www.foghorntx.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318304 - Disclosure - Accrued Expenses (Table)",
     "role": "http://www.foghorntx.com/role/AccruedExpensesTable",
     "shortName": "Accrued Expenses (Table)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321305 - Disclosure - Notes Payable (Tables)",
     "role": "http://www.foghorntx.com/role/NotesPayableTables",
     "shortName": "Notes Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327306 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.foghorntx.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Consolidated Balance Sheets",
     "role": "http://www.foghorntx.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335307 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.foghorntx.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340308 - Disclosure - Leases (Tables)",
     "role": "http://www.foghorntx.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i25bd4e2b11bf41efbe5fc4e9eae184b7_D20200701-20200731",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "fhtx:ProceedsFromUpfrontPayment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Nature of Business and Basis of Presentation (Details)",
     "role": "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails",
     "shortName": "Nature of Business and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "fhtx:NumberOfCollaborativeAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "agreement",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "fhtx:NumberOfCollaborativeAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "agreement",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "ic066e702d698456487c1fe09f0556f0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Summary of Property and Equipment are Stated at Cost Less Accumulated Depreciation and Amortization (Details)",
     "role": "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAmortizationDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Property and Equipment are Stated at Cost Less Accumulated Depreciation and Amortization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "ic066e702d698456487c1fe09f0556f0f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Summary of Earnings Per Share Diluted Anti Dilutive Impact (Details)",
     "role": "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofEarningsPerShareDilutedAntiDilutiveImpactDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Earnings Per Share Diluted Anti Dilutive Impact (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Available for Sale Marketable Securities By Security Type (Details)",
     "role": "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails",
     "shortName": "Marketable Securities and Fair Value Measurements - Summary of Available for Sale Marketable Securities By Security Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Marketable Securities and Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment Net (Details)",
     "role": "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails",
     "shortName": "Property and Equipment, Net - Summary of Property and Equipment Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "role": "http://www.foghorntx.com/role/PropertyandEquipmentNetAdditionalInformationDetails",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.foghorntx.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Accrued Expenses (Details)",
     "role": "http://www.foghorntx.com/role/AccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Notes Payable - Summary of Long Term Debt (Details)",
     "role": "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails",
     "shortName": "Notes Payable - Summary of Long Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i69208d809b134811a688e3aaa1b56f5f_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i5a5c869b237944468340c8ac74252d01_D20211201-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Notes Payable - Additional Information (Details)",
     "role": "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails",
     "shortName": "Notes Payable - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtWeightedAverageInterestRateOverTime",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "ic61be130c3e94434a1523a709ee82e84_D20201027-20201027",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Common Stock (Details)",
     "role": "http://www.foghorntx.com/role/CommonStockDetails",
     "shortName": "Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428413 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Stock-Based Compensation - Schedule of Weighted Average Assumptions Used to Estimate Fair Value of Stock Options and Restricted Stock Awards using Black-Scholes Option Pricing Model (Details)",
     "role": "http://www.foghorntx.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedtoEstimateFairValueofStockOptionsandRestrictedStockAwardsusingBlackScholesOptionPricingModelDetails",
     "shortName": "Stock-Based Compensation - Schedule of Weighted Average Assumptions Used to Estimate Fair Value of Stock Options and Restricted Stock Awards using Black-Scholes Option Pricing Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i5d2903ef2dbb45de898f7a0b55ed8a21_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Stock-Based Compensation - Schedule of Share Option Activity (Details)",
     "role": "http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Schedule of Share Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Stock-Based Compensation - Summary of Stock-based compensation expense (Details)",
     "role": "http://www.foghorntx.com/role/StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock-based compensation expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i25bd4e2b11bf41efbe5fc4e9eae184b7_D20200701-20200731",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "fhtx:ProceedsFromUpfrontPayment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433417 - Disclosure - Collaboration Agreement (Details)",
     "role": "http://www.foghorntx.com/role/CollaborationAgreementDetails",
     "shortName": "Collaboration Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i26f27415158a4a8dad12c8e3b7e94178_I20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436418 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437419 - Disclosure - Income Taxes - Summary of Reconciliation of the U.S. federal statutory income tax rate to the Company's effective income tax rate (Details)",
     "role": "http://www.foghorntx.com/role/IncomeTaxesSummaryofReconciliationoftheUSfederalstatutoryincometaxratetotheCompanyseffectiveincometaxrateDetails",
     "shortName": "Income Taxes - Summary of Reconciliation of the U.S. federal statutory income tax rate to the Company's effective income tax rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438420 - Disclosure - Income Taxes - Summary of Net Deferred Tax Assets (Details)",
     "role": "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Summary of Net Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441421 - Disclosure - Leases - Additional Information (Details)",
     "role": "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442422 - Disclosure - Leases - Summary of Lease Cost (Details)",
     "role": "http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails",
     "shortName": "Leases - Summary of Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443423 - Disclosure - Leases - Summary of Supplemental Cash Flow Information Related to Leases (Details)",
     "role": "http://www.foghorntx.com/role/LeasesSummaryofSupplementalCashFlowInformationRelatedtoLeasesDetails",
     "shortName": "Leases - Summary of Supplemental Cash Flow Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444424 - Disclosure - Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Leases (Details)",
     "role": "http://www.foghorntx.com/role/LeasesSummaryofWeightedAverageRemainingLeaseTermandDiscountRateLeasesDetails",
     "shortName": "Leases - Summary of Weighted-Average Remaining Lease Term and Discount Rate Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445425 - Disclosure - Leases - Summary of Minimum Lease Payment (Details)",
     "role": "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails",
     "shortName": "Leases - Summary of Minimum Lease Payment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i2b2f7dd1e2bf4b02883b7cf61fbce8b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446426 - Disclosure - Leases - Summary of Operating Lease Liabilities (Details)",
     "role": "http://www.foghorntx.com/role/LeasesSummaryofOperatingLeaseLiabilitiesDetails",
     "shortName": "Leases - Summary of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i3e3da7bbe9d045048732fcefce03b848_D20170731-20170731",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "fhtx:AnnualLicenseMaintenanceFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.foghorntx.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i3e3da7bbe9d045048732fcefce03b848_D20170731-20170731",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "fhtx:AnnualLicenseMaintenanceFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i69d3730be48141eba19fe94753d20597_D20220101-20220101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fhtx:ServiceAgreementRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451428 - Disclosure - Related Parties (Details)",
     "role": "http://www.foghorntx.com/role/RelatedPartiesDetails",
     "shortName": "Related Parties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i69d3730be48141eba19fe94753d20597_D20220101-20220101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "fhtx:ServiceAgreementRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "id7943cc4a71f4b42b53e4c968843494e_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 Equity",
     "role": "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "id7943cc4a71f4b42b53e4c968843494e_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "ie0edcb140d2049a79c39501d27f139b9_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "fhtx:StockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 Equity (Parenthetical)",
     "role": "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "ie0edcb140d2049a79c39501d27f139b9_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "fhtx:StockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockOptionPlanExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of Business and Basis of Presentation",
     "role": "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentation",
     "shortName": "Nature of Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fhtx-20211231.htm",
      "contextRef": "i8d44aeede1f74892bf721c7699eee869_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 64,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Street"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title\u00a0of\u00a0each\u00a0class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name\u00a0of\u00a0each\u00a0exchange on\u00a0which\u00a0registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol(s)"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.foghorntx.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "fhtx_A2016StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Stock Incentive Plan",
        "label": "2016 Stock Incentive Plan [Member]",
        "terseLabel": "2016 Incentive Plan"
       }
      }
     },
     "localname": "A2016StockIncentivePlanMember",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_AccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.foghorntx.com/role/AccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for expenses related to research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research And Development Expenses",
        "terseLabel": "Accrued external research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fhtx_AccruedTenantImprovements": {
     "auth_ref": [],
     "calculation": {
      "http://www.foghorntx.com/role/AccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Tenant Improvements",
        "label": "Accrued Tenant Improvements",
        "terseLabel": "Accrued tenant improvements"
       }
      }
     },
     "localname": "AccruedTenantImprovements",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fhtx_AdditionalOfficeSpaceInCambridgeMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Office Space In Cambridge, Massachusetts",
        "label": "Additional Office Space In Cambridge, Massachusetts [Member]",
        "terseLabel": "Additional Office Space In Cambridge, Massachusetts"
       }
      }
     },
     "localname": "AdditionalOfficeSpaceInCambridgeMassachusettsMember",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_AnnualLicenseMaintenanceFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual license maintenance fees.",
        "label": "Annual License Maintenance Fees",
        "terseLabel": "Annual license maintenance fees"
       }
      }
     },
     "localname": "AnnualLicenseMaintenanceFees",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fhtx_AssetsNotYetPlacedInServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets Not Yet Placed In service[Member].",
        "label": "Assets Not Yet Placed In service [Member]",
        "terseLabel": "Assets not yet placed in service"
       }
      }
     },
     "localname": "AssetsNotYetPlacedInServiceMember",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.foghorntx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "fhtx_CashPaymentsRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments made during the period to related parties as part of a service or consulting agreement.",
        "label": "Cash Payments Related Party",
        "terseLabel": "Payments made to related party under service agreement"
       }
      }
     },
     "localname": "CashPaymentsRelatedParty",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fhtx_ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in the operating lease liability and right of use asset as the result of a lease remeasurement.",
        "label": "Change In Operating Lease Liability Right Of Use Asset Re-Measurement",
        "terseLabel": "Increase in operating lease liabilities and right-of-use assets due to lease remeasurement"
       }
      }
     },
     "localname": "ChangeInOperatingLeaseLiabilityRightOfUseAssetReMeasurement",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesSummaryofSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fhtx_CollaborationAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement",
        "label": "Collaboration Agreement [Abstract]",
        "terseLabel": "Collaboration Agreement [Abstract]"
       }
      }
     },
     "localname": "CollaborationAgreementAbstract",
     "nsuri": "http://www.foghorntx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "fhtx_CommonStockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for common stock, including, but not limited to voting rights, dividends, and stock splits.",
        "label": "Common Stock [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockTextBlock",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/CommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fhtx_ConversionOfNotesPayableInToWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of notes payable in to warrants.",
        "label": "Conversion of Notes Payable in to Warrants [Member]",
        "terseLabel": "Conversion of Notes Payable in to Warrants"
       }
      }
     },
     "localname": "ConversionOfNotesPayableInToWarrantsMember",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_ConversionOfRedeemableConvertibleStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of redeemable convertible stock.",
        "label": "Conversion of Redeemable Convertible stock [Member]",
        "terseLabel": "Conversion of Redeemable Convertible stock"
       }
      }
     },
     "localname": "ConversionOfRedeemableConvertibleStockMember",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_ConversionOfWarrantLiabilityToEquityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of warrant liability to equity.",
        "label": "Conversion of Warrant Liability to Equity [Member]",
        "terseLabel": "Conversion of Warrant Liability to Equity"
       }
      }
     },
     "localname": "ConversionOfWarrantLiabilityToEquityMember",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt, as a percentage of the amounts drawn under the Term Loan.",
        "label": "Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid Percentage",
        "terseLabel": "Debt, final payment fee percentage"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fhtx_DeferredTaxAssetsCapitalizedStartUpCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capitalized start-up costs.",
        "label": "Deferred Tax Assets Capitalized Start Up Costs",
        "terseLabel": "Capitalized start-up costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedStartUpCosts",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fhtx_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating lease liabilities.",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fhtx_DeferredTaxLiabilitiesDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from depreciation.",
        "label": "Deferred Tax Liabilities Depreciation",
        "negatedLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDepreciation",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fhtx_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from operating lease right-of-use assets.",
        "label": "Deferred Tax Liabilities Operating Lease Right Of Use Assets",
        "negatedLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fhtx_DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference Between Fair Value OF Shares And Contractual Purchase Price",
        "label": "Difference Between Fair Value OF Shares And Contractual Purchase Price",
        "negatedTerseLabel": "Difference between fair value of shares and contract price"
       }
      }
     },
     "localname": "DifferenceBetweenFairValueOFSharesAndContractualPurchasePrice",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fhtx_EliLillyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eli Lilly",
        "label": "Eli Lilly [Member]",
        "terseLabel": "Eli Lilly"
       }
      }
     },
     "localname": "EliLillyMember",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/CommonStockDetails",
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_FlagshipPioneeringMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Flagship Pioneering.",
        "label": "Flagship Pioneering [Member]",
        "terseLabel": "Flagship Pioneering"
       }
      }
     },
     "localname": "FlagshipPioneeringMember",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in operating lease liabilities during the reporting period.",
        "label": "Increase (Decrease) In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fhtx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in right-of-use assets under an operating lease.",
        "label": "Increase Decrease In Operating Lease Right Of Use Asset",
        "terseLabel": "Noncash lease expense"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fhtx_InterestIncomeAndOtherIncomeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income and income (expense) related to nonoperating activities, classified as other.",
        "label": "Interest Income And Other Income Expense",
        "terseLabel": "Interest income and other income (expense), net"
       }
      }
     },
     "localname": "InterestIncomeAndOtherIncomeExpense",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fhtx_LeaseholdImprovementsLandlordAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The monetary allowance granted by the landlord to a tenant to entice tenant to move into landlord's building which will enable the tenant to prepare the leased premises for tenant's occupancy.",
        "label": "Leasehold Improvements Landlord Allowance",
        "terseLabel": "Leasehold improvements landlord allowance"
       }
      }
     },
     "localname": "LeaseholdImprovementsLandlordAllowance",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fhtx_LeaseholdImprovementsLandlordAllowanceToBeRepaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An additional monetary allowance granted by the landlord to a tenant to entice tenant to move into landlord's building which will enable the tenant to prepare the leased premises for tenant's occupancy. This additional amount will result in additional rent payments to the landlord.",
        "label": "Leasehold Improvements Landlord Allowance To Be Repaid",
        "terseLabel": "Leasehold improvements landlord allowance to be repaid"
       }
      }
     },
     "localname": "LeaseholdImprovementsLandlordAllowanceToBeRepaid",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fhtx_LeasesBalanceSheetLocationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of operating lease liabilities included in the consolidated balance sheet.",
        "label": "Leases, Balance Sheet Location [Table Text Block]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "LeasesBalanceSheetLocationTableTextBlock",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fhtx_LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives": {
     "auth_ref": [],
     "calculation": {
      "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of estimated lease incentives used by lessee to determine present value of operating lease payments.",
        "label": "Lessee Operating Lease Liability Estimated Lease Incentives",
        "negatedLabel": "Less: estimated lease incentives"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityEstimatedLeaseIncentives",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fhtx_LineOfCreditAdditionalBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Additional Borrowing Capacity",
        "label": "Line Of Credit Additional Borrowing Capacity",
        "terseLabel": "Principal amount of long-term debt"
       }
      }
     },
     "localname": "LineOfCreditAdditionalBorrowingCapacity",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fhtx_MarketableSecuritiesAndFairValueMeasurementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for marketable securities and fair value measurements.",
        "label": "Marketable Securities And Fair Value Measurements [Text Block]",
        "terseLabel": "Marketable Securities and\u00a0Fair Value Measurements"
       }
      }
     },
     "localname": "MarketableSecuritiesAndFairValueMeasurementsTextBlock",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "fhtx_MerckMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck",
        "label": "Merck [Member]",
        "terseLabel": "Merck"
       }
      }
     },
     "localname": "MerckMember",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_MilestoneReceivableUponAchievement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of consideration to be received upon achievement of specified milestones.",
        "label": "Milestone Receivable Upon Achievement",
        "terseLabel": "Amount receivable for achievement of milestones"
       }
      }
     },
     "localname": "MilestoneReceivableUponAchievement",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fhtx_MilestonesPayableUponEvent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount the Company will pay for regulatory milestones on each licensed product upon the occurrence of specific events as outlined in the license agreement.",
        "label": "Milestones Payable Upon Event",
        "terseLabel": "Milestones payable upon event"
       }
      }
     },
     "localname": "MilestonesPayableUponEvent",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fhtx_NumberOfAdditionalTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Additional Targets",
        "label": "Number Of Additional Targets",
        "terseLabel": "Number of additional targets"
       }
      }
     },
     "localname": "NumberOfAdditionalTargets",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "fhtx_NumberOfCollaborativeAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Collaborative Agreements",
        "label": "Number Of Collaborative Agreements",
        "terseLabel": "Number of collaborative agreements"
       }
      }
     },
     "localname": "NumberOfCollaborativeAgreements",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "fhtx_NumberOfPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Programs",
        "label": "Number Of Programs",
        "terseLabel": "Number of programs"
       }
      }
     },
     "localname": "NumberOfPrograms",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "fhtx_NumberOfTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Targets",
        "label": "Number Of Targets",
        "terseLabel": "Number of targets"
       }
      }
     },
     "localname": "NumberOfTargets",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "fhtx_OfficeAndLaboratorySpaceInCambridgeMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and Laboratory Space In Cambridge, Massachusetts",
        "label": "Office and Laboratory Space In Cambridge, Massachusetts [Member]",
        "terseLabel": "Office and Laboratory Space In Cambridge, Massachusetts"
       }
      }
     },
     "localname": "OfficeAndLaboratorySpaceInCambridgeMassachusettsMember",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_OfficeSpaceInCambridgeMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Space In Cambridge, Massachusetts",
        "label": "Office Space In Cambridge, Massachusetts [Member]",
        "terseLabel": "Office Space In Cambridge, Massachusetts"
       }
      }
     },
     "localname": "OfficeSpaceInCambridgeMassachusettsMember",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_OperatingLossCarryforwardLimitPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The limit that may be applied to operating loss carryforwards, as a percentage of annual taxable income.",
        "label": "Operating Loss Carryforward Limit Percentage",
        "terseLabel": "Operating loss carryforward limit percentage"
       }
      }
     },
     "localname": "OperatingLossCarryforwardLimitPercentage",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fhtx_OptOutMilestoneReceivableUponAchievement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opt Out Milestone Receivable Upon Achievement",
        "label": "Opt Out Milestone Receivable Upon Achievement",
        "terseLabel": "Amounts receivable for opt out milestones"
       }
      }
     },
     "localname": "OptOutMilestoneReceivableUponAchievement",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fhtx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Table]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fhtx_PercentageOfPrepaymentFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee for prepayment of a loan, as a percentage of the principal amount being prepaid.",
        "label": "Percentage of Prepayment Fee",
        "terseLabel": "Percentage of prepayment fee"
       }
      }
     },
     "localname": "PercentageOfPrepaymentFee",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fhtx_PrepaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment Period",
        "label": "Prepayment Period",
        "terseLabel": "Prepayment period"
       }
      }
     },
     "localname": "PrepaymentPeriod",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fhtx_PrepaymentPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment Period [Axis]",
        "terseLabel": "Prepayment Period [Axis]"
       }
      }
     },
     "localname": "PrepaymentPeriodAxis",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "fhtx_PrepaymentPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment Period [Domain]",
        "terseLabel": "Prepayment Period [Domain]"
       }
      }
     },
     "localname": "PrepaymentPeriodDomain",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_PrepaymentPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment Period One",
        "label": "Prepayment Period One [Member]",
        "terseLabel": "Prepayment Period One"
       }
      }
     },
     "localname": "PrepaymentPeriodOneMember",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_PrepaymentPeriodThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment Period Three",
        "label": "Prepayment Period Three [Member]",
        "terseLabel": "Prepayment Period Three"
       }
      }
     },
     "localname": "PrepaymentPeriodThreeMember",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_PrepaymentPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment Period Two",
        "label": "Prepayment Period Two [Member]",
        "terseLabel": "Prepayment Period Two"
       }
      }
     },
     "localname": "PrepaymentPeriodTwoMember",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_ProceedsFromUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from upfront payment",
        "label": "Proceeds From Upfront Payment",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "ProceedsFromUpfrontPayment",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fhtx_ResearchDevelopmentAndRegulatoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research development and regulatory.",
        "label": "Research Development And Regulatory [Member]",
        "terseLabel": "Research Development And Regulatory"
       }
      }
     },
     "localname": "ResearchDevelopmentAndRegulatoryMember",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_SalesBasedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Based Milestone",
        "label": "Sales Based Milestone [Member]",
        "terseLabel": "Sales Based Milestone"
       }
      }
     },
     "localname": "SalesBasedMilestoneMember",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_ScientificFounderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scientific Founder.",
        "label": "Scientific Founder [Member]",
        "terseLabel": "Scientific Founder"
       }
      }
     },
     "localname": "ScientificFounderMember",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_ServiceAgreementRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service Agreement Renewal Term",
        "label": "Service Agreement Renewal Term",
        "terseLabel": "Service agreement renewal term"
       }
      }
     },
     "localname": "ServiceAgreementRenewalTerm",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fhtx_ServiceAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The term of a service agreement in 'PnYnMnDTnHnMnS' format.",
        "label": "Service Agreement Term",
        "terseLabel": "Service agreement term"
       }
      }
     },
     "localname": "ServiceAgreementTerm",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of shares authorized to be automatically increased on the first day of the fiscal year, under a share based payment arrangement, as a percentage of common stock outstanding on the last day of the previous fiscal year.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Automatic Annual Increase, Percentage",
        "terseLabel": "Percentage of automatic annual increase in number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAutomaticAnnualIncreasePercentage",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "fhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate number of shares that may be added to the plan in future years.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Future Increase Shares",
        "terseLabel": "Maximum aggregate number of shares added to plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumFutureIncreaseShares",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "fhtx_SharePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement",
        "label": "Share Purchase Agreement [Member]",
        "terseLabel": "Share Purchase Agreement"
       }
      }
     },
     "localname": "SharePurchaseAgreementMember",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/CommonStockDetails",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity",
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_StanfordLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stanford License Agreement [Member]",
        "terseLabel": "Stanford License Agreement"
       }
      }
     },
     "localname": "StanfordLicenseAgreementMember",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_StockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred directly with the issuance of an equity or temporary equity security.",
        "label": "Stock Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "StockIssuanceCosts",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fhtx_StockIssuedDuringPeriodConnectionWithExerciseOfWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Connection With Exercise Of Warrant",
        "label": "Stock Issued During Period Connection With Exercise Of Warrant",
        "terseLabel": "Issuance of common stock in connection with the cashless exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodConnectionWithExerciseOfWarrant",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "fhtx_TemporaryEquityConversionOfStockAmountConverted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Conversion of Stock, Amount Converted",
        "label": "Temporary Equity, Conversion of Stock, Amount Converted",
        "negatedTerseLabel": "Conversion of preferred stock to common stock"
       }
      }
     },
     "localname": "TemporaryEquityConversionOfStockAmountConverted",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fhtx_TemporaryEquityConversionOfStockSharesConverted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Conversion of Stock, Shares Converted",
        "label": "Temporary Equity, Conversion of Stock, Shares Converted",
        "negatedTerseLabel": "Conversion of preferred stock to common stock (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityConversionOfStockSharesConverted",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "fhtx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of Series B convertible preferred stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "fhtx_TermLoanAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term Loan A [Member]",
        "terseLabel": "Term Loan A"
       }
      }
     },
     "localname": "TermLoanAMember",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails",
      "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_TermLoanBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term Loan B [Member]",
        "terseLabel": "Term Loan B"
       }
      }
     },
     "localname": "TermLoanBMember",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_TwoThousandTwentyEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Employee Stock Purchase Plan [Member]",
        "terseLabel": "2020 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_TwoThousandTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2020 Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyEquityIncentivePlanMember",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fhtx_WarrantsIssuePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per unit amount of warrant issued.",
        "label": "Warrants Issue Price Per Share",
        "terseLabel": "Warrants Issue price per share (in dollars per share)"
       }
      }
     },
     "localname": "WarrantsIssuePricePerShare",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "fhtx_WeightedAverageContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Contractual Term",
        "label": "Weighted Average Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Contractual Term"
       }
      }
     },
     "localname": "WeightedAverageContractualTermAbstract",
     "nsuri": "http://www.foghorntx.com/20211231",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r321",
      "r476",
      "r477",
      "r480",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r50",
      "r52",
      "r108",
      "r109",
      "r244",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/CommonStockDetails",
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails",
      "http://www.foghorntx.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r243",
      "r282",
      "r331",
      "r333",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r518",
      "r565",
      "r566",
      "r606",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/CommitmentsandContingenciesDetails",
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails",
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r243",
      "r282",
      "r331",
      "r333",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r518",
      "r565",
      "r566",
      "r606",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r243",
      "r282",
      "r311",
      "r331",
      "r333",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r518",
      "r565",
      "r566",
      "r606",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/CommitmentsandContingenciesDetails",
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails",
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r243",
      "r282",
      "r311",
      "r331",
      "r333",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r518",
      "r565",
      "r566",
      "r606",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/CommitmentsandContingenciesDetails",
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails",
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r51",
      "r52",
      "r108",
      "r109",
      "r244",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/CommonStockDetails",
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails",
      "http://www.foghorntx.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r120",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r120",
      "r125",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r120",
      "r125",
      "r218",
      "r332",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r176",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r34",
      "r485"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r34",
      "r106",
      "r478",
      "r480"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Related Parties, Current",
        "terseLabel": "Accounts payable, related party"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization (accretion) of premium/discount on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/AccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r39"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/AccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r24",
      "r56",
      "r57",
      "r58",
      "r558",
      "r571",
      "r572"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r55",
      "r58",
      "r66",
      "r67",
      "r68",
      "r112",
      "r113",
      "r114",
      "r418",
      "r567",
      "r568",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r22",
      "r370",
      "r485"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r367",
      "r368",
      "r369",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of subsequent adjustments to additional paid in capital for convertible financial instruments where a component of equity and a component of debt are recognized.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments",
        "terseLabel": "Issuance of warrants in connection with notes payable"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r335",
      "r337",
      "r373",
      "r374"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r239",
      "r287",
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Conversion of warrant liability to equity upon closing of initial public offering"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofEarningsPerShareDilutedAntiDilutiveImpactDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "verboseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofEarningsPerShareDilutedAntiDilutiveImpactDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "verboseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofEarningsPerShareDilutedAntiDilutiveImpactDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "verboseLabel": "Antidilutive Securities [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofEarningsPerShareDilutedAntiDilutiveImpactDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of leased property"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r104",
      "r156",
      "r165",
      "r171",
      "r190",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r415",
      "r419",
      "r436",
      "r483",
      "r485",
      "r537",
      "r555"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r48",
      "r104",
      "r190",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r415",
      "r419",
      "r436",
      "r483",
      "r485"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r426"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Assets, fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r182"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r180",
      "r197"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r178",
      "r181",
      "r197",
      "r542"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable securities",
        "verboseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails",
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r338",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r2",
      "r111",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Nature of Business and Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r95",
      "r96",
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable, accrued expenses and other liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizationOfInternalCostsPolicy": {
     "auth_ref": [
      "r522",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for capitalizing internal costs associated with exploration and production activities.",
        "label": "Capitalization of Internal Costs, Policy [Policy Text Block]",
        "terseLabel": "Patent costs"
       }
      }
     },
     "localname": "CapitalizationOfInternalCostsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r30",
      "r92"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r10",
      "r93",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r86",
      "r92",
      "r98"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash shown in the statement of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r86",
      "r437"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "verboseLabel": "Supplemental disclosure of noncash investing and financing information:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r102",
      "r104",
      "r128",
      "r129",
      "r130",
      "r132",
      "r134",
      "r140",
      "r141",
      "r142",
      "r190",
      "r228",
      "r232",
      "r233",
      "r234",
      "r237",
      "r238",
      "r280",
      "r281",
      "r284",
      "r285",
      "r436",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CommonStockDetails",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityParenthetical",
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Class of warrant or right, number of securities called by warrants or rights (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r409",
      "r410",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "verboseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper (due within one year)",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails",
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r44",
      "r217",
      "r543",
      "r561"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 13)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r224",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r112",
      "r113",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CommonStockDetails",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity",
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21",
      "r485"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 175,000,000 shares authorized at December\u00a031, 2021 and 2020; 41,299,720 shares issued and outstanding at December\u00a031, 2021 and 36,790,946 shares issued and outstanding at December\u00a031, 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r61",
      "r63",
      "r64",
      "r71",
      "r546",
      "r563"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r145",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of credit risk and of significant suppliers"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r295",
      "r297",
      "r309"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Collaboration receivable"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r295",
      "r296",
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r295",
      "r296",
      "r309"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Deferred revenue, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r295",
      "r296",
      "r309"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r95",
      "r96",
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of stock, amount converted"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "auth_ref": [
      "r95",
      "r96",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by description of stock conversions.",
        "label": "Stock Conversion Description [Axis]",
        "terseLabel": "Stock Conversion Description [Axis]"
       }
      }
     },
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "auth_ref": [
      "r95",
      "r96",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The unique name of a noncash or part noncash stock conversion.",
        "label": "Conversion of Stock, Name [Domain]",
        "terseLabel": "Conversion of Stock, Name [Domain]"
       }
      }
     },
     "localname": "ConversionOfStockNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r95",
      "r96",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of preferred stock to common stock (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r280",
      "r281",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Series A-1, A-2 and B Convertible Preferred\u00a0Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r312",
      "r327",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate notes and bonds (due within one year)",
        "verboseLabel": "Corporate notes and bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails",
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r95",
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Issuance of warrants in connection with notes payable"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r101",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r257",
      "r264",
      "r265",
      "r267",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Notes Payable"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r103",
      "r110",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r269",
      "r270",
      "r271",
      "r272",
      "r449",
      "r538",
      "r540",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails",
      "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument, basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r240",
      "r269",
      "r270",
      "r447",
      "r449",
      "r450"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount of long-term debt",
        "verboseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails",
      "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r41",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument, interest rate, stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r42",
      "r103",
      "r110",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r247",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r269",
      "r270",
      "r271",
      "r272",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails",
      "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "auth_ref": [],
     "calculation": {
      "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "terseLabel": "Final payment fee"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "verboseLabel": "Term of loan"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r253",
      "r446",
      "r450"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Debt discount, net of accretion"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Summary of Available for Sale Marketable Securities By Security Type"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r16",
      "r17",
      "r390",
      "r539",
      "r553"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r393"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r397",
      "r398"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "calculation": {
      "http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Operating loss without expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "calculation": {
      "http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Operating loss subject to expiration expiration"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r396",
      "r397",
      "r398"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r397",
      "r398"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r397",
      "r398"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r392"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "verboseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r90",
      "r155"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.foghorntx.com/role/PropertyandEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r72",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r126",
      "r128",
      "r132",
      "r133",
      "r134",
      "r137",
      "r138",
      "r424",
      "r425",
      "r547",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to common stockholders\u2014basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r72",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r128",
      "r132",
      "r133",
      "r134",
      "r137",
      "r138",
      "r424",
      "r425",
      "r547",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders\u2014diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r382"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofReconciliationoftheUSfederalstatutoryincometaxratetotheCompanyseffectiveincometaxrateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofReconciliationoftheUSfederalstatutoryincometaxratetotheCompanyseffectiveincometaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r105",
      "r382",
      "r404"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofReconciliationoftheUSfederalstatutoryincometaxratetotheCompanyseffectiveincometaxrateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedLabel": "Federal statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofReconciliationoftheUSfederalstatutoryincometaxratetotheCompanyseffectiveincometaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r382",
      "r404"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofReconciliationoftheUSfederalstatutoryincometaxratetotheCompanyseffectiveincometaxrateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in deferred tax asset valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofReconciliationoftheUSfederalstatutoryincometaxratetotheCompanyseffectiveincometaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofReconciliationoftheUSfederalstatutoryincometaxratetotheCompanyseffectiveincometaxrateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofReconciliationoftheUSfederalstatutoryincometaxratetotheCompanyseffectiveincometaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r382",
      "r404"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofReconciliationoftheUSfederalstatutoryincometaxratetotheCompanyseffectiveincometaxrateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "negatedTerseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofReconciliationoftheUSfederalstatutoryincometaxratetotheCompanyseffectiveincometaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r382",
      "r404"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofReconciliationoftheUSfederalstatutoryincometaxratetotheCompanyseffectiveincometaxrateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedTerseLabel": "Federal and state research and development tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesSummaryofReconciliationoftheUSfederalstatutoryincometaxratetotheCompanyseffectiveincometaxrateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/AccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued employee compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.foghorntx.com/role/StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation costs related to unvested options and unvested restricted stock"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period of unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofEarningsPerShareDilutedAntiDilutiveImpactDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment",
        "verboseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails",
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAmortizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r66",
      "r67",
      "r68",
      "r112",
      "r113",
      "r114",
      "r116",
      "r122",
      "r124",
      "r139",
      "r191",
      "r287",
      "r294",
      "r367",
      "r368",
      "r369",
      "r401",
      "r402",
      "r423",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r567",
      "r568",
      "r569",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r90",
      "r276"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Change in fair value of preferred stock warrant liability",
        "terseLabel": "Change in fair value of preferred stock warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "verboseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r426",
      "r427",
      "r428",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "verboseLabel": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasis[Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r426",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r255",
      "r269",
      "r270",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r327",
      "r427",
      "r491",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r426",
      "r427",
      "r429",
      "r430",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r255",
      "r312",
      "r314",
      "r319",
      "r327",
      "r427",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r255",
      "r269",
      "r270",
      "r312",
      "r314",
      "r319",
      "r327",
      "r427",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r255",
      "r269",
      "r270",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r327",
      "r427",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r255",
      "r269",
      "r270",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r327",
      "r491",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r431",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r184",
      "r185",
      "r187",
      "r188",
      "r189",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r201",
      "r266",
      "r286",
      "r422",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures",
        "verboseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails",
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAmortizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r90",
      "r204",
      "r209"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedLabel": "Gain on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r90",
      "r273",
      "r274"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on debt extinguishment",
        "terseLabel": "Loss on debt extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CommonStockDetails",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity",
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails",
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r90",
      "r203",
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment losses on long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r202",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r210",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r385",
      "r387",
      "r389",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r105",
      "r383",
      "r388",
      "r395",
      "r403",
      "r405",
      "r406",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r65",
      "r380",
      "r381",
      "r388",
      "r389",
      "r394",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "negatedTerseLabel": "Collaboration receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r89",
      "r519"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r69",
      "r154",
      "r445",
      "r448",
      "r548"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r85",
      "r87",
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r468",
      "r470"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Lease Cost and Lease Details"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets held by a lessee under a capital lease and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).",
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r469"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r469"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r469"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r469"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r469"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r469"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r469"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r469"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease term extension"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lessee, operating lease, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r472"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "terseLabel": "Future sublease income outstanding"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessor, Operating Lease, Term of Contract",
        "terseLabel": "Lessor, operating lease, term of contract"
       }
      }
     },
     "localname": "LessorOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38",
      "r104",
      "r166",
      "r190",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r416",
      "r419",
      "r420",
      "r436",
      "r483",
      "r484"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r27",
      "r104",
      "r190",
      "r436",
      "r485",
      "r541",
      "r560"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40",
      "r104",
      "r190",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r416",
      "r419",
      "r420",
      "r436",
      "r483",
      "r484",
      "r485"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r15",
      "r254",
      "r268",
      "r269",
      "r270",
      "r540",
      "r556"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Long-term debt, net of discount and current portion"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedLabel": "Less: Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Notes payable, net of discount",
        "totalLabel": "Notes payable, net of discount"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets",
      "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time.",
        "label": "Long-term Debt, Weighted Average Interest Rate, over Time",
        "terseLabel": "Debt, weighted average interest rate"
       }
      }
     },
     "localname": "LongTermDebtWeightedAverageInterestRateOverTime",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "verboseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r544"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized losses on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r86",
      "r88",
      "r91"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r59",
      "r62",
      "r68",
      "r70",
      "r91",
      "r104",
      "r115",
      "r117",
      "r118",
      "r119",
      "r120",
      "r123",
      "r124",
      "r131",
      "r156",
      "r164",
      "r167",
      "r170",
      "r172",
      "r190",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r425",
      "r436",
      "r545",
      "r562"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r156",
      "r164",
      "r167",
      "r170",
      "r172"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r460",
      "r470"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r454"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease rent payments"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r452"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.foghorntx.com/role/LeasesSummaryofOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails",
      "http://www.foghorntx.com/role/LeasesSummaryofMinimumLeasePaymentDetails",
      "http://www.foghorntx.com/role/LeasesSummaryofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r452"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.foghorntx.com/role/LeasesSummaryofOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets",
      "http://www.foghorntx.com/role/LeasesSummaryofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r452"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.foghorntx.com/role/LeasesSummaryofOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets",
      "http://www.foghorntx.com/role/LeasesSummaryofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r455",
      "r464"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesSummaryofSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets",
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r467",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate\u2014operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesSummaryofWeightedAverageRemainingLeaseTermandDiscountRateLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r466",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term\u2014operating leases (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesSummaryofWeightedAverageRemainingLeaseTermandDiscountRateLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r396"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "totalLabel": "Operating loss carry forward"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r39"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/AccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r53",
      "r54",
      "r56"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized losses on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r60",
      "r63",
      "r413",
      "r414",
      "r417"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Total other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CommonStockDetails",
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Noncash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "auth_ref": [
      "r78",
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.",
        "label": "Payments for (Proceeds from) Tenant Allowance",
        "negatedLabel": "Reimbursements from lessor"
       }
      }
     },
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "terseLabel": "Payments of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r311",
      "r313",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Defined Contribution Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/DefinedContributionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r338",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r20",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares, issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Proferred stock, shares, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r20",
      "r485"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 25,000,000 shares authorized as of December\u00a031, 2021 and 2020; no shares issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r28",
      "r29"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering, net of underwriting discounts, commissions and offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from stock purchase agreement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Proceeds from issuance of notes payable, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r81",
      "r366"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r206",
      "r453",
      "r459"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "negatedLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r49",
      "r207",
      "r459"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets",
      "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r11",
      "r205",
      "r451"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "terseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r32",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails",
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAmortizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r212",
      "r593",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails",
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAmortizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r31",
      "r207",
      "r593",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment are Stated at Cost Less Accumulated Depreciation and Amortization",
        "verboseLabel": "Sumary of Property and Equipment Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/PropertyandEquipmentNetTables",
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails",
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAmortizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "verboseLabel": "Property, plant and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAmortizationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r321",
      "r476",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r321",
      "r476",
      "r480",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r474",
      "r475",
      "r477",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Repayments of notes payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r376",
      "r520",
      "r608"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashEquivalents": {
     "auth_ref": [
      "r98",
      "r536",
      "r557",
      "r589",
      "r591"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents",
        "terseLabel": "Restricted cash (current and non-current)"
       }
      }
     },
     "localname": "RestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r6",
      "r12",
      "r98",
      "r590"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets",
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r294",
      "r370",
      "r485",
      "r559",
      "r570",
      "r572"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets",
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r112",
      "r113",
      "r114",
      "r116",
      "r122",
      "r124",
      "r191",
      "r367",
      "r368",
      "r369",
      "r401",
      "r402",
      "r423",
      "r567",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r152",
      "r153",
      "r163",
      "r168",
      "r169",
      "r173",
      "r174",
      "r175",
      "r307",
      "r308",
      "r521"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "verboseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r100",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Collaboration Agreements and Revenue recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Unsatisfied portion of the performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r465",
      "r470"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease liabilities arising from obtaining right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesSummaryofSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Sale of stock consideration received on the transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/CommonStockDetails",
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/CommonStockDetails",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity",
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails",
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/CommonStockDetails",
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock issue price per share (in dollars per share)",
        "verboseLabel": "Sale of stock issue price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/CommonStockDetails",
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Sales based"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScenarioAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domain member used to indicate figures that are adjustments during a period or as of a point in time. This domain member would never be expected to appear in a relationship group without the \"Scenario, Previously Reported\" Member with the same parent.",
        "label": "Scenario, Adjustment [Member]",
        "terseLabel": "Scenario, Adjustment"
       }
      }
     },
     "localname": "ScenarioAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/AccruedExpensesTable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "verboseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofEarningsPerShareDilutedAntiDilutiveImpactDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of Earnings Per Share Diluted Anti Dilutive Impact"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "verboseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r42",
      "r110",
      "r269",
      "r271",
      "r288",
      "r291",
      "r292",
      "r293",
      "r446",
      "r447",
      "r450",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Summary of Long Term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Summary of Net Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Reconciliation of the U.S. federal statutory income tax rate to the Company's effective income tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r337",
      "r363",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.foghorntx.com/role/StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r337",
      "r363",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r32",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails",
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAmortizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r478",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r344",
      "r351",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options and Restricted Stock Awards using Black-Scholes Option Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]",
        "terseLabel": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails",
      "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r46",
      "r102",
      "r140",
      "r141",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense related to issuance of options and employee stock purchase plan"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationSummaryofStockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period (years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r353"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Aggregate fair value of restricted stock that vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedtoEstimateFairValueofStockOptionsandRestrictedStockAwardsusingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedtoEstimateFairValueofStockOptionsandRestrictedStockAwardsusingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedtoEstimateFairValueofStockOptionsandRestrictedStockAwardsusingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Common stock shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options, exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r353"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value of stock options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r346",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r336",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Stock option expiry period (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r358",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofWeightedAverageAssumptionsUsedtoEstimateFairValueofStockOptionsandRestrictedStockAwardsusingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]",
        "terseLabel": "Short-term Debt"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails",
      "http://www.foghorntx.com/role/NotesPayableSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r461",
      "r470"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r99",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "verboseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/PropertyandEquipmentNetSummaryofPropertyandEquipmentNetDetails",
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofPropertyandEquipmentareStatedatCostLessAccumulatedDepreciationandAmortizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r102",
      "r104",
      "r128",
      "r129",
      "r130",
      "r132",
      "r134",
      "r140",
      "r141",
      "r142",
      "r190",
      "r228",
      "r232",
      "r233",
      "r234",
      "r237",
      "r238",
      "r280",
      "r281",
      "r284",
      "r285",
      "r287",
      "r436",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CommonStockDetails",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityParenthetical",
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r47",
      "r66",
      "r67",
      "r68",
      "r112",
      "r113",
      "r114",
      "r116",
      "r122",
      "r124",
      "r139",
      "r191",
      "r287",
      "r294",
      "r367",
      "r368",
      "r369",
      "r401",
      "r402",
      "r423",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r567",
      "r568",
      "r569",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r139",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r287",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock issued during the period shares new issues shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CommonStockDetails",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity",
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r287",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Sale of restricted common stock to scientific founders (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r20",
      "r21",
      "r287",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Vesting of restricted stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r21",
      "r287",
      "r294",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity",
      "http://www.foghorntx.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r47",
      "r287",
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r287",
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of stock during the period new shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r47",
      "r287",
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionPlanExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for option under share-based payment arrangement.",
        "label": "Stock or Unit Option Plan Expense",
        "terseLabel": "Stock-based compensation expense related to issuance of options and employee stock purchase plan"
       }
      }
     },
     "localname": "StockOptionPlanExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r25",
      "r26",
      "r104",
      "r177",
      "r190",
      "r436",
      "r485"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r463",
      "r470"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease income recorded as other income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r444",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails",
      "http://www.foghorntx.com/role/RelatedPartiesDetails",
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r444",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails",
      "http://www.foghorntx.com/role/RelatedPartiesDetails",
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r444",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails",
      "http://www.foghorntx.com/role/RelatedPartiesDetails",
      "http://www.foghorntx.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/CollaborationAgreementDetails",
      "http://www.foghorntx.com/role/CommonStockDetails",
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity",
      "http://www.foghorntx.com/role/NatureofBusinessandBasisofPresentationDetails",
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "verboseLabel": "Subsidiary, Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carry forward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r45",
      "r104",
      "r190",
      "r436"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Series B convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r184",
      "r185",
      "r187",
      "r188",
      "r189",
      "r266",
      "r286",
      "r422",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryNotesSecuritiesMember": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Notes Securities [Member]",
        "terseLabel": "U.S. treasury notes (due within one year)"
       }
      }
     },
     "localname": "USTreasuryNotesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesBySecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r107",
      "r312",
      "r327",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury notes"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r379",
      "r386"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r143",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r462",
      "r470"
     ],
     "calculation": {
      "http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/LeasesSummaryofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/SummaryofSignificantAccountingPoliciesSummaryofEarningsPerShareDilutedAntiDilutiveImpactDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants exercisable term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "auth_ref": [
      "r426"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity.",
        "label": "Warrants Not Settleable in Cash, Fair Value Disclosure",
        "terseLabel": "Warrants not settlable in cash, fair value disclosure"
       }
      }
     },
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/NotesPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r127",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding\u2014diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r126",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding\u2014basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.foghorntx.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(2))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726384&loc=d3e516343-122869"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r609": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r610": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r611": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r612": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r613": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r614": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r615": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r616": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r617": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r618": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r619": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r620": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r621": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r622": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r623": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r624": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r625": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>125
<FILENAME>0001628280-22-005753-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-005753-xbrl.zip
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M9Z $_[S#A]#6MSQZX+.T/@X3&>]4!WV-\2)]>:&.]ZXNWY^?]2_OSKL7R\:
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MRJ[UZ397]_*>1][&-EKS=GU6QH;,]($OENQ:GW[A\6>53[-@QGI)Z+GPFJV
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M=OUR\Y%=J^0/^)@V<I0&:X_2.39=#J7 4U?Z:<E8??]F_^0=_'O:>??##S_
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M(&(QE'AZ^!R8DT$<)7F69ERKN$$?&9A1%9UE^'!LAT_?D7Y_DPY/^!\4D"L
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M';(MO-XC=0JDQU%]*#Q2IP%FV*>"/M,,HTUPR0QCWM2]#',JRX2Q^83H0ND
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M-&II ,N$33R EV;D@^,Y/DH!F6I,?9!X9H^7P-HPU+!J$-2,3FDTUP%LS?^
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MHK/K#$CIU(3-G?1M[*;)(5<&;*/=H1G6*MM(K."P8F=7V^W"$RR3%&4RF<>
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M?;3YF?+ZZN#(S0DV[^WZ8//SI/7[-P?'WX@E<)6L+JDZY\9 %7Z*"[IL4O]
MR\#OPOAK--/58*NI@(5CQ4V%6'*KECJ'5*8PT1G+==H \R/53RF3G1MD(WR0
MW]N(O]-&H+:\'ANQVAK@1G&E.6B0_GOXQ-/ZGP],YK83:4F6,Z=*63K'=6/H
M<XC]E0J/F_:C J1%;_ HHIF<-'N['F.QAEB#/X,L)8ZDVY6'=\BF("@"LV"!
MJSE(^".?8/;^$K*GN;L*3HBY^ MHQX(6- 9JM+?K<1Q/JH$[)Q36L \DO'A$
MF749-:Y5Y- A%T\F9-QB(Q&3.:?_IN+/' G3M>4/>(Q\0Q(%$&ZR@=-/L03W
M)2N^-X1G<3X9",6VQEDV3;]_<WCRCEQ<^N?AX:&=QQ)?VD[4B+[;)H(BRQ*.
M)!\#G@KB].!E.T,QE!C3FB3@7!'//+XTT^0L][ CXZBU&"05R1 IX=G#6&(2
M&ILF2-.M2=.$XE,B66)\A ?IL*;I>"^I;0M&"G,4\2]X^P2V>ZC159(2'<<5
M7SB>\;-IKK (2\J2&)V_. \B@<\.9(A$,EP-DO$L5/@,Y,.'GB61I \B"]K-
M"7+M[7IPQ--VX=7ANCK-.KWTX(&U9%3&FM&;JAN\.H$]:I# >N3 LP16'\]Z
MB7U!B?7A]V=*[&OB 6NBQ'9\ 'X=B74'1JCWM ^)BL('V'@V2!)]</UI22Q/
MJ-V116)FIBS(ED%I9V-NC.6%-%&B]\EHG*B8#C5BUATB>2RL 8C\F[^F02+M
M6BRX>J2[=AK>P2/GMYN7VG1:'PN?VM0$/?4QVZ>7'L5#@1DY#BT\4<0RVRSD
M(1?J'N-<YB/]Q&(^P?/F@<)S<O,AS0<[M2_TI:$2:<I(QXB!7"/*@R0>RE&N
MJ<6+7P.A*D?^YHTE%,)^$R6C!)_/1]@9?#5\0S *S1M(A."#/,4?4Y;.)H,D
M2HO8&GAY>(YN6ZU_I=<D"K\8\ZDH'E42C.ODJLE ZN]L4$#',H:Y3H\A_%5<
MQC0452=(<DQ=PW0KZ*BDY?K/G.NJH ]C76164Y@;QG5X<E@& ].,9SD1@Q,K
M>C*9P(LB_F"&3;<$@RWVAAIMN_ZVRI9.U\.B-%_B%F\=)0EXP!B!K%=%I="%
M'BN0+ S5Z'0S&@ *@HI1TB1NN;V.C\T_:;X^O51SEL]:VZW1N?6C\\CH?)MJ
MY\\<(P>JC*$Y_11+-+RW&<6)P<9V)_#(0!<.PZ([F3D\L72VX/*G0A<+:9 %
M]K"0IRUP^[;-^C"!$E.\W<J.;SV243A?=)VSW\!]R$H@N\DV!V$D1(7-K:\G
M1=;N0751&3O# Q +RJI?@)H2YLK>C6?FVFG",BM! 'XAT4I3@^9R([?@LKEL
M>]A;BV@VUU#TX7@$>]30E "SY,^A(/)K\-QD;"O<RUC:A,Y+D3'B.=AF@@?C
MTJ^RW=5Y_?67+>3VU^P&@63^1F. V^D7,@9;?-L54["WUS[&<4!GN7[THV=H
MJSRL6X0%;B_*_=- OPJ6D*:T_BM\==J461ZX-,N[>X]-<V&0EIB.QLY/X-+\
M/*J%Q?3@A.@=]P24"XN<@LE>I6EXA/&'7:J6+POUZY&'!=53V^R IX)JHU7
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M*DT-[Z=JOF)R7=$\)EASSM.)<"C0MP50-,U=PNU_K>K;69'#[N'C95925E$
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MMR]1^$,I%=AN)87)?@%3:E(NB-IR,5^![KQLVF7R_L^W"0Y>@-O"O@D'<U
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M7&P)%EE#&Y07:?>?A,:E8?+US%3%N!R<L8.K+4#FL>+C_50U_XN^)+Z KV"
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M!M#F]1]EC-0%V1W(/!MU"RDLL=P$>S02EF]&A\ 30ZP)GQ0+Y6D)^$YG 93
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M0JETJP1==T$5BT2L*>4]G#$H$9[F.>XM HW)2:"5)A80Q6N;<:B(4E?H$('
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M^W@S'-[]?F(*B\%,X*Q48&Q32BDGJS9G5F1<53\F:&@0A+ N#UP9%8[:L3>
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M,$PN5##("&T#>: K$,G@ _/U8_#(KAJ$#SL0*YG2__OMJ=9U:G;#VO6VIK1
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MMXW';1+9J0,0;Q5L7IRY'HK#224N8W#\ NX!,9=]$;.>0V5@1#R<5\ RE%?
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M";REI"=0J[AS[G.. 7G+E:I&9P8M575_:&'EP$.G$A5&S+!U6, MCZ[',D)
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M#G78\9KC(;(J9\I-I .W$HQ#+IQ<B3-:'T>QD%%F)@Y>9L/^66D@:_4W'F5
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MR?7P,9'@>ZS;"%Q18,&20@IY\>NNN.2F47BV?\.I;[QUL0##*BNR)YK8;K%
M)1*,ME $O8DP=3\J6G9Y^&BX-CZ<M"9P+I;#]"Y[7V(0@<1GWK@0/$$QV*WC
M(/%]-IOC;[B?WZDZ7_,VBG-O>HT<A6PCPNK:0?+,"69JFI4XI9RG)LE2!F/Z
M -+1JN7F$PURAL^^T3TC&Z6(8:L(T=8:J--:NFEHC;7"UJ$T1RUNR2 ",%Q=
M_YHSQVK]^U(7CJW:DH:-(1>:G$5U__U>2S6MJIR5N9X1PAW$R@[FU#GM/%=#
M?H*YDV<@SL7>=VKO6R%6@R$'#H[]4"E^FN;IPR*J IS \-5!P$W37;:O1D>@
M.SPI#H\LE]3N?R-]<;CNOE1'E>J\M,^B+]5Y9J4ZTH;>:-NVVSAFHGV+777D
MT*T\]'T)<$8SVU1BI.LATQ&$R[B1M9-RT(2TJ"654I^'2Q']H9T%+RJK%;7T
MZ2&D=GTFDA]AR+&-YS^VTD4*I.-#A.F;'=C06E=7;("8\ /AWUOCS*7YG;S5
M6\CE-P=2\8%VXD)QKH77\SKE1KU1US&W+EA;C<#.D#ZBZ C'9+OM:9#*AUN6
MV/*AAFC7XG K@XF> I=L](13FG]-M!^?P@G-3/DS<OQ$EP>*/Y(IRJXE="4Y
M(P]W^G(L!B*Z;]3_.!R)5A.9]%T/(KT'92)$>B'4:N^O[8DCSVM.Z3F&FP.[
MB"G8]RCQYLX]=@6<0T&9[4+.@5=)T;XVXMRY1/QE6"%L'W..DP0#6XXZYARZ
MH_O%G ,/6!]T#D3/ L]@VLU6X$-E-+$,Z-2+H(5^V!U!XQ'O+EJ_'=3>[CA2
M.=)UZWA<YPZE^2,8CIX@XT$A:XCT1?2D'X'=_ /B<X$=/F: SHMJ=,K/^X0U
MPLX;HM30<#]!?[D>:>>^<T1C$K*;NLSES,.\7HV7#@K6WE1\[:J;IB,@$KB]
M74=$+F7SNP(N<]R&EU)\$Z ' I1DZ_S+OJAH0U$1'9\Z<3QP_ZPG1<;@X7SH
MVWKX3A.C1)CA/*1GWV6A$7$=,]J.'E,B['#J,QSQ4[5Z;=&Y2.= EEO0Q)'W
M%I3ZJG'5'3?ALB^/T27%Q !G8 'PH+RK!NZYHR:<477DX-GB?D&F_:&5)ZH8
MO@>M6&/>!(2?,.1I'HFH(PQ7VF(5HZA*"*DB_!N/+0C,8J8 -%@\:)^0M4%2
M)A>-?O/L6SE?S9-J-1\S'-*2CL+M/!"$R9"4QTB=1&C%MT79%/8$#3&J>"Y@
M79SJ@;7#CQ4NO2RO5, ';^$U-./NLC9 I03#"=.0FQ--6,9IV<##_OCP&7[V
MK<3[O[I++I:K_(X%Z5:/YY'+F8KMTOFUQEMLBP_ORJPU"=WH@!&0Q4F)[W4=
MC!QG;6\OM*G4G)0-ZT@1V<(/.+BP43(*17!::O.=F0D-&H9IC8Q'CGLUM19)
M$)E8-^.F<-3D<OL/RD1^%*(=IA(O!*ZS3\6K5/RK/A7_K%/Q4EI2Q;L44S8[
M;A!:;<VJR/31Q?0?SIFBM,IOR/?LE ZM5>ZGWRA+_52F@X?_PD*LX::%9G)[
M<>."=!?XV05:30R_.[8'-Q^/W@S[#KB-3LQ28$\+,:CAQDA;T 55LGY/2GD%
M7.;\9)WTUX%TIX[0?8H* FIR$5])80D3!HF6K7OZ.^TU 1H3FN5DL@K \-ZS
M\RZ@Q.N*PYV**FTV(V1?LU\J6-\:[NY\28%?/6=<#C_#)V[@5->@[_!!.MYK
M%<G"^?+X/.=P9; N^&"*'*_U<$QK%&Q#.6V-U/AV!IYIVS'9PHDC(!C;2_G6
M-N7C&H:630B/Q@H13>A;&X@> (9)%T?I.DG(YG:[+K[>7XW,"PB/"R<O8%0&
MN4U<&@NB67&3Z:#N+07UPRF+D)]MN2MK3-\<O7 Y(]!(>; 96H>,7L-:'EA%
M.T.1N"E=8%W:G"A:<E./>,'GWQ:S&AP2>79,00))KK5.TKF_D+N9RG*0=V4Q
MR^5QXP>P?+CON@%=0N<CI2#LOTL_;.$>/&J=WXX#$_' ;WU/$$O)$4EJQ3<<
M*8/Y$NH=D-D4'8>R'++DD 0=Z[[[__05LHV:H:"&LBG7;J,.A9\KW9>I/<C?
M8ZB<Q&\HG&(B+C@KT^);% D^(M4>OGBS,[(%V1(+T1X=C4[P'/CF,0+%TAZU
MV9A)(>7PJ)F<R\CD+;X18@>.L "IM"@03!CNLVF*FUJ41#;U739;WAU,$8I<
MA%M37:"E:)/?T*[&*B0KTYGSU6Q9+F8('5'@*%*F$%OVT[Q )#0!&VY+1E+M
MWJ?)@):OACZ=T[^0'Q%QE'3DD/2QBPG2UK-"@*NJ R"#<T9C$(22"L:IX6^2
M^-4HJ=3 +RU2:Y94H4#C":WY'BJG*R:]A9Y1M9'[PFOCF'CMQ9%F-CDVQVAK
M4Y7,YI@:Y<JX-4."5]8P@TWRM1O"V(8%[/$&XI6Y*0RZ'+)C$'-] &$SM(($
M-I?7*9-1QA';$Y8(EQQ,8E3E4]#H%8H+13IL<RRR.R(>50TW#4R27O&LYD O
MJ4LJ#TUZ1@$D^FI'I0^;@40_O/_PX5\'9Y_^O/SRZ<.'\[?)YR^?_OAR^G%/
MP$1?Q08F*B'ZJ>HM@G(3/5HQ4'BBR-<J.Q'FAQ>T BE""O^F:.XT8IH-B:>Z
M8>&%-K_+OUB]#<E_U"77A&GXM3,,!N9J^+RR/K*FI$I;TE$D4!;\LS92_"*2
MB@=G&,,$9ZW06XFCBM4Z>CYKZR-]\JJMR2EJD>3S>A37P?=I0ITF?-VG"?=K
MS/:KV)#UV/C[HFN>OKA#&=$PC%(8@HX\Y\*NT+PQ%44R9A-P_;R8=\D#3$).
MBC-#S@:,P3ECK&+=,4&ZAU3U"*H @(YD2"^]\TAM%]P/\^I9**%MRV&>?KU*
MNX1?X9"X]</,C20=;@4S@JV<[CLIFDI&D,4^5 RY>S\Z\JR#&WH3M&@YY V/
ML"FN5B#2:T1M6>+(FJN[M<_G](TQ>#NU)[ZD"4B(K\62O5BXHFR&Y? XI=;I
MST4;23P5DZBP_7:XX=4R<<>M@32,>T(SN>MYC2?#W^#2'W\,^/IGEZU$C2'-
M#41'_2A-8?T6[G-?G('(>O+=6>Y12\(-S754@(9I^Z80S0QFYPT-H&>R.K^1
MJ39=O"Y=!IXQ90I#V;MAHAS9DYME+5QN'.8"#[-=S8$\R_^1JS-/VQ39HC*[
M^+:0P )"Q*6J:R^GR";/T)1A86=.,OSE0@6/,61- GLV6R.VNNMXS?.X=UNC
M%*CXR!JK-%:J4F/-G!QW,3K3NO2 S:4'(#*=04?N)[]&X7ON2?/.J^B:=PPB
M^%+@;,.XS<A>>.Y*>+Z?ZH2V0H[9I5BD:H\-8'U<O#7C5,9/?J=2DB:?*BK.
MJZH5V/'CK.4N>0''L\4A&4>T6N0R5:J+;MSSVAO9O:OL0X?L]KV4?;!]N<3M
MHW($3\7H7CF4ES;*!51=NWPHHT^\ PVRNW_N3\#TH0C"QL $SB_'E#/<]1VX
M\S^*];G4+GAX>\/[K^/B_2\Z]/(Q ^)MXC;;]J-&$:@@GC3HH5%_8E"#N/N8
MJ>%<]?C*V@VOQ1=.&D4@5XAY05[J>UO>8F&VT9,30 M7T3BKQ$M.?Z$(IA%"
MOU.QX8DX1&&=&M.Q4V,TMIQB1;AC$GD"WVU<QSLY8QYCBVHXO:_=6L3I, .M
M?6I-I=9.^M3:L^[ 6S-<OJ:I N__?)N:4^09N1-C_!R.S^O)"KV)-JF* L4%
M\JG*1.C'*;OG?-74BX+@G<0@,E7W-J3N%"//L%J">:,,.</&C+/8X>/I:0QE
M#:+@5$HL+=K<NZ3CAD5SJ1M(NJ%GRFY(VACRG&2Y$LXW!?O!5":931A05!4D
M&WT:ACP^Y>M>WHV<BCQ5I8E]G4 \C0*(D'AN[J1UOZY3J)F%41KMU/48&;.Y
M,-NXVCA?>Q!JC!GA"M2WE8:_2)-EN10:SBZ>SN5+B9FZU5)(&4T9'%<4!%5Y
MM\[%!PL L:V?3KL8%\FUD3:MLGEA9LKLVRF^%9/5DM&)M32@/69?^6-) )F8
M7J@&2M2->;GBJCBES(<*QW2#IT;;X-,L!0S;GB#$H.$:334#&Z[R?M]7-_6,
M 3%V:Y6^D['@[JB"[DDE"OY:% NC04:16%D!^Q L-7G'2)QS[ 7&TEY?5@6$
M$\81V*+C%ETBS*YE20;ZY^ABI+"YC56Z?KQ&V60/'@0T?GB6S8HJSYKD/U?
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MN;*?M#7%[8VFBFR<F.3+4^X-^NSZLG_"I5X05;ZKFXD;QSU53+MK:%*B>L+
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MKTC>G75><.;HI7O?[;;RGO+;[GT;[Q;Y)>$KWN]P9;ZS^#>.(A?\#H>YFFD
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M"#)C! 5!$5J<CC"$-NM3&3AGO^_PK_*_&9LP7,RN"LXLJ!CYPV#_2+A:EPP
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MN>)GG2LV.I\, "9?:G-C=(<:"%9;:BY\&!\[#Y&L/-2=3$)K85?);8,^065
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M7;UEW^&W!ZW>,!BH+A!DJ6KJTZ*Z N(,C@:WEZO@^UCIJZE9VKDQY'6@ERP
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MD8>QZ[0EW)$%MAH.:Q4F[KD70/&Z!HPT<!J87+!A<(:-TTAQF1GB'>0:]\0
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M^Q)!C#UZ(#1/OX^,O^Q]NR_CW3"#:G JQKU.9%R:25O-'W!J4#B,X(PD" @
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M"6?O6:5T[DO6:?%S0:L4%9;F4ZL"^%GC.\(%*,W^?9"&7PON%$P%-2TS@K3
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M"5P8Q^F"-[:[2-W:3FX[6-9SP9YPP7/OHW[&7;'>O1V^@GO[=?3J:6+BGB2
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M."9F>'$4X@9/WCV8[N%A*.S*2;E <U389^??%D75%O2@CW1[R<5U1LYU&%:
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MW!71SL$NVE^521LB76IK[8HWHQ.U3!SBRI/^UE_LT8,+LS7B,H*'57A7XK?
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M?;B^1 "A)9VG25K1BW/[[]X=:CA@0!X62;8O."*\+ APS90- E=@G0T(P=C
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M?;Y-OWZ9].N@3-UO!+]YI*DK9_3?UM0KIO^V4P<'=KW&+1IFS0(N'HR@P1O
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MF=XOD^D=E 4VK'X@?(99%?ZCR'*DC:.^P_A?JG!9KVUVA+$ O.Q\W \!4/X
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M\? )G.UL/!;!&0<#!?)$P!QJ[^W<E67SP[_)X2'^5B0.SQDN]ZC#-#8(%_'
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MMQF(,Q._SJV_*&EV_HU'%^'Q7P1\MKKMDTZIK%3.A1Q[W*=J&>2)T=<$H0T
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MHA"YT8Y5<EE<99(2S7GN-L\Z\M@O#(NN0-R,JD\EA5=M*I66L5Z,&0;>JEH
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M4O3UNMXO!A95N@I/ZAGCFM=JD6!C)Y  @5A7),_+;JS$?5#K3WML#NHXP1@
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M9@Q!G6P>GN+<IF5M."QHEV^F#X"Z,D6_%_0_$9\%G)H:4]0MPHK4ITGQ6%[
MF4EFTHUXCGY,C8$83I?2(+?I,9L>^V&;'ONNTV,M[&3W7&HH47KL2C;'D;;C
MJ6$02X!0#0C9+1V)3VC>Y IZX 0,*;;//9(KN$=\-.5J/ZP/3-JW(%^-"VFM
MM^-X2+?C4S(-/S ;CB,T /O_)AMG@A#$_;DPU\V,8[Y'30U7)!$KN%3>L@1
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M?#:(';\8?I;-F6\\;%!F?4ER[EI W]4%/B]V8VZ!4J8WB=Z5K'%(]Y<^\UN
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M_K@-Q#X8B V5W/.]YZ3M:VGD)2)0PFE]@FPGR:(R_Z4__(2U +/D_K^RG(9
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M%QCM*YAL.-D_E,6B-,M-!W$^*%MSVSHI9K.F9/;.5FP@N(WD5\4*N?AD.OO
M[Y# CTFBS]6")T(?>HL.USFTT/W65MFD3OLZ*'[DUT+_D,(]B28B?S'Q&5:Q
MK469'L3R/@1EC7ANW.-G=I49L<CN\OP!V5.>R&4WPIT'N\,QUP76B-%7DN3@
MTQ@LGE2H"!EBT#+(WPD6\$[E^'O(:_!Y#?L/>0WW.J]!ML PBGM'  @Z V<M
MI$0#I>Z/]A&[HZQX1*[./'B4%13W#D1VBU"&%OFJ63YSWM0HW0-ZF$2GEQL.
MS7GVN+9*@W@W'D)9DDHB;7<;>C7@(3NSE34EAF]X#EPJ<6MF*'"#3R9-V0H)
M!&]R0_0!.E8D3]JK8XO4G-&D>+;4G&C2P*&[:15GT+HE@1T[QY.A\W:14U[G
M.7DC!08*>T $*N)TQ$ AAGX5AM>9::C\X,V]_(<=6+X=6K>XD^@@]^X.H.YV
MPMFE79B2XFUN<WER8=EAZC;V&RUX56@<T!8"_055G(H35/-YBHZF!:=9I&WF
M=_?"6-075F=0/;QLLERS>H7FF0&()8N#$SSP;A41.Y*OXD=A5[@T6"%EU&-%
MWL)@9] D^7S*V6L<U,3!9UN[&XCUO\<@+7 */29P&Q_,YR,%JJ5;&+H87* ?
MM%UH5X5%Q.CUJT/UL]>_72>Q9,AEQ)-F1G*MU0M>M/@AN2/XN>K37>/R"I9H
MBYU$)K6W+KLS3!]P6U<R<A@V.R^B95%:#FL@ S-&@Z,3D]D\,67T/Q#7..-T
MS[QD!.C0L1DT32A\JA:S"^F].G 2=*" ^EU;R'ZIKMN%XLP\8IZN:,U><.YF
M3E?&(8>;X6P)UJP/E-M%TT*HNR@:S+BB7(+@0"(?[]^?F76G6C@"(1$4)9/E
MP5<)8'QN2WD?IXK;Q/:^[#KD6,NKC@35L)G.UIK F5^M-P7%/#@YW2],LKK3
M: O1#Q5\"M^PHF,<AU3(<8+-"7* V_GM5AU&029P+=R: XO(=),*9T4E*M&7
M%2:VL6>79EDDC)-O58#EK@J.MB7VE58__G#X_%\B7?0=BG0!4MJ?4B$T)-W@
MY.V.@V]#/U009 -KO4"Z,L2<SSDLV,[2TU> _":AB#$;WEBMU2XT3318"D[O
MOCD0C0V:@+DLG&3L<WOD$Q@S(3XK_'9.A%'=18THEVZHMR;7XW@L*A_G>GPB
MRH)-ZWI$L6#23$+!QK/*I7F5PJXC)@$$*)W5W=0H*OSQ&>Z]ZA\65(X1U&45
M]CG0!XI@E'F.2W1X&;?2Z?E5.7N,M<@R9()8\\B::A\*,B![7HY,%S/]D3QY
MW!#Y08Y)^0[5*SD>""ZJ26=TU@VTULFZ$([273054[<&[Q#N#%*(6^XQ/3K#
M[[&LQYXK^9M[M2=X\&E^V[.S]_?&LK6/.8NKW&S.P49Y#-Z:/RQ(DU%E/KM]
M@.XKD!:IV*(^H5B36ITL)*A70SF4(O;4<EO+]](7?W.') OF6"@]?1[U#A%H
M)0I,&\"CUJUH%3:73*B5N68;XPHCT4D#9I)+1*(6%[VO0;,H6,8" &3Y9Z+P
MPAJ$>584(%O 'JDO_FP,_@#FNE3S7YF26#9)IMBR! NP6L+-*_A]F<Z0T@ND
MC/SS3T9P1FUX4VZ_-2'FC6Y%&;Y7!0'UBD*Z(+1>=3L(*65>E]=R#UY!LMLL
MN#.6K#%_(G$ M,DYQT=*SZ;VNI#4FIF/"^%#PN%*_&AL]M.BH;!4+"JB5KB%
MVP8_<H*LKW",&U0VS[R>>>I57213ZJ=/=W>*TU\_6[OJ42FEZ(]9$O&0LKLZ
M&MA:6KX]I]9HDE&/&;A?.+4VSD D:NG,K/R:N;"&V<?ZY%>FY)H$6.ZPE%..
MP>:884HY/:453&[.8V>7.M9W<94GER%@L35II*7G%@OD?3]1K=T&:/%OC%?-
M0<N4@<!#]EX$T4:'0C[C&*40AH+@%*=*%3\$)WUP\NE#</)>!R<G*^3%4#1]
MSRRZM(;#5X'A,K05_/-<F])ZR8 ,((]YN+^Z2!2:$@!'3Y?GE _#=HH9'<GY
M/$.S-XRZ44G4M$BN!PQ73<[6]SL:U=L>5$>A1=P5+TN(EO%+S2?D%9K0,$JF
M)$<=^=20/1640$)V(/6NQQ#N\T@4;\)&5T695!JAE7&1@"3.5>L'D('ZTQ V
M!6:SS 2AB#18A)J)]16<X%]S[C!)Q/YGM+0O<]QW<D\/*(,;KL\EYKK_LFL8
M';V*"PW3/V;J<T]8-<9[E%S #ZP3V_+9V9K/LK^V_0WQX0;U9CLP*Z35D"I>
MZ]MGI#U5-:HSNX%]KFM3Z"=BK6=$%S72DU^:3&K,Z*6^SK)%3B$DGJPL#1DD
MTK5DW5(0@D[M7' US8>N3MT,8-O@>^FE40)X9:3A#]#.'-JU1-U)KAA\!0X5
M:)E$L%-TA83WII#[AF"V4&7E+\ XT=Q3#^VZ'M)PAXUVB]!?IH GZ0!,/4%J
M+DXT:1_=^-_@",]W0V6!O$I:KAV6O\8M@D[RYN"4XN2&!J*TD6I"NM,@"Z6_
M$WC=A-L:OX5%\)WZ\< ][)-'7 5OZ18@.9%D&=/0A1XL7>[3@1*6.,HL^K!T
M+2-I2)J##E(AT1$6HZB-C!M11G"Q*Q,GHGAA:2B<$'<F$/\@3UWH4TVE26/X
M#UH^.&]@V$-'\F8Y19<:@F+I"VFM\<^T>.4AOC76I!=8VX0TB-]*=SOG#14>
MZ !EY@J>:M@BX]@7IS+CB/)IA^3:[)!W/@(XVGF%U\J5ZV2NL,/4[29C+OIC
MSCNL/6=LI::2*^4.4O'6M$P_*;W[@U.%5A>EJ:R7??ECZ#.L2MP3[6,A+'J*
M?;$(#!Q[CD-O3+MZ%OM43&L\'1.S!(6N&JX,#B,Z WON,[<XE-6%.PO2*C@>
M+0\A4997&.&(=G33N+"0YN<$N$C9KG-)=WQ*?F[0A\NAZ>^#KVI_-'4H9,$B
MUB':;C#('-_^;GVPIXYXZ;L=@H\4YF[*C:/^=)@ )0[/-:@LDRA=AT\E2G#Q
MJSB.5.BQQI-6*FTPK03D9YJ;C"MIJ41.[ZN+A14",Q<:*W)+,:RR$8_%+0UC
MI4[9O#R5EU&L4HX,BM^9D\G9H>A9ORJ=A"[-&0A+EUE6P<GE,+<(X(X$IO0N
M> ?"V%'DVC>K#T^Y1=)U-,R>)%U/.1]@T]NIAVZZ,HRK5ESEE">"]M,%ID97
M8<8(6:JH*25#Z@750]M%(8G1,1/AE4&B8%@RWO'];<^"&TWM#X=1FY*V]41S
M63:]]/I<L6P&PW*ZM+E1#Q NC!9D$2?U!$"A<^D92N<TD;RQ6)(E4/IBU.US
M7EQE-EG84!(S\([052;%K&&%GXJI.;_R6O-\?,[7VFPZ4V+$25J)-J]T8;V%
MNT6+?309X,<,!=+*HGYI<PN&9(HS=485]>/28ESR7XT&>,(&< <NT_L):Z;L
MI-79RA7/)=,2S$27)%.!<:V^Q]X3TV!<^.[=7EU*,8PM18S+06S>.Y30<P;V
MI["UIKE6H3IO&F]SAV&&3B"6!4AVO<S3VLIAHW*A=;T*,*8<+RQ\Q273/GVR
M3Z9ZZ) <>&3.'=O:#3D:\% Q)FGUSD82#%4WH7AVNL<#'SKHS LJ1ZU7E<AC
M5U>*F _;Y3*U5Z+EJ^;#07;!'*%SX(:0)T=E48>G""?REXN#JJ[H]14C=0O1
M,)60D-MIKH)AIFDMOL)5_*.X59?3=-%P:02&<&$S%!DZ#\W"H!7#A4REF=<.
M)ZTM?02^,W#ZA.'M=7ZDAPBLB\ >/$1@[W4$5M'<OV)+#X3XYB8MN28#I0X6
M!G8$D<1MT(T!-U]R_A*>9K)/7>91+*58F:#PLJ>"=^X5O%](/"BZZ9/T7 50
M8)!MLU8Z&B1;/@2;9<,B+CJCZK*-VV#O7%D$A5]*#8KTXOU52SDEQY9Z_27Z
M"RI6!JID[6*R<B-&L-&C1L>GWQ)^*"3\I0 U&OUA)]2=6A>&O#S;BD1M,W.U
M10MZ- B;XL2"-5')I/F*G$W[M-BN:%D*E25# XO/W$KI+:0XU/&&"G;9IX#[
MP%_C@R"EY $2Y0O,VQW*'B%K*K>N4E'R.?VX23E74&IWMY,F@(-.JVY+XQ#&
MSH566[C">%4\W>T&N^(F?I7W$+.3F9E@X!X'$==KJ_NJ!N>OY5VNXG1P$ 5N
M;Y:9,@U#^^'3M\^ C_K_#0CFSA3]15&R4>63:AY'DT5.37+QI AU7H'UV93@
MT$&Z 9+A^S-8#M<;+-C<-/GWHW3^U!X?S8[M4S/=.SP^.IX>VSU[F)B]9R_L
MP>'AP>_[>X\V8^4,T)^[MM](D'['?AT\NC_:1.\P9[K///J4UE1L_8FS53:Y
M^]K96^P(X1J;_AG:"JLZF/=3!^KU,QYI# B<EK<!+MQ5H!_L;6RFACDM[];L
MIX<;(TY\>2W.L\VMJYO@.BDWJ:(_8<5<IDETELX^2WYT_\]06FQB-)%QB<9S
M70.#/F!;S\$2N_F!DPN38F41KZJ+U,Y!<Z:X+.RA]\SB\Y?EX[-'=Q6XW^J
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M:JUN2-4E>3Q6:-)G;7=APK4 ^G60N(FFJN*:VC[*P@2TW**$=>OB^HMF)KV
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M?(7"CZX\6\!I1G3U.$M3D4;$_G+,N,B_E7F6+$=2A_7A@HH2R*8AML;)!%M
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M5C@S<?0KDQX >U+D7?&',T4/9H:QLNA,>XDY(Y&C[@YEZ,+Q>DF?&6"=$XK
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MM7.\'&3Q%/YS78Z3M_\/4$L#!!0    ( ">):E1D2TJN+2@  -'Q   >
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M9)8+P.4:UJ\*7%_D=R $ 0F@]:-5^9[N(#&$4!DT8CC+,(G@%K-T\]Z- PY
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M5&8TWDH\:B7"N!:1$X,.,P/X%.>HM/M;PSR)!,0#3Y'J2DE'SCQ_?G&.$0P
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M@?@H*N8Z,/6B6:[[=%DEG (U$?<PH_,"39P?Q*TY2<LEJ_M 3?.:T29C6U-
MD3]31&LYKI<"V<E!3JAOZ5)>/)9Y,VVMSUWP\ALTP=LEE$S^'E![B)IC:B:
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M>K1:+K*IR93=WJZNAH'@WSRR.TSD<FUAS:A657\X!<38_WFG#6BG"X5>/;S
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MR6#V-H8-K=DQA$U830HX@:"\"?X<'HBUFA)  C+49*!)/"_6$*';V+/K,8L
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MA]_+1,RU?J-$O.L=9WNKLXRF;</C'2ZXKO&J3OU=7D P651!$@Q56.3^RVP
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MPV@C!MVO\;A*7&Q4\5A6QB[#8UA*5(YWD@3+AD,(O0X0XIC6_48B0&N%'H!
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MR^N=R]Z\L5N\Y;P8A@Y81&-:W[KA&GX+L?(@6EZO"HA5% ?D\"/0,UB94&.
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MNB0!UP?9(H7^,>SQ.=8T;]G4NT!1$J? B(GW858+O%21LXV->W75WR@39_[
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MI_<RBY-,L%'H]_*VHS]=WNBB1L$!ATW-0E$U Y)[IK,\@Q?.Y#<A0\QP^F)
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MS%/.QL9UQGO!ND_R2*4%F&)L:N]3/F3(OI<K2F2,F&H=R_J;K8ICM9W);[1
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MYE=V1#"OF2OE(SY)&ZM#JI.'_D>L&?*%BA/@P]<S>,U >FWW5K-":UGB2B(
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M[X6[3\BU7IL=:+IPJ.;VCOK#IA,S@M?CQ$$VW:9$(BJL@6<W<@8Z*\=[[3=
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MC&S?'YEP"?]-LUGTZO\!4$L#!!0    ( ">):E3+&,_E6"4  +&^   6
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MV^P,QAB+3OMA@>FR!WIS/<^+@6]Z+^C5QY<Q6/+$'65L\M8?@K\\I: 5:4P
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MF=109+!4.":)00I9KHA(ELP['\P[+_SBMY(R@8AU$E/#J4B,LMS)&#B'6;P
M1O-=B',_XWF16?4I$.Z\\"[&6#(,"D\22IE/+4-2 7^E5A"1\B<\B/I9H,R?
M0I#FA7<II8(P21E6"3"5DHQ3Z0S3"38TOLR'G5_>_2G898DQ;^!=9!UQJ6$6
MS".*I0&@0&5B'4[35 F1+GEW+GAW7MA%)%S&L4(,;!.*7*Q@K8YCEW 24\89
MGG]V>:;ZYL$\F5M93_:\I&P#EY1#/^+G$+QB<1HS8A,DA:28)H)8Y%**A)&8
M<[P :_1<X<MYE*+GR;B&V-0JF<:8& H\J\! 0LI89(3&2B^68?1,>66)+&]@
M7(\),$FEXR:F22(DT5(RX&7OES+$+!EW]HP[+[R2)C)1# G$%:4&(<D8C[FE
M%FN7XG3IZ7XD7OD[*2]S!6OGA8&E$9C'5"K,#.5"*TXY11P+#M9U+!9+V2WA
MY=-)T[PPL+!.((.TS[7TX7%!*/'GO<> .!/-%\L^>N8\LX2;-VE@KK0RL97,
MIA0SIBC6B#"F4XUL*A<@^/GS,/"\\(Q*6&RT3(4/W'"12,2U4ZE$EE-_\,M"
M\<RSQU@)41HK@5(D$NI+@VEN+2:46R*)LNCGH-;W,-:\4 O$B&OC&!<,!T2L
MK4!$)X@D%IETL2(%SW[UM"GCV,7.*80HT<SOO.-:,BU,K*E8@),=?KY8G+**
M<6=X8D )8D4X<Q9YX8I]&6*9SO^>CWE$//,4BYN[7,6'VQ(CD;:*&ZO!MJ1I
MBH7D*%4DCK6+"?Q9*.9=.DQ^+N9-K376&,)28%Z,P7X@)$Z3U"7<X92BA6+>
M9\POSPCJ/1SS<DTHC5.>^DP(!2PKA 6\8'DJB)1*+9EW/IAW7OC%)"F%99IP
MFP"_6,TI\ ESTG#+.0#/A>*7Q<!TE_N=%VZKLT H=0;+1&-,-7$""6)AF4Q0
MRH@@BV64S![7/7=N,4P)&BL*H(DJD7H7+'', +X23B9F_KGED0BT1"XW<(M.
M-6'(66:!:7#,?!T%FOB2OI(XF["?EEOFA4")B!.7)"0VL:_]9SEC!'$I"!;<
M*;=81OV\0,NY0B_?#0@N,/=JRITOSX(H32C"4CG,A:8I<"ZS@BZAR\*[I)XW
M]S)I &A+I04U"5*)BYWFF@,B3U*VU+WSPC!+:'<#]TJN%-8FI8(+BDRL9,(8
METQA%U.#Z9)[YX1[YX5AF$*<^^P"8CB5,96I=L!"-.6($MK41ED4AIG3U)T'
M- SBA$F4\-1@26W,58R0!H. <PH6 ]<_![4>-W7GX:B%+*8N(4P";*!,(V5C
M$T %I21&> &\,C_3TJG3.$4TM8Y)31-!.?='9R(I  OBU"Y ZLZ\'*_R*%DZ
MG#FF4J>5UIB"$'&BB$JL<1PTH=4+L%#-(7D>4'IB[A+++2$"8 .V FF4Q#HA
M!.A$Z0*DC<_A.3:/(D@D45Q:;1*)-8V94LC(%,/ZI"1)J7UN@O3DE'I F5+8
M(SSM"'& S8E2U#D1)T"=A!BS .6.Y__LH,<I(&AC9*U*C%6&"B>DL(F56BOB
M$@.0\)F)V*P)]X Y&L@Q)YW12>I/4&>@)ZE%VF^@EE(F"["1Y5Z$>VME98^+
MW%1PY_C+=K=?%F>U+V5!!(X!/C<2)I1Q2A'G2O($$R)-@@087PL0<E@DNCUD
M07]_;!4"59FD5 DN)=!.::J8<TD2+T!9Z3O1+1P$MUY5=E#M%H-#.X"[M37;
MO7U;GF7:+HB4 6P4@!-A$6. 1RQ6*09M23%!BBK"[#.1LIE2ZR&3" CBAB.A
ML#]/',N$<QO#,H85@Z7-S;]L^;VP5UWN@3@'MNR^+61O?4$$1X,E+!FL2019
M,+FH)+&SU*F$&<H$6H"HS(Q)\7!2H:C0%"MC4TNH859Q%AO,4F4 /%A#&E)@
M+):DN(T4(!CB(4";U=R!8""NF,\448X1QE&J1<RX1>H9D.*/^27%^/S:WM#W
MY=KAM4T;\+%MX,X'UW*%P&B22<PPR%HL.9&Q)K&Q?J<$D[(^?] 3MK/P%'X$
M8;MR:N 4C;]S:N#DK3]P:J"*91PSP6T"@"^Q7+!$IHC"?PW3)DD6@("!2.]*
MVY<C_\2[,/@)^EV]M-?['JY;\LRWCR5&7!+X'R5Q0HD@@@F#D'%.:XXE0TN>
MN>F553EX^4'VCAK3PW_=D1=9=]A=<N./<*/#3$LNG7$)IU3 &I3$2 !_*IE@
MPIZC!CLX+Y8\\R,\0R3U%K/B %JHXRE7A/+4:$5C2QE72YZYJP;+>DL-]L/K
M*2!FKH25,8ZI2Q-E8B<2%FMN!<."+;EQN9X^H45@I ^N)&"Q(XHY Q:42!.G
M1<H8<>(Y<N-Q:9<VP0]Q#38IBR7E"5:4,L8YU9(Q[:1%RBF^"(Z F7#-<DU]
M''YDDFF>"$7B5%!*$QY3I+G4*26,&(0#/V(,G-AYJMC(?><M!"40OLN\78E?
M_ @R1LAB&\<BY9;Z4P13";\XE9I42"?C1HX123OMAWF3XW&NRE!5F<ED.=J7
MN=US^X-"GTY'U[??[3V4F.T/8,9#$DPNJ^K&M_F#!HI>N/#X(H<Z)+VCR$W>
M^@.L(P25VI]N)32A& ,+I<JGAB*XD":,-T[^)<?,"<=,AQ<FF>!'#B6EQCDG
M)3$,4XV9T")6W"2<Q8EB:A%PP#VX8>_,ENMY7@Q\TWO] 3S_7+AC]DMX0HE&
MG%N7FL2[FH514F$E#:;4(LSG/VCX<W/0HT2234H2J[&5J4JI/X>.$QNGAFJ:
MF)@LPA%)/B%I5W8G,Y .SHN#XV)8R9XY.(?61CY9:3#:[FG_NC/K'UF0_)<D
MT8(YK F3,25(J9B1A CMJ,/&+L*AU#?09]VGX0<I6422*.PPMV&KN*0FE5(J
ML( 8(B*-"4KK)1D#,'LZ4VCA9>>*H8;PDQMJB:*$^YIQ4ALP;1U/&,-$4ID0
M)%U24Y6T5 T??BZJWFN5#B4'!IMG\.>&30_3-SPR-Y&[<].56W_$=N-:QUAQ
M*4%+ "M)9A H"&R813(E>FR[+383=?MY,;(VJ/)WPU(?R^KQ-7EM7#V$)J=8
MQ2(&TC!FJ8B%C 4%+8 ,<L18;%OG3"WS2W+]B/?D;A)XA;8_(($2"ZN)D\IB
M25D<*T<(XT;1E%%#S0(<_C%G)'T<>!N.T@$@JXF@SBA%N=*&ZU@1H6)DG]NJ
M^S?)M5Q[[\-31C %*MR8U%++L3*)29&A+M58RZ9:]%RSTNRI."'L5PCS(\LM
MXT0 ,E+4@9PG1DH2:V-X2D$U)ZGQPHY9(^R8S;-N7C^7I;E.EP^V&I29'ECS
M!%Y$S.XL77#K0]E)3"B&=8(0M2FEVHHT 1FCB44QPR8-J5XX0;0F(GR(T9*(
MWR!BTD'TCD0,M\;H 8BHD31,(:&TY/[P.NZ<EM;&)DF)X0E9(!<&F+!%UXY]
MLV\++;W3]QI)K2^\M Y3=KF]?O.B#ZT]PJ;$V7LS,%$<V21E*HZI$TIQ:L&R
M(1YB.R6:E/*6P'.]?V[N"8SN3F#T8 1VC"B5,,921$'74FF(36(98X/ \FGV
M##PC"7YC>[:4.=!WW72S7@8J6GK'U3.686Y2[Y @4FCX*V(IN>6.)HFV)L&8
M/S<9GBV)9R+%8)0XA86+=0H@.)$2D!4%!>TT@"LAZ RRJNY+8I]A][H8PJ#*
M/DS9Z(H)O)EG;[,\'SVZ@#Y-;M=XZR>\X,@.KFW]#&.NK[4MW'GOIW+6I2I)
MI4PT97$J@C*7L4)8P])MY]=C-3,>>"B?U)BL_;(X*F7W9KHV%^]-6.+/\P;]
MG&*1@NGKA""I9-I2G0#>CM.?1LKOO%[<#.?6R])G]H84#)C?4NK!0?'.EJXH
MNUM%N3<XMF5UK1Q)V]9D0SWSP1X-<SDHRA_N\]_>-[$H.F_:<G1QBK7F4EA"
MP;Q7CDOX23MA1,(L6O+R8_*R3WNJ_I"5-3L9?!H4W]U&NY!,AI@_K,>7$?:Y
MYHQ+C%@2>YWIBWAKU:Z$\^?!G9N5\$$<ML0HK1-#M>&*,B,YL\Z?[H$0T6EB
MTP4P,N<%GL[ ?HQ3Q) ETJ6QIL8I?UA[K,&T,%9@9.P"4&^)!^:=R218JREW
M*6=249%HR9)$^/\[X#NJZ (QV9V<%&$%7K+(O2 C9ZE"-,6I-%09L&B!7P2.
MA4**NG2.*\-^9_'8L>4CYWD_7*)%.%C;<<>II#16BB/J$;QE1%B&Y!S759XY
M$1ZN@AY)'$DI9A@@+97<2(.)YC96J144ITVE?Y3,7\C4$V&L&?>U[4D8]!7-
MV/YJ3H95V'[QR**!DHE@Z(]4TDT482RUQ%?2%59+:F0BI< TD7[G]0(L8;.1
MD=DO+989(VF<"J4=35,ATUARFQB9\L0P,\=+RS3H.) 7Z\/!<5%"UZ:E:@.N
M5H-,!^I^%YS.RVJCL"9$@TQIS*F3J:1<(:.X$59HI1?@^(7OT24H0U]"'%!B
M_N]AF54FTW?8;38O%(+IDDX17]>+4IM@:70,>-UY>"!CMDB;6&8N0K/7@QPL
M+I)@AX2(*4.,.TV,9;$SUOAST[R\83#ZYX^(P12R,M^L&H%:UWK8]::X!5._
M7UJ=!2MLPU:ZS,)^SCW7UB*?6.+VG,MT$$BIBC(8\OM]J>UV[[7LJC(S1W9'
M5I74Q\/*#AZWRC\6/HO]AV-1U5_N>H!Q."A?^@OW#D+9-$UY"GR"G:$6:^E,
M; &+,DQM3)-X.IL@G4>!_P8(#9>:7[8*X!I9?0]^_D2L^7<3'=*'4U \CE,%
M=B9%&BP=SXFIQ#%BL4[2.-5+!75/+KA;OY_(Q_10JF\:H1"MF:,F\4=XQ2GA
M!@.F=V"06<0(%PN 4.:4=Q82XC#C"$FLM(;'5%&_QR-)98H=ABL,XP7(AGNF
M[#"3S#G&4XP(0RDBG"*!E> T%C%26*$T%G-\1,OSX8)',4RM2!@7<6*,,I2*
M1*D8<V5CRSE1N*UZ-8^[MYXE8:\(]X]4LC)6<$LHXUA0@X2TDBL9:^R48<*(
MAK )F;OR0X_A_/YIN2GID <Y 0=K0ZSCB A%PQ&A1B(2QS1%R%C>'$8TC[O/
M'I:P,Z4E?9@ C$)6:XL1CUU".;;2<,,PEX1QR2QIMNHC0OASI>6Z,9F_*/-9
M4Q64/>D0_@!4C6UL9*J4%091ABA/8^*TA?^A6'$:PFHX!; 6-HJ&#_-&WD=)
MX83YA#O,6R!SK[+K1Z6U#[9>S""G!*<=E$Y OV]M8+URZX^D':78:E]-5RM%
M 31PDCI#-3<Q9Y0D:;V5O*G<XC_,,W,%=?'.QVT/@*- T+TJ ,Z9O'))U770
M$'GF+VR&@3P$XWPC=KR5RZ/J..N_@YLM$*AW].B[VN]:+::^]6',R9@3*8ER
MB#OJ;0V5I$H((UULC!!Z ;P+3\1/"^DM2)FQ/F'9X)A0Y&(N,!/<&*,!<J1<
MS:^W8'ZI^CAA::VQ1'YSB7:4Q0D73E!M4A!+C(55\YNFMA"$>KA4-J33F!*6
M"I)(R@45BB2Q29"V5E 0L.4"?*\%^" ;^(+&VSV3G65F*//+UVUD8$: V?X<
ME]U$F#B-D;)@]E%LE<3" ?^D+#8$,9$N4/FOV==LFGWE+4>LD3J.0=H53:P#
M>A*F&#:)BBDLM0L0LELJA9E'^A+CM_VE5/E_D2)<>2A@$/"1(J2IQ+O$XHO#
M13.!_"2--4MB6%RHHBZ1L,9HSG0*8-)I?V#1SP[Y?X1Y:D^6SNI!ZJUBV#/V
M$=CHQVV,%]G%R])6Q;#4MJJ_'EMI0G]@3*]^@S^-"X#$#(Q"S"Q/*7"*2J3@
M@J4H=326B'SQC'+Y3#48Y< 2W:S7.;;9T?'@)25K*>L/?CW/S.#X)4#?_UH)
MM[[ZK>K+7ON +O*B?/D/8!GDW*\.^MEQLIOEHY?_<P!S7T6[]CSZ4'1E[W]6
M*R!ZIX*1-3=6V5<+#<,[PM?S^KTI0K_F6<^V_< $_=>O?O0=8[4/^0 U7P8"
M^;N@3W)N^A(=E];]OO*/[T]^NO+J0*K<1H6+O+<5N*;Z[84$BOC);0ESG3RR
M/ (*#8K^2R -C'T0&FFNJJ*$GG1@&G+9K^S+]L.O)JOZN1P!EX7!A(=^;=I2
MQ6!0='USOY[9<I!IF7=DGAWU7H9QUI<;)A!BC;/8\\$ &&Y@VA<W++(66.3%
MP%R_)OB:0+=?1FMX?.U%:+ML;VAF/JZ':R(8E)^BWU?BE2OC;D8"=T:F&/IY
M":P ).Q+8[+>T4L4X=#,Y7M>A+FX8:;#X.MY\#7E;;ER*]_#"_X.KR5WX+65
M5Q]WMP\V-Z+]@_6#S?UI[IC#WNYOOO[X8?M@>W,_6M_=B#;_]_6_UG??;$:O
M]W9VMO?WM_=V9SB$NPCWRJM/LCH&7AD4O=5H8^WU6@26&Q5SW^TOM_UG[GEF
M:^_#3O0;+&2]HK<[[$(C.FK6NP]>FV;<4"JM-18[4*:"*)<2K--$"&LM3V[,
MG(QZTB,<8[.7&X4>=AL3=J6I4Q;_.5(;Q=E;\N'L,-X9FI/-L\]OQ,G>R<?1
MSM>/>._@Z&+WTT>Z^_4]W?VTF^UV-]G>QBG>_;H>?SYY__7P8'WT-M[-#[\6
M>.=D!^\>G-*=@S_SO0V-]C;^/#D\^7P,;;#= WV^2P[1#MD\W\GYQ5OR>73X
M22=[&Q_RW8T_3W<W3N//_ET;?W3W/FV.=@_RX[U/AU]W-C[2SR?P[\G',_/F
M3VK^]>_\,\G/U$E!=]]\1+N?WJ.] P/OVT0[;P[9X<$VAN?9YY.=\]V#X^[N
MR<YH]T]^L7ORGNV<',:[&^_QSM>CT9=4^S+%VG426)$ZE"2D(P6U'6_@8LM$
MPA.S\@JCSG\"M+BDR*LY$@#Z@P+PP/WC=^+R7W9D>1KM]>P_;YW)62_N?(W'
MZ.\L[F0-+-L[K>WW@@P4($-R'\AP&SYHEW_2O_  X-<)ELVMNSXU1?_N//P)
M&O:-5W^;>VM8]/CZ;[W7 X/G@^T7Y6 E\E%].8#6+P8O779A36=0#A=3/VYE
MZLW'9)>\O]@AAV3WZ^;7O8W=T]TW[^G.FTUH[\/ISD%^LOLU/]G9>!]#_YMG
M_H1KK/?YH(@_;VQ^A?;BG8,=ND/>H\\;1^>'!_\^_OSF_<7>IYT8_G^^NZ&_
M@DX]?WNP/MC91Q=O#[8O=@[6\1=CD9:8D0YBC'>H0[HCI$PZDOE-B7!%([3R
MZN)6A=HP]Q/S[4.!C\"]Z[N[']??1A\VW^U].(C>??RP_W%]]R ZV(L $!X
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M#N[V ;XU"W7T>N_/[8T.%A'TT-@ND -@6R"_!Y/P+W078*.W6HJR:B HK*E
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MDKKUUOD8W?>Y82WZPVHY_/;$^7%G/3"5ZH#RQ!2$03;#GACG:AW2A7DY/\X
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MSCFLV37<U"LFC-\0+K"FCN, L6P9S(1*YG:U@8\>@ 5Y!9QE,F\>>TSB'_
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M9G]'S;Y-_9&6=[N!=Y=0]7%M5!L09V#*C<"408G,@<8(;E/OLC@/NW!;(RL
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M,]IT=MN@:A)L8))AP7GBKPGT<;W_[.I-;009%XB2MIMI]_IY-VQ[G\-WF7"
M^J=[P3F_V&IK9U\&8]W_<F8PGI/7WP@]7TN85K$Q)I!%0%M64#0>/CF(BNVJ
M!FX-D=A ('O83R![5Q398]%_3X="4'SWL 9+^9>1\?Z9?"$9[W]YO5F((Q#/
MDNH2DM":#.ESY=,##6]E3X,Y'OOZ]"#G,-KG''9C+'^1G,.OM3/6)4+/T[B6
M] !#?+8R>!QPR,M4NU#I%JYJ2'^A\*.UX",NO?G\*)N'A4ER.DWDXAKTS"R2
M6B?2^X.;<R[@%@;P0XA0T NA1G:?L[ME4[ON"9IF1MS:@'DXC## 2I<&NF?
M.99$9+N1M-% NAW]CIPS%#$L%U0'MW8+9.1P1?Q83G_[[=[Z/0,4R@2Q%V Y
M& $$^W9S.EJX< -XD/WEH\,%,6PG76;;]D1X6 CU)"-_8WI9N%77AH,:2^2@
M&WN0 'I5PL-/6TPO_-T%JYFGF([1E1)@09+-0PU"S#7!4[H[$LF4:[IHJ?#R
M6*12B\ET 94:BDOAZ%?IG)OM2::4OPS^WL8%FU;=[*<?MXTMNH+^!3I91#Y\
MZ$?L#JAV/]7^H?R**^XYW]2F:%('>:745TNZJ?VN='%/Y)#_<Y(:-=P+I?%U
MHXO%;4 ,,A,7-PU-8X5;\45GVV,ELE(7DM,!P,_RAE^;?I%H3,.UH9FR6IO5
M!^[;>H<U#7\:S#&:)_]BF$L@,K$$E<@1674^D45%U]0+QD&E\[1"IYM0#F51
ML!_)-)EQB-$UC&&^HVS9**Z>H?&L PO.-W$<\D+ CQH'G>2L-OB?E91D]C_F
MNJSR&9E,Z3 ZY=W0F\RL!8+URF"5Y&BF5IG+*LR0U4KU[M&,TR9?H&$-NDHR
M1UJ"1INRFD[.EADB>VL[X\3<7:QAC=M4D*]%E=H6C\L4:QJ;^Q3JU7[(M04T
MLG)BTB6>% D??9)K@)C;7PJSE^&IUR2A4LQ?<R6J,_YY#QE).JA9_MW&(0R)
MT N>HFD*GWP]6%LV'[(IE^.S\=%=6#YD LF;NRJ&G.]A63\#-$=S 1V"2>6$
M8YI@[^1?4VX&8*YPEP'8>-@XI<KJSO5?<B@O:!Q^M,PM53;3ID+"%:?9G/W;
M'N@-Y_E[QAYG,!ZX6ZV T4'&E[JA6?52)S3G><J535D]1Q!8PL&,NVPJ6[CK
M5DU $-YD11K*/J"V8VGS]:-;!AP;^H988IQ=(_WJ/4D9U504,1T2(7ZD7C*+
M9)KZ&ZL2)*(6+'M3RV&:5DUFJ>JJU)R ?S.24M+2[BJ0UQ:FVRP-KBX+YB (
MA*Q[MC2""CTCN3:_O2SO8OLH>ID4WM7IOYM,RJ']>U/L(RBVBB\$M),H4M(:
M-?_A'.TH&@<S!&@AT=QEW-9@LJ!J,EJ@0!R1AL2U6^+;MNU5ZK9Z@NP"S@W8
M]IHI#X'+$5:^4MC]6# R,)T+KDXO1*MH6+Q]:75M)+%,32<:T9DJ^]J&5ZI=
M'!1#'JU]+B0:*UAZ28^;Q+>7Y;9G-+AP;] = ?+)M@;NG[8[X1Y :]V1IK4P
M,M&IG3?V56@:'%=7W @EIA%-AW'TTXHD*_&[A]F/?J'[[%/O)Z^.>O_,6_ /
M3@7SV[M?,)B"V+I6<E.T+%LW?UO<DJ,7AG^O9L45G7O;(40;BJ?Y3."Z_O%"
MEVOH(=-YV[W!D5=6MANVM^KJZ70ZHOCK&8;^>1&6&7-UQ*J)6T0$MDM=@CO.
MPHR#BAQ;O/<(SJY<0W6:0L/-#*5"Q3BJN6E2S2YDX^LQOX4B7Y)MG6BN-6F_
MXFL_=GR]C>-&\2114(#I^;GA<(7HG*?78@JA$P^$CFV=F?DFZ_M**5FEQPNN
M",:TS9C<DTE@Y2MX %N#10W\N:9@\<OSY*J41!)91>) 0_GJ#= ZMHS<N4BJ
M&9XH<1[C3J]</\@;#)$::8Z.K="5?8@]JQHQ,:/7)RA",WJR8VP:\<PJ76?,
MT!A6YD[Q'AC\4.P4R8B)6+@:B_8&![>V]21%94<F:FQN.$-EK-DZ:3V,FF)\
M7[I<?4Q7@75C$P@B%:JD]9(T@"QU*/KVB:32V-HJ!-E'5-8:9 \MDJ'TB2&'
MG&"R<C1-V1/(I@),D6IVT[$+!<,M;WK9TXJH2K/YA+O-2X-+OAV<4Q7$8K)J
M-F!C?<50QZV3^0\7C'GCAPG>:9A@M\,ROTFEI&)ZENR?F\QM)^"AKJTC:?8,
M%:/HP5S$=96F1X[%-$VX H:$U+]FR%&!"9-)CR'LOX^>5E)GCCKV"[08T8XK
MVE;9X"J*NX5_9$:E5VC'9;I?:4VAWYW+3,8&=W XG,9F_F1_>CWVES]C"<ZR
MTJKXJ)5("LYXX:?D(K3#0%H/&=KG8AT4I195<SC6NTN8/PF*J\VB;:HENUMI
ME)'5KN8*,ZI$:CNQ6W"88QXW EPN9"3J,K;O9WH!4FT&%Z;R5#;5!GFRB 0[
MZ$K2!<:F<$(6;]RT+84O4>!4>IZBI=[*M;O3.^ :%SV=3..KJ*=^W@A.CR%X
MV&4>N7;XS(IS]JC$\[O3(P'24!!T<2Z8\L2H3)Y"2V:P=@NIU38@*3<*VI.L
MAJ*G94U,  PCON;(SU5F.-7YC8C!B]LI^X<[R4RB?>HKF\Z!AI9PRB. 5M=^
MOY<;0]%>5+ E]?:TH2ZRI*5C^./MCYZQ+M:IM< [AQTO9](<1'-2^=S;6)NU
M%HT^G>9)-J_W%7A!-GR\SX;OQEC^(MEPIUI%Y3(N3P\F&>3D1=-\9EZR!%HA
ME>P5<D&UY$/Y.>]>?>BSE4R+V-5Z0TIOH^#NB1 !96]2;R9M6.TI]AB_XD"O
M<WQ@(]9U8Y@G_+N"Q\"?I;/./2CNE8:-+YH$$T>:"YD]I,9AB;+K-Y5DL:>F
M.T'#?NWI["WZFX+F9YE:MGR@9WP-G)L=L(%T+KUC+A0&P5?F*M1 ^&WO]&%T
MW%T&?Q=N^+T9$+G#=(,P.P"L'P,C()<LJZ;-G T1&:ZTLV7#=TKWC(/!ZR2+
MI*IX9JV8W22U':_YMW1.-1C _4YHOSE2K-!1&Z7:4/3%Q0ET8@#V[I9[Z<QM
M++C-=4FK$QOGV,N+]5R/],_0(N<$<8P?F3BIG@)^8?IID4DT3)K8\DJ+F8H;
MF!.C"9?K5 C"9R7/E^5 40/V%5J5!K3\A#E,YYDUH=381?DAU]GHZZ6J->$R
M?G&&74M2.R]S9GJ3O,'3>#*:&MYU:^L#+/=JWBJE,2=!O0NIX8/[Q +"'!6N
M3?AEVJ/*XN#;^KG51";DD*<72%/*^\U+3<:->YE72DLG<1W$J1 QA8;28P)N
M-_OM=F \:)D>^\/%>TFRQUJPR'V1:Z-84Z0P,X;QZ%S-9!+2BL!D6W7?G;X6
MKW;>GNAW+>TLQJ ZA/4'_:80#(4_R&3VKT8"SB["->=XH!BA^MU4#HH)'VJ*
M=$8';54;5,:OP[-A]"ZQ9, ?V%OA0%;TEJ-)TIS\U[-W']["H^3"1C%8D5/G
M>T!"9O+&V*5-Y6!B\-FY_0)J@%%2"V\<X732<ZDTS@8]%E:YPOUFM(&$U(Q8
M)(&)+*_G6G. D,SAM)EE&DG0?#R1\^\T#1ZK"K1DP4HE,FF#B31DO>EC<XJ9
M5R59-A*M;*M2Z%[Q;1'0-2%!SA_;?FFBK_2Y[!FX6?%*Z*+J9'C1I+(480@Z
MLES%"2>;U;V%+%]Z46=//%MYBNS"A,&ORAP$EY?-'(J9_@V.@0E-Q\4!ZV9"
M3BD6QSZS",\VVC_WCN?&'[NBT'R)(E6W\/R#M4NG)@(?DY*NV4KBP=S//))S
M:YZ[+)?N2/)FMQ5"]^%D.='Q@K&3?IJFM$&C(WVJNV%\&6'R;=F:UMG7&'%2
M=) 2*.GU!=.[QTT--:ZXP.JTPH$ ;>N14F_ ,34\4&)JF1S*X), (N*5@^'U
M,]:BQQ;+Q\W[]&5VRSK#E?6:Z'8O<;J0LM<@&V[R@%?0J(,B^G?#,LDJ\MCN
MD@T?>MPY-M'L"EW\(UHS&@3&ABR;-QU%2!1ZSTLTH;#&D\6VB*Q!V:E%I(:Q
MK'/=NPZ>Y=[2)+!;G&C)(-@03]PP^(DD2/9Z,(&E;*T)94@ [-Q5D=-3?+"6
MI4+@,?:.#P"Y'IO?$[&R=LL>Z]W/G]C;7VXHRWY@](RI:#T'\(?M(,]DDCB.
M*?.3ND1C&!8E=\UI*A@%DBDWUCO'43!2N9"1P6DJE%#26]3XMKY7GY]E8"77
MJ<FN^KREF[;1)=7<Q6L+W?CKDL&Y@[,1&/40+QMT,F:I&*%B ]A+ B11M=X;
MLKB#R6I@UAD4&[')X+,AM"+#<J#_C!4TYIER<QZ\K3@/]2-=/9[1%H?.2F8D
M)M&BYYZTD;D;!\;&=S+8_Q,Q _D2G:FYEWC@+S,CJ^'A764:E[:14/LTIVZL
MI>-;662*S.C.1B>&,@A^^X:]#?Z502Y52;MX%_49R9Q'A_?27;CKYOXQ)/<4
M2,)1S#PK8V@1$EPV<K)/]DC!4-QLY-;\@/ '-UO&]".Z7,V/=']>E1(B!W2#
M89$"8'CWZD/<$SP9/[>_3S\-9*#=]PAII:B,W&+@NB>T+PS"JEH]0+G.-SBY
M_O%Y_>/)8/S\*4;)_WYZ\ (3"<'T7J+$L&&NBT!7]),\*_G"8W^8QB9\<X!$
M EVY"\G6M>UP^H505VFW$ZZ;3PIW,[[=28&E>ONSXK\(QV%M2-$[51M.1:3L
MD[GJ/]T+7XA%Q<^M!A1662EC"5*X&CS#J_CF#]]JPW7>+2XHTKYA65JQFAN>
M-$KCKQ$AXV",#PY?#,8'1[039*?K</EP^J4HK.K;1I"[QJ-UYI&!7*@5_SA/
M%>F;1WVJ+JLTO>6YZOG-5@<+OIL[6+TA+!RKT5V/%93_%SE6VT2D7/0$GIKF
M2.5 _@E.XL.95.\J<INFML8)P4@U%M:D@.RM?X.0@IF(C18$MXMI*KE_.#/^
MGZ.F *!/*JJ66>[BI&R3HIZHX )^N,:TF;VGA%'DB6Z=U&V$UI0_3[04$V<0
MD>XI(!LSB2_84&V0XK!Y-"&X9//%Q@[@-R+2**)J8I7PS"UBD/,-V441_8M>
M4W.>"*?(<C:'Q34FCV*>A4 5E@7G)K:U$7*,&,^9YW+PC*7750[[Y+R?G#_<
M)^=W8RQ_E>1\H$(KX5GS^3)-[5;HS$$CQNRG.TP]XWZ%BA9I]9;>Z[5/I5'#
MX0$I^&)YN2E)=:U037V,"^T,HS?G4A6#H:MNUM*FU1:CL+4;>6DJM,U=/C/X
M,M]OO>D.\H)@7@!*8WT>AL]5062:-EWS5$$IWG2M :;   H/J-#:-,.)^H=M
M\58FDF[R:&PVV24Z)7&@*>N;4G_K=GDKP_3V6WS3>M]YJ[=X^##Z#;W3 E+>
M37/FP6QQWN3FU+XPK6%L1-=<IVTTB2ER\$MXNY'D=6,0\]>ZR7Y4QWN@1<=V
M@D->(!N,&)#8EHP$M7,*ONEL%K^2K&VMZY0?K_^NF#>A!=;=_VN32>_(5>^$
M-\T4X78' =+^1W7#6>5,0G"H:HN]>#P=7),QZP/KNFXW(;8('_J%4B'<*$!D
M6S"\1&]K)1/E$""@NU,A0S5UJ,I+(8%@5_G6!7KNNE?2XCI?=U0,T+TI%$(P
MNU?,>U^$W8/3!:\V+[08:V\HS!^?L63Q[>&B^,BON,1!'&#-C:^=0,;K+7EI
MP$4CG !I%]Z-,9IA(>#<+M)HPXTS3E?,-;Y@(?L3!C_!N0*4*<25)Q=5ZE>X
MRT*:*GC#4N87+,](59J_L_[UJGUB_('1T--LJ</HO!"0:+T2.$%'OH:@R'I&
MPB35Y2I-[7XAXPD=]YM5Q0Y"&&3D@(63B:,K(Z=X6Z_@,BDOM]YYV[(R22R3
M[M.0AO\<?H9 NWC_3>;&OP?/;ZA^6+.%BK%OY?5ZQ>0;:*D^:?9H!_AOR$\@
M3V7:=BT=K8!)"SK@)S3B/*O!"6P8W%&BSF)X?4FJ\MK5L<HB>S,P9?/>>OE0
M&O;<. PDL3 U37A'I5;?RX,A>[>R*7*\1WX]C$[H7LF68N4J06(=+9./:=$^
M*KT[$/,]T2PO2^&74;BKC'.Y))%8RCE=K-J'V^<EL'4P$; 2:;"/1BRE/%(;
MT)D='T;'.1=N7,"VYW&3-D\7]=;G/(#I*K:W9W-=:2ZWD-*;:IWD*?#*E8J@
MBU0BI0;.:.K[;8L1X-J"6-UU3+O$J"^Q2/PY=M7?VI>\-M0 P8'! EN+.JL_
M!G;6!AE8Y& &XEI?1L^-#[Y[3[\VC=4 J!OC3W7T/GQ@;[G?$ \9???P<?Z-
MI8H_:Y;RV)Q/KUW&;H?ZWWB]/ 2I DX5#4$FM$G*:/,J: K"(O4]AY0!;^Y,
M7_5\J@U#PM]ZW_*:BIQ=)M4B^L]DOO@N.BDOZ7B]*JO%$$_"-^);-A+I95@C
M^R?-M4A?> >BB6F!TVDX8KM?]/*R22'VKEN8OW+\*43$;+,O4DS-G@8;9@8,
MQ]T X<EX+ N.\H@!CL+&C* 7@]L:;<>->\NU.N%]*EP+!> ,!3;/.]M/)VC0
MK4C.-"C70Q]2O1F\VEFOATSBM]KT]G>65;;Q'W@A-NQPS$U3)&"/GG)IGB&[
M3S^5582P7&:,BII^9$]9&/5D#+P<CJYP[1#6-*%3&=,7&7^LO2VF;V?OMC16
M #;N.9;*( C7%B=T\/N.'$5/$YGO\ <M/MN:+,$LE$3(@'YMK0K8S,2,OV%1
M=)5K@V?]%^Z^GH8_'E/W9W#:/\(3C#4V6&;Y.B.YC=:.'7,:'\6)(&V$I$+U
MN<B./?7BG6K!JN]321WG1\.I,4_XD72B8RT=)B7.C16TF;*$AO"/S:(3;J/?
MN44V_<^@GPVUZ:T[4LDRZ<UH K'[OE0RED5:=:'=_7(E>>Q"^">-ANU;1[K9
MV"ZJRE622R$?:4B.8+A2@;603_JX()6%T>*^Z!#T;1Y<S*E/>?,JJ@1QG$B!
MO/WA/)L-M$?:C$8O4-B<#V=:!#AA*:?0^+N'X!;J-^D1[BI;]+A?.ZU@+KY=
M/UH?;KSSL-V*F8"<A8AX)7_!,VPID-F%DA3FA8:@W1W;N>W89]/2&KW3-@_I
M7 (0CA\&Z%FAKY1 PFV?J"DP#=S*Y5&ZY]F)-<6TJ4")QA2Q#&%'7$ :):-J
MSO_V)"D^LB:>K@2H69<YO6"Z0LQ\GX'W,_!'^PS\;HSE+Y*!%W5@542]C?'O
M(DV6;@>G7XFI1//7/H&B7 O&O+3.4(\J%#7KBH6E& [/TH J7=>+E%U%: ]C
MZMI*(/L@4=52GJ I[O5#T[L<+] (64)79+/8 =#HQF#2F3!=(ZSA;==NQY'>
M%M$)&4K<3B0:'0 S.NJ+)]5V<J%UCTC0S^6G,GIK>>27T<^TAW2E1&M\H/ 1
MB?-^)(\J@5S(@4GXY*D4Q:S#^HO!9PW?7I)^C]3>4#IVW7ER;[3B\^7[4^.R
M2HK?1U_2<;&I?-?!6>,.B>E1Q=A9[T>NH[UCCY6EDLEZ/*9]GKQ/1IVN=^NM
M74A+#\]$*KPJOW6G<0U-4*;V,B"HKB@O+LNJ\'S^9<!,@21@QI:F,5.VC3C4
MK=)#6S6M='\[;ILZ@5XKP[*A[$NO\PD/#PZBL#\Q[XU!3?S]N?TTXNIG-"$T
MC*B\W+HYMME%G]/#3 X"WK1 [_-,EWS*I6L^983=D:$.OB,"\K G!]\\.3 ;
MCL>2EB[*.0<!SDLO']0^5'24!NY@J?!K3:XQ:OT39<)GKPWY&4[2B3T^[_3X
MQ#V"RA6K"Y>8#P0UX1N+C<KDPL(V.O,P%<E+QRA)UY 20QM)GM$X!^?:@FQ9
M?I)FD5JI:0=>.S9P-U2_4MG;L9L/D.<G,Y)]84JA+RXX[:/5X$%[XK^/AH?1
M1&6)/%(SA%F9UEJ/S:_@;!UG\=8MVYKMYJA!1Z6UDK6^=DLDBO!*NR^T_7+V
M;XW[K0YW@9,A!9?DG/N5BNM\]NBKT=<W.-VTOX-9V4P"AQMB=LVA7WFQJ0N0
MD=R#=.,+7XUO&NRZZ$!K!DRX(FO6+,&":_=LX]#[CI3BS+WJ;'Z/&:*4&7 <
M4$.WG!O6V^3_9^]=F]LXLFS1OX+HZ'.O'5%DZ^%GZ]Z)H"G)K6[+UDCJX[@?
M"T"!J!90A:DJD$+_^I-[[4?NK =%>886=(T/,RV38"$K'SOW8^VU]#-4O@WC
MNZDBKNP8^NAN==Y>^B;^XW;9?C5DFQB\0X^"(/Q+M%70!:*,^KV630(GJ3J(
MXM($@22&B7Z/!*ZOK^NE[7V1:8HBA!57-8.]1J0S'#-IPJXD'^A9PN1+/]S4
MWQ?6"''*D;L7%Y&V&/PKG@N1^*T3/O*(XW73PB#B0Q66B!Q=Z1XI)%$IK>$D
M+-/1>H*6F=-&PM< <>FV8]YH9OX(5Y("%Z"105</'&N]1?R> EU+6/9]2W
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M1:IPDRE[#SW%E:Q9=7DJA1$^R >7JWF_*:EZ/GM#?T!9]#,TXXT<:WS:VFB
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M;P__(]PZ*GZJ??_.A""19<U-2GTJQTD]6M[7=Z&G/';?[NVZ<-WQ+;#I<5F
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M#0550ABA)3>QHDGY>F'S"+<@:I@.A-0=[8.KK$C1GG) B0[6_2=E9\N:$06
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M^HOTPW^GYB<%<!*CZ>R9:V"Y2#C'^4/A'F]IIE3\:?:&KY!+THF#ZRK)#FE
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MB+8IHF%>[@-U8C<2IW^HH^UGPJ"L"ZHX9$-?O/5T^!2#4B!16)&;Z.>-1PC
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M/GH0&]OC+:+GG/]+M%-(/R!_5U0];B72%V18/F: E^QB2\%>V+=O\_=ADL&
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M">2:&5%>87+C[2Z8?6*]BGVTLM6BX0Y;XA7IP,P>#M"A-)#G?WMZ]NB[;_!
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MK^0FY'M5,9)2"/]-^?R1)'XVGL+/M*N"X8GGP7?O7\_^5IY@^E+ A<_-@CV
M+)L;#G_;>A^6A883!KUPB14F;_;NK. B^7/TFLE%:TT?4UW:KD48Z@>"!DD]
M6S_/E)^LVTXH00DJ>X9BQI9@^I\>5_FQ?N88)QOY<^QVTGRVY*<3SD.IF&.6
M=[[O<'>Z;$>B8W.BP+PW<H+HB::2VB-J!B>*B-]A%8)9D[XE6H47/S]5#C%N
M%N ?]\D?3@MS7]Q"*6+.-YFT^8JXY9$RVYCT5A3!Z<'KA-%?/QXENA1F=EK$
M^^,GHG(L6@2IQ4)D@&,L)D1$"G(<O\VT7<]0-8[*_[1T][5T6Y;6F<"F"BVB
M0Z0V7)Y(CFT"'$THPK)9"$_7:88GS7;= =5Z6OS[6GSTWNXZ\<PES8]>O[ 8
MHX1*$'!A;"$=<E>\RO?=NN8FY=."W2]IZABX7&6V*-)Q_*BFT65]:;9@Q?L0
M'+0$K+Z%(.NTE+^+X_-A1:N$>!%0YGQ?+=8]]2/NITM7LWVB8@?HFE;M0#11
M(]F9;Z3M$SWU YD-9$2)_HP]LRKV+.H79!-?0-CI\""Z4[@L#WX?UMG;4E^F
M1.;NIMGEAQ"YGG;=[V] _"J@R$LE'^;J+_YKSTT5KM_CM$3W9AB0!BRO"R$C
M9(,0CZ)XUG3/GB@)[S5E(&P("[L?4[)C8Q^0S.>1IQ2-]PLU-$]Y:?)>:?<_
MY\@EF<BM=L(W$,9240NP<4T(_%3@1M.0 J[PA6?=HCWIRN"W8R_X^WH(@E3W
M>/8RO$N-=N72O[Z0SB3^:Y2Q',<"):(T#C;_Z4$\'P]^&7D])$V0#0MK%/Z7
M.R@X(%1235K4B?[(,8(.!AI@SY0BD,T-YEPY\.BHQ@;"GL+SIQ<V2 )UE9WT
M?PJGS9'#1%Y0F\62Y:ILYO+>W"D2XY\54O)O.MG</!T)A0?1BM&4I#Y8>"]:
M*(JNBYS*4E-+T6.::5GA[X"_OBDX(]II32!\#Y]LZO0JP^3D37_@KKO,_;UU
M*( DJF$V'26MP< )>_=KBA7TKZGZKHDZT+!+UV#QHC!,8YV:EUO9?S-KQ>MI
M3'(J\?91N"/$E??K8R#KN'57/F>1NZ@/&TUUFL*)QIH75/X;/DB8V;."&%H0
MMW#=PMO9F\%.0_4.A[T>,R#20'BUKS*FR)*Z%CTB;\JV4)+FENM<#5(4S"C7
M>U8?1*P61BT*Q ;;R!9&V<HK#HRI70F.K94 @+_OC140V3K,(B.":3+\&U_M
M\R9<=H4,6;_67D>Q\)T56=F^]AHAW^+BI5IEN8S<,71@Z.#ATJ32;7]PLJIR
M&K4'SBRX88;5R$/!E1X4?L"<.(3;$A)E=QU,FG%YB/1U#W-!_Y:A&]4)CS-:
M<8QW!Y@@[#O22ZY''Q#Y_GV3DHGHQ\;OG[S'D!1I4#^[6]M@YKXL+_&!-A6Q
MCUILEI[&+.+P.9*?11Z'L<FT^DKD=UG61W[=4K5\7M8F<<!YA1WY@_D")0C<
MMLM]BVO).O HC%IN#D*]PRVW426!HU]NS10TV+\+M'>C1-$6?OK#Q;:F(W-#
MMFP#=]H$*5MPJI$G#!7M3;&4T%IAG"F:Y#UJ)<RO"\FBO9@L^SK"C]"0"9;)
M'D.PW85OL73[ H<*?=LD^%V Q4)"%H\0V.;_(O!%,F?A X0D"4^DU$SZ*VYU
M3R:=<<"X]_-%OBRHR[JL@M'I]K'-^(JNB8I)R*_"W5/J/2Q$BHQ@8:5; ]SH
M4Q0+HIY"9!QS,]CCG![ :X5_Z*7S#72^*-#!?93V'FN_5XS_(HY%Z<]YR6 '
MQSNE!E38(UX%B5]1$W8<=J5,G#T[&/EFN8EO&,<D#*LQLXB>-6'.,!;XN',<
MKZ%9 K_OC%OV-D:^B#I>+L-TM-H3O%B'O4B=:7[ + [$_)8G>*2'1SX\P2./
M8RQ_#'XGW(:S73#Q(/[0^"<;6$CR*OB_Q1[L6S9\BV9?6OFB*32U_%_[<)I6
MU"?L;L(\E0N+LF PJ+XXT@L^PS$NE+$"Q04R)B64PG'=U0.?,=$[)\<=<DJ#
MZYX=3\0 S0&9B)H:]"DYE7,CN'%X"V/>+R,3H]8SIFZG (V* R4OR]%KZ\<5
MR *#/17  H^. 1%2D-A3-)M_N[6E[CN^'.VQP?*+<$7T_,)7>;;,-B%LU0;#
MW1[..PQX0J?AKHUEV9K'$J^=6T&P O9A*&N_V>;80^U7$VM^4U@O5"([DF9!
MG7))+R/*Q 3^[,4>4RT+X,\HKHL_L?X%;>*RUL]>Z&E.+/F]B,!O<N&"E=2.
MN'@?>;6#!3@3UFXRM$I>B6QP5UPQX\%-?K $F'VS:X?C/1MYY&S+BE=HL-^A
MP])2\.>/+[=$V;2?S]Z0JTM[5_D4/!OF;0A<78_\*B='U2J@LV6SOTJ<[!?+
M=;G*[Z72\?T=:RT/O_WJ$Y9:_O0?%#]=%AMJ%"2B)J4WR&9OR^"87=]/,]+G
M-#D75V7=4@]>&HC1>7E]6.:[[@\_0S^'^(;"+:6!DBSMQ8\S=+].41PV13R9
MRK7H,(8I86%*ZQL"=:8>&'@6Z!Z#%1"FL\0X"PFV. AL#V9;YJ(G,A&03P,Y
M$<N[_"$C+DRXA9/^RW\4D4A[%0+4?6.W#+?&C[+6#\O+Q;"XC&W7*DL6D^I0
M-31?$%T+XW(E/KTN*F'.2$$AX]Z1Y I53SF"DRQV'%>P;&@+R-NAAZ'_6GIE
M]C):4S7$"=^-<JPR1$K<.HKY07RM6ZB,K\RNG":5--!VK]UGXNR5,EVFKC>X
M%"4=SEQ3&\7G3"-;Y[>Y>MH,(:P0BZ('$?0'KKKAE7HCAY<? O.=%87RY?P@
M7A@@NX^>7+HTF##G?';IU5_&C89F"JMP4#?AY%(&OVP9()DO>&+&4JV:,9JD
MS5%YE(0 1,H?SIDQEG[-DD?9,Z7N!Q]#&,Z^HN0B3M*^HOSPHMS!J4I=ZV,7
M?J*% $/Y'V0U4MI+X79G.AF81UC]*X)T-N>S2[L,F'6%O?1XK44!O;UXYF4;
MYRE.T_GLAX*%".P+*R>2I1--@^C-=7R&!K&ME$$+I<Y@FB!RW(F'K24GG.J$
MDA^66N^6+=5F<\;S-!;<=L:L@]J7)Q**3#MB877RL31EO6]!Y'JW-?"4<R-=
M66.TT!P5<V>YUXX8$$ F#!&_53CBV*/=)%MTVY:AE2*&[FY=* N%'3<AW!4F
MW:S'^SV"#7 ]_ .WS,A_:/[]2:>.T#9C"T./C21?;BAZHVIG6+ =.TIG29/M
MI!D8+S7<KF&C(_&9$Q"GV4,]42N3=X:W7 AG)Z2_)N<;!V=;A*7EP[(J;NB(
M%/5NP\:C:_*2>5K1U6&  /%(QX:\8JO2'7:%M[;(1 6_# >;*DUD2CHN)1-I
M][IL"I<7= F_5=V,%W*&K.1Q93Z_ NXO(\5L3Y:R++;$0<V4^*[&6U -4!QL
M&-CH?JM/_F&>HIOQ^VO,KTW[[))GL>>=*OO$VE$6J65!N^$V=$6R9'01$*@!
MW'D+]()9BU[E.6)^HQKS)ZP_6]3 -BT8+LI2CY?E8M(J%P'<#Z&4HJ!QW"$J
M7ASOV#O>7(JF68R>;N3$P@;3[<6A(H[HGLN;0)IUI&C;)3UZP9$1],B"\M4@
M^*80-KP:83#TCDU0-3VFHH5 -MMN,F<.$L#!*\$-8F)8]83FAXGFI"DYFE\)
M_TI(D;!5PUL2;2=S:$XK;#/U07\P\J)$1MC#10URJE%6N_\0YIH?BF;@+B*_
M N;YAXOG4K5XSVR.$O)_*"$++*]B^QC,"R!/$KZ_Z,CU"FY,W;9E3Y$8C1[,
M(C8JYV5@) W+D2%AV@9L+YT]#<3O:!=9:GO,.')GFK8J,&%P<"Z%8'-#3J>K
MFPO4D56CY:ZL(TZLED0W=[)24$TPL?']E/WF \7) VMWW4,LDV$^=(3F[-J'
M(*1!0<G2T /<E\'+X-%3V5*;<#TAU=$[D;?M):N(D!/1MO6"]>HY<=7(F],7
MUU2)4O?^FEN/IF8DX\B T_S%LL_ZY/CO4BX8T8],I0OY;DR8<6MC[MZ+3'?8
MNKMZ1[NH9$4)1X[YL:./V:D^6Q5T%SC>*%A1-N/_!D$(J_)RU3$VV_/Y05QU
MICR7Y*+M>,-F>D=](B*;EQ-;0XQB*9RS1 W&"FK;4J\KDGQF CN%[N+P44J
MVY7#X6H<UC7\84[+A;?;(&^ X'95[]ERR&;S2X%AB%,%FMLFM>JID#26^P1U
M\5"71R>HRW&,Y0_"!#96$4BQX^@#X%!K0;CUAJ+O>?@Z40""/:PBD_? @1,>
MZ8&CK*FB&$Q%E .'PJ,QV40& 3%'W1:N(\U]U;'?^4E[UFUUN]Z5/WDG]D@W
MIU-$D#XB"S]*]<B4N>H8Q(:)C1"@W\$3&/Y*LYY5WC3US9U\@O_QN_\W7?TQ
MR3.: .!I<D74T?0!8@6)SHY]6_8L@;@U"?1I) HE3J\4<BX0Z=Y/':X6.4V.
M5@6<#VR=201/%2'IS+0TX-F\Q@9''^5(@\Q$!X5E/F/"0GM1T#7E[,ZMN8FC
M7\@1MD<!K?6Z3B*%$<A:8U^\YFIZ'6:W!;VCI-V<&OY]W>8C7YUGTIXUMDE3
M<)9@%38%K'%TJ_,N9UF-X Y67J'B.F_ ]MS+W7-+1SC7AU;;#C[8O?4QR0".
MQ>U+D]["O)5>&F+EY)]$&XSS"[WR>/C(A0@.QK_VP3(ORUA F9,I*K9P*BSC
M,:?=-@0KR- ._@O&'(Q2RGG\!/^5YS-=IM&_HXMEL6\$4C,B LW]O,8JQ*V5
M^N<&NN"+A44KAIGESR_9K_A/?_^CILO5KX.UC6CNEN4CX=SD)%)DFE_[CA";
MUC<+Y:PD:4$%K;1XH_V:0%MJ,QTG.R*'*DN 6&\['RY53TE+,!]1T3KR1+WJ
MCTWG=&]3;GA"G8/Z[M;I,N:O]MS0I M(>HZ#<X@B-LEC2>(\;)!U&"S6FCW0
M_/:\ZP>883G?&I..Y&PFR5?ZB6@L,Q_"F#;O#XPJNEU9F*[06_+MG&S=3-^=
ML<BAA=Y8V!@4,.I>)>0C:V(^^?R#A[I/DQQ,VK8X:CY $_48+S"M,8FDC=DF
MBZA#1;58=-V.<0-@ 25K[UKPV]AY[PUWO^O?+,HJ]O/:M:H0/+8V<>YN?P48
M!_X"W:%EDD77T4YL#57#&KXI=B7?C[J*NYJ 'S8>3QDM7_J1HW?&$%^G:\%X
M^$8ZWY/$7=+^<>3>U67_W<LVWCA96J(?:X3/<"0Z*NNC>Y15N-QEP1]OW665
MFRRM75L79MUH^AS!3/^(#:J&)CHBX_?;N>>J.5M85U>U+K0>J-&""=H$-/X*
M ]</B[L'5Q.DVHMUL=QO"M\\GI;U>E0*U3Y<EI3(=^)=$GHLI?.3K$D4? M#
MS\: Q=.PLQ[V==IZWQ4.ZWH43DS@]T4H%;TR JOM04'=6@G+,;-1/AX6![\S
MVYDH[")RY&-[HF*[KQ5C/",X-\(*H8WQ-K+,F*K1V+YU_8,.Q'9W#B6)]\K*
MV,@Z9FK4P,]W%Z4VQ44!'(%)AWDP"_1P9!&&C?+ACTK%L([5V^H4P<'-F"'X
M9#'Y^8%Y!!E+JE0K-^O@'=Z(ZXV*?+X0$8)@-4& D#@GE,Y>A5OE1/U\K[M[
M>'7%'=,0S$?O*H_&P"\R9M+9BF*>RV/T>G5UL4<R\$ WU^']6X,::L;9-_J>
MEO]3+']DH5 "5]T'8RU#%I;QGSG2UVB;EBQ+G=3$I-1.=@%D4ML\_O',U41.
M>^#^",#-M\"M8EPMH#@!'GM>0Y5<Z<Z4VJD0BT\+6E;7=+E<\8-NI;R#/RI(
M[@&K7,<Q]H@9..V W]$*:& H'8? \0Y;'[6!NT51E#Y05$NHGW.ZQ' TD>O
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M*Q/1\;T= :.-@?.D"N,R>WWQF:BR(&3Y<9:C4/*4A^V:#G/3I8L<%)!!.-A
MZ3-E$RKLV::MKA"D64* 6LKG ZFCM!W)\):)MJ\ZE'+TYLJ[K%6.F14XI#[I
M8T6.D%K=6<TR! [FV&CTU3)A/M(_IQZCOY85[N&KJK^!.71D92-IRG/S^$.5
M5D#?)]W'O@,&!YD#6H1M<RZ,/M@D(+<@^@B#LT"S F!R(IM?N,!/C=!Y<AZ.
M7@')4:6W27J,SZ/^4*,N2K)\YO;YEU)=JAY#Z-F"?0KLEA-LQ&QE[$S[8E-5
M)DI='SN)2G0V$\]>73^?%\'/KD2,H0M3*Y7(9;Z"FF7"GJ'/F$]E">?"+MB
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M\S[8ZT1"W:0'< M5UH4("Y$C63<'O@W&PKJ[:E2S:U-=T>&.7'0N]!2LN#W
MLD ?9TJ;M&:][&$/#=/;>^8$$B\UF'^-"1NJ6J"+C4?&"/+'=$:H!2D>+G'I
M"*1W7*C,(6."]]@UX #B%4%G5HZ'<ACT)F\7V?(]KHIG>L3/U)\<U^H0=;98
MI)51+K:6.-_B]AMJ%%'"]:-:'D[)T!)L%?L:RZ+2(LJR.D"Z#8T%%&'*I$M>
MS'%Z(-(1YE(GG4A#RKDM;;(M2*D(@]\5!-&?[8H=8Y7&GP"],DZ9"9[3B5OR
MR]G[')*-7KR#C0.M[ZG1^3Y8K=F[.J,-!YA?\-L^9LC$(;BJR88RX'?41O2,
MBO=X8SY88G>ZE9)CL&YQXW0_Z7^R';8T'4X9&>)->XWK,Q"_"5N)8IHR]:S=
M<D%Z4SJ1:%/R$4Z_CHN4WVQ4W8@>\(SS]3C?K\XXW]-XEM\'SE=B.NQ1#>M&
MS0B;C_EL[ ?^;"&]L*IV(F*9FIYXO6;L5-)T2M2_G [03=UN]$3S,"K596(.
M>7,9EL&,;HDNPKO/S;YI\VT4] UV)K_)I&(@KU_U9=_E53B"#?,7G@99K,??
M+K+F/77GX9]/OB5'G[JVKX(!WXD.?<.,H,&+A=%EX;8&Z% ?]+N#M(+D5%<B
M25C;9<@5O<((<I=J2:](Z2;$HB&D#NLZ"C-*<)R.&HXI0^H>/*L8KNQR6Q.^
M;+B/29LFLU6TVGT[(7E?QV!@3"R".FH/")EPWS^YQR6-J? C)NJ9'Q@ 7DW)
M(O/ LC!VU/?<"_8<3"5[:<^,#8EXY\/R>!PA'I+J33IU8J_X0%96TQP"+TZ:
M&U,-6=_H.)KLRF,\Y3:B"\?X-P@X.VU($JB^AJ@R)+<];+CW_M%"*6UE,55B
M??L(?#G#$BZ428X%/EBU?$_9T>5Q+N1)^>^_PH[LN2/;*]V@?575=+0#-0UD
M/-<"9@#:0B"D:%6/,D]0I/:+?W1$?,2+:%HI71)S31-6O?CLGU7RY5?/YG+4
M,!\]Q#HX_L<QKZ!?.L \\&MN>=8ROZJX[RU!/7D>PZRNB0)@*P <)EQM<NO5
M"SMO1;4 ZU04E:F#<SMQP%:SIJ*!BOD[J.WBD4UW89^WRN4T(5[-UL^-#_K0
M,W]:-4O2\.27GGB.==7KG/_<),/?,3<&Y?HA$BGL5YRGY@GV@U1/[/QA"P[)
MA"[R"*<<Z_6\@[^"VV YRZ@4+?Z<2C4-D6^Y19*2<HR4\(ZBH9I[N,?ML:#Z
M9 4XG4#U4[8QGS\8)X; UVV9RZ+OLS@NO__IM>1*1SBO4^::]=$'KFZO9'ZF
M]_A?F5^*>XPIB@[N2,LGJFPDK0[.*!3&I5V)]ZXU(G;":%M44,XJCOI!L.!=
MG2E&E_O%"]87:*JRS#=P%MP@9$>2H(3)J@A66RGK52YVR:WX>XT95#$+/FQ6
M=7;;8/Y26?'H6E2U?!V3=ELTYE 6>*H!MR>M"NF@2I]R4/LB$F%J#,OKDKL"
MT[67_-(5 R-Q:<[2VC6@T=3"Y3P=7[UBLI)RU6LC(XJ*Y:!0*([;7"N&8_U\
MZ!XT,K(#PZR6@WA D-NF'DU1@O;,O.G*J\K(["'.[";FG/TD'^=CM+9*-_1R
M/8PV:'VG-BZV-V(AG",N(M)?1G9'RE!M[0>@C^1 CBQ@(_5!=:;#<ZXI!L&X
MS_]55;Q(.J%RCIO]J%=[) /%)SS47L9B=;1F-=6.5K-NIZU+FZQ,*:0J7BSX
M1L+]K(Y3C][=C)^E&JOZ*BM%-9X+R,_>O)*!)E!XF 1B^;Z8O0DW0K1ZW)WH
M*OV+<#&EJI=:/AZ0U5DJ0-TP;[2KC:4A%I[YP4)>N1V_(<S31"G_F&>M'*WU
M(H,@3.3YX5*5I!_*RIT'&H?K,:P/F;JDR'A*@H+,<31?VPS]$U2=!6HOZC@Z
M03^9(K>UYY@7\BKC&";Q-RC_#[S2I]\?]XSSGCL.5*&EI[,V9MLC=5L8Q+#2
MR&Q&LE1E9 /?4B;=\E>;:D$4=LQ73Q3(X0IJ9JX+!A6CCNN.D+ 9<K)7+(]*
M2WFWJ?:H;1"C6C!$U\7./9?Y"#&YA8-6Z\ME&#$Z;H*#PSZ%ICN0R>!4BQQ;
M!)HP=[7J*4FO1IC9XX2G(!!MU4_/2371)QZ4ODN=/%T),([@0<>1(-X4C:Z-
MJ&Q@WSB=H7Z3\Z5&:![=JEITJZM<&1MX-?&).P=E2T?GJU/4V,OI587UK0QT
MC?'DF59,;V7A-[*X:$G9ZN&WPA:7=M>]IH[#&@^A0JZY4EYVPK9@()"X\"3S
M<^!!5"2G#F89? FJ_7LQNPS#075?&>H6$RO[$=M.J,K6&R)4RZ1>1?FZLA7%
M>I=,#&ZS/PC=8.L(TX$PN;WQ<O3-Z5*:PX> !=7@(9QAW0@9D^1W=)<4E,@F
MFP]7,KQ+P02 5/4%U(:L[,7L3IMD3VK\BZ0M9604SE4CIY/6*F,>S!YH>Y]O
M^^.O*'5=I"?\WT9FR$L[7GQD[%*O>S0M:.9@]ET"?-1 :Q..KAG:X,, 8FH3
M?M3PFR^^FJWHF <%7RG>Q//P6'0P,UOUTZ?SV=/'3[[AC?'+Q=L+_[378:TT
MUUT;HJ3;TNXEBXX.<!&$\VZ\O:#"165:YKPPKYGT<MW5&R[T*A\7S1R1%5?[
M7*[>!#L7_QY7T@D<G@<-Y-N<(D]*!<QY\S4[:O?352^GWH!/ S[%3[2+>&J>
M/*:I>?K8K>LRN&]+VM*H]* \P9F+78@'=E05V5)@X),A9%8E_IV. #':W:()
MP0FVW.!1ON%'B32CQ"M=U1F 4WKSE1FLX)W=Y,$C@XO6>YI5M25G<#GY.#!*
M_]&%"Z>W)).%WDF51B\? 21\W^M[*Y0!4OEH 7#MKBZ0)V'O7,IE3 Q']P^O
MQN<\V$O<[X(W&K8I-LRYUN]K_5^?:_VG\2R_9:W_$QI>+7!;R0=ZS0SZ9D;7
MO)1R-J"/(<BC RY;YTWK8>9F".BT5W/BS$R?%RP8B\OPF\WLR5>PDT^BT0(-
M-Z&C2%80YG!5+3OMTXL2S_3=5=Z$TVXA]IVR#PGX_2;L^K)ELM!M!<,77BUC
M%$)."+3,C*#:2/)5I@UA4B R%PZ=..%,V%;D,"BQD1GG2_"I"S,9SC-YL_C2
MJDM#PRJPUH,/S-,1AX%G+")&\>/X W&:%BEM(]MBHI,/8T[?HDRHE+GJX'EL
MO" !SIB?LGUOML+QM0'.F<B^6\;Y:A9HB^1P=9O5].<M]XR7M,QH,ALT8R+7
MH<LDX86?JSRX'FQ/A@=;N$:YHLM/7",YW7K32 M9\E0R-99>QW&%2"G)[I%K
M%OX=G)46_B >ZF+V4P5DR%+\ 'W&ZWA]SB]KLYW0$0NJ4*G<*4T$'\6]B L%
MD(L28'.NL%X:O/";U =D:0NE:"\HX5)80I6I5*F4L\IVC-<[3%F&:?\N7]0=
M;:/PPD_GPV4GZBS6':'[+YS$U^9+,>^O>AJ\XAZ9K^I=$LP.+B38:<GDRP[5
M"TZY3)0)O!_+*0<[JRH$J@[SW=9%),R7S B'QML\:T N,N*KCHW@FO4 1.+9
M10L4*2!0@&)FH^6-B2R/YE^.+EV!8#YVMW!BB+]<^Q&;2U36S,>O:<L0'3!"
M SY6NVC'$QUW/2@-'2>!7#Y$ 0R,.XV0+"I%8O'TVH2X)<<2[7>TYIP ;.1@
M\O -N 3>1.;)%[+)@PUNPQN&E_\I*[,KFM?OZ^JVY43"2]"EL+5Z9U#\3YX=
MNS]"AM+#U&,Q5AQ.LDR'>[O"6.'XE$9F3E/1O^3:(X71*:;B!$X5[;=?5(8-
M/_%\Y('QO5R%S5/.O@\Q5$-M=N^Y%O;LNLC7LQ<?\F4'7^05U2R(/#/)AB''
M4C567[<:0;7VB([<+E/Q9<CNP#X ;I^<9OQY@_H(F1N&CH!&"EN\:)#^Y+)_
MF'&7$T0]UY"%=1[<DJ64$?M\I5X58J@N01<?D/V?>DKE>3B7*-;O-7-(HO:G
M^H+S%'&BW7##;Z1!L[F8AS$GE\?JNELR/CF+VO1FQP]=FV=;/EX3_>5P#/&E
M8]V(JS\H=M#.(V1?[#W0>J/[D96=FBC#DBR?N53\QW^C-.8 &X6AI&)8_*9U
MV>69HF/\^K45RNMHD].SQ;_PO?@G=*[-Y0EK_']B4)(7_/1GT/T-<R)%<E5+
M;EAI+='\ZPJV":S;JT7T-"*V>I;!];["@7;B1O02>R'-#7_Q1*/96\[;/@F.
M()T8CY \MX6#,C'2D2LKHU N/:XLCLA#D)/TBW+=@/Q-YH$JI+$J*BQ1%[1/
M:O>:FY.J@Q1-7+EN4(#PX)M3MWBO4N",*CG(.\AAYWFZTW9%C$C:T^@Z&%7)
M D"&'D1'G Q?"!NX%VPO60EAXC1S+LVOAL+C'14#VHP_<;%LN-NS;+NHB]55
M3DYATV3+ZZ[)6^E833\B5YJ<P[#+0GBQ"@]8MQ&!J+@Y(C],AR*V?S)VDS !
MRRRR6MO"\CI\%[-G.MP5:TXU[PMFEK,B82JD6$B6OHD8T5'ZA'[A<=J= Z;
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MS>4@EJ%C>"/-FA( PD^RPN2)6Z.!4Q)'N ']%8=8*$)PHS,=UC=\.M#Y^0A
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MX1.TD$UFOEKEW'R&C#SWJLC>)+YK&-3P]+QCH+L9; 93+ZZ523Y,6--RA[:
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M;O=""9= =+%&U]!]*#IT%E _H&*4O0Y T[R D[84*A6C>;^^WZI.V$^Y2M,
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MW(#%<B2-S#K)7<T)]7 :P@>)3K4KB[I>:+6E=;[NF@B*1;&S536#?=JXE8K
MMB(8).7,*\ [/0Y"EJ2XA4O#GOO@V5TP+/1_="3-09!IH_ON)::B2)L,9\K/
M:1DS)00;+>.I (W&MYKOYRI-GG@X6Q;R8F(\S%;"</PR!LG1J(]Q!\_%!\HX
M$6"/W@PX?^_F;"973A_5PZA8/1KPR#M1)E9G'U;48T5*R->H=-7T^)D.D9[%
M59^6SNT = 1<B;Y,VJE[XM551SSF\/OEWJ\$]Z+:!]N.$N?H++:,?PL?,YM8
MCT,,I+YAC.B?3#2VV4NI+"XO[0&E YJ ]14RK9AFX1YDGTZN+4O++>RD0I^
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M-*G.Y<&?'AILX ?)WWC4J:/:#S<N'6=<;,DE 9U26:NXRA[OY/"RB4RSABD
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MFX@F9?2D$*1ATH-OW._ZRS3G"463*.JI?GDO''T0YNE/JPJ)(^EMMR.X75C
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MLU1L[QWQ5F04Z'JV+7W.<U7<5\6_.E?%3^-9?LNJ^$F9(;$;ZH6/;5M*DFH
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M(P71#!@B"(HXI00E_QC:$*:#+%%F6_$LK;FJJ:=!?$V^5OZ!Y*NTVL;566"
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M@N>/U$K:\D%8C%-O9O[%)"=?\9A >?)2.Z-8,G//"F<V;''8&4F$<:QJ*['
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MJWL;?%^ Q8A$YINY$BC.A'6+Z$D_,".YT%<S%:8SCIP[P>^>/.7[A@"TO;8
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MFE%]65Q6<])YHMJ]K]3TE&I,T?VS?+DJA]<#V0<$45*.\*U]LISN+GJ%D)T
MV6!&?J0Q^8CFXF@?7L[$Q*[O+&Z,$J@%];NJM/R^4U-XOY060 N3]< A5%.T
M]8HU_@8%>FD"0[<V=BM3M:;@,XS+D>X?L&18VW1C"3Q;;EQECLBTEC'%X7B@
M [1DFP[!G!UD0H6=ZP%.!6\=C\9RV@_=J6QKHQBF-C41\DV:C\-"U+#[=6"@
M$'?M>&(>,4U-4U6TS?@K/EP=;1E84%G1]SC<YI7\DLZ-4N_<,M?^8 GI;6[A
M_-DWD7_+Q,WF.W^$ :#<+<GNX+Q$&0[UU3TT>C;B-="F4$X*#;PC2&8B'AQ2
MA77A"@I@F$CD.W2A.@J"C9A:374J) H>ME,N[K)A;P<.60<G%1W^"6@*=-GX
MM1@#$\AF7(*XU\PDV]?%".L0$+X%2W P,D 6"XVDTA[D!4W)IOY0>LX%98*[
ML$5T[+#])98\4&*;P/XOAS>T>CV)&$\,SJHV]O@N5Y26RW%X,M>B3(Y]U*.7
M:G.QR-NM3?U*\O&%.L(&T(-\]'[G+S23$XTJ<Z]33( 0S79/&BKA3@9#4LJE
M(O"HP &3!TE20Q@J!#7?J_?*UL_ZHBM<2[PS%*Y4EX,OLO;=9@@*!%I&!RF'
MRN#X3YP]+?YW3+T6W0KX)U-/3X?Q6&6<AH.82+CLTT@$T!RV6%SH" 2..2[)
M4=X AE#AE@_.WV)8.AL03@^1F.PHKQH]:%!R.2Q.RMV;(3P/Y]O#;;VEP+8)
M7#7&28_X^^?9;T!+(TZ#]8"4O@F"Y>WQ =P*72\B')".O2YDL/=W B),<Y*S
MMYV#DS?TN9/##_/VY1DA[DO2A00$&Z$Z2I"<96!X@:WPQOH)?*JX'<#5H9S@
M.1 YE]RE&L4S!8\@>\7N9C,U=I+NG";IR T0/1?UJZL%9.HLSK'_JJZGOF4Y
M?;Z+0(_#K-\?#TAME=V' S&6G]APO(\/5.XF,UH*H0//HYIY;[I$]&1::%JO
MS=?&7+S,' SE\"S5*X- WN.L)T76G/M13*XN"5-G%R#S?NAQ>? *^+3Z?CE,
MLNS?IE@7I=QPK%0MJ$8S 74,65_[K399!9#296W\;U>2J_PTOHGJ +%N(Q<C
M:CPB_!^T= :C^J!6I <E,>D#6N+,'(Q%,GS$O\HLDJ@I0,FJ%(/6/QS)_JK:
M$DN<;CJ;/,>8G[2KU'RI+$\HX:VEFP1>&XS1Q!KGJN=?9BS_%_,Q,ABF;FUZ
MP3HF+M5*:0(6:GX98>Z0]+V1\Z- <='DN)YJGY4F*TB+9$AY;M7E=:M?50/<
M(E0Y3)'+JDR5&)?14$J+4%4 J->QD/:G7BU^:>/1=.[,)N.@41*8"R645YT\
MGIG;G)$^UFUV:@389%KGF6GX^V&GS!NO(XES=]IX\@SNRR!/GH7.*$R<0&F"
MJ"SZ(GEF8D$<]_<=.W?+('R6+Y:!GEC<Q,G7/C]]"<Z^U?FY/%JMNEGE'>ET
M4^E($L1>Y>63V&FF%0I=UC<U5H<:VGM#KJX9[>IK^ I.0>6W?67@80Z]+)22
M@X552A&V_O<8] Q>N'(()4G7I$U5/":7=@+G_[7S 8[UNI[-/1Q>]@4A*>X3
M8]''-CUG-JNL3@ZB;Y;3S3F0B6JZEXU/'52?6JS"3E8U*^E397UG7ZEMU(K?
MZ!Y!)5%QMF%9G>>%P)P_&*ZA)KHRQG-_>.A!09_?R)S7: [E[.O[3D9(T,#&
M>3?J$Z5>G)!#\K<K*#*\3P+72PRI\$A>T"SDX8C'7R\H.,04^:;TOS\?BYB?
M.59-4F%5!_I $OX#83!DPHZ *T8S:B4519;5=_53?#JDY;T7&VZ'Z+1[6<!0
M'S.JQ#H0%TY"AI<6TSZ!'+N*-R"!2"3$U)S$.W) J9WE2&B,WP+9JA=(L\'<
MMRN5!5]YY@7[047'JN*2PC;@\A<2^&_6"Y6#(C5_K <AH)>',"%2%%F>4[V.
M3%,T+V1!9WT ND2EJA]/60(B;5^<$";AV2:/+943LQ$W9*12[]]'<I2O!G!1
ML=8*PDS;N77CN#1WA_G4CVK0)Z-J9#U\*LW*4;&$+9*(:\2346Q4C&.$S$W'
M/>WZUF;/PY_&%-S7>"/9#ZYG1M21OF:X"3=3\0 ]]4[]://Y0I.!'GK2N&Y=
MIJ&Z/;3+U>MI0A 3OK!,=PS$1+9C.)!S<1MN)]J*\9B&"LL9J%0#=B/F5_G_
MDIE]KQWML!EK:4<[;/AH!UWMAA)G5L7;W#B/4G\R%E0%I^JJ@ORZJ:^3XU>?
MH5P&V.##%SEO9U^N[[9U\+$>%Y@Z?JE5J@],WV%[06N[((5-WN I.'$)::=@
MCC&Q.=NPJNZW2EBTE[6NRY*@[UVP7;.!_!,8@G#R\%^)@]N5\&&)AA<;:4#9
M1KY .0DCT<,<WUAR'#@*B.P,;E Z!/=#/X&2DKG(^M$X+X26LA3+9Q+1K;1%
M=0V,"I.H9$3YQ)8LUD46ES@J:9: K3$EW9PLYQ^(7GL7ZS-ODBH$C6D^PC;L
MRCP*]:[680*E(UJB^-6[LV7Y@0(*U/>&O%6,KV7(4*8RZ::[I7B>])RK<'A[
MYVL<J*CK ,$7EQ&.>N92Y8[;"U@;T\FY2Q@$@F/L93$A:,Y*<<_6>G1[NK@K
M:\W--5HPURJ26%39754UT1[ZVB;T"O%5H3U1?*^<C*[M^QFVO1PU549D>[=E
M)<!$"<@]@U[;N_NYN\.,FNH]+.MKL#P/\]C=^J6BJ8<-<5DT5O51:<[A[V-9
M6T,9A"IV/E'HTDB88F1<C9>:)IK-CY53Y+M>GG-'98X>NX>G-P9'MD<=_A-4
M7SLTU:<[NQY)EY4H1J%BKUE1*C++Z'SQ([6*T_*,.\<I+D1=PHQ/E)Q[QV)N
MZMFC.S)&-;>MEB+1V=]FLJ4T;V[KEFCC2&M$V:U5=\VBT?W.*]G'.G.Q]PY=
MJ7);,[3)AM/I0=5I0)N71"N:98OU(\ *%S7BK^X J+!H+=57@HMC)9 ,EU[D
MPQLX+U4#=[O?^4BD3J-J"/N=,CJ$=%[R3)U4YO,/#?[!W.'$#4H/1TP6Y.A:
M=]Z8; DTK#+JNJH*@<Y%--*.$@+"RQAPO72/@./)U)NJ-]1SC.84FQ3U\AO\
M+!5!4+Y53>P;#S2@/)9MBLF+*-0L+.K IAO!H6IR#%?U$F311A7D);9%PQU+
M[*!JT!,-2Z#Z%2RQZ)7\G_*L5ZU!I_EFO+KV4JP IGD/\+*N>EN)Z4_I=?Q2
M=;E8+X^S,+N=(L8"1ZR]D#.@ZG'U6;) PL-1E7ISTM)L@;3A#/E7A<"OFI=$
MCFT+U/>D]$.C]6E"&%U?<O#<8ZK$KH6P:Z=8EN57Q(5U +E4[M<Y]HO(E#SP
MI!JMQOM8!:>&85$J-ZD$-^ELO&5T>])*C.#$CO(%,O>.MZ-BALT\_'[G"'@;
MN5@M3G^S% 03_*XH2>)"T80(_;R>F*3;J0](EJB?0#$NIA>%W,'KHBWB129'
M,@ZJ\12UIS220W4Y."K!!GIX$?(B(^H!BZ7*R[$ 48[ !B[,:&Q*\RF;#BGP
M\NR?XT-FAIO-7\<#!+8%644U-[(T1J]<0>C4P7.XZFWI8&1%]$&O*TR$3\.\
MEW3^(W@/F.Y,UN+KN<!R2B#U!%$9EGI\]0Q-)U2]I]H+T9BNJ5QE15S*%U#M
M"7QK2-_&.84"@2PX%:?12VYP/:J;%QM6\0,CFK I-2M":H A*4<G-2'_9AU"
MN519'T.P+;U;&=@H_Z;'CS1FC\P?,S*K-7:B_$8-]*E)*^4!$AXL7&/OMI)_
MC=&I"MJ#,GCXA Q+?[!_4IXPRC1U.I\N$3Z)2LJK2B;5!-$(9DZ%K>L%*?>=
M&\H&*<G!TLS'U]KPP+U4\_5J1FR9 -/=!.3CSFA_Z%8%,G2I=&(3OK"&S<F'
M,?XVHPAN>9!P3ZK[0F,N+[#E#=>;GPC7<#!9H48@=$ T_>% ]8F)\O@T^:;W
M7J8:L%.-FM6&7=E?4Q/3\KO8+SU ["VTD.554 H+7>:4V/4KF$_8&37HUV=S
MU6=FRCI$'#0^1#6L&JVD75KI81GN372W,APBW%>M*&VLD9;TR+;:A+ N'H*<
M[ -/TBV29%'TR$629F^G#Z\:*]BWZ0?J^F+I1B*\I"R^93)?H)H&!?EBRN:%
MC5/H4_=7RA8AS;WRL*C1@IX@#9F1@C%#(_UZ]J&5PG3F.FL;U[)@7F7CB'\5
MU4SM0JOZ$LB8VO[(%J7:3E *<I:M9!J)Z2QC[[GR:FBZ>Y]0D?)R@%DD49/D
M?-HR4#]!9W3O52<7ST<#-=2SAPR@345-K2W63:,BSE\)UDW88MWL?!G=4]K.
MC:;T,X(5*\VHLU*W/+D*GHN<,F];];C'>QF^>?)-W WV(@WWJHUWF09+:3[)
M+LY*KS3*UAM?IFISA7A<QL"5:AB 05;.XSQ.IV(ATK0H2ATXJUXQ;Q2S5S T
MG3G1W#*2)6;URI9.]U1 NSF.<U9X#FX*-!P&:%3+4U%K3BM'E\Z-DQ&$I/J>
M+*.40Q]5AK7V23)RU3IKX:GIW6RX/7M<ZV,#ZIC7QC:GGUCN]\WP^[!S5C;K
MCW1;&I]O[V.[TS6! <[N;4,S"30>(I:"O=.KH  JF)&("*I'?=ZOAA=@"0W*
M#J2%L3[4).'&GE036T$Q&3:9R8 ?3<<&JT9'W>?-$:BY+_%',,JMX24Z?[T_
MJ7:C*D)U!V8M[(KA[T)#6^N/2S"'!DA25R$)S=S "+1:(YA;-=Z7M:CCXB</
M4(T0T4.2*[B3^IJZ^@U5>Z+N3<2N0O!8\M*3F.Y0C'EQ.=7J>T]_X&@(1X7,
MJ\<ZJYA[#1I>8\U/]>L1S$79&*A7?B? ==EUN.'\KCO&@ Q9191U.B3JG4V(
MDO[TIZL[I>@*X20WD1T$M=',Q'>XH>B(/+7:UZ>8;8K3RF>H.#0U["#F53F0
M0*\*?;.J,JW^3?EH<(GPDFD2@_Y.F1V1BY)-YJ[QNVMHY?-Q_\-^&2-3OF3Y
MQJ(CP!7)="Y%DGHG'][RGO32@ R_,WJ$5.3@^>:ZA12?WAO>@&(?PP-8 @_"
M">$ZW"0P8<'5AQ75C6Z$#,_+ 0LT D>J2AG_W1)BO%-"_0295?>*:EI?!R@>
MTFFC(:67L.UQW^Y$%>M7J"'WTV-I<$@$)+4-U'Z-5>N)RC7$@9)PA03:4;A*
MB+VE)&B3U%0[\TP*@\VBLJX(K33[^EG"4,+W,$"(! 7? B)CDL@Z=2)#V2;A
M L:C0F$SR35(1"\9FM H"HG*_D]T,NIB@ HM.@'1P=),IW._8_?GK0XR;CB!
M?J(L,9K995RM*,8YYGH+-4^HGL!*M6E:44577<IM95C6@^S3B34ZS^6MK0T_
MR.8XF7AX,:!19)(%$PU-4?;8HA%@^U7C<;UHXU[=7VJQ^J0B2D*4\ 3XVPDS
M8Q(J@:)IP+GPWV>-I31:XZ>67C+>]$2/)C@!Y0OK9T$X6!1@$SF516.@%?Z<
M#9/]SJ&L*%FPUUOU>)>/?F;L>W40=[W8:D+$O0?:E=CN]S5[T[59]7=-G=#$
M5<+[0(!5EO+4/0RJKZJC+S5]\T3!WE8U1BJ.WL"KB$!YXHD6ET*,-EWN'-?0
M5>YVQTJM-^'38B1ZTFLM04=D)<C=H"/TF3D 1Z32R/G2(8$%D17G0;Y))Z\&
M[E;LU]R*^Y:+S,8ILR _*;X#FQ>H%U52-<>C+6H57U/*7"C4.=)TRLQ-;@L5
MO%"DS#M*D\+I#Q">7TW!(E"^_7E^T/VKKQ!;X" &N<"2&PHQWHO(0UR@;DHG
M-6;9!]+D>68Y;D/BD3U-%1/Z\8CND*69J%#9NE-&4"VB4^DY<L=GE=;6@EHJ
MI3WA&%*MB5R?Z2V^/C)5F+1[:\M ?)82QDPOIA06$Z^F!O_;;EW6-VSU$CT)
M=[;@4ZFL:I[1L)#-0$F?2:-!8T]J[M,WJXHB)>)F96+(NJK-%G)R0@V.=RWU
MOE:!I50CE"J9V,(IG46J)$Y-10XC('C)5N/%1 98ZC&^%YGY5@90[N6TK%#P
MF#6UBN2B-:G&/26_$@Z6D7_9%Z/+8=*M)&>$H_2^J81<(JZS>"2'G9!(2640
M+E9B4U%*/ :RZ N%CHIE%G59,_-](YH5.*IZQ"\0FK6<KE(STF%?*NF:5$XD
M70$>&M%^K)!("@GP)+%J-!63 8?MLWUB<?DI&9,F94Y<1!>G#TBUT&9RK#.*
MT]FW6<>#T<>,I98]K/!6/15D0#0E1%TD43T6&6$1R5.%YD&Q8!76QIJL^PGK
M&ZHV&6\F@TS-"B+3#'2UVK_>H3P4>12+/7\RFG2_SN!Y+4L\PMDS7YM%K/I.
MZDES7BYU K6<_C9#J<E2H6PTKJIK)&FI^RUK?LJ?E+L&9S!%035IT=8OF&*O
M$AF($NZJ8(4,U$Q"$-Y)9[+(7U:PW'&ZNDI02IL2&UW?)?RM&DLJZWMD3J.B
M5*5=^Q*C#PN')90^U@Q$LE5!+@R(E@);5*9:[:** 0R&93V(,E(QMIF"2UX0
M#''M!JLI0E*ZUY#G54!(W["$5Y8QAFH*4?6>FKZI]E%W!&I"+2NKH^3Q%$3A
M?R.4;FGIYX)5*,'$3>52)JS[.PEY DD15X%HXK3_,AAL5CB6"M+P$AB7D6*8
M\BTHN#&XF/W;+J%=H7Q5N!A854ZO&=1AS/[OXD['84E7; )VJ^Z2^4V@+6/?
MF8VSU9WMLLFC;8LPZD4800M+M!EK>618HB>BMQ7$2TR[)M\6")=,&JHK#WJL
MMSIER<*.L[+EZ4AU 6RV2W-65=+7YU2B,8&&2DYQ<Y+F<_+B#: [/7U0P@6!
M0%(# +^)"H9Y@Z]T]A&]KV_]L+;U[;CA]_?>'.6S"W3^P23*,YE>GO">INNA
M:ZG1REZG6IPRU:5<EJZ&JKG0XS94#$YERQJA[OFPA6VC\L\U*I<8)4Q+:+KC
M^O45('USNM((.#G-5.Z'"@A4Y JE I"-5""*A"2><U6<*P878+$DLIAJ#O6E
M:I97"^6P3M03R> E%\_!%9V-]U;OL&@,EI@ ])O7WER1E70!)KL[)TKH9)^D
ME$;@8_$*6WXPDE-DFG^O5CVL-1G)+LV7[\]:NEH;7>D@GIK 5NL?I\%.JEE+
M=1?0C\H --S-N"CG##>$PV+S3(HU$=-DRJ"YKQD4=GC2DMCZ2$PY*33E:XS#
M<A0QE!13SI)I[V!==U!OADH$LF=6I6IY'T-1/ZH?R+ICK7(FC#K5)RF_658C
ME/HII::ADO.P[6>@X?JK52A01)68:D%MUFHKZKQ<'U$I=0BO@I2LP3J4@GCS
MDW<HZA5V@J1'S#CE=P(R5KW\5/$F[2,6W3)=@$J=[Y08*$3I297^DYK0*ID@
MI>;%$JHSJ818M\9"\HO7/$OT!!.EP+IU[=65&DA^$<V=>;9=3:UV.PU[;@+Z
MI5:#6$W<TLQ:&O?:9Y@#^#+;_9LAS>7":\Q=28[*;FQ('71 Z8!TG[5>"B:L
M9)(]G@FR6!JUD4*0&*F[HAU04S7M#4133"50?0SQ7_=$TQRN P66\3*T,[KT
M$#PM/4(148E47D DF\\6D[,+[F>&NV87R-QW'42\/$:J!9J+N*1 &ALTU)UO
M(]:JH^N-03+_/BA39KI1Z& DI_I@ K"KP'2(PBN$CRK3F'>^#M1TU ''[W?K
MV2A).2H=6:9EJ=9!Y>V "T518 JVGO"C#-Z"3M4<T#?5OZ/'8L@8[4$S\8;5
ML+$:\TS8T&7"%-N8,7*M;&:5LE%-V'>_2F7LFK@TZK7:'U#I5G50,ZI$)_9(
M1S;UYA+E9X"P1;)25PU&O0N2ZRZHO(E3V[H(Y.M:6/6@&5;=CACDZ_OCPK.C
MD*N/6=T1JQ+?13R6$W45)K!&R:)UQS3P3@L!!2;5W$P9U-KO++)E&@>FK0,$
MV)$3IY&8A3*+U4(D5'=7FP,$W2;[@H:Y A,C5!29*]7Y]HDE<S@P5%+YMTQ5
M@^L:LIGFN5+.M\VCWWQU5LV4KU3: HF)":76[-R42JW\)3[R4O"$CG<.XIN8
M.2=V2J=6 ;1:Y*UL5?ND9L9-[DD7U4W/G*K@+ZK;[\JK+\FZ$I]-V&M)!HJB
M)$)$7GE<-1E_-^E5]+UR/,#-RO61"#@>D+)]KB3Q;T_.'TLJEV,%LJ%5R9.O
M?['5*B+3:J.0$&P3OYSV3T9HJ9+> )<DI[GU]89K'"_:!.LK9215[M6C'I3[
MCD;E*-2IMTT@_[7P(XW*E["M?-F,M>P.DLA#)9\2X:C,9LOT+BQBM"6",9-K
MGRT7>3Z0!=-R+"=J<33LL*)35=[@<$D59I%GH&3I;XTG%MB+*<VD\NCZ( =!
M5O*!0*@L+8+'@XFI,S&!D&X2>..2:E\1QSG_ONENUX?I":Q-^):ROA@=9W65
M(_Z]\J0T.$1MZNK-Y!!8^(C^V-S($3XT1K!!K+671(@.%\><,Q7MJI86W6[0
M5:7]Y01?N4\*:7SC68^DD,!6%3)<99AU1+T!2%Z]["L&=.#' ]JG!/CK];2U
M366UC<&KP -Y?@O[D/T&%,@HUSSQRQ*_7)948S/6ID?Y%II[FXJD=))H1/;]
MYT0S<:V@5A%(E<&6X=5G23=K@V5F2#5G5[>)XB%-"S'2/A></_U"TJ6LO==+
MO'=AVJM^9EK[KEZ)@C&E]X-\HJ%,HQ+<3\:*(@&W-9 5WO+SEF&[\D^P-_F'
M9Y;I5<7/:D?U!6"0&CAHD%%@,1H3L%!!<CG+XW%?)LA+]+Q>UL^TB)1G$!C_
MIXS?T0SR64>QX TMM4]O@0G)Y(_.)I<%V'\&_7C[9I-ZG.H'B]..@@FN: <.
MM1KTH^++]YY$!P]!E<#CKIO3HP^EHTW>?U90^)&*\\M^D)J8E-.O2[DKFP8;
M -7@5A-*K2Z(FS7/>28K5#*\DM\2PU:V..B>[QL9N[J %Q:C4NZ5];IX1N"R
M"-E]1[*X47U+QS-#KBT&#.A:>T^IT^]&7T,(2@RZ'U0!LB/=$++9@OQLLF"Z
MP@XF'E1N*T&%8C9**EI.W8-TM>29JG 89FMB)-!&M @CL/#$ZUZ56?DX(/'T
M820KNT#;OSXX>"OED'Q/ U5U@052+8>:KR[1>@A%536((<A3V2-6M>K@MZ[&
MR44=_EAV8$GC0XV(UUU/*#^)OKMU6="MNFNJ@%:CBIE2%>6B='\CG(Q$62CT
M@,:Z@,EFU++/VCF%]"(=0ZRV!H<G10K1)2XGSZ1M@YDHN(5<#)1=0J/6Y1^U
M()/!Z%05-ND(H6[=E)UWJO6KWI#3T$5=;<%I=$4I:V47_*60B6ZR].!6D$RJ
MF^#1<#Q2<+L@W?&7*(E$[0JF#JS$7)9V*$\PXL^OD60'HSJ470$'%:NLM.[A
MFC@\V259]9J1N"W1C%6&'CE'=8;J35)2*,.1%F5K=%&G-WE2\A/J[JMWY!58
M]\8'Q:G#;S@Q7Z;.\4"S<29T.AR;*B,I.<B<3L0(!P; 7T^'(P4(;57^W+W,
M?GTM"+6J(WJ%N(%+5>%UH*<#:>"\%S)\/NB\ GJ3;S -]C_=.AU+J .T H>H
MW635PNP]C"Z'<)-]+%*,M;!7_2@ULFVT)(Z+6I_E V3:T]/ DGZL0AV%LZ<>
M/]SLDV]A@?9["3Q1)^3!<,#F8U#4P[M+C9OI2J%0=L*7O9 3W?_847QG-[UJ
M?I=472*JUS^H@<"I%[[\W XTQ*^@U7RES>-W](%3D&R@_)FR,&R9[O 2W[XV
MI6M2I=R($CYRGL('NPCT'.X)#GETR\KBIE27?DF30$[QJEL&E4)2[=]D((B1
MG$+6L!&FS /U3MCIW M;M$G^D^[$QJUA78W6VC6-K9P2"8= U%G>R 29UE(P
M!&I29D*3LO5] J DGZ1F\&KAFVW?_H;W[7=F5<'BN*L+\I.9TC,I_>_/Q](Z
MVB.8[O2?ZGR-Q.A&B$&]X9_,7MW@_W15OGLO-B#.?J<U JYXCC436]YM>2#G
M4)2C)Q!-KRBD"D>;LIK<>(\Y.5/ME>I,Q9'0_LV;E29S2C;15\^*<CW9X-NP
M]PW+GYK"GD!8*<$CJX2TH*,4@4+:K;+<I!0:+:*$!:F^>J.&@979AEN!(7,<
M9@9OSV*9.B"U=(/C\^ CTJ:8L%A406 C$J",<KW]6L4)#2N<'<M:V$FOS"A4
METJW-N*VRBD?8IR"J_R"Q#F:5'[PLC13+K2L-8UO2VND,@M*($U][A*(2[4I
MT>YY<C66.- %XH"5-:;[P!J\?ZV ORK-M3!ME,%RZ375\G54AJ9*T=O&W'4U
M6X#R2(;YS K^6B'T0I7#5:'9_+ZH7[':)##::I/-6,LCXZRTTFA9:32OF6A>
M?^Y(%&6%<3MX_C$O"AO 9MU4W?"<;+*1,X3'UY,ER>H[V#FALY43+=!IU:[V
M]*'.^^*$E&'1 9]!4?/(:];--)+ C&T/)A,U:=U.*VI0N.@HJV8@>BN^K0Z3
M^+_CH4Y6Z#<KPZ]L."/>HXX^NELR*_4 SJIN?Z 1766\A%KJ;FNW(RLE2KNV
MCNW;' DDQR"5DT('XF(XRE30K0*0+(^I?F3RI&YK8Y/&V*\S*&&>*- @![^@
M'4J=&LJV3?40Q]*=46&#,E!"@549*BFWK6,KTQY)Z;140R4C4=U!L]"(1D8U
MPTZ*O*="6FGU<N7:3+Z)PFNUV05Z0])Y(WM=&_[YF'K62A37_<Y!#^QM'+9^
M(R9&8S4I3FY'7V_OMI:0HA?K8)'<4.^V],BZ]"!2O675LR9?\'7&C7ZM^FZK
M(]8V88E]+@]MT:\CA1 A39.+S-:2XE#K+S."H^&01MK*6:TT_8&2V-C<13,H
MQCV>E]<IPV"XN#Z_PN&2M]H[G/:EE..)7AL^$ X)X1#1<9U>?%>W_ I63JA$
M^7DIDK$<E$T.KN8(/)8:DBONHR]&75GTHWSXLBM2IR:(5?-R7C:&1*5_648*
MFXW8*N6F'09B"?&=^N-F>>^%WGJBP1/4X7,9C;BM.O%*24D>K$(YUM% ^>FL
M/MG\(=!M"Q:.N)M;.+(CLP?[&(@JJH$GGXD-CA9!!7WRS=X[M*-*#LN)]L6X
MC_V$/T2AFYMG3.'6L:LE\%$7BH>0H?9?:B':BP8[)&>4BKPNQ!_Z#W^"KW_=
MX[=_9 /:&'WI3_4LY7JCKPFJD?+9RJTF(UG^6KFA8;@?N#9ZHJ,<_DGTBY63
MND].ZN^C9/IW;KAO6=;<7QO[YMS?W?58T]SW;/]!C[W[=Z[=+M9SYO^Z_MC?
MB1C*4$?)-I) T23M(3G_]YZ]5X5#R.OXP[K^WC&U/R:I#AV124J41+AJS@_N
M8WQ#NFC(HR5'JL,H]Q0NLB<9H'J:74U):MH5RN4)L=P!.31WF]-79^ F]V9_
M- <#G?YL[4W()B5MX*L=4N\=O=.M.KV7E-5L'-8OS03VY#63,;7==XP:>?$-
MSZ7KA0[D+EY:Y7NVY>"-%1S\S+-57+K['&FZ.\B2SZF,9#B&1R3%;[/$[UQB
MF2KU0.B7-+UK_[-N' YQ(^#5\XFQ[DT3;:'=&ITGI?+[MTU7_NRGMEC?&LT]
MVZB]F5W;#&?S\9)DVUERMW>)U?M>.:FK6IK;)IIS;*.EN);B'G%O0?"$,FZU
M]MZ3:'^C.?M#Q\G_6)4SMH#OL;R;LMFO7)&Q*$5+N,ET,V]"QUSBL98[A9GB
M=0-ED-&U+7?K%=^.WY+K=WVSO:4-OR7+ZGKF$QJ1RZGT+9#1\^$\%Y#2VTA
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M-R)5C;A%B;6$/TPR:B[-:T1+9PU+0HL%'G@C>M_ /8 3O93=K=0'*N'!X(2
M2-#:Z]-5<**>R^%-IP=$4=LC_$DOEC8Q8YDD!'!^<C'N*YE )]/GMR2 Z4L1
M'BZ/X03@?;0:$) ]:@FC9_%O/.O1&_0N<]V)W"F&PX%NV(;UJ-@0D*=<8Y?B
MN=2^&1/*!OP_/3LJCT>B4$4CCJ&H)"%+$UY1J83Z*ZY['%@ET?WCN U0GG0"
MY2+A<6.YZQC;C^7/1-X'3I!W &RWWSF#C:7P%;PH;,'G*$?U_KB\U!ML9A^
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M;H.<AU5G$GYY3EY9(&!A3DZS[R)A/T0^;)EX.2;^,<'$MA%&<13;S ZYR9S
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M_KTM^=>R7,OUPYA%4<"9PT/,08J$)7&:1%YBIK%E;1[_[DKD@9)];4'#:FV
M6@:U%2#K$"!'=0/ 3EP[%+'%A&D$S+%YP,(@-%D:1#9WT]B-+&/OA=5UEBU^
M;,,#6Z.UYW!<RU3+,56EE5-A)E;B&\Q++?#= \MG06C'S$U3UT@M$1J!L_<B
M<);,#&Z1S_ZD+*1&ZPXN.CV,:G7H6-@P9>-"K*!$8;>%RLK4N+Z$69'%5IVO
M3O(<U]5Y&O/8#2V#I9:?,B<U0Q8ZX!1$:<2%:0=F@C6)=M!US1T$:6BY>.6F
M0<O%C\;%E?W@F*'-'0=,A\@'H]Q)#<8-RV&):8:QQTTK\+"ZR.H&AK-!7/R
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MM'#-'$?D1M&^1S;!$_YL^Q_M^7CGGZN;#W;>A8F_.&?7SDQ*&YD9=<7,-$(
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MG9*5@460-2(UXMHK9"6/*)!< XF#/.8*U?<G9/^Q2%O"8 H9 C90KH'A$UC
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M>5 *)AZ/<HZ)'15:#CQ]7!*6R_S93.3;"D'PH3F!'S^9+]_%>6AOSND3)6"
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MP"84'9LG^1D0QH^9IH+&/FN5]NHE8"U.H@W_-P7N&D?-=9[:4S?JA>/8[1S
MU%I_ D\[^1)A_=$0?CU-7WJN\=2]BWZ2YWW4&[^'%WIP4SO*+TQ.AN,B_DVQ
MQFA'_?-V)S;[+N^+=N8O;\W>($S!7(9E;,I#YHTVWU%PV4'G?3S/G^I]Z(4I
M6.7=<J$!Z(]\\W8'EYI%<>2;=?_0LTUIHV&8^@E\(X\#MFX!E02[LAWJ?'C=
MSFE^T)RE=0+OYE7NYVTS*EO*P8+E3S?5Q& 20S.&'GS;SZR4SM.CO_:?(6+
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M-U\0OCOJ+E^V&4<&T5&>Q3&0U!Z 6ZZ^,((/@P)K]F9!*-N0^I4EWW+(V!\
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MY*JM -C;;(=N"[5-RP,P%B:9\7FP&<9?7?G-@@827UCY[,@$D[M1N7]&'WO
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MVW/-JVM[?[^S737L]1Q-!K]=9,B'<;(_ %F._X&!U:U^M6)X+PZ.WP8G@XS
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M6YCST;!?9S4L!":&U[S)E*^G%LW<?1XU<O'&C)+O<?QG&'U(]-6J13M;>^(
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M? !3B2AL$9UU#KB#>T4MM3+XJ P/P5T[-ZP%S*<&F+-$8,F%=AA;Q$@*XCG
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M$]SC\^LO_[GX".O9.R!8$6(%0XXIDB8_YASE@+33D4:)G31VL6Z>FR(PZ5F
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M'PX']:^&K\.?IN=;)>1.H&BNVM\J@0F6@$)>)^<G+9 6J7^HL(P')[6.1>N
M6%>.O"OY?S<<V6H(W\F6C48!C$2"B4/$X(BX*2@"#G2(11T5'#C\+[QX16ZN
M(*R1H^()Z ")+SJ^-\XCTJ8."^/<*'ROJ^+'!J;[414^#JJQN<%O58?2Z@1W
M CYSC08B8QI.G""GE$V* 0=U0#"P40@&?2 :(L)=.R:>J._A"7+Q3X^N7US)
MQJTB\9V\/%,D""^8+$A CCJ.>(P>J<@CHLQC'8S'1IFD2+ 5?0!_7N-6!$\U
MV%$K$[F_\!61C[;PN"T\?H2H3ZM2W0D,SS53()AC8HA'$JOD9N$<6<,%\E10
MZ0+3$:O;JE2/7FC<ME-H46TMW5J7HUJK87XGM#729PNK0,ED2*06,;Q(LZA<
MH$AJICA()^*= PU3;TC!GQJR7:.%PF-T-\AW_*4W@26[:U2M_3$TY2#4#P$T
MSM[DO+-Y. H+DZB^U:J!/EH=],Z@LYU&T-@P*DD%Z*B3F'\CET'_.CR&19UW
M<J%@\)W>8#+LF$Z_?N%Q_<*F?N'.3^FZ%SM? 0U\)^_,=#->_+S1.>M-CCK5
M7U,$<.!"YX\_?MWH#$?5KS<2D'32 P[APD,S"9V3%45R_W4#O+-<.TZL#T6@
MW(M@E6">B,)Z3$3PM,([0O2]U@[()PI^M^\8\ [>Q1U@T,>PI0$IB1WB5BED
M(RN0Q4H'1B07R=]%\<ME7WL':+Z?3G>.K)+,J6CKQ<^9$$]/.HDR@6@ E"9E
M/_B;4(@(3D40BEA9P26L-@HJ%"Z<9D(%;*^DD#R2X0_@KYWX*W!*;[(Y7<CK
MX6B4>PG\:DZ, VYIJ>42:J';6Q]3:,98(CSRWGJ@%L. 4&1 ,BI%-;?"6: 6
M<0MB>?WBYY>=:R*>S8<&D-?BS%.@'-;=[1X$IFPA0X%T!/V(LU1;Z5*LW4='
M%#"X]E?BS.D -)Y,"<M8\W+%[S+Z+%-:18+3WXP!IVPPHR1!09*.)QT#_^]$
MD*23U&7D)"21!P?:&26!%_[W%  ,$"W=!:0@_&Z4A-Y/O9\[E](C7 U$_3 D
M^:YZC;]@91\F:2;MGV&4^@F8PS"E0T2?'R&"]O_N(!I'0^0"P0ZG3M+4(<V
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ML6?B!QEX=1=%;R7^W;@I[I-]1VZ*PBKJM* D"(JI7LX3Z06.FK!::&U*FY?
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MI 6>[W3CH?\"IK#OXE6P)KTV:VF<=5&B_9^F8+D02E+A)6A'84VAE52BS,K
M<YVQDQ*4?DP] 'V./E_LXO,__]"[\TYRBN"3D-$J&+AEP6E><B8I2&DJK&96
M4>X4S;86PASYD# GWO&7)N#=IKUU)[=V__(]0,6QXF7<=%T&KA5/AM92(UN
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MB6I),II&OXH^_4%Y,F>0T(@8?L>2'U<-G$@>1.\.5Y<GKUW+POI/N"A4EK%
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M&WI1U(XR76?K#L]D6K/T^LV+*IQ<1;J'A+?3>#]+XA&#7URTFC8:?O@Q>DP
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M*0-VWP+1)0W8#(VV1X>0[E[-RPN+-?@I<:>B@IHJ9MX #A:-V*IO5V](T;-
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M5[^J0$E+0+@=;97$M BQVL-\_69_5!$$]XW*9OTAUHT=Z6[$GU,=Z6*X"?X
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MFRMR(0S(1>8")SS/2V(8E\0'YVP(5&62;^V*.=/2%DG)'Y1W-\"?%5#.R^?
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MUA3#2.6OO<99$^17]RJRW "$0EH)4A32D8]R,@F3::F 2\>UM702?T !YV
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M1_<-6(8.(Y]!-[L$=.)7CQZM=K]1!89CFDC%^?'J7LQK0.%@8K=OO/9"7V'
MM1<11PO=/L/\I9C$@U_>"(IUHR6V#\C3@2VMF2J(-YP2+C-&C!62"/@@]Y1J
MJ70E*.834X(E44&@=NIC-U9TAEY<=#O? 07$HH65,K7+LI0E4 0-CGMJ=7"Y
MYU0(RL'$*?+)4&.Y2A4?+K6:#OY,XHF/3B'PV>6)*'1F*,])5N0@8&301%M
M,BPK;*9+4Q:PY[M%MC/;\:<.)T:W,IQKNTHNC.ID CXDL-L"H@&LC2D@79^J
M5L( Z&AP@3^NE+4@\[PTF2YX9CF--%1JFF<BQSF_I9V/=$?D$NM5XLHP@?']
M.2:2QCR2WK^J-:[8;>H5$H\X^' 2@$08E8Q([C/"L]P2F16&Y#8'GBXS$;S;
MVLUOJ/V,D0_?QI3)YM@QU"F5K934$K1-.5Z 0B]]JX7_FZ@&\PB=BVYVP*YK
M2D-'G=\ \ESHIMM0TWQJ^I0#-7G8?%^XDI2" S6%7!"P_=&>"H4UA2U=#OJ)
M%C>(HKIJ(.4B1(-ZG#XF$4Q-8[58&N*7D9[;:;R93)58-E-B%4KDS%H1N"L8
M"SPOF72T<"(("6\OF%PF!PM3C^&G:77X9_6J[SI=L.(M"-W>NV[G_"@RW$;$
MW4*4QQR)DK.BI"HG#(=[<!P*8$I&B7,*/4Z<E1:;&MQ02KQR I9P@;'":^]D
MS@UW2IBBU"6F)K@@*%TB 6M##P] #Z=7!V^.K_>O[17\71Q<?SH)2N0EF#,$
M0)(BW&2*Z!(%F )F!BPE<R5 8HDYE<!)<BPH?0(CK%5KEDF]>(D1]*YOGAL,
MW0]S 6H9-E?^M4?)6%AB,C7#::*<Y&@RU-XQK>:IKBJ,06[&G.:Q!'O,'([)
MO?T86*ORDK'8H=>(<?+TS9B0V_7GS9[O;5>=%W !Z4)T>:4U8=X"WN!\E-=;
MF:,5#JAO,K/0KO_/H-E-3SO7S79,B=<-JWMG8+NV8H[LBE6D0I8T8P+,;"9Y
MIJA1DN<J![!LLC)78=F*PK]@?\!Z@JWX'59ST&E7N0\;+EMDM^Y?OS_AHJ B
M%(%X+<$LT2$C"G  L;#YUFH/IX M''9FIQP,Q2Z00L];K*-"AWH?U'G,Q$_E
M'-.U.$,B0]+"(&^JX$*WIVW!Q<W03$47W>%Q)NKZ"9Y-JB/]N=%)^3585X!M
MHN+]:_KKG?D5<ML/AQ[<=$FZHLHR3)Q;^7L3H[@8[AZ/*8PE*\TP?<RS7[FN
M6A5"JKQPSH#B4X4Q.97&YUY*9JB0*9T-]=(J1OK45*,-6RQ@B^O]-WLGP5.
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M0ERBT,O]="K4!R'Y4;O@20#BND5"BS[X,K2)MC-G&:!JFHU8$OV@Q\$%:@G
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M%VB!9)>KI>:UK,U6Z;4K?$K8]G,>4_%U<1>36:7TIERZ()7,-<:<Q;!OO"B
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M>Z8%89?9\F+SZONP(&*5ERY0&/LPP548,$6/3XREAGAT\27IPSEE^F1\Q+)
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M()H$!9IHJE 1FR9S!X=;8.8'#N.BF#MI8%<EDUS+0W1_HJ^I;OY^91_5"_D
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MF^'XJ,**2Z(X-XL?_OKFJDVA0:54Y0\N.+B#*<!JS**N4][(V;+R@'DR8B-
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M/= -0')=, N?39$^C8Q%.5D,26'Y)Z,6H$02P7;@S7 VM#[ Q6P>S? SH@'
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M;M2:1OO-^Q TFK5&R6X06^I#\*;LM;98->G+3"N!C>I\B^K;55I31!("TO+
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MG^]]+2N1XFM^6A1HS1FE;>>GQF8Q84;KU+A!YL(#)&+(,RB/MFLC*P Z )L
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M=SPFZ5BXB%NP"K%,G_T1V3YGZHPOC9XK*""!F3,AI^3E)(&UPF5Q62:9A$_
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MX5H'AG#;JK9#11IR 4"21;'@%EAP0W3]8@\G%G.TS]:5%0QM:]%5-GO*558
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M_ER;@3+3,Q];OH_:B;*L#Q A__:W(L+<H58'G<Q-"!MS'GDUL#-;D(Q2>ZP
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M3WT4-+\Y-!\4+F]9!G8%2JKB0Z;B0ZNXXL/EP!O-X3^3<.K\\O\!4$L#!!0
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M5MYMWO.+Q^^!A!6J6&Q5!Y'G0]KQQ!-3%GT--2O&6B,T7H6G#MQ'N= X:?A
M4>'X>1\#1V;8<C$"U351DMLTJ9XPJH*BICLOY4K'-ZP\K^_66R<$Y)G3(%<M
M@XK;_^P%T+/#<<T-2]%;$?HN"U:D)HJ:_U OI,^[D,Z(C>GG7_X?4$L#!!0
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M*K21P $(89W4(F7.1"!W6"/W#((C%UGJ'+.P(99..97M"''WL;Z>+G&.B_,
M+NB,F7P4 E(SQXB)>23+$A5DA13 &=&GLNL*D$$YC&T(<97U^TS]WERONYGG
M"-9C.JO/OSQ"S654]!\K'B@,Y!3,>^X*LS(4'R!E]%?VU*]OE&[[L$%IMZ8R
M[S+=S13>*QC/5]OX/[:2WI9_PGP.TR4992,2<5 S:3U!DE&3GQDE Q^M#UQP
MVRF1?"NL.Y9R/40%T4XL[5)M,)XNJKW'Q=OIRV]UO"?CQ><UM'J0G@:L"WB5
M*2JIW62 )Q940A)OD%QH7BSV8<M/H0VI8JL/8=I*YW[*=.JYCU>3V=>F%3D_
M/K1K\<T-V!O5V9"_71_P;C[[,J9/>_;]SP7FU]-UZ].:&TC+\9?UD:JH-9:L
M#:T1R$R'0%Z$*)FAT%9)E5,*G0*7K3$V: V<$/.BIDQ>+Q8GM?WKV_(>,^+1
MZM* V?0+SI=C^O9RO=HH%^<X]YQ!#*8FGP7SWFIF5UUR@H< ?29G9\@#2P#T
M8.&&9K\'$&_#:M0?<%<PWAZOBO!>?L-Y&M,,C6PL6GDI29&7U0%O9%ZDP Q0
MW$Q>7_*IU^GCGT ;E-=]>';M+ZXN+#HC_>LI#1<F[T[B9)S>%F(Z3</(*:YX
MTH[E((!I31A!)<."J>Z?2P5R?S;="G%(1RWN46?M+[XN[/ICML2SVU%&,D<7
M!'=,BQR8=J[NQM8N%$DZ$RCP=*B[D^DBHD%YZH?GSL[":;B5> S?5T[MVW()
M#<4D3I5H*6JPA6GK G%6!28Q>!FP#K*/WKD)T1V/671. QR&*TVDT]5HO2WO
MYN,O%!B]FT!:14<CB%[8Y"T#@[H>V(^UI[YF41)F1.=<Z*]D;L:W#8_L7U?E
M-!)<T_8<5SI 7+ZMX>DT7W[APCO?D9&=T82E>6W>]P+7_Y[OH=,WGV'Z"=_3
M,%^214[+D?521."*);DJUU6)IC%Y9C*9:8S<.MUG'_NPXVRP^;^)F*\I%%LL
M+Q-3B4B*B->K4TQ--!7'((58[\H2Z(*2$/H45FV/<4A1]8#YOJ':N0<)6E:H
M;*L] P%4F1<FK2#5%LG+HK /&'B/V09I9>ES F/7--D]U\\_>)+N2X+>)#VO
MB;F #PL(GX-E#C*2_06"9LC8!ZZL#V3_C>_C<F^/<4BQ_L,GZ;XDN ^2QF1%
MD%&RG,@9U;XF705'9K4(47F9L^G3\V-7DNY2*7.9%:^GI^T-7YRFGS>V.1P9
M(Z,V43$#I58PU>8(,M6>XD)H;VFJ3*^"FEWP#JONI@\!KQ?B=)=LLS5Y'>N5
MNXY'1L5,\5IFKD9II)$"Q6NE)@&T=ED@E$Y7?OX4VI!\F7NCUC[BZLNB*U=C
MCU0N*7.0S/N:;Y19UY9Z@47(H=:YQR#Z[)-N@VY(+L=]<FD?H;4J(KP*:_/E
M":M6KX6[8J)C-E)4J$VHMRZGR"!$K,U>!<]7\BPW%A-N_= 'L)G0BBE=Y=%1
M^=QZ=<(H)4X!FLLL%2&8UK7IJ["6:?!$:14=83^0'KH5Z) Z/MV;2FHGRF9\
MNWCA,WT_P4TW/T>9A<2ZW\^15D)6D7E+E+ )17$Y*-VI&<<VZ![ YD1K9C47
M6M,2V%IC^7;Z8KPXGBU6O3G?EM.@ +R!8"@*<-X4IK%8%HV.+$AO;<2$V*G1
MS:VPMB&0^XM%=>WD=* Z>V^$X,E(5H3&6M!-RM%YR]"*2-]P74R?-@5[U]G[
MOY;N:2>FPWC85Z^JAF0YFA!K#%!;JVOBME:&"1$\H01E0ALO>X?[P,-?@RK=
MY=*N/&/5,_K_C*?Y[/C1"$SV*4?-!)#&TSX@J3W"@2Z&P(6VI!S[E&)<P[)5
MNI'_-3C32")M[RQ8%[Z^F\#T_,AM5)AES"R#6]W_RQDDE9GG2&;21(2K,7K+
M>PNNX=F*(?=<_-Z:(0TD<\ 37TH9'KERS$(B6%$ "ZF456UK*MIPVRGAW.3$
MEY!_0;^WG<!:]H&?KX.X"Q$< 1HOUOEPBNW>S?%H?'*T6)>2K H<1\Y[85P
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M)S!N /0@4QO[<*B%8 [J7MU8M=]N:^JGC^CA9MUM7,W[\UZ6OBU6R&SJB8=
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MS$ZQ[#6S 7?F$<2"_._#V9=?O\$D#J?P+B^ #ZP!@VZJ1$_#,R*]2<0S&8D
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M5Q_]&=R-M@GJ4M(^$T8M HN^7&Y/JD1<$!5'IJI&UY_603J%*$,5<3=8!^[
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M\M:Q1HQX!-8),J.6$AJL%7]\_#3I3DBN?A_/8/H 7J86$;)R9Q"'*Y'-)&1
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MXE8Q@$N0&A6<.-8.E4=Q1E5#72TJX:QOD-@#V(_VE!LJL'][RBVDW[XAX1V
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M/#&WN@N#GE?CA,C<;1R3F($/P@C]([0_(_M?"RST_U9D_Q+8O\8U#V C(R'
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MPR2>-\T>\Y4)32A?V0'2VFH\&Z\:,&T [$:(T?'!+AR@Y7"X;[>  V/*"G
M0S4JP K*JWNR%-%*$^EQ)_@#>]"I@KV+DD78HFO/#1WPXI_3."UAN)3+D4O-
M(FW:67'J"(HT7G5^U[#,T]+^-4,U0VF:78%@7G'A*]*\BXLP3A<*[DHDXY<
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M*DCR.'"FKUEY>=U5!EP)JB^4+S'9_[*E9:^(86 X-/,49@H'&(?[<RYF]N&
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MT.O*\BYPD:6HR*1_WLD_%]WEUJZ-3+=?O))B\VQ/,BOY.F*\;)&EVE-+$;E
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M]*O87-"P.!1U"4:J_/([7.ULV/M_G\I>UBE^?:S*>Z'LB :(_MV#2@C#-#1
MG'_A]\8U E%>-LV_UCJ0!Y9%]?^,5NV:^5U/"3^#5<.K?VT"A'@+..4!ND3.
M@/XPP#$:<'90]7<*X<]H9+S@^!EC^\CN=Q/^(L ?VET?U\I" \RVT("C%9L_
MFO>+"'\QU73(<=HO4O\BPE^LGJQB&/NKU+](\$<G.K)B&07]*O6O$OQ%;S;_
MI[=_J#=BL\IP 6-01Q-T+_+,^,_#=/I_^##]]>#FURG7\KZ)I,PX<UY;01A
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M7SW"VZ@3#9AV*<"QMMOM29^56=Q3B_8?T(9'!H*6B,?8WZ&@B&;Q/?D4E.9
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MK7@QS&PMKHTY4E7I1E/8#GU&II];B<U*ZK1Z$KFZJ(-4:]QXF!_.HI_(^&>
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M+:CBAHFD _#>R0R,0+(L3:[FOCS;Y?O:Z4=,$J:.Q\1:!@<,D'RW_$N>132
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MV!Q!J[*B@4R\2"GU0-IU6R"&^J5QNG.'B,Q;WSNV7<L>CA&Y(8,YCV(2@ ;
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M>?2V ;4,7QPJA<NVNY_J482M;9)&>SQ(1HWZJ$Y'(S=WQ?[!$8U6_1BYUJ@
MMH=+)GUE2&Z#U*HQJ::X7Z='!%AFX&B_P7+9!@6AHEF&_K(>RO1=[3+_X5N1
M<Z3G"%4N>$(QM&/JK,F@^\A<6S5.9W1(#A).L/38-4S7'D@P\\0ADN%[953J
MXKG_1+BH:QBNZR:W#/@[9]$'G/UZ8?:GJHFZ%=NE8_5[ERD'^A]>1^1:@LD@
M#"#]0>)>#2DM/-YX6W0BUM22I]<[8SN#H-?!6#-H*N994N.;!0^< ::>3@$,
M)9;.?#M9%RK[TBLL0>Z,^L3UXU5H'*,003YV)QO!].-!1;RVRY72$M["ZM1G
MK_R7]J.*M]]("^ZGX1$4@UI9[(1DKC/#GQ+"A]P3>VX91D]3D;>?0U;9YN9@
MC7CPS:44"6-Z3&0>PC[A\>#5DI2#]I3GAY)!K_Q^8,C E=OW;RE>5G@&&J:=
M>O:'7CV??9ZEDJ3![4#8IY)H.P;LOB1%\Q0;/QT0_<&"@U!>D:IJ^OXA>%<O
M:YNP_@FJD'XR>Y)I. .E[N2U.'ZW#D%QE30S'K'6XZ8:V(BZ(Y4_MP#=GO\0
M;L@16_>5=-58=^7*TS/9\X8ORY7'RCBH[-^Y6%H J2J3]3=ROD<KXD@^"C&T
M9'< =C7:+N:/]4*KO K V)I,O=+2G( ;E>YSAE)=LWF"X5RH#=/#Q(SXI^B*
M<9O9,&%NY B;$IK#W-!?^S5-S6.E57VGR<H=YBFC)EC'98N! -/C?4'+[V,E
MD A<1$]GI)EV=FK0A_*Z*X$%TXIPG9",AGB/2@]_?UAN7>[A6:9!B/NI^N7/
M^A]HU%AN#$_8WM!BHJP\HD*W4][JB3V7';HE@*A[;BU(S&S= 3#=JT:SGC6.
MO9%:4?[94_:("DIX."Y=,&6 R#G%MBN:K91L*+*EH/\L".@@[ZXGQWEW@A#6
M#&936RU+5@WO[&Y5!W80OC (3&"0://Q*9',,T'R?C\I*P-*[-?.=^.R7T 1
M$,\P3WD@ZR6K>1^_7\F%K>GJ48'\0TFP$V*ZZ^=C"UVA;0S9%LXNW8*RS$PE
M>/)U=*%[-*3TI>W IYM$/;XO=E1'0=;[&#^#/\:]Z7E$@,L2*L";N>G-?:BR
M>>G4%".;MRR&"II](&=23TY3[77& ZVZ;'2N3DW@ Q/.N,:K:3GNO3)SW&.$
MV=0UTS@.G=>\"X'YL/60>X0'IB/N-0=5J=0=H'KA4DAF^PSKXHD>&(I_!QB6
MMT]%:5F-W2*'WUM9R3Y-_=/B]1:5PKB)L6-P A_(@G@G^<4QQNN/?G!-+8K8
MOH=<E,2U2*M.9,NUB%M25QW)0YPH2SC7$*-SXH&-S]Q+6[:?X1*2O#URARB<
ML/EYV-8DN[[^CS)8:Z TE75PVL>$$TN7F&6G!1AG2/J');/L)S @V^/HT_RK
M8Y)59@]O/>X7J9PU%:BS-3.[G5?.^2Z'#NV7G#^/.Y@A>=1147WSH- @DA2[
M<\#*8Z\(0?R(:YI,!+@MK CAW,W$KCA*2EV3,F5E%*_V?J/0[^G.Q6+2T!$7
M#Q-'!):E>F_.D,3$R]A.RC4I?Z-06P"%Y(J*I^HD8^+26E<VI%,#G^A[.(/4
MLFVW\D=D2E*)!QO01TU66; 0/8,S!,D^*FM"7#&U3<-U'P2(T1+.&8:L,B[P
MG0-E#WW/</2-:2S4[RV)#\H^_U'?(,MGQS!N443ZDM%2B%IE<UUD\3B>>3G1
MK).)V@HTU=H==?H(ZPNL79LK-FW+MGBPP<XZ<J:U!]57XXDD;ZN2_T)-CCQP
M21A3:_,\>CNAI!"OL'1^$>@\V&@K)-5C/)1&N.+;FJ=LI^'A*!$=:LRLUAS6
MW.GL_2CXH*N^&;)<RW@F41NKWD7U1-SO&0JJ4N#LL:#;1HE#[&*(CA?[<L27
MJAN 5+V 7:8T 547;ALE?5/0$;J'45JA$,61/+QNF4Z :4FVL^(-B85[YB+:
MAYO.(0V!$UCU&ZDM 88,LUN2T7CYD:QP42&WC_-$THD-Y>2KCEEKU.0>I2+=
MK%^A-)(MFX::@\VDB&*GS'0'\Y(V."*SIQ]G)^JU\/PCN_/3DOG&.T!GN[00
MNZL@Z/;:=K8AZ2.]U<M;SXA\W$U<7#YA2FV=/F?PH6@P;5%8^U]* C]]>0?0
MAU!L6_ (0XNEW!/^N4VD\/M \]5M^OW4"O#FZU)EML)\#<4?'4C/(\4Y=O=?
MEQ2Y"?LT/LBV]$:K:*FO&W^A);NO:2V3UU&V:#13):!B<HMU).2[3/LA84>N
MO/H*M^_J@.B]SP;TP E^7BKN-T^LJ4YLEAE(?95/%*"$N)?+(QUM:<[VRG>9
MZVB$]I+ ^@>OZ_5?*2?:J![DYG>6V090XV:J0P=(3"!'8N\BI,"[Q*E[I!).
MTR ;'#EI>YY>RK33(O +F*6VE1#^D7JN#3PDC//+.$7-6P&(0PK@E!#I<KD!
M@^RD0P6(/B->]*S?_F>Y5+4)Y>LG"D^54AYKQ71>*IH-RS)VJYFH!<]+/U4S
M#)52XR'V)1E35O3>];[I^THJ5:-L^0/FTGQY*G#>?7GPR6F/35YF2+?A=@3O
M5@_2U%"_=D%IOS(^H2<F2512OBC(KJ4%'2AC>,.H_E9T(V:<)/B4EOF:!;/J
M@]_D#/$"?]^)>)32NA&_YT#MW%Y"XV5@!%>Z2U-:](&,_ EK!-/#6!K_B+?N
M:@6#3VES[P!8Z8D=!6$_[+5A-C3>&]\1)ZTSPH%534(G\E? A)E/2JE<ABM(
MK)O>?DVH*ZI>-/I.+>*R_#[H#D5>6)G/H2U;\O&=S63-$"Q;SU,M2AA.7/A
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MT<(T=!)Z3?L@<>>.ZC>!70SAR(]XNVPL]7'&G'88I%@\3Z-[ R%U?BHD964
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M&'_F$::J)W_S]D'&SDOT!P4D#\XXX]-%')C&2W-GOUDOA?:]".B+(=48NYC
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M?LU$@@*O@Q1[QT7Z6VF17\^$8G.AHU-I_:O8]/%=V%XIF>IT.*,.T "U!(X
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MK+A";\>\6#*AWLK5*A*$?@8.4[2H?<,%-=RT+=Y<>5?W/<>:]K/Q@MM-S_R
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M UUAO@+<!2T^'6I:OW8>CT HQ>-"T&%) ^Z?;_W/>4O^ERN),,>&T!:E#.C
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M#%< !Q6-BGD[T*D$@.]?.$P+<"2E[3P_R<-55)R!EI@#POX%7G<>_M5CF N
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MNOD*9\IT>75E,96YS?9@,Z9M(4E.$1^Q;M^9O4YHX3*F]+3OQ+EWZL4W^VI
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M\,_?]8<0M3R">AN6^NY\9,::TO!(#@<HRQRWFQ\\9FG5&WP%5MWVPI/-J&M
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M6'2=C],3K+TQ62:@['<!ST>/.7/'6L RG7"XP\;F&+$X2V604(7X>ZYB#0T
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MS]6%4S4WDB,<+N$[KM?<)O;V<5VRJ;.I2#,Y<$>(P4]HTY(S\G*F=6<*/*D
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M(2+)M7@ZQ'=8L[HAS#IZW8'(G,!BH<$)1=QG*Y?5='6'X<DJJP2*D&C_$5;
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M^!1[;,GA9X8?&]FZ/R*;@I AJ<OZ37]@WJ2.Q>GJD*!N\1+BM[_CD$+>FQY
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MPNJ%8,NI#1$I\'O^\ LP;%*,[9F#RS[$DLE0G,"NK&YWQ,K.01*G7!LR+>!
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MT/Y3GEO7[Q@]:A9%MB&MLM-#;.4SWRG+U+A=9TZ/>OS_*)QV40D9N'O$#0T
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M8]?*%*GR(0/=0@2/#%S@-80<AE1URPR7?7FN?M1ZNB\7:/(]/4_O]LI:3%A
MEZ*X%XQ 9B\UR S.0!F;Y.OMH*>GH&_2</J!Z'/20M#=8,PH/Y$U2A8O4/.X
M>YS"5[D]5-/3#6'6SD:VZ1E#;T5X45;RS$=5/0RBF4YI\RH9_S::9KYDA\58
MA,>>5]O'L_L9'@R48>_6V'9PK<M4R',Q@@@<.JZ'."B<51"U5_<4ZQ/+GNQX
M04@7#&^9QBD@HCR<EL,I#[2&J#%>Y#DQ*$L^%%(1[%XA[!(][/2T"_:]6UH&
M#WZ[PQMNNZ7BW_J  W9XCG#MM4S3KMS!=\MKIC:Z@ML\^S1]U".&VD%FU-YR
M?L)NOV;S4-,?H;OX?:(=A#?C'J,V88=?PC9P+.7V]8$J4N_EC;";U=#7+1NZ
MJ83.LW)2"!H[XZ)Y]HL5,L("A9K3H-5I;@]!<HKCM*%([DC^.MP7C-VKRUDE
M-9L)63.5E!+?9R$%LWUVF+TT]1ZS/"S1MXR(HR6%:1M8(@./$ON\'H>@ >5A
MLV$F5U/^F#5'/WL"EIR4!M:^"D.,:8O4&R7UB@YN;BYY<^ZN+[Q[OE#2MTH#
M1K1DF%A1&],U/6A@90K6M'T/?&BBSL)EV7-4QDG(NS,A";N@7Y==\[98%B'
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M1D8W@R?D3FL??H]3A?9'(^I47VTXY7#<Z=T0X!X(5:Q U'<[](P0/+!S"U@
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M/<BMI.I>8?:5\AP/*]*U72#-:_SJFC*](J7UF&:W7((Z)Y]E:$R3B!E0C Y
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M:&B%Y,O4'"I_$J'4]+BARM'O%@ 4,HO<N,AL[0IJX.</Y:F?T>\QS=SECS/
M]E]D 7 ZGQ3#],8&KI\-F+GZ/8O6I:(-G_MBKD(HX'H+T"GE]%RE%BTI*RQZ
MGF<YWEF=K=AD599Z[2Z0B7,M%M-F)-@P=G(1:\?^Q%S!CFJHTD26"G;8X3:J
MJOOC76I#5-%P,$/???,[FTTBZ^]R</^_AY'Z#PS9_?,Z;HA6W4AI0:TU8Q4\
M=N:Q99B<B%?LW=-GOK5P@OLKR,.")#X>^YH\6O2\B$W?DK60;Z9V[42[$/R[
M'Q#]GB#./.-5WGAU8W@NTA1^BOLS71@9<-9\OO:KU<?O]VTR?P1M[__KO(C
M9AI(%QIMWP&.+XV25XR_(DJ^D)L+XX.<OR3("XZS+NOW/'V)MVFFA-QO4'?!
M^[V_\"O_@I@< Z9CC"TX]VU"5) ](\V;-+:W #_M:Z:_)#J+KC?%RJ\RC*6\
M0L^4TN^NTI7QU5'SDLQ?$G=G*7'J/GMTR3(*_.JR?XDQ?0M82/@%K_V75&4Q
M6 BWI&DC:<@H^R:^ #PH-H&\AB!4_V(_2OUBT/=_P"7[2U_0Q.]_Q>SD<!^:
MI6!E%JRP6FI#1!C=H&V$RYY!#:E^5YLGI$30V*GZCYC=/]M:L!2J[*SX?+\S
M7?AE)! EDCB#CD&T\?9.=9Q.&38=1'L=YM*@)98@+'/[N< <"&0\"(V-/.=5
M,&&P6LZC3H%K9OGG]V.)$@<5,<.MS.*X(NF8:/V(%BJF/:UIIMY,4=A+'742
M709,CIZHUS]ZDD?4=%123S87[;2E"BVK_]#60H@9;78?9>KDI*@PE^25Z3R^
MHR4^;7((5H#TLBBWFJH4ZK];C8FC:?!+H)+#G0?* U)^P29L8%!Y:U'GX92>
M[]FM2X5&9:V,9(S5_F&]1<>8.MV_N(@YN7MZQ 8@X('OX *$UAH12NB9KS?2
MS^P&V!I3M;-P?$RSA22NE0*\N<DTN@5D?KX%*!_D_+P\O[[NN@0'VZN*DX$M
M)YHWUH$CUTQ78HUWKR(N9.:2_B<5=)I_3/"?/@&=_LZ\=K\S]>R5ZW4Q!YW>
MW='O[[C6_;$B<1.5IGN\>6,)>,?O3SMEX4S_&/V?.5H>]%HW2>F#(:>UYZS,
MZ"U 'O+GB ;99:10E7$WZ-D?EHEH=&^O,>-_DKU&CLLVQ2PLX)\&B'S_+(AE
MO4RHN/\DC#1_$D26=^& MC\+H\R?)7WVBS\G\D_2KOI/D@YG^O]\ LF9G7F=
MN;MG]?#75V'-=_=E/@L'_%])@/YGC!9%-35#G9VIN;J4,A.L_P3GC8KQGR\"
M_[],(.$ L42*_:*2Z<D7/^[7O)R[X^GP3YI@Z*JM\?%!YMUA?]K1ZB!"B?G'
MZ/_Q:#PE^=)'NQKQN3IPL,C,SM2=4?S;W?3X(_K5?SWA^$^:0+^OFY5UK:XA
MUC2$879O+MAS;J*3Q:6>Q3JOAQ6PXA.W^Y:ZIJ7#P+H7_%"0BZR7S-9;5V_#
M^'^CJ#&&BBB^6;9%=3;Y7AI*T'X+\.+>W]W7)V;C^?DCW)5.C=G1_?5?^\^Q
M;__[ZYS_!2:HYOE\2I\A"6:N UV(=QG<,*_]V2BZ]ZN0MFC[#VVU+#P'.FX!
MA#M^Y",G^0>GF]6)VTLY;EQTJR9F^\^[Q!(VQU;!-)+IW"_Q\<KM9ZQ%H]%9
M;!X(A7&G$C.2O[ J6Z: 1(CA#*?JCD+[^2Y_H!OS/@T3P'H9&<.&\Z(M&_)R
MY-HZ7V'1FX-@NZJK8,:@/:^ALUM;A)ALK19C 37/L2[)7XP>D8+R9MF8>)(O
MH]TSXAZU)T:"SB ?)IKY*3%_-&[H-8OU4@Q.OO_TW DCN0^NXV$GY5?_']RA
ML[> UG="T2@;;W.$910NW 17GH^L)Q:!O9N7W:9)8WRXE_6K;+]L#QD8F#U]
M)AV56OO-\<'U<UX':H3MRS&&$2A($53^):+?Q2J7EIU[E/W!V0]E^:.<9Q#^
M793L_F4680KA+3R2\!\O$13FJ)X]%P= -JA#NYYA!O1*3F=R6Z7T;%C\\8I]
M%(S4!!>FH7;&N7X$[3H-CQ9B\+,E;WJ!Z"^8;GM#$\QA6L-/@.HD+'X1(A(M
M;@&(/\9!=,G_G%DF#1X>4*B/U]2 CZ4/_Y )D=)]6"']0WL-Y<-:A? )1 C1
M\V6+W*(KY'YTLH4UQ9R0[!.X;!N[RN+B.T$1[Q1PI^*S5E'E%CW#QE*M<65G
M'C^I.LQ1%A'A"@Q40<;#_**1N'!#>X42/1S0U/1"V,+6 GX#0XE-CF+%>';B
M5J;I$QF5W<W2;^AG+1M0*ULDR^ UQST%B V7W@/<[@+6W3U\"5/1PPY/R_8;
M#/E!GS>+M2Z*8@O*GNQGM3 )ZMTXJ>HT=XH84? 3#1_#^V=%5^*B7SKR9H7:
MR'4[2AWX?HID3;:>"D<LNO0S2!-4Z>LVU]2:,K\\M#;:\MVHW!1[-G2M:'-.
M3GSM'MLI[IM5\D3T1>X](/Z.SK"/QH&Y\/4<"*^+(^Y;"[ND^XJ#1'0C!N41
M2_R!3 A'M4,X/W_<-O7C@+6 G+KAZM20V2! X-,W"8\?>D5:QLAW(227=AGU
M#SG"&<=.KKQ7;(5*%9S(8K6]Y>*K#S,_J9UIC,V=:.$Z:!YUT*<V+WHEPE>:
ML3W<>\@[RXCKOV</<Y;N5T<&:DK0TJC=M[8F_Y$.L=[QS9GK<K=K+_08>"D4
M*!3TT[;UYT^HJ/,*?YA9^,3+AD;=//R.\I(ZLC%8>8?!:O"CB:PM?23>$"\'
MUK1'KRV;OF3R:F6B5-707HHD2"ATDB\V 97>=8!ZEB"'F.H4T]3RN4WUQ($P
M2')9.YC-@9UG87?&I2E2R%\3QN+OP1&5+N,\$=Z#$%V.,NO0NW_SH]'SK"B[
M[FBH(?<U^Z!3,&IMN?922- 2Q2T@^#)JOO9^?.]76?9R=B)2N(%/C:AVM#2G
M7!EPZAPI9:B.;)9!^D/5WM,]8!AN'RE1<Z5=/;'>O4QM)KV6*_'0;^6#UQ$O
M3-G3-\GJ7E?[9$>_E";#'Y-9,VB"\'= <#>QR^=L+UWG2F6_RA$Y=M4\WW,F
MN#P3+%..N04<T4Z!)Y6 -\1LELJ+X#"_I\-O*L>NU4UX>LP,>P@^SCABHK':
MUF<MIKA<:!"Z7<3K]H_%19UI50F+TBR3I +;9CB(;./8WG/3L!L6#]__R*4&
M4%%Z8!!CRGP6OS* ;5OW=:M.NH1J;$9F_?TK'^).OT.R 5'NE"4_!@^_F=8%
MM+*3B*=ZPMX?@F2EL2+E6+NVY5;@2F-^$]+P020Z]"S @E+OT^73'H915:9D
M>);[Q;>>3B513E$6,5G>[W7U=!9:Q4DLL/"?FQ"Q9PBA-C7;1V7OB&NDF5M4
MIS2" A_=9Q;RFI!\EF=!DC(=--?*.H85LN+QO-I];H1XE1KUX#S(H0G78,X&
M;TK.=>V[ [O%S/H,3.<9V5':?3HJ,*4VW4UV,?]/Q('@Y^E; (B5N3W-T\CH
MIGDO#""6+#9FU,HVY>)&MZ,>OAZG5U+B5U#==JC0$C]C.$ "IY!YFYU_\]W?
M7X>)%M3W3OS".7)L9X'2PUUIN)27I5^RKWK4Z4Q7) PWN=/K?O>U.(03$;1T
M]SZPO@5@\NRDLS\BKGM*4S7;3B3GZ'2\%LHVF[9!''_X""F['PC>R41V/^^,
M9+ UUGZC0*CU4!L6!FP_4^3O,B(?&[XXN=%[;#8R"OT>K*O%>SK[[9[ -G=*
MR9M#[I;+Q"\POI15;,?]2LF<SM+Y@.27:2O1GBM44J:(Y;Y6L0<(,+T[^4-%
M:R=6E51O-T[>OG)=GQY"M( 00<$-J&=S3/ZX/<\"EESQ9HI;C$6:CB1:ZCK^
M=4&&W][#JPV(@4;K)T;HK\+F96;U^0G]_1NZF5.'QPCPR_&GPZ>^<FSLZQ$_
M7L52V ^DQDU.B^VXBA8W91X2MGKE\JM-V;K]3+0R3ZNQ.F.BM;_P[^Y#B9T-
M,'(_I%&&C?F)>-CW7G*Q-8Q7E,9F1(I,*>%"-9L.YB/!5CMLK-:))04]I)_/
M(LAT(EBQVE8IS9@?4.'ZY:?D85#4[SHF/BV.EV,QZBKU\.[4PPB/;),85=O-
M:HGE>\&)T41V3Z81-!'C\:YW1OXFES="E ]SERVQVY1,XRE6%R$>8.7Q!O%/
MWBC90JA]@11Y7)HQWU8UD:J4N?V_B43\?SL;Z%^#SME ,HTZF!PRC#H:&4A'
M5#V,JT!=-?HVKGP&R_E5&P2YNEY8T?YG ?>P]M$4"$_J'-(RG>\BV?E*7_57
M%<[$#=+A5TG.GXEB%VT@M.AZ8)\Q.0D(A=)<8AJ"%];_4%'T.Z) BGJ\X!C8
M(/BO<E+=M0%S7[7]@]%_;4;E7:UP[MG-%Z+?AU^WKOH/<YFBCZVD+/XSD.4,
M;;5W[;D+TB I^!\2*DJ$7_XCH>)7-;4#^V)%5>+VD68X9I)SO<N]_'+"Y=GX
M@O?9.E5KC<-A3EO0#P,KVIC'<G2IQ+J#V<Q%1MT%KA!]'_GT:\$".89 <#EA
M+_?&?215UN&$*#BDY$Y/_A2/#%*X!?C? FZ\CM-)#%]2V8R=@-81LB*Q9#UL
M6S'RE_RODW1]GQAKP*#15PZ7-7D,#\X%5@[Z7376\W*I0P=,-%G[4G0^PQDF
M]/5AH>G/HNY>-%FW %MEW[.36J E7W?J R3;5,]6S'@]&-<C2?F0+;9F)%=0
MB3ZL\S%N#1*Z2H/O +V"X%T8/0D&7>?= F1"N#^?92YC-/F"$W01ZO0[*[0?
M$X_F,8[%MZ*GKIU>;1U+IC=*A71Y4^JUJ45E>^ON^VWD>:QT%"TVXU#I*4C7
MJ[[H6"O9W<EP#MK2:$ Y1!_I<N-WEK2S6ZMVA!!V4ZS1/:GJRJ8)-O-QNP7$
MV2R<7I B^XTDG?ER#@Z'#5EC'9:QB3G;;^:V^?'WR"C!C08R8QF0 A_;RC$1
M:YQ@R[SNPW[W,X^]AJ60QYV[-5L+95I0Q(Q8MI.(GG'0*<6*_8PYWYZQ ^/C
MUC1+](9]R8,5A.6R91!H[P4[>]RCHD^W %1A&.F!"I!R+#/D/(.K>A0Z@'A9
M?:4_-\PQ+3;X#;1VML(JNHDZS!L3,;PY/BU7>]"_/&<C^QT6?67^DC*+C"5.
MZ87 OKI5)BD(XB.'$P:Q@J=0C;7<HZD^,?5"_8@Y(.ZEC7^(#GKK0.+QU/#M
M/!FOVT/S,/WS-]=(= D1E]/BXSE;&GPQUID9FT%]:W<AIK=7G*:ZWT'U#Y7G
MZ5<&S5( )S%DU[I#/L]]7#:_)*F-:H<$SD9*^SYN]/7GS<R]-HM0&3G5M>=A
M*5&($AJ<(TM'Q$JB1'[$!'+N&MP"OND+*[Z\,AC;;QTH8>WE[^FCM8MKF\U
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MP!NPW'4B+.=9GH-Q]WJ[E,#"R#&/607\ #V^</L\I;.^1()2(D-X)EM0!?<
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MX?:56K*'9IRDY^% QHXK8O;D??]H9C\@F?D#8U)//Z'$6W7'O.9):DC;#2"
MV)_Y<IVM^7R_%,R=&%)%1=]-1UH_=CJZ-K<@8B"/^0J3GAF/Z)2OFD8X(K:H
M-9[:<'I!CA#_)V/Z^O"ZKJ/;Q8!.6W4UP13QZ[%?I2_2\HKC[0,E/&D%'\/"
M6IZ] %[%=R:$Z*OHA#Y7C%H?U?>+\'/-9IM05;79!7?F/N*.3;6P\D33KYGN
MS&I5PKDHYMJ\+<YI\>3K3Z0:O:;LFG'HTD>2<S.1CZ8T$<8AE@CFJ$'2*=VJ
MA+<E&@=]:H3CIR4QNYT-_FFP@DJ@_:7P!RP7YP;&AJ@N>WYG$??-L(O"VQA<
MVQ WJ@/LXRBN6L7=<#_GW[L[IXW]1(H@RRI5[3R>@9J#]P;P6<)"1JVIVG6G
M61L4W8_45IA "0&+D9;>8FLU1'U,\2@' /.#W'4SB5 H&CY6C/1L5\Q'L52-
M5.\"'\?:'NT&^J.ZGW<LI??"-OQ7^6'@$M!:;<3,]^&#9/ 2)S6],!GEL,%G
M6;Y&=>%*%4.ZL 8-UJJB@Z*I/JCKT; DK$K)UNC1L=S0!I-BPG6E_SPWH<]+
MHV!ILGB%B*SZI.9'"F%"#W]C0RCO\C*^!>?J19 YPE_TM#S+AZB8?9Y?VZVG
MMEJ;855W5B-QC;8./W*0PTUYXN9); M/>]$'PE.I4D?B!SA?7- O$WAIR1X_
M=MIC+ FJ$_:J<)GH5U#PZJ,2[N2?G=HG.^<BH9DI"J5QZ+4OPM2/]O&/7%5I
MMD&!C]"^N4C'_H.AL=G^&\#^75X=!MP-YO%4WRD:ISGQLS&WS!6?^%409\]@
M*_]5>!PNZ'P=<-DH\V(7JNQ],NS1-2Z.V\Z'V810;N;,)\4.*M-X*,)#SD+7
M0:\WJ1$0T[* XY!0,!?O9<->VG)O:PKZQ,50R21H5ES<U1%+\OPY-P1#)QW#
M9)Q+5-?9(5_A_>23+]32B=$183^@15C8(^D=S0C9#@N$<7 Q%Y\84%VI6I,(
M.-I1A=,M )AKO!#<CE38:&%UTP,3V"1 >8\*BO!MMFIQB5'ET>TUV&;B:N+0
MG%06*MF9W$)T$:MT[B HK/2!GB[2#UY3!&5]DS2F^_.%2G\CFZDV=@D)(Z%-
M.MPE.G-KJD%Z,?(!O_"7L*ZQF=<6VM3&&-^'W ^16NL]?E7@D%E0:\A'V^ZQ
M:B& ?GAH'2[I@P J3*)N'-$P!W7K=.R]JG#9:W"71U-RH;[/$=MW'/YCO/<Q
MTZ?HCYYRW0I*LPM8WUDY-6K%V)1B@!\+Y3D#9A8Q@5C"+U73844PZ:D@DQK^
MT13/@+HZ$W+\;X*8< =,Q&Y$$YV@X%C !E[\ IC7L42N_X5IE+V'YQ0V-UBJ
M0F.3S"78.B/$TO2?48P_20]%WQ[0?+G;2BN[HT".R0Z9/3/9WA\]B^H1WL]7
M*(0<,X7CR02%6@(S58WX_K%80\D&85 #C3C)&%^SW1IP.Y^E-_O1*QKO]7Z_
M'T)KJP4:6?&PE@"'3NF:[.S&- NRP$RWX0[TDX:&VM%JP8.L*L-QD-;]S(F7
M *(#W")DRS,W;M ;7=E2_:30>YB97QAO #7:8(@>5-Z%][QJW^>]<YRF[:#,
ML,IX5FMS?02>7*SGSWU_C"F)3;Y!:81*6ZS.L"M=30"U8X;*O *EW3)MHRO1
M 18VU:Z\C,I[(8TOAEE[SA-:!/EP,*%UV?:X37+,G'1^R;6L=3K!BUQ&W^/(
M-)]SX5_ 9-<(%$_!C/'"],Y(<TM:9+5"?V_YIN#ZIR%[A["-"'F]<T(@WNS.
MII2TXZQ*9RG.KL<7%V&[2II$[K3RS"Y&S^%OG-](]K6JZ6G<P'(P>L6),[E]
M.WCHX/MXRF<&5B*(VBV>&+==E1CM:O]]8+6/A;E/R,8'-(.;P@U N;ZE!K;,
M?_Z-*FDR*H\%8]T$MP_NJ]TDMMI,TO5ND-/7)]'VSMUW1-&Q0MU2 /<V5+Z@
MO%U @60C<W@(V]=)'P:DXIL)O0XUV/>(=8*I-[*QIJ=F!:_$NVNK?KT>URP+
MN5"JC]B8-?VZ'ES+YN1W^5"2-JB+@%MA_V[J^SUH=C(;1O<BH\I]-YD+34'N
M[I3'ZB@U 3RD5>P>OCV4%:$2@I(X\I2:3%>W@'%QOAOFT>^ZH&6T3W%9-KFW
MGQJ2-QY7;"X<GZE\L57B,4D6F[<X+[D\U[B5->=$Z_>SM(I&,"S*8;S8R1@?
MI>V:CQ)*-$3P;2;##GF4).(H/EAS^VC0+%M]&^24@?_4SR=CHIC==)5V)/;2
M/-)XI__S:D^?4_+E*A6>_9SR,@5;+YK=*F^U@?(LC=^0XMI(9%I?Y?AG*Y"
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MM7:3)UT)+.OM'39C<ZD$YEK:4K$R,4T\RPB1QDQ'[/\F.'!FIH(\OP'X:GH
MV#XC7T@BK:SO8 9G8\]M\BU.$=X [M\ WHWSX0U$XKA!X=(!Q^J\-<4?$E\&
MBBD$BI+LGM("BLVFV$)=7N1EY>3$[T.ZE]:TFX/7?GVK.I=FE/V>X"CQQ3WF
M ?H]87>^&_:KL6HN(K?V$]6RVL8DOL:@D7D91AP!DA^B=YWZKK355R*QI5>N
M!XIE#M!PC4DP0/>0\P7N.S=-U0M996X/EVUU-]L.B:.(!5L>[])]^MG$8R-X
M_\RZG=#<Q"9=D_?S!6G+V*VP3 5E!35#?=%5V!5<"@F&SX$8JUY.VXQ+?L!(
M[: 6_GY?'@Z($=ED*;;;A>*,<(@3*=<DU!P-@G)3OC1IW)6U3V*L6SM8,Q?L
M,*>]]U%8^W/Q'@@E"?86;*Z=XF*JC^$A7V*7.#H38IB*S#8?/-K4JAO-'ME$
MA,\G2R2,=MC!\C>>H0''FYP%#CU4-/;/F[/T1^?TH_>R,JVHM^V2;7[N.Z'%
MT%0W@*FN5G2H A\'B=:HEVG13J(X62W",BV/+/J]6;A8 YQ.1Q8S2HST8]NP
MZ82Q&\]^.=+"9ZGR&DMN25S9ZU<(EOC%0*KGA( X_L1^M>+N,!XR ?3$&=?K
M.M2=0VU==.R%H>M#C=0'9ZA/=YZ'P%K/'!K4%A<:76H-";AO %KCWY!\3L 5
MMM!KG? ;P/2&X@AF#=K<8L1WQ"3:=\=SHU%,Y4<+<<W(BOSCVC'B(;FUR'=?
MLKB[5P((DV75[(7.:!'!Q:+W<J17O*6D6V)L1_-_CB\:".$Q5I1C0V@>/,2A
M%;S@@RX1GM&^TIM!!G:>V'A(5[*2&[^7"VMTJ));7O_4DZ-2ZD&S>NXR89,Z
M!A,8Y5+9[>UO:4I11F:N#LRI)NTW"5N&F4MP?Y+=>7[QJ8G^VZ*7>&7BN_'B
MTLT),QY# P,9.GFJ/I9-T;"/E RW&#9Y*; ]#RK0@L"L97MNI%N<J<<K"L#I
MXX Z17P]U"D\NM8HJ_#F>85P7@B(VE.9,9IAMIXXTXB*TG"^ 0CU#257N$R+
MI<;5IX);[8HVBGB;P5WT]T'%'%1<%J-G6GA@)Y8!;]*W#M2IUY_N/#:5+2^<
M-=R(!\.+:<]:\0R0QMJ_UEY06TC9?OS)OY*&_5,6_/;80UO%81G_!=)59:RJ
MKX1W8_P]\>Q\^TRTL1#[S$J%AU^7K.WRX&NX3EDK0B7(6%?8B8HC0Y^W5C.6
MWKLF1@<M=39P'NUZ>0,P#-:P3!XW%-%7Z3D0++YWR.?MV9E<B>00E3FVX=9W
M'U]X7?@ ^*G</W8Z#(KRT I()PQJXE@AI!R:U;<^;Q3]Q;^T+\\U,X!UPA]O
M!L!^@'7O8Z(1;E,-[)!/ L_VV'K,N"YF!\,FMHO!9/US*H@Q-1:J;+,9V$0-
MS-B^^B+@U%=@8!,Q"'&PQSX\QNE>]+67ZZG/T&0 -[:B7LB$C4\-&PJC601
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MN2TOJN^J]YTD5A)]S)X!._8U.P',N9P VH;^X#5 GP"4BP,VJTX "PBV_(6
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MI2X$)*N&[Q0+<GO?T*4F>!JN;3X7+D_N>Q22J'$0V@EUF^(:O%X@]HC.2!-
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M$FMV!!TI;E"U0\NB"\S-)N9@/H)9SWG+LCRAY 65VQ4VF3N^1C_]O@XFNYX
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MD_5&)@!K@-)RO-HO0 J8+B<[D6&1^"XEZ.^\[Q6ZB'1W"BPAJ',77$3%O4X
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MHIAZ^*2L(;P+H81C<AW@=:61JH"N6;I#>/WRFJJTK4U#G;>6FG);3/=8QX"
MTSN@W9Z EOSAIVRL4>6EIJ;UR;+<U4O61&)D#5@P4I??:%<R.Z$8LVCO2H-9
M(L\[EGHH?ZRH#UW00>2/!=]("T-P/=D/HP=2R/#*,.";WY\55=0K2R(:%?%Z
M"=J?)_66BHB>R?5!/L+0_>+NMV8'ES12Q>]M%0OJ4,'A?H8+C4@UZBTGL8/
MLJD]D1I.'^9*??A&='J5>Y]2B]N AT_^.DYZC-0T#I6V@Y4_CVU%;G$N P#
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M,2?[]>58T\[GK+=M EZ.I8F=JFH_7D7_@\C9CVS.OL[Y<&"4]O>RJO_K5F2
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M@-R W(#<@-R W(#<@-R W(#<@-R W(#<@-R W(#<@-R W(#<@-R W(#<@-R
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MY7SZEHM6BT"ED](=OK:AK=@A ?HCB:V8>&PK&+IX^# K5]R3R/.(O'6?3Q<
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M4S$[-+SA'V,K!S09;"&WS#M*G@E/[KPG;,Q8")6E1TBT@(P/"_5KH;V7&H[
M!MRMPTGH7P?YG&-[4ABK%P^J?1-Y-$:_9,*F(%B\HV(:.H:VEOQ&K 7G,=F*
MM]YSCYS@1OZ!S[5\K48F^U_)*H6@A^^>X56YA'%\ K+!ON)$Z6N\A\Z3G!(T
M'^C[6-#4[,WT"$LLM\"KH7I2"2[QHI"4KDU"&ALF>/]%-_%7FW:VS,C48H5V
M'^KSFO1N864TTA^[6F3>EX//2XB+*XW;!AJ&A>'NU=!51!56Y]@Q.C,Z^-+S
MU1Y[F^OH%P0\&=W+ >N&-K@O=EN,P2I2J[!Q!G%8W^5W7GHUK\$5+-I 3]U!
MLSUV-H"9Y&<[[BX5@6D;U9,%C.OPSG<5@&.Q/0I%%JI/<_@T-S/[M372!]78
M745;7,IV3!>EGGXQ6M TIY<1W8$1X_E.11XFLXU%I(QE<=_#,@_=U70N_,),
MQ[LL8# F?/MMBPF33]$-)K:""5XC#"1)-%YLL,T:F=1QL6?5 \"[3!)MR2%%
M;$L!D.A/,ET/RJW;\FD^#V34^(<E?+N_\,1O7(9^AT0J-/I)I'%<>L.(GW-R
M2+9[CXVMWFCT_!X,O/=[J "+DH#CB(.ECM7Y-HXG!M5^:#NLE]ZN7/3:+&$]
M_#R7[PA&H7JP[6C.]JSOTJ':RO0=769J23R3=[VIFS:ZQ-T]C^1$:?30WEBQ
MN#$YS=]!5;8UQ!FQW<1D(^,?1VP86T]XV7@[/>3Y]O/X"%,V)$Z^N@DV"BNU
MU;@+0-FIY^0H,^4?,YAF^IG\NOUR5"Z!6HWO-R),.?96RC"U96 X?"-B7N?Z
M&AUKGF#[\7PB9A.S+WX&'O9]FK1:5(-I3U(;IY4]]2.W+6O:*E>UJ8(]"WLV
M\_M^H-L:_ES%>G>7)=\]Y,-7E_)=U63KO2O8XLI!S<XYDOR,C_ ><I!MN;K&
M[;X%-Z V]%"BBQ.WZBGYP/AIODW53-0A3HC4MKA6Z0,AFSL@HDI1^!=/I&GZ
MJU87(<C9DNJ&^$ 23>^VXQW'V>50L?XO>CW]\>6&;(09]$2?D#:>S3([%,SL
M*Q)G?A-.:TC^=ICE3]E"\EDF&+5QYV&V</V'>/FA(66UX@C#$E@!Q-'2%5&C
MT^>(*!_FM1"1O,U<[_82-=6U$A#:''>QZ1(44HKB>3AUZLPYYA:5PK;0M+3K
MO@9KAL6S%[_:.CSK]+>CQ9/-K/?&-4VW/&,:ZD)XWN.F!\_F9Y%D*0M/S)92
MDVY>,DR',KBCIM0$FL^,H_76K&$3LZ4GH<K)>]V\]:$_RE?MP>@TLF^^&$D_
M6OU85H\2L3Y2&C\3E[=9)><B9>+[NUEM1RWZ9,667T ?"W3T>C"J8B9K[@0B
M=92JO2GXY/&(4(KF 5-ZLW.P($$@SY(/P4>)9?/&>^/HBH%G[ZQ2W?0>4*#O
MH*W-0[3R8IBS7DPU.0SQ#DECM7IQ%7EJ,Y-*ONSTX_4I>#=?&IWHG*Z%P?>F
M<[3MJUP$TX1]]?@BT9&^N7PC:D(O%.J^PN(1,>]0R).KZ^$;521([X9$]['T
M?>10]2"ZI+T&)H>HQ3<*K,PL2M7Y26E-> <':C1'-L6GD@4M5 E%="QFYM0I
M%BZ=]AL[O'=BO#=4<K->I,U7.A6F^<8VA#@Z10UJR3NO6\- ]OI;>1LG$?2C
M)[\0UZ]CQ2"RO$BCS[%+7?_BS^<R')S591-?B4>P=C1M%M4G^YCZ71^A>51S
M?;?^=).?#Y.\&:'QUY.*34OLCP3S>E+14O,+J)L)S XXYDF6U,R, V5N%A8S
M[P1A'I.;/D'8%]&35:\OP3L&LM+G4D6@6H[:21N_(U!@LK+FX'QHKBVN3*,B
MT+>U["H1B*B/$6F3+R1B7#ECL.%/LLW17:RO5^Q/6])?()SPY5N*(;O+F]#W
MW,%<'ZT)GBVS/KF#R-%!EQ1- [PSW1RXJV!E^I[P6[P*5PZ;'X$.'8O-6#+G
MF]I[%@*\H8I)EB9VZF!X.7&E6ZCJ=A)?#L,S; 1\9HL_(>O,J#4RDZH*]KSE
M:GS1J&M)/.7.Y9R* :XA+_IBU?N@L/H$9ENCE62-P9BI-9N.?B3,3O8.6_[B
MEF]3&$:BEO[7),0+P.42@CNZ@L_JBKZ 8(H7+A,,0C/4,*99)%Q*1N(;X @8
M03)C<7]8]HRXL0&=+,M?/\CQ=D&?YMPH,6O5\E0YWNW!=MTWQ(<V;&8BPP4,
M&Y-J!*8CDUCL'P-&TDXBDZDUQ=$/#] ^S)]0J4JPXZD/\C9GRYL412[9%[2X
M%D]WL^'53+X!ZFF*,V2L2F%.LNW!RN^^MF3GU1$3>*BM0]J7^&@*YM.S&MOQ
M7)BTN2/NU")_PB9F;VE'SF,;%&ZLSQ)8!/M^?B$ZE/QWRB5C2P]TH-I!R0ES
M$\:.U+JB,:O$\H9WLF5V]4.VNT;0*V"JI& YSF'' AP?G#SV;QJ6IOP49[/E
M=V ?ZV\G3"X85*_[\E!5>X"_4G![DX/W-)!SH"!)]2OMRS@-M-97],[8J \C
M[(0T<>M]97D^\R T[CRI%$>^0YI4@!H)LGJUZ$4=4,SI3[Q:^-Y=YXAND( L
MO8%CD]!(6W)/LN3%NVWWPL"^;DQ*$O)&=BOCP1.A]\(V\DT0ZZ5#3K#DTA<W
M+,(#888F6\6.#5:CH-RH7#SO@A?Y"-VF-BUW!^3(-^&,@4:6DLVO*8&V2TI(
M/+A-F;SA:;YS*;07@/!:Q(2&)_1D PQYG_-'E-"QR)JDS\B%DKM@, J$PS4L
MGRA&+7W^!F;O0ZQL-\$;LZ8]W.U8 2)A!)36])6,V64OF\%94$L\>X[*SQO2
M>4_?&UM@4,VX2IKC<1Y&PTQ "\$(UZ[W)Q#AMBE[I,^;$=V#^SU MPW4_93L
M.9SF0G7UX5U.=SX W:W,I*2&%D&:UP&<RSK 1QV(6"P6L7U=>@2CDQ,UA_NK
MT?J:*27,EJ+B$>;TC(U4,)1BZ7E3%<*B+QEO2T#Y/S%NA'8=X0::FW0:O9>]
M+=-39UL5UY)E4IYV>[B?=80#%6^PXA4)M( ;E96YOZ>O3Z7IRU?A?+9R  #@
M)5M^2-UP[(/=KX3P%%?],;.[O3&75B WT:1SUU'%@=+K$+5V.8[7Z(S0+RL0
M_T[?3^D7 +$GUEQY'.WO1>[U%G<S@]2UJ1#O;6BF"WYDS.0PX]K*#W2X)1!G
M&.$'X::J8*A5.35?4MRTU&P_]L$R+N6=:X1)*TC"Q9*J?T\=/<?13,)N(IPS
M/J(UOI3\W&-8J%F/ Y/XA 55#3A$X$A)C<EI]TT$(RT=X_4&J[#/WND8%4=!
M=8+ERF.(7*?.+,E2])"69U7:%-(XX;1A? )?$:,-E5+3Z<O1.]BQUC3^J_Q2
M;&\FX?!,I%$65:5)G%Y*J#U :YV)&SR>P>LF3&AJ09\4E ""$R5F9 AEL+Q6
M5*0VGW5M#58>WA'(>8JEN<-6GY@V5]G#^!Z[&^UN,&%\_>.$VXM"969<>&I#
MS&[Z1@00 --0TVW<#Z\^:#7/\&E,=!1MWL="(<G??7V\M=9&T\GH5!*_6]7$
MR/3<NY&^687AM2%NGEB20?#V5+O%KJ!#GY*/!CI?N:Y^=$3? MD[&6?;S60H
MAD>.1XICI<X(FK*_VDY]7?XHJU^ J[S>V&BQ<]A=H@[$V_U*\8.BG"6A@)TZ
M 4<I]ID'5CG26Y]3GJY;ZM$]?;K=2_;U*]4% "J\OF]82[^H%JQMINL RY0C
M<>P8]O;E0$-^7BCAFY3G'>D#4J%(;^[BA-UI7G"+KHXHW/'?^KY+T19B>7*B
M;:H=(?!%9LG4N!*O6<9>.ZFUI4*,C[U_1/U0HTY8<VEZ)X$E:G(XV\%_(G2Z
M<=#<NO\,-4X(^FA9MW_FH>-HR05 R060SYC$W?V$G1C=7==<:[FU.[/=2.,T
M5?_1R*(7=+8Y-2 15VJXE*B05Z<Y9*8"RT;W>"VS8ZTFT)4SI>F^+:OY5O07
MRVXG67$_DT.O0==A!?_-K+6D5_TV#\)PDD7S\\W#+9^SB](XTE<TT>T-)W8'
MQROZOXK0-<WY["_#U-P-+V_SF#1[9Z2_M!+WQ4,8RD^584\>CV8H2G#%R#R/
MI?"$96NK+\BA8R";F]G^].5+8L#*-P9^A,(6>KO[0ER6WD.J:AM$6B\1T)&'
M>WT*AY\LVKR'(F\4QS*+],:RM8>FX$LQ!\(^"D65OO4BS>%<R'4B9-)A2K&T
M_ULQ_I&Y,,/!P(AH-=D<;[AF<,O@E( U"VE9J8V<[:9"KE5O,+-JK)Y)75V*
M#*U'P>UC3@;SR'G?0MC=0C@1WSII&E'AIT^I%D(&0@/QCX[.G"9']\LDZ0R@
M.'U!HFZO33A.C?L:/[SJR<]/(_7,;UC/ZG+C7QF6M>ZVHG_04!74U@1);"E&
MCV]ZNT O@$29+L%@M"G2TC!\>I0C]64NXU.-* OU>Y%4#WD.$"$BVUOM9'0.
M\ASD;+M[N]3JF/FL65[\?OU^MS7&<RL*XO5"Y'5995TZ5L+*/MSB>>18O?IB
M[DM.Z62V=QGAY]26%QQIIE7-7)N'Y'G@MB@0;5=465I.8;GL4GZIZILW)@_0
MN<FPT9;>=0Q3Z'*2;'JF->85N$\O8D#A]*4%G@#(R4.+M9U$JPF7]U7LUN,B
MH8\IY&B,W[V++D.)SY>6?,-'):JMKMP<@\_K]03OA8".4=9+"=OIY1Q#.9P0
M=R%^VG;F.1,-#_;/=HJYK6"[$.Y: V,']75M3S;,ND++6;76EVZ4^4Q:^"UH
M:</TU9^280P.- O/SSQ:%U/*1F: 1KUNV]8VF>]=X8[!GS8V;[V=)]A6',QI
M7>Y(=KQOI^P-PBKUT*@:(3PL"I:BU(TLT+<(' ==  (7#R\ ]X%&=D[2,&6*
MM.^<0^=S>0: <\8"9U\S+*T]ZC_WZC^KB1-!L+7=BN'''U53WG/'$=TOB5@H
M#*3 RMWM5L]B6NMR?F5+\Q)"\8E(P ^VI(L!Z]S*R6;5-SW34,XP[1@*%0J>
M/>Y!N)6JSUM,X+:FI'G7$RE J9JJK]VJW!(<JI#-U%TW*46E8)T\QAA#3M$I
M]KKGR;O\,@%PU[<MC_',A#)A<D,,O;V 3[O1PG$[\K7<']Z9\-;(DF&2 I$S
M]3*3*+IG-*7:'V6E:4K)&RCHV4I3&P&5IXR)=EMO=3]?UXW:K?XV?CG+O]]
M/)W4U;7H]"A9S=YB2CDG'19M,L_D LOP(<0NDH?%6S$YI"]VMZ.H#-?'N.Z@
MQJ2&2[6C$#D&/CR,0F[6% J:XRZ;_+(ML#E?I'Q.=H8UU-K[%=J;HDW^6#86
M&!IN4-/D^R:6N?IQNPZ.3(;]_*XV(=X"'L,L+%L(""6;W64GG,C)Y>AH*_YU
M+(X[,RH1T:ZE9ZSH74\,S @"B*1/Q3#!86VDM]PSEL]R%H_N:F:QY)&)=141
MF#07A]L)=FN.?&SLU;U[:G!X.KEN+<@YX/FD 3IDG51L\VXHVC,-NN[N18K(
M\I2:K/"%G:02]@19=NG'X@_\I=F.H:_P<P/0Z.^?W;\%KZPAHZ[,"O_X]4+-
M!: Q+S87MKA\6"G(%&K+KJ>XET?=NHDH-J(WH(#PRFH8N2E(4SJ"<!%%Z#[,
M/=1 ^W)3+/A]R]'E!/78ZUE5#7T@-=OKR$-L<M#EE01R7Z>XE:N O*?"R[)I
MH'H__;J*4+:;,P-9N(2%%&V8JY1=<INY 9\14*\59WW_7+!89;IH,/^@1[G8
MGA>4^\2J<RW;3P^U8UA3^C40M>!Q-T<5JE(4X_S'$;LX7X-NJ9 E>Y>=^ %%
M _?]U51%/$4L"5<?U>$UF8HE#_X&D(U1$7O@"_R:RBKU GKBT,(*!1U6A ZZ
M],5&P5 9(,)ZJ.KD7%*?WGQX61UXVCIC]YQ>;T[]Q(U BM?$TJ"!J\N-Q#?'
M3<\OR#+$(XQD2$W-$*2X6D6UXN**+>,28[GAQ):>FA02.3TU_BF80,+DB0#C
M[%B7SH;1;C80-KH+IRM_29N?,[_-9SG@)79MKQ=,P;+@P>G]/(><F:<"7Q@2
M96+?EFT<SJFOLWK;W48$HN)@S-]K&W1#;N#261;*W1KAZE:WC$Y/7S28O.=^
M5K:2K]?<*4PR6_.R?,G #8F\R3I-]_QQWO. 8M79P=09F[F6A#E[R<>\D9\3
MQY'5G$",:# ZJB?<O!2D7@QD[NN'C_302!6"A93>;W=*VKJZ#/*XOB!H-S(9
MV3_!E(X !738T"R\DV@I&&U^Y3UW3.K^T%5U5%?&&R^EP?)NC[CVPX/<N]HR
MMQ)(&@+PIST[@M-<CC]8G\0RI[UXQO[,O%_B?S5NGN]L.(X6I^IK5'6H36K/
M:*C:U"AJ:VHD5M4>,1.;#GM'C*""+H*8":*TJ#UB%Q6;FC&*&E74_;VXSW/O
M][ZZK\Y_<,[G><XYLCTH@2L:3-TH78;<I2P=[G3K?90/ M C4#\(KP>#(;$0
MV=V_@!X,F)VS;(H5S;$)VWY'[F&3:%5@C>ZMK8CG!2AJ3%^1,W+O&DQD6[R:
M+$6\!8L3VZ)EUM$M##P3]_;%8L*#6^(7:SD>/PH542IP)*.)W1_SIJPJY0,S
M-<J[A"TK,$8^%F7B2TXEPMOU)17I@-&!!J8X*)?YZ[K%=$[ _E[^^>;>GZK$
MP7BN=J%260U.L @5ON@Q2IZ#CB'W(U^*@!Q4L[G*\K^G<":DF5C(_9\/>=-J
MBU(3-:?\)/!PRPRYUX*.E&P9YTGG-R8Z*=< *)*N#@Z'W'ZS5_6NA:>8D,H$
M1+J+X?)#0GE5?YV(5_OOKAZH'![X$Q>8MW,$ L]VCM'T=ABU[V]\EQ2=$U)3
MLR"ZI!].@YW3L,UKX)3Z1D-[E+F!#<M,T[41Q'MY!S @XO2D9&&UX6'XX3SE
M9&,.YH3;@S@UR._Y_ 024CI 31@S6X,D5_(:)V_J>6[6A$Z.:HVD0\268P^#
M:[_DN"G*3#4N;"]Z^"<EXJ0L/M;L?U<VUL0;9K^K:.KY-]>>GX'D!FX@QUS,
MS!A+>D0LS< K"O(!@;52PO,N(:<VE$$L 9+$Y-'%X:1$Z4)T*Z 63"ZI<M+7
M ZMLCNH_B$LKV\7+SR_L&<YXM63S:&@DP? F[1(@GVK,?3Q13&^9"1A$&A%H
M[G5Z(+C="<K4JU5V*^<-;?)==JR?.FYK.X#9ZHJ$:AKB938>$ BJ\K#IK_9C
M "SE;XNY#F(ZAEHD*@0<D7PKY<)6W#_<UKY$KL+^J*]X/QR(;16(?6MV@RL^
M5%X8C10_0).CG#(TF5<4DP<=^\ST;VNC;DS6)8+I>R^II W%1H<]0.L?VB#G
MFG6T93*YZ,T\4GVORU17@2$@CKK27V1\IN/C6TDAI&0#?I$6'?,$GSM*4((_
M21/2*WENL@3:'WWV'VM4,R>G!W)7R$B]=<(=)&O]F,R:TF8Z_B'\6=C.A!T"
M]@WZ=/1 *2>;+;TPA^W82[%\,8XASSG%W+];A[[_KWH'+F=_?EXYV-XDC.RI
MWBJI>6^8=*1!6,E\$;OAWJQ'GNFXZ;J<&6B+,6S*L/YFWY7E?HQXWO<^^_1H
MF5N/?C5)%Y4$J7EZ266R<_Y2/WQG;Z^5M+Y[$G R0:R@V"WL([CO41E6'F&G
MJM&93[M+:8FL]1]L^[LJ^/B\UM]^]_ _2V!+%_F'_[U)C"9>B+9#A?)E9_TG
MKO;\7S>?_Y&D4A<UX:WM7Z5'%!K%RNH^X>_/%9^))D,,>?!O <3.@Y2W0N=P
MU80#K?8F,$C@.I5#>DK #6$=+0F_DO8%P(]U;+.$RT+[,%5!G+E&Z5M3TQHG
MYW 3RH(:J_,'XX9D_/X ,7GE.N\W<Z#!B7,D:KW.'7LJ[!E2IG( #6#<\C[U
M)G5X)\[I3X%T3L=GO+36X=[!>@^;)B:FJ^D!12[8:R*LM@IT:Y7KMDVVY;)0
M:(H4]5<! O?C\\C3\(,RG_"[#WUA,SKOY@_%&WXEJB!.M*<5XZR!\W2+T-2"
M6-:^ROU\7=88JQ%I,I-PQE<IG8PN[;YB;7J@=^\1/W-2=PDC=/[\](#.U$->
M+:@5KVMQ2<48&IB9YFN?[SA!5!*R\0SW_]JS37?#?ISLG/7FCI,G1#FL'TNL
MRK3@U[PW4@L^ !9Q)+0P:8=NGORJPDA6&P;<?24R1PF8?2&SRHTH]W]F-?XI
MC)R+C6X)>G0?&"Z!X:Z4;6I5'^X$\J/GGQ6OAB4XB/^S)\&/WH$K=#G<-8T4
M+<&<0.-?''[K,3X_'U?C7GJZY[Q_<&L'HNDY:P:QTJXJ/7SLAF/W]KU(SH71
M?$!;3ZL6?O9QNL/,,4I[!ZH:S.0N6^-E?;:K,?.Y)+*15J[Q[ RHEO<;K7B(
M^%;H\$[^)3@-JI$NRMCQ![Y),OGQ)EU7;!0^8_="UA,ZKU<=]_W+NU1ZI4!M
MMS((H>\HKLLRK6E\-GG6=ZFY?FNNQ&*TA?7?[=7_7\#9DU.683.\M#N67P:#
MS*.FHJZ5UABL6<W$Z#KP;'8B#QAN\YF[M[.0R)V.+TYS= SZ&XU\<25%U,5S
MQ88'NGI_2_GN0A<TO:N:WR76JDMBDZ@=$0/;E:V&1^HZ59#=:WW3V [G3%.O
M#?D1 _\T:R,LQZ_&#4[-E+%'%8\D ;+251FBXF:]U(+-GP40Y'$98GV=8TOJ
M@-_5":*6!X:2Z?9P)IG:IXBY?.-KFV+RV',I@36_2ZHQGYBIIIE-F,U3C;4O
M6\:MP34RYU4')-/MN5>"7+Y9UD9CN8&39- ^"VG_/0V3;E_83?'KX"%?#]V;
MEU3=%OJ01[S &MU^BO)[A1U]4_X(OS]MK:7>_HU!"P0&0JU&KVTW$<L0/9C\
M(11A5<H>6E/#-PMX71 [)&ON<Q[M\LRDA#AZ!K.*XF'-):4<Q 0&9M+'N;>8
MB$_!RU<E[2@?6<O.N6V;+YK_;OEME DZIW2Z>Y(*LGJ,Q<-G_$P<I;R:H(6X
M8:->:YYIG$<?'YOVP3IQ$8/2&+GE5!4W[5D_-_?YI_1\X;'(UXI.0EA$IT!M
MEW1$4'=C6:!;SO10D%*R0?RUP9UT-IT4E'6L[8H''U6,:#1XKJ8DL::7@_PQ
MEPU/7E;PGAU9GL&$#9+GZ"7;=?]1$0MW'N$94 #4T$D=3C3@UQC7@H0GJRXF
M.5SYL?*\$R+JK9M! LM!/^98!U-%!=J%>VBWF>8#"U03ZOTPOU7C8Y^*K8BO
M/[C9+HH9+I0<MA<<[OTM*36F;ATN^-)[)_JU[1,G^"9.6O\T3A)FTF>!5.WE
ME/5?^S;$LYRA09:KUH]*?R@7$)=V1.2GGOK"WY)_]' XIP?=M:NS5@ B_"DC
M^>W\4G'Q[ >*BG3!(PC,9=3 ;&>5WW)'>&=SH='(.]T)IZ#P5RQ7WJW^2>.
M(FG0^M5/O!O5Y%JF[5<'GQB5+\/&927QMCF<8X&L 9QJKC!_(V"[XQC@#\D.
M2ZT3'!EE_&:166T5Z_8J=[(-&&22-95;ZW*E"8H,[N%71\R"AM:+_PIY$<C!
MG=QEL_+8JHB+T%ACMK:ZW %XMUC%>XW)0[1*ZW-/<E#H%TS4UTBIVBU\&,.3
M^5J8(')+*(VZ.R*0Z4/&GYF%O;.TI%'I2ZH$T-/./KB9R_KD[ZS_Y.3UST4B
M6GWPO6T WX-.IO=+M)5.Z,EV\JFA%!TR/^XO<(/M-?M ;\I4%7QUY]?>65GQ
M\ MB\Z[R07W"";K.^47H[FPY2W20/2GO>*+QB,_-\Y-TM?,.HX$$3_8[%J]J
MKOH#I\I_'.SY:@5%^WM0:,)2Q6U]V>1-=.N](-6&/6X, G^Z&1.]K[5 FQ86
M8GW&VC_,+MZ]:#DQKM7HDO&#DZ/@-]$@)+TE3 ^V=]71M-?2ST$?ZG:WDDLP
M/=S8E_3TP>Y:Q$MNA$35IM.O[*&X[+ZQ9=/ 6..([R:OD5Z<2/1-42OI44JU
M7@FD3/#CA-VF4N&SB].(6RZ__V4V[BKLKDMA6)05&\+=,R]SD-5O)8XP-KJ;
M[9J^S$X:[\ (EZZE;E'$4-X[Y&=)I<FQ=@E/ET82*2L!_HW+TC8\&?E#5R.S
M19HG:Q3D:VQV>9?RW9+*"^(6 RK**[QNE :8XHJ+KG#,3C;/%=N.:.N!?'$
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M>7*\L7MD+JQ6SH?/R,:Z+U_H<X D<X&(E[U"3D?#3\)*8+-&']K@G);'?@+
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M%G]JS;60@#,$@&JFD?7UZO_E)_9+\G\!4$L#!!0    ( ">):E03;)*JGDX
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M_Y^L,<G_]1K[<U"\J#&(&! *.7MGX;]0:Z<X)J?K(! ,+F8.@]K2FMC9@:V
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M+3WGSSW]/_7\_WFZ +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D
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MX[E1+'5MX0205?+!LU3[?NH)0+_X!+#1,I^?V8,[&\03NR/?:'_ @GGE<-A
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MG59L*11Q"EY4F5AZ;-6=<6\6GN,S,VQ-T$AW2L>(1\]',>4:59+JCBN%[)X
M)IKV^M^P!JRZ*D7B;%<\54UE</9-+2ZYEJ]->X71H2FTS#T78444$J1=I:;1
M*L,&+]7,#5L7>O&Y21I&FE<\&BDO:.-+.MDEA^\] 1M":*T,*4.<TQB]@Q*$
M9;M[J^6IF@-%W".S&N07*.'A:[>!@8%/JHT2R!U4U6R6"M]6!!I6Y=W+P4\)
M9;P''.?=$#77EM_ENN&;S]FT!F-Q?7DD#G77*>+E*;EE%KUF^3"(RY$R).8+
M^\O8M*$AD_LKA.7">@I+%A'\#4W,[[D%7_..8%P5T$-A$ND)":0-+7 >#,SF
MCRK5Z,^+^$0V3/!!^6IGW5>LP(S9$FTA/S^?C-C2&>=B%84G=$"$A7TI<'TV
M$N=I(SU+G]=::%#8I@P#(1G]N/=]2@8('J#XB\$ES"_Q+:;>QAH1&QT^VF:+
M+;RZH=IL/MGE.JS:XHXU+0*?7F\<&\\:8U9V!CS-[+&KR6\0,AB2FJOMKT&7
M0GW[;34'LN5X @!V'Y:2'L=\$SQ^K4T?[I^F0J"ITM> ,Q#=;NO#_HF(-R:"
M+VR=<+SN4=11*_T2VPW/U5K695WF/%%BJN;GP(BT[,U7R#SLC+WN*(=R&2G4
M? ?!GCK=]2O\E1B\(^[#08D^?;?(,VQV*-Q>6V8.4@P\>S38*8]D@31HTZAZ
M&P[JVEOP4@W><Z<N8<H3+J5/+)!M=#G8R>S&C_4B4I,3*3JX034^FD,Q0C<)
M8_$0K1SOSL#3HB*LU%-N;8X\)D^\$UK22-=ND^=A6F^TO!MWI"H7GQ%1F]SI
MP <F6UZR&IEGF:3[]D"-*I ^K%SW+3 RXZ\SA$R/<<;*]?C5S+5#YPJY;@E1
M_P$] SZ5[OS=."]IY8?DUA%C'55)2B\0KBQR8V2+'N^6X5TUHC*P?=J,ATRI
MBR3;=W6KC!=F;/8W%GRKFE:_CN<(VE=#@\C;;8F[L66<&"[Y=*1>=9:VT<VG
MEPTE$4.3[Z7(3Y#-5C4MSABGZ97>F/(*G;7S5UFFXS6=*$Z:9F59173,K5Q7
MT$%:B+(K-,:%NMV^;LGGGO4E:&=KC8YEBJ9.=>;QL9M=3)7+FA9P8?#FJ[$@
M%R/]QU[8?8HV%H.86.H49(UW9,#)=YE#\1F\KEQKV966JJ?>S*?8DZ+(R.>"
MWO'TV2Q@S?\<(BB3C-<O^'!G>LWK4X]$(3\IKG8H5TA)8=#7:B8I9LQJ8XH&
MGW;3U&>J[<%B6LAA)97!0"63A]&U;>'CEA(D^8Z$;((LNU9Z;LBUGD$Y5)MI
MDR#%DI)NT?"2I>A(?_U4G.S^2.P/@C)&?G"B7N4[6LVK)P 43@+*&9%]H_>)
MQFN'7[<F1#S&W#QKL_N.BJ\;#X;.50PE-/8W.<,YQ-<"I&*WK!-/ #TI7]>G
MB\&SK\1B1AUWW0X.898/%5=7$K'#\S+UL9;X\A4O5V-G?!G8_^1$4:YT1X/N
M<1""RU"&YP1P1<6IGL?2FN]63..;Q^;Q9(%!KJ5,E"^]N4H92IQ&Z1\5/WNT
MA6+5I247OTBIK,P&%PZK"N_4:%0E2@WIZ.?K[,>\X4-:65 =[N)+T6'0UU-<
M%SGI^A["<DAY4[4@&7L9.[+S>+6:&ET!$:Z.N2=TX\;.'#>=J8\WG<J=L3J%
MAZXW+<++B,'IUN1::$B"$MD"B<JVWJ# F=*/_E0H*!_IR=$(GF O\*Y(LJO[
MQ51'OVQ$5T(+*4G!8IYE$T>V^6D7K^"3P!7(2>@O+\%G:\=^7=$0/3.D.=@5
MQ\K>N=X;7O1TQ^3.O?N]'RN4%DF)-/(7*9RL2B,HAN.8X3WNCO&K2OCO,3N6
M(W@^]IBN*_;WDQ_$3]??(5Y*Q1VNF>6!9-QI%*.Z0F SNSO7\FTE;+0)LN?#
M6M4I/B+"H2-!F?"X);]8JZ-N1Z>1,'>67TBK%?I,2TMF.HIH\BE]N%RX4V[&
M)T+Y 6WY+HOB=K#B;E(04(N@W8;8O<U&2XUJ6D9:2UI+1G.:6<_"A-%GF:/I
M'E\5NE'9X*%\.EL1<;)QE_;@.P6Q,5<7ZV%KJ39B_QFS:ZXN"TDRJB9L&_LT
MU(,[4;=62>K?P7866W*.A!.+GG?6*-8[R<N.-"I9?I)<DH["W@13QI=(SF'2
MX8C9HX=[NGZA@?N'DXT,C$FW65=U"$WV,WU-U[$(_6-J]!-[G6GWT@%--)D=
MQ[""ILS:I,,C$3P(S-;U0,>Z)-65+P<G-M@5O+EWKT^EV@)HIBPEI6A=;Q^\
MEY*7IU3#-#(Z.CHRMKP"_2;BOE:)HI73A=BSEM)&"@K[TRU3JM^,$I24"=!_
M(D$RM^?OB#=J$5*-<E\NP]CAKMLXI$"+ID+L<B9Z<1A5EB^WH:_NT'H <_-7
M>19^DUEYMP(6V5O/!EKFBJMW]%8L#^_0Y3:9W8N(2 K KTV/S&8*(E<?N'*7
M:A)25I7'Z/LJHN-&B(:<?LHB?M6C^-YX CGZZ$>4^/'$1%%S)B'5%D@6PWF=
MI&CVWG:;D%8'2O[9,M(6H4QM[H1BM^,6/[_8FJG((8L=)''A89;X]G#7XI:%
MO#!^@ 0:M7!H'9SZ*3MPZTMR-90UZ;29J;:?SL:QF/F[A1%\5M,ZN$+/@VX0
M7;X!:L),:J>"(.Z_,#.EINT4G0]TZ_362)398^#V#+-WM@/Z4U!]P;(Q<)3@
M?\]1F"7\ J^<>(XU":PNS)B_R1?$!AP# J,H'8HW^84,WJO@/(/2FO&NJWG*
M[S*^+.)BZUO@WB%G]BEYET-2DJBBG1SL%]Z4$8H955OXP,MK\PT!#BZ!C^2M
MI6O!T06BZXVIJ;U*#U28PDFD*O>*L\U2]'U&=.<(@4']K@: _/=H(:[8[K&]
M+,6!0L6]FG;WJ[8TZYI,LMPMZ2*<F4?VY \4N7&2?*=Y99=X$*\-7C#B0UGK
M3LMMY.:1<.1:_MG%NWMI_4U.8\><PY'K<\/(F>&#]UT@I 7GU_<#]CT#,8DK
M!F.,<1BQJF\_ZW8_T&R_I_7:JE]?MS_X_J<IK+H@QQ(Y%0%4WSE7TR,V071J
M=F![,.7XY1$,=U]QOO%1ECO;+DENV#PU*EA4/!%9NJ0KB5LX;^::9K-LOOGU
MBR[&B+!&U80U8S1,!1LW!L?Z)1^> %2CO:"+KN*C15AAW.5A/8WO;:.3O3Q>
M$;!P'U 0V3UD(^:_VAC9.3B"E907C65#X82UI4W,@B^M:F1P<(SUB?RK!W!#
M306GBQ-N^G"UK' TZSC<?'7BX+G!9.;&G:.;O9&A;:ZA;.WC.SWSHLA7TEAH
M6L]NEM'*4\[@=V$V(>0%:Y!'=@>&@D' FL<[$T%^I@<. ;H>0>4&4EGF);?U
M7"UQBA@)GM.]]RG2_ORJ.0[[1IVW.DUOV$8@VGVN-NUZ2C*?GOJ:L1, UX'+
MVF22'?;2%L./8>V:+@*;82WKT>'8F^5OSN9A!C=W6;YQ*V$]%4F;N N*T:[U
MEKP[O_"6* X>BQ/5T+1 AX 5!T.\4U58B@Z&'$4[2_2<]>8*AM]#0FTKJ7AL
MB&P&IO@U(Q4D6^4D>N=!H?*)Z=V+B6XA$'**;LJH+Z.[98_>"2#>^9?L68WE
M:WWL),FXUZAI(JR/-).FM&;K2)F=*8W@K\^K?]7W4@T4>;/S[L=!3:IU;3V=
M8G.QI,>=28>-K]0MT@?+1JG1^6.UZ*M2!*42X$V'+HYX\Z-$/BA'D09DLS.M
M[!5>/@:-FYZ:ED7*/'=[S)UZF"T'#G14OHB6/SX!6*$5Y8Q:AN3EMWKK/D:$
M",5:.80+]6<>5YX 4H6UML6-JAZ<QH;XSBI.Y1>:I".QSNL#PGJ4[)3;X_N9
MA@65::F5MDC35MWP:Q+1>/;SAYQ^#%:H-:O$X[@QLRRIMUAG LNKPX@RS -:
MS"MQT\("7N2_-M^VM;.JR-Y[/$8V^\X=EA JFCGH]X!/.,,JHQ6ZJJ:C*8%W
MW^_2O*N>TS089F3;=Y2HLK,'AV6KO*C-W-J3?8:VFX*EB9CL"YA_*U0G*Q+D
MHQO-,^6;\_:XCSZ67B_&DT-UI^)MFYFZ:!8G7'>.[]$C@[L,O$2//<@- Y7&
MJ44VY8A27.E<WQ+A2,W86=T(Y&2WY!!$>X<[[:4MBF^YHR?F3^CN<3?+_<70
M2J4:IL2ET-K&6#5K8.KC*0+QX));3S)GP7Z-PFK4] 2=\OWL'&U*(N4V]];)
M:)C249);[6@_[QF0?!FL*Z5U'QX9M8]MGC$$&;5)'RR2=MP;6E'(!HY3U@7P
M=3<9=5..>S?MU4D<;YL%7,TAY7R-.'M>V!Z<NUIARY2VCW"W[]%EQY."=UHY
MZ)C,'N0</=U%OJ\*?/A\C[TDY[-KI18JAXUP?J*N%)D]L7)";S0YVH/^/F[!
MO%6F678@I.I*A/\FR1<V07PT?6^(D+^_?>O:^,J=)'=E8#(8+^P]9@&O#GV#
M31]F[\KCT_V2%_4,/8QE'^HU'=>>^]IG;JQ A%D/:M*)EUJ[5-B@.Z*)!XTM
MNFPCC/-RJU^"V^2F3$S!:M9C,"N.13!7./G5=HI];5%!&27WJT,A_3%/#\IK
M<_S5*E\+1!4%*.K5FA;WCB=1V'!%A$0B[#Z+[),?.3>+[(HAP:'-/$F.6ZX:
MTD.^4[[=<BK]H=V\PY.WWJ.-'@;"L_U-DL:IM>UOR^\V&#5]#*Q0P,*#"+Y[
M)-]V&[M@U&:X/_(@\&9RK*J#JI&RU/4F=J,VW&VY\=SA:L^@>!9.=EK7L,_R
MXD.IY&(6I5O+F]-#6?%^X?)O6@X4\YG&0J-:]$DK,88<0FZOWQF;=R"MW&[U
M^FR9]L1VR;!3:/HVD4V%<Z!@<WT?9^;A1ZF!U_7J0]O&-COOIGR9U497O#_7
M:VM,P8K1'_<<4*I[3&JJ(JQHETT3CHW\9X06]%/J%:Z&1$3CF<"?NK)8W#,C
M)1V[L7$;(#2[]T!3O>#R<^QRYV;^D6>5[QRC9P5P_"7&#I1R:H_1Z>,.'8(J
M=GA8:X+993\)W-S +J!G4U=#/-.[!3JD2*S87@M3E\V<LMAR>HL8 ";OAB^^
M(JRQS]DU)S_T=!E;B<8TWX*^, 9?Q>(OVPX 4Y<6=[][<<6LF\DF\N&3]RBG
M"U@Y#PVE<0J1$X )(Q7DZ<H*GO6 #NHW1Q7^!_L, =M/IT7-..7Y$K","LIP
MC+NK-;^:Z4Z]W'?[K&?&W47Q,N.^]'ICS6 28M*UX'@F$B>R<LFU>B>PODE^
M@9Q!-#TS)6"PL< UB3!Z9 !0VV6 \?6YRD[;BL=2QT[V_+5>4>JAJFB4XJR\
MT"5L,6N]]R![GJ#B^O(EJ?N29'VU750#<>'7GUA6*JSM\7'%=R=D!:Z]5(]/
M8/>8!VFD7'$:Q1^S]"._O&H;BO>!Y$M"3%@QWLU>S?4'PQ6%PK*5_JB5HPV"
M^J^O*LQSPT3#ADNC/>7"WV4MK#8O,V_;9WEU3SUL5P)%:N*J5[WVA3IKWJ')
MO3')--BF[C;5NO^U,]=86)AL<?IM<&Y2$MC80?'I+;-^>]O)$=]50<JQ0_W5
M$'LX*.!:K6.5=P*F(SXU:PPE4Z5<67FM"D (U0?=VC!R<-BJ2DP7S",J5%;0
M;[4XETZ9[>/WMMSE+7M''$/,)+]AHT'34R^J>S4V5MP92AB%HS--X^1%8T/6
M&9A+\P]V87QAH>7V\INSCY_STW-(!:T,H-<'/NGNN05*]R[Q#D\)4&(CDB&6
MD4JV98:_T7<DX>K2JQMJ+:,;Z='I?__RW7:QSG7[;8X<]NO&_8V:)$)TF=<M
M#7J6K]U?*>!''9,O-B=&C:1G"IHGU_W:9%J5M7M8%-3>[:VV@ S30ZI:4-D2
MORB'U))R)<=/ZD@WOUFG$/"G? +&*DCU-Z>-5.K>M@4O[, T)*Y)YKSZ3.^[
M@=>GK,H3T1+A.)CH_)G=CN'1I&#O,O2A _*U9Q]22]S$Y=&"2^CZKHO+-R9K
MN:#^!8[KVE^?/V,;K4JNSD >%N^'O1A4K(?6QEZOY@N5[;$6-HLPSY=)[;:]
MAR3H_<"00O8IPQ#3ISB.G"5AS-)CPZYDYRG>DVD^/.%<A:%6'HGXX7*?+[EQ
M,>E%JG ^YJE=9V!@MJUL(FXNWBNA.MXUX<[R_DN+)JW65<I6?AW>'ZON3M?(
MIN47XJY4,R5)II>\0H-'X)(0A^@3H-5S^7TU9G=IZ#LV2LN<"G<)>JXO(V]]
M8\C)QHA"/B756ZPG>G2)5$&.$I!'[]OT?JE[48^D1D:.75FL7ZQ ?@H^J-(B
M*E0@4IP\G.-:M%M<6IP+!/;[]0@#W[FK.>0CZ(E(G<RLUP(847;Z!%7>E+34
M,G!_NN:@H>O7R1;%UN:EED[-V>0W+0,-;A=)+_(;W&[:X9P3I46$^*)3 FT6
M ?8E"U54]FM%(X(8NGI?8EB5%+I+7FIT+A1;V)HA5M-]%(>XI"34>/0,]"CF
M2KP927',:S^F3Q89+38=O/%,IZF\97!<XT$CF"(9G=:6M6A%@6H[]7"S78>9
M*.!>B%9BM6/\#:&.5@IY'FW9Q+*LE9"LG/"7&AZ=5F!W 4MI).^*K0T S?7Q
MJYR@$\ 8: R&4J&%A-2ND,1G+.A]&+*]N=I]"!S26D!(5M/N0D)4*Z3GFR=G
MURKP 45%T[H<L^]VY/K-)-0B.W;'S96MM*4WAJ9=&M,Q4[/H6V2NE@06<;](
M=@T[ =!'\!@>\5?49<.8HA>5+U<7D!LYI(3[R8YF@4!W()L2^46::Q70IR_<
M'NML+.]V]7Q@-A^20GN<)#L4S>+=!H\ J\SP^#X4 <^^?)&5FG+/8PFOY\$!
M_@?^=TOC]N%=BGC@, ;9TIEVA_N[C]/[4#^:<J6&H+5B>Q9#&P+]/VF,5%,@
MJ;:O'3>+K/=4,]^DKF2'/[B%"')VPO^"$Z4$IA"P]1^)*K%1RNTL2ML^DLT(
M+W R3W,LZJK["GRCRC,'_PQU7;X7*KZZ6NK09ZF-$?DI[NP7G,[1\7B:S9<]
M0%?IG-CYL8^M?0XU'E"/*8F!<D57T8^N/ 7IN]1VD(8XM_V'$7*:G5K5X4%Y
M9??PF<T>A81CX+9=LYCV$"SM=?2\))HGV=](I2J?*-=(N!\DD*@QTM3_T2T_
M<X:BFJB%SH/H&0U)8_QT=26S'JF5QO3:P9RM<CD(_.:0;32OG,2 X&I84-8+
M!4*$X-LD[UMRFM)[3?NZ/:JCS1^^."=DCJM(L-@<D2-\>-G)BQYW#.*I=R2!
MXTO**0]U/TJ @--F+QCP3*5WJUKAHCER+)PQIMVN&Y-.!]_4#-<P8POHX R_
M_@9 ;-]YX)+=X3AK7 4J(KQ#U:JQ&)?IX1#AG!HD'Q+T>B?=&QFE7C@4BYH8
MG8X+C6!T,LN5R8A4,BM_)>S[ J.V]GU;BX#15+#E%R/,O'PT??Y):$LON([O
MCI),D;DV5MK$;7Y.\\=M-SYRK(Q\Y#'@*M>;*,=Y1+.AG@L*?FAA#/Z8$=Y"
M2;@57HO!+KA.:MG<1*A+$1>D,46C[J8PR?!VQ9KE\-N^-:> ]<=1I3M SBL(
M53RN1W-/].Z.XG\016ETJ>A]P!!AB[ KU_YTDZTSOX,O]VV.&\22JWB:]YTQ
M91T CL0XX&I9R!=%"?YLHZ,X')&<YZW+9_*,.BU$9##9!PIH%5$/I#3P1\L)
M,9J&'=9 M.>OMEY^BZ:Q.YKD^L5WJ*])=-)V-90]BFA_.'I F*7UCKGEK:5
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M0^9N/LR&P\$50CFRIR,UE08,'+C(/$=HB!UILGE#E[HE\(%Y_W*K04H,\PG
M3$.S]X[ZV&N'=0=(,M@PR[7/:87=#JQ*?.@Y2E(4^:RAOOLH$D8?B,;;KZ6C
M]2E2EB+D,.#0%SQY\S*>F>;-<=M5BX83@(WAA$AJ;Y)W[J#WZS3%T5V>(6 0
M#V"\>+32#'\4=#1580]\J/X4:,6*X,D2M]DU]U-#V_)HRDC+@"3=NS$M26_+
MD\#]F>(.U]# &LZ+,L.PX=UH=PC>?5'5@>&! *P4X6X:="NM25&+<'3<MWCY
M^+*A=8&,<'W*MQOR]7*'E:5O^Q>A"2'YI2JY6?CFIYM-)2HH4+EIQ-XMX,9
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M.CNSC_[U"D^&TS,&9?JQ*S[H@5QQ[/M16[GB0BC+= 0T[/[%Y,X!Q<'-L6U
M]3H(*E$P#84H3(+MI^U<K"A];Y=6CL)<>_+]Y[?X##\J)C_8%/VL9S=?D= ]
MY[4&.3Z40%?947MM</VQ1?2UD3M/@2F1KAWPA=8M"=9UQEOKASDO:1PPF6?#
MY^<#V:%TS\4NCKQ -+ %K:.'7I:_W@8,YGQL6.K,M3DXSRQJY8\$7@H]6'=
MIM+LO/_MP/R/@'W:IWW:IWW:IWW:IWW:IWW:I_]EM/U*T=P)AW.3%15UQ8I
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M.&+0+IP0-S<4 @K9D1+U<'7X/N:Z_7 1#LV)<(' 8:(P-ZSC'LHO2OX'*^L
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M-2""(O15\B,5.P%M8++SR[$71\O5.' =S D[\QP5VRI_!]3&94[39]X98E
MJF#/M]Z@+7\J7H#GJEQ?RDFE:1(,]64KIVU[>D _!GHH\+*J9&A47G,ES&E2
MX6TZLM9G[9U+J#__+/L\98],K]^IX3':+)>K^$K:IU82+X;+6#)0&PBQXZ:^
MK"Y%X=<3G5^+H0.T2-4$7]>%>3&-CXZ$J^F93=Z!;9KHF+I&=DZ6#%E?"^4X
MIPV!#L):E;F?A1<BEY2]TA/I3:5DF)$ZU%PR&330>W0K3?0W.\''R%<]870Y
M0X4O=;"O2LLK1R*+H&K7 ^-RPNXO^$@*Y$A&DI&,I:N7,TEP/8HA2YZI'N(+
M.I":^V!4O9I)2;;BZ.F7-NOZ1D_O_Z&-?GP(9O[@T-VQZ&A7?CD=YO'5^"F6
M!QX;V$FO)Y7YC]]G&KU)X*C+&(SEP8?5<K<G\IGVD9LPWIRYP)@%FE@V"#;G
MT9Z+NE%T&BEA_2#64)\#I]T*S)^6>O00>$6F[#:;^S$1'?*!HSKV@8<-GS4A
M@RX?Y28/7W'FXCI)!"^,K%UO0;1%@E5-U$S4;+>B-Y;ML$>P8LNYJ$R50MZ.
M[.(,33)-CA/)K:D'QZ65O1LR'VEA),^Y,S2R?33CJFH@=>7.U?%\]3+K2EV=
MA#!*9%5ANJ*B^<UK9@:?I-',F#!]26_Z.:KT-+4@K*IZ,W</W?$I1G4!>3F_
M3Q,G3<LC[$8N#@OY7@G_)[=\&S7M<@22/HBZS(<(.PL5#[WQX@_*4>(ASJ2Y
MY7?-XGU%^V3,F2FUI! AZ?)%-54K\KICP^UYC:=&<*/C$64E R5S/BW1Y66C
M?I0O(=$*+FV7N5&TUG78==1 H?])VO":)%.O(HC)YQMMK?6CMC?Z<A^$8Q-X
M3ND^+4L<8.=_T.R6KYX<_+;N;&#HTK7)ZI/ZH)6V?MMGPB'HDLW!<?FR^K95
MS%W.D?X-B\'1=7V1=UOI[S%?O01";1?/Z V]N%7=5V?@WF$Y,',DKH\/X4TA
MY$?MRFL*(UUS<&=IH8Q*SR75;I9I E]\E,:D*!#<J!_VJLX0^1XEGEJ\)6YM
M9*=31:L1254D#G 7.YN9 "%6C0^P\T&ZH)2.WM4-3WIDH8GQ;Y8K3ERWZEO;
M%&S>BFNX8%9ARK$Y>NJAK)_+&>3MW."7.L<$H[RV*@<D"I>KA2G\6@T=&4_/
M=%X+=2Y '7VL$O/:,W6E"_M)Z]H(VN@(J' +T?O:FTL@:W9A?K+&\ZL7>UW>
M_+L#-.X7#(T5M\2OSX8-I<QJ?K(K^#J<P&/7P#R XH8JHK<!P9\:B<\@>>-&
MATUUG*(_E;Q@L!KNRWK)U,4JQ[/J%+H94U*2?-NQ,DLFO05A_1!V[MSU(\4X
MU;(.E:F&5U#C\O>,-[53C/ WWJ%KY/,>?NCDM\LS>17?/+6J4#9VN+Q+Q[@O
MEA\.N>&0$*!CP>1]:X@W)Z.U4XVH7?-M/J3@D=00J< [-ZZ+EX]-W2&=L>E+
M-YZ*RLA>Y6$97W-D%V'J1,:D:5._85I2STWS_<K09EPJZC_V7&[3S1:C5T+6
MDML#ZMC,K[ !'1 C+'34'IIR6,^6V=&[3S8R"!GZ1Z:XAW)V0._4!?1Q']](
M7%)#A+^X=+[H?9%I>WFM9:U^YD9ZT>.5C?8GA\7O"E<JP7D:[S>3!WA^U%=E
MIM+*9%BG/VIRO@$C\/[JQ32/ ]G3LXWIT_85LWG'4'[SL%>$3832G1J5I,)*
M#MU+44_D0 VO%L?"A?/U(SXCKNC-C]9<[L!ZKM^=?$X'AQK5.'0('8JTKX#G
MA8 3'O%8AMP)+\Q=6WT2E=URX%AF@NSGE;YJ&%7URM4MHQ+&<_P)O2G=,&.\
M3'*68:GVT?B!)*!N9FEA;1SR)FV*Y'E^1[.C\7C\=.B;3^$;D=VEI]I%%DB<
M*0*^2'\6E6E2VYRYL%XR?\?U ?]3T#M]-X&IQL<)\A/D8,F880Z+E*LTE@>N
MR9X)O("C='O/T $U.<@X1_M6J=I ILLO&L"DD,YW3+,Z12?T ](ZS/JB+%B?
M1^W+-J#[J^),(Q\JV5>=[;/TS8-SU\X-C'((A2>HA"FG!4))Q"SSVWI0!3SL
MCZ/UI#4;#,2;Z$\D>ZX=ZVD=V$Q=H^KJF6]=F;D>S;7JH"YX/1SW8N:T0TM3
M3\@Q034/%K/'B$IB@2*'Z^Q94:L%VX"0B[TR= R=M3&S\RDQ%Z@\3IZ3R\K=
M"/L2A[#-!&YYDL:,5'CPLL<2'7T+64I8"#UW>.9HIWQ<_04G-0P=V9Q!Z%OQ
M"J8;M;6?UGF>9OF +-4V8D]^VZH%UUF[GFO1A=PZS>([=Z^M_$$D/;A@S'WA
M/%EQ'H^Y>HX3\4JN7FMZ8(P;]:=4BG=FH'1/QU-QGJE]%<<+)/$W]-M#G!WI
ML76'[/3UP]0>2^'YU.1.KQMHZMS(?T0K?'3U_.<@[B#RXJ8U6*SQ@"''P,&6
M&D^EA""+^'EA'>3P]!9O WD+(.*"@2-K.%D6ANT!1=;=VLJ,&!T!5;9PF8Q&
MO-WX>?&FNT%T3+VH0/:N"V[CH?3:2C<#["4:2#UU+-[E^L?,Y220/ED:R-T4
MJ& R_KQ$&' & 9O5UF%@9ZYJAE='7C%=#"<REXO.26HK*CO3=7!NV0>?ULFJ
MHQ39EI'D.&R^/HD_7>Q>IH/1X+)QP*)X5,,G(GLFDV73R.'<,:*CG]_$#=B7
MSF:8W2B"]PD/*\A!^$:NQ/8ZX GKH=P:O_@;-\*#O"-).$ONA"],N5%HT/A%
MLH\UG I9:07/P[UBO%*N2C1J#O:+= S5/%MO-V75-T0;WH33 3>SL:Q" PAR
ME)8.:PQQZ!,&JB_0(_U:M]:*3VAPTTUAK1Z/VNGY><0493;(^:4^J!BT]LWL
M&B7)X75E/F56.71K-JV@F:_154,15#[[UH*6Q* G>N1ZY*N0:O'9@37G:Y*E
M]A06D0_3RW Z7959U8*G\;[RMJ8WAL8S>M\?E3+5.3\RNY3K8&\IQ9A1P#98
MZ]9V_A+78X=2RB)N;@6-RKY:%':$US=^4(:.\>1,[QM9V]6BN@/A$'%7X(+D
MP">66%8(,EB1O21NM;1HPMS<:@9?=#-[!3ITYJT*:?P3XMJ @ZTJ&A>O<,=L
M>;= @29KX6/HUQ_2N^T1',65:_@*=Y3(8GQMKH7,\=ETT 6VMQBLCZ=*-/\&
MU:4B?C*J1,HKTNJA*09';@:]RW%./7V9#F[YR*,FA</9,HL\B*[?SN"!)WA!
MYYQ/%*WH,1J^!X&^=E%Z@1 (5VS_EWK%<(O1L>#D#OWROH'1Q(N]Q:T?RFF]
M-?F -HUR:\/K\Y9TIVS<EZZTT=PP?04J6Q"*IDX0&VH:U+[;_(1/(K#Z9)+M
MHSB:DA,Q)7-!*X_9KE+.RHS%&';[>U+:KHY#%C<6#US E3S/''YQ6Z&,N<,9
M<=ZT,Z<UP+*5L$BRD!*1NX%\L%X7.PSW38P?P$/B1L#/S[I%WL5;,1KIZ6>?
M#\"9N<5VCJ\M6,217P>XT:3?!YZD(1.7=@CI3%\+EV+TGV0+9Z4+T !QM'#)
M1*A_ ?E;9C><H?O*/X;N,N-+#:2F>DY]GL;\M7QN(S!W,$:.[FUV4L^4JJIO
M0\>4JAI8[R#S2//\)>D#':ETS:]84*?&D^Z( XN@D4Q'RA*G3',]5>UNV5(,
M?EQW,W[_J2+4G6T*R?+<]TYN4-! :FXUV)^.C@YLMC)Z"745:<';.K1V.%T&
M?.PUY5G!VA@FPWINWQBV[)!A)KDBV.?/M@K4VX"BYICJXF(/Z=Q@Q[E LU;H
M)BQ?]<.M0R.GUP0^N3>.'1T\B3DTV=+20+H->(H5<)^]#EHH>O&T=B7M\CD5
M4N#02U[!UF:R@J\FX1@@P\S[PL4/C;F\/KR^DZ&?MYH/Q5]?/?M!5O!2-SY9
MP_EDW$WCI]4,5;"E)I.%NL%8CHB'VP"=UQ)>E;Y:J1PUZ*A[7&WKXGDI&]?L
M,L0V-B/E'@QS*X#/U%J_;/>P5>*O3^[6K0^[>_>9M-(M%KQMD_>!)(ZS:4_.
M7M,ZW";@1-7\F?J)LJ86/?ET;?*KNL&BVQO!&B((AX;I$'8NF*1K&]SV1'%3
M NME;L8TP5"IT*M(PR7.\1ENV^82O^>=8&<04WMV4%Z3O/2"A4G!UJQ>Q>DP
M+$5S73AR:"TM<2U7IA 972-3J&9B8F+[-KLN1I'MT+'/;R1S(BZ #"FXZFN.
M)1]6$+M3<G5*NNG=D@:T]DPB,7<,!:,)0]^K#I,)Y: ;F/5/GT!D:B9FER+S
M[@$B52?4O:"DZ/ CHIZD(E ZU2.B[<$W!@0V\WPWET\(8MD\QZDCR*2BSBO'
M1Z#N1Z:7I[I1]07 E(G:;TQ$<@QR-[U1-:,9&\D-'CNR0<G^P<;/"/CR],A6
M>))?SW,WMH#05E4-59*>Y>NCH]<^N@UV<6[XMRXM,7^R[?@R.9'RQE;0S@Z-
M=2-LC5HL@*_42., 0)/7@&NPD./=0V%+%=G;@"RJFS<XO_A"S:K-^\&V!X_-
MC]B'T.FRUOWV Y #%DO9 ]&2XR/!ZOQ9-3'Y'UK[)PI49)L&KC\I4+,]11-^
MPU.7IRHPTI+1F+_?B>?#RH1X<HE(O,^5P<1M0,;PD'DQRA-JM4@M\)2[)N>A
M%.IF;U_SX!<HO %IHC<T'8EX!1,Z+_-8\?BU414R6Z:+EV(RZFY_6!<?>S>K
MV=[TW+9R:*[T_+ US2M9?3,6D><CTFT8VGL6]/ZE [ZYNHQ/Y^6\:)^<A/8/
M!70D/CWND-WI8]"9Y/;V/-;O,2A40R:+-:2O\.7=VVG:-W-2!^!ZZXW<[T1.
MNQ[K^7HD'%W'?V=F%?RQ'T'.QQ\%-]O@^L 9>4%^:%6J_4EQAZ/+@I]S\JT*
MU_89X3>WKI;RJXC3\7J#U'3UMP%:70KU09$W)ZR^BAAF'RHZ7H7AO^65S'P?
MF3$AYU\W,( IS<MC2\Z]L;XF[\ .-[RAQG-T-'Y#N=(F''QV*#1@KN=2>Y%Z
MWNT/=A@$/W@ 6L'[O%=@=8BP4#!RL8;2CBL-W?(6<^G.%N!S]%;KXB\3"[ I
M8Y/1AGV\%)%D9V4*BYI,FG=<F*$+L[(2D;QOJ+%D5GGG\,#XN]5-_=8N?DK>
M""M9D4KM +^'CGA7VZB5$Q-5,L^OD<!R5Z=)#(OXE[TD+GN&S8PQZ'247KC4
M48L_T D;)\'JA+/$+A==)SU-G@"6DFPSNG2S2/]ZL/_)"D%[H]S.3A>F;8!B
M6&JL]"G\C!$&6:Y^J,P]*5G8O;>+J08?L/'TVA1Q7M?*YFAFV./826\]G?-%
M\#&-0"/5OOL214(=KP]!%+FN9>#S;-_<5K__@2MJ_OC<\7SAXU\S/WN+YF52
M\B;T94;$<+Z)YE//;PSC4FK]P#+-)V,[<RN#^\[[VI"-.QHR[:M@3#48["59
M-E#C7,<%,46"Y ;_8=M&],6T LQD^=QD4R!5(.O39[#>-B"95)C&SS)I Y3S
M\L-RBN+JQ%&OJ@^OQ[<V/BVDI,RL$-:'*:2!J9)K+>_KJ9?JGIL]:1!HB+&+
M2-X&O&P@9@YI+$\Y"IPX%^HU(>E-I\=P*965^/PM5PBQH7PAA%1=H&32U[JE
M ERHIF8R </YAVF$LDF805G&N2]-QD_S1QA.LJR:B#_)O]>2>]ZH=U!-*THS
M\BYXH"6,G.5PA.\SX$-@&F&0\KN3>[=P?9/[0K'3J5)KP9.IK3G.Z%GA.3ZE
MRLR:PNM(,()*<ZOZ\ (RBW2%[XGT-B#3Z;VR(5-*Q0+67X8]15WQ^.>QG/'P
M:<R5>C)==C68"0L^IF*U^-7#PJ)0%@.(:@2;?00SCV8'FU?/);YR"$"]D<(%
MR3)00<>@]R[OT\G);4#[.+PM;DIRK^=O#_\?4$L#!!0    ( ">):E2?^5C,
M!#X  %.+   5    9FAT>"TR,#(Q,3(S,5]G,3,N:G!G[;P%6%3;]S=^Z"YI
M01R&DN[N#NE.I88<:IBA&Y%.04FEI$,:%!1I*:5#I1%)"3% X 6\>O7>^_WE
M]WV?__]Y6')BK[W7^JR]]MIUSGA.)D_F $(5!64%  D)&<D;R1L 3C8IIC7M
M7. N[G8NKB!>#BY 2$99#145."6*IT^M^/Y, A342,8 "A6#(C4R )S^42-K
M JB*$&>+\S(,YV4(']^#RNVSI=#9R4Y+/M(:<CC/$SG/6S[+/SV0SE,XKC![
M9[@& NZ*@)\FT<YXFNYP'4L7%^AY"65G. 3BC'#Z<7]VE87"SM($Y[(Z]EYG
M)63LX6<R?^J$P-0MG""Z\H:Z/\&^"VC"7%QL="!PA*N&I8/5*1L7T 1@@,OI
M/QL !.@ $  .( #7<Q%LUY^E?ZB1@<*=_[ (UQ)A#X7;.Y^K/$UCG9>653.Z
M_MV!HF?ED=E_J_&E7VJLX0JW=W%V/^62G]?+%>[\HQ*GE;2$_4QHV[JK_9D#
M<Y;],^$,_S.A:@EU_YE0MX5[_$S(.T'E?B9._?BG:ADK1]L_'/'=0$!;44;V
M]()R?F\- EF[("RE7.: 'Z0(<_X;3P;Z]W(R,&M=/6>X ITV% [\0C)0:] _
M\;7=H?!SOJ875,H@/:SU.QO; V(%=X')6< M?D:%IJVF^X^H.+O_XRI[[@2(
M#?R?U.N>AO8_\76LH-_YFC K*:.?;$(KF(NK@1WDM'%/V\O>V?:'Q_#/,K1/
M;9)Q@<-=G* NSK9_B.#^R#DSX1<^W@^^MKVMW:\9.#\R3FW[R3Z+')3-[S:@
M/#OF/^UD2#^NYU'%>)Z'_V<-)(.^2Z'BG2?/^JG7>9KR9YKF7.O>>1KKAQS2
MN103X7<W_VC^[R@H^^?W2@"GC<UI#O3TC/Z'T'=.3EKZ3P[/^=GX]/R#PW]^
M9O^3<Z[SR_G]:4\Z^4=">7^6_>_/._<%YG>/GML%($M]/_[(H_GII^_IRV=W
M*/P_K?].P:='XT_7_9U^Y37^4?Y?%OA!?PX,@#,">A9@R&>PEBX(9VOWO_1+
M*SCW#S//@OF70 +^$G& S)^1>6Z&]I^!=V8:NCO4W@KBK@]5/>LZ2+_AH)WG
MG=Y<.CTPSA/*<K_HQK"%N2!<?V.AN\#L;>U_CHKR.F="&N>\TS2>!0+N<CI#
M0& 6<(CUN?7>KC\&=>SOA<\X9SG*3K:@_P?U1T' H+]-#>?._YVCYF[[^_2!
M;@&%ZUK8_L;#MX*<RD&\X,KN2KIJJC\&*,P?[-\*8]FYP'RDH?:V/SQ%\+WR
M2C_89]ZUAMA8(,Y'*"P/" S^#\7U?[!_+XYC:2OK G6!_>)<HN\",HH_,\[,
M4'=Q/KMBP5U<3Z<A=\BOCL.&GCKR;UQ<R_.A[F]\'-C9@/87]GD/NO9=[O1
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M7)1S3") $MC7O<.DK*XVV6)T9#:AYV5#5\(&7:-8F#AL(<AS>OHL_P0(_,)
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MGP 9:\XRJXBQ:(\;>&JX%87UO>E\5&QVB\>-?235+\M'N7:ZRBL#U!Y,TJ0
M%W1!%W1!%W1!%W1!%W1!%W1!_QXZF9=4M8/#744X.9W=.2S.'A5P6+DX<7I9
MN')R<W!Q F*27JX65HX0.,@28FOO+ [^\.09&&1O+0XVX%?C4G.5A=C9*_G
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M8BW!^4/P!^-O#</YO67^/]EBW/^76XS[HKG^;!HK%^>SEU#_C28[Q;$X7?Y
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M;CL3A5%\ ]^R:\YOFX,3/1:*T?/N[?MTU+$\WM3ADE-O9E=!M!='O7&XO31
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MCBEED6L@7V*M+\&EHDW2;TR-1M;%K(*<B"F&+CM2.'P"\,N_$%\+&%H7UVW
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M]D.,\O)GM$$;/H/YJXL*$:1RD*6'&';R/4SH&"@QOHIV%"< ^61"_?T[5">
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MK8H W5#/#=?3[=&F+^GB62/L(P@@B9;;W>,>G][34;J&Z=!AXF7\S5$HHJ#
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M-%EG@L.=;'E*_5DT<")VL:JFVKK&]M;U;NQ\L"R,0M9M/U&RXS L-F&U6TF
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MBP^# 45HS9%?E:ZRLJ(DZOYL;?*3J?\#4$L#!!0    ( ">):E1^(=?BU4$
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MVB"#]C1TD/@]FS]](K#F,!3"5O^8[4^P[P:66 S&W0:!]_>U</6"$\14@"6
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MJU3VGZPF7'T0&G)JDK\3_X>-_BXEW*L)5WK)GW?ZW\W\_WTZ #D .0 Y #D
M.0 Y #D .0 Y #D .0 Y #D .0 Y #D .0 Y #D .0 Y #D .0 Y #D .0 Y
M #D .0 Y #D .0 Y #D .0 Y #D .0 Y #D .0 Y #D .0 Y /E?!J'X\Z?D
M$6@W==Y 7DV-;]. +@#Z']*>D_^I#]"W3H">##@+M$% ] "8'@2A!WWK ;@
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M%76FN;(+O!_N[[_ EW/OBGL-H^C#40B]&Y.(>6J/M%Z)F34KT76>.!B$J5-
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M$WO/&6C9"EGU'BZRONPY0EUFV&WO'C(>:CUD4H"ZWF1=%IVB99L>7U-"/1_
M$8J-6>5VC.N]/\ECZE;X2+-'$_ONKL$KX?/SSU:J1)\//:,[2<Y44<]RL\[]
M.-"C7 6E5XN=%CLW_CG4? R_E&O3)5[JDS4^.O[1(7F[C6)NC6N.Z'*"3)76
M"PQ^B J)4KF:1(>*1^B[&95^V+B@H?SBS'9X)^GNG<L>9/RA6_"%VXO%+%$C
M?"DQ6;TS%\P?/$]Q^^=1T<NC>N5*_6GS;72BMX4%^P67$VA\2YFRZJ.^D_'V
MMM"*JI=C\35W+9RN%A^J-:H2XB!3\[2[7%<M%\ZQIC_/+9>D_8!S]_2=+Y4N
M[Z"TEP)3;F@J/7-G>?B&<1F%#\G(N^@=$V#/OB W;70!%9Y6VCB<LOSL*M?+
M4I!VZS+#L1C19";@ C0= "!DBJHNKU37U5>#OU0VFP)0L(;A]IJFRS?@=,<+
MBO[^O/;/.Q$F"M/KPW95B,"\"Z6FSQ>*O(>]&THGF*,-O!!:7F7AE2&7V(YY
MNC;/=OEN#J/H&=+O+ 7Z6O$,&#KVN@MQ:N8O-88I<XIN%U%S;7236IES=ENT
MG!1?;3J4<K_&]T9YT2&=H4!QX@>Z69;''N8JH44%,?H(FV7ELI><FO[LT%Q:
MZ8W7,1\= GGO2<6/X],L[TH_Z$_+5TMZO:I&AGM]9KW_])&;6LJ1@9OO"^QB
M/?E=C+[T!J@FS3$:Q:2;9 >!%'UW>O2" !H]/;U0$\!R(>(N0,5@;M$BNY6A
M!8$=1CT"P"') $/$RR 5/<U 7R VTH3O]3N7Y56.54C?@MIG+K6%5[3ZM*A>
M/5:^9ADRV<%TX5N>;RE*[E76'+_16SK'F!4OD^I9FYQY-E5+V]Z&GK:S<RX]
M3;ZSO,F9$3=[KYQ47Y]1\>7)9QG3E&)Z20_-)HEK#M,=!VCJ$B-?HN7$3UO/
MM9DD7BL9Q7G)5U_U,WOQ0=C9R>YNJ'>.T#<@!>-\<ZH^AJ?G@DL]O9&<I-TE
M3^<VS.(W "<B3.6--7+P[QW.J7A@_Z+F0;$51"YH2S^'7M0,I'<E6<Y7QSC$
MW:K<0TH8].B8MWQVF3.2/8^BL3?M*\NAFFN6EAU(H#\(,W<ARHANE@,$!;=E
M)FBP+VYR\!7YO2>=<3HQ/HH<NS5OSE([ZH-!?PY(46IAD?-2V;FD13@EO:[]
M!D2>4(-=O#\90LK,P--S5],O]%8<!U.G)HSVB>;,S,Z7-;91CZRDT^$39\ZJ
MT_J]?Y^QS WP;0-S=A9;U4OC52/4XLJ3# *:'LE!0Y6<HNJG[0,<&=O0Z6D?
MV?FCWO*/BZ?&-3O[QQCLED)GF&4>%&?7M[YJPEPY%G^KW%_T=EL5BEU<7E2)
M <23P"6\6D"O]*3FZ&?8:K?3Y[PJVY'ZS<:NKF<)3DTA#U\ (U7QQYQ-,DS>
M5^@GUM@M,RT.E;RVT^#]!I![<UB35CZ%\1%U!9SD1MD5"3@JGN;D4R\)0/(Y
M>"XR2,1'F?;9N?&TM<;FYN?,;X]LW8Z)C8$(OVVTF^)4E+MV=79TI.9);^T0
M#>ZI7D,A5:H1V&"=\M6H!JL?9_31..I;<Q73EP/;,XZJ2DC,Q2>8U93,3]Q8
MK!RC?N+K"TWJ3&,PX)^E#5DM4GG*1'W</-BL7M_9QMF!!8%)H9. :CB)Y!C?
MS@AQ+I<A4V%BX:U-F!&>1$8S!#S-#K>_GZX1Z,>9/8;ZN,2,\LIYIZQHYGVV
MV.)\=@G')CF2FN91 )#Q>/BS=,_'SQ:GYIVMNX^/+'GV3JPN'[[Z].GP;<6"
M586$G9;PHLGYKPWE-XNF=7ON"3RB5BQ3-O!.D4\)BKMWQ#5*)R8#/\!Y!6WC
MV'PD._+E&EB((4D-E\?ZM7OM$@,@<<%@-W3M24C>1&)[M+OZZ))5C=ERX"N$
M"1I9HM?O&XE<YLXZF[705JJNWU5B)M!_M?.Y(Z!%E4P*!8MD12MAH1RX03#D
M]28'-_GJ(W<.\I?-1!O+6\(BHZL4US*<^EB1X8KRYVETC^:HZ38+I6XI_;%V
M.GE^CGW"4N>CCF-T2'QBE[TD6B<C$5"!,JO?U&.6&W*/#W\__'A@HZKHQ+N
M1*//Q1A,YLV1/+W*L6UAY8U#2&B:@Z:PQN4!_/ISM4O\4?P>2D!OP)>4-4ZR
MXYCBCB]5!@W\,GP2DK/S^517[E+1]<=?$CXBV6Z*8)8[=>O]QLZ9#$NGP"W.
M5Q^_=!6]3N/86:?('/@&]#57EPM>!YWO2QF_JT7OGNL6?PBO.W["_JT96Q/J
MA-^1(>G&IA;VX/6^^W)\-^^&M TFC@Y,,YQ]H+S\7EWVHZCJ(RB\9L5 !M@6
M#CS9X_^067=R0&R860C+7?KR*?O=4;Q[M^IBD*'EVR/+E4S4H?[.D[H,(HN)
M]PH_R$C38::8F8=JZAW&I*^?\GOY=5!I4EI]$Q+F_\ZC9#M#,TP9K*4B-<PC
M_FX7N19/.G!>K8(^LF,'!B-U[4\T+XJ28][11NN/6KD6/:'@Z(.0%:IC$Z#O
MW-6^#*"K7[$8?]^IVDQX<^XRE&I)D<6L\F(&7W=&1G[8)O/[?)_\\)$PZ.:]
M0>FT6C;ZO$N'@@K':QI:V!LN,:??/E(8<?:2!1F8 Q1I=,L_#EJGB$HD=JPH
M>676C8BQ8[ \#TA%V D/UYA?$WWG_>132PLC@Y0'O_:K8;([=#K;'Q_:6#U^
MO]S@+#A_K6JCRH)3I7Z 89C2RR8H:F*DM.NX]>7N;*OBALZS%&4BP8T?LX8>
MB%_ZU!TZ=''$=O4PB$3BU?*HP;TOYN W8ZG>MR_'H@N&.#V-P2W&O,RW;XJ2
M0>X,78Z;$J-$GZFX+L5H?HM]<_3*':G[5TB5'W(4<";9+=K6>]/&9B [+GA.
M(=40=IW.GOYBC^M&_.,24]^V"5XSM+F.";3JVWFJOD)5.N^,_O -8/]RXZFK
M_'/3!Z3# V'76OW]+TZ93'J<R8R\;I6\2F'\4/A+A0<C.C(*U]MIP)'(?XC'
MQG<N'F-U/^!\_4/C=DZ>CC%P&&US);=YWI%(TY8K2DE?(\..1UB&Z6ZV?W8(
MO"/?4?$YP])S/!W9V-">@L!YXRJ]Y2G#3!NOFN<Y4!X-5&IH>.\-GA*7/()P
MJ)>VR"G2=Y!_8O3(I+KMN>NQN-1+#R_ 3>,''PI;J5RY5VC J'@VT@W.FI(L
M?<4 Q0C(Y,\]+E\T2VB+%A7_,/H-B)@O\1HM!VGP!OC,51)U.P'4@!9_]OSG
M^/@&ZM#5(Y[#UXL]V?TT%YW$TVXKC$=&4CLEG;%?6;E^3J5J[$&!U?L"VKF1
M."\<22F(RKK8.OTN^!- ZX'4 LY,+EPAGM5(IE%>[^,K\$N+,E<8[+BDL]!)
M+3-$E)W7%^/&U=><^"7:.)!49RL4MY)S:?5V<UW_$R^CG@:XX^8'"1&L&8]S
M:Y#!\(V;TI*'L&=?<@K37DY9$FZQN!%%Q/7BM6:I;WMV^9)]Z[5[+?)5E$>=
M1%OJ3["O?0,H%^MI&<G]/I"D0/L^Q9QLZ3IU.*@[2DG6<3:!YE(:!EZMLC#>
MSB0FZU2(1BJD+4T^?]Q<O&57)M\N%MB2H4D\J]SB6/0L53Z4,>53&RYHU()"
MT):VXCT+1660:(2>WE@*?C=_ED)PY>.,0Z:15F3V?0%ZX9T^XR98<&/X42$E
MK3*?S21R3YYK5:%YIC2G/J01;3B)GF9H3KRF@O<O5[%@LO31U^ =0=5(4+$4
M#)9:7\>4=6R[9)[,NT<J4ZIISFY8)2[9M,F<FX$*%J.$I=KU\#^ZDV<D],Z,
MT;<5-9GCGFCP#FKG3-,W:&<?L\R<UV)EW:3UM NMJW=C_O+1';,-X>.V3>'8
MMUZ9\LZ?Q[*HC+\J>2.N,#+1OA*DRC[Y],.ABQ$T?IKDJQ%Y.ING&D;Q;RU(
MBG2-1SRM:QNK[!)"GYNUGGWJU"8J?[3,QKOF[%T6Z:LKD?KW;VT<#QRS([_W
MM.B*I%3B[)/LR>?VIV1;K/,I]$&6IZUU&^1ZCFO3&#X;&)TL/*D[^FZ][RBN
MPOY&0XU?J+O3VQ!,^3< $O_F?)WL"^^CC4]:SN9VK25PS[7G]6SU%I2L/F=;
M/)0P*L&FG?Y>Q'YXPR1"%H@7*Q2O/D&CQB1/R[@^1]0I,VAVZX[$%?]BB0$4
M32Z5?PR'&"<7HYE[AIB;J?5F]5R=@=;9,U(QPH_[MV(N>.8:WE;:DD,9Y_3F
M&5H5/Z=664,VAIU*9R5JIAZ4TDHJ?-T.]0W]3!F[\MFU8;6C^08HD_D;<*T"
ML;ORLK+(Z9JA^EDN]L[/SLD*:3#-CO>Y4Q+2>]\6%)R*<Z^]>+HYYY3G:((5
MCQ3*LT[]#.RT]36?>+>*QN&RWCZ'D[;O1A[::,&SC76-FE@^B+9EGG<*EN=6
MY-?5RPS=?"\5PARSQA?>N[X5P-8Y*'";4\50;\SI';<A#\VJB%VR/\.D GE3
MO"_=P)T LM0CQ0F\9LPKVC)2/&S)Q6 %$2LPH+Y[/S'"8R,I7^-SEK4A:)OT
M8]<-%>$7Z"ZE&]ZJMU7%;-LX1Z.Q5JWV6<3'&C,O2-7;:H\(+#C==M./ _A!
MOI/6 &M$?A"=,#R\;N1V 30X-Y!?=&SUA8][."N2)$[#3[CB&/+3?>/;,AZ!
M4+P$"]/ AWO#O$BV0%XK9QO^'"2;;I:13KH6<+:?>N<;D*5T_U;SSW^-N!V0
M.1BYOA!&FL+=G/3^$;W!<>M+K][KU(^^<.LEWXCB,A"HO^_)O_ AK@,=,+^:
MX"!M>>S-F>W(\[1J08K/-4(O8Y:J)%!'";-WZ[QZN^#%J%DM&=*8% W#_#LH
M/+5)8GSUHDI;*'VIS8BDI_-E0UNYRPZK7A3YW*Q1E/&N!@:[OMP&3Z5;%@.=
M6B8>57LYI[$UC5 M.,1A6(NL-<UX*Q^?T^Y.J[12)C[Y,D,1'$%AG1[TT('6
ML^ -.ZZ2^.'1R*6D8'G^9,YD385Y7,=0X*E#&GQ6GXON'IFW*E34*Y]644@L
M?'#]Q(5=.JA&F#AU"K!K"?50=N @.PE9!,TJK8$&"SHVOKY:D\Y/V5ZY?0?W
M(GDVB.X;8,$6,$F6R]QC9 . XFP OTXR()(LO)E&B4;SDEHZ0$4;UJ'W#AH)
M)$>!/M$\GB7=I)WF =YGR2Z5]CY9V]XX89KJ_@U@<%/<2B?=^KQ^29#6K,W2
M%<YX&[=^+**S<#Q 70.=A(D_TN;>.PI_Q:?O06VR?'7 )IOOR$/W%1M)/S)!
M&3&Z&5) C9;MBT-34:#!M;9N-OL$>^4,D5%/'%>7S 0I>)@FD+[ KG98/L'P
MPH:8.MRH.3S_&LRQB253[JR9"?-EG@9V#C*!FX'$KD[PHX_EG%U$0IX1BS[U
M29SI,)<F395DY+L>4=!\C%9X8SV265UFS;J<"$1;'+T^^!(!][Y^7&;X4;RP
M)4R@OJRA$N[Q#1"'.XTG=HHG,?L%TOLU5OJW"XT6E"^A"^^3+'_T',:5V22/
MWUH]UIO*OQ"[5$*W^V6]P/JU#5F6_A5,[%G/ZZKG13[=-CQFK%YI6U+2^,X6
MO]M\[E;7O?:8DRJ\([4==JS5N6/'%$[;.RF.'*)HP-J.VHMJ\?-1)F4^4!T8
MU!2_\Z:6JT5I0;GS+,=YO_9@>"![GL,#;\Z(RM2A1_Q,U^T'O@2=HQH7\7"/
M\?2@Z&U40;*1"-F:NI=1& ?P\DN6F*OJY&T%!]KB5T(V5+<&/T@5<\25GHUH
MFDBL?]6-:;A'4]+F5"M\5%DHCC1&+JC1TI0VSC6+F-N2D7Y++_@%!6<'3!.^
M);J^.LFOX\SHB7\[^^2&R$2),04UY/Q5IN,^GZ5([G0"BB21F<4<I$/3Z;U\
M65OWN!$@&8]TW-NF+VM=MUM^G-'VOI[FU8D)B-72S0]ZT:?93D](:%43 +0-
M *=/-S*=>1RPW#1CSO>J!6;[MR^(M9?SHS;%'X1H3-YX@%]6/VD88(8V*GT:
M;]-D9-;A+UTE)L<O-NZ1(BO.?K]+NZ5:+B_6M5#0\_*G96:KEG3=9A/#]7$^
M.M?@@4=4+U&%](>JYOF24_F8%NC<)H6N7333@YLLRAGIWXDRR;I?W,\,@;B-
M2N7&G*& T8/HH3VOL!8#R^O9IVR27R?J%DRO[TB57VR2&PE9J6PS;2T=.$4'
M/YYN9Y).Y,T6''SC4USFE'1"JN]06L.%_%7C[G,Q4"NN63HJ$;Z:NET[]&??
M%KY'\7CO+L.66+Y2Y;%[+,M,TRH)O./;X&C7EZU"5DP<<A P17'*HQP/TQZ>
M 9W(6&VB BO61^:A%_L&<1F!-V[^^Q?#WPOZ>I\R;OEK;ZC;8R@2JE!HHR<9
M)Z7C8V5;'[S!&3[)J.](#]"[Z/I(*E6'^C;.Q;*<TO^<4?:.#9D0)C>B@D'(
M57OC[46CCPMNI8)<&^,O[G$6;9DT<+K[>"[:%4^BZ3.JM":><<[$H8K*:.",
M9AX/#6Y3G<@MIRC;+BI(VUP[(0BP0NA'J7#]!6KS :FVP8]W+M=\>BKI-2HZ
MU7W=(=FXKA9RB-'^;:@CWYFJ3Y"J%4O=<_T"OJ(94D)GC,JRPF(2;>[KL7(5
M2J^$,[G$GE77T^8*7K<G>=J@(> ?-1&='[FX,B ;$..T?26ZY40ZJX%U=?_D
MP_.&MR.RFM,?2>1G=5CRZI*'+=BFJF AX:\_?0.(\?R*AWIJ$^XYW0Q7]52L
M9"R^/PT>GGJ!9;7CYRLN>E)DRWMVX^),G*1=Q) F/\N["<9@8"%--3SL>NDG
MVB.EH(GC'?3]CLNZQ*A%(6M;VQD9]BX*SIFQUJG+00_,[YY_(HL1DP%KT9,[
MP4WHC\),VXIY+[%>,0TK2*V;"?W$W';8H^?T-R!VR^7KYQV4_S=@,*6K??5&
M,ZKN@UA:@[-88FOXXB>1:U8],M*?A#+%DO6F[HE1=-GYS]&<*EV\VQP2E-FV
M:_+E<B1M,82"<>1COE\*=./1T]&( JL.QA=W'=P,BQ,T[*X+HJS,B\S039!^
MA8T>KO+[]D8:/0BXJMYPK'18UOO#FSM]%(>H (/PX+[,B71<RLAHF^U7W4]Y
MC2\,-2W8:0H013JC[D)%1QQ4X]"'(VI<BL\:&(BZ<%8[\6N))2_H-L_UL6ZN
MV[)-FK%PGOW ?_;LI4Q,\1;Z,H[]SL@H+Q\Z4[8]Q>JFH.W%'*;NSF9?@8_#
MH%4A*=R+7![I]F>O1S"^-V(3GG^0BR\:0_5_?% DP.^#1O:KEMYLGNX-:,V[
M-AH:N"(0 _O8G^>H6-Z2\VY-S[&9(1CHLC!^?O5EQX=Q%C:OI;/SIVP,'FV\
M-U'QZT&X/F-^69S<=+RMKI_7_K1EZRT%^H7ND^ZE[)S^1,06672=)TU8K4//
M/"YH-W /":=(WC!8_GP>5>5<]:E8(G>QZIS!_4+;FEJ?4T^K(S?2P]N)H\^D
M&49:BFB/N ^3\[Z(B@SIT01 G?#G#RW=PFGS%1X]N 6;(FQG_:KB#* .BZ<:
M9@W-]TT-C2P,9JH-+Y;RL9U*SM'1">KE6I@R;G5+%]-E[._7\('<T],E'VQ4
MYB)<O,<='M6C3\4FX"7!$R4[U##V!+),X=G8YAF+K7:C;CCHNG;@Z;BP C[D
MC+[F>6ZU1.[:BTH:UFD/EI,B>A%ZUN'P,+U92:80_;02<2'P"Y<9U\6&21'*
MZ#8%\P+-ZU=] A:( %/Q>?/"QS7G0O7X<RJM=Z"LF^]?I;5WJ?N-7@RTCQ0O
MH/] HVOSL1.JN3/U]AN0"YV^7N ?.=%$V].*].XR;_5_;'G5,B>4F:LX^OZ\
M]?'+]9X._!EGEKGG9?"X4+R^1:D=Z'4GS/C+Q[/U?9*9QA=[S*%]I4FQT[T?
M7Z8OJIK+JA>*CO#N,"\WKJH[AZRVDDC70;EG UU9%EAO" V[8)-.?VGF\=V4
M3>'[^)K3[]%#?&!'0.]J[!15DWE[]=OXE9NM/6/\LV]EK&5\B.J8G-J&>.R0
M4.*1L <;;$4GBZV8[L]E]Q0MZ%(*8+\O<LP:2]ZEL<N2R@;G8Z*BTSU@.M8F
M*,<F,<5#]+7O>8M&X\[R&I<:VAS-,7VP[7\N=MM-3Z][!DJLF+*X8NC';7;-
M;8PS:Z?QDV!:S'6=[K>C_D;/KPC.9VKEOURL].S52#*7S]:NDV-PG+J?.R]@
MY< Y3\Q=VFD)C[@5\82CP[?R&6$[LYL.?\HU4ER?==7D?(/<C16O:-B[W-ID
M9N0=E:*LA2/29*4YY?FV%WS=8X4CZ:S0+_OS7)EF;9YUF#_;C6>0H4H!!GG6
M4[B#WE6:ZZ?"#EV]7\X;5<Z?7'G5",:K!;52_LS5M<FJ14&B2$Q//ZN\H =(
M797./_&U=:/ORY+\V<-C.W?SNY+<UAUL75XAJK$-#\K+U)C=7[[@J3I_O;OI
M7-#DC:^OK'*<4R4.-Q^C0_?8?K2X$]1G43/1T9X[RB@Q?1C3PA!Q?7"898A"
M_2[H1:)N?T3W%RI1JI?!7>67_&5'U>LL'ETG&D]@5'7*&)MF?\20.DA%/99;
MH1C/4BLY):AO>E&T[)YPY:TQ(XW+;IWTO#.EQ*$;BVMGWTZZ\K]O5^CE#TFX
MQ8&U(DE<^C3D-FF;8"H7=TX<U99SU%I)W+_[W(-U]H\&,\D(S]*^L_CCEYTS
MSE\W$&'N9& Z]5!PC-\D38LC/.R68'?^2-X@?&9YL$-D\A*+R9&GF\$[WJ4!
MYEV5VHIUYM9EE\1T60TM*.[4O;BCWY)J)?_T\'TDL^!]CMDL3O@9O5BZ)=9K
M#.+^[V@:*A^N#"7W38P*H>VR<8?-4_.QS15F>7'QB7XB\)O"[G'Y7 QVRLSL
M=SH\>>>&R 0LR4AG24D/>RAGK;T?,LT2NI+R_+1:Z'OICQ/CQ-<#W[%LM'@5
MJ_'+I:-B'.F+)HZ:2Y^V\;5/RKNOX,C+GZLVV>-PQE<WZ^W5*2$1O: NU&&#
MX-"DUB>"S$X+,^&N[U HQ&W[D:)Q)ZY;+MJL2/*RC/Y>\_8,A6Z?$ROV/JE7
MGKF;;FS >2<!LI!']#*]T,NLB=\ (TMS&1K:LOR\EM>XFS57/Y U=+?<Z(@>
MEPNZ^WJXH"W/[J2RVZ+1U#GS =52,:>8NO>'/]:A3L:SVK^2N<MTC;T$87+9
M4H+1)W!9T-RB^'5AJ[.:O[C+#.,M7AFO6]Q<SVX4D9-977#N;O+4OW=2X9JX
M<#SOT9(LF=J;G(AUPX?6C"G\'CG79WBS7@(XZ3<F/<T)A:IYJU07$SOTL6M'
M1@C'C81C(F-'G5+*)RMNU"UUJVZN+@WHWTRQ%GGO2>=LF#=%26D(M@28K1@X
MM"!IM*S6&LV[H<&?*!NXG2+CG ])/QZJS&UR#_JT<EC&)ZI?RJJSU2K'A#^%
MZK(=)UFS"C&=Z8.8<H'W7+Z1AA-O&;<DFZ)MR%II"XN*[Y;VW_3:?G)+>UL*
M'W7TK,=#<XJ&H$A1W1#SXZ5 (>7UJ4)#0)H*S#&G(R1H"DFR*!@+7"V'J>\^
MN!#BRGMR/F:]\P*4;W"==C&:G..3[$2[4 UJG&O^K!Z.AUOX5=EQ)VN1[;)C
M9<2P(O,M!>-9WS7MLVD*S#EM>.[M"\*Y\>*[N*S@+A?.'<% :$2'B)C4"J\+
M,2,  '[].]WYRJ_7^^>D'SQ??B?)51X6$YB9O/V%EOOMN92)CHBP-H6G8<B0
M'70GB0F6B]?ERKV/P2-IKD,?PL_EZ!OH9]]_*0\XM>M=,Y[VVV5,[R2KI;$$
M*/E#-]^N6=YYO?:Z736E'TWQV<IIXJ161^RE\R5C\\577&W/GD^&D;(.+=CR
M5K!UU?JM)'OI3QF6ML:5!Y0*ZYD6OLTRGFDM##I'-M.[KGGD4W;:*V.0!X!E
M588PZ>8K+R@M!+W86N.>H!28"+E7'*_H]WZZ\$/\JP=U(4/W]9SK2A)M5"2.
M*^E;Y\DG.S/F":1:EO#&9O4HZQ7RG%M;[VOW)D\>4QFV<[1;>.-_Z.VC.B2W
M7-W]=[K1B"PI.I8C"[:.V8\^5)@/G\5S4,06$@.FUUY0<M/BUI<)>Z,GY5L]
MJ[(;#-4>/**K](RT;(V)@4*'Z;GN;5^BBB&O<[_5N#SB6^1>+&(416)I8WH%
ML(X$8)9 9T'$SDO$,3O8>LAN&H(8W&=;8P$>9->T%>0I<M,VK%3=B;^F/H((
MG7"G$*8>4Q0RHL$FF]B043Y[EK\EPAK+AXH]C'\:=G=#L ;O4>)?4Y9(8@!K
M.[-:Y73>YNDC.1#)S15EQ%<D2R<\2F+L_;'(PDC279[M./KLM,61ZQK;AJBH
M?IBH?,C4\(KWQN<@!\8UDHQ</V:.875DK&QF_?N%4<\XP9#5N?[L!V>L;,@3
M84JQ [R"V$H\/ZU%LX#;L;\^"6%;W9K9J+AHB*%FFZDX[/1AHX1N!8:X=L4M
MICYCJHZKY?##SLB!GHR Q%SH*X,CQ&\-RJMO8>/. 0P%C3-M6^7<;$9+26;O
M- J\Y9C$[CUT% U-]'I.BWM^ZX7'T S_6(8>3UZ->ZOVO6-6F7KVM@-%Y*QG
M298JWQVO1IO"9P;#"B9J-$[?3U6-Y57A.GM?F95-[:4-NWU/2OBID/<!*\ZW
M3CXWK6\+T369J @50C0<9GEHWRV10\TZ/'7;7/1=? O3I'181B)HT9@)0=,L
M;R9M=42;-WBA,__6Q9Z(IWZ\P)G#[R^ZAIA^(BUX>"*B?//VQXBJL1N7OYP?
M')YF<!9NSDG+>EH&TKW^=*5Z"<6<W>0DM*APB'%LJD'&\JV&-8TG?"(S(//!
M<'26T7RB-5E2M>$X:- G(@:::-B"7)X(OQD1*HH*GPZWT'KW-K@T5"=BP]W#
M\(:63%)2;AV7N:N@K"&+5<E]^[C+BG)O<I@2+HQF1S5W\X?J3G9\\<HOPM(W
M@M3[:M:256B_ 4H[ZQ.8MOIKSLOQ7S5#KJNJ^A?JJXPL"N)WKM)'M#SD4WJX
M$U+]Y46K?E</'D-M>3$E;$UY;B(K[,AUAN0OQWN-F)6>S/)';'.L]5G(#HZZ
MZFW1&)"\?CT]\$Y*XDKCA/VG/!Q\G)ZEV_9J %'^X\*WB^5J\H6".]6,PSNV
MGGEVQ[*2;]^^>;3UIE+CR,HZ5M9$)<FU(JHG;L&Y2\*--GTVJ]<BZ^R$;^@[
M7/L\()W;5\S&\6$0K*H'TQ\)+0A?$9-/\G)$-"8V1L>,AQ@T,)LB9-W*>J4F
M0]Z7Y=D<G<(=;4S"]B3U6@\A.FPN7A[$=P74D-QUT7\@<#C7;3>5U+FUS^J]
M3YN0M(8CVW._=1*'11JUIP-.'*:"TI<+X:R&::RO3 OA9+MZW??.G59;/X=^
MMO[^C1OQ3%?9OSV"+F)N)7+?)CUHH020-CRSH P"@6:UB-3"NW-Y-^+Q>J'1
M,C$7 B%]R2O;A!O:R.#:B\A5+FF-G?=+M:N).FJQW/Z=E5/)/<K'"VU*P-8<
M9);26L$+%&AE8$VSH'_WLT.7"NWIZSEK%085,13+0\=T.RG*,K0EN3_&=H:>
MGK[(#^*\<3M4(6_^BH(>#3]1SVRV5E>V86I:,R2_DQMZ,E1WE=6(-+/]J<*F
M@&M3>.C1)V/D2YSCMWLCKKHGG93 D@]6GS4FH0$ZZW#9.0\SC6AG^)84'9E-
M8.]YHZ6 %_YD %=GWX//CI1D,6_&3>&3C413!O7::3+"A8_,+[O?*TG54UE)
M=^QZ#>8O"'G$;.=OKF5E1W-][)*%S;H6"$CFOZ/A3?>$O>M"G<OQ"4G_\49A
MA3I?!:(BSN:P>%AF]8/&G.B %D<5'X^3O8X52*;I%IF'M@%18A)1):918..^
M]ORL-U<!-TS^U]C7,^"ZA1%>/5YD.ED.0H3,<IOI&B!BPMT/ #)'(B&(08J2
M/T;ET+?)_P=02P,$%     @ )XEJ5.XIVCEP@   =<X  !4   !F:'1X+3(P
M,C$Q,C,Q7V<Q-2YJ<&?LO 585%W7-SZ M'2G2$IWE[1T=PG# $,-S- A)DA+
M*Z64='<+(BD=0R,J7=(E\@'>>GO'\[SO$]]W_?_7Q?*<.6>OO=;ZK;WVVC4(
M9V-G'P"X2O**\@ $!$0$+P0O .!L'=]7PQ;B"H'90IQI>#FX $+2BJK7K@'.
M"?]NH\*UWXL 4DH$(P 2!8,")2( <'Y1(FH KBF G"PN91@N97!KXQUD]]AB
MZ6QE)B2+-0?L+NM$+NOF+^K/;X3+$J8S%.SDJN[FZNSF>EY$ON!IP%RU+2$0
MATL)12=7$,C)S?''^\53Q@%Z4<:YU-4&>UY(2(-=+W1^MPF"JEDX@G3D#'1^
M@GU7T(!"(-;:(%<W9W5+.^ Y^SI  P %0,[_60-H -H $, 5X 9POE3!</XI
M_<.,M(.KTV\>7;=T SNX@ITN39Z7T2^E950-E;\'4/1"'I']#RW&_Z7%ZLZN
M8(@3[)Q+<MDN9U>G'XTX;Z0E]&=!RP:F^GL-U$GF]X*3Z^\%%4L'V,^"FHVK
M^\^"G*.#[,_">1Q_-RT-M+?Y+1#?'01H*4C+G#^0+M^M:&BL(&Z6MR$? #](
M >KT%YZTPU_EI*%6.KI.KO)T6@ZN@%](VL&*YN_X6C 'UTN^AJ?#;?T'S;^Q
M,=Q!0%<(5-;"U>)G5FC8:,!^9,7%^V]/F<L@@*Q=_\Z\SGEJ_QU?&^CPG:\!
M!=XV_,G&!4(ASOJVH//./>\OL)/-CXAA7U1HG?LD#7%UA3@Z0)QL?E.Y_J/F
MPH5?^%@_^%I@&]M?*S!_5)S[]I-]D3E(Z]]]0&KZQG\^R!!^/"^SBO&R#OOW
M%DC>_ZYU#>NR>#%./2_+9#_+U)=6=R[+Z#_T$"ZUF'"_A_E']W]'0=J[?+\#
MX+2V/J]Q./]$^4WI.R?U1<)/#L_EI]'YYP\._^4G^^^<2YN'E^_G(^GL;PEI
MZ:+ZOU]W&0NT[Q&]] N >/O[_5L=]<\X?2^37[PA\?_T_CL].]=1^QFZO](O
MO$NY9_]$X"?]/C$ G-P<+A(,\0+6$N+F9 7[T[@$NG+_</,BF7])),"?,@X@
M_7MF7KJA]3/Q+EU#@3F @2"8GH/*Q=!!^ ,.\F7=^0O^^8UZ65"4_<4VJ@T4
MXN;\!Q8*! JV ?^<%>6T+Y34+WGG92P+-U?(^0H!@EJX@JPNO?=R_C&I8WP7
MON!<U"@ZVM#\/V@_DAO4X0]+PV7P_\A1A=G\<?E L7!PU;&P^0,/&P@ZUP-Y
MNBK"[NBHJOR8H-!^L/\@C&X+@7I+.8!M?D0*YWOC[_Q@7T37"F1MX78Y0Z&[
M@Z"N?R.N]X/]1W%,2QL9B ,$^DMP\;XK2"O\K+AP0PWB=/%$=X4XGR]#,-"O
M@<-P. _D7[C7+2^GNK_P,:$7$]J?V)<CZ-9WO?,;4?(+X'<^WN4KPO>9YQKA
M9>FB0Y$NRQ?R #2.WP+VZOQF.G_]<)X6YTF!A@\@!2"<C9VM ZY+64$L0>8R
MJ@#$LPT ]F4)8'7_0N]L$O 8<!T-#0T=[3HZ^G4\3 Q,/"*<Z]=QB$@)"(@(
M"$CQKE_2;X^_)P0L3$PL;"Q<;&Q<0FQL;,*+#VS"[RIX_Z,!P!5=T15=T15=
MT15=T17]4SJ;DS2P=75U%N'D=()Q6%QLYCB $$=.3PMG3FX.+DZ F*2GLP70
M'N1*8PDZ/U*(TV[6-='2@*W$:?7Y5;E4G65 MN [WE"0MK>:#M#;'BAL12LI
M@2'F*>+IZ.P(<K6@\71T<(*)>(K37AH7.7^_8'/2TER*N-J+TUYN(6D,5#5H
M9"!0$ T_!R\[D(N;FT9 @(.;CU] @)N-AH>+FX>3Z_P28.?F$^$7$.$1I/F-
M:"4PSC_%H%;6(EJR\K_!G9?$:7]KEX>'!X<'+P<$:L/)+2PL?&&&AX?]7((=
MYN7D:N')[@2C^V[DAQU9$ P(!5]^/T1S4;8X/Q&YBM/28M#\0M^!G'\!^D,
MSRO. \C+^=/RA?%SIH@&%&+E!@1!)53!0"@$!K%V;2FDT8= K6BL(5":GTP:
M7@%^,<X_*/QPD?-//OZ[OI^'_^]]_]'Y?_#]7%I$!@JR<#T_S)R?M/Y7[O]9
MY^_,@63/;PD>+AYN=BY>=FX!'2YA$1YN$2XA5BY^$5ZN7XQ\E_R3#56(%=C:
MZ\\VN+E$^/E$>+A^M?&+Y)]MG">DE86KQ?_*RJ^R_Q=Z1%7UG_>)HR/GWVG"
M7.7<7?^Y)NSB#,JI!8)!W*! D)P[R,F5[N]-:8'^05+_O:ES<;H_IXJJJH@L
M!.CF> ZB*"OAY@:V$A$4$);GY^>39N>5.1_&?/+"<NQ2_-R\['*R@M)2PMR"
MLCRR0I<Q_J/N7^PJ.L%<+9PNOAB1.&=P@,]-\PH+"?#S"4IS"PH)R$ES<TL)
M\/!*"_/*\?+*RLL+\'/],/N+ZE_,?O_*Q,+A/W'[;VS\!><.&'8^'+PD_A#Y
MRT31!KG\D?NCP@%\F3C.%E#8Y9<UXK0_0D_[%X4+G<MD$+$ 7J8BS,(=9"7&
M^0?>/U8"_TUP!?^GX/Y%]1_;][ %.?UUB''S_1ABOTC]8R,7$XR'!10D97,>
M8XGOR\?O/T*1T1:@N:4/=K*">,"8?UC\H\H_-@VTM7"R 5E)</Y0_,'X2\=P
M?N^9_T_VF-#_]1[[?5*\ZC$G"2#$Z>+[PG^AU\YQ+,[W02 H3,(:"G&DL7!V
M=@ #+2ZT.-V=K'Z;<YU_AL@50@-VM+ !<8*<8=8_4'XQ\O^PL58@*/A?2=!?
MO/P9)YK_OS7Z/Q^3_^,2=34F_\C]XW+X8XG]Z_+Y8[OQ/2WE+Q+K?]?/8I<[
MG7]W OV3ZM]9MOJWMA)_T?T[TY#_:+?R#VW\-=Z_A/6_OMVU O[<9CJ[01TN
MCVA60$Z0 ^C"'=CY5I/[CV<0*Z (\/MQXE_;/DE<_!^)?R77_A;H O[\D.-H
MX2KQZ[3T._>_'9^?,^$_.&+^J/[K8>UGE<CE3Y_.CSX@"3XQSK]C_U.GOW//
MS]7G1WK.GV?ZOQOY_WVZ KD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y
M KD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y KD"N0*Y KD"
MN0*Y KD"N0*Y KD"N0*Y ODO@V#\_EOR("<K<5H/6DF)LTF # #A/Z0+(_^I
M#82S-P \-$ THA$2 AX $0\!"0_AK!5 #4  (%Q#0OCE#Z.A(:.@HB,@74/$
M.*]7P04@( ,0$9 0$5&04='04 '7$!"1D%$ J&AX^ 2$-]&)B$E(:?7CN'FE
M!D;H>#0-7#PKZ1F$I1]$IC8S"MW1*JGZLL5T2]["%EIQ;HWRW \ XA_0$*XA
M(Z&@(J*=UXKA70 A(".C7CM_7KOXZX?G6-?P;B+C<TMIHA!8N'Q!I3TW7-),
M.#"W1<=#1"^MA4;,RP=]6'HV ;B.=&X:#PD/( DX_>J,"OAYP8O\]H:)9\P\
M1UD]3I<5U,?<J%K<FP2?;9/4<QN*2GL?9R'*&[[OFA?<'5]9P.*O" U\JV]"
M*)BK/+@M2IR.EU:(M=O&9^I;^HTM@NO;3=,7!2]SG?VL;.2;2MSV8FZO!5;B
M:!>%%):/3K^!F,D31P5GE>1"$&^^F -6.(I/OXE'IMQCGZ=1/WS&O1CF/"OF
M*W+H6QWSJGYYVSM&K%7TY :E/=D8T$31=$P17O?U&TE.:_<1/JK<U+(/J;W3
MFH3R!!"90Y4/+RS]+:8Z+VU1:<,S_KB1AUY,0\%]*3E^+S]$2;!Z\4XGGP'&
MY09-F'11[W>Z+7G XX7?MY6MGA"/3I;X^*.J9JZ>: LNZO5;LB.MYD[3/'MI
M6GCK:3B]!J0'[3['V TQS]-JS^UV=OYFRG*JTQDATT [MSO$HNR5CUJ>?TW>
MMC<;[ZGS$B^ DXQ-*I\!"$4^R7NZ]-B[Q7#-]$WTTTF'YL&<Q%1CK1ZV>)3$
M]44,I>V82P90C$SS;;6ZS1=2]&$14S= )[QSB3:3_)J,Q[B2>LX &N[ND$+F
M.FH9'Z3L1TVOEWI&?(NVM#K>LMLSK#5L,S3IP=VQ6^C6VF=?&IL3AG-5PN]4
M$0$?;OMJ]?*;N+8E?$V)4)-[6_SUML^0 J11+;!XZV,WZ]-X+=L)XZ3>;B_S
MK+RT":W/K<3Y7XOLYV\K*CJ^H._SN-;^.(*<GKKR3B:T8C7K T-A@UA)NJ\9
M+#9W;NNC,85YJWJGKUR'@0_E&4!-/:V@?R6P?*+0CG*#R8*(_TO%R%C^B(W%
M$>\3CD1SKFNI 63&&6MO,X!S]"84%M[R<SL[A]^<JSTS/^4* N^X$,>,$(,>
M'W_,MWLCE'!$KVB&@!R$1W#M2#-?D9HM2@3U3IB=N$&A?!IG&H;.(=)]H?_]
M=4WTJ]0^N5/3ET==?I6"4L"8$5"MLH>;5&9.+:LP2,$:BYL TXKHD"5 &Y=U
M(HKGO>[16YVCCZ?[3 AV P6-%=O=?@\GUJ%D$F,KFMXGZN4K"4;AH]->Z T[
M-NT;R8X1)@<;=?(GX1LC8.]T [5V&&QT_/K=4S=8:7[?I_?]H")[-D>VO9S8
M4IN(S-5 :F'6#R\I%^.HG\,Q62G=##YLUR17-4*]F"?*W#R%DR65=[^5#I6)
MZ(O+#1_$)@I5^66?5DFWC^>O*[6,CY4OD'QZUSBZ/([<)TK$']KRJ<C$W!+3
M,W($C8,X89&5D[*12D_D$TZ ITI*XZ;$]/:GML;3B3E6T&H+"1-0>3!@A.&=
M7MU>:F(+JD2Y:!1(0O9)S;UU"BFXG-Y3W,WG*LO94B _[Z^J$C<XIX[L QJ]
MS,1<(>1>7_5)T9.V$SO$,[])?Q&WL8I]OETEH]=@+*6W\X@Q/+Z]<\-BK;1,
MNTW4^C6!G[K",XD6,O&A\;&5-5WR!77Z.S@JAU[V16_A@9B-+[<H-AMT;>-&
MA=;DRE F+3K0V,"1@Q2*[ 4-U?06%0_NBH6NRVPXW"056F-2];N'_N0=N@P)
MO"RKG0]UE;KIX1Q'S?+04GU)>^O'Q!Y))A]@10D9FR3D<,3)^FYMF'C HZ*M
MR4DVK/O>FV0^W24<(F< _VB*^NL<HP=TL*#<@,8[E:[J117RAL8VXWS<^ENK
M\**.(3,QH<44O3S6Y0#5V6LGL^5U8X4C36L-$K>K.S.6V /,,9,R&;/K::A"
MAH:]$Y^BT4Q3#53&5"8H%C3=9'O5',=76$PV/ZYX_:4BB:G;YR,"2C%_F(7)
MJU_GTG]VX3P)"_>A7N#NBY@*]:X@6E,XIAL(U]F#U.")SP2G;,KN[>VJ(<P'
M5%9[=+(!4*]'*^XHT\M(MW>RU$UOB_=8"O<=W#NHT37=.#D^_H)3(X7A.7V]
M!8M-'9CN"I4B&%L0/P/0C>7#='/ABB<;=EGI+T^Z@C>; &N/7=KMC:_AMHRV
M=22,I5O9CGW29Z63M61*)RV$5C3UC\!B\8CTA['OH?EM*WYYMZW2]H[WFX#/
M?%C*&< **CHTM<_[.7JBG:6B\>"8UB=Y!36!I7;LIF9J$<;-J:B*?GDV]B!C
MD;3>$ J#,)T71K.Q1.(WUB%U\ %QI* #+$^DMLC;N,]:1T^,*65:VNC\-/VR
M1TOP"$;P_,3%Q35)3H10"?3UH[=R $$B[UC4\;OX>'QA6;LJ?3XDD[3^FUGI
M3:>'J&7_RO _OU!;(]OY(,&VXVQ:_(;T4.ZBL#6H-ZM9.VU%C\X)JTEP\,O!
M)*2VE=SV9IK"0N2W2MG+J)HTAU8P_Q[8Q\/3<*B_92Y+UCXG$KQC62"J^'#>
M(:V4.0/%>Y^2/%M/&DO,GJ+Q82OHZ1N&('%JL8^JA&^5VI21QNG(/R/.KO8V
M=KLY2;S$"L-PANU&J@T V78<'="32JU%6MH&)[J@^04%!3CTB9C*QOB*$JW;
M=[AJYFG!],XD,#FRER3EGA1??!IO.&A6S1T<^WSCE,]JW]Q5]R@;FEY*::Q'
M?&[F'O.&+<^JD/RF8RHCP3.#"?K!4QWU ,-$H67* 8*UR&XR[H:RUC. (EUD
MD2P4(>0XHOU;Q3)_OVH0XHHRE=(PP]Y"GF;J^.P8SDO2_J7FN$U-H+W5Q/$#
M!_6']<3X W(6F?2:@HO14RA6H2YSL.3KN*V+E0+" VUMK"_P663;68V""\(H
M/X?E[5NRI&OB>:)Z_ \)7URGXLB=#&ZD(+-UY*@TN1?$ZQ[[-E3WO@=81SO/
M"@,)[ZU8)G.) F)72FCD>B01Y6@N0D%!9XH<63IY9;KJM&&=47AIFM]\4YMN
MBEEOZX3WYU+$:'%-D-FXTUS\2KZCZSQAG-N\Q.V<R/PG5&Q?/BVO?#/G+J+B
MWNM;_\)\JFT_[SII1QH14AIYNZ%'?\[4W^_>/1Q3>.13CU4DS?J C^_KK$UP
M/>:[7P9,2#O>#F*RC2HIVG6D+EF%1S(=&]?5C4XV\2<331])5.049ZW2^%"_
M7BR,Z"<4IHM^A1]\&SMXWVNJD_3C/6L)(ED=2%K6['U5"< '['_C0B#@,[/8
M6_ 1K!L6%6PH+EQ-Z>K?"T^^ED[.+%/1/6_O3CQ:H)TO^V0X3]>6CZBU5J\;
M!*:_BX/3R4J=.A30*-$HLKSSSAQOODE]K6/(3S7_T,YW%S]!XF7Q2\.HWB56
MN;&9O:/V8<-Q@W:2-N(F"5.5_N1=6(U*3ASI_/&NU4WXV]=%+QFZV_M24W;(
MUUY/Y,17]TCXF"JR#>%0M5FO5!X72J/XM\E>+\ZE+Z'BPZ<MM4WD:63ZMCHQ
M<N(L;E=RP$'][[09)4=RF7#"7_U;'I'YFOH9 '?%?\O\:_6U^;^1)NS.NYF3
MLU[P_L6G0%T#OTA9!<RG40@/B+6R7CPJ(=IIO)4&F\34-&6I(!W6A3(!AOOF
M6 ]CK/SQ?.,]IFV*]O11]FRL**3HO554W:4*NJ:,EC":#8(KHM71Y0P7'I+L
MN*#[8!66$)O',<KKL"PE^&+>JM[RZFULG,5R$]CIDGI#B? /+YH^NX.74 N!
M& 0YT,#>KG<RX:Y7K;+POD "XC.(3<_Q;3^:H9$A_,9]!8QVN@_AAI;@.VWI
M(]0-WCLW[MV[-E'TK/,!MC'>)]PCE"<+(80Y8AJ$)14VP<P)N5%MG7X]86>
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M%"!LO[NZNZ\H"K5PMD;8IZ\>$ JQSI/I"QQ:I3$<"0FH10PVVT6Y0'?8^V;
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MD!4Z'I"R7JY5#T_;">77A@G:$H!,> \=G4#=)79D[_Z&^5#WC6'N7!U^ON%
MTJ[%0 "]A+/-U/Y(<VQX_#ZS3*IJZ!/ /"C!?[K99G[!)KORZD/N?$2NI(T-
M]HV^D#)4",QJ$Z<2#AEWJ7.VF&J-WRB)UW%4>9^XF8GPA)B],EVL:7>L%A")
MCO'9,$YK24P]J57=S4#>XO[)QR5^K&%K?:?_! ".JMC6EYG ,@2+[18S#U;"
M-!5PSU9\S&-=]?':A)J;!TG[MR 09Z/EU-';DKJ)#/<6N[@Z/Z\)3E\[=R8T
M7>?M+,DBQ.,LA*\"C1>U<+1*A[\KX2T>QK!795R89=4P+?F+7[/"9G+%9X6U
MA *=CIYD/(P"$PUABK^^E.EWJ1?3+]F*@FILZCZ8[ML8%EK:6-;4\8*<K1C;
M[1W6XVF/58#6<1'G!;%7\<S%/ \S*2JGX#I;I.1WNX<8O;KAR_<8FXR& ;.N
M)(/XA>53_=]5G*V">UMKSS );;Y*2=)910?FC5P),M/*W,\:J.1 %%JL)J$*
MBAZ\A0JJ+IXCY&69$4R]1H([_0Z7]2;Z>H/FAZ]30#"$F0T++V'+I0WYOM:&
M]K!ZP 04<WI9Q@$*'! J=YY< LES&38.@X%'6F!0Z(X $+=H2A4(!-[1T'A/
MZQR$7&WWPH/*0R;Y3Y@3DN+ARBG31+67-I1]_8O/[ BB6X%]X3%?/,<CD2:3
M\\?22'#<Y#1Q%F>Z>1(ILXEL4#I%K87V[PFH0CXC?7))=/S'Q%3H9E6M@6!9
MT5U]\<NSFJ8TIJUDE)QK^5"\, R=WB/P XDN=[@!YA%89^7%J=@XH<AR:%&Q
MM,I[KA&R/W\L-X9YX)VQ$5;Q+%VU# D*MA[OU0*DLEY_T>#ZU7 2#SIY^]8'
M8U:\X/ESS\\:'I'E3<>>I53M81AVJ07SRP3J51HQ\_;'*T[2;IL$R"_4"3(&
M,;65?4A5H*&4BU:"=-JOPUQGH7S91N_MBV57PU[/EHE1RL7=1+?,,-&5R81\
M>4F3 2&KNJ[Z65Z^N'F"0O-%_2Z":;>#H&H@^G3\V[@HK]4T!\480;9S"?+8
MFK[0&Q3T6TP,=%.GZA2F,8H7JWD09DTY<>R0:L^'294].NW'BTS(T?8:/4'L
M:B(1],%(_[IZQ$HK Q17S)>^P\C,2]+#MVQ$BTK2XR9-UTA#$G'MBV1S+RL>
MQ#$*]%BNZ:%.32 O78[B/>R<XZC&]$7:69,X?\-]8 O,!P2P<Y7VB4WDTD3T
MJT9X\8L9^^(M(U11V>W6OCD$7>Z]7#U-(K61_AP_%UR,G+!TI.(S]7+%F;'<
MJA%EN3:A_GAKB&4_37!%(<G2YY3-98Z#'79NGN:X6GMYVW4_S&@*7Y9 1"OV
M=MB@!L@3S)WP\,*/!^/,$YIS!<)^5Y64CX,OD!I!.>/@GU0=5?I*.SOCG=ZU
M-PY[>TEB9@U[O8+E[)RGV^-SXZ)8B]?'Q=#)KW<,0BFL%K""1/(!A$6[H'/P
MDK=.+DVWA:U< 6&NCHGUJ^&JNI)7OQF0+P3=@\JM-X-7@C);;A]O;\Q_LJOL
M%U;7UE VBIL; W-:$>%7QO+G&E(:;$Z@,,_+.3(I*0SY$;NZ,_@;GBI:Z>O<
ME%A6[Z^K/KPW,3MB:S73&8Z+2TXJRYQ6GMJ"XZ@OPX6V)\W7GH\HXJE0M=TI
MNPJ;&PKJR'[C8 @RWCO2BM3RH/O\>7GJ1%)25D_'9#(K?D5?XGMQX)9*27[9
M<&I3#5R"?:LHR' Z^-O-.R26@FG$$0\S))"A%1K+)_.SS$=8A[!S)VG\8>[*
M]=IMI3?.N\?63(]\-MJI?Q:3K$\FQ *9^,W\3HX^/82-3?Q"%,^UEO=">QN'
M[<>DN;$^3S2VO?!J._T(= T<5;@#V4DTRRPY/:]6.&UN$-2O,A_:?'MXO^(
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M6-:(<8!+-[B'E[-N'RET%?=[+^,19'V9R=H]<%$2Q(G0&"_;8Y%\0>S]T7Q
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M>>&E?4%>,8=;3"^KG/#$ADQT293,*67#0ZF-TZW8-)M!YM8@Z-$IX-VK<?\
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M]GBK&6[TSN<O/A1%,3V^X9IDX%%Z,W),SN-S<ARY-JY'+U]HQ!B$62PHJNJ
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M4]/;3.U5CS"[[.ST27UZ68-)%/2W?4U2>ZCP/+]+Y(MY;?76,]FC%ID(OI$
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M5I(3NRT3)%G"C<_VQ3:/A\:6@Q)/WI!G)76"N&5*.WAM?KU6:I_C/LO\D]7
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MA7RRL*A%>D6[R*C%NPOTL@J5LJJ.5JK0LK%JJ\^K@@"P" ^+O$@:M;$7#1H
M$UPBQH5/K+7@I[5!"[W!SL0[QUJR<G/L[,B4S_#_5/*545%_7=L@*D@I2H=(
MEX BG=(-TMTA,'1W27>G Y(C,?0PA(12 I(#,\ 0DD,C,#0,K_][K6>][X?G
M>>[[_7+6;YT/O[WW6>O:<?;9EPH47*"MP:<\J%Q9T.%8PX_@AR>3 U6RG'3
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M'9P\8.(Y8O/[R&U4M.Q94*ID2QNP]::R-=(B."SR](A--0"PC&U2>UQDH-[
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MS2&BT<KCW9 &(MW?%#!W_YJ!<A":(L^ZQ\JV<*30"R\(2KQT9>.A\N#3P&&
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MR!/#QP@>(CZ/[:9I6)/=V,Q<?$: ##_B%\=1_B7A[6"!4J)"?1-@?$]U!U0
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M/PMG9IJ@R\06_Z=W'.40Q?!]Y%G)HD<D;@B4*B27'/95F[1\G]BYB9V)7_B
MF-*:+R;?*@=):Y7G*"KKPK_ 'Y-O5\ZF+/,LJ^0)/ ,(,(8W$+M(CNY<-)QJ
M,IF@%PH\B-E,[HHVW +_QEG<.FSD'C@P\,CX[%:J[V\%B8V:LG99B2B-12YW
MKWP"%2*[C^;_H.O#ZB\E)-RQK?'])Z+<^PJHU+DCY;AS?E+&F&I,K_,VG.C#
MQH2!!UPN_1SX&A<5@,!E[-_V#Q[ZE1:])&>(?/7>U)2I=N@A;+(Q55",1U%>
M.$:[[3>=PUMCPTB7=/A<68GZP6NA\@B#7IIER,Y>%P 16G!V%W17<-=Y[89E
M2=K^5=B$66M2GSVN_5)$@?3U9_X9_XQ&;<;ZP(5!4>$M"\)6LA:0DVV,J8L)
M'-IR!#-\])@ Z+7;YI$^6\ BV$F/;X+JBWAD&!5'S+P&:<EPMFS\G=+[*!U\
MI)G!21UPX!;HX02_"#<W_%]+8R+_*X.1B;8+:I8ZS<%X-R:.J46"1I@<]5O3
M8@W=:_D<U'#Y;E/2"QBO-V@/)$)BWN1@XN.(*K=J0<9//6C3$?4WUS0O\%G9
ME\6MM7"(Q2;27XYS@=O7C[1+N >DC15O9/P)R01I@9?%AA1FOL(>*2F8JC5=
M/=)ZT6;@V!@%EWEGQH@R>NSJ?R75\> 9].3Z5#,(J5E7#@!8Y)H)P&^61_TJ
MX\_:WXF[1IR2-RZSE(K9C@V>CB.W;/A=X/+CCC@JM[^QB4;Z57V,T3C3K7M8
M.1Q@'ZKOK,GR1 LCVCZ!PX9 T@3:4U6WE>7%;+2%^Y7)REX/3\)HR'7IVV,W
MXAM$ZBT@QLC&]'/2MUSI=;3KV42P=Y5G49"[*SGD?7LN+W-P1>NF)<@[I3JE
MD-<PM6%E)3]5MYS40P-?:.FP&!HY<C@RFN'FDF'0FC"\B/ZA(SFY@[1CJ"NY
M@F6DID!.$[GG1@8^)<_4]+83>KM/DWQXCR/T.F2\#<#Z\^<8:>1.DUHXP1J5
M24Z:(8]-]U40[D8N F3F"\LU&^:>#_[(CT$%[)O"LF X'5)]X8_+IB-J3W47
M(O8TS+:61!UP:AF^R>K[[@XV[UFF4WU?H7# 7OLY3?HRHAOJ.[T <<W!B)!T
MA+:?9\@:[Z<?3W?IC^KK15Q6$J4RQ90A94,B+AY)4 8T>SS'-<86DL-\Z&\D
M>+RS_VV:IB#)UJ>[T?ODHG-STX47%3:&_S3OKO0D,"V+KV^!4Y^J35HUCZ.&
M @_V4$T&L4\R&?Z4^CAG^Q)XNUNJG&$OM4@5U7E,D"-1+KH5Y<(M-'W1?.7=
M?1/<838P@YG.&P<S/2>JO@X33F@>:I8&(DUE]'3(_)C6XJ$24_2LUDU* R*O
MY-(@N65?"(,]#-GFJ9MH$E77+%3W4&777M<\@:[VO'17H.SL[AN]!E\3"@V(
MMMRZYX=#Y;&Y]BJ29(M:DF\=^@X!VTZEC$K!5A]?@0^D:6FEGZ2^B<8?[O',
M&VSE@O*&W*(-SD/<RH*3<_YC*EK^BTE_A)?K^CPJH#A5/^=&6E*6;OH*%62/
M& 9XL)Y^'<EB*J@D$37;&,VW,A6@8I-[T&CU10G.4&DOWSSZD%V+Z&?%BN]-
M\"BT$ HYA",V($$^9@2N4._3<XA='0SL!?>P#8S55=<&4KC9)*;;):*JRD_%
M?&)+!06,^HH9>>HE7LSN?"Q^C1?DI+'YWF<![:_!%]6-Z$*'A9FU7I,@<SHD
M/4T73G9"@Z[F1LY$_?(--%]^RT!U?:#)VFQR$C9<=A,)8LL8)).\>AU=98^L
M\IJ7D)<>;)#!NVJU%27MG<:DADP&^S\D%M.X3N8-U5@Y1P?-(^=]3MD3CT>'
M-9X_ZS^I&FZ&^"1I"5)/I*(Q%F-.V4$S++KLU<:)E6<$V=_(.4^T.X+KHGGU
M/_L:6VUD6 RG=D57X$+.MJX<(9V(=)52?7%,WE[PG^[J[MHSA7;_.HV%IXGY
MJV?5>S5^DQR&"KMI6V._-'1D'-V4.:UJ/HZGP0NM1D:?2PT0=UYQ8Q;N[@BA
M"^*NK8TSG?0&:\'P=I)@J7AF#8^ A#B4RQ@!W*PQ&EH1+I\-BG+JC>-^T=-M
MOPXG #/)BLLN=] 93&A\[EXIZK:% 0).(4<A=P%,STQL0J<I"7K>XS_$%+I6
M/16=T24,=_._9=_T0L$,2 %J5%O$I)VY<0@]RYS\6+ZOTRP9_;6&.'U?.DH.
MU&\PB"4J+B[OGL+ :RB4ZV;;)/@">%<*TY\::T>*V8G4$+J6'G@1#E\>52K&
M@4"_-G7R'M,8=P[UJ8WVL*V+M>*4# C'\WZ+L]V!4L6G^=)A!)D@!VZ2H<:>
M/8BB<PD^=WHG9M/L0'$3@4-]LKE)9AWA28RDBFKSE.U76KQ,&^[C:S,U@5/V
M&@2JJT* L&%#E]-6WM5MM;[H&:3U)!AXT5/T[>  7,M3S%KH-S_/Q5U_9G";
M3XSS.6"P+G[]U\')^NS'W>/S7>ZA:H58W@&FJ*C,4(+AA(,<.H;W$<2Z77*"
M'X6+*AC1M]=PF$-AO,<-%E\E_N;2/591"%*Y%&;057RX-Y%="ZSWJQ;LC/SO
M*=8(<>[G_P]02P,$%     @ )XEJ5+J--,OY1 $ Q(X! !4   !F:'1X+3(P
M,C$Q,C,Q7V<Q-RYJ<&?LO =84UO3/[I#[]*+M-"D2$?IO0B(2)4.DD! 6A)"
ME]Y!E%X%D29%40&EBW3IH B"=) B2!&0)NT&/'H\[SGO=[_V_S_W/@\#2?::
M-3._63.SUEXKZ#X>/IX"2*]>4;\"@$ 8("^0%P <KU"<U[Z%<$6XW$(@P2+\
M@H"XHKHF%A: )O*CUVK0/YL +0/(!,"DYU!EP   ]"\#AC: I0J#0TYE.$YE
M2&M2')6W>)/8;BF-R)7HO+,_[9,\[9L[Z4>_0*<M0B3*#NZJY>:*='-%-[%/
M>-HNKGI0!,+Q5$(=[@J#P=V<?EZ??"HYHD[:YTYU]>P\3R04[5Q/=/ZT"4-=
MASC!]%6,]'^!_5#01B$0-GHP5S>D%M3>"LTF K0!%(! _]@ 8$ /@ &N@!N
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M*B=[/ HH :#_(9T8^9_: /UX7--;# M,$-G/QS6U $PG3V;"P/SS44P  ,+
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M4&HUD=B\&MO\LZ5$-VLK*%]&D@9RY9$O*3CS"*@)LK.7"C@-!Q1P0EMWB)2
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M1LUTQ4L-/)[IYJ<,4@HR<I&H^C( ?*IK"B#C8^%[9GYA[P51G&8DD&F+N12
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M-[IRT3GTNA'?5)?BSD618/Z\X0=W/,#!EIU(_E[$8$;"A\Z 59VOM$$OZ,+
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M)KL16#^W:QZY?IL#\<2'JE7&(UJ=0,NX^?MA(<'GOMRFQ.4VJ5PI)<"J&*6
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MQCR'SO43<6!$ZBHO8"/(1 NNP)&H!04:B"!U*1U!>W8?CVP_1VQS]\W>H.1
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MC?*\^89HJ+@F8EV!!8PR>O07.%5>:OSZKZ>%*+FFHP#+I,25)C1%MX%!PQ(
M\B/ONSXOA[^_IRK/=M)A0FF0\$8M8&8%=:+G"JP4B(8DHRMD^B40"18@!MKM
MU>PQ*T!8,WO<W]>E6<P5<A$R(TN&-ARJ9^MGN/?V[/BX,&Q(69BYQ(9K'%X6
ML=JTZ-)*U$0CM*.& P-W(5>>H.?ZM4=3)O)TU#E54^7RM KZ)R'SB.9F-/\
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M\O0I"(W*"+65C>DL9B"Z\[B\(\'7W=5R.\00<C5DR+2O"(K5+0(_OH>/??\
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MD]O)F[#"J(082V"5SEM%[+%(."4@!N@'P3N=@% E)ZVPIB7$E(F%ZB&^:"L
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MT_TLU D\^RLM5-+<F3V5QJ/F28II3(4VOY_DH<I!@RT&&F9B9?RY0U3JXD9
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M"Q&Y?J6*JF;AL@@VEFSS>3S%J1+V=-TVM=2BKH7#.P.]K=AA49D\V4<,P4V
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M2KNS,<*,72*@G>9PVY0.#3W2.502W0 *8-<=#[VOA5F60=)^J^5FX8/1*_\
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M@7%V;O8BR@+I9KJ(!!!(9@JG#%WD[%0#DV#.<DTE)\09Q8N[FQ*G+IN&>SD
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M:M/[2EZI&GBZ1^)PSQ-(6EZ2>'<RMR:R-I*H*R-EM0&])H)<$.RZ%(K99>Y
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M#!,85W#WK])<FH0CCPUS/IBZN&W0>+&]$/1P(2UYZUL7S>D20M7,$NN*"%+
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MD\RY:F0(*[A3^$)( )(# %[MV.%H[F@<R2K&ZD(;1>$&0*\+C]H_M'$.MQI
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MYS=#(7,"Y"BW7HYZ!*B -[="=R6PJ(CSADLWE LE)VZ9HY[$7!9@Y+D]6=V
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MJX@_5H#&SK]^3\5D+S:*-KP[<J@!J5(;MB_QE7K*/$*;'E-FQ!$&=F47I:.
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M3_0UG'OYDTL-^:F>/FD-UV[[B]^)3O\+Z?ZL=I"NN$IHT(^JX]]X)RK"6]3
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M11^%B;+$D;>!*JVT2L:2KO<65TCX!(S0(G45=O388[6 -#I\EE\C+4Z&,%9
M\FKW!]_%Q?_XK_8ISRI'64G?3-KXZG;;K GY8_3R<&XDKD_<MU,T;1('F7RZ
M#]+Y1+^F@+-&2(QJ=%O@_R74SP[KGXG=4U*31R0"9'#VOCUO**CQ4 =;8=*$
MIB::UNU1\V6%;N P[$PB]./G$(IC/8Q.S#9-..LF]K)%/+:HN)FSP31F.N'L
M<E:41*0WH.*7\?HQR=VAU,3%Y5.=X5<#+"U!X3;5$"XK"&*==XRZ/W8@^E3L
MZK._Z9T7$FXAG)(#QP^%H(9D)\DPYETU?35V_AL\X3?@LO?N/,!4/+B6*.YS
M-#]+-_J5TB3EZ6QY<J/KE"K523''QS< EQX[WX4).CU;YZ]%D7G85?\U,\WI
MLTT%?0M&FE)GVZUO563KD_[-RP X&L2HR*S,K)#3@A(;&..)2M!C(7C8Z1'.
M_>%NC?IIW?V,N.(S4F^N',)8.H[-G_[?1VSX?W[TC,>H[Z&?PMH&;8_ >3:O
MMSSH_O=-8JT_5<[5TWLTKI*93-=>XU-9-6PR.?QP;+(R 6$C#^[GYP9DQ,UY
MQB)-V)./AM%K&/5254GA7# \D69]7$0\_W&+ L8?W<K@@; )]\DTY'C)W7;;
M'D;@$Z!2N&?Q[N9Q5?@Q.O2J*X:K0C[<_AJY/Q)8>"O^M$APVDVLD,<57KL&
M^M4Q9H9*CK#@>:Q<!TT)BLK1%9JX9\R/T(0:AG\HN7+E]G>:VU)&LK]TA9D4
MM>V%9#.O25M4BO<$8XCGKGD(5CI-$A,PJW]T2\^A&,P>9>2D9AA:P+#@2+AU
M/0>9P)CIMI EPO[U;0GL&.VEU_/],?/!7[MLS^9VRX\USBF%";>XZKKA&/_#
M[6!RGGK-X6Z02!SCPA?7=JD%SA\>.#.CQ]$&&VN8<Q,WQ]*$_2'\-()C7$__
M L;YMQ>-I&E[,9[^PXB!B#J(ZW<V4/IZOM]*-A$55OFP%#\$P&013B'F9C"*
MZ!* ;S8BF!/)V[]^H'&2$&3Q.;Q%I@L&U]#;S \$6ML2>ITNO:BDBTV-&$M=
MJN>.'T.09"<3R;@BZ=5SMW'FG(G08W7#1I7<-T^GXON.*JA,B.D?EV#3<'VV
MWBREA206U()-3#8/\A(.8_^WVZOZ?BWT$%!;(4?"CYG5XU^14(<6&&/W\\&3
MH,42MNK=B_]&+;3/"D.A!2RN'A]@9F/IA]K9AY-!V\[TU^TMVZA\QHAU;/'1
MI,B-C-_*J:*8%=TG <PU>K+<D&L7EV(V <""F)*1@I(SC1I2SZXL@#@IZ6 @
M3 *M+Z-,HJ5/.1J?I;PQ5T5Q;*6D;<2H13-R4R0\ 0:^?_Q>T=6IJ-#O2[J@
M%5'=YR,=DL\2OW8V+:_"W$9K8&)V!M/F(CDIJ^S)ON[N:>,8&R)V'2$-?,;-
MG _ F"^Z^X 8MZ0Z+HR-L#S=/WI\"6)62L/5!8>Y;MG(S7^22%_KCQPR2&HC
M4UO$<EW0,VL;JY>]H7I0ZJ*7!HAAE3N%T0R67MZ LQ9\^:$^1I'V29O?:0,H
M5LEK+[7^)QLGVU6;.NW*+SQ453X?"ZB72UW/(6;]H<'!:VH$I"W5V5KP8099
ML(C&P]IA_PX04KRIZEI&-FONS:4I28B7I&BS2ZY,F3)9X7#)1A%:O<# )-;&
M5 ^!$7R;BZ/(;E+T/C8>7;:97_W38"KVW?TRE-^8B=^-!AG6*6SD54';P=L;
MJ(?GK=T,/WL!KZ..<RL3>F=SP&1G=P[6HTLS-@H$BW<)4X2;&Z)+P-%C*6)L
M@+=25B+AEZHG2>N=R@N=P#I6$ &1$!9UU3]'2E2)@^:M&=K=G;P_)@/J?WZX
M6E/&I&8G1^3^ZZ+^%?;.U1I)V7&Q4#@T*%,'D\'L+I9DF3VV>:SL'^:'D2%,
M!Z0#9'1#:/?+N/'DBD]]7T/KUTJV4=<_-W2S;#V0^#=@GO,G<<MP*&41*ZQ,
MV&DVGHIQ%(8-'U9G)%PGSVGC=T;5$WUJS*%DQ)TE:;D;@]6^U5Q6M<&C._AS
M]Q=4$T+QB*%FFC)?:NY!+AN8J5$*8.1^]77#I61H= #)AI6_GHD)MNQ,_2L2
MXE3[L]CUG^Z+\CUWT$K_XXD%_"'^R@IG^Y5'E'AP,%7S",&'^MPQ>#A83NE;
M%L2P'0QH?$CN&'3M#;""64<MLI"1Z>H/;\C*1JYAJ8TW3251F4"[2*L)%'KA
M_$+5$=#GS[_UW_>;IV\DN/--9F\ JG1^N:;!3.Q_+2ZU#HM8'=I%3<:QZHLB
M$^G-^GRSM\$BU@^?OFDK-D'HYCU>\_-LW%;)[?\;VOLRI0O:33F83QU!">5
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M'7VWLT[GS='^T],IB-%B%B8NU+IY,1WOASD3)N)&FVUW["VED;,76)>RWG9
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MO5:"UK)S]-[ ?&M/,&WM%1)LB(Q[6N8LWE-%+$L#"AD$X$*_V-L&1CMWUVN
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M69Y("[G_?ST@R@LY:3Z&>>:S<3I4%(7]_DURM"$!$8R7GRXR^ZV6QP)QH==
ME\'&G*%PT_IZWH!I?U$*U9^@TZL\U>PYTROV7WT14&J3?>"5<9RCWYS5V<_9
M;M-_P8%=G1MJDA,AS3-CS!AD23KV%YXL#Z1<\R_6F>-"YO("]?*'+[6:@=C0
M[]'\^PX@Z@XV&<8[@U!TAZP<\OQV>+79//_UQM.&4_Q *KS_.#K2V*\O"S47
M9HJ^)7Z&MPC&O<%)NF;>^W._?)@:U<NL'EOS":<[J"$-7^36G$/U]^*A:Q%_
M,HLF*U"KUD[(.7HQ7W0;?=M^F?;P:=Z_;:S(0R5Q$PEEXLPVM-DKKX[0?L^+
MM2/+6Y_7*WS*'@Y'R.C[\1/^WJ!*($L'NN,[0!+/^<%U-O.AF=-D)'(#]<>"
MN_A2M3Y3.2P7VDI5Y1/!7N?7>,SK[G0$U[\%A;+2OW>&XCE3D+&G4C,=4WP%
MP$P;-_&N,Z_^SW=5*DE?G,,19KC! 7PVQ _K<(4^\?)G^MW9-WG%,HLSAS5$
M=<&99W<"F;ZJ+-/R,>U)W)=2)9"# ]KR\A^=/C[H3322F5H6(U&5JPU%DB]#
MU%)MC:+DY+,HXE[Z8P&-6#[IMFN>R+2.,&*J/>%DF^>Z[1W&\RSTDB-)>K/[
M";"<6@7R.UD2J2A\J!IF(<CJ\I<$!  UO@-G66YY<9%2^8^LSP\7ALKZK5_$
MZ#)^L_N@R5Q4XE\SQ/CHZ?XMH,:AAZ6N(BX:01&+QK>47*A/HI4:U+($%(3A
M)-19T*328ER-)5>2[5T2#<(.^;.0:JX+1W8IV323-R@,XTS7LDP(_HKUF?F9
MOV/UR@@!ZQN)=I^N25#.1:>&"TIR_Z"F=J1=)$(Y5!J+:<6O%*UG-TE2QQ)
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M, )\OY"^0?Z"ODX% L\O=1[FT&B3=$-JK5#7OQ+E@P?^E#V9B3FT(GH3T )
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M"&""N:@C-,]5N>0#O3*^09\DO]?X* GID-[ZA@CE'1 -_QBFSARO'>JL8=@
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ME/BNI2DXH$JHMVWF:;="ZT\*2,$=1Z&<!4W)30>]J[JB5<%0WL9B3GI6T$W
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M.GF3*[\C29_(*M=_#49X_+S@+/E9M1ZJ,_U1GO@S>[.^,CF8%R2KU;*I%^A
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M.?MP-@/ 4U54400@(5U!\D3R! #.UD@?:MM!8!!7.X@S+1\G-T!85D4#!06
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M3$I(2$Q(2(J/=5'^./QS0<*^=@T;!QL/!P>/" <'A^C\"X?H.PO^?T7 61,
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M".:O_R /!%M+T+O32TF>30#D $C_PW(NY'\J ^GBC7=(.E=N(R/A_WCC71N
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MDF0/W22>:-VMO^TQFY=:?*7NS5Q<2V0SN-V%17/V##" 5GV<8!IO/5;^X5C
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M<W'I-[KTMWFDZ_Y;!YAL1C3MT5X^,_7/=U;Q;8LG$NT#-(7W/9D0F[BRVC/
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M,\D4(W)7C]@MX[=H&)QJ<FTW7@&(*1=).YP6S;X&?[YO_H [X&3$N91J*0W
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M&\_.S?"]>GP ?J3/1%570)&4)(S]20B "/8&)AT.>/>/_UOTJ;=O6*WEC(J
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ME5T-HIC98X>0?D?K$\TW$GD"EZ HG)CX]FC*A+30.H"KT(.@9O8=EA:670
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M0HI7P+FH,/-.:P AN50<K1UI.?W+805%_%+7YZ-1:(?;YN'Y.MIB.'/C:U,
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MC$:3D% PI5;C#4%2\J!$(+-Z?T=?);)CQ8' ,O7Y/HA(-P$;E5@\OW6G0C1
M(6-8)T"F2$;@[J<#MGGT#:IA,3T5'*2W'*L7MNMUH646EE$8F-C8JS FI.+<
M3RUMZS-;2T0K\V*>?"'/\X;<>3+E'<[GG6ZXAIT268O&.PHNHM8S?&;5.\G
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M 5##R+S] )@$7R N (*#LU( /V0%"S['D:D&X:!'X?4Q0=B5N=3>JTPA2I2
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M@]_Q#!<V^ER;'7?I9.EB]]EYHJO6B73I2\3\)JGVBY_-[(J-\(I#XW0"6%T
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MI8=6\K^P2R*G2@"A -YWVJ]- <ZSN-X3/:@,JP!,4&NEX9V=KO<3Y7;TZ*L
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MW&[AIE&GZXKJ6Q!#Z-1#$:10!5H=%/EKOY@)MU9NF1;E6$V-4]^$49#O/:$
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MD*+^)LF8X4$E=F0B];-19E2O(S#)ZSCWS&U)"!\GY2UD-]RFGZ?_+0KD^)B
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MZ')VMYHTR*KUW23VB=]U'WT5>[:3F@:U8I0>^U!^7/ST%_<(F$ADW_HSVO$
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M[P7BC;+_S1WC>G<B_'O7"-PT!(ZU/.18M>JPWUZC5K>EF8K)0NEJX(BV'.7
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M;H,K;*!\U<7,@Z5*$MGX["NA 4U[B30#WWPB> !F\\%9"!%?'"(:H-Y!]?N
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MR5^FQ_ITO18X5NSMG5+L]#RKV9]4"/S1]<=0-628KJEPYG6 2"ST2 @(FAD
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M?RACA$+;F=W0V [G.2'AR18$&EIHK<*$M+IT5(*+ Y>G#^UG&'?8#+CB=..
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M$?1W/T=<W&!R6@0Q1BP93GKDPC,"O^(%*&AIB2B#\:Z 9/@QGUQBBXH40'X
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M$N4<JMI4W3T2@/$P<8+G.G%<F9>S)U\>A3QPM)8B#*RP!-P2 1NY %(4,J]
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MY=D]H^,0W/1%HQ>&]_PSU_(\&-HR'SV)M@H-[0D*LC>SC(/,'E]Q=9FCUE=
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M[=#MR!^\A%M)VOZ?;+[/F_]]_O\,=&_OJ[)S].DR_N6#W9^E_PM02P,$%
M  @ )XEJ5%HMV&A<K@  A?L  !4   !F:'1X+3(P,C$Q,C,Q7V<Q.2YJ<&?L
MO 58E-W6-SYTIX"*="@- ]+=,'2W2 S-# R-@B!*2C=(2"/=C8K2)8VDA"+=
M71_@HX^>YSGG/>=]W^^[_O_K8NG,?:^U]UJ_M==>N^[1^WST_#, %R0E*P6
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M^;_DP1!302H7*F&A\W& . #N?TB71OZG-N"^OV I!OX! AS>CQ<L?0"0 >
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M"34*]7%[\D!FM0\ZYP#LX[LV-W@"6,2?U%1U1NJZ%M3DH;I,+P_=6GYP-P3
M_%6ZM#V/P61(2R+/]SW0Z.V+"1Z;T@%Z",U]KF=4-&8)X!A=HV>5 [89]\7"
MQD #T[L6)^Z+$'^IJ+J^=4_BS:_'4UZ&NJ#W#*BZ1,]Q2RO;+7=XENGN]9F9
MYQP'W<"=AGVR5QGL!ZFN97=76:Q/\Q&_< _:K& 7<*5;L-_3@W);%3)SS1H/
MQ8,?W[EA@I1(D14+MV^DE!NV@_(YBZ,DR;.POX>@ C:;+5*2HD,KYT?_8?'#
M616"_=0\52%R^6!?R@+MR\&Y#3KKA_VJ37XZ<FKPA 8*-G=O!:$CV?!,(W]
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M;@9]W5[DU$K\,:W EN=I_5X(_%/X*)R(%#[J4-\]TOY*;<_/W2%L^B.QN/Q
M?;^ZZ*JVE>RX;%X9':V5"+$D61E5,>_/VVEF2M@[ J+MI?FL?=PH&9-/*9YB
M3ZAL2)>0AKB1O_WVNMS]/WN0]&MP)EU\LW:VHTR 62?,4Z)AG[M5<C_ZSJ'=
MYYWB?UQ1.&9 NZO(3:N\9*.34=Y&P>(=-"_E*8;N)EKI\I'<?0UJNTP<^"+
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M&X$[ G,=O<58D3(5+D5A(RVZRNT6](#[;KCC?S&'C40.NK+./LV4=A27)R%
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MKHU8E1\K4B1+D_L8Y"@=%+/UX6[ZJZ>!RK2TP'&)>2RHLVWL*"#(MI->VPS
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MA4E,<E*RI12&CV@\\>PTDRI(GQ3  Y=[&KDW>]&:ORGPXV+ PR]J,P," 0P
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M/Q,["SL6)CB*(@P.)50S0PT#KTE:E-)8+_=V);05O=WAMI+?[_*N>>$\>_W
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M5*+&<\Z&9.4XY'ES;VL@/#AIU;5?'=F"(ZA+C#:)#3SJY$=25$9FJ6T>WSD
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M9=YL8!(>%R80'K*E;2HKFFV6F$(:3&A1?300@I;A1VXS8 0OL"0VVDA*0..
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MMA3\ZPM,)F]>]:AB#I)]]JHP$Z;> (6BO9?[5T\OC6;Y0#19_UX1FPNT )V
M\.<;G;_JUG8E6:VG;;Z2QO-O +:'0_8IGC H\7C0<IDB72-NW"X"F"I!JZM[
M) A;J#00>9,\!VD@8NLU^;IMCD-7!8$)@6[)V)0?AND/>PJ^@\<ZR\<&.#?=
MAT&K7HVOIHC5_5I+^KA?'&]>'AEA!O7_Y>15U-%Q<D-&P&$_/XY[^*:$M6>Y
M59$GL:D%3DPMQ>^%JPB=N6J"_U@9K12!*5!S.4$>G/#U86,CK +D5W,4)/P
MC_7R_+>B:6;!;G+NY!6Z<"E OY7YP@W+P5RX";_WZ_QW68!8 _G9P_\PZC]#
M_]T;'MZSSFL#2WOS*F#9GZ"0(GF];@7?BEF*=[T]J#]8RFSMF3I9P"QB-#;4
M<7QZ83>C43OW8?ZC<F1IY/%G4SRADE&.R/_'%AQ:_*3"_T%$%2N3.BG=O)4.
M'U2;+5IU?0DX982_9_@JJA8>DH,T$;%MM/2"=Q;A.&G#!'/IP=92IL9X1_X
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MRFCE!LFJ!W56/=\ ^R+C+YU06,GC]D#4?/*G@/NCR:[(QY\[V?Q'9I5F@V\
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M>T=G_\#@T/#(Z-CXW/S"XM+RRNK:#@2ZN[=_<'AT#+NZOKF]NX?_?O@'+P0
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M%AS?L?,S3B?^CHB$H;W3^A&'B^ROR4W9R?+O  >Q-X7>K+^NA_Q_0RY");G
MG=U.=$=OL&KD'L[NE=[D6?6]0Z"7X=HP.\=$!>U_I6GSK 79#)T%+@:4]'$
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M;W_3<(_N:DTQR_M<#(ZWP)O*7')X1QU<DE(YFCE+]37$YH-AA@7ZG8W >MS
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M\ 70@KR,/T+NE:(AKSF)HC#]%E3W[47,7P&&<Q_-<!F84C:&LN3-L4IF!YM
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M12Q'R.F@>1:.NQ>1/4RF5* FA3GN\*/2#9,ARBFW$L0*NN9 LUNCD)' HIH
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MO[#M(Y,:V@U:)5@>^G,I996^C7&;YENQ5V9T-Y*WI\FVXT:W0_3OE%@*@WG
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M<2RV&]1@YG_4=Z4'UV7:/JDZ.CSI.(E\*=*)I-#(;;AV(+-<'VK_YU"^1=7
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M:;1S&OYD>;/NVMMN)8JJC(&8#[Z4TN5KRT9>K/5FO&=5"MR9=;5!)JS5?)]
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M2>]]]O911:Q/'7*),59U-0EC7/1HS5@%\HB=]9D4=VKI;^P5_H=B&0.@EMP
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M(+X66XNQ+7L7_>7_N!((_)KX#U!+ P04    "  GB6I4<CZQ2!FP  "(_0
M%0   &9H='@M,C R,3$R,S%?9S(P+FIP9^R\!5B46]<_/(0T2#<(0[=THT@C
MW8W$  ,SQ R-H)1T=RLBW2(E)2(I(-T"4M(B$A+R 1X]>LYYWO_SO._[_Z[O
MNRZ6WO>^]]IKK=^ZUUZ[9G3.QL_F +B*L@JR  0$1 0/! \ X&P3/U?-QL'9
M 6[CX$C#RWD3('1'01D9&7!.^*%-<K)_5@&DE @& "0*!CE*1 #@_"\EHAH
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M9HDJ1K%,$:B#,CHCJ)I#7%Z?$R0+0GU7$6DTQ.40RL*BG3<K/-CE/W'M)SE
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MT"@Q[RJ(.-;.;Y:HB[EC>V] 5Z\&D[8BA-P;"KUO$V-8%#W,:"DC0%>=R-Y
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M]MY-L^<()??L2;_ZEOCNLC5]D(Y5 ,0R6_M]E1@X \116(>8'V:R53CME]2
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MIZ!,I'E3/U?RLH_)C"19O 2I=E]!,]@JD0&*TTI]*WKQ)FQ=$>WM"2F>084
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MGCSG?/>[=GK>W"ML8Q'+CA9-@F1;NU&X4(Y4'"X^/O8!<RD^'G2:V7'F5%&
M1:J4JD['NK.-+AL-DCR GFL38<#%VK^^?A-=M1)/SJ[U3END"))I6EZ+[-@_
M&6U^%>#?_9+=NQ&[!\L8)V,[IPW#_ @_Z9,C<$N+_P#*K:B5$F14==%'TXYC
M05M-^>"P_.PS<6LJC82"[CD:\)J#7M%65+=;!=2UD,NJ,A5D21:GM]S;?;P/
M(VO#.VC"&U_Z[<%[7X37P&L+#O C=W;9$G@NJ\"\5VK^G[MKQO"=J?X8[QC"
MQ-GQ_D@.^<S:6ECVN#FXE'  $#=I&B_0)T9_:UXYAV7[*](_42N/[>;@1MO*
MF9D5KD-?ED)QE682?=L$GGJERG;<DQ@$VY*SR8(@(7#$U[=>@V/'PG-#7@"!
MN@P1&F0FFAL+0OD_Q0W;L7:78_UN8]QQ'P1!<XDN)I$ZT-;+<3DO6ELG3#'3
M'FLGW$E36B<@AM[B%UD]>ZHEW-C)O*^"]4UI*2\BD^2RH\JJHFN4[$##3$)F
M10DT-#TK4KRPQF/:!B-,MAQWI-B*@ 4^P%+K0]NE]I?NO7?:>8'ME$VSW=A8
M9/P69:.X*%"Y,LYSQ5LVVCS@2"Z^\3+JUCT*6['CN@TDEKE04Q77 VI^+A/!
M#B&T.[2L94F_F1>H7T'P,;!XGL!8W9F#%W"/G%KPYIG_ "@[K3NBPG*"<S#!
MW[3;J[W:Z)]_;#'M@,[D9K2;\0O@KMS*K^9#Q[ Y1Y!-?C#+JY%9**TQ^%4*
MU$:)TVY FI2&WUK7U73@[: #ONWH(DF<S44I.ND4O7 _!OBNU[0X;-CNPP9.
M&&NP*,;(IO'>-P+TH"!-912<HZA\CZMNDOJ)E;_6>&Q<1Z59E[F73K5U65R\
M-K+>#A06=CM]=Y'/!R-:S,GMG6$L;2?)D.4-ABSD=ER1'/UW;C>-;$"&L !@
MFSY@$F*BX&HUK$KDX7]-?'/',%_B'AS7[+LV$X-."QVS@/C=83_K/:^-X/H*
MF/I$;LY[^R=ZS=\+MW?;']V>FJZPBX+.+#*,?*7G,EMEVAM;>XBI";D9[;NM
MS6J!^JEU4"34.*!Q6F4<4S_2+NV;Q#!QM#G!F>1H($D5I-BO*[;X=BX.-_XU
MVS_(VC#=N8F*=Z<0@S,N/RVQ-P=!I.Y6WZFDK,?NKBWP/):6/3U4ZSEO0)V/
M9$^S#@1I+S\AINCD3'Y+G:TA(TTR1\I[<^%Y3\9F&"75I:NLTC*O[$KB.\*V
MC&VP>$8#HVMC6XCL1I;]3<7#EM7PR6BX%2;A?EWG?;79A=;'=1#OY$]0-YDV
M/;D/5N%L':I2O5F%E-,J^<LZ#2H3+/K"XU,:=CN.MBXRVJB0KKK<3Q7 PR02
M)$&H<*&V17I\/X7VO;MB?MNS[&6-\.#G;2T$_P"ON#=(<'.#JD$QA@UM 4H]
MG_M>\7S#=#I6Q*QQEO&\IR:'CT"5C^?9IE YB[+N%DPB?F?!L1J-\VYA"]#D
M2P;2S408($=[DTPMO#RW/>FE8K;DN1C^ X6R8!V3&V4':MJP\/'PL<M)=@MQ
M6AS6#=.X8L=Z':@67ZCTGMMRHS"$0JZ@&B^FBDO>7:(&0CQSW"J$O/*KY]E3
M7<M9OM<X0-RA (N!)CARTUM\\=BC9\?^UQ!\Q[G- Q"2")<6@@ 08(FI%ZB5
MW'&XS1J3K:.N.>JBHO*< \G<2<HOGN0E3CW3Z<>$UB&EPDD@ 7Y< >=ULQ,<
M8;78#0 U[IQ&P?K=,%Q,3).0(%>*Q[>[6[<WV40,MM,1QV?E=0U";I[N7 ;.
MR@)",Y$..W*)HS:%HR)UC@D(R7E>03A.(YNRS]>&QTR#O-FAXY$B2,\X7H]C
M\>^(-B\&Q?"O#_$=LV3P[&^<[%V3"Q W!Q/G,&#BDM(DM<T-P\06@9&5D-Z%
M!LJ]V!+:&37R8SK#XDOZ&2TX*@ZR8H2&0]J*BD!#SS[\ZWL# UHPQ#(&X!8-
MCZ;ULO/ ._Y$EW_(ZF*F#G-Z"M8R5@_FYVZ"%!AMXW4N0*.CL\:KXZ(XHPZ*
MYC#$G5#* [R,:<P M&A$1@R@KWIQW:RR[Z^5/-2LQ)YT/ "!:IF8M?.+;Q;I
M]V2PRZD7N-8%30+9\75D/?$V,YB*,D6FY"PH=A.FP(;IBRVTZL&+'(Q%.[GE
M>23G-X()H(]ISR)X"(MMKI3Z>8S#\.-MY6-,3;^9DDM@+C)&XWWO.^)^\)2L
M_?!!'<F!+?:>B-(W$EH:-R([C0 V!*@P:R9IH(R-IYW/G=6/;#;3XM=,7N)X
MO%HIXS3ER6JN?8-0IPNQ;B&D2=7G)<C%7Q&+^UF1*AMEFM9G2GI#<1'A Q)-
MCJ:3&=.E#-Y-0J4?IWV6CU]Q7P\&K(]=D#[DVSCLS+>.DUV2BNHV2,6#;T4(
M2J4R#%C>C'JI+[LBN:AN.&6KWRM72MJH9FE)];\)!Z&8%0KB8V7VN:AXW%8P
MRF*%B<)V!CH +RN0(SN14F5.JW(]<G93C^18U17DB1+<D2)5G7MS7W7'G'R=
MFG"".AD>J>LT/**2-;3]A;!E1T2[%XWN<.Z+-/->E,P7:RIQIZ<\QBM0W+K8
MU?-D0ZEMP&CGS8T!D'WW>XW7.'C[GFP=$K/#WZY7$6]9HNKDG0[L9?9QB^;P
M*VSQUS&A<4:/&+9ZHI["2B62-39T>.8=\N.=I+=$@5!"402FT!]''"(3WF=8
MJ/Y"DE#PK$JZU&\2LA/9"YCK&*K8S7W),Z7CT4A?;@OF\1>NVV\/JN*@$1N*
M9D2J2KI3OK'?-0=)R@DB#;A83'M*L:BV VDQ^P^]L8QQBAL%M*NT<E5UG:(Y
MWUUJU<,5D07ICK4.BF3FP<GTT,6*V5P O17/;3O5.!(FF69MIY7L:+P,UZ6^
MG;.;^?D^6[;4%S>V,*ZAV$DYUQ'5]K)JU::Y4XD:P8AL%;P.(LZQ:CLSC;;C
M$LD?1;($3[_QQS0R#Z<+&XJ0)G/6:!9>V[V\PC;FHE5N#4D>H@65B_:S71E3
MK&9:3WP::.=86EI)F65@Z+##$2*[+EOJS71841@@C1V&P*BOYCVX*-/5Q^2H
MT6,KNQNX]M9L_?6Z8=D;,2JHT;R&SO&FI,!F\R[)8EM4XW4N#43*M(\BA([$
MK FDLJ_N%1IRS^U3W2:E02*P:F:D:"@J.,6H*V 68]AJ?:3'-K,5I=F)=;8;
M;5U>[$QV73W"7]>[&]=^2\;-FW+F1S;-Z0Z2\/=B*OI" M-M@#EWPRD\D@0-
MX"FO32@M:UN2SBG'"<>W"<?N^GMX_NU%DONB*"]U_P"\:P1./_NC[BKSQ[_Z
MUMMOK]./V\\^VIGWH>XMGJG?=U.C_/\ GVU5&V'(>R:*IHB:(FB+JOR BMN/
M/& - JD9FZTV#;?^T;A.JV(B'NOS+XYT4Y:Q2*<^6E>2LS)<\HL6I)N0W%U7
MP*J$VKCDITA?%Y!%2%N$U&<=.7(D*K;;<9@G)"DX" R;A@T3OOOV2>-32*7%
MYCU]+K0%]H?L9GG51U/]%N>6W4?*Z6<*H<OL&6,"E99:4F39=3%6.9);7\BI
MC2:9NIL+*OJ0Q*-!LI,A\(V1,L3VJIZ;(B/.?8[E<QGA;\7"&T;KG,<"9#9L
M8($.!&65:F"&DK>V<_;79S%X;,I_%L$QN"*#Z;SD"BA1Y;OS//"_(6(_*22^
M3BO/"P[-F/NN.O&;SAB5)DU@<AW5<0X1PP0*@9@@\OJ:3&=).<3GK[ZT=V=V
MLLP&J?Z?\#R&1'/*ZERTRC)*B)555G&%]UJH9J*O(Y-=?2TFWI5@Q;*#7.09
M%2^+ZN'&=$RZ/QA^,6!F&)@L#?I! D@V.9<.I$<%]I_HEA_#>'XWXCM/C>,T
M$;$0UCW;2T;N[C?,>78#V@AN$#,@EHAP@@%2)VSVHW$S7 \2D;S;D9!'FRZF
MN*WP_"8<7"*IISX1E7:RSF,S+FVL5:5$:=?J+2F%50A%EI%[![#8F._LPW$)
M#G-F (JX &8'TYTUH-%\T^*6;,/BSQ#:O"B[^S9M;WX+6R6EC11Q<^<0AU2"
M238DDS/@XWTI;>XAONNY%/MS\(Y%@(L+(UR9^P=^\'3?;D/D%C.DSO6=B(+;
MJ/*ZG'"HA%^D7K\/PPNVHX[6%KC0/WVDW,$C(1 &=15>LQ_Z@^)#X+9\.-V@
M.P!M.-B.P!A[NZUY:X@/+8)^8W?G?@3&[=38@-$+:^H BG8K;:-DG @J\^%#
MCM5$7A5'A2]U]]=[NC#8U@N!4<M;@SGR7RW!:_&Q'XV(;DU,$UDW!GVX+T4
MOF[3[>Y?*)PO]RJ2<>RKX5-8S/21ZG[RMKVRZ6T$7GLKN@*BG"JJK[^?W(G'
M\M%D 0!/>N9FJZLHG![2 >>.47YA3P7**BHONGA/=%3630#(-S;OC3R(I*UX
MA>V"T3E<"M>?=<E%7<_IBI<\SG&-PL;RN\VRRRHI\DI7YV(Q*<W;NLR:?CLJ
MU:L1M(4MLA;+'X0-H#8IVR'>5\(NN%M&S.Q'.+'%AM-]Z9!FHB@J#0]%ZGPC
MXAQ=BV4X6+A-VAF\U[0YP;\M[&DX9;&&23O!T.$%M9D$!9+V;VGQ/:##*3$<
M6#N:HZJNJ)-P^RRS,MFH$7X1J9.]$09<ER.UMYU$'M13[001X%+LFSG9L-S2
M(+GDS DT FYT&>O%=5XGXKB^+[1_<8A_Q&XUH).ZTDN#28;)$WW1>>(QIF'2
M/MUFV0;RY3=1V)&0[NPL>@.6\J!%?G8_!I,=AX\L&MDDUWI%F-Q%D/M*JHKC
MQHJKSKE<ZUD3E2!T'&O%==46MH!F3?4#2)SH86))_0ACU)E[V5[3Y@QM1)LJ
M.JQ^V@T^&TKL:PKZW&)V+V/H,-/U;#4Z=!GO2BE/Q9R*X/+HESJ0.Z^6G1-[
M@?(_S/, <:5[=ST1U3]+@V+X+N7?XU@^-2JF7=XS;PIN:TF7RJ5AB/7R9#4C
M)X$6D;ADRDR/75T9FJ2P-B5*A2AC>B=2>%:#@:G2;0;FE;K$[OV9&"NC-DCG
M'=;R&)E,$Q,/JV8K&-W%==P;&SELG+E+(W#GQKB4])W(:6/+ES:F@%VO)FOD
MC*$<:4-8R/7/F<Q"LZB+B_K,"G'*F<Q.6\VRLLVP&#A67WS;\JJW'PO,HUPQ
M$[2=CX'NKC^X^,5[[,E^2Y(>?@T$&DM+!'(R2IC4N7$CQ8SD=I+;C&N>=8IS
M4-:6IJ0),C2LFVL>>-;GIODW^\^*;PW.7M29.)6K]U BQ\.KJRW<D1*C)J:K
MA2\R;<.Q:QA*W*)+UK4DT\S/GQH;S8MG'>]:1;.H-#EIPT/6E4D92*Q:()S,
MP..M>*POG?V?F&W]9D,W'K-4R>U*MMXK_P!U5U6,JVIKS.LDA_'6 -NJXDZP
MS)8=HK[).S:VNB,R@<93T].\_P"9XZJSGE' 7SK'OT6,\)^S;>OL.F-[RYCZ
MF8/[E6FXT9O"FF*^GQ^2_:NVL2NCJRTPU+1N<Z4J6!Q5CR"562:-LT5HDWX4
MX]1%.RLC]._2GO-M-N7.RNURW$FZ.+%/&JZ-65/JVEUC$K) R*5)LWF184[%
MPT<859!.*RVYZ# LM,-DZ5D6FNBRFYT2[8)17[<)'*W/K?+W\YK=RDA),O,=
MR%V^:OX#E5'LI3S#4=B?$BK*A1CKPF,H3+Q]KA(3RS[_ (XY*9YG3A-#7K8]
M+4N[!=C+W&K3+G;G/RRTMQX=^>Y3[-0S13+*^E5M!C>-R*>.U-MV*B!2XI6V
MD0X\Z=:2)EE)@2W) ,QW16Z]SS&D$]RI-:TC/A41-IF*3ZB5'&3T&YD658%>
MIU"69)M7CE7BFT%99;?5$N/A&.U-KB5DY&-8.5UTO(9\VKPJGK+F6OP;+\QN
MNFU\>*#5HW,G?X5M-HKF9U/6YI_$V=D=K8>T&(.XLQ<6&13[/),NS/(;^T8C
M1IMMDV;Y)8Y7?S2C0S.+":D6=O(=8AL..-L ?8BIV^7W5S\N>?8ZK,FB+%F]
M9^GM=FKBON-B&/VQ%&:;B.N68I7RN:ML)HFPKDW^S;50(D<[.T27PI#1:S/L
MP::AO"SO*)-59V-W2R:UF%D5O:VENM6[80IL>QQZ.]=I&F-R*R.C422VQ"2)
M%!Y8L)X8Q&V13SL<^_,&GMN&T2!H%3,0[5[@%4X1%3A/U57A4_=Y5>/_ !T0
MM!I$W/I4^2A?B_;_ $]=]30$+NZ5^E]2Y%..Y=T.JHE545/*\M-D*_1414\I
MK("1$5B1YD<EJ<YS7!LZSG9K?N#YJ8XHCHJ9>%%47N3];GR*>RHJ\(J_L^O'
M*(NIP%[?Q-N]85:3,DT%3UIEP[$RNH_%:5TC D;(D3U#$.%-41/URY1515^A
M+Q]//*ZQ< X0X3:#:TWB]\_95N$0_P";AG<.9  KUXF:B]H-5;5C25TTA^-2
M/.0.Y$9E5[$M%%>>X!*0+G8AHJB7;X4?E7Y4\:';+A/_ -Q@<"(D@B.58SF(
MKJ%RVMVQY:1MCF!A#B U@ J!-P9Z<>*TQ[L?98WFZ6[6X6:Q-R\6IJ/)[:9<
MUM7]RV#3E><N&TQ'CO$A!'-([[2)WQNUWTT]-"]/N%/,^)_">'M>,<9A:UKC
MH(!BEL2;<*=5^E/ O_J3VO8/A_P[X;?X*<8>"X8PV[3_ 'SB[':T.P]YS#X=
MNL!DN,8V(0($NE95Z<?LT,'PN'E$#>.?5;ASYEO72Z*5C9Y'BS]5'BP;"),:
M=G1+&#)D-2?C&1<:!TVS^&$T\H*KS_#OA[ V'!.'B!I>XB'BX@&A >X$20:Y
MC*:>4_J+_7?QC^H>)X0S V=WA&'\/_Z@PV[1_<C:\5F[AL<[YFP8!PB '"&N
MQ =\Z K8Y V=VTJJ6FQ^/@M S58[4Q:2I><CQUGU]5#CLQFHT6T5%M&%&/&9
M$I#<T)+B@CCCY.<FO<MV7Y8#6&0  20T2--3U(^Z^-[9XUXCM^,_%VG&>XXC
MR]\O!;+B28:00!)-&@ 6 $"-2WVJ_P!FU4=7.%;6UN.5<NS@X9E<NTDTIV.5
M62.??4_&(QR:AF)"NGP@0ZQJZ2?'81L%CR75CMK):;-OAXVRN>]C@"[Z@721
M @@D"(C/.^<S/KOASQK V-F._:3AL^4UN)A@ ASG-#C]1&]+CN, ^F8C=!H!
M/C83I4P?;W:O:W&K/'X$S)\0VEQO;2?;.I:BU)@4..,47PDBILB8BR8#X&\\
M["F4HL2'W#E262DFKR\@;,  " #3C CF9S!L21/%>8\3\0=M7CC_ !3#!W'8
MWS&_49W _> !AKAO&2/I!;8D *[\+Z6=J\1Q^VH7L+P:[@V=V[>28LK",2;@
M!()77%<>A,5;41]05PNWXALE#E.U1014<O[8 5$DR?\ $ 29-+9T_%5S/'_B
M ^-'8@W#?AMV8X<CYKG%Q;=QINM( B0"X_Y$$P5J S+I1Q2MZ[H&\V-;<9C^
M>:JW+J&<9:7$8T3:C\UH]T1^8EM&Q:R&$VP">G&:CV0-Q6T[6&0'PO5OPWLQ
M"6ATE\M&Z TM\]X$1$ 1!KDOI.P.\.V_X==C8N)@AF'L[ABXK\3'=CLQPTP*
MM9AO%CO.<UTT#0"%NZ^]=X@8[ Q#  !O@51O,+EM>%^@I^1XH*+[<\HB*GGV
MUV&SA[Q+VAK09OI6\#*YT]?E6&S87[3B,=C.#07!K_EN=-/^L7-J&M86J+<T
M,Y>ZH/RTRB1EM5F=;F.)X#38S6;>/6.W4[:7*K7$ RN?8;GR,*;)MIKXN<KT
MAFX!V(4-&F76FWGFW-&V[6QTB0';P;NN:0"'7)<1]-0(B:&AS/T7X=V78\'8
M2,!I<PX>(]V+AG$9BMQ6GZ W#)^N2"2'0T00ZA@V'DO31M;BF$5>'U>V][!P
M"]W4RRVW/QW;/*XLV]MJS%L9SJD&Y?>R&NIHPTU3E%Q BV*BC1NMV\<^YWUI
M2GTV'AESBT[P9OG?:T@D[LM;<-%"2 8D@@"!;ML+QC:\+%^9LKL$XYPF-P7X
MK',8&XFYB8@+/]1\8C6,.X"2',DN*Q-%Z"MZLGS?%)N9"_ LK:MA6#$B?>53
MD^HPS%8^WE-(I<JJXTL),VP^Z9=A7.M0; &RCRWVS0A=<0NG=X!M@Q&[U #+
MC+##9 )<W?WK&K:&) %POKN%_53X<\/:[#\*:,38W.H&MVG#;B8[@_$#&G$V
M=TDXH>-\N+6N,N,%2*^SVV(WDVX/=.3%Q+;=IZRL6("R<@RN[MW'H,.7,G16
MXRPG<I^'CC+G2WT8:5EHW)!^N)IPB=OX9L6,P$0VA$DB2)(,M@DR3$B",\U\
MP_JWXM\-;?AX.T>"DMV_$WPX,;M# X[H_P!QV,W=LXQN-!^D$3"V!Y=M=N5E
M.,9+56&*[%D];4MQ!.4$:<-G$6Q@/MB;$IW'S< U,R5$^3GN\"B)X]%M& ]S
M"&[ID23 OG!M'#+W^*^#[>_ Q]EVG%+_ .^;B!N)NN.Z<(.W<-I);O.EI <2
MT0!<U6DK!?L]=QMV\8W3IMQLD)3;O(\:GKZ25B-FU*=BVBS7X[QTCV-S5C"(
M-&#,J0BHJ>F:+PH)YK:/",7&WOK+:@-:!AN<Z:G_ )"PX'FOUNSXV^#?!\#P
MS"PL'"?@[3AN=XL_$_\ (8;&-&"V-X-PL0..)B.+2&[I ^H4HKA?Z!<GPKK"
MZ1+R)AFW^7X[ME!I:]<JR''*^ORJ'7?%R95@RXP=]*"S<HWC1ZMD3VY;[+QJ
M['=151=<[!V3$PW8;!) #0"YH;)%!(DS;EI$!>&V[QKX<\1\'\8VHAC=MW]M
M&RMPW;3B3A$SLVZ_=; W*-!8"""7297Z2DCBA1GOA@^4&NTR=3N;0554^5"+
MGM7S[DBK_M+PJZ[_  FN:T@_\ID1J!,_J(C*:_G/$;A8KWO=_O NW14DEM6_
M]0*ZB/95)*&XR9L&+<AQMUJ.^XW\3&8>%%])QR*+L=YU.Y.U0!P45.44DY0E
MV5@@$5!B;5YT%^Y@ZG,8US"]ID%L@?Y5AQ-*7ITDBE-5NZ&R?4C>;HY1;06,
MDN[*?GNTEQBNX-'FJ8AB&.XWC\G#F\MK+';Y[.@=NW)-=&R*-+)(C13%EN&V
M#+HM>GU6/L>+B;VZ22=WZ@YH%*F6D@FE-ZA$'(B/I'A_B'@>%X?@C%^6V!C#
M$PL3#>_$AX)&Z\%P8V6N<6D/&)+!,WV.3:_*#P"WJ)%K#MLDF8U.@P9D*O2C
M;<G2X3K#9-1RNI3D=0=/N$DGMD/"<.J0H6NQPV%F&QA():QK20(% !:PDVJ>
M*^>[2YC]IQG,!:PXN(6 NWB&E\@;Q@FE"=T3[ZTZ+I-ZH<3PG%ZW&=T@J\DD
M;;;FQLNF.1KVU[LANZN#&Q:JE!;;GS%E6 S E QDD!(,*N1>Y8(+QK.]M)FG
ME7TO/!:)]32YI030'GI6Z]'8O9;J2PO)*.VD8M=U>2U4[*W\KR_+]S#OL-SJ
MJLJ>#%I:F%CU=D^3SH$B%8-2)ZS!I(#;4@4%QXVR7E%_R/37U212M#:D1$F]
M*4M]I6(=P^GKJMSD,E?Q3'-R]NG9N82RB5R[GPKF.]$C5UX-9EC<P,YB*H3K
MF?'.9"!BOCUU0U"5B%/FLNM".<"MJ^DVMGZ*C(3)B_#N/O<*4_2-AV_.U609
M95[NU5[:AG=NVU'R ;D;YF/;H[N!?6MDXK.5Y 59B[-9^2%/4/NUE,\]83G4
MD,@ -M-M+1]NB&M.'+D;4K8]1*]#*]HMV7\,ZD<+A.;B7'YRMWVLJQ"_JLXI
M8F2U&(.8OL^%G2P);U[6MT3<B?7YI7PX3#M5*6#+<D%'!'F[,D97XY>N2E!!
ML(F(DCCKG7N>H&"]5KFW>Q..8S?2\,;QS'"8SA*"?2R;5\DW"P-BMB3I&2S\
MF=G6$7:A<WL[.3#L)K4G* C-Q9+[4B#'F.=,]?7UIP!BP$!QUBF@ '+6Q/(P
M<XR1K;K9R_-I^R&0O99.GV6&VS.09#"?H*[#8(PX^(3,9O*VVBDS8M7%RH74
M"Y"-.1AJ=.!Z,VTQ%<'3OO[*B+Z<9@YCGV%WZ7+^L_:;.=H-OLXCYCDD%AVK
M26.',4=U37% Q8Y*4YJXN9K[LQ+ ZB-21HJ)*!UJ=WN3''PFMJV4@&LFHXQ'
M6GG0UH5(+?OIRWCWUWAA9;CVX-CM=BL7:R+'II@';R;.%FX7"68!&KZC<"@K
MZV5'B=D>QF6-'D<9YD7&!CH0IS8OW^QU0&>,^@CF9XUFHE=G87!MV-N<SQ^U
MO<0S6%7_ )&%ANX,^QSV+FHYEFMMDU3)9S^HK'+^<E'35K3-A+D.^E!*-43T
MB%5$\T+C<&="8N8]=/M=4D6GIK2W"XS&2CIU";,]45W+W!K<)P[.+3*<ELMV
M) ;KUFZ$2GH+7%<BPFQI<&P.OQI<JB+43'9\JNKFIQ,U8TEA$'(I5V82#:CP
MC6QY9TY_SR5'#+\3[*?_ $OX7FN'ANF5]2WV)8=>YQ#LMN<+R7*V\OML>I8N
M)8[3W"G8#<9"<-FUR2MM;)JK.[GC&1_UF3:;E>FEZ1;[Y&>!F8.2@YS%S?U^
MW+KB+[0B7*C[(4B0*J-E#\S<S'H#F!2\J?P''L[[J[(WSQG-MQ8,JH=PZH=:
M%VZE._$JW-OZRGIY02JNPGQ9E/(7[L;:'BH*^4<9XG745L%DCHLK;BLZ>,'B
MWL6+ L$<R-_[HA933YO6XK$E7UB^QC%3E]1?Y0Q>UN+QWF:!FQ?R.39S&:L)
M$R0],-YXIKERYSK^:J$5GE)H"(SJ-+BGV74WMZMJ_8S+Z[&,IPO(G(>01G Q
MR_AS<>)FZN3?K85=5U=>Y8K)<;E65I$KI$B6_&DA,)_T(;T9OX@!O$'C.O[_
M %SH)S(K;D.5)U II8JUZ'KDI[#)/R=O=O,FQ;[FRVEP'/;*VG8\D;"\MR!X
MFZN/*:B6DQZQJW1%3?N*X)-?!3E)LEE0-$=F<DFL$WM32_3KJ0;1BW#M^-EM
MY/M#<>F;3;M;=[DM8]TI;B0[^5@V8XYET*AD-[J;?"<2XET%C+B09Q.M]BQW
MY+3C1B0&VB\CI36<J&1^.JHJ,QSO[SUZK:"V2&V!BO*& DB]PERA"BHO<"D!
M<HOZPJHK[BJIPNBHL%\7OY7CVY7C]7V_S^.BUG?DQ::6LGZ3_/;_ )_OT3_4
M[W58V9;@8?M]7':YWFV+876%*;8"QRJ^I,<A(;JH+323+F=&CJ;A**"BDA$O
M*HG&M6,YS&M()$N@4$GEO4BD$B8]MCG-(:&SOAHWZS]4F3!  M%-X#*53D[A
M8G"QT<RFY?C47#G8H3!RIV_JDQXHCB?U>1$O?%/(21[@(3G/4Y1&^Y51%V.!
M.$7,)WBV1 :3,23!-LI+0TY*M(W*@[TDP:R)L2'1:T :'AK9^T&ZL[?&ND??
M/*MC,.L=P;R#@UHE/DUW":QW;-B1+!&6)C>0Y=88C^4[1"1NLIA#N0-.20;
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MA$EH+@  \.8($#>: :23-5[,:J@08T6-&CM1&(S;; LMM\(C3+8M- 1(JD8
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M7-((.\Z7W_ZQ,P;F<HA706U(ACARX'8?<IEWCRB\&A$J%Y1%Y5.=:VL:T0T
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M.L@QJN2Z-X:NC$HID,3U(7=V*=K28,K?EU@4=CU:O)4D4,_3JR.>L5J9PU>
MG'A"BS @/>SWPDR8TH;:+]N^[:K0V<J_@$]F%:R@V-,*Y/'U[\*8@! NLLNG
M@ >MH.WUX5M=,Z^[()*)3P\Z8+U,_\M#.*M"U]NA0R"2/#L7W'NG-(Z[ZH\9
M'@KR'5T;:[:A=I3S0MF#\,K?F2:R15_Z7N2IM9#=J!+V?91AP?F9PFX8.Q:U
MBK9RHQ&1W];?^B,RQ3P4DQ#="8-_&N_/'=N]COMI:[/-X\QR<(:'G_;*",O6
M"+J+H:Q6'-B=]-VM$XNWLA#54C-3*F[4,R$^=IEO6D00":=%MW.WU6!GF4[
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MUYA%+*&F=/];HQ;R=^E_ %!+ P04    "  GB6I4+O.[%0$0 0#DT@$ %0
M &9H='@M,C R,3$R,S%?9S(Q+FIP9^Q]";SC5/7_#(LLLCAL*@H^!P:!,I.F
M:=KD,3.8-DW;=$N3-$G+9M(F;9H]3=ND[OX$!45EWU$6645%%@5$17  !7^R
M@^+"OBGB@NO/O__T]<WV9@#Y#3^=!]//3.>]FW/.O3?W>\_YGIO<._]\Z)^_
M6O VDL@3"Q8NW&IAL#!8L."?CSZ\2\?S[&D ,'O+Q)8ER<N:E@'XH@V RZ+
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MS1F?TQ/#IHR;OD[9RRMM!!1$&HT1$)8&P<G082"4Q!/I9!J/PT0R'EMM^^5
ML9[]84<VU^X'3; @. U&IR%T]7[0=:1>WDC/4KRAZ,I8.QS"5]\8NC&EES<^
M>SC'2F"UXNJ"?RU ;!YC]NJN[W\]9AON Y[W8S8I77_ZK9[+<Z;KZQ;3U;5]
MWWA874=@LE=\W<:M<W&:\437Z]N4:RFJ+J^DQJ?)+ =>0>+_@)ZPU*ML6/<
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M5]\!9BAZS4[6M?KV:[P'K_U0GNGVN)J9,<4GZ?S4I/JIF?HGJX'K"+VRG1G
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M-_$S-K*I-A;^\WL+%FV_X/M;45LO7+1@JT4+MUZT\)^W+GC/@H4+MMIJZ['
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M%:N>B@\Y/:1'3OT$%.K%!%4(!D9X4K599LS*BGR;8-L%>1L?2 ='G#46'$R
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M[M6]J[WOKG97NOOA_3 STNA(\V'.:,YOSLQ_(K6143@&H#8RE8'1+!":<.P
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MZ$(DH#AXDKS4A&FC!_M5F2]X;BHC;'!X\7KQ''":P,XN$3 #$+':A#FE+4R
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MO: T]>T+=['%],Y/Q$*&09W&SL5"N6W--X$FF\"6T%T-BRY#0NOZ.OW@S\F
MA&M7TIB-9_E+R>#,D+RZU$IZ<^]?FZU3>8U7;(H8['#X, W;Z67LUYJH/9XW
M?\DN$%<JLOQ9AU?A+7\>!]%G^^&O)WP*)\\[DD[:&S@ZV&NX?1&3MJ57)B>7
MKW=5A/XP&4DI"6ZI*NW$^#Z5F@]Z9#(!KMM-<[2N?2>E2H'V5^63YJ;5,:IV
MK4ZS9=96.4^P<F\;_>XVLI7@-!'YWI&[PP!#FZ@$P*0G\/L\%1H=?'7;H+,/
MYSNF'HEI]N_G##>' 007DQZN0_-])2'6.F'NP.&D4]<*FWVUYM1W_#\@AKA*
M 91I9/1L:AZ0'*-2S*K?AL$V:Z%M)J0J?7 @_?>)D\B.6?..]/E5U]9@-P"C
MA6:)A*=<5*%,<'>&G4D/_6(VZM:SV/L$M29^1;CT8>S9[=R7)\(]4 E?GQS,
M^[VEVSR&A8Z+DJ'=5>E@ 78:.^R$Z[6;"&L#&+3-ZR$,']\>0"#C;O>$P(%E
MZHL(BY1A\#9(' A&0ZS+%FUJV:VEY-Z97',@$K82NV/!*0'C:,=!LW)AI;NH
MP]C5M%T5C+"G),;77V!%(PZH=)2VZ)IV);<L[%9;%Z!O/1TROH_<6=>ZN!??
MZ"&%JC)?Q=\4'1DFK;WAIT$4S*DK2D(.^;S850UH[4B68VTSMF%43F>SGQOD
M:2M+WE5+D8HM<$!ZN8_L&%T/B#2C5**PNEF$\AV6H;%@:2*\8D[>K+\C?8%Y
M&:@0K@:$^D3G24!(A^.50K)2E*X!KMZ$,L)'DWM?._^') O^OR99]HW^:Y+E
MS-G]E1SLZ67TJ[,!Q)0C\<[S_SO?=% B5)[!F6U@$3(]E:!$1H"TN<S'2NTL
M#]*B%F++]GHTTJ\CN^%%639QW/:?OV3VR/BWR+U;P<4P$XD/X+&[3X5;;0:R
M*BH3_?V'Y[,.4S.5=6Q;3\5P/\XGEK<\9LR5IWW7M+)JPP_(7"[_@TMP&CNI
MU\+]#@^=#AYSFRG1$"5E:<9FI-8+)&QIQ!:O89KCTN(Y?&8WRCP@"0%UOSQR
M"[(Z7K74RI^C=JU@*:-Q'GH> RDH1?;L (&8>Z&P9K92K;?8WLVS0"<@95B)
M0MH:ZHQQ9#L]TUIN)NJ#1PV@)&^+3YQ56G,&K[R+YJK9='[>5)(L'Q71]%$7
MG!E95+LN51/D?Q(X^)<, >4LD1%INR]\^8]]/4.F7O\W#WDX<%B[2NT?I@J-
M<4EG-G3V*RLC7AZ@V"%BAN_Z6/JIZY48C:ST3MM8Q79'[[14LDYMH%A5=MON
MB*E"= OR57:5 8FJI4[[9V3_:NJI2J=YC>V8M:[6<)JZQ$?EA+NI(W<,MLG6
MW.KB]6\ ):@DS H  ;KJ$N3KZ>[#]T?;;&TBB+,)V?S9#X>+U;/YO2>U#$AE
MR8U_R4[24LK.)K?8Z37'AF+CEJ2@Z@;] ODL @<(C6@#'*IP%_8K5O5/?#"E
M_Y2%=GWS$$8;Z?NKM4HYX C?$%5'1-]RKZ*>FO8QV'EOPS[$O!W,0AC&7FI+
M1C(]VA/GH3=Z,('UEJ]E7I#3>[ [(7I5#^G! />V3Z*;S)H,\Z+3WA!7#!30
M#2?3XF>YT'*SQ.)\.J4FIS0#MQ7@P? XEX3!!>,90^F@9EV]-]TY?56C:<!8
M[-H=LZY')G&WR4E^&<\L]C7>]^NZV@E3Z G4&-L7Z%;ZGXG?O]?D'*-#O06\
M27+X%\YSD*:PO,CNR+%D"+ZTYL=\]?A<&UP,K(UT*=M\*1+'#P2KLF@[)\>
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M?\Y.5&4);Y JK9!,0(U[TVC4D4[K%K>EY,:+I.J1G]^PM  5=T[GQE!_/LI
MMG!9W@6WFW("\W=$NH27L:TYB&2Y'&-</3[KY*VXP]H+"X]PFCR5^ '^)(XG
M^$ T=)CM)L!=T<7K.EXTX4BG2;+A*9^88+W5![$ZRO9G1Y)IPB5M[J;8# :]
M.B;;UH:6CA=6AN\<5(PPD6)-8:S3U<5D*CD(+^T/6XK:O=F)/'PYCL^##-YK
M$4C;P6R+$_,-3SU_'8EP?>TSWP#_^7'KX]N:SR_[\E3<4SNV>2'*/#YR3'!\
M1R=TAY<*RQ)]F[()1B82QY<D8\Y(7$AS2(;<>4<OPZ=@(1S,,/W,6O!];$WH
MR*[#Q,+$CDM]JGN31,.#)6R-E>W[]$%/CHE_L/#70.^3 LOBHF2/9Q)3&-WJ
M?RF#T^)M0KWP^]=IM !6?KDE./*V>7W;IF>3&%6(9$6#FW ;>>'=8E^^I=+,
M3R).-EX=@_GIHDWL5Q9PKM_%,1I5K>&>>@)Z=DUUI1=DPP9 IXGF#C)]M(NL
MZK.RB4?WVX+N,>PY7?8>0 O+'>Z8I,KA^NXVV'$C0A.EU'1H5Y_')>"?*\76
M.N..5K6^=*/;G0>#E@]ATU_OJ,ZR&S[90BP^/T\%UUG9W-TRZVM9@4.50M[Q
M U*=$Y\CM,#MD/N.I0P7]:QW>=1+JI/QX]FL4F1!%A@J%SX\8%_DC5T?TE+I
M<MM&LN5TT49+1NSX6_IAM7M)QJUQ7T;S>^'0XH]TW9 \J70)KME@\):KM>.H
M;C2-A'P6X8M#JB:8:*]#$^;-!V6.TV(V?19[<UAD1R>=PXN/=/A5"3N_T6S9
MD#W3E?+)2F_%;S]GZ#5:XM',[#BFH6)3_^A%AZ4K>^U.;K0N_U+@:WH%0T&V
M)CMS$P;'U]MYIQF!1US)KL^L"_5(E!*0BE:&?2=M:_C%RDY[YHER:]O*Z++;
M\N+:#0UFP;OXT9.;,\-W.E':!U.FLD?/OH\LOVVN:_MM69SUO8?>J&W9FKFZ
MHDPWQ?I4Q'7?$KQ&+K#XYX/</_^L?&U38_2LO6TALKR#=+)\)./BNZIAY10H
M&!GU-IR-'5?GQ+TLB;(0U&>N<YW&\9I*%^5J$&S]EC]J1%AE<,3]\'A>8SM+
MXWQ[M8R+_ZO@#2J6M?>:$>(O?OTE&ZIH%@UFN2ZO;Z[QFXRAO6BIE6%]_:XS
M#EYRU%4L&@T1+;5O=D?Z&?=/&,\H,.H)OL.'&SJ1;,7OAX_@7>23G[S79;?\
MJ-M<DGRNSR%E"%4*'E;9FO%^#7.RY&MG16H[/1=!Q";QGWY)YXK6T!Q^JL+(
M>\HFU<U96B?"I<QUM[9X9CC)XE&05* *E,7Z7E/LX8/B3 N_3;[F>C!U9C.'
M3$KC[7@^!@7SU2<I[9EEU<".@9=)%7_)=I?VEX4;J3U:\W1":[4&%5DW);I=
M,JWTG(%O'[Y!7B@3"Q1?VCY3QMN\^+#IL&5QDG*MO/;(L+\R9$WN#&&#*QSO
M/1+KL\-7@4F-;S3Q^98LAC,!YX$Y?H+A<K\D5U9Y6.?Y^418)ODE)14_8=@8
M;(:0-O3\XY],_Y)12"8'CH4199884ZLFIA1JCS. ((?^H7NH G;6U%H$74S/
M+)^$<_=T-OI/;K^)56C[23)Z"G$MQIU+,:(=^2LY'+ =[%*,R^1A4MYVQMW/
MF0SL:58W4-SBR$U*4G<D%"=X4<M<53'F67FC7I#,.Q5LQV^8+RR<C5?NPJ,P
M-]+5[&5_%W,E)=@_B+<AW#)>LR8%_H!]GBG@3FQ2M(KGD_A4$MB%_15[.BKY
M@R5Q9O3T;9JBXD!O1U6B-?D-NVYING+$ @D<)LWBV@04#1IH9H9[P'NB1K.]
M.!PHI.(TR8YC62!Q'02RL KUH2B'>T40-D;#J^-V^))+]TI8-GDQMCZ4__DL
M]%8+=J<_5BM_,KEA^Y>9_]S'IWHQ,<2*X?%,B2I=B;3YEKY\UR/LAGIY74&Q
ME(7VCFM3Y;;'=I%?09>)R=>O?\EX7(E#_RZ^^B8)Y8MVJ[&$X\P3OI'^=S&6
MD%_#NM&,"N;O'!#IJ8^K^?Q^U?Q6]+N@TN9S^H%/OU )S)$H7=M_,%*1TW8<
MVT(FX%.OYB.T!=W;-KZRH(N\HRYQZZ.B^\BN&\[9EZ]]^1>UQ(H;&\.]_)%?
M/AL/Z%5R43S598)\QA6194HVOLKF3>02'D)Q>I54-><9-(^CISW*QI^F9EO?
M+X&)W&P7I'.>HY&>,G/DQ<3W%>QIQ[E;-K#M:(6U\DN(7MS_(Q!L=9T9'T3[
M>U7Z)$L]@87_N8C7<W7@C+^@7Q8+>]I3Q).J[+<6>%1-E)V2V/YBCR^TNIA"
MGS93C<%C?<Q9G"GFV>=_7 18DZ5,W?*V&G#<,Z2>'T^#GX*O5CN;HL?BU?70
MNI[KP1WKZEKDH&Y_=X/:;(\<5+=/XO5HB5+7/T[_V,JL-69_K5T6G7MND$Z?
ML>ZZG:!?H>?'NQI\475Y9J+\O19KW3[#_@5I9#*P<A6C^R\M=2G5-'\R(-C>
M875O%!&ZD?L?B;!?3R;UY]^/']R<C!^\SE/]K?3R$7>HG>J7[XX17=B5YT^=
MKPL>!A#38 T6OU9HBSR0UJ%&=+@H(8BQE7W57/TC)Y((Z>0/0Z<HL"G!HWMY
MUWW+B_'%<0=HZ]+>*M<_;2Y^N;@)OC B:*)AEFIZU:[2&.LJCRQOB7-\LLIO
MDGH4J)YH4#3/,"[#Z#<B#YFVPVE+9\/9=:I(C0?=B<U-+9?N8MEUG7G3K]?3
M;?:NN]V4\$TBZ%*V&L?YTA;FC'Z'C9\S?&$\S'Y5\ '.)\[^<01>\ ZX4]76
MZ',@$E :?I,S8*N92HMS^^9IX'CGCZVVRY/6G'ZB7JMM\\VU!MB3PQL?0?+Q
M;R7YZ0_BQ?5-33I>=)AY(0B-1XW"RVW3KK1K>B[ZX%.0C'JGZUH.@T8GCQNC
MX9,GKJ)/[8]%3[2#G?<^-1LK/#]MRF(2E'E0(CH&4R]6^+4%>DLS,&M,6^7Y
M/@A2P&Z@H5F6GAI<T12X1U3)</JEGJXPC+Z,]?[0+&5U+>0V1> 3.]S-!!R_
M\'RW\H7#=DEEVS;U6=:MN>_G.89^+N<6)UUV%DU!ME%BR1.U5)V&K9N/YI<W
MU*;C]B\A2I<M@\#$II<A\GP$]!/=U(SWML39Q9,[ *UCO@W25=XZ9QA?NO@Z
M=]^8H.^BO\<UE)E<-<"TLD7JI"JX.E*?LCR(US\JFR6M17LOM2AKU)+QF0[
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MIW<+N18GE.2.%=E+;<*(8@KH2HWKRAC/G[H_K>4RP4E6RTQT3+^V'1Y-\/S
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M3SZOJOM77_2$'];'1%R+-:0?F@ZJB3U<S)-]-ZJ/N15@"N'QTVN;*KF4>U)
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M\,GTM2B@QC.^H'^Q2,O=4O,%#? 5% FGG"&VW[G'D&D,/O]-W(_'[/4CW^+
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M]!_!"6KWATO#5?#_R%%TM/SCY0/9Q ZF86+Y!QZ6&?!"#^@*DW.4U5!4^+%
MH?Y@_Z$QFA4$ZG[?SMKR1Z2POW=>]@?[,KKF0 L3IZL5"LT9"(7]37.M'^P_
M-L<PM92 V$&@OP07][N"N,Q/P:4;2A#PY1D-!K&_N PY G\-'+K=12#_PL4T
MO5KJ_L+'@%XN:']B7\T@^N]ZE^DLN@GXG8][583[OO(@$ES5+@<4X:I^V1Z
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M7=,U7=,U7=,U7=/_0W0^+:IC!8/9"["Q@1U932Z_^&(U@X#87$WLV3A8V=D
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M7$V)DZ%N"?7YR@,TQKFUXN*U\OBUA/<5T53=])0:A.R!,4-YL2S<31:6;><
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M]Q$YQ_1:>(H[G0.:^5F]# Y9LV:&ZH",8_Z/U7U4@R':0[8*4V1: ::RN5'
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MBY+U\D>,[.B<8%D,W\Q>1&C(PH8&EW_XQTWF23$XRB,8[\AS*I9;FVG31D^
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MP"F(4/G4.\8TME2N''Z9G)X[TSV +^3B-5"<#LA]Y!\PDD[FC/!)M4":_E%
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MMYNJWW:G'N> (Y*2DB.$97ZR@:_-G4<'QAT%+&(^I4S^HD;?1!I6!C[X3+!
MOF$;YPPL?:7B4Y]4*V$1JHB@^)R;5;QC4#RSY:K5J>2BCJZO=I^$7F*/]Q,5
MO AEAKZ71!K@[(NL^SG ;V7M*Y5(:FI-.,W7$N.FM>F5>'S5,>D7EM6[X^>
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M]=6^-SP-IX\T04G$:+S'A<6O  S6#TXKWQ?O[+05#WQNN<T "U8#CYHKS:\
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M9(BRO4#S+Y)CW;N9._]&$35#U*R01W 5,6@9 &2]\A1&XW#<*!-ZO*Y!=A
M<Q_^GS!"^_MP<$#DO#TV%F46*IHTEXAP $$M?GL1KZ$1  *XXHD%R0("@_P;
MS*\=";[TXD#*2THT55;EZ&P\S%-J!,2W2DH;(Z*EK;9G^*4&./ 2K"7Q^LG1
M@N4MQ,3D14(0R4)A(2,3_J?]< /#\G$< HPJS9LA/'6&5"/#$#F$% U0L:H*
M](?8"*0 AP+UQ@-#C0"&"AB<45OY%E7/48,3S>BWE#(KC3;3/C]7KJXIGZG1
MJJZIJ*ZX-S>C/0D7_EV6H5!P4BOU&9V.?Y)^K.0SNBI'K E^#Z"$'C4"F$_O
M22GLE;:8&BCMU);E7"ZO[_B9>M6A$\>82 C[UYP!=>;I*=:[PG)T]U1YW9"(
M,DD4"WX,Z?Y2AM YY$(*405T)O!_=E8A=H7%D%*('B0S:;BTA/O:^CF(R79S
MEX3N?CSOT9X(<V2EY>X/VHN;U<LJ8/>RK>*%H_=%=/.KT6;<DR?"Y)Z#_I-9
MV"M @.L5X! LR@3YKY[3:8_V"/?Z6J\ PFW1B>A7P.KWQ-:"_VXH^)^&KBZP
M7NI /I_<SI"A[2@56=VJB";_TFSI^&]3M1P4.J8$1O1X!14./)ST0@I$ #^-
MT=% SNS/+!68E9"CR]%*L^W10'5,$3J$W<[;>UX]XAL8O<U!DS!6KQ!B( _Y
MY,)XT%RUDAU"Y]P$Z4ARQ<.P2$[[+@42AQ812;(B(X) [B9DP'Y2S#(+!Z:6
M=U$B3::JTI@X;4?@#]3K'AHI#$)9Y7^S*YH#!UKF%=32FV6Y\'K>,H2HQO^(
M_+R$BLHR%1Q\@T@60LBIR)WIFJG(DZ1T=)?]HC7?/<BG?)4E>K-$_U15$13M
MG'?P->BT%F7/XW_N$N=_[E+@-T/&#XFJ'J=8J(41[R&0"M9>[EF%@N58MQQG
M!GD :40T!0*<)'84*$+RK!\1XS$+E-;<T53$4\G17%0_FU7D7F]>#4O4=NC]
MF_.[K$"^@+G6BC*<8<1TI(Y#JA2 DU[ZIA\93/_/T\//QTC09+7'88W,<@$+
M'O<%U\Q&'O\V\JRL*N$LC_6VAE[*=8@\:QM$GA.1.I$&'T]EA\D7+YP^7>80
M(1%27I@)*8?8E A (*6))30LS2?_;.;YDY 8%A&_L^KIJR$@)\:)9F9F9/#0
MCHB*4"N,I"\QG-=45$ML=T1]I[I$P7*5JM@GRH67>,5*\+.4UX=BGH>RO&XD
MAUM+D4:3(8%[Y*\@7($A>9\!]!87#^"F7PMNU(YJ60"OM'R=%%U:+G?\5/]T
M9N<$))3Q.PUP/U-,\[KA,J_ZVBM-;/18\:&TN>JV4052@]'J,-=,\D5I4IJE
M25$>+*^DRM=CK_<&(MTO;0O5JAWA9IAW(_T@2$QY48<CFNI6O9R5HJF ZG).
MHJ3V0^$_D37:M])L;WO<U[O"[N+"H#C_E8P%7UL^/4V1I<GOFSR;6]DI<9:?
M?1;GJF?5<LO)(]7 S3O;P66.\V:OF'7-1S8[PW>8*UYZ%;\V8))*K* D\[0;
M]HZ>TV;J2PH+?">M99M2I+_OS4K>Z_B]"T8 ,,9?HB<3N)K>:-E5HI/@(DR0
M+3XE6?>MIM16G&V=9OPN:.T;L*%[6G<\V_P)*?DMF&9%?C?:>O,R;"9JT\&K
MY_*EQA)273/8G,VHONKE2&S3=;;:,+-!1G)K)$)*NJ*I9!A-&:91K,J5_%<E
M7,"2/CCY+SM"I&FZ(!)"L)B8F"_6S4.L ]?0U4A2*5A1#E+NH/E-95:Q-'.<
M>XY_:_H@Y!/\+N_B9G=$A'+MNJLMOB+06$&'X6/DO-(!-7939VS)VT5\I_C%
M62N&#C@E\\6TDME?<;PT1 IPC'DTB)Q*_4#$P ?3N!'L9IS-479IG)!]"]Q3
M6IL78(MS>6#[IF3#D+E0N>QR"[6X^:KVE<>[W\$\VE#BC[AFUB!$5B,O<$WZ
MHRKWD#%ZB&E&F_SRV)WU72+!^[6G.RN.WYCY:R6$;T3*G&MTINTY;QC'7GIB
M7"^(/CJSX#:)?,1K_37<4[=D"JD*\\>.!EL\.5*KRPIH1$+BSO#8S1:KB^.8
M],$E,^CSHXY<=C$L?6?6.A!QSO8HWO2E85X+'MK&+/0Q\WBY9?,")L7%D[H$
MMA-E$H56RSBYG./@P'8&J3>L*!\BU2^HHD-<DW<?D6Q_/ X@P#])L04^_PW'
M_FC@^(Z2GH*"!D\-!^1.P1 O)A;0(UD=AH*5FOWL$XQ:2#943.J+(A<O@-FW
M>H5RW$^7J=Q#<D__"D#.>Y9X!7S][&PD2^*#^@I 3+OG#/I/50P1%>".6@Q
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MD!T/T84=ZW"0K+,'Z=_,Q',-/+X]#JC>J#^V.].IN>!]!1QY&#(G\RQ0]=T
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MX6<.Z&)'FJI'2?VD=LK]@4^RVR+85*1O*MB=K/>,K*N[Z/ZE%1L[J4NW/,"
MMS)33WK!\DVC,$_38=_B>N4W3*/GERF*-^1]77W=4_Q7@R^V_]!ZLV?6,T)T
MBQ2FL'HG:N-:XV2^\^!BR$=$:B"ZMN<?$'JBTZVL]/B1'K/U&:6KFUSE!LKR
M[ES=_TC[W*CS0-2KYJ\^E?%]]62?J)F4U=^'HG?N2%Q-1%^NN7QS?+0A!-6C
M5U=,]_3D<[X,LXY+S\_^C( 7HI*JYX,@$]7GF,VZ#JT2?0+KFO9O7EZEF21V
M^$HJDWK+8+?GE-.[8YL50=T5$I;(R +6&]C:DLBB=63E.F'65V&THXT^.^YI
MJE]([[P0CK;?GHEB*B6*!FX.OV2O+]XSOIP:O_5)17X,R .V]+X"_"1&!SS&
MP-TH9*^ ^C_.*#LKF] 'VEERXS)"7SC"*T#).^_[*Z!J=9;MT#N2!]C$G5>=
MF=<BLLKV#V27@PQYO0.^:"'>3E:)Y%VMQO65N!;$,ZX>V&MV[2A47?",AW_,
M \F_]<P;ZU6ZEWO ^\,Q$VOHAB?X^/<"L]GVQN+$*W8U5!3X*9JT-#P1%L@L
MI 0CJ5TW6!'&#)Q_8EA2&G%2'M 2.5RY3;-JAF0J/C)VYIZO/Q\GI<B7=D(B
M<;=V6'765LB\Q80R-IR?G.;<LF)]0WV6IGF^)+R-_['(,ZOG$+,L*YL_,#9+
M;QY&\LOA?>+O%YD]P)GL.+Y2HBUAOBI&@M##RQ/G9S*N)REOW1'I!4DEAX>(
M,];^R-$99F1TH]_BP^H,0CA-48@<29:&E'CER<<MZO5X^1EAN201I25VT#5A
ME]GD/VU/HTN(B  *"HK/2ZB^P<&/J)AS*/3_L*F4')L#&II=\D)3(_ZPM?Y6
M)NEH*HYNMB#'>?:VZ"+I[N<\^;$4J^:QPS6#A?/_GX?S&,@ R0( %KDSN4D/
MAQPZ*:,FRGBQ;<HM2)Y\+$'1.E4"4^.D:)\?2^I]W>/GP(M^Q5O)Q5FJ$NY9
M>3*[.".Z@9,[?-4(R=X^=S.1&Q;A$3,<,$&5S(ZGMNM)9,60"/7 B8#_E; O
M,[2A)@,;F8CQGW2OF]7%1W^+F"+)>U(>(29K#/ %X'&]US/T]IA5H-,RX%+,
M9CFM-SW-:K!=N@D\[A_\K6%RF^>9@J\VUY@MH=(E$!\5RWFJ0U@,T&%/>JMZ
M"BJ3$68<R1XJS,!CE"-!+1]?EO)%C#-9>MAW+RMAHI?CF4S#S0GG\];1\:#;
M*$*/)%:;FU7D;M^?J]!7H_#ZP/:I("$A.M[:/=8U:]*Z_OM;!2D,TO1@4CS)
M K*'6WC_O4LC2=A>N1O&,-/%,&OJM*M +UF_F  Y*@B^*7G?MPB%PZ%+@3GN
MDWUKUW X40O)SD>;L>)<)[Z+#AH2PG40:C!0_+X-MKAX+Q;T)?]V,7\/@\OQ
M(M4N94[W<A[.;EA*#G/QAU6'U# *!P@3I_N1/<+A#X'QMUB3J5^N=!*KUBKF
M.RVV2T_)GX!=HF?/X'^23_6/DIT!7/"A-N[O?- %(5_!!2I\RC\187'_I=//
MUTIF#_Q8L>5V@[S05\\]XV2Q#&.?N=%@)1?U)U3J/E.RO#?'QGRWR@7ZN;OY
MPF) (0W \B-?F==\\Q'C 6."4A@UUOI6VMA[Q:MY]6/_JMURF>\M+W>SG["-
MA\JQ'G_*Z,++%,[Z:E*M<%;)7&[?<B7I:>/4?LIMYRO 4']XQ$=;B8R'T-$Q
MA8,?QRP>RW[W4-6Q!0P.NI"!7V/V'2V"_^F%2\WGE:[W5T)$-ZNBF$X_=I\L
M"#RU.A0L$[U^*;U@"&,RMQ#L7MY<W)P@/3;GS0D^! :_^%^(](K>K7:RO *D
M!G0/GJJKDX+HH[>>FVX67RS.\;NK6S'8V%[>+<_M7>T5P!%RUP))#[6J<G]!
MLR8E=)/.:6-^K-?H#Y/T(*RX.>\*DY@1K_;C:/834R**MGO2T&-&^\TY- F1
M[K9=J*7$:$W7S?<R*]#%*&J*PKY#&/Z!EIY>;MQRI,V&,/#T[*2B [K$WB)C
MPVN>_<("='C!7%$S$#GM<.'@H'KDXWP%L)Q4.SS[WN8ZJTQ&>(ZFSOD++-^V
M&AXZ\G=%:C7^\(R2UX\!"I)DI_P4X9N:%S S7@57-4OR4[,$@)]T1+TS1]-!
MU(5A<708_'%Y%0_WGV24M\UZJL);JSJ"_LV>Q(8(Q2J2FO8M#UVBH ,1?=I)
M)HYX5%R+1R;^C<>21'MU*Z<BG9V=O'"\J<R!PFBI"G_"0,4QS/(DT4>R+3M[
MY:9+D2M;'TBX^&<]V3Q ;+H"!DD>J3)5LAF(E>A&P,6X"5@)5"]/XQA+L*U,
M"GL:D(H2$I!H"\?7P.+H1SX@[^ /K<NN$UO018Z)-.7\$%R99-J1XKL>9<9G
MX$^?_XY?P"9R).NL.)U0*?\!#]D97?W/V??Q,\&_&LR='SD[59;8O_CQ5F?%
MUM9PL-YP_K#4JV&/J6:??I\Y(.3?]D[V*[)]=+M; P-JVW"K"NY[=:^4&3;H
M,&[V\F;AY5T*4Y!KKK;WA6">!Y0:F8:(4:EN>=PN ?-C<V/+:(]T!9/!.ZZ[
M1]*OB)]ETR8S47E\=#/K&C]G-TG/AA'H1,0JAWF+^J\NLM<(@&=$.MVT9KXO
M 3\ )"-(S!&NL:96BKJ?0>%_U%+5__^_!HNI..>'TH^WP6E]^),ADMIYG2:2
MAMW]^Y$$\93D5!!6/UTFLIQ@OD?8M@&1_#W5HD$%ZJ]H%3V(]$=L;)UP+ $C
MSG0_"L(0L1/)OJE8X8U._Y]Z7>K@-Z(?Y%.:[V!4,M:X'D!,<(&T&O5V7=9]
MO>H+)2@$@N1\WFHO@LTP1TF--T9!AQ&&;%7CMY6:L!C"6/YWC?F>!N)SU=C7
MM,:9XD".99<U1=A)8H=3L/7ENQ-!_.>I9%\L<G"M'V8^"&0U27Q?J:31 EV4
MY7XNMCG[<+X.]G+@YUY]8;G*X=,[NR>ME*S_,VMF7'68Q#@J TD6[FBNDVM5
MGSU:QB4W EYC+FB":IM]+PR/?O=6X%2GNPODM:4ZMF ,&VW<\O9*RG>V5:W7
M;7?L=)96OD<W4& ; #5L_]X7A6323\2@6T12-/[02-89)%>OHBS(H3=#]5C*
MUL"&PV&UV"<R/'ZA'Z;;>7TSY2LMM(2=C&YXE%I865==85P9AZ\ .T$'06/'
MEG&\N3IVKP!OP0J$"G4E#%@OV+*O-(4WTEJ.%7UQ1,QC<[257.7HS<,_ G*I
M#,>"UHP?/15D1;X":(S7*[8FA7N[1"9@3R_OC4;O5EC\7$ @>;WH\H/>'M%M
MBU;@,8O#[B%9P=I*8 [\]"7.N*;L[K\X3/L_#M,:]PK8TSRZBJ4[S6MN7%R:
M0-I=57A?WPQ=7HA+B[6:??%SN?.NSLZ2TK.[:X^T28;:M>^A7]-AD;>.M#N
M EC%<-*1\SO4G/3+1"@0%"63^[:QW\_#K(LLP-:.(M!&^]5OHY<F9M-:E&EI
MON%J_EG"[TYF:ARZ;W(FH)!,/^E6KY<=U:0_&X)@NYZE547)&S\+'<+DY2XX
M.LF!J>QW?G3G&P[Y[[#-(A2333CT?+S@H'J\2ATXM]@RP%A5Y&# N"+UEVS/
MXT\;C\.ZQ!'1KZ(5Y,K2[JZY*@YU#8:E5@##?(/PUXGY$*EJ"N/T-#G-+.K"
MM^Q\\B(^=EDMTGD@^.,_9/*Z,W+H-!MZL>\Y(2V_(&YQT_>?]I!NK@-#JNZR
M;'=3: N4$P*P=M:%GG>7BG?!)VH2T;: =_SVKA3J]Z;78ODKEGM'3)>_&[3E
MOGQ8#QQ3K 3K9G4\T'?^TGE(&@MC?<OD6#CCB:SG[+7BH0=#3UJHEY-<A5[P
MZC3^U24?,W_FQ54D:Z1:B$0MFY]6>[.:!Z,N^  -ULJ40?<(_)7IQZ/0<+(D
MB9\=9JC$TY3+9^K1SSRW;,]UGJP5*49B5G1  QCI>E34!8+R(96[AK6V+E*
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MEKQ^EV?(<3DO]X)$O?:@"Y99D^$-W=5,T1>EW1\ZQ\<,FQI-24_.OOH+WF*
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M@S(,AO[R^1J088*&_C-@0^=&*>Q7>-@O7V]X;7A*HT:29RTQ,E@J:"6UL#Z
M\-,C:K0B!DK)W#[W^5]?<BX+J4@.TGYJHCJCEH)/^PZ(VG'SG5HX>:9<*4]B
MM*@_XP.-32_;/"P4F;\#E+DA&,TI:?\>"0+T&X%"[F.N_1_<6KBB.FIFFFFY
M2HQH).G!153P4)!*:")\EXV:8B.]W8KG1F^<>P@UT$:+GI&RX8]?9UX.FP"\
MZH#=!/W.=)Y"3%)[KJ("8"V9!T$PGQ@LR.='65+BL04*D<I>.C=AX#^,3+1]
M!\P>.61]OQISS%QZK;V;4_8S?.9+> ?$+E$_V';@>JP]YL@) A0.<@&$_@"
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MHFY)X CZ](M8^A.^AH>\,-7I?*<V8?F_N*KB?YO+@-%1BF#SRD!Y7)1I+3Y
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M&/!90YROV_#1'CS#_'BO[F@5;-RBS9?&0<-MX1LM6$74@O<GFXT.<7J"0>\
MVCVHW-'CEF+_/PH8Q8B/PC71DMN4<34HX;E\H6RSM?;'^09J8BH3,C1),H[9
M_+2L81VN\MTG/+K#&W=ZGI#+7WPE;MVK[@W</&N0DLZU].#YW77QPJ _;"0
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M?M6%3:M+57;'%/9YBD(K4I+81 &4E<A2SH20'T(W/-@V$KL%0%1"-K$D#68
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M!KV4&31;S*Q[U^&:) OZSV\A@"=*,@6.D,6+NB5>8P7+Y5CF)1PLGOW&\]*
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MB?;D91ZTT.^/Z"##/ X/4Y=E2*++GVF@?M(6+(AJHU;;SI?4<#9/^M4OS 5
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M/2+_V[#]OP3$+,[W_;_<\VOJOU!+ P04    "  GB6I4Y,0N5Q1/ 0#!HP$
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M32A"Q]H-:J1\Q>@7V \%/00<;F\(17FZZ]HXVZ+9!( >@ #@Z)<]  $, 2B
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MFNPP2+);"9"]XH87H3 ?PS.6-9!2,QTX=INU(/E2B2&&Y>LVP WGFF*<QAT
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M===KTJ1]4[N^<,!M/WNJJ*^&,[[(N%%G*>LE(L'#3#C4?GP8%9*O?7/K7O_
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MG L=T0[=]]Y\@7^@5X5<)[98K"W;V3\&XEJO\;\=2&Y66A(5UY!HP@F<#E+
MB9L-^'9P?T$H,N?!?$!X%7.1E1S.A0N? AJ_'QP#O%)D?9_?-=)NWKN1QW)K
M-.X3D6S7P9Z[82^*<MUIHE+]7:UK6@VM709]7PLF]<MNV('TK44- TL-%8V;
M.-1B)J*?U3!O>&\LMYIV1*\X7"X@4\S2_$H6$S<-Z]F8];>E_IIV6,<H=A.!
MQ1"J5FK_J7AE>]S_>N3NVM$Q,!B<[GH57)6V 9NY0ZI0>2NB14'NR/<8D.[F
M)TLTDM9FK^\W_ HRB 7M(>,>W(J<VS@ 7LZDNQH"5?JOFM5X +G6"0QB=2"V
M+#I#3[W+XX'O3,GL,>!FMBO+"2OF4!LM!*?":P,G][_3MX1B^BNT)3(OT^L9
MW\J@#:*#[\)G=]T-^\(>7+2%L2.D2"IZI6:[QK>DR+]^[(8&Q3^2302QO:5;
MBY)N/ :(Z2B^)F5VV^]+1G86KHAUXWR9"+KU3=+5A^WA,5!;&*0GY!5 SZ;_
M=8"X('-;7+8MF,Z!9^%15//2BM@TYN%G68N8Y9JN8-_7<NG2="[INL8F.OL.
M0=:U*\@#V0S,KVF8S@XYGGD3$G;[WL^!C0S%V8VZF71DG%7B(E+C_F-QO*A\
M_FGQBUE=7[NB G$7).AKA).EEYXO19:-TN\O5FQ/CX(/#NO8%R4\5_F;G?Q"
M!+Q:NR;VO6?2_:\2D2T9>!++Y!+ 4]U-T<FFFE5 N:BM']<\6RGKL9HZ Z]D
MZ I.1Q8P=QYEV&$Y;$,"'QU$971''E"@H^""LWA+O'-!9]^+H=DC;L\.WJJ+
M7M_@5@&]\7(F ?S-HEM=4>^^S*0C!,9N;'AA/)'6>0]N%?\2X,70]2ZXV=4,
M] A3YIWT0U73\1J$#H[_C;6Y@"YT;\4UU?W&EEXRI%4M!HY_DYV=[3PX;WOI
MW<NO8:%"SE)/+-;2*F<66SZ/K[5*+<[?DK2RV')];V"45:L3T!DTC>;)OYOP
M?H9E=<>[DP\AL[^XA1/<;#-$F115T_[LGJK^UUNIL[:IQ/H9,C(39&^B&^&5
MZYE+\:0>%1<PHRQ;TF_LC*-'.)&%WS8F*ZLLKI5>L7/_UL'WOORNDSE&F>;6
MV<(LQ%82^-A[G"&](!#?1[-^8R??_HFQ!65,*\FO%V6&Q1 MS?O$AU3TTVYZ
M]J6,;AV/3=GCWQ.Q?#-TTXKO&2&.C$_=F<V_B,\ (:+C(=S_YOEZIXXO%K^N
MWSKAL9_.G2+GH11R1D["HFL#/=C@ C$G.2.!)"(BTDS!R(-KW9M![=\#\GN(
M:4'U<P][K^<XZO(UZ/LZ'@Z6//4SKK^A""/4"2@H1#4&-C'PQ;[..^HK&5QQ
M\DRBG"7,L[0>7847U8[Z7-ZLW)KBCPDM7@C,:</L91I3?/8E\U.9H5-HFZ@*
MJKMF4&IF$#:&NNKW[5""<-X\SX)H</#QMUO53(U$Q@IS_FUI\()\U'V]<6MA
MU;?Q(=FL[&U;S8+'@#9XR']Q W>OG"AVE_^U5>S%V)5%'L&G*?)"S.I;UFL.
M%3 V5&]WUAB1J7:77/[1D)!/MNCL:[82 U.ZEL$1,]*+D+B[#&VR!9ORMG>L
M)^[/K744/Y7):6.<6"5?Z&N5=API9?;H? 0W>&Q*[^ODEIC2>!G?=Y'2/5ZD
MNS#)I)H^V"!81T6LI6#3\J',ON; ;M%>!MZ4;0U%D\;CP0^#T\7=-_(S&#CR
MQ5G9>6IW4+F/2R_R/JZ34-7;M;94I'XI-IL4O?LLFNCI!K3E3>O\5TW*BF?X
MB[@9R(=K3 JQ,5ZLRLZ7<;4I/YC%&E;R4"YK*)PG/\=I</OZ \_%VAR<_ITC
MMJT/F X+H GIQ8?D%AZ'U^[>>C9::>U'S%M%*U1?6EAT#-P)C#D,VC8;,7_N
M'MA9)Q"KHC+]I);EO*JNGCBF6X>L\NP'%CHQ^8OK5,30C!$?8>IG"K@ASR4.
MOJJ)1P\HX![%%Q*D;^$_I(_*RKD=Y4\0T=G.P+8L%;39=@RX&Z'Q,NYY4H,#
M"@.7ZX??6%3 )WF'S 7>#>.**/?[C=:Z%<&F*KE+$HU2#*HL,XV<4#=B'A;E
MJR(,A_!R'VZ++!\##X(O40Z]#WA:/X22"5TYAVG]HKUJ]W.;TAO6I<R]/ISO
MI!YB5"_&JD*GAS\@\4WJY09>9>BB5'H&>J]?_D;>Q#6/-/35KI^H$VJN]C7@
MB9 9?F4SE6^Q[;6,E,4XE-BTKW?K*E4N%17>5A/,K>8OPF3O8EN2\F;KP8I:
M)QUB2KCTS71[BD#T85W0$A?#E>%PDF^D#;;99DFY?M(YR<:Y"X=>]8=F3FL9
M-H'CB'=UF65/N"4(:*C6C-M@T6;WBJ-F@B@+WR2(M'K/B^0Q@C0"H[I>G7O[
MD<Z)EG&O#Z_9U?;2<UV^ON]S:;([JDZB\NX6*Y<O8.9/-5!Z'0/)R0*)@1]8
M/&159RME+/CA(E0?+@=6M1:DM&=\P\#>G'S/=L B]("5PWC@Z=VC#R+; _)K
MJ5O]NBI$JM_RP.*;'8?$0WP=<P3PA39"TS1"AG#%%7\I _Z/UK9WQ#>NS;H]
MK;;O;&91#W4=B= Q4CE"A<1H%RL;NL7=+-_>\3!XO /$?9]-E 4S$*]\F<<:
M]\([RL&%@.\E]YYG6!0)<7IC#:/W&7QE5LH4;AJ#8')5RM)]Z&4Y;G@O\BE6
MEFQD@7YNFT&/6L_Y+V'&6R6Y:UUPG*5G<%I@D^_B.?"]#ZZ!D+;['==?$2=>
M[=A.I\1P__A5K(C:QHFU$1I"]VI9OQ-J>9\#2UWC$_Y[:37:(G6S0L:<P<.Y
M4(FN@[0N^J!!F:SQ-S/TJA&WFGWOXKSSP<II)U9M_:PY<'4@$HIZ&IEY.&4@
MQZBHRQM+3FP3>YGV]NU@:<'QT#V'(?2!Y=8Q\-U:]YW/Q8,W!XF]3R?-307\
M+,@3#L:?$[TT>+JW!PK,PM5NSLZ6FF,A]O\L&Q(@1[SP6?@82 L1W9=XN;<!
M5!%X.;1A9]YB$^$/(%=ZIR:A7"K1ED,3OS;HV3_K)"D13EF@1*/KKT[%Y;+W
MJG!,G3-VC2*^"_$P+'B>+_/U\VJVS)JWTDJR!'NQQT#+<P(0L#-J_XFF8##Y
M]NHSFAH18>9SMXDM9F6$+%[G^,MPC4F=(\/A2])6V1ITV.I,R:I^--$TN=[/
MG2*IN=%0?:B9.;4E^Z)F>UZ@2*],/=RD6%0_EZ(SG$2?^L'WUU>#\@YU=W?0
MUZB%ML\WZ+;W-K"*/AJ,ZI9$NN0]BU:NJ-<=T(S36?6>[ \R6=>^,L1M7&)Z
MW7%RVU6.=)NH\(V)D9J0D4%!5\'S6XQ$E?0ABQ*9 PH]AL-MAX(K],^FL#AW
M1\U=IX-;RC[3/-QF,(,SR> ]S/B<-) S9,BQIJ?1X!=74-L3UP)-P .=<U,Z
MGU#_-M8@*ZTN*#] *W #(VAW5#P(=V\#P[8][*BW.HM/>*;PFJ"9P9VZ'*9-
MQK**19W4:\6X!J3D>I0IJ)J/#4:Q,@8C,EEUTI7A2U*N8L\*J((W=:EP2]FE
MJ>#$79\/+!C\&>R]4EFH %*!NB;#)E=+H92&<*(6%4%CW=3@&MF+VFD:B< Z
M_5T#&Z[\R'-BYG+P!W.7B=GN?_CXN9*.^E'73K3JC=I+G($>Y:P5#E ?\8WI
M7NRIG:[-6;R@M#D#'IBJ;^Y$,*A3RM8?QA= O'-]=Z:26.;U 0C3<0SF]UV\
M4_;Y19W#)F+,GIOWA-V1Y7DKE[=N1V,?U7]1FSC\OA8%(?MD\LA5QRC(&P ^
M<M6;C&YMUGA?^.3OU>?J$,SG/6)5FQH^)(:,H<!MI5W$$=/KE!6,. :6-UO-
MGN&X7&@"W+FV5AZDQJHB^*/]=^@;X<OINS,Q9&G,]TOE$\^#"&-J]J.F>@]?
M[A/,77S5[+W6JG$O ,:EE6CO^@D[3^[".@"L$P?Y+XKUE<,-9^YNEY[+OVGH
M&  47S[D8"$:QZ*['04/LFW!M)DYYYS,5\^FH8EDN7RU7.JC_%O.%\-5SF/T
MI51([VJ_.%>S6JPTE9K%MRZBPFY%1,]S5 ,#WFDG[!1H>=.:70L95/-0PYI*
M\ 0%[G]:7\TDXCS_>@NKK6EMU(D>MF+<:%:[O%W?5^W6G?S)A_2R9T\:?7("
M1RTK85T*(C.$0\!&])H344V!TP/-@#DLEMS"R^YZM[GF*$.EKB0[;Y8F/DNW
M%3I?ID#Q>,PBZL7+^]AF:2UK(N/A(EE?E07H$I);M'R-Y5X5WVSKX.DF+,)5
M0['B<>T2:77.'Q:]*+@YQN(<DE;EI5J1:_6MA.I9=\8#F[=^'W*$$=0]UHMM
M&95TJ6&):P+5N><F-=4,"_&@2:E.XY: TUNJ;JTH#X^B"('E!2HM[C>\0TTF
MV1/G/3'&!_RPG#\TQA14+7M[*D@YTU]8^53WF%^SD+O6^1(9/M=SP[5NC_;$
M@>!G&.88.(F@#*V%%+4GF\.[$8,<K$%JCE\XU3V;'&O*P@?&2G!)8N1OV5_]
MMD8Y7V9E//;X)8G-0&EA/TP21N;)9O)4VK#.B7]@C-;WW>BSK=5)&^?<AR\+
MM1WMYEB3;:I%G.G>.@Y2T$O?UVFZ+$HH:U"2I-TD7^=(X:=M,!VN5\7ME_<!
M47NE1%"/9+FERM'(UR!-\2Z<A9*R)OK%R+X^_BTN,_'G A^VF1:2D!S)CPJ&
M1-(":_W,MGP>#V8/I\49E0]DJCHGB7^WD2LL>B\PKA8JHTE*'<H2/1%JVQPR
ME">4U>K0@Z*X 58A4?4A(%9I>[M=I<;C]T!"N:JHAJ+5L/!%G/XMC'!O/0[#
M2X99$HFL?>&DPO(O2:]7+.A]ZC2WT'O*?E'L,7FPKP?.#:WS@ADF80JOQL;2
M"KP;AT6X5J=&&JYE]Y*O-)JL>269&XN8A=_7).L0,"I_X=\A]-'<(G@,_S[W
M-HZ\*EY!?&@.L"'1'<&BFP/' ;S6W56.B$"?=:9V^II](*\'1:C(G0;:=Q$$
M)#4WO"^J=P9QD459CP:J!DM?4B7*!!?59]F "\'UF!?!F#-1DJ",^8TEO9'&
M[JR)1XY2 @B[ZQ$ONP+NRTRY$]=U+;8"_(P9>J E.D<K ;RXX1I5_[6;_)]P
M7_;5!GV&C'LCV[L)'-7O\SR_>9=D7&;?AX'LIKO:D07%H\@X4G46V74;("LU
M/],+N(XAL\L&N4F<U37];J@JX,F]^_>(;2Z6Y'A4X@!QT9+?91.144.^HV79
MWUA3.+LIWW<[YR,,=[]OB>,$48.MUZ7%V#.^,*OWYG/ZR/<N4E-#B%O<FF[$
M?1+C;"?=3\M_-CK@ZB 947EDI%K7%]0LQLHAWKA$I-,?< N5+K5+_7W<ML7U
MNM\G'S;0:^&%QS !<AZ-PIG9&B_IQD7(VC3Z]O1M)G=EZ&4RLO!5?(^LCUNP
M !]_Q;C_48O;S:^M9L:M16PWI.(>Z\B1WJI@L5L4PZD9AV\L,MSPF4G:8;ZS
MG\0T]US5-O8<)B"W_0G8'G][#'"Y:TPHSZVH^SH;":T;2S_;6$'>OCU'$AO8
M/K/GP]&WU NA"Y]JOTGXTK=PD8W6H9X-[K99FR]86XLPH+[&+1B^>-U9/9H$
M,QBY&&2@_FUC_/ 9N6V\>'+ S2-2PJBTKZLU^PR[# *2L[0;D?C*#9/YG64<
MFI0896 )8Y@HL\Q4 '_<1CU#F[_[U5R_16&R*JJBG%P<6E!<9?=TY[0KG4-+
MAG6K60H^-48USE@^?=JPT]HQH-/5/7UPY"M%I264HS/)77L9:HJ5ZZ[TZZ5<
M;/1XWZ^:_65",BM' 3,609-$>GM'S<B.ZP5<[SRVEZZ9=)^P!3M#H\)QUKZ>
MQZS1MP%''&UT4=U=8&E+VXL*%G)1X*QZ&$!4[5M5(:Y"<U4"NN@_[KGZZ%56
MBCB_&YZFT.7^?&$L8=$/E!S5K%52W"/6@1!5A5B[TF>Q0H$%U,V7ABX(-UHH
M N,2@7KV$:,AH^)T+P,N:+4[#8?EYJ;(3-+Z9 \V[K[G0J$W#NSGF\1#MC$+
M[9<2&,NVA;S]V.8^U*54.LP)0)=H;MB";CF:UX'A.[$X44>A?61?-UNV/UXB
MLI\:)%8.8L/9"1UE>+QR_JO'ZY#4+S$</3'NCIBK#2/U'.Y9P[ &3$T9.GS+
MO00S"DJP#;VV]A#G]OTG!2*%6WXN/&*%;YH8713,60:W&2"A[6H3C;<?PZBW
M3;_PV90G5GP2>!S01#X89?V^KS.<L=$@Y.:FLYF95X3.JK6FFCM&@NJU;D\L
MU076V.@DB1 OG%N;!ZJI5[*2JS*=1(;;%JIVQ0@J> 0(TUJ?#6%+8-7YQV.W
MR;)F))+2<!^T?&J3N\YZ658'&,\-)I*TA8FE^ARTATJ]KKKP6'N/Y_8Y:A52
M$,%05:,K5Y9.(](A+YFB5((B:WA?XN-CB[UY5#*61(%&9EVXUY2C8H*PH$MU
M-?IBQ:#$+A\F9,J0PCPG-N,&4#",2EG(*=X+6Q4G*^0!FV!D1//C7!_XPO"
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M]R-AT^A'!%M:FDN12A?2DJ03D]>%=]TG)S^G\>'?+NB9]]_:J;>5 7\]XA_
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M8 O35Z@5H4I[X&VY.<^<9/V'^X^."GJ&:F=&OW$NE';.2 ,9]\8W'G!P?O\
MEC@F5[:<#H^SYBJ;'/YD9WSX!WQ]@/\ )*Y7IT=Z/&MZL4$8S@=CX[[X((SV
M)[''WQP2.<MP8Q0-40(NJN^-^X.^/((P<?X=N"D#61%8O(CC6X9(-R2-@3W.
M<GUP/0_Y] 0Y%GOZ;QR.1J5)P,@;$9[>.Y!\#8[>^?S*M-9!-[V(S+B>%*A
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M!,L^AL=0D-1T43\1\MM*0IMD/J<2HDA:0E)!)5D#?/#IO]BHOIC^&+KOK;S
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M$?*:N=0*@\>CU*/<'<8./ & 1_(;[Y.,X[\%/2E:UJ2[.Y,@ ATI&Y(&Y/\
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M4F#$BMM1NII">L]#3:.M24_+Z<I)( QG'$) =[7W2;-J^7SZKKCRBE1TI'S
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M%B*F*W< .]#[RA..H^N/'8> 02.X]O?[$RT$?+B*F,V:M53[@]\CT]1C^/\
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MJ5A.D%MH"2 5=$+\L$01G;'GU&V.!:S\2_L%9D<B^(": CS/-,Q$2MH8YB:
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M,O$&=C_EH;YV"#8^?"O^43[[9P/?&3Z^A#]LA&3U@/Q$.R.K!^D9'I]6?XC
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M+;?=A4P.%QL?.2A'6LA>4C*%$?2, $*& C<@Y'!%T#I-/<A6<U3PM#3B:?\
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M9"Z1+'\W!P"X;S$$U&">M#P]MKOB3%4.L]:=THD4UN_,?]?]6.CSK> 5DZU
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M_\&=^E_:?U'4&PV-6L2'/=G).YX=)><N>HVX8B9IJ]=\8Z0OAUH_V&K6)Q&
M"U*_5+".$/#AS'VSJ%O<IWYXJ=F]=K7&(<EHBA(W,O@=YO(PO>&R=;>HUU:)
MM<2R)[.7B>H@2W_<NL%90XEG:+GY8QLB=V<-ZV,(1LFF#H\?'#X<#=T=FAFN
MR $VGO!8-B"X"TX=3)NLIKW(V3E&_ZQH2.<E3]N"=&@9^?)L)E-^>6+Y5GI
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MNOI/^SVL."IPT*G21'!I$0\J;U_8M_=F_!^N )R((&R57)B!RM+/"OJ[OG>
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M_HXMM([9G[O^I&8!,4(0@Y7]"/! X[,@#U*>&^6HKSX(47&(0(>60>)3 '*
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ML]BCK<OO2UQ^.LM"QIG+V'&?E%[NPN>^Q,:^>;?!/L?JF;H4XS*B6YN><+O
M]I=#SQ%"Z#<=\+DRE64],#YT],< OH*8P>;>X"%GGSQ?[+HM)ZI> 9 3:SJ,
MA?#@2^J""KDV!Z6\[>>'ZGT=J[P];<:^B8PGAP1H3<-"-QZ%C%_PR 2MM:-;
M*>;5W>=W .4$-?/;SL7RG%K^;D:F:CCPB[A%W>FW+A2Y'FWO*K^FDA84D[3T
M9=5X%]E>>\Y-V^:(<>-9+2UI0L1E:R@VDQS=+89,MJ=LY':=W9-AH,IOFU;
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MTJ.';O^4;M+#CX[9B%ES# PWA<P,;VT6W@&9Z(F4S=WMN$7U@3_ZL 8@F".
M0JQ@8TA*(3T6M.[/&(*H-06WQ?6XE0*3A3$:DX4H>#[#!IG&:V9>#!AT4BS$
MX[\-,>=*"^8DRU40GS7-![^&.!@)_AEK.A/"@AS<"1"6\,-Z5)1\(7@E7/^
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MJ]E529IG>%0G:5T:^ZY:UGMWK7*[1):*%1FVV6XXC0J*_.?B?+44L+<>2I2
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MXS):3);8,1#3A1\M0^6<<>'Z3\1\?P#AQLQPG$^&A)((<S,C"0:LSN %!X>
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MINBQB'V*?&4EAM++#"W7$%/=S!ZCG?C7U_U_U'C8/"P^%@P8,)\3#BQX/#!
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MI#;C/05C)WZO.W$+GU[>XK(:VJ*27(#SO_$1U9Y@+5TVO2CO5:UQ)#-Y3I]
M>IO[.IC:L.+,DH2W\XJ)'4"0,@?=/W]N^B+ZKWXDEZG*;"B"@ H"%=9ZD]26
MR3W4E) 43L .(X):Y&4@,[%PW!60QY<#F%\AWQ"]4?B7Z5\P=S4JV[CON-8L
MN6Z_9LNU(9DPEQ'66'OP[W3&=PM+JWD'J4>W?!XIH>^_7)11"MKXEGQ';+K]
M'M>17[AGUUZ4Q"CTFMV\5RISKJ6'FVGG"P@J<>6_ALA*<(Z0#MGAWWI]T7VO
M:$U:];CTCL"N:@P6X%YUFUJ#5+AB,)"6XM3F4]EV0@)3LE:"L?.3W0]\P')!
MX0+YQF7]C"MC&1?*O?!<,/C+:_\ .9RY738->T=K55HNE]0I\R55ZG3*<F:F
M/7&G5,L,SU!*UM-+^6I8"@ 0H'.".$Y[Q53O9[<*:KB12?B_<]U"?3*EZCB<
MDI#BD5.C,*95U'J)RI*005';T!P=QP_G@VV>YYHOHZ^$9SJZR\WMF7=)U:99
M:JMLU PJ;5H%*7$A5BG2"E]PI3TAI3K"WG(RE()ZBUDX5D V1:7/)FZ(HZ_%
M;^('S6\I^K=*LK3*TJ9$L^?;C,ZEW?)I4BK"IRW%(5*CEML*0R_#*E,+R<X;
M"LG)P:NM>5H[<[(N55O_ !>OB&UBMTV%251*I,EOEJ#2F+3DXG%0264A\-=(
M#CBL)']S9).QXO>2+Z_N66X=3KKT8L.Z-5J3'HE\5V@TVHUZDQTJ2F)+D1FW
M5A:%@*;=RI7S4*_=7D'/$!?OIPNBYN?%@YZ=6^3"!9*].[0I-9:O!<I<NM5=
MN4N#3W(SJ6FV5J:'0A:Q^Z%$ [9W.0IF>\OCX1<,9?QU.;=U*U"G6(P%!>?^
M+W"&CD I2I9*BG;8[@Y'?@#H9]+<98W?0*,VS  +Z"?A8\U6N'-AI56KTU>M
M^!16:;5VX-#JE-B+BHJD4!/SUH:6!UMME20MS8'J&-AP[<=_/)U5T8U(JE7H
MEKUBKT.GFJU*!!ERV*:K*%2G&4*6TVA0.>MSI&$C)&>+WW1#KV]NM%\[E?\
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M<XI%V)Q>7=P<\BJ]#YIJ-NSLV[**&J/+7S/:QWE5+^OKDGT=G7-7(M.B5>7
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METAR%8'<XW/8D$$G[?[3[<%00W%XL#![<B@(,I< ]O4$Y[8 ].^P('^3P2G
M&CW<5W<Q%6R1@]B ?/?U]!XQX[#;P>"18M:F0NU7R8ZO=!X&Q.?.#@#W[_;;
M;?;;@J7J"1<U#OD-(>6,2Y03C; SY& <[^P'Y><]QYX)67K2NL236=*L8(29
MWR/7&.V/7MCI^^?!SG?!!U:HFT"8-N8 /](-1Q_=P".^V3]M@?SQVX*5<$FU
MV!'%M".R$"M@#G![D_?N#[?;;UX(TEJO0"*%Z^E:ALDR=\9((&#Z$>G;;.W8
M'P!P2YIZPTT=S<N6J[N56D$#?R<_K_+W]\_?@NF"EJVX9_?V57!:1P18.J46
MFUMA<2LTF#5XBWTO"'4X<.H0VY# 4F/,2Q,;<;#R6SA*NGJ22I((ZCFY=\+Z
MK,RP9^WSHU'G8KP2K1M^8S3HK]!HKT6C.I>HK+U,@.-4HAL(ZJ<PN,6H+[:<
MH8_#H2VA"6RH%:1B1?+OAZI^Z"'&A)L?7(ZG0KTNT"E-J4ZQ0J6X_P#/<J*'
M#"AI6:LB-^&;E*>+*G!+?8S%<GJ)>_"X84OH.." 7-VX-+;.[&-#1>2G6I;]
M.CR8E,MVCTZ',0I$F/&I,"*P^RXX\](BNQVXZ$+9<EO/2"V\A32E2'U( *SP
M[.NI]%6K5Y;-LI<2U^BO0[6H--1#13;?HL)NG.NR(#$6DP(;<-Y]!2Z]"^2R
MC\)(=3AF0ZV4K>: 2O*=E$9X-/:W$;ZUISAYJ=-ZA>5\7'%DVI)N.CU.%2HS
MJ'J2JHPW/E4\!P %I;9<1N%;#'8['<8UI3L(*<2_$DT<]LZA33>4JVZ67/V=
MHA"92Z4GYJ+-9;=2I!R' 5Q2,YWSZ=O7B.(UHJG^MS3FZJ9 8IT>S:K#@Q^E
M2&&*,MA)4!C*DM-)0, #L,# (VWX$/N*5[/\A-^/\MWDLS)LB[_ENC^C=8^I
M*@D)@2#N1G PC/M[<5">'=$T]5THNZ:ZXX[9U=<R5)5U4J6YUY)VZ2PH?+(.
M#OCO^4) J?M"*FS=$:Y1*NN>WI].IRI"2EV1$MT,K(SG_LJ&$.X/][J.22?S
M @APE$]<FQKO=0GY%NU=I*4@! @2$@I2 ,XZ,Y5C)!V).1QD'/"7+.6-9#Z?
M?BJ:5&U&NVLO6 U9387/I5<E5DH_$615Y?3CK6]17I>#@8#77&6&DG8GH(&2
MHGOQHD"I'?VYK/5]H[XING^5Z%4JW3;@G:/,.U6GN)6Q4G;7;5+CE*CTEM2X
MH6ZLA*2'#N@_2#@#@XJ\<_3NN2O???$*1U-L.[&([;;=K5EEM#:4H;,!\!(
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MIL6J[2$HW\9W&>XP<YSCUP=]_;L."'^.^'#250[DI4/4#Z2D*!.VQSD;]CD
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M@9VWVS@Y^_!<\YF\\:O,]6DN%4#G/MV[G./('^PD^_;@H0WO\?.J0XSL1D$
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M!"#E*2EEM (!4H[Y.3Z <+=][<>+$?*=WL_!G$:R3>B__]E02P,$%     @
M)XEJ5 N(J+Z(TP$ ZB " !4   !F:'1X+3(P,C$Q,C,Q7V<R-"YJ<&?LO058
ME%O7-SYT=T@SE(1TA]30W2$A$D,.,S@,(2$=@E+2@G0+@D@?ND.44E)$0$)*
M))3\!CQZSGG.>=[O?;_W_;[K_[\N%C/W?>^UUUJ_M==>.^Z9\?9\\OP#@%A=
M64T9@(*"BG(/Y1X <+Y)8Z;K"$/ W!UA;D A7GZ .$A-"QT=@"0:F18'JC^*
M "HZ%#, &BV;"ATJ (!\T:'J M!5P%#K2QFV2QGBQA2(XCYW$HNCPK1LI=Z(
M\V6=Y&7=\D4]\HUR6<)S@SM!$3H>"#</!+*(<<'3=4<8V,!@D$L)-2@"#(9Z
MN/Z\OC@K0. 79:)+70,G[PL)D!/B0N</FV"XMK4KV%#)U/ 7V \%73@,9F\
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M?KQ_KV/X%:<?99J+*S217][_: (Y4L?T5^C^3G_B7<A=R/];@5_TQ\0 @'I
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M7KM3;Y^\'CVZG1F0:_: M8AJ3SO/TN'->LH3T51*Y]%M6,/\ LW<^Z*OT',
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M3YV]CYMOV^\D:I'?F*_:[F!T./915,/BSO8+RL(_!RS,M&*W0NW?86_O[,P
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M<\=5#YM'4RY*W/%#YX!DFY>@'!1#F[U5+ILNZQ?4$0_Q3X?G*KW$H:SNH><
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MXP.7/[WYI$L]P*FE,%88'M@+2(J2C#0%Y6)&W<(UM"'#931[JYN5D4./PPE
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MA6&&M#0WUF8CZ=M9OZ.C5+W>95S^IJBB*!.DG+1J6*$;L?,!0'UJ(7[W<VW
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M,KJ>/=F)3+-T'IC^Y.0?;QOFTA&H/MZ2Q*^&HQ][)^2L'T@IHT,APM#Z<.;
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MPBY[('#%MU#ZFY=X,GP0X+.Y&S[MDOD[;OOPAE8D?QN C"H9%00*</V?;;8
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MXRDOM]&_R#PBU.I.[YU1RO1T<0E,XQD$[;[N/H21[.P[\(R>[#V^*0,Y?_M
M-XPZOZ^^_"*+Z#Y ^88()().6(PS8!&?3 ]V\\(I4'8$(^H-KN=!=1$0Q\ D
MEF?NS>S$??8,>$"RYT6]P>I!V(J3,%CR-W3$G M:Y)NKRL6H4R!0ZO-5*FPX
M?7%G*;"ID9<](IAI^946-"2I$- ^9:E)2G);B_&5XW8!024:;89U=^XK&A#0
M'1V\]9:S8$W,KJ-/Y>9VHU^/8%G3?,31:M7=.I&J2%>ILK4*;:\"65-*N60E
M9N:EI>2CQ8DQ38=0B*A0^N66.(FS^F_5XT2 NWH/PL;Z+$L:AZ>6=;=D6S*&
M5M^UJ/*4:EP(\54>83*2<-*(*(\=8"HL8J!BQHJ@\2(I2B 3PC/,-56@"DH^
MK KV*1[%,9!4L$]2TA(B);*"H..H. ,!]SC/"(0I*('"VJMW55Z40Q,*#E+=
MB#@L%=NKP[8;Z-PB$,"2CNWHJ*H&:NJEH@(J H@!0Z=RP+[.P!V'<L[]L#A
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MF0:U&B092)%"0J9*0(:U%38(8 !0?AO'2*#S"I'5P.S.HZ+&Y]("$H 2 E(
M2E( "000$A(P -@!A@ -N$<BZFBJI(;I5Z*BFZN8;L<@;!@S$N &?QOOPBH"
M^I=:]T4[=LP9+G9@=V]-MF<.W?'"&@UHB?EJ*24"V,#$G<@Y+.^^ WC<_;L_
M""LV@H+9I5=6K5%@)VV.Q*O!P/MLX(],'9#IL%4(5*)JC.K@A8'QW#9!?W !
MP_HW@');*)V)*!&OX%+%3O"(+.27SOLX_P"#L _OPBDV%*L!UULKFU2QAL"'
M[E.0-R7WP_<-M[Y?A%71F<Y(:T=#GH&2 9!VR,D'/JX<G[,_GMPB;E0:,GX
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M17S!+=,114@KC*_V4]<1(A0P$)2>$5B490316 *>"FA%=7/XGJ5"I\BQV_\
M/6TIS@MF=';U\\(IH2<G"Z4\WC:D@L59(R78=\/OMEVSPC!_ME*4!O:V]CN$
MND<I!+DAW&[[ >[;]\!OVX1D'4W";A%W=NRT5NX!P?=G?PP;<CZOLW"( _HH
MHE"5R_/0B>_? 88?&=O#G'TV#<(';SOY=:PR^>V7?SCTVZ6'NWKP@OMY>][.
M6A!)=W)=^WT??&WOV(X07;SR^MR3# R'+M_,DY_X;#Z<(BZ#RWCZP,V<[G ]
M6?.& ()?A#SSV>W2$"Y+9=B^'&X]<@;#N'\MPBE/=Q?++U<>@1 3OD'L^_V
MV[ EOKP@O1'V?=W(!8E *P;EP[>=OJ7+J ]=NW"+O:EQZ47,.ZW4<,Q,P9.7
MC34S%$.7EX:XL6(H_*F&@$J4=W+?[+OL "3E !42J>W4950N2I6F!+8YJN7:
M]+O38-JZO617[U,PJ4_LQ3*U*3-8AS2>LJE8\A#6J8@QTI1$7\**A"OAPUQ
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M$_(ZEWU3)E<I;\E,)3\>?H%C5>2J:Y>*A$]<L+XD>DP*+9*XT:^J=$C8D52
MYNBE<T<YT%MTQ%K-HU:6N6EE8Y?=(;7IMHZ5TR-$FJS=TG3OR%M0K@HTP8OY
M*C22(!-U3:YM4\BZJO4)V-+2\XCI1/S-=A5&7DO1]-XB7A^,Q)R#,0)90):G
MGE 8%"2 "0%=@RDC]5_2_'\-](^H3X^.%Q>02"64(3S2K_<0A,H3[014J)BB
M='D:Y-=.=,M$J)&GX"*[,7BF7NR.B5C5.E4^FJK5.@18$&'1:?4H]-Q*&&)F
M+&AB#$C")$2HIB))[_5.(&+Q$R2D"590O^4TGVS%40!074A,G37]4?5>&X[C
MQC289$LB(9A/,"@Y2O\ :90LO,25(5#+*6BZ4AHCHY)Q$_"TSLB)&)*X<Y%H
M-.FHT8$]28BYB8@1"LJ&<N$[ D <>(E!S*DP54 .R=+J55J1\C_JOU1">'Q9
MO^.1*!RG"E0@),*#%8J 3,I<AWB@?X@TWRUVU:-JV_>]F4>?K*KBILS;M(H4
M@()@T^6JU/BW-&C)I8DI5$"8I")B648\1 5$+ J6">/E\5]8Q>%E'Z<Q))HH
M(HKDR3%;(&U:/P']2_U+PWT_$PSQ_$&7$FF4@2XF*0%^[G,DF).I*@,Q#V6Q
M.DMP5;4'3^V1H31Y/3+2+\FF%1:[7)6#.5K\B@_#5#MZVXD[$A2?4H+$.>K<
M])JA$")^D3J2'Z</QV-QL@QIF4D GE5)5REE ?)&K'JX+C\'ZGP^'QG!S&;A
M<4'DQ)I#AS%%!^W$$A"%@2 KD+&>K7TEM*W)HW!4ESEPW%"ZXD2Y+LFU5*I0
M2H!42-*?$AF3I:2"2E5(E*;!4"4I2P/'M&'+,YEYIC?_ &+5) 8NRYL 8^EA
M</*2)G7,HV1>QW"=C')/W?,W"F9HVG5-%<7#^/"GZ].C\G;-.F$K2%H7,+4F
M9J51Z>KHATZ'.HA*"1/F %))U+(</%!F'*$"Y*#UV.T>R6088$A(6M@JW8ES
M=222NPIFFQKN,5?+Q4JQIM-6C'J\S=M2NC\^J7K\6056(<[-R2:3+2<,5P<C
M% P#/GN$.&=FS[LSLK,RSI$[ZYRS]UXENY+LF7WN."OKCCNBK(Q"V5M6$A$A
MH[Q99:2^[R\\^Q'>L-GZ.G3&+F9JBJA$P1C3C$6>Y ^,E#<24GE.!DJ).*I_
M@(%L9R2V,HCVGCU'N^K4W_0;7"34[CQ909+2C U5$(692E29.X!R=PT4$(5)
M56C8';NS;XTW'59.?3>G,U3V:CPVXQ $#?0@H.M)J]Y($Q8E*'B[Q_6A#&ZI
M\Y,9&FVV/C$Y.FGR[FE:GV5PE6$2.FTGFU-K3E"Z=AWNU#6&B4K;Y?N:HB&]
M+=F)!\SSA+:#'DPI3_#26$4<WGOXHO@VJ7V+%+'25G=J] )8$FR=CS'EJ^\J
MM\.H5J4:$3FTQ#+,$8I28C$%VRK\"2,)[C3L%$'MJ(>9^ADJ*>C9]71>$?_,
MD22&"HF <&Y/L'@?=(^F$N/I[9V!8((:VSM@2?*BEA"$L1LU9T);IB33F#'M
M/T#SM?QOZ1"T^=KM?P!6OUUKT8$,J588WO13CIV"1XP3726J2DST'Z#T'2'%
M]N=\)1US M$PT_U=UL^M0GXHA\3?SS4.\@["=W(FA*7GL]BZ'Y%>G8:J]1XM
MWPUH&"9S$?!!-CNO:CILMQL<4XIT(TSX5=]T32OX])DA$]%ESRW&G+D;GXTY
M#&EO!50'(2=&G*%G^F70I=GG43KG1I-@\Z['IX!- =XK73WCE)>8)$E+*B=#
MHJB41-]?Z^1H'=R=M#P6-I+XA@$2()& >'7\SJ5;G/,:?76 52<UZ;[#L&;U
M.R:H(C )P+S(@4U*G.7\T!9-#JT ,K&9L*1LP $+:?4@0V@CGGK+R6N&4T$S
M04<);G@++@E*&X",.?#WOA%I(:5.4(E[]M&C 3]=%P[(3\EDQI]2HHG,8F(1
M #2Z,G=]G";3.]M1=FF="F*MEST1=N_/K2R[&&G4""54Z>P?8-H*F2'\:,+M
M"TMP5C* #%,R-#TXS:(8/$ =8=0BES\JG*XE^7@AP@&;K:=[GZL+J5:N.[6W
MI(J^48N63O*<PGE,8.HJ)O)ISFBFF,+V[*)^7P:GW,^MP3WPX!R0*_WVA" T
M_+[=?3GT;)@Q-[4V--A5@VZZ_;^=35K1.+U?5W\8#GNN%YX'4[-'7G"<+HNH
MCW>&73V$47_OYP7XG@OP")T?]K&S)G;J="PM_0.,'O<Q#"3IA11H;99[E@(_
M)V9S&!Z9I@2 @C*<FM,,Y9.]1>C#>JAH2WEH1M2%C-=!BGPRB0%5]8_YJXP
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MJ0$+=9=F 4E2ET-WE8YHP)B2*RB/H3>6S $I">MXL%<D/MMCRS+<2:!P#5W
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M>R6DSVHLM]&J]S3F_2X,-&('NBB<UAFK,?)XA*4(DX-W@& DVDSI 4L 2^G
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MJ(OF625^WV-/JW08_ >8/!Y=/_38_QW[?YGX)PX_R5EF^2,>^E[-9GX_(/N
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M,H7*U&8G</&>#P<7$'/Q>$9)RZ3(H5_\26+J;TRBV\.70$I2B'U)2I/405)
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M2:W.>W0&QKND])=7J-,<M=\QHL:7H-NWE*T>!0ZO)PNHIF:-<%K*F*8F4,)
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M,<TUY'>B)FR+&QR?^870+#^&KP?_ -)_Z\7FF_\ 'U_:+]G_ )CL82X40I4
MDEP&#@9]_&V'8\9Q)!BX4TI"3%4!7H5[Y5VCD9DG"%910ZU=K-?LXAHA*2$!
M22Z7<.,IQVR/)]]^&%*9)!*;=?DWKW>!F#N"P2SDE:=*1P)A14Q5K*%!/2>E
M)(<ERV7.P()W&-N..'@F3&GF#8<P4!:S$N"ZIZ6=8O.2BTHJAA94ZCW4UZ53
MH\E6I*=I55I\*?IU1EURD])SB$S$K-RD?^ZF):/+Q0J$N'%AQ%H6%I/4 0H*
M9(X["6;#Q!C8)FEQ 0I$Q5 ;*4!J]5C>)+A3R\IF!!7[4O6NP&S5>,5V7R_:
M/Z=5E-P6'I99MIUR-"B0XU9H-O4FG5!<*8B0X\W BQ9>70LIC*A04+91ZE0D
M'=((]_$?5>/XG"&%C8O$8DB!)9\8SRRB64 #E)1NBD*S ^/#P),.8<O* H)I
M4*:%PJU7H\9IA0UPGZ$GYBN(7/40J-$5$4DN=TJ)2P)### MQX<.02!@A),Q
MW+FC-'L!!%77T0>:C-C!/$?E(RE*"$B'&)4I!6.GX,5W2 20 <!(=2@$9"B#
MT#66.0'VIF2E"_+OU#A6+ Q^:WEVM")9=\Z-:W42<HE!T2U6UBG)"UM(Z3K7
MJ).:A6JNZ:E7INB1J_;TQ<T6WJC5:3.RRYN]K1A4:$+96N/"*$J@F&N9&R+W
M]?YCIF"'#']BW=H_27+14F*I11\-)5&=E!:%Q$15PE*ZT_QQ2F$(BX:D]4,+
M"0YZF>=(Q,II32JH:Z(SYY1W_B(?J)#EL."SY3C?(&,.XVR.$90T%2FA(O5.
MH<?_ -3$51X8"E*6E(2"[]F8%W&P)8D!FR2!GA!"&15W1%+MTJ2G5N-<:"?D
M2M*E%DLCYF+!?S,_2"GYDE3=0+A1'"* A5$KFXS9EJPT0"L:KOQ.5I54N1@)
M4DJ'.KI3@*!;YIP9[[LXW'=MN$4(!,%S4(!9T&E,EC:HC=3;N6P"=P[?\-N$
M0JDN2/4"R*_\QR](]SV#[[$Y[#T/TX1%SW)(.H+/5F#6+ PVRP.V<N2'.WU!
M+.YW]^$99%I9AU7X*(BC8Q<^F<[;[8]'; W<<(TAS*C]W))LKHP!52ZR\$;A
MPVS[#'D=7LS]FX1#K=_W(%&K4[JH'PX 8$G)['+N=M_L3P@ K7(V#6+:5=QU
M'!$BPE(4GX@!)* $E)5F((;!"M]P 68I4X<,>*,TIO\ '?I%0@A2G,H6MODG
MTJ*Q6G6_5ZLT>>I^DVEE-D;JUCO>1FXU)IDV%1*)9UNPUF2G+WO(PE)_+TJ7
M68T*F2\528E9JB(,C A18(FEP19C&@_W:OHB@?"N^QC3;R(_@7R7)]S<P^:>
MKW?:%XU>+^OS$&FRM.KLI#MNJ7!*&%6JI0$JG1)P)RIQYJ+"3"FH4>!+2!F8
M$!"(BX:DP,5%:+W_ #&A-2HN+%V7TMO2/T,S*H2#'CQBD0X0^("M80E,-*<K
M6HX0A(SU*(  ZB0 2,'"EGF!*DJ$ 5B";7VSODDP^?$3,A#5+EAD12Y6IC1+
MSCZN:V5[F4LBU-*[:AUJTC."C0:M3:+*S2ZW4*BB!+W3**KT>47_ ',M*=*4
M3,"(H2:@J-"B%<('C]5P.!@X? XV).1^J)!,922$EE(Y295(#%F"ZTC]UPV%
MA<-],XB8G[I<.4@&H>4 (I="5S))4T&ZVQ+>D[8MNCT*G4Z#3922D91*Y6#T
MA$O',M#_ #/5%Z6FHD68*PJ."(D10,162W'YS&)GGFF)4S+<N%( #,@#^D?C
M^*G&+-S%"7!<D%Z _P"O[ M'L8D>%!AJ BA)3TIZ=E%2@2$H< J) +)2"1W
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MU^4NW[CZO[\(FJZ)2H(STV1-H Q9AAF(?9W)]7=L^OIPB'IF&J-A]J'X+YF
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MDA9Z%(2%! 42GH4">HL^^./*,.?!QL3B)23SF0F45'*B$*U0IT>.H1)6HSU
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MBKPJ%M2<.MW*N:G9NOU>6DD+144VU1*16*S#AQ$E,2+)P9=?]U%5Q"_GGJT
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M]!BRZ1%7+F7^"%&84D)2)=Q%B&($I Z@1]*;Z;QV'A_K3\-B#"1><AD-'U)
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MG:("!*0H5T?V4MU0YQSLSDL"Q([L<G[!G\._&HQI;L,E"E%?0L"SQ$N6.&)
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M.IV=65URV)N;A?%72:HJ1G*:F?E1U)^%-"2J,]*IF %*AP)J8 !Z\3+RY\>
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M(SFZJ%T5_5$JA7L0."[Y+.#VV)W\>-P"_"#)H 4OFAV)N$"AQ0P'L'#$DO\
M<X[ON3X) VQPAJB,E;^R%;EY025+PCEB[-D^642?JP;8=^$!=*4T:BJHSJ3H
M H,/N6VR3W#AW]G&,^?;A#0G)-MUL;% "*AP7DX 8@-GL-B7&Y+#MV/"##WR
M/4.$RWW ;/CR')&Q#X^I#O\ UX1*9ARV11Z]-=0QB)2 Y?<D-LX?9SX[G_OX
M1:FF3U=-T4EG[+ P).^^W8[OCU8Y?^7" LA&[!+!T7=-2KE%@ $DDDAL,P!S
MM_Q[-PA<K91<.045AU5!4FI5L^1EB3W'<'#N'\_R\HJBA2B5&2.G1'N1S *
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M!:T\W. >;_S;(FEYS\A7THE4,4)0R(^]90I'0_+[;C1B0ST0RHYAU\4J:\P
MEU(N=I8<I5:SH4:SQ9GZU'@6&6WD0"1P2 SJL 9RNVR-G/0%':_YA7M9]2/#
MC:NT4JJ(1I5LZ'A<UD.""JK:L/;; 2[A=[#LF&Y)S:.QM?25-<*YJ0V]JP U
MY;.(XN#H9Q,,/6O4![S-^Q9NLA9DD:<VZ6AAZZK&[H!@W+3QV/8U9[0 ZFZ%
M<=M0-9&#V1= ),!JWS&#\S:@3/)H6$0"6+E^DOJXQI X9!$2"/2EJ?O4<H=]
M\DCKVWWJ52LO$-3GZ[@]$_S U]GR*?8LZK?U-[KEO/&M3L<-N8#]SK.8?)4
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MX=(6@%9K6&"/!ZO><LH\>:UTMGQQB4ER'@')3_;):9O7C6"=W(UG6'IY/KT
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MM^=-V\='<ZKS>/KHG>ZTB(WG[CK<P=<'XV[>A=T!?SE_4?,&G"<4^*_I^[T
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MT.;+L.JGU_G[\Y?KF:IW:^%>O*F)1!DV%98R_A/O\:T +M=MHMM"&54ME?!
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M2>W671Y3M1-< F_%OQJW'-LDV>CP7W@.%OY,A</!'K7*[4Y9/J4&"M?0[!>
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M1[[KE72.@MGH<F!*/10BHK(I*>JI,E(4BFTVCR$.'+25,D)2GR4I#) A2DG
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M,:6@?E9*#"@A</X28K E""R0BUW<7",7IF$!3;*,DPB4PTB(HI5L>LI=)/\
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MI4A1GGLWF<#?8ULQ?JX4D4[['0,@;[@GPV!EL'&/^/".=NUS=R'+APPT*W(
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M9G J'%CKARL- F8DPLF)%C1!\4N?B'Q1[J'*9',:5:!.M "C,R)0B^M;"OH
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M9'3.NU6B.$D.0"1\H)&,X)^K]OZ\(.Z*ETH,P%KJ[[ &'W'D^/4D$OOW'U
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M!V!+AL#M@/ZD]N$3YZE'4ET]J*UV3N,EW=CGN_VPP]0.$.WGYWSH(B[*(+'
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M"6P[.#XSG!P<OD9'"(J:@*MP]%ZBR="L(J02D=0V( Z@ZNEQ@#!(W/H<XX0
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M7IA9ERWQ?=QTBV+7M2FQ:M7ZS5YN'+R=,I\N08DQ,%2PL)=28<, %2XL2&@
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M5W\O&G(J]JU>JIBVM NFOU:RZ]"C2E-CRZ-5*A"N2'2;[1,18:YZK4RCW/\
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MGA $-3J#JY(LX"7NT!)&<-U9(<L,#^C'Z=^$&I0I=@2^UBR[*D,,I_5OKO\
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MU/"(V0RJN>2$ZE]J )2>M)"AN$MMEB_TS^Q;B$*$-XH(!!R7UROT/RT!#4D
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MW/\ 4@EL'U+#A!R5ZY)DYH 6](1#!GV!^H.#MMV/N^^X10=+Y@*CW5\R5JC
MH6,@D.^^1X<@#W&_OZ\(F5$T]59>]+!$@W![Y8$#;<#W !=_7TX0HEB-[=5!
M/2 L".Y<#.2 79OJ.$*UUR'HU>^Z)!C&"<AC[N?V[_RQPAFZ%'1ALV>BBAS1
M$'LX9.3V+ ;>-OVVX15VK1V[@]*HI93 23_"20 [-Y)#;>-@VPVX0I5%7VI0
MYUH]ZH.3C8^[;';9@?9@?VX08_E*+5U!*5=:&P6 L^SGU;'@EL-Y?+>1P@[)
MZ+J;NJAA1:(5@<  G<C'_$@L0_U[^O"+4HK?A& (4'1$)H$"0V.'403Z>G@'
MMY8>>$0(E 76J)5*CJ I5*5A=)&P'?(+$?\ $^K_ $X04:KJGJQ! Z6J7!G;
M!<'Y?7+MYR-WP^.$-=KTR=S1D %%0H8FER _^'?'[<(W)0TK9<AF\/A&X.$(
M1V_GMM]<??A&)Z#?X,06 07+ #U&VX_8;;YWXAUL_B1B4D%@O@T;V[1T6AJ2
MKH45*)RX*>EBY;=W_P"/8MSYABB:60J04+%F.F>664=24<H@ZZ9-ZQR03\W2
MIG*2H*?L",-@'_..-2RF3["*!5='\5HS-.H034=$2@152P>]%"(L=D-LX [N
M20?5F;[[=PXXW&/PVB$FOJHJX"/!U@$@K3]5;>[L0_G8G;A!-$9:/7*XW*HY
M9!!U(R>L8W42" V[?]X([$\((0K$*/0LY44N$=71B +2IQU))!'RI4.X=B'Z
ML]PS^!PA1*5JAS__ *JUBB*IA*B(ACJ) P SNW;+';MG+_4<(H5FHRM=414N
M>K0DQDJ4$%@5.,D!]W8._I[\(&8HFQ5$-CG7;<1/J#D%262"X<?7#_S?QOPC
M*-0ZMHOL_J[(^I(#]2=V&0 27(&X#EQ[GR>$1#D7IK X\AP'8Y9L$DC+!R"2
M2'?P>$.E_ .\#@9W<Y(. </GMZCNV>$5^P7SX]'+Q*DD/U) .1D!/DCJ(W(^
M;;;R,\(?CP_GJ-F&!+*=DODC&<>6P_9OH>$'-14BWBDJM?1$17T@J<' 8."X
M) !P=WP6#/MPC08[%2U$!*!;$44JT03,)40D9*O!&!Y.>QPX(SCA%,UM%I79
M58ZA@I>)]0."0<MN1E^YVQ]2^S\(R!?4K]H(;+^ .T+J25-U))ZF(21U ^<N
M<#<.PQPA;1JT?:I (*HI"Y)$@M'S.H,&!=0(<]SX'U"3VX0(I2R(S6&];&9B
ML1?_ +0+@GI!<,"QV)P"&QW^5NW"&VJ%*H*Z,05-$4%28Y!]&]LX[^X.&8,W
MW1F(1"R%NQ2!M_,?7B$B4$F@!)V#F-2U%0?'H?9-4+=(F&0HAD@I4DC+ $$$
M;CN6.^_WDLPF"AQ[]PBZ>L=WGEY/[BI#C(41 J9Q""F&@I2%=05%0Q9F5X(<
MY^;<X\[CA1 )3^']W]W:,##.""H(YP0 ;DLM3<7:L?24>D%1V =B? +MOGV8
M>N_&HY!5&A^1M[QP_F49<@,>DDD !1(#$]6#D8W<CRW"-F8D9*H1.E26OLZJ
MBQS$I9B7\Y?.!NXPYV\^W",.IM\5-AIITA%2 P*NGJ+)#@$D!SARY^C^>$5#
MDJ')JTI=52A47A=2&[>79)<.V#@?5OWX17%5H&4Z,0_9BA9'0*D_+E+/\N22
M?09W]"&'GA$S7K0.%[U+A[I2&5I3@-YW!)\D_,_H3D?MPB(Y6PR1'L$%GMGG
M "&.0Y!(['Z*+$@-GA%N%'SV2BDMN$2L+K2D!2E #()Z@SNP&Y#D^&#X].$1
M&HE*C3-E7(*:G-9!@P=([[N2&/W.=P68^-T#GYI[>D'4&#*  ('IAP0^<X(8
M$L0V_")YY\P!:0P*D@E)+.'QN0'=AE\;@^,H0$I&26)'^\'8E@0Y[D@>'P/5
M!^_OX?6#J2  2 .X/U9^P)(^I=MLHJ5NG[0NM)'\8((QD-NQ8N'^^WGA!"H;
MTKT?V.V:) #DI"6<.W2&+-EF?RX!)X1?5*YH1F,@*/<D(H %)+%*@?++&#X(
M ^S 8].$$.I8HQ*K?=P=.@$#@#=@YP%.?1O&=\^COPA5 :H+)W.0&B7U+ZD]
M7\2=MW#[;Y)8>[/ZMPA8^HI>Z(M=4T5D2D;J2"3W4D'=@6!2^2V<N>^W"!IH
M0+%\G*ED# H@8PWW91=G[$'V\?Y[<((J,RHH!:@?6A&I-50, 8=@_J&/<@ O
ML=V/8G'=$?6Y.]_CK!U)(!2H$'8@X+.<%V.QZANV[-P@AR/;I[M#? ;(/AF;
M/OVSAW9F#\(D<7Q(:PI+]0264,C9AZDL0^"/7U10%[I^.BW'X7@4820>E(8;
MER""2>SG'^<<#,):E 55NF5'#46-B1')H1MU)A!<(XZ4D;GYC@.[D..,B>4@
M(6J+5WVBF3F-22 &947I4EO$["3#2E2@&2&ZMW[=O))<MXVSQJ,$&5NK:+_,
M 6D *ZP.K_>) .Y#.Q. [9PYV'"&C$;W-:_AD!WD%).7#'=BP43LSEG;/8[D
M.W"#FF0 4+OJE1=FO 6+9##R=@X <$C'KW\<((34%7M4D+4 JUK9HJ,E _V@
MY(Q\K.<!G#?O^_""$FFZJ=E1[6 M9("0-]@"YVZ0-CD@ ^K!W8<(NUS0H5S=
MVZE$))!2!PX9C@XV<=WP ,[N^[@<(S9S=?S\&RNJH( H%V4DX8!)!+@MY!+%
MPW?A#X5?+9;U.3)WR&&&#._<$';NP\>>Z)YX(B5(Z5'J2 ._4R0[ER<!FR-W
M ].$5U%>SEO:V2*U1$NI( V;L>WH7\%W=]B#W?A"OCGSQR('[NG;).&8L78M
MD@D98L1Z\(G0^#P[0%0 47&P[@ =G+GSW.&;U/"*C@%NFJ0.E@72P=LAG#_3
M S]26'")^_:_2(D@G)# X=F^I+?U'OPC0!%BX^62KL4[V6 14=125HZL I"G
M(/8,"?7P3XX(<HB*P4E69&*U.9KD!>(_$A]20%H)9PD*#J!V(9@V^P;=R>$5
MRFKOV-22434Y (\G3N2 "'*GPV,_,6 !89!?LV.$$-GMU0Y:.7T*Q QT)5T!
M04H9(!#MZ@EQ]>$43&P;:CT9 = SE!$D1DQ 5!262^''^SNY!\D#=AW'!"*A
M(A*O50E SFSV"US=&CE'?;?+%\^N!GW_ )<(W(J/GZ((?"-P<(0E;?Y\$^1X
M_P [A&)Z#?\ ,=:8((0"%,N(E*BE*BI+H6RAT_P]*F!6HLDEBV.*@*KEFG\[
M,=8S("271 N[R@@+='NPI&N7GKUMUYTCY?\ 5NY].;)F:+/T&1DC0[_36+>J
MQDHDQ5I*37-P[7C2LY,ST0PIA:$P%P@$A:EE8* %?:_H'Z7@?5_K<G!\5,))
M,7&FDEPY@2,8RX9F,O,)\,2 #[R9IN4IR@Q,:::4*02 %Z*C,2A9AFK1KV_"
M^YU.<'6Z\M3J5J%(SVK,C0K?MR:I<DN':EA1*-%FXD_#FHD.+-4R3351-& E
M:TB*5RWRPT(4DK;]Q_7_ /2_!_0<+A\7A_TP<7&Y )"2"!*"5(Q\4,H<@+8A
M"!Y<#&&)BS 2&7[9C,3,2G_J90"KT-1>/T!T2>JT[2)2:JU)BT2I1Y=*HE,C
MS4C.IE8H)4(9G) F 00"DK2.D.6;C^61[BJT#@(2C7*JAHZ:;QJ(U-I&IVI'
M//JG:<G:^J]]67:U TKG(";0U[F])Z%9ZJY(2L[/SLS0I&=I\6X()Z5JBPU1
MEIBY0N#$ZP 0_GSO%":!=0_K_%(Q7>^N7-7;>EG._+6I9D>N6C96K5P6_1M3
MZKJI+TRN6/2Y28H4&-(REL1*'5)N913!&6G\V9I1GS&*RM/4"4*HGY]C^8\/
M0JK6:5RX:K<RL#6[4^6UNLC5^J25H6^K4N;J=%N<TZ8MB!(6=,6%/Q8U,F(5
M61.S4@/AT83B!'^+(K@QPE86.>65'5-RF><6Z615^-+>L6!YH=>M6-4+@T3T
MRTVM346RC7I^]#>T*[I^MZ!TZMS]L6C/5F5D*9><W;-2N.+*&>EESTG"M^!_
MXS7 ARJXJ(,19 U;*];>E?2(!F!_-58=<XK%;7,!J;>NG^HFK-/U+U(I%[:&
MG0JVM*;6N"OTF-#N.9KERW%2[M7<TC)RU,I>HL6OSL@BDR%>3)0Y2)3I&#4*
M?$@S\]'BIJJ*TL^9_)KTA0L*JIR_E(S7RV:H:S4+F7TKMV]Y[4&H5+46K\PT
MOK-6*I>% NC1VITRU)ZNU.Q*EIM3:=7*_.T&GT(2]-M^N3<-5-EY2:7&H]RH
M768]-2 +W2Z:>5R5WB$!*9^N:56ERJ1=SGHKUIT*T+.FKEU"O^EQ:G79REV1
MI;I56%4"\M;[^GJ).R]L6I2:W1E0JS2I>2J$66JT2J(F(5,IB)-,Y<43]"A3
M@7%2Y5D[@A/?HL ^14*4I<&NC"Y0B/*W-J3S!:!\LO+!2YZHV;J!KE>U^Z/:
M.W57ZY%F)VWS4[]34T3]?FC0(LJNXYJA_I9E2FG3TE3;FGS-QC-2@C_F(5KO
M\!G_ )L]1%9T4!5O55*:,04S94(-55_B$<Q]IT"V;CO:UM(YZ6OFK:Y:>VY"
MMLW?+0:-?&C.MEGZ1*O6XYZ;J<U#%H5V-=%2N&=I<.7F%4F!133A<$U&BH3$
MBK:KT3:KBOH\3E%'9+T8O8JUUR#*G#J/S.:[:@(U?T.G[ALJF7UH]4;QN>=O
M'1:J5*2IM2LBS.7:C:@0X,S+U@KGY>I+U$U!L>FPA2R1/T:3G96*4P)B,Z-$
M-FN8&?JGQ<QW-"N>[6G4.UM+K0H\A9EFWC=-;J=JPU:QKK?ZQ;=.LBRZ57IR
MHZBR\"9E%*KFIOZA*U6UI&!%A? M]<U/+,0P%!5!+?)RU^6+ZQ" /<G<(B(Z
M(ZJ*91L:Y0=;*WKWH;9VHUV0;1E+HKL.JIJ%/M.?C5"C!5*JT[345*0B3E0F
M)S]+BKE@M,%:(BH:U/U,ETSIYZQ $I9138YBY5@EF01K/L'F OK1>##Y@;_O
M6Z;CTVF]1^832BO6[4YO]1A4^KTBM3=5TSE*= "296:J4U!G+>@JR!+JD$D\
M'";K7V\'>*0H(NB*BMN:ZNL;/^5N2NNDZ/6Q_I#N&=K>H%V2L>^;AEIV=3.S
M]&F;FC1*O"I$&7))E)"CR<Q+R4LDA+F$M#/CB_A3;M7IOD%B%T-0K(C9FA&G
M[F-'E(U*UIMJ\8NJ$W.ZB25!A\UUQV/4K^3KI3ZW2)RTYRX54N#;T#0JK@3/
M0I41%/75J2D3-&2\:$626R=$&>=GZ:@VC6E;;7?P5C[M*U.U]G+9DM+:=JA>
M*[KYL:4:%IO<**I^:F[2JMK:E7!;MSU.FSI3_P TF85 F)2HHEV5T?D@D]SP
M6IJ_\WS7+\QCDP0L*9%J1?;D U/U%UKO*]+BNFN5J-1](++M30R?I\W$,*7J
MFJUNU"M0M1*_-R(2$F9BPZ519@S3AS5RK+XL2;^T[9]?V3I&U1(#?7<..V/'
M8^@SPCD2I\/GCFL<<P>F!&( <(66+AV!_P!WYO <!SVR0>,SCFDFESEF%[@B
MS]GC>$ <60&AF -*$O5J9M%'^8_6#72Q-,;VK]BZ/QIF>I4*,FCU*8KE,JT!
M<L)U'QJ@FCTYZDCX<)!CI@S3/T!"@,GCV_2N&PL6:3"Q9Q),9@1),4YBY3F,
MP6J$ @E&()2/U'].?3\#BOK?#\/BSRS2'$F#GE$X,R(1S2_W2S$@"8&@VQ#R
M7\P7,MJAI@JN:AZ23%2JDO4)B% K,O-TRU/STM\.E8%#G2)R*F7ZU@S$%XT1
M,,_"05$$>KC^%P.&Q#++B 3<A_[8"BA(/,9RA+%%NRLOU_Z]^C\+]*QN$EX6
M:438@PYL7#EGYS++-B8YYPL^)R GF4?:"W* 03-LPE%Q(LG"C3,JN6F(\&%&
MF).(LSGY:+T!1ERH!9*LD%0203E*7+#Y:T]+.WXKUC\$15K)4K5@N68"G0LN
M@GF>U.UH@:X:A4:B7[4T691.;:TU52TX$[5)&?K-KVSR>36IB;/I$U;E;I-0
MH4.IW#0YJH5J6FY":A5*J)E4*EHZ8BH2\DGHH5P@9 JG\,>^D&7BU&2WS[)E
M2;YZN8RWZ%0).';&EE]W#J!IO9VJEDPK2F*M'CVK0Z]6DT:<MJMT><N%$Y>]
MR4Z4*I^C24G5Z5-W&8,PB!)B8A)A\54UT][CK&6*E4="6J"*UHC;YF,%5OF\
MU=NC56Q=4I[4"S)2DZ>Z45R=FK0@TO6"B4E>IL34*)8$Q K%M2T"5K%1KLNF
M/+B6MVL4^I22IA*):27\XJ0>>>;Q4Z79HR+:WX@O,[=];N>P*':6EM,O&S8^
MJ4S7*Q=-#NZAR<U2M/K0D[P@2]-LJ:KD:KTFI5!,55/B2TQ'F84,*$XN<08)
ME5131\Z>A-[IIJY(Z^=,NE;Q*L<^NM%'G].5:E6G9T^*U)V1J729*P*O<\@B
M5HMQ4N?FIRB3TPM,3]97)S,!"0L),*>ZS#^"0@C@5J'2H8+^$K% %*95/[^\
M8]NOGHYC]/-7K;N6IQK'O&)JEHU8ZK(LRR1=5<H=KSVH-^TJ5IL>ZZ (RY^M
M5RCRLS\*/%I,]0DSZ41I/X Z651;."!+-[9;5JP[1=*N\S&IEU<D>O&HUST^
M<TSU%LB3O*UZ94*12IF47$J4A(P8<A7*=1YRL1:I0Q.*FP\E68AF*;\,Q2"I
M#!FIS?\ -.L0 @G+R^@TH@SBENDMV:NU?4.F<M.L-\WM8='J&IM'JE?D*;JG
M_:Z?H-#BZ+7!<=&D*;JR$IK4^F[;TH$:=C4^*L)HB9.'*]734\Q71&0%<U^&
M_ >%*#H$ 7SPH(^]IYSO\UTA9%PREO2VFEU4'1R?LB@*N._Q=!NK4&CW]KGJ
M'I-:L_%J-)4BBE$"A6Q2J\BJ0U$W(%"(GHZE+-"]$7XH:ES91!EU\/\ .; V
MC)]1YZ>8J#4=5[#3):&4.^N7ZWM8KTO"Z*ZFY:=8E^TJP%674:)0K0I*JRFM
M4BJ5F#=CW56E)N9-NJAP$HA%59089:6=LZ=5IHCHD .V1\?>IJI:,(:V\YVK
M]O7=I5S,T&EW)7[:1<U%T_BZ<V[/U$VC/STGRAZ@:S7A<-62$GJL6U+AN^D_
MVHKX>)_Y#(0$DIZ2+)DHVLOXW2L!>Q]:MFQZ7-6BS%1YU]9#<BZK2YC1*J6-
M0.9/03EVJTL(MP?V@N^/J90["JM:U(LQ K24?HD1-ZQH%I4*+#C*B0:*JXXL
M1848:9S 5TLJ9%$#E$(-^\5&0:NK$Y:!Q2F=!%Q>=J[*O0.6"]KILBO3E.J<
MI4; 13ZU0YH+GD09[4:U:554HB9!:E5"IA0"E%*@' 8@:2IT7*Z-X/1\AFS)
M!NH10N1TNI+JL4?I5^:K1;JD^1V7O>X$ZDPM>8-X1+R5/E5=B<L8@P]4H551
M4PDA$2;G)Z@:9K!2X>J@EP.)U\S]]HNX%'^1DG6+B<\M>CTSE:O":MRYJI1H
MDS<.F=#5<5N5LTRHRM*K.I-LTBJJDZS3%&)3XR*9.3P5,'YDERI3\"2=_P!K
ME\KMI:$J;9M32PJ3DH*[T7OC5VK<HFKD6T='=4:U?]M7CI9;U3CT/4FX:YJE
M"M"_*M<R*;2)BDQY.'.7C6IBOT],^I5O0JRN%%5( (G*&E0C)BNB6[>RJAL=
M<X/=G5C7)?1H[MJ?B5ZD4RUYJLZF6#1404WSJ/HQ2JA3I2L4A=4U7M^<DH%E
M2<Y08\6;F:33+EBST*%'^+-3,6"N#%1\9905*L$]P;I^-=W*M'Q*+JCJA2Z[
M2]:KNNV\IS5)',^-+KETCMN=J5>MG^QHEDP*A3:;I_3B8YJ$G+F+,R<]$^:*
M8:8BE=2FX#OLVXK_ !%(MI7LC&O[1D^XZM;W,;S35B%=%\ZV:-V71N7R!=%+
MH\W<5V:-5"EUZ7N4P(E:FJ/-S,K(S28,L#%ZZU1YR5B!+DQ$$.JOA\R.G;(!
M H%)1<]2G=* %%$5NE_Q%]=K TJDIBGQ[8U".G]O3M2N>>J]M7G6[ANJV$WW
M7;9MBO5RYJ-!MNS+,G*_0J-#B4B?5-5<5Z,F//BA0DS!CD,_<?!$7E'\%&Z)
MO%EJ]SA534F/J7I!>UV2>@:M+Y:_9_7_ %)HLS$@Q+*M&FSE,B:?JM.8JJX\
M!56OVD7#)J*Y0KG0B%5)FDQ(J9&$H//E?BU-8CA$!+YN%5?":FM(LER-P[M7
M8VH%PU2;O1=@W3J!,5K1BV]0:M-UN^Z#84"A42"D5Z?J*OU*6F[FJ J=?IM&
MJ*Q/TVESD*5GBF,F,HT79GZ*S[':!"&N1;.[*KAFL"KQ?1 Z4I 8LE( 2GH2
MP !*4.>D/D!RP8/WXD<C4[GWCYZEI3^86$]48*48<+(ZP%#P,DL7(\J\CC.&
M>::8%)0)D)TS^=ZZ=90"5HA)6Y89!E5415*L 8JQK)JCJY;%N7;-VMI%,5:?
MI<G-Q*5,&X*2N6G(<%$3X$ZJ5EWG8AAPTICFF16C)']TLB('X\?U.:?"PISA
M2&<2A5 *AE,Q"%4&ME1%CX7U?ZAQ'"X>--@8$V+^GAS3&:4E)&7F023&8@*4
M!(!<@@$1@?E7Y@N8?4'3J7K-^Z234Y68E3BRT*=DIN1MB'59!*RF'-1Z9<#3
M$,A ,0PY3JADDB$ AN/#PF-BXF#)--)-,HE!F#64@@RDL@+ $!CE'R_HGUGC
M.,!G/#SS2<Y'ZQF$BE@0APAS<I5Y4 (Y25"QL;I$>/-4^#'FY54E,QY>'$CR
MBHB(JI:*I 4N"8L/^[B&&HE/6CY24D@ %N/LX9)E!(1-DS\^7C]BIFE!(<@%
M"M;50Y1KI_$@K5W4>QM#:=:<O?M4C7;S&6;0*Q;>F5T2-G7I<M$BVS><6/1*
M77:E6J5*R8FHDM+1HZS4J<R),**T'J(V6INRK0TU5/B$H8+D0E15UKUKDD5,
MA:L\S7*[2:Q2)N5G:$C4"YJ_7=(=--9ZI4]>M1[9LZT[6A3U7B3E1TYK0D/R
M4U6%1GFJ]J!$BT"1F(+SU1(^&%'V8I?\_A(M0BT+D*.G\=X]W(<]>N-\4[2B
MX;!D=*JHJXM,5:JZH6-&IMQ*K^G]L4B0G)FHKF:[+7%-TK]4K$Q)&3M6WJO2
M(53G(<2).*"OA Q#D^>PLC_$4(-/WWK\F//WA^('K]9U'M&=J=%T1JU1U?LB
MD7[8<Q1JA<$"D6%)3EUTNC*IFH<><GH_QXYE*FF/*U63@T5**A+19!,-(6%\
M%*BB>K:>^_>)KUH?1-H[]]\_NLMMS5RZ8P8.EE4U4LNX+QE)JIT&U]1;SI5T
MT.V+;AW' JE&MJCSLM+T>6@(*I*XI^Z;UA4^D15)G(,"I _DTNWFN72'IV4>
M\<-N_B :^711H&HU/M33:G6#19KEVDKJH\[,UV)=M15K8%)K"J56(<2-096%
M0YI"URHF>J+.D"6AI1\(<///,TSB('5U=#ID-HP)IYSG:]VM<>ONJ=,GK5KV
MGVG=D656Z[IC=EQ7#4+KK*HFKFM%N526TX$-0F)6O5*4H<C-08,^B(B+/?D:
M1+I3*2L%:9W]4_G/HL5 M'S_ #XC/&[_ %>U9IVG.D-ZZHPJ/<%TP[;HDS5(
M5MVQ3*A5+CFIZ6Z0*9)TZE2-1FHE7_.3<"2F),2:HT")#B08J3\):N-+DN1/
M0-70[Y6B(%(.:CI=1=Q5]ZQHUY?]>=0]9;RC:37YJU?D2F7CSJU.1OVM2M,N
MK3=5M457*6C4.WM,+3J=>I]*-%H4E?\ 2%4V#+1I*%^MPT2Z5&8%S":BQ5\R
M_%.FT6BE,[5[%]+]XO):O,1JQ8W(/;6I%,72;TOR0U1E]&K5JM\JGYFFW+1:
MCS.Q=";2N2M3-&:-/1U6HJCUY502XJ:U_G5DKCK=09CURKZY%+EH,I"',%=K
M/DC46J&,(W)S_P#,UIC2;VNV^[5TDN"B6CJ[K=HI,TFT8-T(G*G<6EECUF]Z
M9=XF:U4H"Y>U:K"EY:WJE(25'JT64BP8]63'AF9^%":@9I5.^BC]X5 70D?!
M;XCT52YH-;;VNNZ.7"X*UIN;OK%3T#F+9NK2"HW*B:E[>O6GW-J%=TO/3%2F
MYZ#!50:!9R:5+3R8P3545=%0,M+"93+P[:@7+<55:L&)0$F(CC*]J, B.'-J
M(]%Q)RX\^^L53TIM2S5R%&EKRE;FT_TOI%;U>FJQ JM;CW)(W%5(NL-=BTT&
M5BV;4I.CS5)H,E#@)-;JDO,_'JTC%@F&G(+.M,LK(22O>*B7S\#74ZQL]Y1]
M;;LUFL^[XNH4:PU759^JM^Z;JF+&G9N);MR2ME5N9IL.LT9,]$C371.(2B,N
M&F/-H@+ZD)FHJ&B&Z->C^5%/6\*JH<("A0/4VS0O=U%(UDW/3.8/4WF!YFZ7
MIE0==ZE<]IZS6Y0K,U+IFL-#MC22P*9+0*74:O#KUB3E:1,5P(D3-H7#_LE6
MTS*I@=,_(9X;5M%4"](^C*3=PW9HMKSS#:A:[7[:FOFE%[W?3;>MNB7;"H%J
MVE&M29E85!M7^P<*(;>N*!<A5\\Q6T3$W-?G09**@I "!540$>+8CVO&UBI:
M@W6>7"?O:GR4G/ZB2FDZ+CB4:&F'#$*Z(EJ0ZS'I\>7@!7Y6)!GE14ID8C*6
MJ&Q8%/ T\:MJGIM$=:(+%G?.RLR*<XU,3=\4;3^P>7C5>P.96\KKYAM48ME3
MUV6#6;[F:O*7Y1KRF963O67D-/IF%511(%E19N<APJC;=-E)JCFF)BU*/$0I
M!3-;HAZU\_,4W!H'!7PC\-$M'ZS<%AZ>\E^JMJZQZA75J?K!JK1+6U%L2OZA
M"]:/>5JUZZJQ3+EC0[=K4>/+T"%1:.(-5A3-!AR<TO\ *!2X$.(7-R1U\\TU
M:!]L_?Q(WY2J B&0'+K42IUJ"C@.DQ%*7TXZ?F.X+?+T\(!W%_/+YO'9X18.
M$(/\^W^/",3T&_P8BS>G;&-SV;U;R/0 \(Y1TIZ6E9V77+SD&7F8$5@N#-0!
M'@K2-WAG'4P4QV],\(W)5\O<@5K'3IU*H]/B1%4JGT^4,1("_P K)IEUKZ?]
MY:0D%(PP9WW=GX(ELBR:.>G7.+,X!+!<U++2J48!J4CZ4Q#1%A1$Q4)B( $1
M2%  $PR(B 6!<!24D9!< N.Z$M>]VU__ -:9N;#R4E;%KTVNU6[)&BTJ1N"X
M8<O KE:@R2!5:O!IR/A2:9R;2D*B)E(9"8(5_#L 1PC9-*JI09HHVH5J/B/A
MKTRL*-1KKH4Q:5$C46]ZC-U*[*8NG2\2!=%2CK@QYFHU=*U],>/-&! "NL/_
M '22KQP@_I:JZ*PC'%+Y1>66@WFK4NF:"Z6R%^0Z@FM?VME[,HWZZBKH0A"9
M^!.E/Q(4S"AH1"1$"@W2%)+8X7_?SV[+!RUKKLJ)3(*IZQD;4727375^CIM?
M5&PK<ONB(BHGD4>Z*13:I)"9@J"?S$,14*,&+%*A\8C^-#I#9=Y?MYWB/5#L
MVCUW97TCS<SR[:&S=;M*[8NE-B"X]/Y>5D;-K@MBE"HVK+4XC\C"I<7X*Q"@
MR"DIB2B$)ZH<1"% N">'GLWYL?<.9'3;W5^Q4JKZ><JG*QH/,PM0$RVF-GT"
MHZLRE2H=\5FA6_3)*IUN6JKQIR!,S4*"B*9:?B@SDTCKZE3S18AB@E?%;VS[
M9=D45R!UK0HF],LPM7HT?=U,Y=-"]7Y>U9#5C2NR]0Y>S8D6/:LG>U$E;CAT
M"+-R\A3(BJ/^="X4I\:#(2<&-\J>J'U$-\Z>&UA["^J5SUJ0)"+FF:G1+&KT
MHB(GII?2+3:E6K:5ER%AVW(V=IS,4N?LN@0Z3(1*7;,:@1(D6DSM"EE((D9J
M0,>/,2I$-0AQH:2D#J/Q 1@'HFA:Q;3P0))))*,YJ2'1^Y-Z"/!:C\M.F=_6
M)6K)@6Y1+354I2\I"2K-"MRVHLW;T742IR5P7O'D9.MT ;L.1/&:Q1IB4NN<
ME(<2Y*=.4J:A5<Q(TNN)!1$AS,L9JH1UJ>[KT0-8%&I5"M"Q(&=/4J[KBCEP
MY&](>7>E7VF0ITC>ER:GS505>U:C6C:5L2D]0ZQ1Z);\S1)>U;;EZ-;%.MZ-
M2;>ILO/T^2DU1IN$(B5)*ELF44HJH <LU6M=$LL'F-4(J*Z@ZE0/V=>UKYR7
MZ7ZW2$E2Y(4;3Z>I,W1H\[,4C3VP;GE:Y2J%38U+HLE7I.[K:GHLS,4F2C*A
MVY,R=1EUT$PX9A*BIAI0N\M#FUJY5TT@M<PZ/0)XE/4Q[/E_Y4M,N6^CT2CV
M3!FXL2D63(6C%GJ@BEJCU:ETN=J%1@JG8$M2I:!+_P#.:E,E$M(+@P4(Z89=
M(<O#N_X@I5%>N@"[5.2]1&29O2/26HVS&M:HV%:4]:L[7U79,T:9H<")2)RZ
MHD^F?56HM.6A:4U(5%$.:3-;A;D*#D<1&HU.Z_O$)(.:!5S=-$]:"/KRVFMK
MTN^Y[4B6E4R]TU6VY*THTP@-*?H=.FQ/2LC!@)'5+(3%8'H)3T@!FQP'Y]OB
M*04<@(^:W>C=%U<QC:G\H_+/1[VCZE4O0/2Z7O\ F:E&K$6]?[&T&;N U*=?
M\W.HJ<Y#$Y"F5E2O[Z&I*@%*Z026X,Z@>CG500>N58%4R"*RT3>7L]H]]*:0
MZ8TN;M>I2.GUJRLU8ZJU'M.:E*-(2\W:L6O_ !U5A=(C)2\L*L8\<S/P3UDQ
M25*&X,S>:90U=%0>@S=3141R=?MVI:%IV;%J4O:EMT2WA<%>J%P5R'0Z="D/
MSU?FD SE7GXJ2/S4U/PI661&6$%3I^92@Y%=.WJ"1Y:),:A;'=B[T1G%^T>[
M=@[LY?(?!?&/1COZ<2.0\Z.?2&7V)^NVY [$'#^<OZ<(1%82I"PI(4DI6%H[
M*'=.0 7#ARV^_?A 5\I>D*'#APDM#0(8&Z0,##]MV=\'^O".B\P)#$ K=BI(
MZYI#62$J*3D9#OT@M@*8N4NSL'R6?/#>.8K;K3K&+8VDVF\Q6XMR3=D6E'KD
MY7H-T3%6G:/"G*A'KT"@1[2E:Y%BQ$$&JHM^?F:'$C=1^)3YA4,JZ04FD#<4
M-!7NQ3)[QVZIE>X_*$*1D4CP4MRF<N,E2[JH$AHEIS*4>^8L";N^1A6E1DP*
MXN!.&>E3- @C\Q)U )J$*+\-:4QD)(!5@1LAY^S;0"D*"N665W*5LL=B6Y:.
M7Z%0Q:*='-/DT&'3DVZJD?V7I!D(-)F)H5H4R @0 $R)J"EU PP@%,Z4Q$LQ
M)%/PL6H4&M*AZ9TTZUCN6MRUZ"V,8QLS2.P;;0J5J\C&-%M:ER$:+ K$DBFU
MJ'-1X02J9@5.10B6F82H:C%A(*5EE9-EGFRFWX*Q$-%*L:#/+,OL@Z_91H;I
M.)^C5/\ T;V6J?H\K(RM%F8UO4V-,4F4I$)4.ERE.CJ0#)2LK#6H? A)*%0U
MF&XX17TH>]O/:/ 2/*%RP4V!7X<EH3I?*P;V1^1NB'"LRC!-QP53:YU$O5 (
M),27E:B\Y!25DIB!)2,,;G=+Z4]5$12H=R*$5/0E$\)MDVB:.Z:6M8\33.@6
M%:](T\CR\Y FK2EJ'3?[-1Y>=*OU"6GJ2284W^HE:E1HA@J<GYR,CB=/,_+:
MO%=,JDW  [$K7Q#X%'*7RWP;-G-.(.B.G2+(GZQ*UR=ME-JTI-*BUJ7(_3ZH
M8#]'QI!"?APU&$N)TDA "5*2J]M>GL2ELXB',^F6345=4NT>MD]$=)Y20BTR
M'IS9LO)1J?;%%F927H-.3*+I=E3D2?M62Z1!AJ5*6O.3\\:#"^"@2G4E00.E
M),\OG3V.4$-FW *-555]5[16#F7Y!M->9>%)+BU=%I4^8B7!&KTC2[#T]KZ*
M_.7;3Z12ZO<\NNZ;=CFBWDND4F'"%?A0XT8A;&$M26-1WR7N%%,_13 &PS2I
M(S*JA*5R9BL61MK0K2>RK8LRVJ59%N0J1I^BIU"U_P U343<S(1YVDQ*%7ZT
MB(2EJQ7*'5*S FI@)2#^IQ 8?3U0N"6NJ!;*2KCHK.UA!4<T/JP1K71V=:Q4
M:M?AL:37!K/:FJXJ,.FT"R+BLJX+:T_IEAZ>20H$]IBI4.U:+2+O%!C5Z7LN
M!7(:Z\JW@0/B_*(L,K*$1$+^ O\ +90YJI95T3I%S+=T6TZMG3J5TF1;U.J=
MF09J--HH=9E8<_3XD]'JRKDBJ5#(2!UUTFK J00F(>D]2@ %,^I6*K^*"B[4
M7VC[J;!L1%Y*U AVM;\&^H5%-I"ZD4R'^O?H:YS]1-#35$I3&32E3X$0P"@@
MD _* DBYG+8(& /E*K&2'1 YH[T)N*:IH,_(2W+_ *22>ED[HY5;/I%Q:<5%
M<]-UBU;EED5FFU!50J"JK-")#BH"2A514(H2I& &V<JE1H&[J?S%-[+U)H&L
M+5L;.GE:+RC<LE M.JV%0]"]+:59]Q+E9^MV]2K+I,E3ZI'IR_B2$W-0T(0(
MD[+J0!!C1$K4EC\Z7<HMZVR=KY7#)'EJWR>:7SM2TX-L4JDV1I[IY=R-1(NG
M-K6A:TE;UW7;*PXD.D5NLS$2%^J)J-$,6)'@Q8:D!2_X%$LGAEY[(4T_,1"Z
MW;IW/L-5K&8H&AFD:-18FJ\#3BSD:DQY(2T:]HENTR)<<255#$!D5,CXR/\
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MFEP98)@H6("0@)0@)AI>&A?1NU3/P;+K!RH5:,;,P*,5OU#JV7DCI2D$N4H
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M Z9]V%12>&(4=LOI3GY-41Y;BY^7@4U LL'ND87AC6_8W;,VP7.\MXY2;H+
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M>HVAS0Q$Q1ZXM( \A&S"D%*&G8*!V![LAPU[.2T*C&)L-7=0GBY52LW3_;(
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M2LXG&"\K"%#&'NYCJ1_+QY^/]^7TA&A9C$"NMF O#]9+C;^+_&O5-@Y6KO9
M6RGN2\%+QM\ZAOM'S_Q_LL<4_M=[[,])\:K'7*5LP*[GS[+^&[T&Q[&"[X.
M$ \I.PC8A=;*S<T99&-U+L7MZ6K[QYSK]M-%4# MR,7*'L@-=/.PNT3Y1<G_
MBXVU!4) _YT _<7*GWZB_?];H__],?E_7:*NQN3OW-^7P\LE]N_+Y^5VXT=8
M*IX'UG^MGR4N=CK_TPGT+Z+_I-GV?[25^)OL/ZD&_UN[E7^IX^_^_L6M__'M
MKJW-SVVF&PSB?'%$L[7A!CH#S\WQ@&\U>7\_@]C:B-G\.$[\][9/4N>_W_OO
MQ-H_ IW#PP\Y+E90J5^GI3^Y_VG__)P)_\41\[+X[X>UGT5B%[^,@!]]@%("
M$MS_Q/X_&OV#"S]7PX_TW#_/]/\T\O_S= 5R!7(%<@5R!7(%<@5R!7(%<@5R
M!7(%<@5R!7(%<@5R!7(%<@5R!7(%<@5R!7(%<@5R!7(%<@5R!7(%<@5R!7(%
M<@5R!7(%<@5R!7(%<@5R!7(%<@5R!7(%<@7R'P;!_/-_R0-=;27IO.BDI<ZF
M 7( A'^3SI7\NSH0+E[6A\"(:(N$@'?YLK[7 )KS-^\A(B(A_/G63G0,-$P4
M5 0D9,1K\ H&N   *N+%Z_B0T:ZAHV$ $"[>U = 0\? PR<@)"*^P8M)1T(O
MHT/*)VK@'C],QL O:&SE>3^ZLI512%8O-C%CG%5.T;!\\*. KAW,*Z9Z>P>N
MEA+A_(U_"+_ _G@[(!(:.KQ4&V[A!20:"C(*!BHR&N "%>\&+PJ^C([5-NKY
M2P"C,PCYREL'T8@^[A#3R^K&,? ;&%H_B!T>$="#>,14,,K9C H*Z<,>MKW^
M_6UZ[Q< EE@(]WA0 :](D2Z2-\VSWIA;BC15'PS4SR1KZ4U7P\CM6E']_)C-
M[*F8Z9Y-Q^.5\Z47W7H@@PQ8VHN1,:2EEENR.17',*G>4N2>FLEHW/YV!Z;
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MC_U?[H9_%UG=W\P3E_45DQ00F7NA998P%I19Q)6V.3XRE&BKWOWZ+K7_8)6
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M_:/6&/U)>OWT]^VL@%T:YB/!8_8S@#GW&:!5_PRPL7 8E!WPV=%BY^,90"0
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M3GWAJYB^D=!8)%3?K9D;HZ?%H2)?PY#TY;6,P2!'R"SB@W4"8UW?.;\XZ9U
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M2E@D-'-$FH=2K/<'':9\FZXWT_ECO@HMI;6;9WHG<U,%.,_PK)LN--."5L.
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M.0-0GP&6W]SJ_6J_V)+V7EP"(D>U_'5K=_B#<\3?;WAB>XL]W4?_<$CX]=F
MI-R->LZ$U,HWV:+<10NPD^2":?T1Q=$:4/YJ2J ^O\%3W'@-(,)._7!,L4T@
M(KXN1*7J;L,A.ZV.0^Y<*CDX-TFZ='(<,N:M-; I C__Z5.XNG=^-A5@N!O]
M?'U[R[@^I&*$^4T()35U^S7:,*_B!#%,IL7DA_0;#"8LR9WL7+.R+'3D3HKJ
MSKCG!O(<?#+[PK,=A]HE:KX>,A:?@W #5S_^2_ ;TQ0F2UQ>0K"Q$U,A\Q&
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M?CY%<34,DN5^Q\,\+LD=DF=8M8RZP)#DR@D4C*^56X'2K@QF8?A]ULW#N+.
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M/663P@U]7  &._&PR4?[MP&EJ9IK]0+</$(HA[$]JZ'^W585);,<T$6A I"
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MX#UFTE?/#9JX]R'[?IZSIRHD4[8"90%^7ZF>@RJX/K)/3.D"4W>A[$80=K9
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MJNP,ONMB$Z7+;8GRGF!LYZ]M-%9 5:GB8%R=']&^OR]AB^3-?AX\I]\.)(;
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MGH69R3QSTOK\/G1ND=AG_'>/8M/B'YL]AM0%OR:M2Z[IWM!T5UCH"BR&I-S
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MCJ;G2ARB!^VB1U(?/NE&KGE1OL$!#I-,=]Z3V62\X*B'R.:* (O7QR+W='1
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MF<XYP0,2)M12)K_2@##>V=0X#G+5"@C=OJTW2;"! 4Y0J%?\$RM4_@@6JTP
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MSMP?NQV?DEF*H!UMU(2WICV^(51@0!>H^Q*7"JFBSG-"1/1ZW\?^3WIG/?M
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M^0%]WI:3;0GLXQB-90TK)C1FE D"<[VB5E=GBA36M:IU3+[FE&JP"N6$S@2
M.#78X74B# *MU(X3OS=[BH\>8H0E74IFV4H@1'DQD-DYM^@T]C)<T B^R%]
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MG>Z<A)%^\A-Z&+T'BWJ/K\F(]%:#;KEB:T7E/EQ15X_.=']#BVTAQ WOX=>
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M=9);DA:U9]0^2#RKKC=0A5>&Z^34F2,VW=;87N=D]N9RL06N$VG/RE0Z!H3
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M*KT5@_!SM7(ILX83\=M9#;Z(]-3XM#B0@#6P2&4+!^KH4:E^M,T(A3:>.\%
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M (S_6:2;!44% $#YC&O[WT:FJ'^7_P=02P,$%     @ )XEJ5*/8LQ0\&0$
MGG@! !4   !F:'1X+3(P,C$Q,C,Q7V<R-BYJ<&?L? <\U/__^/N<O5?9G#W*
MSMY[[UDHG+/=<7?V;!B54,G(*))"H90=0E2*!LDN0K+)7O_WD<;G\_G^]G\]
M'EZZN]?[^7H]Q^NY7L^GKG8^[GP"J/6U];0!" 0/$@P)!H"=:<Y"4W<4%H5Q
M1_G")$7$ %EU/2-\?  <G EUT4F_'@%&5L@) ,K"J\.*!P#@'U8\4P!?!X%T
MVMW#N[N'NCK56W/IZ#5N=XU>E5*SMYZ[:_*[:Z.X=? %V7TB\T5[(+$F_EA?
M?RSX2("#F6*P%LXHE/?N#CTD%H% ^OOLSW&?&MYHW#/5+JZ%1Q!NA[H'%H?S
MBR8";>SD@[#4LK7\R6P/P12-0KE:(+#^OB;.GG 03 Z8 F@ !?ZX C#  D
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M^]WQ#]<M7B+N#>.Q>\D &N:6,+@_.F!O;?=>(0#K("J 'F "V %N0 "L8"0
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M'\1-%%5@:=8?O>/'%9MP7(W2P7%GJYO*??8H:Y3/:7+,D&F &T[>B4^%W#L
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M-^)UOQIV*Q09'+5(5<H:>U+CE4[/71"C>[C_R+>NU1W@4D"P%'@ A9I]I9J
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MY</X#@ )&^FH3[GSHWRX]VT'$%H*7P1=J2P,=6G+\_!"(,>331,;AFAO1]%
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M'G9;1J(KVO):4_LLWUW-*W[V[F2I:@:?%J'.;?A<),I<%I7B,9*CZ"<N_]<
M%V?4$^'[&K0X]ZE&A+%NDF$43H3D91F'(&3$[T]W-P4!;3)(\>UHNRZ;"5))
M:]V9@"@<3F%;M<3"V77%A?CE"Q,8K7@<CD*&>! ) M5OUX,Z6Q."Y$%?M(\
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M$)6!RT8S\S5-F-6DBUV_"X.\47^PA*9,+\[@I]+J%;7!$EV4YDWE!TM%HL?
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M<C-')>,)Q5DI>ULRW/8NR.[JDD&YJ8!VD^!NPDD>9RE/^2>(#5R-4M@\"[U
MOGTNP6-A#H_=K;12@Y7!UI(9OY>P1>IRII%<1,,:IH0)R6(D)?(()2Y/%BYO
M=T%W-0>D3NM23\B)]D\P95RRIH9/[0%')KB(F+H1?U,,4IG\=)RULO&3>8N_
MUP.4':O=51.@2I>6?VI;*]L,8D[HR4\26C)22_<1C6<9"\=*3=_X]>61Y-A[
MNE5X@: EYVT!1S$8""HW&B=9 '$SV3*J)FM>V+(LC48W<R^QN>Z;9X%4>1^
MID8E?%HA28[E*Y09Y7GJW [2QZ5*0T\1,.T?[M>SE38H[[C#*2+=9E5E>VW:
M6:*/C#W8I2U(&^?HM:+=U'UGG25Z7;5_90U,@;X*Q?XD(-/&!;9.<FSUE''_
M ?A2U7Q+MD'--EC>S*R-+F$N&CAOT;<K&B70T6NGC\%]7&;^5;NJXJ$$+RT&
M0P@B5<"V6A&3LM>3:9'*57NE^S6Y.EG'>WCOTI+94W'DU+D7<?0L1^U7+<&0
M'^@&*N-J(&WYZO>R(PS9 :S\87-J(Q'#NTLJP<Q:XY7M,6 T5E6FO'<<++J]
MVB'0H54*9<= EW2>->\BY1I9UW-]93_JZ-]\7N]V>+,M^#*':9CU@4##LK9<
MH>;;5F1[5EW(??PWNR=R!-5AM UYD9B1+&Y](]APCKY@<8<_#HTV1P"(@LN5
M^0B^.Y_5@&T^<K7 !'0#)[/;J+0W@N8_"Y[N8VNJ,YL0+&ESQ$B^)Z<CZ+4N
MG\W*S.=A\=>V@#Q*<?A:E\Z!QPKRN'5*A B(^56"PABK>MA0YI5/JV>ZS+":
M%3[K"_HZ>;9?0?B_N\8P4S( C968VK!<A:HQO!R+ OPTQU9KY>#0W'/XBG#$
M#5,&.!E#6]]!3OM3G'R6*PMKB)8R._@0GJ:K4AD]Z!VPGT.;799>6<(*=/>X
M!">HEQ'FCM+R2\=B5_96)NNJ1A+55IHRF!(I%E7)B0G;3&H:LWAH$SF\XK R
MZOC-79(*Z8=C@%;0M&D:0R?Q#=GGY8] 5L0(,_G[!D(#LR&#I%9)+:C0B(DU
MA3E''J2Y%!CZ=^BBQ,:\@X.S;W R2\R/F*G+:$HCFU+C-ZS67'O:4R5IZJ#H
M)H_K>6TM2_"\FM1];P/8AJ&(^]CBVF(:;@>G@".ZRC"C-6FQ6K8X$+HOW/!I
M-P)-21PL:108M"W8LJ(%=2C%M&<95;*4A#(D"&3;W0/IH3:IQCR66+UM@<BY
M0!_8P@S%I6FE>,%H.SEM\9DAX:[>K4PUA.&8DUS46@N/>7 OBR%#Z3TU^\U@
M!/$/YO@*VA#MKU7 MH[!6;,5^+0-/&P64;948Y'IAY8X3T6Q7JE>'C1I)!E(
M9$O@!^/=A6JQ60I0IJUTIO$0Z$+@U*YE@8."WB2RI1^O,^-2#.GGK#Z?QU1&
M-RGR[B?ME^NA0Q88C,!1VV[AEO(*0?'K'?2U=]QC7>N9%OCH<E^Y>#EXZZ)8
M4!C0N8?02J577# R:_.::EUMWI1 ^0:4WV<1 4518Z'UG8[F(Y;^C+0QHO+:
ME%(9#-5>LM.5*?SVA=$]E4G#<MR]Q*.O.#S!Q9I$=]V-EZ4JY[[;X@X!Q,)=
MJ:H5Q<RE2;!96I7H$V,1VB9(;8/1P!AW:IC6J["]'*)\:D'=[<7^5;_53W*V
MNM'<5?))_>CT5_SH.S!'$\H?M*L*A.\BOZ:@MN*DAL6\V6__$&6NSS7$S01I
M)BL]C05I"&[K?6>/T37I]55I9_ZLXZ%4GJ62U7155]G^C0]_0LY 7+[8 .D2
MAE[$K*'2(ZL?;_^"'KJ]7%]FP#!/P26:S<("6YA(UF:D[-MEL>"=49#B=+U.
M86!"4H&:IZF EH F+BZRU3=%;11DLAIY9(UU F[%*A$5;>HH:WS]RJ48!V7E
M8B+^2ZK,-ATM+P?SZR:J0]_V.$>:R"*@(!=VT@ O@VQK>#_KD6=(D6D C1:;
M>N8K^GJ]4%II&R.BZ2S6XLJ2R6-5E>P8WQ3.5")W:;4!?O)(G=-F;I$"3%BV
MS>Y^3=XZ!A'/D@'L;RO+!ZXG8Y,L+#. LS"S' G11Q<;N*5A!OS\9?+M#.Z4
M)"$X:A5CXY0@'\W '7+>1YB_QNS=8?V1=7VAZUWC&0Y''/NX\F$Z9 G"'NUR
M!+J<%])8K@YO,I9J,I0R@H.3&=+H)W)5]J8A6)<6,RQP-!68[CB(H=)4".MY
MAH^C& /CFXI6M'W7A$E% ;_Y8^ENLMHK81=A"Q9ME7$Y7KO,]I->V'@.$-\2
M(U]Q9M@@*<DMVA;S+=T]U?96]&YX+DP7^QL!#TO)MF;8;[GE#G/B>CS\S)UW
M,.^Q9MP!7ID2YIW)6AX>.B>NH7)4AML^?-[N@GU'.P*"IK;ZTA2N(PU+%71X
MKG.<,K1/QWPR:]VM-#OL3G9/-3T[0,=HQ5HZ(\MU]A CM"&3ULYJ!*W: *C$
M4I:4ZX;&<V&. >=6]>>=GV4##ZM$QU;M,@SGMD=)R<*?T6-EV;:)@]N^X<#3
M)L_9'I3=W!I7O98GOK?,W&;@:QHS# M[2FOD.= OS,/(*"9=P;_R%D!FX_9\
M!BB/:VDS!LY#M^DVTBG*RBIOVEW'V]O\S1?&6(J-E3)U-QHBM+C?2[&-*2'8
M8&@8*')[.IF;,WS4MO PF,Y*P>.79Y2B->K)E3:F!:+;%E8(/0#AEK8,<(S=
MT;TB\#PAV]KV-[&(EDX)X]B@/D%GKTR94C6@E#9CNR8<R;R8/_T0F7&<LCBJ
M$/N]Z7U6[+L8;+N\+[G :!P6?7+#-,;"B5P!&R[A<9V0= =NX-S\L!1<J22'
MW=6*C.J(-4-T@:U2,W,V*$LE"+.(YTVAH1;ABA%MY*O^*@MM#@=5=I7^&7:^
MZZO2^;ER/-YP'IL4J7?TN\,/IA:+$VQCW!9%DF\9)3D1D>JNIC2IO'%^1WZG
MZC@OJ%P;[-)QZ>M_/Q&8Q[>VN3F E__E]BRO3_27T%[=-1:.D)7F_(YSUTX%
MI5_'V> /45^;.U]3+]S-=/YCNJ0>OXO<:XISB@M^8E'_>Q\_#@>"1>/\@\#4
MH4.Z8X_02UUCJA-Q&#]5-PFYL%>$2"A)#YK=W@=,B770VZ?[C3\ \Z^/?B=O
MK>]?_X9]?JG6?=J59__U!Q#PN='G!7I[(A9\?ZFUBM1VN48K(=_Z@BD!'+J)
MMRI6/TF4V,ZYG# *8"W^ _A9<>>T047_$35I1P2U421"8)F_QR%HTL?N<++W
MJ=K+^]GS]/5;QAN;SU_L^O0^#]!/3;?S4#2PM0VV4_B,L#9R_X@!RMGHEG!B
M4V\*@$$A.#"6UY^!4JCX'E1"EH0F'O%TD =N6W/59"$:5RL:\#X]%#&I$"S_
M40JU&E?*%(W+7TQV5>GRV&8!^BDK*HO9A$9?![JU]_ZC(TD((9JS#,GWMK=A
M_,?R>[8,4!3^TO-XC9Q@DA"N'H,B_G2L_B<W)J:LL 95@EC)<?5W[_>1&<'^
M@)IH#0ZUS&.*4>K/?%69E2O"S*E'Y2G\IA;C\-(\;?Y*"SD/E16(H[EBBK"'
M!C=^)+5@=FY87%@]I0?#JBFWK:K1@^N^:IJRH;H"0XPV Z42K8,W8F6Q/[L8
ME4$))W)%W&Q:+GUT$%8Y!O=%8#^O;_HC&4,S3*PYAHY"L9 D<TH'6\-K8);I
M 24?7G>AK<F1H!QOY%K 9I:%@:6X#4[MV[TY4EGYS>!IVDX:LC^5*Y7#R9@*
M3\_24D0W<.ULHJ>G#PI!3,*7&<I@M'&!DV)U5%?)QNBC:Z905XR49+?/XA;#
M* 9X&-C&P<$\B#$,1+#ZRNH=L^A7.%-JP\ *.HB$E%%-1XMWJC#KFWB&F"]P
M+C.H_" *O[FJ:I4.!^]>1$>IFF$>2+6V0QM,!>1=S,OM102.0L(G()6IVF7F
M#U?EJI ',Q;"]D8&%M-9_+\W,5,A8$5_9,)0.X&TT9*A%!_Y6"D5,T-5556=
MAO=*1YL/?W<D-1H\WPPMX6(FX"&>(@[3BDM@R]Z"TF;F&VC+K)#3C;_#T/FV
M;3=A*6\F/>S&AYXJR*?3S)WF8#O?ZK-J!+^HO-QR48A,)V,\?4&NA(M6MX=\
M6IC,8V,H]I5=<(VNR,EBTI,"Z:1^9LEBVXYR(8<\J3>YPJW*5'99TB'M^);,
MD%0W(7I2V])4?#BT$0A*+Z43-I:\;D2:C9-=Z]_8=6@_7S(WTJ>T<+JX+&Z
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MJK&GWRZB7]JC=D0BI0YIVG;2A7< 9!%^7]=;TG?:XC>^1$=^H.I6W\3N<T;
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M)?:[X2Q/$HIO.]U%?THS?A_,(^E1B5,?,,(A+,6#@_3 )80Y+U_9T@53YN*
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M$P(0LK;*,;[I'9M07(00>%R>V)A\>CMJM#H6[?<2PS7&V/6W=J441FREXVB
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M,FP17])?(]:P;#A-4DSXJ %/73<ON">4$V[/K7%M6)]:WU\L@&G)]K>T$+\
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MN'_>IO\0M)EVI[:3%/EZ3.27D<KVP=SA[_8+#K1>-K+A?<8.CXTZ'Z;NS81
MCK'3A[;3&3GMY?OUA0N1A_#7+[!DM.3;O4U$]?AY/&:^W9?0-I1;N]*RP_#
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M').ZT(*EE55&M8_EQ*/W2>:ENZ?K^]V6:$6VYZG]>Y#+ P2NG?MW?P9"A?P
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MPV6TN 8.>7@/$%"BZTE:N[<N"LU(.]-;O[YCWF[,?#T9_3D;^/'XI4#<RJH
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M2W3JVSE!-8Q-998YNGGN)^?[=B[/L\"WZL@+\#U,Y&]UTGI1&-[/BGYILG^
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MCBE$VU(ET04K0\JOV,FIE6F(R(EGFD.N"- 8S$IJ.D"$U'J;IV) X7^H2L2
ME6CT(25"D3G%+R!UXULB)<A&=-!/,+#-@=P?%=8?')PL>"%'A^D5V<B3#4\P
M=WB>)2'=7JU"D2MWWV*P\:-;%&J>O_$2.^$^M+3W.-I@%*&6Z0LA]6[%@*&J
M<S2F!+]<&."D\=8XLJ.YC?OH6'CM  $0O2&;;5)@N-2%N^><]G)X\>'9B%#1
M7,ZNCEJOIZ]S1./0A!TFNFOZ2WG[31&\JK:M2HEF&)T0R4%B:2B&@Y_=F.->
M4!RD@6R;*.+E,:<B71=%GT":_KK"QAYI?OX'2$0Q"TX=0Y=+K?$8/IJ2:XD$
M;.U;21!\3/3DK%T %](J.!JZ_^)] NXV_' B,<SNB#I&QV0/9TK%XE\&M[!$
M/O%#_"V$S1BHR)__54]/R/DXP3GM290(ER1/$ ,:8T2!6;!,74,^*F)C%U<3
M<L0!#&=4IJ_7:*R.!$<)C<+A=Q^@[B1H G4!^-+2KS43/P^SWN8T.A[W<U/K
M!<NO9-HWC)2JY=#'JD^FR;2AJI%UO^X&*<&7MGZ3!PN;DBS08FB;AI"+$L26
MKP-/.=-TS%(1*$=WDXD\E&&&USX;/ A6\B9$#KGQ#$:,$>.L?9.0DFL!^@"2
MAC?^2CV)@"^6Z0,[4FJ ZT9S 89$+?*"$)9FXMWAHL"L6J$]KC#[9%G#S"CF
MZ><DEB2R,03MO^SJAO$, \4;!Q?4O4FFB%0S[1]R=&W>+P E]E=6Q[7!X2H'
MWHP%0T=E9-)NN"AW^DO,R\ZJSA-IQ\0MGO+C",0+)I&):?]G(EC5SV:@5-=Y
MUG+IU*01JK9A 8[(!!>$_]T=P:B1$9[OV(\?],.UM+I13Q&C)C!-SORJU2&G
M3*!T^J@CGC=#<O)B@HO>>'954KC49AR?6MS=;:O;XN">\L]QX@P5:\TTC>E7
MT;WW>14##.JC(9J;@FVN>8@S!+*!=!3B)V#<^M,/U*FX%Y\DK#CD$O6K56/6
M*+X\$X7A.W1((HA$B:&E?A:A)LAB,H*+B#\99%KP?.8_P2@>3&P_$RL0BHX8
MR-/P=P(^J!HFFA*X0Y^2&N'KI;<9_+ZFZ;CMW+,/L!YGT_LF7.=_E*')2C5I
M.J%WE3"&6,?WAN4$V<4CT:^;*VB/NO:3:T"U@B,DQGHE91A Q"C.K"0GV+J%
M*LLY7=)F(FT$LBM&-9CJA>8M8XPCD<*'Z'>UL_\#C C9%YHS9DL)J[]0M5SL
MCT:1><-#,CV7[/)J1GU^6; "<28]9OI28(\$WD:KAZ,8-/HQD;0G#6;N:>'
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M>F@C;G4ZQ).1:JJW;54K=)_,K?0M->7OZ<RGJLY"9FL6G>>7QW]RU4P5\(D
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M4X:."OP:J2$NSJ+VQRR2D_3(N(A']-MW;DT.<'0&76&A?^E.NM_%]9*K(XI
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M#@^3("Z^?C"EZ$A+8C7O;Z,+00M5&=(8%@=ZUZZ/M=0T<W_4*B%]U;(89 K
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MR*1[5T".XJB)=(BC4CR59*I+O^/!9(8?4E/3OOJ$3Z6A<.A8.ZD,1Y=;"8=
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M8E=9/0XF+K,5K=&P)Z!WJT49@\&8M!A5T4@@:A2&CG6),-Z*F91<00K:-65
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M%!?409F@^$S=+P,":MKH]=(P%4BD,B$F("/CK"V>PG&&-2585E;@.1;(@KA
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MI!?2GZ @8# %2V:]7"D+4\)4V 37X)>IA>2'CX(YCZ3DM&)22Q;.^Y"3Q,N
M D8D)=C#AACYDQ01C+S:#(0PT.($$TH)8 DK01GMS8'2$YNOI+<E>:L5SHJ,
M40>!<8I@!%*[PS$O(TZ32AJTF<"$ 2PJ)&!,[Q"Z6.Z&H$+)TQTKSBER=G^V
M<C\%RIJ]",(Z?%8NX/1J0O$X'R0T:8]23>.@QA66!3C4H3**W,$T:C7H% :M
M)56@L_4<9&,$ K)%Q(3P;*AR;Q0CDF <,&NQX DQF/ C*<D*CB 4,B&@FXSE
MX1"+N%V,P$?03#:J'-<S+@E2T;"(!Q5V,PJ%O)#4S"K<.K$VX0J&4UIOB)%)
MXQ2IU'G](8$L,M2"^94@%009@P</Z_5!PL>92,R,VZQ!F4T:TU2V3 FGF :,
M1B>1SUF4>KW.AUH3@%'F\<7<6@] ^!"( Q4:#I/"!I^(0J.02H,[C3CH":2,
M0:.<BA<MHF+!J8^JX(J3XIQY7H@!_&F'UA/G20L)VIR2G"I8X%-YI9EUB>(F
M&O,8/*$TC4C]:9?4%-6F'/JLPY22PZDL:?,C,97@?9Q:I)(\FLF(0TSS6ED.
MM0;I.&5P,Z%00610,S"J="6\?H?:X"O@Z;R!<NL3.:ZT]< +LXT)H:/")O4+
M ;>WM"52REK*@#[ FI!GT^4-$;' 1Q9R@PI[R"*D+V9]#A&,(GM2#8##[$*,
MD\N50!O4J)BOWP'H*$8E@CT=D =&A;3+D;1CHHR_O!V2B)#:@EY!2GQAU@_H
M*2'K\N73DC :,Y$&79*H:"B7^V*"H1+!4DXM\OFM9C^E)#U*7PPA4YQ<CA48
MNTX1D[FS<C'H+A9<M"?*RYE4.A0*X8@?4IEL%*M0 CI_D*G<&SV657C,+&UG
M+7PXC]B]#)(#$Z88$L*<WI.#%)6,<Z-:"1W.RS2T R<+@G5@[5E#'M-6>%C!
MBX8=D,^%6ETFMR=84!5B3-RKTLHIIR&"< K:#YGCH83!(_($I6Q.4HPFLPP0
M+'IY$ Y!K#AMT(E@@X>O\) E_&PZCHF- 7E,EM00.@<1R5%&JPXPRUT(QK)Q
M2H8!!"]-\Q NDP0\L8Q4+X)33 Q5X2(A2S-ZE3P7R'JPRKT (VVP4+&PS8$I
M'$+<D^?=H&#_5$F?!F,X&X-'N9 =\GMY1F_TA[B\D!.EC$EG/I;22;T>3L9H
M1!BEM0OA&\M4\F62!A$T >E$&:/=@L7-F%Z9,?M5EM)MJ8S<1*(JOXUD):FD
M%1*2$UB-IC /'[8@J#@B$@Q"3B8/%&1)?<:I#%3<J,?(.8/1."$A)$*X&XD)
MD8W+983H6%R-9#UF+>OQF)*NG&"1&8/2;\Y(,EFK-U'T,2D6RLA26D >2,):
MM2V2QBJ)CZ;@2=J1!(\KDC(V!."<NNC/QD->M,BZ>"XFA+TFU.7T:UT&B=FJ
M2L8Q@\UJL)F8(.<+H:%T+JYR9.-0(.+61(*56TA1O4P'6CB0]8, S)( FPA(
M]$)":,R*;0+[546RF$7C<E1-)C 0$HQ'"+*#F%L?RY<VVX2<1(+(P8 -=$@J
MDU(*>#QY$"UZ0!2S$':]D"[ER<8P"KW5+2R]!E40106*)E&WOG[ORRI Y=25
M)DM[A5K$;!4F6NS.BJQ P >>MC516(A!6$<R@N1T&!/6.BO/BD"6C"OO5^(*
M&RD65JB1*FWD92-P%I:(L[ZL"6-8B('#:7D0@W4"&ZQ>;5Y(DS'*)==@@@<"
M5<Z$LD0]9Z&REF.44N-0%]VDP1H[%O^P45*@K-TG1I02/278#8K-GORPCL?J
M2*&.#([:740VB,8!P]&M*BE%TL>JLVXB )H2-! (XB(^[,*#LBPN461(M] "
MB!FH.&4)116PSDK3=J/#Z4N&V0B;-0=!A ,+%;^,\#(X:>7"@!_F[;0H+X:<
M6DB93*CS^90ZR)*<.Y_2:UU>G4&(RB680YF7LDG,7N! HS<?I_@LXI%8^'S8
MP08KNR(.'\;99$YQ06B.L(HB?@>8\4-DW!2*&V41*<O8DH27+"0S9F^!-X->
M3J"V.5&,BFQ%ES\!9?41@G4J<KQ2!U?N/-(\$[!9W0X2-YA8C> G5*5$T,.C
MMHP9#WJ+*4LHRWJQ',+GE7ZK :7!9)QCTVF/*\X"19>!UQEM,"96FU@4K=R3
M\F;A<%XLLL6=,DE(8I78C2%'7N/,2X1!SWNAJ,D<DZ54L7P^'W%P1B3D9_$,
M06L]63>2)@NFC):FHPB4RZK2E:?#?9JD5R"L+4ZI\Q3A5!HX9R:F<*91A=2>
M,\JM&!:W\81/T#KO)VDLB"M3F33E=@9MLEA$ERID:)'')#$&Z%"N\N"$P\4Q
M48<ZF*4SBKA;JQ(S'H5.J;1:-&".@UV@+"$N;>[&O:0U)DV#,,>"BBAHUQ>$
MU-Y7H$'(RF=+-\/2@+VRS5(4HC&IQ@Y+ 7<6,0&>+)#B>2'536F9/.(5 CFR
ML;S"6I9O)%H9PY*\$/#7RRNLOIR!+.81AI1B2$I8HL&@X!5=9GM)OYP*ST8<
M(!.#C5G8A;"XRFXAF*+8GC"9 *;B N24*2CC2\^*%4UI"I+@$:T)]B4*!:D[
MA ?3.I5=IS+ZW!*[%9<[Q2=ERP#NC26B=K=?20DA'%V?W@J.#4-.RCO8**M,
M^7W&I-ME1",ZHY!]1SRL1*+1:S'R6 274R,B.X!YB!1.2N5P2 CZ*K-,NV5R
ME$DP]BCJ 8.<&S1)D:R8\)K2'I$:3'HEJ$F<E5E@TI=UDR*[#W1!=A? ZNDB
M((2P,A)R\38RA]A*64QEVYDM[VAD08TN1J:"D#!C=B3H0S6@UR[BT("4].H
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MCX;-K\Y 'GEYVA>]I\\:_U"XD)=,>^3'-_>^-KG+RAWA)SJX^BQX %X:O^M
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MYC)O:^2^R7K7A9X9E<96)-#U-#%*+;LZ'@%]7EG"DK(MQM7(,6J8+-$A<?Z
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MF(6QJ+IG*!+;KI(N[D7X:$,<U#8[^E:PS-*G-\WS,*.3S+@(2-[JPAK*G/M
MJER+]3^+<ON^XRKUL$F-Y%.(8FW_W+N*2<8Y91CDPQA@(<(BK*E?&E[6U1$Q
M]WGV:OQE^@7&6F1&3&(,_0$1J\8TCYT;00IE/N@,C ?0K@?65E 6Z"6QE(X
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MVPWRA1>OZ]E+"*V,ZN(;XBCCD<1,S\P/V\4PR7O=]VP-0A47-!?LW;-WHF\
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M$6K'CE)3!]?:5+_%"'K?S<XWE57C=814)'VB^6X1#5F2RH5_3J6+=R9\!'1
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M1%&J:;O_G8C_ ./K/Q;^/U!+ P04    "  GB6I4_VNNL>!M 0#LQ0$ %0
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M:<[>5RS:I2&KX DU@X_HE%50' -9/<4T;](N"W#&XPN7FE),>QHYYJ:/4GQ
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M1C_:?85LVB>;25KVJH]Q*Y<SO%9<YZ-J*D=K#)R(AO4A,1A/M#.N3#UD+W/
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M> Z[5#OEK4HI4[156SH8P:1?:C$LQKU /P82(+73'\D8&6FJ=IP,#BXE!AU
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M[BE'R][J08[@O)9H/8F:D2QYSN+B7G-$D8S0;E3WG8"M2HO%>'%;V;RNZ.C
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M;.EK(2>XUZ&1)'&MP\\#2ZV-@*-^04'XO%70&^<]N4#P!D"'+I9[LW?@&/B
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M3\.0 M4*W3!F]!R?92.V#3Y[=]2GTUUYUZ*O4]+@:69-QEQGUNPJ"S&A,?%
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M)")<R= =H<3/R%LV=@U*M&>,TP#]^MH5I.AQ21;ZK3T-T;L7Q'G=0H1A<%'
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M1KVVZ3%RB]!-R $3A*/,NZ\-ZZ6DCQ%%K'TX$Q*>U"#SHI8W[#+FR%/7:D<
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MRR;B[6;HGJ)V<9^'<V6:B#Q=TGZFK;1BT=;J_\)M\-3=$PP$C\5I"=@_;@U
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M(=E-E6O9KB,3[P"+YN.#+6NE8%G3E539MK&KGFH<K%?V5]-!-YU9(=Q_E^\
M_&2A%T$X%)5)P8B4T2OS=@\EC'EFK@^4L'O7MH>5KENA^?W-TH04*1T=W3I#
M?NIPDYVZ$C]WO57%-2WF7,A]MF&7TMA?%A7OF--,Q<.;0CG.[5Y/E&S-_P]!
MD*K(RI1I2FCW/W3T[I.ZDN*"-I>G_D6Q*QS3BUG<_'Q/XFGL0!Z96-:!#L(*
MGV1.9#_DI@1?(CV:\]G$<) @[@"?'8^U;*Z++Q-2Q!S>[RU5ZMVDZ;W_3&QR
MK1)E5^W>WKP6]ZFYQG4QCXP5M>,%R3LL>:#]SXOYD<IUJ/8AB^+8)<^7MS6\
M[%ZZ>AECV9.QM(MZ 0>%E]^/#$?$J__.MYT@Q<\3M[<$CJ[PO3Q!36>A-@/P
ME2<^R:YH9\?NERU^B<?L3T+,*)*HR!8>"QG!C^P?8B024V:*/;>NOM@9/66C
M]TB<_>JTN5<18)>T@01?$KI2^5%&BPOUGNXB/R@F9/\.0DALBNF;==\LX>8[
MG5,2O^;7#3_;D-+CRY+]\/F;D*W>6W7U3G1==G-8N9^6P@2*R$5;6]Z8=P=S
M/C&EK^3$LN;]]I7C.V!Q^U:0GQ/-P^#JT75O'AB6_;$<+?E<MB:T/>V7]@U%
MQ"ADU3_V-\,\</J)30!\^RT7;$_8>9[8U81^OUGBW7O._-N\92UE*GO(2"54
ML+4)9#4M&)U[<^LP^^5>\M'3O\/>!C)>U#P5^]$JG=_.=70951=\/*D1#K,"
MM$ &"*U,VF5OHF#4!V?\LW)OV\ZUQ+?"O[/$")V7AQ""WR8HCZ6/K%=:LZH(
M;)7GQ)M7OH+-1G$N%X?]+$18+DY=W_=Z"#1-/ U%/N#S?>?L00+4?<MHK_NA
M.6O'[1UHVNSZYW('@W>:LYQ08TS^"+J(_?.#*-3N"*,LGCT(.^^ I>--H@#6
M5>CZ3+NX([V#J#,*U5\W3R9<QXQ(?^CQ/"V'<C3G,8:LR^6RP+VN]FPZ2>CH
M&97)TMIG[9LAKOC^<%ZD?;74;!;S@MP*]>*@19T<=4,+OZ]]G/<->^%W%B5+
M+IEZS70N:9F7>#OI/[OSES6.TUP>-!-HRJI&U.F0Z8(;\\4,W*"Q'K_78SU;
MJB84DC"A0Y%4-'[NM$AFK*ZF<[2!K5HQR/IN90NC=<1M^N1;[CIWI$ZOB55N
MN&MWTGSD4GI%*ALA7:]?V. P[,!-,,Y$E?%[M%?9]Q&EH/BW_]EGY5+0$'87
M8IHR5A&C/7AYN4Z<D8YOB.PAX6>_@?+/"%J[I68%".I)*==+>!*B6UD.THU7
M?KQ)%_W@2C#1E>9H7,+PDNJ^.V8+I2^3SK;L[O<,WB<N7NI5HI,ZS)F"M5J[
MY1@!S#:'B08KE([B^38-ZQ"[5$R*QS_;*BNY1277C/WIA/W#=IC;Y1.4W7!#
M%O/Z5QE,<=219O.PXV?^4T232SI+7Z-5JZW,!M->Z!ANIFWBLXLU:!JL"554
MTG__QI;5^$'!&R6X8Y&6,'4V8F/<3TNOZ4$BQI9/7\ _SOC+[HT<AU\9V^U+
M$+[^44S9(AZON0;SF$C50%/EL+8QTVC<:"F]F_P02G\0$@>/_& JF^EA+/M7
M"NF*UN<K(MNBR4(:QW@70$%&J =ARE0)DO#?>O&JE<Q,,JM;(56#3N@##;R;
M$9UPE9*YEF_4O=;.*+*EDUH_$1"J.)6+)#Q;U/IJ5$<M;>R<5C"^K5/C6HP<
M)<J;%ETL:E.L-IC-,RSMXC>Z6T2&+!=_-1!2L:JC6_HCF??O)"5/O%1 H42\
MM4@QQ+)(0UI"#JLTA2)-0Y&1*5L=?5<V%4Y>G)(-[RR9@@]+/LJR5HRQ#BEG
M*U&;IL2.QE2Z4VTU6L]E\=MI4VF2S#?L8E4)V:@QI^VF>-XDOM"UTB6-LN@F
M?>/:+4Q"J\A=O&+<%@6P5$(?8V=O4EA<_I_)S[D;JK.#WRAGBW#M;9GE%V%_
MS>).QF%Z&!FB#'[;M[:IG6XY=O%(2J.O4&,J T.%F>%^6MN#222_+I71[EV[
M<EMU  "<QV!28H5D9M8#B5#[7/<#R5(*S$)L'#96GZ@"3UQ<#Z8(Z[&%7485
MA0N&"ZZM.>\:V@,?-:1RT='!GX('22BU]WC/N7MEPP7INLD)I URKL>7?"$&
M*L**P^--<MX_ISBHR:T$SVZT*DJ^3DU:<*0%IK,/_;&Q;S2[5D]UD/!*M'6?
M]>J/](B9BE\GXT,/J2,3_9PJX\ ,"X"3[)NJN(MC70D%I.7H30Z>P>^81Q\>
M=D3#2(KN>,0RD<[B0\9JWP'@S-.N$TKXOE[%]:<LP:[TF&HO[^YSS#7[YI8W
M^NFAY8,NYG19YP;PB6J.Y0W&* O_(B_!,C2",]#BI\-]2E8"'U3"N &H$C4$
M0>%@@@\SAR\'OYL-"$G4WG;K;E\KF\U)4VC7"=CI^8SD:\/4.H7&I4JXP)63
MD''&&W[C./*YWM!;>C:%L+8 NM!,[KR[(#B]\!5>- Q6XKZD<"OX,Q/R69X&
MUK_:GVC:;:[6J-FZ?ZJ07.&6/"'T6&76OY,H*<%4N:RL&49LA**]DPF%!<ZP
M"0B\2@0=Q4OGEBJDBT[XW?XR'G%P%^+5&;T30GEWWHMV8Z=YQW\X7JF^3& >
MH/(B:F!I@ *PUMQ,F>;ODQKQO?@_VYGH70O@=[C6@RD;.,* +4@TNM/M&5'0
M<,N7\SEN.3.$JL=5\YMJ>PHCOSPPGNFPF!9G@"R2X<8'$^W;\=(NG0^NQR3M
MF8L[S-8A=\T=#C6ME  2"C V(@_B@*+3Q@"\T3P^1\PD"&9UP:[]@"1!)F]0
M5M9]G[:)@A&.P+W^P O2/94KZ3D=DVZ.W]-CG3>D<_I-)L?(^KBA9S62\!,E
MA,@VF-8^A+$H5:QPEGO-;A&-36N82W8<<3DJ]W#I_O,N1)_B"YD,5O],@O1:
MNL')(+.;8&+1LK<.H!.FMN;"$6+XV0M,!\B1X:I6LAV9ZY!UFM; G/\%U6IF
MKJ=4N<C8OE,FQB7>@XO(!$LC'>VLX.CM'(0IB!W"FXTO?=H\R?%;.5  Y2"F
M];K@=?H!-KB@F'Y:PQ[$7=<*%W$2&K&<-VM++Q^^0\\,+Q9G&)W?'T[LT+;N
M>6#6+>P3)UIB6Y;USSU5>@PO%$MZ 1'I$QT,6#CD-%M)*3O6_&O&B;)T+2I<
M2N51\">.-,2F(<LGVNA+20]:&;Y=BW!.AKFE@7O8']&BQ_/)BGU[SM4JU\3I
M^@I\Y/&$KO,$'M_\*2J25EUVU3QL_[B@;Z(>KY/$H3D.$_8!>SFD&D).MZ5R
MO:XHW@$%MV^&W,\S:_ >::Y^5+Y9YZ]]5T.+[(_:AN\ SP,_\>R;K#7FCO9L
MF/+(K,))FSN'=P 1%4SK.:I^JD\%LQ^2P&?'C?]@+L9?X)+O Z;=DG9 MO 6
M?%9$U/ 6$HIBSL3TGQ?)B:XG(4W#[N^ V3<0=4?'AMOOM&U-HG&W5]+7S7^"
MFM^:UKS0\6,20+&K_+[$2EB']@H$+O:4\$<3=9G9;Z2/FHJ/.QX?G-:6]V+%
MGB@>7"?F!+(FAOK6UBZ OONE&MD6;>\ A]=[H(I0Z19DN/=^Y7E"]&Y+2>DJ
M_<'AOJEPQ=5OE;/PGO.9QR_VBW/5VN!=3<>+Y0V#5W\V\446[^:YD@?AL$7^
MTYEO!OS])=R^]H>I_]PW_!\E 1^!T\W7Y19:[UF7%O*3S7> XY>@"I_R<^>@
M<P'D)Z[$F[?#MS/J#J%-]^QRP7'B[?Z7JCK""F;[#W&J^C"=._WV!8@OMC)I
MWP$PN?1&.DJ[G;X9U"_N9RU+^]W44RG#O7?$"U[H%P,4-S>@PP^G4AQ7]BS^
M_?M?,([_K)5 A@?N!"QOR 02_*8=[HOG-]QAS[60JM83!<?=WS9?:$X=GOX3
MY]5W/W=[D?KZ/N.#K[9)!*'25%A=9B?PIF/>*FPJ%AQR'GLH@":8(?-X=\X/
MLA_ZGZ69J+5,YT.\U[1/Y!^TS\RN_G1 [HA"$H\2N]Z*T;P]-?M* [.YLBWX
M*,_1HN+_^=%_7O$S/OA^ODGM1WR6123@X?UQ=V3E1V=BA?(%QV&>'P+EI.P.
M?"F*/Z) _:0D.KZ&Z9O_M#_Q8>P=@#*Q_U;49?&Y/CR#T!*DR5TE=<((NY,Y
M2_G30='/Y;"KVJ3)D$* C-9W$P-"X.A=@!M74D 0O$^[DQX3E"?FNJRKKGJ)
MNO1IT/*0[#OI)RA,_3E\3>M[N^=U!5M29SR4QO _1Y,FZJ:"$3&U_;0,X[Z/
M"&),(2FZ&*I)Q3S\PWL#/!+1.#E3JQB('"0!:MX%:8JNFG?/S#5M[$K0:ZD%
M?-+/,;W=P><T&EA4<G3<1/J=QWNYW(99<]D2-39N6QDV:UY1N;P1JLNN4./N
M:7+=7)X(M$HTR@>YC1XO;4WO ,LTOQ^'*C<JBS5D G# 24/F-B)[/MG[ $ (
M=N&0LY_B,_,[0'[UURF\V0%ASCN@@;G[?@P)+HD S\B"[SKMP*Z=T!>RPLQW
M@0:M3VG QH[YIW@5],\UN$1G"00]C9U 31@K<C=)\;(NR7V%=FI4CQI;]4PO
M6?_+%(440>D6F@G!"2CP#G@'!)_US8<+=4P$6#$2LM?.ADB\C=&T,8\1NY[K
M/*7S]0Q(;K)?>.WX-FT?7=S8#S0)V:SF7%?%+^*Q4DXJO0-* :; &>@4+A6A
M0Z7%2MS[U^NE#CX":J6[&/&3+2+W_N,)'D*R<!$Q914\W8X%1A-A2 \*'^QW
M8YN2$!/'21D>W@MBJ7SF-X:[/\4FEA"A%_5:=J#]LK/GD]8K/VC$14?B[KE!
M7&ZU8>%6ENB",^$Q.4+PY&LM0W#1[$Q@X=>$)>@R2EFU;-,XX)67;ZS^PV7+
M1Q<^GKQ#;12Q&&< FO"=/OE!2+5A"VWV%"?RD\QOQKV&E40X-N?9L5AJOI7(
M<7[K3MCC$_FFJ_PU4NWH+/6JVSPVI5&]-R(/'0Y-*>@F/@%X3@#R]]AVOAM\
M/.M8O(#= \0PI:R+R15*B*[M1;P#9 3'#_EXIM$:"*M$?L\!%\^#ETCB0^XK
MTDOKOZQBS/K*%6A2KZA_YLIH_K(0V<>Z[L6G1?A/<SNF?+@@!)OR.P6L?P*J
M](31Y&OZW=CX2NCV)6EOX/'(Q;=*Z>+>YZL^9S_^M_DN4U8ABS\;J$/3'%4S
M 03^Q-.KCC/<086HL0A\Y<!CKK6QNZ$6S&6=,.O QC0C.E-&8SI'1-V$KQ1.
M<6":@* 9NYS+&SPI6Y$@+!Z&=I2=V$3(<2)(Y=OBVF((*LRV!+SN(06A:1%L
M6Z2&IC-03O'1=,7/<6G_!1BTOWKA)/#[#93B;20,L"%+,7KNUA%6G <W#MQ9
M-&SV>_; DA?(+ZLS!;D YRT'I$=VP8ZO$!N7M[...YZWKDY?PUA+[E/0^#L
MYQU ?<O5M3J^\ Z 6C[^24GYFG4BNJ82FZSQ=[:_X<F"\.F>. KF*5L*K>$9
M^&+RTEGQNG(:] XX'?BH S<_=[V)&<IC<:^ 1GU/3^^ F8?3S?FIOO\'S5PN
MY.YM\@+OAN\]1]#LZVA:M9B",/&O,4>08%H?OOL&M=Q/<I_<QR)LZ37SC9<X
MZ:J^#>_OG7/#9K<;>0W,1(*(R[(,5LO?T7W2(-&J17<<0'AR+C7/TZ68;P?]
MC<7>UFOEXLAK^0KA54,V_C(-:-PMQ]_$BH73S3QF68;,1U%^U+[%=-1MM!D
M^%O?,^!@08*1K1*7^ B/DS4[%:%M#Y_1GU=Y7]!T:D_0PY1P/-'G$AC,_X F
MJP;G8PX9X>JZYRQ^>/8[YE>JW]CBB3VR*B?>ZGD'C+I73V5_K,8V5 K9IS0=
MOSV]V1%;B0[7%:-%=I!SJKW]^]J',0FODRRHT_#:V5#?A$_,; ^!G%8X/,M^
M52L4,.]#I,?#VG_-3]J\-;L:JWX=LWH37'^:^'+*H]T&%BJODI^+O?S^#MCC
MZSG--(*2&K)E$^:!]O98=@(MK<.\OCK_?5;$+&B4<>Y(JWZK8'Z!Z)H8U)Q!
M5)=+B_3HS*SV]^UD'-S-]%N&B97W]F0&)PZVU5;K\GG1Q3PW$%T$E$MDH*M_
MH$R7BY2Z7J)2:-GRP_3VC;>CMR>.E]!)?2T5J#Q7V^>6R"G]W",:ED1#2Q$_
MEM2L-I^^?[&""D1-AVVQQN\YI%&7-=6;=!<)?@[8)VN7P9)RO^6R/+7PCG.6
MR"E.VK"EGIIWY_<,VUN.5K2J;D=DXL/8HE/X,E?C+NKFML8$QI&7==[1%0)'
MG\^O6:.N7YFZDA.O"GA"8NMP%L_M/>"<!3P;I43"MKTYZQ(,].D@P\/WSQ,B
MMYZU0M.@MI>9M>P+X$2%%_(]C=,;^?J(0!31/V[(FA<"[AM%K/VO#*./3I\G
M6U[;!<?2^WQT+8-7/QU'H*+Z.QS-#493GE3UF_;QT7+$N=*#P?[1S$INA U1
M7HC<W?R-R:Z)#P&H3[GK2GK=YQU O'AC$=8AM.'.=_M+H.>OGCU3S]QN]O#P
MW?$Y)SPHZV=TK$+[Z\-_KZ9SZH&S\:1QTAOY_*^B)M1?, W1)P"B*^7&=T B
M]>'K3%B'P(9[A,T9D\>:05#!J_4D?0/X""NPE1)1^),93U)<CJPD(JJI!;F#
M$^OQ,C='6)80 C28JG;7L+B**7S;GWP"\VHT)T\VB0(\K-.D;AG]#M"8]5:4
M\*HD8M!:*I?S7V:%?BZH[=53150+KI1]*D*DQI$>>-S.A50R^(N*MQ[J1>__
M+!C]>^AZ!9.SYG>W7KAR"52\,^DRYJQ 9[2QEWF66[X=:9(Z#6_2,$_5:BE?
MPJ=+E"L525 MH@5;<OW5F6O_)VOZ-VI)!!63Q<L4HW^4+C6^.S[=1.^@Z7)M
M@7%&M9DQ6N;D>*G,MJDB#5ST%2[!1C-EOD#KI_2Y=4BTR^KM,5>=;%>!#B,/
M-AG;(0?N;(22".G=9LVB#&TZ;<-P&D-XWB>Y! G*QO#"6A=:N03O\.NERAQ&
M;XOZQH[&LHSS4/23(XB- &DK@X$JGHS(C-[JDP:S[%G)-]MM[:9%+SU5X[Z,
M5C,\2KN">*9<' [U&6L1 IFGG649)/2J+XIRK) Q/D@]MWF'3OE:9GSE,%S%
M$<=BX^YSZ:WL6HU4P>2.%J,E&.\39:0U10V^W6^30558FA+/PH1A JE%FBPV
MMOAOZ=7]/Z@H_*7E".VQD7X;6AB1Y>H9N\'-/)\K,-E-N:#HA3AH-BC:Y8J7
M:=[:%86FY5MWU--&]=39J$NK)*S( I.6R!E4RY(:=9\R%LZ :[3T,.',>B$+
M)?)=\GIP-SF9W3?[5ZAP^E!;V%$IDUZS\#.-;]5*V),%4;5) PQV\J<1)6 4
MCFD9;@DTZ2.\OZZ0<A45JV664H0J;NCVLGIQ-2:=I*N"RD&WE;PYQVU<F>30
M35J5I)1 -.QMKT_T_.C7W=+Z2"$_,ZL)FM-#77MMMU[U9.B0]?EHJUR7PBP'
MU:7.%*Q+W,);3LM9G]W.'J9F\;G6@L2RY9JNN238AF*5\B1J\X0PT&18-!O-
MFHOVY74=Y5OW S:61?ISOU3,8&8XY+OHQXREH/S-2T-SF2V=]R&:FN]_%ITH
MYE#[BD($)IKKJ,;O4VH JM"H-T]MM.A.CS"5DCVC+^J;6W\;03]L[]CYR]%.
MC+3)6W3;##MP8OHW=:%+_FLSM\1S-G=CV0CH<GJD;-J@X?LA89O=9.4"\W*M
M92TC?GQYG4KET).==6URX;K]#$.ZZF ;G7NCNO7MY]RGR!7ETL;0ICX] "YV
MEIG\XW:"\?"%5F::UBZE#HU>4V/X?*1/*???C1D[I\HQ]>9,6VT2RN#A4@9:
M*8JH.'2N'FK?/Y"(@I HT1)Z)UG5#IG/G#+DWEX8M0<>^M24$IT)O4]SI3J]
MNE8IFEFN-7AT^,&;)!:4 E+%W[U,HHB"KR<'W<R0-$_4O+86+#$ I\C V33I
M>X_ DH:Q+YDW;^-5DO_&M#H,?A,TE7-2_(W ;LI0-C?E.>&HOZ=&@.K?_6L!
MRT@.'_L5&6?<+0D^2_7 <TND,!%EIQEI<%LN?>74,H1P0"P4/TY=VDALFH2F
M'(H.4F-1Y!=]\Z8H^)N?!6?ZVK &D:\II )"G(9.'8B2^UD!89<D3GA\][M3
M+,H]+[Q@5-!,(#QXWEH\#IM[N$3TAXBE*O/%4)VU;!!9'9M"@>+>%)^GU9SM
M\?!+JE:R*;=J>9FI>="X(/XO3BLG%M&O+#'JN3J(,+A//I;H/[Q/]TQ]BEVE
M8:5S<MH:!0-05K%G*EPV"O2;?B#LA.OIWHT7*%4>;&W.4!0QA%6UXMM66NNB
MPR>'QHDF0->J;SEWPB$2\EP+% 5@M9E*+R(V)PJC>LS1K7N>4(7O\,1MA?74
M7'JR"DN,)$B31<X5N(E.OHI,61,NRL\B#=-K('7(8@U*M-1:D+$C1'ZM00:C
MK^EJ&V+$:* :^$/P7S,"",0<^&NQ.V]5P1(Z:^M?BOX*=714?'M^F&EUE.G4
MDK.C6[52C=H)_Z)MBKD]923J7+.GBZ3JA"B@N.,"3QZ;-[-)\:V')&%3X69/
MP'(-%/,.N 0:#HFZV-(P?<:2 Y%%5Q<N@8O/QOB:\9+T@ZPFZ2=M1HO$2MF/
ML''4'VJ2D_UW'*3N6Y#H2,Z>(S1[*"X/XGY8EZA#_4&:5E.V:S=?1157,K^Y
M9?\W,!Z7:^2S&].-G^XJIE2E-Z-_8+Y6DAMZ.&Z@D6JL2F@\ISIE;65&0"EC
M#Z;3+:L6E57.4Y7-H'C,B4T]Y<% !2/S(?!-Z:#+D%#\:3M8UUO"D/J8TMJP
ME#N*+'.IA5Z^)NH]FO^^BZ;CC4!ET( VL,;B&6^63<:ZMI+55"TL!Y8@9T-[
MW+5Q2\4@,&.E2O3:A4#V&30ZR45S>*NO\0"\H&@W-6MBL[& C!/$([]=$VH@
MD4#*)NHA74[ELT..PI&>SX_/_?Y(B'9/2E^#N90"+WP<!#.<72]N[>>C@GIS
MH3+B1O6;F _R;(NUDY2].JQ\J1.93LYK.P,>W>\<;8&BX39D6'-NSOJIE=\2
M(VZKM>O.)G*-A->KW@%F3:$K<F*V6[6\(:+.JB"%'W0)D<V4[%4_W7VYM*J-
M SKY]F\NFOA@4S'3<B>^ILWPGF3N,.QGSMN:ZQ[[=[WD^SSX)G=[W?,+2VPH
M?-7V&8?ZA)T3$7W8(WYMT*,2;[GQG2:;F,/VZ+BK*2JH1]8?;BBS9-'&F<:Y
M['Q7H.*YW7;??GLDRHMK;YWZ=45.A"* *9726O-0]2Z0MGEZ0\-]E4XFVTT
MB8<HIKCZLO'FB7LYPA*,D^ HPHL&QK,A8E/3^ NEG&D^>?43%=N?O?EXQKZ6
M9Q#W)4-/E7N,F08+G.F0IDQO8$Q7,.&E%;V"<_8J=\!><W,&&ID4S-8"7!#L
M R\Z&]CBVAO^X2>_>5^6LZT].]\,7DN%\GMV_7:]084ZE$=&T4#%O*9S&RNJ
M66^O[)_)>CUQ-[H-JTZI'AMKY'/=M/P41S(K3^8T*F,^9@%,V0>Q([?E9T7"
M4(.4W2Z6^?6<QJ6IN_;2F6TJY8:+:!NO&>?946Z?A500<<C[[M>%KB\_'R6
MMSQ.,Q+RFCA890K^'BG8=^T,,>[_-?PSC+:+M&$(Y_\#21Y_GIBQ@I4NL"E1
MH*1'9+Q'#'Z2C3T*]$#\G1\*T6DM\FO1IH9"HC@RQB<4Q5URAJ83DS;!D*?V
MJ<V9^[6HTZ/CO_4'F(HVS46T0A0HKK^B68]4OPPG?.PA!1$"'I_*]U[:12]2
M";!W.5-5TVMH^M#'OKKJ,ZEV,=21I6D"5N(SHE!JX2#C0_@^#Y#RJ&?IL'I+
MK[C8<,7 \,)CLJE2[@CTY7Q+EG4G_,UG9G'7^4CM\O$RLK+37N,6N48!0?E3
M[!)A?P*GO+)9#IPQ3/ HY@]Y<8_3@D^DBAC<.+P$@XI\E\LG(Y.;XO!R4(R?
MZA7DDZU(P%26*4VSSP*+DW\3*UQHVENQ0CA;I#LOUDAEIVVF.?*)<M>5*9OH
M>$&IK'_97CY]A2*=)8DQ=(Y#!5"<!D VW@'US)9M5,1V=_7,CI[;:/4WQ8P(
M&(9P_5*!@4C8\5JFF9N__,R>T9X%3PV8:V\8Z5"SKFOJHU&Q/.R.2<FK)%SG
M,Q$,*  H2"G*$6!&\4R6ED=):QI%88+"1]B &L0A;7+;)OR@J$!'" 1T[28S
MZ?=F>+48-RO177G@KEI*]93XS'V:[4O\TO,TKP>77/5IL0IS6"+769YIKAB,
MS=4M32JD%1\'P%DH[_:*68OAR?&66X3ZO 33C?<.@&9U14&.?ESYS2W4\ ZH
MF[#EZ!S'XPI8#L0.-YLGQ#,,/^ZF".K9-TT2 U:;1K.V32^IFK(<PA ,V/2E
MP[[=5&R#4@77,GSA?IU*?8=:.]E..[B,^I/ZJH;GQW#X,57N/JN?HK#>K]UE
MWNM[;GU4,I9)4070#0.32N!4%58;TE&09K%L0J/^#X(D_AP*P6K66OY1BZ0H
MU(+X(W[+4Z*Y$YIQ 8Q5Q$W[=DQ8T=]!+%K96/@"__U^Z%KV,W<;:14WLLGR
MJQ6W()I:$2A?W$$@F>[VQ[P]YT_YO@J(^I[RE:TB3IB_=&@(<(( >Q7()=C7
MU3LP V3='W(6]<2JOB!3Q\V.O-3X+0.VO_GV,3>;>\O5M,$AH_X[#?<2=R=P
MZ%0$YW=JH&<=?-$KE/F^B(U6YU9BXVP_5T&?1@@'EO;B%"P)*TL\//)\1*+N
M@";S=[14A!9M)#FO(0"EG"B&%4C5$4NZ[I.(4_0Z$KGX'W@(K)+$LWJ5G:*\
M3+P#E#OGW0RCO(%U6SB.A@'HY>\ [#PCEU*F=#:R7.1P;J@X^AIFRZTXB5>%
MG@.%,6V177R2[X* 80!$/OI%$32A<'(JM :]S*9<9@>["L):P^[Z-O-:>N*8
M=\",H/C):4/3'ME0_8O:$X<1B>#4<G;83<_A:X-F#_&+\)%4CL\;,-;X\(]B
M3:>(!W3H#K2<!7TC4J/C:]F)>UZ[*Y-\)%HO;-N \+I'3_P)_!(_VM%;:B/:
MK9K> F$M6M+.S>'!YAU<JM 6<9:1>[1/NM*YDLF,^MY&?:N4)W9';!RQY3N@
M[\EPD?IN1J^;.,ICWSC*]?;B=7V&MD+@I_N>&_M]\9]W0*^3S;VBSMF2:LG$
M#OP2#[0@\0S7\;-594S7MJ" 8/SAAD#V#-I]6&55%)\FZ.:.ORMX;Z-\8F0N
M-NZ;Y67098@B#&]WZS$)\K:#'(2H<ESZ8LLWH+!XX"JF)BGJJHV05:#T).Z"
M"HME@Y:57&)8K<MV-.,$94F W%:XF"86PWEN:)UWI15Q^9\ 3%1G]_2.;:('
MIB@T"->84P?;SL^JH^1DL.,7NF5-!EJ*0CI3/$72*6Y(&:[TZ##5,X);)"+A
MZ;6B;G>/5J]UZ43.VXFB@R_0JW&[BMCB, W8&G<]C,BF]PZ8WH3A<[#?10'6
M=N2?9C)Q9><<\F7BT9_S[0A8.B*S&7@L>LZE(DWY!'N+W3S8*-Z^+98U0QX-
MW@(&0(>%$<M>1L&KD;S,,DW,9TT-7?=_A9[/M*Z&K7[!U(19_K3WGJE[!SQS
M:OGE3NQMGJ49_#TN"GT!%L_BY5B<53?4O@,&DOH,=XI55C[>7DU!4<+<+I32
MM8G@.86.; VB[$&0>^NA94Z[C?.PN1"\6AF'X(BWP3O Q^]ZY8J)J-IDAW0)
M_^)?>@OLWFZ9AU\(+R1_\1KN5Q%>^U6N!)J147-*2)5[P^O<7=/;XZ':P\5$
M>L)UJGE6KT#N=9!WC_2.<]+GY)*"4EDEFCW*T2@3( A$=%I8W7\U;9VK*=8J
M7L=)4]9WTM30'<BQI6R$A[=_C^E4M9/H$IKB9C67+KK\(UJKU42VI%#64<[N
MCZ!P#XT2J5J(H0-*^=@X2T%6V?;>LY+8*?F2%V^H$?I U';1V5TMVW!W<R#S
ML.U,[IW0SP.58 $^^JD?_.)21HW'@]O#!R[?#&"V8.-$X]F8[:Z::*=+9_$T
M!%636AR,<R-L]M0RSBEM5+15'V4^49)XV,['-IU4?I-%!5;"#M)%0:D(6[/K
M-AUD9AF&(*Y::6"129JN1I:I,P09)42] _#? <S3H!%!(:&9;$^(Z_=6, EX
M^/@HG7_9+1X7LOZ5XL %^A,CM.+W(-I2A3K+MLXV!N18J";#3O<PQ4XA;MP2
M,!):?QDML+!%,WJBHH@$%!%R;\KZO2FQQE#H*+; <Y7/)"17-?C?<R*%[KA_
MC41_Z> :35VEFSYN: >IV-S(R7IU;'Z ]^<(#D7AZZ=R;;O^6W(5B9W!1B]
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MHS2L^\EISO<]2MY:J>/88ZE[4/904@JI]I)>0S_EK3@FTW-5[.-ZTB@(^/,
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MIJ<D0L3,A^$^!P39^GOAN%G^V77#[5C6&VA=Z"EOGU$C21#L6GQD!%)HLND
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M4.X*C/1'PO"_ %CL\J"_X7H\W&(@"Q#$B?0>K'1KSJK1<>"YS_N;LJ$A\Y(
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MR@ GT8]X,<4&\-48+RV0"F'\U^]57P EO;,I[MSCR\ OP&G9>>J9)7]=8$-
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M?8HLLE"D8>M<5LQ15JG@RINSRM*H0EDY; +1Y8Q'54#!>)27AI/NY&Y#UFU
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M++9JTL7'N;$LK"?K\F_F/GD@)Z/=6TM@=-P9-)?([9>6S@(]50XO26?OM%'
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M=Q%KROXNLW9"S1H%?]\^;N,OP%4\2"T0C8#EUO<\8X?6JN!M(925$:[V6.@
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M[4^EYOB2Q:[C XT7^3^ C@;DOT=1-VQ)3OL++<C2D,>&U/T1COW +\2/E\5
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M"0AN72N=>-L[PX]^/8= 4;_TD3<^&L;^M5A67@Q]R%@+'33,7J^05F6.LQV
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M3 !7+<A^1M^XG5O4\E[ U+,FX*IN:"HX:U+O6!4O! ?'_= Y O0J48FZ P!
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M(&ZWE0OR8+5)X=H8:\0, M@E>3A"GTB/OC: D1DPR3+XK+@;AJ]DWOEL#WP
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MN-]^SYT5T#='<$=&;XTQ=9@TYV8[/)+0'A/[C[#8@;M_F[:KZ9/>6'METGU
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MZN/*D1$@+X)GWBI^3F<[<E=2('J<-PIY.P#J'*BY'L [A&]VL%'A@4'P=W]
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M6K"0!F1E1!A/BT/SP=5TMWQ[(G: P[$28SS:)*4(R^GS[!Z) SQ\/CJ@<EW
M#$'8MH\K[S -SFV,\$N?.DG_!*Q#.K9;OTVA-@.KO91C5+(9^;!)!%X>+T /
MFI(>6\V3"5[]P1=G)W?UXJ\%!V>  _W$T5ER"M8D 7,^6#7[M+M85:U[]Y[:
M&Q/?+8JZZW2,=EO [Z?O%B75F'K+.'-52!=#X[DJI];[BBAW+M8GL7O:9YTB
MRX.ZA9H-D1DR^5OO@+59_J$H,MRL5VVU9>S%<CC"]T=8D$/,Y3*)WM+D[S!J
M$W':]9WW]RE. @>1E E2>N,@[W<;3UZJ\>$\L^X/>W0KTYK>CK@FR7J#;W>T
MV:-FYN\;B3_*/*?BJ3W5+(:8/7 <B4I4(BOE6L7;&GDFBKR!134YE=M]9 O!
MD=B:;*Z!E]6RDTO97P^+-T\$I%DL^ST=34?*T>VI/V:[D>=J47^5XY1\TSJ@
MN+S:,)!)^8<CU..@<S$,KQ5]*1XX>)*7:O#E+C?].=-]?,M4=6 NJ6E>M0':
MF*P?B.GJ. P+?\)P40$_Z:Q [$16)%EB07&))FK)78H?D:+8=E3.&_YC9<7N
M22+OYO!,_KW) /$9X0@/W\+KQKZ42C/J;&-R2W60OP0>]&+Q70#]EG&E<= W
M(]6/&"RX8@A62BSY@&N\* 1K'9"0@O"$]EJ1C93D MS=\J+G6\"W8V1<:S[5
M4"=)?0E[VR<@!L)?SNK?H9I+F.=B38K;2(L33-PKY=R-2+IY:' Z^''\M6VG
ML*2>5$RB;L0/7PS=?_?I'^C5J#&7@UZA(1<7]8BMGJ*\?.^'+UD4]?6W4K ?
M#;'3$-&?<$-)3P"K%%!;82;9^V5H@SN"\;?E]]W9KZ9$I6.RW2RL6AM"^E"I
MM[.AQS4B" >5SMNGA&JD9,VEUR'"XC3^PT3OF-8J+R;5:8_LN?NEB#1FIV!\
MVN$/[].C"<,J\D<' E]J(,Q:W^]G"EAE$T%ZH<.O/K;BI-I4-*/Y+'RL$RU7
M!D',G:".G99(Y;<=$<UF\3..%O$&^RD!,U499=-?)C"]7Q7Y,.6,<G1XF?K&
MC7 9V0,O( ^5SZ'<@"AKRJK(H@6VT8R$;IX?N",68NH:V3YW*J!E8W;Y&=W%
M9H@=U;=S6;+,F.AL@L,)>8PZY$.XRKW3J*,WJ'8F9BX_:(1*YB+(P2YKCUEP
M8?OV!%+]-,CSRPUE_%&*G)D12BWV-; :4*?_!@N8^885*HQ=EB-8W<W33.99
M-$A!O5+@Y.>XAXI+(8\1XNDCOBE_@!+&@+S>2R1OS8WZ-@L^DH_*A5;1PVP6
MSKH;C)L/HGSW.F0AI/D6/VAVS.4:^N/OA7BWL9>/%H(O*,B\]:G1E&\%,0-F
MRRE'63J_#A@>$[X!OM:BX]$<FJ?+@9I2+. YFDMVKT$&$<//7I-I&'_YR=G6
MUJN/<<"WHQ >)_QY7NPJKDQZ:))R+1Z7A62W:?B:+SQOO4\L#DMA$-WAM>VZ
MIZ XZK309L?FO)O8E%'E!$5U/_U1J20OR JQ&P2LI4JGWQDUJ>#)IG RRY0:
M1VKZ256<E,_ZJ/L6UO]6;?R=N3C=X<3NEJ+Q)2;F#\'<GV!;T87*DH-8P87&
M4 J1_''FQA7HQAF"8LZ!YCO>9RYA(2(J4RY1=:>N#0@2ZOH[#3V(HO :">DP
M-5&RP,?V/B9AIW&#5">,<N^CF!"MGKU[R':4,\87(LT\+OBBKL7.3EM<6NB[
MR.%L_^P_<7)5;3<F@OZ?O%Q$<KECHV]ST7UON&RQV-W.;9>% .U(HP'GU-B2
MUZ8I88\-[@%K'(2\2&:%-GD?(;OC7-.HHB3YETKR"H -ATZ\FX76T68NR#+/
M!=;WD?B9V"!'@U=];\3-/+<O8[RYX--W\=&'Q&]V=@7-3F2KB@]$8>:6XG$
M70[_J_[>4[\HOQ84#Z00%9?];[NK=5:M$VAL<\]VKN* U&%9O8ULWPM6+'_;
M3(2_EM4-3[NL7V?HV99)KE,S>PE.SW-*ESF"Q"%&<)TEUAT-F4-/+@SGHST
M/VNFCOX*AZ;W+N;+.H>QUWOAYU6J".8B42$UI<$E>N=R;@Q$IA6B%YZ'VV=1
MG+H9TUK2__EAT:EIW^1;5@#JJ/O>H;<KNBOB^_N:\/\P>10R-^T!M@G2-M[@
M@>#5M/"[1@7KD">1TUL!I5:H>,OM+!G+HLJ#$I9L@,Y>>#ZV K8<S+!CN^,\
M:GU'-\@ FP+ZY&'S"<F8-ELM)#53JY#F,FTZ<&ZQA"1VHKG:E24%D[ *8=RZ
M)"3!H_%SH#0SCV&/9=31\8<B*S__S,_N#1R<3_+B-2%;06N09K%&&7Y+Z@#&
MFGLK*797Q=VBH-DEXT2F0K?!XJA7(T["@*<@4,#A07EVQ+EG5YH]8L]\CMH0
MU5&)Y%!L*5\,@.>3M!'/AI=A7Y7-HY;3E[.H;FXAI8F2.]#7VF)SG%,+"$\]
MGIH'F4A[E5@I%IL&PHV9R,(7NHJC32N,Z]M((<0]ZPET^N="M-77;^&7&JF:
MZB[\,O1Y+X"*%35XQ1Q'C[RS>*V;T%P$SHZ!_:LU<6->BC"78N*MCD$&9Y(%
MIG7*P&U;Q#19DQN'?4<BN(6&3#(=5.X]VBG5)/7F48B=B!/V,;FDT;UKF%(Z
M](DGQ:05RS <K2IO1R"ONI2P^P\JSS2O9?!4+/AIB(CV^IJ#AOI?&->TOKW8
M#I#@G1(U7YRQI%_@JFQ#Q.;@-V6'+C$J>R3OLH:VO@E-)$!RXV4R8V2 &_]A
M<N?L;_[QDL,_R:3,@?8N3=8G2!9"&>8':.5\/_"Z]!T=5*XQAU4G%BI4 SDC
MTVB&/"6][. 4-KGD/X[0&L9!"B)JW!)O5T.2(R:<=:!M$TGO0XT#6_DGC7LG
M/0H/MC5Q;+%4=E?Q,ZUJT\\VG]/N\\]\CK+'4VN[QCN[FJH:@'MCESQT+F"I
M<J8S] B^YICS0^FC4ET2_<?0Z6[M1'=DE?K=A;-F=2FZ-37_7W) 'Q%&WR9,
MB2>*H\/,U(WN9"(,C?F%X?O#I%<<PLZ)GA:I\5V 8(FND;A2RT 102&'B >]
M%0AOF=^%S6H,HW+]QTAAOXHM]BQAXE6]PY[\F9G.-<#XS@+HR%*CVKMN\3"2
MOK#M&V3@;O&E;Z!1^BTRJ7B6?\ZEV+E))PNY:Q.3#TV1O>&&!*7!"W5(ZJH[
MH#<*,^4=*M%5T,$D*V-OXR?5A'B%N4?_6'Q_(^OG=_EZ6R[YSL[(-,MI2-O:
M$.E&'3OW%)O<JT6K:>?78DID'#8*:73]4^652SO<0A:6+(9CE5UAG3.:?T=.
MZ+SZ.]D=SC9(K\GMF;/N":RP\755K+W"4/QKD_(&4;K E-)[DC5DJ;+$]%<-
M:7(52_FG\?*DQM.2-'[:P7V&P[1U<FT?(1B.J]'%K;25-OA_2!)H7A^4ZB_X
M<P/RM,HNRSBU%]Q3UDU$/WU"= IW1FHE+!AAAGD_[/3-.3QZD!(UVWUR\)NR
M?"J?[HHW3,)^_G:SA8+X&>@WA"R+1JEA%$W4]N(1._922[663[\&-FF@3P:&
M%!HIURN9F),_W09W^,B&38OPS"SU"^K^?:-V!E&KH=A0$6K'8/5+AI :/I!D
M#4HP 3]8[S9D#ZWGZK4!]$,;?6$>USJDKH'*$7HO50F(=CL^!+,?7/W*M8;J
M'$"1]KE]]5376,1!= RL*NJ34\6.==1@N]J/[VW;V6GOUF![OLO6BOJJ56CZ
M.=M]$[88,S'A3Z0*P#^YO'QKY2-Y#YKIC8;)]5DJA@(IZB+R5NDJF&OOK2;?
MF+4M%6VL"Q_E:\/4P[^DF&4%+IP.(.+1=3)*J2E$.S.ROGBNG3^-PR=[<?+4
M2(4:XFZ#.)?).:F529:4@H[S_=KL>NJ8/337$^T9LT2B3>H/#U_V8VLR\"I;
M>-^6TN0.6R+#OL#OEZ%_K"]2^=NR=YQ]S@3MXH/0PG4A]Z8CRFE*NM9P=7%3
M&\.+D:)QS4_?R9!.^3:W4NJ::[+#.>M"7SOM,#K\9C?>R.='('P:KY120"]!
M/Y\R#S\G[_3XOC#5#_'YOO2<4U'IS9J/S]6PN400YTM?7P#O6PX>8M0]36::
M.86^/ZI8 Z,*\%-/VZRQ0TC93(UUBGD9W7<)L4:=G-;9P!]186[-YW Q/*G;
M4]%M,.)KA,$U/XMHXCEL[S$W1C#^$XA/WZ!V3@6X5Y)C1U7%G#J"[ XBY8QK
M@.V%0DV:%Z7NP3UZH4F'\]?EKO8-A!Z_7=0T^>(<M@MI]<]?*G-?U$B5^*M(
M51<B^Y-O6!1]?'1K>CEM3;'^->ACV^TQT77 6]CX2+NI;$% SK91(5=C)+0<
M)"?AT=+B>"_*HT/$S%O'SZ,F&@]5'[I&N;H!J1B+8G_A4:$=B_8)1W]Z-2"]
MXP=LQ*_+<* 0M\JV#GN"OJRWV D^E[@4:00=E5>A-9A*FTL:1E[-I_(IO'<J
M/Y-@+)#GWM3_@8K8AF'ZHO+M6Q[N7+L?O3F(KU7$-PMREG'XJR]='D?P:BE*
MW]"C#BYPZAD,[<5(&Z5P_\S\VBU^-5WG?#  J I\(/_:*[=<5[3=A9G-*JET
MB4U6,3CKX.D<CQ^#5ES5T\CM0'5&"O&;@N/6WN:_!LL)L_WQW[^'#?HR?R*+
M>>MD?]744 W'9!3]^JG32>[^NMD7/U5$UZCO?9A?0K4)QMHM">H\^HQH=Z],
M7<O@WW<[B#3+*NLDH?9";>5;\R$+;OG6Z$.;-+O8"?_0T+6+V1%*ZQ6K[P+=
M/96BBQS8]G7"J/DUU+BIF;+#4N#;+.V3JB8.]L8OAX'=^Z;J5)7]):L(,^;9
MM:.S(>!*"$-U-XGCEC9]?U?L-\,_(?I-MEG\?'N:G[T2)4Q.<RFG;U+N\)WU
M461HM(JHSA\+Z^';"*I<-7U[N]9@E6<<J"PJMZ[V V8FQU.B)?)V&;^;XM#C
M$9T3?FDKYW6J;B%>!P/.&>9Z**7.DD?*O-\"LM]6 $Z7ZB)3:K9;FWC*BI[-
MM9<U_L#Y;%FNN#QS6FU+4S\,>4Y<<Y!7VD4&+@JJ$C8/,.V*.B&!.S6SOGC4
M[JBJI2E"-I\)6D;N3.%\$/2QG0$'U@F);OO1Z._Y?AV[H\M^$W]@O"V;UW>P
M3ZVEX$VSN_:9)LF#1=3I]V$+%RH/E<HD?RH:947084MB3]XMFL&?ZR6S*3>@
M'-OV QH"C3O\Q2RJ%AQ%Y:.JO%N &G^5LE@<Z!U</G]5+E)&NA1+3V6SLS=R
MW[N9S.W'*]HS8%F]P C<DV&=W=HL/ZS%WO"W3)IXXL4J62L7G69_Z,7RW><5
MZU8M!U62#A[MN390@Y_F 1T%"1JI9#L["\NE#$.<%4N>Q4I+S3\OO2]/-]X/
M:4\>810Z;$X+=XW"*9]5U/:O_Q$F38E4V(N6U1D]#)UA$"6M+=WRQ1H%!5IX
M5GO[>1)>_#)3P$#O+TR_K1X:B2)=_EE3H98&KC\%;Y*LXL5^$O47R<2"Z&9Z
MSJ_;A*DL+E9Z&UCS\4)K T^+.U%:XW'Y(23*4>_ W1$>,Q:M4=2^+KG[HPXQ
MM=N^X7_6J>"#1SUP:PG_A^JX.>'5X 295<FUC$W>$2&"/1-SJ$K$:VU2JDH6
MGCZ/_@EZ%]<\6.C61XC.;P\A!0N"^+>#'(O"S;*G;[I@1&]].!-XL]R\_A^F
M0&<;Z4+S90XS"D.CTQ?/3Y/2[S"'0]&9/%89FIGGD/J-ON%#FYX?Z_/%#N$O
M5*-&29,*NZ4=P;U5-0D?3ZV0_ZRO[%7B@-L40S0HN6.R[#"T$JE5E;;0S#<U
MJG=\>;CD=*>EH:99\\Z"P>9,"4-PG478/@(40PY9S'-!3<OC]@@77=X;7"[T
M+<L;R*E5V[6.@*5,8JS 5'OW-EDRO)*5/]RM/T44X$&WR\7C!OS!+UDMT[J\
M?A<ZJ.T ZLPT>X/P\U%.T,F-M1:K%]?:L:#GU6JRLG=%];*':\7<J'22YJ=3
MI\:<&T$<[4=&3-G,U.N3?XX-^VIL'U2>Y)=VA#F=USDW;;I\RR]9I/@OE"%C
MOK>@BJ@%CQNGI_FEES"I3L&RI/84"YR8YX]?JR5!*#T;?<"]SS'$ V]&-B%2
M\UHAA#9+(M5L5;B()712+,KI<GN#!:O30EM1&#<$_[+!Q\<TG54YE+3J6'E<
M>_^I2YMR:=:!KYV'$T%,^^=\*[?[&+Y]Q9O23&&-^6\^_VFM5/5(!8;G 24H
M#QV:4)005Q1(\07CXNP*F9X,BSSTN>XA>Y+\:\H3?JM)8VXJNXESU3\XQUG0
M5[.O[#T?JG[*6A4$3(%ZX:Y$B,U-BO'TN&[> TDE6D(D65C[@FV5@%)]=3^6
M]IHL]L6^/TX>O4AV\9JIS2L#5M@&<R60$N:&MSEH*CQQ+R"6ME87PU=?&+SZ
M8]$G$3/.\I'?D(FI/+7G 6U8^-)W-ZUO3W3$F+F,2@IPWW,ALDX)#>%R3>K3
MYXI>32&SBGFT6[8^#HHJUMS-Z$K[5>-V&I0R.'Y+,6;/IS;%>P)0PJHX0$9X
M:7P]KNOWD*RB.%V0?,S?H;SNL)O@)S42RUQ>651HWQ36?^#CQ._K5N4'N]V>
M)BZS4V"98=QXHZ%L4M*X=J?+2]_@D@(=6.].58BY1X676;F%* &30TV@_E81
M+J_[/%Y8LH<9[HX&]G6?DHL>,S<FJQHV$%;9)'P5/QRXS#GRS;_P6[1N7507
MJ-[FFQ$K[[]&[7CD*H#<YZD+JQ #\RB9NU(_G_ST,/6/._>!RZKLY?+R"O@]
MB3K^]8<A5)3B\6.SK8$\,]WBU/QU2?WNK5K+R5]-@A/FJ0RBKJW_HGW'+8OT
M^>,*Q<P0RVE0N8^BKA0\2-HH.=4RS+^[2N$'&72</2*!]3IK Y*/5C3H^[:M
MLH-'*44B[X>DT.45LQV2]\:IC7E80/+\TU,Z_[>+KP%4G-?@*SJ%E[X(X%YP
M4XN<5CK=OK<(H!4F*HSZME5JFIH=MBK.92^V>#%.RNV=TG6I+C14JZ=M^FI-
MVY).[Q3613T?7"=FWJ[VBS7GL\KX%0&G)*GG+D,\R/.Z)IG[(3I3L72,E9A=
MFS0JO8O3)7CYK#3ON$FHL5E)#I_+[<NI(_./%Y]N_-9N7(*H":G?"_;&Q[-O
M ;?ETD_44*=]"A'.TJ!94!S4$QJ09T472_K8FTK[,G!5#B4^DHV*U(FX5]?>
MYR59O@*N;WJI.*R-.>K1Z_14Y\_MTUS8%T9:)*>4((;343M?[P]&B9>4H]4:
M]0,G6<!IR/C+1(E1%(VX:EMJBLXJK?#%.:&K*8W\(=\]MR6TCM=5^I:$8S[O
MS$[)39;:*PD79*_[F+XGO9;\.7$/3F?\_62P];2BS9JIP4!U:O:B#D*78&ZK
MD^+/SV*W0_)B$[(X7$G2[TWN*%]X]S#\6A=@X:@$HS[-*5X V[?F*(/1&"PZ
M4F1G?@X^S/?GAOB_/C XG&1FHD,3L ;?\7)'"E6/ /P BHI!'$>X)(>"(*>E
M>W/0?S?>YBTX;O@V#:UC6-C$RMC:!.BE/?A>FLW4?)55B1%'A7,<]0G:?S>'
M'R$/7A_S;&-/[WGRCR3'KGQ=+FX4X+P=29Z(&=F-PG_)H-E3M?XPTCX8M,^'
MTP, 18N1:0J!'Q)R3S%Q[8&)R$FH/\8C*5@TDKBCC$CXL-<F#BTY[9^5C8G:
MU4A?/[NMUMX\[?E3,,8KW^D-5;"[!$:V(I=6<3Z'=-/.*E7]+/AF=M0^,48Y
MD&SKJ-E7GA7ZPE@,W"+YQ#]4WU-G-CLT9UOHY,O%L,E]%YL][8#[&C'$1VCB
MHFM_HL\6[5G#2:ZB_9<%6X?&L?4T;"G9%H:!H?QS'52Q$)//38\IZ$P\0'VA
M?8H&2 +>3U[^(*LAZ72F4QTUVIHG?)AW(I0IY7NC=';[FV0=HMBQR=%QJ_V3
M;?OV,*?H]%Y*T7R9N@5V.MO+&&,</'.))#NLMZ9MY2FKP7__3"&T*,:5K)(9
M@I!#8&CU[=*-V3Y2(=\V.RI@H>3EJ^I7=BI]N#G8()[:MFI?CKSJG3&EC)M!
MW:P21NCD4JJC9Z![V/[+<J3N,X?=V<[^.5-98L6/!#S#3VT+?<JFR+H]W18&
M*14!._E#FZ(:*U!8%@B40Z+Z6#3H*>]3IJ''QPS\B$@9C$]UQ.CS \Z7EZ[4
MDE]^Y#/,.7(W_^\'X?\7EDI=Z#Y_\ETR->C_ P,+R7EPGY]^N0"X) PE9Q(U
M+QBQ [5NL;U?U[J4\V6U>&P^J&ZV,,QX$DP*G)^QPEJ2H^J,Z4*:5\GF1 Z-
MW1(>@G;0+V<>GN^>6"!1 -\<]S$#04[6@%D,L$F+A=XHG)72N4\,Y9=AN2VT
M=%%NWL3[YG4+;D-*;.F&8]:CE?WF:6'1CP[;F"1[SU]\VU(E7$WV;FH>5I&,
MJ-\'3K06_ICSA51GL+#H+LR(.4.J%I3!;T Y0LW>?K+JV3"2;FY'*!G[W@T6
MX+(SVEB04R@@2S"O%7#G7,3S\KR9\-\I25-713NP0C+87NA]T<8AGBQ]ESB6
MS@6 1#^<_1,VG^)!6']33M;+Z?&JASF4+<;BJA7BJD1W_/AO:=M 0C;=+]5H
M70F!T %<D46IS\N5:EG+VUN*C#E4"(K]2RCT0PY)%M](_^HX0$:&16BEI"$/
MYQ5NV13#\G-W@J#'9_K( M[2X.R7.BQ?8CH/?5(\"I;Z>^S3_'N]C8DTS8HM
M*6AMN;$)YF&U%X5M]5K_P[:\KOI2N DI1XEI[?T8:4QKDZRX].IVFU!]',@8
M&Q)"*UY-:R;)B",50AZ(?FO(.;9_98H[*K+RX=E%M-:4JN76W8C<%/9I+L)-
M0=&OY23+@X$/GXPI),Q;V#@[K?D!#=.O7F!#<ER63R):Y@N'O&XD,+<BBIL$
M>J!.,/BBUK:EQ(L,8ZCAE>!ZO#M(:.0+"<+&ON/S^/(/-0)]1<5=\@R%_?7Z
MU80[T8ES$/=926\>R+X1V@]Q<$5= (OXM3^M4/T(,,647-@.U$58WICZ>Y0<
M".M^.+P$--Z#3:#32 LG,+X*O+F2I2$\ED^FZ(Z)JG21S$/M]!<9NRG0-$?R
MR$.5TN$T697G:QD?]G5ZZ 6X["4L!#O)P_8ZG,1TV69.:DY<TO3R*JY&KU69
MF@4DN!,,U\IY,V/Y@C)"XA\^?7@ID%:7\?@*8O9.1(7C<'$?/G>? KP''G(H
MQ1_%DK@(1SPPS1N?\05RMW(RM)'Q!=^=[+F]*[Z'T]UOW_:F6<=>S[FN# L4
M,#/&V 2SVA9V?PQ=]K^:T.IL5"-RR[ZUCC)7V9.1?IITS?*AS%?[!>S,[X\>
M.OA6!IW5Q[#$PB#"@#>U2,4NP*3@3)SMEBE0!2IL-9^>97M5==/XA1@T&;PQ
MFL(-N-9,]I2K,::5WZ@FV>H5' ,:*8][^%/Q7/S,&ZS+\;.I'DVHQ(OAG-'L
M.F$8@F/RPGGHYVDM);G+&U/KRCI29^MZ]6ZT/L?%6KVO[/9@<VW1Q)P53%R6
MPL1M -^_67*&CSB=)B"E02I5CDFC/#SAL(*#%Y%9N$ $[3B5U"E/U/M8J7$E
M$O\]+;<T5?,K<CDU3\W-_99$)<!YOV6@B?EV9R@+H!X73-3FX[,SU_CB?BL^
MS\I:^X4)*5%#_7;WMZ$%3T[ ((?&A^'T^!);0)(MY=58=D]R+(ZK15HFECP9
M#ZCQ)!E"Y1]3'=4Z1.J9)])J3D60<NV87BEKE,PV;09@^6K\Q0W[AP-UG:3Q
MK;"/O!M?I3.JQNR^+:?B+U9V9BS(-#(P%XK=[^^TO_:R$TL1_](FI\:J*MTD
MI8>:]B=:X7;]NRO?8U55X/)AQ=_ NAL]>8Y:, 2,D)G,1O5$(&MZ\E]I*]>7
M(^[=PWI+]A59H&W5&G7FDX!@G%T%O?CMV])ROC7@5?C+T?<K<X5@FVB!G>J<
MJ2=UQ6Q)ZX8LSD,2UVYY>MRLZ^F<*CPN".1\S75\HM?9DP?;4<ZWU4V7Y(C=
MU*6B+F&!U?RD:1S/9Z:78Z6\7POV>T8()M.:5M32$)$;=$4'"DX\J,)3%6#Q
MN/]Q'TR<-2.# $R\A'$$Y8,SR)"WW",%JSE!N"$/A?B/(&LO!U-Q!<PZXF$S
M0Q0]@"7A\+3>R^-L5]DA^$YFRB6 I<,=/,6<25RYGHW Q OD8OW%GC/SPS^9
M?>O%KGH4>@1YTPKCOD=_V#YM!OG=DR!!:\$#6AOKCWKNR4NH' 2B[9A+^5DN
M/\ACOE^D@/F*C%]6%^T>\M!SAEH)H@\+X(H1!Y?S/ZGV7HM!QGRV!VLZ,'UB
MUXXOJ$H0XO%H[$T#>?KG,]7G!N>D4\0V@V]&5ES@H#7SM?#M3&:CCMJX)2-J
MN%XK%+(91,\I L#;K$4JT$W"K21(7152L3&.<(6+#?Q)AR_=!&>TN=$/2K@,
M>[)'N22$"N$U:.\+N<H6VU?V%,V]^*#]R,G?>,!+"TY[\8<BMEHX?-7!.6@<
M3UN7O*(_Y(R"#PS1"SYF>O,DG+SA[XR-=8';^KM+-J0&JV6PM26H\)"X"G"D
M8)+VAA!S_ 4"P! *JK2+M!#ZI"VU<>\#\D8M(4*I^5!JV%]@ ?S!/S[XS%>B
M"+GI)\IE="4H'4!X=UI^R.8CU>0.,ZN%5>CM<FWTXE=%"X^D!SVGZQU*+X1=
M=8)[:PTYW[MJ/R=3),6BFO'N!'U(!J@'>ZD50VQ5+N*+ LUOWYDGWA(/<LR[
MXGSZ!9\WRO?H4T:G,LU_%ICZR1DPY*DR=7.((&2C1H2+@=94T)X0SL[8[6NM
MJSXPM.L0<%G(0D+F13YX+#*_W@365^U&XC'&=HG1NX<+OJI(*UXW'7[R==)#
MPV%@#>V+-5&(W>)X<[=FM#[[(\WB;H7J->_[5>\3A0:#;V)S4M7(A1FKE5!O
M+ =MDP^2'(B79-/K9Y40A\<58"2$7MXNF5,QX]6N=$?*NONZ#W&QS=]B/1@(
MR8F(%_V SQS2MKRERQ0R%1M:!'P*3!2]P:#VS$0'_X?)O_O/C2R?.AK] ^(7
MOVGOP_)?4+B,#HGK^T%.HOBM:"GX0F9_%!>1;3Y0EJF%I(T_+PKS%-$H619(
M&R,2_18:15Z9RT&7CJ:_(*))6NGA'Y8L?G?U&PR:1P\21#D37U@B$.GB[Y13
MTY[QHH">]US%10>/.6%%R&K@QP(^F;C@8SDF@>;Q0#(/1\-QZ^0J]'R@Q[.9
M%"S'5\GIIL+'HS<.20Z^4E2*?_G#.046G%ET]9:.1[!+EAP_7UWEFJ./?7D#
MQ_:$O8IQDL\K:DQY=XL 42 N(?E#+$6Q^K4F%:&G)=&:E+\>%E1-"1%NA&*=
M>I!O!^=#S\&)AX&:S'\SF%.?_Z/34D[T6N"SMME0EVYJAZORVKB >3!*9JI"
M9*I'J'6XU'5YG+V0_Q6K\.GZI;6#R7"0J,E(U*B&31EPTL_;S<&G2:XT%!@$
M>"\Y+FM&$+?R#R] VY1U^?0V0_@8/9^4H1@(KIX@0TY=- 25QGO?R316GW,I
M'J]Y<F?2(]*8W2=H\G> 1'-""HNDCY0A#%<QPW<59@N\(NV>"9TRY3490LC5
MJZP\DNA+YD==JR@(5\OV:)P?\NF]LVM3H4O!DH")T4URC3O0)%A>*(!.>MA[
M*R->%,)3)9\<#%ENKC=3MR4VLC]\OTB0SG6"(40<PUO8^& 0RPM-Z1ZX0EQ(
M(I<-,'C,%\?2WO:E[WER-1!+=+/P@C[L1\G[;-#3'Q\A!>ZQL\G9)^_ZEZS%
M\U\1AC_>E)1-]%66/L\E"5* Q.YQ^ )@=M[SEY&9S*,"XX!!5KBEV##$#C7F
M<4<48J1 &2=&7M4#:X@562)W5OHHB.8K2@($ M#B0L,8)*.\9(%Y4Q)73K3X
MS7PL]P5PKV1:K@R8BDEY43CBPPD-Z 1".D_<17-A9ZB,4OL)"^;(_LJ% N8B
MN0R)2JF'W"&,BQ>]C6XDW%F889($L1L$2C:^N/CA>?V+\G7M0_YA7%!&M1_.
M\"PU37LE,%<;-&-EGV+2'N>U8&RC->^O4YR #IJ9#YK5W, V*AI!4('!/)Q+
M$59%@-S8II)/!=F0OIRUYKPUD(%;VXN"#5L07V9&5A8!:,)U,:1[T[U(P%9G
M]=@Y5K;:]V( U&G0ZA^O=Z91)0"V<#5F9+$03AB2_:+9_>SO;JS6?)H<0*:D
M;R;^H:5T?*;!MVQTS'73M Q9-!O( A4<)]E[[<4E_T>9D4+,\@23"UDM1KWU
M2O*2X6H[;?SNAFL;=@Q7T6'O3$)QR /@VQ6]Y7K[0,I5"(PM.9M3.]BD >!Z
M(=#(SJL+F6;SUXW9X686X,=J';]2F^3L@K'%PVQ<$W 3T020"[BJ2S%\'L]U
M886+N-\'J3]" +S_ZR"9/QL]56^&\5C8S;.#UIC37A90V-'FG&I$D4VFRJ#\
M&CI7<<GE'-+/FVC\M*CO_^R;_^\!7 JV%#-__N-[UANNY;5[=-7YH T!X?OA
M-? ?)N2';6,JRFGU-A>^BSV>J#"..;N:<%R3#R*9WK)OP,_)_UQ0=CCJJ-=_
M_=2\Y$?B2X<"4+"OFL/*I%N# FW6\RZT8_7J@%*Q)"CCI))V,3#PZ6 3L_SK
M-WM_>:WBR5?KW+5.U)X(NB@+!*[H"$R^L%3*>G7Y\78\ZR;[^@I;J2Q3WE##
M%_[6\+0YQR;2.\^MQ=9U"@JIV]!;6ZEQ4"@]7&H#GJ*TLU>%*9U[.&$R\EYF
M]P8W//AL\WO+HY\?PEYU@.1^#UPFY=F=" YG^5\(X$.ED^GY 8X/PO_#E';3
MSLV46"TE$J$O.?1D1NY'M%PB^/K2CK5XEFV*/P(IGE&QP1BM(04,M.^D&AI?
M'R/WI.=U)"G33F^X;J_#ZN[Y#71C9ZE\6]?J>-(7R4XDF%P I*FTQ<[4\W<X
MGR6Q@ZO7]%<I'\',9T)+6"J'8U @\M_N^D>%BT]^:9BB2-$EX4TSR=A:57@M
M&X#MJ%V"0://>DQ19OF%ALJ2*N@UP[DI;FY"7C*.A3$#694G]^I+Z[,S'52+
MC,T%DT)!/$P;2L:I@\NRO9LO:XBO9)@JF7_R83\5J]G,J/OR-HI=0O>&4WU_
MF%"1;3QO1W6D."9D%6%Z6]G'F5_A,IIF^/A>.&NP_(BDRW :U$)).FV%MT_@
MK9ZLP,=]"7D(ISIAG_Y EECFG:!P^P_T[1(WC9?MQJO]\E>&M^7QCW7$C5.)
M:3Z%A1V/T/@8N41?= 0+B#*W:J.$EK?>L:C\YRG26M"Z8-$?BPJ^CQX=HL!K
M8']S+\"$'="2X]H6]\:_WF8<=.X3Q+XDYTB"PBL$-2K',(VM#%#BB*#8D[Z@
M:[<^#-]BE<!?L"J_JH;-#2$W>_92^6G(UUZ[J3>F5G<X&MSG]Y0R^7<XWL%?
MEC5D@LK^2\'Z-2=+$_8=4_WXJ8HQYXK\E^+2DT7&MV1DED_Y_32^E!DTKSXV
M3D&?8^>[=L>6NC%JOP_J8G[W6I"FJ"VJ:NZ8JWPN'IT8^MR9L?6D(QL1&4YO
M59P=29":HH)%@5?1?A#2F+^><5S=,G"*6T-C*@L3OM+N/=NCV-'A6HD >>6[
M\$>S.NH;O'>WES]OL)P2=->TJ#;&+%H;O/$;Z>:07]I8>N5:22_^Y*5N H[,
M35]H$1X*ZS[YZS7Z]^$N],@_?E]BJ2Z?;(MQ.%:G")X\'6:T@?K(L!63&,S,
M8\*B+ VY-2*%<>]!#FKT>.U7,"[8YT%'5 -;C]\N67&M:[J)B1JI,)1**_QZ
M52'_5C)2S?;?QSB?Z<_;$JC-:1T\;:X=:C\^9UX>(_=331*IC/!1LK]#*;3X
MG3:B/Y2^E)(IKHA2:.,N?-*BF)P8_"5+U3A<R^4%:WENXGWTM[:FF@2?NUBJ
M4M9D:/=*-481MW^QX"\LWJXQOX4K.:PQ3:>=&XOR?Q<(JV'-K$D(. ]14=+)
M>]+6MH\ ?GN@+2"-R[-18UF3N_!XCPF7\B1=-+,P;/S=Y6ZSYP<O=05XTZWI
MV>ILEWAKH-D2B9[@J;RT%G/2I+S .LWZV=);X:X#RKC'Q.Y7RE98RTZ(\P,S
MSVMZ&E<$!.K'+P@,HF&#2BPY(.PV:A/#,-@"+!Z:WH75[/9-)?'LI"X^G%?]
MTJ!"FJQ2$RG=,4D_P@J_%4)V(=Z8-,@ 23&/]]7]5PE'#7$W5Z_&67Q@,5YG
MU;R 5%/8%:]J>8D=?6CKVW\2TM#Q@]+-_6QJ8\ 7X9--9],-0"!>"G'-MXFK
MY=65T0!->DGX'=T)P!6/"LSVR%%G'I*I!WUM]%^BZ\6&&NI"4BC&UOOW73N?
M/'?0:A=M'USM*E#UPS/3AUT]-)<O;\CWNLO-:^YY\./RH6!X(+\5U\Q@6$:+
MWO@5'C>T44?R+38/>MBS,H_V^>*8NEIYYSD;^BGHM!2!S?.$A%*^[TTXDIW5
M]V^_<W<^:8^Q$>OB'02^:D5B#3'"DN]N=>+0F?8QB9Z L&MKGJ'KQS:$AF86
MYE87&^!T,(=*?33*AZ"ML98G2VL03K$K*+S3<G(D6S0EEQX\ZPNAWK9W!"7W
M:@%V'PI,;O=<!-90$C:/^E0[*@^9<28E)0M4&V?0'<S]T.K4'KNH5-2LQ_R_
M6_R3*34L45]F=+WB.9/7GS)RW!BC,YO.9=#=L1;H;?K>SP'ERR7&9!WS3FOY
M=\\&DZ R"E;:?^]L,$CA7V-W%9/4AP.R?X?<A=1*982E[?YQMM*-Z!)G*0C=
M,<B#MF.%0O';PVX+IE.(;C?4'0Q]*!6E>SK70]+X?C 7U$*SY/(;.\FE.+$6
M!+=Z#(^J&$W,%2+1D>&/A,=FFGU^TNN<"*%U<V[5?75W#424 ;(D$51TX37_
M9NG65O":5U\NI:'PZ-YW#)M/L"E,Q>%4NQ4/(CBQ:'WI %<J^+N<!33>;)QI
M<XIY4QSNTUG0 ,+K+GW/#8<(\@T_&Z9\@LOMO7_(J;+R:X:Q,G(7 1;YL,UJ
M;^]P_1)@Y+29RI3[OEGW6F?#!1YXI]RN5'W^?[F/]\$HG@-EZ]G&OZ_2?-A>
M^*8J//%#>YK-:VC1:K@>5HM^&82U?NKL'U&YL4>QP^]>(WD&=^::,/'!#)]?
M0-JX8GP0@M9-+2I*K^<UWI/,,B'N2*4V03]H*2\? KZWN7*O*;S)0!1J8V(Q
M48EWE%,+#^U6B0U&UR]RM*YD?R)$)F?U[ &W[)0&ZRH?S(NU>0=A@>KS^:A=
M>M3?J@!DDRN'8KZLYZQ)=?+?CWFC/'V/OGS0'^F36[Y2: E%,F>CX:WP@_;/
M[%!P0V7!"+7AO2SYS@W&LIV/6$< IG.'7^=-S;BB,$&@Q)SZL:IB_"GE\$JG
MB7%ETDF'3[L"ZF3G)8=6XP?J)]S4:\7K9IX^<,M8W@@6K;6^$>_FVUCFE KK
M-GE8]1!2^ VJ%I4ADHBY<]H;*(5\(T!DVX["=NF?%[BS4-_C18R#27Q [TQ!
M@I;[&X+_!C57N?[I:%0)59A6K?/FT;3_[L&15V&9<*'P405R"JOM9W^J';$7
MA7R[2 (M5L!W[+C6J7EQFI(.'L.',[$.S86;TA*LJK#\[]K+092!*I%\A7]'
M]6L5=QU-%$#(*G097.W"^\=SQYWM\@'Y9'N_7W5YJ;^#B8!@T7I?K OK8^O(
MC2S9/1*IO'U>*>=H1Z:G('5"II&PK'+.V?JK^7W;RH^9]@",5Z6(JLL-:YI9
MNW<S@94LA_#AF 7I7%E3%Q[)%H122Y\\"FB=*NN)Y&X#6$2V $<46S*T7EG@
M/H$>M0D*<:7NUG3CZ=8Z^YG([NKYTOUX*O^W9%HOQG[47Y$'R^K0N8C9:WG\
MT?23:?@B6:WG9A/MKSV1IU:#PZ".QQH(1DF_$Y"2X=I,6&C_YXZK$2G<2BS!
M;7?>$Y7]SE^7QF 1;PKQ-2TQ"^?("),E(9+<6EQ=R<IDX:_V[U#UZ\(* REO
MQ>D:)PD<78O@C+F$*2/^[:"9/V=^VSI3=PR,"L,VY<D2;'[Z,6WJR4L3XF-G
MV,]_8SIFYO=^52'G*_PL@A8)-OLLEQI^3[/#JC2$'[P34\VEPD\OJIG9<PSX
MYNR8X\JI($Y;+D.[<,59?NTUJRHSI9NT/R)._;7A#'*_H%@M9$8D>Z!F3K@.
M6@QNI?Q(S?]7_Q@V%0,2T/<BB;^Q3>@U6$JLY&HR&@B[)7UFTV#GW3A9.EJ6
M>\-VMRFJ1H&XW5(MXM+F^V.K@?L;9M@=+9*G#GX7-D"S<.ERKG 0:57W#-EY
M^&.QD7I-FZ-# *[BKD4=!>0< .U+>GF<X$#)'*:]0O/2 X>;XV]LJTPKSMWG
MGUEO:S+OFA&C(_T@-(W/3W-#9!=S_L(49]KL:MCK 8$3&?O6'2KNU<@O?9D
MQ8B'?5 JD%6Z3FFNG]+@<\Z4U#&YK0GQ9I%O[KW9: H6KW78=61Y>2&%D#3I
M852N[3<2-Z(AT@A22T3%LZS\;L =3PG'853=*)"COKR #,+UVA(O7L:=W5G9
M"9K/,]^4LOOV00-$&D(()Y>Q+S_Y+9P?GZP&\66T4IHL4$^;O2>E=*V>]ELA
M+?,553=*V$,C2L8K)BST$%1'#0W71?+\OTE@EWS/H4KP<Y[!KD.V,*]0J%-\
MZ0%II',%?1YUXK7]W5WU6T*)U%3K+) [Y?4_K^T@XY/EA*L)WXQL!$N^!.(_
M.%\O.!>3=VULG]^75GIYKSH\K5W](B=NW,_:M@91.OUU4O)N8/.(")"JJ/*=
MO5BV2U9:[.^VE'3@%_24AR0[W.7X(E^2$%.YG*RYJ%X<SMQC@E!.?NV,GHBY
M:#HY^RCM9DJ4$*4SL]S!)#H-SN156I6@3V%5U_0DF224:RN3LW?X2'&*$-O'
M7T1W!I[(698<R=A4/M<Z^'B:OA>NR?'[#2,HRGZB]INZQA-T,M&5 (D78($8
M4N\ _64/_4-]./1BN2]#E506<BHM#V'%37(>Z7?"?7&SG^[<H;1RS88#U:WN
M+!&S9R>B;V,*\R_KWS3:AC?:(T?O[[]T[21_QN]Z%9R^APH2_L+V#LW;=I!L
M2.1 J)G).1ME,,%=I_U1EJD%2L2O,MZ"B7ZD]LEMA.315V>5-D^&&0CH+-!<
MIZ+">"'R->/VAYZ%-I19=:6EB0X@.WG8GV19"PQE;%#8ZO-PX['$Q03D->$G
M<3H4W=UGZ'NX]LK(/&S-3-=B<+3GQZ2P$K7%)Y5+MC-4'XI^ '7<.M&\+BO<
MOC=79XJ+-D0+)[N$+Z<>(ROOE-(7P 75M@6+.BHE)(?0HH76TN!1(NP_3+/5
M)(>-**^\'W_=5@0+86\H4[6_!*QDN6&5<-I0FGHR@9-.U['($M<!!L5%#=>O
MHW;#L?KVJ63/Q/_5W'E%-:%P7QX0E*)<1(A2I21" HE21*H70I$DU!3 !+ !
M A*0WBR 1""T$!(B55I(H?<N2B_20E&"H"B(%%$I*GK]OKGS_E^SULS3O)W]
M?,Y:Y[=?]EYRU8A6TI$\OE63U7 _9/;!+%Y.AO\CL&QS](8#B["S<>]G2@-I
MT;/;_^Q1H#N6WR@Y)4TF]3@R("4.Y)>0$.\+T\$L3\J*]RM,^;>%AW.%@(T'
M4WD$OF1938=?#?Z&/VY'GJEEZ9<7B_<=SI1K]>C9@@YUO8G1;I0[/M;J1[H8
M5N),J1]9:GQ3"R5C':A'DO=4J4N1(TV2A1M/ \8A,\:7$YS8^,=^U!IQY)/J
MW@BRW^R8WVFSC_GCLN(%%=[(C(/><7BZ*Y&ZM2NDI.Q09%,@EKWNP!H,"$ 8
M_!7H7U&TV!&-)-7<]0W6[\CU<OGS+88!P$S:-*QCUEW+7 9$DE3G,!&&V[;5
M0YS))^SIZ[,^YBEV]TS42JJFT#:AEG:T=V6QAC%AC)9YYF)WD^]NH&%$HWRC
MC8=+B;(+77_I\DN20TC/UTM(O/0!_7#_(L)'=Z'LU4H-7L3 *C>9TW]E[L-0
MFJ!W"\&1FH@(MD%B/AWN:Z;/>^1_WN'MQ]!G_\.>#XQY'T@TJ<06S^RX?#H^
M0]SB72[S;/KE;9SXA/::>L)L2Q2/40PLWV;$D9.<57\ C5_&)%=BNW50N\Q_
MUU8>:-L *:PI\3-+#]HX..5T&])9;):_)C]^.?^*S\7S.*C_@TI)WLVF/S87
M+>:WPM,MLGRYL:+)6RCJF["A_HL()UHQN!#D,=9!EI".NEG9<%\^ "E1AC*)
M&.P(>U;O6.5OM@*8*(.W[^2-^^43*^=^GKY(]RUSVY8PV[0WH%L]<J^>*T:F
M!""JT,Q6H?)^AC/VIDR.8J J6M1(>/#/1\+C?7;K=69@[N7PYV4!XJ13+=50
M1]>EVBV9WR'K'4%<TI9Y6=^_GJZI*@;0[**^\'EC%;=88N\NJZ2;B_!I(:62
M[3U-H_=N6/K@$PIZK"T[Q8+DEB?J.ZL_I\Z6Q3)/TJT ;SIS<&UL5"7X-)!P
M-=(*>9_WONG9(Z++K=Z;)G8N4/:N^N9:;^N;;" JL>.6[_&VMBJIY1)3#G7N
MY),4[,1M:$I[QY %49(74<.2?USLP9@;OS/WP=_*;W9T*V>DU2^3MW..7X>S
M]J&;,U')^WQ=YA\7;^=]U*^\<H/1KS5:#5H1AP6 ]XDEM^X.S)QOO=]IWAZH
MD++5,PR-3>=S@Q0Z0)6H!ZFH8"'%3TU\-Y:9'(M?7OU#94X%%PB)/;C\#D%7
M6CYXO+*L@4I"C*13/RT];!IL1->@*OIG[;T9/H3FU&Z7@%]E %1CX%7:8L)"
M( -9*TQ(T-\,X63,S5^MZ'&D-)7?+"VF9&@P7NZ?X7_,6MAK@:IU7L)L ,8C
M#)@<K*;,$$3_M][RKW"=RE3G]3EKU5QLSFNF?18 )P*MLG>*0&T;@?24\442
M:1V[15$ @_EGWM]?#70KH#:Z2SZ@.0=7?/HX;S4;QFW8MWK\:UB ,L>217%+
MIUL&Y$7L/-/$AL#-U!I9S.O+>A-8L6VLO57SR">3\*>9340S[LX?Y+UOKM'P
MK/0W1<J8F/UN>:3\E!-I&G-?=XB@CVV5XY(X:F\+\9DZY/YV[" M+_3K:L.F
M<G(0SOKB,;W&38-:SXY?+4IV2?P_KAGEA1&G>_I-4X\>X/H0;:I.3-)&B'Z@
M=*F8PZ*SV^V5G]U%'"Y7\]1IC+]7C?<,1FDX76WB"32PXY>[R$^]\2NS.Q^7
M&R+NV[\KE.;=8H/6KI%G3 1=.10%U%;'*S^T8JT1"-HT;=7G'/Q]M>06&(-
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M> IL1$/BZ5O(!<UJ8YT_XH-+EEQ.Q@3U6>(?Y+8M"$SBPK/D>WW$5C1"5]/
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M2:7R<0ET')RHJ#@\>;FQ_AAY2G=FX=% GFYBKH=ONNB[WG,<HCF5\D5_0LK
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M[0@J:04GLC94"Q86]FH74_Q>A6,X*S5Q1(N4VW![YV_<!RA:TS].]=B3X+&
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MA,F6Z,U+82V/(_IQ/ 8U91#N!2<G3_!SW$?#;TCC(NI5)[H)O;D\6JS592^
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M.C^G"K[1(PV;?/]^-7#Q]F.]^X5564YQ]OVZ2DW4_JY-,?+\C2'+3ZN:PI$
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M5Y@=XW/:FB\\K@4G-S<7M4.VK;LM<5\S)>A":)Y$92A$X3RW\6M0'%([B6U
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M+E)D;91>\10;E"!_[F>(>\KW4Y?G-$&<8"KZ&POYZFU:.C\BM433-A[6),E
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MHN7,CJ?"Z_QB)/A;OZOR$/%*Q)DL7D2%5F;&-][9?82&^VYB,\=0X/D-D#O
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MX+\RV%/EY_'YQXJ K68SQ&VB86S&)^! ?[M2$1BWV*%S9=BUL;Z.8@N(]5#
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M* @C2Y22$JHGLG]/)0% WQ18O3_LLJ!=A1>!?C )IQIEL!KH'?(&^"YL=U/
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MW_%1H%,$]$6*_7<X&2$?DM128YG_6H?F50BJW14LA^)YZ=%Y-PHOO-<*;G$
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M._0Q_L];?K,]#Z&>I:Y6_W"2JSIC\?_<DG]YOM$DQ-#3!Z?]+"RTS\;??@"
M7H,B6I!3'B,D0&1]P%SGU%*1 _L#_)5"![EO:,1+2Q]E#@O8T*;HI0^<I-8B
M?CJR^"IO<1@(H(Z,5&;*:QX#>=.EO&1VJ[OEUUTJ AG_'..N4*9ZAZJ*^T-[
MUG%[FY+^YV]?D^C@ S$)HB?U\Z$?M2+OH!8?HF2D?]1N4UXN&CPA=5^/',_'
M^V$]U@MER,?R_*4S-+!%=FA@HI9[EQCB9W=6=3"MVV3<>U*(A)$=<R$Z86:
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M252Q")Y2ZQST )]&L+Y 0R;U&W:1TCN\8(B>;U<.6:RKVKD]VD. 4NWF!1]
MUSZ +, G-O;@*7[_<?I_UYQ)ALB5@EZWR2FV=DUA2#>=;CI2S]S0HC\ KW1F
MU+=B,!(7@XK93R.=R 1!&F%-0QXP3<!.7R[G3.]XL/_,1D@6<0&-U#JX[U!U
MF'0<.$RW(# 0_1MI6)X&(VV1&LIIV]'R2, ET[J#^TG8RF[SHRG9\V=.ZL>I
M+RBF]MH?<1?KPIJJ_:W7&MN_M4L/G-R1I'WA11:ZV;Z=)=L6RJZD[;]%<EVK
MMEBRB.M-*G),-/<ZNP@^Z/$IP,<="_BM)T_-A0QG9R#=>@.0CGGY/XNW^-3#
MG1EUZ/<,PB:\4UICI:QP:EJ>> ?> !P[K<CP_OZ^VK3%>HQ!/(NTF2):T38%
MM<H2; FI."PNV0 K 9=1-NJ+O GS"L/9TK@?,1.NY6MLRN_HS_DT5J!S*&2&
M5\)^LR[U1A49(NELG=NP5KNTYH.:'2VY*E[&#Y:B,_BP04<'3BY2C#:U$L=6
M/'76$@*"=\@2]5W-^*1AX;>$=+1?-Z2-)#)^#!+-SGXAT7M\ VSR0=\[5M)=
M(3%HO8_);P74C?)FW,DY>X=!K7I7AA.&ZG[MN_W1-_Y&0CM]1-M(*AND66Z.
M6H-,H7CR8_"#F?X: =-2VROULP))3,&E3.V@1Z*[$WFL>[OIG37[D@NSK96.
MR0[N*Q9>!KM2--?'=$("?726$9N\7X$8\M0;E/^D01/*.,W)9)BIH\GNAWV>
M:_0TW($60TY8W0TKI]K/-M'X#2LC'T=]K%UU3)6BU-3NS\(%2G-)-S!]B#]1
M"JU>:F2- 6#%QZRW25%/D0LPQ8'-9+B_(SR>'C]8T"",T"DIG0U<OVYB>J>@
M%%J8RG;D56^^8&<1YE#);*FOK3O6HV G*NM [1)D-9GFS+]++#Y/H5!J%> U
MLC#I6?_$\F>I\O_J["N\VO"Z+5.D!5HH3G%W$HH4EU*@N+L7*U (7ER+>TC1
M8BU.6UP2O!0)#@6*)4#1%)<@P><WW[?FO9FUWLQ:;_Z%?>_9]YQ][EZ[Q50L
MY%JH)XSH@FHD=*DUP/=\?SIE8!Y+#I[":\"0]$,@>_[FIZB3)@\]08^T@>77
MTN.^GE1B=81J^U*L5J5D&R&+4IB#]_MM?'5785[#*(K //YTEK&-0MX\KX]<
M8N_3%+FY?I;(G/QD<<!>JWOMEGWEX3VMI9Z!6\2G7A*\=/3M#@D2L+<*^UBU
M1XQ?FR'1996RE>5L1@(,C QIM+30J.=&;HBSQNE_Z5K>(-=MNE1'FJI/?M8O
MC2'6,^M0472]#>8_;*.TT%5C52*%ONC<'8 I!Q]V9 3VC\J-LY*1NPG5QZ7[
M#1$T_C->)(^\&ZRI*3OEI<,WP8.[DT1M"H[XDM4K<Q=I>Q4=E ;Q_5.TH*<0
M%11=ZN"I/(=-05&?,^[OJ.$#@&""0V7PH5K\EQ(TJHC=9K8C_)_6Z23N\>>[
MBH%+F^30N66;7Z,J$>\([@%;G07_E$(?^*8KZ9TL7OB0>&SWUDTM^AZ0X1A>
M=]>\=,-YVU-W#YA?N3LIOD1<*81/"*;= S"U]P!$C%FU557 8J*/@INQ1]]P
MK@M<JW!9(RQH3(XN/N%=3CX%;^K5P0:SV,5J)Q^_-/.ET75P!*58,T>Y08W2
M.Y^1X3D9ATS^?\?<)HVP/0\ $.!57OB#U7ATIR-*L$:HHFP-HI=X-TWZ+VA'
MA[JSM3%MEQH((']BI2NLQX_M5O29A[+M?$I37!?+EQ8FEQGGSNLERO.+LH8B
MG3I2(]L)=NZIW8ER#L%I<Z->1D6I%-&,*I"(2*IZFI>>+M'3% XW?.Y@S)_Z
M)$@@$ZX(9(<#-3QNY7H]<5[P_Z9&.V\G9E-)$[PA+(8WM=7TSNS=1^?6IND5
M$JSC$9%U"HOHL9VFOS[R>(FXLF77V3CC@1IWZ,6U;;M-W/AC>2$8^K(F. L=
M& ,U9OFF?'+HU@>>-@+W8E"*D'6%+M7Z>>")!P9$DT_W8^SGH5?H-E'\R&!B
MGY%,,V]O1@B)95=\N\=*W 230[WP-V6TV%C9.DS:1OQUSQ[GKH_6<<Q%)?VB
M</*A  (DM"HB9G6.S'@DF&,QK6Z0.ACH@F.0D,(EX+F<VHFH:C'XZZI]8,F"
M&9&3)+P2+$@-HT?)QYAS(I]_3Q,>0!F;#>0"&X(I[#72G=,& K001%%VL7'K
ML13N7<T?T=DC1T!> \'6YC6?R'ZFN><H]-%T]Q>S:VT;"D1W&I7\\80FW(2.
M2]_-IV8\(5\AYJAWRR)]ID*H@RI0>.^D9<;O)S>5HPGYA9T!PU,U8N%%4GRK
MT0W4Q<!-@VGK=*GKI[CIR4?4%429T5S_W,(P&]!NVE)!QD8L0Y8U0F+K>$#W
MV<&>HAV?FWBK>Y!MW1?>)]\E2PNWX0&IL#R2SNT>NRYW#ZS_L;4'H]"FPV5,
M^W1?_:ARW&?U9.9W7$(IK_OW&Q13&^I@TP_Y/8 @3C"?\:R^Q>U"X>CQMOOZ
MS*FQ#UK2Y\J/9<E_]$;^2+HC)%%;H6#+I.,;?\.*FPFJ2]'/>4[2$S0[.)OC
M)D[WY-E1COL($[]K;*@X!_"LHWE059]\"265OB$/Q:7##32NAAT-KXZX(4_/
M/2Y:RB;:9#^N3_U9. X0.79;M'9TVY T\S$1<@G;#B@<=W&.\VO^620I]K<>
ME8OC2J.DJC@Z.<@R;G5Q8M!U#PA[X+CRV',]1#)MHD$\P^IDV[^CG7?<XQ)_
MOU+HP$0F33!_\^=1PRC!:)_=8D7&CQC\4LY!\*M$)+2\=C9P]/JP2USCXKQ[
M3$L)AX"%]'6\G,(C%-G9P_B.VM=/69UU7T'_Z!MG1JQ1?\ADK^_C\:LNCB%M
M4=TS'N0>XOC\4*WY-H"D!?O=:$CB*4N/>V/C>($'F=?CZ<.:U=#UO,A R\!/
MDBC#W7 "R&J_N[=8&=NJBPM\&**0/XS47U8P"CQ&R)@V7+K;7H80AO@/&\_>
M:K0\2J=LE-U@H<PKE.6A4AK<.Z$DFB]P#K-04R-N*Y4BXBFOIUZ?*&['?E+^
M_N9\VK5MO!VYU.&P7#"\99BK([.E%W!&RU2136]G$L*%(Q9*G0=XH$0-<]*8
MMQ[6)5II,/H3H8 O=X?>FOUQ<=SVK\SIIQ'OZ*,FBR<OUL0')!-;$RPKD\/4
MCV(#KJP^:-V"5(1*+#.F)GM)/K?O^LOI=FMRXF'IY^9&0UP;^7[UV9X/52)T
MW<E;\&<B_)N?UA"Z'N"*/]Q>OBCWMG'\9Z -I]J["A9.B\YG\L*.P6(6!;XR
MJ^HY2E'1=ZO]Z6S6>L4"\\M]&SR^7M<5J>*OUB'U9;VEAX74OUN<EAV15C&W
MLGOSK3% H10;[L#0F<5X.CKZ<9_)03O["G\M/.VWLLZ #7/6!V[P,?.9 #<Q
MP3^D6Q:(D]( XPR;]6J@'5PU?V9T=])W+?VCQEISL6[O@SK0D\#MRD,I- N4
MY-/:E./IR,(#+Y^$A6DPLFS@D8WCQ\(>RE)^5(;^+VY[<\A%?+8_=8@ZJM6K
MNBLW>;:[>_;K;I@'S W!JH_S\?UWM?WO5*P*W$HIN.B>V_=H&T]1G3IV%-EK
MF;2^ "<>"_.8#&1BN8)<=1%;B\PFC*M.G4[?<5Y0K]W)?$4Q0D*6>XYQLY0P
M?5.\24\S3F'T[A[ _*(FY/KK:./1[>J3HH]2I5&/I-:^ZQM=G*0JKK>\D0Z#
MT1S.$<QO)LDV*7G+J-&,K"=&XIO))K\@,1J:Z]^:!H-)1DLWYW0V,77:14SY
MP)E[ ,]X84X09+WP>X#\ W2A0"O;>KS3;(EG;(S,SRT+3@3D1CKSTPZ21"K^
MPL)R?LI.R_:Q5VG'<)*.U/"G]P[832D5(7L,IJ'H[U<]*A*/^J"C8*KBAX-2
M4L=GF-.K&4FF&&K.L]!8I5'X4PAPBGK77:%.HTL4J:IVQKE8HOJ^>,WP56*P
M\>?WZ##DU?LT&MM4=KL<O$CC7%*N-PQ;"SYUG7.E=V3@[+UN9JPW^PI"KQ>J
MAB=6_3J)U&&LFC3@;Q?SZEW3M])"YGTB#M.5A2MN?UI[I0+&U"6(V(L+N:ME
M6I>2.D_BP0,*/*_@ZM*06V/,<<_R]+$K@HH0K]WU4-M'0H;;8GZ7]OMT35]'
ME8JDIJ-LSG%[8E]>IUC_XOEZ+MT2)HYY8016(DL< 5D[,)"C'EA.8/V6U.^B
M_JH]>W7@LK\!,QZ^5_5]U-0"&)!:3VOS*?W?KB]EM+>&UCV S/K\RV(6RB"N
MT:J?F)-SCEQ,[BVDZ59MDH.R\/H _&GO3$&*T.RR78% BH-DT_D6*E>AH+*I
MXMVA9WU]N%,7G+ZDV!GDVZ:W0?)L1U#E9^QHUPLUP <#U.-W1&JL:M+J$2P1
MNBA&#H;]@=LK_'QGDR#R3E[9(?5V0X!^<(24+E[$ETY20L#AT/^'VN[YF1)*
M0(07B(?S%(-'=EMBJ)S(_@$K7H3U)B$;ZM!SW'B"+TEM) ?B'C%^9B:4X/?:
M-ESIVS<W%.5)L1375\MV#OA$(XA2C:PHL1P%AF0X7EP]UJ'M,G.-]]W]N;@B
M*\Q08JVN^*>F .Y:'B([+OLG^6'_0( (K#U6^1J8*G;M5^X^YS>O-?:W6CU(
M?ZV9=WYTV.()L*6+_[<G1] XSF%W8E<!.EQ+]#2/YZL>#1%>V4M&<H)'>ZH7
M__.W>XF0C*'*2)9X TAR?+^P@9:\7B"6"*6GKZZ1M4#G)?7J'A"-NY$63C?W
M:1YL*=FW-[?:XVH%#/"Z9:W.)7\@XLW&GM.&[F!.<*<8D,9EP$V1D?O=X_%\
MX)B;3#/X,RG;%J&GI-DK1H*F^%#@L6-],W#F5:24M >0E=]+P-K]295VM#^@
MN&7F=0<O!\6B=NR<?5.XR:]>\;/5*.57H;,4'58WPIQ]2F9C'H^WVN/6E5_/
MW&@<:_.(QMH+S>Q.NP6/N=;-T.&_Y'BDH165+WR1.#J\99+# P,%H09\^C75
M!VN-%R963OS ?JH)&A#A[%0RJ%88Y]*$'J]CDH/$24W+IH1T\K4K<71T94=F
ML@O92<)(JYB4(CI]U\=Y=43#,EX_D^I?QUQ_6)F_"_'\3G3)G>)Y\Y%GV!HV
M>-/FF"6;Y6"!LP@,:JSX"4?9J4,R$!;CSW-:KGL,8R$QBA8.OS0QG>-M2C8I
MIY("3T<#YRJ=+9F0\V$:&98-U(&OP35CA1,_UM8O'K<\)?KETOJRU4$U;0#V
M31-OHC/,(ZTN1X+()"1,-  TWD23WS59)(JS$'I'A]H<0!D6@P(=Y[X7)A\L
M6-K26:V4=5FVH4S3&77=?S7D>L%;K&YS9QMWV%#F00;).?'0H^03AF31K*EB
MA9 _&V!)EUI:+##]06V5G-J)_X':W G])+/"%V43T?^N=^+/-?.U;'=MVGYQ
M'/OD9A$T):#^.OJ[-F52E@8]"-I>KANSPBH\359TVA#<JV=/C22.EG:-CC]W
MTB>M-9KG"U2J<E2^]E_I?X/"I,O%L1;J"^"C+3.RE2O_-:%$Z,PSGQ^CKWD2
MQ\;(M1DS(;+'NPMZ3#)W%MPK9T>^:D=RS24)\C^JQ"Z>^"1(N19@=UH]G@+$
M#H8'PU.>BV3?OLW$S%YT%P]TQ?[0T>H(TG$&%I^F54"%'^=R<C"F8X*Q=\>6
MQ@.W5/%BG!V!43NL_N']^W-8C!M9>%"A'G7QX+:76-*KT:"MN5R>"_9W)]]K
MT_1P@%77YH(FOU>L"M?P!R@Y[;*;^N"FL_I6(L2+FA86^V(M,T!_PG&H[I":
M#RPP['QW@JEQ)C P"?H(\.05I++A7_"U&4_J+;SD@&92.1=I7K*0$Q*N0-)P
MP\UY<7<"SRYK^=ZT/&#Z^(#W <\K<[>*>FY;#EX^QO8IZ(O2[U3$[HFDVO4(
MLR8',$VWCB;?1FQ4:* O/#HZ0L*D\I %[P+HC1W3T /@I6Y"&VL9A^7XMK?"
M$C>Y(QA$"T^9-3?_^S;;I)A@9OJCD-";X'";=VPI$M7-*KUKHELR^;:N'0XU
M7*.97]1>&:6C)OHK8)OW $8\2T,9'EJB2_^M@HD0XQSW/:=)^I>18=#28>"_
MM6Y4UX PT,19.Z+<23'W684#SDS\@7#IM3.8G_TEZ<-[0*:]67$9VV KGC5^
MPL>0+2[J=:>V:H8P>E($P'FMTOBA3OO>3OV/;:_V+,7$#VW&34J-7B0OP!&#
M;QEH#O?%?IGI$HDC(^Y>[N,51'T."8:(23SA/RJN]-N37/[CFG#A0<&BT+GJ
MY\&P3]8BHY:TZ+N,-NAKR<V^KET&T[F%-$G^(3[Z^U&(85;3A*4M,;&1[.UM
MQUJD5Z1?6)!W<JQ6EB:5!(M%>0E@J$3>LY/R._O)'!!:L9CC\J/^LN_:M8=5
MJZRONZ@\O"T6\5VG$@?5-Y#5ENG\'YC;/N),.=N=0M_U7R4S(_F3G>NYQ%M%
MF>\!#6-7_WVOJ6%M>[T"^SN6"/':<*9[@ Y:22^;["LN7+G3^'JC(Y&G;=.Z
M8,J;00G&Z"'0V7!-I%$D;!YQ90T3;PB>CU\<@'[F*;5^>V?FTU(OT\"P<?5O
M5:#^3N6V0T_N\9=S ]8R5K5Y<T.HW)\/T =RR)5[P#Y5.5JTN5>(-BHG"O/;
M(J"%W[T7^&1^+_GJN;FWQO:!GG[45)DD9]_N2E/U9L'ARG:CLA?55V._ZT/;
MP,%4P,E#>^T8JPS3RG5N$8.LXUX]CY9KMQ<;-.N>3>K$('<-2MM+NCX-GZ3;
M-2JBX/2#*4A4/=-\@^HKU>(! A$19TS>!K#BM^JIV7]$=P"=&,!9UE*-?PKU
M(O%AGC?<*9+9](/<M$!6[)QE_PWK"+V6LMY9$7AC_@ ?G8=/-DQ/0FJE/?S.
M&TY]-ATSJ_^_11G3,/;"*\)>$K&?ZND^.MPHO0<XI563/5A@W_,-KV-FGDS;
M;6/[3[NC897+R\5X9H^9VSA4T>=B/D.,"POO2XI.W$XL/?M^&\^3BY4B8J,W
M4=5D&QXKV\I&_%[ 77A!P7D$(=\^/<O3#7&TH?*P<6;XT_13><6-J)*S7W3R
M'LQ!;!L%Q'^+6 *80B"R7;W!\K:-2H=PPSA2@Z5.DF5,G0+AOGHJ H7/;7]6
MS/?A ZRD3JY[_[9HE.R )[?&^?_H1[0CI;A/F;;BO86_,XEKS=L=*^\ :SA_
M6'JS88P]5%^>CJOX8E^43-[.!WH^\>=Z@*']"BG;=U3*P-MYD7IGB?EM<_J?
M\97*])O IHZ)%*)Z)] FC5LT#/*4>$W=A[(SJ)%!Y\.7]P[2]E(K]MF4Y#+3
M(Q/;Z%-3I$"U5Z&3Y>6$&;<1A]Y_B"*6I"2(E94AYHJIA)5PQT$ZNNN _X1_
MK'VI^ES:<>#X?<8,O>-7O/:"G[XQ93F_6!4<]3E50S<A2*VF8>JUC&8 :28/
MY(&H[F5J?CO&)M]Y)0EAV:D1'@/2^_OTBVE^S[03I8V@Q$VJYB@F<\T_3#$S
M&1$&/DYFIJ.NHO#8C$_K<Y<)=JT=2?#)R"JO&]$O!FEVY3=2[ ;(;M5:T\0T
MIR8%'?T(JMTV'YDY.Q_Q7'VLGRVUDK,@R3KP/8JJ8R%CQK7$?<GIJXQ9RTS;
MYTJ8*"^PX]<^B\3B5-ZGC[07*ST.M<R8>P"!=Y/T&"+YTBFM<?X91KLS-"_!
MT<]USU514PQFX_WGK,TR6EE12PS&8-!/^(K<4)72$-EQ)9A\82@K@0AF2+X'
M2'I9Z(L\,A[@9PP<E\ENH/D$M87_+FB4 07'9SPF4O)LYIS4?6F2R%U;T$YT
M-A'HE QO&,S_"!5!Z>#729S8-P<,U[;L,K:B9WUC<S,](;W:\,Z;JE<9AF(J
MD4I&9I(VR2>6LI91J6AX)N:1HC"'9-9B[>S"/$9322<$5M"N H5KP6@!56?5
M&[%38L7X(H4&1[").64.BX1I&^43."8?[I]-!^_L1^5%>U/XQ<GR5_4V:!B_
M!-=L3V]K:;5HQKSV 0,94Z,+C\AJUO"I;$#(&?\'RX(2=]+OMK3%X ZTAM>9
MW^CK>T<%O$%S[04YHN[GUXZ=55\SA1WK9.80",?F5IJ.H"HM,H70\/>-B *\
MTVM?M,PYTG.(D2;/G3=VU2]BJN8RUBD$&[W@5F?A2T6.2<_77P;S 5GPHRNK
M6#(NT=/=*3]G)FYGG_;1Q()NE//.P-A0\0^^F-%<SB+ZE@WX0]\[KT]V#0W>
M<6[CCJ;#P#%Z_\J?[64JT!;#Q9(A1:;B7"_>[";TB& :1H,60U'3S2YT9($:
M#HI8#9-KL9\K5-SHX$_[XDBV!D)<.T',A1#<( /B0<V OZWJR<T=4TROK!UY
M.<L*^%66/V-7%!'Y2*#]H,4_[QOY81]UN+*,4&]'(P)>(SD,"=3(>;XL!=9Q
M "DVP]X-6Y_> Z2BQ)!T?Q*&G4E;S/&?P&6R"8ZLJ*P/Y'817"/A%$PJ?^6T
M'[DDI?VYE9\/3.7R&ULSF%.;.J0)T&5JE'_G34%FFL38^NY]%7#0Z_<5CUN3
M](P!UWI1Z-W02MC7VGZ:VMVYU<.!?/XBLX"3E<$)[PJY-09QOB6OKJ&ZXNG'
M7,T.XH\.O993/."YWI^3A'51W'J,V="368<R,&O%N_3@0A&:_'41NN6%ZJRJ
M.%Q>=K7W3T@I&<U?T=2^(5TI+RVEXN03^/@Y?3XL&D?R6-*WQ3)5 Z=-;6<"
MM)$JNK&LL*,_UB\C,$ Q#)/!F0/U#[?(#/1Z-@ZD@;VGO3ML[)^U[!J=;//]
MV74W8V2S('DXV;3O_)"<CB.'L$;/([=[9/PXW4S-=@<WVCM_P(9I/:0Z8J6Q
MDCCHY)A>6\^I*/WYH*K^DE6Y*(PK%OGHXNNI[TKAOO..!RPY_[.3#)55H*!N
M!TVLHZYG2'NVQ,6S4?>P7)B].*IAQ+5S_*D :Z9RRVC.3 7T9%!#F1BR>L<X
M'=B ER![<1UM8P\)S$Z4*)SM/_S82D.R?BT#HW_'./U\$)AS0Y@J(1:ME.G]
MD;&*B"6J/*.;2.V<K4%M^L-U@ [+GYM,!WO.]9M&YC&A;3[]9YWKXJ;^>18U
MG,12YDI_G\HSM&[+3'_INEN;3O DF2*6BZ\E^C?I_DQSYE;:_0M1DQ]\RA4?
MI/X!WB[P8__9[P\3Y ?M\FB:T:%OC-]X6CG%6R=@N=84WHH\D+J];OVMC6S6
MA]#/2YWSU=R;+RM"+\X,^(N$[7IC/]VA.<-KH?#;]M"IO2VGE.(%AT]++8>R
M_@$N"6YPF<^Q7[1"VNA3.']#,H1WH,WD. KSQ;BR%X[[QCZQQ7^2U$^"Z=S=
M%Y<Z80"4/:%K8\.O4.0GTS-91<(6<BM+2)$:\$-#-8X+]-M@JLH/JYAW<%C.
M^K?(D()+QT([]\E1UX+>WT]"*&FB.J$.5\/$04 JR1W2PB5LL2OCN>]?$]>.
MR*BZ;U=,(U[GF8FQ5- R?]4$,5;N49_W^+^.%%;O =0V>P=7[@E27E=\R E/
MA,/BJOA',R/A\^$-L[6;$"^V348"$$B)*_'GQO,,DI-=!57"2UBMJ/+:/8 0
MY7]$[A[U8B"EC6,=G"EJM?ILU)(\6)/;^BR8C(>_QP%2%T+*DX3R&170R7XG
MJ1QO^1F)O^5 X9UTK%?-]T"M56:B:AG%1L#V*L(MC=4<HZ1WA@3V>USZ4T@[
M3>2HMBZ=T(JUOR]4YT V_)T\=H66(E?2&>!#FI*"O6V<_3RL&O&Q^NI+#[2O
M5]%S1A)(@<Y'J(WRQ?]*&TNDV%$D[3QA?N"CC9\B83XH @).".4)QT+#1;OL
MYEQ#2/JKP16=PH4N-L<)^Y-\+($5@1?+7UVWS[;/MFC0]$>:NQ>E=QG=3_&/
M3/11];&>*B]\>_*]S]HSX4CH@=^>C62FL'LPQ#$=;2K4VI\4J\3="W^L26G>
M!;P'Q#=9)*@FB3U.;6"<R*9PF+.XV*3='M:L-3&WB0_'/;/ >GK*\SE9<;UU
M7Y/9G]&61J#L([S?NL^1_9FJ.7?!F"8-!J9JI<C[@4.4FK*7TTFVW:*XW)QK
M49\<X=3W@+&UCVGAJNM]F]R<T07/D/0_[@&43%7UCV66/PG]A:5&2HJ!ITFV
MF=D[K.'%Q ,KR<B4K$EW\1=*6@B>NOYLUKR.;^!R*0Y-?12X%% :'=D+828+
MH_5>RY=DEH_S$JZ_IMTV^%!^#VB]VW2OJ%CU+$);/.)_*_*=H418>4#;XLU-
M',0RRB/%N1#$F<=/Z.SR%D>7N@OAP,I_ /@Z[NZ9W4\[MX:+=5M?"K(2T/&M
M%2QNM[I@8J@.\5M B&OK&=-Z"+]U!(WE$O7RF4+@\79N0S&P_$!WH(XH]0>#
M-$:)DZ(*ML]W[1X%0+NBN F# -AJ-L1I&ILE;_3L"4G)E[QQ_2[6!G/05#Z1
M!^Y@IDL8)0,1^(?HTMUK7N^V'DU*3A%&,ER@.%!L?4YRF\%=N&Z<_.KV\TW@
M;N_7S"OV]8?US'V'%3)I,3[6<=AEO)I'0W0;<O3;P1F7)M![P,\YAJ'>@]VZ
M34F.O#2&'_T""\2?;HGSL@[FGF4;-9/!P;P+4#V&Y?R@K> K8E((*/@P>TE#
M_L W2/+/]T.\K8,J$3>BE70?>:;W92,!"+I-$S6,0WNTV?ZS,-&2APN,S8U4
M@JIP-"U'Z\G,<'Y^-CA1MIL@PGBZ/$32_TA1Q$-QXM(B9M;X'M#&WNN=A:4H
M)_&!S8-:Y2BFG0Q1H4,AN>]:7FM>NJW.(C,;#"Y,6&-XU%)(%Y8U:JJ;;^2W
M>(7)9^PY7?Q7]KX6!.8=M_PMPNF#OS:A<IRUKO0!60X=79/P]UL*0N:%!=;8
M/#0;:4=*KRW[RZASC7.A[+VD(-!BN4RK(/5,1G].N;K".J.\9^@C*W!)6"W]
MH*3)L=O.PZ5QTVSM.5=-.8(ZK34W^VJ0QC <B5]GAQ%(51\TBM7H/T85OYCF
MC[9\[U/,.7'LDL(ZX @_)JQ4PP7!SB;.C5[=M+\=.N[^:5&^RSB=]9S$\N?^
M/Z7R4$SB'UI!9+N-8U+GO4QJ1[SR%;YU!2;;TR3\.N[?><*[)CWI**QO)[?F
MZR(N>]Q=Y&E@H_-UR8,@ZAX08C*!>!,YV?5,C$A5_BCU5[7SY7(+P3R+6T!Y
MI_39-489_ ^68/B/YM.)*>!/M+#HXQ 2&'; \K+1VEU U7.^K['XIDK?6I_6
M3N2!L\5$6U/3%*%!DCI.?"6,-CJ,Y?:I=XV)X_JXV,Y<Q>B(S-!FNP?BF/X1
MS^I%R(=C,5%'G6R/2(<D?\/+CQ81HW'99.4:/<0RAA ZGWK9B]^*F:TAE[@G
M-LG2=A$W3[K)W.>8!95OE-VC&:49_];P?I>TQ>')WTG\! KZ$C/HP*IAXZW;
MDEW-]SF+%%GP1_,'C%13.] [*6,.*%(8J/+;3:<PZ,UJ:K;4Z V5MSM.SZK7
M@=Z@^,+SQI#8V9M8]]8?P?A&/[YQY5?!C$$BI6K0DTTY3%H#^4YRN)[S/AW3
MT#D99"2PP;<CIS6YV(W*O-584#[S@#G!:K=H>9O\]\CSUB3>*.\-]XK+N/2C
M+I]U9]*-46U>K_4G)F0]@HTUY_&3Z<3($'X&'2O$%)26]1WO<(%49!^<0 2O
M1SP>(K++G<PO23AJ2KA&O#\Q2^W]WJM_K@/][.:Y.T5;\;:/_ []DS^['_UJ
M!'?,5_(+"=$6(94I(< +YI%#[&;LSZ6S$24"SU58+LK-@$,[3,:S?&/(Y3'J
M#).*+KL:_G0VOG31X_;M"+#Y78<+<56VNJNC\\P#?XM!><C/I)7.A,QISNTB
M&L-0P@=;XF@5?"@B_"1K(J7]07QEFMROM"7&Q*PG7#-(OM1UEZ>QGT* S,T'
M!1<K8V&).\7_:@S4IU&9W$A[%+G,K4P:^\1B?!=[UF/%*5:UH)%W?LKU&MZ4
M<< Z:S]V*+55J/%%OJH?7=;%8:$Y#N7:[Z7F;PZ4W>.H $^F;U],LX3AF#7)
M5%.&E/<05/O'QPW(3+J0+%4#86Z$@7*KMX4ND5(<!$;^F9)(]6'\ Z9PL-)
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M OI-<B\<CH>Y=1/FP?-SUI9H;=@#"UK)&5669)-TZ$" 8.QZ,8//URPZJ21
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MA(K).RQ54#1 M9_H!Q=@=4S(ZLTA,@;!@V^?G#N^OO88%"RL+GW(\_WD)?#
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MXU0.&?5 ^ Z:T G^C+V*6,=&JLN_U,<5)D=D%B_*ATIZF_&QU]_\<-J;YQ:
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M];V![< =TPQ+H5?C5,O@OI5>$OWW4">_!RI5Y>U,VUTR;J.^> L.HE-1E)F
M>X#LC[T X&W:C7:F>-W4&?$SAR\%%0?9R"H:GCCWJ'2*1Q#3@&%9@8:8G5GG
MWT/VV?1:J1H8+7RVR68!$?#0&V@8#^[77Y7TK/KU-8O&)?+7MF_9A$/6G23O
M >HE'KZ@$>8A9D$!J7"3V?-Z5'/6PT6-PEW1:CXDY@^9FQ3-V4#9@E&Y=$H[
M],T3%*/S]\1MDQ(M#^BMNE!D;5*_5#GX"'RE.2Y_K/:,,MA]K+[ ]R+DK/7#
MZ[:(#333;&V,^?+/2_$#F5Z_TRS;&#$\PZZW+KG.+0$_U)?I/EM'K\:(?Y5B
MDDZ=TEB<C+9O\/8IUWJ G3AZ_*%IIOQ0^!Y0NVTK]2E)@BC=\D5\C%8ASXA#
M605469^PT+:E+?GYCF6H:[#;.XDURZ-*+VQ]T;;?:*APW6]AA$#]=[RE7T7T
MBS*[D5B(^\=";,+L\IU(T\^B9#Q=E#%.M<\YVU&E :E6*IWMEI&C/1S,I1>=
M,@Q:,$$ZA^D)&AO??-U.:#@=?>29"OGTV-4)[]RT!##BEQ55Z^]HKA@S;Q&#
MY']5LX_CS7EE\!-<=0^P6F:11($(]=P:F<7/\%J'1314?F2<61P&?*$<7$?6
MJ+&1>"H#>V\AZK-XQM9O$CT6O,]V,V<8MT4[$]3(4W^1T4G#-'7"^M!2)[Q/
MU?$6R?9NVGY67"]NOMQ)Y5[<NJ#=*;!R;?:P3-P_K7B.Z,X=5;UIYV-7$S2L
MH ^ ;[\?>390UM#]DER&.Q.>LV!OZ/W(-CYL@G*]%<+P6A ZYC8%L0QKK]':
M9_=N@GSI8R=*V9Z*0@2N1*NO:M>F_EF>XJQ*.IX3"!!(</%A\?<J%(U(,LZ/
M6%1^13/D>0/;W;\'S.6A]K^DDN55F!J#Z\/0[)\%PANB -ZE,?.KN V54DSZ
MXO;O<G=LN<T6IL_(YYW(234QR-E \KGR[_V$?KJV'MGN@SMRW.<YK )CZCDY
M6[2L+#7&II*33#S6:TI$C\S_U.JW$6FEU/D)KPX^HK3+C4B4_Y^7:W#*\D_%
M;[CSSZN4E]VZPJQU'GZ!+@D@RDU_K1V>]C(1W""P-4>/=8]>](S8R%&".*+/
M6A+D@R<?1$1$R9O.#[$2#N[0&V392<[4M?H<T3]/%><8JIUP^+-9Z#[;%G>;
MV\:T>\XJ.GUV^X[^P*-YT_(Q,N<9?4=7\FI8'\Y992I\C):<;/1)0D>Q99;
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MXIVWT/%910[7L1?P@!0H.?S(,2O(X=E17M_5Y!J0-^1+!Y+^XN.([^9>(.:
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MRN([ZPB"A0LDWS#&@&[L\'PA47@YU !PTY+VN-D>7E YS7Z0E'<2%ZPP@,_
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M:%T-\]T1A?-F2-B.>,7.S[.2SW6T5$7J4XO',[<Q4/HVEI;)*$1U04='_%*
MEH/CFK\!_SV ! 8K'(0X%T*2<@=5#JV2GAOA5U<0L.THP125?"=Z9F*&MZ6]
MT?B=(FDH^(^L,.EF?JHM0;Z['SX1E-%_R!2!*@PZ,KV>]P"B@*?&-V\QFC%P
M(ECFU@;Q@CX]!/)%ROI;^"^+P >D7DP!GR!=9\7 E< ^U;,@Z7]:_(]5??L]
M(-,+%+X482;)F\X#-#&0:O:V\/\]PGKZ5T E ,MRHOK\41 @_6+_<A+G5,<W
M1+Q@29Y82<P;2JEJH[>63@X"P*C'7KDCT\E0J0#0?W=F_X&JX3"2E7E6^OW*
M0AH+N4[:VVDQGK*D8_KY#@FN%K?&\]TH[XH_>?$:'K=^VED\#<"TME>8^J]E
MGH-%LR(R2H>&HJABT6WQ 6WB\QN_3ZUC*UE[1;F[;3134*52>S&WY67.K*&H
MH)(BK"K/3>DVJ7\'(_DW. &_I\Q+Y#F:$LYJM?1YCG*YWI'O8U5]S/(R1QA]
MWW0T'HU*-LW6=)^$@C(CSDE?\S73UDB9R8X?R[71B+#/M4P7ODZ'!;3#BKRK
M80RK:Q!8HQ)1^_<;,KJW(J=PW4%D+9BJ:W8N*V%=#9#(1)D8M<^W'7']H'CG
MRKH"7F@R9]:3B#3I^Y3$!>#^HTSP!"'5H_O=U_B!,9C*6NV39\(+^8$MMP*M
M)[&6'Q#?;O!F;#"R524WSV>?V[:,KUZ_^^8JP''H4><<=R #>B[[_IP@,*(U
MPXFRR;U#+NOD1H;G.R'!"'UA6<FPBNNT=\&BU-';1[U\(OE$C2\BI'L'&-9.
MJ0$MDU/2:_@/5U:ESW*L2.:V LF'=N7)_W=O/^07Y 8]IOZ/R&3KI9"HU0)W
M,VYL8 &VQ@AS7N[%'OE^_ "T,;E!BUQUH_&P7**GC+\;.*W(3!UJ9IW&.7D1
M>::I,[7ZO(A7[(6'Y$P"N\O(TT8[QH>+E-3[7(F)\7,SYH19%-VK"B*+!GZ.
MWT]VY,V94CC$AJGWOJUV$,:VE(]E]\+$/;9(NIR?"7%*+/\A#H"!-V:80AA7
MF&,D89RX&^9$2)];C\"'I.IWVZ?^FJ _'BV"50TM5*/4W9S2W^5-$@+G3RL_
M8-?1Y'50PJ/>@U O,S2?Z/:SU+F,06X>W&")/[_WM\WB^!+MF.AP\9WP\+C+
M8\)M"T%,QL8^Z#I;7\97> P9D0)R.IH :#?'+-P]&QNB^3MPGT"NOE8DF$EJ
M,#HGQBA8@^)'/<T+)Q-^@&!F?FI]X9*9:&2.$397K7:?<T>R9!E\\:$]\5_#
M"AB"L"^A.^.*45J#0;+OS36[/SYJ"HVAGW!/YPX2VHT%65U!#3@GU!YJ$;O]
M^4/P K%[1XV##J!K:9G-P[J6?FF?ZC8=L7/H79M\C?D%JZ;8W%A\$#<L%&70
M5-3N%R.ENCHG&LQVG4Z>O*WS^<26&K#SOSEU1.H@3IRH\O@(3S[J(,[<" N:
M,>S?3K_ 'G+2OW:@%C.O+*\T9JYNW/2P#W,ADTU$G+CK_%$Z]F9T1UZ5CT)/
M<VKWB?KW'#FF2]T.6+4W*(HVXTHJW A>,*Q&S+<[NM_1/9J9KV^HFF+J]3H_
M+(<5S/63S_$-U+W"B7VIPIM6+>\]*H68T-G&:'(/L5,./L,PQ%'A5Q7!,HQB
MMA ;3[]U[ B,(8K6Y8'/%Q6/*%L>EWZ9=J9[D]A33W</<#HQWW^_/S/\>D+E
MYO@)_L!^_#AB4O*\BG0S!*I<1_<,4LJCEILXQ%ZM_HR=ZS!39=.4"ME?8YN4
M1L[A(I"^681(K;3. X&/S5I;F]X@$E**.NX!AFLXB;L=P!\ :"BD!!*/Y>G!
M(!>'7*PF> M4]UY:<S\74Z\P39-BYW9Q78![NHZ5@J\<SS(KG#Q,7UQ[+3/M
MR[Q<3Y*"F+;[:'0>YXOS!0$.S=7["XWERZJ,7W_]ZZL'P,O@B'(K#8L1(^_&
MTU;TPY4'RB)-%G>6&28K>#\U3.U[_*4'@8PCB>>MZQKKP:@39MQ9:2$2V+@B
MXQ6?#T#/KBPW3"1&_#V;CFA)$*#?K^9?F_TO1O"_0M.:%T\&/*V-SX'6"F^R
M_2JMEN,3X\K+6/?U6 ;>V_SC4R436]_<]8!;?O$J9Q$<6HR*MNTAQ/S5\_<?
M7-Y91=WN#Y=:N@HG\.V4O1%>RTHR3U\%X^/T6Z@@]]-=9TM4_LV.G=+X3;!"
MN)X\;F!Z*N#R1]F-QCV ("O2HTKD(LRY;:&@O*"\=3CY ;4OQ6T.^\<!]P;!
M(,"< G."O]:CG4S.:FR*;ZG/J-?4_CV@2A?VC9W/$:"6 AU>/91;EC/QJ(1<
M\SKTU-IKL81;QE]-@\(2(27($4?O!YHDI54SX7JCKO*LFD?G=T9\-YRSR:]4
MP"(+M0DF[X[DA]:I"E((Q$<%S#X4__6I!(VWB,D49OR"T(E>D9YD"5ZILE@9
M_^Q2#6>("QT=5V7WKBQCTJQ/6!9G71:+>/6 C9.[8<5"-QZ9;_N4^J-7%$#\
M-)O\9XL2FNT3XBHLQ_O%5T\-4G[-9*4PXV_E=XN%HOR\1$6R[FU"T[')XLR(
M,JSR[$;_:FP,&R1ML-QFHC8R.W'T6(FY7#2[@HW$I9U;):YAB]SO\)\TLXC/
M _.A;6)OC3C)AOU<>PT-@_^8<)+H<EE(B(_*I=R, -3^NXU5TS#1ZHV-7&;$
M\J,J]]NIEN"MS0._%:C?IW!D*HL3?)6PE&>I0.FNS=9B\P5:SYHDTVG NA0P
M243Z#3_V-A^J,U/A,2#LZ/ZF/8S2A6WF]/()U9MWN,5L#UW-^:',6/,5_@@@
M59NPJ<_&CM'SZB,V)?"&?74'E<R7N&QQ%CO<0X(--3TC>LEZY0]QX'HZ;>3K
M*2WN7JHS[R<XV-1+XW/%9D=^='(O.3$VT+ 9<0?<=NOPN$XK371YFI%\$<\>
M?DB^'C%Q6S*[BQZ+:2'$&+QMR^SBLS>8.6MN5N%AIZ5=??) DLX-< _P"I)-
MCU&*IYD(X2$)^Q"G4JZ?IE\-AR6:=A.['@\^^3 VC0BYZV,5G(;SAUW%!K<H
M26FA W%V/OCXG:O)WE3U!4ZL7Y"ROO+?'_%-CI9EP?JC^_<[T3),O6Y+LHD0
M5*GQSX]A5QH>5+2X<ES,Z"#9_OKI\I=S973:H]T)50/T=V%E>*13J<=97^X!
M "@AID:_<1K*G?S@P.Z+6XHGX4LZ9R>&&"E$29";'<[T?_/$P?\-W^$?]*=S
M)FK3EEZO>L>#<<>>3R3"=:LZ#EPX'XRBWE6F%MXVMU"*)J2V_<C%)II,4.H=
MG/&PB"")Y?TNPZ>]<>/-1LA[8XG',(L^>_:_*\-D^\]7H8N<7TD28->6%7:X
M%22D.DT(X5M9!9:9_=;:\(?LDR54Y"Z$VW<TZ.6'M^7"<E\9-Y+!UBAS:M V
MLK:4-*;&LZ ).:JEE895@:8;)$"M,)5?I%VO/<&I*C$/W;;8.K+L5)U>9A+<
MC?-; =:-?#L_1HWCS],V910<)]4UAJVK'"D^<;W2"T8IO"B JA5L!3!B7:]-
MH'(3 10[U6I%.[07*CU-,JV[BPL*#_I_KDNEU%%AS>"'<G"#GF]WC#<LT^M3
MQHSG9=OYV_&Q+8C'&9&QV>S_F.Z?60F%_QNA(0*ENU+[CAYWRU7-MQBT??3M
M9<6SNJATO)0NW']E1GSN/.[<;E,977TC..U<(4(JUH,$V9]_6)+X5&\G(&F5
MN79:'KBPTT5JJ8:U+5RN^>>[EWU2Z9TLU4 R1_'!A ^U\:=*T8Y/Y_4\C9_;
MB!/5$ZC=0I1;R)5OX^^([*[*,_9C8H$+Y>M&3S^6O-WTD8:VV<JI7\"O\]K_
M7QCU?^'MY"3S>3:1 >-&!D1(2>:V5K#2<"U%+WSZL0YR1S^Y,[IU6 S'[V?Z
M*^ /J%[A#2LFJR]PX<5J1F44+7KC[]M85<@;#420LMF,]RJ$K%GA%]1UQ1%X
M[GB;+4M1V6WZ[DH"JE0\^+'$CA1Z(3#H\/H@#4)E8+.W$20[FV4ZY6AEMS'-
M]RG^'0-[BFYL1VJ5L^\CM'.PW8;6H3(J?-L<@,1^0"5'WP/L8Z,%H!HS^K,\
M&LW.>]C-Z>5Y9;WZ%3R&-?+1IK'@<S_@O\*W+X41HUY\=8*//6J+9T\]JUP
M'2!'+;K_/)U+%]B, %RKHW>8#)%J^89Y9A6;@(#G6=2#DCQ]N\]>#5A+/(1!
M-LP7@+HM1S_Z0P(HMNET0']]VDYN!=%TW!BC_A.I-?<%FKQK.FS7N3/![AT
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MR_JG(\;YPQ&K.$*MP0[.5]R[-\?E"'7X>1!7!VD*^=4!6CHK_2Z!.$C^WG&
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M*?8K;0%)",@$"H9H@,%V_ZGP_VKS3^Y 4E>;"!<'%R<K!S<K)Z\&![\ %Z<
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M=+4_M5=3@KI?Z[^,S27@DI)MVZFJ#].XBV=Y]YYA#54R)9#DY2P33&M.#&\
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M.4NH("7.I)ZF.CMDCO"Q(AAS 76EPS&O!9[!V&"X)>0%+U'$G>:H1VEC84W
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M+'3.3*%1N2^.K:NM,P Q'SLD%2FX89J2F>&,EZJF:$N=B?#*'SKP/Z4I44W
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M+[N@L1?/QI.T37GCS7A1X6)?J,JU+Q4%R&K:,%@,=*7E1;-)E8J'L$,S9/.
M<2)TNHFT7V1YY)&C-3GH/Z-IL[27RNO$'TWZ$VB6XA3$5J"0F2QT2F[323M2
M2?%_-D"QT.!G+:?B[M0'\S[+>'IH((J3WLI(.]S?IWB,*QT3CRJ1',MD5P([
MKQR7+=6ICI,0I">O ?LT/,#T@;T#KC;O\_IDZ#Y.Z$ 6HQX^5"F:DRUXP"+C
M65<RJWP\)XK\0'HL'!$*P?A)LZU$"*;\0"RM(<IPEQ:.=^YG8D09O?5V1T8F
M1SP\H*ZB.,46:^2<G@ -5HM?/ 8)=^"@!'?WFV)WN :3W8/-B[IZ]RYL:4HF
M!"9YC5A8/*11B@.*\"J*9/_1B\# P8(&K""VZ?@Q EPS0:9YN**W669ARAT>
M3N:9Q2_,(3$"&<IY'AE5[\THHV*>S!TI\M_Q2D,I?\KX2&0ZFZU 20*7&DL^
MMJHS6N?%D)QRD X-\H[X)4 ZH@PP$!>YDZ3/R^=*\Y7>KK6WT>NX7;RC#TOT
MDS/OE^IZH6F67<_3L?+/3LRV@!S7+Y_'7I;I:8J<8B>42=!4,\&GZ55;@XY0
MG9H&R.SAHG&:6K'C:JS;*A* $>4:5$8KH!ZVG06 G'2"-3,2]#U@#L=4C@U%
M7J_IV^B</=AUF%>]>!J<DAP*/I<A$^O@U7OHV'^.>%6FSP.7!,\.9I * I=^
MO[*A#N6R$SCJ4TQA8R%\29^S[$QN<]]"O>A-=HJ'E779/E9ROC4Q!=C<,4":
M*#I?N,=!3F@PO^9K1<+;ES4#_J$"7Z]_/%XQ[ <L8Z5A9(;/\$.BL0WBFIDR
M'J:LY<..QZS\H$BB4_271W5I)X_/ML"%!8Y!%J<Q+-Y&RIK=J]7N&)JT37N+
MMA'QVZ>5X2Y,I^3.AXP%_!F9SL0*W%$10M7(%&0\-KV)8CE&U'Y?>C\6$X6@
M).4 V$+R]1*[:+&9;&)8Q[-=K4I9B-L&9<IV1? )'7CDF(F;0?2N$O31;#6A
M+(VJ(]EG T!NG!A-BDM 6>F]Z<X>N"0?\A*,1WH@_$.AT1>O]2LMZ,U<K60+
MEU?8")R^RA@X8;*\RU20?B5NC4Y#8?O82I#^J;URBY99.6$4,V\R8:M5+NX[
MRPRZ)+0F!AN4. *#FH"#2619F+=+@OKA=EF3:H_PCNRZA.-?^_4G2LL69JGQ
M('K-,Q5FR<K)WH71Z/N@(=\;8$>_>PEXWBKIMY+-UV[.]8S1*;_H-+,PGR+J
MR;J!%QW^!'0?$8I\;[UMRW40)0:S3?W[$"HR37HV6BYM8Q5*MK0$LA?JT<,@
M7GJ"1*#5"D?(L@T+G;IIV2,L9:]R;L8%P\E*\#1V/(.0R:.)3B.#R3WM(FFS
MRKR\0C[D)'47-,:]+%NID<KEX7!:VJ.-B%D?+VL@4'RJNJ3ABQ"YE3+S-M#R
MT24@>X0I2KLUR_="HVSS*3\FI6#@G$N:.0.8MLVI9-UR+YMHK#@@46Z@N#BH
MGZK [2,1N\S]@&C*1RI&1\=!4BUGN0Q&J\^#/TXY0"H,++]JN8@]3P:U#9>:
MOEJ5()&3CXFJ?Y8F*U_C]SR(V@LQ]+.@>FEO/:<G!4ROL\3_ZN.\O]EP "V>
M#C5KBR+V'M$*-8,J2HB])93$K!E[M)36K)74%K-B5*E-5+5&[%%[%"VA:I:@
M5-NO]WWOO%_>>>^\_^'>SSGWGG,OI,N0UI]J/)7;;-&G#.8W69-9Z<0F4CM2
MSR]VO#HJ&][?2(G/Z?&&7QW@+9_PE+>W:2SP8G-]N9+@4U.+?P0*1;S-DM'-
MN\G0PI& ?L]?*JM,@.TBZL!ZC>D[41/D'>54QD_.6C2K96(Z&],C4I7BCV61
M'V,KI:G#8K,$RF/OM3WZX!SRCBY?LL:?P1Q.&LY1%J^W'-L.['*1CG"\0"ZS
MMYM;==)<UXO&NNQ_M=U?2;_]+Y/U-.XZZ&:>G__$J *M7K%*3_&@.D;A+X(J
MGU1[QI<;X?I[6.U,1?CFS[(');ARXP7C#73J;52?@%VJI5@G+P%"LR(<I5J2
M!IF1"E0%+>1J:5?%;.\^6%8LZA&25&9O[K%%C21=+^=@!UPQ?Y;%?(,@)'@)
M8.R"^/G=B:XZEI(.OYYIOZ#'>5?^>XDQA3OC _BV*?1$-$@A+5/T1,.PVL1,
M:T?D:'H__>380Y3N;]%2BH:#4#+AI]6QD4+?6*8!D.E1:#P%9ZEA3J<O\-3G
M.YJ'JN6< _4= V)L-KG/(K==/EJ=60XWIN@7B$IIR=P3CAAN0 E%OB1;9#!_
M-<F2EXY@7V!9#0^BU!!H?X S<;=<S;!2W,L8[5+JV2#OO1K[+T(-,EPWS@]H
M%_\UX72R>9(GT^],JSL2(O1$QC&O@?S"W"7=#)885(V4@(A8? G.^.'%ZD;;
M8_?'!4?T(W4A9EJM_;6V2:I>%')*2(_AS17%=AU.:Z$X:I!'LW9IGP"@J"3(
MW.26.+#;?:8B/X&[YXBC5M0\]:9+WM\2?=%_\2TERA#ZS)8Z36JE>,!_1M9-
M^-FZ@D2VN9AL1;9WN<";1J7L\N>I9)<<8GW2]'^%6$>UR8W_CH#S?FR=38,J
M-2-N<LL1[#R5SJ[L.7.VM6].K>;<+$^[JN#]WN*5?_.AI$&4&<:IA$A+:[J4
M<$N&P[?!S0)/0:D/MBWVP]3>NOOK_NZF.#UX(-1IV!/\M6;3(1XVSN=IZDCY
MS5ULV:^>N.FK0RH;;D9^FZ-P(62EX%56@2RFRV5=.;?2LD3511A5F&1I.<=Z
M[JD?(,\'^,/<19X>S,LL?U8<1&)9[QW^S4AT?KE.7>AF@V_)*VX>2VVLE@J6
MN8@V1O"R#*.IK^R(:F#.<,I81(S0'^,BU:-WI,K> _V'F.YUMD+G+,.T8\PE
MP&-) VG]Z7IBE%_E[L-J6^G3Z]1VU(1ZO2@6F@84$O]%>AOT *JV.9;8?0E@
M!>UEV#]2=:G9Q>:?^K:N!+BHE==K\Q$6IE<HGT7!3TQ&'DS3II5;;YTWA>T&
MO@T*?97Q\^$_/[;<+P%[-I0;;?^,AC!-G!7]$1AX$>S;TD9_>G >-6@%- 2'
MQ6RA(0[!7JEW-FJ)V_86:Q[N@Y;1X$L .,/V&"3X:.>8J?U*CR#5L4K@E5ZW
M_HF/_K%_-%VD,*3*/B8U'A\/9W#+;X-%"M[OW7AP[E_#4VXUK9_-FF+_A.G.
M-CYNBG3/1K[]F1+5V_N/_?K*VYCU!#QSK4/B<8.P^I,K9]/E\/NNMVJ\H7LA
M15B:]ONJFH'?I6X8G)"G0S_&!L@\?MS4!A'>B@U0DDU/(']J,F'M'!MJDKKX
MSF'G>@JT3MZI@1)R]]O<]K@_)=P,<#'8P>1OUIK<R2(TTH(@G[Z #:.XMYY"
MUWQ5CS2C4"N3F=%WE-[+)QS_&N^JIC.+_;#T'.N8I>-:7NE8;'[AJG@R7MD,
MPVY? E[[4,=T69^>/</<_GYW>N"37H])PFCJS)L'1[3C[<.6+@I9_TPIG.D\
M)[8,3Y&?EE5< IB&-/J^2_ >QA=/W(L(';"2S[ 3$4.&/$P:Q_1HXS*Y(JQU
MJ>(S<O"AT[T[P<VBI.>U%1E=);N$NI*B-O:KTIH.3]J[S.:=-/A^O;!)L9X+
M%.XK5H"D=-8%5'RV^,)M*Y]GV9;#\*#&PA@X&B;EG$<',T54(YYI:2=^;/>B
M;N"B/A@\FA/^UG_0W0P%?PMW]_C!LH:5C$(D?[L$W+4<Q7U.'> TG=[HNA9S
M-O/]V;S@$)51M>YD,["9/6)V &DV17T)Z*O@Z:LV$K(9?96?/A00++9EN\?=
M,0\['R[.$I2\!$#G 6J T+W,=N<<B9WBPPJ1QEN1^,Y)#/T+#>C3ZM.$">1;
M;_?H!?58-E=]RO0^+JA2'^K4J1&+LDS*M'Q-#].Z462S;RJ0OE@E$C8@),=P
MWSZCV6:6H&]N25.%/\#17 *B!/]"$LG4AYQ)E,:*)XZBXXP>EE-#]5'?$ '[
MTF[,%^OHR17,T$LA29@G@X5M(6NF **JD(:!(\SV!FEO;LS<J+3'O\-.X;BR
MCN"9!V;+=!N]+\I!!8>97F']E,';A:Q#?UGB;5WRJ7J3Y?!BO47^M8A%&<Z>
M ,\3%(*WP.VU=%J>5_T8LT]N$FG%CO<_%K65-PQ,"]0N^A5BIG&Q"^:XT>K@
M>G4^WK@AVU,*%"_$,=Q84XIEO4EX[N>=9/3:P'P)J4^>*WSF;,5:J5^08":%
MW+80&37I&622?40'E'GJRUY"3IK12Q?F(E57&A1+L];!A^3-5.W.JS>H1FSM
M:7E?,;-G+KQK(3=V=S*L@=X]?9V"R.W\E&!,>"<\J1X)1,>C)Y1W&ZT@.IS\
MIO; ;-R0!L)37_+ A,^7ON&WRE.S9 8E^O(<8S%X_K3(<'X9\87YC,%<K-&,
MK<LH]^0.N0#=7*!K[W4$M:_S,7&7-85L&>&>E]G?-\>"Z6F!G"HX6*C< C+L
M[NL/U5DPK[$N=_T8IR3,'G/2K+<LG NV#;=4G@&T;V(/?[N/!IZW#$0T7>G>
MW9:2>.V_HVLQ:X#,JS:"EE>5.;D"2E(WL@=COR[K%>JFHVV?.*C[:(C;BD^-
MP;=UK=BR,YHY#0D6-*8W-CBC'_O1'6J9#7?HG[2;0(DUJ;H^VV(B69_GU<%
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M%N=6FM9)PK>*N9ZL#X^'/O0:F:JT/MY@69(!/A#"1^_CM(RBHVLV;\?P[WR
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M#KW((<I1)@SJ"T6A./']6;V1F+.5O0K*62=6<[&1>>@?&PSD18'UK^0_JTL
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M,JIY?4-],'Q-.V,BK*31R8ZPM^N0E"2X/U>O@]S9)T[>:#K/R='M*-#Z.:&
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M[Y)=L-#^5QKOW228K"9$"T/Q0SXR(3J/.2*F@E( RB=)3!IZ[U#  =!&88&
M"**5;RL\3] BRF-.[0*+L%2C>+L:D5.)>UJLH6ZD1=!:E$<7[D'TAJ!%*:%;
M#$(!H[$]!X Q==\K(JL]Z3]-W1)>;PKR]2(OQ+1_3W)TMXEM(%)RHW_6^L!
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MDWNI@R&2DW)Z]%7GNU>08(M-UBF=8<6<^)W'G!4W991(MT&AIG&"0](A>AZ
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MY8EMFOGT1*RN^?3X#ZF-[V_7R5._1O0ITL8!.S'(84N]::-OL8U61([9][5
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M":B*,%9"QABU7SX'H3XF%F&J K/U=<#B%E[E-J[K&!BC(C7S/]6.(1 OV2+
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M"T:-6\N/S)M,Z=W))#]WWQ%SVZ7A9(G\&!H*%?3=P=JV=I/&CSD+Q:@3:ZI
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M4_4 _V?. ?CVK09<*1>1K(I7R!AH?'[M$/3;CT1&_;]%%?GSW+\!4$L#!!0
M   ( ">):E1]LJ]I2U<  ,6F   5    9FAT>"TR,#(Q,3(S,5]G,S(N:G!G
M[+P'6%1+LRX\) F2!92<17+..0>)0U*2PC#DF0%F2!)%$4%R%)6<0:)D!"1G
MD2Q)E"09)6?N@%NW^]O[._><>\Z]S_\_#R5KUJKJKGJKJZN[5\\:U]G'L\\
M0C4E524 "@HJB@>*!P!PMD9-HFT#0\#@-C!'.GXN'H"(G*H&.CH 253[]0BR
M/UG #2H4(P :);,R%2H @/RC0M4&H"N#H>87=9@OZA#6Q#LH['#$,MK(CTL7
MZ_3;792)793-GY<C#Y0+[JJCLRT4H>6"<'1!(%F,<YDV'*%K 8,Y7-10A2+
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M"[\ J#(_CC_*:'[%Z0=/<7Z%)OC+^Q\4A3QJ?X7N[_2[K/:/^O^VPD_Z<V(
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MXN$&2$B[.YJ#[,$(.@NPM2U4DF&CMH&!SM92DL%04(-'PU$>;&.K\L 9K/M
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MY*M@1A0Z39YG?E>9U!?SG.I0$*PFC-7B_=U<Q)9-61*GL?*3(AZ"C -9;?>
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M080.2]P:/<I_<2N")/88N#$_6Z.1$17K9!2_A5H0=ER5_UT.F&Q>:;)91GM
MF_W8>66>_ZJ.3/C)^/YQAF]PYW0M<^(1^R3: MH98 2EKWPZ33GHT#NN*0B0
M<PS\MJECT#:@V>QV QZLS-5)HPS A'&.1J[.U##19/G< X?[I5N&!W\ZSI0\
M96=W<>+#[Y*HW=S:-3C]$H=R GS Y)Z<73A1H"GE+T2V]QD]9IUS'C85-S:9
M9#HDT<!#6SU<];6F3^&@+[O!V[ERGUAT:S]S>GR^Q4@5>[)Z =(>-^G;<6V5
M\D 9.B7:MPX: /(2>WW?I3DVP,#!Y"Z J8B["I5J3F!XTAB'=E5*AY.$5R'4
M.Y;(13J3DH EW]"]IHW-CCM9SP"D45A3$FY:O6/R:["-[H6]Q4S(-Q)(2?E;
M.K?S0ORYE#UZX[5-!\SBJW?. +R+:03W4O:.#SF\,"@SC@VVYED-IDFC2ZNJ
M9E_><EXG77#4%O<?)PRW# NB8?$%[2P-1ICL"R[YQ1,GP.<]'J:H+T&[63=?
MXOF/(9(PWHF*5ZY<W\IO4&1//O&]M]5_;2*-12-21FRZLFV;W?=T6]NWK[&H
MX6 QY71VIRMAX9-.4S).EDLBPI.=R\R_1B%GK?L%4?&][)"9YG" *Z:__N3#
MC>$ ENHP=U"B1G+B)%/YFS, (SI!,C<&/SKYHV[>DU'B0>+6]8BLM9+QVR0B
ML<Q68$OAR3&S+UP%L2)1GO[:Q:Z[4E/VZP*]8JM$<'-;$R+:X8J,+<Q4^-7
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MRFE8F@I#LV70P*<6E9!Y] %_T5\5#U4]H9-W@.01)UW$597W]XFIHZZXAP$
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M<&ITDEU[SE3\79=E4\_>1$AG(63EDWBNZ_4;C,N1!+H\-HL@D4QG]H+6<-[
M:.P#_2T?FX&T3O?4A:CQ@8H/^Q#5 YR:_EW=BAI?&RBW@,77P=%M@^ 'O:D9
MNX.9=PM))@\%[P_F:J:GSE"W?/B&U<CN/?ZIQ8[Z567IR(L1_=7UBEE=A3K2
MY\NQ-G59^:RCZ0P%8F5C'$YP$9,[)@3N&.9B:Z.XB1>;JF,?VM'#'9K3)$P:
M'QIZ4J>>+$:%+>R:R-*$0?6JE&5V#J%*HG#+R-DL2:AECZNV&J-Q&_C%RU-
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MB^-2K;]&(J%VLT!5Z'F%V=0(.&=G)>&@[90>\#6H:S* _L4#%ZPXE7CB=?7
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M.^@:6EA+1WN&]0,C8\R)L-*7-:BP(4]VL"]-#'ZN&=P[A]%1F/M+T&)J['L
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MJS&!N/923_+]@QU[^\2E&.60<5R6N7NA.T%%QBH%-NNU@^M^9T??NWU#'U6
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M"OV.GQ[0!=(P8(OU@"Q#IRQ31D7DHE^\S2@.ZS4Y0+4T:#\M5RO4K)3FDUB
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M"U7G]'?B-:QD#L%/& >,B'8\8AM:UYJ^-L0<JEN:!<\)_?HN)Z'O7JG[T^U
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M(P'AU'^D/?6/7!HD<%$]CI7\3XC)_MU8S>W/*#?US^R=*UO4<Y_7J%C-]*_
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MQ."G\8M7;3N9@ZD]P3.A)7?X="6$?"JK7P#&VJAY=Z1RJYF@+'K+SKGOGNV
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M,8K&;@+^]Z*W]2^Z'"XIW&BN8!)77-9"= EMD6)YZ=E;WB/$&QU"\+1R2<@
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M?-]/7Z?,^94N(H.- :T9@@6T:J"8,=X&3%A $U0*=0)P-7Z:'FM+_O9CU&<
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MT\6BNV%!VXH/RV(5F(],WK+>%YFS:2HLQF^H9?M22-N>6[)SZ\%IEG(5$ O
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MO [V11VQ[GH280'#/&9E%6 4!0:^*)Y>P?6\DFY%'+QQ!6Z]D/)'R]NE+2R
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M3AC*R^Y[:)%NJW=+U !'8TX.?FNM&3_K Y17;\*!D8@=I;%D)=;9^FN0S^]
M<XS*/37N_?YPKMEE4YA6(A$) $8R'8[F>_>+FOT=YWSP6F(NHU4(PB4RRED
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M!=&]546CF.>=+)^H]16ZF,)2PTZ"B[<JA!9)3B1XV*,(;Y?E64WP>96T/>3
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M*=_/A:YX/MEFRT)L7P#RD_97**O]+CO.O\YYYQ49C/N%)4ZB?+FW"1];T,$
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MF(IS"-1D]RN.A,N^)(LW>1A%>YIF-W,T";6F_]-L?4[B78/K9#]G.)8ZTJ!
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M@;;[JHMZR7+4)FB[K!DG\K%<;HA%!XAU!&QGT*'COM0E.T;7AU'+H;FR2&X
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M?+TQ>&0C)G:YZ*L4(' #^'K!G=VDV7YK&!X3S2O>;7JMNY1?[4/L M1I)PO
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M9_"=94O,TTBNG\_D5E"+]7P;A==SO=*8K9Y,/.\7!C48P8H5(?I^>P2N- (
MJQE4M+EC052Z</CNT3Q;X7PJ4.%296'4<7G3C'Z\I[:4ZLA%VFD^_7W,]PO*
MDW;"_/^*'M*H]RD*,=F>5GIV ;:OW\)[;LC=_QWJ"?_THU?V7GUH7B-6D5^X
M8LF'G3<'(W:\$27V>)&K,RWT-,GB^I?/72547=_%Y)89?=&5.C:^9 MDY'HE
M1NR8;1LB:A6X()QND08XA8;/ZJ=DX$V4B^X]V]*OEB?UM+088$Z: (FA=S2F
MW*'A##29962P^E.=/MY'"9^%%F57\MQK_X.1_]L\T]G_97+4_]U4)&K&V6?&
M*Z-I$C63?GB9(S^8]DHG[H:MTS,>ZWU]:'O'_A\<C)9#>+VMAX^[+U,8F,KT
MEMH<Q68ZYBTF,AF09V0W';!<:37638=_AN!_$C-_M$ J;/:QAA";?A$T(G>M
M]PM]@ R%?:8Q?0MJD()%"+F>I7U>2,]0R_>EV-B;")15Q5H@8XR[VQZ(#OJS
M\2@JN"8,2Q7-$Q?U\_NY]_AOF2FAGXH:'S!_4](%JKMFA>+CR\AF3._\\Q?=
M#;V;&"C),89G4A %\0 C-]1)B&)S2D>[Q75<W;;_;/)QF6%:3ZN*Y,);".@:
M6RYKEC-/]+M^;33> ( SLY];**R0G\$13!5UJHT9ISK)%@L4"B8CN<6R1E#H
M.?,TD).?@_J3XX$>><6(:0KJ!O HI@D+*L1FW)N^LBI[TQ3"X\1&3?JU7*06
M>E*<TID9GNSE*06*7#K](*6VRTHLOF92N%%A?W(Y^ZKFAQ_ONGBOIC2(">T_
MBZ/.2&M.\3QO&)7;,:JZ:.4TDG)WVOBU5;K"]%:@Q,[039F'(T''WDM=HU;%
M18D*Y'/XGTLW4!-L-=(\^H%'WT19]5G]9QZF76(O#9 1>7X#T,1X]6*!&J7"
M: A(.E5N?"/ST[/WT$$VDSL4;X/!XW#ZMEC!1% ;-NBNIZ[)0HB=%6/QSMT/
M\A(=$G<OTL<(/92H-P(8L,T%WLTHDR6&L;(T/Z)2HU7[-VH1AB9/B')=6ZYW
M#Q4NQ@BS=<QN?9HD#;HW^02]$D="!KIDW7FZY>4SU^'$1S_7'+UQ@LI$L42_
M,%)N+>:,"\N%CQU+KL"FQ9ZX%W[TZEN(CJY?.!I=DV?.^4??[@;0)?OL'ZJ5
M'+G]QU,_DITJUXQ7\><^GV/+LY@5MM).O:U4_ZK^<AC__2LIW%E9H8('XQ4N
MJO$(M='57^O HC6YU@!O/LJMK7N=9KY@L\Y[SX>KH@S@.TR=BI)[8( U5VB8
M/M'WJ(,!&I7Z5U<N9O%R \;@A#-UWNX[JD+)=KF4O9:PSBHN9OC)PW2+QE+;
MJ31-/G_*[7<@Z>);VSJ;>*NFQ.9%K20L8[6$IRZ+5R.1)TX(ELX9JT3-F/T%
M9@9#72HG9U6NX\(D>Y?%'Y/M*'M!*Q+! Z6S9O:9PHJ?!S< 6^G!+5+/M+"?
M^7PL*?VPA&V%O:]Y6JN\09A[OU# ZWHAQAUDH_"<W5#R!II?^ 8 F1%ZQ)4G
MY8!C^;Y(3'4#B-(SKWV;>'D<CGOCMU^T0D%AVQR65VKT<F=&[IE(')9X%9>$
M:J,#.N5ZI[HO[Z9:'WX:RE==B^Z-:;9^IB77Z1LT]2[-.K'LZ?(N-.1,-V-B
M&U'KG'2+7O^R=(D-7-FBS^+*K_ALH"58&[7)VAU)8U^[-Q._FP,[OMT W"WH
M3X GU-'(B/)&ZV\?<4Y7L2UMPEU_A74J-!.3*DISD[<J0I\VW0"D.;!6*'5_
MOE[QB^!'/@PYOUYSF"2 "KBH]U10/RN!MD819Q04-P!:\^>0QUB74N\5\P8#
MQ_+:,BFB(YE=%YOUW[Q1Z9"^<C\ >+I.*TSCE[VUUA??BB\M&EEP*M.8ER]9
M3Q. &\Q_<2WZ 9UP)J.?KW(V'N,*TY?*A61[E,MIU![JU$2!FC6NA%)-:T_K
MCB<V/+PP;5U&WC> B,^TR7N+9NK.T&,'*]@>SU\EUR /28[=>..2Y(L/O\N6
M*2"\6.MD'=/-)<9)(5:/ ?5G+YZT'2#M=_9$F9@[99*E]&*JH9Z/+14NB/<^
M@SE]5.62VH;0U/P:,KQJ>S[&5Z,_X<\@=K*<:/,_D!<Y8'W*EJX1>&L=):!!
MCO=K7P72S!Q=TYMV PAMT:^Q[2=;.O9'+Q[8IL3!/0\I/EVBX.T8?WBB59;J
M:2:Y\?;7A1=)G$V](:PA(Z]/RVF1!^$0N0)S>"K+YPEVSQ[$T646:2CN5"33
M$1Q9SODR.X>3V<=A?N#:G^)YO:#H=O%#'0].F(, ^.08]M=:$2/4E_:+3<:M
M/<T^0?Y(=KK%TCG JN^P[#$XCGD[%(K:\S8;2[AO+"UAQ3[U800Z:G]0'L"R
M">(+HAJ+>Y4H=T$#9H!^1AB:&#^VPJ]-UJF2^])1<OIG\^K=Y#%TPT++Z7L7
M*CL3:W[^9R#D%M1&G;"2C?8,OW2)U0@MU3Z6VZTJBNMPJHW#IGE?]H)21_3J
M@$)KL(LI-\C3(')D[A:,98_CJ'OYJT,=B3?K',_3P6X:-<+ERFDO"S3K^,E6
MWTK^;#\NHJ+;'*''?J6F ?EQE6@>X1  \'XR[YF5EI'EEKZP_3P=]PIT&PFP
M3CE8:#>#0V9([;AMV"QDK=SPC*F; JXZ0F@RF[6$#9[H!AII15T9RJ!623SY
M) D7$H.NKDO",*9+,*B?DPOJ<:*+B-)E:X\ZFR7:,U#$4&\H9]#6T1]&L3;(
M$AD*-#%AYT TJVDN9E^OM^PY"2_CL^BC_\[LNI=0^]OH&B0_+G#^6!_A=1"/
M7:%G,9-YYD>_S\^_]HSLU:+JXV=I*)\@NV47SNN@7?+7!P:9Y.YQ#^P3[.70
M<=<_<V(L+M^ 2'\_-4EX\.R"&=589K:_5E>2Z'+WV4 B?'-&](FF#SW^>A\<
MW-_'^_VWD%TVKO[%4,.=#*?O[SJ+%VJSLF<FDA!S9?PM%WMCIRPDV"X<Y8^D
ML%-D.5#&Y\FSD>'64M.(<\;80C\67*OO@-3O2$REU8<D*\F[OK/?O>6ZM+TS
MD?Z?$XA6FGC8'"D#RYM'!P;N$15>O:@P]WZDRT#XI>L&8)7<T[+77]^/5-W/
M"(?YGCC_B1C3*3"WJ=G:6KLV'D3Q^KTIH.4GYT)&N40W24L;G@:8>_[P8 9B
MO?(A+ZMAM3-.'D0"R(]+IKE(&D7<&.L&M7&[',EM(J1K\I/\4C>9+PDOJRD=
M:*]PV?$RFL5WCSJ$VXHU^#G1@;I9_U;HOS2NZ+>A3/FZ:.(7=KR>+M&;#RI3
MBJQ5:C[+.KV7F!#9+%J@Z6']2T-\6:E$#-P+Y_0N-< &>]<N/]I.3M%I<>FW
M>4CY4 CS3&9$LD)A0I85:V/:Z"TZK#[DO?(<CK6,T5/1-?Q&C-9BRKV8C10C
M<].L:_RAGK$R&+;[LE/R<3Z^!9.2SY^!P3DAZX-K'Q:++L-/R5+JM+2/!8L1
M]:6M:[/F,A1@--<7]_XK,;$N[V"_S5_I)8OV!E]" CT/?=]/G=TF$BT\5ES?
MTKZW9F(_5L?D"QRS6IR4<R%MNDH>_WRZOM&31IJ])RC>"?NR2>Q **V)1S\J
M(;8C+F66F:^RME4O?AIQ_8?M'4M666'31'Y&U(%-9FJ7P*_HPM:MG<EDO@/5
MY=7X?FBG XI,/8X"*Z3M(?-TRM0A\ SAP[YI)U>#8]MN60(SF$4]AA(D-::V
M7[1!?Y6C(F?G7F!4<>;Q&_X!#W!D='W#Y3:WN:9I .%PYB.(I%^N=_2/1<,Z
M&EO*H=FW0M\7X@-;G?DJL.Q9BC'*A_N/I1/R:%Z05C]GM%FF7O*.>H=>R\^M
M AM9>H&8#9XLS7%TKF(204 1_YRE#LFQW81QZO#O1<1]#2LAAR<5XM^<=V@'
M\M/K)HLV02M2=*4LIT9@Q.Z>57TSNS/@'J#]-#M2Q*S_Z(/24^2VG%3,?AEJ
M-!5H%]N<3JKKJNYJDC!=;<2;N"-EZ7,D1J+79S*4<S&;"D:438!A<C93S*^C
M?\1G_:S_ZN<,'NRS=D<[ZV+++T3ZAFHB)8AXYM/V$:*^T]3AR&8LM'+/HJ$M
MV/#4JNK91YDXKK3Y?[HN5TR/[7O+Q,2FCM$G*V;I]H+%N.!Q)>JJ!AV3]3+4
MVD0=8;V_K-W+2AVV!KP(P$Q]4B'4[D]4"+Z\.F75%PZ++9-:C+O]._>LZS7X
M!A._)W,92/EA2_+VZ%54K8Z2!]/_UM2;%#"NVT/;.7VIT" LG@-(H),0$1HR
MO+]+1)BIS=?5HHB"AK\0-_+%:G6F9404*KI0Q4!9ED/U@CZ17@U'H^ M#?#)
M%3>RQ>GJZD-=52I*+$/X'D)XR\/B!@!]&"A9$9[YZ+CMRPT (3>G[Y7<]O[P
M:K2.U73^S(+N!N \"]9X/0$\MRW):%86T?QWLQ995F+RFV8?[7B=XO1#\XM5
M&(/E74T#%VO=!A_($9]%_L?V7H.9[!*59"U%4B6BV7".C-!1HCEPDTT@K1J&
MBOE=I8D*%=GZO47F$XF5R?CC.\T7(],X"PN6J^,FG7,^EBTC,2J+04G.<<[;
M##8UB8C[78*69<JBU\6MXYMRO?_WJ(AL,9=VIL+)@RZ!YQZ]AH5=!L5D[>_Y
M#_'Y DF9$N[,@3/7U*%OQ!@2];BH$)+%'[CU"HNG@EV-1:3]K^,NIB\_X6/'
M/BHQ[RRCU\N,S12\0\M6*4*"I8N.V>NT]!S=L8(FKQ55GC%J4")6,/LRL4J,
M->&=^\UR1S< X<-W!6CI\M';J ?5G:;.7%\VA/9U^E?_4_9AH_OJ#_IU$3=0
M9FS:X47OYX,?Z*SRLF L-NN2H6$J^F>]?^;).37Q>.*:K^SHQ>RJAA*5?MC_
M%*XV3$L.SUOBR=A?U%DA:,&.])E#(B=SK4CS#.[DO@^6FK 3L^914C7,%+:7
M?=$:AWH(3GXA8I+W+<.TJL&_!W4W^M%F>^9(ZW:?V8RC^Z5?SP1;:S!*+)ZS
MI@% S<Z*1(/5<93#CW"!""CN3@%6#YL=2Z3/S6ZPHA#ZRH2 .9!XY5=XD4;]
M6F-'>.=T[NJ:S) 35JT,A<+U:=?T+=DY&+^_ 00%1=;9H 18M"5JILKRG)2^
M6NHGZ;5,'%\KN!0:S)M2J")!N(]-96)3NW5*4]6EY<]+Z?P8C'J<[MNQKL](
M1XG,[\)T7Q%>$1@[;:E>1Q1UW "8S=B:^RR;PR3?!:B5G:<)<3;AV@#K:8O^
MRQ/BFZ4:2]RP[33]+!E%57LHO^K5)FX)'H*3:Y$)"&F>KW43VNQHPR D9[5/
MH\IP*XZ1/>:TMJV"@AE#9Y>6#^4)4=N$.T:>L)F4\8/JIK UN5;2H+XM#34A
M:]UTJQJN[$C+R1X'$G477B6&ZPU/8L*IM.SP<?DG@:RKS I,F_^MV@NDJ4#A
M/'7VYO;+19CCPTI>"CT3EB1-S7?.KG8%G4T*BU'6;S)3+$OA1F=*'>?:JVO*
M>,.?='3ZR?M49DHJZG&G%IG$6X2> JG/ TP3JL_!B[2$:XJ)272$HBS_Y]_%
MJI281YC"3TI5CMI:OV_\)X\@_$\?K5(3_OYBAOU\>6G(#6G*NM]3\U1KL%K?
M7, O^^]5H:MK#F"][,_FJ=2G"54;0'1#.ST'VPDB)[O<I[U]V#0[[;-^T2-^
M)3M!0XVZ?_K(= +_'Z>=8U?-MEU3\EY4JW[V^[UOL'3DT2^TNGPL;57=#$0)
MG/U[9#2[HZC:Z-FG?=.&Q=J-_%U0SK@\=>V>[*3JI$#MM10!K+8NXD,8Y^:7
M'$" GO6_*M^D8Z!!M7$,\PBRMWO/3 U^6]7 J[]WN=BOOJ^6V!IC='V>$\N;
M&8Y[;&=$T]*TUH,K*]O>H@SC6S1"#Z%_;1<"B+,N24].)'=N7WHU)WHZ.D,0
MAN&P-A C*LN84:3$<V3C>%!-ZE87ID#'FO@'5??OUD8U1 8Y*$>&6%"RGM02
MF.Y:6%@T>69G$Q_'WPV0H-,&   $X/_B5&HK#%>'K"3F:;.3!Y*%FHEY1L(3
M^&312]P78T)QQ2KWL*U6]M9?2#[.[Z7VS>'^X&RNC])G:ZY>M4Z)'H1=7*_'
M-)AU?>![U7_V;4_NV1D3E/@\%2*)+FO!OR[%B;7< #Z'[.(^(&$^V)'%[R<K
MTFT,@(O$3BG'@EQOW<X^T]9+_ROAT(P-CO.8G5&Q&I.^+O">HB[6+LMTAQ-Q
M"J9#Z$-;-FS/XQIW3&7^7W[>6[VI/7=3YJ-W4XQ]8"O\A3<=ZM2O=(><)8'$
ML-<#]&J5=RF#B7;DF:D_K"SB][75VH267XEX< [I(SRF7%-"<Q ]!BOK^$!0
M,RC).U@"=9T/9&134KA.\NJ,]K0_,?J_*C^OP-FPCY0PR;'6,Q.>_K+TEH$]
MTBK!(. >NPR!,TO-[68F^A8Y3T'[?$&\-&&4+KZ<L7P)M+_!=+_"8J9M%:\0
M.EN;>7&_0@9[G]\9PE27[&6PHKIA[25!C._!<9Q%H57Q! /MEC'O\=W-(,;J
MOYK-]-*> 0R)JX\AFVAN "?D]LF-J%8WU'Z%7"B.>9 S.>BQCV]RT[O G46V
MD]]7EZA6Z4Y9BO&K1[_Z\C;U.[E34CF +</7ZS+# !LL/G(I\2\9SZ^JMRY0
M9Z\E\^$C=>>-!%69&D03DY9^Y7B94F^1%W4I9W!X4GUTQK1KC=B.Z<,#K7<8
M-H18H;,*X@^OX]YL*X_9TO[ZM]9,J5/8VHX#3B4!0H%ACB<O6^'FG&(U=(*H
MN' VT=(GJ?Z-,YF%@8(@#ZO07=C$GF'W-*>?Y&W/*I?9]HGI]@[/5WT_MB9V
MPWDG@7P%CW]J.J4V1-Y=5S4>(XZUH5HXE9*)!FM2H0<TM0HRDUIB'N_L.(@/
M&#>?3Y!XI[C]W@ 0'Z6>,#FA/+H0MF$.0EWV\]:M[)]29(OARZN3NQ#I4HA"
M:YP^YBM8AI/\TI1'D\17Y :0.=#*3,16!WLML&*0'>WP3B&0P.) ?_DU3N@J
M?LLLUA"-\&@^H/.%BK:<FEDQ$79=>(4=3U5-.,S0I1Q0GJ5?)"[,)%&!U-1X
M?V-XW_TT;!Q>;)V7/*#VEIWOB;BS:&8Z3W2????083'3: B]W"4CW<60"ZH'
MG4WX* 1W<:1J^I?49M>XVS6ZU17-D?;1$K. HA'A3MK9D7QO WGS\XH06^*9
M=G#7>$>2K[F' 4F.7P.[2/&83T1T7>P%AR(C'044YLYWL';GW[6])Y4:&V*)
MRAG[^3[KK#WKY\*O<P()(:G?^I6NJ=":N$R6>5#W!17IEPG9Z94Y5=>/+,YU
M),]4F(77E4ZVGNK/U2V>$G-G-\>]_O<KF[?U^@2>6C#J[\^5Y.1$GP!BEWY'
MFJC/*_DW<GOIM>!'U0_Q:BV.C?J$A6R!LN88KB\0@I6*"*.RV0@(N-C8#DQJ
M/M=FL505E[)QEUI:TS\,/ TGF?.6&M6:Z@LZV5FT?II$>N"I*EPO@<\K#:)%
M:8ATNT%>3;MKW?'FZX E)]^_A<96-,<+(F&<X3+>?6I%2'-&[')GRME#^PP:
M]%YRHD.12L%V_%8\__,>]J_%W7R,T8RQDED4.>!!MLID(4107N1<3JTY*5'2
MM#!#IO1^R&2!_<DS5[S;F$OQ(W?20V6L/(!!/*Z03'FENW=W@8@B_O0M-U0:
M^N:]>TD =_B[24&@/U)IO(XD:I3:/+?)O7*^YA6F$B_B0_M\K)NYHHX\8W[9
M7\M9H&2>72+8=^2;.S8)./P4/5_[7;[A(]YO5,O1._2K@(=8&!KW^N0:JG^I
MM#:1-%TQW![W@/G=^_?I1\?4>].HIID\5/-!M!F^%I5WP*P:+/;B8'="P9=+
M)&!U@Q4/%LW2&RBU'&,D</9%]M%V4T 25:+I:PL>1G "-EY3& L:,&/$OD4-
M*W8G>\*66*8%'&(Z^8\>>VI$-5@&JY@P7!9')O]H36WA?0EL&6_-=!LJ;;-I
M"_=L>,'PYFQ(+G)[_R44,T'@[LE"<D66'W1J3FQGXOX<49H;()"V75@L[ #S
MU*^=_.1^,O_!QLF^59A4+>28^C8:/M!65J9@B^3&*V)X%<2NI,1T)QI/;: \
MU%21C_2!L@)5K38AB?_?1<4N6((]')#T7M#+Q.YYYH(6[N#L\3%.KP+9QF"P
M<RB3/@[/+.[JGJ&5XX_T5SD+;RB/K82H(\E>=%?E+-RKAX=_%WHO;?7EVB_.
MOFNN :RU?P,0["MC- 7JKO8Z38 ]<$+KYI$'8TO9+2G=&>*8\,#CX^IIA[T#
M2YL[R[H=\[QXOZWHNMQ+VR@@3E,V,\@X,QC,^"DIX_RKGJ.0:-(,+$N,)>9;
MCJ"A[<BF\Y)4&:U93![3I\FEQ;9!M_GB,ER>5=Z\6&^>!UDIW_2:<\Y)^8M+
MIUXS[G-W,@%1Z:=;?H5'3YA+Z'!U]EW(^C3!Y,MNKQ<,UVC)AV;B.EJ7/&/Z
M\ E=',-Y*^UY.HMNCJ*)GKK<6ERK4.:<N?_5%TYLJ%OIZQD<X;BCF#[AO7V=
M->-?-P#ODVL1#>9[,T#Y5QD2LY89[/V3M8<? _T>3;>QC#1_N<VDD[DM#%9T
M;C-I@$RH;)S%\)4*=/#BA&*/0.4-!Q7P+&7I] 8 T^6V,V)._86XSE2M"I[@
M?_]ED@!>4'0%CL9&\"J*TFAOTLS*V6H,^WVM(']<.3_*?+TS5EB*D8 Z*$U$
MU5V5>QML>[BXKS'[J9F:58Q6;+N8DSLMH0;6AVN]:T_JB.X67L9T2%=WO[<H
M>)-1U[X#)?#8V0O [8^L_S8>=3Y\Q1$/(^!_/4);YO>3FK*C[T]ODDJ >?SV
M:F.L"%=HT?#_H.X]HYJ,MK71* @J B*]HU0)19 J)2+2I8ET""*=4$1Z5Q20
MWI1>I/?0";T7D=Z"T@*A]X0:("07]W>^/?:W[W?O/6?<,^X8]\<<(^M'WG>5
MN>9ZYKOF?*;*['#=N&/^!8MA3G^%'V\E+,:@+_?' *YUZ59J[\#.MA8:@VM=
MVPM)0"[0T]5ZBAT6;!9&?O[H^_D*J*<\83 KJ6W*1&UE'BNWJ^!]M9Y4A)5N
M2=!!K;X&VPJ+7;8^8:IEJ:"%U4E.1#X<X!PF6VA?"E R=5=Z]CK*\KNA7RZ(
M>]8T<[0\LX(6/%DW3 :7$5,WNEB<X.\;@1B*;413MSX_WC-"D&;N63?X*^FW
MMYK?#2.=^A-E#.HB%X7T$JB@0T/8X+4+NMKEN@61]$^@0D?L@A7;I#884-<S
MC\8\A6*P/3G0I"A1@NU]FY''/:'TBYFXW:IO56':?F-UTXAE7Q#&XNA\R?45
MU]OBR>8O^K,3"WP+:9,3&]DJQ;][<=6'M_K+@DK;O]9Z'37KU*U4?F/H;D2!
M0AQR(1%G\1+?+%.<5"N.H:K;SD2C[^%M]&,'+7+N>(#&D>HCG6VS]W07UJWT
MT[W] 0I'SL<R%W0F&]187A>8;[.@OF7<IK!7^XL(J;K;(Z"F.SC=-3R 3MK*
MV=^F<&[3YUN*(7V^P1F75\=&Y(EH &)9%U?#DZ1+T\1<)7G)G]8R0;$YLJNT
MINVULWP6(BVUO*-7-W%"$I:JPYKB<)GW[DVLF;1%].\R7G^/]WZGVL>>6#Q
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M[S Y=0I4,,NK#H]1,'S7*I3@@.4#/([UOV"E4<%X0(S(L+'NM+3WBI3*([B
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MQ!_;7VT40W-[%DEC#-"):65;#!%V#,.Q@R/U?0H-,9<Q1SPGS#X/9(2RD C
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M;Y7U</8W#7:R8BUU+*?J]#&$V'EP7_(J*+H6(5B \$"X9Z60UJVU(FGJ4S@
M2WO2Q<?L5<4EY2,9CFY(%?8Y'CI#"TZ3P(Y04;)AU<DKX_)C"XSE.0<KZF$G
MMIU!<H,URFPX,!$/<.^>?1/:SPC=P<(NH;;:;[*G'5<3!I/<:Q%'(^:U..)L
M+*EQ_,N0IQS0HHCIY*6[#5-?OD^*1"FK@_G<J6[>)F3Z//;/NFS__Q R,Z3N
M=%U2-^O]45^[T]\T7:8H&\;#//>]DSTP^_*5S>FG>M3>EV?6$4RGD)M?.=)?
MF":P/N9HD)%1\*V(<:@C5>HPZDV,X1,"FQBU:+?L9A,I2O+=[I.!=!Y?4:Y$
M)Q5V6U@@KP2DO*@X;)W9'']X##X4N7& (T\S:4!]_]+&%_QV>I;-*?<Y0.]X
M*>Z<8;9,\!:T,I-L,JEG1GMA.^CA:0K2RLKCY-9SUMCR60!PI$4%I=D-YD13
M]Y5+P^#EOK"],:.1UU(_&OJ6,?HYX\^9 L/;Z#=E>2=$YA[#(=P3@2M=R/%3
M%4 'X4VI^T1*E;GJ&//E5JD.SP *FE'9#!]#Z*O1)A636,]$'(KMON]]8.6U
M2YM%B 6.2Y,7CQ8;CGK[^O*]F-?T%DP>[R%[(?@#V6Q_O9_YT*S8])G/[;O4
MGMC45HV6FI[ 0U<P&1Y0J8LXM#]Y]I^C+"JH*?$_U1TM[B7A<W@/S;L@>$Z6
M$QZ-1#*J>69NOPGAZ;3V=+C%:@2(;YE;R8IQ;B%8HG#-(X7-3$886+,_X@OJ
MK=H)EC@KN_)<>;>XS9^#%9[(0PL4CXU\O$H5/(T@;P%1@+W1@AT!G&G=8Q S
M"O<M07>2%&R#0_G[2B._/#R@(X9NE-4H;.1)Q+=Z)45&4AUJ(Q$[X"]C%LUE
M9WJO<.#Y<;+[7+.:J<>R'DYY9-UQB$ "#X P^<[,LM"AVD-QS%Z61G;%S/FU
M%GYG#V(9]/9'%H;]G%&G$Z12O97;25K\J$GH)S77CKA//T%7]A?A,UU&!U'[
M"5KHJ6&[MV2;;LEDX]%SHV;=YWJ"]]-6"Z"C&O2OBB>CV6DY[SKA'.?4.!'P
MG^X'D2<5U] QY2]T[-A+TT^G5L #7-M/3LOQ@+L8$G74'&,CB=EVO"O_+K:*
M&RH#S*FNKI\L?P#ON_T7.+X6[:"6>6.[,RSNB1&4YST/W5^XQ^?]^ 1G%QAV
M<FST-STX4^5[^8ZP'0FEDA7_F-_&(*LG2YV: EIMAS:NI\D-_?+\"GV92R#J
M:CK#5_M5NGG&RFX\R-%D(P;7^L[KJ5F5\6T1>%SPX--TZA5FGRM@7^E7E[Z^
MI'H5C\E!S8S1K(H(ER$+I;F\3/2D/U_SCFM53J4SUJQ@5F5UK@9LXD;1\72T
MP%<7A"FN:VL6B; ^'?KB.V."GJH8T#A*LJI8/#7S7I#^%9[$R3ABFONW*>:$
MV#YE>$?3VA0M>.J:<$X&29\2A8P^^#-HD;?U0?K!/<:(F%AR%Z-$E@>3#JN4
M&A7>+C/7_E7_X9:Q?385+^"'&\"".KWXG8N02\G4HPM^L^%6V;4CX>_WK 4$
M1%._F"F4PM)\_ ?7O6-"I/DNHM;&&S+V< /<B:_\U5SC4G?VL-2Y'9UYP1M.
MZ_H_0<'R2WC R>SHU1<.:&K#X7S[O4IT0I"SZ<GV>RMZ/5)S"TDY<6@%N*S4
ML>"/8:31;.]]/, <4&K0K\I3\4$H4C>GS)_)G ZH8'B]#F\,!MJG5'!;.-W@
MI<!S*L? Q<"K>],+5G4N# )1U+5IU1Q' W07;^%F(0YU>[P2#D[+M33:^YS3
M87[QFI/%QQ7">;-]O8?-'--[!5#0JM>)O8KU?;_XZ@C]^B0G?LBAYS,?GIS6
MI[_O\I3%4'+!N*+UNX7EF$_1(5G[>P>J&K]6?YF4G(IN5O"@"F K5[Z&J6*-
M59>R65ZQBZ0-G*Y'CM@;%?IE6[JZU!/"N89Z,<+J/L%4VD9IP?_ZC49G>I>L
M-'?A-TD8?]20.FL&1;=27&2,3Z,"P*_&=SE*4!'SJ0@3V)-%6;? !92P\+)L
M3.F?);D73[8+ !D=FWV\%T+^H-\1BH# *\V^_FAKY-/3)9GVI(QNF6)]X [)
MHL#\<B;W\NS08^%JG&17;&YN!?!QANC>H)-YNM@T&LS"$6,PMG\\( UB#74^
M#L.-NA?^'\R]=53<3[(H/H0 P1."RY @P2$$=PL6@@<&=X(%!F?0(1#< @0(
M)$AP)[B[!PON-A!<9M !AN'EN_O;>W?W[NZYO_?N?>_^4>=\NL_Y].FNZNJ2
MKJI^"7C)A$W .Q>\$BCV;YY A#&X\R/$=(,B\,AL1B!=>L74^$A5X6PT_@_O
MHN+0[!G9H0ZL:>8;;''LCV)(9+;)!HXM7K-0ZX2%X]$7Z,UM1DQ:R],L8OO_
M5ZZ74;20GFU:7/=9/4*P63#, FSY;(LU.N0S=A<979QI!RA$)L=/4C\'%^$+
M$C8/N>$/;E>K/1/JY=+J5X('&=D'D(-)99WBL2)[MQXJ@3-IU%_[>%7@S]2J
MF)(+9A9 M-<.TG0++N:L8H\,52NS0/?#@'I82FM'POW\&.<2?TUNYW;*<2LD
M^(5R5^UMN)1Z;:_QM/=Q3YG:JD85E'@04[2ZG[-\WHC4;+=^=DO#;3(2UF]A
MMU[XRH,^9?BTFM.8\QFU#GNS^U7U3T89VE?!V8%8HE4HJ;)GS?E</_K&&\2L
MM(27#WPCI\K3=)[JIJ4+N5^([N@4&'RUU_:*FOLC1V/N?_N=-EN&AC@K1&G4
M3K= )Q+V SW!9&CS<=>&2GHS! RU/\-[%Y];J/4&)#>M9T6]WK>V$96[[BLT
M>[WCW1A[3WB!I"! ][IB\,J;]C@(I&U,"K6#%M\!DFG:X*90^UU63$S,]_+@
ML)P#-H6D8Z?2W2YS=)DLO_>7JMHY37FRQHF_=_7^3P5SR*SJ9&T<MKU/0"V$
MLY3[*9M$IUF;P?4FPE34 ?H 36&P THA!TI^6.K&%W?8[KOY3/ ^T/4WG2_H
MHTWXX#-AZX2*2K.;ITX\7'J]U@TY1@1GA$%8WK0^BAUOQF?.:W$S=LU/55,;
MQ=OXJL4D(%G$+DC%"S#RS0I04-+LP_RW>VI9&_%7L]9&L]VMK\9TD5[9*W9I
MD$E'IEKU9S\%U_'>!S8>GQ\;<_U[<4:0]I2CN_^S8ZTIZY,RSG7O[40[Q_"L
M9&':#(Q=W:(JA82^\1^1.VLE' 1!$@^RB(EK$?UA+6XWBA#=_:[+.X!CZ*IJ
M4ZSNB8E$J4XXO3#5QD3KCY8O!M5UU;=Y*&!R,KRCX%4SDSRE!@3\ZCSM/['3
M<C)@-'H&AJE:E%-6+=&DQ#T_<1XAU#NIU:/<WS3/G%,=,$YL),LGB+34#FI>
MQOI+5XC=9HK3Y1K9ZIKP^EMX>[#Z33<$+OUBH FG21%WYAMQO0/4@'M*Z!_Y
MA[V$CQ9=E BK2&Q(J_4%O%<^CJ8^!8?XO$0_0QR&A8U,'PA2C,JOU7SZQANH
M+M$4*$4-N [KN0/0N#=SO=QI(ZC^TDL]?_524+I&,U/7I4\RM==*#M[>F_G0
MB;$-65%:HVM8GQ]B_FQN]J<([>.C%PX3+7QKRYB=%_AVZX>"-"\QMSRHO"3S
MXIX5((@CW,<([/I.=1L>5;R4&1KP)_7*8V,MJ7[EOJUK3SJ]./]T03(L!Z*M
M1)XFGUZ7;O-PZ,$4 P+UVC?3S40 $=Q3;\(W"9L4?U1@9 ^U:%SEFG*N5DS/
M=:0$WCH417;WT#^V,HPQ&LR!N(G$CA,?.RF6 +M1L*;]6^R][N[*732^@S_O
MAGG08'SLU;G H)#HN*?),0RM^--\]^>0??^"VKE?>@ZQ/M,1*CG\BJ-+DA+Q
MSN>$QI];.>?&GB8AGL_;1CSX??^&J0/H"\2F,X 'CBX\B;$8+SLJ[^U=>!!K
MFOD%IT[>1U6<WRKQ4]*7%Z/%$Y^^O?IP]8UF4?>R]O+50@BICL.RPJ3:AT%?
MT9<Y-_UE[C\T@[82JR1]W*(91X2L] O+N<UJPH?<V%\&(]._<WR!DNQ15W]N
M$3$;;B4<Z<>3PO.O_Q P^;P1@;69<G('&!,_C/:U;-\UHC=*,GX^OG7JHWB\
M?R+>7O&CNHZ$=G7E=W,9E3(\B% HPPD_2%M\59.VT^'7[4R!ET7D+3DMUV7R
M6-5BN8*'R3W8LR/<I9W.U1>4I7*?O.E=I6P$R8,Y+$RZ$HY.><70;$#T<8 4
M]2E+2E^^*$E/V]M)S]KDY/KMJ1-V:Y>R5%E(7>Z2H1T'%V=*IDE^?F;NW*[+
M866=4D.GF:3EN<3>+U+0N.RC#]YFI7'%!6JDL!PLZTTR.5!K4V4UR=P"3:,0
MQJ_@6 G[6])B^1]<+#9+.HQLG7W<8^V6$?"#Z]Z8LUWNCS"QH1R.1JF]4^-:
M4I D!1'\Y^:6JXGG+9$1^:-UMAM)+^9M1\FU[$B.TJ,_B6V.3(1Z^+&?%"V/
M=;;17O;KXQ-*8DZB[<A!>&8/32:9<0<#_'"Z]5-GI<\$MC0HVOT<5N6153!P
MR>NQ6W0C>'YFXRA/IJ(UXW[(L%PP=6Q>%^.32D^?9[OPZF"Z)FG>LV1U=6'7
M\[')ZO#WQ:[F]#DXEG.]*=FWE@;!C(?CQP(EL=+6QO&W;JMGI8=RG2L"B.4&
M=5)[W07C#*^\O!KK$V>7YOB!L3*W'TWV4[-\*,G3!+U/DV] O[].,KO Y';5
MD$2C&F_Q5 &:"LE%*$W';\/C_!HN%4I/W'L'B*S@%F"#>N0882V$ :T"$T3.
M-@2.DS)P1R8NQS-,]D0EK_^X)//,"/SK0%YMJWB&F-RD((9[P\/. #KE I#$
MQA8;_-3$FEGI^Y=X]&X6\3.$ _)QKT%^#FR5&"7W1;JIYDT0VE#+<UCTZ6*G
M92<@\JB-:#>#NA+^:1(),D@TNC'N3#A!6_@-,G=0FGE34L):\!9[,HG(VNAJ
M/LK= 4C.&0VPY];;U%.<T5*9&>?[IO>.:]+E3!"M_:%=^8G<N0F&#,]Z 076
MA]+ _G^[,A2"T5,CO7JE*% 8CNNWNC2[I<?EJ+-H0<MA)H)-GV"301/KC1(Q
M!W#D'8"(>F&!5?^X_))R \_PD@XA#?SR3Q\!^N^%^Q0IR3/DKL:F8W2M+7)N
M@QQ8.L#-6?%V$C]2/2R$8&J",^"KFU'<(07S)U-\S7/!S 'JI$9>N1DS7,X/
MVX$@+\DL4-(",G$-LT887E>80-) V+!V WNM@3/]YM\DK(GAQG$T8W< ^R1*
MXMO<H)?[]2?RE%F2+A@^]#GV YI HQ)L@.<(P"?)>[MOJ'8\@'K5X;L,;4JR
MX\.(S-M&,B(H]H@/Y2;>W]:AUY_.P_ON7%B>FF3/O]\Y65R>*3=>YFA>5:?B
M:]OCHO"\F-V M4197I]:@9U-@>/E[YGPAOS_C, !/D5LW(BA23()?XM,_Y(#
MH%$;=%[PJMFUW<N+ZGI6:*V(_P'ZF2W'&L>RR=AP_ QR;Z(K2 _)((![66\6
M#;Q1VHW?I2<YXR%=1C9W7Z]^<!^H^#5)+OMR(KO00@$#:RKCEM!*Y9O?2T1[
MA+L@PC.^8%?0P/AG(]]B4_([,F8%)K?$^CDOD8YRI*HO?\7X^2WQLSP1T5%E
MB5EUM8*G)7,0T1M82F18K(##B #)IO_GA6^.V^GS/>#).+7:HK4M)7>><%T3
M8$MS*[Q%U*AOP3"ISXI7T/GY<Y_M]Q])/W)4C;<!N;9C6XR]8&4D"QOJ4\8!
M_9R+=.%BP61/CN0&MH,GZ=CI.+H#N,=KB!]#%/28IFI2.6WBE%KM-@CP%:0C
MWIM);Q*L 60.%'"TN QN6^_QO\T;G@U(.U\=V) DW3]<)\34=RC 2S'0WDMN
M/$(,P ^!OP)1K>S;'<UL[\2]2CI=]49N,TGCVLM-+3]"CXL#BN 5/4(KC^ A
M7W7?BGW1Y&K+S8;Q5K%\@8@LAV(RK=G4>J)IX'4%>2@3!+"2*[LW;T6&VO!5
M%1N!].N8K$U+G$+,2'8UPE=CT/$0=@_2K+0)J>)F_A8OV'XFP>+N3)IJJ9=/
M79DK5^G&YWA*$:JW_<)4P'2?:2ZQWC:FB6^SF?VB\BW/=S6N=OW-&V1<DNXS
MA(E%V43'8JQM1 \B:+I%,ZKX_4V[AV@7,B(\N1GJDNI*]Y.872$XO^A<5M-*
M@)D;])0&D*"Q7EW/:\%4?_NGU36/.4]ZG^&,M0JSJRGC9 1:WO_*\&V@[O3(
M8W#J(G;VY+#>-'5LSL]L:F9#M6WZ#O"=7F6JX"0D+V;>=_%Y_R^[-U]I,48!
M=X# ##9U5-)8>/L%ENGM(SH@-3PSG L[)<\$B=_M4I9SV#3CI,46C2A:CZ<@
MHHUV759GPIN3))N!KEM )K5OZ*^!!7E1OLI^4[<'&5K<O%]C9:B>X(TW/#M<
M/%? U?D$$EAI;4D=@;CU4:!)D(IK[0<[CGGHGVW)*Z82>H?:8B<-YF.S BLF
MR*KK1=A6YKI5Y-+<TF[?[B;[BJVS%26.</^ F,\LF53W\:/Z+GK">1EK^HN9
M&)]9KK>G+*/Y(&$"HJ6UHOU)"629OY BPJD(X:N.4&C,EL^?[S>[0!N8,/71
MMX=8\"8HC_UX@!$X*M/)C.-58(K$S-_K51"$VJ!QX^'[NJWCDN3(Y#N 2FWH
MWIZ$!93+B9N$\N.G<"<O3\T:CSY7'Y>O,:8X?BI3YV!@?>@Y:!P<+#N:XL.G
M9*FKH:QE>NRR#+F4^*[8'?=X"-ZL.8'NI_6Z RR.%"HZ, W(#QN220^\(\AP
M5KJIK<R!^/:<^&E->-RL$BS:7EN1J]O6U=7S"M<:B5 M!KH.J_\@PJ JX'E[
ME9&N'%8;QP R=+\9,L%&9$:W6/N+1SED=^;KFWSFMN)@C9\M_ZUD.M,I"U^%
MT5+;]+=?/3QH/V"C0+]G=O!CAQ\5K;<3[WDN3%?,YV>^288)G))=*@P$TA9)
M3"%F4A%NW6D5$2AF!^MO"[?%,#'DEM4IV?/W1H^3GW@P5*NQ5]7UE?-!;'SK
MAHE)YXU1<L@REW7\=%E?KL>O:U0B8/5/^ \6E?;C40[10=B3?:J.$+'UWN,@
M<4V.7>K-"8B/7M6,$#U?:AS5&A8=QA*VTI72AH!I'Y 4(1 70]$G>>]&_+)*
MFNN8T^F!YG-*P.;'!QU4FX]JS+["\N$Q*3T2<KTD^T#>QKA7-7H$N/D&34TB
M_<31#;0)KFH'T?XK;(V^:0(.[YA)BU<TO=K0IK-R(Z;J>N7GF23(TP[099K_
M:.[P99S[Q9@CC1! [N.P"*7E^T6!N;V9"TD19*/E^CYL%DA?-1&RI+O+D?UZ
M&'N6Z:&/</_DTL3>@FG/B(-,*SRCQ,;.FVRZ*^YP4MREN NO3CP/L!UM0S=F
MV@HZY\%U"*!"A";!B''M!DN9J.UWZ\G!KM_%V,O)NH7H4A@3^]L48I7/9PT=
M;O5^\"_L''KXEOFLSB)8D"*%1D/?]IKDAT^,GL45*CN F<H2&"CQVD.))# P
M:WV8758)_;A\U].Q?YUG<MK[I$^N&.4J,C!TF//]W/BZ$9T8I$#H*3"D4R X
MOBPCH,KV6X3H?_D_>KOQOQAHVV/00%N@U.3,JDGM*I-T./=#F%+U+,ZU+G-[
M1V;8=SEJNGLB^J3WCAD3YHZ\*^2R Y_\X6(M-:^N#.$ZS)*AU51H>*/Q'$ F
M\3<ZQ+RUDH7W6X]8?JS4I356.F6)0LRA%L4[ (O VO$-EO$=X%F%=@7S#$\9
MSQW #HK3&C-%P=YD/,=%\+Y#^+=]6?Q/;,I&:+B@0>]EB!X$:A(GG<&FJ\]C
M=5-"B?,$;7F2190=>=6\[EF_(44)*;?] F/25LQ?CKDH%6G^ -2'[+B8M,+&
MHH D\ #+*8&G+A#%09NWXO-&UV;.4B2LF-6E9=!>:I:0@Y&9]J)%/<4@T.A'
M-J@UG?(U*!G:I8E0A[$GP?/C*$+<B["QT%D]P_M[Q3@_H*,.AM+(1]\,5J%V
MR*:3[5[J'+HQ+L3MBG\BR]5/;(^Q/D>'7B]":WA!-X5H 3.TIGR#=[&B34WD
M>F(113?;8OC"&*6+D!_-S@U%#U6YD35</'49:Z@PKJ\+FL *G2$-90*P,P0"
MBFPQ?Z!<LE%<\+!@[+!RNPM!\EF7]OFNGI>Q.\)B_2,9BDRS]#="JTCJ;N6Z
M^E EQ2B>EMXOSLP_L)E860)Y@_M-N\I14%L>@1AV7+_&"5;](%K!/J[@LS6\
MT^/[MGW;O3/D/B^C"HS4MGC=J%$##T1N.<:*8C2*#B::);MQNP5X*9FCW#1C
MOLQ<&_[:],>%0<,?V<WF*, /<'1G-J]T'P18AU\WTDDFF4HCH?S70?MMP@WH
MJ6EB-GPWPO:J"CE4";0;^' "Q6;SRV[<*?4J>4O-ZN-UXBV'9Q.C\LBISDT3
MSZEXY.<]"$14F,SJ\@LR[PXP4,%\:B:\J[^PW#M2&^[ =KC^Z3M&.2665+IA
M0W-]K=8L7_]#VO1A+%=)MEG^=%.5A!]30QZ2<@H_^Y1TZ;?)0L4>X[VQ/F;F
ML*VP.9%4?]$[^4TVX%JK+O("/%F8)A7NX7MSF+"LQZ0YS.BL=V^C;=5@MY8+
MK#ZA+33+&C./,43?7>8-#3T3:[74N /()PZ</!]A0S\^/#8)RT>JJW]WX>\L
M/_))?;N=J2$&BD^"\=;N+'.AI])G!YT@(H(<O#T:3KS+*"TO4^9F%$6JW(VE
MT:S:,OG8@6<_VL0)A\DGT&?Z"SW.0F[7MFZRJL)V\VMES3-@TC@ T$%)"BJC
M)3#<+K]:S5AEKCSJYOZ06Q"16,0CD9+KB9H+CZ*^'R-;'(VE&<AFF]V*.34W
M-.,N7)L7KNK"SR!^!RA^9R-9JZT,3ZJ+]TEY:&PD. P3!'_:M,P#(=J"!/SY
M#KF*EW:'K&D3'F,Z$O9YHTJ2D.JY@X5ZB\@@1]>3K3?>C+YO_0IDL14WTDZ+
M-;(1[&KIOUJ/YT[LS7=4R O80<F7[0[ '/D7RCDA7BH,6>=O[U7S^.E\LQOZ
M,F(PP7L',)9!Z^R(,#=+*+_B74Z;CH'% &\,)Y(75:>?33*38//).BO1E>#M
MPU8_F#')^#-O0#T7R"VO88W'#U%ZK<T3W!3=U$2Y<=^WMF"$V;Q+@7R)1M.\
MI-X&3N@P+B-5(MVO%;MW $!PAX]->*V_Q85#)JE)BX%:]L48O@B#64:[P?G>
M5>;Z:KB?IG6%.D78$Z&3%>OM2/4F]<O! ^]]DUPF9)F[<T3V F;\S4@_$ 62
M)*_QSXAH[]GLM& \J(G^<C.FD-VRN4-/<A1VK1Y^P%4E<B/*VXF2%X9@]J:P
M"+5)MFI^].Q]T(_^P%&R,'*(@X2F+AYN7>3? 8A/)4BRT[;P75*W8GFC40=8
MWDBD4K7EC5S/0MX8BY3D4MQH7M3:6"@(6]^#*E9DU=T92J YIG\;UR.1YU4C
M18_$+HA"^>9 H'(9FMY8TT-L2F6P3WQ\CY:(@EHNUX][%KGP.^NN>2>/C@4>
M6+F0"NXV_*"*<KF"-96!U^X 82SCW(_50\K*D_ 5>2WFGGA=E*X&M3VJ#).-
MZZDF%CQ93V=8$@[1B?SJ^]6C7-_??-:02VK]#B 7"35(?B;&19^19GK&X[WZ
M"/6FO2EVM5L7C%(3>MV]XZU]I;,LM"X91]:UO#^Y[) 2G/GB1*O#U[+A>M9+
MWH/]4>MVR:F8+C5%R^WV-MKPX<+\HE['DZKZR!7FG?@G.O2!Q9)/9W[KL/S5
M/N_*P<[K?B562ZC+7GO-Z/.R-,^JGSMV)PNB0(DU'A(C.X.M/+JQL',- =\S
MVZ7%CY7W7)*%#[_.?I]P! :?Y)7N3+IO_%@>+M1RS_FQW!7)6A;3]==WV:F<
MFF/X\B\XXQNZ_^3>+!B7IJ*'1R!]T8%I4#0F"U)GD8Z[^S7(6/0'OL8VY]/H
M9\?E[--_N!)POF41O?1[ ]='V,%_SIJ+9@]M4G9)K@K=?$'4>[VSJ:"#%-6V
M1TB2P(_#GXX+Q+SE<+CRA#'$=@K1<F\!0@;/&=J@?&9+)HWU8%QBZIJR@M*L
M/2[!M1>2ILT9GM&"PF,^JPC2&1=#/]LH+8CNGC(7ZL/'F,-/78YTZL*[TO0O
M@_X<-@ 7BPL5!0>B^9'/;M2G:FD&!3CV<QB6!TJ+PI6OG'/H?5H9-#>LX0J!
MXD!^T[HHO9#5B]FO%$"]FS93D3&CV31D#TK[#A#R?BWN4 <>=A&V4 ZM;AMV
M:BE#JX]M'6W3^#@>SP1*7$>>^J$<T<>!4+$%/D3]31L&ZM@6<X*U@G76(S.Z
M#0@_1U?Z4KPW6>E:/F+6:YLS*F:S # 1K'DQY$YX2,50]T59%RWTK\F'7JR(
MA<^HUV'C[5%B1D>O7?_$*1HW 6?&M"_#B;=]%0($[P!>'5+IAP ?>;*-9" '
MLK,0V:X+WWP(80;S?UY/]G+Q9#1G9?;\NIDA,D ?X[B] ;[TP[Q:^8F3J_GO
MX^AE<"-,^XBQ(9[&#F^".U\LRC.Y5"U&U;D:=Q'A8I80G6$<N(.^_.7?\;_\
M)@V,E_=N^[<Y6$ 4>Z&4XC;K [5EW,3W>QTY$Q1*G+FG.Q5973$8BS/^Q2B0
M7W> 2/1SNY7G$WXBXD!<AQ$#MKSW/XT_3[W$<.P7P<EX3KQNZ(U<O%T%H+UJ
M,'9)_WV<&:$H/TU$6&<;6>OLN9+X(ZZRA!*E9-CAUR.S',!'T>_'TL!N>6^%
MD%+46P1Q6,VMQ0^>>WFMMTU&+ZMNOPN#-#H>ON +GDMK_V>+LD7_1FK9_O5*
MO!U.D-;&RV3A<FH9ST=#^>O?@Y0IS^\%2L3^,V+3(H1^+PJBR\5[3BG^^,E4
M+:7[CM][3\]!-C$5JV@>VOC$ P>P% VT>8U^]")0@N&OQHF%06,\9R9&=]<8
M*I]Z E9L &\#)5Y$(J3N(;=AJSWT?_A$=NI6\$,71VT]E\L6VG[U073-8_T=
M<L?Z5H^0.*>M6<1*V2VK?QF]DN8W:2CZH]89<8("5A9<ICY\;CYI^<:2$KTM
M5KU(V>\#N!#E&#G]R^S_9A#3OA4^9/.:%/Y(^3XY&B]MAN*E52W%N\W*C@X+
M'*C!W.1Q&_^>J&/M&>Z:0.06:2KFEXZ.Y_=MZ*ZR_JBK^6]3B/[+V@!GD1S]
MXD*P]F@@JZ.Q.U+\,=6$!YO[/ KA*:0"%"+K%#'];/:5WG[QGRQ%8)4,90:_
MR,O16^E<2TG1;[YA;@PW3@(M&'(E/'\N9K/[AUOPKTA(]=?[)LE!M*+/GUBF
M?;I\ \[1:>[(/%Q"L8A/)L\IC8,I3#=0+$F$L.F] ] @U<9Z1%\#<2,G3J')
M*0R'5C1T'S?9?F_C6U;,N9T*H;],+N=O"#B&!2GIHPB0FO;CW=!SET_^\8,C
M-U'YL:/87/3CIQ=G%7+_,3*(!=8>6=["O#;5-,EIUM;>W!(Y.L,1\@.7:127
M[II^M,4>#/1[?0*6_U4?=C97RJ/UX]KEOO6A7ORI(TM\\-3;UDD8,'W]4*53
M*![9M7V09F5H[9"4:"F[%Z"K/5_=<3W[22*E2XH6&=O?4[7G-=?0&MG[X5MV
MZ)Z[Z@]3Q@83Y3U;S-6_1*UQ_ @0-1AS<?PMZ*H-!]G420S%KFP-;6D:A7<D
M]J<+GP!S^#%&D,U=6LCRA0E6/_G2'87E*(H))[_D%$9*R^"/8J XE 42[/9;
MXH6DY>?QQ(IK%Y>J @330NX J02IJ11;1F[1F[[O365!(AO'#^0WVK%6(#Z^
M_54J^=&I\9A)\PSMLHK&#5E$AFC2P^U;TC&:.\#:Y!V@,N?OVA6OLP/%>4S@
M..'\J_1(D'P5XCBFX/MTV^S%8F(AKR#ZC7DB 38V3&D;7OX/?QW[N\YR W7
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M-P%%+THSK:,)8BH3A$B@&+$^/S%*D;J7FLCT]0H2.7Y\N]S%97E^I_YA2_;
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M0("2FSAD2G+DOP.0A#M:VN%[*U%![I\:&_=EKA\3H#20_B[P.X FW[)]^6Y
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M_6%TW$3RSOF3XN@N>L[5\O]\KTMCVK+.T(N(O@5>W]K"9R>^+^NB.G$NQ!$
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M% QV='/X>7]YE;:'7):QKW2U;#PO):1LH)<ZO]L$0]1,'<#:LG>U?X']4-"
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M$N^5"]2<>(@P#UQH\)&X N,(+CUH!0U_XZ8SFX<$Q4MK$9J[\FS3(U\Z@,+
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M>&'7&SD3:3[0.D9\)<'XB?Q[W!X)1Y.>-KMF48P:X\,')TF@#65P1P_;L,T
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M"2L:DS'=S<B;&LN<W0\^*"@%TFH?4;8/*V6B3GYG][XCLD(MWF8R(TM )TV
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M2JI&F\<^"M=YT)CO&<B1&.L(9:Z2).GZ]&*,6G]K[^"AT\EAQKVK2975"1F
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M'A7M9UB?*"R\8B9YT 1J*P^B8]'MA,@A4<H>[YLRI5T@IE(FSV'TARO0%S*
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M2_7%*+R/0ZN6@"S;H=T7E3Q!^%HDB)NZ4IEJB/<]D\%A8TU/ J^1VX&?+R6
M!<-T#S;Z"8C;2C.%'=M&Y=6/^TR%Z9DP: -UG,O]+@9)VC'S8K6T)TH6%*CW
M\, PW[W&-A^-4>:Q-C(?IB*.B[<#%8!172U(1O+2>$<PQ\/&8$GV.L'H?7.@
M0F@A%=7"-+\*JJ1+O'LU<O0>1@  _K<'67KM3*+8OJ._ZSZ7H0PF#HPT3Q 3
ME"\"C+0]_X:!A)4=9EA8.*DDZJ,PY_J'X=H0(478D#&J:=0P5I5)S%'F=H.+
M*)$X+%40/@F)=F7J?PN() !_LWKA!K_27.).[K0Z$@NO!NNMG3PT!=J7,51=
M,I.YT;^F6"YPNU^TY]&7S#L9C*U;+55PO>"@??GD28]UT-X,O4 /<$6XI.,X
M4T^WQ=3?8O3E.]/"G<@2B?_-YK@XV$6B<W<O<2K@[#.X<63_<W1=5VMN]FHS
M\42(]\* ULMC::;M(GNLQ6^I9.O+* '-JNT<S;(5JE[J0'\&]*^O/L5W^/E#
MZ8U3_J=5A W( 4-Q)07OTB77)<W":I 6ATT!;($ R81\83=-S?^JBB@<<U9P
M)LVG/P2AB*$S-[J 0/7=??4E4/96$K;,Z,+YR+1:.:_G=(<U@T%$0K=^;4+B
M8_;#&N+XXAH:E?AC/_?#*@13]^(X4L$FB6D/5,C:/R5K5/1XX*OCE17QJR],
MVN[5%SFZ0'C6;H=Y()>4L<QVA#IR;(%](+08 L!2DO7F,=5@A;GJ?TL&.]T"
MW13D=47)N9-W]H7-DJ5YP=?/S\J:.5"Y+\]UE';=H5$I:,51SG [@3L]U*U1
M68C_G"7).PH]K.H@!Q][%I'D.-S(4U@0&AR]*Y9Y(7'Q\Z;!97VS _'W3)L5
M[)7UJH'$5 NJ79RR!*E\89Q>6^<3&Q<U>U;J,O;KPC_G?MV#HD_C \14)ML6
MCG;KN,\ZE6YZA8B_<*@R^+]&&">Q;Z?A(.;%1G71CO'D.Y^28K,]"?3[?G,P
MR:>RMJ?G9!/@XL52"#&CI'?-=XR&%9T(FV"30?SNH9Z!%>29FXU6RMZ%5PF_
MYE1$+TN/) X*FI-Q<?JDX'7I:RR\=F^MJI!"BQ&9RF-N7"C7KQ#1S81MW@]+
M+I!N+$/=)$<S=@O3C>MJJ1@U2$KIMBZIIH%M,8S%JIOA=% .A)(:L>7Z;_.^
MWAT/>0O,#-]DM94\CENO4*#:A7?.OYBLK?MJ!<M6CD.^#\$_V\^=VQ[N%&^D
M=6@M)1E#>/3;T4!O1?K:>.S8=DNVY^I=I-MQV IN+QO#BC=4$UD=!(1!"V.3
MI^Z>LQ<^X54/,K(MS+9E"EKWD8L?,P;$B)=/W8O$$ 6[U=2EJY>AIZFUTY_?
MM:4^7YB\E*EK&B,]POG\L4 E]AY=&+UG;3WXS?PC08. N(9$CRL/?4"MM8E0
M;=K=<"4!ACHE>'V/]I878'D6A#!C*I7\$\N61XM$><6?YKQHN;,C5*NXMVB6
M*BJU^)23J$B\0C\-CK#Q$\?I+6Z6/9]Z.8-U1N%4\CP:^VEG05"(5%XWRMV!
M1(84P]<H>YD9[:V"MZ>+%HW7#&_[(]"K+VM%A<?3^N3:&54)(TN9DSWZ^9QM
MU47QVI7FN(6>9Y. M=G<)?WA<DN55U,)TXO]O1BG;JF!7^&; 4/>'J,IP:>$
M;I3WN_T)]ZN?+G9WIB?3RH]<'UF/"=5"Z7':F_[+:[\3()/YFQN=317:4CN=
MV6TP#Z?A;5,&6C1U!NL,%R[7[:1@5<A#.?X&PW;;P;B-N;G;T"$/'-:*%"XL
M"D]:0*-G(-<4P9=J?<8DX2[;I&/U"GX9]>S91?0=\=6 7\UR&/VK/IB-/M%K
M#,6KF_8?4Z :2VVA,06.:FEMZ++'OG#V!PLZ68=/K?0*KDGP?F^-W8XV^0M-
M3 =!9=/?:Q1,-V:I/^?F0Q^837$ %+\;UH;B#A^,+&#T8DBA__DX5\76'Y.[
MC1.X/#%  /\%'.B9/(3<,@D\FH\EZ*K/QN@WVUJ[Y\VE@C47HN#HY*\1+V62
MXC<6_"[R7T0V%\I)#G'];<A^M3289X5OUH(6(KO.V[TX:7="U&VU)L)K<H6T
MLMEXJS^S1W8D<_AMGVP%:C+J[2\%BO8O:--X:\=R$5EK<N\Q1&"K%-DOXV<"
MZU9#R!G!F+[;KZ3/A+.Z#Y./-V\,DQNPS-9L+((\1!QM* [-XF,1 22TE^<$
MD2'Q V2T6VK/S[@U!BC^I"$O%<R;SD#O""66 [MN-%?0;E7YK'%M.#T9&H4)
M\G<7?) &Q$M^(3E9%.&WS)[N)ZT<9E_^<J$]M'M)F8T,1FF;;[KX[W6ZLC%$
M[D-/$XB1$:GUJ^KT(^JQ92V(<%]97@_39EP#N%N2;C6^>$OXSH&LESFM/&RV
MKWV6JO*7UL6?HA4^]C'IQP@I=KT3*W-I:]5:7WBH-!D5:Z:/]QBT%BO*X[:(
M0\=?F_=)X^2XUE%LZEX72<DGK0CEU8JAY32"TNB@($0P4K:&0+X;TL:)PS+-
M$[@F1?&R#/Y%-#_Y%#NMWWR"07RQ^8"T?+YS6>1AUY2=H[X,M>/]^"]HO<?;
M7[N:-(G',%G!'2Q^['C84?B#=B^=,[A4PR*>'W_^Y# C]Z*,@7RMMP+!YG[9
MPO*%FUCXZ6-E+52&A9(39*]\NOM!>;*QVT]P82/GXMG43*0KI$IH%1HQH4>B
MOHNS&[_[L3:U;@P"6_6*'->6&L?KJP=]8'65N/TUB)H/K-'JSWFG^.=54OM0
M4!)/52&R4.;FION\%_WV&Q6,IMOLG$>*5I8CF9')L%B2J'NH:N*4; J9N.A]
M=9?C?P&NU2IF=EX/FR)HD2FH[%*?W=KFD3)1$;:CPCA11;#-6DV-Y#:"%./C
M*2RI"O@-BD?S=5T?T4^+E[-^>]KL*LT;(+94Q!?0T#^$ILK;?@U1)P5:L5+(
MH'&W@+WWJ!;5Y>A/R8HZ\"U@8)HL=GL^&&U,CDQIAHDVX!4?8@BE]]5I^G4[
M+=0 "!&8.@_@A<D:5J+X51V#'!XG8F(D6AA<[%\1')9R6$AU@]VH;?%,GPC/
M</4*%YCKWVM"QEGIV5AX_)&L3*'7JLWOVHEVS_RL]].3,P H,&04A%0(AM&P
M[+W=J'V'A+N M^+@[IX!1$^;9/'C.DFJC1@4*42F60!II:1O'8SV"!^?IL;]
M$5R1ALQ&"V=T">'V"_Z@_:+"_5RR,,IK"&AWC4$$,PT3,RB-.KD WO;3VDN6
M^FT1WY^J\2&<;X1HPKM. ]8E]1LM^HA)I[$OSF-E@PKJ1A]WB;RE=# #9O4!
MKZ]EAM"1@ANAW^M:37OUI5;AE'$1/1%%D&G26%:K?42Q78D8,;$5$T6!B-HF
MZ+XY6.,ZQ$?*:+[AUAU]5-_CA2_;5#.9>%\4T@>M*<(:"W A^^)JDFE)KX6X
M1<ABR*-3;EJ_KZ=KBK(.]&SNP\Z<<S0YCHP4O)<P(YFSY@Q,9U7A5A&?X-+G
MCEQF5?OFD "O_)^<!&\JN*->L(H02S8KB6-*#6MY;_Z=#)$M+-1P/?<>9674
M(#A>["6!- ^2'IBN:+WX@MP<PS1FMW]G@BZYN_TR^<=T QEBTQF#\\V)%EE\
M"B(!H:C8?48L.7U7KWPOC7\C;86JL^5QN<]-2']]-M?9S_E/G"!Q2#.CM,!'
MJ5,$H>NV?/JM,=6R?! B#0UMFW+J.2GN_(DG5T&GR_R-GE[2@B#*&/8Z<W&F
M2PGNO0JC9H/>WHI9/U&02!<8K=&77O2(W-/ZX>IB4/YC7SL%!<UOR$3=2YPQ
M/E2E#2H)3EWLWWA96Y(![;^ RWOG=#_Z6FAU"*F;]B&S=+/1<P?\+DI%W,:U
M/CLVN;ZL1F&K2X5-VXD,W; U YN8F%:@![QXO(N,O4!]T$^R[T'\&N":^GI'
M7F-$S\N.G'Q0K'BP[=)OT7SP%3(90A(!S(%KC(OL]+R4Q-$6^AT>BZ9"YW:A
ML!3+_K=?%%@]#I"J,F57%59-I">HU\+7BNZ3=>N-J$>2^H2Q\^GJEJGULS[2
MSAV.]2,<A39#3%5(C(+'HET;/0LSXA[69V0A2TQ]9! F$J+\@A-V$72[3X?'
M6UD <@DKHGW5P/N&<\U\Z)]\<4A51#I?8T($Z..*6@DX%DH')PA3KO8,'])=
M=W43?KIJZUC4>6(JD[JIBE+)9;U,=K57+?;M?,,U5%^(_83N#5XBAG%$KO?B
M*A$ZZP7XXKW/26=0"B6(>+= ZK!XH.YIQZ-(3K[.G%FT[MI\ID_E(\&7\@.)
M.;_W"8-2/D9TA-]SRUT5QT<[CKZ(LPKEM=+CBM>\-9[AIQL4BT)=B'XS(YV'
M2+$LJRQ2<!A'UV"X\]A\LGS44,QOW\O%VUE]GC VX !*N&%.JC20N7PWYEU]
MD+7TDP_ O.&6OW&_2*2_0 L<YVJ+B<#R^32C1E8)*?+R+ C1,%FC"=+DD9W8
MHH&-JME-5,@;EG*;+!YT%;\Z^VKBGWB400H."'0LB:16C!\HGCDE]B^LI#@<
M9_E%)<)I PP61J3>>[L3T^+3GF[YZL/P'ZW\WJMJA7/59IQC=^3:>]'&2]6X
MUP5)@J/]X9-:A@Z$,>2PJ\5GIHD.T^%'DEF/\P^L"O="18T!96M5 CQ7T),S
MQ4*<]7@7PM(# _RC;42S# LN]/>A56*8A6[9[,5Y>^G)XXSSY/PM@0S#=N:S
M3^>0B\9U/?$ZL6XZ+3B;G5+5W87LW^7QZFMMS%X$<%]X0(2ZE*GC%B5R_C@%
M1=3+'59;W07OZ'<UW51E)"$0H7-<"=N =;WSA6+(KKH[?NG\7#ZV&6N"?7KL
M4%;6_"[C!=>,NB!*&35.B>3(TFJ6-62I>)4YZ2_  .^;D).NQ^0JD@8D-UR^
MU;J:?_Y2O4+UUT(>[RT1D^ ^7Y0/_[I9:5E167WQ@C=YN.<L?OJB\+1A#H.;
M_]4O'@<1\80N3_,&'ZW#-1=*O29&^?UZ18+*E\DX_C12AJJU(N0:A5"=XLXQ
M_'0;Y["0D!VGRKZ+%*&NE_N"P1M2S\E6]H LIPOTW!>K)O[ @+>*P0[']^&N
M%NDBV7('_/U+_Z%!GX?69='BW[+-)V>XI5SMFAQ)DL&?)9R,YNAK*2F>.3\S
M1WY62*)QFT_75?]1H3LFK&47"JW?@-*D6P.FK'MH*Z0J=RB-LD>KTHI4CG&=
M5R&5ET2;%?_W]C)2T,DC4/[J;:1.!BQ\U<$?P9]:NKE8FH_()NM/"4("I1;D
M";I2YWH]'.3XFDH:/^[YX+A,2VG#FB9@Q1XA= >63<F)9%ZZ29,H>S^7X-XP
M#$_(8+O(]ES%6L(\HW^\4*'!91?GI/XAJ65/R"</9&/#.':-PU.$21"*]TOZ
M\!(:WO<-T*7BN51ICZ<GCZ>"W8]%Q8GU),6XG0Z^^T37K[SQ>NC. &/5%XDI
M/LIX<.M"^R:YGX,*!08 V "S6O>JNO:2:=388G+4R?(J+K$I3QCM(D@O5K%<
M._.2=]GGO   $N%(G\RUATCH:4*?_U ,V^6FO#AV(C8\-F?8_EYW4NP>F>03
M:8]5W,G*S?AEW;HV@1.@3Y3J9OHIL#_I;LB_=TD<VV;A$+^U@)(2:J8YAZPH
MN#Y#*S4VW(GLCY9Z\%[=-91@0K+K'D3W5SPAU.9W]W(YV%J/EB_-F";D@"N[
MGUL\"*M6TVJ@0H>E8_M'E;MZ:G7"3.R7]4AB+=5!Z*S'&N041F09V$52HWS[
MH@%F*SD$>FT\;YGXHHD_Z'.KAF2]$_""GRFU%H8P$?X"+"G-6HVM8FN'7F<F
MHEH=([4-?VV7'CP%6MA_PU9)Q?C#ZPUAM%QH'2*9QX(G>; R@2H(P12C#0AC
MGOF.56S40%00,=,'@\J=WJ=GGMH<5AL!D=M.K5^1QX87U@AR'>:_1^(HRO22
M+?*K-2X:R0"2XT-K8$;E5[##\FUL O!=QL?W8DQW\\%$,0Z49L>/D[LQ9FJ8
M<K =*9EE97C4-[-KLM9(AD"0T-.V)< R(<0):G1**+ZK ?.?\2Z'4V%:*G.9
MP$0T:34M833<\@D/G)?)\;S-R=E_YIMR<8+B&P5 .Y<V&&]]?A!=0S!*1'#8
MW.AF)7P<#O'-?;^3)OUH43OA]BLD?>X=!<1OA^7V))22I4?U;W'^7'BQHLZE
MHH5][J7J'8Z76-69$K#\1(7![^WI6T8GQT=N%FNY]?;V%R#"3P%XW))(E\5,
MVJ&"0(2&0[>V;F\+V&9<QL>FAXY!R=Y86T 7)%C4$%'R6+/@'.\>!'(TK,B,
MP*Y2S*1$>*@/8*XPXGG.'\#^/E2(;T[N"Q5ZEKGGHQ0%PS!%#K:TW+E*Z]5*
MPHZP^ANU57F"$MD.V5FR:TY*3K+_Z*4?MG0,F]#=0PEF>"/60*'S[?"3[^.E
M(.D'AX"O52RCPGOVJ@KL#3(2E*CSR+G7NX W6=(YEZ8*)A*Y$9C:8_HL(7!Z
M*GHKRYFDPS*:AOJ1/%&,/ <,FR",+F@5MQ5P"E8B/8'U//<-418H)1W3-@X'
M)G) ]?)35L3(]@(2\HE@8$B"SP7\18X*>$QBDM>0IK%>?#W>.DUOACBW1F:E
M2>/F(WYB,><+0]&>%M'+_P5PR%WLB.R0LA>PW>Y^FY0IW'K"N<1PY+L%U]Q.
M'Q2P79W5$'39*%CQ/LN,L>5X[ H:\PZ3;BE:Q4U/E"')\L%T :9=5[QN/[J.
MMGAG"06.M@)\TK3^(ZC-C/4J5N%!0U:D-!37"K'[N?]K8_$[JV/59*.FJ*JZ
MZQ;Q=U_=I;BPWIJRXTN(XWSUV@+R+[P1;(K)DB]HH)7$156*#=R[CF]JZC;7
MNUXUV#ZF$!NI3Z\0GO88B&_Q0<#[!LGS<5S%8?Y"U\VEY$;*;_M]0Q;*G\VG
M7;8-AZITCQ>9ENN)%OI+8]M+)I,V7/B'$L;6<J $RPJ?M?43C<_W%>HG4B]F
M$*&:NN: WB:/<8=C]JH.AHE"Z7Q(HTZ,M[U8B;2X*B2@X<Q%XI()746$8IG,
M?Y!Y.$?O.RB:T+78\^SASB ('AXA>,6JW"IF)'[.13S '&M4,KG(6%X568V/
M7DYM%\,L-#BX( QZ'4_.&G$O_AN+\ZB\]C&2&G7P&]63'ZI5^>)DG:R*QH9J
M$3EL\=3)*CU,+4!\0Q1 VH.*,4^FA,LM&+/F_[]47CDGNV1"2?5 ]R"**<N!
MU%.VSB!";P$!7V)'BOTXKW]A#C+OQA)*ZLVDB)*NGQ4L=V ,DF$2YL?E!_$!
MI.'D;.>_??GC^1N"/-U2WL*L:T(^3^=$K5+:>HI9^*.2O#4U-LB[=1<TYY5S
M8,A9S4K0R.:%EAVSE@VB@,U4E4&$VX'G50BZV:$9(6</"WJ#?JW] ;287=-1
MRF@@WQQ0SH0+BMZ.[O?;!\ I2O7N-KT6*6CE:X9[7*5-]<V[."S*N1,JC:@0
M&*TIX?KW8L2#TF>H0G:3,</IJJ2F))-]'$\>,(BB,Q+^<*] 6RRM\78:$J,(
M2J"VPO>$^'$VVP53JF$K@AY_;>::]PL[?ES/0&T*!G[O-2XV\N.LBW5Y4![O
MV['<O3[D+1[$W\JD'E_3">:VXI3$NNQ'Y>#936%.Z"-CIW6810I*2DV)Q#W5
M 'X=2\?6""0(R0OXUB<4\1M=_P=U+[=^K7&$F]HPFZ.D(3UX02PJ!0,*"6 V
M/FT16(:+-:Q3='F9"/A(MX0.SV8SK'&I3PQK1I3MH15VW:K]"TAO"$$TBO3
M[+NG?DF3^URR@L['<)_\WVYJS$HC//OSM.$,R\3-0&[%?^@TT.4Q8.V]RV,0
M,C;.W? :: =Q/YZ"O/[4[-HO6KJP-#*\T_6I&B[@.B_[XJ4.MA=SUO_D^: 3
MM,A5YE"T=NYM/G0VK1S27)W0M*'[%=]2D_N;QD/ V1*#7F:;+P*9[^/GE-8.
M!><M/ ^R4H<BCXU,J6"Y6$_F,7<+<;"2";!LM*1;+PUJJ2^7/^3Y]]GPA(=N
MS$S\\$' 3_5X*I((>(094TW-_]DSL<G2KONQ]#3V+^ #/-\-'B,]_0OX9H#[
M!:'T$<C2G/V_!-KZ&AFYDHT8*BGT4))A<*SMOJDIH2L/PO[W)5C 41.Y#)1>
M7 N@I")BA XZDJOH[F_<$"P.OL0!G7[8S]J$H^C\J-GGC2G^!^,;&\.-_ &%
M8^J-PPO?B_\"4E#H)'!Y'7V2RD &MD=6T^X("W:E>/G(A/PW(D13V;L_?S?X
M\318=$UG -LZQ/D"YV\1\^-A< 7JWO(08#$/TRSOO\&),?8+X%@_@:U%I;FB
MKB%T6.V*9B"AD6#XOP!ZN"B6,T]KKN/4<C=^?7SU3R0< FRF;#/;$#L9:[3F
M-9" L[RH[%] ]6]+!$I# I3(OK$P"5:TSQI1HFARJA* 6^C"A:RL&O:!J>QH
ML  ./Q5P77(UI5C2$5>=*H8NNLOLG5YJ%#8L%NJ?@'K12N/_O] HFQ7XV+YZ
M)F/]<MW-\Q=@Q._2\K@TV.WCOD92J;TI$"?>8#9SNB1TU:[Y$FQ=/I$.G>VT
MX60 ^H0HOH#;1&,9+?>>SH180WQ0X8W]N-]%6:9X=E9:7=S.TLXC4MCA:,%]
M6[(!Z7 \2[^,[, ?G&1VJH (^*XZ;P\72J;?*RQH&NZ61.)B^DO2Z#_[E<LQ
M(>'YG.FB28DX2UUB3L'[;5O>SYJ52'[C,6BE@"RLA1O6",-Q9RN9G[@<3::1
M GEG]H):<C,8].+JB-"X<5O [G+&C<%I+A<%05UM!P\!-Z4&IK;W6 W:X4TZ
MG<Q5"W45S8,MTP\Q'>C=BIK<,1%K"A4^)30<T!1<Q6O)>QQD=WN"Q$[<32\^
M#%TUCCSR(QLQM!?2D(WF^P,'>OD8AD;D5)]":A4KN@XBQW[=?H=F!-HL+XJ>
MM4SWQK(64('GB102.9E*$4SV_'+(B7V=5V[9RR\X';7&=K=]7&@%1)>?[3F@
M_!P"Z#E]D%\8,_DVZG$F0D4$GXA)^X:]K"\]G!QS+I\3O1Q-99#Z. )L3D)_
MCN]Q@HU_#\OT!F-!9947+!4#[;6+LI-@1;J37WQ_]\MQ!20NE:8O+QDGR$7%
M*<#P27OAD10PO2Q%-G;U>-[J#LPX$.%V 3S+&&^ERSV2!/&^'.?3AC?A5IVE
M^$1,+@J7QWA3NXQNPZNRN0[44&_'O@;H,J#$H2QSVX9_U0W>BY<!1L-1P9S$
M/DXO2_HEJ(L9,?IJ4Q]6FI5$?=#@45]?7=V/D#^\O$M''4D$D'JJJ"-$$ZH^
MQWC34G23YK\%PYJ.\E/-I)?,:]JU=TEN.PU3;(B$$MW_>U*1_M@]2',5?76@
ME+#]W@?S5A5'"V:4<_]ZD-@T^@EIW@TNNB@@_B\@X^@JSMOG<;B^G@E V<EP
M]:/)R^>TR;;"=K/)^'P2XJ)J"YWPU;KTSXEC7A&(V$,B-P1B.:803_T69AD3
MX?S3367!H"/F^B\@XD]K7":'SIIZ432Y<I!2F 0AE0^26=Q*4/4=M[!M1T#.
M.1-95*=ZPW6'%E*)I4(,_:P?X0>J!;T[YD0F^G4,06!J1"W+N'+ %,.]SU[E
MI;O\=NJ!;AGY7!=_@V F'BQSWHEB8+0J=5T&TMV,5XAO<)PWSW'8Y.^H[$;*
M-1/"G9_<9A9N(-FL0^;W%:JH'V'4*ZH(%B;0]U?+<L0(:*SF8O6HH"Y4S/$8
M14Z9?DI$'K$81%'BK743BLU&ELTF"AO8?/**R+U1:1F6[7=9F"$!K!6OY1,M
M /S\6MJ>U',A08 _P+(#H]6G(J\2-8!# !M9QC2'E52$13C@V[24ZR&O][WS
MJJH^2 Z.:"^DR%6V#UWT*ZDH-9WI2.\L642J<Z[GS4*9>CAM K TN,=%EH5L
M;T@6)JJ73^@6TA5M('C[^*"1(7<9?Z*VBTC?0]6>MOY*ED&F!OY$!4EP?S@L
M9_CFF/COLTY #007<UX="0LU2LRX7@G0,>K0-@-ZJ>@O5<*>;_R.)/T:CE;O
M1J&7$\$,9!PIJ:&A.WQ3(H*QX-)9,OG[JP2U ]*""&F7PK=!/E$:X??;X.%F
M_RDW<;VE=:XZ84-YB1C:(1<DV3$9UM*W5@\$D>_I?K%605T&4M+>=U7")Z,3
M =#*SO&RL"%.FNOQDT]43_5"=\HO2S\Q6Z4YX#D'6).=BA*0ANO4I@-A2-U$
M#9X\(64*X9*Q1K1_<D('0I-#$)(1D@4\7XYS5(0UED_S>.N]KGNI^/93@L^=
M[VA;ED_AH]Z$FDI^E-/;/@ #2N@%91;V7Q\(B?A$E%_(N>&?/[X$G(O'VPHU
M#$JZ(#W+R4/!"#N)T1+=H$?=W]FX"TMZ.ZNHB;H(14ACR\NX)@T+N_B%QC_U
MW!8DF)PS%DD%[PPKSK+0E1;&;Q\1*?L6)FXY^D%7&[XY^1U77#_LW G-GB*[
MTM+1=C\EL^^U'-U/W_#.DHF^^Q[9.A>$U*?<&M'P[A>HAR"2<0L&YZX0709D
MD>_=3:X-E)0VK% =WJB/TD9-F^-LWY#VM\X"5]3CZ/,M)TI**Q,RR)^>D_E,
MVU,Y[UX"TZ/>,$IF'M-4JXRHW\KX/H1WY*ZV#J[]C +!75$/]SL;.G.3654,
M^W*C>_$;'0%F=,'@>=(U<K^+=)794;3[[8K_V-19:B%Z4ZDAI?5>*=_FJ85X
MO?T+\D^G!;LR3;J)99.9T^\@8TU(26OMZSD='@4Z5P;F7C @_5HY\^Q>IZ79
M&_-^YK:H6OS69/A5V6:Y^'(M_;0Y)IK \A'!BR4NH;':XI%R/:.]NQD_J56Q
M?'&\T>HOX+=5^C%W9[?:42%#F?)]7ILPF 2C2)?4 &'_71,ZS&D?Z>";/9=A
M3TG/56Y_]W(+^+]J0Z3*?^H)U8^LC']HJ]T2%Y\/<OPHCSLN*>93MC#@QXX-
M Z66/B>I<F[:HWW.&</]S+MKVIG#RW'^N)^7W_&[JSN0&Y4@E+BJ1?RP0-]
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M! 'L%;1"\F[8%]8L'OI5N*M(>II?PXS[8B@,O4",%FBQ'O( ;_Z-V$@<%J+
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MT6NQWE'"E^>EA%Q$R*NL,\B+H"$K0;GEE^>F+3-U6L4QYXOW\/W+F0_E0OX
M-4[*AHZ</("(YJLNNE"7?LZKJ:1J>*2P&3VC7?R8G'RP*J\(AY;8.V^L+]@>
M%^_<'\,!;Q)/9RX'+1^%'A2B+_<L7@LMGBH? ZKG@)*'%_;4@'C+Z5#ICW@^
M(OP%<.#T"Z2(,OKKCG1NUK7O5A@82#+: !MV)%M.>4A,5DOD]8?76LMNK"L[
M=RT6MEOQ,^9V]ZHP>LQ+IWI9:@DHYK:7S0;L=,R-I,D))WP3![%$9L3"?@1%
MNF'I3T@>CJ5SHPTUW=_=&R;*J%VFT2;4BXG))QAI%)'C^8BFW%#(,] 33;D@
MZ(?$<\(W/;R\'-/Z?]C4-V7]GX=@+!1C2=;W%-.R%"AZDF%=372I")]TY?4H
MY'N<6=G6#)C)D5"\$>7$Z)10_+]>).YM:'PJ-Z!C&^?0T_-+/L5]R?(>)I7T
MNFAN_N&)5G50.I(<].J4O/48!MC5RC#I[G87->C:5')TI*GJT$=X*#E-FOHG
M+QOYW;]."9 %;5#OU5$1R@IK</ABL[E)6$[PG0YX&E:<>+Z6VGH:54E?\A\(
MVX.DQ']1IDD5B4N3EBK&]OCOERTF1JB&87LS"KY")5 5/>T->8E VR4U<:>6
M->3_%)3K'^_KA>V_56#OLXANJ-UF(^,^M]A&3MOT@]JVSW\);RJQ^YW!KQA5
M6T\)CLZ.X:0(DT =,:+\UI?&3WDE;H17)5%M:L73'OP;7P-E;OG[ERB7G "F
M" :LN?&ZD@$U!PVS8.J7@Q8H!3-<GSQ+I*FN*U2O&.V89M))R _"0KG^O>T,
MLKY!LDA^*!Q'<8HT#C]*BL2M[U3ZK8%X7H$X.T+=C9TB\1%F;\I3V<#6XIU\
M=KD?%!XQ.-Q$:DW@_4_ZU4M?:'!#PG:\B!3BPG+V6O?.]CT?QNHN_>_7"L+$
MKU"= 59&S\'[GJ*L50CU9[57TA24#J1HVRA*45'Y.YAAZ51L=U565<5%U$>/
M2I6%;Z-VT'DB V))0<*_;Z]JL@0E2Q6(7/N1.]GNRZ*0A>VS:L>SL:CVMJN<
M@7UD"6,?H5GMBYKA^6;=.,S[ I%!S*6HJ56=%:WGB.BD?P$GMX.-3FQ1P8.R
M$;S6N*4E<CA&3!= :(L[6FY+$W1;I_YI+^,G9TG3CZB\$)%(0IK@$$KX:Q_>
M";SE9>4_*QXQ^@8NE\TG 5$T TIE$ABQM.FP8E^PGTUA:9B8Y6$QV:1;R[KH
M5KTL>:.3+B,KP>$X37\!Y4X/"[,_;E944"\V\C%#X4)C>"?#7(X0#C"#Q):]
M7L-KU/G'\K7,!937OG^ZV\AJ;Z.(I,/U/$F?TT=BQN+>J6(!>H6CP\'!KR;+
M8VO$?_VT;?RGL]-P!ARYVJHH3:E1A]"?"4SI((I!5 SD:JM+2.<PKFW2"=F(
M4 EFK]=%ZXCI/:]EY,J,W!4%2@(B[%HIV D9_P=A;QD4AQ.\#2[N&B! <&<)
M!()#<'=8%DC0X+JXNVMP%G==W-U=$]S=W=V2^_WOK;OWOMS=QZFIFJJ9Z7[Z
M>:J[NE%#OU[PLS*=.)F_-&X"?]?;+U2L>JAEF3X1G#JNI<^L-)#^ T2=:@*Y
M#<1&;PY+95][EZJ  J QDLA^X?1,IWX1->]/NSESY,TA.408IK+]VUN1D@68
MGZ2) IEROW#]$F:#(\$5'\"E8+"&N\B&NV[V_P=0?G#E1?$?.M?5=8^H*S$R
M,T+&VDW#Q M7#+J^^L*\&P.'BM@AN! N]1$F2-OTZ[N.@85.K%BQNE4\4\VT
MSFM)X(]$,!.V<MS..ZZ>S[.\R^%"X8./+:(A')5OX)5(Z*&[@='656HI'U[#
M=@+UX$1?/UZ2,3([9FG\6")?^#ZQHA'[ZA]J>#A4@ZPWAV:4B(>_LT-C@[N,
M-L\MI<,HF$];&V'8QLC$F/B[&72V%_Z\-!&KODR_'*3PSJ=5;*BHT14,&9FW
M<C,_/(4_*Z/70BGV,O&5VQ6_(K^I_;:18VWC0-F)L#%XIY(93:QEZW4Q(L4:
M04L@G^S]!U <<+^8>C;3M&:Z2_@D2R;&2,M']\A(!9=XX7#(?UDY%>[_G,_Q
MD9LN885_Y#MF8"Z<*( 4 #A4_&.J#Y3WSCE];^  ?'^\OY-2^>HT4$ A;"3V
M#T!]_E>;/QP!+3CFBV]X9LJ]]=N?')%7'S491N%*OT>6OSD+(L*3.>]=L/_9
MNWF.C3]4^9]5N1S?<Z33?]%]SZ\*QC 0-H(S!FQ44P7[!1<\9_HUN6 _*,W_
M#2_=.ZRU?IO?7?V/POD5ETS^W00;$+8XE=E_7BW6HU=F*"5=*Y<-A&VE@%[5
M=$$8&,/CM'%(%2&8OY+BN.\,3?LY\1C0*J@C37 3ON(1,1X@\G3K /E>#U-4
M(%IQ(N;OS[X:CT.MRF6+Y8U\A$!6SR)[F>R[""5>]5CN!@G%A!/0FARF9P("
MLP4/^=XA#.HIN[OBVD0JV8&H!N#->_(*V>: -P[&DQ6#T??0<5L,BAFA%2EX
M8([6OP,P5I$GL<<U-7H!S-_1F0#7;+N1'E!"J#WQNZ!UR?Q.+N6NGW9"SZJ(
MDX"6B&:YUM%?9[YF=M"V."XX.,1!NQ4_5UR:X-O3Z!E.]H9+CUGJ2+A8&\7J
M9%]Q\A;%KH121_O;OG=*_+J)]FHU>'-<6@_^L1#$/+-26+P:<[^)'EFF(2ZP
M0HA"63*: ^>DD\*8B*9@)![LVL,,&4SYN.'-RXC-[B7N;63BD(HHV UOLB3)
M;C= K  E-T+DYP#X%:?M47-!;!4<N5^S,>85?#C3\V>,1WT^F X7]]I*YF*$
M^VP3UMR.>'3DS;5LJ:'+0P];+ZNBHR/=ACCD [\'#^)9!/_L<ZOHJVDQ0\YO
MD.=W.UXTV-28#/F,[^=,)#-W+52'+$+D]1^%41D19MLJ_'1NEY93ZGJ@9SQJ
M[:>1D>5^+CRI:7O*\UEJ,35#.7@@#8OGUOFA9$S2W#340#@CI@B#NA#&2A8.
M%$] _58\V.OW=5 B+(OBX"J\CYZ/PS;LIU$HAQCHJA&U:-X<)<B>NR!&I>R)
M+9(WQYXWO:]BW@U.M42#"6JH%/W#BDM6>>+7*98LB&XX.#3U'K?#$,(^!DZ*
M$2U',3!;779\T!W]NJ\8R5<L\1\TT#"8P=A[ 1\)V*PN"*Q$B.Z<!O;^ =QT
M"D9]]ZLG#T3N_G:O!OZG-59/HBA4R@KIJ.70]T?)T/A5Q<?P*]X"@$Z1\LEA
M #J"0OY>BYI E=]MO3%V]DS/BT"8X^'SFXL^QP\7I;4FSXZ6ZD]_UJ+M5 OF
M3IG;3VXMV6FGF(GREYPYZ<NAEB1)-[-XUIX<CL;+.LH"AV-JZ[LQ^K3&_6%A
M;G]U*5%<:8PBF0#K*)X"07I'LFO!'%2HEC6:P!I$+:JO.\O"IK>>+PKU&<."
MKB>-K<Z"X@48D..)>M( +W V1XJS,L1:LID:9%*D/JLDCV 5Q?\(IH,'HR%:
MEQJQUVR/$V\8,GKBB@4C:!,YND^13JE^5C#=+,G)7]+S'OM?[!C;897D8?(_
M=4@ 7[&5Y,'?R_\X?'N=<PC;53LHF"_?5Q$$-FK\_S5T/UA<,=0H;:S5]($-
MRA=(-S>SP+IR7/L=K B6%4JZ>![MF[57FBY:.(%X:S$_Q5J89O:FS 12P,+X
MGN.Y@17BW]7+X7U;D^E7@]2,D PJG;ST)_9XLQ7*/2&.?<<R,-_.IH4_)4(V
M=^<-30R#=A^(3)M)CI-TV Y:6=?'[>QW5@EX]-7!VUIYRSQ0WR*%X#G3T50\
MQJC).; >NOIX2.G#&]"ZH"E[P:;>4V]QWEEA@6C\7JF37-E6>F;N@E]S+MUL
M6-6HT^%'"G<[CV2&;UJ+H]4^KA7!@P%K7MI;@0!^DF!P:4/Y-RSIL9Z@#+AJ
M.$?G_+Y7Z2H!(6-KFQ3J40_6\<X]5B,I 1/>Y!^!/YC$BQL_3<O[C_F#-(L"
MH)\_C(_XZ7"\?C)Y$J7$^QDJC*G)@+-%Q>?QO3N$ %0LB?J!UE].L+B0'UNN
MZ'W\'\#\C6AQI>O+@,3VF=T5GJ%]_#\ >[@1PS;FD^02-56:ZI"Y[7"G)RXU
M0IBV<X'R1NFKD'RBD1TK<*CY=Z_Z+TNV)<BB>9IOZY>VO8.Q*1G&U/>=N-S<
MHOU!7^KI-\*Z#I6F-]Y:#E^"H>&Z)DEI2=!5'W,"XM?>3ST*20SR_KCG[<2D
M<:TY<[I:84T&OYK^?!I80FWJFO/_$VG+0&88=K#!0'X<4I"I\P\P$+@E+H:Y
M^OD^:PXSU$1$L R-FG7L24M#9>4Q8^<?@"HAF!I/CXT';21A&>SGL 3O(VX7
M\@^@1A/>B[WZ9'\11_/7D(!#>X+:1^)XWB/\6B68'B5EFQPJ@'69S'SU)XUL
MQ.\/T\ U7/@!(L!B0=?'S>:138BMG:U@;NC@VSM#%OWS9Q SSNR*%A&9 U:H
M\0SAS>=")%;HM;@<":*)?7T'WDLB3_<UW9&B:+C,K:[HI_Y77=$>1U])-G.D
MW1RT'DD\=YQ^3@ 5<?'/W$C664=%M02E<7S>J)2/%,[.C\AY;8(CD82OSNO<
M\HASFGL:R=8?J7VMXXS'7&EC4FU;65D\%.MF86#P%\2BFH0DF L9SO&7$\E/
M?H2Q*Z_J))QP7VTX+K&*?J4!&4*)=:4XT3#K:"*#+S/[PZH+SS?)GY"_H/W<
M6GK]:++MVI.$Z%AD<T96ZHBH'AZ['6X^R(X'MXD[Q(+G)#Z\$&5NV&;?3(A'
M<(J.))X/*\\A=1F4KEQDI"[.4G58V%O8%J$."8-/\-\2'^-S4,$F?:C@#>&Q
M^?69EIR&3-(HGG@[12B*>P<*4IA;A&H='KU9-ION&!&3Z=-(PC/^ TCLRH72
M?$4&&[MD]UQ,[6FYS9@O)SU-Y4[G#H='&,Y+F@DAYY%#B71!FH=$6W0\30LK
M<0C^" -,V'3D/D_>%$,]_9_'>L8#1BN(OR/:<D:YXEEQ=/J/>G^?L%T;"OHU
M8$0;R=<O1>9TD.;_(Q_O RY-87@W#%\BL$7[X@$"*5QS7G\,88N]OED+0RIK
M)R0"WZ7:(1?QA?_I9^,:EW=) H+BPK=-MO7J^)_8W9<3\K/JKZ93><7">]E^
MX@:]LP^V()]&-AES]XU'XI$0C^13]WPZB"$?V70+G4/4C?S26K+)LW-\'#<W
M=<J<FNI;3O!2<,;/('9/:LL)"R]L6RW5UIP=H<\/8;RCQ TCWCQ5""6I4%1M
M&(,3L\?@!-=@G/T:Y?@01C6:ZQ^ 2H#I5[#OL^66\9IUR\*U,0=W;;"AMX^D
M2]?$3&AK^0,0G/M&C$$;CTZ%-RXL=!3J0+N'J1<E:2"]/1A+54".OL7FLU9O
M<\*JOU4%IHA2+A E1(O4$,@?E6"1U8$TF<K$DA^NJ=BOF-"+R40&*C>/]*L,
M2%,'XAO1^<,]?U=-^.21PZ,6O9)^??-2';QR4=Q4[T$-+EKA)DW74* &[<PQ
M)>)Q-VG$X'BJ*A[,K6:-6RGFJ&[=FJ+ Z5SK<'Z@P2,8(9;>POTNJ'. >_L3
M W/>Z(^(81JK+<Y9NV7Y6$ H+ITLLJR#PWA2>NU!$K8\$!X?G'BX+S1L^]ZS
M2([86M<;YN:.&JU\S<VJS5L6'K6Q[H#9LM98VHJOA<U/4%;#DK A)$F0^D,<
M1)23)4IWPT<7R)U]MG4)P"1/!V+3EV:8N!3IX<3O/@C+DW=!#H**0 ;CG.HJ
M[NA*WT,+2UFKT450;GGP3P@T,TM:R>I0<26^K<"I;G$I2Z2OY*?4CNR5DV/_
M,/,J+M/MA+&2!I(G["BQUT2,<:4W(T.IF=3E 9+T _P3=/9 9A"80/:RC#I;
M4H3*O5*VC-/0L>\^/S1]5>+HSVYD2K7V!S;AE3WA%*.\DFR9=0T-Q*9_  +N
M6U1_PE);'B]\_ 2G-7S.0/#(" .>/;513^.)CCH$R*QQAI/L7;U.U')/.>_"
M8LP$MFQX85FDUVZG:L3F"E8JZH<4%LRQ."RFB6\X__(?-Z4S!=(%13M^%TKC
M)3#R2R:VD*0CSHG#8S\@JS6!2&V&[^H0+NEP=]T)+=4>\5H$T40 &\D?H0H.
M:8V L?R6'][%NA;9D5-$B;TH4?Z&0" MX^'P5LG/$F^@U$T_;G@@,[DHE;E7
M_=Y)8SB,C1E&QUL,R3]+,M"\#8]ID(WO4Z^JZ?M-42&>9:BKNX<H+"O+UZO)
MC[U;L]@G>?+FSZT0GA4=Q6[U8_E&[8?G0S.9O&:S264>DZC!^[@F?]P->$D^
MP3!;";?(G"H@?K-E@L&;@2A@362,%I'SX]Y+D]01:"66P_C43ECAP*+ AI6?
MT+(!*$GZ+>W+UWDC#9[5'/+E+V,.PZ38S#"*@LPY"C8"EDBPS&?\+$A&Y)!R
M**H92;TH8A\-7KRT(W(0;Y-TV7R]\9[6?,90<'^"ZEU)8![[1(HV05E=O]H>
M4J@[91"UE'["B"Q=0>\.*NGS_C\ 'E[X(,(E97)\+=4'7,089>"BX]%<[<1*
M=/7:M9:?S9&U_@?Z>YB$AL0LUQCL[U%<0HD_>S@H@_@;W$%^=9(YK0[BAP"Z
M/N+DOP=.F@2=)#!/)IVHH[G;]XZ4;'))YXG*H_5(J7\ L;6/Q[AFL\RE:6@K
MY"ZM:C3J&?): IFG2E_'*#WT"XX5IA>'Q),;0W*+$&K/.BM%$!CQF.Q0:>#Q
M,(:(.R3[5J_FU (<@575*></9$1OJX]8K;)%TQ;39?@Y8'=,45.[F;+M4?G
M?DC'3;(A@*##B?X[.I":*KN_>C*-A[]VN$4NDI9 LO>#1(<N/^G^Z1!X[O!1
M^-P."+Z1?FRZ6@T$QY$E&<%;$IJ:R8L)I\H&$^!S/(WL_O+*4D,TPW=3HMY@
M0S5,^3#-4B0HO*GW4?K^H^646[/U:;+X!<G#6]*D_RLW3DNY2AV#C ^.M.G3
M4608^:^;0- V9("HEP4(,#;0'QI6[MOQY?HZWH?)WW.5_!Q A[]A-@G2H.S.
M,3#J$BE:KRMTWC?7)1#HG#IW+0'J<%O-Y$];8\T>]\]*:J:':I!/L_-!OS96
M%K'* K7EU8-R"JR-#\_1ICX@7-C97MJEYN.!P]R# A%0ZKM@NLC4(4_'CQ>K
MRNUCH2$M09]#N#'G/HY!-<D,;R4,KX1Q#K^M0Y"2XHX/)S#I11W@20Y?J;GM
M+MJ%0T:,=AYYT-FZULC?5K/:"X9A:X1:.BEJD7OIY%AE+AK<Z2_Q(Z@-3S0(
M,1VG8\^@997/%.[/+EV2$;?YM,ZHHH+3_FYB6.)GPT'=7-JCMJN-&WDL2:N+
M7L&OKD.Z_5]_+S^4SFNN9JZ95$AE>?*%2_Z.[VFYM:>\*W@D6P;%97]+RWFC
MJPX+ PP8TC 71F\]6C55  Q!UE8'RY;QY0_C3L=:4CGPY +TW)NA 9,7;4YX
M3"ZRUS/&\'']2C39P5RA@>B<@ZP/Q$,MJ04<DD;AB022"7*.2I/X!9U2L8LY
M%ZU(^@M7ZK"G5C@;64D9#Y UL6*8,JGHWQWXUAR@'+/LC71^K S7BUN5!VU*
M8\?B(#W(K-2^DYH92\W:CK7QF[@.F@3XOK('[)6$A(A]"I)6#M__S<1IO[+(
MH?A.XH,I%ZUD6?KY<VG8[&CN+HZ,6[.CYEQPTXF7%W-ACA\I[6(80^7M=C^M
M1EI^&92)GB[QQ7AT%*'Y^?F!_![51X8EO\=,P39!VZ4D4NNX5+$M;!4;,W#F
MG3.)+SY!O!LG 5N4?8P]3C;\N[\88E@>#"ZBB'SE!&5R9KSR\OUN>;W"ET!H
M;#VK;K6TD6?-,X/HM8O5"R1YD Y:=AA1JT+_#51\6/5HAL\,7PVG;LQC3!T9
M)5]NV2_Z%.!GU#*> 8,DU<U*>UYMZ.4U4J\E#9WRG+7G.$ 4?"+WF7_2@8^J
MYLNN?U3,K-OOET4++1K_]/1.ZLZ0@K/'L!X:K#[YVLV= ]J$Y!7\4++5,'!N
MVD!>%TZ>IWB'>JW&GXWJEW7R=!$=ZBF!/:@/X13T?S6C)_'1?7Z<5E4V'MME
M?_,\AFIQ6]M6;1KPU%5;?[UMM/62I%'O.\[3!<L/MAE+R)32J%:H _&/\XJG
MT+Z[&K/8T$OM->#;>UW)F#F2W3V*N&3NOUL--7_T4&HY?W+U]A1M*5H'G4S1
MZ-1"]L5?QR]'N5OQI^5BI8PRU06D3$>+TVGI;7EN_.G97H7>)_N!)H?*&(>?
MA1Z6HV?3A)&7;/\L77QK,T9-5(LRM,4J<)<O'G08K(EP85JXU\\_([:5O3-N
MI-\+9GU<M0B&'04'>*<8%SNH1ZD@T;-NM8&7U*Q3#8@RMTYJ3MR+YH-OWV?#
MQU1](7COD_A]:0XWS801I.WX5II[*,:3IJ6<V[*>'\X5)"T;#A>QP5*IXR[H
M<1--)K74(2W]TWJ&BG(2*MYMM*N/[:OM&M^CG4!%FF:K9^!CE872VCR%TNG=
M2=.72J'(,)A1^U=X,)UT-#4J2S3''G4:F69H !-=W+OS>6M%699CEG@00Y$>
M3/V88$FQG<94N81-2""',!E;WU<R+;:1XIOK= CSX1Y/TN$!VF6^R)(0$!;U
MP\K98G9;$!LBX*4X4J(4PAP1?R#E4?-BQO7*EGKRJY@@3-LAQ4#A-TP@Y(H*
MWVN1#9+A&1-3%RUIVMM39"%*7<*>T,C,HFZ*(9[%(I&'OMU;5(&84!B0_R,S
MFFL\N_,@=U)=CJT+-SDA14@\KH*GH?DD1@'4RES;:W,C 52O9J9F$I6_N>S$
MN[0E<9Z<,)?.[\U?Y\*(R1PTVJP$V:)+UEWVSENX$!,";7+[RV.N8WGHFG>[
MCT<L#^:T[8-+Z1L-+56GE2[6L$FRQ%_(B>3^5RHBJIS7SJR"_+KF@K5Q+?TK
MRT+T.!F'0'91F> O@=4(7U9QS.2:._DB 76(4O$<*<BD)W76D;82FYJ.P&KM
M9KR[TK:+T]338$4H.'^]00<[EO]RM:W>I;RKWF6>7L^-<)0[G.,X_H-VY0+!
MV\DO>1\!%MS2J;V6/7>UOE53.+8*?%Z?&\KZZO 5>58VZ#R*!EYI'+5Z0=G"
M\0,H-8#H&X^/>>EJ\MA"<D'3J@4H-7R<C9D9:8[.B2X@G]QF,N[ _?GKN=+V
M4A2M%Z08$C78FH-!ZFC%423J+)T\$,=7:O%=CL3>]ZNT2E?;9<0WCKHWC?H_
MOU?QZ7?VT/J<"X3!K4.2XA\P%/ " 49K&5++WHP[E95;OTN(YI92(UHL;^FE
M@,Y?BR<2,8^,PF7^YJ7@1C*$"^FM+3O[H.1%MS89YF>)=30S)"(U$UQ%J;29
M29B,&-#L[C<1!4-;\D.8=ELA(ME=FS@V:?K$/5L/KJ,9%)0H@?@#K?C;@;JP
MX#HR&3;<W\18N)A 34&_ ?4.N8;:=AVK;1.CVI;+J&MS94Z&"63C!>)=!IJ?
M?DD)$(W_Q+JQM2Q?B7I+>P6T% XQ8RBWJO^&S6VRY3JQ:IUH.88_7BD6+22&
M;X=#4A%/X^:GSK74(B*^82)B/(UJJ"X-KG8%=[,W4VV1LYW5B.5"]SF.,YPW
MW]CBJQI["+U2*1ID#[H]Y%@'#EK6&_8^M1%T9?I/=L,%4'TT9CX]>#ET?/P>
M3B\N%PJ&;Z2B+&WJ-.">>O5Y<.>UT=,0^*UC7U8U.T5A%?^(D<!\;R VDRNY
M+#:50D$MD[Z"-G*[R:@;//EQIR"._6JKIFZ_CY3X)R>O(?9=\&"[+[HWGS"=
M6BIU> +-.DU $ 9Z.[HGX2;L:&&:258PK*T_0=0>>)DS4K)>4ZU:VF#>39#Y
M(="IBND\/)^#^.H[<RC-/\")_ :%9)QO:W69[C;@F5XA3 +[BI^3"TQ0@D1;
MX*68$&)+=$R 5&0>O2J$F)1+#T>/C0W'#*#@.\@%5Z=F&?):R67A]$>9G"VY
MR8R3X;O1E M%&WQKG#8D.)-4Q_0;4,9-P.G#2_S,#A^7TOG;UD"J*$OQ3J,5
M1W?A+:N6.^H@BB:]S?M^S26 P068?]98'>&J!M03D'0<V_,TG@-:"CV;"Q68
MN9?I5I"YRZ7J?O87"R4NZB?#@C,+1U7 QXCL3N3Y8)C"!_=5EX-L%%M.(,&B
MZ<_D45\4Q7RN=.7FZJ]!O3(-H;8&3Y=I[G#4[#FS:6:\'Q@[*[@WFJ')\:/,
M"!$(I*>W/".!)O:]H?U__*6(0TV6*$SL4R/P)"U!J$5)@6B.N?A;P:B&KN8?
MZ=+AD49AQ5%'D](/:0<BYQ^<K^HW_P&LS4T"?B&Q9(-%$0[4Z)Z%7D]Q#AW\
MKOB^_ /8O"\H+Z-KU_HL*EX>RK)*K:PVGHKOKBE4=9-F1Z@R0:V3=9\<D\?]
MRU\+QD#D(! :UB[B@[#+W5;35-@'N"BT$'_\24P.<3YD5\#\V5V5I,(4<B-<
MY(.02G:F)TXA1>H%2X+0,KA[UN<[)L_>][M9)9AB<U;V#3XBM*6?OF8')"\N
M+U-< P=XG&1M?-A#UH71&UY-#Q,8<(G,387;8B13'<A13^'""6O8TL6ABBBT
M;7#=N5F9IZX)S6!3RP3E-,Y&D/GOB;+AHH<9W_4\H@BYZB]&ZC+@!?4-8$IF
M'9$M],>-T$;#S92$1J^[LV [NU@T5938\\HRNZ-\M-GB2)!/B.N@*B1DMI;%
MT+*A6%E^N_C/WIX^DTOXB36JZ+S2_@,TF&H):XUVBD_+/6+/26S,V<RF8%^.
MQ&2DLV:^]V2L&)%H>*S\\I16';MIIFG6\!Z^S]2JDK#2%(=';WVVXS0?C,:W
M%^<3HU%+.'0E1E2\2MF@W0>H>YS5,WS"%>-JI7E>U/I6+E]Y1$ZY8DO'_P]@
MX95?]Z+SP^VAR4.B(_&F5$X];(XB!_ ?%!(DQ*'1W2\][-D/H5SQ"0@)D^OG
M;[VB7W]O<;KAQ&?S^6+MI#4_W9B?7YC5NRY.1JP=O:D*!(%P")BE^L#XVPH1
M='L$1<+<968+D7S;(GW;VS]EQC%5(U,C:LW-B6:I\@203]>]3&%ZNLXYCC-,
M/!/K;;[WW=K18 ="*Q>C1H92H "Y13%+PYQP$?*<>RDV#/,*C83B;>'WJC_Y
MTIYL0#0Q[A9&>F1GOJ\'\]RT:[/*.Y70%QO6XX_KXW[:C_A=-.)'<PJA&L*?
MD?6=R]@QOQ8&?RL.!P?C0)7Q91<$56S#KUF1/Z)]1:7R1\WW3^S89/];(*I7
M)L&C6.<*8#?:FUL[&88*1>C-OD=7LGLP.KAIL$RR%Z[?)N!W7^=1>X-D1[Z)
M3B9NZKK=PC)SMNQ=_@'VTQW+8D0&/++3'GM19(CR96D=FK6H#3<>G7>$U/X!
M!H9+G[IR;J?.\^T">G/^ 117%59#6FACKRFZ71@+HE1A%1<,Q]!R?H:S3)!\
M-QX(_:E4!HTJ3I[C)CX1QC.*-(2"?"9EFB@!/=K0CFH="OKSI:WP#F+IP/2?
MR2C-L6:&%&DY[Q,6[B9HUG59R0V/H?5]K:)R%!A_7E/\[_N ^'[[F:NQV,MD
M?N&W/+?W=QI^QAGJ<+0.;HH W/BH)GM5RSH%FQML\UEE9?7,+\U4]ER"MC3$
M6_:*6S/J8"$+.P-EBUVQ ]\3&1D>&/!_;M;"3-)^F(TF$L'T?C@2])=@"P=B
M^+:U^ ^ %%SJ=#.H7OGZN\^9R.;MT@6EP%K4'WO;MAB T+BMB@BWAAAWH+;)
M/YRYM8=E^#;%+])K:/UWJ>O-TV3DSNSQM<E*1H8H'0PM<7 #,XL$_UW\T^>P
M%3!)-OQT/7ZBW!1=)QI)N64/(1 LVF),Z[+8?9.X?_ ;1D+Y[PU##AT>=4L'
MD5H*W.=PN'_YYV,$8Z^W>YF8=S6,KN3 TQ(0*W+0M6P$)V^Q*&</M!"-4/)N
M&X45>,E),EU0'.\Q$K]7Y1R_&C_ZEF +!>R(J5 1_@JH"%V@L5'W"^I+Q*7^
MA4<L$:<+;V&Y)R]TA-58X.*GQP6N+K"6Z\FM'%@7UP25H+67.&HGR%"\W>#B
M)7E*/)JGT&2+T4'^NGW\!T (;/\'&.>M_OC[,LY-XPG+UE;@UD#/Y*Z^.=EE
M;'[MK3WTHEI<S#;VZU69H.XK%,C$PK6P_Q)N:+4%<*!B9@;-),#'=-DHSV:$
M!VWW,TB&RS'0,F MY=-Q&[G!52$@.)F2F7R*2H#L'Q?P>!&'5Q:$X<O YW\S
M9^'_,9F9N'6X3R)[IMPR(]?E[PP7EJLF;YQ'9PR 5^8K0:!ZE!W"K7H&*J,]
M+E!IK&5[GB:#)3GBI-'HS(615>QV^,:2OA7)',A=N:B)YS<U),'@$P"]LOS#
M3Z^F?FHY*)M2G[J[.O5T%<20^!C1B.6]$&.6SE#L7KPL_'V9)@3)IZN8'!%-
M?KW&"CO!)$(U7"A>93KISHFV9%;[\CS*5M(AETJFS2D<-6%DD!"$%8G:N%=%
MMXN3*1SCZ@*T%L:QIY!<I(C/?@WA>L?O2IX8N>TWG>WS'LM3>MU=X/&_EZZ/
M1F?1YL!8X+>]M:IQ#->#:![*LC-G635TCP?=!%T=LA],=JA7+I,0V9HP),RO
M$\AV@T'.T>N[V&?*NGZ0K.5Q;M9XD<\J9H"/E1BW7 (8.O2SY+X=,"';\XYC
MKXBF#&/%Q%FLWPK<OQ=7+043;123[A]!KM\LDAY^CIEQ?_]:9=I3.*J#,"M&
M%^U2%"!T553UK*X?I?1B7L?[<-3ZXAK;E.RZ6G98W\;9":N!=FMR_P8WLH5:
M9C3:%V]63%./>"))SWWD@Y3>/;D@K[-;UAG5-<V1J+)5KL<EL]Z7<Z^\D9ZF
M+C%\?L5NGVW<['86*' E;[:_)RB?B759KO<[6S7W+&X!_B%Q?BFJE@\2X&)A
MA8FS$$FY'(6')^NK3W2-EZNGNVWFEYOSA.9 7%@:R3V7$LZBC%9J/OG&ZT8[
MG>FT1U@L"Y9HVBZVELV3.J-J7!."C&42E8+0]V-%[YFY"_]@CNTE /2DF['=
MA.ZVVF?^YLWC+&4)Q&,C-F@1/KA.&W+($CRC9U!XNI*B(Z(<5_H_9\[%@KA&
MHA%33% ^;1'D<NVE/?]=<3ZU;RSP\G0[L;9YF#DYN=/]I-24$=70^7ESP75-
M]/C@=]5,F8;5WZU6BQ&S;N^J:J!E9=ELB-B///7TV",.@2+FN2;P+!6@.ZWY
M2XW,Z)/3YT?RSI2/G>TAG8+TWG;KJ=F%O%U*][5)T8DY,UDY/QQ+OVN!N*/J
M>#<^FG@U#DCIZG1^1#H$I33C##MJL;!MY.57Z?@GM7Z&'OH^5]H47A0_03R*
M(5F<3H_ ()NU+)G[17M;EWG5+A8>/:L@7S4WY31&.PCW1M5J8X-8WIIFM&^E
MET1>7G'IHW%M5@Z1]7%X*K9,YTNTNT%68G?;I0ZODV?1VLK?X567]K^[#2RK
M63A%8_I;!JY"#*; 5F"\=JT;3Z/#>)AJ(O*W,L'&DF-GMZ*6)A(]H?O60=BX
M3Q67\W;Z4&"UD0LWHXJMG9:.@5RYK=#@@_.]E_B:U?EOKS5-5FN_AXTT>UU%
M><_#%M93Y?R6).9Z\BU=&)LD#?Y$TU2U'J :G6ZORJA?= WCM1.E[02R=XJU
M>>8UNX]0?'K<JK&DZDHTOX%>5,M6+];B^O([1RY?[:2.K(I?+.F\)>4@;TPW
MRG_V0*:@E,7G#K'PB^2AIG?=3>M'.!>]#V7953R/5LP9F>>VV^OMCGFM@D6S
M^Y7(R?=6^]GGTH?-L*\/H1<5NCAJEFR+>VIV#/J-17JLHKHD[*?%LLF$Y/>6
MT)=W]3 !Z^JV9^+VV073ZCEXUYNSM?35%-.PCM<O#1.KT$\Q%>U^S@\G>HV&
M];[K*I".3YY@SXGRDU+]CI.1+BU="<VUT(04-;PR]6-7_)XKQW41DY*%]6<]
MS\<'NYF#H:-ZDP(P,13=FN.+G3[74$X$?6%WJU82K-0CY%I;XTIE:)@Z(8;O
MW!\8YIZ.BT+T2FE@IK.;/_J_L\)$9><YOJ4O)?\ 1Q=9_P S1*<XI\]_M9DN
M%?PT/(AT-/+1_5W@N#2XI.QFQ_K&H/%+ /M,W^Q_@*I(MT<?[W@E:GWUU2,T
M!$I%>*'7OVU46*<G!C-C#3%4.,61I=.$8>HC;J*JY+<).-X(6\\/+^_<P9)1
M<-G%O_<BF^I[^6\W;WKV[$7B>E[>70SI^M Z?5Z\$+6X$S[+X+UNN(_VR-(Y
MHLE1?G5_)_#.LJ;K_W2R'L/U'@F4P,HC$P-=R?MKHJ+P(](!!/U0A^T6?Q"O
M+Z^Q"P\UCJX?3]!T](! H'PY.ECB(9V_7\HL>6TIZZ-""IOU7K%QM!#:BULF
M*_7L(1(C+7D$,V.,LE.,Z)Z[ZHA0HV'$&K>U0XH.Q3""^7U)PEQ:UB>(S?N6
MM7NV'EACT#0J_D7B"W698E0\=,CMTH5W4$$A"HJ79F4(Q'S95D!@8=2%K21N
M]Y,Q <0M:!QE0_QQ&Z/$ 5X9Z_KO?T]M0<&T;U0/9X*(_@!Y411B60#.K*XQ
MO&Z8P$'D%M73RZZD)H5=O'R[B0FV*$&('WJ-S^PFRJU \  <A$6WOMBX6E*#
MG9TP/E#CD/C\3-#UO.(G7?OI)ML+X;G9_W?%)(NM.7E'S'\1F3;N1@3WV>D\
M\]7ZPP=TC2/!%YH!"3G@CKI_UP]$ &%<!<S_ [2\!C3I8MSM8\0@:13,;HV_
M/[C<^:'M<9-^8,'F57_[?T;^G)";'AW=[0AI%LR6*??;Q1F4D#L9?RM>9<,V
M1:,BQ/?./#6*UKK98I9N4F#.\$PD.=@;#"'B2C9NQ2O%E#;$X24<?"F+#)/'
M"(],D<^R^DJ43.H@)6OS(9^GL?R](_ESE/A:\L3(#*PAC:-,0;V1J<XRSD2Z
M5/@ (0&(MVZHI!RW!6 ^EG,Q1^@VS.?UU5K8D#+I:69J&*%)@T]1"E%2!LT+
M$ I_%O!BA3$#(3"U#%L!_ 98T502X$2%,#![A=9!^/)P\Z,65,H?!I\$N_[-
M)/F$I_ADAHD3LA/,P!]9R!PBHV#!BKK?+=N0ORPGBR!)O7Y[YN'@=50U6M2?
M1CCR==D,S"LJ,6U2,Q$^R9X@3]M./L><0B)>&\R,2%#(2#R$*O'<K;H^"VI9
M7H!VJL/4RZ! (6">:J'C:Y/SBPE:8BZ4VE(G[D V9B^UFME:/=)5,+I4RI;^
M!S8+G;FO<*8,9<UWC4_H4V7<U!$+Z]W ;Z._Y\PX@&&*27.MOS%I3))$2"P]
MM>U7U)BGFN/&A!!966'1N/[Z]UB;E#8I=%%FH6NI,ZM%ZO$TS#'%Y+@T*-JZ
MTEEF7U=</H>1JF-VG+(2,"&O."@UX0=*A\_1-%YV),NL)76'I"&*!J:J+[PF
MTJ"J!?]0EA\>9 /[J<PDM**TEWD 61@/]_/+#W//!Z.5K&S<7:&UY)&)\/1B
M3:PK@F@P"8Q[/'Q[LT]&NLXL;:0>0 BP+Y ?,X%-C2BK:P*UH64NW4;;&874
M$Y%IBH:3"*'B<TM_30%U[H 6B7T8J8Y285-#"",ZR;3TBQ8O26;,#Q_2E$H,
MRY=ZPD<F9^BB<?,QI[8>SP>H9@8]B8(&$KMI8YQ_)L^1K'PRNBPH -@*8S>:
M-:8A8[K>D;(HGXXF#-VM&?EQT- T*R>/3["3O%,3#V65D?SA^?]L=*:^BOVN
MX0+*07A0*#'9,W_*M4T?O?P'^!VS*98?#";71=G58S%K:2JWYM(<_=_N5$IU
M2"WI^_U\"^?9KW2:(" @T.DY9_&%E";K/S#M><$2!=282ZE09B3[I=P,E0'Q
M%PD=T?DG9]^Y_0.BVH C=$$C_D*=,75&%W?3! 0F-Y-^%"*W;XUJX/@!8_[+
M+#Q4N@>^O]HT )G$[)?_\\C_]U(>'1<I5M@O?(Z]+3=5TGD!H5$S!L^^3VGH
M?63^[J]?,LK7XB$K$,UZ;<=OZ%(TG+,,RCX;K/4DP:6+>DXB(5@-(94R2_[(
M\OX+E051_38=!.ZCMVZF8\&#1%=4W$=_E+Y:W>9/FFU?ZZA\0D:73"1P,@[5
MK9RYEB*3RL/\KK^_@GLMV4.X\,ET3GK9]FVYX11]-^0'3#W=X3@N0==P;UB\
M7S9Y15\>HU;7!5(H\,L?6Z7)W2=L)SJ^.5AUFP/P)V0$VHY+AV OBW,3?4'$
MY<C_WKFMU+R]#3031*>.9P]77#*3P UDRF,@-L)-! V'Q@PZ5ZOZF/Q9ABPV
M-KDN+5O7N[&-1_; ;(U'FZN\L)?#%!N/-5)@]01[42L[N<5Z$CLZ8D9T(C^4
MJ4U_P#&21[@TWQ10^,1RS\?YSJ#R%DE8E7I)U:8L[,[Q*EAL;C!08X0.-% V
M'W%<H"6?WK65G/L,RTC,NS)*N,65E(%Y9V-#XX[YYKSTNS)G.BA/4SP<=,G+
M'RK/R0=;7G&:G)H>_@&:K;W6W?2]O/<B8]>^,C^07YN"?U- L'=35,K&S!34
M3^ X2N_E!0YGUUW$,.("40E9^KO.\Y!N=$@:LDR7VH?G7/_>[=I,E9]K"7B;
MA=IZY1MCYJ]6*%72U[7Y((M3Z,P4@L"W:*6E-DWC5AYHD&$"622T@E#ND@N*
MY^^:Y7JG(I8%1+L?!X]UCR>==\]"UR\Z[:RJLC:C077[ZI:S1]S%3(3H=96N
M54AZ?V:-5;R%3W^K+2@B+YS*ZF3JT">^[#6M:'TGY^J/<%!)['RUFA.4K\0/
M<!2VE0U6.[UEG"\]5RNF!X+BU9_2"8T$X_S!R08EHQ*_\UB910N2=Z$X,A,.
M!AR?JBBR3&U]>ALK+NA;K)(7QK177]4JRTKQB&8SW%PU;%<DT2OD9]9QUR78
M5D",2@[*]##GE6@:B1.Q4BGY]<?-.JT4ES?P2>O"2_V*?(6.<+W%NFOGMK7>
M1R&KN31'M0M/H)%.(SI2R??VDRJPT40:A5<?DO"O%[.^$/*77Y*5'[)_I;OK
M)L4ECV^N5SV[&-@U=4K8+%PI5\[RC#M^/CTHL*5O9HEG33\#UL\59Z/?Z:7/
MF6LV93A8Z,C:TRL)[-K20ZL#:Y2S]5[YMUK6TS97_3R./[Y;Q2OE2(8U9V1Y
M0[)^N-1-.'?S]*>F:FAGFE(OXL/0'<0@+769/.A0?\X23VHJZ\UVLS]C\YWS
MC"J/=@-ER^NK\ WK O7H&V7\\#M!U.S6+OQ6);/,%\S8#O?%?^1^_4&3B($/
M_ESQ$WK9]0_PL2J[F$=\1$_NH^_1]X7#M?NY50T.<,O/8?;3\F#&9EDWMKCT
M^/"FHM8/[?$[ F&;6'FB4-;#WLVS(FMEC>YEHW,[-=>8\PN*DR6><APYY46Q
M5:N@1UH0]42N+IZ;0)I!V52AFEF_SYV<(0>3=XYJK\H0QU*@O;CEXVZYCPB+
MX?\]0\<;>^M"JKQQ(7K09],ETJ768F4NC3M]W;66:B@$'E$4_%8*5+!E+<:-
MDZ&G8K8ER&M@8A&@61@W.$<\%K]LL'O=@;9S,2W\79C96K![9*F<S 6SENF!
M69TC;BVA%O%F5=RFQ0MMXKL-)V7R3)*2+1I+1<X3GO7/&J[%(_=?&O2D5*T>
ML:?6,?54*T]:<M?4X@9:H%Z>54W?4W\+MTHD]6MXFD0X+V.!\R)4,R!/40IY
M R5T>/=%_CYVU>9?NP2M4[++/$LTU:$K60+7*E3R*.NOA4OW''&9'6&?R#R0
M?C+AHTZ3]S!$5X$%FDPA*MP?EJE" *K5.2BGDWM]8G^Q#U.F+/R[&1Q\JU-L
MLZMM=<'X(A_I*EC^(..#T"CV,G'V-R4=ALZ-/>V+^I J'G:R?XP."Y-QGG41
M'_ZBX+N-S\(;A"@L=K-Z3[7'&-"FRJ)<E0,GZZ0%XR]0O-VFX=SRL/ISJM>%
M)"Z@KDCRSYI>;F<)'VXKO K=SIS%=69U_X"KSV<P(A'Q8Y-^82*EH,?:P_/Y
M4HA$_#BK"&1'FZ8,N*%=<]-T-:4>Q,N$EZ.F_S:7/8S(=/4L2_7+F!_1N"GR
M\5'MA&7RP_!5 FA+U<#&NT.P>;,]K6>XVQ$='JNC_O*D)+W#X?+)^\OUNQ_<
M^^9?D;M)"*'ZQ"X2^MXW?P+UG#?@[IKY)H50 ZA#R"=5)+]DC@J&FR"-,C[A
MGR^(]-;-)**_AP/!.[=_B?41;F6$5131H^^)C=7D+]&2D#T%.N6DU(R>"=W)
MW"RF."_ R,?\MVH(L_>!9+*(;\^4;%Z(A]>4)-?Y'W(9_N;X@%^"2Q)4:P/Y
MD8HLOWG@RLO@@W.1Q1VV8G:ICF*LY6M$[,_F+KDI\NMD\-;\-W?_N(>PS).)
MN,4:0^'9E=&&LA[+1'87QS;K<E3WXA('*)[E^]IWR60H,[J<@OPY[OEHGSV?
MN2^5R3^DA^VHQ)SL$#EB._3O/4-7#V0O1,8E?7L8CP]+).^Q[4&.#@.(%=E_
M3YZ%P>\JM2,/T^0M&_W*E^93T^JGN/:%3'A/D:H[\;%OP.T0RO'::?U7$:GO
M3L-T<7)#\&#WF">6,1F\@+U?OIY,]W;"I"(I33!=!$K@'XWA.B)[;]/OB$64
M3R.[EUD$>&;#H251ECJP>[0Q4,X&)CX!$3ZR5[8N3GRV4!@-*DKMM-:6T]W!
MXM81^:@(L"9^)! :LMLB0JWL%<=G_*VF R>EO>LUGW\FRV TR;/0E9E?: B^
M=N#P&C\3/M-[=PQ.3MA9YN'FU@KS++N4=E_%#^%;C6\D(ETV2@OZ<*:Q &U.
MO2#YU]=3DWME;U? #>!S==P_ #J?F\IAG!\KWNEQ1NN;P5%A2TUB$G[U-AH&
M,U4F9H*_V*-J[^[]-&68IYODO5><:G<*("XD3HYDC#TGC79=]($/1?)R=:4J
M9,V13",I$Y->"DCAF(#O%+"T1<;2%/Y8Y+@[-CF\R84=M(:$"P)GTGOPJ<H'
MAE$,,,5L1I'PG3G+;%=5*ED^4HS)SY_!C8Q,L@T#XBKHMK8R<>AVFWT(O&8*
M@'<M'Q=9RA0B>ZF%:I/V/N/%#IY@4S+^Q:$W$,NO/MOYVY"?H_KP39GP25B+
M,\?7.&PD)T]89NHHUGHQK"L27"?HSYX '[&?\P_@C_;MCY=Q\PE'/OP_@,YF
MVT+%G"I1U5Y)[3"9"9F/U@0=U3NRLL/SKJ3]EW*</Y$-"?;8\+4)G+O'[^:2
MR M>Z\?5VI9'>5/H!(1+9.9-/L/WSQYS[*A#Q]@/!T"L0:C/RE%;MX?K]:?*
MYH\:D:V3ZM..:D6SB:Q)A%6<%XA5@F,0MKJ23XJA*_<K&+(.<3L$54"!4U_F
M)8?S]S1!\XB,0!LZ^*EDNCZ_-CZ1X;>01<'MRL:W**MMGMR4:V52BU^]'88;
M_OUD+3TTQ&54,;0XX]_]$2V+UUGO?'2664X*W/2TI 0J[B*=T[G0(>3X$I A
MEZ,QB;K"9",B<=5A@@%Q.BK6V31&8BV)*[MC[W\ +(B'H/8WT4@2525*'$>X
MSFNJ2("$D5D<\JT_M?=OA*KW78-YV6_J=7]&@K"N)ISV%2,-PX?EO(9=NL.2
M#04G)$WJ$5#='!:$+)Q#W"YEU#*\VJYYS 8WQH4W5]!_!S LMKMI'J[\ [1;
MW[(QEE4H6NE5HDO,&OXG=[[(I,^>9;(.F%I(:#]03&95'980[OU0Z\\,P^R%
M#URHU["^6/!)@I)F25@S9\DJA1C4-?T#&-KIU1=+U#Y2/.:!>2[R]+O*7%;-
M5IK+D\].]<OU2Y8;2*XMDU8:^]* *0Q?3<:#=V/XH)\6#<8*ZZ_>U,NK"'/J
MO_C.FFDWB:4UW45\8C:\(*^O3_F%HA\K4.#HNU!VL/(Z=A 3/BG[D;3'5FB7
M#YSCJ;-_'.FBX-P0YKOI/1NTD"-S5SE*H6#?QG:TZ>#IN2[8[/"E#(I>P/.^
MXF6&M*Y5,.ZK)%[2>KEXJ+N8V9BO;N(S,I$&F87]H; 3)"*S/\"/H4HF* #=
M%0&M-I[U[%>Y'TS.[JRR=S8^[5O(==A]2H1AO+HRL<><7LQEP!&L-(X2U5I.
MI#35VEGHV+)@(N.>%<HVFA0-SY!YMR44?H2^7C1USLQY3H%5<TKW/*KJB^]X
M6S]I9F?QHJ_7/NR\=[HZ>0LTK%DOVDW DIJJ/87?];QJ@8OM>0M[T\4,U:XK
MSM8K@7VDK=\]%A:%JY)9<*<)XZZ6EX<,J_MCR<EE.G460[@J$2)K#34J-;[4
M;<)&B>BO+20UE\6A;9_LK%4J!G-U9TK!"L#[.L_W#?W:^/HD1H;5Q(6_:QJ0
MS@T[*^;Y-.>TI!8'5G2'- NV-*ZA7\9[*[?SOP745HX[R+-.%K:0(-FNU2G&
M$J^"S6.MI-LMFQ'8$?9ZKQEN^BZ1>K,MN%4KITDKPPH?JT:F#[085IM,*R&]
M5<HMMK+58"JUTME5JRCRM%E@A ]&9."H;5//7:S.\OGU:L8)*\]<OL["L&PR
M]J"6H8Y*N&R*QXJ;QO0/;%X5T^)57TPK"*2(@WZF;C?$0IM !]MRT^>=@+[Q
MBQG.;!<+C%4X^Z6VV>:BZ($^BJ8GQ/"R:\].X[?R.JP]@YM[W#&QS4@B7I/5
MM3(L6[V&\&@(QC6HASUA^I@T93I C<ZTRP,C(I@*J_).6^B$J"QGM<DW5FE+
M[_$,$C7:V6#16E9$)9OMSK"IGJ]::](N,KFXJU;JM=<-HJ]$@P+P(?PNK?/6
MR3@# CV0E*!+.;=-7ZM.[C^!VS?'Z\GT3F?K)WAEMK]MR4[F=%9=2:,Z')M?
MHBTWN# 4M>PZ#Y4XPDX;, *O5E^[\)FYQEA;I1HI8D*/U%,D?'-O'6>935FX
M.X:K]RG76S^]5,Z_BGA*=PMH.-D7Z.&H_>8YK>=ABY>.4*B2:RF8.5SBBCI;
M2_H'Z*!3MXCM1@=6?0>GZRD=P<#)^=*)5Y7V=Z##5[=I)(G(S>OQD?NVN]O_
MJQGPQU0A);M&-XM*R$6'P,R*4F3L#&N\HI[56B5'Z[U._EO'B?U"ROD)MY;=
MA5)+8\6)Y-BO/:)$&M9GS3#"23&GY*1;;8UCM<6,%X^CVCTI[,!)NX)?0^4C
M+"D.//VP3[;[IPS-78*L7ILQMMURBSS'9UT3!G>"%R(J>LSGQ?<Z6H1RGP+7
MD16/W+ <"F6M2EJXPXY5IDH_]Q.T&5_,I*:7)D)? HK^ <ADT%=J"WPN[IKG
M/3UF?\]2>K5!7\6:#8H[!^M9DJ4FC6R(-I8$*R6AR)<K+\5W*W=8$VG:Y<T_
M\I3C93H^V'$[+1%HKVR!]1)N:#GM6O&0T3PF@A:*<Y$I[@AG[G<UOB+5NW6S
MHYF-I&-Q5D\[<YBXZ%G:H8"3LHO=2B"\.O:)2DN'&2T50G4I%K,A]"<4^S)Y
MXE!IQU;V 4<H/539P.1-/M.161)?(GC>_$2$=3U^3:2DW?]@6:-4H5J!M&3]
M1));R%Y5#TZ%S9:U-/K-V-9D$-*Q]BT_M2>7V90M)=*I-Z$"+J_HVSM+SM</
M^V9T#@3WN<W*P$_%&Z.62>U.JF0>^'H.AU+5K V=A/)J5DS6#U#]- O<A&?M
M=T6$8ZH3QC$GY+P3H*/?%V6KHMDO^&O^&:&;D$4]N# 1,[-2S"'T$4/%C%3/
M2;RE$0P+\Y:?@ \E8H_W*"D7)QKYW;@6E*J.;QFE>L+7$]7*V\TS4 >"?P#M
ME?2;;5R ?4>M$^^U=ZC[M2+HUR_H;DL7N'WFQ8P)2WV_Y+<UV./V<!J+YVRO
MCF4.L&*,."S6S( _L2-L&?F]9;AL)4D.S[U)E.\IR-_Y8=9 7V])1Y5S?#+5
M6.M8TC;-G5[QI9D0;V& NYE>I+X>O]F<69XYC;S?@4G*DHD:F1%EM%<U+M,_
M8[:[F1<$=0\X$?@>Y<H)6O]/'?1YSK_ZF)80[54K+Z>/0!.J5?PUQB[[2[&N
MT#7UL?F@_(-H6L6IC[GEUDK:K47,MV8'^24=W?\%A?$1Q(]5 ACE'W0=]AD6
MDV,U,QM++4N*&/:_2X2CHSXU>F8&BG&\QI>]+SQ3&--[\%.^R);SE=9^RX@,
M4NQH&:%L<*90R"2+Z5[VH-T^3ALM86+803I$=XQG9Z[A'-^6&\J]O;5S+JZ
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M)^NGG&^P-S:F8+7],O:5?1[W9PZTGZ[F_0$??3XL_>H6?AI6@QK2I[?M-WJ
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M,H-IIUC,^-)PLV.):;.R>M]/T\W*R%W_$\;_"[?$_]M/_YW\'U!+ P04
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M\I/"[VP;I!R]/:4#\3[2LE(RT@!UK4 ?O*,'P1_J0-C>O&K WM^^"X.Z.6G
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M(-?Q<+([YLVW5Y"I5_7L)R;K*^H7K5B:Z<YKY'HL)#R3?-<'OR6(//%-_%@
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M/;9;Y7;< 8^X($/I0[[B\L9"+C)+,ZQ0I\L][\@2[B &A-%W0 ?)E2'9#37
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MK50.A%$Z_F+&B)H>0!5E*NNQJ@K4U4"A";$DDBJTIU.IPB5;P%AKRM7=7@V
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M.PM5N:*FQ)U462Y(VPB4IH3J!6AU# '7H8%O>X^*C6E_2^RX0JEJM2ZI>^H
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M*'"2I0GK1$&EZKU*$Z81*E&0/4=4J@-P% NT.EFDI4)J$*D)UN$&^$'J"55
M=]#T6YKSAT%D0E1M5 A&RFNWRPB#WZ[H>G.Z@(2@+2T[BH"]J G8A=L($:MR
M#4'1]F:P>$BJM"JI04*$KNGR],(;A=%OM<U'Q0-!<U*(@"7*JE;@[V^F$6S;
MGJ$)6R(*.5$  )VLNA!K6VOENEL(%1RLP(8#>P:]$4J85R@**4(IO2P ]"?K
MA%H5(<.%5!R4E5W1.;11MH@^]0@HNVB@E>Y3",;\Z.$TNJ@&CVK"/W38(4*Z
MI0)YIT55UPA?5M:*Y%?)76QH>TZ?/^S"+W?\;_-^^,6/&4QF%YP*G3B02V.F
M+E]/\HN\V/9+EB$SGF239%;S! L9NS#EG*T=+YK#S:>2>4>WBX)T97,FG#+#
MV-=0$8]AF(9Z/LZ1E)4Z >PKM6[UC$S]&I-<RSF%GD?]D3UWE0\..&D)-9[F
MGAK \/9A$<49>S/H+-LMESR&RYEM]/Y>[ECC+\UC8IJ$?0D)/YK.(6#B0RRW
M"0@'VM:H6LC:\XL_(U?4#=:/;4:QM;5*I4C0WK1$)*G<#SPC3^"!Q=*%;*SV
MU2$A!)Z;DE3Y(>R]SA%_$BQ330E#8&P"& $K4=T&]2M%\@$)UIA$(">GOQU0
MA&OKE_2F)^R[*;(/$?X3J"J_YR/#%+=C\]L(SP_YR?T?]J6,8>('P^([Q'C7
M]>I$".^0<J$I8;)HAZ8X;(?K/CQ_Y9E$Z\,R.]:<X])[4K^TCZ+A1>!]H#__
M ++M"137Y4CK+.9 $W!53D;- 2E_8#K8)7^5<3"_E']5YVW^#R.U0@ZF)V-:
M3A93_P ^.S1_]K-'-\BS>:R.4R"82B/BI=&.I9 EA_"/2Z>#^KNRBL- %DD!
M6&V2R40A,;W(D?D>5#_Q&$EE^R*.^X^Z.L=II2>T'&K_ ,)YQDI^[3F@"60=
M(S<X6>*"-AVX.0Y]=-S!A_$.G#K,#IIAEY#L/&N7GCG+( >,,+S-/'7Q(2KM
M N-Y[]^!C@#*A-69 RHU5""C!%3:,YH"8P,S<,QDNC(:-AGE';^&>L/G;5E9
M5VT0H46.Z@4PC3-*$<T INY->2H(]X@'1*]2JDJ*:'?12,(Q!(]^WWK$\J]$
M04-PB;=$1 +UNB"I[7UBJ+YDZ5/FEK47J17"'R\/?QUA4N&2;W1.JDJG<7.I
MPC)]0SBW)!7Q%R658$)4D4-?W:)9#K3<!-]T-'HR/5=$%WNXHC!(R34J2%)"
M40>8[HN]!A$4VY#6J]:H[%:0Z*.BH4*DJ=;%:KYV6B"UW\/#VD"*-J( UV("
M5OO2M-EP@OO7QK2\ .Z(0**ER5*&ZWTI33"%=?6U.B>"E!0C1*+\Z!1HA4E.
M@KVP@*IR8ZJCA'1RGB30HG^)D+Y6]23V^>$7D3<WMT#HZ^0AJ"MB>UR+&Y4:
M44X1#Z;VJE*AUWM#-44BH("66FM:J*4^8JB4]Z;0D 72FYMJ.Z!4ZD:+A%4Z
M_CKSWK".E2RBH32A6E]$%R,(+=CJJ6]NCEUU@ L*$D$TL3IS'4+\\(ODP\P
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MYP Z+YJMKW3U (U.$7?W9#U5;#2 H*@*;D@VZ^?9#7S17\T0CR6J#<J&/*2
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MXEDL?-X^1PLQ+/F\L <?  G$V&)I,*<$DRB4_9Q\(M,7G +@@;W.]D.T7#>
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MPWC.#/F.&9J3-X.'BG!GQ))<242XHEEF,A&))(5$LTI8$.BJHCHW;+L)VK[
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MAI8(WUN#ROHT=PRW\I>UJ4/#^V:@_P"1\0<58KJ?2/1F*_9F8O\ SWR^NO\
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M._9SG+<HCPRV6P7L&Y+;+33)9::9:#(;9;Y2:@JJX+[+Q>\0B%D;O#=0-'Z
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MSX/\L,NC_P"JJ9CM_D[.]/PQT#C!3B>2.G ,T1HGY!F:;1]-=CC_ &,=H?\
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MXY4KVE[7;Y#MH7%ADN(EE5$# ;\H]*.C';4!F5V';\']=<OM_$Y;#( F^6U
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MTN#7*5*)J1NI"=::]\(+2JBX*-X>>C)"JB$BRUV!"*/5<(+][^/C["-"0D@
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MG*Y)P7S=/,UNG3K(4QSI&&<3UY.,KY:,&^CW69'$)".7#J* =R]MDO0&6&1
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M99@0X(D ((UK10[.L=SSV:R^=Q^VV;RV++BX&/BX6+A8LA*3R3YO$,LTJ@$
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MOOXK*N5H#-6:N#+KA8SEF81&:HJ&G;K*\!+9OF%Q-7<+[ O8:&S2W'>QA9;
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M<^I%NXUI6Z"-[:E45:E+L>0$WJ$U5-Z("B61!A%Y5755:M:U(JY8M H-41*
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MB: 4)I8BA*CO3"*%=]R;:(=5:Q)/6$"@-?/4G_JW7<DUOA!"44>12[+X,-2
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M228W'>%C GQ!,\PGDPR 1WB!*Y8+JFFW^M.1T2LCD&E/](BC:A3T/T/D^/\
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M*!:_)$7M0CK;"&Q;H*Z6HMR@'A''Y=E/*TIFTTS!*LNR.63R=NX=Q.9Q+Y5
MP<SF[J#:?&#8F4;#.'<3'"%,0_\ 8");>^R+YX6.7G*HIF*^!2S/J6NNF@CW
MYC)Y3-&7;,TE<OF3#IHET(^#AHP.BT@:+ B7+SE+012S4HBIA$!-JTH^NI]
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MFV$4JZM8^(\22"O(E:B*^H)U3Y6)*K87N",(Q@IW[;*:A NO5-ZJ4(155^$
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M")N23T6Y-ZCFE;H85@*W5=2:V&^JK2IWPBUHK:-S)*E+/3E 190!4D@;4VU
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M A@J%(1 40(1]?X@?4]<(B4KH02OR?[-.0$!&MF@R"5JMP:?7\+X0Y7*,FQ
M6ST.RND=>Y4=O&,Y\26VG;3++R9Y>Y&F@0RTR,OPP/(31OE*@EE4-#C9Y?\
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M;@;!=L(B&J=2J&SLQ.Z%5*N$2@!0#="MU!!\EKYX0U?=@;@BX%%"*40M6 $
M:D@T'_$@[U).$- NW,M\@ %L"46&30KNA.B*$MT:[WPB)I:SA#<[.*JE%0*
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MF+AFY5/'[V)FD.X@8D?93++V&>OXIHPS-(6]P;V(.WM>L!EE<$S L2A0%#J
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M0["R=$%KVPB&_OWSO"*UN"HU-%1: G5=^]"B$%?X!ZC\L(1__]E02P,$%
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M3\?"&3GS*I/C.DN@QKH,.F/,D#@&N.X][D#8M,E:2A1_:N9]K@!_$2-"31B
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M]%RO_*[8)5>OH7)X4"QZ-5917$1I61JT:F#=VQ\?57TLRVD?;_MLPLH[:9&
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MX\=>!:['!+]5O6.9IS8T6-#0^(*'NAM71#(G[9"IQO!;6JY?9?G"<-EDE;L
MB#RCO]XYM]!9\386AE**)#+' W&]?&[TP8Z,Q4L[6H'>_#; <QZ^NC%_52O#
MTT5OHDP6,)MS)#EID=92^EPU7SO4$M,U6%?T%VT-S,.?M1GK5VB@*00AM<]R
M%)GR'#1S G 2SF>WAP6.%%XL#PL]E8-T5@LDS$3*IP4>%6$T?841/$.G7:9&
MI:7UG.XB$,(I[!N%!^L]Q?3R+BS6JCQ5,O VN)&["1>PM<(4=E -:UE=H/24
M8DQD_O@\('M2J-%SF,BZ(*[^W>L\9RPU AZ1PEB.8^0/EJ/G QJK )I64#\S
M5$T&G^W] I0&>IX&6 ?"VLA\0J1$AJ6-3][-+GY>N9-YF[JS+&II^"W34')&
M^A7>_H^"A07J>C7X,4-W@V4FT<9&8\1"=A@@GOO>==[W:,[%RLB1*A,G3N18
M8>R#)W< /@?%*$T1G;H".?,1,Z,UO"TXN<!<&<+C "2&1HE:\AM-C[ZOQ:)K
MI?W]]@: :XRO1O&CIPWAX>]V 4.-E$M'ZI;O^](>=2K(6MYD]RQ^E&\G8%'!
M>8$Z-K0Z,")&J'*>0J2>F\V<*GD7H+_\P.5ZLN2:L2=1T^D))@\M&,8/EK&L
MQB5YTE_ =,<I;6VQ4!3;W(6G\6SUPZ9%,G=3NET0*C)/K%^(Y\M:7E,;X-@^
MB_DH@>2U9JQ?XL\@&JPP'ULU62X($/(*DWV8$HGQ8&SCR:6 ?,W0([5_-*@[
MD-SM<OI=;&[M3()$25/AC'_^J'NR?QZ>0H MF0$Q7W!=HD_=/DN8CDICO5<F
MUUV25Y3W@>,JS_JY*_=T&480/,Y?D/HO04C9ZF.XO;OMR84G$4]=9([K^ID&
M%2'6+1Z)L8<&+7Z-XVGL=18-*P__"GV18PH%EUCO MKGIS778#J%4$T^R->T
M,':YF.CVD<_/ON21";I<'4P*-(:C4(7\HZ+&2)0O'6+B8^&-!Q+I$=YAY[.J
M^^%W-D3S>"(C-_&?>LA91DP3E@K5>-!R.!@D.\<,1FY\:TC1OWXXB90/P^5/
M.1[,1Y4 ^2A,ZG62U*!TOK+]*;P7BRHK+[[M\9OI* ][HN 7:T]B/C&#-_H5
M]W__(>'F:'%9&$1@')6)0J+4M"YWD\?Y?5Z3FJZ?<2^"\$@@H) 23>D\B%]H
M,B(087!RM9=9](YR9/WV"G_?[(FW%4,\1W:TDV8_>GI\'JSI?_RA RWT@*<"
M2A'80<GOI]%<+7<G-::C6_K#RLMDJ<V%XXE==ITG-?5<C8S#9TI:!A0UQ03#
MDC6>A[ZXR"V.;4YN;NGC+"MIFE&&S;A'GJ35]&O:G/7;?L-6-F8MPQ%K8&7B
M%M7ELD'S=J4'&SM94.R?YGYJU';49]+3Z_YHRLVONCRC&QK)IN\7!UM4\J[6
MB3A<;A8*^>COO\2^]38O?H-<,$U+IY :T[4VXL8C[==Y^EBP#A%4)@H<ES^)
M">\8+!;B\!"DM@ 1\ @$$C9.]!+BOH!@!6+TA!8<-Q1;2^?OBMR*[,R*.M/!
M%.$<X/3676.LQU"-VL],1.))_,:)8F]"^)ET>$8$@PXL_*WDC=P;V_,K5<\J
MV45>&:Z*H8\:/B6)"6;AX2%2[5.W\5>DQ(0,'5__%%7ZX6P\O=1M)J:S/<\<
MH2.PL04\F3<_0P)XN:USXB*_W<ISF;CTT[:>S/1%)DC[QV$&Z68E6ODV6*NG
M%5T:*>F@G%9T(N<=?3J8*T!Q?)DRA6Y4<&]8*ANO1E)PED.<$:(P3C"!4519
MC??1TWL%N.U>>TXBVJ<H*PBG,E%2QD2KG8+Q[;4Q ZXT,B9DR<#S:;-I3[??
M5.,,ANZ>&X .D]*T&./N.3O$&W=JW>Y.F5'73 819A(LV:0N4HAJJ%Z-K6\0
MY2/0L-_,%5>JGO578LL<2A#[K#RS47JZ2'R,XTVNF0&\_'[U_3M6=,F7,()S
M=[6LP-"TEM.M!LR:99_E"#SEA:;XI*2%ZM[T(TYJ0?P0RIFT^=<VUL&*6_TD
MI5"D?R&?95+:QQ4 .':1W##M4W'.(MF4[16]ZU-#*;;ZLQH989$B/9NB!(T+
MIO-M7XT\H4BZ7GN=D =P)7OP]FLIV=ZF@; 38\KU_.U!K*F)?/.)(VHAL5Z]
M1GYOM 53/I&SI9)"EA/*GY-+=A)++?%JH5,5/B3:FU4DH@7O'*V2/JY^@3,E
M!1D\1G.Z)GO8$!Z),.!4S22_169C(S8@IF"W/2M@WE<2GCWA]M(;SS0%$V,5
MB00^3K/B'"([BAPWW[ ]2HXO9<BY;^IG72B!9T]I9!JL-HYEVY3S@4!/+5YA
M)I;Z3"+'=\=M@*C)'Y2U:MBETN!H74E'@'O=ICJ1_58T]3G>FSYJ;[JQRF+:
M05-K!/F4-WTVC<+O>'KX#25], 0L.705M O0B2\_;N5H%I#UDHYJBEP"-45^
MFZYB+?7WTTW7)Y)!,<$G2&*;$BH5Q4(8*#-I$HSP'SGPQZFD6!>KK+LL>]I:
MH4GK%D=WAE^>S0\Q9TX)>>=)BN  XP&PH_& #G<IY83FB# WA]FXX\LWU$),
MU[5"UJK#GZ>R,E %QB"$ VK11'AJM8E@R>G6UGB.MSL<\;&.T FW43;S9J_A
MC,Q'WQQO:/_EB?Z"R5I9$I@X3U U% (@^+7!$$ *L@*LJ;&M0L>Y,1PN 6;]
MQ(IMI3'4-].5?W,LMKQH)SFM,G2/<W.[)4EK2JZE/6&8"G3*?;WP6QX?#\3M
MRV9;@8MFP$"=V!(W3"F^#=]G%R/\B.&R)ZQ<M/=J<G7%*=I"-3:\SP16,UZZ
M@LK7NWB44^9)W^E ;K<0@/8HK"_+(;40ZJP.L?KJOKD=5<S@-[L-*^%[T2Z1
M;[WV3M<AZH.VZ67^$Q*(U/4,B6^&%PG0V11C(SLF2$[/!-0X6O-D^K-K( ]Q
MYX)+X"^A>3.$Z0Y&[@A@O*]=P]*\R^%F2RY#<@ZU\/FA#R_CN#-MI#]*-LWX
MW[O;>8KP-H[\ 5LW27EQF'7CHC:Q9WG:BSM*WM<#W]-"!VYP#R\8H^"@G#<A
M;9I6,+-1$S147<T>5L9 [1SJ3'HBJ&FF%44Q8YN^<#RWQ-:64%!T-8T_&4L$
MBASSI5^BOW3EROAP?D?1NJ%)%<XL+R/Z+CLL8J!SDU7%MN?^+F"_*-9V@W(>
MRX[>.*L>R[3Y_I6*Y62M8/[Y-Z><U1 @/F)K^OG+8!@#%V5:]$#I5<5%A&XB
MMTCO&VOWEU&0N00S7=,W[DX/C21;A%BZN;P5V@O7[,Z,D[.&13<_R#0L*[YW
M0WR9-?JKZ^T(K= \I&:YF>9)BD?>JNC'W@;5@2DQWUZ"7? XK/)%,M 2@T/;
M\?7FZ_=3-\A6P6EXY9.W&=SEQX..I8Z4]%?CQT[>;KM+N"U9&L_Y[E._:Z_%
M99Z"#Z#"9C752DGG,-5HW0K7AR=AH-52D:DCY]I\,=R4(B<(JG*4"9(-C)_U
M! 5,]!KT*IN2>:S;&:CZ\4QRW/UT0%H@V/*"GE>ZS_5O#9LNBTL\K<GZD+,?
MK6^^>V##D#WM:,S&Z2![]'YH>/U<MZ5X2>6J(12,I)CE4]#,SK0]*:+7A=?S
MF(KBIT*JR2 5M3F@>-5\QB;&IMD2FP\CCZM8\9:1A0]**;#'X7.%GZRE)RAV
MCL-0295XU,.7'&RNOO+\G1E>+9(B) J&(;UL^APZGAH2*%<B,(Q4E+PHZIO_
MJM9#&H:,!%OVGN'V@O>X*,^-Y0K!>6*=]N6>I)%@%CHXGH'@!<F4)'F1CVB<
MSC7/4*;_M&!))J-XL\? 5<^K,Y'=C@L4A:.8(8I;Y]!AOM]-N)JD.9H1L#=$
M/ZZYZQ6+.R)((.7LDZ!JC.)\?=)9V1?$#MLQOEB<,)O8Q^86-$2?"EFQ"AJI
MM9]0QRVGM(/;Z<0 -4G&L:U'6^NH,8%EZ"[0KM"ZWOIY%YC?!4[+82Q05FP>
M8@,R1\=4ZWX^U?Z^U0D8F\ SC(.U0I.AJI-0$KSF1Q)%2/W,A%8J*)/L@DZR
M;[BXU^* PQESPT>7I/027]%_?#*#>(?4+^@YKG;F;#9+?"WB"$,V[NEK<:WR
MB38$,64&C.1!QC:9_UVM;)]W[A^CLMY4^7V"M-N("<FN-9Y 4YE$0P*3P P5
MQ$20/'!!:/#5JP[*>>K&)Q23);WR%WSF:F'J2%1>8NC:M8R/2QGZU/Z>UW(Z
MSU?5C?BG=K$7IJN;EH_.]&N<$]XVK<YSOE_OP3/A)QGZ-:?.#JHB/^'*%/=P
MHIN4_R/OU#Q#'EUV,@ '@D%A@9HH\RB<@&G?QMDEJ+.JDV)4=_7'#9SR)@ZL
MS^,@['!U1+!2Y-$9I=*:((U-(^VD%RA+X]GXI]..;A4?%U_)3R]P5K&,U@9"
M5>,\AXM32@3?>QGR- G6]V0_AZ.8'YGEFA,B>34_S][<*2@2$.A(VC*UN"?"
MR( P5F1 J9)90NC?B#NN&<89&I>6QGL)#:9.)&_$*S[C=YXIK,HV?G[2JOU*
M()N"QJN%QALK5 PRM.+8\3C<3KZCTQ1#U6(I\[6RW"EU,[^+S9+R*CGGX1;*
MO! "I7A,9=V3)[T*&=I@GOOO O'F+0PHD"H*]+$M>D,T(]^U1:.H1DV"H524
MWV>H;^ , =J>JF9/D(@J;L;=28T2Y)%+A!0*(+_Q?5@M&!E^6#!47<$$&7DS
MSJ*3INVL0JDV@I*4O?6,L3YZD+'HD2>ZL#I8/49T(:B5"PX#$77/&5T:ZMP%
M%$9K-$R<UR+GVS/J+*E/C^AT2,0,#%^T:W>0?I;!?+;IVB7?02I4NQ9JV A@
MQTR9$)>\R*;S>Q[LE0IN&V?] )FA3;Y^OQ^3Q#+26WU:D3V#'W)^3*U5B@0(
MZ0RJ'75SPP]<=Y<W1=#O!)L[[T25VL>ASS_8G"Y!"[A-OY*+&%$40*(HV;;/
MG2FOXP>?7I+U;%)FQVEX3)7-]XR[;6:Y(:'.]L9ON2E5BURAVA]3OYA/T,>E
M3+M?LG5Z@!"X[?*HO87'\TC[S:E9=9PN;E1=]0;YD[DCF71^81Q!<P:,69\W
M4K<^+L*()>-L[F^]&@F#0I@*M3F-( AB4:_4)3;*YP6_Q93-Q$1[=(;-IV[;
MJ)^,NM!@3UO(P)*_/9 T[.I%P<FCN/&9S:VM#]8YT4:2^$(L37+**HZK/,P4
M*D!?S6NCR,BAQ"#LM^*3('ZK3OF1>EO#@ANTT6J=O _I^)K264.?IYDBKB8I
M&7K* SA!ZXEZLEW3OS'3WAX!IO\\]_6*=4A/K<C*TVV,O9V]O2Z>F1<$B<21
M8RG%^EJ4=7<!(SG5#3 'QV#W]OK.:HFS[-$\SYJ9/OL_7A4QO92$5_VV"]S+
M:MUYXA":U.DO[?VI6:#U21M4I""VJ_9AA-')P?2XT;+71S@QTJ4EE7A?2*'R
MT3@B!;?CU?;4WI0GXBZ"K=:8MG=F'W=V.: 8%@VTUM6)$"BI29@2CH"7G\'Y
M4K$1XBC ]'<UR>G!A"A)LJ/S6UCI%0<@1-A'V#_6>'SVM9.8M?"5C&G1"LN:
MIW=KG%)>KJ7\)JILP_(YKAT55NBH!9O(@Q"U00"U]GEC](N"-58TE38JR$V+
M LX'F2$)"81T$N%)34Q-\P*1,13URVZ+FI>;].^-;B\D8FNUWZY:&XP/FUCJ
M95U*%JLJ;8Z+;GM01#=]'[6^W1-Q77[>KE  E:*5%YH)&\PI#Z 0R349'<NC
M4,^K;.S$5TB6YRES&#'HP@"*Z?Z&XRX/"XMS3*P#SQ&Q C;649)S4DLW*TE
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MQ2ECQ @%7Y4QFWM\B>'2^'@[#17;.]14K;.(Q[*ZGH>!"?)6M.X:1&(%A2<
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MMX%;>"USO>H_7'.L,^E058WM-[*1+"&U<KTWPX-P\^@H_93NYES !!9_SM<
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M9A"<-$<FSB3BD;< +@BE?NH!"0:OXH,3*3S%WMGTHA1K5=)S38YM#E5D#N&
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M VLJJKI^F<:N3M)K[>H_@MF.+Q)+I8U?)^):Z@:VY=U8W\'6MA.S8^#I"DC
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MI?AN(FR?GTB8I>N%]5.?W,E;>-'6'K[LJGA\5IZFA=G;#>5WY4M#2@+M*EK
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MJ6J_U=Y&]Z?XE/)L )#[$E@?K/QSRU+ ZA,>#X":E1S!0?*P[*\PBI7:X:(
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MP1S6?4:74YS9M&P/VZ4G?RM)FC1R/$&H\-:*=(JMPJ:#_,KS=&1+)]XV:]6
M@2+V ^RS8VWJ8T*U1A7!!E2+6ST5Z"9*(Q=\N3G\J78LC801XY(SA"\Y7Z*\
MO%[-3-HTMG#Q<[#W%*).HJ:"!B?"F9;Z/E'FOA7OG'WQQI=)UWA_IFXN:<##
M$$UW1GIGR,\^3+BXYJ72_Q7PUU UCDK/PL53_8N"/+;PR1("C-5!2^5(V>T8
M2)O3_&FD^@<06"RT*EY+@)H\-2$'+G'ZK 2LYA;Z/#.6ZSXJY^2OKK^K_!5S
MK;^.+,9Q)<Y?+O[:[6H81SH4-^_T]P"IWVSC<.'?ASD>N1$B%FKD"4D0/*1T
M,CT23&5S[V\T\_K-;;Z6@.PEL/7(T[B\_1$.DK<3%;)&-^G=VZ8N?^_'?_%I
M%4XF'NKIML]#Z+HLH+P+5<K[6; #MKD%7L">!L2?2$/WTJ"+6(*3QT=QA\@$
MEDMD7 !RC,53=Q1#"&JLU\B\_H!**=;Y8(RNQZ ^-P^- 4_CVP[?]Z21?3&M
M[Q]JM3=T^/;TRB-EB:!Y-P0>2]G^RO%,\GGJZIWCFDB46?\:Z+TW*+:(-M==
MXZ%.WK2\Z\'>='%5]AO7SZ-B^@OO5%S56YLF!<=7,3,<,RYFKBIXSGY BPX]
M)(@@?=MI@F\"LX!Y_/4& 0=$/J@6)@1H00,U#%D<>VPR7NDW,9JM&^V%UYL)
MQUND;^\+-O+PQ1?/U-D2($WN-Q<**0=P?[;'A[)3=1?$ZJ05JOD=G?9?$]U*
M_@.09(Y$>=_GT3FJS"ZUUTM[:622ZOU J!S[30;'/WBR"W9]G:JS]M@C#QHK
MI *Z+#UB"9OE^ZW4UM@:F%B4]2"^<"*\  Y\^D=+E&R0"4BMI$?)="9)$BH0
M*LYQ7+RQWC@*>USKU-N;^Y@#^\>]%"T '8S]&6]D_O@9^7_Z;\2F=-D8DLZR
M8=ZP+6E$_@.0G^H]W2/I['#)3^T78G+LK4CKPCE[%PG.'Z?D$79<!4<2S(BM
MY%)OL[)/-:9I^\Z%Y6H''X:& $,*J95Z=X+@?QYK9T!+Q+6ZC$L+@+[]$0)<
MY;B*QH<'TES=$YTZ(7_6'3F#JD@[5DU%)MYM4Q0LXXG]^E0+!2EX?,DU ;0
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MI#[+.DSIAX-ZB^_]LKBW/RNJ"_VSE<?JZW)HVPH=V36?:$.02WB*B>WX-7D
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M3G+LN&_Q+4G\,?X%48FOS_G8;%G74'A(U1DC34QUC[1ZB9>@JG%#$-_4D.V
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MR+WF\\W_ 4A,^G[#.%'])HDU?Y?UUD)0\J'C9^_8'%\Z]&&$)'SRR)B76&J
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MR"0@TZ,RU@A5S!8N"6L^?G7HL8;KJ>HV2CB'+S.NAPBWQ,20?!+(T'E2P\7
MCZEK4BMF5L3WZG^](C.BZ]"7?':&,_H2W/8FN:D/BA4^B?](+5ODQ/RN^,#%
M0@4!ICQJY"&Z 96+U6R+4.[VU)PS-ORPTZJ8K"@3P#>R3)\3=GRSJ'#2E)WC
M*BQ<*2 *' 6!0Z1RHLM84!/\6M_9>;,.X:(G)6QO*)1!?3^]65A4-6%=Q-&T
M&I E((+0G_+HASF9C[?OCNX,R<OGW2)ECWQ_T<BJ!?-Q"NL^;Z2=UWG-B[*I
MPS<=MQQ-U#W.^:K>.1=T_'9SZVQ3IO>&AJ'*Q%BB!Z3Y/)!OPY^0EM+W>4U4
M)3@'Z"-@?W)/)D[(FJ([92@.*M+(Y$[5Y]TA*&+,Q3(G?T$NC24<:]>P''HM
M]-X6ZA)"%FM'QFZ@,S($6 I1FV#VJER3;N8V%DQ)UP<*T ?94".0J^Y1X(G)
MF< _<]<RV1'T/_0L0Q<$G^Y_\[@4S4M#C<Y'16OG.S,6+RQ;)WC%J\C^FN!Y
MMBA^SR5UBAV!1JDE\3@VNA#SA)+(1V46'3_HC"U )*(5@D/'WQ3!:9_(1VU;
M'=1H:S_T"1O,G"U2GC'X)&,^/XW&"3WW="4MR*^DHJ0GEAJHI/0C )0<BJFO
M3*C:UHM//P;4IM"%U!(0*%-P^^G)SNN6/:[R2*QHAP8AR+-;\Y*2&<$JG/'U
MNR[=\$CY@JJ/W[>9AAB;OR;%P)/UN9I<\P;122;.=H*!D!>)VS'ZL(E",N2N
M;OND'-KY/1>I\D3JJ$XT.4C'AI!4 3$,=!>+^=HR70@L6^,+YZ5&L%CD^,<2
M,:PO?WC?)FT>9".X(9$*#VW5QQ"F5G*]V>#JKHJ#P(+%!6?I\4A[\0A\Z27*
MVQX*"U1)^B%4-[G8VKP(2- $QN-#[!RV@-$Y>3\<'\77>SMK?F H107:WIO5
MA\)/K\$D-NU &HD-?IN1L<?>%R-N#O;9U<[K 2XQ9_HSZWI3+S5J[I8CDO<C
M1AN5)B)I#V;VJU-Q>XDX'$%EP,J]5X_F"4-T91/)%B C!)S5.9V>HZVOO]\;
M\@IJ#;J>Y;;]>3AM!81]EQB\_TL2D63X*7[VY]8ZDO=<,P5*2>[+F?,]>+.7
MZ%8,#P34\V/=?Q,M2JS(H?;AJEI<)KP:9Q1]&<"L#)X#TX67VO^[G$ [IZXH
M>VB__S- 9CS,OQ: R4?I\ZS&$\CDLHIQ7&3G [ Z0"@R]'1$&.I^FHE#H6@+
M_VLUV%=*%AJ;;(O5=]O?)B>91,'-77_2JSX;:X^1C!(O>'J^__5]&S/%H>0^
M6B@0%)B!4*$HZSWVFS(\?!<ZM#_0B'6CK6%'@GK,SU- (VC1\WBFU=_@3S.4
MAG-1).AZ?SVU?X"NJ])9*M,O@1QY]XPGM.*'R_M'NQ[OQM&5X*(4RC*$9'J9
M'M:O/P0I?,V.T-F.<MK.)E.!%.?(G 4LB!4+4&9:CQ>-^T:Y4(#@/6C"MT5-
M7 U5?DXEQ?JV0CB\Q*S//@D+,_*TG G0=;"T!)XXFFL[[3@>:J]R%9DO%7/?
MT.O_//"1J69MLI%#AV0\9L;CM[?FQ-X9.0L]A0?V..J/>EV;^L"=[,+(^L_9
M>43J: $=M8>OFHH%ER) W^XRT-.O;)&]9[Q:+[\I5P0A8K%ND14L>3 *G)A-
MG9)1ZZLA<7F;^<EJ=72-)C>B).TP>_\4?><)KNRL5^-ZJ9PY:H+IH0_"\::<
MY/^6,6<O1FFWCI=*H^G3H83(J/:<=U+[E',+PA[3,/T4PK7.WMY3&[RRO[(*
MR1>3@ F?>TTWG>?CC9*3W*)GL<KVE6 $6?].AG=?F2/?9(:PL:W:J;<K%^PQ
M3. ?(-"!1&D6%J&W0M>,!/ FHE)Z1?!10"R!#ETOK2B#H:0FN; DT[*F\MOB
M1-D[1Z8#5M"81VW_T$19MC]KJ*#;QA?6OX,MT6C:J*-"DI8:84PATDT%&BY8
M%Q F3J_</;9F<.^#2 $^G]S57F]M'08!TI?0Y.0M@3WU+EZ68IIFPUP @8U<
M;SI6MPSF%\Y$A>]/3:&M7?2M$+W_,7Q&]S9'[6#$!_0L3F]0LT[!VU$!&QTK
ML3I,BS^4QHI&K)P?G2ED:S6I6C"4_N!-@;I 2U'<G+&K>8P/_!<B,RQ2]@"=
M\"!K9F5+4<Y*4!(/1T'DUE#2!G/9MX!&W(:$:M.[ZR=5RH\9(IG1^AQS4"\Y
M056']GM\+W10ZZ5R5MCZ\I3#2N^3@'\ K9&8*=7#_XCL#3 QQ,3C>/U2(30:
M(SA;*/G75JD0A5%TS-0HA78$LXPMZ4?JN]PU%* 5,*S\?.'RY)BNM2L+HB0
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MV<IYT5];6(D(;<7.6VZM+CP*PMN"VVW[SSQ24(0GN5A*@=1\.Z2N_N$@MO;
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MGP!JT/X_2LHE14D2(SU!!_/]XKL:5&FE*_#BPV@K44I">"5*("4@D DDD
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M93$>9%2II2>LT*(6\QT4HI60D+0 M!(^[63M&;=+J0I+;;2Y#BCM"#Z5052
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ME_=R[F0-PZ. 8$E=DVMC'[6&THM1'&8SA:2UV0E(?"QRX]W=;_A+2=9.W="
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MW$'C'/3!&.3(!SB()G$"KZ2WZJULY@J)T>TIKV)*H1:/->P^TB<V@_N*%)X
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MR>EB*59\!+][-*]R81@D9'=;<^TTQ"@NX"5+9$Z$]:5 :PPM7H11=8V$$-
MS9H<<9FNOZ6FBH*9704XVJ,,@S6Y=%_Z$PIS"J\\C+WONO^9; 75QPE!(,JC
MRZ$*44N2QKI^TK4RW:;UC,[?^OD,OL50TSBL7C@+'_H9./#V0"#NXPLTJBEY
M0\V"Z4.D#F9P#X-AS/45^2M@K]VC1=2QELG5,_<\6.A*6*AN82%<'&-]4J[4
M)L>?:0?C=[L[^J#.OF3[2YGQO6O)U^&D FVU6,QXT"]R&:1:C) ^K_R9*64!
MC>>YWB!RR%+.:-MXZ3%B$'CTI=^!4I8R8@UMOGDV/FPWWCVZ/Y?H6LJ!+)*?
MHE/9X=*5BM?5OK)YGSU=G?>Y6.X64^5AWDB-19RHJ,;)8>%C .DC![*]GR5O
M,DF+]NBLA+ZQN.:]/_  4'E?B)K14#N$C%_\>VFPIOEI3JC6N?2 T81.'2U"
M8%($\ 0@T,D<K!C5KG,]/1MY_U=1G553^*F=Y:.(LBJYU_?KU9ZR-A>APG_K
M+Q,LJ ;V+JC,KF]:>:;JNYPTS,TT.KI"J<E9 C5T!/C@?2O3,KW.LO'OA3W\
M[80 B/M0,"<GCFC&Z"&YD-$4/UO[>GXBMU%(?O;K9)1ITA=AC"UY^GU58RRJ
M=JL.3@M?/^K8LICWMG-8P/U0K:-5 7>F+]!0%5&21>^83WVNP[8@C3#6;#_2
M**K@R6> SPH)?/D4OQ23!K>X@U1-4]D'1?CX51'KS<P+[O!]_<G0*AI=3N;2
MYX$;TIO3"V!P^FR=IO;!R(E"\*&DG+;41I+QK)B=@(/V6"U;_Z0_M^.ZW,N_
M<L_YT&_M%H0D=>!V*<:-0Y:1R8MT@I@-7B2G8 V8(6?O:412C)N 8((>GZM/
MVJ9NTUG?QZ_)&Z&5]1R!:CQ3O!">[O3-EIK/?4_T#7<--.EL62L&\*]N]:8[
M-SA;BMWA?:YCB!N*MMPO!.%)JRB\IQZ%\0^8\2\V1/#N^$)8WVKB@'@_) QD
M:SNY[4R,L@+_0#=6@,/:*N^C@N'Q/4EB,FE,64BN^*4,9_=\^]'#19$BS?JK
M^.0U$JGYJ:Q90N!U;KDXQ*8)ED6:>]A?7QIA?_PUMU*8X>,<8P,4&$;T:7J"
M%JE:5QSB04?-HF>X ,#*I_C<:)UERQ>T72$X+#7>^,F4RZ*YKXOT?J*0"AH5
M*":S8!O!E"@)"&-;_#0^?0.#_MB'QHC'TN%]KH-$]*!]YG5G"&X64ESDVARL
M@5=%?[PA5T#Y[5K);\"%L*6=XR2G;A;K^L)]5EY_;&Z$NC9[V@!5\D1R@X-T
M3%/3/!EC:-XF( (Q%,Q(0)Q$$W3'GSI.U[&,X_X#_]5SRONUOY:>GHD+"*Z+
M)1-<IAA;#W /<"NYC=U%Z .B@^' N"1)\8M75%)\*850* !;<$,91.5\LG=Z
M_2*UXCDB;:SL<VU-[RN8VTBMDOJ!J FHG=[,Z,IJ_ 5TG7@3?R<FX1W=PUQ]
M^; OIT,[EU-+& 3)G)0%+!Z!IE-XYR'XGL@Q)4&,&7H(/*1IM";QQCH.5X(#
MU;!80Q4M8K4[:1.#7XCAGSI^WIT?]]KQ@_=^*QH\LJ@HX*IV;-4;>YVOX]YX
M[L^"DR9E^$R6B"BH9/U$@%E8&83V+O\3T]D;)B)V?*J+<+D"<,2#303WA>)I
MGU0\^>'X<JE7@JJW7S<2!7;-_?10D@I8B,DUM.U#;>I'6]GK/:.W-1(?KLE_
MM,OE5R=KT#\E'PY:BX$#TI"(@S$N']F&(_Y;K0*TJ@F%\87,5%40&Z7F*KDU
M;]R\2@,1"0-"V"/8EIES:I>3P$;'U0UU(T>Q43,R48R1;$&^MR"DA!=65B(Y
MX-L#W,M;OVU/GQLL.Y$SG)+#=PCB:1(P#/7?A1X+Z;8;Q3)S+#+1X%-!>;B2
M^9F.G#$VQEJ&3SO\'X#L(N8R,A/^V]0 '-[4SPG*!0&V,%+2O0D[)FK!%>^^
M?VHW,*J/_Q,+XQE'I(U:__>V,^G;E]M7.WHLA)[5*P2EH#/KOE=IW^XW).4V
MRH*X39X[)W<H:N;DQ!O;.&FWLOPW1!)Y-)6$VZ]3!?Z=M,K(L;X,#':<P_83
M%(X ?Y)0NN+65 !K!C4F5)ME\B<9RCS'CS0&[7(.)F[INCF] &T,'')@[Z(5
M<&OO;VA!50V5%:GN?O8QG]+Y/H3U8HYX0BV4DQ8*XZGM=_IMMVJEV_,XYFGW
M8SLA/A;2H5<GGWLCC'\!OKQ\%*@@L4^:W.! ^#C/ON%M<C<<<ZGLRU1?<!2F
M-6#L;Y]9N.GV90(CX:,/24J2FOS<Q69Z*B!FS?6U#X#-O4<FF3,J_'5?(M>:
MJ"J.(_"' !A&[872;4#U<Z4,$\\";>=\22/74@76 F7S?(,/>_7AVS(>=1RJ
M0\8-?UDOYALL3EH ,#SU=N7LP3%/EQL&R/S&9R@:1VJT3J16/.Y0$-R6FWG.
MRVAGTN-N<]A7C5GEB=Q&<CQ$),U9^8(^M7)8.)C8?_E8C%%<@DUW3;QO>?K5
MP@FAAJEO@:/L<&# +C*V"3Q$=&>4OKYAPT6M9B96,M^HWPRB 8>J()CCO'?M
M"YL* F[(X3\U1YBY6Q$D217M!'.1+5">:)_$7:<[51ED*Z1GB4+3SQO.\0HZ
M8_K#$,&MF;^Y/,Q1W0GA3:V4V7Y3[6-QCZXR[008]IL?M&]:B*!YWW^P*Z42
M<#30R3U0YL?Z"W:V0S\L&G%[N$>(@/)Q!R/NQ#P$,UC'^B]KC<H-.[@S8_(@
MMR\4 # 8H#I<]_T;Y+NV]CRKW/MV;YX>6L?2ZL&#\F$4KK \*?N#$9?UJ Y-
M\K.9P!>WQ%\YQZ^$\Y8XOPD&JS\& .-< 6GDI0H=HV[7U=V']=KXWT="4.LR
M_UU/E2;.;"[B]0,O;/[-,<6ZN^K&H=E)ED)HVOM'7^3O+%=J]7X4^ED546R^
MN/30M*6IJ5FC7. ?0(!A@11%T2%VGJ2*D,MBQ ('*GAB?Z#?*@B8T"^*=>?5
MY:=R:SFQ06Y]P%;9,,^G2;(J/?57*#H5W"54\X[5_CGD_CWP,1%GM Y[>YI1
MX<]=@"3JOY31EA*PRRCZ9M= / NC_[MZ1;C@#=3=?MB=0WOR/43QQE?TVR)0
M>>J#A89/=G0U37K%SUU+D1J5C4GC> &X\$-IQ,ER7 [#WEQ&X[6'?N!,0-^2
M#RPBBA:;RQ@"+G4A5Z&DMG17H6RBB+HEUMYT5].P-<(+#@QG""=J0$)S">1C
M=NY;+QF MYS&6C_)/ Q>BQBI0-^[1X;E VLCXFS(A18C&6=GL0#M$$:(!YB,
M\_A<)N,<A( +=JZ9>"H$-1"#.)5-MPN)<!/>GA)W6MV3WTJ3W+[CN4'!YSG?
M*K64C [:2X8"53?$G,Y.YX2;#7]N*K?G19\,.UTAA%"%EH]OR[W6(@S)YC;(
ME08JK@S.6/R,[[K; *GD4U5G8Y0,(_APOL+(K 8]GJC^@;N\Z] 58ZY\PS&K
MDP^DDD2# 780'"70.I.O,@<#-<-?LEU'(M)?-N^!LB\;&ZD@ZJ^N29:6G][F
M439C M>3GJ&57G/&VS0ZI:1ZU5G"E5%UM/:2,EFG!S(\SR!CW97&!Z?H)E/A
M$9:25]6E3Y7[97)*>JT"N[]]GI^KV,VA;YX_S9R7_?4SYMG$\0*>G7K%*;HH
MPP)S2F8U;(W[B5#*?DE)W,J.D=$MI($H,_)/S7H=\E54_^5VO/1%63:9&N(!
M.+R?42).BHFP&9@@S2"<Z$16ZBQG=?6@!W'V2MRUN[^"[[QQD1[*&5X<(7C4
M%670%;(JD$J7IO!;7'Z+I^:I0Y.Y3NY0K)8+0 %&KZD02&X3'<//Q&0\#\V,
MD;LMPJV29&PT\^% ?OCITUNRA1@*>B^'GN9U=OX\<]_[-'JTZ\P5R5H&]!8@
M_EN<:=L2]^BN:V1Z7_WE>EW=6%YY2JH<;EX(% HEW@=I%WR';)$\C)?J)YXM
MF=GM?:[(5R65IS39&HAB9?;5&I'#X]SPUS\+F[?L2/6#YBQWMJQ>5*IYX<)_
MY6(I S$R!%\%FP63EH;P@UJ'>T%ZU&N?SB[M'2L;1DIW,A.M7D"F&BU<AQLG
M-MJV#>*&$%K:4-''9XV=2.I]/;*]P0OI&#G&*.U;'??[VY+E7R4$@5>%'[AC
M8>$';%LR@FTVW%T503OH ZL-C4@-(ZCKEI(B7T]LDX6Z-P3)XQ]+C?(O;"8R
M#^GV+^\YC<NKBGB%5OWWNGM@ZO* GE0\\[=<NW"!/^\QZ)\0"%\O>[46W'RT
M9A=H)@R"3H9]XEK_^(K0?#<3%T"Q^T9.6UD:&W6(>HH<_U+9RBZ]>_RFJXFL
M^1PR>%F=RS-7JS-;<BB'&!-?.*.8QZ257_/%3I5LWE.@=6I",1BODH8(ON>,
M7\VTF+H,]]HM;J@+-#(&&VKJ#V3MDK9#UX+)LDH@_FRT7"\]3LOO/#!);H@^
M&PF43KL^W11'?^8V,\"9KY..+= 7T0TW[40J']:,<[L)(R^+#]Z$!P[) T-5
MFX_+/]QF:T95DW\ARB,CQV.H -K,G3N"<8FLCD1HW5UR4 BC[29B'_PJ;%2F
M,NP? %&-K&W7^*%@_"YCU:@ITY_D^;6.*MGE:Z+YF3K2M"1\034IW1UUR=9,
MC<5+%/%_#*8VHTH,,)RQ&D_[:]9DB=Z*4?-7? W'E_C5@'MB(EB60<(OQRV0
MD[<+PQCSJ>6QFKJ'<H.Q"ZA\%J'=6<_3VO2HYS<209SP_2(YI@)-@12;NB%E
M+71=..47$+D/'/KS2=L0SV.)2UQC:2\4B=KRPS='L&JG0^[.1L<Q<7>'G%1K
MZA,?_6]<6\D_T*L(*!H,K"<H\6\E)"@=<3IFYN(Z?A#^ 526?'+YK!,/%3[F
M:$_5+K0)<H[6:EGJBO4+UV4]V[QY).I0D9<?X%M[.Q1?MT8/P2S&6MJ]WFV
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M,D*Z*G9W^\V\((%Y[/G>-+I1&4VNP@[7!MD>12]H_H6MFS15@BQJ'.031-I
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M7 1B[9U'[TJ\XD8_..%D.)4,LGD7%2+H$P8N2<3JRD!V9_P<"1]0X9UN5K[
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M?1NA+"P8$<P?_0\@18E&FPLXO*C1#I7>FI3P/?^C899CRA[X9&9_U*&YLVR
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M9-.G.>>^MPUJZC!1V$DKM23GOE4(*S"*9P77S $X7CNJL+J>&&QH$1:T=C"
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M-?^6Z4%#$^W&U.WNFKZF&R;M)WDH4^2 _.)A7LF6O&?%J0Z;"] (/->=R@O
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MM6D46N#N'_KV?80BV?NX$LX_2R+[X\A4>DSQLU=)U6]\0DI:X<:)] @#+1K
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MICUVGRU\M-#HBM-R66THB)QS)NJ+I\90XX4 ]\Z#S6N$5@N"1Y^WB^430-@
M,"_AOG"F-4 G[?LAG8G!(46@QJ(O2J+0#I-S9. AM1/&X*X%*_XZGK\WS8_4
M@<4Q28M=:(X>,4L[*1N7S]M4"CO? *D8BNR!S)308K9$3^@:E4F*=5G-2*1
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M)14K-4B$C49,4MG0R]NWL>4M(2T[AZC=M896:;^;=SFY)%2,C.T1*863QXL
M/@8:11$X^@:A[1>)AXG=6Z<IWZ'AEF+.R:WUS._CTG76K%6Y--SW?2]FL93;
METX^A8X,@Y%D39<\H:$CY[,I^Q5I.!FFQF:8'06GK9#C9MW8T=#(1[<R@26Y
MT+3D\S[OK:"WFR>HY=.$.LI%4\=(\>>W'\N)YPYR1HOIU,T_OHZ,;7LRJ9,P
M0H 9,9;(-Y._WI;?=$6SV"DA10S+W&SQ*;Q_^XJ-_4:>7)E!P2XY,42?-]P=
MAG4_[Y9$D,A(TZ'A8P(+68LM?,V">IT]XG=!^\/WO>OWK(A,>$IVD/G;K0>@
M)S3&*8<\3JT=K^8/NX8L-C7]/%Z8Y?DN-,+9IR,"]D3P>.DX$ZET;D/$]^-/
M?0"A,[EWN'9'1OIC$Q);(;)N7R_@9G?K.H5:+U_K,>#3L\Q2.X?#WF?1SEJF
MZ$K88I%#S/")93XJ0[3LB@XN5PBV3_67!$10WXA\2I^6[LW-F3I^RRK[;6N7
M+X77&N'4G8JPX<5R"3[D3F)CA(I)-/^C*6J\%(EFZ!+3PY&%[C$J$]'V^T?@
M(X/DY^O]:>IQ3_SNQXC9E3U]0W$>XD23W;&-;WG@<'D"VUG.ROY%RDK7?1PX
M"3(V[YE:;!;>'F%VNAOGBZ@-#1Z(GSYCU5=%I>U%FY:UA$,IBZG*6"NNWI0Q
M;6O[IP<.*[5.JT-/^$EJ:D>^??EPW^'!9OX43I5XB<-RV[6C>/K#C3]<0=N/
M]'5N-'-M:N6 .' :AT8G9QJ![CV:\IZ")KE4%0E')O)&9W\HJM<TL)^H+'4D
MT4M50L2$/#1K^-YPW<^'ZJXC5'Q<B,\@A^E!W\Z"E6!X,/UP-U2LXSUG!A4E
M$588GV.*Y20A/QL0037M2TCX").!4Y_YLQK.X.6OC$5,E[I\&&\XXPIF>-]O
MZ<A9H#-+2K%^(!=F.-(<ZK$DH49F^*X'BO\DEAT2??/1I9)7-_2OW3SW98'6
M:KEX)T-ZSF0-4NDS1.06MB$>.$S_8EN3D^I-N7R6MX2'9QX,&C\A QOD##)&
M/8A$D/,E74R>_99;IK7L,[B0%>$[+J;=9EI'%2/K,YL/K[M+/36S+0&W$%_1
MZ'8IBQFV9^J5TF22.K<BK;1NX/=4Y ]7\5*O#(X;1MLX"PQ(WQ6DJE&Z:F;=
MMNSV]=T;TKNX3:5/>4TE;*]R/@6S!C/):2]/3C*R+-OB%VFPV.Z+0ADO33<]
MX4*^%WWU:)8IX>&%WL>L]<PZF_<MH N(*\GE+=4+G-LBN T#ND-WJUO)D#WR
MRY,/&S2)+P#BV#,BA(Q?:6;NYT.R-[T4VDH/V5'X;C?T:TL$12U[(5*)3H=3
MKM?W>I+942)K4>(^EE&F$J%4'^_Z-I9XOMA,IQT<B$U5?_LL/VK]<'_=FA<S
M_K*\?K%6!?4, XY?907K73L/?<E'_ >3W+V4,7VF,;"9=R+I+V-T5H,X,)K)
M3.T=4.!6KE^QXD4'U<2$5*8 V-H@&*'1S1!L'4,RTO.@FV PWAZ -8^GFF+D
M&D]&+;#0\=' *C_CQO@ [S-F&U66T<H:NZPY#M^+V?RZS(&1<K?@&G:U*0N5
M!FK"B> '7E2)...?=HOYOOE,+8X;@J55# 7<-6Z6)F1??N4U1>&DU*A;"+V0
MT7!=LRI$Q\S@]HM!8]H X>_M).+F)7>8FN]P"EZO@N9N'A6YUU]QTWDFZ\\2
M=TUMMY5'QKATM)W=1'G8Z^T;BSE#&@)NXZ8$>$.L:;S=$&Q@E/A" 9V[0X*;
M'E>8BX=N2<<MN?YR4=JV3MGAK?Y[A,Q347C<:N5K5BSKRKQC^$HRTSSA2NPL
MM*44&#J&Y$GJ "D9=[0O8(NQ@U?7K?KQ=7":?,,/1SF2W0)'O!,=(BT 84(8
M0VP>SV?)40! .E:3WQ>\[6_^=#(4_:]OJ^EXK?JL5"R?W\/JVLR=E4[9M>S2
M?O0E_]UP.E8+I?1ULR0%B_MSW/[\6>E "?,CL?[<E\0>ANZ)VNZA6M2]?(/Y
MN1B-UJRLY'UB)GE*!E7IT"(V9@R]%TA3[7M:%(*%:3+4".2@ 2^,+/;>T(>F
MJ2LSRSZ[[<V.T#0;W*(KY5RXHQKXK3Y85 U5;=D]O(VBNE\8SET''<!FL,$,
M&CH7+W>M/@\IFW5^II]05BGCK#C$7:O;;^G2A!M5J3JQTY%($N005>):O=0<
M,QWPT;;KC@^;86UH^;GBWG)?XF>72S/%\S:?M>LV3+04FH(^'Z+L=O%<?!%1
MK89?0^XT? N1]UOHP-CN7AU3(B7=P:N_<!<_*/3"XU]A9I2X]$+RS3VG.\8)
MOOU,!9?>A:52!1XVX&;>*98.UH=N&,3'O1\1->T<7LM%\GI'N2 SU=X1M<*;
M3*,;)F7<1,,&:!/TB^$=BR6V"YD#OL/W4'Q!>PS>, 3IIDY712H^FV7'BN3C
MG)HJ3D/LARZ=YKJNB>>J6LSL7GV>BIU4)+S!_]FZMXKY\5-#"6L\U_F$@V8J
MLP8-O3B]N;V:C<9YJ@XW1,.">/_FF,G&R[Q1[8</QQA&DJ@3(FDX]"3BA%6>
MW!>_^[7Y ]4%/PJ(V:V"?G?B78]%<6LOB2"O5D'DO)62E!?WT^VF9Y3O_'C:
MG=_<$22!LG/,)CIMXD]I":8AKBVH_Y%PWH)P,,C0A< .6*. I#O=.V0OEQ.'
MBK$@BQ;0YK(0O1D2K(PA$H*-]RE<H3>EQSO1<#HOPV/PO84UZHA9?@7)8HX_
MBM4D1Y3?E0\WZSD/_OYQV*%$C=-9').0M_1 [9RG* SK!J/ER_L><0%&264H
MJ-&=;\R7"+&;.^,A#'P"GR(7Y)RD97 ?*&;C<(Z,E. 0[W$NB&5=#%=BN?*L
MZ"K5&\:X3@26';WV$BNB8Z5VVK3G\4@O*+=3%T22PCPIP^W?7Y<C52OA"@T:
MW.WKJ)1OD7\O0PY/A=R[F[)9@[IVM?VP:VY:2'#GI:]ZQ\R7I[(IMMTVNV]G
M:*T]MV;7,,4/ERZ^R$L%<Q6EV*>%'P,?O)J-,R?*7,*7*_7XQ:DTE5"$G"R0
M6!BI3(#( S!V!/,7BI"0D'0YY@>J=?4;G"?W>"P9ABWS1X)\5V$^D4_G]VBO
MVK[F=JMPN1_4*>:4#C&QT:3]5L;=*^&]>U\YQX,?#AJQ#4JPE%_;2GB8U216
MW:GS?CLF=YE+5VW9Q^$84)O7DTBSO\+.8&3:LDBF+@$E4%<9N^=R>$BNEFE[
MN2U9JY-MG8:5C"4?_% K[LOWK'Z1.SGN[3VW;02<US,J[6^)=&Q:^8X/SX^*
MU!EG1=AO: MX=BHV/GS&FBM[!T)FJ^]I/F.)J[;S("*T6CUY\MS#9G!X#(->
M+<]KW4+#^+7W-895S_9%2X++MS\E:"GE?1-\L!\(PDU]RONL4=^BY+$5G^F3
M,HZ;G=[L,R]O(<IBQ1\?;MZ]CL#S\YN]>*O6\X[]$[\,6_^:9BC_)(EM^:1H
M AOHU4+XCESTVH[M_CIK=8MO1Z</%Z?K&'-Q1D234%&^$MNX#V-P9)[M_2WK
MB(&OH(8E@7S+S@$Y4][!_@_OF%GO!TU\>2VF:_^R7&+)^G8[,$%J;:].SK0]
M54@;YU EAZ%307U/AJ%:YDV+)1L1GU2[>X+5SMW1.@8&+LIUZ9R$3HNGOM :
MJGC,28/J.0\B-L+%Z!Y3S/9K88?C5)[;RTC!1$FQ37?-E9:V>Q7W/ ;CSLEO
M!^PL<JX$]5LT5WIY&:5^N5W&Y%QK;IJL)DH-:G* L)',4-Y3TGSV5"=2#3PC
MWX+>/Z*E_@^W;M'U"F2^MZPHHUAH)#YP&QO2U3QJURGO5@)-B):+Y\8UB&,7
MV+.;<C<X2Q\:K\M<ATXFA0:I?BVLDM[>3BCTLQ.<HK9V;7!JV0J+73*\4P>>
M;VWR-$*RD7F^FA@N,=0]HA:)#T<)3&36@S0_X\94@7+#R=ZRU@Y5I3.WPO<;
M0ZH<G4#K'068 (JHU-3( 'B "\@Z\H2< UBP)D+.+\GLQW\;V DB>T_ N5R?
MVC!9ZG<CV(MCZ+*UE):* T'N"O?6V$K:W3AL5:[W.W8.AHOQI(%6*>E!+W@^
MB3'E@B.:^2I$!>P9[2<#11O('G/1!YLKK*I=@IH<%.NE%.CE- X>'*58W>P0
MN^]6-+,YY=LQ"F,0JX@--%1.FTLL[B8B^EB3)C*%M:>]%[7&V$W66ENT1CV6
M.6_%.]6_F [+28&D5CR.]QZ,W.SM;;X3I=W&RNP5E!8JB#35&*)1U]G#$:/%
MK*[+TUJZE:WK87RCOZ8%3PJ\JL9;I-C.ZVLIVRH0=4,PXX96ZJS3%;<V.@EN
MRN'%\6>"^YVR)LL^7;.=:G=2<(G-/=\IN1[)#5FK]A9+M';&=&^JOY'Q5_YV
M47O%S[)W=]Y&HCMEUOW-.S_<@$JZ4>'9M.S2W@L5:LTW.%M@LI_:/8L+=8Q,
M?8Z!I.]%OA\OWL(3_LIKJF#@RDULV+!V1S3;E?M0SJ0Y.;?<@DQ;0;X37+*;
M//'.<M%Z&B%F8;Y$F288R]/LV:A82VR;FR[1VJV\JD=Z;3'#W&6?)KHVK-BZ
M-1P:5GQ+[2&%M81FAR//< 5A, L9Z8ZW+#HW.]Q<*V/CN7AYEF]W-([*-;5,
M8USIX4B=86)"FA]N_-<)V[QO*')OTJ$R+,;V- (NXEO( Q8+H<2'$UD/-%7U
M#U)6<:I@:>8*@E,H70YYC_#<M'EDZXRT9:J$=G[ENZ</W>@()K+#:Y<JD;G@
M P4M)TAX]15;3?XT3OVB/+F&(\?FEK%7I7UN\H8^-3OT%Y]W\NM65G OVE-]
M?OGT;F)0ZGE+QDTZ!_W%=N@N&7GEPA1A00,^RH';\6Z_S[O'E;."6L-84Z/S
M%ZW)2+&0E0)/#$7V24FEU+G/1X>$? ]E(@F";BF@\LI:)GF2VEK?.C_Z7"5?
M!P:#96WP#%##O26U[@*5E]N!2["M-B%C#U8A2"R'W1'R<FM"4>E#E%YV]3L+
M.O-6OFI_6+?A:N300LO@% (5E'1?B'[[RI5L,#9"+LVJQW(-5/#F-5OU=BQ8
M 33YFA,WN_*A5)T.(03T($;<6O!@3N)SQN"N>Y\\1P=$S9W,H4VBH_/NW+S&
M]&T+ GA\\>"( 0]_[MY@JR&AFOYE2R)7(LJ<UJYN%WS)<@G$AS&* :+VW4&!
M-X/N429+]'M+M7Q4WX6>'!*[9$-FTZA*;B^Q;?!/9CYV?0QYO;;4F=AR6Z9B
MVVM_;)1Y5EX$7'Y;BZ:2GG>GSNRIKJK6)A\XG[--O5QC'+R3WX2C#;^_$&@6
M=:=&&%'L/),?22>=*V#W*&OLOM]5PW(Y5WH4QO.8=$&K\;+#K46YKTI"]1\Q
M\1OOUK1(/F*%Y#:X,^?! G"WN2Y<3CJT+(XQE7,27Z#2X M-O,*HID%861X3
M"7^)SEPTWA]3Y"[%W7-LWTT0*7?\:-.?X$W,A*$?&I6<SXN;GJI<U;X9/1AA
MF.E#3#BQ+1<0;Q>Q&F)$I1 VB$"U' .5 PK5G:$I!MFKKIDS#+A#5<K#E8G%
MB_$<2VHZ?3(^'";J1D:ZW-2^DEJ@\"%W<BZ]QM3S!.0[,1VL>3@;3@G'@,VS
MAH]^!BT,Z\RJ-C;L+0>EG?4O;8L<:>?M%T6O/Z](;8<VJ]>.[$+I*\/"UQ[U
MXV"7:8E1]A'OQ_<)Q5_0GMSS\HK)MN#A+8D)#P"+:/I<O1A];0$%DXDW2AZP
M!@_CB<0:1=\,[P/(SH^L\(4M)Q6#O?844[^H+#R.'CZ8+4/>:W,;N*IY6S#^
M:9AK3=-T?ZVEAZ$P.3&/)%>#T6M9I4UR+0N\J<19Q'ZN/4[.I#B>X.HUB-D<
M?<?SQ-CYW4/=K0&B\_Q'U5D3!R;K3Q^+&<P1RCG,WDC)#*E5C($29S'YDI5<
MVHQGXI[,P5/@&4]4A!^5%#8?*'!=O;1[8]\ZQN.M;S5[AO'F@7S(2(.#I;:V
MPI,M,LWH;6F6 U0G9JGQE4KNO"WEAH_6=.#"W""\=^2J%N]C2R[4ULUH!%K>
M;'"(W]^MNZJQ[-$YIN$DWVQJ82)I=L_=O/6RA%C.ZAYY:L3"GH$HR.F:JH3G
M3-5'$D<::3K$BW";1H\"=SG1^E<5 ]L?4/O(RX=3;FY?$ZEN.&1VUR[&-X,;
M7?L%EP4561MF78:VP*9<54P4-W4M<E23+C9&+B\:-4$K=L2;GS:_B@C+Y(=2
M>S@ VE>=W#>S9"P[(QU=/&17S$+'7+YS\WLD'0@DQW*S.XH\9I\[4#NI,Y5&
M]S<S>@2U=N1PEY8L>=O%FFI\1(H7/!KT2ERI*X;GPT4Y(5P2-C<8/\_G"!(D
M7-NCOKQ';"&VN)E!&_6&7H"Y7:;WMHS70+SY+=DH2_#L%0L9N7ZBKV6$_(<6
M3DN, SS(BU:]<R89GF\/RNN37-+4)^I#AWE0S*ONBYRF)EA+J*OW.8[H%!OI
MAGY5_V*6%N*S)7?U!!Q:70-T$WM6^2?B1G7G0,7%L]'22*<^&SFWRF$1X:":
M>*]+QT 9VRVA<F1.,)4_L%=E7#O'.#QM1:W[B%^.=N9J1MRG_IW87?5H=MC#
M2AQ>;LQ06RW1F]H @)&Z6O*-JOH8,'_1W9GKH/PGMC)"ZJK7-,P0PI>7ESAG
ME/,);CKGY7:(#+]XXT;?A"EB^-YD8Q,\I]E;@.V]3;]X/"A6B#MLSFL-W@&G
MTIP<O[+?-FU)Y#3K3C^6WV^[I+EPR!?;V;%6 U)9WILJ-GSNR^?TJ@;*J*DY
M^%!9QHS<1I[=W*R)?/?:@8'MS,-I!?>'9C79KL2HR30D?;/'8Q(;U$H35#,4
M'Z2GL9.LRYZB6:PK2EH &)&6\%R: 'S2]&G',0%%.X"4^8&2:CTIZ>O@[\'"
MT0X7OQ2:I"ES-DJ4T^PN%9@-LKSC"$LWA*O&ABNSSRJMZY*7@PJ-6"A#O-"G
MTB3_91';89%*?DAVB^U0.X;D+AU+FMD@J:(*>R@[2"M=,;J8&^]K4Z@VB!=&
MN?18O3Y=F6H:$4M.S'!/2XK';U<0O,Q9@5\9I/J\4!N/"S+9]3(O=D"CFC>V
M.J><KXEV/1Y*3L'[X/I7J/>USW1U+MP*#Y):,;VC:9K.![38*+X^B&IID<>X
MND!XH;GJT9UF<!=F],U<?$(5_:'=I/7];_=]#D<.6PRKIBWX&(SK'LU!9A%%
M?1:J#?"'C8D9VRN>2*L443J8['D)[(OQK//1B5"+N>%+:BIBEMH.6N&7<)_C
M6G^(:Z9MUL3;N>K5FT&NV:5ZR$U[E!6 &9*DG!*5]&ULZF+6_-*&^=9<9ENF
MC<PR_90O?5,&CQ.^#Z=UH^X7KAIM34ZPXV5"0IHC'G(4YPZE+EN!/;^S=;QC
M&&49=WH?%N7#B?0'F(;GU]!+H'K4FZ>T I *LT33$K_"Q1[$Q-NN$[[ _&#E
MQKUNFZZ5@^2HJ N]>D['0%]$Y_?4TK6U_I_/ENCBAU:<ZVNOBF6UFME;]TO:
M'FI5YWTPQB/;6;>.PQ_P,$#N<EA*I@1@CL9N9XC?EL6 +V_Q8^I$+G_-C<Q9
M74]G+5E=CQ2Z[J4M>&DS:;'K"S(7;NDTZ<7X=;6Z[5'0,J6.N</+)<]D1A1*
M#0O/N^;"T]3O\7<6SOUA@-C5L9UHVEO#/?7:*I,035EQ8J]Z1=^;X0'[U]<&
MM!6DE0)$IGUWI5CN;+#Y  "NO-=5HW<,-I?;9LK\W]"M%%(U2T(ZX;5%EUIL
M39IG!-2'6&:S^KZRD^+%I*C0/?S":J3YBI2;M@<2W]<OFGI?149H"Z]:RM/X
M[BWUC%93PUDAKE)*8_/F.XGNO(4DZEOF&\O2W)<L%NMVI<49>EOCJ#%1#FJ]
M!3P]XF)KBA5/1U]N\&0AC)5ZS>VR3+?6W/QM85KJS/)+'6^[ [%W;W(\:96[
M%IJX9C-P]U-$8H!^2%SX% MIL)J/T/,2QR_WB8X6ET093WWNT''_Z42M6" -
MH;'.TWRU>V:=5M#E-RN"7U_6O*5*5N,P9*.=EF$)3+3I<,BI*&UGX*Y\=/C>
MT'-^N5:1N8+7^XK$I#\U*FVC(\TT+*2,?4'K,]L<.500_U9N<U5_@N[G-#7V
MB$G*?9ZD/>YB5+]("EO.LK6BL'C.%UL/#XEMJ</*G9WT':3XE4<Q\SV\+XP;
M[0[ U/R0WNI&DN14Y^?/2YWXS413QN](6;9^&"@\4#7<BZU]>BGYJZBRRX>1
MIO6BET:)-9KY.?2W'Y9M'@/J#6!0>$L 7+0;=D-$7I&Z0VBC>K0(NLSS:E28
MX-GFAK5*28E01NE4VGOWYY\U'CL]@M6(";F9R6 O(L2@Q>;&8JG:O-_-E*^2
MR=VJ?6+H1TB0;K *(=$;^>,Y!( )D@> Z*3-";PM^6. QH+&;\T]*6AK):FT
M1:"G3RWS[MRS6<KE&7,U^]7PSG'LV90:!7)&]M)<3D+.;*N05OUE8::'\9A9
MOK)2B0D^UE@V9AXTG4'O[QILB\P< RL78/?8T[\U5N=FX)10NZ60)\$/WB3!
M397;=>IOZA3$/ !#V30'9PG;+>(#J2]=E.;=-TM@:#-=C."FK)0QI!ST&3,*
MH20ISWM@ &"\EAWOI!T5ZVZKX4OXTA7LX28YRT7YY6%6_.0VV07+5(>%[>:<
MZP=T<9D1N/QC%:8!SQ^G,Q3@&A=%8ZA3*'WI]KP]Y!=>J+Y<_<R\WA)49?C&
MVHQDBI0\VZ4IDCK*Z%(WCZ7)6),CV=9C_FP3Y2^\[%6B[,QO-[Y1-YGMSC)#
MQTQVA'VCS:_7M657]P58A#^Q2LVLT-?I>:HBT9L9AZ&GFMR3TP_(Z!B^5E+B
MQ_IQQSD&+KP\!OK!1(U7PN^],[_4_40.Q%PU,.I0LZX GH-NU7 LNVM9:)K0
M3;OZR&&B2 JOF' H@*N_ONK2'?,ABQ4N7TO4G+WZDG;8:,.\N/D8$&VS'G>7
M>J:]7?K^2T57:WSM@#D.%/M*F"0BM=64W#?&D3K)*2Z&L+&,E4E]]+:\:89I
ML2I[3*F03=ZS5[?ZW9-W7QTL?!3)?B5$[WO16-),R^4#.(Q 3^<UOMG^$CU'
M9P:]3;$!GYB"Z<Y-[>1N@UHCS5@@^GLXV=&FT.NAH^0QG=.(^7Q!T9%VLO<S
M'G>SPPQ;]8OA#4SV5*TH!Y$118\US'0YD1$6%8QX%BQR&3++->9/4[F@AH'[
MT8GA;;IS^<)SG>26#-OG"811,81&8R@=9+KKN2)/4_$IGNC/!B94%)P&A^^1
MK[<DDJRW8HGU=H7(8/=[9EZ\K,V\ZY2J*M9T>;$9A$CC:< P>$WVOL#04U?-
M1.;ZHXM=GUN]XB&@6]+'P$[VO>Z*_B/%JT=5#,= I.;PK;=&#4<V$=]WW;-)
M3O.ATG=+A)B_:QM]5^< ,8;K,[XK4L16UKL,'#;:()E:5-E(MK>^-:5X^V!\
MXP0W2$4PS/9*]1PBFE^-DC>&2[3*E%N[RL<H#NZ%V%058N7>-[Z8F8;P9&$:
M"0_M<22A4KP9B,6(SQ1D1!DXDHLN]_$"HAO7[MV.BTA:35Y9VOD8J)*7%B,K
M7@TU?JU=F);QY<-R(?111%94/(;+NO97GV3QD5BO&N9\S9NI;O=A3O=]MN4I
MAN@_1,QNL+PQI+%U]\=@.'B8M\;=JU!@.42^^-(F3#EVC,]Y1T,\_#4_"Z.(
M%Y--="[R^>;%-./AT:.+!&Z<*??)/S13Y-[T5WMLT'"WNN"@YH:SYYK-$%ZE
M:ENJY^87D5=71ZPX=WNV,Q1NJNEYC*9UGS[EIA\N#M46[(A!A;*+5E97#.=H
M<681)**BA&]J@H<-14;L,-,!,!C 8YE=K'E7!M]C8N*K\)@AU*=E=2@;")CE
M8IGS]USRU-:@DS8RXY@VI>*;C$@ESU<247;<U?3F!W**=9INQ%%[U1A"F&=P
MW1F2*92;D,.I/*2%$Y3%+ #>O,+++TE;(+8[9NA<7OB47LH&P7:U>U9.16*G
M15UW+7 C/DM;/MK:M(B1ZK%]]A*.T64#D<>K+]K#!^]J]NL:T1;-@K>.@1(_
M?-[#UW+-G/E.8XAVA[CF1_C:0]Q]55EF&C ZJK=4EW?3:UMX8]O9Z</%R*Y7
M)HYD9TIG!7:1@\$/%_VSF8CHF,B8H_AVG\?1MNH6+:"PC,MHE3E'R=4H'Z"W
M@E(XR2-PL"'C[:S3O3[J[7"#RRY%@O?>"U^UMZPUK;C]Y'S$C"^$0.H#U8;O
MM(,,*6[F5AJ\2W0 ?;IN(J<LZ4Y!V4,B$0^&0!>%D]S2S&JFSP_G:";CVSP*
M%AFS/<]!)9VM9D+!71CO3=L[CXY;%46#8Z";AN,8>%,6$_RY9>K"R^_^DK]O
MSCQ!1I9)G'Q9"\G=W&+4=FT#6B,J!;S%6SC"8D0:SIW5+QR"SO5KM/-4>L:[
MB<I.<;5=]Z=X\XRKI!N$6@YF,NOO)0PX"#KT<[A8<NH_!1E4+]PC%US ,9*N
M3#G76$)VN<!B'L !>)1._XX1NF%, ,"-$$#A <8A,"[=+W;NUOR7=Y@/+QC?
M[C)F%3!ZGM5G5K)+ZM5*(&S28Q*I0/=R#6H3&HG!&TS7V.6 @7G(FC$T#J=Z
MPZPY\GC41;Y7[)(*1->BI7=K.LX]E1[[76H2!:+'(NV:E,!WH@E,#,;!4D66
MS<]L:P1Y2BP4S#CO+R3>"UAGGUU8URI[6;K5XJ.<?LY\CO2.,^FKCKCHMI'=
M6$7MKCAHC@!CW+R0W<OP9>Y-U=@HX:37E47?**N#S0N#.ZT<5$^2@BBH<-C=
MO$5J;W25I+%+PKM#@ET@Z&$[: FT*=4L.UJ(6VN?KNMCR =;+UD<%/UD&QJ+
M)7I1=^I^S$5,8]7>@0?JS3&Q;NK5V:4$Q2D*JR"V-=1P7@^7*2R1\^1E:'H.
MDM=C1S8VC2['(OR(ESAYVZVI-X$0PKA*<!H6;3 WP1,1;4S0!=LW#:1?H2(;
MCKR<TFDEA8<1+ITV[9=T=K03Z$7O2_%O":?!!7!2/E6CF,1TUNBDJAJ5.P1M
M*I\*BJ#&7MTI;W*:%O>QS!&;]8:ZZVY?>C+US;A)7?WRCN_K@4;/&+W!$<%%
M(;/QG7ZO@WZ/G(:D8&AE#2:EZU<-_5QQ#_>L6 _F1AR3(5AL0*!^0MFEJVY7
M-?+JCAS3\]J2OW!DY'A-[RMMI.1R7 T3[.,BF7;YW'VK=1U[N=IDACN94AI(
MU+MW4FM.JE%H1EF8XJ=JD6[QHB)Y*'1%*76\R[WQ*<-9E4XV#:$!&1GPAB6R
M<4VGCMV?[-Z'P!KY)NXO2^"<^B+W)&C")_'1U3U_B;RH%U+YG$U9EX.A4<CH
MS]>;>&.K"(A64QP#G$MCH5H@,O945LT<*/>)6J $'8^$1B&G 8D;^)*V'_G^
MD):P6'6;&(5@;L.@CKZ;EG<G#49,QKA\#H?JF99F]4H:6*F?1TV#J%2?#?#W
M9<&:5MZ1#W:NBZAM\B^[7-EO,OH8%MJD<ND!X;HT)U0%%C9'UE-A0JHS%'9'
M6/HF-M"#D3_D1DHH2'Q)BM21T__#NS;^-#9!O]5D@;>QR8*\=/,HEKI^S-BG
M\Y\_73MZ1_?VY2?7T0N?ZMN"NF?H/3X= TS0'\7Y"/U+^X#!D:J6Y[J!)I]X
M\_SU,)'VBUS/S=/JAJ_>%4OBC1#1!!G+(J#TI;:B76J3URU6'P<)W_*)E8,X
M[)JVV6PT[_GCM.H,P2++V%RTLJUG>2-8M<_Q\<\X\0H[R,<AG[ AKJ%"U?AK
M^D72L49O;/$$%.P7*9D]TS'?;:36$YF?K5?N:@)]'J'S$WUO5ID;J=0HP<'"
MGZZ]DLG\:/]U_M!JB?6 .*AQ#S2IZ#JN+51I6A6TVW9%\\Z\SZX;?5<#DX4R
M4?PY$\:92?6=%<YW!;FHK(,VJFT&!S97Y#$PZJH;9#;*G.,^D63?L=BU8'(@
M4+??!DOBK$Z/D?9;7GA9G#:U4')!YW&%RM74>]?Y+0.*;5/$\%W>SFONJGL>
MBF4XZ-R8X'EB:!/VP27IC5:PNOY.).*T! FEEPNV^FQZ_>D3YUVNZT^0\E2M
MQ:]QZI<Q*B[O]:A2<1AD5UR'9/57Q;[:7;CU]:Y!N&HAC\FY_&)6"E8*G1*0
M<WHQ*SY@E!P!8*:7D(00&J#CAB0$JV#<#4([_O@8J#S(= E\<B%I,3D#:EPW
M6E9G%AA@%*DJ'^V[.-MC(2:ZH#-MXT!6$?V$CC>,,KYAN5(@JJ^QBK&[<#=B
MD)BK@L8Z<7A1?-CJE<_!+LGE<=UFA\_T[R4(XV+"FD3ZQGMTC3&#/C8K:%P@
MQX@"C7/ZC64O7[%:N^Y0LV#*L!;AD/[0XK EV_>=2Q\7[Q['FO]**"<IZY56
M4PY\#HIK7\-Y;^.1"NH%)/U>U=!%++M5]10,2[)B=C6-5_L*ZYQC>[%'>5L/
M:D,02%D$(2-#['L!)+'@2XM5[,;(9G<U<.'C,2M[U^22[F4R)ZO1?>E6)XN:
M;7'16-:#&/ 4'CRG2;9,6R;G,7<:=3A\07 PU)Y!#NWZC,"MSTW$%7<=[5I*
M# 06C*Q=N,/I,S[Z@A/#5+5TAZ1I9_6R:ZM0X-YN=<:0]B"3U?V4/@RYU8.'
M??E1%0?GR\J8:SJ/5GG,^*EQ#5.T5B"&];Q3,VUM[._IF6#-_JDI[(9LUHN7
MS5F+]"I&S2(<PN6B8NEEU"B'#\;+/V)[!$K26#VI-:@6?%.S1-U [4Q?P;>[
MI&?RLJ1TMXXJ"QF*WR>6E5 [/BB>[EMELD/\O'B9<JMT0D^.YF:CX31]F8,V
M6%,T(SYX>,]&%L+&N(E7S2QAGO*5>_"NTVYC;)MG: EYOH21P69>T8(."XN,
M)+JFI)NTY#_8,O6%K[AG)];.\GDEOG(L@ZVP#XMR\H1R>AY\W7"EK9!R6R!G
M0E>B(81&25ORP);VRG#[H%-T%17NHY[>LCNE::\.[W*%^S $<M/JY%XKB\XR
M]L)4!8C*V,GX^K 66&((X1]16NRA6BAT9F./-IG6%;VIJ4):8$1Z$IPG>2TH
MY/0)VJ#JEJ)[@^'=2X-R\MK=GU!#-)?>1X=)^,C9ZS-)9R:ZX'I=->6(X9QI
MH)8K$S@J(=Y!>:>'VH? )-]V)C%P93!G?Q4LLTRJ>2+4Z>H740O+/U3HM;*S
MTE. 1J0%$E^)\&#,A^N:U5#Z6+L]H((N;Q>L/Z>S&<IV)YKT2*9BZM.99QV2
M'%0VDY2P'W^;EM:NJ<MU 8MQ$TLOI7<.F-P=5?*,EZ[<%+9])9"C+<C\><2@
M\9G^\),9/8VLY*;#SU8C:3;F5Y1=*8>)ES3E*68J>3$RM>JSR6,($:4&+ ?/
MLS4.R!Y3GSXM8?(W'I*]12'>DN:[PC?'!Y7P6:8,?C$:?-7?J77X?OVH2)A]
MO D#)O?N<_;U+W";;,KQ_<N@]<40 A9OW >SD[6S<0*SUR*_Z2-=ADT774'0
MC/!8SYN,CV:F=?7&;H*L:K[GZ=?7\5=MX.Z<2Z: H1.*[=3B@)7^ @2>UO$]
M3<(S4HRB=W'=90(AJ=G4URXV.#V@)V??G,NFT2F2+RKFJ!5GCBOZFH"23'A#
MAD!>-7BG4^ 8N''Q$CKAU28-U?Z6J;)P^K5-ER);"%^,Q%=W.)BI&Q1@7L;7
M9]7U*YH_NMU!*N>TBH__]?;J$3)*-:.GMSXDWI&"/L; :91%"Q1E#TG:0E7F
M@750CR\,H<,K?$ F7 <DLWARGYT8XO3"8A*E??B%]A%/N&(6&%OU&#AWD_'^
MAS=3W_HSU!\&^HG9-$J6#AI;Z<^FVL9G6]SS/6]@W1LQ(9N$$?J $S[Z,/Y)
MX,ZC'0"!:W.?\]-T'XGD.\F'1MZ^C35LEZ.#*1>#AC@GZ;^^'I+F8)16FM"'
MG.>VH-F9NEYED90S2D;!DNO-,6>>;?B=T$RQ:J)[I::)]>2I2\&S-)IR79D&
M&Y>!":^OX!FMR"\+@6P^MU6(UWLEC&JX0*-WPZ+<3=+%$-4K%\8*L1]@8LR_
M:E]5,PY2=^Z@"LM,;='ZKJ-E2MNZ(%0A<&ZLB/9M97G;%)^NB:&A\GDR96>U
M:"^\5 [F>"1]"VGZW9-S"E;D:'XI=R<\K!BLU),6GF8A(J+1F&5L4,H=H[&'
M-6>K6.KJ7E,I\7T1Q5?W9G)(R% ^- /R*;HZS]DPJ\BZ0(@J(N5*!&8!C\5S
M4+HL%#.N^&@V5%Y:RC,V;=/K84[0C&/+BXHB/C\&XE;G86^ST-'^^:O:,S!N
MO7D]Y5I5B6R86:6^KODJG;3FJSAGX6\7\I>B0.5N71A*/:8'N/UU9JM%SY\7
M?C9^'/VI_%JF4WU\ G0II9-#G*[183ZF8*&1)_VD4JI(#C%*!P!1+_3*!F2M
ML_AZ4Q9^9!YA01?7T4>/5#^<OYNT#Y X61W8WQ^L/,HUGP=9C&\.??HXLQ(2
M]B&^B*$3#RKF3]BD3T$Z$&,J(HIHQ,]#>>U6J5U\:*J5OW7?M/9#9%>E2[Z^
M<0QJN^.BJA-]AC8Q!UEL6+3#5>H1"\[**EX"=D/F"#43Z4,0)/KHO2VZA!*Y
M"5RHC[+[%G8;0%?W ,:W$";'O+ \Z>_TWAK?^=V??4@0^Q9\<VC@I'B^+FKD
M9C??D9:&C)/D3Y:+$C27)A-/U<'6@1"$*QP#\%B,A7CT>1$;#/B,^@J,=ED0
M'22DCN:V@"**E11T-(NM- AB:&ZGPN'?'(JGI4M#N832K<X/8KVSOHO=6GJ2
M$?2""A107Y>BI:P. C(&2J46U[T-)P\Y I:_Z"%'2C@V-NKVO4E3W:OV1>%L
ML>94M+%K+!AZNRN1,[1^^&RT"!G:^UX;AS-K;Q@DH3>V$_P(-97?&R?2CS9]
M,D,DL55Z)>=EOMP9=G73(-]Y^3U75$-(G_HU:/B+L$T@U&WWZACK%QZ-C\7=
M15R'JC(GUER0D;=*G>^X:KO%V[<XJM2Q2U_<IU[G5EP9ZSO\*+PH.-&*W3+N
M^U [Z,;XC<<9Y[*H+HA/FL3EB]%,QRW*&B<MNB35NGT%3;<+^FQ]N*)VR\7Z
MB9:5;M]:(*+ ?(I3HSD58%6*027'*&&-O#(T9E+5=#O))#D,:59[-/$!*D>=
M&]MIAZ\7&95+J&M,!Y],-V$2DD8X7WB?"1^)C:8=IM,@XDRA8!V!W C!+:B]
M7;,,6_>@;V? PG;ND,O:VF$T$8O3E+ NJ=2#JU <8;(ZA5WD813S7:O.X'N6
M:)JN:VH@,LEUVZ9&XQ//Y>]U*L> ;^M(%#KA8'3N"OC74H9Y7&LWWSXO<#Z)
MZK*=$.=,[E?&"E+#P?Z'C18J=]."N(N],ZK ,R8K $8@*<9G6U2Q6VKYTLYH
MXB1GEZII;2TF;KR6T;4<&U/6;T7B+\1HHU&VY/TL=L#N5"2E[X\?C5(/LGAM
MP:R^!9;X(%%S).B@Z."\&\$@VZ]M)%W"Y-K,>\N">ZZ7M%+0IBDW+#(]FIHP
MRT)P?1LB#TJ8,B@R[-"8W [>%C@P7&QB;,OUPL-S:!^6@>!(>']9\_9W-[6;
MW>78[LNU^$"Z($@^G>!+_)HC6SK.U2$D[B*O(,$>3Z;4Y@O,K;IB#].Y69Y.
MU\$@0\2L?%].?Y7/1AFU^^!H:FJJT>,FM]'*I/PL5%58P4R'ND$_.;O2ZT*Y
M_7C'D?V7FH=5]Z^_H$Y@X(29(UZH%,=JW3H0&?/"# DFO?&5C)0;B XY1_/T
MGHO["''"P/;VTM[,G$F7@K7#7LH(CV0%;Y5 SZJ#1+-E\D?\V5B4:/H3"B?3
M'*P'(K?$HM3=4C2?,Y(C1:%3,D6^_%;%D[G@Z#"'0=(*5"Q/.B%XFE6)T"B]
MX.2O!0-O%/).Z^3XY>Z<9U1CBC9EUV:G)%7A:F6D6YBRZ@(CDW?$^:<Q=243
MXUTXQ"I4'^7/-X J.9<K;XW""(V.-DOY4H/J'=:@[C>>9N5X5>IVO"QBXI4=
MM!"VK$:R*^\(+\RF'M*;=9&+O'GL:RH$HY/22)25IWC,[Q="(9F]J6"O=<6%
MUW#CUOJ-1S;FIMGQM\4H<,P*5-*A*"J+V._.Z;&^J9' ^WVR'12&_66TF9^@
MQ?.JC5X<G+O4_):EO'<1S]=!SLF*Z1I[G,+?T7/BE.G@ 73DH7*0 >JE\^FZ
M[<YRR 7B%PPND8L]G27YX]+ZEI?8([*M9.7H7?(\<5] 18?99T+C*,T,0XGU
M7O:!J'!>99[$UA@'J3+\Z(F1^2"A<6!,\G<UGGO#AN\P=@@]L=+Q=G"_/9PX
M>D?^):(XY_J5[,,T71%CGWWAC;>L6J\*WDUK''I_"O%G#" 9D<\*.-^]Q+FH
M^.=GFW24;7=$D3:1\[)QNE9[;ZL_DAS=N6'Z!'F+)$)*DN?NH<K!LV'/;"IM
MB32PK"$LCT"O(9RA6<N/2Y?-H_*^Q>4,QI'13OZ^4IT2 @)%-\TXI!)XJ%\-
M9"?<G.C^+$8;:T_0EFJ9(!$>E_WR]+,-UNL%1JTWC&P2ZK=)Y^C#WP?'B=C<
MAJ9]&L(&'GCJ^FX#Z=?U#$3T#'D&;7=*SX7GY4S(FNOO.Z8DM3C4%$TP+3A7
MJ_@'U 0I,+Z[H^5'.26U3@0VQOIFMIDBBL1X%L+XW05@X-*]]%L"&&<ZZMR1
M/0H\!CR#NH,_OVK+7)0H;=1SK><+$FZ3XL&Q''4WN= -VPOYJJW#JX;3S&8<
M?2-?FW?FP@30 V+:Y!L@:X%_FI=-\D*0%)Y'S-,+SEJUYH%KKV9*6<['7L74
M$I7SR<$>*4^OH.N->LV48J)#KM88KD-C9/7C$[2+-[KSE.2VOU_=.U+=O9-O
MS=4N[S"[%N]&-6W!(U8YWBCY6C(04GZQ_,D&7TG!4DF55]JL=XN-7AJ5Q3W)
MPAE6AR$BR81[J9(\FM[=#@MBF6/RLBM+SUX_[GS\[:)$T.N-=,9FRU$"FUM>
MBG@THD%J.V$*CC3BN^%6V9R:@ER@\]2)4-0C0":WF&V58IRNO[*")2>.'^6$
M2CF'JJQ$E*8Z)V,/&*J=8S$BC< 00=_I0FX\0AM[9<CMD^@],^;ZN*I[7VSU
MI8<G./>I@U[3+%ZLKL]+,=3,*_V([U<[]3':^"M0^ !?)%![W\IIUL_W\[)5
M43+U2M7E)5]I*^+SJIJH>8F]5'9C-?H<!>)%F-I,W!HG%'@!FJ%VYGZ2B(%'
MHOM.Q8>RA!M#VRB]!.!1*@!PN(,BT =:0#$::X=NXX\/OY6[&(.)_8N. 6KJ
M-U_4<]/2T$G=>N4-_POZ>Y%1GN0TCOMO8FS";6\6W[ZMQ)!'?]=W$H-,.91$
M)^:I# +*@$IR,%2A>9/R-<YR.K7F(,$.[F[C9,7GU7\_\UJ[1+7<)VTL\3QM
M.1LJU8'!Z#H>B0N450[:U0UJL43%J!K-CDBM86^:'Y^%:B_G;HS32QT#S!X9
ME>[KW NO22SVZ\Q%8EJES%J_OY"_LBX9DQ[P+FM1D\RLE_3:P</%\UE4*DR8
M3*H8VC;]SQBL-[= R\:-O8Q4RATQ,5<+%*#655'.M-UW]DP9Q)#M>,> /^=6
MGB(/\6S\W,6)U;V%>[M''G4?=4%]R(E6Z@/K!MQ9"W*9LC'91!_N-*Y7EXUU
M>HAI-0ECI60K.)L#UT@0U9,(BK'!5\$T/APO35P3(CK*9SIO[];KS+3DL0UE
M]GO!\NOZRP3X^["*(<7+NW3\-T?\--3$RCOP2?LMC$A7NJ;7;S$B6P3GZGUM
M7A3-\J:71[W/U.(RUC6E)IOLLMU5@L]OW?6L,-$9+%WI<*EM/&))=33IXW[9
MG&B[I=NB5VW3O!1CG6'5WM<_:L8)N<Q#0,1'([K@:.B1G--T@UEX=Z5@8;CB
MDXPH2GW[4RFGSJ648T#;6UTJ+3<N^<OEC>;-%R]K;HO6P*Z_(NA5]\LH+C+)
MP$L/7.M$J&KVH19P!C]?CM[$8CJ/%[]&!F\R=[DDU,/H*S;\I.D3D[N8E'9R
M<E;5@IO(VU8BB0"[:?6:]5+[:F_-KFP[_MVTS.A!S=;K:2U+_*&7>*%JHKC3
M\OV5J@3ZMC$\(6"484 T/KX,KCV3O]^\K(C5P9>O/=C'@.ON[>X$%YL%LV\:
MYW<933 KWB>_%2ZN(#4 GM[P5<O0%</;9USG/GHD]J3-)>91A$ B8X\W901P
M/<E!9M:P0=O@'?.C,3)3TJ_?/V7'?0F)])>?+5;"D$]D#+$O1<3<80'LRU-F
M=1Y^[JV7U2HO#$XO%@FK/W?PS4N?G+ 0%DF.H?0]6!Y#*!I% JQ\/ECEQN=[
M=H/0'O=-75?@[4TCKO8-2)10,RX5]G@RP$)JC.6/?V=WE;<8Z]EK7DK%>+'L
M_-8FT%K\_%A?)[(P'KS4=BVV,N^13#0B/4(X.D9/E5))4952]0#CI#P*"I1J
M$VV_<2UD([+VSNJ3O-I[<].3+;+KMUD,RF^3E&[I,9Z'YJ5T:JO7MY>^H*),
MT4SOD4&$8A_BH"I]/3LK,Q(G/[DT9KE^3KGTVB#BX_<F\WWR.')*4\P;KLMO
M,3ESNA18@JF&]2^(EJOTRZO>^UPB=>VI(4-@%-$LSTQ@#UF.Y9#98L"AJ>NN
M\+[2IG/[K-'[B;+(@+SH,%*WI5<HQ:SO'V. C1?S7[GN1"W1WQ#0'] &!2#'
MW5ZMP.N6>)LCFJO)H\BJN?3T,,T,&^%71AB[V?=2D5FE-U-,:BA,:N.6WL3A
MR5MOQ<WO;\64%?IAL#P+VEB[/RZD:&)T/5:*#7/LNKGI!KO]\]CJBK'4 F3T
M_'<E7B;*)V\.^ES]=:=X7-Y1)>1 ;._6*-/8]AA4'PR/M7LXF6)RR$JL#HRP
MN8N[FG,8#E_@[*^XY8;2BN4R7P&+*$CN"T;TU=P<3+A3M<F@)3.FN[AM'O>-
MZ8[]7#75?$SEC(N>#(JRO*_8F!]+8J1>(EWG#3M5(,MF4X'G.<N\P<<0BQHE
MMI>UI>.3IJ2DV95X]D8-Y("_7I1*>3O"Z.-<=/UE/0Z<W,#EX<O5CQ1CN!%;
MZ28\%WML&@W>TD0I#7^Z#2U:->O#Z[&YU\<6RF+HB9GLQ>'0PMBE[=K>K(,-
M?HJ;74E[/5WM2RQ%HQZMG)K9J(%P2(R./[:>LJQFARR'6R;J9I]\H'A=J(-!
M@45.!8X:X6AN* K3OS$J95D:,3#80_!UQ,QD '>XU0*N,E^]6C'H<NZA,4\\
MCM4VU4V>X?/#3R)YB$1Y\7*5Z80H*+%)N0ML\>SQSY=;"&#R' -;WZ' \ZCV
M[W>K@AZ9BH?P&A\#M=W";7SJCHIM:X3819Y@$]'SRMT5;JV%++2+[YQ*J3?,
M>[<E#$DO@Q;OLWD(U<3(]W9;/)*^T.U4:\F]-HQ%98 H:\R\I&QJ*.KZ.4)3
MS8R5FK_/ML0D9K#-*:>$YU4L(L/!I8K3*(\04;"@OI6>1)+F(T8]S-ODL"VX
MO$MMBIUN41FEI<; BQR&,92C\ PI\BFB2[U1J!C:/@I.[V2EWO%X*.':>7GG
M*P%KK?DO[Z>F>&8K3%6/6SR]PL+ RC[;."O9WKC3,/KXJALJ\Q)#!77'[=G0
MFNW)5*(&SV)Z. 7&+8]G:@^(RTP;G3M78L5;@<3Z=\$98H8/OM0I,GY\H?L.
M8ML&>0]Y.E#P3F:"=U<H<VB5NP.J[Z6AQ0Y.)Q]%N='O#QNG-]EPXJ*8YEX!
M ;X:&QJ-WP1[4?T='P//SR<U$EZ+"P?>;J1=O_7LR8V(_DK'"Q_$9X?+=^/B
MO]EL+L8U75>GIRZDL717I'$(O'*%S;RA0AI5NP :XI'$5?;%<\&U_IH9/_/8
M=Z^LR,,=5G^0.#.?6[C#V5,Y-N- 5<PG4\?8(Y'B-)DV=R!%-?\@#?J9O<2
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M3RT_7>GBP7:QJ=7GKYA&J"MP4W[C9"Q>[@U!JB]$I2UL_,$M5UC^ADJ.2FE
MP,4R,PQ1/7*^HB%P);KY)61P0W5VI\\3(H4LV>HXG3[V7\X??C>[Y$C49!5Q
M42(E(8V*A>&'A(Y @R@NJ8>9=^1XR9$G-K[L-XSAZW/?(NKWINR$\T[4C]U4
M4M.'[1ALPN+BO5X:UZ15'P=@/7FZP[8RCU:RGHOH.Q=D,M%\*30&'+"SKT8;
MG[/L7#B!GYT/EMVOV*(S#.<LW7^U@#Y]YKRP,BVN87@4)%7GSA#OJUMB8IR]
MP;HOYJ/@;NA4O/]%2X_KW6+F,SAT([B._@U(U? [P)*6:6O/\^BH<$4RP?F-
MEO;M.EB$""WR,_\"5)ZE%#0%UKY/NM2?94Q8D>CJSL,N0%#^6 H&D56STH'E
MS$+6DP&R4OT<A=3H>1IAM$AK'H5!\ZMFUNP4K5A.FT@S]D)N(T?5]'<[ITX2
M!&W>7]^Y".6[C'<7Z4$-G$?C'^:RCAN/@:W%RP.>37*F(2P*)J:$7R$(K>IW
MLNBGCW?/#WO>DE2(1W0LBB^3;"Q?I1$7UA5L0&N);=>'%GC/KL9&R07D2_!(
MENSH0Q.6'U%2N=M1GI$(A,F.0'JM/?3RIVHX^4MJTQFH],#WN\&?)X:-\'<Y
MBW9Y3X,5"8%8LYP?HU$=+E4C @S=+H6$JA9LK_#P 84!QZ\_@X#MZVG3WP;A
M._%++<6Y9[=<SL.#34B]T/B!M(^MJ=O7,'5V7G9#%.W\(_#D)R[-HYC./8@D
M,9PQO2/<I?/I&Q1JLK>IM<F5#=F[Z."L[\K4Y, :FKPP5\MN2CN57_0='5:D
MRGS'X1E:_F>\S(:TW[QI&Y.]Q:[M_!!46<#8^9:@MN+JSE:CK3_:')Q0.R(9
MZ]B4T@9PI/(A=5'B-M '6%J1LD'-0R28%?Y:_)+4N^#<E4#^OD-V6!<-(0&L
MU2WI0N], 1(T+>/VI1YL7(Q7\)7!&4-::&L4.$)N?E(.-@_D1>=(_L-AN>QY
MFX"U,'&B+PFO;GF+6 14>GBB(]W\G9[-N4Z\-U=[+L8@AB?PI*BRQ&6#$M^&
M0$\S' =G':RUAII[G6!B.)67Y$93J4#:L5%7P^KD4DF6Q,_G&__>=M7]IX2E
MW].HC3SS+ZA,!)!_*H8"E@II+F L#\D>\SLM006^GN_\J69@:[?[LW.K?;Z+
M@4?:=S0C2;TM:^;L=Y/;7*&1>V,,M^V:!(3R/B0ZB1 W\S5/^Z<:L(=J6)'+
MYW18^-.:M%H1/7"UTSZMM-N@BO \F:<@5MJ0FX-.G2_V$U]0VS,><A(V'EG/
M*OU_.%S[<27LBR1MDM*-(OA?:@]NTSYE3 08NI9,V7ZGYS)CMWZ!+P*)T?WX
MF 68F#WO).7-6FX&S%\2RK8QUKTR\\"$_8#R^\<'RQU5S.E!MO@F7FI]I.M4
M*SRMK< 8["APS&M/46@6*$88+0.#.'_?3CR?GCASR&U9R#NBP]Y/C^<QU=CS
M\)PKJ2BKO(*L?2C,DQ)=G1^ U%Z[#SIY&T#D%?JIO'"MB^O. W[WGJG.Y+IN
M8/SIGNRGN5]6Z:NQP%."-XYDLUU#6[EI?ITQ %>!@&=.( 61E!+WNNA8'WHC
M WG'#7T()BW24_!;N3M10?%7C?*81FUH="KB3>*+#>KC 0<!(S,O8"@/((J1
M7"TDBY"N63AY(6W=L^Z\#V+6[)H>C*QB<G?>$#$N)'4\463;ADQ\K_J<]1+7
M_K(BMPC/>;\DC:=3*%(A^[7^KY?H*C=Z^B,-DS7*?6;GU@!Q$.S*&3=W,CNH
MJ#=.)HK O]46[P0A&FA$X9KRF(PE]5L%G2#U03Y7L'MM*+$.HBI5WZPI/%7!
MFXK- &)KR(:&4^D+$5#"E*>L&2-P>2:L<'&)+U0]EN4-_!;K3%%(X9"6H76W
M-\_B*1)L*)?$-7+_=-SHNM"JD@'C5QK,OL\Z&RRPQM@]9NQ5!/><BYX7QWH3
M(U"_D40W#V2$5R=Y[\)S7.D8_UK3FQ>+874B(CU8LT:$G23&VJ-\;PO1GL8W
M,VCNS$HZ46]&L2TYBXB 3B/CQ1JO98G&ZZMCC:D5Y&A#@ ZTQ;A,<82LV8K"
MF6 87C&K"??9>CXN!UE/V86I6L?H?>7E30_.N$.G99A\'$IJGD*M!2T5UU7.
M>U[YT5(MF<%\_%4.2 1!@N2/M<#"Y+*D;(!"M!-S73MF!RX2<N1&_(O%W%V/
MUV8(]<>G<F7D06Q\TAI+V!^SC&H@;ST80Q[R"L-$H: )PQL'N/]R@=&7M0[+
M5>^A@\]P)TPG?H>"_0PYS):1HX@74$%8!"VI>!(#+'SQ2#]I1RAU1XA 4Y>4
M](=G\E%P1#:UN7)"H01\)(>)OG4HHVJ9U^=P2/K*>M)AO>O&?=Y"186,')!+
MW.XQUC7L5*/.$D]A%>U@(;HM*N8QYP'P8SEX7RE%Y-*%%=\].7"3ZXU5*I2P
M<H+RB'UG=SH[ID![YT1=ZB$ABRE.Y9J9C.])PV'ZRJ-<OR84""S&:Z7T_-5K
MZ5 YHV&^#9(/'@V%]A1QB2DI8?4_8TOX!^4P\F- S]&N0..T;^MJ$I0;Q71\
M]^7YUZ%*!IQU]_G$LJ9?5QAA;O&U?$>OK^M?VB[F>>!R^MX0T;'HA2JLM.DJ
M@I<;=6&E$8X[,CGO98OMD]0+<C@R&.38FF\8K^][MYP:7[>!<XA "P1@*A"6
M'B2^^,5*>]9%AOP79LXQ;?*)P\9/Z2)=N BHV<R5LN1]<8:%+&Y+VW\/WT,^
M</N3.[2-P4\)!C/#<4GM7 ?S^KD]\I#6X9E *GBT.;'3(+%N8H##@:3J3G7T
M @A:CG?&$[Y;^I+2HPZ#?1_<]/7&\&R=.F#Q3<(LK#+[)\HEPK?-,.A,M-;&
MUN5YYJRVMO&=,N=O6^O8J[&6-.UKE<3 /;%0G]Z9QZA$HQ63F>36"T';+U C
MLXGSI[63RP1J/Z.E'*,NTZO9RAWLRPJWBLN,D+!&D<^)X>%(2(D?<$_+8'H3
M^AQ8OV;K1F(J8U[9:-BR ZN4@$(%G@+U%6IGZ[X6G%;O7:5>E4Z::(R+T:?7
MJC^]YE1.&JG@6X6N6QDXW\XQ"L,QYY=A>5=TZ6GKD?N#ODOS>IO#V4U4-J(V
MPTO3O-8YW/U+5);O$=G@.&=--$C5:*<DOQ7(];[?\ZSA?T$_$X2[-Y1!$+?<
ME(X)CZ&D^XA/J!R[GPGL]&_>(E*0,S5&P=O6+($53(A8#Q*4[0PGMZN[ :GE
M$3/)THZBS"&G^V6-4+"S?H^5B:<(W(S\)PK9/@K=[F; EYK6:/0QD[ZH?T.8
M[.DSCFMVW1^:%/A,2_=2[J.APMJ/&^6H^&1#<AV'%QL5YZZ[34&&XIB/.77.
M$DLRL _$PB@?5Y%E)C.B5PSB]02@<;DZ3L?8&D36\G8=?B66(%Q&12(C/LD&
M;!4XW9T"RT 0GH1TW9T4MH2.!S&-$BF@?->,U+B-N?<\CVU+6V,_N?KXUF='
MN4VHK\RV5%\1=J-)?.#ON?D'[R]$(A1YSN?R&]Q/"TYK[XCOF(?ZMG\HXRC+
M/. 5_'6Y^+^4]JY>+.1&8Y.1X&#P4= B)#,42_+H?DWWZ_<?/R9T<F=/!!50
M9/9DTIXEK_WB2H5=<NR>#L)V;?&YZ9HBB1F,X%V0@+%Y.6GQ#2ZCXS6FY<SE
MC083],I2[-,E/ON6D;ZT:%_RAK)Z9!^%2I+E3LXHO:FSLF=,&6)LJ$'WJ6:R
M5WO'*WV80W%;[$&K28*BJ[G6H>+LAOE75%?/+9%E,Y-=[1"G3T*]N54,1O4/
M4U6H6%(*+8\UIFQW/;M%WW:NTW&9!B A>:O8IGH,7SY+CR(SC.37#^PA_$0%
M37#[&V"P9-@:;KT+K+;NJ2S;Y)&V 7-LM*G_!/>E5C(?4.OT%5MH5VRLO1I9
MD<PY-M&HJGH+GQ$/_[ )5NMR*966]O!-4^=9BFEQK"AA5@%"##V+.$7?DQIK
MN@LQVO\?,EKL%9>3D=R'0HEX?3/$">;/43S4V*GI[B2HQGI]?FRC85V9'.1Z
MR"MFZR"H#^G<=]<K\:;4B=0%9&HAP[:6F7JT?:J(E2U\B0^Q1DZ&V1+$CY5^
M!A77(Q [^<<51 I0=(.VG/?<0K:.4")6P(UT*C4YAB,4Z!@]=GPDS%"Y3?DM
MSV;Y45.]V.1'Z\[PCTMC*/X)R<0/]<X7U#@K).0(:="R<?E$G+_A;P42:BI?
M'W4PM:+HA;;#,FP<T>1**4&]=C7=X33W?FG:M2%%*WGIM)#O.:KL*B^,!17A
M5<37A8^^.!<!L5XW"=JG;WJWH [U$6'(840R0N [GJZS7-YFXK6%[N@-4071
M#%SPY /21L-SW"Q3D@-FO6&_FN$PZU/)4:52WA)$NU34U'X@X=CN6X*B?] T
M(\OZR'E>%_:?!&=)#IG^>VB_>O7GV3^<8\G[2-F,2Y(]DEN'W/]%=OW_\I'H
MCN2"Y+YI)H#K;_\[<%\S^/2_M*-_J_\#4$L#!!0    ( ">):E0!2HD5?X
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M_5]>2*]\_TV CX+ZEA>-0$8+W=R=D)XO#(-(-J6HL>\U [_V!;&%QRPF":/
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M>MB,*H.3E&TP=#_B? =9)>ZP9! I4TCS%"2_ =B<]QX;9G\>2M P@D @"S=
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MFR&\*?;MK1X5<_PC;!*9^@ZCQ#^R['3.;\:R Y]4+N".CM4%&(=7-;XD&0I
MS6TZP]=.Q)^DK# HZ2R)5_T4AVYI^!%AJ(N1X= 1G/4%:3MM/.@W>9(5:0Z\
M_K1'U8%\EAZ(?Q!7TT=2(&E[AK<LM69"$1XGQ-_X9K\6H2[)_$* A]>24IQ'
M(-C:W9*ZGHGN)2LP1GY-A&6YN-+MH""U4)(P$NO(HT_+I::*K_YRLY5I4;%E
M4P[)FL1L1DHSHWE9^-S24GK!O..)L%@=(,GNQ'*DVMGQ7\'[R1^/">O4^ -
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M_!VU?UK!@9J:/02O;LZ&>'S5Q$%EJ)2;,"712)EBJ\/AU-2Z12LKM.(9,.1
M"HYAS;EGPN+26,R?7=UM4GR1RQB >?[TGB[FXAZJ%(60N#=H6WS]DZ@.^T_E
M 16#OY?(OO>8;(KLL"RQE#CT-YDE,ERCIZ_@=H9RWT])I4^9?9(BF0RC8V<]
M9W&%_4&>$\)B5JA1$\@YQO2F*P<,'7/V?)R7^52*U!?2?[!?Y65L5Z<HQFED
M49H=@D>/LV3<A0[5 < 80<G0",E:^OAMNE[$S]4H6&\_52L^XWN#:&X;P?<B
MXD/)/ZV19L6T[@D"2&[UFF> <[>@V^7.V7TV6D9/,MW+!\W G9C1T[!%8^/<
M)N"$_^N1%7B@6W.3+=E]SAI9@C%#R$&4_YB+46J*'4E):_'WNY7OOB_W^1S>
MO.624)BO_MC 'T$L,#[7KP8XIX8:Q^XBHZ4H5E>? 1#T]VYX+9XZ$'^;!H$_
MBP&G4/^X,+K3 ONTFJGOTC/W'W")NK\&MZ!$SC\I];25+;O(.CD;9\Y>Z;06
M[ V=Z+7*=EFST_/X#1?E2^,<Q=8_ Y)OC5;#R7N8"E*JBQ>^/L[EDS2SYVE$
MNZXGT[W)&8=&2/23/6@T7_C'XV?[5SH3I['-D>NJ%%O-3)8GMWOA1"YV]1,[
M!5G'^M1"3N^/#7D^OIF@R'/CQ!0C/0BGJG/(A9+'9<[^;'3[IM23(/);<B2#
M=S[\(!'&%FYC<0<G*M^@IS6SIJ:^"V<2+@B\1NXW;5#LA2Q0B[D%8]"*D:!<
M-Q0R:7YPYR3G8,+49]L>I#RL-[04/6R*2.D0:!"Y!F-J/P,,S?X/JG%PU,OA
M?^WS0;#!>:#FO\D"JA21_A<GX=20 ",;Y]J=T%X>4GN<W-@7G!K-?'=*,IU,
MW??AJ=L42R$X7P/21HW#+Z+QS/@$>62MF;8/* !6@G&9QA"95ORQ2ET+GB/P
M'.!XPZJP>@LYI@AJ6BX+3N)*<(=A>5/9!"MY7Z&DXTL[J3SQ!W!:8Z21\25<
M]R.5IERH2C:6QGF^N.YT4[> I151)9VX8D#(I=W@WUB:T*1PDN,WR"#RRX/E
M'#@N^Q_PT/I><Y!O11I,.=+NXDP"B?!+%5*M%%DXP;@5P%%[\WGK"P:%. G^
M]+EC@\C]F'9M +XU40#3(CT5F=RMT6VNYTBNL@<ZE@F<@E)\SNEB!SULM6 G
M7DJUWLQ9!J"-\^N)?CF\^6;&ZMZJW<3G3P" )IT^L]1US@SCZ_K-Z]?>5',C
M:3A(-X3+C3LAL"MTR:SM+LO;)_Y)X287_7$@^/J?5L=[^'BAG"Q<(^2*,RJA
M55O#\M&^K;4G57DM/!X0>%=:I 5-A$J)(H('Z016>*][7_V[J*IZ(S;0M;Z1
M:,M0"XN!9I<.ZUCCH@3\&P4)L\A5FI<R+W?Z6_XAOY[[?%&5'Q]K0&IW'M-7
M4=ASV4NF]03 *2X[1_J:!.603@2I'0YS)QVNL3BM)2MRL0EPH1HGKBLG#OEI
MYYDIR4]7NBJ @&DG/@-&J(2;CU=7[V3MP5/,)<)2RX^0-)Y;OA>@@R ;F>)?
MFW3:;ME7X7#!%J=MQGEKC9]"$.<4B0!8D7V";8;_#Q;B23G+"FTK0=5_G#D2
MD62Q$,*U%RIQ;W(!"8@.K$47.<8>7VC!/^A 6_YK+(GX2MGC>>&LT=&<(D11
MGL-1Y.YJ.-K,+O6^EC-8@ *MH[:_E:S,W>'B&:!)'J5M\KJ(J,&7_9NSRI."
MU]GD( H8[84XBQ%96R6M_L V87/.CD72T-#8M-U2G=ZYMX<,=((B!3P+.QC\
MG8BA"M64U4F[]9__]DJY9EN!P3.XHK&X:;=D^VNY2V,DQ(U V-IHP6<5J;];
M3W5DV+-T75A8WV*='P:N^K330T"'#WM !P36R C*!^V@"(T_R#L#R062"DT)
M:W8^$1D:FLH/LGSB?PDW$)*-V\B-?WH1\%;CHN)G3T[[KP-8SHDY^U9_1!:Q
M%VDG! 2\+E7^4+JU<;*#E8/W]M[8N)E<<*.NP(?IN(%93\[7( U#4"*DC3RJ
MM3!%=B\\Z>SLNG9&9!,GPP;OH'&]TG?-8U2!%TOF9QD"E8]P_8$Z!WIY=4]O
ML/31U%Y"USF-GP%,\K2_>\1R 6@0';02"2<, 2PWRNP\UK_>3[,CV0#E-8W/
M7<)Q4S@X,0(IC^6HGP$MTNVY;)]N,)M4[-03XC;\1J8.54%X/:UI'7]A]&K[
M_79(X>!P,N0/RS$[NE0ZQ=9[;IV16=PQZ@P2P?>>K8_.WQ^+W+ =@VY&;R9#
M:^S29OUY"7)JXM=R$AE;(SS\+C%95LC/[@,%D4DC1D9$_#$?,TTR?75^=.;_
MB)4GSG]3!(GB!\#J =H7;Q1-0CRA6 VPSEA#U=(T[8[6#&**Y/+T9B&GU[B!
M$VR-%;8A;UI +4A$HZG\'J)J#=[)OZE0W=C6U)'>E%PC19 7:=(/\ D5[V,,
MV';E-F]OXDF>)TE]<S ^I/0G20+WTQ&]J-O/GR%D2#MH&EY <S#D$1WHJ4DS
M?J?5CL80V287:7A)+56\5OJR!V>O$2\@')J:C1]9=_)W.M8\MA@GVC 5@A41
M$.]00U,R6S=7Z?SJ:4G;SY<#?HV$)3+BMNME,5"R*#-HYDEC<>.Y(0GVM.-#
MQ*&AK+<GM&1;/&$+M]WW'!7.M8_/ /\9/(I9Z358FZ>^N94L_#7>Z-\U1<*>
M%#,H1O8^L0N36,\P *QL<K?[=Q[C*$7H&0 *"5O":5L6&7<MG_:;X_879'0M
M*S>9RP5)B^(>=A$D%7,U7?0G^1C]TQ>,/8K5&F@X!R C(LX.=++!/Q&2,?;(
MKA4[Y'IE:;MZ !ID,O>M:J"6O&2VG<H:NQN*@QT71#C_7MW*/'Q(=6]*<BT?
MOF\YQ-\4U_&!*9)$ZWU&=,EHQ#@_@1!*!6)H<P<)4FV)4^M8YF-M=L]9":UG
M"JRYKR&I&0G<;U=FICQL[1,)*%&\L%N-XVMS959=9LZ89K!".>( &]NCC(__
M"FB0O*UL,J]W'A:D#59?M(UF5&FL@Q4K;PDFQSK:<O9V0"9._[4"F*)P(K]7
MB"/-*@U<W!5>?$GMI3",'K=9BI\_.%=*\D^,[:CT(&)S'6]ER!=]LXN7O+2K
M-5O?37=:X,4Q.$B_\"JAJO.%L^WF9%4IACM4.37UUA%O:M*=>@Q$#&10DUI!
MVA%PJZF]@X!KR1<^J2(FS"\^4BC^44:3KIWK=W3N59@;;,\$-@H9*SS1MK#E
M'U3-3'QF$N=(_4:"D@+UR]5$8GZ\G* ]EJ=6%?Z4;3+?/[U0[3BQ1D#3X+>\
MD9-5&U"XVQM3&;^ST3+5]NXO?,FL?6;D#3T;3:J<7N"Y,]>HR(9M"78(Q]X.
MD15+D.:3(KC)TV\AGA9-@O \*G, 0*LD\7Y9=>]1XO36NJ/=E4I]C1GT>9AR
MI)'#%'_=F./!9),_?_"7(^IC_W"A)>:N]&U"N$L3!)+;F2G.*[-!C^F/GCTF
M#0#+FD&?\ -JW[8@#6%<7$I+[N?0Y.G; CTWO>0OQ*1K7QSP4N,2?TG1A])'
MR> XX?Z26:W9:>5X_%0)>/V9LSK%SB0Z%//':;'3/TI:@G)JYC!4+^]C32)2
M%5CWT9%U)3H7=8<A-@4T_G"I7$5+X(&;MGYXI7XQ-RQ+&/I]PH>T-<&V,P<*
MM2"QM3=B?:>0,&7S"5/J)T%D^/I?^L@':\_R"5'(5Y"1=Z"O*S>U)ZM(WF9(
M-^AA6I[%=UP8$B* E/!Y!L1)-,:&O+5=R?5O[K:R-)VA2-S/D;1Z+8<*Z%;"
MYF,NJZ^7W;5**4<&FR^Z-MYP,/\L%;F<\>546>#P#VF<Q-SVDSJJ!WA8-T-K
MMY"UCSP-5FBD?;OSHI\CQB=+WXVEFE,WA_Y=?'CUTR$+NIK,+=O2L'NY[1?H
MQB 7OH+:O<E@TT%LS+V)@@S2C@NCU?Z:8A]<I,?Q^X;B':JSI( SC9HH3?3V
M^D>3S'5*:4 #V^[O6/CU,X!24\KLKS,YOVEOT=0@31GMSV\:9"Q5$P?7Z$6S
MC^QH11>^/Y&/7]O$;Y(D50X*3LR=@[N#D[]F1_#'80#4SUXDD3UQV\)(Z:*$
MXF[3,WF48!JQNSN:0GXYN8*3ZB]18\4C/DS^F,P7& /<U%QOT9S*ML:6<?^E
M+1H1 6D>6D^XNGE]!>BB?B8FQWT;F \6H^625%WA;7P&.%6:N!M1%*C:Y@Q9
M2G_,_3C:1NT9+?[TICN,7]D, ZA8P9M[KQK;&J<:.W$.4MG6J&=IZ1$?5I%/
ML0,(8+]D(1U36T;.5$Z$(XR'MS]:;*SEB4Q)B61J964(DB9,CFQ;,XC AZN$
MBE$=I8"(*)-5&Z*Q%SV0W=B35[VW^3Q3K!-^^T+:5U+! \Q?? YE'5U9I_20
MPWMOZQ[S_7X$ _5$_%.%_Q2RE W3B%%KEYV@E"J;(IJW;O@2Z"@_#;UD7=[[
MI$IYV'1ODLK_2U"'CR9C+J_C6G@IH'9W* !B,-^C[AMV6\RR]$X/KGV=](;I
M,MQGJUF;T^#ZU.  ^2;X>\"5V>KY; 1BTTI9N*9G(?/D@-EDWF9VNR+,S@67
MKNTT@\/P7S\1V?'/O<*E*^*7\*4K42OX[ZV$_!=4JO0^]G.&DJ!<DD41I(7;
MAU.$:+<N/M$YTXDN]>C6:38X_HU-MPF %=M9C'I09F<8?@X9EC+D2Z&R!M,3
MJ5^LA&H/Q\%=;3R$G7]C'?O=Y?KE:N$S*G5P-[U30I-18=OHF_P:N?F 1#)?
MB(+)R'=:ZJP8+E+^RN^MM_7#!4)=L]L$U>!87@'[="]AE6(U0G.13^*+(=RY
MWX;(<W,*V$;4BUR0P9-R=W[O7I@RI?R@=E,%T-W\Q51$E7F-[-Z5)0\QN+ K
M[M[['0L*PP8M]>C3U?#FX_[+R1MFR?+\;@5;GQOSRK\P$VMZ=C6>W4-3@H>H
M?.![H4'GTN90TM2:4+O:C8',MN^?FBU4T1DX,:Q[""K"8G7ESG476T\M6<%<
MZEP!KCP?=)J&4=$-T'Z@17 =I*&%$/8CL)\6S403A29\9KA&S7Z.Y) ;)S2+
M$Z53'.AO<KT0OR&]J?^([![J,DYII9XAL&C15%;KD<O:&%<Q!;P?(.8/BMR.
MD)4-HQBN?U!!DB/,H7P)GWJW2_9VD$I"?P8Q@^3R<G1":>^#C:HB^NB0A="=
MV"<BB",=;O>%V2\ZFJ[$<"*-ZG3+P)5*L1PV(VZ8M[MD)[W9_<>Q/?\8GQW4
MB5V()?;*ZM#BN_GV0D*.5\RA![M1$W?_Q"+!+S\9RH6ZZR+!=5>A4[$5G(!7
MDC:*%-B"P3KD+5TR!$CZ"VJPY^DV4?-JB"24)6M8PG6K9]%*&0C\P*Q*S9@H
MKD/Y&E_+GV;W,K#6NJ5_:">>C@@YM9<'?Z"O!8;1+&E.[OS+OZIV#MQ^&3\D
M%;.A*-SY+K;\-,;;RZTD^VO+XK3>6E\37_[':85BQ^S//<SP+O:!"R9FMW)]
MO?/]C^>?G0T^^@+!TD-A)31)DE?I*M8:J_.V#F6C >YC*9CWYB-FJ)OFVM\5
MKCC(5OR@JLL8M&_Q^JPM,J>6;TK1;O.<7X90[MT73M4&JXLU?O,^9!I769-[
MV4B3.)9QEY[VCXZI(') >XVQ,B2K4N(-8Q7'7G5&HV8L.\R2KAJ< P9A*,IM
M/B6M9FLE*,<KN4:K2U*K= :$QQ=QN0%*TKAZA #T?7Q^Z5I,G7QA@O53.7-V
M.!]#^V6.N:;:W*1Z];"+I)&)MA^F?^X#RSQZ/R&U#J)J*!RO.<7&LKM;P5;"
ML"-SQ8CFE4>W_'K& P/-;:,N4M_&NQ*)J=+>W6ZN"HOG4L@8CPQM'T<C&#$N
M"5%#L/Q[7V%DCB)W9M,B!?F.L-3SY6%T08FK@Q@@$[7*+MSN&"+6<+J[7<';
M>/%;M:OX7/V810$<2$D!8BLS]E!^P.IK1;&!BN1_=Y)P33KVYNRMW_<7A/2
M23M3O/.F(L&JM %B=6FX 92-/7S5P&W6]D^'L[?P<^:EE;U*\X")23#+[GZP
MYRPF:?Z]BA-9D'7$7E<_T&B#:WRKB6H":Z@)U=9>9Z'XSX=9]L?"W_4W!*AS
MTMUNQCT9>0JDK@9?:.2^GZ.'0=+$2_%W5"[Z4O8@S@AG![P>?\T^F*>]$0Q
M.[)K$_$M<J-'>[<X\C&M.B#'M'2YGNV>9D'>CC8A587QRB22Y*LP<68@YB%8
M;B:X*DE(&"$:]_NZZC.D?E/I#6<#M/-WZLT!_4L?:0(5!'Z%MQU,)<0XV-GE
M=L89B%H3'QC1R6@*HAVF94=M') FT%N2TJRSV 1VI135+\OGP$S:,JDGJ&4O
MEV,N\^ZC"NYLCZV8+[1'J=HK8'AF<T:9Y@DB4DV:KZ?'@@*C<=\M<++3"E:U
M!7LY?$D$J)+<T&5#)<+CA&OGXJF,RGQ+YQX[74,Y>GY6M$:;"Y?M&=+_?@6*
M&9LIZ1T-SA94W!P^EJ-[@: ?EC J0PP/WRW]VHC>R.Y9693WI;*C5-KUV#8=
MJO1:_S#+F0;'JC-!AD.M8]P;&O5H5^J)8G23\]XPXF6X"L+G:#Z?KC0&'*F'
MOKW]M$@]?EF6=K98F/#1SX_3')6<4$Q.-IE< S&C_UC-6U]HLLA3L&AZF$K0
M)E2+6?#CZW2'@W7+N(G;&/5J 88Y\M'=,QRZ@P=9_[JY5>CO^#5Q"DZLG$]"
M'K[9?]XTB(;)0G7<$[@WE33C% KZ*\15;U:?H:FY;D58];H4+?9FP^\29<YI
M_TG(9*P^(&UXE?[#ST;>OIG;/)[=MH3U,%]J"NI 6I333 -<7XRZIV6)RU]=
MQC%EO4OP&Q[>DS\VG:#>+]_[,)1T)-P&QRPB-W4P.X$BE6.:[: WPF-9Q&.'
MG1,AN+8E^LFK26%+&Y7YH0Z52&>#3'-G];3KB7/F3L+L!%H#./WE0O, ?'SW
M5<%-R8OC'T 9BJ5Z.(P?S&AT^;#$KI$">4M7ZH &(0W763@3MNQW;09U0^Y"
MD-F(Z_%2);;A'=R- /=!":.L%QLG.>V(#[SX+[.XM92MQ&^D)7YJ)^D!<79I
MC59-NSN76J?R-(@W-]Z=+7# F-^/_UVU='<GK>,B$6 1:'R7HE#]%\6B9/3
M'ND*)6RTH[RG*1$IEP-9272RO ]CBA +CY/!O0 77DR9+9U!GHA=I=U?=V3N
M&"ZM?9]J4WG[BH,-S5U..V@5R5//LJ)GIKA;&(XM-S"=>3PDVSSWB:3D,Q=7
M>/,) >G( U^!I>PN7X*Y24=;#\%K\#K/^;#0Y'@W6E=K7"#%C1ASXM)CAH\Y
M#_G>X[2(O[ZEO<?<T3"+)IV\)/^"<CH6,\._*-<\ \2J_F/?ZS-!8Z]*P<3
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M=6[=JON=[^SN]:MW/]6K=E>OW;OZ^;O\=QOP4E5111& AH8&L/K7 '_7 /(
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M1_^L*)QRHS8]_K;OJMX.10B?-(5C?7%]5*O>,/VP6M(R2-Y:'=D<D\O%\A=
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MNNY1V-*!<YA-VMFM> 9171"7N:JE .Y\^2XU: 4=_>G'<I)!1^*UN,.ECHM
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M=%.U][MJ_P(P'MR\*1Q/ D32'&J \VUY^:+1R9O/" ],.&'Q&R(7?P%C2WO
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MHIN-@JHN1$FP4L>3DPV5>M)[-YKN<?Y.D<\&/S6M?].[7JE9.4H&#2BK$_\
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M %V?\QP>?V7<RWMC4&XVIC:(X-=^5A(NW/P(&,^VR3C(R::?\7+_\SW/!+;
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M&@+56.9@,]!+;ZF-66+?V.-6GDSMF9'WCVT_6TC96N<_BCON!@<3:_X C _
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M&BW5EG%O4C@"E."; 4BY=H1K3+P6,K(@1@"6!1>0@#-L:UD?;E59#L!2T[B
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M;-_IIO%KBPS'X.@+WF)2JW9*G]Y[5^[0/=HW9^%38XK\2SMT-S=W2AS;NZA
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MCN,<"QL[& P^"^(\S\%^GI4=S/Z[$PJJTV>H:>AI:.C9F1B9V/]M(_<"+'3
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M>R]]Z,\Y?%V05-%79;O(^/+-5?9*ZX?<&1JTR4@0WI!@@8<DJP2N=NE\^C#
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MHXD&BY$;S6"ZOJCDJ(!8NYP?]9MA*9!#9%#03.._]P(^\OQ_ 5!+ P04
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MC?=A9 S)$IL?7?P8;'L!PPSTTE@Y7!,T5;0]68XKC!*J?!+]O)YO>(J-8I]
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MP/%I+QZ,3!495T>3*5GSVYW73R?&(?JJLN^?\M&5_9%1?\ZM'E0L.TM?&X*
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M2WQ#)>9K/)IPDUFUTH&6M]=]/G$Z@9ISG&<$Q#%I@T7D18"D@;IOU20)8M1
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M6L#L\\H^2GXO?F-]FEMII:A77^T2'(TM=DTE2FU\T6WF,]GM0-^\38-5\TS
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MB](++?O(4WS^OJA1,4MQ\0((0#$DH=2V;Q,9(+TMN<[-K%ADL\YN!7#300R
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MI?VDQ^)GFUH6^\-BUA81#XQD_>V$&WKZVB(?NO%.^W)<KG;S=3"C:AN818>
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M$"I1RQ!,R!W)>&R\N/3 P](_L_W$TOW;@RU2E?SF1ST33++%==7,5LL1'[;
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M)4OY)?\ 41X\G_65!MN8]O.X\?MY/4NHN'8ATAV>.9.'VL_MPU/K>T6W*@2
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M1M'L [;CD.I$(Z:K<E24A0*@H ?U [6'F<R,&)>:JNIT_4%%%O3J)0G8$[2
M-H@0Q[# /(P*V$?1/K?OGE=76L/G])9G']OKT=C-XG-Y**1:JU)\97^EJU)G
M7[ZYMAY(26)*R'?QL!2OB(=/M!00P(8!MH8N#_=#R#]PYSU[X M=:LI0B\M:
MK1*B0HD@G:IB3M#;5-'I,YM>]W_ZH_\ A_\ ;JA^+8_O_$5V)E]Q^_I79(PC
MC9V8<0P9BQV"IM\ D;_ _'GR?C\;!+D,'/'[_?'85DJ"02H[0 YG ^GZ51_^
MH+W,R4'<?$X3$2T)ZN.H1Q06*;QS7:\DSL;4=Q^+%4B'W'[@0#N?DCKKOP3H
M2+25J2H%>Y1"@<B''F@%G'L#EVXG\=ZU*[RDVU).S:@$2,[@\2H.1R V7%5B
MY74-K-W'&7LW;<E>1IJ[RRF15!_K]M"2@Y+L/M .VVQ ^+_;UNI02CQ"$@LP
M2EB!P  >(>8'=VHE^S;OVQO2%>5Y)$E(+D0&<.PY[C*O[<]PL1"^6T_JNUDS
MIZ:C8CHUH7)*67!"[@;/OR)VW<@$; ;'IVG6W/*L+\P,*9+^I!VL((>>?0U%
M&UX1*;9V)AR 2\8(GW,<N&-1\[G=VH>S$;KA\K:RC9Y9HHTJDU/8K%B4JRLR
M@O+Q(1F7RS[[']X_J6MNE*MUPM).&#EV8 N2<@X(ARS+=-T*2I2[B4J.\G<I
MW())=W$\XR01ZH?2'JBRG:YL)<U#E;NGH^X9LRXK(RU95;!W9>5B)+<QD$DG
MU1E5:C@!'!4E?A12KERW<6=YW F'>68@ AFSW8SVCI'PGJ;AU9LVKK(20EDD
M$,HD*(!$B,.9(]C>WZ,;\6?[2KW-RF=.5[CW9SE_<SDS/DK>&6],D52M [&.
MO7MU.$H5(E;B0"Q^>H#J5B\5>$E"C8NE824L$(8ND*(+@>53$G+%B]=@MZK4
M6P25J8,1[$ $_+DF3^>:DSENX^C.]&C=2Z&B3"Z?U3D<1=HTKUITA]K*UE8Q
M/RC,8 FX?;^"I!\^.H>SI-;IE;[5V\ D_*EE@ M+2[%R<<]A65]0\5TK3N$
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M,"!U5[EG2:E7C>"@W2Y-P;MSD X< =@&,EW<UW+X4ZZ+VE1;L@IM;$$)EO<
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M).Q+>Z%/'J)UVFO6K 0M2E$ DJ4M*R3,[O*&F D) #;13.RE(T]Y2DAE#:
MP9N&42_]Q)>)):L+V1Q&K=08NEFII+U;#XJA8L)7EE1JN3OUP1/!&J@$1JB2
M2*7)9F"[$@D-1[]PZ87RMF424X9P"[L"2XB1FJ18MV[FJUFG0'4JZ"4C#$J
MR6!#@,_):KY_TONP$N:JY;O#J/ Y&/%6 8-&ULM#4DQMQK$MF._F*L+C=;$'
MLBLZLO!5FBD]OF%/7,^N=3*E*MI+$DA@SLYE]@(=B'?DUU#X.^%0B_\ Q]Y
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M.\"NXGCW;S'OYZ4U6BU5^ZAB/!<*\J@A8(!A8*O.DDD[0;9@?-S ZG3VT?\
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M$XUI(Y4JRV+1>5C!(RS<8A&@;VHMT.X:)49_E^3;MTW.KN7CO62"0Q,8$!P
M'<=PX[]V_A>&K:H.T@D3+,0Q.7#LP))+16-O-D]-:=N:E'MM<MV8(JOLRJLM
M<2.I'&4[S)L0&DV8!M_N!Z<(3XC9D=XGZ@?K]:PTD\ L'(.,_K !I2:?U=/F
M8K]/,V()LNZ*\B&R9FFCD@]E)2P?B&>,M&$ '!E# <SN-S92$[6<DNQ>"\Y?
M!)D'WPU*"V%#=,$O^KLQ[,-H:2Y<O550' S0++K XIH-&CPL$%R#.P%V@2 ;
M@KN[NT-P9W%W"!I< @1G(;C;(D%"\. 0['[_.??6/75>^GD>IF:Z9ZJZY[O[
M[4H1:A/&I#B#N[\1T"O>)<W(PS\_9^5LS' 8,'W(&P#8BB\ 4>1?-+95]_#P
MYA+TD?LO6>#006$$,3RU-(*)5X$QMYVCH.L+NV%G<?\.G^<%6>3T](@LVHK$
M_,Q\Y)&L7P2RQ3P&8AG_-"DQCE4(7 LVI*NLL-.,B6(\!6D@'CXE\J%2Y,6.
MC@# U<.O&7H8"V^\+-4PR;GU'XH'L0@<]>:JEU,7=;]@3<=Z<G1;JWZ?86>Y
M2AUY,$N Q"TQZYC$#!DY(<U)YJ7HZ5IG)RLT,$$"D:=4Z9C9.@2-Q[M9O0-)
MB'DT.DS:T#<&#$E]Z]\RB6O85["?KAM2I2X@:& .]M><X_6#?W[^!0VSR Z!
M4W@?(OUBR6HY_]#E&,*H0JFC0FF!4&!#X'::7'.9R=KX,&.CZ.T^80KL5NN?
M#D+CJOY'U=_5#JY#2I'A_*11&^^/WCS+N0X9W&LCXP>&?D&#O88>3S>*AJ/L
MBB.R"2:+S_1&YTLB/LVPL!6R3]Z][<6*GF4G2;T6^VYH&*\/K5O=A_0:.MCW
MUANUO^1NXUG6C%V-''-5J*H9I)TR.WC\2!_064KC]6@D>6\ ^1&KN3BX]O4_
M)>/WYO1FIY93Q%D3RF!",B?"/]/(3/*?Q'EE=Z8];_,3BT67DZ3PQ%5:"H06
M*DAJG:6D(3G0C5GAD2.N\KL!7*WJI9+S@?5"0S V<J+U$&,61C&P]6_AT-?W
M6"#U:K_H[?1WW1L]+ER#'(8@KNSLSEVN]?H&MH^\<Q$X,^<Q[Y(4\-Y]B3;&
M%7VM-F]+\E6-%8 2 NRI!$@66E<O*1WH.J:9K\R!@XMWOX_0B7+#3KD!*9=4
MW1+3&;S+A$_T247G?Z6?NIXQX2HO@/H#$!HX+B.H8OXY]8E1;Y$DI,U1&'T+
M%/B,U"JIM5'\7]D3=X,H^[>T/2,7$I)CESNW1Y_9G*H7\=K:>24G\3V^-SD,
M'F,;C$C>R:+VVDM397@@?0#77S'=HM KN$+=V%T  >_H+S_G_8OXYS2?]ZOO
MS^-B]%R#9>.='T6,L.^/1X^P3+]HZK1TK>1^R18.#2QB[+;4<&.\F,6S\'\-
MTT>:CDAS_;FJ:1PZ3$&.=RB[ZF[U]:BJG-IS$CQ_=@SF#"?:.AS_:2K*Q.0,
M=&&KX4!6!1E'T:->Z:[8CM?E]YM'I$^:,5;;D7@QJ,/CU%S3_?V/<.4OL&XP
M,.D#9_%Z.-HQZ[I+%O06=%B=_2NZ0,I8@%:Z4+^;[54'UJO5LCBB8N)3V9VT
MKYBF&W,O@'0VC2$14^.N$_X[42Q+5Z+2JQ5M<F0X*O^'Y8N_V$B?"X6/$^5=
MVLZRVP9APD%3<]FJVF5<,!D-%)#)J*4G'E[3+<J4[=]#D>5UU9)C=1^8^PB,
M37/><*K50EO'[#:+F)<;[*-IQ' *OHJHFOZ;2AEJ=IZ;_B]=T@88SM0+-A:^
MIG5ES"$XXU!*F+8L&_-\ <C_J=E@W3SW-P@)'S$:UXD\N!A5D;>V*@QF:':9
MTU3O:P?XM/\N"L?53?^N[P60W,![>FBZW<OS@8J$UQ)@"Q%L@8+.3=(==;&S
M4[(3NO!CNF6$<_$<WM%_TVP>C^WV'O=H9_U>C17K:DF?%2P6+8EGSG<!>12*
M\-HJZ*CZ"^N3OD0U J R[DU]M3:6%J\,&YJIL>E[?V>LLSA^8K6Q8E'@7:K=
M/4#'D[DH$\]BTM9:)[6W:Q%+[I6;Y$H0F&F=,)@6?M2:]F-&% XBPH)"T$,S
MW]&>OK7J;"__Q+-<2U)S_7D\[9CXMVC,C,%[>X>(]C)H8A@/I'Z4+G-8)Q3C
M07IS^ F+$80RW@H<H$JX9V@?&[,)9#@DQ8&E9;(GMX[FZU-:A$6<XI'9JLR<
M&A\+%+^1I20Y8)E%,:MFH^3_(S.((-=]2&?5KCJ71Y=&YC.8'HBLQRI%K$J[
M%M)W-GSR54H>K>[Y>!=;&;ZVP)Z(SXHN=<>N#U!-G^&27$/; &^4GO+[Y"\)
MN"X&YHG%'8BUV*FA=F(KLYL($"F;HYNS2N^T&XL= PXM-^KU96*4;DQ..&'
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M>'AP'FXH?[C?C$DLD.Q1&V-4A"5HE+T^A3*?5W\L95JO]IR[6&L-8WX!V()
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M?]=)E BARI[5NI7#C:D#=I77?,F)[)6FB 6][" 74CVM$X-4^3H%] 0E0A!
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M < OHMJATT;!$GGWOC:U<]^4"WF8_)X(O]EZIU"(ZQ@Q"+^E>#Z<:=A#.-P
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MJ4YY+96\4R&Y7:N)_G@CU,(D8=VW-ZT!6P?[7KV=,N^1DKGO2?73G&_9%.8
MF89:6OFV%[>U\:]86OU(L_?\(M37-OP/TXHR&H6%Q&CAY(R)IN/"SA!"6"*:
M$4E50^/^>6JMV86&?0CJ%)Y+5K5RP#(E\N(%X,]%&5"*TI/W I (53RSJ]'K
M<8FYN8=02N.L^CB;X2W3B<LAI5K3=&#I#DDH6.K 7'Y7P@E"AF1# ZO8J5WN
M<S.3!&&+M*<;B[0OCG$/J)Y(@,0L )@W<G>P'JZO*W_CNM66@9E,F'%-47YS
MK%U/Q'&FIM2_U 6WB.8;^](+]$25/(RW\Y,2$+QK)9UJX?DGQV2:FG/&Q@!E
M2*K:B_66T#Z;BZUN#/Z-"_)B"3,']%/WG0 EN9I7/WT-AA%!)-E_/?GPK1VQ
M30C7U.NL:7=8"S8R\,I9>(=]\/$2,PU4UC_;XD%R7PA@UCI0>B5W$T@[]TN9
MKM@4#!6T,%7C3-M]G ?E!-,%%T-<&,9";IU:^'5JQ1/+JB[)^.XZ;^I;3EO^
M_325&!J+[ZQ@?H>#M<RYEI>S:R_2O^C0:P]_:]!59S2_;4;BJ#IDH.[KKH,[
M%XS1NS@6$G4Y=7B6X1VRP9Z?,>:WX%[:P>Y9\]/J '*710=G-:%G0"8S,8;<
M,FP51:[BW)W/>U; <A2A.J+CH5@TZ@,T^M 3S:D(W\4R$0_=>=85U9A&C5X0
M,0@*GP#B0<Y@6JJFC;@5W)Z'*Z$K/'+HJ^_W2#FT4"EY^12)3Y]WD_Y2?A6+
M"1:[^L4ZR]E?5^UM9Z&B"6 %D$:8RJ,U"9D-53QWF@C..6BI445>OH5I3)ZJ
M8'$B:.:WE0Y$.]9'3A">[X<E(18-_X):?1DD:R]]:O+8/%R6>-IC9Z1->/C\
M M=CJV5TG+(?>^;GN=IUO'3#-V/YWWP,J,5_&,7M\=9MS1MEQ=C6*$W#!#)"
MH919;0$HK0RJ=I\MWM1R[H$94W\BDTH?^WKOOR2RA6(B91WX2NKO[OZBLA8K
MT>H92_7A>8)]B,D7MTDD5NF,XZ#;.CIMR"0N 8?E;G.#UF)I*C(BW*A=<L>)
M*^/J#%AQ6C *DY2I&0'4&<'YQNAM7ISRZ^T6/%<+>I)L7F.2^Y#/95D#[$DC
M8I@13+P03P?$SFT"C+TT9PP6ON:88U\N_2&=91>N).K,RS*4JBM(!(+BI"E"
M@7C"O;F:6P7EJB;\JK:=^ F+WO;IS!J'^.X7NYRV]K87Z:RNW-8NZ&E9L@N.
M,D&8*<&#7'T74_]RSFEZ=!8R[$QK5^;8]3ZVK.$54M<E76 %ZRO55W/D"(#"
M4D_!D5[71'1D+@PG)%9)YZPZT)56)TG1Y ;)MKR>(X1&*9LKJ-P*T&:US>8%
M%W5[>-KN_+[:I/"_?TO_'QAA83K\-^E<GOU>O0"^/?I*ZO8!(M[?%C=]//-P
M7Y35]KS5// W&"X*$HUH2_CF@,N>U#S3.BQ@U$&=B4YXA[S:EZ_&GM?3+&5?
MQ?&P%_W\1UJ\T::NWI8@_\]L:NP0(\L&3I)," XZW0UC3OYU]<Q5R.9:FX=A
MVFSWM\GT;YEMAA-CJ>6Z;350>K2W5AEN8I_P<Y T9 &WETNZ!T:OW./?)^(9
MF#O .UNCXXS__6L2U:)8]!=?M+>;+)YH:]?0^-GD(KT !@8G 2V0^5?+=L\3
MMR5-+38VIULV_O,I^LGH_A]S7S.RT?&>:*$Y4&'GJR@"[MF]J/F7;+]S-E=J
MIC=Y/]8&H+-OD2G*;E'=NBFW&&$8+!V^KCOTK MG^%EDS3ERR6W2P:H$%][O
MB.F0F O,%N\>-W8__;:H<Z(%?O,%:NPZ:X-"Y5WYER+6N\9]D4W.). @B][&
MH2AZSA5)_ )0^1U=<TA#LO=V!*)(_*G]1)M^9"R2/ENV,\M$LY;YG]6T5CD9
M\?L->A0I?'DZ)<H/9.@(VLS('U\#\.TX6&K/B=T)</DJW9\#A_0U6;=G[30;
M;CA6$KH^\^)%?V>ZX!*-*S*3MQ% P:9?K/34@$H9I8*#^R%CY.S>:+2V1KIW
M7)]+%YD_%C;Y:-8YPHA+.8^"J4)EC)QM4$;&^&+L.Y/_5'?E?8]);:T2D,]_
M3?UH:%_')%<;%EKF\5_AH8\W'Y2MJ@:'Z+ 8 @;8'&6NSB!BEE &'SKN#";O
M4R8Z5=NZ:]HPW^%4ZIO^7A2]&0<+;->?!&BH:;Q*%WAD3,4J-?GZ'X*V<Q-(
MT^7;XQQ_]X-?R214;%9S.^3$V6J7>!MC[^U4"#:OQK((<F"R],(4RX&#$<*G
M$FGJ'7.^Y=E_#/OVU,&4N'2]2CPCQRCVYK\*%JF?3UJ3^LW<JAV5]_S#6TFR
MT[(;9:&_75.D!6;Y7F'O>DFB"*S=:O6WY[#\:+[O34)!67_"1'M^USG=HCLV
MVN&"(],?VA7UN?XM18A]DR64@S^ZWS?JY+ES:J+\/,/.XF(:9C<FP#GHN7[D
MUP=.\([,#"@3TX]@#I+ .MR<UHB]B6I7V>X%4C=2($7J]X.GZ)8:):<WBI9\
MM6>M:RO1%#M#!#^YKLYK1#\7EV,VF-$J>I<.0HE"]?528.<).IBMR:6NH01]
M@,WTW8O+"\D@##LUB%0]-A;X"R<$$'*+)G'ZMEO<1T+\C$3*.X%XE!Y-K"DW
M_5$<KJ/;H= BOE1U,?PEVKAV-*!E74?JCN%\ZU1J;:?B#2/K4%JLL3"ZW..D
MIU7H4(CQ-/B'UR?DVC9HDB+:$X\YPDWBMQR#Z7QJR<\?;^<5'1##.B5I/Z$G
MCW>P3;% #$30G7LC>]V=7]P6\RXP4,6<+^2*:O;@@C%$O+2>CSK.N%GL B%H
M^<Y5**X6S.O: *I1"PZ:KYO$1/2AC5(Z8M.(N5<YVO*W<>3 0/4$6U T+S#1
MK\Z@;+/J:9L6S[KB"P,RA[K5UB1J5D5X,2Z(8A2XU4!>OFTO0$@1T8EA&-8$
M=26+&44)B]7!9+P9H0I1/:2!@#T8_:KM.+D$5OK0WW%PZZJ"!4W_Z^582?0K
MNW<2( ]VA&!_0\@+P![$C$^K&+M<Y<YKL%GUW7#AMM?,!J'%0KUG3:27BDT'
M5[# &WOM=,I%1WZR4UE74&LXQ&(+,>_D@^1F(NQ1,ETF)>COW.[7^&].JR=3
M&Y#%@TT82J[4W=EE_F^<U SRSN<;6OG*!:L6A@686MYG_J9UE37DUA[Q1U^[
M/.]1(=2=7FMT1*KA8:N?$V&8C#61[3[\JFJ9#R1?^C-;S*&O,G]*F=3.%8VV
M/C!R6QKT]06@N#K6]L:O27>I7==S(W?@5OZF.A'M$QMLPN]P%3;,]-_. HZ4
M5[8I<9'54WKNX?Y .$3DO=Y.")_GLN4_FF<(*&4TCEWLQSAWLT9B(S<H3XZG
MDC_'IE\+C B"P$E]X-<))Z&>F6"Q[9P:IH*$&HHL[O:[+%8=6J,W <7BB"'Q
MB-D[0!+VVE9!7_82^EJ/XWJT3+]B+@G?* %NZ-0!T75Q'5*Q\8UK@3*9F HS
M!E,Y6<G&DLV/<R\GN9M.F*VBB&V^*F=Z:7>Z,0@Q.]ZD.<A*"F/?8[V(P-Q5
M5,0%FMQ<HY];=JK/?+>8T$S&V)L'PY/@98!-;J60/>#7R@& BL&&#;1K;64,
MLY>!F>^:@SEF?5/.QA\C9H[<@;G<>FG8Q#F5;:<25A5B-T3M_EE,&@P_+8O>
M' 4?"QXAVKX'+]HZ&;2W&8Q5PZ+I%%,U>@F]JUD_M="A +#_N1V=Q6@GZ M2
MR=JK/'BCW9Q?GD]/4N,1>KH<NTBSTU[4F05$O !$\5\ 4Y>+"]D/,W+4Q.K_
M UJ] I2.JO<G+X!":DS,VWM-@%--@>]!=M>G^%*I(*I60RE:Q%MLM/.=VZ-W
ML)FI;>V'R/%AO1/=NE52"BCFPI<'"3M:-_SXT87T"/EXN]2]^*+T[DR8MT4X
M@C1^)\L K&70][NVGME4S*.LLVVZN+12*NWUDRPS-^+D)'MQ+T?K=0,$J@08
M1 M&AA+:T'1D7QJ[UQ7,D=\U".%]9%?A))#!"W@SO5B),Q("_A!!/N,9$"OL
MJ#PY/I3P3&JPEJ%=JZB.TC78XWQZ]\BFY^LGD*LG \-F#,87_O4">/.S=?P-
MKP"3)26W*)'*KZZSK92[OX++A DIKF^\"2:96X%\ 7ZSHYPJNX]UDVA$$MMZ
M]>E#:H@C3&3@<2V'^%K@FIW ;"9*8H9@5D,%WVOU>2TW&U^(,4*W2=&Z!C:,
M8X;TSI(98T;6D<A<V_^A%M<MZ\!A;1]UQ4/I=0ZX]SIEC3T7U)];U9XNU(/!
MJ:&J$<78 (=58O+@XU_WKF>Z)\:$+OP;N8F?#NU\$]6FDD8,NY/&\(:.PY9V
MM8R+QUN9\GVH";/:DAA<1%D3ON/_R+-=A84STD,@.,[@A@@65T-GMXV.P.*%
MG+93ZDJEKWV*4G"H-Z=%HTGI+.?O[#)DC><GGO@A7.'OM>P9IT7:[,M?0LP,
M+;=T2M0;_SJU)W>8_7ARY-<,:C:/!@CVI(WN6G18^L[U-MG'CP^;V;NAV;5"
M<[VJ#A WEPHK9Q$TPPWP9\J/B(S@W9*4G*BW"?,F>SK]J WLR97JY&J"X)3[
MV -==()._S+V B('\2+AQ#$QXY:,SY9#^=&FVS(&FADT:E!D(5I;)=QYH.F8
M<LWZ_)]C60VOJAM;_$]IFD^XZ38T6AF@G_AT%0[%N-IR(-)/W]_2BEY(A$RW
MU#(VPS'FN^H]\;S].T#D#ZK$2X<H\T@4.IYWUN&.\+[,1.4T )W,M\]6C/UF
M^#^/)B'=]9%1SI4B[#$ZP6C)6@]=\07.GA(B;C8V[=0XF$*\.PSIF:'R3%EI
ME4Q0J@9@L\/KL08AD%+"N5_/&UGQ]0ET)BYB>N4X3^,6*CQ=YD9M<&F1%JS+
M2WTK9,?M<NZC1^P21]XW C1'2WSN]?8KZBJS,CN.U>^W.!!G(3#&];;).<W5
ME*>5M-?K#PBP;C=S=LGR)DVL4#;$H@:)FC*85.(DUK8K>+G3O\Z[6OL'3DHA
M[44%-W8$2^ 2VO@WD^49GE2/G3L$ZV"CIS & SN)5$5#KGX74/M\Y4OGSR]O
M2AF&W.4R*BZ=Z81:SRS=SR!P.K:1Q>]4P6HUT#6WV3;L>V-4Y9UCRCG NPO=
M8GXVG/;DKC30J-).U_<PYRW"NC>BB^YU9?V(Y.K(<HN;@<]06\)*3K(XT(")
M!C<P>2S0"O%,*_X?(U9M^#I+N42*.MU8P!L,E Z6B6)7,A;BB<E^4_U/7*T1
M%S7U:VH!>R=<D+%^/W,,=BOG.:=N0\VEP!);B;;?=.^O7"]G.\*C((,[ZJHC
MF%KJKRT_\V#2]ZHK1F6VTL#IP'VQ60M&FK0XEG>P.O26*E@0G2\:0+ 5([\)
MF[<5"6^.C:47% C=)<-00B=_:\5.)>?@]J< 9D.K'ICNY+D$LSE@*(D;U#])
M^%'$SC.@*DAR_*K65G?1=N3\)X=9W1?^N(VM@M,MXO(-R-W(QK2_1K=*]H%!
MD^/0@ZUH*D<MN+M>>A55D1HNC6WDO#]'B\7YZX]G[090_^/:*#B=529+*ND#
MG%CA!1![T5_[9!&8=%)8:?E0<+ X^.G GP9O<^S/8VWE\:%(2\/)V9XK>4<^
M^58G,;&F'0AF!ER3N8C6)JJ>^4'X OB$.N=4<<W%T=]@0W82V0AU#BYCW2F2
M?TT?'0EL@1RY0[79I"R!;9P[] S+0@\6?XS>)[]6CO=^+Z)1HYU 81_&1UVZ
M8LZCP)\ %[-%8_MQU(FVY2CJF+U>JYGLI5F[E@?]%$Q> 4X*M$$I2TS58"6J
MIE?%V1@?A--G)6!ZH@</Z1*63\T?=8HGG) 8KEKKT^2,PH9W#6]$AG5S3_ ^
MUXQ(-#:R:Y98>CJ#PTBIO)P(=QR-SKG^^10>LG7/AR![\&/94T5DHD3]29AX
MD@_2*SDD.A3MS*MGM:=\]GF.^GQ7O>:<G*\5/#J9US:VCJ@([YS4#O-$/W$D
M#3[],H9[9:GO**C-#%F2[[3@D+J^S4,Q]2\0]Z!FY??M7+6S1>8HO<,_6".@
M;:=9$'30@U]>OP""C7X$X$L8\-;^^3]?4_\OL,46N@R>M=V @_;:$D\6B?/Z
MHAF6&VI"I5V23_XM*<P.>K+C<K\ !ON@:T]Y,6D,Y[L@2?S[/P2):8IH"W+!
M+P QG 6HXE@E"_,+P%HR\WWPQ)]NMJ_Y<1WC&,Q< @+]*R4",N%ZO M96&Q@
M0G;.&>YEAX&HI^$'FC2YM?3)W5JI!EJ>OB]3_'ECI'4, [H@-8VT5\U\I:=4
MSE(/!/.%_]P_:\2YJ %PQ-[MM.&'!@.D)*8!:,:2XO0NBWX7%_J_L;W2]YGS
M263I  !C2C1R>_ZH83;*%'B=1%Y76A&>RWRUV,6$:"EW%>*U$WB1R@'U'"A6
M&OYQ[%Y]ST&$4[\]E@6I. ]"E69$FM#_C,7$HQJA_QO^ B!8_1P@S3" _B&O
MD!0(.!SH%.;)GL.]QE_L?CHM\+WFE)ERY5H84JK<G15Z8BAOP9!)R"@I*QF;
M@.6J#R6V-KLJT+$N9N\A""[UMA^3 ;%U:3/?#0?+9LW&BZ4Y40A4D]>S*M!F
M.Q('J>U4TM[90T,!+++!@R<!V]1C'^#W7R-KWG-^@F@UA$QJC@WI[J:Q9'%.
M,<;9>U@/G'S4?.]AGKCAD/ECL)T2%"B7?9HP%5I86H$6EB!+ ?&^]1IL+_$>
M66"1@Z@L<>T2)B?R?A'EZ=WG4-_O[FX:0A1+#FK7T,>J[MDU+CS3LH'5]%.I
M?R>@2_5U! Q&4(:ND=P?M+;)V?^!*,)P4;>P!^OQYL9X+-^S&=OHKNIP$IIC
M6$6&WD40+_]CF'XCB_^UA>*9P1+?R+(SCI\7#KPN3IU(V5YSW18#[IX@+L@=
M6KO1%)M)*HO /W0*\U<X(GJ)[.8D#US=AQ>*D_*VXLN2X#M-@,<VX1/-@\1.
M]._3+J'6'SEYFIKJ%=+\,7#O3>4?CA5.!>[2%R+5'[]X[G?M9_3&G/+F%2:S
M2Z^:1(!4">DO3EYK4YTZCI,-61BWK)(R?E;L=/W4L>M%F=<%JC"KISMI4^$?
M/,:@=#(6%3ZVV(\T15  VTU&T!] NS1#>2N[LI>4#QEKM1\K6_AU,]"]-?.M
MMZ% 6-B6&0Y)J5H@BII1T.%*CZMO^IQ!6RL6 8JW)Z?5L43<555>SU>H:;\4
M< ?]9U$!K=H?DZ"8'>M/2J50SS='Z%EC+%H>4IW'4O=T<.A?L5?GL[XY7UW'
M_3Z(N;X 3FDY[42A>/3K=#Q[ P-]Q\QO[6BS?]:*17!<7.\F* _YD!:#&./C
MN-HX4?PY-_SO)"6I;2SJ.LU!RJ(NS_LA5S5E$N27F-?7-X_<YPEWHU<3[*G3
M<HF(I02_1J$&,1X.FUWD!3Y?,7P\)Q_(0N>-HZKT38,=7)J.+FH>!\)TIHKX
M\N\3Y7=J\:/TTW?H/M.J:6!I8&?IK_83#IA"O>[XC5G7=UQ=U1@*,9K4,=/2
MGSM8.I0LVM\HZ6FFFNMFFE+>9$K,BKT ;#?UL<69U0K(U]C:7%CHE4M##S"(
MX3O"2A&G\QE#GM]]C_5)'^D4(>ZQTM!UPCT J;?8U)P-Y_4_Z^.*VOR5/Y34
M@X-&;0D1S;XYRGHQXYG(<N&F]J@=<^<991(K5(P.'#D*KU#Q''?1\VY,6,^<
M$_*OH]B)X5#J*3:80A$>^/D=_I >U%\K[U]"&DZW"WU:BZTID$@I9#3J"WWC
MUIN%BD7)XG6_/Q5\<=^26O0T;!RTQ/8A^_7G8BZ=.Z<H:=^2:]G#?W4G5%B&
M):JF%LLZ4%ON;/D:;17$7+T 0-X)07D5L5$ZIGE]TF#J0U9@F7)IA'OJ+A';
MOPEN%11 R"ND$$_2W>T^]Z6,%X$ATJY&H'68'S]GX/?7/>OH[5L=AYT3W,_F
MUO=%JX)40OAM4:G(@LYJ!<W9BJKP \A&.+WF//"[9AJCW"RQ]"K$)70BV\E$
M3X.JT6"$$$B&'S<I1%UX+'>@<"UZMA0H^E DZB41-9?>_+N,>VF$B167R,+E
M7%H+.6K%#IE3!<U^8X6?9X8\S+MM.MQI#6T>W"K]$6'+CO7RK*17LN 0C<U
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MQ[Q.:D7-+J-(.3#SX3/ U%"Z;3P:%=,DN=A'3+Q:,;T6A*7OX[I.7,!L\=,
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M^P1!E4T=0)K2NIJ_P'X8J$(A$$L-D(NKHXJ9K?F5&!V@"H "(%<_E@ *@ 8
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MKI(JA20$"J+@8>-F->?@Y*3@Y67CO,_#R\O)0L'%P<G%SG'UR\O*>5^ AU>
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MLX/4>D%@:RN)@0B.SMT<^8"6\AI6:T?5\ )GE&<IUC&%Y@I4+/S$>HP./2C
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M; ++8ANH7+*&T?2)?M7!8%*FC,I4E<FQJ 2:P$U/\$@(G^Q>/M#'XD,L6H
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M7UOPL$13=XY:?%@:TM23 Z)JU-KH&?-)&.\2*[XR-E.@C]:-)B_J\'.%L6=
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M?-.RGUM$:8?_#LVVVF!9.H;8>8D57)\C6!7)3>@TT\NW:@=/C%<,S*_B!FT
M(!<6J;+K!F 7\/$CC%\,U[ZT$KX$>$[L;7=/N\I)&WBZPHJM4VPJ6Z7/.0KE
M!^H.OVB)4THK5;9Q'6*GIZ85%N3F1/6;3/[ZL/?=VZ?X^%AV3F)R^N*"FKFP
MAG'K<AEM%_<>1MI"'I^=O%Q22!)V>VM>\($N3SFNF!*;LC,S*93O#O8S:GRL
M%:2,.V@<A#@$2SDV2!;2@/[M<]%G3#T"XER":S3?FP_1/S'UZ,'T 3 P$>(!
M $) DID*S*MN8)) $>T40=L2S,I0@A#C$><2P/ S)X8</#J9Y"ECBW;S9Y9
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M L".O?->CBGC>+3Q#IX1 _[8T:"&VV1XY$*W.O5M/#U_Z;9\>G5^XD"08LT
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M(\_59V<BP4RL"FP%G\:,1#F4^45#< M04Z4GK?PWPO&^-XFGA?#SJ()CPP&
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MDP($+[ ;5\L^/U_Z_%XNH#PZ=6HG3I,D* 7']Q#/K-%W/;W[;HTW*P%;8\5
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M0;*MDF%%1SLG 7+)0H+81$'<%K2LELA:PIRY9LX#OWZ\O3J(8@C4/"058[.
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M\Y8< MQGK!X6@ZAK()U @@LP06,[XMRKD(82!&7+Q!)$K.<4_P F"D%*4CU
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MF@WK4%)!AQ5$J2, $#KY9^LOZ5?)/U5Q_@>/Q-&K1Q?A?B-7%).K61J81C2
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MACE/!4.X)_W.>J _(GT_-3Q9\4KFK\PR .9U>M3$J4M2&20 #P[.<$NV0'+
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M(4"GZ,Z-CRD?CI'K4 (+B9GS899(GG;=@2-]\,:2)5*Y5$).R(&>&IP6B'/
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M#)+LYX?I^W/B\P?L*$$V2DI*1%@ST?E4)3.#SMIE0!#4ZVB'!?) 62_I+/\
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MIX'^>_VM5])(42!NW89VRY!)#.P _-P&8<E72A#)%I\P3&=[B,95(Z3M#OW
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M.< <HV?Q$;7N^C98PJC@#:;>7E%VM/.-C+EW9%U>E0>WYNLY[FK2-^WWDA*
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MCQQ-(<:%,B2S13&AT0WW!&F4TXV++C65??/2=#TC"ZV1TOPASC7K*?0A&S^
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M$G$%OGI4,BFC)CJ=7N,D&E3K$$FU%N\W&*\-C_M4EO9W?-0%[ORL@LQ0::J
MHF_MK.?GZ<<[P*-_.U3IY;<_8M\@9=9\0PY'7LO%>_34_%O^C1V?9F4.@1>7
M5Y0;%?:'7)I5_0M\*R#)122HO>4D_HS+]V]:/.C"D5<*H!BY]K/O?>)?VT.O
M5T,6OTP+SY"ZJMB"!@'K7.%:@W)K')1Q09@LU4"[3U]]('5VQYZK/;<LL6L
M(@:4'WX]<,V6]//2),!'\IJD%[.!HA0Z//3NRDGSUPHM%]E; ,L+.HEG@$AH
M^H<]"I4(RII!6%LX^)2,([\ =O.D+B^5"$+5$_"O.M+!$"L6Y\ IK(,8X!2Q
MJ_2JIM!QR?=,LV3 B!DV\XHYC"YY_F-U$R 8P2#XBJT\O/7T79CQ03?4XZ4S
MA2D^?#V.'EEKO-!V[EHVOVGZM@LPMN>(^F@U^%FCA=[_+[[1+!_=MCC\#RV0
M$UAS"B;88FIIM2?KA>3M]P5Y[73U57(2W>9Y4X>M(ACE-UD9FT4.;^K1FHL1
M[98?&\D.*IK./>_X5C0,=>DA)* "R7PC&-;@9IDX).)@$HA]5/8X2ZT(T2D-
MTJME+E6- :+]4B[:@9FU0,55I8[%E4_R?@>A75O6!;]+6SB>")F_]5<"/-G-
ML#IU56$V@G4;*H<IX+1 11RF"(X5CH6!> W(M078(H*#5J:^[\ 2H&N7'OUD
MLV.\R <Y@:*,'2J:S0S^_*#?EGFFH<Q\Z(C+<TQP_/2$S]R<;OO;8.%$?NN@
MC*6J,9(\:N.::XLHUHA*YOK5S<L;^\OXU3N ^ 5G^W5^>#?X#C#1%+XL'6Y!
ML?D;ST*<"W/[E9A1=OX-6>G[>;1M[ Z NTY:#Z4\D@\5^XG_71F]__CU.XK-
MR97?G8_K\TEXPT@ZZ1)^_7MMV[+[?$';U:SRO0^]T6/N'[$<$H!8*:XR/C8'
M@\J)Y&N;MOL]"VW%H8\NHH<4U'Y,'E$S7@YH@<X]E.S=\ _OYP;7G8QT!#<N
MAKSH7KH&4[@MV0#+L@*+JJ?%#+BI3FK$(I T2!TM(B;6$&,DXA3^;*WOW^;7
M!@6!\24NM]L-(@AT_OG/X\U? )D&:G(T6NU1!G6I845I*HCS$3:-P,9/4(!0
M[E$C:N/CIJZL[]E)7'%8,NM0M[IXD_(0+>!5RNRV"56H *M-7?2 G;@H8LL\
M)M;I?4P+(A\1%O=6DXQ5$R20[[.]Z]N.(B3VVARK:QW$P/.4.Q]:IX@Y5*N7
M_N4M+SM!N*]>=Y[(?*#NRW@KSEU?T)7QIH4\? N&IGN]+1.TMSO_*ZJ4021$
M,\)BQO&728/(8Z<,M5+KB0BIMQ+ :$HC@Y6NF,)_232:CA?QPR>@R^\'8^^5
MX3K,C"G!?P+J1\JUT9K@:HO>I=F4?)^CODUC5A.YF&;X*C+B>I*2_=L%S.=?
M',)!D5))?.D@Y2 17R'\8O3FJU?T<"0UY8JS*D'[O3Y9TD*"*'7JEXNK'-<;
M"3FA"DXD6CD<:Y:\P22NY/"XE?]8"'#E;[^WW?-W[JOQ2M5P1ZU_UP!J:;1_
M\#5\8]]<GSROHPXSE_G*.S"I;;UL]451GV8@S_-AUZ+F$$**1"1A2TC8Q2HV
M,(TN\<?1RT\6W&+=3^0@."A5T#Z8 GP1G*XHSP_/)-;-27V#H##@ENDY*W)A
ME6VE\DE"K]3AKH\_<D32\@D7'W;4S.3U.VY0B./8"%O:3J3]-ZTP$K4O&,!V
M."7)GW&&UW "Y@[./K3?I?1BJXQ9.!]O6%1.&G1J5I-O&3UN1+<8P1.@U4&-
M7DW !FTDWGP2#[D=V&TVDO#D-AKA'0 '@=4B ]^((IG:MYG">IRIK.>^IN7V
ML=O:( $*)0_YRF&7MC!%BAY?@I45^-5:S5C#MWG@$3"W$#Z8Q45.2$NK]8IS
M<&]?@^-<=$/TQL1^H0^_$=)N2#I972^+-E#X00D54U\'-?L%MX602E_L]1@7
M?#%$F_]SZ0VG*-*4^L0^URN:X;S2TKBY_>2K*=K>.N\4)H' C$1PET3A!FFW
M8!<_2>UW"SNFFBYN/0.+'1I*_KQTG;8*8,Y4%F2ZBCG$C#<_-Y^,P-+NXA#W
M;HFBE2R^M(FM'#S^77 @Q?XXU&V<*/\\T9#E4'?@4^!-T;NU,AGP4D5-X&:_
MB9"WWN^RTXFN%]X68O$H[3)5_H;Z#H/RQ5SL'*\(O;N5,%KF>2!R@BB<9)[4
M[O!/@:?!S[9B3IYSQ?^22=EK3J'S>47RI9>4CQE:%=X&GCMN_9*2#Y1BK,2O
M!'J^1</-$VYP(4(G>$NO)\CQC_J?!FU-W]&3,M*E#4@=E+I)DB?2$"<S!'")
M?7AS"(EE@"K-$8F167PKRVLZ#S9@<EX<P 8L#C_?Y/P5.IHO>L.U;TMYH$A^
M< <@/\AYRG.P>1Y"38MY0%AICGMPWC?^&;\$LL38S;?\)#(B/3(MD)N TF ,
M;WH!!$R, H2;T?^P!69CE_JHYT=>A.H?G]T\48>?.ZM"WD:;#1]H"*CLKDU8
M1)$!=N )@?HA'QIK/(L]MHBP/[.G7I&>,JZJR5B&@+A-D:0FZ+UK2Q *>3\\
M+[#D]N:TJY)@IDJI3__@=1V4^[[[06#BAL$>EDJO]*D_/O/E="3.ZA#)E1AT
M,/$1*!OP8W\W6Q-+A9@\_&5[P]RH92)/A2L1["7#9L#8#H$CQYO*T[=[$@KO
M-$\^!=Q\N*2TLYW1L_V^'/KWZ-F68T30XWB]7YP0AA>"&U_X7Q*:Q[.@PA%7
M:F2"M-AUOI^Z&$9*[O?24V3&L51W@)4%]W'17T&VK/8!0Y5Q\X ')<E+9SV=
M(C*3+P+VY?T?^U/%F%749G1'6'X9BK[B7HY':?5J_J&OF&A+$8N-P_$N]^"*
M^> J+&1+1&%0,@UMYCL _VFXK67]U*ASD9WN@"H-[\I[\8).E0 CKB[6GU"J
M!0-<$;;,B2N&I]CQBU$VS3=R IDUFWK7?38% U'9E.FV[.8[ ,]8 :UW1]C@
MTX<)CZ>DNJI@V%H)D[ TB53H*@J*0QK=;^#Q)DK2?FV@(1G03H(B$BI'$UU=
MTZ[QTS,9^6W'9'C  ^(!:&T(F7$A$";@#H@023/JH KY^0@WG57_+HLFF8%)
M@!/'C35)TL9%KDPK%446*Z66"U)H.!$[10:!6--0CCM^SSG<Q!6;#]<&R'+M
MHITM+M6?W3K2S%X=TY/!*W$)><JRR[9<'I%LESQBPK#DHXMH^;:UXZU8F*>:
MH>&$4D/QE-V<(Y5_)HZ526QL^K#')[HOU(,P8Z4<:1>/%G8D7Z%V"POJU4%?
M#!L$<XPD*'K<Y@IQ2^S@[.-+JID<.IBY^?L$PR$$:P+DHJ&39/C$C>=4@\BM
M^,3*X7IA/<RSB20^$29_NJXBSI:$)7C+/AV6FAV]>[WZ"L?$XZV1ZZ6QP[)P
M%94*[7O2"3VB&%+*>H6T"!5!(O]C?>TK1KF$&D+F@>-%[^/]<XWHE,K.';D/
M8S>%30_856SC=?8[([>>DB4MUWP_*#%_LMVLV2A/H%Y5+CW:NL?@#C%5A3]\
M]&(G<3'H9,M6^H;R,#_O^FE^[/E"]-+!*^_>W_B(E_\8[__0"OXVK3(58G(9
MOQ)BJL!SFY_T.4)ZEN>#X3BA(7_O 8"&^I[[R<17NC0R<_-LC5357!E]IG!B
M\R>R=N_A&!( @,1!@DU!\U_CA7^_-"?_SP_1^]_$\4N;<$H9;QX2"=2+C2<:
M7=>VK"NO9YJ^O7!Y^M%9BW<$H;D(K8D[=@U%>,CS F$HI':K]^"T5WYB2^!P
M0=-CY8Q?1ED]<NJP+KG<4;J4)&.:85(R?_O=1\&'-U_?(QI\&.R;J=T:=2AW
M75#AD>DH8ZZB9@KO4L]=&[^SO8D**!L:$=P,I/K+NOZN%H(K+"4%Y=LA@E%*
M=AU7-X%/$Y=%L,]2W\XX,"G-?)PD2U,P9_M:4LI;;,0B=U]X4#T:4%9N U(U
M-.+-@E'_GI\:$>>XOC!2TH0F=A$-#&)=&#1*N!V$15A-TPH@!?6IJ9#-QZ;;
M!5KXH#9V[<B^55/>D%6LZ*(DC0GH;048+A//H8S3^$NRR,%$.X8^]"9:[&N&
M>'*:D(ZF<*WT [O/^_M6MZU@H?,CHU2?*&NV0Q0AZ<P=N4F[/@/ILUWT Q!-
MT5E)1P;J[M=^?L$T$^5P'3W /;^)W)D^#*5QOGNFWRUTK7:!!VU U!/2/X&*
M5R$>4WN?TRXJJ@Z^&@2W0QSLH\L:0X,1[#8<'_8,?_#.N!AF!*PGZ(BZ)A"8
MZLBFS(+;">7R/3N/$K1U/2 "24:O_-JE 1 =G!AA-)$@2H&P\0Z0G3*G46P4
MK*J6_I-:+UE_OX)[(9 )?A&<J!C?&.I5OB$OB&4*:NXGS(U2-ZLP2-GNXKV@
MSGG61!GE?+%IF(WC&"1'CBB4)6<6P1N+'I)0'@SDG]'V:!,7PR]B[[L!:[/G
MHPFO!LUA<B1.!GFK;7XC"C=?FW9#YJ^,2L)4^8K28BE$FLL*9U]06#[<($0(
MWP$&<:&EQN]BYNP^X41Z2<0VLH-D L@<6_9U[/QYKF/E+TU!-H7Q1\\A;+,;
M_(:CH?]HY189*:/A6(T>GK6O3>QW@![AFD'VBM7I<T\J?X8IR8C<_R"_!G3F
M#]M?]#L#W<BDX2"TS[6B+A["PGJ[+!0-]0U\]B_N  $W,F9K@DB 98;@,UB_
M%5]TB@^1S;+$-/X.P-)$5'=)<!-MNL#4>$#[NL")9O#I]A>S0G)QD$392][0
M&'.<WZ"($H8]+MX7QT2P("R3]@FH$5N42CKQ5<%OK4WF(&,GY;GMKS7]\6]_
M<?[TC5:1JQ/EKY@TXX7H%=R2FF#%>@PT H>]CD5%CG:O/M,!X1C%[@T.%??#
M5MLCQ80+SAZW\[VPE>>+!Z]=>CX\Q<2S? M$ J*+-ZE!@ !SF9]>U%]UWH_Y
MXEC,7$Q$+!^X+CM7LFA#CC;BE".D=-4-YXNX:#Y@<1_+!8EXVHR Y#_>67>P
MGN9\\9T)*;BQ/O*:N#RW/;D#T'R.+XTL=EO*WP&D:\LTV#1+^@#2\DQSW[L#
M,?9E7# HE#G_LGKQ_]^%T_W?_3WYR$9;:G!MJK6W,*V=%WV%(VCTG+%-WDOS
MOSB[?</V[3=5TLYXD,?]>9;P/@_-/&*8BC=A,?YTP/<0+\TQ1SEB8LY-"&04
M] /95V<.GZP\X%)RN]FW)IC\G >\]T;"@0D\!2:3"\W6'NTV&YB-3480^E"Y
MGST'?Q&914\(*J,L+]T.-^^=N'"R"T;W]HU(]OY^*!?J=@>(KQP2+WI9J2ZG
M^+IJ=*8^EX_]S]*&6<D=X)4G:4MB$KOO?F5]2XF?X,>^/N[4?A4UT1JJQ\+,
M]15R_%T<AL9E5_GE3Y^F#0[P="2VN3\944W1F'ZP6/GCA:@V2EEX_</"HP<M
MY9(3 5I:39*"9M]?3">G/5 T?E7!5M]YHJY' (N2AQC&_.2XV=MVB/@X8A#Z
M^-*Q4+M".UDO-::)QD*(5TBP"5?=NB=";[S/U2&4GK' ;+Q/JH+'E,6+_6S@
M=>>Z-"?-6.B+'6AJRN0)BC6<CP3;E0A742ZB]0,H<^HX9,PCR$E@M).T,8",
MF6;@\IG9 XGYB3G_BC]?LU$S)C.T)8%JKS?3XG63=-18#7>MNW>:X!43\5$9
M#PR2Y)]DE!>^U2G4*E'_8'"3S5)8=E!8.HCD-GO/?2GRW]04&SG:U)P<7ZE\
M]CD-GV]\1:[[_%%(RM:-<TJ(6T/T:UL4@U[YR\=TTI+$$[GID=83@6U[;/7'
M:]-:U<O([.*)[7<TM).D,X,(F(/Z59543MIYRVF$*:6!T%#&4OCWS)2?E8];
M1"SK7!LIFI,>$)0JXS[I?"L*$(B-H9U84B01S)<*OA!(B^FB@3N#I'$UR@4B
M)%-@;9K<Z(OJ-R1Y%B&2JEM_R]UN%%YK#O7?+'^P-@P3BXHG*?SXB#(=JFV3
MVN303C/";OW)NEO_YCD<HH73KI:K+9Q=^.BD.0[[D1A<MK#$>"W9Q[-T&(I<
MD/Y+ #NJAF7R_$OJ8F/B@8Z2S)^2[(61&"-S.$PAL)Y!,=(I?T?)#&;"N9J$
M5R9\2BFH[_?54S65@;#_ 2M U+_!Y@$S/-R:F,UDI\F-@@CT9)Y8AO;Z$N_T
MBZ>8_-!TB?\ :47TWP4"(OED>: @16@1@%C9Z4%P%!8? _*R2?<$GH!(<\@B
M>B?OM1P0'870DV)LCSRA+3A5.;H<%H4?\J4_X19P ZL!V8$$=\<\]4:62& 0
MEXB!YMBUYBU; .HW "FXWL5*QBYBG&*L[4B'%'/\"QW=P&SRSM_(=>-Q]/%.
MO2.'JT@A^+^X@.UO5RNDZT'0-)89W@0 FS>T3R=!S4=92 (:\Q$8*%@N""XP
M&!9NW(X?K?%_U0-'@XW!X>HD#7JXC+"D:48+R6!VH!P]0C1JO*00:VA)^DT2
MJ9B)6WE1&=#@0U,1MR"26;X5G+]NN;3I\09UZ6!N).5.3LZNKPZ-)(TZBKC2
M-.H@F+ \L3/DD.=6J,M!E9F&D0WWF$4I5ZA@'.3NYS@/[ \.G5JU<37I.DC2
M!&HQI)8L20"PS8GG>N#QG5_MU 8*Z@VY88.QR$FYH&%_@QMH6E6$*?\ ,IMV
M.7Y+-\YQRBX/T,H=QS]D.X@24 Q$[1RY=$  :J8RO\*,#^&2-A]E%L9(;+C@
MX^.I[]^WZ4=WI)FZR()4C?E:QFHES/I"42\8@D G8H.,.,N-SY]L'@]5<Q9W
M]SRO5!F7)*"?<&P"@24V217,;Q-7=.Q]59^A3%4G)6!3).75)PDJCP$0_-#F
M+#$,;%K@EU.>3P_6?ILJT A[E0ZV_P##9<M2N#2JC3U0CS52B09J;DQ-3"%>
M<9: 5(@D*(=8! !/+'#ENJ%T7(^GM<ZSJY@G99@-WYI3T3K8#[VD CR8S[6<
MH("BS!\<X;X?JKIYC\UD%& 982D ;0HNO/<AQYE/GRA\F,P,4X07VJ0M(XRX
M[DG//?-4&=MO\YA2488BDR"&T;@MHJ%>680WW+$R.!"CD]QL(.,'@=W+_4?K
M$>7F/S4!A@& F!]=]U"0%JHS3)(\J-C!=!2V';) <N.??W;HN8]]+]GY4!:B
M\_M =R,VG+@  *AC-;IF"/)B/Y*SPGV/&<9R7)S[=7P\Q%SMZ.<$48<@JP$L
M@YN,!=#)*DC[R'"?(B@-^4;3N/(<!W[\=\#VZ@#V[E53$S)']P9"/XLS87JA
M- .3 F&226""6 23PQ<$ MP1M#9#]%S]\Y=MGM>HRQU$;E@D![0V9ODU&J<!
MF4I\F,WEDYAJ_*4DX.,DO\9![#HNEURWO;U?*M$@RC C!;5A,E3@A;T\388@
M0HSD#&QV+N'8;3\9?LYP>BFX\_?K]Q4NH*<Q<Y8;?GF$#2&:P4^3%/I+DH(8
M_P"YVRQ(!&3T1W'F/S1FX81L 4ME YLH[5"F9!F(@\F(1Y",C:[ <X/?Z? ]
M^B>PG/NPN;7Z4)#W.P /6[(C#BY$D43]Y4["!&#9 *%'CAW!+,27&7/;HOMR
M]];5&#=@=]SM&,V&D  JJ,P'01 CN&.(9R"S]O9S[%(/<!BYCS'YIXC,1ELR
M.IW7H*%@S($:8/DQVR!^&H]\9;GZGOR7 Z+GCVMYC^&:OBLQNK.=Q*$V1Q=2
M3]X!<F%&;@LE0!)[9!"7!X'/TZ+F/,=L_P"*@)  3[&)9V9!5D-\52IL ,(,
M;X/EDE([Y+YX(.>Y]NBYCS'V\]N\51:0;S$1CR"N ("3H64FAY!(A1R?-63^
M&6RLAPP.?H?]W2;GVA$7[VYU&H&)R9@VA(\H-\N1<>(K\D*(EEN3Y:@!W 5[
MO['CAG)(H',0=PSNG'G^::K@Z 03O8G?\^S4,6)O5$2N$H^A3I,)3NH%\$,"
M"G#]L?/42ECG.W3E,=+WV=6G5H\)T:B5<#R++/3IM20"$PD&%!B) 2ARJ$7;
M:!_" P!P _+YYZJPX%@3(6[SN;7Y YX7@T CPG41!( LX5H'61A5*(ZM^[8O
M8!MVB&O..^,Y+D^W43V[D#ZFH6V0?"P0)9&;0")VB;NGQ9@B 4^5%!8\0R 1
MP  S]\>W&>BW7.0?\]JTV8!("0D;)HD<[ ?=($T/)A[H,8X*21#.0Z@"S-]>
M<,QZI$F?-=VR%WO6<!"<02%>+R#ON0:\;J5%)T^OAH<0 VE6FP, 24P#R00?
M]GDANY ZBYC.>4_CF>5:TDV1Q<;DD;G<LG"O)]+:X7^[5O\ H_\ J2EM^0X^
MY0&R2_'4J$:69TW-W_\ ["KE$]49:4Q$A9B0DIP2&"D1(T PUQTPS$5!(6%[
M4GRXCH1%*%.7OWTK0-^IQ?\ =N8RE>ZKAAXI/&IXXM-==]0;1L;2JJ2=&MVJ
MTR2TKMV5\*WB!UJEM9X<Q3).;5$1K=I['3IUIPBI5:)-TB:@UR1C1*) IL*=
MJB(4&)]Z+[^E_?E5CS.3G;J"_8KMI9=4JM<M6@UBNTM-$K50I4C.5>CHB_>$
MTZIQY6%$GI),P I$5$M,*BP0N$N)#44>F(6+*R2 422@.]KR&>F+N0/1;25L
MP3"(!(<E8*"R>"1G]6_5^GOW[^DGLQO"0$F#&>NS" QG>&CFFM^W'0[LNZP;
M,N"YK8W?N[<58MNE5*NT:(8J(L-=.JD_*S,26APHZ43*)<P9B$F=A2T[#$&:
ME8,1+NN@9J>+SST!4ICJ58("QJQUSPXZ'W.*;#N;2G3VO0:54J]59!%3M2E3
MRI6I7/455>O3:5S4O&1&76ZG$^_5I$U#C?MBH)@U">5%CP(*4-N7KUJLWD D
M%W0-I, ;A/F:R_+RPEH$*'"AHA)A@)API<IAP0?)4%AH<.'#5NC;E[D08225
M))AI6%=*$@[9PQ8P;XV._0^ TD*Q9\!(2R15*TP\S\H-1F"79/\ K/\ (.'/
M39JV*K#+-N@S;NN\[+3D:.?PX^#_ (9(:(2"']MIVGY8GWYZ"X5#8QO%WO(F
M8S 40:J"/PD$[F$-!.Z(HMC+LCD$X!YY&'Z5&RU!N6+%WYPX+B;1*,Y/8<^8
MK"1PK\K>K/(#]G#=*C3$B8$&=A!$'GY&##,C; B,DD H<B*H* ?E]I+NR6 )
M(+X+=4!E6YT\4%,D');)<1<75I2VIT,>F&KRU< #=$*AD-ZG#\\N.7R &ZR2
MM^P:YFJQ,@A+^Z_: 'R/D74GI9RX!'(4K:"7P2QVI))]60.,<=6@)>5#9@+J
M&\E%')56J=44>6@#*X@;^\)!4D!W#[20K('=V< /UQZ^%POB/V:^(=)TCQ :
M-7[K$,IQU'2N?AC7^XZ-!U@!ZOVDA;L67,@_6GF,DK(.\(<()\T.A3?Q,XP.
MX)+9RX!SI^&XG#U^(:SJT()\366+V.E;B]T*X?\ JM+\.K2 BB=6G3!/75B2
M3YO$L!$01HA4HQ$%'H:,M84ZDAW"68 8+>_+'KF-UGG>N;7Q.&>'I\/A;E:=
M(-CD$D@[6[ I9U)^[E92OTJ0=OF$ #>?9#]QS_K?F=/6M+<)\Q'?MM7CZM42
M#/,@M-%C#C%NE%EMRB<NE!;S2V00&8.#\NRN<%NLU23+&18Y3(Z>;MT78%)8
ME0'+IBJ<$8Y8!^Q!/';)Z5'8W:\WAZ1LS:>:K!^I.@MC:E5.3K5=EHTO4Y6)
M#2J/)J3NF82"61%*T)<D84SALC=@](]QUW\_2M/%CS1R +$;_BTY/MBU:59]
M%D+?HL%,K3*=#*84,1"E42*M3J7%(0 2L.Y');TN'Z>_?OZT<S<#',J'&U_M
M7HG(PI)"0"Y$12L .224@]F&0'+<\*RQS*+1*D-I!=5<3>XL5A&E1M)*HD0,
M(JS@(6%.Z0^. 2"[X]+BBQ[#U];6[XIXI#'/F$WC)YFQ!BBA^7*5)]0(&]3J
M4.!D.WT=V=B.I5<L F(]< 7%N]ZI0<%1]B?S$IP&XV@9;C'M@]*C'I_R&18G
MJ8>SZB[@)F 4I2'A+ X'&26? _7)Y /5P>H^Z^[[5;)W&DE^B,<]XE[DP$JP
MI(<NW(QD9+':_8OGV#AY4)E_MO<(G%B[AY&*8 %[@W#@'S%.Q=F]/N_N007?
M@JI3OJDF[%QB&2(0Z*HMI3, M_V;N8BF #C:P0S AW*@3RQ(Z>[?>]#>Q_W9
M@OEU/(#<Q4KD!P&(P 8A 8Y=U)/.,'C@L<=*I,@3VQC;(,[8E&FD*_U<%RK\
M4D#OD;23G !.7;VZ5& QG#73"\.Q$*\%U'D3$4 ,3!0220 ,L/S'L1WX['L;
M@=3]J&# _P!ME<,XN&U]1D3 9<A:?=6X^D\G^':W9R2&XR_4H3U+D!F;]P,B
MTF;0H"265N&%$NLAN"2?RD<AN'!)88)5/$K,[V[$H9CF$MW!#+S$9("L9RLL
M_OA)8YP"X['(!-P._OGCGV54!-Q#$R!CRZ1S9J51"@2S]RT56 #@A@>?;#.=
MS<]2@. QDR'XB;%AN,3R,50RZ64,.?6K@@=PG_)A\GI0E)OL6-Y8+488?1CR
MA_"( _[520#$5P%$C:0@$Y[ %_XCA^GORH_VV)AF5<GGE8".P=$D$NIB"&<I
M6HD,_92!AO<9'#GE48)SR#00!ECF$V=^D:BWG.D@IAE3B*ODIR'9D[LE)9_8
M!F2][U?$PI+CS60.8!VZIU+D_=T*+J9"2"8BLL.[)20W)=)YR<8IN>M(*8-I
M&9>\Q*1?*G(&' .0[F*IQCVVX=^X&> W4JDL$)YB8QA3@3%W8I$!\I1VG*27
M$184X&>$$)'(=@_L#TJ$B-\(N,.02"G[EL /!00D[MH<>8K<SDOZA],L"?\
M.FYY1Y=*C)W1>80G_C:5/0I1XS4Q1.G=\) 8BU:T747]1D8[/@'/)P&<!AT'
MV/T*JG^X(["]T2#?/=W3FK[:ZUFVK>Q_]24H>E.X8D8 #'>E\<X#''4J&Y_:
M3-T,1_Q/U\K5@74#Q4Z(Z>:^:6>&BX+KB#6K6>GURN6;9%-I<Y4YJ/1;6E(T
M[/5JKS,&']QH-/F$2D>FRLW49J$F;FDH@PT)<K%?OK<6SY"3SK6_6<.0095L
MG/-"N)MY^%S1[Q@^-CQ4Z9T7Q+RE=NBSIRX;DF_#_J5I?>&[2R_KPI5D6Q*:
MJV!5I6];;DKF1;5*M-)M*M2LA,IH-5FHRT3:X+RR9[]^E43,=07^+5]#ECT&
M+:UI6Y;<>KSE?BT&CR%*BUJHQC,3U4B2$K"E%SLS%6HB)&CF%YBRE@"6]1<E
M;W/?G64RT)\CDCGN"!)!)&:]9N2H@'G@\;B_<AAV[,".S]*A+6V3BY G:[<+
M$HH!C 22 "D@$,1QN/O@!E$92Q!Z499G)@F1(2"U7&T'L"7%R"'!;Y/JP%,_
MI1@*PX*5#)3Z6Z5+3;M+E,,$0X$)5&L%02[.20#Z0&V1&Y+N7=C@ CON=6A8
MV0=H^A,=)RG-8WTE!%H0,D 52L<E@!^T9A@"0003[<CIM0W*'V9@\D3).0@>
M1R'';9'&"\$E@';U</W'=V^O07'VOVH!!).%.!S S.[+Q3X.(4-*=Q_#1[*
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M'9RQSSRY Z4&(!=KE$/E8&TF&0\2$':1RQ<#@Y4?ALY8,0>_2LDL[H0W/6;
M,R>;4!B\@8+!9SR2T)0+Y/MD_P!#W5IAF<6-P6;+,P&\'EC?2=1%H0&P!4JP
M#@Y_TE,$-V/)<XQA^FWOWZU9!/,F8@0^B0$YP560HQ'E1F_^4IN^-^< GGI>
MH;'8!*0<+F0G!S$Q3X1/DP@P#PTA0.0  SD'+@.<$]NGOVJ:197@NS;C+ (
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M 20=!;!6F"IFXQ!3:YFIQ^#\3H\&GB>(G2M,,B+B1*Q^55YR89*22/*9#.S
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M7L2D !^"[]WP1W9_;K-:,\@@9LV8,I#('G9LB%(2H,4  $X=AN#%F)R6/<@
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M(7A@IB0"""1V=_3E"/0<IOWLK+,(52UI!@EA"^/(;AVB!8MXH_\ AP 1@JB
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M&Z/3T;^U7Q:L:8?OH;O;-C0R3$3,Q_[N<P$<Q4D9/U_FWZ]#8;>C_(=^P@5
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M@3N5N.E9!CC\*,7QY)&'?\WL,_U/U;JBXZBK"-S^T'TN">FW9NE@ ^3#!XV
M@$Y&."&#=C\^XZ&YZ]*6 "D@/<Q'T(S9>$@U."-R0S#D%CDMP20 "P=AEP>I
M0Q+'F2T84SU4&:@F63+Q@2"\,I#EG*GV?J5$CEB0.!U1<<B_*LR7(35[DK?T
M$)\J=!_(EV!,"&'#,%)"B0"0W"A]0<]#<]=EZ8Z5K */)LHP0MV8=]HM)M 2
MG<6(<X) Y<O@O\GJ5!)@X5ME(LI+6+["AIXA,)/<^;#(_* V\'EQ@?\ $\=4
M7NH/TM8^[30DIAIJ[2LP<DSC&YHI1#GN"V.78'V/;NW Y+<RJ23(.!#W?>1
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M.VP.HD!\D$ISESD.^&Q@0F(]_3>NOTOBZ1K&,N^^Q\IJ2-_@J<@G^%\_0 D
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M+X =6P>^!@CV!'//L55IC9 2[M;$2H9[":7<R3R[N2"R6!#LP<!RQ4P+NY#
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MZELSGDO XBEZOEE7^EI;FZO>#RKR0&[I"P'/]TW7%,W6=2@FRV1+.#>Q.I>
MXP.UDYL@I%,(:$&MG.D3>]ZUX9'"WC+V0-"LBAQ, \C>'JC?;&P[J-$L/$TP
M56KBVW1\YYJ9$QA2W@B&BP( U]/4.M!%T$>BGP] U?2L7MI!!@@,X?S8N+]_
M"80FZ;*[/.)7L3)F]7BQJ0.6'BBA3<P_OV,PB:)[$^[_'!>RK1\]ZW2S$\$B
M7Y)N1C(06CMVGSMR5\FK "^Q-AUH$I#.HGPBZK\D+H'A^"V[AMS(N*+H]M6J
M\8O=HSP"$N=;]C-FL8Q&GLY^BJE"8!CSL30[&7XNRA'J,M_U:[(:0O@!Y8SS
MN]DN>223F44S*AQF7*R%0B>$1G5-^*7N:D,I@L5#A<3N*@SU:>P0=\I/L'&)
M9VV^=:CIQ(=%M2K%RL-<> 6@%?]'?O'V(5>XH;^R"14V]]4=>B)WJ<1,&GL=
MZ)2@[-)I_'=N8W#5G''10$W2OZGWMJQ]5C:7=@+  94!6C6&<H.^<ZE6!9.:
MB6"RXGR0 'L_\\[D6G="FMQW,F1'':9T+B9(+CHTV)HE3*U()3P%W/1DB66J
M_.0/%M(V %PHR(5 &?.\=< OOWA HU_]*/)#8+\Y]%!-"U@D)X?K)IR^0T2_
M)9SC&+[S%\A'OY-K.RAC=O,7K\[V]IN?_[90,<0_:&1E8!""9.KV=]%1^,V0
MZ)TTDUL52SKX@5>=7P\QP+[&W-JE.E,T:WZ[I0H8>@9,!!&"=J=J:;6<@XFJ
ML0'())\7ITVU";@L'CM>[,62._+A\O^[HR8N<R=K+2>%/?O1SQ%C@MG"IV[T
MTL%,HL3>):#&,7_RD4ZX_],&'9/DSV=K.LF&#]_KWL%V=>L(W=T>(C-L%#$8
MLJ6OGIU:R1I$$XGA'>0J5ZUK6EDYM/) @6*(;WW,^D&(:I=^J/H#5;[!!R%X
M*[+DRL87CKL>ZC/!1! J5Q&[9=CCAPX!=0SHAUX[?\7'#KY%O/EN?G>X)$Y,
MU/V&(!>?CB)<D2))/-*U=565)_5\,5#*P,(?GC*VQ$(=ZO??F-9/$+,%DA=B
M][G^ ^NG_[1"I=A__T[3)?#K?<-KIU7W3@7G=R.)80:*I-F7.=OSJ_^*SO5#
M2S'OU<PQV;85SVX]$1&3(A?WQ,-3&PGV']*1:Q>MI,ULEFF*>8T. "K'+HYP
MP0';],;K>L^40OR%$<:-C?43Z 3W 7&(1[!WT(7:R1AU7WFFKN*OV;F^4JOR
M>IFD1+JW,!7C.L/ "W)CD1U]A%Q;KF"T#P4;WIRH1::8]6@:EX-RL',BWHC0
M-2E-&Z#K7.>X"(IKY_'%;Q7"^A<SJ0_:"=21S.B=Q]*@-J_;=JZR&ZM/-RY,
MHUN/0WZ.KX\WGUKG.:%K>^C7Q+Z^_%OPQ2>!.(>QS#XK?^E0Z.4Q1$I1@ENX
M&+%D/ND6&?C=:<R<"'MC<VY]<%MA)(9!OY/=(T-!G&G49>W\7O5)U\"OO_0,
MZ0E#R"62AVYL:R_JMN6'/TVVU^59,3E!PT.]1>7,5VFWFEAU3,*,0N?Q!EK4
M L3 [K^24?Z3Q6JK9Y_C:LU8V.EZR\PULPGK,?>Z3QC&6KNN?7MS@\5 R'S*
M+UE7BHFF^O!5SA14\V)L5Z"2.J1FJO7*)@K-GCE31AC 6X6D\AI,^'4,&  H
M0*/M2,/A3W2$_A-O ]"3&\849!5A_]+4;V7-5G'WYN*K12X!S4G*3X7M=_<W
MO(]I!]8K/'#&RH8[&M<?VJQ;\H!3Z W4]F5PD%!D<4W#S8^>!>6PAS;R:U94
M=(6]C:L2@VZ<:4#,C3;^"B;0=7F.1'1)9&F8-(5PT0 J3BF4#-9T35P_Z3(B
M5 XPN:&?O #9]4/L"(;0]1R_K77)6P2=: 9NT>3B,_U>>X(>KHZ/;7F2<=1
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M$1I^$9X20'5OX'7MC^^22U&?<8I<]LJFJQ:02\#R!8;.4>0U0_)?25C_STO
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MIO2(R9G+R%0TR% +N2 B/343^MF5!/;&(UIWU"_.QU/<:7VB&D/C9I,DUTR
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M=MMGWEF^;^-0RVTR[H$"HM"JZ&67:@%!A"8G7G]Y.%JU;@O@GZMKY3;[:"7
M\\W)F.@XUL,_[M;0RPKN5>%BFA<9] *\/X\K;5JG*DSPME)U+/S0-WZQH\.:
M1;N6#/I@IVBX8T6 $#6]D'M5NC@TD(?UN-4)DZ=C@*:K>_.C$RQHS5S"5"%X
MN-LTZ GI0NWDG.Z.P]\?4$^$,IBEQ1+,D42!;FF4-\Z9[EF.VX=A2N.>D0QO
M/NH..0RIH.#%4'(EKA5C(1#R\K-$ 0./0D.R],H,$\5(@(Z1B+H6@'X?%E?'
M6YR1H[CS\#;7Y'SG\:[6>7TGC]#;_TSH-:-,4'0OFFC,Y@5*^5=W"6@ZC8,V
M,4OY[(C8F#1$./>F@(P59LN$OUV2C0I.;R<MSJVE")4Q,RI9S\M/HM/*"?'H
MS; 6K_.<-,J?S.9L8(<Q9$R0.$A 7>5Z==5'[-4ZN8P1Z?XEAW)J0R-#9-Q)
MRAF]%K WG^/7^T"4[94+KB.M^%WRX./^V:RJ/XOY%FY?_42^& W5H![1TS:H
M;E3GMG(R9A;+J20PGT3LQ<BMAO'2/._K6]D[I.%EZU V&#NZ-]DNMWY;HR_*
MEF$Y+$9=BO$N5.M+K6D"3F.AZA%Y_?E!WJV7-HN5A@-/[IN\"4[A4XTG\:G*
M,-:ZO6_6%?5L?P1@K#;(/.^=\2<O("M#GS^L8EOC!:_]OA: *GGHUZ"U0,ZO
M6?HKE8N]D.N[2.M03DO?^?SB=A&J\.CNU*UN19Q>Q+F^B')D%".FI-:H!3>L
MDH&2MBD>(Z;N@-XV5O-#7B^%RTRN?E>K;&>Q=V639))WFKKVMDWHD\/:=NW#
MC[87\14-L=V\@;BQC(2ESO ->P5IVOS,<+)W5@0%-G!UBLJ%W.JWD,!;1&\<
M7,O;6H&$?5.)>Q#;O/'H$I#GHFN%3<H-&T[4=P?%3I;?"A?'#8KNSX13&]M4
MN !4)))OE$KDN<QWBG\V<7A3[YWMPI41]]I.X>NF/R?G_*;TGE"FUO9@'@CV
M3FZBM_O$V'P2#8K>BS%N5+VQ\BQW'S(STZS0LM)+%@Z:3)"Q@XMZ;5B%VQ68
M&$U/C_4?V%&HB^W.,-#]JZYBSN0,B;0,;K3V/M3Y$TQ<O_LU^O9OIXC%4H<'
M54-6O5]L6*^*[M2(^Q3*WRY=[XVEC' *<G5%4;]%4GF/[Y[UHV?KWU;\[?C-
M6A&ALX*),1WZ?#J'B5+<_"(XTOI+]LO5CGKO,0<%^6?3RM42#_(<']@(KDQY
MEFXJ[/PN,[Y9"B^N_%!LM:FG)5W*D1]X>%I_'5E+L'M_X\?]!XVO*[6>Z8I0
M3(Q?8]'!5;=];(UTU\EY)*RKC<B2,.;\Q%CJXZA7P[8P@OVPO?YY/I(%D@G6
M#+5QXNR4LONE)V8U^[KX\R;"HL7HIM6]>SD6^-9[C)^M\K1$C2996[=1Z-1R
ML H"R(P;L-Q(J;TMZF,I%X-EW) ]\!EFEOO(3"DCP\*T5F^1B"LK 40A&;'$
M0'U99;O$LPB-#ML J=+[S)"AZU//S>*4@.X$*(8#,N6*X H$N1=V9VT7M/Y\
M)NQ$4 H>:+:_8PHPTOUPU!:'C8KFWNR&R+3"/J\1MN?@2PF[.UO=2=LM;SIG
MJGE/$/$C%(M_!00F]U5'YR&27?V*&,TS62H5ZV9QB#"A()*@@B68!6RHYWX?
M?C6+3?+=29&_XL?Z1C). 620^$Y:$E<"58>PX$P_S7,=FW>O5[J?G'(&5GG.
M:XNSS+7Z^'B,:AXV6<.VUXJ]/2,<XS** F^5J5\4AK*/V:*)'_%ME=*(GV-C
M%&IR@)9Q'T;K,6Z-FGX3H"=E$(#-\0P-]PN5(_U27>3M3W?10PSWG.\^[_P-
M5[3": B[T_XS,*,8J.>5M&NQX.VJ^?<U&:&JZ_M. ?*WLM+/&6N;6X9@A] N
M=RBZ+'E>O ]<4!4Z8PR=WK^>W1!"Q79?#A%/UP=3N0Z,5%%5#.E<7!%O>$$+
MHBAT&O"/J4$V(/W2Y]7;3\PO?H#1KV_9+RKH_[UF_RSGX>_Z>FJXL,"\["TN
MMG&=?>[BJ@K/"NMX$#8)R6[X;',K1SET<4F(#R6*AOSU4(Z)Y3\YY4DZW^$*
M/+U]:@65'M9&$N@E#9^4J 1=O78H:-R'#"?,+&>F!14YGQS$?B\[/CO:'KW=
M-%O,YN(0TIK02/FGK,Q4*[J,+W:618.6H,4O>8.[HV%@*?U;UAMM1WD^38FX
MD6 /KSS!-9+H =P;H-*M0BL)X 8A@89K!47Q3 'VM+F*&0I&!U/J@Q\#O$IS
M)\U8?=\HY.KZ\S@,F3_\@S4@)ZHAW 59_ M??9U^\+P6V2Q47<<TY?!-[ZKT
MF#%N,3"SQ&D8/A)7X%&'AOF7<C-US?M>9&"N>OG%@H<I28^\\3,&U:VH3+ZJ
M"%-FJH*]\1M*/5'26U0G0;"-&\EHJM\0R3V*Y[*AS-K/?O)Y 5;68%>)25=A
MYJ&S"E1Z*_E@0H_'*:1%MNWDX[.VV9Z['ESR6.&N#I*BC#5!2_V6>YU+\4<V
M;(]$41%S2^>M/U4?$"X+[ 6W5U9F3/CU?2!LJ5::T&MR66CA>A"R32*!8J;C
M'U_>\>[\U9?,M!\L&="-/RB>4'JOC4X^9*\NQ6-0'B4[W:03Z!IZM6X3A\%X
M.!W-.!=\S)&$T"9%Q@JZ#3D9/K=4  (XU3X07KB<2:]S3YP\8)H;CNQ7FD*S
M2U6YA#7".-<Z-LJ\ ,7'Y:TA^\7J)X;C:KDA$I]X&URW[WWY#7?C_O95^<F@
M?*F%'# F]OOK\R:%9>94LC3:=0[0T+L7OFBR5?_+Y^4XI', B*<??<[45M8[
MBB#U>X,FLF]@A[ Y(8'.G<[LG=RWKA9)H/A,QGZ@*R&_OOID70?9+WZ_!(2S
M_2BU:%\2Y?HYT;W>KN'PN8?^A2!*<@:S.LY$K,<C#P$E0]B43 )/7%O"%>=9
M<8[U"T.'.^H+5-)\L .I5UO8FSP>]#EUFD^^DE(M'D;FS,+RWGR!A9[09@RJ
MQ@UPJZ)7<[K&JDC(^FFF>#6)QL3KSA$Y0XLZK4ADW%[8A7L:*?B&O\@_BQPA
M9!FMB$B2SOB:.3'#_'T.4PK5;_"-;,<KDHI1G9"N3F6^\)DEAHJ./A# _U6O
MFV#D7_BV[.( $-'LY:?H3LSR4*?B%Y?N294[O#%&DSI;K<*I\:<PQ6O9#Q&X
M<0F$XUD:?_P+44>)3:H-"2N"4MAX*28L8E1KZ/2\.[5[D^+&/U]3A5>)Q@-I
M-&A6[L=>L]F2B*T3AK0^TN;S'S9;I]=5-0/-SLO69>U^CCVJ7O&C!#U^+2N/
M6.>8<.L;X':&)W64>W?85EH\TP4S.CXJ_A;@T+$29+1^'?,M.U8[+SZO6?+>
M;N#^;_QR=ZHA5) /!Q<5G[$0CVX[>E,<]>:BY5$52+BNV/K42*K]%[?9> S$
MMO],^G,%HH2EGLA@I2F4%99.$R'C_%GW:^T5U=X:H7M4CZ3H36^-)E/?=K"K
MOIO$@L"X956;]+*1A.*^Q12>R+^)7=G\5@6K8>$#89L2[P6]83[<'7X01=GA
MD.30FF+X^5073 ,%I,#GC8TY6_,"&V,_$04I-JN42$,C+2?9NYK5)) Q-12_
M6*+)P1U9TQ65"!RXGPG=GA@X?^]&\[")T;BS4.DNK1"(XXW%/1V+MQ(?"N-C
MNLL]\']?C.!IZ/L&6GW7JS<<@RZ!''^&Q7L?B7UV]'+_=I!RJZGG9G4;]MG[
MHV4DJ,/*_&N_E8R@'&-&%7F#55A7;3KQ_)UUIN$5S:>1_/?$!M>:E>816"HL
M;R> E8VAOV$T*MX>89>-$VA*'GWW(6^B_.N/AKFZ5V+/_S25*SGTL:VWU'X]
M._-Q\EELV]YH&IOTF7H7+VW2=)8YK=LK:&AB<"<IJ\W%ND,^L4$7GB^KU'\N
MQJB[YU_YW/2>\EV>TG"SN5 )Y1_)P4E?3EJSJ(\^!WW9:!X:651=@J?6#NN_
M,<W(*[->$'NZSYCD@J(":?L-MIJQ:\1L]SD*G/'?K9^4P$SFC7[Y'&QXSZE;
M+M#'J<>INB9DZYT?54/(F*A1C%?5$%6<::G](;7)2RI71M<AS-*'6=-URP=S
M]'O2TYV+#YJ%\>E\U"R/^N)94#B,40X(^S6^)S7KXHYAO"7=7>1[782^<^W:
MUGYZLPG<A='QNGIN=R=?G<0SYS;?85T'Z->\!3F?S&IK-YW\RI$A#N') [E/
MJR.OP2:ZF2!*/AUY]C\K<FL^/N!0M/1GI]LKHN?F4\-;' :?LBIL)^/9F=Q$
MI,O)*_JVF1F, M+Q;ED[L]W=EJL%AR6:C @]@GWSU.&17>5DLU&SFEE&46+%
ME7GA(&)=)521&'@GG<Y"_TCPFH >CT.W*J DJ7*XO;MPSHWAF:@&ENJ?/?I4
M8+%J\:NWY8]]%*TB[X.G2TLJ^C'&J6>A&SHJS/=^<!F83SYBOO? V_I7\+O@
M;7W!#&>+Y2$CR3N:B0(B"'&#ZF1J+A0=U6.KYAC1(;H3S//=S[L[>GI70L4O
M?GD$YWN,"\]$&[_2C\]-FLQ?IA*)-U??$&1!M HG$;2>/*EY7'*CU7*U))QF
MH8\Q\ZVD9+ZM0#\DEE5FRF?&+;CF:"C4\7VNOQ^_9Y*?>N[&3'AT<HT2HYGL
MO^<!3[ZI?"FJKVGVB7H/3_IG_% _OGHF3 M!#*RW8FO>UEYY,8;6,4K)HF7X
M7*$]PMM2.!RM34H[J<V=<MA0&7]VN\9\T>JIA-![O]ER!*U+-B"#[%S^<MA2
MKJ$APAJ*WN"G-U<]P<-R=(2G'J]KS'CN.8(N >NG#$,<!^?GEX!.SJ85:'Y6
M<L12[*Y.?@.;2J+UO>!WCO:M>195,LGI0G#AK*<93]A%O7Q8VN/Y1&QZ^?BR
MF$PP"/B X7&Q]P-KFC@J1K@*9V/C+1-6V_)-B?LJ1M?>'B"SM/W;A\/G7"HX
MK;126D8>5+>O<L_LGEEQWW^*BZV_P[A.Z!">BO@5T?3Z1*U13(!(-73F\EV[
MY]]A&>W2?)F?EH$7SX[[/4]G&['@OYCZ*^4Y6Q_<S8:&K\%%A!\;5;IMF5C'
M]ZFX]HC;O(2F%@279#JE_R;0CGWGV_SQ1.\UD'YNL_CHKG;L@H30C_MB+M^?
M-...&"-AW*+YE12D9QR&M!))"\]-+S[=*Z\0,O8WSV(D5A$G73G,0S'\?M!4
M8/1L^9\5DS17@\F.N5.@WJM[>C=L[LD&92:[EK^+Y=QM#%A;UHOC%VX+ T/+
MP_H"LOF(2?=,!%#4$FT^1L[(X*WS(U93-'B5@>;98-SDZY$IA[D*YQFG7YO\
M02.&!'87ME2[KA:8FMKI\5F22GP2,FM\=186=/-JHOTM2$5HKJ%O+J(TDZ&\
M>&"Y1Y'BG>4ET,L![3RE+U?W>UE_9-,L9??B<UK&]Y$4&6H?J7QJ(PSZ'3M3
M<X ))C-C.%!=']A<^E,=K)7:X+0L?<P\"@FR[=KF:6L;S_H.-]>X&$-K2?2$
M3P^H7P(O,#6F-PLK:/:[)/8-:ZZF.U%+5(221C*.[?D&_AIIIH]4"\2%Q#B_
MZ HMLPAI.!OV.>[ ^[QTMZ[E;6$VN!CVOP14_GB(I+^_&I6+!_,+9XI*Y3>&
M^U:<J*HP'N_RKI0AYZEPLG7_=#)RFYT?-D5L!)UG+ZX71'_5I#?P_UW<SGS(
M7V'XWLY8^1EH6;CMUOS5U$V!!Z:SEN%[FAJA6=CI2V#]CYIHHW=%83/75O>V
M376T]4O1:O.G^IG.=U-$). Q/N45>#8KV4SQOEFKZ%AULH(0Q\:N[S]KI <N
M=/!9;JI[X>;O\^??DAYNO?W;/7%LS]@][CP^KM86<+AAX13>X.%JI-L6N:A=
M>..-'+=8)W"(IWV9'$70V-Z3Y3J/L/IIB)V=G1_M7<JK^_S JUE#S?ZI/O'[
MWC>#_$2J_G2SS)Q'W#0O*K3,;?A 3!2>A@+HAA076HZG@]'.J^--;\7CI+!4
M;$E/:OY>YWL/NP3T0MN&'_Z]BP"YV*?Z@N9XUKHWS*CDY#L6UJHW[DG7)#RW
M+1S/=N98BOYJ/!4VQ%3,W7I1**JI,B211.GZ/K1ML%:"UT:,U= N0V226ROG
M$;V?:N?0D)*B1PV+M8Z5%8AUF$6?+(;/HG\3I.=&7Y@ R><+?)XM>G)>;JL%
M.Q7O&';$33:(0CW\@C@&0U#SJ^O5UL(^M-/# C14L%_CSY.K65O-5W1M<KX;
M:\;QB'X4*!^R4KR+UNGU+2R!)J#7N[1D++2%V'%2Z*#L]Z4IG@S6M=>5@PO(
M:NC.$D'W0+:D!@SA*^/3GXM9>M0 CI/#;2DCSU!(YB[3Y,B@.6BP:RDU6_96
M?[=30KE-#ZC"EF1PO\1H",M[";R%1M/KRTSY730A_0#Y"=7E)=0Z,+%I[6=S
MV^W.AO5O#NFE@=0J<P_R-U;]VTP8RY;Q(XD;^[C L-6KG\OOX349-8+Q%W,#
M/N3)YE?B()=>PP9IUN-\A[**S6B?B$*1:X6"74A!+QLN2VKQS#Q^Y"OD]N,X
MWLF6:!( G^#8]%G>6.YB>+1=3EDW'MUL:_.T^X9I?543/JE5BZB7R^WS.>2V
M+7?@US<?UZ[U[\?RO-&MM:Q8,:DTY7K'K_\T%Y["(9ST'&_G4D6 _>8I*?[1
M8#AE^CS:Z"S9XO-(L]<_*$>R,O=5C+*1^PB&++ JX"J"<=?*>D0O:F!D</A*
ME%X)='IXS-K_H$QG_#][_+'YE2T^Q\)"U16U)[\JE9IQ;F:DA)K>E(G*MTLA
M9[_R\=%$)XJS&)+IS6!/NFJ]OZN)XF_%/7)#<IABW=F!"D_L&%%3*>024'U8
M_*W" _>QD7LV469B+,N@^_?0!9O+SD#[V6G(ADZ0I[MT*5W"!$6^0R:7QCXZ
M@2Z;9[M@B4W]7!C9O3F=$ZA4QW$W7]A6'$Y2+;)N[?PX[]H-6Z+/TC*IEW)!
M.AEZI"VU]XEXPL[&"$MM@X&<+8U1:0NB9-JT<1>1M[2[.3<'8?P2"8%$L@<]
M3!4\,]'PXK1QGDBE6"R"8B<*IL/N<>W+7JP?#BF1#\ML:*6EFF.?2HKC=HW(
M]0LCY:L0)1BJ/D<UX'L%NXI>'3_!(ZE7A ^"(;'2O5PL8_=4#/T3$L+='ER1
MFXND'6J P7&<\QXRQXR@LVYDQG LM(Y74R>MVQL78=&CE4/(VT4[<F91+D?/
M)TC:19;+V)*$#NDF:W"],I&+,JXHEIDF:AM0K%_/S/=S<_H;J,:>XPWS6%2R
M]U"W[VWRL\+J]KAZ.U3L6MI'XP(R#AL)5IOY$G*+N/*;@I%C)[SL[B@QFUQL
M ?RACRG^.V$4CW9LE(J42W*^RU=-A]?DF(4IBO>H$@(68FEO59CK)#CK]N)#
M[GVLVP#H-5$F@$L@AZ:,QC%^P(]APF@<,DLQ6G]OL%?AO!M@82F@$/A@9$8_
MA*;DJA_\T^W-7P%"%J5'&;9MSVH*?UTRA!(H 7H9DE)_V(34]F35]V^7 'ID
M>-0N*7-N0U*;*+\4^QNG4O^P^$2TK(A=X,C_O,P!&?M39,C<34V<6YRH!,%'
M,@]L3%9\]D".#=2+/S/A?/QBV&H8,@6.C.*=JDYTF^8*+J]2*,@8 PMMTGAM
MLV@KB6LK<+W]R,6C$0\I]@LHRLQ>6'()ZD;HDV=7JKCP!N@K/3+^8SM;!B&K
M&Y/YO/-6'$P!;+-_9']4][C3&TQ$+8$OOIL$UV0,II'D^W"=4@E$-A12;.H%
M &8GKW+0S^]= I^TT]$<\_?9X)!W@+4?M&X9B5!"UX=RU2E&'4-:-[0')>G:
MA-XO-T("?"*KE%0T#006"I]UQDTZAC!,/O?;6KDZ2,^H;^?UMYP=A"17X4^$
M^(-BTLP&-W3<S.8Y'M7]#R% WK^"&238W A$G"@&+ N2&+NS.!G+CMD?ITHD
MM\(]D 3_ +0F[AO<*S.Z2?D' X<\-C+Y;]>E&X;$8A;(F90=P[BF@I<G!]RX
M!(['G)Y=G'T;I5[X(5PIL#<B.UFZ5W4S.-A;D@OG@?[+L _/MTH+0 6>=L&1
M@Y4K)JE/M< NLD9QABY;Y9_C'ZJF]A"^S*;F!T.72$C>P)!"4L"X.=P./DOV
MR4D#\I'2B04&Y-KVZ>@&D7!JB4N0E20' *GX+@,<ME3]N>E,NXA$.>IDWB[P
M 6:<')?NG!8$$]P",C'_ !Z5))&Q:2-@CM?E$NFE6&=."022'#\ACCOWX)'T
MZ567D'&F6F^34P'$0G2$^Y&,G ( !'J;@?+EN_9^E"I %VIS. RDX5V"'9SD
M$)=+E3 'A@EB,9<@@L1P2>,]*,Q8=5$00D%=7W#L'. E(*@GEB6=09W'L #E
ML <GI0"]L,J\ I(+R+:38I')W!MKE^Q!#G.,G@$_'##I5N69&!8AVO&5? N1
M3=P3AR3WQW&00/;ZC^O"H "4H'LL@0=\F)R6JCPD18<-<:&F+%"O*AJ6A*U[
M02LH2X4K:'4I@6 <MD]*%8:0(DE\DS!Z7J1)#N')_P W?CL  ,D/DD'I2&.8
MPKM,3$J2,)N*3S%?PH) X(!+_J QSWZ5L6#OGKFG;@%%U!^&R& =0+'!.<-C
M#N<#I6#+#DG:  ?".O+#V3J@5)#." #@ @D>^!@._J;U<CI0F)"19R&DKST8
M0"Q5 9*F(?+L&#<OP_P<D_5ATJ";ZD?41N3!LP.@_P!U(Z4DD $ES@@<LS.,
M%RS=G[OTK1CR-P3")(O?FY[4TJ2$C+J[ %@#R03\.Y/P..E1-#%WF_,GFX">
MY\)D(< CU$^[I& 1^F'8ME1!?CI4E 24R(&9!!NV0Q/>U-)#-EP0027!=1 +
M.D*<!VX8X)[JH$ZH/2,AD1)E)6^MNJ<U DI6;G(\3RD2DI,3,18R4HE8"XT1
M8 [0QO4O(_ITJZ=.9#Q+'T%]P0NM<[->?M -.K"M2A3FG,*IZC3MZ6Q4:U;\
M]9R[<B_LV!&J*[<E9V7H]>N*W(EU5&'6PN&;;HDQ,5A<*3FYF)*P9>&8O4)7
M^?I6E+VL%81;WE5DKP%W]>UYZ)2LEJ5,5^LWW;U2FX%>O2HPH46A7TFIS<W/
MR-P6E4I*#"I<:CIEWI,6FRRXDY09VG3%-J*HD5$.;FK4+8S/L 7:R2KDJMQ:
MK&@2TNJ8F)E$G*P(,S$CQXF/(@B!$$28!*C"5#ED$QHPCH7#3"0N*65#PJ!B
M;YAS?M)(,<TP *XD^+'[1Z'4XE@T/PXZA0K&D:K4ZQ+7-JG>EO3-O6K:T].P
MH$YI-<U<FK]DJ' AZ(WQ-R=ZB>U*I2JG3ZFFQYZS*!Y=<N&E+BQ3?;*&1]_I
M6E%EF.48)Q',<BJZK^&W4"OZJZ,6%?UST:;H==N*AP)J>EIR2C4Z'/+A1(LM
M"KTA3YF/&G:?1KD@0$5RD4^?(J$I3I^71.I$QN2-%W/^?SUSVK)NL!.YO/-
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MV1@U>?D[$N^VZ=#-3HM1GJ3#16+/EXJU0KZFZ36+8HRT5PB$H4'L/?O?E6U
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M,TRUK8EZO/RJZY<\_+1X=&I*IZ/+R\]&4FFSSIS[/)$7MOVK0E^?.]IP""!
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M/;YU#;5AG.['D+*Q D.KQ,'9"4H;5 !F4X"DJ;S-I2"RB@_A@!BIDCGJ5&V
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MA00G9+PX0 3#2D#:D)2-J0 &#!@.E0Y%BBIQ !/-_?N65;DJ&0Z2"[I?!_B
M=)#?F<L2"".E21L[9N%S@&-1  @%@UAR>T6TWJNHD#5&>MF6C7M!H,W:T>JK
MA0U&IT:<CR$TJ5J<J1Y%81*S,G"5*S4_#BQ9942*J"M!6H*>_?O'G2?5%\LX
M/*\3<5F9@3NP&#N&9\$Y_,QVC<,< E\=*P%.80,Q8-=WY 6*0 $D[79V]CZN
M1SW?)R0,]^E"$1.G,B.CQC%C-TV[$$J.SD[N.7 #EP3^7&<>P9NE)":MG=);
M* #?=C%FJE*E*Q(S=+J,M#FI"H2LY*34K, Q($U*ST)4O-RD9(_*E<)13@@
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M%R!(^BFX1AL32D$DGD !@,$8(8'X=G[DCOTJ1:#-A8@J2%)AP]K512DL6((
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M H,C>#;RN<BG!SP2&<;2SCA\M@DENE:RB4R20&=H@Y ))(S(#I"SEPW=N^
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M=TK3*^N'6:O2Y>4EYNIP?OD"&@Q8FXO?+<^B^V3?<%1(@*U]U>8L5O(6( 8
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M!8Q#!\(!L_+=C\(4 X3QER[NV./^'UPW2G4,8E)-#?"+L0S:*[D'&X;L\-W
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MMPTVD0[>NO5OP]US6",FW_VK596>A2$C:EX1).T(4")49&0@QJW)I#G])O\
MGE=4) C.![Z=JRQJ)H=X[;=MK465D/#%J9<-;U^\ >F^D% ING%9A1Z!IGJ=
M::X'[<D;BF;CO#]HTJ)&AH4I469J=6J\4I1+0)N8AI"52>9\OP$\N&4#2.5_
M7\Q7EK]\$?CBJ7B/LZH52T-6HJ9RU?#/_9MJ':%LTNZXFE*;(HE%D[[HDY=L
MUK;IQ(6 F!48$]^UY"-:58B7#+Q8BX\:?P"F,[]/3*%JM=]OM(-,+[UA\ OB
M6TTT[H=2OG4&\M'[CH%OT.F)E9>=KE>G:1%E8$I([IA4L8\S-)2B)_I":3#B
M[1#5$9(-QDGIYDKSLN@FLL@I1N^BYMQCO7%GQZZ?:G6SK%X-M&=);GBTF]_'
M/X?K%\%/B'M"E7#,)N/3ZT*1-V5=:-6)&W(/G1($"A6=3-8;?K-4A(E9Z/-3
MTO*2LRI:VZ&ZL\/8BZF"+>8,50ENMA]/-">58"U:T#O*_P#Q9>/_ $HT+T!U
M6O/5.V]?O!_;7AXUTM&[IN3L/PR*M'3#1JLWE-W JM75385 E9ZU:9-+J111
MZI,7*LBDP8<PHPY=97".;'N3&+[4&&0+,UG303P8>.&@?:+0KXU'I^J$K.4_
MQ&ZG7[4M:Z5:DO/6/<^D-9A5(6U;]1U+J.L9C3U(F($]+25.TRD=)4+M^/+J
MJ:9N!!@':]XGWVIBV._2/L:^K1AP4G:Y)'N?@-MS[)(/?/2L0@=N; #,.\]U
ML :0I;@ 9< )R P+ 7H'A?@KGGY'PXZ53$8%@4I)YM*.5T<*/2&4  KYS\N^
M& S@N,L/963(NE*21 ,E9*R8YQ3  DOEL)!#ON4&/=3X#CD,S.X)522P_(P@
M2QRVF2""["G$$%G2 "3N4,GELD *+'W !4PXZ48VN&A9*T'>#!!3(V7W!+G!
M.2Q8<Y21D99R"7#X/2HKEH!P1*+8O@F!SZ-.3R6_U2S#VRZ07[##>W'2B.H/
M -V8GGLV2[*8-*#ZE OV#.>/=G)=W9OG+9Z52%: CF3(<]A:2TKI2G! # D$
M);@^Y8Y'=AG&'R.E#)-]B)4&,%,,@KF)!I#A("F(<N3D A3L2SLHCEF^""!T
MHYBP,\A(Z#<C</=*R@00&[-@@  !W8J*BP8L<8(!Z4@L93!#)ES$9# @_1CX
M!!!(YW<LV-H<@<\OV.6Z4D&(!0L"02MT5:3N(+=*E/#A3#D$!+D]\*_F,E_T
MZ5("B3N3 V#5DIZ2"0*8ABS\AF=AP6(<MW8,7'UZ5;-+E(N.4 69)$(JX5!+
M ;2EV.5 AV)#,<@ 8=R^<=^E"1E&1D%69]"8W#&R;TG(?+<H?M[GG_PV.E80
MW/E_-0QU*$5 !(!#D D!QO8M[X&><#I6S_;K_P#;[C\FJ+N7)/I!R2<D1'Y^
MG^?N75D$CP_^Q'T_/M"DA*4RLG"@&?#$L<<?JS_/2J;Z?_1^A_'MFJBJ4E!(
M4H'U<*4!@L&#L,?&>_2J#.D=?_X@_<_2U(DE* 0I3XR5$\J0_)/N?IVZ5=0_
M:3EG_P#E[ZQL*<"01DL4H<'(+Q(SN"X/ZCZ=*XS8=2.T146]8B@!:F\I*FW'
M\R@E2CSW42?C@,,=*WJC3&Y'8$QZ#O.31,0,"0X*DARY<Y^O_EVZ5EKQ<M0
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M_T*O7>&87ET'@:$NHI90B .%J9.3O8VYZ;47N[NCQ1]KKM.O$KE"*&P<3*W
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M->E.<)G%H% FE]U9WY:;QZ"^AXP.NMAW5*VO_]845FVU8'?,^PFUYND(DC,
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M@9PX9Z)=ZOE1K<X;.**3.PU57CWC/ .0VE>[W@)%(YOJ&J^^A^>WFK2.=_'
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M2P!6:33A1BQ"%X\_1+U@S_M,NTT5))0]Y5D935KGN)X1,VG!I0('>$S>W?&
MEN65^7*(56X<#SENN1Q5=H$C@H$(L]X4]@X7[;*-.3JG80W""H:F=A(_3#MB
M(7%8S#-@&TW9P@<!*88>6@::1P=,3A)H;2,>?KN6W>M*9;!CU8F<FWT<=9TC
MN=7841^F,X551F$$EDGZ^O#5>$="(R6_: ?8=Y_"4\51T;#)[G&4INYTRFJS
M'WM55W#J=L2N10XP]"K$!,BM%1"T[K&'0U,O 2@(.*DB&\MP!YB#J8/A9D,E
MGN5#A2TE.&A]'1,^!83LINT06@Q1(XRD3UK[>.,T8Y):8.4YA _QAK6J.O+F
M'6%A=(GTLB716'CK'<R6)/=S0E(B57#!VPF"%C4J8GR#<0JRFF<E[^*[I9"[
M$:TH>J27>O.=@3::_6=O:6BIVF+NYGJZFHRLZBUQ68!6?;HQ!]L?4EP"E"Z^
M5F<N1;\ALE>AL7'(34L>+"/)2A8(,3= S8UM(%KET2B.-NYE3#EKT6:%9S@J
MP.+5?ZN2"J5$TZ^A2YK'QW:BH9Y7#U. 7^5*#N:?PTX\J1]/)SB)71PA3)1U
M<.@.KS/",Q?Q?#1J;32M&B! W_>= 3:FK2W9:9E3+U,8)/WV=:]W0WG-*Q>-
M="#S1 ':A +_TD(J?)'KI&*\,M>RHEI\5\ER)S5CMU6JN+PL+==#I=1("0FJ
M?21XT:15^?PE<@TTE6)+DJ-M%J)BW=$!TH,DD9;(SVHK,*;.KSWM(^G>'F A
MP#WG4GQPB!WRUMPGVWRJ:-Q=\I"OC7-I,8:O2?==ZG (>?-Q)4GSC.]#\ "7
MP$OGO#M6) *#[#@[M/ (""_Z!HP2-5*X]+H>'+V(<;D$%':A!SSC+9/?OD]$
M]+2XY[21)$5NRV<@-73X&4<#6D^-&RPU/,QA=;M*-]HKS)P'%MMR.#A:CXV[
M[V<#=YV+,^_YVPM/RLLJ@M&J&580WK)U15&C"9:33GY/-,/C&='XS(HLI1Z(
MJJ#5"_^(00JIJ8Y^Q <>)3]S2'\S[;ZN[5Q?.F?Y!!&S&\&=>&YI,B=+HI#F
MP+LDS]VV_?J7=+S:PI:TFYIU:;]6I[8.T"ZL:'I0HW/J$VCU[6597 +LN+CP
M9W'0G-@Y%I:'U(Y]*AAM%.ZFMO7%&P8FCS7I"W+.%EI6X9B8\XRDQY*73,NB
M'QW2&Z^A]YV9]:#,GV]4%J[K2<%\X5_CKVRTPF>^$WP!;5#?-*9E!D=9?!0T
M9IE+-1JF'4BF1XEJ&,L%LY!ST9:\3RXAZ& 9D-X+@6(FLE(]&!5(!(&L#V%+
MNQAUQT>IE1,"L93LFBM02?NM>^DZ5_,_^O@!&^8H245<EO+=:,9D>1:!VRZA
MK(5,5"VB:9&]/#X<BY@6_9WT""J[^BO]_!'^)1%(?61KKD_&%[6=3##C@U0(
M;!$0&.D<((E5FE6H>@-&@OWKE*%W#.*$(/93&T((P:^ZZ3JXV;X6H2D0XQ9S
ME:;YBYH71-,</LOLG]^)+MOTT30V-*O53V*>HS5[GR)RU'$_N5(J!(E!4IQE
M:UM[84#A+0[[O+H(U09.8KQ\P=H#HB.*:GW!G'6#$-X^H<&*QO+3 91A7,1X
M>VI9Q[1AQ6;>'B=FRHB.=?,@QBJ5*OC'DIUI&N0D]B9TQ3J60!]2T,,W"EW9
M[J:INN&58P\CZF&0% 94M&FJ2'><F2:7 :98(C@2A%&C>0J,_=HPC-0K+PNS
MJ.7K-OP+!?>5DX\YQ=32YGD><QI\^ZS&EOCI\0K:*]BU^D]XK\HS2^?S.MTE
MP K*UD785'JX[^,)>J@(CBW+S'V)%1-B"&8VX3A7^CB%WH,L2;)@].0'DP3"
M,5* FNX>[96T"_[,3!+Z^=2-[^X.[08]3OY*ND^W[67Y7.U%P;L)%83JG;F:
MMB'M ]A+P,>M73X:=?5R_Z*Q"519?O^E+4G1WDN ;6DX.7ZZQ9J/:4J%/S$;
MG;: [NLJ4E!^W_TGV>>S?6IYH-1B$!]!? Q 0607B-*!^0+E7B#K1B*O80>Z
MG6VG'=-)N@U/K_56A?);3;+*%U3JM9 -02M(G!WN0O^<!=[A>_/W@5K<HNJ5
MLN3PKZ+7,Y6/I5>YDQX@DF,"D3I(%"X!VH8-8?=SDR\!>8KQ"G<OL.^^MDUV
M^CSP@8?+Y_ B7#*>]K%B"6Z\W+F&G[1%S4G^"8W%7BS=:&V$<ZOJ:5C^V#03
M/49RA1*/[>!J!-^4S?NWW-F-,K;*)"!1'A>"917^52>^-0^(6(#!O<P1_!H]
M&3PV)5F#N[D]MG9EC.^BR^PMM:9"D>=PNWK&Y,<P6784QYI+O:D_D(Q F:A@
MVU6[Q3[7R1B$=:_B CCJ6'E"L9)8_8G/3C 7V(>!+>8O:]Z]:<SJ@9YIUVZM
M$KID*'K=#V@A$GCG#20EGMSJZ#5>RXXPX5](U=;FJ?3?HBQ3'@\RN]\BID*6
M7JIA9OQA;#'%*V=6_!3(K% I^/\$APUX\LF0#QV![Y8&>]XPP"5L1MH:K$=[
M ,<D[W)$U.0TKR#?8"I_&D2C\6)JUOQ8<V#UCW:VK])ZJR2+46.'CD9+LXW.
M]U 5A0_WDA8EK9UIU^>,6L'L15\15P T,=9//VID\&*UCG)!QU+@$,1=O8UA
M=ZVIX\+_ %'K&;#\(P^TM:2\L<9I#+?&WGR4-C/6BO*J7V@S1+!X,JQ>4#BQ
M6-@G5O\ MQHC5^.90>H&_P"D4R75VNIYBIYL)QJ28V_@RHR1]0&KB<C&"2N'
MN9E6+]]A""B"QD+^]L*(Q%\4ZXU?KK[P:W#=3VWQ@;1.OO3QB>SM^B:E@"BR
M+];PL'8V-#@I#3XQ84^)" 48%2-(-' /'+3LBG(:*KXW$/>Y7*Y5Y&%3O^S=
M<X D[F!(%*^)?G$CKG"\1R&$0>\QNEM( ;$*V$B,KA9F#V5;.TD V)KHE1A
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M1M>BM]R-DSGQJY.D>UJ\0+4IJ-U-U_I6(5V/H)P<LP(P+.,JK74:4UCB\4<
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MR\2W/@V#81WB5TA^' AT5I.19533&2(&2R#W)()&M1CHPTUT<-S;DU#5K/\
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M18<1C0$GZ;DDWX@W-?HXBMS\S]#'_]E02P,$%     @ )XEJ5 YJ&H/0]@
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MG.J 2K\'Q6U5!KIFV0U(*S:0JQS<:<%?X"3P4J\//',Y[,GI3UBULMK;KME
MN-EY!2J-)S!-&?;)-&:G2\+^.28E0\B=S46F[?4)?J]SW[7>+#=+WG%HT?/=
MLA#%G*G9PA,QAWZ82(APZD&,XACR&,7"EVIRP48Y>,R;G-K*99,C\+MJ;4D6
M(&\]L+375=<+2S0:V 1\&W7">6X?!MJ!6;I%=>/.IIT$NTZ#;X<"TR:,WC6H
M(_D(5EF+]2'"4[7H(H6>RLI[L3E4*.Z%* &OHELD6-%%=E>)I#U?JBT9KB[/
M5^N[>_4_::[4K_LC>=Y,@^WK#MJ$C^7JY-CX&?Q6M%?(A3*E*W&:W1]018>J
M&;J1<K'-1@A^Y$H!G<A%&5RKI:B.UW5$3O.1OGRI:]0N.AG/V3-3(F82+%:*
M7O.?G.4/L'D=SB<2,'K2B!D%;#3;32U@=6>_E=+.G*D]+<NL3@KV)BO88J53
MA&VJ;#/B<T'#&"92!! AED :2@E]'Q$_13+&D94_BT7;4YNXMK*"5TT66Y-*
MW%=W@=E*9"!@!YZV>F)JO2;H@8Y3,]^F_5$M]Q[ [!OC?1[1-UKY7;80M0T_
MU\7?>!+Y,**:F;S$@VD4IY SB<*8QA@1(TOZV,.G1CU-.*T6L%E,VX8?=X [
MSR?7PC$P85@@T2-^^%#E*X.%.P\<.3+X4)7#,. CUTSHP/ ?*V4&:[OUN3I*
M$B%+ Q\A*"/?@X@S#BGS) R%1[@O>!1[+W]DN"OSY&BD/2!ZVH@Y@0/#O7Y^
MP2/#_KTW_3W8BX>&6^7_#,>&Q[MJ&ENS%G+_.79I[3MBE,/#$TWWF\)N^'^M
MBU*W6WQ=W7">Z:;(XI9D_/WR-7G,2K*H1*3[6GS6>1F*K!1?1/Z4,5$'GGP6
M;'6WK)Y2R3]':4("%@001]H?-_752EH(# -._=CWDA1'B<W\-;3 4YN\JIH^
M#;?ME)5I]LWL9K+!N]ML&IM2)PZ]0WW[_O7L^ RUI8$9V"2AEE6>H$)G*]SH
MY&Y2&@MXIS/2X$*/.AV-U07[<]%H[;Y,I/K;[R)G6;$-@?RJZ]._7Y9YMBPR
M5K,3%4F,8HQ@Y'.F%E-40BP(@6D2)RFA*0^"<193%D)/;4*ZN;O+JX!YD+5R
M-@=$*]EXO*QJ[=045:LWEG^FS:LP\'IKH Z>_H+KTW:%U:B^#8/7TUS[RE2J
M3V"UU:.CIK'<LA'\S['>ZM$5KD/IK=KN6XV<EDU*TVS7%T?G\/JJ?]\FY&8!
M#L(HD= G$D%$6*!63V$,8T_& 1%(\M"JR)U-XU.;>+ZL'QYT5)Z:9G8=Z:J<
M=K^2_)^BK#[;*@A>/8--5MZO2B+;FN46764VH0S5 0-/#%KL#JZS;0] U0.P
MRMOX1R7],+G4^\#FN':YA0 C%R^WA^:P>GF/9_2COP^B*(3X4)?E*5B>5<3[
M(5N*]Z5X*.:Q3-. )AZ,O)!"A+Q$6>>$PX!(3-4OE(6I#>-=:&]J)%>+.VOS
M571$MJ.N2S";L95#\ 8FJ-.X@3^TO* 2V"$C&4+CE(0NM3DJ[Q@"L$\UIK?U
MW$58TT+\]UH[C3VI'WK*KPL^SOW8\P*!"?3#,%6\(A-(O0!!DD3$YQR+@!NE
M)[W8TM0892LHJ"2M["#+JJ"7X35<3KL ;>@U<#^\[%>LE[!PN\P\V=JX:\-+
M2A\LZ"[>T#.Y0WY'EMG_5,O#UVKAMUIDO'7ENM7NQXUW]2?Y+M-%KC*RV-0H
M+C8^BFD2)4A( 3V/1VIYE@0P%316S((B3!)*16KDC.54JJD14%>I&=A1J_+O
M[BJF%W<;U;:ENOM[G+KI9S-V&[WW!F;"L3K./BV&2Z#=IM%P(MFX:3=<@GF0
MIL/IP_M1_3](GND5;&5SZJ/5N924^8&'82 #K,O[<)BBA,-0R(@E09R&PFJ-
M>=#"U"BX%;!)/LF4B'8T>HBA&25>A<S ]+8!I5DSOCZ'BC5'G=3<*=\<MC(J
M=YQ4<I\'3E\X0():[8"OZ_IH]ZA;H=Z693GW(BPX12%,=*$=%#,UY"/F0^03
M(I(4(X2MEG^V DR-$0X2U/)&9J#4$B<RTSI,1WNLCPRMK &1']J@NIB.MI6_
M\D6=@4:%D1+2G@%OO(2TQX283D+:,Q!9):0]]YR>CIS+,N/98EUF3V*[E?_V
M.UNLN>"Z1) ^$5VWYM9;DNN$K(5JO#H0O7G0XLS3V ^(AW5:,J$L(Y\C76&9
M0B82'A 1$$ZL'&2<2#4U[NPJ!8KM8:-HU*HK;;&M8GIQ)!K5@'HMZIPO,T J
M]2P].)WTLQG5CMY[ _/O3L=U3HG?[G3<Z]V.:[729%P[OLS S?F.LW?+= FT
M6]]+)Y*-ZV#I$LP#+TJG#^]']6>CY)L:5BBEB*5)"''"/8B".( TH!PF410R
M@;TDEE:.(P9M3HVF/[M)L&*#NAFM.L9R8-+<@?%(:I7+A=BLZ= "(*=D9]+N
MJ%1F <0^4=G<VO^L57$AR9_KXI-5I,K-]ZR8"\XB(@F&//8I1 PGD/(@@6JM
M'0N):1JBR/:L]6A+4Z.<MKIJ)2#X0XO8XX3U.*CF)ZQ70S7T":L-2KW.5<\B
MX/Q<]7AKHY^KGE7ZV+GJ^1OZ>K=*H1,_?27?F^S<HIPG01+Z7L+4@C)"$"7J
M!Z%)#*,H#K%$Q$,$S4OM:6O&!\<:L:*"35/#O>0?=6:L1DY0DN^]LN<?1=.,
M"*[%:& .:,4#2KYM"GV%F>(%[67=A!TL%JMO.M682T_2T[@X]A@]TM#(GJ&G
M53WT #US;<]\6Z30UH?^3Q?H>%(\LRP+99>4>:;CF(]_?[M:9.QY'H=1G#*F
MUB^Q5+Q!90P)21+H)1X5R&-I2*S"AJ\19FI6QE9JP)2\EBFXKND5,^H9"^N!
M*4K+5RUZJE\ZDLY IP?.7%5K!/YH_A_$,=X%UFY3?ETCT+@YP!Q =Y 4S,4S
M1PZ@K:LGO5\J&:NLHD556^7K/5DV05'_4.(+OA,1M<E/,8]21)%,0Q@0H=9Z
M'.EZ:QZ"TB,AIG["<6#E O<R:DR-XK=!ME(GL-G$U^9;XJE#;:N\JD^59B,%
MV5[WNABN8B?_$@R]1+X^$+>& G2P '7!*O7*++=ANC4@W1C=;<JD"83G.NG0
M:03L7J?*GR.$UTEW.0OJ=2.-W71<Y.7\:U;J/97WRZI*U9HL?L_*^\\ZO;5N
M]#Y[_+IZ6V4B;((G4!CJ])T$QD'J:7_$&%(_\&#, L$3BJ4?>29S:(^VIS;Q
M5>+KF6ZK@&6L2I\..#\K#0SKP%-)+T2-"?X*;,ZQLGILAY'57_MLW*?=42CT
M"D!:WKOF$?W6#K>Y=O4KGV_5FU.J]8DFSNJ\2/U>.V;7GIN?M1/3)_E;(:I-
MHE="KG)QP]CZ85WE[G\C'G/!LM;#^^9!9^2OO;_GOA]$U$,QC%$20I3X*4Q]
M]5OL1P'"7DHC9.5:-(+,4R/'5N49>-1*5]L.HE5[!N[R56&YP3Q&QYN9_!/K
MSH%)>=N3E;ZSJBLW*E=_-4K7KJ*@4ANN)%2*U_OE,T KW4%'>=#5OGI*5W]W
MYOR(G>74=A]#[E$-]1$[8M\J'[/I@7;$BE,+A^J'CC7584I*OX]J*#>FHN<3
MGJ9(S6#4EQ#Y5"V_/8P@Y@PA#Z5<6L:1#R#DU.:M2M*KXLZ'Z$E'6U$#]\_
M$Y%-U[C?];D"NW'W=/H(.JT=FRN@MMZ/N:8M^Q(I']1[N+B]7RW;2A^Q6EMX
M 0M@+#F&*%0_2(@3B)G/6<P2RGW?M$3*_L.G1JV5?* 2T+I$R@%PYQGQ6C@&
M9C(+)*Q*I)Q2N7>)E(,'CE8BY90JW1(I)Z_I&994.9-L$BG00"WW]?K?3U(!
MD0@#-31E#,.(")^'J0BHT= \_OBI#<Z;'BY?>X"9&2G]81C:O*@$&R0)Q'&=
MW0:_[#8Q;A3+4?4.PE&.7]4WKJ1:D-T2M:K[JB;S0CU2[S9N7D;!2(I21F%
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MB"$2,H9I(GS(PX@$C/$@$F+^6,7O?"E)7HZSC#Z0TV8 [TL[W%A^)>ZRI4Y
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M?5!?5G];GM5?U6N&Y_)C]<709_ 5W+4BH-9DD]RZ\8C=[:F.0IVRH [/VET
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M'/4=*Q>WK>YEQX"N^]*,*5^PAP9FU N=,VNSV//Z1+T.PM1ZS4"S2S.,T^!
MB#ME9-<RCLK< P&\S_!#-=-S)MC+8:4DR=C<(QP3D09JL4Y"78,\@"10W>W[
ML2=\0L,86]46.MK*U%A9AY4L5D4!'D5>EV %I"SSC*[+:H=P+^/K_6JA8"[^
M^I<T\(._4ZU15;R5KQ8+DG>>8EG']7B/&++RM3@/S*V'.?GTZ;N2T2%-GH/
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M2-$D1:Z_L$R"M0NI&4OU!VKHD]L6H_?GH;#//W548[=II7:;&#=;U%'U#I)
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M@? A\@+F$65Q^6:Q[J>;F!KI?51=KP==ULC7KK@LO84.H30CL.L &IB6;NN
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M+6<U2-CH933<+BY.-S?NTN*BV@<+B\MWN$\S_E%\J[XIYBR6TL-4.P0+M;C
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M[J]ID?&,Y,^?<FW/E<^_BO)>Y^BK<G6++Z3RQ-6;AJ^>#R]N+ZN<;N<Q";#
MG$(1HP#JXP&(XU0J^DDQ0:%/B;1:([H4;FH<M157]1>H!0:U>J 5? :TAML=
M=/H,CM[67M\XU]L>1;A\!0Q/+UZH8P?FT1?I4_MSDP' =WO4XE+ <4]G!H#V
MX$!GB#:N-$%OZMJ Y7-U@LDH364B/8A%Z$/$B ]ID$9J78Y]7P0I2UC:R_;<
M:69JA-XQHC9R]CH:/H&JI<G9&ZOQ;$UCF/K;F$=1&,:XW&WJ9:S*H^J>-">/
M7]W3CMRRCK)2%>=42V%=Z9N)[$GP3\NJ^C=A55%BPN+4YV$$<1@)B#B.()&<
M065 AH0+@G%HE7O9JO6I$4=K#U356'4NYJW\(&\4 .KW\EZ <JN&I9%GU3^&
M5MQ0J ]MIG4-,%U:JXOXYP[B7PW0MC>_^J#FUKZRDF!< ZH/. <64J^'],QS
ME(M'DK7'M3?+.K5B?9S[>IWG8EG.$4*^H)) *F/%=H)A2+P@@3[UTH1Y..38
M+M_1Y3:GQG&-R!OGE;I\<YW1M9:XJ<UNF0') 'TS+G.,Z< ,UL+9B%NA66=O
M;1U3&ID=YD8R!\AMCB2#=L?-E60.Q$'.)(M;>Q>\V,_IVN9SW4:]15X2Z4)/
MR/>Q^H$$Q E'4'T:B5 H.B)6;KL&;4Z-CEX?9)'^FW6QBXLX&SIRN$5O:#<.
ML^30,YV!*<_HN@X:*%?@EE0D[S( KP>"KBMF7&QW[,H9ID <J:!A?&L_9GJ7
M+<F2_?_<O6MOW#J6+OQ7! PPLQLP^U 2)9%G/CE.TB<'V7&0>'?C8'\H\!IK
MIESE+E4Y\?SZE]2E2G53D2I*5K] =[;C2%IK/90>+I+KDM/YIX5^WJ8LYV&V
M-5A(4QSQ#-"(:N<H9@00(04@D5(JYHH)Y-1"XXR<J3'05LU@IV>OW:)SN-JQ
MCP>T!F:</D Y4\@%&+S2QCE9HU+%!8,/Z>'2Y3WWC!Z7J[7)<S05)+<'FC,5
M,:0(T>LCQ"+-"$(!&K,8"!G!%"H)4VR5%=PM9FJ$4&H)UB9%UNCIN+MS&DG+
M;9RK\1EZOV8?FH'B$KIA\+L!<UK4N#LMG>8>;:ET7]V[.<Y!)'NS9I=*")$2
MC5V2"$T!*@48)Q"$B@J888I#)5U:TYZ5Y,0"(W21+9NB.W>T.8.BW>?O!9N!
M&>!$YLP 6QP7D?#=<N:,M+&;RW0;?:*-S(4;^O:)>)&+C?RH-31Q3F;)\8]\
M_7BW*=9Z-;+:-@DUVR7Z?R9K9I;R-(1F T-QE !$-<H$A1&("56*9C%$'+M5
MW^NAA<MW,DY!OKOE7-NTW)XAE2:Y-IMP'PVI1R-D<0HD$C% @F/ 4)B"F".2
MIBBF6#AM+ T\%N-T_!@)>SNN'QC1@6>!6OO D%C0Z!_\S$UOH-J"=K/LQ@B_
MW<JN@-!SDQ%W/49N0=(;J.,&)?T?-5AVN]DRT_^MRL\NQ#NYD"I?%[NBM>T+
M3%^$6:0)$J99!K(00H#25'NUD90 *X5"H=>\"73BQR&4G!J!EJ>X=;EIWM+5
M>_:[^W#:4>Y;#]+ G.R0%=^VHCRQ; R]V2LJOG>9L7;4'/G>8S%VOKR[HE/+
MG>\-=8\\^OZR>I0Y_+I:<BE%8>:K/YXU-HMU7<!\)J(49EG, (4< 81A!AB+
M(>!9AB5.0\2855K6!3E38_%:N^"Y;AC0A+4Y5$+L +6;B#U"-3"7-DH&1LN@
MP:S6TP]48LG+W?OR/1\#LCV!(T!7K@TV^Z^;IQJ3EP'I+#?9<?MXE2<OV[!7
MA-+B\KYA<[L'-[W#[M775?Y"U_+K7 ]R^;K&61BF44P!@RHQ%>92P$+!@""4
M:]-9F$GJ%CEG(W9J[+G_<E=APL_ZX8_4A'[]6$EI3Q". V#GX_J'=2RF+1'=
MMA-<JJ!6.MAJ[3."S@4EST%T5J)'CJ-S@>,XE,[I[EY>G*SGCZ]RE2_%C)E:
M=)AH'I+2!,]!!"B#,2 LCBB!D=EN=O#=]I\^/<YI] N>2P6=_(\#Y*P<M/YX
M#$X66RB^7@V%DP/6'Y+1W"Y;:%Q=K=.F7W"P#FX:TZTZK>^!,W7FHGXNU(>G
MY_GR5<I6/ZRZ2#QC#,>0$4!I%)O>ZBG /(,@T68IBI)4(*>*FF<E38VTJHSJ
M9=UI;KW<>4E\^?2T7%2^DYNC=!YF.]_("W@#,]S)GGZKE;ZDG$5OFH:,_INR
M7T3'JQMT7MJHGL]%HP^=G<LW>/!O[A>R?K&5$I+3& +]MA"S284!E2$%:1;'
M"6(<L:2_H[,5,S7R.)K+ JWJ%5/]#L\>[D\OE,;V@PQ ESG!!:DKO*->B+V5
MF]3Y:EWG*AWAX.0S[>Y^.^?IR().+^KXZAY<:#)&B_(<X/=<_[1>;M](#I4@
MBD.@0LH!XHD &,(,J(C&(:0DSK!5+8MN,5/CPE+1H-0TV*KJ\(6?Q].""[V@
M-+3'= J@/EQX'BD'+O2"V$A<Z/9JN7'A11PZN?#\W>-QX44+]KCP\M4]<[5H
MOBI;N;][W?[X?W*YT@]Z?/TL7[3])L4HCAGD$C* D:GS0](0,)1"@!A$#"&(
MJ5N\GYW8J7%EJ_']5MDRO.'+[=_[9739H6^W_/2/Z<#,>@V<[GE?3NCX30.S
M$SUN5I@3'$=)8FYW>TMPKVJ/'Y;1AW$H1)Q2D#&J*0F2$)"4(, 8(E&"10(C
MITTP6\%3HZ?C5/>K,]U/ V['1T/ .# CG<IY'ZEK@2-80Z>WGQ;^UCGNG9!8
M)+IWW]]S<[ZLM;@M!1'S!"9*)"!3(@((XQ@P0F- ,TKUWU(9ADZ%<?<?/S7*
MJ2N8NK:;/H.=Y39[;T0&9@][,-PWST_:['?'?%_$N-OD)\T[VAL_?96GL/]=
M27\]<=[1U>I5+5<_Z4H47Y;K[QOV7Y*O'Y8??CWG5;+5C*0I$5FL/_*0*( 0
MR@"%0@"(H41(ZG]+G&J?7JW1U,AAUR3#^")E]LYRLS:%P6J%KXSL=QXQ.WX9
M=1P&IJ23,?NMYB5F7/8LN@FT34%ME#E7_7!YM*X/SN^+\+"1^,Y:O6W8?5\0
M+\;8]W[PE5M2M^*_-L7:;%3>JW]0<TB]+F8PHE'(3-/R#&OJU>L^[5H1 BCA
M(D*4<Z7]*Z?63YWRK+[E45L\W3V:P_H@7P3*[)^\E/LG2Q5H7[?^UJNPT9^5
M!<&\:4[3<VOJY"C(F(6"QAE0,!, J=@D-U "6"Q9%DH)1>)6RNGJ,1ASG3V%
M$7#<$[P6U_&V G>:&DP;70?8".R"9)C]OY,2WV;;K\OXL[M]G3=YB$MY^+EL
MSF(EY@I*!F2<(H"@I(# 3(*(ZV5T!,.41%'ON)2MF*D1RW'P@%;UBFB+'9X6
M9[%>4!J8)DX"Y",N98?4%7$IO1![L[B4KE?KNKB4(QR<XE)V=[]=7,J1!9UQ
M*<=7]S[P>%HNRLB_^F7$(42,9"'@F#. DC0$& D!$B)3%J8T%J$5#9Z5,#4&
MK!3\]W\+4_B?W]TC>(\1M#ZJZ(_+\&<2)IZY"GCV'Y9[UG3?)PP'4L8^2CAM
MY(DS@S,7]ONDMTOGZOS!+*!G$<=,ABP!+)*9_J@S"C A$> QC1&-3/DDY%+Q
M[H0,I\]ZA%IWY3Y3F8"W?*X[-#B>39X"TN[;OA*>@;_NW5[<7H5M?]]WA_E>
MO_!3<D;]QCL,/?S*NR[M6=^6/TJQF9=YB>857[]^U<.\OET(<VCQ;'R%JFEB
M$F&L,H+UC$YB@%*5 99)#H2B'#)&10*=TIQM!4]MHF^TO0E*?<NPGZW&/9M;
MVHZ!'6\,@>S@RZ-K0'4OH^N(D-_"NK;"QRVUZPC)4?%=U_O[T56S>6/V[^5Z
M/9?FF9\6=[1XW&[VO,\+/E\6FY6<R2@6,,084)'J90@5U*1#AX!A+B#B*<3"
M*<#*3?S4J*O1/E@LUT%A]"\[7^2+@&L#;MJ;PF)KA!N5.8Z/':$-A_K M+8%
MO#R:W*IN$+\K$6_M'K^_C+@SS_4#SBO;.:HP*N?U@^>0^7H^Y<IEV6=)-5\T
MYS/;+FXRQ3$6$,1E#0C.(:"F,+F,LI@3FF899BY\URUN:OS6"MLPZFZ/KW+9
M=\UV&F4,.5,9%P 2Q0&", )$0 HX3\.,QQD5)'&KZ.P/YY&*-]?]\)8C(>ZX
M8+X:Q='6SJ6F-]N:\:\#5(RW0V68)?5ID6^SNNXT_^Q"N_NNGCTE7FA>NEX?
MERN3'F7Z57R7?+,J/YQ;SC=/F[D)R/C;2B_P_UBL))WG_R.%6>Z_DVJY,HV1
M9Y@G4+%4@325$4 DT5ZNXA%@IK)Y@M)8(.(63^)%K^G%G93:!CMUR^ Q5X+R
M,V9V/#;>.(P5R\>,^]L8<!-L#01:65!H$_7O=F8%)T?L)F"E;7Y+I7O%VF_O
M#2^:C=NGPR>81ST]O#Z\[T'GMFG%BVQ5G]GY]ZWDKC"!*>4<,(Z-+TY"4U W
M BI2).%1*A.<N!V!6LN>FF.^W^OCMJD&Z9SE90^^'=$.!.G =+JG=;L&4FL/
M(?ASH&0O9\ \G\;:RQ_YG-89F.,37/=']&.Q!_GTK.6L7JN\E/+0V-2GE.*]
M9M/%CRHXI-RX^")_EO]2S&1$(Z0)#&3<+'HI10#'J=".)^$9#%6<)D[I87V4
MF!JOM8NR?M?ZFJ(1@7YC]")\G9N-OH/ VIM@4;4?SIL;^;)PI<%>HV?'AT./
MR<#$N%4_J/2_J6-/*A."RH8ZBNRFVG8U#:%_5A=XC-2]!D>O?-E+D5&)\QJH
M#AGTJF?UH])/"[XR.P3O9?7?3U4(SN-RKI]15'I\T\3^L<H[F2DJ6)JD$HB$
MZD5[ED' D(D15HQ',N$QB9W*D3C*GQR!UNH'OS4&_,4<CK1M^(_Z8W8C2==Q
ML>/' =$>F!H=@ [^-"8$M0T>G<>>Z'DE1%<=1N7"G@ =TF#?Q[@QH)#Y['T=
M OY1NZAT_O\D77W4OREF3"]P$YFD(%69 BC5ZU^*&0)9PH4F.9X09=5!ID/&
MU)BL43.H] R,HD&IJ1UQ=<'934Z>0!IZ#] ='VN"L4#@!(D4DO_UQ_+E?^F[
M2_[X)S(_@NK'DC2ZGCL*,5@8UGS\-I?VC! \V7]JEB8)))!A(#", 9(D T3$
M$,2096$J8RG#U"D>\*28J7WFYUK]F=H IH=7L)+5%O9ZN5ODZ05?4^_;!+;)
MNE+R89>49RW),7#P]-#8.3/7 SXP95RL^/U%?SVT>&RZ]WF,#^R$QF\TX&E1
MX\;^=9I[%.G7?77O7DNG@P:W)79$R(F2/ 893RA H?Z)1C$QK>G2F$.*A2".
M;9:Z)4Z->B[$R/8L9'09>#LV\0KGP,1R-9)]VBK9H>.[H](%J6,W4[(#X40?
M)<L;>\9C")$;#J/SKS07)G3O.5_3>9-72Y$,8T5 DJ48(*PR0,V^#5(P42@)
M2:2<JB5U2IL:Z>R4#8RVH(Q<+?5U#)_HA-B.8KP!-S"]G,=L@"Q(*U#\QB5T
M2APWWL#&^*,X JN;>L8':'=4$Y3YCR&I%SHWQ]RWZ[+V4+[X4>X]SV0<*X:X
M F&J$48A@X EE ")$QJF.!8R=CI*LY(Z-68QVI8S;^G"RYW>CD$!5HACP@CC
MC #.D0"(8PBHBE.01%F&-(M'A$BWB%WOF(\4N#LFZG:T[AW)@>E]"V'Y0TOE
MFX"N@T;KZGC18^2%"TI^8RZL)(\;;>$"QE&<A=/-OHX%;SE?;:3XO N0GV6I
M2C*B*(BA"1 C<0182J2FIS2A"*DLC)V2-6R$3FT6J#5LML^J#;+E^E&N^N<2
M6('?]\#O.DC?YI2O ?FS!:(>3O7.0S3P4=X)P6]\?G<>BLN'=AWW]G1.Y[0H
MMO7/[E??\A^/ZR\;X_;>JUTD[1V=SZ5X]]KDM=47%C-!D,DA$R!3L5X((X8
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MFO0O-2/[&3[?T[8GK;QT6&Q*"]X^+3>+]:<%GV^,._'5Y#-KF];:JV";=7E
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MD7C"8I0)"K+0'"8KA $)(0'Z!4ME)A,H%;;C&TN)TR.;MG;]W-)SX+KY^M<
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M[L-8]]VI%[]W%V'LDQ9G!XWOY+@+4L=.D;,#X42BG.6-?<N4T+6L*C%UU-2
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MB+#W KX=G0X(Z<#L>:+88MEVIMF4_ZGU#QH#6J>K_HBR)W9>>=%5AU%IL"=
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MU1:4<(9 I+((<8BEH)%C%)^-W*DMK [KUI8=+,Q74^O;U =QCNNS&@0[]AD
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M#T"[$BR_46E]E1DW5.U*R([BUZY]7C]V_*.0]ZJI9UC,(@GUHB"J#U-03#C
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MF" 8I(SPC$(E)(4NAQI7ZC.U,XX'(R-8&J-,6[.=58%VK!P]@&N'RLYE&'$
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MO]95%QTWO_42U';.JD< !V;U2M/V&76IK&FF7:KK.<S5$ABOKN@EF:/ZGY8
M'#J=MK?U\#2_; Q#W:NOJ^6/%7TJ9C*"F<($@3!*%4 )3P"5* 5,:C<2*L)3
M:-\F]O#I4^..2C\SN3[7&CHX+4?067A_UP R,!?46-RKX*L'+!R<M&LP&<D1
M<\#&S=\Z9WNG3W5TTWA^TSE]]WRCLQ?US 7+?RQRE7.Z6-]R;BI':PXL6Y'E
MLE696Y$XE!%#@'!3/BH,): LP4"$G"%3/DJDB5.>EI78J3%:NZ3ZSH!@9T'0
MF."84F4W"'8.DG]H!^;&"U .U(O3#2:_&3MVHL?-IG&"XRC3Q>WN?E3UD>:K
MO]/Y1KY[_5T[:9NJ9^?'E?SG1B[X:QG^!C,"2:@4$ 1IGHJA,-MU$% <ACB,
M,ZF(4V--"YE3(ZF6GL%64:?H0A? [3C),XP#$U(O!)T)R $3K^QC(W=4ZG$
MXI!W7&[M1SI?Y-J$Z6MOZR474KQ[_:.0XM-BNUS<A9W/E, L#!,!M$<9 L0X
M!1@G,<#0%-)A#*HH<BD>9R_:B8)&*#!GNLMQD]RP,8D\^2)8;K= Z.4P_6O'
MP8Z2AD%WZ&6D!K;,&FG4-FE:O_U1H?R7@;,AW!'SREL.XD>E+W=8#EFLQQ/Z
MD=D#_76WDB+7XE:K5[5<F63CJE^07N')3*8P!CR+-7LE(0-40JXI3(:)9"P)
MJ=76E(6LJ7E,I@ _+W75K*65#6IMW1BJ"UP[2O($V< <9-"JU S:>C:-I_SQ
MC04<7@FF2]ZHC&)A^"&%V-QRY:JK*@!ZNQ"?<\KR><E'M=,E[A??3"7SE2&K
MA?BR7*R:O[ZC15Z4K<AF&4P3&&ERP52E %'" 0L1!C1,<$+T>T<(G+W(%5LZ
MK\ZNU<WE\VIK.-Q7YL.TJ@5<WT7?U>/MN#0<<PP'IDAC4U :90[[:DW+T-FV
MZL&E\>F_I/2%Y3 +SZNU>YOEJ2]0SRYBO0GHR?2;U2)?:V%:P,?\E_FIJ*."
M9"R1E+%9RQ*SK28AH"HC@"<)4S06"D6)(W6?%39!+FYT+3]A56OK2*OGP:4<
M2I8I"; 4"4!1&@.:( HD911C1)-4.57N] /M*&VOAP76<@+R M?0,\H>4HV:
M'JMJVZ/A=TXX+VY<DK]H]A%K7[ZC;T0:+:1IF%IR^N[T3Z_/4TPQ!<I4S4>2
M: Y&. $*29CB*)-(*;=(M)-RIL81K3/74N/ J%Q^!=5?W\LUS>>.I'$.8SO&
M\(#<P'11!YJ54 W9"/H"$IYCS4[+&CG&K-/@X]BR[LM[Q)0]_%P^/"XWA?X"
M'G[*Q?KUPS\W^?KU5)^E.(PBE808L$@1@+ 0@$!* 2<)3;5'I[2_81UM9B]W
M:@RBWR?8OP&8 ][=[#$@BD/O^/U<!HW60:5V4.GMW"K,+8#+':W.T"Z'QXT7
M].5NXUXX6(_;^_8>V,7DE^'W[U[_6.3_W,CWLN"KO*Q86A5S(A&3*E: P4C[
M*3". *$)-<4>(D&%9#2&;HT([ 1/C7:J+G"M+).6OKW",:Q'P,Z+&0+7@8GH
M&DA[]"IPP\=SXP)+X2-W,7"#Y+BE@>/]5\3<WRWG^G=+<X+Z(F]_K&15PG*F
MW9XT36(.. VA:83* 8LS!*(($R03&"ME57S&1MC4*&D7D<_;"@=TJW&/J/1S
M0%MX0Q[A&YAY=C'J>[H&MT,@UR.\WP."HT?[.R/9+_K_ C16R0#GGC%^;L %
M:TZF"ERZIY]#>%![OA%6]:JYWZR+M?9)Z_,)/A,1SU1$$8A)$@%$1 BHE!%0
MF&8ICS(<I4ZE?9VD3XV'MVTP:-T&@]<=K*K.2\N=^O_^;S@*H_]DQHK^?:S<
MALK.?1QL  9F\J,6)+M)L6Y\U5+^)BC5]^=4]D+-JV?IIL&H[F4O< Y]S'X/
MZ4>!'^C*=-LHOLI5^?SW^7RC1<^T4TDE"16(,\I-O5,*6!H)(%3"*8,)3I53
MMM09.5.C-1.=.E\6A:EL5!%50-?K5<XVZZKD_W)+=,;Y-]7EM58UQ8G*II+D
MA)FP5JWG./+=N7&Q8S8/: _,88V&IKI1Q5HW0:VE/ZJZ (-74CHG:U3ZN6#P
M(=%<NKQG/J8I=&1"0/3XS/_O9I47(N?&(Z_WF,-8NTIQ*("2<5+MZ>,$8Q!E
M,)0)A5D6.37KO2!O:A13JEN=_AF%@[;&CCF7%X"VXPJ/\ V^=W8>N0'B""R!
M\9M7>4'FN F5=@ <95):WM9C9^QWNOIO6<[$WTWL6!E>9H(7FO"S5@95*^F8
M4$Q"QF.@4&@*X&!-.#R)0<RA#)-4QBRU*H#37X6I<=#.B&!GA?FR_OW?PA3^
MYR[X,VB;X[ _U&^@+/;;!H=_8 X[C?RMB8@Z#;I=[KBO$7#8MQM\)$9L(F8.
M&K6K+_*":^_?Q*B9=D9/N[$J]KZ20)FQ>BG'ZJEEIJ\J:U=!V[D;V._)X^T1
M7F7YWL[A=4_JZ?E2TY"D/!;ZNLJY;/SJ&8%AQ% : 45Y"%"$**")PH"*R(0>
MASR#CGDCYT2Y?&#CA!X;3<W65%7\,2\*_=$\&Y5;:VP?*^:SX%,8\CC,,I!E
M8080BR2@BBD@I/X\,HYEEKJM-SQ /\I"XZV!MUQ_>(!SZ(5'C62IY$U0JKG;
MN/"XXK@ A=^EQCEAXZXQ+IA\M+BX='U_YFYB[A,N6,:Y %()3=:$A("2, (<
M"II$%*6<.U6!;SU[BA11!&7S9O=OWBU'H2<*(WS90^0@G+#6^\?[)ED&)PP[
M]8E>ET=0A07*I^?EBJ[J<,"CP)LJ-;BNJ"O%3+)(R91C(&@L 4*2 IR)&$ <
M"@()39*4-!W:'FPCAMUTL'JQ]UNW/8SPE>^7B7[6[Z%<K:2H'8.#(PV7N&+'
M$;)8W@\!^$@1QHWF=5SQ3; />^T[5 8$6PL&A-MA+3\@[&.MXCW#[QCEW0^_
M[E!OQV>.&._=S]K]H.^>S[@B(<T<UI:IR:?Z@C>^'X$1Q!D#,=8.($*17JC'
MA(-(0$1A+ 03H7.&FH7@J3F&6U6#O*5KCPPU&]#M',@AH!QX3MBIO,OV*T%M
M:SV ]^D*E?\D-QOAXV>].4!R,@W.Y?X^77U,!:VZ;>DW.2_;!='5^G66)(@G
M*B& F]HS2#,1P((IP"B/<*)$$BIFW\'GC)2I45"C8_!$11EXLZJ4#9Z-ML%F
M(<Q^E5R]F,V8;?BW2U.9<W!;^*D^0!R8?*HB>PV(M9)!J:4/D%RZ['@ :ZR.
M.@:TY[TW3VS*2C?KQW+?-%^*PW>Q/!0JRA^-ITFW+^5R91KQ%)MY53:R>46]
M]>*Y &MWWYUS-X_88^>"_OO]="Y=W">:0*ZV3:-D)FF:)8EV_$0$4,H(P*GV
M VG()-5O31H2JY2_PP=/C55+U5R.D5L86?!B3\L'IL)2JSY]Q]K6NQR-]T-A
M)([K?@4<3ZJ/+>T^?VY=/^*I\K&6^V?%)_Z];XJQ]@CEH^DM]2(_+?CR27Z1
MZWOU0'_-&$\P"1,$.(I2@!(2 4Q1!J!*,(YQ2N(L=2FNW"'+B75&J*;\8&28
M;<:=PF68M6OV\'EP[=:0GB ;VG/;PZE2,_CML\;K+S>!B5#77H;6^":X/0A-
MUS-BEPO<(W_X(ER>4X;/RQLY2_BBX<>)P9=OZ5VV8+VB?/V/?/UXMRG6^LFK
MIKS>ZRR*<1S)5 (HL5X;QMJ%P2C*M.,B%($IC+%RK55P7MK4O)GWS5'&2K[(
MQ<:Q"W4WL+:,X@FNP3FETC/XJ14-&DUO@JVN7JL.7(;$=ZF!#HECUQ>X;/R)
MH@(6-WGM_O Q7] %W^\Z(+C^G#@) 8$9!HA*!0@7'. HA!%*B0SU<Z_O_G!"
M]-3\E6WWA^=6DP+5Z.V[ \2IL;!CGV$0'IB*+G2 V"H_9@>(#L3&Z !Q2OP4
M.D!TP&+9 :+K"3W=(?J<:P;(_Z=<)M^K3POM:2SHW-2H*\J&7:\SBE5(F)2
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MN'!UOZ__DW8)\I59X-^KS\O%C\^:>435TO;_R+GXN%S]4<@932,IB<2 QI
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M@T6LHD3_+29N1^]7T&%J1-YHTCW,#[CE&?DY<+CQF>[J_HEN?SI(G+G]:=$
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MPC[:*8"$4Z/$1E1 V_:Y)WU1J!!UU]UGX^)Q#@ -M]@6SK?77L(Q+%;P<W]
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M9V*!R.F/XJ36T9F(?JAJF[NK[X:.CC.<@XAU9&B\3F7Y[#1/Z3>>K=>X.E/
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MFVAKHC<::YF\H0W"+,0B#>3(@O(YE]3(6=J!N'%ZR+;#UM#ZZ !B-XDO-I6
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MA92"F @7"07W6:7"7:N6DUN)&CLU=CR$':2.'I%U?O!'9FW2#@%3K<1FA5P
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M"I]]6N+&1E^DWS.+.K@ 1DE=BW$TN(@)'"M:8C(JB5O/,K=TSWEHE9$3T&U
M,:QL.S CE\?W&W+;7M.7JXD(M@Y&EE"*K:/[LB4.'#F!VG.1HG78NHKEDI9.
MAD0->(FQGY@[  K%@DLDO+_ L_^^GG]$BAN6=%"?A1'O%[/9J\7RC[#,$Q0R
MH8U(KGZUE%A?74G48+@Q(7@7E6H3QS^%RD[N.?9$Q)V6;XW4TP'T;G'R/"R7
MWVM+^Y/%Z;P^J3KK<']O%>IOBWFJ;?&)^4T'E[.&9ZN)2\ABK3^-Q'AM:^9)
MU$H *R$D$C^RTJ9:?7A>1I]IT AWBZY L/<V^(++Z:*6LR[7+3;#W=?.-MG
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M7KTB(7\(,WQ;MC.GG5!:&-K8UO#Z9)MD6 =.,.VD3 '1B]@&E[L3V>5CB&;
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M>5@NOY.!V$SKFI@@"W<9(>A8*-P4#@+)LS:=-%RQ'!BVP^NCY(WOBQX9-O<
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MM5[WQ7F];DWXI_7Q\M%/)FF47/-A@FN?1S:"<66XAE)#955O=P+& "FK%(1
M%OF/-B!CN'+RL\GIQBJL>ST4S\FKX1F<\:6Z-CDHRZ-PC:H?!N6CVYST4Q#8
M[N7 DU7=A0-[(->_?K__ S;Y,VV31TWN.Q>!_#:ER9LOC$$N%%(RS4P);9YR
M-62JEUSY\=&ZZ!,X'>^B6B%X'CZ;:"6W9),"EII=B0Q<)F-% 8UDJ*S+OLV(
MB<<H&]FH]P*BG<"]ISZ[0.A+\I\7WQ$W]3EOOU1Y7N1<)/,EU50.!=D47?,
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MLUH67'$<;&:*PCN7K34'Z?QE#P,=VNG\&+E-J//U:C/[@(O/N[DZ@27MDF9
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MXNODXF# 21D@1ZV0LQ(D?R:V??JGJ4^(Z^9V_6!P=. !O3_#Q76U5L[6BCI
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MX)FG.:Z^UQSZNUWOK^W>2L9JY#P#$Z(^Q2T.4"8)NM@4DI76B]@,0/>2-.T
MG@[/P-,5UP,";\BOR95WY9:<KJZ&''<R*0IQ9*J>I'-DYC5A1U@>DLRTTQJ]
M8?XI;=,;MA% <,]MVH@:F3I7N7UH_7X_J7=58UF252%+8H2EVGQ% <:H:Y]-
MEKD2P>\?DP\5MSZRRL0@&5F=RQ:R[< 0C6#6WUYW!I"1G%&9!"#C-0PFB?J
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M;5S3AL;EULS&0CY9/9FO5_N FUI 00<WG9M;E6T%?P/ZR%0H/%C0N;X14$*
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M7,UKV=<- \IP[V-60'%D379).C6S") ]"]IXKEEIX__^0,K4!0&CP>0T(7>
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M@>G*\N743F5#U!@8%#04DV?/P"7Z:S)*H2$MY-#F:> HY$^+Y E@-Q[PC\3
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M<Q =(?W^8'1I:A6+/"6NP9;@ZOQF#\$@!\VE=]&(Z%R;_BKWDM,=?(Y1]>,
M.D+N'8#G 9/]]KH"VH92Z&2V$&4JH)CWX#@38)F4Q&M6H5$'L9]1-NW(CFXR
MV<=I:G+?.Z^^S>/-Y5.=;3P+)B>IZZR[HDDZ6$?*)AE .>G09HL4ZPYSO._Y
M]'YRBJ<K;SFF)'N#PH>\R'_CV98/8T00VJF:=ZWQ BKPDC9-5ED@3RPR/^P&
M]I%%IKT1>SI@'"O7J?'Q"M=?KAJ&WY;6+%G4KF1!YVLF:'/GP EFZ1QQP@@2
M3=Q_)/  .!Y:8=H<<SMDC"+1#GR7%W$[R>+JA=7=4M.K!L'*:VZLB"!\03*
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MUT>;K6#O2C%/*A'#\?NM1K733LW9A@<FZGOU^G]+5O1\$,K$P'@*^KM+I^9
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M"8HI%]RR1NRJ+/1P-7N?:L#5DJ$@9$7HSX(79,'C O+RF(#<;.%$G%Q215=
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MONM"E["V,W/8Y0N??.6_[@,T^RG<^?\!4$L#!!0    ( ">):E2"?9N!(@@
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MQM,8(>S6[)._R<:P7AKQU\]^URWA2;UCW3 B"5TRHMB2LQ4*ADFX)KTTS:E
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M1NHF9UFL/3GLU=T6[E8[BC;.2.43K*5Q#R!RX0H[^YVJ,)54N=0;<^CGA!P
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M[JI\YN:D?E;W..9&:?PG4$L#!!0    ( ">):E2KEJARO00  (02   7
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M0M:XI;?JH<D_W(A4S_)^QMP4C?\$4$L! A0#%     @ )XEJ5.\V4"5:= $
M1T,/ !X              ( !     &5X,3 R,2UF;V=H;W)N>&QO>&]C;VQL
M86)O+FAT;5!+ 0(4 Q0    ( ">):E3=[68#-"D  &[K   >
M  "  99T 0!E>#$P,C(M87)E;7!L;WEM96YT86=R965M92YH=&U02P$"% ,4
M    "  GB6I49$M*KBTH  #1\0  '@              @ $&G@$ 97@Q,#(S
M+65M<&QO>6UE;G1A9W)E96UE;G0N:'1M4$L! A0#%     @ )XEJ5),NU=T?
M*    O,  !X              ( !;\8! &5X,3 R-"UE;7!L;WEM96YT86=R
M965M96YT+FAT;5!+ 0(4 Q0    ( ">):E0)MM41U"<  %?C   >
M      "  <KN 0!E>#$P,C4M96UP;&]Y;65N=&%G<F5E;65N="YH=&U02P$"
M% ,4    "  GB6I41:K@6;PC  #)]@  '@              @ ':%@( 97@Q
M,#(V+71R86YS:71I;VYA9W)E96UE;G0N:'1M4$L! A0#%     @ )XEJ5,L8
MS^58)0  L;X  !8              ( !TCH" &5X,3 R-RUE;7!L;F]N8V]M
M<"YH=&U02P$"% ,4    "  GB6I4H]J!VM("   @"   '@
M@ %>8 ( 97@R,S$S,#4P,V9O9VAO<FYC;VYS96YT+3(N:'1M4$L! A0#%
M  @ )XEJ5+/U<Y0\UP, 5>@? !$              ( !;&," &9H='@M,C R
M,3$R,S$N:'1M4$L! A0#%     @ )XEJ5!P6BX-&$@  4+L  !$
M     ( !USH& &9H='@M,C R,3$R,S$N>'-D4$L! A0#%     @ )XEJ5!]$
MZLK1(   Z44! !4              ( !3$T& &9H='@M,C R,3$R,S%?8V%L
M+GAM;%!+ 0(4 Q0    ( ">):E2<;_"NW5$  +.# P 5              "
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M &9H='@M,C R,3$R,S%?9S$T+FIP9U!+ 0(4 Q0    ( ">):E3N*=HY<(
M '7.   5              "  7]^"@!F:'1X+3(P,C$Q,C,Q7V<Q-2YJ<&=0
M2P$"% ,4    "  GB6I4!--,81-H  ##M   %0              @ $B_PH
M9FAT>"TR,#(Q,3(S,5]G,38N:G!G4$L! A0#%     @ )XEJ5+J--,OY1 $
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M='@M,C R,3$R,S%?9S(N:G!G4$L! A0#%     @ )XEJ5'(^L4@9L   B/T
M !4              ( !%]X. &9H='@M,C R,3$R,S%?9S(P+FIP9U!+ 0(4
M Q0    ( ">):E0N\[L5 1 ! .32 0 5              "  6..#P!F:'1X
M+3(P,C$Q,C,Q7V<R,2YJ<&=02P$"% ,4    "  GB6I4<T-X2;S-  #0(@$
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M,#(Q,3(S,5]G,C4N:G!G4$L! A0#%     @ )XEJ5*/8LQ0\&0$ GG@! !4
M             ( !SXP5 &9H='@M,C R,3$R,S%?9S(V+FIP9U!+ 0(4 Q0
M   ( ">):E1,JM8D+L(  ,.3 0 5              "  3ZF%@!F:'1X+3(P
M,C$Q,C,Q7V<R-RYJ<&=02P$"% ,4    "  GB6I4_VNNL>!M 0#LQ0$ %0
M            @ &?:!< 9FAT>"TR,#(Q,3(S,5]G,C@N:G!G4$L! A0#%
M  @ )XEJ5 ]>P_EQJ@  G?L  !4              ( !LM88 &9H='@M,C R
M,3$R,S%?9S(Y+FIP9U!+ 0(4 Q0    ( ">):E02E4IX('0  .MW   4
M          "  5:!&0!F:'1X+3(P,C$Q,C,Q7V<S+FIP9U!+ 0(4 Q0    (
M ">):E3_YW.J>E4  /2C   5              "  :CU&0!F:'1X+3(P,C$Q
M,C,Q7V<S,"YJ<&=02P$"% ,4    "  GB6I4\Q:<!E1=  #2K0  %0
M        @ %52QH 9FAT>"TR,#(Q,3(S,5]G,S$N:G!G4$L! A0#%     @
M)XEJ5'VRKVE+5P  Q:8  !4              ( !W*@: &9H='@M,C R,3$R
M,S%?9S,R+FIP9U!+ 0(4 Q0    ( ">):E2&Z6;?GUP! %S3 0 5
M      "  5H &P!F:'1X+3(P,C$Q,C,Q7V<S,RYJ<&=02P$"% ,4    "  G
MB6I4N@B>R=+Q  #@0P$ %0              @ $L71P 9FAT>"TR,#(Q,3(S
M,5]G,S0N:G!G4$L! A0#%     @ )XEJ5"(VC$Q/YP  N#$! !4
M     ( !,4\= &9H='@M,C R,3$R,S%?9S,U+FIP9U!+ 0(4 Q0    ( ">)
M:E1 %!_=2DH! *6: 0 5              "  ;,V'@!F:'1X+3(P,C$Q,C,Q
M7V<S-BYJ<&=02P$"% ,4    "  GB6I4K\]B_GYH  "#L0  %0
M    @ $P@1\ 9FAT>"TR,#(Q,3(S,5]G,S<N:G!G4$L! A0#%     @ )XEJ
M5 %*B15_@   4X8  !0              ( !X>D? &9H='@M,C R,3$R,S%?
M9S0N:G!G4$L! A0#%     @ )XEJ5.=QZY/:9   :6H  !0
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M &9H='@M,C R,3$R,S%?9SDN:G!G4$L! A0#%     @ )XEJ5 YJ&H/0]@
M@0H* !4              ( !-@@D &9H='@M,C R,3$R,S%?;&%B+GAM;%!+
M 0(4 Q0    ( ">):E04VN"4!Y$  "2/!@ 5              "  3G_) !F
M:'1X+3(P,C$Q,C,Q7W!R92YX;6Q02P$"% ,4    "  GB6I4O*B=M2H(  !E
M)P  %P              @ %SD"4 9FAT>"TR,#(Q,3(S,7AE>#,Q,2YH=&U0
M2P$"% ,4    "  GB6I4@GV;@2((  !0)P  %P              @ '2F"4
M9FAT>"TR,#(Q,3(S,7AE>#,Q,BYH=&U02P$"% ,4    "  GB6I41EK.8\<$
M  "L$@  %P              @ $IH24 9FAT>"TR,#(Q,3(S,7AE>#,R,2YH
M=&U02P$"% ,4    "  GB6I4JY:H<KT$  "$$@  %P              @ $E
MIB4 9FAT>"TR,#(Q,3(S,7AE>#,R,BYH=&U02P4&     #< -P"<#@  %ZLE
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
